<SEC-DOCUMENT>0001213900-24-036738.txt : 20240426
<SEC-HEADER>0001213900-24-036738.hdr.sgml : 20240426
<ACCEPTANCE-DATETIME>20240426172649
ACCESSION NUMBER:		0001213900-24-036738
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		108
FILED AS OF DATE:		20240426
DATE AS OF CHANGE:		20240426

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Onconetix, Inc.
		CENTRAL INDEX KEY:			0001782107
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-277066
		FILM NUMBER:		24885438

	BUSINESS ADDRESS:	
		STREET 1:		201 E. FIFTH STREET
		STREET 2:		SUITE 1900
		CITY:			CINCINNATI
		STATE:			OH
		ZIP:			45202
		BUSINESS PHONE:		513-620-4101

	MAIL ADDRESS:	
		STREET 1:		201 E. FIFTH STREET
		STREET 2:		SUITE 1900
		CITY:			CINCINNATI
		STATE:			OH
		ZIP:			45202

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Blue Water Biotech, Inc.
		DATE OF NAME CHANGE:	20230424

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Blue Water Vaccines Inc.
		DATE OF NAME CHANGE:	20190710
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>ea0203788-01.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Apr 26 21:03:52 UTC 2024 -->
<html xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:onco="http://www.bluewatervaccines.com/20231231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head><title> </title>
<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="margin:0;padding:0;border-width:0;text-justify-trim: punctuation; margin: 0; padding: 10pt;"><div style="margin:0;padding:0;border-width:0;width:600px;margin: 0 auto;">
	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">As filed with the Securities and Exchange Commission on April 26, 2024</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:0pt;text-align:right;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Registration No. 333-277066</span></p>
		<div style="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"></div>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:3pt;margin-top:3pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"> UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/>Washington, D.C. 20549</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">_____________________</span></p>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:3pt;margin-top:3pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Amendment No. 1 to</span></p>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:3pt;margin-top:3pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">FORM <span style="-sec-ix-hidden: hidden-fact-0">S-1</span><br/>REGISTRATION STATEMENT<br/>UNDER <br/>THE SECURITIES ACT OF 1933</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">_____________________</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:3pt;text-align:center;margin-top:3pt;"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-31"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:18pt;">Onconetix, Inc.</span></ix:nonNumeric><span class="Bold" style="font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:normal;">(Exact Name of Registrant as Specified in its Charter)</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">_____________________</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 31.23%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-42"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:10pt;">Delaware</span></ix:nonNumeric></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 31.23%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:10pt;">2834</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 35.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:10pt;">83-2262816</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;vertical-align:top;width: 31.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;text-indent:0pt;">(State or other jurisdiction of<br/>incorporation or organization)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 31.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;">(Primary Standard Industrial <br/>Classification Code Number)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 35.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;">(I.R.S.&#160;Employer <br/>Identification No.)</p>	</td>	</tr>	</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:3pt;text-align:center;margin-top:3pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">201 E.&#160;Fifth Street, Suite 1900<br/>Cincinnati, Ohio 45202<br/>Telephone: (513)&#160;620-4101<br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:normal;">(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">_____________________</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:3pt;text-align:center;margin-top:3pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Bruce Harmon<br/>Chief Financial Officer<br/>201 E.&#160;Fifth Street, Suite 1900<br/>Cincinnati, Ohio 45202<br/>Telephone: (513)&#160;620-4101<br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:normal;">(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">_____________________</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:3pt;text-align:center;margin-top:3pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">with copies to:</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:3pt;text-align:center;margin-top:3pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Barry&#160;I.&#160;Grossman, Esq.<br/>Jessica Yuan, Esq.<br/>Ellenoff Grossman&#160;&amp; Schole LLP<br/>1345 Avenue of the Americas<br/>New&#160;York, NY&#160;10105<br/>Phone: (212)&#160;370-1300<br/>Fax: (212)&#160;370-7889</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">_____________________</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:3pt;margin-top:3pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Approximate date of commencement of proposed sale to the public: </span><span class="CharOverride-5" style="font-size:9pt;">From time to time after this registration statement becomes effective.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="CharOverride-5" style="font-size:9pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act&#160;of&#160;1933, check the following box.&#160;</span><span class="CharOverride-6" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#9746;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="CharOverride-5" style="font-size:9pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b)&#160;under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;</span><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="CharOverride-5" style="font-size:9pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c)&#160;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;</span><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="CharOverride-5" style="font-size:9pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(d)&#160;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;</span><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="CharOverride-5" style="font-size:9pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange&#160;Act.</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 16.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-5" style="font-size:9pt;">Large&#160;accelerated&#160;filer</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 20.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><span class="CharOverride-5" style="font-size:9pt;">Accelerated&#160;filer</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 30.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 16.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-131"><span class="CharOverride-5" style="font-size:9pt;">Non-accelerated&#160;filer</span></ix:nonNumeric></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><span class="CharOverride-6" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#9746;</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 20.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><span class="CharOverride-5" style="font-size:9pt;">Smaller&#160;reporting&#160;company</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 30.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness" id="ixv-144"><span class="CharOverride-6" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#9746;</span></ix:nonNumeric></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 16.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 20.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><span class="CharOverride-5" style="font-size:9pt;">Emerging&#160;growth&#160;company</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 30.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany" id="ixv-157"><span class="CharOverride-6" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#9746;</span></ix:nonNumeric></p>	</td>	</tr>	</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:3pt;margin-top:3pt;"><span class="CharOverride-5" style="font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B)&#160;of the Securities Act.&#160;</span><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityExTransitionPeriod" id="ixv-161"><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</span></ix:nonNumeric></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&#160;8(a)&#160;of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission acting pursuant to said Section&#160;8(a), may determine.</span></p>
		<div style="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"></div>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">EXPLANATORY NOTE</span></p>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_AmendmentDescription-c0_cont_1" name="dei:AmendmentDescription" id="ixv-173"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to Rule 429 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the prospectus included in this Registration Statement on Form S<span class="nobreak">-1</span> (this &#8220;Registration Statement&#8221;) is a combined prospectus relating to the following shares of common stock of Onconetix, Inc. (the &#8220;Registrant&#8221;) being registered on this Registration Statement and previously registered on the Registrant&#8217;s Registration Statement on Form S<span class="nobreak">-3</span> (File No. 333<span class="nobreak">-267142</span>), as amended (the &#8220;Prior Registration Statement&#8221;):</p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation continuedAt="_AmendmentDescription-c0_cont_2" id="_AmendmentDescription-c0_cont_1"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The offer and resale of 4,972,428<span class="nobreak"> </span>shares of Common Stock (the &#8220;Inducement PIO Shares&#8221;) issuable upon exercise of common stock preferred investment options (the &#8220;Inducement PIOs&#8221;) issued to Armistice Capital Master Fund Ltd. (&#8220;Armistice&#8221;) in a warrant inducement transaction (the &#8220;Warrant Inducement&#8221;), which closed on August<span class="nobreak"> </span>2, 2023.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation continuedAt="_AmendmentDescription-c0_cont_3" id="_AmendmentDescription-c0_cont_2"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The offer and resale of 149,173 Inducement PIO Shares issuable upon exercise of Inducement PIOs issued to H.C. Wainwright &amp; Co., LLC, the Company&#8217;s placement agent for the Warrant Inducement, or its designees on August<span class="nobreak"> </span>2, 2023 in the Warrant Inducement (the &#8220;Placement Agent Inducement PIOs&#8221;).</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation continuedAt="_AmendmentDescription-c0_cont_4" id="_AmendmentDescription-c0_cont_3"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The offer and resale of 2,486,214<span class="nobreak"> </span>shares of Common Stock issuable upon exercise of common stock preferred investment options (the &#8220;Sabby PIOs&#8221;, and together with the Inducement PIOs and the Placement Agent Inducement PIOs, the &#8220;PIOs&#8221;) issued to Sabby in a private placement, which were registered on a registration statement on Form S<span class="nobreak">-1</span> (File No. 333<span class="nobreak">-267142</span>) on September<span class="nobreak"> </span>19, 2022 that was declared effective by the SEC, as amended by the Prior Registration Statement (the &#8220;Initial Registration Statement&#8221;)</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation continuedAt="_AmendmentDescription-c0_cont_5" id="_AmendmentDescription-c0_cont_4"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The offer and resale of 220,997<span class="nobreak"> </span>shares of Common Stock (&#8220;August 2022 Wainwright Warrant Shares&#8221;) issuable upon exercise of the warrants (the &#8220;August 2022 Wainwright Warrants&#8221;) issued to H.C. Wainwright &amp; Co., LLC, or its designees, in a private placement, which were registered on the Initial Registration Statement.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation id="_AmendmentDescription-c0_cont_5"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">This Registration Statement also constitutes Post<span class="nobreak">-Effective</span> Amendment No. 2 to the Prior Registration Statement, and such Post<span class="nobreak">-Effective</span> Amendment No. 1 to the Initial Registration Statement shall hereafter become effective concurrently with the effectiveness of this Registration Statement in accordance with Section 8(c) of the Securities Act.</p></ix:continuation></div>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;color:#d2232a;">The information in this prospectus is not complete and may be changed. The Selling Stockholders named in this prospectus may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.</span></p>
		</div>
	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">

						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;color:#d2232a;">PROSPECTUS</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.21%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 30.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;color:#d2232a;">SUBJECT TO COMPLETION</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.21%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 36.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:right;"><span class="Bold" style="font-style:normal;font-weight:bold;color:#d2232a;">DATED APRIL</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;color:#d2232a;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;color:#d2232a;">26, 2024</span></p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:12pt;">7,828,812&#160;Shares of Common Stock</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:9pt;text-align:center;margin-top:9pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:12pt;"><img alt="" src="tonconetix_logo.jpg" style="width:212.48px;max-width:100%;"/></span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="CharOverride-5" style="font-size:9pt;">This prospectus relates to the resale by Selling Stockholders of 7,828,812 shares of common stock of Onconetix, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company,&#8221; or &#8220;Onconetix&#8221;), par value $0.00001 per share (the &#8220;Common Stock&#8221;), by the Selling Stockholders listed in this prospectus or their permitted transferees (the &#8220;Selling Stockholders&#8221;). The shares of Common Stock registered for resale pursuant to this prospectus include:</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-size:9pt;">4,972,428 shares of Common Stock (the &#8220;Inducement PIO Shares&#8221;) issuable upon exercise of common stock preferred investment options (the &#8220;Inducement PIOs&#8221;) issued to Armistice Capital Master Fund Ltd. (&#8220;Armistice&#8221;) in a warrant inducement transaction (the &#8220;Warrant Inducement&#8221;), which closed on August&#160;2, 2023;</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-size:9pt;">149,173 Inducement PIO Shares issuable upon exercise of Inducement PIOs issued to H.C.&#160;Wainwright &amp; Co., LLC, the Company&#8217;s placement agent for the Warrant Inducement, or its designees on August&#160;2, 2023 in the Warrant Inducement (the &#8220;Placement Agent Inducement PIOs&#8221;);</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-size:9pt;">2,486,214 shares of Common Stock issuable upon exercise of common stock preferred investment options (the &#8220;Sabby PIOs&#8221;, and together with the Inducement PIOs and the Placement Agent Inducement PIOs, the &#8220;PIOs&#8221;) issued to Sabby in the August 2022 Private Placement; and </span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-size:9pt;">220,997 shares of Common Stock (&#8220;August 2022 Wainwright Warrant Shares&#8221;) issuable upon exercise of the warrants (the &#8220;August 2022 Wainwright Warrants&#8221;) issued to H.C. Wainwright &amp; Co., LLC, or its designees, in the August 2022 Private Placement.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="CharOverride-5" style="font-size:9pt;">For additional information about the Warrant Inducement and the Private Placement, see &#8220;</span><span class="Italic" style="font-style:italic;font-weight:normal;font-size:9pt;">Warrant Inducement and Private Placement</span><span class="CharOverride-5" style="font-size:9pt;">.&#8221;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="CharOverride-5" style="font-size:9pt;">The Inducement PIOs have an exercise price of $1.09 per share and will expire five&#160;years from the issuance date. The Placement Agent Inducement PIOs have an exercise price of $1.3625 per share and will expire five&#160;years from the issuance date. The Sabby PIOs have an exercise price of $2.546 per share and will expire five years from the issuance date.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="CharOverride-5" style="font-size:9pt;">We are registering the shares on behalf of the Selling Stockholders, to be offered and sold by them from time to time. We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of shares by the Selling Stockholders.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="CharOverride-5" style="font-size:9pt;">Our common stock is listed on The Nasdaq Capital Market under the symbol &#8220;ONCO.&#8221; The last reported sale price of our common stock on The Nasdaq Capital Market on April 24, 2024 was $0.122 per share. We recommend that you obtain current market quotations for our common stock prior to making an investment decision.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="CharOverride-5" style="font-size:9pt;">The Selling Stockholders may offer all or part of the shares for resale from time to time through public or private transactions, at either prevailing market prices or at privately negotiated prices. Our registration of the shares of common stock covered by this prospectus does not mean that the Selling Stockholders will offer or sell any of the shares. With regard only to the shares the Selling Stockholders sell for their own behalf, the Selling Stockholders may be deemed an &#8220;underwriter&#8221; within the meaning of the Securities Act&#160;of&#160;1933, as amended (the &#8220;Securities Act&#8221;). The Company has paid all of the registration expenses incurred in connection with the registration of the shares. We will not pay any of the selling commissions, brokerage fees and related expenses.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="CharOverride-5" style="font-size:9pt;">We will pay the expenses incurred in registering the shares, including legal and accounting fees. See &#8220;</span><span class="Italic" style="font-style:italic;font-weight:normal;font-size:9pt;">Plan&#160;of&#160;Distribution</span><span class="CharOverride-5" style="font-size:9pt;">&#8221; on&#160;page&#160;155 of this prospectus.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Investing in our Common Stock involves certain risks. See &#8220;</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-size:9pt;">Risk Factors</span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">&#8221; on page&#160;5 of this prospectus, included in any accompanying prospectus supplement and in the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. We urge you to read the entire prospectus, any amendments or supplements, any free writing prospectuses, and any documents incorporated by reference carefully before you make your investment decision.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</span></p>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:9pt;margin-top:9pt;"><span class="CharOverride-5" style="font-size:9pt;">The date of this prospectus is<span style="width: 9px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>





	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="TOC001"></a><p class="H1_TOC" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">TABLE OF CONTENTS</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Page</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T12">ABOUT THIS PROSPECTUS</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">ii</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T11">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">iii</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T10">RISK FACTORS</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9">USE OF PROCEEDS</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">54</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T8">DETERMINATION OF OFFERING PRICE</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">55</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T99301">ABOUT THE COMPANY</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">56</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T99111">UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">97</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T99501">ONCONETIX&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">102</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T99502">PROTEOMEDIX MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">116</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T99503">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">146</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T7"><span class="CharOverride-1" style="font-variant:normal;text-transform:uppercase;">DESCRIPTION OF CAPITAL STOCK</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">148</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T6">SELLING STOCKHOLDERS</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">153</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T5">PLAN OF DISTRIBUTION</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">155</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T4">EXPERTS</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">157</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T3">LEGAL MATTERS</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">157</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T2">WHERE YOU CAN FIND MORE INFORMATION</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">157</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T2001">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-1</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">i</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T12"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ABOUT THIS PROSPECTUS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">This prospectus is part of a registration statement on Form&#160;S<span class="nobreak">-1</span> that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) using a &#8220;shelf&#8221; registration process for the delayed or continuous offering and sale of securities pursuant to Rule&#160;415 under the Securities Act&#160;of&#160;1933, as amended (the &#8220;Securities Act&#8221;). This prospectus generally describes Onconetix, Inc. and our Common Stock. The Selling Stockholders may use the shelf registration statement to sell up to an aggregate of up to 7,828,812<span class="nobreak"> </span>shares of our Common Stock from time to time through any means described in the section entitled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Plan of Distribution</span>.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We will not receive any proceeds from the sale of shares of Common Stock to be offered by the Selling Stockholders pursuant to this prospectus. However, we will pay the expenses, other than underwriting discounts and commissions, associated with the sale of shares pursuant to this prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We and the Selling Stockholders, as applicable, may deliver a prospectus supplement with this prospectus, to the extent appropriate, to update the information contained in this prospectus. The prospectus supplement may also add, update or change information included in this prospectus. You should read both this prospectus and any applicable prospectus supplement, together with additional information described below under the captions &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Where You Can Find More Information</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Incorporation of Certain Information by Reference</span>.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">No offer of these securities will be made in any jurisdiction where the offer is not permitted.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">You should rely only on the information contained in or incorporated by reference in this prospectus, any accompanying prospectus supplement or in any related free writing prospectus filed by us with the SEC.&#160;We have not authorized anyone to provide you with different information. This prospectus and any accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus or such accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Unless the context otherwise indicates, references in this prospectus to &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer, collectively, to Onconetix, Inc., a Delaware corporation.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">ii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T11"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">This prospectus contains &#8220;forward<span class="nobreak">-looking</span> statements&#8221; within the meaning of the federal securities laws, and that involve significant risks and uncertainties. Words such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;future,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; and similar expressions, as well as statements in future tense, identify forward<span class="nobreak">-looking</span> statements. Forward<span class="nobreak">-looking</span> statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward<span class="nobreak">-looking</span> statements are based on information we have when those statements are made or management&#8217;s good faith belief as of that time with respect to future events and are subject to significant risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward<span class="nobreak">-looking</span> statements. Forward<span class="nobreak">-looking</span> statements are subject to a number of risks, uncertainties and assumptions in other documents we file from time to time with the SEC, specifically our most recent Annual Report on Form&#160;10<span class="nobreak">-K</span>, our Quarterly Reports on Form&#160;10<span class="nobreak">-Q</span> and our Current Reports on Form&#160;8<span class="nobreak">-K</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Important factors that could cause such differences include, but are not limited to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our projected financial position and estimated cash burn rate;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our estimates regarding expenses, future revenues and capital requirements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our ability to continue as a going concern;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our need to raise substantial additional capital to fund our operations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our ability to commercialize or monetize ENTADFI and Proclarix and integrate the assets and commercial operations acquired in the share exchange with Proteomedix AG (&#8220;Proteomedix&#8221;);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the successful development of our commercialization capabilities, including sales and marketing capabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our ability to maintain the necessary regulatory approvals to market and commercialize our products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the results of market research conducted by us or others;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our ability to obtain and maintain intellectual property protection for our current products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our ability to protect our intellectual property rights and the potential for us to incur substantial costs from lawsuits to enforce or protect our intellectual property rights;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possibility that a third party may claim we or our third<span class="nobreak">-party</span> licensors have infringed, misappropriated, or otherwise violated their intellectual property rights and that we may incur substantial costs and be required to devote substantial time defending against claims against us;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our reliance on third parties, including manufacturers and logistics companies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the success of competing therapies or diagnostics and products that are or become available;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our ability to successfully compete against current and future competitors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our ability to expand our organization to accommodate potential growth and our ability to attract, motivate and retain key personnel;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential for us to incur substantial costs resulting from product liability lawsuits against us and the potential for these product liability lawsuits to cause us to limit our commercialization of our products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>market acceptance of our products, the size and growth of the potential markets for our current products, and our ability to serve those markets; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>disruptions in the business of the Company or Proteomedix, which could have an adverse effect on their respective businesses and financial results.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">iii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">These forward<span class="nobreak">-looking</span> statements are subject to a number of risks, uncertainties and assumptions, including those described in &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>.&#8221; Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward<span class="nobreak">-looking</span> statements we may make. In light of these risks, uncertainties and assumptions, the forward<span class="nobreak">-looking</span> events and circumstances discussed in this prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward<span class="nobreak">-looking</span> statements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">You should not rely upon forward<span class="nobreak">-looking</span> statements as predictions of future events. Although we believe that the expectations reflected in the forward<span class="nobreak">-looking</span> statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward<span class="nobreak">-looking</span> statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward<span class="nobreak">-looking</span> statements. We undertake no obligation to update publicly any forward<span class="nobreak">-looking</span> statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in our expectations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">You should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration statement of which this prospectus forms a part with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">iv</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PROSPECTUS SUMMARY</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The SEC allows us to &#8220;incorporate by reference&#8221; certain information that we file with the SEC, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus, and information that we file later with the SEC will update automatically, supplement and/or supersede the information disclosed in this prospectus. Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or in any other document that also is or is deemed to be incorporated by reference in this prospectus modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. You should read the following summary together with the more detailed information regarding our company, our Common Stock and our financial statements and notes to those statements included in this prospectus.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Our Company</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We are a commercial stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men&#8217;s health and oncology. Through our recent acquisition of Proteomedix, we own Proclarix, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the In Vitro Diagnostic Regulation (&#8220;IVDR&#8221;), which we anticipate will be marketed in the U.S. as a lab developed test through our license agreement with LabCorp. We also own ENTADFI, an FDA<span class="nobreak">-approved</span>, once daily pill that combines finasteride and tadalafil for the treatment of BPH, a disorder of the prostate.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proclarix is an easy<span class="nobreak">-to-use</span> next generation protein<span class="nobreak">-based</span> blood test that can be done with the same sample as a patient&#8217;s regular Prostate<span class="nobreak">-Specific</span> Antigen (&#8220;PSA&#8221;) test. The PSA test is a well<span class="nobreak">-established</span> prostate specific marker that measures the concentration of PSA molecules in a blood sample. A high level of PSA can be a sign of prostate cancer. However, PSA levels can also be elevated for many other reasons including infections, prostate stimulation, vigorous exercise, or even certain medications. PSA results can be confusing for many patients and even physicians. It is estimated over 50% of biopsies with elevated PSA are negative or clinically insignificant resulting in an overdiagnosis and overtreatment that impacts the physician&#8217;s routine, our healthcare system, and the quality of patients&#8217; lives. Proclarix helps doctors and patients with unclear PSA test results through the use of our proprietary Proclarix Risk Score which delivers clear and immediate diagnostic support for further treatment decisions. No additional intervention is required, and results are available quickly. Local diagnostic laboratories can integrate this multiparametric test into their current workflow because Proclarix assays use the enzyme<span class="nobreak">-linked</span> immunosorbent assay (ELISA) standard, which most diagnostic laboratories are already equipped to process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">ENTADFI allows men to receive treatment for their symptoms of BPH without the negative sexual side effects typically seen in patients on finasteride alone. Following a recent business strategy shift towards the field of men&#8217;s health and oncology and deprioritizing of preclinical vaccine programs, we are building additional assets in therapeutics, diagnostics, and clinician services for men&#8217;s health and oncology.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Since our inception in October 2018 until April 2023, when we acquired ENTADFI, we devoted substantially all of our resources to performing research and development, undertaking preclinical studies and enabling manufacturing activities in support of our product development efforts, hiring personnel, acquiring and developing our technology and now deprioritized vaccine candidates, organizing and staffing our company, performing business planning, establishing our intellectual property portfolio and raising capital to support and expand such activities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Prior to the acquisition of ENTADFI, we managed one distinct business segment, which was research and development. Beginning in the second quarter of 2023, as a result of the acquisition of ENTADFI, we operated in two business segments: research and development and commercial. During the third quarter of 2023, we deprioritized our vaccine discovery and development programs, and accordingly, we now operate in one segment: commercial. Our recent acquisition of Proteomedix during the fourth quarter of 2023 and its related diagnostic product Proclarix was determined to be within our commercial segment. The research and development segment was our historical business, and was dedicated to the research and development of various vaccines to prevent infectious diseases. The commercial segment was new in the second quarter of 2023 and is dedicated to the commercialization of our products approved for sale, namely ENTADFI in the U.S.&#160;and Proclarix in Europe.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">ENTADFI has not generated any revenue from product sales, and Proclarix has generated only minimal amounts of development revenue since its acquisition.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2023, the Company closed its acquisition of Proteomedix and introduced Onconetix, Inc. as the new name for the combined company. The closing of the acquisition of Proteomedix for all stock consideration provides Proteomedix shareholders with an initial 16.4% ownership stake of Onconetix, and Series&#160;B Preferred Stock convertible into 269,672,900<span class="nobreak"> </span>shares of Onconetix Common Stock, subject to Onconetix stockholder approval of the same (&#8220;Stockholder Approval&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In light of (i) the time and resources needed to continue pursuing commercialization of ENTADFI, and (ii) the Company&#8217;s cash runway and indebtedness, the Company has determined to temporarily pause its commercialization of ENTADFI, as it considers strategic alternatives. As part of a cost reduction plan approved by the Board and in connection with our pause in commercializing ENTADFI, we terminated three employees involved with the ENTADFI program, effective April<span class="nobreak"> </span>30, 2024, with such individuals to continue assisting the Company on an as<span class="nobreak">-needed</span>, consulting basis. The Company continues to consider various measures, including strategic alternatives, to rationalize its operations and optimize its existing Proclarix diagnostic program.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We are currently focusing our efforts on commercializing Proclarix.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Given Proclarix is CE<span class="nobreak">-marked</span> for sale in the European Union, we expect to generate revenue from sales of Proclarix by 2025. Although we anticipate these sales to offset some expenses relating to commercial scale up and development, we expect our expenses will increase substantially in connection with our ongoing activities, as we:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>commercialize Proclarix;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>hire additional personnel;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>operate as a public company; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>obtain, maintain, expand and protect our intellectual property portfolio.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">To the extent that we resume the commercialization of ENTADFI, we also expect to incur significant commercialization expenses related to marketing, manufacturing, and distribution for ENTADFI. We rely and will continue to rely on third parties for the manufacturing of ENTADFI and Proclarix. We have no internal manufacturing capabilities, and we will continue to rely on third parties, of which the main suppliers are single<span class="nobreak">-source</span> suppliers, for commercial products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We do not have any products approved for sale, aside from Proclarix, from which we have generated only minimal amounts of development revenue since its acquisition, and ENTADFI, from which we have not generated any revenue from product sales, and for which we have determined to temporarily pause commercialization activities. To date, we have financed our operations primarily with proceeds from our sale of preferred securities to seed investors, the initial public offering (&#8220;IPO&#8221;), the April 2022 Private Placement (as defined below), the August 2022 Private Placement (as defined below), the proceeds received from a warrant exercise in August 2023, and the proceeds received from the issuance of debt in January 2024. We will continue to require significant additional capital to commercialize Proclarix and ENTADFI (if we decide to resume its commercialization), and to fund operations for the foreseeable future. Accordingly, until such time as we can generate significant revenue, if ever, we expect to finance our cash needs through public or private equity or debt financings, third<span class="nobreak">-party</span> (including government) funding and to rely on third<span class="nobreak">-party</span> resources for marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches, to support our operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We have incurred net losses since inception and expect to continue to incur net losses in the foreseeable future. Our net losses may fluctuate significantly from quarter<span class="nobreak">-to-quarter</span> and year<span class="nobreak">-to-year</span>, depending in large part on the timing of our preclinical studies, clinical trials and manufacturing activities, our expenditures on other research and development activities and commercialization activities. As of December<span class="nobreak"> </span>31, 2023, the Company had a working capital deficit of approximately $11.4<span class="nobreak"> </span>million and an accumulated deficit of approximately $56.8<span class="nobreak"> </span>million. We will need to raise additional capital within the next 12<span class="nobreak"> </span>months to sustain operations. In addition, if Stockholder Approval is not obtained by January<span class="nobreak"> </span>1, 2025, the Company may be obligated to cash settle the Series B Preferred Stock. Based on the closing price of $0.122 for the Company&#8217;s stock as of April<span class="nobreak"> </span>24, 2024, the Series B Preferred Stock would be redeemable for approximately $32.9<span class="nobreak"> </span>million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Until we generate revenue sufficient to support self<span class="nobreak">-sustaining</span> cash flows, if ever, we will need to raise additional capital to fund our continued operations, including our product development and commercialization activities related to our current and future products. There can be no assurance that additional capital will be available to us on acceptable terms, or at all, or that we will ever generate revenue sufficient to provide self<span class="nobreak">-sustaining</span> cash flows. These circumstances raise substantial doubt about our ability to continue as a going concern. The accompanying consolidated financial statements of Onconetix, as of and for the year ended December<span class="nobreak"> </span>31, 2023, included elsewhere in this prospectus do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Because of the numerous risks and uncertainties associated with our business, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Additionally, even if we are able to generate revenue from Proclarix or ENTADFI, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and may be forced to reduce our operations.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ABOUT THIS OFFERING</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common Stock outstanding prior to this offering</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">22,327,701&#160;shares</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Shares of Common Stock offered by the Selling Stockholders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;"><br/>7,828,812&#160;shares of Common Stock</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Common Stock to be outstanding after this offering</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">30,156,513&#160;shares (assuming the exercise of the PIOs)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Use of proceeds</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of the shares of Common Stock covered hereby by the Selling Stockholders.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Terms of this offering</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">The Selling Stockholders, including their transferees, donees, pledgees, assignees, and successors<span class="nobreak">-in-interest</span>, may sell, transfer, or otherwise dispose of any or all of the shares of Common Stock offered by this prospectus from time to time on The Nasdaq Capital Market or any other stock exchange, market or trading facility on which the shares are traded or in private transactions. The shares of Common Stock may be sold at fixed prices, at market prices prevailing at the time of sale, at prices related to prevailing market price or at negotiated prices.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Nasdaq symbol</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Our Common Stock is listed on The Nasdaq Capital Market under the symbol &#8220;ONCO.&#8221;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Risk Factors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Investing in our securities involves significant risks. Before making a decision whether to invest in our securities, please read the information contained in or incorporated by reference under the heading &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; in this prospectus, the documents we have incorporated by reference herein and under similar headings in other documents filed after the date hereof and incorporated by reference into this prospectus. See &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Incorporation of Certain Information by Reference</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Where You Can Find More Information</span>.&#8221;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T10"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span style="-keep: true">RISK FACTORS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Investing in our securities involves a high degree of risk. You should carefully consider the risks and uncertainties described in this prospectus, in our most recent Annual Report on Form&#160;10<span class="nobreak">-K</span>, as supplemented and updated by subsequent Quarterly Reports on Form&#160;10<span class="nobreak">-Q</span> and Current Reports on Form&#160;8<span class="nobreak">-K</span> that we have filed or will file with the SEC, and in other documents which are incorporated by reference into this prospectus, before making an investment decision pursuant to this.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our business, financial condition and results of operations could be materially and adversely affected by any or all of these risks or by additional risks and uncertainties not presently known to us or that we currently deem immaterial that may adversely affect us in the future.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to This Offering</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Sales of a substantial number of our securities in the public market by the selling securityholders and/or by our existing securityholders could cause the price of our shares of Common Stock to fall.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The selling securityholders can sell, under this prospectus, up to 7,828,812<span class="nobreak"> </span>shares of Common Stock. The sale of all or a portion of the securities being offered in this prospectus, or the perception that those sales might occur, could depress the market price of our Common Stock, and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that such sales may have on the prevailing market price of our Common Stock.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to our Financial Position and Need for Capital</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We have a very limited operating history, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">To date, we have devoted substantially all of our resources to performing research and development, hiring personnel, licensing and developing our technology, organizing and staffing our company, performing business planning, establishing our intellectual property portfolio, potential asset and business acquisitions, expenditures associated with the now paused commercial launch of ENTADFI, and raising capital to support and expand such activities. As an organization, we have not yet demonstrated an ability to successfully manufacture a commercial<span class="nobreak">-scale</span> product or conduct sales and marketing activities necessary for successful commercialization or arrange for a third party to conduct these activities on our behalf. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives, including with respect to our products. We are in the process of transitioning from a company with a research and development focus to a company capable of supporting commercial activities and may not be successful in such a transition.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We have incurred significant net losses since inception, have only generated minimal revenue, and anticipate that we will continue to incur substantial net losses for the foreseeable future and may never achieve profitability. Our stock is a highly speculative investment.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We are a commercial<span class="nobreak">-stage</span> biotechnology company that was incorporated in October&#160;2018. Our net loss was $37.4&#160;million and $13.4&#160;million for the&#160;years ended December&#160;31, 2023, and 2022, respectively. As of December&#160;31, 2023, we had an accumulated deficit of $56.8&#160;million. We also generated negative operating cash flows of $13.6&#160;million for the year ended December&#160;31, 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We expect to continue to spend significant resources to commercialize our products. We expect to incur substantial and increasing operating losses over the next several&#160;years. As a result, our accumulated deficit will also increase significantly. Additionally, there can be no assurance that our current products or those that may be under development by us in the future will be commercially viable. If we are unable to achieve profitability, we may be unable to continue our operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">There is substantial doubt about our ability to continue as a &#8220;going concern,&#8221; and we will require substantial additional funding to finance our long-term operations. If we are unable to raise additional capital when needed, we could be forced to delay, reduce or terminate certain of our products or other operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future. As of December&#160;31, 2023, the Company had cash of approximately $4.6&#160;million, a working capital deficit of approximately $11.4&#160;million and an accumulated deficit of approximately $56.8&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On January&#160;23, 2024, the Company issued the Debenture in exchange for $4.6&#160;million in net cash proceeds. The Debenture, as amended on April<span class="nobreak"> </span>24, 2024, is repayable in full upon the earlier of (i)&#160;the closing under the Subscription Agreement and (ii)&#160;October<span class="nobreak"> </span>31, 2024.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We estimate that, based on our existing cash as of the date of the financial statements included in this prospectus, we will not have cash on hand sufficient to fund our operations for at least the 12&#160;months following the date of financial statements included in this prospectus. We believe that we will need to raise substantial additional capital to fund our continuing operations, satisfy existing and future obligations and liabilities, and otherwise support the Company&#8217;s working capital needs and business activities, including making the remaining payments to Veru, and the commercialization of Proclarix and ENTADFI (should we decide to resume its commercialization). In addition, if Stockholder Approval is not obtained by January&#160;1, 2025, the Company may be obligated to cash settle the Series&#160;B Preferred Stock. The Company does not currently have sufficient cash to redeem the shares of Series&#160;B Preferred Stock. Based on the closing price of $0.122 for the Company&#8217;s stock as of April<span class="nobreak"> </span>24, 2024, the Series B Preferred Stock would be redeemable for approximately $32.9<span class="nobreak"> </span>million. Management&#8217;s plans include generating product revenue from sales of Proclarix, which may still be subject to further successful commercialization activities within certain jurisdictions. In addition, should we decide to resume the commercialization of ENTADFI, we plan to also generate product sales from ENTADFI, which is subject to further successful commercialization activities. Certain of the commercialization activities are outside of the Company&#8217;s control, including but not limited to, securing contracts with wholesalers and third<span class="nobreak">-party</span> payers, securing contracts with third<span class="nobreak">-party</span> logistics providers, obtaining required licensure in various jurisdictions, as well as attempting to secure additional required funding through equity or debt financings if available. However, there are currently no commitments in place for further financing nor is there any assurance that such financing will be available to the Company on favorable terms, if at all. If the Company is unable to secure additional capital, it may be required to delay or curtail any future commercialization of products, and it may take additional measures to reduce expenses in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of time within one year following the date of the financial statements included in this prospectus. Our future capital requirements will depend on many factors, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of future commercialization activities, including product manufacturing, marketing, sales, royalties and distribution, for Proclarix, and ENTADFI (if we decide to resume its commercialization), and other products for which we have received or will receive marketing approval;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty, or other payments due under any such agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any product liability or other lawsuits related to our products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expenses needed to attract, hire, and retain skilled personnel;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the revenue, if any, received from commercial sales of Proclarix and ENTADFI (if we decide to resume its commercialization), or other products for which we may receive marketing approval;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs to establish, maintain, expand, enforce, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending, and enforcing our patents or other intellectual property rights; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of operating as a public company.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our ability to raise additional funds will depend on financial, economic, and other factors, many of which are beyond our control. We cannot be certain that additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be forced to delay, reduce the scope of our business activities.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We owe a significant amount of money to Veru, which funds we do not have. Veru may take action against us to enforce its rights to payment in the future, which could have a material adverse effect on us and our operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Due to recent financial constraints, the Company may be unable to timely pay amounts due to Veru, from whom we purchased ENTADFI in April 2023. We may not have sufficient funds to pay amounts due to Veru in the near term, if at all, including but not limited to $10<span class="nobreak"> </span>million, $5<span class="nobreak"> </span>million of which was due on April<span class="nobreak"> </span>19, 2024 and is subject to certain forbearance terms, and $5<span class="nobreak"> </span>million is due on September<span class="nobreak"> </span>30, 2024. On April<span class="nobreak"> </span>24, 2024, Veru agreed to forbear its rights and remedies until March<span class="nobreak"> </span>31, 2025 with respect to, among other things, our inability to pay amounts due as of April<span class="nobreak"> </span>19, 2024. However, Veru may take future action against us, including filing legal proceedings against us seeking amounts due and interest accrued or attempting to terminate its relationship with us. If Veru were to take legal action against us, we may be forced to scale back our business plan and/or seek bankruptcy protection. We may be subject to litigation and damages for our failure to pay amounts due to Veru, and may be forced to pay interest and penalties, which funds we do not currently have. We are currently considering strategic options for ENTADFI and plan to seek funding to support our operations, and to pay amounts due to Veru, through a combination of equity offerings, debt financing or other capital sources, including potential collaborations, licenses, sales, and other similar arrangements, which may not be available on favorable terms, if at all. The sale of additional equity or debt securities, if accomplished, may result in dilution to our stockholders. Furthermore, any revenue or financing proceeds that we are required to pay to Veru will detract from our ability to use such funds to support our operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Our current liabilities are significant, and if those to whom we owe accounts payable, such as Veru, IQVIA or other creditors or vendors, were to demand payment, we would be unable to pay.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December<span class="nobreak"> </span>31, 2023, we had total current liabilities of approximately $17.2<span class="nobreak"> </span>million, including accounts payable of approximately $5.3<span class="nobreak"> </span>million, accrued expenses of approximately $2.2<span class="nobreak"> </span>million, and approximately $9.6<span class="nobreak"> </span>million (net of discount) related to the notes payable due to Veru. As of the same date, we had cash of only $4.6<span class="nobreak"> </span>million. In January 2024, we incurred additional debt when we issued a $5<span class="nobreak"> </span>million Debenture to the PMX Investor, which comes due on or before October<span class="nobreak"> </span>31, 2024. We are currently considering strategic options for ENTADFI and plan to seek funding to support our operations. However, the level of our current liabilities may make it more difficult for us to obtain adequate financing on favorable terms, if at all. If those to whom these payments are due were to demand immediate payment, as they are entitled to do, and we are not able to make the required payments, we would be subject to liability if our creditors chose to enforce their rights, which could result in our bankruptcy and insolvency. Under such a scenario, our assets would be distributed to our creditors, leaving nothing to be distributed to our stockholders.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We may consider strategic alternatives in order to maximize stockholder value, including financing, strategic alliances, licensing arrangements, acquisitions or the possible sale of our business. We may not be able to identify or consummate any suitable strategic alternatives and any consummated strategic alternatives may not be successful.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We may consider all strategic alternatives that may be available to us to maximize stockholder value, including financing, strategic alliances, licensing arrangements, acquisitions, or the possible sale of our business. Our exploration of various strategic alternatives may not result in any specific action or transaction. To the extent that this engagement results in a transaction, our business objectives may change depending upon the nature of the transaction. There can be no assurance that we will enter into any transaction as a result of the engagement. Furthermore, if we determine to engage in a strategic transaction, we cannot predict the impact that such strategic transaction might have on our operations or stock price. We also cannot predict the impact on our stock price if we fail to enter into a transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In addition, we face significant competition in seeking appropriate strategic partners, and the negotiation process is time<span class="nobreak">-consuming</span> and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our business activities because they may be deemed to be at too early of a stage of development for collaborative effort. Any delays in entering into new strategic partnership agreements harm our business prospects, financial condition, and results of operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If we license or acquire products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following a strategic transaction, license, or acquisition, we will achieve the results, revenue or specific net income that justifies such transaction.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our existing stockholders and investors, restrict our operations, or require us to relinquish rights to our products on unfavorable terms to us.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We may seek additional capital through a variety of means, including through private and public equity offerings and debt financings, collaborations, strategic alliances and marketing, distribution, or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, or through the issuance of shares under other types of contracts, or upon the exercise or conversion of outstanding options, warrants, convertible debt or other similar securities, the ownership interests of our stockholders will be diluted, and the terms of such financings may include liquidation or other preferences, anti<span class="nobreak">-dilution</span> rights, conversion and exercise price adjustments and other provisions that adversely affect the rights of our stockholders, including rights, preferences and privileges that are senior to those of our holders of common stock in terms of the payment of dividends or in the event of a liquidation. In addition, debt financing, if available, could include covenants limiting or restricting our ability to take certain actions, such as incurring additional debt, making capital expenditures, entering into licensing arrangements, or declaring dividends and may require us to grant security interests in our assets. If we raise additional funds through collaborations, strategic alliances, or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or products or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financing when needed, we may need to curtail or cease our operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Due to the significant resources required for the commercialization of our products, and depending on our ability to access capital, we must prioritize commercialization of certain products. Moreover, we may expend our limited resources on products that do not yield a successful product and fail to capitalize on products that may be more profitable or for which there is a greater likelihood of success.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Due to the significant resources required for the development of our products, we must decide which products to pursue and advance and the number of resources to allocate to each. Our decisions concerning the allocation of management and financial resources toward particular products may not lead to the development of any viable commercial products and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate, license, or collaborate with third parties in respect of certain products may subsequently also prove to be less than optimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our products or misread trends in the pharmaceutical or diagnostic industry, our business could be seriously harmed. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other products and/or product candidates that may later prove to have greater commercial potential than those we choose to pursue or relinquish valuable rights to such products and/or product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization rights.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited, each of which could harm our business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, we had U.S.&#160;federal, foreign, and state net operating loss carryforwards of approximately $27.9&#160;million, $18.0&#160;million, and $23.8&#160;million, respectively. Under Sections 382 and 383 of the Internal Revenue Code, or the Code, if a corporation undergoes an &#8220;ownership change,&#8221; the corporation&#8217;s ability to use its pre<span class="nobreak">-ownership</span> change net operating loss carryforwards and other pre<span class="nobreak">-ownership</span> change tax attributes, such as research tax credits, to offset its post<span class="nobreak">-ownership</span> change income and taxes may be limited. In general, an ownership change will occur when the percentage of the Corporation&#8217;s ownership (by value) of one or more &#8220;5<span class="nobreak">-percent</span> stockholders&#8221; (as defined in the Code) has increased by more than 50 percent over the lowest percentage owned by such stockholders at any time during the prior three&#160;years (calculated on a rolling basis). Similar rules may apply under state tax laws. An entity that experiences an ownership change generally will be subject to an annual limitation on its pre<span class="nobreak">-ownership</span> change tax loss and credit carryforwards equal to the equity value of the corporation immediately before the ownership change, multiplied by the long<span class="nobreak">-term</span>, tax<span class="nobreak">-exempt</span> rate posted monthly by the U.S.&#160;Internal Revenue Service (subject to certain </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">adjustments). The annual limitation would be increased each year to the extent that there is an unused limitation in a prior year. In the event that it is determined that we have in the past experienced an ownership change as a result of transactions in our stock, or if we experience one or more ownership changes as a result of future transactions in our stock, then we may be limited in our ability to use our net operating loss carryforwards and other tax assets to reduce taxes owed on the net taxable income that we earn. Any limitations on the ability to use our net operating loss carryforwards and other tax assets could harm our business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Our insurance coverage may be inadequate or expensive.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We are subject to claims in the ordinary course of business. These claims may involve substantial amounts of money and involve significant defense costs. It is not possible to prevent or detect all activities giving rise to claims and the precautions we take may not be effective in all cases. We maintain voluntary and required insurance coverage, including, among others, general liability, property, director and officer, business interruption, cyber and data breach. Our insurance coverage is expensive and maintaining or expanding our insurance coverage may have an adverse effect on our results of operations and financial condition.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our insurance coverage may be insufficient to protect us against all losses and costs stemming from operational and technological failures and we cannot be certain that such insurance will continue to be available to us on economically reasonable terms, or at all, or that any insurer will not deny coverage as to any future claim. The successful assertion of one or more large claims against us that exceed available insurance coverage, or the occurrence of changes in our insurance policies, including premium increases or the imposition of large retention, or deductible, or co<span class="nobreak">-insurance</span> requirements, could have an adverse effect on our business, financial condition, and results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We entered into an asset purchase agreement and management services agreement with WraSer, which have been terminated because we believe that a material adverse event has occurred with respect to the WraSer Assets. However, the termination is subject to WraSer&#8217;s right to challenge the termination and assert claims against us, and WraSer is likely to commence litigation seeking damages for the termination of the asset purchase agreement.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On June&#160;13, 2023, we entered into the WraSer APA and the WraSer MSA with WraSer in connection with the purchase of the WraSer Assets. Under the WraSer APA, we paid $3.5&#160;million in cash to WraSer at signing. In October&#160;2023, WraSer alerted us that its sole manufacturer for the API for Zontivity, the key driver for the WraSer acquisition, would no longer manufacture the API for Zontivity. We believed that this development constituted a Material Adverse Effect under the WraSer APA enabling us to terminate the WraSer APA and the WraSer MSA.&#160;On October&#160;20, 2023, we filed a motion for relief from the automatic stay in the Bankruptcy Court to exercise our termination rights under the WraSer APA, as amended. On December&#160;18, 2023, the Bankruptcy Court entered an Agreed Order lifting the automatic stay to enable us to exercise our rights to terminate the WraSer APA and the WraSer MSA without prejudice to the parties&#8217; respective rights, remedies, claims, and defenses they had against one another under the WraSer APA and the WraSer MSA.&#160;On December&#160;21, 2023, we filed a Notice with the Bankruptcy Court terminating the WraSer APA and the WraSer MSA.&#160;WraSer has advised us that it does not believe that a Material Adverse Event occurred. WraSer has recently filed a plan of reorganization that indicates it may seek damages from us due to the termination of the APA and MSA. Due to the WraSer bankruptcy filing and our status as an unsecured creditor of WraSer, it is also unlikely that we will recover the $3.5&#160;million Signing Cash or any other advances, costs and resources in connection with services provided by the Company under the WraSer MSA.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">As a result of our failure to timely file our Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30, 2023, we are currently ineligible to file new short form registration statements on Form&#160;S-3, which may impair our ability to raise capital on terms favorable to us, in a timely manner or at all.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Form&#160;S<span class="nobreak">-3</span> permits eligible issuers to conduct registered offerings using a short form registration statement that allows the issuer to incorporate by reference its past and future filings and reports made under the Securities Exchange&#160;Act&#160;of&#160;1934, as amended, or the Exchange&#160;Act. In addition, Form&#160;S<span class="nobreak">-3</span> enables eligible issuers to conduct primary offerings &#8220;off the shelf&#8221; under Rule&#160;415 of the Securities Act&#160;of&#160;1933, as amended, or the Securities Act. The shelf registration process, combined with the ability to forward incorporate information, allows issuers to avoid delays and interruptions in the offering process and to access the capital markets in a more expeditious and efficient manner than raising capital in a standard registered offering pursuant to a Registration Statement on Form&#160;S<span class="nobreak">-1</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As a result of our failure to timely file our Quarterly Report on Form&#160;10<span class="nobreak">-Q</span> for quarter ended June&#160;30, 2023, we are currently ineligible to file new short form registration statements on Form&#160;S<span class="nobreak">-3</span> and are unable to conduct &#8220;off the shelf&#8221; offerings under Rule&#160;415 of the Securities Act using our currently effective Registration Statement on Form&#160;S<span class="nobreak">-3</span> (File No.&#160;333<span class="nobreak">-270383</span>). As a result, we may be unable to conduct an &#8220;at the market&#8221; offering pursuant to our At The Market Offering Agreement with Wainwright after such date. In addition, if we seek to access the capital markets through a registered offering during the period of time that we are unable to use Form&#160;S<span class="nobreak">-3</span>, we may be required to publicly disclose the proposed offering and the material terms thereof before the offering commences, we may experience delays in the offering process due to SEC review of a Form&#160;S<span class="nobreak">-1</span> registration statement and we may incur increased offering and transaction costs and other considerations. Disclosing a public offering prior to the formal commencement of an offering may result in downward pressure on our stock price. In addition, our inability to conduct an offering &#8220;off the shelf&#8221; may require us to offer terms that may not be advantageous (or may be less advantageous) to us or may generally reduce our ability to raise capital in a registered offering. If we are unable to raise capital through a registered offering, we would be required to conduct our financing transactions on a private placement basis, which may be subject to pricing, size and other limitations imposed under Nasdaq rules.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our quarterly and annual revenue and operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. Our quarterly and annual operating results may fluctuate as a result of a variety of factors, many of which are outside our control and, as a result, may not fully reflect the underlying performance of our business. These fluctuations may occur due to a variety of factors, including, but not limited to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the level of demand for our diagnostic tests, which may vary significantly;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing and cost of manufacturing our diagnostic tests, which may vary depending on the quantity of production and the terms of our agreements with third<span class="nobreak">-party</span> suppliers and manufacturers;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>expenditures that we may incur to acquire, develop, or commercialize additional tests and technologies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>unanticipated pricing pressures;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the rate at which we grow our sales force and the speed at which newly hired salespeople become effective, and the cost and level of investment therein;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>currency fluctuations due to our expectation of generating future revenue from international sales, subjecting us to risks such as currency exchange rate volatility;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>geopolitical instability, economics problems, and other uncertainties in certain foreign countries in which we operate;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the degree of competition in our industry and any change in the competitive landscape of our industry, including consolidation among our competitors or future partners; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>coverage and reimbursement policies with respect to cancer treatment equipment, and potential future diagnostic tests that compete with our diagnostic tests.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our future financial results. As a result, comparing our operating results on a period<span class="nobreak">-to-period</span> basis may not be meaningful. Further, our historical results are not necessarily indicative of results expected for any future period, and quarterly results are not necessarily indicative of the results to be expected for the full year or any other period, and accordingly should not be relied upon as indicative of future performance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any guidance we may provide, or if the guidance we provide is below the expectations of analysts or investors, the price of our common stock and warrants could decline substantially. Such a stock price decline could occur even when we have met any publicly stated guidance we may provide, and could in turn negatively impact our business, financial condition and results of operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to the Commercialization of our Products</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We depend entirely on the success of a limited number of products. If we do not successfully commercialize our products or we experience significant delays in doing so, these products may not be profitable.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our business currently depends heavily on the successful commercialization of our products. We cannot be certain that our products will be successfully commercialized. The manufacturing, safety, efficacy, labeling, sale, marketing, and distribution of our products are, and will remain, subject to comprehensive regulation by the FDA and similar foreign regulatory authorities. The success of our products will depend on several additional factors, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>establishing commercial manufacturing capabilities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>launching commercial sales, marketing and distribution operations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>establishing relationships with partners having established distribution, marketing and sales capabilities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the prevalence and severity of adverse events experienced with our products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>acceptance of our products by patients, the medical community, and third<span class="nobreak">-party</span> payors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a continued acceptable safety profile following approval;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>obtaining and maintaining healthcare coverage and adequate reimbursement for our products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>competing effectively with other therapies and diagnostics, including with respect to the sales and marketing of our products; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>qualifying for, maintaining, enforcing, and defending our intellectual property rights and claims.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Many of these factors are beyond our control, including potential threats to our intellectual property rights and changes in the competitive landscape. If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our products, which would materially harm our business, financial condition, and results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Obtaining and maintaining regulatory approval of our products in one jurisdiction does not mean that we will be successful in obtaining regulatory approval in other jurisdictions.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Obtaining and maintaining regulatory approval of our products in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a pharmaceutical product, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing, and promotion of the product in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United&#160;States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United&#160;States, a product must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United&#160;States have requirements for approval of pharmaceutical or diagnostic products with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties, and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our vaccine candidates will be harmed.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Modifications to our product, ENTADFI, may require new FDA approvals.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Once a particular product receives FDA approval, expanded uses or uses in new indications may require additional human clinical trials and new regulatory approvals, including additional IND and/or NDA, and premarket approvals before we can begin clinical development, and/or prior to marketing and sales. If the FDA requires new approvals for a </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">11</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">particular use or indication, we may be required to conduct additional clinical studies, which would require additional expenditures and harm our operating results. If the products are already being used for these new indications, we may also be subject to significant enforcement actions. Conducting clinical trials and obtaining approvals can be a time<span class="nobreak">-consuming</span> process, and delays in obtaining required future approvals could adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Adverse events involving ENTADFI may result in product recalls that could harm our reputation, business, and financial results.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If we or others identify undesirable side effects caused by ENTADFI, several potentially significant negative consequences could result, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>regulatory authorities may suspend or withdraw approvals of such a product;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>regulatory authorities may require additional warnings or limitations of use in product labeling;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>we may be required to change the way a product is distributed, dispensed, or administered or conduct additional clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>we could be sued and held liable for harm caused to patients; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our reputation may suffer.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Any of these events could prevent us from achieving or maintaining market acceptance of ENTADFI and could significantly harm our business, prospects, financial condition, and results of operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Once a product receives FDA approval, the agency has the authority to require the recall of commercialized products in the event of adverse side effects, material deficiencies or defects in design or manufacture. The authority to require a recall must be based on an FDA finding that there is a reasonable probability that the product would cause serious injury or death. Manufacturers may, under their own initiative, recall a product if any material deficiency in a product is found. A government<span class="nobreak">-mandated</span> or voluntary recall by us or one of our distributors could occur as a result of adverse side effects, impurities or other product contamination, manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls of ENTADFI would divert managerial and financial resources and have an adverse effect on our financial condition and results of operations. The FDA requires that certain classifications of recalls be reported to FDA within ten working&#160;days after the recall is initiated. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA.&#160;We may initiate voluntary recalls involving ENTADFI in the future. A future recall announcement could harm our reputation with customers and negatively affect our sales. In addition, the FDA and/or other regulatory agencies could take enforcement action for failing to report the recalls when they were conducted.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If we decide to resume the commercialization of ENTADFI, it may not gain market acceptance among regulators, advisory boards, physicians, patients, third-party payors, and others in the medical community.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If we decide to resume the commercialization of ENTADFI, it may fail to receive recommendations for use by regulators, or gain market acceptance by physicians, patients, third<span class="nobreak">-party</span> payors, and others in the medical community. If ENTADFI does not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of any product will depend on a number of factors, including but not limited to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>receiving governing or advisory recommendations for use, as well as recommendations of comparable foreign regulatory and advisory bodies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>prevalence and severity of the disease targets for which our product is approved;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>physicians, hospitals, third<span class="nobreak">-party</span> payors, and patients considering our product as safe and effective;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential and perceived advantages of our product over existing therapies, including with respect to treatment of disease;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the prevalence and severity of any side effects;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">12</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>product labeling or product insert requirements of the FDA or comparable foreign regulatory and advisory bodies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>limitations or warnings contained in the labeling approved by the FDA or comparable foreign regulatory and advisory bodies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing of market introduction of our products as well as competitive products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the cost of treatment in relation to alternative treatments;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the availability of coverage and adequate reimbursement and pricing by third<span class="nobreak">-party</span> payors, including government authorities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the willingness of patients to pay out<span class="nobreak">-of-pocket</span> in the absence of coverage and adequate reimbursement by third<span class="nobreak">-party</span> payors, including government authorities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>relative convenience and ease of administration, including as compared to competitive products and alternative treatments; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the effectiveness of our sales and marketing efforts.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If our product fails to receive recommendations by governing or advisory bodies in either the United&#160;States or other countries, or achieve market acceptance among physicians, healthcare providers, patients, third<span class="nobreak">-party</span> payors or others in the medical community, we will not be able to generate significant revenue. Even if our product achieves market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our product, are more cost effective or render our product obsolete.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Even if we are able to commercialize our products, they may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The regulations that govern marketing approvals, pricing, coverage, and reimbursement for new drugs and diagnostics vary widely from country to country. In the United&#160;States, new and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product<span class="nobreak">-licensing</span> approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial marketing approval is granted.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our ability to commercialize our products successfully also will depend in part on the extent to which coverage and adequate reimbursement for this product and related treatments will be available from government health programs, private health insurers, integrated delivery networks and other third<span class="nobreak">-party</span> payors. Third<span class="nobreak">-party</span> payors decide which drugs they will pay for and establish reimbursement levels. A significant trend in the U.S.&#160;healthcare industry and elsewhere is cost containment. Government authorities and third<span class="nobreak">-party</span> payors have attempted to control costs by limiting coverage and the amount of payment for particular drugs. Increasingly, third<span class="nobreak">-party</span> payors are requiring that drug companies provide predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, if reimbursement is available, the level of reimbursement may not be sufficient for commercial success. Coverage and reimbursement may impact the demand for, or the price of, our product. If coverage and reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize our product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">There may be significant delays in obtaining coverage and adequate reimbursement for newly approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or similar regulatory authorities outside the United&#160;States. Moreover, eligibility for coverage and reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Coverage and reimbursement rates may vary according to the use of the drug and the medical circumstances under which it is used may be based on reimbursement levels already set for lower cost products or procedures or may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">13</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United&#160;States. Commercial third<span class="nobreak">-party</span> payors often rely upon Medicare coverage policies and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government<span class="nobreak">-funded</span> programs and private payors for our product could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize our product and our overall financial condition.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Our products could be subject to marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our products, along with the manufacturing processes and facilities, post<span class="nobreak">-approval</span> clinical data, labeling, advertising, and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of promotional materials and safety and other post<span class="nobreak">-marketing</span> information and reports, registration and listing requirements, current Good Manufacturing Practice (&#8220;cGMP&#8221;) requirements for product facilities, quality assurance and corresponding maintenance of records and documents and requirements regarding the distribution of samples to physicians and related recordkeeping. The FDA closely regulates the post<span class="nobreak">-approval</span> marketing and promotion of drugs to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. However, companies may share truthful and not misleading information that is otherwise consistent with the product&#8217;s FDA approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off<span class="nobreak">-label</span> use and if we do not comply with these restrictions, we may be subject to enforcement actions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In addition, later discovery of previously unknown problems with our products, manufacturers or manufacturing processes and facilities or failure to comply with regulatory requirements, may result in, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>restrictions on our products, manufacturers or manufacturing processes or facilities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>restrictions on the labeling, marketing, distribution, or use of a product;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>requirements to conduct post<span class="nobreak">-approval</span> clinical trials, other studies, or other post<span class="nobreak">-approval</span> commitments;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>warning or untitled letters;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>withdrawal or recall of our products from the market;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>refusal to approve pending applications or supplements to approved applications that we submit;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>fines, restitution or disgorgement of profits or revenue;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>suspension or withdrawal of marketing approval;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>refusal to permit the import or export of our products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>product seizure; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>injunctions or the imposition of civil or criminal penalties.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Failure to obtain regulatory approvals in foreign jurisdictions will prevent us from marketing our products internationally.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We intend to market future products in international markets. In order to market our future products in regions such as the EEA, Asia Pacific, and many other foreign jurisdictions, we must obtain separate regulatory approvals.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">For example, in the EEA, medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA.&#160;Before granting the MA, the European Medicines Agency, or the competent authorities of the member states of the EEA make an assessment of the risk<span class="nobreak">-benefit</span> balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. In Japan, the Pharmaceuticals and Medical Devices Agency, or the PMDA, of the Ministry of Health Labour and Welfare, or MHLW, must approve an application under the Pharmaceutical Affairs Act before a new drug product may be marketed in Japan.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">14</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We have had limited interactions with foreign regulatory authorities. The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA approval. Moreover, clinical studies conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA.&#160;However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not obtain foreign regulatory approvals on a timely basis, if at all. We may not be able to file for regulatory approvals and even if we file, we may not receive necessary approvals to commercialize our products in any market.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Legislation, such as the Inflation Reduction Act, may impact our ability to market and commercialize ENTADFI and reduce our profitability from such asset.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Legislation, either in the United&#160;States or in a foreign country, may impact our ability to market and commercialize ENTADFI and may reduce our profitability from such asset. For example, the Inflation Reduction Act (&#8220;IRA&#8221;) was signed into law in the United&#160;States in 2022 and intended to lower out<span class="nobreak">-of-pocket</span> costs associated with pharmaceutical drugs. Key impacts of the IRA include the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Medicare can now directly negotiate lower prescription drug prices with pharmaceutical manufacturers;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the cost of insulin for Medicare beneficiaries is now capped at $35;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>all recommended adult vaccines are free; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>drug companies are required to pay rebates if they raise prices of their products faster than the rate of inflation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Should we decide to raise the price of ENTADFI, and raise it higher than the rate of inflation, we may be exposed to rebates owed to Medicare. This may affect the profitability of our product and reduce revenues associated with it.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Company shareholders may not realize a benefit from the ENTADFI or Proteomedix acquisitions commensurate with the ownership dilution they have experienced in connection with the transactions.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If the Company is unable to realize the full strategic and financial benefits currently anticipated from the recent ENTADFI and Proteomedix acquisitions, our shareholders may experience a dilution of their ownership interests in our Company without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent the Company is able to realize only part of the strategic and financial benefits currently anticipated from the transactions.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We expect to rely on third-party manufacturers for ENTADFI and Proclarix.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">For the foreseeable future, we expect to and do rely on third<span class="nobreak">-party</span> manufacturers and other third parties to produce, package and store sufficient quantities of Proclarix and ENTADFI (if we decide to resume its commercialization) to meet demand. ENTADFI and Proclarix are complicated and expensive to manufacture. If our third<span class="nobreak">-party</span> manufacturers fail to deliver ENTADFI or Proclarix for commercial sale on a timely basis, with sufficient quality, and at commercially reasonable prices, we may be required to delay or suspend commercial sales and/or production of ENTADFI and Proclarix. While we may be able to identify replacement third<span class="nobreak">-party</span> manufacturers or develop our own manufacturing capabilities for ENTADFI and Proclarix, this process would likely cause a delay in the availability of ENTADFI and/or Proclarix and an increase in costs. In addition, third<span class="nobreak">-party</span> manufacturers may have a limited number of facilities in which ENTADFI and Proclarix can be produced, and any interruption of the operation of those facilities due to events such as equipment malfunction or failure or damage to the facility by natural disasters could result in the cancellation of shipments, loss of product in the manufacturing process or a shortfall in ENTADFI and Proclarix.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">15</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In addition, regulatory requirements could pose barriers to the manufacture of ENTADFI and Proclarix. Third<span class="nobreak">-party</span> manufacturers are required to comply with the FDA&#8217;s cGMPs for ENTADFI and to register their activities and manufactured devices in databases and for Proclarix, manufacturers and developers (software) are required to comply with ISO 13485 and the host of the software with ISO 27001; these parties can be then subject to audits or inspections. As a result, the facilities used by any manufacturers of ENTADFI must maintain a compliance status acceptable to the FDA.&#160;Holders of NDAs, or other forms of FDA approvals or clearances, or those distributing a regulated product under their own name, are responsible for manufacturing even though that manufacturing is conducted by a third<span class="nobreak">-party</span> CMO.&#160;Our third<span class="nobreak">-party</span> manufacturers will be required to produce ENTADFI under FDA cGMPs in order to meet acceptable standards. Our third<span class="nobreak">-party</span> manufacturers may not perform their obligations under their agreements with us or may discontinue their business before the time required by us to commercialize our products. In addition, our manufacturers will be subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for compliance with cGMPs and similar regulatory requirements. For medical devices in United&#160;States, the contract manufacturer will be subject to FDA inspections (while in the EU, these would be subject to Notified Body audits (on demand)). Failure by any of our manufacturers to comply with applicable cGMPs, ISO 13485, ISO 27001 or applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspensions or withdrawals of approvals, operating restrictions, interruptions in supply, recalls, withdrawals, issuance of safety alerts and criminal prosecutions, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Finally, we also could experience manufacturing delays if our CMOs give greater priority to the supply of other products over ENTADFI or Proclarix or otherwise do not satisfactorily perform according to the terms of their agreements with us.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If any supplier for ENTADFI or Proclarix experiences any significant difficulties in its manufacturing processes, does not comply with the terms of the agreement between us or does not devote sufficient time, energy and care to providing our manufacturing needs, we could experience significant interruptions in the supply of ENTADFI and/or Proclarix, which could impair our ability to supply ENTADFI and/or Proclarix at the levels required for commercialization and prevent or delay its successful development and commercialization.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Disruptions to or significantly increased costs associated with transportation and other distribution channels for ENTADFI and/or Proclarix may adversely affect our margins and profitability.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We expect to rely on the uninterrupted and efficient operation of third<span class="nobreak">-party</span> logistics companies to transport and deliver ENTADFI and Proclarix. These third<span class="nobreak">-party</span> logistics companies may experience disruptions to the transportation channels used to distribute our products, increased airport and shipping port congestion, a lack of transportation capacity, increased fuel expenses, and a shortage of manpower or capital or due to other business interruptions. Disruptions to the transportation channels experienced by our third<span class="nobreak">-party</span> logistics companies may result in increased costs, including the additional use of airfreight to meet demand. Disruptions to this business model or our relationship with the third party if, for example, performance fails to meet our expectations, could harm our business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We may fail or elect not to commercialize our products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We may not successfully commercialize our products. We or our collaboration partners in any potential commercial marketing efforts of our products may not be successful in achieving widespread patient or physician awareness or acceptance of this product. Also, we may be subject to pricing pressures from competitive products or from governmental or commercial payors or regulatory bodies that could make it difficult or impossible for us to commercialize our products. Any failure to commercialize our products could have a material adverse effect on our future revenue and our business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In light of (i)&#160;the time and resources needed to continue pursuing commercialization of ENTADFI, and (ii)&#160;the Company&#8217;s cash runway and indebtedness, the Company has determined to temporarily pause its commercialization of ENTADFI, as it considers strategic alternatives. The Company continues to consider various measures, including strategic alternatives, to rationalize its operations and optimize its existing Proclarix diagnostic program.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If we fail to commercialize our products, our business, financial condition, results of operations and prospects may be materially adversely affected and our reputation in the industry and in the investment community would likely be damaged.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">16</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We may not be able to gain and retain market acceptance for our products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Physicians and other authorized health care practitioners may not prescribe our products, which would prevent our products from generating revenue. Market acceptance of our products by healthcare providers, patients and payors, will depend on a number of factors, many of which are beyond our control, including the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the clinical indications for which our products are approved;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>acceptance by healthcare providers and payors of our products as safe and effective treatment or test;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the cost in relation to alternative treatments or tests;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the relative convenience and ease of administration of our products for the conditions for which they are intended;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the availability and efficacy of competitive drugs or tests;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the effectiveness of our sales and marketing efforts;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the extent to which our products are approved for inclusion on formularies of hospitals and managed care organizations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the availability of coverage and adequate reimbursement by third parties, such as insurance companies and other health care payors, or by government health care programs, including Medicare and Medicaid;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>limitations or warnings contained in a product&#8217;s FDA or other applicable regulatory agency&#8217;s approved labeling; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>prevalence and severity of adverse side effects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Even if the medical community accepts that our products are safe and efficacious for its approved indications, healthcare providers may not immediately be receptive to the use or may be slow to adopt such products as an accepted treatment or test for the conditions for which it is intended. Without head<span class="nobreak">-to-head</span> comparative data, we will also not be able to promote our products as being superior to competing products. If our products do not achieve an adequate level of acceptance by healthcare providers and payors, we may not generate sufficient or any revenue from this product. In addition, our efforts to educate the medical community and third<span class="nobreak">-party</span> payors on the benefits of our product may require significant resources and may never be successful.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In addition, even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>unforeseen complications arise with respect to use of our products or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>sufficient third<span class="nobreak">-party</span> insurance coverage or reimbursement does not remain available.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Proclarix is subject to competition from other prostate cancer diagnostics and larger, well-established companies with substantially greater resources than us.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The molecular diagnostics field is intensely competitive and characterized by rapid technological changes, frequent new product introductions, changing customer preferences, emerging competition, evolving industry standards, reimbursement uncertainty and price competition. Moreover, recent consolidation in the industry permits larger clinical laboratory service providers to increase cost efficiencies and service levels, resulting in more intense competition.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The market for assessing men at risk for prostate cancer is large, with many competitors some of which possess substantially greater financial, selling, logistical and laboratory resources, more experience in dealing with third<span class="nobreak">-party</span> payors, and greater market penetration, purchasing power and marketing budgets, as well as more experience in providing diagnostic services. Some companies and institutions are developing liquid biopsy (blood and urine)<span class="nobreak">-based</span> </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">17</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">tests and diagnostic tests based on the detection of proteins, mRNA, nucleic acids, or the presence of fragments of mutated genes that are associated with prostate cancer. These competitors could have technological, financial, reputational, and market access advantages over us.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ENTADFI is subject to competition from other BPH drugs and larger, well-established companies with substantially greater resources than us.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We are engaged in the marketing of a product in industries, including the pharmaceutical industry, that are highly competitive. The pharmaceutical industry is also characterized by extensive research and rapid technological progress. Potential competitors with respect to ENTADFI in North America, Europe and elsewhere include major pharmaceutical companies, specialty pharmaceutical companies and biotechnology firms, universities and other research institutions and government agencies. Many of our competitors have substantially greater research and development and regulatory capabilities and experience, and substantially greater management, manufacturing, distribution, marketing, and financial resources, than we have. We may be unable to compete successfully against current and future competitors, and competitive pressures could have a negative effect on our net revenues and profit margins.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Zydus Life Sciences recently received FDA approval for a combined finasteride<span class="nobreak">-tadalafil</span> (5&#160;mg/5&#160;mg) capsule, pursuant to the FDA&#8217;s Competitive Generic Therapy Program, which was designed to enhance patient access to affordable medications by encouraging the development and commercialization of generic drugs in clinical areas with limited generic options for patients. Pursuant to the program, Zydus has a 180<span class="nobreak">-day</span> period to be the sole supplier of the generic version of the drug in the market and during this period, other generic manufacturers cannot enter the market with their versions of the same drug, provided that Zydus commences marketing the drug by 75&#160;days from approval. As a result, there is a risk that the Company will face additional challenges in resuming commercializing ENTADFI, if it chooses to do so.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Other parties have developed and marketed drugs for BPH that have been accepted by the healthcare provider, patient, and payor communities. Many of these other products have also reached the point where they are now generic drugs, which means that they are sold at a very low price, a price which ENTADFI may not be able to meet which could limit the reach of ENTADFI into the healthcare provider, patient, and payor communities, including government payors.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We may not be able to successfully implement our strategy to grow sales of ENTADFI in the U.S.&#160;market and Proclarix in the European markets or, if authorized, grow sales of either in any other market.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We may not be able to expand sales of ENTADFI or Proclarix through partnering with telemedicine or other partners or with commercial diagnostic providers or through our own commercialization efforts. We may not be able to command a price with private and government payors for ENTADFI or Proclarix that would justify our devotion of significant resources to attempting to grow sales of ENTADFI or Proclarix. We may not be able to compete efficiently or effectively in a mature market, which is heavily generic, or the prostate cancer diagnostics market, which is highly competitive. Failure to grow sales of ENTADFI or Proclarix would have a negative effect on our revenue and future plans.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The commercial success of our in-development and future diagnostic tests and services and our revenue growth depend upon attaining significant market acceptance among payers, providers, clinics, patients, and biopharmaceutical companies.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our commercial success depends, in part, on the acceptance of our diagnostic tests and services as being safe and relatively simple for medical personnel to learn and use, clinically flexible, operationally versatile and, with respect to providers and payers, cost effective. We cannot predict how quickly, if at all, payers, providers, clinics, and patients will accept future diagnostic tests and services or, if accepted, how frequently they will be used. These constituents must believe that our diagnostic tests offer benefits over other available alternatives.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The degree of market acceptance of our current and future diagnostic tests and services depends on a number of factors, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>whether there is adequate utilization of our tests by clinicians, laboratories and other target groups based on the potential and perceived advantages of our diagnostic tests over those of our competitors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the convenience and ease of use of our diagnostic tests relative to those currently on the market;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">18</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the effectiveness of our sales and marketing efforts;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the ability of our distribution partners to meet sales forecasts;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our ability to provide incremental data that show the clinical benefits and cost effectiveness, and operational benefits, of our diagnostic tests;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the coverage and reimbursement acceptance of our products and services;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pricing pressure, including from group purchasing organizations (&#8220;GPOs&#8221;), seeking to obtain discounts on our diagnostic tests based on the collective bargaining power of the GPO members;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>negative publicity regarding our or our competitors&#8217; diagnostic tests resulting from defects or errors; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the diagnostic sensitivity and diagnostic specificity of our tests relative to those of our competitors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, even if our diagnostic tests achieve widespread market acceptance, they may not maintain that market acceptance over time if competing diagnostic tests or technologies, which are more cost effective or are received more favorably, are introduced. Failure to achieve or maintain market acceptance and/or market share would limit our ability to generate revenue and would have a material adverse effect on our business, financial condition, and results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If we fail to increase our sales and marketing capabilities or develop broad awareness of our diagnostic tests in a cost-effective manner, we may not be able to generate revenue growth.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We plan to dedicate significant resources to the expansion of our distribution network and to supporting their marketing efforts. It will negatively affect our business, financial condition, and results of operations if our marketing efforts and expenditures do not generate a corresponding increase in revenue. In addition, we believe that developing and maintaining broad awareness of our diagnostic tests in a cost<span class="nobreak">-effective</span> manner is critical to achieving broad acceptance of our diagnostic tests. Promotional activities may not generate patient or physician awareness or increase revenue, and even if they do, any increase in revenue may not offset the costs and expenses we incur in building our brand. If we fail to successfully promote, maintain and protect our brand, we may fail to attract or retain the physician acceptance necessary to realize a sufficient return on our brand building efforts, or to achieve the level of brand awareness that is critical for broad use of our diagnostic tests, which in turn could have a material adverse effect on our business, financial condition and results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If we cannot maintain our current relationships, or enter into new relationships, with CROs, universities, clinics, laboratories or tissue sample banks, our revenue prospects could be reduced.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We engage contract research organizations, universities, clinics, and tissue banks to enroll or access patients primarily to support clinical studies. The ability of our contractors to enroll patients in clinical studies may also fluctuate in the future, which could have a material adverse effect on our product development timelines, financial condition and results of operations. In addition, the termination of these relationships could result in a temporary or prolonged delay in commercial launches resulting in a loss of revenue.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We engage in conversations with diagnostic laboratories regarding potential commercial opportunities on an ongoing basis. There is no assurance that any of these conversations will result in a commercial agreement, or if an agreement is reached, that the resulting relationship will be successful or that clinical or research studies conducted as part of the engagement will produce successful outcomes. Speculation in the industry about our existing or potential relationships with diagnostic laboratories and biopharmaceutical companies can also be a catalyst for adverse speculation about us, our tests and our technology, which can adversely affect our reputation and our business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We need to ensure strong product performance and quality to maintain and grow our business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We will need to maintain and continuously improve the performance of our diagnostic tests to maintain CE marking or other applicable market approvals and compliance with QMS (ISO 13485). Poor product performance and quality could lead to customer dissatisfaction, adversely affect our reputation and revenues, and increase our service and distribution costs and working capital requirements. Our diagnostic tests may contain errors or defects, </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">19</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">and while we have made efforts to control them extensively, we cannot assure that our current diagnostic tests, or those developed in the future, will not have performance problems. Any performance issues with our diagnostic tests now or in the future will increase our costs and accordingly adversely affect our business, financial condition, and results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The sizes of the markets for our diagnostic tests and services and any future diagnostic tests and services may be smaller than we estimate and may decline.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our estimates of the annual total addressable market for our diagnostic tests and services are based on a number of internal and third<span class="nobreak">-party</span> estimates and assumptions, including, without limitation, the assumed prices at which we can sell our diagnostic tests and services in the market. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As a result, our estimates of the annual total addressable market for our diagnostic tests and services in different market segments may prove to be incorrect. If the actual number of patients who would benefit from our diagnostic tests, the price at which we can sell them or the annual total addressable market for them is smaller than we have estimated, it may impair our sales growth and negatively affect our business, financial condition and results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We have a significant customer concentration, with a limited number of customers accounting for a large portion or all of our revenues.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We derive a large portion or all of our revenues from a few major customers. For the year ended December&#160;31, 2023, we generated 100% of our revenue from one customer, in the context of a partnership with Immunovia AB (Sweden). In 2022, Immunovia AB partnered with Proteomedix to leverage Proteomedix&#8217;s research and development capabilities and to advance their research and development efforts.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">There are inherent risks whenever a large percentage of the total revenue is concentrated with a few customers. It is not possible for us to predict the future level of demand for our products that will be generated by these customers or the future demand for our products by these customers. If any of these customers&#8217; demands decline or delayed demands due to market, economic or competitive conditions, we could be pressured to reduce our prices, which could have an adverse effect on our financial position and could negatively affect our revenues and results of operations. If any of our largest customers terminate the purchase of our products, such termination would materially negatively affect our revenues, results of operations and financial condition.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Our results of operations will be materially harmed if we are unable to accurately forecast customer demand for, and utilization of, our diagnostic tests and manage our inventory.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">To ensure adequate inventory supply, we must forecast inventory needs and manufacture our diagnostic tests based on our estimates of future demand for our diagnostic tests. Our ability to accurately forecast demand for them could be negatively affected by many factors, including our failure to accurately manage our expansion strategy, product introductions by competitors, an increase or decrease in customer demand for our diagnostic tests or for those of our competitors, our failure to accurately forecast customer acceptance of new diagnostic tests, unanticipated changes in general market conditions or regulatory matters and weakening of economic conditions or consumer confidence in future economic conditions. Inventory levels in excess of customer demand may result in inventory write<span class="nobreak">-downs</span> or write<span class="nobreak">-offs</span>, which would cause our gross margin to be adversely affected and could impair the strength of our brand. Conversely, if we underestimate customer demand for our diagnostic tests, our supply chain, manufacturing partners and/or internal manufacturing team may not be able to deliver components and diagnostic tests to meet our requirements, and this could result in damage to our reputation, sales growth, and customer relationships. In addition, if we experience a significant increase in demand, additional supplies of raw materials or additional manufacturing capacity may not be available when required on terms that are acceptable to us, or at all, or suppliers may not be able to allocate sufficient capacity in order to meet our increased requirements, which will adversely affect our business, financial condition and results of operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">20</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The timing of our new product offerings is uncertain.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We have multiple products in various phases of development, and we intend to devote considerable future resources to research and product development, our core business strategy. There can be no assurance that our development activities will always produce tests with the sensitivity and specificity necessary to be clinically and commercially competitive, or that any test will result in a commercially successful product. In addition, before we can develop diagnostic tests for new cancers or other diseases and commercialize any new products, we will need to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>conduct substantial research and development;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>conduct analytical and clinical performance testing (verification and validation); and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>expend significant funds.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our product development process involves a high degree of risk and may take several&#160;years in some instances. Our product development efforts may fail for many reasons, including, but not limited to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure of the product at the research or development phase;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>difficulty in accessing samples, especially samples with known clinical results; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>lack of clinical performance data to support the safety and effectiveness of the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Few research and development projects result in commercial products, and success in early clinical trials often is not replicated in later studies. At any point, we may abandon development of a product candidate, or we may be required to expend considerable resources repeating clinical trials, which would adversely impact the timing for generating potential revenues from those product candidates. In addition, as we develop products, we will have to make significant investments in product development. If a clinical validation study fails to demonstrate the prospectively defined endpoints of the study, we might choose to abandon the development of the product or product feature that was the subject of the clinical trial, which could harm its business. In addition, our competitors may develop and commercialize competing products faster than we are able to do so.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Our access to samples may hinder our ability to research, develop, and commercialize future products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our planned and future products are focused primarily on exploitation of blood plasma or serum as a medium for both biomarker identification and validation and ultimately for our commercial testing applications. Our clinical development relies on our ability to secure access to high quality, well<span class="nobreak">-characterized</span> samples, as well as information pertaining to the samples associated clinical outcomes. Our competitors have demonstrated their ability to obtain these samples and often compete with us for access to such samples. Additionally, the process of negotiating access to samples is lengthy since it typically involves numerous parties and approval levels to resolve complex issues such as usage rights, institutional review board (ethical) approval, privacy rights, publication rights, intellectual property ownership and research parameters. If we are not able to negotiate access to samples with hospitals, clinical partners, or other companies on a timely basis, or at all, or if competitors secure access to these samples before us, then our ability to research, develop, and commercialize future products will be limited or delayed.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Adherence to complex test protocols is required.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We validate our tests in our lab in Switzerland using blood samples obtained from a variety of sources. Tests results can be affected by a number of variables including how the blood is extracted, how the blood is handled, the type of test tube used, the number and speed of centrifuge spins, the temperature the blood is exposed to during processing, the concentration of the reagents, and the timing of reagent use. All of these and other variables in the process are set forth in an assay protocol that we provide to our distributor lab partners along with training in proper compliance. If, due to human or equipment failure, there is material deviation from the protocols, the accuracy of our tests can be negatively impacted. If that occurs, the reputation of our products and our revenue could be negatively impacted.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">21</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to our Business and Industry</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Our reliance on third parties heightens the risks faced by our business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We rely on suppliers, vendors, subcontractors, and partners for certain key aspects of our business, including support for information technology systems and certain human resource functions. We do not control these partners, but we depend on them in ways that may be significant to us. However, if these parties fail to meet their defined obligations to us, we may fail to receive the expected benefits. In addition, if any of these third parties fails to comply with applicable laws and regulations in the course of its performance of services for us, there is a risk that we may be held responsible for such violations as well. This risk is particularly serious in emerging markets, where corruption is often prevalent and where many of the third parties on which we rely do not have internal compliance resources comparable to our own. Any such failures by third parties, in emerging markets or elsewhere, could adversely affect our business, reputation, financial condition or results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We are dependent on third parties to market, distribute and sell our products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our ability to receive revenues is dependent upon the sales and marketing efforts of co<span class="nobreak">-marketing</span> partners and third<span class="nobreak">-party</span> distributors. If we fail to reach an agreement with any commercialization partner, or upon reaching such an agreement that partner fails to sell a large volume of our products, it may have a negative impact on our business, financial condition, and results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We have no experience manufacturing our products on a commercial scale and are dependent on third parties for the manufacture of our products. If we experience problems with any of these third parties, they could delay our ability to sell our products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We do not have any manufacturing facilities. We will rely on third<span class="nobreak">-party</span> manufacturers for commercial supply of Proclarix and ENTADFI (if we resume the commercialization of ENTADFI).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We may be unable to establish agreements with third<span class="nobreak">-party</span> manufacturers for commercial supply on terms favorable to us, or at all. Even if we are able to establish agreements with third<span class="nobreak">-party</span> manufacturers, reliance on third<span class="nobreak">-party</span> manufacturers entails additional risks, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>reliance on the third party for regulatory compliance and through quality management system;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possible breach of the manufacturing agreement by the third party, including the inability to supply sufficient quantities or to meet quality standards or timelines; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Third<span class="nobreak">-party</span> manufacturers may not be able to comply with U.S.&#160;cGMPs, QSR or similar regulatory requirements outside the United&#160;States. Our failure, or the failure of our third<span class="nobreak">-party</span> manufacturers, to comply with cGMPs or other applicable regulations, even if such failures do not relate specifically to our products, could result in sanctions being imposed on us or the manufacturers, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or product recalls, operating restrictions and criminal prosecutions, any of which could adversely affect supplies of our products and harm our business and results of operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our products may compete with other products and/or product candidates and products for access to these manufacturing facilities. There are a limited number of manufacturers that operate under cGMPs and that might be capable of manufacturing for us.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Any performance failure on the part of our manufacturers, including a failure that may not relate specifically to our products, could adversely impact our ability to generate commercial sales. If our contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our anticipated future dependence upon others for the manufacture of our products may adversely affect our future profit margins and our ability to commercialize our products on a timely and competitive basis.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, our manufacturers and suppliers may experience difficulties related to their overall business and financial stability, which could result in delays or interruptions of supply of our products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">22</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Manufacturing risks may adversely affect our ability to manufacture our product and could reduce our gross margin and profitability.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our business strategy depends on our ability to manufacture our products in sufficient quantities and on a timely basis so as to meet consumer demand, while adhering to product quality standards, complying with regulatory requirements and managing manufacturing costs. We are subject to numerous risks relating to our manufacturing capabilities, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>quality or reliability defects in product components that we source from third<span class="nobreak">-party</span> suppliers, including manufacturing compliance with federal and state regulations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our inability to secure product components in a timely manner, in sufficient quantities or on commercially reasonable terms;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our failure to increase production of products to meet demand;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our inability to modify production lines to enable us to efficiently implement changes in response to regulatory requirements; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Potential damage to or destruction of our manufacturing equipment or manufacturing facility.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If demand for our products increases in the future, we will have to invest additional resources to purchase components, hire and train employees, and enhance our manufacturing processes. If we fail to increase our production capacity efficiently, our sales may not increase in line with our forecasts and our operating margins could fluctuate or decline. Manufacturing of our products may require the modification of our production lines, the hiring of specialized employees, the identification of new suppliers for specific components, or the development of new manufacturing technologies. It may not be possible for us to manufacture these products at a cost or in quantities sufficient to make these products commercially viable. Any of these factors may affect our ability to manufacture our product and could reduce our gross margin and profitability.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We maintain single supply relationships for certain key components, and our business and operating results could be harmed if supply is restricted or ends or the price of raw materials used in its manufacturing process increases.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We are dependent on sole suppliers or a limited number of suppliers for certain components that are integral to its finished products. If these or other suppliers encounter financial, operating or other difficulties or if our relationship with them changes, we may be unable to quickly establish or qualify replacement sources of supply and could face production interruptions, delays and inefficiencies. In addition, technology changes by our vendors could disrupt access to the required manufacturing capacity or require expensive, time<span class="nobreak">-consuming</span> development efforts to adapt and integrate new equipment or processes. Our growth may exceed the capacity of one or more of these suppliers to produce the needed equipment and materials in sufficient quantities to support our growth. Any one of these factors could harm our business and growth prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We may not be able to manage our manufacturing and supply chain effectively, which would harm our results of operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We must accurately forecast market demand for our products in order to have adequate product inventory available to fulfil our timeline and customer orders timely. Our forecasts will be based on multiple assumptions that may cause our estimates to be inaccurate, and thus affect our ability to ensure adequate manufacturing capability to satisfy market demand. Any material delay in our ability to obtain timely product inventories from our manufacturing facility and our ingredient suppliers could prevent us from satisfying increased consumer demand for our products, resulting in material harm to our brand and business. In addition, we will need to continuously monitor our inventory and product mix against forecasted demand to avoid having inadequate product inventory or having too much product inventory on hand. If we are unable to manage our supply chain effectively, our operating costs may increase materially.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We may in the future have conflicts with our current or future partners or third-party providers that could delay or prevent the commercialization of our current products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We may in the future have conflicts with our current or future partners or third<span class="nobreak">-party</span> providers, such as conflicts concerning the achievement of milestones, the interpretation of contractual obligations, payments for services, development obligations or the ownership of intellectual property developed during our collaboration. If any conflicts </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">23</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">arise with any of our partners, such partner may act in a manner that is adverse to our best interests. Any such disagreement could result in one or more of the following, each of which could delay or prevent the commercialization of our current products, and in turn prevent us from generating revenues:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>unwillingness on the part of a partner to pay us milestone payments or royalties we believe are due to us under a collaboration;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>uncertainty regarding ownership of intellectual property rights arising from our collaborative activities, which could prevent us from entering into additional collaborations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>unwillingness by the partner to cooperate in the manufacture of the product, including providing us with product data or materials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>unwillingness on the part of a partner to keep us informed regarding the progress of its commercialization activities or to permit public disclosure of the results of those activities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>initiating of litigation or alternative dispute resolution options by either party to resolve the dispute; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>attempts by either party to terminate the agreement.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of our products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We face an inherent risk of product liability exposure related to the commercialization of our products. Product liability claims may be brought against us by patients, healthcare providers or others using, administering, or selling our product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In addition, we face an inherent risk of product liability as a result of the marketing and sale of Proteomedix&#8217;s diagnostic tests and services. For example, we may be sued if the diagnostic tests or services cause or are perceived to cause injury or are found to be otherwise unsuitable during manufacturing, marketing, or sale. Any such product liability claim may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, or a breach of warranties. In addition, we may be subject to claims against us even if the apparent injury is due to the actions of others or the pre<span class="nobreak">-existing</span> health of the patient. For example, medical personnel, care partners and patients collect samples for our diagnostic tests. If these medical personnel, care partners or patients are not properly trained, are negligent or use our diagnostic tests incorrectly, the capabilities of such tests may be diminished, or the patient may suffer critical injury. We may also be subject to claims that are caused by the activities of our suppliers, such as those who provide us with components and sub<span class="nobreak">-assemblies</span> for our diagnostic tests.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or halt the marketing and sale of our diagnostic tests and services. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>decreased demand for our products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>injury to our reputation and significant negative media attention;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>significant costs to defend the related litigation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>substantial monetary awards to patients;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>loss of revenue;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>diversion of management and scientific resources from our business operations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the inability to commercialize our products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the initiation of investigations by regulators; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>product recalls, withdrawals, or labeling, marketing, or promotional restrictions.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">24</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We have product liability insurance coverage at a level that we believe is customary for similarly situated companies and adequate to provide us with insurance coverage for foreseeable risks. However, we may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise, and such insurance may not be adequate to cover all liabilities that we may incur. Furthermore, we intend to expand our insurance coverage for products to include the sale of commercial products if we obtain regulatory approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products that receive regulatory approval. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim, or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash, and adversely affect our business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In the future, we may enter into transactions to acquire other businesses, products or technologies. If we do identify suitable candidates, we may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may fail to strengthen our competitive position and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies, and operations into our existing business in an effective, timely and non<span class="nobreak">-disruptive</span> manner. Acquisitions may also divert management attention from&#160;day<span class="nobreak">-to-day</span> responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or the effect that any such transactions might have on our operating results.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Security threats to our information technology infrastructure and/or our physical buildings could expose us to liability and damage our reputation and business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">It is essential to our business strategy that our technology and network infrastructure and our physical buildings remain secure and are perceived by our customers and corporate partners to be secure. Despite security measures, however, any network infrastructure may be vulnerable to cyber<span class="nobreak">-attacks</span> by hackers and other security threats. We may face cyber<span class="nobreak">-attacks</span> that attempt to penetrate our network security, sabotage, or otherwise disable our, products and services, misappropriate our or our customers&#8217; and partners&#8217; proprietary information, which may include personally identifiable information, or cause interruptions of our internal systems and services. Despite security measures, we also cannot guarantee the security of our physical buildings. Physical building penetration or any cyber<span class="nobreak">-attacks</span> could negatively affect our reputation, damage our network infrastructure and our ability to deploy our products and services, harm our relationship with customers and partners that are affected, and expose us to financial liability.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, there are a number of state, federal and international laws governing the collection, use, processing and protection of health information and personal data. Most states have data security breach laws requiring data protection measures and potentially requiring notification to regulators and impacted consumers. The Health Insurance Portability and Accountability Act&#160;of&#160;1996, as amended by the Health Information Technology for Economic and Clinical Health Act&#160;of&#160;2009 (collectively, &#8220;HIPAA&#8221;), imposes limitations on the use and disclosure of an individual&#8217;s healthcare information &#8220;covered entities,&#8221; which include by healthcare providers who submit certain standard transactions electronically (mostly related to claims for payment from health insurers), healthcare clearinghouses, and health insurance plans, and also grants individuals rights with respect to their health information. Although we do not currently submit standard transactions electronically and therefore are not a HIPAA covered entity, HIPAA has been in effect for over 20&#160;years and accordingly individuals expect that providers of health care items or services will safeguard their health information in accordance with HIPAA.&#160;Moreover, many states&#8217; laws impose similar or more stringent limitations on uses and disclosures of healthcare information than does HIPAA, and such laws also provide individuals rights to access, amend, and withhold sharing of their health information. HIPAA also requires reporting of certain impermissible uses and disclosures of health information, including security breaches, to affected individuals, the Office for Civil Rights of the U.S.&#160;Department of Health and Human Services, and in some cases the media. Notification is not required under HIPAA if the health information that is improperly used or disclosed is deemed secured in accordance with encryption or other standards developed by the U.S.&#160;Department of Health and Human Services. Most states also have laws requiring notification of affected individuals and/or state regulators in </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">25</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA.&#160;Many state laws impose significant data security requirements, such as encryption or mandatory contractual terms, to ensure ongoing protection of personal information. Activities outside of the U.S.&#160;implicate local and national data protection standards, impose additional compliance requirements, and generate additional risks of enforcement for non<span class="nobreak">-compliance</span>. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws, to protect against security breaches and hackers or to alleviate problems caused by such breaches.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We will need to grow the size of our organization in the future, and we may experience difficulties in managing this growth.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">As of April<span class="nobreak"> </span>24, 2024, we had 12 full<span class="nobreak">-time</span> and 11 subcontracted employees. As part of a cost reduction plan approved by the Board and in connection with our pause in commercializing ENTADFI, we terminated three employees involved with the ENTADFI program, effective April<span class="nobreak"> </span>30, 2024, with such individuals to continue assisting the Company on an as<span class="nobreak">-needed</span>, consulting basis. We will need to increase the size of our organization in order to support our continued commercialization of our products. As our commercialization plans and strategies continue to develop, our need for additional managerial, operational, manufacturing, sales, marketing, financial and other resources may increase. Our management, personnel, and systems currently in place may not be adequate to support this future growth. Future growth would impose significant added responsibilities on members of management, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>identifying, recruiting, maintaining, motivating, and integrating additional employees;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>managing our internal development efforts effectively while complying with our contractual obligations to licensors, licensees, contractors and other third parties;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>improving our managerial, development, operational, information technology and finance systems; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>expanding our facilities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">If our operations expand, we will also need to manage additional relationships with various strategic partners, suppliers and other third parties. Our future financial performance and our ability to commercialize our products and to compete effectively will depend, in part, on our ability to manage any future growth effectively, as well as our ability to develop a sales and marketing force when appropriate. To that end, we must be able to hire, train and integrate additional management, manufacturing, administrative and sales and marketing personnel. The failure to accomplish any of these tasks could prevent us from successfully growing our company.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Our future success depends on our ability to retain our executive officers and to attract, retain and motivate qualified personnel.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We are highly dependent upon our personnel and executive officers. We have not obtained, do not own, nor are we the beneficiary of, key<span class="nobreak">-person</span> life insurance. Our future growth and success depend on our ability to recruit, retain, manage and motivate our employees. The loss of any member of our senior management team or the inability to hire or retain experienced management personnel could compromise our ability to execute our business plan and harm our operating results. Because of the specialized scientific and managerial nature of our business, we rely heavily on our ability to attract and retain qualified scientific, technical, and managerial personnel. The competition for qualified personnel in the biotechnology field is intense and as a result, we may be unable to continue to attract and retain the qualified personnel necessary for the development of our business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Members of our management team and board of directors have significant experience as founders, board members, officers, or executives of other companies. As a result, certain of those people have been and may become involved in proceedings, investigations and litigation relating to the business affairs of the companies with which they were, are, or may in the future be, affiliated. This may have an adverse effect on us, could damage our reputation and business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the course of their careers, members of our management team and Board have had significant experience as founders, board members, officers or executives of other companies. As a result of their involvement and positions in these companies, certain persons were, are now, or may in the future become, involved in litigation, investigations or other proceedings relating to the business affairs of such companies or transactions entered into by such companies. Any such litigation, investigations or other proceedings may divert our management team&#8217;s and board&#8217;s attention and resources away from our affairs and may negatively affect our reputation and our business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">26</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent review of regulatory submissions in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The ability of the FDA to review regulatory submissions can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent&#160;years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely is subject to the political process, which is inherently fluid and unpredictable.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Disruptions at the FDA and other agencies may also slow the time necessary for regulatory submissions to be reviewed by necessary government agencies, which would adversely affect our business. For example, over the last several&#160;years, including beginning on December&#160;22, 2018, the U.S.&#160;government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We may be adversely affected by natural disasters, pandemics, and other catastrophic events, and by man-made problems such as terrorism and acts of war, that could disrupt our business operations and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If a disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as enterprise financial systems, manufacturing resource planning or enterprise quality systems, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. Our contract manufacturers&#8217; and suppliers&#8217; facilities are located in multiple locations, where other natural disasters or similar events, such as blizzards, tornadoes, fires, explosions or large<span class="nobreak">-scale</span> accidents or power outages, and other public health emergencies could severely disrupt our operations and have a material adverse effect on our business, financial condition, operating results and prospects. A public health emergency could also affect the operations of the FDA and other regulatory or public health authorities, resulting in delays to meetings and ultimately review of regulatory submissions.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Our employees, independent contractors, principal investigators, consultants, and vendors engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We are exposed to the risk that our employees, independent contractors, consultants, and vendors may engage in fraudulent or other illegal activity. Misconduct by these persons could include intentional, reckless, or negligent conduct or unauthorized activity that violates laws or regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA or foreign regulatory authorities; manufacturing standards; federal, state and foreign healthcare fraud and abuse laws and data privacy; or laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and other business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, kickbacks, self<span class="nobreak">-dealing</span> and other abusive practices. These laws may restrict or prohibit a wide range of business activities, including research, manufacturing, distribution, pricing, discounting, marketing and promotion, sales commission, customer incentive programs, patient rebate programs, and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions or other actions or lawsuits stemming from a failure to comply with such laws or regulations, and serious harm to our reputation. In addition, federal procurement laws impose substantial penalties for misconduct in connection with government contracts and require certain contractors to maintain a code of business ethics and conduct. If any such actions are instituted against us, we may have to terminate employees or others involved and the impact of such termination can result in our experiencing delays and additional costs associated with replacing the services being provided. If we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal, and administrative penalties, damages, </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">27</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, FDA debarment, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our operating results.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Macroeconomic pressures in the markets in which we operate, including, but not limited to, the current conflicts in Ukraine and the Middle East may alter the ways in which we conduct our business operations and manage our financial capacities.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">To varying degrees, the ways in which we conduct our business operations and manage our financial capacities are influenced by macroeconomic conditions that affect companies directly involved in or providing services related to the drug development. For example, real GDP growth, business and investor confidence, the conflicts in Ukraine and the Middle East, inflation, employment levels, oil prices, interest rates, tax rates, availability of consumer and business financing, housing market conditions, foreign currency exchange rate fluctuations, costs for items such as fuel and food and other macroeconomic trends can adversely affect not only our decisions and ability to engage in research and development and clinical trials, but also those of our management, employees, third<span class="nobreak">-party</span> contractors, manufacturers and suppliers, competitors, stockholders and regulatory authorities. In addition, geopolitical issues around the world and how our markets are positioned can also impact the macroeconomic conditions and could have a material adverse impact on our financial results.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Economic uncertainty may adversely affect our access to capital, cost of capital and ability to execute our business plan as scheduled.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Generally, worldwide economic conditions remain uncertain. Access to capital markets is critical to our ability to operate. Traditionally, biotechnology companies have funded their research, development, and commercialization expenditures through raising capital in the equity markets. Declines and uncertainties in these markets in the past have severely restricted raising new capital and have affected companies&#8217; ability to continue to expand or fund existing research, development, and commercialization efforts. We require significant capital for the commercialization of our products. The general economic and capital market conditions, both in the U.S.&#160;and worldwide, have been volatile in the past and at times have adversely affected our access to capital and increased the cost of capital. There is no certainty that the capital and credit markets will be available to raise additional capital on favorable terms. If economic conditions become worse, our future cost of equity or debt capital and access to the capital markets could be adversely affected. In addition, if we are unable to access the capital markets on favorable terms, our ability to execute our business plan as scheduled would be compromised. Moreover, we rely and intend to rely on third parties, including CROs, CMOs and other important vendors and consultants. Global economic conditions may result in a disruption or delay in the performance of our third<span class="nobreak">-party</span> contractors and suppliers. If such third parties are unable to adequately satisfy their contractual commitments to us in a timely manner, our business could be adversely affected.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Conditions in the global economy may adversely affect our business, financial condition, and results of operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Although demand for in vitro diagnostics is considered inelastic in developed economies, the in vitro diagnostic industry that we sell to may be affected by material changes in supply, market prices, exchange rates and general economic conditions. Delays or reductions in our customers&#8217; purchasing or shifts to lower<span class="nobreak">-cost</span> alternatives that result from tighter economic market conditions would reduce demand for our products and services and could, consequently, have a material adverse effect on our business, financial condition, and results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Misconduct and errors by our current and former employees and our third-party service providers could cause a material adverse effect on our business and reputation.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our employees and third<span class="nobreak">-party</span> service providers are integral to our business operations, including confidential information. If any such information were leaked to unintended recipients due to human error, theft, malicious sabotage or fraudulent manipulation, we may be subject to liability for loss of such information. Further, if any of our employees or third<span class="nobreak">-party</span> service providers absconded with our proprietary data or know<span class="nobreak">-how</span> in order to compete with us, our competitive position may be materially and adversely affected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">28</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Any improper conduct or use of funds by any of our employees or third<span class="nobreak">-party</span> service providers in contravention of our protocols and policies may lead to regulatory and disciplinary proceedings involving us. We may be perceived to have facilitated or participated in such conduct and we could be subject to liability, damages, penalties, and reputational damage. It is impossible to completely identify and eradicate all risks of misconduct or human errors, and our precautionary measures may not be able to effectively detect and prevent such risks from happening.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The occurrence of any of the above risks could result in a material adverse effect on our business and results of operations, as we are exposed to potential liability to borrowers and investors, reputational damage, regulatory intervention, financial harm. Our ability to attract new and retain existing borrowers and investors and operate as an ongoing concern may be impaired.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Our industry is subject to rapid change, which could make our solutions and the diagnostic tests we develop and services we offer&#160; obsolete. If we are unable to continue to innovate and improve our diagnostic tests and services, we could lose customers or market share.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our industry is characterized by rapid changes, including technological and scientific breakthroughs, frequent new product introductions and enhancements and evolving industry standards, all of which could make our current diagnostic tests and others we are developing obsolete. Our future success will depend on our ability to keep pace with the evolving needs of our customers on a timely and cost<span class="nobreak">-effective</span> basis and to pursue new market opportunities that develop as a result of scientific and technological advances. In recent&#160;years, there have been numerous advances in technologies relating to the diagnosis and treatment of cancer. There have also been advances in methods used to analyze very large amounts of molecular information as well as new imaging<span class="nobreak">-based</span> technologies used of the early assessment and monitoring of disease. We must continuously enhance our offerings and develop new and improved diagnostic tests to keep pace with evolving standards of care. If we do not leverage or scale our sample and data biobank, discover new diagnostic biomarkers or applications, or update our diagnostic tests to reflect new scientific knowledge, including about prostate cancer biology, and information about new cancer therapies or relevant clinical trials, our diagnostic tests could become obsolete and sales of our current diagnostic tests and any new tests we develop could decline or fail to grow as expected. This failure to make continuous improvements to our diagnostic tests to keep ahead of those of our competitors could result in the loss of customers or market share that would adversely affect our business, financial condition, and results of operations. The development of new liquid biopsy and imaging technologies could negatively impact demand for our products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In the event that our products are the subject of guidelines, clinical studies or scientific publications that are unhelpful or damaging, or otherwise call into question the benefits of our products, we may have difficulty in convincing prospective customers to adopt our test. Moreover, the perception by the investment community or shareholders that recommendations, guidelines, or studies will result in decreased use of our products could adversely affect the prevailing market price for our common stock. Similar challenges apply to all of the products in our pipeline.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We face competition from many sources, including larger companies, and we may be unable to compete successfully.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">There are a number of diagnostic solutions companies in the United&#160;States, Europe and Asia. Notable competitors in the United&#160;States include, but are not limited to OPKO Health, Beckman Coulter, BioTechne, MdxHealth, A3P Biomedical AB.&#160;These competitors all provide diagnostic tests or testing services to hospitals, researchers, clinicians, laboratories, and other medical facilities. Many of these organizations are significantly larger with greater financial and personnel resources than us and enjoy significantly greater market share and have greater resources than we do. As a consequence, they may be able to spend more on product development, marketing, sales and other product initiatives than we can. Some of our competitors have:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>substantially greater name recognition;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>broader, deeper, or longer<span class="nobreak">-term</span> relations with healthcare professionals, customers, and third<span class="nobreak">-party</span> payers;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>more established distribution networks;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>additional lines of diagnostic tests and the ability to offer rebates or bundle them to offer greater discounts or other incentives to gain a competitive advantage;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>greater experience in conducting research and development, manufacturing, clinical trials, marketing and obtaining regulatory clearance or approval for diagnostic tests; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">29</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>greater financial and human resources for product development, mergers and acquisitions, sales and marketing and possible patent litigation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our continued success depends on our ability to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Further penetrate the diagnostic solutions market and increase utilization of our diagnostic tests;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>attract and retain a sufficient number of qualified employees;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>maintain and widen our technology lead over competitors by continuing to innovate and deliver new product enhancements on a continuous basis; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>cost<span class="nobreak">-effectively</span> manufacture our diagnostic tests and their component parts as well as drive down the cost of service.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As we attain greater commercial success, our competitors are likely to develop diagnostic tests that offer features and functionality similar to our diagnostic tests that are currently on the market. Improvements in existing competitive diagnostic tests or the introduction of new competitive diagnostic tests may make it more difficult for us to compete for sales, particularly if those competitive diagnostic tests demonstrate better reliability, convenience or effectiveness or are offered at lower prices.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Performance issues, service interruptions or price increases by our shipping carriers and warehousing providers could adversely affect our business and harm our reputation and ability to provide our services on a timely basis.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Expedited, reliable shipping and delivery services and secure warehousing are essential to our operations. We rely heavily on providers of transport services for reliable and secure point<span class="nobreak">-to-point</span> transport of our diagnostic tests to our customers and for tracking of these shipments, and from time to time require warehousing for our diagnostic tests, sample collection kits and supplies. Should a carrier encounter delivery performance issues such as loss, damage, or destruction of any systems, it would be costly to replace such systems in a timely manner and such occurrences may damage our reputation and lead to decreased demand for our diagnostic tests and increased cost and expense to our business. In addition, any significant increase in shipping or warehousing rates could adversely affect our operating margins and results of operations. Similarly, strikes, severe weather, natural disasters, civil unrest and disturbances or other service interruptions affecting delivery or warehousing services we use would adversely affect our ability to process orders for our diagnostic tests on a timely basis.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">For our clinical studies, we rely on commercial courier delivery services to transport samples to our laboratory facility in a timely and cost<span class="nobreak">-efficient</span> manner and if these delivery services are disrupted, our business will be harmed. Disruptions in delivery service, whether due to labor disruptions, bad weather, natural disaster, civil unrest or disturbances, terrorist acts or threats or for other reasons could adversely affect specimen integrity and our ability to process samples in a timely manner and to service our customers, and ultimately our reputation and our business. In addition, if we are unable to continue to obtain expedited delivery services on commercially reasonable terms, our operating results may be adversely affected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We rely on software hosting our online risk calculator needed to be accessed by the user to calculate the test result. Any internet service interruption or hardware failure could affect availability of the online resource and thus negatively impact our business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cost-containment efforts of our customers, purchasing groups and governmental purchasing organizations could have a material adverse effect on our future sales and profitability.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In an effort to reduce costs, many hospitals in the United&#160;States have become members of GPOs and Integrated Delivery Networks (IDNs). GPOs and IDNs negotiate pricing arrangements with medical device companies and distributors and then offer these negotiated prices to affiliated hospitals and other members. GPOs and IDNs typically award contracts on a category<span class="nobreak">-by-category</span> basis through a competitive bidding process. Bids are generally solicited from multiple providers with the intention of driving down pricing or reducing the number of vendors. Due to the highly competitive nature of the GPO and IDN contracting processes, we may not be able to obtain new contract positions with major GPOs and IDNs. Furthermore, the increasing leverage of organized buying groups may reduce market prices for our diagnostic tests, thereby reducing our revenue and margins.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">30</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">While having a contract with a GPO or IDN for a given product category can facilitate sales to members of that GPO or IDN, such contract positions can offer no assurance that any level of sales will be achieved, as sales are typically made pursuant to individual purchase orders. Even when a provider is the sole contracted supplier of a GPO or IDN for a certain product category, members of the GPO or IDN are generally free to purchase from other suppliers. Furthermore, GPO and IDN contracts typically are terminable without cause by the GPO or IDN upon 60 to 90&#160;days&#8217; notice. Accordingly, the members of such groups may choose to purchase alternative diagnostic tests due to the price or quality offered by other companies, which could result in a decline in our revenue.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We are highly dependent on our senior management team and key personnel, and our business could be harmed if we are unable to attract and retain the personnel necessary for our success.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We are highly dependent on our senior management and other key personnel. Our success will depend on our ability to retain senior management and to attract and retain qualified personnel in the future, including sales and marketing professionals, scientists, clinical specialists, and other highly skilled personnel and to integrate current and additional personnel in all departments. The loss of members of our senior management, sales and marketing professionals, scientists, clinical and regulatory specialists could result in delays in product development and harm our business. If we are not successful in attracting and retaining highly qualified personnel, it would have a material adverse effect on our business, financial condition, and results of operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our laboratory operations depend on our ability to attract and retain highly skilled scientists and technicians. We may not be able to attract or retain qualified scientists and technicians in the future due to the competition for qualified personnel among life science businesses, particularly near our laboratory facility in Zurich<span class="nobreak">-Schlieren</span>, Switzerland. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We may also have difficulties locating, recruiting, or retaining qualified salespeople. Recruiting and retention difficulties can limit our ability to support our research and development and sales programs. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have issued and may continue to issue equity awards that vest over time. Our employment arrangements with our employees provide for at<span class="nobreak">-will</span> employment, which means that any of our employees could leave our employment at any time, with or without notice, which may lead to more difficulty in retaining qualified salespeople and other talent.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We depend on our information technology systems and any failure of these systems could harm our business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We depend on information technology and telecommunications systems, including third<span class="nobreak">-party</span> cloud computing infrastructure and operating systems, for significant elements of our operations, including our online risk analysis software.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We have installed, and expect to expand, a number of enterprise software systems that affect a broad range of business processes and functional areas, including systems handling human resources, financial controls and reporting, contract management, regulatory compliance and other infrastructure operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Information technology and telecommunications systems are vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious human acts (such as ransomware) and natural disasters. Moreover, despite network security and back<span class="nobreak">-up</span> measures, some of our external servers are potentially vulnerable to physical or electronic break<span class="nobreak">-ins</span>, computer viruses and similar disruptive problems. Despite the precautionary measures we have taken to prevent unanticipated problems that could affect our information technology and telecommunications systems, failures or significant downtime of these systems or those used by our partners or subcontractors could prevent us from conducting our diagnostic products development, preparing and providing reports to researchers, clinicians and our partners, billing payors, handling enquiries, and managing the administrative aspects of our business. Any disruption or loss of information technology or telecommunications systems on which critical aspects of our operations depend could have an adverse effect on our business and our reputation, and we may be unable to regain or repair our reputation in the future.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">31</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Our Intellectual Property</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection. If our patent position does not adequately protect our products and/or product candidates, others could compete against us more directly, which would harm our business, possibly materially.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection of our current product candidates and future product candidates, the processes used to manufacture them and the methods for using them, as well as successfully defending these patents against third<span class="nobreak">-party</span> challenges. Our ability to stop third parties from making, using, selling, offering to sell or importing our products and/or product candidates is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The patent positions of biotechnology and pharmaceutical companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in pharmaceutical patents has emerged to date in the U.S.&#160;or in foreign jurisdictions outside of the U.S.&#160;Changes in either the patent laws or interpretations of patent laws in the U.S.&#160;and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be enforced in the patents that may be issued from the applications we currently license or may in the future own or license from third parties. Further, if any patents we obtain or license are deemed invalid and unenforceable, our ability to commercialize or license our products and/or product candidates or technology could be adversely affected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Others may file patent applications covering products and technologies that are similar, identical, or competitive to ours or important to our business. We cannot be certain that any patent application owned by a third party will not have priority over patent applications filed or in<span class="nobreak">-licensed</span> by us, or that we or our licensors will not be involved in interference, opposition, re<span class="nobreak">-examination</span>, review, reissue, post grant review or invalidity proceedings before U.S.&#160;or non<span class="nobreak">-U</span>.S.&#160;patent offices. Such proceedings are also expensive and time consuming.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>others may be able to make compounds/assays that are similar to our products and/or product candidates and/or assays, but that are not covered by the claims of our licensed patents;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any patents that we obtain from licensing or otherwise may not provide us with any competitive advantages;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any granted patents that we rely upon may be held invalid or unenforceable as a result of legal challenges by third parties; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the patents of others may have an adverse effect on our business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We are dependent on licensed intellectual property. If we were to lose our rights to licensed intellectual property, we may not be able to continue developing or commercializing our products and/or product candidates, if approved. If we breach any of the agreements under which we license the use, development, and commercialization rights to our products and/or product candidates or technology from third parties or, in certain cases, we fail to meet certain development deadlines, we could lose license rights that are important to our business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix owns the patents and patent applications detailed above in the chapter entitled &#8220;Intellectual Property&#8221;. Apart from this we do not currently own any further patents, and we are heavily reliant upon a number of license agreements under which we are granted rights to intellectual property that are important to our business, and we may need or choose to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose on us, various development, regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our obligations under these agreements, or we are subject to bankruptcy, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license. Our business could suffer, for example, if any current or future licenses terminate, if the licensors fail to abide by the terms of the license, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">32</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Licensing of intellectual property is of critical importance to our business and involves complex legal, business, and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the scope of rights granted under the license agreement and other interpretation<span class="nobreak">-related</span> issues;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our right to sublicense patent and other rights to third parties;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our products and/or product candidates, and what activities satisfy those diligence obligations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our obligation to pursue or license others to pursue development of indications we are not currently pursuing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the ownership of inventions and know<span class="nobreak">-how</span> resulting from the joint creation or use of intellectual property by our licensors and us and our partners;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our right to transfer or assign the license; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the effects of termination.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If disputes over intellectual property that we own or have licensed prevent or impair our ability to maintain our patents or current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected products and/or product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We have entered into several licenses to support our various programs. Termination of any of these license agreements would have a material adverse impact on our ability to develop and commercialize derived products under each respective agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We may enter into additional licenses to third<span class="nobreak">-party</span> intellectual property that are necessary or useful to our business. Our current licenses and any future licenses that we may enter into impose various royalty payments, milestone, and other obligations on us. Under some license agreements, we may not control prosecution of the licensed intellectual property or may not have the first right to enforce the intellectual property. In those cases, we may not be able to adequately influence patent prosecution or enforcement or prevent inadvertent lapses of coverage due to failure to pay maintenance fees. If we fail to comply with any of our obligations under a current or future license agreement, the licensor may allege that we have breached our license agreement and may accordingly seek to terminate our license. Termination of any of our current or future licenses could result in our loss of the right to use the licensed intellectual property, which could materially adversely affect our ability to develop and commercialize a product candidate or product, if approved, as well as harm our competitive business position and our business prospects. Under some license agreements, termination may also result in the transfer of or granting in rights under certain of our intellectual property and information related to the product candidate being developed under the license, such as regulatory information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The agreements under which we license intellectual property or technology to or from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected products and/or product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In addition, if our licensors fail to abide by the terms of the license, if the licensors fail to prevent infringement by third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms, our business could suffer. Moreover, our licensors may own or control intellectual property that has not been licensed to us, and, as a result, we may be subject to claims, regardless of their merit, that we are infringing, misappropriating, or otherwise violating the licensor&#8217;s rights.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">33</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Similarly, if we are unable to successfully obtain rights to required third<span class="nobreak">-party</span> intellectual property rights or maintain the existing intellectual property rights we have, we may have to seek alternative options, such as developing new products and/or product candidates with design<span class="nobreak">-around</span> technologies, which may require more time and investment, or abandon development of the relevant research programs or products and/or product candidates and our business, financial condition, results of operations and prospects could suffer.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Some of the intellectual property owned by Proteomedix and/or covered by our licenses concerns patent applications and provisional applications. We cannot assure investors that any of the currently pending or future patent applications will result in granted patents, nor can we predict how long it will take for such patents to be granted.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Some of intellectual property covered by our licenses concerns certain specified patent rights (including patent applications, provisional patent applications and PCT patent applications). While in some instances, the licensors have agreed to assume responsibility for the preparation, filing, prosecution and maintenance of patent applications covered by the licensed patent rights, we cannot be certain as to when or if final patents will be issued for those patent applications covered by the licensed patent rights. However, the licensors may not successfully prosecute certain patent applications, the prosecution of which they control, under which we are only a licensee and on which our business substantially depends. Even if patents issue from these applications, there is no assurance that the patents will be free from defects or survive validity or enforceability challenges, the licensors may fail to maintain these patents, may decide not to pursue litigation against third<span class="nobreak">-party</span> infringers, may fail to prove infringement or may fail to defend against counterclaims of patent invalidity or unenforceability.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, it is possible that the patent applications owned by Proteomedix and/or licensed pending patent applications will not result in granted patents, and even if such pending patent applications grant as patents, they may not provide a basis for intellectual property protection of commercially viable vaccine products or may not provide us with any competitive advantages. Further, it is possible that, for any of the patents that may be granted in the future, others will design around the licensed patent rights or identify methods of diagnosis or for preventing or treating infectious diseases that do not concern the rights covered by our patents and/or licenses. Further, we cannot assure investors that other parties will not challenge any patents granted to Proteomedix or the licensors or that courts or regulatory agencies will hold Proteomedix and/or licensor&#8217;s patents to be valid or enforceable. We cannot guarantee investors that, if required to defend the covered patents, we will have the funds to or be successful in defending challenges made against the Proteomedix and/or licensed patents and patent applications. Any successful third<span class="nobreak">-party</span> challenge to the Proteomedix and/or licensed patents could result in the unenforceability or invalidity of such patents, or to such patents being interpreted narrowly or otherwise in a manner adverse to our interests. Our ability to establish or maintain a technological or competitive advantage over our competitors may be diminished because of these uncertainties.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Even if patents are issued based on patent applications to which we have been granted a license or owned by Proteomedix, because the patent positions of diagnostic methods and/or pharmaceutical and biotechnology products are complex and uncertain, we cannot predict the scope and extent of patent protection for our products and/or product candidates.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Any patents that may be issued based on patent applications that we have been granted licenses to or owned by Proteomedix will not ensure sufficient protection with respect to our activities for a number of reasons, including without limitation the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any issued patents may not be broad or strong enough to prevent competition from other diagnostic and/or vaccine products including identical or similar products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if patents are not issued or if issued patents expire, there would be no protections against competitors making generic equivalents;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>there may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>there may be other patents existing, now or in the future, in the patent landscape for our products and/or product candidates that we seek to commercialize or develop, if any, that will affect our freedom to operate;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">34</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if patents that we have been granted licenses to are challenged, a court could determine that they are not valid or enforceable;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a court could determine that a competitor&#8217;s technology or product does not infringe patents that we have been granted licenses to;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>patents to which we have been granted licenses could irretrievably lapse due to failure to pay fees or otherwise comply with regulations, or could be subject to compulsory licensing; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if we encounter delays in our development or clinical trials, the period of time during which we could market our products under patent protection would be reduced.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and patent protection could be reduced or eliminated for noncompliance with these requirements.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Periodic maintenance fees on any issued patent are due to be paid to the United&#160;States Patent and Trademark Office (&#8220;USPTO&#8221;) and foreign Intellectual Property Offices in several stages over the term of the patent. Maintenance fees are also due for pending patent applications in some countries. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to office actions within prescribed time limits, non<span class="nobreak">-payment</span> of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The life of patent protection is limited, and third parties could develop and commercialize methods, products, and technologies similar or identical to ours and compete directly with us after the patent licensed to us expires, which could materially and adversely affect our ability to commercialize our products and technologies.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The life of a patent and the protection it affords is limited. For example, in the United&#160;States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest U.S.&#160;non<span class="nobreak">-provisional</span> filing date. In Europe, the expiration of an invention patent is 20&#160;years from its filing date. Even if we successfully obtain patent protection for a diagnostic method and/or an approved vaccine candidate, it may face competition, e.g., from biosimilar medications. Diagnostic companies or manufacturers of biosimilar drugs may challenge the scope, validity or enforceability of the patents underlying our technology in court or before a patent office, and the patent holder may not be successful in enforcing or defending those intellectual property rights and, as a result, we may not be able to develop or market the relevant method/product candidate exclusively, which would materially adversely affect any potential sales of that product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Given the amount of time required for the development, testing and regulatory review of new diagnostic methods and/or vaccine candidates, patents protecting such diagnostic methods and/or vaccine candidates might expire before or shortly after such methods or vaccine candidates are commercialized. As a result, the patents and patent applications owned or licensed to us may not provide us with sufficient rights to exclude others from commercializing methods/products similar or identical to ours. Even if we believe that the patents involved are eligible for certain (and time<span class="nobreak">-limited</span>) patent term extensions, there can be no assurance that the applicable authorities, including the FDA and the USPTO, and any equivalent regulatory authority in other countries, will agree with our assessment of whether such extensions are available, and such authorities may refuse to grant extensions to such patents, or may grant more limited extensions than requested. For example, depending upon the timing, duration, and specifics of any FDA marketing approval of any product candidates we may develop, one or more of the U.S.&#160;patents licensed to us may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or Hatch<span class="nobreak">-Waxman</span> Amendments. The Hatch<span class="nobreak">-Waxman</span> Amendments permit a patent extension term of up to five&#160;years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">35</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, the applicable time period or the scope of patent protection afforded could be less than requested. If we are unable to obtain patent term extension or term of any such extension is less than requested, our competitors may obtain approval of competing products following our patent expiration, and our business could be harmed. Changes in either the patent laws or interpretation of the patent laws in the United&#160;States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The patents and pending patent applications licensed to us for our diagnostic methods and product candidates are expected to expire on various dates. Upon the expiration, we will not be able to assert such licensed patent rights against potential competitors, which would materially adversely affect our business, financial condition, results of operations and prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms or at all.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">There may be intellectual property rights existing now, or in the future, relevant to our methods and/or products and/or product candidates that we seek to commercialize or develop, if any, that may affect our ability to commercialize such methods and/or products and/or product candidates. Although the Company is not aware of any such intellectual property rights, a third<span class="nobreak">-party</span> may hold intellectual property rights, including patent rights, that are important or necessary to the development or manufacture of our methods and/or products and/or product candidates. Even if all our main methods and/or products and/or product candidates are covered by patents, it may be necessary for us to use the patented or proprietary technology of third parties to commercialize our methods and/or products and/or product candidates, in which case we would be required to obtain a license from these third parties. Such a license may not be available on commercially reasonable terms, or at all, and we could be forced to accept unfavorable contractual terms. In that event, we may be required to expend significant time and resources to redesign our technology, methods and/or products and/or product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, our business could be harmed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The licensing or acquisition of third<span class="nobreak">-party</span> intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We may infringe the intellectual property rights of others, which may prevent or delay our method and/or product development efforts and stop us from commercializing or increase the costs of commercializing our methods and/or products and/or product candidates.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our success will depend in part on our ability to operate without infringing the proprietary rights of third parties. We are not aware of any third<span class="nobreak">-party</span> proprietary rights that our planned methods and/or products will infringe or misappropriate, but we have not conducted any freedom to operate study as we are in the earliest stages of development. We thus cannot guarantee that our methods and/or products and/or product candidates, or manufacture or use of our products and/or product candidates, will not infringe third<span class="nobreak">-party</span> patents. Furthermore, a third party may claim that we are using inventions covered by the third party&#8217;s patent rights and may go to court to stop us from engaging in our normal operations and activities, including making or selling our methods and/or products and/or product candidates. These lawsuits are costly and could affect our results of operations and divert the attention of managerial and scientific personnel. Some of these third parties may be better capitalized and have more resources than us. There is a risk that a court would decide that we are infringing the third party&#8217;s patents and would order us to stop the activities covered by </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">36</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the patents. In that event, we may not have a viable way around the patent and may need to halt commercialization of our methods and/or products and/or product candidates. In addition, there is a risk that a court will order us to pay the other party damages for having violated the other party&#8217;s patents. In addition, we may be obligated to indemnify our licensors and collaborators against certain intellectual property infringement claims brought by third parties, which could require us to expend additional resources. The diagnostic, pharmaceutical and biotechnology industries have produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If we are sued for patent infringement, we would need to demonstrate that our products and/or product candidates or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the U.S., proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and diversion of management&#8217;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, which may not be available, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop, or obtain non<span class="nobreak">-infringing</span> technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our methods and/or products and/or product candidates to market and be precluded from manufacturing or selling our products and/or product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than us or the third parties from whom we license intellectual property because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In addition to the possibility of litigation relating to infringement claims asserted against it, we may become a party to other patent litigation and other proceedings, including <span class="Italic" style="font-style:italic;font-weight:normal;">inter partes</span> review proceedings, post<span class="nobreak">-grant</span> review proceedings, derivation proceedings declared by the USPTO and similar proceedings in foreign countries, regarding intellectual property rights with respect to our current or future technologies or methods and/or products and/or product candidates or products. The cost to us of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Competitors may infringe or otherwise violate our intellectual property, including patents that may be issued to or be licensed by us. As a result, we may be required to file claims in an effort to stop third<span class="nobreak">-party</span> infringement or unauthorized use. Any such claims could provoke these parties to assert counterclaims against us, including claims alleging that we infringe their patents or other intellectual property rights, and/or that any of our intellectual property, including licensed intellectual property, is invalid and/or unenforceable. This can be prohibitively expensive, particularly for a company of our size, and time<span class="nobreak">-consuming</span>, and even if we are successful, any award of monetary damages or other remedy we may receive may not be commercially valuable. In addition, in an infringement proceeding, a court may decide that our asserted intellectual property is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our intellectual property does not cover its technology. An adverse determination in any litigation or defense proceedings could put our intellectual property at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not being issued.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If the breadth or strength of our patent or other intellectual property rights is compromised or threatened, it could allow third parties to exploit and, in particular, commercialize our technology or methods and/or products or result in our inability to exploit and/or commercialize our technology and methods and/or products without infringing third<span class="nobreak">-party</span> intellectual property rights. Further, third parties may be dissuaded from collaborating with us.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">37</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Interference or derivation proceedings brought by the USPTO, or its foreign counterparts may be necessary to determine the priority of inventions with respect to our patent applications, and we may also become involved in other proceedings, such as re<span class="nobreak">-examination</span> proceedings, before the USPTO or its foreign counterparts. Due to the substantial competition in the pharmaceutical space, the number of such proceedings may increase. This could delay the prosecution of our pending patent applications or impact the validity and enforceability of any future patents that we may obtain. In addition, any such litigation, submission or proceeding may be resolved adversely to us and, even if successful, may result in substantial costs and distraction to our management.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and product could be significantly diminished.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We also rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers, and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part of its transparency initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change in the future, if at all. Costly and time<span class="nobreak">-consuming</span> litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We may be subject to claims that our employees or consultants have wrongfully used or disclosed alleged trade secrets.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know<span class="nobreak">-how</span> of others in their work for us, we may be subject to claims that we or our employees or consultants have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail to defend any such claims, in addition to paying monetary damages, we could lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Our intellectual property may not be sufficient to protect our methods and/or products and/or product candidates from competition, which may negatively affect our business as well as limit our partnership or acquisition appeal.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We may be subject to competition despite the existence of intellectual property we license or own or may in the future own. We can give no assurances that our intellectual property claims will be sufficient to prevent third parties from designing around patents we own or license and developing and commercializing competitive products. The existence of competitive products that avoid our intellectual property could materially adversely affect our operating results and financial condition. Furthermore, limitations, or perceived limitations, in our intellectual property may limit the interest of third parties to partner, collaborate or otherwise transact with us, if third parties perceive a higher than acceptable risk to commercialization of our methods and/or products and/or product candidates or future products and/or product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We may elect to sue a third party, or otherwise make a claim, alleging infringement or other violation of patents, trademarks, trade dress, copyrights, trade secrets, domain names or other intellectual property rights that we either own or license from a third party. If we do not prevail in enforcing our intellectual property rights in this type of litigation, we may be subject to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>paying monetary damages related to the legal expenses of the third party;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>facing additional competition that may have a significant adverse effect on our product pricing, market share, business operations, financial condition, and the commercial viability of our product; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">38</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>restructuring our company or delaying or terminating select business opportunities, including, but not limited to, research and development, clinical trial, and commercialization activities, due to a potential deterioration of our financial condition or market competitiveness.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A third party may also challenge the validity, enforceability, or scope of the intellectual property rights that we license or own and the result of these challenges may narrow the scope or claims of or invalidate patents that are integral to our products and/or product candidates in the future. There can be no assurance that we will be able to successfully defend patents we own or license in an action against third parties due to the unpredictability of litigation and the high costs associated with intellectual property litigation, amongst other factors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Intellectual property rights may be less extensive and enforcement more difficult in jurisdictions outside of the U.S.&#160;Therefore, we may not be able to protect our intellectual property and third parties may be able to market competitive products that may use some or all of our intellectual property.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage and changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The America Invents Act (&#8220;AIA&#8221;) has been enacted in the United&#160;States, resulting in significant changes to the U.S.&#160;patent system. An important change introduced by the AIA is that, as of March&#160;16, 2013, the United&#160;States transitioned to a &#8220;first<span class="nobreak">-to-file</span>&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and provide opportunities for third parties to challenge any issued patent in the USPTO.&#160;This applies to all of our U.S.&#160;patents, even those issued before March&#160;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S.&#160;federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, the U.S.&#160;Supreme Court has ruled on several patent cases in recent&#160;years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. This is in particular the case in the field of diagnostic patents based on biomarkers (Mayo v. Prometheus, 566 U.S.&#160;66 (2012)), where Proteomedix is active. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S.&#160;Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Any inability of us to protect our competitive advantage with regard to any of our product candidates may prevent us from successfully monetizing such product candidate and this could materially adversely affect our business, prospects, financial condition and results of operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">39</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Healthcare Compliance and Other Regulations</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If we fail to comply with healthcare regulations, we could face substantial enforcement actions, including administrative, civil, and criminal penalties and our business, operations and financial condition could be adversely affected.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We could be subject to healthcare fraud and abuse laws and health information privacy and security laws of both the federal government and the states in which we conduct our business. The laws include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the U.S.&#160;federal Anti<span class="nobreak">-Kickback</span> Statute, which prohibits, among other things, persons from soliciting, receiving, or providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Federal civil and criminal false claims laws and civil monetary penalties laws, including the federal civil False Claims Act, which can be enforced by individuals through civil whistleblower and qui tam actions, prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government.;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by Covered Recipients, as defined at 42 CFR Part&#160;403, Subpart&#160;I;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>HIPAA which prohibits knowingly and willfully executing a scheme to defraud any healthcare benefit program including private third<span class="nobreak">-party</span> payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services, and which also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information and certain notification requirements and criminal and civil penalties for failure to comply with those requirements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the FDCA which among other things, strictly regulates drug manufacturing and product marketing, prohibits manufacturers from marketing drug products for off<span class="nobreak">-label</span> use and regulates the distribution of drug samples; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>state law equivalents of each of the above federal laws, such as anti<span class="nobreak">-kickback</span> and false claims laws which may apply to items or services reimbursed by any third<span class="nobreak">-party</span> payer, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance efforts.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If our operations are found to be in violation of any of the laws described above or any governmental regulations that apply to us, we may be subject to penalties, including administrative, civil, and criminal penalties, damages, fines, and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert management&#8217;s attention from the operation of our business. Moreover, achieving, and sustaining compliance with applicable federal and state privacy, security and fraud laws may prove costly.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">40</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Healthcare reform in the United&#160;States has been implemented in the past, and we expect further changes to be proposed in the future, leading to potential uncertainty in the healthcare industry. Violations of healthcare laws can have an adverse impact on our ability to advance Proclarix and/or ENTADFI and our operating results.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In the United&#160;States, there have been, and continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect the future results of pharmaceutical manufactures&#8217; operations. In particular, there have been and continue to be a number of initiatives at the federal and state levels that seek to reduce healthcare costs. For example, the Affordable Care Act, or the ACA, which was originally enacted in March&#160;2010 and subsequently amended, includes measures to significantly change the way healthcare is financed by both governmental and private insurers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In August&#160;2022, President Biden signed the Inflation Reduction Act, which extended enhanced subsidies, passed as part of the American Rescue Plan Act in 2021, and prevented insurance companies from imposing significant increases in healthcare premiums for low<span class="nobreak">-income</span> exchange customers through 2025. In addition, under this legislation, Medicare will have the ability to negotiate drug prices for a select list of pharmaceuticals in Medicare Part&#160;D drugs, with the list of included drugs expected to increase over the coming&#160;years and incorporate drugs in Medicare Parts B and D.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We are exposed to the risk of employee fraud or other misconduct, including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal, and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and integrity oversight and reporting obligations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We may rely on government funding and collaboration with government entities for our product development, which adds uncertainty to our research and development efforts and may impose requirements that increase the costs of development, commercialization and production of any programs developed under those government-funded programs.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Because we anticipate the resources necessary to develop our products and/or product candidates will be substantial, we may explore funding and development collaboration opportunities with the U.S.&#160;government and its agencies. For example, we may apply for certain grant funding from BARDA, the NIH or other government agencies to further the research, development, manufacture, testing, and regulatory approval of our products and/or product candidates. We have no control or input over whether an application for BARDA grant funding or any other funding will be accepted or approved, in full or in part, and we cannot provide investors with any assurances that we will receive such funding.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Contracts and grants funded by the U.S.&#160;government and its agencies, contain provisions that reflect the government&#8217;s substantial rights and remedies, many of which are not typically found in commercial contracts, including powers of the government to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>reduce or modify the government&#8217;s obligations under such agreements without the consent of the other party;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>claim rights, including Intellectual Property rights, in products and data developed under such agreements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>audit contract<span class="nobreak">-related</span> costs and fees, including allocated indirect costs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">41</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>suspend the contractor or grantee from receiving new contracts pending resolution of alleged violations of procurement laws or regulations.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>impose U.S.&#160;manufacturing requirements for products that embody inventions conceived or first reduced to practice under such agreements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>suspend or debar the contractor or grantee from doing future business with the government;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>control and potentially prohibit the export of products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pursue criminal or civil remedies under the False Claims Act, False Statements Act, and similar remedy provisions specific to government agreements; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>limit the government&#8217;s financial liability to amounts appropriated by the U.S.&#160;Congress on a fiscal<span class="nobreak">-year</span> basis, thereby leaving some uncertainty about the future availability of funding for a program even after it has been funded for an initial period.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If we received such grants or agreements, we may not have the right to prohibit the U.S.&#160;government from using certain technologies developed by us, and we may not be able to prohibit third parties, including our competitors, from using those technologies in providing products and services to the U.S.&#160;government. Further, under such agreements we could be subject to obligations to and the rights of the U.S.&#160;government set forth in the Bayh<span class="nobreak">-Dole</span> Act&#160;of&#160;1980, meaning the U.S.&#160;government may have rights in certain inventions developed under these government<span class="nobreak">-funded</span> agreements, including a non<span class="nobreak">-exclusive</span>, non<span class="nobreak">-transferable</span>, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S.&#160;government could have the right to require us to grant exclusive, partially exclusive, or nonexclusive licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or (iii)&#160;government action is necessary to meet requirements for public use under federal regulations, also referred to as &#8220;march<span class="nobreak">-in</span> rights.&#8221; Although the U.S.&#160;government&#8217;s historic restraint with respect to these rights indicates they are unlikely to be used, any exercise of the march<span class="nobreak">-in</span> rights could harm our competitive position, business, financial condition, results of operations and prospects. In the event we would be subject to the U.S.&#160;government&#8217;s exercise such march<span class="nobreak">-in</span> rights, we may receive compensation that is deemed reasonable by the U.S.&#160;government in its sole discretion, which may be less than what we might be able to obtain in the open market.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, the U.S.&#160;government requires that any products embodying any invention generated through the use of U.S.&#160;government funding be manufactured substantially in the United&#160;States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United&#160;States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S.&#160;manufacturers may limit our ability to contract with non<span class="nobreak">-U</span>.S.&#160;manufacturers for products covered by such intellectual property.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Although we may need to comply with some of these obligations, not all of the aforementioned obligations may be applicable to us unless and only to the extent that we receive a government grant, contract or other agreement. However, as an organization, we are relatively new to government contracting and new to the regulatory compliance obligations that such contracting entails. If we were to fail to maintain compliance with those obligations, we may be subject to potential liability and to termination of our contracts, which may have a materially adverse effect on our ability to develop our products and/or product candidates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We are subject to U.S.&#160;and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We are subject to export control and import laws and regulations, including the U.S.&#160;Export Administration Regulations, U.S.&#160;Customs regulations, various economic and trade sanctions regulations administered by the U.S.&#160;Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S.&#160;Foreign Corrupt Practices Act&#160;of&#160;1977, as amended, the U.S.&#160;domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S.&#160;Travel Act, the USA PATRIOT Act and other state and national anti<span class="nobreak">-bribery</span> and anti<span class="nobreak">-money</span> laundering laws in the countries in which we conduct activities. Anti<span class="nobreak">-corruption</span> laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">42</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the United&#160;States, to sell our products abroad once we enter a commercialization phase and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government<span class="nobreak">-affiliated</span> hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Owning our Common Stock</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The market price of our common stock has been extremely volatile and may continue to be highly volatile due to numerous circumstances beyond our control, and stockholders could lose all or part of their investment.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The market price of our common stock may be highly volatile. Our stock price could be subject to wide fluctuations in response to a variety of factors, which include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>whether we achieve our anticipated corporate objectives;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>actual or anticipated fluctuations in our financial condition and operating results;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>changes in financial or operational estimates or projections;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our execution of our sales and marketing, manufacturing and other aspects of our business plan;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>performance of third parties on whom we rely to manufacture our products and product components, including their ability to comply with regulatory requirements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>results of operations that vary from those of our competitors and the expectations of securities analysts and investors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>changes in expectations as to our future financial performance, including financial estimates by securities analysts and investors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our announcement of significant contracts, acquisitions, or capital commitments;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>announcements by our competitors of competing products or other initiatives;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>announcements by third parties of significant claims or proceedings against us;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>regulatory and reimbursement developments in the United&#160;States and abroad;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>future sales of our common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>product liability claims;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>healthcare reform measures in the United&#160;States;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>additions or departures of key personnel; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic or political conditions in the United&#160;States or elsewhere.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the stock market in general, and the stock of medical biotechnology companies like ours, in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of the issuer. For example, on February<span class="nobreak"> </span>14, 2023, and April<span class="nobreak"> </span>24, 2024, the closing price of our common stock on Nasdaq was $1.56 and $0.122, respectively, and daily trading volume on these days was approximately 90,326,500 and 104,000<span class="nobreak"> </span>shares, respectively. These broad market fluctuations may adversely affect the trading price of our common stock. In particular, a proportion of our common stock may be traded by short sellers which may put pressure on the supply and demand for our common stock, further influencing volatility in its market price. Additionally, these and other external factors have caused and may continue to cause the market price and demand </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">43</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">for our common stock to fluctuate, which may limit or prevent investors from readily selling their shares of common stock and may otherwise negatively affect the liquidity of our common stock. While the market price of our common stock may respond to developments regarding operating performance and prospects, expansion plans, developments regarding our participation in direct contracting, and developments regarding our industry, we believe that the extreme volatility we experienced in recent periods reflects market and trading dynamics unrelated to our underlying business, our actual or expected operating performance, our financial condition, or macro or industry fundamentals, and we do not know if these dynamics will continue or how long they will last. Under these circumstances, we caution you against investing in our common stock, unless you are prepared to incur the risk of losing all or a substantial portion of your investment.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We may be subject to securities litigation, which is expensive and could divert our management&#8217;s attention.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The market price of our securities may be volatile, and in the past, companies that have experienced volatility in the market price of their securities have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We may have violated Section&#160;13(k)&#160;of the Exchange&#160;Act (implementing Section&#160;402 of the Sarbanes-Oxley Act&#160;of&#160;2002) and may be subject to sanctions as a result.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;13(k)&#160;of the Exchange&#160;Act provides that it is unlawful for a company that has a class of securities registered under Section&#160;12 of the Exchange&#160;Act to, directly or indirectly, including through any subsidiary, extend or maintain credit in the form of a personal loan to or for any of its directors or executive officers. In the fiscal year ended December&#160;31, 2022, and the nine&#160;months ended September&#160;30, 2023, we paid certain expenses of our former Chief Executive Officer and Chairman of the Board, which may be deemed to be personal loans made by us to our former Chief Executive Officer and Chairman of the Board that are not permissible under Section&#160;13(k)&#160;of the Exchange&#160;Act. Specifically, after a review completed by the Audit Committee, it was determined that our former CEO and an accounting employee charged certain personal expenses on their corporate credit cards that were not recorded as related party receivables. The aggregate amount of such unauthorized charges ranged from approximately (i)&#160;$257,000 to $405,000 for all of 2022, (ii)&#160;$86,000 to $122,000 for the quarter ended March&#160;31, 2023, and (iii)&#160;$79,000 to $150,000 for the quarter ended June&#160;30, 2023. The accounting employee was also the CEO&#8217;s assistant and had roles in the Company&#8217;s system of internal control over financial reporting, including controls relating to the Company&#8217;s corporate credit cards. Issuers that are found to have violated Section&#160;13(k)&#160;of the Exchange&#160;Act may be subject to civil sanctions, including injunctive remedies and monetary penalties, as well as criminal sanctions. The imposition of any of such sanctions on us could have a material adverse effect on our business, financial position, results of operations or cash flows.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired. We have identified weaknesses in our internal controls, and we cannot provide assurances that these weaknesses will be effectively remediated, or that additional material weaknesses will not occur in the future.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We are subject to the reporting requirements of the Exchange&#160;Act, the Sarbanes<span class="nobreak">-Oxley</span> Act and Nasdaq rules and regulations. The Sarbanes<span class="nobreak">-Oxley</span> Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, is designed to prevent fraud. We must perform system and process evaluation and testing of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our Annual Report on Form&#160;10<span class="nobreak">-K</span> for each year, as required by Section&#160;404 of the Sarbanes<span class="nobreak">-Oxley</span> Act (&#8220;Section&#160;404&#8221;). This requires significant management efforts and requires us to incur substantial professional fees and internal costs to expand our accounting and finance functions. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. In addition, any testing by us, as and when required, conducted in connection with Section&#160;404, or any subsequent testing by our independent registered public accounting firm, as and when required, may reveal deficiencies in our internal controls over financial reporting that are deemed to be significant deficiencies or material weaknesses or that may require prospective or retroactive changes to our financial statements, or may identify other areas for further attention or improvement. Furthermore, we cannot be certain that our efforts will be sufficient to remediate or prevent future material weaknesses or significant deficiencies from occurring.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">44</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We do not yet have effective disclosure controls and procedures, or internal controls over all aspects of our financial reporting. Specifically, we have identified the following control deficiencies which we believe are material weaknesses.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>We did not maintain an effective control environment as there was an inadequate segregation of duties with respect to certain cash disbursements. The processing and the approval for payment of credit card transactions and certain bank wires were being handled by the former CEO and an accounting employee, and the accounting employee was responsible for the reconciliation of credit card statements and bank statements. This allowed these individuals to submit unauthorized payments to unauthorized third parties.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>We do not have an effective risk assessment process or effective monitoring of compliance with established accounting policies and procedures, and do not demonstrate a sufficient level of precision in the application of our controls.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Our controls over the approval and reporting of expenses paid with the Company&#8217;s credit cards and certain bank wires were not designed and maintained to achieve the Company&#8217;s objectives.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>We have insufficient accounting resources to maintain adequate segregation of duties, maintain adequate controls over the approval and posting of journal entries, and to provide optimal levels of oversight in order to process financial information in a timely manner, analyze and account for complex, non<span class="nobreak">-routine</span> transactions, and prepare financial statements.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>We do not yet have adequate internal controls in place for the timely identification, approval or reporting of related party transactions.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>We did not design, implement, and maintain effective controls to ensure information technology (&#8220;IT&#8221;) policies and procedures set the tone at the top, to mitigate the risks to the achievement of IT objectives and ITGCs in the change management, logical security, and computer operations domains. Specifically, the design and implementation of user authentication, user access privileges, data backup and data recovery controls as well as the monitoring controls of excessive user access and elevated privileged access to financial applications and data were not appropriately designed and maintained. In addition, these inadequate ITGC controls combined with the use of personal devices to conduct business, can lead to an IT control environment vulnerable to breaches and social engineering persuasion.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We cannot provide assurances that these weaknesses will be effectively remediated, or that additional material weaknesses will not occur in the future.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As a result of the material weaknesses in our internal controls over financial reporting described above, and other matters raised or that may in the future be raised by the SEC, we may face for the prospect of litigation or other disputes which may include, among others, claims invoking the federal and state securities laws, contractual claims or other claims arising from the material weaknesses in our internal control over financial reporting and the preparation of our financial statements, any of which claims could result in adverse effects to our business. As of the date hereof, we have no knowledge of any such litigation or dispute.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Our Amended and Restated Certificate of Incorporation requires, to the fullest extent permitted by law, that derivative actions brought in our name, actions against our directors, officers, other employees or stockholders for breach of fiduciary duty and other similar actions may be brought only in the Court of Chancery in the State of Delaware and, if brought outside of Delaware, the stockholder bringing the suit will be deemed to have consented to service of process on such stockholder&#8217;s counsel, which may have the effect of discouraging lawsuits against our directors, officers, other employees or stockholders.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our Amended and Restated Certificate of Incorporation requires, to the fullest extent permitted by law, that derivative actions brought in our name, actions against our directors, officers, other employees or stockholders for breach of fiduciary duty and other similar actions may be brought only in the Court of Chancery in the State of Delaware and, if brought outside of Delaware, the stockholder bringing the suit will be deemed to have consented to service of process on such stockholder&#8217;s counsel except any action (A)&#160;as to which the Court of Chancery in the State of Delaware determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">45</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">(and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten&#160;days following such determination), (B)&#160;which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, (C)&#160;for which the Court of Chancery does not have subject matter jurisdiction, or (D)&#160;any action arising under the Securities Act, as to which the Court of Chancery and the federal district court for the District of Delaware shall have concurrent jurisdiction. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consented to the forum provisions in our Amended and Restated Certificate of Incorporation. This choice of forum provision may make it more costly for a stockholder to bring a claim, and it may also limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders cannot waive our compliance with federal securities laws and the rules and regulations thereunder. Alternatively, if a court were to find the choice of forum provision contained in our Amended and Restated Certificate of Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results and financial condition.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our Amended and Restated Certificate of Incorporation provides that the exclusive forum provision will be applicable to the fullest extent permitted by applicable law. Section&#160;27 of the Exchange&#160;Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange&#160;Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange&#160;Act or any other claim for which the federal courts have exclusive jurisdiction. In addition, our Amended and Restated Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United&#160;States of America shall, to the fullest extent permitted by law, be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act&#160;of&#160;1933, as amended, or the rules and regulations promulgated thereunder. We note, however, that there is uncertainty as to whether a court would enforce this provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Section&#160;22 of the Securities Act creates concurrent jurisdiction for state and federal courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">An active trading market for our common stock may not develop or be sustained.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Prior to the commencement of trading of our common stock on February&#160;18, 2022, no public market for our common stock existed. Although our common stock is listed on The Nasdaq Capital Market, an active trading market for our common stock may not develop, or if developed, be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair value of your shares.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Our principal stockholders and management own a significant percentage of our capital stock and will be able to exert a controlling influence over our business affairs and matters submitted to stockholders for approval.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of April<span class="nobreak"> </span>24, 2024, our officers and directors, together with holders of 5% or more of our outstanding common stock and their respective affiliates, beneficially own or control 5,789,164  shares of our common stock, which in the aggregate represents approximately 26.1% of the outstanding shares of our common stock. As a result, if some of these persons or entities act together, they will have the ability to exercise significant influence over matters submitted to our stockholders for approval, including the election and removal of directors, amendments to our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, the approval of any business combination and any other significant corporate transaction. These actions may be taken even if they are opposed by other stockholders. This concentration of ownership may also have the effect of delaying or preventing a change of control of our company or discouraging others from making tender offers for our shares, which could prevent our stockholders from receiving a premium for their shares. Some of these persons or entities who make up our principal stockholders may have interests different from yours.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">46</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">There can be no assurance that we will be able to comply with the continued listing standards of Nasdaq.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our continued eligibility for listing on Nasdaq depends on our ability to comply with Nasdaq&#8217;s continued listing requirements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On September&#160;18, 2023, we received notice from Nasdaq staff indicating that, based upon the closing bid price of the Common Stock for the prior 30 consecutive&#160;business days, we were not in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule&#160;5550(a)(2). We have 180&#160;days from September&#160;18, 2023, or through March&#160;16, 2024, to regain compliance with the Bid Price Rule. On March&#160;13, 2024, we submitted a plan of compliance to Nasdaq to discuss our plans to evidence compliance with the Bid Price Rule and we received an additional 180<span class="nobreak">-day</span> period, or until September&#160;16, 2024, to regain compliance with the Bid Price Rule.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If Nasdaq delists our common stock from trading on its exchange for failure to meet the Bid Price Rule or any other listing standards, we and our stockholders could face significant material adverse consequences including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a limited availability of market quotations for our securities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a determination that our common stock is a &#8220;penny stock,&#8221; which will require brokers trading in our common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a limited amount of analyst coverage; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a decreased ability to issue additional securities or obtain additional financing in the future.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If our shares become subject to the penny stock rules, it would become more difficult to trade our shares.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The SEC has adopted rules that regulate broker<span class="nobreak">-dealer</span> practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or authorized for quotation on certain automated quotation systems, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system. If we do not retain a listing on Nasdaq and if the price of our common stock is less than $5.00, our common stock will be deemed a penny stock. The penny stock rules require a broker<span class="nobreak">-dealer</span>, before a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document containing specified information. In addition, the penny stock rules require that before effecting any transaction in a penny stock not otherwise exempt from those rules, a broker<span class="nobreak">-dealer</span> must make a special written determination that the penny stock is a suitable investment for the purchaser and receive (i)&#160;the purchaser&#8217;s written acknowledgment of the receipt of a risk disclosure statement; (ii)&#160;a written agreement to transactions involving penny stocks; and (iii)&#160;a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our common stock, and therefore stockholders may have difficulty selling their shares.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Future sales of our shares by existing stockholders could cause our stock price to decline.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If we or our existing stockholders, directors and officers sell, or indicate an intent to sell, substantial amounts of our common stock or securities convertible into our common stock in the public market after contractual lock<span class="nobreak">-up</span> and other legal restrictions on resale lapse, the trading price of our common stock could decline significantly and could decline below the initial public offering price. We have outstanding 22,324,576<span class="nobreak"> </span>shares of common stock as of the date hereof, assuming no exercise of outstanding options or warrants, are or will be freely tradable, without restriction, in the public market. If our existing stockholders sell substantial amounts of our common stock in the public market, or if the public perceives that such sales could occur, this could have an adverse impact on the market price of our common stock, even if there is no relationship between such sales and the performance of our business. We have previously registered 2,330,640<span class="nobreak"> </span>shares of common stock under our equity compensation plans. These shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates and lock<span class="nobreak">-up</span> agreements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Upon issuance, the 1,322,504<span class="nobreak"> </span>shares subject to outstanding options under our stock option plan and the shares reserved for future issuance under our stock option plan will become eligible for sale in the public market in the future, subject to certain legal and contractual limitations. If our existing stockholders sell substantial amounts of </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">47</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">our common stock in the public market, or if the public perceives that such sales could occur, this could have an adverse impact on the market price of our common stock, even if there is no relationship between such sales and the performance of our business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The issuance or conversion of securities would result in significant dilution in the equity interest of existing shareholders and adversely affect the marketplace of the securities.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The issuance or conversion of common shares or other securities convertible into common shares would result in significant dilution in the equity interest of existing shareholders and adversely affect the market price of the common shares. We have issued 3,000<span class="nobreak"> </span>shares of Series&#160;A Preferred Stock to Veru which are initially convertible one year from issuance, in the aggregate, into 5,709,935<span class="nobreak"> </span>shares of the Company&#8217;s common stock, subject to adjustment and certain shareholder approval limitations specified in the Certificate of Designations. We have issued 2,696,729<span class="nobreak"> </span>shares of Series&#160;B Preferred Stock to former shareholders of Proteomedix which are initially convertible, in the aggregate, into 269,672,900<span class="nobreak"> </span>shares of the Company&#8217;s common stock, subject to adjustment and certain shareholder approval limitations specified in the Certificate of Designations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">CFIUS may delay, prevent or impose conditions on the Conversion.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">CFIUS has authority to review certain direct or indirect foreign investments in U.S.&#160;businesses for national security considerations. Among other things, CFIUS is authorized to require mandatory filings for certain foreign investments in the United&#160;States and to self<span class="nobreak">-initiate</span> national security reviews of certain foreign direct and indirect investments in U.S.&#160;businesses if the parties to such investments choose not to file voluntarily. With respect to transactions that CFIUS determines present unresolved national security concerns, CFIUS has the power to suspend transactions, impose mitigation measures or recommend that the President of the United&#160;States block pending transactions or order divestitures of completed transactions when national security concerns cannot be mitigated. Whether CFIUS has jurisdiction to review an acquisition or investment transaction depends on, among other factors, the nature and structure of the transaction, whether the target company is a U.S.&#160;business, the level of beneficial ownership and voting interests acquired by foreign persons, and the nature of any information, control, access or governance rights that the transaction affords foreign persons. For example, any transaction that could result in foreign &#8220;control&#8221; (as such term is defined in the CFIUS regulations) of a U.S.&#160;business is within CFIUS&#8217;s jurisdiction. In addition, CFIUS has jurisdiction over certain investments that do not result in control of a U.S.&#160;business by a foreign person but that afford a foreign person certain access, involvement or governance rights in a &#8220;TID U.S.&#160;business,&#8221; that is, a U.S.&#160;business that: (1)&#160;produces, designs, tests, manufactures, fabricates, or develops one or more &#8220;critical technologies;&#8221; (2)&#160;owns, operates, manufactures, supplies or services certain &#8220;critical infrastructure;&#8221; or (3)&#160;maintains or collects, directly or indirectly, &#8220;sensitive personal data&#8221; of U.S.&#160;citizens.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Certain entities or individuals associated with or otherwise involved in the transaction are, are controlled by or have substantial ties with a non<span class="nobreak">-U</span>.S.&#160;person. Specifically, each of Dr.&#160;Schiess and Mr.&#160;Br&#252;hlmann is a &#8220;foreign person&#8221; (as such term is defined in 31 C.F.R. &#167; 800.224).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">CFIUS has broad discretion to interpret its regulations, and we cannot predict whether CFIUS may seek to review the Conversion. If CFIUS reviews the Conversion and identifies an unresolved national security concern as part of such review, CFIUS could recommend that the President of the United&#160;States order one or more foreign persons to divest all or a portion of the Common Stock that they acquired without first obtaining CFIUS approval. Moreover, should CFIUS determine that any parties to the Conversion were required to make a filing with CFIUS but failed to do so, CFIUS could impose a civil penalty not to exceed $250,000 or the value of the relevant transaction, whichever is greater, on the parties it determines were subject to a mandatory filing requirement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Onconetix and Proteomedix will submit to CFIUS a joint declaration or notice with respect to the PMX Transaction upon the request of CFIUS, but Onconetix has determined to not exercise its right to elect to submit such a joint declaration or notice of its own initiative.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent fraud which could subject us to regulatory sanctions, harm our business and operating results and cause the trading price of our stock to decline.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Effective internal controls required under Section&#160;404 of the Sarbanes<span class="nobreak">-Oxley</span> Act are necessary for us to provide reliable financial reports and effectively prevent fraud. If we cannot provide reliable financial reports or prevent fraud, our business, reputation and operating results could be harmed. We have discovered, and may in the future discover, </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">48</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">areas of our internal controls that need improvement. We cannot be certain that the measures we have taken or intend to take will ensure that we maintain adequate controls over our financial processes and reporting in the future. Any failure to implement the required new or improved controls or difficulties encountered in their implementation could subject us to regulatory sanctions, harm our business and operating results or cause us to fail to meet our reporting obligations. Inferior internal controls could also harm our reputation and cause investors to lose confidence in our reported financial information, which could have a negative impact on the trading price of our stock.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We are an &#8220;emerging growth company&#8221; and the reduced disclosure requirements applicable to emerging growth companies could make our common stock less attractive to investors.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. We may remain an &#8220;emerging growth company&#8221; until as late as December&#160;31, 2027 (the fiscal year<span class="nobreak">-end</span> following the fifth anniversary of the completion of our initial public offering, which closed during February&#160;2022), though we may cease to be an &#8220;emerging growth company&#8221; earlier under certain circumstances, including (1)&#160;if the market value of our common stock that is held by nonaffiliates exceeds $700&#160;million as of any June&#160;30, in which case we would cease to be an &#8220;emerging growth company&#8221; as of the following December&#160;31, or (2)&#160;if our gross revenue exceeds $1.235&#160;billion in any fiscal year. &#8220;Emerging growth companies&#8221; may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes<span class="nobreak">-Oxley</span> Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Investors could find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In addition, Section&#160;102 of the JOBS Act also provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B)&#160;of the Securities Act, for complying with new or revised accounting standards. An &#8220;emerging growth company&#8221; can therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We are subject to increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As a public company, we incur significant legal, accounting, and other expenses that we did not incur as a private company, including costs associated with public company reporting requirements. The Sarbanes<span class="nobreak">-Oxley</span> Act&#160;of&#160;2002, as amended, or Sarbanes<span class="nobreak">-Oxley</span> Act, as well as rules subsequently adopted by the SEC and The Nasdaq Capital Market to implement provisions of the Sarbanes<span class="nobreak">-Oxley</span> Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July&#160;2010, the Dodd<span class="nobreak">-Frank</span> Wall Street Reform and Consumer Protection Act, or the Dodd<span class="nobreak">-Frank</span> Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd<span class="nobreak">-Frank</span> Act that require the SEC to adopt additional rules and regulations in these areas, such as &#8220;say on pay&#8221; and proxy access. Emerging growth companies may implement many of these requirements over a longer period of up to five&#160;years from the pricing of their initial public offering. We intend to take advantage of these extended transition periods but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel will devote a substantial amount of time to these compliance programs and monitoring of public company reporting obligations and as a result of the new corporate governance and executive compensation related rules, regulations and guidelines prompted by the Dodd<span class="nobreak">-Frank</span> Act and further regulations and disclosure obligations expected in the future, we will likely need to devote additional time and costs to comply with such compliance programs and rules. These rules and regulations will cause us to incur significant legal and financial compliance costs and will make some activities more time<span class="nobreak">-consuming</span> and costly.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">49</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">To comply with the requirements of being a public company, we may need to undertake various actions, including implementing new internal controls and procedures and hiring new accounting or internal audit staff. The Sarbanes<span class="nobreak">-Oxley</span> Act requires that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are continuing to develop and refine our disclosure controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in reports under the Securities Exchange&#160;Act&#160;of&#160;1934, as amended, or the Exchange&#160;Act, is accumulated and communicated to our principal executive and financial officers. Our current controls and any new controls that we develop may become inadequate and weaknesses in our internal control over financial reporting may be discovered in the future. Any failure to develop or maintain effective controls when we become subject to this requirement could negatively impact the results of periodic management evaluations and annual independent registered public accounting firm attestation reports regarding the effectiveness of our internal control over financial reporting that we may be required to include in our periodic reports we will file with the SEC under Section&#160;404 of the Sarbanes<span class="nobreak">-Oxley</span> Act&#160;of&#160;2002, or the Sarbanes<span class="nobreak">-Oxley</span> Act, harm our operating results, cause us to fail to meet our reporting obligations or result in a restatement of our prior period financial statements. In the event that we are not able to demonstrate compliance with the Sarbanes<span class="nobreak">-Oxley</span> Act, that our internal control over financial reporting is perceived as inadequate or that we are unable to produce timely or accurate financial statements, investors may lose confidence in our operating results and the price of our common stock could decline. In addition, if we are unable to continue to meet these requirements, we may not be able to remain listed on Nasdaq.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The rules and regulations applicable to public companies have substantially increased our legal and financial compliance costs and make some activities more time<span class="nobreak">-consuming</span> and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition, and results of operations. The increased costs will decrease our net income and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, these rules and regulations made it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs in the future to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees, or as executive officers.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Our management team has limited experience managing a public company.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Several members of our management team have limited experience managing a publicly<span class="nobreak">-traded</span> company, interacting with public company investors and complying with the increasingly complex laws pertaining to public companies. Our management team may not successfully or efficiently manage our transition to being a public company subject to significant regulatory oversight and reporting obligations under the federal securities laws and the continuous scrutiny of securities analysts and investors. These new obligations and constituents require significant attention from our senior management and could divert their attention away from the&#160;day<span class="nobreak">-to-day</span> management of our business, which could adversely affect our business, financial condition, and operating results.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and our trading volume could decline.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The trading market for our common stock depends, in part, on the research and reports that securities or industry analysts publish about us or our business. While we currently have certain analyst coverage, if one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our stock price could decline. In addition, if our operating results fail to meet the forecast of analysts, our stock price could decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our stock price and trading volume to decline.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Our stock repurchase program may adversely affect our liquidity and cause fluctuations in our stock price.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On November&#160;8, 2022, our Board authorized a stock repurchase program pursuant to which the Company may repurchase up to 5&#160;million shares of our common stock, with a maximum price of $1.00 per share, with discretion to management to make purchases subject to market conditions. On November&#160;18, 2022, our Board approved an increase to the maximum price to $2.00 per share.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">50</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Potential future stock repurchases under the stock share repurchase program could be funded by operating cash flow or excess cash balances. The maximum number of shares of the Company&#8217;s common stock that may yet be repurchased under the share repurchase program is 4.5&#160;million. Repurchases under the stock repurchase program may adversely affect our liquidity, which in turn could impact our profitability, financial condition, and results of operations. In addition, repurchases under the stock repurchase program will reduce the number of shares of our common stock available for purchase and sale in the public market, which could affect the market price of our common stock. Furthermore, the Inflation Reduction Act&#160;of&#160;2022, which was signed into law in August&#160;2022, imposes a non<span class="nobreak">-deductible</span> 1% excise tax on the fair market value of stock repurchases after December&#160;31, 2022, that exceed $1.0&#160;million in a taxable year, which may impact the tax efficiency of our stock repurchase program.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Failure in, or security breaches or incidents impacting, our information technology or storage systems could significantly disrupt our operations and our research and development efforts.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our ability to execute our business strategy will depend, in part, on the continued and uninterrupted performance of our information technology, or IT, systems, which support our operations, including at our proposed clinical laboratories. We are dependent on our IT systems for many aspects of our business, including our needs to retain and store our confidential and proprietary business information and to receive and process test orders, securely store patient health records and deliver the results of our tests. The integrity and protection of our own data, and that of our customers and employees, is critical to our business. The regulatory environment governing information, security and privacy and data protection laws is increasingly demanding and continues to evolve. IT systems are vulnerable to damage from a variety of sources, including telecommunications or network failures, cyberattacks (including ransomware attacks) and other malicious human acts from criminal hackers, hacktivists, state<span class="nobreak">-sponsored</span> intrusions and other attacks, industrial espionage and employee malfeasance, breaches, and incidents due to employee error or negligence, and natural disasters. Moreover, despite network security and back<span class="nobreak">-up</span> measures, some of our servers are potentially vulnerable to physical or electronic break<span class="nobreak">-ins</span>, computer viruses and other malicious code or similar disruptive problems.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proclarix is comprised of two components: Proclarix Assays and Proclarix Risk Calculator. The Proclarix Risk Calculator is cloud<span class="nobreak">-based</span> software to integrate the results from Proclarix Assays for THBS1 and CTSD together with age, total and free PSA (from third party manufacturers) to calculate the Proclarix Risk Score. When entering the Patient ID, a warning indicates that the Patient ID shall not contain any sensitive personal patient data. After the risk report is generated, the patient data including values for THBS1, CTSD, total and free PSA together with age and Patient ID is stored for six&#160;months and is then automatically deleted.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">High<span class="nobreak">-profile</span> security breaches and incidents at other companies and in government agencies have increased in recent&#160;years, particularly in the healthcare sector, and security industry experts and government officials have warned about the risks of hackers and cyber<span class="nobreak">-attacks</span> targeting businesses such as ours. Cyber<span class="nobreak">-attacks</span> are becoming more sophisticated and frequent, and in some cases have caused significant harm. Computer hackers and others routinely attempt to breach the security of technology products, services, and systems, and to fraudulently induce employees, customers, or others to disclose information or unwittingly provide access to systems or data. Much of our workforce currently works remotely rather than in our offices, and we may be more susceptible to security breaches and incidents as a result. Our service providers also may accommodate remote workers and therefore may be more susceptible to security breaches and other security incidents.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We have experienced and may in the future experience attempted or successful cyber<span class="nobreak">-attacks</span> of our IT systems or networks. To date, we have not experienced any material cyber<span class="nobreak">-attacks</span>. However, any security breach or incident or interruption could compromise our networks and the information stored therein, including algorithms relating to our products, could be accessed by unauthorized parties, publicly disclosed, lost, rendered inaccessible or unavailable, corrupted, or stolen. Despite the precautionary measures we have taken to prevent unanticipated problems that could affect our IT systems, unauthorized access to our systems, or disruptions or other security breaches impacting our IT systems, any unauthorized access to, or, loss, inaccessibility, unavailability, corruption, theft, or disclosure could also disrupt our operations, including our ability to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>process tests, provide test results, bill patients;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>provide customer assistance services;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collect, process and prepare company financial information;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">51</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:5.5pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>provide information about our tests and other patient and healthcare provider education and outreach efforts through our website; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:5.5pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>manage the administrative aspects of our business and damage our reputation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:5.5pt;">Any such breach, incident, or other compromise of IT systems or data, or the perception that any of these has occurred, could result in liability under laws that protect the privacy of personal information, such as the Health Insurance Portability and Accountability Act&#160;of&#160;1996, as amended by the Health Information Technology for Economic and Clinical Health Act&#160;of&#160;2009 (collectively, &#8220;HIPAA&#8221;), similar U.S.&#160;state data privacy and security laws and regulations, and other regulations, as well as in legal claims, complaints, regulatory investigations or proceedings, significant fines or other penalties, or the requirement to enter into a multi<span class="nobreak">-year</span> settlement and remediation agreement with federal or state agencies. We also may be required to incur significant costs in an effort to prevent, detect, and remediate security breaches and other security<span class="nobreak">-related</span> incidents. Additionally, information obtained by third parties in connection with past or future cyberattacks, or other security breaches or incidents could be used in ways that adversely affect our company or our stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:5.5pt;">Further, third<span class="nobreak">-party</span> service providers who support our operations, and our independent contractors, consultants, collaborators, and service providers also may suffer interruptions and disruptions of systems and other breaches, incidents, or other compromises of their IT systems or data that they process or maintain for us, which may lead to any of the foregoing. We and our third<span class="nobreak">-party</span> service providers may not have the resources or technical sophistication to anticipate or prevent all cyberattacks or other sources of security breaches or incidents, and we or they may face difficulties or delays in identifying and responding to cyberattacks and data security breaches and incidents. In addition, the interpretation and application of consumer or health related data security, privacy and protection laws in the United&#160;States, Europe and elsewhere are often uncertain, contradictory and in flux, such as in the area of international transfers of personal data. Complying with these various laws and satisfying healthcare providers&#8217; and patients&#8217; evolving expectations with respect to data protection, could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:5.5pt;">We do not maintain insurance policies for cybersecurity<span class="nobreak">-related</span> matters, data handling or data security liabilities. The successful assertion of one or more large claims against us could have a material adverse effect on our business, including our financial condition, operating results, and reputation.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Our Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws and Delaware law may have anti-takeover effects that could discourage, delay, or prevent a change in control, which may cause our stock price to decline.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:5.5pt;">Our Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws and Delaware law could make it more difficult for a third party to acquire us, even if closing such a transaction would be beneficial to our stockholders. Our Amended and Restated Certificate of Incorporation authorizes us to issue up to 10&#160;million shares of preferred stock. This preferred stock may be issued in one or more series, the terms of which may be determined at the time of issuance by our board of directors without further action by stockholders. The terms of any series of preferred stock may include voting rights (including the right to vote as a series on particular matters), preferences as to dividend, liquidation, conversion and redemption rights and sinking fund provisions. The issuance of any preferred stock could materially adversely affect the rights of the holders of our common stock, and therefore, reduce the value of our common stock. In particular, specific rights granted to future holders of preferred stock could be used to restrict our ability to merge with, or sell our assets to, a third party and thereby preserve control by the present management.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:5.5pt;">Provisions of our Amended and Restated Certificate of Incorporation, our Amended and Restated Bylaws and Delaware law also could have the effect of discouraging potential acquisition proposals or making a tender offer or delaying or preventing a change in control, including changes a stockholder might consider favorable. Such provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. In particular, our Amended and Restated Certificate of Incorporation, our Amended and Restated Bylaws and Delaware law, as applicable, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:5.5pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>provide the board of directors with the ability to alter the bylaws without stockholder approval;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:5.5pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>place limitations on the removal of directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:5.5pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>establish advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:5.5pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>provide that vacancies on the board of directors may be filled by a majority of directors in office, although less than a quorum.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">52</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As a Delaware corporation, we are also subject to provisions of Delaware law, including Section&#160;203 of the Delaware General Corporation law, which prevents certain stockholders holding more than 15% of our outstanding capital stock from engaging in certain business combinations without approval of the holders of at least two<span class="nobreak">-thirds</span> of our outstanding common stock not held by such stockholder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Any provision of our Amended and Restated Certificate of Incorporation, Amended and Restated Bylaws or Delaware law that has the effect of delaying, preventing, or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock, and could also affect the price that some investors are willing to pay for our common stock.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">We do not anticipate paying any cash dividends on our common stock in the foreseeable future and, as such, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We have never declared or paid cash dividends on our common stock. We do not anticipate paying any cash dividends on our common stock in the foreseeable future. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business. In addition, any future loan arrangements we enter into may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. As a result, capital appreciation, if any, of our common stock, which may never occur, will be your sole source of gain for the foreseeable future.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Environmental, social and governance matters may impact our business and reputation.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Increasingly, in addition to the importance of their financial performance, companies are being judged by their performance on a variety of environmental, social and governance (&#8220;ESG&#8221;) matters, which are considered to contribute to the long<span class="nobreak">-term</span> sustainability of companies&#8217; performance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A variety of organizations measure the performance of companies on such ESG topics, and the results of these assessments are widely publicized. In addition, investment in funds that specialize in companies that perform well in such assessments are increasingly popular, and major institutional investors have publicly emphasized the importance of such ESG measures to their investment decisions. Topics taken into account in such assessments include, among others, the company&#8217;s efforts and impacts on climate change and human rights, ethics and compliance with law, and the role of the company&#8217;s board of directors in supervising various sustainability issues. In addition to the topics typically considered in such assessments, in the healthcare industry, issues of the public&#8217;s ability to access our medicines are of particular importance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In light of investors&#8217; increased focus on ESG matters, there can be no certainty that we will manage such issues successfully, or that we will successfully meet society&#8217;s expectations as to our proper role. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation and on our business, share price, financial condition, or results of operations, including the sustainability of our business over time.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">A possible &#8220;short squeeze&#8221; due to a sudden increase in demand of our common stock that largely exceeds supply may lead to price volatility in our common stock.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Investors may purchase our common stock to hedge existing exposure in our common stock or to speculate on the price of our common stock. Speculation on the price of our common stock may involve long and short exposures. To the extent aggregate short exposure exceeds the number of shares of our common stock available for purchase in the open market, investors with short exposure may have to pay a premium to repurchase our common stock for delivery to lenders of our common stock. Those repurchases may in turn dramatically increase the price of our common stock until investors with short exposure are able to purchase additional common shares to cover their short position. This is often referred to as a &#8220;short squeeze.&#8221; A short squeeze could lead to volatile price movements in our common stock that are not directly correlated to the performance, or prospects of our company and once investors purchase the shares of common stock necessary to cover their short position the price of our common stock may decline.</p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">53</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span style="-keep: true">USE OF PROCEEDS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We will not receive any proceeds from the sale of the Common Stock by the Selling Stockholders. Any proceeds we receive from the exercise of the PIOs, net of our obligations to Veru under the Forbearance Agreement (as defined below), will be used for general corporate and working capital or for other purposes that the Board, in its good faith, deems to be in the best interest of the Company. No assurances can be given that any of such PIOs will be exercised or exercised for cash.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">54</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T8"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span style="-keep: true">DETERMINATION OF OFFERING PRICE</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Selling Stockholders will offer Common Stock at the prevailing market prices or a privately negotiated price as it may determine from time to time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The offering price of our Common Stock to be sold by the Selling Stockholders does not necessarily bear any relationship to our book value, assets, past operating results, financial condition, or any other established criteria of value. The facts considered in determining the offering price were our financial condition and prospects, our limited operating history and the general condition of the securities market.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In addition, there is no assurance that our Common Stock will trade at market prices in excess of the offering price as prices for our Common Stock in any public market will be determined in the marketplace and may be influenced by many factors, including the depth and liquidity.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">55</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T99301"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ABOUT THE COMPANY</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Company Overview</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We are a commercial stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men&#8217;s health and oncology. Through our recent acquisition of Proteomedix, we own Proclarix, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the In Vitro Diagnostic Regulation (&#8220;IVDR&#8221;), which we anticipate will be marketed in the U.S.&#160;as a lab developed test through our license agreement with LabCorp. We also own ENTADFI, an FDA<span class="nobreak">-approved</span>, once daily pill that combines finasteride and tadalafil for the treatment of BPH, a disorder of the prostate.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proclarix is an easy<span class="nobreak">-to-use</span> next generation protein<span class="nobreak">-based</span> blood test that can be done with the same sample as a patient&#8217;s regular Prostate<span class="nobreak">-Specific</span> Antigen (&#8220;PSA&#8221;) test. The PSA test is a well<span class="nobreak">-established</span> prostate specific marker that measures the concentration of PSA molecules in a blood sample. A high level of PSA can be a sign of prostate cancer. However, PSA levels can also be elevated for many other reasons including infections, prostate stimulation, vigorous exercise, or even certain medications. PSA results can be confusing for many patients and even physicians. It is estimated over 50% of biopsies with elevated PSA are negative or clinically insignificant resulting in an overdiagnosis and overtreatment that impacts the physician&#8217;s routine, our healthcare system, and the quality of patients&#8217; lives. Proclarix helps doctors and patients with unclear PSA test results through the use of our proprietary Proclarix Risk Score which delivers clear and immediate diagnostic support for further treatment decisions. No additional intervention is required, and results are available quickly. Local diagnostic laboratories can integrate this multiparametric test into their current workflow because Proclarix assays use the enzyme<span class="nobreak">-linked</span> immunosorbent assay (ELISA) standard, which most diagnostic laboratories are already equipped to process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">ENTADFI allows men to receive treatment for their symptoms of BPH without the negative sexual side effects typically seen in patients on finasteride alone. Following a recent business strategy shift towards the field of men&#8217;s health and oncology and deprioritizing of preclinical vaccine programs, we are building additional assets in therapeutics, diagnostics, and clinician services for men&#8217;s health and oncology.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Since our inception in October&#160;2018 until April&#160;2023, when we acquired ENTADFI, we devoted substantially all of our resources to performing research and development, undertaking preclinical studies and enabling manufacturing activities in support of our product development efforts, hiring personnel, acquiring and developing our technology and now deprioritized vaccine candidates, organizing and staffing our company, performing business planning, establishing our intellectual property portfolio and raising capital to support and expand such activities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Prior to the acquisition of ENTADFI, we managed one distinct business segment, which was research and development. Beginning in the second quarter of 2023, as a result of the acquisition of ENTADFI, we operated in two business segments: research and development and commercial. During the third quarter of 2023, we deprioritized our vaccine discovery and development programs, and accordingly, we now operate in one segment: commercial. Our recent acquisition of Proteomedix during the fourth quarter of 2023 and its related diagnostic product Proclarix was determined to be within our commercial segment. The research and development segment was our historical business, and was dedicated to the research and development of various vaccines to prevent infectious diseases. The commercial segment was new in the second quarter of 2023 and is dedicated to the commercialization of our products approved for sale, namely ENTADFI in the U.S.&#160;and Proclarix in Europe.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2023, the Company closed its acquisition of Proteomedix and introduced Onconetix, Inc. as the new name for the combined company. The closing of the acquisition of Proteomedix for all stock consideration provides Proteomedix shareholders with an initial 16.4% ownership stake of Onconetix, and Series&#160;B Preferred Stock convertible into 269,672,900<span class="nobreak"> </span>shares of Onconetix Common Stock, subject to Onconetix stockholder approval of the same (&#8220;Stockholder Approval&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In light of (i)&#160;the time and resources needed to continue pursuing commercialization of ENTADFI, and (ii)&#160;the Company&#8217;s cash runway and indebtedness, the Company has determined to temporarily pause its commercialization of ENTADFI, as it considers strategic alternatives. As part of a cost reduction plan approved by the Board and in connection with our pause in commercializing ENTADFI, we terminated three employees involved with the ENTADFI program, effective April<span class="nobreak"> </span>30, 2024, with such individuals to continue assisting the Company on an as<span class="nobreak">-needed</span>, consulting basis. The Company continues to consider various measures, including strategic alternatives, to rationalize its operations and optimize its existing Proclarix diagnostic program.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">56</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We are currently focusing our efforts on commercializing Proclarix.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Given Proclarix is CE<span class="nobreak">-marked</span> for sale in the European Union, we expect to generate revenue from sales of Proclarix by 2025. Although we anticipate these sales to offset some expenses relating to commercial scale up and development, we expect our expenses will increase substantially in connection with our ongoing activities, as we:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>commercialize Proclarix;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>hire additional personnel;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>operate as a public company; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>obtain, maintain, expand and protect our intellectual property portfolio.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">To the extent that we resume the commercialization of ENTADFI, we also expect to incur significant commercialization expenses related to marketing, manufacturing, and distribution for ENTADFI.&#160;We rely and will continue to rely on third parties for the manufacturing of ENTADFI and Proclarix. We have no internal manufacturing capabilities, and we will continue to rely on third parties, of which the main suppliers are single<span class="nobreak">-source</span> suppliers, for commercial products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We do not have any products approved for sale, aside from Proclarix, from which we have generated only minimal amounts of development revenue since its acquisition, and ENTADFI, from which we have not generated any revenue from product sales, and for which we have determined to temporarily pause commercialization activities. To date, we have financed our operations primarily with proceeds from our sale of preferred securities to seed investors, the initial public offering (&#8220;IPO&#8221;), the April&#160;2022 Private Placement (as defined below), the August&#160;2022 Private Placement (as defined below), the proceeds received from a warrant exercise in August&#160;2023, and the proceeds received from the issuance of debt in January&#160;2024. We will continue to require significant additional capital to commercialize Proclarix and ENTADFI (if we decide to resume its commercialization), and to fund operations for the foreseeable future. Accordingly, until such time as we can generate significant revenue, if ever, we expect to finance our cash needs through public or private equity or debt financings, third<span class="nobreak">-party</span> (including government) funding and to rely on third<span class="nobreak">-party</span> resources for marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches, to support our operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We have incurred net losses since inception and expect to continue to incur net losses in the foreseeable future. Our net losses may fluctuate significantly from quarter<span class="nobreak">-to-quarter</span> and year<span class="nobreak">-to-year</span>, depending in large part on the timing of our preclinical studies, clinical trials and manufacturing activities, our expenditures on other research and development activities and commercialization activities. As of December&#160;31, 2023, the Company had a working capital deficit of approximately $11.4&#160;million and an accumulated deficit of approximately $56.8&#160;million. We will need to raise additional capital within the next 12&#160;months to sustain operations. In addition, if Stockholder Approval is not obtained by January<span class="nobreak"> </span>1, 2025, the Company may be obligated to cash settle the Series B Preferred Stock. Based on the closing price of $0.122 for the Company&#8217;s stock as of April<span class="nobreak"> </span>24, 2024, the Series B Preferred Stock would be redeemable for approximately $32.9<span class="nobreak"> </span>million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Until we generate revenue sufficient to support self<span class="nobreak">-sustaining</span> cash flows, if ever, we will need to raise additional capital to fund our continued operations, including our product development and commercialization activities related to our current and future products. There can be no assurance that additional capital will be available to us on acceptable terms, or at all, or that we will ever generate revenue sufficient to provide self<span class="nobreak">-sustaining</span> cash flows. These circumstances raise substantial doubt about our ability to continue as a going concern. The accompanying consolidated financial statements of Onconetix, as of and for the year ended December&#160;31, 2023, included elsewhere in this prospectus do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Because of the numerous risks and uncertainties associated with our business, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Additionally, even if we are able to generate revenue from Proclarix or ENTADFI, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and may be forced to reduce our operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">57</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Management and History</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Onconetix, Inc. (formerly Blue Water Vaccines Inc. and Blue Water Biotech, Inc.) was founded in October&#160;2018. The Company&#8217;s initial goal was to develop a transformational universal flu vaccine to treat and prevent infections in patients globally. After deprioritizing our vaccine programs, the Company subsequently shifted its focus toward building a foundation of therapeutic, diagnostic, and service products in the field of men&#8217;s health and oncology.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our Interim Chief Executive Officer, Dr.&#160;Ralph Schiess, has extensive experience with life sciences companies. Dr.&#160;Schiess co<span class="nobreak">-founded</span> Proteomedix, a private commercial<span class="nobreak">-stage</span> diagnostics oncology company that the Company acquired in December&#160;2023 (as further described below) and served as its Chief Executive Officer from Proteomedix&#8217;s inception until December&#160;2019, as Proteomedix&#8217;s Chief Scientific Officer from January&#160;2020 to May&#160;2023, and again as Chief Executive Officer since June&#160;2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Bruce Harmon, our Chief Financial Officer, has more than 40&#160;years of experience in financial positions with life sciences companies and various other industries. Mr.&#160;Harmon has served in a variety of roles, including chief financial officer, controller, chief executive officer, and audit committee chairman. He has been an independent consultant since 2008 through his business, Lakeport Business Services, Inc., and served in the outsourced CFO capacity for multiple publicly traded companies. During this time, Mr.&#160;Harmon was CFO of Marizyme Inc. from 2020 to 2021, CFO of bioAffinity Technologies Inc. in 2022, a director of Dale Biotech LLC since 2017, and a director of Patriax Industries since 2023. He has extensive experience with fundraising, public offerings, mergers and acquisitions, and turnarounds. Earlier in his career, he was a member of a team that, at the invitation of the Environmental Programm&#233;, presented a green building product to delegates at the United Nations. He earned a Bachelor of Science degree in accounting from Missouri State University.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, members of our Board of Directors have extensive expertise in the fields of life sciences, business, and finance. Our directors include Simon Tarsh, a retired Deloitte Consulting managing director with experience in life sciences, Timothy Ramdeen, who has nearly a decade of experience in private equity and hedge fund investing, capital markets, and company formation, and James Sapirstein, R.Ph., M.B.A, President, CEO and Chairman of First Wave BioPharma, Inc. (Nasdaq: FWBI).</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Corporate Name Change and Amendment to Bylaws</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;21, 2023, the Company filed an amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to change its corporate name from &#8220;Blue Water Vaccines Inc.&#8221; to &#8220;Blue Water Biotech, Inc.&#8221; The name change was effective as of April&#160;21, 2023. In connection with the name change, the Company amended the Company&#8217;s bylaws to reflect the corporate name &#8220;Blue Water Biotech, Inc.,&#8221; also effective on April&#160;21, 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2023, the Company filed an amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to change its corporate name from &#8220;Blue Water Biotech, Inc.&#8221; to &#8220;Onconetix, Inc.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the name change, the Company also amended the Company&#8217;s bylaws to reflect the new corporate name.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On May&#160;31, 2023, the Board amended the Company&#8217;s bylaws to reduce the quorum requirement at meetings of the Company&#8217;s stockholders from a majority of the voting power of the outstanding shares of stock of the Company entitled to vote, to one<span class="nobreak">-third</span> of the voting power of the outstanding shares of stock of the Company entitled to vote, effective immediately. No other changes were made to the bylaws.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Nasdaq Compliance</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On September&#160;18, 2023, we received notice from Nasdaq staff indicating that, based upon the closing bid price of the Common Stock for the prior 30 consecutive&#160;business days, we were not in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule&#160;5550(a)(2)&#160;(the &#8220;Bid Price Rule&#8221;). On March&#160;13, 2024, we submitted a plan of compliance to Nasdaq to discuss our plans to evidence compliance with the Bid Price Rule and we received an additional 180<span class="nobreak">-day</span> period, or until September&#160;16, 2024, to regain compliance with the Bid Price Rule.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">58</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;22, 2023, we received a notice from Nasdaq that we were not in compliance with Nasdaq Listing Rule&#160;5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the SEC, given our failure to timely file our quarterly report on Form&#160;10<span class="nobreak">-Q</span> for the quarter ended June&#160;30, 2023. On October&#160;20, 2023, we filed our Form&#160;10<span class="nobreak">-Q</span> for the period ended June&#160;30, 2023, and on November&#160;1, 2023, we announced that we had regained compliance with Nasdaq Listing Rule&#160;5250(c)(1).</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Recent Acquisitions</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Proteomedix</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2023, Onconetix entered into a Share Exchange Agreement (the &#8220;Share Exchange Agreement&#8221;), by and among (i)&#160;Onconetix, (ii)&#160;Proteomedix, (iii)&#160;each of the holders of outstanding capital stock, convertible securities, or stock options of Proteomedix named therein (collectively, the &#8220;Sellers&#8221;) and (iv)&#160;Thomas Meier, in the capacity as the representative of Sellers in accordance with the terms and conditions of the Share Exchange Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Share Exchange Agreement, subject to the terms and conditions set forth therein, the Sellers agreed to sell to Onconetix, and Onconetix agreed to buy, all of the issued and outstanding voting equity interests of Proteomedix in exchange for newly issued shares of Common Stock and newly issued shares of Series&#160;B Preferred Stock (the &#8220;Share Exchange&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The consummation of the Share Exchange (the &#8220;Share Exchange Closing&#8221;) was subject to customary closing conditions and the execution of the Subscription Agreement entered into with Altos Ventures, a shareholder of Proteomedix prior to the closing of the Share Exchange (the &#8220;PMX Investor&#8221;). The Share Exchange closed on December&#160;15, 2023 (the &#8220;Share Exchange Closing Date&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Founded in 2010, Proteomedix develops, markets and sells non<span class="nobreak">-invasive</span> diagnostic tests accompanied by decision support systems to detect and assess the prognosis of cancer. Proteomedix&#8217;s lead product, Proclarix<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span>, is an in vitro diagnostic test for prostate cancer. Proteomedix is working to address all stages in cancer management by developing tools for both more accurate detection and more efficient treatment of cancer including (i)&#160;diagnostic tests to early detect and define the stage of cancer; (ii)&#160;prognostic tools for the identification of patients with aggressive disease; and (iii)&#160;stratification biomarkers to match patients with therapies that are more likely to be safe and effective.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Currently, prostate cancer stands as the most prevalent and second most fatal cancer type affecting men. The widespread utilization of PSA screening since it became broadly available in the 1980s helped reduce the occurrence of metastatic prostate cancers by over half, but also led to a notable increase in overdiagnosis, sometimes resulting in excessive treatment, severe complications, and potential psychological distress. There exists a considerable population of men each year who are notified of their heightened risk for prostate cancer based on elevated PSA levels, with limited options beyond invasive needle biopsies for managing their cancer risk.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proclarix addresses the unsolved problem of prostate cancer overdiagnosis, which can lead to negative prostate biopsies that increase costs for the healthcare system and uncertainty for patients. Proclarix is approved for sale in the European Union under the IVDR.&#160;Proclarix was first CE marked under the IVD Directive in Europe in January&#160;31, 2019. On October&#160;7, 2022, Proclarix gained CE marking under the IVD Regulation (IVDR) and was registered in the United Kingdom and Switzerland under applicable regulations. Clinical studies have confirmed that Proclarix accurately identifies clinically significant prostate cancer through a risk score derived from a clinical decision support system and could help avoid many unneeded biopsies. Proclarix as a clinical support system is designed to aggregate multimodal information in an effort to develop a patient<span class="nobreak">-centric</span> diagnostic approach. We intend to add more information to the risk score in the future, such as other biomarkers or magnetic resonance imaging data, to provide an even more powerful tool to guide the patient&#8217;s diagnostic journey. The markers and the bioinformatics algorithm used are patent<span class="nobreak">-protected</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The guidelines of the European Association of Urology (&#8220;EAU&#8221;) and of the American Urological Association/Society of Urologic Oncology (&#8220;AUA/SUO&#8221;) both recommend the use of blood<span class="nobreak">-based</span> biomarker tests, such as Proclarix, to aid in the early detection and evaluation of prostate cancer. Proclarix can be performed in any laboratory using standard equipment. Proteomedix announced commercial availability of Proclarix in Europe on February&#160;26, 2020, and began marketing Proclarix to selected pilot laboratories offering Proclarix in Switzerland, </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">59</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Germany, Italy and the United Kingdom. Proclarix is currently not reimbursed in Europe, and therefore patients pay for Proclarix out of pocket. The number of sold Proclarix tests current corresponds to the early market development stage and selected few laboratories offering Proclarix. In 2023, we had revenues of $67,380 from sales of Proclarix, compared to $79,085 in 2022. In the United&#160;States, the development and commercialization of Proclarix is being pursued by Laboratory Corporation of America Holdings, more commonly called Labcorp, pursuant to an exclusive license agreement entered into between Proteomedix and Labcorp in 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix was founded by a multi<span class="nobreak">-disciplinary</span> group of scientists and clinicians that include Prof. Emeritus Dr.&#160;Thomas Cerny, president of the Swiss Cancer Research Foundation, Prof. Ruedi Aebersold, a pioneer in proteomics technology development, and the late Prof. Wilhelm Krek, a leader in cancer research. Proteomedix&#8217;s management consists of Dr.&#160;Ralph Schiess (Chief Executive Officer), who developed the biomarker technology, and Christian Br<span class="CharOverride-3" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#363;</span>hlmann (Chief Business Officer), with seasoned experience in finance, business development and product management.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Terms of the PMX Transaction</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Consideration</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In full payment for the Purchased Shares, Onconetix issued shares (the &#8220;Exchange Shares&#8221;) consisting of: (i)&#160;3,675,414<span class="nobreak"> </span>shares of Common Stock equal to approximately 19.99% of the total issued and outstanding Common Stock prior to the acquisition and (ii)&#160;2,696,729<span class="nobreak"> </span>shares of Series&#160;B Preferred Stock convertible into 269,672,900<span class="nobreak"> </span>shares of Common Stock (the &#8220;Exchange Consideration&#8221;). Following the Share Exchange Closing, 22,841,975 and 22,324,576<span class="nobreak"> </span>shares of Common Stock were issued and outstanding, respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of the 3,675,414<span class="nobreak"> </span>shares of Common Stock, was determined using the closing price of the Common Stock as of the Share Exchange Closing Date, which was $0.2382. The fair value of the 2,696,729<span class="nobreak"> </span>shares of Series&#160;B Preferred Stock was based on the underlying fair value of the common shares issuable upon conversion, also based on the closing price of the Common Stock as of the Share Exchange Closing Date. The aggregate fair value of the common and preferred shares issued as consideration was equal to approximately $65.1&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Tungsten Advisors acted as financial advisor to Proteomedix at Proteomedix&#8217;s expense. As part of compensation for services rendered by Tungsten Advisors, the parties agreed that 664,895 Exchange Shares would be issued to certain affiliates of Tungsten Advisors (the &#8220;Advisor Parties&#8221;) out of the total Exchange Consideration issued by Onconetix.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As a result of the PMX Transaction, Proteomedix became a direct, wholly owned subsidiary of Onconetix. It is anticipated that, following the Conversion (as defined below) and closing of the investment pursuant to the Subscription Agreement (as defined below), Sellers will own approximately 87.2% of the outstanding equity interests of Onconetix, the PMX Investor will own approximately 7.5% of the outstanding equity interests of Onconetix, and the stockholders of Onconetix immediately prior to the Share Exchange Closing will own approximately 5.3% of the outstanding equity interests of Onconetix.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Each option to purchase shares of Proteomedix (each, a &#8220;Proteomedix Stock Option&#8221;) outstanding immediately before the Share Exchange Closing, whether vested or unvested, remains outstanding until the Conversion unless otherwise terminated in accordance with its terms. At the Conversion, each outstanding Proteomedix Stock Option, whether vested or unvested, shall be assumed by Onconetix and converted into the right to receive (a)&#160;an option to acquire shares of Common Stock (each, an &#8220;Assumed Option&#8221;) or (b)&#160;such other derivative security as Onconetix and Proteomedix may agree, subject in either case to substantially the same terms and conditions as were applicable to such Proteomedix Stock Option immediately before the Share Exchange Closing. Each Assumed Option shall: (i)&#160;represent the right to acquire a number of shares of Common Stock equal to the product of (A)&#160;the number of Proteomedix Common Shares that were subject to the corresponding Proteomedix Option immediately prior to the Share Exchange Closing, multiplied by (B)&#160;the Exchange Ratio (as defined in the Share Exchange Agreement); and (ii)&#160;have an exercise price (as rounded down to the nearest whole cent) equal to the quotient of (A)&#160;the exercise price of the corresponding Proteomedix Option, divided by (B)&#160;the Exchange Ratio.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">60</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Indemnification.&#160;&#160;&#160;&#160;</span>Until the earlier of (i)&#160;Stockholder Approval or (ii)&#160;June&#160;30, 2024 (the &#8220;Claim Deadline&#8221;), Onconetix may assert Claims against Proteomedix and Sellers for any and all Losses incurred by Onconetix with respect to: (i)&#160;any inaccuracy in or breach of any of the representations or warranties made by Proteomedix contained in the Share Exchange Agreement or (ii)&#160;any breach or non<span class="nobreak">-fulfillment</span> of any covenant, agreement or obligation to be performed by Proteomedix pursuant to the Share Exchange Agreement. Until the Claim Deadline, the Sellers&#8217; Representative, acting on behalf of the Sellers, may assert Claims against Onconetix for any Loss incurred by the Sellers with respect to: (i)&#160;any inaccuracy in or breach of any of the representations or warranties of Onconetix contained in the Share Exchange Agreement or (ii)&#160;any breach or non<span class="nobreak">-fulfillment</span> of any covenant, agreement or obligation to be performed by Onconetix pursuant to the Share Exchange Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The number of shares of Common Stock issued upon Conversion shall be increased or decreased by a number determined by dividing the Net Adjustment by the ten<span class="nobreak">-day</span> volume<span class="nobreak">-weighted</span> average price (&#8220;VWAP&#8221;) of the Common Stock for the ten (10)<span class="nobreak">-day</span> period preceding the third&#160;day prior to the Share Exchange Closing Date and rounding down to the nearest whole share; provided, however, that (i)&#160;there shall be no adjustment to the number of shares of Common Stock issued upon Conversion if the Net Adjustment is less than $1,000,000 and (ii)&#160;the number of shares of Common Stock issued upon Conversion shall not be increased or decreased by more than 10% of the number of shares of Common Stock that would be issuable absent such adjustment. As used herein, &#8220;Net Adjustment&#8221; means the absolute value of the difference between the aggregate adjustment in favor of each party with respect to Losses that is agreed by Onconetix and the Sellers&#8217; Representative or determined by a mutually acceptable dispute resolution firm.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">From and after the Share Exchange Closing and until the first anniversary of the Share Exchange Closing, Sellers, severally and not jointly, are required to indemnify Onconetix and its affiliates and their respective representatives (collectively, the &#8220;Onconetix Indemnitees&#8221;) against (i)&#160;any inaccuracy in or breach of any of the representations or warranties of such Seller contained in the Share Exchange Agreement and (ii)&#160;breach or non<span class="nobreak">-fulfillment</span> of any covenant, agreement or obligation to be performed by such Seller pursuant to the Share Exchange Agreement. Any payment due from any Seller in respect of an indemnification claim by any Onconetix Indemnitee shall solely be satisfied by recourse to the Exchange Shares and the shares of Common Stock issuable upon the Conversion, with each share of Common Stock valued at the same price per share of Common Stock used to determine the Exchange Ratio.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Covenants of the Parties</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Each party to the Share Exchange Agreement agreed to use its commercially reasonable efforts to effect the PMX Transaction. Onconetix obtained a duly executed Stockholder Support Agreement (as defined below) from each director and executive officer of Onconetix and used commercially reasonable efforts to obtain a duly executed Stockholder Support Agreement from each holder of more than five percent (5%) of Onconetix&#8217;s voting stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Share Exchange Agreement contains certain covenants by each of the parties, to be observed during the period between the Share Exchange Closing and Conversion, including covenants regarding: (1)&#160;the provision of access to properties, books and personnel; (2)&#160;delivery of Onconetix&#8217;s financial statements; (3)&#160;litigation support; (4)&#160;Onconetix&#8217;s public filings; (5)&#160;no insider trading; (6)&#160;further assurances; (7)&#160;public announcements; (8)&#160;confidentiality; (9)&#160;indemnification of directors and officers and tail insurance; (10)&#160;intended tax treatment of the Share Exchange; (11)&#160;Section&#160;16 matters and (12)&#160;transfer taxes.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The parties agreed to take all necessary actions to cause Onconetix&#8217;s board of directors immediately after the Stockholder Approval (the &#8220;Post<span class="nobreak">-Stockholder</span> Approval Onconetix Board&#8221;) to consist of five directors, including: (i)&#160;two persons who are designated by Onconetix and reasonably acceptable to Proteomedix; and (ii)&#160;three persons who are designated by Proteomedix and reasonably acceptable to Onconetix.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The issuance of the Conversion Shares, amendment of Onconetix&#8217;s Amended and Restated Certificate of Incorporation to authorize sufficient additional shares of Common Stock to permit the Conversion (to the extent required to consummate the PMX Transaction) and the appointment of the post<span class="nobreak">-Stockholder</span> Approval Onconetix Board requires the approval of Onconetix&#8217;s stockholders. Onconetix agreed to prepare and file with the SEC a proxy statement (a &#8220;Proxy Statement&#8221;) for the purpose of soliciting proxies from the stockholders of Onconetix for the matters to be acted on at the special meeting of the stockholders of Onconetix. Onconetix also agreed to prepare a registration statement on Form&#160;S<span class="nobreak">-1</span> or Form&#160;S<span class="nobreak">-4</span> in connection with the registration under the Securities Act&#160;of&#160;1933, as amended (the &#8220;Securities Act&#8221;), of the issuance of Onconetix Securities to be issued under the Share Exchange Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">61</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Sellers, Onconetix and Proteomedix agreed to, at the election of Onconetix (which election it has determined not to exercise) or upon the request of CFIUS, submit to CFIUS a joint declaration or notice with respect to the PMX Transaction as promptly as practicable, but in no event later than sixty (60)&#160;days after the date of the Share Exchange Agreement. The parties, in cooperation with each other, agreed to use reasonable best efforts to take all such actions within their respective powers to obtain the approval of CFIUS (&#8220;CFIUS Approval&#8221;), and, without limiting the foregoing, the parties agreed to, after reasonable negotiation efforts, agree to such requirements or conditions to mitigate any national security concerns as may be requested or required by CFIUS in connection with, or as a condition of, CFIUS Approval, including entering into a mitigation agreement, letter of assurance, or national security agreement, but provided: (1)&#160;the parties shall have no obligation to (A)&#160;propose, negotiate, commit to or effect, by consent decree, hold separate order, agreement or otherwise, the sale, transfer, license, divestiture or other disposition of, any of the businesses, product lines or assets of Onconetix or any of its affiliates or of the Sellers, (B)&#160;terminate existing, or create new, relationships, contractual rights or obligations of Onconetix or its affiliates, (C)&#160;effect any other change or restructuring of Onconetix or its affiliates, or (D)&#160;otherwise take or commit to take any actions reasonably expected to have a material adverse effect on the operation of the business of the Sellers or that interfere with Onconetix&#8217;s ability to control Proteomedix or Onconetix&#8217;s ability to direct the management and policies of the business of Proteomedix in any material respect; and (2)&#160;Proteomedix and the Sellers agreed not take or agree to take any of the foregoing actions without the prior written consent of Onconetix.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The parties agreed to use commercially reasonable best efforts to (i)&#160;ensure that the application for Onconetix&#8217;s change of control (&#8220;Nasdaq Change of Control Application&#8221;) is filed with The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) and (ii)&#160;to respond to any questions from Nasdaq with respect to the Nasdaq Change of Control Application promptly following receipt of such questions, but in no event later than ten (10)&#160;business days following receipt of such questions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the time between the Share Exchange Closing and the Conversion, Onconetix also agreed, and agreed to cause its Subsidiaries, to conduct their respective businesses in the ordinary course of business in all material respects and agreed to covenants regarding operation of their respective businesses, including covenants related to (i)&#160;amendments to Onconetix&#8217;s organizational documents; (ii)&#160;recapitalization of Onconetix&#8217;s equity interests; (iii)&#160;issuance of additional securities; (iv)&#160;incurrence of additional indebtedness; (v)&#160;material changes to tax elections; (vi)&#160;amendments or termination of material contracts; (vii)&#160;records and books; (viii)&#160;establishment of any Subsidiary or entry into a new line of business; (ix)&#160;maintenance of insurance policies; (x)&#160;revaluation of material assets or material changes in accounting methods, principles or policies except to the extent to comply with U.S.&#160;GAAP; (xi)&#160;waiver or settlement of any claim, action or proceeding, other than waivers not in excess of $500,000; (xii)&#160;acquisition of equity interests or assets, or any other form of business combination, outside of the ordinary course of business; (xiii)&#160;capital expenditures in excess of $500,000 individually or $1,000,000 in the aggregate; (xiv)&#160;adoption of a plan of liquidation, dissolution, merger, consolidation, restructuring, recapitalization or other reorganization; (xv)&#160;voluntary incurrence of any liability or obligation in excess of $500,000 individually or $1,000,000 in the aggregate other than pursuant to the terms of a Contract in existence as of the date of the Share Exchange Agreement or entered into in the ordinary course of business, except in connection with a Permitted Financing (as defined below); (xvi)&#160;sale, lease, license or other disposition of any material portion of Onconetix properties, assets or rights; (xvii)&#160;entry into any agreement, understanding or arrangement with respect to the voting of Common Stock, except in connection with a Permitted Financing; (xviii)&#160;taking any action that would reasonably be expected to significantly delay or impair the obtaining of any Consents of any Governmental Authority to be obtained in connection with the Share Exchange Agreement; or (xix)&#160;authorizing or agreeing to do any of the foregoing actions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">&#8220;Permitted Financing&#8221; means one or more debt or equity financing transactions consummated by and funded into Onconetix during the time between the Share Exchange Closing and the Conversion resulting in aggregate gross proceeds of no greater than $25&#160;million.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Governing Law</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Share Exchange Agreement is governed by the laws of the State of Delaware.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Terms of the Series&#160;B Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Upon Stockholder Approval, each share of Series&#160;B Preferred Stock shall automatically convert into 100<span class="nobreak"> </span>shares of Common Stock in accordance with the terms of the Certificate of Designation, Preferences and Rights of Series&#160;B Preferred Stock (the &#8220;Series&#160;B Certificate of Designation&#8221;) (the &#8220;Conversion&#8221;). If Stockholder Approval is not </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">62</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">obtained by January&#160;1, 2025, Onconetix shall be obligated to cash settle the Series&#160;B Preferred Stock, as described below. The terms of the Series&#160;B Preferred Stock, as described in the Series&#160;B Certificate of Designation, are as follows:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Voting.&#160;&#160;&#160;&#160;</span>The shares of Series&#160;B Preferred Stock carry no voting rights except: (i)&#160;with respect to the election of the Proteomedix Director (as described below) and (ii)&#160;that the affirmative vote of the holders of a majority of the outstanding shares of Series&#160;B Preferred Stock (the &#8220;Majority Holders&#8221;), acting as a single class, shall be necessary to (A)&#160;alter or change adversely the powers, preferences or rights given to the Series&#160;B Preferred Stock, (B)&#160;alter or amend the Series&#160;B Certificate of Designation, or amend or repeal any provision of, or add any provision to, Onconetix&#8217;s Amended and Restated Certificate of Incorporation or bylaws, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series&#160;B Preferred Stock, (C)&#160;issue further shares of Series&#160;B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series&#160;B Preferred Stock, or (D)&#160;authorize or create any class or series of stock, or issue shares of any class or series of stock, that has powers, preferences or rights senior to the Series&#160;B Preferred Stock</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Proteomedix Director.&#160;&#160;&#160;&#160;</span>The Majority Holders, voting exclusively and as a separate class, shall be entitled to elect one (1)&#160;director of Onconetix. Any director elected as provided in the preceding sentence may be removed without cause by, and only by, the affirmative vote of the holders of the Series&#160;B Preferred Stock. If the holders of Series&#160;B Preferred Stock fail to elect a director, then any directorship not so filled shall remain vacant until such time as the holders of the Series&#160;B Preferred Stock elect a person to fill such directorship; and no such directorship may be filled by stockholders of Onconetix other than by the holders of Series&#160;B Preferred Stock. At any meeting held for the purpose of electing a director, the presence in person or by proxy of the holders of a majority of the outstanding shares of Series&#160;B Preferred Stock shall constitute a quorum for the purpose of electing such director. On February&#160;6, 2024, the Majority Holders appointed Thomas Meier, PhD, to the Board.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Redemption.&#160;&#160;&#160;&#160;</span>The shares of Series&#160;B Preferred Stock are not redeemable by Onconetix.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Liquidation Preference.&#160;&#160;&#160;&#160;</span>Upon a liquidation, dissolution or winding<span class="nobreak">-up</span> of Onconetix, whether voluntary or involuntary (a &#8220;Liquidation&#8221;), the holders of Series&#160;B Preferred Stock shall be entitled to receive out of the assets, whether capital or surplus, of Onconetix the same amount that a holder of Common Stock would receive if such Holder&#8217;s Series&#160;B Preferred Stock were fully converted to Common Stock at the Conversion Ratio (as defined below) plus an additional amount equal to any dividends declared but unpaid to such shares, which amounts shall be paid <span class="Italic" style="font-style:italic;font-weight:normal;">pari passu </span>with all holders of Common Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Dividends.&#160;&#160;&#160;&#160;</span>The holders of the Series&#160;B Preferred Stock shall be entitled to receive, dividends on shares of Series&#160;B Preferred Stock (on an as<span class="nobreak">-if-converted-to-common-stock</span> basis) equal to and in the same form, and in the same manner, as dividends (other than dividends on shares of the Common Stock payable in the form of Common Stock) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends payable in the form of Common Stock) are paid on shares of the Common Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Conversion.&#160;&#160;&#160;&#160;</span>Following Stockholder Approval, each share of Series&#160;B Preferred Stock shall be converted into shares of Common Stock (the &#8220;Conversion Shares&#8221;) at a ratio of 100 Conversion Shares for each share of Series&#160;B Preferred Stock (the &#8220;Conversion Ratio&#8221;). All shares of Series&#160;B Preferred Stock shall automatically and without any further action required be converted into Conversion Shares at the Conversion Ratio upon the latest date on which (i)&#160;Onconetix has received the Stockholder Approval with respect to the issuance of all of the shares of Common Stock issuable upon Conversion in excess of 20% of the issued and outstanding Common Stock on the Share Exchange Closing Date and (ii)&#160;Onconetix has effected an increase in the number of shares of Common Stock authorized under its Amended and Restated Certificate of Incorporation, to the extent required to consummate the PMX Transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Cash Settlement.&#160;&#160;&#160;&#160;</span>If, at any time after the earlier of the date of the Stockholder Approval or January&#160;1, 2025 (the earliest such date, the &#8220;Cash Settlement Date&#8221;), Onconetix (x)&#160;has obtained the Stockholder Approval but fails to or has failed to deliver to a holder certificate or certificates representing the Conversion Shares, or deliver documentation of book entry form of (or cause its transfer agent to electronically deliver such evidence) Conversion Shares on or prior to the fifth business&#160;day after the date of the Stockholder Approval, or (y)&#160;has failed to obtain the Stockholder Approval, Onconetix shall, in either case, at the request of the holder setting forth such holder&#8217;s request to cash settle a number of shares of Series&#160;B Preferred Stock, pay to such holder an amount in cash equal to (i)&#160;the Fair Value (as defined below) of the shares of Series&#160;B Preferred Stock set forth in such request multiplied by (ii)&#160;the Conversion Ratio in effect on the&#160;trading day on which the request is delivered to Onconetix, with such payment to be made within two (2)&#160;business </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">63</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">days from the date of the request by the holder, whereupon, after payment in full thereon by Onconetix, Onconetix&#8217;s obligations to deliver such shares underlying the request shall be extinguished. &#8220;Fair Value&#8221; of shares shall be fixed with reference to the last reported closing stock price on the principal trading market of the Common Stock on which the Common Stock is listed as of the&#160;trading day on which the request is delivered to Onconetix.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Certain Adjustments.&#160;&#160;&#160;&#160;</span>If Onconetix, at any time while the Series&#160;B Preferred Stock is outstanding: (A)&#160;pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock; (B)&#160;subdivides outstanding shares of Common Stock into a larger number of shares; or (C)&#160;combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, then the Conversion Ratio shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock outstanding immediately after such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately before such event (excluding any treasury shares of the Corporation). If, at any time while the Series&#160;B Preferred Stock is outstanding, either (A)&#160;Onconetix effects any merger or consolidation of Onconetix with or into another person or any stock sale to, or other business combination with or into another person (other than such a transaction in which Onconetix is the surviving or continuing entity and holds at least a majority of the Common Stock after giving effect to the transaction and its Common Stock is not exchanged for or converted into other securities, cash or property), (B)&#160;Onconetix effects any sale, lease, transfer or exclusive license of all or substantially all of its assets in one transaction or a series of related transactions, (C)&#160;any tender offer or exchange offer (whether by Onconetix or another person) is completed pursuant to which more than 50% of the Common Stock not held by Onconetix or such person is exchanged for or converted into other securities, cash or property, or (D)&#160;Onconetix effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (in any such case, a &#8220;Fundamental PMX Transaction&#8221;), then, in connection with any such transaction in (A)&#160;through (D), the holders of Series&#160;B Preferred Stock shall receive in such transaction, the same kind and amount of securities, cash or property that a holder of Common Stock would receive if such holder&#8217;s Series&#160;B Preferred Stock were fully converted to Common Stock, plus an additional amount equal to any dividends declared but unpaid to such shares, which amounts shall be paid pari passu with all holders of Common Stock in the Fundamental PMX Transaction (the &#8220;Alternate Consideration&#8221;). If holders of Common Stock are given any choice as to the securities, cash or property to be received in a transaction in (A)&#160;through (D), then the holders of Series&#160;B Preferred Stock shall be given the same choice as to the Alternate Consideration it receives in such transaction.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Lock-Up Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Simultaneously with the execution of the Share Exchange Agreement, the Sellers and the Advisor Parties, as shareholders of Proteomedix, entered into Lock<span class="nobreak">-Up</span> Agreements (each, a &#8220;Lock<span class="nobreak">-Up</span> Agreement&#8221;). Pursuant to each Lock<span class="nobreak">-Up</span> Agreement, each signatory thereto will agree not to, during the period commencing from the Share Exchange Closing Date and ending on the 6<span class="nobreak">-month</span> anniversary of the date of Stockholder Approval: (i)&#160;lend, offer, pledge, hypothecate, encumber, donate, assign, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, the Exchange Shares or the Conversion Shares, (ii)&#160;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Exchange Shares or the Conversion Shares, or (iii)&#160;publicly disclose the intention to do any of the foregoing, whether any such transaction described in clauses (i), (ii)&#160;or (iii)&#160;above is to be settled by delivery of the Exchange Shares or the Conversion Shares or other securities, in cash or otherwise (subject to certain exceptions).</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Non-Competition and Non-Solicitation Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Simultaneously with the execution of the Share Exchange Agreement, certain executive officers (each, a &#8220;Management Shareholder&#8221;) of Proteomedix each entered into a non<span class="nobreak">-competition</span> and non<span class="nobreak">-solicitation</span> agreement (collectively, the &#8220;Non<span class="nobreak">-Competition</span> and Non<span class="nobreak">-Solicitation</span> Agreements&#8221;) with Onconetix. Under the Non<span class="nobreak">-Competition</span> and Non<span class="nobreak">-Solicitation</span> Agreements, each Management Shareholder agreed not to compete with Proteomedix, and after the Share Exchange Closing, Onconetix, and their respective affiliates during the three<span class="nobreak">-year</span> period following the Share Exchange Closing and, during such three<span class="nobreak">-year</span> restricted period, not to solicit employees or customers of such entities. Each Non<span class="nobreak">-Competition</span> and Non<span class="nobreak">-Solicitation</span> Agreement also contains customary confidentiality and non<span class="nobreak">-disparagement</span> provisions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">64</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stockholder Support Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Simultaneously with the execution of the Share Exchange Agreement, Onconetix, Proteomedix and certain directors of Onconetix who are stockholders of Onconetix, entered into a Stockholder Support Agreement (the &#8220;Stockholder Support Agreement&#8221;), pursuant to which, among other things, each such stockholder of Onconetix has agreed (a)&#160;to support the adoption of the Share Exchange Agreement and the approval of the PMX Transaction, subject to certain customary conditions, and (b)&#160;not to transfer any of their subject shares (or enter into any arrangement with respect thereto), subject to certain customary conditions.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stockholder Subscription Agreement and Debenture</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the PMX Transaction, on December&#160;18, 2023, Onconetix entered into a Subscription Agreement (the &#8220;Subscription Agreement&#8221;) with the PMX Investor for a private placement of $5.0&#160;million of units (the &#8220;Units&#8221;), each Unit comprised of (i)&#160;one share of Common Stock and (ii)&#160;one pre<span class="nobreak">-funded</span> warrant (collectively, the &#8220;Warrants&#8221;) to purchase 0.3<span class="nobreak"> </span>shares of Common Stock at an exercise price of $0.001 per share, for an aggregate purchase price per Unit of $0.25 (the &#8220;Purchase Price&#8221;). Additional shares are issuable to the PMX Investor to the extent the PMX Investor continues to hold Common Stock included in the Units&#160;and if the VWAP during the 270&#160;days following the Share Exchange Closing is less than the Purchase Price, as set forth in the Subscription Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The offering contemplated by the Subscription Agreement is expected to close following Stockholder Approval. Within 30&#160;days after closing of the offering, Onconetix will file a resale registration statement with the SEC registering the resale of the Common Stock issuable pursuant to the Subscription Agreement and the Warrants.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On January&#160;23, 2024, the Company issued a non<span class="nobreak">-convertible</span> debenture (the &#8220;Debenture&#8221;) to the PMX Investor in the principal sum of $5.0&#160;million, the payment of which shall offset the $5&#160;million subscription amount for the Units&#160;pursuant to the Subscription Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Debenture has an interest rate of 4.0% per annum, and the principal and accrued interest was to be repayable in full upon the earlier of (i)&#160;the closing under the Subscription Agreement and (ii)&#160;June&#160;30, 2024. Additionally, the $5.0&#160;million subscription amount under the Subscription Agreement shall be increased by the amount of interest payable under the Debenture. On April<span class="nobreak"> </span>24, 2024, the Debenture was amended to extend the maturity date to the earlier of (i) the closing under the Subscription Agreement and (ii) October<span class="nobreak"> </span>31, 2024. As of April&#160;24, 2024, a total of $5&#160;million of principal was outstanding under the Debenture.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ENTADFI</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;19, 2023, the Company entered into an asset purchase agreement with Veru Inc., a Wisconsin corporation (&#8220;Veru&#8221;) (the &#8220;Veru APA&#8221;). Pursuant to, and subject to the terms and conditions of, the Veru APA, the Company purchased substantially all of the assets related to Veru&#8217;s ENTADFI business. The transaction closed on April&#160;19, 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company purchased substantially all of Veru&#8217;s assets, rights and property related to ENTADFI for a total possible consideration of $100.0&#160;million (as described below). The acquisition of ENTADFI capitalizes on the demonstrable success of the FDA<span class="nobreak">-approved</span> drug ENTADFI for treating benign prostatic hyperplasia and counteracting negative sexual side effects seen in men on alternative BPH therapies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the terms of the Veru APA, the Company agreed to provide Veru with initial consideration totaling $20.0&#160;million, consisting of (i)&#160;$6.0&#160;million paid upon the closing of the transaction, (ii)&#160;an additional $4.0&#160;million in the form of a non<span class="nobreak">-interest</span> bearing note payable due on September&#160;30, 2023, and (iii)&#160;an additional $10.0&#160;million in the form of two equal (i.e. each for $5.0&#160;million) non<span class="nobreak">-interest</span> bearing notes payable, each originally due on April&#160;19, 2024 (the &#8220;April Veru Note&#8221;) and September&#160;30, 2024 (the &#8220;September Veru Note&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On September&#160;29, 2023, the Company entered into an amendment (the &#8220;Veru Amendment&#8221;) of the Veru APA.&#160;Pursuant to the Veru Amendment, the $4.0&#160;million note payable originally due on September&#160;30, 2023, was deemed paid and fully satisfied upon (1)&#160;the payment to Veru of $1&#160;million in immediately available funds on September&#160;29, 2023, and (2)&#160;the issuance to Veru by October&#160;3, 2023, of 3,000<span class="nobreak"> </span>shares of Series&#160;A Preferred Stock of the Company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">65</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The terms of the Series&#160;A Preferred Stock are set forth in the Certificate of Designations, which was filed with the State of Delaware on September&#160;29, 2023. Pursuant to the Certificate of Designations, each share of Series&#160;A Preferred Stock will convert one year from the date of issuance of the Series&#160;A Preferred Stock into that number of shares of the Company&#8217;s common stock determined by dividing the Stated Value (as defined in the Certificate of Designations) of $1,000 per share by the Conversion Price (as defined in the Certificate of Designations) of $0.5254 per share, subject to adjustment as provided in the Certificate of Designations, subject to certain stockholder approval limitations. The Series&#160;A Preferred Stock is entitled to share ratably in any dividends paid on the Company&#8217;s common stock (on an as<span class="nobreak">-if-converted-to-common-stock</span> basis), has no voting rights except as to certain significant matters specified in the Certificate of Designations, and has a liquidation preference equal to the Stated Value of $1,000 per share plus any accrued but unpaid dividends thereon. The Series&#160;A Preferred Stock is redeemable in whole or in part at the Company&#8217;s option at any time. The Certificate of Designations authorized the issuance of up to 10,000<span class="nobreak"> </span>shares of Series&#160;A Preferred Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Series&#160;A Preferred Stock issued to Seller is initially convertible, in the aggregate, into approximately 5,709,935<span class="nobreak"> </span>shares of the Company&#8217;s common stock, subject to adjustment and certain stockholder approval limitations specified in the Certificate of Designations. The Company is still in the process of obtaining such shareholder approval. If the Company does not obtain such stockholder approval, it will not be able to issue Common Stock in excess of the stockholder approval limitations specified in the Certificate of Designations. The Company also agreed to include the shares of common stock issuable upon conversion of the Series&#160;A Preferred Stock in the next resale registration statement filed with the SEC.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, the terms of the Veru APA require the Company to pay Veru up to an additional $80.0&#160;million based on the Company&#8217;s net sales from the ENTADFI business after closing. The Milestone Payments are payable as follows: (i)&#160;$10.0&#160;million is payable if the Company&#8217;s annual net sales from the ENTADFI business equal or exceed $100.0&#160;million, (ii)&#160;$20.0&#160;million is payable if the Company&#8217;s annual net sales from the ENTADFI business equal or exceed $200.0&#160;million, and (3)&#160;$50.0&#160;million is payable if annual net sales from the ENTADFI business equal or exceed $500.0&#160;million. No more than one Milestone Payment shall be made for the achievement of each net sales milestone. There can be no assurance that the net sales milestones for payment of any of the Milestone Payments will be reached.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, in connection with the transaction, the Company assumed royalty and milestone obligations under an asset purchase agreement for tadalafil<span class="nobreak">-finasteride</span> combination entered into by Veru and Camargo Pharmaceutical Services, LLC on December&#160;11, 2017. The Camargo Obligations assumed by the Company include a 6% royalty on all sales of tadalafil<span class="nobreak">-finasteride</span> and sales milestone payments of up to $22.5&#160;million as follows: (i)&#160;$5.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI of $100.0&#160;million during a calendar year, (ii)&#160;$7.5&#160;million is payable upon the first time the Company achieves net sales from ENTADFI of $200.0&#160;million during a calendar year, and (3)&#160;$10.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI of $300.0&#160;million during a calendar year.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On April<span class="nobreak"> </span>24, 2024, the Company entered into a Forbearance Agreement with Veru (the &#8220;Forbearance Agreement&#8221;). Pursuant to the Forbearance Agreement, Veru will forbear from exercising its rights and remedies under the April Veru Note until March<span class="nobreak"> </span>31, 2025 (the &#8220;Forbearance Period&#8221;). Interest will accrue on any unpaid principal balance of the April Veru Note at a rate of 10% per annum, commencing on April<span class="nobreak"> </span>20, 2024 through the date that the outstanding principal balance under the April Veru Note is paid in full. Any such accrued interest will become immediately due and payable upon the earlier of (i) certain events of default under the April Veru Note or September Veru Note, (ii) a payment default under the September Veru Note and (iii) the final payment of any principal amount payable under the September Veru Note. No interest will accrue under the September Veru Note during the Forbearance Period unless an Event of Default (as defined in the Forbearance Agreement) occurs, in which case interest will accrue from and after the date on which such default occurs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In consideration for Veru&#8217;s entrance into the Forbearance Agreement, the Company agreed to pay Veru:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$50,000 of the principal due under the April Veru Note and up to $10,000 of out<span class="nobreak">-of-pocket</span> expenses incurred by Very in connection with the Forbearance Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>15% of (i) the monthly cash receipts of  Proteomedix for the licensing or sale of any products or services, (ii) monthly cash receipts of the Company or any of its subsidiaries for the sales of Proclarix anywhere in the world, and (iii) monthly cash receipts of the Company or any of its subsidiaries for milestone payments or royalties from Labcorp; and </p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">66</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>10% of the net proceeds from any financing or certain asset sale, transfer or licensing transactions that are consummated prior to March<span class="nobreak"> </span>31, 2025.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company also agreed to a general release of claims against Veru and its representatives. arising out of or relating to any act or omission thereof prior to April<span class="nobreak"> </span>24, 2024.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As noted above, the Company has determined to temporarily pause its commercialization of ENTADFI, as it considers strategic alternatives. As part of a cost reduction plan approved by the Board and in connection with our pause in commercializing ENTADFI, we terminated three employees involved with the ENTADFI program, effective April<span class="nobreak"> </span>30, 2024, with such individuals to continue assisting the Company on an as<span class="nobreak">-needed</span>, consulting basis. The Company continues to consider various measures, including strategic alternatives, to rationalize its operations and optimize its existing Proclarix diagnostic program.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">WraSer</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On June&#160;13, 2023 (the &#8220;Execution Date&#8221;), the Company entered into an asset purchase agreement with the WraSer Seller and Parent (the &#8220;WraSer APA&#8221;). Pursuant to, and subject to the terms and conditions of, the WraSer APA, on the WraSer Closing Date (as defined below) the Company will purchase six FDA<span class="nobreak">-approved</span> pharmaceutical assets across several indications, including cardiology, otic infections, and pain management (the &#8220;WraSer Assets&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the WraSer APA, the Company will purchase the WraSer Assets for (i)&#160;$3.5&#160;million in cash at signing of the WraSer APA (the &#8220;Signing Cash&#8221;); (ii)&#160;$4.5&#160;million in cash on the later of (x)&#160;90&#160;days after the signing of the WraSer APA or (y)&#160;the date that all closing conditions under the WraSer APA are met or otherwise waived (the &#8220;WraSer Closing Date&#8221;); (iii)&#160;1.0&#160;million shares of the Company&#8217;s common stock (the &#8220;Closing Shares&#8221;) issuable on the WraSer Closing Date, and (iv)&#160;$500,000 in cash one year from the WraSer Closing Date. The closing of the transaction is subject to certain customary closing conditions and the delivery to the Company of financial statements of WraSer Seller and Parent for the fiscal&#160;years ended December&#160;31, 2022, and 2021 audited by a qualified auditor reasonably acceptable to the Company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Within 90&#160;days of the WraSer Closing Date, the Company will use its best efforts to file with the SEC, (at its sole cost and expense,) a registration statement to register on Form&#160;S<span class="nobreak">-3</span> registering under the Securities Act, the resale of the Closing Shares and will use its best efforts to have the registration statement declared effective as soon as practicable after filing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In conjunction with the WraSer APA, the Company and the WraSer Seller entered into a Management Services Agreement (the &#8220;MSA&#8221;) on the Execution Date. Pursuant to the terms of the MSA, the Company was to act as the manager of the WraSer Seller&#8217;s business during the period between the Execution Date and WraSer Closing Date. During this period, the Company was to make advances to WraSer, if needed to sustain operations. The Company&#8217;s involvement as manager of the WraSer Seller&#8217;s business ended when WraSer filed for relief under chapter 11 of the U.S.&#160;Bankruptcy Code in the Bankruptcy Court (see below). If, on the WraSer Closing Date, the WraSer Seller&#8217;s cash balance is in excess of the target amount specified in the MSA of $1.1&#160;million (the &#8220;Cash Target&#8221;), the Company was to apply that excess to the $4.5&#160;million cash payment due upon closing. Conversely, if there is a shortfall, the Company would have been required to remit the difference to the WraSer Seller over time. Specifically, as the Company would have collected accounts receivable generated after the WraSer Closing Date, the Company would have been required to remit 50% of the collections to the WraSer Seller until the shortfall is paid in full. The MSA terminates on the WraSer Closing Date.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The WraSer APA can be terminated prior to closing as follows (i)&#160;upon agreement with all parties; (ii)&#160;upon breach of contract of either party, uncured within 20&#160;days of notice. If the WraSer APA is terminated upon agreement with all parties or upon uncured breach of contract by the WraSer Seller, the initial $3.5&#160;million payment is retained by the WraSer Seller. If it is determined that there is an uncured breach of contract by the WraSer Seller, and the WraSer APA is terminated, the Company will have an unsecured claim against WraSer for the $3.5&#160;million payment made by the Company upon execution of the WraSer APA.&#160;The closing of the transaction was subject to various closing conditions, including submission of the FDA transfer documentation to transfer ownership of the acquired product regulatory approvals to the Company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On September&#160;26, 2023, WraSer and its affiliates filed for relief under chapter 11 of the U.S.&#160;Bankruptcy Code in the Bankruptcy Court.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">67</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On October&#160;4, 2023, the parties agreed to amend the WraSer APA, subject to court approval. Shortly after its bankruptcy filing, WraSer filed a motion seeking approval of the WraSer APA as amended. The amendment, among other things, eliminates the $500,000 post<span class="nobreak">-closing</span> payment due June&#160;13, 2024 and staggers the $4.5&#160;million cash payment that the Company would otherwise have to pay at closing to: (i)&#160;$2.2&#160;million to be paid at closing, (ii)&#160;$2.3&#160;million, to be paid in monthly installments of $150,000 commencing January&#160;2024 (the &#8220;Post<span class="nobreak">-Closing</span> Payment&#8221;) and (iii)&#160;789<span class="nobreak"> </span>shares of Series&#160;A Preferred Stock to be paid at closing. The amendment also reduced the number of products we were acquiring by excluding pain medications and including only (i)&#160;Ciprofloxacin 0.3% and Fluocinolone 0.025% Otic Solution, under the trademark OTOVEL and its Authorized Generic Version approved under US FDA NDA No. 208251, (ii)&#160;Ciprofloxacin 0.2% Otic solution, under the trademark CETRAXAL, and (iii)&#160;Vorapaxar Sulfate tablets under the trademark Zontivity approved under US FDA NDA N204886.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In October 2023, WraSer alerted us that its sole manufacturer for the API for Zontivity, the key driver for the WraSer acquisition, would no longer manufacture the API for Zontivity. We believed that this development constituted a Material Adverse Effect under the WraSer APA enabling us to terminate the WraSer APA and the WraSer MSA. On October<span class="nobreak"> </span>20, 2023, we filed a motion for relief from the automatic stay in the Bankruptcy Court to exercise our termination rights under the WraSer APA, as amended. On December<span class="nobreak"> </span>18, 2023, the Bankruptcy Court entered an Agreed Order lifting the automatic stay to enable us to exercise our rights to terminate the WraSer APA and the WraSer MSA without prejudice to the parties&#8217; respective rights, remedies, claims, and defenses they had against one another under the WraSer APA and the WraSer MSA. On December<span class="nobreak"> </span>21, 2023, we filed a Notice with the Bankruptcy Court terminating the WraSer APA and the WraSer MSA. WraSer has advised us that it does not believe that a Material Adverse Event occurred. WraSer has recently filed a plan of reorganization that indicates it may seek damages from us due to the termination of the APA and MSA. Due to the WraSer bankruptcy filing and our status as an unsecured creditor of WraSer, it is also unlikely that we will recover the $3.5<span class="nobreak"> </span>million Signing Cash or any other advances, costs and resources in connection with services provided by the Company under the WraSer MSA.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Business of the Company</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Business Model</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix develops novel diagnostic tests in a highly regulated field. Proteomedix&#8217;s core competencies include the development of high<span class="nobreak">-quality</span> immunoassays and management of regulatory affairs. Our expertise in immunoassay development is the result of a highly specialized workforce that, together with an external software development company, developed the proprietary software integrated in the company&#8217;s lead IVD product, Proclarix. Our personnel also have extensive experience in implementing and maintaining a state<span class="nobreak">-of-the-art</span> quality management system to comply with regulatory requirements, including performing clinical studies and managing key opinion leaders (&#8220;KOLs&#8221;). Our experience and expertise in these fields was obtained by hiring experienced personnel as well as through key advisors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix is initially focusing on seeking to license its intellectual property to third party laboratories. Sales will be through a specialized distributor and/or laboratory partner, but Proteomedix will still provide technical customer support to laboratories that offer the testing service to physicians. Proteomedix does not have production capabilities built up in<span class="nobreak">-house</span>, and instead outsources manufacturing to a CMO in Germany. All of the key reagents used in Proteomedix&#8217;s IVD kits (i.e., antigens and antibodies) are proprietary and owned exclusively by Proteomedix, which uses an independent supplier in Germany to produce these reagents and supply them to its CMO.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">ENTADFI is an FDA<span class="nobreak">-approved</span>, once daily pill that combines finasteride and tadalafil for the treatment of BPH.&#160;To the extent that we resume the commercialization of ENTADFI, Onconetix will initially focus on commercializing ENTADFI through a telemedicine channel. In July&#160;2023, the Company signed an agreement with UpScriptHealth to generate a robust, online telemedicine platform to distribute ENTADFI.&#160;Through this platform, UpScriptHealth will support patients with BPH throughout prescription and coverage process, as well as provide eligible patients access to ENTADFI mailed directly to their homes. Additionally, to meet the demands of the supply chain, manufacturing is outsourced to contract manufacturing organizations (&#8220;CMOs&#8221;) in the U.S.&#160;The product will be distributed exclusively by Cardinal Health 105, LLC, an Ohio limited liability company (&#8220;Cardinal Health&#8221;) as third<span class="nobreak">-party</span> logistics distribution agent for sales of ENTADFI and any other products the parties mutually agree to. As noted above, the Company has determined to temporarily pause its commercialization of ENTADFI, as it considers strategic alternatives. The Company continues to consider various measures, including strategic alternatives, to rationalize its operations and optimize its existing Proclarix diagnostic program.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">68</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Products</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Proclarix</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable more efficient cancer management at all stages of disease progression. Proteomedix&#8217;s tests use proprietary protein biomarkers to address the limitations in current cancer detection, prognosis, and therapy prediction. In addition, Decision Support Systems support the clinical decision<span class="nobreak">-making</span> by integrating different inputs in a risk score (see Figure 1).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><img alt="" src="timage_001.jpg" style="width:591.36px;max-width:100%;"/></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Figure 1:&#160;&#160;&#160;&#160;</span>Product Pipeline</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proclarix</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Proclarix</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proclarix is used to indicate the risk of clinically significant prostate cancer through a risk score derived from a clinical decision support system (Figure 2). On the reagent side it is comprised of two quantitative Enzyme<span class="nobreak">-linked</span> Immunosorbent Assays (&#8220;ELISA&#8221;) that measure the concentration of thrombospondin 1 (&#8220;THBS1&#8221;) and cathepsin D (&#8220;CTSD&#8221;) in human serum. The clinical decision support system is a web<span class="nobreak">-based</span> software running a proprietary algorithm that integrates the values for THBS1 and CTSD, the patient&#8217;s age and total and free PSA levels from third party providers (e.g., Roche Diagnostics, Siemens Healthineers) to calculate a risk score.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><img alt="" src="timage_002.jpg" style="width:441.6px;max-width:100%;"/></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Figure 2:&#160;&#160;&#160;&#160;</span>Proclarix: Assays and software algorithm for risk score calculation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">69</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proclarix is used as an aid in prostate cancer diagnosis as a second<span class="nobreak">-line</span> test after PSA and DRE testing. It enables a personalized decision for each patient based on objective risk parameters (4 serum glycoproteins + age) to triage between biopsy or a monitoring approach. Proclarix has been validated and approved for use in men with elevated total PSA (2.0 to 10.0 ng/mL), a normal DRE not suspicious for cancer and an elevated prostate volume (&#8805;35 mL) (Figure 3). The Proclarix decision support tool returns a risk score that can be used as an aid in discriminating between clinically significant (grade group 2 or higher [GG2+]) and insignificant prostate cancer or benign prostate disease. The risk score of Proclarix gives the physician and patient actionable information to confidently make decisions when considering the necessity of a prostate biopsy which is required for diagnosis of prostate cancer.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><img alt="" src="timage_003.jpg" style="width:544.0px;max-width:100%;"/></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Figure 3:&#160;&#160;&#160;&#160;</span>Proclarix: Finding clinically significant prostate cancer in the diagnostic &#8220;grey zone.&#8221;</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Clinical Studies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix&#8217;s biomarkers have been tested in clinical studies including a total of more than 2,000 patient samples from multiple clinical sites, and results have been published in peer<span class="nobreak">-reviewed</span> journals. We believe these results demonstrate that Proclarix is a valuable test identifying clinically significant prostate cancer thereby facilitating informed decision making for patients considering a prostate biopsy.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Validation Study.&#160;&#160;&#160;&#160;</span>The study leading to the granting of regulatory approval in Europe included 955 samples collected at two clinical sites, a screening center in Innsbruck, Austria, as well as a referral center in Hamburg, Germany. The results of this study demonstrated that by using the Proclarix test the burden of unneeded biopsies could have been lowered by approximately 43% &#8212; twice as much compared to clinical comparators percent free PSA (&#8220;%fPSA&#8221;) or PSA density. High sensitivity of 90% and a negative predictive value of 95% for clinically significant prostate cancer indicated that the diagnosis of very few cancers would have been delayed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">PROPOSe Study.&#160;&#160;&#160;&#160;</span>The PROPOSe study evaluated the accuracy of Proclarix in prostate biopsy decision making. Ten clinical sites in Germany, Denmark and Austria prospectively enrolled 457 men presenting for prostate biopsy. Proclarix detected clinically significant cancer with high sensitivity above 90% and reliably ruled out patients with no or indolent cancer with a negative predictive value greater than 90%. When the biopsy performed was guided by magnetic resonance imaging (&#8220;MRI&#8221;), both sensitivity (97%) and negative predictive value (96%) were even higher. Importantly, Proclarix was significantly superior to the current clinical standard, %fPSA, in ruling out unneeded biopsies (22% vs. 14%) and the primary study endpoint was met (p<span class="nobreak">-value</span> &lt; 0.005).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Naples Study.&#160;&#160;&#160;&#160;</span>A two<span class="nobreak">-center</span> study evaluated Proclarix and the Prostate Health Index (phi) test from Beckman Coulter, Inc. for predicting clinically significant prostate cancer in a total of 344 men. Both Proclarix and the phi test accurately predicted clinically significant cancer. When using predefined cut<span class="nobreak">-offs</span> recommended by the manufacturers, Proclarix (cut<span class="nobreak">-off</span> 10) outperformed phi (cut<span class="nobreak">-off</span> 27) in terms of specificity and positive predictive value (p &lt; 0.002) at similar sensitivities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Clinical evaluation of Proclarix.&#160;&#160;&#160;&#160;</span>Results of multiple clinical evaluations using Proclarix together with MRI for prostate cancer diagnosis showed that Proclarix can be used in a broad range of patients without the need for prostate volume restriction. The aim of one such evaluation was the assessment of the diagnostic performance of Proclarix in combination with MRI.&#160;Blood samples from 721 men undergoing MRI followed by biopsy at two clinical centers were analyzed. The combined Proclarix<span class="nobreak">-MRI</span> score&#8217;s specificity (68%) was significantly (p&lt;0.001) better compared </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">70</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">to Proclarix (27%) or MRI (28%) alone for diagnosing clinically significant prostate cancer. Importantly, Proclarix by itself was found to be useful in men with indetermined imaging results by outperforming PSA density in terms of specificity (25% vs 13%, p=0.004) at 100% sensitivity. In another evaluation of a study of 517 men with suspected prostate cancer, Proclarix performed well in accurately diagnosing prostate cancer in the overall study population and in a subset of men with elevated PSA 2 to 10 ng/mL, prostate volume &#8805;35 mL, and normal DRE (n=281). In addition, a sub<span class="nobreak">-analysis</span> of was performed specifically analyzing 169 men with an indeterminate MRI result and Proclarix was more accurate in selecting appropriate candidates for prostate biopsy when compared to PSA density and online risk calculators. A third evaluation describes which patients with suspected prostate cancer can benefit from Proclarix after MRI and concluded that Proclarix outperformed PSA density in the selection of candidates for prostate biopsy, especially in men with PI<span class="nobreak">-RADS</span>&#160;1<span class="nobreak">-3</span>. In these studies, Proclarix proved to be effective before, after, and together with MRI assessment to identify men at risk of clinically significant prostate cancer and those who can safely avoid biopsy. Proclarix in combination with MRI reliably predicted clinically significant prostate cancer and ruled out men with no or indolent cancer.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Clinical Guidelines</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Guidelines assist clinicians in making informed treatment decisions, taking into account the available scientific data. To reduce the number of negative biopsies in asymptomatic men with a PSA level between&#160;3<span class="nobreak">-10</span> ng/mL and a normal DRE, the EAU guidelines recommend using an online risk<span class="nobreak">-calculator</span> that is correctly calibrated to the population prevalence, MRI of the prostate or an additional biomarker test such as Proclarix. The EAU guidelines specifically state that Proclarix has been correlated with the detection of significant prostate cancer, notably in case of equivocal MRI results.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proclarix was also included in the 2023 AUA/SUO clinical practice guideline. The AUA/SUO guideline covers recommendations on the early detection of prostate cancer and provides a framework to facilitate clinical decision<span class="nobreak">-making</span> in the implementation of prostate cancer screening, biopsy, and follow<span class="nobreak">-up</span>. The AUA/SUO guideline concludes that the evaluation of prostate cancer risk should be focused on the detection of clinically significant prostate cancer (GG2+). The AUA/SUO guidelines advise that use of laboratory biomarkers such as Proclarix, prostate MRI, and biopsy techniques may improve detection and safety when a prostate biopsy is deemed necessary following prostate cancer screening.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The inclusion of Proclarix in the European and U.S.&#160;guidelines is an important recognition of the clinical value of Proclarix. It serves as a validation for the clinical utility and importance of using Proclarix in the detection of prostate cancer and we believe it will lead to broader acceptance of Proclarix and accelerate payor adoption.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Product Quality and Safety</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix&#8217;s quality management system is ISO (International Organization for Standardization) 13485:2016 certified for the &#8220;Design and development, production and distribution of in<span class="nobreak">-vitro</span> diagnostic reagents and stand<span class="nobreak">-alone</span> software for prostate cancer management&#8221;. Proteomedix is annually audited by T&#220;V S&#220;D Product Service GmbH, an internationally recognized notified body headquartered in Germany. ISO certification is a prerequisite for obtaining CE<span class="nobreak">-mark</span>, the regulatory clearance requirement for market access, recognized by the European Commission (&#8220;EC&#8221;) in the IVDR.&#160;Under the IVDR, diagnostic products are categorized under a new system of one of four classifications from class A (low risk) to class D (highest risk). Proclarix, as class C device, was assessed by T&#220;V S&#220;D for conformity resulting in IVDR certification. The certification of Proclarix under the new IVDR demonstrates compliance to the highest quality standard currently in force for tests used in screening, diagnosis, or staging of cancer. Proteomedix is marketing Proclarix as one of the first IVDR compliant cancer tests demonstrating the commitment to highest analytical and clinical performance.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Prosgard</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Prosgard as a clinical support system is designed to aggregate multimodal information in an effort to develop a patient centric diagnostic approach. The vision for Prosgard is to add more information to the existing Proclarix risk score in the future such as other biomarkers, clinical information, or MRI imaging data to provide an even more powerful tool to guide the patient&#8217;s diagnostic journey.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">71</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Prognosis (Px)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A subset of Proteomedix&#8217;s protein biomarkers also correlate with prostate cancer prognosis. Radical prostatectomy provides excellent cancer control of clinically localized prostate cancer. However, approximately 30% of surgically treated men will experience cancer recurrence within 10&#160;years of surgery. Several clinical parameters and the combination thereof (e.g., the Cancer of the Prostate Risk Assessment (&#8220;CAPRA&#8221;) score) have been shown to be reliable predictors of treatment failure. Still, there is a compelling need to identify novel markers that are specifically linked to the presence of biologically aggressive prostate cancer for improved prediction of outcome in populations with moderately elevated PSA levels.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">A novel serum biomarker quintet that improves disease prognosis in men with confirmed prostate cancer</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A clinical evaluation of a multivariable model comprising fibronectin<span class="nobreak"> </span>1, galectin<span class="nobreak">-3-binding</span> protein, lumican, matrix metalloprotease<span class="nobreak"> </span>9, thrombospondin<span class="nobreak">-1</span> and PSA together with clinical Grade Group (GG) and clinical stage (cT) was performed. The prognostic utility of the proposed marker combination was assessed in serum samples from 557 men with confirmed localized prostate cancer. The analysis showed that the proposed model had a better prediction for disease progression and thus prostate cancer aggressiveness compared to the &#8220;CAPRA&#8221; score. This novel biomarker test has the potential to improve prostate cancer patient management by indicating who needs active treatment. In contrast to the existing biomarker tests from competitors that all need tissue specimens, the test is non<span class="nobreak">-invasive</span> and can be directly measured in patients&#8217; blood samples.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Prediction (Rx)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix&#8217;s protein biomarkers further have the potential to predict the response of patients treated with drugs that inhibit the PI3K signaling pathway. Proteomedix analyzed the blood of patients participating in a Phase&#160;II trial (SAKK 08/08). The patients were treated with Novartis AG&#8217;s Everolimus, a drug inhibiting the PI3K pathway signaling by blocking mTOR.&#160;A subset of 8 serum biomarkers could individually predict reaching the primary endpoint (progression free survival at 12&#160;weeks) with an accuracy of at least 75%.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Decision Support Systems</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Recent initiatives are incorporating as well as interpreting clinical information from various sources (e.g., biomarker information and other patient data) enabling physicians to have more comprehensive biochemical insight into each patient&#8217;s disease in order to determine the optimal treatment plan for the patient. Collating multiple data sources in clinical workflows allows precision<span class="nobreak">-medicine</span> resulting in cost<span class="nobreak">-effective</span> diagnostics and therapies. Proclarix already consists of a decision support system integrating different values in a risk score. In the future, additional clinical information like the results of an MRI scan could be integrated in the report to provide a complete picture of the diagnostic situation of the patient to enable effective patient management.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">ENTADFI</span><span class="Italic-Superscript" style="font-style:italic;font-weight:normal;vertical-align:super;font-size:58%;">&#174;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">ENTADFI is an FDA<span class="nobreak">-approved</span>, once daily pill that combines finasteride and tadalafil for the treatment of BPH.&#160;BPH, a condition in men in which the prostate gland is enlarged but not cancerous, is a common problem that affects the quality of life in approximately half of men over the age of 50 and 90% of men over the age of 85. Men with BPH suffer from challenges with urination flow, frequency, and urgency, and about 70% of men with BPH also experience sexual dysfunction. In 2022, there was approximately 44&#160;million total prescriptions and 20&#160;million new prescriptions related to BPH symptoms. ENTADFI is an oral, once daily treatment for BPH that combines finasteride, a 5<span class="CharOverride-3" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span>- reductase inhibitor, and tadalafil, a phosphodiesterase 5 (&#8220;PDE5&#8221;) inhibitor, offering a more effective treatment option compared to other available therapies. Clinical trials have shown that ENTADFI is more effective in treating BPH symptoms, including urinary frequency, urgency, weak stream, and difficulty initiating or maintaining urination, compared to finasteride monotherapy. Additionally, ENTADFI has demonstrated a favorable safety profile, with fewer adverse sexual side effects compared to finasteride. ENTADFI reduces potential adverse sexual side effects, making it preferred choice for men seeking relief from BPH symptoms without compromising their sexual health. ENTADFI has received FDA approval for the indication of initiating treatment of the signs and symptoms of BPH in men with enlarged prostate for up to 26&#160;weeks.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">72</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Commercialization Strategy</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Proclarix</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proclarix is currently not reimbursed in Europe, and therefore patients pay for Proclarix out of pocket. We intend to pursue reimbursement from public and private payors in key European markets to secure broad adoption in the longer term. The market introduction of Proclarix has followed a two<span class="nobreak">-phased</span> approach: first a market preparation phase in which we reach out to key opinion leaders in selected European countries to solicit their support for Proclarix, followed by a market development phase where we begin commercializing Proclarix in those markets with focused marketing and sales activities to urologists and general practitioners. We intend to secure access to testing through partnerships with reference diagnostic labs. We have initiated outreach to commercial laboratories and hospital laboratories that are routinely serving study sites and academic collaboration partners, and have established pilots with laboratories in Switzerland, Germany, Italy, and the United Kingdom.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In the United&#160;States, Proteomedix entered into an exclusive partnership with Labcorp in 2023 pursuant to which Labcorp has the exclusive right to develop and commercialize Proclarix, and other products developed by Labcorp using Proteomedix&#8217;s intellectual property covered by the license, in the United&#160;States for identification, screening, staging, predisposition, diagnosis, prognosis, monitoring, prevention or treatment selection with respect to prostate cancer. In consideration for granting Labcorp an exclusive license, Proteomedix received an upfront license fee and is entitled to royalty and milestone payments based upon sales of licensed products or services in the United&#160;States. Labcorp is wholly responsible for the cost of research, development and commercialization of licensed products or services in the United&#160;States but has the right to offset a portion of those costs against future royalty and milestone payments otherwise due to Proteomedix.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">ENTADFI</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As noted above, the Company has determined to temporarily pause its commercialization of ENTADFI. As part of a cost reduction plan approved by the Board and in connection with our pause in commercializing ENTADFI, we terminated three employees involved with the ENTADFI program, effective April<span class="nobreak"> </span>30, 2024, with such individuals to continue assisting the Company on an as<span class="nobreak">-needed</span>, consulting basis. The Company continues to consider various measures, including strategic alternatives, to rationalize its operations and optimize its existing Proclarix diagnostic program. To the extent that we resume the commercialization of ENTADFI, in order to provide ENTADFI to patients suffering from BPH, we have established relationships with key vendors to distribute, commercialize, and market ENTADFI.&#160;On the distribution side, we have partnered with Cardinal Health to serve as our third<span class="nobreak">-party</span> logistics provider. Under our agreement, Cardinal Health with serve as our exclusive distributor of ENTADFI, and we intend to leverage its title model services, allowing us to utilize its state wholesale pharmacy license portfolio to ship ENTADFI to states where we do not currently hold a license. Utilizing Cardinal Health&#8217;s title model program will maximize access for ENTADFI across the U.S.&#160;while we pursue licenses for Onconetix.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In the commercialization plan for ENTADFI, we have partnered with UpScriptHealth to generate an online telemedicine platform where patients with BPH can interact with a healthcare provider, receive support through the prescription process, as well as provide eligible patients access to ENTADFI mailed directly to their homes. UpScriptHealth is a leading provider of telehealth services, has over 20&#160;years of experience generating effective, web<span class="nobreak">-based</span> campaigns for life science companies with a wide range of services, including virtual prescribing, coverage, and benefit support, as well as long<span class="nobreak">-term</span> adherence support. In recent&#160;years, telehealth has become increasingly popular for both patients and providers and represents a significant opportunity for the commercialization of ENTADFI.&#160;Through telemedicine, we will be able to provide BPH patients with access to ENTADFI without another trip to a doctor&#8217;s office or pharmacy, which can be incredibly burdensome for patients and provide them with a time<span class="nobreak">-saving</span> option for receiving medication.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The current commercialization strategy for ENTADFI centers around our telemedicine platform, and we believe this may be more cost effective versus more traditional sales representative approaches that target physicians. We plan to generate targeted marketing and advertising materials to support our web platform, which will drive traffic to the site and maximize ENTADFI sales. Under the current sales model, we will be offering ENTADFI for cash<span class="nobreak">-paying</span> patients and do not currently plan on seeking reimbursement from insurance or Medicare and Medicaid channels. Though this may change in the future, we believe there is a significant market opportunity for patients to use the web portal to access ENTADFI and receive medication by cash pay.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">73</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Sales, Distribution, Marketing and Advertising</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In clinical diagnostics high throughput assay parameters like PSA typically are performed on closed, fully integrated systems that use proprietary reagents. Integrated systems are provided by a few mid<span class="nobreak">-sized</span> to large diagnostic companies (e.g., Roche Diagnostics, Abbott Laboratories, Siemens Healthineers AG, DiaSorin S.p.A.) with a worldwide distribution network. Reagents are provided in a closed<span class="nobreak">-system</span> approach, access is through collaboration agreements only. Business development discussions with multiple diagnostic companies have already started.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Lower volume parameters are run on smaller, open systems that are used in laboratories for tests with lower throughput to complement the test menu. Access to these open systems presents an option for direct commercialization in selected markets during market introduction. First, the goal is to establish commercial proof of concept and drive initial market adoption.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Market adoption of a new test is driven by KOLs and clinical urology centers. Publication of clinical studies proving the medical benefit of the test and KOLs advocating it at scientific conferences will trigger the usage by other physicians. Additionally, demand is created through urology centers specialized in prostate cancer that cover a large geographical area. Their influence on other urologists and general practitioners in the region will lead to multiplier effects. Diagnostic testing in clinical urology centers is provided either by an in<span class="nobreak">-house</span> hospital laboratory or a commercial laboratory where Proclarix will be implemented.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">General practitioners recruit patients for screening and decide whether to refer a patient to a specialist. They have an important gatekeeper role and Proclarix is a helpful tool for this triage. Marketing outreach of commercial laboratory networks (e.g., Unilabs, Switzerland; Sonic Healthcare, Australia; Labcorp, U.S.A.) provides an opportunity to directly address the large number of general practitioners and urologists in private practices through their specialized sales force.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Market Opportunity</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Proclarix</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proclarix, the first diagnostic product of Proteomedix, is addressing unmet medical needs related to prostate cancer, which is the second most frequently diagnosed cancer in men, with an estimated 1.4&#160;million new cases and more than 395,000 deaths worldwide in 2020, according to World Cancer Research Fund International.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The PSA test represents the current standard of care in prostate cancer diagnosis. It accurately identifies individuals with no sign of disease. Approximately 10% of all men have elevated PSA levels, commonly referred to as the diagnostic &#8220;grey zone&#8221;, of which only&#160;20 &#8211; 40% present clinically with cancer. Proclarix is intended for use in diagnosing these patients where it is difficult to decide if a biopsy is necessary to verify a potential clinically significant cancer diagnosis. The high unmet need for improved patient stratification or diagnostic triage in this segment is addressed only by a few tests. Compared to those tests Proclarix has important competitive advantages: (i)&#160;it shows comparable or often superior clinical performance, (ii)&#160;it is blood<span class="nobreak">-based</span> and therefore minimally invasive and (iii)&#160;it is highly reproducible in comparison to e.g., urine<span class="nobreak">-based</span> tests. The use of Proclarix does not require prior prostate massage. Samples are stable and can be shipped at ambient temperature. Proclarix has a high accuracy and negative predictive value (NPV) and is easy to automate on equipment readily available as well as adaptable to current laboratory practice and thus clinical routine.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The worldwide market for in vitro diagnostic (&#8220;IVD&#8221;) products was valued at $117.8&#160;billion in 2022. Europe and North America are the largest markets, followed by Asia, mainly Japan and China, according to MarketsandMarkets.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">About two<span class="nobreak">-thirds</span> of prostate cancer diagnoses occur in countries ranking very high in the Human Development Index, where only 18% of the world&#8217;s male population resides, according to the American Cancer Society. This underscores a significant market demand for improved diagnostic tools, especially in regions with robust healthcare infrastructure where early detection and treatment are paramount. Our innovative test aims to meet this demand by offering enhanced accuracy, accessibility, and efficiency, positioning it as a valuable asset in the fight against prostate cancer while also presenting lucrative commercial opportunities for stakeholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Currently, standard prostate cancer screening combines a digital rectal exam (&#8220;DRE&#8221;) with the measurement of PSA.&#160;PSA is not a highly cancer specific marker, meaning it picks up many benign conditions of raised PSA levels in the blood<span class="nobreak">-such</span> as clinically not significant enlargement of the prostate or inflammation. The consequences are prostate </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">74</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">cancer overdiagnosis, leading to unnecessary prostate biopsies. It is currently estimated that more than 60% of men that undergo a biopsy have no clinically significant prostate cancer, but due to the biopsy become exposed to potential side effects such as infections, bleeding and incontinence.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The use of MRI for the diagnosis of prostate cancer has been rapidly adopted during the last decade. There is clinical evidence that MRI allows clinicians to verify diagnosis and improve localization, risk stratification and staging of clinically significant prostate cancer over other methods. MRI<span class="nobreak">-guided</span> biopsy has a higher accuracy than ultrasound<span class="nobreak">-guided</span> biopsy. However, MRI<span class="nobreak">-based</span> diagnosis of prostate cancer is hampered by the relatively high costs of US$415 &#8211; US$900 and limited availability. Still, up to one<span class="nobreak">-third</span> of MRIs are inconclusive. Thus, there is a clear need for an improved non<span class="nobreak">-invasive</span> diagnostic test with higher specificity for clinically significant prostate cancer to aid in selecting patients undergoing MRI, MRI<span class="nobreak">-guided</span> biopsy, and biopsy. Proper classification in clinically significant cancer and non<span class="nobreak">-significant</span> type or non<span class="nobreak">-cancer</span> conditions such as benign prostate hyperplasia is important to prevent overtreatment and its associated side<span class="nobreak">-effects</span> and costs. Proteomedix is developing diagnostic tools for disease prognosis and monitoring that are essential for reliable, patient<span class="nobreak">-friendly</span>, and cost<span class="nobreak">-effective</span> disease management. Proteomedix&#8217;s biomarkers have shown the potential to distinguish between those prostate cancer patients who are more likely to respond to certain drug<span class="nobreak">-based</span> interventions. With this information, better choices for drug therapies can be made to maximize the likelihood of efficacious treatment. Proteomedix&#8217;s biomarkers could also aid in clinical drug development.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">ENTADFI</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">BPH is a condition that affects men, primarily those over 50&#160;years old, and is caused by swelling in the prostate gland due to hormonal changes and cell growth during the aging process. It is estimated that about 50% of men between the ages of 51 and 60 have BPH, and that number increases to about 70% among men&#160;60 &#8211; 69 and around 80% of men over 70&#160;years of age, according to Yale Medicine. This translates to upwards of 55&#160;million men in the United&#160;States at risk or experiencing symptoms of BPH each year. Men with BPH may suffer from a range of symptoms, including increased urinary frequency, urgency, and an inability to completely empty the bladder. While there are surgical interventions to treat BPH, many men choose prescription medications to treat their symptoms and, with certain medications, decrease the size of the prostate.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Two medications commonly used to treat BPH are tamsulosin, brand name Flomax<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span>, and finasteride, sold under the brand name Proscar<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span>. According to ClinCalc.com, tamsulosin was the 24<span class="Superscript" style="vertical-align:super;font-size:58%;">th</span> most commonly prescribed medication in 2020 and has increased in rank consistently since 2014. This resulted in over 24.6&#160;million prescriptions and an average per prescription cost of $54.40, resulting in over $1.3&#160;billion in sales. Finasteride, ranked the 90<span class="Superscript" style="vertical-align:super;font-size:58%;">th</span> most commonly prescribed medication in the U.S.&#160;in 2020, has also seen consistent increases in utilization since 2013. Over 8&#160;million finasteride prescriptions in 2020 resulted in over $162&#160;million in sales based on an average price per prescription of $19.83.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">ENTADFI, which can treat BPH without negative sexual side effects seen in some men on finasteride alone, represents a novel therapeutic treatment for patients. There is a significant market opportunity for an additional therapeutic option in BPH, shown both by the prevalence in older men and by the high, and increasing, number of BPH prescriptions written each year.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Competition</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">ENTADFI Competitive Analysis</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Treatments for men with BPH and lower urinary tract symptoms (&#8220;LUTS&#8221;) fall into five drug classes each with a different mechanism of action in alleviating symptoms: (i)&#160;alpha blockers that target alpha receptors to relax prostatic smooth muscle, (ii)&#160;5<span class="nobreak">-alpha</span> reductase inhibitors (&#8220;5ARIs&#8221;) that block the enzyme 5<span class="nobreak">-alpha</span> reductase to decrease cell growth, (iii)&#160;PDE5 inhibitors that decrease urethral smooth muscle tone, (iv)&#160;anticholinergics that block the action of acetylcholine to relax the smooth muscle of the bladder and (v)&#160;beta<span class="nobreak">-3</span> agonists that increase bladder capacity by </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">75</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">relaxing smooth muscle. Figure 4 below lists the current AUA- and EUA<span class="nobreak">-recommended</span> therapies for BPH and BPH with LUTS, their mechanisms of action, and potential side effects. Several of these medications are commercially available as generics.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><img alt="" src="timage_004.jpg" style="width:584.96px;max-width:100%;"/></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Figure 4. Current AUA and EAU recommended therapies for BPH and BPH with LUTS.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Should we decide to resume commercialization of ENTADFI, Potential competitors with respect to ENTADFI in North America, Europe and elsewhere include major pharmaceutical companies, specialty pharmaceutical companies and biotechnology firms, universities and other research institutions and government agencies. Many of our competitors have substantially greater research and development and regulatory capabilities and experience, and substantially greater management, manufacturing, distribution, marketing, and financial resources, than we have. We may be unable to compete successfully against current and future competitors, and competitive pressures could have a negative effect on our net revenues and profit margins.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Zydus Life Sciences recently received FDA approval for a combined finasteride<span class="nobreak">-tadalafil</span> (5&#160;mg/5&#160;mg) capsule, pursuant to the FDA&#8217;s Competitive Generic Therapy Program, which was designed to enhance patient access to affordable medications by encouraging the development and commercialization of generic drugs in clinical areas with limited generic options for patients. Pursuant to the program, Zydus has a 180<span class="nobreak">-day</span> period to be the sole supplier of the generic version of the drug in the market and during this period, other generic manufacturers cannot enter the market with their versions of the same drug, provided that Zydus commences marketing the drug by 75&#160;days from approval. As a result, there is a risk that the Company will face additional challenges in resuming commercializing ENTADFI, if it chooses to do so.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Other parties have developed and marketed drugs for BPH that have been accepted by the healthcare provider, patient, and payor communities. Many of these other products have also reached the point where they are now generic drugs, which means that they are sold at a very low price, a price which ENTADFI may not be able to meet which could limit the reach of ENTADFI into the healthcare provider, patient, and payor communities, including government payors.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">ENTADFI Competitive Advantages</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-bottom:10pt;margin-top:8pt;">Adherence to the prescribed treatment regimen is an ongoing issue in BPH therapy. Adherence rates are low for BPH treatments, as BPH medicines are typically taken chronically and are often taken for up to 6 to 12&#160;months prior to significant symptom relief.<span class="Superscript" style="vertical-align:super;font-size:58%;">1</span> Adherence rates are particularly low in patients taking multiple BPH treatments concurrently, with reported adherence rates as low as 9%.<span class="Superscript" style="vertical-align:super;font-size:58%;">2</span> Delayed symptom relief, adversely impacting quality of life, is thought to be a major factor resulting in poor patient adherence to prescribed treatment schedules.<span class="Superscript" style="vertical-align:super;font-size:58%;">3</span> Importantly, discontinuation of treatment or non<span class="nobreak">-adherence</span> to a prescribed treatment protocol are independent risk factors for BPH related hospitalization or surgery.<span class="Superscript" style="vertical-align:super;font-size:58%;">4</span> A recent study suggested that first<span class="nobreak">-time</span> 5ARI patients with low adherence to their </p>
		<p class="Textfootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Textfootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:10pt;">1<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Casab&#233; A et al. J Urol. 191:727<span class="nobreak">-733</span> 2014.; Cindolo L, et al. European Urology. 68(3):418<span class="nobreak">-425</span> 2015.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">2<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Cindolo L, et al. European Urology 68(3):418<span class="nobreak">-425</span> 2015.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">3<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Casab&#233; A et al. J Urol. 191:727<span class="nobreak">-733</span> 2014.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">4<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Cindolo L, et al. BMC Urol 2015; 96(15):&#160;1<span class="nobreak">-7</span>.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">76</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">treatment schedule are 27% more likely to need BPH<span class="nobreak">-related</span> surgery.<span class="Superscript" style="vertical-align:super;font-size:58%;">5</span> A more effective, rapid acting therapy with a simple treatment regimen could significantly improve patient compliance, reduce the need for medical or surgical intervention and improve the patient&#8217;s quality of life.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">ENTADFI is a combination of finasteride, a 5ARI, and tadalafil, a PDE5 inhibitor, that is indicated for use in the treatment of BPH is men with an enlarged prostate for up to 26&#160;weeks of treatment. Tadalafil has been shown to be effective in reducing the erectile dysfunction symptoms of BPH, although the exact mechanism by which the drug reduces the symptoms of LUTS is unknown.<span class="Superscript" style="vertical-align:super;font-size:58%;">6</span> Finasteride acts to shrink the prostate by preventing the conversion of testosterone to dihydrotestosterone.<span class="Superscript" style="vertical-align:super;font-size:58%;">7</span> This fixed combination of two different, clinically effective, BPH medications delivers rapid and sustained relief from the symptoms of BPH.&#160;The combination of tadalafil and finasteride has demonstrated significant clinical efficacy within four&#160;weeks of treatment with significant improvement in sexual functioning.<span class="Superscript" style="vertical-align:super;font-size:58%;">8</span> A single capsule formulation of these two drugs removes the barriers to treatment adherence associated with delayed or poor symptom relief and a complex treatment regimen involving separate individual medications.<span class="Superscript" style="vertical-align:super;font-size:58%;">9</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Proclarix Competition Analysis</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The molecular diagnostics field is intensely competitive and characterized by rapid technological changes, frequent new product introductions, changing customer preferences, emerging competition, evolving industry standards, reimbursement uncertainty and price competition. Moreover, recent consolidation in the industry permits larger clinical laboratory service providers to increase cost efficiencies and service levels, resulting in more intense competition.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The market for assessing men at risk for prostate cancer is large, with many competitors some of which possess substantially greater financial, selling, logistical and laboratory resources, more experience in dealing with third<span class="nobreak">-party</span> payors, and greater market penetration, purchasing power and marketing budgets, as well as more experience in providing diagnostic services. Some companies and institutions are developing liquid biopsy (blood and urine)<span class="nobreak">-based</span> tests and diagnostic tests based on the detection of proteins, mRNA, nucleic acids, or the presence of fragments of mutated genes that are associated with prostate cancer. These competitors could have technological, financial, reputational, and market access advantages over us.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">There are a number of tests already on the market or in clinical testing or commercial development that are also intended to triage diagnostics in men with moderately elevated PSA levels. Of these tests the majority also target solely PSA as a biomarker. Certain isoforms of PSA are differentiated, or transcript levels (mRNA) are determined in addition to protein levels. Of these tests the best established is %fPSA, which is also available from all suppliers of the PSA test, including market leaders Abbott Laboratories, Roche Diagnostics, Siemens Healthineers AG and Beckman Coulter, Inc. However, the sensitivity and specificity improvements are very modest.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The 4Kscore from OPKO Health, Inc. (Nasdaq: OPK) and the phi score from Beckman Coulter, Inc. measure additional forms of PSA and related proteins but they do not include additional biomarkers either. The 4Kscore test is a blood based 4<span class="nobreak">-plex</span> test which combines the results of the blood test with clinical information in an algorithm that calculates a patient&#8217;s percent risk for aggressive prostate cancer prior to an initial or repeat biopsy (no previous diagnosis of prostate cancer). The 4Kscore test received marketing approval from the FDA in December&#160;2021. The phi score combines the results of three blood tests to provide information about what elevated PSA levels might mean and the probability of finding prostate cancer on biopsy. The IsoPSA test of Cleveland Diagnostics, Inc. analyzes structural changes of PSA to detect underlying cancer biology.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-bottom:10pt;margin-top:8pt;">Over the last decade, gene<span class="nobreak">-based</span> testing in urine targeting additional biomarkers became available. The PCA3 test from Gen<span class="nobreak">-Probe</span> Inc. (now a part of Hologic, Inc.) was the first genetic assay to be introduced to the market. The SelectMDx test from MdxHealth SA measures a combination of two genes and integrates them together with PSA value, prostate volume, patient age, and digital rectal exam to a risk score. The assay targets mRNA transcripts in the patient&#8217;s urine. mRNA is normally not sufficiently shed into urine to allow for direct analysis. Therefore, this test method requires prostate massage prior to sample collection and the urine samples will be collected in a specialized </p>
		<p class="Textfootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Textfootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:10pt;">5<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Zhang H, et al. J Urol. 204(2):325<span class="nobreak">-331</span> 2020.</p>
		<p class="Textfootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">6<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>CIALIS [Package Insert]. Indianapolis, IN:&#160;Eli Lilly and Co; 2011.</p>
		<p class="Textfootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">7<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>ENTADFI [Package Insert]. Cincinnati, OH:&#160;Blue Water Biotech, Inc; 2023.</p>
		<p class="Textfootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">8<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Casab&#233; A et al. J Urol 191:727<span class="nobreak">-733</span> 2014.</p>
		<p class="Textfootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">9<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Lee LK et al. Patient Prefer Adherence 10:1205<span class="nobreak">-1215</span> 2026; Glina S et al. J Sex Med. 12(1):129<span class="nobreak">-138</span> 2015; Cindolo L et al. BMC Urol 96(15):&#160;1<span class="nobreak">-7</span> 2015.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">77</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">practice. The ExoDx IntelliScore from Exosome Diagnostics, Inc., a subsidiary of Bio<span class="nobreak">-Techne</span> Corporation, measures PCA3 as well as other gene transcripts in exosomes harvested from urine. The method does not require prostate massage, however, because mRNA is relatively unstable, the samples require cold storage in shipment and relatively rapid testing turn<span class="nobreak">-around</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Stockholm3 test is part of an academic initiative, OncoWatch, led by the Karolinska Institute, Sweden and funded by the European Institute of Innovation and Technology Health program. Established in 2020, A3P Biomedical AB (publ) is commercializing the Stockholm3 test. It is a blood<span class="nobreak">-based</span> test that predicts the risk for aggressive prostate cancer at biopsy by analyzing five protein markers, more than 100 genetic markers and clinical data.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Except for PCA3, Prostate Health Index and 4Kscore, all of the above<span class="nobreak">-mentioned</span> tests are only available as a testing service through specialized reference laboratories, they are not offered as commercial products. Testing is performed centrally as a laboratory developed test (&#8220;LDT&#8221;) by a single diagnostic laboratory. Uptake of LDTs in the United&#160;States has been limited, and in Europe they are mostly not known to urologists.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In recent&#160;years, MRI<span class="nobreak">-based</span> diagnosis followed by targeted biopsy is becoming the standard of choice in specialized centers. As MRI instrumentation is costly and its availability is still limited, there is a need for diagnostics supporting the decision to perform MRI that Proclarix can fulfill. MRI is not regarded as competitive to the Proclarix positioning, but complementary.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Competitive Advantages of Proclarix</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We believe Proclarix has important competitive advantages:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"></p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 25.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="BL_table" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-12pt;widows:3;margin-left:12pt;margin-top:0pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">Blood</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-based</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> test</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><span class="Italic" style="font-style:italic;font-weight:normal;">Minimally invasive, high reproducibility, no prostate massage required, suitably stable for shipment, the most common sample type in clinical laboratories and therefore fitting in current lab workflow</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 25.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="BL_table" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-12pt;widows:3;margin-left:12pt;margin-top:0pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">Immunoassay</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-based</span></span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><span class="Italic" style="font-style:italic;font-weight:normal;">Compatible with existing laboratory instrumentation in local laboratory</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 25.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="BL_table" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-12pt;widows:3;margin-left:12pt;margin-top:0pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">Easy to automate</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><span class="Italic" style="font-style:italic;font-weight:normal;">Adaptable to clinical routine, fast time to result</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 25.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="BL_table" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-12pt;widows:3;margin-left:12pt;margin-top:0pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">Objective&#160;result&#160;generation</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><span class="Italic" style="font-style:italic;font-weight:normal;">Comparable results independent of operator</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 25.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="BL_table" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-12pt;widows:3;margin-left:12pt;margin-top:0pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">Genetics</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-guided</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> discovery</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 65.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><span class="Italic" style="font-style:italic;font-weight:normal;">Cancer</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-related</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">, highly plausible biomarkers</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proclarix can be applied in any diagnostic laboratory, using readily available immunoassay technology platforms. Furthermore, Proclarix fits very well into the current laboratory workflow, which is important for laboratories that are driven by efficiency and cost.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The stakeholders benefit in various ways from Proclarix:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Patients:&#160;&#160;&#160;&#160;</span>Gain more certainty whether a biopsy is really needed through a minimally invasive procedure with a fast time to result. This results in reduced anxiety about prostate cancer diagnosis and less complications and side effects from biopsies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Physicians:&#160;&#160;&#160;&#160;</span>Focus on relevant patients with clinically significant cancer and increased patient satisfaction by significantly reducing unneeded prostate biopsies and its accompanying complications. No need for additional training or new logistic processes: Standard blood<span class="nobreak">-drawing</span> equipment can be used, and the blood sample sent to the current laboratory.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Laboratory:&#160;&#160;&#160;&#160;</span>Increase revenue with no additional investment for new equipment because Proclarix is readily applicable in most laboratories.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Payer (insurance company):&#160;&#160;&#160;&#160;</span>Increase profits by saving costs for avoided biopsies (accompanied by risk of complications, discomfort) and resulting overtreatment.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Government Regulation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post<span class="nobreak">-approval</span> monitoring and post<span class="nobreak">-approval</span> reporting of drugs and diagnostics.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">78</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Small molecule drugs, like ENTADFI, are subject to regulation in the United&#160;States under the Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and are subject to additional federal, state, local and foreign statutes, and regulations. We, along with third<span class="nobreak">-party</span> contractors, are required to navigate the various requirements of the governing regulatory agencies of the countries in which we wish to market products.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">United&#160;States</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">U.S.&#160;Pharmaceuticals Regulation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The process required by the FDA before drugs may be marketed in the United&#160;States generally involves the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>completion of extensive preclinical laboratory tests and animal studies performed in accordance with applicable regulations, including the FDA&#8217;s Good Laboratory Practice, or GLP, regulations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>submission to the FDA of an investigational new drug application, IND, which must become effective before clinical trials may begin;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>approval by an independent institutional review board or ethics committee at each clinical site before the trial is commenced;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>performance of adequate and well<span class="nobreak">-controlled</span> human clinical trials in accordance with FDA&#8217;s Good Clinical Practice, or GCP, regulations to establish the safety and efficacy of a drug candidate for its intended purpose;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>preparation of and submission to the FDA of a new drug application (&#8220;NDA&#8221;) after completion of all pivotal clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>satisfactory completion of an FDA Advisory Committee review, if applicable;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a determination by the FDA within 60&#160;days of its receipt of an NDA to file the application for review;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>satisfactory completion of an FDA pre<span class="nobreak">-approval</span> inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with current Good Manufacturing Practice requirements, or cGMPs, and of selected clinical investigation sites to assess compliance with GCPs; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>FDA review and approval of an NDA to permit commercial marketing of the product for particular indications for use in the United&#160;States.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Post-Approval Requirements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Any products manufactured or distributed by us pursuant to FDA approvals, like ENTADFI, are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record<span class="nobreak">-keeping</span>, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved NDA.&#160;Pharmaceutical manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon us and our third<span class="nobreak">-party</span> manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. Manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">79</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">imposition of post<span class="nobreak">-market</span> studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a Risk Evaluation and Mitigation Strategy program. Other potential consequences include, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>fines, warning or untitled letters or holds on post<span class="nobreak">-approval</span> clinical studies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>product seizure or detention, or refusal of the FDA to permit the import or export of products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>mandated modification of promotional materials and labeling and the issuance of corrective information;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>injunctions or the imposition of civil or criminal penalties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The FDA closely regulates the marketing, labelling, advertising, and promotion of pharmaceutical products. A company can make only those claims relating to safety and efficacy, that are approved by the FDA and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labelling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off<span class="nobreak">-label</span> uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising, and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labelling and that differ from those tested by us and approved by the FDA.&#160;Such off<span class="nobreak">-label</span> uses are common across medical specialties. Physicians may believe that such off<span class="nobreak">-label</span> uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off<span class="nobreak">-label</span> use of their products.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Federal and State Fraud and Abuse, Data Privacy and Security, and Transparency Laws and Regulations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In addition to FDA restrictions on marketing of pharmaceutical products, federal and state healthcare laws and regulations restrict business practices in the biopharmaceutical industry. These laws may impact, among other things, our current and future business operations and proposed sales, marketing and education programs and constrain the business or financial arrangements and relationships with healthcare providers and other parties through which we market, sell and distribute our products. These laws include anti<span class="nobreak">-kickback</span> and false claims laws and regulations, data privacy and security, and transparency laws and regulations, including, without limitation, those laws described below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The U.S.&#160;federal Anti<span class="nobreak">-Kickback</span> Statute prohibits any person or entity from, among other things, knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce or in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The U.S.&#160;federal Anti<span class="nobreak">-Kickback</span> Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">80</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. Violation of the federal Anti<span class="nobreak">-Kickback</span> Statue carries criminal penalties and fines as well as administrative sanctions under the Civil Money Penalties Law. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S.&#160;federal Anti<span class="nobreak">-Kickback</span> Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Federal civil and criminal false claims laws and civil monetary penalties laws, including the federal civil False Claims Act, which can be enforced by individuals through civil whistleblower and qui tam actions, prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S.&#160;government. Several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of products for unapproved, and thus non<span class="nobreak">-reimbursable</span>, uses.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The federal Health Insurance Portability and Accountability Act&#160;of&#160;1996 (&#8220;HIPAA&#8221;) created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third<span class="nobreak">-party</span> payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. These provisions are intended to punish some of the same conduct in the submission of claims to private payors as the federal False Claims Act covers in connection with governmental health programs. Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, that apply regardless of the payor.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In addition, regulations promulgated pursuant to HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;) established privacy and security standards that limit the use and disclosure of individually identifiable health information (known as &#8220;<span class="CharOverride-4" style="text-decoration:underline;">protected health information</span>&#8221; or &#8220;PHI&#8221;) and require the implementation of administrative, physical and technological safeguards to protect the privacy of PHI and ensure the confidentiality, integrity and availability of electronic PHI.&#160;HIPAA applies to &#8220;covered entities,&#8221; including healthcare providers who submit certain standard transactions electronically, health plans, and healthcare clearinghouses, as well as to their &#8220;business associates,&#8221; which are defined as independent contractors or agents of covered entities that create, receive, maintain or transmit PHI in the performance of an administrative function or service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which are not pre<span class="nobreak">-empted</span> by HIPAA, differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by Covered Recipients, as defined at 42 CFR Subpart&#160;I.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures or drug pricing, and state and local laws that require the registration of pharmaceutical sales representatives.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Because of the breadth of these laws and the narrowness of available statutory exceptions and regulatory safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to significant criminal, civil and administrative penalties </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">81</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">including damages, fines, imprisonment, disgorgement, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non<span class="nobreak">-compliance</span> with these laws, contractual damages, reputational harm, diminished profits and future earnings, disgorgement, exclusion from participation in government healthcare programs and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Coverage and Reimbursement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The future commercial success of our product candidates will depend in part on the extent to which third<span class="nobreak">-party</span> payors, such as governmental payor programs at the federal and state levels, including Medicare and Medicaid, private health insurers and other third<span class="nobreak">-party</span> payors, provide coverage of and establish adequate reimbursement levels for our product. Third<span class="nobreak">-party</span> payors generally decide which products they will pay for and establish reimbursement levels for those products. In particular, in the United&#160;States, no uniform policy for coverage and reimbursement exists. Private health insurers and other third<span class="nobreak">-party</span> payors often provide coverage and reimbursement for products based on the level at which the government, through the Medicare program, provides coverage and reimbursement for such products, but also on their own methods and approval process apart from Medicare determinations. Therefore, coverage and reimbursement can differ significantly from payor to payor.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In the United&#160;States, government authorities and third<span class="nobreak">-party</span> payors are increasingly attempting to limit or regulate the price of products, particularly for new and innovative products, which often has resulted in average selling prices lower than they would otherwise be. Further, the increased emphasis on managed healthcare in the United&#160;States will put additional pressure on product pricing, reimbursement, and usage. These pressures can arise from rules and practices of managed care groups, judicial decisions and laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical coverage and reimbursement policies and pricing in general.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Third<span class="nobreak">-party</span> payors are increasingly imposing additional requirements and restrictions on coverage and limiting reimbursement levels for products. For example, federal and state governments reimburse products at varying rates generally below average wholesale price. These restrictions and limitations influence the purchase of products. Third<span class="nobreak">-party</span> payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA<span class="nobreak">-approved</span> products for a particular indication. Third<span class="nobreak">-party</span> payors are increasingly challenging the price and examining the medical necessity and cost<span class="nobreak">-effectiveness</span> of products, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost<span class="nobreak">-effectiveness</span> of our product. Our product may not be considered medically necessary or cost<span class="nobreak">-effective</span>. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Legislative proposals to reform healthcare or reduce costs under government insurance programs may result in lower reimbursement for our product or exclusion of our product candidates from coverage and reimbursement. The cost containment measures that third<span class="nobreak">-party</span> payors and providers are instituting and any healthcare reform could significantly reduce our revenue from the sale of our approved product.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Foreign Regulation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In order to market any product outside of the United&#160;States, we would need to comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our product candidates. For example, in the EU, we must obtain authorization of a clinical trial application, or CTA, in each member state in which we intend to conduct a clinical trial. Whether or not we obtain FDA approval for a drug, we would need to obtain the necessary approvals by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the drug in those countries. The approval process varies from country to country and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Further, some countries outside of the United&#160;States, including the EU member states, Switzerland and the United Kingdom, have also adopted data protection laws and regulations, which impose significant compliance obligations. In the EU, the collection and use of personal health data is governed by the provisions of the General Data Protection Regulation, or GDPR.&#160;The GDPR became effective on May&#160;25, 2018, repealing its predecessor directive and increasing responsibility and liability of pharmaceutical companies in relation to the processing of </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">82</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">personal data of EU subjects. The GDPR, together with the national legislation of the EU member states governing the processing of personal data, impose strict obligations and restrictions on the ability to process personal data, including health data from clinical trials and adverse event reporting. In particular, these obligations and restrictions concern potentially burdensome documentation requirements, granting certain rights to individuals to control how we collect, use, disclose, retain and process information about them, the information provided to the individuals, the transfer of personal data out of the EU, security breach notifications, and security and confidentiality of the personal data. The processing of sensitive personal data, such as physical health condition, may impose heightened compliance burdens under the GDPR and is a topic of active interest among foreign regulators. In addition, the GDPR provides for more robust regulatory enforcement and fines of up to &#8364;20&#160;million or 4% of the annual global revenue of the noncompliant company, whichever is greater. Data protection authorities from the different EU member states may interpret the GDPR and national laws differently and impose additional requirements, which add to the complexity of processing personal data in the EU.&#160;Guidance on implementation and compliance practices are often updated or otherwise revised.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">European Union</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">European Union Coverage Reimbursement and Pricing</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost<span class="nobreak">-effectiveness</span> of a particular drug candidate to currently available therapies, or so<span class="nobreak">-called</span> health technology assessments, in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a drug product or may instead adopt a system of direct or indirect controls on the profitability of the company.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">EU Drug regulation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In order to market any product outside of the United&#160;States, we would need to comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical trials or marketing of the product in foreign countries and jurisdictions such as in China and Japan. Although many of the issues discussed above with respect to the United&#160;States apply similarly in the context of the EU, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others. Failure to comply with applicable foreign regulatory requirements may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Non-clinical studies and clinical trials</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Similarly to the United&#160;States, the various phases of non<span class="nobreak">-clinical</span> and clinical research in the EU are subject to significant regulatory controls.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Non<span class="nobreak">-clinical</span> studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. Non<span class="nobreak">-clinical</span> studies must be conducted in compliance with the principles of good laboratory practice (GLP) as set forth in EU Directive 2004/10/EC.&#160;In particular, non<span class="nobreak">-clinical</span> studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for non<span class="nobreak">-clinical</span> studies. These GLP standards reflect the Organization for Economic Co<span class="nobreak">-operation</span> and Development requirements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Clinical trials of medicinal products in the EU must be conducted in accordance with EU and national regulations and the International Conference on Harmonization (ICH) guidelines on good clinical practices (GCP) as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">83</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Additional GCP guidelines from the European Commission, focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products. If the sponsor of the clinical trial is not established within the EU, it must appoint an entity within the EU to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU member states, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Certain countries outside of the United&#160;States, including the EU, have a similar process that requires the submission of a clinical study application (CTA) much like the IND prior to the commencement of human clinical studies. A CTA must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and the Institutional Review Board (&#8220;IRB&#8221;), respectively. Once the CTA is approved by the national health authority and the ethics committee has granted a positive opinion in relation to the conduct of the trial in the relevant member state(s), in accordance with a country&#8217;s requirements, clinical study development may proceed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. Currently, CTAs must be submitted to the competent authority in each EU member state in which the trial will be conducted. Under the new Regulation on Clinical Trials, which is currently expected to become applicable by early 2022, there will be a centralized application procedure where one national authority takes the lead in reviewing the application and the other national authorities have only a limited involvement. Any substantial changes to the trial protocol or other information submitted with the CTA must be notified to or approved by the relevant competent authorities and ethics committees. Medicines used in clinical trials must be manufactured in accordance with good manufacturing practice (GMP). Other national and EU<span class="nobreak">-wide</span> regulatory requirements also apply.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Marketing Authorizations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">To market a medicinal product in the EU and in many other foreign jurisdictions, we must obtain separate regulatory approvals. More concretely, in the EU, medicinal product candidates can only be commercialized after obtaining a Marketing Authorization (MA). To obtain regulatory approval of an investigational medicinal product under EU regulatory systems, we must submit a marketing authorization application (&#8220;MAA&#8221;). The process for doing this depends, among other things, on the nature of the medicinal product. There are two types of Mas:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the &#8220;Union MA,&#8221; which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (&#8220;EMA&#8221;) and which is valid throughout the entire territory of the EU.&#160;The Centralized Procedure is mandatory for certain types of products, such as (i)&#160;medicinal products derived from biotechnology medicinal products, (ii)&#160;designated orphan medicinal products, (iii)&#160;advanced therapy products (such as gene therapy, somatic cell therapy or tissue<span class="nobreak">-engineered</span> medicines), and (iv)&#160;medicinal products containing a new active substance indicated for the treatment certain diseases, such as HIV/AIDS, cancer, neurodegenerative diseases, diabetes, other auto<span class="nobreak">-immune</span> and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EU, or for products that constitute a significant therapeutic, scientific, or technical innovation or that the granting of authorization would be in the interest of public health in the EU; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;National Mas,&#8221; which are issued by the competent authorities of the EU member states and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in an EU member state, this National MA can be recognized in another member state through the Mutual Recognition Procedure. If the product has not received a National MA in any member state at the time of application, it can be approved simultaneously in various member states through the Decentralized Procedure. Under the Decentralized Procedure an identical dossier is submitted to the competent authorities of each of the member states in which the MA is sought, one of which is selected by the applicant as the Reference member state.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Under the above<span class="nobreak">-described</span> procedures, in order to grant the MA, the EMA or the competent authorities of the EU member states make an assessment of the risk<span class="nobreak">-benefit</span> balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Under the Centralized Procedure, the maximum timeframe for the evaluation of a MAA by the EMA is 210&#160;days. Where there is a major public health interest and an unmet medical need for a product, the CHMP may perform an accelerated review of a MA in no more than 150&#160;days (not including clock stops). Innovative products that target an </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">84</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;text-indent:0pt;margin-top:7pt;">unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the PRIME scheme, which provides incentives similar to the breakthrough therapy designation in the US PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to optimize their product development plans and speed up their evaluation to help them reach patients earlier. Product developers that benefit from PRIME designation can expect to be eligible for accelerated assessment, but this is not guaranteed. The benefits of a PRIME designation include the appointment of a CHMP rapporteur before submission of a MAA, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review earlier in the application process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Mas have an initial duration of five&#160;years. After these five&#160;years, the authorization may be renewed for an unlimited period on the basis of a reevaluation of the risk<span class="nobreak">-benefit</span> balance, unless the EMA decides, on justified grounds relating to pharmacovigilance, to mandate one additional five<span class="nobreak">-year</span> renewal period.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Data and marketing exclusivity</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The EU also provides opportunities for market exclusivity. Upon receiving MA, new chemical entity, or reference product candidates, generally receive eight&#160;years of data exclusivity and an additional two&#160;years of market exclusivity. If granted, the data exclusivity period prevents generic or biosimilar applicants from relying on the pre<span class="nobreak">-clinical</span> and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the EU during a period of eight&#160;years from the date on which the reference product was first authorized in the EU.&#160;The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10&#160;years have elapsed from the initial authorization of the reference product in the EU.&#160;The overall 10<span class="nobreak">-year</span> market exclusivity period can be extended to a maximum of eleven&#160;years if, during the first eight&#160;years of those 10&#160;years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new chemical entity, and products may not qualify for data exclusivity.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Pediatric Development</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In the EU, MAAs for new medicinal products candidates have to include the results of trials conducted in the pediatric population, in compliance with a pediatric investigation plan (PIP) agreed with the EMA&#8217;s Pediatric Committee (PDCO). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data is not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all EU Member States and study results are included in the product information, even when negative, the product is eligible for six&#160;months&#8217; supplementary protection certificate extension (if any is in effect at the time of authorization).</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Post-Approval Requirements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Similar to the United&#160;States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the member states. The holder of a MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports (PSURs).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">All new MAA must include a risk management plan (RMP) describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA.&#160;Such risk<span class="nobreak">-minimization</span> measures or post<span class="nobreak">-authorization</span> obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post<span class="nobreak">-authorization</span> safety studies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">85</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The advertising and promotion of medicinal products is also subject to laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising, and unfair commercial practices. All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all off<span class="nobreak">-label</span> promotion is prohibited. Direct<span class="nobreak">-to-consumer</span> advertising of prescription medicines is also prohibited in the EU.&#160;Although general requirements for advertising and promotion of medicinal products are established under EU directives, the details are governed by regulations in each member state and can differ from one country to another.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The aforementioned EU rules are generally applicable in the European Economic Area (&#8220;EEA&#8221;) which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">For other countries outside of the EU, such as countries in Latin America or Asia (e.g., China and Japan), the requirements governing the conduct of clinical studies, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical studies are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Privacy and data protection laws</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We are also subject to laws and regulations in non<span class="nobreak">-US</span> countries covering data privacy and the protection of health<span class="nobreak">-related</span> and other personal information. For instance, EU member states and other jurisdictions have adopted data protection laws and regulations, which impose significant compliance obligations. Laws and regulations in these jurisdictions apply broadly to the collection, use, storage, disclosure, processing, and security of personal information that identifies or may be used to identify an individual, such as names, contact information and sensitive personal data such as health data. These laws and regulations are subject to frequent revisions and differing interpretations,</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of May&#160;2018, the General Data Protection Regulation (GDPR) replaced the Data Protection Directive with respect to the processing of personal data in the European Union. The GDPR imposes many requirements for controllers and processors of personal data, including, for example, higher standards for obtaining consent from individuals to process their personal data, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention and secondary use of information, increased requirements pertaining to health data and pseudonymized (i.e., key<span class="nobreak">-coded</span>) data and additional obligations when we contract third<span class="nobreak">-party</span> processors in connection with the processing of the personal data. The GDPR allows EU member states to make additional laws and regulations further limiting the processing of genetic, biometric or health data. Failure to comply with the requirements of GDPR and the applicable national data protection laws of the EU member states may result in fines of up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">EU Medical device legislation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Medical device legislation is harmonized in the European Union (EU) through the European Commission&#8217;s New Legislative Framework. The new regulatory framework for medical devices, published in April&#160;2017, is based on the Medical Devices Regulation (MDR) (EU) 2017/745 applicable for medical devices and active implantable medical devices and the In Vitro Diagnostic Medical Devices Regulation (IVDR) (EU) 2017/746 applicable for in vitro diagnostic medical devices (IVDs). The dates of application of the MDR were May&#160;26, 2021 (Article&#160;123(2)&#160;as amended by Regulation (EU) 2020/561 and Regulation&#160;2023/607) and May&#160;26, 2022 (Article&#160;113(2)), respectively. As regulations, the legislation applies to all the EU Member States as drafted and is applicable in the European Economic Area (EEA) which consists of the 27 EU Member States plus Norway, Liechtenstein, and Iceland.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The new regulatory framework in EU was triggered by the breast implant scandal (2012)&#160;and various similar case scenarios, where the cause identified significant gaps in the market surveillance and supply chain oversight as well as insufficient controls and compliance to state<span class="nobreak">-of-the-art</span> standards and documentation. Europe&#8217;s new regulatory framework for IVDs introduced significant changes for IVD manufacturers; the most important is the up<span class="nobreak">-classification</span> of IVDs (introduction of 7 classification rules and four risk classes A to D harmonized with the international classification system), which require independent conformity assessments for most IVD Classes by independent regulatory compliance assessors (Notified Bodies, NB). Other changes under the IVDR are the increased NB<span class="nobreak">-involvement</span>, a new risk<span class="nobreak">-based</span> classification system and classification rules, increased elements </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">86</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">and compliance to General Safety and Performance Requirements (GSPR), stricter demands on clinical evidence (scientific validity, analytical and clinical performance), stronger focus for post<span class="nobreak">-market</span> surveillance (PMS) and post<span class="nobreak">-market</span> performance follow<span class="nobreak">-up</span> (PMPF), stricter regulatory responsibilities throughout the supply chain for economic operators (like importers or distributors) and traceability through Unique Device Information (UDI, labelling). Overall, the IVDR is a significant expansion of the previous EU<span class="nobreak">-Directive</span> 98/79/EC (IVDD), which has been effective for IVDs since 1998.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Since 2022, due to different reasons, the European Commission issued various updates to the IVDR to introduce transitional provisions for certain IVDs, which are already on the EU market prior to the Date of Application (legacy devices) and which are not to be substantially changed by function and design (Regulation (EU) 2022/112 and Regulation (EU) 2023/6074). The current accepted transitional periods provided for in IVDR Article&#160;120 will end on either December&#160;31, 2027, or December&#160;31, 2028. Currently a new proposal (2024/0021 (COD)) is even proposing extended transitional periods up to December&#160;31, 2029, for some devices (Class&#160;B and Class&#160;A sterile) and December&#160;31, 2028, for medium risk IVDs (Class&#160;C). Due to these extended transition timelines for legacy devices, many IVD manufacturers are not yet setting compliance to IVDR on their highest priority.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">For the Proclarix IVDs (Assays and Risk Calculator software), which are class C devices under IVDR, Proteomedix has already CE marked them in 2019 under IVDD and since then started to comply with IVDR.&#160;This includes the performance and safety of the device, specifically clinical performance testing and addressing the clinical evidence for Proclarix.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Irrespective of the amendments for extended transition timelines to IVDR published since 2022 by the European Commission&#160;&#8212;&#160;Proteomedix AG has selected and streamlined the interaction with a NB (T&#220;V S&#220;D) for a conformity assessment under IVDR and passed this NB conformity assessment for their Technical Documentation and Quality Management System according to international standard ISO 13485:2016 (&#8220;Design and development, production and distribution of in<span class="nobreak">-vitro</span> diagnostic reagents and stand<span class="nobreak">-alone</span> software for prostate cancer management&#8221;) in July&#160;2022.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix AG has agreements signed with Emergo Europe B.V. acting as their EU Authorized Representative (EU AR, also referred as EC REP).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The IVDR<span class="nobreak">-compliance</span> of Proclarix devices makes them as one the first IVDs under the new EU regime and this will have several advantages to other devices marketed under IVDD or without CE mark yet. Because of the mentioned significant changes introduced with the IVDR, other competitors might face problems and delays when trying to get to this stage of IVDR compliance. As mentioned before, every new device or substantially changed device would not be able to use the amended timelines and must fully comply with IVDR before placing them on the EU market. Second, clients (users, laboratories) might expect compliance with the IVDR at some degree as the new normal (of state<span class="nobreak">-of-the-art</span> quality). Third, for the Proclarix devices marketed since 2019 in EU, there is automatically systematic post market surveillance data collected from the field, which further can support the clinical evidence (validity) of the Proclarix devices.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix AG also has an appointed Data Protection Officer (DPO) for data safety in line to requirements from General Data Protection Regulation (EU) 2016/679 (GDPR) and Swiss Data Protection Act although there are no personnel data included or affected in the Proclarix IVDs.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Switzerland and United Kingdom (UK) Medical Device Regulation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Switzerland and United Kingdom (UK) are not part of the EU market and in principle, become third countries with different jurisdictions and differing product regulations. However, these two countries still align to a certain degree on the European CE Mark and CE marked devices currently can be marketed without significant additional approval in Switzerland and UK.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">For Switzerland, the new EU Regulations (MDR/IVDR) required an update of the Mutual Recognition Agreements to include the EU Regulations, which has so far not been negotiated by the Switzerland<span class="nobreak">-EU</span> Joint Committee for Switzerland and the EU at international treaty level. Therefore, trading of devices can no longer move freely between the Swiss market and the EU market and the sharing of information between authorities (incl. EUDAMED) or the mutual recognition of certificates of conformity are not possible and must be regulated through Swiss law separately in Switzerland. The new Swiss law for medical devices, the Medical Devices Ordinance (MedDO) was introduced in 2020 together with certain obligations for Swiss manufacturers such as registration with Swissmedic. As a consequence, Swiss manufacturers must appoint an EU<span class="nobreak">-based</span> AR and/or importer in line with Article&#160;11 and Article&#160;13 of the IVDR.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">87</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">For the UK, IVD manufacturers must comply with the UK MDR 2002 (Medical device Regulation), which has been revised several times with new guidelines addressed in the Guidance on the Regulation of In Vitro Diagnostic Medical Devices in Great Britain. Similar to EU, IVD manufacturers must identify the appropriate conformity assessment procedure for their device and demonstrate compliance with relevant requirements of the applicable legislation for IVDs in the UK for the purpose of affixing the UKCA mark to their device (UK MDR 2002 Part&#160;IV). UKCA marking (UK Conformity Assessed marking) is the UK product marking requirement that will be needed for devices being placed on the market in UK, substituting the EU requirements for CE Marking (CE marking will continue to be accepted in Northern Ireland). Most of these IVDs will then require a designated UK Authorized Body (UKAB)<span class="nobreak">-issued</span> certificate (similar to an EU CE Marking Certificate). EN ISO 13485:2016 is the designated standard under the UK MDR 2002 that covers QMS requirements for medical device manufacturers. In the UK, device manufacturers must further appoint a single &#8220;UK Responsible Person&#8221; for all of their devices, who will act on the manufacturer&#8217;s behalf to perform tasks, including product registration. However, for medical devices with a valid CE marking placed on the UK<span class="nobreak">-market</span>, there was a transition time until 1 July&#160;2023 (no requirement to re<span class="nobreak">-label</span> the device with a UKCA mark), and the UK government recently has extended acceptance of CE marked devices in UK beyond 30 June&#160;2023 (MDR 2002, SI 2002 No 618, as amended).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Therefore, Proteomedix AG with a valid CE mark for EU (IVDR) and appointed EU<span class="nobreak">-AR</span>, and local registration in Switzerland (Swissmedic) is in full compliance to the current changed requirements on the EU, Swiss and UK markets. Proteomedix AG has agreements signed with Emergo Consulting (UK) Ltd. acting as their UK Responsible Person. The requirement to comply with UKCA marking would apply after 30 June&#160;2030.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">EU&#160;&#8212;&#160;Impact and market opportunities on other non-EU markets</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">With the overall intend from regulators to harmonize regulation, the CE marking and compliance to European IVDR for the Proclarix can be considered as a state<span class="nobreak">-of-the-art</span> regulatory compliance with high potential to enter other markets. Some of these like Australia, New Zealand or Singapore and other markets recognize the CE mark and&#160;&#8212;&#160;though they might have separate approval procedures&#160;&#8212;&#160;are expected to mainly rely on the CE Certificate. For example, Australia and New Zealand have a Trans<span class="nobreak">-Tasman</span> Mutual Recognition Arrangement (TTMRA), which means that CE mark can be recognized and sold without additional regulatory processes. Brazil&#8217;s medical device market regulator, ANVISA, recently announced updates to the IVD legislation as Resolution (RDC) 830/2023 similar to the EU definition and classification of IVD under IVDR.&#160;For the U.S., the FDA recently in January&#160;2024&#160;amended their title of their Quality System regulation part 820 (QSR), and integrated elements and concepts from ISO 13485:2016 into their new Quality Management System Regulation (QMSR).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">These examples demonstrate that Proclarix with established CE mark (IVDR) and ISO 13485:2016 QMS has high potential to get faster market access in other non<span class="nobreak">-EU</span> countries, too. It can be expected that more non<span class="nobreak">-EU</span> country legislations will further adapt their approval or acceptance process to the level of IVDR or ISO 13485 in the forthcoming&#160;years.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Intellectual Property</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix&#8217;s biomarkers were discovered using a genetics<span class="nobreak">-guided</span> discovery approach focusing on the PI3K/PTEN cancer pathway that plays a dominant role in prostate cancer development. Applying proteomics technology to a disease<span class="nobreak">-relevant</span> mouse model allowed the identification of proteins specifically linked to the molecular cause of prostate cancer. The biomarkers and the bioinformatics algorithm used in Proclarix are protected by issued and pending patents in Europe, the United&#160;States, and other countries.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Cancer arises from different genetic mutations that can be linked to specific signaling pathways often referred to as cancer pathways. Depending on what pathway is affected in a patient, results in different cancer subtypes that are more or less aggressive and further determines if a patient responds to a certain drug treatment or not.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix&#8217;s biomarkers were discovered by a group of researchers at ETH Zurich using a genetics<span class="nobreak">-guided</span> discovery approach focusing on the PI3K/PTEN cancer pathway that plays a dominant role in prostate cancer development. Using a mouse model and mass<span class="nobreak">-spectrometry</span> based proteomics technology including a glycoprotein enrichment technology led to the identification of proteins directly linked to the molecular cause of cancer and therefore correlating to the disease status in the prostate. Different serum glycoproteins were combined to form multiplexed </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">88</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">biomarker signatures predictive for tissue PI3K/PTEN status as well as diagnosis and prognosis of prostate cancer (Figure 5). The genetic<span class="nobreak">-guided</span> proteomics approach enabled the fast discovery and validation of several biomarkers which in different combinations correspond to diagnosis, prognosis and potentially to therapy response.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><img alt="" src="timage_005.jpg" style="width:524.8px;max-width:100%;"/></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Figure 5:&#160;&#160;&#160;&#160;</span>Proteomics approach to improve prostate cancer disease management.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The biomarker assays were transferred from a mass spectrometry<span class="nobreak">-based</span> to an immunoassay<span class="nobreak">-based</span> platform. Immunoassay<span class="nobreak">-based</span> measurement offers several advantages compared to other analytical methods. In general, immunoassays provide a rapid, sensitive, reproducible, cost effective and easily manageable analysis. The reagents used are stable and the method is established in routine diagnostic laboratories guaranteeing broad compatibility of Proteomedix&#8217;s tests on established automated clinical platforms and thus rapid adoption rates and platform flexibility of the diagnostic tests. The deep knowledge in selecting novel biomarkers, assay development and clinical development enabled Proteomedix to enable several R&amp;D partnerships.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In 2021, Proteomedix entered into a research and development partnership with New Horizon Health Limited, Grand Cayman, Cayman Islands. The partnership builds on complimentary platform and biomarker developments with utility in cancer patient management.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In 2022, Immunovia AB (Sweden) partnered with Proteomedix to leverage Proteomedix&#8217;s research and development capabilities and advances their research and development efforts. With this partnership, Immunovia gained a more flexible research and development organization, increased its research and development productivity, and refocused internal resources on commercial build up, thus further accelerating the roll<span class="nobreak">-out</span> of their proprietary IMMray<span class="Superscript" style="vertical-align:super;font-size:58%;">TM</span> PanCan<span class="nobreak">-d</span> test. The partnership capitalizes on the combined expertise of two leading innovators in proteomics<span class="nobreak">-based</span> diagnostics, who have both launched innovative oncology tests, Immunovia with IMMray<span class="Superscript" style="vertical-align:super;font-size:58%;">TM</span> PanCan<span class="nobreak">-d</span> in the U.S.&#160;and Proteomedix with Proclarix&#174; in Europe.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Patents</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix has exclusively licensed worldwide rights to one patent family from ETH Zurich and the State Hospital of St. Gallen, which describes and protects the use of the proprietary biomarkers for diagnosing and monitoring prostate cancer. The parent international patent application WO 2009138392 A1 was filed on May&#160;12, 2009, claims a priority date of May&#160;14, 2008 (priority date) and was granted in China (CN201027373B), Europe (EP2281201B1), Japan (JP6025607B) and the United&#160;States (US10151755B2/ US9377463B2).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix has also obtained a non<span class="nobreak">-exclusive</span> license from ETH Zurich for certain patents pertaining to specific enrichment of glycoproteins, including EP1514107 (expired June&#160;3, 2023) and US7183118 (to expire May&#160;3, 2024), that ETH Zurich licensed from the Institute for Systems Biology (ISB), Seattle. The license enables Proteomedix to use the glycoprotein technology for the development of new diagnostic products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">89</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In addition, a new patent covering the latest development and clinical results was filed by Proteomedix on July&#160;11, 2017, claiming a priority of July&#160;15, 2016. The patent covers the specific test format and algorithm contained in Proteomedix&#8217;s first product (Proclarix) for the improved diagnosis of prostate cancer. An international application (WO2018011212A1) was filed, and the patent was granted in Europe (EP3270163B1), Japan (JP6979712B2), South Korea (KR102408276B1), Australia (AU2017294979B2), United&#160;States (US11320435B2, with term extension of 377&#160;days) and China (CN109477836B) with the application still pending in Canada (CA3028874A1).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A patent application describing and claiming a method combining Proclarix and magnetic resonance imaging to diagnose prostate cancer was filed by Proteomedix on June&#160;29, 2021. The patent was originally filed in Switzerland and subsequently as PCT application (WO2023274742A1) and as national applications in the United&#160;States and China.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A patent application describing and claiming a method measuring a blood<span class="nobreak">-based</span> protein combination with prognostic utility in prostate cancer patients was filed by Proteomedix on June&#160;29, 2021. The patent was originally filed in Switzerland followed by an international application (WO2018011212A1). National applications were filed in Europe, United&#160;States and China.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Trademarks</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The brand &#8220;Proteomedix&#8221; was filed on June&#160;4, 2010, and registered under no. 602190 in Switzerland on June&#160;22, 2010. This application served as the basis for the international trademark application. The product name &#8220;Proclarix&#8221; was filed on July&#160;1, 2019, and registered under no. 733974 in Switzerland on July&#160;22, 2019. This application served as the basis for the international trademark application. The product name &#8220;Prosgard&#8221; was filed on July&#160;1, 2019, and registered under no. 733975 in Switzerland on July&#160;22, 2019.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Exclusive License Agreement with Children&#8217;s Hospital Medical Center, d/b/a Cincinnati Children&#8217;s Hospital Medical Center</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On June&#160;1, 2021 (the &#8220;Effective Date&#8221;), the Company entered into a license agreement with Children&#8217;s Hospital Medical Center, d/b/a Cincinnati Children&#8217;s Hospital Medical Center (&#8220;CHMC&#8221;), to develop and commercialize certain CHMC patents and related technology directed at a VLP vaccine platform that utilizes nanoparticle delivery technology, which may have potential broad application to develop vaccines for multiple infectious diseases (&#8220;the CHMC Agreement&#8221;). However, as Onconetix has now deprioritized its infectious disease vaccine programs based on a change in clinical focus, we are exploring ways in which CHMC&#8217;s VLP platform can be used in therapeutic and diagnostic applications in oncology.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The license is exclusive, worldwide, and is for all uses (other than the &#8220;Excluded Field&#8221; of immunization against, and prevention, control, or reduction in severity of gastroenteritis caused by Rotavirus and Norovirus in China and Hong&#160;Kong). The license is sublicensable with prior CHMC written approval consistent with the terms of the CHMC Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">90</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The CHMC Agreement includes the below patents, which we refer to as the &#8220;Licensed Patents&#8221;, and any divisionals, continuations and continuations<span class="nobreak">-in-part</span> thereto (solely to the extent that the claims in the continuations<span class="nobreak">-in-part</span> are directed to the subject matter specifically claimed in the Licensed Patents, and they have the same priority date as the Licensed Patents, but do not include any different or additional claims), and any patents resulting therefrom:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">U.S.&#160;Patent <br/>Application No.</span></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">U.S.&#160;<br/>Patent No.</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 22.28%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Granted Claim Type</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">U.S.&#160;<br/>Expiration</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 26.44%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Foreign Counterparts</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/797,396</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 14.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:right;">8,486,421</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 22.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;">Compositions of the vaccine/vaccine platform</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;">1/13/2031</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 26.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;">CN107043408B EP2440582B1 JP5894528B2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">13/924,906</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 14.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:right;">9,096,644</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 22.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">Method of treatment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;">9/20/2030</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 26.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">CN107043408B EP2440582B1 JP5894528B2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">13/803,057</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 14.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:right;">9,562,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 22.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">Compositions of the vaccine platform</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;">11/8/2033</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 26.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">none</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">16/489,095</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 14.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:right;">pending</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 22.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">pending**</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;">[3/15/2038]*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 26.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">Pending applications in Canada, China, EU, Hong&#160;Kong and Japan</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">63/149,742 <br/>(filed 2/16/2021)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 14.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:right;">pending</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 22.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">pending**</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;">[February&#160;2042]<span class="Superscript" style="vertical-align:super;font-size:58%;">#</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 26.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">TBD</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">63/162,369 <br/>(filed 3/17/2021)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 14.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:right;">pending</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 22.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">pending</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;">[March&#160;2042]<span class="Superscript" style="vertical-align:super;font-size:58%;">#</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 26.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">TBD</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Projected expiration if patent issues: 20&#160;years from earliest non<span class="nobreak">-provisional</span> application filing date.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">#<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Non<span class="nobreak">-provisional</span> application not yet filed. Expiration projected 21&#160;years from provisional application filing date. Dependent on timely conversion to non<span class="nobreak">-provisional</span> application and issuance of patent.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">**<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>This is a pending application. Claim type will be determined after U.S.&#160;prosecution is complete. The claim type sought includes compositions of the vaccine and vaccine platform.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The CHMC Agreement also grants the Company a non<span class="nobreak">-exclusive</span> limited license to use and copy internally any technical information in existence and known before the Effective Date by CHMC solely as necessary for the use and practice of the Licensed Patents (the &#8220;CHMC Technology&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The term of the CHMC Agreement begins on the Effective Date and extends on a jurisdiction by jurisdiction and product by product basis until the later of: (i)&#160;the last to expire Licensed Patent; (ii)&#160;ten (10)&#160;years after the first commercial sale or (iii)&#160;entrance onto the market of a biosimilar or interchangeable product. CHMC has reserved the right to practice, have practiced, and transfer the Licensed Patents and CHMC Technology for research and development purposes, including education, research, teaching, publication and public service, but not to use or practice the Licensed Patents or CHMC Technology in the Field of Use for any commercial or profit purpose.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Licensed Patents granted to the Company under the CHMC Agreement are also subject to any rights of the United&#160;States federal, state and/or local Government(s), as well as nonprofit entities, if certain patents or technologies were created in the course of Government<span class="nobreak">-funded</span> or non<span class="nobreak">-profit</span> entity<span class="nobreak">-funded</span> research. The CHMC Agreement also contains compulsory licensing provisions under which CHMC must notify the Company in writing whenever CHMC may become aware of third parties that are interested in obtaining rights to the Licensed Patents or CHMC Technology for purposes that are beyond the scope of the Company&#8217;s development and commercialization plan. The Company may elect to pursue the new purposes itself (and negotiate commercially reasonable development targets) or enter into sublicense negotiations with the interested third party. However, if the Company fails to meet its development targets for the new purposes or fails to enter into a sublicense agreement with the interested third party within nine (9)&#160;months of the notice from CHMC, then the new purpose will be excluded from the license grant and CHMC will be free to pursue licensing of the Licensed Patents or CHMC Technology within the Excluded Field to an interested third party.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Any patented modification, alteration or improvement of any invention claimed in a Licensed Patents or CHMC Technology which is conceived or reduced to practice solely by the Company (&#8220;Company Improvement&#8221;) is owned by the Company; however, for any such Company Improvement, the Company will automatically grant to CHMC a worldwide, perpetual, sublicensable, nonexclusive, paid<span class="nobreak">-up</span>, royalty<span class="nobreak">-free</span> license to use any Company Improvements solely for clinical or non<span class="nobreak">-clinical</span>, non<span class="nobreak">-commercial</span> research, testing, educational and patient care purposes. The CHMC </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">91</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Agreement also provides the Company with an option to license any CHMC or jointly patented modification, alteration or improvement of any invention claimed in a Licensed Patent (&#8220;CHMC Improvement&#8221; and &#8220;Joint Improvement, respectively&#8221;), with option fee for each Improvement that the Company elects to include in the license grant of the CHMC Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company is required to pay CHMC an aggregate of up to $59.75&#160;million upon the achievement of specified development milestones, of approximately $0.5&#160;million, regulatory milestones, of approximately $1.25&#160;million and commercial milestones of approximately $58&#160;million (excluding any royalty arrangements). In the event the Company enters into a sublicense agreement with a third party who is not an affiliate, then the Company is obligated to pay CHMC a percentage of all non<span class="nobreak">-royalty</span> sublicensing revenue. Specifically, the Company must pay twenty<span class="nobreak">-five</span> percent (25%) for revenue received from the sublicensee prior to first net sale of a licensed product, fifteen percent (15%) for revenue received after first net sale of a licensed product or five percent after the first sale of a second licensed product. No annual maintenance fee is required.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the CHMC Agreement, the Company paid to CHMC a one<span class="nobreak">-time</span> $25,000 initial license fee; thereafter, in fiscal year ended December&#160;31, 2022, the Company paid $200,000 in deferred license fees.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Under the CHMC Agreement, the Company is obligated to use commercially reasonable efforts to bring licensed products to market through diligent research and development, testing, manufacturing, and commercialization and to use best efforts to make all necessary regulatory filings and obtain all necessary regulatory approvals, and achieve milestones relating to development and sales, and report to CHMC on progress. The Company will also be obligated to pay the agreed upon development milestone payments to CHMC.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Development milestones include: (i)&#160;IND filings of each Licensed Product; (ii)&#160;Biologics License Applications (&#8220;BLAs&#8221;) or equivalent allowed for Licensed Product in U.S.&#160;or E.U.; (iii)&#160;first commercial sale of licensed product in the U.S.; (iv)&#160;first commercial sale of licensed product in the E.U.; (v)&#160;first commercial sale of licensed product in Japan; (vi)&#160;first commercial sale in Rest of World (ROW); (vii)&#160;conclusion of the first calendar year. Pursuant to the terms of the CHMC Agreement, if the Company fails to achieve milestones or make milestone payments on certain milestones and cannot mutually agree with CHMC on an amendment to the milestones, then CHMC will have the option of converting any and all of such exclusive licenses to nonexclusive licenses.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In addition to the fees discussed above, beginning on the first Net Sale, the Company will pay CHMC running royalties on a quarterly basis as a percentage of Net Sales (as defined in the CHMC Agreement) of the Company, its affiliates, and any subsidiaries. Similarly, in the event the Company enters into a sublicense agreement, the Company shall pay CHMC a percentage of all non<span class="nobreak">-royalty</span> sublicensing revenues received from the sublicensee. There is a 5% royalty rate for products and processes for P<span class="nobreak">-Particle</span> VLP Bivalent vaccine for norovirus and rotavirus; a 4% royalty rate for products and processes for Universal Flu Vaccine(s); and a 2% royalty rate for all other products or processes for other indications. To date, no payments have been made related to the milestones or royalties. Before any Valid Claims (as defined in the CHMC Agreement) exist, the running royalty rates are reduced by fifty percent (50%).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The CHMC Agreement also contains an anti<span class="nobreak">-stacking</span> provision pursuant to which in the event the Company is legally required to pay royalties to one or more third parties whose patent rights dominate the Licensed Patents and would therefore be infringed by exercise of the license rights granted in the CHMC Agreement, the Company may reduce running royalty payments by fifty percent (50%). In the event the Company grants sublicenses, the Company is obligated to pay CHMC as follows: (i)&#160;specified percentage of revenue received prior to first Net Sale of first Licensed Product; (ii)&#160;specified percentage for revenue received after first Net Sales of first Licensed Product but before first Net Sales of second Licensed Product; or (iii)&#160;specified percentage for revenues received after first Net Sales of second Licensed Product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">CHMC reserved the first and sole right, using in<span class="nobreak">-house</span> or outside legal counsel selected by CHMC, to prepare, file, prosecute, maintain, and extend patents and patent applications, and the Company agreed to reimburse CHMC for its legal and administrative costs incurred in the course of doing such. The Company also agreed to reimburse CHMC for incurred legal fees of approximately $177,100 as of the Effective Date. CHMC will provide the Company a reasonable opportunity to comment during prosecution and will consider the Company&#8217;s comments, but CHMC retained control over all final decisions. If CHMC elects to not be responsible for the prosecution or maintenance of any such patents, the Company will receive sixty (60)&#160;days&#8217; prior written notice upon which the Company may elect, at the Company&#8217;s expense, to assume the responsibilities and obligations to prosecute and maintain the patents (among other things); thereafter, the Company will use reasonable efforts to give CHMC an opportunity to comment, but the final decision with respect to such matter will remain with the Company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">92</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The CHMC Agreement contains no CHMC representations or warranties. The CHMC Agreement also requires the Company to indemnify CHMC and other related parties against all claims, suit, actions, demands, judgments, or investigations arising out of any product the Company produces under the CHMC Agreement, as set forth in the CHMC Agreement, and requires the Company, beginning with the earlier of the first clinical trial or commercial sale or other commercialization to obtain liability insurance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">CHMC will have the first and sole right but not the obligation, at its own expense, to initiate an infringement suit or other appropriate actions against third party infringers and receives all therefrom. For joint suits initiated against third party infringers and receives damages or profits recovered therefrom. In the event CHMC does not, within six (6)&#160;months after becoming aware of infringement, secure cessation of the infringement, the Company will have the right to initiate suit at its own expense. Any damages or profits that the Company recovers will be treated as Net Sales subject to royalties after the Company has been compensated for its costs in handling such action. In the event of a joint infringement suit, the Company and CHMC will agree in writing who will control the action and how cost and recoveries will be shared.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company may terminate the CHMC Agreement for convenience at any time prior to first commercial sale of a product or process by providing one hundred and eighty (180)&#160;days&#8217; written notice to CHMC.&#160;It may also terminate for a CHMC uncured material breach. CHMC may terminate the CHMC Agreement for an uncured Company material breach or insolvency or bankruptcy. In the event the Company&#8217;s material breach is for failure to meet any of the milestone payments, the Company is entitled to a nonexclusive license to continue developing indications that have already entered development at any stage or in which the Company has invested in developing. CHMC may also terminate the CHMC Agreement to the fullest extent permitted by law in the countries of the worldwide territory, in the event the Company or its affiliates challenge or induce others set up challenges to the validity or enforceability of any of the Licensed Patents and the Company will be obligated reimburse CHMC for its costs, including reasonable attorneys&#8217; fees.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Manufacturing and Supply</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We currently do not own or operate any manufacturing facilities. For Proclarix, we outsource manufacturing to a CMO in Germany. The manufacturing of Proclarix is outsourced to a CMO in Germany. All of the key reagents used in Proteomedix&#8217;s IVD kits (i.e., antigens and antibodies) are proprietary and owned exclusively by Proteomedix. These reagents are produced by an independent supplier in Germany and shipped to the CMO for manufacturing of the IVD kits. The development and production of the Proclarix risk calculator software and the hosting of the Proclarix risk calculator software are performed by external suppliers. For ENTADFI, we utilize third<span class="nobreak">-party</span> manufacturers for the pharmaceuticals, bottle fill, finish, labeling, bottle serialization, warehousing, and distribution.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Agreement with Cardinal Health</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On September&#160;21, 2023, the Company entered into an Exclusive Distribution Agreement (the &#8220;Exclusive Distribution Agreement&#8221;), effective as of September&#160;20, 2023 (the &#8220;Effective Date&#8221;), with Cardinal Health 105, LLC (&#8220;Cardinal Health&#8221;). Pursuant to, and subject to the terms and conditions of, the Exclusive Distribution Agreement, the Company engaged Cardinal Health as its exclusive third<span class="nobreak">-party</span> logistics distribution agent for sales of ENTADFI and any other products the parties mutually agree to. The term of the Distribution Agreement is three&#160;years from the Effective Date and automatically renews for additional terms of one year each unless terminated pursuant to the terms of the Exclusive Distribution Agreement. Under the terms of the Exclusive Distribution Agreement, the Company must pay to Cardinal Health a one<span class="nobreak">-time</span> start<span class="nobreak">-up</span> fee of $15,500, and if we proceed with commercialization of ENTADFI, upon its launch, a monthly account management fee of $7,000, and other fees for various services, including post<span class="nobreak">-launch</span> program implementation, information systems, warehouse operations and financial services.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Employees</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of April<span class="nobreak"> </span>24, 2024, we had 12 full<span class="nobreak">-time</span> and 11 subcontracted employees. As part of a cost reduction plan approved by the Board and in connection with our pause in commercializing ENTADFI, we terminated three employees involved with the ENTADFI program, effective April<span class="nobreak"> </span>30, 2024, with such individuals to continue assisting the Company on an as<span class="nobreak">-needed</span>, consulting basis. None of our employees are represented by a collective bargaining agreement, and we have never experienced any work stoppage. We believe we have good relations with our employees.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">93</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Properties and Facilities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We currently lease an office located at 201 E Fifth Street, Suite 1900, Cincinnati, OH&#160;45202, which is renewed on a monthly basis.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, Proteomedix leases office and lab space located at Wagistrasse<span class="nobreak"> </span>23, 8952 Schlieren, Switzerland. This lease expires on June&#160;30, 2025, subject to renewal for successive two<span class="nobreak">-year</span> terms. The lease will automatically renew unless terminated. Either party may terminate the lease with 12&#160;months&#8217; written notice.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Corporate Information</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We were incorporated on October&#160;22, 2018, under the laws of the State of Delaware. Our principal executive offices are located at 201 E Fifth Street, Suite 1900, Cincinnati, OH&#160;45202, and our telephone number is (513)&#160;620<span class="nobreak">-4101</span>. Our corporate website address is <span class="Italic" style="font-style:italic;font-weight:normal;">www.onconetix.com</span>. We make available free of charge on or through our Internet website our annual report on Form&#160;10<span class="nobreak">-K</span>, quarterly reports on Form&#160;10<span class="nobreak">-Q</span>, current reports on Form&#160;8<span class="nobreak">-K</span>, proxy statements on Schedule&#160;14A, and amendments to those reports filed or furnished pursuant to Section&#160;13(a)&#160;or 15(d)&#160;of the Exchange&#160;Act as soon as reasonably practicable after we electronically file such materials with, or furnish them to, the SEC.&#160;Alternatively, you may also access our reports at the SEC&#8217;s website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.sec.gov</span>.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Buyback Program</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On November&#160;10, 2022, the Company&#8217;s Board of Directors approved a share repurchase program to allow for the Company to repurchase up to 5&#160;million shares of common stock, with discretion to management to make purchases subject to market conditions. The maximum purchase price is $2.00 per share and there is no expiration date for this program.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the fiscal year ended December&#160;31, 2023, the Company repurchased 57,670<span class="nobreak"> </span>shares of common stock, for an aggregate of approximately $59,000, at an average price of $1.02 per share.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Fundraising Activities</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">April&#160;2022 Private Placement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;19, 2022, we consummated the closing of a Private Placement (the &#8220;April&#160;2022 Private Placement&#8221;), in which we received approximately $6.9&#160;million in net cash proceeds, pursuant to the terms and conditions of the Securities Purchase Agreement, dated as of April&#160;13, 2022 (the &#8220;April Purchase Agreement&#8221;), by and among the Company and certain purchasers named on the signature pages thereto. At the closing of the April&#160;2022 Private Placement, the Company issued 590,406<span class="nobreak"> </span>shares of common stock, pre<span class="nobreak">-funded</span> warrants to purchase an aggregate of 590,406<span class="nobreak"> </span>shares of common stock and preferred investment options to purchase up to an aggregate of 1,180,812<span class="nobreak"> </span>shares of common stock. The purchase price of each share of common stock together with the associated preferred investment option was $6.775, and the purchase price of each pre<span class="nobreak">-funded</span> warrant and associated preferred investment option was $6.774. The aggregate net cash proceeds to the Company from the April&#160;2022 Private Placement were approximately $6.9&#160;million, after deducting placement agent fees and other offering expenses.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">H.C.&#160;Wainwright&#160;&amp; Co., LLC (&#8220;Wainwright&#8221;) acted as the exclusive placement agent for the April&#160;2022 Private Placement and received a cash fee of approximately $600,000, which was equivalent to 7.5% of the aggregate gross proceeds of the offering, and received warrants (the &#8220;April Wainwright Warrants&#8221;) to purchase up to 70,849<span class="nobreak"> </span>shares of our common stock, which was equivalent to 6.0% of the shares and pre<span class="nobreak">-funded</span> warrants sold in the April&#160;2022 Private Placement. We also paid Wainwright a management fee equal to approximately $80,000, which is equivalent to 1.0% of the aggregate gross proceeds from the offering and reimbursed certain out<span class="nobreak">-of-pocket</span> expenses up to an aggregate amount of $85,000. We also agreed, upon any exercise for cash of any preferred investment options, to issue to Wainwright warrants to purchase the number of shares equal to 6.0% of the aggregate number of placement shares underlying the preferred investment options that have been exercised (the &#8220;April Contingent Warrants&#8221;), up to a maximum of 70,849<span class="nobreak"> </span>shares. The maximum number of April Contingent Warrants were exchanged for August Contingent Warrants (as defined below) in connection with the August&#160;2022 Private Placement (as defined below).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">94</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the April&#160;2022 Private Placement, we entered into a registration rights agreement with the purchasers, dated as of April&#160;13, 2022 (the &#8220;April Registration Rights Agreement&#8221;), pursuant to which we filed a registration statement covering the resale of registrable securities under the April Registration Rights Agreement, which was declared effective on May&#160;20, 2022.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Upon the occurrence of any Event (as defined in the April Registration Rights Agreement), which, among others, includes the purchasers being prohibited from reselling the securities acquired in the April&#160;2022 Private Placement for more than ten (10)&#160;consecutive calendar&#160;days or more than an aggregate of fifteen (15)&#160;calendar&#160;days during any 12<span class="nobreak">-month</span> period, we are obligated to pay to each purchaser, on each monthly anniversary of each such Event, an amount in cash, as partial liquidated damages and not as a penalty, equal to the product of 2.0% multiplied by the aggregate subscription amount paid by such purchaser pursuant to the April&#160;2022 Purchase Agreement.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">August&#160;2022 Private Placement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;11, 2022, the Company consummated the closing of a private placement (the &#8220;August&#160;2022 Private Placement&#8221;), pursuant to the terms and conditions of a securities purchase agreement, dated as of August&#160;9, 2022. At the closing of the August&#160;2022 Private Placement, the Company issued 1,350,000<span class="nobreak"> </span>shares of common stock, pre<span class="nobreak">-funded</span> warrants to purchase an aggregate of 2,333,280<span class="nobreak"> </span>shares of common stock and preferred investment options to purchase up to an aggregate of 4,972,428<span class="nobreak"> </span>shares of common stock. The purchase price of each share of common stock together with the associated preferred investment option was $2.715, and the purchase price of each pre<span class="nobreak">-funded</span> warrant together with the associated preferred investment option was $2.714. The aggregate net cash proceeds to the Company from the August&#160;2022 Private Placement were approximately $8.7&#160;million, after deducting placement agent fees and other offering expenses. In addition, the investors in the August&#160;2022 Private Placement, who are the same investors from the April&#160;2022 Private Placement, agreed to cancel preferred investment options to purchase up to an aggregate of 1,180,812<span class="nobreak"> </span>shares of the Company&#8217;s common stock issued in April&#160;2022. The pre<span class="nobreak">-funded</span> warrants had an exercise price of $0.001 per share. During 2022, an aggregate of 1,686,640 of the pre<span class="nobreak">-funded</span> warrants were exercised. The remaining 646,640 of pre<span class="nobreak">-funded</span> warrants were exercised during the year ended December&#160;31, 2023. The preferred investment options are exercisable at any time on or after August&#160;11, 2022, through August&#160;12, 2027, at an exercise price of $2.546 per share, subject to certain adjustments as defined in the agreement. During the year ended December&#160;31, 2023, 2,486,214 of these preferred investment options were exercised at a reduced exercise price of $1.09, in connection with the Warrant Inducement Transaction discussed below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Wainwright acted as the exclusive placement agent for the August&#160;2022 Private Placement. The Company agreed to pay Wainwright a placement agent fee of approximately $750,000 and a management fee of approximately $100,000, which equal to 7.5% and 1.0%, respectively, of the aggregate gross proceeds from the August&#160;2022 Private Placement and reimbursed certain out<span class="nobreak">-of-pocket</span> expenses up to an aggregate of $85,000. In addition, the Company issued warrants to Wainwright (the &#8220;August Wainwright Warrants&#8221;) to purchase up to 220,997<span class="nobreak"> </span>shares of common stock. The August Wainwright Warrants are in substantially the same form as the preferred investment options, except that the exercise price is $3.3938. The form of the preferred investment options is a warrant, and as such the preferred investment options, the pre<span class="nobreak">-funded</span> warrants, and the August Wainwright Warrants are collectively referred to as the &#8220;August&#160;2022 Private Placement Warrants&#8221;. Further, upon any exercise for cash of any preferred investment options, the Company agreed to issue to Wainwright additional warrants to purchase the number of shares of common stock equal to 6.0% of the aggregate number of shares of common stock underlying the preferred investment options that have been exercised, also with an exercise price of $3.3938 (the &#8220;August Contingent Warrants&#8221;). The maximum number of August Contingent Warrants issuable under this provision is 298,346, which includes 70,849 of April Contingent Warrants that were modified in connection with the August&#160;2022 Private Placement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the August&#160;2022 Private Placement, the Company entered into a Registration Rights Agreement with the purchasers, dated as of August&#160;9, 2022 (the &#8220;August Registration Rights Agreement&#8221;). The August Registration Rights Agreement provides that the Company shall file a registration statement covering the resale of all of the registrable securities (as defined in the August Registration Rights Agreement) with the SEC no later than the 30<span class="CharOverride-5" style="font-size:58%;vertical-align:super;">th</span> calendar&#160;day following the date of the August Registration Rights Agreement and have the registration statement declared effective by the SEC as promptly as possible after the filing thereof, but in any event no later than the 45<span class="CharOverride-5" style="font-size:58%;vertical-align:super;">th</span> calendar&#160;day following August&#160;9, 2022 or, in the event of a full review by the SEC, the 80<span class="CharOverride-5" style="font-size:58%;vertical-align:super;">th</span>&#160;day following August&#160;9, 2022. The registration statement on Form&#160;S<span class="nobreak">-1</span> required under the Registration Rights Agreement was filed with the SEC on August&#160;29, 2022 and became effective on September&#160;19, 2022.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">95</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Upon the occurrence of any Event (as defined in the August Registration Rights Agreement), which, among others, prohibits the purchasers from reselling the securities for more than ten consecutive calendar&#160;days or more than an aggregate of fifteen calendar&#160;days during any 12<span class="nobreak">-month</span> period, and should the registration statement cease to remain continuously effective, the Company is obligated to pay to each purchaser, on each monthly anniversary of each such Event, an amount in cash, as partial liquidated damages and not as a penalty, equal to the product of 2.0% multiplied by the aggregate subscription amount paid by such purchaser in the August&#160;2022 Private Placement.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Warrant Inducement Transaction</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On July&#160;31, 2023, the Company entered into a common stock preferred investment options exercise inducement offer letter (the &#8220;Inducement Letter&#8221;) with a certain holder (the &#8220;Holder&#8221;) of existing preferred investment options (&#8220;PIOs&#8221;) to purchase shares of the Company&#8217;s common stock at the original exercise price of $2.546 per share, issued on August&#160;11, 2022 (the &#8220;Existing PIOs&#8221;). Pursuant to the Inducement Letter, the Holder agreed to exercise for cash its Existing PIOs to purchase an aggregate of 2,486,214<span class="nobreak"> </span>shares of the Company&#8217;s common stock, at a reduced exercised price of $1.09 per share, in exchange for the Company&#8217;s agreement to issue new PIOs (the &#8220;Inducement PIOs&#8221;) on substantially the same terms as the Existing PIOs as described below, to purchase up to 4,972,428<span class="nobreak"> </span>shares of the Company&#8217;s common stock (the &#8220;Inducement PIO Shares&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;1, 2023, the Company and the Holder entered into a letter agreement to amend the Inducement Letter to clarify, among other things, that (i)&#160;the Inducement PIOs shall be immediately exercisable at any time on or after the date of issuance and have a term of exercise of five (5)&#160;years from the date of issuance, and (ii)&#160;the Company shall not be required to hold a meeting of stockholders to approve the issuance of the Inducement PIO Shares. Except for the change in exercise period, the terms of the Inducement PIOs remain unchanged.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;2, 2023, the Company consummated the Warrant Inducement. The Company received aggregate net proceeds of approximately $2.3&#160;million from the Warrant Inducement, after deducting placement agent fees and other offering expenses payable by the Company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company engaged Wainwright to act as its placement agent in connection with the Warrant Inducement and paid Wainwright a cash fee equal to 7.5% of the gross proceeds received from the exercise of the Existing PIOs as well as a management fee equal to 1.0% of the gross proceeds from the exercise of the Existing PIOs. The Company also agreed to reimburse Wainwright for its expenses in connection with the exercise of the Existing PIOs and the issuance of the Inducement PIOs, up to $50,000 for fees and expenses of legal counsel and other out<span class="nobreak">-of-pocket</span> expenses and agreed to pay Wainwright for non<span class="nobreak">-accountable</span> expenses in the amount of $35,000. In addition, the exercise for cash of the Existing PIOs triggered the issuance to Wainwright or its designees, warrants to purchase 149,173<span class="nobreak"> </span>shares of common stock, which were issuable in accordance with the terms of Contingent Warrants issuable to Wainwright in connection with the August&#160;2022 Private Placement, and have the same terms as the Inducement PIOs, except for an exercise price equal to $1.3625 per share. The Company also agreed to issue warrants to Wainwright upon any exercise for cash of the Inducement PIOs, that number of shares of common stock equal to 6.0% of the aggregate number of such shares of common stock underlying the Inducement PIOs that have been exercised, also with an exercise price of $1.3625. The maximum number of warrants issuable under this provision is 298,346.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Legal Proceedings</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, we may be involved in various disputes and litigation matters that arise in the ordinary course of business. We are currently not a party to any material legal proceedings.</p>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">96</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T99111"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION</span></p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-1" style="font-style:italic;font-weight:normal;text-decoration:underline;">Transaction summary</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2023, Onconetix, Inc, a Delaware corporation (&#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Onconetix</span>&#8221; or the &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Company</span>&#8221;), entered into a Share Exchange Agreement (the &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Share Exchange Agreement</span>&#8221;), by and among (i)&#160;Onconetix, (ii)&#160;Proteomedix&#160;AG, a Swiss Company (&#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Proteomedix</span>&#8221;), (iii)&#160;each of the holders of outstanding capital stock of Proteomedix Convertible Securities (other than Proteomedix Stock Options) named therein (collectively, the &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Sellers</span>&#8221;) and (iv)&#160;Thomas Meier, in the capacity as the representative of Sellers in accordance with the terms and conditions of the Share Exchange Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Protemedix is a healthcare company whose mission is to transform prostate cancer diagnosis. Proteomedix has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product Proclarix<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> is a blood<span class="nobreak">-based</span> prostate cancer test panel and risk score currently available in Europe and expected to be available in the United&#160;States (&#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">U.S</span>.&#8221;) in the near future. Proteomedix is located in the Bio<span class="nobreak">-Technopark</span> of Zurich<span class="nobreak">-Schlieren</span>, Switzerland.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Share Exchange Agreement, subject to the terms and conditions set forth therein,&#160;the Sellers agreed to sell to Onconetix, and Onconetix agreed to buy, all of the issued and outstanding equity interests of Proteomedix (the &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Purchased Shares</span>&#8221;) in exchange for newly issued shares of common stock of Onconetix, par value $0.00001 per share (&#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Buyer Common Stock</span>&#8221;), and newly issued shares of preferred stock of Onconetix, par value $0.00001 per share (&#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Series&#160;B Convertible Preferred Stock</span>&#8221;), as further described below (the &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Share Exchange</span>&#8221; and the other transactions contemplated by the Share Exchange Agreement, the &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Transactions</span>&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The consummation (the &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Closing</span>&#8221;) of the Share Exchange was subject to customary closing conditions and the execution of the Subscription Agreement (as defined below) entered into with Altos Ventures (the &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">PMX Investor</span>&#8221;).&#160;The Share Exchange closed on December&#160;15, 2023 (the &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Closing Date</span>&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In full payment for the Purchased Shares, Onconetix issued shares (the &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Exchange Shares</span>&#8221;) consisting of: (i) 3,675,414<span class="nobreak"> </span>shares of Buyer Common Stock equal to approximately 19.9% of the total issued and outstanding Buyer Common Stock and (ii)&#160;2,696,729<span class="nobreak"> </span>shares of Series&#160;B Convertible Preferred Stock contingently convertible into 269,672,900<span class="nobreak"> </span>shares of Buyer Common Stock upon shareholder approval (the &#8220;Exchange Consideration&#8221;). </p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of the 3,675,414&#160;shares of Buyer Common Stock, was determined using the closing price of the Buyer Common Stock as of the Closing Date, which was $0.2382. The fair value of the 2,696,729&#160;shares of Series&#160;B Preferred Stock was based on the underlying fair value of the common shares issuable upon conversion, also based on the closing price of the Buyer Common Stock as of the Closing Date. The aggregate fair value of the common and preferred shares issued as consideration was equal to approximately $65.1&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As a result of the Transactions, Proteomedix became a direct, wholly owned subsidiary of Onconetix. Upon shareholder approval it is anticipated that, following the Conversion (as defined below) and closing of the investment pursuant to the Subscription Agreement (as defined below), Sellers will own approximately 87.2% of the outstanding equity interests of Onconetix, the Investor will own approximately 7.5% of the outstanding equity interests of Onconetix, and the stockholders of Onconetix immediately prior to the Share Exchange Closing will own approximately 5.3% of the outstanding equity interests of Onconetix.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Each option to purchase shares of Proteomedix (each, a &#8220;Proteomedix Stock Option&#8221;) outstanding immediately before the Closing, whether vested or unvested, remains outstanding until the Conversion unless otherwise terminated in accordance with its terms. At the Conversion, each outstanding Proteomedix Stock Option, whether vested unvested, shall be assumed by Onconetix and converted into the right to receive (a)&#160;an option to acquire shares of Buyer Common Stock (each, an &#8220;Assumed Option&#8221;) or (b)&#160;such other derivative security as Onconetix and Proteomedix may agree, subject in either case to substantially the same terms and conditions as were applicable to such Proteomedix Stock Option immediately before the Closing. Each Assumed Option shall: (i)&#160;represent the right to acquire a number of shares of Buyer Common Stock equal to the product of (A)&#160;the number of Proteomedix Common Shares that </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">97</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">were subject to the corresponding Proteomedix Stock Option immediately prior to the Closing, multiplied by (B)&#160;the Exchange Ratio; and (ii)&#160;have an exercise price (as rounded down to the nearest whole cent) equal to the quotient of (A)&#160;the exercise price of the corresponding Company Option, divided by (B)&#160;the Exchange Ratio.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Transactions, on December&#160;15, 2023, Onconetix entered into a Subscription Agreement (the &#8220;Subscription Agreement&#8221;) with the PMX Investor for a private placement of $5.0&#160;million of units (the &#8220;Units&#8221;), each unit comprised of (i)&#160;one share of Common Stock and (ii)&#160;one pre<span class="nobreak">-funded</span> warrant (collectively, the &#8220;Warrants&#8221;) to purchase 0.3<span class="nobreak"> </span>shares of Common Stock at an exercise price of $0.001 per share, for an aggregate purchase price per Unit of $0.25 (the &#8220;Purchase Price&#8221;). Additional shares are issuable to the PMX Investor to the extent the PMX Investor continues to hold Common Stock included in the Units&#160;and if the VWAP during the 270&#160;days following closing is less than the Purchase Price, as set forth in the Subscription Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The offering is expected to close following stockholder approval of the issuance of the Conversion Shares (the &#8220;Conversion&#8221;). Within 30&#160;days after closing, Onconetix will file a resale registration statement with the SEC registering the resale of the Common Stock issuable pursuant to the Subscription Agreement and the Warrants.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-1" style="font-style:italic;font-weight:normal;text-decoration:underline;">Pro forma information</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following unaudited pro forma consolidated statement of operations and comprehensive loss are based on the Company&#8217;s audited historical consolidated financial statements and Proteomedix&#8217;s unaudited historical financial statements as adjusted to give effect to the Company&#8217;s acquisition of Proteomedix. These unaudited pro forma consolidated statements of operations and comprehensive loss for the twelve&#160;months ended December&#160;31, 2023 and gives effect to these transactions as if they occurred on January&#160;1, 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The pro forma consolidated statements of operations and comprehensive loss should be read together with the Company&#8217;s audited historical financial statements and Proteomedix&#8217;s audited and unaudited interim financial statements, which are included herein.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma consolidated financial information is provided for informational purposes only and is not intended to represent or be indicative of the consolidated results of operations that the Company would have reported had the Proteomedix transaction closed on the dates indicated and should not be taken as representative of our future consolidated results of operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The pro forma adjustments related to the Share Exchange Agreement are described in the notes to the unaudited pro forma consolidated financial information and principally include the following:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;">-<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Adjustments related to amortization for intangible assets recognized as part of the application of the acquisition method of accounting.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The adjustments to fair value and the other estimates reflected in the accompanying unaudited pro forma consolidated statement of operations and comprehensive loss may be materially different from those reflected in the consolidated company&#8217;s consolidated financial statements subsequent to the merger. In addition, the unaudited pro forma consolidated statement of operations and comprehensive loss do not purport to project the future results of operations of the consolidated companies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">These unaudited pro forma consolidated statement of operations and comprehensive loss do not give effect to any anticipated synergies, operating efficiencies or cost savings that may be associated with the Share Exchange Agreement. These financial statements also do not include any integration costs the companies may incur related to the Transactions as part of combining the operations of the companies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">98</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">ONCONETIX, INC</span></p>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:0pt;margin-top:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">PRO FORMA CONSOLIDATED STATEMENT OPERATIONS AND COMPREHENSIVE LOSS</span></p>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:0pt;margin-top:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(UNAUDITED)</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">For the<br/>year ended<br/>December&#160;31,<br/>2023<br/>Onconetix, <br/>Inc.</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">January&#160;1,<br/>2023 to<br/>December&#160;15,<br/>2023 <br/>Proteomedix <br/>AG</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Transaction<br/>Adjustments</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Pro-forma<br/>Consolidated</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Revenues</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">58,465</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,506,761</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,565,226</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cost of goods sold</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,185,630</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">38,198</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,223,828</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Gross profit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,127,165</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,468,563</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,341,398</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Selling, general and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,770,678</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,139,790</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16,910,468</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,949,406</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">552,232</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,501,638</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Impairment of ENTADFI assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,687,346</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,687,346</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Impairment of deposit on asset purchase agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,500,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,500,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation and amortization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12,221</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">791,572</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">3.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">803,793</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">34,907,430</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,704,243</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">791,572</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">38,403,245</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(36,034,595</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(235,680</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(791,572</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(37,061,847</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other income (expense)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss on extinguishment of note payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(490,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(490,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(671,625</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(78,233</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">78,233</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">3.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(671,625</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other income (expense)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(44,842</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(44,842</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in fair value of subscription agreement liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(134,100</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(134,100</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in fair value of contingent warrant liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(91,967</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(91,967</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other income (expense)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,387,692</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(123,075</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">78,233</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,432,534</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12,593</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12,593</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net loss</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(37,409,694</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(358,755</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(713,339</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(38,481,788</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2.19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1.87</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted average number of common shares outstanding, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17,111,374</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,514,300</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">3.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,625,674</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Other comprehensive loss</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(37,409,694</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(358,755</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(713,339</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(38,481,788</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Benefit pension obligation changes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,963</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(349,202</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(343,239</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Foreign currency translation adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,374,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(175,868</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,199,089</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Comprehensive income (loss) applicable to common stockholders</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(35,028,774</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(883,825</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.79%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(713,339</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.23%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(36,625,938</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;orphans:99;text-align:center;widows:1;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">99</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">NOTES TO THE UNAUDITED PRO FORMA CONSOLIDATED<br/>FINANCIAL INFORMATION</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;1 &#8212;&#160;Basis of Presentation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The audited and unaudited historical consolidated statement of operations and comprehensive loss have been adjusted in the pro forma consolidated statement of operations and comprehensive loss to give effect to pro forma events&#160;that are (1)&#160;directly attributable to the business combination, (2)&#160;factually supportable and (3)&#160;with respect to the pro forma consolidated statements of operations, expected to have a continuing impact on the consolidated results following the business combination.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The business combination was accounted for under the acquisition method of accounting in accordance with ASC Topic&#160;805,&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Business Combinations</span>. As the acquirer for accounting purposes, the Company has estimated the fair value of Proteomedix AG&#8217;s assets acquired and liabilities assumed and conformed the accounting policies of Proteomedix AG to its own accounting policies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma consolidated statement of operations and comprehensive loss are based on the Company&#8217;s audited historical consolidated financial statements and Proteomedix AG&#8217;s unaudited historical financial statements as adjusted to give effect to the Company&#8217;s acquisition of Proteomedix AG.&#160;The unaudited pro forma consolidated statement of operations and comprehensive loss for the year ended December&#160;31, 2023 gives effect to these transactions as if they occurred on January&#160;1, 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The allocation of the purchase price used in the unaudited pro forma consolidated statement of operations and comprehensive loss is based upon a preliminary valuation by management and is therefore provisional in nature. The final estimate of the fair values of the assets and liabilities will be determined with the assistance of a third<span class="nobreak">-party</span>&#160;valuation firm. The Company&#8217;s preliminary estimates and assumptions are subject to material change upon the finalization of internal studies and third<span class="nobreak">-party</span>&#160;valuations of assets, including property and equipment, intangible assets, and certain liabilities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma consolidated statement of operations and comprehensive loss are provided for informational purposes only and is not necessarily indicative of what the consolidated Company&#8217;s results of operations would have actually been had the transactions been completed on the dates used to prepare these pro forma financial statements. The adjustments to fair value and the other estimates reflected in the accompanying unaudited pro forma consolidated statement of operations and comprehensive loss may be materially different from those reflected in the consolidated company&#8217;s consolidated financial statements subsequent to the transactions. In addition, the Unaudited pro forma consolidated statement of operations and comprehensive loss do not purport to project the future financial position or results of operations of the consolidated companies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">These unaudited pro forma consolidated statement of operations and comprehensive loss do not give effect to any anticipated synergies, operating efficiencies or cost savings that may be associated with the transactions. These financial statements also do not include any integration costs the companies may incur related to the transactions as part of combining the operations of the companies.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;2 &#8212;&#160;Summary of Significant Accounting Policies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma consolidated statement of operations and comprehensive loss have been prepared in a manner consistent with the accounting policies adopted by the Company. The accounting policies followed for financial reporting on a pro forma basis are the same as those disclosed in the 2023 Annual Report on Form&#160;10<span class="nobreak">-K</span>.&#160;The unaudited pro forma consolidated statement of operations and comprehensive loss do not assume any differences in accounting policies among the Company and Proteomedix.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3 &#8212;&#160;Pro Forma Transaction Accounting Adjustments</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The pro forma transaction accounting adjustments are based on our preliminary estimates and assumptions that are subject to change. The following transaction accounting adjustments have been reflected in the unaudited pro forma condensed combined financial information:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>This adjustment records (1)&#160;the issuance of 2,696,729 Series&#160;B Convertible Preferred Stock, and (2)&#160;the issuance of 3,675,414&#160;shares of common stock of the Company.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">100</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>This adjustment also removes interest expense related to convertible notes outstanding prior to the acquisition which are shown as converted for purposes of preparing these pro forma statement of operations and comprehensive loss.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>As part of the preliminary valuation analysis, the Company separately identified certain intangible assets with an estimated fair value of $21.5&#160;million. Based on our research and discussions with Proteomedix management, we have concluded that the intangible assets have estimated useful lives of 15&#160;years, resulting in an adjustment of approximately $839 thousand of amortization expense to the consolidated statements of comprehensive loss for the and the year ended December&#160;31, 2023. These numbers may change significantly when the final allocation of purchase price <span class="CharOverride-4"> is calculated.</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Description</span></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Useful<br/>Life</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Amortization<br/>Method</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Fair<br/>Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Trade name</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">Indefinite</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">None</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,018,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Customer relationships</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">15 years</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">Straight-line</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,891,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Internally-developed technology</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">15 years</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">Straight-line</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,541,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">21,450,000</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair values of the acquired intangible assets were determined using variations of the cost, income approach using the excess earnings, lost profits and relief from royalty methods.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The trade name intangible asset represents the value of the Proclarix&#8482; brand name and was valued using a relief from royalty method under an income approach. A royalty rate of&#160;6% was utilized in determining the fair value of this intangible asset. The fair value of this asset was determined based on a cash flow model using forecasted revenues and expenses specifically tied to Proclarix&#8482;. Those cash flows were then discounted at&#160;10% determined by the use of a weighted average return on assets analysis. The life of this intangible asset was determined to be indefinite as the branded name will persist beyond the life of the product rights and customer relationships.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The customer relationship intangible assets represent the value of an existing customer contract and was valued using the lost profits method under the income approach. The fair value of this asset was determined based on a cash flow model using forecasted revenues specifically tied to Proteomedix&#8217;s Laboratory Corporation of America contract (see Note&#160;6 to the audited historical financial statements of Onconetix, Inc). Those cash flows were then discounted at&#160;10% determined by the use of a weighted average return on assets analysis. The estimated useful life of this asset was determined by reference to the estimated life of the product rights associated with the Laboratory Corporation of America contract.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The product rights for developed technology represents know<span class="nobreak">-how</span> and patented intellectual property held by Proteomedix&#8217;s pertaining to its commercial<span class="nobreak">-ready</span> prostate cancer diagnostic system, Proclarix&#8482;. The fair value of this asset was determined based on a cash flow model based on forecasted revenues and expenses specifically tied to Proclarix&#8482;. Those cash flows were then discounted at&#160;8% for the period prior to patent expiration and&#160;16% for the period thereafter. The discount rates were determined by the use of a weighted average return on assets analysis. The estimated useful life of the product rights was determined based on the underlying patent&#8217;s remaining life.</p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">101</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T99501"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">Onconetix&#8217;s&#160;Management&#8217;s&#160;Discussion&#160;and&#160;Analysis&#160;of&#160;Financial&#160;Condition&#160;and<br/>Results of OperationS</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Overview</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We are a commercial stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men&#8217;s health and oncology. Through our recent acquisition of Proteomedix, we own Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation (&#8220;IVDR&#8221;), which is planned to be marketed in the U.S.&#160;as a lab developed test. We also own ENTADFI, an FDA<span class="nobreak">-approved</span>, once daily pill that combines finasteride and tadalafil for the treatment of BPH, a disorder of the prostate.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proclarix is an easy<span class="nobreak">-to-use</span> next generation protein<span class="nobreak">-based</span> blood test that can be done with the same sample as a patient&#8217;s regular Prostate<span class="nobreak">-Specific</span> Antigen (&#8220;PSA&#8221;) test. The PSA test is a well<span class="nobreak">-established</span> prostate specific marker that measures the concentration of PSA molecules in a blood sample. A high level of PSA can be a sign of prostate cancer. However, PSA levels can also be elevated for many other reasons including infections, prostate stimulation, vigorous exercise, or even certain medications. PSA results can be confusing for many patients and even physicians. It is estimated over 50% of biopsies with elevated PSA are negative or clinically insignificant resulting in an overdiagnosis and overtreatment that impacts the physician&#8217;s routine, our healthcare system, and the quality of patients&#8217; lives. Proclarix helps doctors and patients with unclear PSA test results through the use of our proprietary Proclarix Risk Score which delivers clear and immediate diagnostic support for further treatment decisions. No additional intervention is required, and results are available quickly. Local diagnostic laboratories can integrate this multiparametric test into their current workflow because Proclarix assays use the enzyme<span class="nobreak">-linked</span> immunosorbent assay (ELISA) standard, which most diagnostic laboratories are already equipped to process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">ENTADFI allows men to receive treatment for their symptoms of BPH without the negative sexual side effects typically seen in patients on finasteride alone. Following a recent business strategy shift towards the fields of men&#8217;s health and oncology and deprioritization of preclinical vaccine programs, we are building additional assets in therapeutics, diagnostics, and clinician services for men&#8217;s health and oncology.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Since our inception in October&#160;2018 until April&#160;2023, when we acquired ENTADFI, we devoted substantially all of our resources to performing research and development, undertaking preclinical studies and enabling manufacturing activities in support of our product development efforts, hiring personnel, acquiring and developing our technology and now deprioritized vaccine candidates, organizing and staffing our company, performing business planning, establishing our intellectual property portfolio and raising capital to support and expand such activities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Prior to the acquisition of ENTADFI, we managed one distinct business segment, which was research and development. Beginning in the second quarter of 2023, as a result of the acquisition of ENTADFI, we operated in two business segments: research and development and commercial. During the third quarter of 2023, we deprioritized our vaccine discovery and development programs, and accordingly, we now operate in one segment: commercial. Our acquisition during the fourth quarter of 2023 of Proteomedix and its diagnostic product Proclarix was determined to be within our commercial segment. The research and development segment was our historical business, and was dedicated to the research and development of various vaccines to prevent infectious diseases. The commercial segment was new in the second quarter of 2023 and is dedicated to the commercialization of our products approved for sale, namely ENTADFI in the U.S.&#160;and Proclarix in Europe.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">ENTADFI has not generated any revenue from product sales, and Proclarix has generated only minimal amounts of development revenue since its acquisition.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In light of (i)&#160;the time and resources needed to continue pursuing commercialization of ENTADFI, and (ii)&#160;the Company&#8217;s cash runway and indebtedness, the Company has determined to temporarily pause its commercialization of ENTADFI, as it considers strategic alternatives. As part of a cost reduction plan approved by the Board and in connection with our pause in commercializing ENTADFI, we terminated three employees involved with the ENTADFI program, effective April<span class="nobreak"> </span>30, 2024, with such individuals to continue assisting the Company on an as<span class="nobreak">-needed</span>, consulting basis. The Company continues to consider various measures, including strategic alternatives, to rationalize its operations and optimize its existing Proclarix diagnostic program. </p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We are currently focusing our efforts on commercializing Proclarix.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">102</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Given Proclarix is CE<span class="nobreak">-marked</span> for sale in the European Union, we expect to generate revenue from sales of Proclarix by 2025. Although we anticipate these sales to offset some expenses relating to commercial scale up and development, we expect our expenses will increase substantially in connection with our ongoing activities, as we:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>commercialize Proclarix and ENTADFI (if we decide to resume its commercialization), and other commercial<span class="nobreak">-stage</span> products</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>hire additional personnel; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>obtain, maintain, expand, and protect our intellectual property portfolio.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">To the extent that we resume the commercialization of ENTADFI, we also expect to incur significant commercialization expenses related to marketing, manufacturing, and distribution for ENTADFI.&#160;We rely and will continue to rely on third parties for the manufacturing of ENTADFI and Proclarix. We have no internal manufacturing capabilities, and we will continue to rely on third parties, of which the main suppliers are single<span class="nobreak">-source</span> suppliers, for commercial products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We do not have any products approved for sale, aside from Proclarix, from which we have generated only minimal amounts of development revenue since its acquisition, and ENTADFI, from which we have not generated any revenue from product sales, and for which we have determined to temporarily pause commercialization activities. To date, we have financed our operations primarily with proceeds from our sale of preferred securities to seed investors, the close of the IPO, the close of the 2022 Private Placements, the proceeds received from a warrant exercise in August&#160;2023, and the proceeds received from the issuance of debt in January&#160;2024. We will continue to require significant additional capital to commercialize Proclarix and ENTADFI (if we decide to resume its commercialization), and to fund operations for the foreseeable future. Accordingly, until such time as we can generate significant revenue, if ever, we expect to finance our cash needs through public or private equity or debt financings, third<span class="nobreak">-party</span> (including government) funding and to rely on third<span class="nobreak">-party</span> resources for marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches, to support our operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We have incurred net losses since inception and expect to continue to incur net losses in the foreseeable future. Our net losses may fluctuate significantly from quarter<span class="nobreak">-to-quarter</span> and year<span class="nobreak">-to-year</span>, depending in large part on timing and success of commercialization activities, the timing of clinical trials and manufacturing activities, and our expenditures on other research and development activities. As of December&#160;31, 2023, the Company had a working capital deficit of approximately $11.4&#160;million and an accumulated deficit of approximately $56.8&#160;million. We will need to raise additional capital to sustain operations and meet our contractual commitments and obligations within the one<span class="nobreak">-year</span> period following the issuance of the accompanying consolidated financial statements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Until we generate revenue sufficient to support self<span class="nobreak">-sustaining</span> cash flows, if ever, we will need to continue to raise additional capital to fund our continued operations, including our product development and commercialization activities related to our current and future products. There can be no assurance that additional capital will be available to us on acceptable terms, or at all, or that we will ever generate revenue sufficient to provide for self<span class="nobreak">-sustaining</span> cash flows. These circumstances raise substantial doubt about our ability to continue as a going concern. The consolidated financial statements incorporated by reference in this proxy statement do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Because of the numerous risks and uncertainties associated with our business, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Additionally, even if we are able to generate revenue from Proclarix, or ENTADFI, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and may be forced to reduce our operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Certain Significant Relationships</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We have entered into grant, license and collaboration arrangements with various third parties as summarized below. For further details regarding these and other agreements, see the section titled &#8220;Business&#160;&#8212;&#160;Intellectual Property&#8221; and Note&#160;6 to our consolidated financial statements included elsewhere in the Annual Report.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">103</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;23, 2023, Proteomedix entered into a license agreement with Labcorp pursuant to which Labcorp has the exclusive right to develop and commercialize Proclarix and other products developed by Labcorp using Proteomedix&#8217;s intellectual property covered by the license, in the United&#160;States (&#8220;Licensed Products&#8221;). In consideration for granting Labcorp an exclusive license, Proteomedix received an initial license fee in the mid<span class="nobreak">-six</span> figures upon signing of the contract. Additionally, Proteomedix is entitled to royalty payments on the net sales recognized by Labcorp of any Licensed Products plus milestone payments as follows:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>After the first sale of Proclarix as a laboratory developed test, Labcorp will pay an amount in the mid<span class="nobreak">-six</span> figures;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>After Labcorp achieves a certain amount in the low seven figures in net sales of the Licensed Products, Labcorp will pay Proteomedix an amount in the low seven figures; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>After a certain amount in the mid<span class="nobreak">-seven</span> figures in net sales of Licensed Products, Labcorp will pay Proteomedix an amount in the low seven figures.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Labcorp is wholly responsible for the cost, if any, of research, development and commercialization of Licensed Products in the United&#160;States but has the right to offset a portion of those costs against future royalty and milestone payments. Additionally, Labcorp may deduct royalties or other payments made to third parties related to the manufacture or sale of Licensed Products up to a maximum amount of any royalty payments due to Proteomedix.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Ology Agreement (which was later acquired by National Resilience, Inc.)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company entered into a Master Services Agreement (&#8220;Ology MSA&#8221;), dated July&#160;19, 2019, with Ology, Inc. (&#8220;Ology&#8221;) to provide services from time to time, including but not limited to technology transfer, process development, analytical method optimization, cGMP manufacture, regulatory affairs, and stability studies of biologic products. Pursuant to the Ology MSA, the Company and Ology shall enter into a Project Addendum for each project to be governed by the terms and conditions of the Ology MSA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company entered into two Project Addendums as of December&#160;31, 2023. The initial Project Addendum was executed on October&#160;18, 2019, and the Company was required to pay Ology an aggregate of approximately $4&#160;million. Due to unforeseen delays associated with COVID<span class="nobreak">-19</span>, the Company and Ology entered into a letter agreement dated January&#160;9, 2020, to stop work on the project, at which point the Company had paid Ology $100,000 for services to be provided. The second Project Addendum was executed on May&#160;21, 2021, and the Company is obligated to pay Ology an aggregate amount of approximately $2.8&#160;million, plus reimbursement for materials and outsourced testing, which will be billed at cost plus 15%. During 2023 and 2022, the Company and Ology entered into contract amendments that resulted in a net decrease in the Company&#8217;s obligations of approximately $137,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">For additional details regarding our relationship with Ology, see the section entitled &#8220;Business&#160;&#8212;&#160;Manufacturing and Supply&#8221; and Note&#160;6 to our consolidated financial statements included elsewhere in the Annual Report.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Cincinnati Children&#8217;s Hospital Medical Center Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On June&#160;1, 2021, we entered into an exclusive, worldwide license agreement with Children&#8217;s Hospital Medical Center, d/b/a Cincinnati Children&#8217;s Hospital Medical Center, or CHMC, which we refer to as the CHMC Agreement, pursuant to which we obtained the right to develop and commercialize certain CHMC patents and related technology directed at a virus<span class="nobreak">-like</span> particle (VLP) vaccine platform that utilizes nanoparticle delivery technology, which may have potential broad application to develop vaccines for multiple infectious diseases. However, as Onconetix has now deprioritized its infectious disease vaccine programs based on a change in clinical focus, we are exploring ways in which CHMC&#8217;s VLP platform can be used in therapeutic and diagnostic applications in oncology.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Under the CHMC Agreement, we agreed to pay CHMC certain license fees, deferred license fees, development milestone fees, and running royalties beginning on the first net sale (among others). For additional details regarding our relationship with CHMC, see the section entitled &#8220;Business&#160;&#8212;&#160;Intellectual Property&#160;&#8212;&#160;Exclusive License Agreement </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">104</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">with Children&#8217;s Hospital Medical Center, d/b/a Cincinnati Children&#8217;s Hospital Medical Center&#8221; and Notes 6 and 10 to our consolidated financial statements included in the Annual Report. The CHMC license includes the following patents:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 18.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">U.S.&#160;Patent <br/>Application No.</span></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.63%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">U.S. <br/>Patent No.</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 24.28%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Granted Claim Type</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">U.S. <br/>Expiration</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 21.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Foreign <br/>Counterparts</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 18.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">12/797,396</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 13.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;">8,486,421</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;">Compositions of the vaccine/vaccine platform</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;">1/13/2031</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 21.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:left;">CN107043408B EP2440582B1 JP5894528B2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 18.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">13/924,906</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 13.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;">9,096,644</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 24.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">Method of treatment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;">9/20/2030</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 21.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">CN107043408B EP2440582B1 JP5894528B2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 18.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">13/803,057</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 13.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;">9,562,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 24.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">Compositions of the vaccine platform</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;">4/10/2034</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 21.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">none</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 18.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">16/489,095</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 13.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;">pending</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 24.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">pending**</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;">[3/15/2038]*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 21.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">Pending applications in Canada, China, EU, Hong&#160;Kong and Japan</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 18.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">63/149,742 <br/>(filed 2/16/2021)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 13.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;">pending</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 24.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">pending**</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;">[February&#160;2042]#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 21.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">TBD</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 18.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">63/162,369 <br/>(filed 3/17/2021)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 13.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;">pending</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 24.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:left;">pending**</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 16.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;">[March&#160;2042]<span class="Superscript" style="vertical-align:super;font-size:58%;">#</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 21.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">TBD</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Projected expiration if patent issues: 20&#160;years from earliest non<span class="nobreak">-provisional</span> application filing date.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">#<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Non<span class="nobreak">-provisional</span> application not yet filed. Expiration projected 21&#160;years from provisional application filing date. Dependent on timely conversion to non<span class="nobreak">-provisional</span> application and issuance of patent.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">**<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>This is a pending application. Claim type will be determined after U.S.&#160;prosecution is complete. The claim type sought includes compositions of the vaccine and vaccine platform.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">AbVacc Co-Development Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;1, 2023, the Company entered into a co<span class="nobreak">-development</span> agreement with AbVacc, Inc., for the purpose of conducting research aimed at co<span class="nobreak">-development</span> of specific vaccine candidates, including monkeypox and Marburg virus disease with the potential to expand to others using the Norovirus nanoparticle platform (&#8220;Co<span class="nobreak">-Development</span> Project&#8221;), and to govern the sharing of materials and information, as defined in the agreement, for the Co<span class="nobreak">-Development</span> Project. Under the agreement, AbVacc and the Company will collaborate, through a joint development committee, to establish and implement a development plan or statement of work for each Co<span class="nobreak">-Development</span> Project targeted product. Under the co<span class="nobreak">-development</span> agreement, either the Company or AbVacc, whichever party is the primary sponsor of any resulting product (as defined in the agreement), will be obligated to compensate the other party for certain milestone payments that would range between $2.1&#160;million and $4.75&#160;million, plus royalties of between 2% to 4%. The term of the agreement is three&#160;years from the effective date, unless previously terminated by either party, in accordance with the agreement. However, as Onconetix has now deprioritized its infectious disease vaccine programs, this agreement will have little strategic significance going forward.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Services Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On July&#160;21, 2023, the Company, entered into a Licensing and Services Master Agreement (&#8220;Master Services Agreement&#8221;) and a related statement of work with a vendor, pursuant to which the vendor was to provide to the Company commercialization services for the Company&#8217;s products, including recruiting, managing, supervising and evaluating sales personnel and providing sales<span class="nobreak">-related</span> services for such products, for fees totaling up to $29.1&#160;million over the term of the statement of work. The statement of work had a term through September&#160;6, 2026, unless earlier terminated in accordance with the Master Services Agreement and the statement of work. On July&#160;29, 2023, a second statement of work was entered into with the same vendor for certain subscription services providing prescription market data access to the Company. The fees under the second statement of work totaled </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">105</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">approximately $800,000, and the term was through July&#160;14, 2025. On October&#160;12, 2023, the Company terminated the Master Services Agreement and the statements of work. The Company recorded approximately $3.1&#160;million in expense related to this contract during the year ended December&#160;31, 2023, which is included in selling, general and administrative expense in the accompanying consolidated statements of operations and comprehensive loss. The Company had approximately $1.8&#160;million recorded in related accounts payable as of December&#160;31, 2023, which includes amounts due for early termination of the contract. See Note&#160;6 to our consolidated financial statements included in the Annual Report.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Components of Results of Operations</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Selling, General and Administrative Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Selling, general and administrative expenses consist principally of commercialization activities, payroll, and personnel expenses, including salaries and bonuses, benefits and stock<span class="nobreak">-based</span> compensation expenses, professional fees for legal, consulting, accounting and tax services, information technology costs, costs incurred with respect to acquisitions and potential acquisitions, and other general operating expenses.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We anticipate that our selling, general and administrative expenses will continue to increase when compared to historical levels as a result of our dedication to commercialization of our products approved for sale, which includes. Proclarix in Europe and ENTADFI in the U.S (if we decide to resume its commercialization), costs associated with integration of these assets and commercial operations, as well as expanded infrastructure and higher consulting, legal and accounting services costs associated with complying with the applicable stock exchange and the SEC requirements, investor relations costs and director and officer insurance premiums associated with being a public company.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Research and Development Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Substantially all of our research and development expenses consist of expenses incurred in connection with the development of our product candidates. These expenses historically have included fees paid to third parties to conduct certain research and development activities on our behalf, consulting costs, costs for laboratory supplies, product acquisition and license costs, certain payroll, and personnel<span class="nobreak">-related</span> expenses, including salaries and bonuses, employee benefit costs and stock<span class="nobreak">-based</span> compensation expenses for our research and product development employees. We expense both internal and external research and development expenses as they are incurred.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We do not allocate our costs by product candidate, as a significant amount of research and development expenses include internal costs, such as payroll and other personnel expenses, laboratory supplies, and external costs, such as fees paid to third parties to conduct research and development activities on our behalf, that are not tracked by product candidate.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We expect our research and development expenses to increase once research and development activities are resumed. Predicting the timing or cost to complete our clinical programs for future product candidates, or validation of our commercial manufacturing and supply processes is difficult and delays may occur because of many factors, including factors outside of our control, such as regulatory approvals. Furthermore, we are unable to predict when or if our future product candidates will receive regulatory approval with any certainty.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Other Income (Expense)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Other income (expense) is comprised of interest expense on notes payable, the change in fair value of financial instruments that are recorded as liabilities, which includes the subscription agreement liability, contingent warrant liability, and other financing<span class="nobreak">-related</span> costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">106</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Results of Operations</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comparison of the&#160;Years Ended December&#160;31, 2023 and 2022</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes our statements of operations and comprehensive loss for the periods indicated:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Year Ended</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Year Ended</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">$</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Change</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">%</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Change</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Revenue</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">58,465</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">58,465</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cost of revenue</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,185,630</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,185,630</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-17" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Gross loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,127,165</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,127,165</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(100</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Selling, general and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,770,678</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,351,552</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,419,126</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">57.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-17" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,949,406</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,129,688</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,180,282</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(52.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Impairment of ENTADFI assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,687,346</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,687,346</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-17" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Impairment of deposit on asset purchase agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,500,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,500,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">34,907,430</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13,481,240</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">21,426,190</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">158.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(36,034,595</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(13,481,240</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(22,553,355</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(167.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other income (expense)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss on extinguishment of note payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(490,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(490,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(100</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-17" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(671,625</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(671,625</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(100</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in fair value of subscription agreement liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(134,100</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(134,100</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(100</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-17" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in fair value of contingent warrant liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(91,967</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">61,410</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(153,377</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(249.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other income (expense)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,387,692</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">61,410</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,449,102</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,359.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss before income taxes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(37,422,287</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(13,419,830</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(24,002,457</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(178.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12,593</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12,593</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-17" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(37,409,694</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(13,419,830</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(23,989,864</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(178.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</p>
					</td>
				</tr>

		</table>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Revenue, Cost of Revenue, and Gross Margin</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">For the year ended December&#160;31, 2023, the Company had less than $0.1&#160;million of revenue, which was attributable to Proteomedix revenue recorded from the date of acquisition through December&#160;31, 2023. Cost of revenue of approximately $1.2&#160;million, and the resulting negative margin, is attributable to costs incurred on Proteomedix revenue including amortization of the product rights intangible asset of approximately $31,000, and an impairment of inventory related to ENTADFI of approximately $1.2&#160;million. The Company did not have any revenue during the year ended December&#160;31, 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Selling, General and Administrative Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">For the year ended December&#160;31, 2023, selling, general and administrative expenses increased by approximately $5.4&#160;million compared to 2022. The increase was mainly due to approximately $4.7&#160;million in expenses incurred related to commercialization activities and an increase in professional services of approximately $1.7&#160;million, which is comprised primarily of audit, accounting, and legal services, a significant portion of which were in support of the Company&#8217;s acquisition activities. In addition, the Company incurred approximately $1.7&#160;million related to the acquisition of Proteomedix, which consists primarily of transaction costs and Proteomedix&#8217;s selling, general and administrative expenses since the acquisition date. The Company also recorded an impairment of long<span class="nobreak">-lived</span> assets of $0.3&#160;million during 2023. These increases were offset by a decrease in employee and director compensation and benefits of approximately $1.0&#160;million, primarily due to a decrease in stock<span class="nobreak">-based</span> compensation expense. Also, the Company recorded approximately $1.3&#160;million of expense in 2022 related to the settlement agreement with Boustead and approximately $0.3&#160;million for a non<span class="nobreak">-recurring</span> termination fee to the Company&#8217;s former underwriter, for early termination of the agreement with that underwriter, with no related expenses in 2023. The remaining decrease is due to </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">107</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">a decrease in various business activities that occurred during the last half of the year related to the Company&#8217;s change in business strategy, including decreases in business advisory services, patent costs, travel related expenses, and rent expense, totaling $0.4&#160;million.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">For the year ended December&#160;31, 2023, research and development expenses decreased by approximately $2.2&#160;million compared to 2022. The decrease was primarily due to the Company&#8217;s decision to deprioritize its vaccine programs and focus on commercialization activities, which occurred during the third quarter of 2023. This change in business strategy led to a pause on the Company&#8217;s clinical and other research activities, and a resulting decrease of approximately $2.3&#160;million due to decreased costs for related outside services and reduced compensation expense. This was slightly offset by an increase related to Proteomedix&#8217;s research and development activities since the acquisition date, of approximately $0.1&#160;million.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Impairments</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company recorded an impairment charge of $14.7&#160;million on the assets acquired as part of the ENTADFI acquisition during the fourth quarter of 2023. In addition, the Company recorded an impairment charge of $3.5&#160;million on a deposit that was made as part of the WraSer APA.&#160;No such impairments were recorded during 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Other Income (Expense)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Other expense incurred during the year ended December&#160;31, 2023 increased by approximately $1.4&#160;million compared to 2022 and relates to the change in fair value of the subscription agreement liability of approximately $0.1&#160;million, $0.7&#160;million of interest expense, primarily incurred on notes payable issued in April&#160;2023 related to the acquisition of ENTADFI, a loss on extinguishment of a note payable of $0.5&#160;million in connection with the Veru APA Amendment, and the change in fair value of the contingent warrant liability of approximately $0.1&#160;million. Other income recorded during the year ended December&#160;31, 2022, relates to the change in fair value of the contingent warrant liability.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Tax Benefit</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company recorded an income tax benefit of approximately $13,000 during the year ended December&#160;31, 2023, in connection with the acquisition accounting for the Proteomedix transaction. There was no income tax benefit or expense recorded during the year ended December&#160;31, 2022.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Liquidity and Capital Resources</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s operating activities to date have been primarily devoted to seeking licenses, engaging in research and development activities, potential asset and business acquisitions, and expenditures associated with the commercial launch of ENTADFI.&#160;The Company has financed its operations since inception primarily using proceeds received from seed investors and proceeds received from its IPO and subsequent debt and equity offerings. During the year ended December&#160;31, 2022, the Company received an aggregate of approximately $33.1&#160;million in net cash proceeds from its IPO and two private placements, and during the year ended December&#160;31, 2023, the Company received net proceeds of approximately $2.3&#160;million in connection with the exercise by an investor of preferred investment options. In addition, on January&#160;23, 2024, the Company received net cash proceeds of $4.6&#160;million in exchange for the issuance of a debenture. The debenture, as amended on April<span class="nobreak"> </span>24, 2024, is repayable in full upon the earlier of (i)&#160;the closing of a subscription agreement, which was entered into in connection with the acquisition of Proteomedix, and (ii)&#160;October<span class="nobreak"> </span>31, 2024.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future. As of December&#160;31, 2023, the Company had cash of approximately $4.6&#160;million, a working capital deficit of approximately $11.4&#160;million and an accumulated deficit of approximately $56.8&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">These factors, along with the Company&#8217;s forecasted future cash flows, indicate that the Company will be unable to meet its contractual commitments and obligations as they come due in the ordinary course of business, within one year following the issuance of these consolidated financial statements. The Company will require significant </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">108</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">additional capital in the short<span class="nobreak">-term</span> to fund its continuing operations, satisfy existing and future obligations and liabilities, including the remaining payments due for the acquisition of the ENTADFI assets, payment due on the Debenture, in addition to funds needed to support the Company&#8217;s working capital needs and business activities. These business activities include the commercialization of Proclarix and ENTADFI (if we decide to resume its commercialization), and the development and commercialization of the Company&#8217;s future product candidates. In addition, as discussed more fully in Note&#160;5, if stockholder approval is not obtained by January&#160;1, 2025, with respect to the Series&#160;B Convertible Redeemable Preferred Stock issued in connection with the acquisition of Proteomedix, these shares become redeemable for cash, and the Company currently does not have sufficient cash to redeem such shares. Based on the closing price of $0.122 for the Company&#8217;s stock as of April<span class="nobreak"> </span>24, 2024, the Series B Preferred Stock would be redeemable for approximately $32.9<span class="nobreak"> </span>million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Management&#8217;s plans for funding the Company&#8217;s operations include generating product revenue from sales of Proclarix, which may still be subject to further successful commercialization activities within certain jurisdictions, and ENTADFI, which is subject to further successful commercialization activities which we have temporarily paused as discussed above. Certain of the commercialization activities are outside of the Company&#8217;s control, including but not limited to, securing contracts with wholesalers and third<span class="nobreak">-party</span> payers, securing contracts with third<span class="nobreak">-party</span> logistics providers, and obtaining required licensure in various jurisdictions, as well as attempting to secure additional required funding through equity or debt financings if available. However, there are currently no commitments in place for further financing nor is there any assurance that such financing will be available to the Company on favorable terms, if at all. This creates significant uncertainty that the Company will have the funds available to be able to successfully launch ENTADFI and expand commercialization of Proclarix. If the Company is unable to secure additional capital, it may be required to curtail any future clinical trials, development and/or commercialization of products and product candidates, and it may take additional measures to reduce expenses in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Because of historical and expected operating losses and net operating cash flow deficits, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for one year from the issuance of the consolidated financial statements, which is not alleviated by management&#8217;s plans. The consolidated financial statements have been prepared assuming the Company will continue as a going concern. These consolidated financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Future Funding Requirements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our primary uses of cash to date have been to fund our operations, which consist primarily of research and development expenditures related to our programs, costs related to acquisitions and potential acquisitions, commercializing ENTADFI and other selling, general and administrative expenditures. We anticipate that we will continue to incur significant expenses for the foreseeable future as we continue to commercialize Proclarix and ENTADFI, if we proceed with its commercialization, and expand our corporate infrastructure, including the costs associated with being a public company. We are subject to all of the risks typically related to the development of new drug candidates, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We will require significant amounts of additional capital in the short<span class="nobreak">-term</span>, to continue to fund our continuing operations, satisfy existing and future obligations and liabilities, including the remaining payments due under the Veru APA and other contracts entered into in support of the Company&#8217;s commercialization plans, in addition to funds needed to support our working capital needs and business activities, including the commercialization of Proclarix and ENTADFI (if we decide to resume its commercialization), and the development and commercialization of our future product candidates. Until we can generate a sufficient amount of revenue from sales of Proclarix or ENTADFI, we expect to finance our future cash needs through public or private equity or debt financings, third<span class="nobreak">-party</span> (including government) funding and marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. The future sale of equity or convertible debt securities may result in dilution to our stockholders, and, in the case of preferred equity securities or convertible debt, those securities could provide for rights, preferences or privileges senior to those of our common stock. Debt financing may subject us to covenant limitations or restrictions on our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. There can be no assurance that we will be successful in </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">109</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">acquiring additional funding at levels sufficient to fund our operations or on terms favorable or acceptable to us. If we are unable to obtain adequate financing when needed or on terms favorable or acceptable to us, we may be forced to delay, reduce the scope of our business activities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our future capital requirements will depend on many factors, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of future commercialization activities, including product manufacturing, marketing, sales, royalties, and distribution, for Proclarix and ENTADFI (if we decide to resume its commercialization), and other products for which we may receive marketing approval;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing, scope, progress, results and costs of research and development, testing, screening, manufacturing,&#160;preclinical and non<span class="nobreak">-clinical</span> studies and clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA and comparable foreign regulatory authorities, including the potential for such authorities to require that we perform field efficacy studies, require more studies than those that we currently expect or change their requirements regarding the data required to support a marketing application;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any product liability or other lawsuits related to our products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expenses needed to attract, hire and retain skilled personnel;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the revenue, if any, received from commercial sales of Proclarix or ENTADFI (if we decide to resume its commercialization), or other products for which we may have received or will receive marketing approval;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs to establish, maintain, expand, enforce and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing our patents or other intellectual property rights; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of operating as a public company.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash Flows</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes our cash flows for the periods indicated:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Year Ended</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Year Ended</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-17" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(13,581,018</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(8,675,534</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in investing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(8,649,035</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(32,665</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by financing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,035,060</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">32,532,384</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effect of exchange rate changes on cash</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(3,331</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net increase (decrease) in cash</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(21,198,324</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">23,824,185</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Flows from Operating Activities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Net cash used in operating activities for the year ended December&#160;31, 2023, was $13.6&#160;million, which primarily resulted from a net loss of $37.4&#160;million. This was offset by impairment losses of $19.3&#160;million related to the ENTADFI assets and the WraSer APA, the fair value of the subscription liability agreement of $0.7&#160;million, non<span class="nobreak">-cash</span> interest expense of $0.7&#160;million, a loss on the extinguishment of a note payable of $0.5&#160;million, noncash stock<span class="nobreak">-based</span> compensation expense of $0.3&#160;million, a $0.3&#160;million loss on impairment of long<span class="nobreak">-lived</span> assets, other non<span class="nobreak">-cash</span> items of $0.4&#160;million, and a net change in our operating assets and liabilities of $1.6&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">110</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Net cash used in operating activities for the year ended December&#160;31, 2022, was $8.7&#160;million, which primarily resulted from a net loss of $13.4&#160;million, which was partially offset by noncash stock<span class="nobreak">-based</span> compensation of approximately $2.0&#160;million, the fair value of restricted common stock that was issued of approximately $0.3&#160;million, and a net change in our operating assets and liabilities of $2.4&#160;million.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Flows from Investing Activities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Net cash used in investing activities for the year ended December&#160;31, 2023, was approximately $8.6&#160;million, of which approximately $6.1&#160;million was used for the acquisition of ENTADFI, $3.5&#160;million was used for the deposit in connection with the potential WraSer APA, and $0.1&#160;million is the net change in the receivable from related parties and purchases of long<span class="nobreak">-lived</span> assets. This was offset by approximately $1.1&#160;million in cash acquired in connection with the acquisition of Proteomedix.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Net cash used in investing activities for the year ended December&#160;31, 2022, was approximately $33,000, which resulted from purchases of property and equipment and the net change in the receivable from related parties.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Flows from Financing Activities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Net cash provided by financing activities for the year ended December&#160;31, 2023, was approximately $1.0&#160;million, and resulted from net proceeds from the exercise of preferred investment options in connection with the warrant inducement transaction of $2.3&#160;million offset by $1.0&#160;million in principal payments on a note payable, $59,000 in purchases of treasury shares, and $205,000 of payment in deferred offering costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Net cash provided by financing activities for the year ended December&#160;31, 2022, was approximately $32.5&#160;million, and resulted primarily from the close of our IPO and the Private Placements, which resulted in net proceeds of approximately $33.1&#160;million, offset by approximately $0.6&#160;million in treasury share repurchases.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Legal Contingencies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, we may become involved in legal proceedings arising from the ordinary course of business. We record a liability for such matters when it is probable that future losses will be incurred and that such losses can be reasonably estimated.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Off-Balance Sheet Arrangements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the periods presented we did not have, nor do we currently have, any off<span class="nobreak">-balance</span> sheet arrangements as defined in the rules and regulations of the SEC.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Recent Accounting Pronouncements Not Yet Adopted</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">See Note&#160;3 to our consolidated financial statements included in the Annual Report for more information.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Critical Accounting Policies and Estimates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our consolidated financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience, known trends and events and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">While our significant accounting policies are described in more detail in Note&#160;3 to our consolidated financial statements included in the Annual Report, we believe the following accounting policies and estimates to be most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">111</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Acquisitions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluates acquisitions to first determine whether a set of assets acquired constitutes a business and should be accounted for as a business combination. If the assets acquired are not a business, the transaction is accounted as an asset acquisition in accordance with Accounting Standards Codification (&#8220;ASC&#8221;)&#160;805<span class="nobreak">-50</span>, <span class="Italic" style="font-style:italic;font-weight:normal;">Asset Acquisitions</span> (&#8220;ASC&#160;805<span class="nobreak">-50</span>&#8221;), which requires the acquiring entity to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, except for non<span class="nobreak">-qualifying</span> assets including financial assets such as inventory. Further, the cost of the acquisition includes the fair value of consideration transferred and direct transaction costs attributable to the acquisition. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. Contingent consideration payments in asset acquisitions are recognized when the contingency is determined to be probable and reasonably estimable. If the assets acquired are a business, the Company accounts for the transaction as a business combination. Business combinations are accounted for by using the acquisition method of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective fair values. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Acquisition<span class="nobreak">-related</span> expenses are expensed as incurred, and are included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Goodwill and Other Intangible Assets</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Goodwill represents the excess of the cost of a business combination over the fair value of the net assets acquired. Goodwill and intangible assets deemed to have indefinite lives are not amortized but are subject to impairment tests on an annual basis, and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Goodwill is allocated to the reporting unit from which it was created. A reporting unit is an operating segment or sub<span class="nobreak">-segment</span> to which goodwill is assigned when initially recorded. The Company tests indefinite lived intangible assets for impairment, on an annual basis in the fourth quarter, or more frequently if an event occurs or circumstances indicate that the indefinite lived assets may be impaired. The Company may perform a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company determines this is the case, the Company then performs further quantitative analysis to identify and measure the amount of goodwill impairment loss to be recognized, if any. To perform its quantitative test, the Company compares the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of its net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. The Company did not test its goodwill or indefinite lived assets for impairment during the year ended December&#160;31, 2023, given that the acquisition date occurred after the annual testing date, and given that there were no impairment indicators from the date of acquisition through the end of the reporting period. The Company has determined that no impairment of its goodwill or indefinite lived intangible assets occurred as of December&#160;31, 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Intangible assets with finite lives are reported at cost, less accumulated amortization, and are amortized over their estimated useful lives, starting when sales for the related product begin. Amortization is calculated using the straight<span class="nobreak">-line</span> method, and recorded within selling, general, and administrative expenses, or cost of revenue, depending on the nature and use of the asset.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the ordinary course of business, the Company has entered into certain license and asset purchase agreements. Potential milestone payments for development, regulatory, and commercial milestones are recorded when the milestone is probable of achievement. Upon a milestone being achieved, the associated milestone payment is capitalized and amortized over the remaining useful life for approved products, or expensed as research and development expense for milestones relating to products whose FDA approval has not yet been obtained.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company reviews long<span class="nobreak">-lived</span> assets, including intangible assets with finite useful lives, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable (a &#8220;triggering event&#8221;). Factors that the Company considers in deciding when to perform an impairment </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">112</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">review include significant underperformance of the long<span class="nobreak">-lived</span> asset in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long<span class="nobreak">-lived</span> asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long<span class="nobreak">-lived</span> asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value. During the fourth quarter of 2023, the Company determined that there were certain triggering events that indicated that the carrying amount of the assets recorded in connection with the ENTADFI acquisition may not be fully recoverable. A related impairment loss of $14.7&#160;million was recorded during the year ended December&#160;31, 2023. The Company also recorded an impairment loss of approximately $267,000 during the year ended December&#160;31, 2023, related to implementation costs incurred under cloud computing hosting arrangements that were capitalized during the year. There were no other impairment losses on long<span class="nobreak">-lived</span> assets for the&#160;years ended December&#160;31, 2023, and 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Research and Development Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We have entered into various agreements with CMOs and may enter into contracts with CROs in the future. As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel and third parties to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our accrued research and development expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments, if necessary. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by our vendors in connection with research and development activities for which we have not yet been invoiced.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We accrue for costs related to research and development activities based on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors, including CMOs, that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received. We make significant judgments and estimates in determining accrued research and development liabilities as of each reporting period based on the estimated time period over which services will be performed and the level of effort to be expended. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid expense accordingly.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Financial instruments</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company determines the accounting classification of financial instruments that are issued, including its warrants and a subscription agreement, as either liability or equity, by first assessing whether the financial instruments are freestanding financial instruments, and if they meet liability classification in accordance with ASC&#160;480, <span class="Italic" style="font-style:italic;font-weight:normal;">Distinguishing Liabilities from Equity</span>, (&#8220;ASC&#160;480&#8221;), and then in accordance with ASC&#160;815<span class="nobreak">-40</span>, <span class="Italic" style="font-style:italic;font-weight:normal;">Derivatives and Hedging&#160;&#8212;&#160;Contracts in Entity&#8217;s Own Equity </span>(&#8220;ASC&#160;815<span class="nobreak">-40</span>&#8221;). Under ASC&#160;480<span class="nobreak">-10</span>, financial instruments are considered liability<span class="nobreak">-classified</span> if the instruments are mandatorily redeemable, obligate the issuer to settle the instruments or the underlying shares by paying cash or other assets, or must or may require settlement by issuing a variable number of shares.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">113</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If the instruments do not meet liability classification under ASC&#160;480, the Company assesses the requirements under ASC&#160;815<span class="nobreak">-40</span>, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the financial instruments do not require liability classification under ASC&#160;815<span class="nobreak">-40</span>, in order to conclude equity classification, the Company assesses whether the instruments are indexed to the Company&#8217;s common stock and whether the instruments are classified as equity under ASC&#160;815<span class="nobreak">-40</span> or other applicable GAAP.&#160;After all relevant assessments are made, the Company concludes whether the instruments are classified as liability or equity. Liability<span class="nobreak">-classified</span> instruments are required to be accounted for at fair value both on the date of issuance and on subsequent accounting period ending dates, with all changes in fair value after the issuance date recorded as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. Equity<span class="nobreak">-classified</span> instruments are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company applies the guidance enumerated in ASC&#160;480, when determining the classification and measurement of preferred stock. Preferred stock subject to mandatory redemption, if any, is classified as a liability and is measured at fair value. The Company classifies conditionally redeemable preferred stock, which includes preferred stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control, as temporary equity. At all other times, the Company classifies its preferred stock in stockholders&#8217; equity.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company expenses stock<span class="nobreak">-based</span> compensation to employees and non<span class="nobreak">-employees</span> over the requisite service period based on the estimated grant<span class="nobreak">-date</span> fair value of the awards. Stock<span class="nobreak">-based</span> awards to employees with graded<span class="nobreak">-vesting</span> schedules are recognized, using the accelerated attribution method, on a straight<span class="nobreak">-line</span> basis over the requisite service period for each separately vesting portion of the award.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company estimates the fair value of stock option grants using the Black<span class="nobreak">-Scholes</span> option pricing model and the assumptions used in calculating the fair value of stock<span class="nobreak">-based</span> awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Expected Term</span>&#160;&#8212;&#160;The expected term of options represents the period that the Company&#8217;s stock<span class="nobreak">-based</span> awards are expected to be outstanding based on the simplified method, which is the half<span class="nobreak">-life</span> from vesting to the end of its contractual term. The simplified method is used as the Company has insufficient historical information to provide a basis for an estimate of the expected term.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Expected Volatility</span>&#160;&#8212;&#160;Volatility is a measure of the amount by which the Company&#8217;s share price has historically fluctuated or is expected to fluctuate (i.e., expected volatility) during a period. Due to the lack of an adequate history of a public market for the trading of the Company&#8217;s common stock and a lack of adequate company<span class="nobreak">-specific</span> historical and implied volatility data, the Company computes stock price volatility over expected terms based on comparable companies&#8217; historical common stock trading prices. For these analyses, the Company has selected companies with comparable characteristics, including enterprise value, risk profiles, and position within the industry.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Common Stock Fair Value</span>&#160;&#8212;&#160;The fair value of the common stock underlying the Company&#8217;s stock options is based on the closing price of the Company&#8217;s common stock, as reported by the Nasdaq Capital Market, on the grant date of the award.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Risk</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Free</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Interest Rate</span>&#160;&#8212;&#160;The Company bases the risk<span class="nobreak">-free</span> interest rate on the implied yield available on U.S.&#160;Treasury securities with a remaining term commensurate with the estimated expected term.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Expected Dividend</span>&#160;&#8212;&#160;The Company has never declared or paid any cash dividends on its shares of common stock and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company recognizes forfeitures of equity awards as they occur.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">114</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Quantitative and Qualitative Disclosures About Market Risk</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We are a smaller reporting company as defined by Rule&#160;12b<span class="nobreak">-2</span> of the Exchange&#160;Act and are not required to provide the information otherwise required under this item.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">JOBS Act</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;107 of the JOBS Act also provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B)&#160;of the Securities Act for complying with new or revised accounting standards. In other words, an &#8220;emerging growth company&#8221; can delay the adoption of new or revised accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this extended transition period.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">For as long as we remain an &#8220;emerging growth company&#8221; under the recently enacted JOBS Act, we will, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>be exempt from the provisions of Section&#160;404(b)&#160;of the Sarbanes<span class="nobreak">-Oxley</span> Act, which requires that our independent registered public accounting firm provide an attestation report on the effectiveness of our internal control over financial reporting;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>be permitted to omit the detailed compensation discussion and analysis from proxy statements and reports filed under the Exchange&#160;Act and instead provide a reduced level of disclosure concerning executive compensation; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>be exempt from any rules that may be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation or a supplement to the auditor&#8217;s report on the financial statements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Although we are still evaluating the JOBS Act, we currently intend to take advantage of some or all of the reduced regulatory and reporting requirements that will be available to us so long as we qualify as an &#8220;emerging growth company,&#8221; including the extension of time to comply with new or revised financial accounting standards available under Section&#160;102(b)&#160;of the JOBS Act. Among other things, this means that our independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of our internal control over financial reporting so long as we qualify as an emerging growth company, which may increase the risk that weaknesses or deficiencies in our internal control over financial reporting go undetected. Likewise, so long as we qualify as an emerging growth company, we may elect not to provide you with certain information, including certain financial information and certain information regarding compensation of our executive officers, that we would otherwise have been required to provide in filings we make with the SEC, which may make it more difficult for investors and securities analysts to evaluate our company. As a result, investor confidence in our company and the market price of our common stock may be materially and adversely affected.</p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">115</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T99502"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROTEOMEDIX Management&#8217;s Discussion and Analysis of Financial Condition and Results of OperationS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">You should read the following discussion in conjunction with our financial statements and related notes included elsewhere in this prospectus. This discussion contains forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> statements that involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated in these forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> statements as a result of various factors, including, but not limited to, those set forth under &#8220;Risk Factors&#8221; and elsewhere in this prospectus.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Critical Accounting Policies and Estimates</span></p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-1" style="font-style:italic;font-weight:normal;text-decoration:underline;">Basis of Presentation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Proteomedix&#8217;s financial statements are prepared in accordance with U.S.&#160;Generally Accepted Accounting Principles (&#8220;U.S GAAP&#8221;), which require the recognition and disclosure of foreign currency translation adjustments resulting from the translation of financial statements denominated in currencies other than the U.S.&#160;Dollar.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The functional currency of Proteomedix is the Swiss Franc. Transactions denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the date of the transaction. The resulting translation adjustments are recorded as a separate component of accumulated other comprehensive income (loss).</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-1" style="font-style:italic;font-weight:normal;text-decoration:underline;">Cash and Cash Equivalents</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">For purposes of reporting cash flows, Proteomedix has defined cash and cash equivalents as all cash in banks and highly liquid investments available for current use with an initial maturity of three&#160;months or less to be cash equivalents. Proteomedix had no cash equivalents as of December&#160;31, 2022, or 2021.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Proteomedix maintains its cash balances at financial institutions that are insured by Swiss Financial Market Supervisory Authority (&#8220;FINMA&#8221;). Proteomedix&#8217;s cash balances may at times exceed the insurance provided by FINMA.&#160;Proteomedix has not experienced any losses on these accounts and management does not believe that Proteomedix is exposed to any significant risks related to excess deposits.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-1" style="font-style:italic;font-weight:normal;text-decoration:underline;">Collaborative Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix periodically enters into strategic alliance agreements with counterparties to produce products and/or provide services to customers. Alliances created by such agreements are not legal entities, have no employees, no assets and have no true operations. These arrangements create contractual rights and Proteomedix accounts for these alliances as a collaborative arrangement by reporting costs incurred and reimbursements received from transactions within research and development expense within the statements of comprehensive loss.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-1" style="font-style:italic;font-weight:normal;text-decoration:underline;">Share-Based Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Proteomedix accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with Financial Accounting Standard Board (&#8220;FASB&#8221;) Account Standard Codification (&#8220;ASC&#8221;) 718, &#8220;Compensation&#160;&#8212;&#160;Stock Compensation.&#8221; Costs are measured at the estimated fair value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earliest of a performance commitment or completion of performance by the provider of goods or services as defined by FASB ASC&#160;718, &#8220;Compensation&#160;&#8212;&#160;Stock Compensation.&#8221;</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-1" style="font-style:italic;font-weight:normal;text-decoration:underline;">Revenue Recognition</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Effective on January&#160;1, 2021, Proteomedix adopted ASC Topic&#160;606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC&#160;606&#8221;). Pursuant to ASC&#160;606, revenues are recognized when control of services performed is transferred to customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those services. ASC&#160;606 provides for a five<span class="nobreak">-step</span> model that includes:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;">(i)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>identifying the contract with a customer,</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;">(ii)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>identifying the performance obligations in the contract,</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">116</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;">(iii)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>determining the transaction price,</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;">(iv)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>allocating the transaction price to the performance obligations, and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;">(v)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>recognizing revenue when, or as, an entity satisfies a performance obligation.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Product Sales</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix derives revenue through sales of its products directly to end users and to distributors. Proteomedix sells its products to customers including laboratories, hospitals, medical centers, doctors and distributors. Proteomedix considers customer purchase orders, which in some cases are governed by master sales agreements or standard terms and conditions, to be the contracts with a customer. For each contract, Proteomedix considers the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction price Proteomedix evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects to be entitled. Proteomedix fulfils its performance obligation applicable to product sales once the product is transferred to the customer.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Development Services</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix provides a range of services to life sciences customers referred to as &#8220;Development Services&#8221; including testing for biomarker discovery, assay design and development. These Development Services are performed under individual statement of work (&#8220;SOW&#8221;) arrangements with specific deliverables defined by the customer. Development Services are generally performed on a time and materials basis. During the performance and through completion of the service to the customer in accordance with the SOW, we have the right to bill the customer for the agreed upon price and we recognize the Development Services revenue over the period estimated to complete the SOW.&#160;We generally identify each SOW as a single performance obligation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Completion of the service and satisfaction of the performance obligation under a SOW is typically evidenced by access to the data or test made available to the customer or any other form or applicable manner of delivery defined in the SOW.&#160;However, for certain SOWs under which work is performed pursuant to the customer&#8217;s highly customized specifications, we have the enforceable right to bill the customer for work completed, rather than upon completion of the SOW.&#160;For those SOWs, we recognize revenue over a period of time during which the work is performed based on the expended efforts (inputs). As the performance obligation under the SOW is satisfied, any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed to the customer as of the date of the financial statements are recorded as contract assets and are included in prepaids and other current assets as of the financial statement date. Amounts recorded in contract assets are reclassified to accounts receivable in our financial statements when the customer is invoiced according to the billing schedule in the contract.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In circumstances where a SOW includes variable consideration component, Proteomedix estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on which method is expected to better predict the amount of consideration to which Proteomedix will be entitled. The value of variable consideration is included in the transaction price if, and to the extent, it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are reassessed each reporting period, as required, and any adjustment required is recorded on a cumulative catch<span class="nobreak">-up</span> basis, which would affect revenue and net income in the period of adjustment.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-1" style="font-style:italic;font-weight:normal;text-decoration:underline;">Licensing Revenues</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">license revenues are determined based on an assessment of whether the license is distinct from any other performance obligations that may be included in the underlying licensing arrangement. If the customer is able to benefit from the license without provision of any other performance obligations by Proteomedix and the license is thereby viewed as a distinct or functional license, Proteomedix then determines whether the customer has acquired a right to use the license or a right to access the license. For functional licenses that do not require further substantive development or other ongoing activities by Proteomedix, the customer is viewed as acquiring the right to use the license as, and when, transferred and revenues are generally recorded at a point in time. For symbolic licenses providing substantial value only in conjunction with other performance obligations to be provided by Proteomedix, revenues are </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">117</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">generally recorded over the term of the license agreement using the inputs based on contractual remaining time for such license. Such other obligations provided by Proteomedix generally include manufactured products, additional development services or other deliverables that are contracted to be provided during the license term.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Royalties associated with licensing arrangements are estimated and recognized when sales under supply agreements with commercial licensees are recorded, absent any contractual constraints or collectability uncertainties. Royalties which are contingent on meeting certain sales milestones are recorded when it has become probable that milestones will be met.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-1" style="font-style:italic;font-weight:normal;text-decoration:underline;">Defined Benefit Pension Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix sponsors a defined benefit pension plan (the &#8220;Plan&#8221;) covering eligible employees. The Plan provides retirement benefits based on employees&#8217;&#160;years of service and compensation levels. Proteomedix recognizes an asset for such plan&#8217;s overfunded status or a liability underfunded status in its balance sheets. Additionally, Proteomedix measures its plan&#8217;s assets and obligations that determine its funded status as of the end of the year and recognizes the changes in the funded status in the year in which the changes occur. Those changes are reported in &#8216;accumulated other comprehensive loss. Proteomedix uses actuarial valuations to determine its pension and postretirement benefit costs and credits. The amounts calculated depend on a variety of key assumptions, including discount rates and expected return on plan assets. Current market conditions are considered in selecting these assumptions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix&#8217;s pension plans are generally valued using the net asset value (NAV) per share as a practical expedient for fair value provided certain criteria are met. The NAVs are determined based on the fair values of the underlying investments in the funds. In circumstances where the criteria are not met, fair is determined based on the underlying market in which the funds are traded which is generally considered to be an active market.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Components of Results of Operations</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Marketing and business development</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">This classification of expenses includes all efforts related to the marketing and early<span class="nobreak">-stage</span> commercialization of Proclarix as well as general business development expenses related to Proclarix and other business areas (e.g. development services, pipeline products). Such costs are expensed in the period in which they occur.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We expect our marketing and business development expenses to increase in the future and we continue to expand our commercialization and of Proclarix as well as other business areas.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Research and development</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">This classification of expenses includes all costs associated with the development of Proclarix and pipeline products as well as development activities related to collaborations with partners (e.g. research and development collaborations for pipeline products or development services). These expenses include fees paid to third parties to conduct certain research and development activities on our behalf, consulting costs, costs for clinical samples used in clinical studies, costs for laboratory supplies, certain payroll, and personnel<span class="nobreak">-related</span> expenses, including salaries. We expense both internal and external research and development expenses as they are incurred.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We do not allocate our internal costs by product candidate, as a significant amount of research and development expenses include costs, such as payroll and other personnel expenses, laboratory supplies and allocated overhead, and external costs, such as fees paid to third parties to conduct research and development activities on our behalf, which are not tracked by product candidate.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We expect our research and development expenses to increase. If any regulatory authorities were to require us to conduct clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. Furthermore, we are unable to predict with any certainty when or if our pipeline product will be required to obtain regulatory approvals and the magnitude of any additional development costs required to bring those products to a commercial ready state.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">118</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">General and administrative</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">General and administrative expense consists principally of payroll and personnel expenses, including salaries and bonuses, benefits and stock<span class="nobreak">-based</span> compensation expenses, professional fees for legal, consulting, accounting and tax services and other general operating expenses not otherwise classified as research and development expenses.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We anticipate that our general and administrative expenses will continue to increase as a result of increased personnel costs, expanded infrastructure and higher consulting, legal and accounting services costs associated with Proteomedix&#8217;s continued growth.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Depreciation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Depreciation relates to the amortization of our certain long<span class="nobreak">-term</span> assets over their estimated useful lives. These costs are expensed in the period incurred, which is generally the period the asset is in service until the asset has been disposed of by Proteomedix.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Interest expense</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Interest on our outstanding convertible notes payable is expensed as incurred. Interest expense also includes the costs of converting other currencies into CHF, our functional currency. We consider this to be a component of our capital financing activities and therefore include this amount in interest expense in the accompanying statements of comprehensive income (loss).</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Foreign currency translation adjustments</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">This balance is the result of the translation of our financial statements from CHF, our functional currency, to United&#160;States Dollars, our reporting currency. Assets and liabilities are translated using the exchange ratio as of the end of the reporting period, which was 1.098, 1.082 and 1.093 as of December&#160;31, 2022, December&#160;31, 2021 and September&#160;30, 2023, respectively. Equity is translated using historical exchange rates relevant to the transactions. Revenues and expenses are translated using the average exchange rate during the reporting period. The significant factors contributing to the changes in these balances are related to the disparity between CHF and USD as well as changes in the composition of our assets and liabilities during the period.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Changes in pension benefit obligations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As required by Swiss law, we sponsor a defined benefit pension plan for all of our employees. Changes in these balances are related to gains and losses in the underlying pension assets and liabilities, actuarial gains, and losses as well as settlements due to the payment of benefits.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">119</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Results of Operations</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Comparison of the&#160;years ended December&#160;31, 2022 and 2021</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Years ended</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">$<br/>Change</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">%<br/>Change</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2021</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Revenue</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">392,460</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">140,600</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">251,860</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">179</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cost of goods sold</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">48,429</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">31,977</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16,452</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">51</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Gross profit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">344,031</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">108,623</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">235,408</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">217</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Marketing and business development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">240,298</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">200,096</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40,202</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">393,274</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">312,586</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">80,688</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">26</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,671,960</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,766,843</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(94,883</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17,492</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">36,866</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(19,374</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(53</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,323,024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,316,391</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,633</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,978,993</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,207,768</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">228,775</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(63,580</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(41,536</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(22,044</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">53</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(63,580</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(41,536</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(22,044</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">53</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss before provision for income taxes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,042,573</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,249,304</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">206,731</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Provision for income taxes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,042,573</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,249,304</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">206,731</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other comprehensive (loss) income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Benefit pension obligation changes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">179,892</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">397,709</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(217,817</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(55</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">FX translation adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,986</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">32,837</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(37,823</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(115</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other comprehensive (loss) income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">174,906</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">430,546</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(255,640</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(59</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Comprehensive loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,867,667</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,818,758</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(48,909</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Revenue</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Revenue increased by $252 thousand, or 179%, for the year ended December&#160;31, 2022, compared to the year ended December&#160;31, 2021. The increase was due to Proteomedix entering into a significant development services contract with a customer in the latter part of 2022.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Loss from Operations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the&#160;years ended December&#160;31, 2022, and 2021, our comprehensive loss was $1.9&#160;million and $1.8&#160;million, respectively. The decrease was due to an increase in revenue associated with the provision of development services to third parties.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Marketing and business development</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Marketing and business development expenses increased by $40 thousand, or 20%, for the year ended December&#160;31, 2022, compared to the year ended December&#160;31, 2021. The increase was due to increased medical marketing efforts in Europe.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Research and development</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Research and development expenses increased by $81 thousand, or 26%, for the year ended December&#160;31, 2022, compared to the year ended December&#160;31, 2021. The increase was due to a collaboration arrangement with a third party under which we recognized certain costs for personnel, facilities and material.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">120</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">General and administrative</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">General and administrative expense decreased by $95 thousand, or 5%, for the year ended December&#160;31, 2022, compared to the year ended December&#160;31, 2021. The decrease was due to a reduction to our use of consultants for non<span class="nobreak">-core</span> services.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Depreciation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Depreciation decreased by $19 thousand, or 53%, for the year ended December&#160;31, 2022, compared to the year ended December&#160;31, 2021. The decrease was due to existing fixed assets reaching the end of the respective estimated useful lives.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Interest expense</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Interest expense increased by $22 thousand, or 53%, for the year ended December&#160;31, 2022, compared to the year ended December&#160;31, 2021. The increase was due to losses associated with the conversion of currencies received from our customers into CHF, our functional currency.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Benefit pension obligation changes</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Benefit pension obligation changes decreased by $218 thousand, or 55%, for the year ended December&#160;31, 2022, compared to the year ended December&#160;31, 2021. The decrease was due to a non<span class="nobreak">-recurring</span> payment of benefits out of funds held in trust within the pension trust in 2021.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Foreign currency translation adjustments</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Foreign currency translation adjustments decreased by $38 thousand, or 115%, for the year ended December&#160;31, 2022, compared to the year ended December&#160;31, 2021. The decrease was due to changes in the exchange rate between CHF and USD as well as additional borrowings during 2021.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Comparison of the nine&#160;months ended September&#160;30, 2023 and 2022</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Nine&#160;months ended</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">$</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Change</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">%</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Change</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">September&#160;30, 2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">September&#160;30, 2022</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Revenue</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,092,761</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">128,773</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,963,988</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1525</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cost of goods sold</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">22,548</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">28,176</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(5,628</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">-20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Gross profit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,070,213</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100,597</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,969,616</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1545</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Marketing and business development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">151,478</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">172,478</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(21,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">-12</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">275,020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">262,818</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12,202</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,240,875</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,633,860</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(392,985</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">-24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,293</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12,966</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(3,673</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">-28</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,676,666</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,082,122</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(405,456</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">-60</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Income (loss) from operations</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">393,547</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,981,525</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,375,072</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1605</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(74,359</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(48,257</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(26,102</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">54</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(74,359</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(48,257</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(26,102</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">54</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net income (loss) before provision for income taxes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">319,188</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,029,782</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,348,970</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1659</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Provision for income taxes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net income (loss)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">319,188</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,029,782</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,348,970</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1659</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">FX translation adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">172,351</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">344,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(172,606</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">-50</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Changes in pension benefit obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(168,307</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">369,287</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(537,594</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">-146</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Comprehensive income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">323,232</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,315,538</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,638,770</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1464</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;orphans:99;widows:1;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">121</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Revenue</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Revenue increased by $2&#160;million, or 1,525%, for the nine&#160;months ended September&#160;30, 2023, compared to the nine&#160;months ended September&#160;30, 2022. Approximately $1.5&#160;million of the increase was due to the expansion and continued progress of a development services contract with a single customer and approximately $0.5&#160;million of the increase was due to a one<span class="nobreak">-time</span> licensing contract with a single customer, in each case during the nine&#160;months ended September&#160;30, 2023.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Loss from Operations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the nine&#160;months ended September&#160;30, 2023, our comprehensive income was $323 thousand and during the nine&#160;months ended September&#160;30, 2022, our comprehensive loss was $1.3&#160;million. The change was due to increased revenue associated with the provision of development services and licensing fees.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Marketing and business development</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Marketing and business development expenses decreased by $21 thousand, or 12%, for the nine&#160;months ended September&#160;30, 2023 compared to the nine&#160;months ended September&#160;30, 2022. The decrease was due to narrowing our marketing efforts in EMEA and focusing on existing lab partners already utilizing our Proclarix product.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Research and development</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Research and development expenses increased by $12 thousand, or 5%, for the nine&#160;months ended September&#160;30, 2023, compared to the nine&#160;months ended September&#160;30, 2022. The increase was due to a collaboration arrangement with a third party under which we recognized certain costs for personnel, facilities, and material.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">General and administrative</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">General and administrative expenses decreased by $393 thousand, or 24%, for the nine&#160;months ended September&#160;30, 2023, compared to the nine&#160;months ended September&#160;30, 2022. The decrease was due to a reduction to our use of consultants for non<span class="nobreak">-core</span> services as well as reduced personnel costs.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Depreciation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Depreciation decreased by $4 thousand, or 28%, for the nine&#160;months ended September&#160;30, 2023, compared to the nine&#160;months ended September&#160;30, 2022. The decrease was due to existing fixed assets reaching the end of the respective estimated useful lives.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Interest expense</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Interest expense increased by $26 thousand, or 54%, for the nine&#160;months ended September&#160;30, 2023, compared to the nine&#160;months ended September&#160;30, 2022. The increase was due to losses associated with the conversion of currencies received from our customers into CHF.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Benefit pension obligation changes</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Benefit pension obligation changes decreased by $538 thousand, or 146%, for the nine&#160;months ended September&#160;30, 2023, compared to the nine&#160;months ended September&#160;30, 2022. The decrease was due to actuarial gains offset by contributions made by employees during 2023 which did not occur in 2022.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Foreign currency translation adjustments</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Foreign currency translation adjustments decreased by $172 thousand, or 50%, for the nine&#160;months ended September&#160;30, 2023, compared to the nine&#160;months ended September&#160;30, 2022. The decrease was due to changes in the exchange rate between CHF and USD.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">122</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Trend Information</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Other than as disclosed elsewhere in this prospectus, we are not aware of any trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our revenues, net income, profitability, liquidity or capital resources, or that would cause reported financial information not necessarily to be indicative of future operating results or financial condition.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Liquidity and Capital Resources</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">For the</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">nine&#160;months</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">ended <br/>September&#160;30,</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">For the</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">nine&#160;months</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">ended <br/>September&#160;30,</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Year ended</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Year ended</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2021</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash (used in) provided by</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">346,029</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,477,904</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,933,570</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,239,556</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Investing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Financing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(50,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(50,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,277,170</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Operating Activities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Net cash provided by operating activities for the nine&#160;months ended September&#160;30, 2023, was $346 thousand, compared to cash used of $1.5&#160;million for the nine&#160;months ended September&#160;30, 2022, a decrease of $1.8&#160;million. The decrease was due to increased revenue from development services and a one<span class="nobreak">-time</span> licensing fee received during 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Net cash used in operating activities for the year ended December&#160;31, 2022, was $1.9&#160;million, compared to $2.3&#160;million for the year ended December&#160;31, 2021, a decrease of $366 thousand. The decrease was due to increased revenue during the period which resulted in a reduced amount of cash used in operations.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Investing Activities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We had no cash used in or provided by investing activities during any of the periods presented above.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Financing Activities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Net cash used in financing activities for the nine&#160;months ended September&#160;30, 2023, was $0, compared to $50 thousand for the nine&#160;months ended September&#160;30, 2022, a decrease of $50 thousand. The decrease was due to the one<span class="nobreak">-time</span> repayment of a note payable during 2022.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Net cash used in financing activities for the year ended December&#160;31, 2022, was $50 thousand, compared to net cash provided by financing activities of $3.4&#160;million for the year ended December&#160;31, 2021. The decrease was due to the one<span class="nobreak">-time</span> repayment of a note payable during 2022.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Liquidity Outlook</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Since our inception, we have incurred significant operating losses and negative cash flows and have financed our operations primarily through the issuance of shares and convertible notes to shareholders and directors. Our primary short<span class="nobreak">-term</span> requirements for liquidity and capital are to fund general working capital and capital expenditures. Our principal long<span class="nobreak">-term</span> working capital uses include the development of ancillary diagnostic markers and related supporting services to expand our existing intellectual property portfolio.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We expect to incur significant expenses in connection with our ongoing activities as we continue to implement our business strategy. We will need additional funding in connection with these activities. Our future funding requirements, both short<span class="nobreak">-term</span> and long<span class="nobreak">-term</span>, will depend on many factors, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the cost associated with the anticipated expansion of our distribution of Proclarix in Europe and launching distribution in the United&#160;States;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of future commercialization activities, including product manufacturing, marketing, sales for Proclarix;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">123</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs associated with investments in our pipeline to expand our product offering in the future;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the outcome, timing and cost of seeking and obtaining regulatory approvals from regulatory authorities, including the potential for such authorities to require that we perform field efficacy studies, require more studies than those that we currently expect or change their requirements regarding the data required to support a marketing application;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any product liability or other lawsuits related to our products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expenses needed to attract, hire and retain skilled personnel; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property<span class="nobreak">-related</span> claims.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A change in the outcome of any of these or other variables could significantly change the costs and timing associated with our business activities. Furthermore, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such change.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">For the foreseeable future, we expect to continue financing our operations through capital contributions or loans made by Onconetix. We do not currently have any committed external source of funds. If we or Onconetix are unable to raise additional funds, we may be required to delay, reduce, suspend, or cease our product development programs or any future commercialization efforts, which would have a negative impact on our business, prospects, operating results and financial condition.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of September&#160;30, 2023, we had an accumulated deficit of $27&#160;million. As of December&#160;31, 2022 and December&#160;31, 2021, we had an accumulated deficit of $27.2&#160;million and $25.2&#160;million, respectively. As of September&#160;30, 2023, we had cash of $1&#160;million. As of December&#160;31, 2022, and December&#160;31, 2021, we had cash of $470 thousand and $2.5&#160;million, respectively. These matters, among others, raise substantial doubt about Proteomedix&#8217;s ability to continue as a going concern for the 12&#160;months following the issuance of the accompanying consolidated financial statements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for Proteomedix to continue as a going concern. While Proteomedix believes in the viability of its strategy to generate revenues and the ability of its Onconetix to provide additional funds, there can be no assurances to that effect. The ability of Proteomedix to continue as a going concern is dependent upon Proteomedix&#8217;s ability to further implement its business plan and obtaining additional funding from Onconetix as needed.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Off-Balance Sheet Arrangements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We did not have over the past three fiscal&#160;years, and we currently do not have, any off<span class="nobreak">-balance</span> sheet arrangements as defined in the rules and regulations of the SEC.&#160;To the extent we have any contingent assets or liabilities, these have been captured and audited within the accompanying consolidated financial statements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">124</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Directors and Executive Officers</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table provides information regarding our executive officers and directors as of April<span class="nobreak"> </span>24, 2024:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 45.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Name</span></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Age</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 43.99%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Position(s)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 45.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Executive Officers and Directors</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 43.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 45.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ralph Schiess</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">46</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 43.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">Interim Chief Executive Officer and Chief Science Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 45.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Bruce Harmon</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">65</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 43.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">Chief Financial Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 45.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Christian Br&#252;hlmann</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">47</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 43.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">Chief Strategy Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 45.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non-Employee Directors</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 43.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 45.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">James Sapirstein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">62</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 43.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">Lead Independent Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 45.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Simon Tarsh</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">62</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 43.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 45.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Timothy Ramdeen</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">32</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 43.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 45.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas Meier</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">61</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 43.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 45.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ajit Singh</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">60</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 43.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">Director</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Ralph Schiess</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Dr.&#160;Schiess co<span class="nobreak">-founded</span> Proteomedix in March&#160;2010 and served as its Chief Executive Officer from its inception until December&#160;2019. Dr.&#160;Schiess then served as Proteomedix&#8217;s Chief Scientific Officer from January&#160;2020 to May&#160;2023. Dr.&#160;Schiess returned to his role as Chief Executive Officer of Proteomedix in June&#160;2023 and upon consummation of the Share Exchange between the Company and Proteomedix became the Chief Science Officer of the Company. Dr. Schiess was appointed Interim Chief Executive Officer of the Company by the Board of Directors on January<span class="nobreak"> </span>12, 2024.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Bruce Harmon</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Mr.&#160;Harmon has more than 40&#160;years of experience in financial positions with life sciences companies and various other industries. Mr.&#160;Harmon has served in a variety of roles, including chief financial officer, controller, chief executive officer, and audit committee chairman. He has been an independent consultant since 2008 through his business, Lakeport Business Services, Inc., and served in the outsourced CFO capacity for multiple publicly traded companies. During this time, Mr.&#160;Harmon was CFO of Marizyme Inc. from 2020 to 2021, CFO of bioAffinity Technologies Inc. in 2022, a director of Dale Biotech LLC since 2017, and a director of Patriax Industries since 2023. He has extensive experience with fundraising, public offerings, mergers and acquisitions, and turnarounds. Earlier in his career, he was a member of a team that, at the invitation of the Environmental Programm&#233;, presented a green building product to delegates at the United Nations. He earned a Bachelor of Science degree in accounting from Missouri State University.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Christian Br&#252;hlmann</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Mr.&#160;Br&#252;hlmann has been Chief Strategy Officer since December&#160;2023. He was Chief Business Officer and co<span class="nobreak">-founder</span> of Proteomedix, which was acquired by the Company in December&#160;2023. Mr.&#160;Br&#252;hlmann co<span class="nobreak">-founded</span> Proteomedix and served as its Chief Financial and Operations Officer from March&#160;2010 until November&#160;2018. Beginning in December&#160;2018, Mr.&#160;Br&#252;hlmann served as Proteomedix&#8217;s Chief Business Officer. Mr.&#160;Br&#252;hlmann gained 20&#160;years of experience in public and private companies in the life sciences, information and communications and financial industries. Being responsible for product management, business development, operations, and finance, he was instrumental in Proteomedix&#8217;s development from inception to the market introduction of Proclarix. Previously, he worked for Swisscom, Switzerland&#8217;s telecom market leader in several strategic and leadership roles in the area of digitalization. Mr.&#160;Br&#252;hlmann received his Bachelor and Master&#8217;s in Business Administration from University of Zurich, Switzerland and completed executive professional trainings at the Babson College, USA and at the University of St. Gallen, Switzerland.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">125</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non-Executive Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">James Sapirstein</span>, one of our directors since February&#160;2022 and our Lead Independent Director since October&#160;2023, has over 35&#160;years of experience leading, founding, growing, and selling healthcare companies, specifically in the pharmaceutical space. Mr.&#160;Sapirstein is currently the President, CEO and Chairman of First Wave BioPharma, Inc. (Nasdaq: FWBI), where he has been since October&#160;2019. His career began in sales at Eli Lilly, eventually rising to Director of International Marketing at Bristol Myers Squibb from July&#160;1996 to June&#160;2000, and later led the launch of Viread (tenofovir) at Gilead Sciences, Inc. (Nasdaq: GILD), where he served as Global Marketing Lead from June&#160;2020 to June&#160;2002. From November&#160;2006 to January&#160;2011, he served as founding CEO of Tobira Therapeutics (Nasdaq: TBRA), then a private company, and later acquired by Allergan (NYSE:&#160;AGN). Since then, he has served as CEO of Alliqua Biomedical (Nasdaq: ALQA) from September&#160;2012 to February&#160;2014 and CEO of Contravir Pharmaceuticals (Nasdaq: CTRV) from March&#160;2014 to October&#160;2018. He has been part of almost two dozen drug product launches and specifically either led or has been a key member of several HIV product launches into different new classes of therapeutics at the time. Additionally, Mr.&#160;Sapirstein has held board positions on ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) since January&#160;2023 and Enochian Biosciences (Nasdaq: ENOB) since April&#160;2018. He previously served as a director of Marizyme, Inc. (OTCMKTS:MRZM) (Executive Chairman) from December&#160;2018 to June&#160;2021, Leading Biosciences from 2016 to 2021, BioNJ, an association of biopharma industries in New Jersey, from February&#160;2017 to February&#160;2019, RespireRX (OTCBB:RSPI) from April&#160;2014 to January&#160;2020, NanoViricides Inc. (NYSE:&#160;NNVC) from November&#160;2018 to January&#160;2020, and BWAC from December&#160;2020 until its business combination with Clarus in September&#160;2021. He is also a Board Director for BIO, the leading Biopharma Industries Organization promoting public policy and networking in the healthcare space, where he sits on both the Health Section and Emerging Companies Section Governing Boards. Mr.&#160;Sapirstein received a B.S. in Pharmacy from Rutgers University and his MBA from Fairleigh Dickinson University. He is well qualified to serve on our Board due to his extensive network from decades in the healthcare industry. Mr.&#160;Sapirstein brings to our Board a significant depth of experience in the pharmaceutical and biotechnology industries that will be invaluable to the Company as we continue to develop biotechnology assets.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Simon Tarsh</span>, one of our directors since August&#160;2022, has more than 40&#160;years of financial experience, working in both the UK and the U.S.&#160;He has recently retired from Deloitte Consulting LLP, where he was a Senior Managing Director in the Finance and Enterprise Performance Practice, where he had served global clients since 2007. He led a growing global practice focused around Operational Transformation, including supporting Carve Out transactions, joint ventures and hybrid structures, both in the US and in international locations, such as India, China, Eastern Europe and Latin America. He supported high growth companies with their finance operations as they globalized, and was able to advise them on their expansion, while balancing growth with appropriate controls. Prior to moving to the United&#160;States in 2007, Mr.&#160;Tarsh&#8217;s consulting career began with PA Consulting Group, London in 1988, where he was elected as a Partner in 1997, and he built ISG&#8217;s business process outsourcing advisory practice in Europe between 2001 and 2006. Mr.&#160;Tarsh&#8217;s early career was in finance, working with Marathon Oil and Dow Chemical, and during this period, he qualified as a Chartered Accountant. Mr.&#160;Tarsh received a Bachelor of Science undergraduate degree in Business and Administration from the University of Salford, Manchester, UK in 1981, and an MBA from City University Business School, London, UK in 1988. He is a Fellow of the Chartered Institute of Management Accountants (1984), which is considered as a CPA equivalent. Mr.&#160;Tarsh&#8217;s deep financial experience at Deloitte Consulting LLP for fifteen&#160;years offers valuable insights to our Board, particularly given the enhanced accounting rules and regulations affecting public companies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Timothy Ramdeen</span>, one of our directors since January&#160;2023, has nearly a decade of experience in private equity and hedge fund investing, capital markets, and company formation. Since June&#160;2022, Mr.&#160;Ramdeen has been founder and managing partner of Dharma Capital Advisors, an investment and advisory firm focused on early<span class="nobreak">-stage</span> private and public companies. From March&#160;2021 to March&#160;2022, Mr.&#160;Ramdeen was co<span class="nobreak">-founder</span>, chief investment officer, and portfolio manager at Sixth Borough Capital Management, a multi<span class="nobreak">-stage</span>, event<span class="nobreak">-driven</span> hedge fund focused on both private and public equities. Since 2022, Mr.&#160;Ramdeen has been the co<span class="nobreak">-founder</span> of Amplexd Therapeutics, which is a women&#8217;s health/biotechnology company focused on providing low<span class="nobreak">-cost</span>, effective, safe and accessible treatments for early cervical and HPV<span class="nobreak">-related</span> cancers worldwide. Mr.&#160;Ramdeen also serves as a corporate advisor/board member to multiple early<span class="nobreak">-stage</span> companies and investment funds. Previously, Mr.&#160;Ramdeen was the fifth hire at Altium Capital Management (&#8220;Altium&#8221;), a healthcare<span class="nobreak">-focused</span> investment firm, where from July&#160;2019 to March&#160;2021 he served as the sole investment analyst on the private capital markets/special situations </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">126</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">desk (privately<span class="nobreak">-negotiated</span> financings, direct investments, event<span class="nobreak">-driven</span> long/short, and private to public investments in micro and small<span class="nobreak">-cap</span> companies). During his tenure at Altium, Mr.&#160;Ramdeen was instrumental in co<span class="nobreak">-creating</span> the firm&#8217;s SPAC and reverse merger investment efforts and establishing extensive relationships with sell<span class="nobreak">-side</span> constituents, buy<span class="nobreak">-side</span> counterparts, and hundreds of private and publicly traded companies across biotechnology, therapeutics, healthcare services, medical devices and medtech. From 2017 to 2018, Mr.&#160;Ramdeen worked for Brio Capital Management, an event<span class="nobreak">-driven</span> hedge fund focused on small and micro cap equities. Mr.&#160;Ramdeen received his B.S. in Biology from Temple University, where he conducted scientific research across neurology, oncology, and developmental biology. In addition, Mr.&#160;Ramdeen earned his MBA in Finance from NYU Stern School of Business. Mr.&#160;Ramdeen brings to our Board extensive experience in capital advisement and company development, specifically within the life science industry and for publicly traded companies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Thomas Meier</span>, one of our directors since February&#160;1, 2024, has close to 25&#160;years&#8217; experience as a life<span class="nobreak">-science</span> and biotech entrepreneur, executive manager, and board member. Since June&#160;2022, Dr.&#160;Meier has served as Chairman of, and member of the Audit and Compensation Committees of, Santhera Pharmaceuticals Holding AG (SIX:&#160;SANN), a publicly listed Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases. Dr.&#160;Meier has served on the board of Santhera since 2017 and stepped down as the company&#8217;s CEO in November&#160;2019 after having served 15&#160;years as executive manager, the last 8&#160;years as CEO.&#160;In 2020, Dr.&#160;Meier became managing partner of Viopas Venture Consulting GmbH, a Swiss consultancy and advisory firm for the healthcare industry. Since 2020, Dr.&#160;Meier has served as a board member of Novaremed AG, a privately held Swiss company developing innovative treatment options for the management of chronic pain and alternatives to opioids. Dr.&#160;Meier has served on Novaremed&#8217;s Audit Committee since October&#160;2021 and became Executive Chairman of the company in January&#160;2024. Since January&#160;2022, Dr.&#160;Meier also serves on the board of Visgenx Inc. (USA). In September&#160;2021, he co<span class="nobreak">-founded</span> SEAL Therapeutics AG, a privately owned Swiss gene therapy company for which he also serves as Chairman. Between July&#160;2020 and November&#160;2021, he served as Chairman of privately held Pharmabiome AG (Switzerland). Dr.&#160;Meier has a PhD in Biology and qualified as lecturer in neurosciences at the Biozentrum, University of Basel (Switzerland). Dr.&#160;Meier brings to our board experience as an internationally recognized scientist with track record in clinical research of orphan diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Ajit Singh,</span> one of our directors since February&#160;7, 2024, is a Partner at Silicon Valley based Artiman Ventures, focused on early<span class="nobreak">-stage</span> technology and life science investments, with over $1&#160;billion in assets under management. Besides serving on the board of directors of Artiman portfolio companies, he has served on the boards of Sofie Biosciences, a PET radiopharmaceuticals company focused on Oncology and Neurology, Leo Cancer Care, focused on radiation oncology since 2013, Artidis, an oncology diagnostics company with nanomechanical biomarkers for cancer, and Chronus Health, in the area of Point<span class="nobreak">-of-Care</span> diagnostics since 2023. He also serves on the Board of Trustees of American Association for Cancer Research (AACR) Foundation, the oldest and the largest cancer research organization globally. Dr.&#160;Singh is an Adjunct Professor in the School of Medicine at Stanford where he teaches clinical diagnostics and entrepreneurship. In the past, Dr.&#160;Singh has served as a Lead Director on the Board of Directors of Max Healthcare, and as a Senior Advisor to the Tata Trusts Cancer program, which developed a &#8220;plan centrally, deliver locally&#8221; platform for cancer care, and delivered it via comprehensive cancer centers built bespoke with funding from the Tata Group. Until 2023, he also served on the board of directors of Cadila Pharmaceuticals. Prior to joining Artiman, Dr.&#160;Singh was the President and CEO of BioImagene, a company specializing in AI<span class="nobreak">-based</span> Cancer Diagnostics, based in California. BioImagene was acquired by Roche Pharmaceuticals in September&#160;2010. Before BioImagene, Dr.&#160;Singh spent nearly twenty&#160;years at Siemens in various roles, in the United&#160;States and Germany, most recently as the global CEO of Siemens Oncology, and Siemens Digital Imaging Systems. Before transitioning to these executive responsibilities, Dr.&#160;Singh spent several&#160;years in R&amp;D at Siemens Research in Princeton, responsible for research in the areas of artificial intelligence and robotics. During this time, he concurrently served as an adjunct faculty at Princeton University. Dr.&#160;Singh has a Ph.D. in Computer Science from Columbia University, a Master&#8217;s degree in Computer Engineering from Syracuse University, and a Bachelor&#8217;s in Electrical Engineering from Indian Institute of Technology (IIT) in Varanasi, India. He has published two books and numerous refereed articles and holds five patents. His Top<span class="nobreak">-10</span> Book Review is carried by various blogs and reading journals in December every year. Mr.&#160;Singh brings to our board significant experience in the biotech industry and diagnostic field, particularly in a commercial execution capacity.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">127</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Board of Directors and Corporate Governance</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our business and affairs are organized under the direction of our board of directors (&#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">Board</span>&#8221;), which currently consists of five members. Our Board is divided into three classes, Class&#160;I, Class&#160;II, and Class&#160;III, with members of each class serving staggered three<span class="nobreak">-year</span> terms. Our directors are divided among the three classes as follows:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Class&#160;I directors are Simon Tarsh and Thomas Meier, and their term will expire at our 2025 annual meeting of stockholders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Class&#160;II director is James Sapirstein, and his term will expire at our 2026 annual meeting of stockholders; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Class&#160;III directors are Timothy Ramdeen and Ajit Singh, and their term will expire at our 2024 annual meeting of stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws provide that the authorized number of directors may be changed only by resolution of the Board. Our directors hold office until the earlier of their death, resignation, removal, or disqualification, or until their successors have been elected and qualified. Our board of directors does not have a formal policy on whether the roles of Chief Executive Officer and Chairman of our Board should be separate. The primary responsibilities of our Board are to provide oversight, strategic guidance, counselling, and direction to our management.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We have no formal policy regarding board diversity. Our priority in selection of board members is identification of members who will further the interests of our stockholders through his or her established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business and understanding of the competitive landscape.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Directors and Executive Officers Qualifications</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We believe that the collective skills, experience, and qualifications of our directors provide our Board with the expertise and experience necessary to advance the interests of our stockholders. In selecting directors, the Board considers candidates that possess qualifications and expertise that will enhance the composition of the Board. Nominees for director will be selected on the basis of, among other things, leadership experience, knowledge, skills, expertise, integrity, diversity, ability to make independent analytical inquiries, understanding of the Company&#8217;s business environment and willingness to devote adequate time and effort to Board responsibilities. The Nominating&#160;&amp; Corporate Governance Committee may require certain skills or attributes, such as financial or accounting experience, to meet specific board needs that arise from time to time and will also consider the overall experience and makeup of its members to obtain a broad and diverse mix of board members. We believe that our directors should have the highest professional and personal ethics and values, consistent with our longstanding values and standards. They should have broad experience at the policy<span class="nobreak">-making</span> level in business, exhibit commitment to enhancing stockholder value and have sufficient time to carry out their duties and to provide insight and practical wisdom based on their past experience.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Committees of the Board</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our Board has established three standing committees<span class="nobreak">-audit</span>, compensation and nominating and corporate governance<span class="nobreak">-each</span> of which operates under a charter that has been adopted by our Board. Copies of each committee&#8217;s charter are posted on the &#8220;Investor Relations&#8221; section of our website, which is located at <span class="Italic" style="font-style:italic;font-weight:normal;">https://onconetix.com/corporate</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-governance</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">/governance</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-overview</span></span>. Each committee has the composition and responsibilities described below. Our Board may from time to time establish other committees.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">128</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H6" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-4" style="text-decoration:underline;">Audit Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our audit committee (&#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">Audit Committee</span>&#8221;) consists of Simon Tarsh, who is the chair of the committee, Timothy Ramdeen, and James Sapirstein. Our Board has determined that each of the members of our Audit Committee satisfies the Nasdaq Marketplace Rules and SEC independence requirements. The functions of this committee include, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>evaluating the performance, independence and qualifications of our independent auditors and determining whether to retain our existing independent auditors or engage new independent auditors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>reviewing and approving the engagement of our independent auditors to perform audit services and any permissible non<span class="nobreak">-audit</span> services;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>reviewing our annual and quarterly financial statements and reports, including the disclosures contained under the caption &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and discussing the statements and reports with our independent auditors and management;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>reviewing with our independent auditors and management significant issues that arise regarding accounting principles and financial statement presentation and matters concerning the scope, adequacy, and effectiveness of our financial controls;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>reviewing and approving, in accordance with the Company&#8217;s policies, any related party transaction as defined by applicable rules and regulations</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>reviewing our major financial risk exposures, including the guidelines and policies to govern the process by which risk assessment and risk management is implemented; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>reviewing and evaluating on an annual basis the performance of the audit committee, including compliance of the audit committee with its charter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Board has determined that Simon Tarsh qualifies as an &#8220;audit committee financial expert&#8221; within the meaning of applicable SEC regulations and meets the financial sophistication requirements of the Nasdaq Marketplace Rules. In making this determination, the Board has considered Mr.&#160;Tarsh&#8217;s extensive financial experience and business background. Both our independent registered public accounting firm and management periodically meet privately with our Audit Committee.</p>
		<p class="H6" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-4" style="text-decoration:underline;">Compensation Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our compensation committee (&#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">Compensation Committee</span>&#8221;) consists of James Sapirstein, who is the chair of the committee, Simon Tarsh, and Timothy Ramdeen. Our board of directors has determined that each of the members of our Compensation Committee is an outside director, as defined pursuant to Section&#160;162(m)&#160;of the Internal Revenue Code of 1986, as amended, or the Code, and satisfies the Nasdaq Marketplace Rules independence requirements. The functions of this committee include, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>reviewing, modifying, and approving (or if it deems appropriate, making recommendations to the full board of directors regarding) our overall compensation strategy and policies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>reviewing and approving the compensation, the performance goals, and objectives relevant to the compensation, and other terms of employment of our executive officers;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>reviewing and approving (or if it deems appropriate, making recommendations to the full board of directors regarding) the equity incentive plans, compensation plans and similar programs advisable for us, as well as modifying, amending, or terminating existing plans and programs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>reviewing and approving the terms of any employment agreements, severance arrangements, change in control protections and any other compensatory arrangements for our executive officers;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>reviewing with management and approving our disclosures under the caption &#8220;Compensation Discussion and Analysis&#8221; in our periodic reports or proxy statements to be filed with the SEC; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>preparing the report that the SEC requires in our annual proxy statement.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;list-style-type:none;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">129</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H6" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-4" style="text-decoration:underline;">Nominating and Corporate Governance Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our nominating and corporate governance committee (&#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">Nominating Committee</span>&#8221;) consists of Timothy Ramdeen, who is the chair of the committee, James Sapirstein and Simon Tarsh. Our Board has determined that each of the members of this committee satisfies the Nasdaq Marketplace Rules independence requirements. The functions of this committee include, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>identifying, reviewing, and evaluating candidates to serve on our board of directors consistent with criteria approved by our board of directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>evaluating director performance on the board and applicable committees of the board and determining whether continued service on our board is appropriate;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>evaluating, nominating, and recommending individuals for membership on our board of directors; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>evaluating nominations by stockholders of candidates for election to our board of directors.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Board Leadership Structure</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our board of directors is free to select the Chairman of the board of directors and the Chief Executive Officer in a manner that it considers to be in the best interests of our company at the time of selection. Currently, Dr. Ralph Schiess serves as our Interim Chief Executive Officer and James Sapirstein serves as our non<span class="nobreak">-executive</span> Chairman. All five members of our board of directors have been deemed to be &#8220;independent&#8221; by the board of directors, which we believe provides sufficient independent oversight of our management.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our board of directors, as a whole and also at the committee level, plays an active role overseeing the overall management of our risks. Our Audit Committee reviews risks related to financial and operational items with our management and our independent registered public accounting firm. Our board of directors is in regular contact with our Chief Executive Officer, who reports directly to the board of directors and supervises&#160;day<span class="nobreak">-to-day</span> risk management.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Role of Board in Risk Oversight Process</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We face a number of risks, including those described under the caption &#8220;Risk Factors&#8221; contained elsewhere in this Report. Our board of directors believes that risk management is an important part of establishing, updating, and executing our business strategy. Our board of directors has oversight responsibility relating to risks that could affect the corporate strategy, business objectives, compliance, operations, and the financial condition and performance of our Company. Our board of directors focuses its oversight on the most significant risks facing us and, on our processes to identify, prioritize, assess, manage, and mitigate those risks. Our board of directors receives regular reports from members of our senior management on areas of material risk to us, including strategic, operational, financial, legal and regulatory risks. While our board of directors has an oversight role, management is principally tasked with direct responsibility for management and assessment of risks and the implementation of processes and controls to mitigate their effects on us.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our board is generally responsible for the oversight of corporate risk in its review and deliberations relating to our activities. Our principal source of risk falls into two categories, financial and product commercialization. Our Audit Committee oversees management of financial risks; our board regularly reviews information regarding our cash position, liquidity, and operations, as well as the risks associated with each. The board regularly reviews plans, results and potential risks related to our product offerings, growth, and strategies. Our Compensation Committee oversees risk management as it relates to our compensation plans, policies and practices for all employees including executives and directors, particularly whether our compensation programs may create incentives for our employees to take excessive or inappropriate risks which could have a material adverse effect on our company.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Code of Business Conduct and Ethics</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We have adopted a written code of business conduct and ethics that applies to our directors, officers, and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. The code of business conduct and ethics is posted on our website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.onconetix.com</span>. We expect that any amendments or waivers to the code that are required by law or Nasdaq Marketplace Rules will be disclosed on our website.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">130</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Insider Trading Policy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On December&#160;1, 2023, we adopted insider trading policies and procedures governing the purchase, sale, and/or other dispositions of our securities by directors, officers, and employees, which are reasonably designed to promote compliance with insider trading laws, rules and regulations, and applicable Nasdaq listing standards (the &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">Insider Trading Policy</span>&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The foregoing description of the Insider Trading Policy does not purport to be complete and is qualified in its entirety by the terms and conditions of the Insider Trading Policy, a copy of which is attached hereto as Exhibit 19 and is incorporated herein by reference.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:11pt;margin-top:11pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Delinquent Section&#160;16(a)&#160;Reports</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Section&#160;16(a)&#160;of the Exchange&#160;Act requires the Company&#8217;s directors, executive officers, and persons who own more than 10% of a registered class of the Company&#8217;s equity securities, to file with the SEC reports of beneficial ownership and reports of changes in beneficial ownership in the Company&#8217;s securities. Based solely upon a review of Forms<span class="nobreak"> </span>3, 4 and<span class="nobreak"> </span>5, and amendments thereto, filed electronically with the SEC during the year ended December&#160;31, 2023, the Company believes that all Section&#160;16(a)&#160;filings applicable to its directors, officers, and 10% stockholders were filed on a timely basis during the year ended December&#160;31, 2023, except that Ralph Schiess filed one late Form.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:11pt;margin-top:11pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Summary Compensation Table</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">The following table sets forth total compensation paid to our named executive officers for the&#160;years ended December&#160;31, 2023, and 2022. Individuals we refer to as our &#8220;named executive officers&#8221; include (i)&#160;all individuals serving as our Chief Executive Officer during the fiscal year ended December&#160;31, 2023; (ii)&#160;our two most highly compensated executive officers other than our Chief Executive Officer who were serving as executive officers at the end of the fiscal year ended December&#160;31, 2023, whose salary and bonus for services rendered in all capacities exceeded $100,000 during the fiscal year ended December&#160;31, 2023 and (iii)&#160;up to two of our most highly compensated executive officers other than our Chief Executive Officer who served as executive officers during the fiscal year ended December&#160;31, 2023 but not at the end of the fiscal year ended December&#160;31, 2023 whose salary and bonus for services rendered in all capacities exceeded $100,000 during the fiscal year ended December&#160;31, 2023.</p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 28.28%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Name and Principal Position</span></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 7.42%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Year</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 8.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Salary</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 7.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Bonus</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 8.86%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Stock Awards</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">($)</span><span class="CharOverride-5" style="font-size:58%;font-style:normal;font-weight:bold;vertical-align:super;">(1)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 8.86%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Option Awards</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">($)</span><span class="CharOverride-5" style="font-size:58%;font-style:normal;font-weight:bold;vertical-align:super;">(1)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.16%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">All <br/>Other Compensation</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Total</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">($)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Joseph Hernandez<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">371,875</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">153,750</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">525,625</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 28.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Former Chief Executive Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 8.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">569,138</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">437,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 8.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 8.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">696,738</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 10.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,703,376</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-30" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;width: 28.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Neil Campbell<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 7.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;text-align:center;">2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 8.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">114,792</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 7.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">75,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 8.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 8.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">186,377</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 12.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 10.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">376,169</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 28.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Former Chief Executive Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 8.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 8.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 8.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 10.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-30" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;width: 28.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Jon Garfield<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 7.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;text-align:center;">2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 8.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">343,167</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 7.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 8.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">76,875</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 8.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 12.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">72,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 10.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">492,542</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 28.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Former Chief Financial Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 8.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">369,750</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">174,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 8.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 8.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">359,309</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 10.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">903,059</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-30" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;width: 28.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Bruce Harmon<span class="Superscript" style="vertical-align:super;font-size:58%;">(6)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 7.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;text-align:center;">2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 8.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">78,542</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 7.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">24,375</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 8.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 8.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">62,126</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 12.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 10.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">165,043</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 28.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Chief Financial Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 8.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 8.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 8.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 10.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-30" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;width: 28.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Erin Henderson<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 7.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;text-align:center;">2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 8.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">315,972</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 7.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 8.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">153,750</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 8.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 12.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">81,250</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;width: 10.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:8pt;">550,972</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-31" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 28.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;text-indent:0pt;">Former Chief Business Officer and Corporate Secretary</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 8.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">296,905</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">230,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 8.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 8.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">706,449</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.24%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 10.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,233,354</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>This figure represents the aggregate grant date fair value of stock<span class="nobreak">-based</span> awards granted in the fiscal year, computed in accordance with the provisions of FASB ASC&#160;718. Assumptions used in the calculation of these amounts are included in the notes to our consolidated financial statements included elsewhere in this Report.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Mr.&#160;Hernandez resigned as Chief Executive Officer on August&#160;16, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Mr.&#160;Campbell was appointed by the Board to serve as Chief Executive Officer on October&#160;4, 2023, and resigned on January&#160;10, 2024. Mr.&#160;Campbell received a sign<span class="nobreak">-on</span> bonus of $75,000.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Mr.&#160;Garfield resigned as Chief Financial Officer on October&#160;4, 2023. Mr.&#160;Garfield received severance of $72,500 upon his resignation.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Ms. Henderson resigned as Chief Business Officer on December&#160;21, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(6)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Mr.&#160;Harmon was appointed by the Board to serve as Chief Financial Officer on October&#160;4, 2023</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">131</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Employment Agreements of Executive Officers</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Set forth below is a summary of many of the material provisions of the employment agreements with our named executive officers and other executive officers, which summaries do not purport to contain all of the material terms and conditions of each such agreement.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Joseph Hernandez</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Effective upon the closing of our initial public offering, we entered into an employment agreement with Mr.&#160;Hernandez (the &#8220;Hernandez Employment Agreement&#8221;), pursuant to which he was employed as the Chief Executive Officer of the Company, which superseded Mr.&#160;Hernandez&#8217;s prior consulting agreement with the Company. The Hernandez Employment Agreement provided for an annual base salary, subject to annual increases in the discretion of our compensation committee, the Company, and an annual performance bonus. Pursuant to the Hernandez Employment Agreement, following the completion of our initial public offering, Mr.&#160;Hernandez&#8217;s base salary was $595,000. The annual performance bonus was up to 50% of annual base salary (the &#8220;Target Annual Bonus&#8221;), with the actual bonus being based upon the level of achievement of annual Company and individual performance objectives for such fiscal year, as determined by our compensation committee.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In the event that Mr.&#160;Hernandez&#8217;s employment was terminated by the Company without cause (as defined in the Hernandez Employment Agreement), or if Mr.&#160;Hernandez terminated his employment for &#8220;Good Reason&#8221; (as defined in the Hernandez Employment Agreement), in addition to accrued unpaid salary, reimbursements and vacation&#160;days, he would be entitled to certain severance payments and benefits, including: (i)&#160;any unpaid annual bonus in respect of any completed fiscal year that has ended prior to the date of such termination; (ii)&#160;subject to certain conditions set forth in the Hernandez Employment Agreement, an amount equal to (A)&#160;the Target Annual Bonus otherwise for the fiscal year in which such termination occurred, assuming Mr.&#160;Hernandez had remained employed through the applicable payment date, multiplied by (B)&#160;a fraction, the numerator of which is the number of&#160;days elapsed from the commencement of such fiscal year through the date of such termination and the denominator of which is 365 (or 366, as applicable); (iii)&#160;a payment equal to twelve (12)&#160;months of his base salary; and (iv)&#160;payment of an amount equal to the difference between the monthly COBRA premium cost and the monthly contribution paid by active employees for the same coverage for eighteen&#160;months following his termination. The Hernandez Employment Agreement also provides that if a change in control (as defined in the Hernandez Employment Agreement) occurs, and during the period commencing three&#160;months prior to a change in control and ending on the eighteen (18)<span class="nobreak">-month</span> anniversary of the change in control, Mr.&#160;Hernandez is terminated without cause or he resigns for good reason, Mr.&#160;Hernandez is entitled to (i)&#160;any unpaid annual bonus in respect of any completed fiscal year that has ended prior to the date of such termination; (ii)&#160;subject to certain conditions set forth in the Hernandez Employment Agreement, an amount equal to (A)&#160;the Target Annual Bonus otherwise for the fiscal year in which such termination occurred, assuming Mr.&#160;Hernandez had remained employed through the applicable payment date, multiplied by (B)&#160;a fraction, the numerator of which is the number of&#160;days elapsed from the commencement of such fiscal year through the date of such termination and the denominator of which is 365 (or 366, as applicable); (iii)&#160;severance of 18&#160;months&#8217; salary; and (iv)&#160;payment of an amount equal to the difference between the monthly COBRA premium cost and the monthly contribution paid by active employees for the same coverage for eighteen&#160;months following his termination. Additionally, any unvested portion of the equity awards held subject to time<span class="nobreak">-vesting</span> held by Mr.&#160;Hernandez would automatically vest.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Hernandez Employment Agreement is governed by the laws of the State of Ohio and contains non<span class="nobreak">-solicitation</span> and non<span class="nobreak">-competition</span> covenants (each of which remains in effect during the term of employment and for six&#160;months following termination of employment) and confidentiality, trade secrets and assignment of intellectual property clauses.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the non<span class="nobreak">-solicitation</span> and non<span class="nobreak">-competition</span> covenants, Mr.&#160;Hernandez agreed to not directly or indirectly solicit any comparable business from a broad category of customers, request or advise customers to curtail, cancel, or withdraw its business from Blue Water Vaccines Inc., aid any other entity in obtaining business from customers that is comparable or similar to any products or services provided by the Company or otherwise interfere with any transaction, agreement, business relationship, and/or business opportunity between the Company and any customer or potential customer of the Company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">132</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the term of employment and for a period of six&#160;months after termination (&#8220;the Post<span class="nobreak">-Termination</span> Restricted Period&#8221;), Mr.&#160;Hernandez is prohibited from recruiting, encouraging, soliciting, or inducing, or in any manner attempting to recruit, encourage, solicit, or induce, any person employed by or engaged by the Company or its subsidiaries to terminate such person&#8217;s employment or services (or in the case of a consultant, materially reducing such services) with the Company or its subsidiaries, hiring, or engaging any individual who was employed by or providing services to Blue Water Vaccines Inc. or its subsidiaries within the six (6)&#160;month period prior to the date of such hiring or engagement, or encouraging, soliciting, or inducing, or in any manner attempting to encourage, solicit, or induce, any current or prospective client, customer, licensee, supplier, or other business relation of the Company or its subsidiaries, or any such relation that was a client, customer, licensee or other business relationship within the prior six (6)&#160;month period to cease doing business with or reduce the amount of business conducted with the Company or its subsidiaries, or in any way interfering with the relationship between any such party and the Company or its subsidiaries.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Neil Campbell</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In connection with Dr.&#160;Campbell&#8217;s appointment, the Company and Dr.&#160;Campbell entered into an employment agreement (the &#8220;Campbell Employment Agreement&#8221;), pursuant to which Dr.&#160;Campbell served as President and Chief Executive Officer of the Company and was paid a signing bonus of $75,000 and an annual base salary of $475,000. In addition, Dr.&#160;Campbell was entitled to receive, subject to employment by the Company on the applicable date of bonus payout, an annual target discretionary bonus of up to 50% of his annual base salary, payable at the discretion of the Compensation Committee of the Board. Dr.&#160;Campbell was also eligible to receive healthcare benefits as may be provided from time to time by the Company to its employees generally, and to receive paid time off annually.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Campbell Employment Agreement, Dr.&#160;Campbell was granted a long<span class="nobreak">-term</span> equity incentive grant in the form of an option to purchase 3% of the total outstanding shares of the Company&#8217;s common stock as of the Effective Date. Such award vests in quarterly increments over a period of three&#160;years from the Effective Date, subject to Dr.&#160;Campbell&#8217;s continued employment by the Company on the applicable vesting date. Dr.&#160;Campbell&#8217;s option grant has an exercise price per share equal to $0.4305, which was the closing price of the Company&#8217;s common stock on Nasdaq on the grant date.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Campbell Employment Agreement, Dr.&#160;Campbell agreed to be bound by certain non<span class="nobreak">-compete</span> and non<span class="nobreak">-solicitation</span> covenants contained therein.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Effective as of January&#160;10, 2024, Dr.&#160;Campbell resigned as President and Chief Executive Officer and a member of the Board. The Company entered into a Release of Claims with Dr.&#160;Campbell, pursuant to which Dr.&#160;Campbell will receive a one<span class="nobreak">-time</span> severance payment of $158,333.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Jon Garfield</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Effective upon the closing of our initial public offering, we entered into an employment agreement with Mr.&#160;Garfield (the &#8220;Garfield Employment Agreement&#8221;), pursuant to which he was employed as the Chief Financial Officer of the Company. The Garfield Employment Agreement provided for an annual base salary, subject to annual increases in the discretion of our compensation committee, the Company, and an annual performance bonus. Pursuant to the Garfield Employment Agreement, following the completion of our initial public offering, Mr.&#160;Garfield&#8217;s base salary was $435,000. The annual performance bonus was up to 50% of annual base salary (the &#8220;Target Annual Bonus&#8221;), with the actual bonus being based upon the level of achievement of annual Company and individual performance objectives for such fiscal year, as determined by our compensation committee.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Effective as of October&#160;4, 2023, Mr.&#160;Garfield resigned as Chief Financial Officer of the Company. The Company and Mr.&#160;Garfield entered into a Separation Agreement, which provides for two&#160;months of severance payment.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Bruce Harmon</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In connection with Mr.&#160;Harmon&#8217;s appointment, the Company and Mr.&#160;Harmon entered into an employment agreement (the &#8220;Harmon Employment Agreement&#8221;), pursuant to which Mr.&#160;Harmon will serve as Chief Financial Officer of the Company and will be paid an annual base salary of $325,000. In addition, Mr.&#160;Harmon is entitled to receive, subject to employment by the Company on the applicable date of bonus payout, an annual target discretionary bonus of up to 30% of his annual base salary, payable at the discretion of the Compensation Committee of the Board. Pursuant to the Harmon Employment Agreement, Mr.&#160;Harmon is also eligible to receive healthcare benefits as may be provided from time to time by the Company to its employees generally, and to receive paid time off annually.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">133</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Harmon Employment Agreement, Mr.&#160;Harmon was granted a long<span class="nobreak">-term</span> equity incentive grant in the form of an option to purchase 1% of the total outstanding shares of the Company&#8217;s common stock as of the Effective Date. Such award vests in quarterly increments over a period of three&#160;years from the Effective Date, subject to Mr.&#160;Harmon&#8217;s continued employment by the Company on the applicable vesting date. Mr.&#160;Harmon&#8217;s option grant has an exercise price per share equal to $0.4305, which was the closing price of the Company&#8217;s common stock on the Nasdaq Stock Market on the grant date.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Harmon Employment Agreement, Mr.&#160;Harmon agreed to be bound by certain non<span class="nobreak">-compete</span> and non<span class="nobreak">-solicitation</span> covenants contained therein.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Erin Henderson</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Effective upon the closing of our initial public offering, we entered into an employment agreement with Ms. Henderson (the &#8220;Henderson Employment Agreement&#8221;), pursuant to which she was employed as the Chief Business Officer of the Company. The Henderson Employment Agreement provided for an annual base salary, subject to annual increases in the discretion of our compensation committee, the Company, and an annual performance bonus. Pursuant to the Henderson Employment Agreement, following the completion of our initial public offering, Ms. Henderson&#8217;s base salary was $325,000. The annual performance bonus will be up to 40% of annual base salary (the &#8220;Target Annual Bonus&#8221;), with the actual bonus being based upon the level of achievement of annual Company and individual performance objectives for such fiscal year, as determined by our compensation committee.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Ms. Henderson resigned as Chief Business Officer of the Company, effective as of December&#160;21, 2023. On January&#160;17, 2024, the Company entered into a Separation Agreement and General Release with Ms. Henderson, pursuant to which the Company agreed to engage The Aetos Group, a management consulting company founded and managed by Ms. Henderson (&#8220;Aetos&#8221;), to perform certain consulting services for the Company. On January&#160;17, 2024, the Company entered into a Consulting Agreement with Aetos, pursuant to which Aetos will provide consulting services to the Company until April&#160;25, 2024, and receive a monthly fee of approximately $27,083.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Christian Br&#252;hlmann</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In November&#160;2011, Christian Br&#252;hlmann entered into an employment agreement with Proteomedix (as amended, the &#8220;Br&#252;hlmann Employment Agreement&#8221;), pursuant to which Mr.&#160;Br&#252;hlmann serves as Chief Financial Officer of Proteomedix and was paid a base salary of 233,100 Swiss francs (&#8220;CHF&#8221;) in the fiscal year ended December&#160;31, 2023. Mr.&#160;Br&#252;hlmann is also eligible to participate in the stock option plan sponsored by Proteomedix (the &#8220;PMX Option Plan&#8221;) and to receive accident insurance, sick pay insurance, a pension plan, and certain government<span class="nobreak">-mandated</span> child allowance benefits. Mr.<span class="nobreak"> </span>Br&#252;hlmann received a bonus of CHF 90,804 for 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Br&#252;hlmann Employment Agreement, Mr.&#160;Br&#252;hlmann agreed to be bound by certain non<span class="nobreak">-compete</span> and non<span class="nobreak">-solicitation</span> covenants contained therein.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Br&#252;hlmann Employment Agreement may be terminated with notice in writing by either Proteomedix or Mr.&#160;Br&#252;hlmann. In the event of a change of control, either party must give twelve&#160;months&#8217; notice, but for a period starting six&#160;months prior to and two&#160;years after a change of control becomes effective, Proteomedix must, upon request of Mr.&#160;Br&#252;hlmann, release him from his working obligations (&#8220;Garden Leave&#8221;) within 30&#160;days after receipt of such request. During the Garden Leave, Mr.&#160;Br&#252;hlmann may enter into consulting arrangements and accept board positions, provided that Mr.&#160;Br&#252;hlmann&#8217; statutory and contractual confidentiality, non<span class="nobreak">-competition</span> and non<span class="nobreak">-solicitation</span> obligations remain unchanged and in effect. If the termination of the Br&#252;hlmann Employment Agreement is for any other reason than a change of control, then either party must give five&#160;months&#8217; notice.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Ralph Schiess</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In November&#160;2011, Ralph Schiess entered into an employment agreement with Proteomedix (as amended, the &#8220;Schiess Employment Agreement&#8221;), pursuant to which Dr.&#160;Schiess serves as Chief Executive Officer of Proteomedix and was paid a base salary of CHF 233,100 in the fiscal year ended December&#160;31, 2023. Dr.&#160;Schiess is also eligible to participate in the PMX Option Plan and to receive accident insurance, sick pay insurance, a pension plan, and certain government<span class="nobreak">-mandated</span> child allowance benefits. Dr. Schiess received a bonus of CHF 90,804 for 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">134</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Schiess Employment Agreement, Dr.&#160;Schiess agreed to be bound by certain non<span class="nobreak">-compete</span> and non<span class="nobreak">-solicitation</span> covenants contained therein.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Schiess Employment Agreement may be terminated with notice in writing by either Proteomedix or Dr.&#160;Schiess. In the event of a change of control, either party must give twelve&#160;months&#8217; notice, but for a period starting six&#160;months prior to and two&#160;years after a change of control becomes effective, Proteomedix must, upon request of Dr.&#160;Schiess, must provide Garden Leave within 30&#160;days after receipt of such request. During the Garden Leave, Dr.&#160;Schiess may enter into consulting arrangements and accept board positions, provided that Dr.&#160;Schiess&#8217; statutory and contractual confidentiality, non<span class="nobreak">-competition</span> and non<span class="nobreak">-solicitation</span> obligations remain unchanged and in effect. If the termination of the Schiess Employment Agreement is for any other reason than a change of control, then either party must give five&#160;months&#8217; notice.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potential Payments Upon Termination or Change-in-Control</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">See &#8220;Employment Agreements of Named Executive Officers&#8221; above.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Outstanding Equity Awards at Fiscal Year-End</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the number of shares of common stock underlying outstanding equity incentive plan awards for each named executive officer as of December&#160;31, 2023. Each of the awards set forth in the table below was granted under our 2022 Equity Incentive Plan.</p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 20.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="10" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 43.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-8" style="font-size:8pt;font-style:normal;font-weight:bold;">Option Awards</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 33.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-8" style="font-size:8pt;font-style:normal;font-weight:bold;">Stock Awards</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-39" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 20.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-8" style="font-size:8pt;font-style:normal;font-weight:bold;">Name <br/>(a)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-8" style="font-size:8pt;font-style:normal;font-weight:bold;">Number of <br/>securities <br/>underlying <br/>unexercised <br/>options <br/>(#) <br/>exercisable <br/>(b)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-8" style="font-size:8pt;font-style:normal;font-weight:bold;">Number of <br/>securities <br/>underlying <br/>unexercised <br/>options <br/>(#) <br/>unexercisable <br/>(c)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.70%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-8" style="font-size:8pt;font-style:normal;font-weight:bold;">Equity <br/>incentive <br/>plan awards: <br/>Number of <br/>securities <br/>underlying <br/>unexercised <br/>unearned <br/>options <br/>(#) <br/>(d)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.93%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-8" style="font-size:8pt;font-style:normal;font-weight:bold;">Option <br/>exercise <br/>price <br/>($) <br/>(e)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-8" style="font-size:8pt;font-style:normal;font-weight:bold;">Option <br/>expiration <br/>date <br/>(f)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-8" style="font-size:8pt;font-style:normal;font-weight:bold;">Number <br/>of shares <br/>or units <br/>of stock <br/>that <br/>have not <br/>vested <br/>(#) <br/>(g)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-8" style="font-size:8pt;font-style:normal;font-weight:bold;">Market <br/>value of <br/>shares <br/>or units <br/>of stock <br/>that <br/>have not <br/>vested <br/>($) <br/>(h)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-8" style="font-size:8pt;font-style:normal;font-weight:bold;">Equity <br/>incentive <br/>plan <br/>awards: <br/>Number of <br/>unearned <br/>shares, <br/>units or <br/>other rights <br/>that have <br/>not vested <br/>(#) <br/>(i)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.81%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-8" style="font-size:8pt;font-style:normal;font-weight:bold;">Equity <br/>incentive <br/>plan awards: <br/>Market or <br/>payout value <br/>of unearned <br/>shares, units <br/>or other <br/>rights that <br/>have not <br/>vested <br/>($) <br/>(j)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 20.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-9" style="font-size:9pt;">Neil Campbell</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">532,326</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-9" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">0.43</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">10/4/33</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-40" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 20.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-9" style="font-size:9pt;">Bruce Harmon</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">177,442</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-9" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">0.43</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-9" style="font-size:9pt;">10/4/33</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 20.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-9" style="font-size:9pt;">Joseph Hernandez</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 20.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-9" style="font-size:9pt;">Jon Garfield</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 20.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-9" style="font-size:9pt;">Erin Henderson</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">16,276</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">0.01</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-9" style="font-size:9pt;">4/2/30</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">150,000</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">29,700</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.15%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">150,000</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">29,700</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 20.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">153,920</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">46,080</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.70%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">46,080</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.44%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">6.45</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-9" style="font-size:9pt;">5/4/32</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.81%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-9" style="font-size:9pt;">&#8212;</span></p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>As of December&#160;31, 2023, these incentive options, which were granted on October&#160;4, 2023, vest and become exercisable as follows: 44,361 options vest quarterly beginning on January&#160;4, 2024 through October&#160;4, 2026. All but 44,361 of these options were forfeited subsequent to December&#160;31, 2023, in connection with Dr.&#160;Campbell&#8217;s resignation.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>These incentive options, which were granted on October&#160;4, 2023, vest and become exercisable as follows: 14,787 options vest quarterly beginning on January&#160;4, 2024 through October&#160;4, 2026.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Director Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Prior to April&#160;2022, our directors have not received cash compensation for their service except for option grants. However, in April&#160;2022, after a review of non<span class="nobreak">-employee</span> director compensation at comparable companies, the Board approved cash and equity compensation of directors, such that we will pay each of our non<span class="nobreak">-employee</span> directors an annual cash retainer for service on the Board and for service on each committee on which the director is a member. </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">135</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">The&#160;chair of each committee receives an additional annual retainer for such service. All retainers are payable in arrears in four equal quarterly installments. The retainers paid to non<span class="nobreak">-employee</span> directors for service on the Board and for service on each committee of the Board on which the director is a member are as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Italic" style="font-style:italic;font-weight:normal;">Annual Board Service Retainer</span></p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">All non-employee directors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Italic" style="font-style:italic;font-weight:normal;">Annual Committee Member Service Retainer</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Member of the Audit Committee</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Member of the Compensation Committee</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,500</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Member of the Nominating and Corporate Governance Committee</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Italic" style="font-style:italic;font-weight:normal;">Annual Committee Chair Service Retainer</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">(in addition to Committee Member Service Retainer above):</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Chair of the Audit Committee</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Chair of the Compensation Committee</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">15,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Chair of the Nominating and Corporate Governance Committee</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,000</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, each non<span class="nobreak">-director</span> will receive an annual grant of nonqualified stock options to purchase 0.04% of the shares of Common Stock outstanding as of the date of the Company&#8217;s annual meeting, such options vesting monthly over a one<span class="nobreak">-year</span> period and fully vesting upon the director&#8217;s death or disability or upon a change of control of the Company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our Nominating Committee will continue to review and make recommendations to the Board regarding compensation of directors, including equity<span class="nobreak">-based</span> plans. We will reimburse our non<span class="nobreak">-employee</span> directors for reasonable travel expenses incurred in attending board and committee meetings.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Director Compensation Table</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth information concerning the compensation of our directors for the year ended December&#160;31, 2023:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-46" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Name</span></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Fees<br/>Earned or<br/>Paid In Cash<br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Stock Awards<br/>($)</span><span class="CharOverride-5" style="font-size:58%;font-style:normal;font-weight:bold;vertical-align:super;">(1)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Option Awards<br/>($)</span><span class="CharOverride-5" style="font-size:58%;font-style:normal;font-weight:bold;vertical-align:super;">(1)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">All Other<br/>Compensation<br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Total<br/>($)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Simon Tarsh</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;">107,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;">5,120</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">112,620</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">James Sapirstein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;">175,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;">5,120</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;">2,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">182,120</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vuk Jeremic</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;">43,125</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(6)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;">5,120</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">48,245</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Timothy Ramdeen</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;">75,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(7)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;">5,120</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;">2,549</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(8)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">82,669</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>This figure represents the aggregate grant date fair value of stock<span class="nobreak">-based</span> awards granted in the fiscal year, computed in accordance with the provisions of FASB ASC&#160;718. Assumptions used in the calculation of these amounts are included in the notes to our consolidated financial statements included elsewhere in this Report.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents fees earned by Mr.&#160;Tarsh for serving as a member of the Board, Compensation Committee, and Nominating Governance Committee, as well as Chairman of the Audit Committee, totaling $77,500. This figure also includes $30,000 of fees earned by Mr.&#160;Tarsh for Special Committee compensation.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>These directors were each granted 6,360<span class="nobreak"> </span>shares of restricted stock, which vest on May&#160;31, 2024. All such shares are unvested and remain outstanding as of December&#160;31, 2023, except for the 6,360 shares originally granted to Mr.&#160;Jeremic, which forfeited unvested on his resignation date.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents fees earned by Mr.&#160;Sapirstein, for serving as a member of the Board, Audit Committee, and Nominating Governance Committee, as well as Chairman of the Compensation Committee, totaling $75,000. This figure also includes $100,000 of fees earned by Mr.&#160;Sapirstein for his role as Lead Independent Director and non<span class="nobreak">-executive</span> Chairman of the Board.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents travel expenses incurred by Mr.&#160;Sapirstein and reimbursed by the Company.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(6)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents pro<span class="nobreak">-rated</span> fees earned by Mr.&#160;Jeremic for 2023, through his resignation on September&#160;2, 2023. Such fees were earned for serving as a member of the Board, Compensation Committee, and Nominating Governance Committee.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(7)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents fees earned by Mr.&#160;Ramdeen, for serving as a member of the Board, Audit Committee, and Compensation Committee, as well as Chairman of the Nominating Governance Committee.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">136</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(8)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Mr.&#160;Ramdeen was granted 2,386 stock options during the year ended December&#160;31, 2023, when he joined the Board January&#160;2023. The options vested monthly through May&#160;13, 2023. At December&#160;31, 2023, these options are fully vested and outstanding.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Securities Authorized for Issuance under Equity Compensation Plans</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table provides information as of December&#160;31, 2023, regarding our common stock that may be issued under the Company&#8217;s 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) and the Company&#8217;s 2022 Equity Incentive Plan (the &#8220;2022 Plan&#8221;).</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-49" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Plan category:</span></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Number of Securities to be issued Upon Exercise of Outstanding Options, Warrants, <br/>and Rights <br/>(a)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Weighted Average Exercise <br/>Price&#160;of Outstanding Options <br/>(b)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected <br/>in column&#160;(a)) <br/>(c)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Equity compensation plans approved by stockholders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2019 Plan<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">508,028</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.01</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;">0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(1)(2)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2022 Plan<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,396,802</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">718,402</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,904,830</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.63</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">718,402</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The 2019 Plan permits grants of equity awards to employees, directors, consultants, and other independent contractors. Our board of directors and stockholders have approved a total reserve of 1,400,000<span class="nobreak"> </span>shares for issuance under the 2019 Plan.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Once the 2022 Plan became effective, no further grants were made under the 2019 Plan and all shares that remained available for the issuance of awards under our 2019 Plan as of immediately prior to the time our 2022 Plan became effective were rolled over into the 2022 Plan.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The 2022 Plan permits grants of equity awards to employees, directors, consultants, and other independent contractors. Our board of directors and stockholders have approved a total reserve of 3,150,000<span class="nobreak"> </span>shares for issuance under the 2022 Plan.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table provides information as of December&#160;31, 2023, regarding common stock of Proteomedix that may be issued under a stock option plan sponsored by Proteomedix (the &#8220;PMX Option Plan&#8221;).</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-50" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Plan category:</span></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Number of <br/>Securities to <br/>be issued Upon <br/>Exercise of <br/>Outstanding <br/>Options <br/>(a)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Weighted <br/>Average <br/>Exercise <br/>Price of <br/>Outstanding <br/>Options <br/>(b)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Number of <br/>Securities <br/>Remaining <br/>Available for <br/>Future Issuance <br/>Under Equity <br/>Compensation <br/>Plans <br/>(Excluding <br/>Securities <br/>Reflected <br/>in column (a)) <br/>(c)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Equity compensation plans approved by Proteomedix board of directors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">PMX Option Plan<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">58,172</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.46</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;">n/a</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;margin-top:2pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(1)(2)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">58,172</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.46</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The PMX Option Plan permits grants of equity awards to employees and consultants. The board of directors of Proteomedix approves shares issued under this plan and there is no maximum number of shares that may be issued.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The PMX Option Plan does not have a maximum number of shares that may be issued.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">137</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">2022 Equity Incentive Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Our board of directors adopted, and our stockholders approved, our 2022 Plan effective upon the completion of our initial public offering. Our 2022 Plan is a successor to and continuation of our 2019 Plan. Our 2022 Plan became effective on the date of the completion of our initial public offering. Once the 2022 Plan became effective, no further grants will be made under the 2019 Plan.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Awards.&#160;&#160;&#160;&#160;</span>Our 2022 Plan provides for the grant of incentive stock options, or ISOs, within the meaning of Section&#160;422 of the Internal Revenue Code, or the Code, to employees, including employees of any parent or subsidiary, and for the grant of nonstatutory stock options, or NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants, including employees and consultants of our affiliates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Authorized Shares.&#160;&#160;&#160;&#160;</span>Initially, the maximum number of shares of our common stock that may be issued under our 2022 Plan was 1,600,000<span class="nobreak"> </span>shares of our common stock, which is the sum of (i)&#160;200,000 new shares, plus (ii)&#160;an additional number of shares not to exceed 1,400,000 (calculated after giving effect to the Pre<span class="nobreak">-IPO</span> Stock Split), consisting of (A)&#160;shares that remain available for the issuance of awards under our 2019 Plan as of immediately prior to the time our 2022 Plan becomes effective and (B)&#160;shares of our common stock subject to outstanding stock options or other stock awards granted under our 2019 Plan that, on or after the 2022 Plan becomes effective, terminate or expire prior to exercise or settlement; are not issued because the award is settled in cash; are forfeited because of the failure to vest; or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price, if any, as such shares become available from time to time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On August&#160;22, 2022, at the Company&#8217;s 2022 annual meeting of stockholders, the Company&#8217;s stockholders approved an additional 1,000,000<span class="nobreak"> </span>shares of common stock that may be issued under the 2022 Plan. On May&#160;31, 2023, at the Company&#8217;s 2022 annual meeting of stockholders, the Company&#8217;s stockholders approved an additional 550,000<span class="nobreak"> </span>shares of common stock that may be issued under the 2022 Plan.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The number of shares of common stock available for issuance under our 2022 Plan will be reduced by: one share for each share of common stock issued pursuant to a stock option or stock appreciation right with respect to which the exercise or strike price is at least 100% of the Fair Market Value of the Common Stock subject to the stock option or appreciation right on the grant date; and (ii)&#160;1.20<span class="nobreak"> </span>shares for each share of common stock issued pursuant to any restricted stock unit or other &#8220;full value award.&#8221; The maximum number of shares of our common stock that may be issued on the exercise of ISOs under our 2022 Plan is equal to the number of shares reserved under the 2022 Plan at any time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Shares subject to stock awards granted under our 2022 Plan that expire or terminate without being exercised in full or that are paid out in cash rather than in shares do not reduce the number of shares available for issuance under our 2022 Plan. Shares withheld under a stock award to satisfy the exercise, strike, or purchase price of a stock award or to satisfy a tax withholding obligation do not reduce the number of shares available for issuance under our 2022 Plan. If any shares of our common stock issued pursuant to a stock award are forfeited back to or repurchased or reacquired by us (i)&#160;because of a failure to meet a contingency or condition required for the vesting of such shares, (ii)&#160;to satisfy the exercise, strike or purchase price of an award or (iii)&#160;to satisfy a tax withholding obligation in connection with an award, the shares that are forfeited or repurchased or reacquired will revert to and again become available for issuance under the 2022 Plan. Any shares previously issued which are reacquired in satisfaction of tax withholding obligations or as consideration for the exercise or purchase price of a stock award will again become available for issuance under the 2022 Plan. The number of shares available for issuance under our 2022 Plan will increase by 1.20<span class="nobreak"> </span>shares for each share subject to restricted stock units or other full value awards (not including stock options or stock appreciation rights) which are forfeited or reacquired for the reasons described in the preceding two sentences.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Plan Administration.&#160;&#160;&#160;&#160;</span>Our Board of Directors has assigned the authority to administer the 2022 Plan to our Compensation Committee, but may, at any time, re<span class="nobreak">-vest</span> in itself some or all of the power delegated to our Compensation Committee. The Compensation Committee may delegate to one or more of our officers the authority to (i)&#160;designate employees (other than officers) to receive specified stock awards and (ii)&#160;determine the number of shares subject to such stock awards. Under our 2022 Plan, our Compensation Committee has the authority to determine award recipients, grant dates, the numbers and types of stock awards to be granted, the applicable fair market value, and the provisions of each stock award, including the period of exercisability and the vesting schedule applicable to a stock award.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">138</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stock Options.&#160;&#160;&#160;&#160;</span>ISOs and NSOs are granted under stock option agreements in a form approved by the Compensation Committee. The Compensation Committee determines the exercise price for stock options, within the terms and conditions of the 2022 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our common stock on the date of grant. Options granted under the 2022 Plan vest at the rate specified in the stock option agreement as determined by the Compensation Committee.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The Compensation Committee determines the term of stock options granted under the 2022 Plan, up to a maximum of 10&#160;years. Unless the terms of an option holder&#8217;s stock option agreement, or other written agreement between us and the recipient approved by the Compensation Committee, provide otherwise, if an option holder&#8217;s service relationship with us or any of our affiliates ceases for any reason other than disability, death or cause, the option holder may generally exercise any vested options for a period of three&#160;months following the cessation of service. This period may be extended in the event that exercise of the option is prohibited by applicable securities laws. If an option holder&#8217;s service relationship with us or any of our affiliates ceases due to death, or an option holder dies within a certain period following cessation of service, the option holder or a beneficiary may generally exercise any vested options for a period of 18&#160;months following the date of death. If an option holder&#8217;s service relationship with us or any of our affiliates ceases due to disability, the option holder may generally exercise any vested options for a period of 12&#160;months following the cessation of service. In the event of a termination for cause, options generally terminate upon the termination date. In no event may an option be exercised beyond the expiration of its term.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the Compensation Committee and may include (i)&#160;cash, check, bank draft or money order, (ii)&#160;a broker<span class="nobreak">-assisted</span> cashless exercise, (iii)&#160;the tender of shares of our common stock previously owned by the option holder, (iv)&#160;a net exercise of the option if it is an NSO or (v)&#160;other legal consideration approved by the Board of Directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Unless the Compensation Committee provides otherwise, options or stock appreciation rights generally are not transferable except by will or the laws of descent and distribution. Subject to approval of the Compensation Committee or a duly authorized officer, an option may be transferred pursuant to a domestic relations order, official marital settlement agreement or other divorce or separation instrument.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Tax Limitations on ISOs.&#160;&#160;&#160;&#160;</span>The aggregate fair market value, determined at the time of grant, of our common stock with respect to ISOs that are exercisable for the first time by an award holder during any calendar year under all of our stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our parent or subsidiary corporations unless (i)&#160;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant and (ii)&#160;the term of the ISO does not exceed five&#160;years from the date of grant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Restricted Stock Unit Awards.&#160;&#160;&#160;&#160;</span>Restricted stock unit awards are granted under restricted stock unit award agreements in a form approved by the Compensation Committee. Restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. A restricted stock unit award may be settled by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the Compensation Committee or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in respect of shares covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, or other written agreement between us and the recipient approved by the Compensation Committee, restricted stock unit awards that have not vested will be forfeited once the participant&#8217;s continuous service ends for any reason.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Restricted Stock Awards.&#160;&#160;&#160;&#160;</span>Restricted stock awards are granted under restricted stock award agreements in a form approved by the Compensation Committee. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past or future services to us or any other form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. The Compensation Committee determines the terms and conditions of restricted stock awards, including vesting and forfeiture terms. If a participant&#8217;s service relationship with us ends for any reason, we may receive any or all of the shares of common stock held by the participant that have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase right.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stock Appreciation Rights.&#160;&#160;&#160;&#160;</span>Stock appreciation rights are granted under stock appreciation right agreements in a form approved by the Compensation Committee. The Compensation Committee determines the strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of our common stock on the date of grant. A stock appreciation right granted under the 2022 Plan vests at the rate specified in the stock </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">139</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;text-indent:0pt;margin-top:6pt;">appreciation right agreement as determined by the Compensation Committee. Stock appreciation rights may be settled in cash or shares of common stock or in any other form of payment as determined by the Board and specified in the stock appreciation right agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The Compensation Committee determines the term of stock appreciation rights granted under the 2022 Plan, up to a maximum of 10&#160;years. If a participant&#8217;s service relationship with us or any of our affiliates ceases for any reason other than cause, disability or death, the participant may generally exercise any vested stock appreciation right for a period of three&#160;months following the cessation of service. This period may be further extended in the event that exercise of the stock appreciation right following such a termination of service is prohibited by applicable securities laws. If a participant&#8217;s service relationship with us, or any of our affiliates, ceases due to disability or death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation right for a period of 12&#160;months in the event of disability and 18&#160;months in the event of death. In the event of a termination for cause, stock appreciation rights generally terminate immediately upon the occurrence of the event giving rise to the termination of the individual for cause. In no event may a stock appreciation right be exercised beyond the expiration of its term.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Performance Awards.&#160;&#160;&#160;&#160;</span>The 2022 Plan permits the grant of performance awards that may be settled in stock, cash, or other property. Performance awards may be structured so that the stock or cash will be issued or paid only following the achievement of certain pre<span class="nobreak">-established</span> performance goals during a designated performance period. Performance awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, the common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The performance goals may be based on any measure of performance selected by the board of directors or the Compensation Committee. The performance goals may be based on company<span class="nobreak">-wide</span> performance or performance of one or more business units, divisions, affiliates, or business segments, and may be either absolute or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by the board of directors at the time the performance award is granted, the board or Compensation Committee will appropriately make adjustments in the method of calculating the attainment of performance goals as follows: (i)&#160;to exclude restructuring and/or other nonrecurring charges; (ii)&#160;to exclude exchange rate effects; (iii)&#160;to exclude the effects of changes to generally accepted accounting principles; (iv)&#160;to exclude the effects of any statutory adjustments to corporate tax rates; (v)&#160;to exclude the effects of items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles; (vi)&#160;to exclude the dilutive effects of acquisitions or joint ventures; (vii)&#160;to assume that any portion of our business which is divested achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; (viii)&#160;to exclude the effect of any change in the outstanding shares of our common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin<span class="nobreak">-off</span>, combination or exchange of shares or other similar corporate change or any distributions to common stockholders other than regular cash dividends; (ix)&#160;to exclude the effects of stock based compensation and the award of bonuses under our bonus plans; (x)&#160;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; (xi)&#160;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles; and (xi)&#160;to exclude the effects of the timing of acceptance for review and/or approval of submissions to the U.S.&#160;Food and Drug Administration or any other regulatory body.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Other Stock Awards.&#160;&#160;&#160;&#160;</span>The Compensation Committee may grant other awards based in whole or in part by reference to our common stock. The Compensation Committee will set the number of shares under the stock award (or cash equivalent) and all other terms and conditions of such awards.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Non</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Employee</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Director Compensation Limit.&#160;&#160;&#160;&#160;</span>The aggregate value of all compensation granted or paid to any non<span class="nobreak">-employee</span> director with respect to any calendar year, including awards granted and cash fees paid by us to such non<span class="nobreak">-employee</span> director, will not exceed $150,000 in total value; provided that such amount will increase to $200,000 for the first year for newly appointed or elected non<span class="nobreak">-employee</span> directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Changes to Capital Structure.&#160;&#160;&#160;&#160;</span>In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split or recapitalization, appropriate adjustments will be made to (i)&#160;the class and maximum number of shares reserved for issuance under the 2022 Plan, (ii)&#160;the class and maximum number of shares by which the share reserve may increase automatically each year, (iii)&#160;the class and maximum number of shares that may be issued on the exercise of ISOs and (iv)&#160;the class and number of shares and exercise price, strike price or purchase price, if applicable, of all outstanding stock awards.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">140</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Corporate Transactions.&#160;&#160;&#160;&#160;</span>The following applies to stock awards under the 2022 Plan in the event of a corporate transaction (as defined in the 2022 Plan), unless otherwise provided in a participant&#8217;s stock award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly provided by the Board of Directors or Compensation Committee at the time of grant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In the event of a corporate transaction, any stock awards outstanding under the 2022 Plan may be assumed, continued, or substituted for by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to the stock award may be assigned to the successor (or its parent company). If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such stock awards, then (i)&#160;with respect to any such stock awards that are held by participants whose continuous service has not terminated prior to the effective time of the corporate transaction, or current participants, the vesting (and exercisability, if applicable) of such stock awards will be accelerated in full to a date prior to the effective time of the corporate transaction (contingent upon the effectiveness of the corporate transaction), and such stock awards will terminate if not exercised (if applicable) at or prior to the effective time of the corporate transaction, and any reacquisition or repurchase rights held by us with respect to such stock awards will lapse (contingent upon the effectiveness of the corporate transaction), and (ii)&#160;any such stock awards that are held by persons other than current participants will terminate if not exercised (if applicable) prior to the effective time of the corporate transaction, except that any reacquisition or repurchase rights held by us with respect to such stock awards will not terminate and may continue to be exercised notwithstanding the corporate transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In the event a stock award will terminate if not exercised prior to the effective time of a corporate transaction, the board of directors may provide, in its sole discretion, that the holder of such stock award may not exercise such stock award but instead will receive a payment equal in value to the excess (if any) of (i)&#160;the per share amount payable to holders of common stock in connection with the corporate transaction over (ii)&#160;any per share exercise price payable by such holder, if applicable. In addition, any escrow, holdback, earn out or similar provisions in the definitive agreement for the corporate transaction may apply to such payment to the same extent and in the same manner as such provisions apply to the holders of common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Plan Amendment or Termination.&#160;&#160;&#160;&#160;</span>Our board of directors has the authority to amend, suspend or terminate our 2022 Plan, provided that such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. Certain material amendments also require the approval of our stockholders. No ISOs may be granted after the tenth anniversary of the date our board of directors adopts our 2022 Plan. No stock awards may be granted under our 2022 Plan while it is suspended or after it is terminated.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">2019 Equity Incentive Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our board of directors adopted, and our stockholders approved our 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) in July&#160;2019 for grants of awards to employees, directors, officers, and consultants of us or any of our subsidiaries. Once the 2022 Plan became effective, no further grants will be made under the 2019 Plan. However, the 2019 Plan will continue to govern the terms and conditions of the outstanding awards previously granted under the 2019 Plan.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Awards.&#160;&#160;&#160;&#160;</span>Our 2019 Plan provides for the grant of stock awards (collectively, &#8220;Stock Awards&#8221;) to employees, directors, officers and consultants of us or any of our subsidiaries, consisting of (i)&#160;incentive stock options, (&#8220;ISOs&#8221;), within the meaning of Section&#160;422 of the Internal Revenue Code (the &#8220;Code&#8221;); (ii)&#160;nonstatutory stock options (&#8220;NSOs&#8221;); (iii)&#160;stock appreciation rights; (iv)&#160;restricted stock awards; (v)&#160;restricted stock unit awards, and (vi)&#160;other forms of awards.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Authorized Shares.&#160;&#160;&#160;&#160;</span>As of April<span class="nobreak"> </span>24, 2024, stock options covering 508,028<span class="nobreak"> </span>shares, each with an exercise price of $0.01 per share were the only outstanding Stock Awards outstanding under our 2019 Plan. Once the 2022 Plan became effective, no further grants were made under the 2019 Plan and all shares that remained available for the issuance of awards under our 2019 Plan as of immediately prior to the time our 2022 Plan became effective were rolled over into the 2022 Plan.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Plan Administration.&#160;&#160;&#160;&#160;</span>The 2019 Plan may be administered by our board of directors, and our board of directors may delegate such administration to a committee of the board of directors (as applicable, the &#8220;Administrator&#8221;). The Administrator, in its discretion, selects the individuals to whom awards may be granted, the time or times at which such awards are granted and the terms and conditions of such awards.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">141</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stock Options.&#160;&#160;&#160;&#160;</span>Stock options entitle the holder to purchase a specified number of shares of common stock at a specified price (the exercise price), subject to the terms and conditions of the stock option grant. Our board of directors may grant either incentive stock options, which must comply with Code Section&#160;422, or nonqualified stock options. ISO&#8217;s may only be granted to employees of the Company or a &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; thereof (as such terms are defined in Sections 424(e)&#160;and 424(f)&#160;of the Code). Our Administrator sets exercise prices and terms and conditions, except that stock options must be granted with an exercise price not less than 100% of the fair market value of our common stock on the date of grant. Unless our Administrator determines otherwise, fair market value means, as of a given date, the closing price of our common stock. At the time of grant, our board of directors determines the terms and conditions of stock options, including the quantity, exercise price, vesting periods, term (which may not exceed 10&#160;years) and other conditions on exercise. Pursuant to the 2019 Plan, we may only issue 1,400,000 ISO&#8217;s.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Eligibility.&#160;&#160;&#160;&#160;</span>Awards may be granted under the 2019 Plan to officers, employees, directors, officers and of us and our subsidiaries. Incentive stock options may be granted only to employees of us or our subsidiaries.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Restricted Stock, Restricted Stock Units&#160;and Other Stock<span class="nobreak">-Based</span> Awards. Our board of directors may grant awards of restricted stock, which are shares of common stock subject to specified restrictions, and restricted stock units, or RSUs, which represent the right to receive shares of our common stock in the future. These awards may be made subject to repurchase, forfeiture or vesting restrictions at the discretion of our board of directors&#8217; discretion. The restrictions may be based on continuous service with us or the attainment of specified performance goals, as determined by the board of directors. Stock units may be paid in stock or cash or a combination of stock and cash, as determined by the board of directors. Other stock awards valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than one hundred percent (100%) of the fair market value of the common stock at the time of grant) may be granted either alone or in addition to stock awards provided for under the 2019 Plan.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stock Appreciation Rights.&#160;&#160;&#160;&#160;</span>Upon exercise, SARs entitle the holder to receive payment per share in stock or cash, or in a combination of stock and cash, equal to the excess of the share&#8217;s fair market value on the date of exercise over the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such date (the &#8220;grant price&#8221;. Exercise of a SAR issued in tandem with a stock option will reduce the number of shares underlying the related stock option to the extent of the SAR exercised. The term of a SAR cannot exceed 10&#160;years.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Changes to Capital Structure.&#160;&#160;&#160;&#160;</span>In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split or recapitalization, appropriate adjustments will be made to (i)&#160;the class and maximum number of shares subject to the 2019 Plan, (ii)&#160;the class and maximum number of shares that may be issued on the exercise of ISOs and (iii)&#160;the class and number of shares and exercise price, strike price or purchase price, if applicable, of all outstanding stock awards.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Corporate Transactions.&#160;&#160;&#160;&#160;</span>The following applies to Stock Awards under the 2019 Plan in the event of a corporate transaction (as defined in the 2019 Plan), unless otherwise provided in a participant&#8217;s stock award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly provided by the Board of Directors at the time of grant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In the event of a corporate transaction, the board of directors may take one of the following actions, contingent on the completion of the corporate transaction: (i)&#160;arrange for the surviving or acquiring corporation (or its parent company) to assume, continue or substitute the Stock Award for a similar stock award; (ii)&#160;arrange for the assignment of any reacquisition or repurchase rights held by the Company in respect of common stock issued pursuant to the Stock Award to the surviving or acquiring corporation (or its parent company); (iii)&#160;accelerate the vesting (in whole or in part) of the Stock Award; (iv)&#160;arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by the Company with respect to the Stock Award; (v)&#160;cancel or arrange for the cancellation of the Stock Award, to the extent not vested or not exercised prior to the effective time of the corporate transaction, in exchange for such cash consideration that the Board of Directors; and (vi)&#160;make a payment equal to the excess, if any, of (A)&#160;the value of the property the participant would have received upon the exercise of the Stock Award immediately prior to the effective time of the corporate transaction, over (B)&#160;any exercise price payable by such holder in connection with such exercise The Board of Directors need not take the same action or actions with respect to all Stock Awards or portions thereof or with respect to all participants. The Board of Directors may also take different actions with respect to the vested and unvested portions of a Stock Award.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">142</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, under the 2019 Plan, a Stock Award may be subject to additional acceleration of vesting and exercisability upon or after a Change in Control (as defined in the 2019 Plan) as may be provided in the Grant Agreement for such Stock Award or as may be provided in any other written agreement between the participant and the Company or any of its subsidiaries which may employ the participant, but in the absence of such provision, no such acceleration will occur.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Plan Amendment or Termination.&#160;&#160;&#160;&#160;</span>Our board of directors has the authority to amend, suspend or terminate our 2019 Plan, subject to certain conditions, including that such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. Certain material amendments also require the approval of our stockholders. No ISOs may be granted after the tenth anniversary of the date our board of directors adopted our 2019 Plan.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proteomedix Stock Option Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The PMX Option Plan was approved by Proteomedix&#8217;s board of directors as of July&#160;1, 2015, and provides for the grant of options to acquire shares in Proteomedix. The terms of the PMX Option Plan are described in more detail below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The PMX Option Plan is administered by a plan administrator (one or several persons) elected by Proteomedix&#8217;s board of directors (the &#8220;Proteomedix Board&#8221;) from time to time. The plan administrator acts within the guidelines set and approved by Proteomedix&#8217;s board of directors or a committee thereof and is authorized to, among others, determine (i)&#160;which eligible persons are to receive awards under the PMX Option Plan, (ii)&#160;the time or times when such options grants are to be made, (iii)&#160;the nature and the number of options covered by each such grant, (iv)&#160;the time or times at which each option right is to become exercisable, (v)&#160;the vesting conditions applicable to the options, (vi)&#160;the maximum term for which the options are to remain outstanding, and (vii)&#160;any terms and conditions of the options granted, in each case, subject to the guidelines set and approved by Proteomedix&#8217;s board of directors or a committee thereof. Persons eligible to participate in the PMX Option Plan are employees, members of Proteomedix&#8217;s board of directors and consultants of Proteomedix or a subsidiary. The plan administrator determines within the guidelines set and approved by Proteomedix&#8217;s board of directors or a committee which eligible persons are to receive rights to acquire options under the PMX Option Plan.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The number of shares that may be issued under the PMX Option Plan is determined by Proteomedix&#8217;s board of directors. In the event common shares that otherwise would have been issuable under the PMX Option Plan are withheld by Proteomedix in payment of the exercise price or withholding obligations, such shares shall remain available for issuance under the PMX Option Plan. In the event that an outstanding award expires or is cancelled, forfeited or terminated for any reason, the shares allocable to the unexercised or unsettled portion shall remain available for issuance under the PMX Option Plan.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A participant may only exercise an option or stock appreciation right to the extent that the option or stock appreciation right has vested and has not lapsed under the PMX Option Plan. Unless otherwise determined by Proteomedix&#8217;s board of directors at the grant date or set forth in the grant notice, an option or an award in the form of a restricted stock unit or stock appreciation right granted under the PMX Option Plan typically vests as to 25.0% of the award at the end of the first year following the vesting start date, with the remaining 75.0% of the award vesting monthly over the 3&#160;years after the first year following the vesting start date.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If indicated in the grant notice or otherwise resolved by Proteomedix&#8217;s board of directors, upon the occurrence of a &#8220;Corporate Transaction&#8221; (as defined in the PMX Option Plan), all options (i)&#160;shall fully vest and (ii)&#160;may be immediately exercised, except if such options are canceled by the plan administrator in exchange for compensation equivalent to the economic value of the option under the PMX Option Plan.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix has complete and exclusive power and authority to amend or modify the PMX Option Plan in any or all respects. No such amendment or modification shall, without the consent of the grantee, adversely affect his/her rights and obligations under the PMX Option Plan.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Certain Relationships and Related Transactions, and Director Independence.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following is a description of transactions since January&#160;1, 2022 to which we were a party in which (i)&#160;the amount involved exceeded or will exceed the lesser of $120,000 of one percent (1%) of our average total assets at year<span class="nobreak">-end</span> for the last two completed fiscal&#160;years and (ii)&#160;any of our directors, executive officers or holders of more </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">143</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">than 5% of our capital stock, or any member of the immediate family of, or person sharing the household with, any of the foregoing persons, who had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other similar arrangements, which are described under &#8220;Executive and Director Compensation.&#8221;</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Debenture</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On January&#160;23, 2024, the Company issued a non<span class="nobreak">-convertible</span> debenture (the &#8220;Debenture&#8221;) in the principal sum of $5.0&#160;million, in connection with a Subscription Agreement, to Altos Ventures, a stockholder of the Company. The Debenture has an interest rate of 4.0% per annum, and the principal and accrued interest was to be payable in full upon the earlier of (i)&#160;the closing under the Subscription Agreement and (ii)&#160;June&#160;30, 2024. Additionally, the $5.0&#160;million subscription amount under the Subscription Agreement shall be increased by the amount of interest payable under the Debenture. On April<span class="nobreak"> </span>24, 2024, the Debenture was amended to extend the maturity date to the earlier of (i) the closing under the Subscription Agreement and (ii) October<span class="nobreak"> </span>31, 2024.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Related party advances</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December&#160;31, 2023, the Company&#8217;s Audit Committee completed a review of the Company&#8217;s expenses due to certain irregularities identified with regards to the related party balance. Based on the results of the review, it was determined that the Company paid and recorded within selling, general and administrative expenses, personal expenditures of the Company&#8217;s former CEO and an accounting employee who was also the former CEO&#8217;s assistant, during 2022 and during the first three quarters of 2023. The Company evaluated the receivable, which aggregated to approximately $522,000 as of September&#160;30, 2023, and which represented the total of the items identified as personal in nature for which the Company did not anticipate recovery from the related party. As the Company concluded that the remaining amounts are not likely to be recovered, this would not cause an adjustment to previously issued financial statements. The Company recorded a corresponding reserve for the full amount, resulting in a net related party receivable balance of $0 and a loss on related party receivable of approximately $266,000, which was recorded in selling, general, and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2023. During the fourth quarter of 2023, the Company recorded a recovery of approximately $159,000 with respect to amounts that the former CEO agreed to repay the Company, through a reduction of amounts that were due to him from the Company under his indemnification rights pursuant to his employment agreement.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Lease Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;28, 2022, the Company entered into a short<span class="nobreak">-term</span> lease in Palm Beach, Florida with an unrelated party, with a commencement date of May&#160;1, 2022, for approximately $14,000 per month. The lease, which was personally guaranteed by the Company&#8217;s former Chief Executive Officer, ended on April&#160;30, 2023. During the&#160;years ended December&#160;31, 2023, and 2022, the Company incurred rent expense on this lease of approximately $51,000 and $129,000, respectively, and variable lease expense of approximately $4,000 and $12,000, respectively.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Consulting Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;6, 2024, the Company appointed Thomas Meier, PhD, as a member of the Company&#8217;s board of directors. Dr.&#160;Meier provides consulting services to Proteomedix, through a consulting agreement that was effective January&#160;4, 2024.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Director Independence</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Board has evaluated each of its directors&#8217; independence from the Company based on the definition of &#8220;independence&#8221; established by Nasdaq and has determined that each of Simon Tarsh, Timothy Ramdeen, James Sapirstein and Ajit Singh are independent directors, constituting a majority of the Board. The Board has further determined that each member of our Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee is &#8220;independent&#8221; under applicable Nasdaq rules.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Board has also determined that each member of our audit committee is &#8220;independent&#8221; for purposes the Exchange&#160;Act.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">144</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In its evaluation of each director&#8217;s or nominee&#8217;s independence from the Company, the Board reviewed whether any transactions or relationships currently exist or existed during the past year between each director or nominee and the Company and its subsidiaries, affiliates, equity investors, or independent registered public accounting firm, and whether there were any transactions or relationships between each director or nominee and members of the senior management of the Company or their affiliates.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Principal Accounting Fees and Services.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Audit and Non-Audit Fees</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">EisnerAmper served as the independent registered public accounting firm to audit our books and accounts for the fiscal year ended December&#160;31, 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Mayer Hoffman McCann P.C. (&#8220;MHM&#8221;) served as the independent registered public accounting firm to audit our books and accounts for the fiscal year ended December&#160;31, 2022. Substantially all of MHM&#8217;s personnel, who work under the control of MHM shareholders, are employees of wholly owned subsidiaries of CBIZ, Inc., which provides personnel and various services to MHM in an alternative practice structure.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The table below presents the aggregate fees billed for professional services rendered by EisnerAmper for the year ended December&#160;31, 2023.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Audit fees</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">778,568</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Audit-related fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tax fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">All other fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">778,568</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In the above table, &#8220;audit fees&#8221; are fees billed for services provided related to the audit of our annual consolidated financial statements, quarterly reviews of our interim condensed financial statements, and services normally provided by EisnerAmper in connection with regulatory filings or engagements for that fiscal period.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The table below presents the aggregate fees billed for professional services rendered by MHM for the&#160;years ended December&#160;31, 2023 and 2022.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 73.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.80%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 73.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Audit fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">208,426</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">633,629</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 73.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Audit-related fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 73.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tax fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,889</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,975</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 73.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">All other fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.81%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.09%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 73.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.81%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">220,315</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.09%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">643,604</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In the above table, &#8220;audit fees&#8221; are fees billed for services provided related to the audit of our annual financial statements, quarterly reviews of our interim condensed financial statements, and services normally provided by MHM in connection with regulatory filings or engagements for those fiscal periods. &#8220;Tax fees&#8221; consist of amounts billed by an associated entity of MHM for services in connection with the preparation of our federal and state tax returns.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Pre-Approval Policy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">It is the Audit Committee&#8217;s policy to approve in advance the types and amounts of audit, audit<span class="nobreak">-related</span>, tax, and any other services to be provided by our independent registered public accounting firm. In situations where it is not practicable to obtain full Audit Committee approval, the Audit Committee has delegated authority to the Chair of the Audit Committee to grant pre<span class="nobreak">-approval</span> of audit and permissible non<span class="nobreak">-audit</span> services and any associated fees. Any pre<span class="nobreak">-approved</span> decisions by the Chair are required to be reviewed with the Audit Committee at its next scheduled meeting.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Our Audit Committee was formed upon the consummation of our initial public offering. As a result, the audit committee did not pre<span class="nobreak">-approve</span> all of the foregoing services, although any services rendered prior to the formation of our audit committee were approved by our board of directors. Since the formation of our Audit Committee, and on a going<span class="nobreak">-forward</span> basis, the Audit Committee has and will pre<span class="nobreak">-approve</span> all auditing services and permitted non<span class="nobreak">-audit</span> services to be performed for us by our auditors, including the fees and terms thereof (subject to the de minimis exceptions for non<span class="nobreak">-audit</span> services described in the Exchange&#160;Act which are approved by the audit committee prior to the completion of the audit).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">145</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T99503"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Related Person Transaction Approval Policy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">All transactions since our initial public offering between us and our officers, directors or five percent stockholders, and respective affiliates have been and will be on terms no less favorable than could be obtained from unaffiliated third parties and have been and will be approved by a majority of our independent directors who do not have an interest in the transactions and who had access, at our expense, to our legal counsel or independent legal counsel.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">To the best of our knowledge, during the past two fiscal&#160;years, other than as set forth below, there were no material transactions, or series of similar transactions, or any currently proposed transactions, or series of similar transactions, to which we were or are to be a party, in which (i)&#160;the amount involved exceeded or will exceed the lesser of $120,000 of one percent (1%) of our average total assets at year<span class="nobreak">-end</span>&#160;for the last two completed fiscal&#160;years and (ii)&#160;any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of, or person sharing the household with, any of the foregoing persons, who had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other similar arrangements, which are described under &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Executive Compensation</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Director Compensation</span>.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company originally engaged the former CEO, who was also the Board Chairman and prior to the close of the IPO, sole common stockholder of the Company, pursuant to a consulting agreement commencing October<span class="nobreak"> </span>22, 2018, which called for the Company to pay for consulting services performed on a monthly basis. Upon the close of the Company&#8217;s IPO, the consulting agreement was terminated, and the former CEO&#8217;s employment agreement became effective. During the year ended December<span class="nobreak"> </span>31, 2022, the Company incurred approximately $63,000 in fees under the consulting agreement, which are recognized in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During 2022 the Company entered into a lease agreement that was personally guaranteed by the Company&#8217;s former CEO. The lease expired in 2023. </p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December<span class="nobreak"> </span>31, 2022, the Company&#8217;s compensation committee approved one<span class="nobreak">-time</span> bonus awards of $140,000 and $100,000 to the Company&#8217;s former CEO and former CBO, respectively, in recognition of their efforts in connection with the Company&#8217;s IPO. These bonuses were recognized during the year ended December<span class="nobreak"> </span>31, 2022, as selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December<span class="nobreak"> </span>31, 2023, the Company&#8217;s Audit Committee completed a review of the Company&#8217;s expenses due to certain irregularities identified with regards to the related party balance. Based on the results of the review, it was determined that the Company paid and recorded within selling, general and administrative expenses, personal expenditures of the Company&#8217;s former CEO and an accounting employee who was also the former CEO&#8217;s assistant, during 2022 and during the first three quarters of 2023. The Company evaluated the receivable, which aggregated to approximately $522,000 as of September<span class="nobreak"> </span>30, 2023, and which represented the total of the items identified as personal in nature for which the Company did not anticipate recovery from the related party. As the Company concluded that the remaining amounts are not likely to be recovered, this would not cause an adjustment to previously issued financial statements. The Company recorded a corresponding reserve for the full amount, resulting in a net related party receivable balance of $0 and a loss on related party receivable of approximately $266,000, which was recorded in selling, general, and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss for the year ended December<span class="nobreak"> </span>31, 2023. During the fourth quarter of 2023, the Company recorded a recovery of approximately $159,000 with respect to amounts that the former CEO agreed to repay the Company, through a reduction of amounts that were due to him from the Company under his indemnification rights pursuant to his employment agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December<span class="nobreak"> </span>31, 2022, the Company had a receivable from related party of approximately $36,000, consisting of miscellaneous payments made by the Company on the behalf of the Company&#8217;s CEO, and which was paid in full during the first quarter of 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">146</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December<span class="nobreak"> </span>18, 2023, the Company entered into the Subscription Agreement with the PMX Investor, a 5% stockholder of the Company as of December<span class="nobreak"> </span>31, 2023. Subsequent to December<span class="nobreak"> </span>31, 2023, the Company issued a non<span class="nobreak">-convertible</span> debenture in the principal amount of $5.0<span class="nobreak"> </span>million to the PMX Investor, in connection with the Subscription Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A former director of the Company, who served on the Company&#8217;s Scientific Advisory Board until August&#160;2023, serves on the Advisory Board for the Cincinnati Children&#8217;s Hospital Medical Center Innovation Fund, which is affiliated with CHMC. The Company has an exclusive license agreement with CHMC. This director resigned from the Company&#8217;s board upon the close of its IPO.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">147</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T7"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">DESCRIPTION OF CAPITAL STOCK</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our Amended and Restated Certificate of Incorporation authorizes the issuance of up to 250,000,000<span class="nobreak"> </span>shares of common stock, $0.00001 par value per share, and 10,000,000<span class="nobreak"> </span>shares of preferred stock, $0.00001 par value per share. As of the date of this prospectus, we have 22,841,975 and 22,327,701<span class="nobreak"> </span>shares of common stock issued and outstanding, respectively, and 2,699,729<span class="nobreak"> </span>shares of preferred stock issued and outstanding. Our shares of common stock are held of record by approximately 39 stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;ONCO.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of our Amended and Restated Certificate of Incorporation, holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. The holders of outstanding shares of common stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends of such times and in such amounts as our Board from time to time may determine. Our common stock is not entitled to pre<span class="nobreak">-emptive</span> rights and is not subject to conversion or redemption. Upon liquidation, dissolution or winding up of our company, the assets legally available for distribution to stockholders are distributable ratably among the holders of our common stock after payment of liquidation preferences, if any, on any outstanding payment of other claims of creditors. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of our Amended and Restated Certificate of Incorporation,&#160;our Board is authorized, without further action by the stockholders, to establish one or more class or series, and fix the relative rights and preferences of the company&#8217;s undesignated capital stock.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Series&#160;A Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The terms of the Series&#160;A Convertible Preferred Stock are set forth in the Series&#160;A Certificate of Designation which was filed with the State of Delaware on September&#160;29, 2023. Pursuant to the Series&#160;A Certificate of Designation, each share of Series&#160;A Preferred Stock is convertible by Veru at any time and from time to time from and after one year from the date of issuance of the Series&#160;A Preferred Stock into that number of shares of the Company&#8217;s Common Stock determined by dividing the Stated Value (as defined in the Series&#160;A Certificate of Designation) of $1,000 per share by the Conversion Price (as defined in the Series&#160;A Certificate of Designation) of $0.5254 per share, subject to adjustment as provided in the Series&#160;A Certificate of Designation, subject to certain shareholder approval limitations. The Series&#160;A Preferred Stock is entitled to share ratably in any dividends paid on the Company&#8217;s Common Stock (on an as<span class="nobreak">-if-converted-to-common-stock</span> basis), has no voting rights except as to certain significant matters specified in the Series&#160;A Certificate of Designation, and has a liquidation preference equal to the Stated Value of $1,000 per share plus any accrued but unpaid dividends thereon. The Series&#160;A Preferred Stock is redeemable in whole or in part at the Company&#8217;s option at any time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Series&#160;A Preferred Stock issued to Veru is initially convertible, in the aggregate, into approximately 5,709,935<span class="nobreak"> </span>shares of the Company&#8217;s common stock, subject to adjustment and certain shareholder approval limitations specified in the Series&#160;A Certificate of Designation. Pursuant to the Amendment, the Company agreed to use commercially reasonable efforts to obtain such shareholder approval by December&#160;31, 2023. As of April<span class="nobreak"> </span>24, 2024, such shareholder approval has not been obtained. The Company also agreed to include the shares of Common Stock issuable upon conversion of the Series&#160;A Preferred Stock in the next resale registration statement filed with the SEC.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">148</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Series&#160;B Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Upon Stockholder Approval, each share of Series&#160;B Convertible Preferred Stock shall automatically convert into 100<span class="nobreak"> </span>shares of Buyer Common Stock in accordance with the terms of the Series&#160;B Certificate of Designation. If Stockholder Approval is not obtained by January&#160;1, 2025, the Company shall be obligated to cash settle the Series&#160;B Convertible Preferred Stock, as described below. The terms of the&#160;Series&#160;B Convertible Preferred Stock, as described in the Series&#160;B Certificate of Designation,&#160;are as follows:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Voting.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The shares of&#160;Series&#160;B Convertible Preferred Stock&#160;carry no voting rights except: (i)&#160;with respect to the election of the Proteomedix Director and (ii)&#160;that&#160;the affirmative vote of the Majority Holders acting as a single class, shall be necessary to (A)&#160;alter or change adversely the powers, preferences or rights given to the Series&#160;B Convertible Preferred Stock, (B)&#160;alter or amend the Series&#160;B Certificate of Designation, or amend or repeal any provision of, or add any provision to, the Company&#8217;s Amended and Restated Certificate of Incorporation or bylaws, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the&#160;Series&#160;B Convertible&#160;Preferred Stock, (C)&#160;issue further shares of Series&#160;B Convertible Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series&#160;B Convertible Preferred Stock, or (D)&#160;authorize or create any class or series of stock, or issue shares of any class or series of stock, that has powers, preferences or rights senior to the Series&#160;B Convertible Preferred Stock</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Proteomedix Director.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The Majority Holders, voting exclusively and as a separate class, shall be entitled to elect one (1)&#160;director of Onconetix. Any director elected as provided in the preceding sentence may be removed without cause by, and only by, the affirmative vote of the holders of the Series&#160;B Convertible Preferred Stock. If the holders of Series&#160;B Convertible Preferred Stock fail to elect a director, then any directorship not so filled shall remain vacant until such time as the holders of the Series&#160;B Convertible Preferred Stock elect a person to fill such directorship; and no such directorship may be filled by stockholders of Onconetix other than by the holders of Series&#160;B Convertible Preferred Stock. At any meeting held for the purpose of electing a director, the presence in person or by proxy of the holders of a majority of the outstanding shares of Series&#160;B Convertible Preferred Stock shall constitute a quorum for the purpose of electing such director.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Redemption.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The shares of Series&#160;B Convertible Preferred Stock are not redeemable by the Company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Liquidation Preference.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Upon a Liquidation, the holders of Series&#160;B Convertible Preferred Stock shall be entitled to receive out of the assets, whether capital or surplus, of Onconetix the same amount that a holder of Buyer Common Stock would receive if such Holder&#8217;s Series&#160;B Convertible Preferred Stock were fully converted to Buyer Common Stock at the Conversion Ratio (as defined below) plus an additional amount equal to any dividends declared but unpaid to such shares, which amounts shall be paid&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">pari passu </span>with all holders of Buyer Common Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Dividends.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The holders of the Series&#160;B Convertible Preferred Stock shall be entitled to receive, dividends on shares of Series&#160;B Convertible Preferred Stock (on an as<span class="nobreak">-if-converted-to-common-stock</span> basis) equal to and in the same form, and in the same manner, as dividends (other than dividends on shares of the Buyer Common Stock payable in the form of Buyer Common Stock) actually paid on shares of the Buyer Common Stock when, as and if such dividends (other than dividends payable in the form of Buyer Common Stock) are paid on shares of the Buyer Common Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Conversion.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Following Stockholder Approval, each share of Series&#160;B Convertible Preferred Stock shall be converted into Conversion Shares at a ratio of 100 Conversion Shares for each share of Series&#160;B Convertible Preferred Stock. All shares of Series&#160;B Convertible Preferred Stock shall automatically and without any further action required be converted into Conversion Shares at the Conversion Ratio upon the latest date on which (i)&#160;Onconetix has received the Stockholder Approval with respect to the issuance of all of the shares of Buyer Common Stock issuable upon Conversion in excess of 20% of the issued and outstanding Buyer Common Stock on the WraSer Closing Date and (ii)&#160;the Company has effected an increase in the number of shares of Buyer Common Stock authorized under its Amended and Restated Certificate of Incorporation, to the extent required to consummate the Transactions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Cash Settlement.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>If, at any time after the earlier of the date of the Stockholder Approval or January&#160;1, 2025, the Company (x)&#160;has obtained the Stockholder Approval but fails to or has failed to deliver to a holder certificate or certificates representing the Conversion Shares, or deliver documentation of book entry form of (or cause its transfer agent to electronically deliver such evidence) Conversion Shares on or prior to the fifth business&#160;day after the date of the Stockholder Approval, or (y)&#160;has failed to obtain the Stockholder Approval, the Company shall, in either case, at the request of the holder setting forth such holder&#8217;s request to cash settle a number of shares of Series&#160;B Convertible </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">149</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Preferred Stock, pay to such holder an amount in cash equal to (i)&#160;the Fair Value (as defined below) of the shares of Series&#160;B Convertible Preferred Stock set forth in such request multiplied by (ii)&#160;the Conversion Ratio in effect on the&#160;trading day on which the request is delivered to the Company, with such payment to be made within two (2)&#160;business days from the date of the request by the holder, whereupon, after payment in full thereon by the Company, the Company&#8217;s obligations to deliver such shares underlying the request shall be extinguished. &#8220;Fair Value&#8221; of shares shall be fixed with reference to the last reported closing stock price on the principal trading market of the Buyer Common Stock on which the Buyer Common Stock is listed as of the&#160;trading day on which the request is delivered to Onconetix.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Certain Adjustments.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>If the Company, at any time while the&#160;Series&#160;B Convertible Preferred Stock is outstanding: (A)&#160;pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Buyer Common Stock; (B)&#160;subdivides outstanding shares of Buyer Common Stock into a larger number of shares; or (C)&#160;combines (including by way of a reverse stock split) outstanding shares of Buyer Common Stock into a smaller number of shares, then the Conversion Ratio shall be multiplied by a fraction of which the numerator shall be the number of shares of Buyer Common Stock outstanding immediately after such event and of which the denominator shall be the number of shares of Buyer Common Stock outstanding immediately before such event (excluding any treasury shares of the Corporation). If, at any time while the&#160;Series&#160;B Convertible Preferred Stock is outstanding, either (A)&#160;Onconetix effects any merger or consolidation of Onconetix with or into another person or any stock sale to, or other business combination with or into another person (other than such a transaction in which Onconetix is the surviving or continuing entity and holds at least a majority of the Buyer Common Stock after giving effect to the transaction and its Buyer Common Stock is not exchanged for or converted into other securities, cash or property), (B)&#160;Onconetix effects any sale, lease, transfer or exclusive license of all or substantially all of its assets in one transaction or a series of related transactions, (C)&#160;any tender offer or exchange offer (whether by Onconetix or another person) is completed pursuant to which more than 50% of the Buyer Common Stock not held by Onconetix or such person is exchanged for or converted into other securities, cash or property, or (D)&#160;Onconetix effects any reclassification of the Buyer Common Stock or any compulsory share exchange pursuant to which the Buyer Common Stock is effectively converted into or exchanged for other securities, cash or property, then, in connection with such Fundamental Transaction, the holders of Series&#160;B Convertible Preferred Stock shall receive in the Fundamental Transaction, the same kind and amount of securities, cash or property that a holder of Buyer Common Stock would receive if such holder&#8217;s Series&#160;B Convertible Preferred Stock were fully converted to Buyer Common Stock, plus an additional amount equal to any dividends declared but unpaid to such shares, which amounts shall be paid&#160;pari passu&#160;with all holders of Buyer Common Stock in the Fundamental Transaction. If holders of Buyer Common Stock are given any choice as to the securities, cash or&#160;property to be received in a Fundamental Transaction, then the holders of Series&#160;B Convertible Preferred Stock shall be given the same choice as to the Alternate Consideration it receives in such Fundamental Transaction.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Anti-Takeover Effects of Delaware Law and Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Some provisions of Delaware law, our Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our Board. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Delaware Anti-Takeover Statute</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We are subject to Section&#160;203 of the General Corporation Law of the State of Delaware, which prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three&#160;years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three&#160;years prior to the determination of interested stockholder status </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">150</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti<span class="nobreak">-takeover</span> effect with respect to transactions not approved in advance by the Board.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Choice of Forum</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our Amended and Restated Certificate of Incorporation provides that, unless we consent in writing to an alternative forum, to the fullest extent permitted by law, that derivative actions brought in our name, actions against directors, officers and employees for breach of fiduciary duty and certain other actions may be brought only in the Court of Chancery in the State of Delaware, except any action (A)&#160;as to which the Court of Chancery in the State of Delaware determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten&#160;days following such determination), (B)&#160;which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery or (C)&#160;for which the Court of Chancery does not have subject matter jurisdiction. If an action is brought outside of Delaware, the stockholder bringing the suit will be deemed to have consented to service of process on such stockholder&#8217;s counsel. Although we believe this provision benefits us by providing increased consistency in the application of law in the types of lawsuits to which it applies, a court may determine that this provision is unenforceable, and to the extent it is enforceable, the provision may have the effect of discouraging lawsuits against our directors and officers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our Amended and Restated Certificate of Incorporation provides that the exclusive forum provision will be applicable to the fullest extent permitted by applicable law, subject to certain exceptions. Section&#160;27 of the Exchange&#160;Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange&#160;Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange&#160;Act or any other claim for which the federal courts have exclusive jurisdiction. In addition, our Amended and Restated Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United&#160;States of America shall, to the fullest extent permitted by law, be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act or the rules and regulations promulgated thereunder. We note, however, that there is uncertainty as to whether a court would enforce this provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Section&#160;22 of the Securities Act creates concurrent jurisdiction for state and federal courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Transfer Agent and Registrar</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The transfer agent and registrar for our common stock is Continental Stock Transfer&#160;&amp; Trust Company. The Transfer Agent&#8217;s address is 1 State Street, 30<span class="Superscript" style="vertical-align:super;font-size:58%;">th</span>&#160;Floor, New&#160;York, New&#160;York 10004.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Listing</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our common stock is traded on The Nasdaq Capital Market under the trading symbol &#8220;ONCO.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Elimination of Monetary Liability for Officers and Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our Amended and Restated Certificate of Incorporation incorporates certain provisions permitted under the Delaware General Corporation Law (&#8220;DGCL&#8221;) relating to the liability of directors. The provisions eliminate a director&#8217;s liability for monetary damages for a breach of fiduciary duty, including gross negligence, except in circumstances involving certain wrongful acts, such as the breach of director&#8217;s duty of loyalty or acts or omissions, which involve intentional misconduct or a knowing violation of law. These provisions do not eliminate a director&#8217;s duty of care. Moreover, these provisions do not apply to claims against a director for certain violations of law, including knowing violations of federal securities law. Our Amended and Restated Certificate of Incorporation also contains provisions to indemnify the directors, officers, employees or other agents to the fullest extent permitted by the DGCL.&#160;We believe that these provisions will assist us in attracting and retaining qualified individual to serve as directors.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">151</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Indemnification of Officers and Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our Amended and Restated Certificate of Incorporation also contains provisions to indemnify the directors, officers, employees or other agents to the fullest extent permitted by the DGCL.&#160;These provisions may have the practical effect in certain cases of eliminating the ability of stockholders to collect monetary damages from directors. We are also a party to indemnification agreements with each of our directors. We believe that these provisions will assist us in attracting or retaining qualified individuals to serve as our directors.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">152</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T6"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">SELLING STOCKHOLDERS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7.2pt;">The shares of Common Stock being offered by the Selling Stockholders are those previously issued to the Selling Stockholders, and those issuable to the Selling Stockholders, upon exercise of the PIOs. For additional information regarding the shares of common stock issuable upon the exercise of PIOs, see &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Warrant Inducement and Private Placement</span>&#8221; above. We are registering the shares of Common Stock in order to permit the Selling Stockholders to offer the shares for resale from time to time. Except for the ownership of the shares of Common Stock underlying the PIOs, the Selling Stockholders have not had any material relationship with us within the past three&#160;years; <span class="Italic" style="font-style:italic;font-weight:normal;">provided, however,</span> each of Michael Vasinkevich, Noam Rubinstein, Craig Schwabe and Charles Worthman are associated persons of Wainwright, which served as our placement agent in connection with the Private Placements for which Wainwright received compensation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7.2pt;">The table below lists the Selling Stockholders and other information regarding the beneficial ownership of the shares of Common Stock by each of the Selling Stockholders. The second column lists the number of shares of Common Stock beneficially owned by each Selling Stockholder, based on its ownership of the shares of Common Stock, PIOs, as of April<span class="nobreak"> </span>1, 2024, assuming exercise of the PIOs held by the Selling Stockholders on that date, without regard to any limitations on exercises.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7.2pt;">The third column lists the shares of Common Stock being offered by this prospectus by the Selling Stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7.2pt;">The fourth column assumes the sale of all of the shares offered by the Selling Stockholders pursuant to this prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7.2pt;">Under the terms of the PIOs held by Selling Stockholders, a Selling Stockholder may not exercise the PIOs to the extent such exercise would cause such Selling Stockholder, together with its affiliates and attribution parties, to beneficially own a number of shares of Common Stock which would exceed 4.99% or 9.99%, as applicable, of our then outstanding Common Stock following such exercise, excluding for purposes of such determination shares of Common Stock issuable upon exercise of such PIOs which have not been exercised. The number of shares in the second and fourth columns do not reflect this limitation. The Selling Stockholders may sell all, some or none of their shares in this offering. See &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Plan of Distribution</span>.&#8221;</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Name of Selling Shareholder</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>shares&#160;of <br/>Common <br/>Stock <br/>Beneficially <br/>Owned <br/>Prior&#160;to <br/>Offering</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Maximum <br/>Number&#160;of <br/>shares&#160;of <br/>Common <br/>Stock <br/>to&#160;be&#160;Sold <br/>Pursuant&#160;to <br/>this&#160;Prospectus</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>shares&#160;of <br/>Common <br/>Stock <br/>Beneficially <br/>Owned <br/>After <br/>Offering</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Percentage&#160;of <br/>shares&#160;of <br/>Common <br/>Stock <br/>Beneficially <br/>Owned <br/>After <br/>Offering</span><span class="CharOverride-2" style="font-size:58%;font-style:normal;font-weight:bold;vertical-align:super;">(1)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Sabby Volatility Warrant Master Fund,<br/>Ltd.<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Superscript" style="vertical-align:super;">2,486,214</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,486,214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Armistice Capital, LLC<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,972,428</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,972,428</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Michael Vasinkevich</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">237,371</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(6)(10)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">237,371</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Noam Rubinstein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">116,603</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(7)(10)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">116,603</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Craig Schwave</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12,494</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(8)(10)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12,494</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Charles Worthman</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,702</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(9)(10)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,702</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Based on 22,327,701<span class="nobreak"> </span>shares outstanding as of April 1, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The securities are directly held by Sabby Volatility Warrant Master Fund, Ltd, a Cayman Islands exempted company (&#8220;Sabby&#8221;) and may be deemed to be beneficially owned by: (i) Sabby Management, LLC, as investment manager of Sabby and (ii) Hal Mintz, as manager of Sabby Management, LLC. The address of Sabby is Governors Square, Bldg 4, 2<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">nd</span> Floor, 23 Lime Tree Bay Avenue, P.O. Box 32315, Grand Cayman KY1<span class="nobreak">-1209</span>, Cayman Islands. Each of Sabby Management, LLC and Hal Mintz disclaims beneficial ownership over the securities listed except to the extent of their pecuniary interest therein.  The address of Sabby Volatility Warrant Master Fund, Ltd. is Captiva (Cayman) Ltd, Governors Square, Bldg 4, 2<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">nd</span> Floor, 23 Lime Tree Bay Avenue, P.O. Box 32315, Grand Cayman KY1<span class="nobreak">-1209</span>, Cayman Islands.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">153</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 2,486,214<span class="nobreak"> </span>shares of Common Stock underlying Sabby PIOs. The aforementioned Sabby PIOs are subject to certain beneficial ownership limitations that prohibit the holder from exercising any portion of them if such exercise would result in the holder owning a percentage of our outstanding common stock exceeding the applicable ownership limitation after giving effect to the issuance of Common Stock in connection with the holder&#8217;s exercise of any portion of a Sabby PIO.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The securities are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company, and may be deemed to be beneficially owned by: (i)&#160;Armistice Capital, LLC (&#8220;Armistice Capital&#8221;), as the investment manager of Armistice; and (ii)&#160;Steven Boyd, as the Managing Member of Armistice Capital. The address of Armistice Capital Master Fund Ltd. is c/o Armistice Capital, LLC, 510 Madison Avenue, 7<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">th</span> Floor, New&#160;York, NY&#160;10022.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 4,972,428<span class="nobreak"> </span>shares of Common Stock underlying Inducement PIOs. The aforementioned Inducement PIOs are subject to certain beneficial ownership limitations that prohibit Armistice from exercising any portion of them if such exercise would result in Armistice owning a percentage of our outstanding common stock exceeding the applicable ownership limitation after giving effect to the issuance of Common Stock in connection with Armistice&#8217;s exercise of any portion of an Inducement PIO.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(6)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of (i) 95,657<span class="nobreak"> </span>shares of Common Stock underlying Placement Agent Inducement PIOs issued on August&#160;2, 2023 and (ii) 141,714 shares of Common Stock underlying Placement Agent Inducement PIOs issued on August 11, 2022.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(7)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 46,989<span class="nobreak"> </span>shares of Common Stock underlying Placement Agent Inducement PIOs issued on August&#160;2, 2023 and (ii) 69,614 shares of Common Stock underlying Placement Agent Inducement PIOs issued on August 11, 2022.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(8)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 5,035<span class="nobreak"> </span>shares of Common Stock underlying Placement Agent Inducement PIOs issued on August&#160;2, 2023 and (ii) 7,459 shares of Common Stock underlying Placement Agent Inducement PIOs issued on August 11, 2022. </p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(9)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 1,492<span class="nobreak"> </span>shares of Common Stock underlying Placement Agent Inducement PIOs issued on August&#160;2, 2023 and (ii) 2,210 shares of Common Stock underlying Placement Agent Inducement PIOs issued on August 11, 2022.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(10)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Each of the Selling Stockholders is affiliated with H.C. Wainwright &amp; Co., LLC, a registered broker dealer with a registered address of H.C. Wainwright &amp; Co., LLC, 430 Park Ave, 3<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">rd</span> Floor, New York, NY 10022, and has sole voting and dispositive power over the securities held. The number of shares beneficially owned prior to this offering consist of shares of common stock issuable upon exercise of the Placement Agent Inducement PIOs and August 2022 Wainwright Warrants, which were received as compensation in connection with our prior offerings consummated in August 2023 and August 2022, respectively. The Selling Stockholder acquired the placement agent warrants in the ordinary course of business and, at the time the Inducement PIOs and August 2022 Wainwright Warrants were acquired, the Selling Stockholder had no agreement or understanding, directly or indirectly, with any person to distribute such securities.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">154</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T5"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PLAN OF DISTRIBUTION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Each Selling Stockholder of the securities and any of their pledgees, assignees and successors<span class="nobreak">-in-interest</span> may, from time to time, sell any or all of their securities covered hereby on the principal trading market or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods when selling securities:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ordinary brokerage transactions and transactions in which the broker<span class="nobreak">-dealer</span> solicits purchasers;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>block trades in which the broker<span class="nobreak">-dealer</span> will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>purchases by a broker<span class="nobreak">-dealer</span> as principal and resale by the broker<span class="nobreak">-dealer</span> for its account;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an exchange distribution in accordance with the rules of the applicable exchange;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>privately negotiated transactions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>settlement of short sales;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>in transactions through broker<span class="nobreak">-dealers</span> that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a combination of any such methods of sale; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any other method permitted pursuant to applicable law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Selling Stockholders may also sell securities under Rule&#160;144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Broker<span class="nobreak">-dealers</span> engaged by the Selling Stockholders may arrange for other brokers<span class="nobreak">-dealers</span> to participate in sales. Broker<span class="nobreak">-dealers</span> may receive commissions or discounts from the Selling Stockholders (or, if any broker<span class="nobreak">-dealer</span> acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) Rule&#160;2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule&#160;2121.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker<span class="nobreak">-dealers</span> or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker<span class="nobreak">-dealers</span> that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker<span class="nobreak">-dealers</span> or other financial institutions or create one or more derivative securities which require the delivery to such broker<span class="nobreak">-dealer</span> or other financial institution of securities offered by this prospectus, which securities such broker<span class="nobreak">-dealer</span> or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Selling Stockholders and any broker<span class="nobreak">-dealers</span> or agents that are involved in selling the securities may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker<span class="nobreak">-dealers</span> or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">155</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We agreed to keep this prospectus effective until the earlier of (i)&#160;the date on which the securities may be resold by the Selling Stockholders without registration and without regard to any volume or manner<span class="nobreak">-of-sale</span> limitations by reason of Rule&#160;144 under the Securities Act, without the requirement for the Company to be in compliance with the current public information under Rule&#160;144 under the Securities Act or any other rule of similar effect or (ii)&#160;all of the securities have been sold pursuant to this prospectus or Rule&#160;144 under the Securities Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Under applicable rules and regulations under the Exchange&#160;Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation&#160;M, prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange&#160;Act and the rules and regulations thereunder, including Regulation&#160;M, which may limit the timing of purchases and sales of the Common Stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule&#160;172 under the Securities Act).</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">156</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T4"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">EXPERTS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The consolidated balance sheet of Onconetix, Inc. and Subsidiary as of December<span class="nobreak"> </span>31, 2023, and the related consolidated statements of operations and comprehensive loss, convertible redeemable preferred stock and stockholders&#8217; equity (deficit), and cash flows for the year then ended, have been audited by EisnerAmper LLP, independent registered public accounting firm, as stated in their report which is included herein, which report includes an explanatory paragraph about the existence of substantial doubt concerning the Company&#8217;s ability to continue as a going concern. Such financial statements have been included in reliance on the report of such firm given upon their authority as experts in accounting and auditing. </p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The consolidated financial statements of Onconetix, Inc., formerly known as Blue Water Vaccines Inc., as of and for the year ended December<span class="nobreak"> </span>31, 2022, appearing in this prospectus, have been audited by Mayer Hoffman McCann P.C., independent registered public accounting firm, as set forth in their report, appearing elsewhere herein, and have been included in reliance upon such report given on the authority of such firm as experts in accounting and auditing, in giving said reports.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The financial statements of Proteomedix AG as of December<span class="nobreak"> </span>31, 2022, and 2021 and for each of the two years in the period ended December<span class="nobreak"> </span>31, 2022, included in this Prospectus and in the Registration Statement have been so included in reliance on the report of BDO AG, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. The report on the financial statements contains an explanatory paragraph regarding Proteomedix AG&#8217;s ability to continue as a going concern. </p>
		<a id="T3"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">LEGAL MATTERS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Ellenoff Grossman&#160;&amp; Schole LLP, New&#160;York, New&#160;York, will pass upon the validity of the securities offered hereby.</p>
		<a id="T2"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">WHERE YOU CAN FIND MORE INFORMATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We are subject to the informational requirements of the Exchange&#160;Act and, in accordance therewith, file annual, quarterly and current reports, proxy statements and other information with the SEC.&#160;Our SEC filings are available to the public over the Internet at the SEC&#8217;s website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.sec.gov</span>. Copies of certain information filed by us with the SEC are also available on our website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.onconetix.com</span>. Our website is not a part of this prospectus and is not incorporated by reference in this prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">This prospectus is part of a registration statement we filed with the SEC.&#160;This prospectus omits some information contained in the registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information about us and our consolidated subsidiaries and the securities we are offering. Statements in this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should review the complete document to evaluate these statements.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">157</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T2001"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC. </span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Page</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Consolidated Financial Statements</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T601">Report of Independent Registered Public Accounting Firm (PCAOB ID&#160;274)</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;text-indent:0pt;">F-2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T602">Report of Independent Registered Public Accounting Firm (PCAOB ID&#160;199)</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;text-indent:0pt;">F-3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T603">Consolidated Balance Sheets as of December&#160;31, 2023 and 2022</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;text-indent:0pt;">F-4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T604">Consolidated Statements of Operations and Comprehensive Loss for the&#160;years ended December&#160;31, 2023 and 2022</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;text-indent:0pt;">F-6</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T605">Consolidated Statements of Convertible Redeemable Preferred Stock and Stockholders&#8217; Equity (Deficit) for the&#160;years ended December&#160;31, 2023 and 2022</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;text-indent:0pt;">F-7</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T606">Consolidated Statements of Cash Flows for the&#160;years ended December&#160;31, 2023 and 2022</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;text-indent:0pt;">F-8</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T901">Notes to Consolidated Financial Statements</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;text-indent:0pt;">F-10</p>
					</td>
				</tr>

		</table>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-variant:normal;text-transform:uppercase;">Proteomedix AG</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T607">Independent Auditors&#8217; Report</a></p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-58</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T608">Balance Sheets</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-59</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T609">Statements of Comprehensive Loss</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-60</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T610">Statement of Stockholders&#8217; Deficit</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-61</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T611">Statements of Cash Flows</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-62</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T612">Notes to Financial Statements</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-63</p>
					</td>
				</tr>

		</table>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T613">Condensed Balance Sheets (unaudited)</a></p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-80</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T614">Condensed Statements of Comprehensive Income (Loss) For the Nine&#160;Months Ended September&#160;30, 2023 and 2022 (unaudited)</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-81</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T615">Condensed Statement of Stockholders&#8217; Deficit For the Nine&#160;Months Ended September&#160;30, 2023 and 2022 <span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">(unaudited)</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-82</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T616">Condensed Statements of Cash Flows For the Nine&#160;Months Ended September&#160;30, 2023 and 2022 <span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">(unaudited)</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-83</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T617">Notes to Condensed Financial Statements</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-84</p>
					</td>
				</tr>

		</table>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T601"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-align:left;text-indent:0pt;margin-top:8pt;">To the Board of Directors and Stockholders of<br/>Onconetix, Inc.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Opinion on the Financial Statements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We have audited the accompanying consolidated balance sheet of Onconetix Inc. and Subsidiary (the &#8220;Company&#8221;) as of December&#160;31, 2023, and the related consolidated statements of operations and comprehensive loss, convertible redeemable preferred stock and stockholders&#8217; equity (deficit), and cash flows for the year then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December&#160;31, 2023, and the consolidated results of their operations and their cash flows for the year then ended, in conformity with accounting principles generally accepted in the United&#160;States of America.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Going Concern</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note&#160;2 to the financial statements, the Company has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future, which raises substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note&#160;2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Basis for Opinion</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United&#160;States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S.&#160;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We conducted our audit in accordance with the standards of the PCAOB.&#160;Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">/s/ EisnerAmper LLP</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">We have served as the Company&#8217;s auditor since 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-align:left;text-indent:0pt;margin-top:8pt;">EISNERAMPER LLP<br/>Iselin, New Jersey<br/>April&#160;11, 2024</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-align:left;text-indent:0pt;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T602"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-align:left;text-indent:0pt;margin-top:8pt;">To the Board of Directors<br/>and Stockholders of&#160;<span class="Bold" style="font-style:normal;font-weight:bold;">Onconetix, Inc.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Opinion on the Consolidated Financial Statements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We have audited the accompanying consolidated balance sheet of Onconetix, Inc. (formerly known as Blue Water Vaccines Inc.)(the &#8220;Company&#8221;) as of December&#160;31, 2022, and the related consolidated statements of operations and comprehensive loss, convertible redeemable preferred stock and stockholders&#8217; equity, and cash flows for the year then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2022, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United&#160;States of America.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Basis for Opinion</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United&#160;States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S.&#160;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We conducted our audit in accordance with the standards of the PCAOB.&#160;Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-align:left;text-indent:0pt;margin-top:8pt;">We served as the Company&#8217;s auditor from 2021 to 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-align:left;text-indent:0pt;margin-top:8pt;">/s/&#160;Mayer Hoffman McCann P.C.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-align:left;text-indent:0pt;margin-top:8pt;">Los Angeles, California<br/>March&#160;8, 2023</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-align:left;text-indent:0pt;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T603"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Consolidated Balance Sheets</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31, 2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31, 2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ASSETS</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-30538">4,554,335</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-30539">25,752,659</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts receivable, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-30540">149,731</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-1">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Inventories</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-30541">364,052</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-2">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid expenses and other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-30542">770,153</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-30543">469,232</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Receivable from related parties, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-3">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-30544">35,850</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-30545">5,838,271</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-30546">26,257,741</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid expenses, long-term</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="0" unitRef="usd" id="ixv-30547">17,423</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="0" unitRef="usd" id="ixv-30548">38,617</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-30549">60,654</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-30550">14,089</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred offering costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCosts" scale="0" unitRef="usd" id="ixv-30551">366,113</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-4">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating right of use asset</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-30552">148,542</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-5">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Intangible assets, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd" id="ixv-30553">25,410,887</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-6">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Goodwill</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="0" unitRef="usd" id="ixv-30554">55,676,142</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-7">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-30555">87,518,032</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-30556">26,310,447</ix:nonFraction></span></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd" id="ixv-30557">5,295,114</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd" id="ixv-30558">1,499,296</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-30559">2,199,867</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-30560">2,409,128</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Notes payable, net of debt discount of $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="onco:NotesPayableNetOfDebtDiscount" scale="0" unitRef="usd" id="ixv-30561"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="onco:NotesPayableNetOfDebtDiscount" scale="0" unitRef="usd" id="ixv-30562">381,627</ix:nonFraction></ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd" id="ixv-30563">9,618,373</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-8">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, current</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-30564">74,252</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-9">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contingent warrant liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-30565">2,641</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-30566">14,021</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-30567">17,190,247</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-30568">3,922,445</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Note payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermNotesPayable" scale="0" unitRef="usd" id="ixv-30569">118,857</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-10">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subscription agreement liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="onco:SubscriptionAgreementLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-30570">864,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-11">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pension benefit obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-30571">556,296</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-12">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-30572">74,290</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-13">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax liability, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="0" unitRef="usd" id="ixv-30573">3,073,781</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-14">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-30574">21,877,471</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-30575">3,922,445</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Commitments and Contingencies (see Note&#160;10)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-15">&#160;</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-16">&#160;</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;B Convertible Redeemable Preferred stock, $<ix:nonFraction contextRef="c5" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-30576"><ix:nonFraction contextRef="c6" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-30577">0.00001</ix:nonFraction></ix:nonFraction>&#160;par value,&#160;<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" unitRef="shares" id="ixv-30578">2,700,000</ix:nonFraction>&#160;and&#160;<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" unitRef="shares" id="ixv-30579"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" unitRef="shares" id="ixv-30580">0</ix:nonFraction></ix:nonFraction>&#160;shares authorized at December&#160;31, 2023 and 2022, respectively;&#160;<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" unitRef="shares" id="ixv-30581"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" unitRef="shares" id="ixv-30582">2,696,729</ix:nonFraction></ix:nonFraction>&#160;and&#160;<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" unitRef="shares" id="ixv-30583">0</ix:nonFraction>&#160;shares issued and outstanding at December&#160;31, 2023 and 2022, respectively</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" unitRef="usd" id="ixv-30584">64,236,085</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-17">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;orphans:99;widows:1;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Consolidated Balance Sheets&#160;&#8212;&#160;(Continued)</span></p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31, 2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31, 2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Stockholders&#8217; equity (deficit)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;A Convertible Preferred stock, $<ix:nonFraction contextRef="c7" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-30585"><ix:nonFraction contextRef="c8" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-30586">0.00001</ix:nonFraction></ix:nonFraction>&#160;par value,&#160;<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-30587">10,000</ix:nonFraction>&#160;and&#160;<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-30588"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-30589"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-30590">0</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares authorized at December&#160;31, 2023 and 2022, respectively;&#160;<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-30591"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-30592">3,000</ix:nonFraction></ix:nonFraction>&#160;and&#160;<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockLiquidationPreferenceValue" scale="0" unitRef="usd" id="ixv-30593">0</ix:nonFraction>&#160;shares issued and outstanding at December&#160;31, 2023 and 2022, respectively; Liquidation preference of $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockLiquidationPreferenceValue" scale="0" unitRef="usd" id="ixv-30594">3,000,000</ix:nonFraction>&#160;and $0 at December&#160;31, 2023 and 2022, respectively.</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-18">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-19">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock, $<ix:nonFraction contextRef="c1" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-30595"><ix:nonFraction contextRef="c2" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-30596">0.00001</ix:nonFraction></ix:nonFraction>&#160;par value,&#160;<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-30597"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-30598">250,000,000</ix:nonFraction></ix:nonFraction>&#160;shares authorized at December&#160;31, 2023 and 2022;&#160;<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-30599">22,841,975</ix:nonFraction>&#160;and&#160;<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-30600">15,724,957</ix:nonFraction>&#160;shares issued at December&#160;31, 2023 and 2022, respectively; <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-30601">22,324,576</ix:nonFraction> and&#160;<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-30602">15,265,228</ix:nonFraction>&#160;shares outstanding at December&#160;31, 2023 and 2022, respectively</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-30603">228</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-30604">157</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in-capital</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd" id="ixv-30605">49,428,809</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd" id="ixv-30606">42,331,155</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Treasury stock, at cost;&#160;<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" unitRef="shares" id="ixv-30607">517,399</ix:nonFraction>&#160;and&#160;<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" unitRef="shares" id="ixv-30608">459,729</ix:nonFraction>&#160;shares of common stock at December&#160;31, 2023 and 2022, respectively</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="0" unitRef="usd" id="ixv-30609">625,791</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="0" unitRef="usd" id="ixv-30610">566,810</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-30611">56,786,194</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-30612">19,376,500</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated other comprehensive income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd" id="ixv-30613">2,380,920</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-20">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total Onconetix stockholders&#8217; equity (deficit)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-30614">5,602,028</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-30615">22,388,002</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-controlling interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" unitRef="usd" id="ixv-30616">7,006,504</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-21">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total stockholders&#8217; equity</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-30617">1,404,476</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-30618">22,388,002</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total liabilities, convertible redeemable preferred stock, and stockholders&#8217; equity (deficit)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-30619">87,518,032</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-30620">26,310,447</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;text-align:center;margin-top:8pt;"></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;text-align:center;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T604"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Consolidated Statements of Operations and Comprehensive Loss</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Year Ended</span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Year Ended</span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Revenue</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-30621">58,465</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-22">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cost of revenue</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-30622">1,185,630</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-23">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Gross loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" sign="-" unitRef="usd" id="ixv-30623">1,127,165</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-24">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Selling, general and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-30624">14,770,678</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-30625">9,351,552</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-30626">1,949,406</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-30627">4,129,688</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Impairment of ENTADFI assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="0" unitRef="usd" id="ixv-30628">14,687,346</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-25">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Impairment of deposit on asset purchase agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetImpairmentCharges" scale="0" unitRef="usd" id="ixv-30629">3,500,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-26">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-30630">34,907,430</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-30631">13,481,240</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-30632">36,034,595</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-30633">13,481,240</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other income (expense)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss on extinguishment of note payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" sign="-" unitRef="usd" id="ixv-30634">490,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-27">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd" id="ixv-30635">671,625</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-28">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in fair value of subscription agreement liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:ChangeInFairValueOfSubscriptionAgreementLiability" scale="0" sign="-" unitRef="usd" id="ixv-30636">134,100</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-29">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in fair value of contingent warrant liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="0" sign="-" unitRef="usd" id="ixv-30637">91,967</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="0" unitRef="usd" id="ixv-30638">61,410</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other income (expense)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-30639">1,387,692</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-30640">61,410</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss before income taxes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="0" sign="-" unitRef="usd" id="ixv-30641">37,422,287</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="0" sign="-" unitRef="usd" id="ixv-30642">13,419,830</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd" id="ixv-30643">12,593</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-30">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net loss</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-30644">37,409,694</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-30645">13,419,830</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cumulative preferred stock dividends</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-31">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="0" unitRef="usd" id="ixv-30646">96,359</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss attributable to common stockholders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" sign="-" unitRef="usd" id="ixv-30647">37,409,694</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" sign="-" unitRef="usd" id="ixv-30648">13,516,189</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-33; -sec-ix-hidden: hidden-fact-32">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share attributable to common stockholders, basic and diluted</p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-30649">2.19</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-30650">1.10</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-35; -sec-ix-hidden: hidden-fact-34">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted average number of common shares outstanding, basic and diluted</p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-30651">17,111,374</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-30652">12,271,449</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other comprehensive loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-30653">37,409,694</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-30654">13,419,830</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Foreign currency translation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" sign="-" unitRef="usd" id="ixv-30655">2,374,957</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-36">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in pension benefit obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:ChangeInPensionBenefitObligation" scale="0" unitRef="usd" id="ixv-30656">5,963</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-37">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total comprehensive loss attributable to common stockholders</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-30657">35,028,774</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-30658">13,419,830</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;text-align:center;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T605"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:4pt;margin-top:4pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Consolidated Statements of Convertible Redeemable Preferred Stock and Stockholders&#8217; Equity (Deficit)<br/>For the&#160;years ended December&#160;31, 2023 and 2022</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-28" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="4" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">Series&#160;B<br/>Preferred <br/></span><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">Stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-right-color:#000000;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="4" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-color:#000000;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">Series&#160;A Preferred<br/></span><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">Stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="6" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.66%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">Series&#160;Seed<br/> Preferred<br/></span><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">Stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="6" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">Common Stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">Additional<br/>Paid-in<br/></span><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">Capital</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="6" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.51%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">Treasury Stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.63%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">Accumulated<br/></span><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">Deficit</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">Other<br/>Comprehensive<br/></span><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">Income</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">Total<br/>Onconetix<br/></span><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">Equity<br/>(Deficit)</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">Non-<br/>controlling<br/></span><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">Interest</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">Total<br/>Stockholders&#8217;<br/></span><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">Equity<br/>(Deficit)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-right-color:#000000;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">Amount</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-right-width:1pt;border-top-color:#000000;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-color:#000000;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">Amount</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">Amount</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">Amount</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">Amount</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">Balance at December&#160;31,&#160;2021</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-38">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-39">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;border-top-color:#000000;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-30659">1,146,138</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-30660">11</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-30661">3,200,000</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-30662">32</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-30663">7,403,204</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-40">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">(<ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-30664">5,956,670</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-41">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-30665">1,446,577</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-30666">1,446,577</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-30" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Issuance of common stock in initial public offering, net of&#160;$<ix:nonFraction contextRef="c26" decimals="1" format="ixt:num-dot-decimal" name="onco:IssuanceOfCommonStockInInitialPublicOfferingNet" scale="0" unitRef="usd" id="ixv-30667">2.9</ix:nonFraction>&#160;million of offering costs</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-42">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-43">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-44">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-30668">2,222,222</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-30669">22</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-30670">17,138,818</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-45">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-46">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-47">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-30671">17,138,840</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-30672">17,138,840</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-30" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Conversion of convertible preferred stock to common stock upon initial public offering</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-48">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-49">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" sign="-" unitRef="shares" id="ixv-30673">1,146,138</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:7pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" sign="-" unitRef="usd" id="ixv-30674">11</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:7pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares" id="ixv-30675">5,626,365</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd" id="ixv-30676">56</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">(<ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" sign="-" unitRef="usd" id="ixv-30677">45</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:7pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-50">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-51">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-52">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-53">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-54">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-31" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Issuance of common stock and warrants in April private placement, net of $<ix:nonFraction contextRef="c26" decimals="1" format="ixt:num-dot-decimal" name="onco:IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet" scale="0" unitRef="usd" id="ixv-30678">1.1</ix:nonFraction>&#160;million of offering costs</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-55">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-56">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-57">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants" scale="0" unitRef="shares" id="ixv-30679">590,406</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants" scale="0" unitRef="usd" id="ixv-30680">6</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants" scale="0" unitRef="usd" id="ixv-30681">6,858,322</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-58">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-59">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-60">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants" scale="0" unitRef="usd" id="ixv-30682">6,858,328</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants" scale="0" unitRef="usd" id="ixv-30683">6,858,328</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-31" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Issuance of common stock and warrants in August private placement, net of $<ix:nonFraction contextRef="c26" decimals="1" format="ixt:num-dot-decimal" name="onco:IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet" scale="0" unitRef="usd" id="ixv-30684">2.2</ix:nonFraction>&#160;million of offering costs</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-61">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-62">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-63">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet" scale="0" unitRef="shares" id="ixv-30685">1,350,000</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement" scale="0" unitRef="usd" id="ixv-30686">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement" scale="0" unitRef="usd" id="ixv-30687">8,689,302</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-64">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-65">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-66">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement" scale="0" unitRef="usd" id="ixv-30688">8,689,316</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement" scale="0" unitRef="usd" id="ixv-30689">8,689,316</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-32" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Exercise of stock options</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-67">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-68">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-69">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-30690">165,452</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-30691">2</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-30692">1,653</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-70">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-71">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-72">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-30693">1,655</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-30694">1,655</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Exercise of pre-funded warrants</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-73">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-74">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-75">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="onco:ExerciseOfPrefundedWarrantsinShares" scale="0" unitRef="shares" id="ixv-30695">2,277,046</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="onco:ExerciseOfPrefundedWarrants" scale="0" unitRef="usd" id="ixv-30696">22</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="onco:ExerciseOfPrefundedWarrants" scale="0" unitRef="usd" id="ixv-30697">1,414</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-76">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-77">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-78">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="onco:ExerciseOfPrefundedWarrants" scale="0" unitRef="usd" id="ixv-30698">1,436</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="onco:ExerciseOfPrefundedWarrants" scale="0" unitRef="usd" id="ixv-30699">1,436</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Issuance of restricted common stock</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-79">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-80">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-81">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares" id="ixv-30700">293,466</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" unitRef="usd" id="ixv-30701">3</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" unitRef="usd" id="ixv-30702">263,921</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-82">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-83">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-84">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" unitRef="usd" id="ixv-30703">263,924</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" unitRef="usd" id="ixv-30704">263,924</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-32" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Stock-based compensation</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-85">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-86">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-87">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd" id="ixv-30705">1,974,566</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-88">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-89">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-90">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd" id="ixv-30706">1,974,566</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd" id="ixv-30707">1,974,566</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Purchase of treasury shares</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-91">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-92">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-93">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-94">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="onco:PurchaseOfTreasurySharesinShares" scale="0" sign="-" unitRef="shares" id="ixv-30708">459,729</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:7pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="onco:PurchaseOfTreasuryShares" scale="0" unitRef="usd" id="ixv-30709">566,810</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:7pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">(<ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="onco:PurchaseOfTreasuryShares" scale="0" unitRef="usd" id="ixv-30710">566,810</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:7pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="onco:PurchaseOfTreasuryShares" scale="0" unitRef="usd" id="ixv-30711">566,810</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:7pt;">)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-32" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Net loss</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-95">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-96">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-97">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-98">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-99">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-100">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">(<ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-30712">13,419,830</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:7pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-101">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">(<ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-30713">13,419,830</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:7pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-102">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-30714">13,419,830</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:7pt;">)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">Balance at December&#160;31, 2022</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-103">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-104">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-105">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-106">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-107">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-108">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-30715">15,724,957</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-30716">157</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-30717">42,331,155</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" sign="-" unitRef="shares" id="ixv-30718">459,729</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-30719">566,810</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-30720">19,376,500</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-109">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-30721">22,388,002</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-30722">22,388,002</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-32" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-28" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Issuance of common stock from exercise of preferred investment options</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-110">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-111">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-112">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" scale="0" unitRef="shares" id="ixv-30723">2,486,214</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="onco:IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions" scale="0" unitRef="usd" id="ixv-30724">25</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="onco:IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions" scale="0" unitRef="usd" id="ixv-30725">2,272,813</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-113">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-114">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-115">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="onco:IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions" scale="0" unitRef="usd" id="ixv-30726">2,272,838</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions" scale="0" unitRef="usd" id="ixv-30727">2,272,838</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-28" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Issuance of warrants for settlement of contingent warrants</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-116">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-117">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-118">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd" id="ixv-30728">129,184</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-119">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-120">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-121">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd" id="ixv-30729">129,184</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd" id="ixv-30730">129,184</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Issuance of Series&#160;A Preferred Stock</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-122">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares" scale="0" unitRef="shares" id="ixv-30731">3,000</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-123">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-124">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock" scale="0" unitRef="usd" id="ixv-30732">3,490,000</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-125">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-126">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-127">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock" scale="0" unitRef="usd" id="ixv-30733">3,490,000</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock" scale="0" unitRef="usd" id="ixv-30734">3,490,000</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-30" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Issuance of common stock and Series&#160;B Preferred Stock in connection with PMX Transaction</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" scale="0" unitRef="shares" id="ixv-30735">2,696,729</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" scale="0" unitRef="usd" id="ixv-30736">64,236,085</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-128">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-129">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-130">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" scale="0" unitRef="shares" id="ixv-30737">3,675,414</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" scale="0" unitRef="usd" id="ixv-30738">37</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" scale="0" unitRef="usd" id="ixv-30739">875,447</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-131">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-132">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-133">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" scale="0" unitRef="usd" id="ixv-30740">875,484</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" scale="0" unitRef="usd" id="ixv-30741">875,484</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-30" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Assumption of stock-based compensation plan awards in connection with PMX Transaction</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-134">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-135">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-136">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-137">&#160;</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-138">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-139">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-140">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" scale="0" unitRef="usd" id="ixv-30742">7,006,504</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" scale="0" unitRef="usd" id="ixv-30743">7,006,504</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-32" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Exercise of stock options</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-141">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-142">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-143">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-30744">45,920</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-144">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-30745">459</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-145">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-146">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-147">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-30746">459</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-30747">459</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Exercise of pre-funded warrants</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-148">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-149">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-150">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="onco:ExerciseOfPrefundedWarrantsinShares" scale="0" unitRef="shares" id="ixv-30748">646,640</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="onco:ExerciseOfPrefundedWarrants" scale="0" unitRef="usd" id="ixv-30749">7</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">(<ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="onco:ExerciseOfPrefundedWarrants" scale="0" sign="-" unitRef="usd" id="ixv-30750">7</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:7pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-151">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-152">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-153">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-154">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Issuance of restricted stock</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-155">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-156">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-157">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares" id="ixv-30751">512,940</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" unitRef="usd" id="ixv-30752">5</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">(<ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" sign="-" unitRef="usd" id="ixv-30753">5</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:7pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-158">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-159">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-160">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-161">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Forfeitures of restricted stock</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-162">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-163">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">(<ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" sign="-" unitRef="shares" id="ixv-30754">250,110</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:7pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">(<ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" sign="-" unitRef="usd" id="ixv-30755">3</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:7pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" unitRef="usd" id="ixv-30756">3</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-164">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-165">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-166">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-167">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-32" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Stock-based compensation</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-168">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-169">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-170">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd" id="ixv-30757">329,760</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-171">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-172">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-173">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd" id="ixv-30758">329,760</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd" id="ixv-30759">329,760</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-32" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Purchase of treasury shares</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-174">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-175">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-176">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-177">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">(<ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="onco:PurchaseOfTreasurySharesinShares" scale="0" sign="-" unitRef="shares" id="ixv-30760">57,670</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:7pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">(<ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="onco:PurchaseOfTreasuryShares" scale="0" unitRef="usd" id="ixv-30761">58,981</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:7pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">(<ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="onco:PurchaseOfTreasuryShares" scale="0" unitRef="usd" id="ixv-30762">58,981</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:7pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:PurchaseOfTreasuryShares" scale="0" unitRef="usd" id="ixv-30763">58,981</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:7pt;">)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Foreign currency translation adjustment</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-178">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-179">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-180">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-181">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-182">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-183">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" sign="-" unitRef="usd" id="ixv-30764">2,374,957</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" sign="-" unitRef="usd" id="ixv-30765">2,374,957</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" sign="-" unitRef="usd" id="ixv-30766">2,374,957</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Changes in pension benefit obligation</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-184">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation" scale="0" unitRef="usd" id="ixv-30767">5,963</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation" scale="0" unitRef="usd" id="ixv-30768">5,963</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation" scale="0" unitRef="usd" id="ixv-30769">5,963</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-4" style="font-size:7pt;">Net loss</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-185">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-186">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-187">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-188">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-189">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-190">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">(<ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-30770">37,409,694</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:7pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-191">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">(<ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-30771">37,409,694</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:7pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-192">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:7pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-30772">37,409,694</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:7pt;">)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:7pt;">Balance at December&#160;31, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-30773">2,696,729</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-30774">64,236,085</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-30775">3,000</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-193">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.17%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-194">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-195">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-30776">22,841,975</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-30777">228</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-30778">49,428,809</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" sign="-" unitRef="shares" id="ixv-30779">517,399</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.73%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-30780">625,791</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-30781">56,786,194</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-30782">2,380,920</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 2.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-30783">5,602,028</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 3.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-30784">7,006,504</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 0.87%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-30785">1,404,476</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-size:7pt;font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:4pt;text-align:center;margin-top:4pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:4pt;text-align:center;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T606"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Consolidated Statements of Cash Flows</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Year Ended</span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Year Ended</span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from operating activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-30786">37,409,694</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-30787">13,419,830</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Impairment of ENTADFI assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" unitRef="usd" id="ixv-30788">14,687,346</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-196">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Impairment of deposit on asset purchase agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetImpairmentCharges" scale="0" unitRef="usd" id="ixv-30789">3,500,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-197">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fair value of subscription agreement liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-30790">729,900</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-198">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amortization of debt discount</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" unitRef="usd" id="ixv-30791">671,373</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-199">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss on extinguishment of note payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" sign="-" unitRef="usd" id="ixv-30792">490,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-200">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-30793">329,760</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-30794">1,974,566</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss on impairment of other long-lived assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="0" sign="-" unitRef="usd" id="ixv-30795">267,019</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-201">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss on related party receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:GainLossOnRelatedPartyReceivable" scale="0" unitRef="usd" id="ixv-30796">265,648</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-202">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Recovery of related party receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" scale="0" sign="-" unitRef="usd" id="ixv-30797">159,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-203">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd" id="ixv-30798">12,593</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-204">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Impairment of inventory</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="0" unitRef="usd" id="ixv-30799">1,152,369</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-205">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation and amortization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd" id="ixv-30800">43,937</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd" id="ixv-30801">6,752</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in fair value of contingent warrant liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueAdjustment" scale="0" sign="-" unitRef="usd" id="ixv-30802">91,967</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueAdjustment" scale="0" unitRef="usd" id="ixv-30803">61,410</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in fair value of subscription agreement liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentOfWarrantsGrantedForServices" scale="0" unitRef="usd" id="ixv-30804">134,100</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-206">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net periodic pension benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PensionExpense" scale="0" unitRef="usd" id="ixv-30805">13,875</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-207">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Issuance of restricted common stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-208">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" unitRef="usd" id="ixv-30806">263,924</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Changes in operating assets and liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd" id="ixv-30807">62,286</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-209">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Inventories</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd" id="ixv-30808">315,828</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-210">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid expenses and other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" unitRef="usd" id="ixv-30809">412,601</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" unitRef="usd" id="ixv-30810">234,681</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other noncurrent assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="0" unitRef="usd" id="ixv-30811">16,883</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="0" unitRef="usd" id="ixv-30812">38,617</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" unitRef="usd" id="ixv-30813">3,372,648</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" unitRef="usd" id="ixv-30814">1,093,913</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-30815">942,075</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" unitRef="usd" id="ixv-30816">1,739,849</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-30817">13,581,018</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-30818">8,675,534</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from investing activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Acquisition of assets, including transaction costs of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="0" unitRef="usd" id="ixv-30819"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="0" unitRef="usd" id="ixv-30820">79,771</ix:nonFraction></ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" scale="0" unitRef="usd" id="ixv-30821">6,079,771</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-211">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deposit made in connection with asset purchase agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit" scale="0" unitRef="usd" id="ixv-30822">3,500,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-212">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash acquired through business combination</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="0" sign="-" unitRef="usd" id="ixv-30823">1,056,578</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-213">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Purchases of other long-lived assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" unitRef="usd" id="ixv-30824">51,744</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-214">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net advances to related parties</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:ReceivableFromRelatedParties1" scale="0" unitRef="usd" id="ixv-30825">70,798</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="onco:ReceivableFromRelatedParties1" scale="0" unitRef="usd" id="ixv-30826">23,326</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-32" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Purchases of property and equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-30827">3,300</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-30828">9,339</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-32" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in investing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-30829">8,649,035</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-30830">32,665</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;orphans:99;widows:1;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Consolidated Statements of Cash Flows&#160;&#8212;&#160;(Continued)</span></p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Year Ended</span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Year Ended</span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from financing activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Purchase of treasury shares</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:PaymentsForPurchaseOfTreasuryShares" scale="0" unitRef="usd" id="ixv-30831">58,981</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="onco:PaymentsForPurchaseOfTreasuryShares" scale="0" unitRef="usd" id="ixv-30832">566,810</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Payment of deferred offering costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" unitRef="usd" id="ixv-30833">205,093</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-215">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Principal payment of note payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" unitRef="usd" id="ixv-30834">1,000,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-216">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from exercise of preferred investment options, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="0" unitRef="usd" id="ixv-30835">2,298,675</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-217">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from exercise of stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" unitRef="usd" id="ixv-30836">459</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" unitRef="usd" id="ixv-30837">1,655</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from issuance of common stock in initial public offering, net of underwriting discount</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-218">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="0" unitRef="usd" id="ixv-30838">18,400,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Payments of initial public offering costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-219">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" scale="0" unitRef="usd" id="ixv-30839">926,972</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from issuance of common stock and warrants in private placements, net of placement agent discount</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-220">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" unitRef="usd" id="ixv-30840">16,468,123</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Payment of private placement issuance costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfPrivatePlacement" scale="0" unitRef="usd" id="ixv-30841">845,048</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from exercise of pre-funded warrants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-221">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" unitRef="usd" id="ixv-30842">1,436</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by financing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-30843">1,035,060</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-30844">32,532,384</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effect of exchange rate changes on cash</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" sign="-" unitRef="usd" id="ixv-30845">3,331</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-222">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net increase (decrease) in cash</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-30846">21,198,324</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd" id="ixv-30847">23,824,185</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash, beginning of period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-30848">25,752,659</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-30849">1,928,474</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash, end of period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-30850">4,554,335</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-30851">25,752,659</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Noncash investing and financing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Inventory and intangible assets acquired through issuance of notes payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncashOrPartNoncashAcquisitionInventoryAcquired1" scale="0" unitRef="usd" id="ixv-30852">12,947,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-223">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effect of business combination (Note&#160;5)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:EffectOfBusinessCombination" scale="0" unitRef="usd" id="ixv-30853">64,054,991</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-224">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Settlement of note payable through issuance of Series&#160;A convertible preferred stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockAmountIssued1" scale="0" unitRef="usd" id="ixv-30854">3,490,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-225">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Incremental fair value of exchanged preferred investment options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueOfAssetsAcquired" scale="0" unitRef="usd" id="ixv-30855">2,613,011</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueOfAssetsAcquired" scale="0" unitRef="usd" id="ixv-30856">860,204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred offering costs included in accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1" scale="0" unitRef="usd" id="ixv-30857">150,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-226">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Recognition of contingent warrant liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement" scale="0" unitRef="usd" id="ixv-30858">25,837</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="onco:RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement" scale="0" unitRef="usd" id="ixv-30859">75,431</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Warrants issued for settlement of contingent warrants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:WarrantsIssuedForSettlementOfContingentWarrants" scale="0" unitRef="usd" id="ixv-30860">129,184</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-227">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred offering costs previously included in prepaid expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:DeferredOfferingCostsPreviouslyPrepaid" scale="0" sign="-" unitRef="usd" id="ixv-30861">11,020</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-228">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercise of pre-funded warrants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:Exerciseofprefundedwarrants" scale="0" unitRef="usd" id="ixv-30862">7</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="onco:Exerciseofprefundedwarrants" scale="0" unitRef="usd" id="ixv-30863">6</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Issuance of restricted stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:IssuanceOfRestrictedStock" scale="0" unitRef="usd" id="ixv-30864">5</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-229">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Restricted stock forfeitures</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:RestrictedStockForfeitures" scale="0" sign="-" unitRef="usd" id="ixv-30865">3</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-230">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Payment of accrued bonus through related party receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-231">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="onco:PaymentOfAccruedBonusThroughRelatedPartyReceivable" scale="0" unitRef="usd" id="ixv-30866">140,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Conversion of Series&#160;Seed Preferred Stock to common stock upon initial public&#160;offering</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-232">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-30867">45</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;text-align:center;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T901"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="ixv-16825"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;1&#160;&#8212;&#160;Organization and Basis of Presentation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Organization and Nature of Operations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Onconetix, Inc. (formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc.) (the &#8220;Company&#8221; or &#8220;Onconetix&#8221;) was formed on October&#160;26, 2018, and is a commercial stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men&#8217;s health and oncology.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2023, Onconetix acquired <ix:nonFraction contextRef="c58" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-30868">100</ix:nonFraction>% of the issued and outstanding voting equity interests in Proteomedix AG, a Swiss company (&#8220;Proteomedix&#8221;), and its related diagnostic product Proclarix. As a result of this transaction, Proteomedix became a wholly owned subsidiary of Onconetix (see Note&#160;5). In April&#160;2023, the Company acquired ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span>, a Food and Drug Administration (&#8220;FDA&#8221;)<span class="nobreak">-approved</span>, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Historically, the Company&#8217;s focus was on the research and development of transformational vaccines to prevent infectious diseases worldwide, until the third quarter of 2023, at which time the Company deprioritized its efforts on vaccine development activities to focus on commercialization activities for ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> and pursue other potential acquisitions. In light of (i)&#160;the time and resources needed to continue pursuing commercialization of ENTADFI, and (ii)&#160;the Company&#8217;s cash runway and indebtedness, the Company has determined to temporarily pause its commercialization of ENTADFI, as it considers strategic alternatives. The Company expects to appoint a new Chief Executive Officer in the second quarter of 2024, after which the new CEO and the Board will reassess its ENTADFI program in light of the foregoing and other relevant factors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;21, 2023, the Company filed an amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to change its corporate name from &#8220;Blue Water Vaccines Inc.&#8221; to &#8220;Blue Water Biotech, Inc.&#8221; The name change was effective as of April&#160;21, 2023. On December&#160;15, 2023, the Company filed an amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to change its corporate name from &#8220;Blue Water Biotech, Inc.&#8221; to &#8220;Onconetix, Inc.&#8221; In connection with each of the name changes, the Company also amended the Company&#8217;s bylaws to reflect the new corporate name.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;) and include the accounts of Onconetix and its <ix:nonFraction contextRef="c59" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-30869">100</ix:nonFraction>%&#160;wholly owned subsidiary, Proteomedix, since the acquisition date of December&#160;15, 2023. All significant intercompany balances and transactions have been eliminated in consolidation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Certain reclassifications have been made to prior year amounts reported in the accompanying consolidated statement of cash flows to conform to the current year presentation. These reclassifications, which resulted in a difference of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="0" unitRef="usd" id="ixv-30870">23,000</ix:nonFraction> between operating and investing cash flow activity, are not significant and had no impact on the previously reported financial position or results of operations of the Company.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Initial Public Offering</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;23, 2022, the Company completed its initial public offering (&#8220;IPO&#8221;) in which the Company issued and sold <ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="onco:InitialPublicOfferingShares" scale="0" unitRef="shares" id="ixv-30871">2,222,222</ix:nonFraction><span class="nobreak"> </span>shares of its common stock, at a price to the public of $<ix:nonFraction contextRef="c60" decimals="2" format="ixt:num-dot-decimal" name="onco:PublicOfPerShare" scale="0" unitRef="usdPershares" id="ixv-30872">9.00</ix:nonFraction> per share. Proceeds from the IPO, net of underwriting discounts, commissions, and offering costs of $<ix:nonFraction contextRef="c61" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" unitRef="usd" id="ixv-30873">2.9</ix:nonFraction>&#160;million, were $<ix:nonFraction contextRef="c62" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" unitRef="usd" id="ixv-30874">17.1</ix:nonFraction>&#160;million. In connection with the completion of the IPO, all outstanding shares of convertible preferred stock were converted into <ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-30875">5,626,365</ix:nonFraction><span class="nobreak"> </span>shares of common stock (see Note&#160;9).</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c0" continuedAt="_SubstantialDoubtAboutGoingConcernTextBlock-c0_cont_1" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="ixv-16846"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;2 &#8212; Going Concern and Management&#8217;s Plans</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s operating activities to date have been devoted to seeking licenses, engaging in research and development activities, potential asset and business acquisitions, and expenditures associated with the commercial launch of ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span>. The Company has financed its operations since inception primarily using proceeds received from seed investors and proceeds received from its IPO and subsequent debt and equity offerings. During the year </p></ix:nonNumeric>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;2 &#8212; Going Concern and Management&#8217;s Plans</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_SubstantialDoubtAboutGoingConcernTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">ended December&#160;31, 2022, the Company received an aggregate of approximately $<ix:nonFraction contextRef="c64" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" unitRef="usd" id="ixv-30876">33.1</ix:nonFraction>&#160;million in net cash proceeds from its IPO and two private placements, and during the year ended December&#160;31, 2023, the Company received net proceeds of approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfOtherInvestments" scale="6" unitRef="usd" id="ixv-30877">2.3</ix:nonFraction>&#160;million in connection with the exercise by an investor of preferred investment options (see Note&#160;9). In addition, on January&#160;23, 2024, the Company received net cash proceeds of $<ix:nonFraction contextRef="c65" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfOtherInvestments" scale="6" unitRef="usd" id="ixv-30878">4.6</ix:nonFraction>&#160;million in exchange for the issuance of a debenture. The debenture is repayable in full upon the earlier of (i)&#160;the closing of a subscription agreement, which was entered into in connection with the acquisition of Proteomedix, and (ii)&#160;June&#160;30, 2024 (see&#160;Note&#160;14).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future. As of December&#160;31, 2023, the Company had cash of approximately $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="6" unitRef="usd" id="ixv-30879">4.6</ix:nonFraction>&#160;million, a working capital deficit of approximately $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="onco:WorkingCapitalDeficit" scale="6" unitRef="usd" id="ixv-30880">11.4</ix:nonFraction>&#160;million and an accumulated deficit of approximately $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAppropriated" scale="6" sign="-" unitRef="usd" id="ixv-30881">56.8</ix:nonFraction>&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">These factors, along with the Company&#8217;s forecasted future cash flows, indicate that the Company will be unable to meet its contractual commitments and obligations as they come due in the ordinary course of business, within one year following the issuance of these consolidated financial statements. The Company will require significant additional capital in the short<span class="nobreak">-term</span> to fund its continuing operations, satisfy existing and future obligations and liabilities, including the remaining payments due for the acquisition of the ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> assets, payment due on the debenture, in addition to funds needed to support the Company&#8217;s working capital needs and business activities. These business activities include the commercialization of ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span>, which we have temporarily paused as discussed above, and Proclarix, and the development and commercialization of the Company&#8217;s current product candidates and future product candidates. In addition, as discussed more fully in Note&#160;5, if stockholder approval is not obtained by January&#160;1, 2025 with respect to the Series&#160;B Convertible Redeemable Preferred Stock issued in connection with the acquisition of Proteomedix, these shares become redeemable for cash at the option of the holders, and the Company currently does not have sufficient cash to redeem such shares.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Management&#8217;s plans for funding the Company&#8217;s operations include generating product revenue from sales of Proclarix, which may still be subject to further successful commercialization activities within certain jurisdictions, and ENTADFI, which is subject to further successful commercialization activities which we have temporarily paused as discussed above. Certain of the commercialization activities are outside of the Company&#8217;s control, including but not limited to, securing contracts with wholesalers and third<span class="nobreak">-party</span> payers, securing contracts with third<span class="nobreak">-party</span> logistics providers, and obtaining required licensure in various jurisdictions, as well as attempting to secure additional required funding through equity or debt financings if available. However, there are currently no commitments in place for further financing nor is there any assurance that such financing will be available to the Company on favorable terms, if at all. This creates significant uncertainty that the Company will have the funds available to be able to successfully launch ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> and expand commercialization of Proclarix. If the Company is unable to secure additional capital, it may be required to curtail any future clinical trials, development and/or commercialization of products and product candidates, and it may take additional measures to reduce expenses in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Because of historical and expected operating losses and net operating cash flow deficits, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for one year from the issuance of the consolidated financial statements, which is not alleviated by management&#8217;s plans. The consolidated financial statements have been prepared assuming the Company will continue as a going concern. These consolidated financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-16874"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3 &#8212; Summary of Significant Accounting Policies</span></p>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-16878"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Use of Estimates</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation continuedAt="_UseOfEstimates-c0_cont_2" id="_UseOfEstimates-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The preparation of the consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of </p></ix:continuation></div></ix:nonNumeric>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-11</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3 &#8212; Summary of Significant Accounting Policies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><div style="-keep: true"><ix:continuation id="_UseOfEstimates-c0_cont_2"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">revenue and expenses during the reporting periods. The most significant estimates in the Company&#8217;s consolidated financial statements relate to accounting for acquisitions, valuation of inventory, the useful life of the amortizable intangible assets, estimates of future cash flows used to evaluate impairment of intangible assets, accrued research and development expenses, assumptions related to the pension benefit obligation, stock<span class="nobreak">-based</span> compensation, the valuation of preferred stock, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</p></ix:continuation></div>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-16901"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in financial institutions, which, at times, exceed the Federal Depository Insurance Coverage limit for those maintained in the United&#160;States and exceed the Swiss Financial Market Supervisory Authority for those maintained in Switzerland. As of December&#160;31, 2023 and 2022, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p></ix:continuation></div>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-16908"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Segment Information</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_2" id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;), or decision<span class="nobreak">-making</span> group, in deciding how to allocate resources and in assessing performance. Prior to the acquisition of ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> during the quarter ended June&#160;30, 2023, the Company managed one distinct business segment, which was vaccine discovery and development. During the second quarter of 2023, as a result of the acquisition of ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span>, the Company operated in two business segments: research and development and commercial. During the third quarter of 2023, the Company deprioritized its vaccine discovery and development programs, and accordingly, as of December&#160;31, 2023, the Company was operating in <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="pure" id="ixv-30882">one</ix:nonFraction> segment: commercial. Management&#8217;s determination of its operating segments is consistent with the financial information regularly reviewed by the CODM for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.</p></ix:continuation></div>
		<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="ixv-16917"><div style="-keep: true"><ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_3" id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_2"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The distribution of revenue by geographical area was as follows:</p></ix:continuation></div></ix:nonNumeric>
		<ix:continuation id="_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock-c0_cont_1"><ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_4" id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_3"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Years Ended <br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">United&#160;States</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-233">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-234">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Switzerland</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-30883">58,465</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-235">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-30884">58,465</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-236">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
				</tr>

		</table></ix:continuation></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="ixv-16990"><div style="-keep: true"><ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_5" id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_4"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The distribution of long<span class="nobreak">-lived</span> assets by geographical area, which includes property and equipment and the Company&#8217;s right of use asset, was as follows:</p></ix:continuation></div></ix:nonNumeric>
		<ix:continuation id="_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock-c0_cont_1"><ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_5"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Years Ended <br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">United&#160;States</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-30885">10,956</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-30886">14,089</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Switzerland</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-30887">198,240</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-237">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-30888">209,196</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-30889">14,089</ix:nonFraction></span></p>	</td>
				</tr>

		</table></ix:continuation></ix:continuation></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-12</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3 &#8212; Summary of Significant Accounting Policies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="ixv-17073"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Foreign Currency Translation</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The financial statements of Proteomedix, the Company&#8217;s foreign subsidiary, are measured using the local currency, which is the Swiss Franc, as the functional currency. Assets and liabilities of this subsidiary are translated into U.S.&#160;dollars at exchange rates as of the consolidated balance sheet date. Equity is translated at historical exchange rates. Revenues and expenses are translated into U.S.&#160;dollars at average rates of exchange in effect during the period. The resulting cumulative translation adjustments have been recorded as a separate component of stockholders&#8217; equity, as accumulated other comprehensive income or loss. Foreign currency transaction gains and losses are included in the results of operations, and were not significant for the&#160;years ended December&#160;31, 2023, or 2022.</p></ix:continuation></div>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="ixv-17080"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accounts receivable</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company performs periodic credit evaluations of its customers&#8217; financial condition and extends credit to virtually all of its customers on an uncollateralized basis. Credit losses to date have been insignificant and within management&#8217;s expectations. The Company provides an allowance for doubtful accounts that is based upon a review of outstanding receivables, historical collection information, expected future losses, and existing economic conditions. As of December&#160;31, 2023, there was no allowance for doubtful accounts. As of December&#160;31, 2023, substantially all of the Company&#8217;s accounts receivable are due from a single customer.</p></ix:continuation></div>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock" id="ixv-17087"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Inventories</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation id="_InventoryPolicyTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Inventories consist of product acquired in the ENTADFI and Proteomedix transactions. Inventories are stated at the lower of cost or net realizable value, with cost determined on a first<span class="nobreak">-in</span>, first<span class="nobreak">-out</span> basis, aside from inventories acquired in an asset acquisition or business combination, which are recorded at fair value. The Company periodically reviews the composition of inventory in order to identify excess, obsolete, slow<span class="nobreak">-moving</span> or otherwise non<span class="nobreak">-saleable</span> items taking into account anticipated future sales compared with quantities on hand, and the remaining shelf life of goods on hand. If non<span class="nobreak">-saleable</span> items are observed and there are no alternate uses for the inventory, the Company records a write<span class="nobreak">-down</span> to net realizable value in the period that the decline in value is first recognized. The Company recorded an impairment of inventory in the amount of approximately $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="6" unitRef="usd" id="ixv-30890">1.2</ix:nonFraction>&#160;million during the year ended December&#160;31, 2023, as a result of the delay in launching ENTADFI and the Company&#8217;s decision to pause related commercialization activities.</p></ix:continuation></div>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-17100"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Property and Equipment</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment consists of laboratory equipment, computers, and office furniture and fixtures, all of which are recorded at cost. Depreciation is recorded using the straight<span class="nobreak">-line</span> method over the respective useful lives of the assets ranging from <span style="-sec-ix-hidden: hidden-fact-250">two</span> to <span style="-sec-ix-hidden: hidden-fact-251">ten</span>&#160;years. Depreciation expense was approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-30891">7,000</ix:nonFraction> for each of the&#160;years ended December&#160;31, 2023 and 2022 and is included in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</p></ix:continuation></div>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="onco_AcquisitionsPolicyTextBlock-c0_cont_1" escape="true" name="onco:AcquisitionsPolicyTextBlock" id="ixv-17110"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Acquisitions</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation continuedAt="onco_AcquisitionsPolicyTextBlock-c0_cont_2" id="onco_AcquisitionsPolicyTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluates acquisitions to first determine whether a set of assets acquired constitutes a business and should be accounted for as a business combination. If the assets acquired are not a business, the transaction is accounted as an asset acquisition in accordance with Accounting Standards Codification (&#8220;ASC&#8221;)&#160;805<span class="nobreak">-50</span>, <span class="Italic" style="font-style:italic;font-weight:normal;">Asset Acquisitions</span> (&#8220;ASC&#160;805<span class="nobreak">-50</span>&#8221;), which requires the acquiring entity to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, except for non<span class="nobreak">-qualifying</span> assets including financial assets such as inventory. Further, the cost of the acquisition includes the fair value of consideration transferred and direct transaction costs attributable to the acquisition. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. Contingent consideration payments in asset acquisitions are recognized when the contingency is determined to be probable and reasonably estimable. If the assets acquired are a business, the Company accounts for the transaction as a business combination. Business combinations are accounted for by using the acquisition method </p></ix:continuation></div></ix:continuation>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-13</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3 &#8212; Summary of Significant Accounting Policies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><div style="-keep: true"><ix:continuation id="onco_AcquisitionsPolicyTextBlock-c0_cont_2"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective fair values. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Acquisition related expenses are expensed as incurred, and are included in selling, general and administrative expense in the consolidated statements of operations and comprehensive loss.</p></ix:continuation></div>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_1" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="ixv-17136"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Goodwill and Other Intangible Assets</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_2" id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Goodwill represents the excess of the cost of a business combination over the fair value of the net assets acquired. Goodwill and intangible assets deemed to have indefinite lives are not amortized but are subject to impairment tests on an annual basis, and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Goodwill is allocated to the reporting unit from which it was created. A reporting unit is an operating segment or sub<span class="nobreak">-segment</span> to which goodwill is assigned when initially recorded. The Company tests indefinite lived intangible assets for impairment, on an annual basis in the fourth quarter, or more frequently if an event occurs or circumstances indicate that the indefinite lived assets may be impaired. The Company may perform a qualitative assessment to determine whether it is more<span class="nobreak">-likely-than-not</span> that the fair value of a reporting unit is less than its carrying amount. If the Company determines this is the case, the Company then performs further quantitative analysis to identify and measure the amount of goodwill impairment loss to be recognized, if any. To perform its quantitative test, the Company compares the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of its net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. The Company did not test its goodwill or indefinite lived assets for impairment during the year ended December&#160;31, 2023, given that the acquisition date occurred after the annual testing date, and given that there were no impairment indicators from the date of acquisition through the end of the reporting period. The Company has determined that no impairment of its goodwill or indefinite lived intangible assets occurred as of December&#160;31, 2023.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_3" id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_2"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Intangible assets with finite lives are reported at cost, less accumulated amortization, and are amortized over their estimated useful lives, starting when sales for the related product begin. Amortization is calculated using the straight<span class="nobreak">-line</span> method, and recorded within selling, general, and administrative expenses, or cost of revenue, depending on the nature and use of the asset.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_3"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the ordinary course of business, the Company has entered into certain license and asset purchase agreements. Potential milestone payments for development, regulatory, and commercial milestones are recorded when the milestone is probable of achievement. Upon a milestone being achieved, the associated milestone payment is capitalized and amortized over the remaining useful life for approved products, or expensed as research and development expense for milestones relating to products whose FDA approval has not yet been obtained.</p></ix:continuation></div>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="ixv-17152"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_2" id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company reviews long<span class="nobreak">-lived</span> assets, including intangible assets with finite useful lives, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable (a &#8220;triggering event&#8221;). Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the long<span class="nobreak">-lived</span> asset in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long<span class="nobreak">-lived</span> asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long<span class="nobreak">-lived</span> asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value. During the fourth quarter of 2023, the Company determined that there were certain triggering events that indicated that the carrying amount of the assets recorded in connection with the ENTADFI acquisition (see Note&#160;5) may not be fully recoverable. A related impairment loss of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" unitRef="usd" id="ixv-30892">14.7</ix:nonFraction>&#160;million was recorded during the year ended December&#160;31, 2023 (see Note&#160;4). The Company also recorded an impairment loss of </p></ix:continuation></div></ix:continuation>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-14</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3 &#8212; Summary of Significant Accounting Policies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><div style="-keep: true"><ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_2"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="0" unitRef="usd" id="ixv-30893">267,000</ix:nonFraction> during the year ended December&#160;31, 2023, related to implementation costs incurred under cloud computing hosting arrangements that were capitalized during the year. There were no other impairment losses on long<span class="nobreak">-lived</span> assets for the&#160;years ended December&#160;31, 2023 and 2022.</p></ix:continuation></div>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-17179"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value Measurements</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S.&#160;GAAP establishes a three<span class="nobreak">-tier</span> fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level<span class="nobreak"> </span>1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level<span class="nobreak"> </span>2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level<span class="nobreak"> </span>3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. Financial instruments, including cash, inventory, accounts receivable, receivables from related party, accounts payable, accrued liabilities, operating lease liabilities, and notes payable are carried at cost, which management believes approximates fair value due to the short<span class="nobreak">-term</span> nature of these instruments.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_7" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of the contingent warrant liability that became issuable upon the closing of the private placements the Company closed on during 2022, the warrant inducement the Company closed on during 2023 (see Note&#160;9), and the subscription agreement liability that was recorded in connection with a subscription agreement (see Note&#160;8) are valued using significant unobservable measures and other fair value inputs, and are therefore classified as Level 3 financial instruments.</p></ix:continuation></div>
		<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="ixv-17211"><div style="-keep: true"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_8" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_7"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of financial instruments measured on a recurring basis is as follows:</p></ix:continuation></div></ix:nonNumeric>
		<ix:continuation continuedAt="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_2" id="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_9" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_8"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="11" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 59.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">As of December&#160;31, 2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Description</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 1</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 2</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 3</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contingent warrant liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-30894">2,641</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-238">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-239">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-30895">2,641</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subscription agreement liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="onco:SubscriptionAgreementLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-30896">864,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-240">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-241">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="onco:SubscriptionAgreementLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-30897">864,000</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-30898">866,641</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-242">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-243">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-30899">866,641</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation></ix:continuation>
		<ix:continuation id="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_2"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_10" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_9"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="9" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 59.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">As of December&#160;31, 2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Description</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 1</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 2</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 3</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contingent warrant liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-30900">14,021</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-244">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-245">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-30901">14,021</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation></ix:continuation>
		<div style="-keep: true"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_11" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_10"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December&#160;31, 2023, in connection with the acquisition of Proteomedix, the Company recorded intangible assets, which were recognized at fair value (see Note&#160;5). None of the Company&#8217;s other non<span class="nobreak">-financial</span> assets or liabilities are recorded at fair value on a non<span class="nobreak">-recurring</span> basis. There were no transfers between levels during the periods presented.</p></ix:continuation></div></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-15</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3 &#8212; Summary of Significant Accounting Policies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="ixv-17421"><div style="-keep: true"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_12" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_11"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the activity for the subscription agreement liability, using unobservable Level 3 inputs, for the year ended December&#160;31, 2023:</p></ix:continuation></div></ix:nonNumeric>
		<ix:continuation id="_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-c0_cont_1"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_13" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_12"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Subscription</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Agreement</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Liability</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance at December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-246">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fair value upon issuance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" scale="0" unitRef="usd" id="ixv-30902">729,900</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in fair value</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" scale="0" unitRef="usd" id="ixv-30903">134,100</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance at December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" unitRef="usd" id="ixv-30904">864,000</ix:nonFraction></p>	</td>
				</tr>

		</table><p style="margin:0;padding:0;border-width:0;"></p></ix:continuation></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="ixv-17475"><div style="-keep: true"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_14" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_13"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the activity for the contingent warrant liability, using unobservable Level 3 inputs, for the&#160;years ended December&#160;31, 2023 and 2022:</p></ix:continuation></div></ix:nonNumeric>
		<ix:continuation id="_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-c0_cont_1"><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_14"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Contingent</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Warrant</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Liability</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance at December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-247">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fair value at issuance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" scale="0" unitRef="usd" id="ixv-30905">75,431</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in fair value</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" scale="0" unitRef="usd" id="ixv-30906">61,410</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance at December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" scale="0" unitRef="usd" id="ixv-30907">14,021</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fair value at issuance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" scale="0" unitRef="usd" id="ixv-30908">25,837</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Reclassification to equity</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="onco:ReclassificationToEquity" scale="0" sign="-" unitRef="usd" id="ixv-30909">129,184</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in fair value</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" scale="0" sign="-" unitRef="usd" id="ixv-30910">91,967</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance at December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" scale="0" unitRef="usd" id="ixv-30911">2,641</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation></ix:continuation>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_DeferredChargesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DeferredChargesPolicyTextBlock" id="ixv-17577"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Deferred Offering Costs</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation id="_DeferredChargesPolicyTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company capitalizes certain legal, professional accounting and other third<span class="nobreak">-party</span> fees that are directly associated with in<span class="nobreak">-process</span> equity financing as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#8217; equity as a reduction of proceeds generated as a result of the offering. Should the in<span class="nobreak">-process</span> equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to expenses in the consolidated statements of operations and comprehensive loss.</p></ix:continuation></div>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-17587"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for leases in accordance with ASC&#160;842, <span class="Italic" style="font-style:italic;font-weight:normal;">Leases</span>. The Company has one lease agreement for office space, which contains an initial term of two&#160;years with renewal options. The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_3" id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Operating lease right of use assets and operating lease liabilities are recognized on the lease commencement date. Operating lease right of use assets represent the Company&#8217;s right to use an underlying asset for the estimated lease term and operating lease liabilities represent the Company&#8217;s present value of its future lease payments. In assessing its lease and determining its lease liability at lease commencement or upon modification, the Company was not able to readily determine the rate implicit for its lessee arrangements, and thus has used its incremental borrowing rate on a collateralized basis to determine the present value of the lease payments. The Company&#8217;s right of use asset is measured as the balance of the lease liability plus or minus any prepaid or accrued lease payments and any unamortized initial direct costs. The operating lease payments are recognized as lease expense on a straight<span class="nobreak">-line</span> basis over the lease term, and are included in selling, general and administrative expenses in the accompanying consolidated statements of </p></ix:continuation></div></ix:continuation>

	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-16</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3 &#8212; Summary of Significant Accounting Policies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><div style="-keep: true"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_4" id="_LesseeLeasesPolicyTextBlock-c0_cont_3"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">operations and comprehensive loss. Lease payments included in the measurement of the lease liability are comprised of fixed payments. If the Company&#8217;s lease agreements include renewal option periods, the Company includes such renewal options in its calculation of the estimated lease term when it determines the options are reasonably certain to be exercised. When such renewal options are deemed to be reasonably certain, the estimated lease term determined under ASC&#160;842 will be greater than the non<span class="nobreak">-cancelable</span> term of the contractual arrangement.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_5" id="_LesseeLeasesPolicyTextBlock-c0_cont_4"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Leases with an initial term of 12&#160;months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight<span class="nobreak">-line</span> basis over the lease term. The Company applies this policy to all underlying asset categories.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_5"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company additionally evaluates leases at their inception to determine if the leases are to be accounted for as an operating lease or a finance lease. Lease expense for operating leases is recognized on a straight<span class="nobreak">-line</span> basis over the lease term. Variable lease payments are recognized in the period in which the obligations for those payments are incurred. Lease expense for finance leases is bifurcated into two components, with the amortization expense component of the right<span class="nobreak">-of-use</span> asset recognized on a straight<span class="nobreak">-line</span> basis and the interest expense component recognized using the effective interest method over the lease term. The Company has no financing leases as of December&#160;31, 2023 or 2022.</p></ix:continuation></div>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock" id="ixv-17624"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Defined Benefit Pension Plan</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation id="_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix sponsors a defined benefit pension plan (the &#8220;Swiss Plan&#8221;) covering its eligible Swiss employees. The Swiss Plan is government<span class="nobreak">-mandated</span> and provides retirement benefits based on employees&#8217;&#160;years of service and compensation levels. The Company recognizes an asset for the Swiss Plan&#8217;s overfunded status or a liability for underfunded status in its consolidated balance sheets. Additionally, the Company measures its plan&#8217;s assets and obligations that determine its funded status as of the end of the year and recognizes the changes in the funded status in the year in which the changes occur. Those changes are reported in accumulated other comprehensive loss in the accompanying consolidated statements of convertible redeemable preferred stock and stockholders&#8217; equity. The Company uses actuarial valuations to determine its pension and postretirement benefit costs and credits. The amounts calculated depend on a variety of key assumptions, including discount rates and expected return on plan assets. Current market conditions are considered in selecting these assumptions.</p></ix:continuation></div>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_CollaborativeArrangementAccountingPolicy-c0_cont_1" escape="true" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="ixv-17632"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Collaborative Agreements</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation id="_CollaborativeArrangementAccountingPolicy-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company periodically enters into strategic alliance agreements with counterparties to produce products and/or provide services to customers. Alliances created by such agreements are not legal entities, have no employees, no assets and have no true operations. These arrangements create contractual rights and the Company accounts for these alliances as a collaborative arrangement by reporting costs incurred and reimbursements received from transactions within research and development expense within the consolidated statements of operations and comprehensive loss.</p></ix:continuation></div>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="ixv-17639"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Revenue Recognition</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December&#160;31, 2023, the Company recorded approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RecognitionOfDeferredRevenue" scale="0" unitRef="usd" id="ixv-30912">59,000</ix:nonFraction> of revenue, which was solely generated from Proteomedix development services from the period from the acquisition date of December&#160;15, 2023, through December&#160;31, 2023.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_3" id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix provides a range of services to life sciences customers referred to as &#8220;Development Services&#8221; including testing for biomarker discovery, assay design and development. These Development Services are performed under individual statement of work (&#8220;SOW&#8221;) arrangements with specific deliverables defined by the customer. Development Services are generally performed on a time and materials basis. During the performance and through completion of the service to the customer in accordance with the SOW, the Company has the right to bill the customer for the agreed upon price and recognizes the Development Services revenue over the period estimated to complete the SOW.&#160;The Company generally identifies each SOW as a single performance obligation.</p></ix:continuation></div></ix:continuation>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-17</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3 &#8212; Summary of Significant Accounting Policies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><div style="-keep: true"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_4" id="_RevenueRecognitionPolicyTextBlock-c0_cont_3"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Completion of the service and satisfaction of the performance obligation under a SOW is typically evidenced by access to the data or test made available to the customer or any other form or applicable manner of delivery defined in the SOW.&#160;However, for certain SOWs under which work is performed pursuant to the customer&#8217;s highly customized specifications, the Company has the enforceable right to bill the customer for work completed, rather than upon completion of the SOW.&#160;For those SOWs, the Company recognizes revenue over a period of time during which the work is performed based on the expended efforts (inputs). As the performance obligation under the SOW is satisfied, any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed to the customer as of the date of the consolidated financial statements are recorded as contract assets and are included in prepaids and other current assets as of the financial statement date, and these amounts as of December&#160;31, 2023 are not significant. Amounts recorded in contract assets are reclassified to accounts receivable in our consolidated financial statements when the customer is invoiced according to the billing schedule in the contract. Accounts receivable was approximately $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="0" unitRef="usd" id="ixv-30913">87,000</ix:nonFraction> and $<ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="0" unitRef="usd" id="ixv-30914">150,000</ix:nonFraction> as of December&#160;15, 2023, the date of acquisition of Proteomedix (see Note&#160;5), and December&#160;31, 2023, respectively.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_4"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In circumstances where a SOW includes a variable consideration component, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on which method is expected to better predict the amount of consideration to which the Company will be entitled. The value of variable consideration is included in the transaction price if, and to the extent, it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are reassessed each reporting period, as required, and any adjustment required is recorded on a cumulative catch<span class="nobreak">-up</span> basis, which would affect revenue and net loss in the period of adjustment.</p></ix:continuation></div>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-17669"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_2" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company expenses the cost of research and development as incurred. Research and development expenses include costs incurred in funding research and development activities, license fees, and other external costs. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company&#8217;s behalf will be expensed as services are rendered or when the milestone is achieved. When billing terms under research and development contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end to those third parties. Accrual estimates are based on several factors, including the Company&#8217;s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs (see Note&#160;6).</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_2"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic&#160;730<span class="nobreak">-10-25-1</span>, <span class="Italic" style="font-style:italic;font-weight:normal;">Research and Development,</span> costs incurred in obtaining licenses and patent rights are charged to research and development expense if the technology licensed has not reached commercial feasibility and has no alternative future use. The licenses purchased by the Company (see Note&#160;6) require substantial completion of research and development, regulatory and marketing approval efforts to reach commercial feasibility and have no alternative future use. Accordingly, the total purchase price for the licenses acquired is reflected as research and development on the Company&#8217;s consolidated statements of operations and comprehensive loss.</p></ix:continuation></div>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="ixv-17681"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Contingencies</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Accruals are recorded for loss contingencies when it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been </p></ix:continuation></div></ix:continuation>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-18</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3 &#8212; Summary of Significant Accounting Policies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><div style="-keep: true"><ix:continuation id="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_2"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">accrued previously. Considering facts known at the time of the assessment, the Company determines whether potential losses are considered reasonably possible or probable and whether they are estimable. Based upon this assessment, the Company carries out an evaluation of disclosure requirements and considers possible accruals in the consolidated financial statements.</p></ix:continuation></div>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-17703"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company expenses stock<span class="nobreak">-based</span> compensation to employees and non<span class="nobreak">-employees</span> over the requisite service period based on the estimated grant<span class="nobreak">-date</span> fair value of the awards. Stock<span class="nobreak">-based</span> awards to employees with graded<span class="nobreak">-vesting</span> schedules are recognized, using the accelerated attribution method, on a straight<span class="nobreak">-line</span> basis over the requisite service period for each separately vesting portion of the award.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company estimates the fair value of stock option grants using the Black<span class="nobreak">-Scholes</span> option pricing model and the assumptions used in calculating the fair value of stock<span class="nobreak">-based</span> awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Expected Term</span>&#160;&#8212;&#160;The expected term of options represents the period that the Company&#8217;s stock<span class="nobreak">-based</span> awards are expected to be outstanding based on the simplified method, which is the half<span class="nobreak">-life</span> from vesting to the end of its contractual term. The simplified method is used as the Company has insufficient historical information to provide a basis for an estimate of the expected term.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_5" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Expected Volatility</span>&#160;&#8212;&#160;Volatility is a measure of the amount by which the Company&#8217;s share price has historically fluctuated or is expected to fluctuate (i.e., expected volatility) during a period. Due to the lack of an adequate history of a public market for the trading of the Company&#8217;s common stock and a lack of adequate company<span class="nobreak">-specific</span> historical and implied volatility data, the Company computes stock price volatility over expected terms based on comparable companies&#8217; historical common stock trading prices. For these analyses, the Company has selected companies with comparable characteristics, including enterprise value, risk profiles, and position within the industry.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_6" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_5"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Common Stock Fair Value</span>&#160;&#8212;&#160;The fair value of the common stock underlying the Company&#8217;s stock options is based on the closing price of the Company&#8217;s common stock, as reported by the Nasdaq Capital Market, on the grant date of the award.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_7" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_6"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Risk</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Free</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Interest Rate</span>&#160;&#8212;&#160;The Company bases the risk<span class="nobreak">-free</span> interest rate on the implied yield available on U.S.&#160;Treasury securities with a remaining term commensurate with the estimated expected term.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_8" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_7"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Expected Dividend</span>&#160;&#8212;&#160;The Company has never declared or paid any cash dividends on its shares of common stock and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_8"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company recognizes forfeitures of equity awards as they occur.</p></ix:continuation></div>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-17751"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the jurisdictions and&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in operations in the period that includes the enactment date. Deferred tax assets are reduced to estimated amounts expected to be realized by the use of a valuation allowance.</p></ix:continuation></div></ix:continuation>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-19</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3 &#8212; Summary of Significant Accounting Policies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_10" id="_SignificantAccountingPoliciesTextBlock-c0_cont_9"><div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="ixv-17774"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation id="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company is required to report all components of comprehensive loss, including net loss, in the accompanying consolidated financial statements in the period in which they are recognized. Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non<span class="nobreak">-owner</span> sources. The Company&#8217;s comprehensive loss for the year ended December&#160;31, 2023 is comprised of net loss, the effect of currency translation adjustments, and the change in pension benefit obligation. Net loss and comprehensive loss were the same for the year ended December&#160;31, 2022.</p></ix:continuation></div>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_1" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="ixv-17782"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Financial instruments</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_2" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company determines the accounting classification of financial instruments that are issued, including its warrants and a subscription agreement, as either liability or equity, by first assessing whether the financial instruments are freestanding financial instruments, and if they meet liability classification in accordance with ASC&#160;480, <span class="Italic" style="font-style:italic;font-weight:normal;">Distinguishing Liabilities from Equity</span>, (&#8220;ASC&#160;480&#8221;), and then in accordance with ASC&#160;815<span class="nobreak">-40</span>, <span class="Italic" style="font-style:italic;font-weight:normal;">Derivatives and Hedging&#160;&#8212;&#160;Contracts in Entity&#8217;s Own Equity </span>(&#8220;ASC&#160;815<span class="nobreak">-40</span>&#8221;). Under ASC&#160;480<span class="nobreak">-10</span>, financial instruments are considered liability<span class="nobreak">-classified</span> if the instruments are mandatorily redeemable, obligate the issuer to settle the instruments or the underlying shares by paying cash or other assets, or must or may require settlement by issuing a variable number of shares.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_2"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If the instruments do not meet liability classification under ASC&#160;480, the Company assesses the requirements under ASC&#160;815<span class="nobreak">-40</span>, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the financial instruments do not require liability classification under ASC&#160;815<span class="nobreak">-40</span>, in order to conclude equity classification, the Company assesses whether the instruments are indexed to the Company&#8217;s common stock and whether the instruments are classified as equity under ASC&#160;815<span class="nobreak">-40</span> or other applicable GAAP.&#160;After all relevant assessments are made, the Company concludes whether the instruments are classified as liability or equity. Liability<span class="nobreak">-classified</span> instruments are required to be accounted for at fair value both on the date of issuance and on subsequent accounting period ending dates, with all changes in fair value after the issuance date recorded as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. Equity<span class="nobreak">-classified</span> instruments are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.</p></ix:continuation></div>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" id="ixv-17803"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Preferred Stock</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation id="_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company applies the guidance enumerated in ASC&#160;480, when determining the classification and measurement of preferred stock. Preferred stock subject to mandatory redemption, if any, is classified as a liability and is measured at fair value. The Company classifies conditionally redeemable preferred stock, which includes preferred stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control, as temporary equity. At all other times, the Company classifies its preferred stock in stockholders&#8217; equity.</p></ix:continuation></div>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="onco_TreasuryStockPolicyPolicyTextBlock-c0_cont_1" escape="true" name="onco:TreasuryStockPolicyPolicyTextBlock" id="ixv-17810"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Treasury Stock</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation id="onco_TreasuryStockPolicyPolicyTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company records treasury stock activities under the cost method whereby the cost of the acquired stock is recorded as treasury stock.</p></ix:continuation></div>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-17817"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Net Loss Per Share</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Basic loss per share is computed by dividing the net loss applicable to common shares by the weighted average number of common shares outstanding during the period. The weighted average number of shares of common stock outstanding includes (i)&#160;pre<span class="nobreak">-funded</span> warrants because their exercise requires only nominal consideration for delivery of shares and (ii)&#160;the shares held in abeyance because there is no consideration required for delivery of the shares; </p></ix:continuation></div></ix:continuation>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-20</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3 &#8212; Summary of Significant Accounting Policies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_10"><div style="-keep: true"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_3" id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">it does not include any potentially dilutive securities or any unvested restricted stock of common stock. Certain restricted shares, although classified as issued and outstanding at December&#160;31, 2023 are considered contingently returnable until the restrictions lapse and will not be included in the basic net loss per share calculation until the shares are vested. Unvested shares of the Company&#8217;s restricted stock do not contain non<span class="nobreak">-forfeitable</span> rights to dividends and dividend equivalents. Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the Company&#8217;s Series&#160;A preferred stock, warrants, unvested restricted stock, and stock options. Diluted loss per share excludes the shares issuable upon the conversion of Series&#160;A preferred stock, as well as unvested restricted stock, common stock options and warrants, from the calculation of net loss per share if their effect would be anti<span class="nobreak">-dilutive</span>.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_4" id="_EarningsPerSharePolicyTextBlock-c0_cont_3"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The two<span class="nobreak">-class</span> method is used to determine earnings per share based on participation rights of participating securities in any undistributed earnings. Each preferred stock that includes rights to participate in distributed earnings is considered a participating security and the Company uses the two<span class="nobreak">-class</span> method to calculate net income available to the Company&#8217;s common stockholders per common share&#160;&#8212;&#160;basic and diluted.</p></ix:continuation></div>
		<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-17846"><div style="-keep: true"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_5" id="_EarningsPerSharePolicyTextBlock-c0_cont_4"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following securities were excluded from the computation of diluted shares outstanding for the periods presented, as they would have had an anti<span class="nobreak">-dilutive</span> impact on the Company&#8217;s net loss:</p></ix:continuation></div></ix:nonNumeric>
		<ix:continuation id="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_5"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Years Ended <br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c91" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-30915">1,904,830</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c92" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-30916">1,392,654</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Warrants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c93" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-30917">7,899,661</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c94" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-30918">5,264,274</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c95" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-30919">256,580</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-248">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock issuable upon conversion of Series&#160;A preferred stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c97" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-30920">5,709,935</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-249">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-30921">15,771,006</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-30922">6,656,928</ix:nonFraction></span></p>	</td>
				</tr>

		</table></ix:continuation></ix:continuation>
		<div style="-keep: true"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-17923"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">New Accounting Pronouncement</span><span class="Bold" style="font-style:normal;font-weight:bold;">s</span></p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In November&#160;2023, the FASB issued ASU No.&#160;2023<span class="nobreak">-07</span>, Segment Reporting (Topic&#160;280): <span class="Italic" style="font-style:italic;font-weight:normal;">Improvements to Reportable Segment Disclosures</span>. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (&#8220;CODM&#8221;) and included within each reported measure of a segment&#8217;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment&#8217;s profit or loss in assessing segment performance and deciding how to allocate resources. This ASU is effective for annual periods beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2023, the FASB issued ASU No.&#160;2023<span class="nobreak">-09</span>, Income Taxes (Topic&#160;740<span class="Italic" style="font-style:italic;font-weight:normal;">): Improvements to Income Tax Disclosures</span>. This ASU requires disclosure of specific categories in the rate reconciliation and additional information for reconciling items that meet a quantitative threshold. The amendment also includes other changes to improve the effectiveness of income tax disclosures, including further disaggregation of income taxes paid for individually significant jurisdictions. This ASU is effective for annual periods beginning after December&#160;15, 2024. Adoption of this ASU should be applied on a prospective basis. Early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying consolidated financial statements.</p></ix:continuation></div></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-21</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<ix:nonNumeric contextRef="c0" continuedAt="_SupplementalBalanceSheetDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="ixv-17947"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;4 &#8212; Balance Sheet Details</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Inventories</span></p>
		<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfInventoryCurrentTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="ixv-17952"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Inventories primarily relate to ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> product and consisted of the following as of December&#160;31, 2023 and 2022:</p></ix:nonNumeric>
		<ix:continuation id="_ScheduleOfInventoryCurrentTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Raw materials</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="0" unitRef="usd" id="ixv-30923">139,208</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-252">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Work-in-process</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="0" unitRef="usd" id="ixv-30924">194,805</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-253">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Finished goods</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd" id="ixv-30925">30,039</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-254">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-30926">364,052</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-255">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
				</tr>

		</table></ix:continuation>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Prepaid Expenses and Other Current Assets</span></p>
		<ix:nonNumeric contextRef="c0" continuedAt="_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="ixv-18037"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Prepaid expenses and other current assets consisted of the following as of December&#160;31, 2023 and 2022:</p></ix:nonNumeric>
		<ix:continuation id="_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid insurance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="0" unitRef="usd" id="ixv-30927">122,004</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="0" unitRef="usd" id="ixv-30928">148,789</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid regulatory fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidRent" scale="0" unitRef="usd" id="ixv-30929">312,551</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-256">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="onco:PrepaidsResearchAndDevelopment" scale="0" unitRef="usd" id="ixv-30930">89,195</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="onco:PrepaidsResearchAndDevelopment" scale="0" unitRef="usd" id="ixv-30931">231,981</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid professional fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="onco:PrepaidProfessionalFees" scale="0" unitRef="usd" id="ixv-30932">70,708</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-257">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-30933">175,695</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-30934">88,462</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-30935">770,153</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-30936">469,232</ix:nonFraction></span></p>	</td>
				</tr>

		</table></ix:continuation>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Intangible Assets</span></p>
		<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="ixv-18145"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Intangible assets, which were recorded during the year ended December&#160;31, 2023 in connection with the ENTADFI and Proteomedix acquisitions (see Note&#160;5), is comprised of customer relationships, product rights for developed technology, and a trade name, and consisted of the following as of December&#160;31, 2023:</p></ix:nonNumeric>
		<ix:continuation continuedAt="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_2" id="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Cost</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Impairment</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Effect of</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Currency</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Translation</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Balance</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cost basis:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Trade name</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="onco:FiniteLivedIntangibleAssetCost" scale="0" unitRef="usd" id="ixv-30937">9,018,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-258">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" scale="0" unitRef="usd" id="ixv-30938">294,739</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-30939">9,312,739</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Product rights for developed technology</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="onco:FiniteLivedIntangibleAssetCost" scale="0" unitRef="usd" id="ixv-30940">28,447,771</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="onco:ImpairmentOfIntangibleAssetExcludingGoodwill" scale="0" sign="-" unitRef="usd" id="ixv-30941">14,610,128</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" scale="0" unitRef="usd" id="ixv-30942">344,514</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-30943">14,182,157</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Customer relationships</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="onco:FiniteLivedIntangibleAssetCost" scale="0" unitRef="usd" id="ixv-30944">1,891,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-259">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" scale="0" unitRef="usd" id="ixv-30945">61,803</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-30946">1,952,803</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="onco:FiniteLivedIntangibleAssetCost" scale="0" unitRef="usd" id="ixv-30947">39,356,771</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:ImpairmentOfIntangibleAssetExcludingGoodwill" scale="0" sign="-" unitRef="usd" id="ixv-30948">14,610,128</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" scale="0" unitRef="usd" id="ixv-30949">701,056</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-30950">25,447,699</ix:nonFraction></span></p>	</td>
				</tr>

		</table></ix:continuation>
		<ix:continuation id="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_2"><table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Amortization</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Balance</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Accumulated amortization:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Trade name</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-260">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-261">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Product rights for developed technology</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-30951">31,213</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="onco:FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation" scale="0" sign="-" unitRef="usd" id="ixv-30952">31,213</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Customer relationships</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-30953">5,599</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="onco:FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation" scale="0" sign="-" unitRef="usd" id="ixv-30954">5,599</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-30955">36,812</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation" scale="0" sign="-" unitRef="usd" id="ixv-30956">36,812</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Intangible assets, net</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd" id="ixv-30957">25,410,887</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>

		</table></ix:continuation></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-22</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;4 &#8212; Balance Sheet Details</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_SupplementalBalanceSheetDisclosuresTextBlock-c0_cont_2" id="_SupplementalBalanceSheetDisclosuresTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The finite lived intangible assets held by the Company, which includes customer relationships and product rights for developed technology, are being amortized over their estimated useful lives, which is <ix:nonNumeric contextRef="c1" continuedAt="_PropertyPlantAndEquipmentUsefulLife-c1_cont_1" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-30958">15</ix:nonNumeric>&#160;years for customer relationships, and <ix:nonNumeric contextRef="c99" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-30959">15</ix:nonNumeric> and <ix:nonNumeric contextRef="c100" continuedAt="_PropertyPlantAndEquipmentUsefulLife-c100_cont_1" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-30960">6</ix:nonNumeric>&#160;years for product rights for developed technology related to Proclarix and ENTADFI, respectively. Amortization expense related to intangible assets was approximately $<ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-30961">37,000</ix:nonFraction> for the<ix:continuation id="_PropertyPlantAndEquipmentUsefulLife-c100_cont_1"><ix:continuation id="_PropertyPlantAndEquipmentUsefulLife-c1_cont_1"> year</ix:continuation></ix:continuation> ended December&#160;31, 2023, of which approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherCostOfOperatingRevenue" scale="0" unitRef="usd" id="ixv-30964">31,000</ix:nonFraction> and $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherSellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-30965">6,000</ix:nonFraction> was recorded as cost of revenue and selling, general, and administrative expenses, respectively, in the accompanying consolidated statements of operations and comprehensive loss.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the fourth quarter of 2023, the Company determined that there were certain triggering events that indicated that the carrying amount of the assets recorded in connection with the ENTADFI acquisition (see Note&#160;5) may not be fully recoverable. Specifically, as a result of the Proteomedix acquisition (see Note&#160;5) and continued significant cash constraints, the Company decided to pause the commercialization of ENTADFI until a later date, and consider strategic alternatives, which combined, decreased the cash flows expected to be generated from these assets. The Company performed an undiscounted cash flow analysis over the ENTADFI asset group and determined that the carrying value of the asset group is not recoverable. The Company then estimated the fair value of the asset group to measure the impairment loss. Significant assumptions used to determine this non<span class="nobreak">-recurring</span> fair value measurement include projected sales driven by market share and product sales price estimates, associated expenses, growth rates, the discount rate used to measure the fair value of the net cash flows associated with this asset group, as well as Management&#8217;s estimates of the probability of each potential strategic alternative taking place. The Company recorded an impairment charge of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="6" unitRef="usd" id="ixv-30966">14.7</ix:nonFraction>&#160;million during the year ended December&#160;31, 2023, which was allocated on a pro rata basis across the assets within the asset group as follows: approximately $<ix:nonFraction contextRef="c102" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="6" unitRef="usd" id="ixv-30967">14.6</ix:nonFraction>&#160;million and approximately $<ix:nonFraction contextRef="c103" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="6" unitRef="usd" id="ixv-30968">0.1</ix:nonFraction>&#160;million was allocated to the product rights intangible asset and other assets, respectively. After recording this impairment charge, the long<span class="nobreak">-lived</span> assets in the ENTADFI asset group have a remaining carrying amount of approximately $<ix:nonFraction contextRef="c101" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetImpairmentCharges" scale="6" unitRef="usd" id="ixv-30969">3.3</ix:nonFraction>&#160;million as of December&#160;31, 2023. In addition, the Company also recorded an impairment charge on acquired ENTADFI inventory, see Note&#160;3.</p>
		<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="ixv-18449"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Future annual amortization expense related to the Company&#8217;s finite lived intangible assets is as follows as of December&#160;31, 2023:</p></ix:nonNumeric>
		<ix:continuation id="_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Years ending December&#160;31,</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="0" unitRef="usd" id="ixv-30970">1,012,870</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="0" unitRef="usd" id="ixv-30971">1,326,837</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2026</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="0" unitRef="usd" id="ixv-30972">1,326,837</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2027</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="0" unitRef="usd" id="ixv-30973">1,326,837</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2028</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="0" unitRef="usd" id="ixv-30974">1,326,837</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thereafter</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="0" unitRef="usd" id="ixv-30975">9,777,930</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-30976">16,098,148</ix:nonFraction></span></p>	</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, the weighted<span class="nobreak">-average</span> remaining amortization period for intangible assets was approximately <span style="-sec-ix-hidden: hidden-fact-265">13.5</span>&#160;years.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Trade names, which do not have legal, regulatory, contractual, competitive, economic, or other factors that limit the useful lives are considered indefinite lived assets and are not amortized but are tested for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. As of December&#160;31, 2023, $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IndefiniteLivedTradeNames" scale="6" unitRef="usd" id="ixv-30977">9.3</ix:nonFraction>&#160;million of intangible assets relate to a trade name that has been identified as having an indefinite life.</p></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-23</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;4 &#8212; Balance Sheet Details</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_SupplementalBalanceSheetDisclosuresTextBlock-c0_cont_2"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Goodwill</span></p>
		<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfGoodwillTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfGoodwillTextBlock" id="ixv-18536"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Goodwill was recorded during the year ended December&#160;31, 2023, in connection with the Proteomedix acquisition (see Note&#160;5), and consisted of the following as of December&#160;31, 2023:</p></ix:nonNumeric>
		<ix:continuation id="_ScheduleOfGoodwillTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance as of December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-262">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">PMX Transaction goodwill</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillTransfers" scale="0" unitRef="usd" id="ixv-30978">53,914,055</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effect of currency translation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="0" unitRef="usd" id="ixv-30979">1,762,087</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance as of December&#160;31, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="0" unitRef="usd" id="ixv-30980">55,676,142</ix:nonFraction></span></p>	</td>
				</tr>

		</table></ix:continuation>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Expenses</span></p>
		<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAccruedLiabilitiesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="ixv-18588"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Accrued expenses consisted of the following as of December&#160;31, 2023 and 2022:</p></ix:nonNumeric>
		<ix:continuation id="_ScheduleOfAccruedLiabilitiesTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="onco:AccruedResearchAndDevelopmentCurrent" scale="0" unitRef="usd" id="ixv-30981">616,707</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="onco:AccruedResearchAndDevelopmentCurrent" scale="0" unitRef="usd" id="ixv-30982">847,747</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedUtilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-30983">487,579</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedUtilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-30984">1,132,859</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued deferred offering costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="onco:AccruedDeferredOfferingCosts" scale="0" unitRef="usd" id="ixv-30985">125,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="onco:AccruedDeferredOfferingCosts" scale="0" unitRef="usd" id="ixv-30986">125,000</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued professional fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-30987">550,415</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-263">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued implementation fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedMarketingCostsCurrent" scale="0" unitRef="usd" id="ixv-30988">93,787</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-264">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other accrued expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-30989">265,849</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-30990">125,922</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued franchise taxes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" scale="0" unitRef="usd" id="ixv-30991">60,530</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" scale="0" unitRef="usd" id="ixv-30992">177,600</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-30993">2,199,867</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-30994">2,409,128</ix:nonFraction></span></p>	</td>
				</tr>

		</table></ix:continuation></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_MergersAcquisitionsAndDispositionsDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="ixv-18720"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;5 &#8212; Acquisitions</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">ENTADFI</span><span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;19, 2023, the Company and Veru, Inc. (&#8220;Veru&#8221;) entered into an Asset Purchase Agreement (the &#8220;&#160;Veru APA&#8221;). Pursuant to, and subject to the terms and conditions of, the Veru APA, the Company purchased substantially all of the assets related to Veru&#8217;s ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> product (&#8220;ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span>&#8221;) (the &#8220;Transaction&#8221;) for a total possible consideration of $<ix:nonFraction contextRef="c109" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" scale="6" unitRef="usd" id="ixv-30995">100</ix:nonFraction>&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with the Veru APA, the Company agreed to provide Veru with initial consideration totaling $<ix:nonFraction contextRef="c110" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" scale="6" unitRef="usd" id="ixv-30996">20.0</ix:nonFraction>&#160;million, consisting of <ix:nonNumeric contextRef="c111" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" id="ixv-18730">(i)&#160;$6.0&#160;million paid upon the closing of the Transaction on April&#160;19, 2023, (ii)&#160;an additional $4.0&#160;million in the form of a non<span class="nobreak">-interest</span> bearing note payable due on September&#160;30, 2023, and (iii)&#160;an additional $10.0&#160;million in the form of two $5.0&#160;million non<span class="nobreak">-interest</span> bearing notes payable, each due on April&#160;19, 2024 and September&#160;30, 2024.</ix:nonNumeric></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, the terms of the Veru APA require the Company to pay Veru up to an additional $<ix:nonFraction contextRef="c112" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" scale="6" unitRef="usd" id="ixv-30997">80.0</ix:nonFraction>&#160;million based on the Company&#8217;s net sales of ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> after closing (the &#8220;Milestone Payments&#8221;). The Milestone Payments are payable as follows: <ix:nonNumeric contextRef="c113" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" id="ixv-18735">(i)&#160;$10.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> of $100.0&#160;million during a calendar year, (ii)&#160;$20.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> of $200.0&#160;million during a calendar year, and (3)&#160;$50.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> of $500.0&#160;million during a calendar year.</ix:nonNumeric></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Transaction, the Company also assumed royalty and milestone obligations under an asset purchase agreement for tadalafil<span class="nobreak">-finasteride</span> combination entered into by Veru and Camargo Pharmaceutical Services, LLC on December&#160;11, 2017 (the &#8220;Camargo Obligations&#8221;). The Camargo Obligations assumed by the Company include a <ix:nonFraction contextRef="c114" decimals="2" format="ixt:num-dot-decimal" name="onco:RoyaltySalesPercentage" scale="-2" unitRef="pure" id="ixv-30998">6</ix:nonFraction>% royalty on all sales of tadalafil<span class="nobreak">-finasteride</span> and sales milestone payments of up to $<ix:nonFraction contextRef="c115" decimals="-5" format="ixt:num-dot-decimal" name="onco:SalesPaymentsAmount" scale="6" unitRef="usd" id="ixv-30999">22.5</ix:nonFraction>&#160;million, payable </p></ix:nonNumeric>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-24</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;5 &#8212; Acquisitions</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_MergersAcquisitionsAndDispositionsDisclosuresTextBlock-c0_cont_2" id="_MergersAcquisitionsAndDispositionsDisclosuresTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">to Camargo as follows: <ix:nonNumeric contextRef="c116" name="us-gaap:BusinessAcquisitionProFormaInformationDescription" id="ixv-18755">(i)&#160;$5.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> of $100.0&#160;million during a calendar year, (ii)&#160;$7.5&#160;million is payable upon the first time the Company achieves net sales from ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> of $200.0&#160;million during a calendar year, and (3)&#160;$10.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> of $300.0&#160;million during a calendar year.</ix:nonNumeric></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On September&#160;29, 2023, the Company entered into an amendment to the Veru APA (the &#8220;Veru APA Amendment&#8221;), which provides that the <ix:nonNumeric contextRef="c111" name="us-gaap:BusinessAcquisitionProFormaInformationDescription" id="ixv-18760">$4.0&#160;million note payable originally due on September&#160;30, 2023 was deemed paid and fully satisfied upon (1)&#160;the payment to the Seller of $1.0&#160;million in cash on September&#160;29, 2023, and (2)&#160;the issuance to the Seller by October&#160;3, 2023 of 3,000<span class="nobreak"> </span>shares of Series&#160;A Convertible Preferred Stock (the &#8220;Series&#160;A Preferred Stock&#8221;) of the Company (see Note&#160;9)</ix:nonNumeric>. Pursuant to the Veru APA Amendment, the Series&#160;A Preferred Stock will convert to common stock of the Company one year from the date of issuance if the required stockholder approval is obtained. The Series&#160;A Preferred Stock, which was issued to the Seller on October&#160;3, 2023 is initially convertible, in the aggregate, into <ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="onco:AggregatePurchaseShares" scale="0" unitRef="shares" id="ixv-31000">5,709,935</ix:nonFraction><span class="nobreak"> </span>shares of the Company&#8217;s common stock, subject to adjustment and certain stockholder approval limitations specified in the Certificate of Designations. Pursuant to the Veru APA Amendment, the Company agreed to use commercially reasonable efforts to obtain such stockholder approval by December&#160;31, 2023, however, such shareholder approval was not obtained as of December&#160;31, 2023. The Company also agreed to include the shares of common stock issuable upon conversion of the Series&#160;A Preferred Stock in the next resale registration statement filed with the SEC.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Also, in connection with the Transaction, and pursuant to the Veru APA, the Company entered into non<span class="nobreak">-competition</span> and non<span class="nobreak">-solicitation</span> agreements (the &#8220;Non<span class="nobreak">-Competition</span> Agreements&#8221;) with two of Veru&#8217;s key stockholders and employees (the &#8220;Restricted Parties&#8221;). The Non<span class="nobreak">-Competition</span> Agreements generally prohibit the Restricted Parties from either directly or indirectly engaging in the Restricted Business (as such term is defined in the Veru APA) for a period of <span style="-sec-ix-hidden: hidden-fact-266">five</span>&#160;years from the closing of the Transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The acquisition of ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> has been accounted for as an asset acquisition in accordance with ASC&#160;805<span class="nobreak">-50</span> because substantially all of the fair value of the assets acquired is concentrated in a single asset, the ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> product rights. The ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> products rights consist of trademarks, regulatory approvals, and other records, and are considered a single asset as they are inextricably linked.</p>
		<ix:nonNumeric contextRef="c0" continuedAt="_AssetAcquisitionContingentConsiderationTableTextBlock-c0_cont_1" escape="true" name="us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock" id="ixv-18774"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the aggregate consideration transferred for the assets acquired by the Company in connection with the Veru APA:</p></ix:nonNumeric>
		<ix:continuation continuedAt="_AssetAcquisitionContingentConsiderationTableTextBlock-c0_cont_2" id="_AssetAcquisitionContingentConsiderationTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Consideration</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Transferred</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Consideration transferred at closing</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferredOtherAssets" scale="0" unitRef="usd" id="ixv-31001">6,000,000</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fair value of notes payable issued</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" scale="0" unitRef="usd" id="ixv-31002">12,947,000</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Transaction costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" scale="0" unitRef="usd" id="ixv-31003">79,771</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total consideration transferred</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" unitRef="usd" id="ixv-31004">19,026,771</ix:nonFraction></span></p>	</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of the non<span class="nobreak">-interest</span> bearing notes payable was estimated using a net present value model using discount rates averaging <ix:nonFraction contextRef="c118" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-31005">8.2</ix:nonFraction>%. The resulting fair value is being accreted to the face value of the notes, through the respective maturity dates. Management evaluated the Milestone Payments and determined that at the close of the Transaction, they are not considered probable, and as such, the Company did not recognize any amount related to the Milestone Payments in the consideration transferred.</p>
		<ix:nonNumeric contextRef="c0" continuedAt="_AssetAcquisitionTableTextBlock-c0_cont_1" escape="true" name="us-gaap:AssetAcquisitionTableTextBlock" id="ixv-18825"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the assets acquired with the Veru APA:</p></ix:nonNumeric>
		<ix:continuation id="_AssetAcquisitionTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Assets</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Recognized</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Inventory</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="onco:AssetAcquisitionConsiderationTransferredInventory" scale="0" unitRef="usd" id="ixv-31006">1,120,000</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> Intangible</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="onco:AssetAcquisitionConsiderationTransferredENTADFIIntangible" scale="0" unitRef="usd" id="ixv-31007">17,906,771</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total fair value of identifiable assets acquired</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" unitRef="usd" id="ixv-31008">19,026,771</ix:nonFraction></span></p>	</td>
				</tr>

		</table></ix:continuation></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-25</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;5 &#8212; Acquisitions</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_MergersAcquisitionsAndDispositionsDisclosuresTextBlock-c0_cont_3" id="_MergersAcquisitionsAndDispositionsDisclosuresTextBlock-c0_cont_2"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with ASC&#160;805<span class="nobreak">-50</span>, the acquired inventory was recorded at fair value. The remaining consideration transferred was allocated to the ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> intangible asset, which will be amortized over its estimated useful life, starting when ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> sales begin. Acquired inventory is comprised of work<span class="nobreak">-in-process</span> and raw materials. The fair value of work<span class="nobreak">-in-process</span> inventory was determined based on an estimated sales price of the finished goods, adjusted for costs to complete the manufacturing process, costs of the selling effort, a reasonable profit allowance for the remaining manufacturing and selling effort, and an estimate of holding costs, and resulted in a fair value adjustment of approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="onco:InventoryFairValue" scale="6" unitRef="usd" id="ixv-31009">0.3</ix:nonFraction>&#160;million. The fair value of raw materials was determined to approximate replacement cost. The Company recorded an impairment charge on the ENTADFI asset group of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="6" unitRef="usd" id="ixv-31010">14.7</ix:nonFraction>&#160;million during the fourth quarter of 2023 (see Note&#160;4), as well as an impairment charge on the ENTADFI acquired inventory of approximately $<ix:nonFraction contextRef="c111" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="6" unitRef="usd" id="ixv-31011">1.2</ix:nonFraction>&#160;million, which included impairment of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="onco:ImpairmentRate" scale="-2" unitRef="pure" id="ixv-31012">100</ix:nonFraction>% of the acquired work<span class="nobreak">-in-process</span> inventory.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Management evaluated the Camargo Obligations and determined that at the close of the Transaction, the related sales milestone payments are not considered probable, and as such, the Company did not recognize any related liability at the date of the Transaction. In addition, royalties under the Camargo Obligations will be recorded as cost of sales, as the related sales are generated and recognized.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">WraSer:</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On June&#160;13, 2023 (the &#8220;Execution Date&#8221;), the Company entered into an asset purchase agreement with WraSer, LLC, and affiliates (the &#8220;WraSer Seller&#8221;) (the &#8220;WraSer APA&#8221;). Pursuant to, and subject to the terms and conditions of, the WraSer APA, on the WraSer Closing Date (as defined below) the Company was to purchase six FDA<span class="nobreak">-approved</span> pharmaceutical assets across several indications, including cardiology, otic infections, and pain management (the &#8220;WraSer Assets&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the WraSer APA, the Company was to purchase the WraSer Assets for <ix:nonNumeric contextRef="c0" name="us-gaap:BusinessAcquisitionProFormaInformationDescription" id="ixv-31013">(i)&#160;$3.5&#160;million in cash at signing of the WraSer APA; (ii)&#160;$4.5&#160;million in cash on the later of (x)&#160;90&#160;days after the signing of the WraSer APA or (y)&#160;the date that all closing conditions under the WraSer APA are met or otherwise waived (the &#8220;WraSer Closing Date&#8221;); (iii)&#160;1.0&#160;million shares of the Company&#8217;s common stock (the &#8220;Closing Shares&#8221;) issuable on the WraSer Closing Date, and (iv)&#160;$500,000 in cash one year from the WraSer Closing Date.</ix:nonNumeric></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In conjunction with the WraSer APA, the Company and the WraSer Seller entered into a Management Services Agreement (the &#8220;MSA&#8221;) on the Execution Date. Pursuant to the terms of the MSA, the Company will act as the manager of the WraSer Seller&#8217;s business during the period between the Execution Date and the WraSer Closing Date. During this period, the Company will make advances to WraSer, if needed. If, on the WraSer Closing Date, the WraSer Seller&#8217;s cash balance is in excess of the target amount (&#8220;Cash Target&#8221;) specified in the MSA, the Company will apply that excess to the $<ix:nonFraction contextRef="c119" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" scale="6" unitRef="usd" id="ixv-31014">4.5</ix:nonFraction>&#160;million cash payment due upon closing. Conversely, if there is a shortfall, the Company will be required to remit the difference to the WraSer Seller over time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The WraSer APA can be terminated prior to the closing upon agreement with all parties or upon breach of contract of either party, uncured within 20&#160;days of notice. If the WraSer APA is terminated upon agreement with all parties or upon uncured breach of contract by the Company, the initial $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="onco:InitialPaymentAmount" scale="6" unitRef="usd" id="ixv-31015">3.5</ix:nonFraction>&#160;million payment is retained by the WraSer Seller. If it is determined that there is an uncured breach of contract by the WraSer Seller, and the WraSer APA is terminated, the Company will have an unsecured claim against WraSer for the $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="onco:Payments" scale="6" unitRef="usd" id="ixv-31016">3.5</ix:nonFraction>&#160;million payment made by the Company upon execution of the WraSer APA.&#160;The closing of the transaction is subject to certain customary closing conditions, including submission of the FDA transfer documentation to transfer ownership of the acquired product regulatory approvals to the Company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Management evaluated the terms of the WraSer APA and the WraSer MSA, and determined that, at the Execution Date, control under the provisions of ASC&#160;805, <span class="Italic" style="font-style:italic;font-weight:normal;">Business Combinations </span>(&#8220;ASC&#160;805&#8221;), did not transfer to the Company; if the transaction closes, control will transfer then, and the acquisition date will be the closing date. Management further evaluated the requirements pursuant to ASC&#160;810, <span class="Italic" style="font-style:italic;font-weight:normal;">Consolidations</span>, and determined based on the terms of the MSA, and the Company&#8217;s involvement in the WraSer Seller&#8217;s business, that the WraSer Seller is a variable interest entity (&#8220;VIE&#8221;) to the Company. Management determined that the Company is not the primary beneficiary of </p></ix:continuation>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-26</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;5 &#8212; Acquisitions</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_MergersAcquisitionsAndDispositionsDisclosuresTextBlock-c0_cont_4" id="_MergersAcquisitionsAndDispositionsDisclosuresTextBlock-c0_cont_3"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the VIE as the WraSer APA and MSA do not provide the Company with the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance. While the Company was involved in the&#160;day<span class="nobreak">-to-day</span> business activities of the VIE until WraSer filed for relief under Chapter&#160;11 of the U.S.&#160;Bankruptcy Court (see below), the WraSer Seller had to approve substantially all business activities and transactions that significantly impact the economic performance of WraSer during the term of the MSA.&#160;Additionally, the Company is not required to absorb the losses of WraSer if the WraSer APA does not close. As such, the Company was not required to consolidate WraSer in the Company&#8217;s financial statements as of and during the year ended December&#160;31, 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company recorded the initial $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Deposits" scale="6" unitRef="usd" id="ixv-31017">3.5</ix:nonFraction>&#160;million payment as a deposit. The Company does not have any liabilities recorded as of December&#160;31, 2023 associated with its variable interest in the WraSer Seller, and its exposure to the WraSer Seller&#8217;s losses is limited to no more than the shortfall, if any, of the Cash Target amount of approximately $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashFDICInsuredAmount" scale="6" unitRef="usd" id="ixv-31018">1.1</ix:nonFraction>&#160;million compared to the WraSer Seller&#8217;s cash balance on the WraSer Closing Date.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On September&#160;26, 2023, WraSer and its affiliates filed for relief under chapter 11 of the U.S.&#160;Bankruptcy Code in the Bankruptcy Court. On October&#160;4, 2023, the parties agreed to amend the WraSer APA, which was subject to court approval. Shortly after its bankruptcy filing, WraSer filed a motion seeking approval of the WraSer APA as amended. The amendment, among other things, eliminates the $<ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" scale="0" unitRef="usd" id="ixv-31019">500,000</ix:nonFraction> post<span class="nobreak">-closing</span> payment due June&#160;13, 2024 and staggers the $<ix:nonFraction contextRef="c121" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" scale="6" unitRef="usd" id="ixv-31020">4.5</ix:nonFraction>&#160;million cash payment that the Company would otherwise have to pay at closing to: <ix:nonNumeric contextRef="c122" name="us-gaap:BusinessAcquisitionProFormaInformationDescription" id="ixv-18913">(i)&#160;$2.2&#160;million to be paid at closing, (ii)&#160;$2.3&#160;million, to be paid in monthly installments of $150,000 commencing January&#160;2024 and (iii)&#160;789<span class="nobreak"> </span>shares of Series&#160;A Preferred Stock to be paid at closing</ix:nonNumeric>. <ix:nonNumeric contextRef="c123" name="us-gaap:BusinessAcquisitionProFormaInformationDescription" id="ixv-31021">The amendment also reduced the number of products the Company was acquiring by excluding pain medications and including only (i)&#160;Ciprofloxacin 0.3% and Fluocinolone 0.025% Otic Solution, under the trademark OTOVEL and its Authorized Generic Version approved under US FDA NDA No. 208251, (ii)&#160;Ciprofloxacin 0.2% Otic solution, under the trademark CETRAXAL, and (iii)&#160;Vorapaxar Sulfate tablets under the trademark Zontivity approved under US FDA NDA N204886.</ix:nonNumeric></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In October&#160;2023, WraSer alerted the Company that its sole manufacturer for the active pharmaceutical ingredient (&#8220;API&#8221;) for Zontivity, the key driver for the WraSer acquisition, would no longer manufacture the API for Zontivity. The Company believes that this development constituted a Material Adverse Effect under the WraSer APA and the WraSer MSA, enabling the Company to terminate the WraSer APA and the WraSer MSA.&#160;On October&#160;20, 2023, the Company filed a motion for relief from the automatic stay in the Bankruptcy Court so that the Company can exercise the termination rights under the WraSer APA, as amended. On December&#160;18, 2023, the Bankruptcy Court entered into an Agreed Order lifting the automatic stay to enable the Company to exercise its rights to terminate the WraSer APA and the WraSer MSA.&#160;On December&#160;21, 2023, the Company filed a Notice with the Bankruptcy Court terminating the WraSer APA and the WraSer MSA.&#160;WraSer has advised the Company that it does not believe that a Material Adverse Effect occurred. Due to the WraSer bankruptcy filing and the Company&#8217;s status as an unsecured creditor of WraSer, it is unlikely that the Company will recover the $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="6" unitRef="usd" id="ixv-31022">3.5</ix:nonFraction>&#160;million initial payment made, or any costs and resources in connection with services provided by the Company under the WraSer MSA, and therefore the Company recorded a loss on impairment for the $<ix:nonFraction contextRef="c124" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Deposits" scale="6" unitRef="usd" id="ixv-31023">3.5</ix:nonFraction>&#160;million deposit during the year ended December&#160;31, 2023.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Proteomedix</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2023 (the &#8220;Acquisition Date&#8221;), Onconetix entered into a Share Exchange Agreement (the &#8220;Share Exchange Agreement&#8221;) with Proteomedix and each of the holders of outstanding capital stock or Proteomedix convertible securities (other than Proteomedix stock options) (collectively the &#8220;Sellers&#8221;), pursuant to which the Company acquired <ix:nonFraction contextRef="c68" decimals="2" format="ixt:num-dot-decimal" name="onco:VotingInterestPercentage" scale="-2" unitRef="pure" id="ixv-31024">100</ix:nonFraction>% of the outstanding common shares and voting interest of Proteomedix, through the issuance of <ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" scale="0" unitRef="shares" id="ixv-31025">3,675,414</ix:nonFraction><span class="nobreak"> </span>shares of common stock and <ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" scale="0" unitRef="shares" id="ixv-31026">2,696,729</ix:nonFraction><span class="nobreak"> </span>shares of Series&#160;B Convertible Preferred Stock (the &#8220;PMX Transaction&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Subject to any requirements related to the Committee on Foreign Investment in the United&#160;States, upon approval by the requisite vote of stockholders of Onconetix at the Special Meeting of the Stockholders (&#8220;Stockholder Approval&#8221;), each share of Series&#160;B Convertible Redeemable Preferred Stock (&#8220;Series&#160;B Preferred Stock&#8221;) shall automatically </p></ix:continuation>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-27</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;5 &#8212; Acquisitions</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_MergersAcquisitionsAndDispositionsDisclosuresTextBlock-c0_cont_5" id="_MergersAcquisitionsAndDispositionsDisclosuresTextBlock-c0_cont_4"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">convert into <ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="onco:NumberOfShares" scale="0" unitRef="shares" id="ixv-31027">100</ix:nonFraction><span class="nobreak"> </span>shares of common stock in accordance with the terms of the Series&#160;B Certificate of Designation (the &#8220;Conversion&#8221;). If Stockholder Approval is not obtained by January&#160;1, 2025, Onconetix may, at the option of the holders, be obligated to cash settle the Series&#160;B Preferred Stock. The Series&#160;B Preferred Stock outstanding as a result of the PMX Transaction is convertible into <ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" scale="0" unitRef="shares" id="ixv-31028">269,672,900</ix:nonFraction><span class="nobreak"> </span>shares of common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The consummation (the &#8220;Closing&#8221;) of the PMX Transaction was subject to customary closing conditions and the agreement to enter into a subscription agreement (see Note&#160;8) with Altos Ventures, a shareholder of Proteomedix, prior to the closing of the PMX Transaction (the &#8220;PMX Investor&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In addition, each option to purchase shares of Proteomedix (each, a &#8220;Proteomedix Stock Option&#8221;) outstanding immediately before the Closing, whether vested or unvested, remains outstanding until the Conversion unless otherwise terminated in accordance with its terms. At the Conversion, each outstanding Proteomedix Stock Option, whether vested or unvested, shall be assumed by Onconetix and converted into the right to receive (a)&#160;an option to acquire shares of common stock (each, an &#8220;Assumed Option&#8221;) or (b)&#160;such other derivative security as Onconetix and Proteomedix may agree, subject in either case to substantially the same terms and conditions as were applicable to such Proteomedix Stock Option immediately before the Closing. Each Assumed Option shall: (i)&#160;represent the right to acquire a number of shares of common stock equal to the product of (A)&#160;the number of Proteomedix common shares that were subject to the corresponding Proteomedix Option immediately prior to the Closing, multiplied by (B)&#160;the Exchange Ratio (as defined in the Share Exchange Agreement&#8221;); and (ii)&#160;have an exercise price (as rounded down to the nearest whole cent) equal to the quotient of (A)&#160;the exercise price of the corresponding Proteomedix Option, divided by (B)&#160;the Exchange Ratio.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Management determined that the PMX Transaction was a business combination as defined within ASC&#160;805<span class="Italic" style="font-style:italic;font-weight:normal;">,</span> and that Onconetix was the accounting acquirer. The Company determined that Onconetix was the accounting acquirer based on the guidance contained within ASC&#160;805<span class="nobreak">-10</span>. The significant factors that led to the Company&#8217;s conclusion were (<ix:nonNumeric contextRef="c129" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" id="ixv-31029">i)&#160;the Company obtained 100% of the outstanding common stock and voting interest of PMX, (ii)&#160;at closing of the PMX Transaction, the PMX shareholders were issued approximately 17% of Onconetix&#8217;s outstanding common stock and none of the former PMX shareholders held more than 5% of Onconetix&#8217;s common stock individually, (iii)&#160;the composition of executive management and the governing body did not change sufficiently to give PMX or its former shareholders control over these functions within Onconetix, and (iv)&#160;Onconetix was significantly larger when considering both total assets and operations.</ix:nonNumeric> As a result, the Company has applied purchase accounting as of the Closing of the PMX Transaction. The assets, liabilities, and non<span class="nobreak">-controlling</span> interest of Proteomedix were recognized at fair value as of the Closing and the results of its operations have been included within Onconetix&#8217;s consolidated statements of operations and comprehensive loss from that date forward.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnosis. Proteomedix has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The Company expects Proteomedix&#8217;s diagnostic expertise to complement its existing prostate related treatment portfolio.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The assets acquired and liabilities assumed are recognized provisionally in the accompanying consolidated balance sheets at their estimated fair values as of the acquisition date. The initial accounting for the business combination is not complete as the Company is in the process of obtaining additional information for the valuation of acquired intangible assets and deferred tax liabilities. The provisional amounts are subject to change to the extent that additional information is obtained about the facts and circumstances that existed as of the acquisition date. Under U.S.&#160;GAAP, the measurement period shall not exceed one year from the acquisition date and the Company will finalize these amounts no later than December&#160;15, 2024. The estimated fair values as of the acquisition date are based on information that existed as of the acquisition date. During the measurement period the Company may adjust provisional amounts recorded for assets acquired and liabilities assumed to reflect new information that the Company has subsequently obtained regarding facts and circumstances that existed as of the acquisition date.</p></ix:continuation>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-28</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;5 &#8212; Acquisitions</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_MergersAcquisitionsAndDispositionsDisclosuresTextBlock-c0_cont_6" id="_MergersAcquisitionsAndDispositionsDisclosuresTextBlock-c0_cont_5"><ix:continuation continuedAt="_AssetAcquisitionContingentConsiderationTableTextBlock-c0_cont_3" id="_AssetAcquisitionContingentConsiderationTableTextBlock-c0_cont_2"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The acquisition<span class="nobreak">-date</span> fair value of the consideration transferred totaled approximately $<ix:nonFraction contextRef="c130" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" unitRef="usd" id="ixv-31030">65.1</ix:nonFraction>&#160;million, which consisted of the following:</p></ix:continuation>
		<ix:continuation id="_AssetAcquisitionContingentConsiderationTableTextBlock-c0_cont_3"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Consideration</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Transferred</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferredOther1" scale="0" unitRef="usd" id="ixv-31031">875,484</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;B convertible preferred stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="0" unitRef="usd" id="ixv-31032">64,236,085</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total consideration transferred</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="0" unitRef="usd" id="ixv-31033">65,111,569</ix:nonFraction></span></p>	</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of the Company&#8217;s common shares issued as consideration was based on the closing price of the Company&#8217;s common stock as of the Acquisition Date. The fair value of the Series&#160;B Preferred Stock issued as consideration was based on the underlying fair value of the number of common shares that the Series&#160;B Preferred Stock converts into, also based on the closing price of the Company&#8217;s common stock as of the Acquisition Date.</p>
		<ix:nonNumeric contextRef="c0" continuedAt="_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="ixv-19001"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of the Proteomedix stock options assumed as part of the PMX Transaction was determined using a Black<span class="nobreak">-Scholes</span> option pricing model with the following significant assumptions:</p></ix:nonNumeric>
		<ix:continuation id="_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercise price</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">$1.15&#160;&#8211;&#160;28.83</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock price</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonFraction contextRef="c133" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-31034">128.11</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Term (years)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonFraction contextRef="c134" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-31035">0.17</ix:nonFraction>&#160;&#8211;&#160;<ix:nonFraction contextRef="c135" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-31036">3.59</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected stock price volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-31037">90</ix:nonFraction>%</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free rate of interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonFraction contextRef="c137" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-31038">4.07</ix:nonFraction>%&#160;&#8211;&#160;<ix:nonFraction contextRef="c138" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-31039">5.47</ix:nonFraction>%</p>	</td>
				</tr>

		</table></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="ixv-19046"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed at the acquisition date:</p></ix:nonNumeric>
		<ix:continuation id="_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Net Assets</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Recognized</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="0" unitRef="usd" id="ixv-31040">1,056,578</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="0" unitRef="usd" id="ixv-31041">87,445</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Inventories</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="0" unitRef="usd" id="ixv-31042">80,593</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid expenses and other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="0" unitRef="usd" id="ixv-31043">114,615</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right of use asset</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="onco:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset" scale="0" unitRef="usd" id="ixv-31044">149,831</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-31045">39,779</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Trade name</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="0" unitRef="usd" id="ixv-31046">9,018,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Customer relationships</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="onco:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships" scale="0" unitRef="usd" id="ixv-31047">1,891,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Product rights for developed technology</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="onco:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology" scale="0" unitRef="usd" id="ixv-31048">10,541,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Goodwill</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="0" unitRef="usd" id="ixv-31049">53,914,055</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total assets acquired</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="0" unitRef="usd" id="ixv-31050">76,892,896</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="0" unitRef="usd" id="ixv-31051">234,029</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="onco:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" scale="0" unitRef="usd" id="ixv-31052">732,814</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" scale="0" unitRef="usd" id="ixv-31053">149,831</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="0" unitRef="usd" id="ixv-31054">2,994,669</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pension benefit obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="onco:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation" scale="0" unitRef="usd" id="ixv-31055">548,384</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Note payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="onco:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable" scale="0" unitRef="usd" id="ixv-31056">115,096</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total liabilities assumed</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="0" unitRef="usd" id="ixv-31057">4,774,823</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="0" unitRef="usd" id="ixv-31058">72,118,073</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less non-controlling interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="0" unitRef="usd" id="ixv-31059">7,006,504</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net assets acquired</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-31060">65,111,569</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>

		</table></ix:continuation></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-29</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;5 &#8212; Acquisitions</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_MergersAcquisitionsAndDispositionsDisclosuresTextBlock-c0_cont_7" id="_MergersAcquisitionsAndDispositionsDisclosuresTextBlock-c0_cont_6"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The goodwill recognized as a result of the PMX Transaction is attributable primarily to expected synergies and the assembled workforce of Proteomedix. None of the goodwill is expected to be deductible for income tax purposes.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair values of the acquired tangible and intangible assets were determined using variations of the cost, income approach using the excess earnings, lost profits and relief from royalty methods. The income approach valuation methodology used for the intangible assets acquired in the PMX Transaction makes use of Level 3 inputs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The trade name intangible asset represents the value of the Proclarix&#8482; brand name and was valued using a relief from royalty method under an income approach. A royalty rate of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="onco:RoyaltyRate" scale="-2" unitRef="pure" id="ixv-31061">6</ix:nonFraction>% was utilized in determining the fair value of this intangible asset. The fair value of this asset was determined based on a cash flow model using forecasted revenues and expenses specifically tied to Proclarix&#8482;. Those cash flows were then discounted at <ix:nonFraction contextRef="c105" decimals="2" format="ixt:num-dot-decimal" name="onco:WeightedAverageDiscountRate" scale="-2" unitRef="pure" id="ixv-31062">10</ix:nonFraction>% determined by the use of a weighted average return on assets analysis. The life of this intangible asset was determined to be indefinite as the branded name will persist beyond the life of the product rights and customer relationships.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The customer relationship intangible assets represent the value of the existing customer contract with Labcorp (see Note&#160;6) and was valued using the lost profits method under the income approach. The fair value of this asset was determined based on a cash flow model using forecasted revenues specifically tied to Proteomedix&#8217;s Labcorp contract. Those cash flows were then discounted at <ix:nonFraction contextRef="c108" decimals="2" format="ixt:num-dot-decimal" name="onco:WeightedAverageDiscountRate" scale="-2" unitRef="pure" id="ixv-31063">10</ix:nonFraction>% determined by the use of a weighted average return on assets analysis. The estimated useful life of this asset was determined by reference to the estimated life of the product rights associated with the Labcorp contract.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The product rights for developed technology acquired in the PMX Transaction represents know<span class="nobreak">-how</span> and patented intellectual property held by PMX pertaining to its commercial<span class="nobreak">-ready</span> prostate cancer diagnostic system, Proclarix&#8482;. The fair value of this asset was determined based on a cash flow model based on forecasted revenues and expenses specifically tied to Proclarix&#8482;. Those cash flows were then discounted at <ix:nonFraction contextRef="c102" decimals="2" format="ixt:num-dot-decimal" name="onco:WeightedAverageDiscountRate" scale="-2" unitRef="pure" id="ixv-31064">8</ix:nonFraction>% for the period prior to patent expiration and <ix:nonFraction contextRef="c102" decimals="2" format="ixt:num-dot-decimal" name="onco:WeightedAverageDiscountRateThereafter" scale="-2" unitRef="pure" id="ixv-31065">16</ix:nonFraction>% for the period thereafter. The discount rates were determined by the use of a weighted average return on assets analysis. The estimated useful life of the product rights was determined based on the underlying patent&#8217;s remaining life.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of the non<span class="nobreak">-controlling</span> interest in Proteomedix is estimated to be $<ix:nonFraction contextRef="c129" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FairValueOfAssetsAcquired" scale="6" unitRef="usd" id="ixv-31066">7.0</ix:nonFraction>&#160;million and represents the fair value of the vested Proteomedix stock options outstanding as of the Acquisition Date. The fair value of the non<span class="nobreak">-controlling</span> interest was valued using the methodology applicable to the Proteomedix stock options disclosed above. As Proteomedix was a private company as of the Acquisition Date, the fair value measurement is based on significant inputs that are not observable in the market and thus represents a Level 3 measurement as defined in ASC&#160;820, <span class="Italic" style="font-style:italic;font-weight:normal;">Fair Value Measurement</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company recognized approximately $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedAtCost" scale="6" unitRef="usd" id="ixv-31067">1.5</ix:nonFraction>&#160;million of acquisition related costs that were expensed during 2023, including the fair value of the subscription agreement liability, which was a closing condition for the PMX Transaction (see Note&#160;8). These costs are included in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</p>
		<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfCondensedIncomeStatementTableTextBlock-c0_cont_1" escape="true" name="srt:ScheduleOfCondensedIncomeStatementTableTextBlock" id="ixv-19297"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The amounts of revenue and loss of Proteomedix, included in the Company&#8217;s consolidated statements of operations and comprehensive loss from the Acquisition Date through December&#160;31, 2023 are as follows:</p></ix:nonNumeric>
		<ix:continuation continuedAt="_ScheduleOfCondensedIncomeStatementTableTextBlock-c0_cont_2" id="_ScheduleOfCondensedIncomeStatementTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Revenue</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-31068">58,465</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-31069">315,688</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following summary, prepared on a pro forma basis, presents the Company&#8217;s unaudited consolidated results of operations for 2023 and 2022 as if the PMX Transaction had been completed as of January&#160;1, 2022. The pro forma results below include the impact of amortization of intangible assets. This pro forma information is presented for </p></ix:continuation>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-30</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;5 &#8212; Acquisitions</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_MergersAcquisitionsAndDispositionsDisclosuresTextBlock-c0_cont_7"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">illustrative purposes only, is not necessarily indicative of future results of operations and does not include any impact of transaction synergies. In addition, the pro forma results are not necessarily indicative of the results of operations that actually would have been achieved had the PMX Transaction been consummated as of that date:</p>
		<ix:continuation id="_ScheduleOfCondensedIncomeStatementTableTextBlock-c0_cont_2"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Unaudited</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">For the&#160;Years Ended</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Revenue</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="0" unitRef="usd" id="ixv-31070">2,601,310</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="0" unitRef="usd" id="ixv-31071">392,460</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="0" unitRef="usd" id="ixv-31072">38,577,046</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="0" unitRef="usd" id="ixv-31073">16,326,247</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="onco_SignificantAgreementsTextBlock-c0_cont_1" escape="true" name="onco:SignificantAgreementsTextBlock" id="ixv-19382"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;6 &#8212; Significant Agreements</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Ology Bioservices, Inc. (which was later acquired by National Resilience, Inc.)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company entered into a Master Services Agreement (&#8220;Ology MSA&#8221;), dated July&#160;19, 2019, with Ology, Inc. (&#8220;Ology&#8221;) to provide services from time to time, including but not limited to technology transfer, process development, analytical method optimization, cGMP manufacture, regulatory affairs, and stability studies of biologic products. Pursuant to the Ology MSA, the Company and Ology shall enter into a Project Addendum for each project to be governed by the terms and conditions of the Ology MSA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company entered into two Project Addendums as of December&#160;31, 2023. The initial Project Addendum was executed on October&#160;18, 2019, and the Company was required to pay Ology an aggregate of approximately $<ix:nonFraction contextRef="c143" decimals="-6" format="ixt:num-dot-decimal" name="onco:AggregateAgreementAmountInitialAgreement" scale="6" unitRef="usd" id="ixv-31074">4</ix:nonFraction>&#160;million. Due to unforeseen delays associated with COVID<span class="nobreak">-19</span>, the Company and Ology entered into a letter agreement dated January&#160;9, 2020 to stop work on the project, at which point the Company had paid Ology $<ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanServiceCost" scale="0" unitRef="usd" id="ixv-31075">100,000</ix:nonFraction> for services to be provided. The second Project Addendum was executed on May&#160;21, 2021, and the Company is obligated to pay Ology an aggregate amount of approximately $<ix:nonFraction contextRef="c144" decimals="-5" format="ixt:num-dot-decimal" name="onco:AggregateeAmount" scale="6" unitRef="usd" id="ixv-31076">2.8</ix:nonFraction>&#160;million, plus reimbursement for materials and outsourced testing, which will be billed at cost plus <ix:nonFraction contextRef="c144" decimals="2" format="ixt:num-dot-decimal" name="onco:CostPlusPercentage" scale="-2" unitRef="pure" id="ixv-31077">15</ix:nonFraction>%. During 2023 and 2022, the Company and Ology entered into contract amendments that resulted in a net decrease in the Company&#8217;s obligations of approximately $<ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-31078"><ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-31079">137,000</ix:nonFraction></ix:nonFraction>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the&#160;years ended December&#160;31, 2023 and 2022, the Company incurred related research and development expenses of approximately $<ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-31080">15,000</ix:nonFraction> and $<ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-31081">1,329,000</ix:nonFraction>, respectively, and had approximately $<ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-31082">685,000</ix:nonFraction> recorded as related accounts payable at December&#160;31, 2023, and approximately $<ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-31083">476,000</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-31084">669,000</ix:nonFraction> recorded as related accounts payable and accrued expenses, respectively, at December&#160;31, 2022.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Cincinnati Children&#8217;s Hospital Medical Center</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company entered into a license agreement (the &#8220;CHMC Agreement&#8221;), dated June&#160;1, 2021, with Children&#8217;s Hospital Medical Center, d/b/a Cincinnati Children&#8217;s Hospital Medical Center (&#8220;CHMC&#8221;). Under the terms of the CHMC Agreement, the Company holds an exclusive, worldwide license (other than the excluded field of immunization against, and prevention, control, or reduction in the severity of gastroenteritis caused by rotavirus and norovirus in China and Hong&#160;Kong) to certain specified patent and biological materials relating to the use of norovirus nanoparticles and practice processes that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing CHMC patents and related technology directed to a virus<span class="nobreak">-like</span> particle vaccine platform that utilizes nanoparticle delivery technology that may have potential broad application to develop vaccines for multiple infectious diseases. The term of the CHMC Agreement begins on the effective date and extends on a jurisdiction by jurisdiction and product by product basis until the later of: (i)&#160;the last to expire licensed patent; (ii)&#160;<span style="-sec-ix-hidden: hidden-fact-267">ten</span> (10)&#160;years after the first commercial sale; or (iii)&#160;entrance onto the market of a biosimilar or interchangeable product. The Company is obligated to use commercially reasonable efforts to bring licensed products to market through diligent research and development, testing, manufacturing, and commercialization, to use best efforts to make all necessary regulatory filings and obtain all necessary regulatory approvals, to achieve milestones relating to development and sales, and report to CHMC on progress. The Company is obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur. Specifically, the Company is obligated to pay CHMC a single<span class="nobreak">-digit</span> royalty on </p></ix:nonNumeric>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-31</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;6 &#8212; Significant Agreements</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="onco_SignificantAgreementsTextBlock-c0_cont_2" id="onco_SignificantAgreementsTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">net sales, being <ix:nonFraction contextRef="c148" decimals="2" format="ixt:num-dot-decimal" name="onco:RoyaltyNetSalesPercentage" scale="-2" unitRef="pure" id="ixv-31085">5</ix:nonFraction>%, <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="onco:RoyaltyNetSalesPercentage" scale="-2" unitRef="pure" id="ixv-31086">4</ix:nonFraction>% or <ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ProductLiabilityContingencyAccrualDiscountRate" scale="-2" unitRef="pure" id="ixv-31087">2</ix:nonFraction>% depending on the product, until the last valid claim covering a licensed product exists, at which point the royalty rates decrease by <ix:nonFraction contextRef="c148" decimals="2" format="ixt:num-dot-decimal" name="onco:RoyaltyRates" scale="-2" unitRef="pure" id="ixv-31088">50</ix:nonFraction>%. The Company is also obligated to pay up to a <ix:nonFraction contextRef="c148" decimals="2" format="ixt:num-dot-decimal" name="onco:RevenueRate" scale="-2" unitRef="pure" id="ixv-31089">25</ix:nonFraction>% royalty on any non<span class="nobreak">-royalty</span> sublicense revenue paid to the Company by any sublicensee. The CHMC Agreement also provides the Company with an option to license any CHMC or jointly patented modification, alteration or improvement of any invention claimed in a Licensed Patent (&#8220;CHMC Improvement&#8221; and &#8220;Joint Improvement, respectively&#8221;), with a $<ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FeeIncome" scale="0" unitRef="usd" id="ixv-31090">50,000</ix:nonFraction> option fee for each Improvement that the Company elects to include in the license grant of the CHMC Agreement. In addition, the Company is required to pay CHMC milestone payments of up to an aggregate of $<ix:nonFraction contextRef="c148" decimals="-4" format="ixt:num-dot-decimal" name="onco:AggregateRoyaltiesAmount" scale="6" unitRef="usd" id="ixv-31091">59.75</ix:nonFraction>&#160;million; specifically, upon the achievement of specified development milestones of approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DevelopmentCosts" scale="6" unitRef="usd" id="ixv-31092">0.5</ix:nonFraction>&#160;million, regulatory milestones of approximately $<ix:nonFraction contextRef="c149" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:DevelopmentCosts" scale="6" unitRef="usd" id="ixv-31093">1.25</ix:nonFraction>&#160;million, and commercial milestones of approximately $<ix:nonFraction contextRef="c150" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DevelopmentCosts" scale="6" unitRef="usd" id="ixv-31094">58.0</ix:nonFraction>&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company may terminate the CHMC Agreement for convenience at any time prior to first commercial sale of a product or process by providing one hundred and eighty (180)&#160;days&#8217; written notice to CHMC.&#160;It may also terminate for a CHMC uncured material breach. CHMC may terminate the CHMC Agreement for an uncured Company material breach or insolvency or bankruptcy. Pursuant to the terms of the CHMC Agreement, if the Company fails to achieve the milestones, and cannot mutually agree with CHMC on an amendment to the milestones, then CHMC will have the option of converting any and all of such exclusive licenses to nonexclusive licenses, to continue developing indications that have already entered development at any stage or in which the Company has invested in developing. CHMC may also terminate the CHMC Agreement to the fullest extent permitted by law in the countries of the worldwide territory, in the event the Company or its affiliates challenge or induce others set up challenges to the validity or enforceability of any of the Licensed Patents, as defined in the CHMC Agreement, and the Company will be obligated to reimburse CHMC for its costs, including reasonable attorneys&#8217; fees.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Oxford University Innovation Limited</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2018, the Company entered into an option agreement with Oxford University Innovation (&#8220;OUI&#8221;), which was a precursor to a license agreement (the &#8220;OUI Agreement&#8221;), dated July&#160;16, 2019. Under the terms of the OUI Agreement, the Company held an exclusive, worldwide license to certain specified patent rights and biological materials relating to the use of epitopes of limited variability and virus<span class="nobreak">-like</span> particle products and practice processes that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing a vaccine product candidate for influenza. The Company was obligated to use its best efforts to develop and market Licensed Products, as defined in the OUI Agreement, in accordance with its development plan, report to OUI on progress, achieve certain milestones and was required to pay OUI nonrefundable milestone fees when it achieved them. Pursuant to the OUI Agreement, the Company was obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur. Specifically, the Company was obligated to pay a <ix:nonFraction contextRef="c151" decimals="2" format="ixt:num-dot-decimal" name="onco:RoyaltyNetSalesPercentage" scale="-2" unitRef="pure" id="ixv-31095">6</ix:nonFraction>% royalty on all net sales of licensed products, as defined in the OUI Agreement, with an annual minimum royalty payment of $<ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyExpense" scale="0" unitRef="usd" id="ixv-31096">250,000</ix:nonFraction> starting post<span class="nobreak">-product</span> launch, until the expiration of the OUI Agreement or revocation of the last valid claim covering a licensed product, at which point a royalty rate of <ix:nonFraction contextRef="c151" decimals="2" format="ixt:num-dot-decimal" name="onco:RoyaltyRates" scale="-2" unitRef="pure" id="ixv-31097">3</ix:nonFraction>% will apply. An annual maintenance fee of $<ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfPropertyRepairsAndMaintenance" scale="0" unitRef="usd" id="ixv-31098">10,000</ix:nonFraction> and $<ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfPropertyRepairsAndMaintenance" scale="0" unitRef="usd" id="ixv-31099">20,000</ix:nonFraction> was required in the pre<span class="nobreak">-phase</span>&#160;III year and Phase&#160;III year, respectively, and as defined in the OUI Agreement. The Company was also obligated to pay a <ix:nonFraction contextRef="c153" decimals="2" format="ixt:num-dot-decimal" name="onco:RoyaltyRates" scale="-2" unitRef="pure" id="ixv-31100">25</ix:nonFraction>% royalty on any sums received by the Company from any sublicensee (including all up<span class="nobreak">-front</span>, milestone and other one<span class="nobreak">-off</span> payments received by the Company from any sub<span class="nobreak">-licenses</span> or other contracts granted by the Company with respect to the licensed technology). In addition, the Company was required to pay OUI milestone payments of up to an aggregate of $<ix:nonFraction contextRef="c153" decimals="-4" format="ixt:num-dot-decimal" name="onco:AggregateRoyaltiesAmount" scale="6" unitRef="usd" id="ixv-31101">51.25</ix:nonFraction>&#160;million; specifically, upon the achievement of specified development milestones of approximately $<ix:nonFraction contextRef="c154" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:DevelopmentCosts" scale="6" unitRef="usd" id="ixv-31102">2.25</ix:nonFraction>&#160;million, regulatory milestones of approximately $<ix:nonFraction contextRef="c155" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DevelopmentCosts" scale="6" unitRef="usd" id="ixv-31103">9.5</ix:nonFraction>&#160;million, and commercial milestones of approximately $<ix:nonFraction contextRef="c156" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DevelopmentCosts" scale="6" unitRef="usd" id="ixv-31104">39.5</ix:nonFraction>&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The OUI Agreement was to expire upon ten (10)&#160;years from the expiration of the last patent contained in the licensed patent rights, unless terminated earlier. Either party had the right to terminate the OUI Agreement for an uncured material breach. The Company was able to terminate the OUI Agreement for any reason at any time upon six&#160;months&#8217; written notice until July&#160;16, 2022, which was the third anniversary of the OUI Agreement. OUI was able to terminate immediately if the Company had a petition presented for its winding<span class="nobreak">-up</span> or passed a resolution for winding up other than for a bona fide amalgamation or reconstruction or compounds with its creditors or had a receiver or administrator appointed. OUI could also terminate if the Company opposed or challenged the validity of </p></ix:continuation>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-32</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;6 &#8212; Significant Agreements</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="onco_SignificantAgreementsTextBlock-c0_cont_3" id="onco_SignificantAgreementsTextBlock-c0_cont_2"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">any of the patents or applications in the Licensed Technology, as defined in the OUI Agreement; raised the claim that the know<span class="nobreak">-how</span> of the Licensed Technology was not necessary to develop and market Licensed Products; or in OUI&#8217;s reasonable opinion, was taking inadequate or insufficient steps to develop or market Licensed Products and did not take any further steps that OUI requested by written notice within a reasonable time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company terminated the agreements with Oxford during the year ended December&#160;31, 2023, and amounts due upon termination were not significant.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">St. Jude Children&#8217;s Hospital</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company entered into a license agreement (the &#8220;St. Jude Agreement&#8221;), dated January&#160;27, 2020, and as amended on May&#160;11, 2022 and March&#160;22, 2023, with St. Jude Children&#8217;s Research Hospital (&#8220;St. Jude&#8221;). Under the terms of the St. Jude Agreement, the Company held an exclusive, worldwide license to certain specified patent rights and biological materials relating to the use of live attenuated streptococcus pneumoniae and practice processes that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing a vaccine product candidate for streptococcus pneumoniae. The Company was obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur. Specifically, pursuant to the terms of the St. Jude Agreement, as amended, the Company was obligated to make <ix:nonFraction contextRef="c157" decimals="2" format="ixt:num-dot-decimal" name="onco:RoyaltyRates" scale="-2" unitRef="pure" id="ixv-31105">5</ix:nonFraction>% royalty payments for each licensed product(s)&#160;sold by the Company or its affiliates, based on the net sales for the duration of the St. Jude Agreement, and also pay <ix:nonFraction contextRef="c158" decimals="2" format="ixt:num-dot-decimal" name="onco:PercentageOfConsiderationReceived" scale="-2" unitRef="pure" id="ixv-31106">15</ix:nonFraction>% of consideration received for any sublicenses. The Company was also required to pay an additional one<span class="nobreak">-time</span> $<ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesAndLicenses" scale="0" unitRef="usd" id="ixv-31107">5,000</ix:nonFraction> license fee, and an annual maintenance fee of $<ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostMaintenance" scale="0" unitRef="usd" id="ixv-31108">10,000</ix:nonFraction> beginning on the first anniversary of the Effective Date (which was waived if all of the developmental milestones scheduled for completion before such annual fee is due have been achieved). In addition, the Company was required to pay St. Jude milestone payments of up to an aggregate of $<ix:nonFraction contextRef="c157" decimals="-5" format="ixt:num-dot-decimal" name="onco:AggregateRoyaltiesAmount" scale="6" unitRef="usd" id="ixv-31109">1.9</ix:nonFraction>&#160;million; specifically, upon the achievement of specified development milestones of $<ix:nonFraction contextRef="c159" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DevelopmentCosts" scale="6" unitRef="usd" id="ixv-31110">0.3</ix:nonFraction>&#160;million, regulatory milestones of $<ix:nonFraction contextRef="c160" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DevelopmentCosts" scale="6" unitRef="usd" id="ixv-31111">0.6</ix:nonFraction>&#160;million, and commercial milestones of $<ix:nonFraction contextRef="c161" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DevelopmentCosts" scale="6" unitRef="usd" id="ixv-31112">1.0</ix:nonFraction>&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The St. Jude Agreement was to expire upon the expiration of the last valid claim contained in the licensed patent rights, unless terminated earlier. The Company was obligated to use commercially reasonable efforts to develop and commercialize the licensed product(s)&#160;and included defined development milestones. If the Company failed to achieve the development milestones contained in the St. Jude Agreement, and if the Company and St. Jude failed to agree upon a mutually satisfactory revised timeline, St. Jude had the right to terminate the St. Jude Agreement. Either party was able to terminate the St. Jude Agreement in the event the other party (a)&#160;filed against it a petition under the Bankruptcy Act (among other things) or (b)&#160;failed to perform or otherwise breached its obligations under the St. Jude Agreement and did not cure such failure or breach within sixty (60)&#160;days. The Company was able to terminate for any reason on thirty (30)&#160;days written notice.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company terminated the agreement with St. Jude during the year ended December&#160;31, 2023, and amounts due upon termination were not significant.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">University of Texas Health Science Center at San Antonio</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company entered into a patent and technology license agreement (the &#8220;UT Health Agreement&#8221;), dated November&#160;18, 2022, with the University of Texas Health Science Center at San Antonio (&#8220;UT Health&#8221;). Under the terms of the UT Health Agreement, the Company held an exclusive, worldwide license (other than the excluded field of vectors, as defined in the UT Health Agreement) to certain specified patent rights relating to the development of a live attenuated, oral Chlamydia vaccine candidate. An initial non<span class="nobreak">-refundable</span> license fee of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLicenseFeesReceived" scale="0" unitRef="usd" id="ixv-31113">100,000</ix:nonFraction> was due upon execution of the agreement, and expensed during the year ended December&#160;31, 2022, with subsequent annual license fees thereafter until expiration or termination of the UT Health agreement. Pursuant to the UT Health Agreement, the Company was obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur. Specifically, the Company was obligated to pay UT a single<span class="nobreak">-digit</span> royalty on net sales, being <ix:nonFraction contextRef="c162" decimals="2" format="ixt:num-dot-decimal" name="onco:RoyaltyNetSalesPercentage" scale="-2" unitRef="pure" id="ixv-31114">5</ix:nonFraction>% or <ix:nonFraction contextRef="c163" decimals="2" format="ixt:num-dot-decimal" name="onco:RoyaltyNetSalesPercentage" scale="-2" unitRef="pure" id="ixv-31115">3</ix:nonFraction>% depending on whether the product was covered by a valid claim or not, as defined in the agreement. The Company was also obligated to pay a <ix:nonFraction contextRef="c163" decimals="2" format="ixt:num-dot-decimal" name="onco:RoyaltyRates" scale="-2" unitRef="pure" id="ixv-31116">20</ix:nonFraction>% royalty on any sums received by the Company from any sublicensee. In addition, the </p></ix:continuation>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-33</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;6 &#8212; Significant Agreements</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="onco_SignificantAgreementsTextBlock-c0_cont_4" id="onco_SignificantAgreementsTextBlock-c0_cont_3"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Company was required to pay UT Health milestone payments of up to an aggregate of approximately $<ix:nonFraction contextRef="c163" decimals="-5" format="ixt:num-dot-decimal" name="onco:AggregateRoyaltiesAmount" scale="6" unitRef="usd" id="ixv-31117">2.2</ix:nonFraction>&#160;million; specifically, upon the achievement of specified development milestones of approximately $<ix:nonFraction contextRef="c164" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DevelopmentCosts" scale="6" unitRef="usd" id="ixv-31118">0.7</ix:nonFraction>&#160;million and regulatory milestones of approximately $<ix:nonFraction contextRef="c165" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DevelopmentCosts" scale="6" unitRef="usd" id="ixv-31119">1.5</ix:nonFraction>&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The UT Health Agreement was to expire upon the expiration of the last date of expiration or termination of the patent rights, unless terminated earlier. Under the UT Health Agreement, the Company had the right to terminate the UT Health Agreement for convenience, by providing 90&#160;days&#8217; written notice to UT Health. UT Health was able to terminate the UT Health Agreement in the event the Company (a)&#160;became arrears in payment due and did not make payment within 30&#160;days after notification from UT Health or (b)&#160;was in breach of any non<span class="nobreak">-payment</span> provision and does not cure such breach within 60&#160;days after notification from UT Health or (c)&#160;UT Health delivered notice to the Company of three or more actual material breaches of the UT Health Agreement in any 12<span class="nobreak">-month</span> period or (d)&#160;in the event the Company or its affiliates initiated any proceeding or action to challenge the validity, enforceability, or scope of any of the licensed patents.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company terminated the agreement during the year ended December&#160;31, 2023, and amounts due upon termination were not significant.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Co-development Agreement with AbVacc, Inc.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;1, 2023, the Company entered into a co<span class="nobreak">-development</span> agreement (the &#8220;Co<span class="nobreak">-Development</span> Agreement&#8221;) with AbVacc, Inc. (&#8220;AbVacc&#8221;), for the purpose of conducting research aimed at co<span class="nobreak">-development</span> of specific vaccine candidates, including monkeypox and Marburg virus disease with the potential to expand to others using the Norovirus nanoparticle platform (&#8220;Co<span class="nobreak">-Development</span> Project&#8221;), and to govern the sharing of materials and information, as defined in the Co<span class="nobreak">-Development</span> Agreement, for the Co<span class="nobreak">-Development</span> Project. Under the Co<span class="nobreak">-Development</span> Agreement, AbVacc and the Company will collaborate, through a joint development committee, to establish and implement a development plan or statement of work for each Co<span class="nobreak">-Development</span> Project targeted product. Under the Co<span class="nobreak">-Development</span> Agreement, either the Company or AbVacc, whichever party is the primary sponsor of any resulting product (as defined in the Co<span class="nobreak">-Development</span> Agreement), will be obligated to compensate the other party for certain milestone payments that would range between $<ix:nonFraction contextRef="c166" decimals="-5" format="ixt:num-dot-decimal" name="onco:AmountOfOtherPartyPayments" scale="6" unitRef="usd" id="ixv-31120">2.1</ix:nonFraction>&#160;million and $<ix:nonFraction contextRef="c167" decimals="-4" format="ixt:num-dot-decimal" name="onco:AmountOfOtherPartyPayments" scale="6" unitRef="usd" id="ixv-31121">4.75</ix:nonFraction>&#160;million, plus royalties of between <ix:nonFraction contextRef="c166" decimals="2" format="ixt:num-dot-decimal" name="onco:RoyaltiesPercentage" scale="-2" unitRef="pure" id="ixv-31122">2</ix:nonFraction>% to <ix:nonFraction contextRef="c167" decimals="2" format="ixt:num-dot-decimal" name="onco:RoyaltiesPercentage" scale="-2" unitRef="pure" id="ixv-31123">4</ix:nonFraction>%. There is no fixed obligation for either party, and each party will be responsible for their own costs. The term of the Co<span class="nobreak">-Development</span> Agreement is three&#160;years from the effective date, unless previously terminated by either party, in accordance with the Co<span class="nobreak">-Development</span> Agreement. During the year ended December&#160;31, 2023, the Company incurred approximately $<ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-31124">21,000</ix:nonFraction> in costs for research and development related to the Co<span class="nobreak">-Development</span> Agreement. As of December&#160;31, 2023, the Company evaluated the likelihood of the Company achieving the specified milestones and generating product sales and determined that the likelihood is not yet probable and as such no accrual of these payments is required as of December&#160;31, 2023.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Services Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On July&#160;21, 2023, the Company, entered into a Licensing and Services Master Agreement (&#8220;Master Services Agreement&#8221;) and a related statement of work with a vendor, pursuant to which the vendor was to provide to the Company commercialization services for the Company&#8217;s products, including recruiting, managing, supervising and evaluating sales personnel and providing sales<span class="nobreak">-related</span> services for such products, for fees totaling up to $<ix:nonFraction contextRef="c169" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFeeAmount" scale="6" unitRef="usd" id="ixv-31125">29.1</ix:nonFraction>&#160;million over the term of the statement of work. The statement of work had a term through September&#160;6, 2026, unless earlier terminated in accordance with the Master Services Agreement and the statement of work. On July&#160;29, 2023, a second statement of work was entered into with the same vendor for certain subscription services providing prescription market data access to the Company. The fees under the second statement of work totaled approximately $<ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdministrativeFeesExpense" scale="0" unitRef="usd" id="ixv-31126">800,000</ix:nonFraction>, and the term was through <ix:nonNumeric contextRef="c171" format="ixt:date-monthname-day-year-en" name="us-gaap:LongTermDebtMaturityDate" id="ixv-31127">July&#160;14, 2025</ix:nonNumeric>. On October&#160;12, 2023, the Company terminated the Master Services Agreement and the statements of work. The Company recorded approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="6" unitRef="usd" id="ixv-31128">3.1</ix:nonFraction>&#160;million in expense related to this contract during the year ended December&#160;31, 2023, which is included in selling, general and administrative expense in the </p></ix:continuation>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-34</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;6 &#8212; Significant Agreements</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="onco_SignificantAgreementsTextBlock-c0_cont_4"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">accompanying consolidated statements of operations and comprehensive loss. The Company had approximately $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="6" unitRef="usd" id="ixv-31129">1.8</ix:nonFraction>&#160;million recorded in related accounts payable as of December&#160;31, 2023, which includes amounts due for early termination of the contract.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Laboratory Corporation of America</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;23, 2023, Proteomedix entered into a license agreement Laboratory Corporation of America (&#8220;Labcorp&#8221;) pursuant to which Labcorp has the exclusive right to develop and commercialize Proclarix, and other products developed by Labcorp using Proteomedix&#8217;s intellectual property covered by the license, in the United&#160;States (&#8220;Licensed Products&#8221;). In consideration for granting Labcorp an exclusive license, Proteomedix received an initial license fee of in the mid<span class="nobreak">-six</span> figures upon signing of the contract. Additionally, Proteomedix is entitled to royalty payments on the net sales recognized by Labcorp of any Licensed Products plus milestone payments as follows:</p>
		<div style="-keep: true"><ix:nonNumeric contextRef="c172" continuedAt="onco_LicensedProductsPlusMilestonePaymentsDescription-c172_cont_1" name="onco:LicensedProductsPlusMilestonePaymentsDescription" id="ixv-19504"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>After the first sale of Proclarix as a laboratory developed test, Labcorp will pay an amount in the mid<span class="nobreak">-six</span> figures,</p></ix:nonNumeric></div>
		<div style="-keep: true"><ix:continuation continuedAt="onco_LicensedProductsPlusMilestonePaymentsDescription-c172_cont_2" id="onco_LicensedProductsPlusMilestonePaymentsDescription-c172_cont_1"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>after Labcorp achieves a certain amount in the low seven figures in net sales of Licensed Products, Labcorp will pay Proteomedix an amount in the low seven figures,</p></ix:continuation></div>
		<div style="-keep: true"><ix:continuation id="onco_LicensedProductsPlusMilestonePaymentsDescription-c172_cont_2"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>after a certain amount in the mid<span class="nobreak">-seven</span> figures in net sales of Licensed Products, Labcorp will pay Proteomedix an amount in the low seven figures.</p></ix:continuation></div>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Labcorp is wholly responsible for the cost, if any, of research, development and commercialization of Licensed Products in the United&#160;States but has the right to offset a portion of those costs against future royalty and milestone payments. Additionally, Labcorp may deduct royalties or other payments made to third parties related to the manufacture or sale of Licensed Products up to a maximum amount of any royalty payments due to Proteomedix.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_DebtDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-19521"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;7 &#8212; Notes Payable</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Veru APA (see Note&#160;5), the Company executed three non<span class="nobreak">-interest</span> bearing notes payable (the &#8220;Notes&#8221;) in the principal amounts of $<ix:nonFraction contextRef="c173" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="6" unitRef="usd" id="ixv-31130">4.0</ix:nonFraction>&#160;million, $<ix:nonFraction contextRef="c174" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="6" unitRef="usd" id="ixv-31131">5.0</ix:nonFraction>&#160;million and $<ix:nonFraction contextRef="c175" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="6" unitRef="usd" id="ixv-31132">5.0</ix:nonFraction>&#160;million with maturity dates of September&#160;30, 2023, <ix:nonNumeric contextRef="c176" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-31133">April&#160;19, 2024</ix:nonNumeric>, and <ix:nonNumeric contextRef="c177" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-31134">September&#160;30, 2024</ix:nonNumeric>, respectively. No principal payments are due until maturity; however, the Company may voluntarily prepay the Notes with no penalty. Additionally, in an Event of Default, as defined in the Notes, the unpaid principal amount of the Notes will accrue interest at a rate of <ix:nonFraction contextRef="c178" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-31135">10.0</ix:nonFraction>% per annum.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company imputed interest on the Notes using an average discount rate of <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="onco:PayableAverageDiscountRatePercentage" scale="-2" unitRef="pure" id="ixv-31136">8.2</ix:nonFraction>% and recorded a debt discount of approximately $<ix:nonFraction contextRef="c118" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" unitRef="usd" id="ixv-31137">1.1</ix:nonFraction>&#160;million at the issuance date. The debt discount is reflected as a reduction in the carrying amount of the Notes and amortized to interest expense through the respective maturity dates, using the effective interest method. The Company recorded approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="6" unitRef="usd" id="ixv-31138">0.7</ix:nonFraction>&#160;million of associated interest expense during the year ended December&#160;31, 2023. The unamortized debt discount as of December&#160;31, 2023 was approximately $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" unitRef="usd" id="ixv-31139">0.4</ix:nonFraction>&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On September&#160;29, 2023, the Company and the note holder entered into an amendment to the Veru APA, which provided that the $<ix:nonFraction contextRef="c179" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="6" unitRef="usd" id="ixv-31140">4.0</ix:nonFraction>&#160;million note payable originally due on <ix:nonNumeric contextRef="c180" format="ixt:date-monthname-day-year-en" name="onco:DebtInstrumentDueDate" id="ixv-31141">September&#160;30, 2023</ix:nonNumeric> was deemed paid and fully satisfied upon (1)&#160;the payment to the Seller of $<ix:nonFraction contextRef="c180" decimals="-5" format="ixt:num-dot-decimal" name="onco:CashPaymentToTheSeller" scale="6" unitRef="usd" id="ixv-31142">1.0</ix:nonFraction>&#160;million in cash on September&#160;29, 2023, and (2)&#160;the issuance to the Seller by October&#160;3, 2023 of <ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-31143">3,000</ix:nonFraction><span class="nobreak"> </span>shares of Series&#160;A Preferred Stock of the Company (see Note&#160;5). In connection with the Veru APA Amendment, the Company recorded an extinguishment loss on the note payable of approximately $<ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" unitRef="usd" id="ixv-31144">490,000</ix:nonFraction>, which represents the difference between the fair value of the Series&#160;A Preferred Stock that was issued to settle the debt and the carrying value of the note payable as of September&#160;29, 2023. The extinguishment loss is recognized in other income (expense) in the accompanying consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2023.</p></ix:nonNumeric>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-35</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;7 &#8212; Notes Payable</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_DebtDisclosureTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">To determine the fair value of the Series&#160;A Preferred Stock, the Company first derived the business enterprise value (&#8220;BEV&#8221;) using a discounted cash flow method. The BEV was adjusted to an equity value assuming $<ix:nonFraction contextRef="c183" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="6" unitRef="usd" id="ixv-31145">3.0</ix:nonFraction>&#160;million of debt converted to Series&#160;A Preferred Stock, which was then allocated across the Company&#8217;s securities. The concluded value for the Series&#160;A Preferred Stock utilized the Black<span class="nobreak">-Scholes</span> option pricing model, which was classified as level 3 in the valuation hierarchy due to the presence of significant unobservable inputs. The following key assumptions were used in the model: volatility rate of <ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-31146">100</ix:nonFraction>%, risk free interest rate of <ix:nonFraction contextRef="c185" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-31147">4.6</ix:nonFraction>%, <ix:nonFraction contextRef="c186" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-31148">5.0</ix:nonFraction> year expected term, and the Company&#8217;s aggregate equity value. The volatility was based on the historical and implied volatility of a peer group and the risk<span class="nobreak">-free</span> interest rate was based on the implied yield available on U.S.&#160;Treasury securities with a term commensurate with the estimated expected term.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Future minimum principal payments on the Notes as of December&#160;31, 2023, includes $<ix:nonFraction contextRef="c118" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="6" unitRef="usd" id="ixv-31149">10</ix:nonFraction>&#160;million in principal payments that are due in <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="onco:DebtInstrumentDueTerm" id="ixv-31150">2024</ix:nonNumeric>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company also assumed an obligation in the amount of <ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionPriceOfAcquisitionExpected" scale="0" unitRef="chf" id="ixv-31151">100,000</ix:nonFraction> CHF, in connection with the Proteomedix acquisition. This obligation relates to a loan from an investor that was advanced to Proteomedix in March&#160;2010. This loan bears no interest, is unsecured and may be cancelled by the Company at its discretion, however it is the intent of the Company to repay this loan in the future. The loan payable, in the amount of approximately $<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermNotesPayable" scale="3" unitRef="usd" id="ixv-31152">119</ix:nonFraction>,000, is included in long term note payable in the accompanying consolidated balances sheet as of December&#160;31, 2023.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" escape="true" name="onco:SubscriptionAgreementDisclosureTextBlock" id="ixv-19547"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;8 &#8212; Subscription Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;18, 2023, the Company entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) with the PMX Investor, who became a stockholder of Onconetix at the closing of the PMX Transaction (see Notes 5 and 11) for the sale of <ix:nonFraction contextRef="c188" decimals="-6" format="ixt:num-dot-decimal" name="onco:SaleOfUnits" scale="6" unitRef="shares" id="ixv-31153">20</ix:nonFraction>&#160;million units, each comprised of <ix:nonFraction contextRef="c189" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-31154">1</ix:nonFraction><span class="nobreak"> </span>share of common stock and <ix:nonFraction contextRef="c190" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-31155">0.30</ix:nonFraction> pre<span class="nobreak">-funded</span> warrants (the &#8220;Units&#8221;) at $<ix:nonFraction contextRef="c188" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-31156">0.25</ix:nonFraction> per Unit. The Subscription Agreement includes a make<span class="nobreak">-whole</span> provision which requires the issuance of additional shares of common stock in the event that the 270<span class="nobreak">-day</span> volume weighted average price (&#8220;270 VWAP&#8221;) after the closing of the Subscription Agreement, is below $<ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-31157">0.25</ix:nonFraction>. The Subscription Agreement will only close upon obtaining Stockholder Approval for certain transactions involving the Company&#8217;s Series&#160;B Preferred Stock, as further described in Note&#160;5.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Subscription Agreement is accounted for as a liability in accordance with ASC&#160;480, as the make<span class="nobreak">-whole</span> provision could result in a variable number of shares being issued upon settlement. The subscription agreement liability is measured at fair value at the commitment date and at each subsequent reporting period, with changes in fair value recorded as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. The Company recorded the fair value of the Subscription Agreement liability at the issuance date of approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ServicingLiabilityAtFairValueAdditions" scale="6" unitRef="usd" id="ixv-31158">0.8</ix:nonFraction>&#160;million, as an acquisition related cost, as the Subscription Agreement was a condition to close the PMX Transaction (see Note&#160;5). As of December&#160;31, 2023, the fair value of the subscription agreement liability is estimated to be approximately $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ServicingLiabilityAtFairValueAmount" scale="6" unitRef="usd" id="ixv-31159">0.9</ix:nonFraction>&#160;million, determined using a Monte<span class="nobreak">-Carlo</span> option pricing model, and the Company estimated a <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ProductLiabilityContingencyThirdPartyRecoveryPercentage" scale="-2" unitRef="pure" id="ixv-31160">55.0</ix:nonFraction>% probability that the Subscription Agreement will close. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-19558">The significant assumptions used in the Monte<span class="nobreak">-Carlo</span> model, which utilizes Level 3 inputs (see Note&#160;3), are as follows as of the commitment date and at December&#160;31, 2023:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;18,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercise price</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c191" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-31161">0.25</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c192" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-31162">0.25</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Term (years)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c193" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-31163">1.5</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c194" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-31164">1.2</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected stock price volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-31165">100</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-31166">95</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free rate of interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c197" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-31167">4.64</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c198" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-31168">4.64</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table></ix:continuation></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-36</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-19654"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;9 &#8212; Convertible Redeemable Preferred Stock and Stockholders&#8217; Equity</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Authorized Capital</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023 and 2022, the Company is authorized to issue <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-31169">250,000,000</ix:nonFraction><span class="nobreak"> </span>shares and <ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-31170">10,000,000</ix:nonFraction><span class="nobreak"> </span>shares of common stock and preferred stock, respectively, with a par value of $<ix:nonFraction contextRef="c199" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-31171"><ix:nonFraction contextRef="c1" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-31172">0.00001</ix:nonFraction></ix:nonFraction> for both common stock and preferred stock. As of December&#160;31, 2023, the Company had designated and authorized the issuance of up to <ix:nonFraction contextRef="c200" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-31173">1,150,000</ix:nonFraction><span class="nobreak"> </span>shares, <ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-31174">10,000</ix:nonFraction><span class="nobreak"> </span>shares, and <ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-31175">2,700,000</ix:nonFraction><span class="nobreak"> </span>shares of Series&#160;Seed Preferred Stock, Series&#160;A Preferred Stock, and Series&#160;B Preferred Stock, respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;23, 2022, in connection with the closing of the IPO, the Company filed with the Secretary of State of the State of Delaware an amended and restated certificate of incorporation (the &#8220;A&amp;R COI&#8221;), which became effective immediately. There was no change to the Company&#8217;s authorized shares of common stock and preferred stock or the par value. Prior to this amendment, the Company had designated <ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-31176">1,150,000</ix:nonFraction><span class="nobreak"> </span>shares of preferred stock, with par value $<ix:nonFraction contextRef="c63" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-31177">0.00001</ix:nonFraction> per share. In addition, on February&#160;23, 2022 and in connection with the closing of the IPO, the Company&#8217;s board of directors adopted Amended and Restated Bylaws.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Preferred Stock</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Series&#160;A Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On September&#160;29, 2023, the Company filed a Certificate of Designations of Rights and Preferences of Series&#160;A Preferred Stock of the Company (the &#8220;Series&#160;A Certificate of Designations&#8221;) with the State of Delaware to designate and authorize the issuance of up to <ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-31178">10,000</ix:nonFraction><span class="nobreak"> </span>shares of Series&#160;A Preferred Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On October&#160;3, 2023, the Company issued <ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-31179">3,000</ix:nonFraction><span class="nobreak"> </span>shares of Series&#160;A Convertible Preferred Stock in exchange for the settlement of $<ix:nonFraction contextRef="c206" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherNotesPayable" scale="6" unitRef="usd" id="ixv-31180">3.0</ix:nonFraction>&#160;million in notes payable due to Veru, Inc. (see Notes 5 and 7). The significant terms of the Series&#160;A Preferred Stock are as follows:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Voting</span>&#160;&#8212;&#160;The shares of Series&#160;A Preferred Stock carry no voting rights, except as to certain significant matters specified in the Series&#160;A Certificate of Designations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Redemption&#160;&#8212;&#160;</span>Onconetix shall have the right to redeem in cash any outstanding shares of Series&#160;A Preferred Stock along with accrued but unpaid dividends beginning immediately after issuance of such shares of Preferred Stock. The holder of the Series&#160;A Preferred Stock shall not under any circumstances have any right to require redemption.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Liquidation Preference&#160;&#8212;&#160;</span>Each share of Series&#160;A Preferred Stock will have a liquidation preference equal to the stated value (initially $<ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" unitRef="usdPershares" id="ixv-31181">1,000</ix:nonFraction> per share), plus any accrued but unpaid dividends thereon (the &#8220;Liquidation Preference&#8221;). In the event of a liquidation, dissolution or winding up of the Company (which shall include any merger, reorganization, sale of assets in which control of Onconetix is transferred or event which results in all or substantially all of the Company&#8217;s assets being transferred), the holders of the Series&#160;A Preferred Stock shall be entitled to receive out of the assets of the Company, before any payment is made to the holders of common stock and either in preference to or pari passu with the holders of any other series of preferred stock that may be issued in the future, a per share amount equal to the Liquidation Preference. Any remaining assets of the Company following payment of the Liquidation Preference to the holders of Series&#160;A Preferred Stock shall be distributed to the holders of the Corporation&#8217;s common stock and any junior series of preferred stock then outstanding.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Dividends</span>&#160;&#8212;&#160;The holders of Series&#160;A Preferred Stock shall be entitled to receive dividends on shares of Series&#160;A Preferred Stock (on an as<span class="nobreak">-if-converted-to-common-stock</span> basis) equal to and in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of the common stock. No other dividends shall be paid on shares of Series&#160;A Preferred Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Conversion&#160;&#8212;&#160;</span>Each share of Series&#160;A Preferred Stock shall automatically convert into common stock of the Company one year from the date of issuance, if the required stockholder approval is obtained. If this approval is not obtained, then the Series&#160;A Preferred Stock is convertible, at the option of the holder, at any time and from time to </p></ix:nonNumeric>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-37</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;9 &#8212; Convertible Redeemable Preferred Stock and Stockholders&#8217; Equity</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">time from and after one year from the date of issuance into that number of shares of common stock (subject to certain limitations) determined by dividing the Stated Value by the Conversion Price. If the required vote discussed above is not obtained, and the Series&#160;A Preferred Stock is converted at the option of the holder, the Company may not issue a number of shares of common stock which, would exceed <ix:nonFraction contextRef="c183" decimals="4" format="ixt:num-dot-decimal" name="onco:SharesOfCommonStockRate" scale="-2" unitRef="pure" id="ixv-31182">19.99</ix:nonFraction>% shares of common stock (subject to adjustment for forward and reverse stock splits, recapitalizations and the like). The Conversion Price, which is subject to adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization and other adjustments, as defined in the Series&#160;A Certificate of Designations, is initially $<ix:nonFraction contextRef="c1" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-31183">0.5254</ix:nonFraction>. The maximum number of shares that the Series&#160;A Preferred Stock is convertible into, based on the Conversion Price as of December&#160;31, 2023 is approximately <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-31184">5,709,935</ix:nonFraction><span class="nobreak"> </span>shares of the Company&#8217;s common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluated the terms of the Series&#160;A Preferred Stock, and in accordance with the guidance of ASC&#160;480, the Series&#160;A Preferred Stock is classified as permanent equity in the accompanying consolidated balance sheet. The Series&#160;A Preferred Stock was recorded at its fair value as of the issuance date (see Note&#160;7).</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Series&#160;B Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2023, the Company filed a Certificate of Designations of Rights and Preferences of Series&#160;B Convertible Preferred Stock of the Company (the &#8220;Series&#160;B Certificate of Designations&#8221;) with the State of Delaware to designate and authorize the issuance of up to <ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-31185">2,700,000</ix:nonFraction><span class="nobreak"> </span>shares of Series&#160;B Preferred Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2023, in connection with the PMX Transaction, as part of the purchase consideration, the Company issued <ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-31186">2,696,729</ix:nonFraction><span class="nobreak"> </span>shares of Series&#160;B Convertible Preferred Stock (see Note&#160;5). The significant terms of the Series&#160;B Preferred Stock are as follows:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Voting&#160;&#8212;&#160;</span>The shares of Series&#160;B Preferred Stock carry no voting rights except with respect to the election of the Proteomedix Director (as defined in the Certificate of Designations) and except as to certain significant matters specified in the Series&#160;B Certificate of Designations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Liquidation Preference&#160;&#8212;&#160;</span>Upon a liquidation, dissolution or winding<span class="nobreak">-up</span> of Onconetix, whether voluntary or involuntary, the holders of Series&#160;B Preferred Stock shall be entitled to receive out of the assets, whether capital or surplus, of Onconetix, the same amount that a holder of common stock would receive if such holder&#8217;s Series&#160;B Preferred Stock were fully converted to common stock at the effective conversion ratio, plus an additional amount equal to any dividends declared but unpaid to such shares, which amounts shall be paid pari passu with all holders of common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Dividends</span>&#160;&#8212;&#160;The holders of the Series&#160;B Preferred Stock shall be entitled to receive dividends on shares of Series&#160;B Preferred Stock (on an as<span class="nobreak">-if-converted-to-common-stock</span> basis) equal to and in the same form, and in the same manner, as dividends (other than dividends on shares of the common stock payable in the form of common stock) actually paid on shares of the common stock when, as and if such dividends (other than dividends payable in the form of common stock) are paid on shares of the common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Conversion&#160;&#8212;&#160;</span>Following Stockholder Approval, each share of Series&#160;B Preferred Stock shall be converted into shares of common stock (the &#8220;Conversion Shares&#8221;) at a ratio of <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" unitRef="shares" id="ixv-31187">100</ix:nonFraction> Conversion Shares for each share of Series&#160;B Preferred Stock (the &#8220;Conversion Ratio&#8221;). All shares of Series&#160;B Preferred Stock shall automatically and without any further action required be converted into Conversion Shares at the Conversion Ratio upon the latest date on which (i)&#160;Onconetix has received the Stockholder Approval with respect to the issuance of all of the shares of Common Stock issuable upon Conversion in excess of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="onco:PercentageOfIssuedOfCommonStock" scale="-2" unitRef="pure" id="ixv-31188"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="onco:PercentageOfOutstandingOfCommonStock" scale="-2" unitRef="pure" id="ixv-31189">20</ix:nonFraction></ix:nonFraction>% of the issued and outstanding Common Stock on the Closing Date and (ii)&#160;Onconetix has effected an increase in the number of shares of Common Stock authorized under its certificate of incorporation, to the extent required to consummate the PMX Transaction. The Conversion ratio is subject to adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization and other adjustments, as defined in the Series&#160;B Certificate of Designations The Series&#160;B Preferred Stock is initially convertible into approximately <ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-31190">269,672,900</ix:nonFraction><span class="nobreak"> </span>shares of the Company&#8217;s common stock.</p></ix:continuation>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-38</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;9 &#8212; Convertible Redeemable Preferred Stock and Stockholders&#8217; Equity</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Cash Settlement&#160;&#8212;&#160;</span>If, at any time after the earlier of the date of the Stockholder Approval or January&#160;1, 2025 (the earliest such date, Onconetix (x)&#160;has obtained the Stockholder Approval but fails to deliver certificates representing the Conversion Shares, or other documentation as required under the terms of the Share Exchange Agreement, or (y)&#160;has failed to obtain the Stockholder Approval, Onconetix shall, at the request of the holder, pay to such holder an amount in cash equal to (i)&#160;the Fair Value (as defined below) of the shares of Series&#160;B Preferred Stock set forth in such request multiplied by (ii)&#160;the Conversion Ratio in effect on the&#160;trading day on which the request is delivered to Onconetix. &#8220;Fair Value&#8221; of shares shall be fixed with reference to the last reported closing stock price on the principal trading market of the Common Stock on which the Common Stock is listed as of the&#160;trading day on which the request is delivered to Onconetix.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Redemption&#160;&#8212;&#160;</span>The shares of Series&#160;B Preferred Stock are not redeemable by Onconetix.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluated the terms of the Series&#160;B Preferred Stock, and in accordance with the guidance of ASC&#160;480, the Series&#160;B Preferred Stock is classified as temporary equity in the accompanying consolidated balance sheet, as the shares may be redeemable by the holders for cash, upon certain conditions that are not within the control of the Company. Additionally, the Company does not control the actions or events necessary to deliver the number of required shares upon exercise by the holders of the conversion feature. The Series&#160;B Preferred Stock was recorded at its fair value as of the issuance date (see Note&#160;5). The Series&#160;B Preferred Stock is not currently redeemable or probable of becoming redeemable because it is subject to, among other things, Stockholder Approval as described above, and therefore the carrying amount is not currently accreted to its redemption value as of December&#160;31, 2023.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Series&#160;Seed Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company has <ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-31191">1,150,000</ix:nonFraction><span class="nobreak"> </span>shares of preferred stock designated as Series&#160;Seed Preferred Stock (&#8220;Series&#160;Seed&#8221;) and there are no shares of Series&#160;Seed outstanding as of December&#160;31, 2023 and 2022.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Prior to the closing of the IPO in 2022, there were <ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-31192"><ix:nonFraction contextRef="c211" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-31193">1,146,138</ix:nonFraction></ix:nonFraction><span class="nobreak"> </span>shares of Series&#160;Seed issued and outstanding. Each share of the Series&#160;Seed was convertible, at the option of the holder, at a conversion price of $<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-31194">1.52</ix:nonFraction> per share, subject to certain adjustments. The holders of the Series&#160;Seed were entitled to receive cumulative dividends at a per share rate of <ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" name="onco:PercentageOfCumulativeDividends" scale="-2" unitRef="pure" id="ixv-31195">8</ix:nonFraction>% per annum, compounded annually. Each Series&#160;Seed share was automatically convertible into common stock of the Company, at the then<span class="nobreak">-effective</span> conversion price, upon the closing of a firmly underwritten public offering netting proceeds of at least $<ix:nonFraction contextRef="c9" decimals="-6" format="ixt:num-dot-decimal" name="onco:NettingProceeds" scale="6" unitRef="usd" id="ixv-31196">50</ix:nonFraction>&#160;million with an offering price of at least three hundred percent (<ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" name="onco:PercentageOfOriginalIssuePrice" scale="-2" unitRef="pure" id="ixv-31197">300</ix:nonFraction>%) of the Original Issue Price of the Series&#160;Seed. On February&#160;18, 2022, the majority of the holders of the Series&#160;Seed approved the automatic conversion of the outstanding shares of the Series&#160;Seed and all related accrued and unpaid dividends, upon the closing of the IPO.&#160;The number of shares of Common Stock to be issued upon the closing of the IPO pursuant to the conversion were to be calculated in accordance with the original conversion terms provided by the Company&#8217;s Amended and Restated Certificate of Incorporation (&#8220;COI&#8221;) dated July&#160;1, 2019. This conversion occurred on February&#160;23, 2022, upon the closing of the Company&#8217;s IPO.&#160;Also, upon the close of the IPO, aggregate cumulative dividends of $<ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CumulativeDividends" scale="0" unitRef="usd" id="ixv-31198">1,586,162</ix:nonFraction>, or $<ix:nonFraction contextRef="c63" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DividendsPayableAmountPerShare" scale="0" unitRef="usdPershares" id="ixv-31199">1.38</ix:nonFraction> per Series&#160;Seed share, were automatically converted into shares of common stock. There were an aggregate of <ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" unitRef="shares" id="ixv-31200">5,626,365</ix:nonFraction><span class="nobreak"> </span>shares of common stock issued upon conversion of the Series&#160;Seed shares and cumulative dividends as of the close of the IPO.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023 and 2022, there were <ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssued1" scale="0" unitRef="usd" id="ixv-31201">22,841,975</ix:nonFraction> and <ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssued1" scale="0" unitRef="usd" id="ixv-31202">15,724,957</ix:nonFraction><span class="nobreak"> </span>shares of common stock issued, respectively, and <ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" unitRef="shares" id="ixv-31203">22,324,576</ix:nonFraction> and <ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" unitRef="shares" id="ixv-31204">15,265,228</ix:nonFraction><span class="nobreak"> </span>shares of common stock outstanding, respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Holders of the Company&#8217;s common stock are entitled to one vote for each share held of record, and are entitled upon liquidation of the Company to share ratably in the net assets of the Company available for distribution after payment of all obligations of the Company and after provision has been made with respect to each class of stock, if any, having preference over the common stock. The shares of common stock are not redeemable and have no preemptive or similar rights.</p></ix:continuation>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-39</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;9 &#8212; Convertible Redeemable Preferred Stock and Stockholders&#8217; Equity</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2023, in connection with the Proteomedix acquisition, the Company issued <ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonUnitIssued" scale="0" unitRef="shares" id="ixv-31205">3,675,414</ix:nonFraction><span class="nobreak"> </span>shares of the Company&#8217;s common stock as part of the purchase consideration (see Note&#160;5).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;17, 2022, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Boustead Securities, LLC, acting as representative of the underwriters (&#8220;Boustead&#8221;), in relation to the Company&#8217;s IPO, pursuant to which the Company agreed to sell to the underwriters an aggregate of <ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssued1" scale="0" unitRef="usd" id="ixv-31206">2,222,222</ix:nonFraction><span class="nobreak"> </span>shares of the Company&#8217;s common stock, at a price of $<ix:nonFraction contextRef="c213" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-31207">9.00</ix:nonFraction> per share. The IPO closed on February&#160;23, 2022 and resulted in net proceeds to the Company, after deducting the <ix:nonFraction contextRef="c62" decimals="2" format="ixt:num-dot-decimal" name="onco:PercentageOfUnderwritingDiscount" scale="-2" unitRef="pure" id="ixv-31208">8</ix:nonFraction>% underwriting discount, and other offering costs, of approximately $<ix:nonFraction contextRef="c63" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherOwnershipInterestsOfferingCosts" scale="6" unitRef="usd" id="ixv-31209">17.1</ix:nonFraction>&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Underwriting Agreement, the Company issued to Boustead warrants to purchase <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightUnissued" scale="0" unitRef="shares" id="ixv-31210">111,111</ix:nonFraction><span class="nobreak"> </span>shares of common stock, exercisable for five&#160;years at the option of the holder, at a per share exercise price equal to $<ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-31211">10.35</ix:nonFraction>. The Company evaluated the terms of the warrants issued at the close of the IPO and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC&#160;480 and ASC&#160;815<span class="nobreak">-40</span>. Since the Company determined that the warrants were equity<span class="nobreak">-classified</span>, the Company recorded the proceeds from the IPO, net of issuance costs, within common stock at par value and the balance of the net proceeds to additional paid in capital.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During October&#160;2022, in connection with a settlement agreement that was entered into with Boustead, these warrants were exchanged for <ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares" id="ixv-31212">93,466</ix:nonFraction><span class="nobreak"> </span>shares of restricted common stock (&#8220;the Warrant Exchange&#8221;) (see Note&#160;10). The Warrant Exchange was accounted for as a modification of the warrant, with an incremental fair value of approximately $<ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-31213">10,000</ix:nonFraction>, which was recorded as selling, general and administrative expense in the accompanying consolidated statements of operations and comprehensive loss. In addition, <ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares" id="ixv-31214">200,000</ix:nonFraction> restricted shares of common stock were issued to Boustead upon execution of an advisory agreement, which was entered into concurrent with the settlement agreement. The fair value of the restricted shares of common stock, which had no vesting provisions, was valued at $<ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-31215">254,000</ix:nonFraction>, and was recorded as selling, general and administrative expense in the accompanying consolidated statements of operations and comprehensive loss.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The restricted shares of common stock issued under the settlement and advisory agreements with Boustead was valued based on the closing trading price on the date the agreements were executed, adjusted to reflect the effect of the restriction on the sale of the common stock. The value of the restriction was measured using the Black<span class="nobreak">-Scholes</span> model to measure the discount for lack of marketability, using the following assumptions: expected term of <span style="-sec-ix-hidden: hidden-fact-274">0.5</span>&#160;years, expected volatility of <ix:nonFraction contextRef="c216" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-31216">96.36</ix:nonFraction>%, risk<span class="nobreak">-free</span> interest rate of <ix:nonFraction contextRef="c216" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-31217">4.09</ix:nonFraction>% and dividend yield of <ix:nonFraction contextRef="c216" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-31218">0.0</ix:nonFraction>%.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Treasury Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On November&#160;10, 2022, the board of directors approved a stock repurchase program (the &#8220;Repurchase Program&#8221;) to allow the Company to repurchase up to <ix:nonFraction contextRef="c217" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" scale="6" unitRef="shares" id="ixv-31219">5</ix:nonFraction>&#160;million shares of common stock with a maximum price of $<ix:nonFraction contextRef="c218" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" unitRef="usdPershares" id="ixv-31220">1.00</ix:nonFraction> per share, with discretion to management to make purchases subject to market conditions. On November&#160;18, 2022, the board of directors approved an increase to the maximum price to $<ix:nonFraction contextRef="c219" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" unitRef="usdPershares" id="ixv-31221">2.00</ix:nonFraction> per share. There is no expiration date for this program.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December&#160;31, 2023, the Company repurchased <ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" scale="0" unitRef="shares" id="ixv-31222">57,670</ix:nonFraction><span class="nobreak"> </span>shares of common stock, for an aggregate of approximately $<ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="0" unitRef="usd" id="ixv-31223">59,000</ix:nonFraction>, at an average price of $<ix:nonFraction contextRef="c221" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" unitRef="usdPershares" id="ixv-31224">1.02</ix:nonFraction> per share. During the year ended December&#160;31, 2022, the Company repurchased <ix:nonFraction contextRef="c222" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" scale="0" unitRef="shares" id="ixv-31225">459,729</ix:nonFraction><span class="nobreak"> </span>shares of common stock at an average price of $<ix:nonFraction contextRef="c223" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" unitRef="usdPershares" id="ixv-31226">1.23</ix:nonFraction> per share, for approximately $<ix:nonFraction contextRef="c222" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="6" unitRef="usd" id="ixv-31227">0.6</ix:nonFraction>&#160;million. Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. As of December&#160;31, 2023, there are approximately <ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" scale="6" unitRef="shares" id="ixv-31228">4.5</ix:nonFraction>&#160;million shares remaining, that can be repurchased under the Repurchase Program.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Private Investments in Public Equity</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">April&#160;2022 Private Placement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;19, 2022, the Company consummated the closing of a private placement (the &#8220;April&#160;2022 Private Placement&#8221;), pursuant to the terms and conditions of a securities purchase agreement, dated as of April&#160;13, 2022. At the closing of the April&#160;2022 Private Placement, the Company issued <ix:nonFraction contextRef="c224" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-31229">590,406</ix:nonFraction><span class="nobreak"> </span>shares of common stock, pre<span class="nobreak">-funded</span> </p></ix:continuation>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-40</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;9 &#8212; Convertible Redeemable Preferred Stock and Stockholders&#8217; Equity</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">warrants to purchase an aggregate of <ix:nonFraction contextRef="c224" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-31230">590,406</ix:nonFraction><span class="nobreak"> </span>shares of common stock and preferred investment options to purchase up to an aggregate of <ix:nonFraction contextRef="c225" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" unitRef="shares" id="ixv-31231">1,180,812</ix:nonFraction><span class="nobreak"> </span>shares of common stock. The purchase price of each share of common stock together with the associated preferred investment option was $<ix:nonFraction contextRef="c226" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-31232">6.775</ix:nonFraction>, and the purchase price of each pre<span class="nobreak">-funded</span> warrant together with the associated preferred investment option was $<ix:nonFraction contextRef="c225" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-31233">6.774</ix:nonFraction>. The aggregate net cash proceeds to the Company from the April&#160;2022 Private Placement were approximately $<ix:nonFraction contextRef="c227" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" unitRef="usd" id="ixv-31234">6.9</ix:nonFraction>&#160;million, after deducting placement agent fees and other offering expenses. The pre<span class="nobreak">-funded</span> warrants had an exercise price of $<ix:nonFraction contextRef="c228" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-31235">0.001</ix:nonFraction> per share and were exercised in full on May&#160;24, 2022. The preferred investment options, which had an exercise price of $<ix:nonFraction contextRef="c224" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-31236">6.65</ix:nonFraction> per share, were exchanged in connection with the August&#160;2022 Private Placement. See <span class="Italic" style="font-style:italic;font-weight:normal;">August&#160;2022 Private Placement</span> below for further detail.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">H.C.&#160;Wainwright&#160;&amp; Co., LLC (&#8220;Wainwright&#8221;) acted as the exclusive placement agent for the April&#160;2022 Private Placement. The Company agreed to pay Wainwright a placement agent fee and management fee equal to <ix:nonFraction contextRef="c229" decimals="3" format="ixt:num-dot-decimal" name="onco:PlacementAgentFeeAndManagementFeePercentage" scale="-2" unitRef="pure" id="ixv-31237">7.5</ix:nonFraction>% and <ix:nonFraction contextRef="c230" decimals="3" format="ixt:num-dot-decimal" name="onco:PlacementAgentFeeAndManagementFeePercentage" scale="-2" unitRef="pure" id="ixv-31238">1.0</ix:nonFraction>%, respectively, of the aggregate gross proceeds from the April&#160;2022 Private Placement and reimburse certain out<span class="nobreak">-of-pocket</span> expenses up to an aggregate of $<ix:nonFraction contextRef="c231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="0" unitRef="usd" id="ixv-31239">85,000</ix:nonFraction>. In addition, the Company issued warrants to Wainwright (the &#8220;April Wainwright Warrants&#8221;) to purchase up to <ix:nonFraction contextRef="c231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-31240">70,849</ix:nonFraction><span class="nobreak"> </span>shares of common stock. The Wainwright Warrants are in substantially the same form as the preferred investment options, except that the exercise price is $<ix:nonFraction contextRef="c232" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-31241">8.46875</ix:nonFraction>. The form of the preferred investment options is a warrant, and as such the preferred investment options, the pre<span class="nobreak">-funded</span> warrants, and the Wainwright Warrants are collectively referred to as the &#8220;April&#160;2022 Private Placement Warrants&#8221;. Further, upon any exercise for cash of any preferred investment options, the Company agreed to issue to Wainwright additional warrants to purchase the number of shares of common stock equal to <ix:nonFraction contextRef="c231" decimals="3" format="ixt:num-dot-decimal" name="onco:AggregateNumberOfSharesPercenatge" scale="-2" unitRef="pure" id="ixv-31242">6.0</ix:nonFraction>% of the aggregate number of shares of common stock underlying the preferred investment options that have been exercised, also with an exercise price of $<ix:nonFraction contextRef="c233" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-31243">8.46875</ix:nonFraction> (the &#8220;April Contingent Warrants&#8221;). The maximum number of April Contingent Warrants issuable under this provision of <ix:nonFraction contextRef="c234" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" unitRef="shares" id="ixv-31244">70,849</ix:nonFraction> were exchanged in connection with the August&#160;2022 Private Placement. See <span class="Italic" style="font-style:italic;font-weight:normal;">August&#160;2022 Private Placement</span> below for further detail.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluated the terms of the April&#160;2022 Private Placement Warrants and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC&#160;480 and ASC&#160;815<span class="nobreak">-40</span>. Since the Company determined that the April&#160;2022 Private Placement Warrants were equity<span class="nobreak">-classified</span>, the Company recorded the proceeds from the April&#160;2022 Private Placement, net of issuance costs, within common stock at par value and the balance of the net proceeds to additional paid in capital.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluated the terms of the April Contingent Warrants and determined that they should be classified as a liability based upon accounting guidance provided in ASC&#160;815<span class="nobreak">-40</span>. Since the April Contingent Warrants are a form of compensation to Wainwright, the Company recorded the value of the liability of approximately $<ix:nonFraction contextRef="c235" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilities" scale="0" unitRef="usd" id="ixv-31245">36,000</ix:nonFraction>, as a reduction of additional paid in capital, with subsequent changes in the value of the liability recorded in other income (expense) in the accompanying consolidated statements of operations and comprehensive loss. The Company measured the liability upon the close of the April Private Placement using a Monte Carlo simulation, using the following significant assumptions: expected term of <span style="-sec-ix-hidden: hidden-fact-275">4.0</span>&#160;years, expected volatility of <ix:nonFraction contextRef="c236" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-31246">117.0</ix:nonFraction>%, risk<span class="nobreak">-free</span> interest rate of <ix:nonFraction contextRef="c236" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-31247">4.00</ix:nonFraction>% and dividend yield of <ix:nonFraction contextRef="c237" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-31248">0.0</ix:nonFraction>%.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">August&#160;2022 Private Placement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;11, 2022, the Company consummated the closing of a private placement (the &#8220;August&#160;2022 Private Placement&#8221;), pursuant to the terms and conditions of a securities purchase agreement, dated as of August&#160;9, 2022. At the closing of the August&#160;2022 Private Placement, the Company issued <ix:nonFraction contextRef="c238" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-31249">1,350,000</ix:nonFraction><span class="nobreak"> </span>shares of common stock, pre<span class="nobreak">-funded</span> warrants to purchase an aggregate of <ix:nonFraction contextRef="c238" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-31250">2,333,280</ix:nonFraction><span class="nobreak"> </span>shares of common stock and preferred investment options to purchase up to an aggregate of <ix:nonFraction contextRef="c238" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" unitRef="shares" id="ixv-31251">4,972,428</ix:nonFraction><span class="nobreak"> </span>shares of common stock. The purchase price of each share of common stock together with the associated preferred investment option was $<ix:nonFraction contextRef="c238" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-31252">2.715</ix:nonFraction>, and the purchase price of each pre<span class="nobreak">-funded</span> warrant together with the associated preferred investment option was $<ix:nonFraction contextRef="c238" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-31253">2.714</ix:nonFraction>. The aggregate net cash proceeds to the Company from the August&#160;2022 Private Placement were approximately $<ix:nonFraction contextRef="c239" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" unitRef="usd" id="ixv-31254">8.7</ix:nonFraction>&#160;million, after deducting placement agent fees and other offering expenses. In addition, the investors in the August&#160;2022 Private Placement, who are the same investors from the April&#160;2022 Private Placement, agreed to cancel preferred investment options to purchase up to an aggregate of </p></ix:continuation>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-41</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;9 &#8212; Convertible Redeemable Preferred Stock and Stockholders&#8217; Equity</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"><ix:nonFraction contextRef="c240" decimals="0" format="ixt:num-dot-decimal" name="onco:CancelledPreferredInvestmentOptionsShares" scale="0" unitRef="shares" id="ixv-31255">1,180,812</ix:nonFraction><span class="nobreak"> </span>shares of the Company&#8217;s common stock issued in April&#160;2022. The pre<span class="nobreak">-funded</span> warrants had an exercise price of $<ix:nonFraction contextRef="c241" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-31256">0.001</ix:nonFraction> per share. During 2022, an aggregate of <ix:nonFraction contextRef="c242" decimals="0" format="ixt:num-dot-decimal" name="onco:PrefundedWarrantsExercised" scale="0" unitRef="shares" id="ixv-31257">1,686,640</ix:nonFraction> of the pre<span class="nobreak">-funded</span> warrants were exercised. The remaining <ix:nonFraction contextRef="c243" decimals="0" format="ixt:num-dot-decimal" name="onco:PrefundedWarrantsExercised" scale="0" unitRef="shares" id="ixv-31258">646,640</ix:nonFraction> of pre<span class="nobreak">-funded</span> warrants were exercised during the year ended December&#160;31, 2023. The preferred investment options are exercisable at any time on or after August&#160;11, 2022 through August&#160;12, 2027, at an exercise price of $<ix:nonFraction contextRef="c244" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-31259">2.546</ix:nonFraction> per share, subject to certain adjustments as defined in the agreement. During the year ended December&#160;31, 2023, <ix:nonFraction contextRef="c243" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockDividendsShares" scale="0" unitRef="shares" id="ixv-31260">2,486,214</ix:nonFraction> of these preferred investment options were exercised at a reduced exercise price of $<ix:nonFraction contextRef="c243" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPriceDecrease" scale="0" unitRef="usdPershares" id="ixv-31261">1.09</ix:nonFraction>, in connection with the warrant inducement transaction discussed below. As of December&#160;31, 2023, <ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-31262">2,486,214</ix:nonFraction> preferred investment options are outstanding.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Wainwright acted as the exclusive placement agent for the August&#160;2022 Private Placement. The Company agreed to pay Wainwright a placement agent fee and management fee equal to <ix:nonFraction contextRef="c245" decimals="3" format="ixt:num-dot-decimal" name="onco:PlacementAgentFeeAndManagementFeePercentage" scale="-2" unitRef="pure" id="ixv-31263">7.5</ix:nonFraction>% and <ix:nonFraction contextRef="c246" decimals="3" format="ixt:num-dot-decimal" name="onco:PlacementAgentFeeAndManagementFeePercentage" scale="-2" unitRef="pure" id="ixv-31264">1.0</ix:nonFraction>%, respectively, of the aggregate gross proceeds from the August&#160;2022 Private Placement and reimburse certain out<span class="nobreak">-of-pocket</span> expenses up to an aggregate of $<ix:nonFraction contextRef="c247" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="0" unitRef="usd" id="ixv-31265">85,000</ix:nonFraction>. In addition, the Company issued warrants to Wainwright (the &#8220;August Wainwright Warrants&#8221;) to purchase up to <ix:nonFraction contextRef="c248" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-31266">220,997</ix:nonFraction><span class="nobreak"> </span>shares of common stock. The August Wainwright Warrants are in substantially the same form as the preferred investment options, except that the exercise price is $<ix:nonFraction contextRef="c248" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-31267">3.3938</ix:nonFraction>. The form of the preferred investment options is a warrant, and as such the preferred investment options, the pre<span class="nobreak">-funded</span> warrants, and the August Wainwright Warrants are collectively referred to as the &#8220;August&#160;2022 Private Placement Warrants&#8221;. Further, upon any exercise for cash of any preferred investment options, the Company agreed to issue to Wainwright additional warrants to purchase the number of shares of common stock equal to <ix:nonFraction contextRef="c249" decimals="3" format="ixt:num-dot-decimal" name="onco:AggregateNumberOfSharesPercenatge" scale="-2" unitRef="pure" id="ixv-31268">6.0</ix:nonFraction>% of the aggregate number of shares of common stock underlying the preferred investment options that have been exercised, also with an exercise price of $<ix:nonFraction contextRef="c250" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-31269">3.3938</ix:nonFraction> (the &#8220;August Contingent Warrants&#8221;). The maximum number of August Contingent Warrants issuable under this provision is <ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="onco:WarrantsIssuableUnderProvisionShares" scale="0" unitRef="shares" id="ixv-31270">298,346</ix:nonFraction>, which includes <ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="onco:WarrantsIssuableUnderProvisionShares" scale="0" unitRef="shares" id="ixv-31271">70,849</ix:nonFraction> of April Contingent Warrants that were modified in connection with the August&#160;2022 Private Placement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluated the terms of the August&#160;2022 Private Placement Warrants and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC&#160;480 and ASC&#160;815<span class="nobreak">-40</span>. Since the Company determined that the August&#160;2022 Private Placement Warrants were equity<span class="nobreak">-classified</span>, the Company recorded the proceeds from the August&#160;2022 Private Placement, net of issuance costs, within common stock at par value and the balance of the net proceeds to additional paid in capital.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The investors in the April&#160;2022 Private Placement agreed to cancel the aggregate of <ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="onco:CancelledPreferredInvestmentOptionsShares" scale="0" unitRef="shares" id="ixv-31272">1,180,812</ix:nonFraction> preferred investment options issued in the April&#160;2022 Private Placement, as part of their participation in the August&#160;2022 Private Placement. The preferred investment options that were cancelled were effectively exchanged for <ix:nonFraction contextRef="c254" decimals="0" format="ixt:num-dot-decimal" name="onco:CancelledPreferredInvestmentOptionsShares" scale="0" unitRef="shares" id="ixv-31273">1,289,148</ix:nonFraction> new preferred investment options in the August&#160;2022 Private Placement, and accordingly have been accounted for as a modification or exchange of equity<span class="nobreak">-linked</span> instruments. In accordance with ASC&#160;815<span class="nobreak">-40</span>, as the preferred investment options were classified as equity instruments before and after the exchange, and as the exchange is directly attributable to an equity offering, the Company recognized the effect of the exchange as an equity issuance cost. <ix:nonNumeric contextRef="c0" continuedAt="_FairValueOptionQuantitativeDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueOptionQuantitativeDisclosuresTextBlock" id="ixv-19855">The increase in the fair value of the preferred investment options as a result of the exchange was approximately $<ix:nonFraction contextRef="c243" decimals="0" format="ixt:num-dot-decimal" name="onco:IncreaseInTheFairValueOfThePreferredInvestmentOptions" scale="0" unitRef="usd" id="ixv-31274">860,000</ix:nonFraction>, and was determined using the Black<span class="nobreak">-Scholes</span> option pricing model, with the following assumptions:</ix:nonNumeric></p>
		<ix:continuation id="_FairValueOptionQuantitativeDisclosuresTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Original</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Exchanged</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercise price</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c299" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-31275">6.65</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c300" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-31276">2.546</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Term (years)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<ix:nonNumeric contextRef="c301" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-19894"><p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.67</p></ix:nonNumeric>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<ix:nonNumeric contextRef="c302" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-19902"><p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.0</p></ix:nonNumeric>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected stock price volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c301" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-31277">116.2</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c302" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-31278">120.2</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free rate of interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c301" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-31279">3.16</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c302" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-31280">2.98</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluated the terms of the August Contingent Warrants and determined that they should be classified as a liability based upon accounting guidance provided in ASC&#160;815<span class="nobreak">-40</span>. As a result of the exchange of the preferred investment options issued in the April Private Placement, the underlying equity<span class="nobreak">-linked</span> instruments that would trigger issuance of the April Contingent Warrants was replaced, and therefore the <ix:nonFraction contextRef="c235" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-31281">70,849</ix:nonFraction> of April Contingent Warrants were exchanged for <ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-31282">70,849</ix:nonFraction> of the August Contingent Warrants. The value of the April Contingent Warrant liability was adjusted to fair value on the date of modification, using a Monte Carlo simulation, with the change in fair value </p></ix:continuation>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-42</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;9 &#8212; Convertible Redeemable Preferred Stock and Stockholders&#8217; Equity</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">of approximately $<ix:nonFraction contextRef="c243" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-31283">8,000</ix:nonFraction> recognized in the accompanying consolidated statements of operations and comprehensive loss. The remaining <ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-31284">227,497</ix:nonFraction> August Contingent Warrants were measured as a liability upon the close of the August Private Placement. Since the Contingent Warrants are a form of compensation to the placement agent, the Company recorded the value of the liability of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="0" unitRef="usd" id="ixv-31285">39,000</ix:nonFraction>, as a reduction of additional paid in capital. The entire <ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-31286">298,346</ix:nonFraction> of August Contingent Warrants were remeasured at December&#160;31, 2022, using a Monte Carlo simulation, with the change in the value of the liability recorded in other income (expense) in the accompanying consolidated statements of operations and comprehensive loss. <ix:nonNumeric contextRef="c0" continuedAt="onco_ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock-c0_cont_1" escape="true" name="onco:ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock" id="ixv-31287">The following significant assumptions were used in the valuation of the contingent warrant liability, related to the August Contingent Warrants, as of the date of the August&#160;2022 Private Placement and as of December&#160;31, 2022:</ix:nonNumeric></p>
		<ix:continuation id="onco_ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">August&#160;11,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercise price</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c303" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-31288">3.3938</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c304" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-31289">3.3938</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Term (years)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<ix:nonNumeric contextRef="c305" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-19999"><p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.00</p></ix:nonNumeric>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<ix:nonNumeric contextRef="c306" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-20007"><p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.61</p></ix:nonNumeric>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected stock price volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c305" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-31290">127.8</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c306" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-31291">120.8</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free rate of interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c305" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-31292">2.98</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c306" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-31293">4.03</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December&#160;31, 2023, in connection with the warrant inducement transaction, the Company issued warrants to Wainwright as settlement of the contingent warrant liability associated with <ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="onco:ContingentWarrantLiabilityShares" scale="0" unitRef="usd" id="ixv-31294">149,173</ix:nonFraction> of the August&#160;2022 Contingent Warrants, which was triggered upon exercise of the underlying preferred investment options. See <span class="Italic" style="font-style:italic;font-weight:normal;">Warrant Inducement </span>below for further discussion.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">At the Market Offering Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;29, 2023, the Company entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C.&#160;Wainwright&#160;&amp; Co., LLC, as sales agent (the &#8220;Agent&#8221;), to create an at<span class="nobreak">-the-market</span> equity program under which it may sell up to $<ix:nonFraction contextRef="c257" decimals="0" format="ixt:num-dot-decimal" name="onco:SharesOfCommonStockIssued" scale="0" unitRef="shares" id="ixv-31295">3,900,000</ix:nonFraction> of shares of the Company&#8217;s common stock (the &#8220;Shares&#8221;) from time to time through the Agent (the &#8220;ATM Offering&#8221;). Under the ATM Agreement, the Agent will be entitled to a commission at a fixed rate of <ix:nonFraction contextRef="c258" decimals="3" format="ixt:num-dot-decimal" name="onco:FixedCommissionRate" scale="-2" unitRef="pure" id="ixv-31296">3.0</ix:nonFraction>% of the gross proceeds from each sale of Shares under the ATM Agreement. The Company has no obligation to sell, and the Agent is not obligated to buy or sell, any of the Shares under the Agreement and may at any time suspend offers under the Agreement or terminate the Agreement. The ATM Offering will terminate upon the termination of the ATM Agreement as permitted therein.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Deferred offering costs associated with the ATM Agreement are reclassified to additional paid in capital on a pro<span class="nobreak">-rata</span> basis when the Company completes offerings under the ATM Agreement. Any remaining deferred costs will be expensed to the consolidated statements of operations and comprehensive loss should the planned offering be abandoned.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, no shares have been sold under the ATM Offering.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Warrant Inducement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On July&#160;31, 2023, the Company entered into a common stock preferred investment options exercise inducement offer letter (the &#8220;Inducement Letter&#8221;) with a holder (the &#8220;Holder&#8221;) of existing preferred investment options (&#8220;PIOs&#8221;) to purchase shares of the Company&#8217;s common stock at the original exercise price of $<ix:nonFraction contextRef="c259" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-31297">2.546</ix:nonFraction> per share, issued on August&#160;11, 2022 (the &#8220;Existing PIOs&#8221;). Pursuant to the Inducement Letter, the Holder agreed to exercise for cash its Existing PIOs to purchase an aggregate of <ix:nonFraction contextRef="c260" decimals="0" format="ixt:num-dot-decimal" name="onco:SharesOfCommonStockIssued" scale="0" unitRef="shares" id="ixv-31298">2,486,214</ix:nonFraction><span class="nobreak"> </span>shares of the Company&#8217;s common stock (the &#8220;Inducement PIO Shares&#8221;), at a reduced exercised price of $<ix:nonFraction contextRef="c260" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-31299">1.09</ix:nonFraction> per share, in exchange for the Company&#8217;s agreement to issue new preferred investment options (the &#8220;Inducement PIOs&#8221;) to purchase up to <ix:nonFraction contextRef="c261" decimals="0" format="ixt:num-dot-decimal" name="onco:SharesOfCommonStockIssued" scale="0" unitRef="shares" id="ixv-31300">4,972,428</ix:nonFraction><span class="nobreak"> </span>shares of the Company&#8217;s common stock. The Inducement PIOs have substantially the same terms as the Existing PIOs.</p></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-43</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;9 &#8212; Convertible Redeemable Preferred Stock and Stockholders&#8217; Equity</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;2, 2023, the Company consummated the transactions contemplated by the Inducement Letter (the &#8220;Warrant Inducement&#8221;). The Company received aggregate net proceeds of approximately $<ix:nonFraction contextRef="c262" decimals="-5" format="ixt:num-dot-decimal" name="onco:AggregateNetProceeds" scale="6" unitRef="usd" id="ixv-31301">2.3</ix:nonFraction>&#160;million from the Warrant Inducement, after deducting placement agent fees and other offering expenses payable by the Company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Upon the close of the transaction, the Company issued the Holder <ix:nonFraction contextRef="c263" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-31302">1,575,000</ix:nonFraction> of the <ix:nonFraction contextRef="c264" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-31303">2,486,214</ix:nonFraction><span class="nobreak"> </span>shares of common stock that were issuable upon exercise of the Existing PIOs. Due to the beneficial ownership limitation provisions in the Inducement Letter, the remaining <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesSubscribedButUnissued" scale="0" unitRef="shares" id="ixv-31304">911,214</ix:nonFraction><span class="nobreak"> </span>shares were initially unissued, and held in abeyance for the benefit of the Holder until notice from the Holder that the shares may be issued in compliance with such limitation is received. These shares were issued to the Holder in October&#160;2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company agreed to file a registration statement covering the resale of the Inducement PIO Shares issued or issuable upon the exercise of the Inducement PIOs (the &#8220;Resale Registration Statement&#8221;), as soon as practicable, and to use commercially reasonable efforts to have such Resale Registration Statement declared effective by the SEC within 90&#160;days following the date of the Inducement Letter, and to keep the Resale Registration Statement effective at all times until there are no Inducement PIO Shares. The provision to register the underlying shares in the Warrant Inducement does not require payment related to the registration rights provided. As such, while the shares were not registered within 90&#160;days of the date of the Inducement Letter, there is no accounting impact for this provision.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company engaged Wainwright to act as its placement agent in connection with the Warrant Inducement and paid Wainwright a cash fee equal to <ix:nonFraction contextRef="c264" decimals="3" format="ixt:num-dot-decimal" name="onco:PercentageOfGrossProceeds" scale="-2" unitRef="pure" id="ixv-31305">7.5</ix:nonFraction>% of the gross proceeds received from the exercise of the Existing PIOs as well as a management fee equal to <ix:nonFraction contextRef="c263" decimals="3" format="ixt:num-dot-decimal" name="onco:PercentageOfGrossProceeds" scale="-2" unitRef="pure" id="ixv-31306">1.0</ix:nonFraction>% of the gross proceeds from the exercise of the Existing PIOs. The Company also agreed to reimburse Wainwright for its expenses in connection with the exercise of the Existing PIOs and the issuance of the Inducement PIOs, up to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="0" unitRef="usd" id="ixv-31307">50,000</ix:nonFraction> for fees and expenses of legal counsel and other out<span class="nobreak">-of-pocket</span> expenses and agreed to pay Wainwright for non<span class="nobreak">-accountable</span> expenses in the amount of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralExpense" scale="0" unitRef="usd" id="ixv-31308">35,000</ix:nonFraction>. In addition, the exercise for cash of the Existing PIOs triggered the issuance to Wainwright or its designees, warrants to purchase <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:AggregatePurchaseShares" scale="0" unitRef="shares" id="ixv-31309">149,173</ix:nonFraction><span class="nobreak"> </span>shares of common stock (&#8220;Wainwright Inducement Warrants&#8221;), which were issuable in accordance with the terms of the August Contingent Warrants, and have the same terms as the Inducement PIOs except for an exercise price equal to $<ix:nonFraction contextRef="c265" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-31310">1.3625</ix:nonFraction> per share. The Company also agreed to issue warrants to Wainwright upon any exercise for cash of the Inducement PIOs, that number of shares of common stock equal to <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="onco:PercentageOfCommonStockShares" scale="-2" unitRef="pure" id="ixv-31311">6.0</ix:nonFraction>% of the aggregate number of such shares of common stock underlying the Inducement PIOs that have been exercised, also with an exercise price of $<ix:nonFraction contextRef="c266" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-31312">1.3625</ix:nonFraction> (the &#8220;Inducement Contingent Warrants&#8221;). The maximum number of Inducement Contingent Warrants issuable under this provision is <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares" id="ixv-31313">298,346</ix:nonFraction>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluated the terms of the Inducement PIOs and the Wainwright Inducement Warrants (collectively, the &#8220;August&#160;2023 Inducement Warrants&#8221;), and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC&#160;480 and ASC&#160;815<span class="nobreak">-40</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Warrant Inducement, which resulted in the lowering of the exercise price of the Existing PIOs and the issuance of the Inducement PIOs, is considered a modification of the Existing PIOs under the guidance of Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2021<span class="nobreak">-04</span>, <span class="Italic" style="font-style:italic;font-weight:normal;">Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Equity Classified Written Call Options</span>. The modification is consistent with the &#8220;Equity Issuance&#8221; classification under that guidance as the reason for the modification was to induce the holders of the Existing PIOs to cash exercise their warrants, resulting in the imminent exercise of the Existing PIOs, which raised equity capital and generated net proceeds for the Company of approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="onco:AggregateNetProceeds" scale="6" unitRef="usd" id="ixv-31314">2.3</ix:nonFraction>&#160;million. As the Existing PIOs and the Inducement PIOs were classified as equity instruments before and after the exchange, and as the exchange is directly attributable to an equity offering, the Company recognized the effect of the modification of approximately $<ix:nonFraction contextRef="c267" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" unitRef="usd" id="ixv-31315">2.6</ix:nonFraction>&#160;million as an equity issuance cost.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the change in fair value of the contingent warrant liability associated with <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-31316">149,173</ix:nonFraction> of the August Contingent Warrants that were settled through issuance of the Wainwright Inducement Warrants, of approximately $<ix:nonFraction contextRef="c267" decimals="0" format="ixt:num-dot-decimal" name="onco:WarrantsIssuedForSettlementOfContingentWarrants" scale="0" unitRef="usd" id="ixv-31317">122,000</ix:nonFraction>, was recognized in other income (expense) in the accompanying consolidated statements of operations and comprehensive loss, and the fair value of the contingent warrant liability of approximately $<ix:nonFraction contextRef="c267" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-31318">129,000</ix:nonFraction> was derecognized as of the settlement date. The corresponding amount, representing the fair value of the Wainwright Inducement Warrants, </p></ix:continuation>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-44</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;9 &#8212; Convertible Redeemable Preferred Stock and Stockholders&#8217; Equity</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">was recognized as additional paid in capital. The Company measured the liability on the settlement date using a Black Scholes model, with the following significant assumptions: expected term of <span style="-sec-ix-hidden: hidden-fact-276">5.0</span>&#160;years, expected volatility of <ix:nonFraction contextRef="c267" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-31319">117.8</ix:nonFraction>%, risk<span class="nobreak">-free</span> interest rate of <ix:nonFraction contextRef="c267" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-31320">4.24</ix:nonFraction>% and dividend yield of <ix:nonFraction contextRef="c267" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-31321">0.0</ix:nonFraction>%.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluated the terms of the Inducement Contingent Warrants and determined that they should be classified as a liability based upon accounting guidance provided in ASC&#160;815<span class="nobreak">-40</span>. Since the Inducement Contingent Warrants are a form of compensation to Wainwright, the Company recorded the value of the liability of approximately $<ix:nonFraction contextRef="c266" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilities" scale="0" unitRef="usd" id="ixv-31322">26,000</ix:nonFraction> as a reduction of additional paid in capital, with subsequent changes in the value of the liability recorded in other income (expense) in the accompanying consolidated statements of operations and comprehensive loss. The Company measured the liability on the settlement date using a Black Scholes model, with the following significant assumptions: expected term of <span style="-sec-ix-hidden: hidden-fact-277">5.0</span>&#160;years, expected volatility of <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-31323">117.8</ix:nonFraction>%, risk<span class="nobreak">-free</span> interest rate of <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-31324">4.24</ix:nonFraction>% and dividend yield of <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-31325">0.0</ix:nonFraction>%.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Warrants</span></p>
		<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="ixv-20106"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following summarizes activity related to the Company&#8217;s outstanding warrants, excluding contingent warrants issuable upon exercise of the preferred investment options, for the year ended December&#160;31, 2023:</p></ix:nonNumeric>
		<ix:continuation id="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Number of<br/>Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life<br/>(in&#160;years)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding as of December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c307" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-31326">5,910,914</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c307" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-31327">2.37</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<ix:nonNumeric contextRef="c308" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-20149"><p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.7</p></ix:nonNumeric>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c309" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-31328">5,121,601</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c309" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-31329">1.10</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c309" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-31330">3,132,854</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c309" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-31331">0.865</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-268">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-269">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding as of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c310" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-31332">7,899,661</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c310" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-31333">1.68</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<ix:nonNumeric contextRef="c309" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-20214"><p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.3</p></ix:nonNumeric>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Warrants vested and exercisable as of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c310" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-31334">7,899,661</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c310" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-31335">1.68</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<ix:nonNumeric contextRef="c309" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-20231"><p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.3</p></ix:nonNumeric>	</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, the outstanding warrants include <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-31336">70,849</ix:nonFraction> April&#160;2022 Private Placement Warrants, <ix:nonFraction contextRef="c268" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-31337">2,707,211</ix:nonFraction> August&#160;2022 Private Placement Warrants, and <ix:nonFraction contextRef="c269" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-31338">5,121,601</ix:nonFraction> August&#160;2023 Inducement Warrants, which are exercisable into <ix:nonFraction contextRef="c270" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-31339">7,899,661</ix:nonFraction><span class="nobreak"> </span>shares of common stock which had a fair value of $<ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-31340">0.20</ix:nonFraction> per share, based on the closing trading price on that&#160;day.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, as of December&#160;31, 2023 and 2022, the value of the August Contingent Warrants and the Inducement Contingent Warrants (collectively the &#8220;Contingent Warrants&#8221;) was approximately $<ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" unitRef="usd" id="ixv-31341">3,000</ix:nonFraction> and $<ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" unitRef="usd" id="ixv-31342">14,000</ix:nonFraction>, respectively. The maximum number of warrants issuable upon settlement of the Contingent Warrants as of December&#160;31, 2023 and 2022 was <ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares" id="ixv-31343">447,519</ix:nonFraction> and <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares" id="ixv-31344">298,346</ix:nonFraction>, respectively.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Onconetix Equity Incentive Plans</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) was adopted by its board of directors and by its stockholders on July&#160;1, 2019. The Company has reserved <ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-31345">1,400,000</ix:nonFraction><span class="nobreak"> </span>shares of common stock for issuance pursuant to the 2019 Plan.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;23, 2022 and in connection with the closing of the IPO, the Company&#8217;s board of directors adopted the Company&#8217;s 2022 Equity Incentive Plan (the &#8220;2022 Plan&#8221;), which is the successor and continuation of the Company&#8217;s 2019 Plan. Under the 2022 Plan, the Company may grant stock options, restricted stock, restricted stock units, stock appreciation rights, and other forms of awards to employees, directors, and consultants of the Company. Upon its effectiveness, a total of <ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-31346">1,600,000</ix:nonFraction><span class="nobreak"> </span>shares of common stock were reserved for issuance under the 2022 Plan. In August&#160;2022, the number of shares of common stock reserved for issuance under the 2022 Plan was increased to <ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-31347">2,600,000</ix:nonFraction> and in May&#160;2023, the number of shares of common stock reserved for issuance under the 2022 Plan was </p></ix:continuation>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-45</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;9 &#8212; Convertible Redeemable Preferred Stock and Stockholders&#8217; Equity</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">increased to <ix:nonFraction contextRef="c274" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-31348">3,150,000</ix:nonFraction>. The stock options and restricted stock granted during the&#160;years ended December&#160;31, 2023 and 2022 were all granted under the 2022 Plan. As of December&#160;31, 2023, there are <ix:nonFraction contextRef="c275" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-31349">718,402</ix:nonFraction><span class="nobreak"> </span>shares available for issuance under the 2022 Plan.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stock Options</span></p>
		<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-20258"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following summarizes activity related to the Company&#8217;s stock options under the 2019 Plan and the 2022 Plan for the year ended December&#160;31, 2023:</p></ix:nonNumeric>
		<ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Number of<br/>Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Total<br/>Intrinsic<br/>Value</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(in&#160;years)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding as of December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c311" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-31350">1,392,654</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c311" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-31351">3.30</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c311" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" unitRef="usd" id="ixv-31352">670,161</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<ix:nonNumeric contextRef="c312" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-20314"><p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.2</p></ix:nonNumeric>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c313" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-31353">962,154</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c313" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-31354">0.48</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-270">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited/cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c313" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares" id="ixv-31355">404,058</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c313" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-31356">4.87</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-271">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c313" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-31357">45,920</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c313" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-31358">0.01</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c313" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" unitRef="usd" id="ixv-31359">45,920</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding as of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c314" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-31360">1,904,830</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c314" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-31361">1.63</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c314" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" unitRef="usd" id="ixv-31362">94,239</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<ix:nonNumeric contextRef="c313" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-20401"><p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.4</p></ix:nonNumeric>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and exercisable as of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c314" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" unitRef="shares" id="ixv-31363">861,177</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c314" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-31364">2.23</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c314" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="0" unitRef="usd" id="ixv-31365">94,239</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<ix:nonNumeric contextRef="c313" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="ixv-20423"><p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.1</p></ix:nonNumeric>	</td>
				</tr>

		</table></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="onco_ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock-c0_cont_1" escape="true" name="onco:ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock" id="ixv-20425"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of options granted in 2023 and 2022 was estimated using the following assumptions:</p></ix:nonNumeric>
		<ix:continuation id="onco_ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-28" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">For the <br/>Year Ended <br/>December&#160;31, <br/>2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">For the <br/>Year Ended <br/>December&#160;31, <br/>2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercise price</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">$<ix:nonFraction contextRef="c66" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-31366">0.26</ix:nonFraction>&#160;&#8211;&#160;<ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-31367">1.29</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">$<ix:nonFraction contextRef="c315" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-31368">1.06</ix:nonFraction>&#160;&#8211;&#160;<ix:nonFraction contextRef="c316" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-31369">6.45</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Term (years)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c263" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-31370">5.00</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="c264" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-31371">10.00</ix:nonNumeric></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c317" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-31372">5.00</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="c318" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-31373">10.00</ix:nonNumeric></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected stock price volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonFraction contextRef="c263" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-31374">101.1</ix:nonFraction>%&#160;&#8211;&#160;<ix:nonFraction contextRef="c264" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-31375">119.5</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonFraction contextRef="c317" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-31376">112.6</ix:nonFraction>%&#160;&#8211;&#160;<ix:nonFraction contextRef="c318" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-31377">121.2</ix:nonFraction>%</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free rate of interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonFraction contextRef="c263" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-31378">3.5</ix:nonFraction>%&#160;&#8211;&#160;<ix:nonFraction contextRef="c264" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-31379">4.7</ix:nonFraction>%</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonFraction contextRef="c317" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-31380">2.9</ix:nonFraction>%&#160;&#8211;&#160;<ix:nonFraction contextRef="c318" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-31381">4.3</ix:nonFraction>%</p>	</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The weighted average grant date fair value of stock options granted during the&#160;years ended December&#160;31, 2023 and 2022 was $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-31382">0.41</ix:nonFraction> and $<ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-31383">3.40</ix:nonFraction>, respectively. The aggregate fair value of stock options that vested during the&#160;years ended December&#160;31, 2023 and 2022 was approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" unitRef="usd" id="ixv-31384">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction contextRef="c9" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" unitRef="usd" id="ixv-31385">2.1</ix:nonFraction>&#160;million, respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On October&#160;4, 2023, the Company&#8217;s board of directors granted an aggregate of <ix:nonFraction contextRef="c276" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-31386">709,768</ix:nonFraction> stock options in connection with the appointment of the Company&#8217;s newly hired Chief Executive Officer and Chief Financial Officer. The options granted have an exercise price of $<ix:nonFraction contextRef="c276" decimals="4" format="ixt:num-dot-decimal" name="onco:ExercisePrice" scale="0" unitRef="usdPershares" id="ixv-31387">0.4305</ix:nonFraction> per share, vest quarterly over a three<span class="nobreak">-year</span> period, and have a grant date fair value of approximately $<ix:nonFraction contextRef="c276" decimals="-5" format="ixt:num-dot-decimal" name="onco:GrantDateFairValueOfStockOption" scale="6" unitRef="usd" id="ixv-31388">0.2</ix:nonFraction>&#160;million. The Company recognized less than $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" scale="6" unitRef="usd" id="ixv-31389">0.1</ix:nonFraction>&#160;million of stock<span class="nobreak">-based</span> compensation expense related to these awards during the year ended December&#160;31, 2023. Subsequent to December&#160;31, 2023, in connection with the resignation of the newly hired Chief Executive Officer, <ix:nonFraction contextRef="c277" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares" id="ixv-31390">487,965</ix:nonFraction> of these options were forfeited (see Note&#160;14).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December&#160;31, 2022, <ix:nonFraction contextRef="c278" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-31391">200,000</ix:nonFraction> stock options were granted to the Company&#8217;s former Chief Executive Officer (&#8220;former CEO&#8221;), Chairman, and significant stockholder, <ix:nonFraction contextRef="c279" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-31392">200,000</ix:nonFraction> stock options were granted to the Company&#8217;s former Chief Business Officer (&#8220;former CBO&#8221;), and <ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-31393">100,000</ix:nonFraction> stock options were granted to the Company&#8217;s former Chief Financial Officer (&#8220;former CFO&#8221;). The aggregate grant<span class="nobreak">-date</span> fair value of the stock options granted to these individuals was approximately $<ix:nonFraction contextRef="c9" decimals="-5" format="ixt:num-dot-decimal" name="onco:GrantDateFairValueOfStockOption" scale="6" unitRef="usd" id="ixv-31394">1.8</ix:nonFraction>&#160;million, of which approximately $<ix:nonFraction contextRef="c278" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" scale="6" unitRef="usd" id="ixv-31395">1.5</ix:nonFraction>&#160;million was recognized as stock<span class="nobreak">-based</span> compensation expense during the year ended December&#160;31, 2022. During the year ended December&#160;31, 2023, in connection with the resignation of the former CEO and the former CFO, <ix:nonFraction contextRef="c280" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares" id="ixv-31396">250,000</ix:nonFraction> of these stock options were forfeited.</p></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-46</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;9 &#8212; Convertible Redeemable Preferred Stock and Stockholders&#8217; Equity</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, during the year ended December&#160;31, 2022, the Company granted an aggregate of <ix:nonFraction contextRef="c281" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-31397">72,223</ix:nonFraction> stock options to non<span class="nobreak">-executive</span> directors. The grant<span class="nobreak">-date</span> fair value of the stock options granted to the non<span class="nobreak">-executive</span> directors was approximately $<ix:nonFraction contextRef="c281" decimals="-5" format="ixt:num-dot-decimal" name="onco:GrantDateFairValueOfStockOption" scale="6" unitRef="usd" id="ixv-31398">0.2</ix:nonFraction>&#160;million, of which approximately $<ix:nonFraction contextRef="c281" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" scale="6" unitRef="usd" id="ixv-31399">0.2</ix:nonFraction>&#160;million was recognized as stock<span class="nobreak">-based</span> compensation expense during the year ended December&#160;31, 2022.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Restricted Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On May&#160;9, 2023, the Board&#8217;s Compensation Committee approved the issuance of restricted stock, granted under the Company&#8217;s 2022 Plan, to the Company&#8217;s executive officers, employees, and certain of the Company&#8217;s consultants. The restricted shares granted totaled <ix:nonFraction contextRef="c282" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" scale="0" unitRef="shares" id="ixv-31400">487,500</ix:nonFraction>, of which <ix:nonFraction contextRef="c283" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" scale="0" unitRef="shares" id="ixv-31401">150,000</ix:nonFraction>, <ix:nonFraction contextRef="c284" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" scale="0" unitRef="shares" id="ixv-31402">75,000</ix:nonFraction>, and <ix:nonFraction contextRef="c285" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" scale="0" unitRef="shares" id="ixv-31403">150,000</ix:nonFraction> were granted to the Company&#8217;s former CEO, former CFO, and former CBO, respectively. All of the restricted shares granted vest as follows: <ix:nonFraction contextRef="c286" decimals="2" format="ixt:num-dot-decimal" name="onco:RestrictedSharesGrantedVestPercentage" scale="-2" unitRef="pure" id="ixv-31404">50</ix:nonFraction>% in January&#160;2024, <ix:nonFraction contextRef="c287" decimals="2" format="ixt:num-dot-decimal" name="onco:RestrictedSharesGrantedVestPercentage" scale="-2" unitRef="pure" id="ixv-31405">25</ix:nonFraction>% in August&#160;2024, and <ix:nonFraction contextRef="c288" decimals="2" format="ixt:num-dot-decimal" name="onco:RestrictedSharesGrantedVestPercentage" scale="-2" unitRef="pure" id="ixv-31406">25</ix:nonFraction>% in August&#160;2025. In addition, on May&#160;31, 2023, the Board&#8217;s Compensation Committee approved the issuance of <ix:nonFraction contextRef="c289" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" scale="0" unitRef="shares" id="ixv-31407">25,440</ix:nonFraction><span class="nobreak"> </span>shares of restricted stock, granted to the Company&#8217;s non<span class="nobreak">-executive</span> Board members, with full vesting on May&#160;31, 2024.</p>
		<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="ixv-20510"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;16, 2023 and October&#160;4, 2023, upon their respective resignations, the Company&#8217;s former CEO and former CFO forfeited <ix:nonFraction contextRef="c290" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="0" unitRef="shares" id="ixv-31408">150,000</ix:nonFraction><span class="nobreak"> </span>shares and <ix:nonFraction contextRef="c291" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="0" unitRef="shares" id="ixv-31409">75,000</ix:nonFraction><span class="nobreak"> </span>shares of unvested restricted stock, respectively.</p></ix:nonNumeric>
		<ix:continuation id="_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Number of<br/>Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Nonvested as of December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-272">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-273">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-31410">512,940</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-31411">1.01</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited/cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" unitRef="shares" id="ixv-31412">250,110</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-31413">1.02</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-31414">6,250</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-31415">1.03</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Nonvested as of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-31416">256,580</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-31417">1.03</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Proteomedix Stock Option Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix sponsors a stock option plan (the &#8220;PMX Option Plan&#8221;) which provides common stock option grants to be granted to certain employees and consultants, as was determined by the board of directors of Proteomedix. In connection with the PMX Transaction, the Company assumed the PMX Option Plan (see Note&#160;5).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Generally, options issued under the PMX Option Plan have a term of less than <span style="-sec-ix-hidden: hidden-fact-278">11</span>&#160;years and provide for a <span style="-sec-ix-hidden: hidden-fact-279">four</span><span class="nobreak">-year</span> vesting period during which the grantee must remain in the service of Proteomedix. Stock options issued under the PMX Option Plan are measured at fair value using the Black<span class="nobreak">-Scholes</span> option pricing model.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">There was no activity under the PMX Option Plan between the Acquisition Date and December&#160;31, 2023. As of December&#160;31, 2023, there were <ix:nonFraction contextRef="c293" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-31418">58,172</ix:nonFraction> and <ix:nonFraction contextRef="c292" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-31419">57,276</ix:nonFraction> stock options outstanding and vested, respectively, with a weighted average exercise price of $<ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-31420">3.46</ix:nonFraction> and $<ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-31421">3.17</ix:nonFraction>, respectively, and a weighted average remaining contractual life of <span style="-sec-ix-hidden: hidden-fact-280">5.36</span>&#160;years and <span style="-sec-ix-hidden: hidden-fact-281">5.20</span>&#160;years, respectively. The intrinsic value of options outstanding and vested, as of December&#160;31, 2023 was approximately $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" unitRef="usd" id="ixv-31422">7.4</ix:nonFraction>&#160;million and $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" unitRef="usd" id="ixv-31423">7.1</ix:nonFraction>&#160;million, respectively. As of December&#160;31, 2023 there were <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesHeldInEmployeeStockOptionPlanAllocated" scale="0" unitRef="shares" id="ixv-31424">47,990</ix:nonFraction> stock options exercisable at a weighted average exercise price of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-31425">3.94</ix:nonFraction> and a weighted average remaining contractual life of <span style="-sec-ix-hidden: hidden-fact-282">4.53</span>&#160;years.</p></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-47</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;9 &#8212; Convertible Redeemable Preferred Stock and Stockholders&#8217; Equity</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p>
		<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="ixv-20625"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Stock<span class="nobreak">-based</span> compensation expense for the&#160;years ended December&#160;31, 2023 and 2022 was as follows:</p></ix:nonNumeric>
		<ix:continuation id="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">For the&#160;Years Ended</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Selling, general and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c319" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-31426">234,298</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c320" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-31427">1,309,687</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c321" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-31428">95,462</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c322" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-31429">664,879</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-31430">329,760</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-31431">1,974,566</ix:nonFraction></span></p>	</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, unrecognized stock<span class="nobreak">-based</span> compensation expense relating to outstanding stock options and unvested restricted stock under the Onconetix Equity Incentive Plans is approximately $<ix:nonFraction contextRef="c294" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" unitRef="usd" id="ixv-31432">345,000</ix:nonFraction> and $<ix:nonFraction contextRef="c295" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" unitRef="usd" id="ixv-31433">35,000</ix:nonFraction>, respectively, which is expected to be recognized over a weighted<span class="nobreak">-average</span> period of <span style="-sec-ix-hidden: hidden-fact-283">1.79</span>&#160;years and <span style="-sec-ix-hidden: hidden-fact-284">1.57</span>&#160;years, respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, unrecognized stock<span class="nobreak">-based</span> compensation expense relating to outstanding stock options under the PMX Option Plan is approximately $<ix:nonFraction contextRef="c293" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" unitRef="usd" id="ixv-31434">0.1</ix:nonFraction>&#160;million, which will be recognized over a weighted<span class="nobreak">-average</span> period of <span style="-sec-ix-hidden: hidden-fact-285">2.98</span>&#160;years.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December&#160;31, 2023, in connection with the former CBO&#8217;s resignation from the Company, the individual&#8217;s outstanding stock options and restricted stock awards were modified to allow continued vesting during the term of the consulting agreement entered into in January&#160;2024. The Company recognized a net credit of approximately $<ix:nonFraction contextRef="c298" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" scale="0" unitRef="usd" id="ixv-31435">165,000</ix:nonFraction> to stock<span class="nobreak">-based</span> compensation expense as a result of this modification, primarily due to the decrease in the Company&#8217;s stock price.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December&#160;31, 2022, the Company&#8217;s board of directors approved the accelerated vesting of an aggregate of <ix:nonFraction contextRef="c281" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-31436">32,517</ix:nonFraction> stock options to a former director and a former advisor, in connection with their separation from the Company. The Company recognized stock<span class="nobreak">-based</span> compensation expense of approximately $<ix:nonFraction contextRef="c9" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" scale="6" unitRef="usd" id="ixv-31437">0.1</ix:nonFraction>&#160;million related to these modifications during the year ended December&#160;31, 2022.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-20707"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;10 &#8212; Commitments and Contingencies</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix leases office and lab space in Zurich Switzerland, which requires lease payments of approximately $<ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" unitRef="usd" id="ixv-31438">74,000</ix:nonFraction> for the&#160;years ended December&#160;31, 2024 and 2025, and which is insignificant to the Company&#8217;s consolidated financial statements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company entered into a short<span class="nobreak">-term</span> lease in Palm Beach, Florida with an unrelated party, with a commencement date of May&#160;1, 2022, for approximately $<ix:nonFraction contextRef="c323" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeasePayments" scale="0" unitRef="usd" id="ixv-31439">14,000</ix:nonFraction> per month. The lease, which was personally guaranteed by the Company&#8217;s former CEO, ended on April&#160;30, 2023. During the&#160;years ended December&#160;31, 2023 and 2022, the Company incurred rent expense on this lease of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd" id="ixv-31440">51,000</ix:nonFraction> and $129,000, respectively, and variable lease expense of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="0" unitRef="usd" id="ixv-31441">4,000</ix:nonFraction> and $<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="0" unitRef="usd" id="ixv-31442">12,000</ix:nonFraction>, respectively.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Litigation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. As of December&#160;31, 2023, the Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims.</p></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-48</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;10 &#8212; Commitments and Contingencies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;15, 2022, the Company received a demand letter (the &#8220;Demand Letter&#8221;) from Boustead. The Demand Letter alleged that the Company breached the Underwriting Agreement entered into between Boustead and the Company, dated February&#160;17, 2022, in connection with the Company&#8217;s initial public offering. The Demand Letter alleged that, by engaging Wainwright as placement agent in the April Private Placement, the Company breached Boustead&#8217;s right of first refusal (&#8220;ROFR&#8221;) to act as placement agent granted to Boustead under the Underwriting Agreement and, as a result of selling securities in the April Private Placement, breached the Company&#8217;s obligation under the Underwriting Agreement not to offer, sell, issue, agree or contract to sell or issue or grant or modify the terms of any option for the sale of, any securities prior to February&#160;17, 2023 (the &#8220;Standstill&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On October&#160;9, 2022, the Company and Boustead entered into a Settlement Agreement and Release (the &#8220;Settlement Agreement&#8221;), pursuant to which Boustead agreed to waive the ROFR and the Standstill, and to release the Company from certain claims with respect to the April Private Placement, the August Private Placement, and all future private, public equity or debt offerings of the Company. As consideration for such waiver and termination of the Underwriting Agreement, the Company paid Boustead a cash fee of $<ix:nonFraction contextRef="c324" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FeeIncome" scale="0" unitRef="usd" id="ixv-31443">1,000,000</ix:nonFraction>, $<ix:nonFraction contextRef="c325" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="0" unitRef="usd" id="ixv-31444">50,000</ix:nonFraction> in legal expenses, and released Boustead from all claims, subject to certain exceptions. In addition, the Company issued to Boustead <ix:nonFraction contextRef="c326" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-31445">93,466</ix:nonFraction><span class="nobreak"> </span>shares of restricted common stock in exchange for the cancellation of <ix:nonFraction contextRef="c327" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-31446">111,111</ix:nonFraction>&#160;warrants issued to Boustead in connection with the IPO (see Note&#160;9). Concurrent with the execution of the Settlement Agreement, the Company and Boustead Capital Markets, LLP (&#8220;Boustead Capital&#8221;) entered into a three<span class="nobreak">-month</span> Advisory Agreement (the &#8220;Advisory Agreement&#8221;) for which consideration equal to <ix:nonFraction contextRef="c327" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-31447">200,000</ix:nonFraction><span class="nobreak"> </span>shares of restricted common stock, with no vesting provisions, was issued to Boustead Capital upon execution of the Advisory Agreement. The incremental fair value of the Warrant Exchange and the fair value of the restricted common stock issued in connection with these agreements totaled approximately $<ix:nonFraction contextRef="c325" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" unitRef="usd" id="ixv-31448">264,000</ix:nonFraction>. See Note&#160;9.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company determined that all consideration due by the Company under the Settlement Agreement and the Advisory Agreement relates to the settlement of a liability that was incurred in 2022 and accordingly, recorded a related expense of approximately $<ix:nonFraction contextRef="c9" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherSellingGeneralAndAdministrativeExpense" scale="6" unitRef="usd" id="ixv-31449">1.3</ix:nonFraction>&#160;million for the year ended December&#160;31, 2022, which is included in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Registration Rights Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the April&#160;2022 Private Placement (see Note&#160;9), the Company entered into a Registration Rights Agreement with the purchasers, dated as of April&#160;13, 2022 (the &#8220;April Registration Rights Agreement&#8221;). The April Registration Rights Agreement provides that the Company shall file a registration statement covering the resale of all of the registrable securities (as defined in the April Registration Rights Agreement) with the SEC.&#160;The registration statement on Form&#160;S<span class="nobreak">-1</span> required under the April Registration Rights Agreement was filed with the SEC on May&#160;3, 2022 and became effective on May&#160;20, 2022. A post<span class="nobreak">-effective</span> amendment to the Form&#160;S<span class="nobreak">-1</span> on Form&#160;S<span class="nobreak">-3</span> relating to such registration statement was filed with the SEC on April&#160;28, 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the August&#160;2022 Private Placement (see Note&#160;9), the Company entered into a Registration Rights Agreement with the purchasers, dated as of August&#160;9, 2022 (the &#8220;August Registration Rights Agreement&#8221;). The August Registration Rights Agreement provides that the Company shall file a registration statement covering the resale of all of the registrable securities (as defined in the August Registration Rights Agreement) with the SEC.&#160;The registration statement on Form&#160;S<span class="nobreak">-1</span> required under the August Registration Rights Agreement was filed with the SEC on August&#160;29, 2022 and became effective on September&#160;19, 2022. A post<span class="nobreak">-effective</span> amendment to the Form&#160;S<span class="nobreak">-1</span> on Form&#160;S<span class="nobreak">-3</span> relating to such registration statement was filed with the SEC on April&#160;28, 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Upon the occurrence of any Event (as defined in the April Registration Rights Agreement and the August Registration Rights Agreement), which, among others, prohibits the purchasers from reselling the securities for more than ten consecutive calendar&#160;days or more than an aggregate of fifteen calendar&#160;days during any 12<span class="nobreak">-month</span> period, and should the registration statement cease to remain continuously effective, the Company would be obligated to pay to each purchaser, on each monthly anniversary of each such Event, an amount in cash, as partial liquidated damages and not as a penalty, equal to the product of <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="onco:PercentageOfSubscription" scale="-2" unitRef="pure" id="ixv-31450">2.0</ix:nonFraction>% multiplied by the aggregate subscription amount paid by such purchaser </p></ix:continuation>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-49</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;10 &#8212; Commitments and Contingencies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">in the Private Placement. As of December&#160;31, 2023, the Company determined that the likelihood of the Company incurring liquidated damages pursuant to the April Registration Rights Agreement and the August Registration Rights Agreement is remote, and as such, no accrual of these payments is required as of December&#160;31, 2023.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Milestone and Royalty Obligations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company has entered into various license agreements with third parties that obligate the Company to pay certain development, regulatory, and commercial milestones, as well as royalties based on product sales (see Note&#160;6). As of December&#160;31, 2023, the Company terminated all license agreements, except for the CHMC Agreement, which could require the Company to pay CHMC milestone payments of up to an aggregate of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="onco:AggregatePayments" scale="0" unitRef="usd" id="ixv-31451">59.75</ix:nonFraction>&#160;million. As of December&#160;31, 2023, the Company evaluated the likelihood of the Company achieving the specified milestones and generating product sales, and determined the likelihood is not yet probable and as such, no accrual of these payments is required as of December&#160;31, 2023.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Underwriter Termination Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;7, 2022, the Company and its former underwriter, Maxim Group (&#8220;Maxim&#8221;), entered into a termination agreement, whereby the parties agreed to terminate their engagement of Maxim as the Company&#8217;s lead managing underwriter and book runner in connection with the Company&#8217;s IPO.&#160;Per the terms of the termination agreement, the Company agreed to pay Maxim a termination fee of $<ix:nonFraction contextRef="c328" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" scale="0" unitRef="usd" id="ixv-31452">300,000</ix:nonFraction>, due upon the close of the Company&#8217;s IPO.&#160;The termination fee was recorded as selling, general and administrative expense, and paid, during the year ended December&#160;31, 2022.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Indemnification</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not been required to defend any action related to its indemnification obligations. However, during the third quarter of 2023, the Company received a claim from its former CEO and a former accounting employee requesting advancement of certain expenses. The Company recorded approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="0" unitRef="usd" id="ixv-31453">209,000</ix:nonFraction> in related expenses during the year ended December&#160;31, 2023, of which approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DividendsPaidinkind" scale="0" unitRef="usd" id="ixv-31454">159,000</ix:nonFraction> was paid through reduction of the outstanding related party receivable due from the former CEO (see Note&#160;11). As of December&#160;31, 2023, the Company recorded a related accrual of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="0" unitRef="usd" id="ixv-31455">50,000</ix:nonFraction>, which is included in accrued expenses in the accompanying consolidated balance sheets, and which was paid subsequent to year end. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is not estimable at this time.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-20771"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;11 &#8212; Related Party Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company originally engaged the former CEO, who was also the Board Chairman and prior to the close of the IPO, sole common stockholder of the Company, pursuant to a consulting agreement commencing October&#160;22, 2018, which called for the Company to pay for consulting services performed on a monthly basis. Upon the close of the Company&#8217;s IPO, the consulting agreement was terminated, and the former CEO&#8217;s employment agreement became effective. During the year ended December&#160;31, 2022, the Company incurred approximately $<ix:nonFraction contextRef="c329" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-31456">63,000</ix:nonFraction> in fees under the consulting agreement, which are recognized in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During 2022 the Company entered into a lease agreement that was personally guaranteed by the Company&#8217;s former CEO.&#160;The lease expired in 2023. See Note&#160;10.</p></ix:nonNumeric>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-50</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;11 &#8212; Related Party Transactions</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December&#160;31, 2022, the Company&#8217;s compensation committee approved one<span class="nobreak">-time</span> bonus awards of $<ix:nonFraction contextRef="c330" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" unitRef="usd" id="ixv-31457">140,000</ix:nonFraction> and $<ix:nonFraction contextRef="c331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" unitRef="usd" id="ixv-31458">100,000</ix:nonFraction> to the Company&#8217;s former CEO and former CBO, respectively, in recognition of their efforts in connection with the Company&#8217;s IPO.&#160;These bonuses were recognized during the year ended December&#160;31, 2022, as selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December&#160;31, 2023, the Company&#8217;s Audit Committee completed a review of the Company&#8217;s expenses due to certain irregularities identified with regards to the related party balance. Based on the results of the review, it was determined that the Company paid and recorded within selling, general and administrative expenses, personal expenditures of the Company&#8217;s former CEO and an accounting employee who was also the former CEO&#8217;s assistant, during 2022 and during the first three quarters of 2023. The Company evaluated the receivable, which aggregated to approximately $<ix:nonFraction contextRef="c332" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-31459">522,000</ix:nonFraction> as of September&#160;30, 2023, and which represented the total of the items identified as personal in nature for which the Company did not anticipate recovery from the related party. As the Company concluded that the remaining amounts are not likely to be recovered, this would not cause an adjustment to previously issued financial statements. The Company recorded a corresponding reserve for the full amount, resulting in a net related party receivable balance of <span style="-sec-ix-hidden: hidden-fact-286">$0</span> and a loss on related party receivable of approximately $<ix:nonFraction contextRef="c333" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-31460">266,000</ix:nonFraction>, which was recorded in selling, general, and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2023. During the fourth quarter of 2023, the Company recorded a recovery of approximately $<ix:nonFraction contextRef="c333" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-31461">159,000</ix:nonFraction> with respect to amounts that the former CEO agreed to repay the Company, through a reduction of amounts that were due to him from the Company under his indemnification rights pursuant to his employment agreement (see Note&#160;10).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2022, the Company had a receivable from related party of approximately $<ix:nonFraction contextRef="c329" decimals="0" format="ixt:num-dot-decimal" name="onco:MiscellaneousExpenses" scale="0" unitRef="usd" id="ixv-31462">36,000</ix:nonFraction>, consisting of miscellaneous payments made by the Company on the behalf of the Company&#8217;s CEO, and which was paid in full during the first quarter of 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;18, 2023, the Company entered into the Subscription Agreement with the PMX Investor, a <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="onco:SubscriptionAgreementPMXInvestorPercentage" scale="-2" unitRef="pure" id="ixv-31463">5</ix:nonFraction>% stockholder of the Company as of December&#160;31, 2023 (see Note&#160;8). Subsequent to December&#160;31, 2023, the Company issued a non<span class="nobreak">-convertible</span> debenture in the principal amount of $<ix:nonFraction contextRef="c334" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="6" unitRef="usd" id="ixv-31464">5.0</ix:nonFraction>&#160;million to the PMX Investor, in connection with the Subscription Agreement (see Note&#160;14).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A former director of the Company, who served on the Company&#8217;s Scientific Advisory Board until August&#160;2023, serves on the Advisory Board for the Cincinnati Children&#8217;s Hospital Medical Center Innovation Fund, which is affiliated with CHMC.&#160;The Company has an exclusive license agreement with CHMC as disclosed in Note&#160;5. This director resigned from the Company&#8217;s board upon the close of its IPO.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-20797"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;12 &#8212; Income Taxes</span></p>
		<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="ixv-20800"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The components of loss before income taxes are as follows:</p></ix:nonNumeric>
		<ix:continuation id="_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock-c0_cont_1"><table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">For the&#160;Years Ended</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">U.S.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="0" sign="-" unitRef="usd" id="ixv-31465">37,106,599</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="0" sign="-" unitRef="usd" id="ixv-31466">13,419,830</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Foreign</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="0" sign="-" unitRef="usd" id="ixv-31467">315,688</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-287">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total loss before income taxes</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-31468">37,422,287</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-31469">13,419,830</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s major tax jurisdictions are the United&#160;States, Switzerland, and various state jurisdictions, and the Company does not have any pending tax audits. The income tax benefit recorded for the year ended December&#160;31, 2023 related to the Company&#8217;s deferred foreign taxes. There was no income tax provision or benefit recorded for the year ended December&#160;31, 2022. Generally, the Company&#8217;s federal returns from 2019 on and state returns from </p></ix:nonNumeric>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-51</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;12 &#8212; Income Taxes</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">2018 on, and foreign returns from 2018 on, are subject to examination by the United&#160;States, state, and foreign tax authorities; however, to the extent allowed by law, tax authorities have the ability to adjust the Company&#8217;s carryforwards of unutilized net operating losses and research and development credits for all&#160;years.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">At December&#160;31, 2023, the Company had a net operating loss (&#8220;NOL&#8221;) carryforward for federal, foreign, and state income tax purposes totaling approximately $<ix:nonFraction contextRef="c335" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" unitRef="usd" id="ixv-31470">27.9</ix:nonFraction>&#160;million, $<ix:nonFraction contextRef="c335" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" unitRef="usd" id="ixv-31471">18.0</ix:nonFraction>&#160;million, and $<ix:nonFraction contextRef="c335" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" unitRef="usd" id="ixv-31472">23.8</ix:nonFraction>&#160;million, respectively, available to reduce future taxable income. The federal NOL and certain state NOLs of $<ix:nonFraction contextRef="c335" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="6" unitRef="usd" id="ixv-31473">16.8</ix:nonFraction>&#160;million are carried forward indefinitely subject to a limitation of <ix:nonFraction contextRef="c335" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" scale="-2" unitRef="pure" id="ixv-31474">80</ix:nonFraction>% of taxable income. State NOLs of approximately $<ix:nonFraction contextRef="c335" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" unitRef="usd" id="ixv-31475">6.8</ix:nonFraction>&#160;million will begin to expire in 2024 if not utilized, and foreign NOLs of approximately $<ix:nonFraction contextRef="c335" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" unitRef="usd" id="ixv-31476">15.1</ix:nonFraction>&#160;million will begin to expire in 2024 if not utilized.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The NOL carry forward is subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Under the Internal Revenue Code (&#8220;IRC&#8221;) Sections 382 and 383, annual use of the Company&#8217;s net operating loss carryforwards and research credit carryforwards to offset taxable income and tax, respectively, may be limited based on cumulative changes in ownership. The Company has not completed an analysis to determine whether any such limitations have been triggered as of December&#160;31, 2023. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years.</p>
		<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-20899"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The tax effects of the temporary differences and carryforwards that give rise to deferred tax assets and liabilities consist of the following:</p></ix:nonNumeric>
		<ix:continuation id="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">As of December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Deferred tax assets:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net-operating loss carryforward</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-31477">10,214,760</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-31478">2,986,738</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Intangibles</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="0" unitRef="usd" id="ixv-31479">3,349,919</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="0" unitRef="usd" id="ixv-31480">885,176</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" unitRef="usd" id="ixv-31481">1,171,320</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-288">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="0" unitRef="usd" id="ixv-31482">690,760</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="0" unitRef="usd" id="ixv-31483">308,552</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deposit on WraSer APA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" unitRef="usd" id="ixv-31484">854,896</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-289">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="0" unitRef="usd" id="ixv-31485">150,099</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="0" unitRef="usd" id="ixv-31486">186,573</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">License agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="onco:LicenseAgreement" scale="0" unitRef="usd" id="ixv-31487">49,157</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="onco:LicenseAgreement" scale="0" unitRef="usd" id="ixv-31488">82,626</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="0" unitRef="usd" id="ixv-31489">520,207</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="0" unitRef="usd" id="ixv-31490">65,886</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Gross deferred tax assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd" id="ixv-31491">17,001,118</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd" id="ixv-31492">4,515,551</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-31493">15,697,701</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-31494">4,512,546</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Deferred tax assets, net of allowance</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" unitRef="usd" id="ixv-31495">1,303,417</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" unitRef="usd" id="ixv-31496">3,005</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Deferred tax liabilities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Intangible assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="0" unitRef="usd" id="ixv-31497">4,345,449</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-290">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fixed assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-31498">2,560</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-31499">3,005</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesOther" scale="0" unitRef="usd" id="ixv-31500">29,189</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-291">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total deferred tax liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" unitRef="usd" id="ixv-31501">4,377,198</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" unitRef="usd" id="ixv-31502">3,005</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net deferred tax liability</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilities" scale="0" unitRef="usd" id="ixv-31503">3,073,781</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-292">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. The Company has recorded a valuation allowance against its United&#160;States and foreign deferred tax assets in each of the&#160;years ended December&#160;31, 2023 and 2022, because the Company&#8217;s management believes that it is more likely than not that these assets will not be realized. During the&#160;years ended December&#160;31, 2023 and 2022, the valuation allowance increased by approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" unitRef="usd" id="ixv-31504">11.2</ix:nonFraction>&#160;million and $<ix:nonFraction contextRef="c9" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" unitRef="usd" id="ixv-31505">3.2</ix:nonFraction>&#160;million, respectively.</p></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-52</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;12 &#8212; Income Taxes</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-21251"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The provision for income taxes on earnings subject to income taxes differs from the statutory Federal rate at December&#160;31, 2023 and 2022, due to the following:</p></ix:nonNumeric>
		<ix:continuation id="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">For the&#160;Years Ended</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected income tax benefit at Federal statutory tax rate</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" sign="-" unitRef="usd" id="ixv-31506">7,858,680</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" sign="-" unitRef="usd" id="ixv-31507">2,818,164</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">State and local taxes, net of Federal tax benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" sign="-" unitRef="usd" id="ixv-31508">1,192,605</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" sign="-" unitRef="usd" id="ixv-31509">501,277</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-293">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="0" unitRef="usd" id="ixv-31510">16,477</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Foreign NOL expirations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" unitRef="usd" id="ixv-31511">315,927</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-294">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="0" unitRef="usd" id="ixv-31512">196,025</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-295">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subscription agreement liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability" scale="0" unitRef="usd" id="ixv-31513">181,440</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-296">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Officer&#8217;s compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" scale="0" sign="-" unitRef="usd" id="ixv-31514">126,337</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-297">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Acquisition related costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="0" unitRef="usd" id="ixv-31515">164,073</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-298">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Permanent items</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="0" unitRef="usd" id="ixv-31516">55,486</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="0" unitRef="usd" id="ixv-31517">194,705</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">State rate adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment" scale="0" sign="-" unitRef="usd" id="ixv-31518">23,135</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="onco:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment" scale="0" unitRef="usd" id="ixv-31519">19,600</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="0" unitRef="usd" id="ixv-31520">60,599</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="0" sign="-" unitRef="usd" id="ixv-31521">37,260</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-31522">8,214,614</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-31523">3,158,873</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Income tax benefit</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd" id="ixv-31524">12,593</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-299">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Under U.S.&#160;GAAP, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more<span class="nobreak">-likely-than-not</span> to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-31525">50</ix:nonFraction>% likelihood of being sustained. Additionally, U.S.&#160;GAAP provides guidance on derecognition, classification, interest and penalties, accounting for interim periods, disclosure, and transition.</p>
		<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="ixv-21512"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</p></ix:nonNumeric>
		<ix:continuation id="_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">For the&#160;Years Ended</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Beginning balance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" unitRef="usd" id="ixv-31526">17,010</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-300">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Increases related to prior year tax positions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-301">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="0" unitRef="usd" id="ixv-31527">11,517</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Increases related to current year tax positions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-302">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="0" unitRef="usd" id="ixv-31528">5,493</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ending balance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" unitRef="usd" id="ixv-31529">17,010</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" unitRef="usd" id="ixv-31530">17,010</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">At December&#160;31, 2023 and 2022, the Company&#8217;s unrecognized tax benefits were $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" scale="0" unitRef="usd" id="ixv-31531"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" scale="0" unitRef="usd" id="ixv-31532">17,010</ix:nonFraction></ix:nonFraction>. Due to the existence of the valuation allowance, future changes in the Company&#8217;s unrecognized tax benefits will not impact the effective tax rate. The Company does not expect its unrecognized tax benefits to change significantly over the next 12&#160;months.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2023 and 2022, there were no accrued interest and penalties associated with uncertain tax positions.</p></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-53</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<ix:nonNumeric contextRef="c0" continuedAt="_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="ixv-21600"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;13 &#8212; Retirement Plans</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Defined Contribution Plans</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Effective January&#160;1, 2022, the Company adopted a defined contribution savings plan pursuant to Section&#160;401(k)&#160;of the Internal Revenue Code (&#8220;the 2022 401(k)&#160;Plan&#8221;). The 2022 401(k)&#160;Plan was for the benefit of all qualifying employees and permits voluntary contributions by employees of up to <ix:nonFraction contextRef="c336" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" scale="-2" unitRef="pure" id="ixv-31533">100</ix:nonFraction>% of eligible compensation, subject to the maximum limits imposed by the Internal Revenue Service. The terms of the 2022 401(k)&#160;Plan allowed for discretionary employer contributions. No expenses were incurred related to the 2022 401(k)&#160;Plan during the year ended December&#160;31, 2022 and the 2022 401(k)&#160;Plan lapsed during 2022 due to inactivity.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On May&#160;31, 2023, the Board voted to adopt a 401(k)&#160;Safe Harbor Non<span class="nobreak">-Elective</span> Plan (the &#8220;2023 401(k)&#160;Plan&#8221;). The 2023 401(k)&#160;Plan was an employee savings and retirement plan to which substantially all employees could have contributed, including the Company&#8217;s named executive officers, effective July&#160;1, 2023. Pursuant to the 2023 401(k)&#160;Plan, employee and Company contributions would vest immediately, subject to a three<span class="nobreak">-month</span> waiting period for new hires. The Company was required to contribute <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="onco:GrossPayPercentage" scale="-2" unitRef="pure" id="ixv-31534">3</ix:nonFraction>% of gross pay to eligible employees&#8217; 401(k)&#160;Plans. On November&#160;16, 2023, the 2023 401(k)&#160;Plan was terminated. No expenses were incurred related to the 2023 401(k)&#160;Plan during the year ended December&#160;31, 2023.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Defined Benefit Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix sponsors a defined benefit pension plan covering certain eligible employees. The Swiss Plan provides retirement benefits based on&#160;years of service and compensation levels.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The value of the pension obligation is determined using the Projected Unit Credit method. This method sees each period of service as giving rise to an additional unit of benefit entitlements/employee benefits. The value of the Company&#8217;s employee benefit obligations for active employees, or the Projected Benefit Obligation, on the reporting date is the same as the present value of the degree of entitlement existing on this date, in terms of future salary and pension increases and turnover rates. The valuation of pension obligations of pensioners is made on the basis of the present value of current pensions taking into account future increases in pensions. The service costs are calculated using the present value of the entitlements to employee benefits earned during the year for which calculations are made.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As is customary with Swiss pension plans, the assets of the Swiss Plan are invested in a collective fund with multiple employers. Neither Proteomedix nor Onconetix have investment authority over the assets of the Swiss Plan that are held and invested by a Swiss insurance company. Investment holdings are made with respect to Swiss laws and target allocations for plan assets, and are <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="onco:DebtSecuritiesAndCash" scale="-2" unitRef="pure" id="ixv-31535">38</ix:nonFraction>% debt securities and cash, <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="onco:EquitySecuritiesRate" scale="-2" unitRef="pure" id="ixv-31536">26</ix:nonFraction>% equity securities, <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="onco:AlternativeInvestmentsRate" scale="-2" unitRef="pure" id="ixv-31537">12</ix:nonFraction>% alternative investments and <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="onco:RealEstateInvestmentsRate" scale="-2" unitRef="pure" id="ixv-31538">24</ix:nonFraction>% real estate investments. The valuation of the collective fund assets as a whole is a Level 3 measurement; however, the individual investments of the fund are generally Level 1 (equity securities), Level 2 (fixed income) and Level 3 (real estate, infrastructure and alternative) investments. We determine the fair value of the plan assets based on information provided by the collective fund. See Note&#160;3, &#8220;Summary of Significant Accounting Policies&#8221; for additional information on the three<span class="nobreak">-tier</span> fair value hierarchy.</p>
		<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" id="ixv-21615"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following significant actuarial assumptions were used in calculating the benefit obligation and the net periodic <span style="-sec-ix-hidden: hidden-fact-304">benefit cost</span> as of December&#160;31, 2023:</p></ix:nonNumeric>
		<ix:continuation id="_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Discount rate</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" unitRef="pure" id="ixv-31539">1.45</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected long-term rate of return on plan assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" unitRef="pure" id="ixv-31540">1.45</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Rate of compensation increase</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" unitRef="pure" id="ixv-31541">3.00</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Changes in these assumptions may have a material impact on the plan&#8217;s obligations and costs.</p></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-54</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;13 &#8212; Retirement Plans</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-c0_cont_2" id="_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" id="ixv-21656"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The components of net periodic benefit cost for the period from December&#160;15, 2023 to December&#160;31, 2023 are as follows:</p></ix:nonNumeric>
		<ix:continuation id="_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Service cost</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c337" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanServiceCost" scale="0" unitRef="usd" id="ixv-31542">4,278</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest cost</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c337" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanInterestCost" scale="0" unitRef="usd" id="ixv-31543">1,943</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected return on plan assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c337" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="0" unitRef="usd" id="ixv-31544">1,581</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amortization of net (gain)/loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c337" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="0" unitRef="usd" id="ixv-31545">1,534</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Settlements (gain)/loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c337" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="0" unitRef="usd" id="ixv-31546">1,157</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c337" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="0" unitRef="usd" id="ixv-31547">1,949</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="ixv-21720"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The components of accumulated comprehensive loss attributable to the Company&#8217;s pension plan for the period from December&#160;15, 2023 to December&#160;31, 2023 are as follows:</p></ix:nonNumeric>
		<ix:continuation id="_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss (gain)</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent" scale="0" unitRef="usd" id="ixv-31548">7,277</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amortization of net gain</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:AmortizationOfNetGain" scale="0" unitRef="usd" id="ixv-31549">1,534</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effect of settlement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="onco:EffectOfSettlement" scale="0" unitRef="usd" id="ixv-31550">1,157</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other adjustments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-31551">4,005</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total recorded during the period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RegulatedAndUnregulatedOperatingRevenue" scale="0" unitRef="usd" id="ixv-31552">5,963</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="onco_ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock-c0_cont_1" escape="true" name="onco:ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock" id="ixv-21774"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, the funded status of the plan and the amounts recognized in the accompanying consolidated balance sheet are as follows:</p></ix:nonNumeric>
		<ix:continuation id="onco_ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Projected benefit obligation</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" scale="0" unitRef="usd" id="ixv-31553">2,299,970</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fair value of plan assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="0" unitRef="usd" id="ixv-31554">1,743,674</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Overfunded (underfunded) status</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-31555">556,296</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">There were no Company contributions made to the plan during the period from December&#160;15, 2023 to December&#160;31, 2023.</p>
		<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfCondensedFinancialStatementsTableTextBlock-c0_cont_1" escape="true" name="srt:ScheduleOfCondensedFinancialStatementsTableTextBlock" id="ixv-21809"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A reconciliation of the beginning and ending balances of the accumulated benefit obligation is provided in the table below:</p></ix:nonNumeric>
		<ix:continuation continuedAt="_ScheduleOfCondensedFinancialStatementsTableTextBlock-c0_cont_2" id="_ScheduleOfCondensedFinancialStatementsTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">As of December&#160;15, 2023</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c338" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="0" unitRef="usd" id="ixv-31556">2,288,273</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Service cost</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c339" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanServiceCost" scale="0" unitRef="usd" id="ixv-31557">4,278</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest cost</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c339" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanInterestCost" scale="0" unitRef="usd" id="ixv-31558">1,943</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Actuarial (gain) loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c339" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="0" unitRef="usd" id="ixv-31559">7,979</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Benefits paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c339" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="0" unitRef="usd" id="ixv-31560">905</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ordinary contributions paid by employees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c339" decimals="0" format="ixt:num-dot-decimal" name="onco:DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees" scale="0" unitRef="usd" id="ixv-31561">4,005</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contributions paid by plan participants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c339" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="0" unitRef="usd" id="ixv-31562">769</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Settlements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c339" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement" scale="0" sign="-" unitRef="usd" id="ixv-31563">6,372</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Projected benefit obligation as of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c340" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" scale="0" unitRef="usd" id="ixv-31564">2,299,970</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Actuarial (gain)/loss due to assumption changes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c339" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanOtherChanges" scale="0" unitRef="usd" id="ixv-31565">8,834</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Actuarial (gain)/loss due to plan experience</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c339" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" scale="0" sign="-" unitRef="usd" id="ixv-31566">855</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated benefit obligation as of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c340" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="0" unitRef="usd" id="ixv-31567">2,307,949</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-55</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.<br/>Notes to Consolidated Financial Statements</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;13 &#8212; Retirement Plans</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-c0_cont_2"><ix:continuation continuedAt="_ScheduleOfCondensedFinancialStatementsTableTextBlock-c0_cont_3" id="_ScheduleOfCondensedFinancialStatementsTableTextBlock-c0_cont_2"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A reconciliation of the beginning and ending balances of the plan assets is provided in the table below:</p></ix:continuation>
		<ix:continuation id="_ScheduleOfCondensedFinancialStatementsTableTextBlock-c0_cont_3"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">As of December&#160;15, 2023</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c341" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="0" unitRef="usd" id="ixv-31568">1,739,889</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Actual return on plan assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c342" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="0" unitRef="usd" id="ixv-31569">2,283</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contributions paid by employer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c342" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="0" unitRef="usd" id="ixv-31570">4,005</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ordinary contributions paid by employees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c342" decimals="0" format="ixt:num-dot-decimal" name="onco:DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees" scale="0" unitRef="usd" id="ixv-31571">4,005</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contributions paid by plan participants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c342" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="0" unitRef="usd" id="ixv-31572">769</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Benefits paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c342" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="0" unitRef="usd" id="ixv-31573">905</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Settlements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c342" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="0" unitRef="usd" id="ixv-31574">6,372</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">As of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c343" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="0" unitRef="usd" id="ixv-31575">1,743,674</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="ixv-22028"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Projected benefit payments for the next five&#160;years as of December&#160;31, 2023 are as follows:</p></ix:nonNumeric>
		<ix:continuation id="_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Years ending December&#160;31,</span></p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-303">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="0" unitRef="usd" id="ixv-31576">95,100</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2026</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="0" unitRef="usd" id="ixv-31577">95,100</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2027</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="0" unitRef="usd" id="ixv-31578">95,100</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2028</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="0" unitRef="usd" id="ixv-31579">95,100</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thereafter</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="0" unitRef="usd" id="ixv-31580">553,900</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-31581">934,300</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation></ix:continuation>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-22097"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;14 &#8212; Subsequent Events</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On January&#160;23, 2024, the Company issued a non<span class="nobreak">-convertible</span> debenture (the &#8220;Debenture&#8221;) to the PMX Investor, a related party, in the principal sum of $<ix:nonFraction contextRef="c344" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="6" unitRef="usd" id="ixv-31582">5.0</ix:nonFraction>&#160;million, in connection with the Subscription Agreement discussed in Note&#160;8. The Debenture has an interest rate of <ix:nonFraction contextRef="c345" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-31583">4.0</ix:nonFraction>% per annum, and the principal and accrued interest are payable in full upon the earlier of (i)&#160;the closing under the Subscription Agreement and (ii)&#160;June&#160;30, 2024. Additionally, the $<ix:nonFraction contextRef="c346" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="6" unitRef="usd" id="ixv-31584">5.0</ix:nonFraction>&#160;million subscription amount under the Subscription Agreement shall be increased by the amount of interest payable under the Debenture.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Effective as of January&#160;10, 2024, Dr.&#160;Neil Campbell resigned as President and Chief Executive Officer and a member of the Board of Directors of the Company. The Company and Dr.&#160;Campbell entered into a Release of Claims agreement, pursuant to which Dr.&#160;Campbell will receive a severance payment of $<ix:nonFraction contextRef="c347" decimals="0" format="ixt:num-dot-decimal" name="onco:SeverancePayment" scale="0" unitRef="usd" id="ixv-31585">158,333</ix:nonFraction> in two equal payments.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;6, 2024, the Company appointed Thomas Meier, PhD, as a member of the Company&#8217;s board of directors. Dr.&#160;Meier provides consulting services to Proteomedix, through a consulting agreement that was executed on January&#160;4, 2024.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During March&#160;2024, Zydus Life Sciences received FDA approval for a combined finasteride<span class="nobreak">-tadalafil</span> capsule, which is a direct competitor product to ENTADFI.&#160;The Company determined that this is a triggering event during the first quarter of 2024 for its ENTADFI asset group, which includes long<span class="nobreak">-lived</span> assets with a remaining carrying amount of approximately $<ix:nonFraction contextRef="c101" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetImpairmentCharges" scale="6" unitRef="usd" id="ixv-31586">3.3</ix:nonFraction>&#160;million as of December&#160;31, 2023. As such, it is reasonably possible that the resulting impairment test will result in additional impairment losses in the near term.</p></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-56</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">Proteomedix AG<br/>Financial Statements<br/>and<br/>Independent Auditors&#8217; Report<br/>For the&#160;Years Ended December&#160;31, 2022 and 2021</p>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T607"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Report of Independent Registered Public Accounting Firm</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;text-align:left;margin-top:8pt;">Shareholders and Board of Directors<br/>Proteomedix AG<br/>Schlieren, Zurich<br/>Switzerland</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Opinion on the Financial Statements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We have audited the accompanying balance sheets of Proteomedix AG (the &#8220;Company&#8221;) as of December&#160;31, 2022 and 2021, the related statements of loss and comprehensive loss, stockholders&#8217; deficit, and cash flows for each of the two&#160;years in the period ended December&#160;31, 2022, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for each of the two&#160;years in the period ended December&#160;31, 2022<span class="Bold" style="font-style:normal;font-weight:bold;">,</span>&#160;in conformity with accounting principles generally accepted in the United&#160;States of America.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Going Concern Uncertainty</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note&#160;2 to the financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note&#160;2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Basis for Opinion</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United&#160;States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S.&#160;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United&#160;States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 41.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Zurich, Switzerland, February&#160;14, 2024</p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 41.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">BDO AG</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 41.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">/s/ Christoph Tschumi</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">/s/ Marc Furlato</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:12pt;margin-top:12pt;">We have served as the Company&#8217;s auditor since 2023.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:12pt;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-58</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T608"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Proteomedix AG<br/>Balance Sheets<br/>As of December&#160;31, 2022 and 2021</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.16%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2021</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;text-decoration:underline;">ASSETS</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Current assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">470,156</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,546,801</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">236,683</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">96,211</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Inventory</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">95,810</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">110,584</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid expenses and other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">26,280</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">85,632</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total current assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">828,929</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,839,228</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40,130</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">54,003</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right of use asset</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">202,739</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,071,798</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,893,231</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;">LIABILITIES AND STOCHOLDERS&#8217; DEFICIT</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current Liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Convertible notes payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,241,942</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">510,578</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">504,766</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, current</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">67,546</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,820,066</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">504,766</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Convertible notes payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,406,289</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,726,368</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Note payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">108,176</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">164,509</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pension benefit obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">393,640</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">798,476</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">135,193</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,863,364</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,194,119</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Commitments and contingencies (Note&#160;5)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stockholders&#8217; deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock par value 1 CHF, authorized 590,951 shares, outstanding 412,572 and 412,572 as of December&#160;31, 2022 and 2021, respectively</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">466,555</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">466,555</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in-capital</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,377,905</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,916</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated comprehensive (loss) income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">606,583</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">431,677</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(27,242,609</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(25,200,036</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total stockholders&#8217; deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,791,566</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,300,888</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 68.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total liabilities and stockholders&#8217; deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,071,798</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,893,231</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">The accompanying notes are an integral part of these financial statements.</p>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-59</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T609"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span style="-keep: true">Proteomedix AG<br/>Statements of Comprehensive Loss<br/>For the&#160;years ended December&#160;31, 2022 and 2021</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2021</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Revenue</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">392,460</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">140,600</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cost of goods sold</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">48,429</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">31,977</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Gross profit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">344,031</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">108,623</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Marketing and business development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">240,298</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">200,096</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">393,274</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">312,586</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,671,960</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,766,843</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17,492</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">36,866</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,323,024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,316,391</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,978,993</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,207,768</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other income (expense)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(63,580</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(41,536</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other income (expenses)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(63,580</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(41,536</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss before provision for income taxes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,042,573</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,249,304</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Provision for income taxes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,042,573</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,249,304</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other comprehensive (loss) income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Benefit pension obligation changes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">179,892</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">397,709</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Foreign currency translation adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(4,986</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">32,837</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other comprehensive (loss) income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">174,906</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">430,546</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Comprehensive loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,867,667</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,818,758</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">The accompanying notes are an integral part of these financial statements.</p>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-60</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T610"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span style="-keep: true">Proteomedix AG<br/>Statement of Stockholders&#8217; Deficit<br/>For the&#160;years ended December&#160;31, 2022 and 2021</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-25" style="height:12pt;">
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-top:1pt;width: 25.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="4" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 20.86%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;"><br/><br/>Common Stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 11.09%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Additional<br/>Paid&#160;In<br/>Capital</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 12.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Accumulated<br/>Comprehensive<br/>(Loss) Income</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 11.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Accumulated<br/>Deficit</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 12.59%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Total <br/>Stockholders&#8217;<br/>Deficit</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 9.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Par Value</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:1pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 25.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Balance at December&#160;31, 2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">412,572</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">466,555</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">19,928,271</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,131</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(22,950,732</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,554,775</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 25.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Change in pension benefit obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">397,709</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">397,709</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 25.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Stock based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">72,645</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">72,645</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 25.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">FX translation adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">32,837</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">32,837</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 25.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.59%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(2,249,304</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.59%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(2,249,304</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 25.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Balance at December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">412,572</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">466,555</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,916</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">431,677</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(25,200,036</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,300,888</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 25.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Change in pension benefit obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">179,892</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">179,892</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 25.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Stock based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">376,989</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">376,989</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 25.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">FX translation adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,986</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,986</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 25.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.59%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(2,042,573</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.59%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(2,042,573</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 25.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Balance at December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">412,572</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">466,555</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.59%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,377,905</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">606,583</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(27,242,609</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.59%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,791,566</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">The accompanying notes are an integral part of these financial statements.</p>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-61</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T611"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span style="-keep: true">Proteomedix AG<br/>Statements of Cash Flows<br/>For the&#160;years ended December&#160;31, 2022 and 2021</span></p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2021</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net Loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,042,573</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,249,304</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation and Amortization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17,492</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">36,866</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">376,989</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">72,645</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net periodic benefit cost</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(224,944</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(40,881</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Changes in operating assets and liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(140,472</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(32,009</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Inventory</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,774</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">19,522</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid expenses and other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">59,352</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(16,734</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,812</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(29,661</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash used in operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,933,570</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,239,556</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Investing activities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash used in investing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Financing activities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Issuance (repayment) of notes payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(50,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Issuance of convertible notes payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,277,170</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash (used in) provided by financing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(50,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,277,170</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">FX effect on cash</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(93,075</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(26,488</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net change in cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,076,645</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,011,126</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents-Beginning of the year</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,546,801</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,535,675</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents-End of year</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">470,156</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,546,801</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="CharOverride-3" style="text-decoration:underline;">Supplemental cash flow disclosures</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,621</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,735</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income taxes paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">The accompanying notes are an integral part of these financial statements.</p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-62</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T612"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proteomedix AG<br/>Notes to Financial Statements</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;1&#160;&#8212;&#160;Organization and Nature of Business</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix AG (the &#8220;Company&#8221;) is a healthcare company whose mission is to transform prostate cancer diagnosis. Proteomedix has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product Proclarix<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span>&#160;is a blood<span class="nobreak">-based</span> prostate cancer test panel and risk score currently available in Europe and expected to be available in the U.S.&#160;in the near future. Proteomedix is located in the Bio<span class="nobreak">-Technopark</span> of Zurich<span class="nobreak">-Schlieren</span>, Switzerland.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2023, the Company was acquired by Onconetix, Inc. (formerly Blue Water Biotech, Inc) (the &#8220;Parent&#8221;). The Parent issued stock of its common stock in exchange for 100% of the outstanding voting equity of the Company. See Note&#160;10.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;2&#160;&#8212;&#160;Going Concern</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. For the year ended December&#160;31, 2022, the Company had an accumulated deficit of approximately $27,200,000, a net loss of approximately $2,042,000, and net cash used in operating activities of approximately $1,934,000, with approximately $392,000 in revenue recognized, and a lack of profitable operational history. These matters, among others, raise substantial doubt about the Company&#8217;s ability to continue as a going concern for the 12&#160;months following the issuance of these financial statements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">While the Company is attempting to generate greater revenues, the Company&#8217;s cash position may not be significant enough to support the Company&#8217;s daily operations. Management intends to raise additional funds from its Parent to sustain operations until such time as revenues are sufficient to support the Company&#8217;s operations. Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate revenues and the ability of its Parent to provide additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company&#8217;s ability to further implement its business plan and obtaining additional funding from its Parent as needed.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3&#160;&#8212;&#160;Summary of Significant Accounting Policies</span></p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Basis of Presentation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s financial statements are prepared in accordance with U.S.&#160;Generally Accepted Accounting Principles (&#8220;U.S GAAP&#8221;), which require the recognition and disclosure of foreign currency translation adjustments resulting from the translation of financial statements denominated in currencies other than the U.S.&#160;Dollar.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The functional currency of the Company is the Swiss Franc. Transactions denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the date of the transaction. The resulting translation adjustments are recorded as a separate component of accumulated other comprehensive income (loss).</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Use of Estimates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company&#8217;s financial statements relate to valuation of inventory, stock<span class="nobreak">-based</span> compensation, pension benefit obligations, and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-63</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3&#160;&#8212;&#160;Summary of Significant Accounting Policies</span><span class="CharOverride-4" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Segment Information</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;), or decision<span class="nobreak">-making</span> group, in deciding how to allocate resources and in assessing performance. The Company operates in one segment which is consistent with the financial information regularly reviewed by the CODM for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Cash and Cash Equivalents</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">For purposes of reporting cash flows, the Company has defined cash and cash equivalents as all cash in banks and highly liquid investments available for current use with an initial maturity of three&#160;months or less to be cash equivalents. The Company had no cash equivalents as of December&#160;31, 2022 or 2021.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company maintains its cash balances at financial institutions that are insured by Swiss Financial Market Supervisory Authority (&#8220;FINMA&#8221;). The Company&#8217;s cash balances may at times exceed the insurance provided by FINMA.&#160;The Company has not experienced any losses on these accounts and management does not believe that the Company is exposed to any significant risks related to excess deposits.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Accounts Receivable</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company performs periodic credit evaluations of its customers&#8217; financial condition and extends credit to virtually all of its customers on an uncollateralized basis. Credit losses to date have been insignificant and within management&#8217;s expectations. The Company provides an allowance for doubtful accounts that is based upon a review of outstanding receivables, historical collection information, and existing economic conditions.&#160;Normal accounts receivable are due 30&#160;days after the issuance of the invoice. Receivables are considered delinquent based on management&#8217;s assessment of the individual balance. Delinquent receivables are evaluated for collectability based on individual credit evaluation and specific circumstances of the customer. As of December&#160;31, 2022 and 2021, the Company&#8217;s allowance for doubtful accounts was nil, respectively. The Company did not write off any accounts receivable against the allowance for doubtful accounts during the&#160;years ended December&#160;31, 2022 and 2021. As of December&#160;31, 2022 and 2021, substantially all of the Company&#8217;s accounts receivable are due from a single customer.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Inventories</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Inventories consist of raw materials and finished goods. Inventories are stated at the lower of cost or net realizable value, with cost determined on a first<span class="nobreak">-in</span>, first<span class="nobreak">-out</span> basis. The Company periodically reviews the composition of inventory in order to identify excess, obsolete, slow<span class="nobreak">-moving</span> or otherwise non<span class="nobreak">-saleable</span> items taking into account anticipated future sales compared with quantities on hand, and the remaining shelf life of goods on hand. If non<span class="nobreak">-saleable</span> items are observed and there are no alternate uses for the inventory, the Company records a write<span class="nobreak">-down</span> to net realizable value in the period that the decline in value is first recognized. The Company had no inventory reserves as of December&#160;31, 2022 and 2021.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s inventory consisted of the following at the respective balance sheet dates:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">2021</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Raw materials</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">48,408</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">52,942</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Finished goods</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">47,402</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">57,641</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">95,810</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">110,583</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-64</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3&#160;&#8212;&#160;Summary of Significant Accounting Policies</span><span class="CharOverride-4" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Impairment of Long-Lived Assets</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company reviews long<span class="nobreak">-lived</span> assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable (a &#8220;triggering event&#8221;). Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the long<span class="nobreak">-lived</span> asset in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long<span class="nobreak">-lived</span> asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long<span class="nobreak">-lived</span> asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. During the&#160;years ended December&#160;31, 2022 and 2021, the Company did not identify any impairments related to its long<span class="nobreak">-lived</span> assets.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Property and Equipment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment consists of computers and office furniture and fixtures, all of which are recorded at cost. Depreciation is recorded using the straight<span class="nobreak">-line</span> method over the respective useful lives of the assets ranging from two to ten&#160;years. Long<span class="nobreak">-lived</span> assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. Upon the retirement or other disposition of property and equipment, the related cost and accumulated depreciation are charged to operations. A summary of the estimated useful lives is a s follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">Description</span></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">Estimated Useful Life</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computers</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3 years</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Office furniture and fixtures</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2 to 10 years</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the Company&#8217;s property and equipment, net of accumulated depreciation, as of December&#160;31, 2022 and 2021, by significant class.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">Class</span></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">2021</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computers</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">79,199</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">75,311</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Office furniture and fixtures</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">341,318</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">346,040</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: accumulated depreciation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(380,387</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(367,348</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40,130</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">54,003</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Depreciation expense for the&#160;years ended December&#160;31, 2022 and 2021, was $17,492 and $36,866, respectively.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Lease Accounting.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company regularly evaluates whether a contract meets the definition of a lease whenever a contract grants it the right to control the use of an identified asset for a period in exchange for consideration. The Company&#8217;s lease agreement consists of office space. This lease generally contains an initial term of two&#160;years and with renewals options. If the Company&#8217;s lease agreement includes renewal option periods, the Company includes such renewal options in its calculation of the estimated lease term when it determines the options are reasonably certain to be exercised. When such renewal options are deemed to be reasonably certain, the estimated lease term determined under ASC&#160;842 will be greater than the non<span class="nobreak">-cancelable</span> term of the contractual arrangement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company classifies its lessee arrangements at inception as either operating leases or financing leases. A lease is classified as a financing lease if at least one of the following criteria is met: (1)&#160;the lease transfers ownership of the underlying asset to the lessee, (2)&#160;the lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise, (3)&#160;the lease term is for a major part of the remaining economic life of the underlying asset, (4)&#160;the present value of the sum of the lease payments equals or exceeds substantially all of the fair value of the </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-65</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3&#160;&#8212;&#160;Summary of Significant Accounting Policies</span><span class="CharOverride-4" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">underlying asset, or (5)&#160;the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. A lease is classified as an operating lease if none of the five criteria described above for financing lease classification is met. The Company has no financing leases as of December&#160;31, 2022 or 2021.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">ROU assets associated with operating leases are included in &#8220;Right of Use Asset&#8221; on the Company&#8217;s balance sheets. Current and long<span class="nobreak">-term</span> portions of lease liabilities related to operating leases are included in &#8216;operating lease liability, current&#8217; and &#8216;operating lease liability&#8217; on the Company&#8217;s balance sheets as of December&#160;31, 2022 and 2021. ROU assets represent the Company&#8217;s right to use an underlying asset for the estimated lease term and lease liabilities represent the Company&#8217;s present value of its future lease payments. In assessing its lease and determining its lease liability at lease commencement or upon modification, the Company was not able to readily determine the rate implicit for its lessee arrangements, and thus has used its incremental borrowing rate on a collateralized basis to determine the present value of the lease payments. The Company&#8217;s ROU asset is measured as the balance of the lease liability plus or minus any prepaid or accrued lease payments and any unamortized initial direct costs. Operating lease expenses are recognized on a ratable basis, regardless of whether the payment terms require the Company to make payments annually, quarterly, monthly, or for the entire term in advance. If the payment terms include fixed escalator provisions, the effect of such increases is recognized on a straight<span class="nobreak">-line</span> basis. The Company calculates the straight<span class="nobreak">-line</span> expense over the contract&#8217;s estimated lease term, including any renewal option periods that the Company deems reasonably certain to be exercised and recognizes this as lease expense within &#8216;general and administrative&#8217; in the accompanying statements of comprehensive loss. See Note&#160;5 for further information regarding the Company&#8217;s lease.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Research and Development Costs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Research and development expenses are those costs incurred in the discovery, design, and development of new products, processes, or services, as well as the enhancement of existing products. Research and development costs are expensed as incurred unless such costs have an alternative future use. These costs include, but are not limited to, salaries, wages, benefits, materials, equipment, and overhead directly attributable to the research and development activities.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Collaborative&#160;Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company periodically enters into strategic alliance agreements with counterparties to produce products and/or provide services to customers. Alliances created by such agreements are not legal entities, have no employees, no assets and have no true operations. These arrangements create contractual rights and the Company accounts for these alliances as a collaborative arrangement by reporting costs incurred and reimbursements received from transactions within research and development expense within the statements of comprehensive loss.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Commitments and Contingencies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties and other sources are recorded when management assesses that it is probable that a liability has been incurred and the amount can be reasonably estimated.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Share Based Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with Financial Accounting Standard Board (&#8220;FASB&#8221;) Account Standard Codification (&#8220;ASC&#8221;) 718, &#8220;Compensation&#160;&#8212;&#160;Stock Compensation&#8221;. Costs are measured at the estimated fair value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earliest of a performance commitment or completion of performance by the provider of goods or services as defined by FASB ASC&#160;718, &#8220;Compensation&#160;&#8212;&#160;Stock Compensation&#8221;.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-66</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3&#160;&#8212;&#160;Summary of Significant Accounting Policies</span><span class="CharOverride-4" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Income Taxes</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with ASC&#160;740, &#8220;Income Taxes,&#8221; the Company provides for the recognition of deferred tax assets if realization of such assets is more likely than not. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the Company&#8217;s management performs an evaluation of all uncertain income tax positions taken or expected to be taken in the course of preparing the Company&#8217;s income tax returns to determine whether the income tax positions meet a &#8220;more likely than not&#8221; standard of being sustained under examination by the applicable taxing authorities. This evaluation is required to be performed for all open tax&#160;years, as defined by the various statutes of limitations, for federal and state purposes. If the Company has interest or penalties associated with insufficient taxes paid, such expenses are reported in income tax expense.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Revenue Recognition</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Effective on January&#160;1, 2021, the Company adopted ASC Topic&#160;606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC&#160;606&#8221;). Pursuant to ASC&#160;606, revenues are recognized when control of services performed is transferred to customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those services. ASC&#160;606 provides for a five<span class="nobreak">-step</span> model that includes:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;">(i)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>identifying the contract with a customer,</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;">(ii)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>identifying the performance obligations in the contract,</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;">(iii)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>determining the transaction price,</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;">(iv)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>allocating the transaction price to the performance obligations, and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;">(v)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>recognizing revenue when, or as, an entity satisfies a performance obligation.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Product Sales</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company derives revenue through sales of its products directly to end users and to distributors. The Company sells its products to customers including laboratories, hospitals, medical centers, doctors and distributors. The Company considers customer purchase orders, which in some cases are governed by master sales agreements or standard terms and conditions, to be the contracts with a customer. For each contract, the Company considers the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects to be entitled. The Company fulfils its performance obligation applicable to product sales once the product is transferred to the customer.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Development Services</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company provides a range of services to life sciences customers referred to as &#8220;Development Services&#8221; including testing for biomarker discovery, assay design and development. These Development Services are performed under individual&#160;statement&#160;of work (&#8220;SOW&#8221;) arrangements with specific deliverables defined by the customer. Development Services are generally performed on a time and materials basis. During the performance and through completion of the service to the customer in accordance with the SOW, we have the right to bill the customer for the agreed upon price and we recognize the Development Services revenue over the period estimated to complete the SOW.&#160;We generally identify each SOW as a single performance obligation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-67</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3&#160;&#8212;&#160;Summary of Significant Accounting Policies</span><span class="CharOverride-4" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Completion of the service and satisfaction of the performance obligation under a SOW is typically evidenced by access to the data or test made available to the customer or any other form or applicable manner of delivery defined in the SOW.&#160;However, for certain SOWs under which work is performed pursuant to the customer&#8217;s highly customized specifications, we have the enforceable right to bill the customer for work completed, rather than upon completion of the SOW.&#160;For those SOWs, we recognize revenue over a period of time during which the work is performed based on the expended efforts (inputs). As the performance obligation under the SOW is satisfied, any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed to the customer as of the date of the financial statements are recorded as contract assets and are included in prepaids and other current assets as of the financial statement date. Amounts recorded in contract assets are reclassified to accounts receivable in our financial statements when the customer is invoiced according to the billing schedule in the contract.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In circumstances where a SOW includes variable consideration component, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on which method is expected to better predict the amount of consideration to which the Company will be entitled. The value of variable consideration is included in the transaction price if, and to the extent, it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are reassessed each reporting period, as required, and any adjustment required is recorded on a cumulative catch<span class="nobreak">-up</span> basis, which would affect revenue and net income in the period of adjustment.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table disaggregates the Company&#8217;s revenues by type for the&#160;years ended December&#160;31, 2022 and 2021.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">Recognition <br/>Method</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">2021</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Product sales</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">Point in time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">79,085</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55,311</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Development services</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">Over time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">313,375</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">85,289</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">392,460</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">140,600</p>
					</td>
				</tr>

		</table>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Fair Value Measurement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">ASC Topic&#160;820, &#8220;Fair Value Measurement&#8221;, requires that certain financial instruments be recognized at their fair values at our balance sheet dates. However, other financial instruments, such as debt obligations, are not required to be recognized at their fair values, but&#160;U.S.&#160;GAAP provides an option to elect fair value accounting for these instruments. U.S.&#160;GAAP requires the disclosure of the fair values of all financial instruments, regardless of whether they are recognized at their fair values or carrying amounts in our balance sheets. For financial instruments recognized at fair value, U.S.&#160;GAAP requires the disclosure of their fair values by type of instrument, along with other information, including changes in the fair values of certain financial instruments recognized in income or other comprehensive income. For financial instruments not recognized at fair value, the disclosure of their fair values is provided below under &#8220;Financial Instruments&#8221;.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Nonfinancial assets, such as property and equipment, and nonfinancial liabilities are recognized at their carrying amounts in the Company&#8217;s balance sheets. GAAP does not permit nonfinancial assets and liabilities to be remeasured at their fair values. However, GAAP requires the remeasurement of such assets and liabilities to their fair values upon the occurrence of certain events, such as the impairment of property, plant and equipment. In addition, if such an event occurs, GAAP requires the disclosure of the fair value of the asset or liability along with other information, including the gain or loss recognized in income in the period the remeasurement occurred.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company did not have any assets or liabilities at December&#160;31, 2022 and 2021 which required remeasurement at the respective reporting periods.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-68</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3&#160;&#8212;&#160;Summary of Significant Accounting Policies</span><span class="CharOverride-4" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Financial Instruments</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s financial instruments include cash and cash equivalents, accounts receivable and accounts payable, and are accounted for under the provisions of ASC Topic&#160;825, &#8220;Financial Instruments&#8221;. The carrying amount of these financial instruments, as reflected in the financial statements approximates fair value.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Convertible Instruments</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC&#160;815 &#8220;Derivatives and Hedging Activities&#8221;.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">U.S.&#160;GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free<span class="nobreak">-standing</span> derivative financial instruments according to certain criteria. The criteria include circumstances in which (a)&#160;the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b)&#160;the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re<span class="nobreak">-measured</span> at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c)&#160;a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for convertible instruments as follows: Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. Proceeds from these convertible notes are reported under the financing section of the statements of cash flows. During the&#160;years ended December&#160;31, 2022 and 2021, the Company did not have any conversion options which required bifurcation from the host instrument.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Defined Benefit Pension Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company sponsors a defined benefit pension plan (the &#8220;Plan&#8221;) covering eligible employees. The Plan provides retirement benefits based on employees&#8217;&#160;years of service and compensation levels. The Company recognizes an asset for such plan&#8217;s overfunded status or a liability underfunded status in its balance sheets. Additionally, the Company measures its plan&#8217;s assets and obligations that determine its funded status as of the end of the year and recognizes the changes in the funded status in the year in which the changes occur. Those changes are reported in &#8216;accumulated other comprehensive loss. The Company uses actuarial valuations to determine its pension and postretirement benefit costs and credits. The amounts calculated depend on a variety of key assumptions, including discount rates and expected return on plan assets. Current market conditions are considered in selecting these assumptions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s pension plans are generally valued using the net asset value (NAV) per share as a practical expedient for fair value provided certain criteria are met. The NAVs are determined based on the fair values of the underlying investments in the funds. In circumstances where the criteria are not met, fair is determined based on the underlying market in which the funds are traded which is generally considered to be an active market.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Recently Issued Accounting Standards</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the period ended December&#160;31, 2022, and subsequently, there were several new accounting pronouncements issued by the FASB.&#160;Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company&#8217;s financial statements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In August&#160;2020, the FASB issued ASU&#160;2020<span class="nobreak">-06</span>, &#8220;Debt&#160;&#8212;&#160;Debt with Conversion and Other Options (Subtopic 470<span class="nobreak">-20</span>) and Derivatives and Hedging&#160;&#8212;&#160;Contracts in Entity&#8217;s Own Equity (Subtopic&#160;815<span class="nobreak">-40</span>): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221; (&#8220;ASU&#160;2020<span class="nobreak">-06</span>&#8221;), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU: (1)&#160;simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC&#160;470<span class="nobreak">-20</span>, &#8220;Debt: Debt with Conversion and Other Options,&#8221; that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2)&#160;revises the scope exception </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-69</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3&#160;&#8212;&#160;Summary of Significant Accounting Policies</span><span class="CharOverride-4" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">from derivative accounting in ASC&#160;815<span class="nobreak">-40</span> for freestanding financial instruments and embedded features that are both indexed to the issuer&#8217;s own stock and classified in stockholders&#8217; equity, by removing certain criteria required for equity classification; and (3)&#160;revises the guidance in ASC&#160;260, &#8220;Earnings Per Share,&#8221; to require entities to calculate diluted EPS for convertible instruments by using the if<span class="nobreak">-converted</span> method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. For SEC filers, excluding smaller reporting companies, ASU&#160;2020<span class="nobreak">-06</span> is effective for fiscal&#160;years beginning after December&#160;15, 2021 including interim periods within those fiscal&#160;years. Early adoption is permitted, but no earlier than fiscal&#160;years beginning after December&#160;15, 2020. For all other entities, ASU&#160;2020<span class="nobreak">-06</span> is effective for fiscal&#160;years beginning after December&#160;15, 2023, including interim periods within those fiscal&#160;years. Entities should adopt the guidance as of the beginning of the fiscal year of adoption and cannot adopt the guidance in an interim reporting period. The Company adopted the ASU&#160;2020<span class="nobreak">-06</span> on January&#160;1, 2021. The adoption of this standard did not have a material impact on the Company&#8217;s financial statements.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Subsequent Events</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company has evaluated all transactions through the date the financial statements were issued for subsequent event disclosure consideration. See Note&#160;10.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;4 &#8212;&#160;Debt</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On March&#160;3, 2010, the Company received a loan from Venture Kick in the amount of 100,000 CHF.&#160;This loan bears no interest, is unsecured and may be cancelled by the Company at its discretion. This loan is subordinated to the Company&#8217;s other unsubordinated debt. The loan was to be used solely for business development and the Company may, at its sole discretion, contribute funds back to Venture Kick to enable that organization to continue its efforts. As of December&#160;31, 2022 and 2021 the balance outstanding was approximately $108,000 and $115,000, respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On June&#160;23, 2020, Company entered a convertible note payable with a financial institution and shareholder of the Company for CHF 550,000 with an interest rate of 0.50% per annum and a maturity of September&#160;30, 2024. The note provides the holder with an optional conversion feature in the event of an equity financing of the Company. The conversion price in the event of an equity financing is at a 20% discount the share price from the financing. The holder is also entitled to convert the note upon the occurrence of a sale of the Company or at maturity of the note in both cases without a discount. This note was unsubordinated until January&#160;10, 2023, at which point it was also subordinated to all other unsubordinated debts. The interest rate was changed to 2.50% as of May&#160;1, 2023. As of December&#160;31, 2022 and 2021, the outstanding balance on this note was approximately $541,000 and $548,000, respectively. The Company additionally obtained a COVID<span class="nobreak">-19</span> loan with such financial institution on April&#160;16, 2020, in the amount of CHF 50,000 with an interest rate of 0%. As of December&#160;31, 2021, the balance outstanding was approximately $50,000. Such loan was subsequently fully repaid as of April&#160;2022.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On June&#160;23, 2020, Company entered into a series of convertible notes payable with certain shareholders of the Company for CHF 800,000 with an interest rate of 0.50% per annum and a maturity of September&#160;30, 2024. The note provides the holder with an optional conversion feature in the event of an equity financing greater than CHF 1,000,000. The conversion price in the event of an equity financing is at a 20% discount the share price from the financing. The holder is also entitled to convert the note upon the occurrence of a sale of the Company or at maturity of the note in both cases without a discount. These notes payable are subordinated to the Company&#8217;s other unsubordinated debt. As of December&#160;31, 2022 and 2021, the outstanding balance on these notes was approximately $865,000 and $877,000, respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On October&#160;26, 2020, Company entered into a series of convertible notes payable with certain members of the board of directors (Note&#160;8) in the total amount of CHF 161,250 with an interest rate of 0.25% and a maturity of December&#160;31, 2023. The note provides the holder with an optional conversion feature at a discount of 20% in the event of an equity financing greater than CHF 1,000,000. The holder is also entitled to convert the note upon the occurrence of a sale of the Company or at maturity of the note in both cases without a discount. These notes payable are subordinated to the Company&#8217;s other unsubordinated debt. As of December&#160;31, 2022 and 2021, the outstanding balance on these notes was approximately $174,000 and $177,000, respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:6pt;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-70</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;4 &#8212;&#160;Debt</span><span class="CharOverride-4" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On November&#160;23, 2020, Company entered into a series of convertible notes payable with certain shareholders of the Company in the total amount of CHF 760,080 with an interest rate of 5% and a maturity of December&#160;31, 2023. The note provides the holder with an optional conversion feature at a discount of 30% in the event of an equity financing greater than CHF 1,000,000. The holder is also entitled to convert the note upon the occurrence of a sale of the Company or at maturity of the note in both cases without a discount. These notes payable are subordinated to the Company&#8217;s other unsubordinated debt. As of December&#160;31, 2022 and 2021, the outstanding balance on these notes was approximately $822,000 and $834,000, respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On July&#160;19, 2021, Company entered into a convertible note payable in the total amount of CHF 3,000,000 with an interest rate of 0.5% and a maturity of September&#160;30, 2023. The note provides the holder with a mandatory conversion requirement in the event of an equity financing greater than CHF 1,000,000. The note is also mandatorily converted in the event certain milestones are achieved related to an R&amp;D collaboration project entered separately none of which have been met as of December&#160;31, 2022. The holder is also entitled to convert the note upon the occurrence of a sale of the Company or at maturity of the note in both cases without a discount. These notes payable are subordinated to the Company&#8217;s other unsubordinated debt. As of December&#160;31, 2022 and 2021, the outstanding balance on this note was approximately $3,245,000 and $3,290,000, respectively. Subsequent to December&#160;31, 2022, the maturity date for this note was extended to September&#160;30, 2024.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">All outstanding convertible notes as of December&#160;31, 2022 were converted upon the closing of the acquisition of the Company by the Parent. See Note&#160;10.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;5 &#8212;&#160;Commitments and Contingencies</span></p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Leases</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company leases its primary office and lab space at a rate of 5,077 CHF per month. The lease began on February&#160;1, 2012 with an initial period ending on January&#160;31, 2015. This rental agreement can be terminated at the end of March, June and September of a given year with a notice of 12&#160;months. If the Company wishes to terminate the lease without adhering to the agreed dates, it is liable for the rent and the other tenant obligations until the rental is continued, but the latest until the next contractual termination date. If the rental agreement is not terminated in writing by either party after the fixed contract period has expired, while observing the notice period, it will be extended by two&#160;years. As of December&#160;31, 2022 the remaining period of the lease is approximately 30&#160;months.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company temporarily expanded the above lease to include additional space beginning on January&#160;1, 2020 and ending on April&#160;30, 2021. This space had a month lease payment of 2,843 CHF.&#160;The Company appropriately exercised its termination rights for this lease and has no further obligation to the lessor.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company adopted ASC Topic&#160;842, &#8220;Leases&#8221;, on January&#160;1, 2022. ASC&#160;842 establishes principles for recognizing, measuring, presenting, and disclosing leases to ensure that lessees and lessors provide relevant information about their leasing transactions. The Company has adopted ASC&#160;842 using the modified retrospective approach and elected to use the effective method to apply this standard on the effective date to all remaining leases meeting the criteria for recognition. Comparative prior periods are not restated and are presented under ASC&#160;840. In applying the modified retrospective approach, the Company elected the package of practical expedients permitted by ASC&#160;842, which includes:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;">&#8212;<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Existing Leases:&#160;&#160;&#160;&#160;The Company did not reassess whether existing contracts are or contain leases.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;">&#8212;<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Initial Direct Costs:&#160;&#160;&#160;&#160;The Company did not reassess initial direct costs for existing leases.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;">&#8212;<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Non<span class="nobreak">-lease</span> components:&#160;&#160;&#160;&#160;The Company combined lease and non<span class="nobreak">-lease</span> components.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As a result of the adoption of ASC&#160;842, the Company recognized right<span class="nobreak">-of-use</span> asset and lease liability of approximately $250,000 on the balance sheet for its lease that was classified as an operating lease under the previous guidance. The adoption did not have a material impact on the Company&#8217;s statement of comprehensive loss or cash flows.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-71</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;5 &#8212;&#160;Commitments and Contingencies</span><span class="CharOverride-4" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Initially, the Company measure the right of use asset and liability associated with its office lease using the following inputs:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Remaining lease term (in&#160;years)</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Discount rate</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.05</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company records rent on straight<span class="nobreak">-line</span> basis over the terms of the underlying lease. Estimated future minimum lease payments under the lease as of December&#160;31, 2022 are as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">Year Ending December&#160;31,</span></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">Amount</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">67,632</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">67,632</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">67,632</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">202,896</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">157</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Present value of remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">202,739</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The rent expense for the&#160;years ended December&#160;31, 2022 and 2021 was $65,535 and $68,409 respectively, and was included in &#8216;general and administrative&#8217; expenses in the accompanying statements of comprehensive loss. The Company paid $65,535 and $68,409 respectively, in lease payments during the&#160;years ended December&#160;31, 2022 and 2021 and are included in the Company&#8217;s operating cash flows for both periods. The change in lease expense and lease cash payments from period to period is due to changes in exchange rate between USD and CHF as the Company&#8217;s minimum monthly lease payments are fixed for the term of the lease.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Switzerland social security obligations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company issued certain stock options during periods prior to December&#160;31, 2022. If the recipients exercise these stock options it may result in the recognition of additional social security tax due to the Switzerland taxing authority. Management assessed the likelihood of this liability having been incurred as of December&#160;31, 2022 and 2021 in accordance with ASC&#160;450,&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Contingencies</span>, and determined the likelihood was reasonably possible. Accordingly, no accrual for this contingent obligation has been recognized in the accompanying financial statements. Additionally, management is unable to estimate an amount or range of amounts related to any amount that may be owed should a recipient exercise a stock option.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Federal COVID-19 assistance</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December&#160;31, 2021, the Company, as well as many other entities, received payroll assistance from the government of Switzerland as a result of the COVID<span class="nobreak">-19</span> pandemic. The total amount received by the Company approximated $171,000 and was used to reduce wages and salaries primarily within &#8216;general and administrative&#8217; and &#8216;research and development&#8217; expenses in the accompanying statements of comprehensive loss.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;6 &#8212;&#160;Stockholders&#8217; Deficit</span></p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Share Capital</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company has several series of common stock providing the following provisions. In the event of a bankruptcy or liquidation or winding up of the Company, the holders of Series&#160;B3 Common Stock will be entitled to receive, in advance of the holders of Series&#160;B2 Common Stock, Series&#160;B Common Stock and Series&#160;A Stock and Ordinary Stock, CHF 65 for each Series&#160;B3 Common Share they own.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-72</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;6 &#8212;&#160;Stockholders&#8217; Deficit</span><span class="CharOverride-4" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Thereafter, the holders of Series&#160;B2 Common Stock will be entitled to receive, in advance of the holders of Series&#160;B Common Stock and Series&#160;A Stock and Ordinary Stock, CHF 60 for each Series&#160;B2 Common Share they own.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Thereafter, the holders of Series&#160;B Common Stock will be entitled to receive, in advance of the holders of Series&#160;A Common Stock and Ordinary Stock, CHF 50 for each Series&#160;B Common Share they own.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Thereafter, the holders of Series&#160;A Common Stock will be entitled to receive, in advance of the holders of Ordinary Stock, CHF 40 for each Series&#160;A Common Share they own.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Thereafter, the other Ordinary Shareholders will be entitled to receive CHF 40 per Ordinary Share they own and then any remaining assets or proceeds will be distributed pro rata among all Shareholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If there are insufficient assets or proceeds to pay such amount to the holders of Series&#160;B3 Common Stock, the amount available will be paid on a pro rata basis between the holders of the Series&#160;B3 Common Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If, after the full payment of Series&#160;B3 Shareholders, there are insufficient assets or proceeds to pay such amount to the holders of Series&#160;B2 Common Stock, the amount available will be paid on a pro rata basis between the holders of the Series&#160;B2 Common Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If, after the full payment of Series&#160;B2 Shareholders, there are insufficient assets or proceeds to pay such amount to the holders of Series&#160;B Common Stock, the amount available will be paid on a pro rata basis between the holders of the Series&#160;B Common Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If, after the full payment of Series&#160;B Shareholders, there are insufficient assets or proceeds to pay such amount to the holders of Series&#160;A Common Stock, the amount available will be paid on a pro rata basis between the holders of the Series&#160;A Common Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company and all Shareholders shall use best efforts to ensure that any sale, liquidation, disposal of material assets or the entire Company shall be effectuated so as to be tax efficient, particularly as regards any applicable withholding tax, and fair with regard to the Shareholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If in later financing rounds additional preference rights are granted, then the holders of Series&#160;A Common Stock, Series&#160;B Common Stock and Series&#160;B2 Common Stock shall receive mutatis mutandis behind the new shares the same rights (taking into account the respective price).&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Series&#160;B3 Common Stock shall have the same rights and obligations under the Shareholder&#8217;s Agreement and the Organizational Rules as the Series&#160;B Common Stock and the Series&#160;B2 Common Stock, and thus have the same legal status as the Series&#160;B Common Stock and the Series&#160;B2 Common Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2022 and 2021 the following number of common stock for each series was outstanding:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">Share Class</span></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">Stock</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ordinary</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;A</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">65,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;B</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">84,200</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;B2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">83,334</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;B3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">80,038</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total Outstanding stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">412,572</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-73</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;6 &#8212;&#160;Stockholders&#8217; Deficit</span><span class="CharOverride-4" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Stock options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company sponsors a stock option plan (the &#8220;Plan&#8221;) which provides common stock option grants to be granted to certain individuals as determined by the board of directors. All employees and consultants of the Company are eligible to receive awards under the Plan. The terms of each option are determined by the board of directors and are evidenced by a grant notice provided to the grantee after approval by the board of directors. Generally, options issued under the Plan have a term of less than 11&#160;years and provide for a four<span class="nobreak">-year</span> vesting period during which the grantee must remain in the service of the Company. Options are generally granted on either January&#160;1 or July&#160;1 annually and the exercise price is determined at each respective time by the board of directors. Upon exercise by a grantee, the Company issues new shares of common stock from its authorized capital to satisfy the exercise.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company has granted various stock options primarily to employees as incentive<span class="nobreak">-based</span> compensation. Stock issued under this plan are measure at fair value using the Black<span class="nobreak">-Scholes</span> option pricing model as further described below. Upon exercise, the Company issues new stock from its authorized capital. The following summarizes activity related to the Company&#8217;s stock options for the&#160;years ended December&#160;31, 2022 and 2021:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Intrinsic<br/>Value</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life<br/>(in&#160;years)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding as of December&#160;31, 2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37,573</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.54</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18.11</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.99</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">23,084</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">33.14</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited/cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,792</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.41</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">26.50</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9.56</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding as of December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">52,865</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.40</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24.57</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.60</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited/cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding as of December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">52,865</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.35</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24.62</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.89</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and exercisable as of December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">42,459</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.52</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">34.34</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.52</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of options granted during the&#160;years ended December&#160;31, 2022 and 2021 was estimated using the following range of assumptions:</p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">2021</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercise price</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">1.08 to $27.04</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 31.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">1.10 to $27.42</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Term (years)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 31.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected stock price volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">70%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 31.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">70%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free rate of interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">1.15%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 31.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">-0.73%</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The weighted average grant date fair value of stock options granted during the&#160;years ended December&#160;31, 2022 and 2021 was $0 and $33.14, respectively. The Company estimates forfeitures based on the historical pattern of forfeitures for grantees and are recognized as they occur. The Company uses the straight<span class="nobreak">-line</span> method of measuring compensation cost related to stock option grants which provides that the grants are measured at fair value on the date of issuance and the related cost is measure over the requisite service period as the options vest with each vesting period being treated as a single grant over which compensation is recognized. As of December&#160;31, 2022, approximately 16,800 options remain unvested having a fair value $940,702 which will be recognized in future periods as the options vest. The aggregate fair value of stock options that vested during the&#160;years ended December&#160;31, 2022 and 2021 was approximately $329,000 and $68,000, respectively.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-74</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;6 &#8212;&#160;Stockholders&#8217; Deficit</span><span class="CharOverride-4" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-3" style="font-style:italic;font-weight:normal;text-decoration:underline;">Accumulated other comprehensive loss</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The table below details the components and the Company&#8217;s accumulated other comprehensive loss as of December&#160;31, 2022 and 2021.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-21" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Defined<br/>Benefit<br/>Pension<br/>Items</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Foreign<br/>Currency<br/>Items</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance as of December&#160;31, 2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,131</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,131</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other comprehensive income before reclassifications</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">562,461</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">32,837</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">595,298</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-17" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amounts reclassified from accumulated other comprehensive income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(164,752</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(164,752</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net current period other comprehensive income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">397,709</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">32,837</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">430,546</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance as of December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">397,709</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">33,968</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">431,677</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other comprehensive income before reclassifications</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">475,487</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,986</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">470,501</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-17" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amounts reclassified from accumulated other comprehensive income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(295,595</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(295,595</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net current period other comprehensive income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">179,892</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,986</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">174,906</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance as of December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">577,601</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">28,982</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">606,583</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following tables details the amounts reclassified from other comprehensive loss and the related affected line items within the accompanying statements of comprehensive loss for the&#160;years ended December&#160;31, 2022 and 2021.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Item description</span></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022<br/>Amount</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2021<br/>Amount</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.93%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Financial statement<br/>line item</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 23.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amortization of gains (losses)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,303</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">General and administrative</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 23.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Settlements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">289,292</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">164,752</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">General and administrative</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">295,595</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">164,752</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;7 &#8212;&#160;Defined Benefit Pension Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company sponsors a defined benefit pension plan covering certain eligible employees. The plan provides retirement benefits based on&#160;years of service and compensation levels.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The value of the pension obligation is determined using the Projected Unit Credit (PUC) method. This method sees each period of service as giving rise to an additional unit of benefit entitlements/employee benefits. The value of the Company&#8217;s employee benefit obligations for active employees, or the Projected Benefit Obligation (PBO), on the reporting date is the same as the present value of the degree of entitlement existing on this date, in terms of future salary and pension increases and turnover rates. The valuation of pension obligations of pensioners is made on the basis of the present value of current pensions taking into account future increases in pensions. The service costs (SC) are calculated using the present value of the entitlements to employee benefits earned during the year for which calculations are made.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-75</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;7 &#8212;&#160;Defined Benefit Pension Plan</span><span class="CharOverride-4" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following significant actuarial assumptions were used in calculating the benefit obligation and the net periodic benefit cost as of December&#160;31, 2022 and 2021:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">2021</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Discount rate</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.30</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.35</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected long-term rate of return on plan assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.30</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.35</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Rate of compensation increase</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.00</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.00</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Changes in these assumptions may have a material impact on the plan&#8217;s obligations and costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The components of net periodic benefit cost for the&#160;years ended December&#160;31, 2022 and 2021 are as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">2021</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Service cost</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">157,225</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">218,298</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest cost</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,737</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,563</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected return on plan assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(8,195</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,366</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amortization of net (gain)/loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,303</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Settlements (gain)/loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(289,292</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(164,752</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(135,828</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">54,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The components of accumulated comprehensive loss attributable to the Company&#8217;s pension plan for the&#160;years ended December&#160;31, 2022 and 2021 are as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">2021</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss (gain)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(475,487</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(562,461</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amortization of net gain</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,303</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effect of settlement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">289,292</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">164,752</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total recorded during the period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(179,892</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(397,709</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(577,601</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(397,709</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2022 and 2021, the funded status of the plan and the amounts recognized in the balance sheets are as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">2021</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Projected benefit obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,981,655</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,321,683</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fair value of plan assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,588,015</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,523,207</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Overfunded (underfunded) status</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(393,640</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(798,476</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Company contributions to the plan during the&#160;years ended December&#160;31, 2022 and 2021&#160;amounted to $89,192 and $95,527, respectively.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-76</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;7 &#8212;&#160;Defined Benefit Pension Plan</span><span class="CharOverride-4" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A reconciliation of the beginning and ending balances of the accumulated benefit obligation is provided in the table below:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">As of December&#160;31, 2020</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,681,625</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Service cost</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">218,298</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest cost</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,563</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Actuarial (gain) loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(365,169</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Benefits paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(22,148</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contributions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,131,779</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Settlements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1,326,265</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Projected benefit obligation as of December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,321,683</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Actuarial (gain)/loss due to assumption changes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(173,094</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Actuarial (gain)/loss due to plan experience</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(192,074</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated benefit obligation as of December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,956,515</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">As of December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,321,683</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Service cost</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">157,225</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest cost</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,737</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Actuarial (gain) loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(817,009</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Benefits paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(20,470</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contributions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">220,604</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Settlements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(891,115</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Projected benefit obligation as of December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,981,655</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Actuarial (gain)/loss due to assumption changes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(594,309</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Actuarial (gain)/loss due to plan experience</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(222,700</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated benefit obligation as of December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,164,646</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A reconciliation of the beginning and ending balances of the plan assets is provided in the table below:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">As of December&#160;31, 2020</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,444,559</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Actual return on plan asset</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">199,755</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contributions paid by employer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">95,527</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ordinary contributions paid by employees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">95,527</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contributions paid by plan participants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,036,252</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Benefits paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(22,148</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Settlements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,326,265</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">As of December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,523,207</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Actual return on plan asset</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(333,403</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contributions paid by employer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">89,192</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ordinary contributions paid by employees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">89,192</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contributions paid by plan participants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">131,412</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Benefits paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(20,470</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Settlements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(891,115</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">As of December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,588,015</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-77</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;7 &#8212;&#160;Defined Benefit Pension Plan</span><span class="CharOverride-4" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Projected benefit payments for the next five&#160;years as of December&#160;31, 2023 are as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 81.60%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years ending December&#160;31,</span></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">87,623</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2026</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">88,704</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2027</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">89,786</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thereafter</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">627,421</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">893,534</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;8 &#8212;&#160;Related Parties</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As described in Note&#160;4, the Company has several borrowings from shareholders and members of its board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the&#160;years ended December&#160;31, 2022 and 2021, the Company paid approximately $319,000 and $289,000 to entities owned by a member of executive management and two members of the board of directors for professional services. These amounts are included within &#8216;general and administrative&#8217; expenses in the accompanying statements of comprehensive loss.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;9 &#8212;&#160;Income Taxes</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company has established deferred tax assets and liabilities for the recognition of future deductions or taxable amounts and operating loss carry forwards. Deferred federal income tax expense or benefit is recognized as a result of the change in the deferred tax asset or liability during the year using the currently enacted tax laws and rates that apply to the period in which they are expected to affect taxable income. Valuation allowances are established, if necessary, to reduce deferred tax assets to the amounts that will more likely than not be realized.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the&#160;years ended December&#160;31, 2022 and 2021, a reconciliation of income tax expense at the statutory rate of 24.85% to income tax expense at the Company&#8217;s effective tax rate is as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="6" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="6" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2021</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax benefit at statutory rate</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(507,647</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(24.85</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(559,026</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(24.85</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Temporary differences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Permanent differences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">59,955</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.94</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">41,796</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.85</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">447,692</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">21.92</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">517,230</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">23.00</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Provision for federal income taxes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">At December&#160;31, 2022, the Company had approximately $18,361,000 of unused net operating loss carry forwards for federal purposes which may be carried forward for up to seven&#160;years. Unused net operating loss carry forwards may provide future tax benefits, although there can be no assurance that these net operating losses will be realized in the future. The tax benefits of these loss carryforward have been fully offset by a valuation allowance. These losses may be used to offset future taxable income and, if not fully utilized, begin to expire in the year 2023. The Company&#8217;s only significant deferred tax assets are those related to its net operating loss carryforwards and pension fund obligations. The Company has no significant deferred tax liabilities as of December&#160;31, 2022 and 2021.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-78</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;9 &#8212;&#160;Income Taxes</span><span class="CharOverride-4" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table details the Company&#8217;s net operating loss carry forwards and the related expected expiration dates as of December&#160;31, 2022.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years ending December&#160;31,</span></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,126,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,647,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,928,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2026</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,356,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2027</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,416,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2028</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,240,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2029</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,648,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18,361,000</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s taxes remain open to review by the relevant taxing authorities generally for five&#160;years after the end of the applicable fiscal year end. As of December&#160;31, 2022 the only open year subject to examination by taxing authorities is the year ended December&#160;31, 2022.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;10 &#8212;&#160;Subsequent Events</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2023, the Parent and the Company entered into a Share Exchange Agreement which resulted in the Company becoming a wholly owned subsidiary of the Parent. The consummation of the Share Exchange was subject to customary closing conditions and&#160;closed on December&#160;15, 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Concurrently with the closing of the Share Exchange Agreement, all outstanding convertibles notes as of December&#160;31, 2022 were converted into 83,114 common stock of the Company and were then purchased by the Parent.</p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-79</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T613"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span style="-keep: true">Proteomedix AG<br/>Condensed Balance Sheets<br/>(unaudited)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">September&#160;30,<br/>2023</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;text-decoration:underline;">ASSETS</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Current assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,037,425</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">470,156</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">116,374</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">236,683</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Inventory</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">83,183</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">95,810</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid expenses and other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,304</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">26,280</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total current assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,244,286</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">828,929</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39,163</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40,130</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right of use asset</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">140,588</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">202,739</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,424,037</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,071,798</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;text-decoration:underline;">LIABILITIES AND STOCHOLDERS&#8217; DEFICIT</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current Liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Convertible notes payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,704,371</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,241,942</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">230,329</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">510,578</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lease liability, current</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">62,464</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">67,546</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,997,164</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,820,066</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Convertible notes payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,406,289</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Note payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">109,251</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">108,176</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pension benefit obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">546,259</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">393,640</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">78,124</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">135,193</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,730,798</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,863,364</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stockholders&#8217; deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock par value 1 CHF, authorized 466,555 shares, outstanding at September&#160;30, 2023 and December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">466,555</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">466,555</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in-capital</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,539,478</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,377,905</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated comprehensive income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">610,627</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">606,583</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(26,923,421</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(27,242,609</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total stockholders&#8217; deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,306,761</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,791,566</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total liabilities and stockholders&#8217; deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,424,037</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,071,798</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">The accompanying notes are an integral part of these condensed financial statements.</p>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-80</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T614"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span style="-keep: true">Proteomedix AG<br/>Condensed Statements of Comprehensive Income (Loss)<br/>For the Nine&#160;Months Ended September&#160;30, 2023 and 2022<br/>(unaudited)</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Revenue</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,092,761</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">128,773</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cost of goods sold</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">22,548</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">28,176</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Gross profit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,070,213</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100,597</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Marketing and business development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">151,478</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">172,478</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">275,020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">262,818</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,240,875</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,633,860</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,293</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12,966</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,676,666</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,082,122</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Income (loss) from operations</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">393,547</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,981,525</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Other income (expense)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(74,359</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(48,257</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other income (expenses)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(74,359</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(48,257</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net income (loss) before provision for income taxes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">319,188</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,029,782</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Provision for income taxes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net income (loss)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">319,188</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,029,782</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other comprehensive income (loss)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Foreign currency translation adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">172,351</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">344,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Changes in pension benefit obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(168,307</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">369,287</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other comprehensive income (loss)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,044</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">714,244</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Comprehensive income (loss)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">323,232</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,315,538</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">The accompanying notes are an integral part of these condensed financial statements.</p>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-81</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T615"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span style="-keep: true">Proteomedix AG<br/>Condensed Statement of Stockholders&#8217; Deficit<br/>For the Nine&#160;Months Ended September&#160;30, 2023 and 2022<br/>(unaudited)</span></p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 25.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="4" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 20.78%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;"><br/><br/>Common Stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 11.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Additional <br/>Paid In<br/>Capital</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 11.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Accumulated <br/>Comprehensive <br/>(Loss) Income</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 11.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Accumulated<br/>Deficit</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.99%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Total <br/>Stockholders&#8217;<br/>Deficit</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 25.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Par&#160;Value</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 25.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Balance at December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">412,572</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">466,555</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,916</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">431,677</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(25,200,036</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,300,888</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 25.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">FX translation adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">344,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">344,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 25.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Stock based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">282,742</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">282,742</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 25.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Changes in pension benefit obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">369,287</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">369,287</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 25.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.35%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,029,782</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,029,782</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 25.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Balance at September&#160;30, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">412,572</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.35%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">466,555</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,283,658</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,145,921</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(27,229,818</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,333,684</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 25.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 8.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 25.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Balance at December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">412,572</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">466,555</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,377,905</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">606,583</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(27,242,609</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,791,566</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 25.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">FX translation adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">172,351</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">172,351</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 25.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Stock based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">161,573</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">161,573</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 25.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Changes in pension benefit obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(168,307</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(168,307</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 25.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Net income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.35%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">319,188</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">319,188</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 25.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Balance at September&#160;30, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">412,572</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.35%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">466,555</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,539,478</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">610,627</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(26,923,421</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,306,761</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">The accompanying notes are an integral part of these condensed financial statements.</p>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-82</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T616"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span style="-keep: true">Proteomedix AG<br/>Condensed Statements of Cash Flows<br/>For the Nine&#160;Months Ended September&#160;30, 2023 and 2022<br/>(unaudited)</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net income (loss)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">319,188</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,029,782</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation and amortization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,293</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12,966</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">161,573</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">282,742</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Changes in pension benefit obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(15,688</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">47,042</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Changes in operating assets and liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">120,309</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">46,462</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Inventory</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12,627</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,177</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid expenses and other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18,976</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">63,107</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(280,249</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">89,382</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash (used in) provided by operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">346,029</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,477,904</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Investing activities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash used in investing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Financing activities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Repayment of notes payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(50,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash used in financing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(50,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">FX effect on cash</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">221,240</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(91,064</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net change in cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">567,269</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,618,968</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents&#160;&#8211;&#160;beginning of the year</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">470,156</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,546,801</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents&#160;&#8211;&#160;end of year</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,037,425</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">927,833</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="CharOverride-3" style="text-decoration:underline;">Supplemental cash flow disclosures</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,965</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income taxes paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">The accompanying notes are an integral part of these financial statements.</p>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-83</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T617"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span style="-keep: true">Proteomedix AG<br/>Notes to Condensed Financial Statements</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;1 &#8212;&#160;Organization and Nature of Business</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix AG (the &#8220;Company&#8221;) is a healthcare company whose mission is to transform prostate cancer diagnosis. Proteomedix has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product Proclarix<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span>&#160;is a blood<span class="nobreak">-based</span> prostate cancer test panel and risk score currently available in Europe and expected to be available in the U.S.&#160;in the near future. Proteomedix is located in the Bio<span class="nobreak">-Technopark</span> of Zurich<span class="nobreak">-Schlieren</span>, Switzerland.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2023, the Company was acquired by Onconetix, Inc. (formerly Blue Water Biotech, Inc) (the &#8220;Parent&#8221;). The Parent issued stock of its common stock in exchange for 100% of the outstanding voting equity of the Company. See Note&#160;10.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;2 &#8212;&#160;Going Concern</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying condensed financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. For the nine&#160;months ended September&#160;30, 2023, the Company had an accumulated deficit of approximately $27,000,000 and a working capital deficit of approximately $4,800,000, and a lack of profitable operational history. These matters, among others, raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">While the Company is attempting to generate greater revenues, the Company&#8217;s cash position may not be significant enough to support the Company&#8217;s daily operations. Management intends to raise additional funds from its Parent to sustain operations until such time as revenues are sufficient to support the Company&#8217;s operations. Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate revenues and the ability of its Parent to provide additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company&#8217;s ability to further implement its business plan and obtain additional funding from its Parent as needed.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3 &#8212;&#160;Summary of Significant Accounting Policies</span></p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Basis of Presentation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying condensed financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;) and interim reporting rules of the Securities and Exchange Commission (&#8220;SEC&#8221;) and should be read in conjunction with the audited financial statements for the&#160;years ended December&#160;31, 2022 and 2021, and notes thereto. In the opinion of management, all adjustments, consisting of normal recurring adjustments (unless otherwise indicated), necessary for a fair presentation of the financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The functional currency of the Company is the Swiss Franc and the Company&#8217;s condensed financial statements are presented in United&#160;States Dollars (USD). Transactions denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the date of the transaction. The resulting translation adjustments are recorded as a separate component of accumulated other comprehensive income (loss).</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Segment Information</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;), or decision<span class="nobreak">-making</span> group, in deciding how to allocate resources and in assessing performance. The Company operates in one segment which is consistent with the financial information regularly reviewed by the CODM for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-84</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Condensed Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3 &#8212;&#160;Summary of Significant Accounting Policies</span><span class="CharOverride-3" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Use of Estimates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The preparation of condensed financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company&#8217;s condensed financial statements relate to valuation of inventory, stock<span class="nobreak">-based</span> compensation, pension benefit obligations, and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Cash and Cash Equivalents</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">For purposes of reporting cash flows, the Company has defined cash and cash equivalents as all cash in banks and highly liquid investments available for current use with an initial maturity of three&#160;months or less to be cash equivalents. The Company had no cash equivalents as of September&#160;30, 2023 and December&#160;31, 2022.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company maintains its cash balances at financial institutions that are insured by Swiss Financial Market Supervisory Authority (&#8220;FINMA&#8221;). The Company&#8217;s cash balances may at times exceed the insurance provided by FINMA.&#160;The Company has not experienced any losses on these accounts and management does not believe that the Company is exposed to any significant risks related to excess deposits.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Accounts Receivable</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company performs periodic credit evaluations of its customers&#8217; financial condition and extends credit to virtually all of its customers on an uncollateralized basis. Credit losses to date have been insignificant and within management&#8217;s expectations. The Company provides an allowance for doubtful accounts that is based upon a review of outstanding receivables, historical collection information, expected future losses, and existing economic conditions.&#160;Normal accounts receivable are due 30&#160;days after the issuance of the invoice. Receivables are considered delinquent based on management&#8217;s assessment of the individual balance. Delinquent receivables are evaluated for collectability based on individual credit evaluation and specific circumstances of the customer. As of September&#160;30, 2023, and December&#160;31, 2022, the Company&#8217;s allowance for doubtful accounts was nil, respectively. The Company did not write off any accounts receivable against the allowance for doubtful accounts during the periods ended September&#160;30, 2023, and 2022. As of September&#160;30, 2023 and December&#160;31, 2022, substantially all accounts receivable are due from a single customer.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Inventories</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Inventories consist of raw materials and finished goods. Inventories are stated at the lower of cost or net realizable value, with cost determined on a first<span class="nobreak">-in</span>, first<span class="nobreak">-out</span> basis. The Company periodically reviews the composition of inventory in order to identify excess, obsolete, slow<span class="nobreak">-moving</span> or otherwise non<span class="nobreak">-saleable</span> items taking into account anticipated future sales compared with quantities on hand, and the remaining shelf life of goods on hand. If non<span class="nobreak">-saleable</span> items are observed and there are no alternate uses for the inventory, the Company records a write<span class="nobreak">-down</span> to net realizable value in the period that the decline in value is first recognized. The Company had no inventory reserves as of September&#160;30, 2023, and December&#160;31, 2022.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Impairment of Long-Lived Assets</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company reviews long<span class="nobreak">-lived</span> assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable (a &#8220;triggering event&#8221;). Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-85</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Condensed Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3 &#8212;&#160;Summary of Significant Accounting Policies</span><span class="CharOverride-3" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">long<span class="nobreak">-lived</span> asset in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long<span class="nobreak">-lived</span> asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long<span class="nobreak">-lived</span> asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. During the periods ended September&#160;30, 2023, and 2022, the Company did not identify any impairments related to its long<span class="nobreak">-lived</span> assets.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Property and Equipment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment consists of computers and office furniture and fixtures, all of which are recorded at cost. Depreciation is recorded using the straight<span class="nobreak">-line</span> method over the respective useful lives of the assets ranging from two to ten&#160;years. Long<span class="nobreak">-lived</span> assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. Upon the retirement or other disposition of property and equipment, the related cost and accumulated depreciation are charged to operations.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Research and Development Costs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Research and development expenses are those costs incurred in the discovery, design, and development of new products, processes, or services, as well as the enhancement of existing products. Research and development costs are expensed as incurred unless such costs have an alternative future use. These costs include, but are not limited to, salaries, wages, benefits, materials, equipment, and overhead directly attributable to the research and development activities.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Collaborative&#160;Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company periodically enters into strategic alliance agreements with counterparties to produce products and/or provide services to customers. Alliances created by such agreements are not legal entities, have no employees, no assets and have no true operations. These arrangements create contractual rights and the Company accounts for these alliances as a collaborative arrangement by reporting costs incurred and reimbursements received from transactions within research and development expense within the statements of comprehensive loss.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Commitments And Contingencies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties and other sources are recorded when management assesses that it is probable that a liability has been incurred and the amount can be reasonably estimated.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Share Based Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with Financial Accounting Standard Board (&#8220;FASB&#8221;) Account Standard Codification (&#8220;ASC&#8221;) 718, &#8220;Compensation&#160;&#8212;&#160;Stock Compensation&#8221;. Costs are measured at the estimated fair value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earliest of a performance commitment or completion of performance by the provider of goods or services as defined by ASC&#160;718.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Income Taxes</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with ASC&#160;740, &#8220;Income Taxes,&#8221; the Company provides for the recognition of deferred tax assets if realization of such assets is more likely than not. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-86</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Condensed Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3 &#8212;&#160;Summary of Significant Accounting Policies</span><span class="CharOverride-3" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the Company&#8217;s management performs an evaluation of all uncertain income tax positions taken or expected to be taken in the course of preparing the Company&#8217;s income tax returns to determine whether the income tax positions meet a &#8220;more likely than not&#8221; standard of being sustained under examination by the applicable taxing authorities. This evaluation is required to be performed for all open tax&#160;years, as defined by the various statutes of limitations, for federal and state purposes. If the Company has interest or penalties associated with insufficient taxes paid, such expenses are reported in income tax expense.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Revenue Recognition</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company recognized revenue when control of goods or services performed is transferred to customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those services. ASC&#160;606 provides for a five<span class="nobreak">-step</span> model that includes:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;">(i)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>identifying the contract with a customer,</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;">(ii)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>identifying the performance obligations in the contract,</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;">(iii)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>determining the transaction price,</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;">(iv)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>allocating the transaction price to the performance obligations, and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;">(v)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>recognizing revenue when, or as, an entity satisfies a performance obligation.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Product Sales</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company derives revenue through sales of its products directly to end users and to distributors. The Company sells its products to customers including laboratories, hospitals, medical centers, doctors and distributors. The Company considers customer purchase orders, which in some cases are governed by master sales agreements or standard terms and conditions, to be the contracts with a customer. For each contract, the Company considers the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects to be entitled. The Company fulfils its performance obligation applicable to product sales once the product is transferred to the customer.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Development Services</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company provides a range of services to life sciences customers referred to as &#8220;Development Services&#8221; including testing for biomarker discovery, assay design and development. These Development Services are performed under individual&#160;statement&#160;of work (&#8220;SOW&#8221;) arrangements with specific deliverables defined by the customer. Development Services are generally performed on a time and materials basis. During the performance and through completion of the service to the customer in accordance with the SOW, we have the right to bill the customer for the agreed upon price and we recognize the Development Services revenue over the period estimated to complete the SOW.&#160;We generally identify each SOW as a single performance obligation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Completion of the service and satisfaction of the performance obligation under a SOW is typically evidenced by access to the data or test made available to the customer or any other form or applicable manner of delivery defined in the SOW.&#160;However, for certain SOWs under which work is performed pursuant to the customer&#8217;s highly customized specifications, we have the enforceable right to bill the customer for work completed, rather than upon completion of the SOW.&#160;For those SOWs, we recognize revenue over a period of time during which the work is performed based </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-87</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Condensed Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3 &#8212;&#160;Summary of Significant Accounting Policies</span><span class="CharOverride-3" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">on the expended efforts (inputs). As the performance obligation under the SOW is satisfied, any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed to the customer as of the date of the condensed financial statements are recorded as contract assets and are included in prepaids and other current assets as of the condensed financial statement date. Amounts recorded in contract assets are reclassified to accounts receivable in our financial statements when the customer is invoiced according to the billing schedule in the contract.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In circumstances where a SOW includes variable consideration component, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on which method is expected to better predict the amount of consideration to which the Company will be entitled. The value of variable consideration is included in the transaction price if, and to the extent, it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are reassessed each reporting period, as required, and any adjustment required is recorded on a cumulative catch<span class="nobreak">-up</span> basis, which would affect revenue and net income in the period of adjustment.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Licensing Revenues</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">license revenues are determined based on an assessment of whether the license is distinct from any other performance obligations that may be included in the underlying licensing arrangement. If the customer is able to benefit from the license without provision of any other performance obligations by the Company and the license is thereby viewed as a distinct or functional license, the Company then determines whether the customer has acquired a right to use the license or a right to access the license. For functional licenses that do not require further substantive development or other ongoing activities by the Company, the customer is viewed as acquiring the right to use the license as, and when, transferred and revenues are generally recorded at a point in time. For symbolic licenses providing substantial value only in conjunction with other performance obligations to be provided by the Company, revenues are generally recorded over the term of the license agreement using the inputs based on contractual remaining time for such license. Such other obligations provided by the Company generally include manufactured products, additional development services or other deliverables that are contracted to be provided during the license term.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Royalties associated with licensing arrangements are estimated and recognized when sales under supply agreements with commercial licensees are recorded, absent any contractual constraints or collectability uncertainties. Royalties which are contingent on meeting certain sales milestones are recorded when it has become probable that milestones will be met.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table disaggregates the Company&#8217;s revenues by type for the periods ended September&#160;30, 2023 and 2022.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">Recognition <br/>Method</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Product sales</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">Point in time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40,237</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">74,390</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Licensing revenues</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">Point in time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">516,359</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Development services</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">Over time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,536,165</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">54,383</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,092,761</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">128,773</p>
					</td>
				</tr>

		</table>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Financial Instruments</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s financial instruments include cash and cash equivalents, accounts receivable and accounts payable, and are accounted for under the provisions of ASC Topic&#160;825, &#8220;Financial Instruments&#8221;. The carrying amount of these financial instruments, as reflected in the condensed financial statements approximates fair value.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-88</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Condensed Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3 &#8212;&#160;Summary of Significant Accounting Policies</span><span class="CharOverride-3" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Fair Value Measurement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">ASC Topic&#160;820, &#8220;Fair Value Measurement&#8221;, requires that certain financial instruments be recognized at their fair values at our balance sheet dates. However, other financial instruments, such as debt obligations, are not required to be recognized at their fair values, but&#160;U.S.&#160;GAAP provides an option to elect fair value accounting for these instruments. U.S.&#160;GAAP requires the disclosure of the fair values of all financial instruments, regardless of whether they are recognized at their fair values or carrying amounts in our balance sheets. For financial instruments recognized at fair value, U.S.&#160;GAAP requires the disclosure of their fair values by type of instrument, along with other information, including changes in the fair values of certain financial instruments recognized in income or other comprehensive income. For financial instruments not recognized at fair value, the disclosure of their fair values is provided below under &#8220;Financial Instruments.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Nonfinancial assets, such as property and equipment, and nonfinancial liabilities are recognized at their carrying amounts in the Company&#8217;s balance sheets. U.S.&#160;GAAP does not permit nonfinancial assets and liabilities to be remeasured at their fair values. However, U.S.&#160;GAAP requires the remeasurement of such assets and liabilities to their fair values upon the occurrence of certain events, such as the impairment of property, plant and equipment. In addition, if such an event occurs, U.S.&#160;GAAP requires the disclosure of the fair value of the asset or liability along with other information, including the gain or loss recognized in income in the period the remeasurement occurred.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company did not have any assets or liabilities at September&#160;30, 2023 and December&#160;31, 2022 which required remeasurement at the respective reporting periods.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Convertible Instruments</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC&#160;815 &#8220;Derivatives and Hedging Activities&#8221;.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">U.S.&#160;GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free<span class="nobreak">-standing</span> derivative financial instruments according to certain criteria. The criteria include circumstances in which (a)&#160;the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b)&#160;the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re<span class="nobreak">-measured</span> at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c)&#160;a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for convertible instruments as follows: Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. Proceeds from these convertible notes are reported under the financing section of the statements of cash flows. Changes to the fair value of the derivative liability are reported as adjustments to reconcile net loss to net cash used in operating activities in the accompanying statement of cash flows. During the nine&#160;months ended September&#160;30, 2023 the Company did not have any conversion options which required bifurcation from the host instrument.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Defined Benefit Pension Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company sponsors a defined benefit pension plan (the &#8220;Plan&#8221;) covering eligible employees. The Plan provides retirement benefits based on employees&#8217;&#160;years of service and compensation levels. The Company recognizes an asset for such plan&#8217;s overfunded status or a liability underfunded status in its balance sheets. Additionally, the Company measures its plan&#8217;s assets and obligations that determine its funded status as of the end of the year and recognizes the changes in the funded status in the year in which the changes occur. Those changes are reported in &#8216;accumulated other comprehensive loss. The Company uses actuarial valuations to determine its pension and postretirement benefit costs and credits. The amounts calculated depend on a variety of key assumptions, including discount rates and expected return on plan assets. Current market conditions are considered in selecting these assumptions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-89</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Condensed Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3 &#8212;&#160;Summary of Significant Accounting Policies</span><span class="CharOverride-3" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s pension plans are generally valued using the net asset value (NAV) per share as a practical expedient for fair value provided certain criteria are met. The NAVs are determined based on the fair values of the underlying investments in the funds. In circumstances where the criteria are not met, fair is determined based on the underlying market in which the funds are traded which is generally considered to be an active market.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Recently Issued Accounting Standards</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the period ended September&#160;30, 2023, and subsequently, there were several new accounting pronouncements issued by the FASB.&#160;Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company&#8217;s condensed financial statements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In June&#160;2016, the FASB issued ASU No.&#160;2016<span class="nobreak">-13</span>, &#8220;Financial Instruments&#160;&#8212;&#160;Credit Losses (Topic&#160;326): Measurement of Credit Losses on Financial Instruments,&#8221; which requires the Company to measure and recognize expected credit losses for financial assets held and not accounted for at fair value through net income. In November&#160;2018, April&#160;2019 and May&#160;2019, the FASB issued ASU No.&#160;2018<span class="nobreak">-19</span>, &#8220;Codification Improvements to Topic&#160;326, Financial Instruments&#160;&#8212;&#160;Credit Losses,&#8221; &#8220;ASU No.&#160;2019<span class="nobreak">-04</span>, Codification Improvements to Topic&#160;326, Financial Instruments&#160;&#8212;&#160;Credit Losses,&#8221; &#8220;Topic&#160;815, Derivatives and Hedging, and Topic&#160;825, Financial Instruments,&#8221; and &#8220;ASU No.&#160;2019<span class="nobreak">-05</span>, Financial Instruments&#160;&#8212;&#160;Credit Losses (Topic&#160;326): Targeted Transition Relief,&#8221; which provided additional implementation guidance on the previously issued ASU.&#160;The ASU is effective for fiscal&#160;years beginning after Dec.<span class="nobreak"> </span>15, 2019 for public business entities that meet the definition of an SEC filer, excluding entities eligible to be SRCs as defined by the SEC.&#160;All other entities, ASU No.&#160;2016<span class="nobreak">-13</span> is effective for fiscal&#160;years beginning after December&#160;15, 2022. The adoption of this guidance did not have a material impact on the Company&#8217;s condensed financial statements.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Subsequent Events</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company has evaluated all transactions through the date the condensed financial statements were issued for subsequent event disclosure consideration. See Note&#160;10.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;4 &#8212;&#160;Debt</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;3, 2010, the Company received a loan from Venture Kick in the amount of 100,000 CHF.&#160;This loan bears no interest, is unsecured and may be cancelled by the Company at its discretion. This loan is subordinated to the Company&#8217;s other unsubordinated debt. The loan was to be used solely for business development and the Company may, at its sole discretion, contribute funds back to Venture Kick to enable that organization to continue its efforts. As of September&#160;30, 2023 and December&#160;31, 2022 the balance outstanding was approximately $109,000 and $108,000, respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On June&#160;23, 2020, Company entered a convertible note payable with a financial institution and shareholder of the Company for CHF 550,000 with an interest rate of 0.50% per annum and a maturity of September&#160;30, 2024. The note provides the holder with an optional conversion feature in the event of an equity financing of the Company. The conversion price in the event of an equity financing is at a 20% discount the share price from the financing. The holder is also entitled to convert the note upon the occurrence of a sale of the Company or at maturity of the note in both cases without a discount. This note was unsubordinated until January&#160;10, 2023, at which point it was also subordinated to all other unsubordinated debts. The interest rate was changed to 2.50% as of May&#160;1, 2023. As of September&#160;30, 2023 and December&#160;31, 2022, the outstanding balance on this note was approximately $601,000 and $541,000, respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On June&#160;23, 2020, Company entered into a series of convertible notes payable with certain shareholders of the Company for CHF 800,000 with an interest rate of 0.50% per annum and a maturity of September&#160;30, 2024. The note provides the holder with an optional conversion feature in the event of an equity financing greater than CHF 1,000,000. The conversion price in the event of an equity financing is at a 20% discount the share price from the financing. The holder is also entitled to convert the note upon the occurrence of a sale of the Company or at maturity of the note in </p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-90</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Condensed Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;4 &#8212;&#160;Debt</span><span class="CharOverride-3" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">both cases without a discount. These notes payable are subordinated to the Company&#8217;s other unsubordinated debt. As of September&#160;30, 2023 and December&#160;31, 2022, the outstanding balance on these notes was approximately $874,000 and $865,000, respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On October&#160;26, 2020, Company entered into a series of convertible notes payable with certain members of the board of directors (Note&#160;8) in the total amount of CHF 161,250 with an interest rate of 0.25% and a maturity of December&#160;31, 2023. The note provides the holder with an optional conversion feature at a discount of 20% in the event of an equity financing greater than CHF 1,000,000. The holder is also entitled to convert the note upon the occurrence of a sale of the Company or at maturity of the note in both cases without a discount. These notes payable are subordinated to the Company&#8217;s other unsubordinated debt. As of September&#160;30, 2023 and December&#160;31, 2022, the outstanding balance on these notes was approximately $177,000 and $174,000, respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On November&#160;23, 2020, Company entered into a series of convertible notes payable with certain shareholders of the Company in the total amount of CHF 760,080 with an interest rate of 5% and a maturity of December&#160;31, 2023. The note provides the holder with an optional conversion feature at a discount of 30% in the event of an equity financing greater than CHF 1,000,000. The holder is also entitled to convert the note upon the occurrence of a sale of the Company or at maturity of the note in both cases without a discount. These notes payable are subordinated to the Company&#8217;s other unsubordinated debt. As of September&#160;30, 2023 and December&#160;31, 2022, the outstanding balance on these notes was approximately $831,000 and $822,000, respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On July&#160;19, 2021, Company entered into a convertible note payable in the total amount of CHF 3,000,000 with an interest rate of 0.5% and an original maturity of September&#160;30, 2023 which was extended to September&#160;30, 2024. The note provides the holder with a mandatory conversion requirement in the event of an equity financing greater than CHF 1,000,000. The note is also mandatorily converted in the event certain milestones are achieved related to an R&amp;D collaboration project entered separately none of which have been met as of December&#160;31, 2022. The holder is also entitled to convert the note upon the occurrence of a sale of the Company or at maturity of the note in both cases without a discount. These notes payable are subordinated to the Company&#8217;s other unsubordinated debt. As of September&#160;30, 2023 and December&#160;31, 2022, the outstanding balance on this note was approximately $3,278,000 and $3,245,000, respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company did not issue any new notes during the nine&#160;months ended September&#160;30, 2023, all the changes in the above balances are solely due to changes exchange rates between USD and CHF.&#160;All outstanding convertible notes as of December&#160;31, 2022 were converted upon the closing of the acquisition of the Company by the Parent. See Note&#160;10.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;5 &#8212;&#160;Commitments and Contingencies</span></p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Leases</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company leases it&#8217;s primary office and lab space at a rate of 5,077 CHF per month. The lease began on February&#160;1, 2012 with an initial period ending on January&#160;31, 2015. This rental agreement can be terminated at the end of March, June and September of a given year with a notice of 12&#160;months. If the Company wishes to terminate the lease without adhering to the agreed dates, it is liable for the rent and the other tenant obligations until the rental is continued, but the latest until the next contractual termination date. If the rental agreement is not terminated in writing by either party after the fixed contract period has expired, while observing the notice period, it will be extended by two&#160;years. As of September&#160;30, 2023 the remaining period of the lease is approximately 21&#160;months.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The rent expense for the periods ended September&#160;30, 2023 and 2022 was $57,582 and $54,653 respectively and was included in &#8216;general and administrative&#8217; expenses in the accompanying statements of comprehensive loss. The Company paid $57,582 and $54,653 respectively, in lease payments during the periods ended September&#160;30, 2023 and 2022, and are included in the Company&#8217;s operating cash flows for both periods. The change in lease expense and lease cash payments. The change in lease expense from period to period is due to changes in exchange rate between USD and CHF as the Company&#8217;s minimum monthly lease payments are fixed for the term of the lease.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-91</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Condensed Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;5 &#8212;&#160;Commitments and Contingencies</span><span class="CharOverride-3" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Switzerland social security obligations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company issued certain stock options during periods prior to December&#160;31, 2022. If the recipients exercise these stock options it may result in the recognition of additional social security tax due to the Switzerland taxing authority. Management assessed the likelihood of this liability having been incurred as of December&#160;31, 2022 and 2021 in accordance with ASC&#160;450,&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Contingencies</span>, and determined the likelihood was reasonably possible. Accordingly, no accrual for this contingent obligation has been recognized in the accompanying condensed financial statements. Additionally, management is unable to estimate an amount or range of amounts related to any amount that may be owed should a recipient exercise a stock option.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;6 &#8212;&#160;Stockholders&#8217; Deficit</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Share Capital</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The Company has several series of common stock providing the following provisions. In the event of a bankruptcy or liquidation or winding up of the Company, the holders of Series&#160;B3 Common Stock will be entitled to receive, in advance of the holders of Series&#160;B2 Common Stock, Series&#160;B Common Stock and Series&#160;A Stock and Ordinary Stock, CHF 65 for each Series&#160;B3 Common Share they own.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Thereafter, the holders of Series&#160;B2 Common Stock will be entitled to receive, in advance of the holders of Series&#160;B Common Stock and Series&#160;A Stock and Ordinary Stock, CHF 60 for each Series&#160;B2 Common Share they own.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Thereafter, the holders of Series&#160;B Common Stock will be entitled to receive, in advance of the holders of Series&#160;A Common Stock and Ordinary Stock, CHF 50 for each Series&#160;B Common Share they own.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Thereafter, the holders of Series&#160;A Common Stock will be entitled to receive, in advance of the holders of Ordinary Stock, CHF 40 for each Series&#160;A Common Share they own.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Thereafter, the other Ordinary Shareholders will be entitled to receive CHF 40 per Ordinary Share they own and then any remaining assets or proceeds will be distributed pro rata among all Shareholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">If there are insufficient assets or proceeds to pay such amount to the holders of Series&#160;B3 Common Stock, the amount available will be paid on a pro rata basis between the holders of the Series&#160;B3 Common Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">If, after the full payment of Series&#160;B3 Shareholders, there are insufficient assets or proceeds to pay such amount to the holders of Series&#160;B2 Common Stock, the amount available will be paid on a pro rata basis between the holders of the Series&#160;B2 Common Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">If, after the full payment of Series&#160;B2 Shareholders, there are insufficient assets or proceeds to pay such amount to the holders of Series&#160;B Common Stock, the amount available will be paid on a pro rata basis between the holders of the Series&#160;B Common Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">If, after the full payment of Series&#160;B Shareholders, there are insufficient assets or proceeds to pay such amount to the holders of Series&#160;A Common Stock, the amount available will be paid on a pro rata basis between the holders of the Series&#160;A Common Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The Company and all Shareholders shall use best efforts to ensure that any sale, liquidation, disposal of material assets or the entire Company shall be effectuated so as to be tax efficient, particularly as regards any applicable withholding tax, and fair with regard to the Shareholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If in later financing rounds additional preference rights are granted, then the holders of Series&#160;A Common Stock, Series&#160;B Common Stock and Series&#160;B2 Common Stock shall receive mutatis mutandis behind the new stock the same rights (taking into account the respective price).&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Series&#160;B3 Common Stock shall have the same rights and obligations under the Shareholder&#8217;s Agreement and the Organizational Rules as the Series&#160;B Common Stock and the Series&#160;B2 Common Stock, and thus have the same legal status as the Series&#160;B Common Stock and the Series&#160;B2 Common Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-92</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">Proteomedix AG<br/>Notes to Condensed Financial Statements</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;6 &#8212;&#160;Stockholders&#8217; Deficit</span><span class="CharOverride-3" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of September&#160;30, 2023 and December&#160;31, 2022 the following number of stock for each series was outstanding:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">Share Class</span></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">Stock</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ordinary</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;A</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">65,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;B</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">84,200</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;B2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">83,334</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;B3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">80,038</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total Outstanding stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">412,572</p>
					</td>
				</tr>

		</table>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Stock options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company has granted various stock options primarily to employees as incentive<span class="nobreak">-based</span> compensation. During the nine&#160;months ended September&#160;30, 2023 and 2022, the Company granted 5,307 and <span class="nobreak">-0</span>-, respectively, stock options and recognized $161,573 and $282,742, respectively, in expense related to the vesting of outstanding stock option grants.</p>
		<p class="H7" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-decoration:underline;text-indent:0;widows:1;margin-top:12pt;"><span class="CharOverride-2" style="font-style:italic;font-weight:normal;text-decoration:underline;">Accumulated other comprehensive loss</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following tables details the amounts reclassified from other comprehensive loss and the related affected line items within the accompanying statements of comprehensive loss for the periods ended September&#160;30, 2022 and 2021.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 42.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">2023<br/>Amount</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">2022<br/>Amount</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">Financial statement<br/>line item</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 42.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">Item description</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 42.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amortization of gains (losses)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(24,876</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">General and administrative</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 42.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(24,876</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.64%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The table below details the components and the Company&#8217;s accumulated other comprehensive loss for the periods ended September&#160;30, 2023 and 2022.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">Defined<br/>Benefit<br/>Pension<br/>Items</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;"><br/>Foreign<br/>Currency<br/>Items</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance as of December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">397,709</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">33,968</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">431,677</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other comprehensive income before reclassifications</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">374,030</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">344,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">718,987</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amounts reclassified from accumulated other comprehensive income (loss)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net current period other comprehensive income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">369,287</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">344,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">714,244</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance as of September&#160;30, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">766,996</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">378,925</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,145,921</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance as of December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">577,601</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">28,982</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">606,583</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other comprehensive income (loss) before reclassifications</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(143,431</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">172,351</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">28,920</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amounts reclassified from accumulated other comprehensive income (loss)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(24,876</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(24,876</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net current period other comprehensive income (loss)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(168,307</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">172,351</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,044</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance as of September&#160;30, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">409,294</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">201,333</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">610,627</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-93</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">Proteomedix AG<br/>Notes to Condensed Financial Statements</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;7 &#8212;&#160;Defined Benefit Pension Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company sponsors a defined benefit pension plan covering certain eligible employees. The plan provides retirement benefits based on&#160;years of service and compensation levels.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The value of the pension obligation is determined using the Projected Unit Credit (PUC) method. This method sees each period of service as giving rise to an additional unit of benefit entitlements/employee benefits. The value of the Company&#8217;s employee benefit obligations for active employees, or the Projected Benefit Obligation (PBO), on the reporting date is the same as the present value of the degree of entitlement existing on this date, in terms of future salary and pension increases and turnover rates. The valuation of pension obligations of pensioners is made on the basis of the present value of current pensions taking into account future increases in pensions. The service costs (SC) are calculated using the present value of the entitlements to employee benefits earned during the year for which calculations are made.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following significant actuarial assumptions were used in calculating the benefit obligation and the net periodic benefit cost as of September&#160;30, 2023 and December&#160;31, 2022:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Discount rate</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.90</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.30</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected long-term rate of return on plan assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.30</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Rate of compensation increase</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.00</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.00</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Changes in these assumptions may have a material impact on the plan&#8217;s obligations and costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The components of net periodic benefit cost for the periods ended September&#160;30, 2023 and 2022 are as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Service cost</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">69,358</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">118,310</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest cost</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">31,506</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8,080</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected return on plan assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(25,640</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,166</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amortization of net (gain)/loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(24,876</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">50,348</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">115,481</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;8 &#8212;&#160;Related Parties</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of September&#160;30, 2023 and December&#160;31, 2022, the Company has outstanding convertibles notes of approximately $2,422,000 and $2,422,000, respectively, due to certain shareholders and directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the periods ended September&#160;30, 2023 and 2022, the Company paid approximately $127,500 and $183,400 to entities owned by members of the board of directors and executive management for professional services. These amounts are included within &#8216;general and administrative&#8217; expenses in the accompanying statements of comprehensive loss.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;9 &#8212;&#160;Subsequent Events</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2023, the Parent and the Company entered into a Share Exchange Agreement which resulted in the Company becoming a wholly owned subsidiary of the Parent. The consummation of the Share Exchange was subject to customary closing conditions and&#160;closed on December&#160;15, 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Concurrently with the closing of the Share Exchange Agreement, all outstanding convertibles notes as of December&#160;31, 2022 were converted into 83,114 common stock of the Company and were then purchased by the Parent.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-94</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<div style="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"></div>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:70pt;margin-top:70pt;"> </p>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:43pt;margin-top:43pt;">7,828,812 Shares of Common Stock</p>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">__________________</p>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">PROSPECTUS</p>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:70pt;margin-top:12pt;">__________________</p>
		<div style="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"></div>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PART&#160;II<br/>INFORMATION NOT REQUIRED IN PROSPECTUS</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Item&#160;13.&#160;Other Expenses of Issuance and Distribution.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Set forth below are estimates (except in the case of SEC registration fees) of the amount of fees and expenses to be incurred in connection with the issuance and distribution of the offered securities, other than underwriting discounts and&#160;commissions.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">SEC registration fee</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">128.51</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounting services</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Legal fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">75,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_bracket" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">*</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Miscellaneous</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">5,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">*</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">125,128.51</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Estimated</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Item&#160;14.&#160;Indemnification of Directors and Officers.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;145 of the DGCL inter alia, empowers a Delaware corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. Similar indemnity is authorized for such persons against expenses (including attorneys&#8217; fees) actually and reasonably incurred in connection with the defense or settlement of any such threatened, pending or completed action or suit if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and provided further that (unless a court of competent jurisdiction otherwise provides) such person shall not have been adjudged liable to the corporation. Any such indemnification may be made only as authorized in each specific case upon a determination by the stockholders or disinterested directors or by independent legal counsel in a written opinion that indemnification is proper because the indemnitee has met the applicable standard of conduct.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;145 further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise, against any liability asserted against him and incurred by him in any such capacity, or arising out of his status as such, whether or not the corporation would otherwise have the power to indemnify him under Section&#160;145. We maintain policies insuring our officers and directors against certain liabilities for actions taken in such capacities, including liabilities under the Securities Act.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;102(b)(7)&#160;of the DGCL permits a corporation to include in its certificate of incorporation a provision eliminating or limiting the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i)&#160;for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders, (ii)&#160;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&#160;under Section&#160;174 of the DGCL (relating to unlawful payment of dividends and unlawful stock purchase or redemption) or (iv)&#160;for any transaction from which the director derived an improper personal benefit.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Article&#160;6 of the bylaws of the Company contains provisions which are designed to provide mandatory indemnification of directors and officers of the Company to the full extent permitted by law, as now in effect or later amended. The bylaws further provide that, if and to the extent required by the DGCL, an advance payment of expenses to a director or officer of the Company that is entitled to indemnification will only be made upon delivery to the Company of an undertaking, by or on behalf of the director or officer, to repay all amounts so advanced if it is ultimately determined that such director is not entitled to indemnification.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Item&#160;16.&#160;Exhibits and Financial Statement Schedules.</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit&#160;No.</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">2.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/ea190395ex2-1_onconetix.htm">Share Exchange Agreement, dated December 15, 2023, by and among the Company, Proteomedix, Thomas Meier and the Sellers.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(21)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">3.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390022009250/ea156152ex3-1_bluewater.htm">Amended and Restated Certificate of Incorporation filed with Delaware Secretary of State on February&#160;23, 2022.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(3)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">3.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023031827/ea177344ex3-1_bluewater.htm">Certificate of Amendment to the Company&#8217;s Second Amended and Restated Certificate of Incorporation<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(11)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">3.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/ea190395ex3-1_onconetix.htm">Certificate of Amendment to the Company&#8217;s Second Amended and Restated Certificate of Incorporation.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(21)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">3.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/ea190395ex3-2_onconetix.htm">Fourth Amended and Restated Bylaws of the Company.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(21)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">4.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390021056861/fs12021a1ex4-1_bluewater.htm">Specimen Common Stock Certificate.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(1)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">4.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Description of Registered Securities</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">4.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000101376223000742/ea186204ex3-1_bluewater.htm">Certificate of Designation of Series A Preferred Stock.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(19)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">4.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/ea190395ex4-1_onconetix.htm">Certificate of Designation of Series B Convertible Preferred Stock.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(21)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">4.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023062922/ea182728ex4-1_bluewater.htm">Form of Inducement PIO.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(27)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390021052037/fs12021ex10-1_bluewater.htm">2019 Equity Incentive Plan.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(1)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390022000991/fs12022a5ex10-2_bluewater.htm">2022 Equity Incentive Plan.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(10)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390021052037/fs12021ex10-3_bluewater.htm">2019 Equity Incentive Plan Form of Stock Option Grant Agreement.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(1)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390022000991/fs12022a5ex10-4_bluewater.htm">2022 Equity Incentive Plan Form of Incentive Stock Option Agreement (Employee).<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(28)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390022000991/fs12022a5ex10-5_bluewater.htm">2022 Equity Incentive Plan Form of Nonstatutory Stock Option Agreement (Consultant).<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(28)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390022000991/fs12022a5ex10-6_bluewater.htm">2022 Equity Incentive Plan Form of Nonstatutory Stock Option Agreement (Non-Employee Director).<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(28)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390022000991/fs12022a5ex10-7_bluewater.htm">2022 Equity Incentive Plan Form of Nonstatutory Stock Option Agreement (Employee).<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(28)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390021056861/fs12021a1ex10-8_bluewater.htm">Exclusive License Agreement between the Registrant and Children&#8217;s Hospital Medical Center, d/b/a&#160;Cincinnati Children&#8217;s Hospital Medical Center, effective as of June&#160;1, 2021.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(2)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390021056861/fs12021a1ex10-9_bluewater.htm">License Agreement between the Registrant and Oxford University Innovation Limited, effective as of July&#160;16, 2019.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(2)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390021056861/fs12021a1ex10-10_bluewater.htm">Exclusive License Agreement between the Registrant and St. Jude Children&#8217;s Research Hospital, Inc., effective as of January&#160;27, 2020.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(2)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.11</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390021052037/fs12021ex10-11_bluewater.htm">Lease Agreement, dated as of April&#160;29, 2021, between the Registrant and Regus Management Group, LLC.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(1)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.12</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390021052037/fs12021ex10-12_bluewater.htm">Master Services Agreement between the Registrant and Ology Bioservices, Inc., effective as of July&#160;19, 2019.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(1)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.13</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390021052037/fs12021ex10-13_bluewater.htm">Project Addendum 1 to Master Services Agreement between the Registrant and Ology Bioservices, Inc., effective as of October&#160;9, 2019.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(1)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.14</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390021052037/fs12021ex10-14_bluewater.htm">Letter Agreement between the Registrant and Ology Bioservices, Inc., dated as of January 9, 2020.<span class="CharOverride-2" style="font-size:1pt;">&#160;</span><span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(1)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.15</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390021052037/fs12021ex10-15_bluewater.htm">Project Addendum&#160;II to Master Services Agreement between the Registrant and Ology Bioservices, Inc., effective as of May&#160;21, 2021.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(1)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.16</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390021052037/fs12021ex10-16_bluewater.htm">Form of Employment Agreement with Joseph Hernandez.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(1)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390021052037/fs12021ex10-17_bluewater.htm">Form of Employment Agreement with Erin Henderson.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(1)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.18</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="https://www.sec.gov/Archives/edgar/data/1782107/000121390021062397/fs12021a2ex10-18_bluewater.htm">Form of Employment Agreement with Jon Garfield.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(1)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023081324/ea186383ex10-1_bluewater.htm">Form of Employment Agreement with Neil Campbell.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(15)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023081324/ea186383ex10-2_bluewater.htm">Form of Employment Agreement with Bruce Harmon.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(15)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea020170101ex10-21_onconetix.htm">Form of Employment Agreement with Ralph Schiess.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(30)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.22</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea020170101ex10-22_onconetix.htm">Amendment to Employment Agreement, dated October 15, 2020, by and between Proteomedix and Ralph Schiess.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(30)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.23</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea020170101ex10-23_onconetix.htm">Amendment to Employment Agreement by and between Proteomedix and Ralph Schiess.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(30)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea020170101ex10-24_onconetix.htm">Form of Employment Agreement with Christian Br&#252;hlmann.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(30)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.25</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea020170101ex10-25_onconetix.htm">Amendment to Employment Agreement, dated October 16, 2020, by and between Proteomedix and Christian Br&#252;hlmann.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(30)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.26</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea020170101ex10-26_onconetix.htm">Amendment to Employment Agreement by and between Proteomedix and Christian Br&#252;hlmann.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(30)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.27</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023081324/ea186383ex99-1_bluewater.htm">General Release of Claims, dated October 5, 2023, by and between Jon Garfield and the Company.<span class="CharOverride-2" style="font-size:1pt;">&#160;</span><span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(15)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.28</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390024003413/ea191591ex99-1_onconetix.htm">Release, dated January 10, 2024, by and between the Company and Dr. Neil Campbell.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(22)</span></a></p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit&#160;No.</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.29</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023081324/ea186383ex10-3_bluewater.htm">Form of Indemnification Agreement for Directors and Officers.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(15)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.30</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390022020636/ea158617ex10-1_bluewater.htm">Form of Securities Purchase Agreement, dated as of April 13, 2022, by and among the Company and the Purchasers.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(5)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.31</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390022020636/ea158617ex10-2_bluewater.htm">Form of Registration Rights Agreement, dated as of April 13, 2022, by and among the Company and the Purchasers.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(5)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.32</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390022046943/ea164234ex10-1_bluewater.htm">Form of Securities Purchase Agreement, dated as of August 9, 2022, by and among the Company and the Purchasers.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(6)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.33</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390022046943/ea164234ex10-2_bluewater.htm">Form of Registration Rights Agreement, dated as of August 9, 2022, by and among the Company and the Purchasers.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(6)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.34</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390022072376/f10q0922ex10-3_bluewater.htm">Settlement Agreement and Release, dated October 9, 2022, by and between the Registrant and Boustead Securities, LLC.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(7)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.35</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390022026516/f10q0322ex10-1_bluewater.htm">Amendment No. 1 to Project Addendum 2 to Master Services Agreement, dated as of April 20, 2022, by and between the Registrant and Ology Bioservices, Inc.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(9)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.36</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390022026516/f10q0322ex10-2_bluewater.htm">Amendment #1 to Exclusive License Agreement, dated as of May 11, 2022, by and between the Registrant and St. Jude Children&#8217;s Research Hospital, Inc.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(9)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.37</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023039141/f10q0323ex10-1_bluewater.htm">Patent &amp; Technology License Agreement, dated November 18, 2022, between the Company and the University of Texas Health Science Center at San Antonio.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(14)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.38</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023039141/f10q0323ex10-2_bluewater.htm">Co-Development Agreement, dated February 1, 2023, between the Company and AbVacc, Inc.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(14)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.39</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023024177/ea175921ex1-1_bluewater.htm">At-the-Market Offering Agreement, dated March 29, 2023, between the Company and H.C. Wainwright &amp; Co., LLC.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(12)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.40</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023031189/ea177216ex10-1_bluewater.htm">Asset Purchase Agreement, dated April 19, 2023, between the Company and Veru Inc.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(13)&#8224;</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.41</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000101376223000742/ea186204ex10-1_bluewater.htm">Amendment to Asset Purchase Agreement, dated September 29, 2023, between the Company and Veru Inc.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(19)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.42</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023031189/ea177216ex10-2_bluewater.htm">Form of Non-Competition and Non-Solicitation Agreement, dated April 19, 2023.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(13)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.43</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023048740/ea180344ex10-1_bluewater.htm">Asset Purchase Agreement, dated June 13, 2023, by and among WraSer, Xspire, and the Company.<span class="CharOverride-2" style="font-size:1pt;">&#160;</span><span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(16)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.44</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023048740/ea180344ex10-2_bluewater.htm">Management Services Agreement, dated June 13, 2023, by and among WraSer, Xspire and the Company.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(16)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.45</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000101376223005521/f10q0623ex10-14_bluewater.htm">Form of Amendment, dated October 5, 2023, to Asset Purchase Agreement, dated June 13, 2023, by and among WraSer, Xspire, Legacy-Xspire Holdings, LLC, and the Company.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(17)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.46</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023088387/f10q0923ex10-6_bluewater.htm">Exclusive Distribution Agreement, dated September 20, 2023, between the Company and Cardinal Health 105, LLC.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(20)</span>&#8224;</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.47</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/ea190395ex10-1_onconetix.htm">Form of Lock-Up Agreement, dated December 15, 2023, by and among the Company and certain stockholders of Proteomedix.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(21)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.48</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/ea190395ex10-2_onconetix.htm">Form of Non-Competition and Non-Solicitation Agreement, dated December 15, 2023, by and among the Company and certain stockholders of Proteomedix.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(21)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.49</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/ea190395ex10-3_onconetix.htm">Form of Stockholder Support Agreement, dated December 15, 2023, by and among the Company, Proteomedix, and certain stockholders of Proteomedix.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(21)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.50</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/ea190395ex10-4_onconetix.htm">Form of Subscription Agreement, dated December 15, 2023, by and among the Company, Proteomedix, and the PMX Investor.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(21)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.51</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390024004855/ea191886ex10-1_onconetix.htm">Separation Agreement, dated January 17, 2024, between the Company and Erin Henderson.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(23)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.52</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390024004855/ea191886ex10-2_onconetix.htm">Consulting Agreement, dated January 17, 2024, between the Company and The Aetos Group.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(23)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.53</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390024007414/ea192391ex10-1_onconetix.htm">Debenture, dated January 23, 2024 issued to the PMX Investor.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(24)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.54</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390024012608/ea193470ex10-1_onconetix.htm">Consulting Agreement, dated January 4, 2024, by and between the Company and Thomas Meier.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(25)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.55</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea020170101ex10-55_onconetix.htm">License Agreement, dated March 27, 2023, between Proteomedix and Laboratory Corporation of America Holdings.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(30)</span>&#8224;#</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.56</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023061642/ea182607ex10-1_bluewater.htm">Form of Inducement Letter.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(26)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.57</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390023062922/ea182728ex10-1_bluewater.htm">Form of Letter Agreement.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(27)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.58</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390024036645/ea020475101ex10-2_oncone.htm">Amendment to Debenture, dated April 24, 2024, issued to the PMX Investor.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(29)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">10.59</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390024036645/ea020475101ex10-1_oncone.htm">Forbearance Agreement, dated April 24, 2024, by and between the Company and Veru Inc.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(29)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">14</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390021062397/fs12021a2ex14_bluewater.htm">Code of Ethics.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(2)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea020170101ex-19_onconetix.htm">Insider Trading Policy, adopted August 7, 2023<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(30)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea020170101ex-21_onconetix.htm">List of Subsidiaries.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(30)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">23.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="ea020378801ex23-1_onconetix.htm">Consent of Mayer Hoffman McCann P.C.*</a></p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit&#160;No.</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">23.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="ea020378801ex23-2_onconetix.htm">Consent of EisnerAmper LLP.*</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">23.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="ea020378801ex23-3_onconetix.htm">Consent of BDO AG</a>.*</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">97</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea020170101ex97_onconetix.htm">Policy Related to Recovery of Erroneously Awarded Compensation, adopted January 17, 2024.<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">(30)</span></a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">101.INS*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">XBRL Instance Document.*</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">101.SCH*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">XBRL Taxonomy Schema Linkbase Document.*</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">101.CAL*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">XBRL Taxonomy Calculation Linkbase Document.*</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">101.DEF*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">XBRL Taxonomy Definition Linkbase Document.*</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">101.LAB*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">XBRL Taxonomy Labels Linkbase Document.*</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">101.PRE*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">XBRL Taxonomy Presentation Linkbase Document.*</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">104*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Cover Page Interactive Data File (Embedded as Inline XBRL document and contained in Exhibit 101).</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Filed herewith.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">&#8224;<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation&#160;S<span class="nobreak">-K</span> Item&#160;601(a)(5). The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">#<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Certain portions of this exhibit (indicated by &#8220;[***]&#8221; have been omitted pursuant to Item&#160;601(b)(10)(iv)&#160;of Regulation&#160;S<span class="nobreak">-K</span> as we have determined they (1)&#160;are not material and (2)&#160;are the type that the Company treats as private or confidential. The Registrant hereby agrees to furnish a copy of any omitted portion to the SEC upon request.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Registration Statement on Form&#160;S<span class="nobreak">-1</span>, filed with the SEC on October&#160;8, 2021.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Registration Statement on Form&#160;S<span class="nobreak">-1</span>/A, filed with the SEC on November&#160;5, 2021.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Current Report on Form&#160;8<span class="nobreak">-K</span>, filed with the SEC on February&#160;24, 2022.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Registration Statement on Form&#160;S<span class="nobreak">-1</span>/A, filed with the SEC on November&#160;29, 2021.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Current Report on Form&#160;8<span class="nobreak">-K</span>, filed with the SEC on April&#160;19, 2022.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(6)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Current Report on Form&#160;8<span class="nobreak">-K</span>, filed with the SEC on August&#160;11, 2022.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(7)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Quarterly Report on Form&#160;10<span class="nobreak">-Q</span>, filed with the SEC on November&#160;14, 2022.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(8)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Annual Report on Form&#160;10<span class="nobreak">-K</span>, filed with the SEC on March&#160;31, 2022.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(9)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Quarterly Report on Form&#160;10<span class="nobreak">-Q</span>, filed with the SEC on May&#160;13, 2022.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(10)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Registration Statement on Form&#160;S<span class="nobreak">-1</span>/A, filed with the SEC on January&#160;6, 2022.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(11)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Current Report on Form&#160;8<span class="nobreak">-K</span> filed with the SEC on April&#160;24, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(12)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Current Report on Form&#160;8<span class="nobreak">-K</span> filed with the SEC on March&#160;29, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(13)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Current Report on Form&#160;8<span class="nobreak">-K</span> filed with the SEC on April&#160;20, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(14)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Quarterly Report on Form&#160;10<span class="nobreak">-Q</span> filed with the SEC on May&#160;12, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(15)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Current Report on Form&#160;8<span class="nobreak">-K</span> filed with the SEC on October&#160;10, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(16)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Current Report on Form&#160;8<span class="nobreak">-K</span> filed with the SEC on June&#160;14, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(17)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Quarterly Report on Form&#160;10<span class="nobreak">-Q</span> filed with the SEC on October&#160;20, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(18)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Current Report on Form&#160;8<span class="nobreak">-K</span>, filed with the SEC on June&#160;6, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(19)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Current Report on Form&#160;8<span class="nobreak">-K</span> filed with the SEC on October&#160;3, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(20)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Quarterly Report on Form&#160;10<span class="nobreak">-Q</span> filed with the SEC on November&#160;17, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(21)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Current Report on Form&#160;8<span class="nobreak">-K</span> filed with the SEC on December&#160;21, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(22)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Current Report on Form&#160;8<span class="nobreak">-K</span> filed with the SEC on January&#160;12, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(23)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Current Report on Form&#160;8<span class="nobreak">-K</span> filed with the SEC on January&#160;19, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(24)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Current Report on Form&#160;8<span class="nobreak">-K</span> filed with the SEC on January&#160;29, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(25)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Current Report on Form&#160;8<span class="nobreak">-K</span> filed with the SEC on February&#160;12, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(26)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Current Report on Form&#160;8<span class="nobreak">-K</span> filed with the SEC on August&#160;1, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(27)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Current Report on Form&#160;8<span class="nobreak">-K</span> filed with the SEC on August&#160;3, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(28)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Registration Statement on Form&#160;S<span class="nobreak">-1</span>/A filed with the SEC on January&#160;6, 2022.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(29)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Current Report on Form 8<span class="nobreak">-K</span> filed with the SEC on April 26, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:0pt;">(30)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incorporated by reference to the Company&#8217;s Annual Report on Form 10<span class="nobreak">-K</span> filed with the SEC on April 11, 2024.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Item&#160;17.&#160;Undertakings.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:6.5pt;">The undersigned registrant hereby undertakes:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;">(1)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>That, for the purpose of determining any liability under the Securities Act&#160;of&#160;1933, each such post<span class="nobreak">-effective</span> amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;">(2)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>To remove from registration by means of a post<span class="nobreak">-effective</span> amendment any of the securities being registered which remain unsold at the termination of the offering.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;">(3)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>That, for the purpose of determining liability under the Securities Act&#160;of&#160;1933 to any purchaser:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:7pt;margin-top:6.5pt;">(i)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>If the registrant is relying on Rule&#160;430B:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-left:96pt;margin-top:7pt;margin-top:6.5pt;">(A)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Each prospectus filed by the registrant pursuant to Rule&#160;424(b)(3)&#160;shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-left:96pt;margin-top:7pt;margin-top:6.5pt;">(B)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Each prospectus required to be filed pursuant to Rule&#160;424(b)(2), (b)(5), or (b)(7)&#160;as part of a registration statement in reliance on Rule&#160;430B relating to an offering made pursuant to Rule&#160;415(a)(1)(i), (vii), or (x)&#160;for the purpose of providing the information required by section 10(a)&#160;of the Securities Act&#160;of&#160;1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule&#160;430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; or</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:7pt;margin-top:6.5pt;">(ii)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>If the registrant is subject to Rule&#160;430C, each prospectus filed pursuant to Rule&#160;424(b)&#160;as part of a registration statement relating to an offering, other than registration statements relying on Rule&#160;430B or other than prospectuses filed in reliance on Rule&#160;430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:7pt;margin-top:6.5pt;">Insofar as indemnification for liabilities arising under the Securities Act&#160;of&#160;1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act&#160;of&#160;1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act&#160;of&#160;1933 and will be governed by the final adjudication of such issue.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T501"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">SIGNATURES</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the requirements of the Securities Act&#160;of&#160;1933, as amended, the Registrant certifies that it has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cincinnati, Ohio, on April<span class="nobreak"> </span>26, 2024.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ONCONETIX, INC.</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Bruce Harmon</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Bruce Harmon</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Chief Financial Officer</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">KNOW ALL PERSONS BY THESE PRESENTS that each individual whose signature appears below hereby constitutes and appoints Bruce Harmon as his or her true and lawful attorney<span class="nobreak">-in-fact</span> and agent with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post<span class="nobreak">-effective</span> amendments, to this registration statement, and to sign any registration statement for the same offering covered by this registration statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act of 1933 increasing the number of shares for which registration is sought, and all post<span class="nobreak">-effective</span> amendments thereto, and to file the same, with all exhibits thereto and all documents in connection therewith, making such changes in this registration statement as such attorney<span class="nobreak">-in-fact</span> and agent so acting deem appropriate, with the SEC, granting unto said attorney<span class="nobreak">-in-fact</span> and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done with respect to the offering of securities contemplated by this registration statement, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney<span class="nobreak">-in-fact</span> and agent, or his, her or their substitute or substitutes, may lawfully do or cause to be done or by virtue hereof.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the requirements of the Securities Act&#160;of&#160;1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Signature</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 42.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Title</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.08%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Date</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Ralph Schiess</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 42.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Interim Chief Executive Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;">April<span class="nobreak"> </span>26, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Ralph Schiess</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 42.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">(Principal Executive Officer)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Bruce Harmon</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 42.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Chief Financial Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;">April<span class="nobreak"> </span>26, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Bruce Harmon</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 42.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">(Principal Financial and Accounting Officer)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ James Sapirstein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 42.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Chairman of the Board and Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;">April<span class="nobreak"> </span>26, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">James Sapirstein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 42.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Thomas Meier</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 42.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;">April<span class="nobreak"> </span>26, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Thomas Meier</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 42.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Timothy Ramdeen</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 42.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:8pt;text-align:center;">April<span class="nobreak"> </span>26, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Timothy Ramdeen</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 42.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Ajit Singh</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 42.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;">April<span class="nobreak"> </span>26, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Ajit Singh</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 42.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Simon Tarsh</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 42.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;">April<span class="nobreak"> </span>26, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:1;">Simon Tarsh</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 42.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-6</p>



</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentType">S-1/A</ix:nonNumeric>
<ix:nonFraction contextRef="c2" id="hidden-fact-1" name="us-gaap:AccountsReceivableNetCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-2" name="us-gaap:InventoryNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-3" name="us-gaap:OtherReceivablesNetCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-4" name="us-gaap:DeferredCosts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-5" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-7" name="us-gaap:Goodwill" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-8" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-9" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-10" name="us-gaap:LongTermNotesPayable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-11" name="onco:SubscriptionAgreementLiabilityNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-12" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-13" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-14" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-15" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-16" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-17" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-18" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-19" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-20" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-21" name="us-gaap:MinorityInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-22" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-23" name="us-gaap:CostOfRevenue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-24" name="us-gaap:GrossProfit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-25" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-26" name="us-gaap:OtherAssetImpairmentCharges" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-27" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-28" name="us-gaap:InterestExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-29" name="onco:ChangeInFairValueOfSubscriptionAgreementLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-30" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-31" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" decimals="2" id="hidden-fact-32" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">1.10</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-33" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">2.19</ix:nonFraction>
<ix:nonFraction contextRef="c9" decimals="INF" id="hidden-fact-34" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">12271449</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="INF" id="hidden-fact-35" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">17111374</ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-36" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-37" name="onco:ChangeInPensionBenefitObligation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-38" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-39" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c14" id="hidden-fact-40" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-41" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-42" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-43" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-44" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-45" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-46" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-47" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-48" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-49" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-50" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-51" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c27" id="hidden-fact-52" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-53" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c26" id="hidden-fact-54" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-55" name="onco:StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-56" name="onco:StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-57" name="onco:StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-58" name="onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-59" name="onco:StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-60" name="onco:StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-61" name="onco:StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-62" name="onco:StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-63" name="onco:StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-64" name="onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-65" name="onco:StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-66" name="onco:StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-67" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-68" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-69" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-70" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-71" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-72" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-73" name="onco:ExerciseOfPrefundedWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-74" name="onco:ExerciseOfPrefundedWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-75" name="onco:ExerciseOfPrefundedWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-76" name="onco:ExerciseOfPrefundedWarrantsinShares" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-77" name="onco:ExerciseOfPrefundedWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-78" name="onco:ExerciseOfPrefundedWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-79" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-80" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-81" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-82" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-83" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-84" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-85" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-86" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-87" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-88" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-89" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-90" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-91" name="onco:PurchaseOfTreasuryShares" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-92" name="onco:PurchaseOfTreasuryShares" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-93" name="onco:PurchaseOfTreasuryShares" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-94" name="onco:PurchaseOfTreasurySharesinShares" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-95" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-96" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-97" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-98" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-99" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-100" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-101" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c28" id="hidden-fact-102" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c29" id="hidden-fact-103" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c29" id="hidden-fact-104" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-105" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-106" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c31" id="hidden-fact-107" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c31" id="hidden-fact-108" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-109" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-110" name="onco:IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-111" name="onco:IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-112" name="onco:IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-113" name="onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-114" name="onco:IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-115" name="onco:IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-116" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-117" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-118" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-119" name="us-gaap:StockIssuedDuringPeriodSharesOther" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-120" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-121" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-122" name="onco:StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-123" name="onco:StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-124" name="onco:StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-125" name="onco:StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-126" name="onco:StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-127" name="onco:StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-128" name="onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-129" name="onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-130" name="onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-131" name="onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-132" name="onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-133" name="onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-134" name="onco:StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-135" name="onco:StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-136" name="onco:StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-137" name="onco:StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-138" name="onco:StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-139" name="onco:StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-140" name="onco:StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-141" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-142" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-143" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-144" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-145" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-146" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-147" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-148" name="onco:ExerciseOfPrefundedWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-149" name="onco:ExerciseOfPrefundedWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-150" name="onco:ExerciseOfPrefundedWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-151" name="onco:ExerciseOfPrefundedWarrantsinShares" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-152" name="onco:ExerciseOfPrefundedWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-153" name="onco:ExerciseOfPrefundedWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c45" id="hidden-fact-154" name="onco:ExerciseOfPrefundedWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-155" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-156" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-157" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-158" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-159" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-160" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c45" id="hidden-fact-161" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-162" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-163" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-164" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-165" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-166" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c45" id="hidden-fact-167" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-168" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-169" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-170" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-171" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-172" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-173" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-174" name="onco:PurchaseOfTreasuryShares" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-175" name="onco:PurchaseOfTreasuryShares" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-176" name="onco:PurchaseOfTreasuryShares" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-177" name="onco:PurchaseOfTreasurySharesinShares" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-178" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-179" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-180" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-181" name="onco:OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-182" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-183" name="onco:OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-184" name="onco:StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-185" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-186" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-187" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-188" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-189" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-190" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-191" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c46" id="hidden-fact-192" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c49" id="hidden-fact-193" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c50" id="hidden-fact-194" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c50" id="hidden-fact-195" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-196" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-197" name="us-gaap:OtherAssetImpairmentCharges" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-198" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-199" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-200" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-201" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-202" name="onco:GainLossOnRelatedPartyReceivable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-203" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-204" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-205" name="us-gaap:InventoryWriteDown" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-206" name="us-gaap:AdjustmentOfWarrantsGrantedForServices" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-207" name="us-gaap:PensionExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-208" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-209" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-210" name="us-gaap:IncreaseDecreaseInInventories" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-211" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-212" name="us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-213" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-214" name="us-gaap:PaymentsToAcquireIntangibleAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-215" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-216" name="us-gaap:RepaymentsOfNotesPayable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-217" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-218" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-219" name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-220" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-221" name="us-gaap:ProceedsFromWarrantExercises" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-222" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-223" name="us-gaap:NoncashOrPartNoncashAcquisitionInventoryAcquired1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-224" name="onco:EffectOfBusinessCombination" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-225" name="us-gaap:ConversionOfStockAmountIssued1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-226" name="us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-227" name="onco:WarrantsIssuedForSettlementOfContingentWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-228" name="onco:DeferredOfferingCostsPreviouslyPrepaid" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-229" name="onco:IssuanceOfRestrictedStock" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-230" name="onco:RestrictedStockForfeitures" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-231" name="onco:PaymentOfAccruedBonusThroughRelatedPartyReceivable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-232" name="us-gaap:DebtConversionConvertedInstrumentAmount1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c69" id="hidden-fact-233" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c70" id="hidden-fact-234" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c72" id="hidden-fact-235" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-236" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c76" id="hidden-fact-237" name="us-gaap:NoncurrentAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c77" id="hidden-fact-238" name="us-gaap:DerivativeLiabilitiesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c78" id="hidden-fact-239" name="us-gaap:DerivativeLiabilitiesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c77" id="hidden-fact-240" name="onco:SubscriptionAgreementLiabilityNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c78" id="hidden-fact-241" name="onco:SubscriptionAgreementLiabilityNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c77" id="hidden-fact-242" name="us-gaap:OtherLiabilitiesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c78" id="hidden-fact-243" name="us-gaap:OtherLiabilitiesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c80" id="hidden-fact-244" name="us-gaap:DerivativeLiabilitiesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c81" id="hidden-fact-245" name="us-gaap:DerivativeLiabilitiesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c83" id="hidden-fact-246" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c86" id="hidden-fact-247" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c96" id="hidden-fact-248" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c98" id="hidden-fact-249" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"/>
<ix:nonNumeric contextRef="c66" id="hidden-fact-250" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P2Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c67" id="hidden-fact-251" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P10Y</ix:nonNumeric>
<ix:nonFraction contextRef="c2" id="hidden-fact-252" name="us-gaap:InventoryRawMaterials" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-253" name="us-gaap:InventoryWorkInProcess" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-254" name="us-gaap:InventoryFinishedGoods" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-255" name="us-gaap:InventoryNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-256" name="us-gaap:PrepaidRent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-257" name="onco:PrepaidProfessionalFees" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c105" id="hidden-fact-258" name="onco:ImpairmentOfIntangibleAssetExcludingGoodwill" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c108" id="hidden-fact-259" name="onco:ImpairmentOfIntangibleAssetExcludingGoodwill" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c105" id="hidden-fact-260" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c105" id="hidden-fact-261" name="onco:FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-262" name="us-gaap:Goodwill" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-263" name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-264" name="us-gaap:AccruedMarketingCostsCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" id="hidden-fact-265" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">P13Y6M</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" id="hidden-fact-266" name="onco:BusinessTransactionYeare">P5Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c148" id="hidden-fact-267" name="onco:CommercialSaleTerm">P10Y</ix:nonNumeric>
<ix:nonFraction contextRef="c309" id="hidden-fact-268" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c309" id="hidden-fact-269" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c313" id="hidden-fact-270" name="onco:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c313" id="hidden-fact-271" name="onco:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-272" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-273" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonNumeric contextRef="c216" id="hidden-fact-274" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P6M</ix:nonNumeric>
<ix:nonNumeric contextRef="c236" id="hidden-fact-275" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P4Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c267" id="hidden-fact-276" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P5Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" id="hidden-fact-277" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P5Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c292" id="hidden-fact-278" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P11Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" id="hidden-fact-279" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">P4Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c292" id="hidden-fact-280" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">P5Y131D</ix:nonNumeric>
<ix:nonNumeric contextRef="c292" id="hidden-fact-281" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">P5Y73D</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" id="hidden-fact-282" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">P4Y193D</ix:nonNumeric>
<ix:nonNumeric contextRef="c296" id="hidden-fact-283" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">P1Y288D</ix:nonNumeric>
<ix:nonNumeric contextRef="c297" id="hidden-fact-284" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">P1Y208D</ix:nonNumeric>
<ix:nonNumeric contextRef="c292" id="hidden-fact-285" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">P2Y357D</ix:nonNumeric>
<ix:nonFraction contextRef="c3" id="hidden-fact-286" name="us-gaap:OtherReceivablesNetCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-287" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-288" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-289" name="us-gaap:DeferredTaxAssetsOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-290" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-291" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-292" name="us-gaap:DeferredTaxLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-293" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-294" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-295" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-296" name="onco:IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-297" name="onco:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-298" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-299" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-300" name="us-gaap:UnrecognizedTaxBenefits" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-301" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-302" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-303" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" id="hidden-fact-304" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList">http://fasb.org/us-gaap/2023#DefinedBenefitPensionPlanLiabilitiesNoncurrent</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-31894">true</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-31895">0001782107</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="onco-20231231.xsd" xlink:type="simple"/></ix:references>
<ix:resources><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesBConvertibleRedeemablePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesBConvertibleRedeemablePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesSeedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesSeedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesSeedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesSeedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesSeedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">onco:OnconetixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">onco:ProteomedixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-02-23</xbrli:startDate>
    <xbrli:endDate>2022-02-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-02-23</xbrli:startDate>
    <xbrli:endDate>2022-02-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-23</xbrli:startDate>
    <xbrli:endDate>2024-01-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">onco:SubscriptionAgreementLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">onco:SubscriptionAgreementLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">onco:SubscriptionAgreementLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">onco:ContingentWarrantLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">onco:ContingentWarrantLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">onco:ContingentWarrantLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">onco:ContingentWarrantLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">onco:ContingentWarrantLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onco:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onco:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onco:CommonStockIssuableUponConversionOfSeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onco:CommonStockIssuableUponConversionOfSeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:ProteomedixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:ENTADFIMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onco:ENTADFIMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">onco:AssetPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-04-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">onco:ENTADFIMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-04-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">onco:ENTADFIMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">onco:MilestonePaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">onco:MilestonePaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-04-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-04-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">onco:PharmaceuticalServicesLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-03</xbrli:startDate>
    <xbrli:endDate>2023-10-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:ENTADFIMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">onco:ManagementServicesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">onco:WraSerAPAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">onco:WraSerAPAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">onco:BankruptcyCourtMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">onco:WraSerMSAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-15</xbrli:startDate>
    <xbrli:endDate>2023-12-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-15</xbrli:startDate>
    <xbrli:endDate>2023-12-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">onco:PMXTransactionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">onco:ProteomedixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">onco:FairValueConsiderationTransferredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">onco:AggregateConsiderationTransferredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">onco:AssetsRecognizedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">onco:MeasurementInputStockPriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">onco:BusinessAcquisitionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">onco:ProteomedixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">onco:PMXTransactionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">onco:PMXTransactionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:OlogyBioservicesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:OlogyBioservicesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-21</xbrli:startDate>
    <xbrli:endDate>2021-05-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:OlogyBioservicesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:OlogyBioservicesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:OlogyBioservicesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:CincinnatiChildrensHospitalMedicalCenterMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">onco:RegulatoryMilestonesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">us-gaap:CommercialAndIndustrialSectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-01-01</xbrli:startDate>
    <xbrli:endDate>2018-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:OUIAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-01-01</xbrli:startDate>
    <xbrli:endDate>2018-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-01-01</xbrli:startDate>
    <xbrli:endDate>2018-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">onco:DevelopmentMilestonesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-12-31</xbrli:startDate>
    <xbrli:endDate>2018-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">onco:RegulatoryMilestonesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-12-31</xbrli:startDate>
    <xbrli:endDate>2018-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">us-gaap:CommercialAndIndustrialSectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-12-31</xbrli:startDate>
    <xbrli:endDate>2018-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:StJudeChildrensHospitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:StJudeChildrensHospitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb4i4f4wUs/dKlMHRtjt5HiP056YCLyrdSoyPYyQevay5dOg9LR2t/KvbZBYGbO0fRFqRMXruICW071VL4cva1Vo1fRqEHdR31R1aena1W/oLM7lTmOCBLWaZ9ZWyZBU9clRPWAm3ygSKlPhipMHX/wTZ1GpdAQuF5X0Rk/U0peMoZ1GlWBL0QwQ4YYjsaQQj5y1OiFHDkpk+TSIy2jKBgVC6BuLNzQw2d0OQvqtBvmxiw3I1GgCSekvILJhH3efW/nXGhkP0cqcGFqX5dsI+8P] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">onco:DevelopmentMilestonesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:StJudeChildrensHospitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">onco:RegulatoryMilestonesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:StJudeChildrensHospitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">us-gaap:CommercialAndIndustrialSectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:StJudeChildrensHospitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:UTHealthAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:UniversityOfTexasHealthScienceCenterAtSanAntonioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:UniversityOfTexasHealthScienceCenterAtSanAntonioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">onco:DevelopmentMilestonesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:UniversityOfTexasHealthScienceCenterAtSanAntonioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">us-gaap:CommercialAndIndustrialSectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:UniversityOfTexasHealthScienceCenterAtSanAntonioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-01</xbrli:startDate>
    <xbrli:endDate>2023-02-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-01</xbrli:startDate>
    <xbrli:endDate>2023-02-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:CoDevelopmentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:VendorAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-29</xbrli:startDate>
    <xbrli:endDate>2023-07-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:LaboratorCorporationOfAmericaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:AssetPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:AssetPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:AssetPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:AssetPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:NotePayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:AssetPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-09-29</xbrli:startDate>
    <xbrli:endDate>2023-09-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">onco:ProteomedixAcquisitionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-02-17</xbrli:startDate>
    <xbrli:endDate>2022-02-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2022-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2022-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">onco:TreasuryStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-11-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">onco:TreasuryStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-10</xbrli:startDate>
    <xbrli:endDate>2022-11-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">onco:TreasuryStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-18</xbrli:startDate>
    <xbrli:endDate>2022-11-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">onco:TreasuryStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">onco:TreasuryStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">onco:TreasuryStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">onco:TreasuryStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:April2022PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:April2022PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:April2022PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-30</xbrli:startDate>
    <xbrli:endDate>2022-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:April2022PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-30</xbrli:startDate>
    <xbrli:endDate>2022-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:AprilContingentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:AprilContingentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-30</xbrli:startDate>
    <xbrli:endDate>2022-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:AprilContingentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:April2022PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:April2022PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:August2022PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:August2022PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-31</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-30</xbrli:startDate>
    <xbrli:endDate>2022-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:August2022PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:August2022PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:August2022PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:August2022PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:August2022PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:August2022PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-31</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:AugustWainwrightWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:AugustWainwrightWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-31</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:AugustContingentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:AugustContingentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-31</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:AugustContingentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:August2022PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-30</xbrli:startDate>
    <xbrli:endDate>2022-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-31</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:AugustContingentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:AugustContingentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">onco:MarketOfferingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-29</xbrli:startDate>
    <xbrli:endDate>2023-03-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-29</xbrli:startDate>
    <xbrli:endDate>2023-03-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onco:WarrantInducementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-11</xbrli:startDate>
    <xbrli:endDate>2022-08-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c260">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-31</xbrli:startDate>
    <xbrli:endDate>2023-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c261">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-31</xbrli:startDate>
    <xbrli:endDate>2023-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c262">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-02</xbrli:startDate>
    <xbrli:endDate>2023-08-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c263">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c264">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c265">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:InducementPIOSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c266">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c267">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c268">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onco:April2022PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c269">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onco:August2022PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c270">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onco:August2022PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c271">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onco:TwoThousandNinteenEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c272">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onco:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c273">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onco:TwoThousandTwentyTwoPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c274">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onco:TwoThousandTwentyTwoPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c275">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onco:TwoThousandTwentyTwoPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c276">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-10-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c277">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c278">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c279">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onco:ChiefBusinessOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c280">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c281">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c282">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-09</xbrli:startDate>
    <xbrli:endDate>2023-05-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c283">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-09</xbrli:startDate>
    <xbrli:endDate>2023-05-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c284">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onco:ChiefBusinessOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-09</xbrli:startDate>
    <xbrli:endDate>2023-05-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c285">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-09</xbrli:startDate>
    <xbrli:endDate>2023-05-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c286">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onco:January2024Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-09</xbrli:startDate>
    <xbrli:endDate>2023-05-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c287">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onco:August2024Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-09</xbrli:startDate>
    <xbrli:endDate>2023-05-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c288">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onco:August2025Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-09</xbrli:startDate>
    <xbrli:endDate>2023-05-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c289">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-31</xbrli:startDate>
    <xbrli:endDate>2023-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c290">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-16</xbrli:startDate>
    <xbrli:endDate>2023-08-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c291">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-04</xbrli:startDate>
    <xbrli:endDate>2023-10-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c292">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onco:PMXOptionPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c293">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onco:PMXOptionPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c294">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c295">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">onco:UnvestedRestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c296">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c297">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">onco:UnvestedRestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c298">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onco:ChiefBusinessOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c299">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">onco:OriginalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c300">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">onco:ExchangedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c301">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">onco:OriginalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c302">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">onco:ExchangedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c303">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c304">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c305">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-01</xbrli:startDate>
    <xbrli:endDate>2022-08-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c306">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-31</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c307">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c308">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-31</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c309">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c310">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c311">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c312">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-31</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c313">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c314">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c315">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c316">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c317">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c318">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c319">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c320">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c321">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">onco:ResearchAndDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c322">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">onco:ResearchAndDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c323">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-01</xbrli:startDate>
    <xbrli:endDate>2022-05-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c324">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">onco:SettlementAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2022-10-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c325">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2022-10-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c326">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c327">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c328">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c329">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c330">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">onco:CEOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c331">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">onco:CBOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c332">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c333">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c334">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:NonConvertibleDebentureMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c335">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingIncomeLossMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c336">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c337">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-15</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c338">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">onco:AccumulatedBenefitObligationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c339">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">onco:AccumulatedBenefitObligationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-15</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c340">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">onco:AccumulatedBenefitObligationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c341">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">onco:PlanAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c342">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">onco:PlanAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-15</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c343">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">onco:PlanAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c344">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:NonConvertibleDebentureMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c345">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:SubscriptionAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c346">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c347">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-10</xbrli:startDate>
    <xbrli:endDate>2024-01-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="chf">
  <xbrli:measure>iso4217:CHF</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ea020378801ex23-1_onconetix.htm
<DESCRIPTION>CONSENT OF MAYER HOFFMAN MCCANN P.C.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the inclusion in this Amendment No. 1 to the Registration Statement on Form S-1 and related prospectus of our report
dated March 8, 2023, with respect to the consolidated financial statements of Onconetix, Inc. (formerly known as Blue Water Vaccines
Inc.) (the &ldquo;Company&rdquo;) as of and for the year ended December 31, 2022, and to the reference to us under the heading
&ldquo;Experts&rdquo; in the prospectus which is part of this Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Mayer Hoffman McCann P.C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los
Angeles, California</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
26, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>ea020378801ex23-2_onconetix.htm
<DESCRIPTION>CONSENT OF EISNERAMPER LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We consent to the inclusion
in this Amendment No. 1 to the Registration Statement of Onconetix Inc. on Form S-1 (No. 333-277066) to be filed on or about Aprill 26,
2024 of our report dated April 11, 2024, on our audit of the financial statements as of December 31, 2023 and for the year then ended.
Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company's ability to continue as
a going concern. We also consent to the reference to our firm under the caption &ldquo;Experts&rdquo; in this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>/s/ EisnerAmper LLP</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">EISNERAMPER LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Iselin, New Jersey</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">April 26, 2024</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>4
<FILENAME>ea020378801ex23-3_onconetix.htm
<DESCRIPTION>CONSENT OF BDO AG
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 23.3</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-left: 5.65pt; font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 40%; font-size: 10pt"><IMG SRC="ex23-3_001.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="width: 28%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone&#9;+41 44 444 35 55</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">www.bdo.ch</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">zurich@bdo.ch</P></TD>
    <TD STYLE="width: 22%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BDO Ltd</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Schiffbaustrasse 2</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8031 Zurich</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>Consent of Independent Registered
Public Accounting Firm</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the use in the Prospectus
constituting a part of Onconetix Inc.'s Registration Statement of our report dated February 14, 2024, relating to the financial statements
of Proteomedix AG for the years ended December 31, 2022 and 2021, which is contained in that Prospectus. Our report contains an explanatory
paragraph regarding Proteomedix AG&rsquo;s ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also consent to the reference to us under
the caption &ldquo;Experts&rdquo; in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Christoph Tschumi</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 20%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Marc Furlato</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BDO
    AG</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zurich,
    Switzerland</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; layout-grid-mode: line">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    23, 2024</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; layout-grid-mode: line">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BDO Ltd, a limited company under Swiss law, incorporated
in Zurich, forms part of the international BDO Network of independent member firms.</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>timage_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_001.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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M]U[W[KW7O?NO=>]^Z]T /RO_ .R6ODI_X@'N/_WG<C[%O(/_ "7=M_Y[[/\
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MXJEWI6[7CH*O:,%=4@4Z5-11RQ)(ZO4""F2HJ(/=>Z/COG^8+MGK+^8[TO\
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MW7NB2?RTYX*7^??_ ,*&ZFIFBIZ:GB_E[SU%1/((D1(M@Y!G=W8A515!))(
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MPOE=\E.B*/;.T,UW]WB/XEL+9.R<AN&CAJJ_;R[HAVAN"@S&4V]-*:/)3/\
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M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM/W^6/\3OBQ\H/YQ_\
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M]U[KWOW7NO>_=>Z][]U[HIGSM_[(^^0W_B-LS_O:>Q][6_\ *Q;?_P ],?\
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M9]KG*/R4:QQP_;S!JA_=>Z07\Q_^0G\/OYD?>&Q/D_O#?'?_ ,??DCL'%83
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M[KW7O?NO=>]^Z]U[W[KW7O?NO=4H?%[_ +>X_+W_ ,1MN?\ ]VNRO>3'._\
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M/:?<?5_<G1>\,IU?O7";UH,'L+(8K,5&&F:44U2^&,O@F5T1HY0C E2H(^A
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MRNUXUV3@\SEX,>ZT]/.\T>/GD(K6GTZ%]U[H[U-_-ZVEU]_*@J?YG?RN^/\
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M6:!R\=1!35E1)11U,3:3',*7R1LBM&RN"Q.]^]W^8.8X6MKBZ*Q."'2)$BU
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M]U[KWOW7NJ4/B]_V]Q^7O_B-MS_^[797O)CG?_IWNT_\],?_ %;O>L8^2/\
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MPLE4E<U)/4Q(\U*T\=HYC3R,T9=1I?3J7@CW[KW3E[]U[KWOW7NB>]\_+?\
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M58]"=H4^8KL"U>^7\7\/2?\ BF/J8OM?.:BP63Q^-M7OW7NNOBW\S^@_F/\
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M358GK+;[STJVFHL?M])*FD)=B8*Y&;]QI&;W7NJL?Y@/QT^)/6O\_;<G:?\
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M^/KNE_%)$V,?'"KB=7:6)(HW=?=>ZU.]Z]/=Q]4?R:OY/.;[XV+D>K^Q>_\
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MH]ZUM+G<:F)QN2H(15?;544M,DR22T_NO=%F_GL_#O(_&C^6AWSV9\Q?YO\
M\WN]-\9W;%%L;J+IW/[XVWTML_=^[<]64>FDFV5M#!T$VX(*:DCK*QZ2HR-1
M2TE-%+53AO"L@]U[HW&Y</\ RY>T_P"4#_(Z^,?\Q2FW1BL+\BOCY\)MJ_'K
MLW;==5;,;:V_<5U?@),;D$W=%-!2[=KIX*B>&E^Y,L=86DB^VF"-H]U[HL?S
M7V#_ ##_ .0+UELOY._'W^9MVY\T_C_2]J]<=>O\'OFICH.T=S;I??N26E?'
M[4WM3E\T:T0,C4])0XFG6E"356BL0?9/[KW1V=XS25'_  JYZ.J):>6DEG_D
MB5\TE).59XFE[7W6QC<HS(70D@Z6(N."1S[]U[H,_P#A.!VYUI/W)_.QZ)3<
M^'C[?Q/\V7Y2=K5FSIJB."OEV[N?)C$T>1@B9A+4TL61PV0BF**RT[M%Y"IJ
M8]?NO=+JBR./^0?_  J:_O7U'44.X-L_#'^6"O5?R'WEMS)M614FY.Q]X9W(
MXC:.4:.ODH_-#195*^*%*-*E9XZL51<4T I_=>Z@?R+O^/N_X4)?^-B_G'_[
MDU'OW7NJ3,!_W S;W_\ #HI/_@J</[]U[J[[^9[F<3MGO7_A-_N/<62H<%M^
ME^8NU,159S+U*8^DBJMQ['@I,?3R5,I6%)JVJ=8H$9PTKG2@)]^Z]T9K_A0'
M\=]Q]X_R]LIWSTR(*GO_ .!786QOGG\?LQ10394G)_'^9LI7P1I1NLU7%58/
M^(ND*/:6IAI6%GC1E]U[HHO\OKMW:7\WK^;=O#^8OM3_ '._&GX-_$KJ?I#X
MW5%33TE72CL7Y1X6'=>_\E2NVNMH\UMW!Y"/;>1C=(G0N86",LR/[KW6T-[]
MU[KWOW7NO>_=>Z][]U[K5-^4']P?^@L7XE?Z2?[H?W9_X:0SGD_OQ]E]AYO[
MZ=G^'5]__D_EO?1?U7OI]^Z]U9Y_,;PW\IK*?#3OVI^7E-\4CTWC.M=USY;)
M5,>WAE*6H>DD%$VVI:#3F4W-)6+3IC$QCC(35I@BI0\SHA]U[K6BW_F.],[_
M ,(D=RY+O^LW+D-R2X3IV/9-?NZ0SUTVSJ?Y!;13:;M(Y,TE(,*M*M"TA+&@
M6FTDQ^,GW7NK+.XMQ8KXU_SVOY37R,[JRU/MWHSY ?RV,K\-NN]X[CG-!A</
MV+19"IW#%!/75/\ D%#D-S4.6QN-I%\D4]7):$-(J:![KW1KO^%,';O7.Q_Y
M2/R'ZIW/1T6[^R?DO-U[TIT/U13T\.:S.XMU9O<V&J:'^"XDI-55]9AC2G(I
M]O3O-'-30B$I4/ ??NO="WV__+@^67=F ^.]7L'^9M\H?ABG6_QEZDZEW?U?
MTMBL)F<77YW9\-2V0S]1/DUDJ&R-4*N&DDLQ0PT,##U,Q]^Z]U57_.7Z [-^
M-7PZ_E5=:=M_)[M#Y=;NC_GM?#O.OV_V_14=!F9*;+8K>W@QSQT!^U%/0^)Q
M$45;ASJ!:[-[KW1J=]_]Q8?2_P#XQ,RO_OV=V>_=>ZX_\*"54]R?R&W*J77^
M=C\/E5K<@/E4) /U )47_K8?T]^Z]UR^?7_<1S_(0_\ $:?S&O\ WV69]^Z]
MTV=)[BQ7QQ_X4S_.O;?=.6I\!4?/OXH?&?=_Q,S.Y9SCZ;))T7B:/;^Y-IX6
MIJK15&4>NH*_*R4-++K,4;5#PLS!_?NO=2O^%&^]-J;VVG_+R^&NUJ2CWI\F
M^]_YC/QEW5U3LO$I%E<SB,;UM75<V=WB*:-9*ZAQN-HZEZ6HKD6)(J:KJGDF
M6FBJK>Z]UAJ*."J_X5ET,\REI,=_);>LI2&*VD?L^:G)('ZAXIY!8\7(/U ]
M^Z]U/_X4N?\ ,G?Y5_\ XVS^#_\ [J]^>_=>Z4?_  JM_P"W'ORN_P##H^./
M_OQ]J^_=>Z-I_."_[<J_.C_Q2/L'_P!T'OW7NJF>TOG/\B_C+_*Z_P"$^'QC
M^+6\MF]']L?S >B/AOT12_*7LW::;MP'7U!2]<;+2JKDIZP?P>IW/72Y>E&'
MHJ\M#6FGK$$=T,T'NO= E_/9^'>1^-'\M#OGLSYB_P W_P";W>F^,[MBBV-U
M%T[G]\;;Z6V?N_=N>K*/323;*VA@Z";<$%-21UE8])49&HI:2FBEJIPWA60>
MZ]TL?G_D*'"?\)J/Y1NX\Q5P8S;^V,1_)NW!N/-5T@IJ6@H<=A=KF>LK)VM'
M3TT((UR.RHMQ<\CW[KW1OO\ A2;DL?END_Y5==BJ^BR5#-_.S^$'AK,?5)61
M/IQ>_ =,D;,C6/!L??NO=/.V=U83HW_A3EW#C>UX:?:P^9'\NCK/'?&S>6=:
M.@H\WD>H\^HW!M7%UE3XQ49LQ0OD)*"F>204U-%43HOEI]7NO=6K?(;Y]=3?
M'KY,_$OXDU^#W7V'W7\NMU;APVU=I=>?89.JP&)VI2?>9'=NY*>IK:66AVS2
M1+*KU*+++)*C1T\$Y24Q>Z]U3IVC\&_Y?O\ ,I^=/RYW1\6?D]\M/@C_ #%O
MCGNW:>PODIO'XZ]A5/4&0W!)14"'"Y3*;=JI'_O#@FI8J9(LC2I0PUBQ1J\T
MZD,WNO=*;^6/\D_GWU;_ #-/D-_*A^7?R'VI\]-N=2?&?;WR)V_\L,#UW3=9
MYK!5.7S&.QD.S]W8_'2U6.%?7TV0EJZ=)*V:N2*E$IFJHJB7['W7NMDSW[KW
M7O?NO=,VX\'1;GV]G=M9(2'';APV4P=>(G,;>'+0/3RZ6'*MXY&L1]#S[]U[
MK5V_X3I=V[7^(>S.ZOY+7R3W;MSKSY5?#'OWM>CZ]V_NFK3:LN_]B]@9%]PX
MG=>W8JJ9HJT5E1D:Z9J.EJJF:GHI:*:7F23Q^Z]U9;_.$_FE[-_EJ_&O-9S:
M-=M'?OS#[%FQNR_BE\;YX9MWY?=>YL_64=%3:MMXO(4&=K<+1/61/6-2SPR/
MKAI*>7[VKI8Y/=>ZK:^967[.W!_.7_X3,Y[NK;FWMG=OYOK_ .;N8[0VAM.N
MGRF,Q.?R?6>)GRV,H*JJ5*BII:"N>:".:1%>58Q(54MI'NO="C\!?^XCG^??
M_P"(T_ER_P#OLL-[]U[KW_"?;_F<7\^/_P ;9_,/_P!VC>_=>ZX[#55_X5B=
MU%552_\ ).Q3.0+7([8VD+G^IL /]8 ?CW[KW577\NCK??';7_".SOS877&#
MR6YMYY;KWY>5V'V[A:6:OK:X;;W=D<I4TE%34\<M15UE1244Z04\<;//*4A4
M%G'OW7NMH/\ EK_)#I#M[^6K\3N]=B;NVCCNJL;\9.L8,]7'-T%+1;:FV!M^
MCH<[B<I-#-]ECI]N5='54M9&TB+3M P.E0#[]U[JF/Y??SP^SN[.B?@M1_ =
M:WXP9'^8Q\Q-^?%?8?RT^1FPZ+.X+;^%ZYK:'%UF\<)2M4U.(KJC<%?D57;4
M&6\39%:*N#T<17RP^Z]T6/\ GL_#O(_&C^6AWSV9\Q?YO_S>[TWQG=L46QNH
MNG<_OC;?2VS]W[MSU91Z:2;96T,'03;@@IJ2.LK'I*C(U%+24T4M5.&\*R#W
M7NH_S5_[=9?\).__ !:_^35_[[JG]^Z]UNF^_=>Z SY-]![,^4_QW[M^-_8<
M#3[+[PZPWIUEN QL4DAAW=0348JH&4ADJ:.25)X7!NDL:,.1[]U[K2?VEW;V
ME\W/@Y_+Q_D)[]RLTOR/I/FIO[X??/2FQ$6=4T'5G\N>L@S64E:OE>EJX4S>
M!EV53T>0=_MZZ>*KAB6&4F"G]U[K;5_F4_*FO_EZ?R]?D=\G^ONOX]X9;H+J
MVFJ=B;%HL34UE$*NMJZ'!XIJRFH-$Z8+$SUU/4Y!HWC$&.IZB4RQ)&9$]U[J
MI'J+XL?)WO[X;;+^9GSS_GH_(W;'678/4N'^0W8<7Q$R>Q_BYL;;VW]R4,6;
MEQ5%NV@P-5GY<7BZ27[23(C(TU7.J,P\4[:C[KW50G\HZOV_E?\ A,__ #Y<
MIM+*9K-[5R7<O\Q2OVSFMR5,];D:S'UG4&QI**JKYJG_ "F6MJ*9HY)WE_<:
M5F:3U$^_=>Z'?YE_]N.O^$QW_B[G\H[_ -X#=/OW7NK&^E\[A?C?_P *8_G)
MM[N;/4V#J_G_ /$CXT[T^*.5W-(<=35_^@O&TVW-R;/PE54DQ565DJ\=6YB2
MAII4?PHT[P,Q61O=>Z??YO\ W;U6W\RG^15\>(LWB,AW1_L[M?VW48&EDBJJ
MW&;=QVVLABC-6!;RT<66K\A3_;JY45/V4[*&^W)7W7NF[??_ '%A]+_^,3,K
M_P"_9W9[]U[I4?R?]Q8&B_F*?S[]FUF:Q=)NW_9Z.O\ < VS55T5/7FASNU'
M^RK%I'99VIJO[2I\4@0I((G*DA3[]U[HI/SC[\VY_)%_FP?(7YDYE(*#HK^9
M)\&.P=R5>+DIYH::M[S^%6)^XVWC35-(F/I)-SX&J-)3Q.4>KR5=*4;RNPE]
MU[JV+^1O\3]P?$S^7)TMB^R8IY>_N^WS?RL^2N;R-'2TF0K][_(&1<WD#DS2
M 135V,H)<9BY'U-<4"A2J!47W7NK=??NO=4H?%[_ +>X_+W_ ,1MN?\ ]VNR
MO>3'._\ T[W:?^>F/_JW>]8Q\D?]/&W?_GD?_C]CU=?[QGZR<Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z 'Y7_\
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M3BMN4T='C\9C,?1QPTE!CZ"DAA@IZ>"%(8(42*)%154>Z]TH/?NO=%,^=O\
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MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T /RO\
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M]D_^A;7_ /U-[-/^!AM/^4^;_G"G_0?13_P55U_T;XO^RA_^M77O^'P>Q_\
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MYO\ G"G_ $'U[_@JKK_HWQ?]E#_]:NO?\/@]C_\ /A]D_P#H6U__ -3>_?\
M PVG_*?-_P X4_Z#Z]_P55U_T;XO^RA_^M77O^'P>Q_^?#[)_P#0MK__ *F]
M^_X&&T_Y3YO^<*?]!]>_X*JZ_P"C?%_V4/\ ]:NO?\/@]C_\^'V3_P"A;7__
M %-[]_P,-I_RGS?\X4_Z#Z]_P55U_P!&^+_LH?\ ZU=>_P"'P>Q_^?#[)_\
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MX&&T_P"4^;_G"G_0?7O^"JNO^C?%_P!E#_\ 6KKW_#X/8_\ SX?9/_H6U_\
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MJZ_Z-\7_ &4/_P!:NO?\/@]C_P#/A]D_^A;7_P#U-[]_P,-I_P I\W_.%/\
MH/KW_!577_1OB_[*'_ZU=>_X?!['_P"?#[)_]"VO_P#J;W[_ (&&T_Y3YO\
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M_H6U_P#]3>_?\##:?\I\W_.%/^@^O?\ !577_1OB_P"RA_\ K5U[_A\'L?\
MY\/LG_T+:_\ ^IO?O^!AM/\ E/F_YPI_T'U[_@JKK_HWQ?\ 90__ %JZ]_P^
M#V/_ ,^'V3_Z%M?_ /4WOW_ PVG_ "GS?\X4_P"@^O?\%5=?]&^+_LH?_K5U
M[_A\'L?_ )\/LG_T+:__ .IO?O\ @8;3_E/F_P"<*?\ 0?7O^"JNO^C?%_V4
M/_UJZ]_P^#V/_P ^'V3_ .A;7_\ U-[]_P ##:?\I\W_ #A3_H/KW_!577_1
MOB_[*'_ZU=(?L[^<5O[LWK7L+K>LZ5VABJ3L'8^[-D563IMT5M1)31[KH*B@
M>>.-J=5=X5J"ZJ2 2 "0#[--C^[I:[)>V]ZM[*YMYXIPIB0!C%(L@!(<T!TT
MKT4[]]Y6YWVQN+%K&-!<030%Q.Q*B6-H]0'ABM-5:5ST%WQ<_F=[R^+_ %)C
M>IL-U7MG==#CLQF\NF8R>X*K'RLV;F\S(8XH70",\ ZN1]?9[SU[(6_/.XMN
M$EU)$S(B:%C5@-"Z:U+#CT1\A>_4_(NVIMR6<<P1I&UM,R$^(Q;@$;A7UZ,3
M_P /@]C_ //A]D_^A;7_ /U-[!W_  ,-I_RGS?\ .%/^@^AE_P %5=?]&^+_
M +*'_P"M77O^'P>Q_P#GP^R?_0MK_P#ZF]^_X&&T_P"4^;_G"G_0?7O^"JNO
M^C?%_P!E#_\ 6KKW_#X/8_\ SX?9/_H6U_\ ]3>_?\##:?\ *?-_SA3_ *#Z
M]_P55U_T;XO^RA_^M77O^'P>Q_\ GP^R?_0MK_\ ZF]^_P"!AM/^4^;_ )PI
M_P!!]>_X*JZ_Z-\7_90__6KKW_#X/8__ #X?9/\ Z%M?_P#4WOW_  ,-I_RG
MS?\ .%/^@^O?\%5=?]&^+_LH?_K5U[_A\'L?_GP^R?\ T+:__P"IO?O^!AM/
M^4^;_G"G_0?7O^"JNO\ HWQ?]E#_ /6KKW_#X/8__/A]D_\ H6U__P!3>_?\
M##:?\I\W_.%/^@^O?\%5=?\ 1OB_[*'_ .M77O\ A\'L?_GP^R?_ $+:_P#^
MIO?O^!AM/^4^;_G"G_0?7O\ @JKK_HWQ?]E#_P#6KKW_  ^#V/\ \^'V3_Z%
MM?\ _4WOW_ PVG_*?-_SA3_H/KW_  55U_T;XO\ LH?_ *U=>_X?!['_ .?#
M[)_]"VO_ /J;W[_@8;3_ )3YO^<*?]!]>_X*JZ_Z-\7_ &4/_P!:NO?\/@]C
M_P#/A]D_^A;7_P#U-[]_P,-I_P I\W_.%/\ H/KW_!577_1OB_[*'_ZU=>_X
M?!['_P"?#[)_]"VO_P#J;W[_ (&&T_Y3YO\ G"G_ $'U[_@JKK_HWQ?]E#_]
M:NO?\/@]C_\ /A]D_P#H6U__ -3>_?\  PVG_*?-_P X4_Z#Z]_P55U_T;XO
M^RA_^M77O^'P>Q_^?#[)_P#0MK__ *F]^_X&&T_Y3YO^<*?]!]>_X*JZ_P"C
M?%_V4/\ ]:NO?\/@]C_\^'V3_P"A;7__ %-[]_P,-I_RGS?\X4_Z#Z]_P55U
M_P!&^+_LH?\ ZU=>_P"'P>Q_^?#[)_\ 0MK_ /ZF]^_X&&T_Y3YO^<*?]!]>
M_P""JNO^C?%_V4/_ -:NO?\ #X/8_P#SX?9/_H6U_P#]3>_?\##:?\I\W_.%
M/^@^O?\ !577_1OB_P"RA_\ K5U[_A\'L?\ Y\/LG_T+:_\ ^IO?O^!AM/\
ME/F_YPI_T'U[_@JKK_HWQ?\ 90__ %JZ]_P^#V/_ ,^'V3_Z%M?_ /4WOW_
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M]>_X*JZ_Z-\7_90__6KKW_#X/8__ #X?9/\ Z%M?_P#4WOW_  ,-I_RGS?\
M.%/^@^O?\%5=?]&^+_LH?_K5U[_A\'L?_GP^R?\ T+:__P"IO?O^!AM/^4^;
M_G"G_0?7O^"JNO\ HWQ?]E#_ /6KKW_#X/8__/A]D_\ H6U__P!3>_?\##:?
M\I\W_.%/^@^O?\%5=?\ 1OB_[*'_ .M77O\ A\'L?_GP^R?_ $+:_P#^IO?O
M^!AM/^4^;_G"G_0?7O\ @JKK_HWQ?]E#_P#6KKW_  ^#V/\ \^'V3_Z%M?\
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M#Z%?_!577_1OB_[*'_ZU=>_X?!['_P"?#[)_]"VO_P#J;W[_ (&&T_Y3YO\
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M_H6U_P#]3>_?\##:?\I\W_.%/^@^O?\ !577_1OB_P"RA_\ K5U[_A\'L?\
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M?\##:?\ *?-_SA3_ *#Z]_P55U_T;XO^RA_^M77O^'P>Q_\ GP^R?_0MK_\
MZF]^_P"!AM/^4^;_ )PI_P!!]>_X*JZ_Z-\7_90__6KKW_#X/8__ #X?9/\
MZ%M?_P#4WOW_  ,-I_RGS?\ .%/^@^O?\%5=?]&^+_LH?_K5U[_A\'L?_GP^
MR?\ T+:__P"IO?O^!AM/^4^;_G"G_0?7O^"JNO\ HWQ?]E#_ /6KKW_#X/8_
M_/A]D_\ H6U__P!3>_?\##:?\I\W_.%/^@^O?\%5=?\ 1OB_[*'_ .M77O\
MA\'L?_GP^R?_ $+:_P#^IO?O^!AM/^4^;_G"G_0?7O\ @JKK_HWQ?]E#_P#6
MKKW_  ^#V/\ \^'V3_Z%M?\ _4WOW_ PVG_*?-_SA3_H/KW_  55U_T;XO\
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M_P#4WOW_  ,-I_RGS?\ .%/^@^O?\%5=?]&^+_LH?_K5U[_A\'L?_GP^R?\
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M"G_0?7O^"JNO^C?%_P!E#_\ 6KKW_#X/8_\ SX?9/_H6U_\ ]3>_?\##:?\
M*?-_SA3_ *#Z]_P55U_T;XO^RA_^M77O^'P>Q_\ GP^R?_0MK_\ ZF]^_P"!
MAM/^4^;_ )PI_P!!]>_X*JZ_Z-\7_90__6KKW_#X/8__ #X?9/\ Z%M?_P#4
MWOW_  ,-I_RGS?\ .%/^@^O?\%5=?]&^+_LH?_K5U[_A\'L?_GP^R?\ T+:_
M_P"IO?O^!AM/^4^;_G"G_0?7O^"JNO\ HWQ?]E#_ /6KKW_#X/8__/A]D_\
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M "GS?\X4_P"@^O?\%5=?]&^+_LH?_K5U[_A\'L?_ )\/LG_T+:__ .IO?O\
M@8;3_E/F_P"<*?\ 0?7O^"JNO^C?%_V4/_UJZ]_P^#V/_P ^'V3_ .A;7_\
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M0^0?7_2^7ZEVMMC'[S_O7]QG,=N*KKYH/[NX3)95-$4L"(_E>A6,W865R1R
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M_'>@V_E>?]D+='?^5,_][#<'L\]\_P#E:K[_ *AO^T2WZ#_L/_RJEC_U$_\
M:9<='\]Q+U+W7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U2A\7O^WN/R]_\1MN?_W:[*]Y,<[_ /3O=I_YZ8_^K=[UC'R1
M_P!/&W?_ )Y'_P"/V/5U_O&?K)SKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+U\N/^R4?DY_XKUW1_P"\WDO?
MNO=41?\ "9SY%?'W8G\D?X4;4WQWKTWLW=&*_P!F/_BFV]U]G83;U?3??=M[
M]J8//1UE=#40^:GFAE37&-<;HZW5E)]U[HK'S%[H^.GRI_X44_R@(?@5OC87
M;7=G3<'R*K?FAV1T/54^ZZ2BV5245)'CL1NG<V%2IQ\WV4D.ZZ4T=17.U'59
M.DII%@GR-,LGNO=&P[-_FX_S ^QOY@?SH_EF_!?XL]$;W[U^.$_3>?V%VAW5
MNO.X/9]'M;=6V(<QN7+[O_AS1SS9*GS&8VUC<1C:&LIY:Q:JLK7?PXZ=#[KW
M0G]Q?S._G5ANPOCG_+PZ*^.O0/8O\V3LCX_/W[\B<9N'>68P_3?5.%1I:(93
M*Y&DDJ=P9R*7,/1TT5!0U/W#++&[5"?<TOD]U[J)MS^9/_,-^&7R*^-?0_\
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MO^CA?40!'7;%J'D!'T)+4T5C]18V^I]^Z]UCZ3W%BOCC_P *9_G7MONG+4^
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M)]U[HS?;7\E3YA]X=1;XZ+[._G5_*C>'578>S\EL7=>QLI\?^L:>@K,7DX#
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M^<#?];>O?\/!?,3_ )7>M?\ T!A_]5^_?\#MR[Z7/_.8?] =>_X)7F/TM/\
MG W_ %MZ]_P\%\Q/^5WK7_T!A_\ 5?OW_ [<N^ES_P YA_T!U[_@E>8_2T_Y
MP-_UMZ]_P\%\Q/\ E=ZU_P#0&'_U7[]_P.W+OI<_\YA_T!U[_@E>8_2T_P"<
M#?\ 6WKW_#P7S$_Y7>M?_0&'_P!5^_?\#MR[Z7/_ #F'_0'7O^"5YC]+3_G
MW_6WKW_#P7S$_P"5WK7_ - 8?_5?OW_ [<N^ES_SF'_0'7O^"5YC]+3_ )P-
M_P!;>O?\/!?,3_E=ZU_] 8?_ %7[]_P.W+OI<_\ .8?] =>_X)7F/TM/^<#?
M];>O?\/!?,3_ )7>M?\ T!A_]5^_?\#MR[Z7/_.8?] =>_X)7F/TM/\ G W_
M %MZ]_P\%\Q/^5WK7_T!A_\ 5?OW_ [<N^ES_P YA_T!U[_@E>8_2T_YP-_U
MMZ]_P\%\Q/\ E=ZU_P#0&'_U7[]_P.W+OI<_\YA_T!U[_@E>8_2T_P"<#?\
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M/9.-H<-LWJWYB?'[KO:>)Q=#'BZ:EQNRNJNS<;0T\%-"!%3PQ4U-$J1H J*
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MN<KME8VOJ>N^W:*.BR&Z8J%L%1U<E;DL=3K#-7I(TU531!2\\2M[KW0$]O\
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M*KQV:KZ+(N<Q&F%@I,]%2O61,:A,_IHZFLBA>IE]U[IK_P"$X_Q[_F2_%/\
ME-?/[%;&^+5?US\MJ_O.3=G2O4/S?ZBW3UGA]TPT^U]OP5--+1U\VUJZ6FKH
MH:ZEIZA:V.D%:JQ5,J1>9T]U[JLGY4=9];?+CX_9KK;>?_":GYD]+?S8,A29
MK8Z=F_&'H3/]2=4#=U?6^$[G=L=5Q82MPM0$6O=JS$UM+'&\ICSLE([9.3W7
MNMX3^3U\;>]/B#_+/^(7QO\ DGN"/</='5O6<^(W<T-:F23&1Y/+9+(XG;B5
M,4DL-0FU,+6X["K+%(T,@H \),3)[]U[JF'_ (5\[ WPOP)^/?R>V'C</D:[
MXA_,+K'LS./EJ-ZE8*+/P5F*I9',6B0TDFXY=OPSQ"HA\@E0AP\:>_=>ZS?\
M*N>I>Y/F?_*M^-"_%'ICMOY%Y;._+OIKM>FVWT=USE^V\DFWLGUSV+HS$M%M
MZDR-0F-67*XZ)JHI]N):F"/R:IHPWNO=%1ZV_G:?SR#TYL7XW],_\)]ODSM+
MLG"]68'J[8W:G;&W=]X? TM;M7"QT-/E\I%F=B;6Q,40-*)O!4;II(VD*P"I
M9F4-[KW5D7\C?^7#V'_)X^$?R.[R^4>$W!V5\MN],KE^].\]J=,8&J[BS\E/
MLVGKY\'M/$4V%I)JK<6X)9Z_*U$B4<<L#9#)/!!))!"*J3W7NM?C?7\H'^9K
M_.2P'S<_FQ_(;#=Z?%GY>;;SN.;^7A\7,_AZCJS+PX?I:H>OIL7+2YE:/-8*
M6:.\&#JQ48QI]PFKS,W^15<,C^Z]UM"_ '^8+WMV=_*G[([U^?O0/=_Q@[Z^
M,W3'8P[\A[SZ:W!T_%GX^N-O55?_ 'OPT>=Q>'BJJ?-T5/Y:J"ENM)D/N*90
ML/V[R>Z]T3G_ (2"]!93I[^4;0;_ ,U!7TU5\EOD#VIW%C8*^!Z4IC,1'C-F
MT9C1U4F&HDVK55,<ECY4J%96:/1[]U[K:5]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW3/)N' 19N#;,N<P\6Y*JA.3IMOR9.%*Z2F5G0U"4A<3
MO &CD'D$96ZL+W4V]U[IX]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T /RO\ ^R6ODI_X@'N/_P!YW(^Q
M;R#_ ,EW;?\ GOL_^TB/H(>X/_) W+_I7WG_ &CR=%,_E)?]D9[7_P##UW[_
M .YQ]C[[P/\ RLLW_-&#_JV.@#]WO_E6(/\ FK<?]76ZLQ]PIU-O6C+\C?\
MLH7OC_Q,W:'_ +O*[WU#Y,_Y(]A_SQVO_5A.N5'//_);W#_GNN_^K\G0,^Q+
MT%NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZNW_ )8/S[W-M+<.U/C'V:N;
MW7LW<5?38'K'-4=)/FJ_"U-4=,..EBB62>HPLAX0A6:@_/\ D=_ML9/?#VG@
MOX9=\L=$4T:F2Y0E4291Q<$T E'F/]$_T_QY4>PWN]/931;#?ZYHI"([610S
MR0L>$;  DQ>A_P!"\_T_[.F;^97W-0? S_A0GU!WSV?0&?9>[MG]X5%'5U&3
MI<3$E-G]FXK&PR&HJY8*= :_%R1!7E4LS>FY(!PRZS8..M\G;N?Q6Z<%B-QX
M.MI,CB<YC*#+8^MH:J.MBDAR4*3Q.DL+/%(KQ2(P97*L""I((/OW7NGGW[KW
M7S'O^%:GQ?R'7OS^Z0[2W-59*IZV[8V3G*[-Y3%XMXGH89M]96>NCBJ:B):!
MJF"FSU,R"2<*&*&2R2*3[K0/1J?@M_PE ^$_S@^+W3?R.VC\X.[*(=G=?X#=
MV6VWC=L;2SAQ=5D_-%444DE+53V,%72U40#E7_;*L ZNJ^ZWUN8_RR?Y?6T/
MY9?Q7P'Q8V/V'N3L_ 8#=.[]T0;JW7BJ7#UDC[OK9*V6)X:-FA"0O(54@W(
MOS[]U[JP?W[KW58'\YC_ +=M?([_ %^H/_>\VO[V.M'K08_GB?\ ,SOY7O\
MVK^D_P#WD.JO>NM];M'\VCX-4WS[_EC9_IFEFBQNZ:+>>Q=Y[9RB[?7/2B;
M;E:":+0L$]2L9H,A7F\2Z@?U$1M)?W7NM,7^6]_-[/Q9_E%?S)OBWOIFB[:Q
M.+?8G3Z56\/X3*T69V_!M&L2*CK,E3Y,&BAQWD$=%!92VAU"C3[]UKCU:K_)
M$^"4W0?\G?N'Y&;Q\A[([9W?N+$2Q5F#-#/!C*??&QL='$:BJHX:^1&EVMY
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MPW_&+_[@?WA_O5_IYP,&$_XO?\;H?X'_  KP>;_BT9#[G5X_\GMY#[KW7/\
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MGCNS_2[_ *4_]G;^;7<7S%_A_P#<'^Y']V?]+%4:G^[GE_C68_C7\/OI^_\
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MG7O^!PY:_AN?^<Y_Z!Z]_P ,Y_$+_CKVO_Z&M/\ _6WW[_@BN8O^77_G"?\
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M;??O^"*YB_Y=?^<)_P"MG7O^!PY:_AN?^<Y_Z!Z]_P ,Y_$+_CKVO_Z&M/\
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MY_$+_CKVO_Z&M/\ _6WW[_@BN8O^77_G"?\ K9U[_@<.6OX;G_G.?^@>O?\
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M9S^(7_'7M?\ ]#6G_P#K;[ ?_!%<Q?\ +K_SA/\ ULZD#_@<.6OX;G_G.?\
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MT_\ ];??O^"*YB_Y=?\ G"?^MG7O^!PY:_AN?^<Y_P"@>O?\,Y_$+_CKVO\
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M_K9U[_@<.6OX;G_G.?\ H'KW_#.?Q"_XZ]K_ /H:T_\ ];??O^"*YB_Y=?\
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MW[_@BN8O^77_ )PG_K9U[_@<.6OX;G_G.?\ H'KW_#.?Q"_XZ]K_ /H:T_\
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M]_PSG\0O^.O:_P#Z&M/_ /6WW[_@BN8O^77_ )PG_K9U[_@<.6OX;G_G.?\
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MT_\ ];??O^"*YB_Y=?\ G"?^MG7O^!PY:_AN?^<Y_P"@>O?\,Y_$+_CKVO\
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MQ_\ X9S^(7_'7M?_ -#6G_\ K;[AG_@BN8O^77_G"?\ K9U-?_ X<M?PW/\
MSG/_ $#U[_AG/XA?\=>U_P#T-:?_ .MOOW_!%<Q?\NO_ #A/_6SKW_ X<M?P
MW/\ SG/_ $#U[_AG/XA?\=>U_P#T-:?_ .MOOW_!%<Q?\NO_ #A/_6SKW_ X
M<M?PW/\ SG/_ $#U[_AG/XA?\=>U_P#T-:?_ .MOOW_!%<Q?\NO_ #A/_6SK
MW_ X<M?PW/\ SG/_ $#U[_AG/XA?\=>U_P#T-:?_ .MOOW_!%<Q?\NO_ #A/
M_6SKW_ X<M?PW/\ SG/_ $#U[_AG/XA?\=>U_P#T-:?_ .MOOW_!%<Q?\NO_
M #A/_6SKW_ X<M?PW/\ SG/_ $#U[_AG/XA?\=>U_P#T-:?_ .MOOW_!%<Q?
M\NO_ #A/_6SKW_ X<M?PW/\ SG/_ $#U[_AG/XA?\=>U_P#T-:?_ .MOOW_!
M%<Q?\NO_ #A/_6SKW_ X<M?PW/\ SG/_ $#U[_AG/XA?\=>U_P#T-:?_ .MO
MOW_!%<Q?\NO_ #A/_6SKW_ X<M?PW/\ SG/_ $#U[_AG/XA?\=>U_P#T-:?_
M .MOOW_!%<Q?\NO_ #A/_6SKW_ X<M?PW/\ SG/_ $#U[_AG/XA?\=>U_P#T
M-:?_ .MOOW_!%<Q?\NO_ #A/_6SKW_ X<M?PW/\ SG/_ $#U[_AG/XA?\=>U
M_P#T-:?_ .MOOW_!%<Q?\NO_ #A/_6SKW_ X<M?PW/\ SG/_ $#U[_AG/XA?
M\=>U_P#T-:?_ .MOOW_!%<Q?\NO_ #A/_6SKW_ X<M?PW/\ SG/_ $#T8WXY
M? _X]?%_<.5W=US@\Q7;JR=$,;%N'=^43/5-'3M?S14#+! E,*FX$S*AD=5"
M:PA92#N<?=/=^>(5M[V1!$K:O#B7PU=O(MDEJ>0)H.-*YZ&?)GM3LW(DKW%C
M$WBNNGQ)7,C*OF%) T@_BIDT )IT<KW'/4C]>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW0&UWQIZ)R/R(P_RSK>M-OS_(W =7R]+8CM
ML^=,I#M6:OJLHV##+,(&H#D:VJJ-#0,?*Y;5<+;W7NAR]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T /RO_ .R6ODI_X@'N/_WG<C[%O(/_
M "7=M_Y[[/\ [2(^@A[@_P#) W+_ *5]Y_VCR=%,_E)?]D9[7_\ #UW[_P"Y
MQ]C[[P/_ "LLW_-&#_JV.@#]WO\ Y5B#_FK<?]76ZLQ]PIU-O7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW13/G;_P!D??(;
M_P 1MF?][3V/O:W_ )6+;_\ GIC_ ,/0!]T_^5<W'_GDE_X[T&W\KS_LA;H[
M_P J9_[V&X/9Y[Y_\K5??]0W_:);]!_V'_Y52Q_ZB?\ M,N.C^>XEZE[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI0^+
MW_;W'Y>_^(VW/_[M=E>\F.=_^G>[3_STQ_\ 5N]ZQCY(_P"GC;O_ ,\C_P#'
M['JZ_P!XS]9.=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U5OO'%_P Q
M9]W;I?:LN1&V&W'G&VX%S&ST'V#54IH[+/.)P/M_'Q(!(/[?JO[?&BF?\O2<
MA_\ 53H4?CO0?-*G[&@D[SDK6V'_  ;*"43Y+;=4OW9"?;>C%RO57OKY TC^
MU^/>GT4Q_EZL@:N>C[^V>GNJY>Z,=\[YNSMV2]325XZ]>JHCMH197:T"^,4E
M.)K)7S+6+_E/F_SB@_T].GV\FBF>/Y],,'KC_)U$ZCQOSXA[)VA)V=)7G8*9
M4'<XERNU)U^V\;WNE#,U6PUZ.(@6_P!A?WMM%,?Y>O*'KGJR7VQT_P!$2^2%
M!\R:GL&GDZ%>M79']W,:LX@R.W*5?OQ-4^?TY65*F_B^WY \?^IYU>W4TT[O
M\O3+AJXZ!K;N*_F/+N#!-G9<E_!%S.,.9U9G9K#[03I]Q<13F4CPZ^$&K_4\
MV]W.C_57J@#_ .JG5J7M/TIZ)_\ **C^4556[-/QV>J6D2ES8W5]O78.C_<9
MZ;[2XS$B,WI^X_S5P/[?.GVY'I_%_EZ:D#'AT53^$_S-/^.N3_\ /ULK_K_[
M<_3_ -5>FZ/_ *J=6K8(9%<)AUS%_P"+KBL>,IJ9&/W(A3SW,=XR?+JY4Z?]
M3Q;VP>E Z +Y-TW?E5M' I\?&J%W.NXT;,FGJ\52'[#[6H!NV7=("/N/!PA\
MG_(.KW9*5[NJ2:O+HDW\)_F:?\=<G_Y^ME?]?_;OZ?\ JKTU1_\ 53JRGJB/
M?$77.SX^RC(=^)AH!N@RRTLS?=W;7=Z(M2L;:>8B5_I[9:E<=/K6F>DYWY#V
MK4=8YN+I8RKV$:K#G$&">@IF\8JX356?),E&/\F\OZVN?[/JM[\E*YX=:>M,
M=5\_PG^9I_QUR?\ Y^ME?]?_ &]^G_JKTS1_]5.C^?'N#MZGZVHX^\&F;?PR
MN6-49ZC'U3?;&0?;>O&,]);1^ =0_M<^VGI7'3R5IGI<=EQ[OEZ^WG'L N-[
MOMS++M0QR4\+??F%OMK-5E:93Y=/,I$?^JX]U''/6VK3'59?\)_F:?\ '7)_
M^?K97_7_ -O_ *?^JO3%'_U4Z.=\8:7Y"TNW]S+\AFJ&S;9FF.W_ +BKQ%6?
MM! /)8XAWB \U^)"&_IQ[;?3^'IV,$<>C)UPJ#15@H[_ '9I:@4MB!^X4.CE
MO2/5;Z\?UX]M]7/53W\)_F:?\=<G_P"?K97_ %_]J/T_]5>D]'_U4Z-#\8*/
MY5TN;W4WR'>K;$/BJ$;<^XK\#6#[D3-YK#$2/(#XM/,@"_TY]T?3^'_+TY&&
M\^CE>VNG>JM]XXO^8L^[MTOM67(C;#;CSC;<"YC9Z#[!JJ4T=EGG$X'V_CXD
M D']OU7]OC13/^7I.0_^JG0H_'>@^:5/V-!)WG)6ML/^#902B?);;JE^[(3[
M;T8N5ZJ]]?(&D?VOQ[T^BF/\O5D#5ST??VST]U7+W1COG?-V=NR7J:2O'7KU
M5$=M"+*[6@7QBDIQ-9*^9:Q?\I\W^<4'^GIT^WDT4SQ_/IA@]<?Y.HG4>-^?
M$/9.T).SI*\[!3*@[G$N5VI.OVWC>]TH9FJV&O1Q$"W^PO[VVBF/\O7E#USU
M9+[8Z?Z(E\D*#YDU/8-/)T*]:NR/[N8U9Q!D=N4J_?B:I\_IRLJ5-_%]OR!X
M_P#4\ZO;J::=W^7IEPU<= UMW%?S'EW!@FSLN2_@BYG&',ZLSLUA]H)T^XN(
MIS*1X=?"#5_J>;>[G1_JKU0!_P#53JU+VGZ4]$_^45'\HJJMV:?CL]4M(E+F
MQNK[>NP='^XSTWVEQF)$9O3]Q_FK@?V^=/MR/3^+_+TU(&/#HJG\)_F:?\=<
MG_Y^ME?]?_;GZ?\ JKTW1_\ 53JU;!#(KA,.N8O_ !=<5CQE-3(Q^Y$*>>YC
MO&3Y=7*G3_J>+>V#TH'0!?)NF[\JMHX%/CXU0NYUW&C9DT]7BJ0_8?:U -VR
M[I 1]QX.$/D_Y!U>[)2O=U235Y=$F_A/\S3_ (ZY/_S];*_Z_P#MW]/_ %5Z
M:H_^JG5E/5$>^(NN=GQ]E&0[\3#0#=!EEI9F^[NVN[T1:E8VT\Q$K_3VRU*X
MZ?6M,])SOR'M6HZQS<72QE7L(U6'.(,$]!3-XQ5PFJL^29*,?Y-Y?UM<_P!G
MU6]^2E<\.M/6F.J^?X3_ #-/^.N3_P#/ULK_ *_^WOT_]5>F:/\ ZJ='\^/<
M';U/UM1Q]X-,V_AE<L:HSU&/JF^V,@^V]>,9Z2VC\ ZA_:Y]M/2N.GDK3/2X
M[+CW?+U]O./8!<;W?;F67:ACDIX6^_,+?;6:K*TRGRZ>92(_]5Q[J..>MM6F
M.JR_X3_,T_XZY/\ \_6RO^O_ +?_ $_]5>F*/_JIT<[XPTOR%I=O[F7Y#-4-
MFVS-,=O_ '%7B*L_:" >2QQ#O$!YK\2$-_3CVV^G\/3L8(X]&3KA4&BK!1W^
M[-+4"EL0/W"AT<MZ1ZK?7C^O'MOJYZJ>_A/\S3_CKD__ #];*_Z_^U'Z?^JO
M2>C_ .JG1H?C!1_*NES>ZF^0[U;8A\50C;GW%?@:P?<B9O-88B1Y ?%IYD 7
M^G/NCZ?P_P"7IR,-Y]'*]M=.]5;[QQ?\Q9]W;I?:LN1&V&W'G&VX%S&ST'V#
M54IH[+/.)P/M_'Q(!(/[?JO[?&BF?\O2<A_]5.A1^.]!\TJ?L:"3O.2M;8?\
M&R@E$^2VW5+]V0GVWHQ<KU5[Z^0-(_M?CWI]%,?Y>K(&KGH^_MGI[JN7NC'?
M.^;L[=DO4TE>.O7JJ([:$65VM OC%)3B:R5\RUB_Y3YO\XH/]/3I]O)HIGC^
M?3#!ZX_R=1.H\;\^(>R=H2=G25YV"F5!W.)<KM2=?MO&][I0S-5L->CB(%O]
MA?WMM%,?Y>O*'KGJR7VQT_T1+Y(4'S)J>P:>3H5ZU=D?W<QJSB#([<I5^_$U
M3Y_3E94J;^+[?D#Q_P"IYU>W4TT[O\O3+AJXZ!K;N*_F/+N#!-G9<E_!%S.,
M.9U9G9K#[03I]Q<13F4CPZ^$&K_4\V]W.C_57J@#_P"JG5J7M/TIZ)_\HJ/Y
M155;LT_'9ZI:1*7-C=7V]=@Z/]QGIOM+C,2(S>G[C_-7 _M\Z?;D>G\7^7IJ
M0,>'15/X3_,T_P".N3_\_6RO^O\ [<_3_P!5>FZ/_JIU:M@AD5PF'7,7_BZX
MK'C*:F1C]R(4\]S'>,GRZN5.G_4\6]L'I0.@"^3=-WY5;1P*?'QJA=SKN-&S
M)IZO%4A^P^UJ ;MEW2 C[CP<(?)_R#J]V2E>[JDFKRZ)-_"?YFG_ !UR?_GZ
MV5_U_P#;OZ?^JO35'_U4ZLIZHCWQ%USL^/LHR'?B8: ;H,LM+,WW=VUW>B+4
MK&VGF(E?Z>V6I7'3ZUIGI.=^0]JU'6.;BZ6,J]A&JPYQ!@GH*9O&*N$U5GR3
M)1C_ ";R_K:Y_L^JWOR4KGAUIZTQU7S_  G^9I_QUR?_ )^ME?\ 7_V]^G_J
MKTS1_P#53H_GQ[@[>I^MJ./O!IFW\,KEC5&>HQ]4WVQD'VWKQC/26T?@'4/[
M7/MIZ5QT\E:9ZX?)TTR_''OAJZW\-7J'L1\OJ!8?9)B:HUMPMW(^U$UPH+D<
M("UO9GL*W+WUL+*OU!GA$%"H/C&1?#R]%'?3+=OKCHKY@:U2PN3>T^F$$QN*
MAB/ $;>)4)5CV5PO<?+/5._Q4I/E96]08VH^+KU2=2-F<ZN-6DK<#CT^\6:U
M=:+-R1UX/F^I9-!^J7'L2<^1[I%N+KOE?J]":M31L=&GMS"2G#T-?7H-\A2;
M5-MJ-L5!9ZI-&E9$&K4=>)@'^*O$4].K7?C#2_(6EV_N9?D,U0V;;,TQV_\
M<5>(JS]H(!Y+'$.\0'FOQ(0W]./8)?3^'H;Q@CCT9.N%0:*L%'?[LTM0*6Q
M_<*'1RWI'JM]>/Z\>V^KGJI[^$_S-/\ CKD__/ULK_K_ .U'Z?\ JKTGH_\
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M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBF?.W_LC[Y#?^(VS/\
MO:>Q][6_\K%M_P#STQ_X>@#[I_\ *N;C_P \DO\ QWH-OY7G_9"W1W_E3/\
MWL-P>SSWS_Y6J^_ZAO\ M$M^@_[#_P#*J6/_ %$_]IEQT?SW$O4O=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5*'Q>_[>
MX_+W_P 1MN?_ -VNRO>3'.__ $[W:?\ GIC_ .K=[UC'R1_T\;=_^>1_^/V/
M5U_O&?K)SKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z#7N??55U=T]VOV90T%/E:WKOK7?6^J/%U<K015,NT<7
M59"."5T!=(YGIPC,HN 21S[]U[K6!^+G\YW^>'\T>B=C?)?XT?R2>M.RNDNR
MO[S?W*WK_L^FRMG?>_W.S&0P&2_W&Y^IQ67IOMLOBJ^#]^@B\GB\L6N%XY']
MU[H[7Q/_ )QO=^:^7^PO@3_,F^!>Z_Y?WR,[GVEG=W= 99>W\)WILW>:[90R
M5^,HMP85$HZ7.0Q1SR"CCJJXJB(*F6EEJJ**I]U[J^[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5P_-CYR[A^*7R#_E
MY=*X;8&&WA0?-KY$Y;H[.9W)YJ?%S8"'&8K^*#(TD,4,J5TKJDD7BD>)0663
M6=!C?W7NK'O?NO=>]^Z]U[W[KW7O?NO=:YW\Y+^>GN[^5'\C_CKU52_&J'NG
MK7M#8DO9O:^^J+<&2H:[:>!PNY*;"Y7)+0T6+R$57#3P5<3H9IJ9#4&.!I+S
MI;W7NMB+%Y3'YO&8[-8BL@R.*R]!1Y3&9"E<2Q3T]?&LL,T;#AHY8W5E/Y!!
M]^Z]UKP?('^>_5=7?SG^D/Y4NPND=N[YVYO_ '!L#8_8?>-5O6KHY,)N'=-"
M^;K\/2XV+&R4=;4XW!UFWYI5.35XI*\"9%TJC^Z]TI/D/_-6^;^,_FA=E_RT
MOAI\,^FN_=V]<?'';'R5R&ZNS/D%4=-K_!\M58?&UD04X/)P23TV1SE J!9@
MTD;LVD>)BWNO=,_<'\P[^>%\<=E97MWL[^3CU1V1UALRDJ\]V+2_'[YMT>[-
MQX_#XB-JBOR-)AZK;,55E6IZ:.4K345/45$C6NB1AY%]U[JUSX??-KJ/YR_#
M_8'S)Z(DR-1L+L39F8W%0X3<4<5)D<;D-N/4TN3PF5CIIJB&*OQF2I*BFF\4
M\L3E/+#))$\;M[KW0._RC_GGG/YE_P #NH_F/N+KC%=397LW+=F8Z?8F%W%-
MNJGHUV!N;+;?1DKIZ6BDF-2F,$[7IDT&0H-074WNO=64>_=>Z][]U[KWOW7N
MO>_=>Z][]U[H ?E?_P!DM?)3_P 0#W'_ .\[D?8MY!_Y+NV_\]]G_P!I$?00
M]P?^2!N7_2OO/^T>3HIG\I+_ +(SVO\ ^'KOW_W./L??>!_Y66;_ )HP?]6Q
MT ?N]_\ *L0?\U;C_JZW5F/N%.IMZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z*9\[?^R/OD-_XC;,_[VGL?>UO_*Q;?_ST
MQ_X>@#[I_P#*N;C_ ,\DO_'>@V_E>?\ 9"W1W_E3/_>PW![//?/_ )6J^_ZA
MO^T2WZ#_ +#_ /*J6/\ U$_]IEQT?SW$O4O=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5*'Q>_P"WN/R]_P#$;;G_ /=K
MLKWDQSO_ -.]VG_GIC_ZMWO6,?)'_3QMW_YY'_X_8]77^\9^LG.O>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HO
M7RX_[)1^3G_BO7='_O-Y+W[KW6G_ /R&/YW7Q+^(7\J#XJ?'?LWK7Y?[@WOU
M[_IR_C>7ZM^,&X>Q,%-_>SLG>&<IOL<S0H:6L\=)DZ=)M!_:J%E@;UQ-[]U[
MHS*;N[Y_G3?S=_Y>'R#Z[^&GR3^-'PP_EK93N[?FXN\_E3L*3IW)[PS?8-/B
MX:7$[=P50M5+5TOW."PDL;_=:TI*G(25B4%1#2T]9[KW49Y?GY_,!_G&?S9_
M@!M_YV=[_&3XF]-+\8M]R;GZ5W#3X7>&%.4V73&':FT*^2G,^#QNZ,IFJ[*Y
M>N@F^Y#86CHH[0UTVGW7NA<W=4?,GY)?-3;?\E#I7YN=]]<=/_"?XM;'["^>
MGSHVIGJ,]Q;NW#V=3?[]W:U)G*I*H[7KLAC<A3Y<Y"FAGJ?&CCRQ>" 57NO=
M1>]L/\L_Y%O;?PY[8P7S>^7?SC^"G?'R.V;\6/D;UM\UMY4G>6YMJ57<.M<%
MO/![RAQ6*KJ&CQU713QRTU2!1MY8:+2\]932TWNO=,W\TOY0KN?^:?@O@G\K
M/YB?>?\ *U^%K_$S$=L[![.Z$WM2= 9+L#>N6W"]-745?V=D<?D8,+CL-CZ4
MH,>D<,=0QE-5/^_!$_NO='__ )=_QR^8/Q\^0V7&S_YA&8_F$_RO=Z])T^5V
M1O#Y&]RTO>W:6%W[)EI*@B@W;B,-!1;@VK68F9F,E5DR\;/30TE-!#1EZOW7
MNBD5 ^3?\YKYU?.?J#;'S4^0OPP^!/P'["Q/QJC_ -DMWM3=9;ZW[V10P+5;
MKJ,EO&2AR%1B\9MBJCEQ[XZ&F>.I\D32$.LX/NO= ]B,G_,.^$?\\S^5S\"-
MY_-[MKY(_"?MC87RIW3L_+=N5=+DM\YM=G=:[AJ9L!V-F:6"FBW9-MG-XC&9
M/%94T%-5R+D9(:R2J>F5Q[KW1J>VOA=\Q/E1VE\A-^?S!/YE_?O\OWH7%]H9
M'#?%'IGX)_*#!=!QR[,QU(BPYW>FZ*W;\E?E<KDVJIDJL?*QIJ6>!S$9(/MI
M&]U[H!_Y./R]W3@/YH/S%_EB8[Y\[I_F4_'CK_X\;5^170OR"WUV#A>YL[AY
M,-E<)@MT[7S6\\3,YSU:F0W-1'5)K\(I&&FE=WCE]U[HLOPCV5_,6_FT=D_S
M+>O-Y?S+?D_\9>COB3_,=^1^R>IL_P! ;GI\+NK)U292.'%;<R>0\4-7#LK8
M^-PU++28^.I"92HSE:*MP*& GW7NCX?(7=OR@^=/\R?)?RG>B_EKW%\8?CQ\
M.OC)UYV1\S_D#T9G:?$]J;DW'V=31)MK:]!N:HI:H;7FFQ4M'FIZZ"GDJ*C7
M41F,*T3I[KW1)?EM\2/D_P##W^9'_(TZ]SORN[U^8?Q)K/F+FZK9>[OE1E,?
MOSL+:>[:/ R1R8BOWA14V(DW!A<]B6GJ:)*G$/44<V.JT:K\4L$9]U[K<H]^
MZ]T'M;VWU3C:RKQV1[-Z]H,A05,]%74-;O3&TLT,U*YCEAFBDJ5>.6-U965E
M#*P((!'OW7NHW^FCIW_G['6G_H=XO_ZJ]^Z]T(=)5TM?2TU=0U-/6T5;3PU=
M'64DRU,4L52H>.6*1"R21R(P964D,"""0??NO=:P7\S+X_;3^5O\Z_XN_&K?
M(9=J]Y_RJOG9UCEZF,D24R[N8T<5;"5((GH9Y(JB(_B2)38_3W[KW1I/Y+7S
M%@C_ )25/E?DEN''8'?G\MVC[D^+WRKJZW._??PFJ^&HJ*2:HKJNJ\3F1]JT
MF*JY))K:GD<ECR??NO=:VFQNNMUP?+'_ (3<_++M&BDI.YOYC_SH_F"?/7L&
M*;/5.YVI:+O7_1=-LW$P5E5%3N:'%;'I=NQ4\,=-#3P7=((U2Q;W7NCG?(SY
MA[E^$O\ PJ#^2O:NUOB5\H_F5D-P?RS]A]?3=8?$GK:H[2W)00Y7/[)R39ZM
MQ]."\.$I7Q,=)-4'TI55M'&>91[]U[HSG8'_  H=^0'=>Y<O\*_B_P#RI?E?
ML#YV=J["SDW4VP?F])@?C'CHJ:NB-))N&>FW!E,?D<W28DSBJ;'T?BFK889P
ME53QQ2SQ^Z]U:=_*9^!&[OY:?\KGKOXG=A[OPN]^Q=I[7[1W9O\ S&V(I8\5
M%ENQ*W)9JIQV,>=8ZBIH\7]XE(M5+%$]6T+57V],LRTT/NO=%-_X2I?]N/?B
MC_X='R._]^/NKW[KW6Q-[]U[KWOW7NO>_=>Z][]U[KWOW7N@!^5__9+7R4_\
M0#W'_P"\[D?8MY!_Y+NV_P#/?9_]I$?00]P?^2!N7_2OO/\ M'DZ*9_*2_[(
MSVO_ .'KOW_W./L??>!_Y66;_FC!_P!6QT ?N]_\JQ!_S5N/^KK=68^X4ZFW
MH@.Y_P"9U\-]G[EW#M+/]CYBDSNULYEMN9JE38&=JEBJ\)424U3&)8L>T<@2
M:)P&1BK6NI((/N6+'V2YCW&".XAME,<J)(A\> 51U#*:&0$5!&#D>?41W_OG
MRSMD\EM-=,LD4CQ2+]/<&CQL585$1!H0<@D'RZ8_^'7/A#_S\_-?^BYW!_\
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M\?6@@G<#7<S2+W)&RFJN#@^=#GHVW_#KGPA_Y^?FO_1<[@_^MWN/?]87F?\
MY14_[*+?_K;U(O\ P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]
M_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[
M@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y
M^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW
M_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-
M<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*
MO_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#U
MMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_
M &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\
MS_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\
MK=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO
M_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KG
MPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\
M6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6
MW_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_
MP0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46
M_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\
M**G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]
M_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[
M@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y
M^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW
M_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-
M<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*
MO_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#U
MMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_
M &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\
MS_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\
MK=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO
M_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KG
MPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\
M6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6
MW_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_
MP0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46
M_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\
M**G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]
M_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[
M@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y
M^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW
M_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-
M<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*
MO_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#U
MMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_
M &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\
MS_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\
MK=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO
M_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KG
MPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\
M6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6
MW_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_
MP0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46
M_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\
M**G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]
M_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[
M@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y
M^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW
M_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-
M<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*
MO_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#U
MMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_
M &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\
MS_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\
MK=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO
M_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KG
MPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\
M6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6
MW_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_
MP0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46
M_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\
M**G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]
M_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[
M@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y
M^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW
M_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-
M<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*
MO_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#U
MMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_
M &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\ K=[]_K"\
MS_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO_1<[@_\
MK=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KGPA_Y^?FO
M_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\ 6KKW_#KG
MPA_Y^?FO_1<[@_\ K=[]_K"\S_\ **G_ &46_P#UMZ]_P0/*O_*6W_9-<_\
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M'45-M638F5?'=[S4K5$$[?>YK9>%EJJLM1U)8U< T^JX]U[H]7\XK XC:O\
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MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= #\K_ /LEKY*?^(![C_\
M>=R/L6\@_P#)=VW_ )[[/_M(CZ"'N#_R0-R_Z5]Y_P!H\G13/Y27_9&>U_\
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MA_T<K<7"G^V\C'&1_H?DS#^TX#LJ7S9]D_9,;.$WC>$K<&C6]NP_L/,.X/\
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M;L[_ .R'W[_7SY5_Y3O^S:[_ .V?KW^L)S9_R@_]G5G_ -M'7O\ AK?YV?\
M/C/_ &)NSO\ [(??O]?/E7_E._[-KO\ [9^O?ZPG-G_*#_V=6?\ VT=>_P"&
MM_G9_P ^,_\ 8F[._P#LA]^_U\^5?^4[_LVN_P#MGZ]_K"<V?\H/_9U9_P#;
M1U[_ (:W^=G_ #XS_P!B;L[_ .R'W[_7SY5_Y3O^S:[_ .V?KW^L)S9_R@_]
MG5G_ -M'7O\ AK?YV?\ /C/_ &)NSO\ [(??O]?/E7_E._[-KO\ [9^O?ZPG
M-G_*#_V=6?\ VT=>_P"&M_G9_P ^,_\ 8F[._P#LA]^_U\^5?^4[_LVN_P#M
MGZ]_K"<V?\H/_9U9_P#;1U[_ (:W^=G_ #XS_P!B;L[_ .R'W[_7SY5_Y3O^
MS:[_ .V?KW^L)S9_R@_]G5G_ -M'7O\ AK?YV?\ /C/_ &)NSO\ [(??O]?/
ME7_E._[-KO\ [9^O?ZPG-G_*#_V=6?\ VT=>_P"&M_G9_P ^,_\ 8F[._P#L
MA]^_U\^5?^4[_LVN_P#MGZ]_K"<V?\H/_9U9_P#;1U[_ (:W^=G_ #XS_P!B
M;L[_ .R'W[_7SY5_Y3O^S:[_ .V?KW^L)S9_R@_]G5G_ -M'7O\ AK?YV?\
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M;L[_ .R'W[_7SY5_Y3O^S:[_ .V?KW^L)S9_R@_]G5G_ -M'7O\ AK?YV?\
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M;L[_ .R'W[_7SY5_Y3O^S:[_ .V?KW^L)S9_R@_]G5G_ -M'7O\ AK?YV?\
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M;L[_ .R'W[_7SY5_Y3O^S:[_ .V?KW^L)S9_R@_]G5G_ -M'7O\ AK?YV?\
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M?*?,=#9_OCKW^_>7^,G=NSOD7T?5_P![,YMC^";RV!*)\1F/'ALGCHLE]I*
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M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4H?%[_M[C\O?_$;;G_\
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M[_GZF&_\]V1_^H_>_#;TZUXB^O1BZ.KIZ^DI:ZCE$])6TT%72S*"H>.I4.C
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M_4PW_GNR/_U'[OX;>G5?$7UZ%/K_ +3V!VG19#([ W)2;EHL751T5?44E//
M(Y94UJA$\41)*<\ C_'W4J5X]6#!N'2\FEC@BEGF8)%#&\LKD$V6,$L>+G@
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M91F&0?7JT+K_ +3V!VG19#([ W)2;EHL751T5?44E// (Y94UJA$\41)*<\
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MSV=Q.V,+E-Q9ZMCQV%PE#4Y/*5\J/(L,%(I>21E17<A%!)"J3_0>]#/7B:=
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MQV6DQH5<DT32ZP@]9)ACM?Z<_P!?=U<IPZHR!^/0-_[()\=?^=1N?_T*9_\
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MJN8I$QV0?',)UAE@!9TY9?',_'TO8_CW96*\.JL@?CT /^R"?'7_ )U&Y_\
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MO_'>@V_E>?\ 9"W1W_E3/_>PW![//?/_ )6J^_ZAO^T2WZ#_ +#_ /*J6/\
MU$_]IEQT?SW$O4O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW5*'Q>_P"WN/R]_P#$;;G_ /=KLKWDQSO_ -.]VG_GIC_Z
MMWO6,?)'_3QMW_YY'_X_8]77^\9^LG.O>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NM7S_A0S_V5=_PGO_\ &O/0'_O2;4]^Z]UM!^_=>ZU8?Y>N$I?B
M=_PI!_FG_#[K&&'$]%_(7XS=>?.J'9.-9\9CL#NBER.V,/EQ0XY2]('SE=N[
M+5D\\*4^F-*2D,4B4\;I[KW0J]#?S:OD'3?'O^?5\ANU<-M_LY?Y:WS#^7G5
M'1.QL)AH]I1S[?Z0:H&#H\O5TRRSSL6\7WU:0T@IT>1(]8(;W7N@@ZNH?Y[W
M>GQ=P7S]^./\VSXQ?(7=6Z.H,9W'@/@;L[X8;-&Q:[(9+"&N&PX.P)-R4^[Z
M6LCJI'ITGKJJAE_B"+%734U*LBQ^Z]TC_P#A03%\Q.V?Y<?PE[5W?N/ _%O.
M9SOSX>Q]X?&#)]?X[M^;%]@;JSE"U'54F[Z3/TT1H-J9'[Q7I(Z6HCR\1BO4
MT3(Y?W7NCL?S(OE+\Y/Y=/QC_E]Q5W?_ %_W7W?WA_,RZ!^,/<7;E/T#1=94
M&2VAW N\:RHIL;M<YK<,&'KZ.FQF+@6K&4J&D>&2?0@G,*>Z]TBOG!\Y/YCN
M*_G-]2_RU/A>_3=%M3N;X"P=WY3?/:^V#F:;8V57>F[,=D-YU4-/+!7[A@I\
M5M^BQM'A(JFFCFR>0IZFHJ$I8:@'W7N@^;O;^:E_+!^:OP6ZB^;OS0ZR_F _
M%_YY=P5OQ[A[%K?C?@/B_N79F\\W30OM^FIH-LSRXO(T.5R$JPQ+422S2WF2
M-:<I C^Z]T8WYF?+7YP=\?/ZG_E<?RX]]=>_'O=.P>BJ'Y _*_YB]A]?4W<;
M;.QV\*EZ+;>W]L;5K)H\9DMRY!S!5NN2(IOL93)'S!(']U[HC7R/^6'\YK^6
M?\C/Y9GQC[O[]Z>^9/4GS"^<W0G3V7^8$?0F-Z5W$N+W9N6EQ>Y-BYO:&+J*
MW TM758S+457A<Y05D4X2BKX:NFGE"U/OW7NK-?]G7[V_P"'Z_\ AOO^*[>_
MV7'_ (;8_P!F@_A']W(/XK_>K^_7]WO+_%;^?['^'_\ */IT^3UZO[/OW7NE
M;_,3^7G=7QQ^4_\ *GZHZORV$Q^SOEI\L,[U#W)2Y3;]/F)JG#8_!G)1QT,\
MP+T%1]Q'8RQ\E&86OI9?=>Z2FZ_FKWMB_P"?5UG_ "_:+*[?B^.6X_Y:U?\
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M4]7UBS4]'78BEKZA6W'1Y;$FAJH9L4:Q)6D<0ZD"%O=>ZI@ZSV1N7^;SCO\
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MCA-+%%N&IS6\,MB)JO<2Q/2/CX!/,9&HTJ:?QR^6G]U[K91^5_\ V2U\E/\
MQ /<?_O.Y'V+>0?^2[MO_/?9_P#:1'T$/<'_ )(&Y?\ 2OO/^T>3HIG\I+_L
MC/:__AZ[]_\ <X^Q]]X'_E99O^:,'_5L= '[O?\ RK$'_-6X_P"KK=68^X4Z
MFWK5P[D_FB?,'9O;W:NT,%O7;5/@]J]D;YVWAH)MB8NI=*3!Y2JI:=&D>G+R
M,L,2 LQ)8BY-S[SDY;]C.7MRVZUN9892\MM!(Y$\@!=XE8T .,DXZP1YG]_>
M8MJW*[M89(!'#<SQ)6!2=$<KHM3YF@&>@W_X=H^:W_/=;6_]%[B?_J;V=?\
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M?_J;W[_@?^6O]\R_]E$O^?KW_!&<S?[\@_[)TZ]_P[1\UO\ GNMK?^B]Q/\
M]3>_?\#_ ,M?[YE_[*)?\_7O^",YF_WY!_V3IU[_ (=H^:W_ #W6UO\ T7N)
M_P#J;W[_ ('_ ):_WS+_ -E$O^?KW_!&<S?[\@_[)TZ]_P .T?-;_GNMK?\
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MQ/\ ]3>_?\#_ ,M?[YE_[*)?\_7O^",YF_WY!_V3IU[_ (=H^:W_ #W6UO\
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M:W_/=;6_]%[B?_J;W[_@?^6O]\R_]E$O^?KW_!&<S?[\@_[)TZ]_P[1\UO\
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MX=H^:W_/=;6_]%[B?_J;W[_@?^6O]\R_]E$O^?KW_!&<S?[\@_[)TZ1?8O\
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MSQVYW@>ET"5)DHJF=HFC,D>H, 5UK>VH7]U[JM_NKL;^9-B?YE_0NQ^J9OC
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M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1&.^OYF7P'^,';6
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M[KW5;_9O\H?_ (4!?.[K+8/PE_F!?._XKT/PLVQE-JMV3O#I/#Y;/[^WO1;
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MXCD9(7S--55WC\JTP-09+>5>?=>Z*%1_SW=_=V=I_+CXU_!C^7/W3\M/D_\
M$7Y)=F]#;ZV(.U=N]-;8@QO7>9J,'#NW+;ZS\7\'Q4&X:W'9I<5BECJLC.V.
MJ3.M+!HJ#[KW1P?Y=?\ -&'S7[%[Z^-W</QH[)^&?S%^,<&T<CW%\>^Q-PT&
M^XXL?O>'R8_+8'<N,BIJ+.XN4V7SI1P B2"1%>.96]^Z]T W97\XCNG?/?G<
MO0W\M'^77V1_,1;XR;XINN_DAVS0]\;3^-NSL)G8?(<EMW!YK=2RP[JW#B/$
M\=;1TWA%-(T>N5D>,R>Z]T3?^6%\FL/\K_Y]/\Q;LBBZ\[)Z@W'AOA5\<.N^
MR>I.W-O_ -WL_MG<NR\Q+3Y7$5JH\U'6)"[1R4];1U,]%6TTD-333/'(+>Z]
MT<OMS^<7VYNWOSM[XZ?RP_Y?>_OYDVZ_CAN2CV;\A^PL;WSM?XR[#V[G7%7]
MYMJDW9NF"KI<[N/&/3)'64E-3JE.SL#.TD+1-[KW1D/@1_- VI\RNQ>Y/C=V
M1T?V;\0?F9\>Z3!9CMGXQ=PU5!EZU,1N2*!Z/<.W<YBI),9N3;TDTZ0&K@$3
MQR-$98$BJ:62;W7NJS/Y F^]F]7[(_GD=E=B;FPVR]@=?_SA_G5O3>V[]Q5R
M8R@Q>)VQ2XBMR&0K:B0B."EHZ2&665V-E123]/?NO="KMG^=-\T.^\3'WK\,
M/Y,'R(^1?PBF.8J,-\A\_P#(3971VXMQ4&"JJNGFR^TNM,XDN>S>,J4IDEH'
M^\@GK%D,9IZ>2/2WNO='^Z\_FB= =R_RY>V?YD74F+WCN+KSIOISO'LW?'5F
MXL?'LW=F*RWQ^P^0RFX=F9JBFDJ(<7N&DDQST[ S34S>2&J@FJ*2:&:3W7NJ
MYME?SS?E9\F^G^O_ )&? '^3[WW\K?C_ )3;$>9[)[(S/?FU>B30Y''I&F<P
M>S\/FJ*JS&_ZO;U>N0H*JHH:*"EFKZ*6GHI*E'-1%[KW1E\G_,GI_F9_*+[2
M^9_PYZ0['[-K]Q];]J[0S?4&0W;@NI]S;7K\)2U^+W))6UF:KZ7&>?:Q#UK1
MPUWGK*9%-$KU$D4+>Z]T$?\ PFT[.[HW?_+"^,.R=^_&?<_4O6_7_2FTZ;JO
MNC,=F;4W;1;^AR.1S)JZG'87"Y*KSN!3'&*$2)F*.DDE,Z^!9 DA7W7NKV]]
M[YV?UALC>'9/8>Y,/LW8/7^U\_O;>V[MPUJ8V@Q>(VM2RUV1R-;42$)!245'
M!--+(Q 2-&8\#W[KW6OAA?YVGS8[NVXWR%^&W\ECY!_(CX-1-E<A0_(3<'R(
MV=TIN;<&&V]63PUV<VCUEE:6KW#GZ1Z2FDGQL:5,<V2=EI]-(X+>_=>Z-INC
M^=U\,L-_+_ZC_F$;:J=[]A['[_W3A>K^D^HMI8>GGWKN+?.=JZK')LJEQ<U7
M%"F9IZ^AK(Z@M5>"..$SI))&\)E]U[HGW;/\ZK^8/\5-NY/O;YH?R/>X.C_A
M]@*W&KN[NG9/S'Z^[XS^#Q^8KHZ*ER>5V3A*:&KIHG-52"HCDR<:4<A9&J)K
M@CW7NC]?S'/YL/1'\M_XY?'KY5=@X3/;_P"F._N]>INHZ3<^T)K#%8OM3!9S
M<<>[):?[>HJZ_'T.*P4TK4M-3M5S^1%A1G])]U[HB';_ //(^5_QNQ\_R!^2
M'\FWY)]2_P OU,GMV"3Y-57>&S]R;LQN.W+4TE+39G<?5% DN;V_2/-6(&CJ
MLN)8K1HX^XG^VB]U[JU+YF_S#_CG\'_BS3?+'M',9C<6R]U/M#$=0;2V#CAG
MMP[ZSO8L#5.W=N[5QK20G(9;+P+)-&AD18J:*>IF9(8)&7W7NJM]P_SM?E[\
M<H\3V_\ S"?Y0/</P[^%.=W+@=MGY-4OR7V=WK7;=.\J^FH<)6;UV-@Z2GS.
MVJ&J>H1:J22ID:CJWAH5CJYID;W[KW1V/G'_ #4=H?%G?_4?QOZ)Z5WU\W?F
MI\@=J93??3_QDZ:S^,P+OM_'PU+)NK=6YLDS8S:>TJBIII*>+)3PU!ED29H*
M>9*>=H_=>Z!_H7^;GVK#\B.H?BE_,<^ ?9_\NSN#Y%5&;QGQ\W#D>X-L?)+8
M.Z,KA(Q.=NIO3:I@IL9N6JICKI:&IH@L[*8!4+42TD-3[KW7+YG?SI=L_$SY
MIR? ;;OQ@[;^0OR.W7\;L#WET7LWK7-XVDEWGE]Q;DGP<>TZ<5J@8QZ''4&:
MSN1R4S/3T>(QE9-XI9$6)O=>ZL(^%G>/>?R(Z%P79OR,^+.Y?AOVI79K<F'S
M?1F[-]4?8U51+M^J:ECK%RU#18^GJ:3(&-Y:=A2KKA*2"ZNI]^Z]T:_W[KW0
M _*__LEKY*?^(![C_P#>=R/L6\@_\EW;?^>^S_[2(^@A[@_\D#<O^E?>?]H\
MG13/Y27_ &1GM?\ \/7?O_N<?8^^\#_RLLW_ #1@_P"K8Z /W>_^58@_YJW'
M_5UNK,?<*=3;UHR_(W_LH7OC_P 3-VA_[O*[WU#Y,_Y(]A_SQVO_ %83KE1S
MS_R6]P_Y[KO_ *OR= S[$O06Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NE-LS9FZ>P]TX+9.R<%D-R[KW+D(
M<7@\'BX?--/--<V%R%1$4,\DCLL<4:M)(R1HS!#N6Y0;/ ]U=.L<4:EG=C0*
M!_A)X "I)( !) Z7[7M=QO=Q':6D;2S2L%1%%2Q/\@ ,DF@4 DD $];9OP.^
M!VUOB;M9=P[A7'[E[OW+CTCW1NB-/-#C89M+MB,0SJ&2F1@OGGTK)5R*&8)$
MD,,> ?NI[J3\_P _@PZH[*-OTHN!D(QXDE.+'\*Y" T%268]#_:;VFM_;NW\
M673+?2K2:89$8-#X4514*#\38,A%30!56PWW$/4Q=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U2A\7O^WN/R]_\1MN?_P!VNRO>3'.__3O=I_YZ8_\
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M@WK1[)7)1QQU$^U\#A\-@L+C\A4"-3)6-1RU&M4DC>.1 _OW7NC0?[(1T_\
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M\2_]E$W_ $%U[_AHWX8?\\OO;_T/J[_BOOW_  0/,O\ OZ'_ )P1_P";KW_
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MO?\ #1OPP_YY?>W_ *'U=_Q7W[_@@>9?]_0_\X(_\W7O^!XY7_WQ+_V43?\
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M/_."/_-U[_@>.5_]\2_]E$W_ $%U[_AHWX8?\\OO;_T/J[_BOOW_  0/,O\
MOZ'_ )P1_P";KW_ \<K_ .^)?^RB;_H+KW_#1OPP_P">7WM_Z'U=_P 5]^_X
M('F7_?T/_."/_-U[_@>.5_\ ?$O_ &43?]!=>_X:-^&'_/+[V_\ 0^KO^*^_
M?\$#S+_OZ'_G!'_FZ]_P/'*_^^)?^RB;_H+KW_#1OPP_YY?>W_H?5W_%??O^
M"!YE_P!_0_\ ."/_ #=>_P"!XY7_ -\2_P#91-_T%U[_ (:-^&'_ #R^]O\
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MZ]_PT;\,/^>7WM_Z'U=_Q7W[_@@>9?\ ?T/_ #@C_P W7O\ @>.5_P#?$O\
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M>.5_]\2_]E$W_077O^&C?AA_SR^]O_0^KO\ BOOW_! \R_[^A_YP1_YNO?\
M \<K_P"^)?\ LHF_Z"Z]_P -&_##_GE][?\ H?5W_%??O^"!YE_W]#_S@C_S
M=>_X'CE?_?$O_91-_P!!=>_X:-^&'_/+[V_]#ZN_XK[]_P $#S+_ +^A_P"<
M$?\ FZ]_P/'*_P#OB7_LHF_Z"Z]_PT;\,/\ GE][?^A]7?\ %??O^"!YE_W]
M#_S@C_S=>_X'CE?_ 'Q+_P!E$W_077O^&C?AA_SR^]O_ $/J[_BOOW_! \R_
M[^A_YP1_YNO?\#QRO_OB7_LHF_Z"Z]_PT;\,/^>7WM_Z'U=_Q7W[_@@>9?\
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M\2_]E$W_ $%U[_AHWX8?\\OO;_T/J[_BOOW_  0/,O\ OZ'_ )P1_P";KW_
M\<K_ .^)?^RB;_H+KW_#1OPP_P">7WM_Z'U=_P 5]^_X('F7_?T/_."/_-U[
M_@>.5_\ ?$O_ &43?]!=&$^/OPE^/'QES68W+U9M"HI=R9JBCQD^?S^6FW#5
M0TRMK>GI)*@G[6*=])F\84RZ(Q(6"( $N;?<S>.=HD@OY@T:-J$:(L:EN%6"
M@:B/*M:5-.)Z&'*'MALO(TKS[?!ID=0ID=WD<+6NE2Y.D$Y:E-5!6M!0V7L
M]#_KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JE#XO?\
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MTPIE+4#J(/(LDQL]RVFZ_I/MR-0W$TZ:D9APZ*I_LS7SK_Y\5D__ $36XO\
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M>O\ ,=,ZW]/Y='\^/>[^R-\=;4>?[6VW-M3=\N5RU-48B? 56VF6"FD"P/\
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M]VC@<ITWM"HWEGJW<:4&3H*?:U=NLQ4AI:B0S&&@99(P)HXEUL=/JT_4CW9
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M'36M_3^75E/5&<W7N7KG9^>WQBI,'N[*8:"KS^(EQLV':GJ'+:HS2U!,\!
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M?O\ -4N>R=9C\5DL7BJ:2HJXG1Z:KK!15"4E,TWVZS^Z]TB?^$]_R'WQM_\
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M)(ZQQQK_ "9'=W8*%"X7;!))/  'U/OW7NC@_P#"ES_F3O\ *O\ _&V?P?\
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MQ]C[[P/_ "LLW_-&#_JV.@#]WO\ Y5B#_FK<?]76ZLQ]PIU-O5#?97\YO/[
M[&W_ +$B^/\ A\I'LG>VZMHQY-^QIJ1JA=MUT]&)S$,-((C,(=902-IO;4UK
MG*G9/NWQ;O96]V;]E\:&*;3],#I\1%>E?&%::J5H*^G6)N^_>:DV:^N+,;<K
M^!/-#K^J*ZO"D9*T\ TKIK2IIZGI$_\ #Y.XO^\<<+_Z,Z?_ .L?LS_X%Z+_
M *.+_P#9*/\ K?T5?\%9+_T;%_[*S_VS]>_X?)W%_P!XXX7_ -&=/_\ 6/W[
M_@7HO^CB_P#V2C_K?U[_ (*R7_HV+_V5G_MGZ]_P^3N+_O''"_\ HSI__K'[
M]_P+T7_1Q?\ [)1_UOZ]_P %9+_T;%_[*S_VS]>_X?)W%_WCCA?_ $9T_P#]
M8_?O^!>B_P"CB_\ V2C_ *W]>_X*R7_HV+_V5G_MGZ]_P^3N+_O''"_^C.G_
M /K'[]_P+T7_ $<7_P"R4?\ 6_KW_!62_P#1L7_LK/\ VS]>_P"'R=Q?]XXX
M7_T9T_\ ]8_?O^!>B_Z.+_\ 9*/^M_7O^"LE_P"C8O\ V5G_ +9^O?\ #Y.X
MO^\<<+_Z,Z?_ .L?OW_ O1?]'%_^R4?];^O?\%9+_P!&Q?\ LK/_ &S]>_X?
M)W%_WCCA?_1G3_\ UC]^_P"!>B_Z.+_]DH_ZW]>_X*R7_HV+_P!E9_[9^O?\
M/D[B_P"\<<+_ .C.G_\ K'[]_P "]%_T<7_[)1_UOZ]_P5DO_1L7_LK/_;/U
M[_A\G<7_ 'CCA?\ T9T__P!8_?O^!>B_Z.+_ /9*/^M_7O\ @K)?^C8O_96?
M^V?KW_#Y.XO^\<<+_P"C.G_^L?OW_ O1?]'%_P#LE'_6_KW_  5DO_1L7_LK
M/_;/U[_A\G<7_>..%_\ 1G3_ /UC]^_X%Z+_ *.+_P#9*/\ K?U[_@K)?^C8
MO_96?^V?KW_#Y.XO^\<<+_Z,Z?\ ^L?OW_ O1?\ 1Q?_ +)1_P!;^O?\%9+_
M -&Q?^RL_P#;/U[_ (?)W%_WCCA?_1G3_P#UC]^_X%Z+_HXO_P!DH_ZW]>_X
M*R7_ *-B_P#96?\ MGZ]_P /D[B_[QQPO_HSI_\ ZQ^_?\"]%_T<7_[)1_UO
MZ]_P5DO_ $;%_P"RL_\ ;/U[_A\G<7_>..%_]&=/_P#6/W[_ (%Z+_HXO_V2
MC_K?U[_@K)?^C8O_ &5G_MGZ]_P^3N+_ +QQPO\ Z,Z?_P"L?OW_  +T7_1Q
M?_LE'_6_KW_!62_]&Q?^RL_]L_7O^'R=Q?\ >..%_P#1G3__ %C]^_X%Z+_H
MXO\ ]DH_ZW]>_P""LE_Z-B_]E9_[9^O?\/D[B_[QQPO_ *,Z?_ZQ^_?\"]%_
MT<7_ .R4?];^O?\ !62_]&Q?^RL_]L_7O^'R=Q?]XXX7_P!&=/\ _6/W[_@7
MHO\ HXO_ -DH_P"M_7O^"LE_Z-B_]E9_[9^O?\/D[B_[QQPO_HSI_P#ZQ^_?
M\"]%_P!'%_\ LE'_ %OZ]_P5DO\ T;%_[*S_ -L_7O\ A\G<7_>..%_]&=/_
M /6/W[_@7HO^CB__ &2C_K?U[_@K)?\ HV+_ -E9_P"V?KW_  ^3N+_O''"_
M^C.G_P#K'[]_P+T7_1Q?_LE'_6_KW_!62_\ 1L7_ +*S_P!L_7O^'R=Q?]XX
MX7_T9T__ -8_?O\ @7HO^CB__9*/^M_7O^"LE_Z-B_\ 96?^V?KW_#Y.XO\
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M_P#9*/\ K?U[_@K)?^C8O_96?^V?KW_#Y.XO^\<<+_Z,Z?\ ^L?OW_ O1?\
M1Q?_ +)1_P!;^O?\%9+_ -&Q?^RL_P#;/U[_ (?)W%_WCCA?_1G3_P#UC]^_
MX%Z+_HXO_P!DH_ZW]>_X*R7_ *-B_P#96?\ MGZ]_P /D[B_[QQPO_HSI_\
MZQ^_?\"]%_T<7_[)1_UOZ]_P5DO_ $;%_P"RL_\ ;/U[_A\G<7_>..%_]&=/
M_P#6/W[_ (%Z+_HXO_V2C_K?U[_@K)?^C8O_ &5G_MGZ]_P^3N+_ +QQPO\
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M9S.$WC/#1U^U,OE8<=EJ#)4==)CVEEI8)HS-1PRGQNJ-82K[]U[JT#^9EO\
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MWNC?7QQZO^0'6?8'>76C9F+L;J[9VYH\[F,$<#.M)6G+4]*7;'"GJG2!FF9
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M^+?6^;CSVPOA1WC\E*G>/6]+)0U--68^ER=,N/IL_N7&8>>F48^DR^=K(Z:
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M[KW7O?NO=>]^Z]U[W[KW7O?NO=4H?%[_ +>X_+W_ ,1MN?\ ]VNRO>3'._\
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M ':_T._Z0?[V6S&T,M]O][_>K"?P+_CU/%Y/M,C_ ,"M>C]C1-[KW7?\U/\
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MQM+A/N\-E;U%0V3Q3P4A>F6FO-[KW2[ZJ_DG4P_FE]I?S2_ES\C:?Y8=@9?
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M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@!^5_\ V2U\E/\
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M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T+W672F]NT\'V7NK
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M\>>6;1]'JT>+(SZ:_5+6FJE:"O&@X=(S_AB__P "C_\ 8)?_ )W>S+_@H_\
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M &8_]OG7O^&+_P#P*/\ ]@E_^=WOW_!1_P#2,_[/?^W3KW_ H_\ 24_[,?\
MM\Z]_P ,7_\ @4?_ +!+_P#.[W[_ (*/_I&?]GO_ &Z=>_X%'_I*?]F/_;YU
M[_AB_P#\"C_]@E_^=WOW_!1_](S_ +/?^W3KW_ H_P#24_[,?^WSKW_#%_\
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MW_ H_P#24_[,?^WSKW_#%_\ X%'_ .P2_P#SN]^_X*/_ *1G_9[_ -NG7O\
M@4?^DI_V8_\ ;YU[_AB__P "C_\ 8)?_ )W>_?\ !1_](S_L]_[=.O?\"C_T
ME/\ LQ_[?.O?\,7_ /@4?_L$O_SN]^_X*/\ Z1G_ &>_]NG7O^!1_P"DI_V8
M_P#;YU[_ (8O_P# H_\ V"7_ .=WOW_!1_\ 2,_[/?\ MTZ]_P "C_TE/^S'
M_M\Z]_PQ?_X%'_[!+_\ .[W[_@H_^D9_V>_]NG7O^!1_Z2G_ &8_]OG7O^&+
M_P#P*/\ ]@E_^=WOW_!1_P#2,_[/?^W3KW_ H_\ 24_[,?\ M\Z]_P ,7_\
M@4?_ +!+_P#.[W[_ (*/_I&?]GO_ &Z=>_X%'_I*?]F/_;YU[_AB_P#\"C_]
M@E_^=WOW_!1_](S_ +/?^W3KW_ H_P#24_[,?^WSKW_#%_\ X%'_ .P2_P#S
MN]^_X*/_ *1G_9[_ -NG7O\ @4?^DI_V8_\ ;YU[_AB__P "C_\ 8)?_ )W>
M_?\ !1_](S_L]_[=.O?\"C_TE/\ LQ_[?.O?\,7_ /@4?_L$O_SN]^_X*/\
MZ1G_ &>_]NG7O^!1_P"DI_V8_P#;YU[_ (8O_P# H_\ V"7_ .=WOW_!1_\
M2,_[/?\ MTZ]_P "C_TE/^S'_M\Z]_PQ?_X%'_[!+_\ .[W[_@H_^D9_V>_]
MNG7O^!1_Z2G_ &8_]OG7O^&+_P#P*/\ ]@E_^=WOW_!1_P#2,_[/?^W3KW_
MH_\ 24_[,?\ M\Z]_P ,7_\ @4?_ +!+_P#.[W[_ (*/_I&?]GO_ &Z=>_X%
M'_I*?]F/_;YU[_AB_P#\"C_]@E_^=WOW_!1_](S_ +/?^W3KW_ H_P#24_[,
M?^WSKW_#%_\ X%'_ .P2_P#SN]^_X*/_ *1G_9[_ -NG7O\ @4?^DI_V8_\
M;YU[_AB__P "C_\ 8)?_ )W>_?\ !1_](S_L]_[=.O?\"C_TE/\ LQ_[?.O?
M\,7_ /@4?_L$O_SN]^_X*/\ Z1G_ &>_]NG7O^!1_P"DI_V8_P#;YU[_ (8O
M_P# H_\ V"7_ .=WOW_!1_\ 2,_[/?\ MTZ]_P "C_TE/^S'_M\Z]_PQ?_X%
M'_[!+_\ .[W[_@H_^D9_V>_]NG7O^!1_Z2G_ &8_]OG7O^&+_P#P*/\ ]@E_
M^=WOW_!1_P#2,_[/?^W3KW_ H_\ 24_[,?\ M\Z]_P ,7_\ @4?_ +!+_P#.
M[W[_ (*/_I&?]GO_ &Z=>_X%'_I*?]F/_;YU[_AB_P#\"C_]@E_^=WOW_!1_
M](S_ +/?^W3KW_ H_P#24_[,?^WSHZ?;GQXV)\8OY=7=75^Q:<20T?6N:K]Q
M;@GIU@JLOE*E8%JLC5Z2UGET(D<>MA! D4"L5C!,9\O\WW7._.-E?71RUS&L
M<8-5BB!.E%^0K4F@U,2QR>I7W_DZTY&Y-OK"S&%M)6D<COFE*49V^9H !P50
M%& .EC_*\_[(6Z._\J9_[V&X/:'WS_Y6J^_ZAO\ M$M^E?L/_P JI8_]1/\
MVF7'1_/<2]2]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=4H?%[_M[C\O?_$;;G_\ =KLKWDQSO_T[W:?^>F/_ *MWO6,?
M)'_3QMW_ .>1_P#C]CU=?[QGZR<Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MJ^_E#_+_ -J_)[Y>? 'Y>9?L3<&U-R? 3<G>.XMI[0QN&ILC0[A/>>,PN*K8
MLC/+)'/2"BAPR/ T.K4\I\BE5"GW7NK!/?NO=5@?S&_@%W;\\:'9VQ]B_/?N
MWX@]-U>%W7L[Y"]?=.;4Q64JM]8/<Z1K]G#G*^5:C;%9 %FB-3!3525%-434
M]132*8VC]U[H^G3/4/7_ $!U+UMT?U3@8-K];=3;)VWU]L?;],2ZTN,VK214
M=)$SGU2R>*)3)(UWDD+2.2S$GW7NA+]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= #\K_\ LEKY*?\ B >X_P#W
MG<C[%O(/_)=VW_GOL_\ M(CZ"'N#_P D#<O^E?>?]H\G13/Y27_9&>U__#UW
M[_[G'V/OO _\K+-_S1@_ZMCH _=[_P"58@_YJW'_ %=;JS'W"G4V]>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%,^=O_9'W
MR&_\1MF?][3V/O:W_E8MO_YZ8_\ #T ?=/\ Y5S<?^>27_CO0;?RO/\ LA;H
M[_RIG_O8;@]GGOG_ ,K5??\ 4-_VB6_0?]A_^54L?^HG_M,N.C^>XEZE[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI0^
M+W_;W'Y>_P#B-MS_ /NUV5[R8YW_ .G>[3_STQ_]6[WK&/DC_IXV[_\ /(__
M !^QZNO]XS]9.=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=1*^@H<I0UF,R='29'&Y&DJ*#(8^OITK()X*Q#'+#-%(
M&CEBEC9E=&4JRDJP()'MR*5H&#H2K*0RLI(96!J"",@@Y!'#JDL2S*4<!E8%
M65@"&!%""#@@C!!X]0,!MO;NU,<F'VM@,+MK$QRRSQXO 8J##TZO.;NX@IXX
MX@SGEB%N3]?;MU>37S^).[R-0#4[,[4'#+$GIJUM(K)/#A1(U%3I10BU/'"@
M#IZ]INE'7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW4#*8K%YS'5>(S>-Q^8Q-?"U/7XS*4<>0IYXV^J30S*\<B&PNK*1_A[
M=@G>V<21LR,IJK*2K ^H(H1TU- ERACD565A1E8!E(]"#4'K#A,%@]LXNEPF
MV\-BMOX6B\WV>(PF.AQ5+#]S(\TGBIX$CBC\DLDCMI0:G9F-R2?=KFZEO',D
MSM(YI5W8LQH !4L230  ?(4ZK;6T=F@CA1405HJ*%45))H%  J22?F:].OMC
MI_KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z35#LS9^+S^0W7C=J;:QVZ,M#)3Y7<E#@J6DKZF.5HW=*BLCB6HF1GAA8J\
MA!*(2+JMEDNXW$T2P/+(T:FJQL[%%(J*A2:#B> \SZ](X]OMX96G2*-9&%&D
M"*'88P6 J> XGR'ITI?:/I9U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=-^
M6RV*P.*R>=SN3Q^%PF%Q]9ELQF,M61XZEI*7'1M-45-343,D,%/!"CO)([JB
M(I9B%!/MZWMY+N18HE9W=@B(@+,[,0 J@ DDD@  5)P.F;BXCM(VEE941%9W
M=V"HB*"69F)   !))- ,GIIVCO79N_\ "Q;CV'NW;.]MO3SU%-!GMHYZEW)1
M/)2-IEC6JHY9H&>-N'4274\$ ^W]PVRYVF4PW<4D,@ )CEC:-P"*@E7 -#Y8
MSTGV[<[;=XA/:2Q31DD"2&19$)!H0&0L#0X.<'I3>T72[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[IISV?P6UL/D=Q;GS6
M)VYM_$4SUN6SF>R4.(HZ6&/]4M14U#QP01+<79W51^3[46MI+?2+# CR2.=*
M(BEW9CY*J@DGY =)[J[BL8VFG=(XT!9W=@B(HXEF8@ #S)-.HVU]V;6WQ@J'
M=&RMR[?W?MG*?<_PS<6U\S3;@H*C[*:2GF\%72234\WAJ(98GT2'3(CHUF4@
M7OMOGVN5H+F.2&5::HY4:-UU ,*JX!%00149!!X'INPW"WW6);BUECFB:NF2
M)UDC;22IHR$@T((-#@@CB.G_ -I.EG7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TB<7V7USG-W9CK_  N_]DYC?FWJ:6MS
M^R<7NJ@R&7H88'@C>6LQL4[UE-$CU-,K-)"JAI8P3=UN9S[+>6MNEY+!,D$A
MTQSM$ZPNQ#&BN5"L>UL G@?0]%<&]V5S<O9QW$#W$8U20++&TR+VBK(&+*.]
M<D =P]1TMO99T:=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO= #\K_^R6ODI_X@'N/_ -YW(^Q;R#_R7=M_Y[[/_M(C
MZ"'N#_R0-R_Z5]Y_VCR=%,_E)?\ 9&>U_P#P]=^_^YQ]C[[P/_*RS?\ -&#_
M *MCH _=[_Y5B#_FK<?]76ZLQ]PIU-O7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW13/G;_V1]\AO_$;9G_>T]C[VM_Y6+;_
M /GIC_P] 'W3_P"5<W'_ )Y)?^.]!M_*\_[(6Z._\J9_[V&X/9Y[Y_\ *U7W
M_4-_VB6_0?\ 8?\ Y52Q_P"HG_M,N.C^>XEZE[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBP?,7Y@]%_ _X_P"\
M?D[\D-PY7:W4&PZS:U!N7.87;=;NRHADWCE*3#T 2@Q\4]7,):^NID8I$V@,
M7:R*Q'NO=&3QU?3Y3'T&3I"S4N1HZ6OIF==#&.L19$)4_0Z6%Q^/?NO=3/?N
MO=>]^Z]U[W[KW7O?NO=%4^4GS/Z#^''^@K_3ON+,;>_V8[OK8WQJZI_A.V:W
M<GWN[NQO/_":&?[**7[*"H^VFU5,^BGBT_N2+<7]U[HU?OW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H-<[W'U7MCLO8?3.?[ VKB^V>S
M\9NC-]?]<5.7B&9RM#LF%)LO7TF/#&I>@QR2PB>I,8@CDEAA:02S1(_NO="5
M[]U[KWOW7N@USO<?5>V.R]A],Y_L#:N+[9[/QFZ,WU_UQ4Y>(9G*T.R84FR]
M?28\,:EZ#')+")ZDQB".26&%I!+-$C^Z]T#^3^9W0N)^9FWO@/5[AS ^2NY^
MA)_DMB]JQ[:K'H3M"GS%=@6KWR_B_AZ3_P 4Q]3%]KYS46"R>/QMJ]^Z]T:K
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5*'Q>_
M[>X_+W_Q&VY__=KLKWDQSO\ ].]VG_GIC_ZMWO6,?)'_ $\;=_\ GD?_ (_8
M]77^\9^LG.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7N@!^5_\ V2U\E/\ Q /<?_O.Y'V+>0?^2[MO_/?9_P#:1'T$
M/<'_ )(&Y?\ 2OO/^T>3HIG\I+_LC/:__AZ[]_\ <X^Q]]X'_E99O^:,'_5L
M= '[O?\ RK$'_-6X_P"KK=68^X4ZFWKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K5W^5
MOSB_G ]@?SB^V_Y:_P#+LW+\)MK8KK?XI;.^3L^6^5^UMS/&:6KK,%B,E2P9
M';,63J):E\AN"AD@BDQ21B%:DM5!EBB?W7NL_9/R%_X4L?!K8^YOD;\C>I/Y
M;/S/Z*ZUP]5NKM7KCXHYK?FS]\4V#PY2;)Y3$2[AQ5#0SMCJ)*BHDB%!72M$
MCE("5]^Z]U?C\1/E5U#\V_C?U+\I.B<X<[UEW!M:#<>$DG\:U5'/%))2Y'$Y
M&**25(,IALE!5T5;$)'$=3!*JNZ@,?=>Z,=K37XM:>31K\>H:M-[7M];7XO[
M]U[KE[]U[KBKHY=5=6:)@DBJP)5BH:S ?0Z64V/X(/T(]^Z]T3_OG_9V?]F)
M^(G^R\_Z'/\ 98_X[VA_LZ?]^ON?[S_8?98O^Z']S?'_ )+Y/XA_%OXEY^?M
M_%X?W/?NO='"]^Z]UQ1TE1)(W62.15>.1&#JRN+@@C@@CD$>_=>ZY>_=>ZXH
MZ2 M&ZNH9T+(P8:HF*L+C\JP((_!!!Y]^Z]UR]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]T4SYV_]D??(;_Q&V9_WM/8^]K?^5BV_P#YZ8_\/0!]T_\ E7-Q_P">
M27_CO0;?RO/^R%NCO_*F?^]AN#V>>^?_ "M5]_U#?]HEOT'_ &'_ .54L?\
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M.RLI)"XSV2K:1:?8>'R=/CJBGK*O&P#*MCU6KIW>M:-:B/W7NC9?S/?YP?\
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MC)(TV$VENG ;YIXLW239Y5EAI:^"J:$5"HI@>%JBHH_=>Z>/FQ_-<^371/\
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M^M1X(Y3(AJ)EAI:KW7NA2^:/\V/Y*])_S/.K/Y;/QC^*^V/D5O#O?X;4/?\
MUKN?(;SJ-IT&/SE=N?<V,FJ-V91$J*?%['QN"VQ55<M73TE375-=+28ZEA9Z
MR-T]U[I"[ _F)_S1_BM\Q_BG\6_YJ_1_PTK=E_-K=FX^O.EOD#\'MR[O3%XG
M<^)HXZRGP.XL3O=Y,A+)6-(L,4T!A3UJ4^Y\,[#W7NBH?-C(_P Q*G_X42_$
MQNF=G_"W+[GIOB%\C(OCU#V=V1OG;M!6;4EGI&S4^\Y,5M3*5&-W#!7&5**#
M&Q5U'/ J2SU%/(S1)[KW5K'S0^;GS4VU\B>N?@[\"?C1L7L[Y'[TZ@S?<6].
M\/D/4[HVAT]LO'8F>*@2.OR>$QDV0W!E)\A44W^XRAK(:J*GGII)67[A2GNO
M=%'VS_,8_FC_  Z^8'Q&^-_\U_J?X+U_6OSA['R_3_3_ '[\*-W;QQU)A=V-
M#$^*PF=Q.^R:VL;+UU7145*\"TXO*&#U,L;1R>Z]T5_YL9'^8E3_ /"B7XF-
MTSL_X6Y?<]-\0OD9%\>H>SNR-\[=H*S:DL](V:GWG)BMJ92HQNX8*XRI108V
M*NHYX%26>HIY&:)/=>ZMLS?S=W%C/YT/5_\ +RK>I>M:BCW'_+VG^5>3[J5)
MYMP4U;!O#.;:DV]0LZJJ8<_8"I#.3(6DD4H-6H>Z]T4>K_F3_P Q[YV=W?(;
MKG^3MTU\/Y>FOBAVI5]'=H?*?YW[AWC1X'<.\]LQROG]O[0P.QT&9>+$&7'%
MLE52&">.8/%$(YZ>8^Z]T9'X$_S*.YNU?E!W#_+R^>'1VS?CO\X>G]AX+N#$
M0=7;PJ=Z['[ V3FGAI&W/M&LR,-/E*=:+)R&GJ:*J222/@B=Y8JR&E]U[HD?
M6'\US^:+\X.YOGS\8O@?\4?C%@-^?"_YB=O]!Y+Y$_*3=^Z*#KE,!L7.UF&P
MRM1[<CGW%F]ZY9<3EIZNEI!3T&)@^PJ)I*C[R.G/NO='*_EM_P Q/Y/=V?)3
MY,_ 7Y[]']7]._,+XP;3V!V-7YSH;<M?N'8^\-L=@*J09K 1YAY<Q01PU,D"
M/#4U$SCS*CF.:*6,>Z]U=/[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI0^+W_
M &]Q^7O_ (C;<_\ [M=E>\F.=_\ IWNT_P#/3'_U;O>L8^2/^GC;O_SR/_Q^
MQZNO]XS]9.=:TO\ PH(_G6]D_P NB+I#XH_#G:N$[#^=WRJJ:5-AT.4I8=R1
M[9Q65R<6$QN0;"&>.3(YC<F9>HH<'%,GV+34=?-5>44J4E5[KW59F]/@-_PK
M5V-TI6_)"@_F=;=WAW3@<77[UR_QGP-?1ULKT]!25$S8_&K4[/79V2SA$<*+
MCVI8*!Y7?Q5\CI'Y_=>ZO&_D&?S-.ZOYG'PU/9'R,ZAS/6?<FP<UC]M9[<L6
MR<EM';F],?E:05.+W5MMJV/[>6*L1)XJV&EJ9H8*J$R1^&GJ:>)?=>ZM%[P^
M6GQ7^,BX=ODA\EN@OC^NX9?#@/\ 35W#M[JW[YA>XI!G,C0FIT $L8]050S-
M95)'NO="MLC?NQ>S=M8W>G6^]-I]@[.S,0GP^[-D;CH]UXRK0V.NFKZ":HI9
MTL1RDK#GW[KW3/\ Z7NIO[T9[9'^E#KO^^FUL=/F-S[1_OKC?XICJ2ECBEEJ
MJ_'_ '/W='31Q3P.TLL2(JR1L6 =2?=>Z0G3?RP^+7R+J=TT7Q^^270G>59L
M>4P[TI.H.W]O]DRXA@Q2V2CPV0K6H?4K &8("00.0??NO=-_6'S&^(_=F_-S
M=6=-?*/X[]L=F[+JZ^AW=UWUMW1MS>^<QDV*9XZJ.NQ6,R5374S4TL<L<WD@
M7Q2QRQ/IDBD5?=>Z%3(=H]98C>>.ZYRO8NQ,9V%F*45V(V'D-W8^BS-5 5F?
MS4V+DJ%KIXM%-4-K2!EM%(;V1K>Z]T&FP/EU\4>U^R=Q]-=7?)OX^]D=O;/^
M[_O9U;L/N3;N[]Q8S[!M-1]_A<?D:C)4GV[>F7RTR^-N'TGCW[KW43'_ #)^
M(F7[FK_CGBOE+\=<E\@L5-'39+HZA[JVW5[N@EE19!#+MQ,DV72<1R1.8S2:
MU22)V4++&6]U[H=MQ[EVYL[!93=&[L_A-J[9P=))7YK<6X\K!@Z&C@B_7-55
M=5)%3T\*W%WDD51^3[]U[H$.D/E_\3?DS/EJ7XX?)_X]=_5> &K.TG2W<^W.
MT9:(:M(:JCPF2KGIT8VTM(JJP(*D@@GW7NA0WAVAUIUY5X#'[_[$V+L:OW94
MST>UJ+>&[<?MF;)34K0)+%CXZVH@>LDC>JIE985=E::($ R)?W7ND-LKY0?&
MKLGLW>/2O7?R$Z1WYW'UX&;?W5&S>U<%N?<F$"%58Y;!T5?/D\>%9E#>>FCT
MD@&Q('OW7ND?VQ\X?A9T-O&AZ\[Q^7GQAZ:W]D_ <?LCM3OO:O7V7F%5Q$T>
M-RV5I*QEE8JJ,(;,S*JDLR@^Z]TZ_)NLWSNGXD?(>M^/79NSMB]F9_X[=NR]
M)=QYO/TU+@,+G\AMO(_W=W)6Y-J?(4<6)QF2:CK)ZDTM3$D$3R-#,@*-[KW1
M$?Y*^$^<N!^+6_J/^8!\LNF?F/W))W_NFIVUV=T;OC'[^Q-#ME]N[56CP-16
M8[!;>@BR-+E4S-7)"U$[K#6T[F=ED6./W7NC;[^_F(? 'JK?<W5W9_SA^(G7
M79--51T-9L#?/R0V=M3,P3S'3'#48VNS,%93RRL=*))"K.WI0,W'OW7NFS^8
M%VYN+KG^7/\ -[O7IK>,.,W?L#X6?)?M7JW?VWIJ7,I2Y3:.Q\WEL+EJ)W6I
MHJG[>LIJ>>(LDL+Z1J5T)!]U[JGW_A*_\U/E#\[?Y?/<7;GRT[>SG=/8VW?F
M3V#UQA=TY_&XW%34^$Q&R>O,G38]8\714%.T45?E\E,&:$R%IV!<J$5?=>ZV
M6O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TA<_P!H=:;4R+8C
M=/8FQ=MY9(HIWQF?W;C\/4!)Q=',%141R!' .DZ;'\>S.UV6\OD\2"":1:D:
MDB=UJ.(JJD=%USO%I9-HFGAC:E=+R(K4/G1F!Z:H.[>F*J:*FINW.L*BHG=8
MX8(-_8J9W9N JJM669B?H +^WFY<W! 2UK< #B3!* /^,],KS!8.:+<VY)X
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M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UQ=TCTEW1
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M:,<>_=>Z]0?$3X\8SY8YKYQ4/7O@^4>X>DHOCIF.T/[V9R3S;-@RU)G5P_\
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MMZSW7[L?_)-O/^>E?^K2]>^]'_R4++_GGD_ZN]71?.S_ +(]^1/_ (C'/_\
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M@M($8JRL%&6 (8$*"14&E*D!QV%\@/G3\QOCGO'K;#_%O-[&HJ?:<E9V3O\
MK:/)B3.)MV/[M\9MW$38VGJ&R&6JJ>*+P4[5[*LC1L84?RH<;1RERM[=;Q#>
MR;FDY,H%O IBI"9#I$DT@E9=$:L3J;PZD5&JFDE&\<W<U^X^S3V4>U/; 0DW
M$[B6LXC748X(FB5B\K*%HOB4!(-*A@+G\OSKS?\ UK_+_P#DS@NQMC[PV!FZ
MO.=S9:EPV]MLUNU:J6EGV5A84J8Z>O@@F>G>:"=%D"%"\<B@ZD8 /^[V[VF]
M<U[=+9SPSH([1"\,B2J&%Y,2I*,P! 8&E:T(/F.A![,;/>;)RIN$5[!-;N9;
MMPD\3Q.4-G  P615)!*D5I2H(\CU6K_+YWU\F^DZ+LWN3H[K/_3)L:FJ-O;7
M[2Z_QQGFR+$QU=3C,C314L$]5:D)JT:2*&H")+)YH A6:.:?=W;-DYF>VVW=
M+GZ.<B26UN&T^'Q571BS*O=12 2M2HHU:J82]G-RWSEB*ZW/:[47L&J.&ZMU
M+>-4!G1U"JS474P.D-AC5:=P'S#]5_)C^9-\I-J]G=O]5Y?K#IS:#8?'Y&GS
M6*J\71Q8C!5$E9+BZ+^(QP2Y7(Y2>65)YXZ?1&L@,H2.**(A.XW[9/9G8I;'
M;KI+J\FULIC9&<RNH02-X981I& "JEJDC%2Q(%]OL&^>]._PW^Y6CVEE!H5E
MD5U7PT8N442A3(\C$AF"@!>/PJ"/W\\3_CQOC_\ ^'9OG_W#Q_L)_=A_W,OO
M^:,/_'WZ%GWI/]P;'_FO+_U;'0>;9^5?SR^-/1NSNG9/CK6;\D?8N#INH>X=
MOXK)[DHUQ66H8GQ4;04-'+3UE;C:>6.)(99::51'&L\$H_<F-KSD3E3G;<YM
MR&XBW'CN;NTD:*-_%5R)""[@JKD$U <9.EAP4KL^>^;.1MKAVP[:;DB!%M+R
M%99(_"9!X8*QQG4R @4)0X%5/Q,87^5O\+][]18KL'MSO+!5&)WEVAAO[J8W
M:V= EKX,-62K5Y"7)@LTD4^5J4IM5.["6-:<-. \@6,)>^?N3:\PR6^W[6X:
M&U?Q&D3$;3 :4"< 1&I:C#!U47 J19[$>VEWRW'<;CNJ%;BZ7PUC>AD6$G6Q
M<U)#2-0E2:C2"V30%%H.I/EO_+)[SW?N[J/K7+=U=,;KBEQ^O%XNLSL=1C5F
M>IHX\DN.62LQ65QEF3[EZ=J5_))HUB;0D@S<P<O^]NUPV^XW*65[%W=[(FF2
M@5BGB$*\;\= 8.*"M--3'L/+O,/L=NLUQMMJ]]8S=M$5W)CJS('\,,Z21Y&L
MJ4()\VHN3>.S/F)_-#[5V1_?;JO+=$],;+DJD%?F,76XZGI(,J87KJF)LDE+
M-G,M4)!%%%]O2I#$ GD$*&65];=N?+OL=83_ $MTE]>3 81D8L5J%!\,L(HP
M6);4Q9LTJ: ;W/:^8_?6_@%W:/M]C 34NKK0/I+$>*$,LA"@*50*OG2I),G_
M #9NC-[;@ZI^-^R>E^L=\[UQFP:O.X6+%;$VED-VO04&.QN.I*)9UH*>=H8_
M'!H1G"ABI N0?8+]@>9[:SW#<+G<KF&%IU1R\\L<0=VD=VH9&6IJ:FGKT-?O
M"<L75]MNWVVVVTTRP2,H2"&24QQK$J+41JU!04%>K;.F:"NQ?3_5.,R='5X[
M)8[K78M!D,?7T[TD\$])BZ6.6&:*0+)%+%(K*Z,H96!! ((]P!S#*LU_<NA#
M*UQ,RLI!# R,001@@C((X]9";#&T-C;(X*LL$(92"""(U!!!R"#Q'6OM\H=E
M_(#XZ_S$LG\D]G=,;K[&V_4[AI-T[4J<;@J_,T%;_%L%'C*VDEJ<=!*U+4PS
MRU2I&ZA_3'(%DC8%LMN1]SVCG#D]=EN;R*VD"&*4.\:.FF<RJP$C+J4@+4C&
M2*@]8A\];7O')W.;;[:V,UU&7$D6A)'1]5N(64F-6*L"6H"*X!H1UL!]+;SW
M/V'U3L+>^]-I5FP]U[FVY0Y;/;.KZ6IHIL=4U /DII(JR*&I0H1])(E:Q!M:
MQ]XF<R;=!M%_/:VTHGBBD9(YE*D2*.# H2IK\B1UEQRYN,V[V$%U<Q-!++$K
MR0L&#1LPJ5(<*U1\P#T)_LDZ.NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z 'Y7_\ 9+7R4_\ $ ]Q_P#O.Y'V+>0?^2[MO_/?
M9_\ :1'T$/<'_D@;E_TK[S_M'DZ*9_*2_P"R,]K_ /AZ[]_]SC['WW@?^5EF
M_P":,'_5L= '[O?_ "K$'_-6X_ZNMU9C[A3J;>O>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBF?.W_LC[Y#?^(VS/^]I['WM
M;_RL6W_\],?^'H ^Z?\ RKFX_P#/)+_QWH-OY7G_ &0MT=_Y4S_WL-P>SSWS
M_P"5JOO^H;_M$M^@_P"P_P#RJEC_ -1/_:9<='\]Q+U+W7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=5"_.O^3QU_\ //N;&]U;G^:_\QCX[Y+&;"PF
MP5V+\3_DA1=2;9FBP=9D:Q<E48RHVQF)),O4'(M%/4?= /#!3((U\19O=>ZU
MPO@__*87Y+?S#?YL_P 2]]_S+/YM6)ZY^!V[_BS@.H<UM+YDB@S>1A[OP.X\
MIEFW)4UFVZ^@K):>HP],M(:+&X]8XVE$RSLR.GNO=;>/PS^)FSO@-T!)T_B^
M\^^^Z-MX7/;IWWE.U?E?V;2]C;D"Y58Y:A*W.1XW#0#&T$-./"'I5$$0;5(5
M%Q[KW1)Z;_A0Y_)>J^W)^E(OG[T^F[J>LCH),[4X_<%%M$RRK$XT;]FPT>QY
M80LJWG3<+0*0Z-*'CD5?=>ZMBWWVEUMU?UUN+M[L7?FTMD]6[2VY/N_<O86Y
M<]38C#T6+IHA,U?49":1:9*7QE65_)9]2A=190?=>ZJGZ:_X4%_R=._.W*/H
M[K3YQ=?5G8N5S(V]@J+=>T-V=:XS)5TM7!00TN-W#N7;^)V]7U%765$45+%!
ME'DK.9*59HAY/?NO=%C_ )P'\VW8GPQ^87\N;H-?D_MGIS#YSY#XS>'S*P-7
M1?Y3%UT<76/BIZZKDH9Y:7"U^9A(E:BE6:=J?[>5O!YX9/=>Z.'WINKXG=]?
M)7^4_P!Y0?.'>6P:[<\W<F^?BGU#L#<E50;;[OHMXX3;D]6^9QPI;Y:DVYCC
M05]"TK0BF:M>?U L![KW0Z=Z_P T?^7[\9J[O;$]Z_*;K3KK-_&E=A#NO;V6
MFK:O)X:7M+%/F]N4B8VCHZFORN0S6)BDJ:2CQU/5U4T:,4A)4@>Z]UR^%/\
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MOR?VSTYA\Y\A\9O#YE8&KHO\IBZZ.+K'Q4]=5R4,\M+A:_,PD2M12K-.U/\
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MBY-<,W8G66T1E*RC@F#P19&6+#4D,=6(_N(86J(8I$CJ9U?W7NA"^66WMO\
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MD3MBZV.JIZN2GU%#4T-++I!CO[]U[J-_,T95_GZ_\)Z2S!03_,*6[&W+[#H
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M+J<_30B/:FZ:T[:8;EVGFIL!2Y-4:DI9*7*%#*61IJB<^Z]T17%?'WY*P?\
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M3PF_J/#++)2,^+I(JX5U%%(\U0E/44TH(B>21TE25 [@*QBOW.]O/ZC;JME
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M$$'W[KW3][]U[KWOW7NO>_=>Z+;\N_EETG\&_CQV%\I?D5G\GM?ISJ_^Z?\
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MQTZ07J/=>Z$OJ_\ V=G_ &;[Y._Z6_\ 0Y_LE?\  NJ?]E+_ +I?<_WO^_\
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M(*ZEE>6!IA4O,5B9V9Z=HWL4<Y>W/+G,FQ2[[L(\+PD>7M+K'((OC1DE(TL
M#IT4J: !JCHXY+]R.9.6M_BV#F#];QG2,$A&DC,G]FZO"#K0FFK74@$DE=)'
M6PA[Q(ZRZZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NBB=Z_"/H[Y$?(;XD_)_L2FW2_:OPIS?:&>Z/K,)N$XNBAG[@HL
M9CLV,G1>&1,A'-28FE2,,R&(ZV0ZF!'NO=&[]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]T /RO\ ^R6ODI_X@'N/_P!YW(^Q;R#_ ,EW;?\ GOL_^TB/H(>X/_)
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M4AJ'13/3S1^'SO2TWNO=57?RL>_/YX'\Y+X>X?OV;YF]7? S:>&S&^MH[8[
MZZ^,&V.Z-P]@9W;U=6G^*5F.W).^#V[M##M44&--#3T?\4R-7C*Z=ZZ"DJXH
MU]U[HT?47\T;Y;X3XX?SH.BODG'UK%_,)_E,]$]K=C4?96Q=M34>UMYXS([
MSF\>O=W# U3.E#//%0T;Y''?<&$K- 8P@EDBB]U[H#.C]U?\* OY@/P+ZC^=
MO77S2Z*^&&:J.EGW[L;XYT/QEP';R]CRX*@.G,[MW3E6JFVG2[OJ*2HJ:#'X
M?!3MC*"N@6IDJ:Z$20^Z]U/^&_?O\Z3^=-\.>MOE-T5\L>C?Y9NUUQ<VV,='
MMOXX8[Y)97L+='7SOC]QYJLDW76/0;+VE49^"IIZ''TM%E,A&M)+)55E5#4+
M3I[KW5D/\GS^8;V'\OOA%V;VG\K(=G[9[O\ B3W=WM\;OD_E=ET\E'@I,UT
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M0R321Q1@JI>5Q&+N0JBYL+EB /ZD@>_=>ZR>_=>ZQR2Q0J'FDCB0R11!I'"
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MU >'%%&"$12Q(514DDDY))8FGD !D+R7R58>WUD;6S!"U,DLLC O(VD LQH
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M^^_"_P")_P!=X.O_ )>/'\/7H_VNK1\]/ET?_P!5/]T'[C\7_EG_ $/CZ/\
MEW^G\31K_P!MIU_+5Y] U\,_A50?$WKSL'KO*;YINU\9V#FSD\B:S9:[8A$$
MM"M#-1RTS9/*K4QS1AM1,B@JQ0H1R1%[D>Y3<_WD%XD!M6@CT+2;Q3J#EPP8
M1Q4()Q@\*UZ#OMG[:+[>V4]D\XNEGD+L3#X0H8UC*E3)+4$#.1QI3HHFX?Y3
M6XME[RS>[/BM\GM]]&46=<M/MNGDR$;1(93(M*N5QF4H*BHH8=;"**IIII%
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M:CZN[?ZK:+>.)IO'%!'#5RU\]-(U*OV<LE*TL(@=Y:.E]U[JPGNS<>(^+?\
M._\ Y4'RG[PSJ;7^/G??\N++?"G9^^-Q.U!M_ =ATE?-N:EBKLG.3C\=6[JH
M<G1T%()&@DJ6@<"26.!UB]U[I+_\*\_DYT9M/^5KEOC_ )/L';%3W'WIVCU/
M4==; QV7ILCE)J#9.4@SF3S,E)'(T\&)IZ6E2$U;((FJ*NFA5BTW'NO=#_\
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M,JTM>'\<D-2M,NMJ5Q#[KW5\/\GW_MRK\%__ !2/K[_W0>_=>Z*7_P )4O\
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M-R0TM3_>E*62V+Q--0U$E;45-1)#+X0#1TU:L=6]-[KW2CZ0^(>^>S?YQO\
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MHJ7IE87$32-&"39?4;^Z]T9;;&UML[)V_B-I;,VY@MH[5V_0PXS [9VQB*?
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M=3#B-U8VHJYJ?%8>EK*^:*EIXWEF9("L<:L[E5!/OW7NBW?SG^E^RL=_,O\
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M[Q&Z9_VS_P#VP?:_^J7MU_T=KS_5_P!2_HO_ *W>Y7_1HL?VC_O8]>_V8/\
MG#?]XC=,_P"V?_[8/OW]4O;K_H[7G^K_ *E_7OZW>Y7_ $:+']H_[V/7O]F#
M_G#?]XC=,_[9_P#[8/OW]4O;K_H[7G^K_J7]>_K=[E?]&BQ_:/\ O8]>_P!F
M#_G#?]XC=,_[9_\ [8/OW]4O;K_H[7G^K_J7]>_K=[E?]&BQ_:/^]CU[_9@_
MYPW_ 'B-TS_MG_\ M@^_?U2]NO\ H[7G^K_J7]>_K=[E?]&BQ_:/^]CU[_9@
M_P"<-_WB-TS_ +9__M@^_?U2]NO^CM>?ZO\ J7]>_K=[E?\ 1HL?VC_O8]>_
MV8/^<-_WB-TS_MG_ /M@^_?U2]NO^CM>?ZO^I?U[^MWN5_T:+']H_P"]CU[_
M &8/^<-_WB-TS_MG_P#M@^_?U2]NO^CM>?ZO^I?U[^MWN5_T:+']H_[V/7O]
MF#_G#?\ >(W3/^V?_P"V#[]_5+VZ_P"CM>?ZO^I?U[^MWN5_T:+']H_[V/7O
M]F#_ )PW_>(W3/\ MG_^V#[]_5+VZ_Z.UY_J_P"I?U[^MWN5_P!&BQ_:/^]C
MU[_9@_YPW_>(W3/^V?\ ^V#[]_5+VZ_Z.UY_J_ZE_7OZW>Y7_1HL?VC_ +V/
M7O\ 9@_YPW_>(W3/^V?_ .V#[]_5+VZ_Z.UY_J_ZE_7OZW>Y7_1HL?VC_O8]
M>_V8/^<-_P!XC=,_[9__ +8/OW]4O;K_ *.UY_J_ZE_7OZW>Y7_1HL?VC_O8
M]>_V8/\ G#?]XC=,_P"V?_[8/OW]4O;K_H[7G^K_ *E_7OZW>Y7_ $:+']H_
M[V/7O]F#_G#?]XC=,_[9_P#[8/OW]4O;K_H[7G^K_J7]>_K=[E?]&BQ_:/\
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M7]>_K=[E?]&BQ_:/^]CU[_9@_P"<-_WB-TS_ +9__M@^_?U2]NO^CM>?ZO\
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M[7G^K_J7]>_K=[E?]&BQ_:/^]CU[_9@_YPW_ 'B-TS_MG_\ M@^_?U2]NO\
MH[7G^K_J7]>_K=[E?]&BQ_:/^]CU[_9@_P"<-_WB-TS_ +9__M@^_?U2]NO^
MCM>?ZO\ J7]>_K=[E?\ 1HL?VC_O8]>_V8/^<-_WB-TS_MG_ /M@^_?U2]NO
M^CM>?ZO^I?U[^MWN5_T:+']H_P"]CU[_ &8/^<-_WB-TS_MG_P#M@^_?U2]N
MO^CM>?ZO^I?U[^MWN5_T:+']H_[V/7O]F#_G#?\ >(W3/^V?_P"V#[]_5+VZ
M_P"CM>?ZO^I?U[^MWN5_T:+']H_[V/7O]F#_ )PW_>(W3/\ MG_^V#[]_5+V
MZ_Z.UY_J_P"I?U[^MWN5_P!&BQ_:/^]CU[_9@_YPW_>(W3/^V?\ ^V#[]_5+
MVZ_Z.UY_J_ZE_7OZW>Y7_1HL?VC_ +V/7O\ 9@_YPW_>(W3/^V?_ .V#[]_5
M+VZ_Z.UY_J_ZE_7OZW>Y7_1HL?VC_O8]>_V8/^<-_P!XC=,_[9__ +8/OW]4
MO;K_ *.UY_J_ZE_7OZW>Y7_1HL?VC_O8]>_V8/\ G#?]XC=,_P"V?_[8/OW]
M4O;K_H[7G^K_ *E_7OZW>Y7_ $:+']H_[V/7O]F#_G#?]XC=,_[9_P#[8/OW
M]4O;K_H[7G^K_J7]>_K=[E?]&BQ_:/\ O8]>_P!F#_G#?]XC=,_[9_\ [8/O
MW]4O;K_H[7G^K_J7]>_K=[E?]&BQ_:/^]CU[_9@_YPW_ 'B-TS_MG_\ M@^_
M?U2]NO\ H[7G^K_J7]>_K=[E?]&BQ_:/^]CU[_9@_P"<-_WB-TS_ +9__M@^
M_?U2]NO^CM>?ZO\ J7]>_K=[E?\ 1HL?VC_O8]>_V8/^<-_WB-TS_MG_ /M@
M^_?U2]NO^CM>?ZO^I?U[^MWN5_T:+']H_P"]CT&G='>?\U7+].]L8KL3XN]3
M;?Z_R?6F^\?OG/8T-]Q0X>MQ=5'DZR#_ '_-7^]3433R)_DDWJ4?M2?H)WRS
MRQR';[E:26>YW<DZW,#01M\+S"52BG_$4PS  ]RX/$<>B/F?FCW!N-MNX[W:
M[..W:VG6>13W)"T3B1E_Q]\JI)':V1\)X= K\)^W/YB&T.AL/A/CE\?NN.P^
ML(MP;DGH-R[E#?=25514%JR)K;MPXT0R^E?\B7C^T_U]B;W.Y?Y/W#=GEWF_
MN;>Y*1AHX_@"A0%/^XDW$9/<?L'0:]L.8>=-OV>.+9=OM;BU#RE)93WEBY+
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M_P!2_KW];O<K_HT6/[1_WL>O?[,'_.&_[Q&Z9_VS_P#VP??OZI>W7_1VO/\
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MT=KS_5_U+^O?UN]RO^C18_M'_>QZ]_LP?\X;_O$;IG_;/_\ ;!]^_JE[=?\
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M -L'W[^J7MU_T=KS_5_U+^O?UN]RO^C18_M'_>QZ]_LP?\X;_O$;IG_;/_\
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M_O$;IG_;/_\ ;!]^_JE[=?\ 1VO/]7_4OZ]_6[W*_P"C18_M'_>QZ]_LP?\
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M]^_JE[=?]':\_P!7_4OZ]_6[W*_Z-%C^T?\ >QZ]_LP?\X;_ +Q&Z9_VS_\
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MQZ]_LP?\X;_O$;IG_;/_ /;!]^_JE[=?]':\_P!7_4OZ]_6[W*_Z-%C^T?\
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M]^_JE[=?]':\_P!7_4OZ]_6[W*_Z-%C^T?\ >QZ]_LP?\X;_ +Q&Z9_VS_\
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MWB-TS_MG_P#M@^_?U2]NO^CM>?ZO^I?U[^MWN5_T:+']H_[V/7O]F#_G#?\
M>(W3/^V?_P"V#[]_5+VZ_P"CM>?ZO^I?U[^MWN5_T:+']H_[V/7O]F#_ )PW
M_>(W3/\ MG_^V#[]_5+VZ_Z.UY_J_P"I?U[^MWN5_P!&BQ_:/^]CU[_9@_YP
MW_>(W3/^V?\ ^V#[]_5+VZ_Z.UY_J_ZE_7OZW>Y7_1HL?VC_ +V/7O\ 9@_Y
MPW_>(W3/^V?_ .V#[]_5+VZ_Z.UY_J_ZE_7OZW>Y7_1HL?VC_O8]>_V8/^<-
M_P!XC=,_[9__ +8/OW]4O;K_ *.UY_J_ZE_7OZW>Y7_1HL?VC_O8]>_V8/\
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M[V/7O]F#_G#?]XC=,_[9_P#[8/OW]4O;K_H[7G^K_J7]>_K=[E?]&BQ_:/\
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M=>]^Z]U[W[KW7O?NO=>]^Z]T4SYV_P#9'WR&_P#$;9G_ 'M/8^]K?^5BV_\
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ML/-N6&6CK<G2TE7E<_DZW.U.-FEHWKZS,RE8)95AIX6D+>_=>ZI1S/Q^V/\
M(;_A;1VCANR,!MG=VS>N<-U[V[D-I;MP,.XZ.OJ]F_'K9Z84FGJ5> 38W.UF
M,R4+O$^B2B4J ^AU]U[HR?\ PM!%=US\$OBIL'KG%TFR>L=Z?*7-YG?N%V?B
MXMNX^NR>'VU6RXO[^.C2&&>1O)73*LBMKD@27EZ=&7W7NKZ._?C#\&A_)A[%
MZ=R&Q.KZ;XA;:^%6;W5A)*?&4+8^CI=M[3.7QNZ:.J!IP<S!4TM+DHLB*A*F
M6M1*AI_*Q;W[KW6B'T3V?WNG_"1_YB[>7*[F3KS$_P PC96P,)4+4S4D<&VM
MPKL[-9C&4[1B'5C)MSU,4DRF2:*2HKJB-D4D^_=>ZW2/Y:71_P +LM_PGL^.
M^QNXML]<4/Q7WU\&J+>7R6JLC)'M?'$9G!2Y+?6=R>4I#25%%D*&N&3J),DE
M1'64<U.LT-1'+!'(ONO=5\?S9L)_+QVG_P )D?FMLK^6/N7J+</QGV?NGX]X
MB.+IGM&7MG'4&<J.V.L*ROI*W(U65S%;%EY*:JH*JIBJJO[EC4I53*7J3))[
MKW01_!+Y0?#'XE_\)-OBSV7\Z>I-M_('I_);C[PVC@>AMRXG'YM-W;GKNY>Q
MZ[#8NFI\FKT@J*88ZKR)G,;O1P4,U9&C/3@>_=>Z+1\Y.S/YI_R3_D9[LW7M
MKX,?R^_@U_*]?X\;'W]MSK3<._\ *]F[XGV?)5X3([.K=J+CJ*'!XRMJ7EQU
M72-7T-/6NS++(U/,P67W7NH7_=BC_OO^\P_?NO=7O?\ ":7XI]/=7_R??AKN
MQ>N^NLCV)V-1;R[OW-OX;(H$R=3E-T;DS#XRHFKI(9*MZW$8*/%8V.?SZA'1
MIX_&FE%]U[JB'^07_P!Q37\ZC_S(W_\ !%;-]^Z]T W_  KMH>@>F/G7T5VU
M\4MT;OV'_,%W3U/OC(?(;_0ZK8ITVFF%J\309_,5V/EBKJ/<-7MYLW12R(CO
M)@*02UDM+#3T;57NO=;"W_"4?;7P[P_\JG8F8^,5='E^R=Q;DR4ORYR.8CI8
ML[%ORC \F-KD@]<>'H,=-2_P0,=,F/E6I:U745?OW7NME_W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO= #\K_P#LEKY*?^(![C_]YW(^Q;R#_P E
MW;?^>^S_ .TB/H(>X/\ R0-R_P"E?>?]H\G13/Y27_9&>U__  ]=^_\ N<?8
M^^\#_P K+-_S1@_ZMCH _=[_ .58@_YJW'_5UNK,?<*=3;U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T4SYV_\ 9'WR&_\
M$;9G_>T]C[VM_P"5BV__ )Z8_P##T ?=/_E7-Q_YY)?^.]!M_*\_[(6Z._\
M*F?^]AN#V>>^?_*U7W_4-_VB6_0?]A_^54L?^HG_ +3+CH_GN)>I>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ4/B]_V
M]Q^7O_B-MS_^[797O)CG?_IWNT_\],?_ %;O>L8^2/\ IXV[_P#/(_\ Q^QZ
MNO\ >,_63G7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0
M ?+'HO\ V:#XL?);XT?WI_N/_LQ'Q_[DZ+_OK_!/[S?P?_2WMS)8#^*?PW[S
M'_Q#^'_Q#S_;??TWG\?B^XAU>1?=>ZKL_DG_ ,I+_AG?XY]G= ?[,!_LQ7^D
M;NS)=P_WM_T4_P"B/[/^(8+!87^'?8?WDW/]QH_@OF^X^]BOYO'X1X_(_NO=
M7)>_=>ZH^V?_ ":/[J?SMNU?YQO^S'_?_P"DW86.V1_LNG^B#[7[+[#8NV]E
M_=?WO_O3)]SK_N_]YX_[KQ6^X^W\A\7GD]U[H^/S\^!G0'\R'XS[T^+?R-PV
M2K=E;IDH\OA=P[<K$QF9V]F\-K.-SV$JI(IXH,C0M)( LL$U/40R34M5#-33
MRQ/[KW6LG!_PE2^3E?LNB^+^[OYUWR7SGP+QNY*BMI/CA2;,R-'IQ$>DT>)5
MJC>];@46E\4!4';[XY:A9*R#%P33,H]U[K8\VW_+#^&FUO@-4_RU,7U9#_LJ
M>0V#DMA9;:LV0<Y"L.8F-;4YRIRB".H;<<N6/\1%>H5XZU8Y(5C2*.-/=>ZU
ML8_^$H'R3VKL[=/QGZK_ )TWR0V1\%MW[F3)9CXY2;*R=3%-CJO[G^(4%0E#
MOG&;>GDR(K:K[MDV_!15LWV]378^HDI*=4]U[JY'MG^1WTAF/Y.>ZOY/7Q^[
M#S'2/7^XZ384C]Q[FVPO;>7GRFV-\8+?&5S>6QZ9/;<61K\]68>2%EAKJ*FH
MDGC6D@6EI(:/W[KW08P?\)^^G]S?R7^M?Y/_ '#W3F-]4G4NXMU[\V'\C]N=
M<4>SLEC=QYK>6Y]U4>5H]OUV3W#! *>CW1D,-5QC,&2LQ\U7XJBBDJ5-/[KW
M1*,/_P )H/DMO_XMS?#?Y8?SAN]>X_CGL;KZHVM\?.G-I=24W7^WL%E,1CZN
MEVOD=S1'<==E=XX7:=9+0UE!@I,Q10H]%3PI610(B)[KW1R,3_(BS%'_ "-]
MS_R7,G\NXLI197.4]?M[Y$1]!-1''4<?9^.[.>B?:)WM.*MWR%-74OF7<U.%
M6J6?PLT)CG]U[JUCX ?$_P#V1CX:?'OXC_W^_P!*/^@C85/LC_2!_=;^Y/\
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MU[W[KW0 _*__ +):^2G_ (@'N/\ ]YW(^Q;R#_R7=M_Y[[/_ +2(^@A[@_\
M) W+_I7WG_:/)T4S^4E_V1GM?_P]=^_^YQ]C[[P/_*RS?\T8/^K8Z /W>_\
ME6(/^:MQ_P!76ZLQ]PIU-O7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW13/G;_V1]\AO_$;9G_>T]C[VM_Y6+;_^>F/_  ]
M'W3_ .5<W'_GDE_X[T&W\KS_ +(6Z._\J9_[V&X/9Y[Y_P#*U7W_ %#?]HEO
MT'_8?_E5+'_J)_[3+CH_GN)>I>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NJ4/B]_V]Q^7O\ XC;<_P#[M=E>\F.=_P#I
MWNT_\],?_5N]ZQCY(_Z>-N__ #R/_P ?L>KK_>,_63G7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=:4/R,^0_RA^-/_  J#^2N^_B7\)\Y\\>QLM_+/V'M+-=0X#N3&](38["5^
M?V365.Y&RV4Q68IZB*CKZ#&T1I%IEDD;(+,)56!T?W7NC;]^?,C_ (4"?,KI
MSL?XS]1?R6\;\/=P=T[0SO6^1^1'<_S2VMV+BMLXW>%.]'DL@F)H\%A:R>M7
M'R5<=,\2UI@J9(9VHJE8S!+[KW1.OYOGP2SGP&_DW?R;?A#TCV3'B.S^M_YI
MGQ7PF#[HIL662+?N_L9VCF*O=$%'4O,YIJ;=66FJJ6GFD?QTL<%,3I0 >Z]U
M85WQ\./A]_PGL^"WSG_F#?$_:>[7^3(Z$HMDY?N#M??.:[>R.>W/V)N'&8K$
MYG+PY.KG@$U=O'+XVOR2TL5+3U!CO,@1 4]U[K-\3_\ A/%\$NU/BGM+?/SX
MZSS'RN^8GR1Z[VOV7\D?D1V7V1N.NW&VY=[XRGJZFGP5?!5XM\1C\"9HZ+'I
M%10O]M2PK5))8QCW7NBM?&/Y]?(_X)_#_P#GK?&+?'8^?[[[2_D[.G^RW]Q=
MJSC<^1R>V.\,1E)NN:?<DXGBFR]9MVHQR/7GQ4ZM#-%2QN%0>+W7NC#?"?\
MX3]?!OO/X7=>]L?/CJ[/_)KYC_+3J/:/;_R)[\[4[&RF;W32[@[2PE-724.%
MR-!D5H<;#MF.KBH:)J2-XRM'$S//$$4>Z]T6;^<?\;/D#\1?^$S/R%^/GR+^
M1=5\I=S]>]B]*X_9G;69Q]52Y>7:]5V=M2?#8S.5-74U4^3R6)22>E^]+KYJ
M:.G!C5D/OW7NK%?YF/QYZT[Y^/GPA?Y;_./:OQ,_E\[(H<%E?E1UEFM^U73T
MG:XR>VZ>GPFU)]U4^X<.\>*2;[AZG&1TM3-7+*986@J:2FFC]U[K60_FK]K_
M ,B?HCJ"A[[_ )+69;8GSN^,_8O4VZMN=E_%;!]C4^V:3&9K,0155!O#.S4_
M]S:JCR<$,J1P35S5%5)&U&2\4T\$ONO=7%_S[NL-W_)C^8C_ ,)Z^J-K]D[F
MZ9R/=&X_G%MC=&_=@5AQ>8H=N[MVSUNF\*;"UA#O09');6ES5!258!DI)JF.
MI3UQ+[]U[ID_G*_RPOAI_+,_D#?S*MK?#SK3(==8CM;,_$7/;X7+;SR^^JBL
MJ=K]L;$I:-C69JLKJN.**.HJ&6%9A"LDTKQQH9'O[KW5J?\ ,7_EOTG\Q/X#
M]/4&PLC3[$^7GQZVMUUWE\+NYHZS^#U&W-][/QM!6XZ&:N6&H>/#YBHI*:"L
M4P3)$Z4N06&2HH*>WNO=45=$=[_(K_A2GWATU\5/D)UWDNCOB]_+\IML;Q_F
M;[-BJDI*7LGN';5?7XNBV=24]%D:D+M%*_$5M>8):BH\-JE)PTT6'JV]U[K=
MWHJ*CQM'28['4E-08^@IH**AH:*!*6&&&E01Q0PQ1A4CBC155550JJ   ![]
MU[K4#_G([C^2.T_^%!O\GC<'Q&ZYZ_[:^0V/^/7RO_T?=?=I;MEV+@LA]UMK
M>,&6^^RL*M)2_:8.3)5,-A^[40Q0GB0^_=>Z=/FA_-T_GK_#"DV6GR%^#GP?
M^.^P.V,YCNNL+\N-R=P;F[.Z\V?GMU?=18X[P_NY%69K&4XE@1O//BTH&,L0
M>KTK4B'W7NK9/Y.?\LW_ (;]ZW[S[&["[?P'R)^47S>[:R'R-^1W>6U,/%B,
M1EJ_<<U=D:&CP>G5-482DGS67JX)Y7!GGR57/'#3PRI!'[KW5/?\D.F^1=;_
M ,):MZ4?Q';++\EZK:/S,I^E3MZ6GI\E_'IL_G%I!C)*IXH(LF26%&[2+HJ?
M$P.H#W[KW5;OQJI/^$V/=7QNPWQE^36+WY\!/YET/7]+/V;W?\L6WGL/L+!=
MJR1KD*S><^^*Z>CP<U0^X)ER]+#D9\8*JBFAC?'TA\D%/[KW5E_\^&1/C'_+
M!_DWUO=/R-/R+QO1'\S?X-9CL'Y0+@G#[GQ?7>U>P*JJW.U%CZ_<,U3+/C:4
MS/X,A735+JSJ\TLMC[KW4SX;]C;<_P"%%OS+[-[1^2&1JMI?$3X';XV=D^B?
MY<F[*:;#Y;<M=NF@7)8#M7M#&SJB9'%UM+(3B,>HFHU(>.1F@,LF7]U[K;TB
MBB@BC@@CCAAAC2*&&)!&J+& %55  55    L!P/?NO=9/?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW0 _*_\ [):^2G_B >X__>=R/L6\@_\ )=VW_GOL_P#M
M(CZ"'N#_ ,D#<O\ I7WG_:/)T4S^4E_V1GM?_P /7?O_ +G'V/OO _\ *RS?
M\T8/^K8Z /W>_P#E6(/^:MQ_U=;JS'W"G4V]:,OR-_[*%[X_\3-VA_[O*[WU
M#Y,_Y(]A_P \=K_U83KE1SS_ ,EO</\ GNN_^K\G0,^Q+T%NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K/2U530
MU--6T53/1UE'/#54E72S-3RQ2T[!XY(Y$(=)$<!E92"" 001[I)&LJE6 *D$
M$$5!!P00>(/F.KQ2M P="592&5E)#*P-001D$'((X=;-G\N;^8S3=T4V)Z0[
MORT%'V[1P)1[2W;6.M/%N:*G6RP3L;(F<1!R.!6 %T G#*^$GO'[.-RRS;GM
MBDVA-98ADVQ/F/6(_P#&.![:'K.WV7]Z%YK5=KW1@MZHI'(:!;I0/V"4#B/Q
M_$N:@7&^\=>LD.O>_=>Z][]U[KWOW7NDM)N.M21T&V,Y($=E$B+!9M)M<7F!
ML?QQ[]GT/6JCKA_>6N_YY7/?\DP?]?O?J'T/7JCKW]Y*[_GE<]_R3!_U^]^S
MZ'KU>O?WEKO^>5SW_),'_7[WZA]#UZHZ]_>2N_YY7/?\DP?]?O?L^AZ]7KW]
MY*[_ )Y7/?\ ),'_ %^]^SZ'KU>O?WEKO^>5SW_),'_7[WZA]#UZHZ]_>6N_
MYY7/?\DP?]?O?J'T/7JCKW]Y:[_GE<]_R3!_U^]^H?0]>J.O?WEKO^>5SW_)
M,'_7[WZA]#UZHZ]_>6N_YY7/?\DP?]?O?J'T/7JCKW]Y:[_GE<]_R3!_U^]^
MH?0]>J.H-1O:2DN:G;&X(D!Y?Q1.!_R3*2?]@/?J=>K7IZ_O!%_=[^\/V59X
MOM_N?LK)YK:]-K:M.K\VU?3CZ\>_=;Z4'OW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@0^2GR#ZS^*'0?;GR0[CS<>W
M^M.F-BYW?F[,@WJD:#"Q%XZ2EC_5/7Y"H,-+20*"\]5-##&"\B@^Z]UJ'?RK
M_G;_ #&MV_S.?AQO;YL=S[PQ_1W\VOX^_*;NOXX_%>KC<X+9L>ULC/F]KTU'
M5I&R5J3[*PPK*.HF:F>2#)1B:!9YX!+[KW6S-_-/^1F5^)?\N7YI?(;;F9AV
M]O#K;X\]C5VP,W/(T8IMRYJA?%[:E!0JQD7/5V.T*&4N^E0RDZA[KW7?\L>M
M[:A_ER?#[='R4WGN/='<.XOCKL'LKMO>'8>8%;D#DM]X]-P5QR-3(1'$*'[\
MPZ+K'3Q0K$H6.( >Z]T./5GR]^)O>F;WEMKI+Y0?'?N+<?74<DO8. ZL[KVU
MV#6X)8I)XF;,TN(R=7/BU66FJ4)J8X@&BD4\QL![KW0S;3WAM+?F!HMU;&W3
MMS>>V,D:I<=N/:>;IMQ4%0:*:2GF$%91RS4\IAGBEC?3(=$B,C692![KW1?Z
M7YP_"NM[1GZ.HOE_\7:ONJFJ8Z.HZ?I>_P#:=1NF.::.*9(GV^F6.625H9H7
M"FD#%)$8#2RD^Z]T9>OKZ'%4-;E,I6TF-QF-I*FOR.1KZE*."G@HT:2::::1
MECBABC5F=V8*J@LQ !/OW7N@/W;\J_B]L"GZYJ]]_)'H395+W#EZ/;_4E3NW
MN';VVX]TU^0F%/3T.W'K,C"N;K)YR(XX:(S2/(="J6X]^Z]T4I:ZIZM^8'R6
M^5W:G\P/:-=\9<#U;M;J[#?$]LSC<-C=C[BQB0UV2R^6K),W+]UN3,G%Y!*2
ME>@I)$@:6-%F=7?W[KW1?OY%7\P7L+^9!\2<O\E^Z-W];0=C]F]N=HYK;/1V
MQ<I0L^Q]F[6R(V]A<7/2JYR]0TM1C:VKER.0025DU66B6"D%+2P>Z]T7S^5'
M\ZLUV?NO^;C\O_E;\F*;8_Q:V=\^-Z?'#X])W5V3BMF[(VSM[I16B>LQ62R;
M4%''+N)LQ025;25TT:R0104S)IF,WNO=7\=:=I]8]S[-Q'8O3W8VP^V.OL_&
M\V!WWUIN_'[[PU:D9TLU)E,7455%4JK<$QSL >#[]U[IKRW=_2V!QN^LSG.W
MNK\-A^KI5@[,RN6W_B<=3;==]=DSL\U6D6(<^.2PJWB/H;_4FWNO=0NM_D#T
M-W'UW)V_U#W;U%VIU-"<JLW:'6_9.&WQMU#@F9*X-F\96U6-4T;HZSWJ?VF5
MA)I(/OW7NFKIOY/?&KY%G<0^/GR&Z-[V.T*XXS=@Z;[9P'9_\+J5M>GR/\$R
M%=]E.+C]N;0W(X]^Z]T.7OW7NJV/YKOS'W5\,?B#NG='4&(&[_E)W'N#;_QV
M^('7<"TU14YWLGMV1L=M^**FJZFDAJ*?%7J,K6!YTC%'0SF1U4W]^Z]T8;X5
M]$[R^,_Q7Z/Z1[)[>[$[\[+V+L/$479?<?:6^<UV'F-P[BKE-7G,E)DMP9'*
MY04<V4GJOL:62ND2BHA3T<-H8$ ]U[HT/OW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[K7,ZDZ0[IQO_"H;Y0_(#(]0=H4'0VX/Y6NW^OL#W;6[ RU+
MM&NS\.[>NZE\'1[DDI%PU3F$IZ&ME:CCK6J1'3SN8],4A7W7NMC/W[KW6O\
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MJZ6*HIYE>*6-74@>Z]TK??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0 _*_\
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MRZ4Z.U_!14RVDJY]#>)"J@&21 ?=>ZUP>L-L_P#"I?\ FD;=H?D+C_D1UO\
MRX^FMY+'G^LNN$QAP>4FQ=7:2FEF@@Q>4S?CFA(*O7U4+R AU@16'OW6NMK+
MY"?)K8/P-^(>X?D'\F]X(V$Z=Z]Q4^\\U3L'J,QEH((J=::@CDT--697($+$
MM@;N7?2BN1L]>'6I?U1WO_PH=_GI3Y?N?XL=E;7_ ):WPEJ<M5X[K?<E53M%
MF,U!1NR-4PU24-5F\FXTVDFA^SH!)=(6?26]ZZ]UMJ?!CIOOCH#XN]6]3?)C
MO"J^1W=6TL75TF]NXZQJIY,S//42RI,QK2U3^W$Z1^LD^GW[K?#I-?.GOCO#
MH;876N2Z"V_T]G=X[W[5FVCEJCO+/9C;V!QN&P^T-V[JR62DFP=)6USU$$>V
ME1(Q 599)"?4%]^ZU7JCB7^>MW7!U=L_NJ;M/^5K#U5OWL;*=2[6WQ+O#N&.
MAJ-PX4PBJQKR-LX&FDB%1$Q>94C*$N'*JQ&J];ZL0WKWS_-IZZZXW!V]O79W
M\LS;_6NUMJU6]L_O"L[<[#-)3XJC@^YDK6=,"Q:(068:5):X"@D@>]]>ZKJS
M7\]ONC;O2.R/D?G.U?Y6V,Z2[(W;NC8NQ>P*K=_<,=)D\ILLHN4IJ9/[F_<-
M]HSJKR&(1EN%<D'W[KW39T__ #_-^=Z[ZPO6W7'R*_D^Y#>FY*N'';?P^>[A
M[0V6*RIJ3IBIJ>IS&U:*D>HE8@)'YPSL0J@DV]^ZUU;9\=_E+\SJGYB2?%/Y
M9];?&S;TF5^/A[VVKN?H'>>XMS!HHLY+A7I*U,Y0T2I=H3(K1:P01S]1[]UX
M'JTX@,+, 1_0B_OW6Z5ZX^./1X]">/\ U&D6^M_I]/K[]U[KG[]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K2[_ )\/
MS4^._P KOYA'QE_D_=N?(;K?H_X@==[AP7R&_F)[_P!Y[[39E-DAMZ-,GMWK
M:GR,-9!+%7U=.T4]3$H$J2Y+'5L,L,F*F5O=>Z;_ .9[\]O@GO/^8]_(1[Y^
M'?R:Z$[CR'1ORPR/QZWMU]U)N^AS-10;3^1PVWMR/)'[61Q24&"I(,E''#]M
MHF>K2(34VG4WNO=6#_\ "G_,U>\OA7\<?A?BON%R7\P/Y\_%GXPU-725*P34
M>/R&:.;DK84:&9*B:+*8G#1+$P5;S^4L?$(I/=>Z17\S"?<OSI_F6?$;^1GM
M?<NY-@_%'&]"U7RT^=2[3S=1MK(;JV7M:L?#;=V#3Y&B?[N''UV2HZ5,L@--
MY:;(030U0GI%AD]U[I-?SPOY=/PF^&7\M7N#Y;?$#JCJKX.?(GXMX3;61ZI[
MKZ)V71[ RE8N\\O0;7R&V<Y+CDIVW-3;HQN<JL>?XK]Z8YYH*DZA"5;W7N@$
M^0T7>G2WP7_D7?R,NA-\UG2W;WSPV)M3:GR#[5V3.U/5[?V5L';^.W%VBN%K
M%"54&6S%3F,@:2;[/340TE9!/)2?<^5?=>ZME[2_D&_RDC\/-Y?'^@^&/1>U
MJ#%]5Y3$XONNDV+C(>P**JP>.;[;/2[Z:!-Q5&0BJ(4J9S/DC3U#!TJ(7IY'
MB/NO=4Z[/_F"=G9#_A'IO/Y#=V;NW-NGM3.]$]I_%&@WG+E6J\SE6W1OC(=6
MX6NJ*VHJC4U-9286K@DKJF2<U4ZT=356DF<!_=>ZLT_EU_R4OBITG\9/C'VO
M\S^L]J][_+#K'I[X_9_*=G=H";<L>P_]"&*Q]9A-N[-I9/'28+"[7GI&EF^V
MHXWRN0:NR.1^XEK95'NO=4 ]7P=/9_\ X3;_ ,WK^8'WGL7;.^*KYP?+[Y0_
M('JNC[ V=29ZJP6X.U,ZG76U<A2B05D29_#9W-9RJAKZ?0:)IY'B=? TS>Z]
MUL5?$GXZ]$?R@?Y/57WWBNE^M=B=Y]9_R\L1V/\ (K??7&S<9B<[NG<?76RI
M\[44];E%@I)LS.,Y-5PT<E9* SR*[^/6]O=>ZKZ_X3[?R:OC]N_^6G\>NY_G
M1USA?E%N_N''[H[>ZZZ_[O3_ $A[4VC@.S:^:NH9\3MNO5\-_']R4A@R62S$
MU%-DYEJ*:@-7]ICZ:-?=>Z%7_A.%BM@;0S?\ZG>74N'I>L?B9B/YF/;NSNI>
MO,55-+@L)3]2T*_Q;(8V/QC[2+)8RMP<K4T;-#24\-+20#Q0(S^Z]T5#^03_
M "_NJOYA?6_RJ_F(_,;;V0[KZJ^7/S=^0/<_2/QP[1K?XYM2!9\O-1U.Y]R[
M?5WQF>W%%4QU.*H$KS74V'IJ*=\:(GR=4Q]U[I._RO\ ^7+\?_E%_,K_ )QE
M-@:&?"?RQ.F_E+M+JO&?#79==4[1Z]W9V%U5BJO%Y:3.8&E%/#D<#MNM;(SQ
M8_4,9D*FNH:F2&JAQU'H]U[HR/QX^,W0W3/_  J8W7L_X==.;*Z+ZOZ<_E7T
M]5WEMGIW;%)L[ -N3?V[()*./(4E#3+14]?D,37;>J(X$$$U0N/%6-:13ZO=
M>ZVU_?NO=4#]'++_ #(_YLW9'REGJ#E_B/\ RN)-U?&3XUP:Y)<?N+N?=E+$
M.RMXTX#FEJ4VCBYH-NTLNEM-1)52PLKJ_OW7NK^/?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW0 _*__ +):^2G_ (@'N/\ ]YW(^Q;R#_R7=M_Y[[/_ +2(^@A[
M@_\ ) W+_I7WG_:/)T4S^4E_V1GM?_P]=^_^YQ]C[[P/_*RS?\T8/^K8Z /W
M>_\ E6(/^:MQ_P!76ZLQ]PIU-O6C+\C?^RA>^/\ Q,W:'_N\KO?4/DS_ )(]
MA_SQVO\ U83KE1SS_P EO</^>Z[_ .K\G0,^Q+T%NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZGX
MO^)_Q/'?P7[_ /C/W])_"?X7Y/N?N?(O@^V\7[OG\NCQZ/7KMIYM[:N/#\-O
M%TZ-)UZZ:=-#757%*<:XIQZ?M?%\5/!U>)J7P]%=>NHTZ=.=5:4IFO#/6Z[\
M1O\ 3Y_H#V+_ +,G]A_I0^P_RWP7^\^SLOV7\8M^U_&?%_P*\7IU6U_O>7WS
M/]P/W5^]9_W+J^EU=M?@U_B\/S\.OP5S3Y4ZZC>W_P"]OW3!^^]/U>GOT_%I
M_#XE,>)3X].*_.O1E/8,Z&?7O?NO=>]^Z]UHW_\ "E@X^K_FY?R=\5WD0OQB
MEW+A'RHRI/\ #&R,VZHTKA47O$6\0Q8DU#_-$7]!]^ZUPZWA:!**.AHDQJP)
MCDI*9*!:4 1B%4 B$87@($TZ;<6M;W[K?6HM_P +,8>PY/Y;W4TFVAD3L2#Y
M';?;LG[,,8@CXVN&,-5I(/B%3Y;7XUE??NO= '_+PQ/_  ITJNLOB)5==;F^
M%,GPL7%]5MBX=GS;:6H.R$>E^XCIPE+Y!7#&B8$:A*)K@G5?W[K5.MVR+R>*
M+RV\OC3R6_U5A?\ WF_OQZV.JX_YF'_,K>K_ /P_NVO_ 'RG;/O?EUKSZTT/
MY=/P>7YY_P#"9[Y==:XC')7=D==?(KM?NKJ9PB^9<QU]!!524\+FS!J['BL@
M"@^J1H_S8^]=>Z=^_/YM&[_DU_PGP^*GQ4V7E:G*?+KY)]HX/X2[QP=+-:N$
M'7$U)%5U-3"I:94R<<N(4-]"#.";*3[]U[H5/Y]/Q.VA\._AK_(L^*N&QE!/
MA.M^^-L[7W!#+2I)%D*ZM;;SYF>I1EM,:ZKFJ6D# Z@Q#7N;^Z]U:]_PH7_E
M^_"P_P I;OOM_%="=0]:=G],[5V?O;KGL+8>Q\9LC)TN07)8ZF,'W6.IZ62:
M&JBJ90\;LP+:7%G4'W[KW#IH_DQ=I[\[I[!_EV]C]FUU?E=[9S^4/34V7R^3
M=I9ZM<)V!DJ*GJ97;U/)-3P1L6/+?4DDW]Z/6AQ_U?+K:=][ZMU[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW14?G!
M\@=Z_%[XK=S=V=9=,=E?(;M#9^SZ]^L>F.I]AYSL7+Y_<.1'VV'HOL=O8W+9
M&''FNEA>NJQ1M%24BS3R$!0#[KW52_\ )(_E58_I+XI9+NKYV]:;6[<^='S2
MWMDODQ\F,_W1UY@]PY;%9'>Q>HQ^VO'48Q3C?X735$D]91JH6FRM;D88A'3I
M!!#[KW06_P#"C;X!4>\_Y;]7O#X7_%NEKODST3\@NA^Z>J\=\;.C(\ONJ:LP
MN6;#SO38S;>+EKLI34-'G*FLG@DI:BF1:854T7^3++'[KW2Y^8O57>GRS_G-
M_P E^M3J7M6C^/GQ@ZN[S^6/<6\LKUOGJ#:>-W)O?$18_;.%J<Q/0?P-MX4.
M9Q%(R8V:M7)4%+--5"-!,HF]U[I@_F)=)_+'XC?S3^G?YP_QA^.6]/F-UY-\
M8LS\3?E=T)U0\5?OFBPE-E9,_1;EVEB92DF<J#*E+$U#3%ZAY*5(EC"5TE12
M^Z]U53_.6^4/S$_F3YK^6?\ #[/?$/LOX?\ Q4^9_P Q.M]N9_JGY%96FVCV
M]ONDV=78JJSE;4[5Q-75R;2V1M/'Y6.HK)*S(QY2;(O1RK34L5%JJ/=>ZN3_
M )P7Q=^1N+^47\M_^9U\5^H,M\B\M_+ZW7VCBNS_ (R;)>EQ^X,YLON/%18G
M(5^TQ/+'#5YC!TJU?BQB0O+6M/#X3']NZR^Z]T#?RQ_F!?,?^95T5NCX9_RZ
M?@+\U^F-^_(G9*;$[<^2_P UNF*WXN[4ZTVYO^EK*7<BPU=;5R9#/;OIZ 2T
ML4.)CFB@>KCK:6KJG@$+>Z]TG_G_ /RZ]V=>_$'^3+_*B^,76N^M^=%;?^:W
MQ[E^2^\<%US69?$ILWJ-ZW/[QS>\*O&4$V.P8W/N')2Y0M42THJ\B##',0TU
M_=>ZN9_FI;B[5VQ_+A^:U;T9LOL/L'N3*_'7LK9O6.U.J-F5_8.X9\WV#CY<
M#CIL9A\92UM;62T-3DHZI_'2R"**&2:1?%&Y'NO=:UWS_P#A1\B>K/\ A.9_
M+0^*&R/BUVOV5B-F;Z^)>\?G=T)TQM6;/;PAP.0AR>[-]T5+B<?*,A-D_P"_
M&2A6LFI-;P5'DJI7BI%J*J'W7NK!/YP'<7R#^:G\B3?E;\3OB)\OMK=H?+/*
M=?\ 4VW?C[O;HZ7']AX?!S[SA@S%1N';>(GSL&W\5DL'A*W_ "JIK%@@QV0I
MIYI:265%B]U[JY/<>.JOB!\%,SA>J-A[BWI7_&/XHUF%ZSZQZHVO/N'*Y6?I
MS:+4V$P6W</2)YZNMKI<=2TM#2QH"\CQQC2.1[KW5"OPO^/_ ,G/A)_PF*[
MVGBNK^Y,A\T.P?CO\D=_R]<X?K',YS?:;S^1-;EH</'/MML?49VHSV)HLEAV
MK(ZB@DECDI9FG00QD+[KW5M'\J[HW,?"K^5#\0>IL[U[F,#O;JWXN[;W3O[K
M+'8AFRD.ZMS4$NZ=SXK[.ECEDFS#[BR62BE2..1Y:QGT^1WNWNO=$[_X3;]
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MG56*,^YVP'V5929"3^*X.N"8\R9"5*.N+^:6M@@!J/=>Z+!_PG$[D[8^*_\
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MRS?\T8/^K8Z /W>_^58@_P":MQ_U=;JS'W"G4V]:,OR-_P"RA>^/_$S=H?\
MN\KO?4/DS_DCV'_/':_]6$ZY4<\_\EO</^>Z[_ZOR= S[$O06Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NL]+2U
M-=4TU%14T]965D\-+24E+"U1+++4,$CCCC0%WD=R%55!))  )/NDDBQ*68@*
M 2230 #)))X >9ZO%$T[!$!9F(554$LS$T  &22< #CULV?RYOY<U-TO38GN
M_N_$P5G;M9 E9M+:58BU$6V8JA;K/.INCYQT/)Y%&"40F<LR82>\?O&W,S-M
MFV,1: TEE&#<D>0](A_QOB>V@ZSM]E_9=>5%7=-T4->L*QQFA6U4C]AE(XG\
M'PKFI-QOO'7K)#KWOW7NO>_=>Z][]U[KWOW7NFS*P5]33&"@J!2/)<25']I0
M?]1_0_X_C\>]]5->DG2]<;>B=:BK2HKZP2+,:B>H:^I2&!%C?@C\D^]=;Z7%
M3]QX)!2:!4%;1M)R 3^3_6P_WGW[K?2#/7F/R$SU>?J:K)U4GZM4I4#FX _(
M _ %@/?J5ZT.ES14D-!24]%3 K!31+#$K&Y"I].??NM]8J^B2M%,LBAT@J#.
M48V!(CD47'Y%W''OPZT>H5!B],3C(TU"\OD)0P0A1I_ _P!?W[K0'6$8VH_B
M3.U-COX<0R",0CR6MPQ;\\_CWOK6GK)D<6S1H,;34$<FHZS40!Q;\<>]=;(^
MWJ)'BLE"R.8\/4#^W']J8?\ ;$7^A_V!][ZUI_U?ZJ=.46+ABKX*R&%*?132
M1/'&;#4Y'X'!XOS:_P!/?NMTZ=_>NK=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=8*H51I:D430)6
MF"84CU2-)$)2I\9D5&1VC#VU!6!(N 0>??NO=:4G_"=+N#X>]&[[^6?QQ_F
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M_P#+Q33/3PSQQ>Z]U;3F_P#N+9V=_P",=*K_ -[_ "OOW7NGG^6#O#;W2_\
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M]^_?5R_QO_O1_P _7OI8OX%_WD?YNO?W;V[_ ,Z#"_\ GK@_Z]^_?5R_QO\
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MR2122+K5)&B9@K%>0#S;GWH@CCU8,&X=*J21(8Y)976..)&DD=C8*J"Y)/X
M ]ZZWT#/^S'="?\ /X.O/_0II/\ KY[MH/H?V=4\1?7I7[1[/Z[W]45E)LG>
MNVMU5./ACJ*Z#!9>')-$DS%5>01,Q568$ GZGWHJ1QZV&#<.EU[UU;H(*[Y
M=(8RMK,;D.U]AT60Q]544-=1U.Y:6&2&:D<QRQ2(T@*O&ZLK BX((/NVD^AZ
MIX@]>G?;'</5>]<HN#VCV#M'<F8>":J7&8;.05\QCI[:W$<;LVE+BYM87]Z*
MD>76PX/#H2/>NK=!;GN[NH-K9>MP&X^R]EX/-8YXXZ_%9/<%/1SPM*BR*)(W
M<,I:-T87'((/Y]V"D^1ZJ7 \^N&$[RZ<W)E:+!X#LW9.8S.2F^WQ^,QVX::K
MGF<@G1'&DA9VL"; ?0>_:2/(]:#@^?0J^Z]7Z#K=7;O5^Q\FN&WCO_:>V<L]
M+%7)CLWFX,?,89V=4E$<CJQ1FC< VL2I_I[V%)X=5+A>/3%2_(3HVMJ:>BH^
MV=@U-75SPTM+30[FI9'DDJ&"(B*)+LSL0 !R2;>]Z#Z'K7B#UZ&+W7J_2(W?
MV7U]L"2ABWOO/;FU),FE1)CDSV6AQIG6E*"0Q"5EUB,R)JM]-0O]?>P">'52
MP7CTC?\ 9CNA/^?P=>?^A32?]?/>]!]#^SK7B+Z]#'3U$%73P5=++'44U5#%
M44\\3!U=)E#(ZD<%64@@_D>Z]7Z3>[=\[.V'14V2WIN?";6Q]95"AI:S.Y"/
M&QR3%&D\2/*RAGT([6!O8$_CWL"O#K18+QZ0'^S'="?\_@Z\_P#0II/^OGO>
M@^A_9U7Q%]>A6PV:Q.XL70YS!9&CR^'R<"U6/R>/G6JAFC>]GCD0E74V/(-O
M=:4ZL#7J+N3<^W=G8BHS^ZLWC-O86E>".IRN7JTH8(VJG6.,/)(0JEY&55N>
M20![V!7KQ-./09_[,=T)_P _@Z\_]"FD_P"OGO>@^A_9U7Q%]>A)VSNO;.],
M4F<VEG<5N/#2S34\>3P]:E? STYM(@DC+*60\$7X/O1%.K AN'3AELMC,%C*
M_,YFOI<7B<72S5V1R-=,M/#!#3J6DEED8A41%!))-@/>NO$TZ";_ &8[H3_G
M\'7G_H4TG_7SW;0?0_LZKXB^O2\VCOW96_J:KK=E;IP6ZJ2@G2EK:G!9*+))
M%)(NM4D:)F"L5Y /-N?>B"./5@P;ATJI)$ACDEE=8XXD:21V-@JH+DD_@ #W
MKK?0,_[,=T)_S^#KS_T*:3_KY[MH/H?V=4\1?7I7[1[/Z[W]45E)LG>NVMU5
M./ACJ*Z#!9>')-$DS%5>01,Q568$ GZGWHJ1QZV&#<.EU[UU;H(*[Y =(8RM
MK,;D.U]AT60Q]544-=1U.Y:6&2&:D<QRQ2(T@*O&ZLK BX((/NVD^AZIX@]>
MG?;'</5>]<HN#VCV#M'<F8>":J7&8;.05\QCI[:W$<;LVE+BYM87]Z*D>76P
MX/#H2/>NK=!;GN[NH-K9>MP&X^R]EX/-8YXXZ_%9/<%/1SPM*BR*)(W<,I:-
MT87'((/Y]V"D^1ZJ7 \^N&$[RZ<W)E:+!X#LW9.8S.2F^WQ^,QVX::KGF<@G
M1'&DA9VL"; ?0>_:2/(]:#@^?0J^Z]7Z#K=7;O5^Q\FN&WCO_:>V<L]+%7)C
MLWFX,?,89V=4E$<CJQ1FC< VL2I_I[V%)X=5+A>/3%2_(3HVMJ:>BH^V=@U-
M75SPTM+30[FI9'DDJ&"(B*)+LSL0 !R2;>]Z#Z'K7B#UZ&+W7J_2(W?V7U]L
M"2ABWOO/;FU),FE1)CDSV6AQIG6E*"0Q"5EUB,R)JM]-0O\ 7WL GAU4L%X]
M(W_9CNA/^?P=>?\ H4TG_7SWO0?0_LZUXB^O0QT]1!5T\%72RQU%-50Q5%//
M$P=7290R.I'!5E((/Y'NO5^DWNW?.SMAT5-DMZ;GPFUL?650H:6LSN0CQL<D
MQ1I/$CRLH9]".U@;V!/X][ KPZT6"\>D!_LQW0G_ #^#KS_T*:3_ *^>]Z#Z
M']G5?$7UZ%;#9K$[BQ=#G,%D:/+X?)P+58_)X^=:J&:-[V>.1"5=38\@V]UI
M3JP->HNY-S[=V=B*C/[JS>,V]A:5X(ZG*Y>K2A@C:J=8XP\DA"J7D956YY)
M'O8%>O$TX]!G_LQW0G_/X.O/_0II/^OGO>@^A_9U7Q%]>A)VSNO;.],4F<VE
MG<5N/#2S34\>3P]:E? STYM(@DC+*60\$7X/O1%.K AN'3AELMC,%C*_,YFO
MI<7B<72S5V1R-=,M/#!#3J6DEED8A41%!))-@/>NO$TZ";_9CNA/^?P=>?\
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MO84GAU4N%X],5+\A.C:VIIZ*C[9V#4U=7/#2TM-#N:ED>22H8(B(HDNS.Q
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MW=#O/=N;WQCLI#AJ/!I!MW)4%)3^*ADGE1BM3C*N3R%IWN?+IL!91R2XDA3
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MY='?%_8'0.3SV5V=E]X9*HW#04N/K4W-D**L14I)&D4Q"EQ]$RL68W+,PM]
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MU[W[KW7O?NO=>]^Z]U[W[KW13/G;_P!D??(;_P 1MF?][3V/O:W_ )6+;_\
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M_P#[):^2G_B >X__ 'G<C[%O(/\ R7=M_P">^S_[2(^@A[@_\D#<O^E?>?\
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MO^'P>Q_^?#[)_P#0MK__ *F]^_X&&T_Y3YO^<*?]!]>_X*JZ_P"C?%_V4/\
M]:NO?\/@]C_\^'V3_P"A;7__ %-[]_P,-I_RGS?\X4_Z#Z]_P55U_P!&^+_L
MH?\ ZU=>_P"'P>Q_^?#[)_\ 0MK_ /ZF]^_X&&T_Y3YO^<*?]!]>_P""JNO^
MC?%_V4/_ -:NO?\ #X/8_P#SX?9/_H6U_P#]3>_?\##:?\I\W_.%/^@^O?\
M!577_1OB_P"RA_\ K5U[_A\'L?\ Y\/LG_T+:_\ ^IO?O^!AM/\ E/F_YPI_
MT'U[_@JKK_HWQ?\ 90__ %JZ]_P^#V/_ ,^'V3_Z%M?_ /4WOW_ PVG_ "GS
M?\X4_P"@^O?\%5=?]&^+_LH?_K5U[_A\'L?_ )\/LG_T+:__ .IO?O\ @8;3
M_E/F_P"<*?\ 0?7O^"JNO^C?%_V4/_UJZ]_P^#V/_P ^'V3_ .A;7_\ U-[]
M_P ##:?\I\W_ #A3_H/KW_!577_1OB_[*'_ZU=>_X?!['_Y\/LG_ -"VO_\
MJ;W[_@8;3_E/F_YPI_T'U[_@JKK_ *-\7_90_P#UJZ]_P^#V/_SX?9/_ *%M
M?_\ 4WOW_ PVG_*?-_SA3_H/KW_!577_ $;XO^RA_P#K5U[_ (?!['_Y\/LG
M_P!"VO\ _J;W[_@8;3_E/F_YPI_T'U[_ (*JZ_Z-\7_90_\ UJZ]_P /@]C_
M //A]D_^A;7_ /U-[]_P,-I_RGS?\X4_Z#Z]_P %5=?]&^+_ +*'_P"M77O^
M'P>Q_P#GP^R?_0MK_P#ZF]^_X&&T_P"4^;_G"G_0?7O^"JNO^C?%_P!E#_\
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M]"VO_P#J;W[_ (&&T_Y3YO\ G"G_ $'U[_@JKK_HWQ?]E#_]:NO?\/@]C_\
M/A]D_P#H6U__ -3>_?\  PVG_*?-_P X4_Z#Z]_P55U_T;XO^RA_^M77O^'P
M>Q_^?#[)_P#0MK__ *F]^_X&&T_Y3YO^<*?]!]>_X*JZ_P"C?%_V4/\ ]:NO
M?\/@]C_\^'V3_P"A;7__ %-[]_P,-I_RGS?\X4_Z#Z]_P55U_P!&^+_LH?\
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M_@8;3_E/F_YPI_T'U[_@JKK_ *-\7_90_P#UJZ]_P^#V/_SX?9/_ *%M?_\
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MKJ,B^&Q,&2JL/09O(1RU.1P@W-!'0Q2M-/#1U+UM''+$M*T-/[KW0??R"/\
MA0!\.?Y>WP,K?@]\V*'MOJCN_P".G9_;&-VMLW'=69G=E?N ;KS-7EIL-]I2
MT$<F#W)09^LR>/GHLHT"*4@<U:L\U/2^Z]T%_P#PF-W]N;M;_A1'_,][1WKL
M?,]9;R[)ZD^:F_MV];;B@-+D-O9/>/>.P<C7X.OB8!HZS$U53+2S*0"LD3 \
MCW[KW0#_ !=[V^.G\Q+Y[_/?"?\ "BGY==M]3XSK;<<\74OQ+W9W;F^KNN:;
M^ [AR\66P!_A4.*A>JVDD6 CQD4"T==F!-5Y.7[N>"5U]U[H9_\ A.WN3XOR
M_P#"C/Y2-\1]A9?J;XPY[XM=EX7XX;.W+%E*:LJ-O8ZJZZGQF5TYV6;-2)N7
M&T$V<A>ME>KDIZQ9:AFD9S[]U[H;/Y!?_<4U_.H_\R-__!%;-]^Z]T.W_"M'
MKOLWISY(_P K[^9EA=F9K>74?Q@[0P%!V5)A:<S_ ,-K=K[MPNZ\&E6YC:*E
MASGVF0I(9YG6$54<,#$25$2R>Z]UR_GZ_P \+X)_-S^4]V?\=OAKOG<WR&[/
M[[QG66\]T;:V7UQGFFV'MCJ?=NW=UYC.[S>IH::'"T]-4XFCQYU/(3-5I(!]
MM>H'NO=7#?\ "7'_ +<4?!G_ ,N9_P#?Q=@^_=>ZO^]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= W\BMJ9_??Q][UV/M2@_
MBNZ-Y=-]G;4VWB_NH:'[FOW#A*ZCHX//4R0T\/FJ)HTURS)&E]3NJ@L/=>ZK
ME_D*_%SO;X7?RGOBG\:/DOL;_1KW;UK_ *<_[Z[*_O-A]X_9?WQ[)WCG\;_N
M2P&0RN(J?N<1E:"?]BOE\?E\4NB9)(T]U[JW[W[KW5)&[/B)\A\G_P *$NL?
MG%0]>^?XN;>_E<Y#XZ9CM#^]F#C\.\I^P]PYU</_  1\FNXI+XJNI9_NTQ#4
M(U^,U/F5XU]U[KA_-%^"7R;[#^0GQ$_F-? ?(;'J/F#\,Y=Y;9J.INSLY+M7
M;W8^Q.QX6@S.UJW*01LU%7P":KEQLE0XHXIZF2>73-#3NONO=$S^7&W/YP'\
MX3J:D^$>Z_@_3?RQ_CKV5/U[4?+/O7L3Y*;9[IW#58O#9!,GE-J["P^SG)J5
MJ*G'T2/7Y*2E@K:626EJ*2GBDD67W7NK&OG%\9?F3LSHCXHT_P#*SWQAMC[@
M^&&XNOZ:D^,NY\Z-F[4[)V'LR@H\0=CY/)01!,5+3T-#3''SF):9")8I1&DH
M=/=>ZJM^>_7W\U/^=+T1M;X.[Z_EA8'X*[ WCNWK;=_>GR4[T^2NR^X#MJGV
M9F,=75U'L#%[2^\RN2S-9'%4I#55-/14\M,LM)5?:"M$\7NO=&F^5GPT^4/1
MWSXV)_, _ECY7J3N#N[#_&O#_&CY6?#'N+L^+K\;VV=M1H:K;NX<;E88IAB=
MUT51'0TPJ<C3_9M3B 1-$CU<5;[KW5/W\US.?S..[>\OY+W:?S8ZNZB^(>RY
M/YJ/Q2V/UG\,=@=E0]^[BKL[FLW#49#>&YMXX^*EP*)C:>DI<=C<;CXYP!DJ
MR>IJBPA3W[KW5JGR3^-OSJ^*?\X7=/\ ,_\ C=\5L/\ /GJ_O?XX;6^/&]>L
ML;V;MSJ[?'7\VU&I9ER&V:S=4M'C:C!Y-\;"U72Q5GGFJ*N9Y/''#&S>Z]T6
M?^8)\9_YQO\ ,?W]_+^^1.3^*VS>ANK?B3\Y>DNWA\,G[SVGO;?N5Q.$S$%7
ME]][BW.:W';.Q\N'H<8D&.V_CLM6U4D.6JYJJ5JJGBI$]U[JR;^8;\1/D/WG
M_-#_ )*'R*ZLZ]_O1TY\1]\?,C,?(7>'][,'A/[OTW:NV]JX_ 2?P_(Y.DRN
M6^_J\;6QZ<;0UC0>/54+"CQLWNO="3_-V^ W;'S3ZOZ,W]\8=^X+K3YB_#'O
M?:_R6^-&XMWS55/@LAE-M!DKML;ADH5:L3";AIO''4&(>IHHHIKTDM0K>Z]U
M6G\Y<S_/'_F/?"GO'XB[?_ET[9^'&X-W=3;HQ_;?9.\?DYLOLR/=4N(IZB:/
M9?6]!0U*P1#>U=1T]!/E]P9+'4^)QE;/*#+5+#(/=>ZO;_E[=6[[Z.^ OP>Z
M4[2P7]U^S>G_ (@?&GJWL7;7\3H\W_#L[U_LO"XG+T/WN.J*O'U?VF0I*B+S
M4M7-3RZ-<,LD;*Y]U[H&_P";_P!!]M?*/^6?\Q?C[T3M/^_/;W:G4=9MC86T
M?X[C-L_?UTM;13+!]_F*S'XREO'%(==16PQ\6+W(!]U[H9/Y>W5N^^CO@+\'
MNE.TL%_=?LWI_P"('QIZM[%VU_$Z/-_P[.]?[+PN)R]#][CJBKQ]7]ID*2HB
M\U+5S4\NC7#+)&RN?=>ZIS_F%_R]/E-U!_,H^.O\W3^6+U31=E=O53_Z'/G/
M\?<=O';76;;_ -D9"*FC_BT60W/D\+ASEZ.EH:6%Q+7K++446#J$4K15/E]U
M[HQFX?B5\B\W_P *".J/G73]95%-\8<+_*QJ?CUG>P:O=VWA+1[TJ^P=P9X8
M&7#1Y>7-RR)C*^EE:L@QTV.NQC6L:164>Z]T#NQ-_?SJ?@1O[N;JK=7Q3W+_
M #7^BMR]C[Y[ ^/WR&VC\D-I]7;PPV(SAHY,=LS=N#W?+11NN+!GBCKZ&I>-
MA&9/#(TQ2'W7NEM_*&^"'R7ZB^1/SV_F$?+S8/6?0'<GSZW-U?D*+XM]1;JA
MWUCME87KC&/!#'F<U2TU/CLENBOJJJ5LA+0-+1O-'+61S%JYH*;W7N@B_E3?
MRFMV4W\BI?Y:7\Q;J*+9>=WO6=X4>\MG#<NWM]U.)_O5N6NRVWL[CLE@LAFL
M0N5QLQH,C121U<CT]3#'Y55E9/?NO='#_DS[-_F%=%?'O<?Q+_F!;/K\UE_C
M'NNKZ[Z#^4XWSMK<])V;L&DFJ8MOULE!C<U7;BP^5PU%3PT\L>9QM--+1O0,
MU165RY!U]U[JX7W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T /RO_ .R6ODI_
MX@'N/_WG<C[%O(/_ "7=M_Y[[/\ [2(^@A[@_P#) W+_ *5]Y_VCR=%,_E)?
M]D9[7_\ #UW[_P"YQ]C[[P/_ "LLW_-&#_JV.@#]WO\ Y5B#_FK<?]76ZLQ]
MPIU-O6C+\C?^RA>^/_$S=H?^[RN]]0^3/^2/8?\ /':_]6$ZY4<\_P#);W#_
M )[KO_J_)T#/L2]!;KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZV4/Y4_S
MA/8>#HOC5VGF/)OK:V-*]99VOE&O+8G&1\XN5V-Y,ABX5O$>6GHU-QKIG>7"
M[WX]L/W-*=ZL$I!*W^,HHQ%*Q^,#R20\?)7/HP SC]@/=3]^PC9=P>MS"O\
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M ! /<?\ [SN1]BWD'_DN[;_SWV?_ &D1]!#W!_Y(&Y?]*^\_[1Y.BF?RDO\
MLC/:_P#X>N_?_<X^Q]]X'_E99O\ FC!_U;'0!^[W_P JQ!_S5N/^KK=68^X4
MZFWK1E^1O_90O?'_ (F;M#_W>5WOJ'R9_P D>P_YX[7_ *L)URHYY_Y+>X?\
M]UW_ -7Y.@9]B7H+=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3UMS<6=V
MCGL/NC;.5K<'N';^2I,OA<QCIC3STU30.)(9HG'*NCJ"/P?H002/::]LHMQA
M>"=%>.12CHPJK*PH0>E=A?S;7,ES;NT<L;!T=31E934$?ZJ'@<=;A7P4^7N&
M^6O4D&8JS18[M'9ZT6'[,V[3,$5:F56\&3I8SZEH,HL4DD:F_AE6:FU2"$2R
M<[/=+V]E]O\ <#$NIK:74]M(?-0<HQ_CCJ ?4%6H-5!TF]J?<:+W$VX3'2MU
M%I2ZB'X7(-'4'.B2A*\:$,E25J53\[?^R/OD-_XC;,_[VGM#[6_\K%M__/3'
M_AZ,?=/_ )5S<?\ GDE_X[T&W\KS_LA;H[_RIG_O8;@]GGOG_P K5??]0W_:
M);]!_P!A_P#E5+'_ *B?^TRXZ/Y[B7J7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JE#XO?\ ;W'Y>_\ B-MS_P#NUV5[
MR8YW_P"G>[3_ ,],?_5N]ZQCY(_Z>-N__/(__'['JZ_WC/UDYU[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$=^:7\R;X.?R\L!B-P?,3Y%[(Z:
M&XX9:C;&VZZ*OW5N#*Q03Q4TL^,VU@J/*;@KZ6">>))ZB'&O!3ZM4\L:*S#W
M7NB__$+^>/\ RLOG/OG']6_'3Y;;-S_:&9JYJ';_ %SO3;^=ZGS&4F@A>H:+
M#TFZ<7B#F)A!%+(8Z)JB0(CED&EK>Z]U;%[]U[KWOW7N@*^2GR9Z)^'_ $QO
M3Y"?)+LC!=4=0; HH:W<V\,\L]2J&KD6&GIJ6CHX:FOR60K)W2*FHZ.EGJJF
M5EC@AD<A??NO=%]^%_\ ,Y^$O\P'JWL/N?XN]S1[QZVZFS+X#LC=.Z=F9_JN
MEP]3'1KD6%3+NG&8>-H4H62>2:)Y(8D8>5T;T^_=>Z/!M_/X;=6!PFZ-N9*E
MS.WMR8C&Y_ Y>AD\T%519B%*BEJ87_M13P2(Z'\JP/OW7NG?W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=5CUW\QO[/^;9A_Y6O^ASR?Q;X<R_+/_3I_I"T>
M/QY^JP7\ _NQ_ SKO]MY_OO[PC]7C^SX\A]U[JSCW[KW7O?NO=>]^Z]U[W[K
MW58_\M_^8W_PX+E_FUBO]#G^B/\ V3KYC=I?$SS_ .D+^_O]X_\ 1K*L?\?T
M_P #PO\ "/O;W^QU5OA^GWDOU]^Z]U9Q[]U[I.[PW9@=A[2W3OG=5:<;MC9F
MW,WNS<>16EFK33T&W::6LK)Q#3QRSS&*GAD;1'$\CVTHK,0#[KW1<_A%\QNI
M?GY\:-A_+#HJ+<Z=3=F9GL_';+J-X8E,%7U5/UCNW.[1ER#T:S3M34V2JL#/
M54J2LE0*6:'[J&GJ/+3Q^Z]T:[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0 _*__ +):^2G_ (@'N/\
M]YW(^Q;R#_R7=M_Y[[/_ +2(^@A[@_\ ) W+_I7WG_:/)T4S^4E_V1GM?_P]
M=^_^YQ]C[[P/_*RS?\T8/^K8Z /W>_\ E6(/^:MQ_P!76ZLQ]PIU-O6C+\C?
M^RA>^/\ Q,W:'_N\KO?4/DS_ )(]A_SQVO\ U83KE1SS_P EO</^>Z[_ .K\
MG0,^Q+T%NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I8]?[!W9VCO7;77N
MQL/4Y[=F[,I!B,+BZ5;L\LURSNWZ8H(8U>6:5B$BB1Y9&5$8@MW?=K?8K62\
MNG"11*7=CY >0]230*!DD@#)Z--EV:XYANXK*T0O-,X1%'J<DGT50"S'@%!)
MP.MRSXB?%[:GQ1ZBQ77^#:GR>XZPQY??V[$@\3Y/*2H!(ZW&M*.F'[5+$?T1
M#4UY9)6;G#[@\\7'/NX/>2U6,=D$5:B*(' _TQXL?,_( #IE[><BV_M_MJ64
M-&<]\\M*&64C)^2C@H\E \ZDM_SM_P"R/OD-_P"(VS/^]I[>]K?^5BV__GIC
M_P /3?NG_P JYN/_ #R2_P#'>@V_E>?]D+='?^5,_P#>PW![//?/_E:K[_J&
M_P"T2WZ#_L/_ ,JI8_\ 43_VF7'1_/<2]2]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4H?%[_M[C\O?_ !&VY_\ W:[*
M]Y,<[_\ 3O=I_P">F/\ ZMWO6,?)'_3QMW_YY'_X_8]77^\9^LG.O>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K3?[2[:Z*_EY_\*(?D]\C?YH^
MUJK']._*7JCHS:/P#^46_-GU79&T]HMM7$XS&[CV[#4K3UJ[1GJLHU=-4RQT
ML<=/&U175DT%-DYZB7W7NK@OYD?\N_X]_P Y7XL;2R/2';_6&S>RJ/>/7G:W
MQX^</56,I.RZ[!2;?R-+D):O"9; YG$5%9'74'E6+Q9Z-(JAZ>M6\U/$??NO
M=*_YQ?S-X_AIN[I'XC=/]/[T^=?\PCNO:4F7ZZ^.?7N:QNP)9\9M^">*LWGO
M#.9%I<7LW;4]90U:)4SK*))HYXXE\5-43P^Z]T"D'\U3Y4?&GO[X\=-_S./A
M7L_XY[%^66_L7U%TM\C.B_D G>FUJ3>>>BDDQVU=W0UN!VYD,/59)HC'35<*
M55/+(3Z!30555![KW58?_"A_L?YC]W_,#^73_+GV5\8^O=W=?=F_++;7R+ZL
MJ,UW]#B!V;#\6\##F-T;6W5AAA*F+;&"+YVIBBJZN>O6H>C^Y%%>%0/=>Z8/
M^%&':GSJWE\%/CI\+J_X>=0]79G^8EVS\=NC-Q9':'R"H]Q?POL)MX397![-
MI*./ 4!S.',.W\%++FY9:."GFJ13K2MX]1]U[JXO9W\Q;O#J3Y6?RV_@C\E_
MBEL[IK?GS3ZZ^2T\*=?]XGMBAVA4_&6@K<ECL<]:^ PL&7@SFW:*EF,T)22C
MJIXZ1J>92U0GNO=(S^85_.TP7PD^?WP?^"&V>F!VYFODWV?TOL;N;L"IW=5;
M.Q_7='\@=U0;;VK4S2K@\E093)9*"AW;7KCY<C0RBFQ(DU>&H\L7NO=&T^:7
MS\RGQP^1GP:^(_4O6..[H^0/S1[6S>'BVQDMTU6TJ7;&P>N\?+D-X[[KZJEQ
M.7\B86-J04U!(M,<BS5"0U*-3/[]U[HLW<7\UOOG??R?[8^(/\LGX65'S-W_
M /''*X[ ?)ON7??<&/Z&ZXV9E\C35%2FVTS%329*OW%N-#3^"JI*&BM13O:9
MV$-5X/=>Z7WPG_F=]C]R?*[L/^7[\R?BW7?$CYG;#ZEI._</MG =D4?=FT=U
M[)J<E'AVSV#W'0TM"]/)#DI8XI**MHHI>7,<DK0SK'[KW1>=]?SL.U:KYC_.
MKX/_ !D^#FXOE)WA\7LIU!M?J3;>S>V\;M8[IK-];<_C>Y,ONJMS5%1XG8&U
MMGUK4^-:NJLC5_Q2LJ:2GI%2:62.#W7NA![8_FW=S]"==?%[J??_ ,(<_OW^
M:K\I=M[IW#MG^7MT;VWC-W1X2DV[/6Q_QK=G8%91T6#V]MY4@I4J:TPU4,=7
M)40T<F1I:&IKU]U[IQV[_,V^4O0_?70G2W\S'X=[$^-&V/E9OC&]3]#=_=,_
M(>'N_:K;VS,%144.S=SQUV#VWDL+E,FL CQ]1'#54M94:HD90C./=>ZNX]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4<_S9/G)\E>N.ZOAG_+C^"F0V=M#YB?
M/O-]CQ83NGL'"1;IQ/7FT>J<6^3W#N9<1,)8<MG$HHZR7&4U12S44CT-0M4A
MU1*_NO= WO3IG^=9\%-Y]&=O=<_,+>_\U3K7.=D[>V7\H/C5V+TGL?JW+4V!
MW"RO7[RV1F,(F,:BJL(M/4!<=55DE-(M1&ACJ) AC]U[HTGSD_X=3[G^5'4W
MQB^%^Y*#XA_&.IZXR?8G?WSQR/7NW>X,N,E29*&&DV-LW 9G)24U/D:FB5WJ
M:ZOP,D*QU/EI*A9J!X*OW7NJT^].X/YAW\H/Y?? C']J?S#JSY\_&KYH_);8
M?Q<W[U+W'TYM38^\-MUO8DIHZ'=&#RVVTHY9Z.GFE1Y89X5@_9,!CFDJDGI?
M=>Z$'-_]Q;.SO_&.E5_[W^5]^Z]TLNT_DM\Z/YB_\R3Y(_ 7X.?(RB^$_0'P
M'Q/6+?*OY%XGK?#=I[SW-N;MZ@K:O&[7VO29Z*KQ6*Q5-!2UPJ:YH8ZU*W'R
MA"],Z)-[KW0W_'.B_FQ?%/Y6[N^/?R%[+ROSO^&N].DMS]A];?,K+=?;;ZNW
M/L/=.!II2-I;HHL)]G19K'URT-1-25D>/FJ%GJJ>.>5(2(8_=>ZF_P#"=KY6
M_(#YI_RM.H/D#\G>Q:SM3M_<^^^YL5G-YU^$Q>WI)Z?:^Y<A04$1I,/0XZ@C
M%/2011@I2*6TZG+.2Q]U[KW\NKY6_(#NG^:7_.[^/W9_8M9NOJ#XJ;[^&>*Z
M!V9483%X^/;M/VCMK=E?GHH:NCH:>OKAD*O'T<A-;5U)B\06 Q(65O=>Z(-_
M(EW;O38>TOY_^].M^O,GVWV'M;^:E\S,[L7J[#9"CQ%3N',8U'EQN'BJ\A4T
ME%2'(5BPPF:>ICCB5S(S67W[KW0^]=?#O^=_\A.DJ#OCY&_S:LW\+.]MZ8%M
MXP?'7IWXO;"R>R>O35P124V#RM5EY<CF-PR4CQEZZ6?/R!'DDIH:B>*$3S>Z
M]T%'Q5^6_P L?YG/\H#YY[=[%[UQ_4GR;^)_:/R1^./9G?\ TKL/"Y3'[RH^
MEL/'E)JJBQ&4BJ<510;IQM<:"K>*D01J)*NACI7EB6#W7N@ _D%=F;D^!/\
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MJ*7,QM-4XC9NZ-L5==EJ+$"<LU#C:ZNQ& K*F.#1%4U4WW3JTDS.WNO=//\
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M -Y![I_] *D_^N7OW_!/W7_*!%_SF?\ Z Z]_P "O8_\I\__ #BC_P _7O\
MACK9/_>0>Z?_ $ J3_ZY>_?\$_=?\H$7_.9_^@.O?\"O8_\ *?/_ ,XH_P#/
MU[_ACK9/_>0>Z?\ T J3_P"N7OW_  3]U_R@1?\ .9_^@.O?\"O8_P#*?/\
M\XH_\_7O^&.MD_\ >0>Z?_0"I/\ ZY>_?\$_=?\ *!%_SF?_ * Z]_P*]C_R
MGS_\XH_\_7O^&.MD_P#>0>Z?_0"I/_KE[]_P3]U_R@1?\YG_ .@.O?\  KV/
M_*?/_P XH_\ /U[_ (8ZV3_WD'NG_P! *D_^N7OW_!/W7_*!%_SF?_H#KW_
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M^Z]T;JAH*'%T5)C<91TF.QU!3PTE#04-.E)##%3J%CBBBC"I'&B@!550
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M"0TM+45 0G3?P(6M?FU[?T]M]7..JGO^',LS_P ^@QG_ *&<O_UM]J/ ^?\
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MHZC*-B1&'I:BH\H=8*@L;P:=.D?6]^+&R)K-.J2/HZ)-_P .99G_ )]!C/\
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M@CW[KU!TY>_=;ZBU%#15A0U='2U1C!"&HITGMJ^MM0-KV'OW6J5ZC?P7#?\
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M[KWOW7NO>_=>Z][]U[H ?E?_ -DM?)3_ ,0#W'_[SN1]BWD'_DN[;_SWV?\
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M "L6W_\ /3'_ (>@#[I_\JYN/_/)+_QWH-OY7G_9"W1W_E3/_>PW![//?/\
MY6J^_P"H;_M$M^@_[#_\JI8_]1/_ &F7'1_/<2]2]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4H?%[_M[C\O?_$;;G_]
MVNRO>3'._P#T[W:?^>F/_JW>]8Q\D?\ 3QMW_P">1_\ C]CU=?[QGZR<Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZT??^%O?_9,'P:_
M\3UV3_[ST'OW7NLQ_P"$FGR@[6V=AL'VK_/3^2F_>M-R4. K-S==9WJ3<.6H
MZJBD$,[T83)=R9''AUC],4LN+GCC<+(:=POC/NO=;//\MC^6Q\=/Y6WQTH_C
MK\=:/.5>-J\Y4[PWWOO>%3#79O<F;KH8*>7)9*6G@IJ==-/300P00P1PP0QJ
MB*6,DC^Z]UIA_P#"(;J?KC=^]OYC/8NZ=E[9W%O+8^V?B[L_:>>S>!I,K44&
M.[&J.P*K-4U+-40234\61FVYAC.L<B++]M%Y5?QQZ/=>Z%C^9)M[8O8__"MW
MX!=0?(FCPU;\?MN]?]-T6P-D;J,<>WPU+B]UY+!T<-!*PH?!6[WIJ.G, B$=
M2Z1TSQR+9#[KW5H7_"OS9?2-?_*3RF[M^4&TZ;M#:7=G4./Z#RE?'34V2.2S
M5<T>7QF+D>2*HD2;;$>:J9Z>(2J8Z3SO$!!YHO=>Z*?\A_Y=F\?YL/\ PGI_
ME>8[>_R'V%T[\D.M.H.O.Q^N]P_(/>1P^)W-2Y;#?PBEH,ME)I*JMAGRF)DP
M<\%<L%4XGT1RPA:EFC]U[HC/R4^:_P#PH-^ W6E!3_S=_@/\7_G_ /$+K#?.
MWZW*]@]Q=>;4WWCYZR6=Z/;^0ILOMN=L=B*V.LJX8*.KRVQFJKN(I8_N9EE]
M^Z]U8=_PH4^0W6GRP_X3:=2_(OIS:-5U_P!9=M;U^,^Z=H;$K,;2XB3"TTDU
M= V)-/0_Y%&N.FAEIT^WM"R1J\0",H'NO=6B?&_O7X]?&C_A.9\;>[_E9M?#
M;\^/NQ/Y;G0U3V3U[G\+C-R4VY*;-;6P^-I=M?P[-/'B:^HW'D:VCQM/35;K
M!/45443D!O?NO=5 _&'Y(_S2?F?\!]W;L_EP?!G^6G_+:_EH[FQ_?K25?<&5
MR&\:O)X&EJ,G1;MR.&P>!HJ+ PZ):7-4U2F3P4--4U4+1I/#21M,_NO=!S_P
ME65A_(\_F=/Y'*MV?\B5$1"Z5*=1;:)8$+JNVH W8BRBP!U%O=>Z,1_PB>_[
M=S?)S_Q=?<G_ +PNQO?NO=4P_P#";G=7\R&N^5_\S/M3X[]#?$_MGY-Y7=&T
MYN^ZKY.=D97K;(X2LWKN'>E;FX=O/A\9F9JB'(9RED&4#5")&]+CAJG+AD]U
M[JZ?X'_RX_YC6T_Y^6]?YDO;=/\ !OK#9_;&"WGLWY(]*_'[O&OWOD*$9#8M
M%3P&DQM3B:"H-;E-W8+;^8KS5N+"HJYE1F\3#W7NMQSW[KW7SZ_Y#N_Z+X??
M\*.?YG_Q7[U%!L?>'?>ZN^L;UY4YS,1TO\0RF.WPNZ\%0TBR7%0=R;3R55DJ
M1C.)66"*(0O+46C]U[K<K_F,?S ND?Y9WQ<WA\IN]6R.0VYMO)[=P.#V5MR:
MF&:W!D]R5L--%C<-#52PPSUB0/453AY8XTIZ>:662.-&<>Z]U6I\P_YOO\OG
M>7\FFB_F%=W_ !MS7>'QH[IS&$VOUM\8_D/U_@*'(;KW+'E:R&@H7Q^7FS.&
M"T%3A,GD?XA3-7^*CQM1D,>E4T42R>Z]U27\I.T?YO\ \D_Y*W8^_P#"?&#^
M7/\  '^5OD/B%+O+;_4E3E,OOW?5;LRJHDR6VTVY'!'_ '7QIS1DP\F+$]#C
MZVF>9*L$U)@IQ[KW00;=5E_X0T;[)D=P^ZZ-E5@H" ?*?##2ME!()!;U%C=C
MSIL![KW5Y/\ PF;ZWV/C_P#A/[TC50;:P[2=NXWY:9KL<2XV!QEYX=][TVV#
M7CQC[M?X+B*"EM,9/V8Q'?QA4'NO=5 ?\) LAN7$_P NG^:?E=EM,N\<9GUR
M&TVIVT2#)T>Q<I)0%#J2SBJ6+2=:V-N1]??NO=#5_P (EL+U_5?%_P":V_/M
ML56=UY;Y$[=PN[MQ5 BJ<O)M^GV]1UF(CGJ&D>K-))EJK<,HU*J23>1M4CJ1
M'[KW5M&_*?\ EB=*T7\UFN_ER1_&S$?S0J'XS_,3=W8>T^N-PH^]I]RT>)K\
MQ.N0Q<M<DR48W?)BGGC@2*CAJW@%X7,=O=>ZUMO^$L&4_F0;4^('R$SWP0^.
M/PB[4Q.<^2%;A>Q=Y_(#MW.]=[H6?#;7VY-0XI:;#X/(K/M^GBKIYZ626J%Z
MNIR"B)=!>3W7NK<_Y"7\MGYK_#G^8+\]/D1W!DOB)B.COEE0]@;ER75OQK[=
MJ.Q?[N[M3?2Y?"X>GIFQU E-AL#C<SNNAO+JGC<4T6E"90?=>ZJG_D@]8; [
M'_X54?S:\AOK:6W]UU/66\_YC_8.QCN##4N9&.S,G>.&V_\ Q&E%3#+]O5C$
M9_+4XFBT2B.IE0/HD=6]U[KZ%.+Q.*P=%%C,+C,?B,; ]1)#C\71QX^!&JY'
MFE98HE2-6EFDD=R%NSLS&[$D^Z]TX>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z '
MY7_]DM?)3_Q /<?_ +SN1]BWD'_DN[;_ ,]]G_VD1]!#W!_Y(&Y?]*^\_P"T
M>3HIG\I+_LC/:_\ X>N_?_<X^Q]]X'_E99O^:,'_ %;'0!^[W_RK$'_-6X_Z
MNMU9C[A3J;>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NBF?.W_LC[Y#?^(VS/\ O:>Q][6_\K%M_P#STQ_X>@#[I_\ *N;C
M_P \DO\ QWH-OY7G_9"W1W_E3/\ WL-P>SSWS_Y6J^_ZAO\ M$M^@_[#_P#*
MJ6/_ %$_]IEQT?SW$O4O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW5*'Q>_[>X_+W_P 1MN?_ -VNRO>3'.__ $[W:?\
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MK_SC'7O]=SF7_HXW/^]#_-U[_9XOE[_WD7VO_P"A94?]'>_?ZUW+O_1OM?\
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M)*4\\E1)RF+JF=8ZDNP2 Z*DE(TGUQ3[L>RMI>V/U6RVZ13P!F:&):">/B0
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MOO _\K+-_P T8/\ JV.@#]WO_E6(/^:MQ_U=;JS'W"G4V]:,OR-_[*%[X_\
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M>[-H]L[@_EI8+:'=<7R\EP&/ZYES?7&_=OMNQZK<^*QT4&*HJO;6&J,:\U3
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MI_X@'N/_ -YW(^Q;R#_R7=M_Y[[/_M(CZ"'N#_R0-R_Z5]Y_VCR=%,_E)?\
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M:I]Q]C;"Z6V[M7-UD6Y)A49&*;)46/AJS%D)PLE2@E"3NJM*'*J1[KW54O\
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M^N/OW^O#S+_RGR_[S%_T!U[_ %GN6?\ HWP?L?\ Z"Z]_P -S_"G_GP&UO\
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MP?L?_H+KW_#<_P *?^? ;6_\^F6_^N/OW^O#S+_RGR_[S%_T!U[_ %GN6?\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>timage_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_002.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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MO]W_ (;[=QA/B\!S'=]3G0MK:]8@VOCM>KG38KIN+ZK<[\/KW2:_Z"<NW?\
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MW7NB%_+_ /EK_$CYL8^KF[>ZVHZ'?ST9I<;V]L?Q[7W-2F-&2$R5T<;192&
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M0?0W1W77QMZBV+TEU1A(\#L7K_"08;$4H"&:9[M+55U9(B()\AD:J2:IJIM
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M[O*YO96ZL1C*7_0SV#!Y:C)4,\,,>N7:B1IKD=1J=U47NS 7/OV@]>ZUJOY
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MZWKT-V;3A\MMFJ2JP6X::F>GH\WA\B6;'9F@UEKT]9$IU)Y'-/4)/2R-YH)
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ML?AD^UW!31U$<<\9YBJ(=9CFC/JCE5T:S*?;/7NM87_A2;\4:8TG4OS(VQC
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M[-KM_P"1J-T8/8VT=I4F1_@L=7E,_'55$?WE?]O5_94D-)0UDKR?;2%V1(%
M>5678%>O=:_/_03YNO\ [PVV]_Z/&I_^Q;W?P^O=>_Z"?-U_]X;;>_\ 1XU/
M_P!BWOWA]>Z]_P!!/FZ_^\-MO?\ H\:G_P"Q;W[P^O=>_P"@GS=?_>&VWO\
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M+T@R#L3)1;:HYQI;[G*-&?N7C8/340EE#QS/2^2S-3KW7T'L-AL3MS#XK;V
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M\./KY*V T7EI$IJAYUC6&0K[KW1I/?NO=>]^Z]U[W[KW7O?NO=43_P#"B/\
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M.LLGE10TL:8F-7RFY\XL;BL.#PXEIX_' OEK*VHIJ57@A:IJZ7W7NM,#HKX
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M@002/=.O=.7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NDYN[>.TNO\
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M7NK[/?NO=>]^Z]U[W[KW7O?NO=>]^Z]T0S^9=\6*'Y?_  U[@ZJ3&Q5^]*#
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MY*?^'=UU_P"X>4]ZGXCK<?6PM[8Z<Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB
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M]^\/KW7O^@G+MW_O%3KC_P!&)D__ *@]^\/KW7O^@G+MW_O%3KC_ -&)D_\
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MR=R9*DUM32P3#P5U'33+IE6[1@&ZW!>;AU[K=0_X: _EL?\ >)VP?_/KG/\
MZZ^VJGKW7O\ AH#^6Q_WB=L'_P ^N<_^NOOU3U[KW_#0'\MC_O$[8/\ Y]<Y
M_P#77WZIZ]T3G^8/_+"^!?4_PH^2W9/7?QMV9M;?&S.JMP9W;&XJ#)9>2:CJ
MZ,(8YXUFR4L1923P\;+_ %!][!->O=57_P#"9K_LICY#_P#B"Z#_ -W^/]VD
MZ]T;+_A3I_S*[XF_^']V=_[KL5[TG'KW1W_^$_\ _P!NW=@_^)'[7_\ =M)[
MT_'KW5U?NO7NO>_=>Z][]U[KYV7\E[_MYO\ %;_PX=^_^\AN#V\_#KW6UG\X
M?Y(WQ4^7-1EM\;.I3\>NZ,@:JJJ=Y;!Q,,F)RE3.6<RYS;P>GI:F9Y7=Y*FD
MFHJN5V+U$U1I50V&IU[K4I^5?PD^8G\K?L?:6Y\[N&;:C9?)9F'JWNSIW?,V
M-^\?$+$U2D,E/)19K&5*05,!EBJ*:)'#LL,E0B.P<!#=>Z.]\:O^%#_R_P"I
M8J'!]WX#:7R2VU2*D1R&7"[ W&$1@ O\6QM++03Z8[C5482:>1K-).QU%M%.
MO=7=]*_\*%?@7V3'2TO8L_9'0N9ED@@F7>FT9=T8[R3!?\SD-NG*2^$.=)DJ
M:"E L68*GJ%=!Z]U9GUW\WOAWVRD?^COY/\ 16YZJ1=8Q5'V=B*?(*"-5Y,=
M454-?$" >7IE'##ZJ;5I3KW1FZ2MH\A M505=-6TSE@E123I4QDH;$!T+*2"
M"#SP?>NO=2??NO=-^3RV*PM*U=F,GC\31(2'K,G61T$0TJSF\DK(@LB,WU^@
M)^@/OW7NBL=D?/?X4]1M40=@_*;HS Y"E1I*C"1]C8W-9)54D7.,Q\]5D.65
M@/\ )N2"!<@@;IU[JKSNK_A1;\(=@Q5%+U-@^T^^LOXYVHJG#[;/7N'9HQZ5
MGK,_]KE81(Q%C'@)K*&+ $*KVT'KW5'?R5_G_?-OO*.OVYU6=N?&_:F2$E)'
M%UY$^=W$\=2&0QON&N0R0S>H:)L=C\?,K %7!]V" =>Z#7XU_P H'Y^_-K<P
MW_OW"[CZRVON6J3)[@[C^0L]?'DJ\2:0U12XRL9]PYB>6(!H998X:24!0:Y
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MT-^;7DKJC&ID<7E0%JZ*2>DE@J8HJF*\;F*:.30S:74V(]U[K4(_GO=-]3]
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MU[_XN_GO_>EK_;I^'KW7T%-W?\>IN?\ \-[-?^XTOMKKW7S]/Y&__;TGXO\
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M?"\JM=A4=>Z^D!UYV!L_M;8NTNRNOL[1;FV3OG;^+W/M?/8]BT5519>)9H9
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M ,N#XJ_*G<C4S;Y[!Z^EQ/9;4=#_  R%]T==9"MVUN*>"FUN(*:LR^)JZF!
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M^7W_ (A3=/\ T*GO8X]>ZUO/^$S7_93'R'_\070?^[_'^[R=>Z-E_P *=/\
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MV3_[W;4_YZ?;W_GZIO\ K[[IU[KW][MJ?\]/M[_S]4W_ %]]^Z]U[^]VU/\
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M^>GV]_Y^J;_K[[]U[KW][MJ?\]/M[_S]4W_7WW[KW7O[W;4_YZ?;W_GZIO\
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M>WGX=>Z^B;[9Z]UJZ_\ "G3_ )E=\3?_  _NSO\ W78KW=./7NCO_P#"?_\
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MI_[M/0BH#1^)X=.KW7NC]?RHOY2.V/Y;]!W!V7OSN'=/RE^8WR9W"FZOD/\
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MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z^>5\5/^WRW7O\
MXN_GO_>EK_;I^'KW7T%-W?\ 'J;G_P##>S7_ +C2^VNO=?/T_D;_ /;TGXO_
M /E:_P#WW>[?;S\.O=?0L]L]>Z][]U[KWOW7NB#?S2O^W>'R^_\ $*;I_P"A
M4][''KW6MY_PF:_[*8^0_P#X@N@_]W^/]WDZ]T;+_A3I_P RN^)O_A_=G?\
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M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z#CN+_F47:?_B.-\?\
MNLJO?NO=:+'\@;_MY/UK_P"&#VU_[HZGVZ_#KW6_=[:Z]U[W[KW6MO\ S<?Y
MT^,Z,CW)\:?B7G\=G.Z'3(X'L;M/'R"MI=H/ZH9J#%N+PU6Y4.L227>'&L-+
M"2M#)2W5:]>ZID_E>?RHNROGYO)^Y>XJG<.V?CEC]R2UFZ=X9&:<9C>5<96F
MK*'#3SAI)5>4D5^4=F6)W:. SU8F%/9FIPZ]UO6=;];;#Z@V-MKK3K':N'V3
ML39^,BQ&V]L8*E%+34L$1+647+R22.SR2RR.\LTK/+*[R.S%KKW2W]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7SROBI_P!OENO?_%W\]_[TM?[=/P]>Z^@IN[_CU-S_ /AO9K_W
M&E]M=>Z^?%_).S.(V_\ S./C/E\]E<;A,52?Z9ONLGEZZ+&T\7GZ^W7$GDFF
M9(TUR.B+=A=F51R0/;S\.O=;^_\ IBZB_P"?I]<?^AQC/_JKVSU[KW^F+J+_
M )^GUQ_Z'&,_^JO?NO=>_P!,747_ #]/KC_T.,9_]5>_=>Z(E_,Z[2ZRRW\O
MWY:8S%=B[$R>1K>FMST]'C\?N['UL\TCJFE(HHZAI)'/X"J2?Z>]CCU[K7W_
M .$S7_93'R'_ /$%T'_N_P ?[O)U[HV7_"G3_F5WQ-_\/[L[_P!UV*]Z3CU[
MHUO\ACL7K[;G\NO8N+W#OO9N!R<78G:<LN.S.YZ'%SJLV4=D9H9YTD"NO()6
MQ'(]Z?CU[JY;_3%U%_S]/KC_ -#C&?\ U5[KU[KW^F+J+_GZ?7'_ *'&,_\
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M/Y:6/I_-2=L[SSDEV'VF+ZBW'%)PI-[UM!1Q<D!1^[]2+V%R/:#U[HL&^_\
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M[;^%VIM3"XO;>V-MXNAPFW]OX2ACQE'14>,C6&GIJ:GA5(H8(8D5415"JH
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M>D-_I8<>[!SU[JM/L;_A-9\M\#432=9]Q=%]B8N,2>-<Y59GK_(R6N5TTO\
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MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T''<7_,HNT_\
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M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW71(4%F(  )))L
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M997T1KJD=W:[,2=5KU[K5]_D&?\ ,_>[?_$/TO\ [NJ'VIGX#IN/HR/_  H
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MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU O\ A:M_VZRZ#_\
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M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7SOO\
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M # S?\SS^51V5+M[Y!Y?/4O86[>L*;>O^C#.0[BQ5"M-)FMF;@DEIZ 3Y9(
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M(&%P)-OU(4D?4!BK6/YL?Z'W[KW6\&S*JEF(55!9F8V  ^I)_ 'OW7NOF_\
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MQF,FD_B%;.%K*V''KCBB^Z]U<_\ \(J?^W67?G_B_P#VG_[[KJKW[KW1 /\
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MJ-O9?;U'D?-C)YWD2$9*"@JD9'66(QB.HF]U[JB'^:E_-G[V_P"%%G<'6?\
M+&_EA=.[^;I:NWG'NK=V=WE2QX.LW)+M>I\,&X=P"FDK(-K[ V^)EK=55.U3
M45$M*T]/#6QTE"_NO=;Z?\O/X8;'_E\?#;HCXC[!J$R>-ZDV=%09W<@I5HVS
M.=S,LN0S^9DC NAR67JJR=$)8Q1-'#J81@^_=>ZT3ODY_P!QLVVO_%A?B/\
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M#NF3$Y<!Y\7!N#%19*KI)S&761Z!FFB9T++)X]:$JP/OW7NM-[XR]B?SE?\
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M35NW9(FKXX\?5[<W!MRLGQ^<I:FG;4F56)H])>.3A??NO=:.?7?Q'_FV;_\
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MX,Q=3YG9TN_<#MP;3P>4W+O0;#^^%)3/%2R//N?<>W]S;@NM,"8P*BJ\4E7
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MR]#C<;0+H,,.UMOYW#TL@6%8(GJQ31,TE/41P^Z]T&N$^0_0_P 8_P#A8O\
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M^?"?_HWW[0.O:SU[_9P-Q?\ /&X7_P ^$_\ T;[]H'7M9Z]_LX&XO^>-PO\
MY\)_^C??M Z]K/7O]G W%_SQN%_\^$__ $;[]H'7M9Z]_LX&XO\ GC<+_P"?
M"?\ Z-]^T#KVL]>_V<#<7_/&X7_SX3_]&^_:!U[6>O?[.!N+_GC<+_Y\)_\
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MQX]+^.UN&8D#WL4\^M&OET5'*?*O>N$K9L;F.O:'&5].VF:CKZBJI9%_UT=
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MJM]__7[W[KW7O^'+?YCG_>?_ ,V?_2JM]_\ U^]^Z]U[_ARW^8Y_WG_\V?\
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M_,<_[S_^;/\ Z55OO_Z_>_=>Z]_PY;_,<_[S_P#FS_Z55OO_ .OWOW7NO?\
M#EO\QS_O/_YL_P#I56^__K][]U[JQOX!?\*1_P"9_P#!K>D%7G.\]Y_+3J:N
MK'J-T=0?)S>>2[)$PE6&,OA]RY&6LW'MZ>*.$^&.GK7QHDDDEJ,;4R-<>Z]U
MOD? ;^?Q_*__ )K-)A=@;ISE/\;?D=6I2T-+U-W5F:/;E55U=2&O#M/=*M%C
M-P*9 1'2N::NEX9L6%Y][!IUHJ#U9+V%\7]V;<,^0VA(V[,.@:3[55$.0B4<
MD&$62IMQS$=;'_=('/MP/7ILI3HL4T,M/+)!/%)!/"[1RPS(8W5D-BK*P!5@
M>""+CW?JG6/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MTZ8;"9?<.0@Q6#QU9E<C4&T-)10-.YM]6( ]*+?EC95')('OW7NC4[:^-V+V
MYAZW>G=>Z,5M/;6%HI<KEXY<S!BZ>EIZ5=<LN2RD[+2TL$:@F0J^D+SYDM[;
M+^G5PGKUKZ_S#/\ A6#\$OA?1Y?I_P"!6T\3\O.T\?$],V[-OY)L'UOC:E@+
M23[@C62OW;-&&#E<8II)A>/^,Q2JZK0FO3@%.M'/Y-?SS?YK7RI[#KNP=[?-
MCO?80F>5<5L3H7L7,=&;;QT#L62"EQ&VZZACG\8.D5%;)5UKKQ+52?7WKK?1
M<?\ ARW^8Y_WG_\ -G_TJK??_P!?O?NO=>_X<M_F.?\ >?\ \V?_ $JK??\
M]?O?NO=>_P"'+?YCG_>?_P V?_2JM]__ %^]^Z]U[_ARW^8Y_P!Y_P#S9_\
M2JM]_P#U^]^Z]U[_ (<M_F.?]Y__ #9_]*JWW_\ 7[W[KW7O^'+?YCG_ 'G_
M /-G_P!*JWW_ /7[W[KW7O\ ARW^8Y_WG_\ -G_TJK??_P!?O?NO=>_X<M_F
M.?\ >?\ \V?_ $JK??\ ]?O?NO=>_P"'+?YCG_>?_P V?_2JM]__ %^]^Z]U
M[_ARW^8Y_P!Y_P#S9_\ 2JM]_P#U^]^Z]U[_ (<M_F.?]Y__ #9_]*JWW_\
M7[W[KW7O^'+?YCG_ 'G_ /-G_P!*JWW_ /7[W[KW7O\ ARW^8Y_WG_\ -G_T
MJK??_P!?O?NO=>_X<M_F.?\ >?\ \V?_ $JK??\ ]?O?NO=>_P"'+?YCG_>?
M_P V?_2JM]__ %^]^Z]U[_ARW^8Y_P!Y_P#S9_\ 2JM]_P#U^]^Z]U[_ (<M
M_F.?]Y__ #9_]*JWW_\ 7[W[KW7O^'+?YCG_ 'G_ /-G_P!*JWW_ /7[W[KW
M7O\ ARW^8Y_WG_\ -G_TJK??_P!?O?NO=>_X<M_F.?\ >?\ \V?_ $JK??\
M]?O?NO=>_P"'+?YCG_>?_P V?_2JM]__ %^]^Z]U[_ARW^8Y_P!Y_P#S9_\
M2JM]_P#U^]^Z]U[_ (<M_F.?]Y__ #9_]*JWW_\ 7[W[KW7O^'+?YCG_ 'G_
M /-G_P!*JWW_ /7[W[KW7O\ ARW^8Y_WG_\ -G_TJK??_P!?O?NO=>_X<M_F
M.?\ >?\ \V?_ $JK??\ ]?O?NO=>_P"'+?YCG_>?_P V?_2JM]__ %^]^Z]U
M[_ARW^8Y_P!Y_P#S9_\ 2JM]_P#U^]^Z]U[_ (<M_F.?]Y__ #9_]*JWW_\
M7[W[KW7O^'+?YCG_ 'G_ /-G_P!*JWW_ /7[W[KW7O\ ARW^8Y_WG_\ -G_T
MJK??_P!?O?NO=>_X<M_F.?\ >?\ \V?_ $JK??\ ]?O?NO=>_P"'+?YCG_>?
M_P V?_2JM]__ %^]^Z]U[_ARW^8Y_P!Y_P#S9_\ 2JM]_P#U^]^Z]U[_ (<M
M_F.?]Y__ #9_]*JWW_\ 7[W[KW7O^'+?YCG_ 'G_ /-G_P!*JWW_ /7[W[KW
M7O\ ARW^8Y_WG_\ -G_TJK??_P!?O?NO=>_X<M_F.?\ >?\ \V?_ $JK??\
M]?O?NO=>_P"'+?YCG_>?_P V?_2JM]__ %^]^Z]U[_ARW^8Y_P!Y_P#S9_\
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MJWW_ /7[W[KW7O\ ARW^8Y_WG_\ -G_TJK??_P!?O?NO=>_X<M_F.?\ >?\
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M\?X3?^C=W9_]@/OW7NO?] 8_\V+_ )^/\)O_ $;N[/\ [ ??NO=>_P"@,?\
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M7!],RGVV7].G GKTK?D*/DOU[U3D<+\%.FNB]S=I3Q^'"R=[=B9'K;:U&T@
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M?C_";_T;N[/_ + ??NO=>_Z Q_YL7_/Q_A-_Z-W=G_V ^_=>Z]_T!C_S8O\
MGX_PF_\ 1N[L_P#L!]^Z]U[_ * Q_P";%_S\?X3?^C=W9_\ 8#[]U[KW_0&/
M_-B_Y^/\)O\ T;N[/_L!]^Z]U[_H#'_FQ?\ /Q_A-_Z-W=G_ -@/OW7NO?\
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M'W[KW7O^@,?^;%_S\?X3?^C=W9_]@/OW7NO?] 8_\V+_ )^/\)O_ $;N[/\
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M_P#L!]^Z]U[_ * Q_P";%_S\?X3?^C=W9_\ 8#[]U[KW_0&/_-B_Y^/\)O\
MT;N[/_L!]^Z]U[_H#'_FQ?\ /Q_A-_Z-W=G_ -@/OW7NO?\ 0&/_ #8O^?C_
M  F_]&[NS_[ ??NO=>_Z Q_YL7_/Q_A-_P"C=W9_]@/OW7NO?] 8_P#-B_Y^
M/\)O_1N[L_\ L!]^Z]U[_H#'_FQ?\_'^$W_HW=V?_8#[]U[KW_0&/_-B_P"?
MC_";_P!&[NS_ .P'W[KW7O\ H#'_ )L7_/Q_A-_Z-W=G_P!@/OW7NO?] 8_\
MV+_GX_PF_P#1N[L_^P'W[KW7O^@,?^;%_P _'^$W_HW=V?\ V ^_=>Z]_P!
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MW_Y5/P9WS6=6]^?+':T':6+J*NCSG776^W<UV_E,7/0I&\E-FEVSCLI2X.K
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M/4IEKJBEBUK;7ZH]?NO=:L'_  M9S^!W5\D_@=N7:^;Q&Y-N9WXU[SRN#S^
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MS>Z]U1SU7_PJ!_G:_'OMI:_M?O,=M4^%R0I]Y=+=Y=-[=P%/+9H3-3RG#X7
M9W$U(BCM&8:R-8V<N\$NHJWNO=?3!_EG_/WK7^9E\.^K_EMUEB,AM>CWFN6P
M>[MCY>ICK*K [AVI.U)EL5+/$ E1%',JS4L^A#44<U/.T4+2-$GNO=?)V_GX
M_P#;X_\ F%?^+"Y__P!Q*+W[KW5U7SB_X5??S(?E9W!F]A_RS]N9/H7J;"5U
M34;;EVSU;0=R]@9^@Q$DL;9'+C)8O.8[$454)*24TE!BQ-2LJPRY2JCD=&]U
M[HL'Q7_X5A_S;/C?V2I^0V\,!\L=B4.0BQN[>K.V-CX;K?*P#%":"IAQ^?VY
MA<=D,9D3)H$CU]%DXT>'FDUM*7]U[KZ57P'^=/1/\QKXP=>_*GX]Y:MJME[W
MIZJDRNW<Y$E'E]O9K#/X<I@,U3(\BP9#'5 (+)(\%3 T-922S4E1!-)[KW6I
MY_PHW_GQ?S!OY:'SVVC\??BYNCK'$=<9KXV=?=H5M)O+K*CWA5?Q7<6=W5CZ
MEDJIY$D6!J?$4>F.Q"L'8'U6'NO=;,7QL^3?:_:/\H_J?Y?[JR.)D[KWG\#L
M/W_F<K086&CH?[QY+9/\=>:+'@- E*N0-U@-TT (;B]_=>ZT*?B]_P +#_YA
M&T^[MJ[A^65/L+MGH?&8K?LF[.N^L^LL3L;,92NEV[EH]MPPY>29ACZ5-SOA
MI:Z98I9$H8ZGQ05$FB"3W7NBT?(S_A3M_.][AS,W=.R>SY_C/TE6[B?!;0P'
M5/2V&JMMPU5,]14144NX]RX7-5V7ROVL9%1&^4$,H@>2.@IT,B>_=>ZV(?\
MA//_ ,*8.WOF;WEM;X+?/2';F;[=W_19=>D^_MK;>I]G_P ;K]M8Z;(U.$W/
MBJ".'$4^0JZ.BK9J.MH::BII946A:D6>6&27W7NK2O\ A2K_ #)_E!_+"^'_
M $GW1\4\SM#"[WWQ\D\1U?GYMY[/I]YTSXJNVON?+.L=/4,@BG^[Q-(1(&N$
MUK8ZN/=>Z]_PFJ_F3_*#^9[\/^[.Z/E9F=H9K>^Q_DGE^K\!-LS9]/LRF3%4
M.U]L99%DIZ=G$L_W>6JR9"URFA;#3S[KW6M=_-4_X4P_S3/B-_,2^7'QKZ>W
MIT]2=8=/=O9G:&RJ7<'3N/SE;'0TT-/+''45CR(]0Z&5AK9=1 &HDW)]U[H$
M?G-_PK!_F3_*7>F\:;^7IMO+_&+H+85-59ZJR^&ZUQO:V\YL3CTG\V3W7DJ^
MASN$P%$4"S&.AI8OM3&5?*U<>HGW7NHG\LW_ (5P_-OIKN#:^UOY@FZZ/Y,_
M'+<66H\5NK=S[&Q.V-X;6IZQX8OXKCI]NT&-@SE+0@235%%64,]94J6%-61.
MB12>Z]U].K&9+'YG'8_,8FLILCB\K14F2QN0HY1/#/3UT:RPS1.I*O'+&RLK
M V*D$<>_=>ZT.OYU?_"LO?74/;787Q2_EH46T1E.N<OEME]@?*S=V'I=\0'+
MT$;0U<&Q\1.\V*J$Q-:3$^2RM)5TU344\R08Z6D\-94>Z]UKO=<?\*A_YV.P
M-YX_=F1^7$'9E!2U!FR.Q>Q^G=F5N&R"&+Q"&H7%8+$Y*FC!"27H<G22&1;F
M0AY5?W7NK,?E'_PLA^9N^]O='YKXL;2V-T+N^':>X,5\A=D;LV=2=IXJ;.45
M<#CLMMG*59@KDQM?C9 9*2IB$U)41R0>2IC6.MJ?=>ZWM/Y3GR-[.^7/\N;X
ME?)3N>OQ63[1[AZMI]W[TKL'B(L!2/5U%=6Q'[>CA_;IXECAC4*"?I<DL23[
MKW5AWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K79_X56_]N/?E=_X='QQ_P#?
MC[5]^Z]UKO?\(=_^9Q?S"O\ Q&GQ^_\ =INCW[KW2%_X6\?]E7?"/_Q7K?G_
M +TGOW7NMF[_ (2PXBDQO\C/X;5M.H$VX,K\E,O7G0J7EA[4WK0 W4 M^Q0P
MB[$GBU](4#W7NJO/^%M^,HI?A/\ #W,20:LE0?*;+8RDJ?(XT09;:67EJ$T!
MA&WDDHJ8W*EET64@,X;W7NA9_P"$5/\ VZR[\_\ %_\ M/\ ]]UU5[]U[K2/
MV=_W$";6_P#&Q>$_]_7%[]U[KZY_S<H=^9/X8?+K&]65%%2=G9#XP]^4/7-5
MDUE>FBSU7M3+1X>2H$,<TQ@3(-3F01PNY4'2C-93[KW7RMO^$MF6ZTQ/\[/X
MGGL6D>:JR.,[LQ/6U:\JQ4U'N6NV5GA1350:HA#K/1#(TE.OCG/WU32%8E8"
M>'W7NOKS^_=>ZT._^%PV9Z]'6W\OO;U2V,D[6;?'?&9PJBE,M9%MY*#;D&4)
MG52(*:HR38BR.ZF=X2T2O]O*4]U[I _R6<3OK'?\)0_YM-;N@9!=L9ZD^<N3
MZU2OF>=6QE/U;MVBK9*+5(Z14+9RDRJ>-4C_ ,K2KE()EU-[KW55_P#PCNQ]
M'6_S?'J:J!9I\3\5^Z\ACI&)!BFDK-O4C2"Q )-/4SIR"+.3:X!'NO=?52]^
MZ]U\6[XP8FBSW\]7X\8+)1B;'9K^;/U+B:^$A6UPY'N''PRK9E93J1V'*D?U
M!''OW7NOM(^_=>Z^-K_PHO@@I_YUGS\CIX8H(V[0VK.R0QB(%ZK:6W997(4
M%Y)'=V/U9F+&Y)/OW7NOL+=;X^CQ/7>PL5CJ=*3'XS9>UL?04L5],4-'0P1Q
M1K<DZ415 N2;#W[KW7S!_P#A9A24]-_-HV--#'HDR'PQZ?JZMM;-KD3<N^(
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M>JBCDAIJ9T@AB]U[I@WKN'_A31_*5IL/W[VKO3YV]7;"HJO'T=3FNP^T*CY
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M[!R>(VSFWB)*U!J\SC\]A=8 =#%B0?VV7]WW7NJV/^%=O_;Y7?G_ (@7H?\
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M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUV?\
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M\)!3UV\,1W1F<%@Y<BD2K)5Q[=EPN0KX:-YP[K2G<\DB(1&:MV4R-[KW3/\
MRD/YU_\ PH-_F ?/*2AZLH>N>X.JMX[FV[4]O[5WEU7+A.MNO=OTLU.M=4T&
M;QTT69PU:U"LRT<$^;R4];4N':CK65BGNO=?0\[+ZXV=W#UMOWJ3LC!T.Z=@
M]G;+W-U]OG;M? ):>OQ.\**;'Y&DEC?6#%4TE1,A!OPWY]^Z]U\@/^8!\ _F
MY_(&^<^"WSL/.;SVSA-K;YR&ZOB3\K<#C(JRDR=$WW24U/5RRTDF*3<,.->6
MGR^)J*=HI4,Q$$^.J(WD]U[JXRD_X6R?-6'J7^[=5\3?CI6=S+AWH4[4_CN?
MI\.:HIH6N?::S>5G#>MHEW&D3-]%5/1[]U[K6,^<><^:O=/8&!^9_P UL=O>
M;=7S%QN0[+V#OC>F.3!)GL)@Y4QD%3@\</&U)MRC2*&FQVBFCI9*>-&I&FC!
MD/NO=?68_D _]N:OY?'_ (@7'_\ NRR/OW7NKA/?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]T1/^8=_+K^-7\S7X\9WX[_)3:SY'$SO+E]B[[P?
MBH]P;3S:1-'3YO 5TD4H@JHPVF:&2.2EK(2U/5PRPL5]^Z]U\HW^8M_+)^;G
M\BWY1[#S=;NK,04-)N/^]WQL^5_6$=3MVDR-1MR;6A4^6=\+N"E0(]7BYJJ>
MT4GHEK*5S(WNO=?16_X3R?SB&_FO_%7,P]GI18WY5_'.7:^T.\X**.&CI\[!
MGJ>8X?>%%30I'%31YMJ#(1U5-'&J4M;33"-4IIJ4'W7NM8;_ (6\?]E7?"/_
M ,5ZWY_[TGOW7NMH/_A+C_VXH^#/_ES/_OXNP??NO=?-ES&W*OY[?SNJC8O;
MV;RE9#\I_P"9?!U[OC)5>?\ '4PXKLGLE,//34E74,@C^PQ-1]M011@:$BIZ
M:EA&F*'W[KW7V9>N^N]B=1[$VCUAUAM';^PNN]A;?QFU=E[+VKC(L-CL9CL-
M$L-+1T=+"J10P0Q(H50O^)N22?=>ZU(?^%C_ ,-NL.P_@-MCYD0X3 8?NKX^
M=J;#VQ/O%,4@R&7VIV+-4XJ; 35*/'))%2YFLQV0IS+YA (JR.)$^[DD'NO=
M =_PB$_[)@^<O_B>NMO_ 'GI_?NO=>_X6]_]DP?!K_Q/79/_ +ST'OW7NC"_
M\(J?^W67?G_B_P#VG_[[KJKW[KW6EW_PHS[3W/VO_.<^<F0W+DLK60[+['Q'
M5FV*#(U-1+%08OKC"XW%P4U%#.%%+2S3P5-84B18I*BJGJ5,C3O+)[KW5NW3
MG_"QKNOH'JGKWI/J7^7]\:MG=:]6[1P>R-D[9QF]]QPPTF/V_ E/3QBP&N0J
MFJ20^N61GD<EV8GW7NBL_P R#_A3AV'_ #-?BMO;XM=V_"/H?$XG<=1B,WM3
M?N"WEG:C+[;S. J(YZ3+8LU ,8ETK)3SQMZ*BEFG@>P>X]U[HZG_  B:[\W#
MM[YE?+#XS//,VS>T_CE1]QB&2LE>.+-=-;BQ6)IQ#3!&B1ZS';RR!FFUQDBC
M@C;R$QZ/=>Z^D[[]U[KWOW7NOBV]68=_YL7\Z/;%#O?.93-[?^9?SH?*[JR&
MX,K5T=5_=+=NYY*ZLHH)E\E1224FU8Y*3'P(42F\=-31M!#&K1^Z]U]E_KOK
MO8G4>Q-H]8=8;1V_L+KO86W\9M79>R]JXR+#8[&8[#1+#2T='2PJD4,$,2*%
M4+_B;DDGW7NM._\ X67?"SIS=OPSZ]^<5'MG"X3O[J7MC9'5V5WO1T'@K,YM
M+?46408;(21-&*K^&9=:.KH9)UE-*C5\,&@5LI/NO=!7_P (B_D#NO=/0_S?
M^,^9J*^LVMT[V-U'VMLEZJNFK8Z9N[*+/4&7H8(G4Q45.D^SZ.J5$D FGJZJ
M7QJXE>3W7NM2G9W_ '$";6_\;%X3_P!_7%[]U[K[-OOW7NO>_=>Z+U\N/^R4
M?DY_XKUW1_[S>2]^Z]U\HK_A+C_V_7^#/_ES/_OG>P??NO=;V/\ PK(_[<H=
M^_\ B2_CU_[V.*]^Z]UK:_\ "*#X]]9;_P#E+\O/D#NS!4V:W_T!UCUCMWJ^
MIKHEJ(\:_<U9GDRV1@1@1'D!2;=BI8IAZDIZJKC! F/OW7NMOG_A0EU+M+N#
M^3A\[L/NW&4>079O3=;VUMR>IC8O1Y?JFJIL[0U5.\;QR13:Z)H20^EX9I8I
M5DADDC?W7NM)[_A%3_V]-[\_\4 [3_\ ?B]5>_=>Z-Q_PM^[3W/4=N_!#I-,
MEE8-EX?KCMGM.HQ$5340T57E-QY/'XF&IGA 6EJ*K'TF*G2!R7EIXZVH51$E
M4WF]U[JIG^5A_P */-__ ,J/XRP_'/IOX:]&;QJ<GN[<6]]_]I;DW1FL9F-Q
M9#,3N*22O6D'A6/%XM:.AIXU.@1P&6PDFE)]U[JP'>O_  M#^078^T-S[ WY
M\ _C-NS9>\\%E-L[JVSF]Y;BKJ2OH,U"]/54M1$W#Q30R.K#ZV-P0;'W[KW5
M$/\ )1^0]=\?_P"<1\(.S-BT$VV\%NWY1;.ZGK]N)FZFJCIMN?(+(_W/KJ6>
MH\;S9%,9C<\TR"2$M/-2Q.=$FET]U[K[0WOW7NO>_=>Z^5__ ,+%^RMT[N_F
MRXW8N4R>0EVQU/\ &CJG#;4PKUSR4D#;JJ,MFLA5PTW$4-5635D4<\@4R2QT
MM,KN4AB2/W7NM[;^0I\3NIOB?_*J^&V-ZTVQ@\5G.Z>ANJOD-VQN?')3557G
M=R=S8*AS]755V0I]0R"4,=?%043^62.*AI:>*%C&H+>Z]T._\UKX;=8?.GX%
M?)'HSLK"8"LJJGJO?.Y^M-TYK%)DI-M;KVWBJRHP6?HR7BEBEH:U4\PCJ(C/
M2O/2NXBF<'W7NOG)?\)$O^WRNP__ ! O?'_NM@]^Z]T+O_"S;_M['UU_XI1U
M#_[U>_??NO=;PO\ PGFZIP'4'\FCX&8' 4\<2[IZ?/:V7G5S*\]?V[E,AN2J
MDD<JK,R-DA"H((CCBCB4LB*3[KW1&O\ A7M_VYPW;_XL+T5_[EUOOW7NJAO^
M$,?_ '5$_P#+)O\ YKGOW7NM_P ]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=?/'_ .%E/\M3=]#V+L/^9YUOA&R6PL]MK:W3'R/-!3KKQ66PLSTN
MUL_5^.$,U'EJ.>'$23R2D0STF.@'_ N,+[KW4;_A/!_PICZF^/'3FR/@;_,)
MS&0VCLKKQ:7;7Q_^2$&.J<[14.(JI@E-MG=U-2QSU='2XEI2E!E(89*>*AT4
MU=%2QT8K*CW7NMW?;_\ ,6_E_P"ZMBS=G;?^;_Q)R77E-3U-57;SB^1&TH\=
M3)1 &<U=5)EDBHVIP1Y5F:-HK^L+[]U[K7+_ )M__"L#XN_&;9V5ZO\ Y?.Y
M-J?*?Y$9R@K*:G[)Q!.8V!M3RH%CK9J]6CCW/D07UP4E"TE'>-C65<=DIY_=
M>ZN!_DP?S:.O_P";E\6?],&$VGE.O^U>N\EC]C=[[%EH*J7&4.>DI5J1-A,K
M)']O7XS(0'[B&/S&KI580U: B.6?W7NOG3_\*8?BCV)\.?YO_=_9%#B:S:&S
M/D?N3'_)_I;?&V*:; QS5NX!3S;BE@K*:*".+/8W>$62GJ?#.U2HJ*/(3,KU
MT9/NO=?0U_EC_P \+X1_S#.@^OMW?Z<NI>K/D ^T:";M[X_[Z["QFV,WB,OC
ME@I\K+04V1FHILM@6KI4-+D*> Q-%/ DZT]2STZ>Z]U21_PI_P#YW_Q2IOAK
MV;\!OC+W#LON_NWOF?%;3[)S?5&X\;OK#[0P6V<Q15N9H\GDZ22KH?XWE#0O
MC?L8G>II(Y*J6<TD\5.)/=>Z*#_PB@^&6[*;=?RF^?6YL!6XW:=3LRD^,?4^
M9K4GITR<N2R>/W#NV6EC>-89X*"3#[;@^X1VM-+4TZD-'.OOW7NJE/\ A7;_
M -OE=^?^(%Z'_P#=;/[]U[KZ0/\ *=_[=9?RT_\ Q0#X;_\ ONMN>_=>ZTM_
M^%Q'_,XOY>O_ (C3Y _^[3:_OW7NMB'_ (2I?]N/?BC_ .'1\CO_ 'X^ZO?N
MO=$ _P"%L/\ V[F^,?\ XNOMO_WA=\^_=>Z3G_")3_LA3Y;_ /BVD7_O';>]
M^Z]UIK_SW,KE,%_.C^?&<P>2K\-FL-\E,GE<1E\5628ZJI*K'04$U/4TU1"R
M2P5$$J(\<B.KHZAE((!]^Z]U].+^5O\ SI_AY_,?^/FP]Z8WM_K?K_OR#:F)
M'<_0N[M[8_!9O"YJFA$>2DHZ:L>CFRF#EJHY9*2OIZ?Q/ \8F6GJ/)3Q^Z]U
M2;_PJ1_G2?&';OPU[0^ 'Q^[;VAVS\@.]YMM;8[(/768I=W4.T=N8S)466R<
M>4R%.*K'+E<O%1)0+1+.:R""JEJG6G9(&?W7NB0_\(F/B+NF+>GRU^=&>V]5
MT&U&V1B_C%UMN&IFF@3(3Y;)X_<NZXZ>#B*>*B.'VNK3D-IDD>&-@5J%]^Z]
MU7U_PLV_[>Q]=?\ BE'4/_O5[]]^Z]UN[_"?_N'N^/?_ (RCVO\ ^^P'OW7N
MOG8_\)<?^WZ_P9_\N9_]\[V#[]U[KZ_7OW7NOC==+_\ <1QU/_XVSV)_[_:E
M]^Z]UN0?\+8?^W<WQC_\77VW_P"\+OGW[KW7O^$3W_;N;Y.?^+K[D_\ >%V-
M[]U[K2E_GX_]OC_YA7_BPN?_ /<2B]^Z]U]G_P!^Z]U\KG_A8W_V]VQ?_BI?
M2_\ [M-T^_=>ZW>.L_C9E/F%_P )Q>A_C'@*FAH]S]T_RB?CULK9]7DQ>FCS
M==U5@9,*]01RL"Y6*C,C"[(EV4$@#W[KW7SB?Y)O\PB3^3?_ #)1V=W;L3<J
M[0EP6_/C)\D-JTV.MG\+C\EEL=/7S4]%,\(?(X+<&WL=)/2NZM+%!4TZ%9G1
ME]U[KZ=F#_GD_P H3<&P*#LFC_F(_%FCP&1PV/SL6*SG:-#MW<$<.3A\Z15&
MUJYZ?<M/6HGIEI9,2M3!)^U-$DEE]^Z]U\U+_A1%_-@VI_-8^:V*W=TT,W%\
M:NB-C)UETU-GJ1L749F7(54F1SNZ9:">F@K,8V6J9*2EBI9I)'%'C:2=UIZB
MHJ*>/W7NOI _R ?^W-7\OC_Q N/_ /=ED??NO=7">_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7N@Z[6Z@ZE[WV/ENL>\.KNNNY>ML]+C9\YU[VMLG&=AX.M?#5,
M591O5XG+TU905+TM9!!/"9*=C%-&DJ:716'NO=!WT=\0?B9\8JS<.1^-?Q>^
M.WQZR&[J;'T6ZZ[H[I/;74TV4AQ+RR4D.1EP&,Q[UL5,\\[1+,SK&TCE "[7
M]U[K!W?\-_B'\FLM@\]\D?BM\;_D%G-LXZHQ&V\UW?T=MCM>KQ])52>:6EH:
MG/8NOFI*>2;]QXXG1&?U%2W/OW7NA0ZMZGZLZ.V)@NK>E.M.O^G^LMK_ ,3_
M +M===6[-QW7^"QW\;K*C(UOV.(Q--28^D^[R%75U4WBIT\M1-+,^J21V/NO
M=);NWXV_';Y,8+$;6^1_0G2WR!VSM_+G/X';G=O5N#[6H**O,,E/][24>>H:
M^GIJO[>:6+S1QK)XW=-6EB#[KW4GI3X]=!?&O:N0V+\=.C^G^@=DY;<%5NS*
M;.Z4ZTPO5>*J<K74U)1SY.HQ^"HJ"DFR$U)04,#U#PF9X:>")G*0QJONO= C
M#_+B_EY4_8,7;-/\#?AC!VI!O%.Q(.S(?B[L>+<";@BK1DUSJ9E<&,BN97(@
M50K14_<BI_?$OE]7OW7NCG>_=>Z@93%8O.8VNPV;QM!F,1E*6>AR>*RE''D*
M:H@J5*20SP3*\4T4BDAD=2K D$$>_=>ZK0W!_)5_E*[HW!4[HS/\N_XFRYFM
MJJZNK):/IW$XB"6;(D&:22CHX(*)V9AJ%Z?TL69-+,Q/NO='QZDZ6Z?Z"V7C
MNN>CNK.O.GM@XE0,;LSK+9V/V/C(38*72BQM/34_D8*-3F,NYY9B>??NO=*C
M>6S-G]B[3W)L'L':FVM][%WEA,EMK=^R]Y8*EW/B<KC<S$T%9C\ECJZ*>CKJ
M*K@=XYH)X7BEC9D=64D>_=>Z+WTY\%?A'\==WOV#\??AS\5NBM^OB*W /O?I
MSX];1ZQRYH,D\3U%$<EA,10UII*AX(&DA\WC=HT+*2BV]U[HU/OW7NB7XC^6
M_P#R[]O[^Q?:N!^!?POPG:&$W?1=@X7LC$?%S8^-S])G\;6KDJ;.4N8AP29&
MGS%/D42JCK(ZA:E*E5G602@-[]U[HZ'OW7NB;=C_ ,NG^7SW%O;/]E]N?!/X
M;=I]C;KJ8:W=._\ L?XP[)WQF\E-30QT\<V0RN3P=57UDL=/##$K33NRQHB
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M "0OBGNC:6T-J4&S_ECE<OF*&#=M5\9NN\!O'&8'&U/E#Y"7.5@H,)E)HVC
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M (KUW1_[S>2]^Z]U\HK_ (2X_P#;]?X,_P#ES/\ [YWL'W[KW6]C_P *R/\
MMRAW[_XDOX]?^]CBO?NO=4C?\(9*>!JC^:!5M#&U3!#\+:>&<J"RQU3=L-(@
M/U"NT,1(_)1?Z>_=>ZVN/YW7_;HG^8O_ .*E]P?^ZN;W[KW6B=_PBI_[>F]^
M?^* =I_^_%ZJ]^Z]U;E_PM'^#^_>R^FOCA\Y=@XG(Y["_'NIW3U7W528^B^[
M./PG8]30U.#SLS"0-#0T68IZBBJ"(9+RY.D8M$D;EO=>Z '_ (3A_P \;^7Y
MLCXP;+^#?SW;K/I_L#J:LSV,ZF[M['V715& W%@LM4UV6AQ^7S:8UX<'E,(9
M9Z:.7)2Q4M73+1I'5O6L8']U[J^[Y:?SS/Y&?Q6ZTR.^*7M;XU_(C=!IJH;6
MZL^-N*V_VSE\I5Q1N\=/)48R&?%8:)REC4Y*NIHEN ID<K&WNO=#1_*X_FD_
MRT/YJ='EG^,FRJ+;?;G7>"PF\=_]5;YZ6@VYF-OQU]2]/35*Y6FHZC UR?=P
MD1R4.8FE2\;2Q0,ZK[]U[J['W[KW7O?NO=?-_P#^%H?P@W_MGY*]*?/O XBI
MR74G:'7.$Z*W[E**@4IA]U;"GR59C#7S+)JT9_"5>BE)ALKXFI1Y;R01^_=>
MZL*_X3[?\*2/A]0?$?J'X8?.'LG%_'GM+XZ[)P76&P.R=XTDU%M/<NV-J1M1
MX*)LK&:J/$9C#8JGI*2J6O%+35*I#/232/)/3TWNO="7_/1_X4N_"_:_Q)[F
M^,WP>[AH/D#\@.^.O]P=72[ZZSDK/[O[0P^_:6?'9;+#<2I3P5>;3'2U*8^+
M&U$STU5)%5SRPB%8YO=>ZUJO^$B7_;Y78?\ X@7OC_W6P>_=>Z%W_A9M_P!O
M8^NO_%*.H?\ WJ]^^_=>ZWV?Y(O_ &Z)_ET?^*E]/_\ NKA]^Z]U6-_PKV_[
M<X;M_P#%A>BO_<NM]^Z]U4-_PAC_ .ZHG_EDW_S7/?NO=;_GOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[I']@=?['[7V/NWK/LS:6W]^=>[\V_E-J
M;SV9NO%PYO&Y/&YN%H*NBK:2=7AGIYX7971E((/]??NO=:+?\Q;_ (1CT&[-
MU;D[+_EM]U;;V%19FK;)+\=>^I:\XNA>H=6GBP6[<?39*OAI%4N:>DK\14,K
M61\DL=M'NO=4BUO_  D=_G.TN?@PT'5_2>2QTM+E*B3=E%WYA(\?$^/E@CB@
M>.I:GRIEKDEDD@*8UXU2&45,E/(88Y?=>ZM*^#7_  BQ[8K]W8C=7\PGY!;(
MVUL/&Y.*JK>I?CG65FZ,OEJ>G,3?;5>Y,KCL=185)F$J2?:X[(R&*QCG@E;5
M%[KW6^K\=/C=T=\2NH=I=#_'3K7;/5'5.R:66GP.TMJT HX1)5,9*FKJ9#JF
MK<A6S,TM353R25%1*S22R.QO[]U[HMO\Q_\ EJ?&/^:)T#6]"_)/;E5+%13U
M.9ZY[(VTT-%N+:>7FC$8R>%K)H9D7R*J)54LL4E+61*(YXF*QO'[KW6@CWU_
MPC$_F+[-WMEJ;H#MSXY=U]<&=I-NYO<FZ,GU=FS#)-I6/(XJ?%9"@AGCB(=F
M@S,Z. Q4*^F(^Z]T9+X2_P#"+'O7+;[Q.XOGY\@NN-F=8XC++49/K;X]5E=O
M3/YRGIU/^3/G<IC<5CMOQRRE-4T=%E)FA5XUCII9$GB]U[KZ 71'1/4OQEZB
MV'T1T7L?"=<=4]:X&FV[L[:& I_!!34\!+N[LQ:6HJJF9Y)JFHE=YZFHDDGF
MD>61W/NO=:=7\]3_ (39?.;^9U\_=S?*KH7M;XG[1Z]S/6?6FS*7#=O;YWA@
M<RM5LVDD@JI)*?#;$S]"*>1W!B89%G87UHAX]^Z]UMH_"+I3=7QK^%_Q$^.F
M^LAM_+;VZ!^,'072F\<IM.JJ:[%5.5ZKVIB<%D*C&3UE)05<V/FJZ"9Z=YZ&
MGF>$HTL$+EHU]U[K7R_X4:_R-?EG_-ZW[\6=T_&OL/X[;(Q_2&T.T,!NN'O'
M=NY=M35$V]JW#5%(V.7 ;1W,DL4:8Z<2F:2!E9D"+("Q7W7NK5/Y*?P9[:_E
MP?RYNDOB'WAN'KK=79/6V9[9R.<S?5.6R><P<J;\W;FL]1BDJ<OB,'7R/'1Y
M&!)A)C(@LRNJ&1 LC>Z]T6#_ (4._P J[Y!_S:OB?T]T3\<MX]-;*W=U]\AL
M3VUF<CW9N'-[<QLN-H-M[DP[P4LV"V]N2J>M-5F*9@DE''%XEE8S!U1']U[I
MI_X3N?RG_D3_ "D?C9WET[\C]Y]+;UW-V;WBG9>!KNDMQ9S<E!#0+@<7B_%5
MRY[;FVZB.K^XH96TQTLL?C*'RZB47W7NM?W^9O\ \)1_YB'S0^?/RF^4_5W<
MOPOP/7W=_:>3WQM3#[^[$WQB\S3TE;!3QI'D:?'==96ABJ T376'(SI8BTAY
M ]U[I!?/K_A&#W%1=BYG=W\NCN/8&?ZLSN3KLA1]0=^9VNVSF-O1U3RR)04&
M?IJ#)TV=HH+I%!)61T=6L845$M7*KU$GNO=!;\/O^$7'RUWAOC&5_P V^].K
M.G.J*62@J<S@>D\S4=D;MKTD77/1TT];BJ3 8B1"53[MY,DJN&*T<J!7;W7N
MOH5?&GXU]*?$'H_KWXY_'C8F*ZXZBZPPB83:FV,4&DL'=YZFLJZB5GJ*_)9&
MKEGJJVLGDDJ*NJEEJ)Y'DD9C[KW6I[_PH"_X3L_-?^:Q\WMJ?)7X\]H?%O9N
MQ<%\>=B=2U>)[GWKNS;V6;);8S>YLE43QP8/9&XJ,T3P9JE6-VKUE,BRAH45
M49_=>ZV*_CQ\3.QNI/Y6O5GPBW'FMDUO:VR/A+AOC;EMP83(UU3MZ3.8[9PV
M\]73U<^-ILD^)-;ZUE?$QU!@]1I1)^W[]U[K5._DS_\ "7_Y]?R[?YDWQP^8
MO=?;OQ W1UET_P#Z8/[RX+JW?V],WG9_](&PMT[6HOL:7+=?X3'R^+(9NDDF
M\N4ATTZ2NGDD5(I/=>ZWO/?NO=:"G7W_  E?_F#;3_FQ[(^=V1[B^&TW46VO
MYB&VOEM7;<HNP=[2;D?;>&[*AWC+10T<G7D>,;-MC(VB6%LPM*:JR&L6+]\>
MZ]U?I_PH=_E7?(/^;5\3^GNB?CEO'IK96[NOOD-B>VLSD>[-PYO;F-EQM!MO
M<F'>"EFP6WMR53UIJLQ3,$DHXXO$LK&8.J(_NO=>_P"$\7\J[Y!_RE?B?W#T
M3\C=X]-;UW=V#\ALMVUALCTGN'-[CQL6-K]M[;PZ054V=V]MNJ2M%5AZEBD=
M')%XFB83%V=$]U[K7G_F;_\ "4?^8A\T/GS\IOE/U=W+\+\#U]W?VGD]\;4P
M^_NQ-\8O,T])6P4\:1Y&GQW765H8J@-$UUAR,Z6(M(>0/=>Z^@?[]U[K2S_G
MX_\ "<KYN?S3?G51?)SX^]I?%;9^PJ?H[K[K1\1W'O?=VW\N:_:E;F:BHE%/
MA-C[AHOM'3(P"-OX@)"RN&B0!2WNO=;07Q;VA0_!S^7_ /&;K;Y"=A=:;1I_
MBE\2^C.L>WNS*W=B8#:5)/T]M+$X3+Y1<SFXL0L&%^YH)I(JFM@I&\!1YHH7
M+1K[KW6M/_,X_E2_R9OYU/=$&_/BI_,7^(_6GSGWA3BGR,72?=FQ>YZ;?)QH
MB/W.;V;B-QPY2KS--1PO$N2Q]5%*8B#7PUXA@$/NO=4^[1_X1(_-RM[ JL;O
MSY@?%?;?5B>7[+>6T<9N[>VX)+/$$\NVJS#;?QT.J,SLVG=DNEDC0:A(SQ>Z
M]U3[_/N^&_PY_EX?)CJCX5_$W,5N_,YU'TCA\S\ENU<[NA,YE<IOK?-?6S/C
MJ^AIQ]CA!B\!286HAHJ<@1QY&TRM4"6HJ/=>Z^F+_(JVOD]H?R??Y=V*RT?C
MJJOXQ=?[HB72R?Y-O>)\U1-9@#ZJ/(0-?Z&]U)!!]^Z]U;#[]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZT]/YG_ /PD5^.OR\[0
MW%WS\0.UZ;XC;_WE7UV;WUUM6[*_OALC)Y&N:266NQM-25F/KMKU%5/)JJ4@
M^\HFL&IZ"F<RM+[KW57O4G_"(3NFIW=CV[W^<G5V%V'39Z)\I!U)UMEMSY>M
MQ=/."\5/+F9\11XNOJZ8,JRO#7Q4DK!S%6K'XY/=>ZWG/A3\)_CQ_+]^/VTO
MC9\9ME1;.Z[VN9JZJFGE%?D\SE*]8UK<WFZ[0DF0RU=XHO),RJJQI%! D5-#
M##'[KW5.'\[S_A/K_P /)=K](]G_ .S;_P"RY?Z&^O,]L/\ @?\ H$_TO?Q'
M^-Y+^(?=_<_WTVO]GXO\WXOMY]7Z_(OZ??NO=6@_RN/@Q_PVO\$^C/A5_I1_
MTT?Z%_\ 2;_QDO\ N3_HZ_B7^D7>.X=V?\6;^+YW[/[/^._:_P#%UG\O@\_[
M7E\,?NO=-?\ ,C_E>?%'^:7TLO4'R9VG5RUF"DK\CUIVGM.>/$[FVKD:Z+Q-
M5XFNDBFC>&6T?W-%4P3T54(XS- TD4,D?NO=:<&Z_P#A#SV.N[*M-C_S!=DR
M[%ER-<]!4;KZ%KZ?+04C>JFCFAH]R2T=74+<QRR+/3(VGS)&FOP1^Z]U8=%_
MPC<^)N+^&.X^B-O]^9C_ &:#>NZ]B[BW#\O=[=20;U..I-J%VK,%M79\&XL-
M%@\9E9'+32R9^MKV_1+5S4XC@C]U[JV/^2%_)H_X9LZO[RZW_P!F/_V8[_31
MOW;6]_XS_H@_T0?PW^[V.DH/M?M_[T[H^\\VOR>3SP:+:?&U]7OW7NO?SO?Y
M-'_#R?5_1O6_^S'_ .RX_P"A??NY=[_QG_1!_I?_ (E_>''1T'VOV_\ >G:_
MV?AT>3R>>?7?3XUMJ]^Z]T(?\E3^5)_PSY\6-_?&C_3U_LQ']^/D!NGO3^^O
M^B[_ $2?:_WFVYM7 ?PO^&_WCW/Y_!_=GS_<_?QZ_N?%]NOA\DONO=';^87P
MQ^-_SRZ2W!\??E%UMBNRNN,^Z5D5+5N]!78ROID=*?*X;(P,E7B\I2B1_'40
M2*VEGBD#PR21O[KW6E3WI_PB!2;=&3KOC1\[WQNRIH6?#;8[TZF&:RE/(&XB
MJL[@,CCZ2L1EL3*FW*8J1;PL#<>Z]T+?Q5_X1.=.;-WS3;E^8'RYW%W9L[&U
M5)40=8]2;!;J2*O\#%I(LIG*K+YBO%),NE3'14]'4#EDK%) 'NO=;K'4?476
M/0O6NS>GNFMC[=ZWZPZ^PE)MW9NR=J8]<90T%'1CT10Q+R69BSR2.S2RR,\L
MKO([,?=>Z$;W[KW7O?NO=$5^?_\ +C^*/\R_I>7I/Y4=?KNC$T-3-EMD[RPM
M5_ ]Q;:R4J!/XA@LHBM)32NH59H9$EI*I (ZJGF0*![KW6F7V-_PA[W;_>VO
MDZC_ )@&W?[BSY!&QE+V-T94C+4M)(&+)/48S<'V=?41,% =*:C24$MXX=(5
MO=>ZLL_ES?\ "0GX>_%+?6W.X?E9V9EOF7O_ &M5KD]O;&K]H0[ V'2U=/-'
M+355;A3697(Y^>D,0T)5Y2/'OK?SXV9A$T?NO=;=T444$4<$$<<,,,:10PQ(
M(U18P JJH "JH   %@.![]U[K3-P_P#PD6_A/\P+%?.K_AP;[C^&?,:A^6?^
MBW_94/%K^SWJN\/X!_&_])3:=6G[3[[^$&U_N/LS_F??NO=;FWOW7NO>_=>Z
M#WMS8?\ I4ZH[.ZP_BO\"_TC]>;TV'_'/L?XI]G_ 'OQM3C_ +O[;S4_W'V_
MW'D\7W$7DTZ/(E]0]U[K5$_E<?\ "4K_ (;7^=G1GS5_V?/_ $T?Z%_])O\
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M)4RHI9888TBI*5"8Z6GA0L#[KW1ZO?NO=>]^Z]T$G>W1'47R:ZEWQT7WOL/
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MC_(Q_P"&7/\ 9HO^<HO]F3_V9/\ T)_\T3_T._P7_0[_ 'N_[.[=7\1_B/\
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M\?L!MNKZ4W-20-NG<V<AVY2T,N1:@-#%$V6GCB:H,_@5;RF3QC5[]U[H]_\
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M=L.MRF0,<,5+E*+)2U>6VJE74OH@GER.2I$+#[RJI8U,Q]U[K="5E90RD,K
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M\FXLKN"E'CS-341I'''(A6GIZ>**DI(H*:"*%/=>Z^6E_P *7_\ M^%\\?\
MPZ.G?_?<;.]^Z]U]"S^?]\R=^?"/^35VAV-U1GX]K=J=B87J_HG8>X_,T-10
MR]GF&#+5= 4DBD&3IMMP9N2CD1[T]0L=45D6!HV]U[K2,_X2^?R?NH_YE_R'
M[6[8^3>(RNY?CS\5J;8U95==B.?'8_=VY=]29%\;C,C7Q-&\F)Q5-B:BJKZ.
MGE66=I:"*=UI)I8:GW7NOH2=B_R3OY2G9O7N:ZUS7\N_XC8##9O$SXB3/===
M%[>ZQW#3++$T2ST6YL!08[/4M7'JU+,F0#ZPK,6(]^Z]U\LSYU_'?M?^1A_-
MASVRNFNP\[4[@^-G8>Q.W>@>S*^V-J\EA,[34N:Q296/'3TZU -/45&'S$2?
M;P5_BK5%/%25(B'NO=?21_F[=R8#Y%_\)ZODK\@MJ*Z;8[S^$NQ.X=NI)')"
MRT/9=/@<U2JZ2JDJ.L%:@97174@A@&!'OW7NOG5_\)[?Y>?7/\RC^9-L#I;N
M8R5G377VRMU][=H[8IZB6BDSV,V)/CJ.#!BHAEBFIX,AE\OC%JWC<2_9"I2)
MHY726/W7NOH^_P R[^3K\"^]?Y?/>74NUOBAT1UUN;KKHOL3+?'[=_6W46)V
MQE]L9S;.,?)8QL958BDI<BU-5Y#&T*9"D6HTY*'5%4"1F##W7NOGR_\ "5?=
MFXMN?SQ?B1A\)E:C'XS?NW?DAM/>%)"J%:_'4?6F[<[%2RZE9A&F6PN+J04*
MMKIT!.DLK>Z]U]=CW[KW7O?NO=:OG_"O;_MSANW_ ,6%Z*_]RZWW[KW6I7_P
ME,_EB]$?S _EKW3V#\F=GX/L_J#XM;!VGEUZKW'3R56.S&X^SZRMI\+)DX5E
M2.LQF/H\)FI)*25'BGG:F\JM%&\<GNO=;9/_  HX_E/?#OLC^6!W_P!S]<_'
MGICJ?O#XN;"QO9?7?8/7'7F*V!5IAM@UD<V7V]5OB(*#[[$3X.?+"FI)S)#3
M5K0U,$8=6#^Z]UHB_P#"?G^7UU]_,C_F4]9](=PQU-=TULO:F[>[>U=OT<DU
M-)E\5L(TD,&(-1 \<E+3Y',9+%PU,BNK_:M,D3)*\;K[KW7TM?G7_)H_E]=^
M?!CMCX\8#XF]#=8?P'K+>N0Z7W)U7U/A]CY3:^XL?1U-=C<GC*O#T5+6WDRJ
MQR5\'E9,HCSQ5JSB=[^Z]U\W[_A,KNK);5_G=_"%Z#,5N)IMP9KN#:N8CI97
M$=939SK_ '5&M'4QJ"LT$E4*5PKJ5CFCBG&AXDD3W7NMD#_A;7\I]\X+;'PX
M^'&W<K/C-C;^EWYWMV=1TL]33MDYMG2T>(VS2S&.2.GFH:6:KSE3)!*DVJI2
MBG'B>F0R>Z]T[_\ "5_^2!\3.R/B;M_^8I\J.L-H_('>O;VZM[8WI38_9.$I
M]U[:V[A>L\W5X&HR+X2LBDH<AGJ_/8C)?OU<4\=+2P4PI$AFEJI)/=>ZV'_Y
MC'\BSX"?/SI+>VS*CH#J7I_NBJV_)'UMWWU;UWB=D9[$Y+&+))CEJZK&T=.^
M5PQG8I4T53Y(V@DE,/AJ/'-'[KW7S0OY(&T-R=??SOO@_L+>.+FP>[MD?*E-
MH;JPE1+'/)1Y+;0R5%74KO"\D+O3U4,L99)&0E259EL3[KW7T$O^%9'_ &Y0
M[]_\27\>O_>QQ7OW7NM('^2/_.(V]_**^+?\S/<FWL30;M^3G>I^*&UOC=L[
M-T\[XL56V$[,&9W%F'A4!\;MN/+XZ5J0312U]1/34B20Q23U5-[KW7+^3Q_*
MQ^1?\^7YF;\[X^2&\M]9CH_!;ZI=X?*OOO/U$YR.X\GE2*D;4P5<T)ICF*NF
M6$2K#IBPN,:!UBC5\=3S>Z]U]83JCJKKOHWK38O3O4FT<-L/K/K7;&(V;L?9
M^ IA24F/QV#A6"FIXEN68JB@O([-)*Y:65WD=F/NO=?(>_X4O_\ ;\+YX_\
MAT=._P#ON-G>_=>Z^KK\@?\ LAWNW_Q5+LG_ -Y"M]^Z]U\:W^5Q\/L=\^?Y
M@7Q;^)&;SE3MS;7<'8ZT6\<O0V^YCP6TZ"MS^=2C9CICKJC$8JMAIG8,L<\D
M;LCJI1O=>Z^N-NC^33_+&W/\9ZWXG-\+N@<1U3+M^OP^*EQ/6^,@SN-K*VBG
MHES]#N1J=\['N6%*B1ERIR#5I<MKF=696]U[KY4'\LW%[R^.7\[+X3[#QN<J
MJ#<^P/YCO2_2><RL-!_#Y)Z:K[ HMHYZ!J:H$CTZ9'&U.0IY(V_<C29E#"10
MP]U[K>]_X6-_)W>W2W\MG8'3.Q\S/@V^4?>F,V3ORHHYZJDGJ-L;)QM9FZ^@
M26G>)%CK,K#@TJ$E9TFI?- 8761WC]U[JBS_ (2F?R5OC7\Y<'V[\VOEQM.@
M[=Z]ZG[/_P!"W5_2^<=VPE9N#%XG%9W+Y?<-+&R'*4]%19S#Q45%*YHY7FJW
MK(9_' J^Z]UN>?(?^1+_ "F?D7U3N;JO+?!3XU]6?Q[&S4N-[!Z"Z=V]TCN;
M$U0TM35]!F=MX['53RTLR1R>&I:>DG :&JIYZ>66)_=>Z^4]OKXL;G^$?\UN
MD^*&[JY,MF.C?F/U_LJ+-QH(AD<?!N3&U&(R?C%Q$<EB9Z*J,=SXS+HN=-_?
MNO=?;3]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW5,O\ ,=_GT_RZ_P"6-F)]@]X]E9G?'=\>*;*CH?I;#1;Y
MW% DB1/3C+-)546'V^U5'/%)"F2RE+-- 3-!#+&+GW7NJT^@O^%C'\K?MWL'
M%[&["VC\DOCKCLU6)14?8_9NR\-FMOT[5$Z0P_Q*7;>?S.4H5=9%=Y?X5+30
MJLAFG1$#O[KW6HS_ ,*L]^;)[0_FQ97L7K;=VV]^[ WM\:?CMN;9V]=GYJGW
M'BLICLOB99J6NH*^DDEIJNEJ(F5XY8Y&1E(()]^Z]U]'K>-1\>*+^42N3^6F
MUGWK\9\+\$=JY_O';$./ERDM5MO;^S**MR8IX()J>H:KBIX&D@,,\<Z3(CPR
M)*J,/=>ZU\_^$_$7_">>7YH[WI/Y:6W/D7N+Y,'JS>6]*'<7R&Q-35P;;VS3
M5>+QN4I-O5$_CCI9*B3*TD+221U%?+!)-$U7X&DC;W7NMR#=&Z=L['VWGMY;
MTW#A-I;1VMB:_/[EW1N7*P8/'X^AQ4335596UE2\5/2TM/"CO)+)(J(@+,P
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M*LI9Z'*4%.^#*G,W65,++D/=>ZV ?^%>W_;G#=O_ (L+T5_[EUOOW7NJ7O\
MA#=_Q^G\R7_PU_BK_P"Y?8'OW7NMJ#^?]_VYJ_F#_P#B!<A_[LL=[]U[K2(_
MX14_]O3>_/\ Q0#M/_WXO57OW7NDO_PLV_[>Q]=?^*4=0_\ O5[]]^Z]UL"_
M(S^5=\@_YM7_  GM_D^]$_'+>/36RMW=?=7?%CMK,Y'NS<.;VYC9<;0=89##
MO!2S8+;VY*IZTU68IF"24<<7B65C,'5$?W7NOG9==?&'?W9ORYV)\,<#E]H4
MG:'8/R-VQ\8<+GLO7UM/@(L_NS<T&U*:KJJJ''U&13#ID:A)))8\7)4BF#.M
M*\MH3[KW7T'.R.O?F3_PG:_X39]M=='??6]3\F:ONJLV_MWL_I7)9;<^+P5'
MWOF:*";)4M3FL/MVMARU)BH*^.GE..*4U=-2S(9M!'OW7NM2S^4[_(_^1'\Y
M[&?(/L7K_P"0'4FP\CU;FL='GV[9RN5S^;SF9WG'4UPJ9HJ*"KJXZ.:2-_/D
M9V=GG=@D4[K*5]U[K8W_ .$XW\G3^;S\'/G_ -HY[M_<V:^.'QBZIJ<MM3M3
M:*9N/>FW.XZG*T).(?;=$DXI'HJ!)J+(C<4E/!7T) PJPBHJ,S247NO=;]?O
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJX_P";
MWTCO#Y&_RPOG/TSU]BZS.[[WE\<>Q1LW;^/:-*C(Y3;](<K0XZ RVC\V0J:&
M.G0,R@M( 72^L>Z]U\TK_A,)\^.GO@)_,RI-R]_[JIMB]1]\]-[O^/\ GM]Y
MK)1XS#8&MSN5P.>Q.7S4T\L4--0+6;>%%)5/=:5:YII"E.)Y%]U[KZX$.8Q-
M1BDSL&4QT^#DH!E(\S#6Q24C4Q3R_<K4*QA,'B]?D#Z-/JO;GW[KW7RI/^%7
MW\P[JSYO_/O9W7G1&Z\%OWJ;XF]<5W6\F^-OR+D*/)[MW/DI:[<SXZOCE>"N
MQ=%#3X2ACDCC"FKI:YXY9X)(6'NO=;R_\G'8,G:W\@#XK]70O2QS=D_#3>&P
M8I*Z,2PJV\8\YCE:92&#1 U(+@J05N+'W[KW7S _Y>_7WQ.V=_,2V+TA_-)V
MGEL)T+2[]WITUWI$^\*_94VU,Y1BLQ=/7U]=A9#,M+A]QP015Y6?P1TQGJ'<
MI#S[KW7T>,3_ ,)3/Y'F>Q>.S>#Z4WWF<+EZ*ER6)R^)^2.[,C2U5-6HLD-1
M3U$.7>*>":-E9'1V5U(9200??NO=%\K?^$_W_":+&]^1?%G(UV%H/D;486/<
M%/TM7?,;/4FXI*68N%:/&R9U:AY2(W?PJIF\8,OC\?J]^Z]U<5TW_*'^(GQ4
M^$GRK^$?QAV5FMH]6?*;:/;N+WKAMS[]S.ZS/7=K;2&T:N7[^LJY,A2PR8Z&
ME0K!4)HTF2/3(Q8^Z]U\LS^4W\DZ7^57_-PZ,[;^2.'W)M+$_'WM?LWJ7Y 8
M&AIVRE;ATW!B<]L;/FHI*)Y6KSMVKR,E7+!!YGE:BM3)--XE;W7NOLH=<]D]
M?=O['VSV7U5O;:W8O7N\\119_:>]=EYRFW)C,C19&-98*FCK:226">*1&!!5
MS_0V/'OW7NBE=_?S,O@A\7.]^IOC1W[\F^K^LNZ>Z99(]E;,W%G5A>-2LGVL
M^;J4#TFVZ3)S0RT^/J,K/1P5]4C4M+)+.#'[]U[HWV\I8I]C;KG@DCFAFVGG
M)89HG$BNLE'*596!(96!!!!L1R/?NO=?()_X30?]OPO@=_X='<7_ +[C>/OW
M7NOJR?-?Y-?#3XR]/IDOG)V%U;L;IGM3=&W^FWH.VH8,GB\U6;^G2C3'3X^:
M&I6JHDB>2IR$LD!I:''PU-?7204=--,GNO=:;/\ .Y_X2_?$7:OQE[L^?7\O
MW>M-U!2=7]>Y[O/=73.8W4-S[&S6W\%3U.7R<VTLI,]37XK(ST1+XZD^]K,=
M5M'!04<5")TE7W7N@*_X1:?-?N%>_>^O@-G\]F]Q](9#I?.?(38&&R.1:LI]
ML9S:>>PF+RB8R%U)IJ/<=/N-9JM$F$0JZ&&5(/+554Q]U[JC;_A2_P#]OPOG
MC_X='3O_ +[C9WOW7NM[W_A3O\:,Y\C?Y(N[\IMC;M1N;<7QMR_4'R7HZ*DJ
M)(98*'95)4X?<615%EBBFCQFUMPYRJF24.@IX99$C,\<)'NO=:V?_".G^8KU
M)\;^\/D%\.>\-[8[8V.^3PZ_W;TKG-QRT6(Q7]Z=AKDZ3(X:?(RF.6.OW#CL
MC0-1),YIVDQ;P1&*JJHTJO=>Z^D5O'>NS^O-IYW?F_-T[?V;LG:^+J,WN/=N
MYLO!A,=0T=(NJ2IJJRH>.""%%Y+NX'TYN1[]U[KX[7\[CY;X3^:3_-H[5[%^
M-V/J]Z[-W=GNL>A>@8\=BIJ*NW&FW:2APE)4)3U#+(TN<STM8]&&B@;[6:EC
MDB659&;W7NOH<?S..C1\8_\ A-IW3\<ON#6R=#_ 3J[J&JKV*,U3/UW0[>Q-
M14N8@(R]3/222L4 4LY*@"WOW7NM1?\ X15*I_FG=]$@$K\ >TV4D7L?](G5
M8N/Z&Q(_UC[]U[KZ6/='_,G>V/\ Q&F^_P#W5U7OW7NODH?\)<?^WZ_P9_\
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MC*/=>Z^1/_PI?_[?A?/'_P .CIW_ -]QL[W[KW7U=?D#_P!D.]V_^*I=D_\
MO(5OOW7NOE8_\)<U5OYZWP9# ,+_ "8:Q%^5Z>[!(/\ K@@$?X^_=>Z^OW[]
MU[KXW72__<1QU/\ ^-L]B?\ O]J7W[KW6Z?_ ,++_CKO7M7^7)U3W3L_$SYB
M@^-??^,S_82TQ9GHL!V-C:K!OD3& 0\4&;?!PR'ZQK4&0VC20CW7NJR?^$@'
M\U?XW]%; [7_ )?'R%['P'4^Y]_=V'N#H;=._L['A,/F:[>V+P>WZ_:L-=5-
M'1T&4^XPE!44%/),@R$U94107JE6.?W7NMYOY!_+_P",GQ7ZJS_=7?O=W7/6
MW7.WL7+E:G/9[=%)$:E5?Q1P8ZG65JC)UE34%88*>EBEFFF81HA8V]^Z]U\>
M/NSY9S?.G^<%7_+0XB; 8WNWYI[ W/M7!5E+'1U5%@*3<6+Q^W:2O2&HJX#D
MJ?!4>.CK7BJ'BDJEFDC.AE ]U[K[5OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJR?YQ7SEK_Y='\N?Y)?*C;E-#6]
M@[2VOCMK=44E30KDH/[T]CU]-@L'4U5.\U.DU%C*RO2OJHS,IDIJ65$UR,B-
M[KW7RZ/Y3_\ ++^0'\\WYJ[WQ6Y.SLMB=O8^2H[A^5'R#W*C[HR4<>YJYE6*
MDCD9$KMR;@K34+2I--'!%%#5U;ZTI!2S^Z]UNI]A_P#",3^6GF^JHMK]<=K_
M "BV+VGC<9,*'M+,;TPV[XJZM\,BQOF,(V!HZ.2B\[([18^3'2Z4"BH_46]U
M[KYT_P UOBKVY\'/D]VU\1^\)**7L+HG<$>UJZ7$UTE?034>7IX<WC*['-*L
M<B4&5Q^5IJ^)&BC<"J)D192X]^Z]U]:;YL?]P]WR$_\ &4>Z/_?8'W[KW6D1
M_P (R?\ M['V+_XI1V]_[U>PO?NO=6._\+,/YD786#W1U/\ RT>L\]D]N[,S
M6PL9WK\B9\?>E_C8S.1K*3:^WGJ$G$C45"<36Y&MIV@\4\D^,82,::2,>Z]T
M7K^1K_PE>V3\R_CSLCYE?._?78.UNO>U85W'TQTAU;7TVW,ADL"KRQ09O<F7
MK*&MDIJ7,,GFHJ.AACF:B\%6]>IJA3P^Z]T)'\YS_A*5UE\4?C?V/\R?Y?G9
M':,D/16(R7:'9O3_ &EN*DSK4VV]HTIJ\EEMKYFCQV/K8ZG#14\E;+3UTE0T
MD*S/!51R0Q02^Z]U6%_PD2_[?*[#_P#$"]\?^ZV#W[KW6[+_ ,*:/YAV_P#^
M7Q_+8SN2Z;RM?MSN?Y';ZQOQ]V+O#&H1/@:?<&/R.2SN9IYEG@>FK8</C:FF
MHYT\DD%95T]0L9$3.GNO=:%_\B'^1#O;^<%O;?N[=V[]R'3?Q8Z;R&,PF_=^
MX3&19;-9C-9:+[F+;NW8JG_(H:F&BTU%;6U"S1T4<U(!25350$?NO=;/?R'_
M .$3OQ%JNJ=S?[*E\HODIMWNVEQLU7M%^_<IM;?FV:RJIM+I15\&W]I;7R=#
M%6:7A^[CK*DTID6<TE4(C3R^Z]UH=]==:=A],?/;K+I[MG%U^#[)ZG^5'7?6
MF],+DI6GEHZ_8FZ*'%S4H=KZX*<THCA93XS"L9C_ &]/OW7NOK8?S_O^W-7\
MP?\ \0+D/_=ECO?NO=?*3_E=?R^.POYG?S.ZO^)NP<O'M6GW1_%-R]B;^J*,
M9&/;NV-JQB?+98TQEA-5. T--20"11-6U--&[Q1,\J>Z]UNG?S"?^$A'PYZO
M^#?:?97Q.[$[^7Y%="]2[P['I3O_ '5B=SXS>S[*HQE*['U]!%B,<,;6U=)1
M5D.-DHJNF@@J)T^]CJT4,GNO=4,?\)(N^]Z=5_SC>J^JL%5UC;1^3G6/=?6F
M^\5_$Y*>E*;'VOE=]8ZO>E"M#4U=)6[6%/"[!7AAK:KQR!9)8Y?=>ZVK/^%9
MO\TWL?X2_&#KCXM]![@SFS.X/F%'O.+<78NW:L8^LP.RME&@@RT-%5*ZU-)D
MMQU&3AHX9X5UQ4<.2*RT]0::0^Z]UK/_ ,A?_A-=/_-%ZRR_RH^3'9F\NG?C
M!+FLMM'K3']7G'?WIW77[=G-/E:Z&KRE%D\=B,+C:E):19),;53U=6E0BQ4\
M5,):GW7NK2_YB'_",[K;87Q[W?V1_+N[I[SWUW%L+$U>Y?\ 0[\@LOMO<*;I
MIL6CRU6.PF5P6W=KKB\T\"EJ)*JFJ:>JG5:66:C6?[J#W7NJ[/\ A)9_-&[&
M^/7S,V[\!=\[ER&8^.7RKJ\Q0[-P62G:JBVQORAHYZ['UV-,M0BT=)N**EGQ
M];!%"YJ:V3&SVC,,S2>Z]T>+_A<%D>U1O/X"XF1LY'T>VV.Z<C2I3FJ3&S;K
M2KPL50:NQ^RDKJ?$-3?::U\T<4U;XSHEEO[KW17?Y4'\FS^2Q_-,^$F#V+L[
MY==A[#_F:/M//9??& R^X*2GDP^6HYF$+4&RJ^CH5W3M&F2HQWGGQV6-0VMD
MDR%#.WAB]U[K;8_D?_R.M@_RD^@M_P"$S^]Y^SODC\@L?CJ?OCL+!U57C\)%
M2X5:U<5@MN8VHLBT6)7(5CFOJ:7[VMJ9YI7$%+]O0TWNO=:#W_"BO^49\;OY
M1?=OQUZV^-V]N[][8/MSJS<V^-R5?=^Y,#N2K@J\-EOL(HZ&3 [:VU#'3M#R
MZRP3.7Y$BKZ??NO=;/\ _P )3OY0_P ;-K_'#XL_S;\?O?O";Y']C[1^1NS,
MYLJLW+@9-D14M#O;<VSTDI,:FVH\\E0<9@:.4M)N25/NGF<((F2&/W7NM2S_
M (4O_P#;\+YX_P#AT=._^^XV=[]U[KZ>7\QKYQXO^7+_ "U^UOEM5X^#-9[K
MOJO;6/Z[P%6DKP5^Z=Z"CP^W::I\*.ZT0RM;32U1]-J6.:S*UC[]U[KY;7\O
MCX"_,;^?_P#.7L:3/=L5T^X\P\_:OR<^3W8U%)NI<33Y.3[6D*X^":@6MKJM
MXDI,3B*>HHJ:*FIS%"U'04)\/NO=;IE!_P (KOY9L.S9\/D>_/FK7[RJ#CJC
M^^<&^-ET,4,M##5QR14^*_N-+$*"LDJ8)9HYJF>I#4L"T];3H]2M1[KW1#OB
MM_PCY^3'1/SPA[0IOG.>KNB>F]Z8?>?2_<O3F/>@[-R02,RBF:@K(I\#MZJI
M79J6JGFERU)6P%[XYX*F2FB]U[HZ/_"TRM[8H/Y>GQOQ>V:G<,O5]?\ )O'P
M]N5E )HHIZB@V[E7V]'EC2+%2&DEJQ6S".:(0FMBI7B598XK>Z]UKS_R)OY;
MW\E/^8OTEN+J'Y/_ "5['ZV_F";FW;N#';)V73;VH^O85QD4'EQ4^U8<GBJC
M%[IKG2"LEK:1JN:KC5"!201!*B7W7NMN#^19_P )V=F_RD=[]H]\=C=M+WK\
MBMV)N?K?96Y]MT-;LO!X?8]1703QH<1)5SFISN>:@H*JO:HGJ8* QQ4./=_%
M4U]?[KW6S#[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM7S_A7M_P!N<-V_
M^+"]%?\ N76^_=>ZIA_X0V[5Q-9O#^9/O>:EIWSNWMM?%+:N.K6IPTL=)O*J
M["JZV));ZDCFFP5 SH!9S'&3;QB_NO=;8W\\[$8S-_R@/YB5'EJ*"OI8?BYV
M1EXH*A=:K4[?IA7T4P'_ !TIJRF@F0_AT4_CW[KW6@U_PC?VYB,Y_-RSN3R5
M)'4UNSOB+W-N/;\SHKFGK*K,;3Q#S(64E6:@RM=%=2K:9&%])93[KW7U!NT<
M31Y[K/L3!Y&,2X_-;%W=B:^(HDFJ'(X^HAE73(KHVI'869&4_D$<>_=>Z^/[
M_P )OZNHHOYV?P'FI9/%(_86_:1FT*]X\ALG<\$RV8$>N*1UO:XO=2" 1[KW
M6_#_ ,*U\51Y'^2UW+5U*N9L%V[\?\KCRCE )IMRTE"Q8?VE^WK)Q8_D@_CW
M[KW5&W_"&[_C]/YDO_AK_%7_ -R^P/?NO=;2/_"A#*XO#?R8OY@=7E\E08JD
MFZ4BQ455DJR.AC:JSN<Q%#0TRO*RJU165M13T\$8.N:>6.*,-(ZJ?=>ZTS_^
M$36R9J_^8)\J.QER$4=/M7X<9'9,N+,!9YGW_O;:-?'4++J"HM,NVI$92A+F
M=2"N@AO=>Z!__A9M_P!O8^NO_%*.H?\ WJ]^^_=>ZW_/Y-W_ &Z<_EO?^*4?
M&[_WE,9[]U[KY4_Q'_[?V_&/_P :\]+_ /OYL;[]U[KZ+/\ PJM_[<>_*[_P
MZ/CC_P"_'VK[]U[J@'_A#=_Q^G\R7_PU_BK_ .Y?8'OW7NJH_P#A7;_V^5WY
M_P"(%Z'_ /=;/[]U[KZ2/\KG;?66TOY;GP.P73=6N2ZSI_B/T!5[3R_@-+)7
MP9?;&-K),C51&&F:.NR-1435-4K4T+K4RRAX8F!1?=>Z4_\ ,2VSUUO'X#?-
M3;?;@QJ]:9+XL=]#>M3EJA**"FH*3;&3GFK&J'>-:9Z$1"HCG\J&&2-95=&0
M,/=>Z^7]_P )2\[O7$?SO?B]C]K2Y./![HV=\C,%V2E!0"LBDPM/U]N3)P)6
MR&*3[6F&XL=@&64/$34+!!K(F,<GNO=&F_X6;?\ ;V/KK_Q2CJ'_ -ZO?OOW
M7NMX3X*Y/-83^0!\:\SMR1H=PXC^5ALS)X&5)#"5K:#K1):5@XCF*%9TC-Q#
M(1]0C?I/NO=?)_\ Y>6R_FUO7Y6]?P_R\*+=U7\L=OT.[MQ]=2[$RN*PV6IX
MJ7%5=/EZBBFS$]/1ATQ-56!O69!&SM&-2ZE]U[K93_T=_P#"S[_G8?-#_P!&
MAL3_ .N_OW7NBK_*7^6[_P *B?FUA-I[<^6'2?R.[VPVQ<KD,WL^CWYOO8N0
M_AM5EH4@JI:22/-Q2Q?<Q1Q+*H?1)XXRRDQH5]U[K<P_X2[?%_YF?#?^7OOS
MH#YH]5[FZDW3M[Y-;\W'U?MK<V5Q649=K[MP6V:@BF;$55;"L!W&FX9CY:DS
M&6>2ZI$(M7NO=;(GOW7NM=G_ (56_P#;CWY7?^'1\<?_ 'X^U??NO=:X7_"'
M_;N*J?D-\]-V34R-G,)TQT_MW'5A1"T=)NC.96IK(PQ4R!99L10,0'"DQ@LK
M%4*^Z]UMV?S[\GFL1_)Q_F%U6!D:*NE^/&XL9.RR&(FBS=31T626XCE)#XZH
MJE(T@,#I+Q@F1?=>Z^5[_*JV%_-"W7W;OG.?RI:3LAN\]M=:U5-O;)]6Y_!X
M#)T^V<_DL>)U:3-U5+&:6?(TN/#^$EPRH&LCD-[KW5]O^CO_ (6??\[#YH?^
MC0V)_P#7?W[KW1*/E)_*?_X4K_-?<6V-W?*SXY=^]Y;HV9A:G;>V,_OC>^QJ
MNKHZ"KG-4]''/#G(7:G^X9Y%1RRH[R,@4R/J]U[K?E_DZ_%+MFG_ )*O2OPJ
M_F%]49#%[JCZW[IZ,[5ZRWI64&4EDVMFMR;DIL+1R2XN6>D2--I5>+@IVBJ7
MEC6*.1I%J VGW7NM$;^9%_PG._F+_P K?M'(]]?$1^U.\NB=IY;([DV#WGT/
M4U=!OW:-,\S14\>?QN"D@S5-74M)/HGRV)IVQ\D:S5$W\.1_MD]U[JTO^2#_
M ,*M>Y\SVYU?\2?YE>0Q_8>W>R-Q8S8.Q/E/1XBFP&:Q>6W+5QTN(IMWT>/@
MIL;D,1-//'3/E(:6GJ:0>.HK_O$-351>Z]U>C_PK7Q5'D?Y+7<M74JYFP7;O
MQ_RN/*.4 FFW+24+%A_:7[>LG%C^2#^/?NO=4;?\(;O^/T_F2_\ AK_%7_W+
M[ ]^Z]UM(_\ "A#*XO#?R8OY@=7E\E08JDFZ4BQ455DJR.AC:JSN<Q%#0TRO
M*RJU165M13T\$8.N:>6.*,-(ZJ?=>ZTS_P#A$ULF:O\ Y@GRH[&7(11T^U?A
MQD=DRXLP%GF??^]MHU\=0LNH*BTR[:D1E*$N9U(*Z"&]U[H'_P#A9M_V]CZZ
M_P#%*.H?_>KW[[]U[K?\_DW?]NG/Y;W_ (I1\;O_ 'E,9[]U[KY4_P 1_P#M
M_;\8_P#QKSTO_P"_FQOOW7NOKJ_-KX?=1_/;XN=O_$_N^CJYM@=N[:?#5.4Q
M2PC(8BOHI8ZO%9S%O413PQY/#Y*"EJZ<R0O&SQ".9)(7DC;W7NOEF_,3^3]_
M-K_D:=P2?(+JJN[)KNO=AUJ9#:OS&^,T]=!1145/)]XT>Z<?1S5%?M^E(HH_
MOZ7+0RX:?TT_W=<C%3[KW6SY_P )_/\ A3EO/YE=L;(^#?SSQ^#3O/>="V)Z
M;^06UL5%M^DW5E,-2S5,V*W-BJ5(L?B\U74U-))2U5#%!0U=0&I!1TDTE,)_
M=>ZW8/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]UH8_SPO^$I&^NX.UM\?+3^6;3[5ES78>6RV[^T/BSG\W3;-27,Y5IZ
MNNR>S<I720XFG7)U3!I,56U%'3P32224M6D#)20^Z]U0%LG^1]_PHLW5AZ7X
MY4O2'R7VIU/73T6&R&T-V?(7';:V-2TN5(,DM31/NLXF>B@C+/.E-1U$ME*+
M!),R1-[KW1G/E?\ \)$OYC_4.W>@J+XU[-I/ECOK<6P\MFOD7E]M]F[)ZUV[
MMW/M6A:+!X!=Y9[;>9RU+%0\R9!Z55J)/4*>C_S/OW7NOH&?R@.@^VOBY_+/
M^'7Q][VVG_<;M[JOJ.CVQOW:/\=QFYOL*Z*MK9F@^_P]9D,956CEC.NGK9H^
M;![@@>Z]U1/_ #WO^$Q6+_F";^S_ ,NOAAN39O5?RCW$E'-VAL'>TD^'VOO6
M:A2.#^*+74=-5RX/<AI8U623[*2DR,B1M5&DG>>ND]U[K51VY_*+_P"%-?QY
MH!TWU9UY\T]A;(H\CFZ"AVUTO\IX<1M=C.\]5530QX+>L.)AIZUY)Y?)(D0G
MEE96O/(4/NO='G_ET_\ "1+YG][]EX;L_P#F1Y6#X^]3ON";<6\]ATN]*/L#
ML'<Y-0TT\$E7C*K(XO"IDY"6FKI\G4URJSG[)9F65/=>Z^E%M/:^$V1M;;>S
M-M4LE#MW:>"Q.V\%1S5DV0>*CP<$=-31O45,DM14.L,2!I997ED-WD=G)8^Z
M]UJH_P ]S_A,YM;^8]O')_*WXF[GVETW\M,C1T\?8>!W;%/1[7WW_"J9*>EJ
MJRIHXJB?"[AB@AAA-:E%/#61HBU422K]W[]U[K4"P_\ (_\ ^%%_QAKL_LGJ
M7H_Y,[)P^3W U/7U'0'R)QF.P^5EYIXLA(<!NVG1X9H(DM-601/'%H2=86]
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M;N?Q;EIIYHY\=F,96P.DTK3735(S,VH^Z]T/'\P;N[KWXX?!WY9=U]IRTO\
M<?8/0/:.4RN.JI88CDY:G$55+0X6G%1)%!)6YROGI:"EB>15EJ*F*,L UQ[K
MW7S0?^$B7_;Y78?_ (@7OC_W6P>_=>ZV+?\ A;5LK.93X4?$/?U%1U,^!V?\
MFLSMW.5,-,\J02[VVQD):-YI%NL2.</4("U@SLJ@W(!]U[K-_P (H.[NM,I\
M(/DW\=*7,8>F[?V9\H,QW'FMLK4.E;4[=["VMM+#8_+"*61O+%'D=N9"EE,"
MK'#IIO*BRU DF]U[K=(GG@I8)JFIFBIZ:GBDGJ*B>01(B1 L[N[$*J*H)))
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M_P!^/M7W[KW5 /\ PAN_X_3^9+_X:_Q5_P#<OL#W[KW54?\ PKM_[?*[\_\
M$"]#_P#NMG]^Z]T/7\GK_A3KVY_+$Z@VS\0/EUT3OCNOI;:.+Q^;ZES5%FCM
M?>.W,%OFF@SF+HH:;-0BESNVZNBR$59B-=91^&AJH/M)YL?]I%'[KW7/^<E_
MPJHWW_, Z1W/\4_BUT]G/C[TAV+CH\7VQO'>^X8,ONO/T#2!YL)!!C3_  [#
M8FJ552LM5ULU9$6AU4\1D27W7NK0_P#A'G_*H[!ZTI]Z_P S7O':V:V@.R=C
MS]:?%W YVG;'3Y#;V?FI:W,[Q-,Q\HH,HU)1TF)DD2,U%.E961+)1U-%42^Z
M]U4Y_P +-O\ M['UU_XI1U#_ .]7OWW[KW6_A_)_Q]#EOY1O\NS%9.E@KL;D
M_@Y\=\?D*&JC$T4T%9M'&QRQ2(>&CDC9E8'@@D'W[KW7S/OY@/PX^6G_  GG
M_F=8#N#IJGK\)LC:W9V5[,^'G<53B9<[A<I@LAYU;;.3DGDE\]?0XJLJ,/F*
M2:I2IJ(#)5Q,L-5!/[]U[K9[ZD_X6X?%6MZ\Q%1WO\.OD'MGMA**2//8GJ3-
M;<WSMV2H@9U26DR&9RFWLE##4JL<ABDQDK4Q=H1-5B(3S>Z]T3'9_P#PL6^<
M/<_S.VUM3X_?!39'8_4F^:^#8^P?C-29_)Y#?68KZN>7[:MBW714<E+25L\9
MC::G_NS54=-$DFJ5PK58]U[KZ$^T\EF\SM;;>8W+MV39^XLK@L3DL[M.;)PY
MI\765T$<M3CWK*;_ ">J>CF9X6EBO%(4+QDH03[KW2@]^Z]UKL_\*K?^W'OR
MN_\ #H^./_OQ]J^_=>ZUWO\ A#O_ ,SB_F%?^(T^/W_NTW1[]U[K?E^0W1^R
M/DQT/W'\>.RJ1ZW8/=O6F].KMVPPNT4HH=[8^?'SRP2(R/%4P+/Y(9$=7CE1
M'1E901[KW7R-<+4_/#_A-)_,];,5FVJ8[NV--G=NQR9S&31;6[1Z^SU5#YGH
MJH:Y%H,M'2T=0CPS&JQ61AB2H0S4TM._NO=;9V%_X6X?#&;8='D-Q?#GY/8W
MLYL)!/7[3PN<VIFL"F2,2F6EAW#/D\?D):%9RZK5-MB.5HPLAI%9C&ONO=%J
M_E__ /"KC^85\Q?G?B.D-L?!'8'<'7W<&Z<+CMH=4=;;ER&#W%LW$Q2T\64S
M>1W95TU3B\I0XZE:>JJGK,+C(2X2-*FD5E5O=>ZW%OYC'S$F^ WPL[Z^6D/5
MFZ^XZ_I[951GZ'K_ &?1556U34RND$,V2J:6EJY,7@*&245&4R+4KI0T,4]2
MZD);W[KW6D/\!_\ A9_V1L;$[PV]_,2Z/KNYIZ[=&Y=R[*[%^/M-C-HUU%2[
MAK9ZR+;M9@LE54]!58_$+.*6@K%R:5@HH8(ZX5]6):^;W7NM:GOO(G^<#_-@
MW=5?$7X_T'2Y^9'>N'H.NNH,#%#41X[[ZEI*7)Y[)+1104T517?9Y'<><,*F
M&">>O9998X_,_NO=?5G_ )O?PASOSV_EC?);XF;:KYZOL;='7>%S/6]?55RT
M!K-T=49#'[CPM/53RI4I'#F<CAXJ.I=U8K#52NKI(%F3W7NOEV_R>_YK?<?\
MD_Y7]@[LK^I\AO7:^[,9/U+\A>A]T5,O7N5CFVGDBT<T<U305%3BMQ;=K$KX
M?MZFD\;">KI:F..1HYZ?W7NK1?YV_P#PJ!;^9C\:<G\.^@?C[G^F^G]]939>
M>[8W?V1NFES>;RW]R\E#F:/#4>-QL1HJ"A@R^/Q=6U4^1J)J@PB(4U*JEY?=
M>ZNZ_P"$:'P)[,Z/^/7??S6[.Q57MVA^5S["VOTO@<KB9<;5R[:ZTER\U5N'
M5,RF3'Y_(9.*.BM H>''&J22:&KA*^Z]U1G_ ,+-O^WL?77_ (I1U#_[U>_?
M?NO=;_G\F[_MTY_+>_\ %*/C=_[RF,]^Z]U\J?XC_P#;^WXQ_P#C7GI?_P!_
M-C??NO=?3\_GA_S*-Y?RM/@EO+Y%];]4Y7M#L?*9W$=<;%GGPE;D-M[>R>[1
M)'39_=U31H?ML11R*JPPO/3_ ,1KY*3&I4T[50F3W7NM5_X3_P#"SRDVYT+3
M=<_S"OC?O#NCM/"81MOS=I=.?P''4N[:?PF$R[CP&2EQ]#C:^H3BL>@,E'4,
M[O#CJ-+0>_=>ZUW_ .4YU)NSYX_SON@=P= =7XWJ+;4?S'Q_RXK=B;(5ZC#]
M?[,Z[WC!O";'4<R1TGCQ^%I8Z3$8^0Q0ZYY**,(C2*GOW7NOLA^_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NJC/YU?\ *WVW_-D^%F?Z!.:H-G]M;.W#1]H]![\R:S/2X[<N
M%IZFE^VR*TY$LF)S./K*RBJ1IE\!EAKDAFGHX4/NO=?,0DI_YRO\@?N;<RXJ
M;O3XAY[*5B[:K=RT>&@W9L/=7,TU)+3R9&BRVRMQL\-'/+3%X)JNGC692E.P
MGC'NO=#'VG_PHX_G;_*O:^.Z-B^3.XZ7^]. .Q\EB^A>I<!LK<6Y):^ T\TQ
MK\#ADS<&0K(VDU)AYZ"&[$PTT=D"^Z]U<_\ \)M/^$[GR$7Y$=7_ ,P'YR=:
M9;I[K;IS(4G8'0_3V_\ %QT&XMQ;EHTBFPF>RN%K('J<+AL'-)]_2?<K39&;
M)TM'-'$E)&9*CW7NOHP>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z!KY$="]:_*3HOMCXZ]PX5MP=8]S;%W!U_O/%Q
M5#4<S4>X8&A:6FG3UTU92NR3TTZ>N&>..5"&0>_=>Z^2'\Z_Y:O\QC^0K\J:
M#M/9&7[+P6T-H;J.8Z&^9?5-+4T.*K:83Q"GI<O+3_<4V*R$RS1TM?A<F6IJ
MX--"B9"@D+2>Z]T9?*_\*>_YY/R;VIBOC;UIO#!OV)OB&/:]!G/CWT,M1V#F
MI&C8RQ8Y*-<DL-?41)(3)BL-35,8#/3M"1J'NO=4F_-KX>_([X2=TQ=2_*W%
MQX/NO<>QMH]N;GP<NXQNJOHQV9%)7Q09FL0R1-FA=FK%2IJ DK%6G>36![KW
M7UD/FQ_W#W?(3_QE'NC_ -]@??NO=:1'_",G_M['V+_XI1V]_P"]7L+W[KW6
MW7_PHL_DK57\USX_;6WKTL^*Q?R\^.U/N"KZP_BU4,=2;HPV;5)LEM"LJ7D2
M"EGJ*FFIJC&5<]XJ:I66&1H8*ZHGB]U[KY['Q7_F._S6_P"1KV9OSIK:>0WG
MTS5-E&EW]\:_D!LB?+X&2LH9)Z89.GP^1\$E'+.T<B_Q'$5=.,A'%%Y*BJAA
M@T>Z]T:3L?Y0_P \#_A1/'N/:>2GKL]\?>F<#N/LW?>/V7M1NJ>K=OMU]C9\
MG+5YW)QQU3Y+.-3,!0T-5D*^M9G$E%21QBHF3W7NEW_PD2_[?*[#_P#$"]\?
M^ZV#W[KW7TR?G7\,^IOY@7Q4[?\ B9W3%61[*[8V\,>F<Q21-7X;)XN:.MP^
M<QWF5HOO<3DJ>FJ8U<&.70T,H:*213[KW7RFODK_ "N_YNW\DWY*R=B]?;=[
MPQ5-L++U^0ZT^7WQIQV5RF!R>*H9*>82Y*HQ:U7\'AJD:*+(87.QI%4:*B!H
M\A0 3S>Z]T)6S?GM_P *+OYO6&/QBZ_[<^2_?>R-\UZ[)W2O6W7.%ZVPB(YC
MJZBGW3N_;6W\'3T./$,D;52Y+,I#) Z02+)'*D3^Z]U6A3?'K<WQ5_F4;*^-
M&[]P;4W=OKI3Y8]8]:[VR>PLA)FL7_'MM[BQE-F*&CJ7B@EJ/X;E%JJ)V:GB
M<RP/JBC:Z+[KW7U??Y_W_;FK^8/_ .(%R'_NRQWOW7NM(C_A%3_V]-[\_P#%
M .T__?B]5>_=>Z^EAW1_S)WMC_Q&F^__ '5U7OW7NODH?\)<?^WZ_P &?_+F
M?_?.]@^_=>Z^DI_.5_E6=>?S:?B'ENB<_E:?9?:FSLO_ *0>@>SYH)*A,)N.
MCIY:<Q5\4++)4X3,4DLM)70^K2&AK(D:IHZ>WNO=?,?P>]/YQ7_"=SY![HV[
MC9>POC/G\]DZ*ESM'D]NT6^]A;ZI-N3R-3S4TE=2UV"S5-+"9@E32/#DJ6&:
M1!+13EU3W7NGGY5?SHOYP'\W''T7QCW%O#=6_=J[J7'1R?'+XR=0"A_O!4XF
M;SK-64>#HZ[<F:)E\#&EDKI:%'BBDCI(Y=3O[KW6Y)_PFA_D [X_E_U&5^:G
MS'PU!BOE'O':M5M3K'JV.MBRS[%PN>"G)5.1J:::6CDW)F(ECIV2%I%H*/S0
M^9Y:RHC@]U[H&/\ A7=C?YKE=@^DLO\ '/';]'P6V"<;V)O_ #7Q_P ADFW!
M0[[V?DHZS$9?>"8V&+)46&PK1T55A*FFJ9:*#(QRUE<:>MIL3(/=>ZU>>UO^
M%-'\USNOXA[V^'/8_9W7>?VAV1U]DNJ]^=H-UK3TN],K@,] :+*8^KR<50N+
M8Y7&O/15=0N%6KE@FE83K4/YQ[KW6RQ_PD2_E(]^?''/]M_/[Y+]>;IZDR'8
M76PZ;Z(V)O6@DP.5J\+N"NQF:S6XZS&2LM514U1-BL92T"U4$4TBK63"(0/3
M2R^Z]T1S_A;Q_P!E7?"/_P 5ZWY_[TGOW7NMH/\ X2X_]N*/@S_Y<S_[^+L'
MW[KW7SV_^%+_ /V_"^>/_AT=._\ ON-G>_=>Z^L[V-T9UK\FOB_N3X^=Q8+^
M\O5W<?3S=>[XPJ54E!)-C]RXQ:>8T]3$5FI:N$.):>>-A)!.D<T9#HI'NO=?
M*>^?G\H#^9%_(\^3$'>W3![6R_5O6VXZG>72/S-Z:QU2RXZDB6<>/<_V"S_W
M=KTH6FILC!7(,97P/-&CU5)--"/=>Z%N/_A7)_.7CZX&QCV/TA)N$8)L..W9
M.BL6=Q^8QF,9+PB0;7-<I(< [:-,7'JIBMU/NO=&!_D4]1?SY?EW\](?FYUW
MW%WCUOL?LO<F%SWR6^4?==%/EMK;PP6'J?NA@*?!97P46[(V@DFHL73XNGCI
M\%#,?LJK$QI&??NO=;/'_"JK:W\S7?/P<P^SO@]MO.[HZ0S=?FX?F-B^IS55
MF]ZS Q4RO1T<.-IZ=ZJJV=.Z5/\ &TH:EJR0?;05%/+B9,B??NO=:7?5'_"G
M_P#G"]%]!5?QKI^XMM;I_A&WLEL? ]H]J[#_ +U;]P,0@>CC\.:J*J(5F0QO
MUAGR^/R-0DB*)GE"!1[KW5G/_"2W^4CWYN'Y9;0_F1]Q=>;IZZZ(Z@V?N7(=
M$Y;=-!)@FWGG>R,378-*W%4\K1U-5@L;ALC73FM,(I:BHEHUI9*C14>+W7NO
MI.^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HKWR^^&/QJ^>?3=7\?_ )7]
M;_Z5>HZ[<."W75;2_OAG]C:Z_;3N]%/]_MO*X?)KX&D<Z!6B-[VD1@!;W7N@
MA^#'\KCX)_RU_P#2C_LE71G^A?\ TT?W)_TE_P#&3=X]B_Q+_1U_%_X-_P ?
M9N'._9_9_P =RO\ P%\'E\_[_E\4/C]U[HUO=W2O6?R.ZB[&Z'[FVU_?+JGM
MG:68V+V!M7^,Y#;W\0Q6?B,-72_?8JKH<E2^6)BOEIJR&9?JDBGGW[KW1"/A
MC_):_EG_ ,OCMG(]Y?$'XU_Z(NTLMLG+]=9#='^F/?\ O[R8;/5=!75=']EN
M?=6:QR>6JQ="_E6D$Z^+2DJH\BO[KW5G]=14V2HJS'5L7FHZ^EJ**KAUM'KB
MJD*2+J0JRZD8BX8$?4$'W[KW5/'QR_X3^_RC/B5W9L#Y%?'SXE?Z/^X^K\G6
M9C8N\/\ 3SV;NK[&IR%'4X^:3^'YO>>2Q53KI*NHCTU%#*HUZE4.JLONO=7(
M^_=>ZJG^;?\ ),_EG?S"-TQ]@_)?XS;=S?9P:#[SM'8V;R?5VX*Y*:-88XLM
MD-OU>/;-)'"B1Q_Q!*EH44+ T0]^Z]T57I7_ (3!?R7ND]XX7?5)\59.S,UM
M^HFJ\;0]U=C[@[,PY>99D_RW;M=7_P!W\K&L<Q58J[&5,0*1R^/SH)??NO=7
M\T5%1XVCI,=CJ2FH,?04T%%0T-% E+###2H(XH88HPJ1Q1HJJJJH55    ]^
MZ]U5_P#,[^2U_+/_ )@_;..[R^7WQK_TN]I8G9.(ZZQ^Z/\ 3'O_ &#X\-@:
MNOKJ2C^RVQNK"XY_%592N?RM2&=O+I>5D2-4]U[H_P#TWU!UW\?^INM^C>HM
MO?W2ZMZBV3MOKKKS:_\ %J[/?P_#;1I(J''4?WN3J:W(U?V]+#&GEJ:N:>2V
MJ65W)8^Z]U53M'_A/5_)_P!B=][8^3VU/B)_"N\MF]O87OG;>]_]/O:%=]MN
MS;V:BW#1Y7^&5.]9L/-X<Q#'4?;2X]Z-[>)Z=H"8S[KW5B_RK^)_0'S;Z/W9
M\;_D]L'_ $F]+[XJMMUNZ-F?WIS6S/NI=HY*ER^/;^([>R6)RL'V^0HJ66T-
M=&)-'CE#Q,Z-[KW1?_@W_*K^!7\MJM[)R/PLZ(_T,5G;U+M6B[$F_P!*&\^Q
M?XA%LE\@^+73NS<6=6D^U?*UYO3+"9/+:4R!(]'NO=?.(_X5V_\ ;Y7?G_B!
M>A__ '6S^_=>ZW:>@OY3?P _F-?RK/Y84_RS^.^UM_;IPW\OCX9T>&['Q%96
M[%W/34\77FVW6E7/X6HH<E/1*02*6HGFIU+,5B!8D^Z]TK_CK_PFB_DZ?&S?
M.*['VW\7!V)NW U'WF#J.[=]YGM.@I9DJ/N(IEPF0JS@IYJ<B-8I*C&S/&L:
MLK>4R2/[KW5\<$$%+!#34T,5/34\4<%/3P1B)$2(!41$4!515      L/?NO
M=5=_,[^2U_+/_F#]LX[O+Y??&O\ TN]I8G9.(ZZQ^Z/],>_]@^/#8&KKZZDH
M_LML;JPN.?Q564KG\K4AG;RZ7E9$C5/=>Z/_ --]0==_'_J;K?HWJ+;W]TNK
M>HMD[;ZZZ\VO_%J[/?P_#;1I(J''4?WN3J:W(U?V]+#&GEJ:N:>2VJ65W)8^
MZ]TV=X] ](_)CKO,=2?(/JC8'<_6>?,$F5V3V1M>DW9CY):-A)!4+!612K#5
MTT@62"HCT3P2!9(I$=0P]U[JAW<?_"4'^2GG]P2YVG^/?8.VH*C(5M?-MW;G
M?F[H,>?O%8>!$JLI5U,-/"[:XUBJD*E50L8AXS[KW5F/PF_E2?R_OY>$$\OQ
M-^-FRNN=S5M+4T63[&KY*S?&Z:J&K8O+3R[CSE3D<NE(Y/\ P&BJHZ8  +"!
M[]U[JP[W[KW7O?NO=%V^5?Q/Z ^;?1^[/C?\GM@_Z3>E]\56VZW=&S/[TYK9
MGW4NT<E2Y?'M_$=O9+$Y6#[?(45++:&NC$FCQRAXF=&]U[HNWP=_E0? +^6]
MF.PL_P#"[H3_ $,Y?M7&;?P^_:O_ $I;T[$^_IMK2U4]!'X]U[CSL5+X):VI
M;53I"SZ[2,X5 ONO=6)>_=>Z+5\H?AQ\6OFKL)>LOE7T3USWGLRGJ)JW%X[?
M> CKY\;4SQ- ]9B,C&8LEAJYH7>/[FAK*>?0S)Y-+$'W7NJ1I?\ A)G_ "4Y
M,M_$4Z([0@H_%/'_  &+Y![M-)>619%?6^2>NU1*IC7_ "W249BZO)ID7W7N
MKA_A[_+\^&GP&VA/LKXC_'[873.-KZ:DI<[E\'12Y/-984/^;;,;@R,U9F\L
MRGD&JKY0I_2%%A[]U[HW]724M?2U-#74U/6T5;3S4E91U<*U,4L52I22*6-P
MR21R(Q5E8$,"000??NO=4)]_?\)D_P"3;\A-\9CL3-_%Z7KC<NX*E:W,KTKV
M#F^L<9+.U0:B66/!4-9_ Z-ZB[1R?:XZ!2C%E"RA9![KW1U/@K_*1_E]_P M
M_P#C5;\2?CSM_86[-R*\6>[&SN7R786Y:B&58T:D3-YZKR%=18]A$A:CHY:>
MD:0&5H#*[NWNO=60>_=>ZJG^;?\ ),_EG?S"-TQ]@_)?XS;=S?9P:#[SM'8V
M;R?5VX*Y*:-88XLMD-OU>/;-)'"B1Q_Q!*EH44+ T0]^Z]T57I7_ (3!?R7N
MD]XX7?5)\59.S,UM^HFJ\;0]U=C[@[,PY>99D_RW;M=7_P!W\K&L<Q58J[&5
M,0*1R^/SH)??NO=7\T5%1XVCI,=CJ2FH,?04T%%0T-% E+###2H(XH88HPJ1
MQ1HJJJJH55    ]^Z]U5_P#,[^2U_+/_ )@_;..[R^7WQK_TN]I8G9.(ZZQ^
MZ/\ 3'O_ &#X\-@:NOKJ2C^RVQNK"XY_%592N?RM2&=O+I>5D2-4]U[H_P#T
MWU!UW\?^INM^C>HMO?W2ZMZBV3MOKKKS:_\ %J[/?P_#;1I(J''4?WN3J:W(
MU?V]+#&GEJ:N:>2VJ65W)8^Z]U53M'_A/5_)_P!B=][8^3VU/B)_"N\MF]O8
M7OG;>]_]/O:%=]MNS;V:BW#1Y7^&5.]9L/-X<Q#'4?;2X]Z-[>)Z=H"8S[KW
M5OV[=H;4W_MG.;*WUMG ;SV=N?&U6&W)M3=6'I]P8[(4E:NB:EK:*KCEIJJG
ME4D/')&R,."#[]U[K7]['_X2O?R6>Q=WUV\!\:]S;#FR>47*5^WNN.X]S[9Q
M#'QLCP08TY&>"@I9'82&*C%.J,H$/CC+1M[KW5IOPI_EU?#'^7AL:LV!\0>B
M=J]28O,2^?<N;IIZS<V=R\@D>56R^X<O4U^:R*1/(_ABFKF@IE(CIHH8E5![
MKW1U_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1JNCI,A32T=?2TU;23@+-2U<"U,;
MA2& 9'#*P! /(^H!]^Z]TG<)L/8VV:EZS;FS-J;?JY69I*K";=H\5(Q<%26>
M"&-B2&8&Y^A(_/OW7NE7[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZAY#'T&6H:K&96AH\GC:Z"2EKL
M?D*9*R":*86>.6*16CDC8<%64@C@CW[KW21VOU?UGLBLJ\ALOKO8NT*^OEJ)
MZZNVOM''X":9ZLJ97EEI*>%Y&D*KK+,2UA>]A[]U[I=>_=>Z][]U[KWOW7NO
M>_=>Z1N[NN>ONP(8J;?NQ-F[WIZ=62"#=VV*'<J(KNDA")6P3*H+QQL0 +LJ
MGZJ+>Z]T_8?"87;U!#BMOXC%X/%TY<P8W#T$6,IT,ANQ2&!$C7422;*+GD^_
M=>Z=/?NO=5&?SJX?YE.*^%F?[(_E9]HU^QOD3U-N&CWQF]EXSK3:G9U5O':]
M+3U,&7PN.I=U8?,4\.6I#-3Y*F^WA$]4*.:@C62:JA"^Z]UHE_$W_A7G_-&^
M._8&Y*7YA8W:OS(VR&J,57[&W;M+ ?&_/X6OQ<OCE2DRFTMJTT$#*RS1U,&1
MV]6R!PHC>G*.K^Z]U8=WG_PM[S^5Z].,^.7P2I-G]FY?:TB3[M[9[F&\<5@\
MO50%;TN(QFW\9/N"DI)VUI+/D<6TP0"2EC#D+[KW5+?\@;X _(?^:/\ S/MF
M?)K?E)N7,]3]/]]4WRA^2_=^4IOX?397<F'S$>Z(,%#4K1M15>;W)GY*22LH
MX1$\.,EK*I7IRM-Y/=>Z^M[[]U[KWOW7NO>_=>Z][]U[KWOW7NF?.;>P&YZ!
ML7N7!X?<.,:6.=L=G,9#EH"\-]#F&H22,NES8Z;C\>_=>Z9-I]<=>;"5TV-L
M/9FS$D@%-(NT]KT.W0T:L7$9%'!""@<EM)XOS:_OW7NEG[]U[KWOW7N@XH^G
M.HL?GEW50=5];T.YT2-$W'1['QE-7A89'E0"L2E6H 2621P/)P[,PY8D^Z]T
M(_OW7NO>_=>Z][]U[KWOW7NO>_=>ZXNB2H\<B+)'(K))&ZAU97%B"#P01P0?
M?NO=!E_H1Z7_ (K_ !W_ $1=8?QSQ^'^,_W!Q7W>CR>;3]Q]IYM/F]=M=M?J
M_5S[]U[H341(D2.-%CCC54CC10BJJ"P  X  X 'OW7NN7OW7N@YR/3W4>8SL
M>Z,MU9USE-S13551%N+([(QE;7K)7%&G=:N6E:H#S&*,N1)=RBEB=(M[KW0B
MJJJH50%50%55%@ /H /P![]U[KOW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=:R/\ -(_X3,=*?S1_EIGOECOWY0=I=69[
M-[,V5LK^Z.T-E8G,TD4.RZ9J>.;[BMG$SRSEV9AI55X4 V)/NO=7_?&/I#%_
M&7XV?'OXW8/.U^Z,+\?.C^I^D,1N7*TT=%59&EZHP-!@:>NJ8828HJBKBH$E
MD1"45W*J; >_=>Z'#W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5=_,'^2Y_+$^=
MV>GWC\E?B/U]NK?U54TE77=C[3K,IU1N&K>ACEBC_B&9VK7X:NRL:QS.OCK9
M:B,VC8IKAA:/W7NB9;#_ .$MG\DW8>XZ#<R?$_)[OJL96+6T>,WYW7O7<V-U
M(&"I48Y\\E'6P@FYBJHIHV(&I6%P?=>ZO-ZJZCZMZ+V'M_J[ICKO9?577&U:
M-*#;FQ^O]MTFU,71Q( +04=%%# K/:[OHUR-=W9F))]U[H1/?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
$O=?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>timage_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_003.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K30_P"%7/\ Q]WPB_\
M#<[]_P#<G:/N=_9?X;S[8/\ !-T#N:^,7^W_ .?>M1;W./00Z^OKL[_CT=K?
M^&YA/_<:+W@U)\1^T_X>I?'#I1^Z=;Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZTJ?^%5W_
M #.'X@_^(U[/_P#=IC/<^>S']E=?Z>+_  /T#.:_BC^QO\*]:GON;.@EU]AC
MW@OU,'7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]UIH?\*N?^/N^$7_AN=^_^Y.T?<[^R_P -Y]L'^";H'<U\8O\ ;_\ /O6H
MM[G'H(=?7UV=_P >CM;_ ,-S"?\ N-%[P:D^(_:?\/4OCATH_=.M]>]^Z]U[
MW[KW7O?NO=->:S>%VWB:_/;BR^+P&#Q5-)693-9K(18JDIH8N7EJ*F=XX88E
M_+.X4?D^W(H7G8(BEF8T"J"23Z #)/57=8P68@ 9))H!^9ZJ>[U_G+_%_J^H
MK,-US3;@[SW!2M+$TNV+;?PHDB^JMF*V-GF4GZ24F/JHB+D.>+R9LWM/N6Y
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M $7&'_\ J;W[_6IV;_?<G_.5_P#/U[^N]_\ Q)_O Z]_P\)\Y_\ GO\ :?\
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M!U[_ (>$^<__ #W^T_\ T7&'_P#J;W[_ %J=F_WW)_SE?_/U[^N]_P#Q)_O
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M03\YO^>;^/?_ * .8_\ LD]^_P!8K9O]^77_ #DC_P"M/7O]<O</X8/]X?\
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MG7O^@@GYS?\ /-_'O_T <Q_]DGOW^L5LW^_+K_G)'_UIZ]_KE[A_#!_O#_\
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M;W6>W)I:'#42!@8VDBU:LA6*%!-34EW#%O"((F$2Y0\M<G67*Z4@75(1W3.
M7;UI_"/DOYU.>H9WCF"XWEOU#1*XC7"C[?4_,_E3HH'L5]$G7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]TONM.T^Q>G-V8_?/5V\<[LC=>,8&FS&!K6I79+@M#/'ZH
M:JEDT@203QR0RKZ9(V6X]H=QVRWW:(PW,:R(>*L*_F#Q!]"""/(]*;2\EL7$
MD+%&'F#_ (?(CY''6TM\ /YI&U_DI-C.I^XH\5L?N]TCIL+5TMZ3$[F:-"3]
MGK9OLLJ0I+TC.4F)U4C$DT\6-W._MQ+R\#<VNJ2WXM7+Q?Z:G%?Z0X?B XF7
M.7.;4W6D,U$E\OX7^ST/R_9Z"WSW%W0SZ][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM*G_A5=_P SA^(/_B->
MS_\ W:8SW/GLQ_977^GB_P #] SFOXH_L;_"O6I[[FSH)=?88]X+]3!U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]UAJ*BGI()JJJGAIJ:GB>:HJ*B588XTB%V=W8A550"220 .3[VJEC09)\A
MUHFF3T5K>'S5^-^S*R7'578-/G*Z%BLL.T\=4[CC!4Z3_E=/&U$Q!O<+4D\?
M3D7$5KRG?W8U"(J/Z9"G]A-?Y=%4V^6T!H7!/]$%OYC'\^D5_P .%?&[_G<;
MJ_\ 04G_ .*^U?\ 4B__ (4_WL=,?UCM?5O]Y/7O^'"OC=_SN-U?^@I/_P 5
M]^_J1?\ \*?[V.O?UCM?5O\ >3U[_APKXW?\[C=7_H*3_P#%??OZD7_\*?[V
M.O?UCM?5O]Y/7O\ APKXW?\ .XW5_P"@I/\ \5]^_J1?_P *?[V.O?UCM?5O
M]Y/7O^'"OC=_SN-U?^@I/_Q7W[^I%_\ PI_O8Z]_6.U]6_WD]>_X<*^-W_.X
MW5_Z"D__ !7W[^I%_P#PI_O8Z]_6.U]6_P!Y/7O^'"OC=_SN-U?^@I/_ ,5]
M^_J1?_PI_O8Z]_6.U]6_WD]>_P"'"OC=_P [C=7_ *"D_P#Q7W[^I%__  I_
MO8Z]_6.U]6_WD]>_X<*^-W_.XW5_Z"D__%??OZD7_P#"G^]CKW]8[7U;_>3U
M[_APKXW?\[C=7_H*3_\ %??OZD7_ /"G^]CKW]8[7U;_ 'D]>_X<*^-W_.XW
M5_Z"D_\ Q7W[^I%__"G^]CKW]8[7U;_>3U[_ (<*^-W_ #N-U?\ H*3_ /%?
M?OZD7_\ "G^]CKW]8[7U;_>3U[_APKXW?\[C=7_H*3_\5]^_J1?_ ,*?[V.O
M?UCM?5O]Y/7O^'"OC=_SN-U?^@I/_P 5]^_J1?\ \*?[V.O?UCM?5O\ >3U[
M_APKXW?\[C=7_H*3_P#%??OZD7_\*?[V.O?UCM?5O]Y/7O\ APKXW?\ .XW5
M_P"@I/\ \5]^_J1?_P *?[V.O?UCM?5O]Y/7O^'"OC=_SN-U?^@I/_Q7W[^I
M%_\ PI_O8Z]_6.U]6_WD]>_X<*^-W_.XW5_Z"D__ !7W[^I%_P#PI_O8Z]_6
M.U]6_P!Y/7O^'"OC=_SN-U?^@I/_ ,5]^_J1?_PI_O8Z]_6.U]6_WD]>_P"'
M"OC=_P [C=7_ *"D_P#Q7W[^I%__  I_O8Z]_6.U]6_WD]>_X<*^-W_.XW5_
MZ"D__%??OZD7_P#"G^]CKW]8[7U;_>3U[_APKXW?\[C=7_H*3_\ %??OZD7_
M /"G^]CKW]8[7U;_ 'D]>_X<*^-W_.XW5_Z"D_\ Q7W[^I%__"G^]CKW]8[7
MU;_>3U[_ (<*^-W_ #N-U?\ H*3_ /%??OZD7_\ "G^]CKW]8[7U;_>3U[_A
MPKXW?\[C=7_H*3_\5]^_J1?_ ,*?[V.O?UCM?5O]Y/7O^'"OC=_SN-U?^@I/
M_P 5]^_J1?\ \*?[V.O?UCM?5O\ >3U[_APKXW?\[C=7_H*3_P#%??OZD7_\
M*?[V.O?UCM?5O]Y/7O\ APKXW?\ .XW5_P"@I/\ \5]^_J1?_P *?[V.O?UC
MM?5O]Y/7O^'"OC=_SN-U?^@I/_Q7W[^I%_\ PI_O8Z]_6.U]6_WD]>_X<*^-
MW_.XW5_Z"D__ !7W[^I%_P#PI_O8Z]_6.U]6_P!Y/7O^'"OC=_SN-U?^@I/_
M ,5]^_J1?_PI_O8Z]_6.U]6_WD]>_P"'"OC=_P [C=7_ *"D_P#Q7W[^I%__
M  I_O8Z]_6.U]6_WD]>_X<*^-W_.XW5_Z"D__%??OZD7_P#"G^]CKW]8[7U;
M_>3U[_APKXW?\[C=7_H*3_\ %??OZD7_ /"G^]CKW]8[7U;_ 'D]>_X<*^-W
M_.XW5_Z"D_\ Q7W[^I%__"G^]CKW]8[7U;_>3U[_ (<*^-W_ #N-U?\ H*3_
M /%??OZD7_\ "G^]CKW]8[7U;_>3U[_APKXW?\[C=7_H*3_\5]^_J1?_ ,*?
M[V.O?UCM?5O]Y/7O^'"OC=_SN-U?^@I/_P 5]^_J1?\ \*?[V.O?UCM?5O\
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M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K30_P"%7/\ Q]WPB_\
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MKWOW7NO>_=>Z][]U[K30_P"%7/\ Q]WPB_\ #<[]_P#<G:/N=_9?X;S[8/\
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MJ7QPZ4?NG6^JS_YO'_9!_:O_ &O.M/\ WH\9[D'VN_Y+4'^EF_ZM/T%N<_\
MDG2?;'_U<7K3?]Y7]0AU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=7V_R&_^9F_('_PQ-G_^["I]PE[U?V%K_P U)/\
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M?_H#KW]<[?\ @D_8O_077O\ AX'HO_GVO;/_ )S8?_ZZ^_?ZUMY_OV']K_\
M0'7OZYV_\$G[%_Z"Z]_P\#T7_P ^U[9_\YL/_P#77W[_ %K;S_?L/[7_ .@.
MO?USM_X)/V+_ -!=>_X>!Z+_ .?:]L_^<V'_ /KK[]_K6WG^_8?VO_T!U[^N
M=O\ P2?L7_H+KW_#P/1?_/M>V?\ SFP__P!=??O]:V\_W[#^U_\ H#KW]<[?
M^"3]B_\ 077O^'@>B_\ GVO;/_G-A_\ ZZ^_?ZUMY_OV']K_ /0'7OZYV_\
M!)^Q?^@NO?\ #P/1?_/M>V?_ #FP_P#]=??O]:V\_P!^P_M?_H#KW]<[?^"3
M]B_]!=>_X>!Z+_Y]KVS_ .<V'_\ KK[]_K6WG^_8?VO_ - =>_KG;_P2?L7_
M *"Z]_P\#T7_ ,^U[9_\YL/_ /77W[_6MO/]^P_M?_H#KW]<[?\ @D_8O_07
M7O\ AX'HO_GVO;/_ )S8?_ZZ^_?ZUMY_OV']K_\ 0'7OZYV_\$G[%_Z"Z]_P
M\#T7_P ^U[9_\YL/_P#77W[_ %K;S_?L/[7_ .@.O?USM_X)/V+_ -!=>_X>
M!Z+_ .?:]L_^<V'_ /KK[]_K6WG^_8?VO_T!U[^N=O\ P2?L7_H+KW_#P/1?
M_/M>V?\ SFP__P!=??O]:V\_W[#^U_\ H#KW]<[?^"3]B_\ 077O^'@>B_\
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M?_H#KW]<[?\ @D_8O_077O\ AX'HO_GVO;/_ )S8?_ZZ^_?ZUMY_OV']K_\
M0'7OZYV_\$G[%_Z"Z]_P\#T7_P ^U[9_\YL/_P#77W[_ %K;S_?L/[7_ .@.
MO?USM_X)/V+_ -!=>_X>!Z+_ .?:]L_^<V'_ /KK[]_K6WG^_8?VO_T!U[^N
M=O\ P2?L7_H+KW_#P/1?_/M>V?\ SFP__P!=??O]:V\_W[#^U_\ H#KW]<[?
M^"3]B_\ 077O^'@>B_\ GVO;/_G-A_\ ZZ^_?ZUMY_OV']K_ /0'7OZYV_\
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M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U?;_(;_ .9F_('_ ,,39_\
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M(_RCR..I:V[<(]SC$D?V$>:GT/\ JST./LGZ7=>]^Z]U[W[KW6E3_P *KO\
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MTIM;*:])6&-Y",D(K.0/]J#T,G^R._-7_O#_ .4?_I/^[/\ ZT^RG^N6S_\
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M8(/$'K#[MUKK-3T]15U$%+2P35-54S14]-34\332223,%1$106=W8@*H!))
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M?/2#T,?^R._-7_O#_P"4?_I/^[/_ *T^RK^N6S_\IUG_ -E,/_0?2W^K]_\
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MQXC24J"P64[Y+*&^H5BB$B]B5%_H/9-]X(_[@?\ 45_VK]+_ &L_XE?\V?\
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MAKU[W[KW6FA_PJY_X^[X1?\ AN=^_P#N3M'W._LO\-Y]L'^";H'<U\8O]O\
M\^]:BWN<>@AU]?79W_'H[6_\-S"?^XT7O!J3XC]I_P /4OCATH_=.M]5G_S>
M/^R#^U?^UYUI_P"]'C/<@^UW_):@_P!+-_U:?H+<Y_\ ).D^V/\ ZN+UIO\
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M7,A]R1[=<N[=S;-)87;21S,NN"2-AG2#J0JP8''<*4- V>'00YMW>[V&);J
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M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5S?\L+_CPNS_\
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M4G_TR_\ '%ZK[]CSH+]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6T9_PFP_[G/\
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M>V;0WH4@.N3A7XWJ@/F-/#J:=O']5-B:8XEE&H>H:3M3C3X5HQ'J#QZ*!_(
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M4'_&M9^=?2G0Q]QKX3WJP+\,,8%/1G[C_P 9T]68_P C[_MV?\HO_$N]V?\
MO ;2]QY[S_\ *P6G_//!_P!I,_0K]O/^27-_S5D_ZM1]:BWO*?J$^O>_=>ZV
M^?G-DZCO?^15UOVMN<"OW)@=D_&W>59D*R-!(^46OQFUZZL0 ,%>J.4K&])4
MZ)6' )0XI\EQ#9><Y+6+"&6[C '\ 2251^6@?F/SZF_F*0[AR\LSY;1 Y/\
M2+(I/YZC^WH$O^$V'_<Y_P#Y;I_\O?L\^\%_Q _ZBO\ M6Z+/:S_ (E?\V/^
MLW5?_</\GO\ F,;I[;[2W/@?CO\ ?X/<?8V]\]AJ[_2WL6E\U)E\G55%/+XI
MMSQS1^2&1&TO&KK>S*K @#?9_=78+6T@BDNJ,D,2L/ N#1E10140D&A'ECH.
M[CR3N<]Q*Z0U5I'8'Q(A4%B1QD].A@^+7\A[Y4;H['VED_DABMJ]3]8XG-4.
M4W=B9=VX[>67R%)CIU>3'4<.%J,A01M7HF@S35ZK!&YD\<LBB!BGF;WJVVWM
MY$V\O-,RE4;0T<:DCXB9 K=O&@7)'$#/2_9O;N[DE1KL+'&""RZ@[, >';49
M]:X'EY=*O^?;\Q.ONYM^=:?'SJ[<&,W;C.GZC/[B[ W%A:A,C1'.9U(::GQE
M-51L8II<7213M5-&7C$M4L&L34\\:)?9'E2?:H9=PN5*&<*D2MAO#4EBQ!&
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M_<G:/N=_9?X;S[8/\$W0.YKXQ?[?_GWK46]SCT$.OKZ[._X]':W_ (;F$_\
M<:+W@U)\1^T_X>I?'#I1^Z=;ZK/_ )O'_9!_:O\ VO.M/_>CQGN0?:[_ )+4
M'^EF_P"K3]!;G/\ Y)TGVQ_]7%ZTW_>5_4(=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5]O\AO_ )F;\@?_  Q-G_\
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M2_E]=D3=;?*WK&<U'@QF]*^;KG,H1Q+'O ""D0G\!<JN/DO_ +1;Z'V$N>+
M;AMLHI4Q@2K\BF3_ ,9U#H]Y<NOI;M/1NP_[;A_.G6UM[QLZEOKWOW7NM*G_
M (57?\SA^(/_ (C7L_\ ]VF,]SY[,?V5U_IXO\#] SFOXH_L;_"O6I[[FSH)
M=?88]X+]3!U[W[KW7O?NO=>]^Z]TD]][*V]V1LS=&PMUT2Y#;F[\'D<!F*5K
M F')1M&S1L0=$T=P\;CU)(JNI#*#[6[;N$NU7$=S"=+Q.KJ?FIK^P\"/,8Z3
MW=JE]$\,@JKJ58?(BG_%=:8G>?4.XNB.UMZ=5[G5VR&U,Q/24N0-.:9*ZBE_
M<H<A"I+6BK:5XI5&HZ-11CJ5@,^.7-\BYDLHKV'X9%!*UJ4<893\U:H^?'@>
ML6MXVM]FN7MY.*-0&E-2\0P^T9^7#H*HI98)8YH9)(9H9$EBEB<QLK1FZLK"
MQ5E(!!!N#[.F4,*'(."#Y]%H)4U'1O.KOGG\K>I3308#MS/YO#TUD_@&^2F]
MJ4QJ#:)6R"S5=-&IL0*:JA(M:^DD$#;S[:[+O=3);(C'\</Z35]>RBD_Z93T
M)]OYRW';:!)F91^&3]0?9W5(_(CJQSJ[^<_*HIZ/NGI\2V4?<[AZRRF@D@ >
MG$922W/))_C( ^@7\^XJWCV#K5MONOL2X7_G^,?]8_SZ'&W^Z?E=0_:T1_Y]
M<_\ /_5EO3WSF^,/=]=C\)LWLW&T>Z,I/%246T]V4\NU:^:><@)3TZUBQT];
M.Y("I35$S,>!<@CW$F^^W>\<O*TEQ;L8U%3)&1(@ \SH)*CYL!T/=LYMV_=B
M$BE&LX"/5&)]!JI4_83T;?V">A'U[W[KW55O\T/_ (]WJ#_M=;O_ .M%![D;
MV\_M)O\ 2I_A;H)\U?!']K?X!U3S[E+H%]>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5S?\L+_CPNS_ /P[\3_[A>XI
M]PO[>+_2'_CW0WY5_LG_ -,/\'0W]R_&+X[=G;]R6[NP]TUN+W16TF,IJRC@
MWG18952A@2*$_;S1/(I:)5-RWJO<<'V4;5S#?;?"(H$!0$D'PV;)-3D'I?>[
M5;7<A>0D-BO<!P'3[TM\9/CGUON%-U=>14^X-SXV"6*FS-9NA=QRT@JD:*5X
MHXG%/#)+&[(7\.L*Q56568%C=N8+Z_3PYR50\5":0:&HK7)^RO3EEM5M:MKC
MRP\RVJG1"_YB4_>%=G<&=V[<HL5U1BZNHAVG7;?R3YFFJ*NL5M4F0E>&FDAK
MV@C.B)J98XT\BPRS_NR$9\C"S1&\-B9B.\,-)"C^')J*\36O"H&!T'N9#.S#
M6 (P>T@U!/SX9_+[">E)_*[_ .+WW'_VJME?];LE[8]Q/@@^V3_ G3G*GQ2?
M8O\ A;H&OFIMRNWA\PI]I8O3_$MSMUSM^@U\J)LS34E/&6_VD/("?\/9KRG.
M+7:_%;@GBL?L4D_Y.D>^1&>]T#BV@#\P!U9UO_<6S/AC\>TDVQA:::/"BBP6
MWL=(13G)9;)J;U%9(NEY'D$4U1.P.LQQLB:0%"Q[902\UWWZC'NJS'CI0>0_
M: /F>A3<2)LEMV#A0 >K'U_PGJN'97\QON2@W=1UV^*;;F?VA45D29?"8W"K
MBYH*=S9WH)UDU^:,>I5G>57MH)34)%'EWR):O$1"65P.UBU03_2%.'V4IQ^7
M09@YEF5P9-)6N0!0@?+_ &:]'5^<O4>V^T>E*OM##PTK[EV3BJ;<V*S<$0B:
MLQ$NAZJFF<KK>%::1JF(,+I(FD:1+)<)\G[G)MUV+=JZ)#H*_P +\ 1\ZBA^
M1^0Z/-^LUNH#*/B4:@?5?,?LS]O0$?RM?^:Z?^4R_P#EA]G/N+_Q'_YN_P#6
M+HOY4_T7_:?\_P#0@_+GY5UO06Z)-A]3X/ TF\-P10;MWMN:OQXJM,E<@IZ9
M1%J43UC4]-'JDFUI'"(8T1KGQH>6.6QO4?C7+,47LC4&G#)SY"IX#B:G[56\
M[N=O;PX@-1[F)'K@?:<>?RZ=_AE\P-Q]U9S*=>=C4V,&Z*3$R9O!YS%4WV"5
MD-&Z)4P5$ 9HTJ8Q*DB-$%1XQ("B% 7:YKY73:4$\!.@MI92:Z2<@@^F*9\Z
M9SBVR;RU\QCD U 5!&*TX_GT1WY[]/XGK#N"#,[;HX<=M[L3&2;ACQ]-%X8J
M>OII3%D(X5 T+%(S03Z5-E:9U5414!%_)>Z-N%J4D-6B.FIXE2*K7^8_+[>B
M'F&S%K-J44#BM/0US_G_ #ZMER>%W5M?XTT&)^-=/A_[PT>R]NML;RF!XIHZ
MH4\L]1&]2132U=13R3S1O.3').P:6X8WC2*6.YORU^6TF1O$XU!%0!C( - 0
M,@<.A@Z/%:@6U*A5T<*>7KBM/7SX]5W[ ^67R2Z4WK#2_([#;RR>RZZJ-'DA
MG-JQXJIIFD+D5.-J4IZ:&K"FY,7F>-XUM$T9 /L<WO+5ANT5;!HQ(!4:7)!^
M3 DD?;2M>->@W;[O=6+TN@Q4X-5H1\P:"O\ JIT$WRT[VZV[ [AV3V-U#32M
MD=M4N+K,MG:W$-BA6UN(JUJ*/7$^F:4TR1JC2.BLRZ8P2D:GV9\L[-<65K)!
M='#DA5#:M*LM#PP*UX#[?/I'O&X17$R2P\5H22*5(-1^SJSGOW#XSY(?$_)9
MW;T?W$M?M3'=D[7C"B>1*K#Q?=R4H'_*PT/W=&1Q9W8?BWN/=EE;8=R"28HY
MB?THQTU^RM&_+H5;A&-SM"5S50Z_:,T^WB.J9/C%UN>U.\=@;5F@$^*7,1YW
M<*NFM/L-O?Y741R?6RU(B6 &WZI5]ROS#?\ [NLY) :'3I7_ $S8'[*U_+H$
M;3:_5W")Y5U-]BY_GP_/JQC^9CV1%C]I;)ZKHYE^^W#E'W=F8UTEEH\*LD%*
MCW-PE352R,I"W)I2-0%PP$]O[#7+)<G@JZ%_TS9/[ /Y]"7FBYTHL0XL=1^P
M8'[3_@ZIK]RKT">O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z5='_ ,>/N+_PZ]F?^X>>]I7_ +=/]))_QZ+I]?[)O],G^!^J
MF/YJG_;PGY2_^)"A_P#=9C_<K>V/_)!L_P#FFW_5Q^@1SI_R5)_],O\ QQ>J
M^_8\Z"_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UM&?\)L/^YS__ "W3_P"7OWC?
M]X+_ (@?]17_ &K=2Y[6?\2O^;'_ %FZ*KVO_/(^=.SNTNRMHX;(]4C$;5W_
M +QVYBA5=>+/+]M@\C4TL'D?[Q=<GBB74UA<W-A[$6U>S6S7EK#,_CZI(HW:
MDH JR!C3L]3T5W_N#?VT\D:^%19'450UHK$#\7RZ*3W;_-S^>/>N KMIY_N-
M]G;6RE.U+E,-UC@J78S5$<BA7CER%,ARYBE74)(AD1%(K,KHRG2!3L_M5LFS
M.)4@\1P:AIF,E#_I31/S*DCRZ)+_ )WW'<%*&30IXB,!:_GEOV$=5_;$V;F>
MQ=\;-Z^VZ*4[@WUNO;VS<$*Z?[6#[S<]9#14OFE"N8XO/.FMM)TK<V-K>QW?
M7B;?!)<25TQ(\C4%3I12QIPS08Z#-K;M=R)$M-3LJ"O"K$ 5_;T9CYK_  I[
M2^#/:>,ZQ[-KL#N [@VM0[NVWNS:@JWQU;35,LU--$CU=-3.M51U-/(DT14L
MJ-#*?1/'<.<G<X6W.=LUQ;ADT.4='TZE- 0>TG!!P?4$>1Z-N8-@EY>F$4I#
M!E#*R@T(X$9'$$9'H0?/IHZL^<WS!Z6FI).MOD?VW@:6B$2TV#J]WU.Y<4HA
M 5 </E6K<4X55"@-1GTC3]./;NY<E;3NX/U%I Q/%@@1_P#>H]+?SZK:<R7]
MB?TIY!\BQ=?V/J'\NMJ+X1=^2?S<?A+WKU5\D=M;;_O9@FDV3F]R8N@2CI)I
M,Q1/5X+<5/3R+*F.RN-JX7=_%JB$E.DT:HDS4\>-/..Q_P"M=O%O<;>[Z& E
M56-6%&TO&2*:E8>M#1J&M*F8.7]Q_KG82Q72KJ!*,0,&HJK &M"#_,5'&@U;
M_@=\;JKY7?*SJ+IMJ:>;;F5W%#G-_P T'H\.WML?Y;ER9-2^)ZBEB:FB>YM/
M/$ K$A3DESQS .6-LGNJT<+HB^<K]J_L)U'Y ]1#RUM1WF]CAIVUU/\ Z1<G
M]O#[3UME_P QO!?R[N^*S9_1'RB^65;TK5=.U/\ &X^M]D[PPFVF6;<-!3"@
MFR4.1V]FG5J?&O\ Y(D;P*L-7(SI('C*8P<@S[[L8>]VVR^H$PT>+)'*XHK'
M4%*21C+#NK7*BE,UF;F>+;=RTV]W<^%X9U:%=%-2,$ZD8X'"E./GBE>_5_Q9
M_DL]/]C[&[4V/_,)[%Q^[NO=U83=^WZE^U=L>/[G!5"5$<<ZQ['B>6FF*>.>
M/R*)86>-CI8^QUN?,_-V[6\EK-M<925&1AX$]:,*5%9S0CB#3! /0:LMEV*P
ME2:.]8,C!A^K%2H-:&D8P>!'F,=##_/0Z3VK\A?B_P!6?-'J/(8O=U'UU]K3
MY'<NWY370Y':'8$T24]4DD:.9%QF8-.5!,8BCK:QY#J0+[*O9C>9-BW*;:;H
M,AFK1&%"D\0.#4BFI:CSJ54#I;[@[>NYV:7T)#>'^)<AHGID4K6AH?D"3U6W
M_(:ZGH-T?+3='=6XTIXMJ?'7J[<>ZZC)U(9TILCNJ.3&4KL@5@0N+;.2@\E6
MA4J"UBL@^]NZ&VVM+-*Z[J95H/-(Z.?^-:/V]!;VXLA->/<-33#&37T9^T?\
M9U=50_(/MG(][]Y=M]R91JLU/978.ZMWQ05I'DIZ;,5DLM'2$*\BJM%1F"!%
M$C!4C50S  F3M@VM=DLH+1:?I1(AIP+!1J.:<6J?SZ!FZWQW*YEG->]V85X@
M$X'Y"@_+K:)_D??]NS_E%_XEWNS_ -X#:7O&_P!Y_P#E8+3_ )YX/^TF?J7?
M;S_DES?\U9/^K4?6HM[RGZA/KDB/(ZQQJSR.RHB(I8DL;  #DDGZ#WHFF3UL
M"N!UMU_S%:,_&C^2KU!T'NFI2FWEN3#= ]<5N-C9F)R>%-/NC+QA642&FI9\
M/4)Y&1 &\(8(\B1G%?D!_P"L/-\U]$*QJUU,":? VJ)?S/B# KY^0KU-G-"_
MNK88[9SW%8(Z#S9:.?R[#Z= ]_PFP_[G/_\ +=/_ )>_9S]X+_B!_P!17_:M
MT7>UG_$K_FQ_UFZK+[5_FC?/G9/>'9N/V]\E-Z4^+VOVCOC&X;$5=!BLK2QT
MV)RM5#!3O3U6/FCFA2%%33(K7 YYY]R!M7MKL=[8PM):H6>")F8-(I+,BDFH
M<4-37'08O^<-RMKF14G:BRN "J$4#$ 97TZO4^/?>VT?YT'Q&WQTSOS=FX.G
M_D1LK%>#<C[ W-D<#25#9&-H:/<"XFGKX(,S@ZMU:"OQ]7YEII&=(Y(/N:6=
MH7W_ &27VEW6.ZA19[9S5/%16( -3&6*G0XXJZTJ*&AHP$A[7N2<\V3PNS13
M**-H9E%2,, "-2GS4UID>AZU).ZNG-_?'[M/>O3O9V(_@N]MAYJ?#9FE1S-#
M)I"R05=+*53ST5;3O%/3RZ%\D,B/I4FPREV;=X-^MH[NV;5'(NI?(CR((S1@
M:@CU'4*;A82[7,T$PHR&A]#Z$>H(R.MCO_A-A_W.?_Y;I_\ +W[@+[P7_$#_
M *BO^U;J3_:S_B5_S8_ZS=4S]X_-+YC8GNKN#%8KY9?)?&8O&=H]@8_&XW']
M[[IHJ>GIZ++5<<,$$,>56.*&*-55$50JJ J@  >Y8V/E':9K*W=[*T9F@B))
MMH223&I))*5))XGH$;GOM]'<RJMQ. )9  )9   Y   ;H+O]GB^:O_>8'RC_
M /2@-V?_ %V]FG]3=G_Y0;/_ +)H?^@.D/\ 6"__ .4FX_YS2?\ 071;<OF,
MON'*Y'.Y_*9'.9O,5M3DLMF<O72Y*JJJBL<R35%343,\T\\LC,SN[LS,26))
M]B"&%+=!'&H55 "JH"JH'  "@ 'H.BN21IF+.2Q)J2222?4D\>F[VYU3KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KZC'OF_UEQU[W[KW7O?NO=>]^Z]U[W[KW6HM_,6_[+0[S_[7.VO_ '0X
MKWF_[5_\D"T_TLG_ %>DZQKYY_Y*MQ]J?]6TZ)1[D'H)]>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW2LV+L7=O9>[<%L;8V"KMR;JW)71X_$8C'QZWD=[EF9B0D4,
M2!I)99&6.*-6DD945F"+<=Q@VB![FY<1QQC4S-P _P )). !DF@ )/2FSLY=
MPE6&%2SL: #_ %8 XDG &3UM6?"?X3[2^*>TOOZ_['<G<&Y*&)-W[O2+6E.C
MZ7.*Q1=0\5!$X4R2%5DJY%$LH5%@@@PQ]P?<&?G2?2M8[6,_I1>;'AK>F"Q'
M <$&!4EF;(KE3E2+ER*IHTS#O?T_HKZ*/VL<GR /1[CKH6]>]^Z]UIH?\*N?
M^/N^$7_AN=^_^Y.T?<[^R_PWGVP?X)N@=S7QB_V__/O6HM[G'H(=?7UV=_QZ
M.UO_  W,)_[C1>\&I/B/VG_#U+XX=*/W3K?59_\ -X_[(/[5_P"UYUI_[T>,
M]R#[7?\ ):@_TLW_ %:?H+<Y_P#).D^V/_JXO6F_[ROZA#KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZOM_D-_\ ,S?D
M#_X8FS__ '85/N$O>K^PM?\ FI)_QU>I&]O/[2;_ $J?X6ZV8_>/G4I=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6L
MY_-6S;Y;Y6U- Y8KMGKS9N$B!!%EJ/NLE878W&K(,> HO<6O=CD#[;0^'MNK
M^.5V_9I7_GWJ+^;I-=W3^%%'^%O\O5;7L?\ 07Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NE'L[/R;4W=M7=,)D$VVMQX//Q&(:G#8:JBJ%T@L@+7C%O6O/Y'U]I[N
M#ZJ)XOXT9?\ >@1_EZ=@E\%U?^%@W[#7K=E]XC]3GU[W[KW6E3_PJN_YG#\0
M?_$:]G_^[3&>Y\]F/[*Z_P!/%_@?H&<U_%']C?X5ZU/?<V=!+K[#'O!?J8.O
M>_=>Z][]U[IBW+NC;FS,'D=S;MSV(VSM[$P-4Y/-YW(18NE@C7C5+/,R1I<D
M 7:Y) %R0/:FTLY;^188$:1V-%1%+,3\@*GIJ>=+5#)(P50*EF(  ^9/5-OR
M4_F[[9P#5^UOC=A(MWY2-GII>Q-U4<U+BHS:Q;'T!:&LKBI) DG^WB#+J$=1
M$03/'*?L?-=4FW9S$O$01D&0_P"F;*K]BZC3S4]1?OWN7'!6.Q76W#Q'!"#_
M $HP6^TT'VCJBKLGL_?_ '!NNMWQV7NK*;OW1D$BAGRF4D7TQ07,<$$,2QT]
M+31EF*0PQ1Q*68J@+$G(W:=GM=BA%O:1K%&*D*OJ>))-22?,DD_/J(;_ '&?
M=)#-<.7<XJ?0>0 H /D !T@_9ETBZ][]U[KWOW7NK./Y3W5K;Z^4,&\*NE,N
M'ZGVME]T/-(NJ/\ B&67^&8^(_GR6JJJHCXL#2DW!"@Q#[U;S^[MG,"FC7,B
MQT\]"_J,?L[54_Z;J0/;C;OJ]P\4CMA0M7RU-V*/YDC[.MHCWA[UD!U[W[KW
M55O\T/\ X]WJ#_M=;O\ ^M%![D;V\_M)O]*G^%N@GS5\$?VM_@'5//N4N@7U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=7-_P L+_CPNS__  [\3_[A>XI]PO[>+_2'_CW0WY5_LG_TP_P=$V^?_P#V
M4SNO_M1[0_\ ==![%7)7_)/3_3/_ ,>/1)S%_N4WV+_@Z+-UI5[WH]^[4FZX
MDR:;V_C= FW5Q.LRO4-(NF,K'R\+_256!1H]0<%-7L0;@L+P.+BGAZ3JK2E*
M?/S]/GPZ*[4R+(OA5U5%*>O^KCUL+?+/'8G)_'+MN+,1PO3TVTJS(TIE53IJ
M\:R3T;*6!L_W21 $6/-@1?W!_+4C1W\)3B7 /V'!_D3U(V[J'MI-7\)/YC(_
MGT0?^5W_ ,7ON/\ [56RO^MV2]C3W$^"#[9/\"=![E3XI/L7_"W2:[]S5'M[
M^87M#,9!Q'0T>Y>IS5S$Z1''-%1QM(Q_U,8?4?\  'VHV6(S[&ZKQ*34_(L>
MF]P<1[DK'AJC_P G1JOYCNVLIG.A*#*8]*B:GVGOO"YK+Q1!G1::IIJVA\SJ
MH/,=15P*&-@JN_//L-\B7"PWI5OQQLJ_:"K4_8IZ-N98C);@C\+ G[*$?Y>J
M*:>GJ*NH@I*2":JJJJ:*GIJ:GB::2229@J(B*"SN[$!5 ))( %_<QLP45. ,
MDG@!T 0"QH.MC+MAEZ_^'^[<9N"5(JG%=&2;,J6EF7FMR&(7$1KJ TLSU<R*
M+"S$\6O[@G;/\=W1&3@;@./]*'U_X!U)=Y_B]FP;RBT_F5T_X>B9_P K7_FN
MG_E,O_EA]BOW%_XC_P#-W_K%T1\J?Z+_ +3_ )_Z+U_,,VQEL-\A\GGJR*K_
M (9N_;VW<CAZF7UQ$8JEBH*B&%@ %,<M-K="2P,H<V61?9WR/<++8A!2J,P8
M>?<2P)_;3\OET7<R1%+DL>#*"/R%#_@_GU-_EU;9R>7[_7/TT$AQFTMJYVLR
ME7I/C5LL@HJ>(M]!)*TKLJWN5BD(X4^Z\]7"Q66@G+NH _TO<3^5/YCK?+41
M>XU#@JFI^W Z%C^:#E:.;=74F#1HCD,=M_=&5J4 ]8AS-320P%C?])>@J-/I
M'(;D_@L]O(R(YG\BR ?:H8G_ (\.EG-3 O&OF Q_:1_FZ3N![!^7/PQV?M0[
MTV_C\SUMEW^VQ>#S]8F1;'33QO.*):JEE^XQ\S*&=89/+  L@C17$EGYK';.
M:Y7\%BLHR644U"M*T(HWVBAX5Z;CN+S9$7Q "AX FNGY5'#^8Z-GTU\[^MNY
M\]BNO=S;.R>U,[NB08RBIJR2'<V+J9I0=-,\PCAE5IB+*)*+QDD!G'%PUNO)
MMQM*&>-PZIDD51P/6F>'R->CBQW^*]81LI4M@5[E/RKC_!T57^8#\=]B=:Q[
M9[*V%C:?;5/N7-5&!SVW,?'X:/[@P/4P55)"/12ZDAF26*,"(GQLB(WD+B3D
MG?)K\O;S$OH4,K'XJ5 ()\^(H3GC\J%',6W1VVF6,:=1H0.%:5J/3AGH<?Y;
M/:*Y[8FY^ILG.)*W9M:V<P<,I!U8S<#GSQJIO=::NULQ^G^5(/9/S[MW@S)<
MJ,2#2W^G7A^T?X#TOY9N_$C:$\5-1_I3_F/^'I>?$_XWGJ'M7OO<-31&*BBW
M$NTMARR0>/\ W%UJPY>0QL2Q=/'4XV$LME\E/*OZ@RHBYDW[]Z6UM&#G3KDS
M^,53_(Q^PCI1M&V?1S2L1C5I3_2GN_R@?EU5)\INSCVSWCOC<T$XGPM'D7VU
MMID;4AH-OEJ>&2,_ZFJ<2U'^!F(]R3RYM_[LLXXS\1&M_P#3-G^6!^701W:Z
M^LN&8< =*_8,?SX]%Z]GG1;U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW2KH_^/'W%_X=>S/_ '#SWM*_]NG^DD_X]%T^O]DW
M^F3_  /U4Q_-4_[>$_*7_P 2%#_[K,?[E;VQ_P"2#9_\TV_ZN/T".=/^2I/_
M *9?^.+U7W['G07Z][]U[KWOW7NO>_=>Z][]U[KWOW7NMG'_ (3@[EV]B*[Y
MD8S+9S%8ROJL1TAN"GI*^OBHW>AVT=XKD*L"1E_R:B-;2>>3],7FCUD:A[QT
M]_X'D%@RJ2 ;A20"1J;P-(^TZ30>=#U+/M;(JFZ!(!I"<GR'BU/Y5%?MZUV^
MZ\KCL[W+VWG,/609'$9GLW?N5Q60I7\D4]-D<K5S031L/U1RQ.K*?R"#[GC9
M(F@LK='!#+#$K \00B@@_,'J,]S<2W,K*:@RR$$<""Q(/09>S/I%TXXC+Y/
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M$5'(]#ML[R&0K%61U)IJ$UM)YY/T1>:/65UK>/\ W_@>06#*I(!N5) )&IO
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M^Z]U[W[KW7O?NO=>]^Z]U[W[KW5]O\AO_F9OR!_\,39__NPJ?<)>]7]A:_\
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MFI!;AM"+@,S,S%V]6[B!Y <!4L25VNSP6MQ+=**RRD:F/$ *JA1Z#MJ?4\>
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M]#/_ +[?_>&_S=>_T.]N_P#/K.Q__0'R?_U+[]^];7_?T7_.1/\ /U[Z&?\
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M?_>&_P W7O\ 0[V[_P ^L['_ /0'R?\ ]2^_?O6U_P!_1?\ .1/\_7OH9_\
M?;_[PW^;KW^AWMW_ )]9V/\ ^@/D_P#ZE]^_>MK_ +^B_P"<B?Y^O?0S_P"^
MW_WAO\W7O]#O;O\ SZSL?_T!\G_]2^_?O6U_W]%_SD3_ #]>^AG_ -]O_O#?
MYNO?Z'>W?^?6=C_^@/D__J7W[]ZVO^_HO^<B?Y^O?0S_ .^W_P!X;_-U[_0[
MV[_SZSL?_P! ?)__ %+[]^];7_?T7_.1/\_7OH9_]]O_ +PW^;KW^AWMW_GU
MG8__ * ^3_\ J7W[]ZVO^_HO^<B?Y^O?0S_[[?\ WAO\W7O]#O;O_/K.Q_\
MT!\G_P#4OOW[UM?]_1?\Y$_S]>^AG_WV_P#O#?YNO?Z'>W?^?6=C_P#H#Y/_
M .I??OWK:_[^B_YR)_GZ]]#/_OM_]X;_ #=>_P!#O;O_ #ZSL?\ ] ?)_P#U
M+[]^];7_ ']%_P Y$_S]>^AG_P!]O_O#?YNO?Z'>W?\ GUG8_P#Z ^3_ /J7
MW[]ZVO\ OZ+_ )R)_GZ]]#/_ +[?_>&_S=*#;WQU[VW37)C\-U)OYYG.GS9#
M;53A*=3QQ)5UR4U+$>?[<R_U_!]L3[[9VPU/-'^3!C^Q:G^73D>V7$IHL;_F
MI _::#JS7XT_ "#9F5QV^NZ)\9G<WCY4K,/LF@/WU#3RQV:.:OF=0M9-$W*P
MHI@5@&:28>D1]O\ SJ;M3#: JIPTAPQ'H!Y#Y\?LZ%.U\O" B2>A(R%&0/M]
M3_+[>K//<?="GKWOW7NO>_=>Z GOGXR="_)S;/\ =+O7K#;'8>*B648^HRM*
MU-7T+3"S/CLI2O!DL=(W]IJ:KB+#AKCCV<[+S#>\O2>+93/$WGI/:WR9356'
MR8'I!N&UV^ZIX=Q&KCRJ,C["*$'Y@CJD+MW_ (3I]+9^KJ*_I3O??G6RS3/,
M,'O;;U)V52(&M:&GF@J,%60QKS9II:I[?5F//N8=J]^KVW 6\MXIJ"FI&,+'
MYFHD7]@4= &^]LK:4DP2O'\F D4?(94_M)Z*?E/^$Y'>4+QC"_(OJC(1GR>9
MLIMO,8=EL1HTK$M<'U"][LNG@#5>X$T?O]:'X[24?9(C?X0O1.WM=,/AN$/V
MHP_Y^/35_P! YWR-_P"?]])_^<>=_P#K?[=_U_;'_E%G_P!ZC_S]5_UKY_\
M?\?^\MU[_H'.^1O_ #_OI/\ \X\[_P#6_P!^_P!?VQ_Y19_]ZC_S]>_UKY_]
M_P ?^\MU[_H'.^1O_/\ OI/_ ,X\[_\ 6_W[_7]L?^46?_>H_P#/U[_6OG_W
M_'_O+=>_Z!SOD;_S_OI/_P X\[_];_?O]?VQ_P"46?\ WJ/_ #]>_P!:^?\
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MUKY_]_Q_[RW7O^@<[Y&_\_[Z3_\ ./.__6_W[_7]L?\ E%G_ -ZC_P _7O\
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M\_7O]:^?_?\ '_O+=>_Z!SOD;_S_ +Z3_P#./.__ %O]^_U_;'_E%G_WJ/\
MS]>_UKY_]_Q_[RW7O^@<[Y&_\_[Z3_\ ./.__6_W[_7]L?\ E%G_ -ZC_P _
M7O\ 6OG_ -_Q_P"\MU[_ *!SOD;_ ,_[Z3_\X\[_ /6_W[_7]L?^46?_ 'J/
M_/U[_6OG_P!_Q_[RW7O^@<[Y&_\ /^^D_P#SCSO_ -;_ '[_ %_;'_E%G_WJ
M/_/U[_6OG_W_ !_[RW7O^@<[Y&_\_P"^D_\ SCSO_P!;_?O]?VQ_Y19_]ZC_
M ,_7O]:^?_?\?^\MU,H/^$Y??TE2BY/Y"=/TE&0_DGH,+FLC(" =($4E/2JP
M)L"3,+#D _3W1_?VS [;68GYN@'[17_!UM?:Z:N9T_)&/^4=&&ZP_P"$XNSZ
M.M@J^Y?DON+<- #"T^!ZVV+3;3D])NX&4R=;F RM^D?[B4*VU7-[*1[E[_3N
M*6EHB'/=+(9/^,HL?_'CT96GM?$AK/.S#T1 G\V+_P" =74_&GX(?%?XE0K+
MTKU1A,+N1X)::KW]F2^YMP3I4"TJ'+5K35-/#* -<%,8*<VOXK\^XAY@YSW+
MF@_XY.S+6HC%$B%/Z"T!/S-3\^AWM>P6FS#_ !>-5/FQ[G/^V-3^7#Y=&]]A
M?HYZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM-#_ (5<_P#'W?"+_P -
MSOW_ -R=H^YW]E_AO/M@_P $W0.YKXQ?[?\ Y]ZU%O<X]!#KZ^NSO^/1VM_X
M;F$_]QHO>#4GQ'[3_AZE\<.E'[IUOJL_^;Q_V0?VK_VO.M/_ 'H\9[D'VN_Y
M+4'^EF_ZM/T%N<_^2=)]L?\ U<7K3?\ >5_4(=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO='2^%WPD[*^9>^*C#[<D_NQL';K0R;Y[&KZ)JNFH5G!,=+31!
MXOO<E4 $QP"50J RS/&FG4$.;N<+?E.$,_?*_P#9Q T+?,G-%'K3)P/D?;%L
M$N^247M1?C<C ^0]2?3RXGK9HZQ_EP_![XZ[9;+;AV#M/=DN+IH)\[O_ +QJ
M:;<,5X H,TD.0T82@37=OVZ.,\@,[V6V/.X\_;QOLFE)72I.F.WJG'RJG>WY
MD]2K:<L6&VK4HK4XO+1N'GW=H_(#I9XWM?\ ER9RHAVCC=Y_$#(/75)I:;"1
M5FTGAGE=N$C0CP2O(_Z0MRY(TZB1=')M>^P@RM'>B@J6*S5 ^9XCI0E[MLAT
M*]N:\!6/)Z"[Y#?RI_BCW?@:^;9NS<3TKOB6FUX7=76]"N*H%<69!58*%XL5
M44S_ -KPPP3D&ZSBUB9[%[E;GL[CQ9&N(Z]R2G4Q'R<U8'[21ZCI'N7*-G?J
M="")O)HQ0?FHP1^0/SZU/^].D=_?'?M#<_4O96-CQ^Y]LU,:O+2R&HI:RFJT
M$M+7T4Q5?-25<+*Z,55U.J*5(YHY(TR:V7>(-^MDNK<U1QP.&4C!5AY$'_.*
M@@]0[N.WR;7,T,HHR_L(/ CY'_8.>@C]FG2+KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZOM_D-_\S-^0/\ X8FS_P#W85/N$O>K
M^PM?^:DG_'5ZD;V\_M)O]*G^%NMF/WCYU*72![1[*VMT_L+<G9.]9ZNFVMM2
MD@K<Q/04;9"98ZB>*G4I"GJD/DF3@?BY_'LRV?:9M\N8[2W ,DA(4$Z14 GB
M>&!TDO[Z/;86GE)"(*L0*FE:<!]O1&?^'7/A[_STF]/_ $!:SW(O^LOOO^^X
MO^<R=!'_ %Q=K_C?_G&W^;KW_#KGP]_YZ3>G_H"UGOW^LOOO^^XO^<R=>_UQ
M=K_C?_G&W^;KW_#KGP]_YZ3>G_H"UGOW^LOOO^^XO^<R=>_UQ=K_ (W_ .<;
M?YNO?\.N?#W_ )Z3>G_H"UGOW^LOOO\ ON+_ )S)U[_7%VO^-_\ G&W^;HK'
MS6_F"_&[O#XR]E]7[!S>YZO=NY_[F_PFGR.U*G&0M_!=P8K(SZYY/0EJ:DF(
MO]6 4<D>QE[?^V.[<O;O;WERD8CC\745D5CWPR(,#YL.@[S7SG8;MM\MO"S%
MWT4!1@.V1&.3\@>J"O>2_4-=6T_R^?Y@U7TK5XSION3)U%=U%75"TVW-QU+-
M4R[:EJ6_2WZGDPLCM=T%VI6)EB!0R1F$O<_VP7?U:_L% N0*R1C G \QZ2#R
M/XN!S0]25R5SJ=K(M;HUA.$<\8CZ'^A_QW[.MD^CK*3(4E+7T%53UU#74\%9
M15M'.M3%-%4J'CEBD0LDD<B,K*RL592""0?>)SHT3%6!!!(((H01@@@\".IU
M5@X!!J#D$<".I'NO6^O>_=>ZU>_YGG_97V]__#=V)_[JJ;WD1[=_\DN/_3R?
M\?/45<U?[FM_I4_XZ.J^_8XZ#G7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6\
M1[P_ZGCKWOW7NM*G_A5=_P SA^(/_B->S_\ W:8SW/GLQ_977^GB_P #] SF
MOXH_L;_"O6I[[FSH)=?88]X+]3!U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=::'_"KG_C[OA%_X;G?O_N3M'W._LO\ #>?;
M!_@FZ!W-?&+_ &__ #[UJ+>YQZ"'7U]=G?\ 'H[6_P##<PG_ +C1>\&I/B/V
MG_#U+XX=*/W3K?59_P#-X_[(/[5_[7G6G_O1XSW(/M=_R6H/]+-_U:?H+<Y_
M\DZ3[8_^KB]:;_O*_J$.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NMZ3X3]
M"8KXX?&KK'KJDH8*7.G;]#N3?53%$4>ISNXH8ZC(R2LWK?P2,M-$6 (@@B72
MH72,,^;=[;?]PFN"25U%8QZ1J2%'YC)^9/606Q[<-KM4B S0%_FYR?\ -]@'
M6KK_ #(OF/NKY.=W[FV]C<Y6Q=+]<[@R6W]A[;IYO#2U4F(=J6HSE0B&U34U
M\J2M3O)<P4K)&BQLTYDR-]O^5(N7K-)&4?42J'D<\5#=P0>@ (K3BU2:@"D2
M\T[V^Z7#("?"1BJKY$C!8^M?+T'IGJN7V/\ H+]7Q_RO_P"9;M[J7!5O1?R6
MWG7T6R*!8ZKJ_?&4I*O.+C QTS82K>FCJ*I: DK)1N862F/FB>1(# L4*^XW
MM[)N3B]VZ,&0XFC4A=?HXJ0-7DPK4X(!-:R)RGS4MHIM[MR%&8W-33^B:5-/
M,>F16E.BP?S7/DOTU\E^]=K9CIJ8Y[%;)V0-IY??7\.FQ:9.<5U35+%31U,4
M51)1T G<1S/&HDDEE\:F(1RR"+VRY>N^7[-UNQI,DFM8Z@Z!I J:$@%J9'D
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M"2'PMKC'GSW ;E62.W@1))&76^LG2J5( HI!U&A\\ #!K@9<L\K#>T:65F5
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MX88V%_WD7N__ - &B_\ KC[ _P#KTW'_ "BQ_P#.1O\ H'H1_P"MY%_OY_\
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MX*BNVINK%%C1Y*GIF59"@<"2&H@+QB>!QJC+J0SQO'(\I\O\PP<Q0^+#4%2
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M^',/<<F[-TQ=GY'K&M[0HI14TXQ*>*CER$&.>D^T-08GIT2.285)=9294!C
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M/ARAD:,G)H>(!.2"#G(I4U&6[\L6V_$3ABK$#O2A# <*C@?M!'SK3IE^._\
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M]V%/[1;E_N/+_P TW_XZ>E-G_;1_Z=?^/#K<([:K>M<=UUNBM[@3"R=:T]%
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MOXF7SXK!9#-U-;1TSZ2FNGI9)6@A;02MT0&Q(^GN6X[6*)S(J(&;BP4!C]I
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MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K>(]X?]3QU[W[KW6E3_P *KO\
MF</Q!_\ $:]G_P#NTQGN?/9C^RNO]/%_@?H&<U_%']C?X5ZU/?<V=!+K[#'O
M!?J8.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[K30_X5<_\ 'W?"+_PW._?_ ')VC[G?V7^&\^V#_!-T#N:^,7^W_P"?>M1;
MW./00Z^OKL[_ (]':W_AN83_ -QHO>#4GQ'[3_AZE\<.E'[IUOJL_P#F\?\
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M/R@["AWYNZ@QF%&.P=)MW!X##/,]/2TM+)-.?5,[-+/-/42M))9=0T(%"QJ
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MG=&5E)!)T]J;96!,\A (J-*BH],'SZ,&YWF(($:#YU..M@'<GS"^0^X-O9[
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MG\UG9LY\<\U4==UV6&7IXJ=:3(U&(KL7)44D'C,B1R-(HD.I0I!O>]]L;"<
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M-S[:[=)&RQ!D<@A7+,P4^NDL*_97I)#S?=HX+D,H.5TJM1Z5H:=5'_'3:O\
M.]^,?;'35;#_ #9<W\DNB,#OW:Q[AV-WKL.#*YC*;6HYD_BE+09;.1;RR7\5
MJJ5#'%4/FJ=XI'-2TM08S35 3D]IY59=-PA6O<3&58+Z@:F!/R)'V]'B<\(0
M=43 TP P()^9H*#YT/V=;266_F6_%G8'6.\.U^\=Z1](;5V!@Y<_NO*;SCDJ
M:2.&$JEJ2HHHYWK)Y9I(H8*<0)4U$SI%!!([ $,<P<C7FPH9CIDB'%U-"M30
M:E.1^6H?/HZVKF2#=&""J.>"MYTS@C'[:'Y='$ZQ[2ZW[JV%M?M+J+?6U.R^
MN-ZXJFS>T][[)SE/N/&9"EJA=)J6LI9)(9%^H8!M2,&1PK*0 7T(>EY[]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM-#_A5S_Q]WPB_\-SOW_W)VC[G?V7^
M&\^V#_!-T#N:^,7^W_Y]ZU%O<X]!#KZ^NSO^/1VM_P"&YA/_ '&B]X-2?$?M
M/^'J7QPZ4?NG6^JS_P";Q_V0?VK_ -KSK3_WH\9[D'VN_P"2U!_I9O\ JT_0
M6YS_ .2=)]L?_5Q>M-_WE?U"'7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U?;_(;_P"9F_('_P ,39__ +L*GW"7O5_8
M6O\ S4D_XZO4C>WG]I-_I4_PMULQ^\?.I2Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM7O^9Y_V5]O?_PW=B?^ZJF]
MY$>W?_)+C_T\G_'SU%7-7^YK?Z5/^.CJOOV..@YU[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]UO$>\/^IXZ][]U[K2I_X57?\ ,X?B#_XC7L__ -VF,]SY[,?V
M5U_IXO\  _0,YK^*/[&_PKUJ>^YLZ"77V&/>"_4P=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5B_*KYW-L?*
M9'KGIE\=D-QT#2T>X=[3HN0IZ"HC.EZ6AA8-#55<1!$LDFN&)KQB.637XI!Y
M<Y-^L43W50ARL8P6'J3Q /D!D\:@<0MNV_\ TY,4-"PXMQ /H/4_R'S\JE=X
M=C;][ K9:_>N\=Q[GJ99&DOF<M-6QIJ-],4+/X88P?HD:*B_15 ]R9:V$%D*
M0HJ#^BH!_,\3^?0/GNI+DUD9F^TGI%^U?3'7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=*+;N[MU[0K$R.U-RY[;5?&P=:S Y>HQ,EQ;^W!)&3>PN";$<'CVQ/:Q
M70TRHKCT90W^$=.Q3O :HQ4_(D?X.K-?C1_,!S$>4QNR>]ZNGKL76R)1T'8W
MB2DFI7>RQKE(XE6*6F8V!J51'B/KG\JEI(X^W_DE=)FLP01DQ<0?]+7-?EY^
M5.!%.U\Q&HCN.!X/PI]OR^?EY^HM[^YI_M_N_/#]IX?N?NO*OC\>G5Y-=].C
M3SJO:W-[>XPTFM//A3SKT,:^?6;WKK?5!?\ .JVIM/YQ=%9OX4T/9_9'7>(J
M]W;<S'96\.KMROB35PX"9_N]K5M.&-)EJ&JBD?[F&JCE@@K(J64Q32TSQ>Y.
MY7]O#O$'U%TS1JU#&J@:BM0=1U# (^'U^+A0$&[US6+"7PH0KE:ZR2: ^@IY
M@\?V<:T(1\=?C%T;\4NOJ+K3HGK_  FQMN4ZP29&>AIEDK\I4PQK$:[+Y!A]
MUDJYT109IY&(4!$T1JJ+-.U[3;[-$(K= B^=.+'A5CQ)^9ZCR]OI=P?7*Q8^
M7H!Z >0Z'OV8]).O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I&]@]=[$[7
MV=G.ONR]H[?WULC<M(*+/;6W1BXLQ154:.LB"6"960M%*B21N 'CD59(V5U5
M@Q<VL=XABE571L%6 (/Y'IV&9[=@Z$JPX$&A'1>/Y27Q/WK_ "S?FGN>JZQ^
M2NZL-_+P[3VYD)MQ_&7=2S;TCQN[*MFCH,A0556Y.,HZ)6#35T+&NJX0E)D$
MK%@@JH8;W[VR>,O+8M50NI8FJ7K7*@^>.%<DX/KU(&V<XJX5+D48FA<?#3R)
M'V\:8\_EUN312QS1QS0R)+#*B2Q2Q.)%99!=65A<,K @@@V(]Q&05-#@CB.A
MT#7(ZY^]=;Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZTT/^%7/_ !]WPB_\-SOW_P!R
M=H^YW]E_AO/M@_P3= [FOC%_M_\ GWK46]SCT$.OKZ[._P"/1VM_X;F$_P#<
M:+W@U)\1^T_X>I?'#I1^Z=;ZK/\ YO'_ &0?VK_VO.M/_>CQGN0?:[_DM0?Z
M6;_JT_06YS_Y)TGVQ_\ 5Q>M-_WE?U"'7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MT,/Q^ZVP_</=?675^X-T4^R\)OC=^*V_E-SU'CM20UCV=D\SQQ>:0#QQ:W"^
M5TU7'!*=]W%]ILYKF-/$:-"P3.2/LS0<3\@>EVV6BWUQ'"S:0[ %O0?GY^0^
M?6R>O\C#XFA5#]B_(AG"C6R[KVT@)_) .TF(!/XU&W]3[Q__ ->7<_\ ?5K_
M +Q+_P!;^I1_UO[/^.;_ 'I/^M?7+_AC'XE_\_#^17_H6[:_^Q'W[_7DW3_?
M5K_O$O\ UOZ]_K?V?\<W^])_UKZ [Y)_R9_C_P!9]&=I=E;![1[7H]Q=>['W
M+O:FCWYE<+F,=4C:])+6O22+183%3Q/5)"T4<@J&T2.C&.0 HQQL'NS?;A>P
MV\\,!261(SX:R*XUL%J-4CC%:D4R/,<>D&Y\C6UK;R2QR2!D1F&LH5.D5IA%
MXT]>J >J>J]]=V=@;:ZQZVP<^X=X[KKOL<5CHG6%1H5I)IYYG*QP4U-"DDLT
MKL%CC5F)X]S?N>YP[/ ]S<-I1!4GC\@ /,DX ]>HYLK.3<)5BB%68X'^4^@'
MGULC=(_R0.E-NX2BKN^MZ[I["W6]/'+DL3M.O&TL'3NPN\4;^%\I5B,\"<U-
M,' +&G2]A &\>\-Y<.191I$E<,XUR'YG.D?90T]3U*-AR%;Q*#<,SMYA3I0?
MY3]M1]G0J;K_ )./PEWMAZN+8_\ ?79->$6*GS6UM^R;E2*:/4P\T.5_B,<B
ML&76@>-BH&AXR2Q++7W6WBT<&8QR#S5XPM1]J:#]G'YUZ63<DV$ZD(&0^JN3
M_P >U=4%_-?X&=H?#'<="V<J8=Y=8[FK9Z39W8^+HWHXI9HE:0X_)4S-)_#L
MF(4:18O-+%/$KO3S2&*H2";N4.=;;FV,A!X<R"LD1-2!PU*<:EKBM 0<$9!,
M<[]R[+L; L=4;&BN,9]"/(_R(X'B S_ +XX[;^4OR7VEU?O/(5]!L]<;G-U;
ME3%2_;U553;=B$@HH9BK" U4[PI));4L)D,9630P<YXY@DY;V][B$ R%E1-6
M0I;S(\Z &@]:5Q7JG+>UIN]TL4A(4 LU.) \OE6O[/GU;'\DOY+V&RW;/5U!
M\;*NLV9U[N6GSY[.J=TY"HW+!@DPCT1@J*%I3]S5SY!*J9$I9:P$R0:Q*D)E
M:&,=@]VWAMICN $DJE?!" (9-6JH:F %H#J"\#2E:5&.Z<BK)-&+4Z$-?$U$
MMII2A%<DFIP3Y=&VVA_)C^&. P,>+W%C]_[ZS?VFBJW'E]ZU&'E\LNJ\L-+B
MQ1TL2*Q_;22*:RJH=I6ULP8NO=G=YWU1M'&M<(L:L*>A+ZC]N1\J=','(]A&
MNE@[G^(N0?V+0?RZK$_F#_RJ:7XZ[,K^[>C,WN#<G76(J(?[Y[0W"JY'(8>&
MNE$<==35=/%$*O&QR2)'*LL*S4RZ97FGC,C0R+R-[EG?9A9WJJLK?V<BX5R!
M7202:,:5%#0\  :5"G,G* VV,W%N24'Q*<E03Q!'$>M<CC4]4Q8?#Y7<.7Q6
M P6/J\MF\YDJ'#X?%8^!JJ>JJLG*L-/3P1("TDTTSHB* 2S$ "Y]RW-,MNC2
M.0JJ"S,< *!4D_( = 6.-I6"J"22  .))P!UL;?&S^2-M*GV[C]S?*3>&:J]
MQU5-]Y/U]L/)0XRBH!(JD0U^5>&::LGC&KR?;>")'%DFG1=;P%S![P2M(8]M
M10@P)9 2S?,+4 #TK4T\@<"3]KY"C50UVQ+?P(:*/M/$G[*#[>C(?\-6?RZ.
MPZ7*8#8DU;#FJ*.1*VOV'W))N*OHV%DUR4]7496EC979>):,C58$6-B0#W*W
MZQ(>8@J> D@"JWYJJ']AZ-#RAMEP"J @CB5D)(_(EA^T=4L_/#^6UOOX>B#?
M.!S,O8G2N5R46+I]SFB^SR&*J:L,T%+F:>/5$$FTE(:R)A#+(/')'3220QRR
MYR5[@0\U?HR*(K@"NBM5<#B4)S4>:G(&02 2 )S#RM)LOZB'7$3353N4GR:G
M\CPKB@Q6LWW(G04Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[J^W^0W_S,WY _P#AB;/_ /=A4^X2]ZO["U_YJ2?\=7J1O;S^
MTF_TJ?X6ZV8_>/G4I=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW6KW_ #//^ROM[_\ AN[$_P#=53>\B/;O_DEQ_P"G
MD_X^>HJYJ_W-;_2I_P ='5??L<=!SKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[K>(]X?]3QU[W[KW6E3_ ,*KO^9P_$'_ ,1KV?\ ^[3&>Y\]F/[*Z_T\7^!^
M@9S7\4?V-_A7K4]]S9T$NOL,>\%^I@Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBK_ #([;K.H.CL_E<-4O1[EW-4T
M^S=N543%'@FS"2O/4H1ZEDIZ*&J>-A^F41G_  (CY6VP;I>*KBJ("[#U"TH/
MS) /RKT5;U>&RMV9<,>U?D3Y_D >M= DL2S$DDDDDW))_)]SKU&G77OW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z/K3_)/==3\*,OU^
MF3F&9PV^MN=<U.1,K"<[<W-0Y6O@A5[W)#XFHHV'T%(5C_/(+;8(EW=9J=K1
MM*!Y>*C(I/\ QL-_IL]"(;HYL3'7(<)7ST,&(_XZ1]G1$/\ A3#\W>W7ROQE
M_E&_$O=F1VEW_P#-7,4&Z>U]YX&K>BK=N==X2MJ%\T4T-135$ R55BLM5U#P
MS+-_#\)6TR@FM2T5;7MS[M<1VT?Q2,%KZ#B3]@ )/R'0TO;M;&)IGX**_:?(
M?F:#I>;+VY)L_:&V-J3;AW'NV;;F!Q6%GW3O#+29[+9)\; D3UV2K9BTM575
M;(99I&-WD9CQ>WO+*V@%M&L8).E0M6-2:"E2?7J#9I?&=GH!J)-!@"I\NE-[
M?Z;Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@5^"
M7\TKY.=6_P X?)_R[/EONC#9OX[_ "&ZHQ^1^"^9H=K1X),5D=F+DLA-A:JN
M6"2HKZS*4RY:CJ'J\E*J38S#)0T]&F1,#8V<_P"WO8[E(S* LM)$*@@$'!]>
MZH.JG$YH*]2]RO=+<V: $DIVL":D$</RIP_9Y=;;7L%="+KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[K30_X5<_\?=\(O_#<[]_]R=H^YW]E_AO/M@_P3= [FOC%_M_^
M?>M1;W./00Z^OKL[_CT=K?\ AN83_P!QHO>#4GQ'[3_AZE\<.E'[IUOJL_\
MF\?]D']J_P#:\ZT_]Z/&>Y!]KO\ DM0?Z6;_ *M/T%N<_P#DG2?;'_U<7K3?
M]Y7]0AU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TK\!N'?IDQFV]K9S=YFK
M*R''X; 8#)UI:6HR4MHX*:EIWN\T\\EE1(RSR-P"S<H[BVM^Z258\"K,ZK@
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MCS2)8<M!1;A5#>U^!(_YMSS^/:1Q^NA_X7)_QZ+_ #=/J?TF_P!.G^!^C_\
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M715>,1LJU6I#5U*W E?V]"SFO>;G94CD@"%6)5BP)H: KP(XY_9U3]_P]O\
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M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I5T?_ !X^XO\
MPZ]F?^X>>]I7_MT_TDG_ !Z+I]?[)O\ 3)_@?JE#_A/AN_,]F?&7Y)=K;E>
M[B["^9_:.XLO!1B7[>&?.8/:^7J(Z45$U1.E/]YE:ID1YY&&HLSN[.[%OM6/
M\0D/_#V'[(XS_EZ5<['_ !I!_P *!_:S_P";J^SW)G0.Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)S_,$[?[%Z"^&?R"[
MEZDW&VT>R>O-CG<6SMRIBZ+-&BK:>LI%2<4N1IJRAG*J[66:FD3F^FX!!!S3
M<O9[?/)&:,L9H: \:#@01P/IT:;+"L]W$CBH+BHJ1\_*AZV5/Y9G:_8'>W\N
M_P"$/=/;&XYMW]G=K_%GH[L'L#=510TN,?(YC=NW:"NR%:]-0P4M' U3532N
M8X*:*)-6F.-% 48K=39T>+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UIH?\*N?^/N^$7_
M (;G?O\ [D[1]SO[+_#>?;!_@FZ!W-?&+_;_ //O6HM[G'H(=?7UV=_QZ.UO
M_#<PG_N-%[P:D^(_:?\ #U+XX=*/W3K?59_\WC_L@_M7_M>=:?\ O1XSW(/M
M=_R6H/\ 2S?]6GZ"W.?_ "3I/MC_ .KB]:;_ +ROZA#KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z.;_+^W+TAM#Y7]6[B^0(HH]@XRNR%1!D,Q'YL=199*:0XBMR
M*:'O24]<(FU$:(IO%/,1#%(?81YYM[R[VR:.QKXA J%^-HZ]X7YD>7$BH&2.
MC[EJ6W@O(VN::!6A/PAJ=I/R!_8:'@.MO*7Y=?$6MII()OD_\=WIZN!XI8V[
MLVY"2DZD,"/XFKJ2I(_!'^!]XN#E;=%-19W6/^7>7_H#J9CO5D?]'A_YRI_T
M%T6%MO\ \HEV9WJO@4[NQ9F;=.R&)+<DDFLN23[$0EYH'EN7^\W/^;HJ*;,?
M^4/]L7^?IBW'M3^3S5X3)19*K^$<=#]I.U2^W-Y;8I*X)H(;[9L57+D/-8G2
M("9-5M U6]NP7'-2."HW&M134DQ7\]:Z:?;CJDD6RLIK])3Y-&#^6DU_9UKC
M_'/Y2U/P^^2N8[*ZA^\W#UI)G=Q;=JMM9>1J)\UM6IK6:ECG+*6ILA'#%2U$
M,NC5%4)I=7A>:*2?-^Y:_K5MRV]U19@J,'&1',%S2G%2201YC(R 1&.V;O\
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M>JJX?@0:$@T\B/+J9[;ZMU[W[KW7O?NO=>]^Z]U[W[KW6FA_PJY_X^[X1?\
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M%716!'O&O<MKN-GF:"ZC>*1>*N*'[1Z@^1%0>(/4QVE[%?QB6%U=#P934?\
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M !)EKJ-ZNE3Z>J<$FP]B;E#=_P!S7\<C&B-^G)_I'ID_8:-^711OEC^\+9D
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MCW@OU,'7O?NO=:KW\R7Y6#Y!=O-M#:.3%5U5U;45F(P,M++KAR>3)T9'+ @
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M01[PP(IUD3UW[UU[KWOW7NJK?YH?_'N]0?\ :ZW?_P!:*#W(WMY_:3?Z5/\
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M#T5=9(89JB:*GIXI)YYY$A@@A0RN[RD*J(J@LS,Q   N3P/>F8("2: 9).
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MWXR]A=&9?=W961IIMT1UF=BS=?/O"7 O@HJ,,('2".HAIR&@"U >I@G1F)4
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MU#QN"K $>\+MVVFXV.X>UND*2(:,I_D0>!!&01@CK(RQOHMRB6:%@R,*@C_
M?0C@0<@]+OV6]*^O>_=>ZTT/^%7/_'W?"+_PW._?_<G:/N=_9?X;S[8/\$W0
M.YKXQ?[?_GWK46]SCT$.OKZ[._X]':W_ (;F$_\ <:+W@U)\1^T_X>I?'#I1
M^Z=;ZK/_ )O'_9!_:O\ VO.M/_>CQGN0?:[_ )+4'^EF_P"K3]!;G/\ Y)TG
MVQ_]7%ZTW_>5_4(=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW5]O\AO_ )F;\@?_  Q-G_\ NPJ?<)>]7]A:_P#-23_C
MJ]2-[>?VDW^E3_"W6S'[Q\ZE+KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I!]F=:[/[>V/N#KS?>*CR^VMR43
MTE;3M99(V'JAJ::0JQAJJ:4))#(!=)%4V(N"LV^_EVN99X6TNAJ#Z^H/J",$
M>8Z3W5LEY&8Y!56%#_J]1Y=:J_RG^*F_OB_O:7#Y^FFR>RLO65C;&WM @:GK
MZ>(ZA%-IXILA C*)X&"FX+Q:X2DAR1Y;YEAYBAU(:2*!XD?FI]1ZJ?(_D:''
M43;OM$FU/1LH3VMY$>A]#\OV=%;]B/HHZ][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I8;"V#O#L_=>'V/L/ UVY=T9
MVH^WQN*H%!9BH+.[NY6*&&) SR2R.L<: N[*H)]I;V^BVZ)IIF"(HJ2?]523
MY 9/3]M;/=N(XP68\ .MI#X:_$G;WQ;V%]O.:/,=F[G@I9]][HA!=-45VCQU
M SJKICZ0L>2JO427FD"CQ10XY\U\S2<QSURL25$:?\_-_2/\A@>9,K[+LZ[3
M'3B[?&W^0?(?SX]'(]A7HZZ][]U[KWOW7NM*G_A5=_S.'X@_^(U[/_\ =IC/
M<^>S']E=?Z>+_ _0,YK^*/[&_P *]:GON;.@EU]ACW@OU,'5(_\ ,"_EW]I]
MK[UW%WOU9N>LW[F,C340RG6^?GAHZFG@Q4"PI%@:C]FED@1$U"DE6*4N9)%G
MJ9YM!R$]LO=*SV6W3;;R,0JI.F= 2K%C6LHR:^6L5%*#2JBO44<Z<DW&Y2M>
M6[F1B!6)B 0 *=AP*?T33-34DTZH)S&&S&W<I7X/<&*R6#S6+J9*/)X?,4,N
M,JJ::$V>*>GG5)89%/U5T##\CWDO!<1W2"2)E=&%592&5AZ@@D$?9U#4L+P,
M4=2K T*L""#\P<CIM]N]-]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6R[_)^W^=Q
M_'/<FQZB8/5]<]@Y**EAUABE!NN&*NA.GZJ'KOXG_@;&QO>V)/OGMGTFZI<
M8GA4D^KQDH?^,Z.IZ]L[SQ[!HCQBD8#_ $K@,/YENK8_<*]2-U[W[KW55O\
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M/$'_ %<?0^75 OR=_E>=B==S9'=G1GWW9>R%,E2^UR%DW#0)<DHD**B9>).
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MOR#8I<3R3, 3&JZ:^3,3G[:*:='7,]RT4:QJ::R:_,+3'\QT4+^75N+(8KY
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M.J;M/]-?H_IHK]F0?Y=70 *Q5P%)TD*XL>'L38_T-A_KV'N*.AMU2_T+O/\
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M^ON2.9H!:[2\0X(D*C_:O&/\G02V>7Q[Y7/XFD;]JN>C)_S2O^:%_P#E3?\
MY7O9![=?\2/^;7_67HSYK_T+_;_\^=%E^ '_ &4SM3_M1[O_ /==/[$'.O\
MR3W_ -,G_'AT5\N_[E+]C?X.C"_S1/\ B]].?]JK>O\ UNQOLC]N_@G^V/\
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MMJF2@K,W6IC:=WH:C6\?GE*Q+(4:ZJS@O8A;D6]K_<O:[C<K>'Z>-I-,AU!
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MOL,>\%^I@Z][]U[KWOW7NO>_=>Z2V]]Y[<ZZVAN3?6[LC'B=L[3PU=G<WD)
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M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JJW^:'_Q[O4'_ &NMW_\
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M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK-_F6_"_Y1_S!,!\<?BM\?\
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M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K30_X5<_\?=\(O\
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MOW7NL4\$%5!-2U4,5335,4D%13SQB9)$F!5T=&!5D9200000;'CWL$J:C!'
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M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K2I_X57?\SA^(/\
MXC7L_P#]VF,]SY[,?V5U_IXO\#] SFOXH_L;_"O6I[[FSH)=?88]X+]3!U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW0,[P^._1^_:R7([KZPVEDLE4.9*G)QXT8RIE8F^J:HI#!-*U_
MR[L;<?0^S6UWR[LAICE< <!6H'V U'2*;;H+@U=%)]:4/[13I$_[)I\9?^?3
M87_SYY+_ .K?:O\ K5N'^_F_8O\ T#TQ^Y;7_?8_:?\ /U[_ &33XR_\^FPO
M_GSR7_U;[]_6K</]_-^Q?^@>O?N6U_WV/VG_ #]>_P!DT^,O_/IL+_Y\\E_]
M6^_?UJW#_?S?L7_H'KW[EM?]]C]I_P _7O\ 9-/C+_SZ;"_^?/)?_5OOW]:M
MP_W\W[%_Z!Z]^Y;7_?8_:?\ /U[_ &33XR_\^FPO_GSR7_U;[]_6K</]_-^Q
M?^@>O?N6U_WV/VG_ #]>_P!DT^,O_/IL+_Y\\E_]6^_?UJW#_?S?L7_H'KW[
MEM?]]C]I_P _7O\ 9-/C+_SZ;"_^?/)?_5OOW]:MP_W\W[%_Z!Z]^Y;7_?8_
M:?\ /U[_ &33XR_\^FPO_GSR7_U;[]_6K</]_-^Q?^@>O?N6U_WV/VG_ #]>
M_P!DT^,O_/IL+_Y\\E_]6^_?UJW#_?S?L7_H'KW[EM?]]C]I_P _7O\ 9-/C
M+_SZ;"_^?/)?_5OOW]:MP_W\W[%_Z!Z]^Y;7_?8_:?\ /U[_ &33XR_\^FPO
M_GSR7_U;[]_6K</]_-^Q?^@>O?N6U_WV/VG_ #]>_P!DT^,O_/IL+_Y\\E_]
M6^_?UJW#_?S?L7_H'KW[EM?]]C]I_P _7O\ 9-/C+_SZ;"_^?/)?_5OOW]:M
MP_W\W[%_Z!Z]^Y;7_?8_:?\ /U[_ &33XR_\^FPO_GSR7_U;[]_6K</]_-^Q
M?^@>O?N6U_WV/VG_ #]>_P!DT^,O_/IL+_Y\\E_]6^_?UJW#_?S?L7_H'KW[
MEM?]]C]I_P _7O\ 9-/C+_SZ;"_^?/)?_5OOW]:MP_W\W[%_Z!Z]^Y;7_?8_
M:?\ /U[_ &33XR_\^FPO_GSR7_U;[]_6K</]_-^Q?^@>O?N6U_WV/VG_ #]>
M_P!DT^,O_/IL+_Y\\E_]6^_?UJW#_?S?L7_H'KW[EM?]]C]I_P _7O\ 9-/C
M+_SZ;"_^?/)?_5OOW]:MP_W\W[%_Z!Z]^Y;7_?8_:?\ /U[_ &33XR_\^FPO
M_GSR7_U;[]_6K</]_-^Q?^@>O?N6U_WV/VG_ #]>_P!DT^,O_/IL+_Y\\E_]
M6^_?UJW#_?S?L7_H'KW[EM?]]C]I_P _7O\ 9-/C+_SZ;"_^?/)?_5OOW]:M
MP_W\W[%_Z!Z]^Y;7_?8_:?\ /U[_ &33XR_\^FPO_GSR7_U;[]_6K</]_-^Q
M?^@>O?N6U_WV/VG_ #]>_P!DT^,O_/IL+_Y\\E_]6^_?UJW#_?S?L7_H'KW[
MEM?]]C]I_P _7O\ 9-/C+_SZ;"_^?/)?_5OOW]:MP_W\W[%_Z!Z]^Y;7_?8_
M:?\ /U[_ &33XR_\^FPO_GSR7_U;[]_6K</]_-^Q?^@>O?N6U_WV/VG_ #]>
M_P!DT^,O_/IL+_Y\\E_]6^_?UJW#_?S?L7_H'KW[EM?]]C]I_P _7O\ 9-/C
M+_SZ;"_^?/)?_5OOW]:MP_W\W[%_Z!Z]^Y;7_?8_:?\ /U[_ &33XR_\^FPO
M_GSR7_U;[]_6K</]_-^Q?^@>O?N6U_WV/VG_ #]>_P!DT^,O_/IL+_Y\\E_]
M6^_?UJW#_?S?L7_H'KW[EM?]]C]I_P _7O\ 9-/C+_SZ;"_^?/)?_5OOW]:M
MP_W\W[%_Z!Z]^Y;7_?8_:?\ /U[_ &33XR_\^FPO_GSR7_U;[]_6K</]_-^Q
M?^@>O?N6U_WV/VG_ #]>_P!DT^,O_/IL+_Y\\E_]6^_?UJW#_?S?L7_H'KW[
MEM?]]C]I_P _7O\ 9-/C+_SZ;"_^?/)?_5OOW]:MP_W\W[%_Z!Z]^Y;7_?8_
M:?\ /U[_ &33XR_\^FPO_GSR7_U;[]_6K</]_-^Q?^@>O?N6U_WV/VG_ #]>
M_P!DT^,O_/IL+_Y\\E_]6^_?UJW#_?S?L7_H'KW[EM?]]C]I_P _7O\ 9-/C
M+_SZ;"_^?/)?_5OOW]:MP_W\W[%_Z!Z]^Y;7_?8_:?\ /U[_ &33XR_\^FPO
M_GSR7_U;[]_6K</]_-^Q?^@>O?N6U_WV/VG_ #]*3;?Q@^/VTZR/(83J;:$=
M;%()8*C(T!SK1L+6:/[YZGQL+"Q6Q!Y%B3[8GYAO;D:7F>GF =-?]YIT[%M=
MO":K&M?F*_X:]#NJJJA5 55 5546  ^@ _ 'LFZ7]=^_=>Z][]U[KWOW7NJH
M_P"8A_)6_E\?S-Z.LR7R.Z9IJ#MF3&1XS%?(/J^>/8N]J1:2GDIZ02Y6*":G
MS4%"DA^WI<Q0Y&CB(713BP]^Z]T'7Q._DP]>_%/HG&=+T/R,[R[8K,/N+<V4
MHM^=IY"'<59]EEJ@M08XPNQ6*+&4:P4ZBFFIZ>1D>=:6%Y77V/=B]P;O98O!
M*K*H)(+L^L5\JZB*#R%.@QN?*T&XOX@)1J4[0NG[:4&?4UZKF^;/P#_G6T7=
MT]-\"L[\0-P="Q[6P!CRG>KUVW,V^8?S-D52FHFKT%"BFF6)GF#LXE.@)H),
M;SW2O97K!''&M!VM60U\S7L_93\^DEOR7;HM)&9C7B.P4^SN_P /1K/@A_+T
M^>&1ZBW'/_,,W_TCM?NA.Q\O%MC']"8*JW3AWVNN,PYHIJFHJZW'R)DFRS9M
M9(Q"RB!*=@Y+E556/NM/"A%Q LC5J&5_# 6@Q31)FM36OG2F,LW/)$;M6*0H
M*<&76:YS74O[*?GT7#YW_P O[^<ACNW=N0?R\]S_ !(W1TN_7&(EW/D.^XLA
MM;,)NALGF!6PTU/229"-\:N)7"-'(9E8SO4*4 0,R:^]TKR9P;>..-:4*L3(
M2U3FM(\4H*4\JUSAVVY*@1:2NSFO%>P4QBG=^VOY=#M\"?Y>W\PO);#WO)_,
M3WWT1M;L6/=T";#I>@L-4[JQLN%-'"7DK9:NLQTL5<*[[@:!$R>(1D-<L _8
M^ZMQ"I%Q"LAK@J_A #TIHDK]M1]G3=SR3%(1X4A04R&774_;J7_!T&_S\_E]
M_P UO&[AZX3^7+N_XQ[JVY+AL^W:,WR"HJW:<T-<L].,:N+2CGR)FB:#[HSE
MVCTL(PH:[6;O_=.ZF(^GB2("NH.?%J?*G;'3^?5K;DJ&,'Q79_32-%/YM7^7
M4[X ?R^OYIF2R':(_F/;Q^-&U,?#1[0/4;_'N@K=V//,[Y+^-C+"LJ,;X%C0
M8O[8H9-9:?5ITKJW8>ZEU#J^HB26M-.AO"IQK7MDK7'I3Y]>N>289*>$[)QK
MJ&NO\UI_/I4_/K^7O_,=QNV.O&_ES[XZ W5NZ7/9I>RH>_\ $U6U**'&K3Q&
MB:@DI*O(RS5351D#J411&+EB=(]VOO=6XF ^GA6(@Y+-XH(^S3'3]IZK;<DQ
M1D^+(SCRTKHI_P ::O0<? C^7Y_-MR6]M]1_S%=V?%S:VQ(]JT;]>57Q_I:W
M==7+EC5H*B/(Q5DV.\5.*/48V1WNX(91Z3[;L?=.[A8FXB204P%/A4/J322O
MV8ZO<\E02 >$[(:Y+#74?M6G0R_/+^7K\_,=UCM.;^7AOWHW=/;#[\IH]XT7
M?F$J=JXJ/;IQ]>9I:2>DK<C+)D!DAC55#"JF%IF+@JJL]?>ZL\R@6\"QM7)9
M_$!%#BFB.F?.OY=-VW)$49)ED+BF JZ*'[=3?LIT7#X,_P O_P#G.9'N3)0?
MS MR_$3;'2 V'FI,3D>B$R&Z,RVXEK,<*"*:FJWQ\:X]J(Y,R.)RRRK  A#,
M53V7NE>1/6>..1:'M6L9KC-:/\\4_/IZXY*MW6D3LAKQ/>*?9V_MKT;GYL?R
M\OF;C^DIZCX']B=2[E[[_O5@$I<;W7MR;;6"_A+>;^)22U5/D*^85" 0^%5I
MSJ8\LJ@^U5Y[K32I2"!8VJ.YI/$%/,:="?MKTQ;\D1HU9)2R^@70:_;J;_!T
M0OXD? /^?!6_(3K^E^9N;^$> ^-<O]Z_])&6ZAJ,IN#<46C"9)L/_#Z2H%%#
M-Y,^,6D^JI333-,XU,H1D-I[HWT<@:9(W3-54%"<&G=WTH:'@:\/.O2F?DNV
M=2(V=6Q1B0P&?3MKCY]6._+?^7?\H*+X]]@57PR[+ZVS_P E(O[J?Z-\3V]M
M6?;^W9=>;QJYC^(5=/DJV:'QX Y1X--,^JI6%#I5BZF-W[KRR1E8;<(^*,TF
ML#(KV^&E:BHXBG'RITD@Y'1&!DE++FJA-)./74U,_+JLCXS? 7^?W5][=<4_
MRMR_P:PWQZES-0O9^4ZLK,GF\_#0_:5!B;&TM2E)#-+]Z*4.&J$M$9"I+  E
MMM[H7Z.#*L;H#W*H*$CY-5J?L/2R;DRV92$9U;R).H#\NVO[>K9?D#_+K[KI
M>E.S:CXX=I[1RW>\6T<J_5&-W]LU\3A9LT$_R*/*5,>6J)(*%I/\ZZ02.$OI
M4M8>S2?W8=T(CM@K$=K&74 ?4CPEK]E1]O2*+D=58%YBPKD!*$C[=9I^P]4V
M=.? C_A1A/V[U7!W?7_R_P#'=+S=C['B[>R&S,IE\CF(-KR9.E&?FQ-/+#!'
M/DHL2:MJ6-YHU><(K.@)8%$/N?N"NI=8F4$%E"E2RUR :FA(Q6AIQH>ETG)E
MJ5(4N#0T)((!\C2@K]E1]O5UO<?\NGM"#J+M2?I#M?;61[HAZXWQ+U#C]Y[)
M?'8>?=$>,JC@(<M419>>2#&RY84BU4B0R,D!=E1R I.9O=EF1@EL%8@A6,VH
M*U,$CPA4 YI45X5'2"/D8!@6FJ*BH$="1YBNLT^VA^SJBG:WP,_X4N/N?;B[
MQJ/Y=T.T6SV(7=,V#S>7GK4QIJ(Q7-1QRTR1/5+2^4Q*[JIDTAF N?9(ON=N
M((J(B*Y 0@D?;J-/V'HQ;DVT(P7KY=P/^0=;".0_ERUHQ]<<=W#&^0%'4F@2
M;K_0AF"-X@Q.;-E+Z;FQL/9\?=KTM?\ JO\ ]<>BL<B_\/\ ^J?_ %TZUT/]
MD-_X5 ?ZO^6U_P"A!FO_ *D]A_\ US=R_P"$_P"\'_H+HU_J;9_\,_WH?] ]
M;%^/_ERUIQ]"<CW#&F0-'3&O2'K_ %H)BB^4*1FQ=0^JQL+CV(![M>MK_P!5
M_P#KCT5'D7_A_P#U3_ZZ=:]VZ?@9_P *7$W/N-=G5'\NZ;:*Y[+KM:;.9O+P
M5KXT5$@H6K(XJ9XDJFI?$951V42:@K$6/LA;W.W$DT$0%< H20/MU"O[!T:+
MR;: 9+U\^X#_ "'J_/8O\NC=LNR=G2;^[<QU+ON3:NWGWK2XC8GW5)'EGI(3
MDHZ67^-)Y*=*SS"-M"ZD"G2+V]GJ>[1"@-:U-!4^-2I]:>":?9T6-R,"32:@
MK@>'6@_YR=45=I_ G_A1Y#V=V-#U%6_R^J[J>+?F[X^L*W=N6RU#E9MNID*@
M867)P10310Y"3&BF:I1)G5)BZJ[ !B1R^Y^XLQ*"(*2=(*EB!7 )J*T'G05]
M!T9)R;:  ,7)H*D,!4_90T^RO5UG1W\NKMVHZ;ZNG[^[5VMC.[YMA[7D[;QV
MQ]EOD\-!N)Z.(Y>+%5,F7IY)\>E;YA3N\$;-$%+(I) .8/=ET11);!F &IA-
MI!/F0/":GV5-/7HODY&5F)68@5P#'4@?;K%?MH.JC/DS\!?Y_=)WMV/3_%++
M_!K,_'J+,TZ]893M.LR>$S\U#]I3F5LE2TR5<,,OWIJ@@6H>\0C+$,2 57/N
MA?NY,2QHA/:K N0/FU5K^P=+H>3+95 =G9O,@Z0?R[J?MZLW^)'\N_Y05OQ[
MZ_JOF;V7UM@/DI+_ 'K_ -)&)ZAVK/N#;L6C-Y)</_#ZNHR5%--Y, ,6\^JF
M334M,@U*H=C*T]UY8XPLUN'?-6630#DT[?#>E!0<37CYTZ1S\CH[$QRE5Q12
MFHC'KJ6N?EU7%\M_@'_/@HOD)V!2_#+-_"//_&N+^ZG^C?+=O5&4V_N*77A,
M:V8_B%)3BMAA\>?.42#34OJIEA<Z68HI==^Z-])(6A2-$Q16!<C KW=E:FIX
M"G#RKTK@Y+MD4"1G9LU8$*#GT[J8^?5@GPT_EX_+NOZ)P51\XNQ^K-N_(5LS
MN1=Q8OIK;,VX\ M"E6XQ;4M549&AF>5Z+Q&8-3KIEU@%ETDK[/W7EB0">W61
MZFK+)X8IY=OAO_ASTEN.2$=JQRE5]"FH_MU+_@Z)3\V_@!_.KQ_=?V_P)W'\
M/MR]$?W1P+G)=YC(;9S7\:9ZG^(QK34C5\?V*1BD\3M/K9S)=0H4E'>^Z5Y*
M]8(XXUH.UJR&OK7L_93\^E%OR7;HM)69C7B.P4^SN_P]&H^"'\O3YX9'J+<<
M_P#,,W_TCM?NA.Q\O%MC']"8*JW3AWVNN,PYHIJFHJZW'R)DFRS9M9(Q"RB!
M*=@Y+E556/NM/"A%Q LC5J&5_# 6@Q31)FM36OG2F,LW/)$;M6*0H*<&76:Y
MS74O[*?GT!WSW_E^?S;<;O;8L?\ +JW9\7-T[$DVK6/V'5?("EK=J5<66%6X
MIX\=%1S9'RTYH])D9W2SD!5/J/MB^]T[N9@;>)(Q3(8^+4^H-(Z?9GIRVY*@
MC!\5V<UP5&B@_:U>A'^ O\O?^8[DML=AM_,8WQT!M7=T6>PJ]:P] 8FJW713
M8UJ>4UK5\E75XZ6&J6J$810CJ8S<,#J'MRQ]U;B$'ZB%923@JWA #[-,E?VC
MJESR3%(1X4C(//4NNO\ QI:=);Y__P OK^:9C<AU</Y<.\?C1NO'S4>[SVX_
MR$H*W:;P3(^-_@@Q(HZC)>=9$.4^Y+F/05@TZM3::W_NI=3:?IXDBI75K;Q:
M\*4[8Z4SZU^75K;DF&.OBNS\*:1HI_-J_P NO? #^7U_-,R60[1'\Q[>/QHV
MICX:/:!ZC?X]T%;NQYYG?)?QL985E1C? L:#%_;%#)K+3ZM.E=7K#W4NH=7U
M$22UIIT-X5.-:]LE:X]*?/KUSR3#)3PG9.-=0UU_FM/Y]*GY]?R]_P"8[C=L
M=>-_+GWQT!NK=TN>S2]E0]_XFJVI10XU:>(T34$E)5Y&6:J:J,@=2B*(Q<L3
MI'NU][JW$P'T\*Q$')9O%!'V:8Z?M/5;;DF*,GQ9&<>6E=%/^--7H&O@A_+^
M_G(9'MW<<'\PS<_Q(VOTNG7&7EVQD.A(LANG,/NA<GAQ10U-/5R8^-,:V);-
MM)()F83I3J$(<LK-C[I7D+DW$<<BTH%4F,AJC-:28I44IYUKC+ESR5 ZTB=D
M->+=XIG%.W]M?RZ.#\U/Y,V^/DQTOB^LNH?FYV7\9-VR;XP>4W/V5L;:HEEJ
ML#!2UL&3PZ4E/E\?6(];)/321RIFH?"T(\@G0O$Z/??<6ZW:/PX5^G%:DH[%
MR*$4U +C.:"N/3'2C;>4X+%M<A\4TI1E&D'&:9S^?2Q_EC_R'_A;_*\W;F>X
M>L*WM?MCY([MPF;V_O+OWM[?,^2R=;2;FJH:[(TD>,QXH<-'35=;34\SM/1U
M58TD4;R5DCJ&]Q\SER68DDFI)R23G/0J"A108 X#TZNK]UZWU[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=::'_"KG_C[OA%_X;G?O_N3M'W._LO\ #>?;
M!_@FZ!W-?&+_ &__ #[UJ+>YQZ"'7U]=G?\ 'H[6_P##<PG_ +C1>\&I/B/V
MG_#U+XX=*/W3K?7O?NO=>]^Z]U[W[KW0*]X?';IGY';7_NEW'L3#[QQL/E?&
M5=2C4=?023 :IL?D*=HJRBD.E=7BF59 H259$NI-MGWV[V&3Q;21HV\P,JP]
M&4U!'VC'E0](;_;8-S31.@8>5>(^PC(_+JB+O7^1?N.DJ*O+?'3M3'9G'LTL
ML.S>THVQ=7&H)(CAS&/IY::K<@@ 2XZD46NTIOQ-&S>\J, M_"0?]^0Y!^U&
M((_)C]G4?;A[?L"6M9 1_#)@_P"]*#7]@^WJL_?7\N7YL]?2U"9?X\[[S$4$
MC*M3L6G@[#25=5EDC7!SU\Q5P00&B5U'ZT4A@)"LN?\ 9[ZFFZC4GRDK%3[3
M(%'\Z=!6XY7O[:M86/S2CU_WDD_RZ!>3XQ_).)WBE^/?>,<D;M')')U/GD96
M0V*L#CP0018@_3V;CF/;C_Q*MO\ G/%_T%T@_=%W_OF7_G&_^;KA_LLWR0_[
MQ^[N_P#14Y[_ .H/?OZQ[?\ \I5O_P YXO\ H+KW[INO]\R_\XW_ ,W7O]EF
M^2'_ 'C]W=_Z*G/?_4'OW]8]O_Y2K?\ YSQ?]!=>_=-U_OF7_G&_^;KW^RS?
M)#_O'[N[_P!%3GO_ *@]^_K'M_\ RE6__.>+_H+KW[INO]\R_P#.-_\ -U[_
M &6;Y(?]X_=W?^BISW_U![]_6/;_ /E*M_\ G/%_T%U[]TW7^^9?^<;_ .;K
MW^RS?)#_ +Q^[N_]%3GO_J#W[^L>W_\ *5;_ /.>+_H+KW[INO\ ?,O_ #C?
M_-U[_99ODA_WC]W=_P"BISW_ -0>_?UCV_\ Y2K?_G/%_P!!=>_=-U_OF7_G
M&_\ FZ]_LLWR0_[Q^[N_]%3GO_J#W[^L>W_\I5O_ ,YXO^@NO?NFZ_WS+_SC
M?_-U[_99ODA_WC]W=_Z*G/?_ %![]_6/;_\ E*M_^<\7_077OW3=?[YE_P"<
M;_YNO?[+-\D/^\?N[O\ T5.>_P#J#W[^L>W_ /*5;_\ .>+_ *"Z]^Z;K_?,
MO_.-_P#-U[_99ODA_P!X_=W?^BISW_U![]_6/;_^4JW_ .<\7_077OW3=?[Y
ME_YQO_FZ]_LLWR0_[Q^[N_\ 14Y[_P"H/?OZQ[?_ ,I5O_SGB_Z"Z]^Z;K_?
M,O\ SC?_ #=>_P!EF^2'_>/W=W_HJ<]_]0>_?UCV_P#Y2K?_ )SQ?]!=>_=-
MU_OF7_G&_P#FZ]_LLWR0_P"\?N[O_14Y[_Z@]^_K'M__ "E6_P#SGB_Z"Z]^
MZ;K_ 'S+_P XW_S=>_V6;Y(?]X_=W?\ HJ<]_P#4'OW]8]O_ .4JW_YSQ?\
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M;S[8/\$W0.YKXQ?[?_GWK46]SCT$.OKZ[._X]':W_AN83_W&B]X-2?$?M/\
MAZE\<.E'[IUOKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K2I_P"%5W_,X?B#_P"(U[/_ /=I
MC/<^>S']E=?Z>+_ _0,YK^*/[&_PKUJ>^YLZ"77V&/>"_4P=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6FA_P *N?\ C[OA
M%_X;G?O_ +D[1]SO[+_#>?;!_@FZ!W-?&+_;_P#/O6HM[G'H(=?7UV=_QZ.U
MO_#<PG_N-%[P:D^(_:?\/4OCATH_=.M]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:5/_"J[
M_F</Q!_\1KV?_P"[3&>Y\]F/[*Z_T\7^!^@9S7\4?V-_A7K4]]S9T$NOL,>\
M%^I@Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NM-#_A5S_Q]WPB_\-SOW_W)VC[G?V7^&\^V#_!-T#N:^,7^W_Y]ZU%O<X]!
M#KZ^NSO^/1VM_P"&YA/_ '&B]X-2?$?M/^'J7QPZ4?NG6^O>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NM*G_A5=_S.'X@_P#B->S_ /W:8SW/GLQ_977^GB_P/T#.:_BC^QO\
M*]:GON;.@EU]ACW@OU,'7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]UIH?\*N?^/N^$7_ (;G?O\ [D[1]SO[+_#>?;!_@FZ!
MW-?&+_;_ //O6HM[G'H(=?7UV=_QZ.UO_#<PG_N-%[P:D^(_:?\ #U+XX=*/
MW3K?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW6E3_P *KO\ F</Q!_\ $:]G_P#NTQGN?/9C
M^RNO]/%_@?H&<U_%']C?X5ZU/?<V=!+K[#'O!?J8.O>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K30_X5<_\ 'W?"+_PW._?_
M ')VC[G?V7^&\^V#_!-T#N:^,7^W_P"?>M1;W./00Z^OKL[_ (]':W_AN83_
M -QHO>#4GQ'[3_AZE\<.E'[IUOKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K2I_X57?\SA^(
M/_B->S__ ':8SW/GLQ_977^GB_P/T#.:_BC^QO\ "O6I[[FSH)=?88]X+]3!
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=::
M'_"KG_C[OA%_X;G?O_N3M'W._LO\-Y]L'^";H'<U\8O]O_S[UJ+>YQZ"'7U]
M=G?\>CM;_P -S"?^XT7O!J3XC]I_P]2^.'2C]TZWU[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]UI4_P#"J[_F</Q!_P#$:]G_ /NTQGN?/9C^RNO]/%_@?H&<U_%']C?X5ZU/
M?<V=!+K[#'O!?J8.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[K30_P"%7/\ Q]WPB_\ #<[]_P#<G:/N=_9?X;S[8/\ !-T#
MN:^,7^W_ .?>M1;W./00Z^OKL[_CT=K?^&YA/_<:+W@U)\1^T_X>I?'#I1^Z
M=;Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>ZTJ?^%5W_ #.'X@_^(U[/_P#=IC/<^>S']E=?
MZ>+_  /T#.:_BC^QO\*]:GON;.@EU]ACW@OU,'7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UIH?\*N?^/N^$7_AN=^_^Y.T?
M<[^R_P -Y]L'^";H'<U\8O\ ;_\ /O6HM[G'H(=?7UV=_P >CM;_ ,-S"?\
MN-%[P:D^(_:?\/4OCATH_=.M]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:5/_"J[_F</Q!_
M\1KV?_[M,9[GSV8_LKK_ $\7^!^@9S7\4?V-_A7K4]]S9T$NOL,>\%^I@Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM-#_A
M5S_Q]WPB_P##<[]_]R=H^YW]E_AO/M@_P3= [FOC%_M_^?>M1;W./00Z^OKL
M[_CT=K?^&YA/_<:+W@U)\1^T_P"'J7QPZ4?NG6^O>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MM*G_ (57?\SA^(/_ (C7L_\ ]VF,]SY[,?V5U_IXO\#] SFOXH_L;_"O6I[[
MFSH)=?88]X+]3!U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=::'_  JY_P"/N^$7_AN=^_\ N3M'W._LO\-Y]L'^";H'<U\8
MO]O_ ,^]:BWN<>@AT(R=P]N1JJ)VEV,B(H1$3>^34 *+  "JL ![0':[4_Z#
M%_SC3_-T_P#52?QM_O1_S]<O],G;W_/U>R/_ $.<G_\ 57OW[JM?]\Q?\XT_
MS=>^JE_C;_>C_GZ]_ID[>_Y^KV1_Z'.3_P#JKW[]U6O^^8O^<:?YNO?52_QM
M_O1_S]>_TR=O?\_5[(_]#G)__57OW[JM?]\Q?\XT_P W7OJI?XV_WH_Y^O?Z
M9.WO^?J]D?\ H<Y/_P"JO?OW5:_[YB_YQI_FZ]]5+_&W^]'_ #]>_P!,G;W_
M #]7LC_T.<G_ /57OW[JM?\ ?,7_ #C3_-U[ZJ7^-O\ >C_GZ]_ID[>_Y^KV
M1_Z'.3_^JO?OW5:_[YB_YQI_FZ]]5+_&W^]'_/U[_3)V]_S]7LC_ -#G)_\
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MM[_GZO9'_H<Y/_ZJ]^_=5K_OF+_G&G^;KWU4O\;?[T?\_7O],G;W_/U>R/\
MT.<G_P#57OW[JM?]\Q?\XT_S=>^JE_C;_>C_ )^O?Z9.WO\ GZO9'_H<Y/\
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MSD__ *J]^_=5K_OF+_G&G^;KWU4O\;?[T?\ /U[_ $R=O?\ /U>R/_0YR?\
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M1_Z'.3_^JO?OW5:_[YB_YQI_FZ]]5+_&W^]'_/U[_3)V]_S]7LC_ -#G)_\
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MM[_GZO9'_H<Y/_ZJ]^_=5K_OF+_G&G^;KWU4O\;?[T?\_7O],G;W_/U>R/\
MT.<G_P#57OW[JM?]\Q?\XT_S=>^JE_C;_>C_ )^O?Z9.WO\ GZO9'_H<Y/\
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M)CH3_P ]6X?_ *@]^_UY;;_E&E_WM/\ -U[^JK_[\7]A_P _7O\ H%>^4/\
MWDQT)_YZMP__ %![]_KRVW_*-+_O:?YNO?U5?_?B_L/^?KW_ $"O?*'_ +R8
MZ$_\]6X?_J#W[_7EMO\ E&E_WM/\W7OZJO\ [\7]A_S]>_Z!7OE#_P!Y,="?
M^>K</_U![]_KRVW_ "C2_P"]I_FZ]_55_P#?B_L/^?KW_0*]\H?^\F.A/_/5
MN'_Z@]^_UY;;_E&E_P![3_-U[^JK_P"_%_8?\_7O^@5[Y0_]Y,="?^>K</\
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M?Z\MM_RC2_[VG^;KW]57_P!^+^P_Y^O?] KWRA_[R8Z$_P#/5N'_ .H/?O\
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M )^O?] KWRA_[R8Z$_\ /5N'_P"H/?O]>6V_Y1I?][3_ #=>_JJ_^_%_8?\
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M *!7OE#_ -Y,="?^>K</_P!0>_?Z\MM_RC2_[VG^;KW]57_WXO[#_GZ]_P!
MKWRA_P"\F.A/_/5N'_Z@]^_UY;;_ )1I?][3_-U[^JK_ ._%_8?\_7O^@5[Y
M0_\ >3'0G_GJW#_]0>_?Z\MM_P HTO\ O:?YNO?U5?\ WXO[#_GZ]_T"O?*'
M_O)CH3_SU;A_^H/?O]>6V_Y1I?\ >T_S=>_JJ_\ OQ?V'_/U[_H%>^4/_>3'
M0G_GJW#_ /4'OW^O+;?\HTO^]I_FZ]_55_\ ?B_L/^?KW_0*]\H?^\F.A/\
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M_P"\F.A/_/5N'_Z@]^_UY;;_ )1I?][3_-U[^JK_ ._%_8?\_7O^@5[Y0_\
M>3'0G_GJW#_]0>_?Z\MM_P HTO\ O:?YNO?U5?\ WXO[#_GZ]_T"O?*'_O)C
MH3_SU;A_^H/?O]>6V_Y1I?\ >T_S=>_JJ_\ OQ?V'_/U[_H%>^4/_>3'0G_G
MJW#_ /4'OW^O+;?\HTO^]I_FZ]_55_\ ?B_L/^?KW_0*]\H?^\F.A/\ SU;A
M_P#J#W[_ %Y;;_E&E_WM/\W7OZJO_OQ?V'_/U[_H%>^4/_>3'0G_ )ZMP_\
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M81BSE?DZ[YK<B *J)0/(YHJDYH*5)/R QYD5Z)-YWZ#9%!EJ6;X47+&GGF@
M^W\J]4I;0_X5 8FIW+#%O[X>Y'#;/FFM45^T.Y(MRY*FCO\ J2DK=NXFEKG
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MUW=&ID+#50?D3*I/[!]@Z!+^X@#=L%1Y5DH3^00T_:>K=?@;_.#^,'SKRZ[
MPHS74O=#0U%12]8;]FIW;)QT40FGDP63IV^UR8ACUEX62FK L<LHI3!&TOL
M\T<@7W*Z^*^F6'_?L=:*2: ,"*K7URN0*UQT*-FYGMMY.A*H_P# U*D>H()!
M_P /RIT<OYA?)7;WP_\ C7VO\CMSX:KW'B^L\'05D.WJ*H-%)7UV?R%'B,71
M?<"&I^UCJLGD*.*2<T\@@C=I61@A!#VP;.^_WD5G&0ID8C4<Z552S&E16BJ3
M2N>'1IN=^NUP/.XJ$%:#S)( 'YD@5\NJF.G?^% OQOW+\8-V][=S[0RG6>^]
ML[VEV/B^F-LYV+?.1S\TU&E;356(FF@Q02C6-F2LEJ8HH:-U0&65ZBGCD'.X
M>U=Y!?+:6["5&0.9F4HJ"I4ALMFHP 22/+!H';3G.WEMC<2@H0Q70#J+&@/;
MA?7-: ?LZ)MB_P#A4#0ONQ(LU\.JNEV,]<8I*W%]TI7Y:*FU "<4LNVJ:CGG
MT MX/NX4N0OW-EUL(W]E&$=5NP7IP,)"5]*B0D#YZ3]G1.ON&NNA@.FO$."U
M/LT@5^5?SZV3?C3\D>JOEGTWM+O3IK,U&7V1NZ*K6"/(THQU=0U>-E:"LQV1
MI=<GVU=23HR2*)'C8:989)8)(I7A[>-HGV*X>UN!1TI6AJ""*@@^8(-1^PT-
M1T/K&^CW&)9HC56X>1Q@@_,=#Q[+.E?16_FC\I-N_#+XU]E?(O<V!K=UT>PJ
M/$)0[6Q]8,=+D:_<>0I<704GW+13K2Q/5UD1EF,,GBB5W$<C (QUR[LK\PWD
M=FC!3(35B*A552Q-*BN :"N3T7[IN"[5;O.PJ% P/,D@ ?M/5376/_"A+XWY
M?XO9GO+MS9&:V)V/C=]9#86(Z/VKGZ7>F0S4T%)#71U^/J)DQA@Q44-1$E94
MU5-"E/,1%$:F62&.0=7OM3>QWPM+=UD0H)#,RE%0$E:,.[NJ#0 DD9P*T#=O
MSK;O;&>52C:B@C!#,Q !J.&*$5)  ./2I6ME?\*>]JUN](Z3L+XEYS;W7T]7
MXGSFTNU8-UY:FAU@"4XVKPF(I*M]'+1C)0:3P'?Z^SVY]E95CK%=*TE/A:(H
MI/\ I@[D?[S^SHMA]PXV>CPLJ^H<,?V%5_P_MZ.]\MOY^7Q%^/V#VPO4:5?R
M8WMO#:>(WCC\+L_,1[<Q>-I,_"D])'GLK/3U4V.R+Q.&:@3&3U< %JR.E+Q:
MPSL'M=N&[LWCTMT1RA9P69BIH="@C4 ?Q:@I\B:'HXW3G*UL /#_ %690P"F
M@ (J-1/"OI0D>8Z+]\6?^%'W3O;/8F Z][]Z7R/0]+NG+T>$Q78N+WS'OO"T
ML^1;1"V:6;&XBJQE'Y"B-51BK2,N))U@ITEF0VWSV@N=OA::UF$^D%FC*&-R
M!_#1G#&F:$@^0J:#I#MO/<-W((YHS'J- VK4M3ZX4CTK0_.@SULG2RQPQR33
M2)%#$CRRRRN(U58Q=F9C8*J@$DDV ]P\!7H>=:YWRD_X4;_'7J7=&7V7\?NM
M,Y\C*W"ULF.K-[-N9.O]MR2T[R),V-JVH<I7Y2&-T 65:""FG!\E/42PZ)))
M<V/VAO-P0274BVX85":?$D\J5&I0OV%JC@0#T!MRY[M[1BD*F4C&H'2GY&A)
M^T"A\CT6':W_  J!=\U21[U^':TVW9&*5]9M;N@UM;"#8^2&FJ]MT\%218CQ
MM507OJ\HTZ6.Y_90A3X5W5O(-#13]I$C$?L/V=%T7N("PUP$#S*R5/["@K^T
M=;&OQ&^7/37S7Z;Q7=?267K:S;U76U&#SN#S=*F/RF%RM#'#-4XK*TT<L\45
M9#%4027BGEAEBECFAEDBD5C$._;#<<N7!MKD ,!4$95U)(#*:"H-#Q ((((!
M!'0ZVS<XMVB$T)J#@@X*GS!'J*_Y14=:Q?\ PIZ_YFK\3?\ Q'W9O_NRQ?N9
M_93^RN_]/%_@DZC_ -Q/C@^R3_"G5[?\IK,8G;O\L'XO9_/Y/'X3!X3JO-9;
M,9C+5D>/I:2EQ^5RLL]34SRLD4,$,2,[N[!44%F( )]Q?SPC2[S<JH))FH !
M4DD   #SZ&G+K!+"$G $8))Z*1U=_/=ZQ[O^=.S_ (H]2=.Y[>/6V]-SU.R<
M-W=#N-J2>>LI8*B9\G!MXXQG;!J:=KRRY&&84VJL>*,1F!C^^]LI]LVM[^XE
M5)$4.8=-:*2!0OJ^+/#217%>BNVYPBO+T6L2%E8D"2O$@$X6G#'&OSI3HR_\
MV7YV[ ^#W3&R,EO3HW"?(.K[.WG+@<)L'==3346)4;>@%94Y"LEJL9EHV:F+
MTZPQBCUN\NL2((VN3<C<KR\SW+I',8!&FIG4$MDT  #+Q\\\!TOYCWE-FA#L
MGB:FTA20!PK4DAO\'1I/@Y\EMF?+GXN=5=[[#VC+U_M_=.+R.,&Q)/$RX>IV
MA6U.(JZ""2"*"":CAJ*)_MI(X(@].8F:&%RT,9+S)LTFP7LMK*P=D(.L5[@R
MAP<U()#9&:&N3QZ,-IOTW.W2=!I# ]OH02I'[1CJM6/^>=U52?/_ '9\.]R]
M<C:_7&T=[[RZQRO?N8WNE!%2YG84=4F2FKL548Z"*FP\60H:NE-3_%6(1%J]
M)B<HHP;VTN/W2NXK)J=D200!*DI(1IHP8U8A@::?.G$=$*\W1&^-H5HH+*9"
MU &4&M00*"H(K7Y\.BN]^_\ "E[JW:&]*[;GQ]^/^9[>VOC*J:E??^\-['KB
M&M,'I\F.QJ8C*U;4LAN4EJ9*:4J!JI5U>D\VKV;N+F,/=SK"QSX:IXA'^F.M
M!7Y"H^?1;?<_Q0/I@C,@'%BV@'[!I8D?;3JPK^7-_. Z2_F!YC)==0;2S?3W
M=F(PE3N238&<R\6Y:+(4%$\4=1/ALQ%!1&LDI6FC:>";'TLRQMY8EGBCG>()
M\W\@7/*8$I9986;2)%!4AC4@,I)I6AH02/F#3H\V+F>'?*H 4D J4.:CU!Q6
ME?0'Y=6=]E]E[#Z=V'NCL[L[=&)V9L/9F)J,UN3<F:J/MX*:"GMR>"\DLCE8
MXHHU:6:5DBB1Y'52#+2TEOY5AA4N[D*JJ*DD_P"K\N)Z$$\Z6R%W(55%23P
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M#=232>*6U!@Q4J:U&FA&D"F * 4ZF2#;8+>(0*BZ*4TD @CYUXU\Z\>M!/\
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MV+L8Y4>JLQ(U*I<, 30'MI7T-.A5SO81/9F72 T;+0@ &C,%(^S-:>O02?\
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M_%QX4'1??^%/7_,IOB?_ .)$[)_]UN-]FOLM_N5<_P#-)/\ C_2+W"_L(O\
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M UBBJ&0MHDTJO9G=$>VGLR1K63Q@/,JZJA_WDJ*_Z8=,^X-DRRQW ^$KX9]
M5)8?M!/[.KY/Y1GR_P"MODY\-NE<+B-WX^L[4ZDZZVGUGV=L^NKHUR]/5['H
MX\9%DI:8R-++29>GI(ZJ*I4&-S(\;%)XI8HXNY\V";9-QF+(1'+(\D3 '05<
MZJ TXK6A'E3TH2-.6MS3<;2.C5=5"N"1J#**5(^=*@]4P?\ "D+Y>]6[VQO4
M?Q.V%N;%;NW9LO>]7VAV>^#R"U\&&FI\;48W$XRHDBUP-D*F+)Y":6'R"6EC
M2 R(/NDM(OL]L$]NTM_(I5'3PHZBFNK!F(\Z#0!7@230X/03Y^W..14M4(+!
MM;T_#VD 'YG433B!]HZM7_D0=#YWHS^7KL>IW-CI\3FNZMX;F[QEQU4)%D2D
MW3!08[$RLC\(*S#8?'5*!0!XYD8C66) WN=NJ[INTF@U6%5A!'JA+-^QV8?E
MZ="3D^R-E8IJ%"Y,A_VU /\ C('6IM_);_[>=?%/_P ./?G_ +R.X/<[^Y'_
M "1+G[(_^KT?49\H_P#)1A^U_P#JV_7T6_>(_4Z=:X'_  ID_P"R0NC/_%D<
M=_[S&Y/<O>S/_)1F_P">9O\ J[%T!/<#_<2/_FL/^./TH_\ A-)_V0IVQ_XM
MIOO_ -X[8?MOWD_Y*D7_ #RI_P!79^K>W_\ N&__ #6;_CD?5;?_  IN_P"R
MDOCE_P"(/RO_ +OJWV+?9;_<6Y_YJI_QSHD]P_[6'_2-_A'6R7_*Y_[=X_#W
M_P 09LS_ *TGW#W.?_)6N_\ FO)_QX]#W8/]PH/^:2?\='6E_P#S(_\ M\%W
M)_XL+UO_ .X^!]Y#\H?\JY'_ ,\\W^&3J*]]_P"2PW_-6+_ G6U%_/AZ,S7=
MO\O'?E5MO$5.<SG3&\=I=UTV/HW82_:[;6LQF7J%0,JRK183,Y*ID1KCQ0NR
M*TJQCW"?MCNB[9N\>MM*S*T))X5:C*/E5U45_;BO4A<XV1O;%](J4*R #Y8)
M_)2?^+ZHB_D0=4? KY'#MCI+Y.=6[%WCW/%FL=O'K&JW?E*O'SY+$3TBT^0Q
MN.6"OIDGFQE33)4O%XS*T=6TB:XX9?%)ONE>[IM!BN;.61(2I20)P5P206P?
MB!H#_1^RH0Y*M[.^5X9T1I =2ZN)4@ @9\B*G[>KW_D#\#_Y.WQ9ZUSG;G=G
MQ^ZEV;M' 4TTZ-79+*RU5?40H7BQ^,HCE/+D<A4D!8J>-6+$W;2@9A%^U\R[
M_O4RV]M<3.[&E 10#U)I@#S)X=#.\VC;-OC,LL4:J/,C^0'F3Y#IT_E+?(SX
MM?)WJ+N2B^,OQ=C^,^Q=K;UAPFX<-18O'T$.9FW'1.RUCU6-1/-71TD:1S))
M)*]-&U.J2M&R6ISUL]]LMQ%]=<?4.R:E8LS%0&X=_ 5K3R.?.O6^6[^VW")S
M;1>$H:A%%%20,]OG2G\NM13XL[G'\M7^:-LZK[CILA28[H#N/>W7N^:LT#/(
MF+W%0Y3;,V9C@4LTU.,;E1D8O$7,T&AH?)K35/V]Q'G+8V^FH3/$DB"N-2LL
MFFOK5-.>!XTZB_;F'+^YCQ:TCD92?Z+!E#?91M7V=;_&4^3'QYPO6;=RY/NW
MJ^FZL&%BW"F_/[ZT$V.DI*B,212PU$<[K.9E($<<>J21B$1&<A?>*R;3=23?
M3B*0RZM/AZ&U:ABE*>7GZ=36U["L?BEUT4KJU#33UKU\[+O3O>C^3?\ ,&W3
MWOC*)\?A>Q_D3A,QMVCF4I*F+ILI24>+\ZD#34MCZ:F:86L)2X''O+7;MJ.R
M;,+5C5H[9PW^F*LS4^0)('RZ@ZZO1N.X^,O!IEI_I0R@?M Z^E[[PZZGKKWO
MW7NOG>_-3;^<^#_\W+>>^<UAJZKHMF?*G;OR?VO3M&$&1Q&9W#3[QI(Z:1WT
M3*FN6B9S);SP2I(5='5<L^6YEYEY?6)" 6MFMF_HNL9BSZ>3?81U!^[QG9]U
M,C D"99A\U+!\?G4?:.M\/KOY3_'?M/JK&=U[-[BZ^K^M<EA?X\^YJK=5%C8
M:.&-=4\>2$\\;8ZIHV#I4PU CD@D5DD564CWB_=[-=6,YMI8G$@;3ITDDGRI
M09!X@C!&1U,L%]#<QB5'4H17544_/TIY^G6@?_-T^4>T/EM\Y>SNQ^NZNGRG
M7>W:/ ]:;)S]+J*9.CV7$T<V20LJEH*S(35TE.VD:J4PL>2?>5'M]L<FP[9'
M%,")'+2NIXJ7I1?M"@5^=>H5YJW)-SO&>,U50$4C\6FM3^TFGRZW'?D;TAE_
MD7_*!RO4>W<7-G-RY[XD]7YO:N$II6AEK,ML#%X7<6+I(2'0&:IR&*IHXU9Q
M&SLJR'QEO>.^R[F-GWU;ACI5;EP[4K1'9D8^?X6/S],]2ON5F;_;FB J3$"H
MX590&7T\P/\ +UJJ?R3MJ?#+LGY%;TZ3^8VP-H[GF[!VSCDZBK=\Y"IQ%/!G
M=O54GW.)CDAK*0+69:EJB8EDOKDHQ"A$TJ)).?N7/N-I:1W.WR.HC8^*(\DH
MP%&X'"D9_P!-7APC;DZ.UGG>&Z16+ :-?DRDU'VFO\NMJ/L7^67_ "F>HMFY
MWL/L[X\].;%V3MJCDK\YN;<N?RN,I:>.,$^J23*#5(Y%DC0-)(Q"1JS$ P=:
M\X;Y?2+%#<3N[&BJM"2?L ZD>;8=NMU+O%$J@5)(H .@+_E._*WX-=T]J=]=
M:?#/XG1]%XS9N&Q66KNR*7;U#CCN3'4U:]#0BMDB#Y"ED=F>HIJ6IJI2R&HE
M(CF$P)GSSL6Y[9#!-N-SXQ<L!&79O#:@)I7'H"5^0X4Z1\N;E9WCRI:0^&%I
M5@JKK%2!PSZD _Y^J"_^%#G26>Z\^?&0[7J**L_NQ\@=@[,W)B,O( 8'K]@8
MVCVUD:&)KW\M)3X[%3R*1PM9$W.KB5_:3<UN]K^GJ-4$C*1YZ9&,BD_:68?[
M7H#\]69@O/%IB50:_P!) %(_(!?V];=GP6^9'47S!^/'7W9&Q]WX*HW!#M##
M4O96SVRT9R.!S.,I(4RM)74\A2I2&*I$C05+Q+'4T[1U$9*2"T \R\OS\O7;
MP2J0-1\-J=KH2=)!R,CB*U!J#D=2AM.Z1;K LL9' :EKE6ID'_5D9&#U3M_-
MA_G?97XZ[^V[TC\-<_UYO#>6"G_BO;V_*JFBWMC*%XG*P[:I!%.M-+7'2[Y&
M19&-*IBIHV2J-1]O(/(GMJ-YB:YW 2(AQ$@[&;^F:@]O\.,Y/"E0MS+S<=N<
M0VNAF&7)[@O]'!&?7T^TXNCWEO#<W87P*W5O[>NV#LG>6^/B'G-X;MV89'F_
MA&3W+LR6MK\7KD"R-]A53RP790Q\=R ;^XXB@2UW$11MK1+D*K\-:K+0-^8%
M>A<TC36NMUTLT567CI)2I'Y''6HI_P )P/\ LO[<_P#XK=V)_P"[K;'N?_>'
M_DE)_P ],?\ U;EZBWD'_<UO^:+?\?3J_+^9?_-VPOP)[UZHZ,S_ $//V?M7
ML#96/WSV+N*ISR8V.#"YS*Y##R4N-HI**IAR>0@3&U<\T-1-!"R/30ZQYWEA
MBSD[D%^:K66Y2<1M&Y1%TU)<*'JQU#2IU  @$\33%"-=^YG79)DA:,L&&IFK
M0!2Q&!0U(H21CR]<+'>_\IK^5W\S-H8OM79/66V\'C]^X@YO;W9/QZW$^S()
MXLOJE%3%04;2[>DF61FU";$-)&X:)PNDH$UKSUO7+SF!Y7)0Z6CG7605Q2K=
MX_)AT_/RWM^ZJ) B]PJ'C.FM<U[<'\P>M1>;:&Y_@3_-&Q_7'QY[.R>[<GU=
MW]LO:.UMV8AXZ>;*TNY:C'>;#5\5+(]/4L\5=)C,A$+13RI-^U$&$:3T;E.:
MMB,]W&%\2"1V4U(5D#49:Y&5U+Y@$9/$QD(6V/<Q% Y.F5%!_B5BO::8/&A^
M8K0=;2G_  HE_P"W=\__ (G#K+_K7E/<)>TW_)87_FE+_@'4B<[_ .X#?Z=/
M\/0,?\)F_P#LD+O/_P 61R/_ +S&V_9G[S?\E&'_ )YE_P"KLO2+V_\ ]Q)/
M^:Q_XXG5"7S"PVZ?@+_-[W-V)F<;FOX=MGY.XGY+[:,,:QOEMN;JSXW$8:1V
MD2.HCDADKL9(QE53-#/%(497"RCR](G-?+RPJ5J;<VS5X+(B: 3C'!7X<"*5
MZ!NZJVQ[J9#6@E$PIQ9&;4:?S7\NM]'K3OCI[N#K'%]R==]B;5W)UIE<2F:C
MW;2YB&*EIX2NJ1:YI'3[">G.I9XJ@1R0NK)*JLI Q=O-MGL)C;S(RR T*D&M
M?EZU\B./EU,T%U'<H)(V#*14,#BG6A[_ #:>^,)\^?YB;4GQY\G8&)I:'8/Q
M[ZSR6'+U*;@K::LJ6>>@!4:J6?-9BK@IY%+1SPQI5(WCF%LH.0ML;E7:"UY^
MF29+B0'C&ND"A^>E 2.()H14=0US/=KO=^%M^X +$I'!C4Y'RJU*\#2O#K9D
M_FN]<0=._P DGL/J.EE2:EZLZN^*?7%-,CO(KQ['W?L;&(P:0F1@RTH(+$L?
MJQO?W#7(=V=PYDCN&XRR7,A^UXIF\OMZ'_,\ M=I>(<$6%1]BR1C_)U71_PE
MS_[GE_\ +9O_ )H/L8>]O_$+_J)_ZP=$'MU_Q(_YM?\ 67JT7^?3_P!NQ>\?
M_#CZ<_\ >NPWL#^U_P#R6X/LF_ZLR="3G+_DG2_;'_U<7JO[_A,+_P RF^6'
M_B1.MO\ W6Y+V*?>G_<JV_YI/_Q_HF]O?["7_FH/^.CK:,]PMU(/5.G\^G_M
MV+WC_P"''TY_[UV&]R![7_\ );@^R;_JS)T%^<O^2=+]L?\ U<7JKK_A+G_W
M/+_Y;-_\T'V./>W_ (A?]1/_ %@Z#?MU_P 2/^;7_67H1/\ A3U_S*;XG_\
MB1.R?_=;C?:#V6_W*N?^:2?\?Z5^X7]A%_S4/_'3T>/_ (3_ /\ V[6ZW_\
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+][]U[KWOW7NO_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>timage_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_004.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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M$J*4)I33ZCAG/SZ7[NA2Y\>1#)$5%*$TI3U'#.?0]4\_S0=K?-#:W>6T\?\
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M;L_;]?F'DQKT#8V".DI9HJJKR8>3*TTSQ4C&6@F D9G#R!VTB>.\1X898T-
MP96I0\<D<.!SY].6D;QW:/##)&AH&#*U*'CDCAP/V]-O9';&[/Y;7\HCXF[A
M^,L6!VCV+WV>MMQ;JWY48*CS]2*GLC;M5NBMJS#D*>HI*JL58Z6AB-33S1P4
MB&.-+K&Z6AMQN]_*)JE4U "I&%8*!C@//'GU:& ;K?2":I5-0 K3"MI Q^W'
MGT6/X.?S2?E9WQ\X?CQMS>^7V<%WMC\1U#V+E,3M"GH:C.X_!SYK+TM14*":
M:CK(YZV5-5%3TT>DM:,:N%>Y[)!:6TC+JP=2@G"UTC\_SZ5[ELL-M;NRZL'4
MH)P*Z1^?Y].'\USYL]BQ_.7*?&#LZNQ69^*G5?<OQR[ S.S(-IT5165-'38+
M 9G*4\E8T?W-2D_\3R5HC* VI(R= TGVR;:AMO'2OBLDB@U- :LH_P  Z]LV
MW*;?QDKXC)(H-< U91_@'5J/R R'R_[^?#?)3^6)\P^M=X=?8':>-HZCH%,?
MB*FFJ*BC,TLJ?<3TU5X\E61M'&:+(KCI:;PD)5(6"*1VHM[6L-Y$P8GXZD$#
M'EC XU%:^G1+;""VK%=Q,&)^.IJ/R]/F*U].M);)XW(8;)9##Y:BJ<;E<575
M>-R>.K86IYJ>HH9&BFAEC8!HY8I$964@%6!!Y'N258. 1D'(/RZD-6#"HR#D
M=0O>^M]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U9+_*$_[>-_&7_M?[V_]Y7.^R??_P#<23[%_P"/+T4[Y_N))]@_
MX\O6_7[B_J->O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K5=
M_P"$P7_=8C_QJUWU_P!<_?NO=;47OW7NJN_YS_\ V[4^27_E'O\ WOMK>SKE
M[_<R/_;_ /'&Z.-@_P!RX_\ ;?\ '&ZT,_<G=21U[W[KW5N?\M'^:!-\)*+>
M'5G96R*[L_H/?^0DS&5P.,F@>OQE;54Z4E9/14U<Z4%=39&DBABJ:2:6%7,<
M<BS):5)B#>=D_>1#H0K@4SP(XYID4]>B+=]F_>!#H=+C&>!'Y9J/7HU6Y/F)
M_)6ZTBSO8/1?PNW3NSMS*XK+QX+&;RQTJ8*AK*Z$B*66CR^XLSBL?XI64H^/
MPDKQZ6\1CNK% NW[C/1)90%!%2#DC\@"?S/2)+#<)J))* H(J0<D?D 3^9Z+
M9V;_ #"^F]Z?RM.MOA%C-K=FT_:^SZO;DN4W!7XG%1[>=,+F:W(N:>KCS$N2
M=G@J(@H?$QC7J!;2H9EL.T21WK7)*Z37%3JR*>E/Y]*X=JDCO#<$KI-<5.K(
MIZ4_GT;+NG^8[_+8^8FT.H^P/E?TQWME.YNH,1/2+U]LRLIJ/!Y6IR'V4E7"
M:P92G5L//50![O#35<<8EC*3@1"5!;[/>;>S) Z!'_$>( K3R.?LJ.D-OM-Y
M8,RPL@5OQ'B *T\CG]HZ+5_,#_F1=$?,[M/X=;[BZIWU/MCI3)-D^YMA;SBQ
M]!!F(,KD<!69/$8RIHLE6/-1U%/C*VG$\\=+(5E1C"AU!5NU;/+M\<JZEJXH
MC"N" P!-0/4'%>EFV;3+8)*NI:N*(17! 8 FH'J.%>C'=*?/#^5%\.,UO+O#
MXN]1_)<]K;OVC7;7HNN=SY6*'#4B9">*N,$]3-F:X14RU-'3J9PV2GC6PABL
M\K!%<;7?;@!'.T>E374!D^7D!Z_+Y])+C;;V_ CF9-(-=7GZ>0'K\NBK=3=Z
M?RN^TMK4N>^8O5'=6W?D*=]]@[WWCV)TY7-!C]P/O7<F1SL"20C*K)2O00UT
M=(NBBCD$,",M6S:5C77%K>P&ENRF/2JA6I5=*A?,>=*\?RZ63VUY":0,I2B@
M*U*BBA?,>=*_Y.@Q_FA?/_#?._LO8E=LC9N:V=UGU5M_*X/9\.[)8),S62;@
MDII:VLR"TU15T]/J%'21QPI65.D1M*T[-,4C4;)M1VM&U$%F()IP%*TI6GKT
MHV;;#MJ-J(+,16G 4K3C3UZK!]G71QU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U;1\TOGEU%\COAA\-/CKLG;?8^*WO\=]J;$P.]<I
MNG$XRCQ55+M;:M)@IWQ<])EZVKFC>JIV>,ST-,3$0657N@(=NVN2TN99F*E7
M+$ $U%6U9J!_A/1)8;;):W$LK%:.6( )KEM6:@?X>C:=J?SIMK;^_EWR?&JD
MVOV5_LP^X.IMN]1[SWOE,;BXMOSTT<<&/S=='44^7.1EJ<IB(ZA/&<5%&L]2
MY-XHPLB"#EQHKOQJKX8<L "=7J!D4P:>? =((.7VBNO%JN@.6 !.KU R*8-/
M/AT4OXV?/+J+IW^7!\G?A[N?;?8]=V5W1NO>6>VKG<#B<958."+<6%VWCH4R
M%349>EKX9$FPU2SB'&S@(\95F8LJ+[W:Y+F[CN%*Z4"@@DZL,QQ@CS]>E]YM
MLEQ=1SJ5TH%!!)KAF.,$>?KTX_RU_P"9W2_#? [XZ7[AV'D.U?COV+45^1RN
MW\4*:KK\?59:E2AK_MZ3(2PT&0H,G1QQQ5-)-40*2HE60%I4EKO&RG<")(V"
MNN*G@0,C(R"/7JN[[.;\B2,A77%36A R,C((]>CG;,^;?\EWXS[LE[L^/OQ=
M[7S?;]-)6U&UJ;++4)28V>OCDUO3-F=QY&CQ2D.T8FIL=43PJVB!5B+#V72;
M;N-ZOARR*$\^&:?Z503^9Z+WV_<+M?#ED4+Y\,_[RM3^9Z 'XR?S6-AXOYM=
MM_-'Y9[5[!W!N3<6P1U_U1MCJC%XW,4FWZ"6IA9J:V6R^(8"&DIQ&)E>1II:
MJMFDB1I5TJ[S8G-NEO 5 #:G+$@L:?('_4!TJN]D8VZV\)4 -J8M4%C3Y _Z
MJ=5T]C?-[Y1;[[!WUO>F[_[QVY3;PWCN;=%-M[$]N9VBI*"+/ULU5'0TL-/7
M0P0TU(DJQ11Q0I&B(JHBJ H-X=L@B15,:&@ J46IH*5X>?1K#MT,2*I1#0 5
M*K4T%*\//H]OSW_F,])_-CXG= ;&R>T.SJ#Y-=3S8"HW#NW(X7$IM^J>JQ0H
M=QBDK$S-5EO'DJRFH*J-7Q\9!B"2L2JN2O:]HEVV=V!7PVJ *G5QJOD!CAQZ
M+=LVF3;IW8%?#:H J=7&H\@,<./5+_L1]"#KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>ZV _C/_ #)?@EM_^7_L'X3_ "MZ9[V[)QN!J]S56Z:/9--046-K&K=WY/<^
M->#(0[RV]ET:G:KIA(H6-3)&RDR1'U!6\V>Z>Z:Y@=%K2E:U'8%.-##H,W>T
MW+737$+(M:4K6H[0IQI8=.F7_F]_&7XY=4;EZT_EO_%?(]0Y;=T!AKM_]D/3
MO5TTD<1AAK7ABRFX*W-5M,DDIIC6YOPP2'R/#4*\D+T7E^:[D#W<@8#R6N?E
MP4 ?8.J#8IKMP]U)J \EK^S@H'SH.B^?RY_YC/5'Q,ZC^4^R^WL%VON[=G>P
M6IP>:VG0XW.QFJFQF4I)Y<O49/-8ZI5Y:FMCD:2.*I=P9&8:P ZO=]GDOWC:
M,H @I0U'F#B@/^3I3NNTO>O&T94!!2AJ/,'% >JNNE.T\YT=V]UGW%MN"&KS
M?66^-M;VQ]#4N8HJEMO5<52U),R@LL-6D;0R%1J".Q7FWL[N8!=1M&># C[*
M^?Y='5S +F-HSP8$?97_ #=;$G;?\U/^6=O?>VSOE>?BYV%OGY6;6Q6+Q.W*
M;=\<6,Q^-EQ,TTE-6U;09FHQ60EQLDDDE'/_  MZLZH1JI'C1Z8(P;'>QJ8/
M$58R:FGG_*N?/-/M\PK#LMXBF'Q%6,FIIFO\@<^8K3[>H/5/R/P'\P'^<ST!
MW?\ 'ZES>S,#UWU/74^X:?M_;U(E7+2X.EW#396.DI,3ELA TU52[ABBI9GK
MT\$NJH>*00+#/:XM#M6WO%+0EG%-!-*G216H'\.<=;GM3ME@\<M"6?&DXSI(
MK4#^'TZ,INNB^#?RB^9V\/C+OSX$_(EL_D.R^Q*?.]M1YG=.T<%)DJ8U<]5N
M6HHL?FZ.D%!7U-.\M+5S4SJXG281 5$B%#&;FQMQ,DT=-*T7M9J8QE3D5R/E
M\ND2&XLH!,DT?PK1>TM3TRIR*Y'^;K7"^>G0VS?C)\N>ZNCNOLU6Y[9NQL[A
MTP-=DJF.LJ8X=PXG'Y8T51-$J)+-C9*]Z1WT*S- 6=5<L ,=KNFO;=)7P2#6
MGR)'\Z5Z%VV7+7<"2/@D&OY$BOYTKU<Y_*<JE^1?\N?YT?#>GJ$EWE3T.Y=T
M[/HG@\KN-^X9(\>D4: --'!G<"&D*AG0U2"_JB7V'=^'TEW#<>6*_P"U;/\
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MEQZ2TWW*U%+((ZB*,>65[76T3PSFXM6 +<5;Y\?(@@\<TH>'5KK:9XIS<6K
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M8>OK]E]@9VHRJ;3WQEZ[9&XI\'FL-3FDEEDQ[5E46615FIBP:,^Z]T(O:?\
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M+TLE/1%ME5?6>5R5#GJ>'(U-+)?&I-2^:>*1XXWDO[KW0[?-K 8_;7_"MO\
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M>(VL=VJ/#-) [N8B)"%)</50QH64'RZB["H.B\_V%M.MV]VKO[LC=>"3*9/
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M74A(P?3-.D56U=/79/YW9"E?R4E;U_LBHIIBC1ZEGVOD&4V<*RDAEX(#"]B
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M4_/R#^4;?V34]0*#^+KB*NX_UQ^?<Z>VX_Y&_-I\M6R"OE46,M?\/4-\]?\
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MMO>&$W+G]U;^@JZ6A.TZ/!X_#U,-33Y&6FJS42?;)"9->CW7NC9_RUHZ^/\
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M^,FTLCMN85E;-53PY0Y>:N6HC"4< IA'H8S,VI?=>ZL>-/3M"M.T$)IT$:I
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M7KH(I((*UZ=&E1)>61)"-:HQ N UC^??NO=9HHHH(UBACCAB0:4CB01J!_0
M6 '^P]^Z]U$3%8R.>MJH\=01U.254R-0E'&LE0J#2!.X75* I( 8FPX^GOW7
MNNZZGJ'IJU\:]'2Y>6AGIZ&OJZ0U:1R:6,)E17B>6&.4AFC$R:A<!E)U#W7N
MB>_ 7X@4?PC^..&Z<GWB>S-_9C>78?;W=/:\F$_NT^ZM[=P9BKSVY,X<?]U6
M_915%=6-'3P&KF,-+#!$97*%C[KW1T/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7%D1C=
MD1C]+LH/NI0-Q ZL'*\">O%$*Z"B%+@Z2HMP;_3Z?7GW[2*4H*>GEU[4:UJ:
M^OGUR]VZKU@@IJ:E5EIJ>"G5W,CK!$L0+-]6(4"Y/]?;44*0@A%5:FIT@"I]
M<=.RS/,079FH*#42:#TSUR>""22.:2&)YH=7AE>,,R:_KI8BZW_-C[VT2L0Q
M )' D"H^P^76EE905!(!X@$T/VCSZ[EABF4)-%'*@97"RH)!=.0;$$7!^A][
M>-9!1@"..17(^WK22-&:J2#PP:8/V=<M"'7=$/DXD](]7%N?Z\<<_CWO2,X&
M>/SZUJ.,G'#Y=>*(R&-E5D92C(5!!!%B"/I:WX][*@BA&.%/*G6@Q!J#GC7S
MKUP@@@IHUAIH8J>%+Z8H(Q$HO_15  _VWND<2PC2@"@<   /V#J\DK3'4Y+$
M\222?VGKN6**>-X9HXYHI%*R12H)%8'\%3<$?ZX]V=%D!5@"#@@BH/Y'JJ.T
M9#*2",@@T(_,=<@B+ILJC0NA+*!8&W _H.!Q_@/>PH'Y8'V=:+$_GD_;T%!Z
M[JZCN)^TLQEJ:HQ^'V>=L[5PJP,GVC5DGEKJR21FT&64:HQ91^U8,?2/<>?U
M(DN.9_ZP7$P=(;+Z2TMPI'@M(^N:4L30L] @H!V"AZ'1YNC@Y>_<L$3*\MU]
M3=3%A24(NF., "H5?B-3\61QZ%22""5XI)88I)(&+P/)&'*%A8E"02I(XN/<
M@M$KD%@"5R"0"0?EZ= =960$*2 V" 2 1\_7K(0"02 2INI(O8V(N/Z&Q(]V
MI7JM:=<)88IE"311RH&5PLJ"073D&Q!%P?H?=7C6048 CCD5R/MZLDC1FJD@
M\,&F#]G7(HC:KJIUKH>Z@W OP?ZCD\?XGW8J#^>#]G50Q'Y9'V]=E5*E"JE"
MNDJ1<6/%K?2UO?J"E/+TZ]4UKY^O6.:"&HC,51#%/$Q!:.:,2J=/(N&!'!_P
M]UDC64:6 (]" 1_/JT<C1'4I(/J"0?Y=9"JE2A52A725(N+'BUOI:WNU!2GE
MZ=5J:U\_7K&D,,:1QQQ1)'%8Q1I&%5;?ZD 6'U/T]U6-5    '  "@^SJS2,
MQ))))XDDU/V]<9H*6I_:J(8*C04E$<T:RV-SI:S VY4V/]1Q]/>I(4F%'4,.
M.0#G\^MQS/":HQ4\,$C'Y=9F57&EE5EN#9A<<&X^O]#[N0&P>J E<CKQ 868
M BX-B+\J;@_ZX(!]^(KUX&G2#V7L#';.K=V9A:J?+;@WKGI\YG\W61HDKA;Q
MTE(@0>BDH*>T4*7-AJ8DES["/*_)T'+,MY=*S2W%]<-<7$[A0[4&F*,:0*1P
MQ@)&N:"I)+,21/S%S5-S!':VY58H+. 0P0H25'XI)#7C)*_<YQY#@!TN)H(:
MB,Q5$,4\3$%HYHQ*IT\BX8$<'_#V+)(UE&E@"/0@$?SZ#4<C1'4I(/J"0?Y=
M<87IJF(2P/!402H4$D++*C*A(M=;@@'4+7X-Q[WI'H.%/RZUJ/J>-?SZY>"#
MRK-X8O,B&-)?&-04_P!D-:X7_"]O>O"6H:@J!0&@J!Z5].M^*U"M30FI%30G
MUIZ]9"JE@Q52RW"L1<C5];'\7L/=J FO5:D"G7K"X:PU $!K<V:UQ?\ QL/]
MM[]3SZ]7RZQ&GIVF6I,$)J$5D2H,2EP&^H#VU '\B_NAA0MKTC4,!J"H'V\>
MKB9PNC4=)R5J:$_9PZRE5+!BJEEN%8BY&KZV/XO8>[T!->J5(%.O%5+!BJEE
MN%8BY&KZV/XO8>_4!->O5(%.O6%]5AJM;5;FW]+^_4\^O5\NO!5#%@JAFL&8
M"Q.GZ7/YM<^_4 ->O5)%.L4=-3Q!Q%!#&))/-((XE34]P=36 NUP#<\^Z)"D
M==*@5-30 5/K]OSZN\SR4U,304%230>GV?+K*%4%F"J&8@L0+$V%A?\ K8>[
M@ 9]>/5"2<>G#KS*KJR.JLC*596&H$-P00>""/?B PH<@\1UX$J:C!' ])'=
MF,W/-MV>@Z_R>%VSFB\8I:W)8@Y&GC1B?):".2']RQNIN0&'J5@3[#O,5C?R
MV30[/+!:SDC1)+"98E%>[L1X\T^$UH#Q!&.C[8KVRCNUEW6.:XAH=21R^'(Q
M\NYE;'D1@TX$'IGZJZYH>L.O-O[ AJSF(</35255=44XA%1+D9Y:FH?PEI D
M;2S/I36VE+ LQN24>W/(T/M[L=MLL;F98$8-(RZ?$>21Y7;35M(+N:+4T%!4
M\28<\<W2<Z;M/NK)X1E92J*U="QHL:C51:D*@J:"IJ0 ,="&D442HL<<<:QI
MXXU1 @5>/2H'T' X']!['"HJ     4%!2@^7029V<DDDDFIJ:U/SZZ\$'F^X
M\,7W&CQ>?QC7I^NG5;5IO^+V]U\)=6N@U4IJH*T]*\>K>*VG14Z:UTU-*^M.
M%>NWABD:-Y(HY'A;7$SH&*D\74D74V_(][:-7() )&145H?EZ=:61D! ) .#
M0TJ/GZ]<BB,&!1"&8,P*@W*VL3_4BP_VP][*@^0S_J_R=:#$>9Q_J_R]<)8(
M)]'GABF\3B6/RQB32R_1EN#9A_4<^ZO$LM-0!H:BH!H?45\^K)*T5=)(J*&A
M(J/0TZR  $D  L;L0+7-@+G^IL /=Z4ZI6O6)*>"-#''!"D;.9#&D:JI8FY8
M@"UR>;_UY]T6)5%  !6M !2O'J[2LQJ22:4J2:TX=>FIZ>I4)400U"*P=5FB
M64 KR" P(!!_/OTD*3"CJ&''(!S^?7HYGA-48J>&"1C\NLI 8%6 96!#*1<$
M'Z@CW<BN#U0&F1UXJI4H54H5TE2+BQXM;Z6M[]04IY>G7JFM?/UZ0>'V!CL9
MOC='8-353Y3<.XJ3'X>FFJHT5<?CL:H*T-( +K'+4:YY6+7DD() "@>PCMO)
MT%CNUUO3LTMS<I% K.%I;VT0J(8Z"H5G+2.226<BN%4 3[AS5->;9;;2BK'!
M TDK!2:SW$AS+)7B52B(!A5!]3TO?8OZ"_4"CQ6+QTM7/C\;04,V0E6>OFHZ
M..E:=T%@\S(JF1P. 6)(''OW7NI:Q1(\DB1QI),5:9U0*7* *"Q'+$* !?Z#
MCW[KW6&>AHJJ6FFJJ2EJ9J*4ST<L].DS0N18O$S F-R.+J0;<>_=>ZS1Q11!
MA%''&'D>5Q&@2[2&[,;6NS'DGZG\^_=>ZY(B1@K&BHI9W*HH4:I6+,;#\LQ)
M)_)))Y]^Z]U"H\5B\=+5SX_&T%#-D)5GKYJ.CCI6G=!8/,R*ID<#@%B2!Q[]
MU[KF^.Q\E?%E'H*)\G!3R4D&1>E1ITBE.IHDF*^18V8 E0UB>2/?NO=<JNAH
MJ^)8:ZDI:V%)8YUBJZ=*E0\)NCA7# .AY!M<'D>_=>ZXS8['U-52UU104516
MT/D^RK)J5)98?,+/XI&4O'J'!TD7'U]^Z]UG,$)C>$PQ&&7R^6(QC2WG)+ZE
MM8ZRS%KCDDW^OOW7NL-/04-)'30TE%24L5'&\5'%3TR0K$KVU+&JJ BFPN%
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M[AVCB>P.I.PMC]I;"ST$=5@M[]<[LH-[XBMBF19$DI,EC*BJHJF-HW1@T<S
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M/B3N_M'-4E;UG5O09-\QA<)15M;B:45L4\$,U0B)++#+&OJ0CW[KW1/?E?\
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M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UKG?RY.[>G/CY\^OYY'7/R+[
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M5<_6E?6U>UNTLE\<*^HI,ENC8#SFKD? Y*D@%5&9JQT1BT23R7C!]U[HQ?\
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MTHJC)T=1/2Q2,S%TCD5'OZU;W[KW0L=;=7=:=-;-PW774/7FQ^K.O]NTZTF
MV/USM2@V3B*&)0 (Z3&XV"FHZ=+ <1PJ./?NO=+KW[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJN_\)@O
M^ZQ'_C5KOK_KG[]U[K:B]^Z]TWY3_@')_P &C_WL>_=>Z2_OW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z5]'_P !:?\ Y9)_O7OW7NI/OW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[J%DLECL-CJ_+Y>OHL5B<51562RF4R54E#3TU/0HTL\\\\K+%###$K.[
MNP5%!9B "??NO=%U_P!G1^'7_>67QH_]'OM;_P"NOOW7NA>V!V?UKVQAJG<7
M5G8>QNRMOT63FPM9G=@;LH-Y4<59310SR4DM5CJBI@CJ8X*FGD:)G#JDL;E0
MKJ3[KW2Y]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0 _)_Y1=$_#/I3=7R)^2F_(>L
M^FMD5NTZ#=>]:C Y3<D=%)O?,4&!QIDI,-19'(-'-E,G11-(E(R0JYFF:.&.
M21?=>Z'[W[KW7O?NO=>]^Z]T%_5_=O3G=L&]*GIWM/K[M.GZXW]N+JKL";K_
M '?0;N7";FVB8AE,!E30SS_89B@\\!GI)]$\:R1LR!74GW7NA0]^Z]U[W[KW
M15]@_-?XQ=B;,W]V/B^V]K8#KOKGNW?7QZSF_=_U\?7F&J-T];SFER]%BLGF
M6HJ/+04U9'54RU-+++!+/2U<43NU-+I]U[I?[+^27QW[(RTV ZY[YZ:[!S]/
MCJS+S8'8O9V%WA7"EQ^GSU'V>.K:FI,,6M-;B+2I903<B_NO=-WQB^3G1WS)
MZ+V%\E/C=OJ'LGI7LVGS=3LK>D&#R>VA6+MK)UN%KU:@S-%CLG2R4F4QU=3R
M)4443AX6(!4JQ]U[H>O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0&=#?(WJ?
MY)X7?F;ZGSM;EXNK^W.Q>C.P,=E\#6[8KL3NCJNN;'YC&5E#D(*>JB:*01RP
MR&/QU%--!4P.\,J,?=>Z;:OY4]%47>&(^/-3OFEC[)SO1>[?DEC8Q054F(?9
MVQ,UC-OY;+/N%83@X1193,8Z*2&2O6?3,)1&8U9A[KW1A??NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=44?SAOCO_.F[RW1
MT75?RH_E7UE\<ML;<P&^J?N:@W]EH\7)E:_)5&-;#S4^K96ZS(E+3PUZM^]3
MA3(/1)J++[KW6J1OSL3_ (5"]=_S)NE?Y66=_F2;(F^2'?'6>5[7V7G,;48B
MHVG%C,/B]VY:6/(9-^MHLC!5FFV9E@J1X:9#(],ID"R.T7NO=7_?RXOB#_PI
M.ZK^9/46^OGW\\.DNY?B3AH^P4[:ZUVKG8LED<G_ !/;&:I,#]I&.M,"P:CW
M-/A:N1AEZ8B&"47E!-/-[KW6TA[]U[KWOW7NO>_=>Z][]U[K5=_X3!?]UB/_
M !JUWU_US]^Z]UM1>_=>Z;\I_P  Y/\ @T?^]CW[KW27]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW2OH_\ @+3_ /+)/]Z]^Z]U)]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=-V7Q&)W!B<I@<]B\=F\'F\=6XC-87+T4>2I*NDR4;0U-+54TRO#44]1"[
MQR1R(R.C,K*5)'OW7NM3/Y]_R]/@/LG^<[_(?ZKV=\)/B3M7K'N.?^9&G;G7
M6W?CIM##8+= V+UOAZ["#<.)I\1'09G^#ULLM10_=P3?:3NTU/XY"6]^Z]U<
M1NOJSY<?'+)Y+I#^5A\-OY>'0O1%+MZ/L*?>'8F9R/5N&RN\,X\U/6XJEV)U
MMM<2TQ%%C\4*G/561#D2JL6.K!1:)O=>Z(MG?YZ>]]D_RO?F/\T]^_'_ &QB
M>^_@%\PZCX8?([J#;N[ZO<NWY=P;3W[M;:F=R&VLS-2XVHK:)L7N5*RC2=(B
M*F/[:>7Q6J&]U[K+WU_-9_F2_#3>'Q\[$^57P(ZB7XY?+OM;$=!=)=4=*]WU
MN[>Y<-O?L#$Y;(;+V[NZ/)8S';"ER6X:W'PX^HCQV;>BQDSSRME*R.G05'NO
M=#9U7_,&^>'5OSY^.OPX_F(]!?&'KS%_.G;'=VY?BIN;XP=I[F[*J,/7]!83
M%9S.;4WN^>P.(IZW(+0555.N4QL--0ZC34D<$Y,E5[]U[IU^*?SK^>/S;RN>
M[KZ"ZD^(</Q0VQ\E]\]#Y/8F_NT=TXKM7^%=7[I?;><W+6-2X:HV[A<EX:2N
MR%%M^II))*BG^W63*4[3!A[KW1@OB1\]MS_)'YZ_S._AYE^O<#MC _ ;/?%K
M$[7WIC<S45U9N%/D'MK,YRJ:OI98DAHVQLV*6.+PR.)$D)?2R^KW7NJ(OYW_
M ,Q]S?*O^3M_._V3N'9N"VK3?$'YM=,_&3;M=AJZHK'S%#MW?/5F8CRE:D_I
MIZN1LRT31Q$QVB#@C657W7NKF?E5\X?ECE/E1F_@3_+DZ>Z-["^16R>DL1WE
MW#VW\I][YS:'7>R:#>U758_;.-K*3:V.R.Y,_G<U-1U-2M)2FDCBHX?))5 R
M7A]U[IL^-G\RGM<=U?+'XA?.?IG9?5?RB^*W1\'RCH).A]Y5/8>V>Q^M9UG@
MDW/M*FR=/0[AHJC'Y>G;&UN/K:5FBJI:81U,HF&GW7NLGP ^7/\ ,"^9.T^@
M/E'E>KOAECOB%\B<-+NRFV]L7MO=&9[!V=B,G05U3B9,M55&&&VMP9<U4>.I
M<EC:>/&G'233Z:FK:G*-[KW58NU_YP6/^,O7/<.YNB?Y?O5U!E-T_P#"A?NG
M^6=F>K^A7H-DY+?F>GPIJZ3>\LE0F)QC;UW5E8,505,E?5?;QQD323NL2Q>_
M=>Z/WUO\]/Y@_3WS<^//Q?\ YB?Q]^+6R]D?-MNU:7XU]@_%;M+<^_WP&:ZL
MP=-GIMI;X_O+@\/'79"LH8\G)#DL;3TU(SK#3K3N5DG;W7NK$OGQWO7?%_X0
M?+KY%8B):C.]*_'#N7LC;5*]1]FLV5VI@*^KQ<#3!7,2S9".F0N$8H&U!&("
MGW7NM1K^8-UAUC\?/Y$'_">[;G=.(VUCNO$^>O\ +N[4^1])OS&0YG'S?Z4]
MG[\W?V%/N2"HCJ8LE'55.7S3Y/SI,*D--Y1('(/NO=7X?!?L;^1/OKM7=^/_
M ):N%^ \/?\ C>I]V9?-U/QDZ<VWL?<,6UTJL;39%IJ[$X3'U7\+;(U6(2:,
MU'C>5J?4A(4CW7NJIOY.OS<S?Q _D#_RK-I=6=5#O7Y,_*KN'Y#]$_'+J6JW
M0FR,=69BK[5[+R60S&?S+4]8V-VWMW%T<]9D)HJ.><J(XH8M4NN/W7NK,L)\
M^_G]\4_D1\6.E_YG_2_Q)QO7WS1[-S'2?4OR!^'79>YLCB-O;ZR;557M/9VZ
M<1OK'8W)54^Y,?!]O39+'R>.7)(T7V,,<J:/=>Z!_KC^9W_,[^8-=\QL/\(?
MAO\ &J:G^%/R_P#D3\;]\]A_(WN+.;:Q.Z#TMEFAH\)L_&[=QV4RD^Z*K"_9
MU=?4Y-\;BJ.;(44-,:__ "EH?=>Z"G#?SG_YBOR(^"8_F;?$WX0?'W$?$KJ3
MJG=/:O>6,^1G>>:Q^[MUIU)BLC-O^CZQ@V[@JG'4^,VSE\?74L.8S[PS9-L?
M6)#@X@]/.?=>ZMDS7R3^7GR$ZB^+/;7\OOJ+HG-; ^2G2V&[LR?;7RC[&S.U
M*/:U%O3%XC*[?QZ[3V[B:W-;CR60@R509P,GBJ:E^UTM4R-4+X_=>Z)UU%_,
MF^=&_=M?S,?C]E/C/T5E?YD'\MVBZIS]=UAUCO\ S^Y-@]@X_N/;?][<%'M[
M+9+&XK,XW*9'%4]=!%35D#::W[1961)IOMO=>Z6_3G\X/;WS&[$^"_6GPIV;
MB^PLY\ANNJWY"?**3=F2*+T[L;:\KX?)X[<4>-FE,>^ZW=Z5&$QV/=_"\M#D
M*J9Q3Q1--[KW2:^,.9H.F?Y[O\Q_XW8^N:# ?)WXL?&7YX8_:3A1!#FMM559
MUGNO)TJD:[Y5:3;35?+(9HU8!69]?NO=4U9G^1S\J*;YL4HQ.SNA:?8F8^.'
M;O:&+^,6!VWV9A/B/35M%OO:*X[JG.8V+<L\G\2W50ODMP5U12XVFPPR^+H\
MD-EUKPRS3>Z]UNNXJD^PQ>-H134%$**@HZ04>*A^VI8OMHU3Q4T=E\=/'ITQ
MK8:4 %A;W[KW4_W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U0]_.._GN=6?R=-T]$[7['Z"[#[EE[VV_OK/XFMV3N;';>CH5V)4X
MRGFBG%?&YE>8Y.)E*&RA3J^H]^Z]UI-]O_\ "AOI[LK^>=\6/YM-%\=>RL9U
M_P#'WH;</4.8ZBJMV8N;,Y&HS6 ['PZUE-7I&***!)-[TLA1T+%::4#ETM[K
MW6U;_+8_X5(]'?S)OF5U/\-]C_$WN7KO</:U-V#54V^-P;OQ&>QV-3K_ &UE
M]R2O6PT<23B*J3$FEC<&PJ)X0>&]^Z]UM,>_=>Z][]U[KWOW7NO>_=>ZU7?^
M$P7_ '6(_P#&K7?7_7/W[KW6U%[]U[IORG_ .3_@T?\ O8]^Z]TE_?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]TKZ/\ X"T__+)/]Z]^Z]U)]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U1%_,"ZH[3W;_ #H?Y#'9^T^M.P=T]:]357\R->U.PMM[
M+R6=P>V?[\];X>APO]X<M2TTM!A1EZR*6"C-9/"*F5'CAULC >Z]T7+YKT&7
M7^:!V!6?/;H[YR?(7X2S=&]3?[(]M'XK;.[&W]LNGW:6KJ??,&]\3UU600R[
MIJZN6B;%S[CC-#'0@/!)$\#3)[KW51.ZOAC\IY/Y%/\ /'Z6P'PI^0W6G8?>
MG\V7_2WT1\:JO8E9NS<9VAOC=W3F:Q"T)P\F8I<U28G$0SPUE=0Y*MHX)*"M
M$U7JIIV3W7NM@[^>/U/VGVM_PT;_ *+NM.P.R?\ 1S_.O^"_:/87]P=FY'>/
M\!VSM/\ O/\ Q7<>9_AU-4_PO!8SSP?=U]3XJ2G\D?FE36M_=>ZR?S!.H^U=
MW_SBOY#';.T>M=];KZSZ=S/\R:#MC?>V]K5F:Q.VF[$ZRPU'@3G:^GADIL3'
MEZRCJ:>DDJI8HYIT\*N9&53[KW5:WR+Q^$[=^0_5'</\N?X%?S"_AQ_-"W'\
MA.FIN^-QR]';@Z,Z^FVQ'F4EWI4=OYF*L/4^^,0V$?*BFJZ"NRF3KJN:!J.2
M4ZQ'[KW1C=L[B[/_ ):O\XC^9YVSV%\4/E?W;TY_,>V[\1-\?'SL#XM=+9+O
M:E3,_'O;60VWFMK;F;&A%VOEJ[)9B2>BER#PXTT,1J)Z^!0_C]U[JLOY*?''
MYO\ <'\H_P#GSXC<_P -NY]D]^?*+^9'TUVWU_T#@]M5W9&5J<;N'(]+Y-OX
M95XJB>DW!#B*6"JBR60QIJ,73U5%D$2LEAI'F]^Z]U;AV5#V1_+7_F\_)[YM
M93XU=[]Y?$W^8+T7T1A>P>R/C9L#)=W9S8^^_C702X&BASNT,2E3FVV_F]OF
MFT9"@I9DBJT1):<*:FIC]U[IP^/&W>Y.]?YBGRH_G&9;XL]_;%ZPV#_+]H?A
M_P#%SHGL7;-'UWV'V5'B,]5=@YS*#:F;J:&7 /79..DQ&%CS-=1?=>=YZE((
MPK1>Z]T5KJ;9>U*[^8]\6^POY5?Q!^=/PXH-P]L[MS?\R? ]C]'[L^,W3M1M
M0X.I6H@R6V=RM2[8R'8-3F1BUQM1M6CG/[<U34SFG99I/=>Z)3B/B)\JF_NG
M?XW]Y1_<?\+4LK\M!Y^K<U3Z.K\?X/)V%/KHE^VV<?M)_'EI=%%+9?%,_DCU
M>Z]U?G_,AZM[,WS_ #!/Y)N\-E]>;XW=M'J[Y/?('/=F;JVSM2OSN-V[19;K
MG(4M)69VOI8):7$4U55?LPRU4L233$11EI"%]^Z]T</^9KTWN'Y"?R[?F_TG
ML^F2MWCV5\6.\=K[-H9)C3K/F*[;M?\ PJ!Y &*)-D%ID8Z38,>"./?NO=:\
M7?>.[3^;O\GC_A.5OSJC9&[N\<IM;YM?RN-[=S5'7FTY=U_PZCZLVWN+;.\,
M[E*;$T\D5!BL9GE>*OF,,=+1,Y$WAC1M/NO=;<61QM%38O+-0XZGBGDQ=?$/
MLJ)1(^J-O0HC36Y8@64 DFU@3;W[KW6DQ\2?AA\O.AOY8/\ (4^7N.^)W;N^
M.\_Y9W=GS#W+W#\4Y,)/LSL&;K_Y4[SW?29RIPNW\P:%JS<%'B_X#DJ/&U"P
M3U43@)+ AE)]U[JSCY![EWC_ #C?D1_+MV1U#\:/E5U/\>OB!\S^O_G%WUWK
M\E^D,Q\;X!7="4.0_N[LS;V,W32TN8W!D,SE,H8\A)248IJ*FC9S5&0J4]U[
MH>/Y'W4':W4^V/YL)[1ZVWUURW:7\Z#Y[=L=<0[YVK6[5ES>V-UKM>#%[@QD
M-=!!+5X?)RT-6*2KC1H:E8V>%W2S'W7NB8_RYOCKW]M?_A*3V%\;]U])]K;1
M^068^%W\R_9V-Z1W?L#*[4W7+E>P<KVD<%CQ@,A2TV46KS"Y&@:CC:E#5"5,
M#Q!DE0M[KW0)9/9'=&QNI/Y)VV/E[TM\W]S_ ,N_9/\ +0ZOVOW;TM\:-D=B
MOG,9W5M?!;;3'0]I;:V"]'O27;]-BX*NEAHJNE;'IDUEAKX&,F@^Z]U-^$M1
MV]\(?D%_/2^7'47\MOY9;0V+VEU]\!J_X0?'?<'6.<RF8WGD,)@=T;3IXI),
M>^XI\9!5;C\62S*5E9]_M[%UR39:FHY L'OW7NA2^&'P@^17\G/Y>=.=PU>
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MP#S8//[2W1%CY:#(9FERE#2"'(T<,L2Y"&;QZ75O?NO='"[R^>/P\^+=;NK
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MA8';&&'6$5#/MK>6TEH-KO@)):B*GDIYT;(U&0,<A55:3W7NBV_S-_A)V_\
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MS8)VBI*=*92\W4E"7<J@4%W/)-KD\GW[KW2'_P"$_P!U-UAD\K_.XW]DNO\
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M]*9E=Q93###YK.8JJPM55M34%;2TF1$F.K)X_%705,*DB18UD ;W[KW56?\
M,@^$^X?G!_,&_E54V9Z-I,YT1\3>Q.R_E-VEWSD9((FH\AMJ#&?W4V-0!:J*
MMFBW!N*@Q^1RD0@DIW@Q5(LUU8HWNO=6D_)CXQ]%?,7I3>WQW^277>([2Z?[
M"HZ6DW1M'+SU- )#CYXZJEJ::LH9Z7(8^NHZJ&*:GJJ6JAJ()45XY%(]^Z]T
M7SJS^6-\,NGMU_&W?NT>MMS5N^_B2_=D_1&]-\]Q[S[*RF)F^1-#!C-WU%15
M[@S^2ER\^3QU-!2H^0-2:*F40T'VT?I]^Z]T/._OBST5V?W]T!\G]\['7.]W
M_%RA[7QW16\Y,_DZ08*/N[&T^'W,8\=3UD6+K)<EC*:.G\E713R0)K^W:(R.
M6]U[KWQ[^+/17Q8H^VZ#HG8Z[(I^]>]NQ_DMVK_N?R>X7R^]>V9*:3/9J67*
M5E;) U::.E44\#Q4L"1)'3P1(+>_=>ZJ\^<7\MB@RWPBV5_+9^&O5>8V5T'\
MBOE7M?(_);.XWLFM/]VMC9?=<W8G860>MS.<?/5LFYJO'G#PT5)/.!_%?&8X
M:&-]/NO=7=T-#1XRBH\;CZ:&CH,?2T]#0TE.@CCBAI$$<4:*.%1$55 _  'O
MW7NI7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[K5=_X3!?\ =8C_ ,:M=]?]<_?NO=;47OW7NF_*?\ Y/^#1_P"]CW[K
MW27]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2OH_P#@+3_\LD_WKW[KW4GW
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW5-F^/YVGQ_P?8?9.T.JOC7\\/E3LCI+?&5
MZW[N[^^+/QBK>V=C;8SFWYHJ?)XZ7*1U])7YZIQ$LG^Y!<#B\L:)%:6?1%9C
M[KW1T=P_,7"8KNWXD]0;>Z2^1/8.!^7>TM];SP'>FRNL)J[9&T*/9^$ASM+_
M '\RU3-2S[<FS]/,M/CHI*.266L*T\B1EKK[KW0??R_/G;3_ #MQWR_K(NL9
MNL9OB9\\/D5\(ZR&3=R[P7.2="OBBNY(G&-QAH$RL&7A)H62<TLD;H*NH4J_
MOW7NK _?NO=>]^Z]T1[X??,Z+Y8[]^;&QX^N9-AGX=?+'<WQ>;)ONP;F_O$=
MN8+!9DYP0C&X_P#A/F;,M */RUFD0"7[IC*8HO=>Z/#[]U[KWOW7NBN=F_)Y
M.M/DM\;OC:>B_D%O=OD;1=IUB]U;!Z\.?V)LS_1AC%R?CWQGC51#"/G 6IL8
M!3S&HJ]$1"!PX]U[HT?OW7NO>_=>Z(UN_P"8E11?S ^GO@EL79=+NW*YSH/L
M7Y)]\[RES$M&NS=MXBNIL#M1%@BI9XJO);JW'+5Q0P3U-+HH\?6U,9F,8C/N
MO=$!VG_PH?\ A7O+J=?D/B.E?GY+\9$_BT^2^35)\+]U[@V+0TFWZG(4F0R%
M;F\1'D1#1XZHQ=8E6W@9Z4JGW$<7EBU^Z]U=AUUV)L;MW8.S.TNLMTX7?'7?
M8>V<+O+9&\-NUBY"AR>+W%3QU5%6TLR\20U%/*CJ>#8V(!! ]U[I9^_=>Z][
M]U[KWOW7NO>_=>ZUG_D-_/[[GZAZ0^3WS*V'_+HR'9GP<^-O>><^/+]VYCY3
M8/K_ #F>S6T=[8O9&3RM'L\;=S%3!MI\K6U4-#4?Q&>MJ)HH?N:"BIY:BHH_
M=>ZV8/?NO=1:YJU:*L;&1TLV16EJ&Q\-=,]- \X0^)9I(XY9(XFDTAV6)V5;
MD(Q !]U[JM'X]?S,-B]D_!')_,WM?8>]MB5_5N[-X=5?([J7K+:&>[ZS&U-W
M]:;H;:.X\93X[;N'J,WEZ/'9 +5M4PXC]O%O]].D4,<K)[KW07?#3^<W\9OF
M#W+V+TGLW<.U]U[FH?D7O?JSJ"IZ*S5=WY29G9NV-I8;<U'V%NBKP>*:BV%B
M,I5U^2P].,M51QS9.@FIX)Y76=8/=>ZN)]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UH:?RV/Y]W4
M_P#+>[O^<7Q._F5_,_N/Y8TT/>VX-\=(_+.CW-FOD1B9L2O@QTFUFQA+9?:-
M?33PR328VGPT.,IZE*^*+Q0+CYLA[KW6PM\0O^%"O\KOYR_(;K_XM_';N#>^
MY^Y.SUW8=FX',]-[EVK3U/\ <K"9+<.0#U]?CH:.G,6*Q-=*OEE4.R"-"9'1
M6]U[J[7W[KW7O?NO=>]^Z]U[W[KW6J[_ ,)@O^ZQ'_C5KOK_ *Y^_=>ZVHO?
MNO=-^4_X!R?\&C_WL>_=>Z2_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z5]
M'_P%I_\ EDG^]>_=>ZD^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU>MMS?/#^0U_I
MAHQT#!\XOY5%=VYVAWQ3;ZZ;RHQ_;W5&/[/R62W#N 9W;=;II=[X3&5L_D^X
MHIX*B&G:IK:J9(PE'#[KW1D>\/G/N???\SC^05C_ (W=SY*N^)WSBZ]^?6_M
MZ87")''CMW8[975U!N+:4]='40?=PRXJOF,Z1AH98IM<4RFS)[]U[JH?X]?,
MGL?X<_$'^:X_1V7P6W/D+\I/^%0'R9^&G06ZMT8%MS8[#;E[WJ]H1'-55#I:
M"I&&PF/S-;#'4LM-+400Q2^0.(9?=>Z/!\^MA?*G^3/\?$_F-;*_F/\ S5^4
MV-ZF[DZ?R7RNZ/\ E-G=L]E;9WAM+LK,X+9V5H=HXFAP6WEV%D**IR%/78XT
M%=X5G,JU8J!*[M[KW0H[ Q'R@_FD?-CY^Y&G^=WR1^)WQL^$/=N&^,'0?7/Q
M1R6"V349;=.!VO19;<VZ-\U>8PV>DW% F2S5(M'C'C@H?!!''-!Y$J6JO=>Z
MJ^Z,^5ORF^"?QW_F@;?JNSNO-T?.7Y#_ ,]G:GP=Z][O@Z\DHMO2[Q[FVYM"
MD_OE+MIGJ::CD@V[C<GE#CY:IZ&/((*02U,'C2?W7NCX?/K87RI_DS_'Q/YC
M6ROYC_S5^4V-ZF[DZ?R7RNZ/^4V=VSV5MG>&TNRLS@MG96AVCB:'!;>7860H
MJG(4]=CC05WA6<RK5BH$KNWNO=+;Y]?(G([1_F'3[#^:7R\^4_P)^"N5Z2ZO
MG^*/<_0N0?K39^?W[F*K+3[H3?\ OQ-O9:'%5^.@IL9'C<7E:ZCQ-13M))/'
M/),$/NO="G\A>_.]NG?YD/\ (6^.>SODSNWLWJ?O?J7Y^1]V;IE.$>/LI^F^
MI<?F-L[BRK8>AI\8U0N2)R,;XV*FIFEE8QQ^%@GOW7NJQ?A9M;^8U\\OY-&T
MOYDF^OYK'REZR[NV#U)\BM[]'[.Z9BV_M/:E3-T'D-W805':-%6X;+5W8%=F
MZ["ULDH:OHL;24ST*TN,6IHS43>Z]UL]_P OCY"[A^6/P:^)7R5W=0T.-W=W
M?\?NKNQMVT.,C,5+'E=R8FFGR0ID/*4QK6G,2_V4*C\>_=>ZK9_EX39KL/\
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M,;.P>YHNM9IY=K;GP6ZL!C<SD,-N#%0U,M&\,^*J*&HI-:E4FE6>#W7NE_\
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M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7ND)N#J[K?=>]-@]D;FV)M+/\
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M'_K&?^*>_5'IU[2?7KW\&W-_ST/_ %C/_%/?JCTZ]I/KU[^#;F_YZ'_K&?\
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MYZ[_ *QM_P 4]^J/3KU#Z]>_NWO;_GKO^L;?\4]^J/3KU#Z]>_NWO;_GKO\
MK&W_ !3WZH].O4/KU[^[>]O^>N_ZQM_Q3WZH].O4/KU[^[>]O^>N_P"L;?\
M%/?JCTZ]0^O7O[M[V_YZ[_K&W_%/?JCTZ]0^O7O[M[V_YZ[_ *QM_P 4]^J/
M3KU#Z]>_NWO;_GKO^L;?\4]^J/3KU#Z]>_NWO;_GKO\ K&W_ !3WZH].O4/K
MU[^[>]O^>N_ZQM_Q3WZH].O4/KU[^[>]O^>N_P"L;?\ %/?JCTZ]0^O7O[M[
MV_YZ[_K&W_%/?JCTZ]0^O7O[M[V_YZ[_ *QM_P 4]^J/3KU#Z]>_NWO;_GKO
M^L;?\4]^J/3KU#Z]>_NWO;_GKO\ K&W_ !3WZH].O4/KU[^[>]O^>N_ZQM_Q
M3WZH].O4/KU[^[>]O^>N_P"L;?\ %/?JCTZ]0^O7O[M[V_YZ[_K&W_%/?JCT
MZ]0^O7O[M[V_YZ[_ *QM_P 4]^J/3KU#Z]>_NWO;_GKO^L;?\4]^J/3KU#Z]
M>_NWO;_GKO\ K&W_ !3WZH].O4/KU[^[>]O^>N_ZQM_Q3WZH].O4/KU[^[>]
MO^>N_P"L;?\ %/?JCTZ]0^O7O[M[V_YZ[_K&W_%/?JCTZ]0^O7O[M[V_YZ[_
M *QM_P 4]^J/3KU#Z]>_NWO;_GKO^L;?\4]^J/3KU#Z]>_NWO;_GKO\ K&W_
M !3WZH].O4/KU[^[>]O^>N_ZQM_Q3WZH].O4/KU[^[>]O^>N_P"L;?\ %/?J
MCTZ]0^O7O[M[V_YZ[_K&W_%/?JCTZ]0^O7O[M[V_YZ[_ *QM_P 4]^J/3KU#
MZ]>_NWO;_GKO^L;?\4]^J/3KU#Z]>_NWO;_GKO\ K&W_ !3WZH].O4/KU[^[
M>]O^>N_ZQM_Q3WZH].O4/KU[^[>]O^>N_P"L;?\ %/?JCTZ]0^O7O[M[V_YZ
M[_K&W_%/?JCTZ]0^O7O[M[V_YZ[_ *QM_P 4]^J/3KU#Z]>_NWO;_GKO^L;?
M\4]^J/3KU#Z]>_NWO;_GKO\ K&W_ !3WZH].O4/KU[^[>]O^>N_ZQM_Q3WZH
M].O4/KU[^[>]O^>N_P"L;?\ %/?JCTZ]0^O7O[M[V_YZ[_K&W_%/?JCTZ]0^
MO7O[M[V_YZ[_ *QM_P 4]^J/3KU#Z]>_NWO;_GKO^L;?\4]^J/3KU#Z]>_NW
MO;_GKO\ K&W_ !3WZH].O4/KU[^[>]O^>N_ZQM_Q3WZH].O4/KU[^[>]O^>N
M_P"L;?\ %/?JCTZ]0^O7O[M[V_YZ[_K&W_%/?JCTZ]0^O7O[M[V_YZ[_ *QM
M_P 4]^J/3KU#Z]>_NWO;_GKO^L;?\4]^J/3KU#Z]>_NWO;_GKO\ K&W_ !3W
MZH].O4/KU[^[>]O^>N_ZQM_Q3WZH].O4/KU[^[>]O^>N_P"L;?\ %/?JCTZ]
M0^O7O[M[V_YZ[_K&W_%/?JCTZ]0^O7O[M[V_YZ[_ *QM_P 4]^J/3KU#Z]>_
MNWO;_GKO^L;?\4]^J/3KU#Z]>_NWO;_GKO\ K&W_ !3WZH].O4/KU[^[>]O^
M>N_ZQM_Q3WZH].O4/KU[^[>]O^>N_P"L;?\ %/?JCTZ]0^O7O[M[V_YZ[_K&
MW_%/?JCTZ]0^O7O[M[V_YZ[_ *QM_P 4]^J/3KU#Z]>_NWO;_GKO^L;?\4]^
MJ/3KU#Z]>_NWO;_GKO\ K&W_ !3WZH].O4/KU[^[>]O^>N_ZQM_Q3WZH].O4
M/KU[^[>]O^>N_P"L;?\ %/?JCTZ]0^O7O[M[V_YZ[_K&W_%/?JCTZ]0^O7O[
MM[V_YZ[_ *QM_P 4]^J/3KU#Z]>_NWO;_GKO^L;?\4]^J/3KU#Z]>_NWO;_G
MKO\ K&W_ !3WZH].O4/KU[^[>]O^>N_ZQM_Q3WZH].O4/KU[^[>]O^>N_P"L
M;?\ %/?JCTZ]0^O7O[M[V_YZ[_K&W_%/?JCTZ]0^O7O[M[V_YZ[_ *QM_P 4
M]^J/3KU#Z]>_NWO;_GKO^L;?\4]^J/3KU#Z]>_NWO;_GKO\ K&W_ !3WZH].
MO4/KU[^[>]O^>N_ZQM_Q3WZH].O4/KU[^[>]O^>N_P"L;?\ %/?JCTZ]0^O7
MO[M[V_YZ[_K&W_%/?JCTZ]0^O7O[M[V_YZ[_ *QM_P 4]^J/3KU#Z]>_NWO;
M_GKO^L;?\4]^J/3KU#Z]>_NWO;_GKO\ K&W_ !3WZH].O4/KU[^[>]O^>N_Z
MQM_Q3WZH].O4/KU[^[>]O^>N_P"L;?\ %/?JCTZ]0^O7O[M[V_YZ[_K&W_%/
M?JCTZ]0^O7O[M[V_YZ[_ *QM_P 4]^J/3KU#Z]>_NWO;_GKO^L;?\4]^J/3K
MU#Z]>_NWO;_GKO\ K&W_ !3WZH].O4/KU[^[>]O^>N_ZQM_Q3WZH].O4/KU[
M^[>]O^>N_P"L;?\ %/?JCTZ]0^O7O[M[V_YZ[_K&W_%/?JCTZ]0^O7O[M[V_
MYZ[_ *QM_P 4]^J/3KU#Z]>_NWO;_GKO^L;?\4]^J/3KU#Z]>_NWO;_GKO\
MK&W_ !3WZH].O4/KU[^[>]O^>N_ZQM_Q3WZH].O4/KU[^[>]O^>N_P"L;?\
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M TJ(CDII=ZI1P 6"FH/;2A(EY@Y6N.7(K26=HR+RV2ZBT%B5C<D /J5:-VY
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M*JF)?HXA,_B$N&%5/;I5JD4.GCT)]LY4N-UVV]W2-HQ%8FW$RL6$C?4R&)-
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M)RYN%$!72"2X-@0I-SA:P;U'L167ZB6TDO%8*O@B*.58B"VO5K+-4 (10&K
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M(YXR&*D.H9P#BH(8@J00:'HGWG;!L]R]L)H9PA%)K=S)"X*AJJQ"D\:&H!#
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MW=)E):6 O(8*6>N\\D41D<QQLJ%V*ZC[KW0&?S:?Y7?=_P  ?AATE_-<Q?\
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MRM%\Q=PXZCR>\]RUNZ*B*G796RY1!%-73SR1PB221PBL%U,S6NQ)]U[HAO\
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M_P#,%[^^/G66SUJLSO+YL=@=BT WKCL'F=X#<>=I'W&4Q%-1'(T-15X6FG5
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MZ4ZTE6&:IQ&3KHX9S#+]O,R3^*7Q^-O=>Z(3\MOD;_-C_EQ[-V!_,!^3_?\
M\9^R/CE)VWU!LSY3_#K8?24FTZ'KW:W:^7BP9S.T>R*C)U6X=UYW 9++4$=9
M+D\;18_)11++38_%E9EJ/=>Z<*WY*_S3OEO_ #'_ .8W\'OBOW3\?OC7U/\
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M=-)[]U[HSG\T7^5GT5\)=F_R_=\?%S?7>VP=M_\ #GGP5V[V]U7NSN;<?<6
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MF&*(OJ$1D7PVE1M-0QT$5"_A"B\V#9^5]]VJ[A@FEL]PAM;F"%IBDEO+)(H
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MY;4X((%2HTD-D;R?RIL?/%PNW0;1N$$4RR^!NDD\CE62-W!D01+!1BM**>)
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MI[C04X=VI2ODCEW;(]KN]^WB.2>&WEBMX;6.0P_43R=Q#2*"RJBT/;DY]-+
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MM 9XKNWAE*:Q72\<M5K7232IT]&-C[5[>W-=IMFJ22QO[0WENS'3*(I+>:1
MQ2@U*\>:4U "HSTY[FW3WCUED]C[NWGNC:V:VUN[>6!VIN#8N*VZM$F)_O!Y
M DE'DS*U57- 5];2JJN5&E K$J9;]S!S=R%<6&Y;I=6<]K>7UM9W&WPVWABS
M^I+*&BN#(9)BAH&+JH:G:BU-$>S;)RSSG#>6&W6US#<6MI/=07LMP7-UX&DD
M20A0D8:N I)%<L2 ";GWDEU G7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJN_\)@O
M^ZQ'_C5KOK_KG[]U[K:B]^Z]TWY3_@')_P &C_WL>_=>Z2_OW7NO>_=>ZJ!_
MF7]M_P W_I3>O3V\OY;GQGZ6^675L^(W#B>\NK]_;JH]DYZFKI)%?$Y3"Y"M
MW#M^%:95U1U2_P"7ORFFC13+50>Z]U2=LG^7%_-G_FM?S(OC3\VOYJ?575OQ
M%Z ^'>>P^X.LOCUL_>-!O;*92LVGD:/.0*'Q65S:B#+YJFI#DJNMR=.YI*".
MDI,8HE^[/NO=;B=;MC;63J'K,EM[!Y"KD"*]56XFGJY&$8 4%Y(V8A0 !SP.
M/?NO=:QO\TS^63\I/YDO\V[X$8_L'I+%YO\ E7?&W:LNY.R=Q5'8^$Q463SN
M5FKJ_*X>?;\><3<4]+7+AMI8P&#!(BP2US??"-_V/=>Z,7\NO^$Z_P#+6[)^
M+_?FQOCW\/>F.KN]]R=5;SH>G-_8RFK:67&;F%%+)A)S++7M''"V12GCF9E(
M6%Y#8VM[]U[JK/"?RY?YK&^/^$S_ &A_+<[3^-=;1?*G8G;.S\)TELC(]];$
MW++GMEXW?>W-Y+5#-Q[FEP&*CPR5&=H8**KS:2+28V!*= LM-3CW7NBH?\*"
M>E^R?CI_PG>_E.=%=Q;=7:/:G5'9G2FR-_[77,4.X/X?E<'UOO.*KI/OL94U
MN.JC!*&4RTU7-"Y%XY'6S'W7NA4^5GQJ_P"%(WSS^,73'\LWL+IWXVUW0%?%
MUM7;Z^<&W]\4&*@W+@]J?:9';E1F<7-E(<MCZBA-/329&GH-G/-65L5.8!#3
MI.]1[KW1Y?YY_P#*#^1_</\ *<^"WP2^!G7-?WOFOBMV)U/BZR'+[YVMU[63
MX+K[86XMO39RJJ=Q9; XN2IJ\C5TCS04\YD\E26B@\,;F/W7NC?_ ,]SX-_)
M[YF?RE,/\9/C;UQ%V-WAC-T?'_*3;(.\\#L_5#LB/Q91DR6>R>+Q!-*6+6:O
M4R*I\7D;2I]U[JK3YG?RGOYBVW)/Y&ORJZ0Z$Z^^5^]_Y=GQ%^,O2'=WPO[
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MFGEG;-LOMT^@FLGO&=397%SJ\>=W6ACTJ!I(-=1R:4%.E)/A>Q]Z=G_'_?\
MG-@R;0CVK%VFF[<<^Y:'._8_QF@^TH/WH'C-3]TRJP\4)\8-I+6)]GT^T[[S
M9S!RWO5WMQLA9C>/K8C=6]Q]/X]OX$/?&5\3Q" >Q3I![J4Z)X]QVCES9=\V
MJVOA=&Y.VFUD%O-#XW@S>++VN&T: 2.YAJIVUKTD]C4W=W4]7V::7JE-Y87>
M?9N]=VX6*@W70XJL@DR<X2%ZH3R-$U%5P0TS(R/Y82)!+'ZD]A[E"UYL]MY-
MV,>T"^@O]VO[V!8KRWAGC:632AD$KZ#%*B1LI5C)&=8=.'1]S+-RUSU'MVO<
MS:36FW6=K,7MII8G6-*L$T*&$D;,X(8:'!70V#TUP='[]QVU^JQ/0TV3W74?
M)+#=S=C_ &-;#'!1K4/(U48VFE0S+3Q+ I6+66DU: X]3%R^T6\6>W[1JC26
M\;FF#?=T\.1!'"&9VDTF1QJ$:A%HFHLU2H(R5DON5M=W>[EI=H[5>7YMHV_6
MC%Y2JJ$J$4Z2[%B"U %IJ(. LJ+$=I=3=A=DU.UNOSV'M/LG-Q[LQDU'N2CP
M,E!D:B/35Q5HJV!^WE?U+)&C:54"SNVA1;:;;S![<[WN;[?MW[RL]TG6\B:.
MY@MVMKID"2K-XS#]-B P=%8J!2C,: /W-_LG/>T[>E]??076WPFUD#V\LZSV
MZM6-H_"'QJ,%6(J2<A14A_%T5VEF]E]E#-Q8+&]@3]R47;6TY(*E9\=45=#3
MQ/XXVU--'3DRU,"&98Y"RJT@523[!:>T7,.[;5NGU8MH]R;?(]YLF#:K5YHH
MH3I!!+A,R1 N$<D!F 4]"I_<[9-MW';_ *8S26*[2^UW092MPD3NPJ10*7[4
M=@A9:$A22 .EEO6B[>[SP=!UUG.L7ZXV]7Y3"U6_-PY/=-%EU-/B9HZEZ7&0
MT;M--)-+%&4E<*BZ;/8FX$_-=GS)[O6<>QWFU';+:2:W?<;B:[MY@8H9$F:*
MW6W9G9G9!ID<(% R*G >Y<N=@]LKE]WMMQ&X3I%,ME!';31$22HT8>9I0%4*
MK&JBI-:BM*$VE1&32S11)<FGDCCC6R_52 !>P'^W ]Y'RK5"%'X2 /RZ@B)J
M."Q_$"3^?1(.J>H.Q-N5'Q8?,[=:B3KJF[J_OBQR5'/]F=W-6''J?'4.9FG$
MT?\ FA($OZRMC;$;VX]K]\V%^4#=VV@;6N_?7?JPMX)O3-X [)&UE]8^#4%_
M$1UDGSSS_M&[IS*+>?6;]MG^D_3E'BBU$7BGNC&G3H/QZ:_AKT.']SMQ_P"S
M+?W^_AI_NE_H5_NG_%_NH+?Q#^-?=_;^#R_<W^W]>OP^/\:]7'N7/ZK7_P#7
M[]]>%_B7[A^C\;7'_N3]?XVC1K\3X.[5IT>6JN.HV_K!9_U-_=?B?XU^]_JO
M"TO_ &'TGA:]6G1\>*:M7G2F>H^T=G[CP_<W?N[<CC33[>WCC^NQMW(_=0RB
MH.!Q3TU6/&DC31&*;C]R-0WU4D<^V^5N5K[:N:^8MSGBTVU\FU_2RZT/B&VL
MVBE&D,772V.Y17BM1TYO_,%GN'+NQV$,FJ>T>_\ J(]+C1X]R)(\E0K:ESVD
MTX&AZ+CT'N;NC'= 8#!;2ZTIMT4F7I-TP[0W12;GI<7'1M5Y.OBF_BE/4LDV
MJFJO/,C0DK+$8X[K(&/N#/9/?^:;#DJUM-MVM;M9DNQ9W27<,20E[NX1OJ4E
M97_3DUNIBU!TTKVN">I?]TMFY=O.:I[J_P!Q:V:)K8W5LUM)(TH6WA9? >,,
MM'32A#Y5PS94@=*!^C=R]?2].G^Y<'<>U-D[.S&(S&TEK:2-*?,YJKEKI\M!
M3Y-HX*E7EG,27]:)&CZ4*K8]_P!:*]Y).R 6(WNSL+*>&:S#P 1W\\QN&ND2
M[9$>K.46IU(H5@!3HJ7W,L^:UW;_ !QMIN;R[BEBNM$I,EI#$L*P,]L&9"%3
M6:=K%B*FIZGX?K#L22#Y.U]3U_C-IMVAL+#T&SMLX7+4-1$LU'C*^B^T9HF@
MABJ-30M,="P^21BDCJ"WM5MWM]ODB\V3R;=%:'=]N@CL;6">!E#QV=S;^$2I
MC59*E&<T$>ISI=@">DFX<Z;2C<N1)?277[MO97N[B:*96*/<P3>( P=F2@8(
M*E]*C4H..EAC.M]YTVZ/B57388I1]9; S^&WK4??4S"CJ:S;M+01Q6$Q><M5
M(Z:H5D46U%@O/L1[?R%NL&X<FS-!1-IVZY@OV\2*D,LFV0VRK375ZR*5J@9<
M5)I0]$%[SAMTUES1$LU7W&^@ELUT2?JQI?R3EO@HM$8&CE3Y4KCI;[YV?N/,
M=X=%[MQV--1M[9U/V4-Q9'[J&(4YSV,6FI!XWD6:4RS<?MQL%^K$#GV+N<.5
MK[=>;N7]S@BU6UBNZ_52ZT'AFYM%BB&DL';4V.U33BU!T&N6>8+/;^6MZL)I
M-,]VVW_3QZ7.OP+@R29"E5TKGN(KP%3U[^YVX_\ 9EO[_?PT_P!TO]"O]T_X
MO]U!;^(?QK[O[?P>7[F_V_KU^'Q_C7JX]Z_JM?\ ]?OWUX7^)?N'Z/QM<?\
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M09W9-'@-K;:FJMP4^7@S=;DLC'2114E-1.:HG[:1YB"5)*:%N;Z0+M7-^_\
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M5]) 6)+7Q68$X+,T8"\-7#IOF>*WMK1P-]>_=BNBW2.[\-EU EI&G**M!D*
MYK3AQZ#;8>.[CZ1Q^7ZWV_U=%OS;T6<R]?L;=%)NRBPL"4^7E:58,E#4'[B-
MJ9F)=D5M=RD8:P8@'DZQYF]IH9MALMI&X6JSS2;?=I>001K%/(T@2X24^(IB
M+$LR!]0P@)&1AS1=\O>Y,L6\7>Y&RG,,27ELUK-,YDB4*6A:/L(<"BAB-/%J
M5(#W_".U=H=RUV]Z?8E-O.BWYLS9^%S51@L_3X>+&U^&LE262N;S24?JD=&4
M,^G2MB]P3D[=S#RUS3)NJ;>M]%N%C96\[V]Q%"MK<6[$.2MPP9HB'9E*ZFH
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M>GQJ[/WYU9OS)=);!QN\X/N^N\Q4X*OK$IZ?(25T&/?)4<\<,L]/%Y  0!J
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M <0QNY2/6%&K2H/&E S5%]QSSN%QM:[/JC2V!5F6.*-'E*&J^*ZJ&?2>%3Y
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MCAUKMFLW%4[HQ5=2I7TIIJJM@I)(94@DBD$Q?F)D/NO='N_FG;4W3OO^6?\
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M^-W=.9K$+0G#R9BES5)B<1#/#65U#DJVC@DH*T35>JFG9/=>ZV$\?U%VJ?\
MA29G^^?]&^^4Z2B_DK4'4I[<EVM6Q;;;=%7W9%F$V]%F6A&/FS(Q5/+5O21U
M#3QTX$LB*CH6]U[HK??';>^_@+\ZOYY'S[W/UMN^EV!M_P""7PYIND]U[@VW
M7X; ;NWM0TVX,5A=M8?,RT<E%D:VHW/D,/0U$5+]S+3O4H)(2S*C>Z]U;1_*
MK^*^7^&_P'^.G2>\97K>UX]G-V+WQF9ZV3)RU^_^W:F;<V\ZJ6JF EJ;[@RE
M=%'(R)>&*(+'&H$:^Z]UKV=;_'WN/O;^6W_,3_DF;M^.7R9ZP^26>[7^8'8^
MP.T-V=6Y?;G5>;BKNQ/](^RJVB[+IPV"J*#<%5)C:$TZSO4L16+449IHJ@CW
M7NGSJ/H7^45N/&[$V+V?_('^3>/^5M7!M[#]D]=3?"?=&=Q]/G98XERF2D[$
MK*JFV!68$U7GG&4DW,$J(B&5'G=86]U[JRS"=+]F47_"D++=UT?6&]*+H;&_
MR3\5TW2]I)M.LI=L+N1^ZH<K#MNGRY@7'29:/$4TE4:..=IHJ95E=%1D+>Z]
MT2GYB? _Y ?+#Y5_S].O-I; W=@Z'Y'_ ,OWX>;-Z.[!W'@*_;NV]Q;FV!'G
M,F,-09^:!,=52"OHZ6DK1#/+]H*@&I5%-C[KW0??/CYB?*;YP?R@NY/BAU5_
M+2^;U%\GJ_H7";6^1N"W]TCE]E[?VG4[ 2CK,['MW+U5+%+V37Y2KQ34V!I-
MM4%=+5I5T]=6+0TBN3[KW4SY6? SH_K#^8?V)\LOFY\ ^ROFS\4?E)\;OC9B
M)-P=<]99[Y"9+K/?_0F).VZF'*;)P9FS--A\[@GH&2OHJ"HBAJX*E)HX7GED
ME]U[HP\WQ^^)-5_*\_FPC^7I_+;[I^+V1[7^'?=O7V*H]R_&K,=0;B[(KCLW
M=$.)IL!M7(/-O&MBIJVN>&G6IP=&U3/5C[.*I1O)[]U[HQ>X>HNU:/\ X39R
M]#2];[YE[MH_Y*V-ZEGZCHMK5N1W)_>BEZ3AP\FWDPU/#+D)<RN55J3[1*=I
MS4#Q!"_'OW7N@-^4_1/=>1_X2ZX3X\XGJ3LC-]\XS^61\3NO:WIG ;+R.>W0
MF=VGMW9E/D\0,'1T\^2?(T$U'5)/3K3-)&89-2C0UO=>Z*5\C_@1TGU5\]-U
M_*WYP_R_^S?FI\5_D_\ %GXN8.IS?7O6&?\ D#E.L>P>@<&NVJNGRVQ\(9<U
M2XC.8-J!DKJ.@J(X*N"I2:.&2>627W7NK%OBKMWX)]'_ !W^3W;GQ#_E%?(7
M8/7NX8MA[/[!ZTE^+"]<[H[0P=56S4%?)A]D[QR=#G,UB-NT&5R57/2U^/HI
M<A 9X\939"62)9/=>Z)5\,<%)U/\W]U=D?RS?B-\\NKOY?>$^+7>^\_D=\<>
MV>NMQ=)[0W)V-!-'6[1P'3VS.SJS$OC-V5]2F53(/0P4.WE2HAAEJ(G)5?=>
MZ;^IME[4KOYCWQ;["_E5_$'YT_#B@W#VSNW-_P R? ]C]'[L^,W3M1M0X.I6
MH@R6V=RM2[8R'8-3F1BUQM1M6CG/[<U34SFG99I/=>ZVP_?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6J[_PF"_[K
M$?\ C5KOK_KG[]U[K:B]^Z]TWY3_ (!R?\&C_P!['OW7NDO[]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ(_EU_RH,3_+C^17SE[0ZO[QRN=Z.^8F
M_P#"=F;=^-M3LEL-0[%RM'/E*BNDQ^5&<K(:^.M.5D@4)@L>\=)34-/-)5?9
MQ./=>ZMW]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW55?\W+^6
MAD_YJWQ]V)\:JGY&9_X]]<8[N;:/97:J[9V%#O:KW1BMJPUB)@(Y9\MC(<4W
MW%4E7%5209"**JIJ>62@J!$%]^Z]U9KM3:VW]C[6VULK:>+I,'M;9^ PVUMM
M82@C$,%'C]OT\=)1TL*#A8J>FACC0?A5 ]^Z]T_^_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NE?1_P# 6G_Y9)_O7OW7NI/OW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[HL'S&^(W4OSD^/F\_C=W4=V4VR=XU6U\Q'G-@
M[FGV;G<3E=CY2CS6%S&'RE/>2CR.,RM!25$3%)(V*&.6.2)W1O=>Z(ID/Y2N
M?[:GV?M_YC_S _EY\R.D]C[QVEOW'=!=D8[KSK[;^5R>P:ZGR>%DW54[)V5M
MW-[FIZ#(4L%2*6JR@IIIHXVJ(I0ND^Z]U<5[]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7N@^V)U+U;U=5[[K^M>N-B]?UW:.]\KV9V56;+VI0[8EW
M!N/.QPQ5N>S4E%!"V3S%7%34ZS5E09*B58T#R,%%O=>Z[SO4_5VZ.P-A]L;D
MZYV-N#M#JVCW7C^L^Q<UM6AR><V]!ON"&FS<.%RLT#UV+BR]-3P15BTT\8J8
MXT28.J@>_=>Z]U[U/U=U)3;IHNK.N=C=;T>^=\[E[.WI2[%VK0[3CRVY-YR+
M-E\_DDH8(%KLSE)41ZJLF#U%0RJ99&*BWNO=!=G?AO\ $C<_3U9\>MP_&#X_
MYKH?(;BR6[ZOIG)=/X"JVN^7R]=/E*G*_P ">@.-7)39*IJ*IJI:83FHD>;R
M>1BWOW7NI/7WQ%^*G4T. @ZO^-G1'7L>UMB[EZQVX-F]3X+;AHMN;TJ:6LS&
M"IVI*&)H\1EJNAHYZRD!\%3-#'),CN@8>Z]TQ=,?!SX8?'/>6>[%Z!^)_P <
MNE=_;H6JCS^]>K.F-O;$RM3'7,))X'K\;CZ:I%--(-;PK*(F?UE"Q)]^Z]TI
M,W\3OB]N7O+;_P G-Q?'7I'.?(W:E%'CML][9;J_"Y#=U!!!#-31QTFX9:)L
MK L5-4U$,>FJ!CBEEC0JDCJ?=>Z1G>7P)^$/R;W5C=]?(KXB?&SO+>F)@BHZ
M'=G:W2NWM^9%8(  E,]9DL?45$U*@4:8))'B%N$'OW7NA;BZ$Z-@W)U?O&GZ
M;ZMI]V=(8;<NW>F=R4^P<5!7;2Q^\Z>&DR]#MJJ2E6;!TF4I:>"&JAHWACGB
MC2.5610/?NO=/.=ZGZNW1V!L/MC<G7.QMP=H=6T>Z\?UGV+FMJT.3SFWH-]P
M0TV;APN5F@>NQ<67IJ>"*L6FGC%3'&B3!U4#W[KW05[H^&GQ&WMW5@_DAO'X
MP] [J^0.VHZ6/ =U;BZCP.9W11_P\,*9H,Y44$F1CDI5=Q!(*C7 KNL3('8'
MW7NE]1]$=(8_KO/=04/3O5U+U/NFOW5E-S=80;!Q4>WLC4[YR-1E\U/7844G
M\.JY<ME:NJK*QI:9C4U,LDTNN1V8^Z]T%G0OP8^%_P 6<QEMQ?&SXH?'?HC<
M>>A^US.XNI^GL!L3(5,(+,*>:NQU!3U3TREW*PF7Q+J.E!<^_=>Z#C^9?\/:
MSYU_"SN;X[;=W%#LKLG-X[![RZ5WY-53T*X'?'661I-P[2RKSTR25$5/3YS'
M48J&CBD?[9Y@L;DA3[KW0_83JG"[\HN@NR?D!U;U1GOD/U)MY<KA]TQX.EWA
M)M3<>\,/#C]TOM'-5V/I\A0T]>//2O/!#2255($2:,+^V/=>Z&Z6**>*2">.
M.:&:-XIH94$BNL@(964@AE8$@@BQ'!]^Z]TA^L>K.L^E-B;>ZNZ=Z]V5U5UK
MM*GJ:3:W7_76V*+9F%QL5;435<T=#C,=#3T=*DM543S.(X5#2R/(UW=B?=>Z
M /<WP#^#6].WX?D#N_X>_&7='>$%<N53MG<'1^V\QN U<9+)6/E*C'25<E9&
MQ)2=I3,C$E'4DGW[KW2H[\^'7Q-^5)P+?)CXT=$=_2;6D\FVI^X>J<)V)+07
M8NR4DN5HJJ2"&1F)DB1A')<^16!]^Z]TO\IT=TKG.J)NA\SU#UAE>CZC;J[0
MGZ;R.PL56;5?$HH1<8VWY*1L2<>J@ 4_VGB  L@M[]U[I#=+_$+XI_'+:&Y^
MO^@OC;T7TSLC>[53;VVIUGU7A-ET&9-=!]K-_%J:@HH(LEY*7]EON5EO#^U_
MFP%]^Z]TANO?Y>GP,ZEHJK'=8?##XM=?X^MWEM+L2HHMG]#;8V_$<[L"LBR.
M"RRQTV,C6.OPM?#%44$R!7HYE$E.8W%_?NO=&#VSU/U=LK>78O8NSNN=C;5[
M [?K-N9#M?>^W=JT.&RVY9]GT0QN)FSV1IX(ZO+2XS'C[:E:JEE-/!^U$53T
M^_=>Z)#U%\.MXT7\R/Y3?/OMU]DU62W1TYU+\4_C%0;<JI\I78GK_9TL^YMP
M39>6IH*44N2W!O3)U+FFIIIX8Z3'TCM,\DK)'[KW5CWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[JG:#^4QN/K/>';N5^(O\PCY@?$3KOO3M/?'=78/3&Q*/K[LS!0[E[,
MJ36;@R.W)M];+W)EMMC)U9\[T])D/MHI2[T\,6LCW[KW0W87^6CU#L'X)]R?
M!/J#??:G76W^^,7VHG9G=W]XUW7OK*YGO.25]W[HKLM7Q-%/N'-I45*-.*9(
MH R"GAC2&)%]U[HY'1W3NR/CUTUU7T3UKC5Q'7_3W7^TNMMG8\*BF/';-H8*
M"E\FA45IGB@5I&"C7(S,1<^_=>Z%/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0#Q?&WJ@?)&K^6-9AZ_
M+]UMU+1](83<&8R\^1IL+MN+)RYBLHL'CW8TF+ES.0>GER=3#$*BO%'015$K
MPT5/''[KW0\>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HDW\Q
M+X.;!_F/?$/M'X==G[OWAL38_:U5L&IS>Z-A?9?Q6G_T?[CQ.Y:=:4Y"FK*,
M>>JQ$,4ADIGM$[Z0'TL/=>Z.S[]U[KWOW7NO>_=>Z][]U[HOOR-^,/3_ ,K=
MK[(V5W9A,GN7:FPNWNM>[\3@:+<-;@*>HSO4N07*X3^))130_P 1QU/D(X9Y
M**<O33O%'YHW" >_=>Z,%[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM5W_A,%_P!UB/\
MQJUWU_US]^Z]UM1>_=>Z;\I_P#D_X-'_ +V/?NO=)?W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=*^C_ . M/_RR3_>O?NO=2??NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=:KO\ PF"_[K$?^-6N^O\ KG[]U[K:B]^Z]TG-TIE'Q9&)EABJ?N(2
M[3@$:.;CE6YU:?Q[V.M&OET&_@WM_P KF._Y)7_KU[WCY]:S\NO>#>W_ "N8
M[_DE?^O7OV/GU[/RZ]X-[?\ *YCO^25_Z]>_8^?7L_+KW@WM_P KF._Y)7_K
MU[]CY]>S\NO>#>W_ "N8[_DE?^O7OV/GU[/RZ]X-[?\ *YCO^25_Z]>_8^?7
ML_+KW@WM_P KF._Y)7_KU[]CY]>S\NO>#>W_ "N8[_DE?^O7OV/GU[/RZ]X-
M[?\ *YCO^25_Z]>_8^?7L_+KW@WM_P KF._Y)7_KU[]CY]>S\NO>#>W_ "N8
M[_DE?^O7OV/GU[/RZ]X-[?\ *YCO^25_Z]>_8^?7L_+KW@WM_P KF._Y)7_K
MU[]CY]>S\NO>#>W_ "N8[_DE?^O7OV/GU[/RZ]X-[?\ *YCO^25_Z]>_8^?7
ML_+KW@WM_P KF._Y)7_KU[]CY]>S\NO>#>W_ "N8[_DE?^O7OV/GU[/RZ]X-
M[?\ *YCO^25_Z]>_8^?7L_+KW@WM_P KF._Y)7_KU[]CY]>S\NO>#>W_ "N8
M[_DE?^O7OV/GU[/RZ]X-[?\ *YCO^25_Z]>_8^?7L_+KW@WM_P KF._Y)7_K
MU[]CY]>S\NO>#>W_ "N8[_DE?^O7OV/GU[/RZ]X-[?\ *YCO^25_Z]>_8^?7
ML_+KW@WM_P KF._Y)7_KU[]CY]>S\NO>#>W_ "N8[_DE?^O7OV/GU[/RZ]X-
M[?\ *YCO^25_Z]>_8^?7L_+KW@WM_P KF._Y)7_KU[]CY]>S\NO>#>W_ "N8
M[_DE?^O7OV/GU[/RZ]X-[?\ *YCO^25_Z]>_8^?7L_+KW@WM_P KF._Y)7_K
MU[]CY]>S\NO>#>W_ "N8[_DE?^O7OV/GU[/RZ]X-[?\ *YCO^25_Z]>_8^?7
ML_+KW@WM_P KF._Y)7_KU[]CY]>S\NO>#>W_ "N8[_DE?^O7OV/GU[/RZ]X-
M[?\ *YCO^25_Z]>_8^?7L_+KW@WM_P KF._Y)7_KU[]CY]>S\NO>#>W_ "N8
M[_DE?^O7OV/GU[/RZ?H*;L@PQ>+(8@1Z%T HM[?]2/>ZKUJC=9?MNS/^=CA_
M^2$_Z\>_57KU&Z]]MV9_SL</_P D)_UX]^JO7J-U[[;LS_G8X?\ Y(3_ *\>
M_57KU&Z]]MV9_P ['#_\D)_UX]^JO7J-U[[;LS_G8X?_ )(3_KQ[]5>O4;KW
MVW9G_.QP_P#R0G_7CWZJ]>HW7OMNS/\ G8X?_DA/^O'OU5Z]1NO?;=F?\['#
M_P#)"?\ 7CWZJ]>HW7OMNS/^=CA_^2$_Z\>_57KU&Z]]MV9_SL</_P D)_UX
M]^JO7J-U[[;LS_G8X?\ Y(3_ *\>_57KU&Z]]MV9_P ['#_\D)_UX]^JO7J-
MU[[;LS_G8X?_ )(3_KQ[]5>O4;KWVW9G_.QP_P#R0G_7CWZJ]>HW7OMNS/\
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M_P#R0G_7CWZJ]>HW7OMNS/\ G8X?_DA/^O'OU5Z]1NO?;=F?\['#_P#)"?\
M7CWZJ]>HW7OMNS/^=CA_^2$_Z\>_57KU&Z]]MV9_SL</_P D)_UX]^JO7J-U
M[[;LS_G8X?\ Y(3_ *\>_57KU&Z]]MV9_P ['#_\D)_UX]^JO7J-U[[;LS_G
M8X?_ )(3_KQ[]5>O4;KWVW9G_.QP_P#R0G_7CWZJ]>HW7OMNS/\ G8X?_DA/
M^O'OU5Z]1NO?;=F?\['#_P#)"?\ 7CWZJ]>HW7OMNS/^=CA_^2$_Z\>_57KU
M&Z]]MV9_SL</_P D)_UX]^JO7J-U[[;LS_G8X?\ Y(3_ *\>_57KU&Z]]MV9
M_P ['#_\D)_UX]^JO7J-U[[;LS_G8X?_ )(3_KQ[]5>O4;KWVW9G_.QP_P#R
M0G_7CWZJ]>HW7OMNS/\ G8X?_DA/^O'OU5Z]1NO?;=F?\['#_P#)"?\ 7CWZ
MJ]>HW7OMNS/^=CA_^2$_Z\>_57KU&Z]]MV9_SL</_P D)_UX]^JO7J-U[[;L
MS_G8X?\ Y(3_ *\>_57KU&Z]]MV9_P ['#_\D)_UX]^JO7J-U[[;LS_G8X?_
M )(3_KQ[]5>O4;KWVW9G_.QP_P#R0G_7CWZJ]>HW7OMNS/\ G8X?_DA/^O'O
MU5Z]1NO?;=F?\['#_P#)"?\ 7CWZJ]>HW7OMNS/^=CA_^2$_Z\>_57KU&Z]]
MMV9_SL</_P D)_UX]^JO7J-U[[;LS_G8X?\ Y(3_ *\>_57KU&Z]]MV9_P [
M'#_\D)_UX]^JO7J-U[[;LS_G8X?_ )(3_KQ[]5>O4;KWVW9G_.QP_P#R0G_7
MCWZJ]>HW7OMNS/\ G8X?_DA/^O'OU5Z]1NO?;=F?\['#_P#)"?\ 7CWZJ]>H
MW7OMNS/^=CA_^2$_Z\>_57KU&Z]]MV9_SL</_P D)_UX]^JO7J-U[[;LS_G8
MX?\ Y(3_ *\>_57KU&Z]]MV9_P ['#_\D)_UX]^JO7J-U[[;LS_G8X?_ )(3
M_KQ[]5>O4;KWVW9G_.QP_P#R0G_7CWZJ]>HW7OMNS/\ G8X?_DA/^O'OU5Z]
M1NO?;=F?\['#_P#)"?\ 7CWZJ]>HW7OMNS/^=CA_^2$_Z\>_57KU&Z]]MV9_
MSL</_P D)_UX]^JO7J-U[[;LS_G8X?\ Y(3_ *\>_57KU&Z]]MV9_P ['#_\
MD)_UX]^JO7J-U[[;LS_G8X?_ )(3_KQ[]5>O4;KWVW9G_.QP_P#R0G_7CWZJ
M]>HW7OMNS/\ G8X?_DA/^O'OU5Z]1NO?;=F?\['#_P#)"?\ 7CWZJ]>HW7OM
MNS/^=CA_^2$_Z\>_57KU&Z]]MV9_SL</_P D)_UX]^JO7J-U[[;LS_G8X?\
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MU[[;LS_G8X?_ )(3_KQ[]5>O4;KWVW9G_.QP_P#R0G_7CWZJ]>HW7OMNS/\
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M_P#R0G_7CWZJ]>HW7OMNS/\ G8X?_DA/^O'OU5Z]1NO?;=F?\['#_P#)"?\
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M$R*/C\U18_(P&FRF.K(;R4JK)X_)$7B=';W7NC"U50E)35%5(&:.F@FJ)%0
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M-*/=>Z"W^7OM_P";_P#,*[=^<'879/\ ,7[TZOZC^%?\UGY6=+=+]5])PXW
M/E$ZQW)!D3B>R*_)XRK;<.T:; Y##8['XF@DH4BIS53SUCUSJ]/[KW1+/Y@W
MS'V_\.OCKO[Y1_&+^>!\HOE]\QOC'OSK6DWYUZ^3VYN[J3>,N1WEMW%;CVWF
M,#M?8T>R]MBCQ.2KGB%#G(*^$D0RSU-0U$\'NO=;E&]<MO*+K'=N<Z_P^/RW
M8,>P\]EMD8#)51CI:G,ICY9L;1SSVC*T\U<(8W>RV0EK#\>Z]UKH_P H_N;%
M]W[YZP7NG^9%\Q,9_,=VIC,GEOF+\!?D15XSK['5.0J,;5+D<=M[KW+;5QHI
M]KX6LR%+58W+;8JV:6&E@^^K*@/.@]U[H,/AOLSYV_S.9?YEM1O#^9=\E?CU
ML3XK?S./F=\=OC]@/CE'@MHY9I>N<I2Y3'-O#/93$YJIS.U\50Y;$4%!A:&+
M%H(8*UZZHK9*F(P>Z]T6[IG>?\QCYP_R2\I_-UWW_,J^073?;W1/QK^0/:_3
MG5GQSQ&V=@;1RU9\1:#=&(R.1[.Q]5@<E+O;)[SR6V\G5S4R3T&$QZU%']IB
MA/2&5_=>Z.]/\X?D9_,,[(_E>?#'K'O#<?Q$SWRJ_EM[7_F2?+_LOI7%4,^[
M*; ;II,7C<1MO9&4SV+R>*PSY/=$^5:IK#05573TE)&J)&);S^Z]T(W7NXOD
M!_+1_FB?"GX,[H^6WR%^8GQ;^?O3G>^-Z\D^564QG9.^-F[X^*V$I-P5^0DW
MM246'K<OAMRX>H\4M-5T-1)!7F.6*2.!I;>Z]T'/POVO\@_YTW6VZ?GWE?YB
M_P QOC/U3N/O#O#;WP_Z7^(>Y,)U+@<;M3K?(97:N'R^]8<IMK)Y;>68R53!
M49.HI:^I@HHW^WB%(HB01>Z]U53\ENQOD9\Y?@/LR?OWY4]T8KO7X,_SF^M_
MY:?<60ZIQVVMA[9WSF>O>RL!!C>T6PM1ALP]#NJAH,I0R4Q@K8*"/(05#38R
M:F>)#[KW5AG\Z_HOM;I;H;^3UU+M7Y+=E=S=P5/\\+XC0]>=_P#RJIL9V'D<
M?G=UTV[X\%796AVS0;.H<IC=NY&6EGCHDAION(H/!/*XD=C[KW0[UFW?D]_+
M<_F4?R_]GUWSU^4GS!Z:_F%[P[ZZQ[IV#\ILQM[<D>&W)LS:$6X,-N#8Z8';
MN!I]KX_S8QJ>7$4T8HPE1--I>>1I1[KW1IO^% 7R6[F^'_\ *C^1WR*^/^\*
MS8G:_7&XOCS6;;W%1#45CS/9.T<=D:25;AFI<CC:RKI*@*Z.89I!')&^EU]U
M[JMOY^;?_F0?RZ]X?!/N_8G\R_MWN;N7YI_-#J;X/]L]<=U;1P&1Z:QF3^2&
M)W#!CL_M'8F*QF.RN!QNTLQ2Q5=/2G=%37UL,$%/7Y*H5JDS>Z]T-=)'\G_Y
M=/\ -L_ET]!Y?YS_ ">^9/57\RW;OS$H.WML?)_,;=RM/M[<OQOV?@=Q4.=V
M13X';F%AVSCZO5]LV&IA]DJRU-1(9JJ03#W7NC(?R-/DCWE\D]D_S),CWGV/
MGNR:WJ'^;C\Q>B>M:G/" -B-H["I=I2X?!4W@AA!H\>^0K#%K#R#RD%R H'N
MO=54[?\ FG\S-Q?RROB/W%V%W1\F:#I#-_._Y=;-^>7R;^/^V'WSV+M;K?K7
M=>^<?MH4"4.$S5?C\**O'8BBR64HL3+745#$&BD629I#[KW1N/D)\T*;XR?R
MW=K[A^"O\P/=7R]S_P V_F%TY\/?B9\A^VMPX3OFIV%F^]!%CJI*BOI,5129
M>7;-'A\]EH8-QI+5+72)2ULDL/BIV]U[JR?H3X+=Y_''?5)ORO\ YC_R\^2&
MTZO9.[,3VMU;\FI-J[YQF5K\A!))19C;L^)P&WZS9\^/J@BBF@DJZ.>CU020
M_<'[SW[KW6K7\'OGEF?BQ_(G_DH?'G:O=&:^.>7^9W<7S*V[O3O79G6U=W!N
MC;.P^G.Q^P,WN^KVAMS'8G/55;NBO>KPN,H)AA,@*.2O^Z-',8UT^Z]U9/\
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MYL^AW3MS<>R-Q5.S\!4/%F)4K_-34E958\1.WB$%/+01T_NO="_\,]D_-_\
MFB;4[V^?4'\Q_P"0?QMK*_Y!_(3KOX4])]18_;T_6FWMM]+;CGVYAZK?NU*_
M&UE3ORNRM9A:Q\F)<Y2,T-1-_#YJ(O2_9^Z]TQ?RAVW'1_R%8JW?7RYQ7PAR
M6&[\^5.6[7^3NV:?;[4V!@Q7<NY)MPC$S[WI:O"T"994J:&EJZW'SRTR5*RP
MP&K6+3[KW0>]$?,G%=7_ ,U_^7ITK\3OYB7R;^='QK^=NV_E9C.W]K?)C+-O
M>@P-=TYL^AW3MS<>R-Q5.S\!4/%F)4K_ #4U)656/$3MXA!3RT$=/[KW0Q?!
MO"?)_P#G%]2]B_S HOYDGRU^,NR^Q>Y^X-N_#WJ#XXIM3;&U]L[4ZKS4FWL3
MD-SXO.;7R>0WCE<Q48FLK:Z+(5L$2I6/3110^.!H/=>Z"ON_I+OON7_A1EM_
MI_:?RBW+T/NBJ_D7;/7O/OWJ+9V-QV[LEA\/W#5096DV8,NN:PFT:_.[BEP]
M4]9-BLK+14%/4TE"8JB=*R+W7NHR?/+O[^4_M[^=!TAVG\@.P/F%@/@'T5\:
M.Z_BAV=\F<I3[DW;)-\DZ.3;N+VSO'-T%%C7W"E/NU<6XJWC6KJ$J9U>569?
M'[KW14^T?GAF^A^DMN?)/XX_S&/YC7R[^?\ MBNZRW'V7\>NP/BGVUB^GNQX
MI<I"-V;6V]@INH(-K;*HDQ^0RC8;*8_*K4.*2C6JKZXF*5?=>ZW:\;6C(X^@
MR"PU%,M?14M:M/5Q-!+&*I%<)(C ,DB:K,I ((((!]^Z]UKG_P#"COI#<787
M1GQ;WGB?D'WCUA0X[YO?#WKV?8O7F4P=+AJNIWYO[$P4NYJF')8+)U7]XMMN
M/-BI8ZM*5)"?O*2L0A![KW2!^0O46<Z,_G,_\)P^L]Q]V]O?(C+X*E_F\SU/
M;/>N1Q&5W-D5S'6,59%'7SX/#X'&.E!%.E+3^+&1$00QB0O)J=O=>Z-S_(T^
M2/>7R3V3_,DR/>?8^>[)K>H?YN/S%Z)ZUJ<\( V(VCL*EVE+A\%3>"&$&CQ[
MY"L,6L/(/*07("@>Z]U53M_YI_,S<7\LKXC]Q=A=T?)F@Z0S?SO^76S?GE\F
M_C_MA]\]B[6ZWZUW7OG'[:% E#A,U7X_"BKQV(HLEE*+$RUU%0Q!HI%DF:0^
MZ]T[_P W[*]39?\ X3C?,_>?2'S7WG\_NE]Q]D?'',;'W[V=V#C.SZW%4U%V
M5UW356UJG/X>BQ&6JT@JZ:HGD7*NV7IWJY(I*@*L(3W7NC&?+?9?S9_EM[R^
M'GS1S?\ ,<^17R+S_;_S(^-/QP^5OQ_WY3;?Q/4U=A>\*ZMQ%6_7NS\?A8JK
M9DF%K*X3T<KYFOKZJ*"GCR=?6/#J?W7NF[L/YF_*+%]N?\*L-O8_N?=E)AOA
M+\4OCQOGXIT,1I@NR,MNWHS>.Y,E78<FG+B6KSF.HJQQ.TRB:)2JJI93[KW1
M=.WH_P"89UW_ "G.J/YV-7_,O^0^5^0^V/C9\=?DI4?&W$4N#V]TED=K]A_W
M3R53M7)[0?$UV6R6:J,+5I%5;@J]Q3UC5[ULU$M!350IXO=>Z/)VSW_FODQ_
M,MWI\6NV_FUV)\%.C=@?"#H[Y&=/;:ZD[1P/2><W[7]OUN:&?W!5[AS-!655
M7CMG#$4U&N/I3'3B1YJBL6>,O&ONO="C_(0S7=W9?Q\[T[O[@^5?R"^4^'W5
M\ENY.L>E-Y]NY; Y# Y39'1^Y<WBMN[RV?'B-OXBHC@W=0U$?W\LU?6T]3-C
MXI:):6$M&_NO=7N>_=>ZUC?AGLGYO_S1-J=[?/J#^8_\@_C;65_R#^0G7?PI
MZ3ZBQ^WI^M-O;;Z6W'/MS#U6_=J5^-K*G?E=E:S"UCY,2YRD9H:B;^'S41>E
M^S]U[JOO^7+WC\C/B!\+_P"4_P#)7,=BU=)T!E/Y@_S'^*_SEZ_VZRMM>2;Y
M$]D[RQ>V=X 5<2UM'2;<WJD*B?6C&GK(HZE" 2GNO=7B[A^0?R-[K_FN]]=2
M_'S=53)U-_+[^%;9;?\ L"')"GQ6[>Z/DO#5U^RL%G7$8T4V"VWBDK++4ZDE
MR2/(B:8V;W7NBC?RC^YL7W?OGK!>Z?YD7S$QG\QW:F,R>6^8OP%^1%7C.OL=
M4Y"HQM4N1QVWNO<MM7&BGVOA:S(4M5C<MMBK9I8:6#[ZLJ \Z#W7ND/\'=E?
M-+^:%FOYC4?:O\Q[Y0=#]0_%[^:#\Q/CATQMCXLUV(ZVW+*W7&:H\MC)]S;L
MK\9FJO([?P=%EL/0X[!T,&-I98J6K7,OE(JQHU]U[HIR?SH/D!1_%SHSXE]S
M?):MZX^37_#C/RQ_E^_)'YA]>]*5F]MR':GPBHZ7,;EW7M/9N(Q.?:7>.X,7
MG-J8V&2#"Y"*DK:V:M^R=E"Q^Z]T:WXC_,Q]F?S'/BUT5\3/DY\\OFI\5?DE
MA>[\%\@L5\T.F.T*;(=<;@VGB*G<VVMTX7>&^.M]KRR8G/54%?BJK%/E'I*+
M52M210Q+# GNO=9/@[LKYI?S0LU_,:C[5_F/?*#H?J'XO?S0?F)\<.F-L?%F
MNQ'6VY96ZXS5'EL9/N;=E?C,U5Y';^#HLMAZ''8.A@QM++%2U:YE\I%6-&ON
MO=%YQW\Q'YL[W^$?7N([F[:[OQNU_B)_,J^1?P6_FD_,'XF=8O4;WCVQ\=L?
M438?=%#BL?B,_486BSL]=@8\_DL9C9*FC5)I*<P/.VGW7NC#_P P3Y+Y;XX_
MR&/E=\H_@'_,D[7^3D5%O_I+(=,?(3<&_P# =IY[;%/F]\;&V_E]L_QVFQ--
M55P$4N2:9,W3SY.$U\T,TNA80GNO='V_F-YKI+#]R;<P_P A_P";AW[\.L/O
MKKV'$]4_&/XR[GP.P=SUN4Q4^0FK]Y+-1[8W1OK.!8VIXUIQ"F$@%"?N::J$
MM4K^Z]TF_P"0I\L^V/E%T!\LMO=K=L;@[\'Q1_F ?)#XI]9]Z[UPT.WMQ;LV
M=UT<17;<RNXZ*#'8I(LR]#EUCF9J&&9E1!4QBH65G]U[J\#*RR0XO)31,4EB
MQ]9+&Z_4-'&Q!'^(('OW7NM*#XXY3^9%\H_Y$U7_ #8=Z_S2?DSL7NCI3X__
M ";[<Z?Z]ZCQ^V=N;6R$?Q@K]V4D[=DTN3P>:K=\9?<%5MNN9G-=18REII:*
M&'&!Z>:6H]U[H3?E?VA_, ZI_E8=;_S[J[Y^]W'N:#9/Q4[[C^&VQJ7![3Z+
M?9OR/W-L:E;9=9MB;#U^:R>4BQ.<@6IW!6;@FK5J?O3C4Q\%0L<?NO=6?_#W
MYH;YZ"[5_FU="_-#M#-[IIOAUG*KYG=4;YWQ5TRU,G1O;>WGSV/HHJF-(5K(
M=G9'$YG%R3O'YO(8HY=1*,_NO=!1TUOSM_._RH>A_E)\]/YE.^/@FG?/8N8^
M3_9F^*')[5P>3I]H]UMD<ALSJK;^8W7B,B,+3T>$JL'*CX_#-F)9*>6.$Q>6
M<GW7N@L_E[?+/,8S^:UV[\&^JOF5\@_FK\2-X?R]*GY:[7W)\IC-D]S;1W7A
MM^/M:MP6*S5?MC;F8R^ J,56T<JM6)4E'$:K52SQU3S>Z]U7A_+N^1?8/3_\
MCW^1%U!A^^*KXF]1?++Y:_)/IGO;Y08FNQ6$R6W\90;\[<S^-P>)RV<IJS%8
M3([PR>*BH$R$M,[T\:RB'2[^1/=>ZM ^'E%V>?YO'R$ZCZ__ )BOR[^3WQ7^
M,/QBZ_[,EQ&X^V-K]H;<HM]=JG<N(J=C[OR\&V6R&5J:7$KC]Q8R.',4E91R
MI&*V2KATQ>_=>Z+=\'OE%E._OY0O\N;Y(?/_ /FX=P_&!NRY_D]M/>46PL_M
MG8F\NU,Y0]G[EP>WJ>FS?\!RNZM6W\/BX:9*3;5#35,_G22JJ2R0^_=>Z.)_
M)2^5V_NQOE-_,Z^'M3\F.U_F%T1\2\[\4MR?'GOGY 8Z*@WS4XWY";1K<KE\
M/G)4V]MJ7(Q8K+XR=*6JJ,7#-(K.ZAJ>2 1^Z]UL4>_=>ZUBL)0?,7^8!_-,
M_G"?#2I^>WR!^,GQ3^,&0^&]?A<?\:9\7LW?OW7?/6D58,=@]YY+'Y?^[> A
MK<5FJ^M2CQ0R=775=,T63IJ>F>"7W7NEE\0>].^=V_$S^8YT!\D_YAF9Z7S7
MP$^;.\^AJO\ F#[AQ&SJ'<$G7^!? [BI)LK+N''-M.EW#58S)5.%DR,N*F*:
MHZB&&2M$;GW7NBX]$?,G%=7_ ,U_^7ITK\3OYB7R;^='QK^=NV_E9C.W]K?)
MC+-O>@P-=TYL^AW3MS<>R-Q5.S\!4/%F)4K_ #4U)656/$3MXA!3RT$=/[KW
M5A_\C3Y(]Y?)/9/\R3(]Y]CY[LFMZA_FX_,7HGK6ISP@#8C:.PJ7:4N'P5-X
M(80:/'OD*PQ:P\@\I!<@*![KW1$.N_EE\^]\?R,).\^O=Z]Q]@]U2_,3M38?
M:O9_7FV*;L7?^"ZLVOW/G,#N+*[1P\F/KH<GGL!LZB6*B0XVI=$5JD1R30AC
M[KW0PT/SR^/OQ1_EL?-_Y^_%3^8/VW\\]E]:]8[;_NWU[\F.P:;?V0V?OS.U
MCXK$4F8%1A<'O?"R9S,[@PT59B,MH$2TH2@CI-4@]^Z]U6OVC\\,WT/TEMSY
M)_''^8Q_,:^7?S_VQ7=9;C[+^/78'Q3[:Q?3W8\4N4A&[-K;>P4W4$&UME42
M8_(91L-E,?E5J'%)1K55]<3%*ONO=6Q_-+</160[VWWM;N#^=?\ *_XZ]I[K
MPNU][=0?&+XP97";>KNOL8N/H(TGS6V\%LW<NY<_%E*XR3U#[CG\#K6&GH8J
M1DI)XO=>Z-'_ ")OESV_\Y?Y5?Q2^2??62I<[VYN_#=A;;WIN:EI(,=_%JCJ
M_=N>VO'E9Z:E@IJ6GK,C3X>&>I2"%(?.\C1(B,(T]U[JW+W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6J[_ ,)@O^ZQ'_C5KOK_
M *Y^_=>ZVHO?NO=-^4_X!R?\&C_WL>_=>Z2_OW7NO>_=>ZTB_P#A7IMBEW7W
MW_)2PV8P@SFVLWW9WWMC/4-31FKI:B+<6:Z<B:BG%BC"LITJ5$9-Y$62P(5K
M>Z]UM0=$?RX?@/\ &'>'^D/X^?#SXZ]1;^%'-CX=[[(ZIQ&'R\-/4Z3+!3Y)
M*8UE-%-I3R)%,BR:5UAM(M[KW6K]_P *A(Y&_F,?R$M*.WD^1><CCTJ3J;^_
M74_I']3R./\ $?U]^Z]U&_X6KT%=7_&CX.0T-'5UDL_R"W[0014E.]0SSUV
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M#6J-">Z]T?+_ (3\P3S?\)N,O#%#+++4[)^<B4\4<9=I#)7;G10B@$N2XT@
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M ?LCY LA(M<#>&5%Q_47!'^N"/?NO=:N/3^_OA/VM\J?FWB?^%%>R?F!W?\
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MKW2OQ&(Q>W\3B\#@\?1XC"X3'46(P^*QU.M)3TM+C8EAIZ>") $BAAB1$1%
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MU[KWOW7NO>_=>Z][]U[K5=_X3!?]UB/_ !JUWU_US]^Z]UM1>_=>Z;\I_P
MY/\ @T?^]CW[KW27]^Z]U[W[KW6DM_PK>_[*;_D;_P#B=^]?_>@Z5]^Z]U;M
M_.+_ )TV1_E0=V_"K959THW;77_R1D[:FWO)MZ2IK-S4XZ[.!BH:#;6-C>&E
MKLEF*S-QP1BIG2-'T$W!8CW7NJXMT_\ "A3^9#\5_E+T)B?YBG\L_ _&+XA?
M*/>>+VKUCN-=YME]UXBFJJNC@J\EF<C#EJS"U51CH<G0U%3BI\-A*N.+S,LD
MI0@>Z]T7O_A6SOI.K_F3_);[+DP&<W7'UWV9V7OI]K[9IA69+)#:6ZNL<@:#
M'PD@2UU8*?PP)<:I71?S[]U[HQ.XO^%!W\R7XO?*SX_X+^8?_+-P?QD^(WRJ
MWQA]G]6[@BWC)F]V8F"OK**FJ<CF*^GRE=B*NIQT64H)ZG$RX3"UB1>8H\K)
MI'NO=&N_GD_,OJOXR_,?^4YL#?GPE^./RBW!W=W7D,/M+LKNO QY;+[$DI=S
M;%QQK=LR-23F*I>7,Q59U2"/[BAI)-!>-73W7NJ>?YUW>&Z/CA_PIV^"7<VR
M.GMW]_[TVA\:.NHMH=-;#D$.5W#E-SUW:&'Q^/II6BG6!6J\A$\TIA<10)+(
M5(2WOW7NK#.F?Y^'SWZ8_F!=+_#3^;=\#]G?$W!?*O.8;"]#;QZ\W#/NPT4V
M]*Z'$X.#+9&ES6X\+G%?,21TF0FI)\=-C#54T]900P7=_=>Z'KX^_,OJO=7_
M  H[^6WQ$Q/PE^..SNRMC]*+F,W\QL#@8X>P=P1PX#8F0-%DZP4B:J9X\S#3
M-:8R/#04BN[K&J+[KW6NS\EODO\ S1:#_A2WT[VGBO@]M27Y@;5ZR["V7TA\
M:8.V:"/&[SV72;>['I:7/UN:.7AI:5Y<'-E<K]M/5T[B;'PH:=)62-O=>ZV+
M/F7_ #Q/D?\ 'G/_  Q^%_4WPNH>XOYKORBZBVAV%OCXUMO^GQ.V]C5F=QE7
M4U-!4YQ:AJ3+30UF,RQ\:YFF@@H*.2MJ\A"DE,)_=>Z#?I'^=W\]/CS\V^B_
M@W_.5^''5'Q^S?R>RS8#I/OSX_[OER6UZROR553T&+IYJ"KSFZ&:"HR51!15
M$W\=AJJ.>II'GQJTTWG7W7NA!_FA?S]=X?RZOGYMSX9XKXT#O)NP?C=MK?G5
M&.VIDJT;DW%V#V7GLOMS:^U(($CDI*;'560H*=ZBI$<]3XFE2EIYZDP02^Z]
MT'7:/\[W^89\1?A+U[O[YG_R_P#9VQ_G5\AOF!F/CE\=.@\9OR/:>WJ_!SX[
M!U^,W+E\C4YG/&E*UF6FQ,D;92G6:J@%8YQU*[)'[KW5GOP/[>_G YSMG-=:
M_P R#XL?%W96R6ZQS&]MK_(/XK=DY"OP[9N@RF&I*?:-?MO/9#*9J.MJ<?D,
MC6"O6K%(/X>\0#M.A3W7NC:_/+O&N^,_PE^6_P @\3&LV<Z9^./<O8VW*9ZS
M^'B;*;5V_7U>,A,X!:'S5\=,FM59EU71'8!3[KW5&'_"2#J.BV5_*B@[<FK,
MEEMV?)?Y"]R=G[JS&7JEK9Y'VU5P[0AB$MO,\6K;M14L9W>5JFKJ7+F-XU7W
M7NJ+/^$LWPS_ )?7R:^+/S5W-\V^F>A^PAM#LK:F+QF[NWH:.CJ,/B:O 5$U
M<U%E)YJ>?&Q!QY6FBGC,;@.'5@"/=>Z.C_PD<G?"?(7^;9UOTQN#<&X?ACM+
MM[;L_3%9/4R9'%S&?.;LH,3D*>IE0^7(9':F-Q35+K+KEBBI6G5K0D>Z]T5_
M_A)A\"/AC\Q/CO\ ,#-_*+XT=1=ZYG:W;VQ]O[:R_8VTH,_58^CR>#GFG@HJ
MB0>6E226SDQNK:P&!# $>Z]TN.TNC8/^$_?\_P!^%B_$3*;LVY\./YAN7V=U
MYOKHY]SS9NC27=>X/[K5] 8ZWR33T6VLAF\'F\14354E;"\M90+4"D>:.H]U
M[H OF?O_ . '6G_"K+Y>;I_F74&R<E\7(.N>KJ/,4O8'6F8[9QQS-9TMUXN'
M+X?!XK,U\DHGUZ)10E(CZG=!8^_=>ZVV/Y3FX?Y-';5'VOVY_*9V3TYBHL/4
MXCKGMG<_671N>Z5J&:I09.BH*N+<&!P-56PV7RH\<,L2L&&L/J7W[KW6BI_(
MW[J_D%=<?'7LK ?S8=C;2W'W;D^\<MDMB9K<?46\NPC3;3.!V_#3Q&IVS15<
M449RZ9AUB*M,"'=E57BU^Z]UOO[?^2?P&^#?\K3>/RD^&>*V%NKX8])=?[_[
M'V/MOH;-QU6-R%5+DZF2LQE'5325/V==6;DJI8*H5 \E'422B>%6B:,>Z]T0
MCX0?S"/YX?RD@^.7R8S'P/\ B!5_![Y*[PZ]CH\?U_W?74_8NS]G[MRU/C:_
M>67GR&1GPF=I\;1M4Y/^'4>*I,@T"+22PT]3Y-'NO=$__P"%<$DO1.W/Y9WS
MVV9$T';7QF^8$%!M>KIZZ7&-40Y.B3=@I)I8C?PFLV5"ERC%$GG"BTLBO[KW
M6WSMS.4FY]O8'<F/U_8;APV+SE%Y 5;PY:!*B/4" 0=$BWN ?\![]U[IY]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2OH_P#@+3_\LD_WKW[K
MW4GW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5N?$_^:/\>?F/
M\LOF9\.>K-K]QXCLSX-[H@VAVSG=_P"TL?MK"9&KDR.1Q3MMR5,S5Y:NI8JS
M%U(\]5AZ&*:)H:BE:>":.0^Z]U9'[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[K5=_X3!?\ =8C_ ,:M=]?]<_?NO=;47OW7NF_*?\ Y/^#1_P"]CW[K
MW27]^Z]U[W[KW6DM_P *WO\ LIO^1O\ ^)W[U_\ >@Z5]^Z]TX_\*A?^WC'\
MA3_Q8C.?^]UU1[]U[IN_X6Q?]DR?"'_Q._8__O/P>_=>Z<?^%0O_ &\8_D*?
M^+$9S_WNNJ/?NO=-W_"V+_LF3X0_^)W['_\ >?@]^Z]TX_\ "H7_ +>,?R%/
M_%B,Y_[W75'OW7N@)_G,_(#:WQ0_X4[_  @^3?8. WKG.L.C_BYUSO#M*IV'
MMJ?==9B<!7Y7LK#5V=GI*<&0X_$?Q6*IJF'J\2,L8>9HXW]U[I+_ ,U?Y@=#
M_P WK^;_ /R<>FOY?N[9?D'4='=NT&\>Q=Y;:PE?CL31T6;W#L[<F2E6?)TU
M T\>WMN[7K:W(/&K(A84:%ZY)*9?=>Z,]\2/^XR'Y^_^*[S?^\;U/[]U[I%_
MS&^\^K_B)_PK*^$/R-^1>YH^KND<)\6JVERO8V>H*EL?#_>G:7:^V::4R0PR
ML\*9G*44$SHK"#7KDTH"??NO=!Y\A/D_T[\.?^%+GQ[_ )EO:V\*_+_!WYU?
M&/;&4Z@[]JJ/(SX7$X[,;%H]K+5XZ!J"6L%%#DJ#&U-?"(*>2EI]PMD9?0Q2
M?W7NGG^;-\C>F/YO7\V_^3ST#_+[WCBOD1E/CEVIG>T>Y>R.N::HR>$Q.'RF
MX]B9:KFES*P"FE@PF,VE63RRQR/3K/6TU(DIJY_"/=>Z%SY^*K_\*^_Y9(95
M8#X\[18!AJY2/MX@\_D$ C^A%_?NO=7-?SM]J_RI^ZNM>GOC'_-"[/I^E*'M
MO+=@;C^/W;$^0J-G'"9OKRCQ\.2J(-SRT%;M_%5)I<]2Z*7,?Y+D%#JL,STQ
M\?NO=4D_R(^_>[NI_P";'WG_ "Y^E_G)NC^9)_+XV?U#D-^X#N#-5=3O"CVG
M4Q4^(?$4&,SLM7DJ6.*G^X_A4U/C\@,365"RUE)1T=1'5P1^Z]ULP?S>-FYS
M?_\ *V_F#;4VU05V5SV0^(??-1BL5C*)\C4U<V'V[75JTM-3Q_NSU%3]L8XX
MT5G=V541V(0^Z]U7'_PE0S^-S/\ )8^/>.H9TEJMJ=A?(/ 9B-7#&*IJ=Z9G
M**C <JQI,E2O8\V<'Z$>_=>ZUBO^$R?\GSX*?S+>D_D[OCY<=<[HWQG^L.UM
ME[6VC-@>R<WL:.&BS&)EK*B.6+$UE*L[/.JG6]V4<*0/?NO=?08^+'Q%^-_P
MFZEQ71WQ<ZGVUU!UGB9WK5P6 $]7+55<T<<4M?D\C6S562RV1FCAB62JK*N>
MH<(H:0A5 ]U[K0,_X2]?S9_@!_+FZ&^5>T?F+WQ)U+N;L3M;9NZ=DX>+JS>?
M8#5]%AL--2SR+-MG;V9I*9EJ&5 E340LQ.H#1=A[KW1IH.P]Q_\ "BK^>I\5
M^[OC[L7L"@_E^_R\,UM+<N0[BW%@JG;--DLAL#,Q;L=-<\,BP5^Z,M#@:*'&
M%HZ],33RY"04K:O#[KW08?(CY&_#SXK_ /"MCY;]M_.?+;7PO0=#U=UUA,E7
M;PZQR?;E$,GF^E.NX\:K8;$X;/5DDC2A@LHQ[+$>6= ;^_=>ZVJO@[_--_E%
M_(^N[>VG\"NR>OLWN'K?K;)]T]E[+Z]Z!W%TO62X+:CQTTV22GS>UMM1Y?[2
M>LIX#X7F>%ZJ%9/&)T+>Z]U6U\P/YS/_  GJ[J^#7=LN8WATKW)2;RZSW/2X
M?HX='UF+W;7YLQ2IBJ>GQ^2P%'-BLE39=*>:#)230P4CQI7Q58C2.8^Z]T3?
M^0%LS8'QT_D!_)K?W\S&@S.$^$G>W<&6R<>#W3M_-YI/[E]EP[2V7_'(:#&T
M\^4I<5E-PRF6.JI8 (HH#F%=8&^X]^Z]U7S/N+K[^5?\\/A'AOY(/\S7<WR[
MZ?\ D[W92[4W[\%L=OA>YL3B\?G\SC/OGK/X5)_!X&K*.L:*CJ*C$4>>H!13
MU3U];3R5GC]U[JVS_A9SE*FN^ WQ4ZWQ4,V2W!O+YL;9RF%P&/IS6UM9)@=E
M[RH%2E@CU3S.9\Y3QA(XF+231K^ID#>Z]UMJ=;X:NVYUWL+;V31(\E@=E[6P
MV02-_(JSXNA@@E"M8:E$B-8V%Q[]U[I:>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[I7T?_ 6G_P"62?[U[]U[J3[]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NM++YU?R<OYX_8/\SWM_P">GP2[T^)'QEJMPO4[
M5VIO#:&\\]USN#<.VOM8X*6#L'$TNT,QMW<F1I!JC2HJX*F4K!0R/*TM#0FE
M]U[H3OC'\'_^%5^TODC\?MU?(C^8QT%O;X_[9[KZLS_>>S,5N6*KJ\QL[#YR
MAJ-SXJDC'5- 7JLCA(ZZGA KZ4^21;5-/_GD]U[K;_\ ?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW6J/_ ,)D\_@L1)_.%ARN:Q.,FE_FK]]RQ19#(PT3,MXQ
MJ59'4E;@BX%K^_=>ZVK:*OH<E3I5XZLI*^DD+K'5450E5&QC)5@'C+*2""#S
MP>/?NO=8LI_P#D_X-'_O8]^Z]TE_?NO=>]^Z]T#?:_QT^/G?-;LG)=Y=$]-]
MS9'K3,2[AZYK^U^L,)V)/M_(3O32/7827,4-9)BJQY*.D9IJ5HI"T$)+7B33
M[KW6/L_XW?'?NW<?7^\>Y^A.E^W=W=3923-]5[I[/ZMP>_LEMFMEGHZIJS;]
M=E:&KJL-5-58['S&6CEAD,M-3R%M<,97W7NLW<7QV^/WR'H-O8KY =%].=YX
MO:.:&X]J8WN+K+"=FT^,R(0QBOQ\.:H:V.BK1&2OGA5)=)*ZK<>_=>ZP]G_&
M[X[]V[CZ_P!X]S]"=+]N[NZFRDF;ZKW3V?U;@]_9+;-;+/1U35FWZ[*T-758
M:J:JQV/F,M'+#(9::GD+:X8RONO=9NXOCM\?OD/0;>Q7R Z+Z<[SQ>T<T-Q[
M4QO<766$[-I\9D0AC%?CX<U0UL=%6B,E?/"J2Z25U6X]^Z]UA[/^-WQW[MW'
MU_O'N?H3I?MW=W4V4DS?5>Z>S^K<'O[);9K99Z.J:LV_796AJZK#5356.Q\Q
MEHY89#+34\A;7#&5]U[J5FOC[T+N3LV+NO<72/4.?[E@V75=;P=MYKK7#97<
MR;=KFJ&GP*9Z>BDRJX69JRK+T(J_MG,\Q:(F1]7NO=('HGX5?#[XO9C<&X/C
M=\6_C]T+GMUT\5'N/-=0]18'KRJK8(':2.FJ*C%4-+*]+'(S,D!?Q(Q)5 ??
MNO=+3$?&[X[X#N3</R+P/0G2^$^0>[L6,)NSO;$=6X/&[RRE$L-'3BCR.YX:
M%,W6THI\=CXO%-7/'XZ6G33IAC"^Z]TQ]^?$OXN_*BAP>-^2WQWZ6[[HML5,
M]9MN'MWK3$=@?P^2J71*]"V3I*EZ4RK82>)E#@#5>PM[KW3EV#\8OC=VSU7B
M^C>S^@NF>P>E\'18?'8'J?>/6>&W#MR@@V\B1X^*@PU51RX^A2@CCC6F$%/'
M]NJ*(= 46]U[ILZ%^)'Q:^+-)F*'XU_'/I'H6GW%*DVX5ZBZPPW7S5[16T&M
MDQ='325?C"J$\KN$  6P'OW7NGW/?&[X[[J[@VO\A=T="=+[D[]V/BTPFR^\
M,]U;@\QO##T48K0M'B]S5%#)FL?2J,ED0(H*V.,"JJ;+^_+J]U[J1W7\>^A_
MDEM(;"^0O3'5O>&R5K(LC%M7MC8>,[ H(ZF#]%3#2Y2FJHH:E/[,J*LB_AA[
M]U[IKZ(^,'QN^+FW\GM7XV]"=/="[<SF1_C&=P_4/7.)Z\@KZL((Q55R8JDI
M?O*E8E2-99M;K&J1JP1%4>Z]T,^2QU#E\=7XG)TL-;C<I156.R%%4+KCF@K4
M:*6)Q^4DC9E(_()]^Z]UKH_R&/Y?'RP_EA]C?S"_C)V#L3'Q_#/.=YXSMWX@
M]LP;SQ.:JLS#G:>;&Y&FKL=3YBKR]%/2X7'[6AD:MQ%%JJJ:L:.:KAE@:/W7
MNKU^G?CI\?/CO1;BQOQ_Z)Z;Z,QV\,P-P[MH.G>L,)UE!E,@J>,5V1BPE#0Q
MUM8(R5\TRO)IXU6]^Z]T,GOW7NB-U'\L+^6I5YF?<=5_+R^#53N&IRDN;J<]
M4?$O8,U;)6S2F=ZMZIL 9WJGG)D:4R&0R$N6U<^_=>Z./MK:^V=F86BVWL_;
MN"VIMW&HT>.P.VL13X*BIU8EBL-+2QQ01*6))"Q@7-_?NO=%O[9^!_P<[\WE
M5=C=Z_#/XI=T]A5U%08VNWWVS\=]H=C9F:GQ4?BI8)<IF,/65TD--$ D2-.5
MC7TH ./?NO=/?3/PT^('QQR>=S?QY^*?QMZ'S.Z<2N W-E^F>C-K]7U61H4D
M$PHJ^HP>+H9:RD$H#B&5WC#@-IN+^_=>Z"23^5W_ "V9M]MV=)\!OAV_8#[A
M_O<^[#\<MI?>'*^;[@Y(R?PGFO-5^^:@CRFHO.7,Q+^_=>Z.9G-H[3W-MBOV
M3N3;&WMP;,RN*?!93:.<PM-EL94T,B>)J.HH)XI*2:E:,!#$\1C*^DK;CW[K
MW19^E/@#\&OC=O*?L7X_?#WXS]+;_J*"JQ3;VZPZ2VYLK+)25S!IZ2'(8_'0
M54%+.RH988Y4CDT1ZU;QII]U[JG3^8E_+K^3WS]_G)_RZ-[[NZNQE/\ R]?A
M/M_+]NY_LVJ[$Q4-3E=Z9#()E/X#3;?AR+9XK+7[:V4LLKXR&D>C7(%JYY%@
MI7]U[K9$]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=*^
MC_X"T_\ RR3_ 'KW[KW4GW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=:!G\PJJ_F'?S-=\_P Y?Y$;)^>G9_P[^,/\G[</<'6W6_QYZSDRN!R&
M[\MTAAZRIS=;F&P>Y,"\%/G:G#^;&Y:N.4*4U88Z/'P"&I6?W7NC^=^?*SY&
M=&_%C_A*WW?LSO7L^/.]V[K^!O3/R!VMD-]Y&NH.P</W_L3:0S]7NJ":ID_C
M.5IY%J)J6NJ5FE@K*V2I<R2$!O=>ZV]_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW6M9V5_PE$_E*]L=B[^[3WAM_Y 5&[>RMZ[JW_NFHH>Z9J&%\CO*NGR-<
M\,"8_3#$U34RE$'"*0HX'OW7NKI/A+\,NE?Y?_QPV1\5_CW3;FH^I^OJW=M?
MMRFW?GSN:O1]ZY:MS==Y:UHH6E5J[(5)0%/0A5+D*/?NO=&?RG_ .3_@T?\
MO8]^Z]TE_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TKZ/\ X"T__+)/]Z]^
MZ]U)]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6J]_-%_X3P]N
M?)CO#O[Y)? 7YHYWXC[O^777M;L#Y<].9Q\Q6;-["CEQYQBS9!L=5R/2">A>
M:*HADPU?$))&JZ,4E1)4FI]U[H+_ .75_P )O/D;UKW_ /$OY'?S+?FZ?E#/
M\&=M;/PWQ8^/FS/XGFMH[6EV)1P4^#%/7Y^GH)5HMOS4>-J:5*/ 4%145>/Q
M]15U+1TWVK^Z]UMX^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MI.;IGR-/BR^,I4K*@U$*M%(=("&Y+?J7D$*/K^?>QUH]!O\ Q/=W_.CIO^IG
M_8;WN@]>M5/IU[^)[N_YT=-_U,_[#>_4'KUZI].O?Q/=W_.CIO\ J9_V&]^H
M/7KU3Z=>_B>[O^='3?\ 4S_L-[]0>O7JGTZ]_$]W?\Z.F_ZF?]AO?J#UZ]4^
MG7OXGN[_ )T=-_U,_P"PWOU!Z]>J?3KW\3W=_P Z.F_ZF?\ 8;WZ@]>O5/IU
M[^)[N_YT=-_U,_[#>_4'KUZI].O?Q/=W_.CIO^IG_8;WZ@]>O5/IU[^)[N_Y
MT=-_U,_[#>_4'KUZI].O?Q/=W_.CIO\ J9_V&]^H/7KU3Z=>_B>[O^='3?\
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MT=-_U,_[#>_4'KUZI].O?Q/=W_.CIO\ J9_V&]^H/7KU3Z=>_B>[O^='3?\
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MG8/_ #R]'_U-_P#QCWZB]>JW7OXYV#_SR]'_ -3?_P 8]^HO7JMU[^.=@_\
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MR]'_ -3?_P 8]^HO7JMU[^.=@_\ /+T?_4W_ /&/?J+UZK=>_CG8/_/+T?\
MU-__ !CWZB]>JW7OXYV#_P \O1_]3?\ \8]^HO7JMU[^.=@_\\O1_P#4W_\
M&/?J+UZK=>_CG8/_ #R]'_U-_P#QCWZB]>JW7OXYV#_SR]'_ -3?_P 8]^HO
M7JMU[^.=@_\ /+T?_4W_ /&/?J+UZK=>_CG8/_/+T?\ U-__ !CWZB]>JW7O
MXYV#_P \O1_]3?\ \8]^HO7JMU[^.=@_\\O1_P#4W_\ &/?J+UZK=>_CG8/_
M #R]'_U-_P#QCWZB]>JW7OXYV#_SR]'_ -3?_P 8]^HO7JMU[^.=@_\ /+T?
M_4W_ /&/?J+UZK=>_CG8/_/+T?\ U-__ !CWZB]>JW7OXYV#_P \O1_]3?\
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MG8/_ #R]'_U-_P#QCWZB]>JW7OXYV#_SR]'_ -3?_P 8]^HO7JMU[^.=@_\
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MR]'_ -3?_P 8]^HO7JMU[^.=@_\ /+T?_4W_ /&/?J+UZK=>_CG8/_/+T?\
MU-__ !CWZB]>JW7OXYV#_P \O1_]3?\ \8]^HO7JMU[^.=@_\\O1_P#4W_\
M&/?J+UZK=>_CG8/_ #R]'_U-_P#QCWZB]>JW7OXYV#_SR]'_ -3?_P 8]^HO
M7JMU[^.=@_\ /+T?_4W_ /&/?J+UZK=>_CG8/_/+T?\ U-__ !CWZB]>JW7O
MXYV#_P \O1_]3?\ \8]^HO7JMU[^.=@_\\O1_P#4W_\ &/?J+UZK=>_CG8/_
M #R]'_U-_P#QCWZB]>JW7OXYV#_SR]'_ -3?_P 8]^HO7JMU[^.=@_\ /+T?
M_4W_ /&/?J+UZK=>_CG8/_/+T?\ U-__ !CWZB]>JW7OXYV#_P \O1_]3?\
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M_/D]D]M[0^-FY]YY/HK>.V\UMZEW?2+E,G-'+AJEL?E,3AJPQPO3L)(JV"9
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MV3K:')9):.CR4;M2K+'0X?*S3>66,0+25'G,9B<#W7NN_BI\U/BS\X-G[I[
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MO^/51ALWN ]QXW=M(FWX*/;,DT.3FK,C-)%!0C&S4U1'5K4M$]-)%(DZQLC
M>Z]T5'H#^</_ "R/E)VLO2/0_P R>H]_=H5>;KMN8':\-778 YNNQE'#7U--
MMNLRM%08_<\L%'/'*XQ-76A1K!(:.0+[KW0W?+SY\?#GX%[0H-\?+OY!;!Z0
MP>8&0.WZ;<M7/D,KE#B8Q)4KA\#C(*[.9=X%*:UHL=.RL\:$:Y$5O=>Z!#=_
M\VCX'4?Q)[0^7NQ/E!TUNSK+KN7);3J,\VXI*>"EW=-1RS8G;.;I3%'D\+DL
MC4+#&M/64E/-:0,% (/OW7NJ(?GA_.GV_P#+[^07W)WK\2OD)3];?-K;6Q_A
MUOKLG8_QT[!RU!N/8F4[#[,V=CZK%)D*04E>$J6FK*"2/R'[F)YJ:9'CD=&]
MU[K8 Z\_FO?RX^V?DODOA[UO\P>F=X_(S&5=1C&ZZPN?DJ#55M$M:U5C<7EC
M N#S&5HEQU::NAH,G4UE(([U,,6M-7NO=6"RRQP1232L$BAC>61V^@6,7)/^
M  /OW7NJP=W_ ,ZK^5+L*;JN#=_SM^/^";NC"TFY>O):O=3M#4XS(35$%/DJ
MZ>.!X<'CJB6EJ%BJLG)1P2Z&*2,+$^Z]TO=V?S6OY<NQODOM_P"'NZ_F%TKB
M/D=N:NH</B^MI=R&H=<CE9*&*BQ-9DX8I,+C<UD7R5$*/&UF2@KJSR7I:>4)
M(5]U[HT,'R$Z3JN_*[XMT_96UI?D+C>K8^[:[J-*Z^9BVG-DX\,N>:GTV_AY
MRDL5-Y-?$KJ"!J!/NO=-\_R:Z I-Z]R]=U_;6RL7O'X\;,V]V+WAA\QEEP_]
MU\#NNEJJW'Y?,5%4(J6DQ]324-;*LS3Z D$I<KXVM[KW0-?'#^8Y\(_ESO.N
MZ\^.OR&V;V5O6BV[6;QAVY0TF2P=17X7'S4E//F\,,K0T"YW"Q3U]%&U?CFJ
MJ,//$IFNZW]U[H/:W^;O_+,Q_>3?&^J^:W0Z=RQ;VAZTJMJ1[M%1#3[CJ*J2
MACP%5EXXWPE+FGKH9Z<4,V12I-1%)#XO)&ZK[KW13/@/W3VENK^<)_/KZNWS
MVAO7</4_264_EO5W5>QMT[MK,IA-J+V!UAF:W<)P=%53O28:#+55#3U-:M,D
M4<T\?W$JF5G=O=>Z-SL'^;7_ "X>T.W\=T7L3Y:]8Y_L3.YUMJ[5BB.1HL+G
M,M'+50/B=N[JJJ"#:NXLK'-1U"24>,S554QL$#Q*98M?NO=*3^:7N[=>P/Y:
M/\P/?.Q-S[AV5O;9WPO^3.Y]H[QVEFJG;>5Q62P6S<Q4T.1QN0HY8:NAKJ.I
MBCE@GAF26*1%DC=64$>Z]T1?X._SB/@YA_CM_+[Z)^1GS9Z]'S#W_P#$?XG2
M]CXO?6Y:O)9$[QWKLG;=154F[,^T$N)P^ZLQD*Z24466RE+D:R0U$D<$GAG:
M/W7NK>NO^_>FNU-]]O=8=>]B;=W5V'T%GL%MGN79V-J6.0VY7;HI&K\;!DZ>
M1$>'^(42M/3N 8YH@7C9@#[]U[J1L7O/J/LW?/;?6NP-^8/=>^>B,[@-L=O[
M>Q$DD\N R.Z*!<G0T->YC$*U4^/>.?Q)([I&Z&0)K6_NO="O[]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>ZU>/AW\8MC_SN]R_*'YF?S GW;W-T%BOE3V[T7\,OB?-V-F=N
M;"V_M#HJM&".XLM@L'4XF'/;IW!EZ>NJ:B7*2Y".F,41I?&H@CIO=>Z?MH=>
MC^3Y_-D^%_Q8^.6>['3X(?S'^OOD%M;&?'K>N^LSV#M_KWL#X^8B#<5%D-J5
MN;JLGD,)CL]0U*44N.2=X26>=8W2E@2F]U[HZ%'_ #J.C*/XJ_(WOK?7678^
MP^X/C'W]D/BEOOXCY&./(;SK.R,IDHL;M';6#\,8ILO'O<5F/JL7D*=7HFI)
M9ZEY?%0U3Q^Z]T9SXQ?.ZD[Z^2'R1^)>]^H-S]&]Z?&K:71F_=P;;W'N*AW/
M39C#=Y8F:OI\AA*VA5%JJ?$5]-4XRN8Q*$K$ 0M&Z,?=>ZU[/YR7\P;KWNG,
M_$3<& V-OF7K/X#_ /"BGX<]99_?6W,;-OZ;>><ZAP&Y<_NO%;1PN&IZK(Y#
M(XNJ,>'BIT5Y*O*L:=?&%9A[KW5O_6W\UKL6E^4737QM^8_P([M^$E-\JJ[=
M&+^*'9>^NQMH]KX[<61VI0I7R[>W.NT:[(P;(W364PJ9:+'3Y"N2IC1 M4M2
MTU+3>Z]T:'XX_//97R/^7WST^'^ V-NG;NZO@3E_C_B=Z[MS%923X_.GY!8+
M)YRA?%Q0N:F 4$6+FBG$ZKJ9T:.XU >Z]U4O_,M_FR]UK\'_ .9QD_B5T7VU
MB]]?#KN#L?XS;R[QVSO_ &MB/[H5FS\1@LW%OI*3*U=-5U^+E&8@I?M*.FJZ
MY)=;- T U^_=>Z-+T9_-6[5B[7^&O0'RW^"?>OQ=R'RYI\_M/JCN??O:77?8
M6"S6=V5M9-P_;3+L_<68KL;5YR".?[6.LI:823,D<1E?SK3^Z]T=O>7S8VGM
MOYR=<_!/"[.S6\.P=U?'OL#Y+[\W)BLG3Q46T=M;3KX,/BI<K"P:H>;<N9DG
MI:%5T#_)JB4EECL?=>ZJ2VE_PH(WGW'\8L-\TOC;_*\^5G=OQ9VOMW<FY_D9
MVM%O;:77G]U(-FQ5TN8I]L8C.U=+ENRJK"_;0"OEQ-+%C(6>IBCR4]505%,/
M=>Z'_MCOSX)]Q_S"OY(?9-5U7N[M/M[Y-=7?+;L3X0]^X;>==@,3M;#1=<46
MX=P29G QY&"ER<FX=NUZ4M.)J&I>DGNW[;!77W7NDQ2?SKNR.W\U\B-G_"O^
M6Q\COEMO/XG_ "1[8Z#[^3&;]VMT_@<1'U)G9<345N/W%N>>GIMR9W*45+5Y
M"BP&)IZRKCA^T3)3XXUU,[>Z]U:)\)_EYUA\[_C#U3\J.H(,]CME]IX>NJEV
M]NNDCH,MA\EM^MJ<7F<)E8(I9HHLAB,M15E).$E>-GB+QNR,K'W7NJS_ (\[
MD@^2O\^CY^;KRD&4JL3_ "Z?B[\:?B]UJ:PE,?#E_E0M=V!O+(X]%.B2MEIL
M3MW'5,D@\L:4@C0+#,'E]U[JM#^6;_+Z^-?\P/O?^<IV+\JJ?NW?V]>K_P"<
M/\RNJ>N\U@OE1VAUDN'P&W\K#58['4=#M?>&&QJQ8^>JF-.7HG>--$(;PQ11
MI[KW2OSW:K_"7M'^:%_*B^9&]>YOFM\*\7_*[[$^?G2=-V+O61]]TW7N!&3V
M_O3K*MWK#64>6RC23TLIPE;.RU--3PRI45+WC)]U[K/VW\^_D'TG_P ,-[-^
M!WPU[\Q_Q.[6Z\ZHRG6G7V([MV1&=];9S_3<F7Q'6E34;FW#_$*;*[.I!055
M1D<I40TU6U(_V]=43/H?W7NK1OD]_-UI_B/F/A9UUVW\1.^9?D!\WMG=O5G7
M/Q^V)7X3L+/4>Z^L$V^(-G5=7B:RJP;U&4GW#3Z\JN47$X^FIZJLK*I88O5[
MKW2+W!_-L[_I)=F]#[/_ )9/=>_?YBNX.M-R=O[S^%N)[VV%08_96V\;EZO"
MXG+[N[3J:]=HT-+N6JI@V-BIHZNMEB+LU&K1Z']U[HSWP[_F*8[Y+]C=^_'?
MM'H7L[XJ?+'XT4&V]P]G=$=F5V,W,E5@=YQ2R8G<^U-S82>IPVYMNULL$].:
MF!HI8*F,PU-/$Q35[KW5>_7?\^KL'Y"_&O%?+WXG_P KWY4=^_'K;6V,[NSO
MC?L>\MK];G!Q[32K?,XS9F+SD\.7[/S6%$"?>)B*&+&ZQ54M+E:K(4IHI?=>
MZL!R_P#,'W)V+U3\;>U/@_\ $WM[YG8#Y0=;5?:>S]TX3<VW.FMK;?QL$5"\
M4.\MP;GR$4N*RE5-6R01T%#B,I5B6CK1)"@A4R>Z]T"O6'\X/;NY.E_YA^ZN
MX/C5V?\ '_Y$?RQM@5W8GR8^+.ZMX;;WAE$H*C9]7O7!U.#W%@JZMP>4HMP8
MJBG6FJ0\:I(MW3Q/%))[KW1><Y_/JS&#ZTZX^7=7_+I^3M)_+9W?1;#?='S;
MSFZ-L;;_ (0=_5V*QL&7AZYK:N+>N1V935F0J%DSLE'11SQ0156/I:VDK(*C
MW[KW5[W8.PMA]U]9[TZRW]A,9O3K/M;9&X-D[QV]7K]S1Y3";VH9:*NI)0#Z
MX*RBJ94-C?2UP0;'W[KW6HEA?EU\J_@_UAVC_((PF?WAO#Y^5>_\!T7_ "W>
MYL_>KJ,KTKW@F6JJ+LG(Y".EBHEJ^H=N8S<,%:K&.]7C*6*".6.*4CW7NA^^
M070F%^$W\Q+_ (2\?$SJW<V[9]A; ?\ F&X#.5N5S4S5.YLECNO]L5%=N#/+
M&R05N5RF4K\I73.T6E)JR<0K'&V@>Z]U?)_,)Z!Q7RC^#ORKZ$RS/#_I&Z.W
M_C,'D(;"6@S6.H9:_ 92 D'14XK.4F/K(6'J66!&4A@"/=>ZJLQ&]OD9_,E_
MDP_!#N3HS&;ZW-\H]^8+IC=-)OKK?Y15OQ1I]L[QVGC<I@\_O+.96'';D3/[
M?Q68ILBU1MJLVUGJ7*32P0SX^<1>>+W7NBW?\)YNE_E5M;'[>[$[QK^P^Y>N
MLAB?F)M[KCN/'=K4_5^U-N5]!W-FJ?=6WZ[I/'8[#TC9?>FX:.NW/C]RR2YJ
M5Z&66CEDPPBHZ*?W7NMJKW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=%ZZ^S^;R'?_ ,@\'79;(U>&P%-U7_!,545;RT])_$\2\U0:>$L8XC/*
M=4A507-BU[#W"7).]WE]SIS+9S32/!;+L_T\+.3'#XUFTDFA:T4NV6(%2:5X
M#J6.:]KMK7E78KF.*-9IVW/QI54"27P[H(FM@*MI7"U.!PZQ]BY_.8_OWX]8
M2AR^1I,-GHNT!F\53UDD5/5_P[%QRT_W$(81S&"3U1EE)1N5L?=.>=[O+'G/
MEJSAFD2"Y&[_ %$*NPCF\*T1TUJ#1M#96H[3D=7Y1VJVN^5M^N98HWE@.V^#
M*R*9(O$N65]#$574,-0BHP>G/<_R&V)MC<6<V@:'=NX-UX"JH(*S;FUMNR9N
MK>.MIHZMJJ*-' -+3Q2Q^5V9;,P50Y]F>_\ O5L^PWUQMFB\N;RV>-9+6TM7
MN)RLD23>(JH<Q(LBZW)%"=(U''2+9?:;<]ZM(=PUVL%K.KLEQ<W"PQ!DD:((
MQ8'O=E.A0#4"I('2<@[&V'L?<O=FZ,ENK?E<N%JNMSN?"Y@_<T.+.Z8A'0_P
MN$E!&LHE!J;FZZ!>^FY(XN>-FY2W#?;^XO;]_ ?:_JX)R6MK/ZM D/TZD*%#
MZP9LX*@GAT;R\H;IS+9[/90VUDAF7</IIHNV:Y^F;5+X[9J5TTBQFII2N'_%
M_(S8&5W+A]O+1[OQ])N6L3'[4W?E]KSXS#96>2^B.@K9;&8R$ (QB5'++I8Z
MA[.-O][]EW"_AL0E[&ETXCL[V:TEBL;R1JT6"9P-9-.TZ0KU70S5Z*[WVBW6
MQLY;LO:R/;H9+FUBN4DN[9!2IEC6NFE<@,2*&H%.E-O+MO"[0R[;?CVWOS>&
M<AH(,I5XO8^TJC<#P4]2TBQR32CQ4Z%S%)I3S&0VX0ZEU"#F?W'M>6;@V8MM
MPO)Q&LSQ6%E+<E(F+ ,S +&"=#437K-,*:K4FY>Y#N-_@^J-Q96D)=HEDO+J
M. /(H4D*O<YIJ%6TZ17+8-&^/O?KV7KJM[/6LR*[;Q>4@PF8BFQS4]91UDM3
M!2M3U5-(5,4D,E1$7]1 0ZP6%KH4]WMDDV1]_P#$D%K%,MO.&B9)H)S-' 8Y
M(WTE&5I%U5P%.JI&>E3^V&[)NZ;*4C^HEC,T1$@:*:(1O*'1U!U!A&P7&6%#
M0],E!\D-@U]=00#'[SH\7F=RX?:^ W3DMLR4&,R$^=,RTTU'4R.K2TLC02#R
MF)0OI+ *P/LKL_?'9KR6-?#O4AGNH+2VNY;22.TN9+C7X;0R-37&QC(UT &"
M<,"3*Z]H-TM8G;Q+1Y8;>6YGMH[A7N8$AT%UD100K@.#IU&N0,@CH3=S[[P.
MTLKM#"Y0U<F3WOF_X%@J6BI_N6:1$\DLL@U+HIX$L9'YT@C@W]CW?N;;/EVX
ML[6X+F6^G^GMT1=1+A"[,<BB(HJS>6.@9LO+%UOT%U<P:!'9P^-,SMI 4G2J
MC!J['"KBM#GJ'V#V7M+K"@Q&4WC72XW&YC-0X*&M6 SI'+-#/.'FTG4L0CIY
M+D*QO8!23[2<Y\^;9R!##<;I)X,4\XMUDH2JNT<DE6IP73$V<FM  21THY4Y
M-O\ G266#;T$DD4)F*:J,RAT2BUP6JXP2!2I)%.DC3=][,;:=;O'*X[>&V<=
M3YFGP./H-Q[9FQ]=DJBO17I5QE&#)-5BK5KQ:0#8,7"!6(#D'O!M9VU]TN8[
MVUB6=;>..ZM)8KBYED ,8MX:,\OB@]FD5.:A=+4/IO:[<1?IM\$EI<2-$T\C
MV]RDD-O&A(<S2'2L?AD=U?D!4D5C4'?^UZJ;)8VOVOV-M_<=#BY,U2[1SNSI
MJ;)U]+#((WEQU/$\RU>@D%D63R*H9B@"/I9LO>+;[EY8)K7<K:YCA:X6SN+*
M1;JXA5@I:!$,@EI4$JK:P/B44:C]U[57L"QS17.WSV[RB%KJ&[1K>"0J6"S.
MP0QUI0,5TDT .5JBNC/D!+O3!5DF\L?N&CJ:&JW96U>ZJC:LN)PT-#A99'59
MZZPIXZB&G6TBD@AE(;U7]A7VD]YCS;9R-N<=S&T;WKO=/9R0626\$KT#3,/#
M#K&!K4FH(-<@]"/W,]JEY<ND&W20.KK:HMLMRLMV\TRJ"5B^,HSFJD8H13'2
MJHODAL6JJ<6]3A]]X;;6>K*>@P6_<YM*;&X2LEK&*P"*K9C(B3$>AY:>-"#?
M58,0(;3WPVBY>$O#?PVMPZ1VVX3V<D5C.\A(33(3J4.::6D1$:H(8BM".Y]H
M-S@20)+92W$*,\]E#=))>1*@JVJ,"A*^:H[,.%*TJHMY]W;(V-N0[/RXSM7N
M>7"4F<QF$P>%ES%37+6SS0)!110W>:IO3RLRZ558U+LX'LYYH]U]HY2OOW9<
MF=[LP)<16\$#SS7"O))&%B2,%G>L3%A0!5&IB!T4\N^VVY<S6?[PM_!6W$S0
MR333+%'"41'+2,] J4=0#4DL: 'I*3_(;;>3V'O+<6 Q&\XL]M99,=E-KUFT
MYCE,;5U=/++32U]"ID\=*K1L7EUM&H5@3Q[#[>]5AN&SWM]:0WPGM!X<UF]G
M)]9:S/&SH9H1J(CQ5G!* !JG!Z/(O::\L]TM+2ZEM#!<D21W*72?37$2R*KK
M%*0M7(8!5H&-10=)?:';T78_2.<J]UQ[_P!M5='UU69?<^[\7MR7 1NJ0R&>
M?"U3#P3S!5+*$(']+#D![EGW+3GKE*>;<1N-HZ;6\]W>16LMLM/"8N]I(RZ'
M8 $KHKY4Z.M_Y!;E#F2&.Q-C<(]^D5O:RW"SL"772MR@.I5)-#J_.O0A+VEL
MG8/7G7-759;=&Y/[S;=P:;/I#0R[@S^9#4<$JR-3Q+KEJFBDC>=VTH':Q8,R
M@C-/<+:>3MDVR22>[NOJK:W%DICDN=QOAX".&,:+J>0H0TK$ !FR02 0H>2-
MRYIW;<(TBMK?Z>>8W;:U@L;0^*ZD!V-%0,"J 5)48% 2'+8_=.U-[Y2MV\,?
MNG:6Z\?C4S%1M+?.!DVYD#2/Q]Q'$[.DL8) .B5B#]0!S[7<H^Z>W<W7#V0C
MN[.\CB$[65_;O:W/@MC6%8D,M<$JS4/&G2+F7VZON6H$NS);75J\AB6ZLIUN
M(/%'X"P"E3YBJBOET@S\K^LI<739W&X[?F<P7B$N<S6%VA/7TF(#%K#*5"L(
MX)" K:$:5PKH64:O8//WC.7WMTO+=+^XMZ:KBXM[*66&R&3_ (RZ]L9H 2H+
MN RDJ >A3_K%[TD[6LTEE#-6D,,UTB2W7#^P4BK#B*L%!((!-.C&8W(T.7Q]
M#EL9515N-R='39"@K(&UI+#6()(I$/Y5T92/\#[G"RO8MRACN('62*5%DC=3
M571U#*P/H001U$5Y:2[?*\$RE)(W9'1L%70E6!^8((Z8M];YV=UCLK=W9'8>
MYL+LO8.P=M9S>6]=X;DR$>)Q^+Q6VJ:6LR&0KJJ9EBIZ2CI89999'8*B(S$V
M'M5TFZU,OYO7\YKXF_)[^4U\P-J;0VM\H.M]O=Y=65&WOC?W-WA\<-R]1;([
M,J:6MQ>3>FV7N/)TZ4]=-4XN*JJ*:&K2BFK88*G[6.8P3*GNO=7)=U_S:_B3
M\/=S;.^.79M3VMN[Y$UGQVZP[?V+T?U!UAD>T=U;RH]X5.1Q%+0;2Q./U5.:
MR\<V!RU150J$BHZ*!JNKGAB*D^Z]T8KXG_/SHGYA[L[6Z[ZYH>SMF]F]);?Z
M9W/V=UCW)U[6=99_%4??6#.X-NR5&.K290TE&DT52E]='60S4=0L<\;(/=>Z
M$GI/Y6]1_(+LKY)=6]95F=RV<^*?9&(ZC[8RM3A7HL6FXLGBJ?,2XS&UK.5K
MY\;25=**W0@%/-*L1)?4%]U[HF7=O\Y;X?\ 2G<G=GQMCQ7R![I^2_1.4VKC
M]T?'3XY=$YONO>=;!NO;^-W,F7Q>'P\<KR8"AQN7QJUF4JI*2A@JZB*C,[5+
MK&?=>Z"FJ_G]?!#)];[=[ ZBP?RG^2.6KZ3(Y7?O4GQW^,.Y^R=Y; QVW\W4
MX#+Y+L?"QTU.-ETF+KJ')EAD:J*:M@HJF;$PY%$37[KW1P]S_P S#X8[3^'W
M7?SIR/;D-9\>>WJ/:G^B;-8/;>4SN8W-DM\.\.*V[A-MTM)+G:_<U55Q3TW\
M+CH/NX9X9TJ(XA3S-'[KW00_'3^;Q\;^^^Z=F?'3=?67RN^(_>/:>.WKF^F.
MM_FK\=<S\>:[>U#L">2+(U.UY<@9Z'(21T\8K!1/5PY(43K.]$@#A/=>Z--T
MW\R^C>^/D-\K?B_UYEL]6]M?#'(]28OO/&Y+;L^+HZ27NS%5N8P/V%;)^SD5
MFH\?5&4Q']EU"N/4I/NO=5<?S(/YSNU.B?B#\X-]?&?;_;NY.[_B_P!B[X^/
M-7G:;H3+=@;;V[OC9F-Q69>HW-44:RTF/VQ)092F5,E5RP4KS2"#R),+#W7N
MB1_SK_F!1_,3_A/C\N-];:ZY^0?4>?P.:^'F/KYN_ND\_P#&^2JR>1[(V!6'
M(X(;E@Q[56(2:2Z5\4GV\9',H*DCW7NK4NO_ .=M\,^P^_>M>CJ7!?)?:>W^
M]=P8_:'QR^378WQQW'L+J?LG,Y.&MJ(,9LC>N2IX*?,R5$%%KI:DTL-!D%J*
M8XVKK!+Z?=>ZM[]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:<G\[?\ EN?R4-\_*^K^0'=O
M\QG'?RZ/F=F\/B]R;P;9?8F-FR666:EI\3C,[5[6UC-4-4]+2^+[JBJ:-:V(
M32S+*R23K[KW13?Y5OPL_P"$_P!TC\T>D^Z<]_-IIOGS\R*O>.T=O].X[?53
M)M?%UF]\\U'B<+D(,9+%D\E79E*QHX<1%6[GJ*>FDEA_:GJH*6HB]U[K9:_G
MF?*O87PY_EI]]=N=I?';;/RKZ[R$NR>L]X]&[QW0^SL=F:#LW,4>(G%17QXW
M*RPFE6I\\1CI1*LT<;Q2PR(LB^Z]T6K^7-_(0_E6?'7<G3/S>Z6Z W)0]FYG
M8VU.RM@4?9'9V3[0H]J5.]L;2UZ/BH:\I$]?CUJ#%!6SQ2U$7,D31R-<>Z]T
M?#Y\_P L?H7^8_F?C3-\B]V]NG8_QD[8B[GPW4&R\]AL3MG=&:H_MDI#N^"N
MP&3R=?2T5-'64\45#E<=>#(5R3-*9(VA]U[JQCW[KW7O?NO=>]^Z]U1C_)._
M[GW_ /%PMY_]=?<W>]'_ "RO^E;#T3[1_HO_ #4/5YWN$>CCIORG_ .3_@T?
M^]CW[KW27]^Z]U[W[KW6@M\SM^_-W^8;_P **LMGOY=77W3O=V2_E,;/H]O8
M?$=];A:+8<.X:.:II<[65;8S*8FJ;-4VYLU)!#!'DXZ@5.W5DE_:HY(/?NO=
M%8_FB;I_FU?#GY^?!7^<'_,%Z'^+O6F7ZY[!V9U")?B;F<EF(L]BMOOF,EDL
M;E*+-[GS.C)Y#;62W%14]0E=2J\01'(\"2+[KW5B_P YZ_;>^O\ A6O_ "K<
M[0_P_<.VMP_&CK;=.$J98$JX)X9X>V,ACZN-9%(NK"GGB:VI'5'4AE!'NO=.
M7\_YWHOY^W\@NNHV:DK:CNOX]X^>LIF,$KT\O<>#C>!Y$L[0M'45"%"2I661
M2+.P/NO=/?\ PH_W+M_9'\WS_A/UO;>&9QNV=H;3^2FTMR[GW-FZM,=0T&/V
M]V?US5U];5U,I6*"FHZ6-Y9I&8+'&I9B +^_=>Z<_P#A8MOK9'8W\M#XP[IZ
M]WCM7?FV*GYMXNBI]Q[,W#2;HH))L5LW?=/50I64,T].\M-41R12H)"T<BLC
M@,I ]U[HO_\ .7W-3=&?SA?Y!WR1^0L])#\/]L]:='4"Y7+T$53C\'N3;>Y9
MJK.9ROEJHX:6"GQU-E-EU[R&LDEAAQLU1#3B2%?N/=>ZW&]H_,_XC]A]PX/H
MCKSY%=.=B=R9[8F8['Q.Q=@;YQ^^*\[?Q,]-!4Y.4XN:KBI*-IYZ=8VGEB^X
M(/@$OBD*>Z]UJ=_\)MJ"AE_F^_S[\E+1TDF1H_D!O*DHZ^2G1YHHLAV=OYIX
MHI2-<<<[4\!D56 <QQE@2BV]U[HN'QAP/96Z?Y__ /PHKZXZ7S%;MWL/?/P)
M^;..Z\DQB:TBW7ELGUY2X'(_: &&HJZ7)Y)GC9XV;5+*/]VN&]U[HZG_  DE
M^3GQ5Z]_EN=M]8[M[%ZVZB[:ZL^0'8V\>[,5V%N7$[$KGH,OC\.N/W#4"MK(
MIY,7#2TC8YJB98_!44$\#(JB*2;W7N@I_P"$W$4/9/S._GY_)CK"BGE^-?9_
M=N](NL=T4T3)C\@F8W7O[/XZ&D=[&22CP&3Q\KK;5'%6P%K>5;^Z]T2+^1E_
MW#@_SR__  W?D1_[Z:B]^Z]U["?]P4^[_P#Q.%-_[_7%^_=>ZN'WYBL73?\
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M;^5MC:SJ[$;8I?D/M'Y&_$,_!!L%CL8F2H]^3;ZV_3XN+9XE40PU;8(Y4*D
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MHT?7TN+S>U<MM//)V9)CJ3)4"45,OWD6+1)HWJ%,4:3LH]U[JW3^;/#5T_\
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MQ2;,W'@MZK2Y;;U5AH\:C%GJL='48ZF=HO=>ZVC_ /A61_VY0[]_\27\>O\
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M7>_R:[MVWDMU9ZLGRF_>PJNBKLCNBERSY4YC!Y456.H9*67%U]']@8(Q1"G
ML?=>Z1?4/\HOX#=)]I=6][[0Z<S>6[XZ:S6?S6P>\NQ^W]Y]J[PIAN3"Y/;U
M1CZG<.X]P9/)Y'"+BLQD(X,75U$V.IY)3504T=4!-[]U[J-V1_)Z_EV]M]Y;
ML^06_?CW39C>W8U?19CM;;L&_P#=&'V=O*OQM_!7[RV'19JGV;NJL2YUOD\'
M5><Z6J1,R1LGNO="-F_Y9_P?W)\7\S\-,YT+@LE\<<UOK>79S=?U.?S3-1;A
MWWGLCN6NS.(RXR0S>%R$>9RM=/234.1IWH5D\%&8*=5B'NO=([I[^4O\!NC-
MW]9=D[$Z0FD[8ZFWI4]@;7[BWEV5NOL/=\^4J,#F-M(^:W+G<WD,OGZ&DPV?
MRT%%C\C5U./H#4-+0TM/* X]U[I1?);^61\./E=V+1=R=G]>[JP7<U'A:/;$
MO;_2O<&\/CYN:MQ>/,A@QF5S&R,Y@:O,4,/ED$45<]0( 2(/&/?NO=9,?_+%
M^$&,V'T-UK2=**=H_&KY%[8^6W4M+7=@;HRU73=C[/BJ(J#=N6RE7FI\IN;*
MQBID9WS%97I-($DF21XXRONO='W]^Z]U5OV-_)B_ES]L]A;H[!W]T7F<[%OO
M?5;VAV#U;_IIWUCNO=P[ER.2_C-3G<]UU2[DAV3ELA5Y7_*ZDU."DCJZDF>J
MCFE]?OW7NC@8_P"*/06*^3L_S'Q_7]-2?(JHZ#Q_Q@_O]%FLBJQ;%Q><.XX<
M#3XG[S^"TT(S)6H::+')4OHCC>8Q1H@]U[KOKCXI]#=2=]?(SY-]?['? ]V_
M++_1/_I]WF=SYC*C._Z#\1-@ML6QM;7U&*Q?\-Q=1+"?X?0TGW&KR57GE <>
MZ]TA]K_ ?XB;1V1\H.M,;TCMG(=>?,[MKL/O+Y+;(W355V],7NC=':L5'%G\
MG4466JZV"B-?]A22&&B2FIXIXQ40113DR>_=>Z +H+^3E_+U^-G8FSNTNM^E
M,U7[LZQ*_P"AX=H=Q;U[HQNR0D30(-FX7=NX,SA]LM#"QCADH*&&:GC C@DC
MC4(/=>Z&+Y:?R[/B)\W,IL7<_P @>KI\QV%U>F2BZV[:V-O;/=1;PP4685EJ
MZ?&[JVKD\/G(*.H5Y!)3??-3OKDU1'R2:O=>Z6?QD^%'Q@^'FQ=R=>?'WJ;#
M[-P6^<E)FNQ,AD\ED-]YG<U=-!]L]9N;<&X*O*9S<%2T!:,-7Y"?1&S1QA$8
MK[]U[HG>$_D:_P L?;W5/<?1.+^/>7CZ5[TR&VJ_?/5$W>&_ZO;\2[3W/%O*
MDH\#BI=SM2;8QQW+!%63TN)CHX*HHD%2DM,B0K[KW1\OD'\9>DOE/MG9NS^]
MMF'>^W>O^U^N^[MI8\;ARFV_M=S=55PR."R)DQ-;0RU"T=4-1IIWDI9P2L\$
MBV ]U[H<ZBGBJZ>>EG4M!4PRT\RJ[1$I,I5@&0JRD@GD$$?4$'W[KW11NO/@
M7\4^JOAG7?R_-A]6K@/B3D^N.S.IJ_JJ+=^=J3+@>XI,M-N2D.;FR<FX1+E)
MLYE9'J5RHJHWG9X9HV5"ONO=>[#^!?Q3[5^&=#_+\WYU:N?^).,ZXZSZFH.J
MI=WYVF,6!Z=DQ,VVZ09N')Q[A,N+FP>*D2I;*FJD>!7FFD9G+>Z]TF/EE_+>
M^'GS:R'5>>^0G5^2SF\NDI<F>K.QMD=D;GZ@W1AX<Y3FDKZ*FW+M+,87.''U
MU.S)/325[PN29- E.OW[KW2/PG\I7^75MK:O:FQ=O?%K8F"V7W7L;K#KWLO:
MV'R&7QE%D:'IS.9/<^W:D109*/[+.4&X\O790YBE:'+5&0:.MJ:V:IABE3W7
MNE%\8OY9_P .?B+V)G.X^HNNMS5W<NX-JKL*M[A[?[=WAW]NB+;Z57WBX"@S
M>]\[GZ_%X856F5J2BF@AFD59)UED4/[]U[H$Z+^2!_+%QO<.4[IQOQJ@QV9S
M?8E-V[F>OL?V=O"BV!5[IHC$\.?J>N(L^FQ9LA#+!!-&7V^8DJ(XZI8A4HLH
M]U[HY^R/B+\=^O.V?DYWAM?K;'0]E_,C_1ZGR2SF6R=?N6'<\75>$FVY@J:I
MQV2JJO&4M'18:HJ*<T])1P0SB65ZB.61V8^Z]T2_;O\ )'_EP;4W)09C ].;
MYH=KXG.T^YL/TJOR-[(DZXHZ^DD$T4U/UVV[#LU(HI@)(Z4X8T44@5XJ9&1"
MONO=6,]Q]2; []ZE[,Z.[6PDFY>L>X-A[KZS["V[%EJS M7X7>]#/C<G1BMQ
MU125]*:FCJ)H_+3U,4R:M4<BL 1[KW5=?_#(O\L8=A;6[$C^,U##+M'<6$WI
MCNO*?L7=E/L6HS^WE(IMPY/K],ZNR\MG=9,LU;68.:>JJ;U54TU23*?=>Z"7
M^>#\-MW_ ,P?J7XI_$/#=,1]A[#W]\R>IMX=Y=FU51#1KL#977$==5[@R]%,
M:JEK(\UFZ*HDP=*:4M+X,C6FR@:A[KW5U6/Q]#B:"AQ6,I8*'&XRCIL?CZ&E
MC$,4,%&BQQ11H.%CCC554#@  #W[KW4SW[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U!R.,
MQN7I7H<MCZ'*44A!DI,C21UL3%?H3'(K(2/\1[]U[J5%%%!%'!!''###&D4,
M,2"-46, *JJ  JJ   !8#@>_=>Z\L42Q"!8XUA6,1+"J *% L%"_0*!Q:UK<
M>_=>ZKZ^>WPGS?S=7XL;$K.PL=L_HKJ'Y-=>?(3N[8/\#DR$V]J7J R5VWML
M":.>"*CQASWV=;6:XY?(*2"-4^I'NO=6"O%%*8S)''(8I!+$70/I8 @,M_HP
M!(N.>3[]U[K!34%!1R54M'14E)+73&IK9*:F2!II#]9)2J@R.?\ 5,2?\??N
MO==ST-%52TTU524M3-12F>CEGITF:%R+%XF8$QN1Q=2#;CW[KW4A41"[*BJT
MK!Y&50"S!0MV(^ITJHN?P /H![]U[HNGREZF["[8^,G>O3?1.^</TKV3VGUO
MO#8VT^RYL"V4BP%7O6FDH9LRE%324SSUM)!43306F3_*5B9FL#[]U[J5\3_C
MKL[XC_&?HKXR;!]>T^C>K]H=<8JK:/PO5G;=''!45\REG(J,C5">JF];$RRN
M;GZ^_=>Z'^***"-8H8XX8D&E(XD$:@?T %@!_L/?NO=<5IZ=3"5@A4TT9BIR
ML2CQJP *IQZ%(5186%@/Z>_=>ZY1Q11!A%''&'D>5Q&@2[2&[,;6NS'DGZG\
M^_=>ZY(B1@K&BHI9W*HH4:I6+,;#\LQ))_)))Y]^Z]T1C>/PNBR?\P;IOY][
M(WM3;.W-M?H'L?XS]V;1?;C9%=Y[6W%7TF?VXAK(ZZE&/KMK[CI9JB*66DK!
M+35E33A825D]^Z]T>3P0>7S>&+S?\=?&-7TM^JU_IQ]?IQ[]U[KFZ)*CQR(L
MD<BLDD;J'5E<6((/!!'!!]^Z]U@J*.DJZ:2BJJ6FJ:.6/Q2TE1 LT3)_J6C8
M%"O X(M[]U[KFM/3J82L$*FFC,5.5B4>-6 !5./0I"J+"PL!_3W[KW6*NQ]!
ME*66BR=%29&BG&F:DKJ9*N)Q_1HY%9&'^N/?NO=<*JB23&5&-IEBIHY*"6BI
MT1 B1JT9C0!5  1!:P X L/?NO=5Y?RJO@;4?RZ/@3\>?AON?>V#[@SW1;=I
MRKV+0;4;;452_9&\]Q;K#4M%455?-2&FCSB4K-]VQE,)E] <1K[KW5B%=CZ#
M)TST>2HJ3(4DA1I*6NIDJXV,9#*2DBLI*D CC@\^_=>ZRFGIRKJ8(2LD*T\B
MF)2&C35:-A;E!J:RGCD\<GW[KW7)HHFB,#1QM"T9B:%D!4J18J5^A4CBUK6X
M]^Z]UZ6**>*2">..:&:-XIH94$BNL@(964@AE8$@@BQ'!]^Z]US5550J@*J@
M*JJ+  ?0 ?@#W[KW6'[6E\0A^V@\*LSK%X5TAG))(6U@268DV^I/]??NO=%$
M^=?Q<R_S&^+':7Q>P78D?46*[KI<#LKL7=E'MK^\-5+M&MR5(VZ\111+6T"T
M];GMOID,;%5O)(M(:HSF";0(S[KW1I=K;9P6RML;<V;M?&T^&VSM+ XC;.W<
M12+HBI*# T\=+24T0_$<%/%&BC\!1[]U[I]]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=)_<>T]K[OHTQ^ZMNX7<=%&YEBILUC(<DB.>
M-<8F1]#V_M+8_P"/LEWSES;^9HO W&V@NHP:A)XDE4'U =6H?F,]&VT;[>[!
M(9;&>:W<BA:&1XR1Z'014?(U'7MN;3VQM"B;';5V]A=N4+R>:2EPN-AQJ.]K
M:W$*)K>W&IKFWY][V/EW;^68O VZV@M8R=12")(E+>I"*H)^9SUK=]]O=_D$
MU]/-<.!0--(\A ]!J)H/D,=2Z/!X7'9#+9>@Q.-HLKGGI),WDJ6BCIYZML>A
MC@-3*JAYS#&2J:V.D$A; GVHM=HM;*>:YAABCFN"AGE2-5DF,:Z$,C  OH7"
MZB:# Z8N-SN;N**WEED>* .(8V=F2(.=3:%)(7415J 5.3TUUNQMEY+^-_Q'
M:>VZ[^\TV-GW%]YA:>H^_?#6^T>LUQG[AJ:P\1DU:/[-O9?=\I;5?^/X]G:R
M?5-$USK@B;ZAH*>$9=2GQ#'0:"U=-,4Z76W,VXV?@^#=7"?3B1;?1-(O@B7^
MT$=&&@/7NTTU>=>G7+8/"YZ&FI\YB,9F(*.NI<G20Y2ABKUBJ:(EH:B-958)
M-$2=+@!EN;'D^S'<=IM=W54NX8IE21)466-9 DL9JCJ'!HZG*L,CR/2&PW.Y
MVMF>VEDB9T:-C&[(6C<4925(JK>8.#TR;DZ_V+O&HHZS=>S]M;CJZ!0E%59K
M"T^1DC4,6T*\L;,(RQ)*7TD\D7]E.^\F;1S.Z2[E96MT\>(WG@BE9!6M 74D
M"N:<*YIT8[/S7N?+Z/'8W=Q;J^76&9XU8TI4A6 K3%>-//K++L794^.R6(FV
MCMJ7$YFMAR66QCX2F:GJ:BF\7CGGA\?CEE3P0V9E)&A>>![=EY2VJ>"6V>SM
M6AGD66:(P1&.65-&EW73I9AX:49@2-*YP.J1\S;E%-'<+=7 EB0QQ2":37'&
MVJJJVJJJ=;5 ('<?7I_KY*R*AK9<?!%59".DJ9*&FFE\"23(C&*-WL="N^D%
MK< W]G-TTB1.T*AI C%%8Z0S@'2"<T!- 3Y=%5JL;RHLK%4+*'8#450D:B!Y
MD"I \^@DZ'ZYK>L]@08C-_8MNC+Y;+;EW5-C0HA>MR\I8B/2B#1% L$8LH'H
M.D 6]QM[0<CR\A;,MM=^&;N>::[O&B $;7$[ECIH%PJA$&!A<8Z'ONAS?%SE
MNK7%MK%M%%%;VPDKK$,2TS4G+,6;C7.<]"CD\'A<T^-DS&)QN4?#Y*GS&)?(
M44=8::KI+B*I@,BMXIX]3:9%LRWX(]R!?[1:[J8C=0Q3&"59X3)&KF*9*Z9$
MU Z76IHPHPK@] FRW.YVX2"WEDB$L;12B-V3Q(FIJ1M)&I3054U!\QU(R.-Q
MV7HJG&9:@HLIC:R,PU>/R-*E;!*A(.F2*56C=;@<,I'M^]L8=RB:"XC26)QI
M>.1%='4^3*P((^1%.FK2\FV^19H'>.1#5'C9D=3ZAE((/S!Z2^VNMNOMG5,M
M;M796U]O5LRLDM;B,)3T,Q5_JGE2,2"/_:0VG_#V']AY%V7E9VEVVQM+9V%&
M>"WBC<CTU(H-/E6GRZ.MXYPW7F%!'?7ES.@H0DLTCH"//2S$5^=*_/J91['V
M9C]PU>[*#:FWJ+<]>LJUNX*7$005DOGMY-=0J"5C)8:R6NUAJ)L/:FVY2VNR
MO7W*&TMDNY 1)<I!&L[@TKJD"AC6@K4YH*\.D]QS+N-W:)82W,[VR4T0-*[1
M+IX40MI%/(4QY=,T74O5T&8_O!#UWLJ+->;[D9)-M4:RB6^KRJ1#Z9B>2X <
MGDM[+(_;CE^&Z^N3;;$7&K7XPM8!('_B!T5#?TAW?/HQ?GS>Y+?Z5K^\,--/
MAFXETE>&D]V5_HG'RZ5JX/"KFGW(N)QJ[@DQJX>3."BC%6U(LGF%,:C3Y3 )
M?7X]>G5ZK7'L1C:+5;HWPAB^I,0@-QX:^,80VL1ZZ:M&KNTUTZLTKT0G<[DV
MPLS+)X D\40ZV\(2E=&O173JTXU4K3%:==P8/"TN5K\[38C&4^;RL%+39/+P
M4,45341T((A2>=5$LJQ V0,Q"C@6 'O<.TVMO<27<<,2SS*BRS+&HED6.N@.
MX&I@M3I!)IY=>EW.YG@2U>61H8BS1Q,[&.-GRQ52=*EO.@%?/I/4'6_7V+3.
MQXW9&U*"/<\$M+N*.DP%+3K6Q3ZM<52JQ 31/K8E&!4EB2+D^R6TY&V7;Q<"
M"PLXQ=J5N@EM"HN%:M5D 0:U.HU#5!J<9/1K=<X;M>F$S7ETYMV#0%IY&,+"
ME&0ENUA04(R*#..G/([1VKE\'!MG*[;P61V[2PTM/2X*MQ4%321)0IXX5BIW
M0Q1B%/2FE1H7A;#VOO>6]NW*T7;[BUMY;9515MY(8WA58QI4*C*5 486@%!@
M4Z16F_WUA<M>P7$T=PQ9FF25UE8N=3%G!#'4<M4FIR>N&W-F[2VA138[:VV<
M%MZAJ6#55-A\7#CUE(!&J;QHOE:Q(N]S;B]O==CY7VWEF(P;=:V]M&QJR00Q
MQ*QX58(HU&F*FIIU?=^8;_?Y!-?7$T[KA6ED=RHXT743I'G04SU+H-M[>Q6$
M&V<;@L10;<6GJJ08&DQT-/1^*N+M/']LJ"$QS-)(7719RS%@=1NHLMCLMMM!
M86]O#';!606Z1(L.ARQ9?#50M&+,6%*&IKQ/2>ZWB[OKGZR::5[C4K>.TCM+
MJ0 *=9.JJA1I-:B@IP'0<R=38ZI[#VCNJ:/%TNVNN-O5>,V#M7&T(HXZ2LRY
M"U=8X33%I6GB@CAB5-*$-(3K"V!$GMQ;S[W9;BPB6VVNV>';K2*,(D,T]%ED
M.FBT$:(D:!:+W-QTZ1>G/<L.TW5BID:XW"=9+ZYD?6TL40)CC%:M4NS,[$U(
M(7A7H7G1)4>.1%DCD5DDC=0ZLKBQ!!X((X(/N3.H_P"BA;=_E\_ _:)[7.UO
MAE\6]O?Z=L=DL/W.N'Z&VQCUW31YIVDK*+.K'C%7)T=5,[RS03AXI)6:5T,C
M,Q]U[H>J/J#JC'=E3=S8_K/8-#V[4;!H.JI^T*/:-!3;@?;&+K7R--MULPE.
MN0.$I\A(]3'1&H^V2<F58P_J]^Z]U7?_ #5OA;V1\_MF_&/XYXS'; J/CT_R
MKZO[7^7$V\Y4GJZK9G44DN63 82CDI*I)ZO<.62AIZAV:(1T*U,;.5G*-[KW
M5J:(D2)'&BQQQJJ1QHH155!8  <  < #W[KW2!VSU/U=LK>78O8NSNN=C;5[
M [?K-N9#M?>^W=JT.&RVY9]GT0QN)FSV1IX(ZO+2XS'C[:E:JEE-/!^U$53T
M^_=>ZQ=>=0=3]1_WW_T4]9=?]:?Z2^P-Q=L=C?W!V=C]H?Q_=.[_  _Q;<F9
M_A]/3_Q/.Y/[>#[NOJ?)55'CC\LKZ%M[KW2=P?QR^/FV.I*OH';G1O46"Z+K
MQG5KNFL1USB,?M:8;GKILGDA+@(J-<5)]_DJB>JGU4I\M1(\SWD8M[]U[I*]
M _#CXF?%,9W_ &6;XT=$] ONAPVY*CJ#JO"]?35X5@RI638NBII:F*-E4QQR
M.R1V&A5]^Z]UF[E^(/Q1^16Z-D[W[^^-71'=F\>MI#)L#=/:W4^"W_D,->9*
MG3C:O*4-5/2)]S''-HC=5\R++;R*&'NO="+@^G^IML0]A4VW.L.OL#3=M96?
M.=ITV'V;CL;'N2MJL92866JST<-.B9:HEP]!143R52RLU)!%3L3%&JCW7N@2
MVM\"OA!L?JO=/1FSOB!\9]L=+;XW1B=Z[SZGP?2&V\;MS+9? 5%'54&3R6&B
MQJX^MKJ"IQ]!)3334[O U- 8BGBCT^Z]T.W875?6/;>,PN%[4Z[V/V5B-M[M
MVWO[;N+WYM2AW=3T&=V=4"KQ.9HH:^"HCI<IC*E1+2U4:K/ _JC=23[]U[HG
MOQ%^#]'\?N\/F5\JM^Y["[\^2'S2[:H=S[XW?A<-)A:3&;0ZTH(=O=?[/Q\4
M\T\SQ8+;M'3FMJV=7R&2EJ:CQPTZTM/![KW1_P#W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW56WS_\ YR7P
M+_ED[PZ_V'\N^R=T[)W+V=MK)[NVC1;>ZTSF^EFH<35"CFEDFQ5%4Q0,*@Z0
MCN'(!:UK$^Z]U5/C/^%*'_">3"]O;I^0.(W')B^\]\;4QVQ=Y=P4'Q(W#2;E
MRN&Q#0O2XK(YJ/!+D*R@@:FIBD$M0T:^&$!;11Z?=>Z CX?_ #[_ .$KU3\\
M]@=C?%OJ["[<^9G?_:FUNN]@;LB^/N^,=3Q;G[:R/\$I)<515\$FVMJU>3J\
MR\%37T..H7:.=_N9O"#;W7NKI_YX/8?7/5G\O#L_>O:OPL?^8!LO%[PZKAR'
MQE7/Y#;(RTF1SU%3T]<U7C,+N"J48>:1*O2,7(K&(!FC'K7W7NM=;;O_  K3
M^0NTMOX+:NV_Y#7>.'V[MG#8S;^ Q%'WON)(:6BPT"4U+31 ])DB."".-%!)
MLJCGW[KW1Y_@M_PJJZ(^1WR$V!\7OEA\4^V_@7VKVMDJ3#=>UF_]Q_WTV_55
MN;J/M</2UE?5X/:F5H'S%4)*>FF; R4?W($,E2FK4/=>ZVL_?NO=>]^Z]U[W
M[KW5&/\ )._[GW_\7"WG_P!=?<W>]'_+*_Z5L/1/M'^B_P#-0]7G>X1Z..F_
M*?\  .3_ (-'_O8]^Z]TE_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TKZ/_
M ("T_P#RR3_>O?NO=2??NO=>]^Z]T%V\N\>E>NJ/-9#L'N#JW8E!MS,X+;FX
M:[>78&)VQ#09#=*"7&4%;+6U<"4M;D8V5Z6"5EEJ%(:)7!O[]U[J+V=W]T1T
MG08+*]S=U]2=1XO=&0H<3MG)=G=D8;85/D:K*2Q04U-0S96MI(ZNHJ)IX(XH
MXF=Y'D14!9U!]U[I<UF[]IX[;$V]\ANC;M#LNGQ0ST^[JS-TU+BTH2@E%:^0
M>5:1:3QD/YC*(])U:K<^_=>ZJ3^3GSFS:?,#^4;LWXP]Y[!WET5\I^_/D5L7
MN:KZ]K=N=F8[/4/7W7.4SF/HHLU#'DGH'HLO#3U#-CZZFF<HL4SO SQ/[KW5
MN&-W3MC,Y?/[?Q&X\#E<]M23'P[HPF-R]/75F-?+1F:E6OIHI&FHVJ85:2(3
M(AD0%DNHO[]U[KAB]W;4SC9],+N?;V8;:N2JL-NA<7FJ;('&UE"H>:DKQ%*Y
MHZF%"&>*;0Z*064 ^_=>Z0>V>[NJ^STW;B^FNW.HNQ=V;7HZQ:_&;9[ QVZU
MQ]6J$0+EXL555-31P^<QB34BN%)TC58>_=>Z OX;=J]SY3XX]35_S5[%^)];
M\DMS4'8F5W)5_&#>%35[(R-%M/+UXCJMNR9RI?)5<>.P8QIRTFIHJ>N^YL8X
M?&![KW1ANL.Z.G>[<1D,_P!,=L=:=NX'$Y;(8'*YOK#?>+W]24U=B9YJ6JHJ
MBIQ555PPU=-4T\\4L+N)(Y8Y(W4.C >Z]TU[N^0G077^YH]E;\[PZ@V3O*6E
M^^BVEN[LO"[;R;0E!)YEH*RMAJFBT,K:Q%ITD&]B/?NO=*RG['Z\J]FMV+2[
M\V94]?)!4U+;[I]T4,V&$=%.]--(<HLYH0D53&\3MY[+*K1L0P(]^Z]T2_X2
M_P Q#IGYU=29OL'KVOQ.TMQXW?'=FQ8^NLMO3$9O--_H:SN1P,N7CI*2=Y7Q
MM>]"*JGD,%O!+&6^O/NO=$X_DK?S&9_D)_*_^#W=OS?^2'4\'R2^1<_=^#I*
MS>F>VMU)7;KK.O-_[RP=)'B,'3?PBDK*R'"8&G,T>/QXU>&6=HP?(WOW7NKI
M=W[SV?U]MW);OW[NO;6R-IX6'[G,;HW?G:7;6.I([@>2IK:V6&F@2Y U/*HN
M;7]^Z]TR]:=K]6]T[3Q^_>G.RM@=L[%RR)+BMZ=:;QQV^\34K*B2*U/D<74U
M5',K1R(P*3$%65AP0??NO=+#*97%X/&UV9S>2H,/B,72SUV3RN4K(\?34\%,
MI>2:>>9DBABC4$L[L%4 DD#W[KW02[&^27QU[/VKN'?76G?G2W8>R=I5-;1[
MKWCL;M/!;MQ6,FQLTM-4Q9#(4%?44E%)3U$$T4BS3(R21NC ,K >Z]U0Y\%_
MG-WAWO\ [,3\\^X_G_UAANC]@=J_+_:>Q/@/B=F;&PE"=H]+9+)X#:^3JMT5
M,S[W?<61KZ""KDJOO6Q]7YUIJ?'Q)-%XO=>Z'[^3=W3\DOD%T%MKYJ?*/Y^;
M"[?I>[>F<;V?NCXS[;ZWV5U_M_JJ7=%8]?C%I<OCI7W/%34F%BFI:E-P5]8\
M\H:H$\30.LGNO=6]=5=Z](][8S(YOI#N/JKN3#8?(U>'R^6ZJ["Q'8=+2U=!
M-+3STM348BLK(H*F&H@GBDC=U=)(W1E#(P'NO=<]W=X]*]?[DPVS=^=P=7;)
MW?N)HDV_M7=W8&)VWDJ]IR0@HZ&LJX:JJ+D$*(XFN1Q[]U[HI>__ .9!T!UM
M\V]@?"?<VX-LX_<.]NENQNWZ_L.O["PN,Q.$DZZRF*QLF RT=151STV6K?XK
M'- C$$QQR73Z'W[KW1_Z:IIZRG@K*.>&JI*J&*II:JFE6>.2.=0R21NI*NCJ
M058$@@@@V]^Z]T#M!\D/COE>SJ[I/%]]=+Y+N7%Q0SY/J2@[2P=9N>G2H>>.
M-Y\#'7-E84DDIJE5+T@#-%*!<QL![KW5/O\ ,*^7?;^<^>'QA^ GQ\^;/7?P
MOP6[>HN^.[?D'WK'MW9W8^X*)^N)\#CMO;5H8-X-5[?P\V0K,M/4UGW6-EK)
MJ>*-:5J<"1I?=>ZO"V=1YO#;*VK0;OW7!O7<F*VO@Z/=&^4Q$&VHLM74-)$E
M;EA04\DM-CXZ^=):@4\4KQ0!_&CLB@GW7ND1L_Y"=!]A[MR^P-@=X=0;YWWM
M_P O\>V5L_LO"[FR]%X%5G^[QM%6SUE-H5T+>2%;!@3P1[]U[IV["[FZ?ZD7
M%MVMVMUKUDN;G%+A6["WUB]EBLE+!1'2G)55-]Q(691ICU&Y M<^_=>Z?=R;
M^V+LW:=3OW=^]-I;5V-14,.4K-Z;DW'1X/$Q4U2%:.HER-5-%1QP2*RE9&F"
M,""";CW[KW0-YWY9_'ZDZ#W-\D=J=O\ 5/8G5.#VQF=Q8O>6R^S<)F\/E9,;
M025\%#09FFK)\;-4UR(JP*D[ERZE58$7]U[H-OB5\]_C_P#+/XW=/?(S![VV
M7L:B[9V%LG>TVQ=T=AX23*X*3?<:M1XO*K#5Z(J]I28E0A3)("J*3Q[]U[HW
M>Y=T[8V9B*C<&\-QX':F!I)*:&JS>Y<O3X*CB>MD2&%9*FJDBA1III$C0%P6
M=E5;L0/?NO=5)?R??EGWC\I,'_,HJ^_=[4N[C\<?YL_S0^,?5U<=O8K:_P##
M=C=4G;M1@L5.<91T,58<:N4JT^\J5DJY8]'W-1,Z:S[KW5E^V.\NGNREW90=
M6=N]8]AYS:=)5MGL=L3?F)WA48Z2)3I%;3T%54O2L'TBTR+R0+<^_=>ZJ1_D
MK?S&9_D)_*_^#W=OS?\ DAU/!\DOD7/W?@Z2LWIGMK=25VZZSKS?^\L'21XC
M!TW\(I*RLAPF!IS-'C\>-7AEG:,'R-[]U[JZO=&Z]K;'P.1W5O3<N VAMC#P
M?<Y?<>Z,Q3[?H*6.X7R5-95R0T\":B!J>11<@7Y]^Z]TA]@=U]2=U;%J=_=&
M]L=;=O;2>@FGH-X]6[XQ78>,=F@,L31UV*J:RCDU*5=;2D,I!Y!]^Z]U0]_+
M-^:/\Q3Y7_RL?Y7'R5B[.^+6XNW.Z?D=N3:?ROW=\C:5NO9<YL;:_8>]]N5=
M+L3&[3I\7BWW_+B,+CQ00FD2EFFBDDEA8-+[]U[J^3?/>G276&#WCN?LON+J
MOKS;779HU[ W#OGL+$;2H<$<C3_=4XS-77UE/3XPSTO[T?W,D6N+]Q;IS[]U
M[I>;?W%M_=N%QVY-JYW#;FV[F*9:S$9_;^3@S-%50N2!+355,\D$\9((#)(R
MFQY]^Z]T&>"^17Q]W1V3F>F=M=Z]-[B[@VY!'4[AZIP79V$R^Y:".8SA)*W!
M4]=)E*5&-+4@-+2J"890#^V]O=>Z&3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJV?S).
MPOYQWP<S/Q.R&"_F6=-[VV[\Q/Y@W2/PNP.%JOY?F#PM1M.C[[ES+TN<FK/[
MZU@W!+@X,8D;TG@QWWS.7^ZI+:3[KW5AQ^3L_P#*WV/N[>O\WO\ FB]']BT&
M])L6_42T7QNI_CYD*:/;$-;)FX\=MS;^<WEG]W35?W&/+&FI":7P1QI&SU7J
M]U[H]'Q_^7WQJ^876VYNQ/B[W9L?N3;6WZG);>S^0V7E_+4XC)TU/YC09:@E
M6#)8?()&Z/\ ;UE+!-I(<)8@^_=>ZU;?A)_/'H?B%_)#_EI=H?)3O#&]O_)C
MO7M+<NV<^_R![&RN5W!7[(C[QW;M'-[KFRU3]Y6UXV?@:>E]4\\A$--&DGI
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MU(:2'.U$>&J,MN*HJJ2AQ5'NN2D3:E=E*JIHZB..CI\W+4LP2T7[L6OW7NC
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MQC==87/R5!JJVB6M:JQN+RQ@7!YC*T2XZM-70T&3J:RD$=ZF&+6FKW7NA?\
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MG%4+&63*2+4/68^&%Y6H)EEI/NO=>Z$W^4-\[OY7GR5^<'7/QN[A_D<?'_\
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MZ7*_R2(J:"&GB'\^S^7VPC@B6%;M+N2YLH N?];W[KW0;_R]]N=0Y'_A1/\
MSZMP[DQ.Q:WNO;V!_EZ0=5Y/,4]'/GZ3!YGK-1N[^"M*#614,]53[47)-!9-
M8H%F(U1!O=>Z)EL'Y2[.^%7RA_GE9O9?06SN\>C^POYE_P $>FOB[UB\N-PF
MU:SY!=S[<*[TGR&1-+EJ; 1XO<4&)KLGD!B9)XJD1B%7JV*P^Z]T.OR'J?ET
M/YYO\@BH^6,?Q>P>\\YCOYD%'%AOC#D]SY%DH1UA0U%109[);BBH*K+8V.N
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MW98Y"CWFM<GC6DBVL^,D:&M1(DIY6G"*LS,WNO=4>=*T^TZ/^55_PGOI-A-
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M--+4RSQI"859W2+R,/=>Z^F%[]U[KWOW7NO>_=>ZHQ_DG?\ <^__ (N%O/\
MZZ^YN]Z/^65_TK8>B?:/]%_YJ'J\[W"/1QTWY3_@')_P:/\ WL>_=>Z2_OW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z5]'_P%I_^62?[U[]U[J3[]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[JKOO#^=)_+#^.7;N=Z-[?^6>SMN=B[/R='A>P*+&;7
MW)O7&[6J\A+'3P4V[MP8+"Y+;^U)YJB5(E3+9.C;R70@,K >Z]U9CA<UB-R8
M;$[BV_DZ'-8'/8R@S6$S.+JDKJ:KH\I$D]-4T\T9:.:">&1'C=6*NC!E)!'O
MW7NIE54)24U152!FCIH)JB14 +%85+$ $@7L.+D?Z_OW7NJL^G_YR7PF[8^+
MWPN^6-;N/?O5O7WSW[LA^.GQYP/8.P:JLS=7O.JW!F]L08?)4VV6W%0XQ9\M
M@*Y%K)<A]BL9ADEJ8@YT^Z]TK_D;_,TZVZ$^2>"^)>V.A/E/\G^\)^OL'W!O
M_;/QEZMI=]1;-VCN/+38:BSNY*S)9C"TZK55M-5^&@H'KLI)%!)*M%H:$R^Z
M]U9)[]U[KWOW7NO>_=>Z][]U[KWOW7NBR_([YA?'OXF5W1&.[ZWS-LNK^2O>
MFR_C=TY%#M?+[F_BF\.PC*N)QCG%4-:*".I>$H:NK\-)"2IFGC4ZA[KW1FO?
MNO=>]^Z]T5+Y%?+C8GQT[#^*_4V8P>X=X=C?+KNU>F^L]J;6:D%1&F)Q5=GM
MP[CK?NZBF5<)MG#8^6IKFC,DYUPQ0Q22RHOOW7NE;\=OE-T%\L-O;ZW3\?>Q
ML=V+ANL>V-^=&=A/28O(X*HP^[>LZA*;-X3(4.5HZ"NIZNC>6%P6IA%44\T%
M53234T\4K^Z]TX9[Y(=+;:^0'7_Q:S.]8Z;OKM#K_>O:FR>OX<#E,A)4[?Z]
MJ**DRV4GKZ:BEQ6.@IZK(TD48K*ZGDJI&9:5)S%*$]U[H</?NO=>]^Z]T66G
M^87Q[JOEU7_!6#?,S_)[&=%P_)&LZ\_NOEQ&NSYLQ'@?XG_&?L?X(9!DYH8S
M2?Q'[O3(LH@,09U]U[HS7OW7NO>_=>Z][]U[KWOW7N@H[W[1EZ0Z5[8[DBV1
MNKLH]5=>;N[#EV#L<4KYG+Q;.H9\A-08M*ZHI*62OJ(J=U@CDJ8Q)(50-J8
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M_P#L#[]4>G7J'UZ]_#-W?\[RF_ZE_P#8'WZH].O4/KU[^&;N_P"=Y3?]2_\
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M?8/_ #U%'_U*_P#Q?WZJ]>HW7OX'V#_SU%'_ -2O_P 7]^JO7J-U[^!]@_\
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MU%'_ -2O_P 7]^JO7J-U[^!]@_\ /44?_4K_ /%_?JKUZC=>_@?8/_/44?\
MU*__ !?WZJ]>HW7OX'V#_P ]11_]2O\ \7]^JO7J-U[^!]@_\]11_P#4K_\
M%_?JKUZC=>_@?8/_ #U%'_U*_P#Q?WZJ]>HW7OX'V#_SU%'_ -2O_P 7]^JO
M7J-U[^!]@_\ /44?_4K_ /%_?JKUZC=>_@?8/_/44?\ U*__ !?WZJ]>HW7O
MX'V#_P ]11_]2O\ \7]^JO7J-U[^!]@_\]11_P#4K_\ %_?JKUZC=>_@?8/_
M #U%'_U*_P#Q?WZJ]>HW7OX'V#_SU%'_ -2O_P 7]^JO7J-U[^!]@_\ /44?
M_4K_ /%_?JKUZC=>_@?8/_/44?\ U*__ !?WZJ]>HW7OX'V#_P ]11_]2O\
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M?8/_ #U%'_U*_P#Q?WZJ]>HW7OX'V#_SU%'_ -2O_P 7]^JO7J-U[^!]@_\
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MU%'_ -2O_P 7]^JO7J-U[^!]@_\ /44?_4K_ /%_?JKUZC=>_@?8/_/44?\
MU*__ !?WZJ]>HW7OX'V#_P ]11_]2O\ \7]^JO7J-U[^!]@_\]11_P#4K_\
M%_?JKUZC=>_@?8/_ #U%'_U*_P#Q?WZJ]>HW7OX'V#_SU%'_ -2O_P 7]^JO
M7J-U[^!]@_\ /44?_4K_ /%_?JKUZC=>_@?8/_/44?\ U*__ !?WZJ]>HW7O
MX'V#_P ]11_]2O\ \7]^JO7J-U[^!]@_\]11_P#4K_\ %_?JKUZC=>_@?8/_
M #U%'_U*_P#Q?WZJ]>HW7OX'V#_SU%'_ -2O_P 7]^JO7J-U[^!]@_\ /44?
M_4K_ /%_?JKUZC=>_@?8/_/44?\ U*__ !?WZJ]>HW7OX'V#_P ]11_]2O\
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M-U[^!]@_\]11_P#4K_\ %_?JKUZC=98,-OQ)X7FW+220K+&TL8BMJ52"P_S
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M10Q(\LLLKB-56,79F8V"JH!))-@/=7<1@LQ  !))-  ,DDGRZLB&0A5!))
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M]9**'$T,\D7W59,V/]U[JWWY*?S(?GY\O/YG?;W\L3^6MV+TW\5=N?%_9?\
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M'W7NC"P?+GY=_)KYY_,GXP]=?-[H3X0;Y^,^_L-M#H7XO]G=#XSLG-=DX:;
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M7-1O7P4\=721UL8B*^:HDHYIJOW7NG3XY=^?S0?YH&W.V?EM\0_E=\:/C/\
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MS6_^-20LZ1AD\5FK&JHSJBU9SJII('V'EK9+#EP[WNT4\LD>Y/:""*7PQ,1
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M"CRD R\JY3[21G^U,P2'W7NB]?RB^K/GSBOF3_-%S>?^9'4&:VGL#Y[UU/\
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M=/AL31W R,N1-QY?CVO?/I[.Y>%((WD\6Y"22PM*-,?8C!#&U1K!8N "0I-
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MB\?DOM_)YO']]$DNC7I37IU6OI%[7L/I[]U[IT]^Z]U[W[KW5&/\D[_N??\
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MJ615TKV*Q%:')H!YD=!]O39>ZJ'NG.[ZK>JX.YMNYG;6%Q>U:>?(XU?X'44
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M19?'Q9BNKZ3"%:>HQ=:%G;(K!*(P8I&UIJ]U[HI?\_O8W?/Q^^/_ ,"?FO\
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M:'&UF1IJ>5()ZDK ) %D9 VH>Z]T1WOWX^_*[N;Y#_&#^:YC_P"7/MS/=I;
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M8Y:L^3["';;!/#@@73&M2Q +%B234DEF))/$GI5S#O\ =<T7DM_>-KFF(+L
M%&%"@ #  "@ >@Z4WL^Z)NO>_=>Z 'Y/_*+HGX9]*;J^1/R4WY#UGTULBMVG
M0;KWK48'*;DCHI-[YB@P.-,E)AJ+(Y!HYLIDZ*)I$I&2%7,TS1PQR2+[KW0_
M>_=>Z][]U[KWOW7NO>_=>Z][]U[H$.H/D=TOWUGNZ]L=3;TCW;G/CMVQDNCN
MY*%,%D\-_!MTX>@Q^4J<69,C14D5?XJ+*4,AJ**2II"9#&LYECE1/=>Z&_W[
MKW7O?NO=%II/D'\<#\O<Q\5:;=5 /EJOQZQ7R R6R'V]E%JFZ_\ [PS;=@RD
M>5>B_@ST\>X"\#TD61-6CR1S2TPB>.4EL>T6L5V]\L2"XDC2%YJ?J&*-F94K
MY*&=C08J2>/1@^ZW$ELMF9&\!)&E6*O8)' 4M0<6(4"IJ0,#'1EO9ET7]>]^
MZ]T7#O3XH]+_ "/WG\>M\]NX');FR?Q?[6C[NZDQPSU5C\=3;HHZ&HQ]%EZV
MA@D2#)3XV"KJC2"H5T@DE:55UV(]U[J/\C_B/T?\KZGH&J[LV[D]PR?&;Y%]
M;_*KJ(8[<=;MX46].IC5G!Y&H%%-#]]3TK5M06I)R]--<>6-PH'OW7NC+^_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7N@\V?U+UIU_N?LK>NR]D[>VYN_N/<F-W?VIN?&4"PU^?R6%QM)AZ*JRE4
M;S53T>*H:2DIP[E(((ECB5%N#[KW0A^_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NBT?+[XC]'_.CX^[X^,'R.V[D]U].]BU&U*C=F Q&XZW:<]0=E9B@SU %K
M\=-3UD CR6,I';QS*753&Q*,P/NO=&7]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1<
M-W_%'I??GR9ZA^7&[<#DLUW1T-L7L#K_ *FRE5GJK^'X:C[2-.,]44V+$@HC
MDLC!2T].]6\32BG01(RJ6O[KW1C_ '[KW6.6**>*2">..:&:-XIH94$BNL@(
M964@AE8$@@BQ'!]^Z]U4(O\ (U^ F/@RNV]HXWY'];=/YW(9/(YGXW=6?,3M
M'K?K2?\ CD\E37TW]Q\/NNDP-/CZZ>:=YZ.GI8J63RR@PZ78>_=>ZM,Z[Z[V
M)U'L3:/6'6&T=O["Z[V%M_&;5V7LO:N,BPV.QF.PT2PTM'1TL*I%#!#$BA5"
M_P")N22?=>Z6?OW7NO>_=>Z#S>_4O6G9.:ZXW%O_ &3M[>&9ZAWE_I$ZRKMP
M4"Y(X3/"@K<6F8QZ27C@R46/R-?!%4!/+%'42B-D+L3[KW0A^_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I'4NQ-O4F]\IV&D%1)NC+86DV]-6
M3U3RI'1T;B0001$Z(E>50[V%V;G\GV&H.4K*WW67>@K&[F@2V:1G8A8(VUA$
M4FB@MW-3B<GH03\SW<^VQ[2646T4S3A%4 M*XTZF;BQ"G2*\!CI8^Q+T'^O>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[K1]Q_P#.4V[_ "J?YV?\P3KSYS?,#MGY&?&+N_-'+=1_W9WOE.TL
M=TQD,155^0FV9D-A/)"^WC!!608Z.HP^,J5JX8L;4S25+RY*7'^Z]U<)TQ_P
MIN_E"]^]P=4]%=:]X=@9/L;NCLC9'4_7^,K^B]UXB"JS?8F3IL1B::6KGQB0
M4L=17UE/&TTKK%$&UR,J*S#W7NKG/D1L/?7:GQ_[SZPZO[%K^H.R^Q^G>S=A
M]=]M8H3FJVOG=WX6MQ^(W%3"FGIJDU&$R%13UD?BJ8I-<(T2(UF'NO=:!F"_
MX3Q_SJ#_ #+-ZT?_  Y#\GL#41_'FAG/\S1-W;T6LS:RU>- Z[:OCWRNZ7CA
M*-.8I,J]&OV,;&%2T!]^Z]T>_)_\)9/G5W[G=B[:^='\ZWY _)[X^X+>6)W3
MNKJS>&3WQO,UB8PMK3'?WEWUE<=C*ZHA:2!:[[*66G25W1'/I/NO=;KM'24V
M/I*6@HXA!245-!24L*DL$CIE"(H+$DA54#DD_P!3[]U[J3[]U[KWOW7NJ,?Y
M)W_<^_\ XN%O/_KK[F[WH_Y97_2MAZ)]H_T7_FH>KSO<(]''3?E/^ <G_!H_
M]['OW7NDO[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NE?1_\!:?_ )9)_O7O
MW7NI/OW7NO>_=>ZU7ODOOCY';)_X4O-'\3^G-I]S=V;Q_DGX79V(H^SM\OUM
MLW;N/J.ZJ[)5VZ=V9:CI,MFSC:*7&4=##18K!5M965V2I4)I*9)ZJ/W7NK'_
M (5_.OY%]B=__)?X"_.GJKJKK3Y<=!=7;/[EQ6ZN@MQ9'-[%W_L??PFQZ;EV
M[39W_?P89L?FH9**LH:]YGBE=!'43*#(WNO=5?\ \A#=/SHH?Y(O\M[:7PVZ
MF^/6X*7/XWYA5W8'</R.[-S&WL3MJ3&=Q[U7%T=)M?;F)K<UN:JRGFK'>V3Q
M5/2I3 /4N]0HC]U[JT?X*?S%>T^U>Q?GK\:OFIUUU5U#\C?Y==1U;F.Y\UT=
MO'+[YV-E=M]R;4EW=A<[AZS-XO%Y6D*8ZFJA54E5"98],;ZKM)%#[KW5<V[?
MYB?\T'Y0?R^^_?FSM7X+]+/\$>TNC>Y7Z^ZOH^W<K)WU)LG(X[.XP;]FQSXW
M^Y%2L5"D&5. @ROWT]&9DHJNKJ%I$K?=>ZY?%[YU]_\ 3OP-_DF_";X3],=>
M=R_+WY/_  8V5OW&Y#NO>-;LO8>R=H]3;5P_\1W)NN?#TU;GJI*NOK:6CH:2
MAI0T\HG+3I)'#!4^Z]U$ZW[O^1S_ ,_C8X^<?3>S>C]X]&?RI/D=797L+K#=
MM3O78&[=O)OO:^3_ +S[9JJ^FI,U01TJPUE/D,7DJ-:VAJ*?4'J:2II*J;W7
MNC#Q?S(OYF6^/BUF_P"9=U1\4?C=4?"/%['W7W1MCHC>6_=S1=T[HZ[VQ:M7
M=E'6XZCJ=GX?)9' TE?D:+ 24=?-/#+21ODJ>IU4\GNO=+WY0_S?.PMJ;P_E
MD[6^&/QR7Y/2_P T3I;M?LOIE,QN"7K_ /ADF P>S\W@<AN&::-_X7MNFH=T
M5%9GI?MIZVG@HF@I*6:JF51[KW5K7QBKOD_D.F]M5'S%P'2>VOD *G.0[QQO
MQXSN9W'M$QP5DRX^?%U.X*6CR_\ E% *>2:.HIP8IVDC5I$59&]U[JL;XI_.
MOYX_-O*Y[NOH+J3XAP_%#;'R7WST/D]B;^[1W3BNU?X5U?NE]MYS<M8U+AJC
M;N%R7AI*[(46WZFDDDJ*?[=9,I3M,&'NO= +UQ_,[_F=_,&N^8V'^$/PW^-4
MU/\ "GY?_(GXW[Y[#^1O<6<VUB=T'I;+-#1X39^-V[CLIE)]T56%^SJZ^IR;
MXW%4<V0HH:8U_P#E+0^Z]T%.&_G/_P Q7Y$?!,?S-OB;\(/C[B/B5U)U3NGM
M7O+&?(SO/-8_=VZTZDQ61FW_ $?6,&W<%4XZGQFV<OCZZEAS&?>&;)MCZQ(<
M'$'IYS[KW5D/?_\ -'QVT_C)\)^VOCCU-7=W]R?S'JKJS#_$;I[/[@7K^"HF
M[1VZ-TR93=&4>FJWQ.#VS@_)59.2&CGF]*PPQDR^1/=>Z!3"?/OY_?%/Y$?%
MCI?^9_TO\2<;U]\T>S<QTGU+\@?AUV7N;(XC;V^LFU55[3V=NG$;ZQV-R55/
MN3'P?;TV2Q\GCER2-%]C#'*FCW7NH.W/G=_,O^9^YNT-[_RW^@?AR/BQTSW'
MV;TPO8OR\[2W?A<]V5DNI/O,=EYME8S:6&K*'!8?^\<245/D<O6S>5(:B7[(
M:@(?=>ZK"^>_\R7Y<?,GX)_&KN?X\=9];=*5VS_YB/17QS^4G6^]N\LUC-V[
M-[FZT[%QF-DV0U5MC#UF-RFS<DT]*]?6O4P5G\+K89DQE09# /=>Z&?^=?O3
MY6;?Z&_D];\^2/476N9^1.U/YX7Q&W-B^F_BKOFMWCCMP5&VZ;=]7MW!XK,[
MRH=IM#DL_40TU))+5T\--22S^0O+'&=7NO='PZY^>G\P7I_YO?'KXO\ \Q#X
M^?%O96Q?FW)VM2_&G?\ \6>U-S]A2;?S/5N#IL]+M+?!W)@L-'7Y"LH(\G)%
MD\;2TM&SK#3I3,5DG/NO=&Q_FM_.7(?RWO@MVY\Q\=LFC[$?JG.]/4M;M*MJ
MWHA44786]-O[9KY(GC>,FJI*+,3U%.C2(DDT4<<DB(S.ONO=5M]]?S6?YDOP
MTWA\?.Q/E5\".HE^.7R[[6Q'07275'2O=];NWN7#;W[ Q.6R&R]N[NCR6,QV
MPI<EN&MQ\./J(\=FWHL9,\\K92LCIT%1[KW0V=5_S!OGAU;\^?CK\./YB/07
MQAZ\Q?SIVQW=N7XJ;F^,':>YNRJC#U_06$Q6<SFU-[OGL#B*>MR"T%553KE,
M;#34.HTU)'!.3)5>_=>Z,O\ RP_GMN?Y];:^9.=W1U[@>O)?B_\ /[Y$?#;#
M08',U&97+8_I6' S4N;J3411&GK*X9EUE@35&GB!1CJ('NO=$*VM_.?[G[)^
M-'P[W/L7IWIK"_(KYM_,/Y#?%+KQ>S-[Y;;O7VWTZ!R^Z:6ISF=R--25>5JJ
MFOH-N)]EBH/%+65M4*>.JC2)G;W7NC@=Y_.3Y,_!GX;]D]U_,;I[IO>O>6/[
M*VAU#\>>O_C+O[+)BNR<_P!I-C<=M6A!W-C4KMI3UN?K*N"K267*)2T5*U<D
M]06$ ]U[I9="=A?S5I]]4F&^8WQT^(>'ZEWGLG=F0?>GQE[QW!NC)[/RE!!)
M/0XO<6-W3@<.F;@KXE,)KL/,P@K&5'I6I;U?OW7NJ/?Y-/S.W%\4OY!W\JK9
M'4?6%+W9\G?E9V]\CNCOCKU?EMSC96)GR9[2[-R^5SNX\N*>LFQ^V=LX:@JZ
M[(24]%4U;HL<%- \LP*^Z]U;CUM\V_F!TM\S.@_AA_,'ZZ^/BY#Y>[?[>RGQ
MJ[U^*E9NIL!/FNFJ0YW+[.W)B-SPU-7C,E'MMQ4TF17*FFR+T\ZQTM-(XIX?
M=>ZN*]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]T5P=ATV W+\IZW%;-VW197K7 [9SLN6IJ<T]1
MF)*C#U==&N1D2S.(&A*(0;Z7;^UR<?/Z\Q;-N'-LMO8VR3;5;6EPTR+IDOF:
MQFN%$[* 3HT:%-3VL?/J:SRF^ZV?+4<]W</%N$]Q (F;4EHJW<4),(-0-0?4
M:^8'ETG,AWIW)C-DXCN*MZ]VG3=7RT>"K<GC'S-3+GVILN\$8R$"JOV,=.YE
MUQ1,\DIC9&<IZK$M][O<SV.U0\T2;;:+M#1P2RQ&XE.Y&&9HU\= JF%4[]2Q
MEF<H5+%#J .+3VRY>O-REY?CO[IMR#S)'((8Q9"2(.WA,2?%+C31G 5=08*#
MBL/OVMW_ %?9O1+;=H=G5N*FW--D=GMEJ^KA,U<E"7<UZQ0.(J>-&#0O$7?5
M?4H^OMCWDNMZGW_E_P"ACLI(3=M):>/+,I>X%K(3XH2)PJ*IJC)J;5@J!GI1
M[66VU0;+O0NWNTE%N([OPDB(2$S4'A%G&IR11PU%IP)Z7=)V-W%O#,9K;>Q<
M#UY!7[%3&8W?&>W)D,C48Z7+U$*35..Q24J1U+)3!M+SS6LQ \;  N+[?G?F
M;F:ZGL=HM]N63;_!BO[BZEN&MGO6C622"V$2K(1&& :62E"1^FU,AB?E#E_8
M+>&\W.>_9+TR26<%O' LZVJN42:<R,R O2H1*U ^(>32OR/R51MG'T=%LZ)^
MVJ_L')=6G9DV4\=)%D\*$>LJFJ_'J;'0P21R:E0L=80-8&3V6+[XSW%A''#9
M [Q)N4NT?0M,5A2[@HTLAET5,"1D2:@I)U!1YL%Y]H88;UY)+LC:TL(]R^K$
M=96MIJB-!'JH)692M":8U4X+TY;DS'R'AV=O:CS6U^M5J8]LU]=3;BP>XJ^.
MC$(AE6KI_#-#]\M?'&1) X3P,58,Z&P)EO.Y\ZQ[9?1W5IM8D%L\D=Q!=7 @
MT:&$B%7B\43*O=&P'AM0ABAITCV?;^4I-PLY+:YW#2;A$:WFMX#*7UJ8WU(_
MA&(D:76OB"HH"*](GK?/;\I_C9D<SO?!;)W!M'&]3UV4P=-/75F4J<@*"GED
M\.6AJ(5A"2(@!\<K$?C\$!#D;>MX@Y"DO-WM[&YM(MF>:!6EFFENA' [E;E9
M8@H#!0#I9^A'SAMFUS<XQV^VS7D%U)N:1S,J111P:Y%75 R.6J":C4HZ68[:
MR]/MWIG:?7&SL#+O/L/86(W)08:HJGQ.&PN/BH:>5Y)C#&\YIHVD\,,<:!FT
MGD,%1Q0GN1<QV.Q[?L5C;F]W+;H;J*W:0PV-C;+;Q.2YC1G\-2XCC1%J:<10
M AT\AV\MWNU_N]W.+2PO9;=YE42W=Y.9G4!=;!=9"ZW9C05X4J5=ML]H;]Q&
M^Z#K3MO!;6HL[N# Y#-[3W#LFNJ9\=7-AD,E92&&N5:J&>"-3)<DJ5'XX),=
M@]P-XVW>(M@YEM[2.XN;>2>SN;&25K6X:!=4T6B<"5'1>_.H%:\/-#O/)6UW
M^UOO.PS7+P03QPW4%XD8N(1*VF.35"2C*Q.GR(/0;83O3O+=W6R=J[;Z\V1!
MMG$8_*Y#-P9K,U:U>17"-,*ML1' K1PQ0>)EU5,C-(\<@2/]-P)M'N_S;S3L
M*\Q[=MEBMK%'-+.EQ<3">Y$!D$GTJQJRJJE"H:9M3,K 1@:21CN7MERSL&\'
M8[R_O&N)9(HX6AAB\*W,P30+@N069M0-(P JLI+<>C6;-W/1;TVIMS=N.CDA
MHMQX;'YBG@F(+QBNC60QN1P7C)*M;BX-N/>17+&_Q<U;=;;E "([J"*=%;XE
M$J!])IYBM#\QU!G,.RR<N7UQ82D%[>:2)F'!BC%:BOD:5'R/5#7_  J36F?^
M1W\PTK9IZ>C;-?&5:N>EIUK)4B;M?9 D>.)Y8$ED5+E4::,,0%+H#J![T3]3
M=Z?S&OYDOQN[9^-G87S%^(7QUZS^$_RO[UZH^.VWL9L/N/-[V[9ZXS?<C5T&
M!J^PHVQ%/LVMCJJ[^&TM92X2KGCQDOW%LGD5,+'W7NC1?(GYE_)S<GRTR_P1
M^ W7?2^X.Y>O^FL%W=WQW9\D\OF8MD;)H=_U-=0[3Q'\%VT8L_N3<6>FQU;4
MBFBK\=34U! TTM;Y9(XO?NO=!_TO_,'^7W:<'S)^-T/Q8ZJK_P"8O\,=[],[
M=W3UHG<N2V;UMN#;O?<8K]O[]Q6[<AMRKRD>&&&@RT]3C4P]9D(ZNA- 6$E0
MDL?NO=,VT?GE\W.C/G]\8?A-\]NJ_BR<3\X-N][Y#XW]L_%+>>[<I]IEOCWA
ML?N#.83=6%W3BH98T./KRM-D*6M\4S)%(]/ 9I8*/W7NH6[?GQ\^._/F#\E?
MCI_+K^/7QKW-UU\)LOM+9O?G<ORK[0W!LZGW'N[=&%.=?9VQZ7:V*R\E/4XR
MGFH(*[)9-3#!432 T;)' ]7[KW1,/Y1?<_RHW%L?^<AVMU5\4J6F^4&Y?YJF
MYJ>J^-?=_;-+UU1[?R-=MO8=!G5S.Z<9CL_%58_ Q"NJXIL;CJLY:&*#[(*M
M6DJ>Z]T=S:/SR^;G1GS^^,/PF^>W5?Q9.)^<&W>]\A\;^V?BEO/=N4^TRWQ[
MPV/W!G,)NK"[IQ4,L:''UY6FR%+6^*9DBD>G@,TL%'[KW20V1\__ .9-\P\K
MW;V?_+Z^,'Q*W-\5.G>V]^]/;,W1\CN]MR;*W1VAD.J*J+';@J]L4N"VUD\1
MMS%#+)DZ.AJLK5S?</2I*\4,4[&F]U[HC_=_9?RIPO\ PHRV_E?C9\>]M;R^
M1_9/\B[9^ ;9';O8\6T-H['3+]PU67RV9WGG\-!F,C64&$K,?2XM*?!XBNGR
M-?74WCDI:,35D?NO='HZ+_FU]E=;[0_F&[4_F7=7=;]5=^_RT>O=B=K]MUGQ
MOSV4W=M#>>V>R,%49/"Y;9J[@AI<M2SY'(4%90+05TSR0SO3+)4$NY3W7NDC
MVA_,9_F4_%3HS;?SV^7/QB^,^WOAAD*GK')]K=3]6[WW9NGMOK3;?9V3@Q\6
M?S-6^/?;&ZZC$?Q7$/E<9C:"D-'HJS!7UT:^2+W7NM@2">&I@AJ:>1)H*B*.
M>"5#J5DE 96!_(92"/?NO=9??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:=_P#-]_F,?\)[OAI\
MJ]V]>_(;^7MU7\P/E?E:BFW#WEE=I?'C9&Z*K%5>5HJ.HHTW+N'<<E$U7F*V
M@GIY%@IS5O#"H%6],S0I+[KW1U-K/_(YZ9RO\J+N*E_EQ=*=/[C_ )C-9U)O
MCXC]E8KXP['HO[K;LW5BL!NK:6/SF7HY148/<LU3E\='C):&.K5LC"YAG01"
M7W[KW6QY[]U[K2K_ )AW1OSG_F]_SI_DO\#>K_G%VO\ ![H3X6_%WJ[=]%1;
M03-5%-N_)=M4&+R,]<N(Q.>VI#E8)Y,U)BZBMK,Q,E <:U/34KFIJ]/NO=:[
M76WP3[>H/Y4O1O\ .1[,_F/_ "<R_2^0[JQ^R^__ (_]>[MS&R]U;?PO^D*M
MV++D=M;OK=P9ZARN9B$6.RB4=1M&F0PU#P_<7A$\GNO=?5OH:VFR5%1Y&BE\
MU'7TM/6TDVAH]<54@>-M+A674C V*@CZ$ ^_=>ZE>_=>Z][]U[JC'^2=_P!S
M[_\ BX6\_P#KK[F[WH_Y97_2MAZ)]H_T7_FH>KSO<(]''3?E/^ <G_!H_P#>
MQ[]U[I+^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I7T?_ 6G_Y9)_O7OW7N
MI/OW7NO>_=>ZUI_DQEN^?C3_ #]JGYOXKXD_(COSXTXG^5-LWXZ]I;OZ0V!5
M[PKL/4;M[1W#N;[_ !&-$<;[OGQ+;>QL63Q6)FJ,M2TN6I\@*.6G1_?NO="7
M\,=F=E?+C^:%\G?YK&;Z0[M^/_3&-^%VV_@9\<=L]Z[&JNKMT;PI:?=$V\]S
M;KJ]I9"G3-XN@BRL%%1XHU8BDK(7DF$!LGB]U[JC7X4=+_)'HSX<?RA>O?G=
M\=_GF_P&VOTO\Q*GN'H7X_\ 7W8]-N&@[6SG<NZL[M&I[/VQL-Z+>L^U:S:%
M9%)04U52MCFJYK5L+B=4/NO=62_RQOB1NO,_++^>S'C?BIWG\,OCM\R.C?B-
MM3XW4O=&V:S$3U&,BV-OC:.3R2SM7Y5HJYLEKR51C)\E_%L;%7TL>1I:.:18
M1[KW4/XZ?)3Y9=<?RM3_ "NZW^73\MLQ\Z>H?CEN[XF24R=:5N,ZMJ,=B\95
M[=Q>^XNT:J&EV[7X*7!/35WV5 ]5F:JK2;&4-#4S#S>_=>Z0O3G7OR-^"M!_
M([^>&>^,O?O9'6_6G\L6A^$GR]ZUZWZVS&Z=_P"P#NBDV]GL1G)=BP43YRMB
M@S= :++014T=301*99D)C6%O=>Z&;<&SN^_YC?\ - S6]\_\4/D/\<OB=VO_
M "C/F+\2]A=I]P;2K]B9BOF[*S.UTJ<GEL;!JJ]CR5:YB9</CLI4TF?J8\;6
MU[4%-"L1]^Z]T2SXN?$K^7%T5T?UE\=_GO\ R0_D-OCYL]5[7Q'6.]=P]:?#
MW=_R&PW8-9M#_<52;GV]OO#ZMK2X_,TU/3U#-D<IC$QX<Q50IHH25]U[JTCO
M?XY[EH_YJ/\ PG<SW27QPWOL+X]?'+J3^8%C=W8S"[*D.$ZWQ^[NI,1AMMX'
M.U^.-9AL34O6LN/IH3D7%1/%(*9YU1I/?NO=;#C$A20I8@$A5M<V_ N0+G_$
M@>_=>ZU"?D7C\)V[\A^J.X?Y<_P*_F%_#C^:%N/Y"=-3=\;CEZ.W!T9U]-MB
M/,I+O2H[?S,58>I]\8AL(^5%-5T%=E,G75<T#4<DIUB/W7NK(OY'W4':W4^V
M/YL)[1ZVWUURW:7\Z#Y[=L=<0[YVK6[5ES>V-UKM>#%[@QD-=!!+5X?)RT-6
M*2KC1H:E8V>%W2S'W7NB8_RYOCKW]M?_ (2D]A?&_=?2?:VT?D%F/A=_,OV=
MC>D=W[ RNU-URY7L'*]I'!8\8#(4M-E%J\PN1H&HXVI0U0E3 \09)4+>Z]TR
M;U^,/R3V!\+?^$[OS8Z]^-O9/;G;G\L'J3JVC[M^,F,Q\NV=^-M3N7K# ;4W
MS#B,#EC1&KW5MVHQE#*N)J5@J)9(I(A+ !,3[KW0X_(/<N\?YQOR(_EV[(ZA
M^-'RJZG^/7Q ^9_7_P XN^N]?DOTAF/C? *[H2AR']W=F;>QFZ:6ES&X,AF<
MIE#'D)*2C%-14T;.:HR%2GNO=!Q_+H[AWY_)HZ>[!_EU=\?";YH[UH.H>\NX
MLK\4.T/C%T%G?D;MSL/9O:.>KMP8.-,KADJ$V[N*A?(24M=29J:FCA58IOO9
M;5(@]U[HON[?@1\M>I?Y3W;?<&?Z WUNCY&=T_S>]O?S=NW?BQUE)2;_ -SX
M3"5W8&"S-5M/"TU&T5/FL_C=MX>FJ):2GE=VJY:F")W\2(/=>Z.C_,EW%OGY
M[[)_DT]K]$?'3Y1T^#V?_.[^'?96\\#V3T#N'KS.X/:O5\FXSFMUYW"U](M?
M@MMTNH6K\A%30R H\99)J=I?=>Z,_P#S(>K>S-\_S!/Y)N\-E]>;XW=M'J[Y
M/?('/=F;JVSM2OSN-V[19;KG(4M)69VOI8):7$4U55?LPRU4L233$11EI"%]
M^Z]TF/\ A2+U%VKWQ_)S^5'4_2?6^^>V^S=W9KX[4^V=@]<[6K=Y9:M./[-V
M?65+04&/AGJ'BI:.GJ*B>3Q^.""*2:5DC1F'NO=8OYX_4_:?:W_#1O\ HNZT
M[ [)_P!'/\Z_X+]H]A?W!V;D=X_P';.T_P"\_P#%=QYG^'4U3_"\%C//!]W7
MU/BI*?R1^:5-:W]U[K+_ # NHNU=X?SC/Y"_;&TNM]\[HZRZ>S7\R6G[9W]M
MW:U;F\3MD]B]98:CP39ZOIH9:?$Q9>LHZFGI9*J2*.:=/"C&1E4^Z]T2GX+]
MC=\?RMNTOYGGQ;W=\%/F!WEV%WW_ #"?D+\S_BCN/H_JV;=&Q=Y8#Y!4N)3#
M8VN["J)*3;.T,AB&P2+FFS=51QT1G'A-6WC27W7ND?\ $[9&R.I/Y3'6'QO_
M )G_ /+?^1'=&Q=]?('YRYKLS;^R/CGF^\8]EY*#M#.U&&KI\9C(*;?M)3;@
MI<O638+<6)P6@TT!J'J:..KI7E]U[H")/A5\U>[?@YVIF>M^K?E-G^K/A[_-
M!^//S:_EC_'?YEYVNQG9V7V;T+3K'N3!R_WBJYL_0XS*-EMP/MF@ST\61$,<
M4<L<3RPW]U[J_P"^-_\ ,FKOE]NO";(V'\&OG9U9B:C9.X<]VYOGY0=!9#X\
MX_:-3#02-1X",9K][=FX:S(::=H,*M534L0>JJ*Q :>&I]U[K6;Z,_ED]P9?
M^3U_)$W_ -V_"_L_NFM^#7<'R\RWR7^$&X,)D-K;NR_7_P F=Y[SAKZBDVI7
MOCILIFL9 =N9:GQDWAJJJC>:*"_GDAF]U[JXWX!=-?RFLC\E=B[M^(G\I?O+
MHWL?95#N+-0_(/LKX8[G^.^)VI45&-JZ.6C.3WL<5/69:N@GJ*-8L309 QB5
MFJ)*>)ED;W7NMB/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1+,MMG<;YKYMSIM_./#NC9NU:3;
M4B8FH89"6FV]7PR1T)$?^5NDLB(PBU69@IY/O%+<N7[][OGUQ;7!6[L+..T(
MAD(N73:[B-EAHOZA#L%(351B!QZR+L=YLUMN3U,\(-M=W+W ,J P*U_ X,O=
M^F"JEAJI4 GATH-][=W!4_#JCVU38/+U.XHNKNO*"3 TV-FGK1/0)C//":5$
M,WEA\<FM=%UTMJ L?9[S9L=[-[7)MZ6\S70V?;XC;K$[3B2..V#)X:J7U+I.
MH4J*&O#HKY8W>TA]P7O'FB6W.Y7[B=I$6$HYN-+:R0NEM0TFM#44X].V^<!G
M*K<_Q?FIL-E*F' YJHDSDT%!+,E&O\)5-54ZH5IP75E!D*W8$#GCV<\W[/=W
M&X\K-'#*RV]RYG98W98!]"RUD(!"#5V@M2IQQZ0<L[K:P67,:O-$IGA40AG4
M&8_5$T0$U?!![:XSPZ!W)]:[(V;V3V54]J]2;BWO@]Y;GJ=W[3WA@,)7;GCB
M&:)DJL?5143^2EDCJ2WCU1GR W!"A?<6WO(6T<K[[NC\Q;-<7]O?7;7MG>P6
MT]ZJ>. 98)%@JT162I2JD,IP0 !U(-GSCN7,.S[>FQ[I;V<UI;+:W5I/-#;,
MW@]J2HTPHX*4U4(TGYD].>9V50X:GZP[7ZKZ>W7A,;U[O?/UV:V--AS09>MH
MMPTE+2U&0IZ&2HEGD>-::,11.R2-^HQJFIO:_=N4X-J3:>9.7=ENX(]MOKF2
M?;_ \*\GM[J".&29(6D9F8")-$;%7(&54=(MNYCEW!]RV+?-UMII+^S@2&\$
MNNUAF@EDD2)Y51% )D)9U!4< Q-!T/5!ORO[5Q.\,+A-A[TP>-GV?EZ6GSN\
M\4=L+-79")H8J2GIYKS2J [-)/Q&A70-1:XF2PYOE]P;>\MK6POH(C:2JMQ?
M0FT#SR*46-(Y.]@ Q+R4"*0%!8DTBZYY8BY'GM+FYO;2:1;N)FAM)1<E(8V#
MM(SIVJ< *F68&N*4(-;0RN7R7QHW9UG+L7?^*W5M;JC<6"K*?*[6J*6*HJOM
MZF"."ADLQK)9KAE6)&])%_JMXJY;O[J_Y O-A;;]QAO+39KFV=)K25%DF$,L
M2K"U")BY%5$>K!%:5%9#W^QM[/G*UWE;VQEMKG<[>9&BN49HXO$C<M*,>&JY
M!+$9'R-(E/@MU]=9+X_]K_W.W'G\=B^D=N=9[ZPN$QKU>4QWBIHJB*?[ Z9I
M/'4O(DRA0T81@WJ*J4EILVX\C3<N<Q_0W-Q'%L%MM.XP01L]W:TBCE5_!PSZ
M9"RR*!J4 X)H.E$VYV/-T.^;%]7;P22;Q<;C9332!+:XK(R,OBY4510R$FC5
M%, GI7P',]Q=P;*WW1[2W1MO9'5^ W<U+D=V8>3 U&3R&[*;[3Q4M)+_ )0]
M/!$JOY2H!<,EN1J%,*W/N=S18;S':7=K8[3;WNB6\A:VDNKF]B$.F.*0"0QH
M@U:R "W:!ZD$HM_;[E^\VN2ZMKB\W*>UU1VLJSQV\%K)XNIY%[ [,2NFI.DA
MO6GNG-N[@QOQ&7;F0P>7H=P-LWLRG&"J\;-3UADR-7EWIX_MG03>2998RBZ+
ML'72#<>Z>TVQWNW>VJ6-Q;S1W/T>Z+].\3K-JEGO&1?#90]6#J5%*FHH,]>]
MPMWM+SGWZN*:)X/J]N;QED1HM,<5J&.L$K12I#&M!0UX=2NM=\U'7FT_C?UK
ME=LY=L_OK!UU%+!*IH9<<NWX(YI9*FGDC\OTF6ZD)I"NQ/IL57(?-S<E;;RO
ML%S:S_4[A:O&5(*-;"UA21S(C+J'Q@4-",D\*=,<X\LIS9?\P;S!<1>!93(X
M84=;@SNR*$=6T_@.16I( XUZK;_X4B]1=J]\?R<_E1U/TGUOOGMOLW=V:^.U
M/MG8/7.UJW>66K3C^S=GUE2T%!CX9ZAXJ6CIZBHGD\?C@@BDFE9(T9AD-U!_
M2G_GE=6]F=L_'GXJX3JSKS?'9.9P/\R;X.[TSN*V'M2OW=44.&VSNQ9LEEZV
M''P5$E+B\="1)55<JI3TZ'7-(B\^_=>ZKQ^='P7Z&Z__ )I'>_S ^9_P*[%^
M<?Q&^6'371U%#NGK+K;._(BOZWWWT92S[>F3([+P339B#";@V_)CI(LA14%1
M#%50U"2I$]1+)+[KW3-V_P!/;*VS\%^X-Z_R@OY>_P J?AYAL_WM\;<?\GI]
MB]#YGX[]I=B]1;=RU;)O2#K?$5E;3[\&0HJ&JD6"08['5M1%45(Q:SEQ*/=>
MZ#?8?1?7V[?YM/\ )T[L^$OP*^9_4WQIZ2RWS*V[W;\@._\ KK?6#-;E.QNK
MZZCP4.1AW]D:_>L,=%/BJN*;-9.@IL?75V3@IX*^LJRRK[KW1SNH>SNU?Y7G
MSI_F.;,[3^)WRO[JZ?\ FK\AL;\L_C'VQ\8NE\OWO39++[SV_C,3N/9F>_AL
M @VID<;78NE^SGRE=!034K35$D]+!3EV]U[HA5'L+^9SC_B-_-$W]COCO\B^
MA-^=U?S>=@]V=U]2=,35=?V#6=);LV[L:?>6.ZYSF(:G;/;B@QC)0U%9MRKG
M62JI<K28NIF>,-[]U[I3[#Z+Z^W;_-I_DZ=V?"7X%?,_J;XT])9;YE;=[M^0
M'?\ UUOK!FMRG8W5]=1X*'(P[^R-?O6&.BGQ57%-FLG04V/KJ[)P4\%?6599
M5]U[H<_Y=/=78W\G+IK>G\M/M+X&_.KM7.=.]O\ <65^+G8?QSZ%R'<NT>Q]
MK=J[GRN:VX$W;2S+B=MYBD%:(<LF<GQ\&.C\=145!3R,ONO=&RZ]ZV[RSW_"
MAZE^2FZ>DM][)ZYR?\C/:G7.Y-UU&+J,OMW&;WS?<5+G:G9D>YXZ:+$Y+-4%
M%%4R/'!)Y&IXQ4F*.*6._NO=$X^:/\O/O/YI_*G^?/U1@=C[OVWB?DA\%_@Y
MMWHSLK<F+RFT-L9[=G4U5D]P4^)I=Q^!**J2/+XNAILDD,TPIXIRE9'XY"C^
MZ]T&W4?0O\HK<>-V)L7L_P#D#_)O'_*VK@V]A^R>NIOA/NC.X^GSLL<2Y3)2
M=B5E53; K,":KSSC*2;F"5$1#*CSNL+>Z]UM\4E+34-+345'!%2T='3PTM)3
M0((DCBIU"1QHHL%1%   %@!;W[KW4CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7SQ?F[\CMH_R
MJ.V/^% _Q<^672O93;O_ )J6)[T[.^(/ROH\%3;HI\WC>TL'EX:'9E?7R5:U
M5'A-JY/,K14Z4YG:C)85E)34[44TONO=)WJ_YSX#^;+DO^$[?\MWX@=5=G;B
MS?P)W%\)NW?E;W%N/;[XO!X'_98-LX7'[@IZ=:<5;2T2QXW*B&OK9:""IK6Q
MM!2B62N+P^Z]U]#S<&[-J[2@IZK=6Y=O[9I:J8T]+4[@S--AHY)%4L4C>IDC
M5W"@FP)-N;6]^Z]U6[DOBW\0*C^8KMO^9AA?D*FU.\,;\?\ +?&W>.UL%V=M
MIMM;IV[6UAR%*,U25=-59!:O'5RTLT,M#DZ/6U)2K.LL<<B2^Z]U1GV;_P )
MF?@'V?\ *[,=J3?/G=F(^*&\N[ZOY$[S^#=#O'$56!K=VY2H62KEI<M)G/#1
M8^M@>LHI$_N[-DTH:@TM+EJ:.-+>Z]UN$P004L$--30Q4]-3Q1P4]/!&(D1(
M@%1$10%5%4     "P]^Z]UE]^Z]U[W[KW5&/\D[_ +GW_P#%PMY_]=?<W>]'
M_+*_Z5L/1/M'^B_\U#U>=[A'HXZ;\I_P#D_X-'_O8]^Z]TE_?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]TKZ/_@+3_\ +)/]Z]^Z]U)]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2679V#_OC)ON
M2&:HW$V#BVY35-1.94IJ1)6G=*:+]$33RL#*X&I]**3I4#V0#EJT_>9W=E+7
M/TXME=F)6.'69"J+P4NQ!=AW-I4$T4#H[/,-S^[QM@(6W\8W#*J@-)*5" NW
M%@JBBC@*DTJ:]*GV?]$G7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:CW\P# ?\*(^
MG/DAWEO7K?H3XK_S._Y?^^.QUW!LCXQ=F;6V_O7*[;VY]N#68^*DKJ?;.8-9
M5J9X4$=5N6**18'2D9&GBF]U[KA_+E_X4(_#O ]P]._!#N;^6MV9_*L[_P"X
M-R['ZZVGUIANE*3;.U9\OO++KM[;=(:>EPVU<_009*KEAAAEGVD:*D?SPS5J
MQ4YJ)/=>ZN$_FO\ \H3H+^;SU[U/USWWV#V[UYB^G]YYK>NWLAU%D</CZJ>H
MSM"*&:&K.9P^9A: 1JK+XX8W#C]96ZGW7NM2CYZ?\)]_^$^_\M+'[4J/E]_,
M/^8G7N;WVSML[8V(GVOOK<.0@A,JR5T>&PO7==6P8N)X9(VKJB*&C$P%.)S.
MZ1-[KW7#:?\ PG]_X3Z;I^+?0/S/?^8-\V-N?''Y,=EKT_U%O_=>+PN!CKMQ
MMF<S@%QE9"_6,DV&,F4V_EH5J<A'3T9$'D\_C>-G]U[KZ'7OW7NO>_=>Z][]
MU[JC'^2=_P!S[_\ BX6\_P#KK[F[WH_Y97_2MAZ)]H_T7_FH>KSO<(]''4.O
MBDFIGCB74Y9"!<#Z'_$@>_=>Z8?X;6_\<?\ K(G_ $=[]U[KW\-K?^./_61/
M^CO?NO=>_AM;_P <?^LB?]'>_=>Z]_#:W_CC_P!9$_Z.]^Z]U[^&UO\ QQ_Z
MR)_T=[]U[KW\-K?^./\ UD3_ *.]^Z]U[^&UO_''_K(G_1WOW7NO?PVM_P".
M/_61/^CO?NO=>_AM;_QQ_P"LB?\ 1WOW7NO?PVM_XX_]9$_Z.]^Z]U[^&UO_
M !Q_ZR)_T=[]U[KW\-K?^./_ %D3_H[W[KW7OX;6_P#''_K(G_1WOW7NO?PV
MM_XX_P#61/\ H[W[KW7OX;6_\<?^LB?]'>_=>Z]_#:W_ (X_]9$_Z.]^Z]U[
M^&UO_''_ *R)_P!'>_=>Z]_#:W_CC_UD3_H[W[KW7OX;6_\ ''_K(G_1WOW7
MNO?PVM_XX_\ 61/^CO?NO=>_AM;_ ,<?^LB?]'>_=>Z]_#:W_CC_ -9$_P"C
MO?NO=>_AM;_QQ_ZR)_T=[]U[KW\-K?\ CC_UD3_H[W[KW7OX;6_\<?\ K(G_
M $=[]U[KW\-K?^./_61/^CO?NO=>_AM;_P <?^LB?]'>_=>Z]_#:W_CC_P!9
M$_Z.]^Z]U[^&UO\ QQ_ZR)_T=[]U[KW\-K?^./\ UD3_ *.]^Z]U[^&UO_''
M_K(G_1WOW7NO?PVM_P"./_61/^CO?NO=>_AM;_QQ_P"LB?\ 1WOW7NO?PVM_
MXX_]9$_Z.]^Z]U[^&UO_ !Q_ZR)_T=[]U[KW\-K?^./_ %D3_H[W[KW7OX;6
M_P#''_K(G_1WOW7NO?PVM_XX_P#61/\ H[W[KW2CID:.GA1Q9EC56%[\C_6]
M^Z]UG]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6IS\U</_P *
M>_EM\K^\^F/B1FNG/A'\--F[];;W7??>9EQF$S&YL*:>**2L%24WAN<S+(]1
M,DM!A,/&2(XTJ"58^_=>ZE_"W_A+ELWJ[Y"]0?,KYT?-WY%?-SY.]-;YV?V5
ML_)9O/U>)P]-ENOLO%G,&:RJS-;N'<V8I\=E(C4B,YBBIYY7<34K1M(DONO=
M;7?OW7NM(KYRYSX+="_\*!OD]O;^;_L?:F[^G>]OACU3BO@5O;O+J5NRM@X&
M;:M!34>Y,--2S8O(T#Y>7<<63K8,A-2S+C!6O'-44@KJ?7[KW5+N:^=?QO[%
M_P"$S?PN_E/=9;@J^UOGGVUWID<!A.E-HX.6LJ<+593N_=.=Q;Y2OJEIL?23
MYRBR6-IZ&&&JEJ9FR$9:)*9:B6/W7NOJ!X.EK:'"X>BR51]YD:/%X^EKZOS/
M4>6>GB1)9/)(!(^N0,VI@&-[D GW[KW3I[]U[KWOW7NJ,?Y)W_<^_P#XN%O/
M_KK[F[WH_P"65_TK8>B?:/\ 1?\ FH>KSO<(]''5#/\ PHV[-[)ZE_ESS[NZ
MJ[!WQUGNM.\^K\:NY^OMV5^S,@*>MCRGF@%;C:BFJ1#-H36GETMI&H&P]CSV
MWM(KW=%CF1)%,<A*NH9:A<88$=)KIBJ5&,CK09_V>_YP_P#>97RL_P#2A]W_
M /UX]Y%?U;V[_E%MO^<$7_0/19XS_P 1_:>O?[/?\X?^\ROE9_Z4/N__ .O'
MOW]6]N_Y1;;_ )P1?] ]>\9_XC^T]>_V>_YP_P#>97RL_P#2A]W_ /UX]^_J
MWMW_ "BVW_."+_H'KWC/_$?VGKW^SW_.'_O,KY6?^E#[O_\ KQ[]_5O;O^46
MV_YP1?\ 0/7O&?\ B/[3U[_9[_G#_P!YE?*S_P!*'W?_ /7CW[^K>W?\HMM_
MS@B_Z!Z]XS_Q']IZ]_L]_P X?^\ROE9_Z4/N_P#^O'OW]6]N_P"46V_YP1?]
M ]>\9_XC^T]>_P!GO^</_>97RL_]*'W?_P#7CW[^K>W?\HMM_P X(O\ H'KW
MC/\ Q']IZ]_L]_SA_P"\ROE9_P"E#[O_ /KQ[]_5O;O^46V_YP1?] ]>\9_X
MC^T]>_V>_P"</_>97RL_]*'W?_\ 7CW[^K>W?\HMM_S@B_Z!Z]XS_P 1_:>O
M?[/?\X?^\ROE9_Z4/N__ .O'OW]6]N_Y1;;_ )P1?] ]>\9_XC^T]>_V>_YP
M_P#>97RL_P#2A]W_ /UX]^_JWMW_ "BVW_."+_H'KWC/_$?VGKW^SW_.'_O,
MKY6?^E#[O_\ KQ[]_5O;O^46V_YP1?\ 0/7O&?\ B/[3U[_9[_G#_P!YE?*S
M_P!*'W?_ /7CW[^K>W?\HMM_S@B_Z!Z]XS_Q']IZ]_L]_P X?^\ROE9_Z4/N
M_P#^O'OW]6]N_P"46V_YP1?] ]>\9_XC^T]>_P!GO^</_>97RL_]*'W?_P#7
MCW[^K>W?\HMM_P X(O\ H'KWC/\ Q']IZ]_L]_SA_P"\ROE9_P"E#[O_ /KQ
M[]_5O;O^46V_YP1?] ]>\9_XC^T]>_V>_P"</_>97RL_]*'W?_\ 7CW[^K>W
M?\HMM_S@B_Z!Z]XS_P 1_:>O?[/?\X?^\ROE9_Z4/N__ .O'OW]6]N_Y1;;_
M )P1?] ]>\9_XC^T]>_V>_YP_P#>97RL_P#2A]W_ /UX]^_JWMW_ "BVW_."
M+_H'KWC/_$?VGKW^SW_.'_O,KY6?^E#[O_\ KQ[]_5O;O^46V_YP1?\ 0/7O
M&?\ B/[3U[_9[_G#_P!YE?*S_P!*'W?_ /7CW[^K>W?\HMM_S@B_Z!Z]XS_Q
M']IZ]_L]_P X?^\ROE9_Z4/N_P#^O'OW]6]N_P"46V_YP1?] ]>\9_XC^T]>
M_P!GO^</_>97RL_]*'W?_P#7CW[^K>W?\HMM_P X(O\ H'KWC/\ Q']IZ]_L
M]_SA_P"\ROE9_P"E#[O_ /KQ[]_5O;O^46V_YP1?] ]>\9_XC^T]>_V>_P"<
M/_>97RL_]*'W?_\ 7CW[^K>W?\HMM_S@B_Z!Z]XS_P 1_:>O?[/?\X?^\ROE
M9_Z4/N__ .O'OW]6]N_Y1;;_ )P1?] ]>\9_XC^T]>_V>_YP_P#>97RL_P#2
MA]W_ /UX]^_JWMW_ "BVW_."+_H'KWC/_$?VGKW^SW_.'_O,KY6?^E#[O_\
MKQ[]_5O;O^46V_YP1?\ 0/7O&?\ B/[3U[_9[_G#_P!YE?*S_P!*'W?_ /7C
MW[^K>W?\HMM_S@B_Z!Z]XS_Q']IZ]_L]_P X?^\ROE9_Z4/N_P#^O'OW]6]N
M_P"46V_YP1?] ]>\9_XC^T]>_P!GO^</_>97RL_]*'W?_P#7CW[^K>W?\HMM
M_P X(O\ H'KWC/\ Q']IZ]_L]_SA_P"\ROE9_P"E#[O_ /KQ[]_5O;O^46V_
MYP1?] ]>\9_XC^T]>_V>_P"</_>97RL_]*'W?_\ 7CW[^K>W?\HMM_S@B_Z!
MZ]XS_P 1_:>O?[/?\X?^\ROE9_Z4/N__ .O'OW]6]N_Y1;;_ )P1?] ]>\9_
MXC^T]>_V>_YP_P#>97RL_P#2A]W_ /UX]^_JWMW_ "BVW_."+_H'KWC/_$?V
MGKW^SW_.'_O,KY6?^E#[O_\ KQ[]_5O;O^46V_YP1?\ 0/7O&?\ B/[3U[_9
M[_G#_P!YE?*S_P!*'W?_ /7CW[^K>W?\HMM_S@B_Z!Z]XS_Q']IZ]_L]_P X
M?^\ROE9_Z4/N_P#^O'OW]6]N_P"46V_YP1?] ]>\9_XC^T]>_P!GO^</_>97
MRL_]*'W?_P#7CW[^K>W?\HMM_P X(O\ H'KWC/\ Q']IZ]_L]_SA_P"\ROE9
M_P"E#[O_ /KQ[]_5O;O^46V_YP1?] ]>\9_XC^T]>_V>_P"</_>97RL_]*'W
M?_\ 7CW[^K>W?\HMM_S@B_Z!Z]XS_P 1_:>O?[/?\X?^\ROE9_Z4/N__ .O'
MOW]6]N_Y1;;_ )P1?] ]>\9_XC^T]>_V>_YP_P#>97RL_P#2A]W_ /UX]^_J
MWMW_ "BVW_."+_H'KWC/_$?VGKW^SW_.'_O,KY6?^E#[O_\ KQ[]_5O;O^46
MV_YP1?\ 0/7O&?\ B/[3U[_9[_G#_P!YE?*S_P!*'W?_ /7CW[^K>W?\HMM_
MS@B_Z!Z]XS_Q']IZ]_L]_P X?^\ROE9_Z4/N_P#^O'OW]6]N_P"46V_YP1?]
M ]>\9_XC^T]>_P!GO^</_>97RL_]*'W?_P#7CW[^K>W?\HMM_P X(O\ H'KW
MC/\ Q']IZ]_L]_SA_P"\ROE9_P"E#[O_ /KQ[]_5O;O^46V_YP1?] ]>\9_X
MC^T]>_V>_P"</_>97RL_]*'W?_\ 7CW[^K>W?\HMM_S@B_Z!Z]XS_P 1_:>O
M?[/?\X?^\ROE9_Z4/N__ .O'OW]6]N_Y1;;_ )P1?] ]>\9_XC^T]>_V>_YP
M_P#>97RL_P#2A]W_ /UX]^_JWMW_ "BVW_."+_H'KWC/_$?VGKW^SW_.'_O,
MKY6?^E#[O_\ KQ[]_5O;O^46V_YP1?\ 0/7O&?\ B/[3U[_9[_G#_P!YE?*S
M_P!*'W?_ /7CW[^K>W?\HMM_S@B_Z!Z]XS_Q']IZ]_L]_P X?^\ROE9_Z4/N
M_P#^O'OW]6]N_P"46V_YP1?] ]>\9_XC^T]>_P!GO^</_>97RL_]*'W?_P#7
MCW[^K>W?\HMM_P X(O\ H'KWC/\ Q']IZ]_L]_SA_P"\ROE9_P"E#[O_ /KQ
M[]_5O;O^46V_YP1?] ]>\9_XC^T]>_V>_P"</_>97RL_]*'W?_\ 7CW[^K>W
M?\HMM_S@B_Z!Z]XS_P 1_:>O?[/?\X?^\ROE9_Z4/N__ .O'OW]6]N_Y1;;_
M )P1?] ]>\9_XC^T]>_V>_YP_P#>97RL_P#2A]W_ /UX]^_JWMW_ "BVW_."
M+_H'KWC/_$?VGKW^SW_.'_O,KY6?^E#[O_\ KQ[]_5O;O^46V_YP1?\ 0/7O
M&?\ B/[3U[_9[_G#_P!YE?*S_P!*'W?_ /7CW[^K>W?\HMM_S@B_Z!Z]XS_Q
M']IZ]_L]_P X?^\ROE9_Z4/N_P#^O'OW]6]N_P"46V_YP1?] ]>\9_XC^T]>
M_P!GO^</_>97RL_]*'W?_P#7CW[^K>W?\HMM_P X(O\ H'KWC/\ Q']IZ]_L
M]_SA_P"\ROE9_P"E#[O_ /KQ[]_5O;O^46V_YP1?] ]>\9_XC^T]>_V>_P"<
M/_>97RL_]*'W?_\ 7CW[^K>W?\HMM_S@B_Z!Z]XS_P 1_:>O?[/?\X?^\ROE
M9_Z4/N__ .O'OW]6]N_Y1;;_ )P1?] ]>\9_XC^T]>_V>_YP_P#>97RL_P#2
MA]W_ /UX]^_JWMW_ "BVW_."+_H'KWC/_$?VGKW^SW_.'_O,KY6?^E#[O_\
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MA]W_ /UX]^_JWMW_ "BVW_."+_H'KWC/_$?VGKW^SW_.'_O,KY6?^E#[O_\
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MA]W_ /UX]^_JWMW_ "BVW_."+_H'KWC/_$?VGKW^SW_.'_O,KY6?^E#[O_\
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MA]W_ /UX]^_JWMW_ "BVW_."+_H'KWC/_$?VGKW^SW_.'_O,KY6?^E#[O_\
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MQ_[P,^&'_I+FQ_\ ZQ>_?UGW+_E+N?\ G/+_ -!]>\%/X1^P=>_X;@_EX_\
M>!GPP_\ 27-C_P#UB]^_K/N7_*7<_P#.>7_H/KW@I_"/V#KW_#<'\O'_ +P,
M^&'_ *2YL?\ ^L7OW]9]R_Y2[G_G/+_T'U[P4_A'[!U[_AN#^7C_ -X&?##_
M -)<V/\ _6+W[^L^Y?\ *7<_\YY?^@^O>"G\(_8.O?\ #<'\O'_O SX8?^DN
M;'_^L7OW]9]R_P"4NY_YSR_]!]>\%/X1^P=>_P"&X/Y>/_>!GPP_])<V/_\
M6+W[^L^Y?\I=S_SGE_Z#Z]X*?PC]@Z]_PW!_+Q_[P,^&'_I+FQ__ *Q>_?UG
MW+_E+N?^<\O_ $'U[P4_A'[!U[_AN#^7C_W@9\,/_27-C_\ UB]^_K/N7_*7
M<_\ .>7_ *#Z]X*?PC]@Z]_PW!_+Q_[P,^&'_I+FQ_\ ZQ>_?UGW+_E+N?\
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M+N?^<\O_ $'U[P4_A'[!U[_AN#^7C_W@9\,/_27-C_\ UB]^_K/N7_*7<_\
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M_I+FQ_\ ZQ>_?UGW+_E+N?\ G/+_ -!]>\%/X1^P=>_X;@_EX_\ >!GPP_\
M27-C_P#UB]^_K/N7_*7<_P#.>7_H/KW@I_"/V#KW_#<'\O'_ +P,^&'_ *2Y
ML?\ ^L7OW]9]R_Y2[G_G/+_T'U[P4_A'[!U[_AN#^7C_ -X&?##_ -)<V/\
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M_P#UB]^_K/N7_*7<_P#.>7_H/KW@I_"/V#KW_#<'\O'_ +P,^&'_ *2YL?\
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M_AN#^7C_ -X&?##_ -)<V/\ _6+W[^L^Y?\ *7<_\YY?^@^O>"G\(_8.O?\
M#<'\O'_O SX8?^DN;'_^L7OW]9]R_P"4NY_YSR_]!]>\%/X1^P=>_P"&X/Y>
M/_>!GPP_])<V/_\ 6+W[^L^Y?\I=S_SGE_Z#Z]X*?PC]@Z]_PW!_+Q_[P,^&
M'_I+FQ__ *Q>_?UGW+_E+N?^<\O_ $'U[P4_A'[!U[_AN#^7C_W@9\,/_27-
MC_\ UB]^_K/N7_*7<_\ .>7_ *#Z]X*?PC]@Z]_PW!_+Q_[P,^&'_I+FQ_\
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MFQ__ *Q>_?UGW+_E+N?^<\O_ $'U[P4_A'[!U[_AN#^7C_W@9\,/_27-C_\
MUB]^_K/N7_*7<_\ .>7_ *#Z]X*?PC]@Z]_PW!_+Q_[P,^&'_I+FQ_\ ZQ>_
M?UGW+_E+N?\ G/+_ -!]>\%/X1^P=>_X;@_EX_\ >!GPP_\ 27-C_P#UB]^_
MK/N7_*7<_P#.>7_H/KW@I_"/V#KW_#<'\O'_ +P,^&'_ *2YL?\ ^L7OW]9]
MR_Y2[G_G/+_T'U[P4_A'[!U[_AN#^7C_ -X&?##_ -)<V/\ _6+W[^L^Y?\
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MQ_[P,^&'_I+FQ_\ ZQ>_?UGW+_E+N?\ G/+_ -!]>\%/X1^P=>_X;@_EX_\
M>!GPP_\ 27-C_P#UB]^_K/N7_*7<_P#.>7_H/KW@I_"/V#KW_#<'\O'_ +P,
M^&'_ *2YL?\ ^L7OW]9]R_Y2[G_G/+_T'U[P4_A'[!U[_AN#^7C_ -X&?##_
M -)<V/\ _6+W[^L^Y?\ *7<_\YY?^@^O>"G\(_8.O?\ #<'\O'_O SX8?^DN
M;'_^L7OW]9]R_P"4NY_YSR_]!]>\%/X1^P=>_P"&X/Y>/_>!GPP_])<V/_\
M6+W[^L^Y?\I=S_SGE_Z#Z]X*?PC]@Z]_PW!_+Q_[P,^&'_I+FQ__ *Q>_?UG
MW+_E+N?^<\O_ $'U[P4_A'[!U[_AN#^7C_W@9\,/_27-C_\ UB]^_K/N7_*7
M<_\ .>7_ *#Z]X*?PC]@Z]_PW!_+Q_[P,^&'_I+FQ_\ ZQ>_?UGW+_E+N?\
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M+N?^<\O_ $'U[P4_A'[!U[_AN#^7C_W@9\,/_27-C_\ UB]^_K/N7_*7<_\
M.>7_ *#Z]X*?PC]@Z]_PW!_+Q_[P,^&'_I+FQ_\ ZQ>_?UGW+_E+N?\ G/+_
M -!]>\%/X1^P=>_X;@_EX_\ >!GPP_\ 27-C_P#UB]^_K/N7_*7<_P#.>7_H
M/KW@I_"/V#KW_#<'\O'_ +P,^&'_ *2YL?\ ^L7OW]9]R_Y2[G_G/+_T'U[P
M4_A'[!U[_AN#^7C_ -X&?##_ -)<V/\ _6+W[^L^Y?\ *7<_\YY?^@^O>"G\
M(_8.O?\ #<'\O'_O SX8?^DN;'_^L7OW]9]R_P"4NY_YSR_]!]>\%/X1^P=>
M_P"&X/Y>/_>!GPP_])<V/_\ 6+W[^L^Y?\I=S_SGE_Z#Z]X*?PC]@Z]_PW!_
M+Q_[P,^&'_I+FQ__ *Q>_?UGW+_E+N?^<\O_ $'U[P4_A'[!U[_AN#^7C_W@
M9\,/_27-C_\ UB]^_K/N7_*7<_\ .>7_ *#Z]X*?PC]@Z]_PW!_+Q_[P,^&'
M_I+FQ_\ ZQ>_?UGW+_E+N?\ G/+_ -!]>\%/X1^P=>_X;@_EX_\ >!GPP_\
M27-C_P#UB]^_K/N7_*7<_P#.>7_H/KW@I_"/V#KW_#<'\O'_ +P,^&'_ *2Y
ML?\ ^L7OW]9]R_Y2[G_G/+_T'U[P4_A'[!U[_AN#^7C_ -X&?##_ -)<V/\
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M_P#UB]^_K/N7_*7<_P#.>7_H/KW@I_"/V#KW_#<'\O'_ +P,^&'_ *2YL?\
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M_AN#^7C_ -X&?##_ -)<V/\ _6+W[^L^Y?\ *7<_\YY?^@^O>"G\(_8.O?\
M#<'\O'_O SX8?^DN;'_^L7OW]9]R_P"4NY_YSR_]!]>\%/X1^P=>_P"&X/Y>
M/_>!GPP_])<V/_\ 6+W[^L^Y?\I=S_SGE_Z#Z]X*?PC]@Z]_PW!_+Q_[P,^&
M'_I+FQ__ *Q>_?UGW+_E+N?^<\O_ $'U[P4_A'[!U[_AN#^7C_W@9\,/_27-
MC_\ UB]^_K/N7_*7<_\ .>7_ *#Z]X*?PC]@Z]_PW!_+Q_[P,^&'_I+FQ_\
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MFQ__ *Q>_?UGW+_E+N?^<\O_ $'U[P4_A'[!U[_AN#^7C_W@9\,/_27-C_\
MUB]^_K/N7_*7<_\ .>7_ *#Z]X*?PC]@Z]_PW!_+Q_[P,^&'_I+FQ_\ ZQ>_
M?UGW+_E+N?\ G/+_ -!]>\%/X1^P=>_X;@_EX_\ >!GPP_\ 27-C_P#UB]^_
MK/N7_*7<_P#.>7_H/KW@I_"/V#KW_#<'\O'_ +P,^&'_ *2YL?\ ^L7OW]9]
MR_Y2[G_G/+_T'U[P4_A'[!U[_AN#^7C_ -X&?##_ -)<V/\ _6+W[^L^Y?\
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M4WW>5JZZND\M5/*]GJ6"ZM*!4 4 K>]\NN8[EKR]?Q)GTAGTHE=*A!B-544
M P/MSTLAA6W4(@H!P&3QSYUZ%KV4].]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6BE
M\LOCG_/A^.O\WKY0_,S^5;\%<=M+9W:];+MOL&OE[0V9N;:/:U/21:Z+<^5V
MSN#<^,RN"S*U,[22M0U5$)*J#S"-!5Y(9'W7NC7?&/Y2_P#"M#</R1^/V ^1
M_P &>@MJ?'C.=U]68COG=6*3:4=7C-F9+.4,.Z,C2&F[0KJC[JAP;UT\/BH:
MF0R(H2GG:T3^Z]UM_P#OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZTQ_DW\P_YV/\ -!_F$?+WX@?R
MANU^I?C+T)\"MX8CJSM;N;>;Q4<N8W3,];19*GJLC4;8W371FCRV,S=+%18S
M$CQQ8YJFKJG:KIH5]U[K)T+\NOYW_P#*?^:?Q-^/_P#-V[+ZI^6/QB^<7:5!
MT1L3N[KEXZ^HVQN[<,U)1XE!6Q;7VGD6AGK*RE%339'#NCTLD]71UB-0SPR>
MZ]UN:>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[K3.^472/\X+^3Y_,"^7_P ROY:?QNV]\T_B/\Z-
MRTW=?<_1^,Q-=G,U@-U8R*KFRDM)AL7DZ?-RY'+97*9.NCK<5CLB*V*;[.NH
MTGI:.67W7N@UZRZY_G:_SNOFY\).VOG;\5*7X&_!SX9=V[5^2U%LG*XG(;$S
M^:SNR32UU!3S8[<,]3N/(5]5DJ!*8M)BL/24&)K*VSRUXB:H]U[K=[]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]UJ[_ /"G_O?MKH3K/^7%G>J^XNPNFUS_ /,)ZRP.^,KL+?\ D=@)7X9L
M?7S55#EY:"KI$J\4WC#S05)>G(6\B$#W[KW3?_/X^>U/L=?Y8"_&/YE46TQN
M'^9/T;B.XST9\@HL*:[:<OW'\0HMRG Y:,U.VI=0^ZIZTM0R67SHVE;>Z]UL
M387Y/?&K<>7QFW]O?(;HW/9[-5]+B\-A,+VU@,I5U=37.(X*:FIH,A)-//-(
MRJD:(SNQ"J"2![]U[H<O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5H?S0?Y5'QP_FT].[(Z5^2>X^WMI[>
MZ][!B[)VUG.F-RXK;63CKTH*O&M'*^9P>X*&:EEI:V8,C4&L-I9)$(Y]U[JC
M'_H"I_E9?\_\^?\ _P"C3ZZ_^U5[]U[H9_CE_P )&?Y;'QD^0/2/R.V5W'\V
M-P[TZ#[9Z^[EV;A=Z]E['K,149?K/*TN9QB9*''=<XNNFHQ744#2QPY"G>1
M4\B@GW[KW6TM[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NJ4_YQW\TS=7\MKI3L7<6*ZFW?BLA5]5T^6Z
M9^2NZ]C/V1U@-\U>4DIJ;9&Z*/;>6&\,35UE#3M-%7S8JGP[-400#)_>'[9O
M=>ZL#^(WRCI?EUUUD^VMN]3=K]<=;5NX%INJ-T=KX&EVA-O; RT%%54^[<5A
M/OZG-XC$5T]1414]/F:*@R)2$2RTL8DT)[KW1(/EQ_--[)Z)^=&TOY?OQ\^#
M79'S#[PW+\7J;Y85,.T>Z-F=.TM'MR7<^5VK*IJ-X5F/I:BIIZ_&HSHE4'*5
M,1CCD"3-'[KW7#N[^:-W#\3OY?GR-^=OS ^ G9?Q]?H3<.P,1C^D*KO38_9F
M6W'2=@Y_;FVZ?*4V6VO793$XZFAR6X562*I?[@I2S.L1#Q:_=>Z#7<G\W_Y&
M=%;.'<_S(_E*_*WX^_&R@I*+*[Q[SV3VKUS\G8-NXRL02-F\W@-E;@K-PTV$
MI(VCDJJN.@F%/#KDD2R$'W7NK5]S?)WI3;OQBW!\PXM\X7<'Q^P72N5^0,?8
M. K$KJ*MVOC,-)GAD:*6ZK,E3CDUPBX9RRI8,;>_=>Z)C_*@_F:T7\SGI;?O
M864Z,W1\9>S>K^PH-E[\Z.WKN%MRY/'TFYL/C=R;8R\E0^(PC^#<&W\M254<
M;8]?%()H1),(Q*_NO=6F>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[JN7=?S [&P7\UGJ#X*4F V3+U3V!\(NU_DKF=RU
M%#7-N&+.;'WA@MOT5)35*Y!,:F)>BR-4\T;XJ2H>?Q,E3%&CQ2^Z]T9#Y,?*
M/J;XE;+VCO[N.NS6/VYO;MWJ[I+"5&#PLF=D.=[@RL.&PL<L41#QTTE=/$LL
MUB(E.MAI!]^Z]T8KW[KW7O?NO=%U^3'RCZF^)6R]H[^[CKLUC]N;V[=ZNZ2P
ME1@\+)G9#G>X,K#AL+'+%$0\=-)73Q++-8B)3K8:0??NO=&*]^Z]U[W[KW7O
M?NO=>]^Z]T77._*/J;;GRCZ_^'V4KLU'W1V9U%O?NW:>/BPLDV/EP77N0H,9
MDY):]3XH*F.JR=($A9;R*S,I])'OW7NC%>_=>ZUO>E_Y\W?O?'Q@C^<76G\H
MSY'[X^']/BM_[ESO:.R?D+UCF<U2XSJZNR-#G9H=DUF9Q>X\A64)Q=3)]O3T
M[B9-/AF>YM[KW1FOD)_.7VML;_AN"C^+OQVWQ\P<_P#S0-F=J[[^.>#P6_<'
MTPS4?56W\'N2IAR-5NIH*.BKZFAS:HD-1/ D4]--%-,C:+^Z]T*WQ9_F:Y'M
M[Y,9#X6_)KXD]T?!_P"4TG6-5W/L78?9VX]M=F8/=NVL76C'Y&KVUN_9^3RF
M%KJ[$3O :VA=XIXHYEDC\R).8?=>Z%#X)_/C _./</S9P.#ZXR_7W^R8_-3N
M/X:92JRVX8<[_'ZOIUJ6*HSU.D-+3_P^FK9IY!'3.\[HB*[3%G*)[KW2BZ]^
M9\&_OGW\CO@RG74N+E^/G1G1G<\O9S;K%8N6/=%5FZ<XQ<,,=$:(8Q<3&_W)
MRD_W!G9/MX!"'F]U[H\'OW7NJ%OYH?\ .2?^7YV%USUWNSK+?G5&.W%\D?C=
MMS%]U;^ZIR';6S]^;%W174#]DP[/;8^1R&9QN\]M8JJJEI*+-XVBEKJJF=L=
M2Y*GU,ONO=6^_'CMS/=Z]3[=[1W#TUV5T-5;GJ<[+0===N#$19Z+'4=?408S
M(5L&%RF7I:3^+X^.GK4IGJ_N:=9Q#41I*C7]U[JJ_LK^;9WD/G!\I_@[\5OY
M;W:WRXWC\0L?TID.V=W;=^0O7O3U'$G>VV:/<V'--3[QR6,EJ4\%3- YADE9
M9:>0R)&CPM)[KW2F^4O\U7M;X=_%'X[=Z=X? KLG;O>'R3^5^S/B/LOXI4W>
M6R,UE(,[V/'N&7 559NR@K:K:J4V33 #3_EMH#5PBJD@"3M'[KW23SG\XS?O
MQTK=K9;^8Y_+L^1OP0Z:W?N?$;-I_D;ENPMB_(C96%R&X9XJ6@&\,CL/-Y2J
MVK0U=3*(DK:RB^U$A022H&U+[KW5@OSF^8.S?@Y\2.WOEAN;"5N_,9UQMO&U
MFV=D;<K1#6;GS6[:VDQ&V\!C9DAJS]QG<SD<?2Q21TM04$QE$,H30?=>Z3?\
MNSYK8KY__%;9GR*I^OLIT_NJNSN^-@]I=,Y[,'<%?M#=G6>7J\+GMO5M::'&
M-4RT572%EE..IC)#)$YAC+:1[KW1X??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U7+TG\P.QNROYE7SE^&N;P&R:/K3XR
M=._$[L'8NX,70UT6=K*WO:FW'/F(\M439":@FI:<XJC%&M/C::2,&;SRU&M/
M%[KW1D.XOE'U-T5V=\;^H^P*[-4F\?E7V!N+K+J*'&X63)T\^6VQA:S/U45=
M/&;4,7\.H:ADD=2K.H3@L/?NO=&*]^Z]U[W[KW1=?DQ\H^IOB5LO:._NXZ[-
M8_;F]NW>KNDL)48/"R9V0YWN#*PX;"QRQ1$/'325T\2RS6(B4ZV&D'W[KW1B
MO?NO=>]^Z]U[W[KW7O?NO=%USORCZFVY\H^O_A]E*[-1]T=F=1;W[MVGCXL+
M)-CY<%U[D*#&9.26O4^*"ICJLG2!(66\BLS*?21[]U[HQ7OW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[HL_P <OE7UG\M.GLUW/T,N<W-M_%;R[5ZZAH,[CCM.
MIGSG4.7KL%DZ("I)2.-LKCYHHJ@L8F0K+?2??NO=5?8/^9;\S:+Y8?R>OCKW
M[\3]C_&+<?\ ,#QGS_?O_J7.[^7N+.[1F^+.!.<VG/@]SX*KHL%/%GZ2..IK
M89\54O%%61TZ20STTCR^Z]U>S[]U[KWOW7NO>_=>ZKE^!OS [&^4O9G\P[9>
M_,!LG"XSXD?-W>'QJZZJ-HT-=1SUV#V[MO;>6BJ\TU9D*Z.HRSU>7JP\E+%2
M4_A$*+3!T>67W7NK&O?NO=>]^Z]U37U=\NOG/\G?GQ\ENK^A\%\6-G?#[X4=
MY]=]%=P9#M&DW7N#?N\:[.[>QNX-RU.VZG%5E'@=N#!PY6G@HXJS'Y(5TR%I
MIJ1)=,'NO=7*>_=>Z][]U[KWOW7NO>_=>Z+KM/Y1]3;T^3';_P 2\'79I^X^
MC^O^L^S=]XZIPLE/0QXGMI\C'AY:6O),53*[XNL$L8 :+2I-PP/OW7NF;J+M
M;Y&;Q^07R=ZZ[/\ C&_4W2'5E;UE#\>>_&[5Q6[_ /23%NG&3U.X91MVCB6O
MVS_=ROB@IO\ +)G-8)P\03PN#[KW1H_?NO=>]^Z]U[W[KW7O?NO=4+?S0_YR
M3_R_.PNN>N]V=9;\ZHQVXODC\;MN8ONK?W5.0[:V?OS8NZ*Z@?LF'9[;'R.0
MS.-WGMK%554M)19O&T4M=54SMCJ7)4^IE]U[JWWX\=N9[O7J?;O:.X>FNRNA
MJK<]3G9:#KKMP8B+/18ZCKZB#&9"M@PN4R]+2?Q?'QT]:E,]7]S3K.(:B-)4
M:_NO=57]E?S;.\A\X/E/\'?BM_+>[6^7&\?B%C^E,AVSN[;OR%Z]Z>HXD[VV
MS1[FPYIJ?>.2QDM2G@J9H',,DK++3R&1(T>%I/=>Z4WRE_FJ]K?#OXH_';O3
MO#X%=D[=[P^2?ROV9\1]E_%*F[RV1FLI!G>QX]PRX"JK-V4%;5;52FR:8 :?
M\MM :N$54D 2=H_=>Z2><_G&;]^.E;M;+?S'/Y=GR-^"'36[]SXC9M/\C<MV
M%L7Y$;*PN0W#/%2T WAD=AYO*56U:&KJ91$E;647VHD*"25 VI?=>ZMP[B[B
MV+T9TQV;WWOW+P4/7'4W6^[NU-UYF&5)57$;,QL^4JYH6U!)6:EIW,8#?N,5
M5;EA[]U[H@O\J#^9K1?S.>EM^]A93HS='QE[-ZO["@V7OSH[>NX6W+D\?2;F
MP^-W)MC+R5#XC"/X-P;?RU)51QMCU\4@FA$DPC$K^Z]U:9[]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJY?@;\P.QOE+V
M9_,.V7OS ;)PN,^)'S=WA\:NNJC:-#74<]=@]N[;VWEHJO--69"NCJ,L]7EZ
ML/)2Q4E/X1"BTP='EE]U[HR&=^4?4VW/E'U_\/LI79J/NCLSJ+>_=NT\?%A9
M)L?+@NO<A08S)R2UZGQ05,=5DZ0)"RWD5F93Z2/?NO=&*]^Z]U[W[KW1=>XO
ME'U-T5V=\;^H^P*[-4F\?E7V!N+K+J*'&X63)T\^6VQA:S/U45=/&;4,7\.H
M:ADD=2K.H3@L/?NO=&*]^Z]U[W[KW7O?NO=>]^Z]T77:?RCZFWI\F.W_ (EX
M.NS3]Q]']?\ 6?9N^\=4X62GH8\3VT^1CP\M+7DF*IE=\76"6, -%I4FX8'W
M[KW1BO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T77N+Y1]3=%
M=G?&_J/L"NS5)O'Y5]@;BZRZBAQN%DR=//EML86LS]5%73QFU#%_#J&H9)'4
MJSJ$X+#W[KW3-V;VM\C-K?);XW=8=>_&-^ROC_V;1=IS=^?(X=JXK:PZ[EVI
MC%JMN1?W9J8GR>Y/[R9"]%_DDD8I-0GD+(CK[]U[HT?OW7NO>_=>Z][]U[JK
MJC^;W9TO\Y_+_P N.7;>Q3TY3?RTJ+YGT>[DHJ]-RKN0=FC94V.DJ3D&QDF$
MDQL\4R1C%)4I4QLQJGBD$2>Z]T9GYV]Y;M^,?PG^77R.V#0;>RF^>A?C5W=W
M%L[&;MI*C(8JHRG6^V\CEZ&')04=705<U#+4TD2SI#6T\K1EE2:-B''NO=.G
MPL[MW!\E_AQ\3/D=NW%8;!;J^0'QGZ'[MW-@]NK.F/H\AVKM;%9VMI* 5,U1
M4BCIZFODCA$L\D@C5?)([78^Z]T9CW[KW1!/YI/RKW_\(/Y?ORB^5W5F%V=N
M+L+I/KQ-U[4PO8%#6Y+#5%5+D:&B"Y"GQU?BZZ:G5*IV*PY"!R0/W +W]U[H
M[NU<M/GMK[;SE3'%#4YK 8?+5$4%PBOD:>.9U346;0K.0+L3;ZD^_=>Z('NO
MY@=C8+^:SU!\%*3 ;)EZI[ ^$7:_R5S.Y:BAKFW#%G-C[PP6WZ*DIJE<@F-3
M$O19&J>:-\5)4//XF2IBC1XI?=>ZL:]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=5I?S!OY7?Q_\ Y@&T=\U&[<=B=J?(#+]+YKI'K#Y$UNWFWYDMBX[<
MM6]3D:S;6*JZ^DH*#*UL<]33S5],U-7O ZPM5F"-8O?NO=&MZ ^+O17Q=H.P
M<7T/U[A^M,1VEV)E>U]Y[>VS-54N);/Y^EHZ;(5>+Q$E1+CL#3UIHTJ):/&T
M]+1M5RU-88#5553-+[KW6N)\Q<G\K\3_ ,*<NJZGX<;/Z$WOVNW\EV.&OP_R
M,WUGNO, N%;N'=1K)XZ_;F"W#D&R252T*PQ''^%XWF9Y49$#>Z]TJ/Y]64^7
MN6_X3U_/^I^:&S/CQL;LU-W?'.#;V)^->_\ <78^$DP2]J]7M3U%97;EV_MN
MMBRKY!LDDD$="\"P1TTBSM)+)'%[KW6Q6T6U)_CPT.^UH'V/-TN8MY)E-(I3
MBI,';(BIU>GP&C,WDOQHO?CW[KW6A-M[Y=[6Z7_X38?RIOBS\INR*[K+8OS>
M^1^Z-A=J;IW)_>"KRF.Z$ZW[/S.=W=6T-#A\=E=Q5M/58D83$8Z.BI AHLK2
M^&:&F"-[]U[JS#XC_P T;^7EO7^?OA\Q\&^\MN=B]5?S'OC#CNH.V\'BNJ-T
M]6RXKL_XHQ5%;LW*58W-A\"]129G9-178>F,-#*/NJ:.,SB_C'NO=;%/\QW<
M/QQVW\3]\5GRM[D[3Z3Z7J,WL>BSVX.DM[[AV%NO+5,F7I),?M;"56T5.ZZN
MIW-61Q4#T.(*UM=3S34RLL4DI'NO=:Z?5><ZT^.?\Y?^5;@OA9T5\U_B#U1\
MUMN_-;;GR,ZU^3\F]\#A=ZP]8;$QFY-MY?';8WANC,U./S^+KT,M?4O0T%6'
MJD^ZB>HJJXR>Z]TL/Y;GP;ZY_F79;^:9EOFSV/\ (+N?KWI7^;_\YNEND.D4
M[UW-UWMC:Z[:S6-W#%N"GI]KY+#5F5S\%7G:=,?+E:RNAPL>-HOX1!1.)&?W
M7NB@=N?+?Y$83_A.'_,IP#]X=D[I[9_EP?S%I?ACL#Y"9[.ID-Q9G$='=P]=
M38&NR61C&C)SC#9N"@J3/&R5=/%XZE9XY7\GNO='0_FP?#K8W\J7XN8[^:AT
M3W!\E,K\ROCGW)\?-P]R=T;_ ._MP[RK^W<%NS=6/V]N+:NZ\'D<E)M1<)70
MY^MJJ3&XO"8^DQ4@D_AL5)$\VKW7NG38/Q+VS_,8_G(?SI>G?DSVY\@LY\;_
M (];E^!NZ]L_&O:/;&>ZKP,FX>T^K*.2CW!49';F5QN=:?"-M^O>GQR5D..6
MKKI*^6&IJBK1>Z]T(/Q[^.'5/\X;Y5?S&\[\U?\ 31OSICX1_,2/X;_&KXT5
M7;^[>I]MX1?CQ0XJJK=Z5>.VGG</)N#+;GS<B5U+6Y*HJ **.E\<48TK'[KW
M5:W;><^2'Q^@_F=],]2]P][]DX+^09\R_A%\Z>B:[>':M7NG,Y+JWNK;]9N'
M?/4N?S%8KUF8VS@L,F1GHUR-75U#)3)3R2*E,!)[KW5KGSK^6=5W'\S?CO/T
MYGMQ;CZ$^"'P3[E_G#=QT^R7K9(MT35&WJVCZ@VY,:"8+7BOD3-9<8X)*U2D
M%/(MM*:_=>ZJ,ZRVWF_DI\&,#\BIO@U_.2[=_F8]T],U7<77O\QW8F7P>/QV
M-WCV#20YW"1;2@/<N"%!UCB\C'BJ/^$Q[2IX*S&TGDEI)JAUF/NO=61]MXWO
M3^8/\HOY4'P#^<&9[(ZFVMN+^7=NWYE?.CHOKC>^0ZE.]=\X>/;VV/[L9;)[
M;KX<I#A\/FZ_+5[4%)G!&^H><M)!2S0^Z]T\](_$/;?PY_X4.=3[%ZT[&[2W
M!TON+^5_WQN7K7JCLS>5=V-%L,'L+:=/D</MO-YBIK,XVW*R>*.K@H*VMJ?X
M?4252TLZTDL-+2^Z]T('_"CGXO=1=M=)_%_L_>='O>7=^+^;/PXZ=I:C;W:^
MZ=ET9P79O8&,I\M%+B\/F*'&S5[1N32Y%Z1LC0/:2AJJ=QJ]^Z]TA^YOCYL#
M+?S$_B;_ "5]F[B^1W6_PGQOQ4[K^=/=6 Q/R"WU)D.PZ[(;HBVOB-I5W8%;
MN2KWNV)Q%8E7DZW'T^;@0I/0J'\>A8O=>Z<=O=3;6_E,?SA/Y<_Q9^(N5[,V
M_P#$K^8-TQ\H=@;T^,NY.VL]V;MO:^;^)NV*/<^%W?MJ#<];F\IC*ZOI97QV
M0CAR<5/4PWJ9$>: !O=>Z4__  HY^+W47;72?Q?[/WG1[WEW?B_FS\..G:6H
MV]VONG9=&<%V;V!C*?+12XO#YBAQLU>T;DTN1>D;(T#VDH:JG<:O?NO=!S_.
M#Z&@^)W0?\J?XT_$/N#O7XW8KM3^<-\>.I5[&PW:>?[:W-CX^^,1O7%ULRY3
M>V7S=97)%45D4\$5955%/22Q13P4Q>GBC]^Z]TA?YB76'7W\N3&_!S^7_P#%
M;;?S7K.L?GY\H>TM]_)'$]$]K;A[.[+W=B^E-HT^5SFVL%NC=VZ*:7 5>^JU
M\6<B:7<>*+4<.6J*22G8U+'W7NN7QKVGV!TI\^OCQN#X9_ _^8#\!OA/NS9?
MR#V]\^\#\G\G@:/8D$ P-9G=K;\P83M??"8;=-!N2"H3)5GV""MIZUGG\DOE
MD/NO=5U?S%]T_#/J;X$;[^<G\NC:?\S#*]^?'W=W3^<ZJ_F7]A;P[;J-M[I>
MI[ VOCLK+FMP;SW+24N^=M9FCK:RDIFCVW48F6IJ/!0M%!-6!_=>ZLD^3O\
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M/Z<VULC^]V)W>V,6GH,P]=LB2KDR#24D<%;54/W1AIFEM'[KW5SGR([=W?\
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M1MO"[FWSF^QJJE&X*R:OGA_BVX:_)Y:>!:BHE\235T@ACTPQ:8D1%]U[H?\
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5UY7X"0Y+^:MM?^9LO:$L$^WO@YD/
MAE-TX=I"5)Q4;TJ-WP[A7.?Q%3$8_O*FE>B.*?7:.9:F/2T;^Z]TH?YG/P<H
M/YD?P9[X^%F2[&K.I(.Z:'8J0=B4.VDWB^,J>OMT83=5'*^+DK<:*V"6LP<$
M,T0KZ=S#)(4E1PK#W7NB&[K_ )4/SB^1VPWZ*^:_\VS?78_QER>)Q>V][],?
M&/XL[:^)E1NG$43P?<87<&[$S>[]P/ALE2P?:5E+038\55)-4PU,DR3 1^Z]
MT;387\MG9G7_ ,Z>M?EC@]VT6)ZK^._POHOAW\7?B_M[9,.%PVRJ:ORL5;G,
M]#DOO)YZNMK\=08K&PH*2 0TD<PF>I=T=/=>Z?OYDWP,G^>G574N"VCVC#T9
MW9\>?D9U+\G>A>Y)]H5&_8L)N+JZL=F2KPU-F]NR9/'Y3%U60HYZ=LK%&?+'
M.5=X(Q[]U[I1?S$?@]0?/?H/"]5KV3D>G>Q.M^WNKOD+TEVSC-LT^\TV_O7I
MRO\ O\)DJO!5=1309G'!GJ(JFB>MIS-#*P6HC<*X]U[HG>(_E>_)[L+YH?"C
MYT?+3YUXSM_LCX7Y?NN+:G5W77QNH>I-E2XGNW:60VUDQ1P-N+,Y^ES]542X
MBJJJ^JSE?2/#CXZ.FQE(7>I;W7NJG?Y4WQO^:79&;_G%;^^'?SG@^+F1RO\
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M#3J9&B]^Z]T.O1?\O/!]2_,'^9E\I=R[[I^Q</\ S'X_C;B\_P!4UFSAB:7
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MVISFRJ%<73;OV:M=N#$4VV]R5.-!BJS/19"CJY?%4U5/.*>.G/NO=#=_+?\
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M&8TE%48%<G6T<-9DYZE2U+[]U[H]7S+_ )<>[N]=]?%?Y&_'#Y$5?QE^7WQ
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>timage_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_005.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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MFT\9O;8>XVQE5A6J\?EUU0RO1UT-/64LG!5X9X(Y8W!1T5@1[]U[JKWY5_\
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M8$Z)$NWCFC+T]2H,E/+(ER.=O./)E]R->-9WR4.3'(N8YDK0.A\P?,&C*<,
M>LM-@Y@MN9;<7%LU1P93AXVI4JP\B/S!X@D9Z-#["G1WU[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U%KJVFQM%69&ME\-'04M16U<V
MAI-$5*A>1M*!F;2BDV"DGZ $^_=>Z^<7_/(_X4CYOY]]%=V_%W^75UUV7!\8
ML1A<14?)[Y*9[;M1AJBOV[F\K0X:GQ]/0J6? [=S>9R./HI)\DT-97&5:,4E
M.DLGD]U[JX'_ (14_P#;K+OS_P 7_P"T_P#WW757OW7NMOWW[KW7O?NO=!IW
M1_S)WMC_ ,1IOO\ ]U=5[]U[KX7G5M%V3L/'TWRFV)-2T"="]U=*45'EY299
M*;<FY4W'N+;;K#IT2Q ;&RKR7D4@QQJ%8.Q3W7NOLS]^_/?:>U/Y3_8G\QK8
MTT&1P%1\+JKY&];PM5/B!4UN\-KIDMN4$DDJ>:CEJ,K74%+(&A,\$C,IA:9/
M$?=>Z^+WN?J'>^S^M.KNV-PXZ*@VCW)5;\BZ_F>?7-6P=<U5+C\C6^,*52E_
MB-1-2QDR>1IJ6IU1HBQ/+[KW7WIIYX*6":IJ9HJ>FIXI)ZBHGD$2(D0+.[NQ
M"JBJ"220 !<^_=>ZJ]WE_.S_ )2NP-Y5FP=T_P P7XQ4>Z,=D9\3DJ2A[)I<
M]3TU522-#-!4Y#'_ '6.II8959)%DJE,; A])!]^Z]U8MU_V)L#MG9NWNQ>K
M=[[2['V!N[&4N:VKO?8NXJ3=>)R5'6J'AJJ'(4,T])502(05>.5E(/!]^Z]U
M\Y[_ (40_P#<3#\%_P#RPK_WXN0]^Z]U]%KLCLWKGIS9.X.R>VM^;.ZRZ]VG
M0393<^^-_;DH]I8G'TU."7FK,A7S04M/& /J\HN>!S[]U[HA?57\Y#^5EW;V
M#C>JNL/GA\;]T=@9O+I@<!MM.PJ;$RY*MF9TBI<9+7_:T^2GG>,K"E--*TS%
M!$',D8;W7NK+/?NO=$F^3G\R'X'?#+-8_;/RB^5_2G2^ZLK1ID:#:&[]YT\>
M9DII2 E5_"*<SY):5R1IF:E$;<V8V-O=>Z6?QE^;_P 0OF9C,OEOBO\ ([J+
MO>GV\*9MQ4W7>\Z3.5F.%8JM$<ACU<5]"LFH!3/31@M=1ZE8#W7NH7R2^>'P
MU^'F3VMAOE+\E>H>@\IO>AR63V?1=H;QIMIODH,-)%%5RT7W+()UII)X5ET$
MZ#(FJVM;^Z]T9/,;JV[@-JY3>^9R])CMIX3;];NK*YZH<K!!CL;3-5SU<C $
MB&*F1Y&-KZ03;W[KW1<_C9\Y_AY\QJK=]%\6/DCU%W[5; @PM5O6#J[>-+NM
ML7'N1JI*!ZW[9W\ K&HJL1:K:_#)IOH-O=>ZT&?^$[W_ '$P_.C_ ,OU_P#?
MBX_W[KW7T$?D5\K_ (S_ !&VECM]_)_O?JOH;:69RPP.#S?:6]*':$5?7&-I
MC1X]:N:.2NJE@1Y6B@21UB5I&4(K,/=>Z*1U-_.>_E5=X[SQ'7G6'SQ^.FX=
MZ[AKJ;&8#;M5OF/;-17U59J\5-1#+)0I55,A0A8HF>1F*J%+,H/NO='V[6[8
MZVZ,Z\W5VUV_O3 ===:;'QRY?>&]]TURXS'8VE,L</W-94/Z((%DEC#.UE6]
MV( )'NO=$VW+_-C_ );.T.F=O_(;</S3Z!H>EMV;LRVQ=I]A)OB"OH<KE]OI
M%)D*'&?;":?(34"3Q&I^WAD6G##S,GOW7NC==,=V]0_(OK7;7<?0_96S.W>J
M]XQ5\NU]_P#7^?I]S8JM_A-5/0U:P5=*\D32TE=35-//&2)(9XI89522-E'N
MO="C[]U[JLOM'^<U_*LZ8W[DNL.ROGE\<-N;ZPN1;#YS +OZ#-/05<;*DE-7
MS8\5=-0SQ,P$J3S1M$0WD"Z6M[KW1Z>HNYNI._MA83M+H_LO8W;?7&XXVEP>
M^.N]ST>[L94^.VM8ZRAFFA,D1($D9</&WI=5;CW[KW0,?)WYW?#7X7Q8%_E7
M\F.G.AZC=5+D:[:V)[$WM1X3(Y.#$:153X[&-(V1KH:=GC222&E=%D>.,GR2
M(K>Z]T%7Q[_FO_RW/E7O:BZU^/OS0Z#[*[#R9F7$;%Q6]X,=EZXTZJSB@QV0
M%)5U[*K@D4\4AL&/]AK>Z]T:;O7Y ])_&/KO(]N?(/L_9W3W6.'KL5C,KOO?
MN9CP&+II\Y,M-1Q3U<Q$435-0Z11ZF&J1E0>I@#[KW6?H_OCIKY*];X3N'H'
MLO9_;W5NY)\O2X#?VP\S%G\7628"KFH*U*>KA+12FEK:>>"323IEC=#RI'OW
M7N@4Q?\ ,'^$6;^0\OQ*Q7RBZ:KODU#N#,;5EZ*@WG3-N9<C@*2>OK:0XHL*
MKS4]#33U#C180(TMRGJ]^Z]TKODE\R_BA\.\'BMQ_*3Y$=1=#8K/RU,&WF[,
MWQ0[8GR3T::YDQM'/*M9D'B7EQ3P2E;C4!J%_=>Z+WT9_-Z_EC?)3?.'ZRZ2
M^</QXWQV)N.L&-VSLF'?M/@\IE*EEU"FQ=%D_LJC)5++<K%3)+(P5B%(1K>Z
M]U8W[]U[JN'NC^;[_+"^//8==U/W)\Y/CKLGL;$UHQN=VA5=@4V4K,94$1'[
M?+)0?=KB9@LT;%*QH&"'60%!(]U[HZ_4W</5'?.P<!VITGV1LCMGK;=-,:K;
MN^NO-ST>[L56(A*N(:VAFG@:2)P4E37KBD#1R*KJRCW7NA']^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6E30?\)LOD3\
MIOYRW<7S=_F>9CICN;XL;QWSV-O;:O7'7O:.XIZR>DQ,T-%U]MK-4E5@</-%
MAL7A%IQ50T>5TRST0AD>:EGF6?W7NJ<?^%8WP<^('\OCOOX2;]^$6R,3\<^Q
M.R<)VKNC?&U^J<I5;:I\=/U97[6.U-QXJDAG'\$KIZJNS*":B,"M+CXY559X
MWD?W7NOHZ?&3<>^]X_&WX^;N[2Q\>)[-W3T?U/N/L7%0UYRB4V>SF!H*K+TZ
MU)IZ0U*PY"6H02FEA,@&LQ1WT#W7NAP]^Z]U[W[KW7R3?YP/QXS7RH_X4,?/
M+I3;,>0J=T9N/M'=^U,;BC"L]?E>H^CI-X8S&(9_VA_%*_ T](Q8KZ9C9XS9
MU]U[K;R_X1__ "C7M?\ E39CJ/<=8E/7_$3NK?\ LB*HK,I]T?[N;Y6/>-!5
MR^0*U+%'7Y;/TJ1DM&L5$K))9FBA]U[K0L^6#Y3^8)V#_-9_F7U^Z<G7[9VI
M\A=C5&TZ<XP4!GI/D)NG,T.SJ2H$D:O!28C9NUZFG2%D6I=XJ=Y9B8IUG]U[
MKZ,/_";GL;8G4'_">GXF=I]G[KPFQ>NNO-M?+'>&]MX[DKEQU!C,9@.V^Q*F
MLK*J9_2D,$,;L?J3:R@L0#[KW5>'9G_"U[X-[;W;FL+UE\6ODCV;MG%Y;)8Z
M@WIDLA@-@19&&BD\<-?1T,U7D*V.EK &DB6J2FJ5B,?GIX96DAB]U[JZ+^5'
M_/2^&7\W!]Y[5Z1_OMUQW/U[A%W5NGI3M6BHJ#+MAFJHZ(YO%3X^LK:+*XR"
MKGI(:EXIEFI):FF2I@B%33M+[KW0<_S1O^%"GPP_E=]I8+X];QVUVMWU\C\]
MB,)G7ZBZ6PU'6R8RFW095Q7\8R60JZ2FIZO)M$#!14R5E?X9(*B6EC@J:62?
MW7NB =7_ /"O[X<U?;>UNJ?E#\6/E1\0EW754$46].Q<'0Y;'XVGR<C0PY/,
M4BR4&:@Q1FCF1ZBDQ=;H*EC'H65H_=>ZV=NY_D;TK\?N@][_ "?[6W_A=M]&
M=>[$G[)W'O\ CD;,4O\ "$A2>">B6B6HFR4M>)8(Z*"ECFFK9IH8*9)99HT;
MW7NM57+_ /"QSXU9*7=.>ZA^!7S/[3ZHV=65\.?[0BQ6(PM)3P8X&62JJ(Z:
MHRU/11?:6J M57P.L; RK%R1[KW5VW\K#^<I\0?YMVR-W9WX\UF[MI[^ZX>A
M'8_3':&/I,1N'%P95I(Z3)1B@K<A09'$5DD4J15--6.48".JAI972-O=>ZMB
M]^Z]U3]_-7_G:?#G^4;B-C4W?S[ZWQVCV=19++;"Z;ZIQ%+E\Q4X[#SQ4U3E
MJZ>OK,?C<3C$GE\<<E16":KDCG2B@J32U1@]U[JF_'?\+&/C)MG=&UL=\@_@
MG\S>A]H[OJ8UQ6\LSAL7E+TNN)9J]*"KGP\U924BST\D_P!G+4RB-_VXI9#'
M')[KW6U5L_OWK'L[H3%?)/J?<V-[)ZHW-UO+VELW<NW:B\&4QGV3UT30M(JO
M#(Z(4>.6-)(90T<R)(CH/=>ZUD-@_P#"Q7^6YNGJ#N;M#=/7??'7F;ZSR/7V
M$V7U-EZ7 9C<>]:S?L.X)G.#@H<Q+34V/P28)?XI75U33TU,U?CXE:6HJH()
M/=>Z5OP5_P"%;/P&^8?>VU>@-\]==L?&#<?8>9I]N=?;Q[(K,1G]MUN2R4T%
M/08RNR..J148FMR,\Q2!YJ$T6M0DM9$\D:O[KW6R=WOWMU+\9>HM^=[]Z;XP
MG7'5/6N!J=Q;QW?GZCP04U/ 0B(BJ&EJ*JIF>.&FIXD>>IJ)(X(8WED1#[KW
M6HUN[_A;#\%</ONOPNT_BQ\GMX[!HJ^JHX=]25.VMN557'322HM52X6?)RL*
M>H58Y(A49"GGT/\ O0PR*8S[KW6S7\#/Y@GQ=_F2=%4'R"^*N^WW;M!\C)M_
M<^"S% <#G=NY>FBCFGP^?Q;O(]%711S1.K)+-35$3)/1U%13NDK>Z]U57_,W
M_P"%,/P*_EK]I93H"OQO8/R*[ZVR\,6^MA]1PT5/1;<EJ81/%29O.9.>GHX\
M@T;Q,U+1QULT 8"J6!K*?=>Z![X _P#"K[X ?-ONS:'Q]W;LSM'XN]A=BY>A
MVUU[D^TIL7F-N93+965HJ+$G-8ZJ+8^NKI/#'3?=T$-/-42)3K4>9XEE]U[J
MJ3_A9/\ S&J"GPVQ/Y:.U:7M':^]X,]UY\A]^;JQ&?3&;;SNU\UC-U8J+ 5T
M%-61U=;-%EEIJLP5%&])^Q','\R(%]U[JQ7_ (3-_P Y7I/Y8]6='?RT-H=5
M=I[9[2^*7PMQ.X-W;_W(^); 9*+K+([9VS5)C12U\V1$E15;BIIHO-1QCQ12
MZRKZ%;W7NE;0?\*T_@134WRLDWWUEW+U]7_%ZHEV_%@LO4X"NKMZY]\U486#
M"[3IH,F7GD9J.LJYIZO[:*FHH6GEL04'NO=6'?RB/YRW6?\ -QZR[I[3V1T5
MVIT1M7H_<.&VWN+<?9^6P=;AJVIRM'4Y">''9&AKO.9L30Q4L^0^YQ]-%#'6
MTACFGU2B+W7NJN/E;_PL4_ES]#]DYWK?IGKWN3Y6)MG(56*RG9&P?X7M':M1
M/0S2P3KA\CE:G[[+0(\5TJXL4M#4HR2T=540LLA]U[H_?\K3_A0U\$_YI^ZZ
MGJ78$F]>D?D#!2UV1Q_37<<%#15.:I,9%'+4U6W,GCZNKQ^6%.CN9*9GI\@J
M0S3_ &1I8S.?=>Z&S^;A_."Z;_E [!Z?[#[FZL[,[1Q'<>[]Q;,Q%)UC-BDJ
M:2IV_115S25*Y6LH8F@EBD904E+!E *$,2ONO=5*?)O_ (6)?R].C=SX#9_6
M/6G;?R4R<VV]LYO>FX.N\CAL3M[$U>=I5J*G"TN7K:DOG,CBG98JF6EH?X<S
MFU/7S,DB1^Z]T.6<_P"%8_\ *KP_Q!V]\GH-Q]@9K?\ N/,5NUX/B1BL5CI>
MPZ3)8TP^=\E3-D5Q%#@EBG2>++29/[:JB$D5(*C(0S4,?NO=.'\LK_A4+\*_
MYCW?^%^,1ZX[1^.W;>]8JP=9P]B5>,S^'W!5T$;3OBJ;)8Z?RTV6DIXYI88:
MBACAF6-HXZ@SF.&3W7NK3_YC_P#-!^)W\K3INE[@^4&Z\E3ON&KKL5UUUILR
MBASFY]SUV/B$TU-A\?-4TD)C@5HON*NIJJ>BIC+")ZA&FB5_=>ZUY.JO^%J7
MP&W=V#C=M=F_'/Y(=1;&R>73'MV4_P#!-^14%/,SJM=D\3CJM,BL$8$33)0K
MD)U4OX8IV15D]U[J^_Y\?S.>C?A[_+XRGS_QW\7[PZ4S.*V"^S\STUEZ&JFR
M-+V[408_$97&U-54TM,\,<M;3RO>HCD1 ]AY4\9]U[KYQ?\ (3_G?==?RLNW
M/EIVQ\G-F]X?(#/_ "4P77E(V?VOFJ'.Y5J_:5=EZNLK,Q6[@R=--5258R4=
MI//+(S*Q?Z@GW7NM_C^9M_/'Z%_E==__ !Y^/_;O4_9N]LS\C<939+;6ZMG9
M##4&+Q:SYI,([9B3)UU)+!!#++',\D4<P$(<E04 ;W7NJX-T_P#"N[X?S_)3
M>'Q]Z#^+OR7^4E)MN;>5+M_?G3JX.N7<G^C^BK,EE:W;^)J:V&LK<5%08^NJ
M(:CR+-4PP^2*E97C+>Z]U9__ "B_YV?QO_G"X_NU^D]D=C=8[BZ)K=E+NG9_
M:"8]:V>BWZF0-!DJ.3&55;1RTIGQ5;!(HJ3-%(BF:.-)J=I?=>Z1W\W/^?'\
M:?Y/^[^EMA]Q=:]I]L;J[GVWN_=U'B>K)<,LF*Q^V*JBHX:G(KELC0$)E*FH
MK$IC$'!-%4ZRMEO[KW5T.R<]D-U;,VCN?+;<R6S\KN/;& SV3VEF)(YJS%U&
M8I(JB;'53PDQ-4T,DC0RE"4+HQ4D6]^Z]TI_?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]UJ=[V_X37P?(C^;%VC_,'_ )@?>^S/D_\ 'W<V3W/NO"=#UV(S
M>P?X1#A&IXMG8&OG7+U5-7[<VWB8--6BU5'#D)X_+44?V]354S>Z]UK#?S@.
MC>A>AOY[7Q>V-_),IMH8CN%INC\N^Q^D\Q-N';N#[4;=.5C6D5\9D*PXVF.&
MI\+-F\93P04M%2M-+)?[JJBI_=>Z^I[[]U[KWOW7NO>_=>Z^7)\K>J^J^[_^
M%=6Z.IN[]KX'>O4V^_EIUK@M^;5W.YCQ]=03;&PKR05;+)"1$S(A-I%^@Y]^
MZ]UN)=T_R&/^$_67V7DLIV)\9.A.L]M[:H,GE:W>NW>Z\[U N.C6%O+65=?C
MMTXZFDBID4R 5PFIT*EC&>;^Z]UJV?\ "1[;^YMJ_P W;YF[7^/^Y]T[Q^(^
MV>K.TL#FMWO)%-09>BP^\*2FZ[R.2=:>FA;)UU%'DZBE:*GA<QO7E(TA,R#W
M7NKK_P#A3/W-_*3ZK['^)M-_,P^'_>OR>SF9V3VI/U'DNG>TJSKZ/$4E'7X9
M<Q!7Q4NYMNBI>KFDQ[1.PJ"HC<#Q7/D]U[K8_P"S/E#\=OB/\38/DAWAO;%]
M.=#[$ZWVIF*O,;DJ9<A)3TU71TR8[&4T4*35N6RU27AIJ:EIH9JJLJ&6.&-W
M<#W[KW6K1O+_ (6Q_!K$;RK,3LSXI?)W>6RZ3(STB;QKJW;.U*BIA@D9!54V
M)?)5C>*9 )(TGK:>72P$J1/J5?=>ZV._Y='\S[XC_P T7J"?MSXM;UK<BV!E
MQ^/[#ZUW?0)M[=&UZ[(PB:.CS6-2>IB"N/(L57255505+12BFJYC%(%]U[HC
M/S!_X4)_$CX/?S <+\".^]H;YVK75^&V?N?-]^5^5Q%!L_#XS=>/FR!JL@9:
MM<L9*:.GEC$%/CYI*B8PQ0!Y)@H]U[JLC</_  M3_E_8SM6IVK@OCG\G=R]6
M4F=?$GMF*GV_B9JBGAJ&A;*4>WJG*+5M12Q*L\*5%92UC1,%FI:>8&(>Z]T9
MOYI_\*TOY9OQ?FV3B.GI]X_,O<&\-L8C>%8W2=108[#82DSD$%13TF9R^5FA
M,.<:*<^7&P4-1/1212P9+[&H5(G]U[JP[^4U_.F^*?\ -XV=OG(]'T.\^ONR
MNKI<<>Q.G>R8*2+*T=)F=2T>5HZB@J:JCR.)J9HYH1,DD<T<L92HIX0\)E]U
M[I$?S7OY\_PP_E)9'9>QNX*??/:_=>^Z!=P8SIKJ*#'5N3H,,SS1)F\[49*O
MH*3%X^IG@FAI5,DM552HYAIF@AGGA]U[JG[J;_A:O\$]V[SQ& [6^-'R+ZAV
MMDZZFHZS?E+5X7L6GQZ3:@]56T%'/29%Z:$Z"PI(*J<J6*0.RA7]U[K8 _F
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M39+;6ZMG9##4&+Q:SYI,([9B3)UU)+!!#++',\D4<P$(<E04 ;W7NB?=4?\
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M=;N<%18:CP.2QU%43PXN.EJ:B3)TU>6K:BH33]O'#$GNO=64?R/OY&OR&_E
M]N][9.?YE8CM/XX=NTE=#3="0;%KH'AR&*KD. W)+E9LE#1T^:I\.)J.O%-A
M%CK1*@9U2CI@ONO=$8_F1?RCOY8$'\RS.?.7^;E_,YP.5Z[[*QF7R6(^''9>
MXUZSR1I<-&*7$8W#Y/";C&YWV=A::3_@+C,+15,M?IJ)<H[U=3!/[KW6H/\
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M[9Q$DKG%=;X*IB_>9RW\2M)'Y*VHK<CD5]U[KZ-"JJJ%4!54!5518 #Z #\
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M]KRQ2XS;61BWO@Y*_;5"U/-40/08.OB:E@,=1+&8Z>,I(ZV8^Z]T9?\ G._
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M%.F_C=M#IKKC.[ R/3NT(>P9]Q;'Q.2GW?79_$TS9;,;C8TNC)5V6F>225I
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MFI0D,^\_MJO/>W^-;J/K+96:$@9E3BT1/G7BE?A?A0,W4C>W/.)Y9NO"F/\
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M87)+F</B<NL1@7*XR@R2P,_D*"NB24(6L-175:]A?ZV]^Z]TA^Z/^9.]L?\
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M'1VY^UZ3'U=5G_-%2UU3@<77PTE1)#^XD<KH[)Z@I7GW[KW5M'_"C'^4?/\
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MI$J,7:3M;3H6):L65F!K4@=W1_<)ND.YHS300[>I50G:'D9U"JIJM=1D. K
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M9LV'JX5R&ZL7#5PTN<V_71S1K/33%)DCJ@'BD*N"C6/NO=*7_A,#VIV?W/\
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M;"F3Q#+[QW'1[9I=7^I^XK9H(M7(XUW]^Z]UWL_?>Q^P\4,]L#>6U-\X,RM
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M[]VUN_);=QN,RAKJ''X:GJH()8LK05\($4_K5DC5Q=AJTLP/NO=5O=$]B_\
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M?+;Y"]>CMRGH*+NC8E+AL'6;^C?(XZGW/C,W25VY,OD0D\,F4;^.8^8U#S(
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MV5V=-4UN/I*(8Z:HI: 8<'+S"FFJ:F F&C6G6+W7NM83^6;_ "^?DC_PI_\
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MAR*NDJ(/.83+#*"H/N[;4L+VTUW?R0ZF:&(S($@9B*NJ^&4+D#26*T(_#6A
MDE]W;TNLT<%LDE )'T,3( #0$Z@P4$DA=1H?.E:E=Z&_FC?(_H#NSO+M_;M)
ML7/8?Y([WW7OON#IW<F(J\AM6MJ]Y9"JKZLT=*U<U;0O$M;54\+FNF+0,L=8
M*U8T %W,?M%M?,EA:V4IE1K*&.&VN491.JQ(J+J.C2P[0Q&D=U2A2IZ#^S<_
MWNS74]P@1EN9&DFA8-X19V+$KW54Y(!J<4U!J#KC\Q/YG'>'R^V/@.HJW:W6
M_372>VLK!G,?U=U#@Y=OT4]73H^B;(/)42_<K%-/4RQ0QQ04ZNZR/%)/&DPU
MR/[3;?R3<->K)-<W3J4,]PP9E4G@@ P2  22S4! (4D=;YGY^N^98A;%(X8%
M(81Q BI _$:Y -2  !6A() /0\=:_P ['Y ;.V7L# [\Z=^/7>N]^GZ#['J'
MN#MC951FMR80BF%*LRUT=;%))4")(E>>!Z6HF52*B:5FU@.[I[";;>SRR6US
M>6D-RU;FV@D5891JU4TE: 5R P=0?A I3HXLO=6[MXD2:&">2(4AFD4ET.G3
M4FN33B05)'$YZJ][N[J[%^1':>\>Y.U\\^X]^;XR2Y'-Y'P)21@011T]/34T
M$8$<%)1TL4,$$:BR11J"2;L9<Y?V&UY8LXK&S31%$M%%:DU))))XLQ))/J?(
M8ZC_ ';=9][N'NKAM3N:DTH  *  >0   _G4YZ"KV<]%W7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW1GOA5V14=1?+KXV=BPSM30[:[HZ]FRKJ=);'5^2IZ
M3)QWNH'FQU151W)MZN>./81Y^VL;SLE];$5UVLVG_3JA=#^3*#T(>4KT[?N=
MK*/*>,'_ $KL$;_C+'KZ57OEKUFOU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U\S3^3QOG:WQ7_ .%37RCVG\C)EV'N'?\ W'\VNIMHU^[Z<T$7
M]X=[[GGR^%D%56+'XXMQ8ZDECQU4#IKOOZ186=*Q"WNO=;;O_"F'NWJ;J#^3
MA\ML+V7F\/39CN/;FV^K.K=JU=11M79G<&8SF+GITQU)5SPM5-B(*>?*5+0Z
MY::DHYJE$:2-$;W7NJ!_Y$_7&]MG?\):OYOF\-S8J?%[:[:Z\_F&[MZYGGG5
MQD,=@.F*?;M9D(41F\</\:PV3HO7ID:6BE)3QB)Y/=>Z:?\ A#'_ -U1/_+)
MO_FN>_=>ZW_/?NO=:6__  MK_P"R%/B1_P"+:2_^\=N'W[KW33_*3_X3??RH
M_EE_+>^(?R-[LZ:W[N#M;MSJBDW7O?,XWNO<^WH*BMFK:R%GBHJ/(PTM,OCA
MC&B.-5XO:Y/OW7NMCOX0?RB?Y=G\NC)YC<?Q'^-&U.N=[Y^EK<=E>R,MF,OV
M-N1Z/(M3M/CX,[N3(9;)4&,F:DI6DHJ.HIZ662))I87FU2-[KW6M!_PM[_[)
M@^#7_B>NR?\ WGH/?NO=;*G\F:F@I/Y3'\N"*FC6*-_A?\>*EE4DWDK=LXZ:
M5N2>7ED=C_B>./?NO=:,7\GC?.UOBO\ \*FOE'M/Y&3+L/<._P#N/YM=3;1K
M]WTYH(O[P[WW//E\+(*JL6/QQ;BQU)+'CJH'37??TBPLZ5B%O=>ZVW?^%,/=
MO4W4'\G#Y;87LO-X>FS'<>W-M]6=6[5JZBC:NS.X,QG,7/3ICJ2KGA:J;$04
M\^4J6AURTU)1S5*(TD:(WNO=5"_\)<=G]4];_P BOY9[R^;\NS-F?$3O3Y!]
MO+N',]I9J'$8'([2S&VMJ;%RU165#2HE)25N;I,CB49I8IVJJ<K& 33O)[KW
M5<<G_"8CK/Y+5.\/DK_(O_F@]=]A[<V/O_)[8Q6*W=ELOMZIVYEH88ZJJQM-
MV!M6&LK9)(\7DJ;[5VVU%YXI ):Z17DF7W7NN?\ +)_F3?S;OY<?\W_J[^4Q
M\WNY-R?(K:6<[>V)TEOW:>Z-P3][5F)D[GQE%DMNY_;F[9P<_'0TB9O#UE5%
M5SRTE+B_NXI:*CFA$M-[KW0N_P#"Y'_C]/Y;7_AK_*K_ -R^O_?NO=;BW>OR
MWPOQ _E@[J^9$.#&^<?T]\2\+VCMW;;U,V&3,54> I'PU#-4?;S3T,&0KIZ.
M*68TCO3QR/(8F*%#[KW6HA_+;R/\Z7_A1=M?N[N_>_\ -4S?PC^/&S^U\/UM
M4]8_%W8LFV,E)/04%!FJZAQD^,RF"S..QII*ZC2.MR&ZLO/42RU,<]-)34RQ
M3>Z]U6A\..A]H_&'_A6/U7T#LGN/?O?V%ZM^068VS5=N=H;BAW7N#+Y6+K*N
MFSQRM? D:355#G)<C1E2IDB6G6&5GEC=V]U[HUW_  I1R=%A?^%'?\OC,9.?
M[;&XG9OP?R>0J?&\WC@H.V-S2ROHC5Y'T1HQLJEC:P!-A[]U[K89_P"%;VW\
MUF?Y,':^1Q=/+-0[3[GZ"W!N.2,L!%15.>BQ4<CV!&DY')T"<V&IU_-@?=>Z
MHE_D-_ /^8]\LOY=G7V_/B/_ #NMV_%OK?;V^NT=FY/XW;/ZG3?";1RM+FJJ
MNG@JZM=SXYUJ<U3U]+F0CT<9$.1B(+J0Y]U[HSG\LK^5WT_@OYSNV/ECE/YY
M/1WS8^7_ %)O?N7_ $M=.T6PX-L[SSE=CML9[8F;21CO.MG(Q$=0YJ)8<341
M-!3_ *A%*L_OW7NMZ/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=?*#_DN_.7JO^7I_.T^0_>W?R9W!]#;PW-\AN@>PNTZ'!UV9Q^T
MY>Q]X1Y/#Y++BAIZB1*.HR&VUIF C9PDDE0J,M/);W7NKCO^%6?\XWX9?(SX
M;=;_ !!^)?>/7?R"W/OSM_;?9/8V?ZZR/]Z<9A<%L"ER7V].V1IW6E3+9'+U
M-"R1!IF2DIZDRQQF>GD]^Z]T83M_$_+;^4U_PD<ZZP/7F;WIU=W[78;9]9V'
MN[ K)M;.[+QWRFW[4YROIHGO)4XK*4M#GZ+ RU,<D5735=3)4TLE)5+"8?=>
MZK7_ )&_0?\ PG;W!\.$^6?\R_NCI?>WS A[ [.SW9>Q/DK\@*G&55(*>OJ5
MQ[8W8T>3H*G>J93&"&NEFGQV<>:OJYT#+)#'%#[KW06_\)=]X=<[X_G^?(K>
MW4FW:#975F^>M/EUN?JC9=+CX=OP8S [@W;AZ_"XJGHH!X:2.@Q3P1+!$I2&
M.(J@TI[]U[JS#Y(?-_\ D%?S1?G=O_XO?S*OAUO7X8]W;"CW?L:J^5'<6\Z+
MI:NCSO7<S4<6"S68VYDI\>*=\>*FHQM9G:BJQ;^&*"%M=31B?W7NM:;^;C\-
M_@A\ N\_C6W\I3Y^[D^5NZ]TU>ZLIE*OKKM# ]C9W9V7P%7A4VN^-W9UY3XZ
MDGR6:DK\@L,--!'64\M 'O\ Y3$J^Z]UM1?\*H/C]\GN[OY.7P=[WWKM"?+=
MI?'^MZRW;\M,5MJU5'A:KL?9<5#N++:'2">7&X[=D=/2NT<&N*.K6HEACIXI
MY8/=>ZKQ_EZ=%_\ "43LW^7GUIW7\M:_;.P_D=L/JR2+Y#]>[P^3>]-J[IR>
MX]C4\L>3KMO;6Q^YX?XO%N-Z7[S&TV(I)+K50TABAJ4D@C]U[JV3_A--%_*-
M[N[<[J[^_EX_R_\ Y,_%_?7677=)UMOGM+M7M3)]B[8JH.Q:RCKY=N8V>MW;
MEHZC+>3"TU7);#1/!31QM)-#]W'%-[KW5#/0/;]%_)!_X4Z_(+.?+FBJMJ]0
M]G=F_(#&5O8L^.KI8*?9OR5R<NY=J[LIE6B5\A20U*8JFR;4\;QTSIE(XWEE
MH2C^Z]U:;_PJ&_G'?##Y%? 23XE?$3M_9_R9WCV+OKK_ 'YV;G.K*FHW/B=H
M[5V)DXIXZ_)Y2FIWH(:S(;C?!T$-,]0KA:AVE\;O2I4>Z]U;+_PDW_[<H=!?
M^)+^0O\ [V.5]^Z]UL3[PV_'NW:6Z-JS5#TL6YMNYO;\M5& S1KF::6F:100
M0602$BXM<>_=>Z^8]_PG5^7&QOY+O\R[Y<_%'^8!74/1M/O/$/U#N?L'<L-=
M1X[#[IZ?RT\^+:H>6CBD3;NX<?7Y&:ER4D4<+HV.GXIZHRQ^Z]T8'_A6C_-5
M^,'S6V/\=/CK\1M^X3OK:?5/8>0[.[>[AV**G*;>QF6W#B*K'[9V]3984XQ]
M=6U]#_>*KF$52PC6D5%+R)5+3^Z]U?=_W:*?^8E__E7]^Z]T2'_A&=N*OVA_
M+>^<V[,7M?-[XR6V/D;F=PT&R]M-3)DLO-A=B8.ICQF.-9/34?W]>\8@I_/4
MPP^9T$LT4>IU]U[HLW^G_P#X34_SO>]>]:#Y9]+9G^6A\@Z*F2NB[T["[6Q7
MQUK]QUM5.]'FI,A4/+5;%3<^&JHZ37'GJ&IK*I)9'C\JTM8D/NO=4*=U=!];
M_!+^<'\7>O?Y*GR\S/R]S$^>Z8S>R=^;1W?29H)NK.[CK:6MV=D<[LZ%,9G,
M')C:+'SY26GI#2MC\A44U5#(D$^KW7NMC_\ X6U_&'LG=/6_PT^6VVL34YCK
M?J/,=F=0=HU%'3SU;XF?M%L+7;=R%0(:=XJ?&U51A\E1S5,]1$B5DV-ID#RU
MB@>Z]U:C\:?^%+7\LEOY=FP>ZNQ/D!M#:G=>P.C=O4.^OC;.]1_>F7=FU</!
M3U.(PU U-"^4I*[)1%:2NB44O@D22>2G*2K'[KW1<?@S_,+^8'_"BK^6O_,P
MZLS_ ,:.M>E1+T%O#HSK?LS;&^*^7$;C["WEM^OJ8\.:'(4]54XJAH ^$DK9
MC6U;0PY&$IY6N%]U[JF3_A+5_-7^.O\ +=R_RH^#/SLW#'\;\CNGMRFW/MO>
M>_,=645%0;GVO32;>W)MK<LT<$J8*:F_A=$T$]4(J83)605$T4GVZR^Z]TV_
M\*<OYD74/\UWNOX@? [^7C/-\G,QLK?.Y*_);LV!B9J^CS>ZNQ(L=C,-@MLU
MKS0Q9"&BI8J^7)5?VIH09J4P5VFEK@ONO=;W_P >?AKMO8/\N?ISX#]N?8=A
M[9VS\0]E?&#M S42)2YB&DVG3[<SC)3L9ECIJP_=&)#)(8T9 9)&4NWNO=?)
MA[W[%^3'\NK:W\QO^2U7T<^3VCV+\G^L4W.]=KDJ)8>C\E75^'KL314OI9][
MPOLS(%WE<+34%-$M,9IA+3^Z]U]4K^3K\(Z?^7O_ "Y?C+\:JN@BHM]X78M+
MO/N)XY'F,N\NQ#_&-Q+Y)(XGDBH*ZJ:@IRT,;?:TD 9%8'W[KW7SB.M?B]\+
M?CK_ #W_ )(?&7^<YL?.87X_;E["[UI]L;LR6\<KL+&4<^\\R<[L;>==E=O9
M&AJVV_F<,DD 9)7CIZC(Q??PTYHZHTONO=6:?,_"_P#"2?XL]L=4]2]4?%CL
MSYTY;L;'S564K?A_\J-W=CQ8FIKJZFH<-BTF;>\%!ELQEY&KBM#29 U-/X:?
MS1@5U.??NO=&-_X5T]9;'Z7_ );O\JWJ7K/96>ZUZ\ZYW-7;.V3UWNK)-F<G
M@L7@=F8^GHL/D:MZW)M4UV-@1*>>0Y&JURQLWW$P/D;W7NML7^3=_P!NG/Y;
MW_BE'QN_]Y3&>_=>ZH\_X6'?!V+OW^7[M'Y:;8P\];V'\,-[I7Y>:AIJFLFE
MV3V[/08C/1F&G?QLM!EX=N5[3RPN*2DIZYU>&.2=F]U[K65^%O9';?\ PH'_
M )PW\MG;_<F-R64V5\2^@^E:'MR6KKJ2HI\CB_B[3+FMPYRNQ[+%1Q'?>\:B
MBQM5'24SR&"NIB5BB@M2^Z]U]3G<N>HMJ[<S^Y\DM0^.VWA,KGJ]*1%EE,&'
M@DJ)1$K,BM(8XVT@NH)L"0.??NO=5E_RW_YQ?PP_FIY+MO%?$S+=C96IZ3H=
MEY#?1WWL.79:QQ[^DR<>.^V,L\QJ6=L16ZP - 5;GUCW[KW3!_,7_G7?!_\
ME;;ZZ[Z\^5V6[.Q>X.T-IY#>>T_[C=?2[S@DH\76-0S^:6*IB,$R3@>EDL5(
M()Y ]U[JQ[N_M_9OQ\Z6[?[\[%FR-/U]TAU?O_M_?<^(H#E*M,-UKB:O-91Z
M6E5E:IJ%H:*<QQ!@9'"H"+W]^Z]T0[^6Y_-[^&_\U?\ TS?[*5E^P\I_H&_T
M=_W_ /[^;%EV5X_]*/\ '?X5]IY9YON=7]W<EY;6\=H[W\@M[KW5H/OW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZKY_F??*+Y#?#+X
M?=A?)#XW?'&D^4^[>M9L=E]U]52[DK-NU/\ =N\BY?+T0H<;E)\A+B$\4\U(
ML,9:C%3.LNJG6&?W7NM,'8_\Q[_A,9_,BZ:G[#_FA_%;K[XG?+8;AW'4[PCZ
M0ZRW_A3FY8Y&&/RU!N'K2B+Y;[O'2P13Q;B"M'70U#>-X%I*J3W7NBT?\):.
ME-R;E_G8]S]U_#Z#?=#\%.JZ#Y';=KMU[WQQ-3D=E;WJJJ'K_;N5J0\$2[BG
MF@V[EJA%CEM_"Y]4<8>.0>Z]T)/_  HA_P"XF'X+_P#EA7_OQ<A[]U[JU3_A
M8[_+^[5^1'QVZ!^7O3^VMQ;WJ?BMD-][<[6VMMO'39NJCVQV:<5*F>CI*>*6
M=J?"9'%(M8Z*1%35C54VF"EED3W7N@1^'G_"P#KRH^*W3/1.4^('R-[D_F 4
M.PMN]2;5VMUQC\'7;2WCNC$TR8G#51R S$>XJ#^.RQ4L]934VU*LTLLLT-,]
M1&B2-[KW5</_  E#J.RZO^>O\K:KNBE-#W%4] _*2H[8H6\ ,.Y9NP]G-G8C
M]K)+37CRAJE_:E>+C]MF2Q/NO="W_/Q_[BC_ .7=_P"''_+N_P#?G5?OW7NM
MR7^=U_VZ)_F+_P#BI?<'_NKF]^Z]UJ,_R!'[QC_X3;?S@7^-W]YO]-:]@][G
M8QV0U6N<$G^C/9GWC8,X\C(#-KCOO#C_ +4_<_>"'[>\V@>_=>ZKQ_X3K_*S
M^15\7^N.[]P?S.MA[#RWR.@[)Q&X.H=U=I?'W,_(:A_@&*QM*:2CP-)1X;<6
M.PN<I<VN1GEJYJ*BDD66CM6N*95@]U[IQ^*GR.VS\C_^%6/0OR@Q/7&XNC^J
MN\N[L9F>EMO;ZVNVQ)JO:U;UU5;8V=E*>B:.*%:?<U-14-12_;F2!FJECAFF
M #M[KW5EW_"XW9VY9G_ES=@0XBKEV=CD^3&SLAGHU#009/,G9-;1T<K7NDM5
M2T%=)$"/6M/-;_-GW[KW6Q]_*\_FH?&+^:_\:]^]7_&_);N/9/3?QPZAP';F
M.WGL^39]+0YGM? 9G')144CU56:Y*"OP->M3+"\M.B/3&*IJ/(Q3W7NM('_A
M.-_,CZ3_ ),7RL^9/4_S^I-^].T^_P#"[7V+N&N@V;6[MDP&Y^E<KEXY,?E<
M;BH:S(E9TR]<J3TT$\8>(7!CE65?=>Z!S_A2S_,*P/\ ,P^0/0?R$Z5Z]W]A
M/B3MW8&]NG.DNUM_[2FV@^]\SLS+0Y#>.1Q<%1.T[8C&G-X"DC\E-%(M0M4L
MO[FN"G]U[K;W_P"%7_\ VX\7_P 2[\:__CCW[KW1A?\ A*E_VX]^*/\ X='R
M._\ ?C[J]^Z]UJB?SF>A*'^7#_PH+POS;^6GQRQ'R)^!WR'[4Q79E1AMP[=C
MW=ALM0[BV_%@]WXFLI<A2OC9MR;9KY:S,4..E<QU,<6,D$\'EF^T]U[HS_S7
M_F[?\)Z-B8KJ'%_R\OY4/Q'^979V^=W+0[OVKN?XB0]2T^,H9:8Q4M#325FU
MOOLCN')9:JHHZ:*BQ];3>*"K6259I:3R>Z]UL^]C=Y=^?R_OY0.S?D!\9_Y9
M/6NS-\[-VCA>R>QO@-UONG^"46SL9O>6HRFY),>^"VU''D\EAY:M:O)TD.)I
MP2^0E6>9Z8?=^Z]UK ;'_F/?\)C/YD734_8?\T/XK=??$[Y;#<.XZG>$?2'6
M6_\ "G-RQR,,?EJ#</6E$7RWW>.E@BGBW$%:.NAJ&\;P+254GNO=%H_X2T=*
M;DW+_.Q[G[K^'T&^Z'X*=5T'R.V[7;KWOCB:G([*WO554/7^W<K4AX(EW%/-
M!MW+5"+'+;^%SZHXP\<@]U[K;V_G&_SW^K?Y.N[^C-I]D=!;_P"Y7[SVWO7<
M6'KMD;KQVWQ0C9%5CZ:>*ICKX7+F8Y&%HV1_[+AE%E+>Z]U<KOKLRFV-TOO+
MN2HQ,^0H]G]7[A[,GP4-4L$D\>W\3-E6I$G9&5'D6$QAS&0"=14CCW[KW51W
M\FC^=[U?_.3_ -F/_P!&_1N_>E_]EQ_T0?QG^^^Y<=N'^)?Z7_[T_;_:_81I
MX?L_[KS^3R7U^>/3;2WOW7N@/_F\?\*+>F_Y17R3V1\;NP_CAV9W!FM[='[:
M[OI=R[,W=BL!2P4NY,]N7 I0R0UT3RM412[:GE9P=!29% NK>_=>ZV,??NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW56'\ZC<]3M?\ EL_(=Z*40U>=
M3K?;$;G2?V\WNK"1U:V;]1DHA4IQR-6H?IO[ESV+M%O.:;(-D*9I/S2WE9?V
M-0] 7W*N&MMDN2O$B-/R>5%/\B>M ;WT<ZQ!Z][]U[KWOW7NO>_=>Z&;H7X]
M]Q?)SL6@ZIZ-V1D-^;XR%%69-<515--CHX*3'://65E96S4U%14D1DB4RSU$
M:&22.)2TLL:,1<Q\RV/*=J;S<)1#$"%U$,Q+-6BJJAF8FA- #@$G )Z--GV6
MYWZ86]HA=R":5  44J26(  J.)XD#B1TI?D]\5.Z_A]V-2]6=[[<Q^V]VY';
M&.WEC(,7N3'[GAJ,9E*BLI(:E9L?45 BU55!61F*813#Q:S'XI(I)$O*7.%A
MSO:F\V]V>,2-$VI'0JZA6(HP%<.IJ*C-*U! ?W_EZYY:G^GNE 8J'&E@P*DD
M5Q\U(H:''"A!)=/8GZ).C'=_?$CY"?%ZCZ[R'>G7_P#<:D[7PE9N+8$W]Z\)
MN;[^CH$HWEFTX?)9!J70M?2'14K"Y\EE4E7TA;EOG3;.;C,NW3>*;=@DWZ<L
M>AFU #]5$K\#?#48^8Z/-YY;O>7Q&;R/P_%!,??&^H+IK\#-3XAQIQZ+C[%/
M1'U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0A=4=5;][P[$VIU/U?
M@?[S[_WODOX1M? ?Q2BPOW50(Y)O']UD:BDHH?VXG.J6IC7BVJY )9O.\VW+
M]K)>7C^'#$-4CZ6?2*@<$5F.2. /2W;=NFW:=+>W77(Y(5:JM2 3Q8@# /$]
M"#G_ (J?(7;?>F8^--?U9N&M[PV_4TE-FM@[:>EWE/3?>4M/7":2JQ%178\4
ML5'5P33U'W?V]/&Q:>2,(^DLM^<=LN=O7=5N$%HX)69]40;2S+0+(J-J+*0%
MTZF/P@U'2V3EV]BNS8F%C.M-4:T<BH!J2A90*,"36@\R.I?6/Q(^0G<G4G:7
M>O6_7_\ >/JKI:EKJSLS=/\ >O"8C^&QXVC.0F;[&OR5+D:S12 R6I:.<G]*
M@OZ?=-VYTVS8[V#;KJ;1<71401^'*VLL^@=R(R+5L=S#U..K6'+=[N=M+>01
MZH8=7B/KC&G2NLX9@QH,X!_;T7'V*>B/KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZY([QNDD;M')&RNCHQ4J5-P01R"#]#[T17!ZV"5-1U]1G8&X1N[8FR=V++'.
MNY]H[;W"LT,B3(XS5'#4AE>,+&ZMY;@H I'*@"WODG?V_P!'/)%PT2.E#4$:
M6*^>?+K/*"3QD5_XE!_:*]*WVDZ=Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NM=_^;]_PG(^)_\ -;W:_>8WCN;XZ?*1=N46VZGMC:.*BW5B\[!A(S'C
M5W/MRHJ*-,A-01D0Q5=)D:"L-.(X*B:HAIJ6*#W7NJG>N/\ A'ANC?78^Q\_
M\]_YEW:_R8ZSZ\BIJ#"==XC;N5Q];)04TU/(<73Y[<.Z,^V"Q=1% 8IH:'&"
M4J5:"HIWC5_?NO=;7_:WPRZXW3\#.W?@)U#!ANB>LM__ !;[1^+VR)-O[;_C
M=)M?']B;9R.W(*V+%_>4#9(X\5YJ7A?(P25DBL)*I))6F'NO=5B?R,?Y&/\
MPRY_LT7_ #E%_LR?^S)_Z$_^:)_Z'?X+_H=_O=_V=VZOXC_$?[U?],OV_P!K
M_N_S_L^Z]U?][]U[JEO^=K_*"_X>,Z)ZCZ4_V8;_ &73_19VT_:7]Y?]$W^E
MW[_5A\AB?L?LO[S;8^U_X'^7S?=S?HT>+U:U]U[H\7P ^)_^R,?#3X]_$?\
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ML=V92FWBM?'_  $;,7*[-BFQCTOW'E_BYS9IYUE%)I^W#H9;D)[Q7^\]#?\
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M]#MZ<6I\NI4^ZNY)3'3#K^GTRC1(4$@//'_*S:_O?'K2@CK+3;E[?QCEEV#
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M)&1W0RBP"W!YJ#]6-OI[M0]-F/TZ3>Z?D=NC"2"@&"P/FAJ)*5DF^X# J/\
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MR17((*Z1?@_X'_;^_*U>J]3(\72A666))+G_ !_XK[\HIU[KLX?&'DT<1/\
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MQ8_>6V:FMKZ9:AHC4I%/4X+&NT:3+&[1(TB.T<31^Z]TI?YB^Y=S[>_X1T=
M';N1R6/&=^)O\O/;6X*G'32P.V,R59LT5%/))$RE::J,<,$JL=$L4C0.&60J
M?=>Z.!_PD(V=L+;_ /)[VMN7:N/QL&Z]^=]=U9?L[(TRJU149+#5\6+H4J7
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MJ!JR?]6>DDYJW3'7PTU515F<R4CP'!TTE=&T/Z"$!D)==+LP] X4@VO;GW4
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MH]3)0Y]0IZJ0[B_X4-_,7>WWM%U1M'JKI+&3PLE'7T^'E[#S,#O<:_N\N_\
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M6U.>H]3_ ,#\;_P7W[_8ZKT43O#_ (NU5_VNX_\ K2?=^J/PZ-)M+_BT5/\
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MAJ3"4NBE30WBDF%35(JFI8>^;'NOSXW/V[/<(3]/%6*V4XI&IRQ&.Z0U8UR
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M.J,D$C3J%R%,DM]3?4#\'\_7WH8ZV#QZ%RD$,,*0),) @;U'C]1)_P")]W!
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M%))*]H!%CEEEDR%:"VE*BKEJ:J[%(Y%0A!FYR9[;[1[?Q5M(QXFG]2YEHTS
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M=3\. U&P/(,S_P"]+[M2M>MGK6__ )C\ '=761 '/=&[_P G\Y+&V][&,=;
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MNJ]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<7_ $-_P5O]Z]Z/#KW5;_\
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M?W+W/\@=Z4TK=8?'?K&BDSNX<P_*+4U$5-#4MBL.D@/EK9H6]*2_;PU,D;1
M<\G<B7/-A:5GCMK.(CQ[V<A(8AQH"Q76Y'! >)&HJ#7H.[]S)%L@"!7FG?\
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M -;.D1]G=V_BM_\ G(W_ %KZD4?_  GV^?E54+#._1^.C8,35UG8]2\:Z1<
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M_+TLEDUFSU(E7\ZI-7TY^A)]F%N P_/CT'KE_":G''7C'3*;F&*6YOPH-_\
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M3(W_  ,7_J)_Z*]T7B>KKP/5"W\US_B\;D_[7&Q?_=;[\/BZ\?AZMO\ C/\
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M'^\$>ZD@^O7B#QZFTSQ+'*REM*MZKC^G]/S[VO;UHBG61*N!W*!CJ N05/\
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M7NO>_=>ZC5(D*C0SK;43HO\ C_6]T>O7NF090QN(Y"1?U:GGTV_VX_P_K[T
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M65#D^7F?7K(WEL0M>QX0_%CM_@;KO+]D4N5VH^.DS-+4NV&JZ6*5\ZM2VJ>
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M[^1FS7)R73/<&341-27R4N=I@6E82!OW,9)Z@JD ?6U^?;)KPZT37H8MO?S
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M/EUW48I<V\B;ER7)HO8^PFB3)5H7^QJ"AQ72P5J9I3K*#E;G7;^<(]=G)5@
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M\/6NG<K*\#+BR(O1I_=YYMQ^H-^/>^/5SCCUFIC5Q01QU+JTZ@^0H!;DDBW
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MQ-SS^/I[\WRZ\/GT?CP"@1?!9"?1>Y?@<_VK^VS5>O5ZRXQY9*=C,P9A,P!
MMQ9?Z >[K3RZV13IQ]VZUU[W[KW0)_(F,3=+]J06N\W5_8L4=S87DQ-0!?\
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MXS:U^;?3WX=W6N'2@ZTZRB@A;*9:GIY<@U)C*ZHF@K9;&90TDC!1I4 OR!I
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M=PB$G\:F-A_C[;))Z<%*]$^[7^9^T,6DV&VAE]H;CKXCG,6*>FRTBRF6 +%
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M-+*V3&0 CHX**I0GSH3S)-:WT'U'-_9)=;>JQL=1\O\ ".A[MV]N+A&5!BN
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MA/ '^">W.M$U/4[^6+32Q;!@$^M!)UKM1/W./U%_Z^ZD4KU:N.K1:&&GAA%
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MIR?^ZJ@]WZ:3AU<#3_\  RI_WWY]^Z?;@.IDO^;;_8?[V/=7X=-]:V?\Q_\
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M^QO_ '6^[CK9ZMV^+_\ S*_;/_AH;(_]UT?O?6NBY_S&5#=38($7'^D[!?\
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MC\'_ %O>R:#K=:]2Z":6>B=Y7+MY2MR .!I_I[\W ]>/6N)_,?\ ^9Q]7?\
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M&5O_  5_][][;@.M=3,7_P  '_Y;-_T3[VW _P"KTZV>M<G^8_\ \SCZN_\
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MB::55D! :\['T@HRW-PY=_>#WR?$:6L7'X8G8Y_T\K#'E@?.O0@M/8?9+?\
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M3SC-X=,T8I9O$SKJTL3ZV!_VNP_VWL+7>VEV<U&2?*O&O3PF&!3IIH]O;2D
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M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=0Y?\XW^P_WH>V7X]>ZJI_FE_\
M,G]^?^&GLK_WI(?;HZ]U(_EC_P#'BTW_ (C?:G^]M[\>'7NK3(/^ I_X,?\
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M8>K[$P64K*&BJ]6!I8*=Y4CK\ACY\3424$$2RI4T+:9%-1Z_(5]PARSSEO\
M[?V7[FFVN>:2,N+=U#E>]F:G9&XD =C0JPJ#I\NIGYCY0V/GR[&[P[E#%'($
M-PA*!CH517O=#&=  (930C53)Z+A\\/F3LW>?;'1V+Z2GASFR?C=EJ'.8K-#
MR109')XVIH'1()'42O14D.,@C2<6$K2RNNM!$Y&/M;[=7.W6%Z^Y QS;@C1L
MF-4<;*X)(!H&8R$E?*@&#4=!+W-]PK>_OK--N(DBL'60-G3)(K(0 2*Z5$=
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MUL=7C?&(_P#&,J9?JIS>8N#R/JGMOSIUX]#O7 *+!Q9Q*"HX_IP>?\?>BO\
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M5O\ >O>CPZ]TWO"DXT.5 !U>M0WTX_/^O[9 KU[J$M?#)&]/*J0(Y(,DK@*
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TRUO_%SH/]A_T,?=3Q'7NB>][_\
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MR >./KB* ^]'!'6Z5'5K*)3M6UFK5K 8_GZ^_$=>QY=8*"HJ/O(89"NE_(Q
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MU,5'7CGHZ>+6&?!XR(7,B8FAB Y')B4>]5!/SZ\>/7'1]L?$_I"?C]7ZN?\
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MVW4I%3GSI\^JU]Y=;=E;-JI*&7:&]ZF"DJJJE2IGV]74:N*.PU<QNH!'^U$
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M B;3;AB!0'Q"NHY4@K2A!+SUM%UO'U4UK<O;+'HCU7,[7,;FM9%U7!4$ZB-
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MTDK&]K\V)L />ZYIUNG0_P#QS_E!?(?9NT]NP[0/6&-DQ6WL#'^[O2OK+"A
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M]1B75<9 )>*2/2UOIQ?Z^[#JISTJ?C3UUE=E09B.O3*W:MP31ID8]%Q1K*"
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M=R:YZ\!U8'CSC!2Q0/\ :R3PQ_N+(BEKW/UN/>B<5/6Z=<&*U(\$E)#3P/\
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M/_&_>U>O'K77<DV@\%2+7))O[\STX=>Z;GG8LU@MM1_Q_P")]M'/7NN/G?\
MHO\ MC_Q7W[KW7O._P#1?]L?^*^_=>ZF13OXUX7\_@_U/^/NP>G7NLGG?^B_
M[8_\5][UGKW7O._]%_VQ_P"*^_:SU[IKJ7+Y*A)MP5^G^N??@VH];Z*#WO\
M\76H_P"UXG_6D^[CB>M=&KVE_P 6BI_ZCY/^A(O?GX=>Z5Z?I7_@H_WKWX>7
MV=>ZY>[=>Z][]U[K'--#3Q23U$L4$$*-+---((D14%RS,Q 50.22;#W95+D
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M[%TFBDJ)X-&6HX_0J-PU/*Q_4#]3[IK'3RKY]8>L<#68J]1DYJ>KE.06HB>
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M?]7%;HIN?;G9+H4:SB'^DU1_]6V7H*\W_+J^-V5#B@H-Y;9+7TMA-U/.5O\
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M::%6 HH4HP8T+$L"-<F#^(2;/[KIMNP-MS)(;M(Y(()@$*+#*5K5BP92HJ
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MQ6,I9Z[)9.LIL?CZ&EC,LDT]:ZQQ11H.6>21E50.22![;FF6W1I'(55!9F.
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MWW:#8K:2[N6T11*6=N..  'F22 !YD@=&.T[5/OES':6RZI)6TJ.&>))/D
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MP1B1>"HTDDDW_P"-^Z*".O=9_=^O=8)!(W 4:000;_\ &_=&!/7NLRBR@?T
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MKW7O?NO=%M[W^+'5O?=#-+G\8N$W@D CQV^,) D-=&8P1&E2+!*^F4_[KEY
MN(I(B2WL:\J<^W_*3@0MKAK5H')*'U*_P-\Q^8/#H%\U\AV'-J'QET2THLZ
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M$LM;AE,Y >RZI)&+D!5  /XM;Z>S&&7MIUNG1E&C2&ECIXE2RPK&3$ H_;
MX'^M[: )->K TZC1/XP%;@"_)-OJ;^]N.GTDQTG,N*PPO]FU3$?$+?;:AS?Z
M^FW-O;;#5Y=>,AKY]!=74>ZIIG\.4S\0\A;T-4VM_3AQ[H5KU;Q?D>E/@L?N
M" JU7D\O.HEE)6H,_(*6'ZG/ /\ O/NGA"G^QULS$G@>O=@2UTNU,O2T_P!V
MM4V"S4,4L+.7UM3,JE0OJUZB+6-[_3GWY!H^?^3IN=]0 I2G6O;VQUSWO2;X
MFW9C,[VH*./'4-((:"DS*)J="C$2QS:+W/(T^W:UZ2^?06[H^07>513T>V*#
M)]N4E=14M1@?N*7=F7\AF54IU<1(%=9%=;A-6H$V!OS[J5KUL]#U\0ZKY#Y+
ML(5.Y]W]R34#[;S5X\]D<Y-%Y$F@5#>HGT%[ VXO:]O=N'51Z_RZV%J;'H^.
MQ;U-3')5_P /I")*A0T@8HI)NS%KWO\ F]_;>JIZN<GIQHL;5-(Q.3D,1C.B
M-BVD&X^GKM_7\>_-0]>(IU,GTB>.9*E69% "JPOR3]#<_P!?Z>Z9'6QG'4Y6
M@F16D\3-;4VLAB+?DW]^ZT13'61*^!F$(CB"M<D!P1QS]+?X>W*XX=>ICJ1/
M%'+$'#(BQQLS  $6(OS]+?3W[2&Z\.F.7(PQ4YC6)']8-UD'Y_V!]ZI3'\^K
M$4\^LE5)3R2XHCPA9#&9$!4CU%+AO^-^]\.JGHFGS.&XLILI<)MF7-4KT^Z\
M'5+)A#._H%'4ZP$IRI"EY 2;VO\ 7D^]@]5(KU1]UYT3WUL;,5&ZLKN#M+)T
M>-S?\7>EJ\/F:5'CC).@RR3R(JF_UTD?X>[=;I3H8=\UW;/9.'H=MXBB[%H9
M<77C*//1_P 2R)9%22/3XXDC*KJF'.HBX M<BVJ#K5>C%_'C[_!5U-19'KO(
M5&4GS=744F5J\2\,\*&D5=,9DI6D"W1_TN!ZCQ];^.>M]&4[9V1O_>^+V^F$
MS^Z]H>"NFJ'%%!6FZS(%$9\4U/8(>1^/\![T 1UH] YN[JOL/;NT,C'E=P[K
MWNPGI)2E515U06$LT2JEI)ZGB,@O^?\ 6'U][!Z\<=,O2^&W=BL=VC!#B]Q8
MU\SAXJ=5BH:FC+EHZ\ :0BF4J9/I_C_C[T<^?6QT4W)]2=CIVC-F&I-XR1'%
MQP\X&O(OX57]9)'X]^\^O=.57L[?^ZX*V"HPN[P<7'-21/48BMK/\X"+H"@T
M?H' /]/Z>]\>M$=.&#Z)WO-BJ5I*'<@OYS9]L5;?21Q^3[T/3^?6BM<UZ'_X
M=];[IVAN6&2M@SM.G]\*:J/W&'J<<"$BM>[FUO\ 'WL]6Z._VBDLF2F:5Y-3
M9.(GR78W\7^)]UI7'IU5NC7[3@U8V<,>/O9."M_[$?O96O5NE7%$L>H+IN;7
M %O?E%.O=9O=NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]T"/R/W)M+:72/8V<WMB,9N#!4VWJB'^ Y>#[B"LJZUEAH*=EL6!>NDI[.M
MGBMY592FH"CDNRN-QW2WBM7:.0R ^(AHR(M6=OR4'!P>!K6G09YRO;?;MKN)
MKI%DC$9_3<55V.$7\V(SQ''%*]:POO.CK!7K/2TM36U$-)14T]75U,BPT]+2
MPM422._ 5$0%F8GZ  D^Z22+$I9B !DDF@ ^9/5XXFF8*@+,30  DD_(#CT;
M;K7X.?(7L80U3;378V(E(/\ %-^S/@21P3IH1'+DC=3=2:-8V_U8_$>;W[J;
M/LM5$OCN/PP 2?\ &ZA/M[B1Z=2)LGM5O&\T8Q"!#^*<E#_O !?]J@?/JP+K
M?^6CU?@5IZSLG<N=W[7J+S8S',=K8XZC?21"\F0DTC@,M;%?DE!<!8AWKWNO
M[NJV4<<"^3-^K)_QH!!]FD_;U+VR^R-A:4:]DDN&\U7]*/\ XR2^/76/LZL6
MPN'QNWL/B\#AJ846(PN/H\5BZ-9'F$-/CXUBAB5I&=RL<:*HU,38#GW#5S<O
M>2-+(=3NQ=FP*LQJ3B@R37J9;:W2TC6*,41%"J,FBJ* 9J< =.?MCI[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z17
M8W7FTNU]D;DZ[WUB8<WM7=>-EQF6H)?22K$/'+$X]4-33S+'+#*MGBE1)$(9
M0?9EM&[7&Q7,=W:N4EB8,C#UX$$>8()# X()!P>B_==K@WJWDM;E0\4JE74^
MGJ#Y$&A!&00",CK40^5WQAWE\6>SZ[9>X(Y\AMK)-4Y'8.[Q%IARF/5EL;@!
M4K:3R)%5P\&.2SJ&@E@DDZ <A\[6_/-BMS%19%HL\5<Q2?\ 0+4)0^8Q\08#
M!+GGDR?DJ]-O)5HFJT$OE(G_ $$M0''D<CM*DEC]C;H&=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]UVJLS!5!9F(5547))^@ _)/OQ-.M@5P.MF/\ EM?"!^C=
MOKW+VCB?%V[NS'&'"8:NCN^W<76@%HV0C]K+5ZV-03=X(=-,/&SU:OA;[R>Y
MG]:)?W=8M_BD35=QPN)1Y_.-?P^3'NS1*9B>T?MS_5F+Z^\7_&I5HJG_ $",
MYI_IV_%Z"BBG=6USW!/4U]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MTU9*33I2_P"M&XM[:DX]*[9 P->D^%8R,5 O8?\ $?[#W6O3P@%:]*>-?%!*
M;\<?7GZ>VUE*\.D,R@8_;TPU^1AB&EF:ZL?HE_H/;%Q=./LKZ=)64(*CH-<W
MO5,<^E)2H\,<G_ ;7^IBOY_UO9%<[G(AP1P].B^6\T\/\'0?UO9M2S.JU X:
M0)_D0_/T]D4^\S G(\_(=(6W)LT/#Y=)>?L/(U)^W\\;*UFL:15Y7GZCV6KN
MLTAH2*?8.DLV[-(,G'V=0:CL+(0IX!4('E1H@/M%()M87/X%S[<6_D' C]G2
M-]T:E ?EP'3,G9NX**H,*U-.$1; ?9*W+@-];?X^W!N<JX-/V=)EW61#2H_9
MT_IOJOB #SQ^2<!U_P E!'J]O+N$@]/V=/\ [Q9>)X_+J?3;XR1-FGCMI/TI
M1_4?X>W5W!R<D?LZ<3<']<?9T^4N_E9E2>4DLQ'II;<6_P /\?;XOF/G_+I9
M#N>*D_RZ7V(S"U_A=')!$3\QZ?J;>U4-TS$#_)T9P2B;(^WH;J?]0_UV_P!Z
M]C!^'1Z_'J?[HO ]4Z][40_#U[KWMWKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=,=3+X#Y;VT*.;7^I(_P")]L+Q
MZL@!.>@$[FZ\KNQMOSTU)!'4.E)FF >K%'_P,@*#G_$C_8>W@QZ]<)@?RZK_
M .C_ (Y=I=8Y?'U./HL13"E?*2 OEXJWFMA:,\'ZW!_V'O?19-4&OETQ;PZL
M[SW-OFA:LBP$N+@W95O5A*V"%_!55D>NUEOJ,:FWY!]IR]"1T9P?A_+_ "="
MSBNM:G;NZY8)*=(Q'1'A:SS?YY4;Z^_4KT?(XKT:+9L(3+85'' KL>G!OP&4
M>]$5'5+DT_9U'^2&[H<9M^#&PRLLE-N7'ZE-/K $E)5/]3]?U#W2E13H@NG!
M8@_+_!UWU900[:V7N/(1J8W2NBJU;7YOUQQ+>Q_U_I[<B45Z='P]!IDUR.]=
MQU\+^.6FAJEJXQQ3'G2I-QR?J>/9K VBOV=-UZ'G<N*H=KQR82A1X_N88JT(
M\AGY>323J/TXB^G_ !7W[Q0V>MT X=+_ &E1MA\*V5J1HAJL1'+J1O(2$0NW
MI_!M[+IS4G\^K#/19]^]EU.8RTFUMM5 \=13TU5'%5403U17=R9&N1PO ]H!
M3RZT3Z<.EOUEU4,1(^<JJ;34967#Y:I=*[R N"\SD+]%&J0\#_6]JH32O7J'
MHQSQRI&!3:?#J].LW/-[_P"\W]O*Y3'5CC'3I2075_,/5=;6/MP2ZNM:J<.H
MM9 VM@@](92+G_#W762:=:U'CUE2$1Q-&>'8Z@+W_I_Q3W<(:9X]4,Y'4%DK
M8F9H@EBQ -P>#_K^]>%UL7.K%?Y=<5K*O_=Y4Q_VK*/]A].?K[WI!P>K E34
M=9#C*#)HZRK(VI&)LY3F4<^_,@3AUHNSGNX>72)S.*V6J/MS*1Y'U&.I9()&
M_P"#+ZP?\/;(.D9Z]T4E/B#UH=Y4VX_X7E-%5N9,VT@W!+<AZH3ZM'X-FOI_
MV'NP/IUHK7[>C2X7K38VWJG3AH,BDL<<B SUCRC3+9F^OYO;\>ZDENKZ?+I<
ME<3/4TL:^>Z:8K\CGZ>_#MZT>L,T\M/6STT144T5O$"+GD GGZ_4GWL@'/6A
MU'JZO%(PDIS."B7]2D\W_P"*>]Z:8ZVIZG8@4]:9W;4P\!D'U7ZGWXCRZ]6F
M>NZ5J/[J-&$G.L\7_P!2?=0 ,YZL2!PZERYFAB2IIKRZBLD"#QWY *_6_NRC
MJASTV45/CS3A:D2_<ZF_03:WX_P^E_>F?TZV!7J-1P2M.[5 !IX)E9;'G0"2
M?I]3I'OQ8=>^?7#<>W,7EJ,5)BF999XR#YC'_FU9?I_L#[T,?9UXDGIMK*/"
M9W"9#"URU$E-50&BD6-C$=%A_:'(/'U][H?+_4>O5Z3VV>J-M[4FDS&$I:J.
M2MIFHF>:O:<%"ZN1I;Z'5$.?^*^_"O7J5ZS8_9NU*6JAR-'#6#,TKG[%GJ&:
M/D$'4#P?2S_[Q[MY9ZT!7I;5TAAHZ+^*W\7/VXAL3<#F]O\ "WO0/[.M@#AU
M#%'C\S02QLLK4CR!9/48S>,JP^G/UM[H&SGIS2*]0:;:^VJ)I301U0J)2!4>
M6=F&I;VM_AJ+>[L1U4>?7.;:N&D<SU<<_GX4Z9R!8?3@<?3W0-FO7@/7I@&W
M-F82<TZQUZS9B0D@3-("U[?4_I%W]^&>M&G2PH,-@TI8J:):@)'K8*9";78D
M\_ZY]W->O4U''6"+"[6P=?2H5KEJI7\\%I#(O''/T_(/O2YKU7AT6/N[(I1Y
M&6:-B(Y,U&B:DU&QA)_XCW8"G7NC:[8J-=!,8R=/WD@-Q^=$?MMG].MD4Z5,
M08:F;^U8@_[?W9!UKK-[OU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NB$_-+J[NCO>7975W7.(IJ?:=-++NK=NZLWE(\70"J'DIJ"E.D
MRULY@3[F218J.5098&)#+Q+/MEONV<J":_O7)E($4,2(6DTX9VS114Z0"6!P
MP\^HG]S-AW/FOP;"R4"($RS2NX5-0JJ+BK&G<2 I&5/ET&76O\LG96*,-=VE
MO3*[LJ%L[83;4/\ =VB!XNDM0YFK*A/KZH_M6Y']#J/=[]\;JXJMA"D(_CD/
MB/\ : -*C\]?1%LGL=:6]&OYGF/\$8\-/L)[F/V@IT?GK_IWJ[JNG^WZ_P!C
M;>VP6C$,M;140EK)57Z+/73&6MG _P";D[?4GZD^XDW?F2_WYM5Y/)+FH5F[
M ?D@HH_(#J6]HY<L=A739P1Q8H2J]Y ]6-6/YD]"5[).CKKWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z;<IF<1A*=JS-97&XBD4,6JLI714$8"_4EY611:XOS[>@M
MI+IM,2LY]%4L?V 'IF:XCMAJD95'JQ"C]I(Z";+?)#H'"/)'D.X^N%EB.F6&
MEW;1Y*13?25:.FEF=6!^H*W Y( Y]B&WY+W>ZREG<T/ F%U!_-@!T'[CG/:;
M8D/>6P(X@3(Q'Y*Q/2/E^97QDAD>)^W, 6C8HQBHJ^=;K_J72C9&'^(8@_@^
MS)?;7?&%1:2?F8P?V%P>BYO<?8U-#=Q_D'(_:%IUGI?F%\9ZQG6'M[;*%%#$
MU4=70#G^AGIHPQ_P!)]TD]N-\BXVDOY:&_XZQZO'[B;)+PO(OS++_P >4=+_
M  O>G2VXY!#@^V>N<E4-]*2FWECVF_'/A-0);<CG1:_'U]E%URKN=D*RVERH
M]3#)I_;II_/HVM>:=MO32&[MW/HLT9;]FJO\NA1AFAJ(DGIY8YX95#QS0N)5
M8'\JRD@C_6/LB92AH001Q!P>CU6#BH-1ZCAUD]UZWU[W[KW7O?NO=>]^Z]T"
M7?\ T!UY\D.O,EUYV'C?/23ZJK"9NE54KL57(K+%74,K*?'-'<AE(,<T9:*5
M6C8CV)>5.:[ODZ[6\LVH1AT-=$J5RCCS!_:#0@@CH/<S\L6G-EHUI=K53E6%
M-<;TPRGR(_814$$$CK4Y^2WQ@[+^+V^9=I;[H?N<57/4U&T=Y4$+?89:DA<J
M)86);PU*+I\]*[&6!F6^N)XI9,\N2^=[+G>U%Q:M1UH)86(UQ,1P/JI_"XPW
MR((&#_./)=YR7<^#<BJ-4Q3*#HE4'R]&'XE)JOS!!)<O8QZ"'7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]UEAAFJ9HJ>GBEJ*BHECA@@AC,KN\I"JB*H+,S,0  +D\#W5F" LQ
M  %23@ #S/5D0R$*H))(  %22<  #SZV%/Y?'\NAMB2XCO+O["Q/O-/M\EL'
MKW(1K,N() >+)92,W5LJ+@P4Y!%$1Y) :O0M)B3[L^\'[U#[9M3GP<K/.N#+
MY%$/^^_XF_'P'977E7[6>T_[I*[ENB S8:& Y$/F'<?[\]%_!Q/?33=/[QOZ
MR#Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NF7*+JE@YL-+7_
M -O^?=&4DX%>E=M(%!!(&?7K!3I%>_D0^D_T_K_K^Z%2?+^75Y)POF/V]=9"
MK1**I*2*0$OZ9+?D>TDYHII^WHLDD%#G^?1,N^^UJ#:=#C_%E:#[I\M)33P?
MQM:1T*PLUF ):]_P1[#&XS$*,GCZGH-;G>", %J9_BIY=% KNXZVO;4KET**
MA<9MY>5)-KV_UO8,W*<B0#4?A' _,] W<-P&OXZ8'XJ>9Z1N4[KP^*65\IN#
M&8_B8M]YN-:>QB%W'K(MI_/]/82N;XJS=QXG\1\N@[+O2H35QY_Z)_L]!B/E
MMU]29%8*/?&S,G6^,LM N^*<N58$E@H=F(4<WM]/:&QW'O!9J#/%NFX-_1WI
MK7A_OP'H!MS?.'*XW=VWJ>/;5)4457N!HA5G=TJQF):F%1("*<J4*-?ZVM^;
M>SL[E&,^(O\ O8_S]/R;I'4'6.-::QGI8Y7YIU61R4U!B-L8W(UP6*0TM!N=
MZF70J*2VB.G+:1<7-K<^_-ND?'Q%_P!Z'^?IJ7>(R:ZE'^W'2<WI\\L-BUHT
MJJG;E#6?:.5I9M^+3.6C(#+8Q@W4\?3@^[#<$D(HXQZ-_L]4_?"RD=R_[V.A
M=Z3^5%+V#%$U/4XN5GQ-77&.EW7_ !&P@JDAOPHXNPY_!X]K(;Y"::QP_B_V
M>E<&X*336.'\8Z'/(;[J9&6:BK))]$8%J?).W)/TNM^0#[,H;I*?&#^?1M!>
M*XPPX_Q="+UQW=!'D(,7/D*/[JG-)!/!-N#]Q295!#H?4IY^A]F=O<@$=PXC
MS^?1W:7H6G=Z#C\^K;Z.HIY7413PR$E@ DJO]!_@?<FL:CJ2FSTXM-$G#2QJ
M>19G ^G^N?=5&#U6E>O"6(C4)(RO]0X(_P![]J(C0=:I3K)[=Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3'5QM(
M"H!-U'T%_H;^V :=.1?$.H,/F@+H:=Y%<:+,I M_MB+'W9&%:];N<T^WKB(J
M6.0*N/IT%KZA J_7_D'W99-(X5Z+7P>O';>)_<K334)<ZJHDT49(/+_JM>]_
MS_L?;):I./\ 9Z,8&H5'V=%-W]7T=/V1D8B::&$4-%9A(J+<P1G^EO=AP_R=
M'<2T.,]*W:4:5F9PTM),)XH:^@,S4Y$@6[*1J*D@?3\^]'IJZ.1T'7=&/ILY
MO+.8N3(QHU/58ZI,!TSE=%'$MS&7%N)/K;\_X^]Z3Z=$,Y!<G_5PZ%3?)QVV
M-E97'QU],*NMQD%1!3"1*21[,B^E Q9OTGZ#_#VH1>&.GSQI7J+TOBEDI7RU
M=3!$JL)))%)54X(=EE%@KN/4Q _U_=R:'JHP>I0JCE\S293-L<3101-35$]=
M)>)0%D*L[RZ%&IY HN?K:W)]T9^O#..D!OGM&NJ9X-K;0H3N.."KJ\/5SX+(
M/5&"*4K"DSQTZ2!%;U$ L!P0#[3,:D]7^0Z7G7'4_P#!(HLMEO-4U\,U7%X\
MGB0LA250H]<C,X47-N+>VM%<\.O*HZ,,L34%/$M-3>=9H5!6.'2$"*-( 4'_
M %1_I]/>EZ\:-^766*HE\*AZ-@;GZJ5_)_JOO1?_ %5Z\4'KUD21P&'J%^/U
M>[+(3Q'3?7(<\LU_\";^U"'/57^73'F,PF/@DFET(L<0<M+-X@+M;ZD<"_M\
MMJSTGI3!Z"+(]N0T53)"D=%,$E*:AE;<?UX4V]NHW33-H_XOI0;?W]1YYT13
M11.\LL02+(+*?VDUWM87X]O8^76O$KY_SZ=MXY-L1MG+96"8O)383+5\<*U'
MBU&EIVD5 PN?41:X'']/;,^:=*8#6OY=5J;;[6W'V!NF%9J;(XE)Z6=3)'E9
MZH#[1"?RL?+?Z_'M,10_Y>GAGH/.X]^]J;?EH5PN&WGE(@N:O+15E?& *4Q>
M,_M(XLX)(Y_'%_?@:];Z+R?E5OS8MLINVBSF'@_X!EMP;IK,8FNH]2+KGC U
MLJ$J/J1<C@>ZD'RZMJZ7F%^2FZ<KE,7E,4^2RF.@GAFKZBBW14U<,0D]8$KH
MK(H*W_41<>[]5)ZM>Z#W)_I'VIA:R6O$%=48ROK9X4K3D'405C0C5<JY!!4W
M/TX'O0&>O U'56_:/<W9^S]YX6GAV_NRMH9,4*JHF.4KZ:-2TM0FEK1,G]E>
M2?R/>_/KW2OQGS!R>%V^[U]''3U?\+F4P5F[98'$B*S:3JB#:OI^+^_$5Z]7
MHCV&_F$[X??6)H9L#61P34M2[N^^JRPTPU!'!@ ^JCWZF>MUZ,#1?,/=]7EM
MMR2X:OBIZ_)X]C*V[*ID*3RQ$FY@ 90K7^MB/>@>M=&8D^0^[LAO3QXS!9&K
MQ[4-UJ*+-U,T)9$]0&B(IJ!^O-_?C]O7A7JT[ UHR>V-K2.BT\^2V_B)*NSZ
MFC>LIXBVO@%F0L;WL;WO;WI2.K5X] C\FNR9.J>MJ*KQL29JN3=.-H'ITR)H
M'"5L%7,7/C65@%*J+6L;W]^/=CK0QU3+U9\\=X;JW9'MW<&U9=L0Y#<2XY:V
MKW?5#3%(6!F"RT\08+;_ %0'^/N_6NC)=P_);,[(VEA<CMZ:?<T]5FDHI*:C
MW1,A2-X:B0R'PK*=(9 O(MS];V]U&/\ 5QZW7IPZ RF=WAN#%9O+;WS6,-#E
MZR@_A-1EYJA9D6DUB0^2=/[4I%M!%U^O]+=:Z,QVY\@,YU92;=IZ/:K[LBJ<
MI)C5J9LK+ &6!5(E&F"<'7?Z7_V/NI&KJP:G3-V3W_N#</4N>R\>U)-ISQU^
M-I47'Y2:G*A*JFNX801,"X<J?ZC\GZ>]TZU6G_%] GT!W/GLA/V"^0EKYUQ<
M..FB-9GIIP-)K2UM8.B^@7(_XCWOK5>@2WE\DM]9/ORLVUCZ#.)@_P"!4M0F
M1H=QU;P:TI4=E"I&(M6LD$ZKW_Q]Z'7NN&=WUV'F:BDR&WYMVYL88R39!,5E
M*VM$375UCF,6KQD^-K:A^#QP?>^M$YZ!W,_*;M# [DK\ <1N=ZVACIVDI9-S
M5\,JBHBBE!:+Q%E%I%M<<@@_GW[K>JG0@_'GY.[WWOV9M+&9.BS$,=1N6EH7
M^XW-5U@TNK$W22, @?T]U)IPZ\"3U9KW)1"KVMM^O,NFIJ<XC3(%UL-,4P]3
M7U'Z#ZCWNO7NC?;+"R8JIL5/^7R#4+-;]N+W4+4?G_FZ]6IZ5L.H-(A5M*VT
ML;@'Z_3WY!3KW4CW?KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=![V'VQUSU1B_P"+]A;O
MPVV*1TD>FBKJC74U'B_4*6CB$E75,/RL,+D?D>SC9^7[WF"3P[.%Y3BI4=JU
M_B8T5?\ ;$=%&\;_ &>P1^+>3)$N::CW-3^%15F/R4$]5T=E_P SK!T3U%!U
M+L.JS<B&1(MP[TG.,IM2$@-'CZ5VJ9HFX(+U=,]N#&#])FV/V,EEH^X3A!YQ
MPC4WYNP"@_8K#Y]0SOGOE#"2FWP&0Y_4F.A:^H1:L1]K(?ET1;?/S0^1^^S-
M'5]C9+;E!*UUQVRHTVJJ#\J*BE"U[J?R)*Q_Z?3W*NU>V6R[30K;K(P_%.3+
M7_:MV?L4=15NON;O6[5#7#1*?PP 14_VR]_[6/1:LIE\MG*M\AFLID<Q7R +
M)6Y2MER$S $D R2L[D7)^K?D^QO!;1VJZ(E5%_A50H_8 !T"+BZEO&URNSM_
M$[%F_:23TW>WNF.O>_=>Z][]U[KWOW7NE3MG?.]-ESFIV?N[<VUIV<2/+M[.
MU6&+,+<M]O+'J_2+WO<"QX]H+[:K7<QIN88I1PI)&K_\>!Z,+'=KK:S6VFEB
M-:_IR,E3\])%?SZ-GL+^8%\B-G/#%E\UB-_XV,JK4F[<2AFT<7"5E$:2I+D?
M1I7FL>2K#CW'N[>T&S;E4QH]NWK$YI7_ $KZQ3Y#3U(6T^\&\[<0)72X7TE0
M!J?)DT&OS;5T?KJW^8]U%NXT^/[!QF5ZTRTFE&K)2VXL6S$Z1:IIXDJH=1Y_
M<HA&@_5,;7,2;][+[CMU7LV2Y0>0_3EI_I6)4_DU3_#U+>P^]&W;C1+M7MG/
MF?U(J\/B4!A_ME '\71^\%G\%N?%TN;VWF<7G\/6IY*3*X:OBR=/*/ZI-"SQ
MM_C9N/S[B.ZM);%S%,C1NO%'4JP^T, >I;M;N*^02PNLB-E71@RD?(@D=._M
M/THZ][]U[H.>U>I>ONZ]F9+8/9>VZ'<VVLD [4U4I26GFC#".JHZA"LU)5PZ
MFT2Q.K@%E)*,RL;['OUWRW<K=V4C1R+YC@P\U8'#*?,$$?F!T5;SLEKS!;M:
MWD:R1MQ!X@^14C*L*X(((ZUJOE[_ "XNS?CU-E-Y;%BR'9'3\1FJWS%'3^?)
MX>%;L5S%+$H+01K>];"A@LI:=:8E%;,SV^]XK+FT+;796WNS0:2:13'_ (6Q
M."?X&.K^$MFF(G/GM'><KEKBT#7%J*DL!66(?TU'$#^-13^(+YUM>YEZA_KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[H2NJNH.Q^[=VT6R>L-J9/=>X*PJSPT,6F&FB)LU36U3E:>BI4-@99I
M42Y"@EV522[]S#9\LVYN;V58D'"I[F/\*J,LWR )\^%3T<['R_><R3BVLHFD
M<\:?"H]68X4?,D>@R0.MDCX9?RYMC?'1<=OWL%L;V!W*L<<]/D/ TN+P3L 6
M3$Q3*K352M<??RQ)+;B".G!D\N&_N-[OW7.&JUM-4%G6A6M))AZR$<%_X6"1
M_$6Q3+KV^]J+7E(+<W.F>[I\5*QPD\1&#Q/_  P@-3@%!(-EWN&>I=Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z;JY49D#J3=2/K;Z
M_P"Q]O1G'3$KZ2.F_P :1L="V_'U)^O^O[VPT=,,VKI.U;^2AJ46XU+;G_ C
MV3W"DH>F9#BG50WSFIZO"P8_(Q/'&:K=E5<I^Z2%I7;D,I4?3\>PENL9"BGK
M_DZ!F]1ZCG^+_)T0C:7:PR%1#022USM/-4<FB@1;1Q:^2&!_L_T]@?<H3X@X
M5TC_  GH!;HI5_\ :C_">@>[ZJLM-1I+15,<:5;9UOW(UN1)&MK^AK?7FWL$
MWL#:FK3BW^KAT!;SXF^T]$%VYMK*1[D@S51)2N4IYX-:R'5RA4>G0%_/L.RG
MZ9=3<!Z?/'11#.+9];5I2F..>A5>EJ,QG-KQU3)-#1Y.DB="?%Z7FA# % ";
MA?R;^TK;K%Z-^P?Y^E3[M&<D-\L#_/T^9BN_N3O:OR.)UT<JTD%,KHHJS:HB
MB+#3-J7G3]?J/Q[;.ZQ-@!OV#_/TFDW>$&AU?L'^?HL.9V7FNQ<BU09:&:IA
MJ*B"G>JF:DTFI<OR(8[$7_J#[51[JB$#NS3R'^?JT6[1%A0-Q]!_GZ.#\8(Z
MSK3*38[+.ADI=LUU$PQUJI=516T\XL95C)73]3];\6M[-[._C9S6O#T^8^?1
MS:[BC,:5X>@^7SZ.GD.R\I14\IQ=944UD#>NAIY/43:_J5_Q;V([*Y5U-*\?
M\@Z%&WW0*GCQ^7IUEZ(W'7Y[L?+S9:H:J\CX^=2((X/6U5$"2(U3_;?3_#V?
MVLNHI]J_X>A):3ABE*\1_AZV<\!2^-HY+*-,DO\ :)^J6]S<PH.IP/:*=2JM
MBT[@FX$L@'^W]V'#JZBG3C2P:Z<6M8EK@D_@^[A:]-OQZ<U%E _H /\ ;>W1
MCJO7?O?7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NF_VE?ATY%\0_U>76.3\?['W6/IV?@.H,_ZQ_P4?[V?=P:]%<WQ=3T'
MDHZA!]33%>?]J0CW5C0CI;"OP_E_DZ(UVW3TE)O;)32Q%B(,<I*,Q_5 GX)
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M63]?]?W0 MGKU<=&TP-"M/28>B555:*FQ]+(NHL+0JB6!/)_2>38^[!/7JU
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M^Z]U[W[KW7O?NO=>]^Z]U[W[KW357*S5-* #IN;L/Q<CV[&:=-2)KZZ>%=1
M?GBX^OO;/GATWX 8<>F=:$ ^-BPUDGD?[[^GM#(H*GITVP]>@ [LZ<H>Q,6M
M+435<9I:FJJXOMJ6*8LSP,@'K!M]?K[(-PM?$'Y_Y.B3<MK6Y'$\:XIZ=:YG
MR(^-?87767_BF&V[NK(TU%@L;.SS4BPIKK:N:G96,9%K*RD?GZ?CV"]QLP90
M2?PCT^?0 W/9E\05+?"/3U/12:S?6Z,=_N-SV!BH?LB](36-)JO#Z9-5V(NM
MA?V$+K;E9V.H\3T ;O9TUOW'BWI\^L<7:F#HJ8P1MA'J=1<1$F]F(YX']/\
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M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[IO]I7X=.1?$/\ 5Y=8Y/Q_L?;/3L_
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M+6O7J1]*8_X>_'!KUKJ^C$I%6:*MF8+JBEI&3@.D@U*2"">1;^GNH '5V/\
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M(_;IOIJ:Q]7^L?=B:=>KTIJ;YN];5E+'BHMU[>?Q,U188/+*WU/U)CTV]?\
M2_NE3U[J!2]_=,-E:"4[W@%1)4K(D?\ "Z^Q9C<C_@']+G^O^Q]^I7CUX8Z-
M=@J;8O8FV,5EJ?/5LM+6F6KAFHHF@#?;R2P&PFIBP%P?J+W_ ,/?@E>K,U>B
M33_+?JW:NY<7M.3=V(2+,1O5R&HPV3EE'^<3T-' (P+P_E2?K_A[L*GCU3IZ
MW]3?&KL[;='F\KV9GJ>JJ5J\H\6*HY88]<D;+8>;$S-HX_U1/^/OW#JW0 =
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M/U<\W6&[:J"#<=&Q:9:"=K)%E:=.2KQ"RU"J/WH!RKR0PZ8U]R.1EYLM?%A
M%U$"8SP\1>)C)^?%:\&] S=27[;<\MRI=>%,2;68@2#B(VX"0#Y<&IQ7U*KU
ML+TU33UM-3UE)/%54E7!%4TM3!()8Y(YU#(Z.I*LCJ000;$&X]X=NAC8JP((
M)!!P01@@]9AHXD 92"" 01D$'(/6?W7JW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
MP=] !M>Y ]Z8TZ]US][Z]U[W[KW6&>411EV74+@:?]?WH]; KUKG?SJNJNS)
M>H]P[QV9N;(X\;=ZF^1>Y)Z/$4M4\TIIL9!50QH800)1XF5"1^H\?GWI?/KQ
MZIL_D:XGO7LG>^VH,]NG>E#2S[([)J&7<-/7-&&H\E&BZM:J-1Y*_P"'OS9Z
M\!Y];T6,I9**BV_2^<-)!CJ""I9>/(\$:*S$?7U$'Z^_8/7N/2H]VZUUB>30
M0+7XO];>ZLVGKW7#S_[3_O/_ !KW7Q.O=2/;G7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZX.J,+2!2+W&KCGWHT\
M^O=>D)",1>_^'O3<.O=8H68L;DD6_//NJ$GKW4"LBI5NQCB)"K^1_7W5L<.G
M(OB'3098%$C5CQBF17:)9W"* OUTEB!]/?LG'2D@#/6#&9O#5;+!CZB@6)RY
M @K(Y1=1<_I)YX][85/50=(SD_SZC2YS!TU8:4UN.2HJ*EJ=;UT2MK#:?TEK
MDZF^@Y][T$\3U?50"@ZJ6_F'YM\--G)(Z_2O\2VE&'BJ1&/W*2_UO_A[LHH.
MO:ZBO1<NMM\9#?BXW#[?H<ICZDOB\6^1A)JE$M6H1)CXEN "I:U[_P!#[V!3
MKP:O5N'1W6$D>SL)'NZ>ES50M)E/-)D*9PS2&ME*,1)S=8CI'^'^'O1%>JF2
M@X'HV,,%+1T[Q4C0PZK']L@<BP^E_P #WJM.DGGU%AII#-)(:D'6+\L?Q;_'
MW2E>MDU^SK(U&CR+(U3 Q5=/J(/]?S?_ !][T_/K0-.LCT\3*BK/ I46/(_X
MK[V!IZVK4Z]'3^/U+4Q#D^H-;Z_['WYA7K3-7J--%+4N$6M0E69; ZOU&WX/
M'T]^)X=;)].I]-3O!$L3U +*6Y!M^HW_ "??J>IZKUGT_P#-_P#WG_C?OU/G
MU[KVG_F__O/_ !OWZGSZ]UBEC5U*FH0,0+%F']?]?W[37SKUX=15IPAN*N+_
M )*_XW[\17TZL37J3,08V JEOQ;UC^H_Q]^I3B?RZT/GT%'8E!69#:VY$I<@
M(9(\'GM(!)+%Z>0*%"FY-QQ[\&IY=;;'5276E)_!^T*+^]FU*_<T"XVN\K5%
M ^EO) WC!,B$>@_3GVX3U0"G3SVSUYA-WY7!S8OK\8F..KR1<MAWD!%9) 5)
M*(!9 I]U IUOHGO;74.XMN5-56X-:F@4U%! D=!BYXB%EANWZ1]"RW/^/O?6
MNO;:DR=6D<4FS<\:N%H88\@^-E.A@MC(#X[BY%_K[]QZV!U<-\4\U44FSL%C
MLM0ULZTV#R1%/5 QZ6;(,0=++<'2Q_V!]^IU[HBO;_QRASVXL=F<-AZ/%5%%
MBEIXYDPLK.&\TS%@4 M=9+>_#'7J= UN_HWN"#!4M/A]XY>CAC2=!!2X^M0!
M/&UE 3Z"_OQ /7NB28SI[M_'[BHHY,_GY#X9I-0QU<.&CD'Y7_#WZG6B:#HQ
M./V%OW'S;5>JJLS4225.-$C&@J1RC1:B;C\W]^%>O<>CF[/Z_P!U3;JBRE1)
M7F(TE1$5DQ\YY"6'J(M[WUOJW38<T4FVJ.FJJ)W>@PV*IV,BVN8Z?2QY%Q<K
M[;/;UZG2JBJ,<@"C&BX!O:Q^I][J/]7#KU*].JPA495JHD63DKJM_L/K^/>J
M5ZL34]1GHJF,^2*M"J_"Z21Q_M_?B#_Q76N/#K/#!4+ZY*VY#']9M_O)/O7Q
M=>Z[JJ1JQ(U6IC)C)9N=7^QX/'OU#Z]>ZC0TDH_::I4@DD@G_"_Y_P!;WH'/
M6PU.IL=,\5]%2@U6O;CZ>[DU\Q^WKS-JZYF*<F_W@'^%_?@:>G[>O!J>77!J
M>9OK6*?K;G^O^Q]^.?3]O6]0/EUX0S( #6J!_B;?\3[\N,8Z]J'IU$8LTT2/
M4!BQLI+?\;]^PW6Z@CHGW=DKTN5J")=1_C:+Z&M]82??EQ_+IOHT&WGEJ<?/
M<N?\K=?J7^BQGW1C7K8-#TN:92L$2F]P@'(M]/;B\.O'/6;W;K77O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK__ #K^04G;?9<N
MSMOUS2; Z[JJG&T0AEO%79-+QUM>0OI=8V!IZ<DL!&KRH0*AU]Y=^U/* Y>L
M1<S+_C%P S5&4BXJGRK\3<,D _".L1?=?F\\P7QM86_0MB5%#AY>#/\ .GPK
M\@2/BZ(O[E7J*>O>_=>Z,9L/XF?('LS:F*WOLC8'\;VOF_OOX9D_[U83&^7^
M&U,U)-^S5Y*GJ$T5%/*GKB6^G4MU*L09NWN#L^QW#VMU<:)4TZE\*=J:E#C*
M1LIJK X/\^AGM/M]O&^6Z75K;ZXGU:6\6!:Z6*'#R*PHRD9'\NLF\_B+\B]@
M8"NW/NGK+(TF#QL,E3D:W'9C&;A\$4(U/-+%CJZKFCAC6Y>1HPBJ"S, "?==
MM]Q-EW>98(+E2[&BJR2QZB> !D1 2?(5J?+JVY>W6];3"T\]LP115F5XI-('
M$D1NYH/,TH.BW^QKT"NO>_=>Z][]U[KWOW7NE?L/8>Z^S-UXK9&R,5_&]T9O
M[[^&8S[ZFQOE_AM--5S?O5<U/3IHIZ>5_7*M].E;L54EV[;M;[';O=73Z(DT
MZFTLU-3!!A S&K,!@?RZ,=IVFXWRX2UM4UROJTKJ5:Z5+G+E5%%4G)_GTNL!
M\>.X=T=A[CZIP6T/OM_;2HZFOW#@?[P8NF^WAHY::&1_NIJV.BETR5E,+15+
ML==P"%8J57?..VV%G'N$LVFWF8+')X<IU$AB!I"%AA&XJ.'S'1M:<F[E?7DF
MWQ0ZKB)2TD?B1#2H*@G47"G+KP8\?D>@BR-!5XK(5V+KXO!78VLJ:"M@\BRZ
M)J-VCD34C,C:75A=6*GZ@D<^Q%#,MPBR(:JRAE.14,*@YH>!\^@[/"UL[1N*
M,C%6%0:,IH1BHXCRZA^W.FNE!@]J;EW+!F:K 8+*9>EV[BZG-Y^KH:-YX:*D
MHT>1YZJ4#QP1Z8VTEV&MAI34Q *.ZW""Q*+-(J&1PD88@%W)  4<2<CAPXG'
M2VTVZ>_#M#&SB)"\A4$JB*"26/ #!I7CP%3TLNNNENS.V*#=>3V!MK^/T.R*
M2DKMT3_QG'XK[6*N2JDB?36U5,\VI**I-HED(T6(!9 Q;O/,UCR^\27DOAM.
M2L0T2/J*E0?@1J9=>-./R/1CLO+%]S"LKV<7B"$ RG7&FD,&(^-UK70W"O#Y
MCH+?9]T0]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5U7\NKY R;HV[5=([HK6ES>
MT:-LCLJIJ)"S3XE6"RT6IKW?'2.GC&JYIY BJ$IB3C'[R\H"PF&Z0+1)CIF
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M4#W?/6JTZ$*K[VI'G<FOISPHO_"YA^!_A[H?G_J_9UM7IPZC?Z<Z/_E>I_\
MSUS_ /%/>L?+^?5M9Z]_ISH_^5ZG_P#/7/\ \4]^Q\OY]>UGJ/+WC2LXM6TY
M]/\ SK)_\?\ #WL5ICK1:O48]W)<VK*6U^/]QLWO6/GUJO7O]-P)XJZ7_P ]
MLWO>&/GUZO3+FN]<9CDIY,GD((H9VD.I,742<* 7X4$\ _T]N<.JUKUAH>T]
MM9N 9?;^0-5(7:"/RX^>%?V^'],B(> ?Z^ZGN&.MAM)Z5,/>5154<]%+5T=J
M6G-(%7&2BWI*$7_/Z?K[T 3_ ).MD](6LWMMG-U<E-G*Z2-2$E;[6DF0ZHU
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M0BE,&4%;)3/5+4P23F*-88;A9$?1J!.KD2OSKS]=\E_1Q^&DAECK-KU:]2Z
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M62L<,T$C 1^$--Z@%1QMS3[@V^P[;%?PCQ3< > I- :KJ):E:!># 9U=N,D
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M%:;;_5BX7QG\)Q*;M])U0N84#A?T\A5HPH'R3D\.BV_&;J[#;GD^4J];=O\
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M/U_LB.&KAEVYM4RRW6%Y,!2!EL"/2"E_K_0CWH/7KW49^MMG01K,^ VRRN=
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MWVX[!O/CW2Z(H?$57U+28NK(H !)((;50TH0*YZ$;H'_ +>&_(W_ ,,_<O\
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MZ*!W*#04+,:4  SZ*_;;E^YY$AN[_= ($T* I968A-3$]K$5-0%%:DU_-.?
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M2%)95M+2ZNHX25EFB2L:E:UR < "M6TU^S/4KV?M5*\437=W:VLDP#10RO\
MJ,#2F"5S4T(4-3[<= [4_&'M^#N*7HY,%2U6]TC^]C,.12.BEHBH?^(1U4WB
M#4FBYN4$H(:,Q"53&!(G/6W/MO[U,A$%=)JIUA^&@J*]WYT\ZTST&GY#W)=R
M.U!%,U-50P\,Q_QAC3M_*M<4KCH"*^CEQU=6X^=HVFH:NIHYFB)92U*Y1BI(
M4E25-KJ#;Z@>Q9#*)D5QP8!A7C0BO02GB-N[1FE58J:<*@TZB>W.FNE!M3:V
M>WON/#[2VOCWRFX,]6Q8_%8])8X#+++>RZY72-!8$EF<  $D^T>X7\.UPO<3
MMICC4L[4)H!\@"3^72W;MOFW6=+:W75)(VE%J!4_:2 /S/0O8CX_Y>JW'VIM
M3/[RV1M'-=48W(5F4ASN7\"5T^-$GDH\>^@?<5&J,J %L218D$$ARYYOCC@M
M;B&&>9+ME"E$J45J49Q7 ST);7DR26>ZMYIX(7M%)8.V'(!JJ&@J<=2>C_CS
MENY\;O?<DF[=M[$V=U]14=7N+<^YGD,2-7^4QQHD8NUDAD+L6&GT* S. *<U
M<XQ\LO! (9)YKAB(XHJ5(6E34_,B@IZ\*=6Y4Y,DYG2><S1P0VZ@R2R5H":F
ME!3R!)-<8XUZ!/<N)I<#N'.82BS./W%28C+5^-I\]B"S4M8E%*T:U-,S@,T$
MP77&2.5(/T/L46-PUW"DKHT9=%8QO\:%@#I:GF*T/SZ"U_;+9SR1(ZR*CLHD
M3X7"DC4OR/$?+ID]JNDG7O?NO=>]^Z]U[W[KW0D[BZGWKM/8>SNQL_CX,?MO
M?M17Q;69ZQ)9ZF/'*C25'BC+&*$EP%\C*[&Y":;,22RYAM=PNYK*%BTD 4RX
M(52Q( J:5.,TJ!ZUZ/;WERZVZSAO9E"QSDB+N!9@ #JH*T&<5(/RIU-[4ZN_
MT7U.V*?^^>T=Y?WEVW2;B\NT\C_$%H_NF9?M:O@>.I33=E_Q]M;!OW[^65O!
MFA\*0QTE73KI^)?53Z].\Q<O_P!7VB7QHIO%C$E8FU:*_A;Y]!3[$'0=Z][]
MU[I?=:=9[P[<W;0;)V-C4R>=KTFG6*:JCHHXX:8 S3RRRLJK'$INUKL?HJLQ
M )1OF^6W+MNUU=-IC6@J 6))X  >9_9ZD='&Q;%<\QW"VMJH9V!.2% 4<22?
M(?F?0'I&5]'+CJZMQ\[1M-0U=31S-$2REJ5RC%20I*DJ;74&WU ]F<,HF17'
M!@&%>-"*]%D\1MW:,TJK%33A4&G43VYTUU[W[KW0J=&[@?:W<W5>X$D,2XSL
M#:<]2P.F\#5T*5"D_@/ TBG_  /L@YJM!?[9=0D5U6\H'^FT,5_80#T(.4[L
MV.Z6DH---Q%7_2EP&_:"1UM*>\#NL\.O>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+-\S_D;1?$'XE_([Y1
M9# 3;KI^A.F]_P#:2[7@J?LFR,VT,=/5T]#YRK>!:NHCBB:70WC5B^EM-C[K
MW5:7\H;N/^;W\H,!M#Y4_-ZK^#^!^*/R#Z%P/;71G7'0F(W?!OG'U/8#XO)X
M'^/39D/ATQO]W:BL:=8:^LJ)*J2D9'AC29']U[J\;W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U75\7OY@.*^3OS;_F&_#_#]<9#:\7P"J?C;@<QOK)9V.L;<
M>3[XQVY\K4?;4$4 %#0XNFPM"D<CU<DM3+/.6B@2*/R^Z]U8K[]U[KWOW7NB
MB?%K<'S5S>X_DW3_ "]V-TML_;.$^0V^L7\3Z[J"KK:J?+]8P3NNW<ENL5N8
MRGBW5-3JK5JP0T5,&8>*EC]2K[KW1N_?NO=>]^Z]U[W[KW52/\KGYZ]P?-K?
MO\R[:W:NV^MMOX_X:_S$.^OB3UA-U]A\IBIJ_;?5M::?'UN>;)9C+)59N9!>
MHFI(Z*E=N8Z.(<>_=>ZMN]^Z]T43XM;@^:N;W'\FZ?Y>[&Z6V?MG"?(;?6+^
M)]=U!5UM5/E^L8)W7;N2W6*W,93Q;JFIU5JU8(:*F#,/%2Q^I5]U[HW?OW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ1W+\]>X,-_.ZZ^_EKTN
MV^MI.C-V?R[ZWY;9'=<^'RC;L3<E-OC.;:6B@KES"X=<(:#&P2&%L$]5YVD;
M[P1E8E]U[JV[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW11.L=P?-6L
M^6_R:V_VUL;I;%?"_#X3JJ;XF[YVA5ULF\\K75F'I7WE%N^&?,5-''%2YQZJ
M/&&FP]'>E13,\SD._NO=&[]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW10OG?7&B^+/981Y(Y:U]GT,
M;1\<39S&F16-QZ7A613_ %O;Z'W(OM1%XN_6U<@>,V?E!)3^9'4=^Z\IBV&Y
MH2"?!7'SGBK^T5'6NI[S+ZPSZ][]U[K)%&\TL<,>G7+(D::W6,7<V%V8A5%S
M]20!]20/>F8("3Y9]?\ !U95+D <2:#RX_;U:QO?M3K*M.S]B_-KHK<FV^Q\
M+MC%4>.W[MC(I-,U%$\B0UC&AK8I4C,T=0S0J:Q$F,C)$A?2N/\ M>P7T7C7
M7*]]'+;/*Y:"52!K(!*_J(030@:CH)6@)-*]9!;KO]C)X-KS18R17*1J%GC8
M$Z 2 U8W! J"=(U@-4@9Z&KJ_9^=ZE^8R;=JMVY;LK"=D=7R;DPNZ>PJB;<&
M?HJ;"R5"QT*UU21)$@>1R^F-1(C("B.K7#&^[C%S#RWXZPI;/;77AO%;@1V[
MLX4E]"X)H!3)H:Y((Z$^Q;;+R]S'X+3/<QW-KXB2W!,DZ+&S (';('<:XR*8
M!!Z _P"/VX]L[_R_R^[#[!ZYZ_RT.T=DTV53;]%MB"CHRFU(LP[".)O(8I:M
M*1/.Z.#(URW''L4\WV,^T1[19V=S<(9IBOB-*Q>LIA&2*5"ESI!X=!?E&_@W
M:7>+R\M[=Q#"K>&L2A"(A.>!K0L$&HCCU"ZR[$WUV+@-]]T3=;_&OKJ'SX+:
M+]K;THFQN+HDQI666AQN):+(SU59/]R6=S*OE9XHB[B!$C=WW9K399H-L%SN
M5P:23?20D-*Y:H#O)6,*HTT H: $T&HDM[#O=WO4,^YFVVVVS'#]7."L2!:$
MJD=)"S'5DZA4E14Z: ;]PIMW:WR*^(.[]LX/8-5D>VMG5-%N?.X+;/\ #:*M
M$L&-JH\KCJ5]#TD[F5S!+(&G2"012%BHL%K/QK_9MWMIWN MI,K11R2ZG2C2
MH8W85## U 44L*BG0HO/!L=YVBX@2!FNX7661(]*.-,3B1%K53DZ2:L%-#7I
MAH\GC>R.Y?F51[EV;L:4=?==;OQ&#J:?:].LSM22UTBUM3)()3+D"6L9QH8@
M*/Q[5R0/LNV[,T$TX^HN(G<&5M(J(QI4"E$_HY'2:&X3>MRWA)X8#]/;R(A$
M2ZC_ &AU,36K_P!+'09_%#LO)8'XG?(&>#;NS:YNNZ>BK,>F4V^E:M><L]3.
MZ98%Q]]'$QTQ Z=">D7]GON!L:7?,-@#),OU)(;3)0QZ J_IX[">)XU.>B#V
M]WQ[7EZ_81PM],*KJCJ)-6I_U,]X!-!PH,=/PZMP7RBH?B=VM@]LX3%_>;EJ
MMH=TT6WL!3XN!I-N"7)3RS10*L<<=6M!6A68. *VGC)#61D?[^EY$?=MOEE=
MJ1B6R:21F8"2D8 +&I*^(I(%/[-CPR%G[BBY\7:=QCC1:R&*\$<:JI,=9"2!
MP#>&P%:_VBCC@D-^3>[L%O+N_?F0VKC,3B-KXW+/MS;]'A<;!BZ<T^WQ]J:A
M(Z=51ONYHYI]1]1$H!T@!5EKD7;I=MVN!+AG>5D\20NS,VJ3NH2V>T$+3AC\
M^HCY\W*+<]UG>!52)'\*,(JJNF/MK1?XF!:O&A'V UOQMDVYMKX?=Y=C5W7>
MU-^9_:>]\=/AX=QX&++A' PHADD)"S-24<TOW,L2RJKHCJWI9KQ_SLLU]S'8
MV27$L$<L#!S'(4J*SU \M3 :0:$@D$<!U(/)#0V/+=]>M;Q3R13@H)(P]"!!
M0GSTJ3K(J*@'UZ?-\XC'_(#XZ]2]R-UGMB+M$]L8[8<N%V?2#:T&X*>KK)85
MHFTDM&92L0$C3D0$5#JR(Q14FU7#\H;S=[;]3+]+](TX>8^*UNP0-K^=*G '
M=V@@D5Z6;K;ISCLUIN9MHOJOJEA*1#PEN%,A71\JXR3V]Q! -.C.[/P>/W?N
M'L7JSLC$?&RFH*'KNOJ*3I[KK$G,97!_8+10B>KROV=+##)$U3^A!Y4DD@>)
ME"/J NY73[=#;W]D^Y%FN%!O+A]$4^K6:+'K<D'3Q)H0&# U%!UMMLNXS7&W
MWJ[:%6W)%G;KKEA"A!5I-" 4U< *@E2"*&I=/DUVGDY_B/T%JVUL=/\ 2/A,
MC3Y'Q;;1/X>,::656P_[G^0/(5 D*ZM:DCCV-.1M@C3F*_\ U9_\6=2M9#^I
MJU#]3'>!Y<*= OGK?Y&Y=L3X<'^,H0WZ?]G0*WZ>>PXSQQTM=U]-]>[Q^2WQ
M;VID=MX6DVY7=-1;ESF)QN-BQL>1FP\%74(E3X!%Y1)+'&92P8R1JT9X8D%F
MW\R7FV[)NEPDCF1;SPD=F+&-795.G56E 32E*&A\NC7<^6[/<][VR"2-!&;0
MR.BJ%$A0%@&TTKFA-:U (\^NNR!UON_97=^W.R-Q_%2@BPE'E9^FX^LZ_P"Q
MS&'KL.E0*7&US/14@;[C[:".2.,^I_,@C9?$(?;*;W;KJQGLH]U8N4%X;E=4
M,T;E=3I1WX:B03P&DUK75K>Q9[E:WT%])M2B,-]'].])H70-I1ZJN3I4$+Q.
MH4(I0.-W=A87HWX[_%;=.V^N>MLKOC=&#SGW.9W+M.+)RM1XUJ-JU 0L8,U2
MTU*AF=S*D>M8K"21@=;=LTO-6\[K!/<7*012)1(Y2HUMKT^N%HQT@4)H3P'1
M)N6]Q<I[-M4\%O;//+&U7DB#'0H0OPIEB5&HFH%:<3T:/;V/P/7_ ,\\EM;:
M>U]M8G&;ZZFH]S98TV(CADAJ\=)6QM)0F/0E(*M0IJ0B?O, S>JY(#O)9=WY
M36XN)9':"[:)*N2"C!#1JU+:?PU/:#3H=V<46T\UO!;Q1HL]FLKT0 AU9UJM
M*!=0^*@[B*\>@&Z:[-ZRWI'VU59:KZ:ZE[NK][0X_&[EW1L&"JPAQ6/BAAIJ
M:!:B>&CI*BIEIZLSWJ1)+(RRZ9@JI +.9=COML-HL8O+NR6 LT<4[";Q6)9F
M)569E4,NGMH!VU&2P6Y:WZRW/ZMI#9VEZ9]"RRP PF)0%4#4RJ&8JVKNJ3W4
M. I;?FULS<FW=V[+SV>VAUGA(MT;<D-)NKJN9X\=GI,9X&J*QZ1P@I:A150D
MZ4=7CEC J)]%U&WM=N4-Y;S1137+F*05BN@/$@#:J*&%=2]I]*$'M6N0+[I[
M;-9W$$LL-LGBQFDMJ2$G*Z:L5--)&H>M01WM3!)?<H]19U(HZJ6AJZ6M@*B>
MCJ(*J$LNH:Z=@ZW'Y%P./=)(Q*I4\""#]A%.G(I3"ZNO%2&'V@UZVX/?/+KH
M9U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=4_?SQ_GKV-_+W^!FXNS.C:+%9#Y&=N=C["^-OQSI\R()8$W=VP]4*:K\-6C
M453/C<9096M@AJBM+)-3QK4DP>16]U[HJ^._D);DJNCHJ[<_\S;^8_/\ZJNF
M@WGD?E+C/E3N7'8Z'=V@5#14FR%K)-O1[/CK;0KC3 U2*!13QUT8TZ?=>ZK*
M[+[CWW_-%_X3Y_,G>ORK["[1V]\L/Y<,7RGZ'[MFZ9[#K.L\!O3=G4.*I%:N
MW)C<1#0X[<&%RM#4T<E1CVIHJ UGW;1TL,9BBC]U[JZ/^0-\8MM=(?RZ?B]V
MGA^S_D!OO,?(GXH_%G=>XMN]O=TYKLW!;?DP^VFFAHME8?)SRTFU,7;+R1-2
M4*)"T%-0Q:=%)"%]U[J%_P *2>R^QNG_ .2U\S>Q>I=_[VZN[!V[_LNW]W]]
M==;JK]DYFA_BW:^Q:&K^SRF,GIJVE^ZHJJIIY?'.OD@EEB>\<C*?=>Z!#9'\
MFSN#Y ?&[&=N_)3Y^_-;;_\ ,&[0V7A^P9NS>I/D9NG8FSMA;@R5)%68O;^V
M]AT&0I,#+MK;<AAI94J*3[K)&.HJYIXJFK=E]U[H.OC-_, [[^4?_"?G^8IO
M?MO=]7A_F?\ #7H/Y^_&SN7?VRJ^3;%>N^/C_L7*U-'N:@JJ".@:CR,]-4XJ
ML^ZH4AC3(+.]-X6C,47NO=!O_)Y_EZ_(+Y5]$_R^OYDWRY_F#?-G*]HXG8_5
M^Y-G=$;$[PK]L; J]J=>>>FV]!NNCCC7-[GR^Y:2&GRVX*JKS3+D:JMJJ.KB
MJ\<P@]^Z]U#^"^QNS_Y]^_OD5\X_D-\GODKUY\+-D]]=@=$?"WXP?&;N_+=%
M8:OPNP%IHZC?&YLKMFJH,SF\CE7J5$"3O3R4DJUB1N]!)30K[KW0D='Y+O/^
M63_-5ZW_ )7V_/DYWG\D?A9_,(Z5[7W1\7,[WEO9]_;[Z[W=UK2Y'(9[!1;H
MEI%R%7A)\4@-$U3+(M/,U&L4<4L=;/7>Z]T63^3C\%=B[5_G6?SD5H^[/ECD
MO]E$[/\ AE)L]MP_(W<&?.ZO](6T=YM4KV/]S-(-]"A$(7'')"1J ,YIBC-J
M'NO=(3J;Y8_&_P#FF_*/Y@=O?S"/YJ5!\-OCU\=OD;V'\:OBA\*-K?..A^%M
M3E,;L%:9:OL;=;IG,#N//R9PU,*4++(D%#419.BCEDCB=&]U[HS_ /+Z^:6S
M/C7_ #6]K_RU^H/YA>&_F*_#;Y4].[\[-^-^YLA\@L5\H]U];;QZY7*YO-;%
MR>Z\-59">HP%1MS'5]9CFRU2)HTBIZ6)GDCEEJ_=>Z-G_(M[4[/[,[9_G8T7
M8_8^_>P*/KG^<)\K>ONO:3>^\,ANN+ X# Y)TH<)AHZ^HJ%Q>(HE-H*.F$5/
M".(XU'OW7NJGOY#WP_\ D7_-,_EW=?=P?.#Y[_-F?KO;&].UMD=([$Z:^1^:
MZ_KLC'0YJHJ,CNO?.Y;5.Y-PYV/*5>0Q6-II<L<;08BAI1'2F>65A[KW5D?\
MD/?'R"ZC^87\U3^6#VQ\@>Q_D]U?\%=Z?'S,?'WM+NW-/NO>D.&[^PV5S<^%
MS6;=4?*PT$46.6G)BC6GD6K2G5*.6EI:/W7NMDKW[KW6D+_*U^!W:'S4^:?\
MZ@]A?)CO7J7X7[ _F\_+VNDZ:^.?8U?TKE-[;]K=P9>*IGW/NG"+29X;=V]A
MI,-+2XVDRL:5.1G%34",4<:U7NO=6&_&/*=T?RM_YO\ L#^6[NOY&]S?(OX:
M_/'IGLSM;XH_[,)O*?L[=&Q]Z=2"MR^X]L)N.J@^_J\!-@J:>6G^[J6 8T<2
MWK/NZC(>Z]T7SXL?S&.Q/B=\:_\ A25\L.S]Z[L[:;XI?S/_ ):[4Z5VSV=O
MC*;@H,>9<]3X'9NUJ#[J:J;$X 9W*8V!*.C6*&*-V6%([ZA[KW0_?$W^3WV/
M\L/BSM'Y(?/#Y]_S!<K\POD]U[MGMS*YWIOY09CI3"=<2;[HH<IC,%M#:VWZ
MEML0I@H*F&*8RTM525%4D\U/!3I(![]U[HPG\E#Y7_(K=F[_ )T_R[OF%V-+
MW7\A_P"7%W)@MD0=ZU5&E)6;RV-V=#7UVS<IE_###"^<AH:"2.L<AIG5Z<U,
MM55?<5<_NO=4X_R'_AK\A/YJO\OG87=?SB^>?SC?8VSMU]O];=#[,Z<^2^?Z
M]JZZ)<T:W)[QWGGM55F]R[BARE17X?%Q5-?)C\=AZ&*.&E\M1.Q]U[I9_P J
M?H'Y??/G(_-OX:?*GY\_*JM^)?\ +0^8_<OQAZZR75O9U9UYV#V'7[6S>5I8
MWW_OR*"7-5N'VO1X_&U.,HZ&MI7DJJ^5<@TM'14%.?=>Z.=_*$W=W/\ '/\
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MX8Y4EB@5I7D5A/Y/,3([N6<,<R>WNW':SM*!TB+!]8:LGB CO)(()P 12FG
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M@S! \K*I<JK$"][ G\'W[KW4_P!^Z]UBGG@I8)JFIFBIZ:GBDGJ*B>01(B1
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MHW^V,_1[LVUM[=..BJ8<?N7!XG/T,-:B1S)#F:>.HB698WD195210P61E#7
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M+GPIY[0K@!B22VH@&A)(Q5LADE-@V_F$2UMS');%@$ E@@NPV2544 T D5H
M:D@5!#-\JMG;ERG2']\XX>@NSMO8+<5$Y[<ZLHX]M9"BIZ^2*GBI:BCI99Z2
M>"6HJ8T<+6RE&EC8P*4,_M5R!N4%ONOTQ-_:R21M_BET3+&[*"Q8,P5@0%)%
M4%0"-1KIZ2^X.W37&U?4TL+J-)%_QNU BD16(4*55G5@2P![S0D'3C5T*O>G
M8^&Z3[@Z6VEM;I?K&JH-][;V>FZ\KD=FPR2UE/D,C-2?94;Q>.*"> -+*[F&
M0NTT'D5DC"$/\J;+)S/MM[<7%[<AH))C$BS$!&6,/J8&I(-  *B@5J4)KT(.
M:M\CY8W.RMK>SMBMPD0E=H15U:0II4B@!6I8U!J66HH*=1GZ,ZHZL[3^5'9-
M+L_ [IINIME[>WEL[K[(0)5T%'5[CH*VMF>6E9/&D$4U$33@*P@B9S& \<;*
MX.:MPWZPVNQ::2(W<TD,UPI(D=(Y$0 -6I)#]W\1I7!-6SRKM^P7^Z7RPQRB
MU@CFAMV *1N\;N25I0"L?;_"*TR!0%\GD<'\FOBOVKV9NK8VQ-G]@=39B@_@
MNY]G8?\ N_'54]2].[T51'Y)#+JCGEC16F8"1H755;7Y!-!#+R-O]K8V\\\U
MO=HVN*9_$*L P# T%,J"2 ,!@?*@8GGBY[Y?NKZX@@AN+1QHEA30&7M.DBIK
M4,0 214J0*UJ->^=];<ZR[F^,/7VV.LNKV;LO;/5M%OG)Y#9T%35346Y\@V/
MB2%PJ10LDAK)F<*TDT@B$UXXT5@QM6TS;YMFYWD]S=?XM)=- JS,$#Q1^(21
M4DU&E0,!173DF@HW?>(=BW/;+."VMJW,=LL[-""YCDD\, $4 H=3'B2:5P!5
M)[7HNANN/DK\F=KY5=F[#SNG!-U;N'=NVDW!@\,<G2I-D?\ )7,-)27J*NF\
M;231(([PI)&NI)C"_EW;>MDVR>/QIX_U/JHXI#'/-I<JG<-3-VHU: FO<0>*
ME^WQ[3LN^;G _@P24C-M)+&'@AUH&?M.E5[G7BRBG:",AH/=73N5WINSXZMN
MW#=/97:>[>P<5L[(]N=.G^$'+1Y.5Y!155'$X@CD>EI9UAGBGJ1&R2$/%J$+
M.\K\R1[9;[C].]XDL5NTRVEYW^$5 &I6(J0&8:E(2H(P::@US1RV^Z7&W?4I
M:/%+<+$UW:50RAB3H90:"JH0K!GH0:%:Z2-^Y<?U.-X[ZZJ[!R/Q3VWTM0X"
M3"XC;N+J_P"&;MPU7!'$(<A-(]'%##.9)I6>U3<:H3Y')F\X6L9MP^F@O[-=
MUDO6DUO(RZ[29"35  Y)% *8\FP.W2*;V*P^IGV^\;:H[)8]"1*VF[A<!:.:
MJH4U8\#7*Y.=5'%5"M-4U-.LT-2L$\T*U%.VJ.01,5#H>+H]K@V^A'O*B-]:
MAJ$5 -#Q%1P/SZQ3E3PV*@@T)%1P-#2H^1ZN/[!W/+V'TO\ #_966PFR,?C>
M\LQC-L;@J8-O) ^.@:LQX8X,ZR,?4S@E+@-K9@#:]_>-FSV V;<]WN8WG9K%
M&EC!D)$C:)/[7'>HX^5 .LF-XOSO&V;1;2) JWSI%(1'3PU)2OA9[&/ <<GJ
M-4]@[3H/D]3_ !.AZ,ZM_P!$WGHMH34TVV%.2=ZS&I7?Q#[L-^L2.K:C&964
M&8S"9@ZN)L]Q+L1YA-]=?5T:8$2_I@"4QZ--/04I6@^'3IP6GWJ"+?1R\+&U
M^DQ$08_U"3$)-=?M/H2?BU5-16'W;LO&]=]N=B[(PU1]UB-M;LS&-Q<AE\[+
M3QRDPQ2/<ZYH(V6.0_ET8V'T$Z<K[F^\[=;W4HH\D2,V* M3) ]"<CY$=01S
M5M<>R[C<6L1JD<K*F:T6M0"?,J#0_,'H+O9]T0='+^!.S6W;\E-I5+)KH]FX
M[.;RKETWXH8/M:8W_&FOK:1KV_%N"01&ONUN7[OV25?.9HX5_P!LVMO^,(W4
MF>TFV_O#>XF\H4DF;\ET#_C4BGK8=]X<]9B=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U2;_,$_FL=J="?*KJ'^7M\'_BO-\Q/F[VOL2?M_+;4SF_H
M>J-J[-V7#4U5"NX=P9RIIYHYC)64DZBCB>&01*K&;[BIQ])6^Z]T6')?SC_G
M3\,OD+\?.I_YL'P0Z[Z2Z=^3^_,3U7UQ\I?CIW>>T=O8W<VX&CCH\/GL95T<
M=?3:F9WFJ7GIU6 --315D5-6/![KW59O\[WL?YT4W\[O^42^W_C3U-E:C8/;
M_<_^R;19#N[^%CL'[R#:+Y3^\Y7&SC9PHJE8HX6U5AJ$8RE(2#$/=>ZO)_F/
M_P SKY$?RV/Y9FV?FAVY\;^OJ[O@;TV+LWL/HG%]HSUV%Q\^]*NO@*T.Y:?'
MS25JTT,%-()#CU$NIU,<1_1[KW5W/OW7NJB_Y0_\R_<G\S'KGY/[WW3U7@>I
MI_CQ\L.Q/C534>#W/4;ECRD.PJ'%5?\ &)7J:2D:CDJ6R3*:<>58Q&#YGU&W
MNO=$;IOYSOS;^:/>W<_77\H'X)[&^2'1WQWW?E.MNQ/EGWUW,G5>U<KN;#,/
MNL5MBEAB^ZKX8XI*:>.J6HF::&59I:6DIY:.>L]U[JJC+?,[L7Y9?\*/_P"3
MO@.__C5O3XC_ "?Z&V7\B=D]Z]'[JS%-O&CI*K/[-W=D\7D]N[DH!_#=PX++
M4#B6&IIG98Y%EIV>0Q"63W7NMB[:G\QG)9W^=5V9_+%?IC:=)C-E_$F@^1\7
M>D.;D.7J6JJK;]$<+-CC1",0*<LSB<9 FT2)X.2X]U[I"_S!_P";UN3XZ?)G
MKK^7[\+_ (Q;D^;/SW[,VDO8;]9X[<D6P]L[0VXTQ1<UO'<=1%+#0I/%%421
M0#0%00-4U%,U;C8Z[W7NBVY_^<7\[?@YV3UG2_S>/@9L3H3XQ]LY[%[-HOF!
M\<NY&[=VUM3.9MS'24.\<=-3"OQ](^AGEKC)%$B%?MDK2E2*?W7NK!_YH?\
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MC/\ PI!_\77V?_[W7?7OW7NMOW>__'E[O_\ #7S_ /[B3>_=>ZU2?^$G7?\
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MVW%5RQ01QPFHGFD"!I')]U[K<;]^Z]UJ@?SH,'A/^'PO^$\"_P 'Q>G+]O\
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M;PPE-BMRTT]4$JLI-002T=/5U(,S5-+-B\K++Y,DZ1^Z]U]%'I?_ )D[U/\
M^(TV)_[JZ7W[KW0E^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)1_,*^<O6G\NCXI=B_*OM/!;FW=A-E2
M;>PN#V/LR!*C*YW-[RKH,9A\11>3]N-ZNMJ8P\K B&%9)=$A01M[KW55G<7\
MT;^;%\2>GL5\J/E?_*9V7!\>*"?"U?;NV_CS\LX>W>QME8S<4B0QUU;@9-L8
M[$9DX^HFIH:Q:#,O'&9#42STU'%/40^Z]U9+\U?YDOQ_^$/Q(PGRYWX-S[PV
M]V$VQL+T?UULG%FOW)O?<':%*:S;NW<%CW*O+DLA3K+,RG_,P0SRLK&/0WNO
M=5T[Z_F??S5_C5U+0?*KY>?RGMH[3^,>)I7W+W7C^DOEG2=L=B]?[<>*2>3.
MY;;LVW,7B\O3XB-8SD8J#,&6"-I*F58(:>?Q^Z]T/?\ ,?\ YR_4?P0^(/Q%
M^<&VMOT'=_Q^^4/R%Z.ZUDW?C-P5.$&+V?V[M_<.Y:C>%'3PXO(U.5J<;C<"
MS)BS%325#R&(U$,B:6]U[H..O?YF7\QF'J?YN?([Y,_RMS\9.@_CQ\3.[?E%
MT=E=Y_(_$YS<.\'ZTQ]?F<5MO+X7"8[++MNKR6*H9)*^:HJEEQLOCC@HLDDS
M2T_NO=6=_!CY)U7S&^'GQN^4];M"#8%5W[U%L[M&?95+FFW)'BVW72I4_9)7
MO2T35@@UZ?*:2'7;5XTO8>Z]U7GTA_-ZR_;_ ,4OYN'R5FZ&QN!J?Y87;7S2
MZPQNSXNQ9<BF\U^).VY,_%6SUQPL+8$YUD$#1+25_P!F#Y!)4_H]^Z]T4[J3
M^<__ #'?F/\ '?"?*CX)?RJL+VKTG1]68G<>Z=U=F?)^BZUGS>Z\;2SOO#;.
MP<7-A&R&<HMHY2DJL2V5K(<>F4KXY5H*9HHA)-[KW2C^/W\\'Y+_ ,Q;J/:W
M8_\ *X_E[5?=ZX7!4Z?(;</?'>..Z+VSM7=_A2:?K["Y&>AJ*_=N=AI:BBR#
MUM/C:?%Q8^JI#/41UE0:2#W7NK!/Y57\R.+^9!TYVAN'<_3>=^/'?/QU[LWE
M\<_D=TCF\W'NH8'=FQ#&*V&CRT,%-%D*1C(4U>%'BGBGA8.J1SS>Z]U:%[]U
M[K7L_E$;CF^;/S-_F;_S+MU196OQ^/[YRG\O?XG#-T=.T&(ZY^."T55FJK;U
M0D(=Z+>VZZ_^(U[I4S(U71K3>0FB"1^Z]T4?)['PG\V?_A1!WUU/\BL72[X^
M(G\H[J;KFHV%T7N0QY+"9_LCN&DQN2;<F9Q3P1Q5T-&DN0I13U3U<!_A=#(H
M2.LK*=_=>ZV>>Q>D.GNW>L\YTQV;UCL;?'5&Y,%6[:S/7NXMM4N0Q,U#D(GA
MEIQ1M%XHE\;L%:-4>,V:-E8 CW7NB ?RO_Y:M;_+N^..^/BINKO&7Y,]*GN?
M?&^>B=J[YZ]BQ_\ <G:VXZE*BAVBT]5E,Q_'5HJE):PU;PT@^ZJ:CQ4T::+>
MZ]U57_PI1ZVZZP.TOY3QP>P=E84Y3^;Y\5,5DSB=K4..^XI:FFS_ )*:?PP)
MYJ>2PU1O=&L+@V]^Z]ULU8KJ[K+!9"FRV#ZZV)ALK1,ST>3Q6T<?CJB)G4HQ
MBFAITDC)1F4E6%P2/H3[]U[K4!VM\H?BS_+,_GJ_S&NPOYJ6T,GUSN7Y4Y_J
M/)?!WY=;[V+7]B;>_N;@<?!05NWL3D*'%U[[<%'42X1,A.@$,34H&2DHXX:>
M>M]U[JT?YQ?%KX$?SZND=MM\8?ES\?J7Y!]+]E[/[$Z>^6W1L^$[KW/LG);7
MJJ*KJZ2:EQ.X<+D_MZ^B6GUT=5E8(HJE<=DC!)-0TH]^Z]T6#_A7%!7TW\EW
M.4V5KH\IE*?O?X_P9+)PT8QR5$\4]6LTZ4XDE$"S2!G$8E?0#IU-:Y]U[K9!
MGZ0Z6JH)J:IZAZOJ*:HBD@J*>?8&)F21)@5='1J0JR,I(((((-CQ[]U[K5VW
M+UCM/^4G_P *&/B%C/C+0XKK+XO?S:NO^T]D]R= ;<A7![>H-[]24KUE%N7#
M8^.9:&AGK*JNP<"T\-)$D?W&5\6LUB14_NO=6%_S.T_V8CYY_P HOX*PTF7R
M6W*GY![R^?'=L6.RXQE)#MWX986:;;<.8B2J@GKZ'*[]S^!6.E$,\,D]*LLZ
M!(-:^Z]U;)O_ *CZHJMK;UR%5UCU[4U]3@-R5E16S[+QLTTDTU/,[RO(U,7:
M1G)8L6+%C<F_OW7NM>K_ (2H=:=<;D_DP]#Y;<77^R<]E:CLGY )/D\UM2@R
ME0X@W=E$0/-/!)(P1%"J"QL  .![]U[I/_\ "F'/;(ZIHOY-.ZMQ9# ;$ZZZ
MZ_FP_'+<NX<O5F+"8S$8?:HJ*NMJYB D%+14-'!++(U@D<:,> /?NO=6J_\
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MJ6HJ-31C^#T8"D 4\0](]U[HIWQDZ>_F4;.^<?R_['^2OR+ZO[&^$F^OMO\
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MUNF<U!DGRDPJMN4[=@]H1F.WVU R[BSF I)$BDDDE-$/.(6B$;>Z]U=-O?\
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M44I4'\[<VQ<H69G:AE:JPQ_QO3B?Z*UJQ]*#B1T,>2>49><+P0+58EHT\@_
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M[KW5;?<O\Y?Y4]8]>4?47_"@G^1QF:;XX9^KV@.Q>Y.M*.B[OZ^BR6+S>/\
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MM'2X*HPM!N"NW-C8*:G6&LPKUN*@:/&RG&UL=%/04\=5[KW18.Q?Y7/\Q?\
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J]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tonconetix_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tonconetix_logo.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NDOO7>^S^M]J9W?._\
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M J?\Y1%4X /5+D\$]+/-35,,M/4T\LD%13SQO#/!/"YCEAFBD"R12Q2*596
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M=@9&H8N\SN4I\/EI6)8E*6I:_BE,K<G<WEBFT;JV<+'(?/R",?7T/Y'KG/\
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M-$QWEM3'0KY%ZYR-1,_WU)&NG 36DC'\/D9<?#_.7*7T9;=ML3](YD0?@/\
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MF>*SA:NDLJ@R324XQQ:EU $%F9%! )9=Q7;^Y_BU\'\.W4?Q0Z3V?C)<*O\
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M9AC=S8*5WJ<=4$QN(Y5,E)5!&>GFFC&OW"^[;-N.R7/TNXQE#Y'BK#U5O/\
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MGCR'7'W[T7O&?<SG5MGV:4MLVTLT<-#VSS#MFN<$@@GLB/\ OL:J NPZNO\
M8RZQAZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7ND/V=OS&]6=;=A=G9FDKLAA^N=C[LWYEJ#&+
M3MDJW&[0P-?N"NI,>M7/34K5U32X]TB$DD<9D8:F47(565J]]>0V41 :9U0$
M\ 78*":5QGK8%33JG?\ X?=^-O\ SZ7O#_SBV%_]FWN0O]:[>O\ ?\'[9/\
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M "7['_GHA_ZN+U9/C'VCK0K]Y4=+NO>_=>ZV,/Y G_<V7_E"/_FR^X?]U_\
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M6[MY4..KI-[8BGDK:"DW%E\E3T=6].YC,D:JY0E;V-O<@^WU]>W=[<+=3/*
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M/'MJ&&6XE6"!2[N0J@9))- !UH9P.M,_Y3_S'/D'W1W7NW>76W;G;/5/7:U
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M_9)'Q:_\5SZ1_P#?9[8]XK\P_P#)?OO^>B;_ *N-TA?XS]IZ&S=G_'J[F_\
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MV'_!THL_]S(O].O_ !X=?*']XM=?0OU[W[KW6R[_ ,)E?^RD?D;_ .(0Q/\
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M.[$DW/NL4<<,:PQ *J   8  %  /D.O=-ON_7NKPOY.GPJ_TI;[_ -F:[%Q
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M0LWI!]E6^RK#LMW*QIIAE.?](U.JL:*3UOW>\5.D/2#[3_YECV/_ .&'N_\
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MXO5D^,?:.M"OWE1TNZ][]U[K8P_D"?\ <V7_ )0C_P";+[A_W7_X@?\ -_\
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MU--U#\TNZ\4M)]MB-X[A/9^ =05@J:#L)/[PY!J9"S&."BW-4U]&%%E5J8A
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MO>_=>ZWK/@;D*3)?#+XRU%%,L\,?3>R<>[I]%J\3B(,77PG_ &JGKJ.2-O\
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MH,,>Y=N9BJFS&X=LT+3OXI,Y@LU4U-<D",)*FCJW:..U),YA7W)Y?FCNAO\
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MG^)3Y'^1X$$=590PH>M@7KC^?%U-5X>$=N]*=B;?S\<2)4/UQ6;:W?AZR95
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MK H_9))_GZ2S_'^75RV[/^/5W-_X;^9_]UU3[C&3^S;[#_@ZO9_[F1?Z=?\
MCPZ^4/[Q:Z^A?KWOW7NMEW_A,K_V4C\C?_$(8G_WO,-[DGVV_P!SKG_FFO\
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MFYLK(-4>,V_B:_,Y!Q<+=*/'4]34L-1 X7Z^VIKB"V3Q+AUC7U8A1^TD=:)
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M4VB3QRBXN;'W/5O[C\NQ6Z1-XM550>P<0 /XNE0F2G3#_P ,L_-?_E0ZO_\
M0^3_ .M'M[_7*Y;_ .&_[P/^@NM^,G5A7\M#^7;\C/BO\A\IV5VM2[+AVS5]
M9[DVK$^W]T+F:[^*Y3-;6KZ4-2"AIBM.8,1-J?5PVD6YX"7.?.&T;]M*V5CK
MUB17[E % K YJ?4=-RR*RT'5]WN+.F.O>_=>Z][]U[HFGRI^"/Q]^7-")NQ=
MNSXC>U)2BEQ'96TI*;%;QH8HE;[>CK:B6FJJ'<&*B9N*:N@G$:EO"T+,7]B+
M8N:-VY??_$GU1DU,;Y0_.E00?F"/G7JZNR<.J"^XOY(?R9V=55=3U)N/9'<>
M#4.U%2MD(]@[QD(D?3%48O<E0VU8[Q%+2+FSJ?5=$ 4M*NW>YNS7"A=P1[=O
M,T\1/MJO=_QGI\3J>..B8YG^73\WL%)XZWXW=BSMK\=\-28[<4>K0)+^7;^2
MR<6C2?U7TZN+W!'L1Q\Y<L2_#>(/MU+_ ,> ZOXB>O2NV=_*X^=&\ZJEAI^B
M<OMZEJ!$\N2WCG]J;8I:*&5482U5-D\Y%EW*!P&BAI9IU-P4]+68N.>N5[=2
M3=!R/)%=B?L(6G\Z=:,J#SZM'^.7\C+&8ZJHMP_*#L*'< B,<QZZZRFKZ/%3
ML/7X,YO?(TM!EZB!E.B6"@HZ-U87CK"/J!]X]SY9%,.R0Z/^&24)_)!4#\R?
MLZ::<_AZOHV'U_LGJ[:F)V-UWM;";-VC@H#!BL!M^@AQ^.I5=VEGE\4*@SU=
M7.[2SSR%YIYF:21F=F8Q9=75S>SM<W;M)(W%F-2?]7EZ=,DDFIZ6'M/UKKWO
MW7NH62QN.S./KL3EZ"BRN*R=)44&2QF2I8*['Y"@JXG@JZ*NHJJ.6FJZ2J@D
M9)(Y%9'1B""#[LCO&X>,E64U!!H01P(/7NJ//E!_),ZUW_79'=GQPW3!U)G:
MLR5$FP]P05N6ZZJJMV+$8NOIC4;AV?"[N69$BRE.M@D,$*<"3-C]RKZS06^\
M)]0@_&"!(!\ZX;_C)]2>GEF(PV>J?NP?Y5GSCZ^J:A&Z:J=Z8Z%M,69Z^S^
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M:F5Q^$W$E&J!HY,QM/<M=CY8*MVNOBQ]3DUX!UB]A-&V>XVP7D8%X6MI*9#
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MB,+1Q45*)IWO+5UDR1>2>>0F6>=WD<EV8G(JVMX;2W2UMQI2,!5'H *=</\
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M<+22U^6S69RE3'28_'8^C@5I9ZFJJ)555 ^IYL.?;D44L\JPPJ6=R  ,DD\
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M];N'\MC^=WU%\KJ?;_4W?]3@>F_D1+'2XVCGJJE<;UQVEDB8J:)]IY/(3LF
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..OW7NO>_=>Z][]U[K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex23-3_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-3_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  P &D# 2(  A$! Q$!_\0
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M&4ZM?:'X=LKW563"K&VH7%RT<:1Q1E8XXU7:^+O_  5D_P""4/QZ\(7'P_\
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:PBS/^TY9:W@G?-_KSP?L7I@7AE4_>\Y__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>onco-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Apr 26 21:03:50 UTC 2024 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2023" targetNamespace="http://www.bluewatervaccines.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:onco="http://www.bluewatervaccines.com/20231231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="onco-20231231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="onco-20231231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="onco-20231231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="onco-20231231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet" id="onco_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals" id="onco_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement" id="onco_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatementAlt0" id="onco_r_ConsolidatedIncomeStatementAlt0">
        <link:definition>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss Alternate 0</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement_Parentheticals" id="onco_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3" id="onco_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Consolidated Statements of Convertible Redeemable Preferred Stock and Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3_Parentheticals" id="onco_r_ShareholdersEquityType2or3_Parentheticals">
        <link:definition>006 - Statement - Consolidated Statements of Convertible Redeemable Preferred Stock and Stockholders&#8217; Equity (Deficit) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ConsolidatedCashFlow" id="onco_r_ConsolidatedCashFlow">
        <link:definition>007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ConsolidatedCashFlow_Parentheticals" id="onco_r_ConsolidatedCashFlow_Parentheticals">
        <link:definition>008 - Statement - Consolidated Statements of Cash Flows (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentation" id="onco_r_OrganizationandBasisofPresentation">
        <link:definition>009 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlans" id="onco_r_GoingConcernandManagementsPlans">
        <link:definition>010 - Disclosure - Going Concern and Management&#8217;s Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPolicies" id="onco_r_SummaryofSignificantAccountingPolicies">
        <link:definition>011 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/BalanceSheetDetails" id="onco_r_BalanceSheetDetails">
        <link:definition>012 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/Acquisitions" id="onco_r_Acquisitions">
        <link:definition>013 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/SignificantAgreements" id="onco_r_SignificantAgreements">
        <link:definition>014 - Disclosure - Significant Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/NotesPayable" id="onco_r_NotesPayable">
        <link:definition>015 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/SubscriptionAgreement" id="onco_r_SubscriptionAgreement">
        <link:definition>016 - Disclosure - Subscription Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquity" id="onco_r_ConvertibleRedeemablePreferredStockandStockholdersEquity">
        <link:definition>017 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/CommitmentsandContingencies" id="onco_r_CommitmentsandContingencies">
        <link:definition>018 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/RelatedPartyTransactions" id="onco_r_RelatedPartyTransactions">
        <link:definition>019 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/IncomeTaxes" id="onco_r_IncomeTaxes">
        <link:definition>020 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/RetirementPlans" id="onco_r_RetirementPlans">
        <link:definition>021 - Disclosure - Retirement Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/SubsequentEvents" id="onco_r_SubsequentEvents">
        <link:definition>022 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy" id="onco_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables" id="onco_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables" id="onco_r_BalanceSheetDetailsTables">
        <link:definition>996002 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/AcquisitionsTables" id="onco_r_AcquisitionsTables">
        <link:definition>996003 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/SubscriptionAgreementTables" id="onco_r_SubscriptionAgreementTables">
        <link:definition>996004 - Disclosure - Subscription Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables" id="onco_r_ConvertibleRedeemablePreferredStockandStockholdersEquityTables">
        <link:definition>996005 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/IncomeTaxesTables" id="onco_r_IncomeTaxesTables">
        <link:definition>996006 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/RetirementPlansTables" id="onco_r_RetirementPlansTables">
        <link:definition>996007 - Disclosure - Retirement Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails" id="onco_r_OrganizationandBasisofPresentationDetails">
        <link:definition>996008 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlansDetails" id="onco_r_GoingConcernandManagementsPlansDetails">
        <link:definition>996009 - Disclosure - Going Concern and Management&#8217;s Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails" id="onco_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996010 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofRevenuebyGeographicalAreaTable" id="onco_r_ScheduleofRevenuebyGeographicalAreaTable">
        <link:definition>996011 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Geographical Area</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofLonglivedbyGeographicalAreaTable" id="onco_r_ScheduleofLonglivedbyGeographicalAreaTable">
        <link:definition>996012 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Long-lived by Geographical Area</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable" id="onco_r_ScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable">
        <link:definition>996013 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Fair Value of Financial Instruments Measured on a Recurring Basis</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofActivityfortheSubscriptionAgreementLiabilityTable" id="onco_r_ScheduleofActivityfortheSubscriptionAgreementLiabilityTable">
        <link:definition>996014 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Activity for the Subscription Agreement Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofActivityfortheContingentWarrantLiabilityTable" id="onco_r_ScheduleofActivityfortheContingentWarrantLiabilityTable">
        <link:definition>996015 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Activity for the Contingent Warrant Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofComputationofDilutedSharesOutstandingTable" id="onco_r_ScheduleofComputationofDilutedSharesOutstandingTable">
        <link:definition>996016 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Computation of Diluted Shares Outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails" id="onco_r_BalanceSheetDetailsDetails">
        <link:definition>996017 - Disclosure - Balance Sheet Details (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofInventoriesTable" id="onco_r_ScheduleofInventoriesTable">
        <link:definition>996018 - Disclosure - Balance Sheet Details (Details) - Schedule of Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" id="onco_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable">
        <link:definition>996019 - Disclosure - Balance Sheet Details (Details) - Schedule of Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable" id="onco_r_ScheduleofIntangibleAssetsTable">
        <link:definition>996020 - Disclosure - Balance Sheet Details (Details) - Schedule of Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable" id="onco_r_ScheduleofAnnualAmortizationExpenseTable">
        <link:definition>996021 - Disclosure - Balance Sheet Details (Details) - Schedule of Annual Amortization Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofGoodwillTable" id="onco_r_ScheduleofGoodwillTable">
        <link:definition>996022 - Disclosure - Balance Sheet Details (Details) - Schedule of Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable" id="onco_r_ScheduleofAccruedExpensesTable">
        <link:definition>996023 - Disclosure - Balance Sheet Details (Details) - Schedule of Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/AcquisitionsDetails" id="onco_r_AcquisitionsDetails">
        <link:definition>996024 - Disclosure - Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable" id="onco_r_ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable">
        <link:definition>996025 - Disclosure - Acquisitions (Details) - Schedule of Aggregate Consideration Transferred for the Assets Acquired</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofAssetsAcquiredTable" id="onco_r_ScheduleofAssetsAcquiredTable">
        <link:definition>996026 - Disclosure - Acquisitions (Details) - Schedule of Assets Acquired</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofFairValueoftheProteomedixStockOptionsTable" id="onco_r_ScheduleofFairValueoftheProteomedixStockOptionsTable">
        <link:definition>996027 - Disclosure - Acquisitions (Details) - Schedule of Fair Value of the Proteomedix Stock Options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable" id="onco_r_ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable">
        <link:definition>996028 - Disclosure - Acquisitions (Details) - Schedule of Estimated Fair Values of Assets Acquired and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofConsolidatedStatementsofOperationsandComprehensiveLossTable" id="onco_r_ScheduleofConsolidatedStatementsofOperationsandComprehensiveLossTable">
        <link:definition>996029 - Disclosure - Acquisitions (Details) - Schedule of Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/SignificantAgreementsDetails" id="onco_r_SignificantAgreementsDetails">
        <link:definition>996030 - Disclosure - Significant Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/NotesPayableDetails" id="onco_r_NotesPayableDetails">
        <link:definition>996031 - Disclosure - Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/SubscriptionAgreementDetails" id="onco_r_SubscriptionAgreementDetails">
        <link:definition>996032 - Disclosure - Subscription Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable" id="onco_r_ScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable">
        <link:definition>996033 - Disclosure - Subscription Agreement (Details) - Schedule of Assumptions Used in Monte-Carlo Model, Which Utilizes Level 3 Inputs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1" id="onco_r_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1">
        <link:definition>996034 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 1</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2" id="onco_r_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2">
        <link:definition>996035 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3" id="onco_r_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3">
        <link:definition>996036 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4" id="onco_r_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4">
        <link:definition>996037 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofFairValueofthePreferredInvestmentOptionsTable" id="onco_r_ScheduleofFairValueofthePreferredInvestmentOptionsTable">
        <link:definition>996038 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Fair Value of the Preferred Investment Options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofValuationoftheContingentWarrantLiabilityTable" id="onco_r_ScheduleofValuationoftheContingentWarrantLiabilityTable">
        <link:definition>996039 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Valuation of the Contingent Warrant Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable" id="onco_r_ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable">
        <link:definition>996040 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Outstanding Warrants, Excluding Contingent Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable" id="onco_r_ScheduleofStockOptionsTable">
        <link:definition>996041 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Stock Options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb4i4f4wUs/dKlMHRtjt5HiP056YCLyrdSoyPYyQevay5dOg9LR2t/KvbZBYGbO0fRFqRMXruICW071VL4cva1Vo1fRqEHdR31R1aena1W/oLM7lTmOCBLWaZ9ZWyZBU9clRPWAm3ygSKlPhipMHX/wTZ1GpdAQuF5X0Rk/U0peMoZ1GlWBL0QwQ4YYjsaQQj5y1OiFHDkpk+TSIy2jKBgVC6BuLNzQw2d0OQvqtBvmxiw3I1GgCSekvILJhH3efW/5wfZQkZmDSB4bPCthxZV1] CSR-->
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofFairValueofOptionsGrantedTable" id="onco_r_ScheduleofFairValueofOptionsGrantedTable">
        <link:definition>996042 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Fair Value of Options Granted</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofUnvestedRestrictedStockTable" id="onco_r_ScheduleofUnvestedRestrictedStockTable">
        <link:definition>996043 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Unvested Restricted Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofStockBasedCompensationExpenseTable" id="onco_r_ScheduleofStockBasedCompensationExpenseTable">
        <link:definition>996044 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Stock-Based Compensation Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails" id="onco_r_CommitmentsandContingenciesDetails">
        <link:definition>996045 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails" id="onco_r_RelatedPartyTransactionsDetails">
        <link:definition>996046 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/IncomeTaxesDetails" id="onco_r_IncomeTaxesDetails">
        <link:definition>996047 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofLossBeforeIncomeTaxTable" id="onco_r_ScheduleofLossBeforeIncomeTaxTable">
        <link:definition>996048 - Disclosure - Income Taxes (Details) - Schedule of Loss Before Income Tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable" id="onco_r_ScheduleofDeferredTaxAssetsandLiabilitiesTable">
        <link:definition>996049 - Disclosure - Income Taxes (Details) - Schedule of Deferred Tax Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable" id="onco_r_ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable">
        <link:definition>996050 - Disclosure - Income Taxes (Details) - Schedule of Income Taxes Differs from the Statutory Federal Rate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofUnrecognizedTaxBenefitsTable" id="onco_r_ScheduleofUnrecognizedTaxBenefitsTable">
        <link:definition>996051 - Disclosure - Income Taxes (Details) - Schedule of Unrecognized Tax Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/RetirementPlansDetails" id="onco_r_RetirementPlansDetails">
        <link:definition>996052 - Disclosure - Retirement Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable" id="onco_r_ScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable">
        <link:definition>996053 - Disclosure - Retirement Plans (Details) - Schedule of Benefit Obligation and the Net Periodic Benefit Cost</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofComponentsofNetPeriodicBenefitCostTable" id="onco_r_ScheduleofComponentsofNetPeriodicBenefitCostTable">
        <link:definition>996054 - Disclosure - Retirement Plans (Details) - Schedule of Components of Net Periodic Benefit Cost</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofAccumulatedComprehensiveLossTable" id="onco_r_ScheduleofAccumulatedComprehensiveLossTable">
        <link:definition>996055 - Disclosure - Retirement Plans (Details) - Schedule of Accumulated Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofAccompanyingConsolidatedBalanceSheetTable" id="onco_r_ScheduleofAccompanyingConsolidatedBalanceSheetTable">
        <link:definition>996056 - Disclosure - Retirement Plans (Details) - Schedule of Accompanying Consolidated Balance Sheet</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable" id="onco_r_ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable">
        <link:definition>996057 - Disclosure - Retirement Plans (Details) - Schedule of the Beginning and Ending Balances of the Accumulated Benefit Obligation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable" id="onco_r_ScheduleofBenefitPaymentsTable">
        <link:definition>996058 - Disclosure - Retirement Plans (Details) - Schedule of Benefit Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/SubsequentEventsDetails" id="onco_r_SubsequentEventsDetails">
        <link:definition>996059 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <xs:element name="ScheduleOfRevenueByGeographicalAreaAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfRevenueByGeographicalAreaAbstract"/>
  <xs:element name="ScheduleOfLongLivedByGeographicalAreaAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfLongLivedByGeographicalAreaAbstract"/>
  <xs:element name="ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract"/>
  <xs:element name="ScheduleOfActivityForTheSubscriptionAgreementLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfActivityForTheSubscriptionAgreementLiabilityAbstract"/>
  <xs:element name="ScheduleOfActivityForTheContingentWarrantLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfActivityForTheContingentWarrantLiabilityAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfIntangibleAssetsAbstract"/>
  <xs:element name="ScheduleOfGoodwillAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfGoodwillAbstract"/>
  <xs:element name="ScheduleOfAggregateConsiderationTransferredForTheAssetsAcquiredAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfAggregateConsiderationTransferredForTheAssetsAcquiredAbstract"/>
  <xs:element name="ScheduleOfAssetsAcquiredAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfAssetsAcquiredAbstract"/>
  <xs:element name="ScheduleOfFairValueOfTheProteomedixStockOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfFairValueOfTheProteomedixStockOptionsAbstract"/>
  <xs:element name="ScheduleOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract"/>
  <xs:element name="SignificantAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_SignificantAgreementsAbstract"/>
  <xs:element name="SubscriptionAgreementDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_SubscriptionAgreementDisclosureAbstract"/>
  <xs:element name="ScheduleOfAssumptionsUsedInMonteCarloModelWhichUtilizesLevel3InputsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfAssumptionsUsedInMonteCarloModelWhichUtilizesLevel3InputsAbstract"/>
  <xs:element name="ScheduleOfFairValueOfThePreferredInvestmentOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfFairValueOfThePreferredInvestmentOptionsAbstract"/>
  <xs:element name="ScheduleOfValuationOfTheContingentWarrantLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfValuationOfTheContingentWarrantLiabilityAbstract"/>
  <xs:element name="ScheduleOfOutstandingWarrantsExcludingContingentWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfOutstandingWarrantsExcludingContingentWarrantsAbstract"/>
  <xs:element name="ScheduleOfStockOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfStockOptionsAbstract"/>
  <xs:element name="ScheduleOfFairValueOfOptionsGrantedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfFairValueOfOptionsGrantedAbstract"/>
  <xs:element name="ScheduleOfUnvestedRestrictedStockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfUnvestedRestrictedStockAbstract"/>
  <xs:element name="ScheduleOfStockBasedCompensationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfStockBasedCompensationExpenseAbstract"/>
  <xs:element name="ScheduleOfBenefitObligationAndTheNetPeriodicBenefitCostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfBenefitObligationAndTheNetPeriodicBenefitCostAbstract"/>
  <xs:element name="ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract"/>
  <xs:element name="ScheduleOfAccumulatedComprehensiveLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfAccumulatedComprehensiveLossAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_UnlabeledAbstract9"/>
  <xs:element name="LiabilitiesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_LiabilitiesAbstract0"/>
  <xs:element name="CostBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_CostBasisAbstract"/>
  <xs:element name="AccumulatedAmortizationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_AccumulatedAmortizationAbstract"/>
  <xs:element name="SubscriptionAgreementLiabilityNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_SubscriptionAgreementLiabilityNoncurrent"/>
  <xs:element name="NotesPayableNetOfDebtDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_NotesPayableNetOfDebtDiscount"/>
  <xs:element name="ChangeInFairValueOfSubscriptionAgreementLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_ChangeInFairValueOfSubscriptionAgreementLiability"/>
  <xs:element name="ChangeInPensionBenefitObligation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_ChangeInPensionBenefitObligation"/>
  <xs:element name="StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants"/>
  <xs:element name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants"/>
  <xs:element name="StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement"/>
  <xs:element name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet"/>
  <xs:element name="ExerciseOfPrefundedWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_ExerciseOfPrefundedWarrants"/>
  <xs:element name="ExerciseOfPrefundedWarrantsinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ExerciseOfPrefundedWarrantsinShares"/>
  <xs:element name="PurchaseOfTreasuryShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_PurchaseOfTreasuryShares"/>
  <xs:element name="PurchaseOfTreasurySharesinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_PurchaseOfTreasurySharesinShares"/>
  <xs:element name="IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions"/>
  <xs:element name="StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares"/>
  <xs:element name="StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock"/>
  <xs:element name="StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares"/>
  <xs:element name="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction"/>
  <xs:element name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction"/>
  <xs:element name="StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction"/>
  <xs:element name="StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction"/>
  <xs:element name="OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax"/>
  <xs:element name="StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation"/>
  <xs:element name="IssuanceOfCommonStockInInitialPublicOfferingNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_IssuanceOfCommonStockInInitialPublicOfferingNet"/>
  <xs:element name="IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet"/>
  <xs:element name="IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet"/>
  <xs:element name="GainLossOnRelatedPartyReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_GainLossOnRelatedPartyReceivable"/>
  <xs:element name="ReceivableFromRelatedParties1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_ReceivableFromRelatedParties1"/>
  <xs:element name="PaymentsForPurchaseOfTreasuryShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_PaymentsForPurchaseOfTreasuryShares"/>
  <xs:element name="EffectOfBusinessCombination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_EffectOfBusinessCombination"/>
  <xs:element name="RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement"/>
  <xs:element name="WarrantsIssuedForSettlementOfContingentWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_WarrantsIssuedForSettlementOfContingentWarrants"/>
  <xs:element name="DeferredOfferingCostsPreviouslyPrepaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_DeferredOfferingCostsPreviouslyPrepaid"/>
  <xs:element name="Exerciseofprefundedwarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_Exerciseofprefundedwarrants"/>
  <xs:element name="IssuanceOfRestrictedStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_IssuanceOfRestrictedStock"/>
  <xs:element name="RestrictedStockForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_RestrictedStockForfeitures"/>
  <xs:element name="PaymentOfAccruedBonusThroughRelatedPartyReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_PaymentOfAccruedBonusThroughRelatedPartyReceivable"/>
  <xs:element name="SignificantAgreementsTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_SignificantAgreementsTextBlock"/>
  <xs:element name="SubscriptionAgreementDisclosureTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_SubscriptionAgreementDisclosureTextBlock"/>
  <xs:element name="AcquisitionsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_AcquisitionsPolicyTextBlock"/>
  <xs:element name="TreasuryStockPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_TreasuryStockPolicyPolicyTextBlock"/>
  <xs:element name="ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock"/>
  <xs:element name="ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock"/>
  <xs:element name="ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisLineItems"/>
  <xs:element name="ReclassificationToEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_ReclassificationToEquity"/>
  <xs:element name="PrepaidsResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_PrepaidsResearchAndDevelopment"/>
  <xs:element name="PrepaidProfessionalFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_PrepaidProfessionalFees"/>
  <xs:element name="FiniteLivedIntangibleAssetCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_FiniteLivedIntangibleAssetCost"/>
  <xs:element name="ImpairmentOfIntangibleAssetExcludingGoodwill" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_ImpairmentOfIntangibleAssetExcludingGoodwill"/>
  <xs:element name="FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation"/>
  <xs:element name="AccruedResearchAndDevelopmentCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_AccruedResearchAndDevelopmentCurrent"/>
  <xs:element name="AccruedDeferredOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_AccruedDeferredOfferingCosts"/>
  <xs:element name="AssetAcquisitionConsiderationTransferredInventory" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_AssetAcquisitionConsiderationTransferredInventory"/>
  <xs:element name="AssetAcquisitionConsiderationTransferredENTADFIIntangible" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible"/>
  <xs:element name="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"/>
  <xs:element name="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems"/>
  <xs:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset"/>
  <xs:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships"/>
  <xs:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology"/>
  <xs:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
  <xs:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation"/>
  <xs:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable"/>
  <xs:element name="SubscriptionAgreementDetailsScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_SubscriptionAgreementDetailsScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable"/>
  <xs:element name="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityTable"/>
  <xs:element name="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems"/>
  <xs:element name="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsTable"/>
  <xs:element name="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled"/>
  <xs:element name="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedTable"/>
  <xs:element name="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems"/>
  <xs:element name="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockTable"/>
  <xs:element name="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems"/>
  <xs:element name="LicenseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_LicenseAgreement"/>
  <xs:element name="IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability"/>
  <xs:element name="IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation"/>
  <xs:element name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment"/>
  <xs:element name="RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable"/>
  <xs:element name="RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems"/>
  <xs:element name="AmortizationOfNetGain" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_AmortizationOfNetGain"/>
  <xs:element name="EffectOfSettlement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_EffectOfSettlement"/>
  <xs:element name="DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees"/>
  <xs:element name="DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees"/>
  <xs:element name="OrganizationandBasisofPresentationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_OrganizationandBasisofPresentationDetailsTable"/>
  <xs:element name="InitialPublicOfferingShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="onco_InitialPublicOfferingShares"/>
  <xs:element name="PublicOfPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="onco_PublicOfPerShare"/>
  <xs:element name="GoingConcernandManagementsPlansDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_GoingConcernandManagementsPlansDetailsTable"/>
  <xs:element name="GoingConcernandManagementsPlansDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_GoingConcernandManagementsPlansDetailsLineItems"/>
  <xs:element name="WorkingCapitalDeficit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_WorkingCapitalDeficit"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="BalanceSheetDetailsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_BalanceSheetDetailsDetailsTable"/>
  <xs:element name="BalanceSheetDetailsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_BalanceSheetDetailsDetailsLineItems"/>
  <xs:element name="AcquisitionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_AcquisitionsDetailsTable"/>
  <xs:element name="RoyaltySalesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_RoyaltySalesPercentage"/>
  <xs:element name="SalesPaymentsAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_SalesPaymentsAmount"/>
  <xs:element name="AggregatePurchaseShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_AggregatePurchaseShares"/>
  <xs:element name="BusinessTransactionYeare" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_BusinessTransactionYeare"/>
  <xs:element name="InventoryFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_InventoryFairValue"/>
  <xs:element name="ImpairmentRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ImpairmentRate"/>
  <xs:element name="InitialPaymentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_InitialPaymentAmount"/>
  <xs:element name="Payments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_Payments"/>
  <xs:element name="VotingInterestPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="onco_VotingInterestPercentage"/>
  <xs:element name="NumberOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="onco_NumberOfShares"/>
  <xs:element name="RoyaltyRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_RoyaltyRate"/>
  <xs:element name="WeightedAverageDiscountRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_WeightedAverageDiscountRate"/>
  <xs:element name="WeightedAverageDiscountRateThereafter" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_WeightedAverageDiscountRateThereafter"/>
  <xs:element name="SignificantAgreementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_SignificantAgreementsDetailsTable"/>
  <xs:element name="AggregateAgreementAmountInitialAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_AggregateAgreementAmountInitialAgreement"/>
  <xs:element name="AggregateeAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_AggregateeAmount"/>
  <xs:element name="CostPlusPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_CostPlusPercentage"/>
  <xs:element name="CommercialSaleTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_CommercialSaleTerm"/>
  <xs:element name="RoyaltyNetSalesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_RoyaltyNetSalesPercentage"/>
  <xs:element name="RoyaltyRates" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_RoyaltyRates"/>
  <xs:element name="RevenueRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_RevenueRate"/>
  <xs:element name="AggregateRoyaltiesAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_AggregateRoyaltiesAmount"/>
  <xs:element name="PercentageOfConsiderationReceived" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="onco_PercentageOfConsiderationReceived"/>
  <xs:element name="AmountOfOtherPartyPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_AmountOfOtherPartyPayments"/>
  <xs:element name="RoyaltiesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_RoyaltiesPercentage"/>
  <xs:element name="LicensedProductsPlusMilestonePaymentsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_LicensedProductsPlusMilestonePaymentsDescription"/>
  <xs:element name="NotesPayableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_NotesPayableDetailsTable"/>
  <xs:element name="PayableAverageDiscountRatePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_PayableAverageDiscountRatePercentage"/>
  <xs:element name="DebtInstrumentDueDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_DebtInstrumentDueDate"/>
  <xs:element name="CashPaymentToTheSeller" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_CashPaymentToTheSeller"/>
  <xs:element name="DebtInstrumentDueTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_DebtInstrumentDueTerm"/>
  <xs:element name="SubscriptionAgreementDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_SubscriptionAgreementDetailsTable"/>
  <xs:element name="SubscriptionAgreementDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_SubscriptionAgreementDetailsLineItems"/>
  <xs:element name="SaleOfUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="onco_SaleOfUnits"/>
  <xs:element name="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1Table" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1Table"/>
  <xs:element name="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems"/>
  <xs:element name="SharesOfCommonStockRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_SharesOfCommonStockRate"/>
  <xs:element name="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2Table" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2Table"/>
  <xs:element name="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems"/>
  <xs:element name="PercentageOfIssuedOfCommonStock" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_PercentageOfIssuedOfCommonStock"/>
  <xs:element name="PercentageOfOutstandingOfCommonStock" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_PercentageOfOutstandingOfCommonStock"/>
  <xs:element name="PercentageOfCumulativeDividends" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_PercentageOfCumulativeDividends"/>
  <xs:element name="NettingProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_NettingProceeds"/>
  <xs:element name="PercentageOfOriginalIssuePrice" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_PercentageOfOriginalIssuePrice"/>
  <xs:element name="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table"/>
  <xs:element name="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems"/>
  <xs:element name="PercentageOfUnderwritingDiscount" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_PercentageOfUnderwritingDiscount"/>
  <xs:element name="PlacementAgentFeeAndManagementFeePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="onco_PlacementAgentFeeAndManagementFeePercentage"/>
  <xs:element name="AggregateNumberOfSharesPercenatge" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_AggregateNumberOfSharesPercenatge"/>
  <xs:element name="CancelledPreferredInvestmentOptionsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_CancelledPreferredInvestmentOptionsShares"/>
  <xs:element name="PrefundedWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_PrefundedWarrantsExercised"/>
  <xs:element name="WarrantsIssuableUnderProvisionShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_WarrantsIssuableUnderProvisionShares"/>
  <xs:element name="IncreaseInTheFairValueOfThePreferredInvestmentOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_IncreaseInTheFairValueOfThePreferredInvestmentOptions"/>
  <xs:element name="ContingentWarrantLiabilityShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_ContingentWarrantLiabilityShares"/>
  <xs:element name="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table"/>
  <xs:element name="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems"/>
  <xs:element name="SharesOfCommonStockIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_SharesOfCommonStockIssued"/>
  <xs:element name="FixedCommissionRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_FixedCommissionRate"/>
  <xs:element name="AggregateNetProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_AggregateNetProceeds"/>
  <xs:element name="PercentageOfGrossProceeds" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_PercentageOfGrossProceeds"/>
  <xs:element name="PercentageOfCommonStockShares" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_PercentageOfCommonStockShares"/>
  <xs:element name="ExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ExercisePrice"/>
  <xs:element name="GrantDateFairValueOfStockOption" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_GrantDateFairValueOfStockOption"/>
  <xs:element name="RestrictedSharesGrantedVestPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_RestrictedSharesGrantedVestPercentage"/>
  <xs:element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_CommitmentsandContingenciesDetailsTable"/>
  <xs:element name="PercentageOfSubscription" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_PercentageOfSubscription"/>
  <xs:element name="AggregatePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_AggregatePayments"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="MiscellaneousExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="onco_MiscellaneousExpenses"/>
  <xs:element name="SubscriptionAgreementPMXInvestorPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_SubscriptionAgreementPMXInvestorPercentage"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_IncomeTaxesDetailsTable"/>
  <xs:element name="GrossPayPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_GrossPayPercentage"/>
  <xs:element name="DebtSecuritiesAndCash" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_DebtSecuritiesAndCash"/>
  <xs:element name="EquitySecuritiesRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_EquitySecuritiesRate"/>
  <xs:element name="AlternativeInvestmentsRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_AlternativeInvestmentsRate"/>
  <xs:element name="RealEstateInvestmentsRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_RealEstateInvestmentsRate"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="onco_SubsequentEventsDetailsTable"/>
  <xs:element name="SeverancePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="onco_SeverancePayment"/>
  <xs:element name="AccumulatedBenefitObligationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_AccumulatedBenefitObligationMember"/>
  <xs:element name="AggregateConsiderationTransferredMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_AggregateConsiderationTransferredMember"/>
  <xs:element name="April2022PrivatePlacementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_April2022PrivatePlacementMember"/>
  <xs:element name="AprilContingentWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_AprilContingentWarrantsMember"/>
  <xs:element name="AssetPurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_AssetPurchaseAgreementMember"/>
  <xs:element name="AssetsRecognizedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_AssetsRecognizedMember"/>
  <xs:element name="August2022PrivatePlacementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_August2022PrivatePlacementMember"/>
  <xs:element name="August2024Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_August2024Member"/>
  <xs:element name="August2025Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_August2025Member"/>
  <xs:element name="AugustContingentWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_AugustContingentWarrantsMember"/>
  <xs:element name="AugustWainwrightWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_AugustWainwrightWarrantsMember"/>
  <xs:element name="BankruptcyCourtMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_BankruptcyCourtMember"/>
  <xs:element name="BusinessAcquisitionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_BusinessAcquisitionMember"/>
  <xs:element name="CBOMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_CBOMember"/>
  <xs:element name="CEOMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_CEOMember"/>
  <xs:element name="ChiefBusinessOfficerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ChiefBusinessOfficerMember"/>
  <xs:element name="CincinnatiChildrensHospitalMedicalCenterMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_CincinnatiChildrensHospitalMedicalCenterMember"/>
  <xs:element name="CoDevelopmentAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_CoDevelopmentAgreementMember"/>
  <xs:element name="CommonStockIssuableUponConversionOfSeriesAPreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_CommonStockIssuableUponConversionOfSeriesAPreferredStockMember"/>
  <xs:element name="ContingentWarrantLiabilityMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ContingentWarrantLiabilityMember"/>
  <xs:element name="DevelopmentMilestonesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_DevelopmentMilestonesMember"/>
  <xs:element name="ENTADFIMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ENTADFIMember"/>
  <xs:element name="ExchangedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ExchangedMember"/>
  <xs:element name="FairValueConsiderationTransferredMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_FairValueConsiderationTransferredMember"/>
  <xs:element name="HCWainwrightCoLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_HCWainwrightCoLLCMember"/>
  <xs:element name="InducementPIOSharesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_InducementPIOSharesMember"/>
  <xs:element name="January2024Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_January2024Member"/>
  <xs:element name="LaboratorCorporationOfAmericaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_LaboratorCorporationOfAmericaMember"/>
  <xs:element name="ManagementServicesAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ManagementServicesAgreementMember"/>
  <xs:element name="MarketOfferingAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_MarketOfferingAgreementMember"/>
  <xs:element name="MeasurementInputStockPriceMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_MeasurementInputStockPriceMember"/>
  <xs:element name="MilestonePaymentsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_MilestonePaymentsMember"/>
  <xs:element name="NonConvertibleDebentureMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_NonConvertibleDebentureMember"/>
  <xs:element name="NotePayableMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_NotePayableMember"/>
  <xs:element name="OUIAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_OUIAgreementMember"/>
  <xs:element name="OlogyBioservicesIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_OlogyBioservicesIncMember"/>
  <xs:element name="OnconetixMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_OnconetixMember"/>
  <xs:element name="OriginalMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_OriginalMember"/>
  <xs:element name="OxfordUniversityInnovationLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_OxfordUniversityInnovationLimitedMember"/>
  <xs:element name="PMXOptionPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_PMXOptionPlanMember"/>
  <xs:element name="PMXTransactionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_PMXTransactionMember"/>
  <xs:element name="PharmaceuticalServicesLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_PharmaceuticalServicesLLCMember"/>
  <xs:element name="PlanAssetsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_PlanAssetsMember"/>
  <xs:element name="ProteomedixAcquisitionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ProteomedixAcquisitionMember"/>
  <xs:element name="ProteomedixMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ProteomedixMember"/>
  <xs:element name="RegulatoryMilestonesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_RegulatoryMilestonesMember"/>
  <xs:element name="ResearchAndDevelopmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_ResearchAndDevelopmentMember"/>
  <xs:element name="SeriesAConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_SeriesAConvertiblePreferredStockMember"/>
  <xs:element name="SeriesBConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_SeriesBConvertiblePreferredStockMember"/>
  <xs:element name="SeriesBConvertibleRedeemablePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_SeriesBConvertibleRedeemablePreferredStockMember"/>
  <xs:element name="SeriesSeedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_SeriesSeedMember"/>
  <xs:element name="SeriesSeedPreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_SeriesSeedPreferredStockMember"/>
  <xs:element name="SettlementAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_SettlementAgreementMember"/>
  <xs:element name="StJudeChildrensHospitalMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_StJudeChildrensHospitalMember"/>
  <xs:element name="StockOptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_StockOptionsMember"/>
  <xs:element name="SubscriptionAgreementLiabilityMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_SubscriptionAgreementLiabilityMember"/>
  <xs:element name="SubscriptionAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_SubscriptionAgreementMember"/>
  <xs:element name="TreasuryStocksMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_TreasuryStocksMember"/>
  <xs:element name="TwoThousandNinteenEquityIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_TwoThousandNinteenEquityIncentivePlanMember"/>
  <xs:element name="TwoThousandTwentyTwoEquityIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_TwoThousandTwentyTwoEquityIncentivePlanMember"/>
  <xs:element name="TwoThousandTwentyTwoPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_TwoThousandTwentyTwoPlanMember"/>
  <xs:element name="UTHealthAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_UTHealthAgreementMember"/>
  <xs:element name="UniversityOfTexasHealthScienceCenterAtSanAntonioMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_UniversityOfTexasHealthScienceCenterAtSanAntonioMember"/>
  <xs:element name="UnvestedRestrictedStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_UnvestedRestrictedStockMember"/>
  <xs:element name="VendorAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_VendorAgreementMember"/>
  <xs:element name="WarrantInducementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_WarrantInducementMember"/>
  <xs:element name="WraSerAPAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_WraSerAPAMember"/>
  <xs:element name="WraSerMSAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_WraSerMSAMember"/>
  <xs:element name="GoingConcernAndManagementsPlansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_GoingConcernAndManagementsPlansAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="onco_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>onco-20231231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Apr 26 21:03:50 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConsolidatedBalanceSheet" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConsolidatedIncomeStatement" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConsolidatedCashFlow" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofInventoriesTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofInventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofAnnualAmortizationExpenseTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofAccruedExpensesTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofAssetsAcquiredTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofAssetsAcquiredTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofLossBeforeIncomeTaxTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofLossBeforeIncomeTaxTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofComponentsofNetPeriodicBenefitCostTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofComponentsofNetPeriodicBenefitCostTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofAccompanyingConsolidatedBalanceSheetTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofAccompanyingConsolidatedBalanceSheetTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofBenefitPaymentsTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Cash" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredCosts" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermNotesPayable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="onco_SubscriptionAgreementLiabilityNoncurrent" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="onco_SubscriptionAgreementLiabilityNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockValue" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="3" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OtherAssetImpairmentCharges" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="onco_ChangeInFairValueOfSubscriptionAgreementLiability" xlink:href="onco-20231231.xsd#onco_ChangeInFairValueOfSubscriptionAgreementLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="onco_ChangeInFairValueOfSubscriptionAgreementLiability" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="onco_ChangeInPensionBenefitObligation" xlink:href="onco-20231231.xsd#onco_ChangeInPensionBenefitObligation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="onco_ChangeInPensionBenefitObligation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherAssetImpairmentCharges" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="onco_GainLossOnRelatedPartyReceivable" xlink:href="onco-20231231.xsd#onco_GainLossOnRelatedPartyReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="onco_GainLossOnRelatedPartyReceivable" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryWriteDown" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices" order="12" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_PensionExpense" order="13" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="14" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="15" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="16" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="17" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" order="18" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="19" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="20" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="21" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="22" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="23" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="onco_ReceivableFromRelatedParties1" xlink:href="onco-20231231.xsd#onco_ReceivableFromRelatedParties1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="onco_ReceivableFromRelatedParties1" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb4i4f4wUs/dKlMHRtjt5HiP056YCLyrdSoyPYyQevay5dOg9LR2t/KvbZBYGbO0fRFqRMXruICW071VL4cva1Vo1fRqEHdR31R1aena1W/oLM7lTmOCBLWaZ9ZWyZBU9clRPWAm3ygSKlPhipMHX/wTZ1GpdAQuF5X0Rk/U0peMoZ1GlWBL0QwQ4YYjsaQQj5y1OiFHDkpk+TSIy2jKBgVC6BuLNzQw2d0OQvqtBvmxiw3I1GgCSekvILJhH3efW/m0C53OXe/NO/xcko4Ebdu] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="onco_PaymentsForPurchaseOfTreasuryShares" xlink:href="onco-20231231.xsd#onco_PaymentsForPurchaseOfTreasuryShares"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="onco_PaymentsForPurchaseOfTreasuryShares" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfPrivatePlacement"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfPrivatePlacement" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofInventoriesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterials" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcess" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidRent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidRent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="onco_PrepaidsResearchAndDevelopment" xlink:href="onco-20231231.xsd#onco_PrepaidsResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="onco_PrepaidsResearchAndDevelopment" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="onco_PrepaidProfessionalFees" xlink:href="onco-20231231.xsd#onco_PrepaidProfessionalFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="onco_PrepaidProfessionalFees" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="5" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="onco_AccruedResearchAndDevelopmentCurrent" xlink:href="onco-20231231.xsd#onco_AccruedResearchAndDevelopmentCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="onco_AccruedResearchAndDevelopmentCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedUtilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedUtilitiesCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedUtilitiesCurrentAndNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="onco_AccruedDeferredOfferingCosts" xlink:href="onco-20231231.xsd#onco_AccruedDeferredOfferingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="onco_AccruedDeferredOfferingCosts" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedMarketingCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedMarketingCostsCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" order="7" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofAssetsAcquiredTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <loc xlink:type="locator" xlink:label="onco_AssetAcquisitionConsiderationTransferredInventory" xlink:href="onco-20231231.xsd#onco_AssetAcquisitionConsiderationTransferredInventory"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="onco_AssetAcquisitionConsiderationTransferredInventory" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible" xlink:href="onco-20231231.xsd#onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="2" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" order="3" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" order="4" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" order="5" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation" order="6" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:to="us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofLossBeforeIncomeTaxTable">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability" xlink:href="onco-20231231.xsd#onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" xlink:href="onco-20231231.xsd#onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment" xlink:href="onco-20231231.xsd#onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="12" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofComponentsofNetPeriodicBenefitCostTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="us-gaap_DefinedBenefitPlanServiceCost" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="us-gaap_DefinedBenefitPlanInterestCost" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" order="5" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofAccompanyingConsolidatedBalanceSheetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" order="6" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>onco-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Apr 26 21:03:50 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConsolidatedBalanceSheet" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConsolidatedIncomeStatement" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ShareholdersEquityType2or3" roleURI="http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConsolidatedCashFlow" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConsolidatedCashFlow_Parentheticals" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedCashFlow_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_OrganizationandBasisofPresentation" roleURI="http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentation"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_GoingConcernandManagementsPlans" roleURI="http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlans"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_BalanceSheetDetails" roleURI="http://www.bluewatervaccines.com/role/BalanceSheetDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_Acquisitions" roleURI="http://www.bluewatervaccines.com/role/Acquisitions"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_SignificantAgreements" roleURI="http://www.bluewatervaccines.com/role/SignificantAgreements"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_NotesPayable" roleURI="http://www.bluewatervaccines.com/role/NotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_SubscriptionAgreement" roleURI="http://www.bluewatervaccines.com/role/SubscriptionAgreement"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConvertibleRedeemablePreferredStockandStockholdersEquity" roleURI="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_CommitmentsandContingencies" roleURI="http://www.bluewatervaccines.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_RelatedPartyTransactions" roleURI="http://www.bluewatervaccines.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_IncomeTaxes" roleURI="http://www.bluewatervaccines.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_RetirementPlans" roleURI="http://www.bluewatervaccines.com/role/RetirementPlans"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_SubsequentEvents" roleURI="http://www.bluewatervaccines.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_AccountingPoliciesByPolicy" roleURI="http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_BalanceSheetDetailsTables" roleURI="http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_AcquisitionsTables" roleURI="http://www.bluewatervaccines.com/role/AcquisitionsTables"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_SubscriptionAgreementTables" roleURI="http://www.bluewatervaccines.com/role/SubscriptionAgreementTables"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConvertibleRedeemablePreferredStockandStockholdersEquityTables" roleURI="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_IncomeTaxesTables" roleURI="http://www.bluewatervaccines.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_RetirementPlansTables" roleURI="http://www.bluewatervaccines.com/role/RetirementPlansTables"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofRevenuebyGeographicalAreaTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofRevenuebyGeographicalAreaTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofLonglivedbyGeographicalAreaTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofLonglivedbyGeographicalAreaTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofActivityfortheSubscriptionAgreementLiabilityTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofActivityfortheSubscriptionAgreementLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofActivityfortheContingentWarrantLiabilityTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofActivityfortheContingentWarrantLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofComputationofDilutedSharesOutstandingTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofComputationofDilutedSharesOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofInventoriesTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofInventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofIntangibleAssetsTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofAnnualAmortizationExpenseTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofGoodwillTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofGoodwillTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofAccruedExpensesTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofAssetsAcquiredTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofAssetsAcquiredTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofFairValueoftheProteomedixStockOptionsTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofFairValueoftheProteomedixStockOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofConsolidatedStatementsofOperationsandComprehensiveLossTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofConsolidatedStatementsofOperationsandComprehensiveLossTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofFairValueofthePreferredInvestmentOptionsTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofFairValueofthePreferredInvestmentOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofValuationoftheContingentWarrantLiabilityTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofValuationoftheContingentWarrantLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofStockOptionsTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofFairValueofOptionsGrantedTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofFairValueofOptionsGrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofUnvestedRestrictedStockTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofUnvestedRestrictedStockTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofStockBasedCompensationExpenseTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofStockBasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofLossBeforeIncomeTaxTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofLossBeforeIncomeTaxTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofDeferredTaxAssetsandLiabilitiesTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofUnrecognizedTaxBenefitsTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofUnrecognizedTaxBenefitsTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofComponentsofNetPeriodicBenefitCostTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofComponentsofNetPeriodicBenefitCostTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofAccumulatedComprehensiveLossTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofAccumulatedComprehensiveLossTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofAccompanyingConsolidatedBalanceSheetTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofAccompanyingConsolidatedBalanceSheetTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofBenefitPaymentsTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_OrganizationandBasisofPresentationDetails" roleURI="http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_GoingConcernandManagementsPlansDetails" roleURI="http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlansDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_BalanceSheetDetailsDetails" roleURI="http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_AcquisitionsDetails" roleURI="http://www.bluewatervaccines.com/role/AcquisitionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_SignificantAgreementsDetails" roleURI="http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_NotesPayableDetails" roleURI="http://www.bluewatervaccines.com/role/NotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_SubscriptionAgreementDetails" roleURI="http://www.bluewatervaccines.com/role/SubscriptionAgreementDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1" roleURI="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2" roleURI="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3" roleURI="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4" roleURI="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_CommitmentsandContingenciesDetails" roleURI="http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_RelatedPartyTransactionsDetails" roleURI="http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_IncomeTaxesDetails" roleURI="http://www.bluewatervaccines.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_RetirementPlansDetails" roleURI="http://www.bluewatervaccines.com/role/RetirementPlansDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_SubsequentEventsDetails" roleURI="http://www.bluewatervaccines.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#DocumentAndEntityInformation" roleURI="http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredCosts" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Goodwill" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_SubscriptionAgreementLiabilityNoncurrent" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="onco_SubscriptionAgreementLiabilityNoncurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_SeriesBConvertibleRedeemablePreferredStockMember" xlink:href="onco-20231231.xsd#onco_SeriesBConvertibleRedeemablePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="onco_SeriesBConvertibleRedeemablePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_SeriesAConvertiblePreferredStockMember" xlink:href="onco-20231231.xsd#onco_SeriesAConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="onco_SeriesAConvertiblePreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_NotesPayableNetOfDebtDiscount" xlink:href="onco-20231231.xsd#onco_NotesPayableNetOfDebtDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onco_NotesPayableNetOfDebtDiscount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherAssetImpairmentCharges" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ChangeInFairValueOfSubscriptionAgreementLiability" xlink:href="onco-20231231.xsd#onco_ChangeInFairValueOfSubscriptionAgreementLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="onco_ChangeInFairValueOfSubscriptionAgreementLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossAttributableToParent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ChangeInPensionBenefitObligation" xlink:href="onco-20231231.xsd#onco_ChangeInPensionBenefitObligation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="onco_ChangeInPensionBenefitObligation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_SeriesSeedMember" xlink:href="onco-20231231.xsd#onco_SeriesSeedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="onco_SeriesSeedMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions" xlink:href="onco-20231231.xsd#onco_IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onco_IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="onco_StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="onco_StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="onco_StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="onco_StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax" xlink:href="onco-20231231.xsd#onco_OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="onco_OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="onco_StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onco_StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onco_StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ExerciseOfPrefundedWarrants" xlink:href="onco-20231231.xsd#onco_ExerciseOfPrefundedWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onco_ExerciseOfPrefundedWarrants" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ExerciseOfPrefundedWarrantsinShares" xlink:href="onco-20231231.xsd#onco_ExerciseOfPrefundedWarrantsinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onco_ExerciseOfPrefundedWarrantsinShares" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PurchaseOfTreasuryShares" xlink:href="onco-20231231.xsd#onco_PurchaseOfTreasuryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onco_PurchaseOfTreasuryShares" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PurchaseOfTreasurySharesinShares" xlink:href="onco-20231231.xsd#onco_PurchaseOfTreasurySharesinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onco_PurchaseOfTreasurySharesinShares" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="23" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_IssuanceOfCommonStockInInitialPublicOfferingNet" xlink:href="onco-20231231.xsd#onco_IssuanceOfCommonStockInInitialPublicOfferingNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onco_IssuanceOfCommonStockInInitialPublicOfferingNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet" xlink:href="onco-20231231.xsd#onco_IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onco_IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet" xlink:href="onco-20231231.xsd#onco_IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onco_IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherAssetImpairmentCharges" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_GainLossOnRelatedPartyReceivable" xlink:href="onco-20231231.xsd#onco_GainLossOnRelatedPartyReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="onco_GainLossOnRelatedPartyReceivable" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PensionExpense" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ReceivableFromRelatedParties1" xlink:href="onco-20231231.xsd#onco_ReceivableFromRelatedParties1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="onco_ReceivableFromRelatedParties1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PaymentsForPurchaseOfTreasuryShares" xlink:href="onco-20231231.xsd#onco_PaymentsForPurchaseOfTreasuryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="onco_PaymentsForPurchaseOfTreasuryShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfPrivatePlacement" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_EffectOfBusinessCombination" xlink:href="onco-20231231.xsd#onco_EffectOfBusinessCombination"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="onco_EffectOfBusinessCombination" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement" xlink:href="onco-20231231.xsd#onco_RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="onco_RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_WarrantsIssuedForSettlementOfContingentWarrants" xlink:href="onco-20231231.xsd#onco_WarrantsIssuedForSettlementOfContingentWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="onco_WarrantsIssuedForSettlementOfContingentWarrants" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_DeferredOfferingCostsPreviouslyPrepaid" xlink:href="onco-20231231.xsd#onco_DeferredOfferingCostsPreviouslyPrepaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="onco_DeferredOfferingCostsPreviouslyPrepaid" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_Exerciseofprefundedwarrants" xlink:href="onco-20231231.xsd#onco_Exerciseofprefundedwarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="onco_Exerciseofprefundedwarrants" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_IssuanceOfRestrictedStock" xlink:href="onco-20231231.xsd#onco_IssuanceOfRestrictedStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="onco_IssuanceOfRestrictedStock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_RestrictedStockForfeitures" xlink:href="onco-20231231.xsd#onco_RestrictedStockForfeitures"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="onco_RestrictedStockForfeitures" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PaymentOfAccruedBonusThroughRelatedPartyReceivable" xlink:href="onco-20231231.xsd#onco_PaymentOfAccruedBonusThroughRelatedPartyReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="onco_PaymentOfAccruedBonusThroughRelatedPartyReceivable" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedCashFlow_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentation">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlans">
    <loc xlink:type="locator" xlink:label="onco_GoingConcernAndManagementsPlansAbstract" xlink:href="onco-20231231.xsd#onco_GoingConcernAndManagementsPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_GoingConcernAndManagementsPlansAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/BalanceSheetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/Acquisitions">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SignificantAgreements">
    <loc xlink:type="locator" xlink:label="onco_SignificantAgreementsAbstract" xlink:href="onco-20231231.xsd#onco_SignificantAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="onco_SignificantAgreementsTextBlock" xlink:href="onco-20231231.xsd#onco_SignificantAgreementsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_SignificantAgreementsAbstract" xlink:to="onco_SignificantAgreementsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/NotesPayable">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SubscriptionAgreement">
    <loc xlink:type="locator" xlink:label="onco_SubscriptionAgreementDisclosureAbstract" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="onco_SubscriptionAgreementDisclosureTextBlock" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_SubscriptionAgreementDisclosureAbstract" xlink:to="onco_SubscriptionAgreementDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/RetirementPlans">
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AcquisitionsPolicyTextBlock" xlink:href="onco-20231231.xsd#onco_AcquisitionsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onco_AcquisitionsPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_TreasuryStockPolicyPolicyTextBlock" xlink:href="onco-20231231.xsd#onco_TreasuryStockPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onco_TreasuryStockPolicyPolicyTextBlock" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="25" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/AcquisitionsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_AssetAcquisitionTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SubscriptionAgreementTables">
    <loc xlink:type="locator" xlink:label="onco_SubscriptionAgreementDisclosureAbstract" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_SubscriptionAgreementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock" xlink:href="onco-20231231.xsd#onco_ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="onco_ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock" xlink:href="onco-20231231.xsd#onco_ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="onco_ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/RetirementPlansTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock" xlink:href="onco-20231231.xsd#onco_ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="onco_ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofRevenuebyGeographicalAreaTable">
    <loc xlink:type="locator" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_CH" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CH"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CH" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_Revenues" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofLonglivedbyGeographicalAreaTable">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_CH" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CH"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CH" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_NoncurrentAssets" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable">
    <loc xlink:type="locator" xlink:label="onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisLineItems" xlink:href="onco-20231231.xsd#onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:label="onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable" xlink:href="onco-20231231.xsd#onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisLineItems" xlink:to="onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_SubscriptionAgreementLiabilityNoncurrent" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="onco_SubscriptionAgreementLiabilityNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofActivityfortheSubscriptionAgreementLiabilityTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_SubscriptionAgreementLiabilityMember" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementLiabilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="onco_SubscriptionAgreementLiabilityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofActivityfortheContingentWarrantLiabilityTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ContingentWarrantLiabilityMember" xlink:href="onco-20231231.xsd#onco_ContingentWarrantLiabilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="onco_ContingentWarrantLiabilityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ReclassificationToEquity" xlink:href="onco-20231231.xsd#onco_ReclassificationToEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="onco_ReclassificationToEquity" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofComputationofDilutedSharesOutstandingTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_StockOptionsMember" xlink:href="onco-20231231.xsd#onco_StockOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="onco_StockOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_CommonStockIssuableUponConversionOfSeriesAPreferredStockMember" xlink:href="onco-20231231.xsd#onco_CommonStockIssuableUponConversionOfSeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="onco_CommonStockIssuableUponConversionOfSeriesAPreferredStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofInventoriesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidRent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PrepaidsResearchAndDevelopment" xlink:href="onco-20231231.xsd#onco_PrepaidsResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="onco_PrepaidsResearchAndDevelopment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PrepaidProfessionalFees" xlink:href="onco-20231231.xsd#onco_PrepaidProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="onco_PrepaidProfessionalFees" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TradeNamesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_CustomerRelationshipsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_CostBasisAbstract" xlink:href="onco-20231231.xsd#onco_CostBasisAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="onco_CostBasisAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_FiniteLivedIntangibleAssetCost" xlink:href="onco-20231231.xsd#onco_FiniteLivedIntangibleAssetCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_CostBasisAbstract" xlink:to="onco_FiniteLivedIntangibleAssetCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ImpairmentOfIntangibleAssetExcludingGoodwill" xlink:href="onco-20231231.xsd#onco_ImpairmentOfIntangibleAssetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_CostBasisAbstract" xlink:to="onco_ImpairmentOfIntangibleAssetExcludingGoodwill" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_CostBasisAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_CostBasisAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AccumulatedAmortizationAbstract" xlink:href="onco-20231231.xsd#onco_AccumulatedAmortizationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="onco_AccumulatedAmortizationAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AccumulatedAmortizationAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation" xlink:href="onco-20231231.xsd#onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AccumulatedAmortizationAbstract" xlink:to="onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AccumulatedAmortizationAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofGoodwillTable">
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfGoodwillAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ScheduleOfGoodwillAbstract" xlink:to="us-gaap_Goodwill" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillTransfers" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillTransfers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ScheduleOfGoodwillAbstract" xlink:to="us-gaap_GoodwillTransfers" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ScheduleOfGoodwillAbstract" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="onco_AccruedResearchAndDevelopmentCurrent" xlink:href="onco-20231231.xsd#onco_AccruedResearchAndDevelopmentCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="onco_AccruedResearchAndDevelopmentCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedUtilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedUtilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedUtilitiesCurrentAndNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AccruedDeferredOfferingCosts" xlink:href="onco-20231231.xsd#onco_AccruedDeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="onco_AccruedDeferredOfferingCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedMarketingCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedMarketingCostsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AggregateConsiderationTransferredMember" xlink:href="onco-20231231.xsd#onco_AggregateConsiderationTransferredMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="onco_AggregateConsiderationTransferredMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_FairValueConsiderationTransferredMember" xlink:href="onco-20231231.xsd#onco_FairValueConsiderationTransferredMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="onco_FairValueConsiderationTransferredMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredOther1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofAssetsAcquiredTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AssetsRecognizedMember" xlink:href="onco-20231231.xsd#onco_AssetsRecognizedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="onco_AssetsRecognizedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AssetAcquisitionConsiderationTransferredInventory" xlink:href="onco-20231231.xsd#onco_AssetAcquisitionConsiderationTransferredInventory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="onco_AssetAcquisitionConsiderationTransferredInventory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible" xlink:href="onco-20231231.xsd#onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofFairValueoftheProteomedixStockOptionsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_MeasurementInputStockPriceMember" xlink:href="onco-20231231.xsd#onco_MeasurementInputStockPriceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="onco_MeasurementInputStockPriceMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:href="onco-20231231.xsd#onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable" xlink:href="onco-20231231.xsd#onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_BusinessAcquisitionMember" xlink:href="onco-20231231.xsd#onco_BusinessAcquisitionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="onco_BusinessAcquisitionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofConsolidatedStatementsofOperationsandComprehensiveLossTable">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedIncomeStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xlink:to="srt_CondensedIncomeStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ProteomedixMember" xlink:href="onco-20231231.xsd#onco_ProteomedixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="onco_ProteomedixMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PMXTransactionMember" xlink:href="onco-20231231.xsd#onco_PMXTransactionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="onco_PMXTransactionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xlink:to="us-gaap_Revenues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xlink:to="us-gaap_ProfitLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="onco_SubscriptionAgreementDetailsScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementDetailsScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems" xlink:to="onco_SubscriptionAgreementDetailsScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_SubscriptionAgreementDetailsScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_SubscriptionAgreementDetailsScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofFairValueofthePreferredInvestmentOptionsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_OriginalMember" xlink:href="onco-20231231.xsd#onco_OriginalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="onco_OriginalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ExchangedMember" xlink:href="onco-20231231.xsd#onco_ExchangedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="onco_ExchangedMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofValuationoftheContingentWarrantLiabilityTable">
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityTable" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable">
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsTable" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted" xlink:href="onco-20231231.xsd#onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled" xlink:href="onco-20231231.xsd#onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofFairValueofOptionsGrantedTable">
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedTable" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofUnvestedRestrictedStockTable">
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockTable" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofStockBasedCompensationExpenseTable">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ResearchAndDevelopmentMember" xlink:href="onco-20231231.xsd#onco_ResearchAndDevelopmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="onco_ResearchAndDevelopmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofLossBeforeIncomeTaxTable">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" xbrldt:closed="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb4i4f4wUs/dKlMHRtjt5HiP056YCLyrdSoyPYyQevay5dOg9LR2t/KvbZBYGbO0fRFqRMXruICW071VL4cva1Vo1fRqEHdR31R1aena1W/oLM7lTmOCBLWaZ9ZWyZBU9clRPWAm3ygSKlPhipMHX/wTZ1GpdAQuF5X0Rk/U0peMoZ1GlWBL0QwQ4YYjsaQQj5y1OiFHDkpk+TSIy2jKBgVC6BuLNzQw2d0OQvqtBvmxiw3I1GgCSekvILJhH3efW9YCAzgwHV7k/LyAER0gWdt] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_LicenseAgreement" xlink:href="onco-20231231.xsd#onco_LicenseAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="onco_LicenseAgreement" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability" xlink:href="onco-20231231.xsd#onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" xlink:href="onco-20231231.xsd#onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment" xlink:href="onco-20231231.xsd#onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofUnrecognizedTaxBenefitsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable">
    <loc xlink:type="locator" xlink:label="onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems" xlink:href="onco-20231231.xsd#onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems"/>
    <loc xlink:type="locator" xlink:label="onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable" xlink:href="onco-20231231.xsd#onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems" xlink:to="onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofComponentsofNetPeriodicBenefitCostTable">
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract" xlink:to="us-gaap_DefinedBenefitPlanServiceCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract" xlink:to="us-gaap_DefinedBenefitPlanInterestCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract" xlink:to="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract" xlink:to="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract" xlink:to="us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract" xlink:to="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofAccumulatedComprehensiveLossTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AmortizationOfNetGain" xlink:href="onco-20231231.xsd#onco_AmortizationOfNetGain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="onco_AmortizationOfNetGain" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_EffectOfSettlement" xlink:href="onco-20231231.xsd#onco_EffectOfSettlement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="onco_EffectOfSettlement" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RegulatedAndUnregulatedOperatingRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegulatedAndUnregulatedOperatingRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_RegulatedAndUnregulatedOperatingRevenue" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofAccompanyingConsolidatedBalanceSheetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:to="us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:to="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:to="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_RetirementPlanTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AccumulatedBenefitObligationMember" xlink:href="onco-20231231.xsd#onco_AccumulatedBenefitObligationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="onco_AccumulatedBenefitObligationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PlanAssetsMember" xlink:href="onco-20231231.xsd#onco_PlanAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="onco_PlanAssetsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanServiceCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanInterestCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanActuarialGainLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees" xlink:href="onco-20231231.xsd#onco_DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="onco_DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanOtherChanges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanOtherChanges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanOtherChanges" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees" xlink:href="onco-20231231.xsd#onco_DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="onco_DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanSettlementsPlanAssets" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="onco_OrganizationandBasisofPresentationDetailsTable" xlink:href="onco-20231231.xsd#onco_OrganizationandBasisofPresentationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onco_OrganizationandBasisofPresentationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_OrganizationandBasisofPresentationDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_OrganizationandBasisofPresentationDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_OrganizationandBasisofPresentationDetailsTable" xlink:to="srt_OwnershipAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_OnconetixMember" xlink:href="onco-20231231.xsd#onco_OnconetixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="onco_OnconetixMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ProteomedixMember" xlink:href="onco-20231231.xsd#onco_ProteomedixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="onco_ProteomedixMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_InitialPublicOfferingShares" xlink:href="onco-20231231.xsd#onco_InitialPublicOfferingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onco_InitialPublicOfferingShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PublicOfPerShare" xlink:href="onco-20231231.xsd#onco_PublicOfPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onco_PublicOfPerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlansDetails">
    <loc xlink:type="locator" xlink:label="onco_GoingConcernandManagementsPlansDetailsLineItems" xlink:href="onco-20231231.xsd#onco_GoingConcernandManagementsPlansDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="onco_GoingConcernandManagementsPlansDetailsTable" xlink:href="onco-20231231.xsd#onco_GoingConcernandManagementsPlansDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onco_GoingConcernandManagementsPlansDetailsLineItems" xlink:to="onco_GoingConcernandManagementsPlansDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_GoingConcernandManagementsPlansDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_GoingConcernandManagementsPlansDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_GoingConcernandManagementsPlansDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_GoingConcernandManagementsPlansDetailsLineItems" xlink:to="us-gaap_ProceedsFromSaleOfOtherInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_GoingConcernandManagementsPlansDetailsLineItems" xlink:to="us-gaap_Cash" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_WorkingCapitalDeficit" xlink:href="onco-20231231.xsd#onco_WorkingCapitalDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_GoingConcernandManagementsPlansDetailsLineItems" xlink:to="onco_WorkingCapitalDeficit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAppropriated" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAppropriated"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_GoingConcernandManagementsPlansDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAppropriated" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="onco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="onco-20231231.xsd#onco_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="onco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="onco-20231231.xsd#onco_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="onco_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_Depreciation" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RecognitionOfDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecognitionOfDeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RecognitionOfDeferredRevenue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails">
    <loc xlink:type="locator" xlink:label="onco_BalanceSheetDetailsDetailsLineItems" xlink:href="onco-20231231.xsd#onco_BalanceSheetDetailsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="onco_BalanceSheetDetailsDetailsTable" xlink:href="onco-20231231.xsd#onco_BalanceSheetDetailsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onco_BalanceSheetDetailsDetailsLineItems" xlink:to="onco_BalanceSheetDetailsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_BalanceSheetDetailsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_BalanceSheetDetailsDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_BalanceSheetDetailsDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ENTADFIMember" xlink:href="onco-20231231.xsd#onco_ENTADFIMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="onco_ENTADFIMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ProteomedixMember" xlink:href="onco-20231231.xsd#onco_ProteomedixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="onco_ProteomedixMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="onco_ENTADFIMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_BalanceSheetDetailsDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_BalanceSheetDetailsDetailsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCostOfOperatingRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostOfOperatingRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_BalanceSheetDetailsDetailsLineItems" xlink:to="us-gaap_OtherCostOfOperatingRevenue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_BalanceSheetDetailsDetailsLineItems" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_BalanceSheetDetailsDetailsLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_BalanceSheetDetailsDetailsLineItems" xlink:to="us-gaap_OtherAssetImpairmentCharges" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_BalanceSheetDetailsDetailsLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedTradeNames" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedTradeNames"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_BalanceSheetDetailsDetailsLineItems" xlink:to="us-gaap_IndefiniteLivedTradeNames" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/AcquisitionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:label="onco_AcquisitionsDetailsTable" xlink:href="onco-20231231.xsd#onco_AcquisitionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="onco_AcquisitionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_AcquisitionsDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_AcquisitionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_AcquisitionsDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_AcquisitionsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_AcquisitionsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TradeNamesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_CustomerRelationshipsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AssetPurchaseAgreementMember" xlink:href="onco-20231231.xsd#onco_AssetPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="onco_AssetPurchaseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ENTADFIMember" xlink:href="onco-20231231.xsd#onco_ENTADFIMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="onco_ENTADFIMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_MilestonePaymentsMember" xlink:href="onco-20231231.xsd#onco_MilestonePaymentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="onco_MilestonePaymentsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PharmaceuticalServicesLLCMember" xlink:href="onco-20231231.xsd#onco_PharmaceuticalServicesLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="onco_PharmaceuticalServicesLLCMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ProteomedixMember" xlink:href="onco-20231231.xsd#onco_ProteomedixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="onco_ProteomedixMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_FairValueConsiderationTransferredMember" xlink:href="onco-20231231.xsd#onco_FairValueConsiderationTransferredMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="onco_FairValueConsiderationTransferredMember" order="5" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="onco_ENTADFIMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_SeriesBConvertiblePreferredStockMember" xlink:href="onco-20231231.xsd#onco_SeriesBConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="onco_SeriesBConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ManagementServicesAgreementMember" xlink:href="onco-20231231.xsd#onco_ManagementServicesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="onco_ManagementServicesAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_WraSerAPAMember" xlink:href="onco-20231231.xsd#onco_WraSerAPAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="onco_WraSerAPAMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_BankruptcyCourtMember" xlink:href="onco-20231231.xsd#onco_BankruptcyCourtMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="onco_BankruptcyCourtMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_WraSerMSAMember" xlink:href="onco-20231231.xsd#onco_WraSerMSAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="onco_WraSerMSAMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PMXTransactionMember" xlink:href="onco-20231231.xsd#onco_PMXTransactionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="onco_PMXTransactionMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_RoyaltySalesPercentage" xlink:href="onco-20231231.xsd#onco_RoyaltySalesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="onco_RoyaltySalesPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_SalesPaymentsAmount" xlink:href="onco-20231231.xsd#onco_SalesPaymentsAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="onco_SalesPaymentsAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationDescription" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AggregatePurchaseShares" xlink:href="onco-20231231.xsd#onco_AggregatePurchaseShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="onco_AggregatePurchaseShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_BusinessTransactionYeare" xlink:href="onco-20231231.xsd#onco_BusinessTransactionYeare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="onco_BusinessTransactionYeare" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_InventoryFairValue" xlink:href="onco-20231231.xsd#onco_InventoryFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="onco_InventoryFairValue" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ImpairmentRate" xlink:href="onco-20231231.xsd#onco_ImpairmentRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="onco_ImpairmentRate" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_InitialPaymentAmount" xlink:href="onco-20231231.xsd#onco_InitialPaymentAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="onco_InitialPaymentAmount" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_Payments" xlink:href="onco-20231231.xsd#onco_Payments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="onco_Payments" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Deposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Deposits" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsForFees" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_VotingInterestPercentage" xlink:href="onco-20231231.xsd#onco_VotingInterestPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="onco_VotingInterestPercentage" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_NumberOfShares" xlink:href="onco-20231231.xsd#onco_NumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="onco_NumberOfShares" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_RoyaltyRate" xlink:href="onco-20231231.xsd#onco_RoyaltyRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="onco_RoyaltyRate" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_WeightedAverageDiscountRate" xlink:href="onco-20231231.xsd#onco_WeightedAverageDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="onco_WeightedAverageDiscountRate" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_WeightedAverageDiscountRateThereafter" xlink:href="onco-20231231.xsd#onco_WeightedAverageDiscountRateThereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="onco_WeightedAverageDiscountRateThereafter" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_InvestmentOwnedAtCost" order="26" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SignificantAgreementsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems"/>
    <loc xlink:type="locator" xlink:label="onco_SignificantAgreementsDetailsTable" xlink:href="onco-20231231.xsd#onco_SignificantAgreementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="onco_SignificantAgreementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_SignificantAgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_SignificantAgreementsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_SignificantAgreementsDetailsTable" xlink:to="us-gaap_EquitySecuritiesByIndustryAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesIndustryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesIndustryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesIndustryMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesIndustryMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_SignificantAgreementsDetailsTable" xlink:to="srt_RangeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_RegulatoryMilestonesMember" xlink:href="onco-20231231.xsd#onco_RegulatoryMilestonesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquitySecuritiesIndustryMember" xlink:to="onco_RegulatoryMilestonesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialAndIndustrialSectorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialAndIndustrialSectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquitySecuritiesIndustryMember" xlink:to="us-gaap_CommercialAndIndustrialSectorMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_DevelopmentMilestonesMember" xlink:href="onco-20231231.xsd#onco_DevelopmentMilestonesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquitySecuritiesIndustryMember" xlink:to="onco_DevelopmentMilestonesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_OUIAgreementMember" xlink:href="onco-20231231.xsd#onco_OUIAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="onco_OUIAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_UTHealthAgreementMember" xlink:href="onco-20231231.xsd#onco_UTHealthAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="onco_UTHealthAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_VendorAgreementMember" xlink:href="onco-20231231.xsd#onco_VendorAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="onco_VendorAgreementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_OlogyBioservicesIncMember" xlink:href="onco-20231231.xsd#onco_OlogyBioservicesIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="onco_OlogyBioservicesIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_CincinnatiChildrensHospitalMedicalCenterMember" xlink:href="onco-20231231.xsd#onco_CincinnatiChildrensHospitalMedicalCenterMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="onco_CincinnatiChildrensHospitalMedicalCenterMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_OxfordUniversityInnovationLimitedMember" xlink:href="onco-20231231.xsd#onco_OxfordUniversityInnovationLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="onco_OxfordUniversityInnovationLimitedMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_StJudeChildrensHospitalMember" xlink:href="onco-20231231.xsd#onco_StJudeChildrensHospitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="onco_StJudeChildrensHospitalMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_UniversityOfTexasHealthScienceCenterAtSanAntonioMember" xlink:href="onco-20231231.xsd#onco_UniversityOfTexasHealthScienceCenterAtSanAntonioMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="onco_UniversityOfTexasHealthScienceCenterAtSanAntonioMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_CoDevelopmentAgreementMember" xlink:href="onco-20231231.xsd#onco_CoDevelopmentAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="onco_CoDevelopmentAgreementMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_LaboratorCorporationOfAmericaMember" xlink:href="onco-20231231.xsd#onco_LaboratorCorporationOfAmericaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="onco_LaboratorCorporationOfAmericaMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AggregateAgreementAmountInitialAgreement" xlink:href="onco-20231231.xsd#onco_AggregateAgreementAmountInitialAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="onco_AggregateAgreementAmountInitialAgreement" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_DefinedBenefitPlanServiceCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AggregateeAmount" xlink:href="onco-20231231.xsd#onco_AggregateeAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="onco_AggregateeAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_CostPlusPercentage" xlink:href="onco-20231231.xsd#onco_CostPlusPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="onco_CostPlusPercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_Assets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_CommercialSaleTerm" xlink:href="onco-20231231.xsd#onco_CommercialSaleTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="onco_CommercialSaleTerm" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_RoyaltyNetSalesPercentage" xlink:href="onco-20231231.xsd#onco_RoyaltyNetSalesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="onco_RoyaltyNetSalesPercentage" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductLiabilityContingencyAccrualDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityContingencyAccrualDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_ProductLiabilityContingencyAccrualDiscountRate" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_RoyaltyRates" xlink:href="onco-20231231.xsd#onco_RoyaltyRates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="onco_RoyaltyRates" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_RevenueRate" xlink:href="onco-20231231.xsd#onco_RevenueRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="onco_RevenueRate" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FeeIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FeeIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_FeeIncome" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AggregateRoyaltiesAmount" xlink:href="onco-20231231.xsd#onco_AggregateRoyaltiesAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="onco_AggregateRoyaltiesAmount" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopmentCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_DevelopmentCosts" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_RoyaltyExpense" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfPropertyRepairsAndMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfPropertyRepairsAndMaintenance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_CostOfPropertyRepairsAndMaintenance" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PercentageOfConsiderationReceived" xlink:href="onco-20231231.xsd#onco_PercentageOfConsiderationReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="onco_PercentageOfConsiderationReceived" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesAndLicenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesAndLicenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_TaxesAndLicenses" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostMaintenance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_CostMaintenance" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AmountOfOtherPartyPayments" xlink:href="onco-20231231.xsd#onco_AmountOfOtherPartyPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="onco_AmountOfOtherPartyPayments" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_RoyaltiesPercentage" xlink:href="onco-20231231.xsd#onco_RoyaltiesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="onco_RoyaltiesPercentage" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdministrativeFeesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdministrativeFeesExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_AdministrativeFeesExpense" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_LongTermDebtMaturityDate" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalAndContractServicesExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_LicensedProductsPlusMilestonePaymentsDescription" xlink:href="onco-20231231.xsd#onco_LicensedProductsPlusMilestonePaymentsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="onco_LicensedProductsPlusMilestonePaymentsDescription" order="29" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/NotesPayableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="onco_NotesPayableDetailsTable" xlink:href="onco-20231231.xsd#onco_NotesPayableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="onco_NotesPayableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_NotesPayableDetailsTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_NotesPayableDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_NotesPayableDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_NotesPayableDetailsTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_NotesPayableDetailsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ProteomedixAcquisitionMember" xlink:href="onco-20231231.xsd#onco_ProteomedixAcquisitionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="onco_ProteomedixAcquisitionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AssetPurchaseAgreementMember" xlink:href="onco-20231231.xsd#onco_AssetPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="onco_AssetPurchaseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_NotePayableMember" xlink:href="onco-20231231.xsd#onco_NotePayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="onco_NotePayableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ENTADFIMember" xlink:href="onco-20231231.xsd#onco_ENTADFIMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="onco_ENTADFIMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PayableAverageDiscountRatePercentage" xlink:href="onco-20231231.xsd#onco_PayableAverageDiscountRatePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="onco_PayableAverageDiscountRatePercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayable" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_DebtInstrumentDueDate" xlink:href="onco-20231231.xsd#onco_DebtInstrumentDueDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="onco_DebtInstrumentDueDate" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_CashPaymentToTheSeller" xlink:href="onco-20231231.xsd#onco_CashPaymentToTheSeller"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="onco_CashPaymentToTheSeller" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_DebtInstrumentDueTerm" xlink:href="onco-20231231.xsd#onco_DebtInstrumentDueTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="onco_DebtInstrumentDueTerm" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionPriceOfAcquisitionExpected"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermNotesPayable" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SubscriptionAgreementDetails">
    <loc xlink:type="locator" xlink:label="onco_SubscriptionAgreementDetailsLineItems" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="onco_SubscriptionAgreementDetailsTable" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onco_SubscriptionAgreementDetailsLineItems" xlink:to="onco_SubscriptionAgreementDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_SubscriptionAgreementDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_SaleOfUnits" xlink:href="onco-20231231.xsd#onco_SaleOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_SubscriptionAgreementDetailsLineItems" xlink:to="onco_SaleOfUnits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_SubscriptionAgreementDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_SubscriptionAgreementDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ServicingLiabilityAtFairValueAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServicingLiabilityAtFairValueAdditions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_SubscriptionAgreementDetailsLineItems" xlink:to="us-gaap_ServicingLiabilityAtFairValueAdditions" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ServicingLiabilityAtFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServicingLiabilityAtFairValueAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_SubscriptionAgreementDetailsLineItems" xlink:to="us-gaap_ServicingLiabilityAtFairValueAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_SubscriptionAgreementDetailsLineItems" xlink:to="us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1">
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1Table" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1Table"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1Table" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1Table" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1Table" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_SeriesSeedPreferredStockMember" xlink:href="onco-20231231.xsd#onco_SeriesSeedPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="onco_SeriesSeedPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_SeriesAConvertiblePreferredStockMember" xlink:href="onco-20231231.xsd#onco_SeriesAConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="onco_SeriesAConvertiblePreferredStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="us-gaap_OtherNotesPayable" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="us-gaap_PreferredStockLiquidationPreference" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_SharesOfCommonStockRate" xlink:href="onco-20231231.xsd#onco_SharesOfCommonStockRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="onco_SharesOfCommonStockRate" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2">
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2Table" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2Table"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2Table" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2Table" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2Table" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2Table" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_SeriesSeedPreferredStockMember" xlink:href="onco-20231231.xsd#onco_SeriesSeedPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="onco_SeriesSeedPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PercentageOfIssuedOfCommonStock" xlink:href="onco-20231231.xsd#onco_PercentageOfIssuedOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="onco_PercentageOfIssuedOfCommonStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PercentageOfOutstandingOfCommonStock" xlink:href="onco-20231231.xsd#onco_PercentageOfOutstandingOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="onco_PercentageOfOutstandingOfCommonStock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PercentageOfCumulativeDividends" xlink:href="onco-20231231.xsd#onco_PercentageOfCumulativeDividends"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="onco_PercentageOfCumulativeDividends" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_NettingProceeds" xlink:href="onco-20231231.xsd#onco_NettingProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="onco_NettingProceeds" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PercentageOfOriginalIssuePrice" xlink:href="onco-20231231.xsd#onco_PercentageOfOriginalIssuePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="onco_PercentageOfOriginalIssuePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CumulativeDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CumulativeDividends"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="us-gaap_CumulativeDividends" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPayableAmountPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="us-gaap_DividendsPayableAmountPerShare" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3">
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_TreasuryStocksMember" xlink:href="onco-20231231.xsd#onco_TreasuryStocksMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="onco_TreasuryStocksMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_April2022PrivatePlacementMember" xlink:href="onco-20231231.xsd#onco_April2022PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onco_April2022PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AprilContingentWarrantsMember" xlink:href="onco-20231231.xsd#onco_AprilContingentWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onco_AprilContingentWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_August2022PrivatePlacementMember" xlink:href="onco-20231231.xsd#onco_August2022PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onco_August2022PrivatePlacementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AugustWainwrightWarrantsMember" xlink:href="onco-20231231.xsd#onco_AugustWainwrightWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onco_AugustWainwrightWarrantsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AugustContingentWarrantsMember" xlink:href="onco-20231231.xsd#onco_AugustContingentWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onco_AugustContingentWarrantsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_HCWainwrightCoLLCMember" xlink:href="onco-20231231.xsd#onco_HCWainwrightCoLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="onco_HCWainwrightCoLLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_StockIssued1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_CommonUnitIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PercentageOfUnderwritingDiscount" xlink:href="onco-20231231.xsd#onco_PercentageOfUnderwritingDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="onco_PercentageOfUnderwritingDiscount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOwnershipInterestsOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_OtherOwnershipInterestsOfferingCosts" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_TreasuryStockAcquiredAverageCostPerShare" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PlacementAgentFeeAndManagementFeePercentage" xlink:href="onco-20231231.xsd#onco_PlacementAgentFeeAndManagementFeePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="onco_PlacementAgentFeeAndManagementFeePercentage" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AggregateNumberOfSharesPercenatge" xlink:href="onco-20231231.xsd#onco_AggregateNumberOfSharesPercenatge"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="onco_AggregateNumberOfSharesPercenatge" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_OtherLiabilities" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_CancelledPreferredInvestmentOptionsShares" xlink:href="onco-20231231.xsd#onco_CancelledPreferredInvestmentOptionsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="onco_CancelledPreferredInvestmentOptionsShares" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PrefundedWarrantsExercised" xlink:href="onco-20231231.xsd#onco_PrefundedWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="onco_PrefundedWarrantsExercised" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_PreferredStockDividendsShares" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPriceDecrease" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_OtherExpenses" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_WarrantsIssuableUnderProvisionShares" xlink:href="onco-20231231.xsd#onco_WarrantsIssuableUnderProvisionShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="onco_WarrantsIssuableUnderProvisionShares" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_IncreaseInTheFairValueOfThePreferredInvestmentOptions" xlink:href="onco-20231231.xsd#onco_IncreaseInTheFairValueOfThePreferredInvestmentOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="onco_IncreaseInTheFairValueOfThePreferredInvestmentOptions" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ContingentWarrantLiabilityShares" xlink:href="onco-20231231.xsd#onco_ContingentWarrantLiabilityShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="onco_ContingentWarrantLiabilityShares" order="38" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4">
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" xlink:to="srt_TitleOfIndividualAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" xlink:to="srt_RangeAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" xlink:to="us-gaap_StatementEquityComponentsAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" xlink:to="us-gaap_PlanNameAxis" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_WarrantInducementMember" xlink:href="onco-20231231.xsd#onco_WarrantInducementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="onco_WarrantInducementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_April2022PrivatePlacementMember" xlink:href="onco-20231231.xsd#onco_April2022PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="onco_April2022PrivatePlacementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_August2022PrivatePlacementMember" xlink:href="onco-20231231.xsd#onco_August2022PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="onco_August2022PrivatePlacementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AugustContingentWarrantsMember" xlink:href="onco-20231231.xsd#onco_AugustContingentWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onco_AugustContingentWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_TwoThousandNinteenEquityIncentivePlanMember" xlink:href="onco-20231231.xsd#onco_TwoThousandNinteenEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onco_TwoThousandNinteenEquityIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:href="onco-20231231.xsd#onco_TwoThousandTwentyTwoEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onco_TwoThousandTwentyTwoEquityIncentivePlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_TwoThousandTwentyTwoPlanMember" xlink:href="onco-20231231.xsd#onco_TwoThousandTwentyTwoPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onco_TwoThousandTwentyTwoPlanMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_January2024Member" xlink:href="onco-20231231.xsd#onco_January2024Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onco_January2024Member" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_August2024Member" xlink:href="onco-20231231.xsd#onco_August2024Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onco_August2024Member" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_August2025Member" xlink:href="onco-20231231.xsd#onco_August2025Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onco_August2025Member" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PMXOptionPlanMember" xlink:href="onco-20231231.xsd#onco_PMXOptionPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onco_PMXOptionPlanMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_InducementPIOSharesMember" xlink:href="onco-20231231.xsd#onco_InducementPIOSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="onco_InducementPIOSharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ChiefBusinessOfficerMember" xlink:href="onco-20231231.xsd#onco_ChiefBusinessOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="onco_ChiefBusinessOfficerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_MarketOfferingAgreementMember" xlink:href="onco-20231231.xsd#onco_MarketOfferingAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="onco_MarketOfferingAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_UnvestedRestrictedStockMember" xlink:href="onco-20231231.xsd#onco_UnvestedRestrictedStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="onco_UnvestedRestrictedStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_SharesOfCommonStockIssued" xlink:href="onco-20231231.xsd#onco_SharesOfCommonStockIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="onco_SharesOfCommonStockIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_FixedCommissionRate" xlink:href="onco-20231231.xsd#onco_FixedCommissionRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="onco_FixedCommissionRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_StockOptionExercisePriceDecrease" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AggregateNetProceeds" xlink:href="onco-20231231.xsd#onco_AggregateNetProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="onco_AggregateNetProceeds" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscribedButUnissued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PercentageOfGrossProceeds" xlink:href="onco-20231231.xsd#onco_PercentageOfGrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="onco_PercentageOfGrossProceeds" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_LegalFees" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_OtherGeneralExpense" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AggregatePurchaseShares" xlink:href="onco-20231231.xsd#onco_AggregatePurchaseShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="onco_AggregatePurchaseShares" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PercentageOfCommonStockShares" xlink:href="onco-20231231.xsd#onco_PercentageOfCommonStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="onco_PercentageOfCommonStockShares" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_WarrantsIssuedForSettlementOfContingentWarrants" xlink:href="onco-20231231.xsd#onco_WarrantsIssuedForSettlementOfContingentWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="onco_WarrantsIssuedForSettlementOfContingentWarrants" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_OtherLiabilities" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_SharePrice" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ExercisePrice" xlink:href="onco-20231231.xsd#onco_ExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="onco_ExercisePrice" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_GrantDateFairValueOfStockOption" xlink:href="onco-20231231.xsd#onco_GrantDateFairValueOfStockOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="onco_GrantDateFairValueOfStockOption" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_RestrictedSharesGrantedVestPercentage" xlink:href="onco-20231231.xsd#onco_RestrictedSharesGrantedVestPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="onco_RestrictedSharesGrantedVestPercentage" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="40" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="41" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="42" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="43" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="44" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="45" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="46" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="47" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="48" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated" order="49" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="50" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="51" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="52" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="onco_CommitmentsandContingenciesDetailsTable" xlink:href="onco-20231231.xsd#onco_CommitmentsandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="onco_CommitmentsandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_CommitmentsandContingenciesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_SettlementAgreementMember" xlink:href="onco-20231231.xsd#onco_SettlementAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="onco_SettlementAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_CH" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CH"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CH" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LeaseCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ShortTermLeasePayments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForRent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FeeIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FeeIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_FeeIncome" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LegalFees" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_PercentageOfSubscription" xlink:href="onco-20231231.xsd#onco_PercentageOfSubscription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="onco_PercentageOfSubscription" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AggregatePayments" xlink:href="onco-20231231.xsd#onco_AggregatePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="onco_AggregatePayments" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LaborAndRelatedExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LaborAndRelatedExpense" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPaidinkind" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPaidinkind"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DividendsPaidinkind" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherExpenses" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="onco_RelatedPartyTransactionsDetailsTable" xlink:href="onco-20231231.xsd#onco_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="onco_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_NonConvertibleDebentureMember" xlink:href="onco-20231231.xsd#onco_NonConvertibleDebentureMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="onco_NonConvertibleDebentureMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_CEOMember" xlink:href="onco-20231231.xsd#onco_CEOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="onco_CEOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_CBOMember" xlink:href="onco-20231231.xsd#onco_CBOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="onco_CBOMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsForFees" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivables" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_MiscellaneousExpenses" xlink:href="onco-20231231.xsd#onco_MiscellaneousExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="onco_MiscellaneousExpenses" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_SubscriptionAgreementPMXInvestorPercentage" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementPMXInvestorPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="onco_SubscriptionAgreementPMXInvestorPercentage" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <loc xlink:type="locator" xlink:label="onco_IncomeTaxesDetailsTable" xlink:href="onco-20231231.xsd#onco_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="onco_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLossMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingIncomeLossMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/RetirementPlansDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_GrossPayPercentage" xlink:href="onco-20231231.xsd#onco_GrossPayPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="onco_GrossPayPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_DebtSecuritiesAndCash" xlink:href="onco-20231231.xsd#onco_DebtSecuritiesAndCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="onco_DebtSecuritiesAndCash" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_EquitySecuritiesRate" xlink:href="onco-20231231.xsd#onco_EquitySecuritiesRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="onco_EquitySecuritiesRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_AlternativeInvestmentsRate" xlink:href="onco-20231231.xsd#onco_AlternativeInvestmentsRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="onco_AlternativeInvestmentsRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_RealEstateInvestmentsRate" xlink:href="onco-20231231.xsd#onco_RealEstateInvestmentsRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="onco_RealEstateInvestmentsRate" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:label="onco_SubsequentEventsDetailsTable" xlink:href="onco-20231231.xsd#onco_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="onco_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_SubsequentEventsDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_SubsequentEventsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onco_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_ENTADFIMember" xlink:href="onco-20231231.xsd#onco_ENTADFIMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="onco_ENTADFIMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_NonConvertibleDebentureMember" xlink:href="onco-20231231.xsd#onco_NonConvertibleDebentureMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="onco_NonConvertibleDebentureMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_SubscriptionAgreementMember" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="onco_SubscriptionAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="onco_SeverancePayment" xlink:href="onco-20231231.xsd#onco_SeverancePayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="onco_SeverancePayment" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_OtherAssetImpairmentCharges" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="10" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>onco-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Apr 26 21:03:50 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Onconetix stockholders&#8217; equity (deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities, convertible redeemable preferred stock, and stockholders&#8217; equity (deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossAttributableToParent_lbl" xml:lang="en-US">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_IncomeLossAttributableToParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to common stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Total comprehensive loss attributable to common stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization and Basis of Presentation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_GoingConcernAndManagementsPlansAbstract" xlink:href="onco-20231231.xsd#onco_GoingConcernAndManagementsPlansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_GoingConcernAndManagementsPlansAbstract_lbl" xml:lang="en-US">Going Concern and Management&#8217;s Plans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_GoingConcernAndManagementsPlansAbstract" xlink:to="onco_GoingConcernAndManagementsPlansAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfActivityForTheSubscriptionAgreementLiabilityAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfActivityForTheSubscriptionAgreementLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfActivityForTheSubscriptionAgreementLiabilityAbstract_lbl" xml:lang="en-US">Schedule of Activity for the Subscription Agreement Liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfActivityForTheSubscriptionAgreementLiabilityAbstract" xlink:to="onco_ScheduleOfActivityForTheSubscriptionAgreementLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Balance at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl0" xml:lang="en-US">Balance at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfActivityForTheContingentWarrantLiabilityAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfActivityForTheContingentWarrantLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfActivityForTheContingentWarrantLiabilityAbstract_lbl" xml:lang="en-US">Schedule of Activity for the Contingent Warrant Liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfActivityForTheContingentWarrantLiabilityAbstract" xlink:to="onco_ScheduleOfActivityForTheContingentWarrantLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl" xml:lang="en-US">Balance at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl0" xml:lang="en-US">Balance at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US">Schedule of Computation of Diluted Shares Outstanding [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US">Schedule of Inventories [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US">Schedule of Annual Amortization Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfGoodwillAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfGoodwillAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfGoodwillAbstract_lbl" xml:lang="en-US">Schedule of Goodwill [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfGoodwillAbstract" xlink:to="onco_ScheduleOfGoodwillAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Goodwill_lbl0" xml:lang="en-US">Goodwill Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl1" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US">Schedule of Accrued Expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US">Acquisitions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US">Asset Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US">Total fair value of identifiable assets acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl0" xml:lang="en-US">Total consideration transferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US">Total assets acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xml:lang="en-US">Total liabilities assumed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_lbl" xml:lang="en-US">Net assets acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_lbl" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SignificantAgreementsAbstract" xlink:href="onco-20231231.xsd#onco_SignificantAgreementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SignificantAgreementsAbstract_lbl" xml:lang="en-US">Significant Agreements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SignificantAgreementsAbstract" xlink:to="onco_SignificantAgreementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableAbstract_lbl" xml:lang="en-US">Notes Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_NotesPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SubscriptionAgreementDisclosureAbstract" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SubscriptionAgreementDisclosureAbstract_lbl" xml:lang="en-US">Subscription Agreement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SubscriptionAgreementDisclosureAbstract" xlink:to="onco_SubscriptionAgreementDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Convertible Redeemable Preferred Stock and Stockholders&#8217; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Convertible Redeemable Preferred Stock and Stockholders [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares, ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Stock option outstanding shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Total Intrinsic Value, ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Intrinsic value of options outstanding (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Shares, Outstanding at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Number of Shares, Outstanding at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted	Average Grant Date Fair Value, Outstanding at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted	Average Grant Date Fair Value, Outstanding at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNetAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract" xlink:to="us-gaap_IncomeTaxesPaidNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" xml:lang="en-US">Schedule of Loss Before Income Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Total loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US">Schedule of Income Taxes Differs from the Statutory Federal Rate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract_lbl" xml:lang="en-US">Schedule of Unrecognized Tax Benefits [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl0" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAbstract_lbl" xml:lang="en-US">Retirement Plan [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_DefinedBenefitPlanAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_lbl" xml:lang="en-US">Schedule of Accompanying Consolidated Balance Sheet [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:to="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_lbl" xml:lang="en-US">Overfunded (underfunded) status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:to="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_lbl0" xml:lang="en-US">Pension benefit obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:to="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligation_lbl" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation Begining Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligation_lbl0" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligation_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_lbl" xml:lang="en-US">Defined Benefit Plan, Plan Assets Begining Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_lbl0" xml:lang="en-US">Defined Benefit Plan, Plan Assets Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xml:lang="en-US">Retirement Plan Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_lbl" xml:lang="en-US">Schedule of Benefit Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:to="us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Receivable from related parties, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Receivable from related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_UnlabeledAbstract" xlink:href="onco-20231231.xsd#onco_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnlabeledAbstract" xlink:to="onco_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid expenses, long-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating right of use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_UnlabeledAbstract0" xlink:href="onco-20231231.xsd#onco_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnlabeledAbstract0" xlink:to="onco_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable, net of debt discount of $381,627</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_NotesPayableNetOfDebtDiscount" xlink:href="onco-20231231.xsd#onco_NotesPayableNetOfDebtDiscount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_NotesPayableNetOfDebtDiscount_lbl" xml:lang="en-US">Notes payable, net of debt discount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_NotesPayableNetOfDebtDiscount" xlink:to="onco_NotesPayableNetOfDebtDiscount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Contingent warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_UnlabeledAbstract1" xlink:href="onco-20231231.xsd#onco_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnlabeledAbstract1" xlink:to="onco_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl0" xml:lang="en-US">Loan payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_SubscriptionAgreementLiabilityNoncurrent" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_SubscriptionAgreementLiabilityNoncurrent_lbl" xml:lang="en-US">Subscription agreement liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SubscriptionAgreementLiabilityNoncurrent" xlink:to="onco_SubscriptionAgreementLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax liability, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_UnlabeledAbstract2" xlink:href="onco-20231231.xsd#onco_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnlabeledAbstract2" xlink:to="onco_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (see Note 10)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_UnlabeledAbstract3" xlink:href="onco-20231231.xsd#onco_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnlabeledAbstract3" xlink:to="onco_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US">Series B Convertible Redeemable Preferred stock, $0.00001 par value, 2,700,000 and 0 shares authorized at December 31, 2023 and 2022, respectively; 2,696,729 and 0 shares issued and outstanding at December 31, 2023 and 2022, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Convertible redeemable preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US">Convertible redeemable preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Convertible redeemable preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Convertible redeemable preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity (deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Series A Convertible Preferred stock, $0.00001 par value, 10,000 and 0 shares authorized at December 31, 2023 and 2022, respectively; 3,000 and 0 shares issued and outstanding at December 31, 2023 and 2022, respectively; Liquidation preference of $3,000,000 and $0 at December 31, 2023 and 2022, respectively.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Liquidation preference (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred stock, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Issuance shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl1" xml:lang="en-US">Preferred stock, share issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred investment options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US">Preferred stock, liquidation preference (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.00001 par value, 250,000,000 shares authorized at December 31, 2023 and 2022; 22,841,975 and 15,724,957 shares issued at December 31, 2023 and 2022, respectively; 22,324,576 and 15,265,228 shares outstanding at December 31, 2023 and 2022, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Number of shares of common stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in-capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US">Treasury stock, shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Non-controlling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Total revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_UnlabeledAbstract4" xlink:href="onco-20231231.xsd#onco_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnlabeledAbstract4" xlink:to="onco_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Selling, general and administrative expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl1" xml:lang="en-US">Selling, general, and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xml:lang="en-US">Impairment of ENTADFI assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetImpairmentCharges_lbl" xml:lang="en-US">Impairment of deposit on asset purchase agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetImpairmentCharges" xlink:to="us-gaap_OtherAssetImpairmentCharges_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssetImpairmentCharges_lbl0" xml:lang="en-US">Impairment charge of long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetImpairmentCharges" xlink:to="us-gaap_OtherAssetImpairmentCharges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_OtherAssetImpairmentCharges_lbl1" xml:lang="en-US">Long-lived assets of carrying amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetImpairmentCharges" xlink:to="us-gaap_OtherAssetImpairmentCharges_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0" xml:lang="en-US">Loss on extinguishment of note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_ChangeInFairValueOfSubscriptionAgreementLiability" xlink:href="onco-20231231.xsd#onco_ChangeInFairValueOfSubscriptionAgreementLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_ChangeInFairValueOfSubscriptionAgreementLiability_lbl" xml:lang="en-US">Change in fair value of subscription agreement liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ChangeInFairValueOfSubscriptionAgreementLiability" xlink:to="onco_ChangeInFairValueOfSubscriptionAgreementLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl" xml:lang="en-US">Change in fair value of contingent warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Cumulative preferred stock dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_UnlabeledAbstract5" xlink:href="onco-20231231.xsd#onco_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnlabeledAbstract5" xlink:to="onco_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share attributable to common stockholders, basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share attributable to common stockholders, diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_UnlabeledAbstract6" xlink:href="onco-20231231.xsd#onco_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnlabeledAbstract6" xlink:to="onco_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xml:lang="en-US">Other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ChangeInPensionBenefitObligation" xlink:href="onco-20231231.xsd#onco_ChangeInPensionBenefitObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_ChangeInPensionBenefitObligation_lbl" xml:lang="en-US">Change in pension benefit obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ChangeInPensionBenefitObligation" xlink:to="onco_ChangeInPensionBenefitObligation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock in initial public offering, net of $2.9 million of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock in initial public offering, net of $2.9 million of offering costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_IssuanceOfCommonStockInInitialPublicOfferingNet" xlink:href="onco-20231231.xsd#onco_IssuanceOfCommonStockInInitialPublicOfferingNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_IssuanceOfCommonStockInInitialPublicOfferingNet_lbl" xml:lang="en-US">Issuance of common stock in initial public offering, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IssuanceOfCommonStockInInitialPublicOfferingNet" xlink:to="onco_IssuanceOfCommonStockInInitialPublicOfferingNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of convertible preferred stock to common stock upon initial public offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of convertible preferred stock to common stock upon initial public offering (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants_lbl" xml:lang="en-US">Issuance of common stock and warrants in April private placement, net of $1.1 million of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants" xlink:to="onco_StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants_lbl" xml:lang="en-US">Issuance of common stock and warrants in April private placement, net of $1.1 million of offering costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants" xlink:to="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet" xlink:href="onco-20231231.xsd#onco_IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet_lbl" xml:lang="en-US">Issuance of common stock and warrants in April private placement, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet" xlink:to="onco_IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement_lbl" xml:lang="en-US">Issuance of common stock and warrants in August private placement, net of $2.2 million of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement" xlink:to="onco_StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet_lbl" xml:lang="en-US">Issuance of common stock and warrants in August private placement, net of $2.2 million of offering costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet" xlink:to="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet" xlink:href="onco-20231231.xsd#onco_IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet_lbl" xml:lang="en-US">Issuance of common stock and warrants in August private placement, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet" xlink:to="onco_IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Number of Shares, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US">Exercisable shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1"/>
    <loc xlink:type="locator" xlink:label="onco_ExerciseOfPrefundedWarrants" xlink:href="onco-20231231.xsd#onco_ExerciseOfPrefundedWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_ExerciseOfPrefundedWarrants_lbl" xml:lang="en-US">Exercise of pre-funded warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ExerciseOfPrefundedWarrants" xlink:to="onco_ExerciseOfPrefundedWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ExerciseOfPrefundedWarrantsinShares" xlink:href="onco-20231231.xsd#onco_ExerciseOfPrefundedWarrantsinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_ExerciseOfPrefundedWarrantsinShares_lbl" xml:lang="en-US">Exercise of pre-funded warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ExerciseOfPrefundedWarrantsinShares" xlink:to="onco_ExerciseOfPrefundedWarrantsinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of restricted stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0" xml:lang="en-US">Total restricted common stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of restricted stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0" xml:lang="en-US">Restricted common stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xml:lang="en-US">Stock-based compensation (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_PurchaseOfTreasurySharesinShares" xlink:href="onco-20231231.xsd#onco_PurchaseOfTreasurySharesinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_PurchaseOfTreasurySharesinShares_lbl" xml:lang="en-US">Purchase of treasury shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PurchaseOfTreasurySharesinShares" xlink:to="onco_PurchaseOfTreasurySharesinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_UnlabeledAbstract7" xlink:href="onco-20231231.xsd#onco_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnlabeledAbstract7" xlink:to="onco_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions" xlink:href="onco-20231231.xsd#onco_IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions_lbl" xml:lang="en-US">Issuance of common stock from exercise of preferred investment options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions" xlink:to="onco_IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares_lbl" xml:lang="en-US">Issuance of common stock from exercise of preferred investment options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of warrants for settlement of contingent warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of warrants for settlement of contingent warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock_lbl" xml:lang="en-US">Issuance of Series A Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock" xlink:to="onco_StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares_lbl" xml:lang="en-US">Issuance of Series A Preferred Stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares" xlink:to="onco_StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction_lbl" xml:lang="en-US">Issuance of common stock and Series B Preferred Stock in connection with PMX Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" xlink:to="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction_lbl" xml:lang="en-US">Issuance of common stock and Series B Preferred Stock in connection with PMX Transaction (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" xlink:to="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction_lbl0" xml:lang="en-US">Issuance of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" xlink:to="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction_lbl" xml:lang="en-US">Assumption of stock-based compensation plan awards in connection with PMX Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" xlink:to="onco_StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction_lbl" xml:lang="en-US">Assumption of stock-based compensation plan awards in connection with PMX Transaction (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" xlink:to="onco_StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Forfeitures of restricted stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Forfeitures of restricted stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax" xlink:href="onco-20231231.xsd#onco_OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax_lbl" xml:lang="en-US">Foreign currency translation adjustment (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax" xlink:to="onco_OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation_lbl" xml:lang="en-US">Changes in pension benefit obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation" xlink:to="onco_StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Impairment of ENTADFI assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of subscription agreement liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl0" xml:lang="en-US">Warrant liability (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_GainLossOnRelatedPartyReceivable" xlink:href="onco-20231231.xsd#onco_GainLossOnRelatedPartyReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_GainLossOnRelatedPartyReceivable_lbl" xml:lang="en-US">Loss on related party receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_GainLossOnRelatedPartyReceivable" xlink:to="onco_GainLossOnRelatedPartyReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Recovery of related party receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Impairment of inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl" xml:lang="en-US">Change in fair value of subscription agreement liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionExpense_lbl" xml:lang="en-US">Net periodic pension benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionExpense" xlink:to="us-gaap_PensionExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Issuance of restricted common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_UnlabeledAbstract8" xlink:href="onco-20231231.xsd#onco_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnlabeledAbstract8" xlink:to="onco_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US">Acquisition of assets, including transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds from exercise of preferred investment options, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from issuance of common stock in initial public offering, net of underwriting discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0" xml:lang="en-US">Offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants in private placements, net of placement agent discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of pre-funded warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_UnlabeledAbstract9" xlink:href="onco-20231231.xsd#onco_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnlabeledAbstract9" xlink:to="onco_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Noncash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1_lbl" xml:lang="en-US">Inventory and intangible assets acquired through issuance of notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_EffectOfBusinessCombination" xlink:href="onco-20231231.xsd#onco_EffectOfBusinessCombination"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_EffectOfBusinessCombination_lbl" xml:lang="en-US">Effect of business combination (Note 5)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_EffectOfBusinessCombination" xlink:to="onco_EffectOfBusinessCombination_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US">Settlement of note payable through issuance of Series A convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xml:lang="en-US">Incremental fair value of exchanged preferred investment options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl0" xml:lang="en-US">Fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1_lbl" xml:lang="en-US">Deferred offering costs included in accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement" xlink:href="onco-20231231.xsd#onco_RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement_lbl" xml:lang="en-US">Recognition of contingent warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement" xlink:to="onco_RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_WarrantsIssuedForSettlementOfContingentWarrants" xlink:href="onco-20231231.xsd#onco_WarrantsIssuedForSettlementOfContingentWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_WarrantsIssuedForSettlementOfContingentWarrants_lbl" xml:lang="en-US">Warrants issued for settlement of contingent warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_WarrantsIssuedForSettlementOfContingentWarrants" xlink:to="onco_WarrantsIssuedForSettlementOfContingentWarrants_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="onco_WarrantsIssuedForSettlementOfContingentWarrants_lbl0" xml:lang="en-US">Warrants recognized (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_WarrantsIssuedForSettlementOfContingentWarrants" xlink:to="onco_WarrantsIssuedForSettlementOfContingentWarrants_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_DeferredOfferingCostsPreviouslyPrepaid" xlink:href="onco-20231231.xsd#onco_DeferredOfferingCostsPreviouslyPrepaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_DeferredOfferingCostsPreviouslyPrepaid_lbl" xml:lang="en-US">Deferred offering costs previously included in prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_DeferredOfferingCostsPreviouslyPrepaid" xlink:to="onco_DeferredOfferingCostsPreviouslyPrepaid_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_Exerciseofprefundedwarrants" xlink:href="onco-20231231.xsd#onco_Exerciseofprefundedwarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_Exerciseofprefundedwarrants_lbl" xml:lang="en-US">Exercise of pre-funded warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_Exerciseofprefundedwarrants" xlink:to="onco_Exerciseofprefundedwarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_IssuanceOfRestrictedStock" xlink:href="onco-20231231.xsd#onco_IssuanceOfRestrictedStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_IssuanceOfRestrictedStock_lbl" xml:lang="en-US">Issuance of restricted stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IssuanceOfRestrictedStock" xlink:to="onco_IssuanceOfRestrictedStock_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_RestrictedStockForfeitures" xlink:href="onco-20231231.xsd#onco_RestrictedStockForfeitures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_RestrictedStockForfeitures_lbl" xml:lang="en-US">Restricted stock forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RestrictedStockForfeitures" xlink:to="onco_RestrictedStockForfeitures_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_PaymentOfAccruedBonusThroughRelatedPartyReceivable" xlink:href="onco-20231231.xsd#onco_PaymentOfAccruedBonusThroughRelatedPartyReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_PaymentOfAccruedBonusThroughRelatedPartyReceivable_lbl" xml:lang="en-US">Payment of accrued bonus through related party receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PaymentOfAccruedBonusThroughRelatedPartyReceivable" xlink:to="onco_PaymentOfAccruedBonusThroughRelatedPartyReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Conversion of Series Seed Preferred Stock to common stock upon initial public offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock, at cost; 517,399 and 459,729 shares of common stock at December 31, 2023 and 2022, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl" xml:lang="en-US">Foreign currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl0" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_PurchaseOfTreasuryShares" xlink:href="onco-20231231.xsd#onco_PurchaseOfTreasuryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="onco_PurchaseOfTreasuryShares_lbl" xml:lang="en-US">Purchase of treasury shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PurchaseOfTreasuryShares" xlink:to="onco_PurchaseOfTreasuryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_lbl" xml:lang="en-US">Loss on impairment of other long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US">Change in fair value of contingent warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Other noncurrent assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl" xml:lang="en-US">Acquisition of assets, including transaction costs of $79,771</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit_lbl" xml:lang="en-US">Deposit made in connection with asset purchase agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:to="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US">Cash acquired through business combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Purchases of other long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ReceivableFromRelatedParties1" xlink:href="onco-20231231.xsd#onco_ReceivableFromRelatedParties1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="onco_ReceivableFromRelatedParties1_lbl" xml:lang="en-US">Net advances to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ReceivableFromRelatedParties1" xlink:to="onco_ReceivableFromRelatedParties1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_PaymentsForPurchaseOfTreasuryShares" xlink:href="onco-20231231.xsd#onco_PaymentsForPurchaseOfTreasuryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="onco_PaymentsForPurchaseOfTreasuryShares_lbl" xml:lang="en-US">Purchase of treasury shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PaymentsForPurchaseOfTreasuryShares" xlink:to="onco_PaymentsForPurchaseOfTreasuryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payment of deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Equity issuance cost. (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Principal payment of note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" xml:lang="en-US">Payments of initial public offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfPrivatePlacement_lbl" xml:lang="en-US">Payment of private placement issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfPrivatePlacement" xlink:to="us-gaap_PaymentsForRepurchaseOfPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl0" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_SeriesBConvertibleRedeemablePreferredStockMember" xlink:href="onco-20231231.xsd#onco_SeriesBConvertibleRedeemablePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_SeriesBConvertibleRedeemablePreferredStockMember_lbl" xml:lang="en-US">Series B Convertible Redeemable Preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SeriesBConvertibleRedeemablePreferredStockMember" xlink:to="onco_SeriesBConvertibleRedeemablePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SeriesAConvertiblePreferredStockMember" xlink:href="onco-20231231.xsd#onco_SeriesAConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SeriesAConvertiblePreferredStockMember" xlink:to="onco_SeriesAConvertiblePreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="onco_SeriesAConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SeriesAConvertiblePreferredStockMember" xlink:to="onco_SeriesAConvertiblePreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl0" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockMember_lbl0" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl0" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_SeriesSeedMember" xlink:href="onco-20231231.xsd#onco_SeriesSeedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_SeriesSeedMember_lbl" xml:lang="en-US">Series Seed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SeriesSeedMember" xlink:to="onco_SeriesSeedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xml:lang="en-US">Treasury Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Other Comprehensive Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ParentMember_lbl" xml:lang="en-US">Total Onconetix Equity (Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Non-controlling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Organization and Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Going Concern and Management&#8217;s Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Revenue by Geographical Area</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl" xml:lang="en-US">Schedule of Long-lived by Geographical Area</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncurrentAssets_lbl" xml:lang="en-US">Total long-lived asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncurrentAssets" xlink:to="us-gaap_NoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Financial Instruments Measured on a Recurring Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_LiabilitiesAbstract0" xlink:href="onco-20231231.xsd#onco_LiabilitiesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_LiabilitiesAbstract0_lbl" xml:lang="en-US">Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_LiabilitiesAbstract0" xlink:to="onco_LiabilitiesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of Activity for the Subscription Agreement Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues_lbl" xml:lang="en-US">Fair value upon issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_lbl" xml:lang="en-US">Change in fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of Activity for the Contingent Warrant Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_lbl" xml:lang="en-US">Fair value at issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ReclassificationToEquity" xlink:href="onco-20231231.xsd#onco_ReclassificationToEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_ReclassificationToEquity_lbl" xml:lang="en-US">Reclassification to equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ReclassificationToEquity" xlink:to="onco_ReclassificationToEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Computation of Diluted Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US">Balance Sheet Details</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work-in-process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidRent_lbl" xml:lang="en-US">Prepaid regulatory fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRent" xlink:to="us-gaap_PrepaidRent_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_PrepaidsResearchAndDevelopment" xlink:href="onco-20231231.xsd#onco_PrepaidsResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_PrepaidsResearchAndDevelopment_lbl" xml:lang="en-US">Prepaid research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PrepaidsResearchAndDevelopment" xlink:to="onco_PrepaidsResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_PrepaidProfessionalFees" xlink:href="onco-20231231.xsd#onco_PrepaidProfessionalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_PrepaidProfessionalFees_lbl" xml:lang="en-US">Prepaid professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PrepaidProfessionalFees" xlink:to="onco_PrepaidProfessionalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_CostBasisAbstract" xlink:href="onco-20231231.xsd#onco_CostBasisAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_CostBasisAbstract_lbl" xml:lang="en-US">Cost basis:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CostBasisAbstract" xlink:to="onco_CostBasisAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_FiniteLivedIntangibleAssetCost" xlink:href="onco-20231231.xsd#onco_FiniteLivedIntangibleAssetCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_FiniteLivedIntangibleAssetCost_lbl" xml:lang="en-US">Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_FiniteLivedIntangibleAssetCost" xlink:to="onco_FiniteLivedIntangibleAssetCost_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ImpairmentOfIntangibleAssetExcludingGoodwill" xlink:href="onco-20231231.xsd#onco_ImpairmentOfIntangibleAssetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_ImpairmentOfIntangibleAssetExcludingGoodwill_lbl" xml:lang="en-US">Impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ImpairmentOfIntangibleAssetExcludingGoodwill" xlink:to="onco_ImpairmentOfIntangibleAssetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_lbl" xml:lang="en-US">Effect of Currency Translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:to="us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Intangible assets, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AccumulatedAmortizationAbstract" xlink:href="onco-20231231.xsd#onco_AccumulatedAmortizationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AccumulatedAmortizationAbstract_lbl" xml:lang="en-US">Accumulated amortization:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AccumulatedAmortizationAbstract" xlink:to="onco_AccumulatedAmortizationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation" xlink:href="onco-20231231.xsd#onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation_lbl" xml:lang="en-US">Effect of Currency Translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation" xlink:to="onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Annual Amortization Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xml:lang="en-US">Schedule of Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillTransfers" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillTransfers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillTransfers_lbl" xml:lang="en-US">PMX Transaction goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillTransfers" xlink:to="us-gaap_GoodwillTransfers_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss_lbl" xml:lang="en-US">Effect of currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AccruedResearchAndDevelopmentCurrent" xlink:href="onco-20231231.xsd#onco_AccruedResearchAndDevelopmentCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AccruedResearchAndDevelopmentCurrent_lbl" xml:lang="en-US">Accrued research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AccruedResearchAndDevelopmentCurrent" xlink:to="onco_AccruedResearchAndDevelopmentCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedUtilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedUtilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedUtilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedUtilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedUtilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AccruedDeferredOfferingCosts" xlink:href="onco-20231231.xsd#onco_AccruedDeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AccruedDeferredOfferingCosts_lbl" xml:lang="en-US">Accrued deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AccruedDeferredOfferingCosts" xlink:to="onco_AccruedDeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedMarketingCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedMarketingCostsCurrent_lbl" xml:lang="en-US">Accrued implementation fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedMarketingCostsCurrent" xlink:to="us-gaap_AccruedMarketingCostsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Other accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl" xml:lang="en-US">Accrued franchise taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xml:lang="en-US">Acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock_lbl" xml:lang="en-US">Schedule of Aggregate Consideration Transferred for the Assets Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets_lbl" xml:lang="en-US">Consideration transferred at closing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl" xml:lang="en-US">Fair value of notes payable issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xml:lang="en-US">Transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1_lbl" xml:lang="en-US">Common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredOther1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xml:lang="en-US">Series B convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Total consideration transferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl0" xml:lang="en-US">Consideration transferred total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionTableTextBlock_lbl" xml:lang="en-US">Schedule of Assets Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTableTextBlock" xlink:to="us-gaap_AssetAcquisitionTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AssetAcquisitionConsiderationTransferredInventory" xlink:href="onco-20231231.xsd#onco_AssetAcquisitionConsiderationTransferredInventory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AssetAcquisitionConsiderationTransferredInventory_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AssetAcquisitionConsiderationTransferredInventory" xlink:to="onco_AssetAcquisitionConsiderationTransferredInventory_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible" xlink:href="onco-20231231.xsd#onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible_lbl" xml:lang="en-US">ENTADFI&#174; Intangible</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible" xlink:to="onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of the Proteomedix Stock Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US">Fair value of measurement input</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl0" xml:lang="en-US">Significant assumptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl1" xml:lang="en-US">Aggregate equity value measurement input</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Fair Values of Assets Acquired and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset_lbl" xml:lang="en-US">Right of use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xml:lang="en-US">Trade name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships_lbl" xml:lang="en-US">Customer relationships</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology_lbl" xml:lang="en-US">Product rights for developed technology</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Net assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl" xml:lang="en-US">Schedule of Consolidated Statements of Operations and Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SignificantAgreementsTextBlock" xlink:href="onco-20231231.xsd#onco_SignificantAgreementsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_SignificantAgreementsTextBlock_lbl" xml:lang="en-US">Significant Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SignificantAgreementsTextBlock" xlink:to="onco_SignificantAgreementsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SubscriptionAgreementDisclosureTextBlock" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_SubscriptionAgreementDisclosureTextBlock_lbl" xml:lang="en-US">Subscription Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SubscriptionAgreementDisclosureTextBlock" xlink:to="onco_SubscriptionAgreementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Assumptions Used in Monte-Carlo Model, Which Utilizes Level 3 Inputs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Redeemable Preferred Stock and Stockholders&apos; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of the Preferred Investment Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Term (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected stock price volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free rate of interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock" xlink:href="onco-20231231.xsd#onco_ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of Valuation of the Contingent Warrant Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock" xlink:to="onco_ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Outstanding Warrants, Excluding Contingent Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life, ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Weighted average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Shares, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Shares, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Number of Shares, Forfeited / cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xml:lang="en-US">Stock options forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Warrants vested and exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants vested and exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life, Warrants vested and exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted" xlink:href="onco-20231231.xsd#onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted_lbl" xml:lang="en-US">Total Intrinsic Value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted" xlink:to="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited / cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled" xlink:href="onco-20231231.xsd#onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled_lbl" xml:lang="en-US">Total Intrinsic Value, Forfeited / cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled" xlink:to="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Total Intrinsic Value, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Options vested and exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options vested and exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Total Intrinsic Value, Options vested and exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life, Options vested and exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock" xlink:href="onco-20231231.xsd#onco_ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock" xlink:to="onco_ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Unvested Restricted Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Shares, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted	Average Grant Date Fair Value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted	Average Grant Date Fair Value, Forfeited / cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted	Average Grant Date Fair Value, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total stock-based compensation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of Loss Before Income Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">U.S.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net-operating loss carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangibles</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Capitalized research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Deposit on WraSer APA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_LicenseAgreement" xlink:href="onco-20231231.xsd#onco_LicenseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_LicenseAgreement_lbl" xml:lang="en-US">License agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_LicenseAgreement" xlink:to="onco_LicenseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xml:lang="en-US">Other accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Gross deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net of allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Taxes Differs from the Statutory Federal Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Expected income tax benefit at Federal statutory tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State and local taxes, net of Federal tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">State NOLs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign NOL expirations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl0" xml:lang="en-US">Foreign NOLs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability" xlink:href="onco-20231231.xsd#onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability_lbl" xml:lang="en-US">Derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability" xlink:to="onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" xlink:href="onco-20231231.xsd#onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation_lbl" xml:lang="en-US">Officer&#8217;s compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" xlink:to="onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Acquisition related costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US">Permanent items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment" xlink:href="onco-20231231.xsd#onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment_lbl" xml:lang="en-US">State rate adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment" xlink:to="onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US">Increases related to prior year tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US">Increases related to current year tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Retirement Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock_lbl" xml:lang="en-US">Schedule of Benefit Obligation and the Net Periodic Benefit Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" xlink:to="us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_lbl" xml:lang="en-US">Discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_lbl" xml:lang="en-US">Expected long-term rate of return on plan assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_lbl" xml:lang="en-US">Rate of compensation increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_lbl" xml:lang="en-US">Schedule of Accompanying Consolidated Balance Sheet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanServiceCost_lbl" xml:lang="en-US">Service cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanServiceCost" xlink:to="us-gaap_DefinedBenefitPlanServiceCost_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DefinedBenefitPlanServiceCost_lbl0" xml:lang="en-US">Services payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanServiceCost" xlink:to="us-gaap_DefinedBenefitPlanServiceCost_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanInterestCost_lbl" xml:lang="en-US">Interest cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanInterestCost" xlink:to="us-gaap_DefinedBenefitPlanInterestCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl" xml:lang="en-US">Schedule of Accumulated Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent_lbl" xml:lang="en-US">Net loss (gain)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AmortizationOfNetGain" xlink:href="onco-20231231.xsd#onco_AmortizationOfNetGain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AmortizationOfNetGain_lbl" xml:lang="en-US">Amortization of net gain</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AmortizationOfNetGain" xlink:to="onco_AmortizationOfNetGain_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_EffectOfSettlement" xlink:href="onco-20231231.xsd#onco_EffectOfSettlement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_EffectOfSettlement_lbl" xml:lang="en-US">Effect of settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_EffectOfSettlement" xlink:to="onco_EffectOfSettlement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Other adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RegulatedAndUnregulatedOperatingRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegulatedAndUnregulatedOperatingRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RegulatedAndUnregulatedOperatingRevenue_lbl" xml:lang="en-US">Total recorded during the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegulatedAndUnregulatedOperatingRevenue" xlink:to="us-gaap_RegulatedAndUnregulatedOperatingRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock" xlink:href="onco-20231231.xsd#onco_ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock_lbl" xml:lang="en-US">Schedule of Accompanying Consolidated Balance Sheet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock" xlink:to="onco_ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_lbl" xml:lang="en-US">Projected benefit obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:to="us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_lbl0" xml:lang="en-US">Projected benefit obligation as of December 31, 2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:to="us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_lbl" xml:lang="en-US">Fair value of plan assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:to="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xml:lang="en-US">Schedule of the Beginning and Ending Balances of the Accumulated Benefit Obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanActuarialGainLoss_lbl" xml:lang="en-US">Actuarial (gain) loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="us-gaap_DefinedBenefitPlanActuarialGainLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees" xlink:href="onco-20231231.xsd#onco_DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees_lbl" xml:lang="en-US">Ordinary contributions paid by employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees" xlink:to="onco_DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_lbl" xml:lang="en-US">Contributions paid by plan participants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement_lbl" xml:lang="en-US">Settlements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanOtherChanges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanOtherChanges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanOtherChanges_lbl" xml:lang="en-US">Actuarial (gain)/loss due to assumption changes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanOtherChanges" xlink:to="us-gaap_DefinedBenefitPlanOtherChanges_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_lbl" xml:lang="en-US">Actuarial (gain)/loss due to plan experience</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_lbl" xml:lang="en-US">Actual return on plan assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xml:lang="en-US">Contributions paid by employer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees" xlink:href="onco-20231231.xsd#onco_DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees_lbl" xml:lang="en-US">Ordinary contributions paid by employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees" xlink:to="onco_DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_lbl" xml:lang="en-US">Contributions paid by plan participants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Benefit Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_lbl" xml:lang="en-US">2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_lbl" xml:lang="en-US">Change in fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Amortization expense related to intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_lbl" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xml:lang="en-US">Deferred tax liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation_lbl" xml:lang="en-US">Pension benefit obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable_lbl" xml:lang="en-US">Note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_lbl" xml:lang="en-US">Less non-controlling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:to="us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of Shares, Forfeited / cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of Shares, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Net deferred tax liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_lbl" xml:lang="en-US">Expected return on plan assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_lbl" xml:lang="en-US">Amortization of net (gain)/loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_lbl" xml:lang="en-US">Settlements (gain)/loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:to="us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_lbl" xml:lang="en-US">Benefits paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_lbl" xml:lang="en-US">Benefits paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DefinedBenefitPlanSettlementsPlanAssets_lbl" xml:lang="en-US">Settlements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="us-gaap_DefinedBenefitPlanSettlementsPlanAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">United States [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:label="country_CH" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CH"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_CH_lbl" xml:lang="en-US">Switzerland [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CH" xlink:to="country_CH_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="country_CH_lbl0" xml:lang="en-US">Zurich Switzerland [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CH" xlink:to="country_CH_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Level 3 Inputs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_SubscriptionAgreementLiabilityMember" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementLiabilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_SubscriptionAgreementLiabilityMember_lbl" xml:lang="en-US">Subscription Agreement Liability [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SubscriptionAgreementLiabilityMember" xlink:to="onco_SubscriptionAgreementLiabilityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ContingentWarrantLiabilityMember" xlink:href="onco-20231231.xsd#onco_ContingentWarrantLiabilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_ContingentWarrantLiabilityMember_lbl" xml:lang="en-US">Contingent Warrant Liability [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ContingentWarrantLiabilityMember" xlink:to="onco_ContingentWarrantLiabilityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_StockOptionsMember" xlink:href="onco-20231231.xsd#onco_StockOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_StockOptionsMember_lbl" xml:lang="en-US">Stock options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockOptionsMember" xlink:to="onco_StockOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Unvested restricted stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl0" xml:lang="en-US">Restricted Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_CommonStockIssuableUponConversionOfSeriesAPreferredStockMember" xlink:href="onco-20231231.xsd#onco_CommonStockIssuableUponConversionOfSeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_CommonStockIssuableUponConversionOfSeriesAPreferredStockMember_lbl" xml:lang="en-US">Common stock issuable upon conversion of Series A preferred stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CommonStockIssuableUponConversionOfSeriesAPreferredStockMember" xlink:to="onco_CommonStockIssuableUponConversionOfSeriesAPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeNamesMember_lbl" xml:lang="en-US">Trade name [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeNamesMember" xlink:to="us-gaap_TradeNamesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TradeNamesMember_lbl0" xml:lang="en-US">Trade Names [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeNamesMember" xlink:to="us-gaap_TradeNamesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xml:lang="en-US">Product rights for developed technology [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl0" xml:lang="en-US">Product Rights Intangible Asset [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl1" xml:lang="en-US">Product Rights Developed Technology [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerRelationshipsMember_lbl" xml:lang="en-US">Customer relationships [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CustomerRelationshipsMember_lbl0" xml:lang="en-US">Customer Relationships [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_AggregateConsiderationTransferredMember" xlink:href="onco-20231231.xsd#onco_AggregateConsiderationTransferredMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AggregateConsiderationTransferredMember_lbl" xml:lang="en-US">Aggregate Consideration Transferred [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregateConsiderationTransferredMember" xlink:to="onco_AggregateConsiderationTransferredMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_FairValueConsiderationTransferredMember" xlink:href="onco-20231231.xsd#onco_FairValueConsiderationTransferredMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_FairValueConsiderationTransferredMember_lbl" xml:lang="en-US">Fair Value Consideration Transferred [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_FairValueConsiderationTransferredMember" xlink:to="onco_FairValueConsiderationTransferredMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AssetsRecognizedMember" xlink:href="onco-20231231.xsd#onco_AssetsRecognizedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AssetsRecognizedMember_lbl" xml:lang="en-US">Assets Recognized	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AssetsRecognizedMember" xlink:to="onco_AssetsRecognizedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_MeasurementInputStockPriceMember" xlink:href="onco-20231231.xsd#onco_MeasurementInputStockPriceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_MeasurementInputStockPriceMember_lbl" xml:lang="en-US">Stock price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_MeasurementInputStockPriceMember" xlink:to="onco_MeasurementInputStockPriceMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Term (years) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl0" xml:lang="en-US">Term [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl1" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Expected stock price volatility	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl0" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Risk-free rate of interest [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl0" xml:lang="en-US">Risk-free Rate of Interest [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl1" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Property and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockOptionMember_lbl1" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_BusinessAcquisitionMember" xlink:href="onco-20231231.xsd#onco_BusinessAcquisitionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_BusinessAcquisitionMember_lbl" xml:lang="en-US">Business Acquisition [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessAcquisitionMember" xlink:to="onco_BusinessAcquisitionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ProteomedixMember" xlink:href="onco-20231231.xsd#onco_ProteomedixMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_ProteomedixMember_lbl" xml:lang="en-US">Proteomedix [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ProteomedixMember" xlink:to="onco_ProteomedixMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_PMXTransactionMember" xlink:href="onco-20231231.xsd#onco_PMXTransactionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_PMXTransactionMember_lbl" xml:lang="en-US">PMX Transaction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PMXTransactionMember" xlink:to="onco_PMXTransactionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US">Exercise Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xml:lang="en-US">Expected Stock Price Volatility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_OriginalMember" xlink:href="onco-20231231.xsd#onco_OriginalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_OriginalMember_lbl" xml:lang="en-US">Original [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_OriginalMember" xlink:to="onco_OriginalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ExchangedMember" xlink:href="onco-20231231.xsd#onco_ExchangedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_ExchangedMember_lbl" xml:lang="en-US">Exchanged [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ExchangedMember" xlink:to="onco_ExchangedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, general and administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ResearchAndDevelopmentMember" xlink:href="onco-20231231.xsd#onco_ResearchAndDevelopmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_ResearchAndDevelopmentMember_lbl" xml:lang="en-US">Research and development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ResearchAndDevelopmentMember" xlink:to="onco_ResearchAndDevelopmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AccumulatedBenefitObligationMember" xlink:href="onco-20231231.xsd#onco_AccumulatedBenefitObligationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AccumulatedBenefitObligationMember_lbl" xml:lang="en-US">Accumulated Benefit Obligation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AccumulatedBenefitObligationMember" xlink:to="onco_AccumulatedBenefitObligationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_PlanAssetsMember" xlink:href="onco-20231231.xsd#onco_PlanAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_PlanAssetsMember_lbl" xml:lang="en-US">Plan Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PlanAssetsMember" xlink:to="onco_PlanAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis_lbl" xml:lang="en-US">Industry Sector [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesByIndustryAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity interest ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Subsidiary owned, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl" xml:lang="en-US">Reclassifications cash flow activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_InitialPublicOfferingShares" xlink:href="onco-20231231.xsd#onco_InitialPublicOfferingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_InitialPublicOfferingShares_lbl" xml:lang="en-US">Common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_InitialPublicOfferingShares" xlink:to="onco_InitialPublicOfferingShares_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_PublicOfPerShare" xlink:href="onco-20231231.xsd#onco_PublicOfPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_PublicOfPerShare_lbl" xml:lang="en-US">Public of per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PublicOfPerShare" xlink:to="onco_PublicOfPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Convertible preferred stock shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" xlink:to="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0" xml:lang="en-US">Private placement were approximatel (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfOtherInvestments_lbl" xml:lang="en-US">Proceeds from preferred investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:to="us-gaap_ProceedsFromSaleOfOtherInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_WorkingCapitalDeficit" xlink:href="onco-20231231.xsd#onco_WorkingCapitalDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_WorkingCapitalDeficit_lbl" xml:lang="en-US">Working capital deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_WorkingCapitalDeficit" xlink:to="onco_WorkingCapitalDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAppropriated" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAppropriated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAppropriated_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAppropriated" xlink:to="us-gaap_RetainedEarningsAppropriated_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Operating segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Inventory reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Impairment loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xml:lang="en-US">Impairment loss of long lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RecognitionOfDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecognitionOfDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RecognitionOfDeferredRevenue_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecognitionOfDeferredRevenue" xlink:to="us-gaap_RecognitionOfDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCostOfOperatingRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostOfOperatingRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCostOfOperatingRevenue_lbl" xml:lang="en-US">Cost of revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostOfOperatingRevenue" xlink:to="us-gaap_OtherCostOfOperatingRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general, and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Selling, general and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment charge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US">Weighted-average remaining amortization period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedTradeNames" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedTradeNames"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedTradeNames_lbl" xml:lang="en-US">Indefinite life intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedTradeNames" xlink:to="us-gaap_IndefiniteLivedTradeNames_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xml:lang="en-US">Consideration amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl" xml:lang="en-US">Business acquisition, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_RoyaltySalesPercentage" xlink:href="onco-20231231.xsd#onco_RoyaltySalesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_RoyaltySalesPercentage_lbl" xml:lang="en-US">Royalty sales percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RoyaltySalesPercentage" xlink:to="onco_RoyaltySalesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SalesPaymentsAmount" xlink:href="onco-20231231.xsd#onco_SalesPaymentsAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_SalesPaymentsAmount_lbl" xml:lang="en-US">Sales payments amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SalesPaymentsAmount" xlink:to="onco_SalesPaymentsAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationDescription_lbl" xml:lang="en-US">Business acquisition, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationDescription" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AggregatePurchaseShares" xlink:href="onco-20231231.xsd#onco_AggregatePurchaseShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AggregatePurchaseShares_lbl" xml:lang="en-US">Aggregate shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregatePurchaseShares" xlink:to="onco_AggregatePurchaseShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="onco_AggregatePurchaseShares_lbl0" xml:lang="en-US">Purchase of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregatePurchaseShares" xlink:to="onco_AggregatePurchaseShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_BusinessTransactionYeare" xlink:href="onco-20231231.xsd#onco_BusinessTransactionYeare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_BusinessTransactionYeare_lbl" xml:lang="en-US">Business transaction years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessTransactionYeare" xlink:to="onco_BusinessTransactionYeare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Estimated using discount percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0" xml:lang="en-US">Accrue interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl1" xml:lang="en-US">Debenture interest rate percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl1"/>
    <loc xlink:type="locator" xlink:label="onco_InventoryFairValue" xlink:href="onco-20231231.xsd#onco_InventoryFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_InventoryFairValue_lbl" xml:lang="en-US">Inventory fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_InventoryFairValue" xlink:to="onco_InventoryFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ImpairmentRate" xlink:href="onco-20231231.xsd#onco_ImpairmentRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_ImpairmentRate_lbl" xml:lang="en-US">Impairment rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ImpairmentRate" xlink:to="onco_ImpairmentRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts_lbl" xml:lang="en-US">Cash payment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_InitialPaymentAmount" xlink:href="onco-20231231.xsd#onco_InitialPaymentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_InitialPaymentAmount_lbl" xml:lang="en-US">Initial payment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_InitialPaymentAmount" xlink:to="onco_InitialPaymentAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_Payments" xlink:href="onco-20231231.xsd#onco_Payments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_Payments_lbl" xml:lang="en-US">Company payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_Payments" xlink:to="onco_Payments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Deposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Deposits_lbl" xml:lang="en-US">Payment as deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash target amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Initial payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsForFees_lbl0" xml:lang="en-US">Fees under consulting agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_VotingInterestPercentage" xlink:href="onco-20231231.xsd#onco_VotingInterestPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_VotingInterestPercentage_lbl" xml:lang="en-US">Voting interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_VotingInterestPercentage" xlink:to="onco_VotingInterestPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_NumberOfShares" xlink:href="onco-20231231.xsd#onco_NumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_NumberOfShares_lbl" xml:lang="en-US">Number of shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_NumberOfShares" xlink:to="onco_NumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_RoyaltyRate" xlink:href="onco-20231231.xsd#onco_RoyaltyRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_RoyaltyRate_lbl" xml:lang="en-US">Royalty rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RoyaltyRate" xlink:to="onco_RoyaltyRate_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_WeightedAverageDiscountRate" xlink:href="onco-20231231.xsd#onco_WeightedAverageDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_WeightedAverageDiscountRate_lbl" xml:lang="en-US">Discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_WeightedAverageDiscountRate" xlink:to="onco_WeightedAverageDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_WeightedAverageDiscountRateThereafter" xlink:href="onco-20231231.xsd#onco_WeightedAverageDiscountRateThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_WeightedAverageDiscountRateThereafter_lbl" xml:lang="en-US">Discount rate thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_WeightedAverageDiscountRateThereafter" xlink:to="onco_WeightedAverageDiscountRateThereafter_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentOwnedAtCost_lbl" xml:lang="en-US">Related cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtCost" xlink:to="us-gaap_InvestmentOwnedAtCost_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AggregateAgreementAmountInitialAgreement" xlink:href="onco-20231231.xsd#onco_AggregateAgreementAmountInitialAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AggregateAgreementAmountInitialAgreement_lbl" xml:lang="en-US">Aggregate agreement amount initial agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregateAgreementAmountInitialAgreement" xlink:to="onco_AggregateAgreementAmountInitialAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AggregateeAmount" xlink:href="onco-20231231.xsd#onco_AggregateeAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AggregateeAmount_lbl" xml:lang="en-US">Aggregate amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregateeAmount" xlink:to="onco_AggregateeAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_CostPlusPercentage" xlink:href="onco-20231231.xsd#onco_CostPlusPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_CostPlusPercentage_lbl" xml:lang="en-US">Cost plus, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CostPlusPercentage" xlink:to="onco_CostPlusPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_CommercialSaleTerm" xlink:href="onco-20231231.xsd#onco_CommercialSaleTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_CommercialSaleTerm_lbl" xml:lang="en-US">Commercial sale term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CommercialSaleTerm" xlink:to="onco_CommercialSaleTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_RoyaltyNetSalesPercentage" xlink:href="onco-20231231.xsd#onco_RoyaltyNetSalesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_RoyaltyNetSalesPercentage_lbl" xml:lang="en-US">Royalty net sales percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RoyaltyNetSalesPercentage" xlink:to="onco_RoyaltyNetSalesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductLiabilityContingencyAccrualDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityContingencyAccrualDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductLiabilityContingencyAccrualDiscountRate_lbl" xml:lang="en-US">Percentage of product</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyAccrualDiscountRate" xlink:to="us-gaap_ProductLiabilityContingencyAccrualDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_RoyaltyRates" xlink:href="onco-20231231.xsd#onco_RoyaltyRates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_RoyaltyRates_lbl" xml:lang="en-US">Royalty rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RoyaltyRates" xlink:to="onco_RoyaltyRates_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_RevenueRate" xlink:href="onco-20231231.xsd#onco_RevenueRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_RevenueRate_lbl" xml:lang="en-US">Revenue rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RevenueRate" xlink:to="onco_RevenueRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FeeIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FeeIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FeeIncome_lbl" xml:lang="en-US">Option fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FeeIncome" xlink:to="us-gaap_FeeIncome_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FeeIncome_lbl0" xml:lang="en-US">Cash fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FeeIncome" xlink:to="us-gaap_FeeIncome_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_AggregateRoyaltiesAmount" xlink:href="onco-20231231.xsd#onco_AggregateRoyaltiesAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AggregateRoyaltiesAmount_lbl" xml:lang="en-US">Aggregate payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregateRoyaltiesAmount" xlink:to="onco_AggregateRoyaltiesAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopmentCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DevelopmentCosts_lbl" xml:lang="en-US">Development milestones costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopmentCosts" xlink:to="us-gaap_DevelopmentCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfPropertyRepairsAndMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfPropertyRepairsAndMaintenance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfPropertyRepairsAndMaintenance_lbl" xml:lang="en-US">Maintenance fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfPropertyRepairsAndMaintenance" xlink:to="us-gaap_CostOfPropertyRepairsAndMaintenance_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_PercentageOfConsiderationReceived" xlink:href="onco-20231231.xsd#onco_PercentageOfConsiderationReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_PercentageOfConsiderationReceived_lbl" xml:lang="en-US">Percentage of consideration received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfConsiderationReceived" xlink:to="onco_PercentageOfConsiderationReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesAndLicenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesAndLicenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesAndLicenses_lbl" xml:lang="en-US">License fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesAndLicenses" xlink:to="us-gaap_TaxesAndLicenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostMaintenance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostMaintenance_lbl" xml:lang="en-US">Annual maintenance fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xml:lang="en-US">License fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AmountOfOtherPartyPayments" xlink:href="onco-20231231.xsd#onco_AmountOfOtherPartyPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AmountOfOtherPartyPayments_lbl" xml:lang="en-US">Other party payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AmountOfOtherPartyPayments" xlink:to="onco_AmountOfOtherPartyPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_RoyaltiesPercentage" xlink:href="onco-20231231.xsd#onco_RoyaltiesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_RoyaltiesPercentage_lbl" xml:lang="en-US">Royalties percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RoyaltiesPercentage" xlink:to="onco_RoyaltiesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Sales-related services fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdministrativeFeesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdministrativeFeesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdministrativeFeesExpense_lbl" xml:lang="en-US">Total amount of fee expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdministrativeFeesExpense" xlink:to="us-gaap_AdministrativeFeesExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturityDate_lbl" xml:lang="en-US">Maturity term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturityDate" xlink:to="us-gaap_LongTermDebtMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalAndContractServicesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US">Expense related to contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_LicensedProductsPlusMilestonePaymentsDescription" xlink:href="onco-20231231.xsd#onco_LicensedProductsPlusMilestonePaymentsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_LicensedProductsPlusMilestonePaymentsDescription_lbl" xml:lang="en-US">Description of licensed products</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_LicensedProductsPlusMilestonePaymentsDescription" xlink:to="onco_LicensedProductsPlusMilestonePaymentsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xml:lang="en-US">Principal payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl0" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_PayableAverageDiscountRatePercentage" xlink:href="onco-20231231.xsd#onco_PayableAverageDiscountRatePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_PayableAverageDiscountRatePercentage_lbl" xml:lang="en-US">Average discount rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PayableAverageDiscountRatePercentage" xlink:to="onco_PayableAverageDiscountRatePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Unamortized debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Note payable originally due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_DebtInstrumentDueDate" xlink:href="onco-20231231.xsd#onco_DebtInstrumentDueDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_DebtInstrumentDueDate_lbl" xml:lang="en-US">Note payable originally due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_DebtInstrumentDueDate" xlink:to="onco_DebtInstrumentDueDate_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_CashPaymentToTheSeller" xlink:href="onco-20231231.xsd#onco_CashPaymentToTheSeller"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_CashPaymentToTheSeller_lbl" xml:lang="en-US">Cash payment to the seller</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CashPaymentToTheSeller" xlink:to="onco_CashPaymentToTheSeller_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US">Conversion of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_DebtInstrumentDueTerm" xlink:href="onco-20231231.xsd#onco_DebtInstrumentDueTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_DebtInstrumentDueTerm_lbl" xml:lang="en-US">Principal payments due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_DebtInstrumentDueTerm" xlink:to="onco_DebtInstrumentDueTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionPriceOfAcquisitionExpected"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_lbl" xml:lang="en-US">Proteomedix acquisition (in Francs)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:to="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SaleOfUnits" xlink:href="onco-20231231.xsd#onco_SaleOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_SaleOfUnits_lbl" xml:lang="en-US">Sale of units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SaleOfUnits" xlink:to="onco_SaleOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Share of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Share issued of restricted common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Price per unit (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ServicingLiabilityAtFairValueAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServicingLiabilityAtFairValueAdditions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ServicingLiabilityAtFairValueAdditions_lbl" xml:lang="en-US">Fair value of Subscription agreement liability (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServicingLiabilityAtFairValueAdditions" xlink:to="us-gaap_ServicingLiabilityAtFairValueAdditions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ServicingLiabilityAtFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServicingLiabilityAtFairValueAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ServicingLiabilityAtFairValueAmount_lbl" xml:lang="en-US">Fair value of subscription agreement liability (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServicingLiabilityAtFairValueAmount" xlink:to="us-gaap_ServicingLiabilityAtFairValueAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage_lbl" xml:lang="en-US">Estimated probability percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage" xlink:to="us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNotesPayable_lbl" xml:lang="en-US">Notes payable due (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US">Liquidation per shares (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SharesOfCommonStockRate" xlink:href="onco-20231231.xsd#onco_SharesOfCommonStockRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_SharesOfCommonStockRate_lbl" xml:lang="en-US">Shares of common stock rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SharesOfCommonStockRate" xlink:to="onco_SharesOfCommonStockRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Preferred investment option price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US">Preferred stock designated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Stock options vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_PercentageOfIssuedOfCommonStock" xlink:href="onco-20231231.xsd#onco_PercentageOfIssuedOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_PercentageOfIssuedOfCommonStock_lbl" xml:lang="en-US">Percentage of issued of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfIssuedOfCommonStock" xlink:to="onco_PercentageOfIssuedOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_PercentageOfOutstandingOfCommonStock" xlink:href="onco-20231231.xsd#onco_PercentageOfOutstandingOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_PercentageOfOutstandingOfCommonStock_lbl" xml:lang="en-US">Percentage of outstanding of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfOutstandingOfCommonStock" xlink:to="onco_PercentageOfOutstandingOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_PercentageOfCumulativeDividends" xlink:href="onco-20231231.xsd#onco_PercentageOfCumulativeDividends"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_PercentageOfCumulativeDividends_lbl" xml:lang="en-US">Percentage of cumulative dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfCumulativeDividends" xlink:to="onco_PercentageOfCumulativeDividends_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_NettingProceeds" xlink:href="onco-20231231.xsd#onco_NettingProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_NettingProceeds_lbl" xml:lang="en-US">Netting proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_NettingProceeds" xlink:to="onco_NettingProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_PercentageOfOriginalIssuePrice" xlink:href="onco-20231231.xsd#onco_PercentageOfOriginalIssuePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_PercentageOfOriginalIssuePrice_lbl" xml:lang="en-US">Original issue price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfOriginalIssuePrice" xlink:to="onco_PercentageOfOriginalIssuePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CumulativeDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CumulativeDividends"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CumulativeDividends_lbl" xml:lang="en-US">Cumulative dividends (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeDividends" xlink:to="us-gaap_CumulativeDividends_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPayableAmountPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl" xml:lang="en-US">Dividends per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableAmountPerShare" xlink:to="us-gaap_DividendsPayableAmountPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Common stock issued (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl" xml:lang="en-US">Common stock outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonUnitIssued_lbl" xml:lang="en-US">Issued shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonUnitIssued" xlink:to="us-gaap_CommonUnitIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Common stock per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_PercentageOfUnderwritingDiscount" xlink:href="onco-20231231.xsd#onco_PercentageOfUnderwritingDiscount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_PercentageOfUnderwritingDiscount_lbl" xml:lang="en-US">Percentage of underwriting discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfUnderwritingDiscount" xlink:to="onco_PercentageOfUnderwritingDiscount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOwnershipInterestsOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherOwnershipInterestsOfferingCosts_lbl" xml:lang="en-US">Offering costs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:to="us-gaap_OtherOwnershipInterestsOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_lbl" xml:lang="en-US">Warrants to purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xml:lang="en-US">Shares remaining repurchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockAcquiredAverageCostPerShare_lbl" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="us-gaap_TreasuryStockAcquiredAverageCostPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" xml:lang="en-US">Aggregate common stock value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_PlacementAgentFeeAndManagementFeePercentage" xlink:href="onco-20231231.xsd#onco_PlacementAgentFeeAndManagementFeePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_PlacementAgentFeeAndManagementFeePercentage_lbl" xml:lang="en-US">Placement agent fee and management fee percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PlacementAgentFeeAndManagementFeePercentage" xlink:to="onco_PlacementAgentFeeAndManagementFeePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Issued shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AggregateNumberOfSharesPercenatge" xlink:href="onco-20231231.xsd#onco_AggregateNumberOfSharesPercenatge"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AggregateNumberOfSharesPercenatge_lbl" xml:lang="en-US">Aggregate number of shares percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregateNumberOfSharesPercenatge" xlink:to="onco_AggregateNumberOfSharesPercenatge_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">April Contingent Warrants issue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Value of liability (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_CancelledPreferredInvestmentOptionsShares" xlink:href="onco-20231231.xsd#onco_CancelledPreferredInvestmentOptionsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_CancelledPreferredInvestmentOptionsShares_lbl" xml:lang="en-US">Cancelled preferred investment options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CancelledPreferredInvestmentOptionsShares" xlink:to="onco_CancelledPreferredInvestmentOptionsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_PrefundedWarrantsExercised" xlink:href="onco-20231231.xsd#onco_PrefundedWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_PrefundedWarrantsExercised_lbl" xml:lang="en-US">Pre-funded warrants exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PrefundedWarrantsExercised" xlink:to="onco_PrefundedWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendsShares_lbl" xml:lang="en-US">Investment options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsShares" xlink:to="us-gaap_PreferredStockDividendsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceDecrease_lbl" xml:lang="en-US">Reduced exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPriceDecrease" xlink:to="us-gaap_PreferredStockConvertibleConversionPriceDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">(in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherExpenses_lbl0" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_WarrantsIssuableUnderProvisionShares" xlink:href="onco-20231231.xsd#onco_WarrantsIssuableUnderProvisionShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_WarrantsIssuableUnderProvisionShares_lbl" xml:lang="en-US">Warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_WarrantsIssuableUnderProvisionShares" xlink:to="onco_WarrantsIssuableUnderProvisionShares_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_IncreaseInTheFairValueOfThePreferredInvestmentOptions" xlink:href="onco-20231231.xsd#onco_IncreaseInTheFairValueOfThePreferredInvestmentOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_IncreaseInTheFairValueOfThePreferredInvestmentOptions_lbl" xml:lang="en-US">Increase in fair value of the preferred investment options (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IncreaseInTheFairValueOfThePreferredInvestmentOptions" xlink:to="onco_IncreaseInTheFairValueOfThePreferredInvestmentOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Reduction of additional paid in capital (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ContingentWarrantLiabilityShares" xlink:href="onco-20231231.xsd#onco_ContingentWarrantLiabilityShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_ContingentWarrantLiabilityShares_lbl" xml:lang="en-US">Contingent warrant liability shares (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ContingentWarrantLiabilityShares" xlink:to="onco_ContingentWarrantLiabilityShares_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SharesOfCommonStockIssued" xlink:href="onco-20231231.xsd#onco_SharesOfCommonStockIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_SharesOfCommonStockIssued_lbl" xml:lang="en-US">Shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SharesOfCommonStockIssued" xlink:to="onco_SharesOfCommonStockIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_FixedCommissionRate" xlink:href="onco-20231231.xsd#onco_FixedCommissionRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_FixedCommissionRate_lbl" xml:lang="en-US">Fixed commission rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_FixedCommissionRate" xlink:to="onco_FixedCommissionRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl" xml:lang="en-US">(in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionExercisePriceDecrease_lbl" xml:lang="en-US">Reduced exercised price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceDecrease" xlink:to="us-gaap_StockOptionExercisePriceDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AggregateNetProceeds" xlink:href="onco-20231231.xsd#onco_AggregateNetProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AggregateNetProceeds_lbl" xml:lang="en-US">Aggregate net proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregateNetProceeds" xlink:to="onco_AggregateNetProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Issued shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscribedButUnissued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xml:lang="en-US">Shares unissued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_PercentageOfGrossProceeds" xlink:href="onco-20231231.xsd#onco_PercentageOfGrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_PercentageOfGrossProceeds_lbl" xml:lang="en-US">Percentage of gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfGrossProceeds" xlink:to="onco_PercentageOfGrossProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Fees and expenses of legal (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LegalFees_lbl0" xml:lang="en-US">Legal expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralExpense_lbl" xml:lang="en-US">Non-accountable expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralExpense" xlink:to="us-gaap_OtherGeneralExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_PercentageOfCommonStockShares" xlink:href="onco-20231231.xsd#onco_PercentageOfCommonStockShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_PercentageOfCommonStockShares_lbl" xml:lang="en-US">Percentage of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfCommonStockShares" xlink:to="onco_PercentageOfCommonStockShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Warrants issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Outstanding warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Cancellation of warrants issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Fair value per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Fair value of the contingent warrant liability (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock reserved for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Available shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Aggregate fair value of stock options (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ExercisePrice" xlink:href="onco-20231231.xsd#onco_ExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_ExercisePrice_lbl" xml:lang="en-US">options granted exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ExercisePrice" xlink:to="onco_ExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_GrantDateFairValueOfStockOption" xlink:href="onco-20231231.xsd#onco_GrantDateFairValueOfStockOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_GrantDateFairValueOfStockOption_lbl" xml:lang="en-US">Grant date fair value of stock option (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_GrantDateFairValueOfStockOption" xlink:to="onco_GrantDateFairValueOfStockOption_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_lbl" xml:lang="en-US">Recognized stock based compensation expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xml:lang="en-US">Restricted shares granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_RestrictedSharesGrantedVestPercentage" xlink:href="onco-20231231.xsd#onco_RestrictedSharesGrantedVestPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_RestrictedSharesGrantedVestPercentage_lbl" xml:lang="en-US">Restricted shares granted vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RestrictedSharesGrantedVestPercentage" xlink:to="onco_RestrictedSharesGrantedVestPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xml:lang="en-US">Forfeited shares of restricted stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Stock options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Vested weighted average exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Vested weighted average term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Vested intrinsic value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_lbl" xml:lang="en-US">Stock option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated" xlink:to="us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized stock based compensation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Aggregate of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Leases office rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeasePayments_lbl" xml:lang="en-US">Short-term lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeasePayments" xlink:to="us-gaap_ShortTermLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl" xml:lang="en-US">Variable lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_PercentageOfSubscription" xlink:href="onco-20231231.xsd#onco_PercentageOfSubscription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_PercentageOfSubscription_lbl" xml:lang="en-US">Percentage of subscription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfSubscription" xlink:to="onco_PercentageOfSubscription_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AggregatePayments" xlink:href="onco-20231231.xsd#onco_AggregatePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AggregatePayments_lbl" xml:lang="en-US">Aggregate payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregatePayments" xlink:to="onco_AggregatePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_lbl" xml:lang="en-US">Termination fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:to="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LaborAndRelatedExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Related expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPaidinkind" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPaidinkind"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsPaidinkind_lbl" xml:lang="en-US">Approximately amount paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPaidinkind" xlink:to="us-gaap_DividendsPaidinkind_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Related party transactions amounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Related party receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayment of related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_MiscellaneousExpenses" xlink:href="onco-20231231.xsd#onco_MiscellaneousExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_MiscellaneousExpenses_lbl" xml:lang="en-US">Miscellaneous payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_MiscellaneousExpenses" xlink:to="onco_MiscellaneousExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SubscriptionAgreementPMXInvestorPercentage" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementPMXInvestorPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_SubscriptionAgreementPMXInvestorPercentage_lbl" xml:lang="en-US">Subscription agreement PMX investor percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SubscriptionAgreementPMXInvestorPercentage" xlink:to="onco_SubscriptionAgreementPMXInvestorPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US">Federal NOL and state NOLs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl" xml:lang="en-US">Taxable income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Income tax percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Unrecognized tax benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl" xml:lang="en-US">Permits voluntary contributions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_GrossPayPercentage" xlink:href="onco-20231231.xsd#onco_GrossPayPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_GrossPayPercentage_lbl" xml:lang="en-US">Percentage of gross pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_GrossPayPercentage" xlink:to="onco_GrossPayPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_DebtSecuritiesAndCash" xlink:href="onco-20231231.xsd#onco_DebtSecuritiesAndCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_DebtSecuritiesAndCash_lbl" xml:lang="en-US">Debt securities and cash rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_DebtSecuritiesAndCash" xlink:to="onco_DebtSecuritiesAndCash_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_EquitySecuritiesRate" xlink:href="onco-20231231.xsd#onco_EquitySecuritiesRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_EquitySecuritiesRate_lbl" xml:lang="en-US">Equity securities rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_EquitySecuritiesRate" xlink:to="onco_EquitySecuritiesRate_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AlternativeInvestmentsRate" xlink:href="onco-20231231.xsd#onco_AlternativeInvestmentsRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AlternativeInvestmentsRate_lbl" xml:lang="en-US">Alternative investments rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AlternativeInvestmentsRate" xlink:to="onco_AlternativeInvestmentsRate_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_RealEstateInvestmentsRate" xlink:href="onco-20231231.xsd#onco_RealEstateInvestmentsRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_RealEstateInvestmentsRate_lbl" xml:lang="en-US">Real estate investments rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RealEstateInvestmentsRate" xlink:to="onco_RealEstateInvestmentsRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_lbl" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:to="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Subscription amount of interest payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SeverancePayment" xlink:href="onco-20231231.xsd#onco_SeverancePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_SeverancePayment_lbl" xml:lang="en-US">Severance payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SeverancePayment" xlink:to="onco_SeverancePayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AcquisitionsPolicyTextBlock" xlink:href="onco-20231231.xsd#onco_AcquisitionsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AcquisitionsPolicyTextBlock_lbl" xml:lang="en-US">Acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AcquisitionsPolicyTextBlock" xlink:to="onco_AcquisitionsPolicyTextBlock_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb4i4f4wUs/dKlMHRtjt5HiP056YCLyrdSoyPYyQevay5dOg9LR2t/KvbZBYGbO0fRFqRMXruICW071VL4cva1Vo1fRqEHdR31R1aena1W/oLM7lTmOCBLWaZ9ZWyZBU9clRPWAm3ygSKlPhipMHX/wTZ1GpdAQuF5X0Rk/U0peMoZ1GlWBL0QwQ4YYjsaQQj5y1OiFHDkpk+TSIy2jKBgVC6BuLNzQw2d0OQvqtBvmxiw3I1GgCSekvILJhH3efW8GbAc0a/KY3FrkMzsBtEl3] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Goodwill and Other Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock_lbl" xml:lang="en-US">Defined Benefit Pension Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock" xlink:to="us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xml:lang="en-US">Collaborative Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Financial instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xml:lang="en-US">Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_TreasuryStockPolicyPolicyTextBlock" xlink:href="onco-20231231.xsd#onco_TreasuryStockPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_TreasuryStockPolicyPolicyTextBlock_lbl" xml:lang="en-US">Treasury Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_TreasuryStockPolicyPolicyTextBlock" xlink:to="onco_TreasuryStockPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_OnconetixMember" xlink:href="onco-20231231.xsd#onco_OnconetixMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_OnconetixMember_lbl" xml:lang="en-US">Onconetix [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_OnconetixMember" xlink:to="onco_OnconetixMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ENTADFIMember" xlink:href="onco-20231231.xsd#onco_ENTADFIMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_ENTADFIMember_lbl" xml:lang="en-US">ENTADFI [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ENTADFIMember" xlink:to="onco_ENTADFIMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Fixed Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AssetPurchaseAgreementMember" xlink:href="onco-20231231.xsd#onco_AssetPurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AssetPurchaseAgreementMember_lbl" xml:lang="en-US">Asset Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AssetPurchaseAgreementMember" xlink:to="onco_AssetPurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_MilestonePaymentsMember" xlink:href="onco-20231231.xsd#onco_MilestonePaymentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_MilestonePaymentsMember_lbl" xml:lang="en-US">Milestone Payments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_MilestonePaymentsMember" xlink:to="onco_MilestonePaymentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_PharmaceuticalServicesLLCMember" xlink:href="onco-20231231.xsd#onco_PharmaceuticalServicesLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_PharmaceuticalServicesLLCMember_lbl" xml:lang="en-US">Pharmaceutical Services, LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PharmaceuticalServicesLLCMember" xlink:to="onco_PharmaceuticalServicesLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ManagementServicesAgreementMember" xlink:href="onco-20231231.xsd#onco_ManagementServicesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_ManagementServicesAgreementMember_lbl" xml:lang="en-US">Management Services Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ManagementServicesAgreementMember" xlink:to="onco_ManagementServicesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_WraSerAPAMember" xlink:href="onco-20231231.xsd#onco_WraSerAPAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_WraSerAPAMember_lbl" xml:lang="en-US">WraSer APA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_WraSerAPAMember" xlink:to="onco_WraSerAPAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_BankruptcyCourtMember" xlink:href="onco-20231231.xsd#onco_BankruptcyCourtMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_BankruptcyCourtMember_lbl" xml:lang="en-US">Bankruptcy Court [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BankruptcyCourtMember" xlink:to="onco_BankruptcyCourtMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_WraSerMSAMember" xlink:href="onco-20231231.xsd#onco_WraSerMSAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_WraSerMSAMember_lbl" xml:lang="en-US">WraSer MSA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_WraSerMSAMember" xlink:to="onco_WraSerMSAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SeriesBConvertiblePreferredStockMember" xlink:href="onco-20231231.xsd#onco_SeriesBConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SeriesBConvertiblePreferredStockMember" xlink:to="onco_SeriesBConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_OlogyBioservicesIncMember" xlink:href="onco-20231231.xsd#onco_OlogyBioservicesIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_OlogyBioservicesIncMember_lbl" xml:lang="en-US">Ology MSA. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_OlogyBioservicesIncMember" xlink:to="onco_OlogyBioservicesIncMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="onco_OlogyBioservicesIncMember_lbl0" xml:lang="en-US">Ology Bioservices, Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_OlogyBioservicesIncMember" xlink:to="onco_OlogyBioservicesIncMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_CincinnatiChildrensHospitalMedicalCenterMember" xlink:href="onco-20231231.xsd#onco_CincinnatiChildrensHospitalMedicalCenterMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_CincinnatiChildrensHospitalMedicalCenterMember_lbl" xml:lang="en-US">CHMC Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CincinnatiChildrensHospitalMedicalCenterMember" xlink:to="onco_CincinnatiChildrensHospitalMedicalCenterMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_RegulatoryMilestonesMember" xlink:href="onco-20231231.xsd#onco_RegulatoryMilestonesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_RegulatoryMilestonesMember_lbl" xml:lang="en-US">Regulatory milestones [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RegulatoryMilestonesMember" xlink:to="onco_RegulatoryMilestonesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialAndIndustrialSectorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialAndIndustrialSectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommercialAndIndustrialSectorMember_lbl" xml:lang="en-US">Commercial milestones [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialAndIndustrialSectorMember" xlink:to="us-gaap_CommercialAndIndustrialSectorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_OxfordUniversityInnovationLimitedMember" xlink:href="onco-20231231.xsd#onco_OxfordUniversityInnovationLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_OxfordUniversityInnovationLimitedMember_lbl" xml:lang="en-US">Oxford University Innovation Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_OxfordUniversityInnovationLimitedMember" xlink:to="onco_OxfordUniversityInnovationLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_OUIAgreementMember" xlink:href="onco-20231231.xsd#onco_OUIAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_OUIAgreementMember_lbl" xml:lang="en-US">OUI Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_OUIAgreementMember" xlink:to="onco_OUIAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_DevelopmentMilestonesMember" xlink:href="onco-20231231.xsd#onco_DevelopmentMilestonesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_DevelopmentMilestonesMember_lbl" xml:lang="en-US">Development milestone [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_DevelopmentMilestonesMember" xlink:to="onco_DevelopmentMilestonesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_StJudeChildrensHospitalMember" xlink:href="onco-20231231.xsd#onco_StJudeChildrensHospitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_StJudeChildrensHospitalMember_lbl" xml:lang="en-US">St. Jude Children&#8217;s Hospital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StJudeChildrensHospitalMember" xlink:to="onco_StJudeChildrensHospitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_UTHealthAgreementMember" xlink:href="onco-20231231.xsd#onco_UTHealthAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_UTHealthAgreementMember_lbl" xml:lang="en-US">UT Health Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UTHealthAgreementMember" xlink:to="onco_UTHealthAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_UniversityOfTexasHealthScienceCenterAtSanAntonioMember" xlink:href="onco-20231231.xsd#onco_UniversityOfTexasHealthScienceCenterAtSanAntonioMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_UniversityOfTexasHealthScienceCenterAtSanAntonioMember_lbl" xml:lang="en-US">University of Texas Health Science Center at San Antonio [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UniversityOfTexasHealthScienceCenterAtSanAntonioMember" xlink:to="onco_UniversityOfTexasHealthScienceCenterAtSanAntonioMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_CoDevelopmentAgreementMember" xlink:href="onco-20231231.xsd#onco_CoDevelopmentAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_CoDevelopmentAgreementMember_lbl" xml:lang="en-US">Co Development Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CoDevelopmentAgreementMember" xlink:to="onco_CoDevelopmentAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_VendorAgreementMember" xlink:href="onco-20231231.xsd#onco_VendorAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_VendorAgreementMember_lbl" xml:lang="en-US">Vendor Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_VendorAgreementMember" xlink:to="onco_VendorAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_LaboratorCorporationOfAmericaMember" xlink:href="onco-20231231.xsd#onco_LaboratorCorporationOfAmericaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_LaboratorCorporationOfAmericaMember_lbl" xml:lang="en-US">Laborator Corporation of America [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_LaboratorCorporationOfAmericaMember" xlink:to="onco_LaboratorCorporationOfAmericaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_NotePayableMember" xlink:href="onco-20231231.xsd#onco_NotePayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_NotePayableMember_lbl" xml:lang="en-US">Note Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_NotePayableMember" xlink:to="onco_NotePayableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ProteomedixAcquisitionMember" xlink:href="onco-20231231.xsd#onco_ProteomedixAcquisitionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_ProteomedixAcquisitionMember_lbl" xml:lang="en-US">Proteomedix Acquisition [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ProteomedixAcquisitionMember" xlink:to="onco_ProteomedixAcquisitionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SeriesSeedPreferredStockMember" xlink:href="onco-20231231.xsd#onco_SeriesSeedPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_SeriesSeedPreferredStockMember_lbl" xml:lang="en-US">Series Seed Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SeriesSeedPreferredStockMember" xlink:to="onco_SeriesSeedPreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="onco_SeriesSeedPreferredStockMember_lbl0" xml:lang="en-US">Series Seed Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SeriesSeedPreferredStockMember" xlink:to="onco_SeriesSeedPreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_TreasuryStocksMember" xlink:href="onco-20231231.xsd#onco_TreasuryStocksMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_TreasuryStocksMember_lbl" xml:lang="en-US">Treasury Stocks [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_TreasuryStocksMember" xlink:to="onco_TreasuryStocksMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_April2022PrivatePlacementMember" xlink:href="onco-20231231.xsd#onco_April2022PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_April2022PrivatePlacementMember_lbl" xml:lang="en-US">April 2022 Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_April2022PrivatePlacementMember" xlink:to="onco_April2022PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_HCWainwrightCoLLCMember" xlink:href="onco-20231231.xsd#onco_HCWainwrightCoLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_HCWainwrightCoLLCMember_lbl" xml:lang="en-US">H.C. Wainwright &amp; Co., LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_HCWainwrightCoLLCMember" xlink:to="onco_HCWainwrightCoLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AprilContingentWarrantsMember" xlink:href="onco-20231231.xsd#onco_AprilContingentWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AprilContingentWarrantsMember_lbl" xml:lang="en-US">April Contingent Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AprilContingentWarrantsMember" xlink:to="onco_AprilContingentWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_August2022PrivatePlacementMember" xlink:href="onco-20231231.xsd#onco_August2022PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_August2022PrivatePlacementMember_lbl" xml:lang="en-US">August 2022 Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_August2022PrivatePlacementMember" xlink:to="onco_August2022PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AugustWainwrightWarrantsMember" xlink:href="onco-20231231.xsd#onco_AugustWainwrightWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AugustWainwrightWarrantsMember_lbl" xml:lang="en-US">August Wainwright Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AugustWainwrightWarrantsMember" xlink:to="onco_AugustWainwrightWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AugustContingentWarrantsMember" xlink:href="onco-20231231.xsd#onco_AugustContingentWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_AugustContingentWarrantsMember_lbl" xml:lang="en-US">August Contingent Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AugustContingentWarrantsMember" xlink:to="onco_AugustContingentWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_MarketOfferingAgreementMember" xlink:href="onco-20231231.xsd#onco_MarketOfferingAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_MarketOfferingAgreementMember_lbl" xml:lang="en-US">Market Offering Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_MarketOfferingAgreementMember" xlink:to="onco_MarketOfferingAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_WarrantInducementMember" xlink:href="onco-20231231.xsd#onco_WarrantInducementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_WarrantInducementMember_lbl" xml:lang="en-US">Warrant Inducement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_WarrantInducementMember" xlink:to="onco_WarrantInducementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_InducementPIOSharesMember" xlink:href="onco-20231231.xsd#onco_InducementPIOSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_InducementPIOSharesMember_lbl" xml:lang="en-US">Inducement PIO Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_InducementPIOSharesMember" xlink:to="onco_InducementPIOSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_TwoThousandNinteenEquityIncentivePlanMember" xlink:href="onco-20231231.xsd#onco_TwoThousandNinteenEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_TwoThousandNinteenEquityIncentivePlanMember_lbl" xml:lang="en-US">2019 Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_TwoThousandNinteenEquityIncentivePlanMember" xlink:to="onco_TwoThousandNinteenEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:href="onco-20231231.xsd#onco_TwoThousandTwentyTwoEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_TwoThousandTwentyTwoEquityIncentivePlanMember_lbl" xml:lang="en-US">2022 Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:to="onco_TwoThousandTwentyTwoEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_TwoThousandTwentyTwoPlanMember" xlink:href="onco-20231231.xsd#onco_TwoThousandTwentyTwoPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_TwoThousandTwentyTwoPlanMember_lbl" xml:lang="en-US">2022 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_TwoThousandTwentyTwoPlanMember" xlink:to="onco_TwoThousandTwentyTwoPlanMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="onco_TwoThousandTwentyTwoPlanMember_lbl0" xml:lang="en-US">Two Thousand Twenty Two Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_TwoThousandTwentyTwoPlanMember" xlink:to="onco_TwoThousandTwentyTwoPlanMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ChiefBusinessOfficerMember" xlink:href="onco-20231231.xsd#onco_ChiefBusinessOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_ChiefBusinessOfficerMember_lbl" xml:lang="en-US">CBO&#8217;s [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ChiefBusinessOfficerMember" xlink:to="onco_ChiefBusinessOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_DirectorMember_lbl0" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_January2024Member" xlink:href="onco-20231231.xsd#onco_January2024Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_January2024Member_lbl" xml:lang="en-US">January 2024 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_January2024Member" xlink:to="onco_January2024Member_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_August2024Member" xlink:href="onco-20231231.xsd#onco_August2024Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_August2024Member_lbl" xml:lang="en-US">August 2024 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_August2024Member" xlink:to="onco_August2024Member_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_August2025Member" xlink:href="onco-20231231.xsd#onco_August2025Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_August2025Member_lbl" xml:lang="en-US">August 2025 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_August2025Member" xlink:to="onco_August2025Member_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_PMXOptionPlanMember" xlink:href="onco-20231231.xsd#onco_PMXOptionPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_PMXOptionPlanMember_lbl" xml:lang="en-US">PMX Option Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PMXOptionPlanMember" xlink:to="onco_PMXOptionPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_UnvestedRestrictedStockMember" xlink:href="onco-20231231.xsd#onco_UnvestedRestrictedStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_UnvestedRestrictedStockMember_lbl" xml:lang="en-US">Unvested Restricted Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnvestedRestrictedStockMember" xlink:to="onco_UnvestedRestrictedStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SettlementAgreementMember" xlink:href="onco-20231231.xsd#onco_SettlementAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_SettlementAgreementMember_lbl" xml:lang="en-US">Settlement Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SettlementAgreementMember" xlink:to="onco_SettlementAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_CEOMember" xlink:href="onco-20231231.xsd#onco_CEOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_CEOMember_lbl" xml:lang="en-US">CEO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CEOMember" xlink:to="onco_CEOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_CBOMember" xlink:href="onco-20231231.xsd#onco_CBOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_CBOMember_lbl" xml:lang="en-US">CBO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CBOMember" xlink:to="onco_CBOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_NonConvertibleDebentureMember" xlink:href="onco-20231231.xsd#onco_NonConvertibleDebentureMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_NonConvertibleDebentureMember_lbl" xml:lang="en-US">Non convertible debenture [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_NonConvertibleDebentureMember" xlink:to="onco_NonConvertibleDebentureMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLossMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLossMember_lbl" xml:lang="en-US">Net Operating Loss [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLossMember" xlink:to="us-gaap_OperatingIncomeLossMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingIncomeLossMember_lbl0" xml:lang="en-US">Operating Income (Loss) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLossMember" xlink:to="us-gaap_OperatingIncomeLossMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_SubscriptionAgreementMember" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="onco_SubscriptionAgreementMember_lbl" xml:lang="en-US">Subscription Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SubscriptionAgreementMember" xlink:to="onco_SubscriptionAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl" xml:lang="en-US">Revenue, Major Customer [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable" xlink:href="onco-20231231.xsd#onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of Fair Value of Financial Instruments Measured on a Recurring Basis [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable" xlink:to="onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisLineItems" xlink:href="onco-20231231.xsd#onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of Fair Value of Financial Instruments Measured on a Recurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisLineItems" xlink:to="onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xml:lang="en-US">Asset Acquisition [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTable_lbl" xml:lang="en-US">Asset Acquisition, Contingent Consideration [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationTable" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US">Asset Acquisition [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xml:lang="en-US">Asset Acquisition [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable" xlink:href="onco-20231231.xsd#onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable_lbl" xml:lang="en-US">Acquisitions (Details) - Schedule of Estimated Fair Values of Assets Acquired and Liabilities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable" xlink:to="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:href="onco-20231231.xsd#onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems_lbl" xml:lang="en-US">Acquisitions (Details) - Schedule of Estimated Fair Values of Assets Acquired and Liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_lbl" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedIncomeStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedIncomeStatementTable_lbl" xml:lang="en-US">Condensed Income Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_lbl" xml:lang="en-US">Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SubscriptionAgreementDetailsScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementDetailsScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SubscriptionAgreementDetailsScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable_lbl" xml:lang="en-US">Subscription Agreement (Details) - Schedule of Assumptions Used in Monte-Carlo Model, Which Utilizes Level 3 Inputs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SubscriptionAgreementDetailsScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable" xlink:to="onco_SubscriptionAgreementDetailsScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems_lbl" xml:lang="en-US">Schedule of Assumptions Used in Monte-Carlo Model, Which Utilizes Level 3 Inputs [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems" xlink:to="us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTable_lbl" xml:lang="en-US">Fair Value Option, Disclosures [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_lbl" xml:lang="en-US">Schedule of Fair Value of the Preferred Investment Options [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityTable" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityTable_lbl" xml:lang="en-US">Schedule of Valuation of the Contingent Warrant Liability [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityTable" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems_lbl" xml:lang="en-US">Schedule of Valuation of the Contingent Warrant Liability [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Schedule of Outstanding Warrants, Excluding Contingent Warrants [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Schedule of Outstanding Warrants, Excluding Contingent Warrants [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsTable" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsTable_lbl" xml:lang="en-US">Schedule of Stock Options [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsTable" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems_lbl" xml:lang="en-US">Schedule of Stock Options [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedTable" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedTable_lbl" xml:lang="en-US">Schedule of Fair Value of Options Granted [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedTable" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedTable_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems_lbl" xml:lang="en-US">Schedule of Fair Value of Options Granted [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockTable" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockTable_lbl" xml:lang="en-US">Schedule of Unvested Restricted Stock [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockTable" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockTable_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems_lbl" xml:lang="en-US">Schedule of Unvested Restricted Stock [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule of Stock-Based Compensation Expense [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Schedule of Stock-Based Compensation Expense [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable" xlink:href="onco-20231231.xsd#onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable_lbl" xml:lang="en-US">Retirement Plans (Details) - Schedule of Benefit Obligation and the Net Periodic Benefit Cost [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable" xlink:to="onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems" xlink:href="onco-20231231.xsd#onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems_lbl" xml:lang="en-US">Schedule of Benefit Obligation and the Net Periodic Benefit Cost [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems" xlink:to="onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Schedule of Accumulated Comprehensive Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xml:lang="en-US">Retirement Plan Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_RetirementPlanTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable_lbl" xml:lang="en-US">Condensed Financial Statements [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems_lbl" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US">Investment, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_OrganizationandBasisofPresentationDetailsTable" xlink:href="onco-20231231.xsd#onco_OrganizationandBasisofPresentationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_OrganizationandBasisofPresentationDetailsTable_lbl" xml:lang="en-US">Organization and Basis of Presentation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_OrganizationandBasisofPresentationDetailsTable" xlink:to="onco_OrganizationandBasisofPresentationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Organization and Basis of Presentation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_GoingConcernandManagementsPlansDetailsTable" xlink:href="onco-20231231.xsd#onco_GoingConcernandManagementsPlansDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_GoingConcernandManagementsPlansDetailsTable_lbl" xml:lang="en-US">Going Concern and Management&#8217;s Plans (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_GoingConcernandManagementsPlansDetailsTable" xlink:to="onco_GoingConcernandManagementsPlansDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_GoingConcernandManagementsPlansDetailsLineItems" xlink:href="onco-20231231.xsd#onco_GoingConcernandManagementsPlansDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_GoingConcernandManagementsPlansDetailsLineItems_lbl" xml:lang="en-US">Going Concern and Management&#8217;s Plans [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_GoingConcernandManagementsPlansDetailsLineItems" xlink:to="onco_GoingConcernandManagementsPlansDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="onco-20231231.xsd#onco_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="onco_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="onco-20231231.xsd#onco_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="onco_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_BalanceSheetDetailsDetailsTable" xlink:href="onco-20231231.xsd#onco_BalanceSheetDetailsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_BalanceSheetDetailsDetailsTable_lbl" xml:lang="en-US">Balance Sheet Details (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BalanceSheetDetailsDetailsTable" xlink:to="onco_BalanceSheetDetailsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_BalanceSheetDetailsDetailsLineItems" xlink:href="onco-20231231.xsd#onco_BalanceSheetDetailsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_BalanceSheetDetailsDetailsLineItems_lbl" xml:lang="en-US">Balance Sheet Details (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BalanceSheetDetailsDetailsLineItems" xlink:to="onco_BalanceSheetDetailsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_AcquisitionsDetailsTable" xlink:href="onco-20231231.xsd#onco_AcquisitionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AcquisitionsDetailsTable_lbl" xml:lang="en-US">Acquisitions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AcquisitionsDetailsTable" xlink:to="onco_AcquisitionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Acquisitions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesIndustryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesIndustryMember_lbl" xml:lang="en-US">Industry Sector [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesIndustryMember" xlink:to="us-gaap_EquitySecuritiesIndustryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SignificantAgreementsDetailsTable" xlink:href="onco-20231231.xsd#onco_SignificantAgreementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SignificantAgreementsDetailsTable_lbl" xml:lang="en-US">Significant Agreements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SignificantAgreementsDetailsTable" xlink:to="onco_SignificantAgreementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems_lbl" xml:lang="en-US">Significant Agreements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_NotesPayableDetailsTable" xlink:href="onco-20231231.xsd#onco_NotesPayableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_NotesPayableDetailsTable_lbl" xml:lang="en-US">Notes Payable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_NotesPayableDetailsTable" xlink:to="onco_NotesPayableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Notes Payable [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SubscriptionAgreementDetailsTable" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SubscriptionAgreementDetailsTable_lbl" xml:lang="en-US">Subscription Agreement (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SubscriptionAgreementDetailsTable" xlink:to="onco_SubscriptionAgreementDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SubscriptionAgreementDetailsLineItems" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SubscriptionAgreementDetailsLineItems_lbl" xml:lang="en-US">Subscription Agreement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SubscriptionAgreementDetailsLineItems" xlink:to="onco_SubscriptionAgreementDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1Table" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1Table"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1Table_lbl" xml:lang="en-US">Convertible Redeemable Preferred Stock and Stockholders&apos; Equity (Details) - Part 1 [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1Table" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1Table_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems_lbl" xml:lang="en-US">Convertible Redeemable Preferred Stock and Stockholders&apos; Equity (Details) - Part 1 [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2Table" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2Table"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2Table_lbl" xml:lang="en-US">Convertible Redeemable Preferred Stock and Stockholders&apos; Equity (Details) - Part 2 [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2Table" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2Table_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems_lbl" xml:lang="en-US">Convertible Redeemable Preferred Stock and Stockholders&apos; Equity (Details) - Part 2 [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table_lbl" xml:lang="en-US">Convertible Redeemable Preferred Stock and Stockholders&apos; Equity (Details) - Part 3 [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems_lbl" xml:lang="en-US">Convertible Redeemable Preferred Stock and Stockholders&apos; Equity (Details) - Part 3 [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table_lbl" xml:lang="en-US">Convertible Redeemable Preferred Stock and Stockholders&apos; Equity (Details) - Part 4 [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems_lbl" xml:lang="en-US">Convertible Redeemable Preferred Stock and Stockholders&apos; Equity (Details) - Part 4 [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_CommitmentsandContingenciesDetailsTable" xlink:href="onco-20231231.xsd#onco_CommitmentsandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_CommitmentsandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CommitmentsandContingenciesDetailsTable" xlink:to="onco_CommitmentsandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_RelatedPartyTransactionsDetailsTable" xlink:href="onco-20231231.xsd#onco_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RelatedPartyTransactionsDetailsTable" xlink:to="onco_RelatedPartyTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_IncomeTaxesDetailsTable" xlink:href="onco-20231231.xsd#onco_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IncomeTaxesDetailsTable" xlink:to="onco_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xml:lang="en-US">Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="onco_SubsequentEventsDetailsTable" xlink:href="onco-20231231.xsd#onco_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SubsequentEventsDetailsTable" xlink:to="onco_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Events [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_AccruedDeferredOfferingCosts_lbl0" xml:lang="en-US">Accrued deferred offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AccruedDeferredOfferingCosts" xlink:to="onco_AccruedDeferredOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_AccruedResearchAndDevelopmentCurrent_lbl0" xml:lang="en-US">Accrued research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AccruedResearchAndDevelopmentCurrent" xlink:to="onco_AccruedResearchAndDevelopmentCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_AcquisitionsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of policy of acquisitions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AcquisitionsPolicyTextBlock" xlink:to="onco_AcquisitionsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_AggregateAgreementAmountInitialAgreement_lbl0" xml:lang="en-US">Amount of aggregate Agreement amount initial agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregateAgreementAmountInitialAgreement" xlink:to="onco_AggregateAgreementAmountInitialAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_AggregateNetProceeds_lbl0" xml:lang="en-US">Aggregate net proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregateNetProceeds" xlink:to="onco_AggregateNetProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_AggregateNumberOfSharesPercenatge_lbl0" xml:lang="en-US">Percenatge of aggregate number of shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregateNumberOfSharesPercenatge" xlink:to="onco_AggregateNumberOfSharesPercenatge_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_AggregatePayments_lbl0" xml:lang="en-US">Aggregate payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregatePayments" xlink:to="onco_AggregatePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_AggregatePurchaseShares_lbl1" xml:lang="en-US">Number of aggregate purchase shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregatePurchaseShares" xlink:to="onco_AggregatePurchaseShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_AggregateRoyaltiesAmount_lbl0" xml:lang="en-US">Aggregate royalties amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregateRoyaltiesAmount" xlink:to="onco_AggregateRoyaltiesAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_AggregateeAmount_lbl0" xml:lang="en-US">Aggregate amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregateeAmount" xlink:to="onco_AggregateeAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_AlternativeInvestmentsRate_lbl0" xml:lang="en-US">Alternative investments rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AlternativeInvestmentsRate" xlink:to="onco_AlternativeInvestmentsRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_AmortizationOfNetGain_lbl0" xml:lang="en-US">Amortization of net gain.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AmortizationOfNetGain" xlink:to="onco_AmortizationOfNetGain_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_AmountOfOtherPartyPayments_lbl0" xml:lang="en-US">Amount of cash outflow to acquire investments classified as other.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AmountOfOtherPartyPayments" xlink:to="onco_AmountOfOtherPartyPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible_lbl0" xml:lang="en-US">Amount of asset acquisition consideration transferred ENTADFI intangible.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible" xlink:to="onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_AssetAcquisitionConsiderationTransferredInventory_lbl0" xml:lang="en-US">Amount of asset acquisition, consideration transferred, inventory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AssetAcquisitionConsiderationTransferredInventory" xlink:to="onco_AssetAcquisitionConsiderationTransferredInventory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_lbl0" xml:lang="en-US">Amount of liabilities accrued expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable_lbl0" xml:lang="en-US">Amount of note payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation_lbl0" xml:lang="en-US">Amount of pension benefit obligation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology_lbl0" xml:lang="en-US">Amount of product rights for developed technology.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset_lbl0" xml:lang="en-US">Right of use asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships_lbl0" xml:lang="en-US">Amount of customer relationships.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_BusinessTransactionYeare_lbl0" xml:lang="en-US">Business transaction yeare.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessTransactionYeare" xlink:to="onco_BusinessTransactionYeare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_CancelledPreferredInvestmentOptionsShares_lbl0" xml:lang="en-US">Number of shares (or other type of equity) cancelled during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CancelledPreferredInvestmentOptionsShares" xlink:to="onco_CancelledPreferredInvestmentOptionsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_CashPaymentToTheSeller_lbl0" xml:lang="en-US">The payment to the seller in the form of cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CashPaymentToTheSeller" xlink:to="onco_CashPaymentToTheSeller_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_ChangeInFairValueOfSubscriptionAgreementLiability_lbl0" xml:lang="en-US">Change in fair value of subscription agreement liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ChangeInFairValueOfSubscriptionAgreementLiability" xlink:to="onco_ChangeInFairValueOfSubscriptionAgreementLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_ChangeInPensionBenefitObligation_lbl0" xml:lang="en-US">Change in pension benefit obligation,</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ChangeInPensionBenefitObligation" xlink:to="onco_ChangeInPensionBenefitObligation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_CommercialSaleTerm_lbl0" xml:lang="en-US">Commercial sale term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CommercialSaleTerm" xlink:to="onco_CommercialSaleTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_ContingentWarrantLiabilityShares_lbl0" xml:lang="en-US">Shares of contingent warrant liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ContingentWarrantLiabilityShares" xlink:to="onco_ContingentWarrantLiabilityShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_CostPlusPercentage_lbl0" xml:lang="en-US">Cost plus, percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CostPlusPercentage" xlink:to="onco_CostPlusPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_DebtInstrumentDueDate_lbl0" xml:lang="en-US">Debt Instrument due date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_DebtInstrumentDueDate" xlink:to="onco_DebtInstrumentDueDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_DebtInstrumentDueTerm_lbl0" xml:lang="en-US">Debt instrument due term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_DebtInstrumentDueTerm" xlink:to="onco_DebtInstrumentDueTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_DebtSecuritiesAndCash_lbl0" xml:lang="en-US">Debt securities and cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_DebtSecuritiesAndCash" xlink:to="onco_DebtSecuritiesAndCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_DeferredOfferingCostsPreviouslyPrepaid_lbl0" xml:lang="en-US">Amount of deferred offering costs previously prepaid.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_DeferredOfferingCostsPreviouslyPrepaid" xlink:to="onco_DeferredOfferingCostsPreviouslyPrepaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees_lbl0" xml:lang="en-US">Ordinary contributions paid by employees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees" xlink:to="onco_DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees_lbl0" xml:lang="en-US">Ordinary contributions paid by employees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees" xlink:to="onco_DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_EffectOfBusinessCombination_lbl0" xml:lang="en-US">Effect of business combination.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_EffectOfBusinessCombination" xlink:to="onco_EffectOfBusinessCombination_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_EffectOfSettlement_lbl0" xml:lang="en-US">Effect of settlement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_EffectOfSettlement" xlink:to="onco_EffectOfSettlement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment_lbl0" xml:lang="en-US">Amount of state rate adjustment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment" xlink:to="onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_EquitySecuritiesRate_lbl0" xml:lang="en-US">Equity securities rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_EquitySecuritiesRate" xlink:to="onco_EquitySecuritiesRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_ExerciseOfPrefundedWarrants_lbl0" xml:lang="en-US">Amount of exercise of pre-funded warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ExerciseOfPrefundedWarrants" xlink:to="onco_ExerciseOfPrefundedWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_ExerciseOfPrefundedWarrantsinShares_lbl0" xml:lang="en-US">Exercise of pre-funded warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ExerciseOfPrefundedWarrantsinShares" xlink:to="onco_ExerciseOfPrefundedWarrantsinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_ExercisePrice_lbl0" xml:lang="en-US">Exercise price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ExercisePrice" xlink:to="onco_ExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_Exerciseofprefundedwarrants_lbl0" xml:lang="en-US">Exercise of pre funded warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_Exerciseofprefundedwarrants" xlink:to="onco_Exerciseofprefundedwarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_FiniteLivedIntangibleAssetCost_lbl0" xml:lang="en-US">Represents the amount of finite lived intangible assets cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_FiniteLivedIntangibleAssetCost" xlink:to="onco_FiniteLivedIntangibleAssetCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation_lbl0" xml:lang="en-US">Represents the amount of effect of currency translation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation" xlink:to="onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_FixedCommissionRate_lbl0" xml:lang="en-US">Percentage of fixed commission.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_FixedCommissionRate" xlink:to="onco_FixedCommissionRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_GainLossOnRelatedPartyReceivable_lbl0" xml:lang="en-US">Amount of gain (loss) on related party receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_GainLossOnRelatedPartyReceivable" xlink:to="onco_GainLossOnRelatedPartyReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_GrantDateFairValueOfStockOption_lbl0" xml:lang="en-US">Grant date fair value of stock option.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_GrantDateFairValueOfStockOption" xlink:to="onco_GrantDateFairValueOfStockOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_GrossPayPercentage_lbl0" xml:lang="en-US">The percentage of gross pay.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_GrossPayPercentage" xlink:to="onco_GrossPayPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_ImpairmentOfIntangibleAssetExcludingGoodwill_lbl0" xml:lang="en-US">The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ImpairmentOfIntangibleAssetExcludingGoodwill" xlink:to="onco_ImpairmentOfIntangibleAssetExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_ImpairmentRate_lbl0" xml:lang="en-US">Impairment rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ImpairmentRate" xlink:to="onco_ImpairmentRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability_lbl0" xml:lang="en-US">Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under derivative liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability" xlink:to="onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation_lbl0" xml:lang="en-US">Officer&#8217;s compensation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" xlink:to="onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_IncreaseInTheFairValueOfThePreferredInvestmentOptions_lbl0" xml:lang="en-US">The increase (decrease) during the period in the carrying value of fair value of the preferred investment options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IncreaseInTheFairValueOfThePreferredInvestmentOptions" xlink:to="onco_IncreaseInTheFairValueOfThePreferredInvestmentOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_InitialPaymentAmount_lbl0" xml:lang="en-US">The amount of initial payment amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_InitialPaymentAmount" xlink:to="onco_InitialPaymentAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_InitialPublicOfferingShares_lbl0" xml:lang="en-US">Number of shares issued initial public offering of shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_InitialPublicOfferingShares" xlink:to="onco_InitialPublicOfferingShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_InventoryFairValue_lbl0" xml:lang="en-US">The amount of inventory fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_InventoryFairValue" xlink:to="onco_InventoryFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet_lbl0" xml:lang="en-US">Issuance of common stock and warrants in April private placement, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet" xlink:to="onco_IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet_lbl0" xml:lang="en-US">Issuance of common stock and warrants in private placement, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet" xlink:to="onco_IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions_lbl0" xml:lang="en-US">Issuance of common stock from exercise of preferred investment options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions" xlink:to="onco_IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_IssuanceOfCommonStockInInitialPublicOfferingNet_lbl0" xml:lang="en-US">Issuance of common stock in initial public offering, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IssuanceOfCommonStockInInitialPublicOfferingNet" xlink:to="onco_IssuanceOfCommonStockInInitialPublicOfferingNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_IssuanceOfRestrictedStock_lbl0" xml:lang="en-US">The number of shares issued in Issuance of restricted stock&#xd;
 exchange for the original debt being converted in a noncash (or part noncash) transaction. &quot;Part noncash&quot; refers to that portion of the transaction not resulting in cash receipts or payments in the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IssuanceOfRestrictedStock" xlink:to="onco_IssuanceOfRestrictedStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_LicenseAgreement_lbl0" xml:lang="en-US">License agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_LicenseAgreement" xlink:to="onco_LicenseAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_LicensedProductsPlusMilestonePaymentsDescription_lbl0" xml:lang="en-US">Description of licensed products plus milestone payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_LicensedProductsPlusMilestonePaymentsDescription" xlink:to="onco_LicensedProductsPlusMilestonePaymentsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_MiscellaneousExpenses_lbl0" xml:lang="en-US">The amount of miscellaneous expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_MiscellaneousExpenses" xlink:to="onco_MiscellaneousExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_NettingProceeds_lbl0" xml:lang="en-US">Represent the amount of netting proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_NettingProceeds" xlink:to="onco_NettingProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_NotesPayableNetOfDebtDiscount_lbl0" xml:lang="en-US">Notes payable, net of debt discount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_NotesPayableNetOfDebtDiscount" xlink:to="onco_NotesPayableNetOfDebtDiscount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_NumberOfShares_lbl0" xml:lang="en-US">Number of shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_NumberOfShares" xlink:to="onco_NumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax_lbl0" xml:lang="en-US">Foreign currency translation adjustment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax" xlink:to="onco_OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_PayableAverageDiscountRatePercentage_lbl0" xml:lang="en-US">The percentage of payable average discount rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PayableAverageDiscountRatePercentage" xlink:to="onco_PayableAverageDiscountRatePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_PaymentOfAccruedBonusThroughRelatedPartyReceivable_lbl0" xml:lang="en-US">Payment of accrued bonus through related party receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PaymentOfAccruedBonusThroughRelatedPartyReceivable" xlink:to="onco_PaymentOfAccruedBonusThroughRelatedPartyReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_Payments_lbl0" xml:lang="en-US">The amount of payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_Payments" xlink:to="onco_Payments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_PaymentsForPurchaseOfTreasuryShares_lbl0" xml:lang="en-US">Payments for purchase of treasury stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PaymentsForPurchaseOfTreasuryShares" xlink:to="onco_PaymentsForPurchaseOfTreasuryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_PercentageOfCommonStockShares_lbl0" xml:lang="en-US">Percentage of Common Stock Shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfCommonStockShares" xlink:to="onco_PercentageOfCommonStockShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_PercentageOfConsiderationReceived_lbl0" xml:lang="en-US">Percentage of consideration received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfConsiderationReceived" xlink:to="onco_PercentageOfConsiderationReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_PercentageOfCumulativeDividends_lbl0" xml:lang="en-US">Percentage of cumulative dividends.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfCumulativeDividends" xlink:to="onco_PercentageOfCumulativeDividends_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_PercentageOfGrossProceeds_lbl0" xml:lang="en-US">Percentage of gross proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfGrossProceeds" xlink:to="onco_PercentageOfGrossProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_PercentageOfIssuedOfCommonStock_lbl0" xml:lang="en-US">Percentage of issued of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfIssuedOfCommonStock" xlink:to="onco_PercentageOfIssuedOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_PercentageOfOriginalIssuePrice_lbl0" xml:lang="en-US">Percentage of Original Issue Price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfOriginalIssuePrice" xlink:to="onco_PercentageOfOriginalIssuePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_PercentageOfOutstandingOfCommonStock_lbl0" xml:lang="en-US">Percentage of outstanding of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfOutstandingOfCommonStock" xlink:to="onco_PercentageOfOutstandingOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_PercentageOfSubscription_lbl0" xml:lang="en-US">Percentage of subscription .</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfSubscription" xlink:to="onco_PercentageOfSubscription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_PercentageOfUnderwritingDiscount_lbl0" xml:lang="en-US">Percentage of underwriting discount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfUnderwritingDiscount" xlink:to="onco_PercentageOfUnderwritingDiscount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_PlacementAgentFeeAndManagementFeePercentage_lbl0" xml:lang="en-US">Percentage of placement agent fee and management fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PlacementAgentFeeAndManagementFeePercentage" xlink:to="onco_PlacementAgentFeeAndManagementFeePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_PrefundedWarrantsExercised_lbl0" xml:lang="en-US">Number of prefunded share warrants exercised during the current period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PrefundedWarrantsExercised" xlink:to="onco_PrefundedWarrantsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_PrepaidProfessionalFees_lbl0" xml:lang="en-US">Prepaid professional fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PrepaidProfessionalFees" xlink:to="onco_PrepaidProfessionalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_PrepaidsResearchAndDevelopment_lbl0" xml:lang="en-US">Amount of other research and development expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PrepaidsResearchAndDevelopment" xlink:to="onco_PrepaidsResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_PublicOfPerShare_lbl0" xml:lang="en-US">The share of public of per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PublicOfPerShare" xlink:to="onco_PublicOfPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_PurchaseOfTreasuryShares_lbl0" xml:lang="en-US">Purchase of treasury shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PurchaseOfTreasuryShares" xlink:to="onco_PurchaseOfTreasuryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_PurchaseOfTreasurySharesinShares_lbl0" xml:lang="en-US">The number of shares purchase of treasury shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PurchaseOfTreasurySharesinShares" xlink:to="onco_PurchaseOfTreasurySharesinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_RealEstateInvestmentsRate_lbl0" xml:lang="en-US">Real estate investments rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RealEstateInvestmentsRate" xlink:to="onco_RealEstateInvestmentsRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_ReceivableFromRelatedParties1_lbl0" xml:lang="en-US">The amount of receivables from related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ReceivableFromRelatedParties1" xlink:to="onco_ReceivableFromRelatedParties1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_ReclassificationToEquity_lbl0" xml:lang="en-US">The amount represents the reclassification to equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ReclassificationToEquity" xlink:to="onco_ReclassificationToEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement_lbl0" xml:lang="en-US">Recognition of contingent warrant liability upon issuance of common stock in private placement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement" xlink:to="onco_RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_RestrictedSharesGrantedVestPercentage_lbl0" xml:lang="en-US">Restricted shares granted vest percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RestrictedSharesGrantedVestPercentage" xlink:to="onco_RestrictedSharesGrantedVestPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_RestrictedStockForfeitures_lbl0" xml:lang="en-US">Restricted stock forfeitures.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RestrictedStockForfeitures" xlink:to="onco_RestrictedStockForfeitures_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_RevenueRate_lbl0" xml:lang="en-US">Revenue rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RevenueRate" xlink:to="onco_RevenueRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_RoyaltiesPercentage_lbl0" xml:lang="en-US">Royalties percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RoyaltiesPercentage" xlink:to="onco_RoyaltiesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_RoyaltyNetSalesPercentage_lbl0" xml:lang="en-US">Percentage of royalty net sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RoyaltyNetSalesPercentage" xlink:to="onco_RoyaltyNetSalesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_RoyaltyRate_lbl0" xml:lang="en-US">Percentage of royalty.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RoyaltyRate" xlink:to="onco_RoyaltyRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_RoyaltyRates_lbl0" xml:lang="en-US">Percentage of royalty rates.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RoyaltyRates" xlink:to="onco_RoyaltyRates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_RoyaltySalesPercentage_lbl0" xml:lang="en-US">percentage of royalty sales percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RoyaltySalesPercentage" xlink:to="onco_RoyaltySalesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_SaleOfUnits_lbl0" xml:lang="en-US">Sale of units.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SaleOfUnits" xlink:to="onco_SaleOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_SalesPaymentsAmount_lbl0" xml:lang="en-US">The amount of sales payments amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SalesPaymentsAmount" xlink:to="onco_SalesPaymentsAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock_lbl0" xml:lang="en-US">Disclosure of accompanying consolidated balance sheet.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock" xlink:to="onco_ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock_lbl0" xml:lang="en-US">Schedule of Fair Value of Options Granted in 2023 And 2022.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock" xlink:to="onco_ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock_lbl0" xml:lang="en-US">Schedule of Valuation of the Contingent Warrant Liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock" xlink:to="onco_ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_SeverancePayment_lbl0" xml:lang="en-US">The amount of severance payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SeverancePayment" xlink:to="onco_SeverancePayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled_lbl0" xml:lang="en-US">The value for share based compensation payment intrinsic value forfeited.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled" xlink:to="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted_lbl0" xml:lang="en-US">Share based compensation payment arrangementintrinsic value granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted" xlink:to="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_SharesOfCommonStockIssued_lbl0" xml:lang="en-US">Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm&apos;s shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SharesOfCommonStockIssued" xlink:to="onco_SharesOfCommonStockIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_SharesOfCommonStockRate_lbl0" xml:lang="en-US">Shares of common stock rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SharesOfCommonStockRate" xlink:to="onco_SharesOfCommonStockRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_SignificantAgreementsTextBlock_lbl0" xml:lang="en-US">The entire disclosure for significant agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SignificantAgreementsTextBlock" xlink:to="onco_SignificantAgreementsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction_lbl0" xml:lang="en-US">Assumption of stock-based compensation plan awards in connection with PMX Transaction.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" xlink:to="onco_StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction_lbl1" xml:lang="en-US">Issuance of common stock and Series B Preferred Stock in connection with PMX Transaction.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" xlink:to="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants_lbl0" xml:lang="en-US">Number of common stock and warrants issued during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants" xlink:to="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet_lbl0" xml:lang="en-US">Number of common stock and warrants in August private placement issued during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet" xlink:to="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares_lbl0" xml:lang="en-US">Issuance of series A preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares" xlink:to="onco_StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction_lbl0" xml:lang="en-US">Assumption of stock-based compensation plan awards in connection with PMX Transaction.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" xlink:to="onco_StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction_lbl0" xml:lang="en-US">Issuance of common stock and Series B Preferred Stock in connection with PMX Transaction.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" xlink:to="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares_lbl0" xml:lang="en-US">Issuance of common stock from exercise of preferred investment options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock_lbl0" xml:lang="en-US">Issuance of series A preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock" xlink:to="onco_StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement_lbl0" xml:lang="en-US">Issuance of common stock and warrants in private placement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement" xlink:to="onco_StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation_lbl0" xml:lang="en-US">Amount of  changes in pension benefit obligation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation" xlink:to="onco_StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants_lbl0" xml:lang="en-US">Amount of issuance of common stock and warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants" xlink:to="onco_StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_SubscriptionAgreementDisclosureTextBlock_lbl0" xml:lang="en-US">The entire disclosure for subscription agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SubscriptionAgreementDisclosureTextBlock" xlink:to="onco_SubscriptionAgreementDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_SubscriptionAgreementLiabilityNoncurrent_lbl0" xml:lang="en-US">Subscription agreement liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SubscriptionAgreementLiabilityNoncurrent" xlink:to="onco_SubscriptionAgreementLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_SubscriptionAgreementPMXInvestorPercentage_lbl0" xml:lang="en-US">Subscription agreement PMX investor percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SubscriptionAgreementPMXInvestorPercentage" xlink:to="onco_SubscriptionAgreementPMXInvestorPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_TreasuryStockPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for treasury stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_TreasuryStockPolicyPolicyTextBlock" xlink:to="onco_TreasuryStockPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_VotingInterestPercentage_lbl0" xml:lang="en-US">Voting interest percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_VotingInterestPercentage" xlink:to="onco_VotingInterestPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_WarrantsIssuableUnderProvisionShares_lbl0" xml:lang="en-US">Number of share warrants issuable under provision.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_WarrantsIssuableUnderProvisionShares" xlink:to="onco_WarrantsIssuableUnderProvisionShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_WarrantsIssuedForSettlementOfContingentWarrants_lbl1" xml:lang="en-US">Warrants issued for settlement of contingent warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_WarrantsIssuedForSettlementOfContingentWarrants" xlink:to="onco_WarrantsIssuedForSettlementOfContingentWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_WeightedAverageDiscountRate_lbl0" xml:lang="en-US">Weighted average discount rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_WeightedAverageDiscountRate" xlink:to="onco_WeightedAverageDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_WeightedAverageDiscountRateThereafter_lbl0" xml:lang="en-US">Percentage of minimum average discount rate there after.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_WeightedAverageDiscountRateThereafter" xlink:to="onco_WeightedAverageDiscountRateThereafter_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="onco_WorkingCapitalDeficit_lbl0" xml:lang="en-US">Working capital deficit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_WorkingCapitalDeficit" xlink:to="onco_WorkingCapitalDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_lbl1" xml:lang="en-US">benefit cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:to="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl0" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ExerciseOfPrefundedWarrantsinShares_lbl1" xml:lang="en-US">Exercise Of Prefunded Warrantsin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ExerciseOfPrefundedWarrantsinShares" xlink:to="onco_ExerciseOfPrefundedWarrantsinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FeeIncome_lbl1" xml:lang="en-US">Fee Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FeeIncome" xlink:to="us-gaap_FeeIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ProteomedixAcquisitionMember_lbl0" xml:lang="en-US">Proteomedix Acquisition Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ProteomedixAcquisitionMember" xlink:to="onco_ProteomedixAcquisitionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_WraSerAPAMember_lbl0" xml:lang="en-US">Wra Ser APAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_WraSerAPAMember" xlink:to="onco_WraSerAPAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOwnershipInterestsOfferingCosts_lbl0" xml:lang="en-US">Other Ownership Interests, Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:to="us-gaap_OtherOwnershipInterestsOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl2" xml:lang="en-US">Developed Technology Rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl2"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfFairValueOfTheProteomedixStockOptionsAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfFairValueOfTheProteomedixStockOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfFairValueOfTheProteomedixStockOptionsAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Of The Proteomedix Stock Options Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfFairValueOfTheProteomedixStockOptionsAbstract" xlink:to="onco_ScheduleOfFairValueOfTheProteomedixStockOptionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares_lbl1" xml:lang="en-US">Stock Issued During Period Value Issuance Of Common Stock From Exercise Of Preferred Investment Optionsin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships_lbl1" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Customer Relationships</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl1" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonUnitIssued_lbl0" xml:lang="en-US">Common Unit, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonUnitIssued" xlink:to="us-gaap_CommonUnitIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_CancelledPreferredInvestmentOptionsShares_lbl1" xml:lang="en-US">Cancelled Preferred Investment Options Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CancelledPreferredInvestmentOptionsShares" xlink:to="onco_CancelledPreferredInvestmentOptionsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl0" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_lbl0" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl0" xml:lang="en-US">Liabilities, Fair Value Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl0" xml:lang="en-US">Business Acquisition, Transaction Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_GainLossOnRelatedPartyReceivable_lbl1" xml:lang="en-US">Gain Loss On Related Party Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_GainLossOnRelatedPartyReceivable" xlink:to="onco_GainLossOnRelatedPartyReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AggregateNumberOfSharesPercenatge_lbl1" xml:lang="en-US">Aggregate Number Of Shares Percenatge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregateNumberOfSharesPercenatge" xlink:to="onco_AggregateNumberOfSharesPercenatge_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AugustWainwrightWarrantsMember_lbl0" xml:lang="en-US">August Wainwright Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AugustWainwrightWarrantsMember" xlink:to="onco_AugustWainwrightWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl1" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl0" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants_lbl1" xml:lang="en-US">Stock Issued During Period Shares Issuance Of Common Stock And Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants" xlink:to="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ProteomedixMember_lbl0" xml:lang="en-US">Proteomedix Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ProteomedixMember" xlink:to="onco_ProteomedixMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet_lbl1" xml:lang="en-US">Issuance Of Common Stock And Warrants In April Private Placement Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet" xlink:to="onco_IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl0" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction_lbl1" xml:lang="en-US">Stock Issued During Period Value Issuance Of Common Stock And Series BPreferred Stock In Connection With PMXTransaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" xlink:to="onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ResearchAndDevelopmentMember_lbl0" xml:lang="en-US">Research And Development Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ResearchAndDevelopmentMember" xlink:to="onco_ResearchAndDevelopmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SeriesBConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Series BConvertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SeriesBConvertiblePreferredStockMember" xlink:to="onco_SeriesBConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonMember_lbl0" xml:lang="en-US">Treasury Stock, Common [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_lbl1" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfPropertyRepairsAndMaintenance_lbl0" xml:lang="en-US">Cost of Property Repairs and Maintenance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfPropertyRepairsAndMaintenance" xlink:to="us-gaap_CostOfPropertyRepairsAndMaintenance_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfStockBasedCompensationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfStockBasedCompensationExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Stock Based Compensation Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="onco_ScheduleOfStockBasedCompensationExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xml:lang="en-US">Disclosure Text Block Supplement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DisclosureTextBlockSupplementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation_lbl1" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Pension Benefit Obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SubscriptionAgreementLiabilityMember_lbl0" xml:lang="en-US">Subscription Agreement Liability Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SubscriptionAgreementLiabilityMember" xlink:to="onco_SubscriptionAgreementLiabilityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanSettlementsPlanAssets_lbl0" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="us-gaap_DefinedBenefitPlanSettlementsPlanAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_CoDevelopmentAgreementMember_lbl0" xml:lang="en-US">Co Development Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CoDevelopmentAgreementMember" xlink:to="onco_CoDevelopmentAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl0" xml:lang="en-US">Business Acquisition, Description of Acquired Entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_HCWainwrightCoLLCMember_lbl0" xml:lang="en-US">HCWainwright Co LLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_HCWainwrightCoLLCMember" xlink:to="onco_HCWainwrightCoLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_TwoThousandNinteenEquityIncentivePlanMember_lbl0" xml:lang="en-US">Two Thousand Ninteen Equity Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_TwoThousandNinteenEquityIncentivePlanMember" xlink:to="onco_TwoThousandNinteenEquityIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedAtCost_lbl0" xml:lang="en-US">Investment Owned, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtCost" xlink:to="us-gaap_InvestmentOwnedAtCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl0" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_EquitySecuritiesRate_lbl1" xml:lang="en-US">Equity Securities Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_EquitySecuritiesRate" xlink:to="onco_EquitySecuritiesRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl1" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ServicingLiabilityAtFairValueAmount_lbl0" xml:lang="en-US">Servicing Liability at Fair Value, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServicingLiabilityAtFairValueAmount" xlink:to="us-gaap_ServicingLiabilityAtFairValueAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PlacementAgentFeeAndManagementFeePercentage_lbl1" xml:lang="en-US">Placement Agent Fee And Management Fee Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PlacementAgentFeeAndManagementFeePercentage" xlink:to="onco_PlacementAgentFeeAndManagementFeePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl0" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_OnconetixMember_lbl0" xml:lang="en-US">Onconetix Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_OnconetixMember" xlink:to="onco_OnconetixMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SeriesSeedPreferredStockMember_lbl1" xml:lang="en-US">Series Seed Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SeriesSeedPreferredStockMember" xlink:to="onco_SeriesSeedPreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PurchaseOfTreasurySharesinShares_lbl1" xml:lang="en-US">Purchase Of Treasury Sharesin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PurchaseOfTreasurySharesinShares" xlink:to="onco_PurchaseOfTreasurySharesinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PurchaseOfTreasuryShares_lbl1" xml:lang="en-US">Purchase Of Treasury Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PurchaseOfTreasuryShares" xlink:to="onco_PurchaseOfTreasuryShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfAccumulatedComprehensiveLossAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfAccumulatedComprehensiveLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfAccumulatedComprehensiveLossAbstract_lbl" xml:lang="en-US">Schedule Of Accumulated Comprehensive Loss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfAccumulatedComprehensiveLossAbstract" xlink:to="onco_ScheduleOfAccumulatedComprehensiveLossAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_August2024Member_lbl0" xml:lang="en-US">August2024 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_August2024Member" xlink:to="onco_August2024Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl1" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_WraSerMSAMember_lbl0" xml:lang="en-US">Wra Ser MSAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_WraSerMSAMember" xlink:to="onco_WraSerMSAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AlternativeInvestmentsRate_lbl1" xml:lang="en-US">Alternative Investments Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AlternativeInvestmentsRate" xlink:to="onco_AlternativeInvestmentsRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Option, Disclosures [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts_lbl0" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl2" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl0" xml:lang="en-US">Asset Impairment Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Accompanying Consolidated Balance Sheet Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock" xlink:to="onco_ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl1" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl1" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_LaboratorCorporationOfAmericaMember_lbl0" xml:lang="en-US">Laborator Corporation Of America Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_LaboratorCorporationOfAmericaMember" xlink:to="onco_LaboratorCorporationOfAmericaMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfValuationOfTheContingentWarrantLiabilityAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfValuationOfTheContingentWarrantLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfValuationOfTheContingentWarrantLiabilityAbstract_lbl" xml:lang="en-US">Schedule Of Valuation Of The Contingent Warrant Liability Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfValuationOfTheContingentWarrantLiabilityAbstract" xlink:to="onco_ScheduleOfValuationOfTheContingentWarrantLiabilityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SeriesAConvertiblePreferredStockMember_lbl1" xml:lang="en-US">Series AConvertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SeriesAConvertiblePreferredStockMember" xlink:to="onco_SeriesAConvertiblePreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AssetsRecognizedMember_lbl0" xml:lang="en-US">Assets Recognized Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AssetsRecognizedMember" xlink:to="onco_AssetsRecognizedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SeverancePayment_lbl1" xml:lang="en-US">Severance Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SeverancePayment" xlink:to="onco_SeverancePayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl0" xml:lang="en-US">Unrecognized Tax Benefits, Period Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ReclassificationToEquity_lbl1" xml:lang="en-US">Reclassification To Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ReclassificationToEquity" xlink:to="onco_ReclassificationToEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl0" xml:lang="en-US">Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SubscriptionAgreementDisclosureTextBlock_lbl1" xml:lang="en-US">Subscription Agreement Disclosure Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SubscriptionAgreementDisclosureTextBlock" xlink:to="onco_SubscriptionAgreementDisclosureTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_WorkingCapitalDeficit_lbl1" xml:lang="en-US">Working Capital Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_WorkingCapitalDeficit" xlink:to="onco_WorkingCapitalDeficit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_lbl0" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl0" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Deposits_lbl0" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl0" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationDescription_lbl0" xml:lang="en-US">Business Acquisition, Pro Forma Information, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationDescription" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl0" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl0" xml:lang="en-US">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset_lbl1" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Rightof Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Lease Income, Lease Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1_lbl0" xml:lang="en-US">Noncash or Part Noncash Acquisition, Payables Assumed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_RestrictedSharesGrantedVestPercentage_lbl1" xml:lang="en-US">Restricted Shares Granted Vest Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RestrictedSharesGrantedVestPercentage" xlink:to="onco_RestrictedSharesGrantedVestPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_lbl0" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Plan Participant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl0" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SeriesSeedMember_lbl0" xml:lang="en-US">Series Seed Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SeriesSeedMember" xlink:to="onco_SeriesSeedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_RoyaltyRate_lbl1" xml:lang="en-US">Royalty Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RoyaltyRate" xlink:to="onco_RoyaltyRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_NotesPayableNetOfDebtDiscount_lbl1" xml:lang="en-US">Notes Payable Net Of Debt Discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_NotesPayableNetOfDebtDiscount" xlink:to="onco_NotesPayableNetOfDebtDiscount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ImpairmentRate_lbl1" xml:lang="en-US">Impairment Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ImpairmentRate" xlink:to="onco_ImpairmentRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PharmaceuticalServicesLLCMember_lbl0" xml:lang="en-US">Pharmaceutical Services LLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PharmaceuticalServicesLLCMember" xlink:to="onco_PharmaceuticalServicesLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl1" xml:lang="en-US">Other Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet_lbl1" xml:lang="en-US">Stock Issued During Period Shares Issuance Of Common Stock And Warrants In August Private Placement Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet" xlink:to="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AggregateConsiderationTransferredMember_lbl0" xml:lang="en-US">Aggregate Consideration Transferred Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregateConsiderationTransferredMember" xlink:to="onco_AggregateConsiderationTransferredMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_lbl0" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock_lbl0" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Accounting Policy Election, Measurement Date [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock" xlink:to="us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanServiceCost_lbl1" xml:lang="en-US">Defined Benefit Plan, Service Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanServiceCost" xlink:to="us-gaap_DefinedBenefitPlanServiceCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl1" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfPrivatePlacement_lbl0" xml:lang="en-US">Payments for Repurchase of Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfPrivatePlacement" xlink:to="us-gaap_PaymentsForRepurchaseOfPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl0" xml:lang="en-US">Preferred Stock, Liquidation Preference Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl0" xml:lang="en-US">Payments to Acquire Other Productive Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Forfeited Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled" xlink:to="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage_lbl0" xml:lang="en-US">Product Liability Contingency, Third-Party Recovery, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage" xlink:to="us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl0" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl1" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement_lbl1" xml:lang="en-US">Recognition Of Contingent Warrant Liability Upon Issuance Of Common Stock In Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement" xlink:to="onco_RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_Exerciseofprefundedwarrants_lbl1" xml:lang="en-US">Exerciseofprefundedwarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_Exerciseofprefundedwarrants" xlink:to="onco_Exerciseofprefundedwarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl1" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl0" xml:lang="en-US">Interest Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl2" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent_lbl0" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, before Tax, after Reclassification Adjustment, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfAssetsAcquiredAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfAssetsAcquiredAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfAssetsAcquiredAbstract_lbl" xml:lang="en-US">Schedule Of Assets Acquired Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfAssetsAcquiredAbstract" xlink:to="onco_ScheduleOfAssetsAcquiredAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SubscriptionAgreementMember_lbl0" xml:lang="en-US">Subscription Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SubscriptionAgreementMember" xlink:to="onco_SubscriptionAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl0" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl0" xml:lang="en-US">Repayments of Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl0" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfIntangibleAssetsAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfIntangibleAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Intangible Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfIntangibleAssetsAbstract" xlink:to="onco_ScheduleOfIntangibleAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl2" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeasePayments_lbl0" xml:lang="en-US">Short-Term Lease Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeasePayments" xlink:to="us-gaap_ShortTermLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_LicensedProductsPlusMilestonePaymentsDescription_lbl1" xml:lang="en-US">Licensed Products Plus Milestone Payments Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_LicensedProductsPlusMilestonePaymentsDescription" xlink:to="onco_LicensedProductsPlusMilestonePaymentsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_LiabilitiesAbstract0_lbl0" xml:lang="en-US">Liabilities Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_LiabilitiesAbstract0" xlink:to="onco_LiabilitiesAbstract0_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_DebtSecuritiesAndCash_lbl1" xml:lang="en-US">Debt Securities And Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_DebtSecuritiesAndCash" xlink:to="onco_DebtSecuritiesAndCash_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl0" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionExpense_lbl0" xml:lang="en-US">Pension Cost (Reversal of Cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionExpense" xlink:to="us-gaap_PensionExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl1" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl1" xml:lang="en-US">Notes Payable, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ENTADFIMember_lbl0" xml:lang="en-US">ENTADFIMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ENTADFIMember" xlink:to="onco_ENTADFIMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ExerciseOfPrefundedWarrants_lbl1" xml:lang="en-US">Exercise Of Prefunded Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ExerciseOfPrefundedWarrants" xlink:to="onco_ExerciseOfPrefundedWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligation_lbl1" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PrepaidsResearchAndDevelopment_lbl1" xml:lang="en-US">Prepaids Research And Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PrepaidsResearchAndDevelopment" xlink:to="onco_PrepaidsResearchAndDevelopment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1_lbl0" xml:lang="en-US">Business Combination, Consideration Transferred, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredOther1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl0" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl0" xml:lang="en-US">Debt Instrument, Fee Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesAndLicenses_lbl0" xml:lang="en-US">Taxes and Licenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesAndLicenses" xlink:to="us-gaap_TaxesAndLicenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PercentageOfOutstandingOfCommonStock_lbl1" xml:lang="en-US">Percentage Of Outstanding Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfOutstandingOfCommonStock" xlink:to="onco_PercentageOfOutstandingOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl1" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_CincinnatiChildrensHospitalMedicalCenterMember_lbl0" xml:lang="en-US">Cincinnati Childrens Hospital Medical Center Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CincinnatiChildrensHospitalMedicalCenterMember" xlink:to="onco_CincinnatiChildrensHospitalMedicalCenterMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_lbl0" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:to="us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PercentageOfUnderwritingDiscount_lbl1" xml:lang="en-US">Percentage Of Underwriting Discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfUnderwritingDiscount" xlink:to="onco_PercentageOfUnderwritingDiscount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ImpairmentOfIntangibleAssetExcludingGoodwill_lbl1" xml:lang="en-US">Impairment Of Intangible Asset Excluding Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ImpairmentOfIntangibleAssetExcludingGoodwill" xlink:to="onco_ImpairmentOfIntangibleAssetExcludingGoodwill_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl0" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_lbl0" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_RoyaltyRates_lbl1" xml:lang="en-US">Royalty Rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RoyaltyRates" xlink:to="onco_RoyaltyRates_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl0" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PercentageOfCumulativeDividends_lbl1" xml:lang="en-US">Percentage Of Cumulative Dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfCumulativeDividends" xlink:to="onco_PercentageOfCumulativeDividends_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl1" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanOtherChanges_lbl0" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanOtherChanges" xlink:to="us-gaap_DefinedBenefitPlanOtherChanges_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_CostPlusPercentage_lbl1" xml:lang="en-US">Cost Plus Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CostPlusPercentage" xlink:to="onco_CostPlusPercentage_lbl1"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfAssumptionsUsedInMonteCarloModelWhichUtilizesLevel3InputsAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfAssumptionsUsedInMonteCarloModelWhichUtilizesLevel3InputsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfAssumptionsUsedInMonteCarloModelWhichUtilizesLevel3InputsAbstract_lbl" xml:lang="en-US">Schedule Of Assumptions Used In Monte Carlo Model Which Utilizes Level3 Inputs Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfAssumptionsUsedInMonteCarloModelWhichUtilizesLevel3InputsAbstract" xlink:to="onco_ScheduleOfAssumptionsUsedInMonteCarloModelWhichUtilizesLevel3InputsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillTransfers_lbl0" xml:lang="en-US">Goodwill, Transfers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillTransfers" xlink:to="us-gaap_GoodwillTransfers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl0" xml:lang="en-US">Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl0" xml:lang="en-US">Conversion of Stock, Amount Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedTradeNames_lbl0" xml:lang="en-US">Indefinite-Lived Trade Names</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedTradeNames" xlink:to="us-gaap_IndefiniteLivedTradeNames_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl0" xml:lang="en-US">Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues_lbl0" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Issuances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl0" xml:lang="en-US">Stock Option, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_lbl0" xml:lang="en-US">Liabilities Subject to Compromise, Early Contract Termination Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:to="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_MeasurementInputStockPriceMember_lbl0" xml:lang="en-US">Measurement Input Stock Price Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_MeasurementInputStockPriceMember" xlink:to="onco_MeasurementInputStockPriceMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl0" xml:lang="en-US">Reclassifications of Temporary to Permanent Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl0" xml:lang="en-US">Other Income and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl0" xml:lang="en-US">Adjustment of Warrants Granted for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl0" xml:lang="en-US">Payments for Repurchase of Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_August2025Member_lbl0" xml:lang="en-US">August2025 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_August2025Member" xlink:to="onco_August2025Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Other Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PMXTransactionMember_lbl0" xml:lang="en-US">PMXTransaction Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PMXTransactionMember" xlink:to="onco_PMXTransactionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTableTextBlock_lbl0" xml:lang="en-US">Asset Acquisition [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTableTextBlock" xlink:to="us-gaap_AssetAcquisitionTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0" xml:lang="en-US">Repayments of Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction_lbl1" xml:lang="en-US">Stock Issued During Period Shares Assumption Of Stockbased Compensation Plan Awards In Connection With PMXTransaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" xlink:to="onco_StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockAcquiredAverageCostPerShare_lbl0" xml:lang="en-US">Shares Acquired, Average Cost Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="us-gaap_TreasuryStockAcquiredAverageCostPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecognitionOfDeferredRevenue_lbl0" xml:lang="en-US">Recognition of Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecognitionOfDeferredRevenue" xlink:to="us-gaap_RecognitionOfDeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl0" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SharesOfCommonStockIssued_lbl1" xml:lang="en-US">Shares Of Common Stock Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SharesOfCommonStockIssued" xlink:to="onco_SharesOfCommonStockIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Valuation Of The Contingent Warrant Liability Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock" xlink:to="onco_ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SettlementAgreementMember_lbl0" xml:lang="en-US">Settlement Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SettlementAgreementMember" xlink:to="onco_SettlementAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_OUIAgreementMember_lbl0" xml:lang="en-US">OUIAgreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_OUIAgreementMember" xlink:to="onco_OUIAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl1" xml:lang="en-US">Other Selling, General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_OlogyBioservicesIncMember_lbl1" xml:lang="en-US">Ology Bioservices Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_OlogyBioservicesIncMember" xlink:to="onco_OlogyBioservicesIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AccruedResearchAndDevelopmentCurrent_lbl1" xml:lang="en-US">Accrued Research And Development Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AccruedResearchAndDevelopmentCurrent" xlink:to="onco_AccruedResearchAndDevelopmentCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PlanAssetsMember_lbl0" xml:lang="en-US">Plan Assets Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PlanAssetsMember" xlink:to="onco_PlanAssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_lbl0" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl0" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidRent_lbl0" xml:lang="en-US">Prepaid Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRent" xlink:to="us-gaap_PrepaidRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl0" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ReceivableFromRelatedParties1_lbl1" xml:lang="en-US">Receivable From Related Parties1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ReceivableFromRelatedParties1" xlink:to="onco_ReceivableFromRelatedParties1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology_lbl1" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Product Rights For Developed Technology</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_RevenueRate_lbl1" xml:lang="en-US">Revenue Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RevenueRate" xlink:to="onco_RevenueRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PercentageOfConsiderationReceived_lbl1" xml:lang="en-US">Percentage Of Consideration Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfConsiderationReceived" xlink:to="onco_PercentageOfConsiderationReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_VendorAgreementMember_lbl0" xml:lang="en-US">Vendor Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_VendorAgreementMember" xlink:to="onco_VendorAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl0" xml:lang="en-US">Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayable_lbl0" xml:lang="en-US">Other Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl0" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_RoyaltyNetSalesPercentage_lbl1" xml:lang="en-US">Royalty Net Sales Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RoyaltyNetSalesPercentage" xlink:to="onco_RoyaltyNetSalesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl1" xml:lang="en-US">Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AprilContingentWarrantsMember_lbl0" xml:lang="en-US">April Contingent Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AprilContingentWarrantsMember" xlink:to="onco_AprilContingentWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdministrativeFeesExpense_lbl0" xml:lang="en-US">Administrative Fees Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdministrativeFeesExpense" xlink:to="us-gaap_AdministrativeFeesExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_NonConvertibleDebentureMember_lbl0" xml:lang="en-US">Non Convertible Debenture Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_NonConvertibleDebentureMember" xlink:to="onco_NonConvertibleDebentureMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl0" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Transaction Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl1" xml:lang="en-US">Debt Instrument, Annual Principal Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl0" xml:lang="en-US">Labor and Related Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl1" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation_lbl1" xml:lang="en-US">Finite Lived Intangible Assets Accumulated Amortization Effect Of Currency Translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation" xlink:to="onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SubscriptionAgreementLiabilityNoncurrent_lbl1" xml:lang="en-US">Subscription Agreement Liability Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SubscriptionAgreementLiabilityNoncurrent" xlink:to="onco_SubscriptionAgreementLiabilityNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl2" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PaymentOfAccruedBonusThroughRelatedPartyReceivable_lbl1" xml:lang="en-US">Payment Of Accrued Bonus Through Related Party Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PaymentOfAccruedBonusThroughRelatedPartyReceivable" xlink:to="onco_PaymentOfAccruedBonusThroughRelatedPartyReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_RoyaltiesPercentage_lbl1" xml:lang="en-US">Royalties Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RoyaltiesPercentage" xlink:to="onco_RoyaltiesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ChangeInPensionBenefitObligation_lbl1" xml:lang="en-US">Change In Pension Benefit Obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ChangeInPensionBenefitObligation" xlink:to="onco_ChangeInPensionBenefitObligation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl1" xml:lang="en-US">Unrecognized Tax Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_CommonStockIssuableUponConversionOfSeriesAPreferredStockMember_lbl0" xml:lang="en-US">Common Stock Issuable Upon Conversion Of Series APreferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CommonStockIssuableUponConversionOfSeriesAPreferredStockMember" xlink:to="onco_CommonStockIssuableUponConversionOfSeriesAPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl0" xml:lang="en-US">Inventory, Work in Process, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_RoyaltySalesPercentage_lbl1" xml:lang="en-US">Royalty Sales Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RoyaltySalesPercentage" xlink:to="onco_RoyaltySalesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_DebtInstrumentDueDate_lbl1" xml:lang="en-US">Debt Instrument Due Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_DebtInstrumentDueDate" xlink:to="onco_DebtInstrumentDueDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_lbl0" xml:lang="en-US">Shares Held in Employee Stock Option Plan, Allocated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated" xlink:to="us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_MilestonePaymentsMember_lbl0" xml:lang="en-US">Milestone Payments Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_MilestonePaymentsMember" xlink:to="onco_MilestonePaymentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceDecrease_lbl0" xml:lang="en-US">Stock Option, Exercise Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceDecrease" xlink:to="us-gaap_StockOptionExercisePriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_LicenseAgreement_lbl1" xml:lang="en-US">License Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_LicenseAgreement" xlink:to="onco_LicenseAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PercentageOfOriginalIssuePrice_lbl1" xml:lang="en-US">Percentage Of Original Issue Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfOriginalIssuePrice" xlink:to="onco_PercentageOfOriginalIssuePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement_lbl1" xml:lang="en-US">Stock Issued During Period Value Issuanceof Common Stockand Warrantsin Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement" xlink:to="onco_StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_RegulatoryMilestonesMember_lbl0" xml:lang="en-US">Regulatory Milestones Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RegulatoryMilestonesMember" xlink:to="onco_RegulatoryMilestonesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl0" xml:lang="en-US">Dividends Payable, Amount Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableAmountPerShare" xlink:to="us-gaap_DividendsPayableAmountPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PercentageOfGrossProceeds_lbl1" xml:lang="en-US">Percentage Of Gross Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfGrossProceeds" xlink:to="onco_PercentageOfGrossProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl1" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_lbl0" xml:lang="en-US">Common Stock, Shares Subscribed but Unissued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract_lbl" xml:lang="en-US">Schedule Of Consolidated Statements Of Operations And Comprehensive Loss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="onco_ScheduleOfConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl1" xml:lang="en-US">Fair Value of Assets Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl1"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract_lbl" xml:lang="en-US">Schedule Of Components Of Net Periodic Benefit Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract" xlink:to="onco_ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AggregatePurchaseShares_lbl2" xml:lang="en-US">Aggregate Purchase Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregatePurchaseShares" xlink:to="onco_AggregatePurchaseShares_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_FairValueConsiderationTransferredMember_lbl0" xml:lang="en-US">Fair Value Consideration Transferred Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_FairValueConsiderationTransferredMember" xlink:to="onco_FairValueConsiderationTransferredMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_IssuanceOfCommonStockInInitialPublicOfferingNet_lbl1" xml:lang="en-US">Issuance Of Common Stock In Initial Public Offering Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IssuanceOfCommonStockInInitialPublicOfferingNet" xlink:to="onco_IssuanceOfCommonStockInInitialPublicOfferingNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl0" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock_lbl0" xml:lang="en-US">Asset Acquisition, Contingent Consideration [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_lbl0" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl0" xml:lang="en-US">Stock Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl0" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanInterestCost_lbl0" xml:lang="en-US">Defined Benefit Plan, Interest Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanInterestCost" xlink:to="us-gaap_DefinedBenefitPlanInterestCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl0" xml:lang="en-US">Retirement Benefits [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl0" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_OriginalMember_lbl0" xml:lang="en-US">Original Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_OriginalMember" xlink:to="onco_OriginalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants_lbl1" xml:lang="en-US">Stock Issued During Period Value Ofssuance Of Common Stock And Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants" xlink:to="onco_StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SeriesBConvertibleRedeemablePreferredStockMember_lbl0" xml:lang="en-US">Series BConvertible Redeemable Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SeriesBConvertibleRedeemablePreferredStockMember" xlink:to="onco_SeriesBConvertibleRedeemablePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_InitialPublicOfferingShares_lbl1" xml:lang="en-US">Initial Public Offering Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_InitialPublicOfferingShares" xlink:to="onco_InitialPublicOfferingShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl0" xml:lang="en-US">Payments to Acquire Productive Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_lbl0" xml:lang="en-US">Inventory Valuation Reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl0" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl0" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl1" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_lbl0" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:to="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl0" xml:lang="en-US">Temporary Equity, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0" xml:lang="en-US">Payments to Acquire Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AccruedDeferredOfferingCosts_lbl1" xml:lang="en-US">Accrued Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AccruedDeferredOfferingCosts" xlink:to="onco_AccruedDeferredOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AmortizationOfNetGain_lbl1" xml:lang="en-US">Amortization Of Net Gain</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AmortizationOfNetGain" xlink:to="onco_AmortizationOfNetGain_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl0" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_lbl0" xml:lang="en-US">Asset Acquisition, Price of Acquisition, Expected</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:to="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation Nondeductible Expense State Rate Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment" xlink:to="onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_RealEstateInvestmentsRate_lbl1" xml:lang="en-US">Real Estate Investments Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RealEstateInvestmentsRate" xlink:to="onco_RealEstateInvestmentsRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl0" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CumulativeDividends_lbl0" xml:lang="en-US">Cumulative Dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeDividends" xlink:to="us-gaap_CumulativeDividends_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl0" xml:lang="en-US">Proceeds from (Repayments of) Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_RestrictedStockForfeitures_lbl1" xml:lang="en-US">Restricted Stock Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_RestrictedStockForfeitures" xlink:to="onco_RestrictedStockForfeitures_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_TreasuryStockPolicyPolicyTextBlock_lbl1" xml:lang="en-US">Treasury Stock Policy Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_TreasuryStockPolicyPolicyTextBlock" xlink:to="onco_TreasuryStockPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl0" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl0" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl0" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_TreasuryStocksMember_lbl0" xml:lang="en-US">Treasury Stocks Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_TreasuryStocksMember" xlink:to="onco_TreasuryStocksMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsShares_lbl0" xml:lang="en-US">Preferred Stock Dividends, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsShares" xlink:to="us-gaap_PreferredStockDividendsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_CostBasisAbstract_lbl0" xml:lang="en-US">Cost Basis Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CostBasisAbstract" xlink:to="onco_CostBasisAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl0" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl0" xml:lang="en-US">Preferred Stock, Convertible, Shares Issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ContingentWarrantLiabilityShares_lbl1" xml:lang="en-US">Contingent Warrant Liability Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ContingentWarrantLiabilityShares" xlink:to="onco_ContingentWarrantLiabilityShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl1" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl2" xml:lang="en-US">Derivative Liability, Measurement Input</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl0" xml:lang="en-US">Measurement Input, Exercise Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit_lbl0" xml:lang="en-US">Payments to Acquire Restricted Certificates of Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:to="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl0" xml:lang="en-US">Debt Conversion, Original Debt, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl0" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_lbl1" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerRelationshipsMember_lbl1" xml:lang="en-US">Customer Relationships [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl0" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl1" xml:lang="en-US">Business Combination, Consideration Transferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl0" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl2" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ChiefBusinessOfficerMember_lbl0" xml:lang="en-US">Chief Business Officer Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ChiefBusinessOfficerMember" xlink:to="onco_ChiefBusinessOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_GrossPayPercentage_lbl1" xml:lang="en-US">Gross Pay Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_GrossPayPercentage" xlink:to="onco_GrossPayPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_CBOMember_lbl0" xml:lang="en-US">CBOMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CBOMember" xlink:to="onco_CBOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PublicOfPerShare_lbl1" xml:lang="en-US">Public Of Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PublicOfPerShare" xlink:to="onco_PublicOfPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_DeferredOfferingCostsPreviouslyPrepaid_lbl1" xml:lang="en-US">Deferred Offering Costs Previously Prepaid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_DeferredOfferingCostsPreviouslyPrepaid" xlink:to="onco_DeferredOfferingCostsPreviouslyPrepaid_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncurrentAssets_lbl0" xml:lang="en-US">Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncurrentAssets" xlink:to="us-gaap_NoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, State and Local, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_CEOMember_lbl0" xml:lang="en-US">CEOMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CEOMember" xlink:to="onco_CEOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_DebtInstrumentDueTerm_lbl1" xml:lang="en-US">Debt Instrument Due Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_DebtInstrumentDueTerm" xlink:to="onco_DebtInstrumentDueTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_BusinessTransactionYeare_lbl1" xml:lang="en-US">Business Transaction Yeare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessTransactionYeare" xlink:to="onco_BusinessTransactionYeare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_WarrantInducementMember_lbl0" xml:lang="en-US">Warrant Inducement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_WarrantInducementMember" xlink:to="onco_WarrantInducementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl0" xml:lang="en-US">Proceeds from License Fees Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl0" xml:lang="en-US">Goodwill, Impairment Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfUnvestedRestrictedStockAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfUnvestedRestrictedStockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfUnvestedRestrictedStockAbstract_lbl" xml:lang="en-US">Schedule Of Unvested Restricted Stock Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfUnvestedRestrictedStockAbstract" xlink:to="onco_ScheduleOfUnvestedRestrictedStockAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SubscriptionAgreementPMXInvestorPercentage_lbl1" xml:lang="en-US">Subscription Agreement PMXInvestor Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SubscriptionAgreementPMXInvestorPercentage" xlink:to="onco_SubscriptionAgreementPMXInvestorPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AggregateAgreementAmountInitialAgreement_lbl1" xml:lang="en-US">Aggregate Agreement Amount Initial Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregateAgreementAmountInitialAgreement" xlink:to="onco_AggregateAgreementAmountInitialAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl0" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_lbl0" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ContingentWarrantLiabilityMember_lbl0" xml:lang="en-US">Contingent Warrant Liability Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ContingentWarrantLiabilityMember" xlink:to="onco_ContingentWarrantLiabilityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfFairValueOfOptionsGrantedAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfFairValueOfOptionsGrantedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfFairValueOfOptionsGrantedAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Of Options Granted Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfFairValueOfOptionsGrantedAbstract" xlink:to="onco_ScheduleOfFairValueOfOptionsGrantedAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_lbl1" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:to="us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfBenefitObligationAndTheNetPeriodicBenefitCostAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfBenefitObligationAndTheNetPeriodicBenefitCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfBenefitObligationAndTheNetPeriodicBenefitCostAbstract_lbl" xml:lang="en-US">Schedule Of Benefit Obligation And The Net Periodic Benefit Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfBenefitObligationAndTheNetPeriodicBenefitCostAbstract" xlink:to="onco_ScheduleOfBenefitObligationAndTheNetPeriodicBenefitCostAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl0" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_BankruptcyCourtMember_lbl0" xml:lang="en-US">Bankruptcy Court Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BankruptcyCourtMember" xlink:to="onco_BankruptcyCourtMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_lbl0" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_InitialPaymentAmount_lbl1" xml:lang="en-US">Initial Payment Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_InitialPaymentAmount" xlink:to="onco_InitialPaymentAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_lbl0" xml:lang="en-US">Class of Warrant or Right, Unissued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl0" xml:lang="en-US">Prepaid Insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions_lbl1" xml:lang="en-US">Issuance Of Common Stock From Exercise Of Preferred Investment Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions" xlink:to="onco_IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl0" xml:lang="en-US">Other Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfFairValueOfThePreferredInvestmentOptionsAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfFairValueOfThePreferredInvestmentOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfFairValueOfThePreferredInvestmentOptionsAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Of The Preferred Investment Options Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfFairValueOfThePreferredInvestmentOptionsAbstract" xlink:to="onco_ScheduleOfFairValueOfThePreferredInvestmentOptionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_lbl0" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_April2022PrivatePlacementMember_lbl0" xml:lang="en-US">April2022 Private Placement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_April2022PrivatePlacementMember" xlink:to="onco_April2022PrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ExchangedMember_lbl0" xml:lang="en-US">Exchanged Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ExchangedMember" xlink:to="onco_ExchangedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_NumberOfShares_lbl1" xml:lang="en-US">Number Of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_NumberOfShares" xlink:to="onco_NumberOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossAttributableToParent_lbl0" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_IncomeLossAttributableToParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl0" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AggregateeAmount_lbl1" xml:lang="en-US">Aggregatee Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregateeAmount" xlink:to="onco_AggregateeAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnlabeledAbstract2" xlink:to="onco_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnlabeledAbstract1" xlink:to="onco_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnlabeledAbstract4" xlink:to="onco_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl1" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees_lbl1" xml:lang="en-US">Defined Benefit Plan Benefit Obligation Ordinary Contributions Paid By Employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees" xlink:to="onco_DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnlabeledAbstract3" xlink:to="onco_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnlabeledAbstract0" xlink:to="onco_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl0" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetImpairmentCharges_lbl2" xml:lang="en-US">Other Asset Impairment Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetImpairmentCharges" xlink:to="us-gaap_OtherAssetImpairmentCharges_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_Payments_lbl1" xml:lang="en-US">Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_Payments" xlink:to="onco_Payments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnlabeledAbstract9" xlink:to="onco_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnlabeledAbstract6" xlink:to="onco_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_EffectOfBusinessCombination_lbl1" xml:lang="en-US">Effect Of Business Combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_EffectOfBusinessCombination" xlink:to="onco_EffectOfBusinessCombination_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnlabeledAbstract5" xlink:to="onco_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnlabeledAbstract8" xlink:to="onco_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnlabeledAbstract7" xlink:to="onco_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Income Tax Liabilities, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductLiabilityContingencyAccrualDiscountRate_lbl0" xml:lang="en-US">Product Liability Contingency, Accrual, Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyAccrualDiscountRate" xlink:to="us-gaap_ProductLiabilityContingencyAccrualDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares_lbl1" xml:lang="en-US">Stock Issued During Period Shares Issuance Of Series APreferred Stockin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares" xlink:to="onco_StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedMarketingCostsCurrent_lbl0" xml:lang="en-US">Accrued Marketing Costs, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedMarketingCostsCurrent" xlink:to="us-gaap_AccruedMarketingCostsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ManagementServicesAgreementMember_lbl0" xml:lang="en-US">Management Services Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ManagementServicesAgreementMember" xlink:to="onco_ManagementServicesAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl0" xml:lang="en-US">Accrual for Taxes Other than Income Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SaleOfUnits_lbl1" xml:lang="en-US">Sale Of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SaleOfUnits" xlink:to="onco_SaleOfUnits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl0" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees_lbl1" xml:lang="en-US">Defined Benefit Plan Plan Assets Ordinary Contributions Paid By Employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees" xlink:to="onco_DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopmentCosts_lbl0" xml:lang="en-US">Development Costs, Period Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopmentCosts" xlink:to="us-gaap_DevelopmentCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction_lbl1" xml:lang="en-US">Stock Issued During Period Value Assumption Of Stockbased Compensation Plan Awards In Connection With PMXTransaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" xlink:to="onco_StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl0" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl1" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_FiniteLivedIntangibleAssetCost_lbl1" xml:lang="en-US">Finite Lived Intangible Asset Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_FiniteLivedIntangibleAssetCost" xlink:to="onco_FiniteLivedIntangibleAssetCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_CommercialSaleTerm_lbl1" xml:lang="en-US">Commercial Sale Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CommercialSaleTerm" xlink:to="onco_CommercialSaleTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnlabeledAbstract" xlink:to="onco_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation_lbl1" xml:lang="en-US">Income Tax Reconciliation Nondeductible Expense Officers Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" xlink:to="onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted" xlink:to="onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PayableAverageDiscountRatePercentage_lbl1" xml:lang="en-US">Payable Average Discount Rate Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PayableAverageDiscountRatePercentage" xlink:to="onco_PayableAverageDiscountRatePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl0" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation_lbl1" xml:lang="en-US">Stock Issued During Period Value Of Changes In Pension Benefit Obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation" xlink:to="onco_StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_GrantDateFairValueOfStockOption_lbl1" xml:lang="en-US">Grant Date Fair Value Of Stock Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_GrantDateFairValueOfStockOption" xlink:to="onco_GrantDateFairValueOfStockOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability_lbl1" xml:lang="en-US">Income Tax Reconciliation Nondeductible Expense Derivative Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability" xlink:to="onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl0" xml:lang="en-US">Condensed Financial Statements [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_InventoryFairValue_lbl1" xml:lang="en-US">Inventory Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_InventoryFairValue" xlink:to="onco_InventoryFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl0" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl0" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl0" xml:lang="en-US">Royalty Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialAndIndustrialSectorMember_lbl0" xml:lang="en-US">Commercial and Industrial Sector [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialAndIndustrialSectorMember" xlink:to="us-gaap_CommercialAndIndustrialSectorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible_lbl1" xml:lang="en-US">Asset Acquisition Consideration Transferred ENTADFIIntangible</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible" xlink:to="onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl0" xml:lang="en-US">Property, Plant and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_lbl0" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_lbl0" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:to="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SalesPaymentsAmount_lbl1" xml:lang="en-US">Sales Payments Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SalesPaymentsAmount" xlink:to="onco_SalesPaymentsAmount_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SignificantAgreementsTextBlock_lbl1" xml:lang="en-US">Significant Agreements Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SignificantAgreementsTextBlock" xlink:to="onco_SignificantAgreementsTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCostOfOperatingRevenue_lbl0" xml:lang="en-US">Other Cost of Operating Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostOfOperatingRevenue" xlink:to="us-gaap_OtherCostOfOperatingRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AggregateNetProceeds_lbl1" xml:lang="en-US">Aggregate Net Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregateNetProceeds" xlink:to="onco_AggregateNetProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AmountOfOtherPartyPayments_lbl1" xml:lang="en-US">Amount Of Other Party Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AmountOfOtherPartyPayments" xlink:to="onco_AmountOfOtherPartyPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_WarrantsIssuableUnderProvisionShares_lbl1" xml:lang="en-US">Warrants Issuable Under Provision Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_WarrantsIssuableUnderProvisionShares" xlink:to="onco_WarrantsIssuableUnderProvisionShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock_lbl1" xml:lang="en-US">Schedule Of Fair Value Of Options Granted In2023 And2022 Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock" xlink:to="onco_ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_BusinessAcquisitionMember_lbl0" xml:lang="en-US">Business Acquisition Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessAcquisitionMember" xlink:to="onco_BusinessAcquisitionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AggregateRoyaltiesAmount_lbl1" xml:lang="en-US">Aggregate Royalties Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregateRoyaltiesAmount" xlink:to="onco_AggregateRoyaltiesAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RegulatedAndUnregulatedOperatingRevenue_lbl0" xml:lang="en-US">Regulated and Unregulated Operating Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegulatedAndUnregulatedOperatingRevenue" xlink:to="us-gaap_RegulatedAndUnregulatedOperatingRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl1" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl0" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_FixedCommissionRate_lbl1" xml:lang="en-US">Fixed Commission Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_FixedCommissionRate" xlink:to="onco_FixedCommissionRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_WeightedAverageDiscountRate_lbl1" xml:lang="en-US">Weighted Average Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_WeightedAverageDiscountRate" xlink:to="onco_WeightedAverageDiscountRate_lbl1"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfAggregateConsiderationTransferredForTheAssetsAcquiredAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfAggregateConsiderationTransferredForTheAssetsAcquiredAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfAggregateConsiderationTransferredForTheAssetsAcquiredAbstract_lbl" xml:lang="en-US">Schedule Of Aggregate Consideration Transferred For The Assets Acquired Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfAggregateConsiderationTransferredForTheAssetsAcquiredAbstract" xlink:to="onco_ScheduleOfAggregateConsiderationTransferredForTheAssetsAcquiredAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_lbl0" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl0" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ChangeInFairValueOfSubscriptionAgreementLiability_lbl1" xml:lang="en-US">Change In Fair Value Of Subscription Agreement Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ChangeInFairValueOfSubscriptionAgreementLiability" xlink:to="onco_ChangeInFairValueOfSubscriptionAgreementLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl0" xml:lang="en-US">Inventory Write-down</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AccumulatedAmortizationAbstract_lbl0" xml:lang="en-US">Accumulated Amortization Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AccumulatedAmortizationAbstract" xlink:to="onco_AccumulatedAmortizationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl1" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PMXOptionPlanMember_lbl0" xml:lang="en-US">PMXOption Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PMXOptionPlanMember" xlink:to="onco_PMXOptionPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl0" xml:lang="en-US">Noncontrolling Interest [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AccumulatedBenefitObligationMember_lbl0" xml:lang="en-US">Accumulated Benefit Obligation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AccumulatedBenefitObligationMember" xlink:to="onco_AccumulatedBenefitObligationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_SharesOfCommonStockRate_lbl1" xml:lang="en-US">Shares Of Common Stock Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_SharesOfCommonStockRate" xlink:to="onco_SharesOfCommonStockRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_lbl0" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ServicingLiabilityAtFairValueAdditions_lbl0" xml:lang="en-US">Servicing Liability at Fair Value, Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServicingLiabilityAtFairValueAdditions" xlink:to="us-gaap_ServicingLiabilityAtFairValueAdditions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_OxfordUniversityInnovationLimitedMember_lbl0" xml:lang="en-US">Oxford University Innovation Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_OxfordUniversityInnovationLimitedMember" xlink:to="onco_OxfordUniversityInnovationLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl0" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PercentageOfCommonStockShares_lbl1" xml:lang="en-US">Percentage Of Common Stock Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfCommonStockShares" xlink:to="onco_PercentageOfCommonStockShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_NotePayableMember_lbl0" xml:lang="en-US">Note Payable Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_NotePayableMember" xlink:to="onco_NotePayableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PrepaidProfessionalFees_lbl1" xml:lang="en-US">Prepaid Professional Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PrepaidProfessionalFees" xlink:to="onco_PrepaidProfessionalFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable_lbl1" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Note Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable" xlink:to="onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_lbl0" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_EffectOfSettlement_lbl1" xml:lang="en-US">Effect Of Settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_EffectOfSettlement" xlink:to="onco_EffectOfSettlement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AggregatePayments_lbl1" xml:lang="en-US">Aggregate Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AggregatePayments" xlink:to="onco_AggregatePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl0" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AcquisitionsPolicyTextBlock_lbl1" xml:lang="en-US">Acquisitions Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AcquisitionsPolicyTextBlock" xlink:to="onco_AcquisitionsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanActuarialGainLoss_lbl0" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="us-gaap_DefinedBenefitPlanActuarialGainLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_lbl0" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_lbl0" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_lbl0" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfOtherInvestments_lbl0" xml:lang="en-US">Proceeds from Sale of Other Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:to="us-gaap_ProceedsFromSaleOfOtherInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl1" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_lbl0" xml:lang="en-US">Treasury Stock, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl0" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Professional Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_January2024Member_lbl0" xml:lang="en-US">January2024 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_January2024Member" xlink:to="onco_January2024Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PaymentsForPurchaseOfTreasuryShares_lbl1" xml:lang="en-US">Payments For Purchase Of Treasury Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PaymentsForPurchaseOfTreasuryShares" xlink:to="onco_PaymentsForPurchaseOfTreasuryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PercentageOfSubscription_lbl1" xml:lang="en-US">Percentage Of Subscription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfSubscription" xlink:to="onco_PercentageOfSubscription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_VotingInterestPercentage_lbl1" xml:lang="en-US">Voting Interest Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_VotingInterestPercentage" xlink:to="onco_VotingInterestPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl0" xml:lang="en-US">Derivative Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_August2022PrivatePlacementMember_lbl0" xml:lang="en-US">August2022 Private Placement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_August2022PrivatePlacementMember" xlink:to="onco_August2022PrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParentMember_lbl0" xml:lang="en-US">Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_WeightedAverageDiscountRateThereafter_lbl1" xml:lang="en-US">Weighted Average Discount Rate Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_WeightedAverageDiscountRateThereafter" xlink:to="onco_WeightedAverageDiscountRateThereafter_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_lbl0" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_CashPaymentToTheSeller_lbl1" xml:lang="en-US">Cash Payment To The Seller</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_CashPaymentToTheSeller" xlink:to="onco_CashPaymentToTheSeller_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PrefundedWarrantsExercised_lbl1" xml:lang="en-US">Prefunded Warrants Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PrefundedWarrantsExercised" xlink:to="onco_PrefundedWarrantsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl1" xml:lang="en-US">Asset Acquisition, Consideration Transferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLossMember_lbl1" xml:lang="en-US">Operating Income (Loss) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLossMember" xlink:to="us-gaap_OperatingIncomeLossMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_UnvestedRestrictedStockMember_lbl0" xml:lang="en-US">Unvested Restricted Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UnvestedRestrictedStockMember" xlink:to="onco_UnvestedRestrictedStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets_lbl0" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AssetPurchaseAgreementMember_lbl0" xml:lang="en-US">Asset Purchase Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AssetPurchaseAgreementMember" xlink:to="onco_AssetPurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_NettingProceeds_lbl1" xml:lang="en-US">Netting Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_NettingProceeds" xlink:to="onco_NettingProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_UTHealthAgreementMember_lbl0" xml:lang="en-US">UTHealth Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UTHealthAgreementMember" xlink:to="onco_UTHealthAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CH_lbl1" xml:lang="en-US">SWITZERLAND</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CH" xlink:to="country_CH_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_StJudeChildrensHospitalMember_lbl0" xml:lang="en-US">St Jude Childrens Hospital Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StJudeChildrensHospitalMember" xlink:to="onco_StJudeChildrensHospitalMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfLongLivedByGeographicalAreaAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfLongLivedByGeographicalAreaAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfLongLivedByGeographicalAreaAbstract_lbl" xml:lang="en-US">Schedule Of Long Lived By Geographical Area Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfLongLivedByGeographicalAreaAbstract" xlink:to="onco_ScheduleOfLongLivedByGeographicalAreaAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_lbl0" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement_lbl0" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Payment for Settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl1" xml:lang="en-US">Restricted Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl0" xml:lang="en-US">Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_IssuanceOfRestrictedStock_lbl1" xml:lang="en-US">Issuance Of Restricted Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IssuanceOfRestrictedStock" xlink:to="onco_IssuanceOfRestrictedStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Of Financial Instruments Measured On ARecurring Basis Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract" xlink:to="onco_ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_TwoThousandTwentyTwoPlanMember_lbl1" xml:lang="en-US">Two Thousand Twenty Two Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_TwoThousandTwentyTwoPlanMember" xlink:to="onco_TwoThousandTwentyTwoPlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet_lbl1" xml:lang="en-US">Issuance Of Common Stock And Warrants In Private Placement Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet" xlink:to="onco_IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax_lbl1" xml:lang="en-US">Other Comprehensive Income Loss Foreign Currency Translations Adjustment Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax" xlink:to="onco_OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0" xml:lang="en-US">Subsidiary, Ownership Percentage, Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonShares_lbl0" xml:lang="en-US">Treasury Stock, Common, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock_lbl1" xml:lang="en-US">Stock Issued During Period Value Issuance Of Series APreferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock" xlink:to="onco_StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AugustContingentWarrantsMember_lbl0" xml:lang="en-US">August Contingent Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AugustContingentWarrantsMember" xlink:to="onco_AugustContingentWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl0" xml:lang="en-US">Deferred Costs, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Convertible Preferred Stock, Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" xlink:to="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceDecrease_lbl0" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPriceDecrease" xlink:to="us-gaap_PreferredStockConvertibleConversionPriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Net Periodic Benefit Cost Not yet Recognized [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" xlink:to="us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl0" xml:lang="en-US">Measurement Input, Option Volatility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction_lbl2" xml:lang="en-US">Stock Issued During Period Shares Issuance Of Common Stock And Series BPreferred Stock In Connection With PMXTransaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" xlink:to="onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_lbl0" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl1" xml:lang="en-US">Legal Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl0" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl1" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl0" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_DevelopmentMilestonesMember_lbl0" xml:lang="en-US">Development Milestones Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_DevelopmentMilestonesMember" xlink:to="onco_DevelopmentMilestonesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostMaintenance_lbl0" xml:lang="en-US">Cost, Maintenance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_IncreaseInTheFairValueOfThePreferredInvestmentOptions_lbl1" xml:lang="en-US">Increase In The Fair Value Of The Preferred Investment Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_IncreaseInTheFairValueOfThePreferredInvestmentOptions" xlink:to="onco_IncreaseInTheFairValueOfThePreferredInvestmentOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfStockOptionsAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfStockOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfStockOptionsAbstract_lbl" xml:lang="en-US">Schedule Of Stock Options Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfStockOptionsAbstract" xlink:to="onco_ScheduleOfStockOptionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_MarketOfferingAgreementMember_lbl0" xml:lang="en-US">Market Offering Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_MarketOfferingAgreementMember" xlink:to="onco_MarketOfferingAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:to="us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl0" xml:lang="en-US">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_lbl0" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_StockOptionsMember_lbl0" xml:lang="en-US">Stock Options Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_StockOptionsMember" xlink:to="onco_StockOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_lbl0" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl2" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeNamesMember_lbl1" xml:lang="en-US">Trade Names [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeNamesMember" xlink:to="us-gaap_TradeNamesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl1" xml:lang="en-US">Payments for Other Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralExpense_lbl0" xml:lang="en-US">Other General Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralExpense" xlink:to="us-gaap_OtherGeneralExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturityDate_lbl0" xml:lang="en-US">Long-Term Debt, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturityDate" xlink:to="us-gaap_LongTermDebtMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss_lbl0" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPaidinkind_lbl0" xml:lang="en-US">Dividends, Paid-in-kind</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPaidinkind" xlink:to="us-gaap_DividendsPaidinkind_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedUtilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Utilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedUtilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedUtilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl0" xml:lang="en-US">Professional and Contract Services Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl0" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl0" xml:lang="en-US">Condensed Income Statement [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl0" xml:lang="en-US">Federal, State, and Local, Income Tax Expense (Benefit), Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_WarrantsIssuedForSettlementOfContingentWarrants_lbl2" xml:lang="en-US">Warrants Issued For Settlement Of Contingent Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_WarrantsIssuedForSettlementOfContingentWarrants" xlink:to="onco_WarrantsIssuedForSettlementOfContingentWarrants_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_TwoThousandTwentyTwoEquityIncentivePlanMember_lbl0" xml:lang="en-US">Two Thousand Twenty Two Equity Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:to="onco_TwoThousandTwentyTwoEquityIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Estimated Fair Values Of Assets Acquired And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAbstract" xlink:to="onco_ScheduleOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_lbl0" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl0" xml:lang="en-US">Fair Value, Option, Changes in Fair Value, Gain (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfRevenueByGeographicalAreaAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfRevenueByGeographicalAreaAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfRevenueByGeographicalAreaAbstract_lbl" xml:lang="en-US">Schedule Of Revenue By Geographical Area Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfRevenueByGeographicalAreaAbstract" xlink:to="onco_ScheduleOfRevenueByGeographicalAreaAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl1" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_UniversityOfTexasHealthScienceCenterAtSanAntonioMember_lbl0" xml:lang="en-US">University Of Texas Health Science Center At San Antonio Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_UniversityOfTexasHealthScienceCenterAtSanAntonioMember" xlink:to="onco_UniversityOfTexasHealthScienceCenterAtSanAntonioMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_lbl0" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl0" xml:lang="en-US">Cash, FDIC Insured Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl0" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_lbl0" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:to="us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_AssetAcquisitionConsiderationTransferredInventory_lbl1" xml:lang="en-US">Asset Acquisition Consideration Transferred Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_AssetAcquisitionConsiderationTransferredInventory" xlink:to="onco_AssetAcquisitionConsiderationTransferredInventory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_PercentageOfIssuedOfCommonStock_lbl1" xml:lang="en-US">Percentage Of Issued Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_PercentageOfIssuedOfCommonStock" xlink:to="onco_PercentageOfIssuedOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_InducementPIOSharesMember_lbl0" xml:lang="en-US">Inducement PIOShares Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_InducementPIOSharesMember" xlink:to="onco_InducementPIOSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1_lbl0" xml:lang="en-US">Noncash or Part Noncash Acquisition, Inventory Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Liability, Defined Benefit Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl0" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl2" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl1" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ExercisePrice_lbl1" xml:lang="en-US">Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ExercisePrice" xlink:to="onco_ExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_MiscellaneousExpenses_lbl1" xml:lang="en-US">Miscellaneous Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_MiscellaneousExpenses" xlink:to="onco_MiscellaneousExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAppropriated_lbl0" xml:lang="en-US">Retained Earnings, Appropriated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAppropriated" xlink:to="us-gaap_RetainedEarningsAppropriated_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl0" xml:lang="en-US">Interest Expense, Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="onco_ScheduleOfOutstandingWarrantsExcludingContingentWarrantsAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfOutstandingWarrantsExcludingContingentWarrantsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="onco_ScheduleOfOutstandingWarrantsExcludingContingentWarrantsAbstract_lbl" xml:lang="en-US">Schedule Of Outstanding Warrants Excluding Contingent Warrants Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onco_ScheduleOfOutstandingWarrantsExcludingContingentWarrantsAbstract" xlink:to="onco_ScheduleOfOutstandingWarrantsExcludingContingentWarrantsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>onco-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Apr 26 21:03:50 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConsolidatedBalanceSheet" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConsolidatedIncomeStatement" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ShareholdersEquityType2or3" roleURI="http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConsolidatedCashFlow" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConsolidatedCashFlow_Parentheticals" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedCashFlow_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_OrganizationandBasisofPresentation" roleURI="http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentation"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_GoingConcernandManagementsPlans" roleURI="http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlans"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_BalanceSheetDetails" roleURI="http://www.bluewatervaccines.com/role/BalanceSheetDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_Acquisitions" roleURI="http://www.bluewatervaccines.com/role/Acquisitions"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_SignificantAgreements" roleURI="http://www.bluewatervaccines.com/role/SignificantAgreements"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_NotesPayable" roleURI="http://www.bluewatervaccines.com/role/NotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_SubscriptionAgreement" roleURI="http://www.bluewatervaccines.com/role/SubscriptionAgreement"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConvertibleRedeemablePreferredStockandStockholdersEquity" roleURI="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_CommitmentsandContingencies" roleURI="http://www.bluewatervaccines.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_RelatedPartyTransactions" roleURI="http://www.bluewatervaccines.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_IncomeTaxes" roleURI="http://www.bluewatervaccines.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_RetirementPlans" roleURI="http://www.bluewatervaccines.com/role/RetirementPlans"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_SubsequentEvents" roleURI="http://www.bluewatervaccines.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_AccountingPoliciesByPolicy" roleURI="http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_BalanceSheetDetailsTables" roleURI="http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_AcquisitionsTables" roleURI="http://www.bluewatervaccines.com/role/AcquisitionsTables"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_SubscriptionAgreementTables" roleURI="http://www.bluewatervaccines.com/role/SubscriptionAgreementTables"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConvertibleRedeemablePreferredStockandStockholdersEquityTables" roleURI="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_IncomeTaxesTables" roleURI="http://www.bluewatervaccines.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_RetirementPlansTables" roleURI="http://www.bluewatervaccines.com/role/RetirementPlansTables"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofRevenuebyGeographicalAreaTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofRevenuebyGeographicalAreaTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofLonglivedbyGeographicalAreaTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofLonglivedbyGeographicalAreaTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofActivityfortheSubscriptionAgreementLiabilityTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofActivityfortheSubscriptionAgreementLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofActivityfortheContingentWarrantLiabilityTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofActivityfortheContingentWarrantLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofComputationofDilutedSharesOutstandingTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofComputationofDilutedSharesOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofInventoriesTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofInventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofIntangibleAssetsTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofAnnualAmortizationExpenseTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofGoodwillTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofGoodwillTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofAccruedExpensesTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofAssetsAcquiredTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofAssetsAcquiredTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofFairValueoftheProteomedixStockOptionsTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofFairValueoftheProteomedixStockOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofConsolidatedStatementsofOperationsandComprehensiveLossTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofConsolidatedStatementsofOperationsandComprehensiveLossTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofFairValueofthePreferredInvestmentOptionsTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofFairValueofthePreferredInvestmentOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofValuationoftheContingentWarrantLiabilityTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofValuationoftheContingentWarrantLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofStockOptionsTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofFairValueofOptionsGrantedTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofFairValueofOptionsGrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofUnvestedRestrictedStockTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofUnvestedRestrictedStockTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofStockBasedCompensationExpenseTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofStockBasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofLossBeforeIncomeTaxTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofLossBeforeIncomeTaxTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofDeferredTaxAssetsandLiabilitiesTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofUnrecognizedTaxBenefitsTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofUnrecognizedTaxBenefitsTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofComponentsofNetPeriodicBenefitCostTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofComponentsofNetPeriodicBenefitCostTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofAccumulatedComprehensiveLossTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofAccumulatedComprehensiveLossTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofAccompanyingConsolidatedBalanceSheetTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofAccompanyingConsolidatedBalanceSheetTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ScheduleofBenefitPaymentsTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_OrganizationandBasisofPresentationDetails" roleURI="http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_GoingConcernandManagementsPlansDetails" roleURI="http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlansDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_BalanceSheetDetailsDetails" roleURI="http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_AcquisitionsDetails" roleURI="http://www.bluewatervaccines.com/role/AcquisitionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_SignificantAgreementsDetails" roleURI="http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_NotesPayableDetails" roleURI="http://www.bluewatervaccines.com/role/NotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_SubscriptionAgreementDetails" roleURI="http://www.bluewatervaccines.com/role/SubscriptionAgreementDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1" roleURI="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2" roleURI="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3" roleURI="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4" roleURI="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_CommitmentsandContingenciesDetails" roleURI="http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_RelatedPartyTransactionsDetails" roleURI="http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_IncomeTaxesDetails" roleURI="http://www.bluewatervaccines.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_RetirementPlansDetails" roleURI="http://www.bluewatervaccines.com/role/RetirementPlansDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#onco_r_SubsequentEventsDetails" roleURI="http://www.bluewatervaccines.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="onco-20231231.xsd#DocumentAndEntityInformation" roleURI="http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredCosts" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Goodwill" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubscriptionAgreementLiabilityNoncurrent" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="SubscriptionAgreementLiabilityNoncurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesBConvertibleRedeemablePreferredStockMember" xlink:href="onco-20231231.xsd#onco_SeriesBConvertibleRedeemablePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBConvertibleRedeemablePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesAConvertiblePreferredStockMember" xlink:href="onco-20231231.xsd#onco_SeriesAConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesAConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NotesPayableNetOfDebtDiscount" xlink:href="onco-20231231.xsd#onco_NotesPayableNetOfDebtDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="NotesPayableNetOfDebtDiscount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherAssetImpairmentCharges" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueOfSubscriptionAgreementLiability" xlink:href="onco-20231231.xsd#onco_ChangeInFairValueOfSubscriptionAgreementLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="ChangeInFairValueOfSubscriptionAgreementLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossAttributableToParent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_ProfitLoss_0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInPensionBenefitObligation" xlink:href="onco-20231231.xsd#onco_ChangeInPensionBenefitObligation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="ChangeInPensionBenefitObligation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesSeedMember" xlink:href="onco-20231231.xsd#onco_SeriesSeedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesSeedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_TreasuryStockCommonMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_ParentMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_NoncontrollingInterestMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="8.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions" xlink:href="onco-20231231.xsd#onco_IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax" xlink:href="onco-20231231.xsd#onco_OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares" xlink:to="StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfPrefundedWarrants" xlink:href="onco-20231231.xsd#onco_ExerciseOfPrefundedWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExerciseOfPrefundedWarrants" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfPrefundedWarrantsinShares" xlink:href="onco-20231231.xsd#onco_ExerciseOfPrefundedWarrantsinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExerciseOfPrefundedWarrantsinShares" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfTreasuryShares" xlink:href="onco-20231231.xsd#onco_PurchaseOfTreasuryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="PurchaseOfTreasuryShares" order="20.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfTreasurySharesinShares" xlink:href="onco-20231231.xsd#onco_PurchaseOfTreasurySharesinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="PurchaseOfTreasurySharesinShares" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_ParentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockInInitialPublicOfferingNet" xlink:href="onco-20231231.xsd#onco_IssuanceOfCommonStockInInitialPublicOfferingNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockInInitialPublicOfferingNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet" xlink:href="onco-20231231.xsd#onco_IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet" xlink:href="onco-20231231.xsd#onco_IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherAssetImpairmentCharges" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="GainLossOnRelatedPartyReceivable" xlink:href="onco-20231231.xsd#onco_GainLossOnRelatedPartyReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnRelatedPartyReceivable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PensionExpense" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ReceivableFromRelatedParties1" xlink:href="onco-20231231.xsd#onco_ReceivableFromRelatedParties1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ReceivableFromRelatedParties1" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentsForPurchaseOfTreasuryShares" xlink:href="onco-20231231.xsd#onco_PaymentsForPurchaseOfTreasuryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentsForPurchaseOfTreasuryShares" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfPrivatePlacement" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectOfBusinessCombination" xlink:href="onco-20231231.xsd#onco_EffectOfBusinessCombination"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="EffectOfBusinessCombination" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement" xlink:href="onco-20231231.xsd#onco_RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsIssuedForSettlementOfContingentWarrants" xlink:href="onco-20231231.xsd#onco_WarrantsIssuedForSettlementOfContingentWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="WarrantsIssuedForSettlementOfContingentWarrants" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredOfferingCostsPreviouslyPrepaid" xlink:href="onco-20231231.xsd#onco_DeferredOfferingCostsPreviouslyPrepaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="DeferredOfferingCostsPreviouslyPrepaid" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Exerciseofprefundedwarrants" xlink:href="onco-20231231.xsd#onco_Exerciseofprefundedwarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="Exerciseofprefundedwarrants" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfRestrictedStock" xlink:href="onco-20231231.xsd#onco_IssuanceOfRestrictedStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="IssuanceOfRestrictedStock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedStockForfeitures" xlink:href="onco-20231231.xsd#onco_RestrictedStockForfeitures"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="RestrictedStockForfeitures" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfAccruedBonusThroughRelatedPartyReceivable" xlink:href="onco-20231231.xsd#onco_PaymentOfAccruedBonusThroughRelatedPartyReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="PaymentOfAccruedBonusThroughRelatedPartyReceivable" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedCashFlow_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentation">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlans">
    <loc xlink:type="locator" xlink:label="GoingConcernAndManagementsPlansAbstract" xlink:href="onco-20231231.xsd#onco_GoingConcernAndManagementsPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernAndManagementsPlansAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/BalanceSheetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/Acquisitions">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SignificantAgreements">
    <loc xlink:type="locator" xlink:label="SignificantAgreementsAbstract" xlink:href="onco-20231231.xsd#onco_SignificantAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAgreementsTextBlock" xlink:href="onco-20231231.xsd#onco_SignificantAgreementsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAgreementsAbstract" xlink:to="SignificantAgreementsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/NotesPayable">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SubscriptionAgreement">
    <loc xlink:type="locator" xlink:label="SubscriptionAgreementDisclosureAbstract" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="SubscriptionAgreementDisclosureTextBlock" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubscriptionAgreementDisclosureAbstract" xlink:to="SubscriptionAgreementDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/RetirementPlans">
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AcquisitionsPolicyTextBlock" xlink:href="onco-20231231.xsd#onco_AcquisitionsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="AcquisitionsPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TreasuryStockPolicyPolicyTextBlock" xlink:href="onco-20231231.xsd#onco_TreasuryStockPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="TreasuryStockPolicyPolicyTextBlock" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/AcquisitionsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_AssetAcquisitionTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SubscriptionAgreementTables">
    <loc xlink:type="locator" xlink:label="SubscriptionAgreementDisclosureAbstract" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubscriptionAgreementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock" xlink:href="onco-20231231.xsd#onco_ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock" xlink:href="onco-20231231.xsd#onco_ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/RetirementPlansTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock" xlink:href="onco-20231231.xsd#onco_ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofRevenuebyGeographicalAreaTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRevenueByGeographicalAreaAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfRevenueByGeographicalAreaAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenueByGeographicalAreaAbstract" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_CH" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CH"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_CH" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_EntityWideRevenueMajorCustomerLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofLonglivedbyGeographicalAreaTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLongLivedByGeographicalAreaAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfLongLivedByGeographicalAreaAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLongLivedByGeographicalAreaAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_CH" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CH"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_CH" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_NoncurrentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable" xlink:href="onco-20231231.xsd#onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisLineItems" xlink:href="onco-20231231.xsd#onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubscriptionAgreementLiabilityNoncurrent" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="SubscriptionAgreementLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofActivityfortheSubscriptionAgreementLiabilityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfActivityForTheSubscriptionAgreementLiabilityAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfActivityForTheSubscriptionAgreementLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfActivityForTheSubscriptionAgreementLiabilityAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SubscriptionAgreementLiabilityMember" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementLiabilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="SubscriptionAgreementLiabilityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofActivityfortheContingentWarrantLiabilityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfActivityForTheContingentWarrantLiabilityAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfActivityForTheContingentWarrantLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfActivityForTheContingentWarrantLiabilityAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ContingentWarrantLiabilityMember" xlink:href="onco-20231231.xsd#onco_ContingentWarrantLiabilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="ContingentWarrantLiabilityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReclassificationToEquity" xlink:href="onco-20231231.xsd#onco_ReclassificationToEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="ReclassificationToEquity" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofComputationofDilutedSharesOutstandingTable">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="StockOptionsMember" xlink:href="onco-20231231.xsd#onco_StockOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="StockOptionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuableUponConversionOfSeriesAPreferredStockMember" xlink:href="onco-20231231.xsd#onco_CommonStockIssuableUponConversionOfSeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="CommonStockIssuableUponConversionOfSeriesAPreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofInventoriesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidRent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidsResearchAndDevelopment" xlink:href="onco-20231231.xsd#onco_PrepaidsResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="PrepaidsResearchAndDevelopment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidProfessionalFees" xlink:href="onco-20231231.xsd#onco_PrepaidProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="PrepaidProfessionalFees" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_TradeNamesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_CustomerRelationshipsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CostBasisAbstract" xlink:href="onco-20231231.xsd#onco_CostBasisAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="CostBasisAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FiniteLivedIntangibleAssetCost" xlink:href="onco-20231231.xsd#onco_FiniteLivedIntangibleAssetCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostBasisAbstract" xlink:to="FiniteLivedIntangibleAssetCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ImpairmentOfIntangibleAssetExcludingGoodwill" xlink:href="onco-20231231.xsd#onco_ImpairmentOfIntangibleAssetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostBasisAbstract" xlink:to="ImpairmentOfIntangibleAssetExcludingGoodwill" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostBasisAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostBasisAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedAmortizationAbstract" xlink:href="onco-20231231.xsd#onco_AccumulatedAmortizationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="AccumulatedAmortizationAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedAmortizationAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation" xlink:href="onco-20231231.xsd#onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedAmortizationAbstract" xlink:to="FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedAmortizationAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofGoodwillTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfGoodwillAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGoodwillAbstract" xlink:to="us-gaap_Goodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillTransfers" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillTransfers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGoodwillAbstract" xlink:to="us-gaap_GoodwillTransfers" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGoodwillAbstract" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGoodwillAbstract" xlink:to="us-gaap_Goodwill_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="AccruedResearchAndDevelopmentCurrent" xlink:href="onco-20231231.xsd#onco_AccruedResearchAndDevelopmentCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="AccruedResearchAndDevelopmentCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedUtilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedUtilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedUtilitiesCurrentAndNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedDeferredOfferingCosts" xlink:href="onco-20231231.xsd#onco_AccruedDeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="AccruedDeferredOfferingCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedMarketingCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedMarketingCostsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAggregateConsiderationTransferredForTheAssetsAcquiredAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfAggregateConsiderationTransferredForTheAssetsAcquiredAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAggregateConsiderationTransferredForTheAssetsAcquiredAbstract" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FairValueConsiderationTransferredMember" xlink:href="onco-20231231.xsd#onco_FairValueConsiderationTransferredMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="FairValueConsiderationTransferredMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AggregateConsiderationTransferredMember" xlink:href="onco-20231231.xsd#onco_AggregateConsiderationTransferredMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="AggregateConsiderationTransferredMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationTable" xlink:to="us-gaap_AssetAcquisitionLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredOther1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofAssetsAcquiredTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAssetsAcquiredAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfAssetsAcquiredAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssetsAcquiredAbstract" xlink:to="us-gaap_AssetAcquisitionTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AssetsRecognizedMember" xlink:href="onco-20231231.xsd#onco_AssetsRecognizedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="AssetsRecognizedMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AssetAcquisitionConsiderationTransferredInventory" xlink:href="onco-20231231.xsd#onco_AssetAcquisitionConsiderationTransferredInventory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="AssetAcquisitionConsiderationTransferredInventory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AssetAcquisitionConsiderationTransferredENTADFIIntangible" xlink:href="onco-20231231.xsd#onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="AssetAcquisitionConsiderationTransferredENTADFIIntangible" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofFairValueoftheProteomedixStockOptionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfTheProteomedixStockOptionsAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfFairValueOfTheProteomedixStockOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheProteomedixStockOptionsAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MeasurementInputStockPriceMember" xlink:href="onco-20231231.xsd#onco_MeasurementInputStockPriceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="MeasurementInputStockPriceMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable" xlink:href="onco-20231231.xsd#onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"/>
    <loc xlink:type="locator" xlink:label="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:href="onco-20231231.xsd#onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAbstract" xlink:to="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BusinessAcquisitionMember" xlink:href="onco-20231231.xsd#onco_BusinessAcquisitionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable" xlink:to="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation" order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable" xlink:href="onco-20231231.xsd#onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable" order="16.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="17.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" order="19.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofConsolidatedStatementsofOperationsandComprehensiveLossTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedIncomeStatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="srt_CondensedIncomeStatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ProteomedixMember" xlink:href="onco-20231231.xsd#onco_ProteomedixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="ProteomedixMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PMXTransactionMember" xlink:href="onco-20231231.xsd#onco_PMXTransactionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="PMXTransactionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xlink:to="us-gaap_ProfitLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAssumptionsUsedInMonteCarloModelWhichUtilizesLevel3InputsAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfAssumptionsUsedInMonteCarloModelWhichUtilizesLevel3InputsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubscriptionAgreementDetailsScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementDetailsScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssumptionsUsedInMonteCarloModelWhichUtilizesLevel3InputsAbstract" xlink:to="SubscriptionAgreementDetailsScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubscriptionAgreementDetailsScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubscriptionAgreementDetailsScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExercisePriceMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubscriptionAgreementDetailsScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable" xlink:to="us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofFairValueofthePreferredInvestmentOptionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfThePreferredInvestmentOptionsAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfFairValueOfThePreferredInvestmentOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfThePreferredInvestmentOptionsAbstract" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OriginalMember" xlink:href="onco-20231231.xsd#onco_OriginalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="OriginalMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangedMember" xlink:href="onco-20231231.xsd#onco_ExchangedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="ExchangedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofValuationoftheContingentWarrantLiabilityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfValuationOfTheContingentWarrantLiabilityAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfValuationOfTheContingentWarrantLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityTable" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityTable"/>
    <loc xlink:type="locator" xlink:label="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfValuationOfTheContingentWarrantLiabilityAbstract" xlink:to="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityTable" xlink:to="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOutstandingWarrantsExcludingContingentWarrantsAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfOutstandingWarrantsExcludingContingentWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingWarrantsExcludingContingentWarrantsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionsAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfStockOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsTable" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsTable"/>
    <loc xlink:type="locator" xlink:label="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsAbstract" xlink:to="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsTable" xlink:to="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted" xlink:href="onco-20231231.xsd#onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled" xlink:href="onco-20231231.xsd#onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofFairValueofOptionsGrantedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfOptionsGrantedAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfFairValueOfOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedTable" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedTable"/>
    <loc xlink:type="locator" xlink:label="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfOptionsGrantedAbstract" xlink:to="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedTable" xlink:to="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofUnvestedRestrictedStockTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfUnvestedRestrictedStockAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfUnvestedRestrictedStockAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockTable" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockTable"/>
    <loc xlink:type="locator" xlink:label="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnvestedRestrictedStockAbstract" xlink:to="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockTable" xlink:to="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb4i4f4wUs/dKlMHRtjt5HiP056YCLyrdSoyPYyQevay5dOg9LR2t/KvbZBYGbO0fRFqRMXruICW071VL4cva1Vo1fRqEHdR31R1aena1W/oLM7lTmOCBLWaZ9ZWyZBU9clRPWAm3ygSKlPhipMHX/wTZ1GpdAQuF5X0Rk/U0peMoZ1GlWBL0QwQ4YYjsaQQj5y1OiFHDkpk+TSIy2jKBgVC6BuLNzQw2d0OQvqtBvmxiw3I1GgCSekvILJhH3efW/iVkf2/SEYQBx37mpmy8k7] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofStockBasedCompensationExpenseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockBasedCompensationExpenseAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfStockBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentMember" xlink:href="onco-20231231.xsd#onco_ResearchAndDevelopmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="ResearchAndDevelopmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofLossBeforeIncomeTaxTable">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseAgreement" xlink:href="onco-20231231.xsd#onco_LicenseAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="LicenseAgreement" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability" xlink:href="onco-20231231.xsd#onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" xlink:href="onco-20231231.xsd#onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment" xlink:href="onco-20231231.xsd#onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofUnrecognizedTaxBenefitsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBenefitObligationAndTheNetPeriodicBenefitCostAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfBenefitObligationAndTheNetPeriodicBenefitCostAbstract"/>
    <loc xlink:type="locator" xlink:label="RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable" xlink:href="onco-20231231.xsd#onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable"/>
    <loc xlink:type="locator" xlink:label="RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems" xlink:href="onco-20231231.xsd#onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBenefitObligationAndTheNetPeriodicBenefitCostAbstract" xlink:to="RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable" xlink:to="RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofComponentsofNetPeriodicBenefitCostTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract" xlink:to="us-gaap_DefinedBenefitPlanServiceCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract" xlink:to="us-gaap_DefinedBenefitPlanInterestCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract" xlink:to="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract" xlink:to="us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract" xlink:to="us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract" xlink:to="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofAccumulatedComprehensiveLossTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccumulatedComprehensiveLossAbstract" xlink:href="onco-20231231.xsd#onco_ScheduleOfAccumulatedComprehensiveLossAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccumulatedComprehensiveLossAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmortizationOfNetGain" xlink:href="onco-20231231.xsd#onco_AmortizationOfNetGain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="AmortizationOfNetGain" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectOfSettlement" xlink:href="onco-20231231.xsd#onco_EffectOfSettlement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="EffectOfSettlement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RegulatedAndUnregulatedOperatingRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegulatedAndUnregulatedOperatingRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_RegulatedAndUnregulatedOperatingRevenue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofAccompanyingConsolidatedBalanceSheetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:to="us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:to="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:to="us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_RetirementPlanTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AccumulatedBenefitObligationMember" xlink:href="onco-20231231.xsd#onco_AccumulatedBenefitObligationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="AccumulatedBenefitObligationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlanAssetsMember" xlink:href="onco-20231231.xsd#onco_PlanAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="PlanAssetsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanServiceCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanInterestCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanActuarialGainLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees" xlink:href="onco-20231231.xsd#onco_DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanOtherChanges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanOtherChanges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanOtherChanges" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligation_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligation_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees" xlink:href="onco-20231231.xsd#onco_DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" order="17.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanSettlementsPlanAssets" order="18.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_0" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandBasisofPresentationDetailsTable" xlink:href="onco-20231231.xsd#onco_OrganizationandBasisofPresentationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationandBasisofPresentationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBasisofPresentationDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OnconetixMember" xlink:href="onco-20231231.xsd#onco_OnconetixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="OnconetixMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBasisofPresentationDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBasisofPresentationDetailsTable" xlink:to="srt_OwnershipAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ProteomedixMember" xlink:href="onco-20231231.xsd#onco_ProteomedixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ProteomedixMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBasisofPresentationDetailsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialPublicOfferingShares" xlink:href="onco-20231231.xsd#onco_InitialPublicOfferingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="InitialPublicOfferingShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PublicOfPerShare" xlink:href="onco-20231231.xsd#onco_PublicOfPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PublicOfPerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlansDetails">
    <loc xlink:type="locator" xlink:label="GoingConcernAndManagementsPlansAbstract" xlink:href="onco-20231231.xsd#onco_GoingConcernAndManagementsPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="GoingConcernandManagementsPlansDetailsTable" xlink:href="onco-20231231.xsd#onco_GoingConcernandManagementsPlansDetailsTable"/>
    <loc xlink:type="locator" xlink:label="GoingConcernandManagementsPlansDetailsLineItems" xlink:href="onco-20231231.xsd#onco_GoingConcernandManagementsPlansDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernAndManagementsPlansAbstract" xlink:to="GoingConcernandManagementsPlansDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernandManagementsPlansDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernandManagementsPlansDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernandManagementsPlansDetailsTable" xlink:to="GoingConcernandManagementsPlansDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernandManagementsPlansDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernandManagementsPlansDetailsLineItems" xlink:to="us-gaap_ProceedsFromSaleOfOtherInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernandManagementsPlansDetailsLineItems" xlink:to="us-gaap_Cash" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WorkingCapitalDeficit" xlink:href="onco-20231231.xsd#onco_WorkingCapitalDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernandManagementsPlansDetailsLineItems" xlink:to="WorkingCapitalDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAppropriated" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAppropriated"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernandManagementsPlansDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAppropriated" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="onco-20231231.xsd#onco_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="onco-20231231.xsd#onco_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_Depreciation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RecognitionOfDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecognitionOfDeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RecognitionOfDeferredRevenue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="BalanceSheetDetailsDetailsTable" xlink:href="onco-20231231.xsd#onco_BalanceSheetDetailsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="BalanceSheetDetailsDetailsLineItems" xlink:href="onco-20231231.xsd#onco_BalanceSheetDetailsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="BalanceSheetDetailsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetDetailsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ProteomedixMember" xlink:href="onco-20231231.xsd#onco_ProteomedixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ProteomedixMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ENTADFIMember" xlink:href="onco-20231231.xsd#onco_ENTADFIMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ENTADFIMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetDetailsDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetDetailsDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ENTADFIMember_0" xlink:href="onco-20231231.xsd#onco_ENTADFIMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="ENTADFIMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetDetailsDetailsTable" xlink:to="BalanceSheetDetailsDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetDetailsDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetDetailsDetailsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCostOfOperatingRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostOfOperatingRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetDetailsDetailsLineItems" xlink:to="us-gaap_OtherCostOfOperatingRevenue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetDetailsDetailsLineItems" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetDetailsDetailsLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetDetailsDetailsLineItems" xlink:to="us-gaap_OtherAssetImpairmentCharges" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetDetailsDetailsLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedTradeNames" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedTradeNames"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetDetailsDetailsLineItems" xlink:to="us-gaap_IndefiniteLivedTradeNames" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/AcquisitionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="AcquisitionsDetailsTable" xlink:href="onco-20231231.xsd#onco_AcquisitionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="AcquisitionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AssetPurchaseAgreementMember" xlink:href="onco-20231231.xsd#onco_AssetPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="AssetPurchaseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ENTADFIMember" xlink:href="onco-20231231.xsd#onco_ENTADFIMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="ENTADFIMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentsMember" xlink:href="onco-20231231.xsd#onco_MilestonePaymentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="MilestonePaymentsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PharmaceuticalServicesLLCMember" xlink:href="onco-20231231.xsd#onco_PharmaceuticalServicesLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="PharmaceuticalServicesLLCMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProteomedixMember" xlink:href="onco-20231231.xsd#onco_ProteomedixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="ProteomedixMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueConsiderationTransferredMember" xlink:href="onco-20231231.xsd#onco_FairValueConsiderationTransferredMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="FairValueConsiderationTransferredMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ManagementServicesAgreementMember" xlink:href="onco-20231231.xsd#onco_ManagementServicesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ManagementServicesAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WraSerAPAMember" xlink:href="onco-20231231.xsd#onco_WraSerAPAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="WraSerAPAMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BankruptcyCourtMember" xlink:href="onco-20231231.xsd#onco_BankruptcyCourtMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BankruptcyCourtMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WraSerMSAMember" xlink:href="onco-20231231.xsd#onco_WraSerMSAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="WraSerMSAMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PMXTransactionMember" xlink:href="onco-20231231.xsd#onco_PMXTransactionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="PMXTransactionMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_TradeNamesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_CustomerRelationshipsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ENTADFIMember_0" xlink:href="onco-20231231.xsd#onco_ENTADFIMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ENTADFIMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesBConvertiblePreferredStockMember" xlink:href="onco-20231231.xsd#onco_SeriesBConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionsDetailsTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltySalesPercentage" xlink:href="onco-20231231.xsd#onco_RoyaltySalesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="RoyaltySalesPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SalesPaymentsAmount" xlink:href="onco-20231231.xsd#onco_SalesPaymentsAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="SalesPaymentsAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationDescription" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregatePurchaseShares" xlink:href="onco-20231231.xsd#onco_AggregatePurchaseShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="AggregatePurchaseShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessTransactionYeare" xlink:href="onco-20231231.xsd#onco_BusinessTransactionYeare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="BusinessTransactionYeare" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InventoryFairValue" xlink:href="onco-20231231.xsd#onco_InventoryFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="InventoryFairValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ImpairmentRate" xlink:href="onco-20231231.xsd#onco_ImpairmentRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="ImpairmentRate" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialPaymentAmount" xlink:href="onco-20231231.xsd#onco_InitialPaymentAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="InitialPaymentAmount" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Payments" xlink:href="onco-20231231.xsd#onco_Payments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="Payments" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Deposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Deposits" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsForFees" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VotingInterestPercentage" xlink:href="onco-20231231.xsd#onco_VotingInterestPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="VotingInterestPercentage" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" xlink:href="onco-20231231.xsd#onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShares" xlink:href="onco-20231231.xsd#onco_NumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="NumberOfShares" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyRate" xlink:href="onco-20231231.xsd#onco_RoyaltyRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="RoyaltyRate" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageDiscountRate" xlink:href="onco-20231231.xsd#onco_WeightedAverageDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="WeightedAverageDiscountRate" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageDiscountRateThereafter" xlink:href="onco-20231231.xsd#onco_WeightedAverageDiscountRateThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="WeightedAverageDiscountRateThereafter" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_InvestmentOwnedAtCost" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SignificantAgreementsDetails">
    <loc xlink:type="locator" xlink:label="SignificantAgreementsAbstract" xlink:href="onco-20231231.xsd#onco_SignificantAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAgreementsDetailsTable" xlink:href="onco-20231231.xsd#onco_SignificantAgreementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAgreementsAbstract" xlink:to="SignificantAgreementsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OlogyBioservicesIncMember" xlink:href="onco-20231231.xsd#onco_OlogyBioservicesIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="OlogyBioservicesIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CincinnatiChildrensHospitalMedicalCenterMember" xlink:href="onco-20231231.xsd#onco_CincinnatiChildrensHospitalMedicalCenterMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="CincinnatiChildrensHospitalMedicalCenterMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OxfordUniversityInnovationLimitedMember" xlink:href="onco-20231231.xsd#onco_OxfordUniversityInnovationLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="OxfordUniversityInnovationLimitedMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StJudeChildrensHospitalMember" xlink:href="onco-20231231.xsd#onco_StJudeChildrensHospitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="StJudeChildrensHospitalMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniversityOfTexasHealthScienceCenterAtSanAntonioMember" xlink:href="onco-20231231.xsd#onco_UniversityOfTexasHealthScienceCenterAtSanAntonioMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="UniversityOfTexasHealthScienceCenterAtSanAntonioMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CoDevelopmentAgreementMember" xlink:href="onco-20231231.xsd#onco_CoDevelopmentAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="CoDevelopmentAgreementMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LaboratorCorporationOfAmericaMember" xlink:href="onco-20231231.xsd#onco_LaboratorCorporationOfAmericaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="LaboratorCorporationOfAmericaMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAgreementsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OUIAgreementMember" xlink:href="onco-20231231.xsd#onco_OUIAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="OUIAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UTHealthAgreementMember" xlink:href="onco-20231231.xsd#onco_UTHealthAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="UTHealthAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VendorAgreementMember" xlink:href="onco-20231231.xsd#onco_VendorAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="VendorAgreementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAgreementsDetailsTable" xlink:to="us-gaap_EquitySecuritiesByIndustryAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesIndustryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesIndustryMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RegulatoryMilestonesMember" xlink:href="onco-20231231.xsd#onco_RegulatoryMilestonesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="RegulatoryMilestonesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialAndIndustrialSectorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialAndIndustrialSectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_CommercialAndIndustrialSectorMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DevelopmentMilestonesMember" xlink:href="onco-20231231.xsd#onco_DevelopmentMilestonesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="DevelopmentMilestonesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAgreementsDetailsTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAgreementsDetailsTable" xlink:to="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AggregateAgreementAmountInitialAgreement" xlink:href="onco-20231231.xsd#onco_AggregateAgreementAmountInitialAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="AggregateAgreementAmountInitialAgreement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_DefinedBenefitPlanServiceCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateeAmount" xlink:href="onco-20231231.xsd#onco_AggregateeAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="AggregateeAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CostPlusPercentage" xlink:href="onco-20231231.xsd#onco_CostPlusPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="CostPlusPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_Assets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommercialSaleTerm" xlink:href="onco-20231231.xsd#onco_CommercialSaleTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="CommercialSaleTerm" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyNetSalesPercentage" xlink:href="onco-20231231.xsd#onco_RoyaltyNetSalesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="RoyaltyNetSalesPercentage" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductLiabilityContingencyAccrualDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityContingencyAccrualDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_ProductLiabilityContingencyAccrualDiscountRate" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyRates" xlink:href="onco-20231231.xsd#onco_RoyaltyRates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="RoyaltyRates" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevenueRate" xlink:href="onco-20231231.xsd#onco_RevenueRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="RevenueRate" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FeeIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FeeIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_FeeIncome" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateRoyaltiesAmount" xlink:href="onco-20231231.xsd#onco_AggregateRoyaltiesAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="AggregateRoyaltiesAmount" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopmentCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_DevelopmentCosts" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_RoyaltyExpense" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfPropertyRepairsAndMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfPropertyRepairsAndMaintenance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_CostOfPropertyRepairsAndMaintenance" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfConsiderationReceived" xlink:href="onco-20231231.xsd#onco_PercentageOfConsiderationReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="PercentageOfConsiderationReceived" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesAndLicenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesAndLicenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_TaxesAndLicenses" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostMaintenance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_CostMaintenance" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmountOfOtherPartyPayments" xlink:href="onco-20231231.xsd#onco_AmountOfOtherPartyPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="AmountOfOtherPartyPayments" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltiesPercentage" xlink:href="onco-20231231.xsd#onco_RoyaltiesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="RoyaltiesPercentage" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdministrativeFeesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdministrativeFeesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_AdministrativeFeesExpense" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_LongTermDebtMaturityDate" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalAndContractServicesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicensedProductsPlusMilestonePaymentsDescription" xlink:href="onco-20231231.xsd#onco_LicensedProductsPlusMilestonePaymentsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems" xlink:to="LicensedProductsPlusMilestonePaymentsDescription" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/NotesPayableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="NotesPayableDetailsTable" xlink:href="onco-20231231.xsd#onco_NotesPayableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="NotesPayableDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AssetPurchaseAgreementMember" xlink:href="onco-20231231.xsd#onco_AssetPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="AssetPurchaseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NotePayableMember" xlink:href="onco-20231231.xsd#onco_NotePayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="NotePayableMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ENTADFIMember" xlink:href="onco-20231231.xsd#onco_ENTADFIMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ENTADFIMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ProteomedixAcquisitionMember" xlink:href="onco-20231231.xsd#onco_ProteomedixAcquisitionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="ProteomedixAcquisitionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PayableAverageDiscountRatePercentage" xlink:href="onco-20231231.xsd#onco_PayableAverageDiscountRatePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="PayableAverageDiscountRatePercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentDueDate" xlink:href="onco-20231231.xsd#onco_DebtInstrumentDueDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="DebtInstrumentDueDate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashPaymentToTheSeller" xlink:href="onco-20231231.xsd#onco_CashPaymentToTheSeller"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="CashPaymentToTheSeller" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentDueTerm" xlink:href="onco-20231231.xsd#onco_DebtInstrumentDueTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="DebtInstrumentDueTerm" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionPriceOfAcquisitionExpected"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermNotesPayable" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SubscriptionAgreementDetails">
    <loc xlink:type="locator" xlink:label="SubscriptionAgreementDisclosureAbstract" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="SubscriptionAgreementDetailsTable" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubscriptionAgreementDetailsLineItems" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubscriptionAgreementDisclosureAbstract" xlink:to="SubscriptionAgreementDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubscriptionAgreementDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubscriptionAgreementDetailsTable" xlink:to="SubscriptionAgreementDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SaleOfUnits" xlink:href="onco-20231231.xsd#onco_SaleOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubscriptionAgreementDetailsLineItems" xlink:to="SaleOfUnits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubscriptionAgreementDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubscriptionAgreementDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ServicingLiabilityAtFairValueAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServicingLiabilityAtFairValueAdditions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubscriptionAgreementDetailsLineItems" xlink:to="us-gaap_ServicingLiabilityAtFairValueAdditions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ServicingLiabilityAtFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServicingLiabilityAtFairValueAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubscriptionAgreementDetailsLineItems" xlink:to="us-gaap_ServicingLiabilityAtFairValueAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubscriptionAgreementDetailsLineItems" xlink:to="us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1Table" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1Table"/>
    <loc xlink:type="locator" xlink:label="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1Table" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1Table" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesSeedPreferredStockMember" xlink:href="onco-20231231.xsd#onco_SeriesSeedPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesSeedPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesAConvertiblePreferredStockMember" xlink:href="onco-20231231.xsd#onco_SeriesAConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesAConvertiblePreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1Table" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1Table" xlink:to="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="us-gaap_OtherNotesPayable" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="us-gaap_PreferredStockLiquidationPreference" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesOfCommonStockRate" xlink:href="onco-20231231.xsd#onco_SharesOfCommonStockRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="SharesOfCommonStockRate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2Table" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2Table"/>
    <loc xlink:type="locator" xlink:label="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2Table" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2Table" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesSeedPreferredStockMember" xlink:href="onco-20231231.xsd#onco_SeriesSeedPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesSeedPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2Table" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2Table" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2Table" xlink:to="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfIssuedOfCommonStock" xlink:href="onco-20231231.xsd#onco_PercentageOfIssuedOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="PercentageOfIssuedOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfOutstandingOfCommonStock" xlink:href="onco-20231231.xsd#onco_PercentageOfOutstandingOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="PercentageOfOutstandingOfCommonStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfCumulativeDividends" xlink:href="onco-20231231.xsd#onco_PercentageOfCumulativeDividends"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="PercentageOfCumulativeDividends" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NettingProceeds" xlink:href="onco-20231231.xsd#onco_NettingProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="NettingProceeds" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfOriginalIssuePrice" xlink:href="onco-20231231.xsd#onco_PercentageOfOriginalIssuePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="PercentageOfOriginalIssuePrice" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CumulativeDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CumulativeDividends"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="us-gaap_CumulativeDividends" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPayableAmountPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems" xlink:to="us-gaap_DividendsPayableAmountPerShare" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table"/>
    <loc xlink:type="locator" xlink:label="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="HCWainwrightCoLLCMember" xlink:href="onco-20231231.xsd#onco_HCWainwrightCoLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="HCWainwrightCoLLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="TreasuryStocksMember" xlink:href="onco-20231231.xsd#onco_TreasuryStocksMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="TreasuryStocksMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="April2022PrivatePlacementMember" xlink:href="onco-20231231.xsd#onco_April2022PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="April2022PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AprilContingentWarrantsMember" xlink:href="onco-20231231.xsd#onco_AprilContingentWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="AprilContingentWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="August2022PrivatePlacementMember" xlink:href="onco-20231231.xsd#onco_August2022PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="August2022PrivatePlacementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AugustWainwrightWarrantsMember" xlink:href="onco-20231231.xsd#onco_AugustWainwrightWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="AugustWainwrightWarrantsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AugustContingentWarrantsMember" xlink:href="onco-20231231.xsd#onco_AugustContingentWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="AugustContingentWarrantsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table" xlink:to="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_StockIssued1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_CommonUnitIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfUnderwritingDiscount" xlink:href="onco-20231231.xsd#onco_PercentageOfUnderwritingDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="PercentageOfUnderwritingDiscount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOwnershipInterestsOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_OtherOwnershipInterestsOfferingCosts" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_TreasuryStockAcquiredAverageCostPerShare" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PlacementAgentFeeAndManagementFeePercentage" xlink:href="onco-20231231.xsd#onco_PlacementAgentFeeAndManagementFeePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="PlacementAgentFeeAndManagementFeePercentage" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateNumberOfSharesPercenatge" xlink:href="onco-20231231.xsd#onco_AggregateNumberOfSharesPercenatge"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="AggregateNumberOfSharesPercenatge" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_OtherLiabilities" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CancelledPreferredInvestmentOptionsShares" xlink:href="onco-20231231.xsd#onco_CancelledPreferredInvestmentOptionsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="CancelledPreferredInvestmentOptionsShares" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrantsExercised" xlink:href="onco-20231231.xsd#onco_PrefundedWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="PrefundedWarrantsExercised" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_PreferredStockDividendsShares" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPriceDecrease" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_OtherExpenses" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsIssuableUnderProvisionShares" xlink:href="onco-20231231.xsd#onco_WarrantsIssuableUnderProvisionShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="WarrantsIssuableUnderProvisionShares" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseInTheFairValueOfThePreferredInvestmentOptions" xlink:href="onco-20231231.xsd#onco_IncreaseInTheFairValueOfThePreferredInvestmentOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="IncreaseInTheFairValueOfThePreferredInvestmentOptions" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContingentWarrantLiabilityShares" xlink:href="onco-20231231.xsd#onco_ContingentWarrantLiabilityShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems" xlink:to="ContingentWarrantLiabilityShares" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table"/>
    <loc xlink:type="locator" xlink:label="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:href="onco-20231231.xsd#onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MarketOfferingAgreementMember" xlink:href="onco-20231231.xsd#onco_MarketOfferingAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="MarketOfferingAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_StockOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnvestedRestrictedStockMember" xlink:href="onco-20231231.xsd#onco_UnvestedRestrictedStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="UnvestedRestrictedStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="InducementPIOSharesMember" xlink:href="onco-20231231.xsd#onco_InducementPIOSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="InducementPIOSharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" xlink:to="srt_TitleOfIndividualAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChiefBusinessOfficerMember" xlink:href="onco-20231231.xsd#onco_ChiefBusinessOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="ChiefBusinessOfficerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefFinancialOfficerMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AugustContingentWarrantsMember" xlink:href="onco-20231231.xsd#onco_AugustContingentWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="AugustContingentWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WarrantInducementMember" xlink:href="onco-20231231.xsd#onco_WarrantInducementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="WarrantInducementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="April2022PrivatePlacementMember" xlink:href="onco-20231231.xsd#onco_April2022PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="April2022PrivatePlacementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="August2022PrivatePlacementMember" xlink:href="onco-20231231.xsd#onco_August2022PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="August2022PrivatePlacementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" xlink:to="srt_RangeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" xlink:to="us-gaap_StatementEquityComponentsAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" xlink:to="us-gaap_PlanNameAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandNinteenEquityIncentivePlanMember" xlink:href="onco-20231231.xsd#onco_TwoThousandNinteenEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandNinteenEquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:href="onco-20231231.xsd#onco_TwoThousandTwentyTwoEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTwentyTwoEquityIncentivePlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyTwoPlanMember" xlink:href="onco-20231231.xsd#onco_TwoThousandTwentyTwoPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTwentyTwoPlanMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="January2024Member" xlink:href="onco-20231231.xsd#onco_January2024Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="January2024Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="August2024Member" xlink:href="onco-20231231.xsd#onco_August2024Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="August2024Member" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="August2025Member" xlink:href="onco-20231231.xsd#onco_August2025Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="August2025Member" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PMXOptionPlanMember" xlink:href="onco-20231231.xsd#onco_PMXOptionPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="PMXOptionPlanMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table" xlink:to="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SharesOfCommonStockIssued" xlink:href="onco-20231231.xsd#onco_SharesOfCommonStockIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="SharesOfCommonStockIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FixedCommissionRate" xlink:href="onco-20231231.xsd#onco_FixedCommissionRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="FixedCommissionRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_StockOptionExercisePriceDecrease" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateNetProceeds" xlink:href="onco-20231231.xsd#onco_AggregateNetProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="AggregateNetProceeds" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscribedButUnissued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfGrossProceeds" xlink:href="onco-20231231.xsd#onco_PercentageOfGrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="PercentageOfGrossProceeds" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_LegalFees" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_OtherGeneralExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregatePurchaseShares" xlink:href="onco-20231231.xsd#onco_AggregatePurchaseShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="AggregatePurchaseShares" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfCommonStockShares" xlink:href="onco-20231231.xsd#onco_PercentageOfCommonStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="PercentageOfCommonStockShares" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsIssuedForSettlementOfContingentWarrants" xlink:href="onco-20231231.xsd#onco_WarrantsIssuedForSettlementOfContingentWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="WarrantsIssuedForSettlementOfContingentWarrants" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_OtherLiabilities" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_SharePrice" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice" xlink:href="onco-20231231.xsd#onco_ExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="ExercisePrice" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantDateFairValueOfStockOption" xlink:href="onco-20231231.xsd#onco_GrantDateFairValueOfStockOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="GrantDateFairValueOfStockOption" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedSharesGrantedVestPercentage" xlink:href="onco-20231231.xsd#onco_RestrictedSharesGrantedVestPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="RestrictedSharesGrantedVestPercentage" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="39.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="41.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="42.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="43.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="44.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="45.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="46.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="47.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated" order="48.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="49.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="51.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:href="onco-20231231.xsd#onco_CommitmentsandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingenciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_CH" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CH"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_CH" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SettlementAgreementMember" xlink:href="onco-20231231.xsd#onco_SettlementAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="SettlementAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ShortTermLeasePayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForRent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FeeIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FeeIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_FeeIncome" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LegalFees" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfSubscription" xlink:href="onco-20231231.xsd#onco_PercentageOfSubscription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="PercentageOfSubscription" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregatePayments" xlink:href="onco-20231231.xsd#onco_AggregatePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="AggregatePayments" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LaborAndRelatedExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LaborAndRelatedExpense" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPaidinkind" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPaidinkind"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DividendsPaidinkind" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherExpenses" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="onco-20231231.xsd#onco_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CEOMember" xlink:href="onco-20231231.xsd#onco_CEOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="CEOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CBOMember" xlink:href="onco-20231231.xsd#onco_CBOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="CBOMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NonConvertibleDebentureMember" xlink:href="onco-20231231.xsd#onco_NonConvertibleDebentureMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="NonConvertibleDebentureMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsForFees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MiscellaneousExpenses" xlink:href="onco-20231231.xsd#onco_MiscellaneousExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="MiscellaneousExpenses" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubscriptionAgreementPMXInvestorPercentage" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementPMXInvestorPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="SubscriptionAgreementPMXInvestorPercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNetAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="onco-20231231.xsd#onco_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLossMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_OperatingIncomeLossMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/RetirementPlansDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossPayPercentage" xlink:href="onco-20231231.xsd#onco_GrossPayPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="GrossPayPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtSecuritiesAndCash" xlink:href="onco-20231231.xsd#onco_DebtSecuritiesAndCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="DebtSecuritiesAndCash" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquitySecuritiesRate" xlink:href="onco-20231231.xsd#onco_EquitySecuritiesRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="EquitySecuritiesRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AlternativeInvestmentsRate" xlink:href="onco-20231231.xsd#onco_AlternativeInvestmentsRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="AlternativeInvestmentsRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RealEstateInvestmentsRate" xlink:href="onco-20231231.xsd#onco_RealEstateInvestmentsRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="RealEstateInvestmentsRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="onco-20231231.xsd#onco_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ENTADFIMember" xlink:href="onco-20231231.xsd#onco_ENTADFIMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="ENTADFIMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NonConvertibleDebentureMember" xlink:href="onco-20231231.xsd#onco_NonConvertibleDebentureMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="NonConvertibleDebentureMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubscriptionAgreementMember" xlink:href="onco-20231231.xsd#onco_SubscriptionAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="SubscriptionAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeverancePayment" xlink:href="onco-20231231.xsd#onco_SeverancePayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="SeverancePayment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_OtherAssetImpairmentCharges" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="onco-20231231.xsd#onco_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>101
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M@5,%\PDI/3T EU3)"GJ!"%31U8<K59R <Z6Q@_A'$^AJ_B@R$L+<4.5: #^
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M'1%!\X][A*6_0-V8132Y6:1-+EUE3(X=6L:@-!=*\Z"T.93FCZ&)O](-]8!
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MZAMWC2YWU\SSXB'-J@-A]UT-04X<K%F4=P8%\G3>.W/)KHF@\]X-UC6#RB>
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M<+@75<98WJ\R]LQ$QKL)IUKJ1[!S&YWJ-MFE<*ID3H^''8<1,-%X.U9\9G3
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M;"]W;W)K<VAE971S+W-H965T,3$N>&ULI5=I;QLW$/TKA%H4":!(UI&CB6W
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M?Z#A^Z=D2:Q."E(C8!?KA[.Q<*') $<JY9IP@%$6*=TH&2E EP)Y*$Y:49]
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MT-5 ET_JD)GLS+2O H._25%8%W%B *_S(6**4X0J0V]@?@$+*3@4!87QA?S
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MXNJ8_VUP5R?/"_"]=ACT_0,[.-[^S_\#4$L#!!0    ( $"+FEC#O]U1F!X
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M9>&= IXIDH6NLBK769G8!CX +6]LHBM\" V-;NY!#YI5\F5\.T[^=77U$0S
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M:7IQ?'[P23FS+1DV;+&@XL_!DRGLY_3B!.89).-RFEZ>G?]L0]D:WBC)87U
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M_3YB&WR,PP;NX$ SK.*3 3TF[&E</+F8I.!6R#"VVJYPKJC'F[=%KD 9G4Q
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M\W';#Z0TG+L-!JBX'Y8ZV,WU*KTN)Y6]*8+*PJ-$U0+(YK#.IB9W8E>L\$B
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M%\#GZP*RD?T#-_"_)?3VOP%02P,$%     @ 0(N:6*X+2[0'#P  T"X  !D
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MYS<9- [KYP5/U^L6(X+XE%=56T'&JLY4(_563FXX5!]HPS%T%9@YJ&T@MGL
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MG'6X1]MXTXXOWC3A=KLT'G?E\%CBQPE9-L#WPB#K[H4#]#]WSO\#4$L#!!0
M   ( $"+FECN^(] /P,  !@'   9    >&PO=V]R:W-H965T<R]S:&5E=#$W
M+GAM;)55VVX:,1!]YRM&F[9*),)>@)0F@$1(J_8A;92D%ZGJ@_$.K(77WMHF
MA+_OV L;JB9(?=CU;<Z9,[.>V>%:FZ4M$!T\EE+9450X5YW'L>4%ELQV=(6*
M3N;:E,S1TBQB6QED>0"5,LZ2Y"PNF5#1>!CV;LQXJ%=."H4W!NRJ+)G97*+4
MZU&41KN-6[$HG-^(Q\.*+? .W=?JQM J;EAR4:*R0BLP.!]%D_3\LN?M@\$W
M@6N[-P<?R4SKI5]\RD=1X@6A1.X\ Z/A :<HI2<B&;^WG%'CT@/WYSOV#R%V
MBF7&+$ZU_"YR5XRB000YSME*NEN]_HC;>/J>CVMIPQO6M6VW%P%?6:?++9@4
ME$+5(WO<YF$/,$A> &1;0!9TUXZ"RBOFV'AH]!J,MR8V/PFA!C2)$\I_E#MG
MZ%00SHWO5C/+C:A"BB8+@T@9=\/8$;>WB/F6Y[+FR5[@23.XULH5%MZK'/._
M"6(2U2C+=LHNLX.,5\@[T$W;D"59]P!?MXFT&_BZ_Q4I_)S,K#-T.7X]%W1-
MV7N>TA?,N:T8QU%$%6'1/& T?G.4GB47!P3W&L&]0^S_\6D.\WS6#F$ ;XX&
M69I=P MY^** ,H[E# VD@SKK;7 %PE27%5,;("LTF(-03@.C,M[C80W/L8=X
M7UER\;RK<)A>G-!-=T7P<'/] SZI!Z3;;MJP+C3,D+,2O1>G^;+0,B=9>DXJ
MN5;HQ",P%Z!<:BO4PI_MF.X-4Y;517]L$<$GP$(?F,HA34^ 6EDPMDRB!V8)
M59:4WGZEA+-M0,8+X!2W$98B)IL43N<K?[/AE/01[C1G&[@GEA?R*2QU'*Y7
ME+0\>&2T 5*PF9#";2B+X=SD3'&L4S&YFT)OD+2]J==7LB4V[J;,2+T=6O]\
MJ:>=7<6TWC^BX20?* B.K5>0=++^;KA'4\+Q!IFQ)ZVTTZ<G(T1%O9+DAJ37
M.'C0DKD@N94F2>MUZUV?7K?"+D_G%"L8YD(21;@=UK5ZG;,>6=3#<V40[W6K
M$LTB]&0+(5=UXVIVF[8_J;O=DWG]S[AF9B&4!8ES@B:=M_T(3-V'ZX735>A]
M,^VHDX9I0;\N--Z SN>:[L9VX1TT/\/Q'U!+ P04    " ! BYI8:O@B@>49
M  " 7   &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6S-7%ESVTB2?N>O
MJ-#8LW8$"!$@>-EN1TBR/>V)=LMAN;MW8V,?0*!(80P"; "4K/GUFT=5H7#P
M4-L]T0^V2!"HRLKSRZPLO+K/BR_EK925^+I)L_*'L]NJVKXX/R^C6[D)2S??
MR@Q^6>7%)JS@:[$^+[>%#&-Z:).>^Z/1]'P3)MG9ZU=T[6/Q^E6^J](DDQ\+
M4>XVF[!XN)1I?O_#F7>F+WQ*UK<57CA__6H;KN6-K'[9?BS@V[D9)4XV,BN3
M/!.%7/UP=N&]N SP?KKAUT3>E]9G@2M9YOD7_/(^_N%LA 3)5$85CA#"GSMY
M)=,4!P(R?E=CGIDI\4'[LQ[]':T=UK(,2WF5I[\E<77[P]G\3,1R%>[2ZE-^
M_Z-4ZYG@>%&>EO2_N.=[9Y,S$>W**M^HAX&"39+QW_"KXH/UP'RTYP%?/> 3
MW3P14?DFK,+7KXK\7A1X-XR&'VBI]#00EV0HE)NJ@%\3>*YZ?95G=[*HDF4J
MQ2<92Q Y?OP(O)%%(6-Q4^71%Q%FZM-MGL:R*/]+O/U]EU0/K\XK( *'.H_4
MA)<\H;]G0L\7'_*LNBW%VRR6<7. <Z#>+,'72[CT#X[X1D:N&'N.\$?^^,!X
M8\.2,8TW_KXL^?O?YKXW>ZD8(_[W8EE6!2C=__7QB"D(^BE 0WQ1;L-(_G &
MEE;*XDZ>O?[[W[SIZ.6!]05F?<&AT?\,D1^>\.>\DF(AB$'^2_%]^'NQJV[S
M(ODWW'\5;I,J3,5%*?*5 '60FZ4LC$K02/#!=T1U*V'ZS3;,'D12BK >H\KA
M0KF3PI^,G-&(_HGK3+R3RV('WDKX8T<-DF0BRK-,N97[I+JE<:,T+Y-LC23@
MU_<?KYOSK9(4YC&WW\BHD!6.# _<5"&P2#UIOKR1:7@?%A(6($)PA& NM!90
M";PE%A&R<95$ZOXDB_)BFQ<A$?8,QT*F^:.7%W\/-]N7G\35]7NZXKU\[HC[
MVR2Z%4L9P=A"KE:2'*1(-AL9)S!D^N"*S[<2YK\/2Y'E(KH-L[5$5EGK4F)I
M,+.\!:I)&%&^V0 MI9'HUDB9K^4%#;8-"W$7ICOI@AXD>!$G01'ANN%?U63F
M;1B#[RV3=4:,\!R/Q=;1HAM9)$#*14/KVC>!G&_DMF*U\1>L-GW2"\55D^5O
M% W <%HO!;625LJ3R"QB3AA"VI,KJ>N);+'5Q.^?5<O3TJR._@ S#;.(-B,K
M>@ 5/P0Z\9G=%N_VC/Y?1U5.QM3'%+*8&'[#FW_-*U1_M.C-EC10&_Q/"9AL
MS%I9<\7\_":Y2V*0<BF&R6H8L9QD/*SR(:O/D%6%)5C:(U> #\2JR#>\JE4%
ME.:9% \2](FN([FQM@^]SB0C]0HKD>U(YO#C'IU]5NZ6_P++0*Z@N0',$6FR
M 7]#W'\.C(5)(3 #'Y8/(L:U(!N,(&+Q*^HU_LBL,XL 18] W]^S_ L)3$*M
MN$-O&2<E!/\256Z9HU&B 58B7R(!,G9HO>Q&]J@5/&%8*6"E>'/.<E$:QWZU
M*=%-^$ 3L2\,C_.'G CXDGR7QD)^C21:X\)=+)Z>PM$P_A= '#1O ?@2_X&^
M:B>'?)+JH7*;)E7IP-6(G7WR;V5TFA%I\D4^)X?5X;%V=<"2_KE!IC@$S A?
M@%[D!,\;*]UT;#H<7- R80-$#Y;#TP!T02U2T+LVC40BWU+/"6L!IPKPD31'
M$7"*O3NXC"1+JB1,TP?Q9.1._$G "P=<F&QVFZ[42-=/5!?RD&@A#L%=(#WK
MU5RDOS?<HM?>;HL<:*$H(B;.;+1P%N.)D@ZKFD1_3P:"HZ,1E28"[J&2U3Y!
M+ ^1+B9;-FYOC3Y&>;&+FRL1S$?.\36G85D"I]%&2K$%(L(,E4 RR%!RP>F(
M:+1L8%.9I^C/T.3#E.8D ,Y"V#L=1E'0#2"<+1(46JS"1 4^Q<Z&/R;']:R4
M4A"$FH%^J]$OC\4S(Q9O\F>&L\-T' ]ME__QT.:#,IKHUL.E/>CNXX?_%I^+
M,"M#^H&L%T!+I=>XW14 C\!?H7J RV 0UALN?6>ZF#HS?Z%#YHEQ<@@+^(98
M>166MR"VJDHE.3U]O2=@/\Y,+[^KF79&ZYHI #5$N0"=_Y"9DNSP?N4<,>8M
M,0";5$3%:I5X4&B*@'L.J!!P2<, F"%.V%3(OZ(Z8NS$I2J*X):J@)R^:0BN
MN(CY273A31V)<\FA7C_*"U,667",@CM <<L264 &D )P9R!=NWX#*-0RB7;Y
M51914G:6J B,:K59R;#:%;+AT[JR^6:?-GE^9 :%?*(=7,LJB":6G( ?$&>6
M_'F%J4R^0=G;HH1@O(/U)E4S_(,2@+6L55Q&@:TAM%KYIKC & ;+X#A=1D6R
MU'#,P"^@-2_8TT1A49#BP;B[K.K2#=H)"9]*-:N2B%1V9S.K$T^-S[]!;'7(
MW=IF"[ZHD169G*HO444#,@DRYGOX'SP=3!UO/!?#.CF\8B3'\YV4;^OAX.L\
M\)S%;$*_@\.=^8&SF,S$CTT=;.>5S1021@)V)E7*C$2P3X 9;52& /)(V\6M
M!#A*1H"ZR?)J/$O6D%H.MQ6K8&P>"1PY*)+Q,9D$0P=@7K7I%>%="/ /Y8*T
M ("O0&-V#  I,=F&#QL-,%/P"<LT6=>AMC&42690!1.R1Q3H4LH,W%6LW"E8
M]5:!65HZ>4E"?>R%$T*R#CQZA_+>UB$EU^["9BX;XK[<73DWR[202A@:K^/8
MI,QW9)0&"1-\<!\9:0N09XXUB*]@,R"@,MD;2L?.=#9Q B]HE&J\F=-3[P'6
MRX*P-H+_3.PRT+K[(J$0'*YQ 2@=&Z3\8M]RH6]IPI++'!"]#&,LZ.SP5@E^
MY*>?KASRVC@TFCJ5\3),&N],G<<0@,K_3$VIAZO+- D6OU-6TCVE%ZHU 0)!
M%TOJP/E.0Z60>C*94H+RJ8$:)&"5:0VWK17&\AW?IW_BHS4T/M;/EUX)P1.&
M0P#8 $&!Y<!%@Y<\#QR-YXEA,!)#*\Z_ 6;"Z+K^L+?T%L*"#*:IQ4@1&:-3
M0^P-B1&]I:S)(C\%.2R5N6(RX\78":93,@RLND'>4^VO;ZDE$U,98%B4H4G'
M8,MY\5"36;9T" FF8! W<R_MLJLBC-F4,0%3/U)$)9A@#<M+ 96LJ%I >2>+
M [Q 2E[C5E?]M$+J%9([Y+'+,)4U.&C["HY;/4_C.C8R+'?(^5VI"R*7:0AL
M&MY$$&*!?Y"ZBN$*: 9D33<_U/G+S^"BV%^,;&->YE@?@!EC@#:@&H7*->\H
MFV$Q@+5IY8)?UD6X:1CUI_KGC_RS,6AT#&F:W[<C@34B)Q$3 0XNQ97N*XNP
M:NJ$7,EK)9YX+H3C+58+\$&';\1J#V #9>&0@H9KI<7X[4N=730*&)NP^"(K
M"X:Z3<;-3V9<AJ5C%($I[C8)AXM/_ ;ANC),* <4;9NHJC,IXXJJNO";XK^K
MK1F'IMH<%[,[T*'I0FJVQV(R U=/0.8.9W@/*$@54M I?-Q!,(W,U@!0G=+:
MS?T?0?.8I< B_MU;]$4)3!MP?U(G/!98"I$;--K6C-8HLA^8MG;GVY8OY8P*
MW8.53]!LI0DHM;<,:V?+F0V#1K4BM44!^475A_0.$=CKO">+D1.,IF"D.Y)7
MKP-OAXWV0_KOQ6X-/FB?6'YTKUSQ&Z15]P0:!&U8 #TN!5,3'NL[C-&&D>(#
M.;2O40K^YLZ6$1B3JB\>8X+;@-!UR 3D9M,6=@>7#(<LT\5+D(&%%&MG[N0I
MPUYW]-31P W(Q/1/2:=FXKK(2[(=K*:6=1W[H%YSS339+'=8-=4Y:KZKQ#!?
M#;?@E,!7G":+$]/_@^3\IE4%Z;)JY+H2^0!^A&K&2]G*[DU.#^%DQQ;.L9 @
M.^;XD%ZA5IM* H'DF,NHJJ1 T^+GN3?I0(M'K0\2+ISMV]840JH1+I,4%_;(
MQ>@%!.Y(!<O#PD/_QC=XWO=V<(<F_K,]',^]..+A#E'8Z^(\9ZQRY+:_ E@Z
M'SESS^_\HO_:+N&13N@0G7]U+W10_1[EADXUQ(,S_M4]34)0!0&7*B$<=N-&
MW!'.F+:$ ARI];+>2T\,'%)[?*76[Q/F;->RDX*^)5&R94RGQSBNM <IXI0,
M42,OC=HA*$_1Y:7TH95^>8X_7SA>,!>9O#^RWA.(5'4@JDJ#7-,'KE]0646)
M6TU,/GN3Q[PSH;;Y-&W()Z4[PS3)OJ!+0,&KO&9P#0::9&$Z>*L7 Y]4W94
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M_W5PX[Z8M\O=_SM\PML+7HA8*E;8.CR;37M,NV_Y[J)4A?U^OE0EWAKMSXV
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M;VF0JS$NN9BB6SZYI?(=D;8NTI(E=QGH3MQ*M]38MXIUN3\TU9,BHW/%Q1Z
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M+==B.U*DDS0&BLW*,2S%%4QH1;5VO>>A1/E>UR/K;Z"*;Y]P9BIJ\8#6#;Q
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M<<)8Y"4L)F[FM$HUNE.*L&CL92%#,!QTE5D[$$#^2QP]C4=KW!/:#C"VK:$
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MB:.V6%%L?2GU6<)(!EVK1UJ><)_!)AI$V2, P5EY)BO8-BUZD)'#B$8^C3/
M7Q1DZ2.:':Q&@'%.'5 !R=WL:\#)_!R$9: \X"GT\LCG80[J1UX'@:^%:)8P
MGZ6I2SD>PJ-CF09L!*G9@-3L7Y[(>G4[K^]#[CCKFT<'KAZ$\RZ0@ YG(KK"
M 0 /3> ==Z+:/3-M$V"GCQ]AK/'U\'S8^L@!''42XH+'7D-Z\YP<L(!NEY(@
MBA^T0X+M<$M!<?9XZ:E6";N@!+[8$K$\B.&7!\G.(@>%QKHH9$"\W0Z5]@4
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MI@R=%RZROGLQ]R?1:T7+NBU:/_^+G)N"8D$XMZ.+(Z0]ZJ3.2!!'V=O-!B/
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M)E P'DBM)Q>\PBDL+;E@<& 'L.)G3]S(>3T&<4JS9"*S >"@ QR8W.,UHRE
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M1Z4AH6;=/E3[8))+XM6Q,]M NU\_VPDI5)"U*OU";,?G^)Y[K\/IK[BXE1F
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M5[HA[##3+AF$V:#?SSE7ZXDYH/;=X3]02P,$%     @ 0(N:6#;E$(?Q @
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MZ:"?SSA7SPUSJ%0=(D9_ %!+ P04    " ! BYI8T5R4\^("  #_!@  &0
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MJ.&!DI@R&WC^[Y"7!98QRI\37QN5EJN?;!7-&T7A$46]$!:"ZT+!-YYB^C>
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M-@'75U*:I\"VVNYES?X!4$L#!!0    ( $"+FEC9)WXEX (  ,,(   9
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M\OP ]?V2,?FVDQ>H7XV9_P]02P,$%     @ 0(N:6(%+^5QT @  X08  !D
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MH!0Y*Q&'=&S<6-<3"VM '?$MA[78:2-M9<;8L^Y\GH\-K!4!A41J"J)>*Y@
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MU<C_CT]L]LB*UNFG=GYG@4"M0BB-0FDAE!:A:*:*M)_HUEX59,*R"S46H;0
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M?MNAVZMCU[.Z_;;8_458?EQ M@+YLRD.G>JF',_4ED4P<;#>%,@=.-,WK_S
M^]#!WJ_9^U:]U\9NTD0.LD]^?,4AY(N&3#72]O\#[:"F'71&^G%\]4%\F291
M*A3/DR;F4G5@5<W^M)L&GOV-W5T#3E#C!)TXGQB79,?2PE9'+C0HLF6_V0K+
MA2M5-"_[4C,X@/'IJ!^VTH0U3=A)8Y<;*S>Y2"BMFIR'1\[#41CZS9Z'M>=A
MMV>A68H^6Y+3Q#$\#L+(HT$KRJA&&3V?DAN;DI<58Z?\"Y>W[SWLPMX_+L=*
M\!\#'QP;_C,5F65(B>=3=-N(YQ\E>A@.^L-^<YI]^N"8=CI>@N18;G.S['8@
M-3=%AU.L4MP.1(^ @C[M!=YPT(+T< SXW>? "\J@4GRT,PU\WQ\$HR<T[L'9
MGH%,[ U&H;<BU^4Q7_?6MZ19>3=X&%Y>L2Z83#@>\RFLT=0[#=&]+&\M94.+
MK;TIK(3&>X=]W>!-#Z09@-_7 K>ZJF$<U'?'Z1]02P,$%     @ 0(N:6.)B
MB2^5 @  Y04  !D   !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL?51=;]HP
M%'W>O[C*IJF5MN8#"&L;(D%I-:1UJJ#='JH]F.0&K#HVM1UH]^MG.R%C6LI+
MXH][SCWG)O<F.R&?U!I1PTO)N!IY:ZTW%[ZOLC661)V)#7)S4PA9$FVV<N6K
MC422.U#)_"@(8K\DE'MIXL[N9)J(2C/*\4Z"JLJ2R-<),K$;>:&W/YC3U5K;
M S]--F2%"]0/FSMI=G[+DM,2N:*"@\1BY(W#BTELXUW #XH[=; &ZV0IQ)/=
MS/*1%UA!R##3EH&8UQ:OD#%+9&0\-YQ>F]("#]=[]AOGW7A9$H57@OVDN5Z/
MO"\>Y%B0BNFYV'W%QL_ \F6"*?>$71,;>)!52HNR 1L%)>7UF[PT=3@ 1-$;
M@*@!1$YWG<BIG!)-TD2*'4@;;=CLPEEU:"..<OM1%EJ:6VIP.AUGSQ55U%9(
MP<D4-:%,G<)G6)C/GU<,010P5@JU A<K,3>WS<D<,['B]#?F[QYOL5RB_)7X
MVLBRY'[62)C4$J(W)(01W JNUPJN>8[YOP2^\=.:BO:F)M%1QBEF9] +/T$4
M1#UX6$SAY,/I$=Y>6ZR>X^V]52SK&@Y*!H_?3 C,-):JTWG-U^_FLPUWH38D
MPY%G.DJAW**7?GP?QL'E$;7]5FW_&'LZXUOD6LC7+F$U=."@MG&W:1B:1@Z"
MQ-]VY!RT.0='<UY_OQ]/;V;&P[!_"3.N"5_1)<,N"353?"AA>![$PV'8K2%N
M-<1'-=P+31@4A$K8$E:Y/YCFIA2TH,1H 5+_O*3YG;NTQ?^7YSR(.K3Y!ZU7
MHERY :,@$Q77=1>VI^T,&]>M^S>\'H"W1*ZHZ4*&A8$&9T.37M9#I=YHL7&-
MO!3:C 6W7)LYC-(&F/M""+W?V 3M9$__ %!+ P04    " ! BYI8QU&^'%L#
M  "]#P  &0   'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6S%5UUKVS 4_2O"
M@]'!&EO.1Y,N"?1C8X6%E7;K'LH>5/NF$;4L5Y*3%/;C)\FN[:Z)8*8A+XEE
MZ1Z=>WVDPQVON'B0"P"%UBQ)Y<1;*)4=^[Z,%L"([/ ,4CTSYX(1I8?BWI>9
M !+;();X81 ,?$9HZDW']MVEF(YYKA*:PJ5 ,F>,B*=32/AJXF'O^<45O5\H
M\\*?CC-R#]>@?F:70H_\"B6F#%))>8H$S"?>"3X^Q2,38%?<4%C)QC,RJ=QQ
M_F &%_'$"PPC2"!2!H+HOR6<09(8),WCL03UJCU-8//Y&?V+35XG<T<DG/'D
M%XW58N(-/13#G.2)NN*KKU FU#=X$4^D_46K<FW@H2B7BK,R6#-@-"W^R;HL
M1", ][8$A&5 :'D7&UF6YT21Z5CP%1)FM48S#S95&ZW)T=1\E6LE]"S5<6IZ
M$CWF5%)3(8D.SD$1FL@/Z!!=Z^\?YPD@/D=?"!7HAB2Y':D%H$O!%7 &,5VC
M:\6C!_0]*S .7XS1[0S8'8C?8U]IMF9//RJ9G1;,PBW,SB'JH"[^B,(@[+X,
M]W625:9AE6EH\7I;\ I:F: 1.%DY4<PA.989B6#BZ5,@02S!F[Y_AP?!)P?'
M;L6Q:]&[6S@V"CT#(G,!^@ H=)%FN9*(I+&=)+:R/R!:I/0Q!XENOVD<=*&
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MI(^(*'K%8J!X9ONS.ZYTMV<?%[J_!F$6Z/DYU[U6.3 M7]6Q3_\"4$L#!!0
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MJ3[<'=3L[O7@=SS$49*R)(T&/+0TI/\1AWO^/,1"VH7AE/F!QP;J@+8\I.-
M1'5=0@NG7O4N%J>QSQ(:#*BW9*3C:/P+28"%4&R)!-Q7$=FLF/W3K\O"Z1B0
M:$M#.H[#6]B =JNVY4\O>.@R<<K2-(BBH9%HL4A?X&*SSUU! 1N!=%Y)L:TH
MT6NDR\5I&"1^,C0F+1KI.!L_* NC<[&+QRFEH3=4":S%(QO'8UV-\FS7A)59
MYOT5R;J$G 9Q'"1L8+EF+2+9."(_P-B*S+H4C!G%]2$>$C[;@8Y3\-[MD@M5
M3#-56*VD=)4A"@NXY^M='%D7C=,8#V.A-S -6(M&-H[&-@FC8&3=36(44IP/
MG8*8G9U0W&GO/==;@5MM"1MLZEW$&$/7!ZCZQJI]=6A9*8NK9G6YPT,G:/<!
MOM\HG*G-C3L'G8ZQRW\!4$L#!!0    ( $"+FECD<3.X.@,  #8+   9
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MQH>)[FS4<L.Z1#>K4"U&-8UJAM+<RK=Y\]B?-W>=<'5_>H!_!SKW"II5HYI
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M]LAM;DR^J!_.53Q5NEJ@_/Y=7IY:FB^J%3SD^GN]V:/_ U!+ P04    " !
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M!?4\H#0&I7$H34!I$D4SWT#1>1Z^W?-H[V0_.MW)VIFNB1)*"Z$T!J5Q*$U
M:1)%,W78622^=VIWLC[4-H'20BB-06D<2A-0FD313!5WMHEO'=!VN9-M2<8$
MNVG?NU#L13H+"^ID0&D<2A-0FD313&'MO"G*R<EX99:G'>;<LAU:([U*#:'%
M,BB-0VD"2I,HFJFMSLSPCS(S7NX"DM_)T=-%[64Y2P]J<D!I#$KC4)J TB2*
M9NJS,SG\DS,Y?*C) :6%4!J#TCB4)J TB:*9*NY,#M_)Y'@M@Q_Z'.WK%P[[
MAU"O TIC4!J'T@24)E$T4UV=U^';O8[M PE_=%* G>_<XD&]#RB-06D<2A-0
MFD313$UV'HE_?G)Y&SJU!4H+H30&I7$H34!I$D4S5=RY+[[=??G3\T9;_FOS
M1NW5<!8;U(V!TOAQ)T1 "Y4HFOFNY,YF"6!32X*>J25]KTB&NB90&H/2>,\)
M.7@],M0*0=%,K7162&"?+>+\W$K+LS\;<FTOU5DP4(,"2N,]Y^- ,%#7 44S
M!=.Y#H'==7#J_#O.+;(7[=JC@M)"*(U!:1Q*$U":1-%,N79>1G!RRUX$4$,$
M2@NA- :E<2A-0&D213-5O+/\A=TU<>G103T1*"V$TEA+>Z7ORJ&%"BA-HFBF
MK#JS(["OC^'>^8-:%5!:&!PN4='ST#*T3 ZE"2A-HFB-MH8[RZBM5/Y0+ZE7
MD'FV2<MF1;7MM]ME^S[4B]4-N]V;-?\^1?E#G!8D4?<Z='0VU17-FV7TF@]E
MMJX79;O+RC);U9M+%>FT7.V@?W^?9>7SAZJ [6*&5_\#4$L#!!0    ( $"+
MFECL(#V8  <  ')#   9    >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;,V<
M6V_;-AB&_PKA#5L+=+%%6;*=)08:B\0*K&O0H-M%L0O%9FRA.G@BG;3 ?ORH
M0RS3EFEK>#>D%XTDZWL^2B^/KRU=/67Y%[D20I&O29S*Z]Y*J?5EOR_G*Y&$
M\B);BU1_\I#E2:CT;K[LRW4NPD49E,1].ACX_22,TM[TJCQVFT^OLHV*HU3<
MYD1NDB3,O]V(.'NZ[CF]YP,?H^5*%0?ZTZMUN!1W0GU:W^9ZK[^E+*)$I#+*
M4I*+A^O>6^>2NUX14)[Q>R2>Y,XV*2[E/LN^%#OO%M>]05$B$8NY*A"A_O,H
M9B*."Y(NQU\UM+?-603N;C_3>7GQ^F+N0REF6?Q'M%"KZ]ZX1Q;B(=S$ZF/V
M](NH+Z@LX#R+9?D_>:K/'?3(?"-5EM3!N@1)E%9_PZ_UC=@)</PC ;0.H/L!
MPR,!;AW@GALPK .&YP9X=8!W;H!?!_CEO:]N5GFG@U"%TZL\>R)Y<;:F%1NE
M7&6TOL%16M2L.Y7K3R,=IZ:S+'T4N8KN8T$^BH70];;8O-7ZBCP7"W*GLOD7
M$J;UUBJ+%R*7/Q+VUR92W\BK0*@PBN5K\A.Y#7-%J-[X=!>05]^_ONHK7<(B
M3W]>E^:F*@T]4AJ'DO=9JE:2L'0A%B:@KR]M>WWT^?INJ)48B/D%<9TWA ZH
MVU*@V?GAM"4\."/<\8YF9_;PM^M<AT^.9N?V<"[N+PAUV\*->^ENZXI;\MS_
MKZY\_E7G(.^42.2?;=6E*M"PO4!%KWLIU^%<7/=TMRI%_BAZTQ^^<_S!SVU2
M(V$!$L:0, Z"&55DN*TB0QM]VM0%6=:%A9#1,@W5?ENNU*U8?LDJAL#'J3<:
M3":N=]5_W!7.FK.K<(=)J3_Q1W1B)F7(I!P$,S3QMIIX5DVJ5IFMBY%<DD<A
MCZCA'=P89S#84\*:J:L22!A#POCAK?!\ZKM^4S$-)?RM$KZ]=8A\+E*E9VPD
M>R"1E!O=4/36/$L2/<LJFTR;,A75<7;*,[B@>])84W>5!@EC2!@'P0S]1EO]
M1AWTT_-TJ?1@%Z7+<T0<G2.B-7]7$9$PAH1Q$,P0<;P5<7SF$!6E16>HETFJ
M[AW).H_F@JR%7GJMPER05U%*@BR.PUPV1UOGM55.O8#95=>CWG!/X.J\\6XG
MJT\S3PJL%]!5N+IDNYV9?S$:[8VQ')33D&2RE632H5W--\DF#HL%)UE$C]%"
MI O9=LNMS*YSPTE;ZQR,]X1!IF1(& ?!#/F<0;.('%@%_$TH572#ZSR;"[&0
MNPVG?1EHY745KZ;M-CYO4/W;$Q":ET%I'$4S-=PQ ARKAA_R:!FE85S-2ZJN
ML%4Z*Z:S=,YAPW/W14-F9% :1]%,T6@C&K6*-FOI*T\W/BNSLX)(6@"E,2B-
MU[3=;L;QQK[CT_9E@=,8*XYU43X-MMK]F[F''=Y93ZA- J4Q*(W7-',RYHZ/
MB-E8(([= WEW^X%\?B^2>Y&W>EKV\,YR0<T1*(U!:1Q%,V5M7!3'>VGNIX,T
M-6906@"E,2B-HVAF36E<'N>$S7-\A2EW78-6R9%FR:RF&9Z>,_0==W]A TW+
MH#2.HIEJ-IZ/<\+TV6O@UJX=Z9+,H+0 2F-0&D?13(D;1\@9O[BN'>GQS*"T
M $IC4!I'T<R:TAA5S@FGROQ^ZTTU*V^UI^RDS@HC:0&4QJ T7M/,,<LSO!SS
MEP"-2T7M+M6=R",AR<U!P[9UZ79F5QFAM !*8U :1]%,K1LWBSHOK4NG4&,,
M2@N@- :E<13-K"F-A4;M%EJWGRS889U%AGIG-<WX:<.HQ05GT+0<13/U:[PS
M:O?..@S)->GD#9K94W;6!>J!06D<13/%:[PR:O?*3@[)Y&\RJ[Y8/V.HAAIK
M4%H I3$HC:-H9AUHC#7ZXHPU"C76H+0 2F-0&D?1S)K2&&OT7&/MK*'ZT/RJ
M?^EWV-]#?SP%I3$HC:-HIH*-F4;M9EK=W]\)K6&G51C46(/2 BB-06D<13/E
M;HPU^N*,-0HUUJ"T $IC4!I'T<R:TAAK%&:LT=,&42T>U#.#TAB4QE$T\[&0
MQEASSS+6K+VZGLB?^F+<GJ7STQY0JPU*8U :1]%,]1NKS7UQ5IL+M=J@M !*
M8U :1]',FM)8;6XGJZWNY.L'(5IUAKIM[J$_UOYM.#0M@](XBF9*N/,(H-UM
M.[.K[S*WMV?L+#+V*3_L8W[8Y_S^"^O.;:P[=_CBNGVHP0>E!5 :@](XBF;6
ME,;@<^T/(':8V[LM#R&VSNWM*3N+!_7<H#2.HE7B]7=>%9"(?%F^U$&2>;9)
M5?54_?;H]L41;\O7)>P=OW$N9]7K'QI,]3:*]V&^C%))8O&@D8.+D;Z O'K!
M0[6CLG7Y0H+[3*DL*3=7(M2=0W&"_OPAR]3S3I%@^YJ-Z3]02P,$%     @
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MVL\4:+=RQX7[AR/=\^ZX.ZH=C[ #)RPG64ZQG&:YE.4REC,L9S&N-@E$>Y.
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M-J!(V3\71;%8[[;:_O/^_6IK9[@JC=[A2FHFJEFH9J.:@VHNJ@E4\U#-1[4
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MQ7(VRSDLY[*<8#F/Y7R6"U@N9+F(Y>(C=WX#'#IORG(2XUJA:]1"5UT 1#?
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MQW(^RP4L%[)<Q'(QRR4LE[*<Q+A6!-<:@(:Z ?C;9E%<[W/7S(MLN=L49XJ
M:JY_\K)%0)2S6,YF.8?E7)83+.>QG,]R <N%+!>Q7,QR"<NE+"<QKAG0PUH1
M</CVBH!#M@B(<B;+62QGLYS#<B[+"9;S6,YGN8#E0I:+6"YFN83E4I:3&-<*
M^5H1<$@5 =50_VAFBX H9[&<S7(.R[DL)UC.8SF?Y0*6"UDN8KGXR#56*PW#
M&+9[@.BT*<M)C&MEKE'+7'4/T'FZM^KU8I=I-XV[L&YK87R^ :B>I7\@LPU
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MSY7+C9F&EF)QC,*LX7U6\TX.\(X3N%;2%@8N98[Y7P%"$J%5(GE2XBSI1;S
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MVT#?ETK9IXEST/;)\S\!4$L#!!0    ( $"+FECE3)=Z_ (  .4'   9
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M&NKRQ3"A>QB5#:#UF93F;6);?7VSAW\ 4$L#!!0    ( $"+FEA<5/;LV@,
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M;UL*H"-^)[ 2M3%1J4P8>U"3FZAK6$H1I!!*14'QL80^I*EB0AV/):E1[:F
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M9*H=D>7E"I!Y)D26E)MKH/*AJ#A!?K_,,K'?*1IHEBE-_@-02P,$%     @
M0(N:6(<L.!*] P  [0\  !D   !X;"]W;W)K<VAE971S+W-H965T-S$N>&UL
MM5==;]LV%/TKA#84*=!&HA1)=F8+:)(-"Y"L0;-T#\4>:.G:%BJ1+DG':7]]
M24J6OV@Z,[P\Q"+%>WC.%7D_!@O&OXHI@$0O=47%T)M*.;OT?9%/H2;BG,V
MJC=CQFLBU9!/?#'C0 IC5%=^& 2)7Y.2>MG S#WP;,#FLBHI/' DYG5-^/<K
MJ-ABZ&%O.?&IG$REGO"SP8Q,X!'DT^R!JY'?H11E#524C"(.XZ'W 5]>XU0;
MF!6?2UB(M6>DI8P8^ZH'M\70"S0CJ""7&H*HGV>XAJK22(K'MQ;4Z_;4ANO/
M2_0_C'@E9D0$7+/JG[*0TZ'7\U !8S*OY">V^!-:0;'&RUDES'^T:-9&D8?R
MN9"L;HT5@[JDS2]Y:1VQ9H"3/09A:Q!N&USL,8A:@\@(;9@963=$DFS V0)Q
MO5JAZ0?C&V.MU)14?\9'R=7;4MG)[);FK ;T-WD!@<YN0)*R$F_1>_3T>(/.
M?GT[\*7:1:_U\Q;QJD$,]R#B$-TS*J<"_4X+*#8!?$6OXQ@N.5Z%3L0;R,]1
MA-^A, @C"Z'KUYN'#CI1Y[+(X$6O<=F7._46W4JHQ;\V7S50%W8H?4<OQ8SD
M,/34)13 G\'+WOR"D^ WF\X3@6VHONA47[C0LT=))*"_/MX)F\S&-C:V.G(\
M9^\Q[H=)$ _\YW4)EH5Q@,,T[=9ML(L[=K&3G;K2ZL+2O?P:ZV1MVPC'_3#=
M8N?<Q.Y@Y/!MTK%/G.P_DVI.FJA6J;A*: XV$<F.[S!6X5K];<E(=M5NK=N@
MF78T4R?-]N!+\H)FP'.@4@5Z&]$&!N,U L'Y]DEP[G7D8>YU2GI.)4^40\XF
MM/P!A=$S @KC4EK/3F_7[6F MWU^:-4&SW['L^_D^5'Y61T,.D&M[\_NF%#A
M^<L]U"/@UHCC1/RO$>=$8!OB<;#*3<'I(FV+=2+AIT+;5+Z6E;$[GD&AOGR%
MRN[*627CG8L>IGU;1'!O=ZR<<"4G?%5X/B GW)&#>X%5CG.[8^6L"@#LS+1M
M+CP@)MK]-E'/*N;_2.MXE=>Q.[$OCYI*G8C0 @EGHL>["1PG=EG.;8^5M2H(
ML+LB4$&#C*KE5[)*B6UIJK<MXXB:X+",566 W:6!N^S"NR7!GH_AW.58%:O"
M ;LKAT/E66N^<:IB;!5RTK+!7VN<:N 3TT\*E+,YE4U_TLUV/>L'TZEMS5_I
M7M8T9"N8IA&^)WQ24H$J&"O(X#Q5(GG36S8#R6:F/1LQJ9H]\SA5_3APO4"]
M'S,FEP.]0=?A9S\!4$L#!!0    ( $"+FEBV+A=MH@(  "L'   9    >&PO
M=V]R:W-H965T<R]S:&5E=#<R+GAM;*U56V_:,!3^*U8V3:VTDAL$VH5(!5:M
MTBI5I=T>ICV8Y$"B.G9FF\O^_7P)*: 0]6$OQ)?S?>?[#O9QO&7\5>0 $NU*
M0L78R:6L;EQ7I#F46/18!53M+!DOL513OG)%Q0%G!E02-_"\R"UQ09TD-FN/
M/(G96I*"PB-'8EV6F/^= &';L>,[^X6G8I5+O> F<857, ?Y4CUR-7,;EJPH
M@8J"4<1A.79N_9MII.--P(\"MN)@C+23!6.O>G*?C1U/"P("J=0,6'TV, 5"
M-)&2\:?F=)J4&G@XWK/?&>_*RP(+F#+RL\AD/G9&#LI@B==$/K'M-ZC]##1?
MRH@POVAK8X>>@]*UD*RLP4I!65#[Q;NZ#@< /SH#"&I < KHGP&$-2 T1JTR
M8VN&)4YBSK:(ZVC%I@>F-@:MW!14_XMSR=5NH7 RN:<I*P$]XQT(=#$#B0LB
M+M$5FJOSDJT)(+9$WYD0: +JS !Z ZB@E_D,77R\C%VII&A"-ZW33FS:X$Q:
M/T /C,I<H*\T@^R8P%4>&B/!WL@DZ&2<0=I#H?\9!5X0M@B:OA\>=,@)F[J&
MAB\\P_>.\OVZ70C)U3G^W58_2]]OI]=W^T94.(6QHRZO +X!)_GTP8^\+VW>
M_Q/9427Z327Z7>S)2V_>:S-H40.#TKUFDUR%0]^+!M?7L;LY5-\2Z8=]_WH4
M>DWDD;1!(VW0*4TU G7-:9LZ"XR.U/F#:#0ZT=:9H+VRJ*.H4:,\ZE3^S"0F
MB.B#M; 'J[ '2^J+W&8H:BMW/PB"T?#$4DODF7*[!WVG!+XR[5B@E*VIM#>W
M66TZ_JUI="?K$_42V,;]1F.?D0?,5P45B,!247J]H=+%;6NV$\DJT]T63*I>
M:8:Y>LV ZP"UOV1,[B<Z0?,^)O\ 4$L#!!0    ( $"+FE@Q&;B^700  +$0
M   9    >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;*U8;6_C*!#^*\AW.NU*
MFQILXY=>$JG;:.\J[=U5FWWY3&V2H+5-#DC3WJ\_<%P[#02U4K\TQIX9GF<8
MYH%.]US\E!M*%7AHZE;.@HU2V\LPE.6&-D1>\"UM]9<5%PU1>BC6H=P*2JK.
MJ:G#",(T; AK@_FT>W<KYE.^4S5KZ:T <M<T1#Q^I#7?SP(4/+WXPM8;95Z$
M\^F6K.F2JF_;6Z%'X1"E8@UM)>,M$'0U"Z[0Y34JC$-G\9W1O3QZ!H;*'><_
MS>"FF@70(*(U+94)0?3//;VF=6TB:1S_]D&#84[C>/S\%/U31UZ3N2.27O/Z
M!ZO49A;D :CHBNQJ]87O_Z0](6SBE;R6W5^P[VUA ,J=5+SIG36"AK6'7_+0
M)^+( 25G'*+>(7JI0]P[Q!W1 [*.UH(H,I\*O@?"6.MHYJ'+3>>MV;#6+.-2
M"?V5:3\UOVE+WE#PE3Q0"=XMJ"*LEN_!!"QUP52[F@*^ @NZHD+0RIB!*RFI
MDH"T%?C,R!VKF6+:=P*^+1?@W:_OIZ'2N$STL.PQ?#Q@B,Y@6-#R L3H XA@
M%#O<KU_N'CUW#W4VAI1$0TJB+EY\-E[/5FFVI&-[Z2)UB)*XHYCM=RFWI*2S
M0.\O2<4]#>:__8)2^+N+XAL%>T8X'@C'ONCSOZF:Z+X@B&+M&M1<2E 2(1YU
MD]@34;FX'P+B+J#I%/=S!".49"F<AO?'O&S#J,C3+,X'NV>0DP%RXH5\TRK2
MKME=3:4+WL$Y/9HUCI.B0,4).MLNSS'*4C<X/(##7G#79,L4J=E_NH;,:A%1
M;KK]4M%[W3>WN@LJ%VILH4$H0W%TFE/O[.Y: 9XR20=:J9?64O'RY\3TS KH
MIJ&%1!+3BEU44HM*6D"[.FRS&.881^[\9P/0S MT0;=<,@6T2OP09$D%N+J]
M<J',[.7'25ZD)RB]L[T^W_E (_?2N"I+L7M!KG.[;#"$Q6FM.\SR%&>Q.]?%
M ++P@OS,2HV- K(6E)XK[,*:.BD0SDX VE9YE$9G]B*"H\!!+\)_U$97 .F3
M21],+MU=HP]TC !K38&G0!UV*<[S<TB/I!AYD?XA3.NM;/EQ@D7V>F80(H3R
M4[BV98(1QAB= 3P*)?+*TOP[J7?D<!JK]7F0M"5U0HTL !.$TR++(#K%ZC#5
M8".<G,ON*'+(KW(.6?\ 6GU0U@<</_S8SG0,XP19=6$;QA#B,\!'J4/)R\\C
M]7CD<AY*D%<W7WLJ>:MHSYF/.HK\0CJJO&\CV+(Y2>($)\EI!_3/]OI&CD;E
M1'[I_,0>]/IY.-A".(FP)9<N,T^%C7J)_(+9M4@G+ELA)U&!<BNS;RR1:-1(
MY!?)KUR?M)[WS*,MXN1D"Z&NERQ#A=4X'9:>=(^2B?R:J<_;;L2/3KR%=836
M*+(XRZWFZ9WV%:L0'MTGS67^+R+6K)6@IBL=&5YD&HPXW(\/ \6WW17SCBM]
M8>T>-Y145!@#_7W%N7H:F%OK\%^*^?]02P,$%     @ 0(N:6,=0#^%1!
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M=_E**1#F2'^="5[@+WVR1?N]C_$C>_[>?5R"6K@VI4DN5\+4UUFSVG3"<]<
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M#R88%T#[I=;X.'%-/#S!V1]02P,$%     @ 0(N:6*[U? ;* @  4@<  !D
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MPQVP!*1Y .]OA-"O)P:@^2RS^ =02P,$%     @ 0(N:6"/+)*-@ @  VP8
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M&^!+D/D)YOA*"/VTD0]0_P?#]#]02P,$%     @ 08N:6"5-9JIK P  TQ<
M  T   !X;"]S='EL97,N>&ULW5C1;MHP%/V5*%VG5IH:0M9 5D#:D) F;5.E
M]F%OE2$.6'*<S#$=].OG&X<$J"^C?5C)@DKL>W+./;:OD]!!H=:<WBTH5<XJ
MY:(8N@NE\D^>5\P6-"7%5993H9$DDRE1NBOG7I%+2N("2"GWNIU.Z*6$"7<T
M$,MTDJK"F65+H8:NWZECCCE]C74T_.@Z1F^<Q73H/ER\_[7,U,T[QYS//IR=
M=1XN;_;C%R5PZ7I6T>LC1*\Z<*#2!L82A,<E.*2.2?>.DCZ@C GW=X4;H;\1
M(POQO.:=([1>QYIOBPD=C.S;9^%N(I'":)"#I='K'EL:ARL#DP^.E#^H7HI[
MU08:#9),-/LH<$U 9R<I=1X)'[ICPME4,F E)&5\;<)=",PRGDE'Z0VL[?@0
M*9X,[)L>[.U*)V4BDV5ND\%\3ZO+]X!-#PPRSFN#7=<$1H.<*$6EF.A.>7$9
M? 8Y5?M^G6N'<TG6?O?:;0CE22>99C*FLKF?N)O0:,!I G8DFR_@K++< U"I
M+-6-F)%Y)DCI8<.H&EIV1CF_@QO?SV1'>Y5LK6M9RJ)N:D-5T\B8#NAOJQGM
M;=G>JW2=G#UFZLM2#T>4?:@6>BMIPE9E?Y74!C!U'U<G><[7GSF;BY2:P1^=
M<#0@&YZSR"1[TMF@5&8Z0*7K/%*IV&P[\EN2_)ZNU*:<5@GNN=M"S_]VGN=4
M4$GXMFE=^Z<\RZ]V7+THO(7G\K:R[]AJ,NB=OL?JY>C4389M,-F*Y>ZWP634
M I.]-[MKON .U(J)]-M@LML&D\%)FO2J%]^MM^N==^LZZL!OF*'[ WXQ\2:I
M,UTRKIBH>@L6QU0\>\76\HI,.=W5U]?'-"%+KNYK<.@V[>\T9LLTJJ^ZA8FH
MKFK:WV!X?EC_@-*YF(CIBL;CJBOGT[+IZ(;.6AU V$<FY6%',([![ A@6![,
M <8Q+"S/_S2>/CH>@V'>^E:DCW+Z*,>P;,BX_&!Y[)Q('_:11E$0A"$VH^.Q
MU<$8F[<PA#^[&N8-&%@>R/2RN<97&Z^0PW6 K>FA"L%&BE<B-E)\K@&QSQLP
MHLB^VE@>8&"K@-4.Y+?G@9JR<X( 5A7SANU@'(DB#(%:M-=H&"*S$\+'OC[8
M+@F"*+(C@-D=! &&P&[$$<P!>,"0("B?@WO/(V_SG/*:?^./_@!02P,$%
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MN37J,)(I'=)*P.R5+VXR:\52WLONO#^AD$8"9H^L]FN;&[WK$LMSS"@=\D?
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M4$L! A0#%     @ 0(N:6/N*K7OU P  C1   !@              ("!V18
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( $"+FEBD>BX4
M6 8  %L;   8              " @00;  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " ! BYI86ZF_?LD"  ##!@  &
M@(&2(0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 0(N:
M6/N&NM['#P  DK@  !@              ("!D20  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( $"+FEB?J'V?C@(  .D%   8
M      " @8XT  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" ! BYI8,#E11W<+   #.P  &               @(%2-P  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 0(N:6/!,K-9J @  T@4  !@
M             ("!_T(  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( $"+FEB$F2WM@@8  $,0   9              " @9]%  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 0(N:6 \0A+^!!@
M"1   !D              ("!6$P  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " ! BYI8P[_=49@>  !170  &0              @($0
M4P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( $"+FEB<
MZ8IP. D  %T7   9              " @=]Q  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ 0(N:6)N^?0G:%P  5T@  !D
M     ("!3GL  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $"+FEC5-1R!U@H  $ @   9              "
M@?+%  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ 0(N:
M6*P&"G6E!@  @A   !D              ("!_]   'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " ! BYI8OAF9X8 *  #=&@  &0
M        @(';UP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( $"+FECT*S^FM@D  %P9   9              " @9+B  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ 0(N:6 .P](:% P  C0<
M !D              ("!?^P  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " ! BYI8U8()D"T@  "2:@  &0              @($[\
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( $"+FE@1P/E@
M=@4  .\/   9              " @9\0 0!X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ 0(N:6#\M',AV!@  ?!$  !D
M ("!3!8! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !
MBYI8/*\?;H0&  #M#P  &0              @('Y' $ >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( $"+FE@4:>D,K@(  +T%   9
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M970S,BYX;6Q02P$"% ,4    " ! BYI8H@)2.*8#  "[$0  &0
M    @('C/@$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M $"+FEBY#P/YL ,  #L1   9              " @<!" 0!X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ 0(N:6,H/H-G] @  @PL  !D
M             ("!IT8! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " ! BYI8-N40A_$"  #P"@  &0              @(';20$ >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( $"+FEAQ@4G2H@,
M % 4   9              " @0-- 0!X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ 0(N:6-%<E//B @  _P8  !D              ("!
MW% ! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " ! BYI8
M&T,?%4X#   N"0  &0              @('U4P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( $"+FEC<:,VFX0,  /<1   9
M      " @7I7 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ 0(N:6+CS"C72!    QP  !D              ("!DEL! 'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " ! BYI8GAA&3WX"  !E!P
M&0              @(&;8 $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( $"+FEC9)WXEX (  ,,(   9              " @5!C 0!X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ 0(N:6%QS,;11
M!0  )B,  !D              ("!9V8! 'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    " ! BYI8@4OY7'0"  #A!@  &0
M@('O:P$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( $"+
MFEAREQ5LBP(  &P&   9              " @9IN 0!X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ 0(N:6-FAI]PG P    H  !D
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M=#4Q+GAM;%!+ 0(4 Q0    ( $"+FEA'DX1Q< 0  -(.   9
M  " @>^0 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @
M0(N:6.1Q,[@Z P  -@L  !D              ("!EI4! 'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6Q02P$"% ,4    " ! BYI8GG<P\'H4  "50@$ &0
M            @($'F0$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4
M Q0    ( $"+FEBS!=^_6PH  -"&   9              " @;BM 0!X;"]W
M;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ 0(N:6,[WTWK: P
MYQ,  !D              ("!2K@! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX
M;6Q02P$"% ,4    " ! BYI8;(K D4$#   G#P  &0              @(%;
MO $ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( $"+FEB>
M\HG''PD  -AP   9              " @=._ 0!X;"]W;W)K<VAE971S+W-H
M965T-3@N>&UL4$L! A0#%     @ 0(N:6.P@/9@ !P  <D,  !D
M     ("!*<D! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $"+FEA<5/;LV@,  &L0   9              "
M@<P< @!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ 0(N:
M6*1I+AUK!   :!0  !D              ("!W2 " 'AL+W=O<FMS:&5E=',O
M<VAE970V-2YX;6Q02P$"% ,4    " ! BYI8=LID1Z4#   '#@  &0
M        @(%_)0( >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0
M   ( $"+FE@"0KJ;3 ,  "@+   9              " @5LI @!X;"]W;W)K
M<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ 0(N:6)&8]H0[ P  RPL
M !D              ("!WBP" 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q0
M2P$"% ,4    " ! BYI8T32O%S &  !R+P  &0              @(%0, (
M>&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( $"+FEA-TTP-
M,P4  +(D   9              " @;<V @!X;"]W;W)K<VAE971S+W-H965T
M-S N>&UL4$L! A0#%     @ 0(N:6(<L.!*] P  [0\  !D
M ("!(3P" 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " !
MBYI8MBX7;:("   K!P  &0              @($50 ( >&PO=V]R:W-H965T
M<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( $"+FE@Q&;B^700  +$0   9
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M970W-RYX;6Q02P$"% ,4    " ! BYI8KO5\!LH"  !2!P  &0
M    @($R50( >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    (
M $"+FEA;/M*NO0(  -,&   9              " @3-8 @!X;"]W;W)K<VAE
M971S+W-H965T-SDN>&UL4$L! A0#%     @ 0(N:6&4^YM>5 @  &0<  !D
M             ("!)UL" 'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q02P$"
M% ,4    " ! BYI8^AJL*Y0$  "B$0  &0              @('S70( >&PO
M=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( $"+FE@CRR2C8 (
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( $&+FECDG6!<=04  / V   /
M      "  9]N @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !!BYI8-$X[
M?7H"    ,0  &@              @ %!= ( >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " !!BYI8(' .V20"  "I+P  $P
M    @ 'S=@( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     6P!; /08  !(
%>0(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>348</ContextCount>
  <ElementCount>627</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>123</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Convertible Redeemable Preferred Stock and Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Convertible Redeemable Preferred Stock and Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Convertible Redeemable Preferred Stock and Stockholders??? Equity (Deficit) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3_Parentheticals</Role>
      <ShortName>Consolidated Statements of Convertible Redeemable Preferred Stock and Stockholders??? Equity (Deficit) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Statement - Consolidated Statements of Cash Flows (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ConsolidatedCashFlow_Parentheticals</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Going Concern and Management???s Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlans</Role>
      <ShortName>Going Concern and Management???s Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/BalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Significant Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/SignificantAgreements</Role>
      <ShortName>Significant Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.bluewatervaccines.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Subscription Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/SubscriptionAgreement</Role>
      <ShortName>Subscription Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquity</Role>
      <ShortName>Convertible Redeemable Preferred Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Retirement Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/RetirementPlans</Role>
      <ShortName>Retirement Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/BalanceSheetDetails</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/Acquisitions</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Subscription Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/SubscriptionAgreementTables</Role>
      <ShortName>Subscription Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/SubscriptionAgreement</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables</Role>
      <ShortName>Convertible Redeemable Preferred Stock and Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/IncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Retirement Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/RetirementPlansTables</Role>
      <ShortName>Retirement Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/RetirementPlans</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Going Concern and Management???s Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlansDetails</Role>
      <ShortName>Going Concern and Management???s Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlans</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Geographical Area</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofRevenuebyGeographicalAreaTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Geographical Area</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Long-lived by Geographical Area</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofLonglivedbyGeographicalAreaTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Long-lived by Geographical Area</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Fair Value of Financial Instruments Measured on a Recurring Basis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Fair Value of Financial Instruments Measured on a Recurring Basis</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Activity for the Subscription Agreement Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofActivityfortheSubscriptionAgreementLiabilityTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Activity for the Subscription Agreement Liability</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Activity for the Contingent Warrant Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofActivityfortheContingentWarrantLiabilityTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Activity for the Contingent Warrant Liability</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Computation of Diluted Shares Outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofComputationofDilutedSharesOutstandingTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Computation of Diluted Shares Outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Balance Sheet Details (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails</Role>
      <ShortName>Balance Sheet Details (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Balance Sheet Details (Details) - Schedule of Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofInventoriesTable</Role>
      <ShortName>Balance Sheet Details (Details) - Schedule of Inventories</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Balance Sheet Details (Details) - Schedule of Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable</Role>
      <ShortName>Balance Sheet Details (Details) - Schedule of Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Balance Sheet Details (Details) - Schedule of Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable</Role>
      <ShortName>Balance Sheet Details (Details) - Schedule of Intangible Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Balance Sheet Details (Details) - Schedule of Annual Amortization Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable</Role>
      <ShortName>Balance Sheet Details (Details) - Schedule of Annual Amortization Expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Balance Sheet Details (Details) - Schedule of Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofGoodwillTable</Role>
      <ShortName>Balance Sheet Details (Details) - Schedule of Goodwill</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Balance Sheet Details (Details) - Schedule of Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable</Role>
      <ShortName>Balance Sheet Details (Details) - Schedule of Accrued Expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/AcquisitionsDetails</Role>
      <ShortName>Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/AcquisitionsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Acquisitions (Details) - Schedule of Aggregate Consideration Transferred for the Assets Acquired</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable</Role>
      <ShortName>Acquisitions (Details) - Schedule of Aggregate Consideration Transferred for the Assets Acquired</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/AcquisitionsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Acquisitions (Details) - Schedule of Assets Acquired</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofAssetsAcquiredTable</Role>
      <ShortName>Acquisitions (Details) - Schedule of Assets Acquired</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/AcquisitionsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Acquisitions (Details) - Schedule of Fair Value of the Proteomedix Stock Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofFairValueoftheProteomedixStockOptionsTable</Role>
      <ShortName>Acquisitions (Details) - Schedule of Fair Value of the Proteomedix Stock Options</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/AcquisitionsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Acquisitions (Details) - Schedule of Estimated Fair Values of Assets Acquired and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable</Role>
      <ShortName>Acquisitions (Details) - Schedule of Estimated Fair Values of Assets Acquired and Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/AcquisitionsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Acquisitions (Details) - Schedule of Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofConsolidatedStatementsofOperationsandComprehensiveLossTable</Role>
      <ShortName>Acquisitions (Details) - Schedule of Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/AcquisitionsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Significant Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/SignificantAgreementsDetails</Role>
      <ShortName>Significant Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/SignificantAgreements</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.bluewatervaccines.com/role/NotesPayableDetails</Role>
      <ShortName>Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/NotesPayable</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Subscription Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/SubscriptionAgreementDetails</Role>
      <ShortName>Subscription Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/SubscriptionAgreementTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Subscription Agreement (Details) - Schedule of Assumptions Used in Monte-Carlo Model, Which Utilizes Level 3 Inputs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable</Role>
      <ShortName>Subscription Agreement (Details) - Schedule of Assumptions Used in Monte-Carlo Model, Which Utilizes Level 3 Inputs</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/SubscriptionAgreementTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 1</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1</Role>
      <ShortName>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 1</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 2</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2</Role>
      <ShortName>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 2</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3</Role>
      <ShortName>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4</Role>
      <ShortName>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Fair Value of the Preferred Investment Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofFairValueofthePreferredInvestmentOptionsTable</Role>
      <ShortName>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Fair Value of the Preferred Investment Options</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Valuation of the Contingent Warrant Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofValuationoftheContingentWarrantLiabilityTable</Role>
      <ShortName>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Valuation of the Contingent Warrant Liability</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Outstanding Warrants, Excluding Contingent Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable</Role>
      <ShortName>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Outstanding Warrants, Excluding Contingent Warrants</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Stock Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable</Role>
      <ShortName>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Stock Options</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Fair Value of Options Granted</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofFairValueofOptionsGrantedTable</Role>
      <ShortName>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Fair Value of Options Granted</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Unvested Restricted Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofUnvestedRestrictedStockTable</Role>
      <ShortName>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Unvested Restricted Stock</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Stock-Based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofStockBasedCompensationExpenseTable</Role>
      <ShortName>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Stock-Based Compensation Expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/CommitmentsandContingencies</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/RelatedPartyTransactions</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/IncomeTaxesTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Income Taxes (Details) - Schedule of Loss Before Income Tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofLossBeforeIncomeTaxTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Loss Before Income Tax</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/IncomeTaxesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996049 - Disclosure - Income Taxes (Details) - Schedule of Deferred Tax Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Deferred Tax Assets and Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/IncomeTaxesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996050 - Disclosure - Income Taxes (Details) - Schedule of Income Taxes Differs from the Statutory Federal Rate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Income Taxes Differs from the Statutory Federal Rate</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/IncomeTaxesTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996051 - Disclosure - Income Taxes (Details) - Schedule of Unrecognized Tax Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofUnrecognizedTaxBenefitsTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Unrecognized Tax Benefits</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/IncomeTaxesTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996052 - Disclosure - Retirement Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/RetirementPlansDetails</Role>
      <ShortName>Retirement Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/RetirementPlansTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996053 - Disclosure - Retirement Plans (Details) - Schedule of Benefit Obligation and the Net Periodic Benefit Cost</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable</Role>
      <ShortName>Retirement Plans (Details) - Schedule of Benefit Obligation and the Net Periodic Benefit Cost</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/RetirementPlansTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996054 - Disclosure - Retirement Plans (Details) - Schedule of Components of Net Periodic Benefit Cost</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofComponentsofNetPeriodicBenefitCostTable</Role>
      <ShortName>Retirement Plans (Details) - Schedule of Components of Net Periodic Benefit Cost</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/RetirementPlansTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Retirement Plans (Details) - Schedule of Accumulated Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofAccumulatedComprehensiveLossTable</Role>
      <ShortName>Retirement Plans (Details) - Schedule of Accumulated Comprehensive Loss</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/RetirementPlansTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996056 - Disclosure - Retirement Plans (Details) - Schedule of Accompanying Consolidated Balance Sheet</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofAccompanyingConsolidatedBalanceSheetTable</Role>
      <ShortName>Retirement Plans (Details) - Schedule of Accompanying Consolidated Balance Sheet</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/RetirementPlansTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996057 - Disclosure - Retirement Plans (Details) - Schedule of the Beginning and Ending Balances of the Accumulated Benefit Obligation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable</Role>
      <ShortName>Retirement Plans (Details) - Schedule of the Beginning and Ending Balances of the Accumulated Benefit Obligation</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/RetirementPlansTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996058 - Disclosure - Retirement Plans (Details) - Schedule of Benefit Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable</Role>
      <ShortName>Retirement Plans (Details) - Schedule of Benefit Payments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/RetirementPlansTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="ea0203788-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996059 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/SubsequentEvents</ParentRole>
      <Position>83</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="S-1/A" isDefinitelyFs="true" isUsgaap="true" original="ea0203788-01.htm">ea0203788-01.htm</File>
    <File>onco-20231231.xsd</File>
    <File>onco-20231231_cal.xml</File>
    <File>onco-20231231_def.xml</File>
    <File>onco-20231231_lab.xml</File>
    <File>onco-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>timage_001.jpg</File>
    <File>timage_002.jpg</File>
    <File>timage_003.jpg</File>
    <File>timage_004.jpg</File>
    <File>timage_005.jpg</File>
    <File>tonconetix_logo.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/srt/2023</BaseTaxonomy>
    <BaseTaxonomy items="1143">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="10">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>108
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0203788-01.htm": {
   "nsprefix": "onco",
   "nsuri": "http://www.bluewatervaccines.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "ea0203788-01.htm"
     ]
    },
    "schema": {
     "local": [
      "onco-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "onco-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "onco-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "onco-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "onco-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 493,
   "keyCustom": 134,
   "axisStandard": 30,
   "axisCustom": 0,
   "memberStandard": 40,
   "memberCustom": 68,
   "hidden": {
    "total": 307,
    "http://www.bluewatervaccines.com/20231231": 83,
    "http://fasb.org/us-gaap/2023": 221,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 348,
   "entityCount": 1,
   "segmentCount": 123,
   "elementCount": 943,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1143,
    "http://xbrl.sec.gov/dei/2023": 10,
    "http://fasb.org/srt/2023": 2
   },
   "report": {
    "R1": {
     "role": "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "onco:NotesPayableNetOfDebtDiscount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "onco:NotesPayableNetOfDebtDiscount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement",
     "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "longName": "004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R6": {
     "role": "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3",
     "longName": "005 - Statement - Consolidated Statements of Convertible Redeemable Preferred Stock and Stockholders\u2019 Equity (Deficit)",
     "shortName": "Consolidated Statements of Convertible Redeemable Preferred Stock and Stockholders\u2019 Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3_Parentheticals",
     "longName": "006 - Statement - Consolidated Statements of Convertible Redeemable Preferred Stock and Stockholders\u2019 Equity (Deficit) (Parentheticals)",
     "shortName": "Consolidated Statements of Convertible Redeemable Preferred Stock and Stockholders\u2019 Equity (Deficit) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c26",
      "name": "onco:IssuanceOfCommonStockInInitialPublicOfferingNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "1",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c26",
      "name": "onco:IssuanceOfCommonStockInInitialPublicOfferingNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "1",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow",
     "longName": "007 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow_Parentheticals",
     "longName": "008 - Statement - Consolidated Statements of Cash Flows (Parentheticals)",
     "shortName": "Consolidated Statements of Cash Flows (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PaymentsToAcquireProductiveAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PaymentsToAcquireProductiveAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentation",
     "longName": "009 - Disclosure - Organization and Basis of Presentation",
     "shortName": "Organization and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlans",
     "longName": "010 - Disclosure - Going Concern and Management\u2019s Plans",
     "shortName": "Going Concern and Management\u2019s Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "011 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.bluewatervaccines.com/role/BalanceSheetDetails",
     "longName": "012 - Disclosure - Balance Sheet Details",
     "shortName": "Balance Sheet Details",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.bluewatervaccines.com/role/Acquisitions",
     "longName": "013 - Disclosure - Acquisitions",
     "shortName": "Acquisitions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.bluewatervaccines.com/role/SignificantAgreements",
     "longName": "014 - Disclosure - Significant Agreements",
     "shortName": "Significant Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "onco:SignificantAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "onco:SignificantAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.bluewatervaccines.com/role/NotesPayable",
     "longName": "015 - Disclosure - Notes Payable",
     "shortName": "Notes Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.bluewatervaccines.com/role/SubscriptionAgreement",
     "longName": "016 - Disclosure - Subscription Agreement",
     "shortName": "Subscription Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "onco:SubscriptionAgreementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "onco:SubscriptionAgreementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquity",
     "longName": "017 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity",
     "shortName": "Convertible Redeemable Preferred Stock and Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.bluewatervaccines.com/role/CommitmentsandContingencies",
     "longName": "018 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.bluewatervaccines.com/role/RelatedPartyTransactions",
     "longName": "019 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.bluewatervaccines.com/role/IncomeTaxes",
     "longName": "020 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.bluewatervaccines.com/role/RetirementPlans",
     "longName": "021 - Disclosure - Retirement Plans",
     "shortName": "Retirement Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.bluewatervaccines.com/role/SubsequentEvents",
     "longName": "022 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables",
     "longName": "996002 - Disclosure - Balance Sheet Details (Tables)",
     "shortName": "Balance Sheet Details (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.bluewatervaccines.com/role/AcquisitionsTables",
     "longName": "996003 - Disclosure - Acquisitions (Tables)",
     "shortName": "Acquisitions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.bluewatervaccines.com/role/SubscriptionAgreementTables",
     "longName": "996004 - Disclosure - Subscription Agreement (Tables)",
     "shortName": "Subscription Agreement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "onco:SubscriptionAgreementDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "onco:SubscriptionAgreementDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables",
     "longName": "996005 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Tables)",
     "shortName": "Convertible Redeemable Preferred Stock and Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueOptionQuantitativeDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueOptionQuantitativeDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.bluewatervaccines.com/role/IncomeTaxesTables",
     "longName": "996006 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.bluewatervaccines.com/role/RetirementPlansTables",
     "longName": "996007 - Disclosure - Retirement Plans (Tables)",
     "shortName": "Retirement Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails",
     "longName": "996008 - Disclosure - Organization and Basis of Presentation (Details)",
     "shortName": "Organization and Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ReclassificationsOfTemporaryToPermanentEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ReclassificationsOfTemporaryToPermanentEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlansDetails",
     "longName": "996009 - Disclosure - Going Concern and Management\u2019s Plans (Details)",
     "shortName": "Going Concern and Management\u2019s Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProceedsFromSaleOfOtherInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProceedsFromSaleOfOtherInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "996010 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofRevenuebyGeographicalAreaTable",
     "longName": "996011 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Geographical Area",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Geographical Area",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c71",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofLonglivedbyGeographicalAreaTable",
     "longName": "996012 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Long-lived by Geographical Area",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Long-lived by Geographical Area",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable",
     "longName": "996013 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Fair Value of Financial Instruments Measured on a Recurring Basis",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Fair Value of Financial Instruments Measured on a Recurring Basis",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofActivityfortheSubscriptionAgreementLiabilityTable",
     "longName": "996014 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Activity for the Subscription Agreement Liability",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Activity for the Subscription Agreement Liability",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c84",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c84",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofActivityfortheContingentWarrantLiabilityTable",
     "longName": "996015 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Activity for the Contingent Warrant Liability",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Activity for the Contingent Warrant Liability",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c88",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c89",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofComputationofDilutedSharesOutstandingTable",
     "longName": "996016 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Computation of Diluted Shares Outstanding",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Computation of Diluted Shares Outstanding",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails",
     "longName": "996017 - Disclosure - Balance Sheet Details (Details)",
     "shortName": "Balance Sheet Details (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCostOfOperatingRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofInventoriesTable",
     "longName": "996018 - Disclosure - Balance Sheet Details (Details) - Schedule of Inventories",
     "shortName": "Balance Sheet Details (Details) - Schedule of Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable",
     "longName": "996019 - Disclosure - Balance Sheet Details (Details) - Schedule of Prepaid Expenses and Other Current Assets",
     "shortName": "Balance Sheet Details (Details) - Schedule of Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable",
     "longName": "996020 - Disclosure - Balance Sheet Details (Details) - Schedule of Intangible Assets",
     "shortName": "Balance Sheet Details (Details) - Schedule of Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "onco:FiniteLivedIntangibleAssetCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "onco:FiniteLivedIntangibleAssetCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable",
     "longName": "996021 - Disclosure - Balance Sheet Details (Details) - Schedule of Annual Amortization Expense",
     "shortName": "Balance Sheet Details (Details) - Schedule of Annual Amortization Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofGoodwillTable",
     "longName": "996022 - Disclosure - Balance Sheet Details (Details) - Schedule of Goodwill",
     "shortName": "Balance Sheet Details (Details) - Schedule of Goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:GoodwillTransfers",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:GoodwillTransfers",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable",
     "longName": "996023 - Disclosure - Balance Sheet Details (Details) - Schedule of Accrued Expenses",
     "shortName": "Balance Sheet Details (Details) - Schedule of Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "onco:AccruedResearchAndDevelopmentCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "onco:AccruedResearchAndDevelopmentCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
     "longName": "996024 - Disclosure - Acquisitions (Details)",
     "shortName": "Acquisitions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c114",
      "name": "onco:RoyaltySalesPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c114",
      "name": "onco:RoyaltySalesPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable",
     "longName": "996025 - Disclosure - Acquisitions (Details) - Schedule of Aggregate Consideration Transferred for the Assets Acquired",
     "shortName": "Acquisitions (Details) - Schedule of Aggregate Consideration Transferred for the Assets Acquired",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c131",
      "name": "us-gaap:AssetAcquisitionConsiderationTransferredOtherAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c131",
      "name": "us-gaap:AssetAcquisitionConsiderationTransferredOtherAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofAssetsAcquiredTable",
     "longName": "996026 - Disclosure - Acquisitions (Details) - Schedule of Assets Acquired",
     "shortName": "Acquisitions (Details) - Schedule of Assets Acquired",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c132",
      "name": "onco:AssetAcquisitionConsiderationTransferredInventory",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c132",
      "name": "onco:AssetAcquisitionConsiderationTransferredInventory",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofFairValueoftheProteomedixStockOptionsTable",
     "longName": "996027 - Disclosure - Acquisitions (Details) - Schedule of Fair Value of the Proteomedix Stock Options",
     "shortName": "Acquisitions (Details) - Schedule of Fair Value of the Proteomedix Stock Options",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c133",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c133",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable",
     "longName": "996028 - Disclosure - Acquisitions (Details) - Schedule of Estimated Fair Values of Assets Acquired and Liabilities",
     "shortName": "Acquisitions (Details) - Schedule of Estimated Fair Values of Assets Acquired and Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c139",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c139",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofConsolidatedStatementsofOperationsandComprehensiveLossTable",
     "longName": "996029 - Disclosure - Acquisitions (Details) - Schedule of Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Acquisitions (Details) - Schedule of Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c140",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c140",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails",
     "longName": "996030 - Disclosure - Significant Agreements (Details)",
     "shortName": "Significant Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c337",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "onco:SignificantAgreementsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.bluewatervaccines.com/role/NotesPayableDetails",
     "longName": "996031 - Disclosure - Notes Payable (Details)",
     "shortName": "Notes Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "onco:PayableAverageDiscountRatePercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.bluewatervaccines.com/role/SubscriptionAgreementDetails",
     "longName": "996032 - Disclosure - Subscription Agreement (Details)",
     "shortName": "Subscription Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c188",
      "name": "onco:SaleOfUnits",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "onco:SubscriptionAgreementDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c188",
      "name": "onco:SaleOfUnits",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "onco:SubscriptionAgreementDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable",
     "longName": "996033 - Disclosure - Subscription Agreement (Details) - Schedule of Assumptions Used in Monte-Carlo Model, Which Utilizes Level 3 Inputs",
     "shortName": "Subscription Agreement (Details) - Schedule of Assumptions Used in Monte-Carlo Model, Which Utilizes Level 3 Inputs",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c192",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "onco:SubscriptionAgreementDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c192",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "onco:SubscriptionAgreementDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1",
     "longName": "996034 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 1",
     "shortName": "Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 1",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c63",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2",
     "longName": "996035 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 2",
     "shortName": "Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 2",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:PreferredStockConvertibleSharesIssuable",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "onco:PercentageOfIssuedOfCommonStock",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
     "longName": "996036 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3",
     "shortName": "Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c212",
      "name": "us-gaap:StockIssued1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c212",
      "name": "us-gaap:StockIssued1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
     "longName": "996037 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4",
     "shortName": "Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c260",
      "name": "onco:SharesOfCommonStockIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c260",
      "name": "onco:SharesOfCommonStockIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofFairValueofthePreferredInvestmentOptionsTable",
     "longName": "996038 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Fair Value of the Preferred Investment Options",
     "shortName": "Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Fair Value of the Preferred Investment Options",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c299",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c299",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofValuationoftheContingentWarrantLiabilityTable",
     "longName": "996039 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Valuation of the Contingent Warrant Liability",
     "shortName": "Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Valuation of the Contingent Warrant Liability",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c304",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c304",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable",
     "longName": "996040 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Outstanding Warrants, Excluding Contingent Warrants",
     "shortName": "Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Outstanding Warrants, Excluding Contingent Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c307",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c307",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable",
     "longName": "996041 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Stock Options",
     "shortName": "Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Stock Options",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c311",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c311",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofFairValueofOptionsGrantedTable",
     "longName": "996042 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Fair Value of Options Granted",
     "shortName": "Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Fair Value of Options Granted",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c66",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c66",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofUnvestedRestrictedStockTable",
     "longName": "996043 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Unvested Restricted Stock",
     "shortName": "Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Unvested Restricted Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofStockBasedCompensationExpenseTable",
     "longName": "996044 - Disclosure - Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Stock-Based Compensation Expense",
     "shortName": "Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Stock-Based Compensation Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails",
     "longName": "996045 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c323",
      "name": "us-gaap:ShortTermLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c323",
      "name": "us-gaap:ShortTermLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails",
     "longName": "996046 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PaymentsForFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "onco:SubscriptionAgreementPMXInvestorPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.bluewatervaccines.com/role/IncomeTaxesDetails",
     "longName": "996047 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofLossBeforeIncomeTaxTable",
     "longName": "996048 - Disclosure - Income Taxes (Details) - Schedule of Loss Before Income Tax",
     "shortName": "Income Taxes (Details) - Schedule of Loss Before Income Tax",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable",
     "longName": "996049 - Disclosure - Income Taxes (Details) - Schedule of Deferred Tax Assets and Liabilities",
     "shortName": "Income Taxes (Details) - Schedule of Deferred Tax Assets and Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable",
     "longName": "996050 - Disclosure - Income Taxes (Details) - Schedule of Income Taxes Differs from the Statutory Federal Rate",
     "shortName": "Income Taxes (Details) - Schedule of Income Taxes Differs from the Statutory Federal Rate",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofUnrecognizedTaxBenefitsTable",
     "longName": "996051 - Disclosure - Income Taxes (Details) - Schedule of Unrecognized Tax Benefits",
     "shortName": "Income Taxes (Details) - Schedule of Unrecognized Tax Benefits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.bluewatervaccines.com/role/RetirementPlansDetails",
     "longName": "996052 - Disclosure - Retirement Plans (Details)",
     "shortName": "Retirement Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c336",
      "name": "us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c336",
      "name": "us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable",
     "longName": "996053 - Disclosure - Retirement Plans (Details) - Schedule of Benefit Obligation and the Net Periodic Benefit Cost",
     "shortName": "Retirement Plans (Details) - Schedule of Benefit Obligation and the Net Periodic Benefit Cost",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofComponentsofNetPeriodicBenefitCostTable",
     "longName": "996054 - Disclosure - Retirement Plans (Details) - Schedule of Components of Net Periodic Benefit Cost",
     "shortName": "Retirement Plans (Details) - Schedule of Components of Net Periodic Benefit Cost",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c337",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c337",
      "name": "us-gaap:DefinedBenefitPlanInterestCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofAccumulatedComprehensiveLossTable",
     "longName": "996055 - Disclosure - Retirement Plans (Details) - Schedule of Accumulated Comprehensive Loss",
     "shortName": "Retirement Plans (Details) - Schedule of Accumulated Comprehensive Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofAccompanyingConsolidatedBalanceSheetTable",
     "longName": "996056 - Disclosure - Retirement Plans (Details) - Schedule of Accompanying Consolidated Balance Sheet",
     "shortName": "Retirement Plans (Details) - Schedule of Accompanying Consolidated Balance Sheet",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable",
     "longName": "996057 - Disclosure - Retirement Plans (Details) - Schedule of the Beginning and Ending Balances of the Accumulated Benefit Obligation",
     "shortName": "Retirement Plans (Details) - Schedule of the Beginning and Ending Balances of the Accumulated Benefit Obligation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c338",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c338",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable",
     "longName": "996058 - Disclosure - Retirement Plans (Details) - Schedule of Benefit Payments",
     "shortName": "Retirement Plans (Details) - Schedule of Benefit Payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.bluewatervaccines.com/role/SubsequentEventsDetails",
     "longName": "996059 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherAssetImpairmentCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c346",
      "name": "us-gaap:InterestPayableCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203788-01.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r976"
     ]
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r1130"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r848",
      "r918",
      "r981",
      "r1132"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361"
     ]
    },
    "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued franchise taxes",
        "label": "Accrual for Taxes Other than Income Taxes, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r105",
      "r937"
     ]
    },
    "onco_AccruedDeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AccruedDeferredOfferingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued deferred offering costs",
        "documentation": "Accrued deferred offering costs.",
        "label": "Accrued Deferred Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
      "http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedMarketingCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedMarketingCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued implementation fees",
        "label": "Accrued Marketing Costs, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional fees",
        "label": "Accrued Professional Fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "onco_AccruedResearchAndDevelopmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development",
        "documentation": "Accrued research and development",
        "label": "Accrued Research And Development Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedUtilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedUtilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Accrued Utilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for utilities, such as electrical power, heating oil, natural gas, and water."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "onco_AccumulatedAmortizationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AccumulatedAmortizationAbstract",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated amortization:",
        "label": "Accumulated Amortization Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "onco_AccumulatedBenefitObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AccumulatedBenefitObligationMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Benefit Obligation [Member]",
        "label": "Accumulated Benefit Obligation Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAccumulatedComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accumulated Comprehensive Loss [Abstract]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r678",
      "r680",
      "r681",
      "r682",
      "r683",
      "r685"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r166",
      "r274",
      "r775",
      "r794",
      "r795"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAccumulatedComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r678",
      "r680",
      "r681",
      "r682",
      "r683",
      "r685"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive Income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r23",
      "r54",
      "r657",
      "r660",
      "r695",
      "r790",
      "r791",
      "r1016",
      "r1017",
      "r1018",
      "r1029",
      "r1030",
      "r1031"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining amortization period",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions (Details) - Schedule of Estimated Fair Values of Assets Acquired and Liabilities [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions (Details) - Schedule of Estimated Fair Values of Assets Acquired and Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_AcquisitionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AcquisitionsDetailsTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_AcquisitionsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AcquisitionsPolicyTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions",
        "documentation": "Disclosure of policy of acquisitions.",
        "label": "Acquisitions Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in-capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r976",
      "r1137"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r602",
      "r603",
      "r809",
      "r1029",
      "r1030",
      "r1031",
      "r1109",
      "r1141"
     ]
    },
    "us-gaap_AdjustmentOfWarrantsGrantedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentOfWarrantsGrantedForServices",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of subscription agreement liability",
        "label": "Adjustment of Warrants Granted for Services",
        "documentation": "Adjustment for noncash service expenses paid for by granting of warrants."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction of additional paid in capital (in Dollars)",
        "label": "Adjustments to Additional Paid in Capital, Other",
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdministrativeFeesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdministrativeFeesExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total amount of fee expenses",
        "label": "Administrative Fees Expense",
        "documentation": "Amount of expense for administrative fee from service provided, including, but not limited to, salary, rent, or overhead cost."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r860",
      "r1140"
     ]
    },
    "onco_AggregateAgreementAmountInitialAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AggregateAgreementAmountInitialAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate agreement amount initial agreement",
        "documentation": "Amount of aggregate Agreement amount initial agreement.",
        "label": "Aggregate Agreement Amount Initial Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "onco_AggregateConsiderationTransferredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AggregateConsiderationTransferredMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Consideration Transferred [Member]",
        "label": "Aggregate Consideration Transferred Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_AggregateNetProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AggregateNetProceeds",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate net proceeds (in Dollars)",
        "documentation": "Aggregate net proceeds.",
        "label": "Aggregate Net Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "onco_AggregateNumberOfSharesPercenatge": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AggregateNumberOfSharesPercenatge",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate number of shares percentage",
        "documentation": "Percenatge of aggregate number of shares.",
        "label": "Aggregate Number Of Shares Percenatge"
       }
      }
     },
     "auth_ref": []
    },
    "onco_AggregatePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AggregatePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate payments",
        "documentation": "Aggregate payments.",
        "label": "Aggregate Payments"
       }
      }
     },
     "auth_ref": []
    },
    "onco_AggregatePurchaseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AggregatePurchaseShares",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate shares (in Shares)",
        "verboseLabel": "Purchase of common stock",
        "documentation": "Number of aggregate purchase shares.",
        "label": "Aggregate Purchase Shares"
       }
      }
     },
     "auth_ref": []
    },
    "onco_AggregateRoyaltiesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AggregateRoyaltiesAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate payments",
        "documentation": "Aggregate royalties amount.",
        "label": "Aggregate Royalties Amount"
       }
      }
     },
     "auth_ref": []
    },
    "onco_AggregateeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AggregateeAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate amount",
        "documentation": "Aggregate amount.",
        "label": "Aggregatee Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation expenses",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r599",
      "r609"
     ]
    },
    "onco_AlternativeInvestmentsRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AlternativeInvestmentsRate",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RetirementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alternative investments rate",
        "documentation": "Alternative investments rate.",
        "label": "Alternative Investments Rate"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Description",
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r133",
      "r177",
      "r462"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization",
        "terseLabel": "Amortization expense related to intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r73",
      "r77"
     ]
    },
    "onco_AmortizationOfNetGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AmortizationOfNetGain",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAccumulatedComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of net gain",
        "documentation": "Amortization of net gain.",
        "label": "Amortization Of Net Gain"
       }
      }
     },
     "auth_ref": []
    },
    "onco_AmountOfOtherPartyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AmountOfOtherPartyPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other party payments",
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Amount Of Other Party Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofComputationofDilutedSharesOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive securities",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofComputationofDilutedSharesOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofComputationofDilutedSharesOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofComputationofDilutedSharesOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "onco_April2022PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "April2022PrivatePlacementMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 2022 Private Placement [Member]",
        "label": "April2022 Private Placement Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_AprilContingentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AprilContingentWarrantsMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April Contingent Warrants [Member]",
        "label": "April Contingent Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable",
      "http://www.bluewatervaccines.com/role/ScheduleofAssetsAcquiredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.bluewatervaccines.com/role/ScheduleofAssetsAcquiredTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable",
      "http://www.bluewatervaccines.com/role/ScheduleofAssetsAcquiredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total fair value of identifiable assets acquired",
        "terseLabel": "Total consideration transferred",
        "label": "Asset Acquisition, Consideration Transferred",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r972",
      "r1106",
      "r1107",
      "r1108"
     ]
    },
    "onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AssetAcquisitionConsiderationTransferredENTADFIIntangible",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofAssetsAcquiredTable": {
       "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAssetsAcquiredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ENTADFI\u00ae Intangible",
        "documentation": "Amount of asset acquisition consideration transferred ENTADFI intangible.",
        "label": "Asset Acquisition Consideration Transferred ENTADFIIntangible"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable": {
       "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of notes payable issued",
        "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable",
        "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1106",
      "r1107",
      "r1108"
     ]
    },
    "onco_AssetAcquisitionConsiderationTransferredInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AssetAcquisitionConsiderationTransferredInventory",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofAssetsAcquiredTable": {
       "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAssetsAcquiredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "documentation": "Amount of asset acquisition, consideration transferred, inventory.",
        "label": "Asset Acquisition Consideration Transferred Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferredOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable": {
       "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration transferred at closing",
        "label": "Asset Acquisition, Consideration Transferred, Other Assets",
        "documentation": "Amount of tangible and intangible assets included as part of consideration transferred in asset acquisition, classified as other. Excludes cash."
       }
      }
     },
     "auth_ref": [
      "r1106",
      "r1107",
      "r1108"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable": {
       "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "label": "Asset Acquisition, Consideration Transferred, Transaction Cost",
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r972",
      "r1106",
      "r1107",
      "r1108"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionContingentConsiderationTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Contingent Consideration [Table]",
        "documentation": "Disclosure of information about contingent consideration in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionContingentConsiderationTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Aggregate Consideration Transferred for the Assets Acquired",
        "label": "Asset Acquisition, Contingent Consideration [Table Text Block]",
        "documentation": "Tabular disclosure of contingent consideration in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable",
      "http://www.bluewatervaccines.com/role/ScheduleofAssetsAcquiredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "us-gaap_AssetAcquisitionPriceOfAcquisitionExpected": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionPriceOfAcquisitionExpected",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proteomedix acquisition (in Francs)",
        "label": "Asset Acquisition, Price of Acquisition, Expected",
        "documentation": "Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "us-gaap_AssetAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAssetsAcquiredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Table]",
        "documentation": "Disclosure of information about asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "us-gaap_AssetAcquisitionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets Acquired",
        "label": "Asset Acquisition [Table Text Block]",
        "documentation": "Tabular disclosure of asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charge",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r78"
     ]
    },
    "onco_AssetPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AssetPurchaseAgreementMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Purchase Agreement [Member]",
        "label": "Asset Purchase Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "terseLabel": "Assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r269",
      "r301",
      "r336",
      "r350",
      "r354",
      "r398",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r650",
      "r654",
      "r671",
      "r768",
      "r853",
      "r976",
      "r988",
      "r1058",
      "r1059",
      "r1121"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r277",
      "r301",
      "r398",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r650",
      "r654",
      "r671",
      "r976",
      "r1058",
      "r1059",
      "r1121"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_AssetsRecognizedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AssetsRecognizedMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAssetsAcquiredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets Recognized\t[Member]",
        "label": "Assets Recognized Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assumptions Used in Monte-Carlo Model, Which Utilizes Level 3 Inputs [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r707",
      "r708",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718"
     ]
    },
    "onco_August2022PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "August2022PrivatePlacementMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "August 2022 Private Placement [Member]",
        "label": "August2022 Private Placement Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_August2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "August2024Member",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "August 2024 [Member]",
        "label": "August2024 Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_August2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "August2025Member",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "August 2025 [Member]",
        "label": "August2025 Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_AugustContingentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AugustContingentWarrantsMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "August Contingent Warrants [Member]",
        "label": "August Contingent Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_AugustWainwrightWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "AugustWainwrightWarrantsMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "August Wainwright Warrants [Member]",
        "label": "August Wainwright Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofthePreferredInvestmentOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r571",
      "r572",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598"
     ]
    },
    "onco_BalanceSheetDetailsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "BalanceSheetDetailsDetailsLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Details (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_BalanceSheetDetailsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "BalanceSheetDetailsDetailsTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Details (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_BankruptcyCourtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "BankruptcyCourtMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bankruptcy Court [Member]",
        "label": "Bankruptcy Court Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r963",
      "r966"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable",
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r114",
      "r646",
      "r963",
      "r966"
     ]
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration amount",
        "label": "Business Acquisition, Transaction Costs",
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionDescriptionOfAcquiredEntity",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business acquisition, description",
        "label": "Business Acquisition, Description of Acquired Entity",
        "documentation": "With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "onco_BusinessAcquisitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "BusinessAcquisitionMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Member]",
        "label": "Business Acquisition Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionProFormaInformationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionProFormaInformationDescription",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business acquisition, description",
        "label": "Business Acquisition, Pro Forma Information, Description",
        "documentation": "Description of the pro forma information, nature of adjustments made to historical information to arrive at pro forma amounts, amounts excluded from pro forma information, any material-nonrecurring items included in the pro forma information and limitations of pro forma disclosures."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofConsolidatedStatementsofOperationsandComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofConsolidatedStatementsofOperationsandComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r644",
      "r645"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofConsolidatedStatementsofOperationsandComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Business Acquisition, Pro Forma Revenue",
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period."
       }
      }
     },
     "auth_ref": [
      "r644",
      "r645"
     ]
    },
    "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less non-controlling interest",
        "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value",
        "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total consideration transferred",
        "verboseLabel": "Consideration transferred total",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r20"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B convertible preferred stock",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredOther1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferredOther1",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Business Combination, Consideration Transferred, Other",
        "documentation": "Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of the contingent warrant liability (in Dollars)",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r120",
      "r647"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "documentation": "Amount of assets acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating lease liability",
        "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation",
        "documentation": "Amount of lease obligation assumed in business combination."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts payable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accrued expenses",
        "documentation": "Amount of liabilities accrued expenses.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred tax liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade name",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "documentation": "The amount of inventory recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total liabilities assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116"
     ]
    },
    "onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Note payable",
        "documentation": "Amount of note payable.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Note Payable"
       }
      }
     },
     "auth_ref": []
    },
    "onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Pension benefit obligation",
        "documentation": "Amount of pension benefit obligation.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Pension Benefit Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product rights for developed technology",
        "documentation": "Amount of product rights for developed technology.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Product Rights For Developed Technology"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116"
     ]
    },
    "onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use asset",
        "documentation": "Right of use asset.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Rightof Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships",
        "documentation": "Amount of customer relationships.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Customer Relationships"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest",
        "documentation": "Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payment amount",
        "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Costs",
        "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofConsolidatedStatementsofOperationsandComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Separately Recognized Transactions [Axis]",
        "documentation": "Disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_BusinessTransactionYeare": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "BusinessTransactionYeare",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business transaction years",
        "documentation": "Business transaction yeare.",
        "label": "Business Transaction Yeare"
       }
      }
     },
     "auth_ref": []
    },
    "onco_CBOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "CBOMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CBO [Member]",
        "label": "CBOMember"
       }
      }
     },
     "auth_ref": []
    },
    "onco_CEOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "CEOMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CEO [Member]",
        "label": "CEOMember"
       }
      }
     },
     "auth_ref": []
    },
    "country_CH": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CH",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofLonglivedbyGeographicalAreaTable",
      "http://www.bluewatervaccines.com/role/ScheduleofRevenuebyGeographicalAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Switzerland [Member]",
        "verboseLabel": "Zurich Switzerland [Member]",
        "label": "SWITZERLAND"
       }
      }
     },
     "auth_ref": []
    },
    "onco_CancelledPreferredInvestmentOptionsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "CancelledPreferredInvestmentOptionsShares",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled preferred investment options",
        "documentation": "Number of shares (or other type of equity) cancelled during the period.",
        "label": "Cancelled Preferred Investment Options Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
      "http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r771",
      "r820",
      "r846",
      "r976",
      "r988",
      "r1006"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, beginning of period",
        "periodEndLabel": "Cash, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r181",
      "r296"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r181"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash target amount",
        "label": "Cash, FDIC Insured Amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "onco_CashPaymentToTheSeller": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "CashPaymentToTheSeller",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payment to the seller",
        "documentation": "The payment to the seller in the form of cash.",
        "label": "Cash Payment To The Seller"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ChangeInFairValueOfSubscriptionAgreementLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ChangeInFairValueOfSubscriptionAgreementLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of subscription agreement liability",
        "documentation": "Change in fair value of subscription agreement liability.",
        "label": "Change In Fair Value Of Subscription Agreement Liability"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ChangeInPensionBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ChangeInPensionBenefitObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in pension benefit obligation",
        "documentation": "Change in pension benefit obligation,",
        "label": "Change In Pension Benefit Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ChiefBusinessOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ChiefBusinessOfficerMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CBO\u2019s [Member]",
        "label": "Chief Business Officer Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Officer [Member]",
        "label": "Chief Executive Officer [Member]",
        "documentation": "Person with designation of chief executive officer."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Financial Officer [Member]",
        "label": "Chief Financial Officer [Member]",
        "documentation": "Person with designation of chief financial officer."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "onco_CincinnatiChildrensHospitalMedicalCenterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "CincinnatiChildrensHospitalMedicalCenterMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CHMC Agreement [Member]",
        "label": "Cincinnati Childrens Hospital Medical Center Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2",
      "http://www.bluewatervaccines.com/role/NotesPayableDetails",
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3",
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r270",
      "r271",
      "r272",
      "r301",
      "r324",
      "r325",
      "r327",
      "r329",
      "r334",
      "r335",
      "r398",
      "r431",
      "r433",
      "r434",
      "r435",
      "r438",
      "r439",
      "r470",
      "r471",
      "r474",
      "r477",
      "r486",
      "r671",
      "r798",
      "r799",
      "r800",
      "r801",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r821",
      "r838",
      "r862",
      "r885",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r991",
      "r1024",
      "r1033"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price per share (in Dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Outstanding Warrants, Excluding Contingent Warrants [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issuable",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants shares",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding warrants",
        "verboseLabel": "Cancellation of warrants issued (in Shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Outstanding Warrants, Excluding Contingent Warrants [Table]",
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightUnissued",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase",
        "label": "Class of Warrant or Right, Unissued",
        "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "onco_CoDevelopmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "CoDevelopmentAgreementMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Co Development Agreement [Member]",
        "label": "Co Development Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Agreements",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Basis of Presentation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_CommercialAndIndustrialSectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialAndIndustrialSectorMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial milestones [Member]",
        "label": "Commercial and Industrial Sector [Member]",
        "documentation": "Sector of the economy consisting of companies engaged in commercial and industrial business activities."
       }
      }
     },
     "auth_ref": [
      "r947",
      "r1143",
      "r1144",
      "r1145",
      "r1146"
     ]
    },
    "onco_CommercialSaleTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "CommercialSaleTerm",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial sale term",
        "documentation": "Commercial sale term.",
        "label": "Commercial Sale Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies (see Note 10)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r143",
      "r770",
      "r837"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r424",
      "r425",
      "r919",
      "r1056"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r920"
     ]
    },
    "onco_CommitmentsandContingenciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "CommitmentsandContingenciesDetailsTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock reserved for issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "onco_CommonStockIssuableUponConversionOfSeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "CommonStockIssuableUponConversionOfSeriesAPreferredStockMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofComputationofDilutedSharesOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issuable upon conversion of Series A preferred stock [Member]",
        "label": "Common Stock Issuable Upon Conversion Of Series APreferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3",
      "http://www.bluewatervaccines.com/role/SubscriptionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r978",
      "r979",
      "r980",
      "r982",
      "r983",
      "r984",
      "r985",
      "r1029",
      "r1030",
      "r1109",
      "r1134",
      "r1141"
     ]
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockOtherSharesOutstanding",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock outstanding",
        "label": "Common Stock, Other Shares, Outstanding",
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "verboseLabel": "Par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r838"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Number of shares of common stock issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r156",
      "r838",
      "r859",
      "r1141",
      "r1142"
     ]
    },
    "us-gaap_CommonStockSharesSubscribedButUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesSubscribedButUnissued",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares unissued",
        "label": "Common Stock, Shares Subscribed but Unissued",
        "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.00001 par value, 250,000,000 shares authorized at December 31, 2023 and 2022; 22,841,975 and 15,724,957 shares issued at December 31, 2023 and 2022, respectively; 22,324,576 and 15,265,228 shares outstanding at December 31, 2023 and 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r773",
      "r976"
     ]
    },
    "us-gaap_CommonUnitIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonUnitIssued",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued shares",
        "label": "Common Unit, Issued",
        "documentation": "Number of common units issued of limited liability company (LLC)."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss attributable to common stockholders",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r281",
      "r283",
      "r291",
      "r763",
      "r786"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r237"
     ]
    },
    "srt_CondensedFinancialStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedFinancialStatementsCaptionsLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Statements, Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r258",
      "r259",
      "r260",
      "r306",
      "r993"
     ]
    },
    "srt_CondensedIncomeStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedIncomeStatementTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofConsolidatedStatementsofOperationsandComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Income Statement [Table]",
        "documentation": "Disclosure of information about condensed income statement including, but not limited to, income statements of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r306",
      "r993"
     ]
    },
    "onco_ContingentWarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ContingentWarrantLiabilityMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofActivityfortheContingentWarrantLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Warrant Liability [Member]",
        "label": "Contingent Warrant Liability Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ContingentWarrantLiabilityShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ContingentWarrantLiabilityShares",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent warrant liability shares (in Dollars)",
        "documentation": "Shares of contingent warrant liability.",
        "label": "Contingent Warrant Liability Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockAmountIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of note payable through issuance of Series A convertible preferred stock",
        "label": "Conversion of Stock, Amount Issued",
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued shares of common stock",
        "label": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April Contingent Warrants issue",
        "label": "Conversion of Stock, Shares Issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options vested",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r86",
      "r155",
      "r200",
      "r481"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock shares (in Shares)",
        "label": "Convertible Preferred Stock, Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of nonredeemable convertible preferred shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 1 [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1Table": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1Table",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 1 [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 2 [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2Table": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2Table",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 2 [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3 [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3Table",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3 [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4Table",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of Options Granted [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of Options Granted [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Options [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Options [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofUnvestedRestrictedStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unvested Restricted Stock [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofUnvestedRestrictedStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unvested Restricted Stock [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofValuationoftheContingentWarrantLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Valuation of the Contingent Warrant Liability [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofValuationoftheContingentWarrantLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Valuation of the Contingent Warrant Liability [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_CostBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "CostBasisAbstract",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost basis:",
        "label": "Cost Basis Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostMaintenance",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual maintenance fee",
        "label": "Cost, Maintenance",
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered."
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "us-gaap_CostOfPropertyRepairsAndMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfPropertyRepairsAndMaintenance",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maintenance fee",
        "label": "Cost of Property Repairs and Maintenance",
        "documentation": "The aggregate costs of keeping the property in good condition but that do not appreciably prolong the life or increase the value of the property."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r301",
      "r398",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r671",
      "r1058"
     ]
    },
    "onco_CostPlusPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "CostPlusPercentage",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost plus, percentage",
        "documentation": "Cost plus, percentage.",
        "label": "Cost Plus Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CumulativeDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CumulativeDividends",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative dividends (in Dollars)",
        "label": "Cumulative Dividends",
        "documentation": "Amount of cumulative cash dividends distributed to shareholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships [Member]",
        "verboseLabel": "Customer Relationships [Member]",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Series Seed Preferred Stock to common stock upon initial public offering",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r64"
     ]
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionOriginalDebtAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of debt",
        "label": "Debt Conversion, Original Debt, Amount",
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r64"
     ]
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes Payable",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r298",
      "r440",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r456",
      "r463",
      "r464",
      "r466"
     ]
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails",
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails",
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal payment",
        "verboseLabel": "Principal amount",
        "label": "Debt Instrument, Annual Principal Payment",
        "documentation": "Amount of the total principal payments made during the annual reporting period."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/NotesPayableDetails",
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails",
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails",
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r148",
      "r149",
      "r217",
      "r220",
      "r306",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r688",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r1025"
     ]
    },
    "onco_DebtInstrumentDueDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "DebtInstrumentDueDate",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note payable originally due",
        "documentation": "Debt Instrument due date.",
        "label": "Debt Instrument Due Date"
       }
      }
     },
     "auth_ref": []
    },
    "onco_DebtInstrumentDueTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "DebtInstrumentDueTerm",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal payments due",
        "documentation": "Debt instrument due term.",
        "label": "Debt Instrument Due Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amounts",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r136",
      "r441",
      "r688",
      "r953",
      "r954"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-related services fee",
        "label": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/NotesPayableDetails",
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated using discount percentage",
        "verboseLabel": "Accrue interest rate",
        "netLabel": "Debenture interest rate percentage",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r134",
      "r467",
      "r688"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r465",
      "r688",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r1025"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity date",
        "label": "Debt Instrument, Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r952",
      "r1111"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/NotesPayableDetails",
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails",
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails",
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r306",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r688",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r1025"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized debt discount",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r136",
      "r1061"
     ]
    },
    "onco_DebtSecuritiesAndCash": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "DebtSecuritiesAndCash",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RetirementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities and cash rate",
        "documentation": "Debt securities and cash.",
        "label": "Debt Securities And Cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Offering Costs",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_DeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred offering costs",
        "label": "Deferred Costs, Noncurrent",
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r1007"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal income tax",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1027",
      "r1102",
      "r1103"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign income tax",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r1027",
      "r1102"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax benefit",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r208",
      "r243",
      "r638",
      "r639",
      "r1027"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r218",
      "r628"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liability, net",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r618",
      "r769"
     ]
    },
    "onco_DeferredOfferingCostsPreviouslyPrepaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "DeferredOfferingCostsPreviouslyPrepaid",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred offering costs previously included in prepaid expenses",
        "documentation": "Amount of deferred offering costs previously prepaid.",
        "label": "Deferred Offering Costs Previously Prepaid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income tax",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1027",
      "r1102",
      "r1103"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangibles",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, net of allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net-operating loss carryforward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1101"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposit on WraSer APA",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1101"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r1101"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1101"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1101"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued expenses",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1101"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net deferred tax liability",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r1100"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangible assets",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1101"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1101"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fixed assets",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1101"
     ]
    },
    "us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPensionPlanLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.bluewatervaccines.com/role/ScheduleofAccompanyingConsolidatedBalanceSheetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
      "http://www.bluewatervaccines.com/role/ScheduleofAccompanyingConsolidatedBalanceSheetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Overfunded (underfunded) status",
        "terseLabel": "Pension benefit obligation",
        "label": "benefit cost",
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r150",
      "r202"
     ]
    },
    "us-gaap_DefinedBenefitPlanAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Pension Plan",
        "label": "Defined Benefit Plan, Plan Assets, Accounting Policy Election, Measurement Date [Policy Text Block]",
        "documentation": "Disclosure of accounting policy election to measure plan assets and benefit obligations as of the month-end that is closest to the fiscal year-end."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actual return on plan assets",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r961"
     ]
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial (gain) loss",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofComponentsofNetPeriodicBenefitCostTable": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofComponentsofNetPeriodicBenefitCostTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of net (gain)/loss",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r530",
      "r554",
      "r961",
      "r962"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rate of compensation increase",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected long-term rate of return on plan assets",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate",
        "documentation": "Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanBenefitObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Defined Benefit Plan, Benefit Obligation Begining Balance",
        "periodEndLabel": "Defined Benefit Plan, Benefit Obligation Ending Balance",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Benefits paid",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r562"
     ]
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions paid by plan participants",
        "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant",
        "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "onco_DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary contributions paid by employees",
        "documentation": "Ordinary contributions paid by employees.",
        "label": "Defined Benefit Plan Benefit Obligation Ordinary Contributions Paid By Employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanBenefitObligationPaymentForSettlement",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlements",
        "label": "Defined Benefit Plan, Benefit Obligation, Payment for Settlement",
        "documentation": "Amount of payment, which decreases benefit obligation of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract. Excludes decreases to benefit obligation for remeasurement due to settlement."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial (gain)/loss due to plan experience",
        "label": "Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions paid by employer",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r517",
      "r558",
      "r959",
      "r960",
      "r961",
      "r962"
     ]
    },
    "us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Benefit Payments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable": {
       "parentTag": "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable": {
       "parentTag": "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable": {
       "parentTag": "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable": {
       "parentTag": "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable": {
       "parentTag": "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable": {
       "parentTag": "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofComponentsofNetPeriodicBenefitCostTable": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofComponentsofNetPeriodicBenefitCostTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expected return on plan assets",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r529",
      "r553",
      "r961",
      "r962"
     ]
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Defined Benefit Plan, Plan Assets Begining Balance",
        "periodEndLabel": "Defined Benefit Plan, Plan Assets Ending Balance",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r515",
      "r517",
      "r518",
      "r959",
      "r960",
      "r961"
     ]
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanInterestCost",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofComponentsofNetPeriodicBenefitCostTable": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofComponentsofNetPeriodicBenefitCostTable",
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest cost",
        "label": "Defined Benefit Plan, Interest Cost",
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r496",
      "r528",
      "r552",
      "r961",
      "r962"
     ]
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofComponentsofNetPeriodicBenefitCostTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofComponentsofNetPeriodicBenefitCostTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r550",
      "r961",
      "r962"
     ]
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RetirementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes components of net periodic benefit cost (credit), excluding service cost component, for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r550"
     ]
    },
    "us-gaap_DefinedBenefitPlanOtherChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanOtherChanges",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial (gain)/loss due to assumption changes",
        "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change",
        "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofAccompanyingConsolidatedBalanceSheetTable": {
       "parentTag": "us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAccompanyingConsolidatedBalanceSheetTable",
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Projected benefit obligation",
        "verboseLabel": "Projected benefit obligation as of December 31, 2023",
        "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation",
        "documentation": "Amount of projected benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r961"
     ]
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accompanying Consolidated Balance Sheet [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofAccompanyingConsolidatedBalanceSheetTable": {
       "parentTag": "us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAccompanyingConsolidatedBalanceSheetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of plan assets",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r549",
      "r961"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Benefits paid",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r1069"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions paid by plan participants",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant",
        "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "onco_DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary contributions paid by employees",
        "documentation": "Ordinary contributions paid by employees.",
        "label": "Defined Benefit Plan Plan Assets Ordinary Contributions Paid By Employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofComponentsofNetPeriodicBenefitCostTable": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofComponentsofNetPeriodicBenefitCostTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlements (gain)/loss",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment",
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1067",
      "r1068"
     ]
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanServiceCost",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofComponentsofNetPeriodicBenefitCostTable": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofComponentsofNetPeriodicBenefitCostTable",
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable",
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service cost",
        "verboseLabel": "Services payments",
        "label": "Defined Benefit Plan, Service Cost",
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r527",
      "r551",
      "r961",
      "r962"
     ]
    },
    "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanSettlementsPlanAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlements",
        "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement",
        "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RetirementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permits voluntary contributions",
        "label": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage",
        "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Deposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Deposits",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment as deposit",
        "label": "Deposits",
        "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r79"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r340"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueoftheProteomedixStockOptionsTable",
      "http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r127",
      "r827",
      "r829",
      "r843",
      "r844",
      "r845",
      "r849",
      "r850",
      "r851",
      "r852",
      "r854",
      "r855",
      "r856",
      "r857",
      "r873",
      "r874",
      "r875",
      "r876",
      "r879",
      "r880",
      "r881",
      "r882",
      "r903",
      "r904",
      "r905",
      "r906",
      "r938",
      "r978",
      "r980"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent warrant liability",
        "label": "Derivative Liability, Current",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueoftheProteomedixStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of measurement input",
        "verboseLabel": "Significant assumptions",
        "netLabel": "Aggregate equity value measurement input",
        "label": "Derivative Liability, Measurement Input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product rights for developed technology [Member]",
        "verboseLabel": "Product Rights Intangible Asset [Member]",
        "netLabel": "Product Rights Developed Technology [Member]",
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_DevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DevelopmentCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development milestones costs",
        "label": "Development Costs, Period Cost",
        "documentation": "The capitalized costs incurred during the period (excluded from amortization) to obtain access to proved reserves and to provide facilities for extracting, treating, gathering and storing the oil and gas."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "onco_DevelopmentMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "DevelopmentMilestonesMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development milestone [Member]",
        "label": "Development Milestones Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Directors [Member]",
        "verboseLabel": "Director [Member]",
        "label": "Director [Member]",
        "documentation": "Person serving on board of directors."
       }
      }
     },
     "auth_ref": [
      "r1035",
      "r1136"
     ]
    },
    "us-gaap_DisclosureTextBlockSupplementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureTextBlockSupplementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block Supplement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPaidinkind": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPaidinkind",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Approximately amount paid",
        "label": "Dividends, Paid-in-kind",
        "documentation": "Amount of paid and unpaid paid-in-kind dividends (PIK) declared for classes of stock, for example, but not limited to, common and preferred."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r201"
     ]
    },
    "us-gaap_DividendsPayableAmountPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPayableAmountPerShare",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends per share (in Dollars per share)",
        "label": "Dividends Payable, Amount Per Share",
        "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "onco_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "onco_ENTADFIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ENTADFIMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails",
      "http://www.bluewatervaccines.com/role/NotesPayableDetails",
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ENTADFI [Member]",
        "label": "ENTADFIMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to common stockholders, basic (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r321",
      "r324",
      "r327",
      "r328",
      "r329",
      "r331",
      "r665",
      "r666",
      "r764",
      "r787",
      "r942"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to common stockholders, diluted",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r324",
      "r327",
      "r328",
      "r329",
      "r331",
      "r665",
      "r666",
      "r764",
      "r787",
      "r942"
     ]
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Computation of Diluted Shares Outstanding [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66"
     ]
    },
    "onco_EffectOfBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "EffectOfBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of business combination (Note 5)",
        "documentation": "Effect of business combination.",
        "label": "Effect Of Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "onco_EffectOfSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "EffectOfSettlement",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAccumulatedComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of settlement",
        "documentation": "Effect of settlement.",
        "label": "Effect Of Settlement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.bluewatervaccines.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax percentage",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State rate adjustment",
        "documentation": "Amount of state rate adjustment.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense State Rate Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal",
     "presentation": [
      "http://www.bluewatervaccines.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxable income",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, State and Local, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax settlement."
       }
      }
     },
     "auth_ref": [
      "r1097",
      "r1104"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock-Based Compensation Expense [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized stock based compensation (in Dollars)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized stock based compensation expense (in Dollars)",
        "label": "Employee Stock Ownership Plan (ESOP), Compensation Expense",
        "documentation": "The amount of plan compensation cost recognized during the period."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofRevenuebyGeographicalAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Major Customer [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Redeemable Preferred Stock and Stockholders [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r261",
      "r285",
      "r286",
      "r287",
      "r307",
      "r308",
      "r309",
      "r311",
      "r317",
      "r319",
      "r333",
      "r399",
      "r400",
      "r488",
      "r601",
      "r602",
      "r603",
      "r634",
      "r635",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r664",
      "r678",
      "r680",
      "r681",
      "r682",
      "r683",
      "r685",
      "r695",
      "r790",
      "r791",
      "r792",
      "r809",
      "r885"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r396",
      "r397"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interest ownership percentage",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_EquitySecuritiesByIndustryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesByIndustryAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Industry Sector [Axis]",
        "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r826",
      "r894",
      "r898",
      "r902",
      "r909",
      "r947",
      "r980"
     ]
    },
    "us-gaap_EquitySecuritiesIndustryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesIndustryMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Industry Sector [Domain]",
        "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r826",
      "r894",
      "r898",
      "r902",
      "r909",
      "r980"
     ]
    },
    "onco_EquitySecuritiesRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "EquitySecuritiesRate",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RetirementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities rate",
        "documentation": "Equity securities rate.",
        "label": "Equity Securities Rate"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ExchangedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ExchangedMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofthePreferredInvestmentOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchanged [Member]",
        "label": "Exchanged Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ExerciseOfPrefundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ExerciseOfPrefundedWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of pre-funded warrants",
        "documentation": "Amount of exercise of pre-funded warrants.",
        "label": "Exercise Of Prefunded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ExerciseOfPrefundedWarrantsinShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ExerciseOfPrefundedWarrantsinShares",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of pre-funded warrants (in Shares)",
        "documentation": "Exercise of pre-funded warrants.",
        "label": "Exercise Of Prefunded Warrantsin Shares"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ExercisePrice",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "options granted exercise price (in Dollars per share)",
        "documentation": "Exercise price per share.",
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "onco_Exerciseofprefundedwarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "Exerciseofprefundedwarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of pre-funded warrants",
        "documentation": "Exercise of pre funded warrants.",
        "label": "Exerciseofprefundedwarrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of subscription agreement liability",
        "verboseLabel": "Warrant liability (in Dollars)",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r16"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueoftheProteomedixStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueoftheProteomedixStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of the Proteomedix Stock Options",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofActivityfortheContingentWarrantLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofActivityfortheContingentWarrantLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r130"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Activity for the Contingent Warrant Liability",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r130"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r668",
      "r710",
      "r711",
      "r712",
      "r953",
      "r954",
      "r959",
      "r960",
      "r961"
     ]
    },
    "onco_FairValueConsiderationTransferredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "FairValueConsiderationTransferredMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofAggregateConsiderationTransferredfortheAssetsAcquiredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Consideration Transferred [Member]",
        "label": "Fair Value Consideration Transferred Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r517",
      "r522",
      "r668",
      "r710",
      "r959",
      "r960",
      "r961"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r517",
      "r522",
      "r668",
      "r711",
      "r953",
      "r954",
      "r959",
      "r960",
      "r961"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "verboseLabel": "Level 3 Inputs [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r668",
      "r712",
      "r953",
      "r954",
      "r959",
      "r960",
      "r961"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofActivityfortheSubscriptionAgreementLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofActivityfortheSubscriptionAgreementLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r130"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Activity for the Subscription Agreement Liability",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r130"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofActivityfortheSubscriptionAgreementLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value upon issuance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Issuances",
        "documentation": "Amount of issuances of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofActivityfortheSubscriptionAgreementLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofActivityfortheSubscriptionAgreementLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning",
        "periodEndLabel": "Balance at ending",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r710",
      "r711",
      "r712",
      "r953",
      "r954",
      "r959",
      "r960",
      "r961"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofActivityfortheContingentWarrantLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value at issuance",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues",
        "documentation": "Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r129"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofActivityfortheContingentWarrantLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r30"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofActivityfortheContingentWarrantLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning",
        "periodEndLabel": "Balance at ending",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs",
        "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r128"
     ]
    },
    "us-gaap_FairValueOfAssetsAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfAssetsAcquired",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental fair value of exchanged preferred investment options",
        "verboseLabel": "Fair value",
        "label": "Fair Value of Assets Acquired",
        "documentation": "The fair value of assets acquired in noncash investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r33"
     ]
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of contingent warrant liability",
        "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)",
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOptionQuantitativeDisclosuresLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofthePreferredInvestmentOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of the Preferred Investment Options [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r674"
     ]
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOptionQuantitativeDisclosuresTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofthePreferredInvestmentOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Option, Disclosures [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value under fair value option."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r674"
     ]
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOptionQuantitativeDisclosuresTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of the Preferred Investment Options",
        "label": "Fair Value Option, Disclosures [Table Text Block]",
        "documentation": "Tabular disclosure of information about asset and liability measured at fair value under fair value option."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r1112",
      "r1114",
      "r1115"
     ]
    },
    "us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal NOL and state NOLs",
        "label": "Federal, State, and Local, Income Tax Expense (Benefit), Continuing Operations",
        "documentation": "Amount of current and deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1103"
     ]
    },
    "us-gaap_FeeIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FeeIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails",
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option fee",
        "verboseLabel": "Cash fee",
        "label": "Fee Income",
        "documentation": "Amount of fee income including, but not limited to, managerial assistance, servicing of investment, and origination and commitment fees."
       }
      }
     },
     "auth_ref": [
      "r1139"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofActivityfortheContingentWarrantLiabilityTable",
      "http://www.bluewatervaccines.com/role/ScheduleofActivityfortheSubscriptionAgreementLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r465",
      "r484",
      "r662",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r785",
      "r948",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1036",
      "r1037",
      "r1038",
      "r1039"
     ]
    },
    "onco_FiniteLivedIntangibleAssetCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "FiniteLivedIntangibleAssetCost",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost",
        "documentation": "Represents the amount of finite lived intangible assets cost.",
        "label": "Finite Lived Intangible Asset Cost"
       }
      }
     },
     "auth_ref": []
    },
    "onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of Currency Translation",
        "documentation": "Represents the amount of effect of currency translation.",
        "label": "Finite Lived Intangible Assets Accumulated Amortization Effect Of Currency Translation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable",
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r419",
      "r420",
      "r421",
      "r746",
      "r747"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of Currency Translation",
        "label": "Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Annual Amortization Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, gross",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r747"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable",
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r76"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAnnualAmortizationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r746"
     ]
    },
    "onco_FixedCommissionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "FixedCommissionRate",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed commission rate",
        "documentation": "Percentage of fixed commission.",
        "label": "Fixed Commission Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "onco_GainLossOnRelatedPartyReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "GainLossOnRelatedPartyReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on related party receivable",
        "documentation": "Amount of gain (loss) on related party receivable.",
        "label": "Gain Loss On Related Party Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on impairment of other long-lived assets",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value."
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow",
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement",
      "http://www.bluewatervaccines.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on extinguishment of note payable",
        "negatedLabel": "Loss on extinguishment of note payable",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r81",
      "r82"
     ]
    },
    "onco_GoingConcernAndManagementsPlansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "GoingConcernAndManagementsPlansAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern and Management\u2019s Plans [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_GoingConcernandManagementsPlansDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "GoingConcernandManagementsPlansDetailsLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern and Management\u2019s Plans [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_GoingConcernandManagementsPlansDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "GoingConcernandManagementsPlansDetailsTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern and Management\u2019s Plans (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
      "http://www.bluewatervaccines.com/role/ScheduleofGoodwillTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Goodwill Beginning Balance",
        "periodEndLabel": "Goodwill Ending Balance",
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r413",
      "r761",
      "r951",
      "r976",
      "r1043",
      "r1050"
     ]
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofGoodwillTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of currency translation",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r414",
      "r415",
      "r417",
      "r951"
     ]
    },
    "us-gaap_GoodwillTransfers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillTransfers",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofGoodwillTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PMX Transaction goodwill",
        "label": "Goodwill, Transfers",
        "documentation": "Amount of transfers into (out of) an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "onco_GrantDateFairValueOfStockOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "GrantDateFairValueOfStockOption",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant date fair value of stock option (in Dollars)",
        "documentation": "Grant date fair value of stock option.",
        "label": "Grant Date Fair Value Of Stock Option"
       }
      }
     },
     "auth_ref": []
    },
    "onco_GrossPayPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "GrossPayPercentage",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RetirementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of gross pay",
        "documentation": "The percentage of gross pay.",
        "label": "Gross Pay Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross loss",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r301",
      "r336",
      "r349",
      "r353",
      "r355",
      "r398",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r671",
      "r944",
      "r1058"
     ]
    },
    "onco_HCWainwrightCoLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "HCWainwrightCoLLCMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "H.C. Wainwright &amp; Co., LLC [Member]",
        "label": "HCWainwright Co LLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2",
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO [Member]",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "onco_ImpairmentOfIntangibleAssetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ImpairmentOfIntangibleAssetExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment Of Intangible Asset Excluding Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of ENTADFI assets",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r31"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of ENTADFI assets",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r1023",
      "r1053"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss of long lived assets",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r193"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r195"
     ]
    },
    "onco_ImpairmentRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ImpairmentRate",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment rate",
        "documentation": "Impairment rate.",
        "label": "Impairment Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r287"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofLossBeforeIncomeTaxTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofLossBeforeIncomeTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r640"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofLossBeforeIncomeTaxTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofLossBeforeIncomeTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r168",
      "r223",
      "r336",
      "r349",
      "r353",
      "r355",
      "r765",
      "r782",
      "r944"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofLossBeforeIncomeTaxTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofLossBeforeIncomeTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r640"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Loss Before Income Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/IncomeTaxesDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r423",
      "r869"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/IncomeTaxesDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r869"
     ]
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r613",
      "r621",
      "r625",
      "r632",
      "r636",
      "r641",
      "r642",
      "r643",
      "r803"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement",
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax benefit",
        "negatedLabel": "Income tax benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r244",
      "r318",
      "r319",
      "r341",
      "r619",
      "r637",
      "r788"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income Taxes Differs from the Statutory Federal Rate [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r615",
      "r616",
      "r625",
      "r626",
      "r631",
      "r633",
      "r797"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/IncomeTaxesDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign NOL expirations",
        "verboseLabel": "Foreign NOLs",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected income tax benefit at Federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liability",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under derivative liability.",
        "label": "Income Tax Reconciliation Nondeductible Expense Derivative Liability"
       }
      }
     },
     "auth_ref": []
    },
    "onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Officer\u2019s compensation",
        "documentation": "Officer\u2019s compensation.",
        "label": "Income Tax Reconciliation Nondeductible Expense Officers Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition related costs",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent items",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/IncomeTaxesDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and local taxes, net of Federal tax benefit",
        "verboseLabel": "State NOLs",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofIncomeTaxesDiffersfromtheStatutoryFederalRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "onco_IncomeTaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "IncomeTaxesDetailsTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaidNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other noncurrent assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "onco_IncreaseInTheFairValueOfThePreferredInvestmentOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "IncreaseInTheFairValueOfThePreferredInvestmentOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in fair value of the preferred investment options (in Dollars)",
        "documentation": "The increase (decrease) during the period in the carrying value of fair value of the preferred investment options.",
        "label": "Increase In The Fair Value Of The Preferred Investment Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedTradeNames": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedTradeNames",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite life intangible assets",
        "label": "Indefinite-Lived Trade Names",
        "documentation": "Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trade name to gain or protect exclusive use thereof for a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "onco_InducementPIOSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "InducementPIOSharesMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inducement PIO Shares [Member]",
        "label": "Inducement PIOShares Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_InitialPaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "InitialPaymentAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial payment amount",
        "documentation": "The amount of initial payment amount.",
        "label": "Initial Payment Amount"
       }
      }
     },
     "auth_ref": []
    },
    "onco_InitialPublicOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "InitialPublicOfferingShares",
     "presentation": [
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock (in Shares)",
        "documentation": "Number of shares issued initial public offering of shares.",
        "label": "Initial Public Offering Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Other Intangible Assets",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r742",
      "r743",
      "r744",
      "r746",
      "r939"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
      "http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r75"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r224",
      "r288",
      "r339",
      "r687",
      "r870",
      "r986",
      "r1138"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r460",
      "r468",
      "r955",
      "r956"
     ]
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription amount of interest payable",
        "label": "Interest Payable",
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r1130"
     ]
    },
    "onco_InventoryFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "InventoryFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory fair value",
        "documentation": "The amount of inventory fair value.",
        "label": "Inventory Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofInventoriesTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofInventoriesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.bluewatervaccines.com/role/ScheduleofInventoriesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
      "http://www.bluewatervaccines.com/role/ScheduleofInventoriesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Inventories",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r934",
      "r976"
     ]
    },
    "us-gaap_InventoryNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventories [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r266",
      "r275",
      "r409",
      "r410",
      "r412",
      "r741",
      "r940"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofInventoriesTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofInventoriesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory reserve",
        "label": "Inventory Valuation Reserves",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r1013"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofInventoriesTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofInventoriesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work-in-process",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of inventory",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_InvestmentOwnedAtCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentOwnedAtCost",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related cost",
        "label": "Investment Owned, Cost",
        "documentation": "Cost of the investment."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r824",
      "r825",
      "r895",
      "r896",
      "r901",
      "r908",
      "r980",
      "r988",
      "r1135"
     ]
    },
    "onco_IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and warrants in April private placement, net",
        "documentation": "Issuance of common stock and warrants in April private placement, net.",
        "label": "Issuance Of Common Stock And Warrants In April Private Placement Net"
       }
      }
     },
     "auth_ref": []
    },
    "onco_IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and warrants in August private placement, net",
        "documentation": "Issuance of common stock and warrants in private placement, net.",
        "label": "Issuance Of Common Stock And Warrants In Private Placement Net"
       }
      }
     },
     "auth_ref": []
    },
    "onco_IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock from exercise of preferred investment options",
        "documentation": "Issuance of common stock from exercise of preferred investment options.",
        "label": "Issuance Of Common Stock From Exercise Of Preferred Investment Options"
       }
      }
     },
     "auth_ref": []
    },
    "onco_IssuanceOfCommonStockInInitialPublicOfferingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "IssuanceOfCommonStockInInitialPublicOfferingNet",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in initial public offering, net",
        "documentation": "Issuance of common stock in initial public offering, net.",
        "label": "Issuance Of Common Stock In Initial Public Offering Net"
       }
      }
     },
     "auth_ref": []
    },
    "onco_IssuanceOfRestrictedStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "IssuanceOfRestrictedStock",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of restricted stock",
        "documentation": "The number of shares issued in Issuance of restricted stock\r  \n exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Issuance Of Restricted Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of restricted common stock",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "onco_January2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "January2024Member",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 2024 [Member]",
        "label": "January2024 Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related expense",
        "label": "Labor and Related Expense",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "onco_LaboratorCorporationOfAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "LaboratorCorporationOfAmericaMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laborator Corporation of America [Member]",
        "label": "Laborator Corporation Of America Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases office rate",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r693",
      "r975"
     ]
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fees and expenses of legal (in Dollars)",
        "verboseLabel": "Legal expense",
        "label": "Legal Fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r301",
      "r398",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r651",
      "r654",
      "r655",
      "r671",
      "r836",
      "r943",
      "r988",
      "r1058",
      "r1121",
      "r1122"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities:",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, convertible redeemable preferred stock, and stockholders\u2019 equity (deficit)",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r222",
      "r779",
      "r976",
      "r1026",
      "r1040",
      "r1113"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r265",
      "r301",
      "r398",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r651",
      "r654",
      "r655",
      "r671",
      "r976",
      "r1058",
      "r1121",
      "r1122"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueAdjustment",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of contingent warrant liability",
        "label": "Liabilities, Fair Value Adjustment",
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesSubjectToCompromiseEarlyContractTerminationFees",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination fee",
        "label": "Liabilities Subject to Compromise, Early Contract Termination Fees",
        "documentation": "The amount of early contract termination fees included in liabilities subject to compromise."
       }
      }
     },
     "auth_ref": [
      "r1120"
     ]
    },
    "onco_LicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "LicenseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreement",
        "documentation": "License agreement.",
        "label": "License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "onco_LicensedProductsPlusMilestonePaymentsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "LicensedProductsPlusMilestonePaymentsDescription",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of licensed products",
        "documentation": "Description of licensed products plus milestone payments.",
        "label": "Licensed Products Plus Milestone Payments Description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturityDate",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity term",
        "label": "Long-Term Debt, Maturity Date",
        "documentation": "Maturity date of long-term debt, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "us-gaap_LongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
      "http://www.bluewatervaccines.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note payable",
        "verboseLabel": "Loan payable",
        "label": "Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "onco_ManagementServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ManagementServicesAgreementMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management Services Agreement [Member]",
        "label": "Management Services Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_MarketOfferingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "MarketOfferingAgreementMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Offering Agreement [Member]",
        "label": "Market Offering Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofOptionsGrantedTable",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueoftheProteomedixStockOptionsTable",
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails",
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r427",
      "r429",
      "r430",
      "r566",
      "r740",
      "r789",
      "r828",
      "r829",
      "r893",
      "r897",
      "r899",
      "r900",
      "r907",
      "r930",
      "r931",
      "r946",
      "r957",
      "r969",
      "r977",
      "r1060",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price [Member]",
        "label": "Measurement Input, Exercise Price [Member]",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueoftheProteomedixStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term (years) [Member]",
        "verboseLabel": "Term [Member]",
        "netLabel": "Measurement Input, Expected Term [Member]",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputOptionVolatilityMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Stock Price Volatility [Member]",
        "label": "Measurement Input, Option Volatility [Member]",
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueoftheProteomedixStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected stock price volatility\t[Member]",
        "verboseLabel": "Measurement Input, Price Volatility [Member]",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueoftheProteomedixStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate of interest [Member]",
        "verboseLabel": "Risk-free Rate of Interest [Member]",
        "netLabel": "Measurement Input, Risk Free Interest Rate [Member]",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "onco_MeasurementInputStockPriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "MeasurementInputStockPriceMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueoftheProteomedixStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock price [Member]",
        "label": "Measurement Input Stock Price Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueoftheProteomedixStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/Acquisitions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r209"
     ]
    },
    "onco_MilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "MilestonePaymentsMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payments [Member]",
        "label": "Milestone Payments Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofOptionsGrantedTable",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueoftheProteomedixStockOptionsTable",
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails",
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "verboseLabel": "Property and Equipment [Member]",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r427",
      "r429",
      "r430",
      "r566",
      "r740",
      "r789",
      "r828",
      "r829",
      "r893",
      "r897",
      "r899",
      "r900",
      "r907",
      "r930",
      "r931",
      "r946",
      "r957",
      "r969",
      "r977",
      "r1060",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interest",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r221",
      "r301",
      "r398",
      "r431",
      "r433",
      "r434",
      "r435",
      "r438",
      "r439",
      "r671",
      "r778",
      "r840"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary owned, percentage",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "onco_MiscellaneousExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "MiscellaneousExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Miscellaneous payments",
        "documentation": "The amount of miscellaneous expenses.",
        "label": "Miscellaneous Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182",
      "r183"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to common stockholders",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r312",
      "r313",
      "r314",
      "r315",
      "r321",
      "r322",
      "r326",
      "r329",
      "r336",
      "r349",
      "r353",
      "r355",
      "r944"
     ]
    },
    "onco_NettingProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "NettingProceeds",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Netting proceeds (in Dollars)",
        "documentation": "Represent the amount of netting proceeds.",
        "label": "Netting Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "onco_NonConvertibleDebentureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "NonConvertibleDebentureMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails",
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non convertible debenture [Member]",
        "label": "Non Convertible Debenture Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncash investing and financing activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashOrPartNoncashAcquisitionInventoryAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory and intangible assets acquired through issuance of notes payable",
        "label": "Noncash or Part Noncash Acquisition, Inventory Acquired",
        "documentation": "The amount of inventory that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashOrPartNoncashAcquisitionPayablesAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred offering costs included in accounts payable",
        "label": "Noncash or Part Noncash Acquisition, Payables Assumed",
        "documentation": "The amount of payables that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling Interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r488",
      "r1029",
      "r1030",
      "r1031",
      "r1141"
     ]
    },
    "us-gaap_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofLonglivedbyGeographicalAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total long-lived asset",
        "label": "Long-Lived Assets",
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "onco_NotePayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "NotePayableMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note Payable [Member]",
        "label": "Note Payable Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note payable originally due",
        "label": "Notes Payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r220",
      "r1131"
     ]
    },
    "us-gaap_NotesPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable, net of debt discount of $381,627",
        "label": "Notes Payable, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "onco_NotesPayableDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "NotesPayableDetailsTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_NotesPayableNetOfDebtDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "NotesPayableNetOfDebtDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable, net of debt discount (in Dollars)",
        "documentation": "Notes payable, net of debt discount.",
        "label": "Notes Payable Net Of Debt Discount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating segment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "onco_NumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "NumberOfShares",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares (in Shares)",
        "documentation": "Number of shares.",
        "label": "Number Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "onco_OUIAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "OUIAgreementMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OUI Agreement [Member]",
        "label": "OUIAgreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ObligationWithJointAndSeveralLiabilityArrangementLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Agreements [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "onco_OlogyBioservicesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "OlogyBioservicesIncMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ology MSA. [Member]",
        "verboseLabel": "Ology Bioservices, Inc [Member]",
        "label": "Ology Bioservices Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_OnconetixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "OnconetixMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Onconetix [Member]",
        "label": "Onconetix Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r349",
      "r353",
      "r355",
      "r944"
     ]
    },
    "us-gaap_OperatingIncomeLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLossMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Operating Loss [Member]",
        "verboseLabel": "Operating Income (Loss) [Member]",
        "label": "Operating Income (Loss) [Member]",
        "documentation": "Primary financial statement caption encompassing operating income (loss)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLeaseIncomeLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease expense",
        "label": "Operating Lease, Lease Income, Lease Payments",
        "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r694"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating right of use asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Basis of Presentation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Basis of Presentation",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r212"
     ]
    },
    "onco_OrganizationandBasisofPresentationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "OrganizationandBasisofPresentationDetailsTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Basis of Presentation (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_OriginalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "OriginalMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofthePreferredInvestmentOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Original [Member]",
        "label": "Original Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued expenses",
        "label": "Other Accrued Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_OtherAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails",
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow",
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement",
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of deposit on asset purchase agreement",
        "verboseLabel": "Impairment charge of long-lived assets",
        "netLabel": "Long-lived assets of carrying amount",
        "label": "Other Asset Impairment Charges",
        "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value."
       }
      }
     },
     "auth_ref": [
      "r1023",
      "r1054"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAccumulatedComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss (gain)",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Tax, after Reclassification Adjustment, Attributable to Parent",
        "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive (income) loss for defined benefit plan, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r22",
      "r213"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement",
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign currency translation",
        "negatedTerseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r676",
      "r684"
     ]
    },
    "onco_OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment (in Shares)",
        "documentation": "Foreign currency translation adjustment.",
        "label": "Other Comprehensive Income Loss Foreign Currency Translations Adjustment Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAccumulatedComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other adjustments",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r32",
      "r280",
      "r283",
      "r290",
      "r678",
      "r679",
      "r685",
      "r762",
      "r784",
      "r1016",
      "r1017"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss",
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCostOfOperatingRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCostOfOperatingRevenue",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "label": "Other Cost of Operating Revenue",
        "documentation": "Other costs incurred during the reporting period related to other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(in Dollars)",
        "verboseLabel": "Accrued expenses",
        "label": "Other Expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_OtherGeneralExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherGeneralExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-accountable expenses (in Dollars)",
        "label": "Other General Expense",
        "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncomeAndExpensesAbstract",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense)",
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of liability (in Dollars)",
        "label": "Other Liabilities",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r767",
      "r832",
      "r833",
      "r988",
      "r1136"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r976"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense)",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_OtherNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable due (in Dollars)",
        "label": "Other Notes Payable",
        "documentation": "Amount of long-term notes payable classified as other."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r220",
      "r1131"
     ]
    },
    "us-gaap_OtherOwnershipInterestsOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOwnershipInterestsOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering costs (in Dollars)",
        "label": "Other Ownership Interests, Offering Costs",
        "documentation": "The cumulative amount of offering costs allocated to the other unit holders."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid other",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1041"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party receivable",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r847"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable from related parties, net",
        "verboseLabel": "Receivable from related party",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherSellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherSellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails",
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general, and administrative expenses",
        "verboseLabel": "Selling, general and administrative expenses",
        "label": "Other Selling, General and Administrative Expense",
        "documentation": "Amount of selling, general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "onco_OxfordUniversityInnovationLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "OxfordUniversityInnovationLimitedMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oxford University Innovation Limited [Member]",
        "label": "Oxford University Innovation Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_PMXOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PMXOptionPlanMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PMX Option Plan [Member]",
        "label": "PMXOption Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_PMXTransactionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PMXTransactionMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofConsolidatedStatementsofOperationsandComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PMX Transaction [Member]",
        "label": "PMXTransaction Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ParentMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3",
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Onconetix Equity (Deficit)",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "onco_PayableAverageDiscountRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PayableAverageDiscountRatePercentage",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average discount rate, percentage",
        "documentation": "The percentage of payable average discount rate.",
        "label": "Payable Average Discount Rate Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "onco_PaymentOfAccruedBonusThroughRelatedPartyReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PaymentOfAccruedBonusThroughRelatedPartyReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of accrued bonus through related party receivable",
        "documentation": "Payment of accrued bonus through related party receivable.",
        "label": "Payment Of Accrued Bonus Through Related Party Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "onco_Payments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "Payments",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company payments",
        "documentation": "The amount of payments.",
        "label": "Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial payment",
        "verboseLabel": "Fees under consulting agreement",
        "label": "Payments for Other Fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "onco_PaymentsForPurchaseOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PaymentsForPurchaseOfTreasuryShares",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of treasury shares",
        "documentation": "Payments for purchase of treasury stock.",
        "label": "Payments For Purchase Of Treasury Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent expense",
        "label": "Payments for Rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfInitialPublicOffering",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of initial public offering costs",
        "label": "Payments for Repurchase of Initial Public Offering",
        "documentation": "The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfPrivatePlacement",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of private placement issuance costs",
        "label": "Payments for Repurchase of Private Placement",
        "documentation": "The cash outflow associated with the repurchase of amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of deferred offering costs",
        "terseLabel": "Equity issuance cost. (in Dollars)",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash acquired through business combination",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of other long-lived assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of assets, including transaction costs of $79,771",
        "label": "Payments to Acquire Other Productive Assets",
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of assets, including transaction costs",
        "label": "Payments to Acquire Productive Assets",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r1106",
      "r1107",
      "r1108"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireRestrictedCertificatesOfDeposit",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deposit made in connection with asset purchase agreement",
        "label": "Payments to Acquire Restricted Certificates of Deposit",
        "documentation": "The cash outflow from temporary investment with specific maturity and interest rate that are prohibited for current use."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RetirementPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plans",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r514",
      "r516",
      "r522",
      "r540",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r560",
      "r561",
      "r563",
      "r961"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofBenefitPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Liability, Defined Benefit Plan",
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r491",
      "r513",
      "r1130"
     ]
    },
    "us-gaap_PensionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net periodic pension benefit",
        "label": "Pension Cost (Reversal of Cost)",
        "documentation": "Amount of cost (reversal of cost) for pension benefits. Excludes other postretirement benefits."
       }
      }
     },
     "auth_ref": []
    },
    "onco_PercentageOfCommonStockShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PercentageOfCommonStockShares",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of common stock",
        "documentation": "Percentage of Common Stock Shares.",
        "label": "Percentage Of Common Stock Shares"
       }
      }
     },
     "auth_ref": []
    },
    "onco_PercentageOfConsiderationReceived": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PercentageOfConsiderationReceived",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of consideration received",
        "documentation": "Percentage of consideration received.",
        "label": "Percentage Of Consideration Received"
       }
      }
     },
     "auth_ref": []
    },
    "onco_PercentageOfCumulativeDividends": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PercentageOfCumulativeDividends",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of cumulative dividends",
        "documentation": "Percentage of cumulative dividends.",
        "label": "Percentage Of Cumulative Dividends"
       }
      }
     },
     "auth_ref": []
    },
    "onco_PercentageOfGrossProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PercentageOfGrossProceeds",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of gross proceeds",
        "documentation": "Percentage of gross proceeds.",
        "label": "Percentage Of Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "onco_PercentageOfIssuedOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PercentageOfIssuedOfCommonStock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of issued of common stock",
        "documentation": "Percentage of issued of common stock.",
        "label": "Percentage Of Issued Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "onco_PercentageOfOriginalIssuePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PercentageOfOriginalIssuePrice",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Original issue price",
        "documentation": "Percentage of Original Issue Price.",
        "label": "Percentage Of Original Issue Price"
       }
      }
     },
     "auth_ref": []
    },
    "onco_PercentageOfOutstandingOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PercentageOfOutstandingOfCommonStock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of outstanding of common stock",
        "documentation": "Percentage of outstanding of common stock.",
        "label": "Percentage Of Outstanding Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "onco_PercentageOfSubscription": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PercentageOfSubscription",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of subscription",
        "documentation": "Percentage of subscription .",
        "label": "Percentage Of Subscription"
       }
      }
     },
     "auth_ref": []
    },
    "onco_PercentageOfUnderwritingDiscount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PercentageOfUnderwritingDiscount",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of underwriting discount",
        "documentation": "Percentage of underwriting discount.",
        "label": "Percentage Of Underwriting Discount"
       }
      }
     },
     "auth_ref": []
    },
    "onco_PharmaceuticalServicesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PharmaceuticalServicesLLCMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmaceutical Services, LLC [Member]",
        "label": "Pharmaceutical Services LLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "onco_PlacementAgentFeeAndManagementFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PlacementAgentFeeAndManagementFeePercentage",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Placement agent fee and management fee percentage",
        "documentation": "Percentage of placement agent fee and management fee.",
        "label": "Placement Agent Fee And Management Fee Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "onco_PlanAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PlanAssetsMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Assets [Member]",
        "label": "Plan Assets Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred investment option price per share (in Dollars per share)",
        "label": "Preferred Stock, Convertible, Conversion Price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionPriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleConversionPriceDecrease",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduced exercise price (in Dollars per share)",
        "label": "Preferred Stock, Convertible, Conversion Price, Decrease",
        "documentation": "Per share decrease in conversion price of convertible preferred stock. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r487"
     ]
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock designated",
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative preferred stock dividends",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockDividendsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendsShares",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment options",
        "label": "Preferred Stock Dividends, Shares",
        "documentation": "Number of shares of preferred stock issued as dividends during the period. Excludes stock splits."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockLiquidationPreference",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidation per shares (in Dollars per share)",
        "label": "Preferred Stock, Liquidation Preference Per Share",
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r155",
      "r1024",
      "r1062"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockLiquidationPreferenceValue",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, liquidation preference (in Dollars)",
        "label": "Preferred Stock, Liquidation Preference, Value",
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r474"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2",
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock",
        "verboseLabel": "Preferred Stock [Member]",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r978",
      "r979",
      "r982",
      "r983",
      "r984",
      "r985",
      "r1134",
      "r1141"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in Dollars per share)",
        "verboseLabel": "Liquidation preference (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r470"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "verboseLabel": "Preferred stock, shares",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r838"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2",
      "http://www.bluewatervaccines.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "verboseLabel": "Issuance shares (in Shares)",
        "netLabel": "Preferred stock, share issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r470"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock shares outstanding",
        "verboseLabel": "Preferred investment options outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r838",
      "r859",
      "r1141",
      "r1142"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Convertible Preferred stock, $0.00001 par value, 10,000 and 0 shares authorized at December 31, 2023 and 2022, respectively; 3,000 and 0 shares issued and outstanding at December 31, 2023 and 2022, respectively; Liquidation preference of $3,000,000 and $0 at December 31, 2023 and 2022, respectively.",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r772",
      "r976"
     ]
    },
    "onco_PrefundedWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PrefundedWarrantsExercised",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded warrants exercised",
        "documentation": "Number of prefunded share warrants exercised during the current period.",
        "label": "Prefunded Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.bluewatervaccines.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
      "http://www.bluewatervaccines.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Prepaid Expenses and Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses, long-term",
        "label": "Prepaid Expense, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid insurance",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r949",
      "r1041"
     ]
    },
    "onco_PrepaidProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PrepaidProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid professional fees",
        "documentation": "Prepaid professional fees.",
        "label": "Prepaid Professional Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidRent",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid regulatory fees",
        "label": "Prepaid Rent",
        "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r936",
      "r950",
      "r1041"
     ]
    },
    "onco_PrepaidsResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PrepaidsResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid research and development",
        "documentation": "Amount of other research and development expense.",
        "label": "Prepaids Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlansDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofValuationoftheContingentWarrantLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement [Member]",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow",
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock in initial public offering, net of underwriting discount",
        "verboseLabel": "Offering costs",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of preferred investment options, net",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "verboseLabel": "Private placement were approximatel (in Dollars)",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock and warrants in private placements, net of placement agent discount",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLicenseFeesReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License fee",
        "label": "Proceeds from License Fees Received",
        "documentation": "Cash received from licensees for license fees during the current period."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recovery of related party receivable",
        "label": "Proceeds from (Repayments of) Related Party Debt",
        "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfOtherInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from preferred investment",
        "label": "Proceeds from Sale of Other Investments",
        "documentation": "Amount of cash inflow from the sale of investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r29"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of pre-funded warrants",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "us-gaap_ProductLiabilityContingencyAccrualDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductLiabilityContingencyAccrualDiscountRate",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of product",
        "label": "Product Liability Contingency, Accrual, Discount Rate",
        "documentation": "Rate applied to the undiscounted amount of estimated damages for product liability to arrive at the present value recorded as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductLiabilityContingencyThirdPartyRecoveryPercentage",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubscriptionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated probability percentage",
        "label": "Product Liability Contingency, Third-Party Recovery, Percentage",
        "documentation": "Percentage of the estimated recovery from third parties recorded in the period pertaining to product liability damages from specified products."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "us-gaap_ProfessionalAndContractServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfessionalAndContractServicesExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense related to contract",
        "label": "Professional and Contract Services Expense",
        "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow",
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement",
      "http://www.bluewatervaccines.com/role/ScheduleofConsolidatedStatementsofOperationsandComprehensiveLossTable",
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r279",
      "r282",
      "r294",
      "r301",
      "r310",
      "r318",
      "r319",
      "r336",
      "r349",
      "r353",
      "r355",
      "r398",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r649",
      "r652",
      "r653",
      "r666",
      "r671",
      "r765",
      "r783",
      "r808",
      "r861",
      "r883",
      "r884",
      "r944",
      "r973",
      "r974",
      "r987",
      "r1018",
      "r1058"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed Assets [Member]",
        "label": "Property, Plant and Equipment [Member]",
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r766",
      "r781",
      "r976"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r238",
      "r242",
      "r780"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails",
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful lives",
        "verboseLabel": "Estimated useful lives",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "onco_ProteomedixAcquisitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ProteomedixAcquisitionMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proteomedix Acquisition [Member]",
        "label": "Proteomedix Acquisition Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ProteomedixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ProteomedixMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails",
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofConsolidatedStatementsofOperationsandComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proteomedix [Member]",
        "label": "Proteomedix Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_PublicOfPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PublicOfPerShare",
     "presentation": [
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public of per share (in Dollars per share)",
        "documentation": "The share of public of per share.",
        "label": "Public Of Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "onco_PurchaseOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PurchaseOfTreasuryShares",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of treasury shares",
        "documentation": "Purchase of treasury shares.",
        "label": "Purchase Of Treasury Shares"
       }
      }
     },
     "auth_ref": []
    },
    "onco_PurchaseOfTreasurySharesinShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "PurchaseOfTreasurySharesinShares",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of treasury shares (in Shares)",
        "documentation": "The number of shares purchase of treasury shares.",
        "label": "Purchase Of Treasury Sharesin Shares"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofOptionsGrantedTable",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueoftheProteomedixStockOptionsTable",
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails",
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r427",
      "r429",
      "r430",
      "r514",
      "r566",
      "r595",
      "r596",
      "r597",
      "r713",
      "r740",
      "r789",
      "r828",
      "r829",
      "r893",
      "r897",
      "r899",
      "r900",
      "r907",
      "r930",
      "r931",
      "r946",
      "r957",
      "r969",
      "r977",
      "r980",
      "r1055",
      "r1060",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueoftheProteomedixStockOptionsTable",
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails",
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r427",
      "r429",
      "r430",
      "r514",
      "r566",
      "r595",
      "r596",
      "r597",
      "r713",
      "r740",
      "r789",
      "r828",
      "r829",
      "r893",
      "r897",
      "r899",
      "r900",
      "r907",
      "r930",
      "r931",
      "r946",
      "r957",
      "r969",
      "r977",
      "r980",
      "r1055",
      "r1060",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128"
     ]
    },
    "onco_RealEstateInvestmentsRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "RealEstateInvestmentsRate",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RetirementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real estate investments rate",
        "documentation": "Real estate investments rate.",
        "label": "Real Estate Investments Rate"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ReceivableFromRelatedParties1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ReceivableFromRelatedParties1",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net advances to related parties",
        "documentation": "The amount of receivables from related parties.",
        "label": "Receivable From Related Parties1"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ReclassificationToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ReclassificationToEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofActivityfortheContingentWarrantLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification to equity",
        "documentation": "The amount represents the reclassification to equity.",
        "label": "Reclassification To Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationsOfTemporaryToPermanentEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassifications cash flow activity",
        "label": "Reclassifications of Temporary to Permanent Equity",
        "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r214"
     ]
    },
    "onco_RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognition of contingent warrant liability",
        "documentation": "Recognition of contingent warrant liability upon issuance of common stock in private placement.",
        "label": "Recognition Of Contingent Warrant Liability Upon Issuance Of Common Stock In Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RecognitionOfDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RecognitionOfDeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Recognition of Deferred Revenue",
        "documentation": "The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_RegulatedAndUnregulatedOperatingRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RegulatedAndUnregulatedOperatingRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAccumulatedComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total recorded during the period",
        "label": "Regulated and Unregulated Operating Revenue",
        "documentation": "The total amount of operating revenues recognized during the period."
       }
      }
     },
     "auth_ref": []
    },
    "onco_RegulatoryMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "RegulatoryMilestonesMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory milestones [Member]",
        "label": "Regulatory Milestones Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails",
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails",
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r699",
      "r700",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r858",
      "r860",
      "r892"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "verboseLabel": "Related Party [Member]",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r699",
      "r700",
      "r701",
      "r702",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r858",
      "r860",
      "r892"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party transactions amounts",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r699"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r699",
      "r700",
      "r1119"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r865",
      "r866",
      "r869"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsDetails",
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails",
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r699",
      "r700",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r858",
      "r860",
      "r892",
      "r1119"
     ]
    },
    "onco_RelatedPartyTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "RelatedPartyTransactionsDetailsTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r696",
      "r697",
      "r698",
      "r700",
      "r703",
      "r804",
      "r805",
      "r806",
      "r867",
      "r868",
      "r869",
      "r889",
      "r891"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Principal payment of note payable",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment of related party",
        "label": "Repayments of Related Party Debt",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r1096"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r1096"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement",
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r611",
      "r1129"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "onco_ResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ResearchAndDevelopmentMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development [Member]",
        "label": "Research And Development Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_RestrictedSharesGrantedVestPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "RestrictedSharesGrantedVestPercentage",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted shares granted vest",
        "documentation": "Restricted shares granted vest percentage.",
        "label": "Restricted Shares Granted Vest Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "onco_RestrictedStockForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "RestrictedStockForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock forfeitures",
        "documentation": "Restricted stock forfeitures.",
        "label": "Restricted Stock Forfeitures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ScheduleofComputationofDilutedSharesOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested restricted stock [Member]",
        "verboseLabel": "Restricted Stock [Member]",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted shares granted",
        "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings",
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r201",
      "r777",
      "r793",
      "r795",
      "r802",
      "r839",
      "r976"
     ]
    },
    "us-gaap_RetainedEarningsAppropriated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAppropriated",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings, Appropriated",
        "documentation": "A segregation of retained earnings which is unavailable for dividend distribution. Includes also retained earnings appropriated for loss contingencies."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r165",
      "r300",
      "r776"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r307",
      "r308",
      "r309",
      "r311",
      "r317",
      "r319",
      "r399",
      "r400",
      "r601",
      "r602",
      "r603",
      "r634",
      "r635",
      "r656",
      "r658",
      "r659",
      "r661",
      "r664",
      "r790",
      "r792",
      "r809",
      "r1141"
     ]
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanTypeAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Type [Axis]",
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r538",
      "r539",
      "r541",
      "r544",
      "r547",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r563",
      "r564",
      "r565",
      "r568",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968"
     ]
    },
    "onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Benefit Obligation and the Net Periodic Benefit Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plans (Details) - Schedule of Benefit Obligation and the Net Periodic Benefit Cost [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_RevenueRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "RevenueRate",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue rate",
        "documentation": "Revenue rate.",
        "label": "Revenue Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r932",
      "r941"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement",
      "http://www.bluewatervaccines.com/role/ScheduleofConsolidatedStatementsofOperationsandComprehensiveLossTable",
      "http://www.bluewatervaccines.com/role/ScheduleofRevenuebyGeographicalAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r301",
      "r337",
      "r338",
      "r348",
      "r351",
      "r352",
      "r356",
      "r357",
      "r359",
      "r398",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r671",
      "r765",
      "r1058"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofLonglivedbyGeographicalAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "onco_RoyaltiesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "RoyaltiesPercentage",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties percentage",
        "documentation": "Royalties percentage.",
        "label": "Royalties Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty payment",
        "label": "Royalty Expense",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "onco_RoyaltyNetSalesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "RoyaltyNetSalesPercentage",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty net sales percentage",
        "documentation": "Percentage of royalty net sales.",
        "label": "Royalty Net Sales Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "onco_RoyaltyRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "RoyaltyRate",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty rate",
        "documentation": "Percentage of royalty.",
        "label": "Royalty Rate"
       }
      }
     },
     "auth_ref": []
    },
    "onco_RoyaltyRates": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "RoyaltyRates",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty rates",
        "documentation": "Percentage of royalty rates.",
        "label": "Royalty Rates"
       }
      }
     },
     "auth_ref": []
    },
    "onco_RoyaltySalesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "RoyaltySalesPercentage",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty sales percentage",
        "documentation": "percentage of royalty sales percentage.",
        "label": "Royalty Sales Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlansDetails",
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.bluewatervaccines.com/role/SubscriptionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued shares of common stock",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubscriptionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per unit (in Dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "onco_SaleOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SaleOfUnits",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubscriptionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of units",
        "documentation": "Sale of units.",
        "label": "Sale Of Units"
       }
      }
     },
     "auth_ref": []
    },
    "onco_SalesPaymentsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SalesPaymentsAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales payments amount",
        "documentation": "The amount of sales payments amount.",
        "label": "Sales Payments Amount"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast [Member]",
        "label": "Forecast [Member]",
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r1003",
      "r1032"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofAccumulatedComprehensiveLossTable",
      "http://www.bluewatervaccines.com/role/ScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable",
      "http://www.bluewatervaccines.com/role/ScheduleofUnvestedRestrictedStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r567",
      "r992",
      "r1032"
     ]
    },
    "onco_ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RetirementPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accompanying Consolidated Balance Sheet",
        "documentation": "Disclosure of accompanying consolidated balance sheet.",
        "label": "Schedule Of Accompanying Consolidated Balance Sheet Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "onco_ScheduleOfAccumulatedComprehensiveLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfAccumulatedComprehensiveLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Accumulated Comprehensive Loss Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RetirementPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accumulated Comprehensive Loss",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r1116",
      "r1117"
     ]
    },
    "onco_ScheduleOfActivityForTheContingentWarrantLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfActivityForTheContingentWarrantLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Activity for the Contingent Warrant Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ScheduleOfActivityForTheSubscriptionAgreementLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfActivityForTheSubscriptionAgreementLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Activity for the Subscription Agreement Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ScheduleOfAggregateConsiderationTransferredForTheAssetsAcquiredAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfAggregateConsiderationTransferredForTheAssetsAcquiredAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Aggregate Consideration Transferred For The Assets Acquired Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofComputationofDilutedSharesOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Computation of Diluted Shares Outstanding",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "onco_ScheduleOfAssetsAcquiredAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfAssetsAcquiredAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Assets Acquired Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ScheduleOfAssumptionsUsedInMonteCarloModelWhichUtilizesLevel3InputsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfAssumptionsUsedInMonteCarloModelWhichUtilizesLevel3InputsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Assumptions Used In Monte Carlo Model Which Utilizes Level3 Inputs Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ScheduleOfBenefitObligationAndTheNetPeriodicBenefitCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfBenefitObligationAndTheNetPeriodicBenefitCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Benefit Obligation And The Net Periodic Benefit Cost Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Components Of Net Periodic Benefit Cost Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleoftheBeginningandEndingBalancesoftheAccumulatedBenefitObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Statements [Table]",
        "documentation": "Disclosure of information about condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r258",
      "r259",
      "r260",
      "r306",
      "r993"
     ]
    },
    "srt_ScheduleOfCondensedFinancialStatementsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfCondensedFinancialStatementsTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RetirementPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Beginning and Ending Balances of the Accumulated Benefit Obligation",
        "label": "Condensed Financial Statements [Table Text Block]",
        "documentation": "Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows."
       }
      }
     },
     "auth_ref": [
      "r1004",
      "r1028"
     ]
    },
    "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Consolidated Statements of Operations and Comprehensive Loss",
        "label": "Condensed Income Statement [Table Text Block]",
        "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r1004",
      "r1028"
     ]
    },
    "onco_ScheduleOfConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Consolidated Statements Of Operations And Comprehensive Loss Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RetirementPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accompanying Consolidated Balance Sheet",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]",
        "documentation": "Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r93",
      "r94",
      "r95",
      "r96"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Taxes Differs from the Statutory Federal Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock-Based Compensation Expense [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofRevenuebyGeographicalAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r396",
      "r397"
     ]
    },
    "onco_ScheduleOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Estimated Fair Values Of Assets Acquired And Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Financial Instruments Measured on a Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r668"
     ]
    },
    "onco_ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Of Financial Instruments Measured On ARecurring Basis Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ScheduleOfFairValueOfOptionsGrantedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfFairValueOfOptionsGrantedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Of Options Granted Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Options Granted",
        "documentation": "Schedule of Fair Value of Options Granted in 2023 And 2022.",
        "label": "Schedule Of Fair Value Of Options Granted In2023 And2022 Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ScheduleOfFairValueOfThePreferredInvestmentOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfFairValueOfThePreferredInvestmentOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Of The Preferred Investment Options Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ScheduleOfFairValueOfTheProteomedixStockOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfFairValueOfTheProteomedixStockOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Of The Proteomedix Stock Options Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r76",
      "r746"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r76"
     ]
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RetirementPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Benefit Payments",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "onco_ScheduleOfGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Goodwill [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Loss Before Income Tax",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "onco_ScheduleOfIntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfIntangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Intangible Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventories",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r162",
      "r163",
      "r164"
     ]
    },
    "onco_ScheduleOfLongLivedByGeographicalAreaAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfLongLivedByGeographicalAreaAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Long Lived By Geographical Area Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RetirementPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Benefit Obligation and the Net Periodic Benefit Cost",
        "label": "Schedule of Net Periodic Benefit Cost Not yet Recognized [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts related to pension plans and/or other employee benefit plans in accumulated other comprehensive income or loss that have not yet been recognized as components of net periodic benefit cost, such as the net gain (loss), net prior service cost or credit, and net transition asset or obligation."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unvested Restricted Stock",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "onco_ScheduleOfOutstandingWarrantsExcludingContingentWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfOutstandingWarrantsExcludingContingentWarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Outstanding Warrants Excluding Contingent Warrants Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Fair Values of Assets Acquired and Liabilities",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "onco_ScheduleOfRevenueByGeographicalAreaAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfRevenueByGeographicalAreaAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Revenue By Geographical Area Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue by Geographical Area",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-lived by Geographical Area",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r169"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofLonglivedbyGeographicalAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r167"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Options",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r99"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubscriptionAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions Used in Monte-Carlo Model, Which Utilizes Level 3 Inputs",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "onco_ScheduleOfStockBasedCompensationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfStockBasedCompensationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Stock Based Compensation Expense Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ScheduleOfStockOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfStockOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Stock Options Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Outstanding Warrants, Excluding Contingent Warrants",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r971",
      "r1098"
     ]
    },
    "onco_ScheduleOfUnvestedRestrictedStockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfUnvestedRestrictedStockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Unvested Restricted Stock Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ScheduleOfValuationOfTheContingentWarrantLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfValuationOfTheContingentWarrantLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Valuation Of The Contingent Warrant Liability Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Valuation of the Contingent Warrant Liability",
        "documentation": "Schedule of Valuation of the Contingent Warrant Liability.",
        "label": "Schedule Of Valuation Of The Contingent Warrant Liability Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Annual Amortization Expense",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofLonglivedbyGeographicalAreaTable",
      "http://www.bluewatervaccines.com/role/ScheduleofRevenuebyGeographicalAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r357",
      "r358",
      "r822",
      "r823",
      "r825",
      "r894",
      "r898",
      "r902",
      "r909",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r933",
      "r958",
      "r980",
      "r1064",
      "r1133"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r357",
      "r945"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Selling, general and administrative expense (in Dollars)",
        "netLabel": "Selling, general, and administrative expenses",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative [Member]",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "onco_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Convertible Preferred Stock",
        "verboseLabel": "Series A Convertible Preferred Stock [Member]",
        "label": "Series AConvertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1",
      "http://www.bluewatervaccines.com/role/NotesPayableDetails",
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3",
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A",
        "verboseLabel": "Series A Preferred Stock [Member]",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1008",
      "r1009",
      "r1063"
     ]
    },
    "onco_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Convertible Preferred Stock [Member]",
        "label": "Series BConvertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_SeriesBConvertibleRedeemablePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SeriesBConvertibleRedeemablePreferredStockMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Convertible Redeemable Preferred stock",
        "label": "Series BConvertible Redeemable Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2",
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B",
        "verboseLabel": "Series B Preferred Stock [Member]",
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1008",
      "r1009",
      "r1063"
     ]
    },
    "onco_SeriesSeedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SeriesSeedMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series Seed",
        "label": "Series Seed Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_SeriesSeedPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SeriesSeedPreferredStockMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series Seed Convertible Preferred Stock [Member]",
        "verboseLabel": "Series Seed Preferred Stock [Member]",
        "label": "Series Seed Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServicingLiabilityAtFairValueAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ServicingLiabilityAtFairValueAdditions",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubscriptionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of Subscription agreement liability (in Dollars)",
        "label": "Servicing Liability at Fair Value, Additions",
        "documentation": "The value of new servicing liabilities, that are subsequently measured at fair value, acquired or created during the current period through assumptions of servicing obligations and servicing obligations that result from transfers of financial assets."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_ServicingLiabilityAtFairValueAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ServicingLiabilityAtFairValueAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubscriptionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of subscription agreement liability (in Dollars)",
        "label": "Servicing Liability at Fair Value, Amount",
        "documentation": "Fair value of a liability representing servicing arrangements under which the estimated future revenue from contractually specified servicing fees, late charges, and other ancillary revenues are not expected to adequately compensate the servicer."
       }
      }
     },
     "auth_ref": [
      "r722",
      "r723",
      "r724",
      "r725"
     ]
    },
    "onco_SettlementAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SettlementAgreementMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement Agreement [Member]",
        "label": "Settlement Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_SeverancePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SeverancePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance payment",
        "documentation": "The amount of severance payment.",
        "label": "Severance Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofUnvestedRestrictedStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, Forfeited / cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofUnvestedRestrictedStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted\tAverage Grant Date Fair Value, Forfeited / cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofUnvestedRestrictedStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofUnvestedRestrictedStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted\tAverage Grant Date Fair Value, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofUnvestedRestrictedStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares, Outstanding at beginning",
        "periodEndLabel": "Number of Shares, Outstanding at ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r583"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofUnvestedRestrictedStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted\tAverage Grant Date Fair Value, Outstanding at beginning",
        "periodEndLabel": "Weighted\tAverage Grant Date Fair Value, Outstanding at ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r583"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofUnvestedRestrictedStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofUnvestedRestrictedStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted\tAverage Grant Date Fair Value, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofOptionsGrantedTable",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofthePreferredInvestmentOptionsTable",
      "http://www.bluewatervaccines.com/role/ScheduleofValuationoftheContingentWarrantLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofOptionsGrantedTable",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofthePreferredInvestmentOptionsTable",
      "http://www.bluewatervaccines.com/role/ScheduleofValuationoftheContingentWarrantLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected stock price volatility",
        "verboseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofOptionsGrantedTable",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofthePreferredInvestmentOptionsTable",
      "http://www.bluewatervaccines.com/role/ScheduleofValuationoftheContingentWarrantLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate of interest",
        "verboseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Warrants vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Warrants vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Intrinsic Value, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Forfeited / cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable",
      "http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Cancelled",
        "negatedLabel": "Number of Shares, Forfeited / cancelled",
        "verboseLabel": "Stock options forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable",
      "http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Granted",
        "verboseLabel": "Stock options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Total Intrinsic Value, ending",
        "terseLabel": "Intrinsic value of options outstanding (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Intrinsic Value, Forfeited / cancelled",
        "documentation": "The value for share based compensation payment intrinsic value forfeited.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Forfeited Cancelled"
       }
      }
     },
     "auth_ref": []
    },
    "onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Intrinsic Value, Granted",
        "documentation": "Share based compensation payment arrangementintrinsic value granted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable",
      "http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Shares, ending",
        "terseLabel": "Stock option outstanding shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable",
      "http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price, ending",
        "terseLabel": "Weighted average exercise price (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Intrinsic Value, Options vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Options vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Options vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested intrinsic value (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested weighted average exercise price (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r571",
      "r572",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable",
      "http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Cancelled",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable",
      "http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r573",
      "r592",
      "r593",
      "r594",
      "r595",
      "r598",
      "r604",
      "r605",
      "r606",
      "r607"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value per share (in Dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofOptionsGrantedTable",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofthePreferredInvestmentOptionsTable",
      "http://www.bluewatervaccines.com/role/ScheduleofValuationoftheContingentWarrantLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term (years)",
        "verboseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Life, Warrants vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable",
      "http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Life, ending",
        "verboseLabel": "Weighted average period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Life, Options vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested weighted average term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate fair value of stock options (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesHeldInEmployeeStockOptionPlanAllocated",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option",
        "label": "Shares Held in Employee Stock Option Plan, Allocated",
        "documentation": "Number of allocated shares held by the Employee Stock Option Plan at balance sheet date. Allocated shares are shares that have been assigned to individual participant accounts based on a known formula."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails",
      "http://www.bluewatervaccines.com/role/SubscriptionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of common stock",
        "verboseLabel": "Share issued of restricted common stock (in Shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock per share (in Dollars per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "onco_SharesOfCommonStockIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SharesOfCommonStockIssued",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of common stock",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Shares Of Common Stock Issued"
       }
      }
     },
     "auth_ref": []
    },
    "onco_SharesOfCommonStockRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SharesOfCommonStockRate",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of common stock rate",
        "documentation": "Shares of common stock rate.",
        "label": "Shares Of Common Stock Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease",
        "label": "Short-Term Lease Payments",
        "documentation": "Amount of cash outflow for short-term lease payment excluded from lease liability."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r297"
     ]
    },
    "onco_SignificantAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SignificantAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_SignificantAgreementsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SignificantAgreementsDetailsTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Agreements (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_SignificantAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SignificantAgreementsTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Agreements",
        "documentation": "The entire disclosure for significant agreements.",
        "label": "Significant Agreements Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "onco_StJudeChildrensHospitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "StJudeChildrensHospitalMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "St. Jude Children\u2019s Hospital [Member]",
        "label": "St Jude Childrens Hospital Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2",
      "http://www.bluewatervaccines.com/role/NotesPayableDetails",
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3",
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r270",
      "r271",
      "r272",
      "r301",
      "r324",
      "r325",
      "r327",
      "r329",
      "r334",
      "r335",
      "r398",
      "r431",
      "r433",
      "r434",
      "r435",
      "r438",
      "r439",
      "r470",
      "r471",
      "r474",
      "r477",
      "r486",
      "r671",
      "r798",
      "r799",
      "r800",
      "r801",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r821",
      "r838",
      "r862",
      "r885",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r991",
      "r1024",
      "r1033"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3",
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r51",
      "r261",
      "r285",
      "r286",
      "r287",
      "r307",
      "r308",
      "r309",
      "r311",
      "r317",
      "r319",
      "r333",
      "r399",
      "r400",
      "r488",
      "r601",
      "r602",
      "r603",
      "r634",
      "r635",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r664",
      "r678",
      "r680",
      "r681",
      "r682",
      "r683",
      "r685",
      "r695",
      "r790",
      "r791",
      "r792",
      "r809",
      "r885"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofLonglivedbyGeographicalAreaTable",
      "http://www.bluewatervaccines.com/role/ScheduleofRevenuebyGeographicalAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r257",
      "r357",
      "r358",
      "r822",
      "r823",
      "r825",
      "r894",
      "r898",
      "r902",
      "r909",
      "r917",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r933",
      "r958",
      "r980",
      "r1064",
      "r1133"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3",
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r333",
      "r745",
      "r796",
      "r821",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r838",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r849",
      "r850",
      "r851",
      "r852",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r860",
      "r863",
      "r864",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r885",
      "r981"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/NotesPayableDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofAccumulatedComprehensiveLossTable",
      "http://www.bluewatervaccines.com/role/ScheduleofBenefitObligationandtheNetPeriodicBenefitCostTable",
      "http://www.bluewatervaccines.com/role/ScheduleofUnvestedRestrictedStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r567",
      "r992",
      "r994",
      "r1032"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3",
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r333",
      "r745",
      "r796",
      "r821",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r838",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r849",
      "r850",
      "r851",
      "r852",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r860",
      "r863",
      "r864",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r885",
      "r981"
     ]
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued (in Dollars)",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64"
     ]
    },
    "onco_StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assumption of stock-based compensation plan awards in connection with PMX Transaction (in Shares)",
        "documentation": "Assumption of stock-based compensation plan awards in connection with PMX Transaction.",
        "label": "Stock Issued During Period Shares Assumption Of Stockbased Compensation Plan Awards In Connection With PMXTransaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock to common stock upon initial public offering (in Shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r50",
      "r86",
      "r201",
      "r457"
     ]
    },
    "onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and Series B Preferred Stock in connection with PMX Transaction (in Shares)",
        "verboseLabel": "Issuance of common stock (in Shares)",
        "documentation": "Issuance of common stock and Series B Preferred Stock in connection with PMX Transaction.",
        "label": "Stock Issued During Period Shares Issuance Of Common Stock And Series BPreferred Stock In Connection With PMXTransaction"
       }
      }
     },
     "auth_ref": []
    },
    "onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and warrants in April private placement, net of $1.1 million of offering costs (in Shares)",
        "documentation": "Number of common stock and warrants issued during the period.",
        "label": "Stock Issued During Period Shares Issuance Of Common Stock And Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and warrants in August private placement, net of $2.2 million of offering costs (in Shares)",
        "documentation": "Number of common stock and warrants in August private placement issued during the period.",
        "label": "Stock Issued During Period Shares Issuance Of Common Stock And Warrants In August Private Placement Net"
       }
      }
     },
     "auth_ref": []
    },
    "onco_StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series A Preferred Stock (in Shares)",
        "documentation": "Issuance of series A preferred stock.",
        "label": "Stock Issued During Period Shares Issuance Of Series APreferred Stockin Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate of stock options",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in initial public offering, net of $2.9 million of offering costs (in Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r155",
      "r156",
      "r201",
      "r798",
      "r885",
      "r911"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of warrants for settlement of contingent warrants (in Shares)",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited shares of restricted stock",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r155",
      "r156",
      "r201"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of restricted stock (in Shares)",
        "verboseLabel": "Restricted common stock issued",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r201"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeitures of restricted stock (in Shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r155",
      "r156",
      "r201"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation (in Shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture",
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable",
      "http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable",
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options (in Shares)",
        "negatedLabel": "Number of Shares, Exercised",
        "verboseLabel": "Exercisable shares of common stock",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r155",
      "r156",
      "r201",
      "r579"
     ]
    },
    "onco_StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assumption of stock-based compensation plan awards in connection with PMX Transaction",
        "documentation": "Assumption of stock-based compensation plan awards in connection with PMX Transaction.",
        "label": "Stock Issued During Period Value Assumption Of Stockbased Compensation Plan Awards In Connection With PMXTransaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock to common stock upon initial public offering",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r51",
      "r201"
     ]
    },
    "onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and Series B Preferred Stock in connection with PMX Transaction",
        "documentation": "Issuance of common stock and Series B Preferred Stock in connection with PMX Transaction.",
        "label": "Stock Issued During Period Value Issuance Of Common Stock And Series BPreferred Stock In Connection With PMXTransaction"
       }
      }
     },
     "auth_ref": []
    },
    "onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock from exercise of preferred investment options (in Shares)",
        "documentation": "Issuance of common stock from exercise of preferred investment options.",
        "label": "Stock Issued During Period Value Issuance Of Common Stock From Exercise Of Preferred Investment Optionsin Shares"
       }
      }
     },
     "auth_ref": []
    },
    "onco_StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series A Preferred Stock",
        "documentation": "Issuance of series A preferred stock.",
        "label": "Stock Issued During Period Value Issuance Of Series APreferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "onco_StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and warrants in August private placement, net of $2.2 million of offering costs",
        "documentation": "Issuance of common stock and warrants in private placement.",
        "label": "Stock Issued During Period Value Issuanceof Common Stockand Warrantsin Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in initial public offering, net of $2.9 million of offering costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r155",
      "r156",
      "r201",
      "r809",
      "r885",
      "r911",
      "r987"
     ]
    },
    "onco_StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in pension benefit obligation",
        "documentation": "Amount of  changes in pension benefit obligation.",
        "label": "Stock Issued During Period Value Of Changes In Pension Benefit Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "onco_StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and warrants in April private placement, net of $1.1 million of offering costs",
        "documentation": "Amount of issuance of common stock and warrants.",
        "label": "Stock Issued During Period Value Ofssuance Of Common Stock And Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of warrants for settlement of contingent warrants",
        "label": "Stock Issued During Period, Value, Other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails",
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of restricted stock",
        "verboseLabel": "Total restricted common stock issued",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r155",
      "r156",
      "r201"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeitures of restricted stock",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r201"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r155",
      "r156",
      "r201"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r51",
      "r201"
     ]
    },
    "us-gaap_StockOptionExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionExercisePriceDecrease",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduced exercised price (in Dollars per share)",
        "label": "Stock Option, Exercise Price, Decrease",
        "documentation": "Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionExercisePriceIncrease",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(in Dollars per share)",
        "label": "Stock Option, Exercise Price, Increase",
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueoftheProteomedixStockOptionsTable",
      "http://www.bluewatervaccines.com/role/ScheduleofStockOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option [Member]",
        "verboseLabel": "Stock Options [Member]",
        "netLabel": "Equity Option [Member]",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "onco_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofComputationofDilutedSharesOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options [Member]",
        "label": "Stock Options Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares remaining repurchased",
        "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased",
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate common stock value (in Dollars)",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "documentation": "Amount remaining of a stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Onconetix stockholders\u2019 equity (deficit)",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r159",
      "r160",
      "r188",
      "r840",
      "r859",
      "r886",
      "r887",
      "r976",
      "r988",
      "r1026",
      "r1040",
      "r1113",
      "r1141"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity (deficit)",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r261",
      "r262",
      "r286",
      "r307",
      "r308",
      "r309",
      "r311",
      "r317",
      "r399",
      "r400",
      "r488",
      "r601",
      "r602",
      "r603",
      "r634",
      "r635",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r664",
      "r678",
      "r680",
      "r685",
      "r695",
      "r791",
      "r792",
      "r807",
      "r840",
      "r859",
      "r886",
      "r887",
      "r915",
      "r987",
      "r1026",
      "r1040",
      "r1113",
      "r1141"
     ]
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Redeemable Preferred Stock and Stockholders\u2019 Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Redeemable Preferred Stock and Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r300",
      "r469",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r482",
      "r483",
      "r485",
      "r488",
      "r663",
      "r888",
      "r890",
      "r916"
     ]
    },
    "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock",
        "label": "Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r153",
      "r154"
     ]
    },
    "onco_SubscriptionAgreementDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SubscriptionAgreementDetailsLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubscriptionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Agreement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_SubscriptionAgreementDetailsScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SubscriptionAgreementDetailsScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofAssumptionsUsedinMonteCarloModelWhichUtilizesLevel3InputsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Agreement (Details) - Schedule of Assumptions Used in Monte-Carlo Model, Which Utilizes Level 3 Inputs [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_SubscriptionAgreementDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SubscriptionAgreementDetailsTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubscriptionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Agreement (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_SubscriptionAgreementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SubscriptionAgreementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Agreement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_SubscriptionAgreementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SubscriptionAgreementDisclosureTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubscriptionAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription Agreement",
        "documentation": "The entire disclosure for subscription agreement.",
        "label": "Subscription Agreement Disclosure Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "onco_SubscriptionAgreementLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SubscriptionAgreementLiabilityMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofActivityfortheSubscriptionAgreementLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription Agreement Liability [Member]",
        "label": "Subscription Agreement Liability Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_SubscriptionAgreementLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SubscriptionAgreementLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription agreement liability",
        "documentation": "Subscription agreement liability.",
        "label": "Subscription Agreement Liability Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "onco_SubscriptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SubscriptionAgreementMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription Agreement [Member]",
        "label": "Subscription Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_SubscriptionAgreementPMXInvestorPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SubscriptionAgreementPMXInvestorPercentage",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription agreement PMX investor percentage",
        "documentation": "Subscription agreement PMX investor percentage.",
        "label": "Subscription Agreement PMXInvestor Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r686",
      "r705"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlansDetails",
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r686",
      "r705"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlansDetails",
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r686",
      "r705"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlansDetails",
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r686",
      "r705"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r706"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlansDetails",
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofValuationoftheContingentWarrantLiabilityTable",
      "http://www.bluewatervaccines.com/role/SubscriptionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Going Concern and Management\u2019s Plans",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "onco_SummaryofSignificantAccountingPoliciesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisLineItems",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of Fair Value of Financial Instruments Measured on a Recurring Basis [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofFairValueofFinancialInstrumentsMeasuredonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of Fair Value of Financial Instruments Measured on a Recurring Basis [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "onco_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Details",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "us-gaap_TaxesAndLicenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxesAndLicenses",
     "crdr": "debit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License fee",
        "label": "Taxes and Licenses",
        "documentation": "Amount of tax expense, excluding income, excise, production and property taxes, and licenses and fees not related to production."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Convertible Redeemable Preferred stock, $0.00001 par value, 2,700,000 and 0 shares authorized at December 31, 2023 and 2022, respectively; 2,696,729 and 0 shares issued and outstanding at December 31, 2023 and 2022, respectively",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r433",
      "r434",
      "r435",
      "r438",
      "r439",
      "r608",
      "r774"
     ]
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible redeemable preferred stock, par value (in Dollars per share)",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r83"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible redeemable preferred stock, shares authorized",
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible redeemable preferred stock, shares issued",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible redeemable preferred stock, shares outstanding",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals."
       }
      }
     },
     "auth_ref": [
      "r1035",
      "r1118"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r362",
      "r363",
      "r364"
     ]
    },
    "us-gaap_TradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeNamesMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails",
      "http://www.bluewatervaccines.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade name [Member]",
        "verboseLabel": "Trade Names [Member]",
        "label": "Trade Names [Member]",
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share (in Dollars per share)",
        "label": "Shares Acquired, Average Cost Per Share",
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock, shares of common stock",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "onco_TreasuryStockPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "TreasuryStockPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "documentation": "Disclosure of accounting policy for treasury stock.",
        "label": "Treasury Stock Policy Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, at cost; 517,399 and 459,729 shares of common stock at December 31, 2023 and 2022, respectively",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r89",
      "r90"
     ]
    },
    "onco_TreasuryStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "TreasuryStocksMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stocks [Member]",
        "label": "Treasury Stocks Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_TwoThousandNinteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "TwoThousandNinteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Equity Incentive Plan [Member]",
        "label": "Two Thousand Ninteen Equity Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_TwoThousandTwentyTwoEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "TwoThousandTwentyTwoEquityIncentivePlanMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Equity Incentive Plan [Member]",
        "label": "Two Thousand Twenty Two Equity Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_TwoThousandTwentyTwoPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "TwoThousandTwentyTwoPlanMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Plan [Member]",
        "verboseLabel": "Two Thousand Twenty Two Plan [Member]",
        "label": "Two Thousand Twenty Two Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofLonglivedbyGeographicalAreaTable",
      "http://www.bluewatervaccines.com/role/ScheduleofRevenuebyGeographicalAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States [Member]",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "onco_UTHealthAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "UTHealthAgreementMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UT Health Agreement [Member]",
        "label": "UTHealth Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_UniversityOfTexasHealthScienceCenterAtSanAntonioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "UniversityOfTexasHealthScienceCenterAtSanAntonioMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "University of Texas Health Science Center at San Antonio [Member]",
        "label": "University Of Texas Health Science Center At San Antonio Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofUnrecognizedTaxBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r614",
      "r622"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofUnrecognizedTaxBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases related to current year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofUnrecognizedTaxBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases related to prior year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
     "presentation": [
      "http://www.bluewatervaccines.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns."
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "onco_UnvestedRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "UnvestedRestrictedStockMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested Restricted Stock [Member]",
        "label": "Unvested Restricted Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r234",
      "r235",
      "r240",
      "r241"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "onco_VendorAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "VendorAgreementMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vendor Agreement [Member]",
        "label": "Vendor Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "onco_VotingInterestPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "VotingInterestPercentage",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting interest percentage",
        "documentation": "Voting interest percentage.",
        "label": "Voting Interest Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "onco_WarrantInducementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "WarrantInducementMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Inducement [Member]",
        "label": "Warrant Inducement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4",
      "http://www.bluewatervaccines.com/role/ScheduleofComputationofDilutedSharesOutstandingTable",
      "http://www.bluewatervaccines.com/role/ScheduleofOutstandingWarrantsExcludingContingentWarrantsTable",
      "http://www.bluewatervaccines.com/role/SubscriptionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants [Member]",
        "verboseLabel": "Warrant [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r978",
      "r979",
      "r982",
      "r983",
      "r984",
      "r985"
     ]
    },
    "onco_WarrantsIssuableUnderProvisionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "WarrantsIssuableUnderProvisionShares",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued",
        "documentation": "Number of share warrants issuable under provision.",
        "label": "Warrants Issuable Under Provision Shares"
       }
      }
     },
     "auth_ref": []
    },
    "onco_WarrantsIssuedForSettlementOfContingentWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "WarrantsIssuedForSettlementOfContingentWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow",
      "http://www.bluewatervaccines.com/role/ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued for settlement of contingent warrants",
        "verboseLabel": "Warrants recognized (in Dollars)",
        "documentation": "Warrants issued for settlement of contingent warrants.",
        "label": "Warrants Issued For Settlement Of Contingent Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "onco_WeightedAverageDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "WeightedAverageDiscountRate",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "documentation": "Weighted average discount rate.",
        "label": "Weighted Average Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "onco_WeightedAverageDiscountRateThereafter": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "WeightedAverageDiscountRateThereafter",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate thereafter",
        "documentation": "Percentage of minimum average discount rate there after.",
        "label": "Weighted Average Discount Rate Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of common shares outstanding, diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r329"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of common shares outstanding, basic (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r329"
     ]
    },
    "onco_WorkingCapitalDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "WorkingCapitalDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.bluewatervaccines.com/role/GoingConcernandManagementsPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital deficit",
        "documentation": "Working capital deficit.",
        "label": "Working Capital Deficit"
       }
      }
     },
     "auth_ref": []
    },
    "onco_WraSerAPAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "WraSerAPAMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WraSer APA [Member]",
        "label": "Wra Ser APAMember"
       }
      }
     },
     "auth_ref": []
    },
    "onco_WraSerMSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bluewatervaccines.com/20231231",
     "localname": "WraSerMSAMember",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WraSer MSA [Member]",
        "label": "Wra Ser MSAMember"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481288/505-10-05-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(27)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.28)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "330",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-3"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-4"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB TOPIC 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480489/718-40-50-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480489/718-40-50-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "720",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483384/720-30-45-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-30"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-30"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.12)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(1),(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-20/tableOfContent"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-40/tableOfContent"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-03(30)(a)(3)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4,6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//250/tableOfContent"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-15"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r198": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r199": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r200": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r201": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r202": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3"
  },
  "r203": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r204": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r205": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r206": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r207": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r208": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r209": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r210": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r211": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r212": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r213": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r214": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-3"
  },
  "r215": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r216": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r217": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r218": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r219": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r220": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r221": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r222": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r223": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r224": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r225": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r226": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r227": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r228": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r229": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(u)",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "5",
   "Subsection": "04",
   "Paragraph": "c",
   "Subparagraph": "Schedule I",
   "Publisher": "SEC"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "7",
   "Subsection": "05",
   "Paragraph": "c",
   "Subparagraph": "Schedule II",
   "Publisher": "SEC"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "9",
   "Subsection": "06",
   "Publisher": "SEC"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-4"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-30"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-31"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-32"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-5"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-21"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481260/860-50-45-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481260/860-50-45-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481260/860-50-45-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-12"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-11"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "11",
   "Subsection": "03",
   "Publisher": "SEC"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-4"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-31"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-32"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>109
<FILENAME>0001213900-24-036738-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-036738-xbrl.zip
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M@^?K&]O69.#*+^VS&6YL;#[#KT=^KLS[JJA]<>"+VL)$>;HU'+Q<,;1<H6_
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MCZ.S9$=(@C^*DA#HC3<QG><[ _O* +Y2V=(D@#[R&:R.K/9;>"NSWAV+8B_
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MW7DK:%MO_V7D"4^&92XS4C'P1/FYL,DH@YOI,E3Q40<!E>((#,41FOQ@R?>
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M*[G&(;L7$J:3BR2!?/AR=O$:E@'T#[#FHR2.$IAMG)+%SL?[ZO\:4X!^(-\
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M4X&MD$^B,:9K83B>.=DX4G%(Z$VKU7SZ(U3 /U+L(_-?Z3$S@T<)E_7._2"
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M#E8.GP?L"9,/>V8XK@J6="G+S3C+8!UH6#+Q*55=A=*]$*\E#PCG$$NL)E?
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M20EF,[7(?-3X*7-@#F==X;MR2CZGVW3$XR@)QV0!^0M"&.T:^,H#Q>D9,NF
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MQ!*9ZB2:\6*57%1(TYYC!B+>@U/G^;3,O$VQ((@X;^1CLW9;D: L6P%[QG>
M2Y(O63DK HJP%NR?-(>\GCV,:?EGOJE5"_TI\#N."A!X&RAH)4^XD]5HN*#:
M9/'J:N$2C)TEOJ"!M<O&>M:Y >NJ/M8-,0C^V.14I+.JP$)S-WJ>Y![3BECE
MG[KBH"[_>AI0L_,M=?(JH>J,<+>%X>AL5D%A)W@S.ZNU\N%J35.P1&I)5P8I
ML3U'1.4F[:I2T76#-3MGQ,X6U\AZMI:]*FNUANZ\!'FLTW7MIG=X<\#@;OD$
M"V#9/X[H)"@70B >!G7FX'U>E3[ B7C/6;K3E*.M"Y,(G]J9N[J&S+C@D2AL
M'SWNF)9%8N)0')=%8"-CIZ044T-]G?3@5/+'H)(?6< T5I$1D8BEI?>T,2B
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MKT*:E=!:*RRJK5=J= D=FI(PBL6D?&Y7;;!9D;#@[9%AIR@2_]OQ%,W7JIZ
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M46T:H3DDZ&J2-:9]"9>29 T942+H#($ XPF\DT[_K.'ZDG%0=<6I\,RZ "=
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MOTD;"C9F8GO++IC;37LVM%GL1LX#!UARX1>BPI???V-.[/MO7EAH'-3%I U
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M9:XD%1C41[F9L&KP)3H&Z[>,C70 N(1FY%BL=,0UY9C\VMA?K(&TF0Y&:F_
MIY&38GVZK")5Q@,+).<#0'(N=#G@L,9IE"G5@0N,FZ'V^2U%M<(&;.ZLH!J+
M%?X*5K@0Z-[5 Z(WKCMY,4(RR4D:B[;#VM1XL<UBFX^US0L)FQ#X(H>Z0Q:4
MVN]CFB4,&W2(X$5'_(B*H+;.1=MSN#?ODXRHF&XQW?<PW;5)QHZ3=N=V@7[1
M-ARF(KWGE$-#5&@KZN17P7H7VWNOZ9DLB=6 $LB@ A=YFCSUA8=H:V5"O(%!
M$*91%$ $*,U0^R&#&%H7+1L5M9I&PC9D HY+R&7:&WG4Y . F(NM_)K]W_N;
MO@AVZ.S0?=G5H_Q3HW4%>DBH+D@4U+94#L'1/66%42;<O35Q>2VB^=))%2'Q
MF <!PWRW5MP?YD/T,"B[W"A,-6HF"@O3XO75=G6&N;NNL?DQO2W?\K:1R1,N
MS+%B$^/?@&09>U%OAP!)+ 3KQ^+SNW,"U[ L2,XWW=\G(4_>A/JXNUJ]\OJ.
M\(^5JJC3D9IAU=\!LT,+I!9U*;UD%VAN&75[_H!.4G-V >FVIR-?K5ZL;C"M
MV*$8?Z&$#N56D E:!9TN][9O)_((#"GB2[@^P7.@ -;%V?$8\B;N=V$NGFLI
M+[[D9G^8-.6SNEJ\?$R1T-KM:F/F\+1%81B8*2M9@&5\T3[B 3,#@L=I1HJ)
M&!DG95CGV^0%;NC!#T Z=63U@[!=S^JO=._KV&T!@*I+! X1F,Q5_7<B4V;;
MS< %4B,V/!A>F\/8,*^\W 2G*8=^4$)(' /%&RPVL$?WPVMZ.+)?;] .8<_B
M5VPSFMF!F^UK@)H[?F)#G@!%1+A=%'V?_*Z_F Q:?8KD]7)]AC%7&,657-,O
MIDPI5W!F?$O%=74DTC>!E4>5*UDQ7==#&HA;4!>K[(*A6Y-#Z/>FP.H(LEW[
MQQ @74S:*D\2][MH<+ZH<:-V)^<_UJ_#0F>,PW%'Q2X/RKV<43C ^6G>!9X^
M5F!SZ1,]ASZ1CJ>%-4/"A81_'VR@[9QS,;8+&.HK*/4;K+7SP$R _-'DT"O:
MW#8CC.^ZKVE=4A2V.XWD 6LT;SV_1S-LA*Y#>3J<IE;<I<\80$K3Z3=H.CW>
M<@PP;$!?.&OZ6K?1'43PRB&;>QBY8G7!WL 1<]F>'DX*\S!C US!W'V<7[+Y
M3MYSE7@A2FZF2XU(!5X]HH683W&FL%?D*632RH9"6.;3D=CRWIS4OA9S)%9F
ML& P)_RL'4GO.=,G)4U'/J\Q^A[[TMTK19C']U6PW&%7$OEKCA^WA@MNH$+8
M?A<0/(UGGU&%.QUU6YJZX!&QN/EL"E]>L>'WL.%[N/)8=[$9*2L/.I8B)BSX
M*C=VP.F[#LL56RRV^&A;="'/KA\/"/4?&_-8R,00'WJ34<;.;)9\+_C-^,.1
M[*=8;['>]V(>C4-W;(.4." ?X V;WF(-BI5\$'&%P&$5WM"+DI*HTDO=2R<5
MU3[I6.J@B^%^'(8[O_"N[\+SM>9[>'2[4U9E+O;W$=M?D;DK@W(?QZ#<EV50
MK@S*E:WAX]D:GF-H,H<?"^^'T3.-:"IG]!Q]FB9G3&BIKCU+^WV.IIKAYX<$
MK6?8!9UF8TV9:,N1=,J)HQ6K+5;[U+G?L=DK1;6VX.YE4W(-#<\=6RC9BS%^
M"&,$ZQ=OX['RQ8@HE9$$65ZK]%L@=[0/%;,K9O=>9E??UDUK,%1NS+Y=C4(8
MDIHUHPU.[]Z[2&7?A";U4WO%IHM-OX]- R]#=M&I>&YLD_%LT@G\E!>LM=_2
MVUM3)& 6JY%K?3T&Q>4\9'V4-5'6Q,>T)B2*$"J(V] UL=O!L ?&U"<Z9H"1
M'4_>J&F9D0R=![ZR$I:#DS(!6 SW/9UYQ"UT3@M]26F(/M@/QS+P]71X8M_C
M!SQXO \?3)OB,H)0:CG8:D-C^E-+I-%Q*B)R&<L\O&)X+P':,\!-4EU#!0J0
MF?=!'GL*GPNXXRJ*(A@_O ZM+,*(%3Y\M?I6IUXR,(_<Z'A^IQD^V9TC#MCP
MZ,\"S!BX#!"+X52@'XLN'9QM8;WK^K:_L=&=R%2VD>/A=ZR(LZUO>Y3M3O;N
M^0-=3MH;/\UY;ES4*Z:.YJ&U##%R/?;DCT(92GD.0REFK62%3 *HYG>?9A$/
M( DI!J/C'???U)E!A9AE:AU8: /]O$D>>!\&C$&MQ5FXQ3[@:>W=,.2,"O%L
MX+C,ICSI7O)S(IX7QF_X%]DMEEGDU2ZJF([9!/A<-!->;3-,-V=:AB)>0I>$
MV3R>89=MY226RS_RB-XEW0WF:NXB[V,;;IJQ=4P%V42[XWJ)*@=S>GW@(#R1
MGXFG>&(75@80=17,VBP14B8"]-5/K-AANV4:7G8Z"R;;J&H>+$^#YW6N%"+O
M 1.=IE/B]F'3 Y&UZL1<A"?;AD33NTSMS O;+;F:T(V.B3/)^HRBKZ.7PK(D
MUB^2$["!A'$]- =^'V=Z.W:AV"!'[WM4(CA/PV7B%D)T,HTJ]R+.I%VP3W^%
MQ8$\#?M 3JIZ>>?)5?68>=9/5X'XB_85TX*B"V"AC5YWBX=*]=(.-::XC1U3
M6_,L5DR-DU*6%&#1](07<M4?V<!P'+*FO7B]6YQ0_T"VRY/_%2MSW Q\!G()
MF#FG6# <,:L]INFX=PUO,:?V;O&P3A?*PQ*W*Y/&N%>4WIC2'H6'$9-PS;B;
M/3P>OH/:5!86'P=]-^R+KW[226^WP9.5D-%HEYB.$.Z,<H'#36U%XQ17J[\L
MUM<>(T>O _O'8]@?CI&%F1V%>&K*>;@[SC3%WG9X(]C#?TJ!\A1-QU$_\P.$
MCUN#-8*.T9[>/45)0_>1CH+]^SJ.Y6LF!)>Y(0<_[+EGC[H&KD\)7E#VD#U"
MZSV(Y'=UVX;N1D'=]F?1?Q+B9\N';/F!#L ]AOSE^PPF+0JVF#0+:7I3^1*G
M@U6(0/,#8F3'#B1[5!SNO'AF, PQR8.\CG0:\QQOO86&'NQ:9NXW8<\A I1J
MA08[[K.5=TL\G;J^?-A&QU7C4P$C^.C_W;7L^&SF4];1I;SP8<JB9>]ZLN!W
MB 2!"]*P673WT!V(HM/VE( V*?$2SB4]B)Z4\_(X+KRKQ=$>IN'00Y,ES<-E
M(H'C)1S/2$>"_[I R7F_H-W5ZA5=#2ZP(D?>W#2ZJ\MBO+A"XDAWPW)64J"8
MCU#3K1[J1CP3"&[H5ZQG9WJ]*R[(: @."A85(1Z/68/&4015$CQ+;J'\-:J7
M!TZ=_>+VEB<F[+>2:E:5*/'//1)O,+=:*TG)@%OB^QJ>G)QXW?%F=X^O&KBJ
MAN^*CN,:Y"O*&X)W,XU1PHUW#-NW8HVK&=;3?N12TJC$0TI+S];!=(!J89$>
M:?%YF&K &,1XV_XNR/UE%2FG/,E$37QD>BVT:GL)?B@.ZM.@D6ZK\KPE B)7
M<XM-ZHK<4-S/\&<)5B)+IY2YKIEO?R,FG#9$+EE=\].+=#:QNNDB-ZLS<O0F
M-R#QFVW-'7\/9JI)9-'Z*2,,'\,(P^_+"$,982CAWI-H_: T\":R[K3UG18!
M4<$*7#RD'RBR6'-L@PXGC\3R?N7JEHBL).EUI77XGPU"&]E1=;_C".^B=C(S
MMEG.\\X-L2TXX@;45*<#W=$KCA6XZZ-QR($\8N3/L\370\@ADQJ.-BFL-(:S
M,K\>XVJ%ND_3N<H/-*T/>&@J/)Z%C(F")YY9@B!^CF1"N[?3&VX1Z$1RP[B[
M*R3.;^\S >1(',?BXY%S<9GK[TQNJ3J31*T;"'373"! T6381(3&<CH7=57Y
MB5#HN\ G6-IMSZ'=]H.O9SIV[EC%3B5I<QUQ.$-5..BEL\V+2#P^+9EA8JIW
MASN$KFY%ZOFB=/ EV6!D6OPE2(L-@CR:R.Z.M( /'+.#!K4->Q5S]K7:TH1[
M\AJZJQ.TO=$RB)%XTE1515,O3K^'6^)&T(&2M@N>T]HCYCN3=FI]K*LX'52)
M2SPVH_Q#_/:^UQ88&KRW4DA@R7H(R$20@67YYQV=>;^-Q_LWUJMR]8M4+5\N
M7S!YVQCFW3O4!H)HJH^CD5SYZS:'/ZH&[#8<3^YD]SRWN)H3*!7=[-H1P')8
M (+?FPCBX[^TF@G[BZU6ZVD8L/?]I>\WCD,8'_Q1&^BK3QCP]?E7Z[^\^I%_
M_.*K3\\5VQ/X)UG /^A98X^BNYB&VI"&E*2#W:/OM(*"CD5G7'?&^\IEE'X]
MR0GDUMP9Z?9JK5 (:U.LM["44$W>* C(-T)^LN:+G.9U" <Z1B+(7;<]Z_/I
M^PY"2_T.AKS/Y'WC2T]A&HH2W*N)/,]"96LM52G?JE!BJJIY$>1:&B!2I$D"
M]%J0NVVBS65'L#5UM?HK!8!<4TMU?^Y2[W =QX'L>SL)H0L*263$;:CY47MC
MXZMO1C'9.XX_0#PT<I/,7P^, E;SQ1^_\@S@V179XT=0"T^"M]G=<$R6;5J=
MK[<-HQ[6$%;V?))M]-OMI98RSFTO#=4M?JA"BRG5-K^C'769IVNIEK?')7W*
MLF4]#0;1,RAC[0Y2IN,&*#M@\N_]-"(=Z5YWR"0NAQM5;F@Y&?Q]N]Y*.9=Y
M@3\H+#+I>I5SK!2J&+NTW<U8.#L+;/KQ>/_<@3[2RMFLS<C+_$FQQP]ECYX,
MH$KA4Y7%=-PQUQY448@L5O@!K-#E$DXP_3$IJPCK5=95-'GU)#WR#L>D0+8I
ML]S%NM_/NI5VA9UF=VR.+:. CO1@BED5LWJ\6:6",<,>3)(KP]3.2LG%WHJ]
M/7Z3WDYCS>T%K1FA_;!1>'V;]*I0^J5?I.T\EIBRSQE<E"NSQ3*+93[:,K<8
M#*NX(-@<M>K,Y::;?K@)1E4M+6;%B/$P9[&Y8G./M;EQ8N5OM36_%V]]UT$S
MBF)IQ=(^P+X+]' C\PL".(+MA3?R4Q[Y%8LK%O=8B[/>\1B:?TY#*%0QQ9S>
MQYP@CMPEH)-Y+WDE3-S5W#:<Q*X'T'YB*,UP307V]AQ@;]^E%JN".SU"QZ;>
M@9*P:?"_3T,S;JSQ($.H,^'Z%$5E%0W 4P81C*[;MDB5/FU;_Q<FF\',;P0S
MVH2,UW[/7I*-_C,G #]Q]V66SSX_ /!2/1, K'<KE:/_]ML7U>K%V-2K'^LU
M)O$J';'J3EK;7[0NP89 #%YM<PS@LCZ&12,M^)"G,:3O.')E8%AEB'=^P3S#
M)IM !-*"L0@XK.O9</%&"1\<Q<;J570;+P0:^,\Z]BQ?F1+YGX5"@ZD@#+7V
MZH4,(G\[#?TAU(J01VEA]0(*WZ<X*"Q4>_,I=45X[0,+P([*C+6U.R,[?2UR
MMNC@CU:58/WO9GQ]H25U';JP;2+IY77=&C+/#WQJX_:Z'AL^Y<@SB5@BV%(9
MW8B>VEHIOE %42Q@Y?&. =.,]5K(5?Z_FLXH3^3'C*1#,#:O=-3PF\!3>_-'
M]..K;^AQZF6^$@9#QOW\50@2_J.^9M0\'>F7T&YKS&OB!?WU/WZI9+%:C1%/
M+)4-=9CQ_*I6+[;;NAGH0M9'8TBIXRAG?%(V5FOPOD9OM"S[7V79%^FG![Z0
M,C?Y*\]-_DN9FRQSD\6I_UI) <_.[>I-Y*K@#*".^1UM^4O",;/AC<33Y0@%
MA *!4;AIGE*(UKI%)K:(! KC,0ZJJ*A(G [9N&0UGA71P:;9;I%*2..\/BY]
M(>'FZ]:S8L13*^S(@$P2:/2=4;Z=,NH79OT4HH(+O!SX<LZO>K5Z81?M)F0B
MU8;.--3N,P\^M#PO_U5<.,"HS"AZ[UM\KRNP0Z>W3"=-=Z>A>QR7J".R&\T^
M$++D?"P+V=W26]"ISR[<"$5VFO8\[K(44=&W\7K59)<>2&;%H\QSV""2HC0L
M[H=XS=A3/@,+$.![O(/<S'Y)A$%JAO><FL&<-5L\\B8D!L)F<L0%9 =S[$/;
M1FF=%H_(*4+B$\6',QHCHQ?N FZZSKY[/_,;UF!WTJB\E/R>0\GO/Q*I9I55
M:5YV6^7:_%LPO:87F !T!%RS@6DM!<DPFC>2;[__^<4WW[W443$POYC=\+"X
MT@_!4^L5C&P^I2#X='M_9@?*$GZ1P&"E[$XS5W]Z;^.0F9T'&L@JJSW=8[-Q
MU/+EWU[$2<L[LG-0@1FG45O?W7/#])<O/__R2QT21.%4 @EA?7@'N1.EE)KM
M%3/Z5*4E_%_!'F8L0-$=Q!WHR+M62Y< HR^-O=+8>V1C+U&(T%F[_HYB9XH!
M0/%!T50//N\0Z4T<YZ\6Y+ALN&3%V114P3$4^WP?C1+3[@,C;RLQ<Z*^D>HZ
M.53.-IC*\P[$+8? U#S_S^__4,ROF-]CS0^97I1:@45M,%-\2_D^-Y5@@-LA
M%'A-,;/W,K,99W1BE99(\\"AL7!B-EMAN!"&*MV")4)L_-!(/1ZYR:9TL]PL
M9Q^J87+IECU-<O73CBFDP((A].V17<SS55LFI$(;_/?FN-K1C=S[%CUI!D"D
MHQB,&0L%;OQOVRV9<UYJ6;74R+0%[5*M?GO&:Z9IF4+NSU.8IA1\GD7!YVOV
M,,I+LZ/?@:(@E?Z4[%U#JF,:/+,TG>*N'X?^&'H /-ZLZC6Y*-DV1DGL43"&
MB4:VFOZNHW/LF@/E%>VD-#=!*[:)M(QKZ^N^ZX(D[O'[QX&>=*)]*56A)U6@
MPQLPFP'E=&=%9K,5+D/0CKIB7JQPTZR%O"5R'ZHIC<:*!=9TQTX7+0QUY^Z8
MU8,N69IP-9Z9L&/ JY.QQ8TQ&2)WM<(H)6L<RNX01D?1C]; A7#JE-NUWHZ,
MHG=1DDWHL(<(!EKZCO%^F^A)_FCG#Y8/[@_YO@]XMI"*L_[HG?4OXB"%!8LY
M7]EY)G&VG&D&2?%L^= %#,V;XC:?'!1YU)[B&(*HK$RB9G#G7ZG0\>5O]B%<
MP/EKG\D/B<"-\O2)GB04.->OC:1W/*(#[$0/_C'!7QCZ,5H-?]CLZ1.E<4L!
M;!@GZ%H>QZR@SR'IIUSQ#^&H^BQ7RV8I&C<@\P(L$*DU6I-O>"#O5O4UXXVR
M@@M\]2.?DG&JJGS3+*#1"YH+TM2L_'+6@>78)'^ @L+DEOO1'8+WAWKLNRBV
M&#*6.Y_B2?.;YZY'ULJ:70F_Z=\E4DC=W)97_.J7';K Z4RVO30;QI3BNBB+
M55:]1SY3[MC?AK8_"._QG:<29#&5^B YA;&)+EYL%>6\N,TNBI%M\QI/7&3X
MZH0,8/I%D>6)R8H[ZN^R]\GO _ 2%G@*$F*.BF%/Q':/O'V'.S"\3#<Q;)BN
MR;'707J093N65X'*_^E:W:@5(2A F#),!Q?&&&^U_8*R/7^FS<3OF"<P$NH>
M-G90]:1VJT,\GE,/[['>PS]HA**'/ &WT=5TN^A*-2,7%(P1.9+K2;P#0'/;
MQDM#G*5,?&T_&EFKZ-ITEPEO62B&OMP/QRT*;_392SM:V<J> ="W"*04H.^C
M@+Y_*$#? O0M3OW7)_6]I"L@FSS*R13UTIO%QJ_1@8N"[@E 'RQM.LMF9HV/
M&6,TT)21^!K<Z>=Q)2<GX&F7":-F\)3V.FIH)X2<JTP^4:0!FOSK.M(/^TAR
M3NK*F9N$OOCG)V._/=[1I7]Z[_6__.F'U1>__Y<__2%BF7?:U^;ZCAXC??;+
M/]*J_$J)LBVMTW"1?MEYDNQZVB@M3M.-AZ!EGM6+$:I['*I5/K3#D5@_3O71
M9H%]>JL\Q<5T\HRQUGR-Q]<P'#>-BGRV_&(.\Y7R'!WP^V]>> )'D)[S[ST\
MEJ]_W8::>>U'G4.##2;B4AX/-"KY*+R8)LI4T*:K]] LY[<!6ORQ,;'3//!D
M*"RJ?C<[ 8KG?VX\^AO/ZN')PM>O?M"G\,/CTU837,AZ@9(IQ%<DM\Y,^[P@
M&C^?BRS<O2&H"6[J8:/2/N^1^:!A0,:/]VB/_9H\DM*"^==1WPPAF"8SF?84
MY0692YSE(X)^]GH:T58?;?CO'/!/+V%Z"Q)YEM[A3\M/U:V?OKOI.1%A5?5F
MS2(J73]I:R(NJ;F41:Z[P/.BYCX8&UECHM+27[=X^$G(^^*BS+FDIW?'@G8T
M84CGL\[!BI76G[LC!C>R&U^Z;U8(<+?WR1T7#FR6]S\K=3]W"S(XW_>83J7G
M\^=^<S(/] FP85SV^?13NFQ-,=7-:&<Q?QLS+YFD.N7Y5,EO5LDM<J:8/JG/
M3?M0>7XZUL9;<1UX3>^E2XHYU$QW5!G('--%I:P6D<FB4M'8:I6HHV;"/Z)]
M8AZMRJ6FG-:!3^]%E0M\>Z=*22"USJ3'I(^/XV13PS;MVX9!=3P2Y\9 ][:>
M]!SZS$U<_>'Z6+8.JR45J\I$L_A]6D7"-+IZ-B:8;,/<#ESO8KU5N0#7ILE]
MK<GQBHV0^QQ7-R@$WD#37=35,&URLFU&GA=?@W "1RG3BP4^VWY86T,U*4:Z
M^A%700='RT5]VIE<*Y2['<[BW*N5HL23M26YA8W7WT@HL?RVDZ6-\@VO_=R@
M?#NU5J&#Z[K TU^E>:AY-.IM(ED$^9GC70B=[G3QV^2W^V.N-]P@2@E=&&Y.
M.@TG!"RB&6^T*?F%08M.JLAG"\K?X9E_R=?,I:)IE7D+ -";88[FUZ-<KKM*
M=U/5A^/6G9?7M5F@7D-88](,F-0O547=8FV1@)G-$%S ,I6&YL?7T/RF&:-!
M(N8:O,&VIUBHWUP8E. 6-GCRDN6(Z\^TJM;T=#J3 ;]HHXR DKVOC5@H66RX
M][B;)5Q4::,^]3SR4O<;\H;1M5G3,#K467_D@=E-VZ->T*Q'A\#$KF_FIOE^
MWCD\JW<$1O2]QREG()9-OEHBAB,M@&CIDZ+^XCH(,TV:M++(G<=;0I?FP'L=
M?D/QW0V&K1'@U2M48ODASDY9'^HU-SO3(;=3:+5Q&P>/I8F#GA)3J78'&94:
MHJ(J7+VTJV0)Q\POV[>N5M\\_"EX-!D&GM\EP;WT/E(:,7-./G'@W3_-KINH
M2C-L!UZ#9_WPLYMJQO0 ]CV9VDK%;5E;#Y\#<"G%';'33TYS6[&GB[-P&L%R
MLH 6WQA/CP/*FJHMO=&<@ )>'_:7[?0Y;*<Z_LW0!AA "V>)0//^ZDC9QIYX
M&[-R60IHV].]Y:M?@BW_==^V-3UT\718\  QVJC]H4>71G+SB!791^HTVA9-
MSCP;U'>< 2[&9O7+71,8RTCW$T:*RFMXF6.CL7G4_5S5J%1WUK&7^F*D-!,P
M!\YUM7I!B?\%74? 8231"I R#5%N';QL#=,XI)1>N3R2?+AL(>Z^32$]*Z)=
M]\S@P95=\75,X-:X!)!KYB@)I1+QVPN,+[K33)+P$BO"NU1=E$)14?914/RR
M5RY+]E=JD+6\;9,U?])\*M756(F6<8B17@SJ"EX87BO9AVD8)X8_G>6Z\S&/
M3QI_>$4#I_Y6/>Y6P]3=U2<=/=^$:XIYI3#G\<.[>J38 M6(II.K.090B]=2
MTF(0U2)4+[^B$0N#)6>Y:^,0QZTR@=X:QX^=V>[:%+_XJV#[@2PH11TUKVP?
M+"T?M9*I&(F@L(BXFY77%GN*F/;VM_!&M9=32K=IZINN1Q2'Y7<SU/NR8IZL
M))?KUE_PAM4'*BXG!DCQI^UY+J^IH<30ATES!2V#T5U-S&6ILL_R.S)#UHDS
M[6,*KC,P(IU0<'*;8E?/ W]6B"8+_NQ1^+-_+?BS@C\K18^/M^@QX[R[8702
M1^8,5-HKWU3*3+>:49<RR&\2(?YHI0,_L*0$DJ" WPFC./<_#TPYBG@M QL)
M^]#U/**4=J4$:K&/>*:>>8,FJ\$P.+V^4I+Y6?DB^^KU22],KPM-6;JFRHHB
M&I9RY:$2>,TF\/ .CPUEXR!'_LP^@V0(?<VIUT"543M].R\M%YJO0C#R86B4
MC-F6;BLJ>,(QBC5FIE]'WM>P*?Q)Q>X>S9^4O.L%;^I\Z)D#!DUCO0W6Y05*
M$:.A0(3MM2@-@NABH,5 WYM?C@6+=(01B/I4G4P&-YK%%4K#8G+O97)B:K<,
MU:9X5'E+X.9JA0]L]J*X$POU>50;98RT<.IW<F;8@9,UMMIBK<5:W\=:LY%[
MKS+%RH^N8\ODQ<5)%K/[(&870SZ!&H@+C&08YU"'8F_%WM[+WI2:JW];1LQ[
M+5=I1#R>*8GWZ"4HC<ZN'QGG&$=.T3:4\E8_W-2=]M^+Q1:+_7 ;,^_%MV$P
MJJ=Z$_XQB49JL[^>AE''4TXY5522_FB8L@Z1J*.BC>7:K$:K-4\1]TFPK%DA
MEU$8&?PCTG8G_<FFA*=E%3QZ%3#W4AV%R>]JED?EN6VT@H19M#8W'L%5&'R-
MT^CGDZ0LFL1JJ/$;T??3>@MT S>%\[M8[OM8+KI5%,M:XC]"$4W=N.%#\5(T
M"B[PSR=J57ZKZFBB RTC]PD1)O5LA12?Q8>^6(W\F%&0'"L>G0-Q[9=JN21N
M3<]FCRN@+;Q5OD"<7-D1>19J#$:F '!UV]]QZ7+3'XZRJ?M*.G#;)E-X5D*_
MOZ#4'$&%8=6DJ]4ORI1+%W]IO.;8?\9_C=)'>Q9LYR)!?:P9%,X=4YX-G_7S
MZ;+W_6R*";<@$_SCQ#0-@U$'2 [HZ!]FM3*=]!9XNXA16V3$,ZJ\XMZE3Y$I
MYFEK.1OL!2J^.T4DMY+P>F#\&46%H?5!X$<?P0$O6""3QSQPKLGZ*JHM;ES!
M,XIWF73B,=ULACCAG$V?JX.3RB<'BE_Z#7B;3,(Q7R!JX&?HE\Q>W3*+Q#Y*
M?7.&A\#+9M1[LRW@@Q+I/#;2Z>A%^UF>8UCONAXSEZIUT@#XPORG8HKXG2C5
MUK?]0.9J1.OR@6Z& 8H?YT9>:A3S,!!3$67KI+\>>WI*H:2=Q:0?:])3I_S>
M7>*PED&% >0R/*H+9B@==M.9X-P,AV)_Q?X>:7^>1>:AP: O[VF9D#VD+PY&
MMIHA[!E4*P7&-I29\.< CT[3<,WHAVUCCQ:M"F0CD3-+..N8P'MP(W02\M.A
M;B#3?A?:]C/*$LD0FG''' A6'U8V_&M0"QYE%LL8NU+ZP'OV5$#73YLQ8%!S
M3Y'.&HVI[-UNFP!V)TWI>6S.=_&98VE7 X<=!)]]#;VY0[-QH1MGI713-^@@
M;)$^PG^X4"]&=48V@0_S8"S=2K\71=EM&(*0?9+_&6YT;M9L%8E.W_)(>IS9
MBQR6U<QU@:QQ0#JC2;)(J[FC7:U>T9.%ZZM,;P@CJQA16AX//&"BEG9J608)
M/ZLS^2@2DXF!C=&5":"R8(H#%H^RIUY;.\6^(P19-O$H-REQK+Z6[.++HGFZ
M12.9,.I?4!L?1[P;LC$PFU%X]YK_,O>=C=J)"H3L53N*WQ]J,".9?(+^@W
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MQS?"[JA3B>[W42_CHE[-F4 -P%B@]^(>)Y"-%[]J0,=B^T_%7C@$!>/O)!*
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M0VB5H7%FJ&-83PH^$]OFJHQR9\%'M^T%K.2:7"=M<61$_PP;PU?&3(/W)_0
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M>?*$XDSG0/.))7:4"V]:>&@7^TBUP.YS#@K:GI!M6H,IRN29\AB%BP!H@5=
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M8+7,KM+8LS#DG9Y39//B,?!*$1UK?Q/^PMSQ^$J E\KZ_?9D(S+@:O7=- !
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MZ0%/NKW7M$V?_AE63*G%E#FK>H^A;8D^Z0WSF'Q64'4*?7B,S9Y%@B^\C6N
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M6D$,4^N5@0V+U /^%#\'#FU<A/#[:.:H%!/[/6*!DR XZ 9M $/Q&(QMI<U
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M)6C9\(+C>RR<H<*4ZH$W0=P=FPP!H6RS,;/UM/&\EHZ9-._\M[ :00$FVVP
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M[2,%E*E7NC"Y? 9,+J_JH!,WEQ11JEE+,1%8 T('O$D\PPY GNG-8XIU(HC
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MW*0[1+)]<GOA6K/%Y-21C5X5CK#X1((AX$2#.L.TIMB2:OCT4@U#EY;J?QP
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M%?:54L51A>*#FL_U28/?":</\!7Q3'>D#$)9+&%BLY]$[Q'?6#A2%P3HIX
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MQXXG(WTMW;YGY#\#JH7?5 K#K$N^8+<>3B78,+N&#C.BK.4\F'_="4NEF$A
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M1=_Z(3_O9Y;YB[H,O67^[.-KU3O^_\???7N9H>$RL'9-W@_O@-ZYC,WP=9E
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M'BXSY8IN7'([PNGY(YQW$[WW5C\&/""<E";V:^-X@O],FY6_!*.:9[SI 8Q
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M7?;U-U?9=W>WDT_O#2RG]6=P6C__\>5OKYBF&G006:1C:.#VU=QNP#7J5CW
MYV&_7@[.!STX^6T10(<Q*$(#YFX*/U6ZC+FZHW4<^F\, **UL=Q.J)'?+EY=
MI,UNC@'^0PS,.:7L@@!?%"U$Z%!=M]F*AU>T%B%#PV,,PP&HB:YNSBOD=?TO
MN.--1CTSQ!GV6A&K]X?Q;B8GS#MN%[3BQX_$T\;)\,$@9-H(]J)S>)>YT\@K
M;\A1469W^]/-OL:J C*#R-3]Z8Q,>-5Y<RW/_MRZ#>E#$1Q/L]$V$@JA55\Q
MJSFZ)Z=>H'_**KRFO<@)'^L34_&W/40LMLD-,]T$#E$W\>#RMA?7#&+%((?<
M1JR'/RE;TCF_A7N8T*A 33#KCWU"^'O8%OPKP)P571_K%<?2$:.0_?YI[\:0
MK?BT2K>[#H\ [L:_"8=OG(F$^38N*6)0]-;+H&->4@&P8I$WL2$YT?-$-Y?P
M5/F9\,/L68T+C0;]AOXELV0NE@6.8?K ;P*N"]P[!)\9VQ[?('0C1,(J0P;$
MT#+I85!Z&^'S(Y286K\0Z 3TAPY<6) ,ABE3BJ!,%:7]%%T#;5Z1<T^;I^%3
MMU/F?>@:/?>#NUZL?@1QS]L<KSL;09P8,C?P\/42TB(B8]+ND$?HF\4RQ(+!
M!&[]W%3&B2$K,%3#7S(V9SS+^+%(LM"/@J=U"U/XC(T16Y9N.W9_8'DZ1>3I
M$QHFILF!@5M^,).K==_QU7BFQU\(8$5Z=9D FH3%;^H]$KY,)OGURQ=3=JB3
MSJS7A"V;&"X^_=/JT6.!2#%_)$FBDP<)<X9U9C@S>JRAGGBC=OFZ(6>SI3R7
M<+.V%-XHV9O: &)%:+T'@7ITJ@63N)([^]41]!O<Z'YMCX*DR'NPL%T;9FUX
M([\LFCRLZW KJ-E\)7?3CO"6H]X25&<!CE&>[9$-\0VY@]_;L?_<&/4@*+.'
M&^S,#&_\%__;37G?BT?VNWAD8@R!:$Q>X4VQ[?-R+#N2" #)>@L;4;([HJJ8
M-RX08 H)7!,$E$)=T$*@J[J:\8=^$T<HF H;T\7J%0=U&T2GV4H5*E\T\K57
MFWU!!)O^+/A)__A#\___?U=/K[[?E]X6JJ0_+]UC[K('?_5X]?SBQXM?+U:X
M^#??K[Z]O+RXNGKRY6+$#QU6K)LZWQ+>M''J"I&OX%W,CIKAS3&9*:."^%C^
M.SC=@O<28\O6N3?&JQK$D"B#ZQG,'GGZ!7;#\2#(/9!XYUT\7>"@X(A3VAFF
MQU?7$UE]B'LYL.RBVF-GX,4P805.=5))(.DK4DRW:F^&CD3O?HX.F<*J=D6#
MQ.1:P>0\_,!>N_K)W[DFZ8IV3\\TB _$!X R60Q+!C-,S"82IVV9NX3PW1RH
M\>;"EX53 0X$_IKW4]HZG5$)&/+5QF^")9S\O!1I5>(0W3C_TR^NGEXB"ZJ*
M#X%_G-':WH_-4P=;.",AT8'=XYID)/PC2T9"GZSH;%Q$3V737J,0U.*IE]WF
MH0B _ +UN\M;6M=)NK1@Q LTW_SK$D-?_;V&= R0E;ERG#9*#S3JB\$"_NE_
MKUZ;HS0P ^%E2Y*?KIV1-<?Q8 <,YD/V#:L-6$G:_@J5.2F#=!N-EU7$;AVK
MORTN ?Y@24[X#6))DWX.:5(&56/?2XF=*FW&@4M&/57TEBO2:"K5=VN#.)VD
M(@+"$:5WYGMN'(X'JG='W3A5DXL,O2L?8_3;A$!7-[B^%=(AG,_8XEI_%3FH
M1YIU#)&>E*UC//\L*#I0)RSP_G_&[OF78&\C*XL'.&,=$QFH)Y=/@@Y4WJQS
M;P0S@<+/;TL7"*^@RH0HI')($:!="#E;-C5I,,1Y7;"8IC%<6#/;4U@AWLH3
M*];VP^ ^OO-RPW60#708_??Z+K)RC^U[(QW(M" H$^BTAZDED@3HO+"$0.B4
M$B"I?B/[V.#+A:1X 5_>"WSY[0*^7,"7RS'[(.#+'*PGZ@*-3UX*L2M$MC[\
M]>>8M._^S9GZD^:-0Z(A%-).<@BQ!D3--^ ")_[$<9&KJ %868ZC#[KUIS[P
M%V$P01PG'J!^3!NN4')/-:4B1O0K)%]N" X+E&"XU+4WZ8'*&PO# _"D6W/C
M)O8"$VN"CZSZBON3^$Y%$R_*Y_3']V&16B<7EB\6G':P->+G\>GK=2E%3?1B
M5&C,JZ?>+H]1=#1D$ -7@^\853[]#4L!3^R$H508R/CVSLI#)P6U5&H:0%P_
MX=<L^)H"<>?=\R6H_!R"2K\[Y%0.UM2Y7Q:XT?7JNJE/W5YKOII##P*PPCTW
M1PN0=M%-7[0(\&_*](VPY43DD7?4MD0*BG4T[B7B>]"([ZYF$DJO^:C"_1\_
M__ *H1R=2 AMO*E(_N)NIL=DQSF4B-$5WJY>^'@PTAY_]9AHC[]9/:+3Q-NE
MW]6 -YT),1U8Z#C W-5E69^4K6)7[%#&JBHPK5"X&1&U0'^HP!$=PI-]U6$#
M+4DW:=M3LW6J20H]TB^!F""&:TG-;$!K!CM?O\>2](]8%JZ1@%M/^$W1;/H#
MZG-4TX[Z5J'@+3@AP0Z'[/>8H9*KZ*N]*ZG\5]65Z8KE9'J[^N*;2^'V]NNH
MI".I5;#&?_25D()_=4EX4YD>/"PHS9G"X3[/'MO,XSL<FP7*WU?QJ?&$_G(M
MDA4^CN]=?(C'%U=?/16<@#P&F>C9&M2%#NXO<]N:#@_OE+RG?(MB@H@/ZBMB
M*APFM 4D&OM&W;?&.4BV5"ZA-&ZPMS+&1RPPC,"^<?;]S/6V4Y(4N?]R1RJO
M'<F0%<118.Y/>.2/DLW)IHX/XP@1:WE#8_=SQ'SX:3>X^#%,A>Z?V^9ZH&!G
M"&PD 328ZP%5/CT=4,>L\N5-?%TP,,R_N:*%%WA3 U]<S8V( 56A=78DVW:-
M/U<H$N6;?=^A7'3F.TO94OOI^8?("[V,>NW,RET(8_>MI^3:L1]XTET6F [:
M@@/[4FC\)6V^Z##>[0:Y%?CC]BK1C\OENW<7/$XXR,6)E(M11?.F1IUW8:=_
M,.(6BQI+5OOCRRM=[7J2<S0B*5/=G^ZZ<X.[8;PU,D=<QY*(5'IET",O]$@G
M5U3IZ+YAI8E'/RBD2O:EV*]#VPZK6V#?"Q5E"22Q_HA1=$/A8L*6CYCT?9XJ
M4%41G)TWUZVT^IOM?^I6XN0P,5K\*Y^0$;2#$^#,Z>_BAN-NV?>7J.LSBKH,
M+,"?UL)INZD)$ALW67+*0H:!/DA.^W,6ME&C@%RTR6F_=71^I9"M SD06 %&
M'R26A9<@Z\%5B<>O]H0WLNE345>B]<C,#I(9NBGW%EZ);LB@UBRVHAB$Z[ !
M)?O&V7J+:G\I9C =UHR+RMR9[^D,ZH:M8='E%8D,Y:R+2\[[>[N7.?*9)06+
M3&$)NR>Y$F+*$F)9X20%WRQF#V,7JM'G(@W^$[LN21J2SJ"6^P3NZ?T*/,F^
MT=07K6[UY_F[Y!VW8+ LVGUHHZ.4K*NT=3TB XRGC>_%Q%_(,%(*41AF">VM
MPL$&@QW(="]6/_9-1X+-_KO_T9<AK'U\R7T +^KM=F9&?O0'^QN=D;\!F_:J
M:Y :_15KZ4 C>>XGN$=O(X%S&$1#DR=HK;M>GGYSRI$(]D.'6_V:7%;:?R=U
MDLWC2N0PY>\3EX#;6G.01,=[C&PEK,;*K\K&2,V1WD0M6SF;,2?. _A1[MC2
MT^2$%0< J V@[9Q<?Q]IV/0=QT>,M[]8S<:P7'X.9G\@.2&5-T[-E1EIR]J;
MCL9D^&I_Y.XB%3-#[&S"+WC[E '?:59^.IM"":-!-6+H-+:WN8TM0:RD"'+=
MYZ"4<P.M1JF/V",SJ3P,G[FMZTK9G-?]]IJ:@FH6!5.>57($UV?9=_L*&S-,
M,.S0%PR\U(B1V%'; R^?P,A<EX+M=]5-T=156.KV6WM_C,7.&[9@=@-02"!9
M[:!F'NH:#:\VO.?2Y5L!D@7_ 'Z!-386O9^*US7?9:]D;-<X%W*X5%LM(W &
MJL)<AKP0J".Y&2(MM> +T(V+< UY?&(_])-4'/UO+E8_IYY0/!D9%UOY2:)W
M+CY1/D%P168E_A&_??,0?@%=-_F!G\/'LDB;B"'/'I,VNT%M_*E_1PU.Y(?=
M;Q<2#N7AZ[KN"S!&<W^>_YTY]=YGEZ(#@[?[.UK$*MCZ@*-,UUM9O$%B@LJ5
MT3TU1D.SS\1E,)E!PHHVNKE70I.A5('3&R>-P5;H9GRLT5DY8<ET+:I@4#I%
M2(YI!T40B >9F>@-G7'>/"QG*"Y<GI>$Q^>A[KZPUBW J7L!I[Y;@%,+<&K9
MU'\?;J=Q=6M8Z^%ZV&2ZA3#RXI=0394B#BW.15*"$(^'0(&*;?YEC-$[$G=M
MW); 5OCGGD-X?-]D@BWVARIR+#A]K\R*/G3,! 7 UF1>X+;1#A^)@[XA.EJC
M->T9+:J>JNJUMDF+(P9@ /GV<W<7?SV.(10_N3F;WXZ%HUFA&AO%K<,CLN_;
MASA=:X8Z.42#$0P&@3CE4#=8?MLLP->PO/J#MSFB%HE0-LF4:1LMW%<-/Q/*
M(EPX.J48=" YN.MC%%48/!?]![6.OXC*CC!V#7-LC[_[ZLDHQX9+C'Z745?M
M9M,?>HXSV$$]'/J*6N"W*V'1][%\A?"K-(%*ZCHKP3^'9QJW)B\=$1,'01;1
MB 2F& ]7!C=<M R80VX S=\H_4DUB8^<-5BM-T;T_3L0B3H:=%V.UU,8/)&"
MG-RD.%E,SHM*#\H[BK KSS8X#HC"7:QVF^#6 ;=AX\JJZ@G-QV0@I"(:"=IE
MMS/[S:Y OBTI^;-AQ1)\%X1=_. H$)^!H,Y/<=Q_SJ,L"VVC 9DXJNAKP#A>
MG1^UP60J"RVKXKW3NP&?.<*%9O= A7)U4CDX*&F@T 9]$4?"C$KB+<Y_A$ 0
M'0B]QQO.9_'KH*::N@NM8%MW\#?L&JT,#!7CWWLF@I+NW4T%HF%"%DM9$K/0
MZ7W$D?>5CENH.VC3908+;6J;G(W,0!XH934-DIWN3-/,Y1T$.@8D+,5N/'(Y
M)!,I]T&J<:YO3^!ST$EC[3BN72R)@X?C#YW.+:7PK&$A9T2=49Y-\1<&=>?$
MTT?/.0$2-)'K!H= PZ<13HK*(B '>=:88:4T/[MQ(8$;Z;^(92#!ET.HL*$$
MK! ^JY98->BO2RI7NK;X'8234I9N+8HAH^JZI'_YCW3]BN04Z*36UCLMRV@_
M &TQ_'OL$/1H24M&>$YRXN7B8;]HXVZ-W:I+"'T&A%/=+:G+ P1*?5PPT"[E
M7#24^:BX %<D=DF*^JU*+EG%I14:'5GSK8 ['3+.L\<U\J0F81YFQ/0IVOYD
M8CGVGB8];N&WE!Q[)FM!V^X49>[ //C5"'M@DY.$? .KEC1[4EQHV4O@;DF,
MCMY6>ZRE7C0R:+$)Z6.8-'G3;4&K;#S?<7(%&B<OBI[9GU<E._R&BH-T08(]
MU]Z[PLV##%9F_HXS!9I\PC&%ZF5PJX,CO2!]/@.DSZ 6U;G\0!0/JI..U=H4
MY';0UZ:R$@L,YT%/]E<@>/$[RX%0Y.W$22=O\<;=Z366YYFCF+2F0Q."@>+X
MY\M97'4*>Q.=5XG&+9RQBZ>=_UMYEJ:%MZLR/Y%GK0P^$Z[)J')*SZFN9]L3
M8F#7E^QB.^Q#!5=?^3<T3:;Z3FF+*8.VP7 *@@FUZ9I8@<!SDC8+VL HYCYV
M;DNOS/"ST_.&,CF[V<C?M9O&[Z.,93!?]P]0GD-M.G0921&10**#"BX<*5"#
MTGFAOH)]FN@KL2^$<]-513URFB1H"%Y6T9C?YB<__XJ9X.ATF\]:5/U'?*@B
MN?$V P\E[? ;4<K?T>$:!4C+D?0Y'$DO$\-GKD _D.8<%X%0?]*J;8G;R.7-
M9D_.B/[16X4&V7"%JIU_ZH:BGOCU? WRL-2<AG!_Q:YJNX!(\J61]'("/G1L
M>Y?N#2$<)@@@V,\"%9I:@-F\5?GG'9:GUL66T[<J(FLD*/>4"70&_$-'<8#5
M\Z5"C$&)%\N2)PG"<,O3ON8OXW9^2JIKG,N38K)WM_T[F?X[LD732:@D:\B=
M;SZ"R)E23!_JW?>:FI/6S JWX^DD$IR/7H;>/NX-0HM3K7IE9FQ XKEU!REP
MW)(FHQ@YP,?HO)^6<LZ9%-SN$ G]TW+N?/+GSL_AE8*WP*\1&)@ M\C+G/1#
MRL)[5END)R+%P:X$OW'$P Z,93DM'IA+<?5?8!L)+;??4B/V%>]!/U!"PX@Q
MY/-&X/\ 42"*"WA+Z**BC.3DPH\87?PT[3F.6C1C13AA)S[D;XM#?XA)_"\>
M7UQ>(C3B7\L74_Y9&Q1)2D@'DHC'RFD9Y4I\3#6<GL=3\R--GRQVKJG#6N"Q
M=L#^CU]<)0->,OZ?!U1PX5A;H(+W@0H^O5R@@@M4<-G4?Q?GY9>:$FUYJ:6K
MH7-BTXS\&1VZ4^Y+(/;<]=2(!*F$$+[Y"&WO'=>:NLW!-X)Z*/ZVSDOB:.&J
ME![V50^'@9*4=Y;7XP@;;M+923>3CG%KGV)N_$6[>G*1.E07JU]OF8E[^?$:
M[:$TV#=*OJ;5.*Z/[GP4P47)]Z_W)E'T;>]Q8O14%Y9*+[7D3+R%,8?%C0^)
MF2R64@1R32($R4D=E(O J41RDH"=5_(<WBWT72)LYTZQE]6.:\/^7:&P+)V2
M0T03'$[IKX(.!H,H2>FQS %973WKK_WZL5_G/M7V5DF/+=_3/[ZFG1__&^P;
M- 5=_E8S0KN\:$940^.U1LM]FMCI2N!$RM[OO?;4]R=TE+\EO0KT&MJV-(.H
MPZBT>+$YIY328YM8<@N?0V[A1X%G%E7&L J1X<!0-WM--FY(4J,58Z"V>0:G
M1<QM4&JB&A>*0,A^,:VZP@),D<?O<3Y0;/IC9[-U6B)B3)])A0ITE)&;$,3J
M%HZ%!TY6@ %!\"XD!0)8Q:#/E!&0UV>%"2')/<YQ*W2/0=%]165;6 *C/H8"
M\M-&1M;Z\G6F%J9;%D2_E(H_&I5M.LC#87DD3#@2H=0F[(\B=)#632&RSXR:
M5S2PX$]>O@Y&O>.*I#^M2<%B!&>R=V6H%*C2"&0C"7=BOFHT9<XX2FZFY48"
M?YKYKS9GV\H;9T-D-!M'H,_8? ")-E+*@(VCN1V+&EX%W^SH?TVMSRXO27]C
M0TI^O,Q*%%.'^&FJ,D'234%A_B4WFED\1IH!^2HT,J!Q9M#Y>B![NZL/JLCM
M#L>R/A-6QWM04?.M'A0N"#$8*]RVG9N;?9D,U]"PAFV,!UC<Y!O^;PS+CIB*
MW46;5OXY 4^VPN5J,E=Z<XXTORZL%<!*;OJR<DU  ^<'['U4>\ZI_\5U7#;W
MSS4@%>P@11+Z A2V7+GN5#=O%#P/^/-Y#6/N?&3;KAX92@N_$=2'$[';\:=?
MFCZ0 [9]ZK[9]P>2P^R$1\#/]J$ #&SO?T-6@O^@/GH400CS.^.X "#6>D,*
M  QO#TW?QLV; 7X\FDQ+5;!JUQZ!/;MVR>O'*'=^\EG47 ^>3  %>O1L>R%$
ME1_Y+8/41H'^]WN:HQ_C)R1W"96]HLV!WF^MR-(60^A<F.#$4-9^P#//W!\#
M-D!XGS,&D*H3!(A:P\9PU,C(FU)J&,?]N2431R0#"1IOQMZSI9O,"N&V<N>,
M0" ]W#QO_[W200]?]*;>)HA!.65)@+"I_4 .B[S@0X7(?C/VKZ!X2]N;?WD-
M,:4A(#UQHUU=P;;_M(K??-:V8&H0<27YXZ]%^V;U/"\WO 7RCCC[,=VMK/LY
MEH(UPEHUY[;>=;1[B%;<=:/PT5 VQ78Q&B#.OM=__>'58^:<>?WJA;_"-4O'
M<;T !>2N[A21W?@U^\NK9ZM' LDIFBVY!6>KVMGXW0O@?GD6'LC@05_YX\J1
M"C )-Q+3"7]/SK67+Z!;ZA]*SH4MBXY&ZO;X142GPF&";3X7RM()S4X]-'&
M7*R>4;1%LX0AB?P/I,U<1?P;6XXP[:_,ID]QG)G#C"9P<KI&D\JF$9^@:/E8
MYX)Q6[R5V,X_SEY 623)5Z&45.. )*U('/6@7EGV@H?9"_[JQS*S'BEM$[,
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MK\'$=)K^6@7WURMT*+@@2WEYG0RO"0S2Z%P/@;#<1_><1"?S%NA>L!;O2]
MRIE^AN.(IN;%NJ;M(ACQHLFNG.Q@19:@)$=)&8LFNFO ?EK5&X-E+8KU1^\1
MZ7W -XO!*Y^V:64!/K]0KD+G60EVZ=D6/V#CQ2R<>P$YL4;>24^TVFB[J<R
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M&6+ETJ*5&I6&W(I\4MYW@55.5.1('&27(T_.Z>$=N]@U5L !T-P-N2CYB=;
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M4TJ=FL5^_3D]1+ S42==.;VU,>]T?IG3^6UZU Q?8@L;6(N@;682,P1B30P
MP-X[]*L; <5_ ($$A_*G_=[;V#>!=\&XDD^[D*%FN.L0S@LGR^"IH,%#N,U%
M[V/2(UK+!-E"8^8R=M<A'C)E#Q1K^F!@J'12M!<VVK0LF1@TK9W_;WG!OO)A
MT!U;9-"X8"\69V\V/X?JP68%#VK&964:/D>1]'A5R9_ XSLOL<M0>#2>6#YT
M^1/\7Z'A6YF['7Z)W#UZ=#A<]J\=7Y8KGM=IV0;?TFY)QE4SQ6+GPE'V(PPD
MA!4RXWY*Z0LI%%)M_R5+W[T=*P#70Q7JO9 6,G.!(+F 5^G*!X\A$:1T#>NH
MFL0'CA.)":LBDS$QZWJD"I'1W%"H/Q,^_'^NM15QD517929]1/K-FS\!W'S/
M'2DZP"B.YPT2J1*O,PNO*6L,D"QZ0'BO!QQU_=-R7C><Y+D73F$\E'1:P=<T
MH3PI07/D$VHM?\K#)KVQ@96@HU6S1W'E;QHGFXJU])8C/+PW^B5?HU_R2U5^
M1U[VB@)9E_# 9V<BJBD>Z>BT?*U.B]^G_)-+3L^(]GC7F_C9"Z2<>1?& 55C
M3T9<@,B;2>G0+P>.YIE?8?Z GN_X01,L/_<+1W:X-ZN*PE(?$<SKE\$K/NL?
MPO /SGJ&X)TQ-R^Q<,U^\MZIEM[:6-0AZW^!D?Z,,+-GK7+ 1:XI)T:\9'BO
M2S:):C;B!,=R!('*4L@W"^GM@6?;9*E3)58?T:MP[/ .68I,[R%'ZPUO8I01
MR#?R_28V.;KJDFRY*JI-)J?CC#8NS9$X\Y+^1]*9SLG]Y 7F_;;>LPA8P!6D
M'=WHN(19O%P@]8.$KV7#A[<6'+ZTUI7B)MYX0$9"Z*]$4W?D(QR!:9\%3+L_
M M-&8-H8FWT%L5F8J#I;KX#E&D.QKS84"SSGKERD16F._::#T+BHN/@U2'\S
MZ49B.U=.S,J\ZYN^M+M5D)Z@=HB<K (Z:&%9'")UQN"ZT<.@JT-#DKW4:P<V
M>F\,+10MVC6G+@T?ZACW]):QGG0W<Q6YSZHI+#'-WE2'I5&!;YIQ*;Z\=I=4
MM,^>R?\$*CB#2C>2+[]WXW&-J;6OWWQ/D>M=Q>DT7F[/LRG]<UUGHT6_38O^
MJE]Q:<MTT!^?9[,,]1[M.GS$;8?'8<=9U_SVO^W([O9^)<XJV7A>E1#*KEB&
M#HQJ=7Z)4M:*/'JGF??-R?Y!)*^##]<E4%_A;=_C$V_6V5[C,\X+U7F3,8[2
MU<( $W--YS$8(VI$QO=6]5#R1>2(+-5@Y:GA)-X_Y!L^QQ94LI*#_>//DD!@
MU"7.ZWJ&8H9BX&GB*)XZ.$0F2)YT(K,<:ANY>\N/\%6>,_FU-:":PI-]^0V^
M'+3;!P*7VO1>9[Z/7#$AT>ONR"IV_ZPP2)&V9%GV#C('Z%3/<*BO7O![S+"!
M3W_]Q^F;,%-W]/# =6XV-TO$ ?H/$*B(ZV*4T11(43QL-.1K]:[_,?ET>U)"
M7.$6K5BR7LM580IBPZ]'8)1>'D^JH8N='!O[R3^D7?,X7%B2:+:V%&-!U!%-
M(G1R4;!.-0/=&8),NQ(H?2E-,2F!=[%X["^>Z7<RMZSUIWU@3+<%NP*1.\YL
M_-FLU+AF;V?-OB[C[G^<P)ZJ$JEV.-W&L[&S&,50RYS>N9U)<_/!(E/N/+/P
M(-HRPWFWCZI9+WM/9&4+U4XSUZX@>$%:^["1^,8WL4X>P[G=.E3DIU%\!D;]
M9LMW7*VW9V'=^I&@MW1"PTFM4*3[^P??LC^1EN5ZZ4IJP6+BJMQL5J_%NY2?
M7Z6-0[0&/4K<N>@H<P)VC8A P(SNVA4J=Q@Z[^+]?5UJ1]_Q@6R\T*<Q#V[;
M#>U;O=?>VF%HC<?&'4P>NNUFPV; 7]5-/!/<GM)L%KM]1E@1;TO\>\-$ITJ"
M [ </#%Y0\L48LCM1E!EYJE%4YY\UFPGKV=M1<'&[@$?'[IWP*XN/Z/:1?<L
M*8VKE:Q(UZ;01WZ-X2G#MJ>^B=S.0!S?S0S$E-R/+Y-_>/SXCTY #.4;GM(S
M?%+.@1_Z+W][\<N[T^<O7XV)A%OV2X+==_C8L@.A5Q+G!TIIQ K GLX*L!/[
M:U:OP:NUCRW\C[P!LI&[:KS*QIZZ*/AJKV >7^/TS6DOZE<.FB#YR!@-EBSB
M=+1+/#(JE,-$O5S\6/8 \_Z6,[;7TG+F&LJJQ(;,_3&Z8ETGH:HG!2!)CC&8
MNK%GED=OYO:\F1N^].CU&B^RRH)@<;F6G&!)V"J0_)8<6JNJ:>"B,Z[7-\?@
M+#L\..AZ&7W*1+*6TMD_U[E7O;=;*4,SO<O&<.7S; DR_9J=B68],Q8_[F]Z
M?CH034CMP:>WYO7Z/'H@] 4SM10=I33]F  $K?D,H/*LIKB[R5/==VO8"94J
M*I%\ J2JR3ZBS0N3X%H-&PAWDTT@HX'AI]I*A*\_??,C5QCH ;,Q.+VE#?*F
M$WQ%^F_]QE.+8,AMBA:)?(]/@)S".MI5G;7/&P-+XYNC[@:8R%>;5M,ISN/_
MYD%WJW"+GXL2.BF8J''2._]Q]^$W][O7[-#O[HJ^S6UW-,;D-/-RAUZ*N?+S
M-?.3G&6K-LB\:^!Q/#%G>6!XAUOFH3,^,(=)[^1>OD]! J?!L5>WPI=[G_DD
MCCM"<^P5+=:\%(H]>;;MT^Q^W"F)O\N2^*7R7(7\Z/WS<K\CMZO?V;[&:!1N
MS3/LO*FCFWF'B#BW*D9B1>Q/(2X[M#%*N]*U1_&/-5;?VL;1'MQ>LH/;\8I/
M7_)@YV)=L$:EK;DAR]4L0 _"%L>I-869,/4)Y6C?VK<1[\=EFA<\.)24FIXQ
M^0EF$W$4W,X1_-K]P!<@L;8^C_V4!G(\.;BYU';8#WRZ+0NW"%_VN/>^#GCM
MR/LXPFL_"UY[,L)K1WCM:-3_L#3$H++V]LG+F,DN\&!8/=>QHL"=63#OM*\I
MM^[[17K%@)A!WR-NL+_VGL/*#MM/Q-5PK5\RAQ/ZFK:9+T,M@^NGB=U.[L#N
M(T<+?!>7UA$Y&B/8R_!*3'6=66@<8$04 [;9JJ]_%_?$'80;YK$Y5@0*NI@9
M8O)9US[8/SDZN1\"?X*$:.J(#/O$0G>^SQY,9PB&=5C5(E]JIY=F/:]Y2TVD
M/R3S4:<M&;Y-DIO,I]?%$;F;:]_>EU,BFG"5<T!]7&EOW(30?/$$TOPNT[8%
MH!G8V)Q#A9O,,C.^L6!L(#$7J!%[;J2MA=BWL)1C:>-JK0%UDI_55EAA;_BZ
M NG#'A(#KWD2OQV%/@<D@7*[';,1BG=$D0X@@"O,P>'!%XMGQ@#F]LZZZY88
M0UWH]0HM#=:<)@X]H5C..2C=40[2.-%< VS1QWPIT?7)Y.'!X\GCXY.;KI/K
MC,N@10U:'JXSC9]D%G2G."@071T'ID/H5);2%S$)USG<A.W2#K?V*GK"9%YE
MPONH2A1;;0ZIDZ+(6SFI\>TI3;L"/$5JO4N?YN6"<+<_<#ZX?=AGG14?*G=U
M[S0Z'&*5(R]<?U._@K]4TIJ_!KK7=;9>/!NMS.U8F6T$3V_EPH2<H@V!RD6Z
MD>_(,=/)PS_:RL-/4ZWE]IF.DEQUK)* RKU;'HYQH[*\?Z;%0\N5G.$WDE!L
M5/!/TIBIH9B;@..IKT00T#WWFS9@M.BQ;C),<3Z$A!/;K:=D&997MNLY?_!P
MCGJ&PPG38QO1R34C^CUW/]FZ^W[R2Q50O>)E;KW6@'0:(C"&@*3H*<\N71\$
M1U-^5$N["J\5NOX,"O'@)T-M>EU+0OA"?;&>WXGZ7@#:#'B>>E8>FWW&Y=$X
MLE$&_9;,V$O1'L0*ZB6@W2IM1H586@@H7=35)BV4/L.]_TCA08!QN_ [O"K3
M>5JDBR',X7<4IJ:,39\[_''(GQU5@Z9J7S&F9RF>NTK>T&&]3&?9FI48<0A?
M4@Q,,=%//SWK:5=BI.#A0_4%]!JO@Z>RYW?!M;I/ZA^DR8-OW=PPUJ#038)M
M\.G/RM"C>)/9_FI\Q/+-T=%^![/8;\FW *>!G7)5[D5>0[D+C.O1FQ?;L77T
MF D; )MHNTQ*Q@1D@6G-:9C(H#_L#OX+CVK;@ ^.*K;K.P^^+S&RXYN.;+2-
MMXM/_!0$=']E.GE9U0 Y\*%YVH-9#,O5O=_MYR!E@%7?UR<&B4$/D'Q!%IRV
M\7'W&="%'EY6HPJ=F^P.7[J#I*"_4%28_)R2\;X1R/ID\+G>,'U40%[M /K,
MA,JI)#:9-)6:3/*HZRD9SB!'VQVE"0/S%P[C-H& 0[6ZV=LUA(AQ6[MLL?-]
M0@#X]B"'9S/79*/V'^PGIT9UN=VV(,X1C3Z+ROJ %S TL&N&.GAZ1V9W:6?%
M/%NDZZ+=,3PZCWN0,&*KT4NKCMWVA7I^Y6%':B01Y71<PZ!S0SH5MKL3>J[,
M_F_>MWIV#RAHW-Q>E_1;[LND=?'B4H?X7)^S)V'>NP/O)=5L1EMUXK4Y9B(K
MW#-6WIHQC5PLV"S2K#H$N?!X"MQFNWL )H2G&F%U,U ,X^5K/6C0)@^ &#45
M\/W6"WWZT_]9WNF7">$R^>%WJTJ@PM_#'-)DA7]K-ZOL>W  [WS[]Q]Y/HE;
M70#??8K,UY1,==9VNDO<3/[E;WRF/7@BO]$OR0M*CAZN/CX!B6"1;KZGQ5*0
M$?EN6E0,?Q@2_;I&#$S_YYL3KE/8D>AMZ7R]ZPB"R=&HX=!=@%[@0$Q2+>@U
MSSYD#KB)EN:R8;4%,DFUA$*_@DQY()3LW1A/QH5_)Q9^=^ E!9A?Y6XX//DV
M["1D>GL4=D#,S0(A*W&"(CHI2XN)*I0*9EGONS@HU7R-%@)\[E('[ X-WB&T
M^)7C08+GC1:0G/PX%HZR>[OL  T,2C3,<K5AS4US-JZJNI@'..XO<N^^?$*M
MJ8O<8M6?TBD:J9[PO<<M>W>W[,B8.D(Z[P:D\\$(Z1PAG>/1<'>.AJ_2F_/R
ME<B>,Q@EFS>6--EP.DES>K5+=4FA251 0]4>[]Z%$IV2S4/U&['^>KEDU!M%
M2T(F]@DISS$M<_N-U1U\3IJ<9V56IU"W9 %8AN<4:8XN_7-( +2^-LA9\&Q5
M9PTT&-$'W.S30I 4.1D!CHAKZ;GF5:,4I3-6C*J6><.X'@$X+OR2^83*P;AD
M;@FRPR@T<%Q!#"I.QUUP6M?AL9''RY8@C:"W2*$?%*9XJ7 !H9Y!+^)?KJ]>
MJWC,U\>,D)(N!(H.=8CS?!;VF3=,/<-(5N[XG57@-<H06S(2MT"97'OCK;3\
MM$IKZ0[L2:Q4Z]I&6$8#Q'IU8[L2A!**Y8QVA=B<E^O(R\NJN RQ9%::I(&<
MU^ERXD5S;[*VK;-V(A?D_#6$T2[S^9JVJPBJ" LC:\!)_W44LNZ&5Y>TV1UW
M@#1Q0U$=; $ 5<< OHCPT5Y/@B5>K9MDR?+CHMYENN3];VZ"WTL:F!D0>$F
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M(9C&#WBEK+R+N[<Y_4K,!OYC6L&*W!,._\ &<Q!TA?W."5)82UH[M/>#NYB
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M][MBDCQA;&EHA]?RA)O][-C[4""PL:=!#C;A^<ZS!9W)C?1V2\<>;0!Z4\"
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MHEYX'=J59%* HCT7VD!O6P>(.,!!:"]"HDTEQ%GZ%ENADF%]Y9EQ_V/0]"2
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M25,%[,2 @NF$+A)=A<;.I,@? J5+^XF7=.UE+IEOX5_G#]#5T\MCVGFURFG
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M0FK3QO/CML@G3(M&R^^_<VQ*7.GDHJCRGJLCL5-+?]:?QF5U0XU;3,FXF_6
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M LHE!D/(=X,PH+1/1SINS&"@=7H^Y=F.:0^*,H(&?U&MUB?,4 P*C'PW_MR
M<S &E%]=0#E8$/5,5V. ^.4MGX[O<##)>.P5*+UKX1%? 0@#MA0&" OI;B5=
M4$4+;5O!L6@Z8 /2;[MB(]!AM):0B?%FU-=E63&3T<&*698/!R$.4(H =MO4
MUA,E &FG_&?R=^:CXT:U^_B?0\-^T0N[:)44;%TGF!TMNG*KCUOL?QX,W:'Y
M6$,SP,?-#$654BPN" >]]EO.]#M>D2*=)J;R#TP?&I8#;83SJG^OEJ]._WGT
MW6=ZKB-[KJ>NS#>L81+/WD3$!EMF1B0G2;KF_MWE#,FF<P!2K!.A\01[\EJ=
MSUPS _ +N>LJPD.NZN#^1H\H'6;;R[/%X=@!*/EYGMA7:%]:<QOSUQ>MJJU[
M%S\,X=H>._\$D8!+/OPH=#"NZUE=:A?EW*T<;VUQ1V6N@DMB[*E&".^CCX:A
M[72Z?Z89N>O7MH:%+#0 3/\YB,7,&V=BV%WA'Y14]2H $O3T7WG5]HP1!0*#
M)\.BKM?DD+A%[WB0.BH70K7F^@/>BON0FNKM>UL5U:.[4BV-BZIF=>67^J\?
MI'_@-GDT(D.@?U:KG-VV*]GA)2.("K./_EA=]I_1_\.,#4_7/_OS];F/TT=?
MZC3E<^T:_^C@BYVHMW<&$X=2&#V4Y9[40&CEK-X_)GNQ(H.)Q0$DR6W&F@B:
MGHZG#_]?W30G>9M/_]=_'-VY\YAV(6.!]K/_SMXV-?WW\-'A#P^.'NS8>@_N
M>(O&$/?'V0D]'BVA[-7$KB0Y7/KV6]&JV,_N/]R[<^N'NX</=USU[M&]Z*KW
M!L)71 M^\2W_HHOOX,97GBR\HQM;>+^[5L:E\G4OE3O?H(T:E\B-+I&[?YXU
M>?+ZA%<(FX;'V:/[>X?W;OT@7SK<M5JL&<V6R<BC-X(</Q?(\?Z(-!I!CF,*
M\D9 CMM)',Y\'#WXKD]*PVQ13TY_W(EHY%2(^1"?-_UQ+Z0_>%2>RF<B[&F9
M9KTT"6J-("TK[ WD4:5F$F4D)7?&A&B6]F(F@T*4'+A?0NJUGC3+='0TU[-%
M8Y"PK'%F5R[L:^B]%-U8?KS1-E<C3@%\PN<3D^;^G--D2BQBV G\.NV'F6C[
MB(C1S#@?&$FTL-)G2%-*:VC1AGXH:"0)%W)$'AURZD?:]7[EW+LVR7GN9[_:
MJ *9H')3<8;7[Q*IBD,31.OR#L33H.*8;]I%5TGK38]+9 +,Z87I[8&C>A8W
M5$TW6G_T=7[9)*H6%5T+2,2,>>3?532XSV02[IM)>!XW&*-LBUK#15-4[U+6
MFNG&Z-%L%F9U%0,L7+NN<:%:NH[FQ<5F#A*K\.O/-'1SGH7I8%&\=_/^0EQ?
MU:&-;1*STD6FSY=N%"@S=R7#\<PF,KRM!>&)FVNQ0, 7_3=$%U(B 2':3H?B
M%UF/_H(7W=PMZ=9K%5>/&?,\2:7P@XE1+E NZII=2UIV1'P9-: B_U-9U[FM
M67J3G^F=/ PG#'JY2V<X*&S%I4DH>*0 OQ]&)S0T 9>ZZJ<YN4&N"4PTR[1^
M$A'P\8/.M:"#8@LJ+FEA1XIMRJCS?J@:6%W6):L,MP[*!VL7Z6'%*^,SS=&C
ML0_ZFRG[!]6DJ(]][(3^T]B!EW7IN/P<<67"]KMR[L7=N(2;*)(!VGB1HS6:
M9O WP3J)<?=8;(%J"_?:Q"LSLK:BJ4+&8O;0M<.'&1]'CU(OA7?%],4G&=G:
MYESA<[9PZ+=F:NB1H0V\\8H7+=SC8CGMFE;,=%<IS=9ZHXAB0)JBJ^UGKVEF
M:R;BU6HFF&J0K$CX;?RMR!@M06#*7E*DMA8I<-$2NV0:&04VL0WV+;U,_N,E
M6PP+;M\QP;^D!,YQAKZ69/#CIKFY31/DN[C+GX4.F8G%ZO&QWER@9>9UHD@-
M9H^+NPJ8G,9K,ZYJOO"./@"/Y\?K8#+$228*U8(C!HU!6(,1YE^B5-]KP%J-
M+F<V1479@KAY.)(&5"7@A1EI)T%(Z$[@:5FYRC%3-_;GBFY\P30T]$A7V@T?
MP+C3;G[N%/%CHG8#8Y3=TV/TU6V"+L):6EFBMI"TPZ-Q,2MP6?R[*XQS.=MC
MW1C5^2:7]-8'ZP\*R#EEFXZHI 00;J)00M2]=@5,W?+-S\>@Y9F5CKZ7SPI8
M*R5G%PZB&:^%19.?"]8'E(_=.C=(>!M(BOO.6V_=,3]1F_1FQ T8B;V>Q NK
M<2O<D)',D^BU&3 ^R%(*NU8W-F7<G E2GLH\HG;2)5G2S>8;6W_ZRD1GT)]/
M^"BSYC>Q=E?<O!!6%V#&7N*5XP>60(V]!9%65K-6SYW*X0Z(U^YGO_A(Q5E[
M,L.]D'#B>RFA"=H/Z!KX*C<Q>(KF_>Q$R3*+MD8,U*KPE.QRBTUY0\B> M,I
M1Q6F%[6'[7=+K<(:9W@E+'$&W5?5:6S6ZP8^!;N\8^70H@4,FTS\=PL:2B11
M+4S2OF]9>@S(SEEGA>]D,&7B&-FL;P_J(?CD\11K-'MEEIUQT&_J&7W[:7@=
MD^RL@,/39C\RKIH>CK_\0OHPW>P=MM))#6X\<G1>5K-(?T 4M2MTSET6ZB?%
MG/E1V"MFE9'B>.GM !_VN/V_E =R]R<6/I3U],OI3[_HR];WN?=SWL[S?_^
M/]TRV=YL=5%DT=>&EX(JNL5M+.DNXT9&@1?:@<;:,=Q&,*^Y(\!Z/*.+1!SK
MKD ^7-33[$%8J8%3GW(<RREZ=Y<K4KKW\5'L6PY4R4[Z#> U^_TEEPV"$-X8
M1@3T; - PW0.@W2Q%#-('T*$Q"C:K60Y>2FS ,.$0WA^SKKVEP/T^@8Y9G+B
M@AMK&>&Z INAN2.5R"4P;_UU.A^W!B;0=^0%#ROTY5F&#=UZ!=0[9PYGARF
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MH"R+DJ5W$J:(V-1]O+N&;+G843]CR)A;#=T_6)VJHH(25-3WC ?![.:2\QN
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M'2+S>S15D'5!E:&C55NQ:S:O9UWH-X^CZTEVWN25]&1JDQ^O(R.G#6Q5M:
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M2N'G2+>^A@U3D?%81(Y(@'8J5X^Q\5W7XS8NW3]YZ>Z($>5@>T]6>,DV>]&
MA=%<>0>%\(C+]_7QL8])Q<(='2I-SCS?M';J27V#B7V6^;]PM/;\2R/WD3I4
M5RW=.J+NUQ,QZC7D!Z (5&J. FOF=3^C8(B%#.?6HJ;CQ(ZK:F$ XA:RPWO1
M0+.]H.7 A%'P;V@=UJOV%IB%M@1TU,&FZ>6>TY'Y<41%?A6HR+LC*G)$18Y'
MZ1<X2J\!2<K1.G!J21^-ZX$!1%;LFF-0>W =#;2P8#0'&\%4Z %QN3F7X6/X
MC1#Z2%NV:JR$_!H.S-,W+U\_4Y:?25"L%.87.OO@SEW2CX88T\B'IS$*MSC-
M:-E-A2,Q*NU,[\#G_&5==M4ZY^ 8-\SR BU@.3JKZ=7-/%)-$L.,-&J[%1J0
MO+<1/UWHWW#IX;L][<"#KC$*G^\.0G0\QWE@N!84QKS(R_J\TVI^('S6 4@]
MOUX6C&7UPYB(;C)Y2;09-+?@@3+1T-%_):F(=H55 59!_G#D3=&5+ES)?UAF
MPNL(E6@N]6.,!;@!3].+0VF&9T(=>,E1RSN(WP]";%F!NO[2A16Y3"%LD,YV
M3C$H;/:\RQF1!G ,4J9Z4\'H#MS5A+$TG 6>UEYD+KY;D_/K=E"<%FJ'/A*1
MW,M)_Q7Q/(;8(Y]?LIC5.GOG>G"THJ3-5/.+,I2+)Q'%3'!XLHCR[/WIT-VD
M\V_K? N0TXY-73<$=WN=*QJ)B] %OT@*6WQ LB#[)4[]AEX:(*9<_5YSSU_O
MCTJFD:3$U? VM+2O+.A .&*H)Z&[V J%06.61D:?%'%/<">!Z$HX)=K"4J^6
MV0($"B*4U5R%)54DU+31+FECZ[68$J=B?C)DFR(J#TS$CH%A9@+RB&8!M1]^
MZ!%E]"VBC)A-%L8O9)-50>VR\!IFH_&Z,:PNL$, [D6$>S@"NTH)?GW>/WY-
M^]G;%7-;(^?.0NO'D[0M7II4)B+#9XGB;9S0)!+JU Q^QG,:F47FLL.JB09@
M>9G(AJROZMZ7AL;]<F$P=K&V6Q=6@[IBPN2U"HF"^)G[_,T1]=EP[3<BR\=4
M7)Y7;Y<YNY9V0F"I/"2MYX8BK54"S)1O3>K5A1-\$@]$'/3AP4OJ2;.U<P&'
MYOXD66R_@,#R++8[*B(,C(-.Q$71M,.5Y@@ML?UZMB8_1[0 =V;1E;_W)HP8
M-&#-@@1+'RU'<4!19I87E(?D4YP.L%5KV HI0<N9OJ4:-OSP0\_))+0E;O<!
M1]SN2=&R%.UN])-PX);[O"C>&F1UJ_B)BL7$7B\&)2]E:'>)9E<R'1,K$5W4
MY=S#]5K><\E4L")FQ413G,F$%8C@ 9%L;"O+)AE3Y#9'[DK<NU,T??8XA*\4
MF4CHJHLW$1:R[61!B))H0%D;:Q<!E7M?"*?8VAA1][,?ZRMPGQOVG8.,$&-(
M7!.*I1% WQ16+>W\-FI4&:2-DY@G'[:82N4?F&H1ZEA@P)#"GLD:_:!OT0\Z
MI9@]!X]8S,LQNC]_!AWUVPG">N5OH4D: ID%9+/P4]1)-D%$@\662I]&0MK!
M+H%_WZMZY97&!OA]\NBC":R9LS;9WNE+T&XP#W7H3(ES5F%E!03EWNG3DU\4
MGDP7 !<.]W :$,+H%;WDL*@KRS&C@#=UED!^I5FQ=*AFYQ-%R,"\+,6XJ6,A
M408=Z'!H9'RX2=$Y!V&/:YK<BY<'+1:>=A-H$!T\N#E!Y]P/7_^-1Y6S?NUQ
MTVV'>B^.'?\\?0JHA/4T\#[%M6=6$<<[W\^\,-_V8*W[.4S3H*\G)_M57D0-
M1#PM[--)KL 4[G :(*4HBA,,4J'C$B.'/!WD\9)AMMQ?*JWL#*R+U.L:FAL\
M':_"BZ*<DR^C7K% $44?7/F-4A+M^ ZB?(H!S68=/(I*8#(\0=%R%]9Q>Z9M
M97#?K[X;;>C/= 9/A5/<\)RRB:.]IAG+J"=6UJ'X,PI(H@5$3N%KP2V<!9R6
M-)3:YE81>VSZL*O]<O"-8Q.6&)+'-,+,27_*DGQG6[Q7="L9U8O6>N.QRU2+
M1*@U38 %F%71UU%WD-.3>\6"H4[\0E2D< OJ%'M2MT;'X9MT'.IV??O8VE_>
M1!UXH_?P)[!27L=)R4QX/H9J->WE&S>;71Q@/:Y)> B-N\ ^OTP:M6 $6R8G
M#HB7GII"U(Y!=_]^"\*U6QUZ"STHQ[7%@XIAX;8ISU^B3UA4PK*\G00V<CU.
MWP1*DR ]II%.(:GM5H^=[>M<7=2P=%XX54UIF!%^ C)_<L/][">W253=S'T+
ME4NO"<=8LJ[5 BF6.3.NJX <2F&!7RVM#TFH3N>..@VB#:57;LD+.WO[IAVP
MN^,._1([]+@LV9\')"RF(T!UI&C?82O2;7U!--M[@P8B!4E:AJ+_25W OIM!
MU3(D'[#JV#.DJ\VD+&A:@%*E5>>4'4/1(436A!Q"*]?RW5H4/>M9D2>]YW$'
MX*Y=RQ(B2.::WJ*)B"1RABTS+YA7ISO]];%FK,Y0GK^F4*3#3=@E@]O=@!ID
MEY!-XGUX(9MH:*)GHN\H$LV1S:0$H:P_P*FF!=K/^9TDFY WV22@53T-273)
M 8;^CQVXCLJX8\8]_27V]-_^:R1W'&&,7P.,\=X(8QQAC*-1_V)U:':OUX)G
MTQ+(LC8/98@G60EGHCB)162CAH_?N<0DAMZUXFF)@##-+^2+BA9D138@507B
MU%DT6"G8=-4B+YI8V,@3)4.?I]S]>*@M(A\7RNUQJBCB@&Z+EB,V[Q&&!K5N
MN<P;T[R5"CL%3'196E;T,F8!;M8(JDU2IHL=[DZ93UT9M0CI)!:<%;X@UYCI
MJ(1#?L<EUO5M#!EJ5;[2'<T CY3][)6@G#R.TEYKN--63=7+'2ET(&4AXL+W
M1ZXE!L1&')R>*V1N//E:#YU#;;N4+X@:EB1L8]9M(_E*6PY5Y2@6$8K5=ICZ
MDMLB1T?R!FT.+L;A68T7"7(8$0? Z_6XE(@DS9:B95<\$_\QC2XP2SP+S!*2
M,-?MZ_,J1P^V&^56Y$ED/]<-.4Z3[%7A9I HIRVOZNXO9XYBU)'&\(:6QW//
M";>3\Q1U0P.SAP_1ZWH%$&1VO 1:)4=H>=P6M#K<_OG^I*_>=FNB!<3(A'F=
MO7X VR<L#=I5M$"1'L1QM%M-EU5T=\KGOI1"R$SX+/+SO-!BT+8@4O,[H@1@
M9#9\\Y^B"/!R 4HG:*!]NNZ8L$)]Q=ICDU%\[*]5V&F*2RLZ<[4W*OG!M1W+
M.S=Y /Q#T *#,8:8UL3EVZW[\_;,/.!P2##W!_:SON?PXM7YM_<.KFINQ=IQ
M<4;<AWY^)A=ARR3%$R;A\95I4=V&8+3@\8>Y2?CKJ0"F-#A 8-H-+\W^C'C^
M6<U#Q^B\ '>)4K_[=&@.3ZR@'WJ:H4S./VWJ?!Y$X69U6<J0)F!/G:!7NJ&5
M,6$-U+)NN9E<VV-\X :3V2@-\-"<R0DDA!R+PK4FNTV'0J?P&/WC)BUD!=^@
MRI<X'!C1FT(%= 25DFG[^_,4V]>U%0^_,ZVHP478*QKZY#A:AEI?KY( 1#A<
M: -1%+;65S;:E9LI2BE?XT:"V:.#PX?B9KW0:)8;)$[#_HJ(GO=>/#U]<POE
M1!28Q%CT/QZDW8:D?L/R3Q:\@(MZP0U3_TF]"??5S=P*Q^A6S*W*AZ75N?5.
MM12YDSM%T@ 3_JY[GP/5-<DNZ$6).5(=-*[I>J90A%'.D-YAJVE%S<0$N.DQ
MO1^7BYIZBFQ*L :MP/C"9;@J37=O7'5.UQ%XD*],\R3Q4F)@;X&6U?8"[8+X
M(" V*D!B&-VI=$T*4_3,+"-W;NF>Y1Z*M02@9HYJ//H&U@43EP"+0M-H,OTK
MX;#3QJO(7LB+:%TWKZO-DH'X>\6^HRCDG=OL:E"HY_X\N16N$M7.XHH=HYRN
M1!BZ$4'@HIGON#3T5C8)]8RL#P9!5I4NX+CB&:U5P5!&;S5:F>0ZTV[;/L^X
MX>Q=4DL<-)T+0?#)J[&X*[T]T@',=C<MZJ5;:Q]"8IMW*!UOA7=T-1GU=H3D
MR;@'#]G=%#L&4F,U<1%N6W!3;PT>SSOW[Y*=F1P<\/\Q[H__=/<[3[Y?0^'R
MJF[*.9B^:6@55ORZ:RH&VGGPHR.SP^TE%')4G.=$MX >]T#/(X$GNW@2N1,]
MJ6X*DFC>!JNF8Z#R]0<JC)64YO:YXU[GDLQA6\;E\=&;N)GVXYWO@3>BBCM&
M2?3D<,_VGKV]E<6\=0.X,8\KQ^2_LAO0+GX.'B:R&>_$$@-I$R4Y%O97:2%,
MQHG$1V?)=J3** (JO3_T8)(P)3 Z1;_^5+Z>^$2OGY)+Q ^"[W[_X.Z]7I*G
M?W,YS\1' IJ<E@1_=.ACN/G+*OL[2]D^+?+SJD9!Y=H!O?Q[?T3W^R/RZKCS
M<,G^[7&=5B'[TGF0<A5ZY,[3-W0"T[D3?,K[$ZAX'&9[QQ X*[7'_/#HSMZ1
M,?O2XRT%M#W=)*.781\=?'_O_B%/0?BCO:&C.]_?/W@@K,G]FQ[U;WJ(FVXI
M%!VW:;B(!XD7+S^GG."Y4 D/(+3;;-Y@@PFKB>@<?6"F_MFSX^MS\^FM=N?F
M)V-R_L^IW>PT-Z)PC2Y4\M+.S^/./(P#,$#9]%F+KA[:<7NT3?W& !VSTGM:
MBRE2XO1A<EKH]YS;4 :Y3!HN?'9@GF0ZSO.5E_/5MDZ*.BY=40J$5>"CG,J8
M70 O&\"KD:HNE/A\PXK)R_N"M&92T).#E;I+#GIQFP9QF]SO(#YM$5:,4M0L
MD6R:(')VG6&'D4(J@7/5O0DPT1W]7 I]?BSS4LO[H"@*WRB$::);[>R>IE_X
M8,I#"!<RC#T;AYG'!UGZA4C[>U%WC6 [^2.@A\<L/HW/3.^^%XF <N^: @B]
M92DO=?43Y3=Z;8CBN&_=\]EH;STF )-SHL.8;I*O1A,?O6^Y"F*GO9]-A^A)
M+26AGY]X;1][ 9VG6,39).H1_%@63O[\9!=7>1!5TMF>:-_J=5PBN*9/>@[-
MEK:];[^;.,9UI09,(Y/A" '\&B" ]T<(X @!'%VZ&]%WWG9P+#]^%IB;3X5F
MES\1-\)E>R_.3M_<0@D(Q7(Z^^8.S%.<</5P!H?67'QU+V*A8/$7Y6'(RXVP
ML"<D+:MP4[E#36=L(\+2TJRTNY% W$#OA,7>X-[IZS,)J3[X^]%(Z,;(@>[X
M&OE3^A6ZR^GS>&(2\(/V4D$"NPB$]M8FGOBJG+:WF$KP">R.L)JM.'3<W]8@
MWTXWFW;XNSQ@K+3MLP]OJ^+?G=. FF+N4"3;>_OTY21C4"+T#N#="*/*)+@T
M3/ 8^Y[N/3UO&X7)Z+AAKWZGQJ&OG-AD/7KX_8-'WS\[X5#\J??PH#C \@BA
ME=I[PBU(*[/#1X\>CK'@3;5A8L9%M'3>L:60&J=XSWGK\PM#/9&JY&$1G_3K
M>9E07EI<(]+X!DNW:JV6P-W]4EJ-99VP$":16HA):M2>?DBCP42B^BE3*RVR
MXUAA#CKNLXVEA&*=*EP8/?/2UA])G<H.)9/$4>^BJP*SJ'!A9GL#Z9ZC[P\/
MCWKI'O]'3O?<U524ZLDR*R7C =(IX0;(UH@/YI;MXIGL9:,.I&?.L2!*Y@H.
M6:"*@<R+?.C.(2>5'G WU^"?'D:2O!J9"'6%Q/5'=[\_X$S8R2]/;]WBSGLT
MY\M'A'O.Z)2&'D/J)(,W?B2E2R:A\"D[#N+D8T]X-J-?'-.VI\N63E[C\--,
M?,*R6TIX*I%M=)T3>A%/9:$+-F+@$7K5R'093:2"NQ61^S4%E:C6K==2<HW/
M8'Z-LHZ+1NH\K:[C02*BT>1]*6PJ4X0T-?"/Q7M=),=M"^$ WL58.B=Y.9/#
MG9;I8GU%[_=6;)CX)64G?OE*F@#O>"*(@AH+\7VB"W3R3*P7I\91A$>.^U'X
MZE-):Q7*M@'IIKQ1GNFX*HJ[>(ZTPK=CMU;G]8[--@6+#'?BNUO%Y@VX9Q00
M"CV(%K ;+><FH%;O!6*C^!D=E_(-43 UD?25OE\N3(0,V?7FS8Q2J">UWB&X
M1IO2%, >'AT>J1!8O.*/7_"B]QI(0@9#S[XLF33&)P7S"+.09S\_R?9^_5__
M@1Z OV=G\L/36\K%.)@$C/:<^/[X$ZX/(:TG.[ZC34)D@7_U6GM/XQ0N7^K_
MJ+[]Z]"[?J;)-X9K*UPDS6U:7CA[>?9+=GCG[L-[/]#^ON];&YZ*"R'>A*<M
M\SAF[VF8SZ\.>+$+',E5,/.WHV(8_?G<8\-Y4+M:L\LZ:"F:E3.M-.F]$?G&
MJ(??-V>0]?KOKO1(K*.C<=O?S+8?V&O,:":['DO,TN_/EJXYKW4+9T_V_[[/
MI5L8=<-ZD4-]')A&WQB)E!2I]_!7.L\8Q\M\G0VSRF<4UKUY=CIR<=Q@R0Y6
M;B?JS-S,J*@3_!OS4(#F:L7SR%MNH%M[8E/V@4*E Y& J'V#^TIJ^44K(0?C
MF5O'682,16[7^;D<)H)7"O=#H.8[ MF_T<X.9$74&8+#O)\]4?HU3YUC;65#
M);&H8N:K3.)X6=,1"'H*SJDLN22XR(5F=EJZI5;M7 EW3_C4FHW:<PA0<&@
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MV-"#U$4'#R:[UY*>=-CAL9V_^_W<.KL*A<#V0I;C18$%*IP?1W1,6'K3\9=
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M1MS[)?4'A.@=F<K@)ZF.J0 Z5'"$O*[_M&96GS (8^REUL(?[S]9K[04T?'
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M\BCE!AGN_-6[ 93(N8_<$>JD+JMW%8!AEU]@3PHWV+G=\].4P&*UKO0363I
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M8W5*VMXN'")=%.-G%0J''T\Y,IT!O.L!-'@6MA2-A&?RZSV"SRBV:5WP'L[
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M?^WZQ.8.[DD*(;!#$Q=$>H@#3,-@#C. $UN=5.Z;X\)QW*U5 7I%@ [X%:4
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MF 306M<"[5=[?%=V=QXHN-6.U8)'BJ&V+E#;R4,MG"$1IF-]R<2MB;1GF>W
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M!AS.;#=\5FA1_?G%.3YTFKT^Q*>GY]O3RGC!BB[8^KFD(NFFWMJO_"CE9="
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MW>SJ!5GC@R/<1Q&%]R,*,2?%R<^=3TOA:N;.;><NF&CGI=@@Q/69*;\U#S4
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M#D1V[HCL;"+5^;C ]PI/%IA:>+9DI8A*$95;N%&K;TA_?^T=$5'Y*$7EW_#
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M.G^JI>.=)4$\\<K95'F7<9)X0^5%"B8\@>XBC^;N_:/SN<-M CT5*JQ8[A9
MAI-IHI!(OXP5$HMIJL@J6%X8=9A4D>('E]5-1")LUU"<)\%?]N\9=<8E[&AX
MUZB3 MM7 <^++(YN#7G.<8$=PMZKA@1Y3Y.W*[YD69I+L/?J=/A/V$?O+'OV
M1EVH))OB14+>Z7FN%%\IY!K23;OB#QCS3IH5QW<&RY9*%;8M/J1>,_^KYP,P
MZ@]\8CXL9!JD,X^<)\#H@-XS$!%AMD211/6&6D5B]A4$1SGV>/-][WT:=GR
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M+++WZL-4Y4$)J^6I;U.5%DK*> D6VJK459$3FZU*'RMQBY=GPP2%0'21*[O
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MX+><'22.(&&%NW.G NE:S.Q;5.WKI$HL%4<!&NW_&2D-BQN1&2S["[/DRB=
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M6!<Q^=WI=DPZEER#8K>429V8 V9([I0T,7E0>)PY'F>9#:0U[B^C<X4<[L,
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MGCR/;@.BLH>T4A057+;J8@/?#[MAL"_@VT7PYZ6Y7&AU<C-:C7+P%-WPJ=*
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MCU)_Y&6FM_ ]LP.*31DCTX^9^?.UILOEX_D$M@QL-HZ(.\V/.V]*"IYSLR:
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M5X Q/YTQ[YSTCWOVWD$')KQBB*[-BJ^9!LM7<(*G=(*,G&RX#X :;C[N $A
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M8A*H];:#$U@ 8&SC_ S4&D[U4'5&Y\@^Z/7A58V.7J#6#74?Q"10ZVT')[
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MQJ89-:A?NRRXU^G8G>,#F#"HW_8Z 6 <U*]]$ /, &8TR:A!_=IEP9STZ^
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M-/ ,%!O>U1[O>M:W#PZ1Q6YV.%LMUX8;06L,_KTYW7MWK3'H '!LF?P9!].
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MQ3XT^ B?\ 04,(36L!F>T0BMX1D]X8(Z@H9BJ@(YT'V@ C7R$BL<T#U$@HC
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MH<%QFE).5$3V[GO_$9I7 OP2LC)]&*84PLAV4@9>F;79FJ$D\F?L^&9^FSL
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M&P2"F;F3+ ?+&!;^';.T2((I'/QQ'/Q7)W!T^H^BAN\1^,<Z2ZZ'+)-6R[9
MGR.+#*_S305:LRP$K"3PY!Q*SM68A(D=:UESHK(]PW&V+T132<F?IP%;GE'H
M9)9Y@R52K!U[%!++O\A?PS"^RR+;,Y+F9;)3OO=\P[(<:.U'122F7V6-GP_
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MICO+WS$<U?OKGVF@BD=(=Z53>G4W#.)T,G&D'^AG]'[6^=B)%-W5)?.X4-9
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MS+V$, <0PD (@TG"*B8)%7.HE@K0=C!4\3?KF8D22^-NH"["Q"NS #,[E1U
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M*WAWQM(=GTA;M2)M5:D5?5=-7U<7-=!Y*]</8XD[O;) S\!W)0O+4UHVJV4
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MBLLGD>D]-C'7H91SQEA8XPA?*O;@N(Z4K<L2MT4EVSS9^X;ND,H*G5:-RH$
MLJ)LRK9R8VB2."SR?5\4%_.32_(ST_(,L%Y)U/<TC5S\*L4:W])050C4X'9P
MNX>[W5TLKE(D@H)%JBJ+\X5@K[3*/^4*(WPLB;[9 F?F$X5CKJ:<.]/$2:1
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M3F"Z_9J#ZB-!=4'U9W"6&];43[N"ZH+J:Z*ZCM,AX"UCBNA7)[#H!_[D6T4
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M$GAODR =>\%\GB9V88A<(###_+8Z$,S%;@H03P%XF$]A]!L%\A)D\CRX]50
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MT(,-1[ES)[(4]^S,5$XL"9(CC">X,#H=P*&12F/ZWE0M8$JUB;IND.ZA_/*
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MDAL0J^8B'A6[=3JC$K>%LYD:AT&NHEMOGH8X1$*CY$! ^HFVE?"TTR2*8![
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MR42%N?.,EE\3.#0LK0POO0;D?TTKP+Z9*AC!-0)[Q\$G*!.G*H(]AE_*";S
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M*TMU/#,N$O4@$\K<_AB\05TC*J) QD(D)CVGO-(Y?-=Z.&YX4_V-MD)JI>*
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M Z3;E8C7 K83(9K.X0B>ZG@/IK2ZI;L#2'YL8?#*RO*J:<@H#U(S#", 4QS
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MZFM0DWD>(1,EPT?V..$4/79I,B)-H[(:N\"8?8GF2$4&&<\ 7E9D S-2V%)
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M!?IYN9OBN"M2H(M9$D9W9#L#7[CQ*[]Z@<P2^2X&V)7#Z!); [6YWKVT"K^
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MQ>A[KA+K^M$$RP3AK[YX7R"SI>LT<RKDT![BT;\1R"J0?2HV8$U3._;<%LG
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MSR"55$&=N(AV6HD?OV!/J"$FIB/FWR=AKB1%.UC#IF63UXNWS1>DU),S5I^
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M)BPXCRKV@P65G!.TK27JF4IE4D>-P/VR<6B0'J\8D)\T*PW1P6U1ISVD5RV
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M!"CO0RKM-+'L$J:._='STK#>*3[__'OWFV+S][*@+F6T)N8 N=(4S4C\D!J
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M/:G7<9[A>2JY\#I)+KR2P?C3)+GP"^8-OKOJGEY^,LX_J^:A[>;[V#'\EM4
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MH#,UXD&$'BY*:LF&,7<D,];K5X$%-[S(A^D31YET8]$=.,T <SJ&ENT[4],
M(]IR',#>0%EX*?P\@=$$\A&9E4Z>-_$".R3.'=)E:CL7W,;,0^%]D2/W#GZS
M_?P.RB\765Z8"3P9D0#NSX,=CHAV(S=$RIWX-HQ]XL"*WPD77N' :L/O&*X:
MX+WXS#]<)'LY;I)!-*[3,2Q-WV)M4FYM\KN'^PPF15_X+NN-;>J-V[R>*!0]
MI%IZ C@6A-#$0BD'>Q*-\89P9(494?)@@U0"?@;FC00*%LNX\Y0*P@VN&*>!
M,;"#?A0$DH'1<RU9MX[2<YX$-#.O&<&303!$4O"#L@IA:_ &)8;@A:@U8-,#
M&W4=_M^$1!\*)_%(LA)?%P\5/M,#X88[UP8=86$&7?YI6HKA#@1"D 8:1F'D
M"]-X&-G]D>%;-KTV-::!%_5"P^IY46C8\%JK9SLHZ]*O+UJI[Y8+NXZS5TH,
MU "H;IPYR-\[1-=RP0*!BB!$0 W; XHA\(R!"/J^W9M9XXIQ.T_'##S4;;@,
M3C2 QZ!F&"!9R9]IK\=(ODKZ&T/?&]-RP,RH ("T@1T8$<X@M&PWG++X+;?X
M_60%MJ1K!>M9!&]9! =SV!%96>+.8 *PRE92(XO=8LDPCH5%Q;@$,9:[RR9I
M!X(/OD>$IB&G-N+RCRL<4<]"F>U)S$K&1E QP/@@H6-,HIYC]]/@;6C[8Y14
M=@"+"'<2N,.W7<E+M30_36Y!/V% ,D:Z#][-8KOWQCN%K:^ZIY>?$F,$)#N.
MQ$>HK[!X#T5_<@P0#4!!9:UL]" 04<,X_ $91_%0_ZC<5.3;AV!T^+@@ M0$
MX&@@9\=ZB.&N84TF,"E2"7Z$@!5_\,F'+7&QVKF;Y'Z\XNRQ#V1W1P,9VT&@
ME12M$TYP5H(R*V[(B@;5.XCZ:%G$%#Z/+E"[#X!"XVV5>R5)Y7;D!>E+%$E*
M%?H@2(W3)@.^0,M'T@^]#JC2ZZ'JA)NLP'.)GA!O^?1^B2(>1@+N\.>;B\@'
M0U^01HYM1*0N?8D9/V,@P0^8KZ #X+]#'P8B44+,&@$!@S1C(2@TX5L?I@/O
M@CD)]PYVA7Y4LT+34<T*AH'(QT8/M&M)A.A[ -> W5,S\.E8+B!@@HF ->G.
M>"],?$^>Q=5JP:LB%PU^7'24)/C*15]G]&!1<8H:WTTB?X);" ]1,A.OFA6;
M8CB4/@ 7Q>H<T;S,K(G2X"/:^+BH2F"['B!*0)?J]2P2MB,2+E-2@$!QS+'2
M-^'UQ0"P?R#=/@'N%&EL._@1S&4]32;%5LZ3;&FFA49^""A;I-97=@$2, VE
M8MP@\:0NCJ<C'H$ 7'B4B21M&:!?0]3S-@Q%W-NP2'VAC UI[P$#CE%92^6%
MEAR81NJ9<Z<E(8E<2;).DO??6TXD32SMM9SU_$0(.\BQE[+-8*#VF'P]8PNL
ME=XT!8%,M*<>!)BB\&_N%<A\Z#I3'C4K[1 K'ON?:/XZMKA7 CS1#;"BN$9H
MNZ6D=2^&U"G?'K/LYH)33P6C?@U^-<[LP!7^Z1@8Q_CV[8IWXE5V0D<I8%GN
MR8=4J"PM>5*G\MN@!YHYIQQAW;/SFXNSZ]/O5V?7Q$48N#T/0#"Z)BWF_P'P
M):;T]2D(;T="X9J,(S1Y$U]C$P]2?IRUY.Q]XYP]SME;*6>OSCE[9<O9>X64
MO3JG[&TS96^Y6 !GW^V>AE\\^XZ064$&GBI6>6%.6#Z#KY@D./97IMC?93X&
ME$KPX:R^UW8^KBNK3W*D\0Y]AL)WIL8/UWMPT?[^Y$3"^!-]E,:_X,FV"]N
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MU3XX:9GU3LNLU9K<.9,5-"MHEFRLH$OG*6 R?G4%_9+*Y!<HZ..#DYK9['1
M21\]IZ YO8!]2GOE4_(C,3#$XT2X 6<8,&1ER%I6@5$^7<\1+78D[2KM;M"1
MA!KU6Y*UMQ14[1R<U,T:0-7C(SY@F!4S*V86;JR8V8&T1[2[00?2"Q3S4145
M<[/:,6OUXRWXD-A?M$9&94_1RSU%%UXHXM0CTW!%:'A#8,9>: SL@'RS^,7/
MZ\;5GMOW/M#+E>?W0H27P\_PWL_JM8OQ;VW]DF5=0ZL?G#2.:^91O0CQLPG
M)L!;,0$80&T7_+.@8(?<SI#MIAQR:06]%.)O')QTS*/:L=EH-U@/LQYF/<P"
MC?7P*_K?%CW:]Y@I?.LG^Z[O4%_.H^(\JIWSCEU.A&^%L%J&(ZQ Q$U;IJ;1
MEYB3@S&,&G<;-7( EP.X[,AAVGTM1TZL8[^ABM5QW.E2/IWFP4F[:=9;1>?
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M*PW7^*E:K<:WI+"DD1+%H5%5_R"E_F.5Q(BCA?,BNE_G0'RY*P7]W]2P:R\
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M..6^"LI&" D&<3<"UL.S8%+'U*>:Y[^*#<*0F]/*S9%<+.J$.LE&%_S1N1'
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MP=K(1BNLS;D1H&R(4L$3> )/SIH6Y/O.K+*">#TK"+YG!>,7"]7W6Z7>$9F
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M(,67Z".F6A*.;$HK!,BFZJI:9%.E_8!KGRR;ZD E^:E4PVP*&Z 5 JYI%T2
MD*^/3L$/)F1!,5PU'J#."% *0+00+2DHLW=YH N]Y*<7Y0$96(;YUIYHQ#',
MMZ((L$5#'02* AP> (KA 61D&![@W A0@$.T$"TH V6PTM)S!BNM/<6(2EAI
M11' %R!:B%8ARG PB,[$V'TPB'N<#06O1=_"W[*MD09K.R/MMYM@N]&WFW[7
M:[8['?83E"(<8ODU%PFB)Y9?600<TRNH<0?,N^LA9O*+&?/N< T0#=<@+\-P
M#>=&@$(AHH5H%:1,M^#!(Q4O>O&AE_STPGS+$)@PW]H3C3B&^584 <PWHH5H
M%:*,:[H.Z\1TIP>36['-4(P()"/#L,WG1@#;C&@A6H4HTS:]WJDFA_@65)*?
M2M2GL0%J(X -J*MV80-*4H8U+CH38_<:EXY\:UPZK'&1+1Q2^=-<)(B>6'YE
M$<#R(UJ(5L$!<S96U9\>#)@3U%5%@*!>5]4BJ)>DC&>Z!9>@4,=3AQ@[ZWB^
M?&6\+F4\V:(A93S-->+5X"E>)<M7LV1U\<NX=1/<3L+6=795X_-X]#Z,\G<^
MQ8^#>#*?1BW'?VKT?G%3;2=O$N+N)JYKMH^4:2O+M?S*FT]\U63+VMG@6BMO
M=#O?W-)\^SA/AO<B/!KQG3$3_4GGR9]&F@7-% =+VJT@ IYI'3P7 )<@NTN@
M,(A"J8H A<&ZJA:%P=*C?;YULGG^-E22GTHUG.>_I1_VRR9/[0[6>W5A/ K(
MX\<,?$/T;;- M^CXLCZ7QI/Q"&LQW=*[RD%US)Y?"M2\J9V8YMW>@!1?HH^8
M:DDXLBFM$"";JJMJD4V5]@.N?;)LRH%*\E.IAMD4-D K!%S3+H@ (5\?G8(?
MS+^"8KAJ/$"=$: 4@&@A6E)09N_R@ N]Y*<7Y0$96(;YUIYHQ#',MZ((5+$A
MP]ZNP4/,Y!<S7 .N :+A&N1E&*[AW A0LD.T$"TH V48_9:>,UAI[2E&5,)*
M*XH O@#10K0*4::*<T.@A^STP#9CFZ$8$4A&AF&;SXV 8WH%-:[0GL."G<'P
M:SAKH5%GU:B_[3Y%S"N^_7 <#>.+U?Z)5W<WR]T3\QV'TW&T^/?Z3L-I_LRT
MUK8<3I>?6=]UN-?H>VV_V75\]ARNB7U!(ZK6B.<;J9;3C+]C:; T"B)PMDH@
M0B:'V2$A.X [W8)'D.S''5@C/6M.G"+L=PB)W^BW.YUFS[9(!Z0(BZ0#ZND!
MZ0#I0'T1.&TZH*QHR7.HRQ/$&_I&-G!ZZKBFZQPZ.(!0:6'0T#5T31NF8<K.
MC0"S-55/*A&M$U.F;7H]9FOJ3@]F:Q+4546 @=?:RQ?1O21WJEB+ 4.D9\@K
M@ZR=<PRRVA:#K'*%0 99U=,#!EFQ_O5%@'J>ZOJ%XS_YX.KA.X9"#]GI03V/
MH*XJ M3S:B]?1/>2W/%,M^!""NIY"C)D=SW//TLYSZ:<)U<$I)RGGAP<OYPG
M7B7+5[-D==W+N'43W$["UG5V0>/S>/0^C/)W/L6/@W@RGT8MU_E.48'ZER2>
M1Z,+XZ?!X.W;=^]^N5_<<]O)>P#!=Q/<-=M'RL*5I:(\,V:_/QKEZ'<9SHQ)
MG*8X6/)O!1'P3*O@G(!G3N-1L"M^S'AFV ^S7<8CC2?CT:%??]E39]G3_2W-
M?!+:RBJG;":&HB6B63<$BJ=L!ZK>'AD?0EI3(:5\6GIPU+=TM3Y['_/8AMU2
ML[N&)SQNZ8?]LLE3>ZCU7NWF[J+CK\;OFAFPE[VK'%3'[/FE0,V;VHEIWNTJ
MQ1SWAKZ3!I,&JXP :3!"*HV0D@:7=DVN7?LTN .[I69W#=-@S))6"+BF7:[B
MH(#,(IT*2B>453&_J6YB)^24@)QD+1@:11&041TQ.>@H.@J+*Z@(=6&\U(RG
M(J0?\4ENM*(H09GD1E$$BF^<0[46S:1:BZ'!T.A+3@P-AD91!&141TP..HJ.
MPN(*JK4]&"\UXZG6ZD=\DANM*$I0)KE1% $9U9'D!AU%1XNPN/CQ9.J,N>R=
MR/BP6VIVD\CH%ZI)9+2B* &81$91!!S3.ZTZDK2@F4P[P=! 3HG)B:'!T"B*
M@(SJB,E!1]'18BSN%CQH3FT6[UNMM2T+RDM-><JU^L5OLANM*$I4)KM1% $9
MU?%<V0W'@R*HBM/9-5U'U]$72"LS:7<?\>UTBY_Q/4];7X+@X>)C$M^-9_^*
MTXV#O=/\V6CM.N';:?1MM^G9?K/G<LBWCDZAVCP**5'O>'#X2FXE*P(R*B8C
M1XI+*BG5B5G<-KV>KBG5_J-$-O26FMZ,$N&6U$8 MT0F*I^N8IM*TEGGI9"0
M5F;2OE*)[IRA$NU2B=;<*5")EEM*J$236]47 1D5DTJTXI)*2G7RR3WZ[NB_
M?R7:@=Y2TYM*-&Y);01P2V2B\NDJMJDDG3W3/>W23RK1D':/2K1_AD*T1R%:
M<Z- (5IN)3E^(5J\2I:O9LGJNI=QZR:XG82MZ^R"QN?QZ'T8Y>]\BA\'\60^
MC5J._]3>_>+^VD[>&C*P6P9<LUVP,+,O"Y6E77[ES8>_:M[E]%FG72MO=#OU
MW)=!_+=X,GI&L!<W8?F#;\5'?WG.P=^"21 -0R.8&;^'PW!Z&R8+E^[:3<.Q
M' >W3OE#000\TSKKS)W?)L)R&([9%M\=Q7,1HG[P[=4?7_34KJ#,[.XT1HZR
MPBR;']KE?]H_\#][B#65:*18?01D3#"/*<\HKF09Z$$*_%<,<*E1?M_"?GF(
M ?9+.2'8T@_[99.G=F7KO=HM#XN.O^H(:F;I7O:N<E =L^>7 C5O:B>F>;>K
M')^4,EZTB1?$"^64A71=*P1(UU%<TO5Z<=XQ79MTO8,88+_J+038KW,CX)IV
MN<J(5E+<18J1XGH+@8QY6*7S<F&Q BQFP0Y.2E$$9!10"EF*2RV%+#@O$>?W
MSZAZ"(3J7HR,2C]Q(*.J&XO)J,BH%$7@W'MW'=-)(:AJ"NK.W2E<I_SV%->B
MBV%Z-9^ELR#*(%_?I>)I<XHT_]3F_A3M1M]N-[N.U_3;7?:GP+7AVA07&5P;
MKDU9!&044.K@BDLM=7 X+Q'G8;N:QNIXV=LL'GZ]%XV$2?KV?^?CV9\?HN%D
MGH'_,4ZRMM[,9LGX=C[+M@^[B2_C*&L[B2<3\9$/HA<BK9MM3?E>[$?8R?(]
M$CT=-8M$KUYZ1*)'HJ<L C(**(F>XE)+HB<UY\]]0BE)G;+,/E-2YZJ1U'4;
M?<]INJ[=M-MM<CL-K0FY7;UDB=R.W$Y9!!S3.ZV GMWG<6J',LJZ^X@@USO2
M)*R71P5MFXW5$T:N[3>[CH^+P\6]XN(0'67K1QQKC[-3$0$91?5<57OD5UGY
MI7Q?COS=TQ[K*N4\+6A/JG>$XOX>1\GZC7Z[TVGV;,Z1U=''D!S*+5,DAU)3
MFN3PW C(**HDA\@OR>%)MEMP'<;\H+B*B6!;K430L1I]VV^ZW4ZS;9$+ZFA;
MR 7E5BIR0:DI32YX;@1D%%66]Z"ZI(#'XWS;]'JZIH#[[UWL(P9J)XOL78S]
M4AT![!>*B_VJ%^=970VS9?-2N^ON79GJ[C\NM]N-ON,TW5ZO:5D.Y78-K0FK
MJ^LE2ZRN)K=3%@$9!93<3G&I);>3FO,Z'V8#O]6V4C^JEL-JO)3L"."ET%J\
M5+TX[YGN:9<Q4R?7A=GGJ9.K<;*$XU FU]R94":OERJ]6B87KY+EJUFR:O\R
M;MUD:M*ZSBYO?!Z/WH=1_LZG^'$03^;3J.5^1_]61,,O23R/1A?&3X/!V[?O
MWOURO^B&[>2_#J78K12NV2Y8'")E)&E7%P'/M I.=.%N\[RKBT!Q*[@? MO-
MF;*V++_RICFJVI?EY9QU6];*&WUNS9X@WG!PKS@U[P=.C=D*!XV;^1:A8L?=
MWM(/^V63IXX@Z[W:G<DN.OYJ(EM/5-=Z5SFHCMGS2X&:-[43T[S;&Y#6##[\
MFU8(X-_P;_BWDE'&M?%OA(JZ(.":=D$$N-OG#LQ'&B0CCA/'M6$:D>7<")"$
M(%Z(EU340;PP:F@=6B<3TS!JYT:@^%(_[C:1A<A"9)&;:426<R- "0#Q0KRD
MH@[BA5%#Z] ZF9B&43LW A@UQ OQ*D6=XIL@(U3G%BI,&;H&TS!E<B/@F%Y!
MK>-N$UF(+$06N9E&9#DW J3[B!?B59(ZW8)[.2)>,HH71@VM@VD8-;D1P*@A
M7HA7*>JXINM0/5-+J#!EZ!I,PY3)C0"F#/%"O$I1IVUZ/4P9H:(N"! J"!6$
MBI*S7YA7J9I0D;^C:S -4R8W I@RQ OQ*CFHPE8QA(KZ($"H(%00*DI1I_BA
MUPC5N86*_!U=._"<7:?WU"AGZA8A<!5GZD*_(]'O^Z-1CF\?TG0>1,/0B.^,
M83R=QI'X9#S\:MPE\=0(_PB3X3C-__J0A'?B<N'(&$??PG0V%9TRXH?L1/L4
M'T(2I2 "59R>O%W9/N=MYQ]55N2LEQI3L<;E%]XT#C\0N$,,1<^Q'3(E%$I%
M!$Y;YD&UY%$MRCNE1P(./^?ZU]'XV^J6MM)PV!K_T;H?CP38%\;BW^*!'\Y:
MMFW!)?FY]",'(%#N:TJI+?W@,'-=4%WKG6Z'F2.FJHJIEH0CG=(* =*INJH6
MZ51I/W#XL?/[IU,V7)*?2S5,I_ !6B'@FG9!!(CY^N@4_%!ZTA84DX=BV&H\
M@*((4 M M! M*2BS?WW @5_R\XOZ@ PTPWUK3S0"&>Y;402J6*^--,DJ3;^.
M_Q _-GJ7"-<VCL6WQ=]%@Y_"NW\TAI[=,$;A<"QNA;BBU3#NLMLR^T=C_(>X
M1?-I:Q3/6LL/-(PHF(H&XF@87UQG"U.R!2OAZ/=Y(L#\*&")1_\.)O-PM8[E
MZFZ0KV+)/_LNB:=OETM8KNX^KA:P?'A:OW*U6+XRCJ[%[PI3\7O$4Q_FG9I'
MXT5_T^6?QJ.LA]]:KM5UW$;?:7J]3M.QO5]_WORQ_35%1HRQ.V@*=@>[4W,$
M*#8B6HB6%)2!++*2Y3A9PT&9P=:,8)Z.-M,!3Z0#;?( *0A/'J"Y2A!2R0.4
M18 \ -%"M I1IHKM]B&&K,38[?D=>3U_.QL"<+I.LV>[6'\IPB+67W.Q((IB
M_95%P#&]@AIWR$1)%S637\V8*(EM@&C8!GD9AFTX-P)4#!$M1*L@9;H%#_BH
M>IF2![_DYQ?N6X;(A/O6GF@$,MRWH@C@OA$M1*L095S3==A;2W=ZL+<6MAF*
M$8%D9!BV^=P(8)L1+42K$&7:IM<[W?20-ER2GTL4J/$!:B. #ZBK=N$#2E*&
MY2XZ$V/W<I>VO,M=.D_+7=P>RUVD"(N4 #47"Z(HUE]9!+#^B!:B57#D_/ ]
M<:&'[/1@Y)R@KBH"!/6ZJA9!O21E/-,MN!B%>IXZQ-A9S[/D+>=U*>?)%A4I
MYVFN%:\&4?$J6;Z:):N+7\:MF^!V$K:NLZL:G\>C]V&4O_,I?AS$D_DT:CF]
M[W0,AE^_)/$\&ET8/PT&;]^^>_?+_>)&VT[>#<B\F\RNV3Y2%JXL__(K;[*@
M:@)F[6SPKY4WNIV#;FD.KD*K$=\9CT&2B'N29G%9W,S9;!)F<33[4Q;&!2[9
M?ZT^A?DE8U<0 <^T#IY.@+&0W5A04T2A5$6 FF)=58N:8NF!0M\ZW5J!#ER2
MGTLU7"NPI1_VRR9/;0_6>W5A/ K(X\<,?$/T;;.HM^CXLJ:7QI/Q"&\QW=*[
MRD%US)Y?"M2\J9V8YMW>@!1CHH^8:DDXTBFM$""=JJMJD4Z5]@.N?;ITJ@N7
MY.=2#=,I?(!6"+BF71 !8KX^.@4_F+0%Q;#5>( Z(T M -%"M*2@S/[U@1[\
MDI]?U =DH!GN6WNB$<APWXHBP'8.=1 H*G!X "B&!Y"187B <R- !0[10K2@
M#)3!2DO/&:RT]A0C*F&E%44 7X!H(5J%*,-9(CH38_=9(D[QS0?G:>M+$#Q<
MY/L-9CLEA:/?YXG \Z- )A[].YC,PZO9?9CLM\=@K]&W';]I]SQV&)0B]N'O
M-5<$0B7^7ED$'-,KJ'&'S++S43/YU8Q9=M@&B(9MD)=AV(9S(T!9$-%"M I2
MIEOP2)**U[@X%OR2GU^X;QDB$^Y;>Z(1R'#?BB* ^T:T$*U"E'%-UV%9F.[T
M8"XKMAF*$8%D9!BV^=P(8)L1+42K$&7:IM<[V?00QX9+\G.) C4^0&T$\ %U
MU2Y\0$G*L*9%9V+L7M/2/ON:%I\U+7+%/NI\FBL"H1)_KRP"^'M$"]$J.#S.
MKJGZTX/A<8*ZJ@@0U.NJ6@3UDI3Q3+?@BA.*=NH08V?1SCIWS<ZUJ-G)%?JH
MV6DN"*]&2O$J6;Z:):N+7\:MF^!V$K:NLZL:G\>C]V&4O_,I?AS$D_DT:CG^
M4Z/WBYMJ.WF3$'<W<5VS?:2T6EFNY5?>?.*K)EO6S@;76GFCV_GFEN9;%B.#
M:!@:\9UQ+>Y?F"X8^,;XF(1WXNOAR,B#*>:5C%M!!#S3.GC,'\\@NV>@)HA"
MJ8H -<&ZJA8UP=(#?;YUN@G]#ER2GTLUG-"_I1_VRR9/;0_6>W5A/ K(X\<,
M?$/T;;->M^CXLER7QI/Q"&\QW=*[RD%US)Y?"M2\J9V8YMW>@)31&'5D=.=H
MC.L7'XZ)HV'\H[&8:]&G,%W5GZ[N%M6G-T]EI_QKXVCQL:W#->GR3^LC-G:C
M[S8MRV*\AL10<01(#.NIPB2&!S@;USY=8NC")?FY5,/$$!^@%0*N:1=$@)BO
MCT[!#V:603%L-1Z@S@A0"T"T$"TI*+-_?<"#7_+SB_J ##3#?6M/- (9[EM1
M!-A8H@X"104.#P#%\  R,@P/<&X$J, A6H@6E($R6&GI.8.5UIYB1"6LM*((
MX L0+42K$&4XND1G8NP^NL2I=MU=O@?B*\ON]ML=T<G6VGF^Q7H[:8(BQE]S
MJ2"&8OR51< QO8(:=\CTNS9J)K^:,?T.VP#1L WR,@S;<&X$J!<B6HA60<IT
M"YZ:4O7BEP[\DI]?N&\9(A/N6WNB$<APWXHB@/M&M!"M0I1Q3==AO9CN]&"2
M*[89BA&!9&08MOG<"&";$2U$JQ!EVJ;7.]WTD"Y<DI]+%*CQ 6HC@ ^HJW;A
M TI2AL4N.A-C]V*7MJR+75P6N\@6%"D :BX5Q%",O[((8/P1+42KX+@Y^ZSJ
M3P_&S0GJJB) 4*^K:A'42U+&,]V"2U&HYJE#C)W5/$O68IY',4^VF$@Q3W.E
M>#6$BE?)\M4L65W\,F[=!+>3L'6=7=7X/!Z]#Z/\G4_QXR">S*>18/1W.@;#
MKU^2>!Z-+HR?!H.W;]^]^^5^<:-M)^\&9-Y-9M=L'RD'5Y9_^94W65 U ;-V
M-OC7RAO=SD&W- =7P=.([T2DGDY%P$ZSJ&D$T<A8Q-,%37\SGL*JD<=58YS'
M]BA<A/G'\>S>^/A__]NX2<0/7P1.W#$IO8((>*;%; -M7<?._,3M59N@7(L^
MA>GW#&602VS^X3?1:*&OOVWF*Q^BP9.J_D>(JM#4-4G=FLVD>2N;"4V[T7>:
M';_3[#H^"0V:K#@"E%GKJ=:460\8._4M;(RNQ#BIC7E69SV.BWE1D^TT^AVO
MZ;B=IM5KU]'#;.F'_;+)4UN;]5Y=B+P_$@]V]N@9HF^;5=I%QY=%VC2>C$?X
MHNF6WE4.JF/V_%*@YDWMQ#3O]@:DF"K58@<S;D@%U46 5+"NJD4J6-H/N/;I
MUM'WX)+\7&(=/3Y ;01<TRZ(P"&BYB-JB)KNE&+B'D3#B6,;=$: \@&BA6A)
M09F]W;=KP2_Y^87[EH%FN&_MB48@PWTKBD 5&WH@3;)*T^Z=_&Q=YM9WL\7"
MG6Z[Z=E>'>>EX7J0%ER/,@S#]9P; 6J.B!:B)05E((NL9#EI\G">%2T]D3AT
MR1BDD 8R!LWUA.!+QJ L F0,B!:B58@R'!*D,S%V9P>.#MF!W^CWLD$%CQ1!
MCO!)BJ"YJ!!M21&41< QO8(:=\@,3!LUDU_-F(&);8!HV 9Y&89M.#<"5!81
M+42K(&6Z!0\LJGK]DP._Y.<7[EN&R(3[UIYH!#+<MZ((X+X1+42K$&5<TW4X
M UQW>K C,;89BA&!9&08MOG<"&";$2U$JQ!EVJ;7.]WT$!<NR<\E"M3X +41
MP ?45;OP 24IP[(8G8FQ>UE,6X-E,9ZU7!;38Z\M.<(GI4+-185H2XJ@+ *D
M"(@6HE5PA/WP37FAA^ST8(2=H*XJ @3UNJH60;TD93S3+;AHA;J?.L386?>S
M="C[V93]Y(J>E/TTUY17@ZUXE2Q?S9+5Q2_CUDUP.PE;U]E5C<_CT?LPRM_Y
M%#\.XLE\&@D^/S5ZO[BIMI,W"7%W$]<UVT?*S)7E6G[ES2>^:K)E[6QPK94W
MNIUO;FF^O1$A=?J0A^_X3GQ(!,[6;9"&@@SQ]"$4X3+_V\-$7#EX#))1:HSS
M2+^,K,:C"*V&B*W&6G#%*Y/@*XB 9UH'SU+ 7\CN+RA!HE"J(D )LJZJ10FR
M]+BB;YUN"8('E^3G4@V7(&SIA_VRR5/;@_5>78A,,A)(9^ ;HF^;M;U%QY>E
MO32>C$=XB^F6WE4.JF/V_%*@YDWMQ#3O]@:D&!-]Q%1+PI%.:84 Z51=58MT
MJK0?<.W3I5-MN"0_EVJ83N$#M$+ ->V""!#S]=$I^,'<+2B&K<8#U!D!:@&(
M%J(E!67VKP]TX)?\_*(^( /-<-_:$XU AOM6%($J=G_8WS9TOT-#$-(@""D;
M>>191_3T1&P$*8(1P:A^"% *PD$C6E &RC"J*CUGJ.MH3S&B$E9:403P!8@6
MHE6(,E6<E;%_*;0'E^3G$B.H,D0AG+;V1"-HX;051< QO8(:=XAM\%$S^=4,
MVX!M@&C8!GD9AFTX-P(4Z! M1*L@9;H%#[6H>-E#=AHI_)*=7[AO&2(3[EM[
MHA'(<-^*(H#[1K00K4*4<4W78:\>W>G!K%)L,Q0C LG(,&SSN1' -B-:B%8A
MRK1-KX=MUIT>V&:"NJH($-3KJEH$]9*4J6*I"/20G1X$=6IA4(P()"/#L,WG
M1@#;C&@A6@6'D _?;!)BR$J,7\=_B!\;O4N"X6P<BV^+OXL&/X5W_V@,O4[#
M&(7#L;@5XHI6P[C+;LOL'XWQ'^(6S:>M43QK+3_0,*)@*AJ(HV%\<3V+AU\_
MI.D\'/T^3P28'P4L\>C?P60>OA%O3Q^RQJ[N\L_=!FDX&L33AS!*@^S]CY,@
M>O,8)*/T0S2(HRC,N_:?\>S^X__][YM$W-1%9\6/$H]^F/=L'HT7G9ZGHX8Q
M'F5]_-9RK:[G-/K=IF5UFFW+^_7GS9_;7U,$Q  'HP ".)AZ"C4.IC1E/-,M
MN 0%!Z,.,78Z&$L# ^-B8&0+GQ0Y-1>55Z.M>)4L7\V2U<4OX]9-<#L)6]?9
M58W/X]'[,,K?^10_#N+)?!JU7.<['8/AUR])/(]&%\9/@\';M^_>_7*_N-&V
MDW<#,N\FLVNV#ZY-<$C"D0Y)^/YHE./@VS_"9#A.0R.^$Q\1<=:(\ZB;8H+)
MW!5$P#,MYA]H[QN8?X!"J8H M<6ZJA:UQ=*CH[YULHTD/1LNR<^E&FYELZ4?
M]LLF3VT/UGMU83P*R./'#'Q#]&VS9K?H^+)DE\:3\0AO,=W2N\I!=<R>7PK4
MO*F=F.;=WH 48Z*/F&I).-(IK1 @G:JK:I%.E?8#KGVZ=,J!2_)SJ8;I%#Y
M*P1<TRZ( #%?'YV"'\S)@F+8:CQ G1&@%H!H(5I24&;_^H +O^3G%_4!&6B&
M^]:>: 0RW+>B"+"'A<[2M'L/"[OX$M!YVOH2! \_6@5Z+;H5IOD?KQ8K4E9+
M549;5W2F^><W%W5ZC;[7;OJ.Q8I._ LB@7^1F&'XEW,C0/40T4*TI*#,_M5#
M#W[)SR^JAS+0#/>M/=$(9+AO11' ?2-:B%8ARE1QU@K$D)48NPON3N4%]WS;
MQ?WK[2]V4&QGQ7:?2KL4<1"OK[DZ$#;Q^LHBX)A>08T[I$381LWD5S-*A-@&
MB(9MD)=AV(9S(T")$-%"M I2IEOP5):J!^@[\$M^?N&^98A,N&_MB48@PWTK
MB@#N&]%"M I1QC5=ASVI=*<'>U)AFZ$8$4A&AF&;SXT MAG10K0*4:9M>KW3
M30_IPB7YN42!&A^@-@+X@+IJ%SZ@)&58WZ(S,7:O;VE+M[ZEP_H6>>(@-3_-
MU8&PB==7%@&\/J*%:!4<*C]\\UCH(3L]&"HGJ*N* $&]KJI%4"])&<]T"ZX^
MH8"G#C%V%O LZ>IW7>IW\H1!ZG>:B\.K45.\2I:O9LGJXI=QZR:XG82MZ^RJ
MQN?QZ'T8Y>]\BA\'\60^C5J._]3H_>*FVD[>),3=35S7;!\IQ5:6:_F5-Y_X
MJLF6M;/!M5;>Z':^N:7YM@J&1GQG/"1AZVXN6AL9CT&2B-N38E_)N15$P#.M
M@V< X!1D=PI4!5$H51&@*EA7U:(J6'JHS[=.-[V_!Y?DYU(-I_=OZ8?]LLE3
MVX/U7ET8CP+R^#$#WQ!]VZS2+3J^+-*E\60\PEM,M_2N<E =L^>7 C5O:B>F
M>;<W(,68Z".F6A*.=$HK!$BGZJI:I%.E_8!KGRZ=\N&2_%RJ83J%#] * =>T
M"R) S-='I^ 'L["@&+8:#U!G!*@%(%J(EA24V;L^T+;@E_S\HCX@ \UPW]H3
MC4"&^U84@2HV9$":9)6FW9NOV<47;\;1,+Y8+4*YNON8A(L5*/]9+D 91]>B
M9V&Z=:UFNOS3^G+-7J/?\3K-CF>Q9!.[@B9@5R1F&';EW A0+$2T$"TI* -9
M9"7+R5W_?CNS^(U^%Y,O!9LQ^9I+ /$2DZ\L F<S^8*WP?!K.&NA7JB7FMPY
M\F$J,$0.AOQMM\=WCNOQT_QQ:>TP^]D$$<R^'('P^&8?5:A:%9[O+%=.)?Y.
M""4!4! !Q_0*ZMXA<QEMRAFRVQWF,M;%2D T,F\U&89M.#<"3 Y M!"M@I3I
M%CRZI>J51 [\DI]?N&\9(A/N6WNB$<APWXHB@/M&M!"M0I1Q3==A^RO=Z<'V
M5]AF*$8$DI%AV.9S(X!M1K00K4*4:9M>[W330URX)#^7*%#C ]1& !]05^W"
M!Y2D3!5K7?;W 1Y<DI]+^  9HA 5-^V)1M#":2N* $X;T4*T"@Y4'[Y++/20
MG1X,5!/4546 H%Y7U2*HEZ2,9[H%UWY #_7H05"G%@;%SAF!Q*MD^6J6K"Y^
M&;=N@MM)V+K.KFI\'H_>AU'^SJ?X<1!/YM.HY?C?Z1@,OWY)XGDTNC!^&@S>
MOGWW[I?[Q8VVG;P;D'DWF5VS?:045EG^Y5?>9$'5!,PW+UKG7RMO=#L'W=(<
M_)"F\R :AD9\9R1A.DO&PUDX$I^.AU^)?22T"B+@F=;!@]M8!]FM ^X<A5(5
M 4IN=54M2FZEQ]%\ZW0SUMIP27XNU7#&VI9^V"^;/+4]6._5A?$H((\?,_ -
MT;?-LMVBX\NJ71I/QB.\Q71+[RH'U3%[?BE0\Z9V8IIW>P-2C(D^8JHEX4BG
MM$* =*JNJD4Z5=H/N/;ITJD.7)*?2S5,I_ !6B'@FG9!!(CY^N@4_&!:%A3#
M5N,!ZHP M0!$"]&2@C+[UP>Z\$M^?E$?D(%FN&_MB48@PWTKBD 5NQT@3;)*
MTZ^;A](;0_%WT6!^C/W0LQO&*!R.Q:U(\Z/N[[+;,LO.M1>W:#YMC>)9:_F!
MAA$%4]' /&U]"8*'B^MLM4FV$B4<_3Y/!)X?!3+QZ%IT*TP_/:U*R3_VYC%(
M1N^3.$U%/\73'.:-S:/QHA]I_IV&,1YE+7]KN58W.Z:X;3M-W[-^_7GS)_37
M=!:)Q<2@%)@83$S-$:"$B&@A6E)0!K+(2I93YP+_#B;SL%@J,$]'FWF (_(
M,@ IJ$X&H+D^$$S) )1%X&P9@.!M,/P:SEJH%^JE)G>J.%H$ADC/D+_M3@"<
M,R8 :?XLM79E BZ9@"Q1\OB9 ))1M60\WZ:NG(3\G?A*=J @ H[I%=2]0^9&
M]JAUR.Z%F!M9%RL!T4C+U608MN'<"#"M -%"M I2IEOPG)6J5R;Y\$M^?N&^
M98A,N&_MB48@PWTKB@#N&]%"M I1QC5=A^VT=*<'VVEAFZ$8$4A&AF&;SXT
MMAG10K0*4:9M>KV330_I6'!)?BY1H,8'J(T /J"NVH4/*$F9*A;"[.\#;+@D
M/Y?P 3)$(2INVA.-H(735A0!G#:BA6@5'*@^?-=9Z"$[/1BH)JBKB@!!O:ZJ
M15 O21G/= NN_8 >ZM&#H$XM#(J=,P*)5\GRU2Q97?PR;MT$MY.P=9U=U?@\
M'KT/H_R=3_'C()[,IU'+\9\:O5_<5-O)FX2XNXGKFNTCI:O*<BV_\N837S79
M\HV*UKG6RAO=SC>W--_>Q<E=.)[-$W%'XSLC>=JP3'PA'GXEU)&_*HB 9UH'
MCV7C%&1W"IAQ%$I5!*BPU56UJ+"5'C;S+8*Z[O2H55#?T@_[99.GCO7KO;HP
M'@78\6,&NR'ZMEER6W1\67%+X\EXA%&8;NE=Y: Z9L\O!6K>U$Y,\VYO0(J,
M(J-2$X[<2"L$R(WJJEKD1J7]@&N?;O&. Y?DYQ*+=_ !:B/@FG9!!(CY^N@4
M_&!*%13#5N,!ZHP M0!$"]&2@C+[UP=<^"4_OZ@/R$ SW+?V1".0X;X51:"*
MG0HXZ5IZC?K;KYM'RQM#\0'18GX8_="S&\8H'([%O4CS ^OOLOLRRTZG%_=H
M/FV-XEEK^8&&$073,#O!OO4E"!XN\F/O/Z3I/!S]/D\$H!\%-/'H6O0K3#\]
M+3;)/_;F,4A&E^'LZFYM48KHLWC$P[S=-'^NQ,,RC\:+OJ7Y=1K&>)3UYEO+
MM;IMK]%WVE;3MJU??][\6?TU%4: -;(XZ$C5.O)\(5HY7?D[M@?;HR "9RLZ
M(F1R&"*2-NFX VND9\W)TXA_!Y-Y>'@6,4]'FRE$N]%W21ZD$ *2!_74@^2!
MY*&^"#!C077](F<X,66J.'H$8LA*C-U9@2-'5O#C9*!#,B!+4&2RA.9200S%
M^"N+@&-Z!37ND#F6'FHFOYHQQQ+; -&P#?(R#-MP;@2H%R):B%9!RG0+GK52
M]0JG-OR2GU^X;QDB$^Y;>Z(1R'#?BB* ^T:T$*U"E'%-UV%;+MWIP;9<V&8H
M1@22D6'8YG,C@&U&M!"M0I1IFU[O=--#.G!)?BY1H,8'J(T /J"NVH4/*$F9
M*A:[[.\#NG!)?B[A V2(0E3<M"<:00NGK2@".&U$"]$J.%!]^.ZUT$-V>C!0
M35!7%0&">EU5BZ!>DC*>Z19<^P$]U*,'09U:&!0[9P02KY+EJUFRNOAEW+H)
M;B=AZSJ[JO%Y/'H?1OD[G^+'03R93Z.6ZWRG8S#\^B6)Y]'HPOAI,'C[]MV[
M7^X7-]IV\FY YMUD=LWVD5)89?F77WF3!543,-^U=)U_K;S1[1QT2W,PWYFL
M=1NDH7C\X^E#&*5!MKL8<8]D5D$$/-,Z>& ;VR"[;<"9HU"J(D"YK:ZJ1;FM
M]!B:;YUNMEH/+LG/I1K.5MO2#_MEDZ>V!^N]NC >!>3Q8P:^(?JV6;);='Q9
ML4OCR7B$MYANZ5WEH#IFSR\%:M[43DSS;F] BC'11TRU)!SIE%8(D$[55;5(
MITK[ =<^73KEPR7YN53#= H?H!4"KFD71("8KX].P0^F9$$Q;#4>H,X(4 M
MM! M*2BS=WV@:\$O^?E%?4 &FN&^M2<:@0SWK2@"['10!X&B H<'@&)X !D9
MA@<X-P)4X! M1 O*0!FLM/2<P4IK3S&B$E9:403P!8@6HE6(,E6<:@$Q9"7&
MK^,_Q(^-WB7!,-N@R!B*OXL&/X5W_V@,/:=AC,+A6-P*<46K8=QEMV7VC\;X
M#W&+YM/6*)ZUEA]H&%$P%0W,T]:7('BXR+= ^I"F\W#T^SP1>'X4R,2C?P>3
M>7@M^A;^ENV.-%C;'$GT43S)8=[0/!HO^C!/1PUC/,J:_-9RK6Z[V^B[CM_L
M=JQ??][L>W^-WC ;PX]$$#LQ_#5'P#&]@AIWR+0[&S637\V8=H=M@&C8!GD9
MAFTX-P+4"1$M1*L@9;H%C^^H>M&+ [_DYQ?N6X;(A/O6GF@$,MRWH@C@OA$M
M1*L095S3=5@GICL]F-R*;89B1" 9&89M/C<"V&9$"]$J1)FVZ?5.-SW$A4OR
M<XD"-3Y ;03P 775+GQ 2<JPR$5G8NQ>Y-*6;Y%+CT4N<@5#"G^:2P2Q$\.O
M+ (8?D0+T2HX7LZ^JOK3@_%R@KJJ"!#4ZZI:!/62E/%,M^ 2%*IXZA!C9Q7/
MDJ^(YU/$DRL64L337"%>#9WB5;)\-4M6%[^,6S?![21L76=7-3Z/1^_#*'_G
M4_PXB"?S:=1RG:=&[Q<WU7;R)B'N;N*Z9OM(>;:R7,NOO/G$5TVVK)T-KK7R
M1K?SS2W-MX_S9'@O@J,1WQDST9]TGOQII%G(3/&O)-T*(N"9UL'S ' )LKL$
MRH(HE*H(4!:LJVI1%BP]UN=;IYOD[\$E^;E4PTG^6_IAOVSRU/9@O5<7QJ.
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MA@"#@G55+<J&I0<%?>MTQSSVX)+\7*KA,8];^F&_;/+4]F"]5Q?&HX \?LS
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MQI-8_)#;+.L13]2[5A<%*/-0Y:6$K8^4\[PQP=O N$\RE_[3S=7 LFPAZEF
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M-8(!5:'=?04#;J*)"*3O/U.^?+#(G0@W<_T/:L-VO=MHU!L-E(S"E@.[0M4
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M4C=<_I4CX@.Z_',:=S-??[\V;#>[]7ZK#V=_I4TU,"Z<_4"Q1[2\</976WP
MO+ZRL[_9 +G#V5\"JJ\(@@0K5,/9C]Q_!  J$@"X#<3,=&Q#J!/+5!L1/YH(
M(OTX".@>W5\$( F&596T,1PT)=>SITK=" ]4CH@/&![0^OB=& O2OK8^2/32
MLV]8)U]*5;Q9W&!0&W::K7JOT43<H-)6'S@:<0/ VR-:7L#;(Y$C@+?["2"
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M-PE*N4Q!RI9!M@LRI=OU;K]9;S11\E0=;8PX6[EE >)L,!\@L& ^'*%H@_F
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M6ZFB;5P-9/$)(7$H;#Y'W/'N11C1\AFL5^X=U 3!?#YM]0WS^5@4/<QGQ-O
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MG#%T]=L*HT+MSQ*K64^[^0)S8\G8:ZV0SO962&MS*V2_.497^X8I@X.(F3W
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M&/:D$>\'/TCT[LWXB]:ZGZ72W:@#;[M9&W;[]4&_B=K?ZIEO8-W7K^ ]6;X
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M4.%I=8KQG-L_BQB@F !66^6T+@3(_@5(097/YM0LK+>]^?HA*,H/SR%7(%>
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M# (['<9:;KV2M;R9\=LGX[=;O^BVZKWN ,9O990P<@I+*@N@6F$AG+IP@H4
M,79T?';,%3Y@I]>T$)K]4IL( V[_/&CUZYT+9(E51PG#0BBI+-A#8*W90-D1
MHFAECJ()ST;\#-8Q%/,;XZUK6M^,UGF7QK/]F 3YBA&3'Q=FWWR.==RJK!@K
MFPI?S S_.R1:>4)I^^0O<-:K&LIEMI.[C=JP4^]V._5V&VFDU5''.[63(0K@
M@H:M4-7E+9]P@JU0<3$&6Z'40378"I7EK"JGW76;2+NKI#Z&L5!26;"'H-H
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M(SQ0 JJO")@$*U0C/(!0 $(!I0H%W)J/R4'$IF4%?$3QR/?BT(@F@1_?38Q
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M3YCWA19)!/>\+^IQ@=*]4OW+PQ@)1,6,J+05FRU^P6>C]Y>M^(> 1E\Q#^+
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M-H6HVI^H6@8?F062A;V:F,$-D4S@V.*LG:[QBI7(OW5M>!D:_MAX)RPQ'8E
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M[[ 71M$=#P.T,<DZ<C*?A^ W0?Z0]KZN6@/ZV4W4HR@6 %/X7Q$&NA-D%NE
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MCCI%L;_$8R;>,N+-#V20<ZO1'FQ'S?=3-Q8G(!,<8&)^<!_:\Q(*E]APQ8$
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M!&@BR!H,&QNCFCC%;NS)QESS(')UPP/\!L@0&U@EMF=A&ZLX;1U&2X2YTZ^
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MRA(+Y@4MMXPJS8W(4^6%']O^K0NG9TF2R<L/1;0?DQELM9.GV6;-4F<MQF=
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M&1S+Z<JYFC=OCSQ@RJ]4>^272O55#@K@J\!-N1@X'O_V,G \;I[!P)$-/,^
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MZ;3J5KO9[M01\TLNM<U9/2%9]1+V,3P/HOAR<@GKA3GZMY^!0N'&;79,7>H
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M55)O,DK7B0@W;.@ZJ(UZG?JPU:TW>SVND,4HE5%J;?1^,A$.)1\X21@*WWG
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MSNE"+\?CP8GO._8E<N90)8,'VX_MO;"ALRV5R)MYW4YKHU:]U>:<=P:P+Q+
M[K&.]84?V_XM]FEA0<8XN*HXF/.+*L<8JX=I.+^H:K%]G%]TQ-?I.ZL("O-D
M^&0S5:$/JD*_/FPN"]#C6@*L/[PX_6$G:4?YX$D7W^1.7(KJ*405<90]*Q0O
M7J'@/*0C1T"<A_2B=!7.0SK:FWJX/*1'*#W[R4,:["</J3PSZ9>Q>R=_F)+Q
MGY_W';GV?6+W#Q6Z1N'HWRA\7?T1(T<IO-"RO7O[(2HPHC?$:93%Q)@[C-0P
M(M[5\H@E6?G]*#Y)VR(?--9AJ858V:&D/S1/U*(CA1.E _UT!<=Y\IGZ7L)O
MG< +8"$WR%VQ>N])NU?>LG;B)='T6=+4;O)!%K2\E*;:BYD@O]G6-$3&\>/U
MY3G5#"<#!BINV-40\XI^^\56<>!PLW^#&Y[JAW;D.B=X)B? 4&9BBS.IY<_U
MCXJ*N&W#6W.G258=?9S#8<EYW@5P,1^7X&/PB46&4IS$D_7ZRX_GEQ_?7U_\
MIVY=?#QO4"#J1TIOC .D$V(QE)WVP?5MWW%M#\Y!M:Z/\A@V.W4<X0L?_1..
M/C\_TX*TN[/'4Y+6@QZU;6^U?[4,=+(^_KF]X?O41[61]0J!1>-U@6Y6=W;]
M2X2W(HS,F9WYXW=N- _4/^%OS-I,0A$M)IYU5&O7)P[3YMS%?><N7CRMA[G,
MN,W:D>OX(DK0EDVV90NLS(JITY1GMNMCON3RWL8XANT!19B9NGN,R7!3GX?N
MG7X_=9TI[(KG63<"4X=AS/^%N00PNN7&^1QT,4D\RW,G H@JMD/*P;Z?"G^?
M4XY 9<'<;CC4AN0C^6.@_O"S>>A&..N)=1^$7Y<FWI_,P\ 1D>9!E%D=VO>8
M] V7!'0O>71Y@_16(^;IPT@&O[%I@D",OK&G<G4P>R=-#I\ T413^.XV"*A_
M^QB)7C7"IGJ]2"BX9@]&IY_ ;4\FH*$E5$= S:BN'E;#1L+S\%LQ@7'@X&T@
M4#L*?$)O\).)&Q,IWM,UT4VW,R+.OP,W;F%$3%//%H<OGH)(D#< 9B*?D-G[
M=(0P!V.GY3HIT1Y^23WMO]% WH/UTTKMN6GJSB>]S3V&:; @MO[X&V>1ZLBG
MJW3D86W4;'06E&/)4X 7>_"O,DK*D5J10.!0C47#/LU!LY&%!W#[Y'@Z\S]C
M/+[EPD=N*!\$.7HKD,H,1B*ONH6^Q#G.8O>;F;-$7*33.:?91!OM::M9&[6Z
MC?[J3;7&DOSHG@1)"+S\GP08$? J6%B[V>Y8KR(AK R#=%_7L7;"/= J_G>C
M[5ID,EL29*O5^DZ["/I8JZ1R1FX3-=-W?<=+D(:,'8&%;DX=[2UN6OH*+ VR
M81V0%I;O+XG+_5GSM*S8P*-8=*/<7L (;,<(;&D)E7,;GPVLRQL8FM#1XVNH
MI/5.I$B=I>5.YFEUEAW66-$O\US[QO6P7(R:XUA)OL(4&Q;"4" A.=\P>+"]
MV(5Y4K[FTLW0N"QC]Q$) WP#K9.8V^+J<:FWPD?(23)BG$U_O$CU?W0/3.\N
M9ETX^Z;WG%)=9G3=J4Z]3(&^H+66J;3F+A15VG^']A5,<9DEA/G4/OC4I6_]
MW\17P*'5J2M @=<+#1GMYJ_OOPDG(:GXSD:$ 1^V?GV=9QAD4B/T@(C.5^@+
MA!N@#6!?]FTH)"\D550>=-WZ\\]SQ80F$V H5+_+?+-\SKH"'"-"_>*R)\X^
MG>FO&]:G)(P2."4 EW+T*+GYKW!BK6HBFY4L%YBB9$ZH,,@%90/6-412'YW+
M;L^T"=8K@K$3J>0(4"!>Y[8#42Z\+5U_Y'ZS/KP[6R*M"67=I8$^%E !T)(C
M$E(;LW"@,(B 60LL<.;!3H_A6YI\7:$:4CKL<.P&7G#[ /.'W\-75)&,'L,U
M R3Q4:_1PJEL-^F%Z8;R13S(1?Q7*A0E@2IY:A+D*A(SGY4$@^KLFBIF>0S^
M%@OJ 68T['J?PN #[N>%+T$O?/1.2/L&_)D'KIW:Z)7[6C*2GSJ-7EZ) :IS
M[&B*D"&"'4):75CAK]8K-QVANVP$=2U1]),&].J;^LFP*?\[MA_@NN!Q22/
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M:0UK(Q6]ML!. &A'\1(\J]P*:4BN$>FQ$"[=E5'&L7V+ZMI&V_D4OOI=HV.
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M/F $)2)GB(,P,U7650!EXGON5Z%CS1?B&]$T<R?V%;RH08N.7P28\D%L6'X
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MQZ9/L3N7+@#K1EF%5U@T8F4Z<DR?<% )<>U;'Z@,=#1S<+Q-+LY(UF/W@2.
MDN6BH>0K<@TRLZ(-0VIZP*.H^1;0V](7H#TCD'^F\=_V_,'@;'F)+;[-!6;0
M&=-*25@-BMD5^%@8NU+YD=TX99P,E31PHUBUXI232H-MX&!D/,T<*Q7 =6#D
M>4 ;7MH_2,62(CV852^T+F_G^61:;Y9T6Z4H(8\GBM$M?E/>IDLL1%-!;R-H
M"VPV:_N:<=W(8+O%XJZ2+G6ZA"%3=#I"*2Y6CH2T0:R=3P:5K1*4^JK[)4@\
M12P_38_&=DDZ-S5]HRP@JU""T2@SWU98=_%3GH+8_F;NLER6L:>J((=L6V>:
M2"6B4+ 43CI-H5XR2UA;B@SM&T!9$D39CIJ1XX9.,D/HY6@5G*YJ6N:D_!1D
M.Z*LGL+O9V>?) B8"1N]E?)"RY8:TBZ$)X!-(@C%%QO$+!3Q+60.R30?+"'D
M8;]!"8CT'F'.GQWKP.O28/2NW.%MR8VV/]4\S'W=>*?>98DF)5MC+I%L2M3Q
MMY02TG0<)+Q-;RW9U288;&[YP/T65E"$;6BR$O\D$JJFA!.*6VP<AM?LB82S
M*@"06?WN6'W-B'_AXL@<6/D] RL''%C)@94<7<>!E7ST'%BYY\#*T]T$5O9@
MNU?/D[JHYFIDD1X*!WNNC*KT*^+"9<67Y32?-DJ;PS\/8B')SF>)O1EYIC8T
M&];CU!]K'&7:Q4:6IHQM;\%'LJ:B0N<I)2Q*JL/E*2V;76NCJ@LPF]%I;UTU
M3ET"D;9"!HYH;X[G!?=(G<LUP^)%W,'-P>+G5+$JDV$G].C)%5)U>H?D34&7
M6J/Y<XK*,7W;GD> CO5?^JLW!/!)C%H_-IO-]"=J( .#DT(06TWU'X12J''!
M>N.P?%;6%W?\NY!+^AS<GP=>,O-/3M/)3N554^*"QH+!QBF#.,\TN)QZH6ZR
MU"_RW\AIMV! ]3G>5,T_LD_IQBY^#->H;&S\.'M6<2?-$[K&1\06.L8'DC.8
MG^!-Q?52^"Q0J[KI<K#\0$UYT?$8!IU&I_,SZE^2,Z(F1/_KH&8&6M'BJ=7P
M3L/0N'<XMMY@4ZLYW[>*/#P(!.KDX<?^-61E=U 4^TL\9N(%XBU;3+/X@N;"
M"PPR;S7:@^VH'+AT+$Y D#G W/S@/K3G)90O6?N*@P*VB,*0JDV\K$/;XG!Z
MC<Z6IU,P"H'8A N$=\J"_:(@B8+A2.V%,ATQ"]NWD<\XY=H*3:JSG>:6 S1K
MU;3N-H/3:L;H6*#!WU"), \0(LX?K0-K7[?E6@Q\F5<+<YP?_@I'CP%#@XS?
MV,[76XJV?&/]>'[^_OV'#[^N TAOEW"K!3:S-4]:RGPZVS.?3E7@#H8Z':VV
M:1I9]N066##@GK2:F;+9HIN=!:.5W8-G19TK7UA1,'/L>[[-]O9;^]C><K;Q
MA=Y/CQXM!]D_Y*"!-T8<1<Y3&_WT['G*%O3=:9QNR3\6B9G)>/]D+"WOFYH_
MG]QK9)GU\Q)C(C,3Z*HF(IU6;33 0GR#DD)\< -W"VP9Q#*(K12(S1=#,$L9
MS-/"""\#X3*8K<SV;@MFGVA:*SN=)PZY./NVFOWF(#OQ1.MHF5OU@(F^7<S&
M'@^JGW@K#GBI^#J]!)S__I_$C1]TD?-(%D<Z\\=4#>G&$YMI .W:Z+1;;W=.
MZ\W!8@>*W2L!;-UFQ:#RBL$3 Q:O*1=Y:?#4"O?1\R9[5BI8J=!#OL4L"ZO=
MZ,VQDU<"TF+)B/K+A=FW'J-45#36^PA1T*+1?F>N]I^80U9.7]GG?>6;NF]]
M95<WLQ**SX:^C0Z&=]=;K5:]=UK2*2=C,0L*S@_T!VHPG/'[O5(7%I,1%BM9
MF27X=,VFJ("[L8Q0K@"7+@N5*SRW;&Q9QRE-"B^V@I.I^8M375UE>>.IRI@V
M*DFQ^(ZL+F%)+<+UDU#>CHC*6=9E%_+][9.10;6LUEBS5LA3^@!+_AM73 D3
MF 3U9U8FX"]9D&!\Z7_&JI=8J  >^!CXH?XGYH9&?^L*%]?"F?KN/XF(EN15
M %,1P%7F<(?C,!%%]G20R63\JS6D3%AF--^#T2SM?YA5E(D WH1+ZZ+?4S7#
MM%1@(LMO20BU) _KRL$2FCJ545>/Q;N'OYT%8^%EM>S3U*-<!4":G)QHEI)D
M5#U;FI!TZ(OV;!*8V*I9:M5L-OI]MFI6SZKY/E=S=WWBTK,C4+8_'HO]\4D1
MNC+?Y5G%-AZX\ \'#/S_[+UI<]M(EBCZ^?6O0*C:$W8$Q>:^V/48(<MVE_J5
M+5W;53/W4P5()D6T08"#13+[U[]S3BY820#<1$HY$35MD6 B,\^^9W&X5V]U
M#B/5-,+N 6'_WJPWNQQKR3IMON-_M ;U0?M E5I:P],:WDEI>-RU$ZEWFG5K
M[4YK=Z?'+)Y66.IRJX,K>AIK#]%J97/PL1T//K8J!1\_J"%:TO.Y^AQU/+YQ
MEF&0&W-<PA/)H&/G8M0$E;.9[2JE4RFU2OH"5=+OS%L8K[%ENO]&2QFMDVJ=
M]$2YQ5-+=^UQU(KHF:!J@2+:.05%M'LQ:M2;_37-31,NTH+C=$_A.+V+4;O>
MS4OCTUT*M ;]K#7HCS3"3+8B$/EX#ZYM\G%I6F)JI5HKU2?*0)Y:4]%*M5:J
MSP15"[30WO:E)?O30OL7HV$CHX.^TJY=K9B^0,7TJ^7_N)QYC!D>#IS$>=*B
M&846.%HGU3KIB?*.IQ;T6B?5.NF9H&J!3MH_!<_HX&+4J3>RCMY7U3V]@U,X
MS_!BU*UW<LZS7:EVE8K3;Y,YFX8VNYU]5>/B;Q KK)D%C_#J.#&W.EDE=\4+
M [>K+=WS:Q-5I)V>KB(]2A6I*LGDM8T %W@.+L.GBLVEQVQK83FFMUHSR5V.
M'2\Y'5W4>*>GE%<K_#P<OC^;$D\]HT[/J-O,M4Y^P).>4?=<9]2U7QK0*@!'
MSZA[1BSLD"VMOK# X*K.F0^HBW0X/9].=_!]X;&):].?/WL7X\87GJ@"<^YW
M?K*A"7K_LW+W/GGC3%THN1&_F_7ASG%YC<8G,*]BN->VK5E?(FJ2);R)*+/A
M"YQK 6@"/_5+-7KM-"Y&S5JCVZMU^X.B!/&72JM[D44I"WF#24Q?:='UE#2_
M/LRNBR2TO??<[+VKR<0-06(8'ILP$!^ MUI5TY;>.4E7+2Y/4UR^5*36YMVY
MX.Z9F'>AY\$/^)-?E9@N:>31I/):IU,XH_"EDJNV\%X:V1_4PM-1/FWUG;S5
M=^,\P.<NSKG1FINV]LY)TFK1>9JB\Z4BM;;VS@5WS\/:DZ)Y5<Z\:X%YUZAU
MAVUMWFGS3M.Y#N!I4^YEF7)W'EN:UM1@/Y?,\;'2S9D:;C!G@.#<<2AJX[32
MI@V]<Y*Y6HB>IA!]J4BM#;USP=WS,/0283TAQ3]R(0[/WZ($Y]^5,P3;%Z-F
MLU/K-76@3UN"FA$<WA+4@3YM'9Z\=?@57XP]4D)?]$C1*ITV \])X&H)>IH2
M]*4BM38#SP5W]V\&NL[$W:L-2.+9G?WA\X?+67HX*K$SK W:A;,27RJ-:DOO
MI=&ZCOEIJ^[E6'5WGKL$2*XHUL= OBRQ66S-<+1YI\V[\Y*R6FR>IMA\J4BM
MS;MSP=WSB/))47UGP]V+)BTDK<O9>MV+47M8Z_<+!WB^5'K5IMY+HWL=U-/F
MW\LV_[Y[YI21S-*:F[;VSDG0:LEYFI+SI2*UMO;.!7?/P]J[<0+3N;?*=V?I
M78R&M49S4&LTLO-QM8FG3;P72>PZFJ?-N9=CSEV'/NR,>8;';!(__MQ:ZG(]
M;=J=E8#5$O,T)>9+16IMVIT+[IYRGJ:4S5_CHKF<:=?'Z0J#85.;=MJTT\2N
MHW?:W'MR<C@)<^_.<Z?A)#!H SZ*,Y!O#\QVEVQJ!&PR=US;O5]I74[;?^<D
MA;58/4VQ^E*16MM_YX*[IVS_15F<*+.I7,__Y'H?I,#^KN1U.:-P $9AH];M
M:*M06X6:!>B G[8 7Z %^$_7G3Y:MJW5-6WBG:I(38G/1\!E]Q&QVF@N@TW2
MU'=M:UI&(E==,KO[EMA]>=D=VJQYMKSKG,3V2Z6SZE;GCE1Q1*+2Y'1VAO".
M.:Y24<FUB;^4[5<SO!AUV[5ALU-K='5STO,1T/LSF36?.!]K6<=0M05]\A;T
M=S<P;3'7PC"%M-)ZJ#:G3U5:ZXCI^0C1EXK4.F)Z+KA[<H9BKH%887I%MW$Q
MZO=J@V$+_NMI&U''136AZ[BHMNI>EE5W-9FXH0,6W=)<(=)JY4P;=.<D6K>0
ME4 RYN0'"R[/EG.<D]!\J=A]8,M.(_'^D?CU>=AX8HAA_ LAQ.^X#"]G_C4O
M1JUVI]9HZ3ZGYVW[:5:P;U:0UJ O1F]TY$_;B"_81O1"%HV[UVJ>MA'/201K
MF7H",E7;B-I&? 9(?  ;<>^5D[D&(DIP,>J^9'RP=3'JMUNU0;.C#41M(&H^
M\"0&HC8&M3%X4L;@[9)Y()Z<>\-FIL\,6T@9W3Q'6X5G)7>U(#T!0:JM0FT5
M/@,D/I?(H;FT  E^1\%].X:3TG+EK,'VQ:C9&=8&[::V!K4UJ.E?APNUA7AR
ME'$2%N('-F.>AXU5S9_:/-3FX7D*8BU93T"R:O-0FX?/ (G/Q#R4@ON[^3/V
M93GSL',Q:M6&PTZMU]/YI-I U!Q APNU,:B-P=$=<WR4>&/FL)D5&*YR.VJ=
M3AN$YR1XM20] 4FJ#4)M$#X#)#Z'+%(AN=]SP5TU7-B]&'4[@UI[H)-'M36H
MR5^'"[6%>'J4<1(6XA<W8+K[C+8)3UW\ID3M,YK.H46\-E-/T4S=D3R.2%V:
MKK3E')O2 1I-I58\O8M1L]FM-70;UC.2UOL=U:%YQ?F:V=JDUB;U29G4?%2'
M'0DF'-N!DDGKH]J^?KD26]O7ST6V:_M:V]>:KL[$OCY$JG+E_.3^Q:A3Z_<[
MM4&KK8WLLQ'9VL@^;8:A8]G:\#X-RC@)P_L+"\2$3*V9:DO[5,6V'HQY6D)4
M6[-'3VK6N/O"!F."9"YG* XN1OU6K=D<U!I];2F>=^ZRIG(]%?,D*4O;<:=M
MQ_T.4@>YSB4*,\^U;;@XPP*YYC$_T&J:-NU.5<[J(.KI<K9S$NHOE>!T$%73
MU;D%4<GN]2W\Y^T,-9?O<-QFHW''O GL]0OF-RLMYD8H,9],R_O3M,.2&<I#
ML(IKC4:OUFWH@M[S$=8Z?'K:K.+0X=-60\=/M=U]/G;WK\#-''F?[UU[JJYS
MS9G%^<;P:"+\:IC"&?SK/W#)D=9QM<W^<M6 ]S8P?Z-5[\)Z4S<$$;%F1?EE
M9O?-;6SVUMDRP]/7$Q*<\GIN>K> N)XU99?M:CSS[YI#GIP7X)#TJBGUT/'P
M?5'FR076_^FZTT?+MO,SLF&]?%=#*0]#KW$QZG5KS6:SULWM(*V8E.9/IZAB
M[-73H-G1";(CJ=^OU1:XE^)O] ]D'B.B8F0(EA.:@HS3G]#C4^N!_U#APN]?
M?WLN.+!W,QJ=NLS;C + )!K(#> _\8\ &4;JA89I/YHK/T6W;TE[$/&%V-YA
MI3JMDS@><1PC>1_I)^E:^(.Q<QCB($8$%/7#.$0- BE E !Z]PW >?F5W8>V
M";^=N+8+!QFCQ@1(^NFR-12X&6,L\,Z_9G;HSY\E3@W@I1*K6OMSSBB<:J5?
M!DS%-.8>BO%?OM]>-QK-BQ$Y'@UW9ERCEN)@ KS)N03\W__S*U"X<NN8OC6Y
M1)A<@GA?L HPN4C"];<3E1/$,+>%)CEC)3B'PQQX/KA F,4 _7?H@QJW6L<G
ML@PEO8F=W7&W7ZYOOWS\?O,_->/FRW7]U['W#^KVYQN!BWA"+,8,V-3X!%JH
M,[%,&^  'RPX L4E301U7.$O#?H=0)_<7]SQNS_8(Y2XQM U_NN70:O9>F?$
M I4*NFNUDU;)]XF/+D;&:U0LZF]2>)-2. SQ!YM>@:WTUV?FW3//C^\,K)L/
MEK]TQ9_P[XGM^B%8,LBSWMONY,?EI/$7KO-7G]LPNR[3@^M.2BL VFDB^$G(
MJCS\;G6B4$([*[&^SYEQ+^Q7PU/&KF'ZA@E_^Z$=H/0*X+&[S_]C?/=@A\+N
MMN"1(/"L<4AJK;'TP*;VX*Z1C;&?2S9!%N:O'$ "ZK7B3&D=C$0LX =3X]'U
M?L!!)B0@[SP@#1<L9NMGW0"+F<GWJNW!"]6R\(HQ T-_&L)F\.VPCF&!F;U@
M-%]Q&7J 8\ROYVL]&H\.@$<ST_+0G WA@@3L9+@)8.+<$YP0"RPG^I.'I1Z9
MA]"$/2XL!QY'1\R]0?=$;$*N-W']H";A;"Z7GFM.YN)I_)[]G&"**C,]!S[R
M:P;PE@ PTYU9 <= C]D6FQDSSUT8GKLR[6!E+%@P=Z=^W<!3I!?' W$6R1\#
MQ?I^!:^$72+.!?23]'G4N2TGEW86Y@^X)%@$#_8[>V"VT89GEV&@,?:(&!MX
MYI21$S #0T"4)? _U+@(@H37BA5Z+L#&LWZ"".\,0(2//<0M6@C_\0CLDWX@
M,=G<@'=&"/OUX'=IU*L;5^I1#]0_?/M&YV<C[OILE6_R^)6_Y"N\0SDE4=%0
M7DG@IBSIE@33)MN4\14=/ PLFV0(X+XD:4F?$8O@5PDL/7WQG IS'N1@P3?$
M&,781$*$BS"-B>G/C9GM/AH+=PH$Q6\>T06^09GA 9TYH9!$*$D<$!"&#Q+%
MFJ'?$267Q65+&L"X*1 GT3L$RX(SP2%!AW%#!U]A!ILAU&QTMX31?Q.U@7H&
MBB"0PP?QSBHP:UV,FHT<H,6O<T5@$HS)-![%6PV3OQ;N, @]ARY<<#K'M%>^
M)9BG;<W60S8-.R[#D5IG@"$!/D5O)V)B@IQ(\B]!B;2 D8_9RA5:1/0FU#Q<
MU ,,8B\<O!-@"$!+'M(=%R%S:ZEYZQ%Y:RX$<D2EXK-9-LM^ M"1B-5:%$8!
MQ 6T".;&[^9X N<S7ON,&9%EU7N3SX0);>+Z0(+_!EG9?P16M([[2%68;,3^
M.U^=5=[ _CC2X.DX4OOP'(D!!BW(F0)+S$([R:+R 0GB%D>^,@<L$P!'D%AF
M$^/Q?7=BT5.$G_A(!FZ:!1V-!:7 @^KZ%'5M=XETQB9SAROS1=IZ3!7\X;B/
M">>,X]+.+T:7<_B&^UB(_2Q-]/?2H@&S;3!;0]/&+8$P X5NSFS"-'P7?F(*
M)<DUD#,!&P)VAYZ_-2^#_YFNY.M@41_]@\ , &7AD)9Y[\!'U@3,;^ WBUJN
M0K,7UJ:^.C5%J_5T;*US,1KD<#5I+@*X+1 [2_C_'MX!QQ2\*,OCEB;>V_&/
M!Q@!:(5T6?:@7>#?>69 ZJ2!6IBCG80C6359X_^ +#_#$]8A.FT ]0)[A63)
M0:2$L<<6@EYQ:<W2G\+') $*F+>&1\9R;B2GE+7*R.EC6A:Y%A76<+OD[YL)
ML)7(,[KL5DHT4E5&M[-D*I$BO-ZFG*#>Q:A?S^I-7/L%#+(E#TGY,+*7]\"(
M8<>O C3MR0_#70J_6QB :'&FY,10;KB80]_X '>6+TVVA4VNXAYWOH%^;H,<
M02-"J&?K#S#E 0;D'F/W 79ZY2>>?B1/-_#B!Q*@[@+VLMIPU%KZ)A?,Q/ %
MQN80C10'\0'+2=SAY^39@U^"V#(]O!><^ SD_$"'$&H'(/P/S-0G"S?TX] S
ME9,P_CKB73-B7+#$U;=KC@&#5J-F).[]!OM^3/(B1Q9]DQ\Y0BPU"$V-S]%;
M!;@TTSL>T[L66!F/SZ")^I,8%FA3!;QJ!TYUXR"+0+C?/CH8'+QV8YF+&[E4
M'Y2#>K> 2Z& CU$8^0K@>.CG%_1"VH%0(J?&-/20([0:K3;% >QPNLZWR P_
M'/L3SUIRG>K>8YQLY " 5<UXG%N3N> !R";(V> "NZ.?2#4F;0^D_ V#-\3_
M?":VC13.M\8)TV?$YVK&/7- @;&)PLTIND7] #6^!Q9IR8(7F!/!BL2.HIP
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M2K124BCU,#I<=IR09I.:39X!T"H IUMO5X2.9I,OE4VV#F$/Z$+4(_IO=1G
M/@M1GW,:[\87GJC0/_<[UZ4!+R>G6I<&;,3O5KT]U*4!IX_&A:4!S=T'?L;S
M@^X\]Q.N(,1PJ9J!?@.TUUJOT:RU<_H9/^?IG%J(GS23TT+\S+F?%N(;\5O7
M]YT'&A<*\=8)"/'FQ:@];-4ZO4(1KKM/:+?3<W,[Z>X36CO5VNEI,XK3$^L2
ME37/T'ZE<\/=I_$K@9SE!3:E.U+T6Z"8#FK=?K_6Z&3'K3QG]Y*6U2=SO5I6
MGSN_T[):NX_.%7>?QGVTA:S&D9:]6KO5J[4Z_3TTD,KOOE-AF =.??OK6S2,
MZ$K.0<FI=U\SOH,&QVU>(CZMHSUHQ>OF=0N'W5LX'*)?0T_U:XB!UHA@NZXO
MQV^=(\,S/J/J<!T0$A#-8VQ' >AVD[IN:2S:>\O%D6+6A/DU _A6W7@=S3?"
MN4I>-.ETO#*^$#LQ;>,K\RW;PFFW_&?ISAJZ \;1)GQ1[BV?&>L:IO$9YZEZ
MQC<!U8@XC==(NZW&.P[YS]^NZ._FNS<U@W?:^5=HRVYR0VPGA_^?AA+3+R1^
MQ%>1*]!(4L]]L*;,D/@DYO$  &GB'OQO?/K6. RH^85M+2PQ0#$V79>::LR8
MASWW7.R.(8?PXD%J?'8GJ7%R'C>.[EN('G8U8_+/SW<&H$LXPQ89'KS8HYY@
M@>NM#'.&4[_\&C7W\ ,QUPO^!1MCU 9C;.$N0$B*P9]^W;@+/3]$7B>&!ZH[
MK,6; =*2_"M_;MHVAXV$#&@(_V838)=3 /$T7%"W/&8"L2W%-WR*Y+T+2FIL
MJ"E.&I5#C\28,35J4.U#S]9[8LH+'MT,A'W15R5_[A3OU6B!6HC-K3+8@1R8
M_623,. -*6\G@:O6: XD@?+1C]&F\&<>$RR;)@6O!):8.- .N,$]CL3"OH]5
MY@%VVHF)@+WRTX.OY#L5)[JBB6$W_.#JTU(3 ON=BU%G\WS NO$A))838I=*
MYF.KFRFSS55VV/KU[9\W']9,&VT.A4A;1^$IOFNS@*2E8K>"I\:;=!)7;35P
M<SZ@E/'H>C_DY&#! VHXIIJ+X*5K(<.)O1S;^2Q-2^Z@$LBJ63@?^(S0]\R!
M?P1WMND(@9*8Y;C1JL%!SXU&K='(AL:)\RDYP;F>$!]33A4^0UY73!2?37&U
M+4Y4S2Q!6$""8R!W.:=W#4'P,7;5Z:*SQ:3,)%TP3@_E\+]W,6K5LUV&$Q0
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M:=A/"W-O&6JF#(=0>&P9N!/,Z_&-I</"A>M8)CN_-+-U)RG(.CMVKM1R4YE
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M3+&E$6':[21PHV*G5IY:F(J$5,!I/TE[<D'L:.]-*V+ +ET@[CQW!EA+#7%
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M\N<[N(:E;:[> LEBX\W+,=H$]#MD+N7_OQ*H]#]75 @3J/;<2'A(88IUTA0
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MDKDS#I^O3AY X?V2=JI,?Q-UG;&R\B(+9)?J1F)X0E*50LQ.&2.0WX TB5V
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M)^E:^(.Q<QCB($8$%/7#.$0- BE E !Z]PW >?F5W8>V";^=N+8+!QG;0/&
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M)3ZW#I:D8\ N3Y.@3T+#R -HJQ-E@;2S>L85C:W/GTU/1 ?_:-5HKOVUNP#
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M6(L%FUJP)"";\7W.X/V/IF\XKC$!,-PS9-*Q<PG;*J'FE5<2#! [N)C2"NJ
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M+# S<UO\V(B2N2U3HY2?#6U3%0;#?\Z:1')5<2&SQM,H78LR%&.\TC1FEK>
M_9!_]M&S@H#!#\(QJ(KP/> I/NBP@-R_8%9@CR'>"CTP;(8.O<UTDH#E9:\\
M,+_P=]Z)5Y::J33L78RZ12.5> V($YU.4;PZ4C#WP-Z;PYV@3K'D:&6\/CC2
MWH)XM<#2)KF1Y $%.-N_&+5S]*U7R@DMES9H;='-9@V)UXW,M.3FH!8)4V-A
M_ANTPF"5Y*7K609OS"O<-(H.XB@J?ID_]R5_32REMVW@/C;7"\6T!_P\/>TA
M'_>%GE"/BD4*DR2!3J.N_AO6Q/)G]!^HE-W848E_\H4 M).0;W^-,\J58(LM
MP/U<>*/6E$<$\O+E<B?<IG(6;Y(#IF4>=C14VN ^J7^%=CP2U1RBI%#=DS@
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M4 _$SZCI4V-3TZ>Z48%V6EO3SJY95@>GG2X8C8 /_5;6;MRJFG1+%-HA%^M
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MXR(I_EW8SE_?)G- *)O=SOXDURRL?CL#U(FN4MSD[_)@9"1EY7OSPF  S"4
M,_!")A$%7_)VUY<D<:'/?<HSU[;=1[PR'^0E>8607T21-P[ZT(^DQH-\NX36
M)$*8Q[17J@80M$WAD=KL]2+2%$M*3U7T"XYFB&)95DF Y#_.Q\JWZ79QZS0[
MO*%]0W3T*\5-\@M*E.ZFLDD;]<8KY8:9 'C,I<_>&O)?\JNWY-$A)#=^ 4ZG
M?A*+U!DQ#U!@-,3_H.W\MVW*7'JERURN?UL3/^4:)'<HY456FSM$5G/6WAAP
M[50/N+;*!UP/6QAS?6B?Z/ H-N\!8J";7:+"T;PQ8>?E(>^Z'(<3SQM$0 %;
M1%.=JG9?%M J *=3;S:J02<5!0 % 0@(:<J ^]J4WL$O0[.P0T=UDDE<:SU@
M[6JNNKBJU6S6"AULG2K+TWFFJ,^3.O66Q^,M3 <:D4.X\'453X.:7]*3IYF^
M9OIG#;0*P.G6VQ6AHYG^BV3Z&9/Y>;-]W1I;=WYX"9T?Y/1FWA3[V9>I;'SA
MB>HRYW[G9U#X=K8\Y/2K!?[^['G*Z32!T&A\K(JW]HE4O$GQ?8?2>UW4^XYY
M>7'> ?9^: _;NN;MO&O>--7K8FVM!9_ZG6LM^.4P$JT%;\3O S> T&A\+"VX
M\PRTX*'6@K46K*F^G!:L>U_K",ASBX#@E&[C-0X%]]]H+4T;>><D5K6</$TY
M^5*1>C_QC0UU->U&-V%F7/IL\G8:>LB^<TV,<;&),:XR<P>E13.R()I#^+]$
MM:TFMT.16[>.E7JBCTRL2D?3G;;17APQ:-FC]=7S8S&:9VB><4I(O9](Q$9]
MM7=2^FJKT6CTM;YZ%'+KU'M-K:]J?543PZ%C"KK20L<93C[.("4R7"(VK:-Z
M"^-!C7#6:IDVY<Y)^NKA#"<N5U\J=NM!FV>'Q 5I9HD^_NVG3#/C$OQ/);0K
M#!@:-BY&S5:_KO/,SMLFU/2O9VUJ9?@97:]6AI\)']'*\-%++302'UT9[CT+
M9;B)RG!#*\-:&=;TOXTRK LQ=(#DN05(<'KSY<QCS/!$7W=+S''6&ITV!\])
M\&I)>@*25)N#.C;R#)"X2FSD"4OP47A_ ME](T1V%6.P=3%JU8?:%M2VH"9^
M'1C1FO")7*_6A)\)']&:L Z,/ ,DKA(8.5--N(U5(XVVUH2U)JR)?]NHR-_H
M'QCVX*57\=&=-,Y3CT;?YVCTU"LO1A]"#ZZ.AK)BF:/!')S,FSMRM5VC,<JN
MXS#.T_]_]MZTR4TLV1]^??M3$.KN?]@1E%J@W?951+E<[JX;;I>CRCTS]WGC
M0'!48AJ!AJ66^^F?S',  4(2:"N0<B)ZK))8SI+++Y>3&;?]C5K$PBN#L'VK
M#U]X0B"FFU2;('SA#4]1&V+?D?ZIF?837Q3L^.HQW[?$0PHTH\6^MHYN\G:T
M?#P;6CJKY5LZ\TZ]JYO$WH=U"@LTL1YV&B.E,Y25_K+66-D:-[>M+LA*?0JK
M >L'"_? L($S[T7.HA8AX>-$:Q[>0'GNL@ES7=[U]Y&)UMR2(_1@4[IG3$KU
MZ[E!^:CG]>DQ^2]YY-\8A4.4;A:D$#;N&3/+><+UEB:!R]L^&Z:G!YX'[V]&
MS7MC;O^C?60^3TYJCVVE4ES.P[<1FP^'.7S^Z)C&EHR^+)+C5V8Z2WV$.93:
MW:B5H,])ZD_-!7TIW4Z FI"N+A\ 0.%.ISLTD>0^K.2^M7$G]&DH*H:1C$X*
M6]Z C#,\B%E8.MC![^MV4'J#=_^_GP>JVGI_^?W/Q2_\.^7]6R%D_VA>-<5[
M%[);_/W_M-G\/;R_*4M?OESQ_M\>R$5/TAZ6GO^0>*Z,BD"')?(9#E3S4Q1K
M.WSU&J,+N/]BQH<?4IO$_A.@'IB[SH.KS83 "^6CZ4LS[04(Q;) .N(;?MF@
M'OI;J@>A!&XGL/ SQ[['0X,W7-'EZH6<TK;#;F/4EH>MEMS"PDDYRD'<%,GU
M<(=Q^93^>P][WL.+P^.*R546(XNW;^(Z,\D'CN+-V_F_4]<)'H0BOUS>)"""
MB$ZBAS2EO_@B\SN21"(G'O)DPJ*/&9*@"?J<-XO7^#!-+O)AB^'OB?D,/T4I
M!!LV9U ^FXYOSF=\R57\YC(V7@\+#B_OQZ_1-CRXCN<A[>F,&9Y87:8!Z2'1
MXT5B^4.J7%JP)F?'B%NGP"RV(SEC$ FB=SVL&1(OL)%M)-;6Q.O\Z$*QMN/@
M10+=&EW^$HUP>0 QL^-#D3]P)^ &3@U>X(%-;<#=L.?YM\%;0*K,3!MW+?63
MF$Z29 09+"[G& 7OB;["64;()[DR*#CF>(W/YP=P@9DY,(%4RT&,@@@H.M$V
MZHX'6#V+M7-VS662R_CFF!,SY'K8"-QGS9+FFFEP(T*;(\R04 P@]ZP0]B 7
MM$C,CS4/R/YIRNR4A@.!,K>8SP6C&.L:9KN$&UPV Y6%<S*B68K)Q0+K&9U*
M8NBA]<&;H6KB.#C\@P_C@M@!"N4D['%>PK&X#$;HF8],LE R>%,GL 3KSBT-
M+*?$FL*[M#'<Y\"W1-G'H>Q+OF^KS%L0OJ&6G6JP@V,&Q 9[;V0H*A)N9+74
MP6I9MDC)3CFRG?(_@?62Y;759DH:RZ[S6BR\'0G/$Y>O$N@$>&8*RB9<$E_X
MKVF;1I.F0#"9>_[@7\47@NQ@SZ;G;W*G2&_"^[_=W"ZP-TP.$*8.,(^50?.:
M,+L=V%03E2A+=8'%1VRR:H8['$/!(=SR6:4:=]S8:*QY)1MX#/N8/=3M])8M
M'%"E8E'DR$4(\T@ZPQ1!.FIJ?ZZCW4@N=%/Z%KA>@$P?ZO"EK1?T)W873%-
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M$0;?5-#C:N%TRSO%FE,3)QRWLD/^?LZSUZ;U=\JG]:O%T_K#?6@/FH/A_DN
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MZO5;LG)FW?U(\5=:,!Z^[8FBUJ4)>CNW"3H)^?T+^4%3/50G]$4F 64-4-9
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MP&59Q"NS2<.7EA6)A-4<S_.T-"]LF^V]V[3,6]2,YV SL<9\ &$/;<Q<!<,
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M([4O")96[A@!HD, HF\NL)0S S/@6;+X^H,JG&"W:F0E2QM+/&R-JOK_ ^4
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M,AIAB=W<1M,K,F5@I"XJ1R?*HL!8SJ)(]R2PHOB['/(R7L:3L6SFK\ZZB)(
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MJ#:_'_Q\V2* 1\$Z"M:=4K#N*_/S0W4O%*@CL_OL-3^9W:>+$5*2\VJJN;=
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M=8UAPC:#435QG1DWF3P0D# R]T7ZS& [0&2ZL.T2&&P;+2XC8/A\?,K$06L
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M&/7E07<@]P8MJD!Y0*5TL -9Q/.O74?RI/B" /+IRR(2+I44+@20Y[M41R"
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MT;T3#60UAL"BMW[H?CMSS:_B6E^M&N,T]A,:^R1*^;((GWZ'F>!LJVG9A-!
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M <Q02:F1$M=+@]O=CM% -02H7Y6- #7@2']7+OU]->&1D]!H,9\[,9_V4GZ
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M!*XGE[HX"1_33>+S7*B06=DRJ_5F0[OU$!8GO7DU\.XRNYH*YO/G/TY2&&4
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M[:L)CYR$1HOQ[Q,>Q#RNC+-&=<G1AQ=$7P^< -$_1+4T@&*O0 &*#EPY!5L
M)U$>:H =P X5E1N91<6  ISDI' %C;F53!$*\7W5MUC6/KY1U'K_<*)O7"8*
MG6# ^FGL!3R.V8#?<3^<C.D<.%J0=)U\+W:W4+/>OJI*C?TK]=)@NV$:=K<#
M%=8C)H(1 ,9!_?0?7E _8,:I*37VI]1+@VW3-,QN"RH,ZE==(T#U+%+CQ[8*
M)5+CGWG,G<@=R<PX$N*(BC3UOG"G:KK3JBHU$N)Z:7"]6S?L=@,JC*BHND8
M& ?UTP]B@!G #)64&@EQO32X;ME&LX.$.*A?A8T =>%(?E<N^4TZRR/'E[EO
M9S#V B].1$>).PYG@!A()U\+YZFF\ZRJ4B/]K9<&6T:K;1G=E@DE1A1473,
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MC4[7A@KK$1/!" #CH'[Z#R^H'S#CU)3Z(-MD0H-+T^!ZMVVTS2Y4&-2OND:
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M8; Z(FT=@GN2X.QS<T?) 6FKB;2NFXY3WTGXH""OL_5)\IL7?\J.<Q_SCG-
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M>NB"(!YV/J&S(XY J150ZEKOA6T;W:9IM.NG/^5^>GP1%H&=B\ A=1QS<$B
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M[\U3GUO: I=J_AN)36"6\L'",T%GBU@#.'8".(;TTC,7&X$;P*; #< -P V
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MQX8H+E/&-?%^_MC6,^*[-==^-.QK[![VV=N'?;D86NWS;K/\?B>7^R8=W8/
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M(468C#CI?AI%=$[>J0+^ E&23NX8_E5-_UI5I49^7"\-;G:->A-1$J*D"ML
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M@8.K;4I[GRN:S5I495ZHD/ORM<VE*Y4]=50)8K_-X,ZT>\-P([0ZO@0.V1]
M6V]A'7_B=,%Y398<2Q4CG7+TOXPF4H";P\+-GJ@MT GHI)JY@!\=6P+@1T"@
M"NM_&1V6 #?@1T"G)Z,3^N>7E+ O,\D'$]G/SK'Q4C'XZ\KX:U2B''UXP?7U
M@ IP_4-47@,H]@H48.G E5.P!7 2Y:$&V 'L4%&YD5Q4#"C 24X*5] R7,DL
M(;I(E-Q%PEN3.(2?!4=7U?7NO]P?[8XU7P^ < '-(V!4>S"JCFW9L"JUO1>Z
MB"MK/O!)H-;5!B>P ,#8R=E957M"P*A K2OEO4"ME36?\F=QZJC_WG)E!OI
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M.,#YLR(D6L(ED;RI7G.=P+XI$:1T'6T #B6FO\<A?9C!I7B72 2X\& 2 (@
MY65*&..*.5 J]D6 V./!3EUK\(%[*+A"LU9'_%$S.%>OR[U.I,2)N?H2E=)4
MW%@WD2/[ *\.[->OX2T2-X3=P%6Z0:1H;?B^+JQ8)C.\/+V-R]"'.'8;I%/8
MRTC>NB$\8H[K4AWQZZ1VJ._BVH+("S,?=M[<P=S O+URRC<IOJPR;[IPA<*=
M"N EP5CS\$"@(1->+X%/9G1$4#^>W@;IAA3R)?X*TJF);._F)D X^'8<@;Z%
M30$[$#8%J3B&&WZ3B1<HZ7?$_^%M:M>#=_#Q-7USU?+MG-7+RY?E"\(/<?GU
M2F_]V; /FQZ&>$O81[@051(0"^\%!EP%QZ*81.CHXMAS(T^&:#P8R"F("M=9
MULW@!=PD079#^BSK(\:E7>,2;33B@2)^#B6 @BP3!5B+!$=J40&[0@:$6C@O
MVT6MHAD)I#$1 %E ^.*SCK@T; :BGS\*H0<P9^'+(IC@H_#G5(!G8)FE&.3M
M)>!M #7P9C.9OA8O>B\UE^+W##O#PM5$ ES$MX Q:AK,[8VT9KS#.VGH T'1
M%^([.^)%?^EN!EJ+;R%,&=" J^=9 F")3ZV]_=1-RY<&:H6,6P&')0R67PCE
M!B[5.#US_PW_SMTDM6^5R!G<!I\*-D 4SP)/A,%$KGII>,:P] PP.A4B(^JD
M_!J5Y9*JUS!W[S0KR/]DA+L)J@DI?03'L4IADP)"<_A/3C8W2*JW+:3[WL)\
M9$R5MZ_\X$:[)#DV?/FRZQ&#SP,+3S5CD*:^?Z,I\>:'%$,'"P\$DMZZ=VK!
M@W]-P2]3[EQ:.^;.Z3Z5UZ/8@ZCNQ^(W:5OT%TOO(<R+B((H^85EB@HB*5"4
M"/KY*Y#S^(NVN-[@$-$87F2, 3_@J(_')Z-Z13,),S7=2Y[:CJI9*H[+>:J_
MK&3>NF*:R,G?CG[\X]-5M]L#M8/F (+!%;P8PLG;5ZZ9:PZ2_18DW%+CG:L"
M[QAI<OPQ<6=R YH<5>GZ>YS*/W_I-9.HFPXCW8E/>Z]QI"7']7,"6QJ#G1E\
M$Y=_?SM.7EW@)BM49!^U1@>K[FL*EN),$WE>1Y*&1O*V1Y+S\RW%&582Q:RO
M7!6[*L#P#EYKLUFQ2"437=+_D%/5?Z-_^9K-X(EW*,Q?8<%@U('!GY8B#>(S
MZ 8OP%;A.N*P,MPQO.>ZS$='%^(%N@^=EQS+V*'/4.&\*G]I>%^V*\$H?#$J
MF99+]G! ,0'R7EV!44@ "MA)7T0N=9@G>SF@[V$ U$NU+SMU;]#3!$,$WA"^
M&MSH>$;)>D?36)O:,O*KIBN:S^N\D&C1CT$W)"J['_B\W//PI8*?QWCQ.+[1
M09)%/\8^P=-A >VL5((G\$X*7VG17<(5P6-71'?A41C<92_Y:;SD+Y_^J1D7
MR:)BC,U+$X!:<GTQ^F+B111$0[#L=]]\H5@<4/2?&(;%>]$?>F]$'-4&K,9N
MB($3H:88!^R(JRQ)T#W#T%<81]<KHBW(Y#;.,H\3'1&"QVI^# -W'(1!&E#@
M2W>O N&YUTOT3MXLRH>]W9TC/+T\LWQ:Y?<NLM^]UP:LEP>;[>B($JD2:5W:
MNMOGP5$$$-C))8PR&9?Z*!E1H69+USUQR<'&*,LD(\"K.M<=\6M$JP#P@/7H
M: S%+R,_#]!5_Y+OJ@V<8&AM!G?S=+P37B:;PT[/8C_'HVJ0\Y: "!@,37/8
M%V H'S"A" CJ& /LA AF<U3I>H]6Q(H<6FPZS11!'.RR3U\%MDKH&V : A(E
M.IY#M\68$KIHR)>)40ACL/_)H*PNHS98L;B)=3'JG#\T&+L*=I_@'V]@6:YR
MOV)GY^ 4XD;"*C+4%W>XC+D;^/BAZWE)EC-)'B;!3<!O9I$[0W'\+PF4#F[[
M00*J#=Y8X6H_+<B)R?S9B+ 7@W&%5],NP3>)3K0]F,J[=A,?J8!KM\D$VBB]
M$.):9-#_9$$B*W2'O9VY?U66'&48PG'$?S(W25$J'.";*)WB#ZCEK&2 ?9?8
ML!2LRK_!W<M#\-5'&SC!P3'P$J [8:]3#& E\4V@$*9,4'HRP4VQY@&Q"V$2
MQ<RJNZ#2Q$4Q7H&%F/JR6$@;5=6\-F!O O ;W,PF9>,;L\LVBIVS61UH.&8/
M"&(H#U27>2ABA7:=&,M?%2\LYP2(U_(MPAL%!)L5=B*M52"ZR;YH-O4157 ;
MT+"RZ!QH= ;VULO!U:O<I4,ZX1\2.86[HWT4Q@KV^2N@0>$WC+1QE"7$ED$T
M03N 7EHS+MYS9=*&4]-[GIK^ E#N)N@*1%C.<"/#>$[ <87 R+[=DUJZ95KX
M)5I4M%$ZC<F^4%J?H^GG6Z#P ^4A+H*J  \)EN$LW0LP Y /D=_//+04X"</
M+0A%Z@5(<!-X^ N UZT,0ZN>931U<WMF DL"L$+HL#<"ZV_5\O5:<>WF14CG
MYVO/(M*=I''T5\G5!+XHNYK&5@-3AA1)>0M0M3EBG*7T##2CPF 6:/,:F IT
M71+@&]T"T>"?,<#N),!71R4!7!3"CZB;:;5ZQW 3IV"#&3,!4RII"@YGEEH+
M3>=\5KRQBY4]9)8R@.XY@%ZAR3R.K=Y&C7MI"QT8/Y\MGZX-.BSBQ5(?#*TC
M5(#<DHDEKP,/DZ0!>1QY88K2804*GLH$L[N!#JAKD),YV*' O[+V,]C5%C6I
MW@<6'L_@>1UQ:9Z@A$<E&^!1W9G 6_'('+/ &@O)K$\)K6R\38*_%]])_ BC
M;R82 H!COY FZ(7-3760LO!8J1W0SZ\4?!#EE'$4BXUS=>Q864<#[Y2_!M4+
M>&6.+S\&WPY\,O2TL$J@JJ&T?1S,QEFBS*( 627<PA>3))[IB@$$3@R:&$-Y
M)< N&-3:A?B.7<Q(O.](/ .M7WC^F-X$4LJHG/]@)'X*)/ZM%)=#'$'Y(_#)
MZ0&X$5!\C60?B!',R.;$L)L)8>'UUR96-L%2/;!5900V(5V.1AIYM"K.$J\4
MJ4DP;$IU?D 0UR"3OK%4Y>0&@/=86W/XF5N*-6',;"RQ4K",7N2)SQ <A0>D
MKM;VY3$'AID]AYFO4^2T=RZZ,:@T0<68X1.,,,]CZU5,%G3D4JP:!D,OT\H@
M4"J3RT75VH,#$V1.'NUUC ' D@NLH2DVT5S8^MP2HX"KAU!#]B,9C47-12G[
M_C4%X' 37[R+\;\O3#[JX^77=R8#]=)^O?CN52E+D%]"A<#FBM/>F6-36V4.
MK"L02&/O+U']$MVEHP,\A)I%)#Y=2+HL%P]6*M$+"VXI7;-\Y4K"@&,^#;PI
ME=-C7B F($<T!ES5:T.8UO'C_):KZ;Q4,%]'PX+*\,A2V;7)AX'5&8*:277-
M/]C6%#5%8GNYE2'H.7 _:<O.R]\#6UCG2LA#2.HYS%7Z?('V#) MBHKOK5"9
MT6@7:'1TL>4:VM^XAI9K:!]60WO"-;1<0_O\1.4:VCTF"=?0/E,-+8<.]BIT
M\&L$_H(4?[C?."#YM.&"7Y<=]L+1&G9S1ZM,(<<6B9;3(\:?4^4( M;\6!<0
MW#E)$</4_6:3-<$$(X5A\-_\?++. 9F_&I<W#/Z2X9WV4J,X[8CW]E:!7E3I
MCE0!68JQHA>/KFB6&O_7#R9PL:2DS5BFMQC,U%745JOEZ1(=VX1[ZVH_='CK
M'T)A4CJ#G$B5A2D5';C?M"4$CY28&@OP-QTE5;8JP:3NQQ0RP[8:D:N+RN&A
MH7NKGY10+9@[Q^+&<H[=5F;!O2A,8.H<BM>S=06V3MW5-6QV97KS.N)?=-J?
MCL[B.5:WN%9A3C]04QLVCB360Z!*H$),2OS5D=4LT(2$RTO0H6&JH<1JTIQZ
M-FL5Z)(*_&CNWMD-! L3P()^L\QEV@%4:Q\I#*/#6'Z6V/*MHG- W5H7:,EQ
M@:>#'=B]I7K?O,BNE*(PP2,Z"V%Z4]BF$R!R660+#TMH,(]5H/.EJ?L7<"Z=
M!ZZPH?[<R"$8-(EN0$&EL\FJRK_2$Q()HALMU "72UQK5X/=,X1K,;4.W2RT
M*AOTA$6-)94WPBZ[I0X(\AMP6*3WPL34RB#A?J.*SBR=QHEF;=W?HK2#05YZ
M:W?%;+7!2CHL/9<$9J4^%\Y"="ZEZ",(&8@@@F>&>(7%_5AKI%/OCBZUE'Y>
MUDDHB^?387/D4H,,2C0%Z+-0J#$IY[<6CCH$D<JPBT= 1;VHG@06/SM:E2R4
M*V,*7@>\@R7PX?S4GAN97^2-C#(IOA2&"=N:3PGZ'\@ P;(3 )__=:,,3 F-
M*_K$3*]Z],/UXSE**]BCXH]X'GCZNR?=D]PJM22EA-25J>$QQ4I7MMS(0FHE
M8V3N9%-''?$95$"&_BT@8?D;>(R!'K)TY(%L(MO$"&U7F[PH4!3M&=/OPX!L
M7@3E4*XLLE82V9!@Z(32,_T\JIF:6VO+V?IZ+(<*]3V7\W=8"&N7TZF\3M5.
M=^GTX(JS!2J5<WNV8!;[,C0U J;MT.OEH,]O?\Y:*S'#L_FZV3V[$YKC[TC-
MB^"E)I#96-M*\W3^[8T?J'GHWKT&HB#('8_#F,+?-II3_U]#5--IZ\Y:.WF_
M+A(?-V=5APG]1(1>0>G! RB]@L;E1&P,SITN(U*%(:Q9@$G^9"1?0?/N1C0W
MU"X?PB0_NJ@<!=P'9<!T?2JZWFR1K!B7\?0AS%JJEB)"=<)-!S>8\$]#^!5T
M?P2$6XN3#B0;>Q=-3SJ5Y!)UM35X)[#$15&K/'<%,]0XN4-V<A^=I5OEROY*
M[[J9"TO95XP8BZ]NR.F0YZN>A*T#YTCE0I=.DSB[GN*Y.1W@PL8!^<&7_#P<
M]DN,?#R/9UK"8H@0#S#C(;DX63CNK608JNJ=REYBZ7"V.5H2ZR-[X.+-D8?P
ML)ZDXSRFC 8^\&,/'Z3/AJQ\LO4O5?ZTHETD\8TR]8=H'"H,EGEY%XYK/ 9H
MPG\S5V'/5;TKI>,[6,YG@YCZL#VN!YZJP[YXL%Y'8DMVIUKT/3KB(\9N73H!
M:6S32I"@> M35#@+3.L=XW>7#G32;:@3 ;X5-:2ELYITSWPMI0;$*Q0J-<+X
MKJU56>9R3V6]7/Q>0$TJ_VU\>YWL(&SWD8%ULX+%3A.13!<"!/ 50RV;<E$+
MH8(J^2=9. DLZ]6^YT+.R>RC9?_(LSTO],?+H0XBK*4CZYWFZYWR*?>O)GK$
MZN?9#FK:0!WV5<'07CG$".)%3705YCWH'&6N,1)9B*"K;*2TCK8V,%KHF%3J
ML^L8&QP'0)GD+YF4#\\#[=T[<X1^\>RA/5]9]RA"VR(NJC-8L"<!O&+FAMK@
MS3/O^E=$ZCCY*X_;?OWT?WFE?^4,)^D,ZM<V"3Q840AJFRKCE])4A5I9N<BB
M\WNQ7&KKD@++TBOGA^-M^Y;WE61SCJ3Z:)2V&:KE\'0J4S]T$2CK3E#@W^'E
M'0P"T]G6M-Q&?XR%!Y5;V"0Y*6-?=UC2JH8ZU)>"V/2UVJVP1D_>3,:DT8N#
M#-3!G]Y*VA5V-.'^K[R+-@*EM2]\29^5Q2-NX2J7E;/P[:C.YP[77)W_P.K\
M4Z[.Y^K\YR<J5^?O,4FX.I\[7#<5R!_@'%ZM]"&HH(YB_R8 9?Z^(JZCO2^7
MC'$,V]S-;3L@=#CAR^0O@1>"W<>,?^*[J4N'F;$@;^;Z\- ;-PC+!<FY_X&Q
M*W!@]>%B7 !]4@238$&1/OAK?+6[W$\S>>C"E_@EOL7SS[J T%9ZPI^5>0L=
M\R(_,2A7WLQ+Y3SEQ>6UG%.@+':MI,^IGL=ZD#9K5O:V)':']"0M_SN>%ZW%
M>D; M8E;'+(F5VS9%RQ>]V->OH/OZ%2=M8I/EH]$PWN@:VI*GHM:\.5-R0O-
MZ96P[!%;@L@)_!G<Z!=!-,]2];(C+M7WV<>LFZ*7)NWD.T1W6^0N70H1NX4S
MB7R*F[8<'USJ[9RW+M GZ?4Y]TOJ3VJJL<SML;L==HFZD^G*>RN[T3XU]+5]
MTY<J_A=ZI;BJJ(DIE8LO+M6TVRVW7O%L6VS;GGO-0VE1\&ZS_'WUTX-H^>EZ
M=46#> SQ+&\47AIG2?T;4M5:->* 6090BRCW.O1 T0R]B;BE5'WL3:6?Z7N7
M(_;LJC]9P;P7)%XVPYR*I_,(P T&Q.TD0'IQY(!J;@ 1)XZHAV,E*6%B.:I\
M7 ,8=<5=J/I/3>,L]#&M4!:!^@1(E@:ASEN;B6P6=J@.7S>LF$F N[Q-QBQ6
MJ:V(-^O17\"VG0A7>+/8'G@QURZ,8QC+-*6T#Z;%TH576Y$SJ70<-\,$JVF3
MO+W&BLT)U#TV))@X-B.HMR(EFM1W75(EJPY!+U%N/KNL]$+9C,8[WA3JH5RB
MBN^"Z!A[ $F%[.>')K S^T)!O2WGKW])'*<F_Y/!ND/$8A6'-V:+E"PQE)T7
M2<VE?!W[*SK@:<WE:-6@#R X>4_R4MHK/YT0E'!1]V,O7AOTM3==4<*:S2N=
MMIW<7$ >-N>ARLH)TVKF9( A8J%DBW4QYCU=-J08KJ@;S/J!<J^OL4&WQ:VE
M$0K60,"8_]W\X4.J<S+K)^>^\S%%48Z_(@F.E@J\NIWNSWFHCCI"SI5\+>Q/
M]D^O*>I'X3OQ8[?;S2\Q-RH%YBA*F(JN^0?C*S_H,>AI4K\J\6?@_UU&],F7
M^/8J#K-9=-SKYJN=:L8P?JH9KY[Z.3M?%7'=2M#1\)V..E;_HM?=@QN:SY&O
M++<7GQ)_+7\,1*^[-WY<?-?(DN7@8>DC8N)!Z8-BBKW]!/D*WQ>0-$5_Q_"E
MOEGU1EW-EDB'4;\S.OD9H[):CC$^2O\?8+PVB-XLD^T(E07<&O<.[VTWN(P7
M5[L.G)\_2>QE4(U[[#YN;K(1AF-?I3XS+S!OW<MT%Q_077I B<U[G?[99EP.
MFC25QS0Y^S68&+>).Z_A?%O)R(2J1YG5!!EV>MW-*+*0'@*E"4*#<B1@OVAD
MV$(*R>R%22(Q;.TZW5>B\KHCCZ/-PL2EXXR"<@'_(+>H&IMEM-P+M 0K$JGZ
MMZ/^H1&-D9.1<]O(B=X>PR3#Y!X1;0/BC#J##:G#,'FH,-E; Y/P4W+QD'A4
MT5UE['I_72=Q%OFOQ8]75Q\^?/SXYGLAJG<K1'M))C<6X)62.MA<4@=-"3B-
M8_^NM='I<GW-CLHUEPKKCGO=(CC=*YW*4_I4WG?LA;:SY]H'-E3UMWW/=^KC
MW!<D_J2'T5=;BQ>[U\9TXWLKXV4U#G 2!Y'N% G;Q7#"</*<<-(Y[>UB>QEA
MG@%AR)(YNOAI[S%E _[N=P;GK"[;PLQ'%Z?G3O=LM/<<S%JQT:C!6K'E0,):
M<2U_#SHG&^(',_-S:L71R!GT>CN*P7*\E>.MC8JWEMM2J+P;#:,W&W\<87UV
MA&B:<JR+L'ZBUC6'$%UEU&C,]F[J,CZRIJ*..H^\Y?+J^V;U]P>X+)0-;?C1
M0FPKI(MA[.$!W4=*!0O5O@G5H#=P!J?['V1FXZ QV\O& >,8&P<-C&NS<<!"
M51&JLY'3/SOG<N=VA-_9P&#[K24A8=Y+9M7#=#7>8?-G 7 /]_/C#'3CBCO:
M/RZMOO<0JZBA76Y;:!5Q-4VC0Y(L7RV7KZ.+P7G?&9YT6:K83F [@7&LI3C&
M=D*CHY,L7RV7KZ.+WK#KG'1K[00=GOR!?L#XX\+0Q=,GID*+AR[ZV'"8^AZ_
MIH[W.+/Y@>,8*]TW!IN-95R]EJ.+CVZ0B']19^I_2%=E"?5XYZD<#Q;$!S0I
MOOQZ)?Z(YX&G3<JS?M>Q,Q?KR6-F&#JVN[72#;_M;(NB:7\0J33)=-?^<:6M
MMTMMS>'F$WP"M297^"$V_1^[(0UL4%,I]6P!U1'Y% TSDZ/N&4#)#,?BXM#$
M<;HP0#Z1U$8\;\BM)\M^9TD.#F?0V_+/SE<SX>+OEY>?2[,M(Q'/;2]V&6(_
M[N(&=K9!8"92IM1DO+3DCEBX;VE+J56T%\:X[?GTA=)V84?O,%RU%=A@.O%#
M'(!" X/SF;UW^8B(=;3 625NDMSARNTX##.4H4(?I><;U].\^I#B]LYF;[VP
M--L5&^=7YP\#"H<Q#@_!!O":1X*(9G\@;9S2A%!OBG,WE6V/OK"CZYFX]$+P
M'=-G'5[?S,R(9_-$3F6DL*N[_NNZ[='\N&J+[K,5NND^,B(.- CC6S/:Q(IO
M_MA?B\<:Z>46\$^#KK_'44%]/06EP"D@WAP8[HXZMJ,,S TO8R?_\H5AX(Z#
M,$@#J5:*;YV\UK677Y1?DD _EIHAYSBC.ZT^O30ZIKP0"Z$SK1KJD:0$W<NB
MGE]+9V1P/+#>F%6/6Y8 FD>$MZ+Y$(FD23^%&&,G_?*&TWATV(X@L4^T)'#$
M/,1!%15*T)QT9'X#(G:!YL;ZH:KNS=9!=SX# ]\3X<.^Y=V]00POO\87Q*MC
MM0*9JA,@:C9<[YG/6/#TP[']P"=YHP%=-#5$<WV)'0)M$WUGR(.9")(;-E42
M:Y'$.2<X7T8/6:D.,5$Y]6OFX_[&\W%Y/N[#YN.>\7Q<GH_[_$3E^;A[3!*>
MC_M,\W$Y#+M?8=BZ0 %'89_)-\@]]?JPD9G2"/Z^FI(70#^@^0_>I79WZT:J
MTG1"^_G<O<,/G7P<K/D+^ \8IRP&Y%)X26$,%7%H*50\<NX5:Z(!E OQ">,%
M*[DJ@DFS%2>A'HMIHW6U(V_GL,IO9FYCX68O>[6,6GN%6F#B4BX;N9MQZ_EQ
M2TB4.ST]M0PV-/B<:*5H9#BE2Y3 H(9?S(G.25G%.C/0F2*6%!<###+HTQM9
M\'D/-+BA8:KZT;](_QJ1YA)#'A1(X:CWDW+%JOR.1YQB@\?!)$L\'&A>PQV3
M))Z9>.\49RJ7N:+$73:M-D-U,4FD7#%'%X=.(S7M-%T_YY@56K8R1]R&D[TD
M@'T+7*/0S&^%1J[,MP[LE.<7[DN]%S0R&=XUG@4>YJ%P_#C< ';7TR\%/_^5
M3UK/Y:.TUF*%>4;3"Z6;A#J%@"%G26.-0S<MYLC?_YFTU78RNB->C$LKG]Z-
M <'+2Z"T+RPS]I&BP)W3>RT\\I>?A:DLG0];04";9+ $K&3+C,&B0^;$<005
MI51?Z;LZ *IQ![8N AHKDQNX,V.F<8DO///N+@CS'/8MK;Q%/FE:N3,I8$MG
M]B;?>_];.W_<CJ;&S$G]=QFNGEZ)U:BM9;V$8$-SG=5K\1Z+#3#?HR_+;6>P
M;,'B10XTUR0T]ASNAEF:^,98V,@Z5ORLW%+]0I[O(E/7ITH(_"+PBYP12G;$
MYR3VI/0+N%2RLN8H+F:9&ZXO;'L#? !Q2NHA[V89)=L:<VGH7DSP73OB?9:8
M]-/&PZB=RHSZI?1'C0I82&Q8=8%?L:^[J!O8YM]SF_^]!*X%9G@G(_@I%9^Q
MV@(8XG/H1FSX/Q=FJCG(:PQ(@'I,$VAL"#0W!,+LNGB!(FML=J28L<I?@O0#
MKR"R2%@.(1= 7!C?22P@P"?AMXNBJT2F@4EPFN=@68-"6(V**TT<I8Q46&*@
M.W%J>PG6#^O3F!)BNT[S./MB>5J="KUTPA[U I4!S,T;4*P&7V"2$1 B?&:4
MR75+J7WBXNHW,%.?+A=D7)J" S<,[ZJH:8P@19=5'E^JF2C5O6D+S9>H8X J
M=%EU"6YA;N*E^D?<*VT;%J^/GR^63BV^3'YM;OJ6KR+3"K<W5L6'%=4$E]$+
MG;P!)9S-,JT,ZXJKL.:A2JE,X=V\-$-)"X7V1/4>Q L[8%D2WW .^F.9F^!I
MRNRF!ZHG2,W#;&6-YX9>9E7UG'8.;B=0RF5*$?N_)&7T,ZVH5;EVPYH*(LE=
M9?EMKL-<L)0LB825%TW5CKBBTI84\[A_23*:-8?H_2O9D;"#BHH0C996LKP*
M-B>?+Y9;QD%-MFO@M01E7/LE8)DI6]H3 9$UV&B7Y<7OE_]ZB?4:@!%D1B+2
MSM%OPH,<Q#[@@AEON.3JY,6!BPXL+6 F4\W6<'>]I%Q._ ).:XHD\2.ME"F>
M&X#EIM(\8&.A05'U5-4GO@51EAH5RBM!2Q!6X^@'!6KE0DI/-;)0@1IZ+-T1
MG$I\;_TGN&&QV25IT05L*&>Z-$;?DFW(/;<AOTC,QP,K_ K0"&Q0RJA^Q3"1
MF_@<1'Y2P"S<2ENLN,ZEU%DKE8T5N(9$2;*20.IO\3\*JTT!%2/8Y5+]/6!A
M!#][QK$--.VQF!R>^O'RZSL3L/S@ F+DN:GJ5924<N=S8#J=/INZ>+)!4AWF
M;1"&A"<^.+#%K8TBZ(A_N)&K8P%%M>T8[%U8KBX']<U! BSLC^Z*-:Q^"7S\
MU/7SIVMO6F FC*P@+'7U4@N>J].+A<//)L+3<#QHQLOL&J[33 =LW75R3K3,
M>?GUG\6?5\1%NR<&JIPB&3).:\I)*$Q%4<NK(M2"@O2)[.M/)NCRXFLV3C'%
M*X:GJYX)B]'/?$DW6)%]J5G#E8GVDIWP 5@Z+;CQTRU\])\,7:5\#7FB9\5"
MAOE"7I=1'*V@%<E!6F!E&>Z:E1C_5+PP6[L10:QSZQ@K1($TAL$D,,[4PM&@
M]0=/;#B[$KT'@*B4"IO*]?0.K3JP>6"UK\6+G@EC?^?QI>VBZ.-BOJ7\!7#$
M)A(+QP$28N\O1#KPG\#4-!@NO^$*X9?K+-"9.WBQ/&]W#[ZJ\+*)L'Z7=1U+
M+7)Z\Y231.*:C%,Y::1=/=KI4NQQ(L&93<QN4N2S[H^8.:"==O+< )@3U:#D
MTH[",Q<V#ABK;ZB3R)M &=* >SC'3?2DU@<%)&]0H:DOJJOI_L(UW5S3_;":
M[G.NZ>::[N<G*M=T[S%)N*;[F6JZV=';@J-7X;PJ?VEX)R.Q5.Q1LL/+1O(]
M?!X=[$VDM+5-JRJ9T"^P)2FY"4M&,D9*J6P'5_RM*!@B_S,I<EO@$&E+7Q<9
MP8K0D=#I!OQ\"KP/-K*Y(+>-RW[!4@0ZS^OC:^@K\EOK+/\;78<SJ#&1:QV+
M_DG1N>*#+>SY# ["5PR:%^Y!;)]=\0WRG([P@S## ,X'8.%U12#CNU+(/IBL
MH)>YNJA<FLET&OL+1XOSE<R Q=!/4/ 0$^U7,DU#'3C"Y<RS9!XKTZ[ +%KG
ME8IEWTXE>;:ELJ.9>X?1*7TS772)[DUL<@JFD</7#U? 1J'$4\W@@9B4E0+1
M@\]*9T?S0CYGLR@%QN+E9&+.HA('!PK>HIRD'4L0F8@JQ5$X%Z* O9&CS[T6
M&;4 -7$PLP=:R56D1$1,U>4+]^^(#[I@SL;;L(L"G7J'W:..'R**L3(L#*A0
MQHT>NL:NWE/LTJ&3F);*S[5I ^<QNV995$VI@HWVKRJ-13:Y6(X]_DXWU.EA
M#'#:S==^=H3!T)H;!H:+]4H7CRY7,\ V[HHWV&Q[81G_ZT89*&:S6YK#3,ZW
M%)9-,:RB3(Y@H89INU%73CGM5<KI:YZL$!]N^)#"<]8J8<[$'E3P"9O3!!;D
M>K9B)HFS:YU.IHK+E<>.*-ED(O6Z)BBGL>X.4NH!8I/.KB[;_"JE*!R%7K=&
M_MG/>[2?MPNG;BB6DBHLRD\CRB=5=^J$"/LI$O]P$V]J7&Y4W+UNM6A.GX&D
M(OLP=DWM\+_@42B8_U\ 7HTI6BG.)?:Z7:?;[8JK7SZ:K# E5.CR,9E;8"&2
M50+.EX/F618IZ>DF2&#0&%O;0QLF#)=RP7AX 0O1$""P^ PAH7@ FAC9F Z?
ME ]Q+-H1VJ*$YY:_BXD&;;;0K6Y=VZ4IPR(:%8>4I\#L!WHNV!S.+PTIMR<S
M\G)#%YPXLU:\MK1@1Y_<",!:MF4W.!0(GU;96FR*%U'\DAS..+D&K^&_KFV8
MAS<)HDS7Y8&)"^8=%D"2&?F]OC=D9IK2R3A+<R_XUJT<"847_JG7/2-ZXK4_
M]< 8AE^<4E.<\([SWL\EOO^;109;^P/M-3G%@4(2,93<Q4,-]@2S3@NZ"Z&/
M(,URYX*\6QV@L+Z(O3WEB7_Y*$8C+>[Z7E$NV52AB1=U.Z/NSU1_!YY*-M,'
MT-#@SY) UWM^E>![E+BU2Z\RU+*H%VR+EW6&D-9C'Z@]C-I,I 4GTW!L0LW'
M=+2D.+]1?2]S.JVXU3P)O/O=**".4RZL_>>B3I5RDA2)T#?*\YSY=?J)YJ7P
M'J&*M;,;:@ SY-/%C;@;*_JVN4*YH5RD$_K0:66[\_O 2U$ RW,Q(H+["5"
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MY]_>@ #/0_?N-1 &_:;C<1A338GMS%/_7^-5?;!=##7\O%[U];+$VI8 \**
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MR.67KQN$5PS>*^;=$6& KZ9V_+)^'P]8YEH6Z[1D+,8$TBWRY4^2>&;N@*.
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MG1C%^ I)!GNN 1SVQK-/2TOB"_ND]":5YMW6J>Y)/I"N4.+PT)S$^-190:@
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MTEH$:7X.A >6EOB[^Q1);F;F[4T''9TZ_3Z?.]@V1.\^O<U"L#4AL,;)GLL
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MLCAP&2-;D&W<<[8@&5S8@GR&WMO,U3NP($<G?6=XTF-F9@ORX,6!6S!PZ/U
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M)^<_P:) PIL+6* )=8$VD/!=%$= PF%=VTAXS_;:GMUU!C QK7T:2+C>MO1
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MO-5NVX,.=J#5LNL!=@)? !;:: F A0)YFJ?W8*&FZ3B2/&"AL!/X K#0.DH
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MX[=9 F6 \R9+ #@/G&^@WC\^)PR8 =";+ $ /8"^>7K_^+Y H,RQ469O91J
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M((^RY=O%'^\\J?L4MNX9"XSZ<8FVZ]F=G@?D _*9)0']XB6@H>%H>'>&U _
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M=C;7<X,AU]C'-]7.FEKO@5'MS*A:[:[M>*CRZ.V]$'=J:C[P2:#630<G='T
MS^IK<$TM[<"Z]M!3Y=KM7L\>.&U8F-8N#5U5>IO2 [NJGES[<1UL]5E>VUF_
MMK-VI5W7C!I!]A^RN$N-W[+<"+>.+X%#[O@WUH.XQZ^8KCBT^9JS:6+TLQO]
MW\58*,#-8>%F3W07Z 1TTLU<P(^.+0'P(R!0@_5_%\.3 #?@1T"G)Z,3AM_K
MV ,.:WCN":_I6HOWSXUQS6A$.?KR@M:; 16@]8=HK 90[!4H0,B!*W6P!7 2
M[:$&V 'LT%&YD4?4#"C 26J%*SM($C:Y5W OB4/@%7BCCNY@_QWHV%IM>(LZ
M*"SF%<"H]F!4?<_U8%5Z>R_,*]#6?."30*V;#4Y@ 8"QVME94\<4P*A K1OE
MO4"MM34?M!_K647 ".J]CJ#.)U#3_]WM2(8S0:397%\-4EQCK]Y4.T,1!T:%
M2+,!W@N1IK;F Y\$:MUL< (+ (S5SLY0Q(%1@5HWP'N!6FMK/CLOXF"6=/7:
MSOJUG;4K[;KXTP@._Y#%?<#H+$11QY8 -C#7?Z,A]'^K_F/NBGEPLR=J"W0"
M.NEF+N!'QY8 ^!$0J,'ZCQDPYL$-^%&MT G-W#HV<\,:GM/&_3:(_&@48)8T
M^DO,J-"!UIOG.)NJW,AI:@84(.3 E3K8 CB)]E #[ !VZ*C<R"-J!A3@)+7"
M%<R2-B5Q**= F-M!ZQW?3D[./XJY?SNC/UGQA/ IHS6A7[!BP^>"K^OJAO??
MY8_M-#7>#]!4.\/X!Q@5]J@UP'MACYJVY@.?!&K=;' Z%@L@2_9'7T1V"CP#
MGFF4GJ\'QX9U[=ZZ7G0<VW$<F)?6_FRW9!MVM&L[6L^'GYS_A.9PHVH\F/2]
MNTG?DPW]XG PB$>;Z[^1E3;<P2,,1:D'1H523R.]%TH]VIH/?!*H=;/!"<EH
MX%E]#0ZE'E@72CU-\F<H]>AM1_LN]6 >>/7:SOJUG;4K[;I$U BF_Y#%?<#X
M,\1:QY8 -J'7?[,H]'^K_F-VCGEPLR>Z"W0".NEF+N!'QY8 ^!$0J,'ZCSD^
MYL$-^%&MT DMWSJV?,,:GC4/_'\M,9F(46;%D37RTVECW#(Z4(Z^O(>D])_E
M_>5'C44,W>IGC:/R>^FDA@8?4X,]S[6]-CHI#(E]8 2 <5 _\Y?W2-0//50
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M=/<YU'.R :E\^/(TNI73/?GHO$6R^5W5B4(K28JT.(UVG&<K9 )$+2POL^Q
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MF]"E>>WXVL4"5\'B8M\M H.#%)A:JQGX_7<(Y'T7N<:^S,907E+>32_CK-_
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MD48U2),TP@: T$ZD:67#Z04.:$X, X#?PE4!6CB+X!$%::EW@ <M:D%<^%J
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MB\VVQ9'#(&))@1F3,,,T;WIPW*PWB%@2L213H, ,^4\*S!!HD/\D_TFFL.7
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MDF]IDXZIN<UTS/H,8KQXRC'MB%FIWW3B>I64^>#8LKOU-NT^V31";VW["-E
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M($L@?YG81.' 1?RI/Y'=P7%&0?ARPPU6'XB%KX8,2R:"D& PO$"Z%Y3F_"N
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M9F$H5&QE9V>OMUCP 1RMB+C/KH0O>"QPY>/4Y]XHGH]5J#3,YD*HHE@X2OZ
MQUR<AB,@ 1.C#MO:WD[2 C4A&D(TQ'1L01I"-2J)AI@C;J(AAD+%1@(<C6;+
M:B(-Z5GMGJ5IR%QP0]./C'1DAW9:#<DZ6@NLHT RY/=G47UKE:EL^W',X2?Y
M :G!L?SH>K?JRUPIOUY](5U<HHL.*!_(>XDJ:FF!0B BP#_Z0X*@,=<@X_X=
MG\0?V R2PKUP1QSZGON!%?HN>0H^9^;U).JP67G,7RG%HBXLO ?3+\*F@Y+?
M6!Q1)H<41E0.Z.4U#.?AE;A)?0[W.J$?PHOT?>[\"2IX?GZ8[>4L(!RT^<?
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M&\06N'V+VT ;%DXQ/PU=@6L/GY*AYVPR'=&F  *1 #+N<A) T0,B >:(FTB
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M\+__^A4L/!L-=<3%1?_?@''RT(N+6Q%% !"'UAK#,_OG6!^'01YXUQYX2=[
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MM'Z/%O&O7#G6D<L3NK$4!<]AR$;B![\O"N39CL JZ<("+IZ&HY&7H';$)P'
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M-8^P:6,8;3/54D>49"SS;.Z&F_5P_3'=1/(M Z5*)S)88;-V3@$8QM:LGU,
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MZ_=-[(VV2FSN&.#<R\5RP*Q[6.-2]<C 6#,'_I.)]?Z8"+6[-,KD\YCBQ"F
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MO:Y<8# 7%.E(/J,V>'IMQ>8$H%.B/@%>U ;NNFWN7W=-?P=02P,$%     @
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MZI95:#PDT.E[;_C?JT(<-Q 745;-R\EJ176W*_Q8J9RPI)'C26%:;9M9?PX
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MJY6KTL4(PBV(!<.USX'I2D:]8,B%XPP@_!'0DO1/1+=Y&P&WYY$ AWRGOX"
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M$0<\Q&ON>U%0!CO 9X\(8.8!RX=DF$+T1N@5MPXE@4VFD%V"3WZ1/!61-(.
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M?&>S*HIH_EP. B2WXD<DI8/I%*O4/0Y;&#2GB3(:$F2!TIH,)NQ!\R+JL"M
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M*"7)O;-UGMDGFLRU/@:57?:<N+&_8:C4TS98*EVC@!Y?]&Z5^L]L'(\.S^1
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MQ?  +;@D$D/JZK3>.'[,",T7^Y7!K\-28"2@ZN*A%UCOPXK5K50+YGX2QZI
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MM4$??'6<.0%SMCVN"$DO2.KXQ3W,R '@)VQ*64SJ63]FFTWQ\("T+-1H&H>
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M(*Q-6$E@H$%)HM_I\<<H\K[X08"_,1Q2LFEE VP!':*37\%ZWL"*CM8-K\-
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MH17$A)-J7M+^E H8QU$\,<DI@JDG4_ WRJ8N790UV.8+^E\_7++(%+6,:>$
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MRZ%W;%Y9GECE-T X/ 4^I^'<>H;\C&7#%2\/.?A:&*#$H'?S=1]'&Q*GV_O
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ME>524S_.$PM9]&URT/5"BX^;[AX)W)*S**1-?$"@K'1T/AA" HUF!H/T,AA
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M+ 9T6M2,&@*D3G8F[% ]P/>2*K(QIC2Q896B0$$U&VP(Q;B*,GQ'C!H7(TO
M'E0S"AB&"]*3,^2_C&"_R+GXJO4BAV&X>#\A0XR9*S]QG8"QECRM2$R<13J
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M3G!+/%8;^YRPU 4-V6L..8YRAQPT=,6#<U*^+NBXGT+_A<0)-3ZOPS!Z<8J
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MJ[8\@9 <1^W!)[^*>$*3%[$URT=@C02IL;8A,;41"&MCD%"N;^ED4Q*RRIW
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M21K[;HI9!J>;AD7#"#&.K_VDW2E;K,@R1J-(?WT'_BS5&'K*S9NZ@XF[)3A
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MQ H"!51VARW:\=.R 3@^VM-N$+@5R@-95]4'/_G]*B:DNN^/75$[^3T^Q]N
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M3_S5Z^W>C%5N*]I"=5YAA=H:;Y1";<\8Q8+:N1SOK^=%+0N-Y<__VJK=Q,^
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MJC-,XS1P)T]ZQX<3B7)RZDQ#J+1.-3N'Q.$E#3:!EYQJ75T1CBHY'3S6HQ]
M"O TFLKW[W[L[>F/M6:[*$>&!D&WYT&G",MZ%\O@TU'@2+P#5\^:W'.J>X$9
MJ*<LS7U+54>9Q38A_(<?Y#(51N)-DG_MQ&V/8J26?B<%5%C6T?KAOHT;O3=0
M-:Z#5T%SI5_?*C5(0/U$?GR@,G'ZN?Q-@75*_"_;^'A5_'$.=?%_*I1K0SF
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M=^(ZV]M)3F-CF:&HDXHQ>&!9GK#X['W4J_=:5<(0 U6UC$X7H$%5QU#2LDJ
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M&R7YS;8@KQ:(]]CTG>6@?TMW#>.W3?N<< !5W1N KU$"RC;?^+U#X$FH=QW
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MS](D3V,4T1].@QSE)" 1YABVY:^J)]KG, \S1"MPDY23928VS-<M;APBF#_
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MMC:=NMHBH[Z6HY71\ )^\=_ USN(U]\,5IU5P U6G;UY]I#5R^Z(6,G ZH\
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MM=&190DT>HN9T1BQHLC0X[:@?*6W03:(%)^\5NSQZ=Q*LS84?B6?LG[/UZL
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MMJNDJ!+ME&>W7R%:/17X)(?50;""UFX')K'BX=I@"K^\J(KJ^U=!V0";5.L
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MYMQ4'_(P^C1NB;\$S^13K_F4^)/>R:7%')Q>3K7F,IT 2$Z^_29N3<$^\?$
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MG=BV ,(RQ"E95HQ('F"/)1KO!I<EK<A%WL\0JE)$Z^J&G\CS'#Z6BX:XQNQ
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M2:"K=P2_VV>6'76<J@VQUS-4HH&7/UW!NJBK;JSW=!0-(";+4MDU+07NZ3?
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MY>MXX0?X#;7% BRK#;,VK J:ZX(?<%8*$\3;IPK^>9?BRV3R.@^!D @4HQ
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M+Y^%J6J,3=$PW*L,Z>'09D#6 ]!6C%C"&V&8(5++,R/2S@FVD,V&"XALIFE
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M"[+2%D.K>WNSXX@JQ/IU M0>U@*C[;M>(3$&P>?+:+ YR#RYPK 9:8_62RN
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M9'*KI[[?;J/B.=_<)/=9LB&OVZPZ7J_S/:V!=96GR3K!Y1FNHB0MZZLDWPA
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MER@0<\C"L!0L3PBFX?_267].2-(.C!BGU6I%@#Z+.V$]RU15#R&+G42,(W(
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M6)X7.R6%Z5FA5@D#4=ORR-"=%UXY $" LSK11][#)\Q!GX1,498@[5&TAT6
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M'G;"2LD4WNG,HXU(;(V7W1-'O?Y%"^V78H>_^FP:0[O0/=VNBIP<EMOH(MO
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M'Y:&#F725-TXYR,6B";J+.YW-.^@GC&T<NY !'7DD2,M0RG=I_OM/J4](^O
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M$$'DKHN39&)?Q,7Z7[NVD_>[*L($\6O6JZ4&R_]M4X.Y<GVY_]P"FHK6VB[
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M><X!59P_YJ<CB/-N^;.H? QA$S7*?THW(V[]LDR#EWO31%H.+[X6S5IG5O'
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MQ9>BW,+A\+9NN'/VC/Y^*UE-%%_0'R<;]@;EG\_ZWCF73$_J@(^:O[1KD8<
M1-3W%M$=\RGC/1PW-D\X;ZD+'C)>BO;)E.NKUF_+BIU7$#S8T>=V3*^5!*S"
MAO!2TC0()^)1:G/!Y48QC$W91&FE?Z34SQ02S>!Z$:D_.S8RJ7B#%Y.RX]!
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M@5U P<I*K @97/DPS"OG*PFRQ]F9P]9015?P6U[4]</?[YN"-5N%7# !RX$
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M\9:MC(Z^+[^ _[!C0B]5,2V%:8U.".]%>#=B^LDHT6SJ<@1'CDH3(X!D!B6
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ME=*@K1\PN*73,E.T%TR[^L*6061A)\P&;>RFRA(-(!:";/AQF+F&TZ'204_
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MDD::EZTX48M$G%TY)V3"&+]H]-(T826%P"H?JW)3KN"YKK!DV]YXT$O?]#*
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M3J:B@;;&P_G'RL.*'I 1*-15D?(PAZ*Q?E[<[37"=EK;S11XI1 B@2BA:/D
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M8C+OG:1"3^I]]JS"L=3[,=:3)[#)\!!NK0R>S:8Z#V^K+;["$)I;%4,8P:-
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MCI2\O&==I9[-?L-^>&#G'+3X_U!+ P04    "  ZBYI8KKG9WJJ+   MT@D
M%0   &]N8V\M,C R,S$R,S%?<')E+GAM;.R];7/C-O(O^OY\BKFY;^ZM6]G)
MS"3__+.U>T[)3Q/OVI;6]F0V>^I4BJ8@"1F*5/C@L?+I+\ 'B10!$@ ;;%+6
MB]W,>$QTX]>-1J/1Z/[;_WI9>V^>21C1P/_[-^_^\MTW;XCO!G/J+__^S:>'
M;R</Y]?7W_RO__GFS?_XV__U[;=O/A*?A$Y,YF^>MF_.@_7FP:5O'D/'CQ9!
MN'[S_\3K__?-MV]6<;SYZ]NW7[]^_8O+?B=R:4BB( E=$O$?O/GV6S9@,>1Y
M2/B ?WUS%=(WDTWXYOU_O7G_[J_???CK#]^]^?1X_N;]=^^_SS[Y'W_SJ/_E
MR8G(&\:W'_W]FQ*EEZ?0^TL0+M^^_^Z[#V^+7_PF^\V_OO ?5'[_ZX?TM]_]
M]--/;]-_W?UJ1$6_R(9]]_;?MS</[HJLG6^I'\6.[W("$?UKE/[P)G"=.$6R
ME:\WTM_@?_NV^+5O^8^^???^VP_O_O(2S;_)<'OSYF]AX)%[LGB3<O[7>+LA
M?_\FHNN-QQE*?[8*R>+OWP1,FFR0]Q_>O<^&^+_Y3WX+?SL/_"CPZ)QC?^9X
M?"H/*T+B;][PH3_=7U<F\>0EY"O[U?#9<5WJ9W)\RW_SK72@M_:9_6WFA,2/
M5R2FKN-%8+P?CFMI*M?L1VOR$+,_KQFY3NP?CI6Q;)UG2 FT# TYHX<5&WL5
M>'-F^B[_2&B\?62#O _"#]HS:!@JY=@ROUT%H#XRW&S*0C]WHM65%WSMI#F[
M01B/UCB$5'79F%#\3\.EX],_T]W(\9EMBV@4+&9L&V;4TI]JLZ\P)*"9_!@P
M%X0AYI*04[MU?&>96H5HQLRT/OAMXP$NU62]=L)ML'B@2Y\NF%S]>.*Z0>+'
MC(49TP"7$H-UJC8LGP?(-,K;X06)'6J@\:(Q '5DXC)[%5&N>OJ\53X&W5I*
M\EF&)%,R?7$+1X'3TKL@)M',V3I/_!--YBH?@V*7/$5N2#=<*KMI&RP5T2B@
MVQ<[,L7TB8\S9\-S')@A7) P)/.'.'"_,!.3_K>RL9KL&&:$(.>Z7M,XU3Y&
MBC'$K0T[(IJ8L*:Q(+7HGGA\CV5;*W-F^-G4<<ULA'0@0".6.;V/SHL!H.5O
MX41^SYR1,%TS9EOMX?=0/@U?UN2/A(U[^6QF4P\'@,.LOA.?;=,_Z2_ZAJ'Z
M=E(>N;VQY:KD@P,N)8&[83@#^4A0REQV/PR9% P!YOT)MU!C=9"/!1RE,-HM
M#:?5D1SDS$O[@.%DZB/ ;LB5'<&01_$H@#;179%YXI%@<4_8_I"0I^U'$BQ#
M9[/BA_-)2)Q'(W=9>6"PG7)'\";PEQY])G/XN;0.#7HPV)&]<FCXB\,89'^D
M["CO4L>[]J,X3%+'\I8X4<+67^ []\1-PI#M.&FHHNMTN]&UH:43YHP^,X.R
M",)X1816]H8Z3]0KC$Z'V>O3 MS796SL3A#Q9R=D[KFMZ;;1@5^V_&8MR8)J
MP>*">@D[A:2!VFB:Q/S>B5_0=9VD!A$[2_G:YVYX$!;.8(>YU(:RL>#8YKYQ
MZ/SR94/\B/ S[)1I1WC.5CLC/HDB$G>>B#H-&S.\]IG8E]RE@9F->#PKQM#W
M$[;YK-F"S6/4.82=34'SP/!K_V,0S+]2S^O*>'4<N)-!R4BZ84)VJMK=Y@J&
M@X=WLF0;UI(QPZ]CZ)QG,S"99BD,J>>>V?Q,7],C%OM9Y[F9$[4A.-BY29BV
MZ?DQK&9A$!-V9IG3E_2,-=WL#\(P;EX;$3N;XF44TS6/.NXXB0XQ9IM"X8$
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MZT8"&%3LY=3]Q(+D&KJ??##J?E+C(G-T>! G\-E?(YMN@Y#6,*K;MSL.8J
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M-$*']!$X"WI00Y:F@'0@+)5(:R$VZJ.?*J!@]2I 3<%A3>Y^K$"-ZO$:@#K
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M81>,6R](XSZ7+QOB1W9BWBH41[68E2 LY-PY<@;\0,'N@M8@/*9-70?/0O
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M<&UP=Y\'XIQFU,"1.<99_?.,)6#OJS8\YMNNKAYII35C#3? >O&8I[C=R\=
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M&6B@PM%VU\);73FU1AV^FV: %%;463G,>?<XN;BZWM=H !5N??1AK=!.4A9
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M9#'=Y&T,(B8'ABMC9<7/H\_D)HBZ%^H0DYV6R$X$9 VK=70D9E3FD]&<\]N
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MT.;.A<ARGS*,CSS#&$GWD3*31YLG^@N)^#S]^:XP2,!_-/2,966V3W8?6 W
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M":8&[$J-8JW:B;V8W] 8GN&*:8B=ZYT2S$CH<D26T-=YZG0Q@S\V FQE)=)
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MN@DB:",L(3)V,<JP WN/8+2S[IB9+FX"?WE#G\D\Z]/P&)R1"QIMV"%B/EU
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M\Z61TD #7ZIJ8&#WJSMX&^.XO3PTVI,94+*#QA(LXP15<-A$>H4IR-/>.9/
M@A-1&(O,A.A ]47OOM@^^<XZ"&/Z)YD7UL'JJA/1PXY%&Z] (7A@%8 -C6GY
MA 4LRLK00\JH:919%1"X^KI:TJGR>Y&0^HE"VJ=.].7 _0[)=,%*Z&JB?^Y$
MJ_Q\^1@\KL@#\3S%6S3)IX/7?MF4H0KCFKU0+*<B/*S8/*/K*$HL%..0$AKX
MPE&!JD/9VL.SE8D4/SK4CVZ"*"+1U+]\X15V$QJM^)2F"PO>7SN]$3D0"N"!
M5<,U]0[/ Y_I"7_>.@WIDOJ.QW^:'37>6? .F^F-2+@*X*%6VKT@(7U.2Q/L
M7L >7C> B[>=XIA"8 KXF93E%=S.='(NE1LXB+\<^!XIF2Y8F5V('+GT/GZZ
M*/VDN,BSG#?70'CP/JL)F) %>3M55K%X[A:2&(_9%"/4H02OX(8 IUK"0_*T
MJ_VP>R]5+IN@HU#BP6CD>@'?8L0%%"1V774LW<2>I@FK%TQH'\5@/38-6E-/
M8_9NJF42>E]^FDK"EZ&"S! *)^Q>*3#NZ)PZX9;W\+'X%DI*!\F0*B^ERIL.
M.5HP,C02X9X5_@IWNG@,'3]B6FCKK8 "0=3KH5:=KHA4 ;W: RK#VL;K=>#;
M>S=5'Q_YM92.& 3@8+^1^NSP\E0:130T9%4=&SO&HB6I U@L))H,=1=0='%Z
M+UJ1">V33Q4K+9=_'R/6H.4JIL"7)PB5GVBTU=J[,SF\)1G88F@\88KO1[ B
M B4;ED8N9B1,&;3G!57)H/@^YK*3H@55!,/TN?DS9<?]Y;Y89'SET/ 7QTO(
M9#Y/PU#@AQ0UHEC;M;F,%<&$2D2$%[B-?$05B@-T2SI(&CA;$;PW[^.*AO.T
M.\(]<0/F'VZMI8F;<C$VA3!&&RI'$BDTG-T#QY2Y\/=DSO#BSGPUJ\/QL_^N
M H]--;K\(^'/)S),.2SOM$/(NU58&Y;'WBV5X&TAIA]7@H!./1@-1\TD,0V
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M["X6B_T<A=="GBT\PZ"J&&J?CSC]>4,0VL;42D1I-G6)EN*[, MQ1$:+U#$
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M6)TH@1@UZ0Z_,U-K*N_C/C07&QEVQU@AL7YRE*WW55AOW_,H:9Q;=_] [$&
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M:G!G[+L'4-/1MRX:1<6&B(*""%$!D2Y=:1'I3:0W :6#%!5"D 2BJ"!=0+J
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M[P-'Z==%S^0S@"K.&^J!%+TWC@.?""2V_IA#N?MZ?Y@/G2'4#L[=J);SU]%
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MEI$QM J[(#(3F7L2^D5\PC[QOD#,BT^6,0LQ.N=R?1_/^7HN&DTS<C?'UKO
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MYOB]$Y?=0-:RTVF*04F_# E[JYW>E;.".*/1N3.H(]@$V6;Y=GAH#.RX(54
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M>#2^K$2  &NJ@?-J-2O.G@@0(D2=+%?5QY=+:+M"(]Y@2W^K]B!*)R53 ZU
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M4GD[^H+8<:F?FK9/Q/<"EUB<5(<FI<UEP?5686;YZ'=,L5;C)3\4'@11O4_
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M,;<'F#\F?4RHO(@-JQ?SR)2DXI%$@+_0<6IO"YR+96L]4\5O]KQXO]75#:6
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M]%%,!DO\-HX^\W\<8[:D_<>8X6,^'RHA!M%N3BS-1;M:9A^$8ZN$"PW?Q[B
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MNK3,AQBY]"!HDHG$RS=@W1@]M!2R!#W0AP5JDUL)TV"!"M5EYFOM2)&]N)G
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M<8]767&FM_"<'3-C@=[?FU=3X;(6B,Z&B9J.=#S5NEWP"4@IGF%F#80:QS3
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MQO&P960V@T#JJ6?$(M,XVF$IUQ)"7V5B4B2^QWR?3O2KEUH,3ZW]RN2U#2'
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M@V7 K64"(S+5BS#JIL%!B(WTHH.UE9G.B0M<]3-34-KBG6/4.M<2Z&2?+H"
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M46]LM8^.121K&;D' \BFUT8%EZP3WCJ2GUWJ[K9L"=7SX^$MB[@+\5E=U23
MK-3^"=6QAP/_9S$[B &LP8H'=&#AO>&H8X&HZ>W[YRC<C&1?/)U4R0)5O=G[
M/? 5"R1ZJHN92$7OHB2TE>AZR(D+&TB&)H+$7 +;D;YR,XHKD3WGH:OCRT>I
M@2Q0HBTWO<B#!;*T+E*@<OJH[OQ#9OO_8$!;:<G]();:[L[0F4!3JW8AN[5,
M"SD,,P!89MQ_@[U9H(6'T\BE.!B-=*.6\A6PX;EE$J, O3_NQNV406>!.D>
MM7 /O_O6O1\YCJ2;RR)7)9A#E]6A&7./<OXQY?+_ZPVL)D#DD5/3(0#+SJE.
MLT#[U1./*';I+-#*S 9T:PA\8-VT=IXNPLQ0);% UX'  2Y?73L@0*VN_1/<
MZG#@D-S^YP\<DML_=."0W/[7&!"K[27_V)GIF!%Z66^?'^'F"B^I4XL)>:#O
M92D] $_5*W))E4SJD8WZ[0SO_\'>>T8UV47KHO%#Q8Z*B((0E29%4*K2\B'2
MP4@)" A1Z2 @TJ1&005ID=Z$*)T@A!Z*$!$A]-XA]!X($$H2$I(3]CD_]KEC
MCW'WON/N?;Y]KS^9)#/K76O.9S[/>E?YVZ7Y9T  \WM%3.)_+)H6!UJB[T'I
ML4-;AV*".?;?#:=1VR%T"U@'3"9E#,2N_'#&N_O9^H31Z 36S(6G.@E?^"M.
MNO.,NXGA[/;.E952(VFB47_6X"60^QDV?@>I3/E@0MU@"O7?.G<:Z2G700\F
M=,> ! .%=NFS'=:U!;,2^S(,P*-[7)UEYN'96%AVAT?R4\ZQ>:%/PI(@3S7V
MVH/RTC>:O>(AUP\]#/YKOV&H9D0R[C1Q'$24<O:(FNFP(\(X_#9\:0X$2)LS
MLK,F3@&#LG7T+SPF.J3&.=4 OKGO^)4-?/TZEL_=U9,0:?)OQ?[;J9BIFS68
M69.'>] 6^FJ;]:LTR$ JC-I;+TG^HD@-RDCY8/<Q;3$J+-XR)RNSZWV69I?Q
M/B2TA)DM8:!E,?@\4Y6!2*4,P$XZFID19H=CY(1AQ21[_P(NWJ_TOKQ$]IXR
M=Z\TL:T[X]?O'.&B86_WB@'X/6:='2OPKK-WKG1@IP(,?EQLE**JHZ!V_:/#
M*9FZX9I3RLZP>X@@Z!$_H/U.HK>7^'*W]Q"E2=G/V0.LZSED585^6BYR-:$H
MD_M]=MY3?W?^US].FRI>-,)>ZNOG+VF0RJTA:4'#IKJ6*(&T"D*+LK2S$@.
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MG-R-\(]F ,#<W@Q N@8# !_9]:1O(;Y_^2>$U?]_#.'#[7"J # 60499]#(
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MBD9GQ>2^LKN9>&?'H_?QXX&#1K&26B.AB3Z*TG#-)S0H&;1]EFQ#%)V#JC(
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M$+@KCZV<D*H\%A+5VJNUG)[RIN]A3?%9[DPTD\)K,)_EH1TEC#:23;>$<9)
M;30&P)#0A</3:R;\)%/+MLQYZX1+D[Y<QK<TA"% QQ3CMF_[WT.FU&CDA[0>
M3[%-@-TY'W\X2X6RV#O>N9[VKE1!IPA]3LK[Y3GLF+EWP,O(P0](LS'%!"'/
M/E4+>%%V\DFMZ\BL=.$+[Z[_SRH'_X\GD@14'+06%_@(-EOGK4'?]I%@#J0C
MD[N=)- ? ]M!"T#B.W+XY-3U>AY/H*/7'I,D@Q&3Z]3J9;Q-$8J^MA>XV]CC
M,\8UD@ERBL#V&F9G M&G6-Q?!PS7C''.P7]UAS( YV^5&0$Y ^4\L ^:JBT%
M)SQYH,,CN%S#S]0 91G4]^QW(GB^<,U;L8]6/RX ^&.9,7F#&0K[]X#T2X?W
MEI]KD8R%Z.C0,,LS 0^/\'@UY?D< 3[0,52SVKTLNW]X98?5BE)3&'F.^5D[
MRG E-?<V^&T>A;2E.J>\04Y.GBC[$B"K)2_!KH$F"?;_&A@T$XG(''YLLF#]
M+3O1-$PV[XUITN'5Y=FP7Y&DG(')<3#%QU]F;"#.KW]^RH\!N(N(J"U >ED*
MW&Q;=+LR65E4D*KP0TW:2<#SG!RWAL%.!4=+";_1H">8OUV/ \)DT)[C"@4G
M>S&;N>(SS7L_I*E/_%OH%CQV4>31'V6%/,=X7?D&?':Y@QUG\2+^+S)E7WP@
M7GQLJ!ASRM$>*:1&[%]EYM1@O:K__JHK'"H8*$#30C40ZAL)F$3S@E<SE45]
M^.[BUL%G=Q4,8C<D%="O#0>&^MI5*QUNFD)6]6T2M/0S<X->QR0Q&Y(E$9KV
M->T&;08V P[H%<1U$LC[(<A [KWWJ3K.C]MC6VTXGWE:NHJYC>S;7]1"BA:H
M"7T\D1F9KF4!X4AZRQQ"_/3Q9LHZ;519@,D'T@*HM$D_UZ^R;+Y:/\K(Z1_)
MM]%[&D]F*P6!+M:B;C$O1-#IT--?)B075F(^+'Y/R+!)"#.Q[R@-'0(SQX@#
M0]9;=S4<IM4R !_.Z?2FH>NH2_G/ID#<;K7 :BIW ,3+R\F]=U:8&OAYT<F;
MPY6B_G)8[TRIFMED2JCN:RQ5-YT9K24(LC;DVB5,*]LL;3/?5%*A?=["1E_,
MC"CTC*#]ZF]0UINO$4_<7H$'#L-"$O8KT.(FL^5+G?Q1)5C@=@DEC*BY=@%B
M>&L^!@PXTGIXRY:1$ZVI,GV?[@B5]6ND9-,DR8/#N.&M1(JNL>=0#\XI/EA(
M1Z[U6J(&P=Y;<*.A1UDY>[9MQBM']H; -<2O)>K(D(!^0A@RZF,B$T#FE(7\
MOZUT)S-9T3YJOON!BYE>[R .52E<1C[5YL/>KG-3RG#X!3Y#W;6B=5;T6U[F
M]UPG18X[K>P $V935$CML(BT)J+4 9 !R'!-!5U7YCF\P;X.QLS''DMV.UO8
M#^@D< ;C1#.DCJ+=Z: 9H)7AWI33]""I@A<FGN3/?&AV,/DE*@E&J@4RN<'^
M40\2 ^!T> HSS]0GS#6JU5P]T,?*SWR1\XU__?>)43$]+Z 2CAR)"D'^:H*'
MV2]D?=,K>-]@H*1DV%)Z/R5^<>BMC[;#0R:P,I\)M$%U-]EFIN3OTY\9 %R"
MPB'@C5.8K)T?MJ!RJ'.6IN5<O#@; N&3/)$CL+/U8EZR9-S]"3T;CU'=R?71
M>V+IX!NFW,8'/_J&30; TLCG6[4*?Z4\.APLRRD5F@UY8PMJIS4\Q2VO6N K
M8=/]A"+263V8R@<LS4<Z6M>M.@X%G="ST3JCD6 ;HR=K8?8W"U/]UI!Y:,.R
MPVW0ST#9P#.TNO$TBQZH<+V,=_WJZ#W+N$[;  4,RHQ+Z*<+DK^]5C4NEK],
M<??23HQN<>_ G..IT-7>5*:7#&987O<W)I_M"3CY@<*Z%6ZW:X=%+!9P^GE4
MD],@6ZVWY.?\")'8*F]9/F!T;N+I][[&':A-Q[#12+U'RB\JA,&G=8^98^5J
M2 ^&MX?" VG[:QL+:%K,JUJT1!DZL>U+DUQ+=Q(UV+%'?REGO!:84U(AE5B4
M$:4>=LJ_:":WI>),7^M9/NLMH\]9L11%(9Q?IMPXM-5P$?C&\S)YN;Z+[@D3
MD0N!>/%VM[ZT&"XI10#WF].#RCACW_[<<1&^L[.M<AZNJ1[T)"L462[!C3R\
M[BZ7SJY#E/,AP#_Z;4_#?:VO,P"V3I1G>WMKY+31)PGI-X0;G,?VE_?B7YX/
MS7<$?5#3T;((R4AWO)62(R:7'!'S(XH) 2/#_Q8A_:\ZG-,,Z\VZ_91B5>KG
M5.YE>[$,I<[MX"6^-W[EG4G9L8<9B2RQ^=FY1"V23A'XDE9^>7AJZFEJ9[K%
M'OLSG"S5/%FMN;IP)G[E#HM1=$'*V>-!N3S/IJ0"9GR"'2:*UE]<KKE1G<X_
M>/IR[[7O0;F_.:3_RDECA6YN0N^"%KP+83O'@0<F:TMT5A>+G6H&X$LC_>UR
M+/VDI=5..?,OIC0R]R71%#D[P!0+//3@2 @# *&2:.<F:E?<&8#[(0='AC'3
M\8L@'3#EY]0N&@5K;/#_S91(DQ7,9+X"VX5B8#_7V^L30=M)L!X>OS^._SC^
MX_B/XS^._SC^1SM^L.>Z#:*HC9NS>NY6KA>,@"O1"3<S3Z8\]>JY9)@DXOQ=
M36("$TF^+ \NLX@=P<$3";-U:$Y>?G%^/8.@FI!3D7_5<;BFTS<F&NQDXG]6
M;BY%9@;<*786NV7OKZI*\>CM8P ZX/.Y#W9SQE8#@B$E<V/FAF3L9ES[.G@6
MPD(F/"@0 ,6X5NG!%F1B'7;"Q>,7A_=RD^N21JM+]_5^;6"W;'I1#[^9E$I'
M/':07E=YNK4B)$J=JR-^>&_N^16]F3&<^52W<S]&,2=+4W1B,6GFT0<@^8U$
M$H)8.X399V&C%^RI,@ L:/']IPQ UW,&X&\/)B<),DDZN U:8H$-31XNIC^V
MS4XW\652F;^9'Q@,//C?O^"Y01;P@??UTU_)'3CCI_YW0K$QM:GP>B.[F[8(
MW&&U_./YC^<_GO]X_N/YC^<_GO]X_N/YC^<_GO]X_D=[#L]IIV FS4_7D39:
M?AQ3'[#$KOFKN;"_UC%%?]"[$%3O[_DPZ!14DHQH#<\N(7*?M:(^/8.6>"E;
M-^P0;)O8M.]G=U$C1UOY*__3RMBGVI.6Z6E_[4UYR5D4>%=-SIX/T.NPO2^C
MKNNK%3KC&<2VC$K>WEUN8@#^KQJUV/5?"]J>_O_NNOJ/X_]\QS+0BYC4Q<6.
M/7YSC84K8SO<X-=UMR]S!SK3=)Y;_8:4<1C&P3LEZ^4S#0H>U>B) HC'WV6]
M 7QA $@^'X<Z)EX&BNKPF$Y'!R<;TB][H-X0G^*O7'K&PG;P@XKM]/.]C9XY
MI7;[LD)H7 :S19L_36NYR4W2URJ,8FI9&A1E[C0:ZDE#+NU>T%!D;[@>SR-P
M)+IW(-[&YGK0R:/<\#=Q;8\_JQSE.O]*A<=FO_C5"1G6ZU%'/1-QOE,/O9<V
MNB<CZ!9*[!:3!S.6 K\;T\=KW3DKML:#V4):AP=<1."G#C)LB%?(V9I\6HNQ
MJF5'(T/-C]N0S.[A==HP9*/<;0U*8KW('H)((>N%9S14:F>>/FXH5"8GYSW4
M*/[ +#_/.C^@6I5#1C3"XT8ZWZ6F+])AZU=*2.:L!<MTS8-1VG0MJH2:4D!)
MG%ZM#.QI7#];"!TDMSWZVN7Y7FIH0:3@8K60_][E3\B(2[U]'$]$M!YT]/WU
MO7*3QPGB^\/U<'?-^"Q"<T\CP*O2,I:SK*;?8<';UN!^Z<X5'Z3AE?.G?$TE
M(49&.1D^V4%7&@=N26J&!^A^I1;N9K$%PGX5T6UH[PC._7T,0#MH5M<GY:GR
MW/??O2Z=#1];2.<>%(5IY=_=\5R)&BO1.\8%_ARC;D)%5DT*14D+JL("\1:F
M&\2:*5#W<$6@^KH_$_EH/Q1T,A9::^;WZCESRL;/@4]D=2A\$NA:U^2X9-(W
M.\BV=>P@V<; 'WZ!1.#QK:D9FYNJF5);6K!KB>!L$O\P94&J?G5?J?O#2*Y3
MH2T[&^0LQ\.IR8@NT%E@E%G03>BUZJ/1%0$0S6O1&X?WP(YCNG,K298L9VON
M0-M<%].\6-VL5EY7Z4;<4_RR9=1OG!=S]5L"#TI,,BNTK:VW;57EV),@-HP)
MRF,/E@[R.7X!38132DL1)!WGCI\P_#ZLQGO?G8[&&-?9SWV?VB3AJ R ;S"E
MM;O_8#\91?]=1RW<R1L#=057R?%X/4 HT<J5-3TMY3C#7Q9Z+:_7?,G!-JGG
M9*0GW+.L=$;P.^@K#MX-C7X[W,(*>=<KC7]F4O""/(/#SF/4=S$^SBE7*RL5
M2KSJI=PTT.Z?L_T'P-"+/\J;,TY"1"Y>/7U3;RZB[:N"Z@4KKK$T@XIEX_YZ
M^IP&@F5O#Y.XSH^AQ2[M,P E#,#S#2.\YXK#!L[U/V]%F,;48CL#X.8"$T+0
M_J[C9@#JAMT.%X;M,@ SJ@$<0[@EVE=EIZ81<Z_@NR:#=6JIA(!W"2EI9BB.
M=/R#9'GY&N'U^5R'H9/"(M)WB'U&8)95K2M 3T*%VA2B(W-QJ1E(UDDD5A L
M@S;JL$,67QD  >]A;%C=PL??+THY.+A!J*6UL:?B7$]*I3G*ZZ]Y\IX^#;[T
MZ5'LF[P,-CX%72(5Y5F>N,V?37? Q?8B.-R@Q^CJ'G*_U^%56WY2=XFU"QJN
MMBN&H-"O+4V?RISWSZ3+9U[0M[=N@PQ^<A(6RH\6SG=8=8 LI1XN5^#<,J&$
MT^K):-I</2_M]E>Z6P"4-AUXUS_9U*N9-F$.>SDM%("):SL3\[-D_E6U(@,P
M;J+?K:,A+7&.4)";GY62(__EI8&&E@2S_^ AVX:43MHO914&0#8]EJXSU1Y;
ML\D 7%[%R\_R#E XB)((5K5:2?+^RRBI&PDQGX3Q-[TRL[$S+[#@4[WM8 L+
M:'3V)^1R_LT8TX#A&CZ@G+(>3!ZQ4$?["8L'-3X:I3  .E-U>C@&X+HL#X^=
M^WK7MT9/+W??9Z2/M+&1+T-C.++7_2IA!"O8D-_#,VE_>3$]\5:[-$I&VAE8
M0U(]ODU!T$:I&/JEN]MPBAT-2H&&KA85N.1_#7&R(^W]_+TQIER<H0!%N8\J
MC:*+%T^)I#54I1<5E0$U="SB'#6C'!VK+PE<\U4:KGGJ?X-B1>M4O@13[N D
M)E!*MO]R_8(S)Y[.(X&?>R)>+,@>EW@Q;+6$7<<UU.83)71T2P=?5, \M\FC
M)06)+7T??$7"O#\9-:?C<?=H891V&C/>4B2V;3? "Y&T,KKZ.OCCP<G-[;/Q
MX?/@5L?;N1J8[?CJ[_S1LZ4['LVNXB&9W<81%N+R,?[.#_3@K<.0^53LL4O*
M>-RM0&':/-T&UHZ@5.QJ$+_2K7$SH93,009 I#+"+W7.KG55*1A<XGZI0JHI
M)BP%?KU\!7RTMUZ5U4+'5$-&_5%IBO;W &O/YI3,]0,JRD-3V0HF#8U.P] F
M RUIX@3PXF@L72\ V)-\BN=3[YWG-7^=W4M%5FPQ 'Z\=J]<GIOHONH=;E+B
MU98K[#3H&;":S\;V-VI9B.U*^J$\89@V;B5:(_\RG0%H]2^A(+9 2VC#QNCN
M>>7;M&_D[5H']ZNKM(!;16R\"QF_9AR\%J['I-T=].A52RPLS$@Q0\KG._)I
M^[ ?XB!=']0YM;1'I&LR )V<BPR P\9:;NO49]!5M/*;7?.-IY?O"^?=VJ+:
ML1KO<A@]22HN,9I[A8):Q!=8.$F7[Q#52[G5@W%^&4Y;X$7.+GBBQ=UB!;],
MV(PN#AI)P565)MU"<_Y"Q2EIH>M!ZUF%K9"YQ?R&7FNB48Q5Z8:*'BGF8(C/
M8: QNJJY_R"U2;2=4#?<PY8CN(Z,RL;[U"Z>J\LE)([ZO=F+\90UQLA5GO,P
M5)<T>.;X.NX)+2(I'_D0_DCDUEP\GXW&D$G+)![G),0 G-I9LR"Q$G=7@!$X
MF"$\I\7_%^7= $XO[:IPQP4]>$.315KVNU%S(ZV#Q6_C[HKU5R%\'QKT7-[[
MH3R@H)EG/*X5^^Z4N_Z*JTJQD=\:7TX64CYM48OVTH4X57G%4Q*Y2VL*RMS*
MI3<-'QPUVFS2T[N89?]7QMN"G[Q,]!O3F6ON&JO[L)GZK5*<,CX2.5[F#6L^
MES>>FOG2;IFOM=>DQV:O4OD44AOI \E,.3GK96)L<.)PU>@ '_TB&NU][G09
M*!W4$) VDMINO2MGZFTIRC/HXUP'.;4HN_@H\S9FKV"I9!!R9T!#7&V+ZN22
M?+F4*\4!"ORK];3ZKC"HAJ0V!8,I=B\FTU".="\&X#8X4:]>^;'_8BN!IT)U
M4PJSO,<A<,9'_E&_XU,] 4]!T:LJ%]J:!U \@5PIZ3'5F*B(**[2_)0T/A*A
M;HA9V7D#>?V3)J;:0DKI( 9 \A%Q G8S4,4_?-FRL]G;UO!>$LU&<,KE=\-@
M?P/ZSLK'K.P<?;15^IU=/'>GX6<MQ^C??R5<84+0C:G-:%AT<CJ1KN\'LW(1
MB[(2CB<W3?(D]\9Y)B.31>=?ZO;.>;L(WK.+GK?24 77< 6EWVQ<G\G4Y(L4
MG@NBXW'.Q_[C=2AVO-;QF=SDP 05Z-D#XQBCMKO:5N;,-QT,#(#<5:H<LC._
M!W?K\?_+%K)HF29)S<2!J.\L;)Z$(& X@E->:,;[X9IK))!+5FY?9D6\@KX-
M>UUI0DJ]^R.PG3J7U&)'A!)T0)_;%E8#ER3B40@2?F&+XJ]O_X$ODHELP,.\
M-Y=OG^7$!J9M3'W&W/*=0\%JTU:(J ->6&[=UL%:EPT# (=EI)R\F\1&N@J-
M13;.TG]]- D_P%JM*)*&#1<_L_+B<4+UEOZ7R8CMQA=6-?@%;YWU]+&?STK/
M)HW%5VP//9.Z(K]TTG?MLA^[H4KJKT'$-=^L3-3[%@YC/7MI*LER^1HYFI9;
M?Y1V<^UV^P3/D=[HN5J$]^,OC_RJ:]D#",K+N!C]<NF=Q; S](UV6Z*1M#-8
M2X>]44?Q;DNT>BGK"29'6K:A^&Q:S<*ZSWZ X^'Q.(E*!2?7::*03(73ZXN#
MT\P&S%X*(+"^>N%H+Y5DEM/+6WVK]'SR Y'V0@ T$(\[BCB/B8<V (,5^CV]
M8-BHR)Q&K\6]G%1@-34V<$/LD![LI]SOBY+#%BW@JG6'+!.OK< SSNJ 32Z=
M>QZ9%9FL>KCSP0L/#\%<JXFM#U3S3\'3J^"L.(R8%9Y<__?&?>]'KK*U'WS1
M0$'1HX5A+=;(S9'!C*\IFJ'8N?RC,Q4#E/0.YGB@QJ!D\# Q$>MZ;1+_V]^4
M?BQT8OP3VG)^50DSP;W$,ERQVU52( .%&KAH>GGL1%Q_RW6Y,>#=D]ZS=R,]
M#GMRTV/C)P/P"0;T ]?5IF;[NK,/C9/FBUB*O##N \X!#<G?FA;LY6,OC2A5
MZX'1L$^RN%]%$I>)*E>;9O/2&EN(Y3&:!"9$B2F+^(.7V=ZG <OI<K3G(Z#E
M]NP])>/YPC&J%+4_91+F)$YHA=@0S](T7LV7CIK2YVZ80V[G%'W60&'/:\9?
M8&83FRR42",G#RN %P);1P*<DL>NL*4>1(Y:5!#=F#G_TE7,QG9V0JF^5'"V
MU7#AYH1HW#@\6LL:>OEB&??1(Z$Y81>8F?+-=2ZQN3Z"#.\;YYO#8,6K?WG:
MZ7D.R>=>+:]4OZB=,O)5F[* 1";X(BFK>")'?+QAMQ+$PN+I+D2JE7^078NO
MC,G$HD&7E2_1;,C@D+7(ZBU8H3E2%OO2R]@/[9W0C]W0:ZQR8WWE$@ *, UK
MLI4<O1:(^_B5W]%^2WI 6COZ]Z='^9>>,Q]'FOZO$OBKWSRKRJY$FW+*F@2\
M;ITI$3%*JF-))V6;#\9 V-=^=AO+-C'W4]@PC4-61 ]TS*VN&M\1Z]F&-<W#
MJNV+*/ 2TO"T,_/(-9[&U!S8]!_ RGS1197#6_(=4YMKG-"Y_))[8<"ZE@'(
MO B]'Z@%YDQ!%CE^\G!*,>6W=2?4];P[U <;E I:'BAQ>/O"2QOO=GBD'ZA,
M3OEB"I>8.CVCQ7KO\EQ0.NNY\DP0NJ#$QS0O'N7H@,S.Y4H*?2?'Q,T>M4TJ
MY3(#(,H6E!;)YDKS('^KO).6KR)F."U')^.NTL=;G\^'"4\3I[-Q]W5KGHOP
M<B'?QV1\O"<BH-$K5A065H_'79NP:P1&/H$G^,4NR0B9BR%$Y$Q,>G;J32I>
M*]0J)7F,D5?R5ZU^6VUQ^&AM7@DURT@1MO&]!I'NU[3VR8[.2<+4D-2##P]T
M 1<J7Z"]6-F(.5@G,@"%OGUZ^43V^6:YE[/4=M]>UX F?1T$W$Y%3R\RQKE6
M/S'U91_$4%7K"H=TDJ-OHEV>CX W$NEPN"4R_?_@\0"]B?.N!W$2_K!9VW6V
M@TD3OU6@(*R5MY'^9AVV^LNS+<J'^1N3,PR TC!L-_#1.\0+RZ!_S+Z@/X;_
M)H:G).(LW:K,DW_$)73#OZ."QU1?[,E!=!WQ8C+4^4>NKH=GC,QHL=COHZ^U
MO@K1C1B :5E9:NO:R%0CH=;@B,<1AVE]E5>LE_7I![O 9<0*73%]SW"RK'U!
M-A*'=[0O?H25Q;[5$#I@[6$ OKT"Y6Z^K#VZ.=!X5D^ZU\AP0.W:)OAHD)%'
MW'$-#0-(?%S0"?[S+DHSYL(/5(Z>MU=I..KY1:3AY_6!:T'W+@R]1VQF%296
MP9*\MU7( 9M6U@.&&O#Q.K?Q^SR=*!EP&.BW[)[2]@,5B(" CF%\=EZ.*N<G
MVCO"@U%3!S//DG2T!-EN<RJ[GLVC:'(E,'I\<!SF.E>2ZB!9$#U1,9YAEM)Q
M3C"$G716R:/TO.6I$T5\4;=::T\,[7'C<=Q 9D?Y;\!FGF(DY5B?T^+(&YL(
M9[MO36M<:=F)(8&%EN.:$\9+Z!]7*#8<ZSP6)A^/5#QS4GFD%WP^YJHTDUH5
M8BDB3':>1G_* )R7+PKF&;__%.JQX5(P)H&K-O7JHN.BP3';PPNY46F/IN#
M,W<&;1PY]&0D@\(*\M<+#P95NLWE=NP"=J&M/,%:HSBY:FN<GR#Z1G2SP:+
M+Y-U8O^L]9T!H7'K? >1Q(=OPY,>H >UKE%)YBA53HQG?0$+I2.<R8I1T9AI
MW-\:])!4Z"06\MRRW(W^6FEA3"F@'I9PG-W!)3BL22]\Y59V%OUD%&H @Q-'
MO989Z.V\O@L6GL&NTM\Y%Q7VOF, /@@]]@\C)T[A;+:E\N1T[]5%5U76-XY+
M'>S*<BL:2D!Y24W:&1_+>$@J7"$<1P9);%=>/'E2 AD$X'&NK%NL"X*#&PQ
MZ($?\:+\RF(3>)!;U=O%,?N73H2-PUZ7W'WC5NVF<1K.],;CZ(,/\]#)?9(9
M%\V7XCT&[6"CY-"*UFOJL/P'^B6!8M.O1_RM%=RO5JJ:S$G6.;SU3)$ZJZ[7
M(SN+_'S$..P)GV//1Z'>U:T47G0H'<+) %BSSJG1,<M+9QD LT0<G#?%DF4-
M.+WZZP!?\)^;<&9,P@?J3-QV*@0A@ V@-,15^G%:$B6\G'[?_]EJV/Y88/HJ
MSWA-\:"I/R]I_>1BPZ#+M>.X[GZK@KFLML<#6NPJ_+V-BA>EY04CX34D?>4G
M_ECZX>QA9H:W]T]""1VLE+CI[K"'"QS]36)SIX463:3*1BD>E0E_NE->X9?K
MN+:K*9@>=,-R0-HTI4RK*%U>.@8IK,1DZM_I@8BV]@IY=PJ0 9" !B'.[8.K
M K46E95H;\<JN(L2,_<3I48H(OGXRG1*_H1?.NKJVZ]%^9F9K827/XC) O"'
MKR&-IS6[V@MP?KF@I86MI05>P_D08L+&[85-!N!'O3=,0CQNQ%SHZB2"73[8
M==%]L,=ES-" <B;*]?0G=DC[TN_6\*@X8WV-O[>M'(MW!\M[%T^U$NIZ7TZD
M:4VF?:#A8+%+;441=-VZA4V_Z5RHZQ?;@89GE8G- LUV>4,8X6O)D;@1,@\<
M#-4IO0N&5.6KB=J>D3'H[UEX;: C9J+)I,#*T$Z_67 WZ".FB[4 DY;X$QY!
MD4AZ<FJRE '0F!*H84<Y)"@UF0KR'1.?$._I[9LO@[1'-T3<S4)B7X@B'41*
M[JH9@@6N13=)U) @0K1N*F;)M8T!6&RGA5%U%D*:1, ?QJV\:5]6KW%B,?#4
MX,#(K1\WPWA[1V%-V^.5SS_]5@M#2.\^>9/OUGD^/?)6#C6I-^LBF% WV.7_
M@#Q*%'6&_2H&)<%:ZK ] 8-HNK*K:T3KN]&T]=35#H*H[0+^(W=N!E7,=BD]
M2%$@ )IX-09\AJ-/"QF3[3%Y\H$?RC,6HRQ+^]3! /RJHE^DQ?SV$/)8")1?
M!T<HH([4^&US#U:WK<='HO+Q];B,J/ ;-2^^O>3@>1I?+>8IWRCCJ]D/,7QX
MZ<>6J!_*X^@>LT?\Y^C:H"Z=>?3VY65@:$#DMLD,6U?2ZPH<IE3YOK/71&J9
MBRW)V5G\10U2UT) QE*#,#<1;>TXE_>D6;(T44@:$FLXA&7)K2%IPR(/I+91
ME";8?>5@NMW4]4!Q+^\&UQ#@B<H*=6"6[W#=W;)GWH&K[0]'<Z+<(O-SOA9E
M2]F\O@L9-M+2MC>("4H(BEQ=3,\HDO DU-"MJ9@*.TKD!#<+!0F[N0];9-EB
MD?G0,JLL1$LF<_3<KYO!+"_S)6G&F2<J@*OX.UXXY60A3_*[V;[2.09A[X[,
M:6GD&S!D/B03"-_CF<&>3EJ!QT$[N!>*^LB#4\ 3])/>T,?#NVCL1CCTII[;
MI(_VF-FJR \OQ_KPFTMWN9X_R^I6T]Z-OING2T^13VGYYIO,)/%.3&=S-#^Z
M->82 Q WW+UFW$RN@ Z#;A=0N_1&^^I4MV%Y:+#I#$E7F@IU;3#4N\WC/VY6
M8^:X_*TH.S?/;&3EF.-WB&26I1W8DU @M*!ANHMNA\-'BRHG89LIB&2EV[01
MR4O)A5%IJ5LAWZ0.M 99O$V&R(^6O+"0IO>%OP:.FI$<._2<Q=Q^Y"BNQ46-
MWF<&_"0[1<G?>0,<"FH'S7(V,TFB7Y!2(X['?,A]5LY=U2R9OUDCMMVZ]%Y:
M5?Q=+3&9DQ5W*JK61-HO19X)>JO(_[OU4 L\9^*\_]K93<Q?@4JT])$W$\KJ
MM;/ #O&2M8ZYA;S)[&<9W0VF8=G1'6;\TC$N][UH4K]%;A!//@YAXSJDR7(T
MD:5\O]A%&+&0W(.YY&M525=;*,.([SM5K%1.:7AV02N)6NC2 />1&JF+O<ZK
MNI$/K(R?%LD+(H7W9LV2^(B.*7>8LI&#MY+NA>B^OK/81)[J!VTB7&,5=$I?
MU9F^6UV/'$LK07M/ EETS"M>E?3T+Q"C;;T$AWXWG9?.<#VFOI(5F24*R+>U
M.<M,M6@8'VRA<036.C<#;"$0*1KO)WCBB>-UDM6!.QM*^?U7N(IFNUO!90[X
MI89U1379RS&.A4U5 ND84?V;^EBQLY];%<]K\9\/RV=V[_!< .P6<-&)-E\,
ME .E EM>ROGZFU)\*K>K%NF60$XILF_4]_;&D!7'$%1.4[M.LIGBT"G3S!]7
MY$OT(QQ()PLZ.NEJ)F?@A+JA'@P EB3AY^5-S%V+VJ50>Y2FMH+KZZ4\L%;G
M:"$_]IU>>=!,R?MSKA"FX/#;[%UR>_,&F;_M840WRQ-V*4]FJ\IY7'Q0>PB8
M]YF1&+1SV3 7$^=\G 'H5('J08CF\VR.WI=E3Y%YXW*D+O!*V?8F]0YJ?<S0
M*X 87DM0-LHS-K;?.1PN!^C_.0(JU5KUZH+M]+CDTITM%VTD>VS..-%Z1GM%
M.#[M[ ,#3O8?1S(_^QRU<?DNX2E+LER9^W_VD_]E>\0D:9$,0.F'#3A-%_>-
M :AMVPA0G>^F\(W NGE0!T\>5>MW@XCF$Z"EF@TZJK5':DVGQ_R?='[!'\-_
M$\/J.@.0P-9=UUF./C= QHX6I.+\Y-Q,^I_Y8F4TM)0=,:<-C3P:HQ)N)6BM
MWBGE/?_!]BN- 8B>6B^)G6)SF,9\M"!B'QJJY^C$">@+ZC<U2/^EOPCJ!?73
M?/37Y&K[1_4N-\**[+-N*IA>DFH]S7NA&!#+R0SH!]L'H+655$H\28;U9S?Y
M,>*Q=[==S]4]2\+HP8R^AHE^;/;OWW&C!ZEAS8TW\@H23GD<QW#RJUA"Q#I7
MJJ]?D\3+GI.?$G)9VC+//18Z\49^3#=*Z'[$UW8KO+UC9F&8YNO'65OR.J<5
M#42;;MZQ>?W]A(CF=2HS[Y>820R]NT$VSFVBA5C2Z"OG^B8&3472*]<C8[\4
M=2[<?8/^M/P\-<#&KBA*)"4TX1WR64ZWH>1)H5-7OL6TWHPEE+.IYTZC:0(L
M,Z NMG"<'%'!GC9-:+LQBH.]Q8TZHR/'N77NN7F:@J0AEPRT="!*$1P>%?J
M!>A>6_&YH@(">F@1U"Y$"7!F6TC<@A[9LK+:XYU?HQUG\2 <]!Y?Q;U!/E6R
MAM?BK0L3A#Y&IIS__..#4?!K .;P/4<QC E#QJS;20P VMD_B@& YH%(/\;H
M>_*]>!7XTB<&0$J!8LD C&&R& #2YU64+S[ I9<VIGS6T)]*?S)*3\Y.$7-9
MR9CTX_19_Y*QOMNM+?C3Q3C(OER,?>"[;? -2]>+JZR[%[BU8)Z$\B:Z^53G
M&LV4K@_M2)V=W+<-KRRYAQY)4XXW;R3K%EZV<VTH=[HH(M\1KZS+=<MM4H7G
MTF6#,9X'D<H'0U6[CIA6]NDX'"LMC1HR;[M%Y&U93YNJ*KG89!HL+=40D3O%
MS<US33T#&<5%N9 ]-OGWF1R)B6+S;&Q-C1O> ;Y@R-19+%NY#,"%(6YZ!:HN
M74GV"^N(?#'&=_7_1(51@76R4@0(KJE OOW<16P3(AF7N&FW@'TR6UDT]'W*
MS^2L,JG1KH3[9CU:^%-NRTRLU$=H]3=485Q"@B-2!&FP$U^U^L$CALE!@R0B
M$2WP^@)E9T_6;O"B&ZV1Y-KM,D1>T"WL41!,S2\Y4$/?D=EJ-Q3S$<Z_A1<1
M=K0)\OF&_.3@ED0Y:Z,D70'A<- [JL4L^VW*_ZYD/T)_[.^!=TT$\?J%SX%<
MYZ#"PSS#Q67CI]T;CYQ4O+MX4_2L)_?GAQ#R6'9048P.D$/W@I95[F&MPQ"G
MR;UC4V<#.3TTF@*GUY6J<=SAW[S>\]B]6W.NJ$!Z64-J_9P55-!?$3R&YM'V
MCB5)[W0>K%6XQ!1*:O]55@KW),#_]1E5JQA0\L9O\7;*RB:^))!_M_O58P\;
M.0^3=8O:43^Z<YW@8@'WH]@;8/.TICGA!-\W0V@IL.ZMB-(6*VV?W)K[-BPX
MOTRW?B6UXAK6?/G^S'WT2=X)?%36R+A5T9[R.4%B0*64?6^CJ@:WTKL$E3.W
MK#]'&MRW<S4\G'4Y&?C_P@E2+!0%(BR#SKWSD4+A(*H6NRG9#01XPZ-JW0@O
MD3I&3:M93X3M\_*%,U/*;D07Y<?<<W 0_IK@L^"IV1.+9:H^GM+#I1L@#J+Y
ML,,+!<0L:?L"^<, #EYEOX<VI>52;+:4R_)]VQ7,D^+YFIKTJD&?AK6TJT/#
M!PRT3%3 )W(B)Y':)N4:S%[HW490DF@VY",ZP^2ND<02/_9*:E#N;8T^!N":
M,NBE=M3DVNTI\8LIVBG1P>-Q!@\WP%S8KX,0H[[>[T71%0]*F QH^2PYE[9<
M?X>63.BLW4I\XVG7#OJ X$<7\4FEX2>C*(,]'%.\97X)B:X9[<;40*W5TBO?
MLWI_-C_7X]6$_#@IUOK(X&H84PC54\QIN'I.VAT*F]J6TP^T+ 5+>N2=49)&
M+9/].(#?7\=#JDHHN";SBBVR4K5.%/OP(LDBT 1H.MUDH-]Z/R?,#"T,/M.G
MP22?X%4,61_<8-%=0V4KJE=9 R7 _O(S?/;RI((Z AGHXG'6Q(!P&_LAIE3^
ME)9LD030/"V_<YX(*5/540W_<%R#S\@ZA%O/?"9^&.?W[?1<R'87N7<*)E2)
M^%VXT@.24[[NA7)L2D(N2^RYU]\?\+!@?=;X[MVJ"-2I4UF],L/XTA8E4[O-
M3)7_]=^A>D8YR4R.?J7>@@&XQ^R6$X%_/_9_MO&4 7C1@%,(SBH.6"KU,F[&
MZ\*?#1'D;_=6(_<2I$ZB[;=T]*%)$[NCOERE2:N^ZM99'QU7YL-B3BZ&X_RR
M<IN[E_BVJ'7U*L_JA;U<M?PKR&I$4?\YR>2NW%4&()5'"OBX^\?RUJ4>XP'E
MH59]F[*DI]D0&8$'Y3NJ_/'16ARZRL<=?=B8$?D1FHKHZ)\+:1#+P8[@@B,(
MXI,;C_J;%TL/(%N(.1!D7J&L6(Y'?,J$BOSB=2H8>\THND8:YFYNKJ5K?2;(
M/"N%^6RW@5= Z7),6?<9<6,/VB3>3-[=#IYF  *]XDSWHQ CH/N!]P8\K%.K
M91<4X^-U@O)UHXQ33&>R(FHU]&_?=[A]YK@#UUVA&I(JZ' 68VL3/>/:8@8*
MK\/7R-5+56];L$=N'*255U;^+)J,5PCA29V U$*![\?+JV9D IT\AQ?<!M.O
M6=R^%LME;U/P.FZSDY^9I2P,  <F'=@,C8%=]T(W.6_U8J3H[+3@M:>!T-L#
M!S;;B7,3.';36H?BSUSY\^/$(IW;6D8KVJ5:LPD95X'8ZQ]L^K+KAFO,7<(V
M@L)I>/DE8$+CWFD&X.X2'3HXJ&!W7^?VJW&M@4P?NP1MWS@9U2NO0]S/!/]U
M:PS5W!NX\7&5V2W/*#HT?* TS8UPT+J5^<P#TP'^@K@N>TSV<FW%?NXT&#N&
M^$SA01P/$.'/<>Y4]"1WN,AG/,SE[PO8B?\T']KZ*+0#SPSE*/)]6FO@'=@=
M1=BSQKZKD2OH6F!NZ<@:I[L'R/VEXV3>E)\V2H(M/5XJU9V_0/^2C C_$^17
MWS M@3![@V_9'XV@GH1/E?MT&.CT*X786E]L@2]U(;$-_-GB["0N<8OZAN9
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MHNW_N&1->K5L4A[8V["^ ]1WR]%9X=SEGRW.[P[A\<=\JJK>><QJK$6XNNJ
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MF#GL#=O+@.%&BAT*L4!@@(YQN/#K@3N&U,UC>)Z,G#D A/U@@%;8F$<5"&2
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M*U,R;$T]W$(NM2O[)/0R'R=CS*ZV]\8>VMZC5"&&F=;FI2)^0=D+5#FV0JB
ML7%,T)/E3I*%OE>AB:?C6B&U1*JB/D,NZBI[W&_^[J''UX?8!V6]O+97U'4O
M#'EMM*Y&XM%#+V$_GG.HPVXD]<N"%\PWQ;7-XSC)(B#$HH0+4,O,[G[-V0=
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M;1J=R&-YQD9'QA105;?Q&A+OJK\<>]6@BYO%07AA O&?75_=<T('>W&<(4;
MJN":WIULT40BI]J1'/]4/WK)I"Y^ Z='-URIM5*-Z W,&(DE?L;)4VL2I3T!
MX1];#98LM*Y>U@+R^-D:- '-/BJ6NX # "&C-XQHYU+T1VH3G/3B&NQ,!6SG
MLKL&0_S?==[,2I@RY0]7H52]E8?XO,T(?FZ)E^QW=R;U,51GO4BU)T=MZ%<0
ML53$65W=^[;5"P;23][%C9NCGI-F".-LI1J]H-EIQ7<4O!W+EBIB+N-]B(+-
M=@I"QB<TEWUX%V1WA$EM&%P)[[9;34/>;L2^6]K".]B'#51%Z[W[\47M:C;H
M<OM1DW+U!+$V?@(Z\C%GQ[W0)E!@G^A=U59BI7>J+QZ]9,2[H+QM+,6)F&WO
MV> !6>,6=T,T>X6PWOK$S[GDD?AKRK%/2XG%-:M98EZ\E@_ 4O&+\7:K$8OK
M]-DJ*%#C)R=)+%F U<<7>C(1XS9T2 V5"2_4EF6!? *=?)2TRB1]'K(KA(N:
M_LU#OX]W?F^RL( ',6Q^:/'CEO;FJC8I./WGE@:1HGK2#XN&12XP6=L9FD9_
M*\OWK*S&':/&Y5/?;4EXGUC?N9N7S$+_ EBWPFZ%OP8=Y)<F5O T3<MY?:!E
M[<-A,)G&&#]0J.&5P2#LHVO,G:J'F3.S)+F.ZU8U?,,34O)C"8W^4HXK_:(C
MFZ$;YHQ%WX@\OD2!P'M5>5BC%V%S6%L)5JP=#B $\<<!:(1;>)&DB[:0@C+:
M<F]D3?O"ID!:'E.0=9@K?T"HDOAJJ'VWDEI2;E)]E*YW!G?$&^,4^M]2^ICE
M3 G3=BZ"QF/-,V%@@IB9ANSGV2HQH_K1"A?GJC?,,]2[:<&1%6=LG>#/KQ I
M"J,#PS!ZI=NCF@^U<_7P^"('/ BQK9[SE$#KGOJ<]/]D17I7':+*:K@&%^>M
M?69G&T!7^)7ZOX;I447[_Z1UN]4TT[O7-#'7_/\?];#5223";P>B$VN:KXWO
MT?U$L]>=WX=$3345,LP4>9!5LAY13%%"O5J"SSQ &#6@&M4,NE_:MQN!K/Z]
MHT #_?^FL_^SOH]IWHN'RQZJ9@DDKTL =I^]Z80T6F(E_ ,.(.K2<O)!>%56
M%+^*';[C4K=;SEM87@Z6/9.T_5>0!'\&_A,&=C528C44>.\6%'#)B0( Y]'[
MKT=9BC]I#QFG7BM.Q@%B77\5XP##;G-IX%-3D%AU#>'[W3/NJ8$B^?BL(&+/
MKHHVO=1<4?&W$3XS-Z[D942IL!X-'(PN 9OG5V><U(.KI]GDZ!N_)FU]BHOZ
M*M_NE8EE7GIT-:7@MIEKJ<$D_/"+79VA:&2OTP.-JGRBLK'G%EH#H"4Z(X+/
M>Q\I_)91ETVPU7TLH\T@WAOJQ^[:_2\">43YO\FG./_O#\>^WVOY8G@;*V];
MY'..ID*2(0@A=M;*"]DS;DT(N#=!E8@:NU)0>GYAD1\U*&)@V6IK"=:F9:@O
MK);UBSPIPUWC6C^C8#U*1]AL2;;-,$RH8+<;N;T,ZE0.F--Y\SZWV^S<+-T%
MJC4Q)JOXY!Y,3).40DJT^T&J?<'AW0S94IH9[#:<LZ$"D08;C)IUHJYHECD&
M*;EBAW^9(N9J;8KA*1^^[+ZS899_P)*M^)63Q,6_.2ZUBM6RX ,9['[/XR3M
M-O/(5KS"2FYH9L48H3DK[.E=#ZD0ZXJNMNTSX+%II?Q*$5"Q_<4Z?7!^9J[E
MFP+NRCH:^6_FS&&1\X ##NM'IOY8 3;OR7IY:"ODR[;DZ%G; 0ZPC*D$,A3.
M<@Y55M$35EEJF6@T*5$8:=I(,+.&S1=Z]-F*IZ__>"Y_-#+:-V#L+X!G^OPV
M-.P$=>0?75N_[881V_PM8,F62%PIJIY[[Q_0-KN0_"J4\/0O+DEFB<OJL>W*
M-TF-%PF*2OI&T35>+9ROZ=RNWOI$"EJ/TH"7^=R$\-BM&6*Z).(GNP9C6JYX
MU* _>DEB]>J\!,ZW2XIGZ6/]X'5TU6JV:YLU!/0W!,)M$][G9%&',-Q^Y[CD
M$'.@DBT79#EM>?]ITV3]K.<M9 6B9&9/?_#PF:TS4'X7!XCPG"7#$+JCJLD*
MGVL7K\:GWQOJ.-41&R2X[EY_#J+DI4FEWLX*5WK"LUEY[SJ^I1OC.Q?"IE.W
M?GI%]1ZS*)CX2-LHOIZZ4[R0R%7<.FGWSH9 B=.&/$;[<I3SMIGY)E-&M['%
MS .K$0'_@IS'V2RQ>G#/$OIU)!0QV V'WNA&TPXW*<S/RD15B\92SNT.-'6X
MW*$74S3,R4BE*^9451N[8L\4PCX5._Y1$K^XH"S&>0,8,BM=304SB-EJ#IE6
MU52(3+,""_SJM":BMC3C&%3A%^!*2A+*_=CO3J^S8U,PA\>A35*\_"029\ 4
M%?Y<\5'$Z)WA  MU2L44&@(SO:?[JN]K+DW%V99SW)YN\SCS\_.-'54Z5$;*
MLL$8F:RW=/G8?_\>QY@8P7 :L)J<7F=87V@<+C@1LZO#Y$E8>,KP[..'DY5
M?M5F$6H%)06F<<6^T:YAJL3$)$V7CW@UK'3)CBQ$I'7VMR3-&-(+$V8+W[;<
M4TP?L.6L&&G2\L63J+>5)#UW47%&Z]NW:AH:-.89P;T<-BRA]\5TU:_@>]++
M;M4!4[50FEP-7&1I"]@)F,MU;SZR"[V0+ASXD',1'<M+IS3P9ASOW+S'&W$
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MI9U-+J:QF6;74EYL\] .?UL)@YWZX^,BS^Y'FCB]"+'3T]+H3YE_G,0?51]
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M#P)OP:\T%*Y 9:U#6Z-F9@M+RQ*\L(_?9'0AS#**8Y<M$'(1E$&)".',2-H
M4>#V7NNM1>%T>]'SCNIF)6?-@P&$P,#,CJ*!EDAB/GE"GS,Y?UEC^5T]^<J8
MO$^;JN[O7YQ?3+\2K3^P]SJGO\07+>E^R>46244_,WQ!;P%84Z'ZMC5:GJA
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MV>.15*/MR"_S!JC/P=O^.K"K\DMX%^'4X+S2WF2BZS37CO']]N%?Z3]-KA<
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MJ?((MVRM<+&FB#D3]NB9V<@H*;9$7X_=+7EE#%$A:/9#[H5TA(*T-$8_CP2
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MP5A-L2XGW+C4Q/5&4W\5^R4*KX<HN^-Z@X<';)/Z_IE&=%YA>GYJJOVU.SD
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M.B>Z@N=Z$+:AP/(-G[K98A,>:AK5:7[NS?@;SV,IT4C8CU%5?9ZAK)T1/0G
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M:\'=\%P2HV3CNFKWE?T[!7F>PK[=BB%.L<6_9#ENPGNE]&&1757?ACE$YLV
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M:2PY4NX6+F"_O;'\TFK4;4:-!-VUR/VPZTNT'(/0_5_J?:N[CW?.NK;6E2S
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MB>'EX=G)L4J5Z<+%RRAH*F0^;M=M]48BAOHCQFT2M;H;O2S6K@8/+_GI!K;
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M;X!P^;&@ R)GL(EC9.YU$M#Z6VT'_#<3*#/3(#>W0 (P-+TC['1\H\1+L(<
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M8<C!>G9O^\U54LHPC+E:%S;*F9Y?C:1LT<9[=^,-N9)[^^CO)&]:>_V@[1A
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M[YJ(?+V-=R-B)O.AZ\*D'5DSK:^@]/M6X >SO@_.EG#J$)C'S?KIE@'H(8A
M-7R6F40RWPK[=#FM;0?33JAJ+'3/^/0ISR_;P?,.*>_+3EQ0K-ZL=4:24.U1
M7I 3O\ES?#P TI @2!"LW5RF'R^.)T<@ELBEHPR@FV5N_N3):*RI=56%9O?+
MPB\F3JCZ-S/-0Y5Q'79<>?R. K>C=3+D-,Y)?[ 1R+Q %C029 5GV8!CFZ<)
M9I_I#@$QU&^!O S@%@V[,5@D?Y=8V$? 1S, +G?<W9H@N:%*7!OWW(1,(&*
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M,E..A1C:'Q^6V^\(/ISY=^>A!(:QSR)6I*FDT\ZOWARKSJ!ZT0:H<<2;UGM
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M:>+2,&K]C3Q$0AZV_EKI9J<ICM(56I3U9T95O/Q(4:]B_-=?2Y97VFC;FZB
MW=?X"^,/\HP<$]D,'^I/?#W#&JXS94!<'$B/HL]/)&"OFQI;"R=,7XS&$$MR
MA7(+U>56QWMJC\7)CP%=8W(6D99<G?"]G;Y3GHIO7]63)_<=M8*S&4Y>D'0D
ME"M962MN:Y@I6+_7\\)[*^ZR\J53K7FQKK.^+3^?PT;*%FOX6=(/O*38<"1D
MW[7AQY*H%HLF0\4(\R-=FM<Y6G:X1)\%%P)[4:O=9*IIKQNZO*U(LG5C1+&1
MN"R-SF6C1[-UP@ZE /Z%]X4<- [/\HU</_J"+9=^O5?ERE4GZR9%\TASBVI2
M!?SR-=V9^4/TP,A1Y!I[6_W7PO5HM(??_EH'7Z!GF(+[EB@IG:6%BVH6N#K<
MW1FQQ$R23.I1'\')L8(5;A5G7J+$.%_ FZN_9M#L+6YZU,MBS1:KJTWSM8R
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M6L3J1$-K;0!VTT:->?,+>EOYF>]SHNX!^%)&*$5$G% '[HMD&#V-HV"(JTO
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MORUV=D56A>M;C!+>4[J'E6_I[27Q1)T7\1-7C<<@<R3LLXH_R/)+RX0TE)
MMMR.\D -CR5/3\CI*;ICS;,M)KR>2W">.HY+L^6X3DN6=W5HSIJ+U+Z\;*LT
M94A!'RLXH=9B@ 2"C85)#A-%>0V[HEP[HUFN.84<6!2PE9CENT;[\>I?),6R
MT;ZX@DLX=\Y9\VY:<B0^-EQ4X!_^)O2E,EJHO8***R0H?=HVUX9^3_;RH4OW
MR(W138A""W_; I0#7WYE9'9I84F(0^-C_I"*,MB3BT9@<%:YSL=BOMN06*,U
MIBMCCZ33F+ZHLHH^*H*9O:RTRK"/U"C^+?:1T ])7/)U,U/@RQYR\_QZ'\-(
M7:\D16?.4*PFK(>*)*0CM)R!TJBC6^B5MJ#(TG',H9!Q-WMA692]2Z9)AUM[
M/KNLX(A\_5%PH_SW\6/L*R4J?#<F#NR\O2G'EFJ5:'4@X2&Q.ID($5/2!Y',
M*L>W!@"U!VQ%:T5GD)')60INV\I<_9\)5**?,DL_8FFES2K1*)+2\@'AN[BJ
M_M9#IYTY7US$8!UR'5P")!1O[&[NO/S'>'F8$JVM\TJR"F:3&!_]P+G!V5[1
MY[B2WYV<8@%Z6,A'Z&92$HGAL!#&0-KH3*FN;3$63:!Q.]-*A>AQ?E-@ 5N3
M,B54O(@S^UH]A;;N(1(K^"S;=)UQS9P^<5M:/*)URM.AG6WTP"183GDDF>6)
MA$/?V$,EEDO1?,6%.ZD!:OIZ5&_/3]NP1^_+\*P3+)<*YQJ)M0B3GI,@B,2>
MGJ__=H/S3OV^7B-+_%H_0(W1ME44I;E2%5I]XP0Q<;HW^R9PE\G<C2[C#OZ,
M/D>K)Y$286^RJ#@T=;/3R[-U8XMCRX4]^)[-*' Z/$I^R/MPP^OII&&;H\I!
M.J5^9). 1&2\HK50'P<#@BZ\@_R5X;5P/6QYM.$]BM(Q9(_B.5YMM>[73WMB
MV,#]?=S!GEA*@YM]ZQML39>E,+'P57%W6JG=85F:D2JZ:DX=GX/WD3J#G#81
MA7J$5/6F7S/  77K;:."PC%M_%CJ9/(&VRQ4SXN&>=0E&>:"\@[X)P+W3S)3
M&,+0O[@+]7_*V5L!=L@>$Z0C')BZ=0];\KK]_*T1Y)FJ94O(T\.6Z!G*,A'(
MR<!$<X6#3%[" 'TJE<,*LZ[;9:\V2V3YI/8@5@JB8K7J/"G_\IRADF%ZC)C[
M>UN)5V:I, DW0+C(,39M5]VS6<H]Y4=]ZYV#CAQGH]I/L)CG5[ID83PEDC*2
M*1FV0%3N84UTZUU+TAG/D'&+78NUC4P(+@_=1O54FO5 H=:'RD:AZT8_+2N&
M5L#ZCS4@VZZ4XEK;RDZ<2[3B#&=#")/"V_Z@R_HEYK&"6*?]F)9$YEC346VB
MT0&-[SN)E?F%6L(6_,?3/(EH*WKB.EA:W%%0MUL;[82YL6R$,$5,F7EB7E@'
MRR<#.YNR6&*TAI&UX3-[%@VQ=G5N=>I2(MF3O7N <)0+!DJ4*^^N!JLU'?7P
MC,.=Y>P,-# D')*$'*I]%]CA.B_X8;QLA:0R6+Z(I+Z,]&R"DV2>7XM09R4)
ML1\#HQ]GL[_)/CHUG4JX7:B%ZUE4V,YDZEJ1-'J 6_':A=,^3VLK2(#5C;6&
MYU24_[ ^?H9FU1 0(70P&TIFK0M>9%TKB< N,2+W,@[U\XGN?S3=-$O!XU^Q
M**)^MN.]MDWZ&^[6O(0=:T'%\CAR<1)\ <8B6^QWL,9X7-*II,Z[>OTD)J-9
M]&:V,HFQ6326D+:UEG1.:TQF=M;:PC W(2]-RRYJ<-2CG8LP#X#LPY]SSK!I
M@\S^LH>0V^UHR (.[.1TXMU>AZ@U:#NNY:T[YW>T.&NJ4HU0/]?7>OVL./H!
M*6X0X._OBIN0HKO_W;ZH_Y<V *2Y[@$GD&YET-:#,^F[?3>I@<Z0>P KK 4-
M/+D'G#))!=/]N@>,8+G= XH"]N\*1F8^H+7,;^2!YO< 0E/D/:!M:!EYCG4/
MX.+>N)8G_-LL!KA;OP?L&H2@'=9 "XM'XP$_LU2[_K-C+8D;R9Y'T%ZHHTE4
M-S:$,2IQK&:_9*P;<D*X>U>'EMJ\WB#M%M\'TL7;.%Z+JPMSB6AQ\D?X'.1#
MP:^FJ/2$+B>$&(:<Y0*6V@4D&U SH'3]";5BF"GC!1_BO?_H[=+J789<VO&A
MU'O40>\LRN_'B9'_'\8PTQ$EN<38_(XWIC+@1V40,;W(-PO6%TNI5OD@S[/D
MNPE4A  %X8YE0P]D?XCV,"1GATW>VLMUF*[]9&(@SJ!4D+:@T9VP54!8E=0#
MS+]M=ZVU8'4Y;Z/-[:$SIWTWJJ- ,L;7#C?41W3#'_[>-1LJ0ZO02W#< U)I
M12A%OIF^SJ& --38PA*W+3Q'!U:F)3(^.WTR9[2M2K0J-;!,"%S[FM3SK_;/
MMP^UV3Z$,#D)6*H[^/NT3CJ-;GGXE*#OU*5J!2D?8N^,0G/O1+=UI05!_,(&
M9VWG<%E>@$C<IM6-537L\Q7WBPWNEMI+[@%[<FMW^J@E*1$7M8B5GN'MO465
M_7W;37=CXAI1UP 47U19_K'$_-RC\C5*->BP$HY4U%/E^2]3U._ =O7>A<7E
M)1%[=I9PLX,9_Y#;B"M]2]3,/>!;A_,1BMP!%:P>CN3:B?V)X+\BQ&IH,.XA
M?9=0?!S8\W,@?0W1&%PN\0$8SA9=@WQ3#X[@L2P,&9,XY/I75FF&^+0@S=Z3
M<@^X%EX'38ANJP^>7E[CYDNI>Z@M'Q&F!SR929[_(QD1.^8Q(=Z\O&'L3JJM
MK4YWRO9"0?6[OQ-W4X7KB@!BVP#C^(JXO4]7[KM#$X0I],,M?KO=E%[W@'Y0
M].N:O;K+L!+[4_HD(9T.]R:X_*]PR>AAW3T'$34!IPKGF*JF6A+#%YJL7IH.
M1>F-(ZS<'O,_M<^Z%EI<U=+/\&INM<VUO&%\.C>JZO*6H&0RE2H!R1F<P5'5
MQD,X2U96V_&2ZU3K8O+FUD33H_>D3*$5CS2#%?<N?6 &_P)]/V'.M!=J6H6"
M"$CJ+D@FK;2B*]"N/:3B? W'[4A+:]%,<7?GT[7$D?@URL,OC4T<X3\U2LKS
MVZORBD)]$W7_%98L8_T_7R*5?WI5LP5ZZP\]N%NY[-FYZ;T'*'7Q=7,VPUP.
M5G+6,Q?'D65>L<HI?'&N6^) UHC1WAL$'J>A,[Z'A2K=&]G^R9BSKCG;X9RP
M>P UVL Y.V?E[AZP)+UQVC:=-;2$^7_^]OP\$.@(>@*#&:N;J@2-^=:V?7#Z
MLV&)(]\4N%AO%,G1F5[.L6LETWT,>X.JN,V9IA?Y*^WE[XJ0K 7-NJJ<1U:U
M&+>+V,)+A!NDCDP+$HO&MJ&WL>LC%FZU =TRD1!C65.*)(58C4O! F"-1]49
MW?>C:M2AZI_+C6:O&GA-"9#+RDIL'^AT#]A.XR9?WZQOO <X2M)?/G.VIM/*
M&,$MF7CDH5US9"CK_J]BS.<>D#,U.-'4+$4#8C^/A4DO^-+TJ'KT7"O<OJAE
M%WGT4I1Y.7FY*VK)V-CWXU8X%ZN[U='1%R&#TL.R<H=Z86+?%T$5V0K@M*ZE
M=ND.8@3^/8"3M^WTK@5F[+BE!@T8JFMHDYQ9 JI\.5>=Z/1R61FQ<; _=G!L
M/AL:LW'TBJ7RY;+_5&K>U"<?/UG!_92XT%IRJ5V2GKF;T=\;X8P. ZV$'&_\
M#D*/[7LY3268RJ+1XWOSZ!>=[? I%#T_>E/ 9Z,'*=V6@4IL.;.S7D#^GC5T
M/NN:!>X1]II'@*3$MGC+$%]FJ67;FD-)5>4"G]EJ%5 G]"_HRDPKZ8=-6)84
MC&UQFKV<G=72ES$!U#MH_/MF%20=F3.J_HNOCW=TQ%M?T>-;!<SP@^.FU1G=
M](GIU#IU>G:88C^/7-SX.<VD2P.Y\N7#V&2WMRPR>JJ./_X53^JCWM]>)B$L
M0Q$#IDO=H&0@L+#H]C#\E/#<QDV:8"*'1S_+2?KB_4@U+!%A=%2&/KW$-Q&^
M'5 /U1+&!&OUQ&WHY49K!WQ[:91NZ'CCG-[/7^<>H @Z(/8' 053XWY)'QH%
M2]B [@8UK X_(]1[\B*8[@%NK__V/&J:\[%BG6J'FZ*";R,NMW>E+/,:[BZ7
M>C8Z>P;53E<VF/Y*U2!7,J'TO:*0'\GJW\=]+E8D/ SY&I-QD,J_R_-2#H6%
M0OZ5V+-WO_>W/U"'9)EF')HGFFHVB*=4M#R=4T]<04))VCA!DD\=2RJ*XTG*
M\JI+'%,=RHK#\IF48G7;,"SSGF\[Y4H:;9A#AN2S\28T0/F4CMR(&FX?U)GJ
MMW;8-L'C?$">')<5^5DB$R_/IVQ*/SNKI>MQV'-80$AU7RA^Q6"=AT<%FLG?
M9P15]Q.U57V\(3TJV36KA?+HNPF'-[RA#[>9@E1,-M/?,EDMN8SX5WEBS.-U
M&U9-A;(H^5E&]0^FXLU?2$GXEXQ[B("ZQ>!(>,KM"*Q#?,=<8>$> !3,L+Q]
M>;5,%'%)&4='S18;Q7J3^'7#W@RL(W#WLCC^"V99Y.KOFU]UWPJC1E\AJ5]<
ML^5?9E7"[..'=T1>>N6X[S73&5.CK"V55^W<H$#FJ&$IJ4:Y)^F)1A$<V8IY
MF0/[81S$,&#AT*CT+OT%UAZO:Z4WR-?#<J>#N/BF6]KRSY"C4_8@3-*PX\NM
MB8[N\[FM''?GRD4NX?C<,+'VB>>+B_/EDG+O(XJ5([(PR&75=P]XZ;I;$K0*
MLV_ZTD/Q>?X><)#1U2P]TE72R;P!K:==X$4=>Y:9\.Y,G#^^'FD7Y=$%5.2\
MI_3O<J;GQ.=_\1XSF+RG__D)Y6G37Q1L\_+M%(\A N06I^B'J[MN$0J7EG9>
M0AW0+[K"O'VYPSK6%KW-O"8-FPYICD?EK,(+%"MN'\QE]80^Z6#0"MN_$JW5
M\Z#;YD9>L W94P#K*"&-H_!!1E4@G[I[!!Z4YAET<LDF3#B=#!*T<"G1O&7Y
MLJCR.D(^M9&# 1,7;U RM]*7*K_T#44U_!4/58MFD53%[1+-%G$ 3C?A%>7A
M/$6R%O[4X7F]W6O2*#QN1V%KCRLFP'==22F,(?UND9?$VT,#T4/^^W_I:T"M
M::"D &AGH!P\U!P35VWW@)ASGGL 1PY?ZN6>FR]%78\W!\]-\A,56?)9*KNA
M?P3Z![=?/8YB"O*F)E-'$O@+H=#JI\P7FQ8[C;ZQ9;EV6A:83UO N O;/\-Y
M^12<5Y1S-O>\:4@A>O[6<-O5\RPZY?^@&[07NZ2G"A!L5M+I+A-'W<L'4KU#
MOZ<FU&.2%A;_$'ZTXCJ^2&[C%!2SLNC3LZIK/ZX3)O&U8ZH<M,HM@2A307)F
MBO,*XV# <O.-A9R+^L#KPY,23'8U$_"N[M*X 7!GW('6W_0.&X:*!U>062(=
M3C+;.KUN*B(3KN8=F2:THU8NK'1MO0HC(34J"A@%A<9D&J"=PP:,N,CY635S
M"?>S_1Q0M1IPG#QZ9IZ0T4'ZCH= I.TJ636Z^(<E!*@K1?TBVI=1Z>7C/Z2D
MI$V!G)YE1CX899>+CD2;TT_%(?#AKG[.YKL%<UW2UU.;WKXN)Y C*%+;WY4F
M<'5XTSJOB-^";53;RIMWH:)@HH]D>F9!74X[,6]4:WM1B9Q:4UA,&Q../CW)
M0U=AB*X,],>.<\0H2)0F=C@/H=MZL6"PGGM0%9X0(JR$(=_H3\S0"5U=5EHU
M64IY_@R/>4L[=@XWSWO !5-Q>WW=L:(-QDT*RB >O@QQ!30IUA4](L*%#HRF
MOS@.<*()(W> X_Z57]4%>6I+FSF;$,G=;81(\AX&(TR<G:B*?\J'#.WP;/KL
M8,*KZWH.8>^_<A9WJUGS0SW;U'ZV9]T\4I*CUB_\Z4I7!3JA&4)_:ZVV-.X:
M67[0$[0C.-^1V-*+8TFS6O;JN@#1.#@Y,XI9YT7FUU=HDQX!M -J&:V1U7:9
M42(]:VZ&,CW+K#X]-^U%QS=73Z!QX\I@7;Y)RG&-:Y3CNE[JN@1/N=CBZ%7U
M&2[LV%D229(P"%@RI;Y;=&W;+KTIW_- RM>S1/D>X!O(_KNX]XB&S^:F!C,M
M ] F6-R<OYNS(A^-&S^E=::\@4T9[>Y0V#<9MS='+:[ KHZ9V+_#*&@C<Y%
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M0+=(YM:S4X4F02+[&.84\!\R35,]XOH>X"I_@"$78Q0FGX =P-.Z,6G@:$P
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MWMI3WS[[O0HU+A>QF9ARODM(JUH%;E-'D2"4_4YXF%55-8WC5?2LF'P_:6J
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M\<V%O+)1@UIW''JX+;">XYZBM"HG=TZK96R.K7M(29+P-8:+6W]E"6E$*^0
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M\[0L,^!_!#;EZ.<R$TL0;A?6&!GF:_"P-+H Z+N+><*3?V1O:U$0.9'K="1
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MR"I)95?YKT%ICF+FW&MY.7A[N[=W)^2CD_AR; J#/OR>>YX>%'FQIO> G$3
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M'G5S2$9WJ-&$X---T[L<5QQN=]$.^JQWG[]!TA17#1.QR)@O=(76P;1]1^>
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M6'DJGZ:4*HM;)\NRN(6 MFK)Q0E3E_])RQ236@0$40OTH,W0D]MB-5.HVM^
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M-9A2&-3M,/E#*+/ (].Z_R"U#QE6Q9GYK$"-?UR3]7EE5L;/%YC'Y>UU[2\
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M=N=@5!S,K#[@,S9^G+X_3AGMP&O@2Q1UB7)+-$"N9B\UF1 QE;>%;5P5TG$
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MI\%>S84_0RO#. /3LRW>YQ9F9L7J<RM0U#MT%"K:-1T?>_C@TZLO03]:\Z(
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MH,9:SVE)?LNZ+?,GC/L<F1VVU3&&TC?#>1__4:NH,*IQI_M$]*6_50QA@E+
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M.7138%F2/6EI;:#K6I=EHT3\8*^S;]WOPUWZ)VW6;)R6:Z\,-K VFBN.-YR
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M^Z&\T4<6'%^DK#TI&=E_TA&\I2P*9__(OGMCUW/WX"_D#.7D2>=43;G4*<W
MIE<ICD(.A0]S/@[_,?2[?O*=-X>.UH0]599& 5/UWJ&_4^D1R>';F7E (MVD
MKYU)INB)675EXJSFUE-6)!M=3BB)>S_+G;FU:!#2W.3TH#;(5[3]M(; ;)%M
M4<&?KW1_.C\#!.?XQGI\_<R9P78"-SJL>);]KN@=6>%D$=Y\S?W%U]>+,F!B
M%Y8>YA>.=9Y//YI\Z')H#+YY*+:15SDJ+[ WP4U *58BDM_81]- +>\^NW(
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M)5H>'@6#L*_->[V>K-QPC:(TE^NHF\14F>1014Z+W%@3<':(/1W_W/%BP ^
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MAO,4J/"+9GVV'O@9\R(U>O)-.TBO^AV._:[X88VT,BPS)U)1CUO;:/&V94"
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M/<!":RC#: -YP[HJSA*G#??V9B]<B$%<#@P=SFL3GYNG6W5<;R&_0U5&]D&
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MPOAK-Z%9QKR,\,9TT0&4EU0819W*^)3I)'<J#"I$;EG!)*)UBDEP%E\;L/[
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M)FP^5]3MF*WW.<'0KCL>42T.MYYEEZ,%;$EB[#];S\@D/(KTN,"0KAH72PZ
M-'8'\E ^"2BHL'>&BE+AF3DX?DX^UIAJ351.&;/> K=&E@8+O]B>Q#]O-HR,
MY$XL?W;#=<67RJIW(N[T^QO%%UI947N&J&I*,/4SS0G>!5ST7A_+L,YK4J%B
M]@\;:/>AKA2^VKTL"8<*WW>R6:81=PB^WP*3G 0?&,S6*_Q*W1)\8));+KF8
M7/?WL4)&C%; ?KQ03*A387!]/I9J,FB^[W#U"NT<6-Z4&K%N6_?#,RLM-3+0
M?LC95^.P<&H-7EJ(@%_.3!"*C_AB?^-S3J[_R"/AQ:VN-G7&L]I],!V8_<?
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M>2P@\\?V6X?&H;X3=WM45++=['M!>OV)XE$3=ZW2YA[%Y[B*"%1_4+\C^E"
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MAMD3,P#KF2BIHOD^PZ3@W:#N>&YFW+ADZ!5$VO@5OW,[K2 1*%A%#:B.7)C
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MJ$(G5[MVW$AWL_U;L+E;3W\=<4+JZ^,:QE-X8T+W[4BQ<^<TFZIL.+!7FC!
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M/0FH@/O-DT6'GU#GB9.S?RC>KVTYF$W54$[14HA0/C:@MTFS4;QZ_:6.L9D
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M&F1%M9R,\R/04'D7^[ZF\:JIYN' LM9E]HYN>L&K=^6$@F?N)HADZ_]1/F+
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M'&C]G$ME1WN/$Y$;4E!/?IGXP4>BPG6TC>$2"C4,56HY/N9R<+H>L=0QM'#
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MAXO_TMO@H2P :X/5O/],QEC84JW'P/\.SQN7,A)5/"^N#<>N$_VG49<_]2]
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M@:F+ 4[ZQ[4=C(12HR9# 1O(TI#VR!H7Y&=!+$M@;G%VO%7N@'JKRK..B-+
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M*L?KP\:-+>VC-#3EHG^P%G!1*=Y^F?4!@,7ZG3C\O2$TZWNODL$]$JCV%-L
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M 8-102[N(V$L+LCD2M& DY6"( E<OJ%+K*9]!FI)*"EU#:%IK'=9 +6$5^W
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M@= ]>;<G7=_<T9KN\W_$7JZ$E,Y^D%6[(2ZM'I_3J*"MK<TB/D[-W\TZ+J#
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M&DQ#'LNC'R+WZ*S@\Z-39S-HO!Y@&_$;D00)D,\H(*M=G0&EH@!?:OX3W7-
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M\[T"GLT0_MC)CXGM-'19;=!I]?;^P9NCC!<>[(,E_>-X<MY0']F&3+3>=GP
M)LR\];K7YW$>04DQM@:N342N_<>J&SQT_?35T7T&]5\ 7;/.3-1"]]A!-.',
MN40#TS[#@JQI+Q16?YX*VFM]H[>V%J7*?C9>;U<Q"Q6+Z'Y305/\<L6YDO9Z
M.%7T>-?AT=/.%6U+BU_ZM(VH?":,#W#3[6SNW./%_V5_2I@P76+$%&%:_/&J
MP@,S<X=IJ5]M'A6&.DUT2X7WZSIR2^K>^+6M7+[J7#6J)'=X?9PZOC<*H/[-
M!9__U8>FWO7N"Q-[[K6 ]P0@040L5_,112QX.1)P=^(0Y-%;T15Y<6 4I_>
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M6Q3.)!!6+/J89YD)_V0;>8"V!@CY]N$M'!GQ%5WB.1<6O,VH&F*]'T,"50@
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M'P4!KJ/B'TAJ 6 T#WA3$WR8Z#9$Q%XY$/KO !__AS;HI._ 2+/SN]B3@Y(
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M1,TR!^,MS<OPW:M9N9+S"ZY[#GU$@6WGU0#G>:H.TQ1<8VDYC*=$[?EE);7
M[E'KQ<XEL0LQ$4P^J[8#G9<7HI*8/\Z]@XC58V45V\SBR" !>.+ [AO\<@V,
ML='M6&G7=0YN1XS$S4^FD$'##70T,1W;?#)Q+1TQ2?FAEV-"D/3RE*OMX\S4
M-2&19QVX"M+#8Q<_O@ $ Y%D31+K9,X"NO;_A2?,F. ;"9)IHJX:Q/>SQK?F
M-AJT79V/!"M,RAK$?(<:;]. *428'(X:5Y,NKY-XM359'ZH998N%7-NI 7"[
M)TU&A@R2Q"0?T]:0S+?A2]'&OR/@WL6HML,2):+AVD HBZ*/LW-D$+I24_=G
M&2S#>3Q",E@\.O7C:DYGD6K22GY.ZIVO'Z\\:5I'L]$MTA*_2;HN,:#P+$-D
M$']U=?\$1LS_@K? \=5=_3.E/![OND2Z)']Z^S-0!S^LQ/D-T#+(YK4.*;#F
MV;S2M>1\!&2 #,0B77,S@G'/$5>!(H,X'9L3XECF&4V@KC9;SHBH7M0^Y0BF
M(;K&C/Z+ST:UXLUA2_N7#1Z,']KUM#>)3CJXO-91G8=558.J?6< M*TQ_*>N
M^R]H:-"UM=;5ZFWERP^-@H! ,EF$(9&N]1<,(DP\;]8!FKT8]CO '[R1O;G5
MV<:)O4T&M74<>M*[^2_-MNB]B[SC6<,;5<1A5>A(&>;KF<:KU#O!O>U=AQE;
M1Z /U4@\9ZP#VEI_I#4?R?\,'!!:2O<YM6%;A1AI@)0T:A[44-]3</XEP@G>
MWVR76WQ'Y*HJA07X((YX$9+PC8@F.?B<:"\9U(@LPU8U[Y8YDT%[*':<#^B?
MHNR?HNR_0T/:7HUWG[?! =CV4.^!H_[VEWA3Z-(!YM%Q=$B!,G5A*P'"HFW&
M<#?IM>Y\4"8'M\3W&^&?<G<I7SP^^5#\5/M71.=V&*;?%0]W<MF<08/+:R!:
MWN]O;[9LJT=LA#C(].>TCVT^S_;G+&&,49Z!BES1:SGLN5^;KL(UI*;&%2FB
M>P56 BT!=])],I;#<Y)!HHC%%*'=$0S+NLT!=H\*?PDMMROWDUYTNQC#XN-T
M$<X1E-FU_56/L]RG^ZO5=6:'+KZF-;F<8)Q[&X6UJ,""/:0>JQB/=T5IN&[C
M-.![OS8N?N>/V>A'3IN=EXC.S>YM1^G,B;JL3--#)QT$'G^IT)AW+"B[3MV=
M\'.(7DT'X[DVK-H_NXZ6 E+;NQJHF/TB/,YLEPQ:7_-U6<*?V57$!WI"K.9>
M7CN(O NAJCCB=)@I7D0/\;/JE,W_DO#MU>]2K:-XI[PC 4!_Q4@5I,L,ITV2
M2)#[T+\!6:PCUN47Y.1>^?[9E_$%$=&=97\U_7.?8F3WAN]G3WZZ:QIEWJ>+
M+P&C*^"Q6C)/@2D$@*.;VZDO?-&]'A'::+TKN>SMZ(Q/\[C2$9GE5U=>H$E4
MNS ZZ"(E$!*)U\S[F:0<M/2, ?(7"1*W%QV'D$'"9-""V1[5JRV*:6.>' )R
MB;(%8\A[A^%59MI&>*T#&52?E*$TRCN?@9Q.%)3;G-;24>)-8J_6!(HS'>RD
MB60M0?$7NQP9)-9/;+,ZQ/KX#I*\X*=E+%_<N3^@,C_M9U;MS:!H?: PW:F3
MJ</SF\\Y.36:KX15[<%7/)]MKAN?RE4@Z%XB>H)Y/N#%=EF67??0F]3G;=:5
M#@]W<*.__64?\Z1>C,6-ZD?F]VWY<#-X^QW4Y>U"/Q?0<;D]'5+8I'C,@X9E
MN?XX_D6<:4["/-E$)/F9[%U-;XY#/,4&;<V\+JY:OUB(>_\6S]%H-2TI)&T<
M1 6NJ_&W>H$2C/&Y\"[5H'JABRI*G$(B_M55-"QCAYA2"D-4PU/!>\;;Q9UX
MQ7I_<_G?S5D^WK^"AO$4#8=;4U,T.F)^SQN"O30[E"J%$_P:;QA(HZH?C.R<
MLV>:0\:<MXE$=)+6T<PE.+7POA^'/,J 3BRA%^N*,,0V$M3WX^8GT^62]D9I
M7YB0[99 .(^S.5<2;(3Y.=1NH.OLK0YZ$>AYU<_I;Z*W&D=]G$D?\(V[>Z1K
MDL09,:H.Q!*5XF_+*O]'T(%VMH*I.E5D:U'*;EQQ@_GV<:-L@J_+7=I)LZ?W
M1'AC,[,[1WJ4HQJM)KGVI!PB"U/7T1? W#*7?5,VP+% A7^3B"7!1=#8IOMH
M;&63X;YW>SUX4;Q:M,_&M&:>:SLROR398\,IW2\=0A3-Y%6NJI-8\S&,,LH*
MEV@/>J98CS6&_=>C454^R;$!P_&[ %\.YX<LB4]>/\S >7^88MW<85R .\F(
M9MY2*LO9.J>EEA?37<6/OW/GOGB=>;CRI/U25A"U46[.O1$=S0< CW*0<8=+
MN'Q826D<-A;[U3ZW&I'2+-"D[*6HOS'[";<\RCH@FQS/_PF#JABH*V<2;+SX
MRTET)JO]N_:C+K6G^QW/X#J7![A,U]%ZS7VS;>RWX2DK.)8]QR5&1]][./O2
M)KY-_Y&UBTWKJ2NY.$S8EB"JUBK 0WA1+%9:3R:C//Y*A?YWACLZ;5)%X:]7
M/U%MT0+JU)4G=DEXX)_YNN/AQ,*C/3S,N5?O:+.V.4FLW6]H-W@AB*9B#\%A
MV8[?>S6QDVSFL=W;[RA.<=OQ/F=^";+EN]'[%ZUZ>CJHUB-35^A6"948&>3F
MM+%-M,S6)V'Q9D!2$R%"MOL0Q ;PE^T]18#;[3%Z;K)]G&R6 A[5\,W".4X=
M1T1'V/ZLB0D+>632]S9G8&RDXR.3DY<RDD4)$AZ;MV[ZRL%0+X.O_C3@W.P2
M ,NI:%(D@^ZAFXG-_FR67NQ=)@'R*-:(QB83WY@)Z;</$M0KXVYI?OIF'N?K
MS.K/(X;HMN:TN]T!9\A*2KD^4-0GJ",,Q+XF_'<R&83 T,C<)(,$\YIN^U;B
M98?@UYOD?<VVFS]/L]?4(YHDM2G&#!V,<%ANJ%5H>"#OYT#<C":3:0J&S>')
MJ*P(U4B^&1J6KHVGPH:C\;S$83+HEVSC?$4IK(2B0I*FW/^\M9>6JQ2MPF11
MR8_A%PT,$9=3C/AJY_*"V>N$*T?JG%['<;T6/J@<CJ78!)PNP^^WV5="S;SB
M=P"<XV&^[C\&OFPU59&L,/?V"!?YG!QL3,/3QH91(S8,X?*OUIK?: SH1MTK
ME^CDI19Q/ZW9.%YOZNN#:R&&$\"_>)2)WTCF9C+>^OTFJ#I1__[-NSV=OJ'X
MQKI=>\V&74UY$^WJ/)\>^KH\LRUA0^_<]*SI@=#"?%?VJ=Y8Y=ZBK<8Q"$Z=
MGD'("U .9EFXIEKF1R?TX>V?^(@]AE!'*,-R*QGDY<YB&@\N_3UH>8])RF+=
MUUF!PUE>A!D2I/S:PD3AOC3@\:>(YZ<:>/! ;?!#&8O8/5H);Y^";2]Z=:[U
MSV ,9T.F8$EO2SPUQYW9#@8.[TYUC,]SQ:@\;<B1TKT@$J5:EM6CUR1^QN?D
M-,0^R8R]7^ZGH@V1:JUX<,,UVH]UB%"#K(]XX712(UA/L0:$K/>.]<Y,VX0(
MW%5D,GO?^<7:1U'&(JCXAJ7\IZ>=H,BA=NNOY[<:A\Q)LB*PEF;28[AH\U*H
MZ$C_1E,4'K\K5.2&8,JMN7B[@$8S>;*9.;<"Y^N_8^ H]2#$N8/2)J'071,Y
M/:*M)W^MHF,-X&VH>"(7AC23/FB&BR(](8.V+6-/+C?JDOD/ \L;]E@RZ%#%
MC!N\ \*RD_;JV"UF90%IMJ;)(.E#^&$DNRS=2_A"0!U\N&F/-+2PD@/G%2+<
MD@:JL>#B8S)H9G[##QL E%)QKOA,JF-C5I#_-GRW$.CBH0MX;1UJ(_-+/6<V
MSZP4'BTS@)G&PK;KPP]G:B>QQ=LS#=6^GI*<<>F\&+>Q/H/!PK#/>M"/.7S7
M<P4H.AEKOD9/R>R,2\IG,81:7SUG'GZSW9;BG5V>EHA%98G!P-?C*:>:Y*YM
MYD/H@SZ!MJ>:GW/T;6_J_&;.&Y8C75^W @H%V2W$,2@/?+2XT4$Z3RC!/PXE
M>8"/3PVY$JD/P;L(,'$N@G@,^_/A;<QO"!K>?=9L+Y$,6KG82 :=;HP@(@?(
MH$>99!#8E P*DI@$8S_#@!KE,1^$5 ?#$J]BS78#&(E+\*,S)?!O)98GIZ7)
MH/X[9-# >/.O\&K(\0+;*ADT2!U-!A6; EH[>SQ.3),'F B"]&8=\YM_ BA@
M? %@"@'O'6SC+(N YUY3U</W3V<!]"J^&?X=#"6#[ER&]]N206D2V'\$^$>
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MHN6;O;H7Y7F0_3(&W8ZW[2KI'8S\3GG.8L6.C-%LTJSB-Y*.Q$VG5F?S,:\
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M5$2M!_2/0PE-@\<I PS0F0&ZA>+"U(%Z_H%6&5V-IE6X;N9B9]^".R17BQO
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MLI>JIQB99!E$FIGFQ$Q_0,E+<E3P'91YS?X3A>%_+&9T<@%^&#O6!:7=5\0
M3HF@/EX7#9]'U3)  X$9ASGJ/U6FP=3K;E8[98T,4+6?G&!&MQ:]<^ %H,IK
M:#CY[@$X\#=\P2Z5[@A@<"/,?3 *1RNZ .\S1^PW8$T1W_0+Z_Y9YOKO:/B[
M%-D_<</?I<C^H2&;N 2CI4!FY_?1V?ZX0V )]I["?S8?3J-PE(']ZPR0%N#2
MT(UWEY>5QC8 A9:W6J?)*:1#%?:)^1VU(T!7124M>/B[YR\I<-EI!NA,.WX+
M[8'?I"IU\(5;1D*SC5*G_N6,^-'[X7S@Z04GJ=<8(%XPQ6Y@SQ&]= L]$<<
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M+%W>L,A5F? 3R7)+:XD/OQRIX2EU^_,^>X"H#*1/61W*Q&XD?3_2]I.U)T!
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ME!1(JC%I;#WC,V*+/$_^X=;5NI.T_2<%VN I/X7WM2:8V*6>CLN;%E?G?N%
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M(Z\ CW# 2HKM#4BFJ\+9FO\,".X0>$+[O)+^9A69CIZY,J$IVF(QUI0Y>NW
MFA1O^I3?[NGYZETU,\TNCXFKVSH&!KF*]WTU6($)GJ4-D]7[1<@T_K*%\Y>I
MGW:9W(T"D&N=05+>B_1>C::]]/V<F?!:F&\I;\[,L.2&2*EF8K2#TP1[:6(>
M._O'5Q='*,N_(@LMH<"J^WRGGJ91 =7!*W53VFN;CWF7>9-=%%VK]ZQ,:4 \
MX]V;&5]#]MK9\]_ N&N/5*U>0OCJ.#@*)K)VSMU:S@O.JK<HR)<BM7, TWM'
ME:2EH%#%Z-E[BFA:%5V.W[@+D6"^6%4B2R?TCA**+8?B?(CGZEYL*"ZA2,*)
MTR/C_K=6"AT=A1,3'W\(\-;_-7@_5FJDTNGHQI8=;4,)Y#O6/[!P+(52/WC@
M>3J52#L!R:ZS'Y^8P(YIU?*6E*W=NS7%&_&.7Z'HD^9J&*0Y)!FYQI/I%,;F
M_#MJ2*R!; 3=1-32=7S=E9_+$GL8H/"NK6,HH6W8.ZZDE<\H",O4)R;NV^XL
M5]44FGDB92(BGN=<N'NIQ56TQ.L1?0W+@?AW1<F?QTAH>M>+^7SZ=6X\ S3C
MR[MN_J\JG_ 0F&G1LF+[QC/P286T*P,+_ R0K4,-0"=V<>B#+X&(YDT(J;*/
M 9)Z!N!LFZ_,6"+=\"-DL01S:.%6C)D6')X:C4#SPM<S84#_EV4=X002"J=#
ME:0_V@-O8UXP0$:72PT\!VB)9&8J 7 %122O<P>7=J[^C\=*^27UWZI0ZHJA
M6 X'8?-WT_)P?HVDUD7Q(7:_%:0CI\:YP;L+%ES*X'<[UX/5J\=J==WN-%[.
M:GPEJ*[&8F1TY?I.:2O=M=2VOLXGRF1<3BY%HC(E&#*B\AU?,DR_X4/?)+HC
M%%TG.;:=##:8!NKO3)*N5&:U,?E.H!XD^]^J87O^M1MYYN,E0R,#&$\*,\O#
MZ2'RR:02JKEO?45-O/85=U5>?B$A&YOOC=Z_?CR+21,UM/QZ .LUYARK,K?"
MMCY/-%GM:3%[__;&F=A+]Z4+[H&VGJO=A(Y+9N;_-P F+WTE'X"'@0-" ![F
MFLP P: VQ!?P!>LI!F@I#[*Y\P<92C?LP]#] #6(VN& "P\<\+A% 5@>^-NF
MD-][?L0,6HDQ;I<)\%N)AR</_U7*%2J!?_6?!B7_+]A0J#)'/FS"+!#IO*X#
M0-RT2"#>O(>CIQ&&_N-=I!'43 4B%K*"=V. MCL9H*T#[E+T42J!M'\F+/[?
MM:$81Q,2$S=L;N8)T*>HAZ8[>D(@S4$T)PI19\?[5,(=_,UNSO<C!H,2&DN)
MG#^N73$4CS^AT^MV$8R%E<1O4I#GS@NPOFO7+[DMQA25U6[C9)!X<0B?9?(\
MXO*K!VIA]V2/JEJ;M=@G<J4R0&?F)J4.8:P3*E/@[J#'=?[M49&%^.+B-K>
M!<6_+/Q_Z JDLS^^/1YRS]Y8*(77W!^ L#\CQ\#7E?SA=]T.B=1F/MIG]V!<
M3Q(>\M)!COO=MWT&J/CE8?AX6GW]GLCMY/WBF^I>>L;/9!8'LDN0V5=VI<8G
MN\-B_C"*W=5O09 MESTH@23Y!5_,P*)Z(R3!JH?PNYAJK/Z-?@=#6L,S=XL@
MS/!R2[+Z(5G3WAQPV>HZK[O\>2VC"Q7>?]YS*A*\)3BI>3_2)%ST,0@P= ZR
M0/= JA7 1#ZS^L'%$ O;T]^8/V&%-X<N5I@O0GIKUU*>3$XG<&0$2GD/IUZV
MMGFU]UW7H V16Q;*$UT<E6?BP,)]U_K@;A(O,,NZ+=:3M.$@T8#5$LH02;Y.
M5F  \H$K<LC/LF<"+.H+,7[N/R1?X?OD:H'*S8'I2\]B,[CBLKOT5:15I3I.
MI%DZ1K^V5E,C6ZXHTA+HSVGAU.=;54LG>^BS,[MI-6/U\!0K0<0/!9;S\FR?
MPC**&R8?/CTO!I:1"_X\TC'RCD>+15O?<.01CUI*EOYW8)7"X6)-2[0V>&I9
M>S&FG[N8[A'/)3M]D.'AMA]9M<6;*V=C0^A#C);4K2(%Q>558'ING-IJVSW&
MQBW:?[E:>*O:W?SV8O2Q8V&VF69]TUC#Q68O^!VK1</AH]?<13#AH'4D/!3>
M)]P$0^<VBVVX-D4^YE[6;_ \:%/'63LBT8W7*KB7)[\]?;^A)628<J4HC=?Z
MI\I=8%PX.&"B  OG\\^H:^:#BPR\$]\0'=O&+_B<*/.PDS>N\ CU>.8_]GS]
MPQU[%.O+.<&P'D.9!_X*.7=?YT8Z.@L["5G'=TD,_1P!I*?7[#B'3ADC)5-6
M,Q26T9]+=ZCDN@8UM/5\LUF /Z$T9$+^\N5O/C,O1)4C^Q9D'A]8AH0*5Z]5
MH/UW+ZC<UFL^]9N)7Z/(S+VV !B8'MW;JA<Z+ZO^&YW ??)WOSZ_U21:6NGY
MKJ&%F-7SPBV)^;HD2[S'SQ$"4S-_%_[5UMPMX0P/5V)S3\N?6A&(QPR0!^=-
M"X#/7,U87/IR=.84%,3OGK%H*K MWP(/:,B'>W,_0<_F#5,PM5FK^XUNE.GQ
M+\>G-!$"T=O$QV]"%*(+"GL,Y_'%16%G<)6AYX=^!88VD,UU-L[U&>$G858O
M1W]R&KK!W&8EI5^W\21MY';KJRI$.POE-HKQ:"4<G]P#0P&W8$S>]J"(QM%M
MK7J6YL$_N-"H0AF9]?4(H]$>EY*NV _Y6>&28\F];G,=RM&G8C6_[:\6/_6J
MN:06R2?^>$@M5L%:!N YV73 ()1<>S9'W5"43-I:L^">>XM;7PO>AVBY418[
M'J" C1N&M927Z]O,=@XM;FD8C'\J2A'Z-'/JR9/8V%,YZ96U80R06_H:UH+8
M@8M@@)@VL6738"4E&?Q+MHWM;<2Q,8ZD<OELQ[WS*J_G9"TEG?&Q3&CCB#>V
MR%K:%9R]X8_Q_4>16N*Q3OROC@C/QS+2$RJ4)+"8)[;$ '4JS>#BW)K3"Z@'
M,XJZ6V?/GI!GU5!&K,T4I @]#1B6_*F/,;0B5QEVQ@V/&O22!C0[_KC"?AGP
M8!9>\.YF,M%]J6Y;'M\_L^'?LB4YZ_"C-+Z%>#[GG8N-47IV%:PT3V'W]O,J
MIH<2O4X^$\@\?^\R9Y4;A5LB/Q\=;7]@:;7RGM1*N(PH>INWO!PM"^TH^R2P
MF-1YSAACN33!I5T-N^RS*)-WLT$N$%VS5U[6KORA?4,;!;(O[#=43NRU1PIH
M/G(67T,4%I0 2K?"  E"DG BJT?;5'>@"Q[;[E4OK:X?P'Z/:B')/JU4P<BI
M*QR7>5 ^H3[X&WWXN?Y9CY=MD?E=LP6D:W9.*W'DH(79@C%I,>R1/6A!$C%N
M<!GH8GL=W=;G*NOB"F5DBX_VB_I'&&5M^H"WL!9A[3;=,?QC3!U:M]<\RD(I
MN/.MJ;#NV;F1>]T%$A,1(P]7-)C4%#UVI5F:U[#LT(7"[>UY 5,R$$CE*1=I
M&%B5XU[_;[J9B6@FUB.@,>D/Q%JR9Z 'VN? #8.<IA1[Z5@7(/=&V;/9MPV^
M?Y6#\AG*+>0>-  BC$9?) ML*]-?F5NB%C^ >TJ(M&JEJ^XNI82OE/R?6)6A
M*7-/XCJ=F<GH5D%=WN[T5.T[\;]N=6IKF?VTJ:BV>J' S%D^<DV/O9L! IB/
M+*F5:D?JSUY0[X,#8TSRWIC!$<I"-W<!V+8&C37WM/^U.X@[.%;GV#B^3ZN]
M])8!"M5;\O#6%%SCRPH^XQ"K<J:M-'G5&7!LQ9"WATLT'#P5;4G[T;<#[>NU
M:D\/SZ$.DMA#"YNA\PW'_IBZ)[CG=J,T]""SPI\!NA;[>VOD]3D+MO2GI8ME
MA:F\4C52PU(E.CLC)(0WX4T KHTY!<S' ,W>_^R67D9W:!I*PUH!!&96W_?$
MR?G/RX0Z-L7L;RBZR1[MP$R$TT0S$&TT]>[%?'K3ZJK'JT<YCYSPN6<?7P8B
M\[1@EJ/@[[=+*86S(;=2D/G06!7V-[9Q#[)>O+H]J6LT/W'_*"Z;_H]"%5[J
M#%#RR5:F,AHFZ)JO6!O74K/GH6LM*NZ0&WYI!F7# ?U<FL4 J:>6_=4PNZD_
M4CG419:^=O=KX&,IC'#E?CR V99G7+ -*!5'5XN\!%?+5!O7WWNK8U(0%_MK
M9B:%[_/N]/-*G*IQ&IUT=U4[RK+V*^Z_?L3_)U.X(E'Z4_ 9 :K\>*@?,2!@
M[5<@+#H_]:5\9J2DZ;5J[?/G!6@_=&,U%_4+KPM>N+5[L3,ZOW%F\?RCJOT7
M1F#SESD"Q>(I[P2I5/75D7MGE-.:8O:JM]N71BW**)$H)N]9A:SW#Q6-^Z$)
MK.$&KJE0*%0#^A<_WX5?OWZUL2A*2RMHG?/ G/GP\*$.R\4K("0(^*IK/.XK
M<:E7@V\X+E9C6]&+Q^ ZZ,P?;TZ CA7/K(W\G8;@?\N&O],0_.=I"-31*0-=
MYR-"Z5>$:;G[:\VHHI)]:$$0YP[..Z!TG0L[-87GJMA4%YR\,'\'Y<ZEI1BP
MI:(4^"K5BO5NE#XX*LPG/44]QNXCL+8.:0L \[I$UTWCKY:0#\E8A)B2G^ U
M^# ;I944\M/#GF^2?E>]PS*X$+FM_(9R6L:26:K2VH:*PI9T&#,@J"NX!?&M
M8PLG7_DD]4$6-[8A#L9>N"Y$FKQ<?C%=9J?V=TIF)9?#B)14]=J;S$Y5'07*
MEV8S31%M0^\;.4\J]0[7=W82ZL\T"+E[$PJRJ8KPVU;S;*@@+K>2"MK@GIBQ
M=_Z 6#CVPY2\V$+I#!&2 !OZ*O%YX8=#44Z;883VS8/OLZL5X1\R.+2XW"2B
M-/T_S0G9)6;N'EW3^ 6_@8M ]^@+D,[.YW>[+QS0&CVY_ACB<C67?>C%VMO7
M0A*K\DW:-_[:VZ9NW(!\B1+P-QC00$SML)W1O.M$:D56$:%Y)_(3Y<9Y .8D
M34N"5>4T<]/2Z#Y6G'3#/;CE#KB3G;BHBF6 !/!M/GN[F1/,*6O-(R82')ZO
M\,*O$J1VDA\'1+.M.MR!\@T[F4/)6T,U#S5GUK#7N+IHBY)IN*U4:D/ IV4Z
M,A<>"KXH)UG^$L>A9&9;)6W2K=2/>SW-XL6R0V%G6^'9_GUGZKV^7ND3]I"H
MDKP/3FWWHM6!N&2U-?3-MX[TE %ZCPMX1.1*V&J3Q=8TP8<53:?2:D9M[AG6
MO)*2 O.]*JNONVJ=I1S9;?"0PD:6:'IXZ5='_$^U-87X\B$4T-,@!  3PK34
M%W2YO;KM5Q3F;8[2H!NTMBD8K[</SM0G_T<4K6.]#C>5\A>RLZ6:?+4WOR@V
MO:'.TT%'.39,Q/#F ^<!(PODU^"L9$!)+\+(Y;"VQ:4@!JC5(@A"BYJ0?CTS
M/#,$7@23?-UZ/A1,CEQK7,)H)ZLD_^B+_;%OQ<3D8_84"=76J_BX:OO8-T)>
MZN@%%R=LK+S6J@U-T5>W#/A U?C2[NV@0DNAFXZ@V1HDZ^OZ?#?3JE%K?S4[
M5HV8!Q6)W;ERS7E"/-[[)J0Q/9TMI?G47,*JT'%U+*R8 1HXMM#11ZT?';>:
M7]N4K_0AOJ;E4Y,;?:Y.;PB5IO<.[C&=--OM."GZJ8_@.M3XHD#(,ISMT8Z@
MQH6<Q$KVE :S_ L(ON%/^H2FH73\A(D;0%4_< ;<7 X(NIHM.(;K)E,=W6^/
MM"]XR^O_<E.:+0ZU&1PRS%'9F"V@$R.\#:5>*=6S\:7<#?Y5G Y,S #>^D&:
MG(ZG&\![NL/R68TRQ"&??<V7#B0=;6<UOWERP;;F>#]CAT=>-DKFQ.O"+[4/
M2USA-GT6)M%Z\_/1D2>UHX0+)Q@@2:M%42RZ![%4UE)"G*P/_0X7YL9]=V^N
MIEYN<MP[YS=;4X>.JM];U!>-S\.,+:Q4)%0:6N,OJ/S6EJKQ/J$1 (6*-9 ?
M,$#=X$44+<87@E'J>-?<;!? 1W3[VNNRCG)+SV[?JQTE!)3:)Q?FV*AH55>,
MC$R$142T#?Y9<N451ESMTH/O<H /,;;J@KH'?*8X,4"GJ=2W$Q.E->OL?WVD
MC5)Y-E%9=9>,9!8ZU@ME6@TW(E0-1:)K#*6HBNV(WGG>J+M(VQ3VA5)$_^Z+
M/P%<*,( \5HE0?YLYF2 ;C)_2-554O,F+./JTXKJ*T<"U:OKM,_OX:A-Y/%[
M$>EP_NH*#LB57PZOV)!RQ6$Z*MK<=QN]MO1[]*\C++1@95X&\$1W?R)3*JT"
M" OH[8_K"E<A)R?!_/(9"_DVZY/.Q1]$:G2M&\Q/&[\;3W7.%U#G4):ZIMUF
M%=?^JUK"X&:T0^1\;.8NT)$=>A:"DU.Z3+.C0YL$1P*WL8I:6S:5=.F-C8E8
M8FDI(;TU>X+C'0<]GGQ5R^=9%0GOR:P:7Y0]\]H5$])I$S03:^M3@F#5'-*&
MXH^.+<$H->.IDP@D)*.,=DO2TZ6XSM(5$:_X/!Y#NSV%&N,&S"YQPHJSUO8
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MIS)3B;D@ON[$,]/PUS-$OE6O$^1;?I&.7+6:\-WGUNSZ(0P'&D#.#2AD.J1
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M6*"7C9U=?+=&V%U N?-.7+E/'L7Z+*\86G\6V?Q[3>W_$+AYZE!;QZX +#]
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M'P;"K+2!#OD@#G]P&@$\@ X/V&%NK, #GC;PX?+1"!O"N)\0F2UEG2U[ ?&
MM>0K>,!XRUGI(;(9#WC6CW7' YJBD*U8U*_6DV1X;68SM'6=&A0%0L?"H'A
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MXRHJ=44YZT&EINLMR3]L[_M5U!YM\=]Y$"=65GAXIO?E/AUPKIU:@EEWS 8
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MZK;LIM%=:]S];[.NBA^,9KS-S_ B4D4&>%L-N6Y_*+ZUM-DW3LV3)WZEJ6D
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MY#G;<^.+[$V2=+%"4<IGJC<"_WCJQ'J1%+J@=SE=+T:Z$?<8\0V%UP4$-8N
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MB.[B:(@V]?$Q[7O*_8:?_7R'1NNX4Y[3AL>8WO!PA7-)  >#G]5=(P,IH[2
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M;@9CR1[\,_(/UJ%K'!ZP_7(9(]9S'.\2]29IZ2TWC.F7P'OY]!\RI/USRE_
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M-YLB<9/'C/<C?WUZG1_MUFYZ3K6<Z)$/N?F:)U:F:"^FST3NU W$2;Y;2DM
M\<?_D2?U_R(#\!\78,S,QU) T?HO@.5N2:& 9IRH:)AP#.>&$_VUVRD@8+!$
M+ [Z-U>!Z5;Z7ZHL0Y?C*2#W'4(0!?1!WXL"^E&X;0-0,[,!O,;XR2=T)YST
MR(N+B$(3F],"<NS^8599W/]65MG?CDHV4;&XD^:Y7W5D=ED<!>1'^W5K91Z
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M+4=;5_U#*='\G=V#WY[LJ9^1B$$'R/Y&VS+>*/_WT<]KPJT^9>,;;LF-1)J
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MN]B'7S9<@*\ :&./#4'W"+(W1/#; \SY<%I#S0VRA1Q1-W*60W]7<Z'/UC-
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M^0AWZ*(2E-D0)D(3A62I4>@8<Z.?+^T4.;)PXN^Z6*-+<SGP&&=H3/I,_L.
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M5DQ$K\1-T7+?>*:T7@H"TX+-BZW.J__IIOR7XK._>UNG#0'P9LCZUWA+# '
M,M^Y5/%AC6T[2B0.90RA8A6*8GPXG*.H)7]<]Y=E;YG3Z6J9E4+T+/:D@ !
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M=<-0J1@_2]:5*C'I[F]?:W?K3E0<DB+2DC/NB RW94RV+<9E*M/F>5L07TT
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MCE;IXY_.'NT%G^\!7ZMIP2AJ;XW-$?TY\J^--SMKN1<W7S/6>D(Z]MR3*EC
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MHNM]Y-F$K(7H)HS7[#PO,7'>J>0^7EWK+V)S ?/IK"WSG5=;?WWZ1Y_S_ZW
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M?QV0B_GV\Q'-N.N!3N+!_,!7-57UN-;+2H]UGI/(7)J6P(#^8X+MO]KV_@4
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MQ<3])"]>])?\@]%6M3:$NX"NDW% ]BEV)I 62[X/M3@@N[FP/?5UFR'TRW3
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MZX.WMQ[,70J8>";5\.O^@7O06.GA'ZT;_IS?_Q\"X/Y]1RSU5!8-_O%FZ>G
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M8WA>6N:C]]K6MC//[7(B'BZDL0S)W[EN#<Z+6^N8&TDJ1N40+8"$&"O5*Q
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MNXY"]=T- X%%6@) &(.$[I(/$@#;ZV&3X<=DZ;&E$<%JN-<3! "UO[8_1N'
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M_=K=:_F@<RO","J8R<FO=S;>$:S&.35T^[(G1:^@GGQ^#"N5O&>$,YS"WG]
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MM:6AP,\C)__"0_0P8>P^=.*!%PK/&_.# )BQ\ WP)Y-)T0EFU%5$,2;@%H6
M[&,CLXS%/IY!?)KAL*!7B42:-I_/ILSRT6#;'5H2TEAD8?;D?IS&[K!W-;YY
MRHFJ'^M?-/(#,];2Q;F$ZI#N^D3D],>2YK:"MYMXK-;R9F+')2/@F5?K45HO
M"AQ-^#->#2VJI.KRZ<4D]78-=U'/,;K(2OE/:#LY-9+UHNOX\JLK1/3YJFL$
M:3:OSGY;R*8\.$C4?Z=%8F^KX5HA1VH;(?.):>A@Q1".4YL\#NK';08\7K9K
M>QG@LTC>-3T06^A:DN4743K%DJQ(6@)"=[/T,L7G6\>(-246<WL\/\L0R2DL
MK0C*7YNIEO]FZ@;E;\FPWOSNS>9N+9;9L^6T+R=VD[M=/[]@E40E38*.[8VP
M_!&8EE='J)NB4HTA(56GL:PD[XCSI/'$/BW6Z.4KRBM_R9T%!%^KFI8<H,-;
M!BG62 ;,00,'G"4>L\/' RYY>->,=32:Y>=V'+91*6@]N>]^0P$6DID3KQI<
M9,]F%*U''?4CIFJ"D8)\4;C%O;X_-@A1SK-NSVU;0VX]M.@:*1KQ%=3T4$N9
M*T>B[#;XQW"/WM,+*]ZDDQU&?0_]X:ZKJ;@S"EPDWMG8[,=ICCW,V_I_L/>>
M44UU[;IP[ HB#U*D1Z5)$:0C57J7'J3WWD0)':*H(+WWWDGH-70$I(/T&D*D
MB?0:(!*2+SS[W6><L_?9^SOC&^=\^_UQ_F0,YF*5>9?KOJZYYIH3\>,$8CRS
MRA:;="=O<4"QL:;]5I1TD<J@?_7'PII^-?M[[!1VR,EZSIDH#2-U[8E)S4F=
M<2V=3D5%Q9L"=0D)5>7B6O*O<YFB1,9N*HT#]/2N.GAM5_BU!\69FRR:IW\D
MEL?X3'*D8.E"4BWSMK7E%A]EHU=4*?6;;JU;MJ)%4<UI>J1/R2E5G"+70M$*
M>^55*FO@/,X9[JC?W,7GJ)KLBC]VSAIU0DZ_2L\ 7:I-[Q"YVI6L,07[%/-A
M.U_D>/L?1Z3$V7R5;+I^CSDVO2?<&OV3?0;>0=RQB[XD5+[03^L;N!W^K"FI
M;U+<):T:(#!VRX^8I;K]H8T[]0*L67@'US]OXF<@2)>2,LFG;\<6BE2R"?,^
M"'X)$(IER#/7FJ-:IG1MP(I"<!H2\G!1U/+K[TB1+16W?6&W-?Z+;<]U+4%E
MWJ#F4H:HHJ,7LS\+<O)#U+P."XZF^H..Q20+!25<Y.^ DG?;RV=RD7C =/K[
M$CP@8];87"A3@(*::W^@(_)B*YU&'5 <E>:RF=(Y"^JA_52@X+0.C;W^15=1
ME^CZ$51=YTA"0)[4R/M"=;+-$8P-$6H'<AYYU9P]#Q I&=A]G5Y)+13#R?70
M[EWC'%NF:^%GE&N<3!G]-?H)*$D)I=[+/O7'V\YF#KY>Y:"+/AQJX L>\+WS
M<!L/\+ZLW54ZEYK>GH2$7YIFNB@3W :&[1\[;C[#,?O';4,2+\F;W-/)W4]9
M(4Q-+-]6.2R":N+==X_IIYO"#!_=LNM=IRJ41*NYD2X.</P@ I4%3LF!(]F*
M%G4DB*0&^%>#'U7!><S]^W?$=Q\<+IUG3J8B_,P8#$Q3#1?4BEQ92H=<Z6.X
MC@I=K,'1)$S*MN;H^+]Z<L$G(Z_'9V/T)9QS7IGK?7@<=/?IST_GDH0<EDOV
MQP.X@9\E(INRO5VSHR[XU$ZF:]8<MUX(&CQ/)Y%#/[".,X2)"X)O41H-KM6F
M0E%&#T?>*0L_4,PVG"!5\*H0K2QOAKATUXG"K5P"/C;DQ!91!Y0&?R(E'\0*
M3-[5,O19ZM:MX>]'+5CM%<R6G[2?5?S3##O^^W'(,*D[[?QG9P/(XU;/T;X?
M_=WHHA5$^FOQO??LJ4LTY6F)%-H@Z=>/E0\2:.ZMNXG'MH<RO=EIKG<$4%9T
M>I\,!GF#[;SQ@+7XH^ZJ=[J<*"#;Z1<0:Y@'V6CTB*OI!#2*E6G@9SB_^I<P
M]KL\YJSU.QI3T2[>W]XR&,E[H_T(Y!3'@;;[+EG]J>Q/>UR#$ENY\X]?B_-0
M[6*FY'Y56CDT^)U";"^LNC?T/F]OK$S08.&",K--2C5TZZ<.3 ,/^'('LI@/
M62=<:)T',>:#,]%^7:FSRLH)_'2.&A.)4.?R>+/HI8H.>,[ )5<E%WY/[M9\
M.'_UGUI^*EN6E"3F)+KHUV#5CH,<DI&4@FU4)$+H+H>1VP8\V=S5.5.EUEN[
MUD%S%6IO]98B-TZ)W^?AYT9S*&NB^9O2L?M9Z8'EB&7/'@3#^T.IU:6YA1?:
MBE]-"^=IX-"\2":5YK9QZ=LJ[:WG R#?K86F#=NI6;[ /*Z NMX"]%OV\8PS
M4_@,3#TB?S-[HY016.%@FDT3O[LH"[*J5NRC-D4NU*&;>MBI8^7^TK7EM.'=
M)*:.CJ;ZH*5!@0?H5ZKCN,LJ,:B]B';4^>N4#&?^ <5VL4\6+OX773NE#"S,
M-.(3XKEZGQ2<#DY4;E#2SI.@;X%<R9 SJ!!9TJ/$!3^(D__]3<>(ASIUB#HW
MDOE&)W-=$JV8\N%9'24;ZTMM'9T)'6UDJ'G"5J1E VW,=+21*8,!:<,?N/0#
MXM5]F5V7-61X@Z]BB>>&>;VM_F/$_JV91F<%ZRD[D&Y%QCK[[_QR?A"+W+88
M!JW"'*/T1LS,-W1;=RL8LBR-.GN&PICB 1C54RPC)%DWOG3M'(T'\!'G=QR2
MHHMQF_9M5=Z$(CL/8:.E=W/S/]P+1"UI<B&Z&>K%2*NJ*5+_8BGYQ-;![S$U
MC?[05G LJQI;7N1YCZ"87$J@C_E"W^9X+%BCZ]WJD"^GV?  "9?4#T-8G?F6
MB9K,VZOSR*9/>9VS7S17LCTTUY@J"J>DW2AZTY) 1-(\&C3BUR7:[HT2" GU
M_OHC/,#U^!R#!R2:X0%^ 4-[-5C%2U,3%Q'P:ZD?HT#E) QBO+'LLY2[=-RF
M9&W?3.>:?7VW0:N7\3O6 AOP5$375N>7O;OB%Y[ SVC0ZLQTK#P%F?Q-,L7[
M?_7&RMY78I)3^D8$RP%<+7] =>/C%5BJ $?3<0/$%5*'UIXAN&.Z;L28.[8Y
M_^#W,H3+[.+Q?B0><&YGC0><N<7]_68[Y$'(?ER;Z@P2.8Z,G@VH.=$U G(V
MU CZB%]:1$G]W/T:";,<[N'ZS,RWLO95]PX75?\0RZJ=CJ:]H^CAJ.&S'6?7
M1YZ>"GV;EY,+Q\O-KJZ3*B_A_@-O4K8X3+KUE&5-&A_W_FB&%L%R"@IM^;Y%
M48DD%>0I]( RB"8E^(^V ]OA<WY2I:=48]M+';W:RZ>FH]^LJOQ<@V);875U
M6E\4^=[9);E:)]FR_(I=TK?ULGT66JEQL!G2X"M6XH>X036_]Z!Y(?-+<%'J
MEKT#G)6=TS3)@")?75%K$YJ?&I/()RW@JAL+ZUW"WJ,717..T4U#ALZ6*U7M
M'.!2IAY4([U[M+3Y)E$CMK\JE] "\0%R=>\VG/@T%)]"+'*?Z60R&U_,O_/_
M,P;P<&_[_WTJL2&A.'=]ZMC3ZCAJPP..DG?E"'&N/C F6'453<</EL3H;.T.
M\ "V!A"_@VMF,?P]=:L:<J#]J:^_Y[LHFIQB7Z4J$K5R2@%8,$7*][MC%=HC
M^[;RC&;]X%VVV?S.0SK,\YVE=%2CZ<R^"QY ZK*769]8..IR"?W:HQS9U6,F
MMRT@F'BLI\QBJI=;<ETN,J_X:S,TU4[;BL(!;&Y5_KE8/WXWJW(&"NE7I8R&
M8IX@YGTVK9)9PC=]'-S1KY5Y676$P_E_&VV2L"&^"SI,4?!!B?9HU+!WU/MF
M9K(F/38,";2#S=CDCJO_T5[4/&KJ&0)%7G]QI\K]?!$6"F-_3X<04]<PT_?1
M8R&?Z#0S>#VRHDVB-9U;5JC6J"GJPN>[T++@FK$%@V3\&$3XI?\LPBWZA#EZ
M#:-G?F^/#-7!,JXQ@PV<D0\>YC(Y!4^R2G&"3&YUVX,X/4#Z3\^;2P^V*]?Z
M&FMI]H-:^*(Y."((T'+Z -FEH;O+%A>A3[M^2*5UH:6KKRN7P__E,/'FM5P)
MGI[9^! ]NXG#2<_]XZ&E>L11!DU#A]LI-L4X4"FT=0+-*-3!$!1[<[#,_R\K
M^VV+L8*<+T2\NK.[,UU@K:1M1RF'YO<%K+BMI9I=9S 5L,YWP]+S-1.=$5:5
M(1R%D 6V.N1 #UO-W._3T/JFY&7W,!75:RX8))TR^\T)+,]"3;,\LT87C.ZX
M634D]2P@WMOLJLE,<;,Y[XJS""WV380-%)2D$&AP#XG =<-0F\03A>8"+\\6
M7C:]2M-M?=2_&XU)O1J-R6?" X@ 2 ,.R8YS1,U3PT\ABV)]55YZ[TN!?T'G
MI]XLJ+Q:65 +YMIU#5+_1NJTN%!U/ZOUTFBTFR2VX<_^BE=?9'G=:I&Q@(1B
M#3_07:DD5$^OV=YBT)JS[59"?4" C;KL7]^I$M*S*QM2IK(J;HGR,]^^]>;Z
MW<=!W'>E/NVUN96KXCB<=TC-(&*I0JZS']F%3F_  Y6TEG];$4$U;KBXS#[5
M4?B+HTRW$ZOT_.W7:TTW+W1[H1>B]OXFSA^/V0@HMVZ&X_3R@>SS)IQFBD37
M>2PO3PM=;8[F_N9D(9OU?;@J\- PLGO&&^JDS(4'N"FJIZ2))*W!GL7YT-1]
M,-Z<,9)Q\(1PPS*=%7>C*F=*(?^.HW<0.'JZ*5LY5*)H\T?=$LZY[7VUI*1_
MU_":KZ)7Q@.KJM-"TPU4NJRSLA#[ =AO@2-,[8M4VO78<J'EO#2'I03)PJ@\
MS<-R@9/E1/E%_DF-3].M$&;7S*V ZL/F#KAGKQU#LYA8]?O$\ZQO95%\M19,
MB'B1_&\<_;##3^1])OQ?B#6GR7P+HK)NDZ@I"VSUBS8'W;A>=NWF7]*/;@([
M3V?U?\?M9Z]W'X14P_GW228/4;;*66D-QI$F"K=+66HM2K)RA^-4]12#*W+R
M2GV,D]X+BFU;&E0HLR[W'V\;2O_^@>[30\,U=AL]0T [+I550E,/!;I)Z]^.
M6:SXF 6G61!Q:HC-.28I^-!=J 5,I:';DY?0_Z5?T/_'XI^>9ST<#[!F..S
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M;*OJ]-YH!<&M$ZD$L\N6T=4-G![D<O>,I\'F//I/:W/SVZUL2.:CR^3]/CP
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M$K/1=&7G1T^'=-_F)Y/.[-7[DEO\I#"N&KK*5Q_AG% M4-L<J_-\6O4/.""
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M$S3H@PQN&!D4BD[?88P"_@-L_@O ,MSKOR U#O]W(71LRT6ED+##KEI%WTX
M-&BI15'XKQ V^!F5J'BB0!K)^(D2:91]V@A]"4@IXT[D]#>+*H?91C1(+!GS
MQ/_9J%TR?Z1$6VV)O.J/"RL7-YA/"?7+.]^-.,,'K4&"U3?D?>M#T0%</U-#
M=,=$Q5 ,[318]_-:=1U<<#.*)FA$?[*>6\?;NBCYK:VCI>V,A7^BU9"X[D[G
MO: ;%/>UWO0:R/KE\[I*O"'RL&\C]#D;::3A[);9EK1@-.JV# ?-CFH-2:<B
M,%@/ T/1$MM+K1$-OM9W/&/AE3>O<[V2O#0$[\%*_?$ YM'/%]TB\QGJ4@[H
M*3[= 3W).U9N]K1?ABO+8UB=Z%)+@KF5[E&J6>A_G@#4YMDRZ+_ZO81]>\Y_
MF+Y2.AJSQ=U<D(<4?*NLJM\.)S%.3Q8X?$VA?!\\+3_"()ZK,T#"(4WQ158I
MH@OW^X=1M!'1'855I"]*WBBGG=S?ZKPC>V0O*F);:D_2RWUY\EIJ!0ZS1S+R
MJT YOX3,NY;&^3/O@GUL/;,CU@@4)UW[TE7"GLC#,8#061F<+![PW"P4R%(+
M3J_U0V,1?GYK!MDL;;YGK)Z98)WV&)NRR(?. 2[21'?2\H(-RGM;W/>VGYC6
MZ3(2="Q0*M&L&P^(0D33M1X8*;Z<HQLB%B5 )X^C[=/%?44![AI%+75Y#67I
M4)42$[*\C-6(L2H2BJ^S;"Y/7.LH'@3["W>B(L6\UM@QJI_FP"E[F_'LC;6)
M8HG"P;9%-$[")@RVDNVYA\>S0Z_*)5@\-G/9)YB;Z]Q+(TVWRR:R3%RS F@8
MUNL\S\Q=2&:KX)Y2Y^V32Q=N+^N\)#GW-G(NRCS7"I/"&K)'5;D$7V"@18GB
ML>KTT "MYL;[ B2BJ%=GA.P):[MWZ 9L<C<AKR+D4QU=>RTP9E$3XLLOEK['
MVL-</=E>UJOX^-![PN%6GC6H;>[A-3K;OZ,Z@H<0U6$-0^?JA]&58K7"1YQV
MZ.R#P+5%GTA4]O ^*0%4^WU@9VOQ0TG)YP$@0W]=B!>+VH:*)DP>-E9F_HSJ
M"I8*1=TQUP[.5CL&53+A>DN(![4![>-![=FNW[QF5A&Z)]W/QNMER[F!/-%%
M/D6\<K3ZH84<86DG)3>N,GJ%<PQ5XPF:WH[,APLQ]G5I[;;EUU4+>$NT?<HA
M62DJS'D5VULXO_;>PM/+,TZ!9<W6TU;PY7; C8['DBQ8'XRR!IS] E5>XH4Z
M4W#$-.SJV!ZE.Q8EG^?UUI.5FS*V '4/U%>^UO'PRQF0G3CI6=A8MEYI6IUM
MUZ8%!L7J!I21,SW8ELG6Y?X[2Z%?K"T2,8N5JJKD_(JOZU-58 NSP7\M/%6$
MVH2]B%6@8I8S(3>%3USM4_3/-''S_S;\KS:X>RG%KL7.B*R"?)@][\)*N)79
M/@#6KH9J\B*;(2G ;VW1;<]\4;[8Q?/0V@MR=HE;W/P6KMEQ?OQNOV L@S^F
MZJH[PTM'9$T$$@65QKY#K_&IW+<G#I(@<%*'@Z9A[M7>25O/4ZM'6=]!I1*,
M^L0QX>SJSV1T4XH_KH6]HO[+H[KZ)J$*;4[^DYCC_S;\[VTX(L7YHKC$]#=(
MCT$8FR.O(G(ILQFSNWQBP'(A+XO=+5!AB*NE;_8['7-[OI$WQB7.E98VI5OV
M-!IQ\J6*2JUO538)%YK2P;AAVSNQQ^?"A_GKP50JUW00;69!@_OTKJ+5G*M]
MKL:OG%TW>C /:=_VT67G]T]^.CUT?#/]W;[L#H%>16T0?N+I^OR<?[0@T!?P
M*F'/N3F$/B5-,EL3/"HPWGEU,^$Z6,/(B(MBK/RCL ^@ZFK[5;F3C7[&+QAR
M./,2$-C24M(RZ2"OQ<+<4EPLQD8R/[>>],A[B;6B"S2KPQ7*[%JH!K]?=K>1
MB=!UF7W"[3Y&K6. AZNK68PDW4?D[;Y6>6\IM14IA=XW^2G>F:%X)_"#23ZJ
M6-A$]D:MDLP'^KCOSS:B"::[9V3GL1NY'=2[%YG>>" &=_[E,%-)UMCPPS1;
M0EJ?_)*EJ+0PSM!G52I8F1JX3<C18A3AK"<M-^I$)Z%5VGM1DSL2D3/IMK<2
M-Q9-/K:X7PA]N4D,'9I><V2'3CT]^C[P;>V*]Q7HO_9//4<=L7X\Z@"V2WM$
M^UJN4)*PJA:+F=V8G]IBMSY4,71F"? P5^3)W5M*/DEGO$IGX?\9B=V$\Z9^
M=]FQ\7232NS]>3 WZ%4Z8'-,.6[%[K 2C5:5D!N.E:?%&61<PUP9]4YSR!H>
MT)L=HR<6')XK*7MBYS7C0OLG K13L,6X\,U3M[$9)I-GZ!SA[?S%:5Q7SD2V
M[X6B]JO'QE=$]?T_6VP?B^,!7SX[I[;P8(;\I;?3G#^_28O$ PY6<X34:)1_
M"BJK7936BPE]Y&!DL7:@HLIXJ;GUAO@Z#X1P'5(['!DY:L[/IJ'OF&1;!,[X
M?)+I8\))D=.MO)JOH>P9H,D]CM!-(K42N?%.IMY78 7SJT@.@\MCT3@7U$%&
M1U8+\:K;\>T=B4V$&37<Q?1Z /(#TN_X^2*=9ZFCG:-V6,#J[,OF/P['%()&
M 1-YRKS5VI,!D]W/&3Q%7\+8.9\07+DY*FNB&)^7/V"U95&6TZ\].:LY/=D8
M]]*B5)I9F^D!#0/-&V#_XZOU634[SM6+CUYA2K%0,=0:Q!R;EUW,T;#O#&9=
MF$=8OJY"@<4:K,N[?H$:M/0I7W/26D;^M-2:&O#4IN8IUF\^,X)<N:]MPK_Q
MO#!FU^R$7/KH_>JTF]=E$PP/D/7('&_8\M+_JO24#^(5SSP/H4[X/'WJ.>6Q
MA+TZK>LJZGY=X@'$WGA 3<6Y(H'9H3NDS@JNO#!QY]\ZZ!82L8AT/T24M #;
MQ/S>:;L\J-F*S$Y'B2'<9[+E!6]?I\JRU6.$VL8\BZ).VA<HBWW,O47:?&8F
M$GEX)(5IAG05XU1.2=6QY@._)$6Q@/GY-%KCO0=P?NXY1$J&A)5>M[I!^Y%(
M3UR+UUY&#TV6?&<WU_EY*I-2;M"SXL&AO;;I_)V.<SG%GBV71%G5N6RAEGWA
MN8[N1>O:=!XKE]W*+Q=0\@GS'GUNR\;)'K8I23MCF,B+^,TSTZTBG KV-LX-
M<I#"@+@S2*#M3THO("LW6\)8E@S\76[9""T8'(-UW_SAX![:_A/Q19Z"S\:@
M!,K.=R)8*Q(+NEG9.Z6J?G]I&^G&C\V%I"F"\  AJ5 1TA@Q3H;;0SM<E%YG
M/*U_4M9FV800BQY:(1YA9FJ)U!$%+(Z']:2T=0E[EHF@(J*ODTB_4C6"/<??
M[I*FH,A\9<6B%I"31_FK(9I[SKT*7 I,KJ<AWBZ1'\WT]%\2)=1-I3H7LLBA
M'WR_%<EDQ_R!:H/@#]D&U**?G^?*,_CMZ5$+N- =%IIDAG0$1HE?X'U>7&$N
MM,CG2:+L=>X*^4Y& B;X7'UG\P%RT#1Z48C"F8[B 7Q2!$>Z[A\"<0.*JT <
MYZPJ'K O''GU6%^N?DP6S40DJ9QQW_.W&!!'%RM[L[L9$0K^$/T];CQ@P5N]
M1Y14JH*>Y;4A5T(I3E5G<)+L@@\/Z!.&-Y\IF :WA[#+*\?U@K2MW:=/#J;'
M9L>F6(SYY35S\Y/8K;CB%+:D0:#'07>9"7&W9?;OUB &GNMZ73;F;PCCC(1Q
M..[VJ^?QQ0,^?\8#$!E"R3@N'L)?>R:/""<V?"(<'"-9A'!(OL!Z?N0(?(6-
M^NT:7A2;H[0E%@T_/7N33UMY+&TF')NK;=TX<0T=>+4_4BZGM>>#KIUA"KKB
M"N'VL1V26EV9B;WGL4WV<).;GV&-9--CZEJO-V1+W9_\_'1R57!4\ ""O>PO
M""GB1T@1\W-!/"!TNP9REO6)<-1(&@]@1UV DX\F\8 >P+D;'M"^[7J567C
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M6G616DHA'[=D?+\5O_VK)4%"9;#:/U<;/1(:\0>6;^$!O_2,CC0>S5/O)Z,
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M2DX#C\S&;K>!%;"$*2QQS_.?$RP3%'XAZLQ"%7;ON?\$#>2^3K>%!Z@^GKU
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MY"2:-V== &B[] CP+R#P-#VF .8RZ WP,AS]<PQ&*'UEB-W<G=6F06-P%$0
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M4<@6T/=)XC4U=DNL6A@&FS9Q/K6&IAN$SS-?4F!"'\^]504>LL6C\'%+<D6
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MPE="HV-8@C.-RH(*0YBCX..C\S52+A21'<VB* V%G<6Y^^MGX3S$L0D3 #S
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MI[1_+&!CU4W/*X1WWX?<O"%*#..4P[!^-$8:S:G]NL$X9%E>]G#S 8@./=I
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MEMPIERJKI3I^#&V&ZHB$A]H$)P=_#+]ODS\K?1(;>BU:I9-4<D_;82\"<Y4
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MS[.BQO'Z,0\\0PTF'#P#QDT2 $-0%/C$C_0R'3;;#4Y</EDF 'K33KB+T 3
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MZ=XJ4S__V_9N41[^]B;#VY;0W"AE1K>FO/Y_ ;WZ5[:)?T?9G3[@HO 4[@3
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MRUU9=0=6^'-&/-+^S!ZK<*VN:DG#Q5QM;O+G3J5-DDY%X99%F3D.PQ\B- D
MRI8?O;RVL.1@Y>]E$Z_B9=ALQ:R851TO7LKIBAJXL874_?.CDL)\*@[/A6)=
M]T='M<3;+@@+\3T)[SW0>GXA*>(7X,^:,1OC#*8G=\GDO4::1ML%=&A71JTZ
M%&!S.;L:TTS7UM](W[C\"_O-R^U-W,JF_5;C%#U9I(;#5SZ^:X+<6KJ"F+6<
MFB7;P._A5Y9?I@>#E?+F$>;CN8!<956O==^_4G6:_PY NN_W6FK,A#/S-AD[
M\,MEG)KERN7,PE#RH?/I%/>*>J.U76G8^##HTA%2UA5Q1-X>MEHEM<Q2 T,A
M/T6\JLF(@!O>XNO?TIA.<@VYH581TTT[X+PY\.M@\IDXWU88O:!XN;B O/P%
M!6Y[Z4N1TFC'@G&2DWK[W(9.G3H5^?'>75Y%L]< AC^5&$.=C'$V,RFU,I']
M*&N35P47.S0KQKIRX$?Y5V1H6<,TZBE:SCMO9?]8:[ZRLK-AG#O)Z'T+#&A]
M/LG,%%3A=E18Z!TBNE5:J82*#5(G7W3JK^ZF'/[P=$4!;5ST5YCJ?Q)@=//R
MW??2YV_*;H.)" WDQS&R#!T$@=U,0_(NU&<)TW;(:'0M[PNSCY[A7!L4,H_6
MKTKS()/7ND_^-&#D..9K&CL0W2\F+Q.<D_;<[J.+OK!&"*/"7GO(RP <3=C,
MKT^TM\U,3[0XY>FM-OARR^[+DDVT:,RWW#<(;I2R3=KL7<KS[N9\\MY0Z81:
MRWFSW&[XO69VX+_,:?[_ I"N7.I%:>J$JBL2 B-QN"G4\=@]X9!787W09+][
M>0UOX<.L8+CZUM_V,VI,FU@=@QZY:"YYD'&DG#E7P"'/%*TU\C(WE>L<E)??
MQ)*/]0*;S:T0;%-3?OJ!DPA0UQ[2^/[!=$L;HTT$7,JT?#0N^M/AJ,2UC"K_
M(6&%[;X0+"G,&+BR>/^K'&#_KP!7/0@ %7O'%D7VKGE9,I/ 3,F@*XJ:;Q[O
MI;)ST^#8Y.Z^*<Q-<[\NK\UC'/SM.**> /A^+\SC-MMF$YM8!6617,I$[N3T
M)^$Z N #DX1+,3[-8WQ4B"E,Y\=J6,AX",-QH1/*\MD'#F^^G.(<(@&DR9)_
M"0/M6V>%,R:/HY^U'KZI7-']_[>7.05.@5/@%#@%3H%3X!0X!4Z!4^ 4. 7^
MBL#S%$P@;G5==;%N5Z),"G1T-(HR'']]6"QC-E\AX5&T6G:8%)3B9R5P?$<G
M)X(3%)IA$5S ?JV[N%KPGNY]QI^9WB6NB@1 +&I_\'@8AT++NSH8?UQKVE^'
M]D7\L$<VU]E*@.G?P]NT;Q_EE>1D*S'_JMOH?A)5+6[&'V<*$+1^H'P!;;RV
MX?M_B#@6!^OEQ%-/^A][[\54-/'A](^1-=BNBJP:.>771_*V1V38M#/!,6\<
M,.?%["UI&$-RDG-RKJN8CJBKZJH;O30HOS)VQRI788V3^/ 9<!3S?D0_ ?"X
M*6D+THJ4O!&X\GU;V?TB:N(P]MT- D $D]7U8!8N[*4MQRV@-YEW7?S.(TIE
MS8+ 6_SW)<?K&]/^&Z?; $4 2/0?J^GB'CG9'43H@<NC\#U.O\W7>XYP>#$\
MA  8)-_9_I7$/TL V!RAIAL'T1#0/@14^TEU9;=FC?BX49@/ &."[P>VJ$:
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MJ$(X:VHXN%6>03]^RS"G;%F*'-)IT53BS-/S&2)J_.'R2DE*@PL7KN1W B;
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M#VR[^UDQN 3J9:F4![W/#&<@*@45*@"\4^BTE#" K/G0BPO?Z/'H-DXHZ!J
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M$W?/SYH$C/Z5XFH?1-U0W$T5MRB3@QDO9=[3R3WHV%2PRVR#-6M(?]=WGCA
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M_</)>J)ZQ748JO^$K]6)T#HG,73W_C_WA"5=I7\_P)JU6QG0XTC3$+P'2MI
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M)KQPL%_]*KW=RZ;D;*8-D(9[J%^\5!A"Q\2'4DG4CVDS,7)J6!D>@O!Y)BC
MS^9D=JW?2.=V6IR^HS5T_4</1"EH!.0N\>KA<15\"H#**LB,!>Z09$&B"R*
M9!+,(?2[L5R ;BY3!%<AH:B.IMG(I7&R-@N#-25B92-MEZ%2\<(S425E2U'(
MZP&UC*]9^<6/#3)U K@Y3%4T-2^Y78L\<?>,J54T/5:2J>QN.ZCBNI E<.LF
M>>S>#>6Q+K_$E8:?4XD//[2J1$3=_K):],4(WUJ@JL^?>!O^J7,NWR8^.46M
M]7?7R41;8(!$0'.#P>=\4,6XQ JX--SA%29M;5?JNR(WYS&E76]PV'A.=M3"
MFG]RB/C,JIEIR+V2@PFA7E*H+3STHZRH+@O]%J!X:JQ4]MZ=K*+8W  >2GVK
ML\@3J6K6JMV&T[6$!.5@1JT?55?E ]N67"J2Y>-$#@(OP8**I!4.&#V*"O6,
MM$X 5+X)]8M?L@6Y,+<;SC"?S\VU!Y%)N*0X?8EB:[G>YJ%>%Y&#_/Z/RE<+
M8V6S$2 P5[13WY@CY7[00&GHGK2,JCQSP1H"O.-Z6G7U3JBT^V)FM4+2JMGC
M4['W7[?8I#_MDVK+JZZ7S*,GM1\X4Y_A.JOG>G<'B/UE 4K[RCU-<T(23WT8
MTSO6Q<LUW12K771/J0BF=5E=E\G+CRGXQO+^LC&C@G5P9(* _=\P7F#-/N-F
M8!F=XEE8%<J)#53RF&Y4U>%2.PT47G-<W_!RW4]=,H,-7B/;H*S.>*,'WS/<
M^F3/REY@V55&_CK+;4G#$4,1?>TK;!Z.P,H9Y=! 9Z-(X(P62B I:N=R0;4,
MK+(Z4?=O@,;?G9RL6"Z5SVLZTW).UK9Z/;QAU<+0^KL=+?<ZM-F5_(IRKZGX
MEKI#(3,V^,-#Y3H:J%E@%7R\2MBB6Y@7_2VRKPE^OC10B_X&ZOB07L0"%\/-
M]^] 7E'^4FTS6+"2GGXR\?XN8TK1\%B\=QV[W33NTDC-LY*U-DN./HX[@8+:
M@0DQ]A<+6YEZ[RA(AM 941=GU!P-I+F)C>FD(+L]$,UYRY^F6XO7?#;1(4X#
M!B^"+V"3\\%<%V0%8A(8K=]U9+9>)G8G2W\_!2S]3COQ/ :CQ$+94;[I82,N
MF)B=O\:R&-V?ILO[NN2I4$[N3\]<N1.F;*H53F6/A04O>SL82\VDR/-$=K/&
M*Z]-(8 ?/O^2!JIV\[,$YCHZB2+_VOJW8))Z28D&0BR2Y($M**V%$(+&Z"1_
M(/&_OQLZB*<^RV#P@9,"**HK-%!D Z2BS/OI74Y^A#:.<'WV6U8[PJ()ILFY
ML)=<FR"P4%!<7/2F[;*++DMD EOD6<L(0(N0/@!4*E-9QHDE MQSLG[GV+K*
MA2QG[\7>NQ9)T*T.SLYM[6N,QE^!ZGY)B4Q/$G@G*?_#1KT*YL'DX&!K_0]?
M.%V,+V].D_'^W(#@"QQOV*GVNO!*K+.)!N+'AI7^VCK'P^% =/-M+;I[;5ER
MB]?\7GI!>OV=2EV>W$<6VA@M1 1 ES_@@<"\L#($Z=(FQ5D>VK8Q8[U0.OLF
M!INHS_755K!F_NWC1L,JR3$16>YSL>[?'3@P\LN._+DVY\VA*DHB87W:=^G
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M]K?5[Z@^?FNDJG8"QO8 ! +]TP3@JEI@+969(D "UPM6$]J0(7AV\I*__HS
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MNB'F@P<$Z/HYR0%#W0L*I7*FT1WS!NF"$?FKPBY#%Q4[PDNTO M?VNX4&P7
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MJV=^F[RM>26>#<M@]C3HAFLW/9\3MQT#?FO>.<N_>SREM#;AZZI;.H:7D0O
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MHGZ$]#-LXS</%;18*LFHK2?+Y%Y9'']L[YEP^YW* [IYX7L()&E44_L!2OT
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MI:BV]+2?U/\@((NO&Z#'<Y[DK6]^IPI3SA]S'RSNCZ%:E5N): ! ?'<J[]%
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M7*G(LG(S 9/7Z;X]1BIB<3S=ZEKQ5U3BOR]L8H+]@_^',4+OZZRI'E01<U[
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MFY+:\;8M<W.W^^OEHU5-)E7AR_OJUU+TQATD3D.9V7R@'PUI3)UQ[QPW!B!
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M3FN*"&-(T?$I-%O-?)*\Y,\$1 HOR,9H/^.7J+83&_N)^\RL=O!PLHN'"\*
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M\MB(8GPY0SC[8IUC^M7BQ.H8S%)1Y,/76L=5A?D '71A6C %MGYL#->IX7^
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MF<Q G!A0KJHSM]DJ_KMGWN?S7DIJ0>XW%TXCKX]J)J:F$051UQC@Y^""B>6
MU_BAII6'I,FS^V"+<3TTGRSP81WZ?LJ-W5/HT/+9RP-CIJK='E38[878[#,?
MQFH9EA1*?4V[]?'F'_&K-K$:>Z?!D1U&5_SS%+J*Z9"T88GY?#Q#QOPTMR<
MR4JRT/N>PW-3\$K/(7+;*.5'L,O'XKB?Q1ZP*XZ\6LJ/3PK.1Z@J>86)^(P
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M)$TG!NN-P\OXZ1!MKMXRY'OU<L154M5 O1R[I[W*$+%J::_K3%R7O>YKWC[
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MU?9CD6CQKM;A6H+U_1S=:3_L-0MUU%-F]NSLQ(R8G)/&KSJW-@$K$.W_OZW
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MTL9\?E2.IZ?#&[P:Q91U.0+$%9(\G^ZR[BP6,@R2A5UKWL*,!)<R(VU2,?^
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M0]A14_Y9MI_ID%DQ=(?<TRT%QFXT"]&_J8CC456E3P]YRG_$W=KSZI-"_:@
MHOYPRYG:,(Q0MM7)W*<O D?J&J8Q:RHE*XVA-;_K\Q2V;?=-'CN;26=.I/%@
M#Z;X!UO[OK\ZIZJASGI31+ET._MQI+>7W0VTY]9;V/\P&?[O!_]_>T ?^U]0
M2P,$%     @ .HN:6/0)!,/@!@( ?'P#  X   !T:6UA9V5?,# S+FIP9^Q]
M!U04W99ND40Q((BB(C0*B&1)(K%!% 1#DQ$06LE!0,FY%!0$)4=!:$1R5#((
MM$K..2?).4,W38=Z[9UY$^^;=?^Y,_<Z\SQKT<WZNE;7/E_ML_>W3YU3#0U!
M/X"3JDHJ2@ %)04%/P4_ $!K +^:I;V3O:.E_5-V4<&KP/4;*O>HUH"?[>3/
M(P *@.+_OD/KP"D%4WMC,\#T^4^$!J!4N0F- B_)A_R91DE!2?FGOW_=J,CM
M3R__HOWCX524__:#?VC4Y/:/;]3_\/IO&_058#A,F71HC8J" :!DH*!BH(#J
M*%+(5AZBI*( _JG1'CY$0WV$BHZ2 CA*A@_]//,_?4C^B(J6\C#%$8#NZ$F
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M 8M'0,"M!A@$9%7CB=8N]M@QU$XTN0N#Z'QR(5N'VJ J &N_>RU 0!($6$'
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MK;=U>"[<4D8*R+]VY_*]^/3BNCEFTGGND6D\G/$B*?B(X'.3Z:^FTS1Z\MQ
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M.?6+#Y(;UZT;C?OCA@.UWW (+*2%04!,JP ?+O/SS!C*2KU[ Y/:\SU/H)+
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M2W!?6IE20>QOR-/<DKW%=7.W1.W>/>U[8L5[8OT,8B+*G/S:W=W/39T>*?(
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M!P'#=^&[,%5RX"/+C.W@9Q!PW10"DCV.NF*5776UZB\0/_82/PYTM:KQ7$H
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M?[^$ZQ;A#<D:N4A;*=&I1NYIZ(8%5K#LG,K/AV:1T\17GX7]8!H!NX)BTOK
MOI-WQQOOULG[.6^63@7PXL6)YJ-3-0>=]/7'G+SEJJ4,(Z>W>M#'W4[(*GU9
M* <K[&9+#KP]#I^O,A3/SGFZ.?+>JF[W"%E_DOWIARBX:@X!.YI#?B3:21P(
M 45(O/MB!M&9[&N#I!P(&&3[.9=/9OAY.P1\)L?[]I\/^'J!)2$A8'60-.&!
M/5B!@-8"HBXY%<AZDMC(*82"?)B)! 3$)Y$S"-4&@>RHPP7$JKV-O4$(B$4>
M%$# 0P\L019%HI(@-=A#@+@L_E^<?F5RA7R$('H/22K?0U1C1]!+M>6N&T]
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M<"/74/U'?-OXF'3:E_TVPY&Y>FMET3FO'I.X@ P3W:!XRU?RNND]42O:ZD>
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M5%AN.GUB#V$/8GO)EK%TOV%]K%3Y^* ;5VO?])4>-(_X+:^S3>PAYCRP".M
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MHF'&?]+V^&HS!$,'<@N$ MC'4$!\F]O2I>\=.Z(Z)[P+A!844B=AG677%2A
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MI/OV4=[WV4S]@2N_^ZT^;UH4DX?;&FN)#Y(O"7T%<?FT!!!-N'EBE_\1PLU
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M+SZ*SB42UDN'?3<Q4/VTK.K_$&0NHB= 2H23ZR]+'4&#+;YGY8%<N (CMGQ
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M&=.54!!-T$K1JZ)2*Q/^POC%;9'60H^=KA=B5*'794>QX9?R+D_+]UX'WE8
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M'K(&#F-,]3).'^(GG*U>G8\L\4N^$C9F]=+-CZ7BDNV9F5PALXEQ"V[/"E"
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M**P6CAAO_/]SX*!CVUJU3Q$4/-LPN%7E2C399><A.! ^6C1DN-$5?,5Y0*K
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M,"GC=U=M8_<Z;LOSSTIPXR6?7W,[*XRL-ODU</&$44C92E!,NC$SY''*!H5
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MW]9S?A30MG+[&SH\"QT[LD/3F=)]\"W&*?CV]=%*JRUX91P\(H,")(QO*%#
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M$19X _+')KG[)(@X &V/NR[:A!@XF>O$/R)SO2H,_DJ@_;LDT/X9NO*7X+]
MD!^"8-]"BA\%F5S;N1TAUP_HG*!5: "QM8![S;Q-,^S]'@78HP#QB\+ZQM[,
M$!,3(S2KIXV<^2/)\QX*:!CW:B\29[S,.+[@B:1AO9TLNT CSN$U9)]$+?C
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M@G4HJZI8T%M 0Q #,ET! #PI0J^;!Q,C)1[(!65_OH^EB9WB4/3X-(]M2],
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M@F4R"\IZY.;U>25$X,M@UE>"%^&>&'OCN4C/E4L5L3\*\M?%H@#GEQ7O5CZ
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M*V=/8DA5_A+=K;3,^VDRI"G;]F@1BB--%LXQ-MGE&:U*.*UQCS;HVXWSY=(
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M6&_W:V :OQIZ; T['I/K6NZG=I\ R<91T)05_<SP^NHZ2Y4JI_)$!D2W$Z<
M7D,!@Q6.N9@<@N^ZY\(082:PJS)PF^QEW<:AW<9*\YJCV:XC@5[#Z522DH<%
M7[?LUZQ"B# EN]E4/_6#'P^#GKOQ<#R"R+NFNM+4B>5/O# %U$DK\_7ZL&//
M6"[Q"+$*SYR;;>:6?LXV^&^34F,@*S+DB595SR@6P327XIH5;NF+_9?:B]G2
MZM]S*'Y'IE*N/Y@BX!R;,J%@M'+&RRM:, YRB>9\9V>Q_N)J+NCX>U@DTT&A
M_8X:\=+>WJ8LGU/U&;_M>-+ZG1_7_*_$]<HEVB=R8.^V-I<R^.I'=@KS\K,*
M%YNI*OG/QM59(A^;\"?V: FH55R^_YK+GG.<2635VNEG8*O><X^!*4Q*5"7.
M0?.L5]6QIDWP#$J@=""UH:TY>746A(YV@],9UU_R4<!2F7V=3RF:.J')4$H.
M\D7KRY&,!7ED- KHC7JS\DAD:V-FX_HB^GKO! 44Z0C1,C@EA1/.Y)6^,/E-
M;%?<7[*[YEG<^+873$Q@I#9UR ZQC$F0#9;[(E3O$?MA_N#H\\7YO(N5Z3W*
MVCBU'#Q\JP.R;B*\\ OEG$\M"3\7#.3UM>YQ* N'L7R]X_1ERM,EU@S,BCP:
M0@$)E[2(GP8X0<$0ESQ(@?M,#^G2LD*,96'-3B.VV5?8=,'>T6SZEEYW*"-$
M^BS7!NX5A;"HD.J?;#-W5JTJ!?=)9.CPM-35$A!UI<U5%5>/'WG[\JQM@FV&
M&_W5$<J\!I[6TH9O'(=*N%0C!I3>S!LN&?CY=#]*Y(2GO"'O9-XP9#G65IOJ
MH^90H2'8#,67^Y(F*:.C<Z+.9NAY\5IB@!PYH.F% E8)%Z%PZ(+X1H6SQ'H&
M'>*<Y=8@,9.'&04T*J,](Q4IGD9$-X)5?46 Y:*CN5I5VX"@-:!+6X)G!T.R
M,I4F8F45HY3\<CV>%/#.?)=[2K%D6%XX%F!B4[>]?E*NBSD >A!C]()S"O;-
M G'[^"QM@24$#X)1\HS6&T !/%IET<M4]3S!O0>+Y=N+>F+0L,31\'8S?A?!
M&N?1W/PF3[VGE@RVV&7C&)6,.X<&D3.LW_H*_5,C[F!$S4L6;=\_:PDG2PZE
MQF#ROR2LB]HC@KN-+** ;OU4%.#1[[.6CO:BI_4H('WT9D X@1--D=.A9])(
M[SV]MO2#LM\3-&'U(AQFVBEOEE=*]6C3YEK(XB9NK"VMQQ5.-:9EG1V\RKI"
MM67D#0.67/OJ0RF7WX'>]0ZKQA(E26R^8"FLZSG9?ZIG^I+66,8C\%3,UBH@
M:W<T_M9VBB:CX?*UCNEG%:HJUW1^IW$!_K%9S1 U&EW6= QZFT]3%PJ5;[+6
M>#/<Y_@73Y>Z+D_ZI>7"!JCY4 #:8@7[VBLTUFT>'9 Z5DV]FWK6)[&+B*(M
M7H$5(S*'Y2$F7^!ZC@U?O)T;2J],S6DI6!.?U([G*>,()_]D30]^IJ$?\DI]
M2RO@U^3(5T8O^\%"G:N@%-VI4FE<Y6=#/D31N(/BIID9SP]+B2;R)-N=.FK[
ML*8\$2?KGKGVCE>2*G_CDL<RXS+=A>@_(0,K312 5X[VR<X37!1 7&&! @XG
M*0Z]+TWA'!7G)V#_&QPGDVZZGRN_C6O%KIX[D^SM\Q[=N4GZUW--_A+\WR>8
ME$:2.:&1J%L'#T)(! U4'5VC&E?FP,%G!X&(A\Z$FVV\8+2_9GA.&2RNC4E7
M5)2/H( H>1OP[T9TO%^T;/TUE4$,5[WV3.PEC//=F;GYXX 8.JB;T<U#+UOV
M5&^W3]+7Z6R@Z[6X-WK0W<GS1UL2,!;%RUX4H$->)G2[ 58+^;<1KG*O6=6+
M\'GO!.:V>O*8G-A!Q>A>D!CIB6#H-'4EW_]B[RW#XNJZ+=%*2 (A$"1 $JQP
ME^ $JR2XNUN"2X#@3@4(+H5K<"O<W=W= H4$=PA.05%U^<YSGZ?MGK[]=9][
M^KVGW[_C1^U=<ZTUYAAKK[GF0(21^*SOM325=ESQ]X[3)X]Q%G$T)#G29*2H
M?9_]\!G[P7>,W$M(9L@]0D[$1/(E2.T!P5OIM)8=+[NX-'.Y I3ZYBD /NG#
M?8-FV%X8U@=KM."-5N;[K6_B0MJ,>Z7MXQ/6RLK*FLK"^GKGZNKJ\JSB\O)B
MI=PQTEQ$KJY&VLN_8D:D:6*DVZMIE;X#&)X!W@!>1L=HS6RFTY>(7,\UN7?8
M"G?7<BJ;N;1Y\M2=_6'.?:_W3,5+6.8Y*Y3EXDR2*;"B 7N\SKPN<L])IN@
MP9(5=$@1^3/4_/N^!).W6A388A_;V]M%HZZ<-K:T>-#$>I^VN*R\O-!C<#O!
M07LK0?MM;HRDD2P7!TUJ+-@UDB?D$Q3PZ ,@$^ .$"AN=)#%EQZDI[E\M7Q;
M_H^83I7;V+6>5BUJ+,"&G8]XT[7,D^OFUDLZ7WN SVW[$BQJ!< FZ9+K*U-+
MOSK=[VLL+CKF0G^!]GSW;FQSZY&C"^"I2L,_>/-DPVWU=>=N6RLD_<ZVC50Q
MTMFQ#L?$+0?,(](NJNK<N5SXTM2QCF"?NDJ_\;LWDZ IJG*$T\M6GI%$X*(@
MWZT9/8+F<J5_0;"XRM5GZ9<N\(5J@ZO+T;#*YZLKHHB<2)G0E.UITB];;FL1
M=L/2-"&D5B\&]D.U;*_.6-OHT\TP@O.2(RP =TR*OSC=7M;:V5[;5O;Q<!$#
MA,9W9@LNK\],X*;QAV2UP8>D!M.+=\_T(CEMYIL9ZO.(M->RV4HU"6E96"Y5
MYC'\<[]D:LGER<IN-'M&L+<NPJA]%]&HAT6SL$P_VE%)]Z5L;M><E8N^L!5O
ML523S5/)47V&3NY$:HUH^N6Y9>=H PY" 8CXS Y[PEWPKO(G\Q;(U/VPJ#0&
M1^48OM7$G>+V2>UVL8SYRA<6;AE]*OSRY&QNFI[[F/&%>FVC>^HMX<QF1L:C
M<^I"9M<V^83)7 )B33GC6[5LWROP=^<<9W%Q<7VQ2V?'T8<YQUU+R,.#7S,E
M33.BO;P<8NYJ),OQ,.7HD.>T:A0 S$??GP'0H("8O@*:4^$OUVVU_X1[_+?J
MKY=MB>@"'49XPE  [!)-Y%$ELC_]%PHPZ#&.M.*[U_7Q%]IZ<+W#D(N,\S\'
MVJMA*,#K._0M]L^=U75.S_R??[#<O\Z_*"ZPM#@E<*@DEV;1'-<42=2Q,OUV
MSD^3M!9IF3T<^:^>NWF&MG5LD)ID]B>[*_0M#77M:T0N' <4]22BNDDPI^EN
M8][0R&.GS)[*_]4'(3C6CUO3DD$-F:+J^?FQHC:/PHNPU"<1C\7Q);$LPGX@
M>D<T]2:=YEUM"E,Q<UX01V+F#$H>T>7&2 N;!$[7=%=U47Q7EGQUD]RR $D&
M'6("T#^A %4BX?_I-.9?QO$O@G;:[V->NX'7ZB,>Y'@>>HO39CN<21<%* "=
M]NUKKCZ0]WOP% H0YUQ8WI*T#_R7\:P%_3?VV+Z]"7BF"$%ZO$*6#D_4QX*7
M'N1]RH,0!2K$98R]0IJS:X#7.1_DG4MMV_2=-G)]]$$Q22+L/3S30'60>\J'
M;$$>@M/=MM#GE#%P7+D*7PS,@\6Y>Y3P;D)?E!IE+<U4;^1#H[SEG#(<:K&(
MCBQ:F?J&Q!&S=;PG7U@PF+9$*2Y-*+_?R3/"+T2K#%Z0Y$97U.9XAV.4;^D@
M]0U<S]_<S#:V23G[C"^EF6+S_EYN]=2.'=K@4+MD>"G[MC&K@,=2G-$>*W8_
M-SN!EM52B3^BMJJXNR5D!.^0CYVL5YT60%30L2O/Q#_=X+\7B@A:&JZMV\&O
MT3:A\47(=&AD5) 7V6V@=RI<KR[7U[:WM3HV-YT;'Y5VAX\<C\Q==LP<9=#R
M4KEMQ\3X"32L)Y1EE]"'D-.XY<R8N$PUZ<AMLSE45=6"GZDE2*I *RL\B)ZH
M0^4!ZQ\'?PN@'PD^[3EG#PX/+7E!]$0-30?SM!S:KV&.F&_VQZZ]Y81 LTL"
M]2<7X"7R:K]Z4J\I>XZLH >YQ?$:MRIR <*DRN@542&A5N^$<TYL7.H;6_C4
M#@.T- >:_6H>E#9-AIPFY%.Z;:N6#0+82_GF0IVG_ @ [G46A*NZC+UV]O+Q
M*>6)DFQLJA=,P0DS?T&]X:JNM\# -&GG"CEALC9R0,^*YM$=2"D\5OAU-;^J
MJC 8[[A52D )K$"#(R :6R2U*; NA'(L)!:_ SDEJ1YTYOC;U>M086'9X6MZ
MT[)P0*4K^>; 5EVZM=DZW9(\F8A5MG1V7EE@LDEZ@L<[)"--#$W 18AZ5VW"
MIZT5QZJ6NH_<A03!OOHFGVN9 $6Q'SZN WC.=IF;SNY[7G%$O)U,BF=B[IG[
M@17J\>=\]]:+ 6E XFAE@[6"@'^L^K; .IA:D$"J,+84*ZFK&-C7EY);5/*<
MLD N0KK9X7 F*CM->91F\ U7:N.^;+(&69,$1D'C5&;S+9:F% H0 51Z*D;R
MFK6$P:1)2>N/QH#ZI8@Z:,#'^S5HJU^^!MKFY))'WIF\[T)+MWQD91.O3'.D
M,F7T>6R"C6=1\E)*)_R3++G.M5"&><O-5-OH\PQ\HA\#C KG)%;],(.P]Q94
MQ_@82$"5Y?G1'".B:?R_//5R8C ';J@&_\M!88/2_V20-0I.SPGOYV]4*U"
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ME)V5,N9>F;\M2D$!>B^V^@7TI&K$U7@V3HVG@G*\SUU=$+'PV,GIBS[!313
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M=L1>M7V*4..!X:]V!(:*3/=D5/D?[0Z NS7 ;)'=>4.?>6EF*[:A.=',UE=
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MT#)HT;AA!MS@?G$T2QZ?P]NMK4)9Q*#_U,:,C2,0OPC"$"@6[W(/G6Z1,/5
M4X,EKZ"@5.[!2,B$?7WR@Y]GHX/2RO1UIECCUM56K(HO^27DF+4*'A3UXY D
M$B,VVSSNL'.K4^UN_E6[NKF=#!VODHBD(CL[TP/9,7GMYW<J'PE]&U\>^?EW
M:O3/*Q7_86B[&\+78CX.?,%;ZQR?(UA5IZ.:/@8;H>15IW=T\U]G^CH-4?K@
M$I,Y)P^T5T?SR)/LW\,!0&X/3VQM6E@G*'" >'2&KESEIF3F'PW[_:T"M^\K
M5D.;+Z?9-614[3BB?H[%9$J7,_)()1E&&L-HWYAL?]@O7"=E?+54I(<)T"WN
MI$X,C.8AW.?;]0!YAHWO_MFZ>6 T>S/6BN0G$"W;^J>XJVS5>#(3O5<&'^O$
M$FY1#T(H(&:08._QB[F98:7RBNZ61SMO_V4X02D^/B56>^$'6=&^#H>GZ9&=
M:AM%=5J)N_<\$.8/UB)7(T_#IE^'R$6Q>#T-RTG2DE\/^SI1)U);\ZB+]<K=
M--! F_\%'GX4-1_^,!D1?HQUJ*,:]6!]:-LSM4Z.>>GC$^18P#=1.2G!JK*D
M_[K._O_KB'/ZW(DS8.LP,B-^5LSEZ*+@:C?/_?8BI5='M3?<6FWOJ]6"]LB(
M9K_VN=[E6Q@JC"$O/Q+:79"K7B@@@^?!^#UF_SV%6E.RIIJF)KDB5%."P%\Z
MMZ6?4<&'P50U#E >DV<MKLV:#S;]%?J'6?G_?4&6U9J@[#XH;IYC.H.\K4KD
M"WF-#R\ Y2$6.ZOM.D[][*V7:4HMTT1"XFEE?Q'SH[@H[4KQ].E/(ID+Z24D
M3D_>5G'&:05\]RTBPLKE"7BH6+#W)3"K2/##-J5 '9.#0)HF<BNTWN79J G-
M%8JYT>7QHV]-S>9N+,/]3NQ];T(,8(\K/HQ?]KTZUAQ17RW8*(LC=K7))";V
M3)/J?!(IKQ[:JHJY]]]3Z+-<3%9/>%)6:6XIA5NBT%6UDEHB/7NXP-AS,FO6
MUY7U=T,&X+'[O4^M"PL>J%%I:63]9ESS\RYJ\,>G(;LG&GJ\8U5W5?]_4N;^
M'R_804%B%M$#BS&@2U-['  SK87ZU+J#_3&%M;WFX73&N4Y.H)IT##LDN&DF
M>D'<C>VOA<4D.(!0QD>FQ_&P9MG,C#3:I$>"%56U[&T)OL]7GTA$0":4:V?(
MX,OD/JE^Q:U%8'OP+7T*2#Z-X;F-"6+X9L:+@I$!T79II#GDTYDB=KTMX _E
MJ/X>8F\K3K9'W0Q<%U1>BGN8E/RXY5E]B/+6\R\J53<MOBK:2^4.RL><V-6$
MUS>3O&MS:GWXV/YP0ZU+?$:$^]RV?'VDK</A3/!#>8R#W)[JX;'FR:XCB6?W
M>,??&>!NBLM=E"$NU\<?E]=< *.R5MC\QYS>I6G>,:^JW>F7E/C$P8/,H\E[
M'[GRD3DEL!)JRJFUWNM5="4B5%DP,9OX>Q5(3D]+B+?QDT0\W&-P02QJYH )
M_30<_G,S$&L5G55XO*L:.36=WN]U.#=E9>4R<7SH>[ $=='>++2E#S<O20*S
M]ZH>\=0*!023AO:%QJIKM,M4-_7;UE?4*0F-^%)(4DGA$=@HTAR59WC&V767
MO&N$)^VX-[B+,PI4?8^1+$\4TNP?*[:Y+$;/"*J.8.FJL J:4TX.#9G"!L:]
MG3_*4W,-8V",RGQRB<%X:J/?HDK8JRM*$DL/R#9!%D]:)S[4Q)*OI5!AXR&Y
MKY[YRQ9K1@+<F)P/&\D,1SFNFGZ3?5P C>$=D:1<XU]E[S9,\+0/8XW[X*WC
MW?F1D'F4%4M>(<^E8F=Q1-7[(WF"3.I5\=2GL61ZTY2N.O@^7:W]=@TS&]:<
M.9ZYQNPKG_?ILY /U#R#QKMM?"C1IGI&1B2W--5Q@$<[0E%)QL.NL#]GR$@:
MFQ];[=_KKQ (@7 3/%S9V_ME2%C](7(GKLB>7CR'66L2F$UELWU:\WF4)8FH
MO,P<OVO,-O.*#1:FH.2FF]B2(%)BAXR;$QKF7B)18&T-GY5?<<]1[%3SBBMZ
M@Y6X+YY[G\FUX=QH]%_.<>\40]* :)]621S KG01!S!X)M;SKU?ONI)OE >"
M:N'?A6%0YV2)O_OT]S]6D&<$1'NBON  ]UM3<8 &KT,;$Y0K#J# BO;FA)KL
MI6-X(!^OBDC6G(X]X%@#M/Z^\222>;:YNJ&9TE_I\%Z3H/])B<'.4&7V+$JX
MB-W!AM:LDT[&02O !J-1+XI2VH\<2'[L0FCJJMQ3BV8G$\A":H>AKSR^9NN5
MM:NKJ(<XI8ZOP"ONE[G,A0V#_R@V^2L$['!!5+^[K\UEQH+1?N4'A,>+YJ8A
M2Z6&"J%]A(*F262::R'LTXLW?&ZNE!HR^3H"454L#?3%;\C\KC&<7]$OP] ?
M29'\@.^)+#F11* !5[A=K2'B4]C.3?[;%.7K:I#VR0$(7O.AIR_L4N:(8PWV
M=M5]$NCG,=3MG[/?NA@V4^.FAU814(*\W:IRBS%[6UK2,RDM37MVOR+W[(RL
MY)WT(..-;O*KK]X"V/^6-E/DGKY="XOD6)^+>17!>4?ZZCF1*[PV=VZH8E^Q
MG#ST)_=53Q24#4Q%8[#,3DK$RD"4]YF]Y-7]Q0POVP$:YA]2OM2%':U12?F*
MY,C" Y.7;U%MULG)@NF!["-\03^C,4477#DDT[(DL8\!;C"+O<S%&2'.'[MS
M^YS+LXB0!*UAW3&ZYR5MJ38[3^T4P-I@!O.T1VI'#>S?'QQ27SCDKYHU^!CF
MLCVEX8&N22Y)4N._C<HW?+Q5_RS)6H_G90$CFG X"I\V:/1PQDGQWU>'_IE@
M_0<F6-E @E<J*,1JYL7LY16X>5Z(2M-GKV<4]#PR%J' >/D40&91EN/=I'7E
M#<-/)S%U5)O' 5Q,NAEI&/V_0K?I4T'O<OR-*)R20"TO4@$'=/W85,@O=I!X
M[8N+>"/I/P)*^1\1>$/Z@+EK>=F+&<B4''/[&#&?JMPTGJ8LF&=1U1EWR'+L
MIN(S,IDK/G[NQ23Z9;BKH)\*71P]L)AUUI;"OR_-MWT+TELG+#WW<G4:_K8?
MB)!$TI=-S<D-;_YY'OZ.[P0779PP(_7$)=U/'.[EQ%,::4_44J9$W*VIVOW,
M&L\J*_><"*#P, _EK>FA>=?2<YH81G_",>NOA"W1NSPIY>0$6.%;"ET6^4:O
M.%(+@W\(=Y?Y;( 6!<4I9"M^R!N\]U@://?BZM'ZL-,@UC>/)_RGU1/2%H.\
MAX#070@?1!7/)Z:PY7O*FMP31#H*,M*RK-!</1*GGNQ,-.[GDTQI?Z[JYD-R
M\HAC^D19_-[>N^]ER51Q/+X3(7(S,38Q<K((6:1+9>^*8:,!6M$Y0HSH!.49
M_51X&KH".WFYHXK$/JZI1^;L^(\4'&G*1?7IDBS-O/KZR60YE=J5")9:FA\'
M4T[+, TTJ+N[<&3U%9/;MEZJB=#9F-/:4;^JC!+;X5 #A=ERZ]SI*(0G>QTC
MO')=-*A5^2KW7# /^7JQY- GQ<7T_18?&IX;*PFFEN5WO?L]?350ILML^ P6
MDIE.]UA%]$1^4BO\66QJ2CH!/A364$1EO#XIU&YI25Q$H,1+ R!,91IV%8J3
M"5.J!#QCB@\ 4#)A,FPK$2;\/*WI)TKF'BW:B36/[Y0*;LS!9H3J[[:]@'_N
MX=!1>"YJ4SB@6:N<*.IUHZ_FJJ^=FCJY"N6?+L<U6!=#8[/LPF'&6^4>X,?(
M=V<]</Q S.S7^J #I%G._?:#SJ>?@+\KYKLR2]C!&43TTJ6EB8D31M3ZU-(<
M;.-$CI+X[R7I?W\/=XL5\S@T^B<<^A,<>J.#-KQ$'1'ZND=KH&UV6JO',.\]
M,(ZK(G*V3$>CF#.W^^))!NE:*J*9"FQ;A8SBS39AGJV]^CV3(XC]F 0U_D@'
M\,_N.MBFS,WC;4%>Q=&%'JHI!6+X$\6Q\_A)$].#4.^_08-D24G]A++L+K-"
MR](><]OM@F?/MG-X>ODF'!G#GXT[#S%6%7WL92)Q3=+^J-2(I_70]#W@1BZT
MPLU<FI% 74,><)_I*]YP;9NXN >)X9*NRZ%8HO;G=K[3T_V8-WFWE&7/WLBR
M* H7A3%,_GS&\S3R-?,9J5C,?LM$_<'QI< )H3<Y3*E48E7%-@NKW>7I:N55
M9:3'&O;<0O=&K:;BU38+%"HQ54DB8V0>0EW$$IZ9R<::Z45&Q1!\M^R0C;@@
M/*N:EQL X 3?7$@-O*&01<VT!!">)HB\I; D3"U8WIVYMMO:XJ%S-,.OYWNC
M5XFB$2\QJR=TMC+1E%Q.25=T>-==NR6VX*Y4.G=]!79^T,=_G^NCTTN/WCMY
MDS6]WRP 5TN_AV3K?>@FPCWCNK0_:!:J<.S*,KFF[?XJV+L_65K>O7>O46"I
ML+.=4E6"V8'SU1/%P'YJKV)6V*='[+.ZQOFC]O>B:WWJD':51;7C'V^2/;K[
M,[:;F&JE+8.U$F$U%T9:EMWXZD8BLO+F-RM,/"0.>'( .3O\C@.<C<T KY8<
M@,>Q.(!6/@Y0ZD<-T2[' 19-CAIP@"WQ=&<HN;CT"IMQ67DICT8G37.5Z?'T
MW%R=I$L^,?ML6 H.(,'(A,4[WQ,]J_DUJ[,LB8V3#SIO>H;UTU U:(O0^@EA
MD055ZF5^F9<1/8T?4M+&'Y_0&E, :ZJH/Y9F<I;J-**CNB4GBT\JP1!(!*\T
M$(JYI4'T-"LBD"1E*S*A\%L[%<,185[FCUVCHQFD;03+3\292!"S@@R+5!&5
M56 D8\A3BI9XK?Z[M]W?4BI__/H["VJ!RC]RJ,J*6__!)BS)$ ?N><:ZWR5Z
MI6M1/]A0*:]5>0/&H.:7^W%4JBFDFMI0/[)'4T7.)+JHX%M9;H$T;:R*_,8K
M,S?1XIQBCING#-%V*XF6:EN2.G@)4?@/U.1FA16WS)CUU (E"4,9"0O:#B?^
MEIWPEW. @FOU,F^Q*JY@BU/.C4&+N@/"ZKHC1.J;A=M/XJHR63.I4[<[I11(
MXL\E:$8"6O?\,_LOC%H][+Q>?$TDXXR382>0[/36MG"UM]#7NJ$U?K.C-$W\
M^>G]Q<O"H^IO6-Y]Y0TSY_VHH!V'S^.&D/<'%('"5[-B'R-A79K:.L36*S!*
M36GE2*XH)A7S;6U#O%",ZCR)\7\8[Q9HP'U(>W\O4><Q:";#+ZA_N(K9D8.[
MY6BZ+T4YO"Q;CZ50P>QY1,G-9TTQ<O@^O$$6+4V23&K*.YX\/_=@_?ALA+EQ
M)NUW*+T8-80"=XC08=O5F%>G4#26LP0'& D*PP%VX(XX@&X]"5+V>@5^Y8$,
MBVE>9-2CSKF0/=#-W<7MH5P<8//(S0H;00O& ;11%V<^[W& !+MH9 <KYN84
MW L!@9M>_S,,Z]^*_7H%QD(>Z4"VVG]>+W83..3?O=CG;WUQK3BR([G3JDWO
M(L2$,+Y[XP,_JF-0.J%3ISL6EBH^FNK6*?K\2+X>WTCO2Z#8!JS^O5A=KW4<
M!P=1@?9'';K!GS0/)H5.?+]PKHL\N7LGG%22L-:W&PR_[V_FY!2&0AS8M.V^
M/\M<+@IPRHBP&JTJF@&%FIW%THEK9+[DJ_VAQ4"J*O% B=C1=TW$WZW^6_8;
M!O&[X\N;>85QG["V/LD#C[Q,TIC7>VW91[@Q\M<ZK9^^0Q&U'S/:_:K9:XU'
MH%@)IHU\,O+F1 S?CX:G$5^9Y24FC[T0>ZUBP[93N'8W7FJ'7I! [X;8LOM^
MS9R]!XF=:S"3M*PF.E24B)$AXL&DK-ZB3./K:JGVV&!)X)+XI_<,:_3)_OW>
MNO\L-O[#BXU_$DS6  ?B5^;!RNZ)<I;[OC[WJ_=%,XQE[CZ(IQ<4U"SRWB&L
M&*/55EDKS'L$*$RC4*N9L@]8HS=[7%I1'X,M8;A[Y-F%AY+[L1@KZAWQ"FHC
MH''9(\+$CP,HHN71E]$#7FX&"VOW _\0K.3O$$CA *]/NW8/%X801A8U[YQ:
M!K5O\W@)!.=]IHO.9[?CH12H(!WK\B3X'"<;12&N0$K6NNL>;5[O$^;Y[/N)
MI2B%[] QI2BADCOJT9R%7OQ0&);RA'7O&H<)(\;*W._/[<Q_J?4^L='P2YJ?
M%;)5%A!@--VKZ9CB*P&0J&NRQ>EG3GD9S1UW+W"9+/0V#)STV?[JC-Y<$Y=X
MZWT_W]#.K3;23%)&#8"&3V0FM8VZ_M_SF@CZ772(_ HBA1S1G$.P^]R9FT.6
MH*HF' #\Z!*89<6/5L=$8BEW-1==K"0YVSKH?YL4!A7]P%J!V'& 88@6?>4L
M-5?]WL%,]Z0:4TTUU6;G4NX$@;L$S]5*9LE.7IY=X;@M2V3'Z'0_=OC8ZBS\
M8F?3 (%X:1^A($BI?'1SQ1'TZ8'LULVAN4Y4-N)[!+;D^T=5-N"-Z24P 7(\
M^G.IB=@&B1[J?S/[2*93"I1A1UB.]PC%"'>FCFH;N+;31_B7AZ4]8R.K:\>T
M#N(*T -9 7>]Q*787'4*4Z(6-='*'A+:L-JRI?0TJ6(>6[&&R)1P.S9%.^H<
M8IH,V=P;^*QI3@8C)6E2([6$;DK!MYJD=9K *?Q=! 22S\6[Z B;YC973-YR
M6?O:;*OLV.I4E3-/7;+3UBK6E7K=:P;^'@B[BO]@(J=!Q!0C21A[B(><LL<,
M-1LA1C]:.N=<W?=]C0-$5.RR-;I?7 1'D.ODY1C)72GRU:.MZ2- %7 YHS_I
MIFV('L8!5N=W2%!&US'J:D3R0/;\!*4 'X5=&F9!^7T?8$JQ>!.BJ(0F@K]<
M!9;S67[4W9JX@"KWI+MRIJ02@X9WCG,R O6F5S7%+?5C[U;+H8KO*H#9V",B
M!GK<@G5TB%S\+P0&:?WOW7SEN,(AD?6>D)+_9.O"%)$S1]>B."+QO5.A'-DD
M@AGZS9JW[=WO92%\0IC\X_ N_1W&KS_Z,2O%O4S'IJ8V@\]CM15X* M?6X^7
MA>A:.!A(XC^I=<F;:9#)2(Q-X7 OR&))++CYF3ZZW,L;CYRJ_2X>(]-D:KY=
M=Y'4!9<K_L[N%>,21'7M"F9IU<QX.WG@ -/[*7ONU5/>,\\$&'4P>;MRS&@_
MJ>8]T=CGP?W<":^:"HDK68Y^Z2JX/#6L*N*@I"NR@^&/!_W\C71]5;%^24-I
M(_E<@I5)HS%?3)@5+H05WG/\/+C'/AC02",J?IHSIR3.TM9Z+'7[?'7$UC,O
MZ<1S7?$2PWD@_>1)R>2-3/"BY8*&I-@=69T( O;'NJ3<D6)DAPA['Y\G45DO
MA5AJ., GIZ];(YH8_K)_+GVT NM>C&@-'DGUFY_1I[&I?^V6.EWM=G)X^SU7
M8'C$RX^C1#M/8$^R[JC1Y]\>24D$%/'X1#7&^\X]=\+76?J4O4UST_/342_^
M42<>'?%Y9-/DQHUCM#:_<.B8*KW9_J!WF5AY_;LY%,)Q7]C[. 'UV75%8(]:
M6E7K4[]VMW+UI=(;TBK"84/,->Z&FO6G#K:\8*/6LLSSG5#(@W &J;]FCF$0
MU7OA/Z9X]@[([<_@-J3HED3HLT<S<#6A>4#K/C^HN<G#$6-0<$QQ=K>678<*
MK7V'7WA'^P[Y\PBI0IF[1.N.UE#W!FO+.U)Y"05Y1(RTJL_\YUP9%^JL2TS)
MY S&;VH:C--B&G:J6WOH"/YS$P6KQB!\1#S.?_U$&'U,H'* IOSJ4$HOY[>+
MQB,6D2-7G9.HY2U12^7DNWWGE@;_C?F5%4-#&Z8 6S>#@CR(L->PUMCZ:#-1
MG$VL.9^&LQUX\V1Y) ?9/];Z9'Q&[/,CC59QWB<I>0-URP@^1&#.A^<?-/A!
MLY./B@J+"F VJ3OD2DK9ZG2KVMP];T1Z4:4+&U5^*O(:36\*WJ2-OP78!!V7
M>49%UN\^>][G*<12:Y"TK$@;KQHJ5PF3_&O#M?8(#M =W0#_O3L#17W./$_$
M >K!IW&0[NSM,VPO?(SU$ECT':L$?=DF[[MT.3';.G&<7FTG8E8]M1:R/YOC
MINN EIV%+%]BJFLXGL!0]BR@QS+FA3TZXN5UD[Z?'K(74 K6>3@;.?R4MV5,
MS5&^RR _FW)S,.R7R]C75>(.=^)PVPA>7X0F,?:[</V0,U!2]6^ &R'@:/;2
M!2,-:FF\MI?W+!^MLVJ07"T%R%VB2$[T\Q$N. "?"9KNL;U4?0P. #,N@U5N
M?\B(EYMNY5![JASL\6:5US7Z1>C4U\(^S3%EO"M,AB,/(6BXR66HQ7W6Z#PD
MZ .0^%>/#88@,@52IT^$CM9H/2Z]3!H^XKX%W/\2 'D:<%8^J,)WZD9)D:BN
M -96$JV9>*G81,WT,;SI)4A6!_\!1JX%)D<&Z+,EPG_P/2AVG*5/+>:]Y#<@
M]TC"95A%%^J0KHR=@=ST');N9=[!F5=' 9L-NA0LCTM:PNCJ3DV#H!Z@^73[
M!#X;&[+KZ2DKO^QQ^I4!/.Z$3AHS>[)ZX0!V'5@^.1VN8Q]GM8/%\-:@C"XZ
M5TK^Z2)%A8\-L=PB95$1BO6 [?3V4D?.FP"_GRVIUI,B<P] /V^2B=TQ%-$\
MGE#]_*9#J &1Y[:D^/$DMP^4(8P'269%3X+0,#CZZ_FS"R?L4\C@M>OO&.%Z
MB@/DX "#Y5>](\;S<":?T<]NCK;LJOUS,1HC![03+_AN/Y?4$/9.?4#J/S6B
M!1"+J,."$<R! G:N3%V?OJXEXB-/@4V+Y62Z-W0 O #N[^3'VY*3B]S-G^T<
M[1U4M^8I#9OM%0R54P=TC).H%_?GQY68^7IIP!1'W0599%3]_@V(W^D>YSB
M4VOPIP>AN8 M"Z9[6M\9XHA8HSBVY,!Z+BH3+0$]ZZ,Y:@SO3[X!:*Z\?)NH
M(2E XY4/7I'?IANFG^:5S84T$S:\MB4%<W(_]38())S4O!TGZ-3738KV(?'1
M;VKI?9&3%KJU?7Q7_MVYSB<_6(ZQ6Z7>#*NZU(0.,H: 9*\ DR&#-<(!CI#N
M7-C'0E!,GY/'A1GJ#@19<"T<F? "HO0AH^67X->'S: -%_=-+-/^-1EH-H [
M$W)">L6GL%Y+UZ!=:=C0'0=POO:#:560[B')Z.K,+U?_DR@\>_5XMPUV"3^J
MKF_&)MM+MVSNS!>ADL1*Q?4K% S,"@*!=W1>B.G#&E(R3-.4#$_341P+]>0U
ML[W.CW1#FFHF$WMHK6U0PH;U!GZNV[?YQFT,=*!+NY9.(4"&'7%]7[G+L6/O
M8MN.RB)_25>(_L5=% _T)2*86V5:+_S-M^X\'TWU6M-1&BA5RJB4^5CYS^11
M;J["H1SN_SC4VH=8T\5S [K-ZZ6<48L#--'JMBR>EV/E'T*WS:_M-.H6Z7N"
M S ;1M>"=F9=%<5ZQ/#_<SM%@3N@*0C$BO\Y*LVI:4[,JL$VZ_&F&?5I25$=
M>(4*8RX'3H!%W'OQ/I$(GSP&7^/'C<U?TO6;AMXTS#]N+@VJTGL;I#X#;\ :
M?=LICN%\2OUQX]K99E>QUY2M?ZOC_$'0FNQ4ALV,#VO]N>J=BJ8+$:4&][KE
M/$H^RM-N)0ZN? /OT+11S0G-'FJ6X'%11^(*?)\?^PB;AND#^LEM8OF0"!B2
MU)-45I**L22BLNV+<YAE<! C<2#HNQ_1DF2/&"<FZ;3\GY6Q?W1E[$^"&+_4
MR690?9WXTN[@17@T5UT],_FHSEAMDORT][?"_)AB*MO"O-M,/'BNL5K37P*K
MG>#)=JE6P35--$&[.R0%C/A>4?'SALQKEJ\(M(-)KEKED@V*T;#+0G@;UZ'-
M>^25394/!Y>^'N*QC\3'PMWM%>%/FC8KZ4]N\(0MO<U?:C%89GO22V^XH><5
M3B=O\_3CBMP&;-R[\!@4^ZU;7>"P1J%6[/$SL)W7@RT_DOYS5QU,Z-6S/P+/
M_UM2^2$_ID4ZJB^,@69[HO?<U^>I9Z/KNU8**!Z:9E4W-R>&4YE*##%5"7?3
MW#CHRX+:.#EE([)M\M^&9N="S[3BUVZ!P0A#,43H*D'*[YNEN>(T: 7$XL/S
M1XA?UB=TZ8U+>5"_@U!)UPG*65&WF\+%^>(QE6M%K:^3TR1R.BF$-@=]!UFY
MA]Z4**C30(8&,8SH$,)4GK;^ZK(Q.J%F7P>LY#%P*%J.<5HWI^Q?AO^WE>TF
M&'& EUSKB[-^Y:T>CWS.+#=+%ALC(OE)^]S:_#VM=VR6.B4J<O5HHF?RXO!?
MC[,QZ^5QFL=:%68Z$#X1J[I0'+*H5ZD[YB8N%+:24*PT,^CCL5LOT=((4BPH
M5Y<3=E;I6N<P-FR,#:4,"\4'L$V_9\.0*X^/QZL6L'*'##C,Y?F3O#>MTA.=
MY,Q7%,T$<DMS\A2E6:MDLFUO:B514V"TAU^BH[VX"'YZR#.%)8X$:R>$Z-!G
M!4H"K=3&*UKNJH\7WY0J(6) M_=LUR-:!?_S#5IU>.R_N/D![3*73I_]]LS/
M9?K5L\)WDU1YMW9#V+=4H46?R["LV%M=71=U3*C-.C^6G62 J:=6_,Y1W&<L
M;T[A+D)DB+X]6]0T-@ '4%QZB;5HJ@.]+]<0_!]K&IXHQ@$XX)>M%T!,49TN
MQK'7)Q+S\Y(!=1U8;KB^6 >'@RLA/^8-!.ZX=Z0L& 556W*+Z8PYE.NO B#?
M5<9>&]#9G3$7V7 TBCZP .:BHC;JN&5H<X)V@?NQU>@4U^=11H[;:&'P6@=Z
MZ:Q<UC!_\_/:NIRBS$U,RWPA_0SL 5FNF=VN=C;T6(M30":QD5D"9.@BV-D4
M5'^G:4WZ&BW [G1@MC0+UO=L/)8@'6S8<>B)6T69B_.8PV#W9+-XY+O@"U4E
M?AE*]BRU&D.7![H:&Z S\5>3P1+ &;.AI1^DB-35),W+&VDX@$*&W"7'^!>F
M;('7P-!8) $K>E[G\XGB-;AXA ,D"EX_A\Z$]29'C%@'R*1Q('H*&WP=1'RW
MOOG:7F:T^$N/3ZRMEGVQLW^CHJ%A?B&FS5;L95E5K3&L&1(!%LYA<[<A$PIB
M8TX)G0;#3YX;4MU1<7Y9(&$CN=/-1Y]IA3Q5J=T[;+1L4OO@R(^\7T**QK]L
M_>QMU/AU$?%-\(6KO[!KR4)*B<6;*F7 /179<:ESEJU\-A#>%ZPD:$JERZ G
M-O]C5VRC^GF&R3H=T75(FBR<_34;?9H [-',+CT&+5GZ%+Y_17=1X9(HTF]E
MRF#;LGY+-H/MV)54[FI'(92(@RV'OM"(,6S51#TL1S?VM0_)J_RU%>IQQLKL
MV-_<I[\D3U=-#%:S,X:29T>48^/Z>"0O \ZZ@>LCAI<7DUIBW7,^C&4\;F="
M<X[+)3UULE6A!2F:RP6V5>3/F4=?ZUN$)\92YUCHO.V4Q_=Y<)@>Y*!3I9I%
MEJ5&3VE)S-$1;#>BBK#ELM(+RV*:_&J-!UK;:1>$'B/R"O9*Q%AZYI!W!?55
M0FPQW0ES]Q[JE"5EISG<2HN1K2E^512ZJ^-VYU88C9R?^NOO7U3].!R[S.]Q
M%CTS*(J1(^]*$/_Z0='\E!&:A)=@;4J6R+06*/KY/JC_FW@ZTL/7?>@=4[3C
MH=^VH3[!LOTYR'F59X?E3M&8-"7A9W"A@HSUHDJKZ7J8C\O@*==5;!?A[P2W
M[IZD\LW,Q/N&=;$^^FW#WW& ^**2PZB$.:,[T_R(QR!U>D5N)7!"NY7-]FP2
M^Q5[53_M]F/>E SS*+W<B&;K. &\>;YF>83 (?T9()6 1YJ-G[VC?W.'!";Y
MXD=G'?*N _2EIY:K*Y;;EWG::&@4OC@_U%#_XO[2'&5JG_+MGRKXKN-*8:G;
M.5[?D@B]85XK[A\V(ZCZLK=\>O=8!T3G!28\EKH*M*62)@SJLNX3";5W"6%_
M10N41HE,B\H^IXHC8)-4]K;*&EJ.?FU_\'/O;JG[_J)"X"^WS U$(RW+7%8!
M+-P^8GJVD-F+<"[228FVII*1:'D*%;A/S5'0D7:1:O]..UQ,B?VE)<.()$6^
MZ);O4#)404"EE=.<>2&8BI2 5_KDN/O:Z2S.R]6*P-Y!7"Z2ELH0>GK56J_J
M>E=W; II%:*B++2XM&EC\3DXXK?AM ^&&N 6<VNSED>F:H.YI41,:F/#0>O#
M0^^KE;9.7[&SWY,1;5NH1>T;EW;O^Z_WGSD9;D)&7[,E=9F^I)SN5 RSM>51
ME^J*27&Z.016YY#:?YPP_BGC7AE?NL!\;]F+AQO+OIRC _<!@*^;? RZKU">
M*0?' ]*O0AC+&8B]XFYQ1[B9TCFAZP5^@0@?NC37#_I29F>P%[]'&9>E/U*0
MI;IA5M@ST0'Z6MKC'B6D)DATD,6+5XX\5P#*Y)HF9EGA5_N%$\$V3?J_,=<_
M?UI6.#TU\ ( M.'' 5@518>.#[<PF\$%Y3O^?8.2^C0*!&+O^H>=E&W2..I2
M@_G4E".FB#MMHV(M'\0163[=3._7O>-"-A9&8R  Z\N-7D>>[A[/M^SJO9F:
M_):,U$2+:9O8GAD?;K=NQDPC)L/9W]22R6D2R#S/]_9NL@W\0=.D3UP8=]OU
MY2-M"PMS-UU9=<;]Y@3#$BEK%<EVPO#8GT HVD22HU^PTN7QT8H8T1D=D"O2
MA*A.]X.KG1.F.WW.U3#9107ZQ8[6]??8J$8$WXGZSQ,99M%HS;7B0$WF//55
M/'+I$.>[B\@FA[*3[Y%:V393:@K" ?:D,B\_1(D1";2&BR @#[[8VF[G/7LF
M?WI&=]?("5TG\.B")T1U:.B@5[!.-ISM^.5^2>*+>YSB"@GU@4!F9H6".#I)
M8SF7QU7S#W3/*!=/3K%L5V[@N[1V^$GT^1%L)JJ,4WEU<Y7T'U>2QF6M)6XB
M:4Y5!0E_7M&U'L-L3^^F-]FB[V]XBV9;,<"BB*>M+<.+\N69HR_>*:Y'Q;W6
M95>OE>,.TVYYJTG(4X.R6]C*89;]NOU"FY+VGDC;PM,V/[+>&J*RR45M:<NV
MM^9C^]U(F['N0> 7A/3JR9YO77>?95$%JF!]BX-[YBIEER4DA[3FH*J33TV"
MAFW4?;RD7DZIF*<M!;$N_B[9Y^CAVV_Q"@22@)!R4H4>V%5ANE.ZAL.L 8_U
M!#[M<#@$^HWCFSCIWL'LY4%KI$G&G)J37^^M;:A==W3: SGE:9JB(AK/(K;9
MC+R"DW$-$85\-W%![6AI-DNNA<8FHRK4=VU-&HHI@QWA #/I-VH"W-W1BN?[
M85PO6J14\R?ROQ+<IF4[WO:8-.GO-C7C%@K//%MTT_*!"=(ZJ=14O I_SO>^
MI5UW?U#FM1O9U+CLP;>(&T(=,446AB+9<Z]6;*B#O[[-/G+7,?5WQ2< .H!G
M1K\8&T9J44_O@#Z1 I"6M>C"4=VUS\?8+GNQY+2]^[!?FU4)",<XWS(/6T?@
M/=^N.!*MDQ%MS0Z53B;)7,^\X-0<78MT@] US8J3:F/%BKFB2-GP735VSQNW
M157928!<+W]M]A??H'["M$W)[A(=2[$\8>N04?MU022(I+9N4MR^S$?,!!S9
M:;9486-9**!>&)[];*V:ET"&("48_R.F\X=!CL*3[ (FJ(3PG0YRU792K7@)
MX?K62'2]]^*=>K/>\XWS7SKKD[&LO?G$;>E.9FS4WSDS;<.]-K^^7HCE52"N
M9_K!^8+*V&7_YU#^+/^=-[8$&7 &":"E_T*(FO. >JFE*3B#B!AD77XI_BM(
M[ +=\GOB3,2%?U0$<Z$SVG/PAH7Q0X>NKDQ:P;?<W@F9>ZI22671[2IZ">J*
M%G&WHE[A6^LI/#E%F5@-W?\8=R!V_T%X#+7T2_S@)T4R\EFB'&O"2A_Z;3L-
M",?S ASQ U3EGP:,C65U;'AT.D0/4T5&9DPC'3JTP9FEY3_6G]43*/,/6.0$
MLT1ELST)A,I6KI$]D>+*S8]]K^REF;*QD/DZY=GHS1M9$>2*-/%(UV2?63/$
MA &/LSS#YJ;QS6S"/;MAC[^M&6BP!DN&=KJ\G;'/&7I97;DKC"IY7%5EV++$
M4>]NX@T_NILD\DB:;]$KO:Q'9Z:PLL8N9RC+^CD%[RL+T<]6=/DS#R+4>O6!
M3!-##BX=Q"^YQVB'1,">RY&NZKJTCZ(O]4[KS[FW0'\#KQWN/UK%6B5K0Y8/
M W& TOX]L4'HL4KC-4SCPMZ/K..ZX &>KA;3[PVBF^]LE.N+:2W0ZNSNTNH,
M]O$*)-8Y<26C= 1/ VJ/1I/,?N3G?#A@G#F'+_@V?\C5SFZPT<7DJE^3_(@D
M]/;P#O9BJ]ZZN'V%"((0&</R$;XV6]_XB5VYB-HBE5[N<ARZ?]RU;<2(&7R$
MJ@#=F#B:T"/)WK[RB4/><<&LUW5KZH17"J(4;:[?EHC>'99.W<-&'6VWH[I1
MCJ"C+&\Z?S'X%?UE/\)HC('4\D(DH[F6V6X.\XU/ZUC.E*;CB;:(/-XC [LY
MPX A_NA%U&#='$_L13_R(@8R^PPVV"0TC0/,&R_RSUQ":T&<(S@ #0O<2FEO
M$=-<!D1I.>  F%V;UD0$I&\:,M:+ U@/CL[@ &LAH%$8QM@X#?1ODI,Y\_#+
M,!S@&M_NDB@?<UV!T+,X0$G&TWK@][;%_@/: X-T9[<J30O>5\J1PN"4/HY/
MI1GK$LOO][[]J&BX*X/]A/%+T4=EO',BEAV9TU;7&F',TY;HWHE6C9MS=ABO
MXKT5'AQ&:77"A ,0*HI%_C;?IRV]OW.@@JFQ/I^\7_0\TN$^3Y'\$G3_<4^E
MEJYN]^L8B7:G)P]X*<?#-; R"HVHQ+.1FL>^/*FT-G>_:^E2$@?O^/%VOUH>
M._?]=EK"W!1[H[ 0D$9C];S=6NP#UC\0FDIW&+2?T1^$0 @73.T;?4W\Y=P7
M(K1KYRS.S?B#ZI:MM^>*5F2/D?UH#+&UI>@Y*LEB>MFK[%8J,\PI[>ED(C+.
M5B[FYJ^<[ 6;!7+G6+/0";+6!>6NK^)2*2"G1!*I1\>'.$!T?R7D]\Q/'.!
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M93!@7$Y1]]3(P.F9JW;-H0*?AJQ]+Y,S@:N;**4%OK]<(S.M_$TV?-K >Y)
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M#8<=W6&+'_0MWKV;;\5HDM0[:<E+IKWF[.:L.\3!^;116H&OY/@5<9912CI
M/&B6WCKR'<)""T]".PL $)GJ<<VQ=&&>LPACBH^S]2<?F;[V6$?[;B28<D$K
M[.J(S^U_^>[3R.'_:K0<2;M\@0.8ET_ D=?K\5 N^1SX[W2V^;<Z2\]B@K[N
MT[?//YX2BR_HT[(XGJA2:_G5^2Y'WV2?+4N6V#202+&()=91Z9Y%6*H @@*1
M):\&H)3Q=U"./V'-(ECO-^H9Y2Y5@/5XW:_#VQ)=-SZY;*P\UF_<[)G0=1M4
M%7RBKK.>FWYI[S)<+7_U142^XDVC@[)JCB7K'&NKU M!:LJ7^+6 ]Y1/X/WC
M8?4]EC4Z]G$)_"=Y<DCA$O!Z;?VSX];U]%_:G115#@[!B<5=R8^L=YP3^1+\
MM1JNM6%**N,UO9=;SQ![(+4Y,^!N&W34@X<,H"Y$28"2)8WU0D77HY>EP34Q
MH';C3\ -&W@U=&$_<E)-9T)S?ZNNZE TF$*#:J6PL%=G8E3"4@WR?C0//_CF
M';;$T$;1)^?87E$V3B*"VLNWR  *;ABB&.D*2W-\;/#Z=G[&:^\X>6!5QB-(
M4&MTQ@P=JN9]C?8)RTV_B;:9.:K\U$^\?N,:?KE-7%E@ K70G.V);[D1I$Q.
M5BW+;Y/=5=<\9/D+3RB>YNP]A?<@70TKYOD>$6>=PVWHY6Y!,[Q%@ ,76%'.
M"AR@ WX]DPW&/XRO?8H3U]5UO*??NDB#5X%/N]%TFJR-AEER?],-=\:@/MU-
MCQZN#>;AUL+C.VMUNO8;/G3^THX921P"^=-!-J.8*"Y'!\7+Y'VVWN@>=AXW
M\]8#K2(,A8\5PG"&2V!6#*2H$VG--OO@L7A^F<M$8]O\V^8B+-_]1<=\D]_/
M=D8Q?[%S\K\64/N+0@:.=\K18K]-SAK]/C=68Q7J02<R.$#[2%TG=D,:^]75
MM T"YN=RWQ=.\S(/S(:65FBV\RFKQZ[T6^KKZSE3Z]T@N@*^ ]G%B"/88]4<
M:4E]V\,YHY CX?/?J)XR,V+VK\BPJBO09F%66',T@<*%5ZMGBZHJC8/@B\9P
M#17*SH1+7K5<-C\!GOKM-1^6M=YN3D</0]_\L+D^,)JSA&23F@F3076";]*Z
MM]0DJ?.= 0*NB>[]#H3*1Z<@B57"JKQ]LKAYB[OK7O*E[EU$EC&E/5N(2I.M
M#6G,>\6FKQ@]&4%Q0RS5!T+NZ"%HF!N$DGL&99!W!CW)(JDXC4XS?_B^W1RV
MI#:(O,=XGB%W[LIBB0/LS[_' 69SG*XWLZ'*7B8"J].!S02C9!TC6'& .*IK
MEP\]\_*VQKZ!GNCA ,>9UX_+;+3[-2!G15^CPQ(QWA[X%@YP8H>M<I6],,8L
M"NV?-&YT'XI-R;Q@V?Y%H\\F>,_H572W]C,C DL:UR@".*U/[)Y L7ZI*<E=
MV4IF.YJT"3E:5[*FUE06/QZAG-IG VQS_GYZ7/+N]Z>11A7'?@IS+T<G#^U?
MW!D*_T6T&EB6?8> \C3.^BG[E=Q1V(](WB>RYFZ\[)U?>VM5>BZ4_-[*!P]2
M\V@;7E+ILL^,;=R3D?RV95=C(C<0DVZ7=3?\Y70A\*<8E=<5=J$XOKKI\-6$
M#T*PRN-&L8ZI+:AWEU$J=D)3E7]LXO5M 84<AMFU'%O9,[8+3GM$C>%\U9O.
M]A"YM(H5V ;)_NKF,/G[2K\ZR^#+*,*>H._1]9BH*-A_3'!%M4YC?RQB;4%H
M5]?G:Y!]BVN#PI?%R-NNV4SJ( )Z&5]_^*?(WT/;>.UQ4";(S2!L*9>D P+3
MEXZU[<4!@&*WQ']Y<_V/$L0 DP2ZP\C+SF&Q;XNID7"CIDJ_=_6JJV6(Z=GI
MHS-*]9+?WT<Z^ J.<CX*?"NT=S"5.;A3[_#306#T3<5S1J-K@[ZZB6[EJ*P1
M''O.,%R9!TXVY$6K(O'"D49'7U9Q@-X6^OD>!UHNB!NAR3F6U<ZBF+%GPFR[
M^2:U2GQ(5+:G]M,D;\\=;;I8J23\\H<7872JK52@_YAQ**@_^5-P'3X$H=[L
MEV.&5UHW<(!:R+%$#0Z@Q(HQCB^QVX0BV>?\"G$ G;%L]0/)+=:_G+MX SP^
MQ1K'N]=,1QT>H%_78-Z!GVNC>"UU?YKZ_3RB4]#5B;1\0U-!0!I@=TU'$Y72
M0KGF25QO]3UV1*35$];IZWZZ.7A-?^!BX"4<0.5W+SJ^%]3"-S]?OOTABA<;
M=@(:/@5^P7!U5OXDE5:YRS<^W D&@RG>2^(_"(TE8Z!4IY30UE:[!N" BHOP
MB,Y>IO&O<9[QXTL$+X7[#XV<2OE R[J@HPO?IW_Z)!D<<L%JC<K )%\ZB4^#
MV@4E#NQ6'Z$@R(M2F=9?8OC"5U=[AY>G[O78QRE@3->7A7L*1\!KHWPN]'V_
M+7>0X50TA'4"GDO^*1=H]^OZAX5HZ@/)\V:LDAHD+QU;"I)T=+G>V:Y0>\C9
M!^\QR(+N&='_V\>$_D7@!^]QPEHZ]0#1W (0[!Z[WP_C,\@[.QR GPD'B"K7
M^-?[O.V[#X'""7]WKI=\/SK*B''^-Q4*5"9PL%'\(#1[L%;$C.=#T1?V[O@<
M;^]3R7=;E#3W@L<1,W6(M@6'6W7'523+I6J8H@F3]=''K75WKGVHNN%F.]SZ
M&]9/M^X2JR8FF1R7[1<TX[-I(?IKB([%-CS>6Z,#DOTZZ-)(_3K,"G(P.>U@
MNP7\M^9E)$75>T\T1N*O-_HUK0M*IDV_.=YU &>4O8DF1)[>O"9FK'1[\93?
M#N^5JH/?Y1NT0G5?KV&=:'14<[#Y0"N.@Y+7EO/M2'D2])6PA!<;.@]X2(@-
M%)/% 4)<]H!(C(@@#B!9='B%.5C<+21$Y\!1LSA >BE$ XJY@A^RHC$^6.JA
M"LCFZ=XBYE8Q?/<"#BG+!1Y'78<#.ZQC*T81<K&# [1 3\X.+ZW$VZ]Q\%@U
MY)2F# <H7\!@FV(@?=<PL+4<V71QQH8#+!9CCR%#4_#EKRA"+$1U\)KJVC9C
MX3X75SO_%WMO 57EU_6+/@H(HH)(J'1W2R@IW6X:*>DNZ683 M+=TMW=(* @
M+4@WT@U2&S:[+O_WW/-]YZM[W[K?ZSGW90S&8/SVXMGS66NNN>9OKKGFNGUO
MQA,DI&O[8'6J& 7X5<-NC9OHN_\@Y\G_*F?U/^7\IYS_E/.?<OY3SK]53FP2
M$/3E4;BG9/M!^_F\!^Y^WH*W>+9]VWS,1%E=/2/Q@0-44I=<^+5>BKYW*0WN
MCV8-:'L*4AX?+LP<&A\+MF*AN"A["HU?_;E[[LK?0Q&I+\S++H,QRZ,;\5[U
M61;;8!>]8%.I:4@?73AS (1@DN61N+P7XR?\GAKE.XO9K^P%2YC/DM2N:0X)
M1*33:#;E=F_&#!OKAG(8KK-;4( 0[@!.U#7P/WYT9B!/=W>J$/^9?_"W%22N
MT5"=U%(#R>@J89B1J7.K3:M.BS?B#9)VEQ=\_%F>ST19BH[70WX8;4*5&"M6
M0CD>*(QUH)@;C".VCHLV+0PO0ZJ3L/B!'Z^ R;;[75<.?5UY!;$KGM405O90
M1\7I*/*,[M>5R<F^27Q;FJ*>M?-&\:IHPV[2H>U>%OM=H[0$!*\C)<QRQ=46
M)Y_=&+)/LC!L)IO]_04BPS?Q&C2O<D;JE?.F[X -,961UVP&>3,U?(@8%3//
M?IY2?)HLTZ*=D_2@1^,-1( ^1)O:FXS==_/;=/O"26Q$A!S1V[%[:MTWCRW5
M;P+OD)N4W+(ZAVS;V+[WD9%",<4E-.@^/30%'/7L<?]R/E8Z8>W60R"S.BO/
MOY*,3[5<]=EHFI%78XA23?%F62NC3;CI?ZAQQ$2*C/"7)>]9^7F4W=FDVR(-
M"IS@N+$L943;EE<[WY4:<N\2:^EA2/GX&!&O@7LX;3!<V2_\,U1;^$]#I=$U
MBHL47LFY]=IG;DE1)0'YYK]62+U_KM5#L;#ZDTQMK%4AQ^"_=@BM4<#0"9+#
MMQ\%6%<FH0#=NG<;8$<1+)%YT>[,!YYJZPF'!K^:Y4X2=6<19#[[\]X_MGY-
M_'Q:;>WDI%<-)>A;JWI*H:3N](9CX.DF7@\XQ4ZDW3R>@^_T]:T;WPOF%"@Z
M$ITTR+^QK)Z/!:=HO;Y;JW5';D*\I7;M4"GF@H_B8,X[7(#$50'QH ,%3.">
M8RYYUYH^F31UT@\&12>*)FB0DP=:$]-W#FS'I]_J^@T.V['6BIU(A(EL1_?'
M[(N1GIASAIPWJZ)3]HK(PFX8D(.4*&S^MVG15L)M*"",X@\"?7'UQSXFN/G6
M2@C<_D7JKKER<A+1LES+Z]0I;ZL37;;B N?YI8!QI_^Y/MI=O^W$?N7(9_=F
MI*:3DB1T+QLRV-=-T1"/E9Z?4395;[[W^Q[--YCRON&!P=>UYA*>XO/G^YG-
MH%YPK*Z%&Z@1O^+JS4^S<FLO4LARKU+"-W4JOF@CO3#(Q>Z!L>29Y.#%^P(*
MIZ3F%W-+4NO7)2VEFI0OH6IA\/)Q=KOT=88?N1GC 1JBV7>@E\Z9A'4EGUG@
M+K+-$-7H=+U'[!:>#O(#9F<29%*.LY!QBBO;N-Z&BWVB;<_^HZ!-C2N"DZ<6
MJ2?E6 PJZI&>L4)CQ6E0'"$!DK>O^3*L9:691WS*?+JZ17PUM'KM^E3:D=9'
M=HM:%.'E+O8B$TL:7#;<5@G\(=_5V_:%&M-5.: WL/A7Z7=L&CHD FF911<Z
M3."9Z$V>/MY;SM?ITHBRG7P&^$37=C *V%*Z_?6>_]<D]$AH->(!H@L._6%V
M?0<%F+UH%#V2:4<!5_JBM9@"MS16& 5,,L ]7+2&NXY5$5%(G$B.<TD4$+'Z
M!KQ0[H4"9@X=ZD3MD?>1<RB@&_'LW*"/8FYU[5U4<[<!C)[M5EEM]#?^=.[.
M*,OEEG%]R#8&]S_-C[ZUV8Y:1P[7I_N)?.JU/:O>\E:9)N'D*]W#K-$NP6_/
M58B,P0 @=\6F'S[_DN(D! 646^0(41R+HX#1/X)T^T=^SK9DJW.=3_F>FOXL
M=R<WCG$[@M>OU]9"]\FQ,"2Y>51BU(.)76C9!I1'+]2.:3=A<Q4<O",]ZOEL
M(.QT4N3W4,'+]J7%O<@GKFABW])NEQ&-TU-*^]4H7UASB:"SO3D?^XM&OFT)
M6Y-]YXLNB_OIVGOF1;&M NKAJ<8!/0)YO(P39336:/867 X0Q9F*NF=O7V%;
M6XGCGO%"QR=SCK]3V+2H<"<^85)Y1UA" ]TXWQV!PZ^7.[VYR^W<+ R,=I;2
MA(@((2MKW1OCPV\O:L;8E%@O:H*\$DB3>%EH+1\VF3)7H5E2;G;>L'4(=QP5
M:C>64WP@!L1$-')RUWX4<Q[%N!:][9,EH'0LM&8ZZ+W01Q+[J!_=;S>QA^#<
M+'@N)S1"A&W,GPB/165@:NEJWQ68^ I24(Z;PMKX5% G^P.=,9T@^;WZ>3HT
M?DF7YW';P-DCX0_<95/J\5QQ_B\O=.OLGEQ_D2,HJ_(.OB_R]A7T@@$%O& ?
M[9N2J+V)#BQC_I2$(W75M!'"Y.I;"_.T<CP=P.A.MMRWWIR0-8OY-C/)'&]P
MA%P9,FTS>BT3TB44N%KG[]MXL:?%HW^7"*^73&8K$/,:)+WXLQD1WZ6) C9/
M_BB$;3!G\0F\6<@/7[P=;;D?WWJ0ZS+(1:3(LLUY*PK8V%H2A70,@X\EL[:'
MP8>S"&84X.]*-GK:O #^^B/X6O]6>P6G4 "D<11\7-8U3\$''A1QJ 5O'/R(
M'D1NR4"RK_=VSU$ #\<UI"T4.9M1?ZN"NYU!B'\YSW)KD#YC(6=0 + [^N\W
M-7#/8^")1;?>!/C22H!G3G1)%@4L@OL7*]U]O^M+(VS53M60@QS57;^^+U'
M4@R.'VR#H$S#R$SP1OE40@,*:+%")J* #Y=J8 S8B^<SG="/MEOJ+B]]#\*J
MYBY=ZP=HPI\[Q4].J0Q2T3*7:ZKVX#F]%F,R%@^YHG..7IF%R+PNE_[R6F@
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M@Z-O+T2\B5W(_IH #&A/;_N%G=NJWDZ]AIQ$6-_)0T)-Z2;0CX<L IBW)K3
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MF"*QSW)44VIP.WP4E?.$ZF*8NR%^3(,Y9L(BZW7(-IV2DB/YC^&F13YC58,
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MA:*A@!#Z,12P' QJ45BI/F0#;Q=DGT[O_VLI\\I4Q,:.:LKO%*;Y1P-6:B@
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M(&)46*;S=^G%/P^0-H\IX\<0[5WN6W"(+O&Q-VAN,A-F[7D90]%LZ3RE-I,
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M-L(.HSH3%5$8&OLYK-5DHBFF)*O$/&BPW9@+);T@W!;15MIS+20RY%Q1Q$P
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MH',_G".1Z7FM*V[9MR\;<_[>C0>W#])  0<Q4C)QX+7;KP4AVURKW?:NGZ,
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MJ5&"2:&&LV%(F1H,D'P$&=*A1@T[H1%QZ$\MB/HE="]/-\%EY_X^!AA63L4
MVP2>Z/(]#' <<_7U\"YC@/1Z^'Y2*;RO!1:" ?HG6Z8_(IYB &?4_.(%H]TB
M2O1@<4*P!:WT9VZ8@-X)B2YJU.%_O#C\DGF15O@ U-"  =[*7]6?^8*7%YVU
M&*!'M06Y$83VV5FLMVY99,<  SP8@.?/R+&DU6^H%;@39+-@$'**TP+1.,,
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MY1^HFTW'W]#'AAG"L/'OD#^S("=C9]&*.1C [8^?;Q=B@!:2LS_>>W'+;8T
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M.I< #:OU2<1U^^S,2EO!J[$<R&7V,>9J%5QU4,*KJHI%J_H1O]P7@^87T&*
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M56K/CR#BPKDEITC)D./>4:)-$C-5=\ ]2PZVLDW'B='E_LWE;,P9M>W618L
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MVR$G%F=EL:0GDUSCZ,;/^U&BRDFY)7,N/;GX49&OMPJQ8<L,&0DK,$GC_(+
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MCD<T-DD9_MMY@4\!3V*U$2FT%9JJ-GE'^.IZHN0+*\SGLS&R[WP_Y+#VG%R
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MC<<OJK(D2W1;ZBC:*]P[U#N_#)>H;<'_1V.M#<==G-W[4A@@C"KRTOW7;(_
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MP [=XE]MQI8RITS[ZC#+ZT9)")>[CGC/Z8%U+P8W#M"<2!6D]"0;8P!/F_3
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M[R5^JSM/K@T4:$[]B<I-.^A*B1;%!^A]81[_=TFR>_Q7A(Q+XVM771N8T X
M3)U6%?YR'55NAGCI(>F=!TZNZ"]9GM\_%ZDX6*5.;[7JU\$F?Y^_\D;#HHJW
M&OR"X\U\@*?2,X#/CAR3@;G4ZJYS:;/SI*V OLY'3+\<SK6JA9#M_?'X^*/(
MQ'![4FZ5D,<Z  H0\66V<&W0!;GJ>:Z. A!((%" UJA_-V+WL2@ LW)6-?BN
M#:B9Q8:6?CD@.B,.EJXNC6Y"']4R'/ZS(L02G>OO]L8>#&B\D1?4\<MM1V,/
M"=8H0";Z55KE@7F#\=@3C70@O-V\1.?+MTGH HY7/Y*K\!X%6!7[>.^RJHX
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M^Q-G^QLD#=%TI\G2VH-[+LC?8)>PC;U"SSF]WM(?96<(3VC0QNJ/0 UU$Q2
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MZYVT/."T^#C7=FC_*2'E:G!R6.%*OUG3R,38[9,L5W99V1 DS3N<<O]C0:J
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M/W3\.CW[1DS-WCW._DFY@S'>I>=CB!__?X<T^O]0 +7POP%02P,$%     @
M.HN:6&DC+?8#[00 ,'$&  X   !T:6UA9V5?,# T+FIP9^RY!5!<3;?W.W@@
M2'"7!/?@!"<$#\Z@(;B[.Q,B$#QX@.#N[A[<97!W'PC.P#!S>9[W/:>^^]5W
MZ]Q[OW/KG*K[KJK9>Z]?=W6OV;NZU[^[$0N(#< +)3E%.0 2,A(2!Q(' ("
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M_[\"QF_.=I-A7R1H0(+P6;B->.>%9$V0TDGYR!SMJ/4.AN$&BY^\#R2P448
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M=0_B@KP+RNJ9\9W#*J3GD.&3-8$VM("B9[1=9#OP0#1N[^>Y7G-_\'>EI."
M >9BC\P1O WGL8S:-?\1J(=WQ6G!252R'$UKF2A7UHBJU2]%1D[Q#\ Z?M\
M.UW;.)::YQJ&[SZ*4P@,B.($W;<L?^!<PF$^YZ8(*%+@O^J&&]G?]HVO;3K]
ML)7\[@HKLK$]_#*+)#_SF"OFO^;WL7F=N&[56DM??B$Q@5*GI0.;J&D_Z0V8
M6^RU(JYP[Y_WE.,'Z*'[TPYL]]\?_)-;4NVD.(W5/GY=UZ!U=KM5KY#W#!3W
M\QR_4O.&^$&2(U96A99:O9D7:2^YSA?7VD:VF"?<L1" )CT[ENUXUJ.B3Z!X
MCK8ALON6=65/PL_ F6]WWTW>/C8/[,\E'0FAAFJ2;KT,1H&,BZA8^]V"' -G
M:7I76FE]'%?/^>^6]+R<O!UUMG@KN<RE\Z)<9U_(ZTT#,<W_%(5<'!LAU3]?
MM9(WLNNJ<'M&3^7>4UHV>%STFG[FA9Q$H/F:X?. ZW$3Q]/?BVFU9M9+<=B?
M-VZ35LN6B4.PXHZIME);R)C^#$XUZ4[EAU>A+CQ<N>7]+NH.Q?K\#&[D]$;'
M5/ME:!%=S.YDH>RYZ*Z@,KY,D^LZA3^\$RD>Z.#D%E%P2PRDEO*<P2;FV38@
ME_XHERQ$]2A>Y;R!'J)P?%AN#Z?Y*32)HH;/?E@.FIB4:6F(/EYH'AZK;F_H
MWUQ<3J9A'9=Q=BKC5%VK^ 24JWUGE5<:3O&]+59$Q"[23DZ'%)76CC[6DB+A
ML[@T*H@K4Y%$HUB!?H8B9G?VZ"D]</TX%O/JA1I?6K?<)"VO^3/G".*Z$S>^
M;LTE)/%+*>7Q6>1K+N[C?$_0->NJ+A-36$ G%GIFI1X<:?F%JL_MY-Q03H%+
MFG^ ,,\:4A[4/>G\DXLZ5=1G"&V0*>27:BSL^$%$ 0%@=0YI1[I,9K^8\ OX
MUFW%&%%9</S8$])S0E7JT"),"5)L*;G )!9@^U35R\-_J(+5,D! HHZ75YH&
M@;6:A)F*>2+KV3&K_A!^;#X<.[TW:GI732,2S*"=+B*U?7-EWE(+!8'8$8!,
M0]$:%@F2LXZ#!>KJ*A</?:+^LV:&HCR"W6\&ZNV>G(YB$*"L^#OT-QD1+'%:
ML90U][-,\H+'_O4UCPHZ.A+:%:P&6A,2YGGQ3MYIYJQ-6,"81+'B)P2AMA]2
MG%V-C\U;>X.MT[U&_LOZHZ(6R</(IB#DHUT$KBUV!+U%*:M9:E(440]WA3[P
MF=S+[Z@/))3?^W_H2SM_)4 2N,+(5DQ'0S)Y'D#W [,R2US8J2+YE#.":2K4
M_UK2\N2P%4GF1+A1IW?8<6_L\V3^^7-=9<PA'$_^8S]7YA*]@=DYN/+/W6)=
MK<*M7!2UAE JL?OI#_*,2C7I8C9=8$CV@%)@S_F7G8:I94)GH\7S[;:;_K'"
M0KN6J.4FOV3);_T,"IB\[8&J$FS 2("B.0L 98)F6?G 0D3G'?.D2/P#^RS!
M#>G?#N^3,^E=^Z3&@VZ(@8&XW8N4G0$Z6]47NS4)_I*..J?ZML6F+S\6Y(BP
M6/O83J7(*&S0,2#[WES%,[SQ>OX!ZP?[@Y^78AQMU.?Y;PK$C^UL!R)X[;RM
M)$Z3?5>-#CLMXZGD)6RB!%\JW(E_LFP7,"B<)4='51_$_I#A*4)2V(EQ3&M*
MK".56N\ILGM,K-06TD"?-/($X68;+QI<A2ZURGN>E5VCSRU2FKN<44\DQF[U
M0<9*OQ6O"%QS4B1;%N;FA=N%I6CH?U<8 A!>T:S&R7ZW,P-<,R#![EUW]$(*
MZ/ T;20S#9% S)VAE""^-*AK0X<>S)'9%>+4? P;G^WRCM&?B"S/_M"]8L]H
M1,UE%D>^25A/)3,:&_'S$X[G#=$>3E<P_N?W)"9*@CC\Y]-!@>A"RQ>H5IBO
M]8-9%OC!_:'[D]ZP!,%U]=M-J-HY98.@ZO2XXN*CSD.AC5-9TGQ.Q;#93F]U
M[WR')#T'IZZ:!J%E=;W'<%Q1M)(^HR&)?_MH%&-Q^!:O7%(V,;^$.6TL1J'O
MMXR% 1$"_OIG%7@_!W:DC^*\Q\?'KO>NURA1W/JH);87E@M='$Y@+VI%&)T6
M2U/#B_%3-,++_B@@L>0%#V+$F"GD$;*X=G^B/WG5_BSGQ_OL ?2_4VG2S;[N
M?^H2,4KH=TR,9D A5!Z<3K57PR'X9Y5GI+7D0%K?Y+?C7?[@'D.T,G&(5G1>
MD8)12*QH+T?O-Q9O]L[LX)U+%-K#:(Q+\5<K7!W1)/&CV(&%*-","E)H+HA#
M+>KQ^7E&_ Y&W[>)$96:![E<\YO/.]X.RSEHG^: )H5"*8J?2TF;64US8I%(
M;=>!,-L3R1IGO@]CFZI!C"4;V&#=Y**)=Z*"YYRC:T0SP[,NZ#X( $]&_7;?
MUH7O:"(N[?/HRE'+BT07=7,>O98WO,0"A+.O%;(_/TO<3=6G^J8MR]'["4FB
MKZP;33&+2K&+&BOE<_@OI#V_ULI=RC^G'8U[8LM\NX7]OZXHG9FGEH]=(9#&
MM55=P[#\DJ*^G:H7Y9:,@G;A9$<T&6S-I ;L-@2/<MDG IU. ,.CIU7.$:8\
M,2!D.P_6@GN6O"%=@HDF\TGI=1&J4#;4T]#H;+IU6/4(*FXXMZK;:B\R4O:0
MV^A*W"R>6VM?0^9 C+LVJGNW45R27Q@73ZNF*$-!J?R*PZ7(W)+TQM7>+8?E
M2]7,8,BWD (&/"TMK:GZ^N'OV[@]6J\H"-@44>:9"K/8+3U/X2=E=0LT+0L/
MG2!KUB*FX1G3!IVE\E6@ZS1XB$A3NUT FW"T[I#C3ZZ".ITMOB): K'FZ(_P
M5C0JMEXDXXE\7J6J\&8L8>T?:"")C ;=][<8EE87K?85+84UWO#M[N%)JQOX
M\$*SRJRAW-'T2Z42)0K]_4*3/\-YBA3I"MM'Y79#[E1TI)[J/@1=*#?:U_I<
M]-^13TKPD/4 0<,9*4*=QF=KM1/*]:WT%D[PCI4_,M3O'MS](26KQ1]CAT=+
MZ:?F>]34BT:C4<A.E*K0-Q[JM!AZ-%^;'N7APUJ>EF6_B_ZQ%,N/YMM>#[*J
M:75'"SV KX]8W4;3!/;4N=R-UXWISEJZ7OUFBFNE5",F'#.2)\M !K^-H0BC
M9PRI;[6Z($9-5D)YZ\F)=/6F>T EK>D30XLZ!6&1.JU,9K*&8+*LMQ<"L.+_
MQ?I$]1=$Y;BU(?W#W>-L?4/RQ]U;)GER<8YX&0YR+ J1-R4V!=$&?E\M4ADL
M??(TD>10W(QD7V"/9U%]?OJKOU5]KJV;H^G(TZ7$,$V0'MC<I[5\'8P@\_I+
M4>4+HJ*>#BIC<K%#NHU"26NER\3G'(W3TQKS,FAOV?46ZDPH*0/%UYXD1O$S
MTZ-G]%!/GUW]D+Q_RHVHI+N1"WFDNH)UZ'I,^OJWA829<B.-=K=5C8P!,_IO
M1-4I%UKJC!2]Q'K)?&@ 0G\\A_(3KJ5WW]6P,#1!EGZ6SB_=\Q2^WJ,;P(>O
MGOD#IS,J)J"B 51WUY<4>'%05?C Z:]$4HU)3T=59)S&IKWE35VOJ E&CW@?
MTB&^$M/B7G-UY#,71329@)YFE<8[LU?HY< BC)!4UP<_/.?EKPT29-^#2X%V
M2)L%OX+6FF]6:2_4!J]#8 -7G-R#;*<G%4N+X1+%.8/2OTH^.W8#GS.QL9K_
MX%6(T^%7TBZ>]==;7W4<WZDH,*)@$X#1XF5>'%51]QF];^'7MKL+HI7<G7H\
MFH@6I__S)( ]U=R<G3\)2'+Z@^MX$UX[MZ>W>*&FB,WQ/?0WBS3ZTI=U[[-Y
M7:-34D=%$TR9F]NRY46.<#AJ&BGMM<6[MMK,@3!)6A3L6/,QXCD5F=I\ M-)
MQKR9-CT&:WT4ZK-QI&RE=V05F>=#%Z?]-YW[<9..C+^F3UWR57?@6HA.U+K[
M7XH:58F@^#G8WE);2CRG3\P=,.5I:@N2)XQ[A?;A:Z+[#AB'OUPA0UOSQ_-E
ME_8X_X1&Q3H6=0JI&=3IO+AG5_GL Y"C^?DX-9<?'$M$+&@]ZH1*<0KTTPF5
MM(WE(%%)O,2SS!^/D>WDY_.>#LU\AO&,AE$'U+'!%:NS3?A*4^#924Y&&@F*
M1 .[5;NAFQ??]7L_\E<9FS61&;SMX @NDJPS ]CM6&2J9;[U(3/H[>#XM+UM
M!G#FB0N4"$0/#)TQJIP!7OE4+!S3]!QC%\B1L_'<K?4L^G(F:HBY',PSO-XI
M+LY+)!VB7M0.+G;RI5D/V1*-[!^>V<[[ D?V"V*=#LAEUXJ.P[L3N?WH26I_
M PFT8B^^'ZAZD&2-#A&)#!&J%/RH[#<C3;5TI<@OO&27\DKN?,C*$G!H3X/7
MJ?)ONS12"  FM9_^-'8KVWQ(#L:=WVM:*@F2FWG_@-AE26KW9<-JOTY&P^2"
M['7]7YVZ%A=\D'"_P8(XMI4&7JO^(17L2HK^D)R2%/V?^D,;>6TKN?5?1_,-
M[Z1,5V.[]N?WIY7;^T5M(K-*_0 ]K:$H&;\Z' (83IQ#5KL[!'$\F2[75CWK
MV;TR1 E79ZGMC6I=4FQO)4@B.$P*$_<')\,.\XN+\VW K'Q\T\-S;RGXYU:;
MF38I&FW,#0JR]-1C+R2 F_OS#8]]W)."*!0W=JCA!!+RPVUB]VCGZ^1P^=T;
M/R\:YNU;;TM!U 3V^)B [99"<<-0.RMINJ(/O[1QWIGPU%3]4,M5Q/%_$5AL
MOP"L2WDA8/MVQ. Q\?"F[9NAH@?&M[_WQ+*4ES(2_F\<X_S_#^AS7WQ% !JC
M8)8(0#W\!@%8TQ4]R00A *X,#Z1PL7:BL\Q3ADP3!""&V_#Z(>(^RN\_5CRS
MWG!"- 3 \SL"T%_N/?_H_M3AW,S'IY+2SGU)!,!I!LJ( "3X(P#^D/*3X^3.
ME4$$8!D!&*#,C?KR.!+SV AS;9F<6$F?B?T[SGK0@$=E&IQP?>FP+C?N?8MC
M]&' UG8N#O-GZC'^%*:T:.!KTR69NT^!/ALXOFIKI:4A18?P"U;8/9H1^#9U
M_BX>+O+DS,HL[&=7&HK?[C_VK$YU7E-6==X6#3V@+B$ 0\"..00@^@JG'@&(
M2PLL1P"H#RVK[233Y/B*[VF]G6GC:5_ <:YN5A?3F GKO:QM@.8-#O4_QQKE
MY7'$FMGL8*KJJ>$E/L6I)6EWN_C?9X@-_'0D&)RD38QFS9.L&6;*514OLFEC
MLV'W3FHY7$?%'*.*PS,[\;^_!LF%7AXRPJZKJ5UK.@P#7D+*]X/S!DW8\VW\
M19(RR6K'8G][SFWVS*FHO>8@*:LG46UAD%/W2$<;3GQVQDD:A[FME>JU_X6W
M"@&@.UPSXF8@?/4+3AO/&PN7GKJ!(OV @M8G0J"LL&H)T^N*/\<GN.#^J1D/
M+/-S8OY98B(K6TNUIHS4TH&XLJC<R"D+76I.H:]?2]YV$Y7,&"[-40[^Y)&D
M5J S'R&CLF,W5HW@_$HR&W[*A*TVH*4!]0OHLS^<$H3KM[:BM75@[ ?1>50.
M<I#V2:;^/.U=!;Z!NB\8J&U=SVI8PHJJ-.;J^'3">*JUMJWB?@[IOIWD>9TP
M7?/3F2>AA93@91Q!3@)3 OA(V%I2(OGT0'-_(!8[EI@HFS]?7!Y[?_):37(,
MPSY@<FEUM^X< 1#DO7/<;C\7=Y:IOY$TAZ0JV?! 1W%IF>-+HWUV\G,',-E,
MRH: #+_ML/P2T>DY+/C=!E\N,C3ZQ("1T4MJ,M@44&:V:0IS(2F0-;ZK:Q2@
MTM_HWB^CU'QQ0N[QOWA<SFVFIU]@/"9)1H.&A!K8V0U"'=4W[JT=ST+M$O,C
M[F@NCL.Q/RHICL"7Y>71-$J1RE 3SAOR+'&KK[PR]066<,5W@Z88Y2&;T"N4
MZ/FCO1;I@;;*)8;*RR? L 5'WFJ(N;0YX?[Y)B!0 .^]:4O>;:"$IJ6&/.Z?
ME=>SFS5T)<]KI57DXT:53LMD9;5YY?2#SVN6L_V)&VE)RB7%D2,E4U!.J'F7
M4_P9/P48U"$ =>2TH^ 3:A*GIM/1T,&S77?8W$/G*^;(&^Y!FN-Q<U8[QYV"
M_HK%!8^[5*%JNGH2+@IA[J  [YL:?U-K7WO2/WDFCRTKF7MJRDR-]\JM-@C
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M MWZ\XQPZN8GN8X 0)D3>_'J*E:@&;WEH^]C\W?]R@KP<!@?J8X'IGN(ETX
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MT*J9Y'FIT34"\.'QK^U[TJ>2DC/H! *P7"^A"-JE00#6'NS]17;/;GDE;Q"
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M=>1,L!VBUVG 5=AAXR*8'40@ 9S0Z0?OO7+G02H\B]/Q0:A6DUM:0S+S_%V
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MFX01D7,P C#JG-_Q&M8.U;I J?+*M+'T\O:;<[8;JXQ<;(I456-6?MQ9V1=
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M!V,O#]8$XBIJK7$757/UXH*O4#YW[!A=6%P];JD5Y;8>TK9/(PX;FE>3$*4
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MS^$R&1F7Q;5.<"ID[?!);U!76;/(98YSW?BN>=W -^F>F<"F&[0']$DBDW>
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M8)6T<C"O!XB"W.99^)O;>AP]*L1'(6-[H.F<I";"N<#&/0=?X>D?PX^'G;2
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M;SE5.HQSE7W.>"& A<N L*&%_47\ON:(&<Y:1*T%09(">F2@D<@9T4N7EIS
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MI'-.1D,:NE=$"^D'LB#4:A4S2$[X$_F'0+85BJ#7@?1\";Q&%B&%Q<6?>O*
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MMXZ#SD&'^G@'7Q*@;SD9+S].7F:WP$F-(@L.^D-H_)M8[[=C\_J:"KN?4[I
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M<P2E\X97_\ZY!S.ZV<,:<YP4(&#F?B7!9%")S_5)[1^F#PP!?S0P[K]QJ*[
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MS07VI2>FBJ%J.^^K\O?;&D_O'%V[==CP4'\*&2UL>1$QW/%D44?K3#/XVJ1
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MM#8G_:+E51*OQGJZWMQD3(@?3> [97Z8*U!:81?MJD](W79Q(@%6!)$\_+#
M;7MPO.((4R5'1>176WK_$\SSPF0!P%L?)2YO3K.Q^)J2RJO_CJ[YI#-V1Q(U
MX(-P?*G;B&:8DC]8"-UP.![H#U3@O"7EP9FZ33SL_[6''>[3'[B:\L9WK;HA
MFR[UU<ET]8L9O;+/B'(83GEK,ZH/E2URKK$_#LX)35,28G<G <3&B#OUN1UE
MMZL:DC/9H1?BK:T2K($?$[VN B96SK@9KK[^>+LD;<P0)55,3OT]HCN[-.P.
MOIR@]H,$$-+^C,SUV^QV"2G +D4C&>NR*N=-W8RP.T%A,/2Y?"\,=_=B8"Q=
MR?UE\_9A/<L1XEVE["#<5F*B[=][Z!AQ(KYN[!LIA/UN*US!2,( 3&9KS>.8
MXGSC,)\-@G_<N<U_%,Q^K:U;6L?P_3$S USTZOV>5OY&KQ%QNL.9\TI^QWP'
MVLL9 QTH#*=FV5S&/L*+SR5L$:T5&2ND&?;.>UM(@/196SS8+\EAH%7@:=;8
M\%)NKZ?Q/O_V69ZR]Y1:5M_[_\'<>P<U^7W]HE$1% 5$03I([R =:1&0WGL'
MZ1VD! 0"4?C2>T>0WD/O38C44*6#E(!4Z;T3PDU^]YX[[YUYSYDSY_W=F7<F
MDS]VDB?/L_9:G_59:^^]UJJBF.>TQB2Y?1ECF*0HQP=8ZZ7.,"*T)L#J'D!K
M]D\FQ?$D^,+K]'!T([==@O22>]@U5IPU>O"C*,W3L*O;]/*?!XN0.6WU;A.%
M[ST*ERU.GI\(#<2NPG;L4CS#D]%J(N&OT@!+,!LP7;Q:;A+\>_KVNN'DM-;-
M?W+FKF+:!*<#Y>;UM_^1=&OK CU> #MS<V.P9\N#+\:<%E^U]%**\T*2^..5
M-&@2E= Z8 ],F1:70TK0(%F@;9U"<VK?4;K\GW0_9_2<JI^K?AY]J>",QT!G
MIU0B$B?R^I'F,L(O#SBMLXPS!\F2&$>9)Q/K0V+$@Y&KNQ<];9-[EWB,7(C1
MM0O39T(AH]HNG"W/M/>Z);7"M+!=?*$B#KY]!<4IA890X?5+TRT!./B?I8RV
M59K3Z:OKJ6Q./[[KKVC<R\I &2"R$[=CDQ$-\FV1]-&(A50;ES#W=A^"C])1
M?9H7_)_WM(F($V8QI2(U1MX6EI78?P\Z:)_J*$(0@@GWN==YD%T=DA,7KYE7
M)2#7M&?>G0?P/;M/R0NAKJ"4/6CG?N9XY/"!KZ(^4^E/31>!Z:C2 =+G\G9_
M;F>*BPI]Y%HOY1Y]NO V@O!S_\4[(EG'Z1X98+8'>Z&,J7A.I4'>9OW[-<%0
MU):>;8""<[IS;M"<?A1R6TTI:6BB7," K;> F$=2GOJ="4/JQ?]]8(JAU3 =
M>*4D.!!1F>5K8+9&<(H-E8?2VI'VFK2+JMI9X?Y\13DV0!DV4Y?/SLHFB;9F
M,L@7,WX1I17F$PN4)@6LH]8OB"KZ(#/R&+BF9];]I4O0MZC,XZ*/5S*T^&TX
MO77A"_5I%8Z<II@GWY*I.]5:+_4._TU]P/\_ PTF]X!_.B$("^!QF0DZH#7&
MM*]O(,&T.3[)/L)7N^*''%JB,5[A?Y2 ?K]O"X?$7E.O]8$C^CUM56?!@5TK
M1LXK;3-UY=7)HH.)E,=J#W**%@^EYII9HHAU--)>MEBP\I<6*\<0M%Y*M?L_
MQM<-:2)+S"L8L'373B8BHP3YB^A*BA&'6::3Y<;QN_=R. UN#>HD)7^4Q!Q,
ME<DF//)845W><9X>^TP3>@]X?91)W%$W953L=]9(OX::[-OG^*5&/J6F$C^X
MW^_V-+1?;[)#B')\2EMC@$V \YT>]I-Z]"/) (\*1C>JEF%<L-1[0-]H#'#H
M=NW7\F+LY#V [B+&*Q$J^%K.X9R+#Z?Q[:V:IWDNZ8YQD?2CL.+<?&B_^OND
M^HK/">]WGP2^PWBHR@Q+)/Y5JE++S4*[D&LO=ZP.A$FP:&KNK.Z2REMS?R_K
M;U'_"L^X)O^Q;311,@Q$<-#7P*II-2:OP(\YWH!O,GG\-R= ?O^'R\CUJ_%V
M\64_:;R,4 \+P2K/\RR2^IKZ;VR?V5@M^[74_[*4E7ZL5#1L+='U#+?6+TIY
MN\+P"8V'V7-W%!.9"]49T-OLXINF)I'.PEY5A-O<'21\^??+*R;=7(_0P0F=
MM2&-VM(O=^TK;TC/XC"=D$E\S@AD+KBUF:4/E])W$!L3ZG^.16TR2IJXNGHW
MO::$][ 4L"4BGC.<5447%\&[B124*#T'ZP?#:)_F.A^TC\DU!0"0K^>-^%S/
M9Q:O[(\=7U5?9"%S]L5KZEE;"1PA^/ #L.9P4D9,3'*-,YZ$;X)(>,+S0):R
M$"&[M63U9$P7W6;TVQ@M D86((A,A?]QHZ'OD/ ,[7^N.E-1/N <9>MU+H'3
M4'H\38:E#V7."165-*.BG.P+2Q!3C-J!ELL#,%T@Q2>7\25HD9_[M:UO'JTV
M]:&B!F=>3OM(9&WMU\SHO$Q1(^-5">X=EU\O+IZ"3\(GT6JD&#-ZA3A>;O.F
M,3ND_KNEFKJ/0$S-*?#YZ[7Z <L^^=TR-CI:9\64E@G>>>F&5);A:4_K[X'[
M#-^9QPVIJ-$Z?^K30_@5XV]LN<1?D]2QB>S"6D/+;ZO,=;0G9T;J_/0LU[PO
M^$?E.U=*B'P4'4I>YI$\R$]65Z  ]/_\XH]&Y(0MLW":UQT<$S8L 0)(CVWJ
MX.)%S8*%8-_(\K<(\/0^<3WY'(^GYX3.55>)&GOS>X#1 \S)-FX0TF\+DF D
M[\0=U\XSW;Y2JUO+$66DURA(S5?-0E\:=*;=K914!(T@3T(-EY31H4@Q\N&K
M#J!'ZNW\*EE$$,[< RA:V2T]B\YSABV:JC3W THZ5QHW'5+=9#C(<,%]Y+A$
M\ W:BD![BTRVT@V#/*^8]_V*F#W^ARY@QZN_=:U^],=K=F<$BLXN7X8MF[!I
MN,?;/*!'^N*9.@IMI@:\]0VB-NF!'!QG<T)97F716]_8R.7XV%,=T<^\4GV#
MDR=25T%3V HO%$FL%/'Z,"S#K.4DT=SMC%<[U&SEXX[[2?B&#6Q@N&T=OX,S
M/V_K92_PF@']4Q-!YI,>E+&X>3M/>^2LV:. -T[1Y\'EX)AGH'U(3)L:GE%L
M25SB7[@:-BL%#6_@8)7:FI54?[!&1#;H('3OLN\PYK:L61#6;S(^ELG=(GII
MN3KYM/:V6WRZ6:SOJ'M<EEUJ?/520.;YMW)_MJB4#T]R*F+>LD&=8#"N*M!!
M@;<9O"/TFK$^I.OZV225T1(%HR-=?V^#GZ7YFNC#0)$TH(PR?PMZEG-+U?8&
M(VJY5T+1>)E^0[^&TW<8F0%A;@@0/&-6\^1:_&4%B;+]="<]*YSU(["C_$V4
MCAX36T+J(9LNH_R,04-K7REY]0<=-%O%S_H_@W"]\7O 3T/(M57V(>9H>>+_
M^(PF@ILE&TZ3)FOQRHX\L :KLJHRX;U@>^4#S,9;U;BG+W,G:/GMCN1$2Z;*
M- =*B6/?R ]0_93(*SM_@VFKRO [2D?&7U WGRPVFU6&HE<N(3WBG0.= G>I
MQ;>D ?*&D:YJS%9<+3$-'V64,+*/AS#C_92. BW(WS-0H6'?'=-R-+<WJI>C
M(3EN[7A70I/?\*:DE)Y $]JHP1?\8Y#HMP.#_F\WS&'-P;#@.0V=PH\GO"6/
MTUB,:FBT"K6-40":]QBXZJ6+H*>-$5[C[;=.RL.:Z@$85)Q; $C$CC ?&J$U
M.P!+]\SUU_*F^2F.:,=1QNBC4U35ZH??OYI0N^)\^U-7 _6UHB[F!D8"VD<;
M^*8.&R51C)0/T^1RHX;G,2<5J?G/]G$GZU^D>Q)"WUMH?I&2?/]Z_KUFWJ*;
MN6LQYJ@21AB/J=E)8E(JP0&"@2%._Y2)@Z<\W2;J#P([-ZUT>(4I'_;$"6.D
M*@2W7*^*9#DC4DL,S%*4Y^56C!:189T:9^@%1U*\Q2IQ?#6 :?6PH2<M8_82
M30*5C'"5*'>)342T2SZKC'<U?Z0B>#/_YP3S9'U.7A)%T)36O,"(O,;0@0N=
M1,V"VN[-UQ"BJ,*U*6$1^>8;3#6%=X&O*+K,P[JY4X<(H^Q=WS&><Y:#4BQF
M*1-<SS'-B4A+6&CS2'_;E=+!GQBFJ<LHQW>O?9*66\5])8D5V.HD*8;1E!@@
M16S/!%PZ(B>O;ZR[K%LNME!1.%&C99+2H:1)+(, [:\\*G+S!C1'I./S"_O5
MIXIC\F(:,]GRXEWP4]%8L?J'X@4:X$")^]MG75E//+6('#R/.?-Y J'JAOTZ
M"@]GJO]@_H;V@XV<E>SG\\^+)8R@(Z> O+5=].Q72K#\R(-0!IB3A:GD..#V
MO&SM:%4 S%\T8[1+@ZU&OW4G0J1UT?FQM:Z$AOAC%1U*T,OWJVO&7#N&S.LG
M!9@=MZK6NIKEC]@?EI=S/0&JRZUCQJ3@:SS-::89)+&Y?9,#_ W<V!()(OR\
MJBXGQ-$Z2BT;Z;- C*64QTK+,!KK'"HHGH_),+S0;1?A+TDXZ4\@K- ((WE0
M_J^=?2.4&A](92C=0N,WW,BQVN1=AIT=ZZ@5;K)'T>K10L?PL=RNI#!S,"^8
MO-!BV G(T9, 84CPP>@#<02##X/\F@(3VZ1(CN8&0%T_1C\8\.P.!Z,%ZR7A
M95)TCNZ'A5*(C!V5CH)[@!GZQBV)SG:?:96_B/!^R?Z33OT?985/NO/R%GU(
M#P\(9BM^S>38N*:DBHJ2@I**"J85,NOV]@119(C9@LP#K8EA\3>?Y)$8AN$6
M2Q4;TIC/3/R8R("M/S>PBI:*C>&D4!QISY#[(2;<HX#O!2P2,RW3:7L!TOOW
M@#!U#3W_0BD=S;L--NVKPMBS >H&YY?<*\%A2(Q Y>WR[.F3\Z,+PT1ZZ=]P
MY"DYX ;D" 3O^53#,)8^:\%C\(YE<\"2Y_JIVZG_"%;#E,9T_4NWV[CZB#[F
M/[Y)0?!9](2J8I[\JT9DGZXL;1E<74>J0:K%HB0_!O2JE$&9..DK"T.FU[0[
M1GAC)"?=%:+ %A2_=[;Z&=QB#$1B>Q%JX/(+-D^5']\SE*D"TVC;MLI)Y*1B
MX-,:$-#!$SM54L;J?RS5,]PIB9%^!S,2-+=,B.([T^M3"=J=]Z>8OI6NY-%Q
MI@G>^;60'X,;<9U4%Z\1#WTUK;)K89T\,HJY0]G'XXQR,1\,Z.,-&**G1&J;
M:["HG] '$F#H<$'7RB:\DLY8E==8$TN[3T'RU>17PJD<*?6^ATWTDYWK&*BP
M+RYFV_GX3WE<A5B$A28Y_[3=;Z,D\O3!S^O' QCRPXXRASRKO@< )9@/EZ/>
M<76-@C@RLKEG,^J<O; 7NC5<%'A\LJ"+I",CP5E@504:FI0<XQ2F).UQU8=J
M3T%ZX6?R6;N(%Y6;*&.(6(#[WAXW_'#SV<GEFN[I5>GKB]\4HS6-!'!@Q#O3
MND4*A.\LM\SWG)Y-/J/$@(/YYZI<9;22JM.E,=T,IQ^*2/\&F\2B'ZOJ$7U$
M[R9K+Y,9A612X4NX<%'_.-R$]'.+W%.VVEVC# KC  PB<>:%Y[WE=ZOG) O/
MM7JL&&]1&! LOSK3@&%S,T_L6.QSB@J+\PJ*B_+9[+97BN3SPTK>D(YKL[T@
MJR@@*$5UH"?^5\V'6(9P2GN&7D-;;5SC'-QGA$,O<AY <C"[VW4.T>$=OFV'
MS7[6/P/G,'>A#]ZVO57Q?L -'*5#A[MPA;FK=T*O1^!6QV[C!R9M.AI2[I];
MH1P5'YRFKLE%=KR><G)J.Q4(H<.%QOQK'V3+-1_"C,Q/Z#H<_&W+=.CW/>"%
M7\;3$_82$8\U()PC54-C]C S7\E *7#4Q;AO<TETE%[LLVYY0E%6Q%>6?(><
M!"7V<@>,2V[YGQ:[T5^-8*&+>4(?0VH>31="&B=;4O.%6.?] YWW   'SB/T
M-XRI4]+U?!B* Q48OI9:Q:_HV82/#%O%>Y"))8M!,(RAY2KOKFHA]@*_Q/_1
MF&=2ZSV@5,0@E"90;@R#[G@F>,1@)3P0(Z<3*X='N8[GMF;NBI <[LH73[$@
MQZ!^C.0MB3ZTD:YQ<C@21:F_'$PO+X>P"31\74N\PSC@9KB*VK/7$4\L+/A3
M8ABE+:^:'\7@H,?S)=A)F*0HZ]/F<08G>QE>6"W%")9\2#*(9V)?US8_?_ %
MB($0CTJXY8F;'+YB8"3M<X$7T[W$(#8=Z)"J*R6TEOUQ/ ';3Q.U-[$8;/B<
ME]1G%?/NN>93"ZZO9]58V$9WI ]EX&*8J_A8A%,KO!2>4(BH_U5"U/*>Z#5]
M"NW[A_< 24SIGQ8V.A)K&=WDH/[!G-<?<UUZ_%63-3RN /Z8(A7CI-=*1ZU<
MJ,/E?V!,C5D71;LQB"O;A;9$3\NZ1.>^Q:??YQ"%P:4_754RU>DJ<Q*>G/+'
MRH@18RLDI%1&D)&G?-3'['<_UM&<F)D<4C!2>6S"L669E0XE+HF>N@=8CW?J
MTOR1P_ I)24E&35B1F)^HJ3J-S&X#OJZ6?P:=TD?'FA#OF 0Z^__R@7D_6\)
M4^7)U_GW$0R@#_8/O_1:<FB_.J=5XGET[.%:BE$K BR10LASP[\Z"LM]7#M?
MOE#.[P$L/P:D C&0I%%RG+;H^6)B[?B,G[_^1*S^;,HS?E*.0JF$CXX.6O;6
MNP7PJF1Y!^."X[?L"LHBVK=935N?% 3BSA;+)K\T-7@I)0#E>?A'(/8O^FH&
M>1$L]/JY,<(6DH7TX5@..&< _0>H;LS_O"*.BO&=+SF>(IQ:3]:B5T]R*T_&
M#9)_U6RB^:7@"VD&O@3&( Y:LW*WR\S(SSQ;?.QLBW.KR@H$["G3];NL93YG
MZ5LFA=CU#)088VN""$ 'X8<_S<*(($]0PBNM[OZK?GP0&Z%4\XM+SXL?:6H'
MDP<5^XMD$3\NUG]10A"Z=TDZQ-/15&+8E99X'&\_6+L'Q[9>RDG_%RM1]<:3
M(N))[[@&"5J3\'KPRRFK'OH>?V#/R2-J%E&,_.1Z=N/O<[E/EY137)QJ.N5H
MF'YS?3Z$:*W2?U-45*AKZ/"9=7JQ?Q=+Z07'LB[M^Q;@[(*&5%P@H8Z#@^<7
M-G^WR=KATQ<FWTI8!%[:B?/-,@<^98BQIPW?#-4+T8OB8X)5IM#M0D9BV^L5
M>W@ \3_CV"2Z-V92=-6U7SY8?< /M#O=;3&/L'[*KS'X-;EK,%#2<YWBA4SG
M#8W?YQE)64#,.^+^6]\)^?'TTC='G44$<[.<3T"(%]?"B1/BQD;9NW!*E/BA
M_"_LS\B;F?RH[Y^N0:MA_9;6NK*:4<&26(063VX,EV/]V)[DDJZHL8%R>LB#
ML@1.JXS?!.+:S9#;610'<Q>QT!.RP,YT  072]N42D\FOK!0 @ $OT5^)-3#
MM1)ZCAD2(/:[+181GY?(\F/L"C1K9=B>$G]%$@MA02K%Y\:M'NL_Q']"EX.2
M@^;76_$F/.E_,Q8[#.JGX\I@BWZ6RY&C3_$)F//'#?5HJ>OK]4?_3+L:8);:
MPIBZ[T%E?G-V?1V9@T-4 (UM9EW#I[)'S/,"5EF&.P,,-F/620Y1!G+[^CQG
ML6Y_S^F48FQ1U<;*5+2U-TI*GPH^<]+OIFOVC-6-O<FA"@S-'=_<^K-QN%C]
M8? $X:\RU1O,^*35,@K 1AQ KW5LY;:EG?"$\7-!"FE! C;WHP%2]^#@<"E)
M-OG5M<7 <?8X_8=Z;^*>XFQLCU%96V&QOA%\@O5%;G2V_)^'DF]>%NW(MT>'
M-:-">F*]"GTK[&>?_J<3!OH/$U;['R:,+FR^$@JJ#&T-^L3=B<I/A%]E>[$1
M_ VZ *GW!!C0N)HD:Q;BEDJU*L:[6?96G#6TWP0FG9SM3@M495?I;P:2APWK
MO.@54Y:TVXQ2+%:C6_E*27-T:4!O()L"B)5Z0#-:)D?_ <3ZYB90$F5BQ5:H
M2*P9[)E,MPJ/--IV]&MXS+JQ/>W@: 8TK2EXVQ</I]1@<-/O)9<EUEW>>?^:
M1NOL4B=:&P  ? +@$M25\4?U)"@PAS-,W;6[I>,:9L^7A.!&/V8D'"$?LO0H
M+/^YD"P(G'([NRRE50BFDL9_!_A[NNLV?)2>3RSV5AZ^,6.CXU:8;.""EV;\
MR44"-G;;\J#:-X?17>3X07#:0RZ\,!B;"\'-GR_^5Q'G?^PG"*SWGGO]JD!\
M"X9F<S8+5?J"-R%"!N0,E:^/)S3?2&X5Y!37JQ>.A!0QI$ITB54-C+D/-Z4J
MCG#VGG<;&ZNN2#=@I^63OR_XU/=0MB6GE*'NY0=D[XB6!Y97XX8N"\>?%YVX
M+[4#6!D$UABJ%O]22W^AXF+ZS\5YP9$@D&3_\<G9&T+D#=Y_D*=;\#;4XN7/
M(VU)-J*74D-LO+ETLT:!#Z8X _#@[=O40<% KH:2FRP!Y,W&GZ#!NL\6IW2D
M$V:D4T3W "N!2A(DMZOO44IN"=OC!SDEU,EGNP'LZA4J3TN)^9EGLMK1DQ5$
MK#GTJ5RF?_J\!FG:C2AY6J53^C#3MVNE7 #PWM'#IJ'W'M#7?=<$TQJMTALJ
ME\W*+#),Q&+*)8YG>ZYHC'WSY6+J 3+R-C?XF>.$P'/LG!(:5^I*ID^M E3,
MC YV:G/=Y87:U190 Q?BL!;RCD9@Y&^_]@<".\EOM*J(-3LC2JV;=>G6'6Y^
MH[C-#Z>P9JNTOZJVF_OKDE<XZVXN3Z#NU"3:S;A^$$N_QLU-[TQ[]JIXV^.Z
M812F_LBT75-&I)=*0$RR1UV:-$&-/U X64"\<VKFX?XGO%&)K;@"T$2.]M38
M ZW="^1-V_")EM8K24E-%9SBN9-=%IW':6PA%L]><*@$!]\#*D+;OF#[?SZ7
M4H 7X_\8K"R/@?8/ZB2'Y$A_DL0)?'*Y^@B7,J@']$<Q/8KPYUD\(FUD5!"1
M%51U\MFD+IV;M+!BP )?-HO? IP2^([V;HBBM.5!:*G^JSW185VADSE^4;%J
MPU_RXPS5WRPT3 ]Z/I^J_3/SY1C+,G\_XF)0M"$5%.,89@=B<+]RYSDYL';R
M(0Q2Q:+^=E-6:>?;726(^AE2ODG;/:G#J .2$?Y'6RD^RS ]]"@ECL&98[10
MH#&IFJ-O/<G/HW_LUJ]FP:FFY=M'63QZKFS"]?@-KTG=B6<M>5-CZMK'3)3'
M(Q,>1?L2.P,K9 :*>0V>''8U)=,RI;B!18%%!0">L9!XF9=Y<$JW<ONU:(V'
MCTW%V7#&/@G3C/E1LK&A#?2!I*0B0:HDDY>[ D."@X.CUNEN%1:U:_-1[R6Y
MF"F$=+9XMUBGP1ZV>G%I]A3DF#.MZ)!3(<X.+_M<42RCFCZKHL*^JTJ\VQ3"
M2BZ4P++^V<A8>8NT5,Q$@43+M?^R,=HX\#V#E;9NZ,;V3(KL^_<,CX*D%6.S
MJXPCZ+$?OPCY.(P;Y-Y8 YR*)+CH7AH,6N=#59V@_8G/=T@9LOU3RA/F\;\A
MK#]4&6.'2!.5N,=3_LR%GE/>EO743JICA^3ED--HF$F4)]3K3,B7Y.;2Y8]-
MEG\!*  >]NV];QCYTH(J^DG@72A2Z#B#YLK\/' L5HIW<7WQT%(+%_TOG.X^
ML/._B->,&N\!Q!4 HBKJRHDZ\@2%0C:%"F'0=NGVCC;CAQ=3=-4@@SR#]^S]
M;]Z^>8$.W!E8W^:7F,/?4*+\?=]EO=*V* YY2HIL'7S_4>>+]4=I5A(LFA)Z
M1'\E@3;V-ZK/T&06'47B">W(2&I.U\**PRFBXM1BT](*\)VOY,H%MBA9AY#<
MQZEIM:1%T8A$FM"B="B_#GRM!HH[-@'@JAG2J/31;UB/"WR/BU,=LS PIG\P
M:S19I^3A'O^^?,7>U?E%28@(;K M)WV"@BU=LPY K=E#>S;#NG$BHJ;SD0+[
M8Z:Z17D/CN15'98P;&+)<W%N_\B;9^</8XDCX4IZ$D *26E!*9VL#@<1X6U#
M;\F/I[QLWRCQ'UC(4V)"3L/>EV()#&X%B<3VF>JL[E]8..0XI+X\1@5AN+EY
M5D@$U- >6LKJ8).7-"K'<;;-)[6N_T/Y9]IB#%<!!28#5S[>2R3YCP:<U(=:
MCS!'J3YDKV^FC6<]NQ2)B4(2Z&1Q^R(B#!:A+!I078Z^[I-A!>83!68,JY7*
M[[4XGI@>C>T;4Q^)2[:M2H^)$='-'-,7&XXHDGOT13_A7[F.S:L]</*Q-75@
M^,DGK0$%;)EMC6+Y0I%TAK2J>$L;0#*>A0]FH<<8NF57MJKO6,KJ:*Y@F6E1
M5JR83/"T55CO^:/<=0IC:@Q7;QZ)@4]-:\YJJVMHZXY=2PS6.FBGZ(.[1E?C
MDW[XAN(HD-!@TBBV;Z4L/ROSD%J?7%OP1'/^9>@H;(BI'39<2U#Y5RC:K28I
MK4#%SY^DG52CT7>LT:NF'%>N>#%5 RUY4M2U\AX;DUK=^=]*PNW88M(RO43J
MLC72E)]Z@A3E7CZ9(M@"5#^ZPX1X8<6G-%?Q[0%N2(6E92)!,[M)SQF2)CX*
M&M>+F*W89UR&1<[)DLD%Y8MI8@[2XF^+H:-KI694F[;CQ.(?UO,I,-DW'. (
MSK5/;+;94'Z=Q*/SBXNNLVC\L]SM<L$%A$";@\FD7%CNCLIHTVGU9*4(>2L9
MDUY!)Z[^S[(H6I"[/JTN^A8'\W-R(FK!_VAKQ\].RU'J"(Q/TJG0=7=Q) 3C
M[^0\>]A#@ G&VDUB<P8UAV02\PKZQU7Y1Q1,E)/=A%'1E!']W7?_4I1C&2)"
M.2Q"^',TEY!^+D^OK?\3%YH#0+\ KQ]]Q7SCK?JXYI"6 "<C)_]T;?@N8V F
MK?WW9SC)28_HO_;^3G3!I!)"4@DC<J$5%;E]EEN[[II/W04\ZS4FA]37MB;E
M(ZAU::;#,7FWM/]5ML#8-"M+?X<NX8E51#GOM.PQ>WGNF.R'+Y'"+ \SEG8
M-YC,%K'XX\=41)_G%=D4C3W?WM5K$YT-8+%35:SI)TNQZ2_(&QD=8^ZX=E)K
M]-'$"!:?E@)-^/9&N%5TRLR$>F"A\U4#)GZ(B0B)I%#"PQ>)2:615LX2\15A
M\RR,$&@1T13NRGN6X(0)5&?L\B*>S+!8QI#&V<NO2I)_O0.\!D"J,2&LTB%!
M: ;..O=GI.G^TO"0=1V%QZK-QN+=MYD[,7M6X!>U]MIZ]LANE[TT.\.B?-KZ
MXSKK1$+<(2HQ8K*GCE2,)8'QVVA9"%'_&Q=\_]\!G>4K99*[&?I[ 'G#LMGY
M*%JN1AJ8U2,8ZST L'X/"))#76":E:?^NTL#_[L'/*OR[P%?ZN\!)P/ )<P7
MF/^?#\>QKUF1W3?P-8BY+HA2G/UD=QUH;^'%!*SSQAZX:CC.</=F7_OD8Q@Q
MZ. +7:P0%^=:CJGTAL^0UI2E@LMWR:]8K/FTPOUG6PNJ_A:?2A<&.-X#NKPZ
MS"Y'X2H#+4Q=%FTT^8T2?E0MC4O25=[4\P@JR,("]?-*@G=A_3)J<=V;QSK4
M] RJ7[X<J[SZX2Z[?] ^#4=^0SG< UZ@F+V_P\ANY81^^TC< \IWVLL6C.B+
M?8?*>>^*6[R=7Y\,;KH1Z=\5!G9V&B2/6B?XPY+3H>2^?%1XE$R5C79O:$=;
M+]6R7]P#TE*EP'][O647=A?5',_-W,^4+#^U;Q_#UH&FHU.WMW;:+L,>>I;X
MMCAB#3SDQL'"7D7E^15E^=_I21VH/.O\JD 5LR?B*#<@&8K\'L!T#PC-(*EK
M#!T,F(@LLVL;Z9#V2I4&^RR:S-6U5D;RP"XK(2_]'GFN68)=R!8>Z(4FJ6N-
M&,3G%Y7G^4+9''RP(M'F,"R.0';> (MY[H2XGCEY%_?_N.P7_Q:WIYH^#WQ]
MH_4.T?"M_+7(<W^EC?DF&M4T2BX1^=KF4SQ9,Y[8" _.7-MCE34T:'EW'69G
MXIT6D\TM;V4EUC?JWFY334?-F4Q/M!].7YNF+[6I,6;F&X=(/-]<&I8F5N&U
M8@E/2;>R-T]B@-;ZT,6_0OCE,F\4#QY\NU(9%RU>A_0_W["9WXG^EO;[L\E
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MJN.I]2>\%H);.V02X[NBCZ[Z5%YG):EK["0.8?WQ+Q__M;2+0)MY%.1MX^'
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M.R6!Y^%</UP2-R)DU= &S@C)$#K%0] \\E6R]PJ9Z0*A=G_?I0;MX54P.A.
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MJ0-<D3O8CP*>#_K5A4-R8&A8/RF_)/6WK*G>)W'7]N4_*\4R_]C<G34."Z1
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M=)>)8,3$:2M*J"937D@OHI])8K  CR:9#C$,^8<X_W]7,-P2S_AUA G:!$\
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MVC'QU]",NO3K#Q5;U*11GJ""EL<'5R\LSP[/60W^,ILI7B9<,<7S*-YI_M8
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M?JW@Z%W/09:'"\,CXX,B(V&>J#MX>\TO046&>:=E,7UIK,K/Y'9TH)\+9VW
M0[#WUNO(SC4UACE1)O%+A>SQ)-;\MR2N%)COESKUKU>\29MUP/,I9>&5%%U@
MDOW7#@>V2WQXA;1% ?N11KOPWVNGJ9.BTU@>G4")Y=T@WR@AO=]IKEKE^!]G
M,?[?"?HC9,!7(PC!"KI[FF2)_P<8TA_"'\(_,*%,JVU!#O)76QJ])[B.](8,
M$&A+LE7?F9_<9OO<B_2Y-"O=ZADP$\T2/T?WQ,=U3%VA"=? Z!3)6ZDU4<(K
MW-/W#93SD8EB373Z4;),L@LF)L?[\8N48(B_'1\R46LRAKURO$,*YL&:Q(X^
M:?:7_2U72-LHT);UNE-P:BOHF9J3E&WLZ06(Y6B"DR<GD5O8%=RW"3;#L:P'
MI$U#J%<*MADDW5UWB-WZ>E86WIZ3)G6_-15KO3)M^:V3W2.$>G,^+-&NNO#<
M_QWROW*F2QYFO: <UIF"/8!:/BX*0CHZ(,(_MFTK73P):8FJ4?#V8*(@UCDT
M[@<9,'F:.#A"1+\NSOM]L/MS-IWDR_:["[*8>:*Y,54#-6TA,KE#AN7) (-A
MHC8:)BUQ&+\UU1;H[$)8AVPQD %A?@>*A::C_KY'>\!!,D":YL12%JL>4/1K
M"ZD.-R51-[:M99,!I;8DKMT)U@P_I8,M]+=Z<>(OV8,(,J!3^G?N&-Q>IL4/
M+[9*!F2&D"JA^,(V'5_0#N<4'/(OAK@9_;KESQ#_#/&_<H@;A]2-S<@[J>(V
MGZRT2I:<SQ#]3P=:HO'[(/FXOJ5MK9S"#OS[H.0I+VORFR7Y[O[N0O_3<\<I
M,_K#^(?Q#^,?QC^,?QC_,/YA_,/XA_$/XQ_&/XQ_&/_!&:T#G7<?K06MH (,
MX@SF#8C 3=V[52>R]Y=.@^L#&OAS-L2!\W^<9ZLU(0,^?8.@+&2Q)28'9,";
MT^II+3WEE_1]Z-XU=;P(9-<2C3A2@OSW5YS_?8+R;UG\%74R@#?^Y/1"8RW_
M__XA_2'\(?S_EO"_VC:Q^5DV0QT7N.VRXMH@PW!PI &V+2"(SJ %C^#F3F70
M6H?ZTJ;'#TP'H Z:6J/:S2*B^SI3UE5,B. [U[L^BSRU/\--@SAZ919$!@RT
M$Q!>];WE99O1<6R]W2"B]88:RK@A"RV]$KM=C(OY:=%E7B4Z[M;"L[@QZ=+<
M,SHR\M[&F/']]V4#RAPJ3G/V\>G=GF_%KHV@)+= RV\[@,#D>N'T:K<5F &'
M1\-)HPJ?M?6+B%=G[A8&*UJ\ G"=WC@_66363T.B)0,,<5-KXL9@C6V7,(U?
MUP9VOPA86/GR5'%[M3B[Y0J(C3HE)-Q04^&_'_=9SICURM-7N+&IX9O6]I&7
MA1M.CWHPCL;U$B)1LF=EDY+]P-EX@G&]ZTE91;6T0O1L;3H<D)X6=,L70WQX
MNZ9?@;TKKGY&?]R[UY$WS;1K\G1?F>Q*Y?PQ^;2Q^JO99\B])KU<>OT9EMX?
M+7YM1[5ZM^XT."@)&0<'/]W,S(QEB,M\&!MZH\30Q?ST9KJHM5.#OD(&!-TC
M X0$XLWZ.1=IU+S8.K\4#'7L^A_LRU)//NTKVZC)F7\,N5(Z*YG,=[]=720V
MSSVM65< XUN:-DZCVXTXTA^;\NG;&9PZIG>S&N!\T.#I.3UD12T5<(=(<'C$
MF?S\S88Z1Z2YN[GYJ4_@_>=VUBA:'_+]4X#_8?U@= H9<%WF%AG \T:_-VWX
MLW_+3 NP87_OB"CYLLI!!C&7./O6>I.KQ/7'V//$@_&;(JX*NL(Y5<'+MRCR
ME-M-+"$#,@MXU@I[9*;QZOL7E_CQ>$><>J&=<"IX5]L9/(;99-PTJ=2F%E/9
M*4$SA17EP7..$4^-TGR%611X2W05]'6OQW=C6B;(@'_A[@Y(\F8#VLOUN#-D
M@.W62<I UU@_I.I@/ZJI&($^+JO)0L[S*HAC67CT?]H<(P(/L:9ZE3^GKYP>
M#.I$]\^=9YEZ"MN@XE+]=Y<$V:NDAX>K4SM$N#EX!>V-:=I4)77,ID1T70N\
MES1D7G?P=$Z4KG';\V5<IFJ4VV?'W,XINN@>3$G>!8K6]/WK=J7_G*K^3YO9
M1Z@):L3A "HB)_K)? U!?=_Q[:])8O]V&G]W]BQ3$F^BKLK;*D/&4@49W<F/
MP65O<Z&<"KHJS'%"%]/$%!IK*3.[+2-*[,?7XNCA^R?96,<6B=V6.CUT63(#
MM ^$">"M2?G=L$!W-IK]59?$ $@GAB[V/NPCO??TJZQL:LH'*J#Y*"LB44@(
M(FINFJ7X/PB=Q[-68;C]T6*H=L^7W-&7T@O\HQN$FASOT?F+R=Y+S(D<XPPN
M_<N\1S6:/NI9NZ;ND>GZW-^+^9R_R  QB;3<M3IY BCBY>_H9E<RX)8=R0K"
M"E:C/W(P*=-N2K>1Y@7UQSJ]'_R6^+CI*SZQ4&2TI%MGGZ>C=0O%3/,_OMN+
M*ROZ.!62&>0O/RKJ"0A/@.;!E+(GZT\DK>0Q3<V1UK(U#$H=7PKO'EL^.Z(Q
MD?--U%FH]<'X9F<61.T])\HOVVL1.L@6#GWB*0:I:N4\$IO [(37'IF\[!K&
M2!<DNGY32<K/S87'!<L9JJD()-IMK:\T1)2GZ@V^>T:9T.F9@NM%1$="-U9E
M]<+2KG0AMK[Q'4M)@XR8)S/*$/6$R"_,&4VB_O(!=GWLDANMR#NKXGEEY9JH
MNH_*, :KCW9+Q;:A$_Y3"#GP%Y(-Y%P X^'M6\4D-7#<#(O*#%.XW9(XALEF
M=4,HE7NC8J8TX_7MZ/OWNS7TU@M@_5HZH\^'='HU&2+/.%)A6G[48N-7:3IW
M4V<?-E4&\!S!C8_*ASN6XZG3^PX.%\,?3V_V6AB.QG.J>)1V34A=B^,5U<&^
MZI$/XCDUJQ'1_^GB;8&AUT-4H*Q*[</A!7.4Z'3?EXEKR&2><SZ7BM:7#0I*
MPB)ZN#D*PO1?^.@)A0W !BY1459)_9]O/\F!3Y$! A+]53*&X%"\Z\<.%P?G
M'_C!2@GMBGJ,+5=X3N!Y7<5YK'5!AT(H+)Q=%*2@*V2^=MP)95)CMGGUXN:X
MJ3H]XNAE[O^^"QSW12",+ANE;6ZF^7)S<_O MGBX5XWL<L)257IYJY[J1#T9
M41$6//.,(^9TUT/.0O43_\ZP[C5/DCY3QG?KXGOP3IMW$R-6&PYOB\_DIF7F
M7/2V"5.X6Y*;:-YS>F/\1C_E/:H-&;WU[A,,:5*LD"MI);.IXM\QC&]>ZUV-
M2*#[',JCI9<G)*DU_GDY<D KZ%UI64''+8H+GOI/+4.1O"WD"1D0E[& 1/.(
MB7>:K:B@VMCK]#O,$DQJL2J5D@+G]RU+?F-MAG\=N.;UM+#2>]@(&G)99%)1
MJSU1\/!(O"]4VL_K2C$V_B1J,D"0-84PHH[T<W?8F>_:P.#Q9$"#:[KBLF)7
MP-ZLO,VN='KLX'/<CR]!-P<UU0S#^Q1H1RWW=4#:(Y,O(K ]?W%+3R'^MJV4
MOZ5S/[H8P5/=*G[ ]E;?IE@\NJ_UZYR)];C&TKLJJXVU?F $GTT C'MC22P[
M' ^BEN>(RC<<YSP?<BJ!^O]CIGF3.)1W9$CUD2EAN/;YVSH;Y!"F>6Q4[D@H
M3*V)XM^5PA[+Q<E=%<AW%F6Z@J/\(8L,6.H&@W;[6",WH;$L:H9Q/:!"=R<P
MC;F3[]P0ORJ?3@.J]_*XMK0"1UNC.E=D<-%LHM2IWEK_W>3J2X37MKYT88LQ
MX_3=JB8)MFE[A.CI'23(LOIAF_3IFLB 457C0@;IUPL)0.23I#8G,L"+9_%C
M.K'*5O3C.^RYO0:*@S]'!@QRKIB2 7@Y8EN )KA\<X!_:,XD:-3?.QWN8.YW
M-KC^07 1+)E=_@7]/?4H>.>4VNMBG6T]YD_77K$UG-^E6'@4LM$>-VL&7..V
M#&/\,DE%DU04=N63?L]8MS#,@1=)]^6#YT/T:?SC<4*9-VR98BYYCMF7G+O7
MI4-_>-RY"N^536KCE$A?LE75QGS121T 7CQ*RM_W*W%=+EJ"93F$4==68WWZ
M)M5;/C5OJ=^Q>,/N!P>A<<](;\>A_2%+2>(-@BV2#:T*AU''VX.Y8RB^'Y**
M$K,N#Q!>%S:-8'7YP;6"J<7V=[/;EZH2QP8:8#&58_;6&@M3%+\NCM5>UNLE
MN&+K<TEJ!\.)8K8^H,RQ;? #EA<Y/L7T;EJ*4M._@_]Z/V$)4QVO_DU_9.Z:
MYW^ZNTSVG_=WE203DL%?MUV"I6VQ:%]0 945AAGJ#$;A"[$EKMJ[:8S;GZZ_
M/>YV4PSMGQCAE[T7&2=5*WW/79&CJE^=N4-J?.*OJVH4:!#Y=V6ADE$%?]XR
M"_6_@C3C\ N&\\E/LDC6PNJ3#DN_69A)&M)1W^J*DZ)U38S+'N\I?)[QPG3J
M;Y*1#7E,!J2F#R]RRGM ^ENRTMWO88_IYOWOJ>Q''W<'9CKTO:[%^"9\56MP
MK>4R5$U!MK0D#_PLV33*8<AQN+.YY'K+/L8/[D$&$#MEO&@^G"B(.ZS\SJVN
M%S#1V1[J*YUC.:@Z+&4)K9<X9@_N?G[L7._S=MU- X,<8+7EU*H4?<EVPX2%
MXYV:V$ME1K?:4]52@'##5R]!2>:RK!+'-26_H;X+&]!\A"4/XKCSL/#HBK5S
M!BZCL^UHC:X2:PA.:&JL.+85/Y>P86(2&994::674PP+/8>CK+;=_T9WLG#4
MO*0C3Z/7M>'N%?;BN70M9IWCP#L5RI&JJ47-XWD](Z7J*V&#5K%A'T6#.-X$
M]Z=NBS,=9U1="D09?C9:O7OGSJ>M<HFX[-?Y@[1QYWF4HZ*<";[[74/4WPWZ
M9N=2]2Z)<MV\8RS_4] \OW+NO+OR6%$CD%"[EU[MY!21)/=S+KV+-V\V(,AN
M-46UP9M8O9G(;I<S=L="%+%9>7;U:^%<8[L+THM'K6!1JU[_NR60-?3.J[MJ
M+GJZW#5O(E_H)= ]V3AFU6^9*^7W>F1)[6)G>:NUYOS5LGR[_$!1M3.CU#Q?
M0/06GM>8*BQ06@O%53KM=BZJF,[>B 3!YZ9P%WSSJ-QBVMMQS,/G$4AF7/'M
MN?QE$JAF3;?943<Q((RTY)+<J6LT",S5?ICLFSUY.3Z_84)1'2?+_<8MN\XX
M.+(5-G1EFBC4%:M>\@JH7..:-7XYBM9RO&RF3:RU-QWXK5&(1IY_9X[6V.Q<
ML:*H65+U/5=:VW8F_$3D!Z^JLPH]]/?T!7'!Z#Z@0_U^RN#*@*?G+R4VDX[:
M'RUA2+E\45%:G]@Q)GJ>>=S].=$OYIVE-.ZB)O2J@D3%EJ0\UZQBD:\;YMMJ
M/R!Y+X?1T\ =D^8BP<=6V>F6F+3!_"0'O&6057'."R]?=^;1Y/<A .%/CH$>
M9SN"GCI^X?.!&4\#)W4=K]17I_3 J)0_1RG;>\$TOY[_F!8XJWSSP>HUO8:5
MGK('&;GW]V?X<WX8)$;V F3RC<2=GXT_L<UOJS23*Z\8UY%74I?6E?_\LR#8
M*'3Y;EU"D(JPP5FUA%M?V^I6$M^^]!+1/1_Z"Z#S!8QP>Y3FI2.G9T%+HZ4&
M&![.F^^;3_>JJ)N7]=Q1GNIY6Q5<;+>9EY<4E#*BQG$SD':#.4S+(,/'F.G-
MS;\X0A*?EG=GE-Z?.YRY6H=SW)O+[5**1(KMQ.H&,?S5,\C-_<CWR:K,FZ85
MR5Y>@1A%$5]0D?4[JAS$T;VW#J4TS.]$I+E;/B/8_R7.,>EM<)54ITJ>:T0&
MY[7_7.<6,F1,#-J\K*":G_)Y2<]+C/F\EM*A;JN+WERCK>C)DMW'>?$D_=$!
MW>NW.94_=E.]/Y<941=9X'^XR2.I.\$[5-E5>_F*8%;_]8M(=<-WALW.*]\M
MO*XQ9DTL"J<@>>N$BK[_6GTE=*.T\FF4@M+U*J$,WNR0'^_]&ZLQD\<'>>*3
M9>5,GW/3.$?[84]U)#+XZ8)T I^?87W+FDZ9=9U?*I"?7K6B!_NJECI_)*P"
M%D?]U]-S@<N^H$/+4=9_H]L-*KSONCG&7L7*WY2JZN?Y/*$GZ&EC^1:6=5-)
MC IETO&V^CK@7)P:@(HC#HRHNA<3I*'$ 0 4<_P$7(0:;#@4E]@OE.06?2R/
M*Q ]/272NBCJA2O(RN.!X:O?UU_);)S;</OX:L;DSMG2/*$*J;_N9P5N2C3_
MD*Y.6=;3TY+GH9!=SS%>#U L):$VRO_F]/G=*][-0ORV@4'&:G'Q M,W,(:/
M)T1^=/P:(0- Q4GE63I-JG'9WI&Y([3)YC:C3P]I4(3),6O4X4F:;L)@XY5J
M*N[BT("H>\+X3PWFNM((79C"M4SI2X=#%.?O.8L:%8M0L !V]'5^BCP0NA/_
M[+)<[K7-JA_OX->23;M8+DC\^P8P$(3AYLNN$[^PV=.I*R,+7*@R[)M^%,N1
MNMCY'?>JDC>:D8%!(XCZ?CAR^Z),KT\T.#Q)[#BC[]T.2^G-N5>5[TWB:.WO
M/++1, @2*3ECRN'A6+EST^6HPN"[KNFBW<+SY4_4[)_.AP6+G%M]G^;#6@4L
M/6#=G$V'>%C&%? &+'^WJ!Z_H7>_6Z@]Y:/$YR1=Q=C;S^(>O2W_*OK5XNGA
MZK?FS@'/V[.?SGS2UY!WO?..ZO-:I+7&U]MGBKYGW3SS4YVUN'G'S<DK?D95
MI]=%I.+I<^7D4*08]RLM!9T?,=1//HRAJYW#?5_9',U/S3;%.P!Y6^4VJF>1
MJE^,W2(TU9]\660W=!#@=:W16-=7\6$!F8WY,5VH-W69/50YEJY:U4JF7S5W
M9 UEZGA\UT<R4;F,BB:BS#%L+?>D/DG RU$R'<].?3XE8DZFQN2L'G=&Z;>T
M/+9/C-K2/">AOG?_Q9?.XY_?9A9;F9<\LM(8L\KI!\VENTF-'VAT).R3 ;Y<
MF; OHPC5_2<ZD9_2%J,&@1(?VBH">H?JT@\W&G:NE^8 *Y"A,Q,O7 Y<14;P
M5I*WGN6)Y1NQTC&LJS>YY7<-UT]CM&IL>+#OS'5Y30+2Y)BVSC^CX[V\85.T
M)!_U3S(0S@*Z6@NBO:&GU6NBQ"PTH:FH$2VBI EA4KKS8,2T6XF;R@!)FC8N
MRGP9:J)2=#[F,7]VR7.]6L"/'[%0?JBCX4W1Q-B/@O?>%%_N]'YO_US![4PW
M5.D+*Q%Y'.WF/)C_N4=:S\]*)3+$=93Q:?9U,2.Q.&JA9D=:1"+K;Y::&'FC
MQ64F]2? XY63U1D@EU\XU5\(M9N/(H:"1B/ZZ&"T1([1U *)IW.-ID=VU;5M
M#1&\]!_EG7__2+[Q6 ]6<MOHILQ=GC<^ORH.'Z[+_B<"((.M(NN2HJRPJB3E
MS5<+2; PB4\^.<KA>.2K;_QAAQ)*&HQ=4X??42_V190W39[Q?O@ HC:Z65MT
M(?A3!,'CV*@GMK0TXD;HY957>CP=5,HW>6*N2?V^5G+L9ZT)M^$0!:4R8O([
MR8#;\W>0$I=N&HP46Y>\^+!V?6R8([;][AG;"G-;[K\XJ/TP-A-VXAKE^[W5
M\DOH%[$5(.TK0]E7/[![6D<6*V;=C]#/!L+O8L0O.O,6,SK'X?7B)(OUS.]W
MJ)R;W#SS3DTOCYEJ= QH6W2D-S=[G,N<*&AY]/ 676966.7MITG,'3?&7U3!
MI#Y7G8N5/^]YIISJQG"EWG^H+8%-0U,/NWVD$SI5DW J5 D<Q=X9N19Y01RZ
M:I< 8Y]9I(_%UNO_9A5N:+95C*-"HK>4[O8R'ZHXZF*FN?7N#-XMR"VB'8B^
MEZ+,R>],^TS_%4>#V#DN\2=&WUH4*^F2-Q_4Q&$-N/'W'ZT8?.:#ZU4-:IR]
M\<SAZX\;O&_*7,7&'NXSRIZ53*RU?M"LS=Z]>/9"AH3]1Q"5V7WA4?0T/&OJ
M=/5^^$VWQ'_:<O+DAW/)IPU,K5733E.WU1^N_-4SI3<Q<<$ZZ@[R5<QY71L;
M'[IG%8TVNG?+O=9*7K_XR.7,GNG#SZGBZ.AHT%$]+/SQ>4Z2 NUE%6&A(JK(
M5^<,^Z2@[D/"2LPT5Y7.J4GAYIY&W;'0.L/[S6 Y!@"(/SS[/-YIC<WM;26A
M\7'C8-,#-^51<Z\'U[LGQVIN2BG8AIHJ:"G?UF()O*=_84 :ZF1<C.9C1]AQ
MU@F=5:5_Q)XI=*?X6O87JK"/=S[F7;?SY9SW_%8]UU*1QO#]AE+97.^5C]FP
MTN?Q7<%9U[\&QHX=50>$_?Z[<2BJ!8T_^15E]+O/Z-%J)J.!54F1LK6/P[64
M):T5^5=K09J]4@#_2E<0718U#^SL-SG/4T^KJ<6M])59/5G]F^.#$9Z;PC'Y
MGW5YGQ<5/WS_XTS''JO_0[=9G.."N,WT# -OX+=&\0A#I;J3RR.#CU/?80FV
M$]PO1Q0*'G<X@B8LS@]^N/L?X\SUU>[$72^>*QE]=]J-D7<Z=LO.R//8&W&]
M'=1^YA&HO,;"*QV*H#GX;RP!.%!"V4L?R0!$!V1)KVF+U'@:?#D(4'X17Y']
MR0S=LR,#YD\SSG&DO^=5$21_:+_LZO!0.9IDS(+>RS&-(>&)=[>'?NQ(;,I@
M4'3' 6%.28I<4S[^S274YZEU$L<AH!KNR=KS:KP?Q2(MX_;IHU%^.9&5D(QH
MG )>E_C=]\I/,@#W'K^#G66HD5'#\.76_.YN#9#475XOUC.9T6@H$K*C8*V4
M_1I-6QCVE^ZO,8T%V+IN?MG9G-3B3Z0ME*'B@!E>TW9_$B^X+US1RN?5NK;S
MVW1F$U=WRUL3Z)Q?.CSR_+B))GIH)$\WV.YF5ITXY\OMGOPS;MFAVJ>GM \3
M'^42HIQV"HFQ7,>W"MUUA;X1N^JB#9T"\F"]%@]S8.EV1YYT7ORFY3F)R*>/
MD/Z9U:,]5:CL3 2'E:4?)8@J'\9)Y>"#]K86"O=U,>A/; (R#P_7^MA64&DS
M#?SM2'^6_5NV+E))+ZO=A])W>9**NQ:$=5/M71_OIJF.:Z\K75?(B+4]S_"9
M\O$MX7A-,^=M#!E !GS:/X3[@ Y?0GDJC_TN8>FKQ/+]^9X5*V;/&\_:+G-]
M>T<_&3MTXYNN-<C:6N^\XNG^!^+P<7(U@H=TRX484T\&Z+B8=%=Y\7-Z$^W+
MCLO:4F$=?%KFORD(2K]3R31A3/ZHAD97A:I7G<LN[P<B@0*R6L;95ON),$GT
M(N=W8 MQ,8]D9<;C)[P6W-W[JWQC6WHA;4YD^@N['#)52I>A&\C(["_-8HK.
MZ5K9OT/02]WB=CV@K9"ZR'*A5I 2RM>2 4%,7IAM@AI%RL@ DB[D?OVO)WBO
M-3=/LQ<N*(R@2%=8+(YAJ (U:OT@_WUS\&7#K>9]A1NQ ZY5V9X\191'7("(
M05>\4&0 (.".1S+N#<6'"$(334)QVI<:)(PO(8[$M-T?LM]246HK2M/-0FJ,
M*)YW9F*(@A5F1VBJZ6HJ:*M&Q6DI%&M0%@E,!LB*TW1&)Y(!ER')9OT"F= !
MO\;6OXC^Z#8V3RC(F92UT8(Y 9E-SP1,(6?-7!\P8RWN]J\*N;Y=G^6ALJQL
M\.TUPR=NK!4DLMM3M&'*]B=G#SP4RB +56_'9) TH-R29$"E#)57'6NZG>>:
MB0LBLE,I6#(=I(4Q4H8]>G><>ZM^\T%PFC(U/#GZ[CBU+IV"@L[U">DGOJ<*
MY\]^6E_!^> E]]-7%3L%UJ2)O\0+VZ&!AM O35%MR_I]>?/'ZA>G79T,]PSF
MQ!V=C1JJ!+_:"=$9%G-SFEW6U)(_$JI-NCO4UTH96V4T_K7S=" A&/(8DHH>
M<FR0E"_#HN^5"#UEK2C!IU8\JM(1G>5/?Z>QA'VRG>2'+[W>RZN](+:1DQV7
MIISB8!W6:I2:719FQ&@&PL#\V'!'I_?*"0TGH86.C0ECX.^[O/H*%D<M>EUX
M?6QNT48] NC@7Q\%[_?/7(2%.UE4>>Q;<Q5?>+J4Y'/3"(%(ZX59QB4^VL@Z
M,MV<(0,6),P&XKU^@"A*[[I5VNWM8A8+O=EZ\0=F?@_?.7N"BNT9A@+C(X%K
M?%(^OLTQA44%6?!V8+/-<PDE+BYC-I'&<S>ZF?)HY[=0=.B5!\3*)C1A&#1L
M Q&%Q[8-7%RAUP>G]WK)G'PG.@P=7, 9%!TVIWMHZ0QRC*<^*N&V^'HU84-%
M_5/7U-*2,O>#_7&UM4LTB"-%3M)-4/3<,:1 -IU5P-,V>''>6SV>P!NPBJ+%
MGA2BK; -I<V@VG58\>(QK"9.]XS^ZRS [7J*00QFPRLJFKM@NDAF:/8J5%"K
M>,!QWPBX<^[)IE0F;JZV*2>'&S1CS*]Y3EM?72KV.T><XE^E]-K"1MM*1Z;K
MP60 +QS*DHUE)WA"OK\/T%WV*O?RW&6-(?#%?0=QI!^QQ\S_:B!._N[5 694
MWQQ3$REMP+LW1C@JG15YMZZ];+=T=0O3,EI_NCYWB<.XB_CD"=F!_I:VE,+!
MG4+<5%N%<77 SC7D5NM8H9%)BXI)2B\_XT7A)?8Y]T>1,JN^#M2]X04?-EF3
M8F\^>3%*43@#6>C4_B9R.GJ-GEA;&7]TU..4KXZ[2&"H/"01>B==##B2K>M4
MO+:!<#Y]L]1'RT[,WZ4B:BM#YRLM2Z/H-9>BN_RG$,A^")%V&D(/2;R]B?]$
M!@S0M[7*@)*&C4J']@F5TRSAS\3+)2^FSE.YKMFSN29T:&LR1U(KF-Y. SW[
MM3>N: =+!=^B:&R."^[^-G3%$BO.,BD]0TR#I$SUHTYP34Y>_/0WYOQVI1%'
M7]#S5Q]>83$=LW7S:6Z=^&J.<]=:$S2PLRC,@Q5UZ6LN<XMJZ6AQV B ,/ 0
M$JTB*B,\'4[2FUU;I@)_R2+I9"175:8WK;YA8^*QGAVSJF):3?NPT(&Y6%AD
M9*XD2F?EVJFB:5 B);QLF1V_F\2@C?(KX2?I-$:O0+ EB[(#D$1T?_P*FZ,7
M39<T?!(X+0G/:U*LPDE^#"_+6^=]N=DWU1WU%<.MK/:M[MK/@@QD&441)/"5
MOT"T<?WG['8P+9.Y9 !+@!9%"F0SFM0;20H0274H]-$C&1N7\IZA980*$&0C
M'E! 56)7*3(>>#$9.>ZMRFI\Y3P8%$9ZQ&B?&Y:4E%KPLCRI *8.PM1!*3XC
M'SQ..(.[0O!QD6"+.>X6GC&.7MKUMI:(MS_D7X?#!E:%[G ]3G$:9!&SO*<O
M@K-R=(VW<GBK'/QN-7KG?HQ(K A%"D#5]?]N_/L_.YZ@3#W AAC43[2E&'XQ
M$,1\0>8I,8(@9ZQ+3#:?E5U'+UT8Z7!1Z[YIU13N,32C5"QLN-/T*@5A5GMC
M\%&YO9[A3]V@"=0212V>DW1;!BN:N@F%$%'2W!!H:!</G&?)GT!1RRGNI2,0
MOYM*ZTGR0(\5&74Z361J VOJXZ?>58UO/GGC'WY?$1H9T^ZFTIV$)(_64.#!
M+?45:9QX78 ,A'UWN1^;OG2.Q46VWR4#-;Q?7^P;\@#Y'1QUR]G\4-'FD-_%
M9]=H6X%.[4& ,U]]Q+$F"ZWNX[P)4$*)R'K(BU8*U"A?)U 1.\B ))>>Z$_I
MCJOPOLP\0ALV=Q7=\SG@T7(]1GS)6K;+?Z+RZ,A!U-^F4Q5T&]UOZVJ84:9[
M"(\L/EY,K%D4*4NKDUMI0QRI09F;<(0L,D"$NG%6EJ_U'K$</X*%+EV3;?"3
M+)?A K6NXT<$P&HMV R%N#M*]:RX.0H>*WTSW<=,T@OAM<_^KNG#M<&8)L\[
MJG!_G**]&B1-<#\2?9X,@!ZH!X##LL/JO9=E8VE,0,ZS6Z95/E75+M>&MYT/
M0M_-TMO6.GGLZ^K9[-/ZT%3[)H1TRJGHQI1>'].<D#+=0C$.QZ.%VE(@'9@0
M?+SF?FY#JPS1&BTK)*.^*M;M?/2KQ?7VWC24]3#?DYX]M7VG$<;CYB%B'"BK
M+<W'S^4^XU!4"?'$]8T/7W5ED)Y"-,J&/G$^:@=-*IX\ 2=L#2?=6,9M)6Y=
M6YR6ME>85#>NA]G9?;)/*NRP=O/F)GY<UKZ[6,V8X#$ZUGO6'Z;$U$01R==H
M'E_TZIHJ&2#%+#L\'X,7;".9_0*W]>T'+D;IG[!Y[IJ!4+H/5V#;Q(*=1".H
M-T9*04'5HP%I)-3%J*_GT/#)3;B;6X!BZOT6T3@W/'0>Y;Y_R_,09.+R76T"
M2^__$[&[8FL ;NXSEPBNM[2J#U+*F\6M" DM+W_K#YT;*X]0 /O<NB;W_I7S
MBF[+%$*9.$5R1#/6T>P3".;[[HO1/?PI!$[$[S;[D6V3>(4?TO&A&)\+I!V"
M]OG*2G?Y.@>W:D5MLR_E!=Z+=NW-CX?O1]YXU7]ZG0O1&5^M1$QL]8;P@!_P
MHFTG99_(W*?Y"'DH//Y.P[(R$;4Q^1UX4%__6B[//399H'G?D \=62 +TBWJ
MB>U1NM%+T;M2J#!)U9STB SXGH9HK\:UR.\+((JX9>/FC$WJDKOX$_N/AA9#
MJS(Z$;9TN(5WE;WZM[G/O-)RJ#.CU>H_YP12/<4,CV5[$6TL^[NK1[C+) =I
MXPJ[WY)+1_XCH.2NEOJ)IV'(JYZ'O<Z0J%O+=D</5[?Y*B/L%Y"&V1P56IH:
M$Y.#L4FAK9CL>U'>1A 0)D(=)T2R2,T,);!CIQ;TS8C1^)F]7>DY)BKP4;(K
MN)P@F]RA$#KC)V"M/[*P7KQG4(HQOO*Y'S,XD5$JDL!E$F-DY&T/VS3*K,R]
M'@W"?'19(1#[ZE_O$1IG(/T4^$KLQ2\0.P5I96]K+^^J@;_AL;K5Q?FN==6T
MLUZN3B<'83.&S4D7DMVTQ_66]CWB?HQHC W+2WT:Z^K[3%'BFRX1$'[93/HA
M@16O.DAJW5?"/:QZ=K$O&5!VG.MO*<%O%M6V(7_"(_Y2!Z/J;&HR#(4-6*2;
MCTXN[QW$_- PM^/FC+0KAL&J1O.MQBLICLJ<97"_;7G8'B)0_H5DZZ^&DRPD
M7?-@4>^0KMV_V% 7;0W6E'W@<-[3C^VVT@:V=JO%LZ/_<6:V8$*"O9(VG[7F
MIQ?SAI\"3NM3B*8U 9S >D8^,=O/<2WBQ%VE,L#!\W!W?3=NFEG=,!)J7.MF
M,J-D;#P*NB6D\_IQ;2V-FKIB>EZ2X4(8+$L[7RZ12HDB5!^6249'M_$D1PK8
MI?F=DWOIHB+1"1\JZPTNZILPS^K554?X1;4ZL+;,>M3:O$QFXS#8-C46T))2
M6?LTEF5C<MH'JA,RVD;!LQF0WN&5VV3 8#W0:ZV#E#K;(CS6LH0<_:6#9K79
M)OC))"_EF_XLG$ML)"XWSMV;$9S0^>FF@R?:W \NT&3A%;VUDEIBQ$T1B4_H
M6,@ /:$4)/#-N8WDI8O*P*+MP=I%'>" [8'H_<UVCS$7U2AYN(R\,U]^>+=5
M29,17% ^-IH"VVF&Y+59^%@O)]]Z[OB@L)A!/"_*EN(D)HGC)&M#!VBZ9.Y/
M4A<!A74G.&UG9FWPA<RT3.U#EF_+VRY[4=M $+<1)I75GC*WP-:NQV_'1Q<?
M0?D2RDO#[UN$&2E[KXL,V)ZF4-J)A9"4\A6",9)BC@-X73#KZ^H)?M#%"PN;
MX*11@B46RAY2A/0/K&EJ8S$Q"8>)I*AB D*8&A^+IC0'2PJJ4QN-A2;1?P!X
M_E-KCMDX5(:"R89GLXLE2E;U-0XF+=V(#PF"#;[N@@VM#R!YYY#'>O'N.W>J
MC%T>*(MW<7D]\ >ZRTD]->.[5!C)2*4@Z"I$,>AV[UHVB-_)@!3UGN@$%LF]
MHY5"=;#2!LU'Z;+J $E/,S^!;E5(S^#@M']HG9TK0?HH,J?#NOJ7 77^QTZE
MQUVO^"BJ%,HM(J5^\PX%EPF2 ?WTJ\E^1[:6X!F\Y?[1"9.5C"'XS(YT>(W7
M/&&35SH ^=5YIP1E$"I^H0OUV*)DN=A)1N5>Q,<"J2@9WB =G8GK(4JWN3\G
M4P1$SJPG.@8J*?,*(C@X1FR3N>%UT0BL-XUF]KU5UC2U7-]S@A[;.UIU*^&:
M355NJ,,,S!Y[L9N%MX_*R[#3&^KKQF;Z+,L\B^F^HFT$1_GE0(@M?A?;)-()
M^1")%ARNRK0BVN]7=*=9\-.6M6EIJ=H[Q N+LRS^G]&IC&H3:F$]ZJ)Z9\O;
M:&[#MM],Q.?3>>@*CDV,CYRTJ%(4G#Z9Y-)RTDP2L GPLY1-I]D?V>3ODZ1Z
M=V1F"N%FZ<_8FHLX\/-]E-N_(!:U,C?#,AN-CO5\Z7CQ=5%!7&9P</J]&-K(
MR*(;W1J49[$ PXF=)!V(R.NCZ1-V8O.Q<6D Y[9TX=[44G0_6[Q)_0R+&DV/
MR7!D'QC>-6I;E_F]_>UK=[K W)+\KXR(TDB@U03SX"O[;+N)9@H6D05C".[$
M81(5T1<O'U(Z0#0G4.\GMU 6>,H,K%PP^ /X>SYCUKC]#-);>D1L'IS/ GRI
MIY:;$B^L$!G58L?#,[+X8?)#1VTX,^L6ZI(LN\QK8C])G^V\>+TM$4:X-,+&
M*_/*T\7O8$J+".JGX!;9VW6F;'SS=#H&R*O."W9N!$.;V293\Y3>\>7, HG&
M2H_\AS>4X=JG33B&%W$Z\U"&IJE%6H;HU>$]8T+6-EL"A$-B:@GB<G#Q!?P-
MT&2X@L<O\A93*,KO)4MAL]!3WJC!SK6<,*DO3S^[B6+;C1XHCUF%L8$P(<.K
MU'-M _J+9( !,8Y (X"3Q(M.-+7E>TZY>9D9@H5@^*.H7FV,?_[4N ]O*YNS
ME?O3':Q:<XFXJ>G'J#@JD["<W#R'&8[@JWZ\/X;5,"UC%]TH:AF%WIY+WJ^>
M]7-I1J );@=P'!4^6FU?77C?K-93C*?RI]IP9O<.+$)6']CK=>UEN).6C<.0
M9T[><*Q1*K?]0MAE95=-=F.47W;;ZNX0),;LW&_.11=UE^A8,SHA-JY60R_^
MG:TWG/VF(U^[QTQ<ZNH"Q@M[G'GA;]?>)3)%*1O"]OP,!6,N/SFBX[N@**A]
MR;"8*]_@M/N"BNA$LF6*MH0\EHUHN^8N.^"U&(U3V=Q-27%>S__J"5%0F9J6
MGIDRKBZIC,?X@@.6NK:E.TTB8<CTP!LL0%:A[$I[8Q9=1D5=3:W!!Z<PDVUX
MS1 G62.;/+6/WA5(.I%4"RI'9V@W(!Z-6%;_"M57TU5H]B)-?UW9>%V3:)Y6
M>".^/(IA0.BD>2 >GX_%SU*6\];^[+(+SI+TQD_\+>0Q6_P)&8"%5LD\59KU
MEZN6T29*3/L_>#B6O84J0Q*\*VR%:_SNYW+J-GB9>IV)Z]=0-.179U*([E6X
MV:\6W9F8ZD !<>_*"#S$L59C,H!B1U;%]_P6VSR( ?BI<3+@6CU]E^J).&3W
M6D%@D_O>M]G9*_29!<AWP*="!@B'(O=&]:4)NJ<(V)Z]O;UE;E:A#U*) O,W
M(-&[T-6+Q':2$KAX4S;8C!L1N+#VG'A[!U6(W:KP*VZ562*I8B*/IYG<X@*Y
M6@5%4K9;79C>(_%2PJ\;BIG;]6-$:31TOF*S BD3+FXF [[H#T0EX,D 7'^!
M9# TKWM0_0/D$4GPE[H],626Z8JH887K"6A_-">SQ,5+QLRAQ0FDL_5YM@OQ
MIN A\W+"GEXG5?.&TA/U (K:M\S4R;AXTG]3CS-.+R<#4H^Z(7%,XEZ_3O1V
M-C%'[<0WWU;IL#4II:B7FQW*3?K>HSO;B=<<F?C%>*VMSC(V6Y96Z9 !-R:S
M_. >;\B !)HW$"$IL_TH/"IC6I:_5;!?KJGU\2_:C/-!V[OA!$9&UN;VE^-C
M-IONB?@6+,MK/#S$Q6<Q]]KCA.^UED7%ENKE5)B6*;Y*G-\*1(FR +MAT"M>
M],.[4;)2=?3#+*G[N3?JQ&U-/89F9_P"8>(NSX$.)IU*V@F!3ICF8%GA#[U2
MM;'M*H9TTO8&C.S:(@G5.KJ4@9E1XIAK-*M0=7 2R=F_&PD50017%_E2K4;M
MH,@ _HH4,B"T)*AX?K :T7\FOK3?7,C-)77*ZANK*!?MZ$FYAF-!(NGGI>_M
MF)91!C(@?1?B(AL^ \V<'EYM)];XAE=%?9V3GIJ"]H6XK?D>L4N;SH<]VL>K
MY39ZB2EZ+ATMF\2F?1N#<>459F<7]%B=9[=T..<Z3D'HQDI@O=T!^CYH!)JM
M51488>)YY0P:)3J)^A;^=7DYRB'MKR::&TH)M'0"5Z34-%\X1-Q,\'R.K=12
M.&U:#!G^=WO=&]%[4#0AY6\G5# EXR!D@'O1J0JG#$=TBA.Y EO6MG+C0\ZB
M>PXS<YNLVT6?:Y(!WDO;ROFST;&/H?4,M>WY M.IP">Y= ^AA\33R-B9I'I\
M[._"AE?U'$&GM_DZ#TZT.LB(@T^*BN;]XETG;86&']+[' 9),T?'PM*,NGQ?
M<14O!45T=#)KYM#I:% 4JPP<W8Y))=!50A8>H\)GJP])J_.0!V+EG=/_#W/?
M]=74%VT=*PH"2A$$ 15$.E(C_8=(ET[HO=>$'B! %!2D]RX@O8.T! @017J5
M7D((O8<JA$C[\!_XQKCWZ;Z=IW/V66>N.><Z8Z^U SNSBHB4:,3<#!=OP^B,
M2:7PGVN/3WC)L"0X;$SO%)4MJ;WB_+!%Q%OG[4X8%E9N0;0>Q?7M00@4W:>9
MTYG ]=A^[$5=\RU7UZRF ^I\%+!1 LY2)]H@HJ=M)(5M5&?UL-YX33RO/U*/
MLT<RK[@,RA86T!.3OQ7_.Y7,Y-+XR5ZZU-%YV75B ;LUHID^SL+@R+_4:WN#
M5X"(*\#]HCWR14/IX]E&\J;'C^ON( 0Q8:QQ567%0U9Y?5._?X)X85< \C*'
M/^/TCOF<UR!1K1 W)EH0('J$ZNZH*X#B^>RIY9&S18#!CMK!S!6 X:P<C;*O
MK(65F6;*0>=[D[KWQ$[6[<;DDK^%RO>-V6QEJ#@5J?0\OC]+2S#;)NGF(D\^
MKT8O I/1 ZK+")F:TB"%/98/67(@4/K@"7@?'^#*!PT8C/EE+=B(K?PZL"IZ
M0IKZ*&'HI4MI3*>V=J&4&'7Q; ?HVA?=A+&62O#;_=&;V$%_P/67$WLMT.E5
MOW/*H:&L:]4>:Z_3(RBZJ]MMOI4/ZYQ(JF$;-))F);*#J]^\Z+X"^"Q'/G5:
MHDGR<DCX=UY9OO,DG.8U? !._'D%$*O*)ZK-FC^K96'^>PNX3^=K*<V/9\8.
M><?<@0*=CT$TX\3FJ**9?NLC;8V/J9 5<FEIKNF:X"K$^T_QNN/)OM=UY@.8
M_6J8=X#N+OQ4S]SB>.@*,/]H]5+<"WTX6[QA4.N73N 5'>^#M%7W6W494\=6
MG_61^G\I+W,L7[\"L GH#K^/U:OE^#<(4 4NK+%*-F[^5"8!X@]-U2.D]JIH
MQ N;TM8"8WMB9N:DCIHE%'*00PN)MRB"(OT6"(_-64-38A#V9RTNXS1)W@;-
M)=\RGA1$ES^KN#;?RD3.N3\LK]!I>T[GH+V<B!QQ:?MSLU._ \7E.U)TG;B(
M^J0W%ZUI6)87;J G+:'[..>$^;/[0')R"B:'&H,,G83*O)@2FZR-R[6[R=<I
M\!VW,A9-!-:BC-<I37=COA"=1^!W+>9,I=JDJ5V&TY/_B&5AD"O8-W-1Q@1G
M'?TQB.D>KQXF;^"Z]%S*3V178Q.)O<^62>F]FWN^FL#;?WZM 0EWAX?7;;KP
M%_E3Y@/&]8C)FTX3Q<4#N_R[>D!J&K/[3_3*ZNBB,IH13#?6/E)!->-:5J_#
MS<8R\(I8%$"[I;%>/I+)NI;C;_FWN_ *D#K5A=^>3HN0K4="[:15&X/>CXXM
ME3HZ"T@H@NW?:>$O$66E9<K.*_+4=B]>M]MH<5W3:\:E"E/J 68-V(E;ZSXO
M;P-"39K44Z<#P^:>Y'RY*)]J=$$:ZB[Y;Z_IBDF>S+\I<_DJ[*?"T_8#6[>:
MGUZ86S0B,SN?!?HBO8U]7T&LFS==/(\-$@PP[-IM.2%91_=HQ#.:$Z5.**PB
M.?E4@2%S%Y99.3>F,S.*$ D&Q:%EF986W'54DW7E<KP!U*]]N%BN?8_U$KI3
M.NO2&?TB*&@LX-<50 U%R+T$!)3].F<X11X4L\[!4.4^EU0YRQ3<#R881YO#
MG-9KJ'9YAM8'?,M+MP^]:656W$?3EJ)H#:X1]<RT^E!F):=+K?5\1":I&W0>
MLSO+6SV5(PU/07?A8LW9@.I7@))YS+#5#GQ-E=&V#N6?Z:'7*:JA,)W?M>)0
M YH0.5SAS*UT)]>EI?$:_;?1<@@N;+YJ/V)^WP=R>(%CH0-.P5R8D-<&PV]?
M'WQ" .T.K<T%=G[ @<1:#^ZH\:WVRS8?IANZ8Y",9E4'*P*UVMTBO/)JM&H\
M-8&96O\J<]R $.TY2D)NU290ZY#.*6"2&#V?C!7[I'":>E#LYF.V\L/EG&S"
MIK (2W21'AAPQ=<UU(DYKF2(![19\S*K6ZLJ-4XJA-Z\)HEOIIV'UBB?[O-7
M.&*']L*94.M)(+!];VTD<4,C1DRZ<XX6%0;'DR?7P:S+RP5@GD*F<7T@71MN
MMQ';;8>UHM*>WD<:+V\G]"K=C/7>K5 DUL%?L41@'YU77+H1"LTVB?S7#,A:
M<\%BC@82W/:JDTW#-3.1/IJG5J5SAH.E:DVE)RY[VO8ENKGT-V(+BVV+BXMB
MA/]M!06R<+71_B'I0J_('!%<CVWOGN1V[%T!0@)#9B7B?&3<=B_7[ ?PV+B)
M<8BBZ/Z0_:NN3H)NTJ6XD_*S(D.OYG;&?RTO#$$UIZWCY@-0HO_YS9W81%-(
MR)QI*>6O[/(=J9 X''TI$"0].L_T<ZI1HVG.\6-9Q@/;(&=RO6U>FH:D+G\Q
MT&SZ)GO\W#7F+:4?P/G-(DY9:[X;M"$[M"=\7.U5O%BT"*\<?\N"$ HGY1L\
M#W^.['Y-P;W_;/8BT=W6BI]=H9ECMKEM?-/<T(!C,^IZ.2PL__,^&5 SYK(O
M<27LHJRY[@K@_1#6;29[!2C^/"ASI&IW!:A_N>6V3DG4]H-?.NV:GR1=\$';
M_@PNHLH+1 .IM:)$CT)J&87KM K&J#]T%:K)A%J)_#I#5RL?QS >[)@/MF"@
M]4=F/QOD%D_IEKT.CI_97P$>-QA:_Y[31RT5=[SV?W"(X\. )9M:=JF<#RHI
M< LC/>93C0)MA?3@>=H%#W'^5IDP?,O.!5;Y.R&&Q'*Q%+9<PY7)#4)2>TV"
MIB3&M@L%--B\_M0KD^JDQ+$E-"6W._Z^_[FU&B.6" V\E,H^P4$^B\5Z>@IA
MR'K7<G1!L:K-;.YW=,NU5JSPQ0IQ[RN'ST)_(?B&V3<=I78&:PTXPL'D]5IO
M'ZM(%^A!XVK\>4$ +:.MS9/,5D**CI.WS7'2= 33:)#\8K/G]Q<QX4X+=A\+
MC(H+J+#?_%[X&HAGYC\FVUR>Z9 ^V$U%@4</V>[[^F601WIH9BSQ5&RSRI=S
M&*J\EM1-N"O.DXEA:NXZ\U":U4=<_!3%6ZDFN]W3#E83?G#K[NVGCU36I7AD
M6EJ;9BX^HFNDX*C7F62.QT7:.> &$'@ZUG,PI9?'3"6MD%J9;G;TQZIF6FQ"
MQVL>@R^=YFB_U!QD91?&#H7$[)PT)4RWI 3OJO974W;$&QMW+W9]3H91U'4(
M5-+(G&5:KK26=05.3CIO5W:)YJB8--0:8;9&HYII&U"D<8R(AMNDH(^MD3,2
M.54^U;YVM?05(AK6=F<K^/<^S RI;XA"AHT+L;]74^P*-!/?EY?:V&A&]2C;
M1A(5LPD42ACD=OD7"]>AY;2V" Y:S&;VWZ4W#[6BGW8 ' &_DAC4$[79I.U7
MSO@@;3.5>2FVW\-L_I:^M#5G<GUN[Q)!2\501OTV-_J_%Q_"S_IEL!>O(O)V
M>!?1/E< 2U>ENC<9ILM(BYEX/.);4;\RDU@F(^AVK9JV9=9DNQ<J^ W=G]BF
M8MC:L"-^#(8%DIEV#6B0FF%XOS0X.]C91)JVQ/>R*FE-,ZC<MPAH^6C2VG X
MU7C4-H:<'K;VLDJNY&/ 5]T^?%?QUTX1I/N@#%[WAC6VM#Y#3?AP\(E.T7TV
M!>9O+@4AEZSS2DI_WO[Z'7\F'LRJTJBS=>.B]>%%*=84U;AOSE3RG0KO/7Q2
M"7366;7ML>H485-TG%2*F^#1='0>'97GR::QH>ZY60>8(H1];=A=%]P[":AC
M*AZY4#]$M0^,OM.C'TP:H/JO)N/RJ]+@8G">_C>>;U,5.3BIIFG1R,J_JKF>
M"Z[1".&W8JHJ[5LO>3YGY[<I@"9_)!G%D8OK:^]"XG294LU'M<'XPIP^&]%.
M]M.\'2=L5>-D]W+T^Z1D+@'=HWM<6](K[^+*U;^1];*^$9650KX^RLJ^ KSB
M%%E-[A@U+%ID7CO)?H1 '&0_(1E3Y$LW-TN.>D)S0]\'\NFA1IU'X>3 UQY>
M\+=H/J/!DS]-@O?7]R=UI27#RX1'2K]^%A$&W4Q^0:(%,3V07L&#&W!-*N2]
M.=MBB)7ZL]J0QVE:IFI-&QE5U")L[ZTB?-O)S60TRI7:HM\+GO1G$)PC+W 6
M\W8Q6^M.SMK(^';$TA(WRE.0+MR@K'ES=TQ^$-"II)_3Y.D2,>PR+]HX/T_>
M87*WP>_!_(.4L7N9[Z-$!#.6]=S-Q0%(2S D_J)PPHLI/F+>6,.U58K"+,#L
MD6B!'W2P_W-&WI.@OW[,(MV*//LM[I62+S^ ?#Q+8MVO "^/*"7/HOMK()-3
M"+U/BD+RD#_!G@'[DC7(J)W-!6YQ6E"X*N"64$;RANL@(Y##0_WT3/(D5?]&
M]LL$:X\1,I%T:^_]9+DG$>6AUJP 92XZIGL&V+,6E$3EB>@%Y@SCX*U')A11
M&3B6-F!-+2 )&O?,T+E#-:EQYX&;W[>RXZ%1J18?.;M&G.LZ^? <4R1DW@52
M<9+IM^@)Y1FYOZ(\<OXBWG=4D:K$*['YOY5H83,14C./-EQO9N?N%-3>NVF0
MIH0W+T*.2I@OF[WT <?AX]'-3Z0-$SKM7P;1<XS=9\A#[OOQ<QCG@-7F3.<B
M>\A>"[OX/4?N*?[(THHO&JHT==JI10E,%"4#G[85VC*_Z]@19+R,F>WJL]<F
M+P-3?FM &F6I>( OG,7L-0\*$EYJY8_^-"CM^QH13['=PPB?= &^QLP9=C:;
MI-G79B@*_K!JBF$?W2GYXW:L_>,AQZ_HNRXX1Y^"@W/G7RXS/H?V$C!+/1LA
M:EL.79V?6LS<3 ;'-5TIKL*.(KKE-Q^R<96 \^;GYBZZUIY,)5?Z#!=2[\&\
M$H9&"U]$R-<W?.TK(U?ZHLS]Y2/#1ID2X,\\IE?BJ6(:&/A(+,RI56GI4=,!
M$_E@QUM!=>[G[^2>TQJE/-GZ]XL"6P<%JA^W,F]BC,L]]PIVZ 6-([F1B93J
M^N0TM*]!(KQ"3/SR*F/("#%:>V^0G69@U9JT]5H;:$Y4*E2BW+B_L@.LRCL^
M.7\;OK3YM/359^JGG4\\%\LYDH.#^RBH=F#\O$?D*?@695=W5U<;E_=N\F+)
MVT*2+A]7GE"]T:K\*%#*=DL]TQ$*[.&BZ*_>Y 3ZC ZO"C):)09H^8B ITR<
MK0^ZBE14DNG+_#[1>K-XO% "%6O>68G_RO@\\'^0I3PY=JNJE>EB<49860:3
MADS\IH<-]?!B14F '[6N8[Z.&*F30]D=+CM+5+'/CB04MB3!APB!VHD;Y8#U
M1G9)'_B['B2IX=ZS?8OP]XV4UQ!2'V%-&R\Y?$@;83KN:K8-ELPA>3V[=Z@(
MDVY/J>4=<*_\CC*>%FFOBC#4ZA\Q*!G#?O B"#2>>5L.4KL@&06E*HQ1)JP_
M=NU%NR;5!&M16EE>H<\$2L>T%<INBQJCD$%#F'&I,,-Y*:W6K93W\NHKF^?T
MG0H'LO')5'D/;'5%1FWLRO,-P0&Y25]F(F94&C6\")YNJ\YL\X6X$QCA[N/F
M&=?!;S8QBJ!XW@+5T*S5+U(:X26BP5Z5]UXX4[HB+BU0@452F9YU1BJ(LPJ<
M-BA;Q"I:4)*;M/NYB4,NPX=*M?^",U&-*))Z"6.+G<H))")F?I;$'C0&+JM$
M,2]4? 0R"W"]*"XNB%\*ADN6:^[Q#,V+@.3ERC]^6PNR7U>WF/=1*]N=[9OO
MWC"%,$^;#$5Z.]26L;WOB3$,J4E0> X W7/6I'8-2VW2L<4 U?IF8:6[;95&
M,_8.+SPA;M9\AQSVIEQ:;Y\QA+/%J^=90Z$VD/EB/!8=/VSI+H&K$LJL=K:O
M2VI\;JH6G]\YVK/3^][NBXZR/J.@DYZTE'BP23(-QB\U<)W";)ZGN!$9YH;A
MX]M9;S2&4W&G67UIRWT4'R":S*@FQW1;EW^1E%^4/">9@"W;I6=/&78+G5R[
M9V258-S/%@'@>Q3YI>?N)ZA>1HUVT2DR8MXKR[IN^PA6&\*/V/8I>H,_O\WH
M[E[[._K=K,J(%BOHK^\:S7K._HDW 88AJ(+-:E)V=SDKL_LHBY"J6M0_.(V$
MV[A/&SN]7E7WYT%@_(A-0GEC9:49]Z>FQ.ZLJ@>1HB3W^CABQ7X!BQ7T(/P1
MYH"HX67XO;3DMR?BWK2WKWV<A5I;R!R>O?*5FHCF: OWJI&?_S&%8K'FA*D(
M;3&#WVA;4!95=N\.\_A6BXC"81\!:+S[M(VJFL83JQJ+&:^_J51>EEN<("X>
M6I'(N_+9CL](Z0KP-I6KF;2-VY,@[DF'?.R*,MDSMAU [%&.NSZ:[7[HE>"P
M9!L^^&LN5'.UX<VSC]KYRN3Q+3E]F2R2)GS8NR.-LC3]_!^;E25C0 E -QM9
MJI\*W"J<2__='J?UW^,$"F,7#UH1%IW=C5NE,!5)EZ:%/35 >9=.Q='@T_?,
M.FHJ8THU%9$K\;1D'SK.7A/\]E;6+O4NIA;)4DP7WDTQ1&EMUW^1:,Z]\T?!
M-/D6'X*T.8G*G^]DT"5_M<J",?:+ZP1B[%EPL"*W^W.0=GMD97NI%47RRQ*E
M8I4'[+L[V,^SC6:(';7A2)POGH@\(@:6-G&*[AA;^7*+[KCJ@!1YA:F4J<<J
MWS2+V<7]%1$0KX+5'_%=])YW0K[OI;KM/MH5G1(RQ+ZLG55^>O*MGXWWJ<N6
M]:.,?-TV@)6:,M<<@BDU0U0,&5TTJ\K)4QS,7>[3Z)SD6T6OD,#=7$["'PP@
MZPH)DRV:G$>S J?4BB$C$-Y\Y&+[$O"N]E/ ;/P*1A@%5BDH]>\+B[\KHS/6
M%Z^HP33TV3Z.1/2&!T[TJ%O<H_9(D@ZAUTX/MC6&%% S[A4Z)@_4"A5_(%/H
MBZ1*G'U2L/OL ;+-9)7"<(WZN[*CMUB& :O0A:H"+WE[EZ9"1.72[S=VCI1+
MS_@AJGTQ*]BS$_7B65-O=D;777#G# L.V_FU3^OKK.6&E=:3,R<Y-JLB1^?'
M#OF"KU5?L8X;"23-;X!-EC#2F)HTWBJD%)J0/'#TO/&QW@^N$_E*245'U1>I
M%O4ZFLX@LD[\+JYOV1.-[9AZ?$*7(W]; !T,+GJE'Y!A_+;"UK ^8IV$QIY'
M='^G"KTSV#H9&-WD;KP;%K @E'RF 1USW3AIU=;#EZC)@WA!+R5Z5:P<% J\
MGVUQ%1&^&]<?29_U9EY4_6S#RC6R+[JZO\S:,B93_MR9YYO0S:-5UUV0.QY5
MP' 2YSPJU6TQ0RRWR_&;Y5VMA7$NJI;K9559OYZ3_N05W]Y6:6#AQ*FS:I;6
MS.])2+5WQ=?,/,&/(04D=-GU,@*;Y)%YI9E\]?Q:MR95024,)#&EPFQ:[ DU
M5.>M%TEG,@,F,[M,T=D7?M[.=W*IN8VZ7:H(V8S*3Y(+QR6IV(QX' H<Y4HF
MOMOO@OO[35*AGG6S&!-53X-T,+./;@,?JSM#(64$*=/['2<R0"/3\^],'P^Y
M?;QR=\M<L?6ODS+AE-G]5P HNKDWP67 V,XHN3RA*K<@=D>L./U%1+;$]_\&
MG_'_D+!=CX&N@;4O$8I0:W#*;Y/A/SCE9<:)>L=WH8J"KT)TJ&\K)65PL*OO
MW$>:Z:XR1:9= <ICG;V%AGD>^5X!M*T?1[O5I'4XT;:8XVGJE!Q$'M)L]G>M
M[[0=_CH> JX\;<HJEZTWDD*FI)9M[@<W%73NJD0H6::\[V\>XIYQTJI7))6G
M]RPW9D]P')"\ @QFZG7220A/QL_0-J3AR2!+0K.FJC>Y13#BZ%AE.4==@RDM
M$D.3U)V6K'Z)T+U77#SZ_%[D'7*>CO5WFI Q^K:/%VCW/T9%U DU"!0P_ 'Z
ML&7N3,KKQ.*STL?/U#8XVX90O,%% _JZ>F(^\39B#&7^')L3#T0-?O7-HYI-
ME5+]QO?(.6"!\_V.]0)5X2\1,7XK7U->:35FO/EDX9A7P@=#I7S[@DG2=WF4
ME.J,FML-0=1'.+[X_((&$'L3&-<D7F;PF?YGSW,F$BM["9)E=%#5<EF'K0>&
M+Z?NY#TF[&8PU_L$RPTR>5-2[N:RH8203?%[-U)^UG]IF\KF(V+BB5'FPH*#
M%JBV^:G'R^^!;\FL]&Q,WP.\W3^H9+/>_0#S[M.;*QU$/:DSM(K (S _;Z^D
MNP[4?1@1>$:E6YTM6R+)I3!4UZ^U($Y77==$(O#;TC_2R;;\JT%R&%-H<88V
MWW^-[R##3>88;!=O3J)/?],@:XA=78;<1OQTUP[\67')\M<*-JQ8WM_)Y_J9
MWLWA).6]/AOH@9A(EK^0^2;>+)V9WX0P;8O:2#G#[&ZO+-G.":$QG7FE$B=G
MMLI8SG-U7^K/[Z+\3-@_MX[>O@*88H?.G%TO@/B,><C]W1?3:;,"#F'^<FR5
MXG.!JM_.G]-(.(ZLL<./$9@*PIT98SOLJU@C6?9]M/8WI7&]>%8#(\H[!@=6
MW4J\)6.LM/JN-H=GOY8?_5)450W&?U4X&%ASY"JU+LN6J?DU.BE+HQ/OF\%I
M[QU7V/#1NIMY!1/KL0MD&DN^DY=G#-$TUQ 4YU8*EJ"O>@1"W]>+"V-=*GSC
MS2+;$S?M>MY]?"?#M<I8R<K63M<5JOUNH/\TA.OFMW.1:N8T"0FW$\3O7"QC
M"AB_[8J.^ZF]5M<8A+C<'1W@=CAH5_Y6E%!46^/!;ZA%^F*>7NM!01EONB'I
MQ<]YO]B49Z@Y"B+"N!><2O?0-4>5\?["%\EP1F61'UF%WIHB"F7-O:3USTJK
M7^(EF*\ O T9.V>?#@9^_^);7.Z1?&+#%;7XXDL[JP+;R'36BX+QA[8V$I[^
M>_YMA3.M@:*L3KO@7],TK;&-=>DJE,NED=W#I)M&3CILSEH\$T8C#V)HN#QN
M6&EMHSV0ZJZ)]AA1A>#1;0],JE=3ML/@C_H&&Z/;D48D]LD1I3ZD-S,BLB=Y
MQ<A<5^NQ0*9Q54^(90 FL.4?T=KKB_#]-<@KT_JB9?25@508/(;-&AG#*J*.
MB-<""94V9TK%N.,KNS60"GR&SWK&V4!:4];'RDHQJ3>!$7KC]"FD?7S=C2V#
M@])3AYW'QYT3A7/[@TZ\8#W,3[L8PW@VP]S)D5!:O(W30P^:J-9>1CJ^LQ"T
MT>S/:T=/$V_"&.G3>$!K]J;_>801R;/+9S\T/[Z5E;H?N-A:=\9(5KOM\V=?
M5MJYS@<\72U"TZ_+D"C$5B[. 1_=H3$,8SW8"=Q%BLQ[)%<F(6SE-)JGC91+
MY6Z1=WQ^2KHOO!#0?/?,N=^G9= 3RC1M9^"SC4H:[73DX2I4+G[('?_CSU,7
MV4SP#M$%Y5@3GN/0G.YV:)>B5V 4^DOO7D:NQ<7D9Z/.X(<=9#?YW5D.'9HE
ML4-O.SKXA'?F[W\5^Z3ZA]J1[V$H%X62]GWZV^X;Y@-KTQXX[LSAAS]-QSH?
M;E*E75;QRI*=A+)^?//4P=>K-VW']6PJL\XB*LQM)V8H'PO;(ZDA4 QT+CBX
MT[XY&7Y"MUMJEE'KGT@K\>VVKMF.+O592)<YZJCKJ.<L!;N\]UBB (J*;L-Y
MVM+6/U0%@[UC'PO1=L06DGYXU]![2]]MU!9Y&#,UF$(W_WC,#RE5F3059]HK
M.=K])D3Y]Y)2O,@;$6:6.#:*^373&B1,6R.!*?4.T,:R]% 8!;<#K6[CK!4%
M09I]N[^U"F3\\[*5K)N?A-1X;HU2,O?[D*>F9683Y-6&L*:N"$+ZT#S]M3?5
MCK_S-SXW"?0^V154%:_B9=T*QC <!LT-(_M&Z@F.5&23=SD_W"C@7<BRC'G[
M$+"H,[:VN9<U6 ^U]U_ZEM^QROT=%E9RDF-B;5]L), G%Z0YKK14Z]#7K_4T
MB"2.7+8^5]Z&1#OMB*0E];RIZ>A.'AM5+\2S=@;O_GK_>&Y74ZE#I4].O"KX
M#XVX;LF+ACNH5PTGL(N8?@G)FH+?X%3C3Q&=?W[:"G+L3Y25J']O*.2:_<*F
MV0CAN5;)/]E<D=^1H1>8B\\-+P:6'*$QV! [1<1L<"8OF]>:BZLN5:^(<BC4
M^/[H[KT%\U%4!K3-Y20;"VP=<VN8<^G8+\373D?J(4+ME!HPO4\3A#\S?2SX
MED+2W_N*WS6@85=RKQY_(C2-I2]T5@U%.7^4C.>63H^? -WBRMD9NK>\==:"
MS'%<@:$O:'9X$/._K,O%NV*ANO8>IS7)_F0V=H491=F @XC>@E9A1YJ$"M72
M F!#.%KHR/[UO"?D&&*?,DN/<U1=:\QF%4!> 1@2'GO]U[M4%Y11)E3&:SA4
MYOCR:VL_BJF8-^@"^R+;D-H=!@KEE'PN<]JL5+(CY^LD,9.N6_--2V6J."AW
MWGB54&UU;&ZY6H/)!-8D@E?<,=4LD>^?5^7//7QR(SOAA66H0QKO'S?5AWPT
M0D_.[ ?.4.#,5+X]3WEOZ7E>VYA##CW<UO.FJ 8S-IZ2K?XLX;N-]*6RPW.M
M"#ZL99NK@#*$?#-;C+<@;G"A_]8F/OZ#G1YM4<4"B^"-4(*(-[678NE9OA1Z
M:&'.((:PM5O:I6DG.(W/K??$M9<[";ZV2L]3:2E(GG ?U^XVYDJ(U&!(BAGT
MDZX._WY6Z3ET=^D$ER8:G<>QGL'-+1'BR)8JT#Y(G[):G,46;6O[\O%+[7*Y
MTO-#/0BXTD]7UM&]=M?X:RR-MJFI[#'G4TJ.!]8?+</C!YP4\ED9&N3I>KMY
M#\E@J_Z)182NH:[%1"](54?W3E3*XYJ0457-*T 'I]'+5)WZUQKZ:@\B^I][
MAP=OL27BS9;WS+8;/2:[6US=?AX;QZP_QO%0O=XWTCG63*8@HU5(H;6U4'40
MKE3S5[;&JV.LT6",W2);T6Q?NVK/VGN5FMB;_W4ZW!+L9N6\[<C#K6)=/+C>
MAN(NW4=!(>#L]IETU]5I6)F1I/K.H.7"[/0 NW3"[90VQWSJ%R!2P;[OZ2_E
MGL??_A1?&.-7G$D8!O/R5B"9^MJ=L7T'"8R]"ZH2JHPV4<I"S:??E!?=8G5R
M/3:>CFM%BL%2?(+\F[)WN[IVN57)+ YG?W'/S<VK#_53E?Y6\4UZ^:?\#NFL
M>SR+_<FD\:-91D4K_9/YWMTH]K/B(46U=$R--8>S.ZC15TVE4^>Q8)&#44+9
MZUYJP?MDD8__"'B=U^V:G,%?&[J,[CUF7&$,GKN=/6Y4<)+X(]2BEK>B*I23
MAO:MKFCN6[7[]DTA<0OH&3ZD$@(UF.?,_JD>>'=QL2E4?[]7H3':0"GT\P=Q
M!U\;Q_@&(+\7080/$K!CNH<0U1LM'EIU-P:2&->GNGU->@,]"!QZ6U.LS)F0
M!X*1^O;*GU,AO9\VH3TUF@6&43N$$Q]157=AT==2.1.,!1];9*@<W_=HV=@Z
MW4LIJ^]E;<HBV*T.@^>9ZCSKFEJ:':Q2=FV:7Y-!DYQ&:"SO>7R(Q=^[_5?O
M(WF=&U.K3 ^X/4:]_8?UT7?7P&C3QJ(0>SZ5^YO%/)NR=YLC/'+ (HH$\5LJ
MO,\CA#9OF!G,$%/,H',A8-&1 42F5^H=EP!=7\."%S3L#CV<<VVB&6WT73F4
M;X,LL3[WFE1^5'XZ_&\*6 HFGXD>E?\FV,#JO_W+%_1<^N&.T&BU[][[>1^6
M=)AZ:\D0JZW+>Y6%#AK'V]_ Y&A3*<4,$$/Q14^J0OD&G59W797C&J9U56S9
M)?/7OL\%@K]X]*/YN;-+8X*:BR"V3WCJ0_<[270_ F/MD7QN=&[</Q/@U&1[
M0;:A)5S:OACMV+&R7N1[9H2$N.S%MD(^8U$Z%GKV?\.<P#PGI]A#G33W/S1I
M6P:61@9<1<'9>;6UN3;OJ)0+0?2;8)7'F+-H]N[ZP_EN5S][I%17O[VG.]Q_
M9 .!C)FE'U=(Z&60K.T%:>(+[E@7MD29Q^=CD>0$WZ:&YC8EH'')L[H&*N=L
MNVQ%*SR#1(%[[NUDVI<?2HZ,CV6<5KEAW)P3,X%7@/HSH\RSDDSDC;:3[WG%
MU@LE1DX9I*?N1X,JR1RFMFHW("RE825<9(%-!&9G[%\SL\8Y%X+W7P$_2*.1
M+ZF2X3M!.7%,ST'X#5MO#AI:D6>Z (;U*H5@C'TL#%G3C&'<BJXXT9<6HM@8
M".=1$V=-$N;RUD?=^OCR^L&$[+^902Y#!=L!H4"(/9"/F[?)$X5\&?6D>G%Z
MQ_(@7U9IU3+;*?SXV:1799*!,U]8T**GP@'?@74_C";>6,/[ 4&?KK9S^8*W
MGNT9YR.NJEU\<>-OG3"?0NZ5&%,,Z^PN ;\D]BITWJ!RL2%&CG)<XY4[^8O@
MOI)ZJ2:Q/Z,_;+U?N?V&KBK(/,_\:0?-ELF#JNY$C\A^,7IDFM=@\T%O>68E
ME#11FRV\P\6*0VMJHN1>]AJ%??VZ:+!?95%K;&JUVN<YMU,KS^-'M;Z_']LJ
M4MV,>A1!R]4O!Z*RK3]'>_?U\V@.DA=D3GQO0?BIICG?U]M?O6&8*$M!1F[T
MD81&ZO[$!3X^<SF;KN;[R"]VXES<DD\57PC^)WDC-Y=TE\/D7=%:#:9W_8QF
M&]\8<=.[>]C-M15?( :D _?Z/BOW^"M3G[)\'5^HY&-YZ*AGH?^=V3/+!P$X
MT1$WI5JDX%S?WVCYB%=1!=^/]=[QR#R2>CLGL1<T///=VPN;_F'K;Y3=$":=
MRV5>U55[!>=NPYT44:/"S1Z:P>5;\+:-XT,:HI7]U^\NPB"F9>Y'2PNFL&U\
M9,98)5'5F::R::ZW1(GUH."=[MLDCI .MHS7MTA%LPUFEV:,8:;-@;TVJ,;H
MW)@E@\Y/]V1CS3_%[.R0>P,M:$JJ:9!>BQ)OS=I/SYYBMF]I))0-ZFIK]JO5
MW_X]NK(I0"BO&GEI5O;%26SDEN!I6RYF<T=BMVAB@ IB@J!8=$D0^?6"MI8G
MWK0P/YT]W^3FQE*N%9O#<F6CEQ]^<K6V:*PMN38]WP#T562"V=@GY\]26><[
MFW/U&U,;XK2(H9/Y$2C*VPS.']N_7-,J)-_,[<SIMAGE>!@95U28DJLK&<I1
MH&PVXLS58C 'B_.1!F.MUUFV5E=JU&A@5&;*+]Z^$#2-+%FTOV6\J?# (5FX
MR_\61!*)0/,$G3=$*!4D0F$V"DD]5)@?"?)OE4S?D\;\O>DYQK>*5UN,FD.S
M'B0EZSHK3V*=P^<P(+-0H !H8MF)R[30BE_PB;4V;15@>7,'F2;U:PZQ/6\7
MS!ZK,-4@!W4T^,DMA-'@Y($_G*#_>5BRT6VW$MUV,IRZ%F^"6&Q4A7C(?2>G
MFF.SX#A_I?HTBO@G9 ""CGL#KOP%G3!;GS7_J4.)\/1N==1 TD[FA0B.EW&Q
M\(R2?JI,$9N4>^K.IN7,)9)TXV-F\9NC;$S_;\]$K&'@&V1#4Z*3L5,X;_%K
M0F:1VY)5=;5*7E=&Q,B?8'E&.(]'T7)K?]\!QM2WR_B+CIMS\ //=C;QVS>\
MZ,=S-0<Z9S\L%07SV0="YG_N1 PU;9/_"I])8K1W7H0R;V']'I""G7+X5M]E
M1T1D)!A:%1N/O8G'3F<'BH[9,X%;L"V>*1?LG=]-?MHR%1;0 5,]C".;O+&
M_5]/7=D<9#1:T\.7. 3F'F&(ULZK:EG P*W[X/FE-6>8L\U73'?17%*"8CSH
M*R&:B\;//M;!\)"$;$[ Q?4KJAB&]T]4G3$V9F)<$JU3)'@,ZOL_2&I7'M=1
MO3-C6Q@EJ5'P.LGIF>+\$=YD*%/^"QI=;Y59F>0=.A@6A?=H>[##8+E8JY?P
MMCE^4W/;Z$9W@W$L?]LZ](\HE+L<TA07#I;=3Y)7MC3E\"ZWJ*A4,(K3'"T
ME<P%AM>C%/-]V%?F&@/'H>$[1,\FH\#*Q^09DLPB7"6C--2Z] \\;E6F:,P]
M?O"&>84LVV*>Z)SF![=K:PK>V[X"P!C34WX;)R FRX5EZ3I294D>R#%9?V&Z
MD3<K&GUF,P^5D/!S;4LDN(6R-SE^<*QB$".C"B_+7[SMDTU29%K3"$M%/1^
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M7'_4\CR^<K=U0O?\\2G_%8"4X5*',7$EM7TX5.K507]-,QU*0A3M<XSLEU[
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M.]*).P-T0?C+PHKNSBQ/<I#TVTQ^?=5XY6W.S9H)(6UIGI_*!L?.RHD];Z\
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M?1[,5U'&*U)BCE@%  GSV*Z'Y=8/IR]]VG<#VH>A])N0*'<G Z=85GA1V.-
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M/S37?3XL]_BMH6-=YZ9C6=E5/K/WT<MF_&1?+KJ[TCA=GB;_'[F54K,K1I"
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MO_26@+:..8SV\'5B)UM<;PCU42!UA&L&JTM>/RF",$^6)^=]:5QO_O0MSEQ
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M)F;D1)A: :K:;>UN.?H$NEEW8LBO0KKQV80Z1#I9L_O:Z@LI*;&F;\0\BJ#
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MN"KU#9A'KFOFV0?(MP3A/_5D0:%V@JO,D1DL+-PY=9]9+)5??'![]2#J3MU
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M[T8>_N4_0DXB#=U[U<)+GU%XUVFJ64;G511FE_F^+E,ITFB6M(MP+LXQ8W'
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M_#JGX /KQX&5V[?C9&S9[ZY=N)2OIE:MK^TN;JKG2L?Y'! :0,DHTI8-;8O
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M+0YD31Y]A ?<CSWCQ12ORT&TVP92A(>7@3WS!/(V)9$8J7? $1A\-+HU_WO
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M=+1SS*'<(+95C0I0L(WK6BH5>>89Y6^"_2A^R3%UMWCS*WNRN5R49,2GX\I
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MT GF=2,%R1GM?;\F,\R$GAHG%8M0XLGY!EZ,^@H:X)Y$#M9VD;(,_(3T]I%
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M\Q3O'B=_Q_+J7V[R]%.G 9HO.0V-3>1;_$/C@?#2YQ!18R<O2&50))6=[JR
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MUHLGU44?)X<K/,UGB_H)[C\HZFD6X/UU%D !_.X*(AEU?H=XM<73=9>/.#2
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MFFF&D ^QK60&[0?YK#7@G.'.<T+2V+!_1A>IF2@/$[=#?O=%52X>L:8=Z[D
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M:%O70V5>I.(,4$<H(3_%^VJ)K]IL?XO>OY5Q#AGWKR5@TR!LC(6MK1+9@#R
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M?%;.Q/@1LFFVH>3VHTN9W@TPX/M9ZV+ 5?[RXKZQY6R=0Y?P% LQ-_9J1+
M,B.KJG@@N@;\:;L'EG0T.@Z6Y*8LY*P/M^?0/;]C%)(<%H/B)DD7TNPP0N(=
M2]1/FP$@IU/B4BVI?MK/_FQ=OXN:>Y/-!LF/<T(%C'60!>(.:8;I*-H NFNR
MNQ_,\-NR_S8+'J@L*K[5W:4_>1C)FTG6"&WPQ77E$Q6A)9*>ZS9Y)YO<?Z>X
ME][(C2HI8-NE7\/PNX5T'0E**M-B-U230ES:[Y3-R*'IC!O.V=7.AKIP.)-$
MVHKQ3=KM8]#.S.&%AC@I0-[-W8"K4O DS%'-?;W2)$5V8)@HH.YA1MK"^%B
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MZFXJF0J:FCD_^M@A\>H[7X!%C&_>OT9IEK5L+'ICG'HHMSI"P<]#N$$O5EF
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MYI*+;"E!"1Q!K&(-$ J$=;)G Q,:*-%N%#LM<D8=N.QF#*W,W[K&K;NFNH6
M3:Y&(%Y:D*X-G7*QL >ZG==6%EA:-_!?U,G(K7:+:?4DM7W/8[Q3M"/,($2
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M9^_FVM4S'E]@LB ]WUKVV.PQMG1Q>$Y!+XF8_F0/W3W\A?F<PEB$9+0]K3G
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MZ;?>SUB6E/J>#A<X>TW;^JD8Y;909Y$U)\,#Y+(UH!;N8_M3%PF]0W"B](H
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M5S<[';"Y!JS+-IX*A9GVM4D[ -RS,2AP*2%?(2M6!RKNK[4R%SYANK*B#25
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M%S#"E)]N/".-B>=]:52'GC8=_22V=3+@&'VTO<,6AV0Z  D%D2W&ATYF.3_
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M87+@ )@1_OC9Z-,JZS[8#APXMBXS;Y3BU1@C4Z9JV=2<\I+2<I%)M'\Y9+9
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MB.N9$I8XI5QHU-&S??Y6SH>M^S#-0+()-PY?9@K^BZU5\O(B#>!$-O3H4:I
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M!-3>P K=('"CFG1H3WR*;. D_OY;I[%(CPEJP+[/0;-)958W^*<Q>SRNP&7
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MM)=PE8R^F=.<.G@BM(NC>BP!_: )L0KM*Q\>/,IZZ28V\27?9^&H:#,CCS_
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M/QJ@X*8 TC(9A![(*3P'Q%7X0=W*" ?C<VQ5329+6+U>E4JB<HW<!"<*([^
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MO>6]=%_INNTL+T-,^Q<MQ<]5[2NYQ7U,,5K?XU$!.9#]N<6LH;)*TN]C] &
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M$GW#"$S[81P' \(D^[5<#M>7J!X+H?&;V2!EL&7*-BQ]=$A?4S\MYW>;7):
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MM]W4B9^;3&2"?#^,W:HN+<C)C6W)XH,\YXK-$^7^^$PR#T!5!M9A4N_QD(*
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MAI %*<G9M@FKHV[DQ&+>R;:?M<!8!!O\-2;2,):+5J\UB!KQ"ITX+-GB92F
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MV)*JCP61\,2W,PC6^.P,]:"\CN'Q$<S+H NAB4%YB2V1>4F:9"JRJ74GVE,
M/S[ TE0V-W9B2,M0PX(625^!:51,39WSZ8;IUWK)K$FLD21*$SNDE]=9TJVJ
M$]OS#*2G<78<4:RWK)*ZZ>N1$",&PC9/[(^-[>J,?E?3H/,X&"OO ('.JE_5
M?72#[^[[;^!G (YW-+R8]F_P<OP6!<"-.\F$D5X(KE$ IG[]\P>P7GYR0OD!
MJ!J610'T*XVO03_X/-IHY:4  !@*(%"5?$3]@D?2OP F_A\2/,JR*8!WU10
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M%E$ Q*L-"!-K7QA.?F7H1"BP$HJT\\#98)U3MYJ*@UA>D+>^+3K8UV*9<CO
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ME:-"QA3\>#[NS^3<=*/&3/7 H&-.UO59K6+3"W\?OXY Y)30$LK]A!4<&GV
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M8[25X[*^\.%7*D.@/H0WZV\Q6@F3*H@D=]@Y;WKK3WP9<[*[-J;0;K=4+]I
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M,N-'1^1/";_S%3_ ;$SE(N3N&QR@<%3#F-1).RR5X5; V":A[(> ZH7!5<*
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M,T]Q -:#JVP(QI1O"P<P"QA=/H4,\V"3JD^UZB&Y.,"HPLR6WQ??%]N=7#@
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MM.=&_QM[[QW4]/;N^V=O"]N"B I(5VE*E2Y=1$! "+T*$>F]$WJV(""]@X"
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MJB#8^(VBJ)[!;B>?;C7[&/4]J_R'@:0$[1,1$/KHF,X>TX/VP&F-GW--GFU
MS\3!UNU2.LBLD"DIXP9?JS(-N5KO0"LU>?FX,+_PR-38[-Q<7^F@9P\B50HL
M8^C#FS&&L&PYG9,<!T@G:93,1=7MWNHE I3EAF"+,-L3.@R%]2HX;I^YMHX(
M( UA76 6&ZR7*'"_E59XF (Q-8XM>8)/P!6H.T"\4#5$P%/^7*3I$GY%+A[F
MZ,3?L""55][L+XKOM3NS@3@A*DPR?R*3IMNLPO(ZQ/S:,^CM#@2M=AYOVVU9
MEB8^7L^2?MRMI"=[<8-(\'G, FL?O Z6OM'5AMC76:?P]:8+))6?$P\3)CQ&
MR<9MSS0H=<T;4L7K-B9W6CBT7,]55:^M$[H?UO%H/5-<3YF9^K./NHG/*(EX
M A%P%ZKT:QNX)CC)RD@$I!,!Z 4<-8*1+C#@/:X_8W<05B,KL7[6+9.6&%(G
M7'_??NO@TZ\G#4@.L<6"_DGUX#G#S[0AZG\4^V4\V]XR(Y7X=X0L3< $:B$D
MJR1])Z@"IYZS/1P.&Z18&1ZL6HL[6%@W\VZAGYD)S/Q=M\.RVM%_OER6*:<0
MW2=FXBH[\V482/M2@4FKGPG(*XXQVR8"VL6) "'[O31XU;4:,=:.JJPLHXCB
M&:EP&7CFQAJ%O*6L],I)S&N1.Z(L?PIFG"-G&AV$&.QF;W)/Z&C_9"G-K?ZC
M**R(%+&L3X5QEIBK()P,A%V="$# ;IS)-3L$48(I^@<:>B$?&$.NQ<_"6P1(
MCLD)SCX,:\]-LC=HEW0L=*#_ YYN'V YSU!:*I[Q6& C\>)FGL:%OTU%\84U
M<AS>_$AL!+[@K#_/G]5*$\4[+O?@C&<I=@.[%S&;0G-_MEG"=@CHSZ1[G&Z_
MR56<9U@M0G_I?DI&KJI/^L66%Y3M'Y0"_^.$.P/0F3F7#%R#I!-^I;-9S'DB
M'Z[-R?DU[(6Q4QOH9L+O!%:<27[-HZ=1>NG!V<!6[;FFH',4[KBKOL.DY<8S
MY%]A+_A-Q5H^SICG$K[>ZGBEKON.@J6&O\>WUL09J"/] &XZU_9=Z,M3'M#W
MQ7[$Z=O25(82S6M+HR&!2$2'SOYVG)/.6_2Q5"1_Y4[?M:<BTS-%%7=_<PH/
M7RMX*>QK?M!;X6GJ"?W"&YA]:-WC+U[?VU#0.N@I%MC.YEPMI<$>*_6V=ZDT
M;;Q9XZMJ),/^9E6JN/^KP [_G@R.!JF4LXC9EX:J$HVCL[TW"NHI.>M$[ZV,
M07'?;;@;Y+IP)=]F5#^Y2I1&""?)R_/V*L%^Z(GJ27XU=C4UDH^OF+XML3(S
M++Z+ 3/&\8BX]O6[N*][&R)2_SCBK8__^P6EZ9=Z;K>>?*;:YMD.JP'[PY>%
M/KHOZ,?IXR;NOKP\L2^/K!3N_ +FFFQALSX!6NF>5&D[\^V%S)MD%X&1,DM_
M_S!P]EFFS[4L[9E0?$E0-6(KX5N9H$=?<GT1BJ&=1]..])VA-O%=M6] \ 73
M>F36+NW8?*G/(OW;A+=E+_55DTOC^UR? [P>S!S&K@U(R<YGLFRYV(@6U,PB
MC($B8@/S5/:J,4_S@I,G7HCDI,M(K'OKW6+(*9<"E9[Z>RT)MOFW'1[/5,2(
M,?VVVK%MH.3@XU-ZD1VF&F&3L&)L^U-+BCWF--H^(W/V')Z\.)MDMZYA.N.\
M&.?4WI08"/N^7\75T!S\S#+]H1U]^M\1(DI=;]ZG:(WRM7Q:FV-UGVX8G)RU
M$]A=?.5RN1EIGG'-,N&1KQ[U<\X71N,T3)?NRO\^EH?QG!G<;7W:J![>]M1G
MYB3(+#5'JO5 V9%W8N:OC/LE3[;66T>+;PVRXY5"/2D5*SG5;KFDS3'Z]SN8
MW-A\))98.@=ZX71I^%&RX:B$U#3@9VOR7_E7KD2(1%7ZON-7SAY=7S\9M:-%
M<=HZ<=!Q/(P)J8O>FBT"<%M]8EA.?C#YNV\-#6(0MS'JKP83>+R<G(OG#+G[
M BHGBPLB<\N0VV]CK]/S=M<85=+KL[NHT)U6+%>:P)IAJS<&0Z'GW8S]ZAGK
M,Z,.*EJ6GQ1X5;_5__6IB4:+I9S:6%=?86'7:1?7-^5K J=WJ@1+^2;D-BG9
M+A^PN8]&^]@W7:ZF9V5[E8SEFYHR$H@[KSH?FO/%>POD>V\8[97SWV4X]GT-
MCLS@_EAT=JG03MI+X-'KKPI*U"%^D24J=K7.TJ39L ?K[[DY9=H.ISK44WE&
M&43%HU@]",7-4TO>FL<,R9>";26UQ#8L!G_O9=)-P#O8,[NZ5ZQ$1B]#&\NC
MH]OY=?7N"=VQG;CWG:L@@$)XSK2CI@'!,HI@=+'T"KH$%N57]C9?_3YNB6:L
MR41*Z]8E$@'),M+4W+#DXBN='$T,H4\KAIOF1LQ;>^S #A9U\/G-5#0M-'%[
M_>3AK4_+\==NVH;HUP#X9BE*+N<NP%&@UMG59FACZUQ1_01S>9FT][YQ[_*V
M+]TW*4&>PORMAVUVJ,_PEA#& WKO=06*M*]SE+7^0I_?EA[4ZDS2"XGZ@HOB
MD%F7YU52#?OXH[YYC5+V-/NK5\\CYV<+8KI:1^;.639A&@>2@Z5&>_1TG594
M^K<*%+GM'PM/M?U ( 4D,-O+&5PAVR?K!ZDO;>MZ:(HMRN_4:><+5ERA]/'B
MJ0 /*ILYR<6<.Z3 );R']\J9O>Y]4RT,>^..Q+)E&'';K<;U'Z4[YW/&5_X\
M==1S9Q47YW!JK?KV9G;X6"JTK%LW.,:1SUR%Z5=T<WCW%<J_>J6?C#&M]#\9
M3,-WM':XT;VW$GIFKFP2(E7S6%E_#'M+T?[5I1B_"AA66T#+NRH PB67P@P<
M#71I]W>I!7L[K-3+SDS+>-27@5.-ZU;.Q&TF=>ONW<?:%/N4V&YM<W,E]:P$
M_Y6?H?]JY).EN"9$%;*1,M&6#I=C">)>DJRM$N^Q7'>5&\A<1!T-+4-9QJL0
M$_>>.=6VT#JFFD&9 FCN:"\?_$[@T'M3FGRTZ37X2.#BU:<JUBS6*Z>,541
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M8WM*/G[CC&>C)/MTOGOYMG8'I:B(H,Z83A?3O:-]I4<O7_VM^U+Q#SV:YP
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MY$ZY_VM'/N?$G^!*!,Q;!903 :/A""+@W >3 )IH:R%H.<$V+H..J!2SA8D
MZO.B*DCMPF$XX9!GS8:0+$L:VG=Z8!#]DSV<(I0(^$P-^2WCWPU9EJL[WON/
MRMS;GB=]>0Q=. P6.*6H\AG&*Y]DMQ&&(4.L9P-5*3FGFF<P(J"*Y?S<! Y;
MHX437$G-?WZ\1T\$?"2,3<%F]G"=1(!O"KJ6"%!E!1,!QRL+L#)_,#X7#AGZ
M"[;)TK8B=\ ZZX<YDR$"GD'VA-KU(5L**"* T.J/.79Q)@*235QP'73GEZ9:
M;0AL9T S(L &MD%UOF[0-WS^.'"!")B*"R)4(!?044ZD$AX1 5_\,-%$P$^(
MW<["+@:_1 2T]N&,B( "JA8BX/1@;^%?(9D=Y&#CD#+^Y]DD%G*8=!"/W-%7
M#(0(,),Y.VUH@/3Q-> 7HPCO=^;),,DPR3#),,DPR3#),,DPR3#),,DPR3#)
M,,DPR3#),,DPR3#),,DPR3#),,DPR3#),,DPR3#),,DPR3#),,DPR3#),/^O
MAYGWQX'4^O# '*8/$O-,>J,_+JGI,[_-*H7Z<NW]@*I 5'D,GRF_LMN*>7%A
M25$F[P$0**VQQ>X<'1NM]UY;N:;M,&WW44VC%;3AYH/DX(?1MU\ZRE_F_PLM
M8R9A^*UW67H8I#OLDSDR;"QYTMU-L)0;7L#%$P%/63*W7'(8,8M%/_;6-N!U
M,.:#<81_W("B3L9<HVIT(9>$C#KM75=DR6&*W,]OZ1'1$TW)145Y28PT?$]]
M[3DQJ+;QF,S)A0$8X>[:H<TB]$9=>X +*(<(^*O= Q\"SZ'%%%+5;*+'FRAA
MV0M)HUK+[H:G3/.KB#LKG(7V<<UW--<'1'6/ZNLF=(,,\C_Y5WDUYO0*),BH
M'_#D^BNOAOLY6\[* ,<9]1O +M)[<!G/B"O"[)ICHV,_;];K34QHCXV.?@]Y
M<RRL>-WO\\4+M#IFK41 Z"TB@#-GX\9<)MU2U8! N!ZVHJ1-_(T/(7L>QO6M
MQ<+=_.NPY?BHEB*'%9]CO;\.6]*A**_HO6/@7>G@:_9Y=_BKO% 1LOX79\>P
M$0%K._,CQT0 6HU@J MZ&F1<Z2 3/)N5!:WV/1]^45\[;A"=(CO:;VWBN?=F
MC%WS]:;K]+:CXQ$5Z_1J?KYVQ,5?G93_]35#);E>*<(&R;3H;OB2[ OD 6YC
M1?>13,A1YBZ2=1-VJ'GL.[_$$BMYZTRNV"^SQ;MC1F9XXAP,;Q&LN9=N4><O
M9V4!/N&=T*2XK9MQLT+4E&ON.7M2#U>4L;T3^QN$>L7JI,#R\SU&2WLE2WL6
M"6TJ8VY&"ADZ(-:9:FV%"/"AWR?YC(J'!<E;HF9RCG/<25[0DH,;%CBGF)"^
M1Z ^HR!Y0=@BP4P.\S[GIMQ1FI@<$6#8=G8ZW 3I,QW&;Z010G;FKT/^.@^I
M@G2Z0@18S[X/A[&>JF6R$@'E9N?G-G.P-?X-@D<_$2!_O'=%[D-0QQ1LJ5$N
M+>Y\T::3ZIQC,(X(F!0((M2B0.@T#R) 8HWD5Z>8X)P?<F]W%O;G6/M["/O"
M2^&$Q/4>4D2A@T&,, (XM2:2%Z&)@-^!_AW )=9O7GO_48L68.5G:?B".2)@
MR!>R*=NV6+0?-RV)P8M3H ](SGH3:TX$Y#=5DYRU:V]A,K"?H(V";$C#CEC-
M]G6PRKO,_@3&$)P/*5!=#7A*"E1OIDF!ZAUF;T=V[>*R++G#;- I597/$SS;
MR:TV(H"R ]\*V;LD>Q^RQ>\((523HLJ_\IQJ)?,D\R3S)/,D\R3S)/,D\R3S
M)/,D\R3S)/,D\R3S)/,D\R3S)/,D\R3S)/,D\R3S)/,D\R3S)/,D\R3S)/,D
M\R3S)/,D\_Q/\M0P=%D[W&=S7CLP"7'!/\2&!@\OUNA*?.9TH3PHL[;@>;PC
MF%A^-.&9\M1<V]XOPS>!/=(082:NY_GV.ZMGTB?,M>0\Q!NA;P]"I/-O*_[U
MH/XOMH\[/SA8%$YNQ>S5.'_>T:;ZO- WAH/BW^+&%G(&Q'&<X%L=0OCRHI\H
MN40(W=G#;SX_^VU.4GCCM7MC',\?=!C(@_CT M_UZGSZ.?%[:GSB2GEV8O5H
M#L+_2\^* ?H;P0LF37 (,,9YX'>E3"JA1=H!"@N?LI>W%Z+\+ST,K4AHX+^$
MM'<[79X9Y+SU5YI@3/>4_J3>1BW-7<5[C;\>A<66Q,@U8Y3+"#016M)RO>*K
M(FZJ!ST&TS 6NVTM]9#<O=?27TU.W[-K-9QN4ZTL-&.,1X@ <;GU8WPFP8@(
M>#P(V]]9$>L87/+O+"V19&XVSLC[\F5&]YD*U$M?+,F5CT7+:#:%VY7O4\R1
M"2I]ZI=1QL7]@S5Q:Q@\%K(DP=H/SS\!&GE>[=QM;QI6J#L9I+!PZ0/%#B?,
M&>$+.'CM3$RSYF0]$OJD)A@B:-0B?10^;6XMAK]40[5-HO[U)L,*3U)75OV2
M_; U%S[D"'3&0#2/K0T$T'!_2[=G0SV[Y6(]Q:5%,>L1147A7"9J[/OE?W_U
MU-?\7B).BXF?WW$_66KEGSSQGKI;BOQ=)O*T][&.ZN]D?<"8B RU4U*^V0-O
MO7.%G^\)+%5$@,4>,F*FQ3G*UPMZ/&L:4B>DK=<9BS!A=1M!#3@IK*SY<!DZ
M%',6%Z1\R99@B^?-SRMC,TI^_R?($ A5-6^*?95O;!^K:SNG^R=W^1\TEZFC
M0\QB1R;E]1[$:=K+I:DNV$DV_!-.,R0+9($L_!>$NT/A.,P!W>J"7T $=FK$
MM$=^.G#D0$XZ$[1Z=:0;^>9$5@:68-\WYS$"-8;1J(7VZLJ#8BL+LP1Q#+5
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MDYL"6=MX=2X&KA* $.WBU:^+[4?$4QCTP;'!YTE"J7W/2U=\)E:MUWQK1$3
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MO:P6]O2Y-Q%?X8+H\\;E=0HL@8>3;MM&=R +W1?T<"G0*XS1)J:)%-^_/#X
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M>&,OC_8R+]55H *^LJ%NH-B([%;3F)>_ZG8QK1P6E]0CGIOAY.C"]VIOX@X
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M8>9V:QB,UG H>VS!J86:BMR[*VYU?D5<-:/VP@C/9];@1NY,ECTW>;*I M3
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MR.$8I7Y(.172 ?[="NZ?P/]) *_F_QM02P,$%     @ .HN:6"P(*"K"8@0
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MY Y=)I.F7%XF48V;]_<HZ7#5 PTR2Y<$FW96"77V.+1OT2<"Z#-0EE'%#1@
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MUTJ-;S?E&*T/C_1>;OYF8Y3J>$8J=?>$EG(<+,^F<-[MX41\Y&/!1T#F;1)
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M3>X20'&^&Q6<DR83N&9/97^/1H-TE#;2S;I@HQ^A7.OI@$3&2ADC52H-BI6
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MAV;&VQFU*.&ZB?PT9B-J=(%^;K?%4DY^=FX29SP, QE7):.G4(4(E7[K**8
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M7D/U@'=.RE^*I>S6Q:(]R-&S$2*#UV]MF?4?A_WC;IWJ?^VH(UP3VP0P::#
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MR!=Q;?RA^Z6+%_[4$!/P\CA$.1F04:A*-)@'"MV'_#G;DS75:)3IRF@6L5/
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MS)EVQ;9' 5?&T*P(_/!!A=CW$F1S9"Z<C0@3D/%B=ZYA,2O;C[:.+,J10G?
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MO:6J;G;1C\;FZ1YOC5337=8';W.IWPA*/;H731]KNJRJ7TJ-.3X8P.,6P4/
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MFXIES8\6KJDQSR\?LKJ'M,2*B# *]>",G3PB3 W3N OC*/"BC#C=QDYLV7'
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MN"<A[G(G3O"\K&O+$B9%4-8[II.0\UYFVDE,]/OHM8W^BD0NNAHT>YL0*)Y
M]1&IR-SJRYXH/<[!T7AJG\AE899]J*9C9_*A>Z93RXA'N>';P)^=K!\%[\ZS
M&FK!'3'@)! 9($<!WJ1>E"+]#/TD,15O5UMTK&&RHY=1GQ]"[)FW#>61SW#"
M^$HQ["E,Q>EHZ%E\S2W,?Y=?WML=!XNU;CRC )TBDK'6 3_A"YB?LQ_/3.R3
MXUZC[L6.(L^,&MH$O44V4'8JC2&]_ WU(T&W19CF4 W1K<@8S8/&%C79:+;>
M5\8];>%R PVU%@_."X5A0<(H\(@?B5ZY_?08TZ9* %'03P;7W5/5=[W-,M#E
MK1U][V8JH\3.B3+ @F4,"?43JR5>O5[E$0M!,$)SM).D#(/-Z>\>F%*\HR=Z
MP*:R??F9@X(2R)5D!<JHV$%_0@_N8W6A?Y39$0@'#$XG!9:7Q[*@-('\RYYW
M*TB7X=.$B=E:39;@PZT"1N/?5UW*)RC@=$R8XNP_$64)[PX\5GL[=XY[]J+1
M/$HJ+XY&U?9LU5>'_3]K>(?-Y/=.3;D2QXQG3)=\ _;'3;7HL#QOF^3YBP3L
MSTU^6^!(>(A=7ETQW!&:!<OV=KQ75)@E29_7K7>G2>[1C?+2J_?>JS"='WD9
MG?[GB*?[G_R@)[:!.0RWG]T]4?X"I'[DM-V6V'=&!KP<5#74M1)9'&OQTN%-
MHH[SGM#>M['B>J=HW;15&!OY)A3UY+(7DT9(H\-T$]N+R\XBVSBZ[_D6GW_"
M5?(XJYI1BVZR-;'U3&>/-=U>APFX19S>XG*(2E\+F4E<U VX\?^%K5N<4[9^
M,J :M2M&-/.BB$MK8.\QQ.$=FG#/A@P8[Q [U6C:LCMR(&DGD &C0F3 U!\Y
MR;-B2JO3G9'N/<CH;BCR0+XT$&RW-S*]>$H&\/+*T-^/[S/$'+O8%]Y[4&<P
M^SL]=;GHJM76]*,54L'2QR-P2T3]%$+%E39I7(^VQ;#,[IED+UL!4%7ZFO5O
MFHD<ON4=8LIQPH+6VZ]W$Q4^7>8-;X86:%VLE:J@2U';(ZR VC>'CU7&'6A)
MRALX^<&7?V](U9WF^2]MKPP;EFO004C7HKN,+9Z"I(TQXFA_#YZOIO;643D6
M]"I&;-?"]HB)0(3T-*$A3TT$9?YX@?%M#$FH;T#M:>!$;N,/OB1!+=DFXJ!7
M8.5N?6EY9:;^@(KA0 'CA;N:E[<.+G^P#J=*!$N@VL>!)81L,D DL_7@@3"M
M@?':F[-DO:Q<E.B7F.*RVK(/^15W%ED?;AW3K.2D/]&(- V,]ID/.F8"6OF!
M70<R5IO=?-_ %G(@35-")S&U?4),U5?["M0U5"$!D?,8X/SXOD 4?NDS+&%>
M_;U'^/5-AL<*=)RQZCO=H(WY;!D9+Z^@-W^#M"G89(=O9?YQ655=D3ZSU]2&
MN]^DX6_#W<I$"H:YY5D0ABFZW<FH"&*H?C:&SX/Z'+R]59.2@CUB-?(JQP9!
MM5A7E;CSM6/L\G>]Y)AX2YC,7W@84P=I'%]K4FW,D_JMBB@VNS;/J1Y  W>O
MFW1Z3//SMLHS/;E['!_00/#*Y\,C5$9[DV25%[8)"TF<:P5'+LP]-D^(8]3Y
MWNW(!'5/&PX?4UI%)HOK&'?E<[T9%N)YU-?/X]72S/\8Z!\_R]=8YKV:-J8E
MPBTT:,>-_V12?'VCD/'E!>I%[^+*0P_%">,GN^-2KYX6L>L)AE[O\ELK><RX
M+6-#,-NU^TKLE2D<*IL[D(3[GM&WA6GO8E';J/HYZP\-U<C.$.SC;1S+79!1
ME^\_?Y%&P6*:R4X'H3K1_(1D!JG%;;H6>N^[Y:=W9?SJ%LP-O*0^:'SD*#5,
M?L=6:.ASS9)1$. 9253T-O#)JUM,\4M8$;^T(-SW*?MVX3M!N$(4[NJ]<"V.
M)M#)=9(3&;#P%,Q$!FSQYY !?T+( )?OB62 /OK-J3=XFUGK21S)_%3Y[S<R
M8-H^&G$((P,0)9X^1-D0.C(@\,XI\RF%O0@&])X 1T]J6V\!D\D (<;V$QN?
MDR:45>^AVAZJ&?>9  6+VF,7Z4QNCL\_YAS,04G[)U%:_YU%;:_^G#&+*AU^
MF%<PH"/Y0. ;5(+[RK.VE7:W=X'VGFNAV X:5AX//Q:^#UG<&,&902-(>$/Q
MB!R[W_0N9V_+;HKQY /\<M0PT].JQ"/: "5_EE$5YA&QM4LM;?[$3'"RP]W3
M]B()Q2>+C\^RH0O(\!IY)=<==JK8G*Y!B\\D=@,SK=2"XMR<R)S;U5([@FRO
MK?*^]BSMQ2MN?T;N%AXK;7B\$?6R-HN]^&FF;%%/PD.P3U7<^)FL%^VU,FU"
M!?+=DW(RX#CB.R[8Y)-H%Q269 IWN_Q(\,=:I$?Z7?[V-"X@$8AU2%:^KL2U
M&Y?(722S]VQFVJ"1I.W%S0G&7UEF^"L5[$[5IY+</?';5(4H7.;\=E30T-1L
MHC:**;WLTN+,6^Q:U<YIUK%(W&3K> 1D0+LP]B;,C4L%\JRSA5&7V<R=+5D1
MF!D$U!M\4X,TWOYUJ\JU09OKYM.+\*WI'+T+-_SRDXL*0FJSBG^07J. B\&T
M%8V(&17B)WS,*"2KI%G65-S+;D'\FA[[H$!A1VB6G&Y\8E]556YQ83JOEG.Q
M%L?L\XR6EL*&W3UA(WLK[).+\Y(KUOCTJ(O5T#>U!<"/EPP9HOWEJ_2PTSOJ
M>SZ*,&4K.()A_/&G"T(.R5?[[_TS0K*+_TX;Q1O)_"K#'S1['<&[9R>;JQ&N
M@J*")7[&_\JW="?_VC-)#;\+YU7]67*W[HN)6!EJ/<&M]:,OXFC >:%NN_3*
M?5Z0&D*VGL3BOC%9)'V?)@8 B%U)&+?WBYK;+."YPX#7[5CT,H4I7C+!7;*=
M3(G]/"/6KOR=>?B+C,90S$9WUFXW-GCFA=>62&-<_S@6#Z_Z:V"D9DB0F\ZI
M@$1;WDOP]&RP3OG&X2$P*\V3?L>;/1M+TIKO.G5WF*^6_<HM7V)SF_N]1F1.
M4J74G6L,I@R.ZHQ6;L[_;/M#7K4 W3[H785_TKWAUFMUOW9"Z,?W2&KJ$M=-
MO>%#ZFM5\NETZSD0?([*V&.10C.&YEYJ\X-N:/1Q*:LU6R-/KU9<B%GBL]!8
M$9WA7&G8VX[?1V<>U:.^GN\TL5<V\[E@2^:2>'\)HSH+B-73D9S?IQX9OA"!
M]K#K*C05/1&UU2011YQV:+:K]>V]=X$MIQ-!>M4"\-='ML@\9='?^:6N;KG=
M_18"O;T"4"TGB8+[$98MY?,?)H>\#=3JER607:*:$E$3W0^2)-S8HGY<3"_Y
M>>%@^[98C+K;#4#4O_9(6G=ZHXF>PHC'&_F]=9F\_^'J%TX)-*"EC*80'VZ<
M1Z4D7TVU'#\SHTM?<7G1@:E3H']"_JW>P)<'2HOP=#8)SXO&>D_#USA:EQ"+
MW/'JG2!9#^=\9L_G/VY.-A88S*V\MPVI! L&)&9-'%KL>9B\DC2WI/;2MV?[
M'=IT;3S,VB-Q^I<]KK/8[W\BUI\,J&W*+I'O?>D:@F@ZF:@X_5B*T-@?W1.S
M"X0.]P9>N<Y-O%.=S:UV/!M3)VVO5+$KP9"4;$AP0W<;W3#A2^-6/R^ =&*"
MF5$!><PWTG[%3>2=@'\$ZMN\,?,>@HULZM=V_+,7+!2RT]/24-+/XPK/_9&?
M<5^:E^H&G>%^6A9;\ -7@1ON;=LHWN;>%;JNT<2Z#"#W@<G*<:]/?"-MGEY\
M[GPR"C,.]*AWZ>Z$!N>7?.80!;/&ASR$VU]E,XOXYO3Z=P,OT^(VBD7S7CCT
MJEMQSOG+2P^7"@O#Q>\\>'Y>V8^F" Z@_#&=GQ7TVJAI).25]#JY"93@_OV=
M&+,PG/Z9;#A,:\RR%ODZ_T:"V@-)(2$!<V.5R^?Y58!,=AS72DH/Z[&(04]%
M#)BS36%R[W&5H0\-)'8S%#%9 =6]7>3.T*]TB3W.?37/O:D&\+WAT[! G,&W
M/6SKA+KLLG*GKJQ?_X'\;1PWAD]H56INJ'PCI<VW]7K=ZZ ,IYK*83V[>*\Q
M)@&_6#LK R,CAL/T/>&JP0>:.^4_*6!7K)G$3E0E2$-_;;1I$LWQZ(/K3^I]
MIUAB$>E8$@3)46$1EP]/'!81H=4',CM(\RHDAF%ZZ7,E3Z*A&Q10IZZ8;*5=
M>:.4IKJRX=Z9"E?\.8!V .X1],D 8<@HVNKFT [7^_8[LF$G@]/@V\-8A0W5
MW8'^DBWA"]GWRE26*]+>LV7E/F'=D?Z/9XPXRQKKZ]='?KT\:AO[Z2A3/O=K
M7$,E MGLQWCE9B3D:OMSJ=JDJFX# YJ%.>Y8T[#SB*/WD"Z\&^X2XE22"F57
M@S/ ^+P.XIPA73B;VRWO^C-<T8J0D3\M,9Y*;:\:=:H*>&)ML%SG?3B.AR?N
MKK\2EKL+/0_JV6@*A,V@Y8%BM4'ER)\^M,79>8D<64CV0CJ#!O&IV@.D+:._
MF>^PGLEU2SN>+TG(;Q3!SA6;00_X$9P"] D]@0ZV1&I\6LWQXIUF?-9U/\<0
M29\)TU=;:G\G7Y$!?=J&^BER/(6:<V)_A,Z/OZG/CX(,";?W-9:#!MT7S$U6
MT=UAG_8\IVG2K87YEG:PY5W>0\EWZ6M]>!@:!>%60L5+WW)C6GPG!66^%>N=
M!TI6X\D G E&N9NCSJZ&).E/9_"7<WY@6E1'^LN6?DNWIU0%7'/\OMDWSP 1
MA32:JAN^O>M%[YQQN7RM@C^ %?[<@;+6 :-O/%N.;0-'.N9:,V>0\$A;E_59
M"JKV'/.YH?XLR]$ELH8C/C(W <;'-9? =R[:HF0 %QF0LO<+'9VF>^2' 7>U
MQ[4*9:$8C%\>7P%7R%70(82V-GDO2S-,_38N,S&L&]YLZ;BHQ2>?0)$*_^8_
MZ"@R@*'MT6BC>Y@TZ!7^'VZ]\%UW],=@4W\?G=VV E#UBUA50YC6/LL"T(*7
MW6PJ]?):%Y^;;@@H#AR _?$/W6D0Q:$RE[:XM>43#68/:6\XUL"1 7NR7@%H
M=:_0Q,9JY45X<NE Z!&0_2ML8(H,N%/R/*MDT)0,\)7XXC*])$L1EP90--X+
MI[PV+4O[A:",&X4U;\5YF[)EMI*23D[96_AZF[=NOG;W$%@MSK]SY<4V0U$Y
M[?='YZ>NYF)+%1TQREKM/0-T46@V$\S"')OML(/FI'_8?/E\'6.MY-FD])0E
M*ZX:([B=!S];*TI/6Z</VTMT. ]BU;$UZ!Z-F>5,*L'/A..WQRP=( %_&[79
M2!^Z_G&B>SV+EX:G6D,]);TL?3?#$P0'"#S%F6SO2VMJ].ZYL50=VV]VYI.>
M$$'X"80$4!Z3\OSOS%.ONXO>>H-I\RC^:19]>,_4*BR<QJ+/S'"IZ+6 NY ]
M%)I.K_!-"O;P94Q]U&^Z_U^J[?/KM<K)&@<3V++#A)V1*?Q]G$%HX!7WNK=6
MN^CLS1M4>F'J.>92]*M;5'?:M.UNJQ? =?.+QK6,58[M_VQXBK;-VIG5/N(
M3IUROPYH^S6?N@52GYD]O>YEY$E4DDGX]DQ-1R6F5]5 3</@SOL[CU\\-P30
MG"OJUY0^G_=<5\.L77W9\U9[NTCA>QQC'PJE@C-'YQ0=ORP0'KZ0 _='A*I)
MFM6)%6A&P%Y_8+X6=BXY_QI)=""11=2KZB:#$*(JOK.ER:<,?J>F0BX[\"_?
MU +2ATKBZ60N2.E.,Z.2++LR4KY[M1 6.^399Z-UC])>85<DKKK^Y@CR+*A*
M)FQZS@Y<N\_ ;N'A:5> V)199V?]VOVL=K)A(4P"PO*ZZ(] \=C+Z"R6.RR8
M"[<OOC]_6TO_B PX:"/9 @WJZ5ME1G_%1:>*HKY*&S6Z(;!B>3*['* G<@B)
MP<1"_Q_7#!+>6:U*&^6:,KN"^0I?ALXTL2K//<6GD+XKSWTG YR#,!6G$N"
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M2FGPB(JG"SRT<G_\FJ(ZHL+" LX/TM\Z.\M=YOQ"A:4C[_>47'CDGDU7/PG
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ML*P =B7!+OY>XZ9_G_=3+NW>O"?.&0'58-GB*K*+(9( C^G65:*)ZF'<:R3
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M+Z/CK9SRR;&\LJSH[FN_HQONU1YV?*PR%6;=<YVSM_%DTBY>F (\J" [*Q*
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M#S/^42)[]%[6HD@X7L-]FU;8$<O$./-R,$D/0C:_B61,Z@6Z&\8?< SKT\M
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M=O/R"G8R:U8\D17NJ;I'_[]IKDM.U\#KBM?>:E.W2GC1+V=X+M8]'_.^8].
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M2_5\]:_R\.*:.PBB#8XD^IF3U[UV.E6MOG[:M*>=6Q1,IO.,\'W7ZW)763)
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M,JQ7=PU6_ QGC<U.BV?"?1"8?%GOAEII=AI;_"4BL8;%M/V7TS'"K20_J+"
MB.YA&\\,Y\8ELD=,)"!@#]2%@6@IY%F.'".P]',7.)72K$K#V6U?;TI$3V-$
M&INJ6(L2(R@7%%&*E91;9,=8-K5C$KFRO.( %[-N#_LRGX=']^<*+J%(J*/V
MYV_?;FE.1)KVU[+>?JA3\_*H36/\I&L@2^TS<P:3LR#JAZR:/["(.MG\:)<(
MD'_JC/ 0<>(C)I>@BN%UN-DG%Y;A?<BN#*?&VY7EJ6G!OWGY#!+<GVK.QM.L
M<4,M92FXE7,-2/I$N@[3G"G*/P0MEM:K=Z]^J$P0D?E@F?6:O_3TD0'U)P^B
M!=_Q"N^NED'-6H6;F>!<1C*)U6NL-"U&%=:$Z:GCJ@PP_GN#K.7C+N1(D/J5
M[N2*X%"R7FD'R^6!0?O/A$[KVI%I-46DII\&CL9D7\43%IW)R4E-B;^\O[!>
M$3S4]_=O-V'H6. 79F+X&;SH3$"R"=*?B<"-[:4GJY$:^ON)T5NS853 J?&0
M?76Q*%G L-N!A&5G*W];@;>;V(0H8%!;2ZO\RJ;5U99'^#NCAH9>_,AF[8>,
M$!WCK5(#QOZA\T'Z^(8TQ;?R%D.^%HKB9KZ_')P;X^@5 -HZL@!U0#8 <$9(
M:1G]=VM++JZIE8=L8_HG(U*4]Q98Z/>?\+"PMT>$VVDT&OSVZL)#.3KFR?B=
M6NA'M\HX52X?LJ>/ <9S,@0JE4%9",5A8JQC]];$3-FC2BJ]4_ND8:#0;/G.
M@L4KPS]?U=DTBM]^I29$ME"(QGF8_V\]1\0.K(,%VHY3NK;>^C<+C,#VG6OG
M!.TS.]N\.X[Z>\-[UW>9G4H-MF._>5D4A^?D)\LIK.O%3:NUP U!W@)(=O%_
M[P:7#51:)]& MV+RWLZP'EUE15PT(//+DK5TK/ZA?8;G6ZG2,O:KB=<>=X=/
M7B#]=F?O)U"7O449F)WD@S=OD4/"N-_SO!9;]]?A?2\FIBF+IN_F%25EWZ[Q
M:M#7R4+<??8&AIP"+6C<ZK4:* ,&*6JU)H8I-(4PZZ]6^V^4G_G_Q@/RGDIG
MQ1NC&$]6T_99/O5LIO:P2S2 RO]AIG_AS5ZISQJ0-R)V7KGF,6R*_5H\/4AT
MK.&+$%Q2]SS_]@ 7>+"@^*(I QK6(S%E_>WBV\5-NG\3I7_I^0Y2=1LFG$ZN
M%=>K/=GU=."-7U%+C*APZ8HR2K$:O@J;;6$V*88=%35JEN$')]<N1:<5?].4
M>K3?3R<C/E)2=[MBNK/LI-I_>,#P@I<(]C8B2S]:FEMU(N&V7#^0Q:E/[,)]
MMH6B^+P=*JK* 3RBMR US-+UY,!*F7 9EI_H72E1;9_X3I=^^(WUVDM*P9,1
M )U40T)0'1>LN[,M_5J_#AL O;5$Y<'(IFTT0 B['2"TG+OHU_MFY_#O R.+
MWSB1Y"EHP%Z,5Y'A?N.B2>T'U(:T.:(5C!*$2V2U&QGLAP1='BG0Y<CLW^A)
M+3P72+B(%D$#?H.K6G%PZ]VG2J,[84FQ[V,L9!19 "J6%^#38O@1G:@/SN5#
MITZ81]QG83*NS>BXAI0W$VQ.* V4V$5AP[Y-NU]"@#>_T&-[CM;<4NK:F/>Q
MP13Q04FL%V+PS?V9,!>M<_*Z5G>Y-(.;A61P%VZD5GF$J QY^O3;P)N\,-.<
M_8ACL?6<[.!,KR><AZUX9O&HVN'A4OE+>+70-.L4!>CBB"*@)NTM% -&_4:@
MU)?&D:Z:T!@,N[=-\8*K&H)2S$PFV2)O0=4(02A56D)O"YEG"\%DDMCZD6,0
MMZ=J6\C6.;9,K*)[<;:X4ESW-_@>KJA]V-D^.\?^X;QE4BD_$:\;2:6ZPTVU
M ,4450[<#U3OL#FA 5?SY?C,SFDDS<X9C%*WNM,5H-".@5<%[:9YY)<M!X[+
M)(;=44XLZU\JERNPY[.C 9N,2+5VU[U.A=U2%=@2D3OO^.4FS_[#97&&=MJ5
MLSK4VPMA/U?[@)8DL;TCQ8\>756[%P.\"NH*>"+ @>&JXP"_B6"A095F?R#)
M9LJGW\/9/3(M:$"]=! +MHA_B=*E/7YO(9O7UM%V[[2LUNQ[:>&A  61%-K!
M422.^-AM_ISTS.[NY P=^X+'5JY]>S+S1MIS(HNKEW?8QV XU'KS-X5?;DX5
M;AJ!A]<%G\:4IB.+7WR$Q'1Y9#7U=_MO%]A+T@\%428?\B]_"L #1S5$V&=X
M(U7IF:S-.)_^#0;^,_OG?@&WC_"X*>G=G+$3T'.5F8TTEZ2=TX]' \ W)5=G
M#'A*ZF07:]Z<CM/=.8UL-&U^"BH!I$^@?-@+(90B98;KQ2>;PKAOV&,7!A5W
M:Z:&+_FK(:EW\F++A,8>.YKRN.ENY)#&A<]YWRVT%*(*I!\BSWN1^8%.AZI9
M\9_%I,NU82N0FMI6Y>I='1R?SI0^V>&8-R4W)X&(Y';M'/.LZK56Z0:6/L?0
MWEY-&7HK;VFFZN=??(O%=?EO_!OP5%+OA%2.P'&PO&?4V21L>&ED/YD-WMU^
M_5V,!CS[VGXW)6LJ:BSCIP3IJ[A4)+ NY9_!)?E$*^!UFTEGDF@Z3;Q1#:\M
M\*N1\GOB3XSX>DS!-I<1R+$\K[574IF3,,!-%O;U[_>+J6_%BRNG1Y&X#HC+
M0^P<Z?(@7>?R*]IT89WOL&I%^H9JWB]W,]_6G.A",QKZ,&[*(^%=)GVJG;WG
MX=)9E=??77I!]I:M!]J_34N7@Y]"CU%.AXV\O1\O*(J&,\\9E-=&%A8^200;
M?3<JBRT"GZ4#76[\YWI-J^3D/[N@_@RN[I_5PTSC/S.;\J?IIZFP6$DL+OO?
MX;7CS[;(JITE5+\W2J#[@=H[G*A7H2 KNJT(RB%WMX^%7 +5@@K?^YWL]>VX
M3<Z:[^TO)V?:!N?]"8]PE#C-<E:$EJ,"=ZQLJSPNHTOLP[7;[,C#QYHDG=7:
MJXQH,S_X0PS_*V-!)>?6>LWH)R!'3**^E=%PQ+Q^Q2EAQ+=?XN,SMN19B26G
M?7K:)+L:X1H[MIH[S\P9_?F:@@ZV')Z)1U@2([>C5R_?.C]%3&*'21Q_81>#
MV+2H*2#5$'\'.4>O><[VMTN."TS,>_^? QB/[ 6C%(9:N.[\LJ +!,55#\<B
M=UOK.*(3,7,/+@&5XK%@:9XB+%24BXV-C0,#"SKJ5/X\8]^H_*6Q;D]&R5&@
M(K@51LE4W^S K&E56+QDXA"G0Q,2I$/Y$LH<I'D%'L*=3&CR#U6!\I^ENZQ>
M3<4[E8N?"%FJ?#^[%K<<?/_Z 0_6I\73;E0^!;C_*B#.]D+7$"GJQ+C'WSAU
M4?FYZ7!G-M4W=/U7I5CAML27;\(/-&3IHUZ[)VR/NUTQ[T3^ITQ%T0 2#.KW
M#D 6S1,%)C6X4VK,&F'?;LO.P-P]O>4_R58SU\% [6\43GRHQ[1'8_NJXXFT
M7Y4JTF<QY?O2_:(%-4,6#UL3.9[D#[J*+.-GKC>$]7PVI]J)]V;2Z111!&A_
MQ8E_/_>!]CS5@J?' B1JP><+EHB7OM:,^)OU*.09[^/8SUJMRN7>4.6K=Z=[
ME7V=HXWPD3^C>D[#@Z'%'JE=6A(S[SY8LA.>*(58A7Y>RDMC5+2TD=>E$P5[
M0U8J+-H:OIQ^_!_L?7507%^49B?! DF(((%@08.[6PC!W2U $EP;=^@$=VDL
M:.,T[FY)<-?&FL;=79ONY5>U_TS-3-5.S6SM[-;^]>J=>G6MCGS?N_><^W,\
MF D?*HA!]M()AVK=A6S![<:M:''>=9+65BMD=&,7IT_L:\ $]ERR[+^O9(5E
M#3_Z#MNZ?\Q?>[3>^/:G=B]SJL8.EQ=RBK@<L\89CA29JNU( [?S3@Y$$1.Z
M76=R05$D\)"_/ZI6/RZ+>OG-(\K79>-7W32-ZT*?S Q=7+S[^[VH4M=6^478
MI_&5JH2WQ5*:KWX2"=$&<Q X9#&]P'ZR+7JJ;J5X..)10R1NQ;LG//X)D-OW
MZ$[(^7)&^[_4AMJ]Q8_K.E(-FMRW>BA_I!D[FCJF<;%&J9UJU!_7<BDHO="N
M$(PO_W,@:T/RA>ZS1W;PJ";+LZ#/=:K*,V !Q0>MMU- UH#B=3I5?HB3"*V5
M63;3%%UU.&KN/R-G]W3G.]DKM??F;^+6PU72@] I?V+:357D+(&61,>3)BJI
MJ,AKTY_VKZ>JN!X6"V_)(.F(2_P^^JS.+C&CR*_<L)?Y\"DUZMPS3^?;@+"#
MQDB##@O3;CNQY7F75V8.LVUM(B=2TB-QNP7RLV(75J1RA:\?#-$1,AQP4^Y*
M?/KSNB+D4&PMI^*@? R1^+1:*+F4#QE6N\OOMI*5J[?'D)K7;?P"&T\^2\50
M:[GXSBSI+55P<8[E/QFW96;5'<?%1YN0AN;5@/7@%91"6@/>"9 NLMN>Z<7B
MP(HW,6']+F=3G51N:8"W2CVQ?;^2'G.V?_9WR_QGT-2P%[XSS?/N-ZH@GA<9
M*-LEPAV4O"L??,'@1</3UNI[L[E[NV93_8'2%ZM_)L9FAN4(?=2Z51*SH+WK
M)Q>:L#AI?]G-$P4"0M4IC>[#MNE6.!!%.$Y$N4$Y<!1]GWO<P9U<LB-28?D
M;>6^>4FZ:P.C1F>]>\V/(NVGNK\657&O?HL@2WGF<O.E3+%?U+1V;$R.4)37
M]HA,W;O"!<L"M&((X6CGOZ(8AT-$0 GMJ.NCF9:R>/I?7_8.HUL6)?$W7BF!
MN]2!+$04(6)6<-6GUCATX/$Z0]$+?-?#!LVT=15Y=:1WQ(:A^_>#=%!OOU=2
M1!NVU?2Z2<AKO@(9@I1&;G%GIV#P%].JD<B\/6W5GQ& A]68='<'_:UKE[\Z
ML@:6E2$KQ1,K;'SR]D8Z+-?[[>=+B786FU*L+*SS V@,&^J-&&CY+LAU\U-V
M4'L,/-%Q?8;?7<$"_Y0O[5B?00-P.7?1@$UG^+O<U0J@2[O!*F30MTZFT4EW
ML770(F_A[<*YM[R.8C<YII3A"^[WDI#.')Y$C^;F]^S!@IO!5E*B\A*';1-O
M;BI!?Q/<&OY2QHTAJ:XC3CH=D),WSL^5Q4F:+^MQV]O3R(/Z-AF?&[*1XGY1
MYF;\M9!R]&12B9>03+7WF;J55T>3'.,DPCMGYL0=12C3P=%!Y\;> ]RL.WY3
M[?=X0UBZY'GTO&A0HZ-!A*V$%)\?=%)-<\OM<+]SM;JVD63#(\<GGU=+7:-M
M/37#*K)FTKO"U0,T8G(38T^Y879<R' Z:7WAA]^X=Y(17\DG.)<R/"PVZ:_K
M7C+5!<,S5%+0WS[FD?WM6U,245&P$O) =Z<NW9$L.I76;L3Z6V)</J0A336S
MRJ5=;L:#D>#-J^?:B[,7)'-;G,O+?:HK<RE6'\!OM))*7TZP*K3Q.,@>#^8^
M:/R"5[PCT&X)YFO3(LQLKN8Z^MW>-ZB6_\7=WKZ;[]67MRP]%I0J&N#.SGAP
M!.D-SDD=6$FYCC6F@!L'&?SVPI)B#X%C]-^$!_[?*]A):B!A_<+^"LQ%]N'B
M,79>P#7%=HER*<X>P2\!HW APY<+G\95+FJPB&AN9\^.3"EJA>09= \:UUIU
M2[TTL<X'1()_W\L\6(?QR=&4F*]WB,2%<6];^@W/\.#//VU2O,X;/H6C%;JQ
MBKK.=E)):, $ZEYRNAG#^\V[9P83+>0QT4*Z$ZGAG]5\J8^SQ:=.59JQ>O4+
M;,8'NL9-LCJ7AVK#: L)8[XO0Z!A;'X=\2B*HR]^AL9*(+;T]SWJPSHL!\_\
MB*/["?NHRN/\\*\I+U'(,J.2J;X3EVP]LS#:I@>,>UW1\:'0:*\FI(="B>PS
M&J NAP:$7=FWS3SEF+W\5*)$6E67>G MOG<W?N-ZF,N&%76!&_H]19,20-?&
M<-]QN[A+$"UJW_8-A4W]:MG#1.V<HJ+H%H7?\5+% 'JZQW[\@39<JSB:),]R
MH&M+;6+H^>C:KAT*ON1_L>KUVVV?.HPJC$IN^E./L5:I'!\:X(G*W,_)L+Q(
MJ7KS*_QISO.\#P_,MUMT[#VY;COCM"Q'0CN=?M\WJ*/3L-OZPBQ*+."!1._O
M9GP+ *I%I#9^@PI%Q^\2$:$!WVZN6B\.6V*>KF1JA^7(O@O-(6VC1N)?]2X6
M&8D:RI++H\@.A'BBWDT&O5_=W H ]B[#SZZO5/-<'SB0JT#CFG=.3XZ.C:\'
M!AK0<[^8837[2+E9T5J&,HLJG9/:2 7[Y.!W'3G]3-[%TO'UG,&U?[XJU;6,
M6*Q?[IVXD3C<N\@0,'.Z,^Q5-&E['B?I*$/ZF^UQ4 <QV8,6%%V.#IWG:^>2
M>6T4AT*?*FH[B'*A =*H#N.](T]R[\Y1/64>V*=H?5ZW[T,3K\62*0X%7*MK
M]Q(5"8KTL*-Y-,?=JI"(CMY[H-66=1&RHW.ZR_1%U52W(F[-)UH9O\?QYTB4
M;Z)ZW<[OCR1[0F,K@8I54@H*]"513KHH-D]@-IFW"ROW=,D$MWAR%KRJ=?01
M5(=0^6_*U"[!7^07-,"20K0II_;F_/:<0*4C=S3^(>#01$P_DDY@?K1Z_\5_
MJ60^3Y[4)8_7I[DSLF1A4G/G2]XR::AZ%P4O)QI@=7DM[W+[4N#\S&A.G/F/
ME@:=9)&TR7>_+-U[]M]\5W:\:Y-_0EZ YVPW#"FXFJ'KG[G5?Q\1KFO:5-S&
M^I;C6DU(][[P?P:T&T4:-2<SB_JZO/Q3S&$:(9VC,?6\=SGNR(L9)H1_QUU7
MPARP=FG;1/;L0N :0SVW9[>Z=$AO),/BUQ3[Y%)H]IYYINYVCBE?A3V09<&/
M?'N\STEM5*2.<V"^];#D/A3_CM)]-UU(D'>)TKU-;*ZD=]W=G*@Z1SXT'^-I
M;^$74[RW$LM%2.]QJLQ2*1DU1Q#V!^X0RH0%O%HN-YZ4=YJLYCG6//VLI<6\
MHD%H /$E7*ZP3+M5(#K*ON=Z;2;-/AP7>WZ6(5^F&(1![<"K" 1I!!RPE/.Z
M!!N'%Q:*%/;Z592F\MOE_CQY'SM,$"7 ]M;_XV.5/NS[COJPE4D,C?*G)\"<
MKJ=@^W8XAZ:B(E"->>K]>[E'<MP&VP'W#6VIT75?7$BF-JNB:>??,9"(+7RI
M+^9SH>K>D,PWW#>UP31P1,$7^RKTGQL%6(\T]]HM9$A;N*F/;156Q#&N>P2$
M<,URN,&R',* WH7Z]!FZ6*/2Q;TC"J!XW_,(%M:1')K(!VL3%X_Q8E(QJ)"_
MU0JCS128E/;/C=D9[7BD7"HEE':(T/G?DW7I='.%'#]% P;OUD-T#YZ?P<:/
M#L/VV^MBA-D,;&9 +Q8:%^H9&&,+^GE%7-6?F:O'CM=3]LJ?JLF":T]Y36AD
M7@]G(KSE,]?MXH>!X@'N&/,N?<P8<<WOY1-)QXMI2P#+432R_;M"FX=>(A#W
MUTK$81A5\9H\B>2ZP9WD+#B,$EHT](5/<O=.&C;Q>]F36BSME4/W[SM:%0G&
M-<WY9GZMGGF,LA<J*^"KTU3DDW8R#7SCD)?@&*36B_0<)DMN.G5I)UI[TJTA
MY64=MH-\4:=]]PAZ!CAGF6OR'P7%=-4FFE)\)15" PHT/HES7KJ8BP8U"_[[
M"Q)P.#>K25X$\TV>%I2*.LF(J.2/[NYC&2SS$6X@5Y.@S[XA9<*O(<]UL"LX
M?)?7*<GB5"9JXK!V$PU>G"_;Y_JT6D+-]=+CY8 F&A!2\4O9Y!48?N-3@,TM
MPR?,&=@W\YVK\?8'1JSFFIFE1=!O6NQP35<^AEC?B^!%E^8HL\A@&=6!SI_:
M@("; *-*;4M]Q#P_@=GW4E$2)1QDZ$X+','_;Y-K3Q0+&L V"N[@XE/>6\H@
M"88+#BD/(QI%TU)R!^QYN[3"2T\*.?O)5-[0J'>2?TSR5"RF#A<D#TK^=98N
M.CK?1+HJ;/<G3QO,ERA?D#_1'/1TZKF<_B-%L-!;IRM:8V<15M&*8"TR:4G.
MY^H$:,#3W\_5;?;&3L7C*8?EO!N<7:(HN,N9;?B4Q_\ 18]FQX_X\^8;P^UZ
MF%+!N$.)6L]%599:7< #4^.J"DR?M+.G/OY5^;9T<3DKY6]<E?Z4UB,GX"_6
MZJ=4ZT\E<86-@.X?]%FF&KG BS+$\T$#?)P=*;=DO5<?OD]A)&#K6/'@6GY0
MQMFN]VFX)CRE6;&3GH(T'/\B112V9X$-,V9;\ 7XC;"ICJG[SD^T2U7E"&7#
MIJ6BO3PBJQ9E1:!@+MPF]@6[&@B&?W^&:2@JCYL]A,O?RI#WJY2#+'W(\T]2
MLDWQ\4>>!A)-N&HH$AJA7(8HYH\2!98?H2OZI.^>IR#CVJT/#QKJN0F=SPMZ
M%[Q[\8A 0%>_NP.<X[M4+_T\J_>@E;%QF-2[05)AC\4RTPB%O#V"T.TL^!&H
M_AVC$2^Q>IY==F'X<U6LMZ)#NTKXF:D4U%D!8]'P^:B)55ZGKU&_-*5/7]&)
M=4M3CAX42D&*0<G&_:CYI8RCZ;>(LN#YM+,U/VK%&>N#X:,,19[:V"[Z[U:+
M!"7^#>J?3*-6$W-2&:)U3<&"A*$E7E<REG.L96QSB[I  Z66OZD!KR1BN^77
MQ_R9<*A^R'SVMJ"Q?Y<^"0^27:\'#%3SXI3)%L3^7M;.&@M_*2N*W89W\J31
M3\:UM\]H<L^2;Z%%9XVB/Z926.+,<W1%ZVD,.( _#LN?D@#BS@^W0X;DJGL%
MVH ,_U1PGM4E,R/T]! >F73(]F>DQ.I[,Z_=2:.H:]B<PV]=C&M.83U7F,-=
M0CSSO:L*1:%"+GV(K"<:LJ.%R=HW4V@ J=!1#0BL*(C$U[JP;;MO$_M\(-8$
M%RV,GYOMXX[K;V[!Q@LI*/3MO 0F^$?F&P?]'='Z:J&$^50#YXALQK7V;$^&
MKKMWO-N"=M2^NBDT=-\T(8XH*ZBX[NTUU.;+!=W!W3-B9&EIG.3%:^6XTFX"
M 7:WJO!V\&_5,635U-*F(#*';MLX&@T@=V?_M!]NG9Z)R.]=%EYLKG'NSQRU
M< =9S]BE\U$G4U*&?8,6Q##0*?(<3_8J8<AN*N'S3/33B59<%=[^:5J4:I+_
MU*]3^Y@CMA-HG_RZR7;J]8_7R@4\V3P /.>*AB>V-0W>M(3R+%U57 HLP\\L
ML3Y(%Z_525ECRFU7*B CVQT*Z(N*-K87@N^R?Y/=6RB/71ZPP'/H3EC^9NQ$
M":U]WJ>@>X[4.1B438(H6%^R&;=2LJ< J/<_&W]LXMOZ+5A0O,NN^.;8^L]!
MN1"5V,1A]E.LQRNN'I^,IU;TS3[-#*X6CJ1L]Z$!S.P_VKI;^,PMUI--#L1Z
M]NURQPSCC0TG0*^MW.O8!F,<@0=A/ EGVAM87O4AKX)S_JP;]S(G$6J,$FH"
MWW4_43=]W'YX%V5B(W3@%H/!9?2QQ+WQ5ZKD\_3?')K'<8N2U.80'/4\T@Q9
MWSZ17%<6Z=,-LSC6#1/,7[$?O$,'&<U?#)3D5W6]_E/R4QJ*GZK5AHB_T5@4
M5(F;91(M0W@JG1G&+WF;D!M*Q1?TC,9%,Q9!&8LY8;P)\1IJ8Z(LG%RPH1X>
M8Y8*_KA(>)_CP?'^95A=$QCV'8\@4*@FB);[Y6XI'L=W*4#1[\<9TCY35T[V
MW'6G@;_:#!^I$V41JJK&?M0'6*N4V\ R0&,B$&$T8"OW^@0-R'WR@*9FEQIS
M44_]C-  WT4T8.1MQQY($G*1B@!%PU%.#QA=O[D,]&OIN;?-\I'Y<C.DB=G-
MS&]K0?@-R:S+&UO;;F7[6%6S:A)%6P7:.DV>UZP?H5TP(HFGJL%<9$E,U1":
MLV&(^+SH1FBBB5SJ:SHM[>FB=ZF8[@1Y ;QK7URP-XWT&C?TIA?7L\TC99^9
M5D[H)9\P;4)]VH08%WL,L?]UV!)]B-S$)>*3Q*,Q$2UBL@6IX3&UCL)G'ZH*
MZGC:C,"'<KD)B5\K1QHK\.)MPGA*F+GBR.]J6E#K&X,W04QC/,S&!OY4/=(R
M86J77B[LZZP=5TE'-B1E1!+O"_,^]J>3O<ZB;)BIR!EM-[M($?TOSX\]H_GG
MJN$+\P,X&C"DL=8+G%&#SMZGG+ _K;F<5C*X6+]M<+$7K.')!\$T-.Q%:)O;
M S5_7FC\,_^\"N7+@I$CL8(]Y:V]A38L;Q.W^J[YMJ#:FK<#77T2:C&(<]69
MB7ZR\5M3+,;I]4=]5#\DGCS G8Z;&^19^V,0*V4LN<7)VH;1\6*:L].E\N^R
M?1/(_#O1JXL7N/XL/WK'011Y/2IB7BG5$]U&Y^:0YYKE"5KTTJ'7G]OW$$2@
MK7'D&"BYXZ_8S]V$&X,3"TOD(D+T*FI!,#IRV^YFIC&R#>-\]JWCA99@),Q^
MJ]OTC9W):E%)ES0)IRL)0Y$+SSD;(U-^_I71;BK*&@E]6(67R#\H0PA]@[+)
M<G(W&N!OC&%V'=_*3W]6N+]P9GY5+V/9ZU]2TJ?V#4I)QVO/U*PH)$G.0GC'
M0$C[AHN@1.[1'=#U,'CI^G,)YS7=Z1P>7]"-;62)WR.[C 8)*E^VC\1H@"[H
MGWJ 6@Q(AIIO!U$;: "NZ4U5RH* K;)^2^D>RN-H.%=,XQV%Q+:3T^5S"NPC
MRTQE*^L>8<'80,4 W7"K[T2OP:(SS37LUP8%(_ +R"L4T27&]:X.PL![W?X!
M-Y76J'^<[(Y9-# OJ&]/L2:E48]3T?#O:9&.9[$?IY&-'N\:?\ J^:CO=\G.
M!T?7,C(?R5OB^DUZW%>!IV=P _]"<IY*81,NK30>38U^6L5\J^)(AS],5>,L
MZCPO2$R9?&>:!2B/8Z,R*NO1@%/O>7BR]=I)I7W;S9(A+'E_/XJK1%/3M!)V
M\GU;/?_W-,9;)A'C:*YNK2]]621&J#V$P>+<=0:RBG.)@S_$ZR"S^+J,?_C6
M=Y9;N,.KDXV8LX/SIJP[+.(J+UH^Y50W_!9)IVEWYR!!>YY(H<#CG 1R/6P'
M4@Y<-:" MC%;KF=/&E 42!6X,:^84N318.2(PC?@\))4E7C(GZ:&;A'/MF%"
M/P6:R,]]DKRZN1^8?,HHI!VS?FP\3*'.>.OI"?P&#0 )V&5,&KC7@N*#>W>5
MNB?2TAPWZS<?G,_]576-GMR'!D,659V5=:_[-=,L:&92<'ZBRLV\9=\3V,-0
M2F50!&_"#UOQD?06:_5+-W0QQ=T^_O I",XE&N ZIJ.EICV2EHL9)J^XM: 4
ME63K4M,N31H<MV-F[>;4\V25^<%\<K,?@!SKGF]:+1H 1@.4#]/IE[K&MKS=
M:UKVW(#[&:*/9<24:_":J[WMD^3[/:T#L!CP)#&^M3&28N(-$CVX'G/\_T8I
M]O^O"/Q+4$\T08-/0=O_N+@<B5GQ,\YJRHLG4@]!A^824N$"M$0#5B?]T8 Z
M+>Q[:Q7[&S]# 9%;[]Q;_&MF4-M=L>-.>Z&W^W^T[RGY?-8UFCL6E;N9MG#/
M\ZFZTSV<CG7=.X2EXZ0F=/2+H:NNGR#V?4PSGPULAF O4,UCDWTD@P\#<M%6
M7Z:<R"B"K2KBJ#%4+<PQ\>!58+[BTQ1(TI!\?Z&B.Z$5HPICTG#'=0HIQ^]O
M@C H8<#^JTIKK^D?Q<RH<E&&W6).CV*Y'O7\G9SJ@?U7^>_E'J,"07VHS,D%
M3K.=4_\,#-?[.BT) PW)'[9V9D**YR>B2F0KX48#<NPOF\0/:.Z_'3Q^ENH2
M%R0D=<C84&Y 5<<>GOLJW'+5(FJ<-?O7/6D6I(@R!MCSL[D>HIPX6,<MJ.B'
M>ZYLR+@S])<I5+M'ZP'NZ8C'^I;I)FC$&. K)SI9.&;XAO,TI<9)L+P)<<DD
M8>J[JW'=Q'2P%R^</#O8"*1(U[-FC@8GMNU4\AUR,VC#@S%*D\ %Y6#!*M[3
M$A&<(>R<%\0:>(@02H@[!SY$Z\1F[ E[']OT DEQZDC;7SO% XR3]WG0HKS4
MV.9/T/C7->N,NI:_N"*R&HF)R>XJ0S]D[?P1?#*8I<$]DW$S*[C@<Y=F,J8V
M5AJ#^?FZM.P9W?>,P1K #>-(MI\HP[W) <S+8:]'<JP&NQLYK/R$G$"@=2H1
M9_]4FOOM,:#5_XJ/4EU<[)QN0D7_Q%+H93UV-Z(JHFIXRCY<J,J0)>YSDQ"C
M1%2.UC,?EVK\J;=^61ZWWD6_HAM67WJ]@>;",]P--614C-5IXM" X-\VX\4*
M./JKFV]5L;;BOXK.-H0^VM,_,\HHX0N\*5T7CN\4#,8%U5A19WX8(WS!HE;Q
M7KQ1D S4>I?E2YWAW;6M&QTR*AGJ3[7O>#[53S6%V6H9 +;%WQ%7L2.B[H!H
ML2HB;YV+)*04KDY>3S[%D##=L%WPQ8QZ<(AW4-)J$"P3K&R-X)SI5-*2TDOO
MESTF(^=)'*\5SPK$^F3HTL)Q_H(@P 8.<06\2-TN HKU#0)9-MQZ.V6BRG)Z
MZNBUGY"+U$YF<-!7C_(4D:A>L+"\I"R<[DK3X-U3TC?)KJGPNGS&5 K[V_PT
MLX T4;LH6&( #Q4H8HP$'DD5P<[7LD!MM$%,BYG$;-0CG[&R@, GOAY/S@Z7
MB+6VIVR=Z<2HRU(^JL7&@CT?W&^7./9BV!FY5R"I2VUAG"G72Z#WFS^4!G<3
MGA>'^=X=_[4_</R5NXX6(W<_F$(/E#=V1QJBJ5Q!?NXH9NLJOD8M^7FHX3HP
M)Z?(G _W*96W %S0"PWP$K(]*$R_E7H&!O42H!9C%^W=X!XP1Q;'&#UR55!/
MZ';B4<?64V23%TI# 7S#WL -2\W7#/ANUWIX+\VQ#4-IA77#QJ 7472[":)I
M$M_+ODTC]BNX#[\7F5 _,[<(?Y-Z([_=&Q+;"WDU9GZVH)3:-WX85V*\WSG8
MN45:2>8SXM/H6@8YR[F!G:1M7EA\TCEG4_'0V?#Z[<;&[S1ESYIYYX6;:KC0
M* B=3]4K?K919)%5(BV=9RBM_N<<.I/@U^T-:G%ZV6K83:,%^<.8H[I/RDY
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M$^KTHX>"4;X\+A.=JFS1\IT@S%P1HL8J==&[W;4+\<KSC#(ZDQ_BEFB N$K
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ML(BJ&X*()KK)$Q5Y,G19'Y^9+YVL<+M?),TO9M*<Z?(J9E*QI;Y.'PG[<+=
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MWR36#Q>&9/WL#0[BV:BRS4FIDBY>LK'G&E2]2U'P"/A]P'D!.6ZJOICU/O)
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MPN-8;*JJ;JHLH2PJ>9S )LRB$OHLSGZ!X1(\G.:Y_+,%YI"I^Q0=2MI5CJ/
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ME00!9X>IAZ-Q#:O M;F@40M1Q>?E[[<=RR+QS^J<*B.F@X,CT-!@FM\SK6'
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MI&'1N]Z*@SCI2;F7*_4.ZRE&]:3;&ACTC3<4:/NKS& !H">W^1>8H.>RHKM
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MY1]I,A=$Y$K/W7;:'1!94Q52P1O\\?>35(9? 7LZ[(!>!+/:M#]X3TN:+I_
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M24HK&I#U47QN::M=/OBE96M^>^WWM4]_N,0#WVF.N]Y;A:4_[&QS2S)@2H*
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MOKW//GM\=^QSQ]WY+S/)FW>\:ZXYGV<]<\WEY7%)PK!W\OH<?\ &.60,9B?
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M C0N14Y6QM2=S@PK*J#4'K^R0"388NQQ>I3%A;+)9NP_61=+%0F6"P$K<BY
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MC5/1JJ I*]K,L!*_:&%MBSQ1;M:@,ZU@P-:71+G-R3B?/-CS^8/'G<VY=<I
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M6CSR6S[E'>S6DSZ5R[=;N=(F:EWD_S-;?\\YI^N,:V&Z91='_'1RE$"J=J_
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M,"@]NY 2_T>EPA'7.)D3Z,DZT01YT#[HFKF^2H<FVSOLG=*KQ9=\ 3CO12Z
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M ?2.P5N;N(CGWR=XN2LR )H),BHC4*E3[NGB,E5/&:G\*NL97NGL<HI8&HX
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M57!^N_^JN:R$$,1A]*J7O*RE[M'%E=VW%U/G7KS_7/-P3"Q(Q\B8Y,DW-Z8
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M,;WAY7:]%TIQY5)8:[N+RIJ?')N:/VY)29R%;0A65%<M"XWPO^*J1Y9%U=P
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M8Y4L<M; ZZV4E 5<-^:GQE6FXD9##'3T$T->DFL%RGS9?%L>A.B;8&DA 8+
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MY2BF]:]F9G?F)KA<9X,O"<+O:];HJS;[Z3DK'-DB23818[($O]S)Y]]@YB1
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M0K(&M6>A.GX[+!W4^A)WAI=1-%^_9%_DAXD'%= 6@C:WI!NGNI\%4C@4CUP
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MF+M&+ 6]TAU>G1Q=7 &"[-1:?8YF0X+*(,P!Z!6B/#%C,E6QG%/DGU&IY=Q
M$2 W'I:DTIIVB/WL>[2]M5ST?\0YC9%A!3+1C[?>6SV7!%IB=O[1+&$#&15.
MVV@OR?_JG%C'PB<X$5[43A;5&I VHP1-X4?RMWC,:"]ILQG"F[+ON(9L(+M[
MAIVB2IJ\1DG]15IN43+_+>=!+5A#L'VF_:=K:A\;)A<VH;@Z;&1F1E&H[S'<
MUN_MK,_<U.?IXQH<G$H^I2]:W:.?NJ)#V"M!:\,V+S5#(4G4I$<S?V4F(&MN
MK YL9\E*5-WVGYYA+I%3%PW.GV6.JE<T3NA<*A3B%M70(HH%Y]\1,%>.$H&W
MX[*D*B9"RY5FT;H,,O$_3+R>, $U53@G\+!M3=&1U/V1).G[=M=>_+#G-AH6
MRXP@*,L@-F0G)2!N,69"UIYZO^DQP]DDP);L:*JDH1(9\HNQB7A%4]QC]!FT
M3@(;6M)\.OX_0<L+//Z[\L[? >9@?6#_8Z(-\3(@MX%LX;NJM"AE"ZSR 9H$
MB&%,(P'HFD=) *B;OXS4J4$*)9X"N&=-/)&ME>-H&K<C ;S^]D1^.:U:G6C(
M?+Q610(PS5U":2=8% G0L/"1W?G8=8&)!%@SW$;@Q9\I$S=S3IMKAGR([_:E
MP<_(B^)I[19!H_#?.:([=?SE?EQ-5UIZ0HRML<V#QG3Z(!OD)9OHK4V^9-2+
M6.PH^SUXHI?VZ);,7>P'DQ8N8CPE/KN7H-P48WGI DY#7$23(]<TR',]E9Y+
M=_:LX F$+_4K_ZT3J_TS'H T9%*FTCU/3_QJWU),R%_?WPF_OFE; [Y1>>M1
MEF[G/.(G-X:(7HCV@.R1#626MP3!LS(&[!C'QJ4)+3-+1;(;-SF*QV3A(B0
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M1+W5E*68[#)V^^/"/&\,(>(Q5$?+_=*O0_TJJ]3[12LI$D--E]^:$O$TSZ(
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MO^I(HWP\="K_3;Q)BDSA7'\@*BNPD;JH7Y5  &T1K6#XE>F#A[A*V162&>3
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M"0T!(D8>2Z^I-:0A]PNEH,@]I2O@>2S^=\<[+<U1PE1:K4K>YN1^- $#S34
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M/&IW9[Q7_%' I\K-=V%!)?;W"^%#312LQ#)F:X:99VSO]:U4=])=0?DW<3J
MD(YQ$/Y8,^YIT=WBTBG&>H6)<"/Q:*(=S"4T\"G0J%I[N4</R:1G^ZY[$@)#
M+:8]GFP#ISBN7,E?2=<\N<#5OA$_,]Y:520D^%WH#NJ>U\:"]XMP7O^EDW'4
M&Q&'7GG7@+?7 #E&L*22Y6;N&>+2PAFTYP?%%.'^+@><*<*=(+T%,'SAZC4@
MG^5L8VFRS0BV:77.<PWH#)RZN5H["/X_V6OX/S\0>_ KN)\#?9Z]..U8[&B7
M655_SK6F52I1=I>/"A39Z4#XGHPI[-:IR.G"D)7'A&"R#D:PE?%8_1QZO"%]
M\,X=_\FV\YUC2*X"T0;+.>3XS/0=;C/3^-9_O*!FP!,&1M;#;)L@P_-ILPGL
M7G?<?I#BR=!94TBFAX'1V JO+YA<F%U$MN !Y+9+KN/AOFWZ QEUNGIBJWO8
MZC6QL1VO!</EUS.C2VI<0[%P'OE5:NE?>M(DG^]6HI$FA0.GP_T3L^XC;JO)
M[KJ&'4FL+^6/V*7?4W^Q65I-&%\.J%C(.I=H\EH4:E=;0=JM'35\MFS]N6^!
M"N]>=F'Y:>M+SR[4\-[:R<FY?$2&6']E9ZDT)_0Y%9L^3X%JM#W>YDP\T-*L
M:7XW76U.R%.BAI^^/6E9D:>D)"'":)#IZZ@I]=H-@LQK7>?-*3_\K'2[GX<E
M1T#<6?;#JP</*L*FJ^\QN%8A^+LDP40FNW2:7H_'@\]&9D_V6_[JOFFGYCIK
M6H 7@=$807<2S_+BA!*)#./"LA0EY:+;:9$)[P^8O$)6.BT:="V,%V66GDRZ
MJ[_ZN1+VN>A>K]9MU0_WZ<]YQ\6.TYKV<D?M$F:.!CPH.6*N :9$>CWGM5\H
M'_< >I**'/O<X]</\%;7 (: 8]JX;MN+]E7?-WO;G9D,IO!5)>.U6ESU5X-!
M+3:\L<\:L?Y$<!DO8UPL=RJ2Q]*$RK;,^*)[/G[%QR?]>=,YG4:1L7EAC[?S
M[4B'!XTKEAAAHMOYRD>XF5^%+@HQ>_ 2.>K"8(*B#\+W2R.(A5]P*T]IQWVM
MN2T.68+J+8M3N)\EVKJ2)0&O 3I3[16\GZ9QG$4B<\,Z<I&]$_HHDBY-'H\6
M/X?2A/A5X]Q&'?51/:J7]^VC#8:D5O:?2%1FVZ6=4M]>8'>R[TCV[AB*77A&
MG<?TI%@VQ3NCBJM(H 87^-:EB6/-_\[>8:ZB<7Y#?".;ZA!A F4*,6$5L;8S
ML2HZXCDO]CUX7F!(:9MO8G/>@-XN>9L&5VC[=L/QG<EEN9)^FH-'/U#]A5ZW
MB89HELIL-]VB>P7.DX)OA!6ZP-LOYKNSG,#\OMGZMP.5'TMYYJ&T;D_%@SM4
MO.6MKPV-B!I\/ ]N_ 5;"JU]HZ@G<X$&.QUS="W@-HS_PXQ3: 8 /NB12"\S
M$4A$\;4';!5\(G(E42U)^?EY;RQPK[EBBQX,5#<+IW,NLRE+6,O@VK9-'N,&
M%#,7?HW&$F2?T6_O%:1L_[P@N]?5_OYMKB@=92^3(H\?N3Y ^>"[9?3_[W6@
MX.M7RK16N@CA._KC:"%,XSL=0[3.UZ!4!9*XVH&3M=47DM%4<?:*(RH6&BY?
MBT)GY W?4<6&#3S,NT_%].S!!T_3!X<P8Z0XG_O Q[I(9N-X]@]"A+%9Y*]4
ML][!M3O;41;_TNW(.1B[FQQ:^!^!;JVS)(+!FI.A9;M\XT_CL?7E^2FGG2L1
M/&E>+F(M;,1W?0>9@>OSPA(%;9F@T4#:1M9C<8B#K$7*7G[]' O<-6-4/Z#.
M<B8)PF1VBFF#=;EC1KK^C6>-%WXY-&G]@*I><;"4%J)S\@^6UFW<F?>*)/SX
M*%2Z!L!SIQ$Q<?:G86?>_E\='/!O!LS-3IHO*7&'.S;T',]4,HJ=*M>^@)TV
MC$:@L,G#_6+,<MJ6<A;B,/A-P4 _J^U8.5F=T)V/# Z\&Z.5M,[$P\4AF5=6
M>S."V\=;31E=%J^U;75+F(&R2 T:OK;5I#MMN7>FN&Y2*ZM9#3<])!92/\Z[
M@?KV\05)]8.:MO0GU" UKY.S6A<MT!I^V* ZX"S\"H[7N ;$X_Q91EPLX<O@
MWK)&K^K%([)+C]E.$WO4VI@->QS2UK0\HTV<)T+_74$Y82F@;6;)\E1$"JW8
MRZ4 >9X5<@T8+L_"TOYM*^35G0UWLWOI?F),Y\9B\S>0[=<JI#/;9/R.0G?T
M.F$\X99."-GM68T-N<BQU]#>(YPX<]LLF)M*[!@V7#ZY8.$V;292KDKC$WE6
M%I927I[.XS [CG9>3N@V$FS[H(33 80$Q^QBXXHU8R>@G_ 1FV+^M7X-!\5D
M?Z\!]2,A7RJ+F?Y.OMUQM+VR%Z]G(R$(?I@9KQ%SX;F+G_UBG!B.%\8CY5./
M_E2;W\"?FSO0 6Z3&M)?7F_;PS+/P^J82JOU__[],R6,S^J]!FB-0&KTVY$Q
MYTY64/C:V*LZ'KP4H\!I0*)&1^E6@?';BJ)W;=&CR097BANA![KJ=G3<XW>B
M$\41F3B@M429;)]DF5#U_4B!KG9RCQ\)*IR)>:=J+0O9+'=X30^%K@&<6I\>
MX8.DK'8Q RGMP6NSW9'3M-GLY/E?> 0;#-+STY4-F7HUNY5]:D5K)!F",Q_:
M"*XH0&8A(YT\B:YHWHH;N8X6;L%C@L/;7[4,S&&HL;UZW:DOU*C5;"?T%;5_
M6.G1Y H3EU7U-2(;GD@NJ#Y>>LB(O ;(GH ?3L])=%R!IK=WVD#Y-9U>T87@
M@ORLSL/[<@82;GZUJ2)?P N*=^9RB0BO 8DU"1M=M,7T:;]">+#!.?=VFY9H
M. T\M_##BFJ[!B4F'5VD/$8]%!KXCBLE#!Z:^%:M(F7/U-\;3%K]&GL!J4<?
M2O*P*CKV)PR6?0T!9GPI58&I1701^5X@/+3K+,7"-=-529.#E/_DDDW\N0;T
M!#J;'<">;9)*5NPD0",)F%'0IAQ"BYS&K4 !QWW^1AT3>L8%M\[>#P_?F">#
M?I;E?JV)R07*0TH1Y:<MITD>%Q53@E?/08/%\$8GF.<PPP+C<%[S2J+\<IL4
ME)[%SFG;-"%54*7<E<Z/'!*#I@DI<.+WV+J"PYL+%B0MN;6&KQ)2?S4[_NFY
M++N97UUN W-Z_F?]GKUR)95&'LM+\OL$B3N[WP4^)=U(#W0J_K;J Q7\Z!K@
M *,P399.C3)Z[GT^\>;>Q7$(!'9R6JE6,5A4G88%#TA&)Q,36#_[+CD3<^%U
MPCAY$0CVZO%&\8O_="[F]R2)WVZMIT!B+@*#=3L-<L.CM)+[V'1_S-&^\]@?
M (/W"ZX.]AM"!%#,:COXR)M[CT5R*Q7$AW5$PU@YXGV8G+J@<!S!@2VJZI9E
M7:&S@8N9;F3SQ<H"TO1_[-8KU=7!TD/[W11/49#SY/T(WLFVI%'S,)A"1 OC
MD4#(S:5K>2]0[:YPP@>I&B'J:T !$G$'9@8W9^EN !\:-MHFU+(RP[BWQ,.)
M\?4GXQ#8RL(/%)S"LD@MGERU+B;.)ZF_F'RRM1,."1B=K$"'JLOC[=-J4+"?
M2HP'#E<[BV'@;4P?E+A4'\T1XBHT"ST5O<"=_0A9:)SPM2Y84O-R(?/AR DL
M'=0GV]%A!,T$>E[Y$\P38/:SZFFSR3[&V/?9>J*3.W*Y5BOA">EJ3OQOS#]H
MA"Z?G=6=[+PQRAO(7"4S^$70#WKC^L#)4+:"^,"4. F \>(26<6#&,YTE<QX
MB*!Z2O[@+PI)'K]B;=Z6F;M?D-_#-Q\' \]3Q,?%-QC],3;Y7E,2)"95;SL<
M(=UX=QQ&F=Y/&XN)\_4U_L42L=A.$]9"&#\O.R=XB3\X#ZQR058]WIHLEY@L
M+>,0'#\%6>IQ 3*@_BM+M>[2XB6,5H%TK\'U"642V"B(L$;]6*"9:+./M6OP
MN%Y+DSON\;HG??U#*6>Q4NE(CL2]-SD=,,MB%@6F!! <<4NSX2FX@M,B:&@@
MZ!-6 F$6L%&$M'9N"O+_K.E5LS8G]"/(W,^431^'H+273>0F :H*<Q&2!R_"
MC:K&+Z#KB<HCOQI%S($QZ,-J=Q([R6.E:>.^V ;M.^N/.:LZ&3-N9/MV/^)F
MY4U/7(NP"H?'A''O+7I1)ZJ+#76&IR(L&7O6$W>V%7XA&"Z5AJO&.IU#+[%X
M#]>Y2%D$54T@K=.^J7/UERD21?3>LP"TT\K\])-D2>\4Y2J>']&_KO(RV(S)
M HDU.[Q&@)<U$D1NZV^GQ:JZ<[Z/=-J35;\G5\GX]9UYDEU58D'E"_$C,?X;
M_.>STUTU9=5RD;_D7*Z)G'H)D+=.H)^5_G;T?.'+WHT#1N/R53'U"2FMN<L[
MD3.!6ZN+M,\_ELP/"5'0CRLQ7A;JYZC^-+@2N7OC.N0@ 51T7I,MF.-SO+/%
M8&(B]H-/IP:GM<[$'UIWS !*O[N#JG3Z&M#^.6^&QL%1C>@A:3R& (MH1U4Q
M-&$VKP'KG&-F6D4!!;%P"(:FK&![/O2.J:'/Q,MTS,BRDTY/[)")F;9X:"M1
M^'YEXXYM+,8 ,C2(+72]ZFW^2>R\YJ/@31F<V+134#Y[U:EE^$SXAU'%EC(K
M$U.*"_G3>%EDZH%SPXX!W#0?\GQW[3&V<<1?O&W >&L+)V:?45U0*Z18\B"C
M7;F'IQ2!3CYPJ$H\QIRX__*!6^I<FDU%^U;_+BW/]'!@%JIJ+>WN&2:U3/7@
M%2GL;2&:%YJL"I^H@P*:OQHC,BS4J.RO 3A7?VB FC9/\Y/9;I_9+^^*NS4I
M,A[<P9=\\_+PA1OL../G]D):,O-YR]9V][)ES,A,W3^&SOJ,%M6K3C6/46,>
M_)3^9MJ3G8P]LS!9&O^P8YP8 WU5LHWX+*%W1T0VVW-I:58BI5H]W0?O_)K8
M<(6G,J[8(7;SNYMOJ\@?1A^63OV@MH;%]8H%,P?F,:!7^@^?AP\RZL'>&\ZV
MVXZ"$F./1@=3>ZQME55B[9Q,GAD:L,MPG )2@%M:AI+BD[X%HKD/*B@2*X;<
MOQJ ;;K335CZUPM*4U':LADO^W[]"'5)A*$6HT@PEDV-/3Z+9JLA-+X:DF;M
MMGMM,R'U^24PU>!^!9+Z%\A;5=(I'.BF2_-CS-E^)2F1J4I0W-QL@%;R5;8.
M1R!I1H+*80"O77^W-ALK8R*&Z/F?9&N0SD7@/.^X"HRA^1[>S(I'7.#M+FEW
M\V)30$' 7-,95:V<SE1+&XU&;9I3L;4PR?"06]\UX+$[$,6&J7'D'D>\Q056
MU.N/K*/JF_BT5UFIN&K=MVG&>JZH>J5)7E_,+O1CP6W6G:"'F]M>1H\2(;O4
M[R.'LML9M$:[,C+^:2F"0TU7)CJA0V00UTJDA^NS+(OQ)OO(\*8S-STUK9SB
M'%41V=#P5_?YRF490C(0[>$3;>*T%-AP,,Q@F74F/FLG8)A40\.SO&)W@,\+
MDC&U=;@5>,O]877P9E7 HI('Y&S89#U SG._TLIZUZ>T>KMC_8_@2G,.94F6
MZIP:FN6^KIN1(1NOB5;)'S*P/LP2J*MW&3'[Y;)A:BCQS1*O$SE[F4'EPJ$A
MLHQ*6ISM<^G;L@@\PFIG;\QSW&DT>"8GJJ;L58I?LSTJU';PB4,B2.7>E49_
M0Q@>H]D\T8UXTEY?]F>SJZNP>E<*H<*,7%.+S5E*-&RW=>YK<:HF3<1Y>'-$
M15EN'7?A8.6\;5HA6 GB-S),1<B"'E\P ?7MIJ2YD)L$CS$09EH54 R)OH).
M;JQ&>74J[DV?-"A]0Z<?[3\32G"Q9;TBL7TP2?<7F1@(-]MY ]M?J(3(GC[\
MH> 2\F<>+6D&/;]Y_J'4[,IX&2H"Y(61^_F]G?4M/(:Z9_^"HB+\&B"*Z)X-
M)ZAZC+99 )K:'\+>[(K=@6\M"(E>0 8] @C_Z>IKU5B@-](DT)@R(V?2;UQ=
M$+K')]7Q!<)P9:59J4\F!7T!A$[.ID_P<9S.B)ED<3O\71%EYY!ID/U.4T59
MZ1W)1.%RV^W@VP5&+R%M;'5!5 WUF!@05+E*3('IRC:=.%MV##BDW-9:5!RM
MZ"ZP]QBG>Q_)!-%[HX5#=DY.WCR^'C5PS.P0D<\<NQ6(!VPDW40-@G\8(X8/
M@EW^31WH_V8/4@(&E@I3MHT >BY"EP2N(,AYH2TLIE%HZZ.;@9UW6;5S2Q&G
MOAX*2QE^SIP3RK@+G$MH'#-C1K4+<$J@#=[XH%$J3.EK4%==S=50EPP[MNR0
MX/,'X/VOF^^,+X7LZ=SHV;F=2/Z,ZA0SH_]PB\0]5"TEO')#-NV4GFP_S]?\
MM-%?/O\M6S:7!,AA6NU?YDORT'/='CRN?KOV\6T/+^3Y%;#4>*<;1O)TY;*M
MFBQ.J+.XR5D0@_D<?Y;LQW,L_=U,(REV.2#X]MKH<%%V A!;@ %J(V'#>9G-
M.X$HYND6,2<1*\=BDNPS 3:XEEIF"E6D:X088?H'SFCV/8@F]._I*-5KX$O/
MT<'M+5%]?^.R>F/S7;Z&QLICV_Q2O?<RVD&U-^8' ^T$8KP3FC0"&H+8M#3B
M>]O;0_;H*2.,*9OW\EEWAB?GGVY4W!F?-#%-LGV?P=;A^^ ,/WP>>&@=T/55
MKP W+<:]L_&)AHY<8%[;[[*V-57E2/14^HDD1&>/*VVR<*1-29;1<JFP9^_2
M0D%>1?MXY'/VL#JK*#E%8%.!%L.51C![[D<2[-\ML.3)B5E(6YU/9"Z7?9QD
MJOB/0K.>@EW7.X.W\)R)P^U5G5Y6F)"%) UVVJA,[ 6[67?C*]KZ=T9N= S4
MY5RUT\Y#ZJU!4K*F53IHE=,=B2(=+@, -:!/9O7N)4Z;7^87)%-Y0</2@MB,
MH.0PV_!IG4G6N>B=(/)Q@07[=X>5O3P !2V^NJ$EZO4?I]< L]E%+3EM%SR\
MN62,!WM"M2IHM>BV)Z/*N_!,H[U-XT5Q=/")&[V"J4!<2:,Q2IT:97U/I#&J
MT5GH8<<;PL/CS;GEOT*?'SAN.G$Y'=Q/_CBBPR]XM6S\B4N$[AI@&=(UIKJ2
M:"J"!V]U<[+Y.7.7]VSI\'GOZ=:\BHX1_+1%=R,5O]-N4JMMS%9/PI=-Y@S3
MSL7DL@3EDL(HU?'"#^,\ZF]MQIX_@CAFX_D]7(5;W#FOK)HKXKP%1\>TEQ[H
M]=*SK:MIK#]F4]!HF#(SNH#N8,^LBF'0?Q+VBC(80ZN!NGT2M=0]3,I'!"F>
M8!/85KNUE%M-6]:8,C:RLM&WRAE.I:$Y6ED_WH9BP=)0J4FD&:!_4UIMNTK!
M9O+97VD-EHL.%F3/6*2G#.NCW*YJY81MWTVL>H)I^$B#TJV:=74I<Q5"[]76
MOYS?]:\/"6XR,_DM7N4T5E$JGGSX(Y,[JQS*K4?WY5Z6>A.K7CIX+*^?+V'"
M["]H-G#:%%/C-!H5H)_T7>,QY:"F_#T;:;X[:8_N9CLU$\P_V()9OKV\\%%]
MHFH PV4Z&/(Y,&V+LLUBK(ZO@J>J D:0NN1WC><E*]6NGBUJG4%#B&4FVJ(]
M=XUK2]W=?B9>J"V&Z57<A67JYL,.&2<K4B :706+:-Q?5;!E$0[Q[]25-[-O
M0_(XKYH[Z6X B;#9;>F(SV1]'N>3;7XY@=4@OVO X7?$:N$U0!%W%C/9]CG.
M@BHVG4^@"-<B_ _+=-?_"XV$U:V!BV;_7Y?:_^5 ^34 [TAU$SYY]AQUM*M"
MY*JW[/GN,^N]MX;=<57(-N<1(S3.%;!FA]@F@5[.I)X;_DG$<:9!,DL1"TJH
MP68Y]#?0[C(K7K,1=)8+?'-C*?_>YPQOKI/<P#=[[M,[5\,SE#1#33]F Z&T
MT#F_G%8E+2LC(VKZKF5Q_=CR\EBBA)*"UX79!OJVLF,O4Y;TDX^%B^?QBY+4
M?#&2R0V>#1'IE @G:P-S]&W54:UW5#\#)-;:V\V(SSD[C1QMDFW!<=P^HW,
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M8^5ZWAC"%T<<AT[UP6Q/#/N][0[94"ZW9P8^W^9 N3\-E0Z2;4O0#VO()^S
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M66FE>9015E:'([^-AXSHD_'RWD&P_DHA=YT49U#O@*MY0K<$K/J7L.5DT8R
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M,N589Z.SRZ-%+9C(J1F7>.+L1 Q,FR2M4=5:@-+N_&0*J@4Z9-@VA27J$S(
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MJ5ZZ=Y2;CY;S$(%T9+I#8/M'F[AEV3E[.N)17A+L9%%3@TV?R'S^FW6M"EA
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MT#L2X'%O,]5[@3GF4A-M<T/O 9HS*KUWH-S%WOF1+H9E37'$+1VK[HV.[#V
M;I<2>IQUUWTDT4$&W_N2@AVW9A[.)7"_6[L1;3'6YK"=L>+:FJ;ZXF;I<>T>
MTI5G%Y.B!ZLPSHNZ(SLPL3]T[;?#YPW+,6)2K-XRT3S;9?,_RD;[:5X/2<&(
M/08:T$^R+$ZK0ISG/'Q6-_F_W0/L+Y]8VO/[LPX>,X2#?;[H%Y%U2L?I_.I5
MTLHE!^#"K0)=398J2M<7EXI$*"->>_Q];+P)9PJC%A]I637H;VL)F,TK3OA\
MUZB3_KLW]\C()D/Y989BAD/6=IJ1Z>"O2?KZM_1I=NQ)RJV2HWHR,<0/@@D
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MZWN SFX?\XGD,4/<,P)=F<*GT$>"!&5MA!3E1*&/V*89((6*3LYBJ]4'(_>
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MD4W_J\U86=8$UD2?=;GCX!_(M.+,^T*92?4%)&FOP/:]T8<208JA_(RW/M\
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M,V^ )E$[DJ^]W5$'O$2V"G8QN8<H8T*VZNQL)W$O0@$XGD_W]>KJUF&S=8R
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M/UO)S\3,05QX?NT"ND83NKQ]+Z@HK>K/,K+M2[IP-/T^(N7U>.W"I/Y!;52
M3UN?O-ZKY46*2SYV]=(A=I&59C@4?DO"2Q4$0Y%T;.WJ967]NNY(?!?+8/O]
M6Q>+M>)UY/MQ@9-(UH^.JFJ!Q!',]:UDZ]Q-B#V$S%?@;P/33MS8TM\D)+\U
MY&A?6;0J\6R\P;F.E.]IO^<YKNE<_%J]^;8\23Y^R:3J]3XH 1+<M.;0,4OX
M^^<\/<<NL&MXG-N$\3H!C"G:/?V:\Z\S.R,> '[T6 4T;>U^/JI4=]PN(>7*
MO/^\%U6FKGIQ%P(><&)BO^\BV5B=2X/2LL\$[5 _ -[H2TYZ%IRR=:\.@!:
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M.Y -5*'5R]+:$A-0$^ZH[@MBF2Y._^$H=(T9D[G0\VI:<]OK^5U=?O11.[!
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M6 J;? MAY:Q;$E"BVK/<@/+HBDE S+@EVY+$^9U"+;;*.R-,&&GTB<]-.;_
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M1HL*R:RWP56:;05@@H!DC4^W"6*IVQ+B84BM&P,(Q!#)7>6 ]J.MTU8["!I
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MC%5EOQX%?G</[%X[@@Q4.6 ZW83D$Q(^-#NK"=;+<O*-6B!OL3!?N]NQ9??
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M^H3(T^[U>P=M7O*N; UTC;E,:XQB--^!T_!W=-"P.BY?#<U,H;LRHW;W3X3
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M+[&S]D&MW[PT:=_8;POH4<SF1+J+"#=F6_13RSN4Q!Q5,84JI$N>!,1;S+M
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M7S(8OPEJA*>JVUD.X>RJYWU0#Z@P@2JDW0<=> Y%A#3OCRDS S)Q&7BU$:?
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M +)\,FZ;[F^54PPQ\6UX_RU38;%*Z)&F45:XGI:[TBU FA5]*KQO88 #S7H
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MTX2E[* A27U'KI*RXL5'3Q67Z*/)(K_5Y3Y->L:R<.7F!GE\ S!@;C;_+$[
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MNMD:)KE7[-E<\A3S+3^Y>[2B,_H+-8C[W"_65!==XODCGS11WR8<^ )<T$^
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M)OP3H+&7N0_B2^=ZGFJ1$Z9,O]80!G/$$)J :;XJ6D+KKR1#<%P:46(&BC>
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M0G5TDA>O\ELP2V_3=-<*\W')CD._$V)XD^EG@B@N[@=_/6G$SS-[H%[PZI:
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MRF_L-Q',+3 ED7/OHF9M7%3527#D_;3?I;"P\WKP:GS<S'E4ATWB/\_%PF\
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M/4(!SZBB.@T=S1K]6U:7IQ=!'O/-YX]O /'0_!*87;/GU2=@\^454V[K95T
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M_7XZ98K^JJ5A*)0,U#-W=XC;0@HX6,F-U-B^-230"3%!C4Y$5?G/G]\ O@1
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M_$P0-AW[N0< R4+V'6HEP=NH5C:E[L:,ZMZCDG4O/WF!S/9[?OKK8@O7O0=
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M%,?S'[]VFY$Z82F\:W$,1&1[/YWVK1Z*0YC@5FYBM5 H?K0HGNU\&S+EM?,
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M*X8Y.>39',U".L^)X #&(?IH8_+(BM)TS[A[Y&9I,OFF7*Q",9^<+'8KHG3
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M_38P>?X D/)"=[_=:]M+/Z76[&3U3T\16X=6O5R]Q0RWL^E,'.DI4[_10#O
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MH&?$<%=6VMU&7O-Y2;&G[]3VYP_3D\-4A5[IW[&Y45Z$RALK^?\X;.C[7ZW
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MA2W,B/T [OD!S8V6P_FAXAD!(G4&&8/!B&8V+3Y^$.YD1=7[S*%A M+IU@=
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MQZ 5T9P[H*VWC'+3GNZ/[S7;,H^C ?+([.$#K $.P!G\!1UTLLETXK(,'8!
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M_P'QKX">\(>V4^>\]V1D3"D\86#C5_D&J ?,(0]RH31-9^K]V8@I<5K1J=0
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M]NVW+=X&#YV>42L/"[(>"QA 09_/[9V\W>,?;B>$^?T3XN.TJ-!50@L]]?F
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MF?J#@B3%]+?C2G-KB6&^F;="!N6XDC7]'WD("RYX2,NOE+OU$J6$4^G)N)5
M 8JB1#\VTLGO_#":@?SH-7@1;AB9%W)_T0":^"*<F28C\P.%-DD_\V>)R?3G
MS']O:08!=OK"^CYR*OZX,YC3N'8QS "C_T]5<_U//? D[C/6/)OM6'Q#>)#Q
MJQ&3PWD.5T/;4QP@?_BTI%E8]^E3Z:9:QNU7B67L4O SSPS87JI>%,M+T,^N
MD6UGIN-XO9LG_WW43QBVL)'H290R.LAYOVRNA6$#'=HDO+BYJSK4]-HWJK5&
M6GVZWD#LW\2?J4D;]N/Z<>7'G#_><;@VE/X9C600Y.X_:!TG/'F'M:4GP!3!
M'MH&1J,IZ\5#_1VSMQ>H'J=TK_S3NA6VX*=_#(]_V,Q?K:W]/GN!UCV1;UNQ
MB2L1R95CQO^K[ Z3(O--B0<'P.^IA G/73!\![P92P"VW,OU+U DY&6;H(^+
M;F#C-C%42T- JMO#^-W9J'I\B$CVL]+&,D(PHI!%(*9F6-LLNO]AK3HE[.+=
MHCB6O!/3W*OZ^_OP&CR"XA@F9A]4DWA)UDH/-ZH'M9/$7'76<Z"(PZ]\D@Q_
MV.7U2QA:--0[\*AX"-^41W6NIX!/KN KAQA6' !=Z0))NC(Q_G)\9R..;8-P
M,*=_5S12=Y[,NT<HDX:.+A&BS=\M&QM59%O :LM2ZF^G5NQ9A6=VNYBL]OUQ
M""( !R#/7_7!'J</X_5&%G^I[7/=G+\IC#42QF)?M=TT^_E,@X[REB+H?5!0
M2S-):?.K-#,,:G[^CKV3:N>19EK^A3,PT/HBSYRV4[I^C%O<@E]$XK>>/-?*
M"5>BBF>"JHI-<;A=?B0>Z=^5%,.\WQ^.@AQE+VWDMV!EG?3/>?O:TX-(,0.2
M5CY"78J#F[<2#E0CLLBI#"1#J+>.9C !$^\(MG>*BL.BQ?@D=Y%&4L>R.$"3
M# [P*AZCW0;! 9"?)/%+%RRM0X^32W& A"+E-9+C$:S98>;EYJ0GD!G.5==&
M@HD;W'^$#3 [N$Z<B;Z8F $OG)YZC8PYT[W.39GL-AR9,\#.(YAK>GGT8!<?
MH$HNBCC ]X@3R&7WR7R>M[RY!9[Z+QT?;3M/]WJU]TF<U-1FNZC/PC=_\IWI
M1_5Y3SYS!D=SZ'SN')F2&?YXZBJF.Z)*5[92\ED*=J&P%(8#</US6<;;#;L+
MNA43B"9-1-)[S4(DKKC^KF*T>RV%&*P;X[WDZQMS-L(K_0-3><@G!$[# PN>
M]&J]18WWO]416 %*"-3@M29SN+($!/&0K$LO@M@E*4$B[6&@9]59'AZ8A#VU
MV4OY$[;&8%K3 '7[ Z>P&35[%%S7>/IZJI].5\N9A3MWB_,9D3\K6$DA_5V*
MNTY E9=E.\*C+I@ZL QKBG::QK2 4I>ZZ&./\O/\5V"-R>A(<TE:BW_"HFE+
MHHIU5$H_V3Y9CCN;%13GDJM95!9_8(VZ6Q%2^$SLGSB>/U?C %^O0(,KV$#0
MY;Q4.NBJ_K^T 6+)7'  YX];O!A%T O01<W 31F \G@0K\(K4$=8^PD#Z.JW
MWLV@Y4W8L'N/*<>S>H@FYA':!;,M!$64$D]/X  T5\+H+DQ?Q>Y2RF']<1;$
M9MQ%C*=;4,C%[L!^016?W;PTS9<<)RWLN73%# ]Y+!4Y6^G2\&QR"^.Y^ 8'
M$.'=Y!L##@H7G8./(M"!(%Y(_'5LW3]^V,7&;X37\#_9/;5_A>7=&Z7GZ\_L
M,^-? !M15)S#3U4EB/FU+(O[=1*T>\SQJV4$&E\&@-$H%!.6@@TE[/3==5&B
M##/79BKYBSHP9B9*;@%.Z#'J'-28ZO7Z7A*-WK"9&X++UHL4?"S/[)_8.@V3
M6'J" RR_PP$>PKA6H)].-T\(%[(N5FR&2.*"'*:O=9 @>CAA89,+"A/NX"C/
M@(QXT<#A=OD])B"4L9F3/4Q'M* T:W\E74)97BVO$&_T9%*)4(4+[XT#D@U9
MS(CX;DE3VKMU4'JOEV-,E?HIU&SU#XE4Y"XV T^P]@?# QB4)1X#^=63@<UA
M,S-C#_)NTX3Q'+2.N?P/E;1T!'%!?P<.Q^, M#8G)#B =^Q-S^7NB$TM(8;=
M!TLNZ>_,R0'W#>2\'/&OI$OIR,R^>+XSE(PAMF<VU14Q8CO/G0FA<%8?OPE8
MJYB**THT\=ETKU@R9E3LT-$E?N,[,J,U;=UD$%TV8E!YM3>X>#JT/G_IQ'"'
M(*'#QHA%->%',NEC27!(VJ=:_LQTS!B".V<7R7"X)CUCL#^.P;O3]P.@/\9G
M 4C&%9!L%2BYAX5N&9\TK<RT^*M&-[EE?#)9K,JZES!>02#K3%-&K)60'_?&
MC9HH$N4EHS,^0 B[D"O#/MW' ?BCT2@<8-41:X8#'(S>M#W2!7[=QI8=J%_J
M5/5R QW/%O_L?=<=QJKSM@M-L04Z_7,:4I3/Z#P'GQ?E]W<K&]#5XP!^BL1.
M'\/E8NI5L JG?<4(O%@=5L F=6A*_ >XTXY12]2/8AF/Y[!F1NWB<XRW?7K6
M!^2?"9MZLWKG2L6>*8DS4K *,VE(B'3G^]Y1%1)Y.36MM\YI@3>ZZ$"CW</U
M7$QQP/ Z8<?A)N51U<K44V=G4!)]Y+S4?:SE^7"G(XG=OO%0-?S!D(FP/0*&
M \!FF:(&G+H*4R0(/OQ6EQGK5WQZGRQ.J<KKH#P-[>SMTLF;"AIDY,'/3.,]
MAE^&UK21>ZI_TM,= _%QRW<Z@N0VWUQM<@A9/-#[NAN3Z30HD$K^,G+0:_*^
MS.B[U&KMO%Z@/,CK ,QX"W3 !-E<P@&^C:/=<8##VLZ;&HXTUEQJD+"T30Q3
ME;P*/5&Y;*AVAR 8F_SA%,:3((XF]8_3/N&+$7X2LCRLRHXN_LRY@^-F#WSL
MV'?"15\E:2D /^BHJAZT3LH':NTN?<T:1__%Z.P-K_%^0>JK?9F#@WXR8ZVN
M#DN+FX*7=L0&%(\N3^<"_),OD6_^L@QD[C1^_V@^:?K*M"Q$9*VP/%MB&H9<
MPMN@X7P@ 0[0' >"@+!,ZNL('* -07Q3=0)U!+5ON($DI3!.D$&IZ[F; EX-
M"#FSA YCQ-K?%*AFQ?^3H*J;@8^T7-$J(>9 EG<M!N;\W3'V?5.Y";>]REE^
MAG%7]!FY@G)O7IG& ?#3A:WJJ&+NB4%YLP<LJILS!6/+WOC9;]5,H!X86V@Q
MC[^1^Y(]*5=$:0Y8B\?/%MPWWJR[F.+ASV+RVJ]8#4OH81IT^K3_:KG00L#N
MS2T-1>Y1>@UEVF@I]IW.L5\0KX.4MO^K:EXQ-5TE+^GMB?5:;2J83:JI4DRL
MI:>"<>CK=\>U)>ZE70\7?T%^_\=6S7-\.4PSBXIL2[9+5I+\HR+72%\ROZN#
MPY^41OU(4@3<\L O6:ZM,V' :5OF-IG2<.KA<#0YJLVBK;YJ'ELDPQU;F/JE
MYF\("1->1)K_0P'>;N>*[F;67'^C336SF?+^4>I9XF@9_/8'CL04_H0'U9OX
MN5K7_[,>-P)B=<RR)%##S5ND!ID\L6F(,"US$'R "P>80:F>8JXEHEON;6X+
M9PE+>N2!_DCCH]LP\F[+\=).HT/W:8@</MA9 #%74[78D^ARNO^0<PP.H(6Q
MJMP+A@^>%P54G]L8['VW]I>H4P4C:P?R\FK K)QW'6Q7[_FF\)DK3F^/4[N8
MJIEMILZZD'70^E5:VV(T$[[,I4K^5+<3N.+/B?@)[XMMG95<%NP2JN:Z-%NO
M\E@=2Z'_I3<X3;55TU=:*Y8?J6&<RDRD_9HP'# 3'>>(1V)5-6.9,:OKVR/$
MG^]^=C@YVXUH/?N_^TO?7#8W+\FSN0 2&V\A$.,]*:?#N:C+QCH)<V4)%=]U
MN:3\;FH+<N;FAVM6WL(O!&8C6=)>SQU0>AA\Z"[XS)%VEQ/,?$M+Z;MUZIVI
M5H;%X_4II WQWL ST7Y2G]N# $(= EO^J(1@[2VA<Y]1RO_0S(LSA@=-4O9G
ME4C].>!JP(F=!;.L)C9JX)),[H7CA[QGUL+//BH^?WC%NL%5E3M_8%TA\)X_
MV%R("7VTM0O>#VYR;0A/G78C@E3W_<#^3C[>M0?ZDDX%_*^.$K(736W:@<%;
ML>BQ;(.YUOQ&(8@U)F:1<<$D87<.UBYIXZ[WZW17#R/.^,0_DH.O3$?MK$$E
M6E6I5HXUU43_YF<<KTW^.U7MM%]!T?&>(!G,SF4AIJW)>W+_4[Q'X._YK$./
MLZ*-^?2WLB8SN=#=.>[L('L;!_NZ%#]#N\((BH_/R9L-)VULN^)IP)9XC<^H
M;TB,XEG4AOA/*3 QP^2^_M6)Y2DQ;]]"Y4')[Y6GMHJA927=8Q4\$OZ;C )H
M#5:3]'2(2Z]ZH=7+@H1<_*:J2?Z;4X\)U_CTL)7#KH+.U?PA3'JAN_M9+1<]
M]LFDY%X4[F-.8AR[.Q:%<78ER_X1X=E=#LRH7/?< EDXB==!-.,Q%CTTT3X(
M6FD"!O[<NFZ=@>M5P%G;_5>K?=6FNE9?^_5!S#:.J6@Z]52_(3;9F12Y^,9_
MLK[]7IAK:4/:8CN-#,C/QDL'SSJP0.!@0#X>NC*,'A)OCL+U&KPK>7_ KWPQ
M[HNOO=M(2$.+2_XX1MD3P6#EYLLG&3,;W8H,<K?(ZQ#J'P<K&3)?DS?!+G1O
M_;=>4=Z^$829;)/" 3BPU;NOIM $U5>=U:ZM-;-N9[I3G9YRTQT'/]/[A^++
M^E_D0(2;&]> SBB-OBBSXDS=U$09,44KO,[*I;8XEZ*D+JJD-DYP@(*,1AS@
MROQ&F3WXU)]V4G/Y #/8],RGLDW2^][6?"NRP16T2#\Y(C%4!]W-GI56O_/-
M06#\9ZK^S^_IL.2_59^L#9OVF4=L.,BK%7GQ= 32)+6LLD0%\VFX$B\^Q@'N
M@C+#MQ%>-F:':LT#SD&QJ% 7ZZ,,FMC$I)(>=6!$15KP&,(@NAR<6EB0O9UG
M9^J[9IO/_3&@RO.>4]6E'NBWQ';B@F]0]E$=NN!@L'&X0L5YOWN_*LY(7%PC
MNCA)<<4P,(:\-8V[GK^^OD&!S$J.YU&90\]?/)-QQ0$0N^@?9^HG%+M_%O !
M<:LJ58(^=GNPXC&71"A:?(IJL7Y [_KZT>2NQK>BW 7JYIT271'FV((D7Q[>
M'[=?=>*U^&4.>%3)&WJ% SR&1Y@'OL#:&TT#SIZ.L7K8!3K,B2?%()3>@5]H
MR<_R?[",22SQ0CJ_NFF+2,$!3BE<NAFOIB$G?CC F,H\Z+I& N^+]C@ FU2F
MGFR@,M8$+HU.\FXR]NGPW#B:#:)OS=O]+CG:6?FOMWO);9616CJER[+IL3"E
M8G*OD"[5\<>8W2@_IHR723_R=O%XJ@?#CPX8PP'>2@IZ 0<JOR"FUOZ--PK]
MV^"K]RLH+!I8*2TI\ ^,>RJL*J\'5%7,Z-+MEN"QY-,=)ANBI;+)>19G<V&R
M38CIP/J?X@#'DY>M<*RA3]'\7O;TM#B7:)TKM0JOEAG*;V$AV24F5?)58LEV
M'74,\9UN>EDE@>YC!025>303( )O[*!&_M. .B>G_?&XJ"*ZX/7?*QZGKZ?R
MY-](9T#C\E@R+/Q(K;03I0D24P1_6=/A(0)$XO]Y7!OW.0J41S&N,G;4M'?7
MVV(YSOF"_F2+\6R.KS?&JS8$B?S#V_-V[_\^>U(=+R>I;]F(DTZT<6#.92'J
M//16\OX!'F9\:$?2T _GQ#N.M%\P5I^#UZI.IE4JZ&C<TOVGE*LJWR7&?;KQ
MC%ZQ);N89SV[_MP;+T,D1AL:6:=_34P(O)X<4A>28J20D-'0KFQ_Y\:9E&1G
MJAI)/ R[^,#V?V >T4?6PCR PH'5+7?/#MD4K34.IO)XS=MW;!,-O "JL96O
M@O"'XV3/"V'_&R*R'$XUQFX6>=<^FNJ6CC: 0AL N/W+]49BX88T'#MV7#;Y
MA9FUH</G@N[C!4F=%TID0/*OE/%]/^Z-R>7^;KZ1%0W&6XI#S>Z-)[D?C:Z5
M=U%5H5(?@HU32:&\B3'4^6:IS)S,G+C[=G;/P\&9.8)11/Z^X/NC'_4Y7WXN
M_1$$ -R$4NO_TR-C#K:VM=ICHY:VVPY;&Z,;!150I6)(S^]I;6=J6F7.1+??
M@#AY_)%K?]\EKY9657VD?3J!DB>0>$OZ+9'L.04IZ3L=V8\ _%_U3:<5\ :)
M:B^C*%)39FE^Z@J5O9"'[NV6VIKGV-;S6:$&!DS$^9CMS"R&I_&?5I/\[[+.
M=DOU941?;WJ@B6CMZ(LX[OR/79.<A08"Y>N!/VRMC>[](Y/\>O7?Z/\_#B)=
MU6MQG+*1S/9>/K'06L_>_I]V>4RM>T%!%,+M4F@5/]T CS6W_H:#D_#B*5G5
M_P&%1IK&4A"$Y+$3E1*.   WF[\I8IB6%A960,%)C9E$,(.17@E!;2X-VA(L
M(C^D7.K7#7*VR.T=L>!(BJ>558POB('+*TNKI"26)(#-R01U""*94?TWV%+S
M?P:VG!3&?,$!P@ X 'M\C,0H[SOOP\'LW/B]GT&.(LA>Z7KOX,V]G]XT17:9
MD/TZZM:6L('E8LZ\5#IMK7[CS0*-REH1)DMK?(0Y\N+] _E&?S)7,F;,>TQ9
M$2!=M['S" C2W ]*_$[[=;B.7\MBN\2'7M!83() ]XU]3*7D"V8=-9GDN\_?
M- .]#EH"F]$(%-/?X%_0O:4T"50-3-IVC:VLL$.Y90=:T6?%VMN]D0,A_MK[
MWBAK2%N:(F/E1Z^V0BYX1Y 'K^]7$*+V[Y#C::P9+3@H&J6WSC"Z9!RMKIY0
MC@/(P4,),W=Y.M]2%2IRLOWH.@AT?EG%I?Y(DSE)^4,J7T_FSYAPT0_X#.(>
M8+,&D3U56]^)A<PCTYJ\[ZT>\HP;U\(@M) D_<<.'#'0*UB4F!T96QAS./A$
M-%-AU%S/?4ZC#^_RE2QX(=+B "SI\*^GR8$'NZ$M8>XK<=O1CLYVC:"%V@A2
M/$EY>F]>YO>J6*P-"E)->#[T,9WJ1J->GJ)TP>J,BN">:8TU/@,BL<#8>VKA
M)9S;F]"R]]Q:G0*.HXA'-;4PL1I=32HRXIM_43&NP0&(F+"J03SS3F-9JQO8
MKF1_S77@@XRRV0!ISW-=$GK=N@:^$+C[_L(S+9>.[8_Q=%/]KPO'3,K'NVUN
M:J V>N<0(Q_G7W.M91.TA_;>-D8N@=K4K?EMWFKN$+?5-^0-E+?M#0?TDJ@!
M5I:NM-KN7'++Q@;RL N=B+GV80A:\71)T_$Q:A'([TU^[30G7N6ZMQ\&GIWW
M</,FUE6JLO4%12,>LQ&&]UFE,<8(/BF4=1CE>:FRK<)JG\$4UCH-$Z'O/YE>
M[NVMC)D%L8BWKZD;>ODH>LOQ/TC;;3W[62=/PA!,W_L>H_G5S+8@QK*V;M("
M-) ?DAEG, A K(X\8-A%/I&,P(N<$L1ZF'@-^;:-;41G-3U?O$IC4XR82_!F
M-'9Y7/!C0,>2DPR<DY/,TW*.97O6H,./())6E_@D^%0@JD9FCXX-=O&.$,.1
MA0X=#Q3$&DN4U?R#KUGA\RUL?\]ZO&C;WK@F ?*@Y0V5&\PU_7I)Z!Y,A'9O
MA^.U3L.7'=.2D-H$L6%E;OYO5OCM&%[\:D];HL6:88+F \9706[[P>OS\T\I
M&\6N C8;N\Z>=DOG="_S-7CY_BOA- MKVZ'BW%Y+FOM,QL$SC ]6D3:.H(YO
M.$ R4-E[WK/H$MU>P[R8TJ+786U_;C*"E$@-[=4IWU<QK5R ^Q"DS!_!M)EZ
M!6M5.#S3R@10!O@,HCL[>0V=0LY7"U79G]V[FLO.F)I?HKCG8GN8G?P=NN [
M&,8C^RL37)NZ%OZ.VH#NWB1=U&BSGJX&/@(XXO.Z+PXP,/PWWK)*#9."MJD_
M[[7[S2F?,V,D[N#,L-!O)I/X7@P'\'T^YQLS^EOE]$Q@7%[]DVE9#O4S>U^6
M:*UXKX,2'P>?815,.EXGVAB] TC\=48=/*#4)^T8NN"Q7W%1P^^Z67,F9099
MTI[D>V!NL5)24!IER\FQIIV3X[L6[KN:2DT(NS *N2D<R@U?:C0-MD<P,DEZ
MX "O2+Y<UQR'/P)VJ\8NM69I8'J$)&<6SJYTW.J<QAO5[A$/O=4.MUV->_I=
M@2%+JU1'6_51X@0/CPS>S('MORL'L2I2]_R95B\, ]GW<HIV*F/0N3.M>  C
M-:9YZ-0/6UZ$AYHBXN>O>AK3>%M*W3-$(4\N,4$L6E-Z!0*H]S2Y"B]/\23/
M-)@!)%2U?G*RVR N78AE#HSH]J$T\R)@D=/R,T>)"[LME[1U@!O<AI-[K-ZD
M1W&;.%!Q9;R@T*9(?=*2](!TCB;3[Z9IGA(MB\& 4J"=E8-EVXNGZ(AZM];$
MR#[EF(4K"[.]ZZ&%-V;6158&N8-#]=4M,$<G;8*()+ =N-K#WL/"Q>N@7&JU
MO;\J?HE';)Y^_J:H[6/A(V]DQ9:3E.6UI[+@]XTL+V'.WC"%QB:O_"N*!8\T
M5!G/5RGQ<7[4Z4!]HPKSLTUR?W%CX;K[N*I"2$A\%7L=7WJEF\7&XSEY*I[C
M3Q/S/< _F5)=7DA9,".-45E"26.5@XO-]LG 4]ETO!1B+Z&8-1P G#9$'S'7
M&C_2SG5^3\OQU)JHR>OBSN& 8]I'[?T%2=&W==:U EFUT<0?FV4^"%J:*[*G
M'M[Y4U?6U;:+) 322T'DC[/01DNN&)LM/(F ZWEXGRN_,(J<NW1L&UJX8@@5
MUXE/[F9Y12C\O6.UNL4>"KHD(98(0!BF@<,XS?02@Z9A34OX'&9/@ ,\U,4!
MF@P\&;&\.( NZ!"V?P,6C&SPR+GC"R@9!U#VJ=#KE?R-KIF^7$1TX[UI<54D
M&][<9/+P:>*/3$.[+7<XE"*B8MZ30OOLM3+%!^64>TFR7'I_A=IA%]+0$U&D
MN$T@B/UP@_YGH\ERAS,R'P9*TT-\Q\XA:1VX[GDP)N0.G%4NXQTKJC9C'5I:
M6!PVN@H6I::_;V5^_P:), &/TOS,0]&D&(8</Z9P*@NT*/>XTHJ@;'QSP/TZ
M?K+;I9\5F6<>J^-C0-CC/_\UHIGD[8=O9R^?@"Q5X26UH0]3^_:0:; KRCO2
MVE:O?4LO7MVYD_2+-7(RR?I3=*%@M(X :<@J,J#,;:=M9O<5:H;6ID',)WA?
M\L]NT'I<!$]#4UO?'ZT#;B>OMTN*'#O;.0K?[[AVZA:8ZGPV?7=#RB5M0:(X
MP#H$T^ZC;0PZCE\7&IW-CG^I.21LM%_^S*&>?Z)F"@JF=M<?JHE%3*R\!+^H
M%*XTM$IU6GEE\!YOTWV!<NA9%,EF7$_)GLLWY%D-'.ZP6E 8*C!OGY?/F-BC
M;$PV]$@TD%4I)T+P6X["S.NH)L:[$8E%?[_@R;?11M,)XZ4R!MZ8P^:#Z403
MU/E[9[E%)=>?[SMZP2&NUK+D"=+B*T*+S]*8<OK&QY6U5!H$GU@L9B8C:'54
MB82J;NP@'W/1GD'2X;+!A;)!^[J01 1=-8B'I.&-0% ]%G5(W*ZL#&RHF[%(
MZCJ\7P+D::K33M]#$DA8IJ1^R,PS)("6'O79%:9J?,/''M__::\-"%OS>68,
MRFD]-,DQ?-0C!J<TH@;L1+QX*OMR9L$]KC-Q?]=N;DHV]77?P$"P_7O&0<^A
MKH<>M'*S>IH%@>E/0)U3Q>+Q!,8-%X\#G"S'>Y/F6[X7/7Q!'[4-(14?'^#V
M>Y8D].]JBSAU;JF3;ONH+_HE#E#H]4@J<1=R,15K]C9!JIOVIQ,V@ZH$:U'D
M8N^O_%_VY6@D7U_K";REQ0SWJ<I4(KZ0G[9C #J53UCG*&R7_)&KY'L^G:23
M M?Y)%1(#(WW13?OD2*&BJ3(5F'WFO>2XDO+Y\C''T3=/>WV[XNM R6]TB3S
M]3XS "^UB?5"&P2K*TW""UL]U'+@\OY.\;$2^5.,#-X^:EX]'M9K*",#'V]I
M+Z>" <LZGI:=]1^96IJJ,9GF%J4*&WB_MGW929.K6N.4?-(:-G7BX>>>S(3X
M6ZY)'L7XX.YGN]/AQ$_6A9$2[$O"^J(OL=/6C75-OL;FJ$S]3D7AJ(TW#KOS
M7>$EW0" %U/%/_G*QO@_V%\S LUTK[2LM;T*G?_FSF=P:@]T?T"'1OM\T75[
M(4W;S__!UW<YD9Q!D,8E<-2O^3B[=5YA]W4+:7V44MI]%L#Y6 / _IC[P<X\
M&]?L_L]9-_MOL0\:WG [WKF/2"\5+U.B23W5)-291K;^0;8F=+ (#<R*,]ZI
M-^U;\9X2MS%38\[D*%!O,IRVL[+;#+]OIASR[7%>8E'C3\0 IN[ZDSS/VY-^
M/KW4HJ"@O_2&KNP/S .'B9+5<G/L-^)WF7[HFX6+>!4H$]E>OY'+-A!\SLX@
M'0NHDM>R<;YN&0<^^#?<L.T_;^K<>B9EOMDXQ<4$]SY>T^5/*!X4&%,9E9"0
MZ?HX.O3()Z?OTQ.BD"*^A<;9EK3,5][G+<U1MUSHXFH4=&&Z3P#%IN(+?#UV
MNSD%UTT>$6 _DVE7(U^6[PN*- (UX;DVF04C)1+?M&TH3GN5]T._]3B1Q&>)
M-WBO0>B%VDW/L?L+M/$>!R9[7XJW GF ^JNDWZ)H["&/V&MDBIA])S4LO1CD
MI$GE#EVOXE!"2U*'U$Y[*W$B>;5B!<6QA)$ON!M8"R9"[-\M&WYW>L(Z7]?9
M_,Y[JY*7Q<\*?%Y&_Q#NZ_:YXAT[P:W;GW.8-;Y$=/.4'?=DB4W2@X06%H)L
M=(!W1?S=8-4B$DOD_ZS ANQY,DIF\H^2>BM%QCBH!D8[/<$4IH=7$;Q4):[,
M<6L<KP(Y-NNY/E,E*=L_IR%3Z#9ZD:1E.H_^JFSD00?N_OR.)>1A]2R+]D=B
M0*(AP%Z!XBY_8.GL?!K'&..2R/+6JS_S,SS=,IM-8K5Q$@T)>="J)$[?$GOV
M;:N<)%^6XI)8.A['0AK]F5^%C["3[O?6"=IV3[N6YOJ9G; <GBHU<'9N?7X"
MTW>:LA^U;PO2;&_S-HM[3M/J38QU[ @D@GKVWT7)Z+[XD*KK9:H,"!AZ0*@F
MZ,EY ;58AJDWBQG9.3FG[=*4$E\TGOL[_ZR4M^YD;DA!/XJ9@%C)H7Q70GSO
M*'.UA'_8%V"0M8QY07)<A&#CWV]JHJ1L>O$CR8*,N^NN58QDT;V"T'> XA^Z
MA0^J/CRV7V):C_TS,+?X9Z:B0X;%^ZO.9 %'H<(/ GO]"1JP8121%_4__E*Q
MNGJLMK?JJ^%?!YG.1;,! 7Z.!VU][U(]R;T"XD(:&VW J<D]";*"I )_N>Z_
MM.'[C.H9^+M1T1E</;=G:/=2V$/QT3210N*8*"F V#!)^@)$6NBJ:O2VK&F/
M\JKPN),N;^K^1CCR,P?M3^>UU$) >5![!Y?*EW= ML3?F,S+JKG6#%BC4-?L
M]9>)V2B2OW"(C1D. $=-:DVTBK=2R 0K/H+EY^B/&EK?E@N;U&E WQV1YF5R
M.6\4.AD6;)T3:BX"/2D#_'HM0#X0HG#GUI?C'^9^*YMM0%A;<\A]9QXZ6S#Y
M"'6 6A*GP\<N@"(%Y[L*>\'#[+,F,41+V^NS<WQ:K;+>:ZV;K#?:9$N8'=&>
M5)5M.2:.CWSA6D+.G433G]%1GZSP\JF)R*@^7X,3OTN6]::?Q-#T97V:ZNWR
MP2=O-2Z_)FJJRJ7>N27KN99))!RT0A_M,<_]M[&Q8M ;(2[PO"5.\>WK6^2W
M([08F#/U #IL#5LPVDI))4S&'%IG%DXB#KV+-&KV<9Y3_1W:29?-J9J(YYH>
MQ"PL.YS;/YV81Y_''14D5A:D=V"-Y_UGA?I74=#X,\E2D0*^8:$TSNQ.+6%[
M0=L'56Z$46G[J'WQ5^B67]A'9)K\3LPU$2'TMM17:JDFFR;<>=D_8L)#D<;B
MJ8M9=:MES@O"ZE;>.?M[=+I_^LXWU2#+A#P,:GH)&CH:72OWU_P-#::H5W(*
MY/I?D#S+?2@^@.EGF'5IOA9?9*XQJD?8^2TM4P#L=5\6W#,K45 *>6U7+#A$
MUWA5V(,\X[!%*;O6""(+/PY0)>>FT!"5/BFGWGJ?:[C-%+S>>R:R*+Y;"B=D
M0JD[G38\OJWRBLEY90<'"'=>$/Q$VO6B3Y5IM/L1?P9K:LZD,$VNI#RKBXAA
MCU/G]H_V.N,IY:EDHSY$Y9@E\R3@L2+Y[?1CQ\?(EUDSY9)%06VHQN(]L,0#
MLL:LYD\$^9FE88(6OZ:YDK.UW72(QK4GQLM')LJ?#A%-:#46KY'R?=SRA4E4
M$K=]#1CXMF08GDL!&$%1T)$,EVNEOA7BO"_ K.TJ(%",9JB4JO9YVQHQA@.0
MG.L:/:CENUP\'K00ZOE;$NK"3!+WI8QO.>[1+A.CE@C+JSL.UH"YBXO8+(G/
MLTT2BQO"V9G=-/J_$Q*9;).O/OD4KZZ_$^N/7<$<TEJ/.KU\5Q:X3?Y57IU8
M4>G28,_BEUO_CJ"ZZ;X82?($#O T=^M/!0X@L^C/DRLH,&^FIKA81Y.ZU"6Y
M)[Q+)M:83YV:0AW38?VXDG78[567W]<EXR!C&E.9]B) 2F^^J@0!AR%)A-KW
M9Q#_$)Y3]Z.:AG\J,N_CSQ[P/1"<WI?\"HG6494UNW!&])PM.7N_ZNO4#IIB
M<G(>[!&F?)'V!Z%.5]!)'N]1:<MD%2>-]K0P.WT*Y3IP^;D_=:$9]3:128C]
MH18SR0=W21FONQZZTPR(Y@7#+OO$@8&,BF<- ,B;'R.8WUNOSH-&">5Y_ZH-
M.<T?:]EIUSKDSS;O;1Q7&@NOA),T% EC[*HJ"ASF4<X/[LJU[3L#X>>*>G^L
MXRAP ,>Y>>SKV(F,?=;YJ\Z R)^YBJPN_9XDEQ-1_C,^BW1GZ=G_BV[/-%U.
M[F(=Z$M&()RP"'1 (.-EE?"@>E9K50W;/J9QXH_+EG^^/1[1$ZOJ$!W0__Y>
M LT4C4E-22[.CUQ.D"GM<6DNZ1W3Q;,M?7?@'ZE-]4[>A'9&,0BZ.O#);EO2
M]E+RU<G3R2"WX[15J$_.Z/P,<JB91F3K"+UG94SG=3J7D;U1XK<]:4HL**"3
MJ*7[EF$7J>MRTKH'RB9?^G.(EFE;NAR?F#6,#9V_'L;VUQL\/L ^$R<\?#['
MFX(]2>WY(^2:5Z*?']:@2_/5@D-!@8_$ZZ"*#1V/ _!7)3(B+-#63I!,^A94
M>U49_*^+:G1= $F>6U"^A#<EH^1I6=7GBL?KT-XA%OMQ:0*!$.EXC5=0+3KY
MTX J+Y\;.E3<ODZ"05RPG?#M0I*OECS/3 A+H)>HX\X:24$MC;\7$G+K\1R/
M.W*[=7  JM0=.PZ:."5P_YM,MW7]+E,T1*,)=B'CG(7^@YE'YR\BAZ>! X1_
M<WK0+T:7Z"^"M2K@3]<A03YOO$PF!PX<^4E@W4Y1^N97I9<644IVJZ6&D9FV
M5@:%A050<)S_L-=!:3[/B7A-L &H W^ZY+8[[5A!%_5O. #;/UHK3.2LQ.[H
M51F?ZD_;;<ZZ*V$?2Y2?!+R%G? (V1F"^"@"ILFTL8J3!6?G2#\!JWL=-+Z:
M@PS:L&1CO8PS,#7 (J%L5GXKC.(/-".EOW16POJ.86F9RR@=]\RJ#-,3#@1_
M9,^[+)G(OVO-%R;;#S&_<8"LJ;7+[6.;RO:TPPX<(,8H>6-X.'AP3GG&9<IW
MO_]9Y[RXM+- -Z7@3Q]Z&<W.#\G=%#*)[P0(WM_1GM 2=!82._0ZB'8&H;LQ
M^Y>BLQ(VRIA%R7N.:E\O>^=%]TR&\M!?4(@6VB;OJ8D_U@N]BM(_W<:UB#!!
M3%LVX.9^<H6PX%DN)>THD-=!.2,Z%P<0J*S$&@8)5@N'Z2*&+Y:\? Y.>L]
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M8QQ@E-X'D]=8.;_W>'='-;HY_W!QOSSYUL\ )N)&+ET:6"D_>86RD='=%5$
M"U5OX6<A-GR$-,(?H,X-)8\]]EB=QL;%-N$ T[SX'6@L8;B8L NY2^V725@)
MT*%%U,VEA%F@1$4_?DMNP8%>TS(NJK^SBK':C$-DT?8'V)+%K) DQ^]!'G.B
M]G16?+V6M4T/Z.]$VA67LA7K@3]I=$U/J <*:?JU3L/JAB]UQ;E S%B,U8M4
M.-<J@HNC^?GA(YUO4@DWUVB@:UX<X(U/"0Z HG%4OYX<N[HPV5+^_RQAC-R9
M ;&*I95?915(2CH_ZE&J:Y9\C_C)LEN1V/0ZE3:D>!6&C77@-UC(+9*/)_G<
MRYQRU)]0[FLW5UD$CF)+JBRB B(#H&T7Z(>C[93_5GGGEUZ*X[-PK\'?@J)0
MEE9Q$K=QIU**S)9ZK7%Y%NG<XK*2A*_A.2Q^&RXJ;G5N-UT'P-GVHV*7M;36
MBQYA"PNL"2(LC2\A@CH.*8XH$FY#_,[@%+SK_[U(W47K?2RT^1:T@GRDMU@@
MZ67X36/ M.1[S.QE \IEU=AG\-7N/H85GUC>R]>]49\/<*!(WG\4>(H,,Y*-
MZYC4D&VP]?!JH?D49O(AUB(3#+:M5V*QUI=6:-M%ZLA?$]!CHJ0.1=O/#>#1
M.$##S=U=A O>((>7T$J!'8?$$:CV50B"\30229^EDYXW<\5_???<9/1JVY5J
M;K#5$ <@_;.W8,V9U1G?.XGPC]H*]<78&NK*N."7B?\.&O+X2WF\'O^4$ %)
M% =67 C]S8WG:(*=A](F+HF#&\$&F03ET7="\_LL\W/?%)1R0D,XS4=AD=$<
M-_YQ1^I1>\[P<0-ZN[W$/VMU>N ML8VC9:'^:V.'F0 ;_DEJQ_)X>I4.;N:
M\%!&]>_%^AQLJ=NH,T%!4KG<C2A!*S9D0'[9\=6&3T_5EVQAO>,[ZR!+4%YE
M?NZ""$^)#AS4@KX^R6MWAQ>2,YHUH@QBLOSFA&FZ26-Y_.C?4^)E7&H'6O[8
MWE=;6Y23Q/O]B+E!JU/]Z62@Z_X<5:C:;^U^@?E[(F8Q9()ODSB?P_D)[L9[
M'50RK5[TN^ 3&I?_>7)#F] %I8F/B_&4SH1%LM?9G\VBA8F:28WY(45-.V1!
M?GG4CDF.9YSEH_*^.QR2NT@!3#Y:>H+Q\;\ KD7CY32$N9 0K[NC1$Z^B]-.
MZWQBV8"WB7.HBUFQ+5\*Z9"!D99><K\6Z[<\\\3=U'TZYYL6B)8]T*4F\-AH
MYU7G4K;Z#-Z_LAS/&?5=)$:GLTZ<VGN=IQ"-4ORU9=">=795$RD+G1$=&J4=
MNQ5^+9TA==98UR%FQTI\Z&.2VF(_7,/'>K\A'*!V: %X777C/A:T=>AD#-?,
MM16*J_E"W1/T<#<^F[:IO)&W.[87&]=DY7(!Y5KP1$WNPX!UT-^JP*]8)G5N
MEW7$V(BT>I"@YKM?7PY:1S=NZN$F,Q#^-D%OX ##T:59;0#3Y70_,/8JP,JY
M;6O7Y2 81(NA":UAYT.K".  /9RHCZ9OI/RD4W^DR3[6+57X"6-3*% DE9B&
M/:='XP!$%%AU/%X13Z[&2EU $.T'4LY>NLO%<UD7=J ?KT86VLV 2M^.WU]<
M!J4F].C8&3S9A59D\@<0,M,&5'ER8I2QWHP#PYL,5_D[AS%+?+"30&]=S;RB
MY#O5P@Q/7;T8;+AXZ,5UAI[1TOZLG@^NXV?6+N&NK'\]01''\>ES]8 6,J",
M&VE4YNAHW !9#!AW7?8&C\PUQX3_79C/=UM;[EA%G8JD9_J7#LS!(N*([.U]
M-185F1,UR)^9W]Q03Q(Y'UYJVQPKS\(7FRRG,,WE0T)O&HJY+JQ'MXU1<-<H
M5'3=^X0?\^,5@<__R=2[3<ALIB.G;Y)O6?E6&PZP+96<;1=R(!4?!*T5CR]K
MXM*5#UNB!S4_7_!%%_8JC$R,9_SP/IK4'*R@.U(@L[4D8(FE(KWIU:-U/7C$
M,/YKHTEM$[%Z1.OB;%Y+O8#UX-%-(:_WU$_/\<\LS5CCHGO]_I'SP=YO'>TD
M1PD\*";$:*!U1I>$8 _-,-F72+B]S[2RMQE2VMJYM+4I>>X-'CBZG_CQM";R
MQ UJ?EPKZ1+]I.HI/:1([16CD)GO:8U/?;SJ@3^V#X[W&!,DU&L\SIQF(917
M=ZBGZ<=KZM)+J@WH5*U7NC5M^"A"'DP$33$*1U:$YS,"[T@(:D9J,"+N]N7L
M(JFD_M^^AM<'B8.2X(@5WN,B=,.2L8]&,]_5A>,9Y070>N/\YP,);UZV>>I/
MSB-Y@[_7K/1[GN6_33U6[@\7\TG5F+TM#+MXUW[,??D>58:';JF,G<7>$ U'
MZEK(<ZS0&6' !4, 5Z-=G4Y6!#_2R(4QN\*Q0M;2 Z%#(.!'D!]RS^(N^2BS
MAERD:] T#.JRGG:T6A9, NHHE4HGU/0,)R2M^Y?L#N)5Z75V#(H."5>R5R$W
M3OPI%E7U(KHP<C:)2,2#*\E?X44]^82[UOB'Q-[[LO@L6G-PF"EAOW24.PP)
MFCRN6HX8BH<\P8CG[?Z)NDR=;J>4E-# 1'2?S<0EFQ@)@GNTK5!//DZONS]9
MXW1K<+^>J.#1"890SHY^PWO8)F:IS<4<:^_5JW4NU=F^_A"#%)/>'.Y97)FA
MAZ)P@'9A]5\4LZ2:LJ$5TN#.]6/?1U,./'K?*O)YGN<)O/G-H_VZ//.%WQG>
MT[S;E^6SQ)\>9[JL<4W3)\8-F7DO]4.RD?+30?\;<^\9U63TO0O&B@U1I+>(
M]")(%Q B(KU$2D"ZTCO2D18% >G2.U%Z[S4T$:FA=PBAA=X)-1*2&WXS'V;6
MS+T?[OK?._,%UGK7REOVV7L_SW/./OO$!406BW:ZO6S%1#N:NDZOWV43<:?H
M"N31 S_[S)+"U]/Y'GBUK@0^LCYW/K1IBUL8:&W,VN#+Z]@9C#LWF$>N%[YX
M[Q<2V=51[Y(A5(5)D6K2"WDTEOU.VZQ(H.87:V@"[F.V:<\.&?Q,6Q*CM<KA
MZ ;%L32AZ]:GF]I$OLVC8D89Z0_1%RA9B5(+IODA2XM.78VQOM_)FG[E$6GD
M95]4'CS9^HI.84D@&H1>&@@5;/L&>XSG<5_H8JK'RP$'!8L_+'JH$Q6/12G>
M(-FA\W*]M"0WTF4FHO]$LC'*.%M(/%'/V)U;8Y)5<5%QF2A7DH 'Z;[[I@[0
M.%A_=V$=M+,\"4@E?7MOX*P&_P:GN,V?(,48M\4=V:+5G)D'\U@2".6!F#[-
MUJ]^8U/ B8'<)^5]K.S FT $J8U8Z!\)_T>XC[O[042BZR]_!E0YZ78Z95=8
M$46?+T65[S+F*K6ANW:-2NM$RY:3:"-S$0JZ"C*WP1Q-=A8E%]Y>\P7=CPH^
M4W%.$#^N(7HM*1"O:4+;:H23P#;BVB^&I"+G_!Y7N+8X'>HNK7CI^_]!QH%C
M$C97Y[Q:@H*1M3-;Z4$"1;\"]_)*7C9DAE.1TQ05,IL10XJ5   -K3T_1*\K
M8%;W,W(G8 BA-=0MD/Z*MX_OKDEJ2^<A=UJ>A_J4;_#N[/$3%=G,/DB93?[@
MJ$71BV+%Y'/V@MCB?I;48%IN:F*N$R( @FX92!+Y<DF_H_UH=\*<.Z/N@7Z=
M_:ZO'41G=.5,M,L[A50VD*\1-=?C[AW.J-MXQ?'BB.AP<]]H\] 5>W>?H5Q5
MM[5][K*\3AIT/.&(1E(<H(L^=)T^_1G]BL4=_#:%ETW$0VI-8RU*(L_+F"M1
M_&K[1I&O--X">E>:!:>SW18AY40D2^D6.NV_=](M@6X( US]"V3XQ9"!G@K=
M:C5MRI:G*T.+O*4K;U7SEG9VB6+,[YB_Q(3%#(H#>9^".F>@&5UV%L04&G*8
MM)CX=QK9MK;_5ST/*S(LKEY3_@>"?J&7'KR#/+=5N)C3_3*I^>[>*PNJ-P7/
MA5\T,NE9$?6- @>>?.RPOIB; $BTG,*F-)U&S2\ V:3M3J%0#Z?/GE0[G;(-
M0C-A$52XN29_3FZ>HNS8]YONRT7<LYG/*FHA%FJR7(E65U,!O :ZRU;*ONI$
MN[J<[/++[410&^T.7N!-FLY6V-=FT_0C3 \K]D@1,2@:AEPY1O+'8/G&VTAG
M"(+B<??=@DR;Z[=C>HG)W/EJP<[V*V[CA1?XW)?_''R= "#IW$2<$@ ]>0C^
M@W,';9F9O),;"OMIU?XM)EJ71.;OIM^VI&4D5>,3MS:%XVA#G_HG%(B2N?OF
M[#U,1HW3B*_^3OIS.K^S@:.RS!3G-,]+O0:1B2U6$%"ACV'1^RIVE:^'B1+9
MUT0;^ARX:G*DTM+*[!9M[.9INA,=^<G=LF>NA6/"J_DVF![<R+-1M\;T[OS?
MK43EYTU:*;2D6ECFW$<(7;8$UJO2L(]X6:)+X4%N)!CX>5 FTL^FFD=LH:<M
MN@6">=(H>8/G2V[_FN=#JZ87-4V)'GTK6Q]L^WH*XKBY;)9CY:/NF-VE6441
MC5G6&K#=TG1 @J>\U28MYNO2K;D#C#:1:+W-T<OW9S,#;M;E\(\455>=DLI9
M33-GSLF<E9[1%/>1_ [ZAM![B*__36)*^ 'MBUM>5_$$'9WCO5LV9PWH;[2)
M)765;6S-Z:IE3,D+Q3=PEYWFSH5F(-YI:'_F7$* %6H*N'0J9,X>C[T:[G[&
M.AI\9KS)@NO"4QP_/">.JQ24)^*VG?G'J+]8\6%44NR^8V-NMX+<-Y0(B$[@
M O'YP^K@\.MG(;QQ%B_27/<^%.G9K-*$47FEH$V)%/ ^[*!T,&$;]0O7]"]P
ME<QD-Z-QZG+ST&Y53'WM7WBE1]Y,-]KE_89+L='-AIZB6Z(Y7:D; I1XP"O+
M8EKY3K=L'I]R][JK'OBU8L17"=XI:NW#&Q/%@O=60!V,WJBM+25?QK[H5:2^
M<*46 EZG8#G<_:HHLRZ*(UWHULJ7UU<5=[JKDR:(IB48!*?Y!_?\-\YG:VLH
MV@L5?OFGU]YW<B@+T9$07,1(.3&CQVV:ZHVK4_[9"]$R$"Z'L!FD!HHE#A+S
MV80"UFD/U4O4V;'U.,ZQ)36/E<$]OZ\'RDYK=J,H+NG% N7-PPO(J?R.OJ_F
M^*W(M2C>1!"7GF<$92Q<3O[QG:40E$]66C*6:QI$3P L4<+HH2-E8.=%H<O-
M&<9"(OPQ-WI,L"#8'K)XG5%;FU>_R<I]W'F+#TP=5-3U:D=SU_"'PK.!5U>5
M^"CH\A0&?UYY"$8_[#FOK/ &E^B6>^![NG<=9A3TJ@YGP/N,JO$VX(3>]9S,
M'ZVF]?Q/$Y53B@*;X<<_'D.(*;#4 92DOI.$M< =$PWZ"/=F<]9PP*H+&HX"
M!V,;1R\5(LGW. ]H5?>ZH]U7!.BA0'(5X5 C)EW&MS5]_:O.;AHW;51+\-LH
MVOUSE?RNUKHA*-\<V9!Z%_(]4Q]6[\BN6G*]4C*DR3./*>F3X[WV^OI6'X?.
M:.7-35R-UVG<+38#S;&JUV/CKX(<'U_E13YL[:0D>!&,X_3!JGOF=T7PB970
M8X,[%S(>8^+,[3=^(:<C1Z@&\SI$1 U8HO,BWLX\UFVHK'5X$?G@A"95QW+<
M5M_$?2^M+7%R?'L?!CSX"5H7P%BUB.9RF%GYD^RI_R2:JHE^.MFBI[W6YI8\
MIF.5^V"<4H/.R[R@=%9<.<Q[B#9)WKC*FG7,@(5(P&0( !RWS]+^FT4DUMFW
M#\GH65M7[\EQ=',#%)T6[K';K^VE']%UPT,F?:C]MJK6G>4R7PO'69/:1.MY
M:\T\ZU$9^H2KO-('?;&P7GM C_WHJ3Z] 8K'#HYU>3S<V\+Q.RTM3E\Z2!_F
MO+3'&X@%Y7_FSBX(-2L004*?T3UG+;HSCZ\@@9_)EF/6\+9 "FBJ\?!.Z=&A
M DN;BX]/D2<[M<U>7^19-=!2D<>UIDKG3?RATJLAP3LL;/-]UY[>3T,2(8[Q
M?\5,A_X_7_RVC2A_SX-6ETQ89]".-YT12O:9/.26$M A)AKR13"U(%+VZS'E
M76AY<]MIN ]]V7#,$]TZLR?>F^<_+E/58_#Q)]^-]^U#;%&S%A0J">2!JG;G
MAGZU=-'_/HX\.^,\H?K/LQY\.O/8#LGEAC,[7WCMTK6,-L%5PS6UTW\4F@!_
M65*:QLM<J+1G/S\YN>2E=]2I=QAVG,TY_&;\2+\\)%\\+Q(R=*BU.ISRN6C)
MH[IF,[I=T"NW8)Z]*%!Y>TP52NKO1WIAMPXT7_K4Y!$M62W1Y+\GE:1 ^;!O
M(6W(3E1!(%HQJ4L8HJ!QU^K]!"#FK4OCK?7/*:&GE"VG97UK>G1<9:7HY,34
M.Q;W'P37GBNGZS2(W @(8KQ7XC?14A<FDDIO$,I\[6.F=;@*3:[TTS]YR06_
M7KVOE+KM0[*R8+'#-#,G-?:X?<]OOW&C2IC6IEZ-XH1B)X4CWT636Z*(*OHO
MU\<H-KU7-C3#Y.WV/DTN(E&[]=UU0'+.9Q;FCP6#BX)I^<KUMUF7<]9:'NV^
M.O&KV1-T-.M(_ Q)Z"_JM.Y4ORZHF0J@_4F3+[<^W?W32?:A;I.8CEFNQ]3;
M<?3I/P?&8OCZ/ TN@J*6R/-3O_YX$*<ZX: \?"TVLZ_&&I]\:3E0(.;4=WJ*
M3&^JJLD4KKRCIV3R@/, <_O+Q*5 YW=T% 6YH:M<Y^ ,U2@"&$B19_&!_B^O
MK^J3DE*0]L&[3T)=Q:T56#FXQ(5YN?Y:G>/O7=) M7C[>0Y'CX</5D>#"U<$
M:^)+JI[*V3#I6)A#M:-S"F)?KQKL,[<W&_FY:1GJ#^K*]CK^NU_*)=^. 6@_
M_L*C?X]^Y]6E](#=L6"'D[LCO;["I]0:$3O(4"'[-X:X-]QV@OS)J!&@W=0I
M4F?1JL_\0*G6KJY6GBWGCU)X:&W>JY'/?^=OQE<'7Y1+YSFOCNZ5C/DXU(G.
M-WFD7"_)Y.YC\%K6"OA7,YICFNHV_$#[QECQGO&&V.TY=WF][(,(.? 74]K[
M^1!K4C5WVT+Q7RP%4I$8J+.30Z3>I(&GF?L"9$>U3A,F FMWWP,LMWT?'ZT!
MTT.:$$_-HQ2Y9M[(!Q\^M;2 O-M#]/S8];3S$SZCULJ*CU()%?&RE2%1!)@'
M?XSU2K^1F3*/Q3B,CI1\")B?)/F 86OV]I6_^;A@,OZ6]N*-64%Y"0D3%KSQ
MF'U4QW3'1[-_9O4"[\MJD5A5>1,.!95F\_9U-9TWXBO9Y5F%Y*/:-,P_A637
M=*O>]IGRZJ'YE$]7ZU6X\*7E#HQEYKIRS^]DDC[^0<MH_:?DG_XW\T!]4_5U
M$^<IVY:03:K!7:H91L: _@\PPR\);K:%/]54WMDH/S:,095BDNKKRJWV,J<#
MGT<CUL_@(M+[G>O.?^KI?^3?"Z7D/?Y^2!F<^A(=]82BLI?A0Q?K,(:GSQ,7
M5.](]=AAE98E\$65"%MDE<KMIZNA;$5W.(0+*,)VQ(G:'KF_.G>CN%>:74&_
M\]D7@.;/"$[ \SM/36O8RQA+,7%>'H[#(6652-V/)S 3=CF7"4EP607++3!$
MLX25'*(W8SP:_51;<;Q!YX=D5H55$O8>TJQ1K)SW3(S.[:XCZV1?32[U]>0N
MI<[7/SGRL2&P,D_$1_,8&0>G8KTPE/!MV\E2F.'PM=0GFB2J]/4KZB?S1N&3
M4FGQG;O60BB-J!FO@28E&3E=2H:1'?U-08K@.G&>W%2%6!L]2P'M-[2\C^2G
M3*L=5Y!&57UK7:+QW1YCPD$I]PLS!>AMF $4-^I^%7A-A2C6\[G"4?P.Y2OO
MOR46W^NB-&1^I&AN]+J1/>?L7=E+K6@50Y-^]?Y?"T:AS3P534#)\%WG:*.3
MJ9D(X9-SB5]1>5$Q=!*?BU8*PL#7'RD5NKLL-,1RRQ?H@NI.!6>12);!2)OB
MWPT*D QW 5?-1]>YH=\>K\BPQAE 7<JSFAH:W0+>PL?02+C0ZUEM=HK&IYL4
MXD^Q 8!KH&D"@,.S]>+GS/0#47J;DZC1:=J->O6)V<O/H2^]O00_2?8RR83W
M"DEI:ZI(,AO=>Q"E+%1I6FVQ8F!4N):JF[AE][U?$_'IWTS6T^O)-VJ^7"M5
MO_VZ6_&LS >.TJ0Q573X6/]#A4)G\Y?..Z6'MFKOR15S;ZO)B&^H]/AN[Z3"
M[<ODH\W=':DKJQL$ZHX8RT-G!\"IJ3_X,MF$:NS$\EA<(FDXX:9&C\][ED[S
M^D2U;?8R9X!_5703*T+0'6HVW</K'.SY<3[5/L^J2Z@*73:76D;?ONWDVBX(
M.T!K1(<$W>5B"[5DC55B38L%KUS$O\[7^"BR,<#?Y["&$OJ^V8>JKQ9\X1"0
M;>WDW6P8(A)Z5[-6^9B21S!72M4^2R2%1?=0ST2/KN4KF-F =.",+=9"D !P
M 'Q<1,QJAVAR]]EIYL08AGW:\&I=-/+?4:O-#FKFW['B]K7^XO#ZU^VO(8#?
M-U3ITH]9%8X6:B8I^E2JX*G95::==>32,TF6G(/W+-58/^M8?%/47_O#EH^C
M<RIDS9]5N>XK(#5=QU\R>[=-%N)W;S+3T!VJDOUK;_6<B3E@>"YHF*\?5)H%
M8U&>DE:Z?!@J+\MLD%A>UK=2E%?6LU+,[4)[;S9)L%>8.)(JO!&?K6+E+4W]
M<^+VW@53U,M% B"0>T4OKA?\O+$"V.++M&KTB'VCEQ(NQ,26/!YWQ#I5X#^W
M6586B#4[:6YH^=7JHPR_'@VO<D.:71]]>G/485<3HAJ)C?)NG!0:VLY]Y4?6
M;'6&\'XRU_XAY()-L!>?J7R+9(W2[A2D)[3CV.>P:]7F?%G]?>R2U9U7H:=:
M:U>]E&6.;'S__Z/M\I/-L($G6"U/ZE[^Q!:_(QC6#3?>B7N#-V-4&9LQ;DQ-
MDOCAJ,JT,;M4;)&5.XA^0*N0G1_5QH-.S/-K2LQQ\]8CO5N4G1-'O-M;,BA4
MQ&E="E=>7&=I@AWPY=S@.S\/9S^=01HWK:YW;N5FVE-Z>-#-ZO3J+F=Z5V#2
MOH2S3R-'&F-M]6V+0HL*-^-0/K_LL!T6AQ>!V D"X(]C]70*?ILR;:<5AT!S
MNPG[*_O&&[!;FX_^%MR.')_^(K?S^DI=&T'_M+3M#M+7$P!4U%EM9WSU5XMP
MTIH36I.C8SJCRG&C$^VD$.'#M.+N=[]&IG"TBE?[WO4=H'\^"Z9XX@U@@QTB
M%3G1/)G05*"82QJ?H;L916&)0TAP$L.PMI:L3J=EVA]-Q<(U4>98<=)XHJ3V
M@2YQC$^_!,6:="LY"PSG^EE]P(44SNTJRL1L)_FL+446V2L]B3!_OTI=>?"]
MC8H#Y?/3#!NQ> H1PW'!L#2.#'ZBW-(=_>XF??8Z.X5?S?1G7IP_KX2O_"Y5
M BB.'T[J[@%O9^EJ:=^LG("Z[U6ZUU]V'F)(" !:HR " #78<T6>'=P?HO#6
M/M5X"FK<EA (@?;$/9V5Z@WJ===A\58ZDDARG1Q7J^'F%#A<(@#@Z_:F54<Y
M7*2W6<Z_I_Q2D1;FKKY>2?R23]+^OH^)"H<9MWR>/=-&Z__.\PQC_-NM_*.V
MO=Z9NL_='SNH- ,EOI&YER63(IN""1=\1:E12E5>_Y0]V*D$.X7CM\U>7(W!
M@PN[4DG^0E"Z HX-G=WZUC&C>AIK##L/A-?)NU94&D0UN9FZ&HR9[I1$2=>S
MR/SH16]PV\WZ!@LYC<OHOM2'%YJ'*8=9LXY>S5D[#"6^E$IH;.7%Q2%1"6IA
MQ=O]ZS)GMWG\M*RHQ+)\I3SF>Q1B]7]Q6N,7=F:=V']J/^^]VJ&F7?T_7#@O
MRL>Q ?'F_$<\!$!7 >X;T9*B4U<M%<#GRFRD#'X<N'Z,$IA\BNAXPHYGOPJ+
M[UMY.4]GM+ ^KL25@"'O^D"WY?&M_W$W05LZ1:) E0?UB+'&'Y;Z&8]@2V6U
MM$E*E[IW<!$_Y+LO59T@[W1QYE>S'O;8JU=X UHR,="!^?GZXXTDGY6SQ7>,
M[@/7[E>*EJJ;D+RK2:BIW&-@UX_9LEXUCS$M^FK)_R3^0Q5W;,[]JQ8AX&@\
M><RPS# "UP=-S>YB5 T%]OCRVFLSO:F<+:.(.693:ZT#@8G/TEO';..58->A
MB=(^GSRHNW=CFLX4/!UQPM.D,Y@;\/J(C- FNT([#DJ(1MC76P\YZ,].F"U*
M[!V?A1;3/KO(YNYX!';?*ZW^/Z/##+J+!AWD '%&?C "H&7*[VJSM1-JGP!@
M,B;^Z3 !$0 -<5<7WT+/U<4P(+PN[!4!D)B'PE[#M*&I_T%V^_96=OVN5O_&
MP!]W'-SH;;,2.']>D-8W?3KO/."-$@EC9IG'2#YZ3G3H0^@P'Z@G&W]@10!8
M6C6T77RX6J(6)CJG.109+WE& )";=)=?[CA?"?P*DQ000*(<FT0 /.^#AEUF
M4P@[-?Y+^K@&1WO?06@[M$P$_)5A?R*NKC6ID_DKPEWC(;=U7F&>DVK>_#;*
M!GQ$@@WT\/B'EVLC8E="_2#W:COT!7 5.[L ]%X7!\/FGL>7SS>).3D]8!/E
M<1D#:Y,7<XG<)!\9FQ@/%-(>'0CO0_#'L6X"X6<F<DS$=TB1'"< SB-%.?!;
MFU=S;FP7_W/]?..A+\K36VQP<&DN#_Z^UK%V1P?4MQE-AQT^,K.='O)LGHR!
M?>X-@61?.>JX4[0W?#:YH^_W]X]Z;"/,,O0^Y>Z0C$[<2%L:]=_,S$[? JP)
M+L_#$,C$R?%GXG0/>7Z$&61"[3@D1,QIL@I,Z2R:(VEVY,W16^QYP9760OP,
MEK(:O,?CSF -,OB9CLJ1+C86!SV7/62YBUGW)QUJ%CW[*-KUYQAJ9)^N5SZ7
MMO#)(XBK!-GD>2O:I9Q/A5F]JK\/VM_^ %-5&2U+?!<CR6TL#"H"C312D<$4
MKZYC,F<EP6@F]H0S?G?T/Y75# Y[#WZ3W>XPI97!U;H=I"MU.&)LF>7]H#SW
M@_;$.[/**3IW;-8/B=:4(@ $"(!U_G'H3>FG.#EL>UW=)8DGSA\KBZ'.AD^J
M+43,4;Z4"9^Y;*H_>[A:,$_A=K",$1'73W<4N]Z?7$TIG$#&_'U<]IF-D_M>
M8%0+WM*DWY(I']N(D5P9PM2#:"7(T-U_!W>Q<B,S1NL8T)/T.<GV?V- DY1.
MA^96ZKM1"#YD<:]I@7ELJVU8;A(]?]1+SBHE(14PT6DS<#18#L@1_=)ZUW[\
M2=,;TJ^0A1:YZB9YOP255(=>IN?U1MS:E[&Z+<^?Z-P1V<2D*KHC=2/Y/Q)_
M^ODXY,C[:NJVDW]M":/C&-RU: M-I';P'=U^X#@47FG1DW=D$BKIJ(J#5$\Q
M\#[_*CXI<^-M30(Q.LA^*&G]NUH@U(+'88>(UEE()@ 8#V#<TG>AW"7\ML<9
M0!U33Z9-E%$*QC^\U&I@K]F!=[]9=+"]<^";?;!+N/4J%W?E\X22$*84Y?-5
M_7N68<RLQ,#@Q(.@KX"Q!$"_0<%IO1D!P!.]NJN+V@YJU\KO<>A88$1';;14
MUWI"@]AAY16-M!NV/&>.'G3Z8;R!DV-HFT-GLZW"!R>/)[7I%*6(,0I>A>!Z
MEO'FC.*S]"&NQ_.>Z&Y?G/O>P.KAT(JGXMJ1\]ZOKZBT1UT\'[,1LK>$]>[)
M"U),+"F$>>4'!18I7%4%Z5-?S6GNX#7HHYS20$+0E+8C/I2&A=WA.1[;!^6'
MAG:(*:@/FTJLHP-&()9%=2=OWC!NU-=ME^-9C#>U!$6,Z,8^W\VZ2XQ3.2!'
MY0%L (:GD%DP F-XJ%5:I9]!.??RME,C@T9\?G3'_K&Z8&FP$6ADGTM)UVIG
M@ R/Y#3>TP!KGWP"+KD)<BIN\W M$!-YI@]UCH1/O?>0^!ACVJ0DO:^[_$J[
MSF[)D/'>\UJ5'W\'9'^$+B6F:]08<R9U[5!F:WL-I(KJ *+=][Z38-KP^K5M
MB"9TU/EY(;RIRR1.BML'YNN4&3K;M%YNVDV4?!YUZ$+E,,:LL0D+(6"W3E@N
M6XF($^G3BZ+4:$IAFRRB32 F."Z%4OCVC9JV^,/V'<:$(''P&O90BS+N94:I
M;-1%F'ZJ/0$0FPI]<'<M/[9#V\G-[G[@?X!H(FQKKZK=G*MJ6AH^G6Q?^D1H
M9.700 $851":H2P09FTSJM@K;\'VWO#_V"6^_8XH,D.6AS#]>.^V?KN*MM3$
MX=Z3P56L%FSK55+[0I+!ONG4*?L\?FW1^>"=SNZ.^IL0:N.+3QKC*M]4OVW<
M%!#AI.7B1 =G>B\0006X3MU9_A4X5)SC@?3]B'4]_)>T E0Y-1[:4<_$.HQ4
M+TF6N^ZD)TX59147YZ0F/6GXU BJ+\_2]W-SUWO_+"S7>8;E9MR[T:L=Y%1D
MY[H4E,<+O9[B:@EET5SQ^?O0Z /SJD\C$2[:8(H3.^%-==;XU]6*M']-=8<?
M9JC9P=SWZF1@.1+Z17<+B[Q#BK>XBI[%W@O[?'J;W3R&_981(]V/8A:NIP%W
MGDX?7J&U43W_^UW0*@<!<(_F/"CB'"$;MLT?OC!07'X!-C_C>.W0HTM27R#6
MIJG98D&UVF&&3K&VMBHI*FO_77,P^C;FLDNWLV2251N_C7IO<B0)/C65_DP
M<+8%5(Q:8 Q<\E>8,-A#5*59%9I6Z2'JW"(HU:'^H2EK48#W/X:RRZ%%'0F-
M!P>]4MP(B9N!^E=;E]((@()_6<5V3H9!NN]/=M7\U&^XZ&CK#%4=5JNQCFGU
M[_/TC'?.RKN\KS3MC.QMNPJ:+0+@6X%[OJ$C>*5C&.O0.77!(950L /[<5<:
M+%++*9CP\"EJYNWK(_#-V!=OWQ7=IP< %J\Z"! Q_=['(?NHPBR\FF2QL_D+
M^B=E\&UL!<YEKBF$7\?TCYD C5\1-_>V[=I35HH:;>%/*KR1'V*Z(KQN$&F#
M3C$!0.:.RX+NFQ+QF@ X_D3\OWV%<85C6,B9IX9O%!'0&0@ \<&U#?^N6:/J
M"4D$>NHO_U[Y!WO#OWHX'=F+EAH/>>ZF7=NEYQ1M=K&_2O*2E(X''GS_K+7_
M'Q[M[QM_+GFXCB5&RY\@T,S 'C@2I72YC[U_6'])3P!4D\!/\=-XYLN%G 4B
MT0-]@S(F@D"S?GO\>\W4(VMY& -#SS/C+?ZC[(6VF]!D-:L_@]%X'0-8KF0Q
M-G;$-W^;$3O64G\((@U=<'4?1,U  O*EX)Z.T+OT:.<+.TI=4>[\79ZBM $]
MAB>RJEVTC'Y3\#K^<TTKS;,D5R@7?G4V@[I*+-IJ$NW9K>'$-[C-^-5 A,GL
MD_U 1D9N^1"Z($B84D2K0M%FB^FES6I2Y\VH'X-:[1SP,R-?*KR+2<]"D[>3
MF3O'6\_R;J;O2-"?T_G.+IS=;KH[R>M>!=Z:\8JQ#[\ZUW]U+[NJ!RWFZPE,
MB!R?/.&*$E^-?\&TC7H(0T1CC>VAJ[LH D#$AQ^][V":=]YT1.]CWSJU/12.
M-/F8]^1&A4OREGX!9N+E@V;QK2W].7\7Y0K3W+P_Z,(-&ZX"ZY_D,@JD+5-P
MGH6!J<5HQ$)ZO-]AU XTH9:1 ]<(K\ZIOIA-^@F79,3Q>)SJ+,XVT&+&Y%K.
M&!4S;#PR^.1O!@F,5\:\#]#-Y,P/"ZLEXH ;T1,;" !DF/0# F"UGP#87]ZY
MJC"0P9L:C((#H0-66 L<XJ^NUB+\:(UJ#0%]#HZO>9-9IH@I;P4?EA7U*3&^
M*E9UH7G>RZ3.;* !YHT_GRWJ>9P=;&-\=4#1@_\"(0P)/ "N[??"$C)01]$E
M30N+Y;:^RC-0&A\MVDH)<$W3[?!/FL,>>7SU_,T"F/4#TA0D#9T2YV(.<CJL
M3IARYJ7OYS"[P4<=; KP,V5@/$A 6LXMI-\D:('Q7_=2B(5G^3O?6,2>*M3%
M]\=LC=[,08O%0W)]N8!L<7:0X\JA<ZZWMK+9Q4Z7N$)H6$W /Z)'"9GP7-A5
M2-"C33P]Q2#NMY>QUZ8O+:8DDS[;M\;-OI@<-S]3E[U[0PW\[:>JPVV=EJ+B
MC+?.WP5J!;=85 6!2D0F6:*YJWIVI(G7_:P6AW'*]RSO=!C $ !H_ ;2*' \
M+2RQBO>TIVRN&**FLAHB$MX)2<5I'VKJ=-6^3Q:1R"MP8R*^19Y),$P0E K$
M(#:9JO#&T&=M\5.]1+Z,K,^N&#L!OO;]?A[/*2;?A3)PLI1;1L8Z\K: P]+,
M+VMOO!OY7"4OSA9%E5#HORQ^M9L[#(HQ1!+)>CT(Q^6)S2'2GGZ'MBE)CF:M
M)3PB9Z?EZU1:HM^8[%>I%OQWUS39&RK&!T7FYL@+A?M*T;WC)0&B/6_6DM74
MEZ\*;G9] S8) "+M[@O$YOM^P5LLT/N+>'@.F(2TO3Q5G\C"6HSZ/5%22UE(
M [N>=+)^,JM_2'8;PNTZ+L3J[I*<9?E,-?BM=J]ZY7!SYC;J]>[^&C^1-*?D
M[6TY1<,0P*7R ?#J89U)Y2?:\ABHB+_3L3]/$;V30Q];3!&GZ.0"0J6ALBD8
M7OLJ-894&_%L],WQ>,6$M'(TRN=7-19]K.#ID=13OJ(4OX4OW8U:_'L\=?1Z
M(_((F59L=G*J\EFV_L#KU=YT;+6SH\W!L>#H1P%G!;"&\$G"L]18-B6:JF>,
MTE<-%HY$9GV*_8GV:ELCK?3@FYVC'_-Q G\#\IQF#LX@P:1:#9A&^S+T].=_
MK_R%:*.SHVSAN" _P^%V,/@FO_"1A!RY4%4A,<TE2R"Q'_;;4@F @U2^L//[
M,R_]AH91*][TMN9UIT+5I[4>P^6_'?%M0]J6 MJ-.\9O8@2U*2:B[^24D,IS
ML^04Q[[_T?,(Z+Z7YNV*G<+]/6\?0\K^Q'\B #C:UAQ:_-^?!(]T[$1T[9]W
MC BC4)7U"<:H"/3BH*:CH;\RC4U;Q#VOO%1N9=6 #N$J;JIWH<0,GGV!RUK"
MV_BLTV)(5J!'_#W\[S,/=Z[%GV\?P!-Y154N:1WL?1,L6'HM.0OB6 SB^^YN
MM@<7LX@'TYFG+&9E%BG?(P9]\12>G.MPN\U?A&BBUMWIMF?_0 T2)#X6K4ZG
MZCN=.WO;VZI3D%5;9PB2K-1ZL7<,?52C3>EJME;\L^PK-_F3^P/@5\JK2S&Z
M*)\<CB'45\R-)86C\1GH@ __07VSM M.MQ^GV75LJ$T T-7Q,M8W2Q  SII3
MI"+'32ZVW]EY^ZJ2;1-MO?UHE1MF\[C0]T'P,QG@D0_V&JZ]+1V,V=[CRSZW
MPM7@]=SJ549&EIO(&JO;!/Z=7=(Z94Q0:Z]N5--<9D_Z^7TMG9LI.=4IYY=1
MTS[1NO-38$2$@?-H/"?FJH +E$+=74[DXJ+0)5$:OMSMJ!_S\3 V(1BM-+UC
MQ%3WW!YYO=V>A&J^WL0.KFX=N1V!T!K1A5)W\PEQ,&A7:W5(J?QA"1,2KI0G
MLA"YP5VC"1R> (A;\,!]0"W0MBK@R'?5\J.WU:JKGF$5IB!(2MMZ)UV-Y2,*
M<5[GXE]1MJA*70,PGV"96Q[ENP[AW46EMS)$M:I\O'Y4C@T]#,RO"Y'!+>'!
MT'ZD-ZYRFS0[9(8V<N$P),NFJ<G,B;NEB;:[/3UGK@$7_V(,2D-QJ":L'9]R
M*]C&7)OWUQ-BQE5PQ1HZ -<LYB7OKX(<B&#%-59>1XSH!W@SZE&3.S;9?U84
M#':*SC$4U6,KU11N/#]*^BRYMI_)!Q<S$WW!+561,[\H":APU<,*1[\?G03K
M(;-Q6EC=Q4AB?7"C6)M#F-EIDIFC4S"0#?_(W9 1RVY@MV^?(6^JZK_7G2?[
MF.D^#UC7$-.0J,AJ&UK,G)^3&97X(,@$?O8>+[!, "3K]@R=:RQH^JYBJ0^J
MX=*2QWQ+Y_PM'OGO%!I/C558TW2=M'3VZ'PMR:!6A1\+D T.9TG]#%U&%=E/
MN;D$L*KFFEU6? -[+9-H)J+9)O.Q=6Y@+P^%HW#\&U3&E)_8;--9J;=/C<\Z
M,](OJ.K?$3_\DX\^3.!R]$+IC$D_.,K[ :N(B8/&DO?L=QT3BM3[UG9$GV"
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M]NX PCW9#_.R4?F^>WWM!O!Y<1Z:2?#$)G-D*NMH8M71U5(I _28*$7O+1,
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M/UP(WK$)86?E+%)I7LCCW 0KGH4'EZ7FW?:RY=JRL0I37(F<8:01K-0D(_I
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MO9O]))*1Z5Y2R:= 6SCV="5.]QB/JIYG8?]'5?VO^]XNTECK)^JBY>-/RTM
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MD;'%W :J&X6"BKJU(#T]MMP=E,FI(U%T_2$I^Y!534/U8]IN_NAQILA&\3;
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M<1*E9 9"R]HW/'_JL/4\L$ Z=#'E>-*O'KKWM#@!9EV<'V,,XS*0T9<JB"C
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MC"Y1D4XU;8S>N-9G5& YW9DG?D3:&9=,%+8@<LZ?D+CSD#2<T;'68)_!*>?
M\.*63.H8#-6:DEHK=<_"I$UO-C(O,?,'2,5@2O)?AF5L9LVVXQ^-U2%?^*DJ
MB42RN;G=%++ZM'&&<!)L3;++$';@>1 $SRU/$L850<**SW^TXL-O7P+V,)>
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M4W2'V\2V1,70GA_G;G#T@]1OZQZ3X0=_5D&!AMK<_K>4_@V1)?)R^U^GO7O
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MS?>=VO\]_ZE]SMWW[%.U_[IUNZ9FJOI]:U97=Z_NY^GU+M0":AU I**@K !
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M!+<%DA#C*CY*CJ;%)-@(??:!T:J3OT3P:7,=X]+U5? 2[6%-B7F](NWV;]I
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MAJ/C[<%3VNV:B;%9YA!$6KO(QVMUN+PR0NL(/X%G?I%<NG59]&"078.:YFW
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MKNC^&OP(::-_B.%_&;,6D.<%@XV[VGR#%4^VN<M_M2CK37"D!;ZL3%B*8:3
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M-)@ %79Y^Q)<'W>.K:PT++3Q;@16^6TS#>B1]T;)Q97(&P79$1)K<#5(L;S
MB8OF,#+X#.'BXRGUG1E-EK!;<6Y<@%K:-2KU2=O<U-TD)4UM:Q:&Y4.6CEK^
MGM\6+$%4O8^_=L<L9?&Z[5S9[8[JXIJ\78.UMH^,63-J O/Z%..@/5) .0YV
MNZEBCM#^'R3PK,^? Y6,-O;F!,VX>@'24P&3=#:7SL'J]RF=QNY+XB:EUQ4+
MIE*RFNC-,MYVN^-NQ9\&3X=>PE32>#_'9CPN(E-0R;1IQ?O0Q/'^^&%HP=6@
M)#]Q/5Z(4@?107AO<S&9@85W86.#E(6TZC3(GYF[21E$[V'D6"=%YY1-@U\
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M5;[]LV!(Q9#JJG*PW";">MSHM6J=A=AA+9(H_;9C8%2A<G9ICQXR3&<%"PB
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MGNU7X>_KCL-TYN<2434N1M]/YA$.1@@2(UT](<?':O(2("(YII G$V]E+<3
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MWBR40.FPP4+2]B HBO>D< XJT- /?- P>M!$A9F-5_ _&Q,9[MMWYS;&7_C
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M*_D4B6LG%W<&,_%V<Z(8K<6WN22*:!*Q38HG<Y@BKU73VMW@OIHE5U]JD&W
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M*S> T\WPPD&O<QW_F_\@%F"JM>L1)Z#X7W["NAN=B.%2.1WN=B^9A#]?K%R
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MT[]8%V$[-5OJ5PK\1%=/3?AYZT#L(G@F=O,Q<RD]/NI,'!CFZ?3OYT:L6@I
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M* F=!5T#W;R)G% Z!W7#G]%(!RR:Y:T\OP!F 1DOY7];IF-7GHC7U-;T#95
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M\DS,X,;Z*1I MAO)C"^ =#>XEY$XD<](7 5!EW,%^>LICY%F7J55EF,TX)?
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M7J."Z\T@*^_!-PSQ#=EE49[VOZNPUX4_@BM/V??Z3G8K/;. (W7*;1QTIX1
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M,R1G8<G#KHWJZ4BB9SQW]%'!U0Y<8AG%I9;JVKM.#N;TAH7V6EP1=8.>BR6
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MV>;F;JZL^]+T<?NT_?V=R>,_(.YQDS(=SS2.69^_E1K&5%=Z"//_",,$ '
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M<5AV;=;1A'5&K/[T]MJ_,=*BASK!&W&G(IO/:HA:%,=F4BFCOQ@;SWK=FLT
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M              "  0    !E83 R,#,W.#@M,#$N:'1M4$L! A0#%     @
M.HN:6!J-$KI? @  K@H  !\              ( !$Y0( &5A,#(P,S<X.# Q
M97@R,RTQ7V]N8V]N971I>"YH=&U02P$"% ,4    "  ZBYI8N.5Q&88"  "M
M!P  'P              @ &OE@@ 96$P,C S-S@X,#%E>#(S+3)?;VYC;VYE
M=&EX+FAT;5!+ 0(4 Q0    ( #J+FEB4:&2 3P0  "H6   ?
M  "  7*9" !E83 R,#,W.#@P,65X,C,M,U]O;F-O;F5T:7@N:'1M4$L! A0#
M%     @ .HN:6-/5KQQW(@  W+T! !$              ( !_IT( &]N8V\M
M,C R,S$R,S$N>'-D4$L! A0#%     @ .HN:6)AH[?:C&0  !&T! !4
M         ( !I, ( &]N8V\M,C R,S$R,S%?8V%L+GAM;%!+ 0(4 Q0    (
M #J+FEB;?/@"QHL  ):("0 5              "  7K:" !O;F-O+3(P,C,Q
M,C,Q7V1E9BYX;6Q02P$"% ,4    "  ZBYI8.YGG6U1- 0"WNQ  %0
M        @ %S9@D ;VYC;RTR,#(S,3(S,5]L86(N>&UL4$L! A0#%     @
M.HN:6*ZYV=ZJBP  +=() !4              ( !^K,* &]N8V\M,C R,S$R
M,S%?<')E+GAM;%!+ 0(4 Q0    ( #J+FEA\?L'V<&L$ &$?!P .
M      "  =<_"P!T:6UA9V5?,# Q+FIP9U!+ 0(4 Q0    ( #J+FE@D.-B*
MH9<" -B@ P .              "  7.K#P!T:6UA9V5?,# R+FIP9U!+ 0(4
M Q0    ( #J+FECT"03#X 8" 'Q\ P .              "  4!#$@!T:6UA
M9V5?,# S+FIP9U!+ 0(4 Q0    ( #J+FEAI(RWV ^T$ #!Q!@ .
M      "  4Q*% !T:6UA9V5?,# T+FIP9U!+ 0(4 Q0    ( #J+FE@L""@J
MPF($ $OX!  .              "  7LW&0!T:6UA9V5?,# U+FIP9U!+ 0(4
M Q0    ( #J+FEAG)1'2P,   (K=   3              "  6F:'0!T;VYC
E;VYE=&EX7VQO9V\N:G!G4$L%!@     /  \ W0,  %I;'@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>ea0203788-01_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:onco="http://www.bluewatervaccines.com/20231231"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="onco-20231231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesBConvertibleRedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesBConvertibleRedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesSeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesSeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesSeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesSeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesSeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">onco:OnconetixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">onco:ProteomedixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-23</startDate>
            <endDate>2022-02-23</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2022-02-23</startDate>
            <endDate>2022-02-23</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-23</startDate>
            <endDate>2024-01-23</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">onco:SubscriptionAgreementLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">onco:SubscriptionAgreementLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">onco:SubscriptionAgreementLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">onco:ContingentWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">onco:ContingentWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">onco:ContingentWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">onco:ContingentWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">onco:ContingentWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onco:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onco:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onco:CommonStockIssuableUponConversionOfSeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onco:CommonStockIssuableUponConversionOfSeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:ProteomedixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:ENTADFIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onco:ENTADFIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">onco:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-19</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">onco:ENTADFIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-19</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">onco:ENTADFIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">onco:MilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">onco:MilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-19</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2023-04-19</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">onco:PharmaceuticalServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2023-10-03</startDate>
            <endDate>2023-10-03</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:ENTADFIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">onco:ManagementServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">onco:WraSerAPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">onco:WraSerAPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">onco:BankruptcyCourtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">onco:WraSerMSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2023-12-15</startDate>
            <endDate>2023-12-15</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-15</startDate>
            <endDate>2023-12-15</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">onco:PMXTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">onco:ProteomedixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">onco:FairValueConsiderationTransferredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">onco:AggregateConsiderationTransferredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">onco:AssetsRecognizedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">onco:MeasurementInputStockPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">onco:BusinessAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">onco:ProteomedixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">onco:PMXTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">onco:PMXTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:OlogyBioservicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:OlogyBioservicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-21</startDate>
            <endDate>2021-05-21</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:OlogyBioservicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:OlogyBioservicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:OlogyBioservicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:CincinnatiChildrensHospitalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">onco:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">us-gaap:CommercialAndIndustrialSectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:OUIAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">onco:DevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">onco:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">us-gaap:CommercialAndIndustrialSectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:StJudeChildrensHospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:StJudeChildrensHospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">onco:DevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:StJudeChildrensHospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">onco:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:StJudeChildrensHospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">us-gaap:CommercialAndIndustrialSectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:StJudeChildrensHospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:UTHealthAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:UniversityOfTexasHealthScienceCenterAtSanAntonioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:UniversityOfTexasHealthScienceCenterAtSanAntonioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">onco:DevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:UniversityOfTexasHealthScienceCenterAtSanAntonioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">us-gaap:CommercialAndIndustrialSectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:UniversityOfTexasHealthScienceCenterAtSanAntonioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-01</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-01</endDate>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:CoDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:VendorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-21</instant>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2023-07-29</startDate>
            <endDate>2023-07-29</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2023-07-29</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:LaboratorCorporationOfAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-19</instant>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:NotePayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2023-09-29</instant>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2023-09-29</startDate>
            <endDate>2023-09-29</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-29</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">onco:ProteomedixAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-29</instant>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">onco:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2022-02-17</startDate>
            <endDate>2022-02-17</endDate>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2022-02-17</instant>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">onco:TreasuryStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">onco:TreasuryStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">onco:TreasuryStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-18</startDate>
            <endDate>2022-11-18</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">onco:TreasuryStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">onco:TreasuryStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">onco:TreasuryStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">onco:TreasuryStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:April2022PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:April2022PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:April2022PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:April2022PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:AprilContingentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:AprilContingentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:AprilContingentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:April2022PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:April2022PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:August2022PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:August2022PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-31</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:August2022PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:August2022PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:August2022PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:August2022PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:August2022PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:August2022PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-31</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:AugustWainwrightWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:HCWainwrightCoLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:AugustWainwrightWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-31</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:AugustContingentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:AugustContingentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-31</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:AugustContingentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:August2022PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2022-08-31</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:AugustContingentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onco:AugustContingentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">onco:MarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-29</startDate>
            <endDate>2023-03-29</endDate>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2023-03-29</startDate>
            <endDate>2023-03-29</endDate>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onco:WarrantInducementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-11</startDate>
            <endDate>2022-08-11</endDate>
        </period>
    </context>
    <context id="c260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2023-07-31</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-31</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2023-08-02</startDate>
            <endDate>2023-08-02</endDate>
        </period>
    </context>
    <context id="c263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onco:InducementPIOSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onco:April2022PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onco:August2022PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onco:August2022PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onco:TwoThousandNinteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onco:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-23</instant>
        </period>
    </context>
    <context id="c273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onco:TwoThousandTwentyTwoPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onco:TwoThousandTwentyTwoPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onco:TwoThousandTwentyTwoPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-04</endDate>
        </period>
    </context>
    <context id="c277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onco:ChiefBusinessOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-09</startDate>
            <endDate>2023-05-09</endDate>
        </period>
    </context>
    <context id="c283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-09</startDate>
            <endDate>2023-05-09</endDate>
        </period>
    </context>
    <context id="c284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onco:ChiefBusinessOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-09</startDate>
            <endDate>2023-05-09</endDate>
        </period>
    </context>
    <context id="c285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2023-05-09</startDate>
            <endDate>2023-05-09</endDate>
        </period>
    </context>
    <context id="c286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onco:January2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-09</startDate>
            <endDate>2023-05-09</endDate>
        </period>
    </context>
    <context id="c287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onco:August2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-09</startDate>
            <endDate>2023-05-09</endDate>
        </period>
    </context>
    <context id="c288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onco:August2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-09</startDate>
            <endDate>2023-05-09</endDate>
        </period>
    </context>
    <context id="c289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2023-05-31</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-16</startDate>
            <endDate>2023-08-16</endDate>
        </period>
    </context>
    <context id="c291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-04</startDate>
            <endDate>2023-10-04</endDate>
        </period>
    </context>
    <context id="c292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onco:PMXOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onco:PMXOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">onco:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">onco:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onco:ChiefBusinessOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">onco:OriginalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">onco:ExchangedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">onco:OriginalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">onco:ExchangedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-11</instant>
        </period>
    </context>
    <context id="c304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-11</endDate>
        </period>
    </context>
    <context id="c306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">onco:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">onco:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-01</endDate>
        </period>
    </context>
    <context id="c324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">onco:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-09</endDate>
        </period>
    </context>
    <context id="c325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-09</endDate>
        </period>
    </context>
    <context id="c326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-09</instant>
        </period>
    </context>
    <context id="c327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2022-10-09</instant>
        </period>
    </context>
    <context id="c328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2022-02-07</instant>
        </period>
    </context>
    <context id="c329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">onco:CEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">onco:CBOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:NonConvertibleDebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingIncomeLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="c337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2023-12-15</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">onco:AccumulatedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-14</instant>
        </period>
    </context>
    <context id="c339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">onco:AccumulatedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-15</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">onco:AccumulatedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">onco:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-14</instant>
        </period>
    </context>
    <context id="c342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">onco:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-15</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">onco:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:NonConvertibleDebentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-23</instant>
        </period>
    </context>
    <context id="c345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onco:SubscriptionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-23</instant>
        </period>
    </context>
    <context id="c346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-23</instant>
        </period>
    </context>
    <context id="c347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-10</startDate>
            <endDate>2024-01-10</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="chf">
        <measure>iso4217:CHF</measure>
    </unit>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-31">Onconetix, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-42">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-131">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-144">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-157">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0" id="ixv-161">false</dei:EntityExTransitionPeriod>
    <dei:AmendmentDescription contextRef="c0" id="ixv-173">Pursuant to Rule 429 under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), the prospectus included in this Registration Statement on Form S-1 (this &#x201c;Registration Statement&#x201d;) is a combined prospectus relating to the following shares of common stock of Onconetix, Inc. (the &#x201c;Registrant&#x201d;) being registered on this Registration Statement and previously registered on the Registrant&#x2019;s Registration Statement on Form S-3 (File No. 333-267142), as amended (the &#x201c;Prior Registration Statement&#x201d;):&#x2022;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The offer and resale of 4,972,428 shares of Common Stock (the &#x201c;Inducement PIO Shares&#x201d;) issuable upon exercise of common stock preferred investment options (the &#x201c;Inducement PIOs&#x201d;) issued to Armistice Capital Master Fund Ltd. (&#x201c;Armistice&#x201d;) in a warrant inducement transaction (the &#x201c;Warrant Inducement&#x201d;), which closed on August 2, 2023.&#x2022;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The offer and resale of 149,173 Inducement PIO Shares issuable upon exercise of Inducement PIOs issued to H.C. Wainwright &amp; Co., LLC, the Company&#x2019;s placement agent for the Warrant Inducement, or its designees on August 2, 2023 in the Warrant Inducement (the &#x201c;Placement Agent Inducement PIOs&#x201d;).&#x2022;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The offer and resale of 2,486,214 shares of Common Stock issuable upon exercise of common stock preferred investment options (the &#x201c;Sabby PIOs&#x201d;, and together with the Inducement PIOs and the Placement Agent Inducement PIOs, the &#x201c;PIOs&#x201d;) issued to Sabby in a private placement, which were registered on a registration statement on Form S-1 (File No. 333-267142) on September 19, 2022 that was declared effective by the SEC, as amended by the Prior Registration Statement (the &#x201c;Initial Registration Statement&#x201d;)&#x2022;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The offer and resale of 220,997 shares of Common Stock (&#x201c;August 2022 Wainwright Warrant Shares&#x201d;) issuable upon exercise of the warrants (the &#x201c;August 2022 Wainwright Warrants&#x201d;) issued to H.C. Wainwright &amp; Co., LLC, or its designees, in a private placement, which were registered on the Initial Registration Statement.This Registration Statement also constitutes Post-Effective Amendment No. 2 to the Prior Registration Statement, and such Post-Effective Amendment No. 1 to the Initial Registration Statement shall hereafter become effective concurrently with the effectiveness of this Registration Statement in accordance with Section 8(c) of the Securities Act.</dei:AmendmentDescription>
    <us-gaap:Cash contextRef="c1" decimals="0" id="ixv-30538" unitRef="usd">4554335</us-gaap:Cash>
    <us-gaap:Cash contextRef="c2" decimals="0" id="ixv-30539" unitRef="usd">25752659</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c1" decimals="0" id="ixv-30540" unitRef="usd">149731</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c1" decimals="0" id="ixv-30541" unitRef="usd">364052</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c1" decimals="0" id="ixv-30542" unitRef="usd">770153</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="0" id="ixv-30543" unitRef="usd">469232</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c4" decimals="0" id="ixv-30544" unitRef="usd">35850</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent contextRef="c1" decimals="0" id="ixv-30545" unitRef="usd">5838271</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="0" id="ixv-30546" unitRef="usd">26257741</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="c1" decimals="0" id="ixv-30547" unitRef="usd">17423</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="c2" decimals="0" id="ixv-30548" unitRef="usd">38617</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="0" id="ixv-30549" unitRef="usd">60654</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" id="ixv-30550" unitRef="usd">14089</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredCosts contextRef="c1" decimals="0" id="ixv-30551" unitRef="usd">366113</us-gaap:DeferredCosts>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c1" decimals="0" id="ixv-30552" unitRef="usd">148542</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c1" decimals="0" id="ixv-30553" unitRef="usd">25410887</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c1" decimals="0" id="ixv-30554" unitRef="usd">55676142</us-gaap:Goodwill>
    <us-gaap:Assets contextRef="c1" decimals="0" id="ixv-30555" unitRef="usd">87518032</us-gaap:Assets>
    <us-gaap:Assets contextRef="c2" decimals="0" id="ixv-30556" unitRef="usd">26310447</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c1" decimals="0" id="ixv-30557" unitRef="usd">5295114</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c2" decimals="0" id="ixv-30558" unitRef="usd">1499296</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c1" decimals="0" id="ixv-30559" unitRef="usd">2199867</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-30560" unitRef="usd">2409128</us-gaap:AccruedLiabilitiesCurrent>
    <onco:NotesPayableNetOfDebtDiscount contextRef="c1" decimals="0" id="ixv-30561" unitRef="usd">381627</onco:NotesPayableNetOfDebtDiscount>
    <onco:NotesPayableNetOfDebtDiscount contextRef="c2" decimals="0" id="ixv-30562" unitRef="usd">381627</onco:NotesPayableNetOfDebtDiscount>
    <us-gaap:NotesPayableCurrent contextRef="c1" decimals="0" id="ixv-30563" unitRef="usd">9618373</us-gaap:NotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c1" decimals="0" id="ixv-30564" unitRef="usd">74252</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c1" decimals="0" id="ixv-30565" unitRef="usd">2641</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-30566" unitRef="usd">14021</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c1" decimals="0" id="ixv-30567" unitRef="usd">17190247</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-30568" unitRef="usd">3922445</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable contextRef="c1" decimals="0" id="ixv-30569" unitRef="usd">118857</us-gaap:LongTermNotesPayable>
    <onco:SubscriptionAgreementLiabilityNoncurrent contextRef="c1" decimals="0" id="ixv-30570" unitRef="usd">864000</onco:SubscriptionAgreementLiabilityNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent contextRef="c1" decimals="0" id="ixv-30571" unitRef="usd">556296</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="0" id="ixv-30572" unitRef="usd">74290</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c1" decimals="0" id="ixv-30573" unitRef="usd">3073781</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities contextRef="c1" decimals="0" id="ixv-30574" unitRef="usd">21877471</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c2" decimals="0" id="ixv-30575" unitRef="usd">3922445</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c5"
      decimals="5"
      id="ixv-30576"
      unitRef="usdPershares">0.00001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c6"
      decimals="5"
      id="ixv-30577"
      unitRef="usdPershares">0.00001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c5"
      decimals="0"
      id="ixv-30578"
      unitRef="shares">2700000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c6"
      decimals="0"
      id="ixv-30579"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c6"
      decimals="0"
      id="ixv-30580"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c5"
      decimals="0"
      id="ixv-30581"
      unitRef="shares">2696729</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c5"
      decimals="0"
      id="ixv-30582"
      unitRef="shares">2696729</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c6"
      decimals="0"
      id="ixv-30583"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c1" decimals="0" id="ixv-30584" unitRef="usd">64236085</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c7"
      decimals="5"
      id="ixv-30585"
      unitRef="usdPershares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c8"
      decimals="5"
      id="ixv-30586"
      unitRef="usdPershares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c7"
      decimals="0"
      id="ixv-30587"
      unitRef="shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c8"
      decimals="0"
      id="ixv-30588"
      unitRef="shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c8"
      decimals="0"
      id="ixv-30589"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c8"
      decimals="0"
      id="ixv-30590"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c7"
      decimals="0"
      id="ixv-30591"
      unitRef="shares">3000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c7"
      decimals="0"
      id="ixv-30592"
      unitRef="shares">3000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="c8" decimals="0" id="ixv-30593" unitRef="usd">0</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="c7" decimals="0" id="ixv-30594" unitRef="usd">3000000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="5"
      id="ixv-30595"
      unitRef="usdPershares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="5"
      id="ixv-30596"
      unitRef="usdPershares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c1"
      decimals="0"
      id="ixv-30597"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c2"
      decimals="0"
      id="ixv-30598"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c1"
      decimals="0"
      id="ixv-30599"
      unitRef="shares">22841975</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="0"
      id="ixv-30600"
      unitRef="shares">15724957</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c1"
      decimals="0"
      id="ixv-30601"
      unitRef="shares">22324576</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="0"
      id="ixv-30602"
      unitRef="shares">15265228</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c1" decimals="0" id="ixv-30603" unitRef="usd">228</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c2" decimals="0" id="ixv-30604" unitRef="usd">157</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c1" decimals="0" id="ixv-30605" unitRef="usd">49428809</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="0" id="ixv-30606" unitRef="usd">42331155</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c1"
      decimals="0"
      id="ixv-30607"
      unitRef="shares">517399</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c2"
      decimals="0"
      id="ixv-30608"
      unitRef="shares">459729</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue contextRef="c1" decimals="0" id="ixv-30609" unitRef="usd">625791</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="c2" decimals="0" id="ixv-30610" unitRef="usd">566810</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="0" id="ixv-30611" unitRef="usd">-56786194</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="0" id="ixv-30612" unitRef="usd">-19376500</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c1" decimals="0" id="ixv-30613" unitRef="usd">2380920</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="0" id="ixv-30614" unitRef="usd">-5602028</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" id="ixv-30615" unitRef="usd">22388002</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c1" decimals="0" id="ixv-30616" unitRef="usd">7006504</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c1" decimals="0" id="ixv-30617" unitRef="usd">1404476</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="0" id="ixv-30618" unitRef="usd">22388002</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c1" decimals="0" id="ixv-30619" unitRef="usd">87518032</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="0" id="ixv-30620" unitRef="usd">26310447</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="0" id="ixv-30621" unitRef="usd">58465</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c0" decimals="0" id="ixv-30622" unitRef="usd">1185630</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c0" decimals="0" id="ixv-30623" unitRef="usd">-1127165</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-30624" unitRef="usd">14770678</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c9" decimals="0" id="ixv-30625" unitRef="usd">9351552</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-30626" unitRef="usd">1949406</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c9" decimals="0" id="ixv-30627" unitRef="usd">4129688</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c0" decimals="0" id="ixv-30628" unitRef="usd">14687346</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:OtherAssetImpairmentCharges contextRef="c0" decimals="0" id="ixv-30629" unitRef="usd">3500000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" id="ixv-30630" unitRef="usd">34907430</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c9" decimals="0" id="ixv-30631" unitRef="usd">13481240</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" id="ixv-30632" unitRef="usd">-36034595</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c9" decimals="0" id="ixv-30633" unitRef="usd">-13481240</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c0" decimals="0" id="ixv-30634" unitRef="usd">-490000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpense contextRef="c0" decimals="0" id="ixv-30635" unitRef="usd">671625</us-gaap:InterestExpense>
    <onco:ChangeInFairValueOfSubscriptionAgreementLiability contextRef="c0" decimals="0" id="ixv-30636" unitRef="usd">-134100</onco:ChangeInFairValueOfSubscriptionAgreementLiability>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c0" decimals="0" id="ixv-30637" unitRef="usd">-91967</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c9" decimals="0" id="ixv-30638" unitRef="usd">61410</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="0" id="ixv-30639" unitRef="usd">-1387692</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c9" decimals="0" id="ixv-30640" unitRef="usd">61410</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent contextRef="c0" decimals="0" id="ixv-30641" unitRef="usd">-37422287</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="c9" decimals="0" id="ixv-30642" unitRef="usd">-13419830</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-30643" unitRef="usd">-12593</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-30644" unitRef="usd">-37409694</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c9" decimals="0" id="ixv-30645" unitRef="usd">-13419830</us-gaap:ProfitLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="c9" decimals="0" id="ixv-30646" unitRef="usd">96359</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c0" decimals="0" id="ixv-30647" unitRef="usd">-37409694</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c9" decimals="0" id="ixv-30648" unitRef="usd">-13516189</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-30649"
      unitRef="usdPershares">-2.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c9"
      decimals="2"
      id="ixv-30650"
      unitRef="usdPershares">-1.1</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-30651"
      unitRef="shares">17111374</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c9"
      decimals="INF"
      id="ixv-30652"
      unitRef="shares">12271449</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-30653" unitRef="usd">-37409694</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c9" decimals="0" id="ixv-30654" unitRef="usd">-13419830</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c0" decimals="0" id="ixv-30655" unitRef="usd">-2374957</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <onco:ChangeInPensionBenefitObligation contextRef="c0" decimals="0" id="ixv-30656" unitRef="usd">5963</onco:ChangeInPensionBenefitObligation>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="0" id="ixv-30657" unitRef="usd">-35028774</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c9" decimals="0" id="ixv-30658" unitRef="usd">-13419830</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="c11"
      decimals="0"
      id="ixv-30659"
      unitRef="shares">1146138</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c11" decimals="0" id="ixv-30660" unitRef="usd">11</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c12"
      decimals="0"
      id="ixv-30661"
      unitRef="shares">3200000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c12" decimals="0" id="ixv-30662" unitRef="usd">32</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c13" decimals="0" id="ixv-30663" unitRef="usd">7403204</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c15" decimals="0" id="ixv-30664" unitRef="usd">-5956670</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c17" decimals="0" id="ixv-30665" unitRef="usd">1446577</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c18" decimals="0" id="ixv-30666" unitRef="usd">1446577</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <onco:IssuanceOfCommonStockInInitialPublicOfferingNet contextRef="c26" decimals="1" id="ixv-30667" unitRef="usd">2.9</onco:IssuanceOfCommonStockInInitialPublicOfferingNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c22"
      decimals="0"
      id="ixv-30668"
      unitRef="shares">2222222</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c22" decimals="0" id="ixv-30669" unitRef="usd">22</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c23" decimals="0" id="ixv-30670" unitRef="usd">17138818</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c26" decimals="0" id="ixv-30671" unitRef="usd">17138840</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c9" decimals="0" id="ixv-30672" unitRef="usd">17138840</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c21"
      decimals="0"
      id="ixv-30673"
      unitRef="shares">-1146138</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c21" decimals="0" id="ixv-30674" unitRef="usd">-11</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c22"
      decimals="0"
      id="ixv-30675"
      unitRef="shares">5626365</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c22" decimals="0" id="ixv-30676" unitRef="usd">56</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c23" decimals="0" id="ixv-30677" unitRef="usd">-45</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <onco:IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet contextRef="c26" decimals="1" id="ixv-30678" unitRef="usd">1.1</onco:IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet>
    <onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants
      contextRef="c22"
      decimals="0"
      id="ixv-30679"
      unitRef="shares">590406</onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants>
    <onco:StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants contextRef="c22" decimals="0" id="ixv-30680" unitRef="usd">6</onco:StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants>
    <onco:StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants contextRef="c23" decimals="0" id="ixv-30681" unitRef="usd">6858322</onco:StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants>
    <onco:StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants contextRef="c26" decimals="0" id="ixv-30682" unitRef="usd">6858328</onco:StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants>
    <onco:StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants contextRef="c9" decimals="0" id="ixv-30683" unitRef="usd">6858328</onco:StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants>
    <onco:IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet contextRef="c26" decimals="1" id="ixv-30684" unitRef="usd">2.2</onco:IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet>
    <onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet
      contextRef="c22"
      decimals="0"
      id="ixv-30685"
      unitRef="shares">1350000</onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet>
    <onco:StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement contextRef="c22" decimals="0" id="ixv-30686" unitRef="usd">14</onco:StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement>
    <onco:StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement contextRef="c23" decimals="0" id="ixv-30687" unitRef="usd">8689302</onco:StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement>
    <onco:StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement contextRef="c26" decimals="0" id="ixv-30688" unitRef="usd">8689316</onco:StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement>
    <onco:StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement contextRef="c9" decimals="0" id="ixv-30689" unitRef="usd">8689316</onco:StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c22"
      decimals="0"
      id="ixv-30690"
      unitRef="shares">165452</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c22" decimals="0" id="ixv-30691" unitRef="usd">2</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c23" decimals="0" id="ixv-30692" unitRef="usd">1653</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c26" decimals="0" id="ixv-30693" unitRef="usd">1655</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c9" decimals="0" id="ixv-30694" unitRef="usd">1655</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <onco:ExerciseOfPrefundedWarrantsinShares
      contextRef="c22"
      decimals="0"
      id="ixv-30695"
      unitRef="shares">2277046</onco:ExerciseOfPrefundedWarrantsinShares>
    <onco:ExerciseOfPrefundedWarrants contextRef="c22" decimals="0" id="ixv-30696" unitRef="usd">22</onco:ExerciseOfPrefundedWarrants>
    <onco:ExerciseOfPrefundedWarrants contextRef="c23" decimals="0" id="ixv-30697" unitRef="usd">1414</onco:ExerciseOfPrefundedWarrants>
    <onco:ExerciseOfPrefundedWarrants contextRef="c26" decimals="0" id="ixv-30698" unitRef="usd">1436</onco:ExerciseOfPrefundedWarrants>
    <onco:ExerciseOfPrefundedWarrants contextRef="c9" decimals="0" id="ixv-30699" unitRef="usd">1436</onco:ExerciseOfPrefundedWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c22"
      decimals="0"
      id="ixv-30700"
      unitRef="shares">293466</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c22" decimals="0" id="ixv-30701" unitRef="usd">3</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c23" decimals="0" id="ixv-30702" unitRef="usd">263921</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c26" decimals="0" id="ixv-30703" unitRef="usd">263924</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c9" decimals="0" id="ixv-30704" unitRef="usd">263924</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c23" decimals="0" id="ixv-30705" unitRef="usd">1974566</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c26" decimals="0" id="ixv-30706" unitRef="usd">1974566</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c9" decimals="0" id="ixv-30707" unitRef="usd">1974566</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <onco:PurchaseOfTreasurySharesinShares
      contextRef="c24"
      decimals="0"
      id="ixv-30708"
      unitRef="shares">-459729</onco:PurchaseOfTreasurySharesinShares>
    <onco:PurchaseOfTreasuryShares contextRef="c24" decimals="0" id="ixv-30709" unitRef="usd">566810</onco:PurchaseOfTreasuryShares>
    <onco:PurchaseOfTreasuryShares contextRef="c26" decimals="0" id="ixv-30710" unitRef="usd">566810</onco:PurchaseOfTreasuryShares>
    <onco:PurchaseOfTreasuryShares contextRef="c9" decimals="0" id="ixv-30711" unitRef="usd">566810</onco:PurchaseOfTreasuryShares>
    <us-gaap:ProfitLoss contextRef="c27" decimals="0" id="ixv-30712" unitRef="usd">-13419830</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c26" decimals="0" id="ixv-30713" unitRef="usd">-13419830</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c9" decimals="0" id="ixv-30714" unitRef="usd">-13419830</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c32"
      decimals="0"
      id="ixv-30715"
      unitRef="shares">15724957</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c32" decimals="0" id="ixv-30716" unitRef="usd">157</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c33" decimals="0" id="ixv-30717" unitRef="usd">42331155</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c34"
      decimals="0"
      id="ixv-30718"
      unitRef="shares">-459729</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c34" decimals="0" id="ixv-30719" unitRef="usd">-566810</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c35" decimals="0" id="ixv-30720" unitRef="usd">-19376500</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c37" decimals="0" id="ixv-30721" unitRef="usd">22388002</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="0" id="ixv-30722" unitRef="usd">22388002</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares
      contextRef="c41"
      decimals="0"
      id="ixv-30723"
      unitRef="shares">2486214</onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares>
    <onco:IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions contextRef="c41" decimals="0" id="ixv-30724" unitRef="usd">25</onco:IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions>
    <onco:IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions contextRef="c42" decimals="0" id="ixv-30725" unitRef="usd">2272813</onco:IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions>
    <onco:IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions contextRef="c45" decimals="0" id="ixv-30726" unitRef="usd">2272838</onco:IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions>
    <onco:IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions contextRef="c0" decimals="0" id="ixv-30727" unitRef="usd">2272838</onco:IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c42" decimals="0" id="ixv-30728" unitRef="usd">129184</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c45" decimals="0" id="ixv-30729" unitRef="usd">129184</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c0" decimals="0" id="ixv-30730" unitRef="usd">129184</us-gaap:StockIssuedDuringPeriodValueOther>
    <onco:StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares
      contextRef="c39"
      decimals="0"
      id="ixv-30731"
      unitRef="shares">3000</onco:StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares>
    <onco:StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock contextRef="c42" decimals="0" id="ixv-30732" unitRef="usd">3490000</onco:StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock>
    <onco:StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock contextRef="c45" decimals="0" id="ixv-30733" unitRef="usd">3490000</onco:StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock>
    <onco:StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock contextRef="c0" decimals="0" id="ixv-30734" unitRef="usd">3490000</onco:StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock>
    <onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction
      contextRef="c38"
      decimals="0"
      id="ixv-30735"
      unitRef="shares">2696729</onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction>
    <onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction contextRef="c38" decimals="0" id="ixv-30736" unitRef="usd">64236085</onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction>
    <onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction
      contextRef="c41"
      decimals="0"
      id="ixv-30737"
      unitRef="shares">3675414</onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction>
    <onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction contextRef="c41" decimals="0" id="ixv-30738" unitRef="usd">37</onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction>
    <onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction contextRef="c42" decimals="0" id="ixv-30739" unitRef="usd">875447</onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction>
    <onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction contextRef="c45" decimals="0" id="ixv-30740" unitRef="usd">875484</onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction>
    <onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction contextRef="c0" decimals="0" id="ixv-30741" unitRef="usd">875484</onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction>
    <onco:StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction contextRef="c46" decimals="0" id="ixv-30742" unitRef="usd">7006504</onco:StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction>
    <onco:StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction contextRef="c0" decimals="0" id="ixv-30743" unitRef="usd">7006504</onco:StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c41"
      decimals="0"
      id="ixv-30744"
      unitRef="shares">45920</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c42" decimals="0" id="ixv-30745" unitRef="usd">459</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c45" decimals="0" id="ixv-30746" unitRef="usd">459</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c0" decimals="0" id="ixv-30747" unitRef="usd">459</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <onco:ExerciseOfPrefundedWarrantsinShares
      contextRef="c41"
      decimals="0"
      id="ixv-30748"
      unitRef="shares">646640</onco:ExerciseOfPrefundedWarrantsinShares>
    <onco:ExerciseOfPrefundedWarrants contextRef="c41" decimals="0" id="ixv-30749" unitRef="usd">7</onco:ExerciseOfPrefundedWarrants>
    <onco:ExerciseOfPrefundedWarrants contextRef="c42" decimals="0" id="ixv-30750" unitRef="usd">-7</onco:ExerciseOfPrefundedWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c41"
      decimals="0"
      id="ixv-30751"
      unitRef="shares">512940</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c41" decimals="0" id="ixv-30752" unitRef="usd">5</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c42" decimals="0" id="ixv-30753" unitRef="usd">-5</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c41"
      decimals="0"
      id="ixv-30754"
      unitRef="shares">-250110</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c41" decimals="0" id="ixv-30755" unitRef="usd">-3</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c42" decimals="0" id="ixv-30756" unitRef="usd">3</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c42" decimals="0" id="ixv-30757" unitRef="usd">329760</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c45" decimals="0" id="ixv-30758" unitRef="usd">329760</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c0" decimals="0" id="ixv-30759" unitRef="usd">329760</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <onco:PurchaseOfTreasurySharesinShares
      contextRef="c43"
      decimals="0"
      id="ixv-30760"
      unitRef="shares">-57670</onco:PurchaseOfTreasurySharesinShares>
    <onco:PurchaseOfTreasuryShares contextRef="c43" decimals="0" id="ixv-30761" unitRef="usd">58981</onco:PurchaseOfTreasuryShares>
    <onco:PurchaseOfTreasuryShares contextRef="c45" decimals="0" id="ixv-30762" unitRef="usd">58981</onco:PurchaseOfTreasuryShares>
    <onco:PurchaseOfTreasuryShares contextRef="c0" decimals="0" id="ixv-30763" unitRef="usd">58981</onco:PurchaseOfTreasuryShares>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c44" decimals="0" id="ixv-30764" unitRef="usd">-2374957</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c45" decimals="0" id="ixv-30765" unitRef="usd">-2374957</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c0" decimals="0" id="ixv-30766" unitRef="usd">-2374957</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <onco:StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation contextRef="c44" decimals="0" id="ixv-30767" unitRef="usd">5963</onco:StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation>
    <onco:StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation contextRef="c45" decimals="0" id="ixv-30768" unitRef="usd">5963</onco:StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation>
    <onco:StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation contextRef="c0" decimals="0" id="ixv-30769" unitRef="usd">5963</onco:StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation>
    <us-gaap:ProfitLoss contextRef="c47" decimals="0" id="ixv-30770" unitRef="usd">-37409694</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c45" decimals="0" id="ixv-30771" unitRef="usd">-37409694</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-30772" unitRef="usd">-37409694</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c48"
      decimals="0"
      id="ixv-30773"
      unitRef="shares">2696729</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c48" decimals="0" id="ixv-30774" unitRef="usd">64236085</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c49"
      decimals="0"
      id="ixv-30775"
      unitRef="shares">3000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="c51"
      decimals="0"
      id="ixv-30776"
      unitRef="shares">22841975</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c51" decimals="0" id="ixv-30777" unitRef="usd">228</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c52" decimals="0" id="ixv-30778" unitRef="usd">49428809</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c53"
      decimals="0"
      id="ixv-30779"
      unitRef="shares">-517399</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c53" decimals="0" id="ixv-30780" unitRef="usd">-625791</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c54" decimals="0" id="ixv-30781" unitRef="usd">-56786194</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c55" decimals="0" id="ixv-30782" unitRef="usd">2380920</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c56" decimals="0" id="ixv-30783" unitRef="usd">-5602028</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c57" decimals="0" id="ixv-30784" unitRef="usd">7006504</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c1" decimals="0" id="ixv-30785" unitRef="usd">1404476</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-30786" unitRef="usd">-37409694</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c9" decimals="0" id="ixv-30787" unitRef="usd">-13419830</us-gaap:ProfitLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c0" decimals="0" id="ixv-30788" unitRef="usd">14687346</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:OtherAssetImpairmentCharges contextRef="c0" decimals="0" id="ixv-30789" unitRef="usd">3500000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c0" decimals="0" id="ixv-30790" unitRef="usd">729900</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c0" decimals="0" id="ixv-30791" unitRef="usd">671373</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c0" decimals="0" id="ixv-30792" unitRef="usd">-490000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="0" id="ixv-30793" unitRef="usd">329760</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c9" decimals="0" id="ixv-30794" unitRef="usd">1974566</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges contextRef="c0" decimals="0" id="ixv-30795" unitRef="usd">-267019</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <onco:GainLossOnRelatedPartyReceivable contextRef="c0" decimals="0" id="ixv-30796" unitRef="usd">265648</onco:GainLossOnRelatedPartyReceivable>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c0" decimals="0" id="ixv-30797" unitRef="usd">-159000</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-30798" unitRef="usd">-12593</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:InventoryWriteDown contextRef="c0" decimals="0" id="ixv-30799" unitRef="usd">1152369</us-gaap:InventoryWriteDown>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="0" id="ixv-30800" unitRef="usd">43937</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c9" decimals="0" id="ixv-30801" unitRef="usd">6752</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:LiabilitiesFairValueAdjustment contextRef="c0" decimals="0" id="ixv-30802" unitRef="usd">-91967</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment contextRef="c9" decimals="0" id="ixv-30803" unitRef="usd">61410</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="c0" decimals="0" id="ixv-30804" unitRef="usd">134100</us-gaap:AdjustmentOfWarrantsGrantedForServices>
    <us-gaap:PensionExpense contextRef="c0" decimals="0" id="ixv-30805" unitRef="usd">13875</us-gaap:PensionExpense>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c9" decimals="0" id="ixv-30806" unitRef="usd">263924</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="0" id="ixv-30807" unitRef="usd">62286</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="0" id="ixv-30808" unitRef="usd">315828</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="0" id="ixv-30809" unitRef="usd">412601</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c9" decimals="0" id="ixv-30810" unitRef="usd">234681</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c0" decimals="0" id="ixv-30811" unitRef="usd">16883</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c9" decimals="0" id="ixv-30812" unitRef="usd">38617</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="0" id="ixv-30813" unitRef="usd">3372648</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c9" decimals="0" id="ixv-30814" unitRef="usd">1093913</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c0" decimals="0" id="ixv-30815" unitRef="usd">-942075</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c9" decimals="0" id="ixv-30816" unitRef="usd">1739849</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-30817" unitRef="usd">-13581018</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c9" decimals="0" id="ixv-30818" unitRef="usd">-8675534</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="c0" decimals="0" id="ixv-30819" unitRef="usd">79771</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="c9" decimals="0" id="ixv-30820" unitRef="usd">79771</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="c0" decimals="0" id="ixv-30821" unitRef="usd">6079771</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit contextRef="c0" decimals="0" id="ixv-30822" unitRef="usd">3500000</us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c0" decimals="0" id="ixv-30823" unitRef="usd">-1056578</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c0" decimals="0" id="ixv-30824" unitRef="usd">51744</us-gaap:PaymentsToAcquireIntangibleAssets>
    <onco:ReceivableFromRelatedParties1 contextRef="c0" decimals="0" id="ixv-30825" unitRef="usd">70798</onco:ReceivableFromRelatedParties1>
    <onco:ReceivableFromRelatedParties1 contextRef="c9" decimals="0" id="ixv-30826" unitRef="usd">23326</onco:ReceivableFromRelatedParties1>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="0" id="ixv-30827" unitRef="usd">3300</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c9" decimals="0" id="ixv-30828" unitRef="usd">9339</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" id="ixv-30829" unitRef="usd">-8649035</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c9" decimals="0" id="ixv-30830" unitRef="usd">-32665</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <onco:PaymentsForPurchaseOfTreasuryShares contextRef="c0" decimals="0" id="ixv-30831" unitRef="usd">58981</onco:PaymentsForPurchaseOfTreasuryShares>
    <onco:PaymentsForPurchaseOfTreasuryShares contextRef="c9" decimals="0" id="ixv-30832" unitRef="usd">566810</onco:PaymentsForPurchaseOfTreasuryShares>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c0" decimals="0" id="ixv-30833" unitRef="usd">205093</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c0" decimals="0" id="ixv-30834" unitRef="usd">1000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="c0" decimals="0" id="ixv-30835" unitRef="usd">2298675</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c0" decimals="0" id="ixv-30836" unitRef="usd">459</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c9" decimals="0" id="ixv-30837" unitRef="usd">1655</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c9" decimals="0" id="ixv-30838" unitRef="usd">18400000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering contextRef="c9" decimals="0" id="ixv-30839" unitRef="usd">926972</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c9" decimals="0" id="ixv-30840" unitRef="usd">16468123</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:PaymentsForRepurchaseOfPrivatePlacement contextRef="c9" decimals="0" id="ixv-30841" unitRef="usd">845048</us-gaap:PaymentsForRepurchaseOfPrivatePlacement>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c9" decimals="0" id="ixv-30842" unitRef="usd">1436</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" id="ixv-30843" unitRef="usd">1035060</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c9" decimals="0" id="ixv-30844" unitRef="usd">32532384</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c0" decimals="0" id="ixv-30845" unitRef="usd">-3331</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="0" id="ixv-30846" unitRef="usd">-21198324</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c9" decimals="0" id="ixv-30847" unitRef="usd">23824185</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" id="ixv-30848" unitRef="usd">25752659</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c18" decimals="0" id="ixv-30849" unitRef="usd">1928474</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c1" decimals="0" id="ixv-30850" unitRef="usd">4554335</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" id="ixv-30851" unitRef="usd">25752659</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NoncashOrPartNoncashAcquisitionInventoryAcquired1 contextRef="c0" decimals="0" id="ixv-30852" unitRef="usd">12947000</us-gaap:NoncashOrPartNoncashAcquisitionInventoryAcquired1>
    <onco:EffectOfBusinessCombination contextRef="c0" decimals="0" id="ixv-30853" unitRef="usd">64054991</onco:EffectOfBusinessCombination>
    <us-gaap:ConversionOfStockAmountIssued1 contextRef="c0" decimals="0" id="ixv-30854" unitRef="usd">3490000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:FairValueOfAssetsAcquired contextRef="c0" decimals="0" id="ixv-30855" unitRef="usd">2613011</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:FairValueOfAssetsAcquired contextRef="c9" decimals="0" id="ixv-30856" unitRef="usd">860204</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1 contextRef="c0" decimals="0" id="ixv-30857" unitRef="usd">150000</us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1>
    <onco:RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement contextRef="c0" decimals="0" id="ixv-30858" unitRef="usd">25837</onco:RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement>
    <onco:RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement contextRef="c9" decimals="0" id="ixv-30859" unitRef="usd">75431</onco:RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement>
    <onco:WarrantsIssuedForSettlementOfContingentWarrants contextRef="c0" decimals="0" id="ixv-30860" unitRef="usd">129184</onco:WarrantsIssuedForSettlementOfContingentWarrants>
    <onco:DeferredOfferingCostsPreviouslyPrepaid contextRef="c0" decimals="0" id="ixv-30861" unitRef="usd">-11020</onco:DeferredOfferingCostsPreviouslyPrepaid>
    <onco:Exerciseofprefundedwarrants contextRef="c0" decimals="0" id="ixv-30862" unitRef="usd">7</onco:Exerciseofprefundedwarrants>
    <onco:Exerciseofprefundedwarrants contextRef="c9" decimals="0" id="ixv-30863" unitRef="usd">6</onco:Exerciseofprefundedwarrants>
    <onco:IssuanceOfRestrictedStock contextRef="c0" decimals="0" id="ixv-30864" unitRef="usd">5</onco:IssuanceOfRestrictedStock>
    <onco:RestrictedStockForfeitures contextRef="c0" decimals="0" id="ixv-30865" unitRef="usd">-3</onco:RestrictedStockForfeitures>
    <onco:PaymentOfAccruedBonusThroughRelatedPartyReceivable contextRef="c9" decimals="0" id="ixv-30866" unitRef="usd">140000</onco:PaymentOfAccruedBonusThroughRelatedPartyReceivable>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c9" decimals="0" id="ixv-30867" unitRef="usd">45</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="c0" id="ixv-16825">&lt;p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Note&#160;1&#160;&#x2014;&#160;Organization and Basis of Presentation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Organization and Nature of Operations&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Onconetix, Inc. (formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc.) (the &#x201c;Company&#x201d; or &#x201c;Onconetix&#x201d;) was formed on October&#160;26, 2018, and is a commercial stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men&#x2019;s health and oncology.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On December&#160;15, 2023, Onconetix acquired 100% of the issued and outstanding voting equity interests in Proteomedix AG, a Swiss company (&#x201c;Proteomedix&#x201d;), and its related diagnostic product Proclarix. As a result of this transaction, Proteomedix became a wholly owned subsidiary of Onconetix (see Note&#160;5). In April&#160;2023, the Company acquired ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt;, a Food and Drug Administration (&#x201c;FDA&#x201d;)&lt;span class="nobreak"&gt;-approved&lt;/span&gt;, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Historically, the Company&#x2019;s focus was on the research and development of transformational vaccines to prevent infectious diseases worldwide, until the third quarter of 2023, at which time the Company deprioritized its efforts on vaccine development activities to focus on commercialization activities for ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt; and pursue other potential acquisitions. In light of (i)&#160;the time and resources needed to continue pursuing commercialization of ENTADFI, and (ii)&#160;the Company&#x2019;s cash runway and indebtedness, the Company has determined to temporarily pause its commercialization of ENTADFI, as it considers strategic alternatives. The Company expects to appoint a new Chief Executive Officer in the second quarter of 2024, after which the new CEO and the Board will reassess its ENTADFI program in light of the foregoing and other relevant factors.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On April&#160;21, 2023, the Company filed an amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to change its corporate name from &#x201c;Blue Water Vaccines Inc.&#x201d; to &#x201c;Blue Water Biotech, Inc.&#x201d; The name change was effective as of April&#160;21, 2023. On December&#160;15, 2023, the Company filed an amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to change its corporate name from &#x201c;Blue Water Biotech, Inc.&#x201d; to &#x201c;Onconetix, Inc.&#x201d; In connection with each of the name changes, the Company also amended the Company&#x2019;s bylaws to reflect the new corporate name.&lt;/p&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company&#x2019;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United&#160;States of America (&#x201c;U.S.&#160;GAAP&#x201d;) and include the accounts of Onconetix and its 100%&#160;wholly owned subsidiary, Proteomedix, since the acquisition date of December&#160;15, 2023. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Certain reclassifications have been made to prior year amounts reported in the accompanying consolidated statement of cash flows to conform to the current year presentation. These reclassifications, which resulted in a difference of approximately $23,000 between operating and investing cash flow activity, are not significant and had no impact on the previously reported financial position or results of operations of the Company.&lt;/p&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Initial Public Offering&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On February&#160;23, 2022, the Company completed its initial public offering (&#x201c;IPO&#x201d;) in which the Company issued and sold 2,222,222&lt;span class="nobreak"&gt; &lt;/span&gt;shares of its common stock, at a price to the public of $9.00 per share. Proceeds from the IPO, net of underwriting discounts, commissions, and offering costs of $2.9&#160;million, were $17.1&#160;million. In connection with the completion of the IPO, all outstanding shares of convertible preferred stock were converted into 5,626,365&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock (see Note&#160;9).&lt;/p&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c58" decimals="2" id="ixv-30868" unitRef="pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c59" decimals="2" id="ixv-30869" unitRef="pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="c0" decimals="0" id="ixv-30870" unitRef="usd">23000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <onco:InitialPublicOfferingShares
      contextRef="c60"
      decimals="0"
      id="ixv-30871"
      unitRef="shares">2222222</onco:InitialPublicOfferingShares>
    <onco:PublicOfPerShare
      contextRef="c60"
      decimals="2"
      id="ixv-30872"
      unitRef="usdPershares">9</onco:PublicOfPerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c61" decimals="-5" id="ixv-30873" unitRef="usd">2900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c62" decimals="-5" id="ixv-30874" unitRef="usd">17100000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ConvertiblePreferredStockSharesReservedForFutureIssuance
      contextRef="c63"
      decimals="0"
      id="ixv-30875"
      unitRef="shares">5626365</us-gaap:ConvertiblePreferredStockSharesReservedForFutureIssuance>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="c0" id="ixv-16846">&lt;p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Note&#160;2 &#x2014; Going Concern and Management&#x2019;s Plans&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company&#x2019;s operating activities to date have been devoted to seeking licenses, engaging in research and development activities, potential asset and business acquisitions, and expenditures associated with the commercial launch of ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt;. The Company has financed its operations since inception primarily using proceeds received from seed investors and proceeds received from its IPO and subsequent debt and equity offerings. During the year &lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;ended December&#160;31, 2022, the Company received an aggregate of approximately $33.1&#160;million in net cash proceeds from its IPO and two private placements, and during the year ended December&#160;31, 2023, the Company received net proceeds of approximately $2.3&#160;million in connection with the exercise by an investor of preferred investment options (see Note&#160;9). In addition, on January&#160;23, 2024, the Company received net cash proceeds of $4.6&#160;million in exchange for the issuance of a debenture. The debenture is repayable in full upon the earlier of (i)&#160;the closing of a subscription agreement, which was entered into in connection with the acquisition of Proteomedix, and (ii)&#160;June&#160;30, 2024 (see&#160;Note&#160;14).&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future. As of December&#160;31, 2023, the Company had cash of approximately $4.6&#160;million, a working capital deficit of approximately $11.4&#160;million and an accumulated deficit of approximately $56.8&#160;million.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;These factors, along with the Company&#x2019;s forecasted future cash flows, indicate that the Company will be unable to meet its contractual commitments and obligations as they come due in the ordinary course of business, within one year following the issuance of these consolidated financial statements. The Company will require significant additional capital in the short&lt;span class="nobreak"&gt;-term&lt;/span&gt; to fund its continuing operations, satisfy existing and future obligations and liabilities, including the remaining payments due for the acquisition of the ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt; assets, payment due on the debenture, in addition to funds needed to support the Company&#x2019;s working capital needs and business activities. These business activities include the commercialization of ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt;, which we have temporarily paused as discussed above, and Proclarix, and the development and commercialization of the Company&#x2019;s current product candidates and future product candidates. In addition, as discussed more fully in Note&#160;5, if stockholder approval is not obtained by January&#160;1, 2025 with respect to the Series&#160;B Convertible Redeemable Preferred Stock issued in connection with the acquisition of Proteomedix, these shares become redeemable for cash at the option of the holders, and the Company currently does not have sufficient cash to redeem such shares.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Management&#x2019;s plans for funding the Company&#x2019;s operations include generating product revenue from sales of Proclarix, which may still be subject to further successful commercialization activities within certain jurisdictions, and ENTADFI, which is subject to further successful commercialization activities which we have temporarily paused as discussed above. Certain of the commercialization activities are outside of the Company&#x2019;s control, including but not limited to, securing contracts with wholesalers and third&lt;span class="nobreak"&gt;-party&lt;/span&gt; payers, securing contracts with third&lt;span class="nobreak"&gt;-party&lt;/span&gt; logistics providers, and obtaining required licensure in various jurisdictions, as well as attempting to secure additional required funding through equity or debt financings if available. However, there are currently no commitments in place for further financing nor is there any assurance that such financing will be available to the Company on favorable terms, if at all. This creates significant uncertainty that the Company will have the funds available to be able to successfully launch ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt; and expand commercialization of Proclarix. If the Company is unable to secure additional capital, it may be required to curtail any future clinical trials, development and/or commercialization of products and product candidates, and it may take additional measures to reduce expenses in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Because of historical and expected operating losses and net operating cash flow deficits, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern for one year from the issuance of the consolidated financial statements, which is not alleviated by management&#x2019;s plans. The consolidated financial statements have been prepared assuming the Company will continue as a going concern. These consolidated financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c64" decimals="-5" id="ixv-30876" unitRef="usd">33100000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromSaleOfOtherInvestments contextRef="c0" decimals="-5" id="ixv-30877" unitRef="usd">2300000</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:ProceedsFromSaleOfOtherInvestments contextRef="c65" decimals="-5" id="ixv-30878" unitRef="usd">4600000</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:Cash contextRef="c1" decimals="-5" id="ixv-30879" unitRef="usd">4600000</us-gaap:Cash>
    <onco:WorkingCapitalDeficit contextRef="c1" decimals="-5" id="ixv-30880" unitRef="usd">11400000</onco:WorkingCapitalDeficit>
    <us-gaap:RetainedEarningsAppropriated contextRef="c1" decimals="-5" id="ixv-30881" unitRef="usd">-56800000</us-gaap:RetainedEarningsAppropriated>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-16874">&lt;p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Note&#160;3 &#x2014; Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The preparation of the consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of &lt;/p&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;revenue and expenses during the reporting periods. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to accounting for acquisitions, valuation of inventory, the useful life of the amortizable intangible assets, estimates of future cash flows used to evaluate impairment of intangible assets, accrued research and development expenses, assumptions related to the pension benefit obligation, stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation, the valuation of preferred stock, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in financial institutions, which, at times, exceed the Federal Depository Insurance Coverage limit for those maintained in the United&#160;States and exceed the Swiss Financial Market Supervisory Authority for those maintained in Switzerland. As of December&#160;31, 2023 and 2022, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;), or decision&lt;span class="nobreak"&gt;-making&lt;/span&gt; group, in deciding how to allocate resources and in assessing performance. Prior to the acquisition of ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt; during the quarter ended June&#160;30, 2023, the Company managed one distinct business segment, which was vaccine discovery and development. During the second quarter of 2023, as a result of the acquisition of ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt;, the Company operated in two business segments: research and development and commercial. During the third quarter of 2023, the Company deprioritized its vaccine discovery and development programs, and accordingly, as of December&#160;31, 2023, the Company was operating in one segment: commercial. Management&#x2019;s determination of its operating segments is consistent with the financial information regularly reviewed by the CODM for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The distribution of revenue by geographical area was as follows:&lt;/p&gt;&lt;/div&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Years Ended &lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;United&#160;States&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-233"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-234"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Switzerland&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;58,465&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-235"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;58,465&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-236"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The distribution of long&lt;span class="nobreak"&gt;-lived&lt;/span&gt; assets by geographical area, which includes property and equipment and the Company&#x2019;s right of use asset, was as follows:&lt;/p&gt;&lt;/div&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Years Ended &lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;United&#160;States&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10,956&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;14,089&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Switzerland&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;198,240&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-237"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;209,196&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;14,089&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The financial statements of Proteomedix, the Company&#x2019;s foreign subsidiary, are measured using the local currency, which is the Swiss Franc, as the functional currency. Assets and liabilities of this subsidiary are translated into U.S.&#160;dollars at exchange rates as of the consolidated balance sheet date. Equity is translated at historical exchange rates. Revenues and expenses are translated into U.S.&#160;dollars at average rates of exchange in effect during the period. The resulting cumulative translation adjustments have been recorded as a separate component of stockholders&#x2019; equity, as accumulated other comprehensive income or loss. Foreign currency transaction gains and losses are included in the results of operations, and were not significant for the&#160;years ended December&#160;31, 2023, or 2022.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company performs periodic credit evaluations of its customers&#x2019; financial condition and extends credit to virtually all of its customers on an uncollateralized basis. Credit losses to date have been insignificant and within management&#x2019;s expectations. The Company provides an allowance for doubtful accounts that is based upon a review of outstanding receivables, historical collection information, expected future losses, and existing economic conditions. As of December&#160;31, 2023, there was no allowance for doubtful accounts. As of December&#160;31, 2023, substantially all of the Company&#x2019;s accounts receivable are due from a single customer.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Inventories consist of product acquired in the ENTADFI and Proteomedix transactions. Inventories are stated at the lower of cost or net realizable value, with cost determined on a first&lt;span class="nobreak"&gt;-in&lt;/span&gt;, first&lt;span class="nobreak"&gt;-out&lt;/span&gt; basis, aside from inventories acquired in an asset acquisition or business combination, which are recorded at fair value. The Company periodically reviews the composition of inventory in order to identify excess, obsolete, slow&lt;span class="nobreak"&gt;-moving&lt;/span&gt; or otherwise non&lt;span class="nobreak"&gt;-saleable&lt;/span&gt; items taking into account anticipated future sales compared with quantities on hand, and the remaining shelf life of goods on hand. If non&lt;span class="nobreak"&gt;-saleable&lt;/span&gt; items are observed and there are no alternate uses for the inventory, the Company records a write&lt;span class="nobreak"&gt;-down&lt;/span&gt; to net realizable value in the period that the decline in value is first recognized. The Company recorded an impairment of inventory in the amount of approximately $1.2&#160;million during the year ended December&#160;31, 2023, as a result of the delay in launching ENTADFI and the Company&#x2019;s decision to pause related commercialization activities.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Property and equipment consists of laboratory equipment, computers, and office furniture and fixtures, all of which are recorded at cost. Depreciation is recorded using the straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; method over the respective useful lives of the assets ranging from &lt;span style="-sec-ix-hidden: hidden-fact-250"&gt;two&lt;/span&gt; to &lt;span style="-sec-ix-hidden: hidden-fact-251"&gt;ten&lt;/span&gt;&#160;years. Depreciation expense was approximately $7,000 for each of the&#160;years ended December&#160;31, 2023 and 2022 and is included in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Acquisitions&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company evaluates acquisitions to first determine whether a set of assets acquired constitutes a business and should be accounted for as a business combination. If the assets acquired are not a business, the transaction is accounted as an asset acquisition in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;)&#160;805&lt;span class="nobreak"&gt;-50&lt;/span&gt;, &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Asset Acquisitions&lt;/span&gt; (&#x201c;ASC&#160;805&lt;span class="nobreak"&gt;-50&lt;/span&gt;&#x201d;), which requires the acquiring entity to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, except for non&lt;span class="nobreak"&gt;-qualifying&lt;/span&gt; assets including financial assets such as inventory. Further, the cost of the acquisition includes the fair value of consideration transferred and direct transaction costs attributable to the acquisition. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. Contingent consideration payments in asset acquisitions are recognized when the contingency is determined to be probable and reasonably estimable. If the assets acquired are a business, the Company accounts for the transaction as a business combination. Business combinations are accounted for by using the acquisition method &lt;/p&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective fair values. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Acquisition related expenses are expensed as incurred, and are included in selling, general and administrative expense in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Goodwill and Other Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Goodwill represents the excess of the cost of a business combination over the fair value of the net assets acquired. Goodwill and intangible assets deemed to have indefinite lives are not amortized but are subject to impairment tests on an annual basis, and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Goodwill is allocated to the reporting unit from which it was created. A reporting unit is an operating segment or sub&lt;span class="nobreak"&gt;-segment&lt;/span&gt; to which goodwill is assigned when initially recorded. The Company tests indefinite lived intangible assets for impairment, on an annual basis in the fourth quarter, or more frequently if an event occurs or circumstances indicate that the indefinite lived assets may be impaired. The Company may perform a qualitative assessment to determine whether it is more&lt;span class="nobreak"&gt;-likely-than-not&lt;/span&gt; that the fair value of a reporting unit is less than its carrying amount. If the Company determines this is the case, the Company then performs further quantitative analysis to identify and measure the amount of goodwill impairment loss to be recognized, if any. To perform its quantitative test, the Company compares the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of its net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. The Company did not test its goodwill or indefinite lived assets for impairment during the year ended December&#160;31, 2023, given that the acquisition date occurred after the annual testing date, and given that there were no impairment indicators from the date of acquisition through the end of the reporting period. The Company has determined that no impairment of its goodwill or indefinite lived intangible assets occurred as of December&#160;31, 2023.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Intangible assets with finite lives are reported at cost, less accumulated amortization, and are amortized over their estimated useful lives, starting when sales for the related product begin. Amortization is calculated using the straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; method, and recorded within selling, general, and administrative expenses, or cost of revenue, depending on the nature and use of the asset.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;During the ordinary course of business, the Company has entered into certain license and asset purchase agreements. Potential milestone payments for development, regulatory, and commercial milestones are recorded when the milestone is probable of achievement. Upon a milestone being achieved, the associated milestone payment is capitalized and amortized over the remaining useful life for approved products, or expensed as research and development expense for milestones relating to products whose FDA approval has not yet been obtained.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company reviews long&lt;span class="nobreak"&gt;-lived&lt;/span&gt; assets, including intangible assets with finite useful lives, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable (a &#x201c;triggering event&#x201d;). Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the long&lt;span class="nobreak"&gt;-lived&lt;/span&gt; asset in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long&lt;span class="nobreak"&gt;-lived&lt;/span&gt; asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long&lt;span class="nobreak"&gt;-lived&lt;/span&gt; asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value. During the fourth quarter of 2023, the Company determined that there were certain triggering events that indicated that the carrying amount of the assets recorded in connection with the ENTADFI acquisition (see Note&#160;5) may not be fully recoverable. A related impairment loss of $14.7&#160;million was recorded during the year ended December&#160;31, 2023 (see Note&#160;4). The Company also recorded an impairment loss of &lt;/p&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;approximately $267,000 during the year ended December&#160;31, 2023, related to implementation costs incurred under cloud computing hosting arrangements that were capitalized during the year. There were no other impairment losses on long&lt;span class="nobreak"&gt;-lived&lt;/span&gt; assets for the&#160;years ended December&#160;31, 2023 and 2022.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S.&#160;GAAP establishes a three&lt;span class="nobreak"&gt;-tier&lt;/span&gt; fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level&lt;span class="nobreak"&gt; &lt;/span&gt;1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level&lt;span class="nobreak"&gt; &lt;/span&gt;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level&lt;span class="nobreak"&gt; &lt;/span&gt;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. Financial instruments, including cash, inventory, accounts receivable, receivables from related party, accounts payable, accrued liabilities, operating lease liabilities, and notes payable are carried at cost, which management believes approximates fair value due to the short&lt;span class="nobreak"&gt;-term&lt;/span&gt; nature of these instruments.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The fair value of the contingent warrant liability that became issuable upon the closing of the private placements the Company closed on during 2022, the warrant inducement the Company closed on during 2023 (see Note&#160;9), and the subscription agreement liability that was recorded in connection with a subscription agreement (see Note&#160;8) are valued using significant unobservable measures and other fair value inputs, and are therefore classified as Level 3 financial instruments.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The fair value of financial instruments measured on a recurring basis is as follows:&lt;/p&gt;&lt;/div&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="11" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 59.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;As of December&#160;31, 2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH_left" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Description&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Liabilities:&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Contingent warrant liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,641&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-238"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-239"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,641&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Subscription agreement liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;864,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-240"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-241"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;864,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;866,641&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-242"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-243"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;866,641&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="9" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 59.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;As of December&#160;31, 2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH_left" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Description&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Liabilities:&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Contingent warrant liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;14,021&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-244"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-245"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;14,021&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;During the year ended December&#160;31, 2023, in connection with the acquisition of Proteomedix, the Company recorded intangible assets, which were recognized at fair value (see Note&#160;5). None of the Company&#x2019;s other non&lt;span class="nobreak"&gt;-financial&lt;/span&gt; assets or liabilities are recorded at fair value on a non&lt;span class="nobreak"&gt;-recurring&lt;/span&gt; basis. There were no transfers between levels during the periods presented.&lt;/p&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The following table summarizes the activity for the subscription agreement liability, using unobservable Level 3 inputs, for the year ended December&#160;31, 2023:&lt;/p&gt;&lt;/div&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Subscription&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Agreement&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Liability&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Balance at December&#160;31, 2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-246"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Fair value upon issuance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;729,900&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Change in fair value&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;134,100&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Balance at December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;864,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;&lt;p style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;"&gt;&lt;/p&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The following table summarizes the activity for the contingent warrant liability, using unobservable Level 3 inputs, for the&#160;years ended December&#160;31, 2023 and 2022:&lt;/p&gt;&lt;/div&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Contingent&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Warrant&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Liability&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Balance at December&#160;31, 2021&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-247"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Fair value at issuance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;75,431&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Change in fair value&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(61,410&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Balance at December&#160;31, 2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;14,021&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Fair value at issuance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;25,837&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Reclassification to equity&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(129,184&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Change in fair value&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,967&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Balance at December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,641&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company capitalizes certain legal, professional accounting and other third&lt;span class="nobreak"&gt;-party&lt;/span&gt; fees that are directly associated with in&lt;span class="nobreak"&gt;-process&lt;/span&gt; equity financing as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#x2019; equity as a reduction of proceeds generated as a result of the offering. Should the in&lt;span class="nobreak"&gt;-process&lt;/span&gt; equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company accounts for leases in accordance with ASC&#160;842, &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Leases&lt;/span&gt;. The Company has one lease agreement for office space, which contains an initial term of two&#160;years with renewal options. The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Operating lease right of use assets and operating lease liabilities are recognized on the lease commencement date. Operating lease right of use assets represent the Company&#x2019;s right to use an underlying asset for the estimated lease term and operating lease liabilities represent the Company&#x2019;s present value of its future lease payments. In assessing its lease and determining its lease liability at lease commencement or upon modification, the Company was not able to readily determine the rate implicit for its lessee arrangements, and thus has used its incremental borrowing rate on a collateralized basis to determine the present value of the lease payments. The Company&#x2019;s right of use asset is measured as the balance of the lease liability plus or minus any prepaid or accrued lease payments and any unamortized initial direct costs. The operating lease payments are recognized as lease expense on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the lease term, and are included in selling, general and administrative expenses in the accompanying consolidated statements of &lt;/p&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;operations and comprehensive loss. Lease payments included in the measurement of the lease liability are comprised of fixed payments. If the Company&#x2019;s lease agreements include renewal option periods, the Company includes such renewal options in its calculation of the estimated lease term when it determines the options are reasonably certain to be exercised. When such renewal options are deemed to be reasonably certain, the estimated lease term determined under ASC&#160;842 will be greater than the non&lt;span class="nobreak"&gt;-cancelable&lt;/span&gt; term of the contractual arrangement.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Leases with an initial term of 12&#160;months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the lease term. The Company applies this policy to all underlying asset categories.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company additionally evaluates leases at their inception to determine if the leases are to be accounted for as an operating lease or a finance lease. Lease expense for operating leases is recognized on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the lease term. Variable lease payments are recognized in the period in which the obligations for those payments are incurred. Lease expense for finance leases is bifurcated into two components, with the amortization expense component of the right&lt;span class="nobreak"&gt;-of-use&lt;/span&gt; asset recognized on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis and the interest expense component recognized using the effective interest method over the lease term. The Company has no financing leases as of December&#160;31, 2023 or 2022.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Defined Benefit Pension Plan&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Proteomedix sponsors a defined benefit pension plan (the &#x201c;Swiss Plan&#x201d;) covering its eligible Swiss employees. The Swiss Plan is government&lt;span class="nobreak"&gt;-mandated&lt;/span&gt; and provides retirement benefits based on employees&#x2019;&#160;years of service and compensation levels. The Company recognizes an asset for the Swiss Plan&#x2019;s overfunded status or a liability for underfunded status in its consolidated balance sheets. Additionally, the Company measures its plan&#x2019;s assets and obligations that determine its funded status as of the end of the year and recognizes the changes in the funded status in the year in which the changes occur. Those changes are reported in accumulated other comprehensive loss in the accompanying consolidated statements of convertible redeemable preferred stock and stockholders&#x2019; equity. The Company uses actuarial valuations to determine its pension and postretirement benefit costs and credits. The amounts calculated depend on a variety of key assumptions, including discount rates and expected return on plan assets. Current market conditions are considered in selecting these assumptions.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Collaborative Agreements&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company periodically enters into strategic alliance agreements with counterparties to produce products and/or provide services to customers. Alliances created by such agreements are not legal entities, have no employees, no assets and have no true operations. These arrangements create contractual rights and the Company accounts for these alliances as a collaborative arrangement by reporting costs incurred and reimbursements received from transactions within research and development expense within the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;During the year ended December&#160;31, 2023, the Company recorded approximately $59,000 of revenue, which was solely generated from Proteomedix development services from the period from the acquisition date of December&#160;15, 2023, through December&#160;31, 2023.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Proteomedix provides a range of services to life sciences customers referred to as &#x201c;Development Services&#x201d; including testing for biomarker discovery, assay design and development. These Development Services are performed under individual statement of work (&#x201c;SOW&#x201d;) arrangements with specific deliverables defined by the customer. Development Services are generally performed on a time and materials basis. During the performance and through completion of the service to the customer in accordance with the SOW, the Company has the right to bill the customer for the agreed upon price and recognizes the Development Services revenue over the period estimated to complete the SOW.&#160;The Company generally identifies each SOW as a single performance obligation.&lt;/p&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Completion of the service and satisfaction of the performance obligation under a SOW is typically evidenced by access to the data or test made available to the customer or any other form or applicable manner of delivery defined in the SOW.&#160;However, for certain SOWs under which work is performed pursuant to the customer&#x2019;s highly customized specifications, the Company has the enforceable right to bill the customer for work completed, rather than upon completion of the SOW.&#160;For those SOWs, the Company recognizes revenue over a period of time during which the work is performed based on the expended efforts (inputs). As the performance obligation under the SOW is satisfied, any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed to the customer as of the date of the consolidated financial statements are recorded as contract assets and are included in prepaids and other current assets as of the financial statement date, and these amounts as of December&#160;31, 2023 are not significant. Amounts recorded in contract assets are reclassified to accounts receivable in our consolidated financial statements when the customer is invoiced according to the billing schedule in the contract. Accounts receivable was approximately $87,000 and $150,000 as of December&#160;15, 2023, the date of acquisition of Proteomedix (see Note&#160;5), and December&#160;31, 2023, respectively.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In circumstances where a SOW includes a variable consideration component, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on which method is expected to better predict the amount of consideration to which the Company will be entitled. The value of variable consideration is included in the transaction price if, and to the extent, it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are reassessed each reporting period, as required, and any adjustment required is recorded on a cumulative catch&lt;span class="nobreak"&gt;-up&lt;/span&gt; basis, which would affect revenue and net loss in the period of adjustment.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company expenses the cost of research and development as incurred. Research and development expenses include costs incurred in funding research and development activities, license fees, and other external costs. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company&#x2019;s behalf will be expensed as services are rendered or when the milestone is achieved. When billing terms under research and development contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end to those third parties. Accrual estimates are based on several factors, including the Company&#x2019;s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs (see Note&#160;6).&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic&#160;730&lt;span class="nobreak"&gt;-10-25-1&lt;/span&gt;, &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Research and Development,&lt;/span&gt; costs incurred in obtaining licenses and patent rights are charged to research and development expense if the technology licensed has not reached commercial feasibility and has no alternative future use. The licenses purchased by the Company (see Note&#160;6) require substantial completion of research and development, regulatory and marketing approval efforts to reach commercial feasibility and have no alternative future use. Accordingly, the total purchase price for the licenses acquired is reflected as research and development on the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Contingencies&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Accruals are recorded for loss contingencies when it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been &lt;/p&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;accrued previously. Considering facts known at the time of the assessment, the Company determines whether potential losses are considered reasonably possible or probable and whether they are estimable. Based upon this assessment, the Company carries out an evaluation of disclosure requirements and considers possible accruals in the consolidated financial statements.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company expenses stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation to employees and non&lt;span class="nobreak"&gt;-employees&lt;/span&gt; over the requisite service period based on the estimated grant&lt;span class="nobreak"&gt;-date&lt;/span&gt; fair value of the awards. Stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; awards to employees with graded&lt;span class="nobreak"&gt;-vesting&lt;/span&gt; schedules are recognized, using the accelerated attribution method, on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the requisite service period for each separately vesting portion of the award.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company estimates the fair value of stock option grants using the Black&lt;span class="nobreak"&gt;-Scholes&lt;/span&gt; option pricing model and the assumptions used in calculating the fair value of stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; awards represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Expected Term&lt;/span&gt;&#160;&#x2014;&#160;The expected term of options represents the period that the Company&#x2019;s stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; awards are expected to be outstanding based on the simplified method, which is the half&lt;span class="nobreak"&gt;-life&lt;/span&gt; from vesting to the end of its contractual term. The simplified method is used as the Company has insufficient historical information to provide a basis for an estimate of the expected term.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Expected Volatility&lt;/span&gt;&#160;&#x2014;&#160;Volatility is a measure of the amount by which the Company&#x2019;s share price has historically fluctuated or is expected to fluctuate (i.e., expected volatility) during a period. Due to the lack of an adequate history of a public market for the trading of the Company&#x2019;s common stock and a lack of adequate company&lt;span class="nobreak"&gt;-specific&lt;/span&gt; historical and implied volatility data, the Company computes stock price volatility over expected terms based on comparable companies&#x2019; historical common stock trading prices. For these analyses, the Company has selected companies with comparable characteristics, including enterprise value, risk profiles, and position within the industry.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Common Stock Fair Value&lt;/span&gt;&#160;&#x2014;&#160;The fair value of the common stock underlying the Company&#x2019;s stock options is based on the closing price of the Company&#x2019;s common stock, as reported by the Nasdaq Capital Market, on the grant date of the award.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Risk&lt;/span&gt;&lt;span class="nobreak"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;-Free&lt;/span&gt;&lt;/span&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt; Interest Rate&lt;/span&gt;&#160;&#x2014;&#160;The Company bases the risk&lt;span class="nobreak"&gt;-free&lt;/span&gt; interest rate on the implied yield available on U.S.&#160;Treasury securities with a remaining term commensurate with the estimated expected term.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Expected Dividend&lt;/span&gt;&#160;&#x2014;&#160;The Company has never declared or paid any cash dividends on its shares of common stock and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company recognizes forfeitures of equity awards as they occur.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the jurisdictions and&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in operations in the period that includes the enactment date. Deferred tax assets are reduced to estimated amounts expected to be realized by the use of a valuation allowance.&lt;/p&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company is required to report all components of comprehensive loss, including net loss, in the accompanying consolidated financial statements in the period in which they are recognized. Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non&lt;span class="nobreak"&gt;-owner&lt;/span&gt; sources. The Company&#x2019;s comprehensive loss for the year ended December&#160;31, 2023 is comprised of net loss, the effect of currency translation adjustments, and the change in pension benefit obligation. Net loss and comprehensive loss were the same for the year ended December&#160;31, 2022.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Financial instruments&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company determines the accounting classification of financial instruments that are issued, including its warrants and a subscription agreement, as either liability or equity, by first assessing whether the financial instruments are freestanding financial instruments, and if they meet liability classification in accordance with ASC&#160;480, &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;, (&#x201c;ASC&#160;480&#x201d;), and then in accordance with ASC&#160;815&lt;span class="nobreak"&gt;-40&lt;/span&gt;, &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Derivatives and Hedging&#160;&#x2014;&#160;Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;(&#x201c;ASC&#160;815&lt;span class="nobreak"&gt;-40&lt;/span&gt;&#x201d;). Under ASC&#160;480&lt;span class="nobreak"&gt;-10&lt;/span&gt;, financial instruments are considered liability&lt;span class="nobreak"&gt;-classified&lt;/span&gt; if the instruments are mandatorily redeemable, obligate the issuer to settle the instruments or the underlying shares by paying cash or other assets, or must or may require settlement by issuing a variable number of shares.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;If the instruments do not meet liability classification under ASC&#160;480, the Company assesses the requirements under ASC&#160;815&lt;span class="nobreak"&gt;-40&lt;/span&gt;, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the financial instruments do not require liability classification under ASC&#160;815&lt;span class="nobreak"&gt;-40&lt;/span&gt;, in order to conclude equity classification, the Company assesses whether the instruments are indexed to the Company&#x2019;s common stock and whether the instruments are classified as equity under ASC&#160;815&lt;span class="nobreak"&gt;-40&lt;/span&gt; or other applicable GAAP.&#160;After all relevant assessments are made, the Company concludes whether the instruments are classified as liability or equity. Liability&lt;span class="nobreak"&gt;-classified&lt;/span&gt; instruments are required to be accounted for at fair value both on the date of issuance and on subsequent accounting period ending dates, with all changes in fair value after the issuance date recorded as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. Equity&lt;span class="nobreak"&gt;-classified&lt;/span&gt; instruments are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company applies the guidance enumerated in ASC&#160;480, when determining the classification and measurement of preferred stock. Preferred stock subject to mandatory redemption, if any, is classified as a liability and is measured at fair value. The Company classifies conditionally redeemable preferred stock, which includes preferred stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control, as temporary equity. At all other times, the Company classifies its preferred stock in stockholders&#x2019; equity.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Treasury Stock&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company records treasury stock activities under the cost method whereby the cost of the acquired stock is recorded as treasury stock.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Basic loss per share is computed by dividing the net loss applicable to common shares by the weighted average number of common shares outstanding during the period. The weighted average number of shares of common stock outstanding includes (i)&#160;pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants because their exercise requires only nominal consideration for delivery of shares and (ii)&#160;the shares held in abeyance because there is no consideration required for delivery of the shares; &lt;/p&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;it does not include any potentially dilutive securities or any unvested restricted stock of common stock. Certain restricted shares, although classified as issued and outstanding at December&#160;31, 2023 are considered contingently returnable until the restrictions lapse and will not be included in the basic net loss per share calculation until the shares are vested. Unvested shares of the Company&#x2019;s restricted stock do not contain non&lt;span class="nobreak"&gt;-forfeitable&lt;/span&gt; rights to dividends and dividend equivalents. Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the Company&#x2019;s Series&#160;A preferred stock, warrants, unvested restricted stock, and stock options. Diluted loss per share excludes the shares issuable upon the conversion of Series&#160;A preferred stock, as well as unvested restricted stock, common stock options and warrants, from the calculation of net loss per share if their effect would be anti&lt;span class="nobreak"&gt;-dilutive&lt;/span&gt;.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The two&lt;span class="nobreak"&gt;-class&lt;/span&gt; method is used to determine earnings per share based on participation rights of participating securities in any undistributed earnings. Each preferred stock that includes rights to participate in distributed earnings is considered a participating security and the Company uses the two&lt;span class="nobreak"&gt;-class&lt;/span&gt; method to calculate net income available to the Company&#x2019;s common stockholders per common share&#160;&#x2014;&#160;basic and diluted.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The following securities were excluded from the computation of diluted shares outstanding for the periods presented, as they would have had an anti&lt;span class="nobreak"&gt;-dilutive&lt;/span&gt; impact on the Company&#x2019;s net loss:&lt;/p&gt;&lt;/div&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Years Ended &lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Stock options&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,904,830&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,392,654&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Warrants&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7,899,661&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5,264,274&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Unvested restricted stock&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;256,580&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-248"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Common stock issuable upon conversion of Series&#160;A preferred stock&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5,709,935&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-249"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;15,771,006&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;6,656,928&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;New Accounting Pronouncement&lt;/span&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;s&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In November&#160;2023, the FASB issued ASU No.&#160;2023&lt;span class="nobreak"&gt;-07&lt;/span&gt;, Segment Reporting (Topic&#160;280): &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Improvements to Reportable Segment Disclosures&lt;/span&gt;. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) and included within each reported measure of a segment&#x2019;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment&#x2019;s profit or loss in assessing segment performance and deciding how to allocate resources. This ASU is effective for annual periods beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In December&#160;2023, the FASB issued ASU No.&#160;2023&lt;span class="nobreak"&gt;-09&lt;/span&gt;, Income Taxes (Topic&#160;740&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;): Improvements to Income Tax Disclosures&lt;/span&gt;. This ASU requires disclosure of specific categories in the rate reconciliation and additional information for reconciling items that meet a quantitative threshold. The amendment also includes other changes to improve the effectiveness of income tax disclosures, including further disaggregation of income taxes paid for individually significant jurisdictions. This ASU is effective for annual periods beginning after December&#160;15, 2024. Adoption of this ASU should be applied on a prospective basis. Early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company&#x2019;s management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying consolidated financial statements.&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-16878">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The preparation of the consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of &lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;revenue and expenses during the reporting periods. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to accounting for acquisitions, valuation of inventory, the useful life of the amortizable intangible assets, estimates of future cash flows used to evaluate impairment of intangible assets, accrued research and development expenses, assumptions related to the pension benefit obligation, stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation, the valuation of preferred stock, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-16901">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in financial institutions, which, at times, exceed the Federal Depository Insurance Coverage limit for those maintained in the United&#160;States and exceed the Swiss Financial Market Supervisory Authority for those maintained in Switzerland. As of December&#160;31, 2023 and 2022, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-16908">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;), or decision&lt;span class="nobreak"&gt;-making&lt;/span&gt; group, in deciding how to allocate resources and in assessing performance. Prior to the acquisition of ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt; during the quarter ended June&#160;30, 2023, the Company managed one distinct business segment, which was vaccine discovery and development. During the second quarter of 2023, as a result of the acquisition of ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt;, the Company operated in two business segments: research and development and commercial. During the third quarter of 2023, the Company deprioritized its vaccine discovery and development programs, and accordingly, as of December&#160;31, 2023, the Company was operating in one segment: commercial. Management&#x2019;s determination of its operating segments is consistent with the financial information regularly reviewed by the CODM for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The distribution of revenue by geographical area was as follows:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Years Ended &lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;United&#160;States&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-233"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-234"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Switzerland&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;58,465&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-235"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;58,465&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-236"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The distribution of long&lt;span class="nobreak"&gt;-lived&lt;/span&gt; assets by geographical area, which includes property and equipment and the Company&#x2019;s right of use asset, was as follows:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Years Ended &lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;United&#160;States&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10,956&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;14,089&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Switzerland&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;198,240&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-237"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;209,196&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;14,089&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments contextRef="c0" decimals="0" id="ixv-30882" unitRef="pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock contextRef="c0" id="ixv-16917">&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The distribution of revenue by geographical area was as follows:&lt;/p&gt;&lt;/div&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Years Ended &lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;United&#160;States&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-233"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-234"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Switzerland&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;58,465&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-235"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;58,465&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-236"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:Revenues contextRef="c71" decimals="0" id="ixv-30883" unitRef="usd">58465</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c0" decimals="0" id="ixv-30884" unitRef="usd">58465</us-gaap:Revenues>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock contextRef="c0" id="ixv-16990">&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The distribution of long&lt;span class="nobreak"&gt;-lived&lt;/span&gt; assets by geographical area, which includes property and equipment and the Company&#x2019;s right of use asset, was as follows:&lt;/p&gt;&lt;/div&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Years Ended &lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;United&#160;States&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10,956&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;14,089&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Switzerland&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;198,240&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-237"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;209,196&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;14,089&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:NoncurrentAssets contextRef="c73" decimals="0" id="ixv-30885" unitRef="usd">10956</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c74" decimals="0" id="ixv-30886" unitRef="usd">14089</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c75" decimals="0" id="ixv-30887" unitRef="usd">198240</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c1" decimals="0" id="ixv-30888" unitRef="usd">209196</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c2" decimals="0" id="ixv-30889" unitRef="usd">14089</us-gaap:NoncurrentAssets>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0" id="ixv-17073">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The financial statements of Proteomedix, the Company&#x2019;s foreign subsidiary, are measured using the local currency, which is the Swiss Franc, as the functional currency. Assets and liabilities of this subsidiary are translated into U.S.&#160;dollars at exchange rates as of the consolidated balance sheet date. Equity is translated at historical exchange rates. Revenues and expenses are translated into U.S.&#160;dollars at average rates of exchange in effect during the period. The resulting cumulative translation adjustments have been recorded as a separate component of stockholders&#x2019; equity, as accumulated other comprehensive income or loss. Foreign currency transaction gains and losses are included in the results of operations, and were not significant for the&#160;years ended December&#160;31, 2023, or 2022.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c0" id="ixv-17080">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company performs periodic credit evaluations of its customers&#x2019; financial condition and extends credit to virtually all of its customers on an uncollateralized basis. Credit losses to date have been insignificant and within management&#x2019;s expectations. The Company provides an allowance for doubtful accounts that is based upon a review of outstanding receivables, historical collection information, expected future losses, and existing economic conditions. As of December&#160;31, 2023, there was no allowance for doubtful accounts. As of December&#160;31, 2023, substantially all of the Company&#x2019;s accounts receivable are due from a single customer.&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0" id="ixv-17087">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Inventories consist of product acquired in the ENTADFI and Proteomedix transactions. Inventories are stated at the lower of cost or net realizable value, with cost determined on a first&lt;span class="nobreak"&gt;-in&lt;/span&gt;, first&lt;span class="nobreak"&gt;-out&lt;/span&gt; basis, aside from inventories acquired in an asset acquisition or business combination, which are recorded at fair value. The Company periodically reviews the composition of inventory in order to identify excess, obsolete, slow&lt;span class="nobreak"&gt;-moving&lt;/span&gt; or otherwise non&lt;span class="nobreak"&gt;-saleable&lt;/span&gt; items taking into account anticipated future sales compared with quantities on hand, and the remaining shelf life of goods on hand. If non&lt;span class="nobreak"&gt;-saleable&lt;/span&gt; items are observed and there are no alternate uses for the inventory, the Company records a write&lt;span class="nobreak"&gt;-down&lt;/span&gt; to net realizable value in the period that the decline in value is first recognized. The Company recorded an impairment of inventory in the amount of approximately $1.2&#160;million during the year ended December&#160;31, 2023, as a result of the delay in launching ENTADFI and the Company&#x2019;s decision to pause related commercialization activities.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryValuationReserves contextRef="c1" decimals="-5" id="ixv-30890" unitRef="usd">1200000</us-gaap:InventoryValuationReserves>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-17100">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Property and equipment consists of laboratory equipment, computers, and office furniture and fixtures, all of which are recorded at cost. Depreciation is recorded using the straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; method over the respective useful lives of the assets ranging from &lt;span style="-sec-ix-hidden: hidden-fact-250"&gt;two&lt;/span&gt; to &lt;span style="-sec-ix-hidden: hidden-fact-251"&gt;ten&lt;/span&gt;&#160;years. Depreciation expense was approximately $7,000 for each of the&#160;years ended December&#160;31, 2023 and 2022 and is included in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:Depreciation contextRef="c0" decimals="0" id="ixv-30891" unitRef="usd">7000</us-gaap:Depreciation>
    <onco:AcquisitionsPolicyTextBlock contextRef="c0" id="ixv-17110">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Acquisitions&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company evaluates acquisitions to first determine whether a set of assets acquired constitutes a business and should be accounted for as a business combination. If the assets acquired are not a business, the transaction is accounted as an asset acquisition in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;)&#160;805&lt;span class="nobreak"&gt;-50&lt;/span&gt;, &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Asset Acquisitions&lt;/span&gt; (&#x201c;ASC&#160;805&lt;span class="nobreak"&gt;-50&lt;/span&gt;&#x201d;), which requires the acquiring entity to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, except for non&lt;span class="nobreak"&gt;-qualifying&lt;/span&gt; assets including financial assets such as inventory. Further, the cost of the acquisition includes the fair value of consideration transferred and direct transaction costs attributable to the acquisition. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. Contingent consideration payments in asset acquisitions are recognized when the contingency is determined to be probable and reasonably estimable. If the assets acquired are a business, the Company accounts for the transaction as a business combination. Business combinations are accounted for by using the acquisition method &lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective fair values. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Acquisition related expenses are expensed as incurred, and are included in selling, general and administrative expense in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;</onco:AcquisitionsPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c0" id="ixv-17136">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Goodwill and Other Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Goodwill represents the excess of the cost of a business combination over the fair value of the net assets acquired. Goodwill and intangible assets deemed to have indefinite lives are not amortized but are subject to impairment tests on an annual basis, and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Goodwill is allocated to the reporting unit from which it was created. A reporting unit is an operating segment or sub&lt;span class="nobreak"&gt;-segment&lt;/span&gt; to which goodwill is assigned when initially recorded. The Company tests indefinite lived intangible assets for impairment, on an annual basis in the fourth quarter, or more frequently if an event occurs or circumstances indicate that the indefinite lived assets may be impaired. The Company may perform a qualitative assessment to determine whether it is more&lt;span class="nobreak"&gt;-likely-than-not&lt;/span&gt; that the fair value of a reporting unit is less than its carrying amount. If the Company determines this is the case, the Company then performs further quantitative analysis to identify and measure the amount of goodwill impairment loss to be recognized, if any. To perform its quantitative test, the Company compares the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of its net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. The Company did not test its goodwill or indefinite lived assets for impairment during the year ended December&#160;31, 2023, given that the acquisition date occurred after the annual testing date, and given that there were no impairment indicators from the date of acquisition through the end of the reporting period. The Company has determined that no impairment of its goodwill or indefinite lived intangible assets occurred as of December&#160;31, 2023.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Intangible assets with finite lives are reported at cost, less accumulated amortization, and are amortized over their estimated useful lives, starting when sales for the related product begin. Amortization is calculated using the straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; method, and recorded within selling, general, and administrative expenses, or cost of revenue, depending on the nature and use of the asset.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;During the ordinary course of business, the Company has entered into certain license and asset purchase agreements. Potential milestone payments for development, regulatory, and commercial milestones are recorded when the milestone is probable of achievement. Upon a milestone being achieved, the associated milestone payment is capitalized and amortized over the remaining useful life for approved products, or expensed as research and development expense for milestones relating to products whose FDA approval has not yet been obtained.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0" id="ixv-17152">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company reviews long&lt;span class="nobreak"&gt;-lived&lt;/span&gt; assets, including intangible assets with finite useful lives, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable (a &#x201c;triggering event&#x201d;). Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the long&lt;span class="nobreak"&gt;-lived&lt;/span&gt; asset in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long&lt;span class="nobreak"&gt;-lived&lt;/span&gt; asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long&lt;span class="nobreak"&gt;-lived&lt;/span&gt; asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value. During the fourth quarter of 2023, the Company determined that there were certain triggering events that indicated that the carrying amount of the assets recorded in connection with the ENTADFI acquisition (see Note&#160;5) may not be fully recoverable. A related impairment loss of $14.7&#160;million was recorded during the year ended December&#160;31, 2023 (see Note&#160;4). The Company also recorded an impairment loss of &lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;approximately $267,000 during the year ended December&#160;31, 2023, related to implementation costs incurred under cloud computing hosting arrangements that were capitalized during the year. There were no other impairment losses on long&lt;span class="nobreak"&gt;-lived&lt;/span&gt; assets for the&#160;years ended December&#160;31, 2023 and 2022.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:GoodwillImpairmentLoss contextRef="c0" decimals="-5" id="ixv-30892" unitRef="usd">14700000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="c0" decimals="0" id="ixv-30893" unitRef="usd">267000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-17179">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S.&#160;GAAP establishes a three&lt;span class="nobreak"&gt;-tier&lt;/span&gt; fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level&lt;span class="nobreak"&gt; &lt;/span&gt;1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level&lt;span class="nobreak"&gt; &lt;/span&gt;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level&lt;span class="nobreak"&gt; &lt;/span&gt;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. Financial instruments, including cash, inventory, accounts receivable, receivables from related party, accounts payable, accrued liabilities, operating lease liabilities, and notes payable are carried at cost, which management believes approximates fair value due to the short&lt;span class="nobreak"&gt;-term&lt;/span&gt; nature of these instruments.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The fair value of the contingent warrant liability that became issuable upon the closing of the private placements the Company closed on during 2022, the warrant inducement the Company closed on during 2023 (see Note&#160;9), and the subscription agreement liability that was recorded in connection with a subscription agreement (see Note&#160;8) are valued using significant unobservable measures and other fair value inputs, and are therefore classified as Level 3 financial instruments.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The fair value of financial instruments measured on a recurring basis is as follows:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="11" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 59.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;As of December&#160;31, 2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH_left" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Description&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Liabilities:&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Contingent warrant liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,641&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-238"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-239"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,641&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Subscription agreement liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;864,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-240"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-241"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;864,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;866,641&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-242"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-243"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;866,641&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="9" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 59.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;As of December&#160;31, 2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH_left" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Description&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Liabilities:&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Contingent warrant liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;14,021&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-244"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-245"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;14,021&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;During the year ended December&#160;31, 2023, in connection with the acquisition of Proteomedix, the Company recorded intangible assets, which were recognized at fair value (see Note&#160;5). None of the Company&#x2019;s other non&lt;span class="nobreak"&gt;-financial&lt;/span&gt; assets or liabilities are recorded at fair value on a non&lt;span class="nobreak"&gt;-recurring&lt;/span&gt; basis. There were no transfers between levels during the periods presented.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The following table summarizes the activity for the subscription agreement liability, using unobservable Level 3 inputs, for the year ended December&#160;31, 2023:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Subscription&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Agreement&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Liability&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Balance at December&#160;31, 2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-246"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Fair value upon issuance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;729,900&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Change in fair value&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;134,100&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Balance at December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;864,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;&lt;p style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;"&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The following table summarizes the activity for the contingent warrant liability, using unobservable Level 3 inputs, for the&#160;years ended December&#160;31, 2023 and 2022:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Contingent&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Warrant&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Liability&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Balance at December&#160;31, 2021&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-247"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Fair value at issuance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;75,431&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Change in fair value&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(61,410&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Balance at December&#160;31, 2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;14,021&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Fair value at issuance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;25,837&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Reclassification to equity&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(129,184&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Change in fair value&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,967&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Balance at December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,641&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c0" id="ixv-17211">&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The fair value of financial instruments measured on a recurring basis is as follows:&lt;/p&gt;&lt;/div&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="11" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 59.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;As of December&#160;31, 2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH_left" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Description&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Liabilities:&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Contingent warrant liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,641&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-238"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-239"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,641&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Subscription agreement liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;864,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-240"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-241"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;864,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;866,641&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-242"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-243"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;866,641&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="9" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 59.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;As of December&#160;31, 2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH_left" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Description&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Liabilities:&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Contingent warrant liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;14,021&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-244"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-245"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;14,021&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c1" decimals="0" id="ixv-30894" unitRef="usd">2641</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c79" decimals="0" id="ixv-30895" unitRef="usd">2641</us-gaap:DerivativeLiabilitiesCurrent>
    <onco:SubscriptionAgreementLiabilityNoncurrent contextRef="c1" decimals="0" id="ixv-30896" unitRef="usd">864000</onco:SubscriptionAgreementLiabilityNoncurrent>
    <onco:SubscriptionAgreementLiabilityNoncurrent contextRef="c79" decimals="0" id="ixv-30897" unitRef="usd">864000</onco:SubscriptionAgreementLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c1" decimals="0" id="ixv-30898" unitRef="usd">866641</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c79" decimals="0" id="ixv-30899" unitRef="usd">866641</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-30900" unitRef="usd">14021</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c82" decimals="0" id="ixv-30901" unitRef="usd">14021</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c0" id="ixv-17421">&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The following table summarizes the activity for the subscription agreement liability, using unobservable Level 3 inputs, for the year ended December&#160;31, 2023:&lt;/p&gt;&lt;/div&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Subscription&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Agreement&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Liability&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Balance at December&#160;31, 2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-246"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Fair value upon issuance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;729,900&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Change in fair value&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;134,100&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Balance at December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;864,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;&lt;p style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;"&gt;&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues contextRef="c84" decimals="0" id="ixv-30902" unitRef="usd">729900</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease contextRef="c84" decimals="0" id="ixv-30903" unitRef="usd">134100</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c85" decimals="0" id="ixv-30904" unitRef="usd">864000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c0" id="ixv-17475">&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The following table summarizes the activity for the contingent warrant liability, using unobservable Level 3 inputs, for the&#160;years ended December&#160;31, 2023 and 2022:&lt;/p&gt;&lt;/div&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Contingent&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Warrant&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Liability&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Balance at December&#160;31, 2021&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-247"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Fair value at issuance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;75,431&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Change in fair value&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(61,410&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Balance at December&#160;31, 2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;14,021&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Fair value at issuance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;25,837&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Reclassification to equity&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(129,184&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Change in fair value&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,967&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Balance at December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,641&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues contextRef="c87" decimals="0" id="ixv-30905" unitRef="usd">75431</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease contextRef="c87" decimals="0" id="ixv-30906" unitRef="usd">61410</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs contextRef="c88" decimals="0" id="ixv-30907" unitRef="usd">14021</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues contextRef="c89" decimals="0" id="ixv-30908" unitRef="usd">25837</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues>
    <onco:ReclassificationToEquity contextRef="c90" decimals="0" id="ixv-30909" unitRef="usd">-129184</onco:ReclassificationToEquity>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease contextRef="c89" decimals="0" id="ixv-30910" unitRef="usd">-91967</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs contextRef="c90" decimals="0" id="ixv-30911" unitRef="usd">2641</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="c0" id="ixv-17577">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company capitalizes certain legal, professional accounting and other third&lt;span class="nobreak"&gt;-party&lt;/span&gt; fees that are directly associated with in&lt;span class="nobreak"&gt;-process&lt;/span&gt; equity financing as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#x2019; equity as a reduction of proceeds generated as a result of the offering. Should the in&lt;span class="nobreak"&gt;-process&lt;/span&gt; equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-17587">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company accounts for leases in accordance with ASC&#160;842, &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Leases&lt;/span&gt;. The Company has one lease agreement for office space, which contains an initial term of two&#160;years with renewal options. The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Operating lease right of use assets and operating lease liabilities are recognized on the lease commencement date. Operating lease right of use assets represent the Company&#x2019;s right to use an underlying asset for the estimated lease term and operating lease liabilities represent the Company&#x2019;s present value of its future lease payments. In assessing its lease and determining its lease liability at lease commencement or upon modification, the Company was not able to readily determine the rate implicit for its lessee arrangements, and thus has used its incremental borrowing rate on a collateralized basis to determine the present value of the lease payments. The Company&#x2019;s right of use asset is measured as the balance of the lease liability plus or minus any prepaid or accrued lease payments and any unamortized initial direct costs. The operating lease payments are recognized as lease expense on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the lease term, and are included in selling, general and administrative expenses in the accompanying consolidated statements of &lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;operations and comprehensive loss. Lease payments included in the measurement of the lease liability are comprised of fixed payments. If the Company&#x2019;s lease agreements include renewal option periods, the Company includes such renewal options in its calculation of the estimated lease term when it determines the options are reasonably certain to be exercised. When such renewal options are deemed to be reasonably certain, the estimated lease term determined under ASC&#160;842 will be greater than the non&lt;span class="nobreak"&gt;-cancelable&lt;/span&gt; term of the contractual arrangement.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Leases with an initial term of 12&#160;months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the lease term. The Company applies this policy to all underlying asset categories.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company additionally evaluates leases at their inception to determine if the leases are to be accounted for as an operating lease or a finance lease. Lease expense for operating leases is recognized on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the lease term. Variable lease payments are recognized in the period in which the obligations for those payments are incurred. Lease expense for finance leases is bifurcated into two components, with the amortization expense component of the right&lt;span class="nobreak"&gt;-of-use&lt;/span&gt; asset recognized on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis and the interest expense component recognized using the effective interest method over the lease term. The Company has no financing leases as of December&#160;31, 2023 or 2022.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock contextRef="c0" id="ixv-17624">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Defined Benefit Pension Plan&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Proteomedix sponsors a defined benefit pension plan (the &#x201c;Swiss Plan&#x201d;) covering its eligible Swiss employees. The Swiss Plan is government&lt;span class="nobreak"&gt;-mandated&lt;/span&gt; and provides retirement benefits based on employees&#x2019;&#160;years of service and compensation levels. The Company recognizes an asset for the Swiss Plan&#x2019;s overfunded status or a liability for underfunded status in its consolidated balance sheets. Additionally, the Company measures its plan&#x2019;s assets and obligations that determine its funded status as of the end of the year and recognizes the changes in the funded status in the year in which the changes occur. Those changes are reported in accumulated other comprehensive loss in the accompanying consolidated statements of convertible redeemable preferred stock and stockholders&#x2019; equity. The Company uses actuarial valuations to determine its pension and postretirement benefit costs and credits. The amounts calculated depend on a variety of key assumptions, including discount rates and expected return on plan assets. Current market conditions are considered in selecting these assumptions.&lt;/p&gt;</us-gaap:DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c0" id="ixv-17632">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Collaborative Agreements&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company periodically enters into strategic alliance agreements with counterparties to produce products and/or provide services to customers. Alliances created by such agreements are not legal entities, have no employees, no assets and have no true operations. These arrangements create contractual rights and the Company accounts for these alliances as a collaborative arrangement by reporting costs incurred and reimbursements received from transactions within research and development expense within the consolidated statements of operations and comprehensive loss.&lt;/p&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0" id="ixv-17639">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;During the year ended December&#160;31, 2023, the Company recorded approximately $59,000 of revenue, which was solely generated from Proteomedix development services from the period from the acquisition date of December&#160;15, 2023, through December&#160;31, 2023.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Proteomedix provides a range of services to life sciences customers referred to as &#x201c;Development Services&#x201d; including testing for biomarker discovery, assay design and development. These Development Services are performed under individual statement of work (&#x201c;SOW&#x201d;) arrangements with specific deliverables defined by the customer. Development Services are generally performed on a time and materials basis. During the performance and through completion of the service to the customer in accordance with the SOW, the Company has the right to bill the customer for the agreed upon price and recognizes the Development Services revenue over the period estimated to complete the SOW.&#160;The Company generally identifies each SOW as a single performance obligation.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Completion of the service and satisfaction of the performance obligation under a SOW is typically evidenced by access to the data or test made available to the customer or any other form or applicable manner of delivery defined in the SOW.&#160;However, for certain SOWs under which work is performed pursuant to the customer&#x2019;s highly customized specifications, the Company has the enforceable right to bill the customer for work completed, rather than upon completion of the SOW.&#160;For those SOWs, the Company recognizes revenue over a period of time during which the work is performed based on the expended efforts (inputs). As the performance obligation under the SOW is satisfied, any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed to the customer as of the date of the consolidated financial statements are recorded as contract assets and are included in prepaids and other current assets as of the financial statement date, and these amounts as of December&#160;31, 2023 are not significant. Amounts recorded in contract assets are reclassified to accounts receivable in our consolidated financial statements when the customer is invoiced according to the billing schedule in the contract. Accounts receivable was approximately $87,000 and $150,000 as of December&#160;15, 2023, the date of acquisition of Proteomedix (see Note&#160;5), and December&#160;31, 2023, respectively.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In circumstances where a SOW includes a variable consideration component, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on which method is expected to better predict the amount of consideration to which the Company will be entitled. The value of variable consideration is included in the transaction price if, and to the extent, it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are reassessed each reporting period, as required, and any adjustment required is recorded on a cumulative catch&lt;span class="nobreak"&gt;-up&lt;/span&gt; basis, which would affect revenue and net loss in the period of adjustment.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:RecognitionOfDeferredRevenue contextRef="c0" decimals="0" id="ixv-30912" unitRef="usd">59000</us-gaap:RecognitionOfDeferredRevenue>
    <us-gaap:AccountsReceivableNet contextRef="c1" decimals="0" id="ixv-30913" unitRef="usd">87000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c68" decimals="0" id="ixv-30914" unitRef="usd">150000</us-gaap:AccountsReceivableNet>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0" id="ixv-17669">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company expenses the cost of research and development as incurred. Research and development expenses include costs incurred in funding research and development activities, license fees, and other external costs. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company&#x2019;s behalf will be expensed as services are rendered or when the milestone is achieved. When billing terms under research and development contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end to those third parties. Accrual estimates are based on several factors, including the Company&#x2019;s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs (see Note&#160;6).&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic&#160;730&lt;span class="nobreak"&gt;-10-25-1&lt;/span&gt;, &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Research and Development,&lt;/span&gt; costs incurred in obtaining licenses and patent rights are charged to research and development expense if the technology licensed has not reached commercial feasibility and has no alternative future use. The licenses purchased by the Company (see Note&#160;6) require substantial completion of research and development, regulatory and marketing approval efforts to reach commercial feasibility and have no alternative future use. Accordingly, the total purchase price for the licenses acquired is reflected as research and development on the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c0" id="ixv-17681">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Accruals are recorded for loss contingencies when it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been &lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;accrued previously. Considering facts known at the time of the assessment, the Company determines whether potential losses are considered reasonably possible or probable and whether they are estimable. Based upon this assessment, the Company carries out an evaluation of disclosure requirements and considers possible accruals in the consolidated financial statements.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-17703">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company expenses stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation to employees and non&lt;span class="nobreak"&gt;-employees&lt;/span&gt; over the requisite service period based on the estimated grant&lt;span class="nobreak"&gt;-date&lt;/span&gt; fair value of the awards. Stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; awards to employees with graded&lt;span class="nobreak"&gt;-vesting&lt;/span&gt; schedules are recognized, using the accelerated attribution method, on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the requisite service period for each separately vesting portion of the award.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company estimates the fair value of stock option grants using the Black&lt;span class="nobreak"&gt;-Scholes&lt;/span&gt; option pricing model and the assumptions used in calculating the fair value of stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; awards represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Expected Term&lt;/span&gt;&#160;&#x2014;&#160;The expected term of options represents the period that the Company&#x2019;s stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; awards are expected to be outstanding based on the simplified method, which is the half&lt;span class="nobreak"&gt;-life&lt;/span&gt; from vesting to the end of its contractual term. The simplified method is used as the Company has insufficient historical information to provide a basis for an estimate of the expected term.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Expected Volatility&lt;/span&gt;&#160;&#x2014;&#160;Volatility is a measure of the amount by which the Company&#x2019;s share price has historically fluctuated or is expected to fluctuate (i.e., expected volatility) during a period. Due to the lack of an adequate history of a public market for the trading of the Company&#x2019;s common stock and a lack of adequate company&lt;span class="nobreak"&gt;-specific&lt;/span&gt; historical and implied volatility data, the Company computes stock price volatility over expected terms based on comparable companies&#x2019; historical common stock trading prices. For these analyses, the Company has selected companies with comparable characteristics, including enterprise value, risk profiles, and position within the industry.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Common Stock Fair Value&lt;/span&gt;&#160;&#x2014;&#160;The fair value of the common stock underlying the Company&#x2019;s stock options is based on the closing price of the Company&#x2019;s common stock, as reported by the Nasdaq Capital Market, on the grant date of the award.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Risk&lt;/span&gt;&lt;span class="nobreak"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;-Free&lt;/span&gt;&lt;/span&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt; Interest Rate&lt;/span&gt;&#160;&#x2014;&#160;The Company bases the risk&lt;span class="nobreak"&gt;-free&lt;/span&gt; interest rate on the implied yield available on U.S.&#160;Treasury securities with a remaining term commensurate with the estimated expected term.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Expected Dividend&lt;/span&gt;&#160;&#x2014;&#160;The Company has never declared or paid any cash dividends on its shares of common stock and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company recognizes forfeitures of equity awards as they occur.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-17751">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the jurisdictions and&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in operations in the period that includes the enactment date. Deferred tax assets are reduced to estimated amounts expected to be realized by the use of a valuation allowance.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c0" id="ixv-17774">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company is required to report all components of comprehensive loss, including net loss, in the accompanying consolidated financial statements in the period in which they are recognized. Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non&lt;span class="nobreak"&gt;-owner&lt;/span&gt; sources. The Company&#x2019;s comprehensive loss for the year ended December&#160;31, 2023 is comprised of net loss, the effect of currency translation adjustments, and the change in pension benefit obligation. Net loss and comprehensive loss were the same for the year ended December&#160;31, 2022.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c0" id="ixv-17782">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Financial instruments&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company determines the accounting classification of financial instruments that are issued, including its warrants and a subscription agreement, as either liability or equity, by first assessing whether the financial instruments are freestanding financial instruments, and if they meet liability classification in accordance with ASC&#160;480, &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;, (&#x201c;ASC&#160;480&#x201d;), and then in accordance with ASC&#160;815&lt;span class="nobreak"&gt;-40&lt;/span&gt;, &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Derivatives and Hedging&#160;&#x2014;&#160;Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;(&#x201c;ASC&#160;815&lt;span class="nobreak"&gt;-40&lt;/span&gt;&#x201d;). Under ASC&#160;480&lt;span class="nobreak"&gt;-10&lt;/span&gt;, financial instruments are considered liability&lt;span class="nobreak"&gt;-classified&lt;/span&gt; if the instruments are mandatorily redeemable, obligate the issuer to settle the instruments or the underlying shares by paying cash or other assets, or must or may require settlement by issuing a variable number of shares.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;If the instruments do not meet liability classification under ASC&#160;480, the Company assesses the requirements under ASC&#160;815&lt;span class="nobreak"&gt;-40&lt;/span&gt;, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the financial instruments do not require liability classification under ASC&#160;815&lt;span class="nobreak"&gt;-40&lt;/span&gt;, in order to conclude equity classification, the Company assesses whether the instruments are indexed to the Company&#x2019;s common stock and whether the instruments are classified as equity under ASC&#160;815&lt;span class="nobreak"&gt;-40&lt;/span&gt; or other applicable GAAP.&#160;After all relevant assessments are made, the Company concludes whether the instruments are classified as liability or equity. Liability&lt;span class="nobreak"&gt;-classified&lt;/span&gt; instruments are required to be accounted for at fair value both on the date of issuance and on subsequent accounting period ending dates, with all changes in fair value after the issuance date recorded as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. Equity&lt;span class="nobreak"&gt;-classified&lt;/span&gt; instruments are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy contextRef="c0" id="ixv-17803">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company applies the guidance enumerated in ASC&#160;480, when determining the classification and measurement of preferred stock. Preferred stock subject to mandatory redemption, if any, is classified as a liability and is measured at fair value. The Company classifies conditionally redeemable preferred stock, which includes preferred stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control, as temporary equity. At all other times, the Company classifies its preferred stock in stockholders&#x2019; equity.&lt;/p&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
    <onco:TreasuryStockPolicyPolicyTextBlock contextRef="c0" id="ixv-17810">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Treasury Stock&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company records treasury stock activities under the cost method whereby the cost of the acquired stock is recorded as treasury stock.&lt;/p&gt;</onco:TreasuryStockPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-17817">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Basic loss per share is computed by dividing the net loss applicable to common shares by the weighted average number of common shares outstanding during the period. The weighted average number of shares of common stock outstanding includes (i)&#160;pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants because their exercise requires only nominal consideration for delivery of shares and (ii)&#160;the shares held in abeyance because there is no consideration required for delivery of the shares; &lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;it does not include any potentially dilutive securities or any unvested restricted stock of common stock. Certain restricted shares, although classified as issued and outstanding at December&#160;31, 2023 are considered contingently returnable until the restrictions lapse and will not be included in the basic net loss per share calculation until the shares are vested. Unvested shares of the Company&#x2019;s restricted stock do not contain non&lt;span class="nobreak"&gt;-forfeitable&lt;/span&gt; rights to dividends and dividend equivalents. Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the Company&#x2019;s Series&#160;A preferred stock, warrants, unvested restricted stock, and stock options. Diluted loss per share excludes the shares issuable upon the conversion of Series&#160;A preferred stock, as well as unvested restricted stock, common stock options and warrants, from the calculation of net loss per share if their effect would be anti&lt;span class="nobreak"&gt;-dilutive&lt;/span&gt;.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The two&lt;span class="nobreak"&gt;-class&lt;/span&gt; method is used to determine earnings per share based on participation rights of participating securities in any undistributed earnings. Each preferred stock that includes rights to participate in distributed earnings is considered a participating security and the Company uses the two&lt;span class="nobreak"&gt;-class&lt;/span&gt; method to calculate net income available to the Company&#x2019;s common stockholders per common share&#160;&#x2014;&#160;basic and diluted.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The following securities were excluded from the computation of diluted shares outstanding for the periods presented, as they would have had an anti&lt;span class="nobreak"&gt;-dilutive&lt;/span&gt; impact on the Company&#x2019;s net loss:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Years Ended &lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Stock options&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,904,830&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,392,654&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Warrants&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7,899,661&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5,264,274&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Unvested restricted stock&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;256,580&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-248"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Common stock issuable upon conversion of Series&#160;A preferred stock&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5,709,935&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-249"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;15,771,006&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;6,656,928&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0" id="ixv-17846">&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The following securities were excluded from the computation of diluted shares outstanding for the periods presented, as they would have had an anti&lt;span class="nobreak"&gt;-dilutive&lt;/span&gt; impact on the Company&#x2019;s net loss:&lt;/p&gt;&lt;/div&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Years Ended &lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Stock options&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,904,830&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,392,654&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Warrants&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7,899,661&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5,264,274&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Unvested restricted stock&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;256,580&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-248"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Common stock issuable upon conversion of Series&#160;A preferred stock&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5,709,935&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-249"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;15,771,006&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;6,656,928&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c91"
      decimals="INF"
      id="ixv-30915"
      unitRef="shares">1904830</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c92"
      decimals="INF"
      id="ixv-30916"
      unitRef="shares">1392654</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c93"
      decimals="INF"
      id="ixv-30917"
      unitRef="shares">7899661</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c94"
      decimals="INF"
      id="ixv-30918"
      unitRef="shares">5264274</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c95"
      decimals="INF"
      id="ixv-30919"
      unitRef="shares">256580</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c97"
      decimals="INF"
      id="ixv-30920"
      unitRef="shares">5709935</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="INF"
      id="ixv-30921"
      unitRef="shares">15771006</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c9"
      decimals="INF"
      id="ixv-30922"
      unitRef="shares">6656928</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-17923">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;New Accounting Pronouncement&lt;/span&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;s&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In November&#160;2023, the FASB issued ASU No.&#160;2023&lt;span class="nobreak"&gt;-07&lt;/span&gt;, Segment Reporting (Topic&#160;280): &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Improvements to Reportable Segment Disclosures&lt;/span&gt;. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) and included within each reported measure of a segment&#x2019;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment&#x2019;s profit or loss in assessing segment performance and deciding how to allocate resources. This ASU is effective for annual periods beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In December&#160;2023, the FASB issued ASU No.&#160;2023&lt;span class="nobreak"&gt;-09&lt;/span&gt;, Income Taxes (Topic&#160;740&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;): Improvements to Income Tax Disclosures&lt;/span&gt;. This ASU requires disclosure of specific categories in the rate reconciliation and additional information for reconciling items that meet a quantitative threshold. The amendment also includes other changes to improve the effectiveness of income tax disclosures, including further disaggregation of income taxes paid for individually significant jurisdictions. This ASU is effective for annual periods beginning after December&#160;15, 2024. Adoption of this ASU should be applied on a prospective basis. Early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.&lt;/p&gt;&lt;p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company&#x2019;s management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c0" id="ixv-17947">&lt;p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Note&#160;4 &#x2014; Balance Sheet Details&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Inventories&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Inventories primarily relate to ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt; product and consisted of the following as of December&#160;31, 2023 and 2022:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Raw materials&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;139,208&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-252"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Work-in-process&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;194,805&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-253"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Finished goods&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;30,039&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-254"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;364,052&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-255"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Prepaid expenses and other current assets consisted of the following as of December&#160;31, 2023 and 2022:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Prepaid insurance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;122,004&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;148,789&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Prepaid regulatory fees&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;312,551&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-256"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Prepaid research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;89,195&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;231,981&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Prepaid professional fees&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;70,708&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-257"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Prepaid other&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;175,695&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;88,462&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;770,153&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;469,232&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Intangible assets, which were recorded during the year ended December&#160;31, 2023 in connection with the ENTADFI and Proteomedix acquisitions (see Note&#160;5), is comprised of customer relationships, product rights for developed technology, and a trade name, and consisted of the following as of December&#160;31, 2023:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Impairment&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Effect of&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Currency&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Translation&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Balance&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Cost basis:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Trade name&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;9,018,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-258"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;294,739&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;9,312,739&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Product rights for developed technology&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;28,447,771&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(14,610,128&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;344,514&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;14,182,157&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Customer relationships&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,891,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-259"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;61,803&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,952,803&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;39,356,771&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;(14,610,128&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;701,056&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;25,447,699&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Balance&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Accumulated amortization:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Trade name&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-260"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-261"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Product rights for developed technology&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(31,213&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(31,213&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Customer relationships&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(5,599&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(5,599&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;(36,812&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;(36,812&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Intangible assets, net&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;25,410,887&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The finite lived intangible assets held by the Company, which includes customer relationships and product rights for developed technology, are being amortized over their estimated useful lives, which is 15&#160;years for customer relationships, and 15 and 6&#160;years for product rights for developed technology related to Proclarix and ENTADFI, respectively. Amortization expense related to intangible assets was approximately $37,000 for the year ended December&#160;31, 2023, of which approximately $31,000 and $6,000 was recorded as cost of revenue and selling, general, and administrative expenses, respectively, in the accompanying consolidated statements of operations and comprehensive loss.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;During the fourth quarter of 2023, the Company determined that there were certain triggering events that indicated that the carrying amount of the assets recorded in connection with the ENTADFI acquisition (see Note&#160;5) may not be fully recoverable. Specifically, as a result of the Proteomedix acquisition (see Note&#160;5) and continued significant cash constraints, the Company decided to pause the commercialization of ENTADFI until a later date, and consider strategic alternatives, which combined, decreased the cash flows expected to be generated from these assets. The Company performed an undiscounted cash flow analysis over the ENTADFI asset group and determined that the carrying value of the asset group is not recoverable. The Company then estimated the fair value of the asset group to measure the impairment loss. Significant assumptions used to determine this non&lt;span class="nobreak"&gt;-recurring&lt;/span&gt; fair value measurement include projected sales driven by market share and product sales price estimates, associated expenses, growth rates, the discount rate used to measure the fair value of the net cash flows associated with this asset group, as well as Management&#x2019;s estimates of the probability of each potential strategic alternative taking place. The Company recorded an impairment charge of $14.7&#160;million during the year ended December&#160;31, 2023, which was allocated on a pro rata basis across the assets within the asset group as follows: approximately $14.6&#160;million and approximately $0.1&#160;million was allocated to the product rights intangible asset and other assets, respectively. After recording this impairment charge, the long&lt;span class="nobreak"&gt;-lived&lt;/span&gt; assets in the ENTADFI asset group have a remaining carrying amount of approximately $3.3&#160;million as of December&#160;31, 2023. In addition, the Company also recorded an impairment charge on acquired ENTADFI inventory, see Note&#160;3.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Future annual amortization expense related to the Company&#x2019;s finite lived intangible assets is as follows as of December&#160;31, 2023:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Years ending December&#160;31,&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,012,870&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2025&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,326,837&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2026&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,326,837&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2027&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,326,837&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2028&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,326,837&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Thereafter&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;9,777,930&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;16,098,148&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of December&#160;31, 2023, the weighted&lt;span class="nobreak"&gt;-average&lt;/span&gt; remaining amortization period for intangible assets was approximately &lt;span style="-sec-ix-hidden: hidden-fact-265"&gt;13.5&lt;/span&gt;&#160;years.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Trade names, which do not have legal, regulatory, contractual, competitive, economic, or other factors that limit the useful lives are considered indefinite lived assets and are not amortized but are tested for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. As of December&#160;31, 2023, $9.3&#160;million of intangible assets relate to a trade name that has been identified as having an indefinite life.&lt;/p&gt;&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Goodwill was recorded during the year ended December&#160;31, 2023, in connection with the Proteomedix acquisition (see Note&#160;5), and consisted of the following as of December&#160;31, 2023:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Balance as of December&#160;31, 2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-262"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;PMX Transaction goodwill&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;53,914,055&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Effect of currency translation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,762,087&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Balance as of December&#160;31, 2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;55,676,142&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accrued Expenses&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Accrued expenses consisted of the following as of December&#160;31, 2023 and 2022:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;847,747&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;487,579&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,132,859&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued deferred offering costs&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;125,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;125,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued professional fees&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;550,415&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-263"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued implementation fees&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;93,787&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-264"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Other accrued expenses&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;265,849&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;125,922&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued franchise taxes&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;60,530&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;177,600&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2,199,867&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2,409,128&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c0" id="ixv-17952">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Inventories primarily relate to ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt; product and consisted of the following as of December&#160;31, 2023 and 2022:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Raw materials&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;139,208&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-252"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Work-in-process&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;194,805&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-253"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Finished goods&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;30,039&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-254"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;364,052&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-255"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c1" decimals="0" id="ixv-30923" unitRef="usd">139208</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="c1" decimals="0" id="ixv-30924" unitRef="usd">194805</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="c1" decimals="0" id="ixv-30925" unitRef="usd">30039</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet contextRef="c1" decimals="0" id="ixv-30926" unitRef="usd">364052</us-gaap:InventoryNet>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c0" id="ixv-18037">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Prepaid expenses and other current assets consisted of the following as of December&#160;31, 2023 and 2022:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Prepaid insurance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;122,004&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;148,789&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Prepaid regulatory fees&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;312,551&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-256"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Prepaid research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;89,195&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;231,981&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Prepaid professional fees&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;70,708&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-257"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Prepaid other&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;175,695&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;88,462&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;770,153&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;469,232&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance contextRef="c1" decimals="0" id="ixv-30927" unitRef="usd">122004</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="c2" decimals="0" id="ixv-30928" unitRef="usd">148789</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidRent contextRef="c1" decimals="0" id="ixv-30929" unitRef="usd">312551</us-gaap:PrepaidRent>
    <onco:PrepaidsResearchAndDevelopment contextRef="c1" decimals="0" id="ixv-30930" unitRef="usd">89195</onco:PrepaidsResearchAndDevelopment>
    <onco:PrepaidsResearchAndDevelopment contextRef="c2" decimals="0" id="ixv-30931" unitRef="usd">231981</onco:PrepaidsResearchAndDevelopment>
    <onco:PrepaidProfessionalFees contextRef="c1" decimals="0" id="ixv-30932" unitRef="usd">70708</onco:PrepaidProfessionalFees>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c1" decimals="0" id="ixv-30933" unitRef="usd">175695</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c2" decimals="0" id="ixv-30934" unitRef="usd">88462</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c1" decimals="0" id="ixv-30935" unitRef="usd">770153</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="0" id="ixv-30936" unitRef="usd">469232</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c0" id="ixv-18145">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Intangible assets, which were recorded during the year ended December&#160;31, 2023 in connection with the ENTADFI and Proteomedix acquisitions (see Note&#160;5), is comprised of customer relationships, product rights for developed technology, and a trade name, and consisted of the following as of December&#160;31, 2023:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Impairment&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Effect of&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Currency&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Translation&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Balance&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Cost basis:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Trade name&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;9,018,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-258"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;294,739&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;9,312,739&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Product rights for developed technology&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;28,447,771&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(14,610,128&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;344,514&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;14,182,157&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Customer relationships&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,891,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-259"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;61,803&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,952,803&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;39,356,771&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;(14,610,128&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;701,056&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;25,447,699&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Balance&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Accumulated amortization:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Trade name&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-260"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-261"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Product rights for developed technology&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(31,213&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(31,213&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Customer relationships&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(5,599&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(5,599&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;(36,812&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;(36,812&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Intangible assets, net&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;25,410,887&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <onco:FiniteLivedIntangibleAssetCost contextRef="c104" decimals="0" id="ixv-30937" unitRef="usd">9018000</onco:FiniteLivedIntangibleAssetCost>
    <us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss contextRef="c105" decimals="0" id="ixv-30938" unitRef="usd">294739</us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c104" decimals="0" id="ixv-30939" unitRef="usd">9312739</us-gaap:FiniteLivedIntangibleAssetsGross>
    <onco:FiniteLivedIntangibleAssetCost contextRef="c106" decimals="0" id="ixv-30940" unitRef="usd">28447771</onco:FiniteLivedIntangibleAssetCost>
    <onco:ImpairmentOfIntangibleAssetExcludingGoodwill contextRef="c102" decimals="0" id="ixv-30941" unitRef="usd">-14610128</onco:ImpairmentOfIntangibleAssetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss contextRef="c102" decimals="0" id="ixv-30942" unitRef="usd">344514</us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c106" decimals="0" id="ixv-30943" unitRef="usd">14182157</us-gaap:FiniteLivedIntangibleAssetsGross>
    <onco:FiniteLivedIntangibleAssetCost contextRef="c107" decimals="0" id="ixv-30944" unitRef="usd">1891000</onco:FiniteLivedIntangibleAssetCost>
    <us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss contextRef="c108" decimals="0" id="ixv-30945" unitRef="usd">61803</us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c107" decimals="0" id="ixv-30946" unitRef="usd">1952803</us-gaap:FiniteLivedIntangibleAssetsGross>
    <onco:FiniteLivedIntangibleAssetCost contextRef="c1" decimals="0" id="ixv-30947" unitRef="usd">39356771</onco:FiniteLivedIntangibleAssetCost>
    <onco:ImpairmentOfIntangibleAssetExcludingGoodwill contextRef="c0" decimals="0" id="ixv-30948" unitRef="usd">-14610128</onco:ImpairmentOfIntangibleAssetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss contextRef="c0" decimals="0" id="ixv-30949" unitRef="usd">701056</us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c1" decimals="0" id="ixv-30950" unitRef="usd">25447699</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c102" decimals="0" id="ixv-30951" unitRef="usd">31213</us-gaap:AmortizationOfIntangibleAssets>
    <onco:FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation contextRef="c102" decimals="0" id="ixv-30952" unitRef="usd">-31213</onco:FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c108" decimals="0" id="ixv-30953" unitRef="usd">5599</us-gaap:AmortizationOfIntangibleAssets>
    <onco:FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation contextRef="c108" decimals="0" id="ixv-30954" unitRef="usd">-5599</onco:FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="0" id="ixv-30955" unitRef="usd">36812</us-gaap:AmortizationOfIntangibleAssets>
    <onco:FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation contextRef="c0" decimals="0" id="ixv-30956" unitRef="usd">-36812</onco:FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c1" decimals="0" id="ixv-30957" unitRef="usd">25410887</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c1" id="ixv-30958">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c99" id="ixv-30959">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c100" id="ixv-30960">P6Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c101" decimals="0" id="ixv-30961" unitRef="usd">37000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OtherCostOfOperatingRevenue contextRef="c0" decimals="0" id="ixv-30964" unitRef="usd">31000</us-gaap:OtherCostOfOperatingRevenue>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-30965" unitRef="usd">6000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:AssetImpairmentCharges contextRef="c0" decimals="-5" id="ixv-30966" unitRef="usd">14700000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="c102"
      decimals="-5"
      id="ixv-30967"
      unitRef="usd">14600000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="c103"
      decimals="-5"
      id="ixv-30968"
      unitRef="usd">100000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="c101"
      decimals="-5"
      id="ixv-30969"
      unitRef="usd">3300000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c0" id="ixv-18449">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Future annual amortization expense related to the Company&#x2019;s finite lived intangible assets is as follows as of December&#160;31, 2023:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Years ending December&#160;31,&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,012,870&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2025&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,326,837&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2026&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,326,837&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2027&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,326,837&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2028&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,326,837&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Thereafter&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;9,777,930&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;16,098,148&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c1" decimals="0" id="ixv-30970" unitRef="usd">1012870</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c1" decimals="0" id="ixv-30971" unitRef="usd">1326837</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c1" decimals="0" id="ixv-30972" unitRef="usd">1326837</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c1" decimals="0" id="ixv-30973" unitRef="usd">1326837</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c1" decimals="0" id="ixv-30974" unitRef="usd">1326837</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c1" decimals="0" id="ixv-30975" unitRef="usd">9777930</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c1" decimals="0" id="ixv-30976" unitRef="usd">16098148</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedTradeNames contextRef="c1" decimals="-5" id="ixv-30977" unitRef="usd">9300000</us-gaap:IndefiniteLivedTradeNames>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c0" id="ixv-18536">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Goodwill was recorded during the year ended December&#160;31, 2023, in connection with the Proteomedix acquisition (see Note&#160;5), and consisted of the following as of December&#160;31, 2023:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Balance as of December&#160;31, 2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-262"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;PMX Transaction goodwill&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;53,914,055&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Effect of currency translation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,762,087&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Balance as of December&#160;31, 2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;55,676,142&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:GoodwillTransfers contextRef="c0" decimals="0" id="ixv-30978" unitRef="usd">53914055</us-gaap:GoodwillTransfers>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c0" decimals="0" id="ixv-30979" unitRef="usd">1762087</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill contextRef="c1" decimals="0" id="ixv-30980" unitRef="usd">55676142</us-gaap:Goodwill>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c0" id="ixv-18588">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Accrued expenses consisted of the following as of December&#160;31, 2023 and 2022:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;847,747&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;487,579&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,132,859&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued deferred offering costs&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;125,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;125,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued professional fees&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;550,415&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-263"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued implementation fees&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;93,787&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-264"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Other accrued expenses&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;265,849&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;125,922&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued franchise taxes&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;60,530&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;177,600&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2,199,867&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2,409,128&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <onco:AccruedResearchAndDevelopmentCurrent contextRef="c1" decimals="0" id="ixv-30981" unitRef="usd">616707</onco:AccruedResearchAndDevelopmentCurrent>
    <onco:AccruedResearchAndDevelopmentCurrent contextRef="c2" decimals="0" id="ixv-30982" unitRef="usd">847747</onco:AccruedResearchAndDevelopmentCurrent>
    <us-gaap:AccruedUtilitiesCurrentAndNoncurrent contextRef="c1" decimals="0" id="ixv-30983" unitRef="usd">487579</us-gaap:AccruedUtilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedUtilitiesCurrentAndNoncurrent contextRef="c2" decimals="0" id="ixv-30984" unitRef="usd">1132859</us-gaap:AccruedUtilitiesCurrentAndNoncurrent>
    <onco:AccruedDeferredOfferingCosts contextRef="c1" decimals="0" id="ixv-30985" unitRef="usd">125000</onco:AccruedDeferredOfferingCosts>
    <onco:AccruedDeferredOfferingCosts contextRef="c2" decimals="0" id="ixv-30986" unitRef="usd">125000</onco:AccruedDeferredOfferingCosts>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent contextRef="c1" decimals="0" id="ixv-30987" unitRef="usd">550415</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="c1" decimals="0" id="ixv-30988" unitRef="usd">93787</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c1" decimals="0" id="ixv-30989" unitRef="usd">265849</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c2" decimals="0" id="ixv-30990" unitRef="usd">125922</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c1" decimals="0" id="ixv-30991" unitRef="usd">60530</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c2" decimals="0" id="ixv-30992" unitRef="usd">177600</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c1" decimals="0" id="ixv-30993" unitRef="usd">2199867</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-30994" unitRef="usd">2409128</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="c0" id="ixv-18720">&lt;p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Note&#160;5 &#x2014; Acquisitions&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;ENTADFI&lt;/span&gt;&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On April&#160;19, 2023, the Company and Veru, Inc. (&#x201c;Veru&#x201d;) entered into an Asset Purchase Agreement (the &#x201c;&#160;Veru APA&#x201d;). Pursuant to, and subject to the terms and conditions of, the Veru APA, the Company purchased substantially all of the assets related to Veru&#x2019;s ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt; product (&#x201c;ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt;&#x201d;) (the &#x201c;Transaction&#x201d;) for a total possible consideration of $100&#160;million.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In accordance with the Veru APA, the Company agreed to provide Veru with initial consideration totaling $20.0&#160;million, consisting of (i)&#160;$6.0&#160;million paid upon the closing of the Transaction on April&#160;19, 2023, (ii)&#160;an additional $4.0&#160;million in the form of a non&lt;span class="nobreak"&gt;-interest&lt;/span&gt; bearing note payable due on September&#160;30, 2023, and (iii)&#160;an additional $10.0&#160;million in the form of two $5.0&#160;million non&lt;span class="nobreak"&gt;-interest&lt;/span&gt; bearing notes payable, each due on April&#160;19, 2024 and September&#160;30, 2024.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Additionally, the terms of the Veru APA require the Company to pay Veru up to an additional $80.0&#160;million based on the Company&#x2019;s net sales of ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt; after closing (the &#x201c;Milestone Payments&#x201d;). The Milestone Payments are payable as follows: (i)&#160;$10.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt; of $100.0&#160;million during a calendar year, (ii)&#160;$20.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt; of $200.0&#160;million during a calendar year, and (3)&#160;$50.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt; of $500.0&#160;million during a calendar year.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In connection with the Transaction, the Company also assumed royalty and milestone obligations under an asset purchase agreement for tadalafil&lt;span class="nobreak"&gt;-finasteride&lt;/span&gt; combination entered into by Veru and Camargo Pharmaceutical Services, LLC on December&#160;11, 2017 (the &#x201c;Camargo Obligations&#x201d;). The Camargo Obligations assumed by the Company include a 6% royalty on all sales of tadalafil&lt;span class="nobreak"&gt;-finasteride&lt;/span&gt; and sales milestone payments of up to $22.5&#160;million, payable &lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;to Camargo as follows: (i)&#160;$5.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt; of $100.0&#160;million during a calendar year, (ii)&#160;$7.5&#160;million is payable upon the first time the Company achieves net sales from ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt; of $200.0&#160;million during a calendar year, and (3)&#160;$10.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt; of $300.0&#160;million during a calendar year.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On September&#160;29, 2023, the Company entered into an amendment to the Veru APA (the &#x201c;Veru APA Amendment&#x201d;), which provides that the $4.0&#160;million note payable originally due on September&#160;30, 2023 was deemed paid and fully satisfied upon (1)&#160;the payment to the Seller of $1.0&#160;million in cash on September&#160;29, 2023, and (2)&#160;the issuance to the Seller by October&#160;3, 2023 of 3,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of Series&#160;A Convertible Preferred Stock (the &#x201c;Series&#160;A Preferred Stock&#x201d;) of the Company (see Note&#160;9). Pursuant to the Veru APA Amendment, the Series&#160;A Preferred Stock will convert to common stock of the Company one year from the date of issuance if the required stockholder approval is obtained. The Series&#160;A Preferred Stock, which was issued to the Seller on October&#160;3, 2023 is initially convertible, in the aggregate, into 5,709,935&lt;span class="nobreak"&gt; &lt;/span&gt;shares of the Company&#x2019;s common stock, subject to adjustment and certain stockholder approval limitations specified in the Certificate of Designations. Pursuant to the Veru APA Amendment, the Company agreed to use commercially reasonable efforts to obtain such stockholder approval by December&#160;31, 2023, however, such shareholder approval was not obtained as of December&#160;31, 2023. The Company also agreed to include the shares of common stock issuable upon conversion of the Series&#160;A Preferred Stock in the next resale registration statement filed with the SEC.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Also, in connection with the Transaction, and pursuant to the Veru APA, the Company entered into non&lt;span class="nobreak"&gt;-competition&lt;/span&gt; and non&lt;span class="nobreak"&gt;-solicitation&lt;/span&gt; agreements (the &#x201c;Non&lt;span class="nobreak"&gt;-Competition&lt;/span&gt; Agreements&#x201d;) with two of Veru&#x2019;s key stockholders and employees (the &#x201c;Restricted Parties&#x201d;). The Non&lt;span class="nobreak"&gt;-Competition&lt;/span&gt; Agreements generally prohibit the Restricted Parties from either directly or indirectly engaging in the Restricted Business (as such term is defined in the Veru APA) for a period of &lt;span style="-sec-ix-hidden: hidden-fact-266"&gt;five&lt;/span&gt;&#160;years from the closing of the Transaction.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The acquisition of ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt; has been accounted for as an asset acquisition in accordance with ASC&#160;805&lt;span class="nobreak"&gt;-50&lt;/span&gt; because substantially all of the fair value of the assets acquired is concentrated in a single asset, the ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt; product rights. The ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt; products rights consist of trademarks, regulatory approvals, and other records, and are considered a single asset as they are inextricably linked.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The following table summarizes the aggregate consideration transferred for the assets acquired by the Company in connection with the Veru APA:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Consideration&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Transferred&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Consideration transferred at closing&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6,000,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Fair value of notes payable issued&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;12,947,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Transaction costs&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;79,771&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total consideration transferred&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;19,026,771&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The fair value of the non&lt;span class="nobreak"&gt;-interest&lt;/span&gt; bearing notes payable was estimated using a net present value model using discount rates averaging 8.2%. The resulting fair value is being accreted to the face value of the notes, through the respective maturity dates. Management evaluated the Milestone Payments and determined that at the close of the Transaction, they are not considered probable, and as such, the Company did not recognize any amount related to the Milestone Payments in the consideration transferred.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The following table summarizes the assets acquired with the Veru APA:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Assets&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Recognized&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Inventory&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,120,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt; Intangible&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;17,906,771&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total fair value of identifiable assets acquired&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;19,026,771&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In accordance with ASC&#160;805&lt;span class="nobreak"&gt;-50&lt;/span&gt;, the acquired inventory was recorded at fair value. The remaining consideration transferred was allocated to the ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt; intangible asset, which will be amortized over its estimated useful life, starting when ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt; sales begin. Acquired inventory is comprised of work&lt;span class="nobreak"&gt;-in-process&lt;/span&gt; and raw materials. The fair value of work&lt;span class="nobreak"&gt;-in-process&lt;/span&gt; inventory was determined based on an estimated sales price of the finished goods, adjusted for costs to complete the manufacturing process, costs of the selling effort, a reasonable profit allowance for the remaining manufacturing and selling effort, and an estimate of holding costs, and resulted in a fair value adjustment of approximately $0.3&#160;million. The fair value of raw materials was determined to approximate replacement cost. The Company recorded an impairment charge on the ENTADFI asset group of $14.7&#160;million during the fourth quarter of 2023 (see Note&#160;4), as well as an impairment charge on the ENTADFI acquired inventory of approximately $1.2&#160;million, which included impairment of 100% of the acquired work&lt;span class="nobreak"&gt;-in-process&lt;/span&gt; inventory.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Management evaluated the Camargo Obligations and determined that at the close of the Transaction, the related sales milestone payments are not considered probable, and as such, the Company did not recognize any related liability at the date of the Transaction. In addition, royalties under the Camargo Obligations will be recorded as cost of sales, as the related sales are generated and recognized.&lt;/p&gt;
		&lt;p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;WraSer:&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On June&#160;13, 2023 (the &#x201c;Execution Date&#x201d;), the Company entered into an asset purchase agreement with WraSer, LLC, and affiliates (the &#x201c;WraSer Seller&#x201d;) (the &#x201c;WraSer APA&#x201d;). Pursuant to, and subject to the terms and conditions of, the WraSer APA, on the WraSer Closing Date (as defined below) the Company was to purchase six FDA&lt;span class="nobreak"&gt;-approved&lt;/span&gt; pharmaceutical assets across several indications, including cardiology, otic infections, and pain management (the &#x201c;WraSer Assets&#x201d;).&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Under the terms of the WraSer APA, the Company was to purchase the WraSer Assets for (i)&#160;$3.5&#160;million in cash at signing of the WraSer APA; (ii)&#160;$4.5&#160;million in cash on the later of (x)&#160;90&#160;days after the signing of the WraSer APA or (y)&#160;the date that all closing conditions under the WraSer APA are met or otherwise waived (the &#x201c;WraSer Closing Date&#x201d;); (iii)&#160;1.0&#160;million shares of the Company&#x2019;s common stock (the &#x201c;Closing Shares&#x201d;) issuable on the WraSer Closing Date, and (iv)&#160;$500,000 in cash one year from the WraSer Closing Date.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In conjunction with the WraSer APA, the Company and the WraSer Seller entered into a Management Services Agreement (the &#x201c;MSA&#x201d;) on the Execution Date. Pursuant to the terms of the MSA, the Company will act as the manager of the WraSer Seller&#x2019;s business during the period between the Execution Date and the WraSer Closing Date. During this period, the Company will make advances to WraSer, if needed. If, on the WraSer Closing Date, the WraSer Seller&#x2019;s cash balance is in excess of the target amount (&#x201c;Cash Target&#x201d;) specified in the MSA, the Company will apply that excess to the $4.5&#160;million cash payment due upon closing. Conversely, if there is a shortfall, the Company will be required to remit the difference to the WraSer Seller over time.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The WraSer APA can be terminated prior to the closing upon agreement with all parties or upon breach of contract of either party, uncured within 20&#160;days of notice. If the WraSer APA is terminated upon agreement with all parties or upon uncured breach of contract by the Company, the initial $3.5&#160;million payment is retained by the WraSer Seller. If it is determined that there is an uncured breach of contract by the WraSer Seller, and the WraSer APA is terminated, the Company will have an unsecured claim against WraSer for the $3.5&#160;million payment made by the Company upon execution of the WraSer APA.&#160;The closing of the transaction is subject to certain customary closing conditions, including submission of the FDA transfer documentation to transfer ownership of the acquired product regulatory approvals to the Company.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Management evaluated the terms of the WraSer APA and the WraSer MSA, and determined that, at the Execution Date, control under the provisions of ASC&#160;805, &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Business Combinations &lt;/span&gt;(&#x201c;ASC&#160;805&#x201d;), did not transfer to the Company; if the transaction closes, control will transfer then, and the acquisition date will be the closing date. Management further evaluated the requirements pursuant to ASC&#160;810, &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Consolidations&lt;/span&gt;, and determined based on the terms of the MSA, and the Company&#x2019;s involvement in the WraSer Seller&#x2019;s business, that the WraSer Seller is a variable interest entity (&#x201c;VIE&#x201d;) to the Company. Management determined that the Company is not the primary beneficiary of &lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;the VIE as the WraSer APA and MSA do not provide the Company with the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance. While the Company was involved in the&#160;day&lt;span class="nobreak"&gt;-to-day&lt;/span&gt; business activities of the VIE until WraSer filed for relief under Chapter&#160;11 of the U.S.&#160;Bankruptcy Court (see below), the WraSer Seller had to approve substantially all business activities and transactions that significantly impact the economic performance of WraSer during the term of the MSA.&#160;Additionally, the Company is not required to absorb the losses of WraSer if the WraSer APA does not close. As such, the Company was not required to consolidate WraSer in the Company&#x2019;s financial statements as of and during the year ended December&#160;31, 2023.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company recorded the initial $3.5&#160;million payment as a deposit. The Company does not have any liabilities recorded as of December&#160;31, 2023 associated with its variable interest in the WraSer Seller, and its exposure to the WraSer Seller&#x2019;s losses is limited to no more than the shortfall, if any, of the Cash Target amount of approximately $1.1&#160;million compared to the WraSer Seller&#x2019;s cash balance on the WraSer Closing Date.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On September&#160;26, 2023, WraSer and its affiliates filed for relief under chapter 11 of the U.S.&#160;Bankruptcy Code in the Bankruptcy Court. On October&#160;4, 2023, the parties agreed to amend the WraSer APA, which was subject to court approval. Shortly after its bankruptcy filing, WraSer filed a motion seeking approval of the WraSer APA as amended. The amendment, among other things, eliminates the $500,000 post&lt;span class="nobreak"&gt;-closing&lt;/span&gt; payment due June&#160;13, 2024 and staggers the $4.5&#160;million cash payment that the Company would otherwise have to pay at closing to: (i)&#160;$2.2&#160;million to be paid at closing, (ii)&#160;$2.3&#160;million, to be paid in monthly installments of $150,000 commencing January&#160;2024 and (iii)&#160;789&lt;span class="nobreak"&gt; &lt;/span&gt;shares of Series&#160;A Preferred Stock to be paid at closing. The amendment also reduced the number of products the Company was acquiring by excluding pain medications and including only (i)&#160;Ciprofloxacin 0.3% and Fluocinolone 0.025% Otic Solution, under the trademark OTOVEL and its Authorized Generic Version approved under US FDA NDA No. 208251, (ii)&#160;Ciprofloxacin 0.2% Otic solution, under the trademark CETRAXAL, and (iii)&#160;Vorapaxar Sulfate tablets under the trademark Zontivity approved under US FDA NDA N204886.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In October&#160;2023, WraSer alerted the Company that its sole manufacturer for the active pharmaceutical ingredient (&#x201c;API&#x201d;) for Zontivity, the key driver for the WraSer acquisition, would no longer manufacture the API for Zontivity. The Company believes that this development constituted a Material Adverse Effect under the WraSer APA and the WraSer MSA, enabling the Company to terminate the WraSer APA and the WraSer MSA.&#160;On October&#160;20, 2023, the Company filed a motion for relief from the automatic stay in the Bankruptcy Court so that the Company can exercise the termination rights under the WraSer APA, as amended. On December&#160;18, 2023, the Bankruptcy Court entered into an Agreed Order lifting the automatic stay to enable the Company to exercise its rights to terminate the WraSer APA and the WraSer MSA.&#160;On December&#160;21, 2023, the Company filed a Notice with the Bankruptcy Court terminating the WraSer APA and the WraSer MSA.&#160;WraSer has advised the Company that it does not believe that a Material Adverse Effect occurred. Due to the WraSer bankruptcy filing and the Company&#x2019;s status as an unsecured creditor of WraSer, it is unlikely that the Company will recover the $3.5&#160;million initial payment made, or any costs and resources in connection with services provided by the Company under the WraSer MSA, and therefore the Company recorded a loss on impairment for the $3.5&#160;million deposit during the year ended December&#160;31, 2023.&lt;/p&gt;
		&lt;p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Proteomedix&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On December&#160;15, 2023 (the &#x201c;Acquisition Date&#x201d;), Onconetix entered into a Share Exchange Agreement (the &#x201c;Share Exchange Agreement&#x201d;) with Proteomedix and each of the holders of outstanding capital stock or Proteomedix convertible securities (other than Proteomedix stock options) (collectively the &#x201c;Sellers&#x201d;), pursuant to which the Company acquired 100% of the outstanding common shares and voting interest of Proteomedix, through the issuance of 3,675,414&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock and 2,696,729&lt;span class="nobreak"&gt; &lt;/span&gt;shares of Series&#160;B Convertible Preferred Stock (the &#x201c;PMX Transaction&#x201d;).&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Subject to any requirements related to the Committee on Foreign Investment in the United&#160;States, upon approval by the requisite vote of stockholders of Onconetix at the Special Meeting of the Stockholders (&#x201c;Stockholder Approval&#x201d;), each share of Series&#160;B Convertible Redeemable Preferred Stock (&#x201c;Series&#160;B Preferred Stock&#x201d;) shall automatically &lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;convert into 100&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock in accordance with the terms of the Series&#160;B Certificate of Designation (the &#x201c;Conversion&#x201d;). If Stockholder Approval is not obtained by January&#160;1, 2025, Onconetix may, at the option of the holders, be obligated to cash settle the Series&#160;B Preferred Stock. The Series&#160;B Preferred Stock outstanding as a result of the PMX Transaction is convertible into 269,672,900&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The consummation (the &#x201c;Closing&#x201d;) of the PMX Transaction was subject to customary closing conditions and the agreement to enter into a subscription agreement (see Note&#160;8) with Altos Ventures, a shareholder of Proteomedix, prior to the closing of the PMX Transaction (the &#x201c;PMX Investor&#x201d;).&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In addition, each option to purchase shares of Proteomedix (each, a &#x201c;Proteomedix Stock Option&#x201d;) outstanding immediately before the Closing, whether vested or unvested, remains outstanding until the Conversion unless otherwise terminated in accordance with its terms. At the Conversion, each outstanding Proteomedix Stock Option, whether vested or unvested, shall be assumed by Onconetix and converted into the right to receive (a)&#160;an option to acquire shares of common stock (each, an &#x201c;Assumed Option&#x201d;) or (b)&#160;such other derivative security as Onconetix and Proteomedix may agree, subject in either case to substantially the same terms and conditions as were applicable to such Proteomedix Stock Option immediately before the Closing. Each Assumed Option shall: (i)&#160;represent the right to acquire a number of shares of common stock equal to the product of (A)&#160;the number of Proteomedix common shares that were subject to the corresponding Proteomedix Option immediately prior to the Closing, multiplied by (B)&#160;the Exchange Ratio (as defined in the Share Exchange Agreement&#x201d;); and (ii)&#160;have an exercise price (as rounded down to the nearest whole cent) equal to the quotient of (A)&#160;the exercise price of the corresponding Proteomedix Option, divided by (B)&#160;the Exchange Ratio.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Management determined that the PMX Transaction was a business combination as defined within ASC&#160;805&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;,&lt;/span&gt; and that Onconetix was the accounting acquirer. The Company determined that Onconetix was the accounting acquirer based on the guidance contained within ASC&#160;805&lt;span class="nobreak"&gt;-10&lt;/span&gt;. The significant factors that led to the Company&#x2019;s conclusion were (i)&#160;the Company obtained 100% of the outstanding common stock and voting interest of PMX, (ii)&#160;at closing of the PMX Transaction, the PMX shareholders were issued approximately 17% of Onconetix&#x2019;s outstanding common stock and none of the former PMX shareholders held more than 5% of Onconetix&#x2019;s common stock individually, (iii)&#160;the composition of executive management and the governing body did not change sufficiently to give PMX or its former shareholders control over these functions within Onconetix, and (iv)&#160;Onconetix was significantly larger when considering both total assets and operations. As a result, the Company has applied purchase accounting as of the Closing of the PMX Transaction. The assets, liabilities, and non&lt;span class="nobreak"&gt;-controlling&lt;/span&gt; interest of Proteomedix were recognized at fair value as of the Closing and the results of its operations have been included within Onconetix&#x2019;s consolidated statements of operations and comprehensive loss from that date forward.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnosis. Proteomedix has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The Company expects Proteomedix&#x2019;s diagnostic expertise to complement its existing prostate related treatment portfolio.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The assets acquired and liabilities assumed are recognized provisionally in the accompanying consolidated balance sheets at their estimated fair values as of the acquisition date. The initial accounting for the business combination is not complete as the Company is in the process of obtaining additional information for the valuation of acquired intangible assets and deferred tax liabilities. The provisional amounts are subject to change to the extent that additional information is obtained about the facts and circumstances that existed as of the acquisition date. Under U.S.&#160;GAAP, the measurement period shall not exceed one year from the acquisition date and the Company will finalize these amounts no later than December&#160;15, 2024. The estimated fair values as of the acquisition date are based on information that existed as of the acquisition date. During the measurement period the Company may adjust provisional amounts recorded for assets acquired and liabilities assumed to reflect new information that the Company has subsequently obtained regarding facts and circumstances that existed as of the acquisition date.&lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The acquisition&lt;span class="nobreak"&gt;-date&lt;/span&gt; fair value of the consideration transferred totaled approximately $65.1&#160;million, which consisted of the following:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Consideration&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Transferred&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Common stock&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;875,484&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Series&#160;B convertible preferred stock&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;64,236,085&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total consideration transferred&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;65,111,569&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The fair value of the Company&#x2019;s common shares issued as consideration was based on the closing price of the Company&#x2019;s common stock as of the Acquisition Date. The fair value of the Series&#160;B Preferred Stock issued as consideration was based on the underlying fair value of the number of common shares that the Series&#160;B Preferred Stock converts into, also based on the closing price of the Company&#x2019;s common stock as of the Acquisition Date.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The fair value of the Proteomedix stock options assumed as part of the PMX Transaction was determined using a Black&lt;span class="nobreak"&gt;-Scholes&lt;/span&gt; option pricing model with the following significant assumptions:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercise price&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;$1.15&#160;&#x2013;&#160;28.83&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Stock price&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;128.11&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Term (years)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;0.17&#160;&#x2013;&#160;3.59&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected stock price volatility&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;90%&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Risk-free rate of interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;4.07%&#160;&#x2013;&#160;5.47%&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed at the acquisition date:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Net Assets&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Recognized&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Cash&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,056,578&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accounts receivable&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;87,445&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Inventories&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;80,593&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Prepaid expenses and other current assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;114,615&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Right of use asset&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;149,831&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Property and equipment, net&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39,779&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Trade name&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;9,018,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Customer relationships&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,891,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Product rights for developed technology&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10,541,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Goodwill&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;53,914,055&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total assets acquired&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;76,892,896&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accounts payable&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(234,029&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued expenses&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(732,814&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Operating lease liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(149,831&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(2,994,669&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Pension benefit obligation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(548,384&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Note payable&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(115,096&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total liabilities assumed&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(4,774,823&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;72,118,073&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less non-controlling interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(7,006,504&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-20" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Net assets acquired&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;65,111,569&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The goodwill recognized as a result of the PMX Transaction is attributable primarily to expected synergies and the assembled workforce of Proteomedix. None of the goodwill is expected to be deductible for income tax purposes.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The fair values of the acquired tangible and intangible assets were determined using variations of the cost, income approach using the excess earnings, lost profits and relief from royalty methods. The income approach valuation methodology used for the intangible assets acquired in the PMX Transaction makes use of Level 3 inputs.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The trade name intangible asset represents the value of the Proclarix&#x2122; brand name and was valued using a relief from royalty method under an income approach. A royalty rate of 6% was utilized in determining the fair value of this intangible asset. The fair value of this asset was determined based on a cash flow model using forecasted revenues and expenses specifically tied to Proclarix&#x2122;. Those cash flows were then discounted at 10% determined by the use of a weighted average return on assets analysis. The life of this intangible asset was determined to be indefinite as the branded name will persist beyond the life of the product rights and customer relationships.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The customer relationship intangible assets represent the value of the existing customer contract with Labcorp (see Note&#160;6) and was valued using the lost profits method under the income approach. The fair value of this asset was determined based on a cash flow model using forecasted revenues specifically tied to Proteomedix&#x2019;s Labcorp contract. Those cash flows were then discounted at 10% determined by the use of a weighted average return on assets analysis. The estimated useful life of this asset was determined by reference to the estimated life of the product rights associated with the Labcorp contract.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The product rights for developed technology acquired in the PMX Transaction represents know&lt;span class="nobreak"&gt;-how&lt;/span&gt; and patented intellectual property held by PMX pertaining to its commercial&lt;span class="nobreak"&gt;-ready&lt;/span&gt; prostate cancer diagnostic system, Proclarix&#x2122;. The fair value of this asset was determined based on a cash flow model based on forecasted revenues and expenses specifically tied to Proclarix&#x2122;. Those cash flows were then discounted at 8% for the period prior to patent expiration and 16% for the period thereafter. The discount rates were determined by the use of a weighted average return on assets analysis. The estimated useful life of the product rights was determined based on the underlying patent&#x2019;s remaining life.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The fair value of the non&lt;span class="nobreak"&gt;-controlling&lt;/span&gt; interest in Proteomedix is estimated to be $7.0&#160;million and represents the fair value of the vested Proteomedix stock options outstanding as of the Acquisition Date. The fair value of the non&lt;span class="nobreak"&gt;-controlling&lt;/span&gt; interest was valued using the methodology applicable to the Proteomedix stock options disclosed above. As Proteomedix was a private company as of the Acquisition Date, the fair value measurement is based on significant inputs that are not observable in the market and thus represents a Level 3 measurement as defined in ASC&#160;820, &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Fair Value Measurement&lt;/span&gt;.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company recognized approximately $1.5&#160;million of acquisition related costs that were expensed during 2023, including the fair value of the subscription agreement liability, which was a closing condition for the PMX Transaction (see Note&#160;8). These costs are included in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The amounts of revenue and loss of Proteomedix, included in the Company&#x2019;s consolidated statements of operations and comprehensive loss from the Acquisition Date through December&#160;31, 2023 are as follows:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Revenue&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;58,465&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net loss&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;315,688&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The following summary, prepared on a pro forma basis, presents the Company&#x2019;s unaudited consolidated results of operations for 2023 and 2022 as if the PMX Transaction had been completed as of January&#160;1, 2022. The pro forma results below include the impact of amortization of intangible assets. This pro forma information is presented for &lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;illustrative purposes only, is not necessarily indicative of future results of operations and does not include any impact of transaction synergies. In addition, the pro forma results are not necessarily indicative of the results of operations that actually would have been achieved had the PMX Transaction been consummated as of that date:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Unaudited&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;For the&#160;Years Ended&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Revenue&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,601,310&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;392,460&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net loss&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;38,577,046&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16,326,247&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="c109"
      decimals="-6"
      id="ixv-30995"
      unitRef="usd">100000000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="c110"
      decimals="-5"
      id="ixv-30996"
      unitRef="usd">20000000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity contextRef="c111" id="ixv-18730">(i)&#160;$6.0&#160;million paid upon the closing of the Transaction on April&#160;19, 2023, (ii)&#160;an additional $4.0&#160;million in the form of a non-interest bearing note payable due on September&#160;30, 2023, and (iii)&#160;an additional $10.0&#160;million in the form of two $5.0&#160;million non-interest bearing notes payable, each due on April&#160;19, 2024 and September&#160;30, 2024.</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="c112"
      decimals="-5"
      id="ixv-30997"
      unitRef="usd">80000000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity contextRef="c113" id="ixv-18735">(i)&#160;$10.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI&#xae; of $100.0&#160;million during a calendar year, (ii)&#160;$20.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI&#xae; of $200.0&#160;million during a calendar year, and (3)&#160;$50.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI&#xae; of $500.0&#160;million during a calendar year.</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <onco:RoyaltySalesPercentage
      contextRef="c114"
      decimals="2"
      id="ixv-30998"
      unitRef="pure">0.06</onco:RoyaltySalesPercentage>
    <onco:SalesPaymentsAmount
      contextRef="c115"
      decimals="-5"
      id="ixv-30999"
      unitRef="usd">22500000</onco:SalesPaymentsAmount>
    <us-gaap:BusinessAcquisitionProFormaInformationDescription contextRef="c116" id="ixv-18755">(i)&#160;$5.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI&#xae; of $100.0&#160;million during a calendar year, (ii)&#160;$7.5&#160;million is payable upon the first time the Company achieves net sales from ENTADFI&#xae; of $200.0&#160;million during a calendar year, and (3)&#160;$10.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI&#xae; of $300.0&#160;million during a calendar year.</us-gaap:BusinessAcquisitionProFormaInformationDescription>
    <us-gaap:BusinessAcquisitionProFormaInformationDescription contextRef="c111" id="ixv-18760">$4.0&#160;million note payable originally due on September&#160;30, 2023 was deemed paid and fully satisfied upon (1)&#160;the payment to the Seller of $1.0&#160;million in cash on September&#160;29, 2023, and (2)&#160;the issuance to the Seller by October&#160;3, 2023 of 3,000 shares of Series&#160;A Convertible Preferred Stock (the &#x201c;Series&#160;A Preferred Stock&#x201d;) of the Company (see Note&#160;9)</us-gaap:BusinessAcquisitionProFormaInformationDescription>
    <onco:AggregatePurchaseShares
      contextRef="c117"
      decimals="0"
      id="ixv-31000"
      unitRef="shares">5709935</onco:AggregatePurchaseShares>
    <us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock contextRef="c0" id="ixv-18774">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The following table summarizes the aggregate consideration transferred for the assets acquired by the Company in connection with the Veru APA:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Consideration&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Transferred&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Consideration transferred at closing&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6,000,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Fair value of notes payable issued&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;12,947,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Transaction costs&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;79,771&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total consideration transferred&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;19,026,771&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The acquisition&lt;span class="nobreak"&gt;-date&lt;/span&gt; fair value of the consideration transferred totaled approximately $65.1&#160;million, which consisted of the following:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Consideration&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Transferred&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Common stock&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;875,484&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Series&#160;B convertible preferred stock&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;64,236,085&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total consideration transferred&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;65,111,569&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferredOtherAssets contextRef="c131" decimals="0" id="ixv-31001" unitRef="usd">6000000</us-gaap:AssetAcquisitionConsiderationTransferredOtherAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable contextRef="c131" decimals="0" id="ixv-31002" unitRef="usd">12947000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost contextRef="c131" decimals="0" id="ixv-31003" unitRef="usd">79771</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c131" decimals="0" id="ixv-31004" unitRef="usd">19026771</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c118"
      decimals="3"
      id="ixv-31005"
      unitRef="pure">0.082</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:AssetAcquisitionTableTextBlock contextRef="c0" id="ixv-18825">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The following table summarizes the assets acquired with the Veru APA:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Assets&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Recognized&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Inventory&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,120,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;ENTADFI&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;&#xae;&lt;/span&gt; Intangible&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;17,906,771&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total fair value of identifiable assets acquired&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;19,026,771&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:AssetAcquisitionTableTextBlock>
    <onco:AssetAcquisitionConsiderationTransferredInventory contextRef="c132" decimals="0" id="ixv-31006" unitRef="usd">1120000</onco:AssetAcquisitionConsiderationTransferredInventory>
    <onco:AssetAcquisitionConsiderationTransferredENTADFIIntangible contextRef="c132" decimals="0" id="ixv-31007" unitRef="usd">17906771</onco:AssetAcquisitionConsiderationTransferredENTADFIIntangible>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c132" decimals="0" id="ixv-31008" unitRef="usd">19026771</us-gaap:AssetAcquisitionConsiderationTransferred>
    <onco:InventoryFairValue contextRef="c0" decimals="-5" id="ixv-31009" unitRef="usd">300000</onco:InventoryFairValue>
    <us-gaap:AssetImpairmentCharges contextRef="c0" decimals="-5" id="ixv-31010" unitRef="usd">14700000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="c111"
      decimals="-5"
      id="ixv-31011"
      unitRef="usd">1200000</us-gaap:AssetImpairmentCharges>
    <onco:ImpairmentRate contextRef="c0" decimals="2" id="ixv-31012" unitRef="pure">1</onco:ImpairmentRate>
    <us-gaap:BusinessAcquisitionProFormaInformationDescription contextRef="c0" id="ixv-31013">(i)&#160;$3.5&#160;million in cash at signing of the WraSer APA; (ii)&#160;$4.5&#160;million in cash on the later of (x)&#160;90&#160;days after the signing of the WraSer APA or (y)&#160;the date that all closing conditions under the WraSer APA are met or otherwise waived (the &#x201c;WraSer Closing Date&#x201d;); (iii)&#160;1.0&#160;million shares of the Company&#x2019;s common stock (the &#x201c;Closing Shares&#x201d;) issuable on the WraSer Closing Date, and (iv)&#160;$500,000 in cash one year from the WraSer Closing Date.</us-gaap:BusinessAcquisitionProFormaInformationDescription>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts
      contextRef="c119"
      decimals="-5"
      id="ixv-31014"
      unitRef="usd">4500000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts>
    <onco:InitialPaymentAmount contextRef="c1" decimals="-5" id="ixv-31015" unitRef="usd">3500000</onco:InitialPaymentAmount>
    <onco:Payments contextRef="c0" decimals="-5" id="ixv-31016" unitRef="usd">3500000</onco:Payments>
    <us-gaap:Deposits contextRef="c1" decimals="-5" id="ixv-31017" unitRef="usd">3500000</us-gaap:Deposits>
    <us-gaap:CashFDICInsuredAmount contextRef="c1" decimals="-5" id="ixv-31018" unitRef="usd">1100000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts contextRef="c120" decimals="0" id="ixv-31019" unitRef="usd">500000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts
      contextRef="c121"
      decimals="-5"
      id="ixv-31020"
      unitRef="usd">4500000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts>
    <us-gaap:BusinessAcquisitionProFormaInformationDescription contextRef="c122" id="ixv-18913">(i)&#160;$2.2&#160;million to be paid at closing, (ii)&#160;$2.3&#160;million, to be paid in monthly installments of $150,000 commencing January&#160;2024 and (iii)&#160;789 shares of Series&#160;A Preferred Stock to be paid at closing</us-gaap:BusinessAcquisitionProFormaInformationDescription>
    <us-gaap:BusinessAcquisitionProFormaInformationDescription contextRef="c123" id="ixv-31021">The amendment also reduced the number of products the Company was acquiring by excluding pain medications and including only (i)&#160;Ciprofloxacin 0.3% and Fluocinolone 0.025% Otic Solution, under the trademark OTOVEL and its Authorized Generic Version approved under US FDA NDA No. 208251, (ii)&#160;Ciprofloxacin 0.2% Otic solution, under the trademark CETRAXAL, and (iii)&#160;Vorapaxar Sulfate tablets under the trademark Zontivity approved under US FDA NDA N204886.</us-gaap:BusinessAcquisitionProFormaInformationDescription>
    <us-gaap:PaymentsForFees contextRef="c0" decimals="-5" id="ixv-31022" unitRef="usd">3500000</us-gaap:PaymentsForFees>
    <us-gaap:Deposits
      contextRef="c124"
      decimals="-5"
      id="ixv-31023"
      unitRef="usd">3500000</us-gaap:Deposits>
    <onco:VotingInterestPercentage contextRef="c68" decimals="2" id="ixv-31024" unitRef="pure">1</onco:VotingInterestPercentage>
    <onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction
      contextRef="c125"
      decimals="0"
      id="ixv-31025"
      unitRef="shares">3675414</onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction>
    <onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction
      contextRef="c126"
      decimals="0"
      id="ixv-31026"
      unitRef="shares">2696729</onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction>
    <onco:NumberOfShares
      contextRef="c127"
      decimals="0"
      id="ixv-31027"
      unitRef="shares">100</onco:NumberOfShares>
    <onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction
      contextRef="c128"
      decimals="0"
      id="ixv-31028"
      unitRef="shares">269672900</onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity contextRef="c129" id="ixv-31029">i)&#160;the Company obtained 100% of the outstanding common stock and voting interest of PMX, (ii)&#160;at closing of the PMX Transaction, the PMX shareholders were issued approximately 17% of Onconetix&#x2019;s outstanding common stock and none of the former PMX shareholders held more than 5% of Onconetix&#x2019;s common stock individually, (iii)&#160;the composition of executive management and the governing body did not change sufficiently to give PMX or its former shareholders control over these functions within Onconetix, and (iv)&#160;Onconetix was significantly larger when considering both total assets and operations.</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="c130"
      decimals="-5"
      id="ixv-31030"
      unitRef="usd">65100000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferredOther1 contextRef="c130" decimals="0" id="ixv-31031" unitRef="usd">875484</us-gaap:BusinessCombinationConsiderationTransferredOther1>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c130" decimals="0" id="ixv-31032" unitRef="usd">64236085</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c130" decimals="0" id="ixv-31033" unitRef="usd">65111569</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c0" id="ixv-19001">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The fair value of the Proteomedix stock options assumed as part of the PMX Transaction was determined using a Black&lt;span class="nobreak"&gt;-Scholes&lt;/span&gt; option pricing model with the following significant assumptions:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercise price&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;$1.15&#160;&#x2013;&#160;28.83&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Stock price&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;128.11&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Term (years)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;0.17&#160;&#x2013;&#160;3.59&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected stock price volatility&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;90%&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Risk-free rate of interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;4.07%&#160;&#x2013;&#160;5.47%&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c133"
      decimals="2"
      id="ixv-31034"
      unitRef="pure">128.11</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c134"
      decimals="2"
      id="ixv-31035"
      unitRef="pure">0.17</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c135"
      decimals="2"
      id="ixv-31036"
      unitRef="pure">3.59</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c136"
      decimals="0"
      id="ixv-31037"
      unitRef="pure">90</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c137"
      decimals="2"
      id="ixv-31038"
      unitRef="pure">4.07</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c138"
      decimals="2"
      id="ixv-31039"
      unitRef="pure">5.47</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c0" id="ixv-19046">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed at the acquisition date:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Net Assets&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Recognized&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Cash&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,056,578&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accounts receivable&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;87,445&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Inventories&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;80,593&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Prepaid expenses and other current assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;114,615&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Right of use asset&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;149,831&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Property and equipment, net&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39,779&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Trade name&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;9,018,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Customer relationships&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,891,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Product rights for developed technology&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10,541,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Goodwill&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;53,914,055&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total assets acquired&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;76,892,896&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accounts payable&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(234,029&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued expenses&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(732,814&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Operating lease liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(149,831&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(2,994,669&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Pension benefit obligation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(548,384&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Note payable&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(115,096&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total liabilities assumed&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(4,774,823&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;72,118,073&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less non-controlling interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(7,006,504&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-20" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Net assets acquired&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;65,111,569&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c139" decimals="0" id="ixv-31040" unitRef="usd">1056578</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c139" decimals="0" id="ixv-31041" unitRef="usd">87445</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c139" decimals="0" id="ixv-31042" unitRef="usd">80593</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="c139" decimals="0" id="ixv-31043" unitRef="usd">114615</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <onco:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset contextRef="c139" decimals="0" id="ixv-31044" unitRef="usd">149831</onco:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c139" decimals="0" id="ixv-31045" unitRef="usd">39779</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c139" decimals="0" id="ixv-31046" unitRef="usd">9018000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <onco:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships contextRef="c139" decimals="0" id="ixv-31047" unitRef="usd">1891000</onco:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships>
    <onco:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology contextRef="c139" decimals="0" id="ixv-31048" unitRef="usd">10541000</onco:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c139" decimals="0" id="ixv-31049" unitRef="usd">53914055</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c139" decimals="0" id="ixv-31050" unitRef="usd">76892896</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="c139" decimals="0" id="ixv-31051" unitRef="usd">234029</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <onco:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses contextRef="c139" decimals="0" id="ixv-31052" unitRef="usd">732814</onco:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation contextRef="c139" decimals="0" id="ixv-31053" unitRef="usd">149831</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c139" decimals="0" id="ixv-31054" unitRef="usd">2994669</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <onco:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation contextRef="c139" decimals="0" id="ixv-31055" unitRef="usd">548384</onco:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation>
    <onco:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable contextRef="c139" decimals="0" id="ixv-31056" unitRef="usd">115096</onco:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c139" decimals="0" id="ixv-31057" unitRef="usd">4774823</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c139" decimals="0" id="ixv-31058" unitRef="usd">72118073</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue contextRef="c139" decimals="0" id="ixv-31059" unitRef="usd">7006504</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest contextRef="c139" decimals="0" id="ixv-31060" unitRef="usd">65111569</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest>
    <onco:RoyaltyRate contextRef="c0" decimals="2" id="ixv-31061" unitRef="pure">0.06</onco:RoyaltyRate>
    <onco:WeightedAverageDiscountRate
      contextRef="c105"
      decimals="2"
      id="ixv-31062"
      unitRef="pure">0.10</onco:WeightedAverageDiscountRate>
    <onco:WeightedAverageDiscountRate
      contextRef="c108"
      decimals="2"
      id="ixv-31063"
      unitRef="pure">0.10</onco:WeightedAverageDiscountRate>
    <onco:WeightedAverageDiscountRate
      contextRef="c102"
      decimals="2"
      id="ixv-31064"
      unitRef="pure">0.08</onco:WeightedAverageDiscountRate>
    <onco:WeightedAverageDiscountRateThereafter
      contextRef="c102"
      decimals="2"
      id="ixv-31065"
      unitRef="pure">0.16</onco:WeightedAverageDiscountRateThereafter>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="c129"
      decimals="-5"
      id="ixv-31066"
      unitRef="usd">7000000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:InvestmentOwnedAtCost contextRef="c1" decimals="-5" id="ixv-31067" unitRef="usd">1500000</us-gaap:InvestmentOwnedAtCost>
    <srt:ScheduleOfCondensedIncomeStatementTableTextBlock contextRef="c0" id="ixv-19297">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The amounts of revenue and loss of Proteomedix, included in the Company&#x2019;s consolidated statements of operations and comprehensive loss from the Acquisition Date through December&#160;31, 2023 are as follows:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Revenue&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;58,465&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net loss&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;315,688&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Unaudited&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;For the&#160;Years Ended&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Revenue&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,601,310&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;392,460&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net loss&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;38,577,046&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16,326,247&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</srt:ScheduleOfCondensedIncomeStatementTableTextBlock>
    <us-gaap:Revenues contextRef="c140" decimals="0" id="ixv-31068" unitRef="usd">58465</us-gaap:Revenues>
    <us-gaap:ProfitLoss contextRef="c140" decimals="0" id="ixv-31069" unitRef="usd">315688</us-gaap:ProfitLoss>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c141" decimals="0" id="ixv-31070" unitRef="usd">2601310</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c142" decimals="0" id="ixv-31071" unitRef="usd">392460</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c141" decimals="0" id="ixv-31072" unitRef="usd">38577046</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c142" decimals="0" id="ixv-31073" unitRef="usd">16326247</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <onco:SignificantAgreementsTextBlock contextRef="c0" id="ixv-19382">&lt;p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Note&#160;6 &#x2014; Significant Agreements&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Ology Bioservices, Inc. (which was later acquired by National Resilience, Inc.)&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company entered into a Master Services Agreement (&#x201c;Ology MSA&#x201d;), dated July&#160;19, 2019, with Ology, Inc. (&#x201c;Ology&#x201d;) to provide services from time to time, including but not limited to technology transfer, process development, analytical method optimization, cGMP manufacture, regulatory affairs, and stability studies of biologic products. Pursuant to the Ology MSA, the Company and Ology shall enter into a Project Addendum for each project to be governed by the terms and conditions of the Ology MSA.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company entered into two Project Addendums as of December&#160;31, 2023. The initial Project Addendum was executed on October&#160;18, 2019, and the Company was required to pay Ology an aggregate of approximately $4&#160;million. Due to unforeseen delays associated with COVID&lt;span class="nobreak"&gt;-19&lt;/span&gt;, the Company and Ology entered into a letter agreement dated January&#160;9, 2020 to stop work on the project, at which point the Company had paid Ology $100,000 for services to be provided. The second Project Addendum was executed on May&#160;21, 2021, and the Company is obligated to pay Ology an aggregate amount of approximately $2.8&#160;million, plus reimbursement for materials and outsourced testing, which will be billed at cost plus 15%. During 2023 and 2022, the Company and Ology entered into contract amendments that resulted in a net decrease in the Company&#x2019;s obligations of approximately $137,000.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;During the&#160;years ended December&#160;31, 2023 and 2022, the Company incurred related research and development expenses of approximately $15,000 and $1,329,000, respectively, and had approximately $685,000 recorded as related accounts payable at December&#160;31, 2023, and approximately $476,000 and $669,000 recorded as related accounts payable and accrued expenses, respectively, at December&#160;31, 2022.&lt;/p&gt;
		&lt;p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Cincinnati Children&#x2019;s Hospital Medical Center&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company entered into a license agreement (the &#x201c;CHMC Agreement&#x201d;), dated June&#160;1, 2021, with Children&#x2019;s Hospital Medical Center, d/b/a Cincinnati Children&#x2019;s Hospital Medical Center (&#x201c;CHMC&#x201d;). Under the terms of the CHMC Agreement, the Company holds an exclusive, worldwide license (other than the excluded field of immunization against, and prevention, control, or reduction in the severity of gastroenteritis caused by rotavirus and norovirus in China and Hong&#160;Kong) to certain specified patent and biological materials relating to the use of norovirus nanoparticles and practice processes that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing CHMC patents and related technology directed to a virus&lt;span class="nobreak"&gt;-like&lt;/span&gt; particle vaccine platform that utilizes nanoparticle delivery technology that may have potential broad application to develop vaccines for multiple infectious diseases. The term of the CHMC Agreement begins on the effective date and extends on a jurisdiction by jurisdiction and product by product basis until the later of: (i)&#160;the last to expire licensed patent; (ii)&#160;&lt;span style="-sec-ix-hidden: hidden-fact-267"&gt;ten&lt;/span&gt; (10)&#160;years after the first commercial sale; or (iii)&#160;entrance onto the market of a biosimilar or interchangeable product. The Company is obligated to use commercially reasonable efforts to bring licensed products to market through diligent research and development, testing, manufacturing, and commercialization, to use best efforts to make all necessary regulatory filings and obtain all necessary regulatory approvals, to achieve milestones relating to development and sales, and report to CHMC on progress. The Company is obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur. Specifically, the Company is obligated to pay CHMC a single&lt;span class="nobreak"&gt;-digit&lt;/span&gt; royalty on &lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;net sales, being 5%, 4% or 2% depending on the product, until the last valid claim covering a licensed product exists, at which point the royalty rates decrease by 50%. The Company is also obligated to pay up to a 25% royalty on any non&lt;span class="nobreak"&gt;-royalty&lt;/span&gt; sublicense revenue paid to the Company by any sublicensee. The CHMC Agreement also provides the Company with an option to license any CHMC or jointly patented modification, alteration or improvement of any invention claimed in a Licensed Patent (&#x201c;CHMC Improvement&#x201d; and &#x201c;Joint Improvement, respectively&#x201d;), with a $50,000 option fee for each Improvement that the Company elects to include in the license grant of the CHMC Agreement. In addition, the Company is required to pay CHMC milestone payments of up to an aggregate of $59.75&#160;million; specifically, upon the achievement of specified development milestones of approximately $0.5&#160;million, regulatory milestones of approximately $1.25&#160;million, and commercial milestones of approximately $58.0&#160;million.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company may terminate the CHMC Agreement for convenience at any time prior to first commercial sale of a product or process by providing one hundred and eighty (180)&#160;days&#x2019; written notice to CHMC.&#160;It may also terminate for a CHMC uncured material breach. CHMC may terminate the CHMC Agreement for an uncured Company material breach or insolvency or bankruptcy. Pursuant to the terms of the CHMC Agreement, if the Company fails to achieve the milestones, and cannot mutually agree with CHMC on an amendment to the milestones, then CHMC will have the option of converting any and all of such exclusive licenses to nonexclusive licenses, to continue developing indications that have already entered development at any stage or in which the Company has invested in developing. CHMC may also terminate the CHMC Agreement to the fullest extent permitted by law in the countries of the worldwide territory, in the event the Company or its affiliates challenge or induce others set up challenges to the validity or enforceability of any of the Licensed Patents, as defined in the CHMC Agreement, and the Company will be obligated to reimburse CHMC for its costs, including reasonable attorneys&#x2019; fees.&lt;/p&gt;
		&lt;p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Oxford University Innovation Limited&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In December&#160;2018, the Company entered into an option agreement with Oxford University Innovation (&#x201c;OUI&#x201d;), which was a precursor to a license agreement (the &#x201c;OUI Agreement&#x201d;), dated July&#160;16, 2019. Under the terms of the OUI Agreement, the Company held an exclusive, worldwide license to certain specified patent rights and biological materials relating to the use of epitopes of limited variability and virus&lt;span class="nobreak"&gt;-like&lt;/span&gt; particle products and practice processes that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing a vaccine product candidate for influenza. The Company was obligated to use its best efforts to develop and market Licensed Products, as defined in the OUI Agreement, in accordance with its development plan, report to OUI on progress, achieve certain milestones and was required to pay OUI nonrefundable milestone fees when it achieved them. Pursuant to the OUI Agreement, the Company was obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur. Specifically, the Company was obligated to pay a 6% royalty on all net sales of licensed products, as defined in the OUI Agreement, with an annual minimum royalty payment of $250,000 starting post&lt;span class="nobreak"&gt;-product&lt;/span&gt; launch, until the expiration of the OUI Agreement or revocation of the last valid claim covering a licensed product, at which point a royalty rate of 3% will apply. An annual maintenance fee of $10,000 and $20,000 was required in the pre&lt;span class="nobreak"&gt;-phase&lt;/span&gt;&#160;III year and Phase&#160;III year, respectively, and as defined in the OUI Agreement. The Company was also obligated to pay a 25% royalty on any sums received by the Company from any sublicensee (including all up&lt;span class="nobreak"&gt;-front&lt;/span&gt;, milestone and other one&lt;span class="nobreak"&gt;-off&lt;/span&gt; payments received by the Company from any sub&lt;span class="nobreak"&gt;-licenses&lt;/span&gt; or other contracts granted by the Company with respect to the licensed technology). In addition, the Company was required to pay OUI milestone payments of up to an aggregate of $51.25&#160;million; specifically, upon the achievement of specified development milestones of approximately $2.25&#160;million, regulatory milestones of approximately $9.5&#160;million, and commercial milestones of approximately $39.5&#160;million.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The OUI Agreement was to expire upon ten (10)&#160;years from the expiration of the last patent contained in the licensed patent rights, unless terminated earlier. Either party had the right to terminate the OUI Agreement for an uncured material breach. The Company was able to terminate the OUI Agreement for any reason at any time upon six&#160;months&#x2019; written notice until July&#160;16, 2022, which was the third anniversary of the OUI Agreement. OUI was able to terminate immediately if the Company had a petition presented for its winding&lt;span class="nobreak"&gt;-up&lt;/span&gt; or passed a resolution for winding up other than for a bona fide amalgamation or reconstruction or compounds with its creditors or had a receiver or administrator appointed. OUI could also terminate if the Company opposed or challenged the validity of &lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;any of the patents or applications in the Licensed Technology, as defined in the OUI Agreement; raised the claim that the know&lt;span class="nobreak"&gt;-how&lt;/span&gt; of the Licensed Technology was not necessary to develop and market Licensed Products; or in OUI&#x2019;s reasonable opinion, was taking inadequate or insufficient steps to develop or market Licensed Products and did not take any further steps that OUI requested by written notice within a reasonable time.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company terminated the agreements with Oxford during the year ended December&#160;31, 2023, and amounts due upon termination were not significant.&lt;/p&gt;
		&lt;p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;St. Jude Children&#x2019;s Hospital&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company entered into a license agreement (the &#x201c;St. Jude Agreement&#x201d;), dated January&#160;27, 2020, and as amended on May&#160;11, 2022 and March&#160;22, 2023, with St. Jude Children&#x2019;s Research Hospital (&#x201c;St. Jude&#x201d;). Under the terms of the St. Jude Agreement, the Company held an exclusive, worldwide license to certain specified patent rights and biological materials relating to the use of live attenuated streptococcus pneumoniae and practice processes that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing a vaccine product candidate for streptococcus pneumoniae. The Company was obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur. Specifically, pursuant to the terms of the St. Jude Agreement, as amended, the Company was obligated to make 5% royalty payments for each licensed product(s)&#160;sold by the Company or its affiliates, based on the net sales for the duration of the St. Jude Agreement, and also pay 15% of consideration received for any sublicenses. The Company was also required to pay an additional one&lt;span class="nobreak"&gt;-time&lt;/span&gt; $5,000 license fee, and an annual maintenance fee of $10,000 beginning on the first anniversary of the Effective Date (which was waived if all of the developmental milestones scheduled for completion before such annual fee is due have been achieved). In addition, the Company was required to pay St. Jude milestone payments of up to an aggregate of $1.9&#160;million; specifically, upon the achievement of specified development milestones of $0.3&#160;million, regulatory milestones of $0.6&#160;million, and commercial milestones of $1.0&#160;million.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The St. Jude Agreement was to expire upon the expiration of the last valid claim contained in the licensed patent rights, unless terminated earlier. The Company was obligated to use commercially reasonable efforts to develop and commercialize the licensed product(s)&#160;and included defined development milestones. If the Company failed to achieve the development milestones contained in the St. Jude Agreement, and if the Company and St. Jude failed to agree upon a mutually satisfactory revised timeline, St. Jude had the right to terminate the St. Jude Agreement. Either party was able to terminate the St. Jude Agreement in the event the other party (a)&#160;filed against it a petition under the Bankruptcy Act (among other things) or (b)&#160;failed to perform or otherwise breached its obligations under the St. Jude Agreement and did not cure such failure or breach within sixty (60)&#160;days. The Company was able to terminate for any reason on thirty (30)&#160;days written notice.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company terminated the agreement with St. Jude during the year ended December&#160;31, 2023, and amounts due upon termination were not significant.&lt;/p&gt;
		&lt;p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;University of Texas Health Science Center at San Antonio&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company entered into a patent and technology license agreement (the &#x201c;UT Health Agreement&#x201d;), dated November&#160;18, 2022, with the University of Texas Health Science Center at San Antonio (&#x201c;UT Health&#x201d;). Under the terms of the UT Health Agreement, the Company held an exclusive, worldwide license (other than the excluded field of vectors, as defined in the UT Health Agreement) to certain specified patent rights relating to the development of a live attenuated, oral Chlamydia vaccine candidate. An initial non&lt;span class="nobreak"&gt;-refundable&lt;/span&gt; license fee of $100,000 was due upon execution of the agreement, and expensed during the year ended December&#160;31, 2022, with subsequent annual license fees thereafter until expiration or termination of the UT Health agreement. Pursuant to the UT Health Agreement, the Company was obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur. Specifically, the Company was obligated to pay UT a single&lt;span class="nobreak"&gt;-digit&lt;/span&gt; royalty on net sales, being 5% or 3% depending on whether the product was covered by a valid claim or not, as defined in the agreement. The Company was also obligated to pay a 20% royalty on any sums received by the Company from any sublicensee. In addition, the &lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;Company was required to pay UT Health milestone payments of up to an aggregate of approximately $2.2&#160;million; specifically, upon the achievement of specified development milestones of approximately $0.7&#160;million and regulatory milestones of approximately $1.5&#160;million.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The UT Health Agreement was to expire upon the expiration of the last date of expiration or termination of the patent rights, unless terminated earlier. Under the UT Health Agreement, the Company had the right to terminate the UT Health Agreement for convenience, by providing 90&#160;days&#x2019; written notice to UT Health. UT Health was able to terminate the UT Health Agreement in the event the Company (a)&#160;became arrears in payment due and did not make payment within 30&#160;days after notification from UT Health or (b)&#160;was in breach of any non&lt;span class="nobreak"&gt;-payment&lt;/span&gt; provision and does not cure such breach within 60&#160;days after notification from UT Health or (c)&#160;UT Health delivered notice to the Company of three or more actual material breaches of the UT Health Agreement in any 12&lt;span class="nobreak"&gt;-month&lt;/span&gt; period or (d)&#160;in the event the Company or its affiliates initiated any proceeding or action to challenge the validity, enforceability, or scope of any of the licensed patents.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company terminated the agreement during the year ended December&#160;31, 2023, and amounts due upon termination were not significant.&lt;/p&gt;
		&lt;p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Co-development Agreement with AbVacc, Inc.&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On February&#160;1, 2023, the Company entered into a co&lt;span class="nobreak"&gt;-development&lt;/span&gt; agreement (the &#x201c;Co&lt;span class="nobreak"&gt;-Development&lt;/span&gt; Agreement&#x201d;) with AbVacc, Inc. (&#x201c;AbVacc&#x201d;), for the purpose of conducting research aimed at co&lt;span class="nobreak"&gt;-development&lt;/span&gt; of specific vaccine candidates, including monkeypox and Marburg virus disease with the potential to expand to others using the Norovirus nanoparticle platform (&#x201c;Co&lt;span class="nobreak"&gt;-Development&lt;/span&gt; Project&#x201d;), and to govern the sharing of materials and information, as defined in the Co&lt;span class="nobreak"&gt;-Development&lt;/span&gt; Agreement, for the Co&lt;span class="nobreak"&gt;-Development&lt;/span&gt; Project. Under the Co&lt;span class="nobreak"&gt;-Development&lt;/span&gt; Agreement, AbVacc and the Company will collaborate, through a joint development committee, to establish and implement a development plan or statement of work for each Co&lt;span class="nobreak"&gt;-Development&lt;/span&gt; Project targeted product. Under the Co&lt;span class="nobreak"&gt;-Development&lt;/span&gt; Agreement, either the Company or AbVacc, whichever party is the primary sponsor of any resulting product (as defined in the Co&lt;span class="nobreak"&gt;-Development&lt;/span&gt; Agreement), will be obligated to compensate the other party for certain milestone payments that would range between $2.1&#160;million and $4.75&#160;million, plus royalties of between 2% to 4%. There is no fixed obligation for either party, and each party will be responsible for their own costs. The term of the Co&lt;span class="nobreak"&gt;-Development&lt;/span&gt; Agreement is three&#160;years from the effective date, unless previously terminated by either party, in accordance with the Co&lt;span class="nobreak"&gt;-Development&lt;/span&gt; Agreement. During the year ended December&#160;31, 2023, the Company incurred approximately $21,000 in costs for research and development related to the Co&lt;span class="nobreak"&gt;-Development&lt;/span&gt; Agreement. As of December&#160;31, 2023, the Company evaluated the likelihood of the Company achieving the specified milestones and generating product sales and determined that the likelihood is not yet probable and as such no accrual of these payments is required as of December&#160;31, 2023.&lt;/p&gt;
		&lt;p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Services Agreement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On July&#160;21, 2023, the Company, entered into a Licensing and Services Master Agreement (&#x201c;Master Services Agreement&#x201d;) and a related statement of work with a vendor, pursuant to which the vendor was to provide to the Company commercialization services for the Company&#x2019;s products, including recruiting, managing, supervising and evaluating sales personnel and providing sales&lt;span class="nobreak"&gt;-related&lt;/span&gt; services for such products, for fees totaling up to $29.1&#160;million over the term of the statement of work. The statement of work had a term through September&#160;6, 2026, unless earlier terminated in accordance with the Master Services Agreement and the statement of work. On July&#160;29, 2023, a second statement of work was entered into with the same vendor for certain subscription services providing prescription market data access to the Company. The fees under the second statement of work totaled approximately $800,000, and the term was through July&#160;14, 2025. On October&#160;12, 2023, the Company terminated the Master Services Agreement and the statements of work. The Company recorded approximately $3.1&#160;million in expense related to this contract during the year ended December&#160;31, 2023, which is included in selling, general and administrative expense in the &lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;accompanying consolidated statements of operations and comprehensive loss. The Company had approximately $1.8&#160;million recorded in related accounts payable as of December&#160;31, 2023, which includes amounts due for early termination of the contract.&lt;/p&gt;
		&lt;p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Laboratory Corporation of America&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On March&#160;23, 2023, Proteomedix entered into a license agreement Laboratory Corporation of America (&#x201c;Labcorp&#x201d;) pursuant to which Labcorp has the exclusive right to develop and commercialize Proclarix, and other products developed by Labcorp using Proteomedix&#x2019;s intellectual property covered by the license, in the United&#160;States (&#x201c;Licensed Products&#x201d;). In consideration for granting Labcorp an exclusive license, Proteomedix received an initial license fee of in the mid&lt;span class="nobreak"&gt;-six&lt;/span&gt; figures upon signing of the contract. Additionally, Proteomedix is entitled to royalty payments on the net sales recognized by Labcorp of any Licensed Products plus milestone payments as follows:&lt;/p&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;After the first sale of Proclarix as a laboratory developed test, Labcorp will pay an amount in the mid&lt;span class="nobreak"&gt;-six&lt;/span&gt; figures,&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;after Labcorp achieves a certain amount in the low seven figures in net sales of Licensed Products, Labcorp will pay Proteomedix an amount in the low seven figures,&lt;/p&gt;&lt;/div&gt;
		&lt;div style="-sec-ix-redline:true;-keep: true"&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;after a certain amount in the mid&lt;span class="nobreak"&gt;-seven&lt;/span&gt; figures in net sales of Licensed Products, Labcorp will pay Proteomedix an amount in the low seven figures.&lt;/p&gt;&lt;/div&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Labcorp is wholly responsible for the cost, if any, of research, development and commercialization of Licensed Products in the United&#160;States but has the right to offset a portion of those costs against future royalty and milestone payments. Additionally, Labcorp may deduct royalties or other payments made to third parties related to the manufacture or sale of Licensed Products up to a maximum amount of any royalty payments due to Proteomedix.&lt;/p&gt;</onco:SignificantAgreementsTextBlock>
    <onco:AggregateAgreementAmountInitialAgreement
      contextRef="c143"
      decimals="-6"
      id="ixv-31074"
      unitRef="usd">4000000</onco:AggregateAgreementAmountInitialAgreement>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c143" decimals="0" id="ixv-31075" unitRef="usd">100000</us-gaap:DefinedBenefitPlanServiceCost>
    <onco:AggregateeAmount
      contextRef="c144"
      decimals="-5"
      id="ixv-31076"
      unitRef="usd">2800000</onco:AggregateeAmount>
    <onco:CostPlusPercentage
      contextRef="c144"
      decimals="2"
      id="ixv-31077"
      unitRef="pure">0.15</onco:CostPlusPercentage>
    <us-gaap:Assets contextRef="c145" decimals="0" id="ixv-31078" unitRef="usd">137000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c146" decimals="0" id="ixv-31079" unitRef="usd">137000</us-gaap:Assets>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c143" decimals="0" id="ixv-31080" unitRef="usd">15000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c147" decimals="0" id="ixv-31081" unitRef="usd">1329000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c146" decimals="0" id="ixv-31082" unitRef="usd">685000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c145" decimals="0" id="ixv-31083" unitRef="usd">476000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="c2" decimals="0" id="ixv-31084" unitRef="usd">669000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <onco:RoyaltyNetSalesPercentage
      contextRef="c148"
      decimals="2"
      id="ixv-31085"
      unitRef="pure">0.05</onco:RoyaltyNetSalesPercentage>
    <onco:RoyaltyNetSalesPercentage contextRef="c0" decimals="2" id="ixv-31086" unitRef="pure">0.04</onco:RoyaltyNetSalesPercentage>
    <us-gaap:ProductLiabilityContingencyAccrualDiscountRate contextRef="c1" decimals="2" id="ixv-31087" unitRef="pure">0.02</us-gaap:ProductLiabilityContingencyAccrualDiscountRate>
    <onco:RoyaltyRates
      contextRef="c148"
      decimals="2"
      id="ixv-31088"
      unitRef="pure">0.50</onco:RoyaltyRates>
    <onco:RevenueRate
      contextRef="c148"
      decimals="2"
      id="ixv-31089"
      unitRef="pure">0.25</onco:RevenueRate>
    <us-gaap:FeeIncome contextRef="c148" decimals="0" id="ixv-31090" unitRef="usd">50000</us-gaap:FeeIncome>
    <onco:AggregateRoyaltiesAmount
      contextRef="c148"
      decimals="-4"
      id="ixv-31091"
      unitRef="usd">59750000</onco:AggregateRoyaltiesAmount>
    <us-gaap:DevelopmentCosts contextRef="c0" decimals="-5" id="ixv-31092" unitRef="usd">500000</us-gaap:DevelopmentCosts>
    <us-gaap:DevelopmentCosts
      contextRef="c149"
      decimals="-4"
      id="ixv-31093"
      unitRef="usd">1250000</us-gaap:DevelopmentCosts>
    <us-gaap:DevelopmentCosts
      contextRef="c150"
      decimals="-5"
      id="ixv-31094"
      unitRef="usd">58000000</us-gaap:DevelopmentCosts>
    <onco:RoyaltyNetSalesPercentage
      contextRef="c151"
      decimals="2"
      id="ixv-31095"
      unitRef="pure">0.06</onco:RoyaltyNetSalesPercentage>
    <us-gaap:RoyaltyExpense contextRef="c151" decimals="0" id="ixv-31096" unitRef="usd">250000</us-gaap:RoyaltyExpense>
    <onco:RoyaltyRates
      contextRef="c151"
      decimals="2"
      id="ixv-31097"
      unitRef="pure">0.03</onco:RoyaltyRates>
    <us-gaap:CostOfPropertyRepairsAndMaintenance contextRef="c151" decimals="0" id="ixv-31098" unitRef="usd">10000</us-gaap:CostOfPropertyRepairsAndMaintenance>
    <us-gaap:CostOfPropertyRepairsAndMaintenance contextRef="c152" decimals="0" id="ixv-31099" unitRef="usd">20000</us-gaap:CostOfPropertyRepairsAndMaintenance>
    <onco:RoyaltyRates
      contextRef="c153"
      decimals="2"
      id="ixv-31100"
      unitRef="pure">0.25</onco:RoyaltyRates>
    <onco:AggregateRoyaltiesAmount
      contextRef="c153"
      decimals="-4"
      id="ixv-31101"
      unitRef="usd">51250000</onco:AggregateRoyaltiesAmount>
    <us-gaap:DevelopmentCosts
      contextRef="c154"
      decimals="-4"
      id="ixv-31102"
      unitRef="usd">2250000</us-gaap:DevelopmentCosts>
    <us-gaap:DevelopmentCosts
      contextRef="c155"
      decimals="-5"
      id="ixv-31103"
      unitRef="usd">9500000</us-gaap:DevelopmentCosts>
    <us-gaap:DevelopmentCosts
      contextRef="c156"
      decimals="-5"
      id="ixv-31104"
      unitRef="usd">39500000</us-gaap:DevelopmentCosts>
    <onco:RoyaltyRates
      contextRef="c157"
      decimals="2"
      id="ixv-31105"
      unitRef="pure">0.05</onco:RoyaltyRates>
    <onco:PercentageOfConsiderationReceived
      contextRef="c158"
      decimals="2"
      id="ixv-31106"
      unitRef="pure">0.15</onco:PercentageOfConsiderationReceived>
    <us-gaap:TaxesAndLicenses contextRef="c157" decimals="0" id="ixv-31107" unitRef="usd">5000</us-gaap:TaxesAndLicenses>
    <us-gaap:CostMaintenance contextRef="c157" decimals="0" id="ixv-31108" unitRef="usd">10000</us-gaap:CostMaintenance>
    <onco:AggregateRoyaltiesAmount
      contextRef="c157"
      decimals="-5"
      id="ixv-31109"
      unitRef="usd">1900000</onco:AggregateRoyaltiesAmount>
    <us-gaap:DevelopmentCosts
      contextRef="c159"
      decimals="-5"
      id="ixv-31110"
      unitRef="usd">300000</us-gaap:DevelopmentCosts>
    <us-gaap:DevelopmentCosts
      contextRef="c160"
      decimals="-5"
      id="ixv-31111"
      unitRef="usd">600000</us-gaap:DevelopmentCosts>
    <us-gaap:DevelopmentCosts
      contextRef="c161"
      decimals="-5"
      id="ixv-31112"
      unitRef="usd">1000000</us-gaap:DevelopmentCosts>
    <us-gaap:ProceedsFromLicenseFeesReceived contextRef="c0" decimals="0" id="ixv-31113" unitRef="usd">100000</us-gaap:ProceedsFromLicenseFeesReceived>
    <onco:RoyaltyNetSalesPercentage
      contextRef="c162"
      decimals="2"
      id="ixv-31114"
      unitRef="pure">0.05</onco:RoyaltyNetSalesPercentage>
    <onco:RoyaltyNetSalesPercentage
      contextRef="c163"
      decimals="2"
      id="ixv-31115"
      unitRef="pure">0.03</onco:RoyaltyNetSalesPercentage>
    <onco:RoyaltyRates
      contextRef="c163"
      decimals="2"
      id="ixv-31116"
      unitRef="pure">0.20</onco:RoyaltyRates>
    <onco:AggregateRoyaltiesAmount
      contextRef="c163"
      decimals="-5"
      id="ixv-31117"
      unitRef="usd">2200000</onco:AggregateRoyaltiesAmount>
    <us-gaap:DevelopmentCosts
      contextRef="c164"
      decimals="-5"
      id="ixv-31118"
      unitRef="usd">700000</us-gaap:DevelopmentCosts>
    <us-gaap:DevelopmentCosts
      contextRef="c165"
      decimals="-5"
      id="ixv-31119"
      unitRef="usd">1500000</us-gaap:DevelopmentCosts>
    <onco:AmountOfOtherPartyPayments
      contextRef="c166"
      decimals="-5"
      id="ixv-31120"
      unitRef="usd">2100000</onco:AmountOfOtherPartyPayments>
    <onco:AmountOfOtherPartyPayments
      contextRef="c167"
      decimals="-4"
      id="ixv-31121"
      unitRef="usd">4750000</onco:AmountOfOtherPartyPayments>
    <onco:RoyaltiesPercentage
      contextRef="c166"
      decimals="2"
      id="ixv-31122"
      unitRef="pure">0.02</onco:RoyaltiesPercentage>
    <onco:RoyaltiesPercentage
      contextRef="c167"
      decimals="2"
      id="ixv-31123"
      unitRef="pure">0.04</onco:RoyaltiesPercentage>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c168" decimals="0" id="ixv-31124" unitRef="usd">21000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="c169"
      decimals="-5"
      id="ixv-31125"
      unitRef="usd">29100000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:AdministrativeFeesExpense contextRef="c170" decimals="0" id="ixv-31126" unitRef="usd">800000</us-gaap:AdministrativeFeesExpense>
    <us-gaap:LongTermDebtMaturityDate contextRef="c171" id="ixv-31127">2025-07-14</us-gaap:LongTermDebtMaturityDate>
    <us-gaap:ProfessionalAndContractServicesExpense contextRef="c0" decimals="-5" id="ixv-31128" unitRef="usd">3100000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c1" decimals="-5" id="ixv-31129" unitRef="usd">1800000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <onco:LicensedProductsPlusMilestonePaymentsDescription contextRef="c172" id="ixv-19504">&#x2022;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;After the first sale of Proclarix as a laboratory developed test, Labcorp will pay an amount in the mid-six figures,&#x2022;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;after Labcorp achieves a certain amount in the low seven figures in net sales of Licensed Products, Labcorp will pay Proteomedix an amount in the low seven figures,&#x2022;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;after a certain amount in the mid-seven figures in net sales of Licensed Products, Labcorp will pay Proteomedix an amount in the low seven figures.</onco:LicensedProductsPlusMilestonePaymentsDescription>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0" id="ixv-19521">&lt;p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Note&#160;7 &#x2014; Notes Payable&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In connection with the Veru APA (see Note&#160;5), the Company executed three non&lt;span class="nobreak"&gt;-interest&lt;/span&gt; bearing notes payable (the &#x201c;Notes&#x201d;) in the principal amounts of $4.0&#160;million, $5.0&#160;million and $5.0&#160;million with maturity dates of September&#160;30, 2023, April&#160;19, 2024, and September&#160;30, 2024, respectively. No principal payments are due until maturity; however, the Company may voluntarily prepay the Notes with no penalty. Additionally, in an Event of Default, as defined in the Notes, the unpaid principal amount of the Notes will accrue interest at a rate of 10.0% per annum.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company imputed interest on the Notes using an average discount rate of 8.2% and recorded a debt discount of approximately $1.1&#160;million at the issuance date. The debt discount is reflected as a reduction in the carrying amount of the Notes and amortized to interest expense through the respective maturity dates, using the effective interest method. The Company recorded approximately $0.7&#160;million of associated interest expense during the year ended December&#160;31, 2023. The unamortized debt discount as of December&#160;31, 2023 was approximately $0.4&#160;million.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On September&#160;29, 2023, the Company and the note holder entered into an amendment to the Veru APA, which provided that the $4.0&#160;million note payable originally due on September&#160;30, 2023 was deemed paid and fully satisfied upon (1)&#160;the payment to the Seller of $1.0&#160;million in cash on September&#160;29, 2023, and (2)&#160;the issuance to the Seller by October&#160;3, 2023 of 3,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of Series&#160;A Preferred Stock of the Company (see Note&#160;5). In connection with the Veru APA Amendment, the Company recorded an extinguishment loss on the note payable of approximately $490,000, which represents the difference between the fair value of the Series&#160;A Preferred Stock that was issued to settle the debt and the carrying value of the note payable as of September&#160;29, 2023. The extinguishment loss is recognized in other income (expense) in the accompanying consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2023.&lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;To determine the fair value of the Series&#160;A Preferred Stock, the Company first derived the business enterprise value (&#x201c;BEV&#x201d;) using a discounted cash flow method. The BEV was adjusted to an equity value assuming $3.0&#160;million of debt converted to Series&#160;A Preferred Stock, which was then allocated across the Company&#x2019;s securities. The concluded value for the Series&#160;A Preferred Stock utilized the Black&lt;span class="nobreak"&gt;-Scholes&lt;/span&gt; option pricing model, which was classified as level 3 in the valuation hierarchy due to the presence of significant unobservable inputs. The following key assumptions were used in the model: volatility rate of 100%, risk free interest rate of 4.6%, 5.0 year expected term, and the Company&#x2019;s aggregate equity value. The volatility was based on the historical and implied volatility of a peer group and the risk&lt;span class="nobreak"&gt;-free&lt;/span&gt; interest rate was based on the implied yield available on U.S.&#160;Treasury securities with a term commensurate with the estimated expected term.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Future minimum principal payments on the Notes as of December&#160;31, 2023, includes $10&#160;million in principal payments that are due in 2024.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company also assumed an obligation in the amount of 100,000 CHF, in connection with the Proteomedix acquisition. This obligation relates to a loan from an investor that was advanced to Proteomedix in March&#160;2010. This loan bears no interest, is unsecured and may be cancelled by the Company at its discretion, however it is the intent of the Company to repay this loan in the future. The loan payable, in the amount of approximately $119,000, is included in long term note payable in the accompanying consolidated balances sheet as of December&#160;31, 2023.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="c173"
      decimals="-5"
      id="ixv-31130"
      unitRef="usd">4000000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="c174"
      decimals="-5"
      id="ixv-31131"
      unitRef="usd">5000000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="c175"
      decimals="-5"
      id="ixv-31132"
      unitRef="usd">5000000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c176" id="ixv-31133">2024-04-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c177" id="ixv-31134">2024-09-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c178"
      decimals="3"
      id="ixv-31135"
      unitRef="pure">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <onco:PayableAverageDiscountRatePercentage contextRef="c0" decimals="3" id="ixv-31136" unitRef="pure">0.082</onco:PayableAverageDiscountRatePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c118"
      decimals="-5"
      id="ixv-31137"
      unitRef="usd">1100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestExpenseDebt contextRef="c0" decimals="-5" id="ixv-31138" unitRef="usd">700000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c1" decimals="-5" id="ixv-31139" unitRef="usd">400000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:NotesPayable
      contextRef="c179"
      decimals="-5"
      id="ixv-31140"
      unitRef="usd">4000000</us-gaap:NotesPayable>
    <onco:DebtInstrumentDueDate contextRef="c180" id="ixv-31141">2023-09-30</onco:DebtInstrumentDueDate>
    <onco:CashPaymentToTheSeller
      contextRef="c180"
      decimals="-5"
      id="ixv-31142"
      unitRef="usd">1000000</onco:CashPaymentToTheSeller>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c181"
      decimals="0"
      id="ixv-31143"
      unitRef="shares">3000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c182" decimals="0" id="ixv-31144" unitRef="usd">490000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="c183"
      decimals="-5"
      id="ixv-31145"
      unitRef="usd">3000000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c184"
      decimals="0"
      id="ixv-31146"
      unitRef="pure">100</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c185"
      decimals="1"
      id="ixv-31147"
      unitRef="pure">4.6</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c186"
      decimals="1"
      id="ixv-31148"
      unitRef="pure">5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="c118"
      decimals="-6"
      id="ixv-31149"
      unitRef="usd">10000000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <onco:DebtInstrumentDueTerm contextRef="c0" id="ixv-31150">P2024Y</onco:DebtInstrumentDueTerm>
    <us-gaap:AssetAcquisitionPriceOfAcquisitionExpected contextRef="c187" decimals="0" id="ixv-31151" unitRef="chf">100000</us-gaap:AssetAcquisitionPriceOfAcquisitionExpected>
    <us-gaap:LongTermNotesPayable contextRef="c1" decimals="-3" id="ixv-31152" unitRef="usd">119000</us-gaap:LongTermNotesPayable>
    <onco:SubscriptionAgreementDisclosureTextBlock contextRef="c0" id="ixv-19547">&lt;p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Note&#160;8 &#x2014; Subscription Agreement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On December&#160;18, 2023, the Company entered into a subscription agreement (the &#x201c;Subscription Agreement&#x201d;) with the PMX Investor, who became a stockholder of Onconetix at the closing of the PMX Transaction (see Notes 5 and 11) for the sale of 20&#160;million units, each comprised of 1&lt;span class="nobreak"&gt; &lt;/span&gt;share of common stock and 0.30 pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants (the &#x201c;Units&#x201d;) at $0.25 per Unit. The Subscription Agreement includes a make&lt;span class="nobreak"&gt;-whole&lt;/span&gt; provision which requires the issuance of additional shares of common stock in the event that the 270&lt;span class="nobreak"&gt;-day&lt;/span&gt; volume weighted average price (&#x201c;270 VWAP&#x201d;) after the closing of the Subscription Agreement, is below $0.25. The Subscription Agreement will only close upon obtaining Stockholder Approval for certain transactions involving the Company&#x2019;s Series&#160;B Preferred Stock, as further described in Note&#160;5.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Subscription Agreement is accounted for as a liability in accordance with ASC&#160;480, as the make&lt;span class="nobreak"&gt;-whole&lt;/span&gt; provision could result in a variable number of shares being issued upon settlement. The subscription agreement liability is measured at fair value at the commitment date and at each subsequent reporting period, with changes in fair value recorded as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. The Company recorded the fair value of the Subscription Agreement liability at the issuance date of approximately $0.8&#160;million, as an acquisition related cost, as the Subscription Agreement was a condition to close the PMX Transaction (see Note&#160;5). As of December&#160;31, 2023, the fair value of the subscription agreement liability is estimated to be approximately $0.9&#160;million, determined using a Monte&lt;span class="nobreak"&gt;-Carlo&lt;/span&gt; option pricing model, and the Company estimated a 55.0% probability that the Subscription Agreement will close. The significant assumptions used in the Monte&lt;span class="nobreak"&gt;-Carlo&lt;/span&gt; model, which utilizes Level 3 inputs (see Note&#160;3), are as follows as of the commitment date and at December&#160;31, 2023:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;18,&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercise price&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;0.25&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;0.25&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Term (years)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.5&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.2&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected stock price volatility&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;100&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;95&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Risk-free rate of interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.64&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.64&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</onco:SubscriptionAgreementDisclosureTextBlock>
    <onco:SaleOfUnits
      contextRef="c188"
      decimals="-6"
      id="ixv-31153"
      unitRef="shares">20000000</onco:SaleOfUnits>
    <us-gaap:SharesIssued
      contextRef="c189"
      decimals="0"
      id="ixv-31154"
      unitRef="shares">1</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="c190"
      decimals="2"
      id="ixv-31155"
      unitRef="shares">0.3</us-gaap:SharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c188"
      decimals="2"
      id="ixv-31156"
      unitRef="usdPershares">0.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c1"
      decimals="2"
      id="ixv-31157"
      unitRef="usdPershares">0.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ServicingLiabilityAtFairValueAdditions contextRef="c0" decimals="-5" id="ixv-31158" unitRef="usd">800000</us-gaap:ServicingLiabilityAtFairValueAdditions>
    <us-gaap:ServicingLiabilityAtFairValueAmount contextRef="c1" decimals="-5" id="ixv-31159" unitRef="usd">900000</us-gaap:ServicingLiabilityAtFairValueAmount>
    <us-gaap:ProductLiabilityContingencyThirdPartyRecoveryPercentage contextRef="c0" decimals="3" id="ixv-31160" unitRef="pure">0.55</us-gaap:ProductLiabilityContingencyThirdPartyRecoveryPercentage>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0" id="ixv-19558">The significant assumptions used in the Monte&lt;span class="nobreak"&gt;-Carlo&lt;/span&gt; model, which utilizes Level 3 inputs (see Note&#160;3), are as follows as of the commitment date and at December&#160;31, 2023:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;18,&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercise price&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;0.25&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;0.25&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Term (years)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.5&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.2&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected stock price volatility&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;100&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;95&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Risk-free rate of interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.64&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.64&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c191"
      decimals="2"
      id="ixv-31161"
      unitRef="pure">0.25</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c192"
      decimals="2"
      id="ixv-31162"
      unitRef="pure">0.25</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c193"
      decimals="1"
      id="ixv-31163"
      unitRef="pure">1.5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c194"
      decimals="1"
      id="ixv-31164"
      unitRef="pure">1.2</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c195"
      decimals="0"
      id="ixv-31165"
      unitRef="pure">100</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c196"
      decimals="0"
      id="ixv-31166"
      unitRef="pure">95</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c197"
      decimals="2"
      id="ixv-31167"
      unitRef="pure">4.64</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c198"
      decimals="2"
      id="ixv-31168"
      unitRef="pure">4.64</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-19654">&lt;p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Note&#160;9 &#x2014; Convertible Redeemable Preferred Stock and Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Authorized Capital&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of December&#160;31, 2023 and 2022, the Company is authorized to issue 250,000,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares and 10,000,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock and preferred stock, respectively, with a par value of $0.00001 for both common stock and preferred stock. As of December&#160;31, 2023, the Company had designated and authorized the issuance of up to 1,150,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares, 10,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares, and 2,700,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of Series&#160;Seed Preferred Stock, Series&#160;A Preferred Stock, and Series&#160;B Preferred Stock, respectively.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On February&#160;23, 2022, in connection with the closing of the IPO, the Company filed with the Secretary of State of the State of Delaware an amended and restated certificate of incorporation (the &#x201c;A&amp;amp;R COI&#x201d;), which became effective immediately. There was no change to the Company&#x2019;s authorized shares of common stock and preferred stock or the par value. Prior to this amendment, the Company had designated 1,150,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of preferred stock, with par value $0.00001 per share. In addition, on February&#160;23, 2022 and in connection with the closing of the IPO, the Company&#x2019;s board of directors adopted Amended and Restated Bylaws.&lt;/p&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Series&#160;A Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On September&#160;29, 2023, the Company filed a Certificate of Designations of Rights and Preferences of Series&#160;A Preferred Stock of the Company (the &#x201c;Series&#160;A Certificate of Designations&#x201d;) with the State of Delaware to designate and authorize the issuance of up to 10,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of Series&#160;A Preferred Stock.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On October&#160;3, 2023, the Company issued 3,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of Series&#160;A Convertible Preferred Stock in exchange for the settlement of $3.0&#160;million in notes payable due to Veru, Inc. (see Notes 5 and 7). The significant terms of the Series&#160;A Preferred Stock are as follows:&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Voting&lt;/span&gt;&#160;&#x2014;&#160;The shares of Series&#160;A Preferred Stock carry no voting rights, except as to certain significant matters specified in the Series&#160;A Certificate of Designations.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Redemption&#160;&#x2014;&#160;&lt;/span&gt;Onconetix shall have the right to redeem in cash any outstanding shares of Series&#160;A Preferred Stock along with accrued but unpaid dividends beginning immediately after issuance of such shares of Preferred Stock. The holder of the Series&#160;A Preferred Stock shall not under any circumstances have any right to require redemption.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Liquidation Preference&#160;&#x2014;&#160;&lt;/span&gt;Each share of Series&#160;A Preferred Stock will have a liquidation preference equal to the stated value (initially $1,000 per share), plus any accrued but unpaid dividends thereon (the &#x201c;Liquidation Preference&#x201d;). In the event of a liquidation, dissolution or winding up of the Company (which shall include any merger, reorganization, sale of assets in which control of Onconetix is transferred or event which results in all or substantially all of the Company&#x2019;s assets being transferred), the holders of the Series&#160;A Preferred Stock shall be entitled to receive out of the assets of the Company, before any payment is made to the holders of common stock and either in preference to or pari passu with the holders of any other series of preferred stock that may be issued in the future, a per share amount equal to the Liquidation Preference. Any remaining assets of the Company following payment of the Liquidation Preference to the holders of Series&#160;A Preferred Stock shall be distributed to the holders of the Corporation&#x2019;s common stock and any junior series of preferred stock then outstanding.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Dividends&lt;/span&gt;&#160;&#x2014;&#160;The holders of Series&#160;A Preferred Stock shall be entitled to receive dividends on shares of Series&#160;A Preferred Stock (on an as&lt;span class="nobreak"&gt;-if-converted-to-common-stock&lt;/span&gt; basis) equal to and in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of the common stock. No other dividends shall be paid on shares of Series&#160;A Preferred Stock.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Conversion&#160;&#x2014;&#160;&lt;/span&gt;Each share of Series&#160;A Preferred Stock shall automatically convert into common stock of the Company one year from the date of issuance, if the required stockholder approval is obtained. If this approval is not obtained, then the Series&#160;A Preferred Stock is convertible, at the option of the holder, at any time and from time to &lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;time from and after one year from the date of issuance into that number of shares of common stock (subject to certain limitations) determined by dividing the Stated Value by the Conversion Price. If the required vote discussed above is not obtained, and the Series&#160;A Preferred Stock is converted at the option of the holder, the Company may not issue a number of shares of common stock which, would exceed 19.99% shares of common stock (subject to adjustment for forward and reverse stock splits, recapitalizations and the like). The Conversion Price, which is subject to adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization and other adjustments, as defined in the Series&#160;A Certificate of Designations, is initially $0.5254. The maximum number of shares that the Series&#160;A Preferred Stock is convertible into, based on the Conversion Price as of December&#160;31, 2023 is approximately 5,709,935&lt;span class="nobreak"&gt; &lt;/span&gt;shares of the Company&#x2019;s common stock.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company evaluated the terms of the Series&#160;A Preferred Stock, and in accordance with the guidance of ASC&#160;480, the Series&#160;A Preferred Stock is classified as permanent equity in the accompanying consolidated balance sheet. The Series&#160;A Preferred Stock was recorded at its fair value as of the issuance date (see Note&#160;7).&lt;/p&gt;
		&lt;p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Series&#160;B Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On December&#160;15, 2023, the Company filed a Certificate of Designations of Rights and Preferences of Series&#160;B Convertible Preferred Stock of the Company (the &#x201c;Series&#160;B Certificate of Designations&#x201d;) with the State of Delaware to designate and authorize the issuance of up to 2,700,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of Series&#160;B Preferred Stock.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On December&#160;15, 2023, in connection with the PMX Transaction, as part of the purchase consideration, the Company issued 2,696,729&lt;span class="nobreak"&gt; &lt;/span&gt;shares of Series&#160;B Convertible Preferred Stock (see Note&#160;5). The significant terms of the Series&#160;B Preferred Stock are as follows:&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Voting&#160;&#x2014;&#160;&lt;/span&gt;The shares of Series&#160;B Preferred Stock carry no voting rights except with respect to the election of the Proteomedix Director (as defined in the Certificate of Designations) and except as to certain significant matters specified in the Series&#160;B Certificate of Designations.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Liquidation Preference&#160;&#x2014;&#160;&lt;/span&gt;Upon a liquidation, dissolution or winding&lt;span class="nobreak"&gt;-up&lt;/span&gt; of Onconetix, whether voluntary or involuntary, the holders of Series&#160;B Preferred Stock shall be entitled to receive out of the assets, whether capital or surplus, of Onconetix, the same amount that a holder of common stock would receive if such holder&#x2019;s Series&#160;B Preferred Stock were fully converted to common stock at the effective conversion ratio, plus an additional amount equal to any dividends declared but unpaid to such shares, which amounts shall be paid pari passu with all holders of common stock.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Dividends&lt;/span&gt;&#160;&#x2014;&#160;The holders of the Series&#160;B Preferred Stock shall be entitled to receive dividends on shares of Series&#160;B Preferred Stock (on an as&lt;span class="nobreak"&gt;-if-converted-to-common-stock&lt;/span&gt; basis) equal to and in the same form, and in the same manner, as dividends (other than dividends on shares of the common stock payable in the form of common stock) actually paid on shares of the common stock when, as and if such dividends (other than dividends payable in the form of common stock) are paid on shares of the common stock.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Conversion&#160;&#x2014;&#160;&lt;/span&gt;Following Stockholder Approval, each share of Series&#160;B Preferred Stock shall be converted into shares of common stock (the &#x201c;Conversion Shares&#x201d;) at a ratio of 100 Conversion Shares for each share of Series&#160;B Preferred Stock (the &#x201c;Conversion Ratio&#x201d;). All shares of Series&#160;B Preferred Stock shall automatically and without any further action required be converted into Conversion Shares at the Conversion Ratio upon the latest date on which (i)&#160;Onconetix has received the Stockholder Approval with respect to the issuance of all of the shares of Common Stock issuable upon Conversion in excess of 20% of the issued and outstanding Common Stock on the Closing Date and (ii)&#160;Onconetix has effected an increase in the number of shares of Common Stock authorized under its certificate of incorporation, to the extent required to consummate the PMX Transaction. The Conversion ratio is subject to adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization and other adjustments, as defined in the Series&#160;B Certificate of Designations The Series&#160;B Preferred Stock is initially convertible into approximately 269,672,900&lt;span class="nobreak"&gt; &lt;/span&gt;shares of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Cash Settlement&#160;&#x2014;&#160;&lt;/span&gt;If, at any time after the earlier of the date of the Stockholder Approval or January&#160;1, 2025 (the earliest such date, Onconetix (x)&#160;has obtained the Stockholder Approval but fails to deliver certificates representing the Conversion Shares, or other documentation as required under the terms of the Share Exchange Agreement, or (y)&#160;has failed to obtain the Stockholder Approval, Onconetix shall, at the request of the holder, pay to such holder an amount in cash equal to (i)&#160;the Fair Value (as defined below) of the shares of Series&#160;B Preferred Stock set forth in such request multiplied by (ii)&#160;the Conversion Ratio in effect on the&#160;trading day on which the request is delivered to Onconetix. &#x201c;Fair Value&#x201d; of shares shall be fixed with reference to the last reported closing stock price on the principal trading market of the Common Stock on which the Common Stock is listed as of the&#160;trading day on which the request is delivered to Onconetix.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Redemption&#160;&#x2014;&#160;&lt;/span&gt;The shares of Series&#160;B Preferred Stock are not redeemable by Onconetix.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company evaluated the terms of the Series&#160;B Preferred Stock, and in accordance with the guidance of ASC&#160;480, the Series&#160;B Preferred Stock is classified as temporary equity in the accompanying consolidated balance sheet, as the shares may be redeemable by the holders for cash, upon certain conditions that are not within the control of the Company. Additionally, the Company does not control the actions or events necessary to deliver the number of required shares upon exercise by the holders of the conversion feature. The Series&#160;B Preferred Stock was recorded at its fair value as of the issuance date (see Note&#160;5). The Series&#160;B Preferred Stock is not currently redeemable or probable of becoming redeemable because it is subject to, among other things, Stockholder Approval as described above, and therefore the carrying amount is not currently accreted to its redemption value as of December&#160;31, 2023.&lt;/p&gt;
		&lt;p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Series&#160;Seed Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company has 1,150,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of preferred stock designated as Series&#160;Seed Preferred Stock (&#x201c;Series&#160;Seed&#x201d;) and there are no shares of Series&#160;Seed outstanding as of December&#160;31, 2023 and 2022.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Prior to the closing of the IPO in 2022, there were 1,146,138&lt;span class="nobreak"&gt; &lt;/span&gt;shares of Series&#160;Seed issued and outstanding. Each share of the Series&#160;Seed was convertible, at the option of the holder, at a conversion price of $1.52 per share, subject to certain adjustments. The holders of the Series&#160;Seed were entitled to receive cumulative dividends at a per share rate of 8% per annum, compounded annually. Each Series&#160;Seed share was automatically convertible into common stock of the Company, at the then&lt;span class="nobreak"&gt;-effective&lt;/span&gt; conversion price, upon the closing of a firmly underwritten public offering netting proceeds of at least $50&#160;million with an offering price of at least three hundred percent (300%) of the Original Issue Price of the Series&#160;Seed. On February&#160;18, 2022, the majority of the holders of the Series&#160;Seed approved the automatic conversion of the outstanding shares of the Series&#160;Seed and all related accrued and unpaid dividends, upon the closing of the IPO.&#160;The number of shares of Common Stock to be issued upon the closing of the IPO pursuant to the conversion were to be calculated in accordance with the original conversion terms provided by the Company&#x2019;s Amended and Restated Certificate of Incorporation (&#x201c;COI&#x201d;) dated July&#160;1, 2019. This conversion occurred on February&#160;23, 2022, upon the closing of the Company&#x2019;s IPO.&#160;Also, upon the close of the IPO, aggregate cumulative dividends of $1,586,162, or $1.38 per Series&#160;Seed share, were automatically converted into shares of common stock. There were an aggregate of 5,626,365&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock issued upon conversion of the Series&#160;Seed shares and cumulative dividends as of the close of the IPO.&lt;/p&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of December&#160;31, 2023 and 2022, there were 22,841,975 and 15,724,957&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock issued, respectively, and 22,324,576 and 15,265,228&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock outstanding, respectively.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Holders of the Company&#x2019;s common stock are entitled to one vote for each share held of record, and are entitled upon liquidation of the Company to share ratably in the net assets of the Company available for distribution after payment of all obligations of the Company and after provision has been made with respect to each class of stock, if any, having preference over the common stock. The shares of common stock are not redeemable and have no preemptive or similar rights.&lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On December&#160;15, 2023, in connection with the Proteomedix acquisition, the Company issued 3,675,414&lt;span class="nobreak"&gt; &lt;/span&gt;shares of the Company&#x2019;s common stock as part of the purchase consideration (see Note&#160;5).&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On February&#160;17, 2022, the Company entered into an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;) with Boustead Securities, LLC, acting as representative of the underwriters (&#x201c;Boustead&#x201d;), in relation to the Company&#x2019;s IPO, pursuant to which the Company agreed to sell to the underwriters an aggregate of 2,222,222&lt;span class="nobreak"&gt; &lt;/span&gt;shares of the Company&#x2019;s common stock, at a price of $9.00 per share. The IPO closed on February&#160;23, 2022 and resulted in net proceeds to the Company, after deducting the 8% underwriting discount, and other offering costs, of approximately $17.1&#160;million.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Pursuant to the Underwriting Agreement, the Company issued to Boustead warrants to purchase 111,111&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock, exercisable for five&#160;years at the option of the holder, at a per share exercise price equal to $10.35. The Company evaluated the terms of the warrants issued at the close of the IPO and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC&#160;480 and ASC&#160;815&lt;span class="nobreak"&gt;-40&lt;/span&gt;. Since the Company determined that the warrants were equity&lt;span class="nobreak"&gt;-classified&lt;/span&gt;, the Company recorded the proceeds from the IPO, net of issuance costs, within common stock at par value and the balance of the net proceeds to additional paid in capital.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;During October&#160;2022, in connection with a settlement agreement that was entered into with Boustead, these warrants were exchanged for 93,466&lt;span class="nobreak"&gt; &lt;/span&gt;shares of restricted common stock (&#x201c;the Warrant Exchange&#x201d;) (see Note&#160;10). The Warrant Exchange was accounted for as a modification of the warrant, with an incremental fair value of approximately $10,000, which was recorded as selling, general and administrative expense in the accompanying consolidated statements of operations and comprehensive loss. In addition, 200,000 restricted shares of common stock were issued to Boustead upon execution of an advisory agreement, which was entered into concurrent with the settlement agreement. The fair value of the restricted shares of common stock, which had no vesting provisions, was valued at $254,000, and was recorded as selling, general and administrative expense in the accompanying consolidated statements of operations and comprehensive loss.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The restricted shares of common stock issued under the settlement and advisory agreements with Boustead was valued based on the closing trading price on the date the agreements were executed, adjusted to reflect the effect of the restriction on the sale of the common stock. The value of the restriction was measured using the Black&lt;span class="nobreak"&gt;-Scholes&lt;/span&gt; model to measure the discount for lack of marketability, using the following assumptions: expected term of &lt;span style="-sec-ix-hidden: hidden-fact-274"&gt;0.5&lt;/span&gt;&#160;years, expected volatility of 96.36%, risk&lt;span class="nobreak"&gt;-free&lt;/span&gt; interest rate of 4.09% and dividend yield of 0.0%.&lt;/p&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Treasury Stock&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On November&#160;10, 2022, the board of directors approved a stock repurchase program (the &#x201c;Repurchase Program&#x201d;) to allow the Company to repurchase up to 5&#160;million shares of common stock with a maximum price of $1.00 per share, with discretion to management to make purchases subject to market conditions. On November&#160;18, 2022, the board of directors approved an increase to the maximum price to $2.00 per share. There is no expiration date for this program.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;During the year ended December&#160;31, 2023, the Company repurchased 57,670&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock, for an aggregate of approximately $59,000, at an average price of $1.02 per share. During the year ended December&#160;31, 2022, the Company repurchased 459,729&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock at an average price of $1.23 per share, for approximately $0.6&#160;million. Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. As of December&#160;31, 2023, there are approximately 4.5&#160;million shares remaining, that can be repurchased under the Repurchase Program.&lt;/p&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Private Investments in Public Equity&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;April&#160;2022 Private Placement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On April&#160;19, 2022, the Company consummated the closing of a private placement (the &#x201c;April&#160;2022 Private Placement&#x201d;), pursuant to the terms and conditions of a securities purchase agreement, dated as of April&#160;13, 2022. At the closing of the April&#160;2022 Private Placement, the Company issued 590,406&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock, pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; &lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;warrants to purchase an aggregate of 590,406&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock and preferred investment options to purchase up to an aggregate of 1,180,812&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock. The purchase price of each share of common stock together with the associated preferred investment option was $6.775, and the purchase price of each pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrant together with the associated preferred investment option was $6.774. The aggregate net cash proceeds to the Company from the April&#160;2022 Private Placement were approximately $6.9&#160;million, after deducting placement agent fees and other offering expenses. The pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants had an exercise price of $0.001 per share and were exercised in full on May&#160;24, 2022. The preferred investment options, which had an exercise price of $6.65 per share, were exchanged in connection with the August&#160;2022 Private Placement. See &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;August&#160;2022 Private Placement&lt;/span&gt; below for further detail.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;H.C.&#160;Wainwright&#160;&amp;amp; Co., LLC (&#x201c;Wainwright&#x201d;) acted as the exclusive placement agent for the April&#160;2022 Private Placement. The Company agreed to pay Wainwright a placement agent fee and management fee equal to 7.5% and 1.0%, respectively, of the aggregate gross proceeds from the April&#160;2022 Private Placement and reimburse certain out&lt;span class="nobreak"&gt;-of-pocket&lt;/span&gt; expenses up to an aggregate of $85,000. In addition, the Company issued warrants to Wainwright (the &#x201c;April Wainwright Warrants&#x201d;) to purchase up to 70,849&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock. The Wainwright Warrants are in substantially the same form as the preferred investment options, except that the exercise price is $8.46875. The form of the preferred investment options is a warrant, and as such the preferred investment options, the pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants, and the Wainwright Warrants are collectively referred to as the &#x201c;April&#160;2022 Private Placement Warrants&#x201d;. Further, upon any exercise for cash of any preferred investment options, the Company agreed to issue to Wainwright additional warrants to purchase the number of shares of common stock equal to 6.0% of the aggregate number of shares of common stock underlying the preferred investment options that have been exercised, also with an exercise price of $8.46875 (the &#x201c;April Contingent Warrants&#x201d;). The maximum number of April Contingent Warrants issuable under this provision of 70,849 were exchanged in connection with the August&#160;2022 Private Placement. See &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;August&#160;2022 Private Placement&lt;/span&gt; below for further detail.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company evaluated the terms of the April&#160;2022 Private Placement Warrants and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC&#160;480 and ASC&#160;815&lt;span class="nobreak"&gt;-40&lt;/span&gt;. Since the Company determined that the April&#160;2022 Private Placement Warrants were equity&lt;span class="nobreak"&gt;-classified&lt;/span&gt;, the Company recorded the proceeds from the April&#160;2022 Private Placement, net of issuance costs, within common stock at par value and the balance of the net proceeds to additional paid in capital.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company evaluated the terms of the April Contingent Warrants and determined that they should be classified as a liability based upon accounting guidance provided in ASC&#160;815&lt;span class="nobreak"&gt;-40&lt;/span&gt;. Since the April Contingent Warrants are a form of compensation to Wainwright, the Company recorded the value of the liability of approximately $36,000, as a reduction of additional paid in capital, with subsequent changes in the value of the liability recorded in other income (expense) in the accompanying consolidated statements of operations and comprehensive loss. The Company measured the liability upon the close of the April Private Placement using a Monte Carlo simulation, using the following significant assumptions: expected term of &lt;span style="-sec-ix-hidden: hidden-fact-275"&gt;4.0&lt;/span&gt;&#160;years, expected volatility of 117.0%, risk&lt;span class="nobreak"&gt;-free&lt;/span&gt; interest rate of 4.00% and dividend yield of 0.0%.&lt;/p&gt;
		&lt;p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;August&#160;2022 Private Placement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On August&#160;11, 2022, the Company consummated the closing of a private placement (the &#x201c;August&#160;2022 Private Placement&#x201d;), pursuant to the terms and conditions of a securities purchase agreement, dated as of August&#160;9, 2022. At the closing of the August&#160;2022 Private Placement, the Company issued 1,350,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock, pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants to purchase an aggregate of 2,333,280&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock and preferred investment options to purchase up to an aggregate of 4,972,428&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock. The purchase price of each share of common stock together with the associated preferred investment option was $2.715, and the purchase price of each pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrant together with the associated preferred investment option was $2.714. The aggregate net cash proceeds to the Company from the August&#160;2022 Private Placement were approximately $8.7&#160;million, after deducting placement agent fees and other offering expenses. In addition, the investors in the August&#160;2022 Private Placement, who are the same investors from the April&#160;2022 Private Placement, agreed to cancel preferred investment options to purchase up to an aggregate of &lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;1,180,812&lt;span class="nobreak"&gt; &lt;/span&gt;shares of the Company&#x2019;s common stock issued in April&#160;2022. The pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants had an exercise price of $0.001 per share. During 2022, an aggregate of 1,686,640 of the pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants were exercised. The remaining 646,640 of pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants were exercised during the year ended December&#160;31, 2023. The preferred investment options are exercisable at any time on or after August&#160;11, 2022 through August&#160;12, 2027, at an exercise price of $2.546 per share, subject to certain adjustments as defined in the agreement. During the year ended December&#160;31, 2023, 2,486,214 of these preferred investment options were exercised at a reduced exercise price of $1.09, in connection with the warrant inducement transaction discussed below. As of December&#160;31, 2023, 2,486,214 preferred investment options are outstanding.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Wainwright acted as the exclusive placement agent for the August&#160;2022 Private Placement. The Company agreed to pay Wainwright a placement agent fee and management fee equal to 7.5% and 1.0%, respectively, of the aggregate gross proceeds from the August&#160;2022 Private Placement and reimburse certain out&lt;span class="nobreak"&gt;-of-pocket&lt;/span&gt; expenses up to an aggregate of $85,000. In addition, the Company issued warrants to Wainwright (the &#x201c;August Wainwright Warrants&#x201d;) to purchase up to 220,997&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock. The August Wainwright Warrants are in substantially the same form as the preferred investment options, except that the exercise price is $3.3938. The form of the preferred investment options is a warrant, and as such the preferred investment options, the pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants, and the August Wainwright Warrants are collectively referred to as the &#x201c;August&#160;2022 Private Placement Warrants&#x201d;. Further, upon any exercise for cash of any preferred investment options, the Company agreed to issue to Wainwright additional warrants to purchase the number of shares of common stock equal to 6.0% of the aggregate number of shares of common stock underlying the preferred investment options that have been exercised, also with an exercise price of $3.3938 (the &#x201c;August Contingent Warrants&#x201d;). The maximum number of August Contingent Warrants issuable under this provision is 298,346, which includes 70,849 of April Contingent Warrants that were modified in connection with the August&#160;2022 Private Placement.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company evaluated the terms of the August&#160;2022 Private Placement Warrants and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC&#160;480 and ASC&#160;815&lt;span class="nobreak"&gt;-40&lt;/span&gt;. Since the Company determined that the August&#160;2022 Private Placement Warrants were equity&lt;span class="nobreak"&gt;-classified&lt;/span&gt;, the Company recorded the proceeds from the August&#160;2022 Private Placement, net of issuance costs, within common stock at par value and the balance of the net proceeds to additional paid in capital.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The investors in the April&#160;2022 Private Placement agreed to cancel the aggregate of 1,180,812 preferred investment options issued in the April&#160;2022 Private Placement, as part of their participation in the August&#160;2022 Private Placement. The preferred investment options that were cancelled were effectively exchanged for 1,289,148 new preferred investment options in the August&#160;2022 Private Placement, and accordingly have been accounted for as a modification or exchange of equity&lt;span class="nobreak"&gt;-linked&lt;/span&gt; instruments. In accordance with ASC&#160;815&lt;span class="nobreak"&gt;-40&lt;/span&gt;, as the preferred investment options were classified as equity instruments before and after the exchange, and as the exchange is directly attributable to an equity offering, the Company recognized the effect of the exchange as an equity issuance cost. The increase in the fair value of the preferred investment options as a result of the exchange was approximately $860,000, and was determined using the Black&lt;span class="nobreak"&gt;-Scholes&lt;/span&gt; option pricing model, with the following assumptions:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Original&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Exchanged&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercise price&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.65&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.546&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Term (years)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3.67&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.0&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected stock price volatility&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;116.2&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;120.2&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Risk-free rate of interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3.16&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.98&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company evaluated the terms of the August Contingent Warrants and determined that they should be classified as a liability based upon accounting guidance provided in ASC&#160;815&lt;span class="nobreak"&gt;-40&lt;/span&gt;. As a result of the exchange of the preferred investment options issued in the April Private Placement, the underlying equity&lt;span class="nobreak"&gt;-linked&lt;/span&gt; instruments that would trigger issuance of the April Contingent Warrants was replaced, and therefore the 70,849 of April Contingent Warrants were exchanged for 70,849 of the August Contingent Warrants. The value of the April Contingent Warrant liability was adjusted to fair value on the date of modification, using a Monte Carlo simulation, with the change in fair value &lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;of approximately $8,000 recognized in the accompanying consolidated statements of operations and comprehensive loss. The remaining 227,497 August Contingent Warrants were measured as a liability upon the close of the August Private Placement. Since the Contingent Warrants are a form of compensation to the placement agent, the Company recorded the value of the liability of approximately $39,000, as a reduction of additional paid in capital. The entire 298,346 of August Contingent Warrants were remeasured at December&#160;31, 2022, using a Monte Carlo simulation, with the change in the value of the liability recorded in other income (expense) in the accompanying consolidated statements of operations and comprehensive loss. The following significant assumptions were used in the valuation of the contingent warrant liability, related to the August Contingent Warrants, as of the date of the August&#160;2022 Private Placement and as of December&#160;31, 2022:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;August&#160;11,&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercise price&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3.3938&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3.3938&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Term (years)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.00&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.61&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected stock price volatility&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;127.8&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;120.8&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Risk-free rate of interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.98&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.03&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;During the year ended December&#160;31, 2023, in connection with the warrant inducement transaction, the Company issued warrants to Wainwright as settlement of the contingent warrant liability associated with 149,173 of the August&#160;2022 Contingent Warrants, which was triggered upon exercise of the underlying preferred investment options. See &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Warrant Inducement &lt;/span&gt;below for further discussion.&lt;/p&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;At the Market Offering Agreement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On March&#160;29, 2023, the Company entered into an At The Market Offering Agreement (the &#x201c;ATM Agreement&#x201d;) with H.C.&#160;Wainwright&#160;&amp;amp; Co., LLC, as sales agent (the &#x201c;Agent&#x201d;), to create an at&lt;span class="nobreak"&gt;-the-market&lt;/span&gt; equity program under which it may sell up to $3,900,000 of shares of the Company&#x2019;s common stock (the &#x201c;Shares&#x201d;) from time to time through the Agent (the &#x201c;ATM Offering&#x201d;). Under the ATM Agreement, the Agent will be entitled to a commission at a fixed rate of 3.0% of the gross proceeds from each sale of Shares under the ATM Agreement. The Company has no obligation to sell, and the Agent is not obligated to buy or sell, any of the Shares under the Agreement and may at any time suspend offers under the Agreement or terminate the Agreement. The ATM Offering will terminate upon the termination of the ATM Agreement as permitted therein.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Deferred offering costs associated with the ATM Agreement are reclassified to additional paid in capital on a pro&lt;span class="nobreak"&gt;-rata&lt;/span&gt; basis when the Company completes offerings under the ATM Agreement. Any remaining deferred costs will be expensed to the consolidated statements of operations and comprehensive loss should the planned offering be abandoned.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of December&#160;31, 2023, no shares have been sold under the ATM Offering.&lt;/p&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Warrant Inducement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On July&#160;31, 2023, the Company entered into a common stock preferred investment options exercise inducement offer letter (the &#x201c;Inducement Letter&#x201d;) with a holder (the &#x201c;Holder&#x201d;) of existing preferred investment options (&#x201c;PIOs&#x201d;) to purchase shares of the Company&#x2019;s common stock at the original exercise price of $2.546 per share, issued on August&#160;11, 2022 (the &#x201c;Existing PIOs&#x201d;). Pursuant to the Inducement Letter, the Holder agreed to exercise for cash its Existing PIOs to purchase an aggregate of 2,486,214&lt;span class="nobreak"&gt; &lt;/span&gt;shares of the Company&#x2019;s common stock (the &#x201c;Inducement PIO Shares&#x201d;), at a reduced exercised price of $1.09 per share, in exchange for the Company&#x2019;s agreement to issue new preferred investment options (the &#x201c;Inducement PIOs&#x201d;) to purchase up to 4,972,428&lt;span class="nobreak"&gt; &lt;/span&gt;shares of the Company&#x2019;s common stock. The Inducement PIOs have substantially the same terms as the Existing PIOs.&lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On August&#160;2, 2023, the Company consummated the transactions contemplated by the Inducement Letter (the &#x201c;Warrant Inducement&#x201d;). The Company received aggregate net proceeds of approximately $2.3&#160;million from the Warrant Inducement, after deducting placement agent fees and other offering expenses payable by the Company.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Upon the close of the transaction, the Company issued the Holder 1,575,000 of the 2,486,214&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock that were issuable upon exercise of the Existing PIOs. Due to the beneficial ownership limitation provisions in the Inducement Letter, the remaining 911,214&lt;span class="nobreak"&gt; &lt;/span&gt;shares were initially unissued, and held in abeyance for the benefit of the Holder until notice from the Holder that the shares may be issued in compliance with such limitation is received. These shares were issued to the Holder in October&#160;2023.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company agreed to file a registration statement covering the resale of the Inducement PIO Shares issued or issuable upon the exercise of the Inducement PIOs (the &#x201c;Resale Registration Statement&#x201d;), as soon as practicable, and to use commercially reasonable efforts to have such Resale Registration Statement declared effective by the SEC within 90&#160;days following the date of the Inducement Letter, and to keep the Resale Registration Statement effective at all times until there are no Inducement PIO Shares. The provision to register the underlying shares in the Warrant Inducement does not require payment related to the registration rights provided. As such, while the shares were not registered within 90&#160;days of the date of the Inducement Letter, there is no accounting impact for this provision.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company engaged Wainwright to act as its placement agent in connection with the Warrant Inducement and paid Wainwright a cash fee equal to 7.5% of the gross proceeds received from the exercise of the Existing PIOs as well as a management fee equal to 1.0% of the gross proceeds from the exercise of the Existing PIOs. The Company also agreed to reimburse Wainwright for its expenses in connection with the exercise of the Existing PIOs and the issuance of the Inducement PIOs, up to $50,000 for fees and expenses of legal counsel and other out&lt;span class="nobreak"&gt;-of-pocket&lt;/span&gt; expenses and agreed to pay Wainwright for non&lt;span class="nobreak"&gt;-accountable&lt;/span&gt; expenses in the amount of $35,000. In addition, the exercise for cash of the Existing PIOs triggered the issuance to Wainwright or its designees, warrants to purchase 149,173&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock (&#x201c;Wainwright Inducement Warrants&#x201d;), which were issuable in accordance with the terms of the August Contingent Warrants, and have the same terms as the Inducement PIOs except for an exercise price equal to $1.3625 per share. The Company also agreed to issue warrants to Wainwright upon any exercise for cash of the Inducement PIOs, that number of shares of common stock equal to 6.0% of the aggregate number of such shares of common stock underlying the Inducement PIOs that have been exercised, also with an exercise price of $1.3625 (the &#x201c;Inducement Contingent Warrants&#x201d;). The maximum number of Inducement Contingent Warrants issuable under this provision is 298,346.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company evaluated the terms of the Inducement PIOs and the Wainwright Inducement Warrants (collectively, the &#x201c;August&#160;2023 Inducement Warrants&#x201d;), and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC&#160;480 and ASC&#160;815&lt;span class="nobreak"&gt;-40&lt;/span&gt;.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Warrant Inducement, which resulted in the lowering of the exercise price of the Existing PIOs and the issuance of the Inducement PIOs, is considered a modification of the Existing PIOs under the guidance of Accounting Standards Update (&#x201c;ASU&#x201d;) No.&#160;2021&lt;span class="nobreak"&gt;-04&lt;/span&gt;, &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Equity Classified Written Call Options&lt;/span&gt;. The modification is consistent with the &#x201c;Equity Issuance&#x201d; classification under that guidance as the reason for the modification was to induce the holders of the Existing PIOs to cash exercise their warrants, resulting in the imminent exercise of the Existing PIOs, which raised equity capital and generated net proceeds for the Company of approximately $2.3&#160;million. As the Existing PIOs and the Inducement PIOs were classified as equity instruments before and after the exchange, and as the exchange is directly attributable to an equity offering, the Company recognized the effect of the modification of approximately $2.6&#160;million as an equity issuance cost.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In addition, the change in fair value of the contingent warrant liability associated with 149,173 of the August Contingent Warrants that were settled through issuance of the Wainwright Inducement Warrants, of approximately $122,000, was recognized in other income (expense) in the accompanying consolidated statements of operations and comprehensive loss, and the fair value of the contingent warrant liability of approximately $129,000 was derecognized as of the settlement date. The corresponding amount, representing the fair value of the Wainwright Inducement Warrants, &lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;was recognized as additional paid in capital. The Company measured the liability on the settlement date using a Black Scholes model, with the following significant assumptions: expected term of &lt;span style="-sec-ix-hidden: hidden-fact-276"&gt;5.0&lt;/span&gt;&#160;years, expected volatility of 117.8%, risk&lt;span class="nobreak"&gt;-free&lt;/span&gt; interest rate of 4.24% and dividend yield of 0.0%.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company evaluated the terms of the Inducement Contingent Warrants and determined that they should be classified as a liability based upon accounting guidance provided in ASC&#160;815&lt;span class="nobreak"&gt;-40&lt;/span&gt;. Since the Inducement Contingent Warrants are a form of compensation to Wainwright, the Company recorded the value of the liability of approximately $26,000 as a reduction of additional paid in capital, with subsequent changes in the value of the liability recorded in other income (expense) in the accompanying consolidated statements of operations and comprehensive loss. The Company measured the liability on the settlement date using a Black Scholes model, with the following significant assumptions: expected term of &lt;span style="-sec-ix-hidden: hidden-fact-277"&gt;5.0&lt;/span&gt;&#160;years, expected volatility of 117.8%, risk&lt;span class="nobreak"&gt;-free&lt;/span&gt; interest rate of 4.24% and dividend yield of 0.0%.&lt;/p&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The following summarizes activity related to the Company&#x2019;s outstanding warrants, excluding contingent warrants issuable upon exercise of the preferred investment options, for the year ended December&#160;31, 2023:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life&lt;br/&gt;(in&#160;years)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding as of December&#160;31, 2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5,910,914&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.37&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.7&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5,121,601&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.10&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(3,132,854&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;0.865&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-268"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-269"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding as of December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7,899,661&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.68&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.3&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Warrants vested and exercisable as of December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7,899,661&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.68&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.3&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of December&#160;31, 2023, the outstanding warrants include 70,849 April&#160;2022 Private Placement Warrants, 2,707,211 August&#160;2022 Private Placement Warrants, and 5,121,601 August&#160;2023 Inducement Warrants, which are exercisable into 7,899,661&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock which had a fair value of $0.20 per share, based on the closing trading price on that&#160;day.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Additionally, as of December&#160;31, 2023 and 2022, the value of the August Contingent Warrants and the Inducement Contingent Warrants (collectively the &#x201c;Contingent Warrants&#x201d;) was approximately $3,000 and $14,000, respectively. The maximum number of warrants issuable upon settlement of the Contingent Warrants as of December&#160;31, 2023 and 2022 was 447,519 and 298,346, respectively.&lt;/p&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Onconetix Equity Incentive Plans&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company&#x2019;s 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;) was adopted by its board of directors and by its stockholders on July&#160;1, 2019. The Company has reserved 1,400,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock for issuance pursuant to the 2019 Plan.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On February&#160;23, 2022 and in connection with the closing of the IPO, the Company&#x2019;s board of directors adopted the Company&#x2019;s 2022 Equity Incentive Plan (the &#x201c;2022 Plan&#x201d;), which is the successor and continuation of the Company&#x2019;s 2019 Plan. Under the 2022 Plan, the Company may grant stock options, restricted stock, restricted stock units, stock appreciation rights, and other forms of awards to employees, directors, and consultants of the Company. Upon its effectiveness, a total of 1,600,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of common stock were reserved for issuance under the 2022 Plan. In August&#160;2022, the number of shares of common stock reserved for issuance under the 2022 Plan was increased to 2,600,000 and in May&#160;2023, the number of shares of common stock reserved for issuance under the 2022 Plan was &lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;increased to 3,150,000. The stock options and restricted stock granted during the&#160;years ended December&#160;31, 2023 and 2022 were all granted under the 2022 Plan. As of December&#160;31, 2023, there are 718,402&lt;span class="nobreak"&gt; &lt;/span&gt;shares available for issuance under the 2022 Plan.&lt;/p&gt;
		&lt;p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The following summarizes activity related to the Company&#x2019;s stock options under the 2019 Plan and the 2022 Plan for the year ended December&#160;31, 2023:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Total&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;(in&#160;years)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding as of December&#160;31, 2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,392,654&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3.30&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;670,161&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;8.2&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;962,154&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;0.48&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-270"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited/cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(404,058&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.87&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-271"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(45,920&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;0.01&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;45,920&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding as of December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,904,830&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.63&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;94,239&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;8.4&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options vested and exercisable as of December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;861,177&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.23&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;94,239&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.1&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The fair value of options granted in 2023 and 2022 was estimated using the following assumptions:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-28" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;For the &lt;br/&gt;Year Ended &lt;br/&gt;December&#160;31, &lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;For the &lt;br/&gt;Year Ended &lt;br/&gt;December&#160;31, &lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercise price&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;$0.26&#160;&#x2013;&#160;1.29&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;$1.06&#160;&#x2013;&#160;6.45&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Term (years)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5.00&#160;&#x2013;&#160;10.00&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5.00&#160;&#x2013;&#160;10.00&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected stock price volatility&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;101.1%&#160;&#x2013;&#160;119.5&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;112.6%&#160;&#x2013;&#160;121.2%&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Risk-free rate of interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3.5%&#160;&#x2013;&#160;4.7%&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;2.9%&#160;&#x2013;&#160;4.3%&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The weighted average grant date fair value of stock options granted during the&#160;years ended December&#160;31, 2023 and 2022 was $0.41 and $3.40, respectively. The aggregate fair value of stock options that vested during the&#160;years ended December&#160;31, 2023 and 2022 was approximately $0.7&#160;million and $2.1&#160;million, respectively.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On October&#160;4, 2023, the Company&#x2019;s board of directors granted an aggregate of 709,768 stock options in connection with the appointment of the Company&#x2019;s newly hired Chief Executive Officer and Chief Financial Officer. The options granted have an exercise price of $0.4305 per share, vest quarterly over a three&lt;span class="nobreak"&gt;-year&lt;/span&gt; period, and have a grant date fair value of approximately $0.2&#160;million. The Company recognized less than $0.1&#160;million of stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense related to these awards during the year ended December&#160;31, 2023. Subsequent to December&#160;31, 2023, in connection with the resignation of the newly hired Chief Executive Officer, 487,965 of these options were forfeited (see Note&#160;14).&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;During the year ended December&#160;31, 2022, 200,000 stock options were granted to the Company&#x2019;s former Chief Executive Officer (&#x201c;former CEO&#x201d;), Chairman, and significant stockholder, 200,000 stock options were granted to the Company&#x2019;s former Chief Business Officer (&#x201c;former CBO&#x201d;), and 100,000 stock options were granted to the Company&#x2019;s former Chief Financial Officer (&#x201c;former CFO&#x201d;). The aggregate grant&lt;span class="nobreak"&gt;-date&lt;/span&gt; fair value of the stock options granted to these individuals was approximately $1.8&#160;million, of which approximately $1.5&#160;million was recognized as stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense during the year ended December&#160;31, 2022. During the year ended December&#160;31, 2023, in connection with the resignation of the former CEO and the former CFO, 250,000 of these stock options were forfeited.&lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Additionally, during the year ended December&#160;31, 2022, the Company granted an aggregate of 72,223 stock options to non&lt;span class="nobreak"&gt;-executive&lt;/span&gt; directors. The grant&lt;span class="nobreak"&gt;-date&lt;/span&gt; fair value of the stock options granted to the non&lt;span class="nobreak"&gt;-executive&lt;/span&gt; directors was approximately $0.2&#160;million, of which approximately $0.2&#160;million was recognized as stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense during the year ended December&#160;31, 2022.&lt;/p&gt;
		&lt;p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Restricted Stock&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On May&#160;9, 2023, the Board&#x2019;s Compensation Committee approved the issuance of restricted stock, granted under the Company&#x2019;s 2022 Plan, to the Company&#x2019;s executive officers, employees, and certain of the Company&#x2019;s consultants. The restricted shares granted totaled 487,500, of which 150,000, 75,000, and 150,000 were granted to the Company&#x2019;s former CEO, former CFO, and former CBO, respectively. All of the restricted shares granted vest as follows: 50% in January&#160;2024, 25% in August&#160;2024, and 25% in August&#160;2025. In addition, on May&#160;31, 2023, the Board&#x2019;s Compensation Committee approved the issuance of 25,440&lt;span class="nobreak"&gt; &lt;/span&gt;shares of restricted stock, granted to the Company&#x2019;s non&lt;span class="nobreak"&gt;-executive&lt;/span&gt; Board members, with full vesting on May&#160;31, 2024.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On August&#160;16, 2023 and October&#160;4, 2023, upon their respective resignations, the Company&#x2019;s former CEO and former CFO forfeited 150,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares and 75,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of unvested restricted stock, respectively.&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Nonvested as of December&#160;31, 2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-272"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-273"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;512,940&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.01&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited/cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(250,110&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.02&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Vested&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(6,250&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.03&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Nonvested as of December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;256,580&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.03&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Proteomedix Stock Option Plan&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Proteomedix sponsors a stock option plan (the &#x201c;PMX Option Plan&#x201d;) which provides common stock option grants to be granted to certain employees and consultants, as was determined by the board of directors of Proteomedix. In connection with the PMX Transaction, the Company assumed the PMX Option Plan (see Note&#160;5).&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Generally, options issued under the PMX Option Plan have a term of less than &lt;span style="-sec-ix-hidden: hidden-fact-278"&gt;11&lt;/span&gt;&#160;years and provide for a &lt;span style="-sec-ix-hidden: hidden-fact-279"&gt;four&lt;/span&gt;&lt;span class="nobreak"&gt;-year&lt;/span&gt; vesting period during which the grantee must remain in the service of Proteomedix. Stock options issued under the PMX Option Plan are measured at fair value using the Black&lt;span class="nobreak"&gt;-Scholes&lt;/span&gt; option pricing model.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;There was no activity under the PMX Option Plan between the Acquisition Date and December&#160;31, 2023. As of December&#160;31, 2023, there were 58,172 and 57,276 stock options outstanding and vested, respectively, with a weighted average exercise price of $3.46 and $3.17, respectively, and a weighted average remaining contractual life of &lt;span style="-sec-ix-hidden: hidden-fact-280"&gt;5.36&lt;/span&gt;&#160;years and &lt;span style="-sec-ix-hidden: hidden-fact-281"&gt;5.20&lt;/span&gt;&#160;years, respectively. The intrinsic value of options outstanding and vested, as of December&#160;31, 2023 was approximately $7.4&#160;million and $7.1&#160;million, respectively. As of December&#160;31, 2023 there were 47,990 stock options exercisable at a weighted average exercise price of $3.94 and a weighted average remaining contractual life of &lt;span style="-sec-ix-hidden: hidden-fact-282"&gt;4.53&lt;/span&gt;&#160;years.&lt;/p&gt;&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense for the&#160;years ended December&#160;31, 2023 and 2022 was as follows:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;For the&#160;Years Ended&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Selling, general and administrative&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;234,298&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,309,687&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;95,462&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;664,879&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;329,760&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;1,974,566&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of December&#160;31, 2023, unrecognized stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense relating to outstanding stock options and unvested restricted stock under the Onconetix Equity Incentive Plans is approximately $345,000 and $35,000, respectively, which is expected to be recognized over a weighted&lt;span class="nobreak"&gt;-average&lt;/span&gt; period of &lt;span style="-sec-ix-hidden: hidden-fact-283"&gt;1.79&lt;/span&gt;&#160;years and &lt;span style="-sec-ix-hidden: hidden-fact-284"&gt;1.57&lt;/span&gt;&#160;years, respectively.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of December&#160;31, 2023, unrecognized stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense relating to outstanding stock options under the PMX Option Plan is approximately $0.1&#160;million, which will be recognized over a weighted&lt;span class="nobreak"&gt;-average&lt;/span&gt; period of &lt;span style="-sec-ix-hidden: hidden-fact-285"&gt;2.98&lt;/span&gt;&#160;years.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;During the year ended December&#160;31, 2023, in connection with the former CBO&#x2019;s resignation from the Company, the individual&#x2019;s outstanding stock options and restricted stock awards were modified to allow continued vesting during the term of the consulting agreement entered into in January&#160;2024. The Company recognized a net credit of approximately $165,000 to stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense as a result of this modification, primarily due to the decrease in the Company&#x2019;s stock price.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;During the year ended December&#160;31, 2022, the Company&#x2019;s board of directors approved the accelerated vesting of an aggregate of 32,517 stock options to a former director and a former advisor, in connection with their separation from the Company. The Company recognized stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense of approximately $0.1&#160;million related to these modifications during the year ended December&#160;31, 2022.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c1"
      decimals="0"
      id="ixv-31169"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c32"
      decimals="0"
      id="ixv-31170"
      unitRef="shares">10000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c199"
      decimals="5"
      id="ixv-31171"
      unitRef="usdPershares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="5"
      id="ixv-31172"
      unitRef="usdPershares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c200"
      decimals="0"
      id="ixv-31173"
      unitRef="shares">1150000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c201"
      decimals="0"
      id="ixv-31174"
      unitRef="shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c202"
      decimals="0"
      id="ixv-31175"
      unitRef="shares">2700000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c203"
      decimals="0"
      id="ixv-31176"
      unitRef="shares">1150000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c63"
      decimals="5"
      id="ixv-31177"
      unitRef="usdPershares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c204"
      decimals="0"
      id="ixv-31178"
      unitRef="shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c205"
      decimals="0"
      id="ixv-31179"
      unitRef="shares">3000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:OtherNotesPayable
      contextRef="c206"
      decimals="-5"
      id="ixv-31180"
      unitRef="usd">3000000</us-gaap:OtherNotesPayable>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="c201"
      decimals="0"
      id="ixv-31181"
      unitRef="usdPershares">1000</us-gaap:PreferredStockLiquidationPreference>
    <onco:SharesOfCommonStockRate
      contextRef="c183"
      decimals="4"
      id="ixv-31182"
      unitRef="pure">0.1999</onco:SharesOfCommonStockRate>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c1"
      decimals="4"
      id="ixv-31183"
      unitRef="usdPershares">0.5254</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c1"
      decimals="0"
      id="ixv-31184"
      unitRef="shares">5709935</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c207"
      decimals="0"
      id="ixv-31185"
      unitRef="shares">2700000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c68"
      decimals="0"
      id="ixv-31186"
      unitRef="shares">2696729</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c1"
      decimals="0"
      id="ixv-31187"
      unitRef="shares">100</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <onco:PercentageOfIssuedOfCommonStock contextRef="c0" decimals="2" id="ixv-31188" unitRef="pure">0.20</onco:PercentageOfIssuedOfCommonStock>
    <onco:PercentageOfOutstandingOfCommonStock contextRef="c0" decimals="2" id="ixv-31189" unitRef="pure">0.20</onco:PercentageOfOutstandingOfCommonStock>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c208"
      decimals="0"
      id="ixv-31190"
      unitRef="shares">269672900</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c209"
      decimals="0"
      id="ixv-31191"
      unitRef="shares">1150000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c210"
      decimals="0"
      id="ixv-31192"
      unitRef="shares">1146138</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c211"
      decimals="0"
      id="ixv-31193"
      unitRef="shares">1146138</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c2"
      decimals="2"
      id="ixv-31194"
      unitRef="usdPershares">1.52</us-gaap:PreferredStockConvertibleConversionPrice>
    <onco:PercentageOfCumulativeDividends contextRef="c9" decimals="2" id="ixv-31195" unitRef="pure">0.08</onco:PercentageOfCumulativeDividends>
    <onco:NettingProceeds contextRef="c9" decimals="-6" id="ixv-31196" unitRef="usd">50000000</onco:NettingProceeds>
    <onco:PercentageOfOriginalIssuePrice contextRef="c9" decimals="2" id="ixv-31197" unitRef="pure">3</onco:PercentageOfOriginalIssuePrice>
    <us-gaap:CumulativeDividends contextRef="c63" decimals="0" id="ixv-31198" unitRef="usd">1586162</us-gaap:CumulativeDividends>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="c63"
      decimals="2"
      id="ixv-31199"
      unitRef="usdPershares">1.38</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c63"
      decimals="0"
      id="ixv-31200"
      unitRef="shares">5626365</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:StockIssued1 contextRef="c41" decimals="0" id="ixv-31201" unitRef="usd">22841975</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c22" decimals="0" id="ixv-31202" unitRef="usd">15724957</us-gaap:StockIssued1>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c51"
      decimals="0"
      id="ixv-31203"
      unitRef="shares">22324576</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c32"
      decimals="0"
      id="ixv-31204"
      unitRef="shares">15265228</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:CommonUnitIssued
      contextRef="c68"
      decimals="0"
      id="ixv-31205"
      unitRef="shares">3675414</us-gaap:CommonUnitIssued>
    <us-gaap:StockIssued1 contextRef="c212" decimals="0" id="ixv-31206" unitRef="usd">2222222</us-gaap:StockIssued1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c213"
      decimals="2"
      id="ixv-31207"
      unitRef="usdPershares">9</us-gaap:SharesIssuedPricePerShare>
    <onco:PercentageOfUnderwritingDiscount contextRef="c62" decimals="2" id="ixv-31208" unitRef="pure">0.08</onco:PercentageOfUnderwritingDiscount>
    <us-gaap:OtherOwnershipInterestsOfferingCosts contextRef="c63" decimals="-5" id="ixv-31209" unitRef="usd">17100000</us-gaap:OtherOwnershipInterestsOfferingCosts>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="c1"
      decimals="0"
      id="ixv-31210"
      unitRef="shares">111111</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c1"
      decimals="2"
      id="ixv-31211"
      unitRef="usdPershares">10.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c214"
      decimals="0"
      id="ixv-31212"
      unitRef="shares">93466</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c214" decimals="0" id="ixv-31213" unitRef="usd">10000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c215"
      decimals="0"
      id="ixv-31214"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c214" decimals="0" id="ixv-31215" unitRef="usd">254000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c216"
      decimals="4"
      id="ixv-31216"
      unitRef="pure">0.9636</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c216"
      decimals="4"
      id="ixv-31217"
      unitRef="pure">0.0409</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c216"
      decimals="3"
      id="ixv-31218"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="c217"
      decimals="-6"
      id="ixv-31219"
      unitRef="shares">5000000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c218"
      decimals="2"
      id="ixv-31220"
      unitRef="usdPershares">1</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c219"
      decimals="2"
      id="ixv-31221"
      unitRef="usdPershares">2</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="c220"
      decimals="0"
      id="ixv-31222"
      unitRef="shares">57670</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c220" decimals="0" id="ixv-31223" unitRef="usd">59000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c221"
      decimals="2"
      id="ixv-31224"
      unitRef="usdPershares">1.02</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="c222"
      decimals="0"
      id="ixv-31225"
      unitRef="shares">459729</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c223"
      decimals="2"
      id="ixv-31226"
      unitRef="usdPershares">1.23</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="c222"
      decimals="-5"
      id="ixv-31227"
      unitRef="usd">600000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="c1"
      decimals="-5"
      id="ixv-31228"
      unitRef="shares">4500000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:CommonStockSharesIssued
      contextRef="c224"
      decimals="0"
      id="ixv-31229"
      unitRef="shares">590406</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c224"
      decimals="0"
      id="ixv-31230"
      unitRef="shares">590406</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c225"
      decimals="0"
      id="ixv-31231"
      unitRef="shares">1180812</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c226"
      decimals="3"
      id="ixv-31232"
      unitRef="usdPershares">6.775</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c225"
      decimals="3"
      id="ixv-31233"
      unitRef="usdPershares">6.774</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="c227"
      decimals="-5"
      id="ixv-31234"
      unitRef="usd">6900000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c228"
      decimals="3"
      id="ixv-31235"
      unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c224"
      decimals="2"
      id="ixv-31236"
      unitRef="usdPershares">6.65</us-gaap:PreferredStockConvertibleConversionPrice>
    <onco:PlacementAgentFeeAndManagementFeePercentage
      contextRef="c229"
      decimals="3"
      id="ixv-31237"
      unitRef="pure">0.075</onco:PlacementAgentFeeAndManagementFeePercentage>
    <onco:PlacementAgentFeeAndManagementFeePercentage
      contextRef="c230"
      decimals="3"
      id="ixv-31238"
      unitRef="pure">0.01</onco:PlacementAgentFeeAndManagementFeePercentage>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c231" decimals="0" id="ixv-31239" unitRef="usd">85000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c231"
      decimals="0"
      id="ixv-31240"
      unitRef="shares">70849</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c232"
      decimals="5"
      id="ixv-31241"
      unitRef="usdPershares">8.46875</us-gaap:PreferredStockConvertibleConversionPrice>
    <onco:AggregateNumberOfSharesPercenatge
      contextRef="c231"
      decimals="3"
      id="ixv-31242"
      unitRef="pure">0.06</onco:AggregateNumberOfSharesPercenatge>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c233"
      decimals="5"
      id="ixv-31243"
      unitRef="usdPershares">8.46875</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c234"
      decimals="0"
      id="ixv-31244"
      unitRef="shares">70849</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:OtherLiabilities contextRef="c235" decimals="0" id="ixv-31245" unitRef="usd">36000</us-gaap:OtherLiabilities>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c236"
      decimals="3"
      id="ixv-31246"
      unitRef="pure">1.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c236"
      decimals="4"
      id="ixv-31247"
      unitRef="pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c237"
      decimals="3"
      id="ixv-31248"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:CommonStockSharesIssued
      contextRef="c238"
      decimals="0"
      id="ixv-31249"
      unitRef="shares">1350000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c238"
      decimals="0"
      id="ixv-31250"
      unitRef="shares">2333280</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c238"
      decimals="0"
      id="ixv-31251"
      unitRef="shares">4972428</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c238"
      decimals="3"
      id="ixv-31252"
      unitRef="usdPershares">2.715</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c238"
      decimals="3"
      id="ixv-31253"
      unitRef="usdPershares">2.714</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="c239"
      decimals="-5"
      id="ixv-31254"
      unitRef="usd">8700000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <onco:CancelledPreferredInvestmentOptionsShares
      contextRef="c240"
      decimals="0"
      id="ixv-31255"
      unitRef="shares">1180812</onco:CancelledPreferredInvestmentOptionsShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c241"
      decimals="3"
      id="ixv-31256"
      unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <onco:PrefundedWarrantsExercised
      contextRef="c242"
      decimals="0"
      id="ixv-31257"
      unitRef="shares">1686640</onco:PrefundedWarrantsExercised>
    <onco:PrefundedWarrantsExercised
      contextRef="c243"
      decimals="0"
      id="ixv-31258"
      unitRef="shares">646640</onco:PrefundedWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c244"
      decimals="3"
      id="ixv-31259"
      unitRef="usdPershares">2.546</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PreferredStockDividendsShares
      contextRef="c243"
      decimals="0"
      id="ixv-31260"
      unitRef="shares">2486214</us-gaap:PreferredStockDividendsShares>
    <us-gaap:PreferredStockConvertibleConversionPriceDecrease
      contextRef="c243"
      decimals="2"
      id="ixv-31261"
      unitRef="usdPershares">1.09</us-gaap:PreferredStockConvertibleConversionPriceDecrease>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c244"
      decimals="0"
      id="ixv-31262"
      unitRef="shares">2486214</us-gaap:PreferredStockSharesOutstanding>
    <onco:PlacementAgentFeeAndManagementFeePercentage
      contextRef="c245"
      decimals="3"
      id="ixv-31263"
      unitRef="pure">0.075</onco:PlacementAgentFeeAndManagementFeePercentage>
    <onco:PlacementAgentFeeAndManagementFeePercentage
      contextRef="c246"
      decimals="3"
      id="ixv-31264"
      unitRef="pure">0.01</onco:PlacementAgentFeeAndManagementFeePercentage>
    <us-gaap:OtherExpenses contextRef="c247" decimals="0" id="ixv-31265" unitRef="usd">85000</us-gaap:OtherExpenses>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c248"
      decimals="0"
      id="ixv-31266"
      unitRef="shares">220997</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c248"
      decimals="4"
      id="ixv-31267"
      unitRef="usdPershares">3.3938</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <onco:AggregateNumberOfSharesPercenatge
      contextRef="c249"
      decimals="3"
      id="ixv-31268"
      unitRef="pure">0.06</onco:AggregateNumberOfSharesPercenatge>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c250"
      decimals="4"
      id="ixv-31269"
      unitRef="usdPershares">3.3938</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <onco:WarrantsIssuableUnderProvisionShares
      contextRef="c251"
      decimals="0"
      id="ixv-31270"
      unitRef="shares">298346</onco:WarrantsIssuableUnderProvisionShares>
    <onco:WarrantsIssuableUnderProvisionShares
      contextRef="c252"
      decimals="0"
      id="ixv-31271"
      unitRef="shares">70849</onco:WarrantsIssuableUnderProvisionShares>
    <onco:CancelledPreferredInvestmentOptionsShares
      contextRef="c253"
      decimals="0"
      id="ixv-31272"
      unitRef="shares">1180812</onco:CancelledPreferredInvestmentOptionsShares>
    <onco:CancelledPreferredInvestmentOptionsShares
      contextRef="c254"
      decimals="0"
      id="ixv-31273"
      unitRef="shares">1289148</onco:CancelledPreferredInvestmentOptionsShares>
    <us-gaap:FairValueOptionQuantitativeDisclosuresTextBlock contextRef="c0" id="ixv-19855">The increase in the fair value of the preferred investment options as a result of the exchange was approximately $860,000, and was determined using the Black&lt;span class="nobreak"&gt;-Scholes&lt;/span&gt; option pricing model, with the following assumptions:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Original&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Exchanged&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercise price&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.65&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.546&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Term (years)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3.67&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.0&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected stock price volatility&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;116.2&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;120.2&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Risk-free rate of interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3.16&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.98&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:FairValueOptionQuantitativeDisclosuresTextBlock>
    <onco:IncreaseInTheFairValueOfThePreferredInvestmentOptions contextRef="c243" decimals="0" id="ixv-31274" unitRef="usd">860000</onco:IncreaseInTheFairValueOfThePreferredInvestmentOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c299"
      decimals="2"
      id="ixv-31275"
      unitRef="usdPershares">6.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c300"
      decimals="3"
      id="ixv-31276"
      unitRef="usdPershares">2.546</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c301" id="ixv-19894">P3Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c302" id="ixv-19902">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c301"
      decimals="3"
      id="ixv-31277"
      unitRef="pure">1.162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c302"
      decimals="3"
      id="ixv-31278"
      unitRef="pure">1.202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c301"
      decimals="4"
      id="ixv-31279"
      unitRef="pure">0.0316</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c302"
      decimals="4"
      id="ixv-31280"
      unitRef="pure">0.0298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c235"
      decimals="0"
      id="ixv-31281"
      unitRef="shares">70849</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c255"
      decimals="0"
      id="ixv-31282"
      unitRef="shares">70849</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c243" decimals="0" id="ixv-31283" unitRef="usd">8000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c244"
      decimals="0"
      id="ixv-31284"
      unitRef="shares">227497</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="c0" decimals="0" id="ixv-31285" unitRef="usd">39000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c256"
      decimals="0"
      id="ixv-31286"
      unitRef="shares">298346</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <onco:ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock contextRef="c0" id="ixv-31287">The following significant assumptions were used in the valuation of the contingent warrant liability, related to the August Contingent Warrants, as of the date of the August&#160;2022 Private Placement and as of December&#160;31, 2022:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;August&#160;11,&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercise price&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3.3938&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3.3938&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Term (years)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.00&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.61&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected stock price volatility&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;127.8&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;120.8&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Risk-free rate of interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.98&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.03&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</onco:ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c303"
      decimals="4"
      id="ixv-31288"
      unitRef="usdPershares">3.3938</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c304"
      decimals="4"
      id="ixv-31289"
      unitRef="usdPershares">3.3938</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c305" id="ixv-19999">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c306" id="ixv-20007">P4Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c305"
      decimals="3"
      id="ixv-31290"
      unitRef="pure">1.278</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c306"
      decimals="3"
      id="ixv-31291"
      unitRef="pure">1.208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c305"
      decimals="4"
      id="ixv-31292"
      unitRef="pure">0.0298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c306"
      decimals="4"
      id="ixv-31293"
      unitRef="pure">0.0403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <onco:ContingentWarrantLiabilityShares contextRef="c252" decimals="0" id="ixv-31294" unitRef="usd">149173</onco:ContingentWarrantLiabilityShares>
    <onco:SharesOfCommonStockIssued
      contextRef="c257"
      decimals="0"
      id="ixv-31295"
      unitRef="shares">3900000</onco:SharesOfCommonStockIssued>
    <onco:FixedCommissionRate
      contextRef="c258"
      decimals="3"
      id="ixv-31296"
      unitRef="pure">0.03</onco:FixedCommissionRate>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="c259"
      decimals="3"
      id="ixv-31297"
      unitRef="usdPershares">2.546</us-gaap:StockOptionExercisePriceIncrease>
    <onco:SharesOfCommonStockIssued
      contextRef="c260"
      decimals="0"
      id="ixv-31298"
      unitRef="shares">2486214</onco:SharesOfCommonStockIssued>
    <us-gaap:StockOptionExercisePriceDecrease
      contextRef="c260"
      decimals="2"
      id="ixv-31299"
      unitRef="usdPershares">1.09</us-gaap:StockOptionExercisePriceDecrease>
    <onco:SharesOfCommonStockIssued
      contextRef="c261"
      decimals="0"
      id="ixv-31300"
      unitRef="shares">4972428</onco:SharesOfCommonStockIssued>
    <onco:AggregateNetProceeds
      contextRef="c262"
      decimals="-5"
      id="ixv-31301"
      unitRef="usd">2300000</onco:AggregateNetProceeds>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c263"
      decimals="0"
      id="ixv-31302"
      unitRef="shares">1575000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c264"
      decimals="0"
      id="ixv-31303"
      unitRef="shares">2486214</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="c1"
      decimals="0"
      id="ixv-31304"
      unitRef="shares">911214</us-gaap:CommonStockSharesSubscribedButUnissued>
    <onco:PercentageOfGrossProceeds
      contextRef="c264"
      decimals="3"
      id="ixv-31305"
      unitRef="pure">0.075</onco:PercentageOfGrossProceeds>
    <onco:PercentageOfGrossProceeds
      contextRef="c263"
      decimals="3"
      id="ixv-31306"
      unitRef="pure">0.01</onco:PercentageOfGrossProceeds>
    <us-gaap:LegalFees contextRef="c0" decimals="0" id="ixv-31307" unitRef="usd">50000</us-gaap:LegalFees>
    <us-gaap:OtherGeneralExpense contextRef="c0" decimals="0" id="ixv-31308" unitRef="usd">35000</us-gaap:OtherGeneralExpense>
    <onco:AggregatePurchaseShares
      contextRef="c0"
      decimals="0"
      id="ixv-31309"
      unitRef="shares">149173</onco:AggregatePurchaseShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c265"
      decimals="4"
      id="ixv-31310"
      unitRef="usdPershares">1.3625</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <onco:PercentageOfCommonStockShares contextRef="c0" decimals="3" id="ixv-31311" unitRef="pure">0.06</onco:PercentageOfCommonStockShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c266"
      decimals="4"
      id="ixv-31312"
      unitRef="usdPershares">1.3625</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c1"
      decimals="0"
      id="ixv-31313"
      unitRef="shares">298346</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <onco:AggregateNetProceeds contextRef="c0" decimals="-5" id="ixv-31314" unitRef="usd">2300000</onco:AggregateNetProceeds>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c267"
      decimals="-5"
      id="ixv-31315"
      unitRef="usd">2600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c1"
      decimals="0"
      id="ixv-31316"
      unitRef="shares">149173</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <onco:WarrantsIssuedForSettlementOfContingentWarrants contextRef="c267" decimals="0" id="ixv-31317" unitRef="usd">122000</onco:WarrantsIssuedForSettlementOfContingentWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c267" decimals="0" id="ixv-31318" unitRef="usd">129000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c267"
      decimals="3"
      id="ixv-31319"
      unitRef="pure">1.178</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c267"
      decimals="4"
      id="ixv-31320"
      unitRef="pure">0.0424</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c267"
      decimals="3"
      id="ixv-31321"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:OtherLiabilities contextRef="c266" decimals="0" id="ixv-31322" unitRef="usd">26000</us-gaap:OtherLiabilities>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c0" decimals="3" id="ixv-31323" unitRef="pure">1.178</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c0" decimals="4" id="ixv-31324" unitRef="pure">0.0424</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c0" decimals="3" id="ixv-31325" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0" id="ixv-20106">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The following summarizes activity related to the Company&#x2019;s outstanding warrants, excluding contingent warrants issuable upon exercise of the preferred investment options, for the year ended December&#160;31, 2023:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life&lt;br/&gt;(in&#160;years)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding as of December&#160;31, 2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5,910,914&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.37&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.7&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5,121,601&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.10&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(3,132,854&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;0.865&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-268"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-269"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding as of December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7,899,661&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.68&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.3&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Warrants vested and exercisable as of December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7,899,661&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.68&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.3&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c307"
      decimals="INF"
      id="ixv-31326"
      unitRef="shares">5910914</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c307"
      decimals="2"
      id="ixv-31327"
      unitRef="usdPershares">2.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c308" id="ixv-20149">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c309"
      decimals="INF"
      id="ixv-31328"
      unitRef="shares">5121601</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c309"
      decimals="2"
      id="ixv-31329"
      unitRef="usdPershares">1.1</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c309"
      decimals="INF"
      id="ixv-31330"
      unitRef="shares">3132854</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c309"
      decimals="3"
      id="ixv-31331"
      unitRef="usdPershares">0.865</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c310"
      decimals="INF"
      id="ixv-31332"
      unitRef="shares">7899661</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c310"
      decimals="2"
      id="ixv-31333"
      unitRef="usdPershares">1.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c309" id="ixv-20214">P4Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c310"
      decimals="INF"
      id="ixv-31334"
      unitRef="shares">7899661</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c310"
      decimals="2"
      id="ixv-31335"
      unitRef="usdPershares">1.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c309" id="ixv-20231">P4Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c1"
      decimals="0"
      id="ixv-31336"
      unitRef="shares">70849</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c268"
      decimals="0"
      id="ixv-31337"
      unitRef="shares">2707211</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c269"
      decimals="0"
      id="ixv-31338"
      unitRef="shares">5121601</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c270"
      decimals="0"
      id="ixv-31339"
      unitRef="shares">7899661</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SharePrice
      contextRef="c1"
      decimals="2"
      id="ixv-31340"
      unitRef="usdPershares">0.2</us-gaap:SharePrice>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c255" decimals="0" id="ixv-31341" unitRef="usd">3000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c256" decimals="0" id="ixv-31342" unitRef="usd">14000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c255"
      decimals="0"
      id="ixv-31343"
      unitRef="shares">447519</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c2"
      decimals="0"
      id="ixv-31344"
      unitRef="shares">298346</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c271"
      decimals="0"
      id="ixv-31345"
      unitRef="shares">1400000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c272"
      decimals="0"
      id="ixv-31346"
      unitRef="shares">1600000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c273"
      decimals="0"
      id="ixv-31347"
      unitRef="shares">2600000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c274"
      decimals="0"
      id="ixv-31348"
      unitRef="shares">3150000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c275"
      decimals="0"
      id="ixv-31349"
      unitRef="shares">718402</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-20258">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The following summarizes activity related to the Company&#x2019;s stock options under the 2019 Plan and the 2022 Plan for the year ended December&#160;31, 2023:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Total&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;(in&#160;years)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding as of December&#160;31, 2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,392,654&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3.30&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;670,161&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;8.2&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;962,154&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;0.48&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-270"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited/cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(404,058&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.87&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-271"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(45,920&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;0.01&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;45,920&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding as of December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,904,830&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.63&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;94,239&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;8.4&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options vested and exercisable as of December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;861,177&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.23&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;94,239&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.1&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c311"
      decimals="INF"
      id="ixv-31350"
      unitRef="shares">1392654</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c311"
      decimals="2"
      id="ixv-31351"
      unitRef="usdPershares">3.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c311" decimals="0" id="ixv-31352" unitRef="usd">670161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c312" id="ixv-20314">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c313"
      decimals="INF"
      id="ixv-31353"
      unitRef="shares">962154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c313"
      decimals="2"
      id="ixv-31354"
      unitRef="usdPershares">0.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c313"
      decimals="INF"
      id="ixv-31355"
      unitRef="shares">404058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c313"
      decimals="2"
      id="ixv-31356"
      unitRef="usdPershares">4.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c313"
      decimals="INF"
      id="ixv-31357"
      unitRef="shares">45920</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c313"
      decimals="2"
      id="ixv-31358"
      unitRef="usdPershares">0.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c313" decimals="0" id="ixv-31359" unitRef="usd">45920</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c314"
      decimals="INF"
      id="ixv-31360"
      unitRef="shares">1904830</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c314"
      decimals="2"
      id="ixv-31361"
      unitRef="usdPershares">1.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c314" decimals="0" id="ixv-31362" unitRef="usd">94239</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c313" id="ixv-20401">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="c314"
      decimals="INF"
      id="ixv-31363"
      unitRef="shares">861177</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c314"
      decimals="2"
      id="ixv-31364"
      unitRef="usdPershares">2.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c314" decimals="0" id="ixv-31365" unitRef="usd">94239</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c313" id="ixv-20423">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <onco:ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock contextRef="c0" id="ixv-20425">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The fair value of options granted in 2023 and 2022 was estimated using the following assumptions:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-28" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;For the &lt;br/&gt;Year Ended &lt;br/&gt;December&#160;31, &lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;For the &lt;br/&gt;Year Ended &lt;br/&gt;December&#160;31, &lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercise price&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;$0.26&#160;&#x2013;&#160;1.29&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;$1.06&#160;&#x2013;&#160;6.45&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Term (years)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5.00&#160;&#x2013;&#160;10.00&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5.00&#160;&#x2013;&#160;10.00&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected stock price volatility&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;101.1%&#160;&#x2013;&#160;119.5&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;112.6%&#160;&#x2013;&#160;121.2%&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Risk-free rate of interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3.5%&#160;&#x2013;&#160;4.7%&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;2.9%&#160;&#x2013;&#160;4.3%&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</onco:ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c66"
      decimals="2"
      id="ixv-31366"
      unitRef="usdPershares">0.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c67"
      decimals="2"
      id="ixv-31367"
      unitRef="usdPershares">1.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c315"
      decimals="2"
      id="ixv-31368"
      unitRef="usdPershares">1.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c316"
      decimals="2"
      id="ixv-31369"
      unitRef="usdPershares">6.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c263" id="ixv-31370">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c264" id="ixv-31371">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c317" id="ixv-31372">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c318" id="ixv-31373">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c263"
      decimals="3"
      id="ixv-31374"
      unitRef="pure">1.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c264"
      decimals="3"
      id="ixv-31375"
      unitRef="pure">1.195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c317"
      decimals="3"
      id="ixv-31376"
      unitRef="pure">1.126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c318"
      decimals="3"
      id="ixv-31377"
      unitRef="pure">1.212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c263"
      decimals="3"
      id="ixv-31378"
      unitRef="pure">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c264"
      decimals="3"
      id="ixv-31379"
      unitRef="pure">0.047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c317"
      decimals="3"
      id="ixv-31380"
      unitRef="pure">0.029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c318"
      decimals="3"
      id="ixv-31381"
      unitRef="pure">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c0"
      decimals="2"
      id="ixv-31382"
      unitRef="usdPershares">0.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c9"
      decimals="2"
      id="ixv-31383"
      unitRef="usdPershares">3.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c0" decimals="-5" id="ixv-31384" unitRef="usd">700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c9" decimals="-5" id="ixv-31385" unitRef="usd">2100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c276"
      decimals="0"
      id="ixv-31386"
      unitRef="shares">709768</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <onco:ExercisePrice
      contextRef="c276"
      decimals="4"
      id="ixv-31387"
      unitRef="usdPershares">0.4305</onco:ExercisePrice>
    <onco:GrantDateFairValueOfStockOption
      contextRef="c276"
      decimals="-5"
      id="ixv-31388"
      unitRef="usd">200000</onco:GrantDateFairValueOfStockOption>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense contextRef="c0" decimals="-5" id="ixv-31389" unitRef="usd">100000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c277"
      decimals="0"
      id="ixv-31390"
      unitRef="shares">487965</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c278"
      decimals="0"
      id="ixv-31391"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c279"
      decimals="0"
      id="ixv-31392"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c9"
      decimals="0"
      id="ixv-31393"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <onco:GrantDateFairValueOfStockOption contextRef="c9" decimals="-5" id="ixv-31394" unitRef="usd">1800000</onco:GrantDateFairValueOfStockOption>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="c278"
      decimals="-5"
      id="ixv-31395"
      unitRef="usd">1500000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c280"
      decimals="0"
      id="ixv-31396"
      unitRef="shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c281"
      decimals="0"
      id="ixv-31397"
      unitRef="shares">72223</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <onco:GrantDateFairValueOfStockOption
      contextRef="c281"
      decimals="-5"
      id="ixv-31398"
      unitRef="usd">200000</onco:GrantDateFairValueOfStockOption>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="c281"
      decimals="-5"
      id="ixv-31399"
      unitRef="usd">200000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="c282"
      decimals="0"
      id="ixv-31400"
      unitRef="shares">487500</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="c283"
      decimals="0"
      id="ixv-31401"
      unitRef="shares">150000</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="c284"
      decimals="0"
      id="ixv-31402"
      unitRef="shares">75000</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="c285"
      decimals="0"
      id="ixv-31403"
      unitRef="shares">150000</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <onco:RestrictedSharesGrantedVestPercentage
      contextRef="c286"
      decimals="2"
      id="ixv-31404"
      unitRef="pure">0.50</onco:RestrictedSharesGrantedVestPercentage>
    <onco:RestrictedSharesGrantedVestPercentage
      contextRef="c287"
      decimals="2"
      id="ixv-31405"
      unitRef="pure">0.25</onco:RestrictedSharesGrantedVestPercentage>
    <onco:RestrictedSharesGrantedVestPercentage
      contextRef="c288"
      decimals="2"
      id="ixv-31406"
      unitRef="pure">0.25</onco:RestrictedSharesGrantedVestPercentage>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="c289"
      decimals="0"
      id="ixv-31407"
      unitRef="shares">25440</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c0" id="ixv-20510">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On August&#160;16, 2023 and October&#160;4, 2023, upon their respective resignations, the Company&#x2019;s former CEO and former CFO forfeited 150,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares and 75,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of unvested restricted stock, respectively.&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Nonvested as of December&#160;31, 2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-272"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-273"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;512,940&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.01&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited/cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(250,110&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.02&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Vested&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(6,250&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.03&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Nonvested as of December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;256,580&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.03&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="c290"
      decimals="0"
      id="ixv-31408"
      unitRef="shares">150000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="c291"
      decimals="0"
      id="ixv-31409"
      unitRef="shares">75000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c0"
      decimals="INF"
      id="ixv-31410"
      unitRef="shares">512940</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c0"
      decimals="2"
      id="ixv-31411"
      unitRef="usdPershares">1.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c0"
      decimals="INF"
      id="ixv-31412"
      unitRef="shares">250110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c0"
      decimals="2"
      id="ixv-31413"
      unitRef="usdPershares">1.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c0"
      decimals="INF"
      id="ixv-31414"
      unitRef="shares">6250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c0"
      decimals="2"
      id="ixv-31415"
      unitRef="usdPershares">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-31416"
      unitRef="shares">256580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c1"
      decimals="2"
      id="ixv-31417"
      unitRef="usdPershares">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c293"
      decimals="0"
      id="ixv-31418"
      unitRef="shares">58172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c292"
      decimals="0"
      id="ixv-31419"
      unitRef="shares">57276</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-31420"
      unitRef="usdPershares">3.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-31421"
      unitRef="usdPershares">3.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c1" decimals="-5" id="ixv-31422" unitRef="usd">7400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c1" decimals="-5" id="ixv-31423" unitRef="usd">7100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:SharesHeldInEmployeeStockOptionPlanAllocated
      contextRef="c1"
      decimals="0"
      id="ixv-31424"
      unitRef="shares">47990</us-gaap:SharesHeldInEmployeeStockOptionPlanAllocated>
    <us-gaap:StockOptionExercisePriceDecrease
      contextRef="c0"
      decimals="2"
      id="ixv-31425"
      unitRef="usdPershares">3.94</us-gaap:StockOptionExercisePriceDecrease>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c0" id="ixv-20625">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense for the&#160;years ended December&#160;31, 2023 and 2022 was as follows:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;For the&#160;Years Ended&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Selling, general and administrative&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;234,298&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,309,687&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;95,462&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;664,879&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;329,760&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;1,974,566&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c319" decimals="0" id="ixv-31426" unitRef="usd">234298</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c320" decimals="0" id="ixv-31427" unitRef="usd">1309687</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c321" decimals="0" id="ixv-31428" unitRef="usd">95462</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c322" decimals="0" id="ixv-31429" unitRef="usd">664879</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="0" id="ixv-31430" unitRef="usd">329760</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c9" decimals="0" id="ixv-31431" unitRef="usd">1974566</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c294" decimals="0" id="ixv-31432" unitRef="usd">345000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c295" decimals="0" id="ixv-31433" unitRef="usd">35000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="c293"
      decimals="-5"
      id="ixv-31434"
      unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense contextRef="c298" decimals="0" id="ixv-31435" unitRef="usd">165000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c281"
      decimals="0"
      id="ixv-31436"
      unitRef="shares">32517</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense contextRef="c9" decimals="-5" id="ixv-31437" unitRef="usd">100000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-20707">&lt;p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Note&#160;10 &#x2014; Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Proteomedix leases office and lab space in Zurich Switzerland, which requires lease payments of approximately $74,000 for the&#160;years ended December&#160;31, 2024 and 2025, and which is insignificant to the Company&#x2019;s consolidated financial statements.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company entered into a short&lt;span class="nobreak"&gt;-term&lt;/span&gt; lease in Palm Beach, Florida with an unrelated party, with a commencement date of May&#160;1, 2022, for approximately $14,000 per month. The lease, which was personally guaranteed by the Company&#x2019;s former CEO, ended on April&#160;30, 2023. During the&#160;years ended December&#160;31, 2023 and 2022, the Company incurred rent expense on this lease of approximately $51,000 and $129,000, respectively, and variable lease expense of approximately $4,000 and $12,000, respectively.&lt;/p&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Litigation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. As of December&#160;31, 2023, the Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims.&lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On April&#160;15, 2022, the Company received a demand letter (the &#x201c;Demand Letter&#x201d;) from Boustead. The Demand Letter alleged that the Company breached the Underwriting Agreement entered into between Boustead and the Company, dated February&#160;17, 2022, in connection with the Company&#x2019;s initial public offering. The Demand Letter alleged that, by engaging Wainwright as placement agent in the April Private Placement, the Company breached Boustead&#x2019;s right of first refusal (&#x201c;ROFR&#x201d;) to act as placement agent granted to Boustead under the Underwriting Agreement and, as a result of selling securities in the April Private Placement, breached the Company&#x2019;s obligation under the Underwriting Agreement not to offer, sell, issue, agree or contract to sell or issue or grant or modify the terms of any option for the sale of, any securities prior to February&#160;17, 2023 (the &#x201c;Standstill&#x201d;).&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On October&#160;9, 2022, the Company and Boustead entered into a Settlement Agreement and Release (the &#x201c;Settlement Agreement&#x201d;), pursuant to which Boustead agreed to waive the ROFR and the Standstill, and to release the Company from certain claims with respect to the April Private Placement, the August Private Placement, and all future private, public equity or debt offerings of the Company. As consideration for such waiver and termination of the Underwriting Agreement, the Company paid Boustead a cash fee of $1,000,000, $50,000 in legal expenses, and released Boustead from all claims, subject to certain exceptions. In addition, the Company issued to Boustead 93,466&lt;span class="nobreak"&gt; &lt;/span&gt;shares of restricted common stock in exchange for the cancellation of 111,111&#160;warrants issued to Boustead in connection with the IPO (see Note&#160;9). Concurrent with the execution of the Settlement Agreement, the Company and Boustead Capital Markets, LLP (&#x201c;Boustead Capital&#x201d;) entered into a three&lt;span class="nobreak"&gt;-month&lt;/span&gt; Advisory Agreement (the &#x201c;Advisory Agreement&#x201d;) for which consideration equal to 200,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of restricted common stock, with no vesting provisions, was issued to Boustead Capital upon execution of the Advisory Agreement. The incremental fair value of the Warrant Exchange and the fair value of the restricted common stock issued in connection with these agreements totaled approximately $264,000. See Note&#160;9.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company determined that all consideration due by the Company under the Settlement Agreement and the Advisory Agreement relates to the settlement of a liability that was incurred in 2022 and accordingly, recorded a related expense of approximately $1.3&#160;million for the year ended December&#160;31, 2022, which is included in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.&lt;/p&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Registration Rights Agreements&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In connection with the April&#160;2022 Private Placement (see Note&#160;9), the Company entered into a Registration Rights Agreement with the purchasers, dated as of April&#160;13, 2022 (the &#x201c;April Registration Rights Agreement&#x201d;). The April Registration Rights Agreement provides that the Company shall file a registration statement covering the resale of all of the registrable securities (as defined in the April Registration Rights Agreement) with the SEC.&#160;The registration statement on Form&#160;S&lt;span class="nobreak"&gt;-1&lt;/span&gt; required under the April Registration Rights Agreement was filed with the SEC on May&#160;3, 2022 and became effective on May&#160;20, 2022. A post&lt;span class="nobreak"&gt;-effective&lt;/span&gt; amendment to the Form&#160;S&lt;span class="nobreak"&gt;-1&lt;/span&gt; on Form&#160;S&lt;span class="nobreak"&gt;-3&lt;/span&gt; relating to such registration statement was filed with the SEC on April&#160;28, 2023.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In connection with the August&#160;2022 Private Placement (see Note&#160;9), the Company entered into a Registration Rights Agreement with the purchasers, dated as of August&#160;9, 2022 (the &#x201c;August Registration Rights Agreement&#x201d;). The August Registration Rights Agreement provides that the Company shall file a registration statement covering the resale of all of the registrable securities (as defined in the August Registration Rights Agreement) with the SEC.&#160;The registration statement on Form&#160;S&lt;span class="nobreak"&gt;-1&lt;/span&gt; required under the August Registration Rights Agreement was filed with the SEC on August&#160;29, 2022 and became effective on September&#160;19, 2022. A post&lt;span class="nobreak"&gt;-effective&lt;/span&gt; amendment to the Form&#160;S&lt;span class="nobreak"&gt;-1&lt;/span&gt; on Form&#160;S&lt;span class="nobreak"&gt;-3&lt;/span&gt; relating to such registration statement was filed with the SEC on April&#160;28, 2023.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Upon the occurrence of any Event (as defined in the April Registration Rights Agreement and the August Registration Rights Agreement), which, among others, prohibits the purchasers from reselling the securities for more than ten consecutive calendar&#160;days or more than an aggregate of fifteen calendar&#160;days during any 12&lt;span class="nobreak"&gt;-month&lt;/span&gt; period, and should the registration statement cease to remain continuously effective, the Company would be obligated to pay to each purchaser, on each monthly anniversary of each such Event, an amount in cash, as partial liquidated damages and not as a penalty, equal to the product of 2.0% multiplied by the aggregate subscription amount paid by such purchaser &lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;in the Private Placement. As of December&#160;31, 2023, the Company determined that the likelihood of the Company incurring liquidated damages pursuant to the April Registration Rights Agreement and the August Registration Rights Agreement is remote, and as such, no accrual of these payments is required as of December&#160;31, 2023.&lt;/p&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Milestone and Royalty Obligations&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company has entered into various license agreements with third parties that obligate the Company to pay certain development, regulatory, and commercial milestones, as well as royalties based on product sales (see Note&#160;6). As of December&#160;31, 2023, the Company terminated all license agreements, except for the CHMC Agreement, which could require the Company to pay CHMC milestone payments of up to an aggregate of $59.75&#160;million. As of December&#160;31, 2023, the Company evaluated the likelihood of the Company achieving the specified milestones and generating product sales, and determined the likelihood is not yet probable and as such, no accrual of these payments is required as of December&#160;31, 2023.&lt;/p&gt;
		&lt;p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Underwriter Termination Agreement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On February&#160;7, 2022, the Company and its former underwriter, Maxim Group (&#x201c;Maxim&#x201d;), entered into a termination agreement, whereby the parties agreed to terminate their engagement of Maxim as the Company&#x2019;s lead managing underwriter and book runner in connection with the Company&#x2019;s IPO.&#160;Per the terms of the termination agreement, the Company agreed to pay Maxim a termination fee of $300,000, due upon the close of the Company&#x2019;s IPO.&#160;The termination fee was recorded as selling, general and administrative expense, and paid, during the year ended December&#160;31, 2022.&lt;/p&gt;
		&lt;p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Indemnification&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#x2019;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not been required to defend any action related to its indemnification obligations. However, during the third quarter of 2023, the Company received a claim from its former CEO and a former accounting employee requesting advancement of certain expenses. The Company recorded approximately $209,000 in related expenses during the year ended December&#160;31, 2023, of which approximately $159,000 was paid through reduction of the outstanding related party receivable due from the former CEO (see Note&#160;11). As of December&#160;31, 2023, the Company recorded a related accrual of approximately $50,000, which is included in accrued expenses in the accompanying consolidated balance sheets, and which was paid subsequent to year end. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is not estimable at this time.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LeaseCost contextRef="c71" decimals="0" id="ixv-31438" unitRef="usd">74000</us-gaap:LeaseCost>
    <us-gaap:ShortTermLeasePayments contextRef="c323" decimals="0" id="ixv-31439" unitRef="usd">14000</us-gaap:ShortTermLeasePayments>
    <us-gaap:PaymentsForRent contextRef="c0" decimals="0" id="ixv-31440" unitRef="usd">51000</us-gaap:PaymentsForRent>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c0" decimals="0" id="ixv-31441" unitRef="usd">4000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c9" decimals="0" id="ixv-31442" unitRef="usd">12000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:FeeIncome contextRef="c324" decimals="0" id="ixv-31443" unitRef="usd">1000000</us-gaap:FeeIncome>
    <us-gaap:LegalFees contextRef="c325" decimals="0" id="ixv-31444" unitRef="usd">50000</us-gaap:LegalFees>
    <us-gaap:SharesIssued
      contextRef="c326"
      decimals="0"
      id="ixv-31445"
      unitRef="shares">93466</us-gaap:SharesIssued>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c327"
      decimals="0"
      id="ixv-31446"
      unitRef="shares">111111</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharesIssued
      contextRef="c327"
      decimals="0"
      id="ixv-31447"
      unitRef="shares">200000</us-gaap:SharesIssued>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c325" decimals="0" id="ixv-31448" unitRef="usd">264000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense contextRef="c9" decimals="-5" id="ixv-31449" unitRef="usd">1300000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <onco:PercentageOfSubscription contextRef="c0" decimals="3" id="ixv-31450" unitRef="pure">0.02</onco:PercentageOfSubscription>
    <onco:AggregatePayments contextRef="c0" decimals="2" id="ixv-31451" unitRef="usd">59.75</onco:AggregatePayments>
    <us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees contextRef="c328" decimals="0" id="ixv-31452" unitRef="usd">300000</us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees>
    <us-gaap:LaborAndRelatedExpense contextRef="c0" decimals="0" id="ixv-31453" unitRef="usd">209000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:DividendsPaidinkind contextRef="c0" decimals="0" id="ixv-31454" unitRef="usd">159000</us-gaap:DividendsPaidinkind>
    <us-gaap:OtherExpenses contextRef="c0" decimals="0" id="ixv-31455" unitRef="usd">50000</us-gaap:OtherExpenses>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-20771">&lt;p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Note&#160;11 &#x2014; Related Party Transactions&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company originally engaged the former CEO, who was also the Board Chairman and prior to the close of the IPO, sole common stockholder of the Company, pursuant to a consulting agreement commencing October&#160;22, 2018, which called for the Company to pay for consulting services performed on a monthly basis. Upon the close of the Company&#x2019;s IPO, the consulting agreement was terminated, and the former CEO&#x2019;s employment agreement became effective. During the year ended December&#160;31, 2022, the Company incurred approximately $63,000 in fees under the consulting agreement, which are recognized in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;During 2022 the Company entered into a lease agreement that was personally guaranteed by the Company&#x2019;s former CEO.&#160;The lease expired in 2023. See Note&#160;10.&lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;During the year ended December&#160;31, 2022, the Company&#x2019;s compensation committee approved one&lt;span class="nobreak"&gt;-time&lt;/span&gt; bonus awards of $140,000 and $100,000 to the Company&#x2019;s former CEO and former CBO, respectively, in recognition of their efforts in connection with the Company&#x2019;s IPO.&#160;These bonuses were recognized during the year ended December&#160;31, 2022, as selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;During the year ended December&#160;31, 2023, the Company&#x2019;s Audit Committee completed a review of the Company&#x2019;s expenses due to certain irregularities identified with regards to the related party balance. Based on the results of the review, it was determined that the Company paid and recorded within selling, general and administrative expenses, personal expenditures of the Company&#x2019;s former CEO and an accounting employee who was also the former CEO&#x2019;s assistant, during 2022 and during the first three quarters of 2023. The Company evaluated the receivable, which aggregated to approximately $522,000 as of September&#160;30, 2023, and which represented the total of the items identified as personal in nature for which the Company did not anticipate recovery from the related party. As the Company concluded that the remaining amounts are not likely to be recovered, this would not cause an adjustment to previously issued financial statements. The Company recorded a corresponding reserve for the full amount, resulting in a net related party receivable balance of &lt;span style="-sec-ix-hidden: hidden-fact-286"&gt;$0&lt;/span&gt; and a loss on related party receivable of approximately $266,000, which was recorded in selling, general, and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2023. During the fourth quarter of 2023, the Company recorded a recovery of approximately $159,000 with respect to amounts that the former CEO agreed to repay the Company, through a reduction of amounts that were due to him from the Company under his indemnification rights pursuant to his employment agreement (see Note&#160;10).&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of December&#160;31, 2022, the Company had a receivable from related party of approximately $36,000, consisting of miscellaneous payments made by the Company on the behalf of the Company&#x2019;s CEO, and which was paid in full during the first quarter of 2023.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On December&#160;18, 2023, the Company entered into the Subscription Agreement with the PMX Investor, a 5% stockholder of the Company as of December&#160;31, 2023 (see Note&#160;8). Subsequent to December&#160;31, 2023, the Company issued a non&lt;span class="nobreak"&gt;-convertible&lt;/span&gt; debenture in the principal amount of $5.0&#160;million to the PMX Investor, in connection with the Subscription Agreement (see Note&#160;14).&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;A former director of the Company, who served on the Company&#x2019;s Scientific Advisory Board until August&#160;2023, serves on the Advisory Board for the Cincinnati Children&#x2019;s Hospital Medical Center Innovation Fund, which is affiliated with CHMC.&#160;The Company has an exclusive license agreement with CHMC as disclosed in Note&#160;5. This director resigned from the Company&#x2019;s board upon the close of its IPO.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:PaymentsForFees contextRef="c329" decimals="0" id="ixv-31456" unitRef="usd">63000</us-gaap:PaymentsForFees>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c330" decimals="0" id="ixv-31457" unitRef="usd">140000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c331" decimals="0" id="ixv-31458" unitRef="usd">100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:OtherReceivables contextRef="c332" decimals="0" id="ixv-31459" unitRef="usd">522000</us-gaap:OtherReceivables>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c333" decimals="0" id="ixv-31460" unitRef="usd">266000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c333" decimals="0" id="ixv-31461" unitRef="usd">159000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <onco:MiscellaneousExpenses contextRef="c329" decimals="0" id="ixv-31462" unitRef="usd">36000</onco:MiscellaneousExpenses>
    <onco:SubscriptionAgreementPMXInvestorPercentage contextRef="c0" decimals="2" id="ixv-31463" unitRef="pure">0.05</onco:SubscriptionAgreementPMXInvestorPercentage>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="c334"
      decimals="-5"
      id="ixv-31464"
      unitRef="usd">5000000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-20797">&lt;p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Note&#160;12 &#x2014; Income Taxes&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The components of loss before income taxes are as follows:&lt;/p&gt;
		&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;For the&#160;Years Ended&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;U.S.&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(37,106,599&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(13,419,830&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Foreign&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(315,688&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-287"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-29" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total loss before income taxes&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;(37,422,287&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;(13,419,830&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company&#x2019;s major tax jurisdictions are the United&#160;States, Switzerland, and various state jurisdictions, and the Company does not have any pending tax audits. The income tax benefit recorded for the year ended December&#160;31, 2023 related to the Company&#x2019;s deferred foreign taxes. There was no income tax provision or benefit recorded for the year ended December&#160;31, 2022. Generally, the Company&#x2019;s federal returns from 2019 on and state returns from &lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;2018 on, and foreign returns from 2018 on, are subject to examination by the United&#160;States, state, and foreign tax authorities; however, to the extent allowed by law, tax authorities have the ability to adjust the Company&#x2019;s carryforwards of unutilized net operating losses and research and development credits for all&#160;years.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;At December&#160;31, 2023, the Company had a net operating loss (&#x201c;NOL&#x201d;) carryforward for federal, foreign, and state income tax purposes totaling approximately $27.9&#160;million, $18.0&#160;million, and $23.8&#160;million, respectively, available to reduce future taxable income. The federal NOL and certain state NOLs of $16.8&#160;million are carried forward indefinitely subject to a limitation of 80% of taxable income. State NOLs of approximately $6.8&#160;million will begin to expire in 2024 if not utilized, and foreign NOLs of approximately $15.1&#160;million will begin to expire in 2024 if not utilized.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The NOL carry forward is subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Under the Internal Revenue Code (&#x201c;IRC&#x201d;) Sections 382 and 383, annual use of the Company&#x2019;s net operating loss carryforwards and research credit carryforwards to offset taxable income and tax, respectively, may be limited based on cumulative changes in ownership. The Company has not completed an analysis to determine whether any such limitations have been triggered as of December&#160;31, 2023. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The tax effects of the temporary differences and carryforwards that give rise to deferred tax assets and liabilities consist of the following:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;As of December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net-operating loss carryforward&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10,214,760&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,986,738&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Intangibles&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3,349,919&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;885,176&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Capitalized research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,171,320&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-288"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Stock-based compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;690,760&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;308,552&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deposit on WraSer APA&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;854,896&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-289"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;150,099&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;186,573&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;License agreement&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;49,157&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;82,626&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Other&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;520,207&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;65,886&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;17,001,118&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4,515,551&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(15,697,701&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(4,512,546&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Deferred tax assets, net of allowance&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,303,417&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3,005&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Intangible assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(4,345,449&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-290"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Fixed assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(2,560&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(3,005&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Other&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(29,189&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-291"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-29" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(4,377,198&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(3,005&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Net deferred tax liability&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;(3,073,781&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-292"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. The Company has recorded a valuation allowance against its United&#160;States and foreign deferred tax assets in each of the&#160;years ended December&#160;31, 2023 and 2022, because the Company&#x2019;s management believes that it is more likely than not that these assets will not be realized. During the&#160;years ended December&#160;31, 2023 and 2022, the valuation allowance increased by approximately $11.2&#160;million and $3.2&#160;million, respectively.&lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The provision for income taxes on earnings subject to income taxes differs from the statutory Federal rate at December&#160;31, 2023 and 2022, due to the following:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;For the&#160;Years Ended&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected income tax benefit at Federal statutory tax rate&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(7,858,680&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(2,818,164&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;State and local taxes, net of Federal tax benefit&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1,192,605&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(501,277&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research credits&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-293"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(16,477&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Foreign NOL expirations&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;315,927&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-294"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Stock-based compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;196,025&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-295"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Subscription agreement liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;181,440&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-296"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Officer&#x2019;s compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(126,337&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-297"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Acquisition related costs&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;164,073&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-298"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Permanent items&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;55,486&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;194,705&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;State rate adjustment&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(23,135&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;19,600&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Other&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;60,599&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(37,260&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Change in valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;8,214,614&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3,158,873&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-29" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Income tax benefit&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;(12,593&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-299"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Under U.S.&#160;GAAP, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more&lt;span class="nobreak"&gt;-likely-than-not&lt;/span&gt; to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, U.S.&#160;GAAP provides guidance on derecognition, classification, interest and penalties, accounting for interim periods, disclosure, and transition.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;For the&#160;Years Ended&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Beginning balance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;17,010&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-300"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Increases related to prior year tax positions&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-301"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;11,517&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Increases related to current year tax positions&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-302"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5,493&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Ending balance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;17,010&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;17,010&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;At December&#160;31, 2023 and 2022, the Company&#x2019;s unrecognized tax benefits were $17,010. Due to the existence of the valuation allowance, future changes in the Company&#x2019;s unrecognized tax benefits will not impact the effective tax rate. The Company does not expect its unrecognized tax benefits to change significantly over the next 12&#160;months.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Company&#x2019;s policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2023 and 2022, there were no accrued interest and penalties associated with uncertain tax positions.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c0" id="ixv-20800">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The components of loss before income taxes are as follows:&lt;/p&gt;&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;For the&#160;Years Ended&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;U.S.&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(37,106,599&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(13,419,830&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Foreign&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(315,688&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-287"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-29" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total loss before income taxes&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;(37,422,287&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;(13,419,830&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c0" decimals="0" id="ixv-31465" unitRef="usd">-37106599</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c9" decimals="0" id="ixv-31466" unitRef="usd">-13419830</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c0" decimals="0" id="ixv-31467" unitRef="usd">-315688</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-31468" unitRef="usd">-37422287</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c9" decimals="0" id="ixv-31469" unitRef="usd">-13419830</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="c335"
      decimals="-5"
      id="ixv-31470"
      unitRef="usd">27900000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="c335"
      decimals="-5"
      id="ixv-31471"
      unitRef="usd">18000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="c335"
      decimals="-5"
      id="ixv-31472"
      unitRef="usd">23800000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="c335"
      decimals="-5"
      id="ixv-31473"
      unitRef="usd">16800000</us-gaap:FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
      contextRef="c335"
      decimals="2"
      id="ixv-31474"
      unitRef="pure">0.80</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="c335"
      decimals="-5"
      id="ixv-31475"
      unitRef="usd">6800000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="c335"
      decimals="-5"
      id="ixv-31476"
      unitRef="usd">15100000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0" id="ixv-20899">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The tax effects of the temporary differences and carryforwards that give rise to deferred tax assets and liabilities consist of the following:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;As of December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net-operating loss carryforward&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10,214,760&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,986,738&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Intangibles&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3,349,919&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;885,176&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Capitalized research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,171,320&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-288"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Stock-based compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;690,760&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;308,552&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deposit on WraSer APA&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;854,896&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-289"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;150,099&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;186,573&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;License agreement&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;49,157&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;82,626&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Other&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;520,207&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;65,886&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;17,001,118&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4,515,551&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(15,697,701&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(4,512,546&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Deferred tax assets, net of allowance&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,303,417&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3,005&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Intangible assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(4,345,449&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-290"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Fixed assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(2,560&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(3,005&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Other&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(29,189&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-291"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-29" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(4,377,198&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(3,005&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Net deferred tax liability&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;(3,073,781&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-292"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c1" decimals="0" id="ixv-31477" unitRef="usd">10214760</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c2" decimals="0" id="ixv-31478" unitRef="usd">2986738</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c1" decimals="0" id="ixv-31479" unitRef="usd">3349919</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c2" decimals="0" id="ixv-31480" unitRef="usd">885176</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c1" decimals="0" id="ixv-31481" unitRef="usd">1171320</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c1" decimals="0" id="ixv-31482" unitRef="usd">690760</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c2" decimals="0" id="ixv-31483" unitRef="usd">308552</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsOther contextRef="c1" decimals="0" id="ixv-31484" unitRef="usd">854896</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c1" decimals="0" id="ixv-31485" unitRef="usd">150099</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c2" decimals="0" id="ixv-31486" unitRef="usd">186573</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <onco:LicenseAgreement contextRef="c1" decimals="0" id="ixv-31487" unitRef="usd">49157</onco:LicenseAgreement>
    <onco:LicenseAgreement contextRef="c2" decimals="0" id="ixv-31488" unitRef="usd">82626</onco:LicenseAgreement>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther contextRef="c1" decimals="0" id="ixv-31489" unitRef="usd">520207</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther contextRef="c2" decimals="0" id="ixv-31490" unitRef="usd">65886</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c1" decimals="0" id="ixv-31491" unitRef="usd">17001118</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c2" decimals="0" id="ixv-31492" unitRef="usd">4515551</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c1" decimals="0" id="ixv-31493" unitRef="usd">15697701</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c2" decimals="0" id="ixv-31494" unitRef="usd">4512546</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c1" decimals="0" id="ixv-31495" unitRef="usd">1303417</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c2" decimals="0" id="ixv-31496" unitRef="usd">3005</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c1" decimals="0" id="ixv-31497" unitRef="usd">4345449</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c1" decimals="0" id="ixv-31498" unitRef="usd">2560</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c2" decimals="0" id="ixv-31499" unitRef="usd">3005</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c1" decimals="0" id="ixv-31500" unitRef="usd">29189</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c1" decimals="0" id="ixv-31501" unitRef="usd">4377198</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c2" decimals="0" id="ixv-31502" unitRef="usd">3005</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c1" decimals="0" id="ixv-31503" unitRef="usd">3073781</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c0" decimals="-5" id="ixv-31504" unitRef="usd">11200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c9" decimals="-5" id="ixv-31505" unitRef="usd">3200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0" id="ixv-21251">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The provision for income taxes on earnings subject to income taxes differs from the statutory Federal rate at December&#160;31, 2023 and 2022, due to the following:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;For the&#160;Years Ended&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected income tax benefit at Federal statutory tax rate&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(7,858,680&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(2,818,164&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;State and local taxes, net of Federal tax benefit&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1,192,605&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(501,277&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research credits&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-293"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(16,477&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Foreign NOL expirations&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;315,927&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-294"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Stock-based compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;196,025&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-295"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Subscription agreement liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;181,440&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-296"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Officer&#x2019;s compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(126,337&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-297"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Acquisition related costs&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;164,073&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-298"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Permanent items&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;55,486&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;194,705&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;State rate adjustment&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(23,135&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;19,600&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Other&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;60,599&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(37,260&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Change in valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;8,214,614&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3,158,873&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-29" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Income tax benefit&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;(12,593&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-299"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="0" id="ixv-31506" unitRef="usd">-7858680</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c9" decimals="0" id="ixv-31507" unitRef="usd">-2818164</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c0" decimals="0" id="ixv-31508" unitRef="usd">-1192605</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c9" decimals="0" id="ixv-31509" unitRef="usd">-501277</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c9" decimals="0" id="ixv-31510" unitRef="usd">16477</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c0" decimals="0" id="ixv-31511" unitRef="usd">315927</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c0" decimals="0" id="ixv-31512" unitRef="usd">196025</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <onco:IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability contextRef="c0" decimals="0" id="ixv-31513" unitRef="usd">181440</onco:IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability>
    <onco:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation contextRef="c0" decimals="0" id="ixv-31514" unitRef="usd">-126337</onco:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c0" decimals="0" id="ixv-31515" unitRef="usd">164073</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c0" decimals="0" id="ixv-31516" unitRef="usd">55486</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c9" decimals="0" id="ixv-31517" unitRef="usd">194705</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <onco:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment contextRef="c0" decimals="0" id="ixv-31518" unitRef="usd">-23135</onco:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment>
    <onco:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment contextRef="c9" decimals="0" id="ixv-31519" unitRef="usd">19600</onco:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c0" decimals="0" id="ixv-31520" unitRef="usd">60599</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c9" decimals="0" id="ixv-31521" unitRef="usd">-37260</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="0" id="ixv-31522" unitRef="usd">8214614</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c9" decimals="0" id="ixv-31523" unitRef="usd">3158873</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-31524" unitRef="usd">-12593</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c0" decimals="2" id="ixv-31525" unitRef="pure">0.50</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c0" id="ixv-21512">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;For the&#160;Years Ended&lt;/span&gt;&lt;span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Beginning balance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;17,010&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-300"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Increases related to prior year tax positions&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-301"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;11,517&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Increases related to current year tax positions&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-302"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5,493&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Ending balance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;17,010&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;17,010&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c2" decimals="0" id="ixv-31526" unitRef="usd">17010</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c9" decimals="0" id="ixv-31527" unitRef="usd">11517</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c9" decimals="0" id="ixv-31528" unitRef="usd">5493</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c1" decimals="0" id="ixv-31529" unitRef="usd">17010</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c2" decimals="0" id="ixv-31530" unitRef="usd">17010</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease contextRef="c0" decimals="0" id="ixv-31531" unitRef="usd">17010</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease contextRef="c9" decimals="0" id="ixv-31532" unitRef="usd">17010</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c0" id="ixv-21600">&lt;p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Note&#160;13 &#x2014; Retirement Plans&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Defined Contribution Plans&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Effective January&#160;1, 2022, the Company adopted a defined contribution savings plan pursuant to Section&#160;401(k)&#160;of the Internal Revenue Code (&#x201c;the 2022 401(k)&#160;Plan&#x201d;). The 2022 401(k)&#160;Plan was for the benefit of all qualifying employees and permits voluntary contributions by employees of up to 100% of eligible compensation, subject to the maximum limits imposed by the Internal Revenue Service. The terms of the 2022 401(k)&#160;Plan allowed for discretionary employer contributions. No expenses were incurred related to the 2022 401(k)&#160;Plan during the year ended December&#160;31, 2022 and the 2022 401(k)&#160;Plan lapsed during 2022 due to inactivity.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On May&#160;31, 2023, the Board voted to adopt a 401(k)&#160;Safe Harbor Non&lt;span class="nobreak"&gt;-Elective&lt;/span&gt; Plan (the &#x201c;2023 401(k)&#160;Plan&#x201d;). The 2023 401(k)&#160;Plan was an employee savings and retirement plan to which substantially all employees could have contributed, including the Company&#x2019;s named executive officers, effective July&#160;1, 2023. Pursuant to the 2023 401(k)&#160;Plan, employee and Company contributions would vest immediately, subject to a three&lt;span class="nobreak"&gt;-month&lt;/span&gt; waiting period for new hires. The Company was required to contribute 3% of gross pay to eligible employees&#x2019; 401(k)&#160;Plans. On November&#160;16, 2023, the 2023 401(k)&#160;Plan was terminated. No expenses were incurred related to the 2023 401(k)&#160;Plan during the year ended December&#160;31, 2023.&lt;/p&gt;
		&lt;p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Defined Benefit Plan&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Proteomedix sponsors a defined benefit pension plan covering certain eligible employees. The Swiss Plan provides retirement benefits based on&#160;years of service and compensation levels.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The value of the pension obligation is determined using the Projected Unit Credit method. This method sees each period of service as giving rise to an additional unit of benefit entitlements/employee benefits. The value of the Company&#x2019;s employee benefit obligations for active employees, or the Projected Benefit Obligation, on the reporting date is the same as the present value of the degree of entitlement existing on this date, in terms of future salary and pension increases and turnover rates. The valuation of pension obligations of pensioners is made on the basis of the present value of current pensions taking into account future increases in pensions. The service costs are calculated using the present value of the entitlements to employee benefits earned during the year for which calculations are made.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As is customary with Swiss pension plans, the assets of the Swiss Plan are invested in a collective fund with multiple employers. Neither Proteomedix nor Onconetix have investment authority over the assets of the Swiss Plan that are held and invested by a Swiss insurance company. Investment holdings are made with respect to Swiss laws and target allocations for plan assets, and are 38% debt securities and cash, 26% equity securities, 12% alternative investments and 24% real estate investments. The valuation of the collective fund assets as a whole is a Level 3 measurement; however, the individual investments of the fund are generally Level 1 (equity securities), Level 2 (fixed income) and Level 3 (real estate, infrastructure and alternative) investments. We determine the fair value of the plan assets based on information provided by the collective fund. See Note&#160;3, &#x201c;Summary of Significant Accounting Policies&#x201d; for additional information on the three&lt;span class="nobreak"&gt;-tier&lt;/span&gt; fair value hierarchy.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The following significant actuarial assumptions were used in calculating the benefit obligation and the net periodic &lt;span style="-sec-ix-hidden: hidden-fact-304"&gt;benefit cost&lt;/span&gt; as of December&#160;31, 2023:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Discount rate&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.45&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected long-term rate of return on plan assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.45&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Rate of compensation increase&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3.00&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Changes in these assumptions may have a material impact on the plan&#x2019;s obligations and costs.&lt;/p&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The components of net periodic benefit cost for the period from December&#160;15, 2023 to December&#160;31, 2023 are as follows:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Service cost&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4,278&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Interest cost&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,943&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected return on plan assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1,581&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Amortization of net (gain)/loss&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1,534&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Settlements (gain)/loss&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1,157&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,949&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The components of accumulated comprehensive loss attributable to the Company&#x2019;s pension plan for the period from December&#160;15, 2023 to December&#160;31, 2023 are as follows:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net loss (gain)&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7,277&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Amortization of net gain&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,534&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Effect of settlement&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,157&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Other adjustments&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(4,005&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total recorded during the period&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5,963&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of December&#160;31, 2023, the funded status of the plan and the amounts recognized in the accompanying consolidated balance sheet are as follows:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Projected benefit obligation&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,299,970&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Fair value of plan assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,743,674&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Overfunded (underfunded) status&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(556,296&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;There were no Company contributions made to the plan during the period from December&#160;15, 2023 to December&#160;31, 2023.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;A reconciliation of the beginning and ending balances of the accumulated benefit obligation is provided in the table below:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;As of December&#160;15, 2023&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,288,273&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Service cost&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4,278&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Interest cost&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,943&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Actuarial (gain) loss&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7,979&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Benefits paid&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(905&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Ordinary contributions paid by employees&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4,005&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Contributions paid by plan participants&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;769&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Settlements&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(6,372&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Projected benefit obligation as of December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,299,970&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Actuarial (gain)/loss due to assumption changes&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;8,834&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Actuarial (gain)/loss due to plan experience&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(855&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accumulated benefit obligation as of December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,307,949&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;A reconciliation of the beginning and ending balances of the plan assets is provided in the table below:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;As of December&#160;15, 2023&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,739,889&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Actual return on plan assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,283&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Contributions paid by employer&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4,005&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Ordinary contributions paid by employees&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4,005&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Contributions paid by plan participants&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;769&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Benefits paid&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(905&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Settlements&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(6,372&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;As of December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,743,674&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Projected benefit payments for the next five&#160;years as of December&#160;31, 2023 are as follows:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Years ending December&#160;31,&lt;/span&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-303"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2025&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;95,100&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2026&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;95,100&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2027&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;95,100&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2028&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;95,100&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Thereafter&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;553,900&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;934,300&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
      contextRef="c336"
      decimals="2"
      id="ixv-31533"
      unitRef="pure">1</us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage>
    <onco:GrossPayPercentage contextRef="c0" decimals="2" id="ixv-31534" unitRef="pure">0.03</onco:GrossPayPercentage>
    <onco:DebtSecuritiesAndCash contextRef="c0" decimals="2" id="ixv-31535" unitRef="pure">0.38</onco:DebtSecuritiesAndCash>
    <onco:EquitySecuritiesRate contextRef="c0" decimals="2" id="ixv-31536" unitRef="pure">0.26</onco:EquitySecuritiesRate>
    <onco:AlternativeInvestmentsRate contextRef="c0" decimals="2" id="ixv-31537" unitRef="pure">0.12</onco:AlternativeInvestmentsRate>
    <onco:RealEstateInvestmentsRate contextRef="c0" decimals="2" id="ixv-31538" unitRef="pure">0.24</onco:RealEstateInvestmentsRate>
    <us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock contextRef="c0" id="ixv-21615">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The following significant actuarial assumptions were used in calculating the benefit obligation and the net periodic &lt;span style="-sec-ix-hidden: hidden-fact-304"&gt;benefit cost&lt;/span&gt; as of December&#160;31, 2023:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Discount rate&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.45&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected long-term rate of return on plan assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.45&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Rate of compensation increase&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3.00&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate contextRef="c1" decimals="4" id="ixv-31539" unitRef="pure">0.0145</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate contextRef="c1" decimals="4" id="ixv-31540" unitRef="pure">0.0145</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease contextRef="c1" decimals="4" id="ixv-31541" unitRef="pure">0.03</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock contextRef="c0" id="ixv-21656">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The components of net periodic benefit cost for the period from December&#160;15, 2023 to December&#160;31, 2023 are as follows:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Service cost&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4,278&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Interest cost&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,943&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected return on plan assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1,581&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Amortization of net (gain)/loss&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1,534&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Settlements (gain)/loss&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1,157&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,949&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c337" decimals="0" id="ixv-31542" unitRef="usd">4278</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c337" decimals="0" id="ixv-31543" unitRef="usd">1943</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c337" decimals="0" id="ixv-31544" unitRef="usd">1581</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c337" decimals="0" id="ixv-31545" unitRef="usd">1534</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1 contextRef="c337" decimals="0" id="ixv-31546" unitRef="usd">1157</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c337" decimals="0" id="ixv-31547" unitRef="usd">1949</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c0" id="ixv-21720">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The components of accumulated comprehensive loss attributable to the Company&#x2019;s pension plan for the period from December&#160;15, 2023 to December&#160;31, 2023 are as follows:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net loss (gain)&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7,277&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Amortization of net gain&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,534&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Effect of settlement&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,157&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Other adjustments&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(4,005&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total recorded during the period&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5,963&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent contextRef="c0" decimals="0" id="ixv-31548" unitRef="usd">7277</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent>
    <onco:AmortizationOfNetGain contextRef="c0" decimals="0" id="ixv-31549" unitRef="usd">1534</onco:AmortizationOfNetGain>
    <onco:EffectOfSettlement contextRef="c0" decimals="0" id="ixv-31550" unitRef="usd">1157</onco:EffectOfSettlement>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c0" decimals="0" id="ixv-31551" unitRef="usd">-4005</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RegulatedAndUnregulatedOperatingRevenue contextRef="c0" decimals="0" id="ixv-31552" unitRef="usd">5963</us-gaap:RegulatedAndUnregulatedOperatingRevenue>
    <onco:ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock contextRef="c0" id="ixv-21774">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of December&#160;31, 2023, the funded status of the plan and the amounts recognized in the accompanying consolidated balance sheet are as follows:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Projected benefit obligation&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,299,970&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Fair value of plan assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,743,674&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Overfunded (underfunded) status&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(556,296&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</onco:ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation contextRef="c1" decimals="0" id="ixv-31553" unitRef="usd">2299970</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets contextRef="c1" decimals="0" id="ixv-31554" unitRef="usd">1743674</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent contextRef="c1" decimals="0" id="ixv-31555" unitRef="usd">556296</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <srt:ScheduleOfCondensedFinancialStatementsTableTextBlock contextRef="c0" id="ixv-21809">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;A reconciliation of the beginning and ending balances of the accumulated benefit obligation is provided in the table below:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;As of December&#160;15, 2023&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,288,273&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Service cost&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4,278&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Interest cost&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,943&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Actuarial (gain) loss&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7,979&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Benefits paid&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(905&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Ordinary contributions paid by employees&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4,005&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Contributions paid by plan participants&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;769&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Settlements&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(6,372&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Projected benefit obligation as of December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,299,970&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Actuarial (gain)/loss due to assumption changes&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;8,834&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Actuarial (gain)/loss due to plan experience&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(855&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accumulated benefit obligation as of December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,307,949&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;A reconciliation of the beginning and ending balances of the plan assets is provided in the table below:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;As of December&#160;15, 2023&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,739,889&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Actual return on plan assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,283&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Contributions paid by employer&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4,005&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Ordinary contributions paid by employees&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4,005&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Contributions paid by plan participants&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;769&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Benefits paid&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(905&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Settlements&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(6,372&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;As of December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,743,674&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</srt:ScheduleOfCondensedFinancialStatementsTableTextBlock>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c338" decimals="0" id="ixv-31556" unitRef="usd">2288273</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c339" decimals="0" id="ixv-31557" unitRef="usd">4278</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c339" decimals="0" id="ixv-31558" unitRef="usd">1943</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss contextRef="c339" decimals="0" id="ixv-31559" unitRef="usd">7979</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid contextRef="c339" decimals="0" id="ixv-31560" unitRef="usd">905</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <onco:DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees contextRef="c339" decimals="0" id="ixv-31561" unitRef="usd">4005</onco:DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant contextRef="c339" decimals="0" id="ixv-31562" unitRef="usd">769</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement contextRef="c339" decimals="0" id="ixv-31563" unitRef="usd">-6372</us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation contextRef="c340" decimals="0" id="ixv-31564" unitRef="usd">2299970</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanOtherChanges contextRef="c339" decimals="0" id="ixv-31565" unitRef="usd">8834</us-gaap:DefinedBenefitPlanOtherChanges>
    <us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease contextRef="c339" decimals="0" id="ixv-31566" unitRef="usd">-855</us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c340" decimals="0" id="ixv-31567" unitRef="usd">2307949</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c341" decimals="0" id="ixv-31568" unitRef="usd">1739889</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets contextRef="c342" decimals="0" id="ixv-31569" unitRef="usd">2283</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c342" decimals="0" id="ixv-31570" unitRef="usd">4005</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <onco:DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees contextRef="c342" decimals="0" id="ixv-31571" unitRef="usd">4005</onco:DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant contextRef="c342" decimals="0" id="ixv-31572" unitRef="usd">769</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c342" decimals="0" id="ixv-31573" unitRef="usd">905</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets contextRef="c342" decimals="0" id="ixv-31574" unitRef="usd">6372</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c343" decimals="0" id="ixv-31575" unitRef="usd">1743674</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="c0" id="ixv-22028">&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Projected benefit payments for the next five&#160;years as of December&#160;31, 2023 are as follows:&lt;/p&gt;&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="CharOverride-3" style="font-style:normal;font-weight:bold;"&gt;Years ending December&#160;31,&lt;/span&gt;&lt;/p&gt;

					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-303"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2025&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;95,100&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2026&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;95,100&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2027&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;95,100&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2028&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;95,100&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Thereafter&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;553,900&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;934,300&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo contextRef="c1" decimals="0" id="ixv-31576" unitRef="usd">95100</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree contextRef="c1" decimals="0" id="ixv-31577" unitRef="usd">95100</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour contextRef="c1" decimals="0" id="ixv-31578" unitRef="usd">95100</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive contextRef="c1" decimals="0" id="ixv-31579" unitRef="usd">95100</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter contextRef="c1" decimals="0" id="ixv-31580" unitRef="usd">553900</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent contextRef="c1" decimals="0" id="ixv-31581" unitRef="usd">934300</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-22097">&lt;p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Note&#160;14 &#x2014; Subsequent Events&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On January&#160;23, 2024, the Company issued a non&lt;span class="nobreak"&gt;-convertible&lt;/span&gt; debenture (the &#x201c;Debenture&#x201d;) to the PMX Investor, a related party, in the principal sum of $5.0&#160;million, in connection with the Subscription Agreement discussed in Note&#160;8. The Debenture has an interest rate of 4.0% per annum, and the principal and accrued interest are payable in full upon the earlier of (i)&#160;the closing under the Subscription Agreement and (ii)&#160;June&#160;30, 2024. Additionally, the $5.0&#160;million subscription amount under the Subscription Agreement shall be increased by the amount of interest payable under the Debenture.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Effective as of January&#160;10, 2024, Dr.&#160;Neil Campbell resigned as President and Chief Executive Officer and a member of the Board of Directors of the Company. The Company and Dr.&#160;Campbell entered into a Release of Claims agreement, pursuant to which Dr.&#160;Campbell will receive a severance payment of $158,333 in two equal payments.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On February&#160;6, 2024, the Company appointed Thomas Meier, PhD, as a member of the Company&#x2019;s board of directors. Dr.&#160;Meier provides consulting services to Proteomedix, through a consulting agreement that was executed on January&#160;4, 2024.&lt;/p&gt;
		&lt;p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"&gt;During March&#160;2024, Zydus Life Sciences received FDA approval for a combined finasteride&lt;span class="nobreak"&gt;-tadalafil&lt;/span&gt; capsule, which is a direct competitor product to ENTADFI.&#160;The Company determined that this is a triggering event during the first quarter of 2024 for its ENTADFI asset group, which includes long&lt;span class="nobreak"&gt;-lived&lt;/span&gt; assets with a remaining carrying amount of approximately $3.3&#160;million as of December&#160;31, 2023. As such, it is reasonably possible that the resulting impairment test will result in additional impairment losses in the near term.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="c344"
      decimals="-5"
      id="ixv-31582"
      unitRef="usd">5000000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c345"
      decimals="3"
      id="ixv-31583"
      unitRef="pure">0.04</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="c346"
      decimals="-5"
      id="ixv-31584"
      unitRef="usd">5000000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <onco:SeverancePayment contextRef="c347" decimals="0" id="ixv-31585" unitRef="usd">158333</onco:SeverancePayment>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="c101"
      decimals="-5"
      id="ixv-31586"
      unitRef="usd">3300000</us-gaap:OtherAssetImpairmentCharges>
    <dei:DocumentType contextRef="c0" id="hidden-fact-0">S-1/A</dei:DocumentType>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="c2"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryNet
      contextRef="c2"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="c3"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredCosts
      contextRef="c2"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c2"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="c2"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="c2"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c2"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c2"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermNotesPayable
      contextRef="c2"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:SubscriptionAgreementLiabilityNoncurrent
      contextRef="c2"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="c2"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c2"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="c2"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c1"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c2"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c1"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="c2"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MinorityInterest
      contextRef="c2"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c9"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="c9"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="c9"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="c9"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="c9"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c9"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="c9"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:ChangeInFairValueOfSubscriptionAgreementLiability
      contextRef="c9"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c9"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="c0"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c9"
      decimals="2"
      id="hidden-fact-32"
      unitRef="usdPershares">-1.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-33"
      unitRef="usdPershares">-2.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c9"
      decimals="INF"
      id="hidden-fact-34"
      unitRef="shares">12271449</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="hidden-fact-35"
      unitRef="shares">17111374</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c9"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:ChangeInPensionBenefitObligation
      contextRef="c9"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c10"
      id="hidden-fact-38"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c10"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c14"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c16"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c19"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c21"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c24"
      id="hidden-fact-45"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c24"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c25"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c19"
      id="hidden-fact-48"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c19"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c24"
      id="hidden-fact-50"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c24"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c27"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c25"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c26"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants
      contextRef="c19"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants
      contextRef="c20"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants
      contextRef="c21"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants
      contextRef="c24"
      id="hidden-fact-58"
      unitRef="shares"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants
      contextRef="c24"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants
      contextRef="c25"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement
      contextRef="c19"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement
      contextRef="c20"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement
      contextRef="c21"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet
      contextRef="c24"
      id="hidden-fact-64"
      unitRef="shares"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement
      contextRef="c24"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement
      contextRef="c25"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c19"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c21"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c24"
      id="hidden-fact-70"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c24"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c25"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:ExerciseOfPrefundedWarrants
      contextRef="c19"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:ExerciseOfPrefundedWarrants
      contextRef="c20"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:ExerciseOfPrefundedWarrants
      contextRef="c21"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:ExerciseOfPrefundedWarrantsinShares
      contextRef="c24"
      id="hidden-fact-76"
      unitRef="shares"
      xsi:nil="true"/>
    <onco:ExerciseOfPrefundedWarrants
      contextRef="c24"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:ExerciseOfPrefundedWarrants
      contextRef="c25"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c19"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c20"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c21"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c24"
      id="hidden-fact-82"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c24"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c25"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c19"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c20"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c21"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="c24"
      id="hidden-fact-88"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c24"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c25"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:PurchaseOfTreasuryShares
      contextRef="c19"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:PurchaseOfTreasuryShares
      contextRef="c20"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:PurchaseOfTreasuryShares
      contextRef="c21"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:PurchaseOfTreasurySharesinShares
      contextRef="c22"
      id="hidden-fact-94"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c19"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c20"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c21"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c22"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c23"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c24"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c25"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c28"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c29"
      id="hidden-fact-103"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c29"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c30"
      id="hidden-fact-105"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c30"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c31"
      id="hidden-fact-107"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c31"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c36"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions
      contextRef="c38"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions
      contextRef="c39"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions
      contextRef="c40"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares
      contextRef="c43"
      id="hidden-fact-113"
      unitRef="shares"
      xsi:nil="true"/>
    <onco:IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions
      contextRef="c43"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions
      contextRef="c44"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c38"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c39"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c40"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c43"
      id="hidden-fact-119"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c43"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c44"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock
      contextRef="c38"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock
      contextRef="c39"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock
      contextRef="c40"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares
      contextRef="c43"
      id="hidden-fact-125"
      unitRef="shares"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock
      contextRef="c43"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock
      contextRef="c44"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction
      contextRef="c39"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction
      contextRef="c40"
      id="hidden-fact-129"
      unitRef="shares"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction
      contextRef="c40"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction
      contextRef="c43"
      id="hidden-fact-131"
      unitRef="shares"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction
      contextRef="c43"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction
      contextRef="c44"
      id="hidden-fact-133"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction
      contextRef="c38"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction
      contextRef="c39"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction
      contextRef="c40"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction
      contextRef="c41"
      id="hidden-fact-137"
      unitRef="shares"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction
      contextRef="c42"
      id="hidden-fact-138"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction
      contextRef="c43"
      id="hidden-fact-139"
      unitRef="shares"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction
      contextRef="c43"
      id="hidden-fact-140"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c38"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c39"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c40"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c41"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c43"
      id="hidden-fact-145"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c43"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c44"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:ExerciseOfPrefundedWarrants
      contextRef="c38"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:ExerciseOfPrefundedWarrants
      contextRef="c39"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:ExerciseOfPrefundedWarrants
      contextRef="c40"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:ExerciseOfPrefundedWarrantsinShares
      contextRef="c43"
      id="hidden-fact-151"
      unitRef="shares"
      xsi:nil="true"/>
    <onco:ExerciseOfPrefundedWarrants
      contextRef="c43"
      id="hidden-fact-152"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:ExerciseOfPrefundedWarrants
      contextRef="c44"
      id="hidden-fact-153"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:ExerciseOfPrefundedWarrants
      contextRef="c45"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c38"
      id="hidden-fact-155"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c39"
      id="hidden-fact-156"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c40"
      id="hidden-fact-157"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c43"
      id="hidden-fact-158"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c43"
      id="hidden-fact-159"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c44"
      id="hidden-fact-160"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c45"
      id="hidden-fact-161"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="c39"
      id="hidden-fact-162"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="c40"
      id="hidden-fact-163"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c43"
      id="hidden-fact-164"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="c43"
      id="hidden-fact-165"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="c44"
      id="hidden-fact-166"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="c45"
      id="hidden-fact-167"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c38"
      id="hidden-fact-168"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c39"
      id="hidden-fact-169"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c40"
      id="hidden-fact-170"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="c43"
      id="hidden-fact-171"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c43"
      id="hidden-fact-172"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c44"
      id="hidden-fact-173"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:PurchaseOfTreasuryShares
      contextRef="c38"
      id="hidden-fact-174"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:PurchaseOfTreasuryShares
      contextRef="c39"
      id="hidden-fact-175"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:PurchaseOfTreasuryShares
      contextRef="c40"
      id="hidden-fact-176"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:PurchaseOfTreasurySharesinShares
      contextRef="c41"
      id="hidden-fact-177"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c38"
      id="hidden-fact-178"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c39"
      id="hidden-fact-179"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c40"
      id="hidden-fact-180"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax
      contextRef="c41"
      id="hidden-fact-181"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c42"
      id="hidden-fact-182"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax
      contextRef="c43"
      id="hidden-fact-183"
      unitRef="shares"
      xsi:nil="true"/>
    <onco:StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation
      contextRef="c40"
      id="hidden-fact-184"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c38"
      id="hidden-fact-185"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c39"
      id="hidden-fact-186"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c40"
      id="hidden-fact-187"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c41"
      id="hidden-fact-188"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c42"
      id="hidden-fact-189"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c43"
      id="hidden-fact-190"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c44"
      id="hidden-fact-191"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c46"
      id="hidden-fact-192"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c49"
      id="hidden-fact-193"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c50"
      id="hidden-fact-194"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c50"
      id="hidden-fact-195"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="c9"
      id="hidden-fact-196"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="c9"
      id="hidden-fact-197"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c9"
      id="hidden-fact-198"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c9"
      id="hidden-fact-199"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c9"
      id="hidden-fact-200"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="c9"
      id="hidden-fact-201"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:GainLossOnRelatedPartyReceivable
      contextRef="c9"
      id="hidden-fact-202"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="c9"
      id="hidden-fact-203"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c9"
      id="hidden-fact-204"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryWriteDown
      contextRef="c9"
      id="hidden-fact-205"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentOfWarrantsGrantedForServices
      contextRef="c9"
      id="hidden-fact-206"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PensionExpense
      contextRef="c9"
      id="hidden-fact-207"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="c0"
      id="hidden-fact-208"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="c9"
      id="hidden-fact-209"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="c9"
      id="hidden-fact-210"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="c9"
      id="hidden-fact-211"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit
      contextRef="c9"
      id="hidden-fact-212"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="c9"
      id="hidden-fact-213"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="c9"
      id="hidden-fact-214"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c9"
      id="hidden-fact-215"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c9"
      id="hidden-fact-216"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="c9"
      id="hidden-fact-217"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="c0"
      id="hidden-fact-218"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering
      contextRef="c0"
      id="hidden-fact-219"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="c0"
      id="hidden-fact-220"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c0"
      id="hidden-fact-221"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c9"
      id="hidden-fact-222"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NoncashOrPartNoncashAcquisitionInventoryAcquired1
      contextRef="c9"
      id="hidden-fact-223"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:EffectOfBusinessCombination
      contextRef="c9"
      id="hidden-fact-224"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="c9"
      id="hidden-fact-225"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1
      contextRef="c9"
      id="hidden-fact-226"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:WarrantsIssuedForSettlementOfContingentWarrants
      contextRef="c9"
      id="hidden-fact-227"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:DeferredOfferingCostsPreviouslyPrepaid
      contextRef="c9"
      id="hidden-fact-228"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:IssuanceOfRestrictedStock
      contextRef="c9"
      id="hidden-fact-229"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:RestrictedStockForfeitures
      contextRef="c9"
      id="hidden-fact-230"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:PaymentOfAccruedBonusThroughRelatedPartyReceivable
      contextRef="c0"
      id="hidden-fact-231"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="c0"
      id="hidden-fact-232"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c69"
      id="hidden-fact-233"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c70"
      id="hidden-fact-234"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c72"
      id="hidden-fact-235"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c9"
      id="hidden-fact-236"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NoncurrentAssets
      contextRef="c76"
      id="hidden-fact-237"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="c77"
      id="hidden-fact-238"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="c78"
      id="hidden-fact-239"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:SubscriptionAgreementLiabilityNoncurrent
      contextRef="c77"
      id="hidden-fact-240"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:SubscriptionAgreementLiabilityNoncurrent
      contextRef="c78"
      id="hidden-fact-241"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c77"
      id="hidden-fact-242"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c78"
      id="hidden-fact-243"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="c80"
      id="hidden-fact-244"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="c81"
      id="hidden-fact-245"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="c83"
      id="hidden-fact-246"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="c86"
      id="hidden-fact-247"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c96"
      id="hidden-fact-248"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c98"
      id="hidden-fact-249"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c66" id="hidden-fact-250">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c67" id="hidden-fact-251">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:InventoryRawMaterials
      contextRef="c2"
      id="hidden-fact-252"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryWorkInProcess
      contextRef="c2"
      id="hidden-fact-253"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryFinishedGoods
      contextRef="c2"
      id="hidden-fact-254"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryNet
      contextRef="c2"
      id="hidden-fact-255"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PrepaidRent
      contextRef="c2"
      id="hidden-fact-256"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:PrepaidProfessionalFees
      contextRef="c2"
      id="hidden-fact-257"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:ImpairmentOfIntangibleAssetExcludingGoodwill
      contextRef="c105"
      id="hidden-fact-258"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:ImpairmentOfIntangibleAssetExcludingGoodwill
      contextRef="c108"
      id="hidden-fact-259"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c105"
      id="hidden-fact-260"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation
      contextRef="c105"
      id="hidden-fact-261"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="c2"
      id="hidden-fact-262"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="c2"
      id="hidden-fact-263"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="c2"
      id="hidden-fact-264"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c0" id="hidden-fact-265">P13Y6M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <onco:BusinessTransactionYeare contextRef="c0" id="hidden-fact-266">P5Y</onco:BusinessTransactionYeare>
    <onco:CommercialSaleTerm contextRef="c148" id="hidden-fact-267">P10Y</onco:CommercialSaleTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c309"
      id="hidden-fact-268"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c309"
      id="hidden-fact-269"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <onco:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted
      contextRef="c313"
      id="hidden-fact-270"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled
      contextRef="c313"
      id="hidden-fact-271"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c2"
      id="hidden-fact-272"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c2"
      id="hidden-fact-273"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c216" id="hidden-fact-274">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c236" id="hidden-fact-275">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c267" id="hidden-fact-276">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0" id="hidden-fact-277">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c292" id="hidden-fact-278">P11Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c0" id="hidden-fact-279">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c292" id="hidden-fact-280">P5Y131D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c292" id="hidden-fact-281">P5Y73D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c0" id="hidden-fact-282">P4Y193D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c296" id="hidden-fact-283">P1Y288D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c297" id="hidden-fact-284">P1Y208D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c292" id="hidden-fact-285">P2Y357D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="c3"
      id="hidden-fact-286"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="c9"
      id="hidden-fact-287"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="c2"
      id="hidden-fact-288"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="c2"
      id="hidden-fact-289"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="c2"
      id="hidden-fact-290"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="c2"
      id="hidden-fact-291"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilities
      contextRef="c2"
      id="hidden-fact-292"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="c0"
      id="hidden-fact-293"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="c9"
      id="hidden-fact-294"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="c9"
      id="hidden-fact-295"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability
      contextRef="c9"
      id="hidden-fact-296"
      unitRef="usd"
      xsi:nil="true"/>
    <onco:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation
      contextRef="c9"
      id="hidden-fact-297"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="c9"
      id="hidden-fact-298"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c9"
      id="hidden-fact-299"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c18"
      id="hidden-fact-300"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="c0"
      id="hidden-fact-301"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="c0"
      id="hidden-fact-302"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="c1"
      id="hidden-fact-303"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList contextRef="c0" id="hidden-fact-304">http://fasb.org/us-gaap/2023#DefinedBenefitPensionPlanLiabilitiesNoncurrent</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList>
    <dei:AmendmentFlag contextRef="c0" id="ixv-31894">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-31895">0001782107</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666108494560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Onconetix, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">Pursuant to Rule 429 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the prospectus included in this Registration Statement on Form S-1 (this &#8220;Registration Statement&#8221;) is a combined prospectus relating to the following shares of common stock of Onconetix, Inc. (the &#8220;Registrant&#8221;) being registered on this Registration Statement and previously registered on the Registrant&#8217;s Registration Statement on Form S-3 (File No. 333-267142), as amended (the &#8220;Prior Registration Statement&#8221;):&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The offer and resale of 4,972,428 shares of Common Stock (the &#8220;Inducement PIO Shares&#8221;) issuable upon exercise of common stock preferred investment options (the &#8220;Inducement PIOs&#8221;) issued to Armistice Capital Master Fund Ltd. (&#8220;Armistice&#8221;) in a warrant inducement transaction (the &#8220;Warrant Inducement&#8221;), which closed on August 2, 2023.&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The offer and resale of 149,173 Inducement PIO Shares issuable upon exercise of Inducement PIOs issued to H.C. Wainwright & Co., LLC, the Company&#8217;s placement agent for the Warrant Inducement, or its designees on August 2, 2023 in the Warrant Inducement (the &#8220;Placement Agent Inducement PIOs&#8221;).&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The offer and resale of 2,486,214 shares of Common Stock issuable upon exercise of common stock preferred investment options (the &#8220;Sabby PIOs&#8221;, and together with the Inducement PIOs and the Placement Agent Inducement PIOs, the &#8220;PIOs&#8221;) issued to Sabby in a private placement, which were registered on a registration statement on Form S-1 (File No. 333-267142) on September 19, 2022 that was declared effective by the SEC, as amended by the Prior Registration Statement (the &#8220;Initial Registration Statement&#8221;)&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The offer and resale of 220,997 shares of Common Stock (&#8220;August 2022 Wainwright Warrant Shares&#8221;) issuable upon exercise of the warrants (the &#8220;August 2022 Wainwright Warrants&#8221;) issued to H.C. Wainwright & Co., LLC, or its designees, in a private placement, which were registered on the Initial Registration Statement.This Registration Statement also constitutes Post-Effective Amendment No. 2 to the Prior Registration Statement, and such Post-Effective Amendment No. 1 to the Initial Registration Statement shall hereafter become effective concurrently with the effectiveness of this Registration Statement in accordance with Section 8(c) of the Securities Act.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001782107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666107687392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 4,554,335<span></span>
</td>
<td class="nump">$ 25,752,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">149,731<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">364,052<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">770,153<span></span>
</td>
<td class="nump">469,232<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,838,271<span></span>
</td>
<td class="nump">26,257,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expenses, long-term</a></td>
<td class="nump">17,423<span></span>
</td>
<td class="nump">38,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">60,654<span></span>
</td>
<td class="nump">14,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="nump">366,113<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right of use asset</a></td>
<td class="nump">148,542<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">25,410,887<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">55,676,142<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">87,518,032<span></span>
</td>
<td class="nump">26,310,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,295,114<span></span>
</td>
<td class="nump">1,499,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,199,867<span></span>
</td>
<td class="nump">2,409,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable, net of debt discount of $381,627</a></td>
<td class="nump">9,618,373<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">74,252<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Contingent warrant liability</a></td>
<td class="nump">2,641<span></span>
</td>
<td class="nump">14,021<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">17,190,247<span></span>
</td>
<td class="nump">3,922,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable</a></td>
<td class="nump">118,857<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SubscriptionAgreementLiabilityNoncurrent', window );">Subscription agreement liability</a></td>
<td class="nump">864,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent', window );">Pension benefit obligation</a></td>
<td class="nump">556,296<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">74,290<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability, net</a></td>
<td class="nump">3,073,781<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">21,877,471<span></span>
</td>
<td class="nump">3,922,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (see Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Series B Convertible Redeemable Preferred stock, $0.00001 par value, 2,700,000 and 0 shares authorized at December 31, 2023 and 2022, respectively; 2,696,729 and 0 shares issued and outstanding at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">64,236,085<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series A Convertible Preferred stock, $0.00001 par value, 10,000 and 0 shares authorized at December 31, 2023 and 2022, respectively; 3,000 and 0 shares issued and outstanding at December 31, 2023 and 2022, respectively; Liquidation preference of $3,000,000 and $0 at December 31, 2023 and 2022, respectively.</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.00001 par value, 250,000,000 shares authorized at December 31, 2023 and 2022; 22,841,975 and 15,724,957 shares issued at December 31, 2023 and 2022, respectively; 22,324,576 and 15,265,228 shares outstanding at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="nump">49,428,809<span></span>
</td>
<td class="nump">42,331,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost; 517,399 and 459,729 shares of common stock at December 31, 2023 and 2022, respectively</a></td>
<td class="num">(625,791)<span></span>
</td>
<td class="num">(566,810)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(56,786,194)<span></span>
</td>
<td class="num">(19,376,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">2,380,920<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Onconetix stockholders&#8217; equity (deficit)</a></td>
<td class="num">(5,602,028)<span></span>
</td>
<td class="nump">22,388,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="nump">7,006,504<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,404,476<span></span>
</td>
<td class="nump">22,388,002<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible redeemable preferred stock, and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">87,518,032<span></span>
</td>
<td class="nump">26,310,447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Receivable from related parties, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 35,850<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_SubscriptionAgreementLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subscription agreement liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_SubscriptionAgreementLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666107663408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_NotesPayableNetOfDebtDiscount', window );">Notes payable, net of debt discount (in Dollars)</a></td>
<td class="nump">$ 381,627<span></span>
</td>
<td class="nump">$ 381,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">22,841,975<span></span>
</td>
<td class="nump">15,724,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">22,324,576<span></span>
</td>
<td class="nump">15,265,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares of common stock</a></td>
<td class="nump">517,399<span></span>
</td>
<td class="nump">459,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=onco_SeriesBConvertibleRedeemablePreferredStockMember', window );">Series B Convertible Redeemable Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible redeemable preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible redeemable preferred stock, shares authorized</a></td>
<td class="nump">2,700,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible redeemable preferred stock, shares issued</a></td>
<td class="nump">2,696,729<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible redeemable preferred stock, shares outstanding</a></td>
<td class="nump">2,696,729<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=onco_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred stock, liquidation preference (in Dollars)</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_NotesPayableNetOfDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notes payable, net of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_NotesPayableNetOfDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=onco_SeriesBConvertibleRedeemablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=onco_SeriesBConvertibleRedeemablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=onco_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=onco_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666108198672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 58,465<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">1,185,630<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross loss</a></td>
<td class="num">(1,127,165)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">14,770,678<span></span>
</td>
<td class="nump">9,351,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,949,406<span></span>
</td>
<td class="nump">4,129,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of ENTADFI assets</a></td>
<td class="nump">14,687,346<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment of deposit on asset purchase agreement</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">34,907,430<span></span>
</td>
<td class="nump">13,481,240<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(36,034,595)<span></span>
</td>
<td class="num">(13,481,240)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of note payable</a></td>
<td class="num">(490,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(671,625)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ChangeInFairValueOfSubscriptionAgreementLiability', window );">Change in fair value of subscription agreement liability</a></td>
<td class="num">(134,100)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Change in fair value of contingent warrant liability</a></td>
<td class="num">(91,967)<span></span>
</td>
<td class="nump">61,410<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(1,387,692)<span></span>
</td>
<td class="nump">61,410<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss before income taxes</a></td>
<td class="num">(37,422,287)<span></span>
</td>
<td class="num">(13,419,830)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">12,593<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(37,409,694)<span></span>
</td>
<td class="num">(13,419,830)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Cumulative preferred stock dividends</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">96,359<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (37,409,694)<span></span>
</td>
<td class="num">$ (13,516,189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic (in Dollars per share)</a></td>
<td class="num">$ (2.19)<span></span>
</td>
<td class="num">$ (1.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding, basic (in Shares)</a></td>
<td class="nump">17,111,374<span></span>
</td>
<td class="nump">12,271,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (37,409,694)<span></span>
</td>
<td class="num">$ (13,419,830)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation</a></td>
<td class="nump">2,374,957<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ChangeInPensionBenefitObligation', window );">Change in pension benefit obligation</a></td>
<td class="nump">5,963<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss attributable to common stockholders</a></td>
<td class="num">$ (35,028,774)<span></span>
</td>
<td class="num">$ (13,419,830)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ChangeInFairValueOfSubscriptionAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of subscription agreement liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ChangeInFairValueOfSubscriptionAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ChangeInPensionBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in pension benefit obligation,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ChangeInPensionBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666111414880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="num">$ (2.19)<span></span>
</td>
<td class="num">$ (1.10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding, diluted</a></td>
<td class="nump">17,111,374<span></span>
</td>
<td class="nump">12,271,449<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666107311232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Redeemable Preferred Stock and Stockholders&#8217; Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th">
<div>Series B </div>
<div>Preferred Stock</div>
</th>
<th class="th">
<div>Series Seed </div>
<div>Preferred Stock</div>
</th>
<th class="th">
<div>Series A </div>
<div>Preferred Stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Other Comprehensive Income</div></th>
<th class="th"><div>Total Onconetix Equity (Deficit)</div></th>
<th class="th"><div>Non-controlling Interest</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 7,403,204<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (5,956,670)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,446,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,446,577<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,146,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in initial public offering, net of $2.9 million of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">17,138,818<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,138,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,138,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in initial public offering, net of $2.9 million of offering costs (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,222,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock upon initial public offering</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock upon initial public offering (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,146,138)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,626,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants', window );">Issuance of common stock and warrants in April private placement, net of $1.1 million of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">6,858,322<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,858,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,858,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants', window );">Issuance of common stock and warrants in April private placement, net of $1.1 million of offering costs (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">590,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement', window );">Issuance of common stock and warrants in August private placement, net of $2.2 million of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">8,689,302<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,689,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,689,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet', window );">Issuance of common stock and warrants in August private placement, net of $2.2 million of offering costs (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,653<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ExerciseOfPrefundedWarrants', window );">Exercise of pre-funded warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">1,414<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ExerciseOfPrefundedWarrantsinShares', window );">Exercise of pre-funded warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,277,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of restricted stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">263,921<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">263,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,974,566<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,974,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,974,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock-based compensation (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PurchaseOfTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (566,810)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(566,810)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(566,810)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PurchaseOfTreasurySharesinShares', window );">Purchase of treasury shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(459,729)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,419,830)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,419,830)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,419,830)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 157<span></span>
</td>
<td class="nump">42,331,155<span></span>
</td>
<td class="num">$ (566,810)<span></span>
</td>
<td class="num">(19,376,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">22,388,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,388,002<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15,724,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(459,729)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions', window );">Issuance of common stock from exercise of preferred investment options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">2,272,813<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,272,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,272,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares', window );">Issuance of common stock from exercise of preferred investment options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,486,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of warrants for settlement of contingent warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,184<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">129,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of warrants for settlement of contingent warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock', window );">Issuance of Series A Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,490,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,490,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares', window );">Issuance of Series A Preferred Stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction', window );">Issuance of common stock and Series B Preferred Stock in connection with PMX Transaction</a></td>
<td class="nump">$ 64,236,085<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">875,447<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">875,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction', window );">Issuance of common stock and Series B Preferred Stock in connection with PMX Transaction (in Shares)</a></td>
<td class="nump">2,696,729<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,675,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction', window );">Assumption of stock-based compensation plan awards in connection with PMX Transaction</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,006,504<span></span>
</td>
<td class="nump">7,006,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction', window );">Assumption of stock-based compensation plan awards in connection with PMX Transaction (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Forfeitures of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Forfeitures of restricted stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(250,110)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,374,957<span></span>
</td>
<td class="nump">2,374,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,374,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax', window );">Foreign currency translation adjustment (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation', window );">Changes in pension benefit obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,963<span></span>
</td>
<td class="nump">5,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ExerciseOfPrefundedWarrants', window );">Exercise of pre-funded warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ExerciseOfPrefundedWarrantsinShares', window );">Exercise of pre-funded warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of restricted stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">512,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329,760<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">329,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock-based compensation (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PurchaseOfTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (58,981)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,981)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,981)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PurchaseOfTreasurySharesinShares', window );">Purchase of treasury shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57,670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(37,409,694)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(37,409,694)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(37,409,694)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 64,236,085<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">$ 49,428,809<span></span>
</td>
<td class="num">$ (625,791)<span></span>
</td>
<td class="num">$ (56,786,194)<span></span>
</td>
<td class="nump">$ 2,380,920<span></span>
</td>
<td class="num">$ (5,602,028)<span></span>
</td>
<td class="nump">$ 7,006,504<span></span>
</td>
<td class="nump">$ 1,404,476<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">2,696,729<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">22,841,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(517,399)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ExerciseOfPrefundedWarrantsinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ExerciseOfPrefundedWarrantsinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock from exercise of preferred investment options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_IssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign currency translation adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_OtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_PurchaseOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_PurchaseOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_PurchaseOfTreasurySharesinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares purchase of treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_PurchaseOfTreasurySharesinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumption of stock-based compensation plan awards in connection with PMX Transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_StockIssuedDuringPeriodSharesAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and Series B Preferred Stock in connection with PMX Transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock and warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock and warrants in August private placement issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInAugustPrivatePlacementNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of series A preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_StockIssuedDuringPeriodSharesIssuanceOfSeriesAPreferredStockinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumption of stock-based compensation plan awards in connection with PMX Transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_StockIssuedDuringPeriodValueAssumptionOfStockbasedCompensationPlanAwardsInConnectionWithPMXTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and Series B Preferred Stock in connection with PMX Transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock from exercise of preferred investment options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfPreferredInvestmentOptionsinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of series A preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and warrants in private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_StockIssuedDuringPeriodValueIssuanceofCommonStockandWarrantsinPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of  changes in pension benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_StockIssuedDuringPeriodValueOfssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666109170960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Redeemable Preferred Stock and Stockholders&#8217; Equity (Deficit) (Parentheticals) - Total Onconetix Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_IssuanceOfCommonStockInInitialPublicOfferingNet', window );">Issuance of common stock in initial public offering, net</a></td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet', window );">Issuance of common stock and warrants in April private placement, net</a></td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet', window );">Issuance of common stock and warrants in August private placement, net</a></td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and warrants in April private placement, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and warrants in private placement, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_IssuanceOfCommonStockInInitialPublicOfferingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in initial public offering, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_IssuanceOfCommonStockInInitialPublicOfferingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666107868112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (37,409,694)<span></span>
</td>
<td class="num">$ (13,419,830)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of ENTADFI assets</a></td>
<td class="nump">14,687,346<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment of deposit on asset purchase agreement</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of subscription agreement liability</a></td>
<td class="nump">729,900<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">671,373<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of note payable</a></td>
<td class="nump">490,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">329,760<span></span>
</td>
<td class="nump">1,974,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Loss on impairment of other long-lived assets</a></td>
<td class="nump">267,019<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_GainLossOnRelatedPartyReceivable', window );">Loss on related party receivable</a></td>
<td class="nump">265,648<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Recovery of related party receivable</a></td>
<td class="num">(159,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax benefit</a></td>
<td class="num">(12,593)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Impairment of inventory</a></td>
<td class="nump">1,152,369<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">43,937<span></span>
</td>
<td class="nump">6,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of contingent warrant liability</a></td>
<td class="nump">91,967<span></span>
</td>
<td class="num">(61,410)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Change in fair value of subscription agreement liability</a></td>
<td class="nump">134,100<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionExpense', window );">Net periodic pension benefit</a></td>
<td class="nump">13,875<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of restricted common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">263,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(62,286)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(315,828)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(412,601)<span></span>
</td>
<td class="num">(234,681)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other noncurrent assets</a></td>
<td class="num">(16,883)<span></span>
</td>
<td class="num">(38,617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,372,648<span></span>
</td>
<td class="nump">1,093,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(942,075)<span></span>
</td>
<td class="nump">1,739,849<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(13,581,018)<span></span>
</td>
<td class="num">(8,675,534)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Acquisition of assets, including transaction costs of $79,771</a></td>
<td class="num">(6,079,771)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit', window );">Deposit made in connection with asset purchase agreement</a></td>
<td class="num">(3,500,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash acquired through business combination</a></td>
<td class="nump">1,056,578<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchases of other long-lived assets</a></td>
<td class="num">(51,744)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ReceivableFromRelatedParties1', window );">Net advances to related parties</a></td>
<td class="num">(70,798)<span></span>
</td>
<td class="num">(23,326)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(3,300)<span></span>
</td>
<td class="num">(9,339)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(8,649,035)<span></span>
</td>
<td class="num">(32,665)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PaymentsForPurchaseOfTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="num">(58,981)<span></span>
</td>
<td class="num">(566,810)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of deferred offering costs</a></td>
<td class="num">(205,093)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payment of note payable</a></td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from exercise of preferred investment options, net</a></td>
<td class="nump">2,298,675<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">459<span></span>
</td>
<td class="nump">1,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock in initial public offering, net of underwriting discount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">18,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering', window );">Payments of initial public offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(926,972)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of common stock and warrants in private placements, net of placement agent discount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,468,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfPrivatePlacement', window );">Payment of private placement issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(845,048)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of pre-funded warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,436<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,035,060<span></span>
</td>
<td class="nump">32,532,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(3,331)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash</a></td>
<td class="num">(21,198,324)<span></span>
</td>
<td class="nump">23,824,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, beginning of period</a></td>
<td class="nump">25,752,659<span></span>
</td>
<td class="nump">1,928,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, end of period</a></td>
<td class="nump">4,554,335<span></span>
</td>
<td class="nump">25,752,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1', window );">Inventory and intangible assets acquired through issuance of notes payable</a></td>
<td class="nump">12,947,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_EffectOfBusinessCombination', window );">Effect of business combination (Note 5)</a></td>
<td class="nump">64,054,991<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Settlement of note payable through issuance of Series A convertible preferred stock</a></td>
<td class="nump">3,490,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Incremental fair value of exchanged preferred investment options</a></td>
<td class="nump">2,613,011<span></span>
</td>
<td class="nump">860,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1', window );">Deferred offering costs included in accounts payable</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement', window );">Recognition of contingent warrant liability</a></td>
<td class="nump">25,837<span></span>
</td>
<td class="nump">75,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_WarrantsIssuedForSettlementOfContingentWarrants', window );">Warrants issued for settlement of contingent warrants</a></td>
<td class="nump">129,184<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_DeferredOfferingCostsPreviouslyPrepaid', window );">Deferred offering costs previously included in prepaid expenses</a></td>
<td class="num">(11,020)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_Exerciseofprefundedwarrants', window );">Exercise of pre-funded warrants</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_IssuanceOfRestrictedStock', window );">Issuance of restricted stock</a></td>
<td class="nump">5<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_RestrictedStockForfeitures', window );">Restricted stock forfeitures</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PaymentOfAccruedBonusThroughRelatedPartyReceivable', window );">Payment of accrued bonus through related party receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">140,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of Series Seed Preferred Stock to common stock upon initial public offering</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_DeferredOfferingCostsPreviouslyPrepaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred offering costs previously prepaid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_DeferredOfferingCostsPreviouslyPrepaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_EffectOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effect of business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_EffectOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_Exerciseofprefundedwarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of pre funded warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_Exerciseofprefundedwarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_GainLossOnRelatedPartyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on related party receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_GainLossOnRelatedPartyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_IssuanceOfRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in Issuance of restricted stock

 exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_IssuanceOfRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_PaymentOfAccruedBonusThroughRelatedPartyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of accrued bonus through related party receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_PaymentOfAccruedBonusThroughRelatedPartyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_PaymentsForPurchaseOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for purchase of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_PaymentsForPurchaseOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ReceivableFromRelatedParties1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables from related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ReceivableFromRelatedParties1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recognition of contingent warrant liability upon issuance of common stock in private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_RestrictedStockForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted stock forfeitures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_RestrictedStockForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_WarrantsIssuedForSettlementOfContingentWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants issued for settlement of contingent warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_WarrantsIssuedForSettlementOfContingentWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment for noncash service expenses paid for by granting of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentOfWarrantsGrantedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionInventoryAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payables that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the repurchase of amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from temporary investment with specific maturity and interest rate that are prohibited for current use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension benefits. Excludes other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666109271520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Acquisition of assets, including transaction costs</a></td>
<td class="nump">$ 79,771<span></span>
</td>
<td class="nump">$ 79,771<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666109275456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text"><p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;1&#160;&#8212;&#160;Organization and Basis of Presentation</span></p>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Organization and Nature of Operations</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Onconetix, Inc. (formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc.) (the &#8220;Company&#8221; or &#8220;Onconetix&#8221;) was formed on October&#160;26, 2018, and is a commercial stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men&#8217;s health and oncology.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2023, Onconetix acquired 100% of the issued and outstanding voting equity interests in Proteomedix AG, a Swiss company (&#8220;Proteomedix&#8221;), and its related diagnostic product Proclarix. As a result of this transaction, Proteomedix became a wholly owned subsidiary of Onconetix (see Note&#160;5). In April&#160;2023, the Company acquired ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span>, a Food and Drug Administration (&#8220;FDA&#8221;)<span class="nobreak">-approved</span>, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Historically, the Company&#8217;s focus was on the research and development of transformational vaccines to prevent infectious diseases worldwide, until the third quarter of 2023, at which time the Company deprioritized its efforts on vaccine development activities to focus on commercialization activities for ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> and pursue other potential acquisitions. In light of (i)&#160;the time and resources needed to continue pursuing commercialization of ENTADFI, and (ii)&#160;the Company&#8217;s cash runway and indebtedness, the Company has determined to temporarily pause its commercialization of ENTADFI, as it considers strategic alternatives. The Company expects to appoint a new Chief Executive Officer in the second quarter of 2024, after which the new CEO and the Board will reassess its ENTADFI program in light of the foregoing and other relevant factors.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;21, 2023, the Company filed an amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to change its corporate name from &#8220;Blue Water Vaccines Inc.&#8221; to &#8220;Blue Water Biotech, Inc.&#8221; The name change was effective as of April&#160;21, 2023. On December&#160;15, 2023, the Company filed an amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to change its corporate name from &#8220;Blue Water Biotech, Inc.&#8221; to &#8220;Onconetix, Inc.&#8221; In connection with each of the name changes, the Company also amended the Company&#8217;s bylaws to reflect the new corporate name.</p>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;) and include the accounts of Onconetix and its 100%&#160;wholly owned subsidiary, Proteomedix, since the acquisition date of December&#160;15, 2023. All significant intercompany balances and transactions have been eliminated in consolidation.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Certain reclassifications have been made to prior year amounts reported in the accompanying consolidated statement of cash flows to conform to the current year presentation. These reclassifications, which resulted in a difference of approximately $23,000 between operating and investing cash flow activity, are not significant and had no impact on the previously reported financial position or results of operations of the Company.</p>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Initial Public Offering</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;23, 2022, the Company completed its initial public offering (&#8220;IPO&#8221;) in which the Company issued and sold 2,222,222<span class="nobreak"> </span>shares of its common stock, at a price to the public of $9.00 per share. Proceeds from the IPO, net of underwriting discounts, commissions, and offering costs of $2.9&#160;million, were $17.1&#160;million. In connection with the completion of the IPO, all outstanding shares of convertible preferred stock were converted into 5,626,365<span class="nobreak"> </span>shares of common stock (see Note&#160;9).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666109419664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern and Management&#8217;s Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_GoingConcernAndManagementsPlansAbstract', window );"><strong>Going Concern and Management&#8217;s Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going Concern and Management&#8217;s Plans</a></td>
<td class="text"><p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;2 &#8212; Going Concern and Management&#8217;s Plans</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s operating activities to date have been devoted to seeking licenses, engaging in research and development activities, potential asset and business acquisitions, and expenditures associated with the commercial launch of ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span>. The Company has financed its operations since inception primarily using proceeds received from seed investors and proceeds received from its IPO and subsequent debt and equity offerings. During the year </p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">ended December&#160;31, 2022, the Company received an aggregate of approximately $33.1&#160;million in net cash proceeds from its IPO and two private placements, and during the year ended December&#160;31, 2023, the Company received net proceeds of approximately $2.3&#160;million in connection with the exercise by an investor of preferred investment options (see Note&#160;9). In addition, on January&#160;23, 2024, the Company received net cash proceeds of $4.6&#160;million in exchange for the issuance of a debenture. The debenture is repayable in full upon the earlier of (i)&#160;the closing of a subscription agreement, which was entered into in connection with the acquisition of Proteomedix, and (ii)&#160;June&#160;30, 2024 (see&#160;Note&#160;14).</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future. As of December&#160;31, 2023, the Company had cash of approximately $4.6&#160;million, a working capital deficit of approximately $11.4&#160;million and an accumulated deficit of approximately $56.8&#160;million.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">These factors, along with the Company&#8217;s forecasted future cash flows, indicate that the Company will be unable to meet its contractual commitments and obligations as they come due in the ordinary course of business, within one year following the issuance of these consolidated financial statements. The Company will require significant additional capital in the short<span class="nobreak">-term</span> to fund its continuing operations, satisfy existing and future obligations and liabilities, including the remaining payments due for the acquisition of the ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> assets, payment due on the debenture, in addition to funds needed to support the Company&#8217;s working capital needs and business activities. These business activities include the commercialization of ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span>, which we have temporarily paused as discussed above, and Proclarix, and the development and commercialization of the Company&#8217;s current product candidates and future product candidates. In addition, as discussed more fully in Note&#160;5, if stockholder approval is not obtained by January&#160;1, 2025 with respect to the Series&#160;B Convertible Redeemable Preferred Stock issued in connection with the acquisition of Proteomedix, these shares become redeemable for cash at the option of the holders, and the Company currently does not have sufficient cash to redeem such shares.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Management&#8217;s plans for funding the Company&#8217;s operations include generating product revenue from sales of Proclarix, which may still be subject to further successful commercialization activities within certain jurisdictions, and ENTADFI, which is subject to further successful commercialization activities which we have temporarily paused as discussed above. Certain of the commercialization activities are outside of the Company&#8217;s control, including but not limited to, securing contracts with wholesalers and third<span class="nobreak">-party</span> payers, securing contracts with third<span class="nobreak">-party</span> logistics providers, and obtaining required licensure in various jurisdictions, as well as attempting to secure additional required funding through equity or debt financings if available. However, there are currently no commitments in place for further financing nor is there any assurance that such financing will be available to the Company on favorable terms, if at all. This creates significant uncertainty that the Company will have the funds available to be able to successfully launch ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> and expand commercialization of Proclarix. If the Company is unable to secure additional capital, it may be required to curtail any future clinical trials, development and/or commercialization of products and product candidates, and it may take additional measures to reduce expenses in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Because of historical and expected operating losses and net operating cash flow deficits, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for one year from the issuance of the consolidated financial statements, which is not alleviated by management&#8217;s plans. The consolidated financial statements have been prepared assuming the Company will continue as a going concern. These consolidated financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_GoingConcernAndManagementsPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_GoingConcernAndManagementsPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666109447216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;3 &#8212; Summary of Significant Accounting Policies</span></p>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Use of Estimates</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The preparation of the consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of </p></div><div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">revenue and expenses during the reporting periods. The most significant estimates in the Company&#8217;s consolidated financial statements relate to accounting for acquisitions, valuation of inventory, the useful life of the amortizable intangible assets, estimates of future cash flows used to evaluate impairment of intangible assets, accrued research and development expenses, assumptions related to the pension benefit obligation, stock<span class="nobreak">-based</span> compensation, the valuation of preferred stock, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in financial institutions, which, at times, exceed the Federal Depository Insurance Coverage limit for those maintained in the United&#160;States and exceed the Swiss Financial Market Supervisory Authority for those maintained in Switzerland. As of December&#160;31, 2023 and 2022, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Segment Information</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;), or decision<span class="nobreak">-making</span> group, in deciding how to allocate resources and in assessing performance. Prior to the acquisition of ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> during the quarter ended June&#160;30, 2023, the Company managed one distinct business segment, which was vaccine discovery and development. During the second quarter of 2023, as a result of the acquisition of ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span>, the Company operated in two business segments: research and development and commercial. During the third quarter of 2023, the Company deprioritized its vaccine discovery and development programs, and accordingly, as of December&#160;31, 2023, the Company was operating in one segment: commercial. Management&#8217;s determination of its operating segments is consistent with the financial information regularly reviewed by the CODM for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The distribution of revenue by geographical area was as follows:</p></div>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Years Ended <br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">United&#160;States</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-233">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-234">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Switzerland</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">58,465</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-235">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">58,465</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-236">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
				</tr>

		</table>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The distribution of long<span class="nobreak">-lived</span> assets by geographical area, which includes property and equipment and the Company&#8217;s right of use asset, was as follows:</p></div>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Years Ended <br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">United&#160;States</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,956</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,089</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Switzerland</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">198,240</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-237">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">209,196</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">14,089</span></p>	</td>
				</tr>

		</table><div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Foreign Currency Translation</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The financial statements of Proteomedix, the Company&#8217;s foreign subsidiary, are measured using the local currency, which is the Swiss Franc, as the functional currency. Assets and liabilities of this subsidiary are translated into U.S.&#160;dollars at exchange rates as of the consolidated balance sheet date. Equity is translated at historical exchange rates. Revenues and expenses are translated into U.S.&#160;dollars at average rates of exchange in effect during the period. The resulting cumulative translation adjustments have been recorded as a separate component of stockholders&#8217; equity, as accumulated other comprehensive income or loss. Foreign currency transaction gains and losses are included in the results of operations, and were not significant for the&#160;years ended December&#160;31, 2023, or 2022.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accounts receivable</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company performs periodic credit evaluations of its customers&#8217; financial condition and extends credit to virtually all of its customers on an uncollateralized basis. Credit losses to date have been insignificant and within management&#8217;s expectations. The Company provides an allowance for doubtful accounts that is based upon a review of outstanding receivables, historical collection information, expected future losses, and existing economic conditions. As of December&#160;31, 2023, there was no allowance for doubtful accounts. As of December&#160;31, 2023, substantially all of the Company&#8217;s accounts receivable are due from a single customer.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Inventories</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Inventories consist of product acquired in the ENTADFI and Proteomedix transactions. Inventories are stated at the lower of cost or net realizable value, with cost determined on a first<span class="nobreak">-in</span>, first<span class="nobreak">-out</span> basis, aside from inventories acquired in an asset acquisition or business combination, which are recorded at fair value. The Company periodically reviews the composition of inventory in order to identify excess, obsolete, slow<span class="nobreak">-moving</span> or otherwise non<span class="nobreak">-saleable</span> items taking into account anticipated future sales compared with quantities on hand, and the remaining shelf life of goods on hand. If non<span class="nobreak">-saleable</span> items are observed and there are no alternate uses for the inventory, the Company records a write<span class="nobreak">-down</span> to net realizable value in the period that the decline in value is first recognized. The Company recorded an impairment of inventory in the amount of approximately $1.2&#160;million during the year ended December&#160;31, 2023, as a result of the delay in launching ENTADFI and the Company&#8217;s decision to pause related commercialization activities.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Property and Equipment</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment consists of laboratory equipment, computers, and office furniture and fixtures, all of which are recorded at cost. Depreciation is recorded using the straight<span class="nobreak">-line</span> method over the respective useful lives of the assets ranging from <span style="-sec-ix-hidden: hidden-fact-250">two</span> to <span style="-sec-ix-hidden: hidden-fact-251">ten</span>&#160;years. Depreciation expense was approximately $7,000 for each of the&#160;years ended December&#160;31, 2023 and 2022 and is included in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Acquisitions</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluates acquisitions to first determine whether a set of assets acquired constitutes a business and should be accounted for as a business combination. If the assets acquired are not a business, the transaction is accounted as an asset acquisition in accordance with Accounting Standards Codification (&#8220;ASC&#8221;)&#160;805<span class="nobreak">-50</span>, <span class="Italic" style="font-style:italic;font-weight:normal;">Asset Acquisitions</span> (&#8220;ASC&#160;805<span class="nobreak">-50</span>&#8221;), which requires the acquiring entity to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, except for non<span class="nobreak">-qualifying</span> assets including financial assets such as inventory. Further, the cost of the acquisition includes the fair value of consideration transferred and direct transaction costs attributable to the acquisition. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. Contingent consideration payments in asset acquisitions are recognized when the contingency is determined to be probable and reasonably estimable. If the assets acquired are a business, the Company accounts for the transaction as a business combination. Business combinations are accounted for by using the acquisition method </p></div><div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective fair values. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Acquisition related expenses are expensed as incurred, and are included in selling, general and administrative expense in the consolidated statements of operations and comprehensive loss.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Goodwill and Other Intangible Assets</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Goodwill represents the excess of the cost of a business combination over the fair value of the net assets acquired. Goodwill and intangible assets deemed to have indefinite lives are not amortized but are subject to impairment tests on an annual basis, and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Goodwill is allocated to the reporting unit from which it was created. A reporting unit is an operating segment or sub<span class="nobreak">-segment</span> to which goodwill is assigned when initially recorded. The Company tests indefinite lived intangible assets for impairment, on an annual basis in the fourth quarter, or more frequently if an event occurs or circumstances indicate that the indefinite lived assets may be impaired. The Company may perform a qualitative assessment to determine whether it is more<span class="nobreak">-likely-than-not</span> that the fair value of a reporting unit is less than its carrying amount. If the Company determines this is the case, the Company then performs further quantitative analysis to identify and measure the amount of goodwill impairment loss to be recognized, if any. To perform its quantitative test, the Company compares the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of its net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. The Company did not test its goodwill or indefinite lived assets for impairment during the year ended December&#160;31, 2023, given that the acquisition date occurred after the annual testing date, and given that there were no impairment indicators from the date of acquisition through the end of the reporting period. The Company has determined that no impairment of its goodwill or indefinite lived intangible assets occurred as of December&#160;31, 2023.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Intangible assets with finite lives are reported at cost, less accumulated amortization, and are amortized over their estimated useful lives, starting when sales for the related product begin. Amortization is calculated using the straight<span class="nobreak">-line</span> method, and recorded within selling, general, and administrative expenses, or cost of revenue, depending on the nature and use of the asset.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the ordinary course of business, the Company has entered into certain license and asset purchase agreements. Potential milestone payments for development, regulatory, and commercial milestones are recorded when the milestone is probable of achievement. Upon a milestone being achieved, the associated milestone payment is capitalized and amortized over the remaining useful life for approved products, or expensed as research and development expense for milestones relating to products whose FDA approval has not yet been obtained.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company reviews long<span class="nobreak">-lived</span> assets, including intangible assets with finite useful lives, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable (a &#8220;triggering event&#8221;). Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the long<span class="nobreak">-lived</span> asset in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long<span class="nobreak">-lived</span> asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long<span class="nobreak">-lived</span> asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value. During the fourth quarter of 2023, the Company determined that there were certain triggering events that indicated that the carrying amount of the assets recorded in connection with the ENTADFI acquisition (see Note&#160;5) may not be fully recoverable. A related impairment loss of $14.7&#160;million was recorded during the year ended December&#160;31, 2023 (see Note&#160;4). The Company also recorded an impairment loss of </p></div><div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">approximately $267,000 during the year ended December&#160;31, 2023, related to implementation costs incurred under cloud computing hosting arrangements that were capitalized during the year. There were no other impairment losses on long<span class="nobreak">-lived</span> assets for the&#160;years ended December&#160;31, 2023 and 2022.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value Measurements</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S.&#160;GAAP establishes a three<span class="nobreak">-tier</span> fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level<span class="nobreak"> </span>1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level<span class="nobreak"> </span>2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level<span class="nobreak"> </span>3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. Financial instruments, including cash, inventory, accounts receivable, receivables from related party, accounts payable, accrued liabilities, operating lease liabilities, and notes payable are carried at cost, which management believes approximates fair value due to the short<span class="nobreak">-term</span> nature of these instruments.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of the contingent warrant liability that became issuable upon the closing of the private placements the Company closed on during 2022, the warrant inducement the Company closed on during 2023 (see Note&#160;9), and the subscription agreement liability that was recorded in connection with a subscription agreement (see Note&#160;8) are valued using significant unobservable measures and other fair value inputs, and are therefore classified as Level 3 financial instruments.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of financial instruments measured on a recurring basis is as follows:</p></div>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="11" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 59.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">As of December&#160;31, 2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Description</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 1</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 2</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 3</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contingent warrant liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,641</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-238">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-239">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,641</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subscription agreement liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">864,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-240">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-241">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">864,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">866,641</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-242">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-243">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">866,641</p>	</td>
				</tr>

		</table>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="9" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 59.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">As of December&#160;31, 2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Description</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 1</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 2</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 3</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contingent warrant liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,021</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-244">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-245">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,021</p>	</td>
				</tr>

		</table>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December&#160;31, 2023, in connection with the acquisition of Proteomedix, the Company recorded intangible assets, which were recognized at fair value (see Note&#160;5). None of the Company&#8217;s other non<span class="nobreak">-financial</span> assets or liabilities are recorded at fair value on a non<span class="nobreak">-recurring</span> basis. There were no transfers between levels during the periods presented.</p></div><div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the activity for the subscription agreement liability, using unobservable Level 3 inputs, for the year ended December&#160;31, 2023:</p></div>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Subscription</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Agreement</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Liability</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance at December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-246">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fair value upon issuance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">729,900</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in fair value</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">134,100</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance at December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">864,000</p>	</td>
				</tr>

		</table><p style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;"></p>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the activity for the contingent warrant liability, using unobservable Level 3 inputs, for the&#160;years ended December&#160;31, 2023 and 2022:</p></div>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Contingent</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Warrant</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Liability</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance at December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-247">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fair value at issuance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">75,431</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in fair value</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(61,410</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance at December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,021</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fair value at issuance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25,837</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Reclassification to equity</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(129,184</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in fair value</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,967</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance at December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,641</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Deferred Offering Costs</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company capitalizes certain legal, professional accounting and other third<span class="nobreak">-party</span> fees that are directly associated with in<span class="nobreak">-process</span> equity financing as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#8217; equity as a reduction of proceeds generated as a result of the offering. Should the in<span class="nobreak">-process</span> equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to expenses in the consolidated statements of operations and comprehensive loss.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for leases in accordance with ASC&#160;842, <span class="Italic" style="font-style:italic;font-weight:normal;">Leases</span>. The Company has one lease agreement for office space, which contains an initial term of two&#160;years with renewal options. The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Operating lease right of use assets and operating lease liabilities are recognized on the lease commencement date. Operating lease right of use assets represent the Company&#8217;s right to use an underlying asset for the estimated lease term and operating lease liabilities represent the Company&#8217;s present value of its future lease payments. In assessing its lease and determining its lease liability at lease commencement or upon modification, the Company was not able to readily determine the rate implicit for its lessee arrangements, and thus has used its incremental borrowing rate on a collateralized basis to determine the present value of the lease payments. The Company&#8217;s right of use asset is measured as the balance of the lease liability plus or minus any prepaid or accrued lease payments and any unamortized initial direct costs. The operating lease payments are recognized as lease expense on a straight<span class="nobreak">-line</span> basis over the lease term, and are included in selling, general and administrative expenses in the accompanying consolidated statements of </p></div><div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">operations and comprehensive loss. Lease payments included in the measurement of the lease liability are comprised of fixed payments. If the Company&#8217;s lease agreements include renewal option periods, the Company includes such renewal options in its calculation of the estimated lease term when it determines the options are reasonably certain to be exercised. When such renewal options are deemed to be reasonably certain, the estimated lease term determined under ASC&#160;842 will be greater than the non<span class="nobreak">-cancelable</span> term of the contractual arrangement.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Leases with an initial term of 12&#160;months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight<span class="nobreak">-line</span> basis over the lease term. The Company applies this policy to all underlying asset categories.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company additionally evaluates leases at their inception to determine if the leases are to be accounted for as an operating lease or a finance lease. Lease expense for operating leases is recognized on a straight<span class="nobreak">-line</span> basis over the lease term. Variable lease payments are recognized in the period in which the obligations for those payments are incurred. Lease expense for finance leases is bifurcated into two components, with the amortization expense component of the right<span class="nobreak">-of-use</span> asset recognized on a straight<span class="nobreak">-line</span> basis and the interest expense component recognized using the effective interest method over the lease term. The Company has no financing leases as of December&#160;31, 2023 or 2022.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Defined Benefit Pension Plan</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix sponsors a defined benefit pension plan (the &#8220;Swiss Plan&#8221;) covering its eligible Swiss employees. The Swiss Plan is government<span class="nobreak">-mandated</span> and provides retirement benefits based on employees&#8217;&#160;years of service and compensation levels. The Company recognizes an asset for the Swiss Plan&#8217;s overfunded status or a liability for underfunded status in its consolidated balance sheets. Additionally, the Company measures its plan&#8217;s assets and obligations that determine its funded status as of the end of the year and recognizes the changes in the funded status in the year in which the changes occur. Those changes are reported in accumulated other comprehensive loss in the accompanying consolidated statements of convertible redeemable preferred stock and stockholders&#8217; equity. The Company uses actuarial valuations to determine its pension and postretirement benefit costs and credits. The amounts calculated depend on a variety of key assumptions, including discount rates and expected return on plan assets. Current market conditions are considered in selecting these assumptions.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Collaborative Agreements</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company periodically enters into strategic alliance agreements with counterparties to produce products and/or provide services to customers. Alliances created by such agreements are not legal entities, have no employees, no assets and have no true operations. These arrangements create contractual rights and the Company accounts for these alliances as a collaborative arrangement by reporting costs incurred and reimbursements received from transactions within research and development expense within the consolidated statements of operations and comprehensive loss.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Revenue Recognition</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December&#160;31, 2023, the Company recorded approximately $59,000 of revenue, which was solely generated from Proteomedix development services from the period from the acquisition date of December&#160;15, 2023, through December&#160;31, 2023.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix provides a range of services to life sciences customers referred to as &#8220;Development Services&#8221; including testing for biomarker discovery, assay design and development. These Development Services are performed under individual statement of work (&#8220;SOW&#8221;) arrangements with specific deliverables defined by the customer. Development Services are generally performed on a time and materials basis. During the performance and through completion of the service to the customer in accordance with the SOW, the Company has the right to bill the customer for the agreed upon price and recognizes the Development Services revenue over the period estimated to complete the SOW.&#160;The Company generally identifies each SOW as a single performance obligation.</p></div><div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Completion of the service and satisfaction of the performance obligation under a SOW is typically evidenced by access to the data or test made available to the customer or any other form or applicable manner of delivery defined in the SOW.&#160;However, for certain SOWs under which work is performed pursuant to the customer&#8217;s highly customized specifications, the Company has the enforceable right to bill the customer for work completed, rather than upon completion of the SOW.&#160;For those SOWs, the Company recognizes revenue over a period of time during which the work is performed based on the expended efforts (inputs). As the performance obligation under the SOW is satisfied, any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed to the customer as of the date of the consolidated financial statements are recorded as contract assets and are included in prepaids and other current assets as of the financial statement date, and these amounts as of December&#160;31, 2023 are not significant. Amounts recorded in contract assets are reclassified to accounts receivable in our consolidated financial statements when the customer is invoiced according to the billing schedule in the contract. Accounts receivable was approximately $87,000 and $150,000 as of December&#160;15, 2023, the date of acquisition of Proteomedix (see Note&#160;5), and December&#160;31, 2023, respectively.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In circumstances where a SOW includes a variable consideration component, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on which method is expected to better predict the amount of consideration to which the Company will be entitled. The value of variable consideration is included in the transaction price if, and to the extent, it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are reassessed each reporting period, as required, and any adjustment required is recorded on a cumulative catch<span class="nobreak">-up</span> basis, which would affect revenue and net loss in the period of adjustment.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company expenses the cost of research and development as incurred. Research and development expenses include costs incurred in funding research and development activities, license fees, and other external costs. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company&#8217;s behalf will be expensed as services are rendered or when the milestone is achieved. When billing terms under research and development contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end to those third parties. Accrual estimates are based on several factors, including the Company&#8217;s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs (see Note&#160;6).</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic&#160;730<span class="nobreak">-10-25-1</span>, <span class="Italic" style="font-style:italic;font-weight:normal;">Research and Development,</span> costs incurred in obtaining licenses and patent rights are charged to research and development expense if the technology licensed has not reached commercial feasibility and has no alternative future use. The licenses purchased by the Company (see Note&#160;6) require substantial completion of research and development, regulatory and marketing approval efforts to reach commercial feasibility and have no alternative future use. Accordingly, the total purchase price for the licenses acquired is reflected as research and development on the Company&#8217;s consolidated statements of operations and comprehensive loss.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Contingencies</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Accruals are recorded for loss contingencies when it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been </p></div><div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">accrued previously. Considering facts known at the time of the assessment, the Company determines whether potential losses are considered reasonably possible or probable and whether they are estimable. Based upon this assessment, the Company carries out an evaluation of disclosure requirements and considers possible accruals in the consolidated financial statements.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company expenses stock<span class="nobreak">-based</span> compensation to employees and non<span class="nobreak">-employees</span> over the requisite service period based on the estimated grant<span class="nobreak">-date</span> fair value of the awards. Stock<span class="nobreak">-based</span> awards to employees with graded<span class="nobreak">-vesting</span> schedules are recognized, using the accelerated attribution method, on a straight<span class="nobreak">-line</span> basis over the requisite service period for each separately vesting portion of the award.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company estimates the fair value of stock option grants using the Black<span class="nobreak">-Scholes</span> option pricing model and the assumptions used in calculating the fair value of stock<span class="nobreak">-based</span> awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Expected Term</span>&#160;&#8212;&#160;The expected term of options represents the period that the Company&#8217;s stock<span class="nobreak">-based</span> awards are expected to be outstanding based on the simplified method, which is the half<span class="nobreak">-life</span> from vesting to the end of its contractual term. The simplified method is used as the Company has insufficient historical information to provide a basis for an estimate of the expected term.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Expected Volatility</span>&#160;&#8212;&#160;Volatility is a measure of the amount by which the Company&#8217;s share price has historically fluctuated or is expected to fluctuate (i.e., expected volatility) during a period. Due to the lack of an adequate history of a public market for the trading of the Company&#8217;s common stock and a lack of adequate company<span class="nobreak">-specific</span> historical and implied volatility data, the Company computes stock price volatility over expected terms based on comparable companies&#8217; historical common stock trading prices. For these analyses, the Company has selected companies with comparable characteristics, including enterprise value, risk profiles, and position within the industry.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Common Stock Fair Value</span>&#160;&#8212;&#160;The fair value of the common stock underlying the Company&#8217;s stock options is based on the closing price of the Company&#8217;s common stock, as reported by the Nasdaq Capital Market, on the grant date of the award.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Risk</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Free</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Interest Rate</span>&#160;&#8212;&#160;The Company bases the risk<span class="nobreak">-free</span> interest rate on the implied yield available on U.S.&#160;Treasury securities with a remaining term commensurate with the estimated expected term.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Expected Dividend</span>&#160;&#8212;&#160;The Company has never declared or paid any cash dividends on its shares of common stock and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company recognizes forfeitures of equity awards as they occur.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the jurisdictions and&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in operations in the period that includes the enactment date. Deferred tax assets are reduced to estimated amounts expected to be realized by the use of a valuation allowance.</p></div><div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company is required to report all components of comprehensive loss, including net loss, in the accompanying consolidated financial statements in the period in which they are recognized. Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non<span class="nobreak">-owner</span> sources. The Company&#8217;s comprehensive loss for the year ended December&#160;31, 2023 is comprised of net loss, the effect of currency translation adjustments, and the change in pension benefit obligation. Net loss and comprehensive loss were the same for the year ended December&#160;31, 2022.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Financial instruments</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company determines the accounting classification of financial instruments that are issued, including its warrants and a subscription agreement, as either liability or equity, by first assessing whether the financial instruments are freestanding financial instruments, and if they meet liability classification in accordance with ASC&#160;480, <span class="Italic" style="font-style:italic;font-weight:normal;">Distinguishing Liabilities from Equity</span>, (&#8220;ASC&#160;480&#8221;), and then in accordance with ASC&#160;815<span class="nobreak">-40</span>, <span class="Italic" style="font-style:italic;font-weight:normal;">Derivatives and Hedging&#160;&#8212;&#160;Contracts in Entity&#8217;s Own Equity </span>(&#8220;ASC&#160;815<span class="nobreak">-40</span>&#8221;). Under ASC&#160;480<span class="nobreak">-10</span>, financial instruments are considered liability<span class="nobreak">-classified</span> if the instruments are mandatorily redeemable, obligate the issuer to settle the instruments or the underlying shares by paying cash or other assets, or must or may require settlement by issuing a variable number of shares.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If the instruments do not meet liability classification under ASC&#160;480, the Company assesses the requirements under ASC&#160;815<span class="nobreak">-40</span>, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the financial instruments do not require liability classification under ASC&#160;815<span class="nobreak">-40</span>, in order to conclude equity classification, the Company assesses whether the instruments are indexed to the Company&#8217;s common stock and whether the instruments are classified as equity under ASC&#160;815<span class="nobreak">-40</span> or other applicable GAAP.&#160;After all relevant assessments are made, the Company concludes whether the instruments are classified as liability or equity. Liability<span class="nobreak">-classified</span> instruments are required to be accounted for at fair value both on the date of issuance and on subsequent accounting period ending dates, with all changes in fair value after the issuance date recorded as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. Equity<span class="nobreak">-classified</span> instruments are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Preferred Stock</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company applies the guidance enumerated in ASC&#160;480, when determining the classification and measurement of preferred stock. Preferred stock subject to mandatory redemption, if any, is classified as a liability and is measured at fair value. The Company classifies conditionally redeemable preferred stock, which includes preferred stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control, as temporary equity. At all other times, the Company classifies its preferred stock in stockholders&#8217; equity.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Treasury Stock</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company records treasury stock activities under the cost method whereby the cost of the acquired stock is recorded as treasury stock.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Net Loss Per Share</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Basic loss per share is computed by dividing the net loss applicable to common shares by the weighted average number of common shares outstanding during the period. The weighted average number of shares of common stock outstanding includes (i)&#160;pre<span class="nobreak">-funded</span> warrants because their exercise requires only nominal consideration for delivery of shares and (ii)&#160;the shares held in abeyance because there is no consideration required for delivery of the shares; </p></div><div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">it does not include any potentially dilutive securities or any unvested restricted stock of common stock. Certain restricted shares, although classified as issued and outstanding at December&#160;31, 2023 are considered contingently returnable until the restrictions lapse and will not be included in the basic net loss per share calculation until the shares are vested. Unvested shares of the Company&#8217;s restricted stock do not contain non<span class="nobreak">-forfeitable</span> rights to dividends and dividend equivalents. Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the Company&#8217;s Series&#160;A preferred stock, warrants, unvested restricted stock, and stock options. Diluted loss per share excludes the shares issuable upon the conversion of Series&#160;A preferred stock, as well as unvested restricted stock, common stock options and warrants, from the calculation of net loss per share if their effect would be anti<span class="nobreak">-dilutive</span>.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The two<span class="nobreak">-class</span> method is used to determine earnings per share based on participation rights of participating securities in any undistributed earnings. Each preferred stock that includes rights to participate in distributed earnings is considered a participating security and the Company uses the two<span class="nobreak">-class</span> method to calculate net income available to the Company&#8217;s common stockholders per common share&#160;&#8212;&#160;basic and diluted.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following securities were excluded from the computation of diluted shares outstanding for the periods presented, as they would have had an anti<span class="nobreak">-dilutive</span> impact on the Company&#8217;s net loss:</p></div>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Years Ended <br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,904,830</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,392,654</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Warrants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,899,661</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,264,274</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">256,580</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-248">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock issuable upon conversion of Series&#160;A preferred stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,709,935</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-249">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">15,771,006</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">6,656,928</span></p>	</td>
				</tr>

		</table>
		<div style="-sec-ix-redline:true;-keep: true"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">New Accounting Pronouncement</span><span class="Bold" style="font-style:normal;font-weight:bold;">s</span></p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In November&#160;2023, the FASB issued ASU No.&#160;2023<span class="nobreak">-07</span>, Segment Reporting (Topic&#160;280): <span class="Italic" style="font-style:italic;font-weight:normal;">Improvements to Reportable Segment Disclosures</span>. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (&#8220;CODM&#8221;) and included within each reported measure of a segment&#8217;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment&#8217;s profit or loss in assessing segment performance and deciding how to allocate resources. This ASU is effective for annual periods beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2023, the FASB issued ASU No.&#160;2023<span class="nobreak">-09</span>, Income Taxes (Topic&#160;740<span class="Italic" style="font-style:italic;font-weight:normal;">): Improvements to Income Tax Disclosures</span>. This ASU requires disclosure of specific categories in the rate reconciliation and additional information for reconciling items that meet a quantitative threshold. The amendment also includes other changes to improve the effectiveness of income tax disclosures, including further disaggregation of income taxes paid for individually significant jurisdictions. This ASU is effective for annual periods beginning after December&#160;15, 2024. Adoption of this ASU should be applied on a prospective basis. Early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying consolidated financial statements.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666109158144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Details</a></td>
<td class="text"><p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;4 &#8212; Balance Sheet Details</span></p>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Inventories</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Inventories primarily relate to ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> product and consisted of the following as of December&#160;31, 2023 and 2022:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Raw materials</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">139,208</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-252">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Work-in-process</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">194,805</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-253">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Finished goods</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">30,039</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-254">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">364,052</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-255">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
				</tr>

		</table>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Prepaid Expenses and Other Current Assets</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Prepaid expenses and other current assets consisted of the following as of December&#160;31, 2023 and 2022:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid insurance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">122,004</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">148,789</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid regulatory fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">312,551</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-256">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">89,195</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">231,981</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid professional fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">70,708</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-257">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">175,695</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">88,462</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">770,153</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">469,232</span></p>	</td>
				</tr>

		</table>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Intangible Assets</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Intangible assets, which were recorded during the year ended December&#160;31, 2023 in connection with the ENTADFI and Proteomedix acquisitions (see Note&#160;5), is comprised of customer relationships, product rights for developed technology, and a trade name, and consisted of the following as of December&#160;31, 2023:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Cost</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Impairment</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Effect of</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Currency</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Translation</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Balance</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cost basis:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Trade name</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,018,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-258">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">294,739</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,312,739</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Product rights for developed technology</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">28,447,771</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(14,610,128</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">344,514</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,182,157</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Customer relationships</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,891,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-259">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">61,803</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,952,803</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">39,356,771</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(14,610,128</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">701,056</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">25,447,699</span></p>	</td>
				</tr>

		</table>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Amortization</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Balance</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Accumulated amortization:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Trade name</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-260">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-261">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Product rights for developed technology</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(31,213</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(31,213</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Customer relationships</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,599</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,599</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(36,812</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(36,812</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Intangible assets, net</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">25,410,887</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>

		</table><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The finite lived intangible assets held by the Company, which includes customer relationships and product rights for developed technology, are being amortized over their estimated useful lives, which is 15&#160;years for customer relationships, and 15 and 6&#160;years for product rights for developed technology related to Proclarix and ENTADFI, respectively. Amortization expense related to intangible assets was approximately $37,000 for the year ended December&#160;31, 2023, of which approximately $31,000 and $6,000 was recorded as cost of revenue and selling, general, and administrative expenses, respectively, in the accompanying consolidated statements of operations and comprehensive loss.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the fourth quarter of 2023, the Company determined that there were certain triggering events that indicated that the carrying amount of the assets recorded in connection with the ENTADFI acquisition (see Note&#160;5) may not be fully recoverable. Specifically, as a result of the Proteomedix acquisition (see Note&#160;5) and continued significant cash constraints, the Company decided to pause the commercialization of ENTADFI until a later date, and consider strategic alternatives, which combined, decreased the cash flows expected to be generated from these assets. The Company performed an undiscounted cash flow analysis over the ENTADFI asset group and determined that the carrying value of the asset group is not recoverable. The Company then estimated the fair value of the asset group to measure the impairment loss. Significant assumptions used to determine this non<span class="nobreak">-recurring</span> fair value measurement include projected sales driven by market share and product sales price estimates, associated expenses, growth rates, the discount rate used to measure the fair value of the net cash flows associated with this asset group, as well as Management&#8217;s estimates of the probability of each potential strategic alternative taking place. The Company recorded an impairment charge of $14.7&#160;million during the year ended December&#160;31, 2023, which was allocated on a pro rata basis across the assets within the asset group as follows: approximately $14.6&#160;million and approximately $0.1&#160;million was allocated to the product rights intangible asset and other assets, respectively. After recording this impairment charge, the long<span class="nobreak">-lived</span> assets in the ENTADFI asset group have a remaining carrying amount of approximately $3.3&#160;million as of December&#160;31, 2023. In addition, the Company also recorded an impairment charge on acquired ENTADFI inventory, see Note&#160;3.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Future annual amortization expense related to the Company&#8217;s finite lived intangible assets is as follows as of December&#160;31, 2023:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Years ending December&#160;31,</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,012,870</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,326,837</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2026</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,326,837</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2027</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,326,837</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2028</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,326,837</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thereafter</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,777,930</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">16,098,148</span></p>	</td>
				</tr>

		</table>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, the weighted<span class="nobreak">-average</span> remaining amortization period for intangible assets was approximately <span style="-sec-ix-hidden: hidden-fact-265">13.5</span>&#160;years.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Trade names, which do not have legal, regulatory, contractual, competitive, economic, or other factors that limit the useful lives are considered indefinite lived assets and are not amortized but are tested for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. As of December&#160;31, 2023, $9.3&#160;million of intangible assets relate to a trade name that has been identified as having an indefinite life.</p><p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Goodwill</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Goodwill was recorded during the year ended December&#160;31, 2023, in connection with the Proteomedix acquisition (see Note&#160;5), and consisted of the following as of December&#160;31, 2023:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance as of December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-262">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">PMX Transaction goodwill</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">53,914,055</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effect of currency translation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,762,087</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance as of December&#160;31, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">55,676,142</span></p>	</td>
				</tr>

		</table>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Expenses</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Accrued expenses consisted of the following as of December&#160;31, 2023 and 2022:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">847,747</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">487,579</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,132,859</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued deferred offering costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">125,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">125,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued professional fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">550,415</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-263">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued implementation fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">93,787</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-264">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other accrued expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">265,849</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">125,922</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued franchise taxes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">60,530</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">177,600</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2,199,867</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2,409,128</span></p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666109249088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisitions</a></td>
<td class="text"><p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;5 &#8212; Acquisitions</span></p>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">ENTADFI</span><span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;19, 2023, the Company and Veru, Inc. (&#8220;Veru&#8221;) entered into an Asset Purchase Agreement (the &#8220;&#160;Veru APA&#8221;). Pursuant to, and subject to the terms and conditions of, the Veru APA, the Company purchased substantially all of the assets related to Veru&#8217;s ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> product (&#8220;ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span>&#8221;) (the &#8220;Transaction&#8221;) for a total possible consideration of $100&#160;million.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with the Veru APA, the Company agreed to provide Veru with initial consideration totaling $20.0&#160;million, consisting of (i)&#160;$6.0&#160;million paid upon the closing of the Transaction on April&#160;19, 2023, (ii)&#160;an additional $4.0&#160;million in the form of a non<span class="nobreak">-interest</span> bearing note payable due on September&#160;30, 2023, and (iii)&#160;an additional $10.0&#160;million in the form of two $5.0&#160;million non<span class="nobreak">-interest</span> bearing notes payable, each due on April&#160;19, 2024 and September&#160;30, 2024.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, the terms of the Veru APA require the Company to pay Veru up to an additional $80.0&#160;million based on the Company&#8217;s net sales of ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> after closing (the &#8220;Milestone Payments&#8221;). The Milestone Payments are payable as follows: (i)&#160;$10.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> of $100.0&#160;million during a calendar year, (ii)&#160;$20.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> of $200.0&#160;million during a calendar year, and (3)&#160;$50.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> of $500.0&#160;million during a calendar year.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Transaction, the Company also assumed royalty and milestone obligations under an asset purchase agreement for tadalafil<span class="nobreak">-finasteride</span> combination entered into by Veru and Camargo Pharmaceutical Services, LLC on December&#160;11, 2017 (the &#8220;Camargo Obligations&#8221;). The Camargo Obligations assumed by the Company include a 6% royalty on all sales of tadalafil<span class="nobreak">-finasteride</span> and sales milestone payments of up to $22.5&#160;million, payable </p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">to Camargo as follows: (i)&#160;$5.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> of $100.0&#160;million during a calendar year, (ii)&#160;$7.5&#160;million is payable upon the first time the Company achieves net sales from ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> of $200.0&#160;million during a calendar year, and (3)&#160;$10.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> of $300.0&#160;million during a calendar year.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On September&#160;29, 2023, the Company entered into an amendment to the Veru APA (the &#8220;Veru APA Amendment&#8221;), which provides that the $4.0&#160;million note payable originally due on September&#160;30, 2023 was deemed paid and fully satisfied upon (1)&#160;the payment to the Seller of $1.0&#160;million in cash on September&#160;29, 2023, and (2)&#160;the issuance to the Seller by October&#160;3, 2023 of 3,000<span class="nobreak"> </span>shares of Series&#160;A Convertible Preferred Stock (the &#8220;Series&#160;A Preferred Stock&#8221;) of the Company (see Note&#160;9). Pursuant to the Veru APA Amendment, the Series&#160;A Preferred Stock will convert to common stock of the Company one year from the date of issuance if the required stockholder approval is obtained. The Series&#160;A Preferred Stock, which was issued to the Seller on October&#160;3, 2023 is initially convertible, in the aggregate, into 5,709,935<span class="nobreak"> </span>shares of the Company&#8217;s common stock, subject to adjustment and certain stockholder approval limitations specified in the Certificate of Designations. Pursuant to the Veru APA Amendment, the Company agreed to use commercially reasonable efforts to obtain such stockholder approval by December&#160;31, 2023, however, such shareholder approval was not obtained as of December&#160;31, 2023. The Company also agreed to include the shares of common stock issuable upon conversion of the Series&#160;A Preferred Stock in the next resale registration statement filed with the SEC.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Also, in connection with the Transaction, and pursuant to the Veru APA, the Company entered into non<span class="nobreak">-competition</span> and non<span class="nobreak">-solicitation</span> agreements (the &#8220;Non<span class="nobreak">-Competition</span> Agreements&#8221;) with two of Veru&#8217;s key stockholders and employees (the &#8220;Restricted Parties&#8221;). The Non<span class="nobreak">-Competition</span> Agreements generally prohibit the Restricted Parties from either directly or indirectly engaging in the Restricted Business (as such term is defined in the Veru APA) for a period of <span style="-sec-ix-hidden: hidden-fact-266">five</span>&#160;years from the closing of the Transaction.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The acquisition of ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> has been accounted for as an asset acquisition in accordance with ASC&#160;805<span class="nobreak">-50</span> because substantially all of the fair value of the assets acquired is concentrated in a single asset, the ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> product rights. The ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> products rights consist of trademarks, regulatory approvals, and other records, and are considered a single asset as they are inextricably linked.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the aggregate consideration transferred for the assets acquired by the Company in connection with the Veru APA:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Consideration</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Transferred</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Consideration transferred at closing</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,000,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fair value of notes payable issued</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12,947,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Transaction costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">79,771</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total consideration transferred</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">19,026,771</span></p>	</td>
				</tr>

		</table>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of the non<span class="nobreak">-interest</span> bearing notes payable was estimated using a net present value model using discount rates averaging 8.2%. The resulting fair value is being accreted to the face value of the notes, through the respective maturity dates. Management evaluated the Milestone Payments and determined that at the close of the Transaction, they are not considered probable, and as such, the Company did not recognize any amount related to the Milestone Payments in the consideration transferred.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the assets acquired with the Veru APA:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Assets</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Recognized</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Inventory</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,120,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> Intangible</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17,906,771</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total fair value of identifiable assets acquired</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">19,026,771</span></p>	</td>
				</tr>

		</table><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with ASC&#160;805<span class="nobreak">-50</span>, the acquired inventory was recorded at fair value. The remaining consideration transferred was allocated to the ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> intangible asset, which will be amortized over its estimated useful life, starting when ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> sales begin. Acquired inventory is comprised of work<span class="nobreak">-in-process</span> and raw materials. The fair value of work<span class="nobreak">-in-process</span> inventory was determined based on an estimated sales price of the finished goods, adjusted for costs to complete the manufacturing process, costs of the selling effort, a reasonable profit allowance for the remaining manufacturing and selling effort, and an estimate of holding costs, and resulted in a fair value adjustment of approximately $0.3&#160;million. The fair value of raw materials was determined to approximate replacement cost. The Company recorded an impairment charge on the ENTADFI asset group of $14.7&#160;million during the fourth quarter of 2023 (see Note&#160;4), as well as an impairment charge on the ENTADFI acquired inventory of approximately $1.2&#160;million, which included impairment of 100% of the acquired work<span class="nobreak">-in-process</span> inventory.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Management evaluated the Camargo Obligations and determined that at the close of the Transaction, the related sales milestone payments are not considered probable, and as such, the Company did not recognize any related liability at the date of the Transaction. In addition, royalties under the Camargo Obligations will be recorded as cost of sales, as the related sales are generated and recognized.</p>
		<p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">WraSer:</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On June&#160;13, 2023 (the &#8220;Execution Date&#8221;), the Company entered into an asset purchase agreement with WraSer, LLC, and affiliates (the &#8220;WraSer Seller&#8221;) (the &#8220;WraSer APA&#8221;). Pursuant to, and subject to the terms and conditions of, the WraSer APA, on the WraSer Closing Date (as defined below) the Company was to purchase six FDA<span class="nobreak">-approved</span> pharmaceutical assets across several indications, including cardiology, otic infections, and pain management (the &#8220;WraSer Assets&#8221;).</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the WraSer APA, the Company was to purchase the WraSer Assets for (i)&#160;$3.5&#160;million in cash at signing of the WraSer APA; (ii)&#160;$4.5&#160;million in cash on the later of (x)&#160;90&#160;days after the signing of the WraSer APA or (y)&#160;the date that all closing conditions under the WraSer APA are met or otherwise waived (the &#8220;WraSer Closing Date&#8221;); (iii)&#160;1.0&#160;million shares of the Company&#8217;s common stock (the &#8220;Closing Shares&#8221;) issuable on the WraSer Closing Date, and (iv)&#160;$500,000 in cash one year from the WraSer Closing Date.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In conjunction with the WraSer APA, the Company and the WraSer Seller entered into a Management Services Agreement (the &#8220;MSA&#8221;) on the Execution Date. Pursuant to the terms of the MSA, the Company will act as the manager of the WraSer Seller&#8217;s business during the period between the Execution Date and the WraSer Closing Date. During this period, the Company will make advances to WraSer, if needed. If, on the WraSer Closing Date, the WraSer Seller&#8217;s cash balance is in excess of the target amount (&#8220;Cash Target&#8221;) specified in the MSA, the Company will apply that excess to the $4.5&#160;million cash payment due upon closing. Conversely, if there is a shortfall, the Company will be required to remit the difference to the WraSer Seller over time.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The WraSer APA can be terminated prior to the closing upon agreement with all parties or upon breach of contract of either party, uncured within 20&#160;days of notice. If the WraSer APA is terminated upon agreement with all parties or upon uncured breach of contract by the Company, the initial $3.5&#160;million payment is retained by the WraSer Seller. If it is determined that there is an uncured breach of contract by the WraSer Seller, and the WraSer APA is terminated, the Company will have an unsecured claim against WraSer for the $3.5&#160;million payment made by the Company upon execution of the WraSer APA.&#160;The closing of the transaction is subject to certain customary closing conditions, including submission of the FDA transfer documentation to transfer ownership of the acquired product regulatory approvals to the Company.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Management evaluated the terms of the WraSer APA and the WraSer MSA, and determined that, at the Execution Date, control under the provisions of ASC&#160;805, <span class="Italic" style="font-style:italic;font-weight:normal;">Business Combinations </span>(&#8220;ASC&#160;805&#8221;), did not transfer to the Company; if the transaction closes, control will transfer then, and the acquisition date will be the closing date. Management further evaluated the requirements pursuant to ASC&#160;810, <span class="Italic" style="font-style:italic;font-weight:normal;">Consolidations</span>, and determined based on the terms of the MSA, and the Company&#8217;s involvement in the WraSer Seller&#8217;s business, that the WraSer Seller is a variable interest entity (&#8220;VIE&#8221;) to the Company. Management determined that the Company is not the primary beneficiary of </p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the VIE as the WraSer APA and MSA do not provide the Company with the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance. While the Company was involved in the&#160;day<span class="nobreak">-to-day</span> business activities of the VIE until WraSer filed for relief under Chapter&#160;11 of the U.S.&#160;Bankruptcy Court (see below), the WraSer Seller had to approve substantially all business activities and transactions that significantly impact the economic performance of WraSer during the term of the MSA.&#160;Additionally, the Company is not required to absorb the losses of WraSer if the WraSer APA does not close. As such, the Company was not required to consolidate WraSer in the Company&#8217;s financial statements as of and during the year ended December&#160;31, 2023.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company recorded the initial $3.5&#160;million payment as a deposit. The Company does not have any liabilities recorded as of December&#160;31, 2023 associated with its variable interest in the WraSer Seller, and its exposure to the WraSer Seller&#8217;s losses is limited to no more than the shortfall, if any, of the Cash Target amount of approximately $1.1&#160;million compared to the WraSer Seller&#8217;s cash balance on the WraSer Closing Date.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On September&#160;26, 2023, WraSer and its affiliates filed for relief under chapter 11 of the U.S.&#160;Bankruptcy Code in the Bankruptcy Court. On October&#160;4, 2023, the parties agreed to amend the WraSer APA, which was subject to court approval. Shortly after its bankruptcy filing, WraSer filed a motion seeking approval of the WraSer APA as amended. The amendment, among other things, eliminates the $500,000 post<span class="nobreak">-closing</span> payment due June&#160;13, 2024 and staggers the $4.5&#160;million cash payment that the Company would otherwise have to pay at closing to: (i)&#160;$2.2&#160;million to be paid at closing, (ii)&#160;$2.3&#160;million, to be paid in monthly installments of $150,000 commencing January&#160;2024 and (iii)&#160;789<span class="nobreak"> </span>shares of Series&#160;A Preferred Stock to be paid at closing. The amendment also reduced the number of products the Company was acquiring by excluding pain medications and including only (i)&#160;Ciprofloxacin 0.3% and Fluocinolone 0.025% Otic Solution, under the trademark OTOVEL and its Authorized Generic Version approved under US FDA NDA No. 208251, (ii)&#160;Ciprofloxacin 0.2% Otic solution, under the trademark CETRAXAL, and (iii)&#160;Vorapaxar Sulfate tablets under the trademark Zontivity approved under US FDA NDA N204886.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In October&#160;2023, WraSer alerted the Company that its sole manufacturer for the active pharmaceutical ingredient (&#8220;API&#8221;) for Zontivity, the key driver for the WraSer acquisition, would no longer manufacture the API for Zontivity. The Company believes that this development constituted a Material Adverse Effect under the WraSer APA and the WraSer MSA, enabling the Company to terminate the WraSer APA and the WraSer MSA.&#160;On October&#160;20, 2023, the Company filed a motion for relief from the automatic stay in the Bankruptcy Court so that the Company can exercise the termination rights under the WraSer APA, as amended. On December&#160;18, 2023, the Bankruptcy Court entered into an Agreed Order lifting the automatic stay to enable the Company to exercise its rights to terminate the WraSer APA and the WraSer MSA.&#160;On December&#160;21, 2023, the Company filed a Notice with the Bankruptcy Court terminating the WraSer APA and the WraSer MSA.&#160;WraSer has advised the Company that it does not believe that a Material Adverse Effect occurred. Due to the WraSer bankruptcy filing and the Company&#8217;s status as an unsecured creditor of WraSer, it is unlikely that the Company will recover the $3.5&#160;million initial payment made, or any costs and resources in connection with services provided by the Company under the WraSer MSA, and therefore the Company recorded a loss on impairment for the $3.5&#160;million deposit during the year ended December&#160;31, 2023.</p>
		<p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Proteomedix</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2023 (the &#8220;Acquisition Date&#8221;), Onconetix entered into a Share Exchange Agreement (the &#8220;Share Exchange Agreement&#8221;) with Proteomedix and each of the holders of outstanding capital stock or Proteomedix convertible securities (other than Proteomedix stock options) (collectively the &#8220;Sellers&#8221;), pursuant to which the Company acquired 100% of the outstanding common shares and voting interest of Proteomedix, through the issuance of 3,675,414<span class="nobreak"> </span>shares of common stock and 2,696,729<span class="nobreak"> </span>shares of Series&#160;B Convertible Preferred Stock (the &#8220;PMX Transaction&#8221;).</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Subject to any requirements related to the Committee on Foreign Investment in the United&#160;States, upon approval by the requisite vote of stockholders of Onconetix at the Special Meeting of the Stockholders (&#8220;Stockholder Approval&#8221;), each share of Series&#160;B Convertible Redeemable Preferred Stock (&#8220;Series&#160;B Preferred Stock&#8221;) shall automatically </p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">convert into 100<span class="nobreak"> </span>shares of common stock in accordance with the terms of the Series&#160;B Certificate of Designation (the &#8220;Conversion&#8221;). If Stockholder Approval is not obtained by January&#160;1, 2025, Onconetix may, at the option of the holders, be obligated to cash settle the Series&#160;B Preferred Stock. The Series&#160;B Preferred Stock outstanding as a result of the PMX Transaction is convertible into 269,672,900<span class="nobreak"> </span>shares of common stock.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The consummation (the &#8220;Closing&#8221;) of the PMX Transaction was subject to customary closing conditions and the agreement to enter into a subscription agreement (see Note&#160;8) with Altos Ventures, a shareholder of Proteomedix, prior to the closing of the PMX Transaction (the &#8220;PMX Investor&#8221;).</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In addition, each option to purchase shares of Proteomedix (each, a &#8220;Proteomedix Stock Option&#8221;) outstanding immediately before the Closing, whether vested or unvested, remains outstanding until the Conversion unless otherwise terminated in accordance with its terms. At the Conversion, each outstanding Proteomedix Stock Option, whether vested or unvested, shall be assumed by Onconetix and converted into the right to receive (a)&#160;an option to acquire shares of common stock (each, an &#8220;Assumed Option&#8221;) or (b)&#160;such other derivative security as Onconetix and Proteomedix may agree, subject in either case to substantially the same terms and conditions as were applicable to such Proteomedix Stock Option immediately before the Closing. Each Assumed Option shall: (i)&#160;represent the right to acquire a number of shares of common stock equal to the product of (A)&#160;the number of Proteomedix common shares that were subject to the corresponding Proteomedix Option immediately prior to the Closing, multiplied by (B)&#160;the Exchange Ratio (as defined in the Share Exchange Agreement&#8221;); and (ii)&#160;have an exercise price (as rounded down to the nearest whole cent) equal to the quotient of (A)&#160;the exercise price of the corresponding Proteomedix Option, divided by (B)&#160;the Exchange Ratio.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Management determined that the PMX Transaction was a business combination as defined within ASC&#160;805<span class="Italic" style="font-style:italic;font-weight:normal;">,</span> and that Onconetix was the accounting acquirer. The Company determined that Onconetix was the accounting acquirer based on the guidance contained within ASC&#160;805<span class="nobreak">-10</span>. The significant factors that led to the Company&#8217;s conclusion were (i)&#160;the Company obtained 100% of the outstanding common stock and voting interest of PMX, (ii)&#160;at closing of the PMX Transaction, the PMX shareholders were issued approximately 17% of Onconetix&#8217;s outstanding common stock and none of the former PMX shareholders held more than 5% of Onconetix&#8217;s common stock individually, (iii)&#160;the composition of executive management and the governing body did not change sufficiently to give PMX or its former shareholders control over these functions within Onconetix, and (iv)&#160;Onconetix was significantly larger when considering both total assets and operations. As a result, the Company has applied purchase accounting as of the Closing of the PMX Transaction. The assets, liabilities, and non<span class="nobreak">-controlling</span> interest of Proteomedix were recognized at fair value as of the Closing and the results of its operations have been included within Onconetix&#8217;s consolidated statements of operations and comprehensive loss from that date forward.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnosis. Proteomedix has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The Company expects Proteomedix&#8217;s diagnostic expertise to complement its existing prostate related treatment portfolio.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The assets acquired and liabilities assumed are recognized provisionally in the accompanying consolidated balance sheets at their estimated fair values as of the acquisition date. The initial accounting for the business combination is not complete as the Company is in the process of obtaining additional information for the valuation of acquired intangible assets and deferred tax liabilities. The provisional amounts are subject to change to the extent that additional information is obtained about the facts and circumstances that existed as of the acquisition date. Under U.S.&#160;GAAP, the measurement period shall not exceed one year from the acquisition date and the Company will finalize these amounts no later than December&#160;15, 2024. The estimated fair values as of the acquisition date are based on information that existed as of the acquisition date. During the measurement period the Company may adjust provisional amounts recorded for assets acquired and liabilities assumed to reflect new information that the Company has subsequently obtained regarding facts and circumstances that existed as of the acquisition date.</p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The acquisition<span class="nobreak">-date</span> fair value of the consideration transferred totaled approximately $65.1&#160;million, which consisted of the following:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Consideration</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Transferred</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">875,484</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;B convertible preferred stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">64,236,085</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total consideration transferred</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">65,111,569</span></p>	</td>
				</tr>

		</table>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of the Company&#8217;s common shares issued as consideration was based on the closing price of the Company&#8217;s common stock as of the Acquisition Date. The fair value of the Series&#160;B Preferred Stock issued as consideration was based on the underlying fair value of the number of common shares that the Series&#160;B Preferred Stock converts into, also based on the closing price of the Company&#8217;s common stock as of the Acquisition Date.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of the Proteomedix stock options assumed as part of the PMX Transaction was determined using a Black<span class="nobreak">-Scholes</span> option pricing model with the following significant assumptions:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercise price</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">$1.15&#160;&#8211;&#160;28.83</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock price</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">128.11</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Term (years)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0.17&#160;&#8211;&#160;3.59</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected stock price volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">90%</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free rate of interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">4.07%&#160;&#8211;&#160;5.47%</p>	</td>
				</tr>

		</table>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed at the acquisition date:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Net Assets</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Recognized</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,056,578</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">87,445</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Inventories</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">80,593</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid expenses and other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">114,615</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right of use asset</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">149,831</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39,779</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Trade name</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,018,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Customer relationships</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,891,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Product rights for developed technology</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,541,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Goodwill</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">53,914,055</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total assets acquired</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">76,892,896</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(234,029</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(732,814</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(149,831</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,994,669</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pension benefit obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(548,384</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Note payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(115,096</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total liabilities assumed</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,774,823</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">72,118,073</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less non-controlling interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,006,504</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net assets acquired</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">65,111,569</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>

		</table><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The goodwill recognized as a result of the PMX Transaction is attributable primarily to expected synergies and the assembled workforce of Proteomedix. None of the goodwill is expected to be deductible for income tax purposes.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair values of the acquired tangible and intangible assets were determined using variations of the cost, income approach using the excess earnings, lost profits and relief from royalty methods. The income approach valuation methodology used for the intangible assets acquired in the PMX Transaction makes use of Level 3 inputs.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The trade name intangible asset represents the value of the Proclarix&#8482; brand name and was valued using a relief from royalty method under an income approach. A royalty rate of 6% was utilized in determining the fair value of this intangible asset. The fair value of this asset was determined based on a cash flow model using forecasted revenues and expenses specifically tied to Proclarix&#8482;. Those cash flows were then discounted at 10% determined by the use of a weighted average return on assets analysis. The life of this intangible asset was determined to be indefinite as the branded name will persist beyond the life of the product rights and customer relationships.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The customer relationship intangible assets represent the value of the existing customer contract with Labcorp (see Note&#160;6) and was valued using the lost profits method under the income approach. The fair value of this asset was determined based on a cash flow model using forecasted revenues specifically tied to Proteomedix&#8217;s Labcorp contract. Those cash flows were then discounted at 10% determined by the use of a weighted average return on assets analysis. The estimated useful life of this asset was determined by reference to the estimated life of the product rights associated with the Labcorp contract.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The product rights for developed technology acquired in the PMX Transaction represents know<span class="nobreak">-how</span> and patented intellectual property held by PMX pertaining to its commercial<span class="nobreak">-ready</span> prostate cancer diagnostic system, Proclarix&#8482;. The fair value of this asset was determined based on a cash flow model based on forecasted revenues and expenses specifically tied to Proclarix&#8482;. Those cash flows were then discounted at 8% for the period prior to patent expiration and 16% for the period thereafter. The discount rates were determined by the use of a weighted average return on assets analysis. The estimated useful life of the product rights was determined based on the underlying patent&#8217;s remaining life.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of the non<span class="nobreak">-controlling</span> interest in Proteomedix is estimated to be $7.0&#160;million and represents the fair value of the vested Proteomedix stock options outstanding as of the Acquisition Date. The fair value of the non<span class="nobreak">-controlling</span> interest was valued using the methodology applicable to the Proteomedix stock options disclosed above. As Proteomedix was a private company as of the Acquisition Date, the fair value measurement is based on significant inputs that are not observable in the market and thus represents a Level 3 measurement as defined in ASC&#160;820, <span class="Italic" style="font-style:italic;font-weight:normal;">Fair Value Measurement</span>.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company recognized approximately $1.5&#160;million of acquisition related costs that were expensed during 2023, including the fair value of the subscription agreement liability, which was a closing condition for the PMX Transaction (see Note&#160;8). These costs are included in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The amounts of revenue and loss of Proteomedix, included in the Company&#8217;s consolidated statements of operations and comprehensive loss from the Acquisition Date through December&#160;31, 2023 are as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Revenue</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">58,465</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">315,688</p>	</td>
				</tr>

		</table>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following summary, prepared on a pro forma basis, presents the Company&#8217;s unaudited consolidated results of operations for 2023 and 2022 as if the PMX Transaction had been completed as of January&#160;1, 2022. The pro forma results below include the impact of amortization of intangible assets. This pro forma information is presented for </p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">illustrative purposes only, is not necessarily indicative of future results of operations and does not include any impact of transaction synergies. In addition, the pro forma results are not necessarily indicative of the results of operations that actually would have been achieved had the PMX Transaction been consummated as of that date:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Unaudited</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">For the&#160;Years Ended</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Revenue</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,601,310</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">392,460</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">38,577,046</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16,326,247</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666109159728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SignificantAgreementsAbstract', window );"><strong>Significant Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SignificantAgreementsTextBlock', window );">Significant Agreements</a></td>
<td class="text"><p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;6 &#8212; Significant Agreements</span></p>
		<p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Ology Bioservices, Inc. (which was later acquired by National Resilience, Inc.)</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company entered into a Master Services Agreement (&#8220;Ology MSA&#8221;), dated July&#160;19, 2019, with Ology, Inc. (&#8220;Ology&#8221;) to provide services from time to time, including but not limited to technology transfer, process development, analytical method optimization, cGMP manufacture, regulatory affairs, and stability studies of biologic products. Pursuant to the Ology MSA, the Company and Ology shall enter into a Project Addendum for each project to be governed by the terms and conditions of the Ology MSA.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company entered into two Project Addendums as of December&#160;31, 2023. The initial Project Addendum was executed on October&#160;18, 2019, and the Company was required to pay Ology an aggregate of approximately $4&#160;million. Due to unforeseen delays associated with COVID<span class="nobreak">-19</span>, the Company and Ology entered into a letter agreement dated January&#160;9, 2020 to stop work on the project, at which point the Company had paid Ology $100,000 for services to be provided. The second Project Addendum was executed on May&#160;21, 2021, and the Company is obligated to pay Ology an aggregate amount of approximately $2.8&#160;million, plus reimbursement for materials and outsourced testing, which will be billed at cost plus 15%. During 2023 and 2022, the Company and Ology entered into contract amendments that resulted in a net decrease in the Company&#8217;s obligations of approximately $137,000.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the&#160;years ended December&#160;31, 2023 and 2022, the Company incurred related research and development expenses of approximately $15,000 and $1,329,000, respectively, and had approximately $685,000 recorded as related accounts payable at December&#160;31, 2023, and approximately $476,000 and $669,000 recorded as related accounts payable and accrued expenses, respectively, at December&#160;31, 2022.</p>
		<p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Cincinnati Children&#8217;s Hospital Medical Center</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company entered into a license agreement (the &#8220;CHMC Agreement&#8221;), dated June&#160;1, 2021, with Children&#8217;s Hospital Medical Center, d/b/a Cincinnati Children&#8217;s Hospital Medical Center (&#8220;CHMC&#8221;). Under the terms of the CHMC Agreement, the Company holds an exclusive, worldwide license (other than the excluded field of immunization against, and prevention, control, or reduction in the severity of gastroenteritis caused by rotavirus and norovirus in China and Hong&#160;Kong) to certain specified patent and biological materials relating to the use of norovirus nanoparticles and practice processes that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing CHMC patents and related technology directed to a virus<span class="nobreak">-like</span> particle vaccine platform that utilizes nanoparticle delivery technology that may have potential broad application to develop vaccines for multiple infectious diseases. The term of the CHMC Agreement begins on the effective date and extends on a jurisdiction by jurisdiction and product by product basis until the later of: (i)&#160;the last to expire licensed patent; (ii)&#160;<span style="-sec-ix-hidden: hidden-fact-267">ten</span> (10)&#160;years after the first commercial sale; or (iii)&#160;entrance onto the market of a biosimilar or interchangeable product. The Company is obligated to use commercially reasonable efforts to bring licensed products to market through diligent research and development, testing, manufacturing, and commercialization, to use best efforts to make all necessary regulatory filings and obtain all necessary regulatory approvals, to achieve milestones relating to development and sales, and report to CHMC on progress. The Company is obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur. Specifically, the Company is obligated to pay CHMC a single<span class="nobreak">-digit</span> royalty on </p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">net sales, being 5%, 4% or 2% depending on the product, until the last valid claim covering a licensed product exists, at which point the royalty rates decrease by 50%. The Company is also obligated to pay up to a 25% royalty on any non<span class="nobreak">-royalty</span> sublicense revenue paid to the Company by any sublicensee. The CHMC Agreement also provides the Company with an option to license any CHMC or jointly patented modification, alteration or improvement of any invention claimed in a Licensed Patent (&#8220;CHMC Improvement&#8221; and &#8220;Joint Improvement, respectively&#8221;), with a $50,000 option fee for each Improvement that the Company elects to include in the license grant of the CHMC Agreement. In addition, the Company is required to pay CHMC milestone payments of up to an aggregate of $59.75&#160;million; specifically, upon the achievement of specified development milestones of approximately $0.5&#160;million, regulatory milestones of approximately $1.25&#160;million, and commercial milestones of approximately $58.0&#160;million.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company may terminate the CHMC Agreement for convenience at any time prior to first commercial sale of a product or process by providing one hundred and eighty (180)&#160;days&#8217; written notice to CHMC.&#160;It may also terminate for a CHMC uncured material breach. CHMC may terminate the CHMC Agreement for an uncured Company material breach or insolvency or bankruptcy. Pursuant to the terms of the CHMC Agreement, if the Company fails to achieve the milestones, and cannot mutually agree with CHMC on an amendment to the milestones, then CHMC will have the option of converting any and all of such exclusive licenses to nonexclusive licenses, to continue developing indications that have already entered development at any stage or in which the Company has invested in developing. CHMC may also terminate the CHMC Agreement to the fullest extent permitted by law in the countries of the worldwide territory, in the event the Company or its affiliates challenge or induce others set up challenges to the validity or enforceability of any of the Licensed Patents, as defined in the CHMC Agreement, and the Company will be obligated to reimburse CHMC for its costs, including reasonable attorneys&#8217; fees.</p>
		<p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Oxford University Innovation Limited</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2018, the Company entered into an option agreement with Oxford University Innovation (&#8220;OUI&#8221;), which was a precursor to a license agreement (the &#8220;OUI Agreement&#8221;), dated July&#160;16, 2019. Under the terms of the OUI Agreement, the Company held an exclusive, worldwide license to certain specified patent rights and biological materials relating to the use of epitopes of limited variability and virus<span class="nobreak">-like</span> particle products and practice processes that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing a vaccine product candidate for influenza. The Company was obligated to use its best efforts to develop and market Licensed Products, as defined in the OUI Agreement, in accordance with its development plan, report to OUI on progress, achieve certain milestones and was required to pay OUI nonrefundable milestone fees when it achieved them. Pursuant to the OUI Agreement, the Company was obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur. Specifically, the Company was obligated to pay a 6% royalty on all net sales of licensed products, as defined in the OUI Agreement, with an annual minimum royalty payment of $250,000 starting post<span class="nobreak">-product</span> launch, until the expiration of the OUI Agreement or revocation of the last valid claim covering a licensed product, at which point a royalty rate of 3% will apply. An annual maintenance fee of $10,000 and $20,000 was required in the pre<span class="nobreak">-phase</span>&#160;III year and Phase&#160;III year, respectively, and as defined in the OUI Agreement. The Company was also obligated to pay a 25% royalty on any sums received by the Company from any sublicensee (including all up<span class="nobreak">-front</span>, milestone and other one<span class="nobreak">-off</span> payments received by the Company from any sub<span class="nobreak">-licenses</span> or other contracts granted by the Company with respect to the licensed technology). In addition, the Company was required to pay OUI milestone payments of up to an aggregate of $51.25&#160;million; specifically, upon the achievement of specified development milestones of approximately $2.25&#160;million, regulatory milestones of approximately $9.5&#160;million, and commercial milestones of approximately $39.5&#160;million.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The OUI Agreement was to expire upon ten (10)&#160;years from the expiration of the last patent contained in the licensed patent rights, unless terminated earlier. Either party had the right to terminate the OUI Agreement for an uncured material breach. The Company was able to terminate the OUI Agreement for any reason at any time upon six&#160;months&#8217; written notice until July&#160;16, 2022, which was the third anniversary of the OUI Agreement. OUI was able to terminate immediately if the Company had a petition presented for its winding<span class="nobreak">-up</span> or passed a resolution for winding up other than for a bona fide amalgamation or reconstruction or compounds with its creditors or had a receiver or administrator appointed. OUI could also terminate if the Company opposed or challenged the validity of </p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">any of the patents or applications in the Licensed Technology, as defined in the OUI Agreement; raised the claim that the know<span class="nobreak">-how</span> of the Licensed Technology was not necessary to develop and market Licensed Products; or in OUI&#8217;s reasonable opinion, was taking inadequate or insufficient steps to develop or market Licensed Products and did not take any further steps that OUI requested by written notice within a reasonable time.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company terminated the agreements with Oxford during the year ended December&#160;31, 2023, and amounts due upon termination were not significant.</p>
		<p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">St. Jude Children&#8217;s Hospital</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company entered into a license agreement (the &#8220;St. Jude Agreement&#8221;), dated January&#160;27, 2020, and as amended on May&#160;11, 2022 and March&#160;22, 2023, with St. Jude Children&#8217;s Research Hospital (&#8220;St. Jude&#8221;). Under the terms of the St. Jude Agreement, the Company held an exclusive, worldwide license to certain specified patent rights and biological materials relating to the use of live attenuated streptococcus pneumoniae and practice processes that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing a vaccine product candidate for streptococcus pneumoniae. The Company was obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur. Specifically, pursuant to the terms of the St. Jude Agreement, as amended, the Company was obligated to make 5% royalty payments for each licensed product(s)&#160;sold by the Company or its affiliates, based on the net sales for the duration of the St. Jude Agreement, and also pay 15% of consideration received for any sublicenses. The Company was also required to pay an additional one<span class="nobreak">-time</span> $5,000 license fee, and an annual maintenance fee of $10,000 beginning on the first anniversary of the Effective Date (which was waived if all of the developmental milestones scheduled for completion before such annual fee is due have been achieved). In addition, the Company was required to pay St. Jude milestone payments of up to an aggregate of $1.9&#160;million; specifically, upon the achievement of specified development milestones of $0.3&#160;million, regulatory milestones of $0.6&#160;million, and commercial milestones of $1.0&#160;million.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The St. Jude Agreement was to expire upon the expiration of the last valid claim contained in the licensed patent rights, unless terminated earlier. The Company was obligated to use commercially reasonable efforts to develop and commercialize the licensed product(s)&#160;and included defined development milestones. If the Company failed to achieve the development milestones contained in the St. Jude Agreement, and if the Company and St. Jude failed to agree upon a mutually satisfactory revised timeline, St. Jude had the right to terminate the St. Jude Agreement. Either party was able to terminate the St. Jude Agreement in the event the other party (a)&#160;filed against it a petition under the Bankruptcy Act (among other things) or (b)&#160;failed to perform or otherwise breached its obligations under the St. Jude Agreement and did not cure such failure or breach within sixty (60)&#160;days. The Company was able to terminate for any reason on thirty (30)&#160;days written notice.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company terminated the agreement with St. Jude during the year ended December&#160;31, 2023, and amounts due upon termination were not significant.</p>
		<p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">University of Texas Health Science Center at San Antonio</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company entered into a patent and technology license agreement (the &#8220;UT Health Agreement&#8221;), dated November&#160;18, 2022, with the University of Texas Health Science Center at San Antonio (&#8220;UT Health&#8221;). Under the terms of the UT Health Agreement, the Company held an exclusive, worldwide license (other than the excluded field of vectors, as defined in the UT Health Agreement) to certain specified patent rights relating to the development of a live attenuated, oral Chlamydia vaccine candidate. An initial non<span class="nobreak">-refundable</span> license fee of $100,000 was due upon execution of the agreement, and expensed during the year ended December&#160;31, 2022, with subsequent annual license fees thereafter until expiration or termination of the UT Health agreement. Pursuant to the UT Health Agreement, the Company was obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur. Specifically, the Company was obligated to pay UT a single<span class="nobreak">-digit</span> royalty on net sales, being 5% or 3% depending on whether the product was covered by a valid claim or not, as defined in the agreement. The Company was also obligated to pay a 20% royalty on any sums received by the Company from any sublicensee. In addition, the </p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Company was required to pay UT Health milestone payments of up to an aggregate of approximately $2.2&#160;million; specifically, upon the achievement of specified development milestones of approximately $0.7&#160;million and regulatory milestones of approximately $1.5&#160;million.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The UT Health Agreement was to expire upon the expiration of the last date of expiration or termination of the patent rights, unless terminated earlier. Under the UT Health Agreement, the Company had the right to terminate the UT Health Agreement for convenience, by providing 90&#160;days&#8217; written notice to UT Health. UT Health was able to terminate the UT Health Agreement in the event the Company (a)&#160;became arrears in payment due and did not make payment within 30&#160;days after notification from UT Health or (b)&#160;was in breach of any non<span class="nobreak">-payment</span> provision and does not cure such breach within 60&#160;days after notification from UT Health or (c)&#160;UT Health delivered notice to the Company of three or more actual material breaches of the UT Health Agreement in any 12<span class="nobreak">-month</span> period or (d)&#160;in the event the Company or its affiliates initiated any proceeding or action to challenge the validity, enforceability, or scope of any of the licensed patents.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company terminated the agreement during the year ended December&#160;31, 2023, and amounts due upon termination were not significant.</p>
		<p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Co-development Agreement with AbVacc, Inc.</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;1, 2023, the Company entered into a co<span class="nobreak">-development</span> agreement (the &#8220;Co<span class="nobreak">-Development</span> Agreement&#8221;) with AbVacc, Inc. (&#8220;AbVacc&#8221;), for the purpose of conducting research aimed at co<span class="nobreak">-development</span> of specific vaccine candidates, including monkeypox and Marburg virus disease with the potential to expand to others using the Norovirus nanoparticle platform (&#8220;Co<span class="nobreak">-Development</span> Project&#8221;), and to govern the sharing of materials and information, as defined in the Co<span class="nobreak">-Development</span> Agreement, for the Co<span class="nobreak">-Development</span> Project. Under the Co<span class="nobreak">-Development</span> Agreement, AbVacc and the Company will collaborate, through a joint development committee, to establish and implement a development plan or statement of work for each Co<span class="nobreak">-Development</span> Project targeted product. Under the Co<span class="nobreak">-Development</span> Agreement, either the Company or AbVacc, whichever party is the primary sponsor of any resulting product (as defined in the Co<span class="nobreak">-Development</span> Agreement), will be obligated to compensate the other party for certain milestone payments that would range between $2.1&#160;million and $4.75&#160;million, plus royalties of between 2% to 4%. There is no fixed obligation for either party, and each party will be responsible for their own costs. The term of the Co<span class="nobreak">-Development</span> Agreement is three&#160;years from the effective date, unless previously terminated by either party, in accordance with the Co<span class="nobreak">-Development</span> Agreement. During the year ended December&#160;31, 2023, the Company incurred approximately $21,000 in costs for research and development related to the Co<span class="nobreak">-Development</span> Agreement. As of December&#160;31, 2023, the Company evaluated the likelihood of the Company achieving the specified milestones and generating product sales and determined that the likelihood is not yet probable and as such no accrual of these payments is required as of December&#160;31, 2023.</p>
		<p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Services Agreement</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On July&#160;21, 2023, the Company, entered into a Licensing and Services Master Agreement (&#8220;Master Services Agreement&#8221;) and a related statement of work with a vendor, pursuant to which the vendor was to provide to the Company commercialization services for the Company&#8217;s products, including recruiting, managing, supervising and evaluating sales personnel and providing sales<span class="nobreak">-related</span> services for such products, for fees totaling up to $29.1&#160;million over the term of the statement of work. The statement of work had a term through September&#160;6, 2026, unless earlier terminated in accordance with the Master Services Agreement and the statement of work. On July&#160;29, 2023, a second statement of work was entered into with the same vendor for certain subscription services providing prescription market data access to the Company. The fees under the second statement of work totaled approximately $800,000, and the term was through July&#160;14, 2025. On October&#160;12, 2023, the Company terminated the Master Services Agreement and the statements of work. The Company recorded approximately $3.1&#160;million in expense related to this contract during the year ended December&#160;31, 2023, which is included in selling, general and administrative expense in the </p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">accompanying consolidated statements of operations and comprehensive loss. The Company had approximately $1.8&#160;million recorded in related accounts payable as of December&#160;31, 2023, which includes amounts due for early termination of the contract.</p>
		<p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Laboratory Corporation of America</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;23, 2023, Proteomedix entered into a license agreement Laboratory Corporation of America (&#8220;Labcorp&#8221;) pursuant to which Labcorp has the exclusive right to develop and commercialize Proclarix, and other products developed by Labcorp using Proteomedix&#8217;s intellectual property covered by the license, in the United&#160;States (&#8220;Licensed Products&#8221;). In consideration for granting Labcorp an exclusive license, Proteomedix received an initial license fee of in the mid<span class="nobreak">-six</span> figures upon signing of the contract. Additionally, Proteomedix is entitled to royalty payments on the net sales recognized by Labcorp of any Licensed Products plus milestone payments as follows:</p>
		<div style="-sec-ix-redline:true;-keep: true"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>After the first sale of Proclarix as a laboratory developed test, Labcorp will pay an amount in the mid<span class="nobreak">-six</span> figures,</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>after Labcorp achieves a certain amount in the low seven figures in net sales of Licensed Products, Labcorp will pay Proteomedix an amount in the low seven figures,</p></div>
		<div style="-sec-ix-redline:true;-keep: true"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>after a certain amount in the mid<span class="nobreak">-seven</span> figures in net sales of Licensed Products, Labcorp will pay Proteomedix an amount in the low seven figures.</p></div>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Labcorp is wholly responsible for the cost, if any, of research, development and commercialization of Licensed Products in the United&#160;States but has the right to offset a portion of those costs against future royalty and milestone payments. Additionally, Labcorp may deduct royalties or other payments made to third parties related to the manufacture or sale of Licensed Products up to a maximum amount of any royalty payments due to Proteomedix.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_SignificantAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_SignificantAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_SignificantAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_SignificantAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666109322480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text"><p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;7 &#8212; Notes Payable</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Veru APA (see Note&#160;5), the Company executed three non<span class="nobreak">-interest</span> bearing notes payable (the &#8220;Notes&#8221;) in the principal amounts of $4.0&#160;million, $5.0&#160;million and $5.0&#160;million with maturity dates of September&#160;30, 2023, April&#160;19, 2024, and September&#160;30, 2024, respectively. No principal payments are due until maturity; however, the Company may voluntarily prepay the Notes with no penalty. Additionally, in an Event of Default, as defined in the Notes, the unpaid principal amount of the Notes will accrue interest at a rate of 10.0% per annum.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company imputed interest on the Notes using an average discount rate of 8.2% and recorded a debt discount of approximately $1.1&#160;million at the issuance date. The debt discount is reflected as a reduction in the carrying amount of the Notes and amortized to interest expense through the respective maturity dates, using the effective interest method. The Company recorded approximately $0.7&#160;million of associated interest expense during the year ended December&#160;31, 2023. The unamortized debt discount as of December&#160;31, 2023 was approximately $0.4&#160;million.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On September&#160;29, 2023, the Company and the note holder entered into an amendment to the Veru APA, which provided that the $4.0&#160;million note payable originally due on September&#160;30, 2023 was deemed paid and fully satisfied upon (1)&#160;the payment to the Seller of $1.0&#160;million in cash on September&#160;29, 2023, and (2)&#160;the issuance to the Seller by October&#160;3, 2023 of 3,000<span class="nobreak"> </span>shares of Series&#160;A Preferred Stock of the Company (see Note&#160;5). In connection with the Veru APA Amendment, the Company recorded an extinguishment loss on the note payable of approximately $490,000, which represents the difference between the fair value of the Series&#160;A Preferred Stock that was issued to settle the debt and the carrying value of the note payable as of September&#160;29, 2023. The extinguishment loss is recognized in other income (expense) in the accompanying consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2023.</p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">To determine the fair value of the Series&#160;A Preferred Stock, the Company first derived the business enterprise value (&#8220;BEV&#8221;) using a discounted cash flow method. The BEV was adjusted to an equity value assuming $3.0&#160;million of debt converted to Series&#160;A Preferred Stock, which was then allocated across the Company&#8217;s securities. The concluded value for the Series&#160;A Preferred Stock utilized the Black<span class="nobreak">-Scholes</span> option pricing model, which was classified as level 3 in the valuation hierarchy due to the presence of significant unobservable inputs. The following key assumptions were used in the model: volatility rate of 100%, risk free interest rate of 4.6%, 5.0 year expected term, and the Company&#8217;s aggregate equity value. The volatility was based on the historical and implied volatility of a peer group and the risk<span class="nobreak">-free</span> interest rate was based on the implied yield available on U.S.&#160;Treasury securities with a term commensurate with the estimated expected term.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Future minimum principal payments on the Notes as of December&#160;31, 2023, includes $10&#160;million in principal payments that are due in 2024.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company also assumed an obligation in the amount of 100,000 CHF, in connection with the Proteomedix acquisition. This obligation relates to a loan from an investor that was advanced to Proteomedix in March&#160;2010. This loan bears no interest, is unsecured and may be cancelled by the Company at its discretion, however it is the intent of the Company to repay this loan in the future. The loan payable, in the amount of approximately $119,000, is included in long term note payable in the accompanying consolidated balances sheet as of December&#160;31, 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666109150176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subscription Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SubscriptionAgreementDisclosureAbstract', window );"><strong>Subscription Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SubscriptionAgreementDisclosureTextBlock', window );">Subscription Agreement</a></td>
<td class="text"><p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;8 &#8212; Subscription Agreement</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;18, 2023, the Company entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) with the PMX Investor, who became a stockholder of Onconetix at the closing of the PMX Transaction (see Notes 5 and 11) for the sale of 20&#160;million units, each comprised of 1<span class="nobreak"> </span>share of common stock and 0.30 pre<span class="nobreak">-funded</span> warrants (the &#8220;Units&#8221;) at $0.25 per Unit. The Subscription Agreement includes a make<span class="nobreak">-whole</span> provision which requires the issuance of additional shares of common stock in the event that the 270<span class="nobreak">-day</span> volume weighted average price (&#8220;270 VWAP&#8221;) after the closing of the Subscription Agreement, is below $0.25. The Subscription Agreement will only close upon obtaining Stockholder Approval for certain transactions involving the Company&#8217;s Series&#160;B Preferred Stock, as further described in Note&#160;5.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Subscription Agreement is accounted for as a liability in accordance with ASC&#160;480, as the make<span class="nobreak">-whole</span> provision could result in a variable number of shares being issued upon settlement. The subscription agreement liability is measured at fair value at the commitment date and at each subsequent reporting period, with changes in fair value recorded as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. The Company recorded the fair value of the Subscription Agreement liability at the issuance date of approximately $0.8&#160;million, as an acquisition related cost, as the Subscription Agreement was a condition to close the PMX Transaction (see Note&#160;5). As of December&#160;31, 2023, the fair value of the subscription agreement liability is estimated to be approximately $0.9&#160;million, determined using a Monte<span class="nobreak">-Carlo</span> option pricing model, and the Company estimated a 55.0% probability that the Subscription Agreement will close. The significant assumptions used in the Monte<span class="nobreak">-Carlo</span> model, which utilizes Level 3 inputs (see Note&#160;3), are as follows as of the commitment date and at December&#160;31, 2023:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;18,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercise price</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.25</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.25</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Term (years)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.5</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.2</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected stock price volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">95</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free rate of interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.64</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.64</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_SubscriptionAgreementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_SubscriptionAgreementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_SubscriptionAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for subscription agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_SubscriptionAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666109249088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Convertible Redeemable Preferred Stock and Stockholders' Equity</a></td>
<td class="text"><p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;9 &#8212; Convertible Redeemable Preferred Stock and Stockholders&#8217; Equity</span></p>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Authorized Capital</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023 and 2022, the Company is authorized to issue 250,000,000<span class="nobreak"> </span>shares and 10,000,000<span class="nobreak"> </span>shares of common stock and preferred stock, respectively, with a par value of $0.00001 for both common stock and preferred stock. As of December&#160;31, 2023, the Company had designated and authorized the issuance of up to 1,150,000<span class="nobreak"> </span>shares, 10,000<span class="nobreak"> </span>shares, and 2,700,000<span class="nobreak"> </span>shares of Series&#160;Seed Preferred Stock, Series&#160;A Preferred Stock, and Series&#160;B Preferred Stock, respectively.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;23, 2022, in connection with the closing of the IPO, the Company filed with the Secretary of State of the State of Delaware an amended and restated certificate of incorporation (the &#8220;A&amp;R COI&#8221;), which became effective immediately. There was no change to the Company&#8217;s authorized shares of common stock and preferred stock or the par value. Prior to this amendment, the Company had designated 1,150,000<span class="nobreak"> </span>shares of preferred stock, with par value $0.00001 per share. In addition, on February&#160;23, 2022 and in connection with the closing of the IPO, the Company&#8217;s board of directors adopted Amended and Restated Bylaws.</p>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Preferred Stock</span></p>
		<p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Series&#160;A Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On September&#160;29, 2023, the Company filed a Certificate of Designations of Rights and Preferences of Series&#160;A Preferred Stock of the Company (the &#8220;Series&#160;A Certificate of Designations&#8221;) with the State of Delaware to designate and authorize the issuance of up to 10,000<span class="nobreak"> </span>shares of Series&#160;A Preferred Stock.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On October&#160;3, 2023, the Company issued 3,000<span class="nobreak"> </span>shares of Series&#160;A Convertible Preferred Stock in exchange for the settlement of $3.0&#160;million in notes payable due to Veru, Inc. (see Notes 5 and 7). The significant terms of the Series&#160;A Preferred Stock are as follows:</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Voting</span>&#160;&#8212;&#160;The shares of Series&#160;A Preferred Stock carry no voting rights, except as to certain significant matters specified in the Series&#160;A Certificate of Designations.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Redemption&#160;&#8212;&#160;</span>Onconetix shall have the right to redeem in cash any outstanding shares of Series&#160;A Preferred Stock along with accrued but unpaid dividends beginning immediately after issuance of such shares of Preferred Stock. The holder of the Series&#160;A Preferred Stock shall not under any circumstances have any right to require redemption.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Liquidation Preference&#160;&#8212;&#160;</span>Each share of Series&#160;A Preferred Stock will have a liquidation preference equal to the stated value (initially $1,000 per share), plus any accrued but unpaid dividends thereon (the &#8220;Liquidation Preference&#8221;). In the event of a liquidation, dissolution or winding up of the Company (which shall include any merger, reorganization, sale of assets in which control of Onconetix is transferred or event which results in all or substantially all of the Company&#8217;s assets being transferred), the holders of the Series&#160;A Preferred Stock shall be entitled to receive out of the assets of the Company, before any payment is made to the holders of common stock and either in preference to or pari passu with the holders of any other series of preferred stock that may be issued in the future, a per share amount equal to the Liquidation Preference. Any remaining assets of the Company following payment of the Liquidation Preference to the holders of Series&#160;A Preferred Stock shall be distributed to the holders of the Corporation&#8217;s common stock and any junior series of preferred stock then outstanding.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Dividends</span>&#160;&#8212;&#160;The holders of Series&#160;A Preferred Stock shall be entitled to receive dividends on shares of Series&#160;A Preferred Stock (on an as<span class="nobreak">-if-converted-to-common-stock</span> basis) equal to and in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of the common stock. No other dividends shall be paid on shares of Series&#160;A Preferred Stock.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Conversion&#160;&#8212;&#160;</span>Each share of Series&#160;A Preferred Stock shall automatically convert into common stock of the Company one year from the date of issuance, if the required stockholder approval is obtained. If this approval is not obtained, then the Series&#160;A Preferred Stock is convertible, at the option of the holder, at any time and from time to </p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">time from and after one year from the date of issuance into that number of shares of common stock (subject to certain limitations) determined by dividing the Stated Value by the Conversion Price. If the required vote discussed above is not obtained, and the Series&#160;A Preferred Stock is converted at the option of the holder, the Company may not issue a number of shares of common stock which, would exceed 19.99% shares of common stock (subject to adjustment for forward and reverse stock splits, recapitalizations and the like). The Conversion Price, which is subject to adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization and other adjustments, as defined in the Series&#160;A Certificate of Designations, is initially $0.5254. The maximum number of shares that the Series&#160;A Preferred Stock is convertible into, based on the Conversion Price as of December&#160;31, 2023 is approximately 5,709,935<span class="nobreak"> </span>shares of the Company&#8217;s common stock.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluated the terms of the Series&#160;A Preferred Stock, and in accordance with the guidance of ASC&#160;480, the Series&#160;A Preferred Stock is classified as permanent equity in the accompanying consolidated balance sheet. The Series&#160;A Preferred Stock was recorded at its fair value as of the issuance date (see Note&#160;7).</p>
		<p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Series&#160;B Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2023, the Company filed a Certificate of Designations of Rights and Preferences of Series&#160;B Convertible Preferred Stock of the Company (the &#8220;Series&#160;B Certificate of Designations&#8221;) with the State of Delaware to designate and authorize the issuance of up to 2,700,000<span class="nobreak"> </span>shares of Series&#160;B Preferred Stock.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2023, in connection with the PMX Transaction, as part of the purchase consideration, the Company issued 2,696,729<span class="nobreak"> </span>shares of Series&#160;B Convertible Preferred Stock (see Note&#160;5). The significant terms of the Series&#160;B Preferred Stock are as follows:</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Voting&#160;&#8212;&#160;</span>The shares of Series&#160;B Preferred Stock carry no voting rights except with respect to the election of the Proteomedix Director (as defined in the Certificate of Designations) and except as to certain significant matters specified in the Series&#160;B Certificate of Designations.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Liquidation Preference&#160;&#8212;&#160;</span>Upon a liquidation, dissolution or winding<span class="nobreak">-up</span> of Onconetix, whether voluntary or involuntary, the holders of Series&#160;B Preferred Stock shall be entitled to receive out of the assets, whether capital or surplus, of Onconetix, the same amount that a holder of common stock would receive if such holder&#8217;s Series&#160;B Preferred Stock were fully converted to common stock at the effective conversion ratio, plus an additional amount equal to any dividends declared but unpaid to such shares, which amounts shall be paid pari passu with all holders of common stock.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Dividends</span>&#160;&#8212;&#160;The holders of the Series&#160;B Preferred Stock shall be entitled to receive dividends on shares of Series&#160;B Preferred Stock (on an as<span class="nobreak">-if-converted-to-common-stock</span> basis) equal to and in the same form, and in the same manner, as dividends (other than dividends on shares of the common stock payable in the form of common stock) actually paid on shares of the common stock when, as and if such dividends (other than dividends payable in the form of common stock) are paid on shares of the common stock.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Conversion&#160;&#8212;&#160;</span>Following Stockholder Approval, each share of Series&#160;B Preferred Stock shall be converted into shares of common stock (the &#8220;Conversion Shares&#8221;) at a ratio of 100 Conversion Shares for each share of Series&#160;B Preferred Stock (the &#8220;Conversion Ratio&#8221;). All shares of Series&#160;B Preferred Stock shall automatically and without any further action required be converted into Conversion Shares at the Conversion Ratio upon the latest date on which (i)&#160;Onconetix has received the Stockholder Approval with respect to the issuance of all of the shares of Common Stock issuable upon Conversion in excess of 20% of the issued and outstanding Common Stock on the Closing Date and (ii)&#160;Onconetix has effected an increase in the number of shares of Common Stock authorized under its certificate of incorporation, to the extent required to consummate the PMX Transaction. The Conversion ratio is subject to adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization and other adjustments, as defined in the Series&#160;B Certificate of Designations The Series&#160;B Preferred Stock is initially convertible into approximately 269,672,900<span class="nobreak"> </span>shares of the Company&#8217;s common stock.</p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Cash Settlement&#160;&#8212;&#160;</span>If, at any time after the earlier of the date of the Stockholder Approval or January&#160;1, 2025 (the earliest such date, Onconetix (x)&#160;has obtained the Stockholder Approval but fails to deliver certificates representing the Conversion Shares, or other documentation as required under the terms of the Share Exchange Agreement, or (y)&#160;has failed to obtain the Stockholder Approval, Onconetix shall, at the request of the holder, pay to such holder an amount in cash equal to (i)&#160;the Fair Value (as defined below) of the shares of Series&#160;B Preferred Stock set forth in such request multiplied by (ii)&#160;the Conversion Ratio in effect on the&#160;trading day on which the request is delivered to Onconetix. &#8220;Fair Value&#8221; of shares shall be fixed with reference to the last reported closing stock price on the principal trading market of the Common Stock on which the Common Stock is listed as of the&#160;trading day on which the request is delivered to Onconetix.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Redemption&#160;&#8212;&#160;</span>The shares of Series&#160;B Preferred Stock are not redeemable by Onconetix.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluated the terms of the Series&#160;B Preferred Stock, and in accordance with the guidance of ASC&#160;480, the Series&#160;B Preferred Stock is classified as temporary equity in the accompanying consolidated balance sheet, as the shares may be redeemable by the holders for cash, upon certain conditions that are not within the control of the Company. Additionally, the Company does not control the actions or events necessary to deliver the number of required shares upon exercise by the holders of the conversion feature. The Series&#160;B Preferred Stock was recorded at its fair value as of the issuance date (see Note&#160;5). The Series&#160;B Preferred Stock is not currently redeemable or probable of becoming redeemable because it is subject to, among other things, Stockholder Approval as described above, and therefore the carrying amount is not currently accreted to its redemption value as of December&#160;31, 2023.</p>
		<p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Series&#160;Seed Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company has 1,150,000<span class="nobreak"> </span>shares of preferred stock designated as Series&#160;Seed Preferred Stock (&#8220;Series&#160;Seed&#8221;) and there are no shares of Series&#160;Seed outstanding as of December&#160;31, 2023 and 2022.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Prior to the closing of the IPO in 2022, there were 1,146,138<span class="nobreak"> </span>shares of Series&#160;Seed issued and outstanding. Each share of the Series&#160;Seed was convertible, at the option of the holder, at a conversion price of $1.52 per share, subject to certain adjustments. The holders of the Series&#160;Seed were entitled to receive cumulative dividends at a per share rate of 8% per annum, compounded annually. Each Series&#160;Seed share was automatically convertible into common stock of the Company, at the then<span class="nobreak">-effective</span> conversion price, upon the closing of a firmly underwritten public offering netting proceeds of at least $50&#160;million with an offering price of at least three hundred percent (300%) of the Original Issue Price of the Series&#160;Seed. On February&#160;18, 2022, the majority of the holders of the Series&#160;Seed approved the automatic conversion of the outstanding shares of the Series&#160;Seed and all related accrued and unpaid dividends, upon the closing of the IPO.&#160;The number of shares of Common Stock to be issued upon the closing of the IPO pursuant to the conversion were to be calculated in accordance with the original conversion terms provided by the Company&#8217;s Amended and Restated Certificate of Incorporation (&#8220;COI&#8221;) dated July&#160;1, 2019. This conversion occurred on February&#160;23, 2022, upon the closing of the Company&#8217;s IPO.&#160;Also, upon the close of the IPO, aggregate cumulative dividends of $1,586,162, or $1.38 per Series&#160;Seed share, were automatically converted into shares of common stock. There were an aggregate of 5,626,365<span class="nobreak"> </span>shares of common stock issued upon conversion of the Series&#160;Seed shares and cumulative dividends as of the close of the IPO.</p>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Common Stock</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023 and 2022, there were 22,841,975 and 15,724,957<span class="nobreak"> </span>shares of common stock issued, respectively, and 22,324,576 and 15,265,228<span class="nobreak"> </span>shares of common stock outstanding, respectively.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Holders of the Company&#8217;s common stock are entitled to one vote for each share held of record, and are entitled upon liquidation of the Company to share ratably in the net assets of the Company available for distribution after payment of all obligations of the Company and after provision has been made with respect to each class of stock, if any, having preference over the common stock. The shares of common stock are not redeemable and have no preemptive or similar rights.</p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2023, in connection with the Proteomedix acquisition, the Company issued 3,675,414<span class="nobreak"> </span>shares of the Company&#8217;s common stock as part of the purchase consideration (see Note&#160;5).</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;17, 2022, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Boustead Securities, LLC, acting as representative of the underwriters (&#8220;Boustead&#8221;), in relation to the Company&#8217;s IPO, pursuant to which the Company agreed to sell to the underwriters an aggregate of 2,222,222<span class="nobreak"> </span>shares of the Company&#8217;s common stock, at a price of $9.00 per share. The IPO closed on February&#160;23, 2022 and resulted in net proceeds to the Company, after deducting the 8% underwriting discount, and other offering costs, of approximately $17.1&#160;million.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Underwriting Agreement, the Company issued to Boustead warrants to purchase 111,111<span class="nobreak"> </span>shares of common stock, exercisable for five&#160;years at the option of the holder, at a per share exercise price equal to $10.35. The Company evaluated the terms of the warrants issued at the close of the IPO and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC&#160;480 and ASC&#160;815<span class="nobreak">-40</span>. Since the Company determined that the warrants were equity<span class="nobreak">-classified</span>, the Company recorded the proceeds from the IPO, net of issuance costs, within common stock at par value and the balance of the net proceeds to additional paid in capital.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During October&#160;2022, in connection with a settlement agreement that was entered into with Boustead, these warrants were exchanged for 93,466<span class="nobreak"> </span>shares of restricted common stock (&#8220;the Warrant Exchange&#8221;) (see Note&#160;10). The Warrant Exchange was accounted for as a modification of the warrant, with an incremental fair value of approximately $10,000, which was recorded as selling, general and administrative expense in the accompanying consolidated statements of operations and comprehensive loss. In addition, 200,000 restricted shares of common stock were issued to Boustead upon execution of an advisory agreement, which was entered into concurrent with the settlement agreement. The fair value of the restricted shares of common stock, which had no vesting provisions, was valued at $254,000, and was recorded as selling, general and administrative expense in the accompanying consolidated statements of operations and comprehensive loss.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The restricted shares of common stock issued under the settlement and advisory agreements with Boustead was valued based on the closing trading price on the date the agreements were executed, adjusted to reflect the effect of the restriction on the sale of the common stock. The value of the restriction was measured using the Black<span class="nobreak">-Scholes</span> model to measure the discount for lack of marketability, using the following assumptions: expected term of <span style="-sec-ix-hidden: hidden-fact-274">0.5</span>&#160;years, expected volatility of 96.36%, risk<span class="nobreak">-free</span> interest rate of 4.09% and dividend yield of 0.0%.</p>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Treasury Stock</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On November&#160;10, 2022, the board of directors approved a stock repurchase program (the &#8220;Repurchase Program&#8221;) to allow the Company to repurchase up to 5&#160;million shares of common stock with a maximum price of $1.00 per share, with discretion to management to make purchases subject to market conditions. On November&#160;18, 2022, the board of directors approved an increase to the maximum price to $2.00 per share. There is no expiration date for this program.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December&#160;31, 2023, the Company repurchased 57,670<span class="nobreak"> </span>shares of common stock, for an aggregate of approximately $59,000, at an average price of $1.02 per share. During the year ended December&#160;31, 2022, the Company repurchased 459,729<span class="nobreak"> </span>shares of common stock at an average price of $1.23 per share, for approximately $0.6&#160;million. Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. As of December&#160;31, 2023, there are approximately 4.5&#160;million shares remaining, that can be repurchased under the Repurchase Program.</p>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Private Investments in Public Equity</span></p>
		<p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">April&#160;2022 Private Placement</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;19, 2022, the Company consummated the closing of a private placement (the &#8220;April&#160;2022 Private Placement&#8221;), pursuant to the terms and conditions of a securities purchase agreement, dated as of April&#160;13, 2022. At the closing of the April&#160;2022 Private Placement, the Company issued 590,406<span class="nobreak"> </span>shares of common stock, pre<span class="nobreak">-funded</span> </p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">warrants to purchase an aggregate of 590,406<span class="nobreak"> </span>shares of common stock and preferred investment options to purchase up to an aggregate of 1,180,812<span class="nobreak"> </span>shares of common stock. The purchase price of each share of common stock together with the associated preferred investment option was $6.775, and the purchase price of each pre<span class="nobreak">-funded</span> warrant together with the associated preferred investment option was $6.774. The aggregate net cash proceeds to the Company from the April&#160;2022 Private Placement were approximately $6.9&#160;million, after deducting placement agent fees and other offering expenses. The pre<span class="nobreak">-funded</span> warrants had an exercise price of $0.001 per share and were exercised in full on May&#160;24, 2022. The preferred investment options, which had an exercise price of $6.65 per share, were exchanged in connection with the August&#160;2022 Private Placement. See <span class="Italic" style="font-style:italic;font-weight:normal;">August&#160;2022 Private Placement</span> below for further detail.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">H.C.&#160;Wainwright&#160;&amp; Co., LLC (&#8220;Wainwright&#8221;) acted as the exclusive placement agent for the April&#160;2022 Private Placement. The Company agreed to pay Wainwright a placement agent fee and management fee equal to 7.5% and 1.0%, respectively, of the aggregate gross proceeds from the April&#160;2022 Private Placement and reimburse certain out<span class="nobreak">-of-pocket</span> expenses up to an aggregate of $85,000. In addition, the Company issued warrants to Wainwright (the &#8220;April Wainwright Warrants&#8221;) to purchase up to 70,849<span class="nobreak"> </span>shares of common stock. The Wainwright Warrants are in substantially the same form as the preferred investment options, except that the exercise price is $8.46875. The form of the preferred investment options is a warrant, and as such the preferred investment options, the pre<span class="nobreak">-funded</span> warrants, and the Wainwright Warrants are collectively referred to as the &#8220;April&#160;2022 Private Placement Warrants&#8221;. Further, upon any exercise for cash of any preferred investment options, the Company agreed to issue to Wainwright additional warrants to purchase the number of shares of common stock equal to 6.0% of the aggregate number of shares of common stock underlying the preferred investment options that have been exercised, also with an exercise price of $8.46875 (the &#8220;April Contingent Warrants&#8221;). The maximum number of April Contingent Warrants issuable under this provision of 70,849 were exchanged in connection with the August&#160;2022 Private Placement. See <span class="Italic" style="font-style:italic;font-weight:normal;">August&#160;2022 Private Placement</span> below for further detail.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluated the terms of the April&#160;2022 Private Placement Warrants and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC&#160;480 and ASC&#160;815<span class="nobreak">-40</span>. Since the Company determined that the April&#160;2022 Private Placement Warrants were equity<span class="nobreak">-classified</span>, the Company recorded the proceeds from the April&#160;2022 Private Placement, net of issuance costs, within common stock at par value and the balance of the net proceeds to additional paid in capital.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluated the terms of the April Contingent Warrants and determined that they should be classified as a liability based upon accounting guidance provided in ASC&#160;815<span class="nobreak">-40</span>. Since the April Contingent Warrants are a form of compensation to Wainwright, the Company recorded the value of the liability of approximately $36,000, as a reduction of additional paid in capital, with subsequent changes in the value of the liability recorded in other income (expense) in the accompanying consolidated statements of operations and comprehensive loss. The Company measured the liability upon the close of the April Private Placement using a Monte Carlo simulation, using the following significant assumptions: expected term of <span style="-sec-ix-hidden: hidden-fact-275">4.0</span>&#160;years, expected volatility of 117.0%, risk<span class="nobreak">-free</span> interest rate of 4.00% and dividend yield of 0.0%.</p>
		<p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">August&#160;2022 Private Placement</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;11, 2022, the Company consummated the closing of a private placement (the &#8220;August&#160;2022 Private Placement&#8221;), pursuant to the terms and conditions of a securities purchase agreement, dated as of August&#160;9, 2022. At the closing of the August&#160;2022 Private Placement, the Company issued 1,350,000<span class="nobreak"> </span>shares of common stock, pre<span class="nobreak">-funded</span> warrants to purchase an aggregate of 2,333,280<span class="nobreak"> </span>shares of common stock and preferred investment options to purchase up to an aggregate of 4,972,428<span class="nobreak"> </span>shares of common stock. The purchase price of each share of common stock together with the associated preferred investment option was $2.715, and the purchase price of each pre<span class="nobreak">-funded</span> warrant together with the associated preferred investment option was $2.714. The aggregate net cash proceeds to the Company from the August&#160;2022 Private Placement were approximately $8.7&#160;million, after deducting placement agent fees and other offering expenses. In addition, the investors in the August&#160;2022 Private Placement, who are the same investors from the April&#160;2022 Private Placement, agreed to cancel preferred investment options to purchase up to an aggregate of </p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">1,180,812<span class="nobreak"> </span>shares of the Company&#8217;s common stock issued in April&#160;2022. The pre<span class="nobreak">-funded</span> warrants had an exercise price of $0.001 per share. During 2022, an aggregate of 1,686,640 of the pre<span class="nobreak">-funded</span> warrants were exercised. The remaining 646,640 of pre<span class="nobreak">-funded</span> warrants were exercised during the year ended December&#160;31, 2023. The preferred investment options are exercisable at any time on or after August&#160;11, 2022 through August&#160;12, 2027, at an exercise price of $2.546 per share, subject to certain adjustments as defined in the agreement. During the year ended December&#160;31, 2023, 2,486,214 of these preferred investment options were exercised at a reduced exercise price of $1.09, in connection with the warrant inducement transaction discussed below. As of December&#160;31, 2023, 2,486,214 preferred investment options are outstanding.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Wainwright acted as the exclusive placement agent for the August&#160;2022 Private Placement. The Company agreed to pay Wainwright a placement agent fee and management fee equal to 7.5% and 1.0%, respectively, of the aggregate gross proceeds from the August&#160;2022 Private Placement and reimburse certain out<span class="nobreak">-of-pocket</span> expenses up to an aggregate of $85,000. In addition, the Company issued warrants to Wainwright (the &#8220;August Wainwright Warrants&#8221;) to purchase up to 220,997<span class="nobreak"> </span>shares of common stock. The August Wainwright Warrants are in substantially the same form as the preferred investment options, except that the exercise price is $3.3938. The form of the preferred investment options is a warrant, and as such the preferred investment options, the pre<span class="nobreak">-funded</span> warrants, and the August Wainwright Warrants are collectively referred to as the &#8220;August&#160;2022 Private Placement Warrants&#8221;. Further, upon any exercise for cash of any preferred investment options, the Company agreed to issue to Wainwright additional warrants to purchase the number of shares of common stock equal to 6.0% of the aggregate number of shares of common stock underlying the preferred investment options that have been exercised, also with an exercise price of $3.3938 (the &#8220;August Contingent Warrants&#8221;). The maximum number of August Contingent Warrants issuable under this provision is 298,346, which includes 70,849 of April Contingent Warrants that were modified in connection with the August&#160;2022 Private Placement.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluated the terms of the August&#160;2022 Private Placement Warrants and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC&#160;480 and ASC&#160;815<span class="nobreak">-40</span>. Since the Company determined that the August&#160;2022 Private Placement Warrants were equity<span class="nobreak">-classified</span>, the Company recorded the proceeds from the August&#160;2022 Private Placement, net of issuance costs, within common stock at par value and the balance of the net proceeds to additional paid in capital.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The investors in the April&#160;2022 Private Placement agreed to cancel the aggregate of 1,180,812 preferred investment options issued in the April&#160;2022 Private Placement, as part of their participation in the August&#160;2022 Private Placement. The preferred investment options that were cancelled were effectively exchanged for 1,289,148 new preferred investment options in the August&#160;2022 Private Placement, and accordingly have been accounted for as a modification or exchange of equity<span class="nobreak">-linked</span> instruments. In accordance with ASC&#160;815<span class="nobreak">-40</span>, as the preferred investment options were classified as equity instruments before and after the exchange, and as the exchange is directly attributable to an equity offering, the Company recognized the effect of the exchange as an equity issuance cost. The increase in the fair value of the preferred investment options as a result of the exchange was approximately $860,000, and was determined using the Black<span class="nobreak">-Scholes</span> option pricing model, with the following assumptions:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Original</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Exchanged</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercise price</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.65</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.546</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Term (years)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.67</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.0</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected stock price volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">116.2</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">120.2</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free rate of interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.16</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.98</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluated the terms of the August Contingent Warrants and determined that they should be classified as a liability based upon accounting guidance provided in ASC&#160;815<span class="nobreak">-40</span>. As a result of the exchange of the preferred investment options issued in the April Private Placement, the underlying equity<span class="nobreak">-linked</span> instruments that would trigger issuance of the April Contingent Warrants was replaced, and therefore the 70,849 of April Contingent Warrants were exchanged for 70,849 of the August Contingent Warrants. The value of the April Contingent Warrant liability was adjusted to fair value on the date of modification, using a Monte Carlo simulation, with the change in fair value </p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">of approximately $8,000 recognized in the accompanying consolidated statements of operations and comprehensive loss. The remaining 227,497 August Contingent Warrants were measured as a liability upon the close of the August Private Placement. Since the Contingent Warrants are a form of compensation to the placement agent, the Company recorded the value of the liability of approximately $39,000, as a reduction of additional paid in capital. The entire 298,346 of August Contingent Warrants were remeasured at December&#160;31, 2022, using a Monte Carlo simulation, with the change in the value of the liability recorded in other income (expense) in the accompanying consolidated statements of operations and comprehensive loss. The following significant assumptions were used in the valuation of the contingent warrant liability, related to the August Contingent Warrants, as of the date of the August&#160;2022 Private Placement and as of December&#160;31, 2022:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">August&#160;11,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercise price</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.3938</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.3938</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Term (years)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.00</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.61</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected stock price volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">127.8</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">120.8</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free rate of interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.98</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.03</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December&#160;31, 2023, in connection with the warrant inducement transaction, the Company issued warrants to Wainwright as settlement of the contingent warrant liability associated with 149,173 of the August&#160;2022 Contingent Warrants, which was triggered upon exercise of the underlying preferred investment options. See <span class="Italic" style="font-style:italic;font-weight:normal;">Warrant Inducement </span>below for further discussion.</p>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">At the Market Offering Agreement</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;29, 2023, the Company entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C.&#160;Wainwright&#160;&amp; Co., LLC, as sales agent (the &#8220;Agent&#8221;), to create an at<span class="nobreak">-the-market</span> equity program under which it may sell up to $3,900,000 of shares of the Company&#8217;s common stock (the &#8220;Shares&#8221;) from time to time through the Agent (the &#8220;ATM Offering&#8221;). Under the ATM Agreement, the Agent will be entitled to a commission at a fixed rate of 3.0% of the gross proceeds from each sale of Shares under the ATM Agreement. The Company has no obligation to sell, and the Agent is not obligated to buy or sell, any of the Shares under the Agreement and may at any time suspend offers under the Agreement or terminate the Agreement. The ATM Offering will terminate upon the termination of the ATM Agreement as permitted therein.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Deferred offering costs associated with the ATM Agreement are reclassified to additional paid in capital on a pro<span class="nobreak">-rata</span> basis when the Company completes offerings under the ATM Agreement. Any remaining deferred costs will be expensed to the consolidated statements of operations and comprehensive loss should the planned offering be abandoned.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, no shares have been sold under the ATM Offering.</p>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Warrant Inducement</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On July&#160;31, 2023, the Company entered into a common stock preferred investment options exercise inducement offer letter (the &#8220;Inducement Letter&#8221;) with a holder (the &#8220;Holder&#8221;) of existing preferred investment options (&#8220;PIOs&#8221;) to purchase shares of the Company&#8217;s common stock at the original exercise price of $2.546 per share, issued on August&#160;11, 2022 (the &#8220;Existing PIOs&#8221;). Pursuant to the Inducement Letter, the Holder agreed to exercise for cash its Existing PIOs to purchase an aggregate of 2,486,214<span class="nobreak"> </span>shares of the Company&#8217;s common stock (the &#8220;Inducement PIO Shares&#8221;), at a reduced exercised price of $1.09 per share, in exchange for the Company&#8217;s agreement to issue new preferred investment options (the &#8220;Inducement PIOs&#8221;) to purchase up to 4,972,428<span class="nobreak"> </span>shares of the Company&#8217;s common stock. The Inducement PIOs have substantially the same terms as the Existing PIOs.</p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;2, 2023, the Company consummated the transactions contemplated by the Inducement Letter (the &#8220;Warrant Inducement&#8221;). The Company received aggregate net proceeds of approximately $2.3&#160;million from the Warrant Inducement, after deducting placement agent fees and other offering expenses payable by the Company.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Upon the close of the transaction, the Company issued the Holder 1,575,000 of the 2,486,214<span class="nobreak"> </span>shares of common stock that were issuable upon exercise of the Existing PIOs. Due to the beneficial ownership limitation provisions in the Inducement Letter, the remaining 911,214<span class="nobreak"> </span>shares were initially unissued, and held in abeyance for the benefit of the Holder until notice from the Holder that the shares may be issued in compliance with such limitation is received. These shares were issued to the Holder in October&#160;2023.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company agreed to file a registration statement covering the resale of the Inducement PIO Shares issued or issuable upon the exercise of the Inducement PIOs (the &#8220;Resale Registration Statement&#8221;), as soon as practicable, and to use commercially reasonable efforts to have such Resale Registration Statement declared effective by the SEC within 90&#160;days following the date of the Inducement Letter, and to keep the Resale Registration Statement effective at all times until there are no Inducement PIO Shares. The provision to register the underlying shares in the Warrant Inducement does not require payment related to the registration rights provided. As such, while the shares were not registered within 90&#160;days of the date of the Inducement Letter, there is no accounting impact for this provision.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company engaged Wainwright to act as its placement agent in connection with the Warrant Inducement and paid Wainwright a cash fee equal to 7.5% of the gross proceeds received from the exercise of the Existing PIOs as well as a management fee equal to 1.0% of the gross proceeds from the exercise of the Existing PIOs. The Company also agreed to reimburse Wainwright for its expenses in connection with the exercise of the Existing PIOs and the issuance of the Inducement PIOs, up to $50,000 for fees and expenses of legal counsel and other out<span class="nobreak">-of-pocket</span> expenses and agreed to pay Wainwright for non<span class="nobreak">-accountable</span> expenses in the amount of $35,000. In addition, the exercise for cash of the Existing PIOs triggered the issuance to Wainwright or its designees, warrants to purchase 149,173<span class="nobreak"> </span>shares of common stock (&#8220;Wainwright Inducement Warrants&#8221;), which were issuable in accordance with the terms of the August Contingent Warrants, and have the same terms as the Inducement PIOs except for an exercise price equal to $1.3625 per share. The Company also agreed to issue warrants to Wainwright upon any exercise for cash of the Inducement PIOs, that number of shares of common stock equal to 6.0% of the aggregate number of such shares of common stock underlying the Inducement PIOs that have been exercised, also with an exercise price of $1.3625 (the &#8220;Inducement Contingent Warrants&#8221;). The maximum number of Inducement Contingent Warrants issuable under this provision is 298,346.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluated the terms of the Inducement PIOs and the Wainwright Inducement Warrants (collectively, the &#8220;August&#160;2023 Inducement Warrants&#8221;), and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC&#160;480 and ASC&#160;815<span class="nobreak">-40</span>.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Warrant Inducement, which resulted in the lowering of the exercise price of the Existing PIOs and the issuance of the Inducement PIOs, is considered a modification of the Existing PIOs under the guidance of Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2021<span class="nobreak">-04</span>, <span class="Italic" style="font-style:italic;font-weight:normal;">Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Equity Classified Written Call Options</span>. The modification is consistent with the &#8220;Equity Issuance&#8221; classification under that guidance as the reason for the modification was to induce the holders of the Existing PIOs to cash exercise their warrants, resulting in the imminent exercise of the Existing PIOs, which raised equity capital and generated net proceeds for the Company of approximately $2.3&#160;million. As the Existing PIOs and the Inducement PIOs were classified as equity instruments before and after the exchange, and as the exchange is directly attributable to an equity offering, the Company recognized the effect of the modification of approximately $2.6&#160;million as an equity issuance cost.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the change in fair value of the contingent warrant liability associated with 149,173 of the August Contingent Warrants that were settled through issuance of the Wainwright Inducement Warrants, of approximately $122,000, was recognized in other income (expense) in the accompanying consolidated statements of operations and comprehensive loss, and the fair value of the contingent warrant liability of approximately $129,000 was derecognized as of the settlement date. The corresponding amount, representing the fair value of the Wainwright Inducement Warrants, </p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">was recognized as additional paid in capital. The Company measured the liability on the settlement date using a Black Scholes model, with the following significant assumptions: expected term of <span style="-sec-ix-hidden: hidden-fact-276">5.0</span>&#160;years, expected volatility of 117.8%, risk<span class="nobreak">-free</span> interest rate of 4.24% and dividend yield of 0.0%.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluated the terms of the Inducement Contingent Warrants and determined that they should be classified as a liability based upon accounting guidance provided in ASC&#160;815<span class="nobreak">-40</span>. Since the Inducement Contingent Warrants are a form of compensation to Wainwright, the Company recorded the value of the liability of approximately $26,000 as a reduction of additional paid in capital, with subsequent changes in the value of the liability recorded in other income (expense) in the accompanying consolidated statements of operations and comprehensive loss. The Company measured the liability on the settlement date using a Black Scholes model, with the following significant assumptions: expected term of <span style="-sec-ix-hidden: hidden-fact-277">5.0</span>&#160;years, expected volatility of 117.8%, risk<span class="nobreak">-free</span> interest rate of 4.24% and dividend yield of 0.0%.</p>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Warrants</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following summarizes activity related to the Company&#8217;s outstanding warrants, excluding contingent warrants issuable upon exercise of the preferred investment options, for the year ended December&#160;31, 2023:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Number of<br/>Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life<br/>(in&#160;years)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding as of December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,910,914</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.37</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.7</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,121,601</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.10</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(3,132,854</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.865</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-268">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-269">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding as of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,899,661</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.68</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.3</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Warrants vested and exercisable as of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,899,661</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.68</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.3</p>	</td>
				</tr>

		</table>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, the outstanding warrants include 70,849 April&#160;2022 Private Placement Warrants, 2,707,211 August&#160;2022 Private Placement Warrants, and 5,121,601 August&#160;2023 Inducement Warrants, which are exercisable into 7,899,661<span class="nobreak"> </span>shares of common stock which had a fair value of $0.20 per share, based on the closing trading price on that&#160;day.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, as of December&#160;31, 2023 and 2022, the value of the August Contingent Warrants and the Inducement Contingent Warrants (collectively the &#8220;Contingent Warrants&#8221;) was approximately $3,000 and $14,000, respectively. The maximum number of warrants issuable upon settlement of the Contingent Warrants as of December&#160;31, 2023 and 2022 was 447,519 and 298,346, respectively.</p>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Onconetix Equity Incentive Plans</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) was adopted by its board of directors and by its stockholders on July&#160;1, 2019. The Company has reserved 1,400,000<span class="nobreak"> </span>shares of common stock for issuance pursuant to the 2019 Plan.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;23, 2022 and in connection with the closing of the IPO, the Company&#8217;s board of directors adopted the Company&#8217;s 2022 Equity Incentive Plan (the &#8220;2022 Plan&#8221;), which is the successor and continuation of the Company&#8217;s 2019 Plan. Under the 2022 Plan, the Company may grant stock options, restricted stock, restricted stock units, stock appreciation rights, and other forms of awards to employees, directors, and consultants of the Company. Upon its effectiveness, a total of 1,600,000<span class="nobreak"> </span>shares of common stock were reserved for issuance under the 2022 Plan. In August&#160;2022, the number of shares of common stock reserved for issuance under the 2022 Plan was increased to 2,600,000 and in May&#160;2023, the number of shares of common stock reserved for issuance under the 2022 Plan was </p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">increased to 3,150,000. The stock options and restricted stock granted during the&#160;years ended December&#160;31, 2023 and 2022 were all granted under the 2022 Plan. As of December&#160;31, 2023, there are 718,402<span class="nobreak"> </span>shares available for issuance under the 2022 Plan.</p>
		<p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stock Options</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following summarizes activity related to the Company&#8217;s stock options under the 2019 Plan and the 2022 Plan for the year ended December&#160;31, 2023:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Number of<br/>Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Total<br/>Intrinsic<br/>Value</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(in&#160;years)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding as of December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,392,654</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.30</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">670,161</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.2</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">962,154</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.48</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-270">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited/cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(404,058</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.87</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-271">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(45,920</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.01</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45,920</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding as of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,904,830</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.63</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">94,239</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.4</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and exercisable as of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">861,177</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.23</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">94,239</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.1</p>	</td>
				</tr>

		</table>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of options granted in 2023 and 2022 was estimated using the following assumptions:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-28" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">For the <br/>Year Ended <br/>December&#160;31, <br/>2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">For the <br/>Year Ended <br/>December&#160;31, <br/>2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercise price</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">$0.26&#160;&#8211;&#160;1.29</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">$1.06&#160;&#8211;&#160;6.45</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Term (years)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5.00&#160;&#8211;&#160;10.00</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5.00&#160;&#8211;&#160;10.00</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected stock price volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">101.1%&#160;&#8211;&#160;119.5</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">112.6%&#160;&#8211;&#160;121.2%</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free rate of interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3.5%&#160;&#8211;&#160;4.7%</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2.9%&#160;&#8211;&#160;4.3%</p>	</td>
				</tr>

		</table>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The weighted average grant date fair value of stock options granted during the&#160;years ended December&#160;31, 2023 and 2022 was $0.41 and $3.40, respectively. The aggregate fair value of stock options that vested during the&#160;years ended December&#160;31, 2023 and 2022 was approximately $0.7&#160;million and $2.1&#160;million, respectively.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On October&#160;4, 2023, the Company&#8217;s board of directors granted an aggregate of 709,768 stock options in connection with the appointment of the Company&#8217;s newly hired Chief Executive Officer and Chief Financial Officer. The options granted have an exercise price of $0.4305 per share, vest quarterly over a three<span class="nobreak">-year</span> period, and have a grant date fair value of approximately $0.2&#160;million. The Company recognized less than $0.1&#160;million of stock<span class="nobreak">-based</span> compensation expense related to these awards during the year ended December&#160;31, 2023. Subsequent to December&#160;31, 2023, in connection with the resignation of the newly hired Chief Executive Officer, 487,965 of these options were forfeited (see Note&#160;14).</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December&#160;31, 2022, 200,000 stock options were granted to the Company&#8217;s former Chief Executive Officer (&#8220;former CEO&#8221;), Chairman, and significant stockholder, 200,000 stock options were granted to the Company&#8217;s former Chief Business Officer (&#8220;former CBO&#8221;), and 100,000 stock options were granted to the Company&#8217;s former Chief Financial Officer (&#8220;former CFO&#8221;). The aggregate grant<span class="nobreak">-date</span> fair value of the stock options granted to these individuals was approximately $1.8&#160;million, of which approximately $1.5&#160;million was recognized as stock<span class="nobreak">-based</span> compensation expense during the year ended December&#160;31, 2022. During the year ended December&#160;31, 2023, in connection with the resignation of the former CEO and the former CFO, 250,000 of these stock options were forfeited.</p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, during the year ended December&#160;31, 2022, the Company granted an aggregate of 72,223 stock options to non<span class="nobreak">-executive</span> directors. The grant<span class="nobreak">-date</span> fair value of the stock options granted to the non<span class="nobreak">-executive</span> directors was approximately $0.2&#160;million, of which approximately $0.2&#160;million was recognized as stock<span class="nobreak">-based</span> compensation expense during the year ended December&#160;31, 2022.</p>
		<p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Restricted Stock</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On May&#160;9, 2023, the Board&#8217;s Compensation Committee approved the issuance of restricted stock, granted under the Company&#8217;s 2022 Plan, to the Company&#8217;s executive officers, employees, and certain of the Company&#8217;s consultants. The restricted shares granted totaled 487,500, of which 150,000, 75,000, and 150,000 were granted to the Company&#8217;s former CEO, former CFO, and former CBO, respectively. All of the restricted shares granted vest as follows: 50% in January&#160;2024, 25% in August&#160;2024, and 25% in August&#160;2025. In addition, on May&#160;31, 2023, the Board&#8217;s Compensation Committee approved the issuance of 25,440<span class="nobreak"> </span>shares of restricted stock, granted to the Company&#8217;s non<span class="nobreak">-executive</span> Board members, with full vesting on May&#160;31, 2024.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;16, 2023 and October&#160;4, 2023, upon their respective resignations, the Company&#8217;s former CEO and former CFO forfeited 150,000<span class="nobreak"> </span>shares and 75,000<span class="nobreak"> </span>shares of unvested restricted stock, respectively.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Number of<br/>Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Nonvested as of December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-272">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-273">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">512,940</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.01</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited/cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(250,110</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.02</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,250</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.03</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Nonvested as of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">256,580</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.03</p>	</td>
				</tr>

		</table>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Proteomedix Stock Option Plan</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix sponsors a stock option plan (the &#8220;PMX Option Plan&#8221;) which provides common stock option grants to be granted to certain employees and consultants, as was determined by the board of directors of Proteomedix. In connection with the PMX Transaction, the Company assumed the PMX Option Plan (see Note&#160;5).</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Generally, options issued under the PMX Option Plan have a term of less than <span style="-sec-ix-hidden: hidden-fact-278">11</span>&#160;years and provide for a <span style="-sec-ix-hidden: hidden-fact-279">four</span><span class="nobreak">-year</span> vesting period during which the grantee must remain in the service of Proteomedix. Stock options issued under the PMX Option Plan are measured at fair value using the Black<span class="nobreak">-Scholes</span> option pricing model.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">There was no activity under the PMX Option Plan between the Acquisition Date and December&#160;31, 2023. As of December&#160;31, 2023, there were 58,172 and 57,276 stock options outstanding and vested, respectively, with a weighted average exercise price of $3.46 and $3.17, respectively, and a weighted average remaining contractual life of <span style="-sec-ix-hidden: hidden-fact-280">5.36</span>&#160;years and <span style="-sec-ix-hidden: hidden-fact-281">5.20</span>&#160;years, respectively. The intrinsic value of options outstanding and vested, as of December&#160;31, 2023 was approximately $7.4&#160;million and $7.1&#160;million, respectively. As of December&#160;31, 2023 there were 47,990 stock options exercisable at a weighted average exercise price of $3.94 and a weighted average remaining contractual life of <span style="-sec-ix-hidden: hidden-fact-282">4.53</span>&#160;years.</p><p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Stock<span class="nobreak">-based</span> compensation expense for the&#160;years ended December&#160;31, 2023 and 2022 was as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">For the&#160;Years Ended</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Selling, general and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">234,298</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,309,687</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">95,462</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">664,879</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">329,760</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">1,974,566</span></p>	</td>
				</tr>

		</table>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, unrecognized stock<span class="nobreak">-based</span> compensation expense relating to outstanding stock options and unvested restricted stock under the Onconetix Equity Incentive Plans is approximately $345,000 and $35,000, respectively, which is expected to be recognized over a weighted<span class="nobreak">-average</span> period of <span style="-sec-ix-hidden: hidden-fact-283">1.79</span>&#160;years and <span style="-sec-ix-hidden: hidden-fact-284">1.57</span>&#160;years, respectively.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, unrecognized stock<span class="nobreak">-based</span> compensation expense relating to outstanding stock options under the PMX Option Plan is approximately $0.1&#160;million, which will be recognized over a weighted<span class="nobreak">-average</span> period of <span style="-sec-ix-hidden: hidden-fact-285">2.98</span>&#160;years.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December&#160;31, 2023, in connection with the former CBO&#8217;s resignation from the Company, the individual&#8217;s outstanding stock options and restricted stock awards were modified to allow continued vesting during the term of the consulting agreement entered into in January&#160;2024. The Company recognized a net credit of approximately $165,000 to stock<span class="nobreak">-based</span> compensation expense as a result of this modification, primarily due to the decrease in the Company&#8217;s stock price.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December&#160;31, 2022, the Company&#8217;s board of directors approved the accelerated vesting of an aggregate of 32,517 stock options to a former director and a former advisor, in connection with their separation from the Company. The Company recognized stock<span class="nobreak">-based</span> compensation expense of approximately $0.1&#160;million related to these modifications during the year ended December&#160;31, 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666107660144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;10 &#8212; Commitments and Contingencies</span></p>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix leases office and lab space in Zurich Switzerland, which requires lease payments of approximately $74,000 for the&#160;years ended December&#160;31, 2024 and 2025, and which is insignificant to the Company&#8217;s consolidated financial statements.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company entered into a short<span class="nobreak">-term</span> lease in Palm Beach, Florida with an unrelated party, with a commencement date of May&#160;1, 2022, for approximately $14,000 per month. The lease, which was personally guaranteed by the Company&#8217;s former CEO, ended on April&#160;30, 2023. During the&#160;years ended December&#160;31, 2023 and 2022, the Company incurred rent expense on this lease of approximately $51,000 and $129,000, respectively, and variable lease expense of approximately $4,000 and $12,000, respectively.</p>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Litigation</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. As of December&#160;31, 2023, the Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims.</p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;15, 2022, the Company received a demand letter (the &#8220;Demand Letter&#8221;) from Boustead. The Demand Letter alleged that the Company breached the Underwriting Agreement entered into between Boustead and the Company, dated February&#160;17, 2022, in connection with the Company&#8217;s initial public offering. The Demand Letter alleged that, by engaging Wainwright as placement agent in the April Private Placement, the Company breached Boustead&#8217;s right of first refusal (&#8220;ROFR&#8221;) to act as placement agent granted to Boustead under the Underwriting Agreement and, as a result of selling securities in the April Private Placement, breached the Company&#8217;s obligation under the Underwriting Agreement not to offer, sell, issue, agree or contract to sell or issue or grant or modify the terms of any option for the sale of, any securities prior to February&#160;17, 2023 (the &#8220;Standstill&#8221;).</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On October&#160;9, 2022, the Company and Boustead entered into a Settlement Agreement and Release (the &#8220;Settlement Agreement&#8221;), pursuant to which Boustead agreed to waive the ROFR and the Standstill, and to release the Company from certain claims with respect to the April Private Placement, the August Private Placement, and all future private, public equity or debt offerings of the Company. As consideration for such waiver and termination of the Underwriting Agreement, the Company paid Boustead a cash fee of $1,000,000, $50,000 in legal expenses, and released Boustead from all claims, subject to certain exceptions. In addition, the Company issued to Boustead 93,466<span class="nobreak"> </span>shares of restricted common stock in exchange for the cancellation of 111,111&#160;warrants issued to Boustead in connection with the IPO (see Note&#160;9). Concurrent with the execution of the Settlement Agreement, the Company and Boustead Capital Markets, LLP (&#8220;Boustead Capital&#8221;) entered into a three<span class="nobreak">-month</span> Advisory Agreement (the &#8220;Advisory Agreement&#8221;) for which consideration equal to 200,000<span class="nobreak"> </span>shares of restricted common stock, with no vesting provisions, was issued to Boustead Capital upon execution of the Advisory Agreement. The incremental fair value of the Warrant Exchange and the fair value of the restricted common stock issued in connection with these agreements totaled approximately $264,000. See Note&#160;9.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company determined that all consideration due by the Company under the Settlement Agreement and the Advisory Agreement relates to the settlement of a liability that was incurred in 2022 and accordingly, recorded a related expense of approximately $1.3&#160;million for the year ended December&#160;31, 2022, which is included in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</p>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Registration Rights Agreements</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the April&#160;2022 Private Placement (see Note&#160;9), the Company entered into a Registration Rights Agreement with the purchasers, dated as of April&#160;13, 2022 (the &#8220;April Registration Rights Agreement&#8221;). The April Registration Rights Agreement provides that the Company shall file a registration statement covering the resale of all of the registrable securities (as defined in the April Registration Rights Agreement) with the SEC.&#160;The registration statement on Form&#160;S<span class="nobreak">-1</span> required under the April Registration Rights Agreement was filed with the SEC on May&#160;3, 2022 and became effective on May&#160;20, 2022. A post<span class="nobreak">-effective</span> amendment to the Form&#160;S<span class="nobreak">-1</span> on Form&#160;S<span class="nobreak">-3</span> relating to such registration statement was filed with the SEC on April&#160;28, 2023.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the August&#160;2022 Private Placement (see Note&#160;9), the Company entered into a Registration Rights Agreement with the purchasers, dated as of August&#160;9, 2022 (the &#8220;August Registration Rights Agreement&#8221;). The August Registration Rights Agreement provides that the Company shall file a registration statement covering the resale of all of the registrable securities (as defined in the August Registration Rights Agreement) with the SEC.&#160;The registration statement on Form&#160;S<span class="nobreak">-1</span> required under the August Registration Rights Agreement was filed with the SEC on August&#160;29, 2022 and became effective on September&#160;19, 2022. A post<span class="nobreak">-effective</span> amendment to the Form&#160;S<span class="nobreak">-1</span> on Form&#160;S<span class="nobreak">-3</span> relating to such registration statement was filed with the SEC on April&#160;28, 2023.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Upon the occurrence of any Event (as defined in the April Registration Rights Agreement and the August Registration Rights Agreement), which, among others, prohibits the purchasers from reselling the securities for more than ten consecutive calendar&#160;days or more than an aggregate of fifteen calendar&#160;days during any 12<span class="nobreak">-month</span> period, and should the registration statement cease to remain continuously effective, the Company would be obligated to pay to each purchaser, on each monthly anniversary of each such Event, an amount in cash, as partial liquidated damages and not as a penalty, equal to the product of 2.0% multiplied by the aggregate subscription amount paid by such purchaser </p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">in the Private Placement. As of December&#160;31, 2023, the Company determined that the likelihood of the Company incurring liquidated damages pursuant to the April Registration Rights Agreement and the August Registration Rights Agreement is remote, and as such, no accrual of these payments is required as of December&#160;31, 2023.</p>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Milestone and Royalty Obligations</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company has entered into various license agreements with third parties that obligate the Company to pay certain development, regulatory, and commercial milestones, as well as royalties based on product sales (see Note&#160;6). As of December&#160;31, 2023, the Company terminated all license agreements, except for the CHMC Agreement, which could require the Company to pay CHMC milestone payments of up to an aggregate of $59.75&#160;million. As of December&#160;31, 2023, the Company evaluated the likelihood of the Company achieving the specified milestones and generating product sales, and determined the likelihood is not yet probable and as such, no accrual of these payments is required as of December&#160;31, 2023.</p>
		<p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Underwriter Termination Agreement</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;7, 2022, the Company and its former underwriter, Maxim Group (&#8220;Maxim&#8221;), entered into a termination agreement, whereby the parties agreed to terminate their engagement of Maxim as the Company&#8217;s lead managing underwriter and book runner in connection with the Company&#8217;s IPO.&#160;Per the terms of the termination agreement, the Company agreed to pay Maxim a termination fee of $300,000, due upon the close of the Company&#8217;s IPO.&#160;The termination fee was recorded as selling, general and administrative expense, and paid, during the year ended December&#160;31, 2022.</p>
		<p class="H4" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Indemnification</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not been required to defend any action related to its indemnification obligations. However, during the third quarter of 2023, the Company received a claim from its former CEO and a former accounting employee requesting advancement of certain expenses. The Company recorded approximately $209,000 in related expenses during the year ended December&#160;31, 2023, of which approximately $159,000 was paid through reduction of the outstanding related party receivable due from the former CEO (see Note&#160;11). As of December&#160;31, 2023, the Company recorded a related accrual of approximately $50,000, which is included in accrued expenses in the accompanying consolidated balance sheets, and which was paid subsequent to year end. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is not estimable at this time.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666109275456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;11 &#8212; Related Party Transactions</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company originally engaged the former CEO, who was also the Board Chairman and prior to the close of the IPO, sole common stockholder of the Company, pursuant to a consulting agreement commencing October&#160;22, 2018, which called for the Company to pay for consulting services performed on a monthly basis. Upon the close of the Company&#8217;s IPO, the consulting agreement was terminated, and the former CEO&#8217;s employment agreement became effective. During the year ended December&#160;31, 2022, the Company incurred approximately $63,000 in fees under the consulting agreement, which are recognized in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During 2022 the Company entered into a lease agreement that was personally guaranteed by the Company&#8217;s former CEO.&#160;The lease expired in 2023. See Note&#160;10.</p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December&#160;31, 2022, the Company&#8217;s compensation committee approved one<span class="nobreak">-time</span> bonus awards of $140,000 and $100,000 to the Company&#8217;s former CEO and former CBO, respectively, in recognition of their efforts in connection with the Company&#8217;s IPO.&#160;These bonuses were recognized during the year ended December&#160;31, 2022, as selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December&#160;31, 2023, the Company&#8217;s Audit Committee completed a review of the Company&#8217;s expenses due to certain irregularities identified with regards to the related party balance. Based on the results of the review, it was determined that the Company paid and recorded within selling, general and administrative expenses, personal expenditures of the Company&#8217;s former CEO and an accounting employee who was also the former CEO&#8217;s assistant, during 2022 and during the first three quarters of 2023. The Company evaluated the receivable, which aggregated to approximately $522,000 as of September&#160;30, 2023, and which represented the total of the items identified as personal in nature for which the Company did not anticipate recovery from the related party. As the Company concluded that the remaining amounts are not likely to be recovered, this would not cause an adjustment to previously issued financial statements. The Company recorded a corresponding reserve for the full amount, resulting in a net related party receivable balance of <span style="-sec-ix-hidden: hidden-fact-286">$0</span> and a loss on related party receivable of approximately $266,000, which was recorded in selling, general, and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2023. During the fourth quarter of 2023, the Company recorded a recovery of approximately $159,000 with respect to amounts that the former CEO agreed to repay the Company, through a reduction of amounts that were due to him from the Company under his indemnification rights pursuant to his employment agreement (see Note&#160;10).</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2022, the Company had a receivable from related party of approximately $36,000, consisting of miscellaneous payments made by the Company on the behalf of the Company&#8217;s CEO, and which was paid in full during the first quarter of 2023.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;18, 2023, the Company entered into the Subscription Agreement with the PMX Investor, a 5% stockholder of the Company as of December&#160;31, 2023 (see Note&#160;8). Subsequent to December&#160;31, 2023, the Company issued a non<span class="nobreak">-convertible</span> debenture in the principal amount of $5.0&#160;million to the PMX Investor, in connection with the Subscription Agreement (see Note&#160;14).</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A former director of the Company, who served on the Company&#8217;s Scientific Advisory Board until August&#160;2023, serves on the Advisory Board for the Cincinnati Children&#8217;s Hospital Medical Center Innovation Fund, which is affiliated with CHMC.&#160;The Company has an exclusive license agreement with CHMC as disclosed in Note&#160;5. This director resigned from the Company&#8217;s board upon the close of its IPO.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666109310704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNetAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;12 &#8212; Income Taxes</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The components of loss before income taxes are as follows:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">For the&#160;Years Ended</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">U.S.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(37,106,599</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(13,419,830</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Foreign</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(315,688</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-287">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total loss before income taxes</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(37,422,287</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(13,419,830</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s major tax jurisdictions are the United&#160;States, Switzerland, and various state jurisdictions, and the Company does not have any pending tax audits. The income tax benefit recorded for the year ended December&#160;31, 2023 related to the Company&#8217;s deferred foreign taxes. There was no income tax provision or benefit recorded for the year ended December&#160;31, 2022. Generally, the Company&#8217;s federal returns from 2019 on and state returns from </p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">2018 on, and foreign returns from 2018 on, are subject to examination by the United&#160;States, state, and foreign tax authorities; however, to the extent allowed by law, tax authorities have the ability to adjust the Company&#8217;s carryforwards of unutilized net operating losses and research and development credits for all&#160;years.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">At December&#160;31, 2023, the Company had a net operating loss (&#8220;NOL&#8221;) carryforward for federal, foreign, and state income tax purposes totaling approximately $27.9&#160;million, $18.0&#160;million, and $23.8&#160;million, respectively, available to reduce future taxable income. The federal NOL and certain state NOLs of $16.8&#160;million are carried forward indefinitely subject to a limitation of 80% of taxable income. State NOLs of approximately $6.8&#160;million will begin to expire in 2024 if not utilized, and foreign NOLs of approximately $15.1&#160;million will begin to expire in 2024 if not utilized.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The NOL carry forward is subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Under the Internal Revenue Code (&#8220;IRC&#8221;) Sections 382 and 383, annual use of the Company&#8217;s net operating loss carryforwards and research credit carryforwards to offset taxable income and tax, respectively, may be limited based on cumulative changes in ownership. The Company has not completed an analysis to determine whether any such limitations have been triggered as of December&#160;31, 2023. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The tax effects of the temporary differences and carryforwards that give rise to deferred tax assets and liabilities consist of the following:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">As of December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Deferred tax assets:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net-operating loss carryforward</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,214,760</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,986,738</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Intangibles</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,349,919</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">885,176</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,171,320</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-288">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">690,760</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">308,552</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deposit on WraSer APA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">854,896</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-289">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">150,099</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">186,573</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">License agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">49,157</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">82,626</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">520,207</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">65,886</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Gross deferred tax assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17,001,118</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,515,551</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(15,697,701</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,512,546</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Deferred tax assets, net of allowance</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,303,417</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,005</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Deferred tax liabilities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Intangible assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,345,449</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-290">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fixed assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,560</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(3,005</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(29,189</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-291">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total deferred tax liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,377,198</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(3,005</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net deferred tax liability</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(3,073,781</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-292">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. The Company has recorded a valuation allowance against its United&#160;States and foreign deferred tax assets in each of the&#160;years ended December&#160;31, 2023 and 2022, because the Company&#8217;s management believes that it is more likely than not that these assets will not be realized. During the&#160;years ended December&#160;31, 2023 and 2022, the valuation allowance increased by approximately $11.2&#160;million and $3.2&#160;million, respectively.</p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The provision for income taxes on earnings subject to income taxes differs from the statutory Federal rate at December&#160;31, 2023 and 2022, due to the following:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">For the&#160;Years Ended</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected income tax benefit at Federal statutory tax rate</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,858,680</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,818,164</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">State and local taxes, net of Federal tax benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,192,605</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(501,277</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-293">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(16,477</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Foreign NOL expirations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">315,927</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-294">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">196,025</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-295">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subscription agreement liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">181,440</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-296">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Officer&#8217;s compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(126,337</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-297">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Acquisition related costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">164,073</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-298">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Permanent items</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55,486</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">194,705</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">State rate adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(23,135</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">19,600</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">60,599</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(37,260</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8,214,614</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,158,873</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Income tax benefit</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(12,593</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-299">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Under U.S.&#160;GAAP, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more<span class="nobreak">-likely-than-not</span> to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, U.S.&#160;GAAP provides guidance on derecognition, classification, interest and penalties, accounting for interim periods, disclosure, and transition.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">For the&#160;Years Ended</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Beginning balance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17,010</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-300">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Increases related to prior year tax positions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-301">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,517</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Increases related to current year tax positions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-302">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,493</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ending balance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17,010</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17,010</p>	</td>
				</tr>

		</table>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">At December&#160;31, 2023 and 2022, the Company&#8217;s unrecognized tax benefits were $17,010. Due to the existence of the valuation allowance, future changes in the Company&#8217;s unrecognized tax benefits will not impact the effective tax rate. The Company does not expect its unrecognized tax benefits to change significantly over the next 12&#160;months.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2023 and 2022, there were no accrued interest and penalties associated with uncertain tax positions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666109201456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAbstract', window );"><strong>Retirement Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plans</a></td>
<td class="text"><p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;13 &#8212; Retirement Plans</span></p>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Defined Contribution Plans</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Effective January&#160;1, 2022, the Company adopted a defined contribution savings plan pursuant to Section&#160;401(k)&#160;of the Internal Revenue Code (&#8220;the 2022 401(k)&#160;Plan&#8221;). The 2022 401(k)&#160;Plan was for the benefit of all qualifying employees and permits voluntary contributions by employees of up to 100% of eligible compensation, subject to the maximum limits imposed by the Internal Revenue Service. The terms of the 2022 401(k)&#160;Plan allowed for discretionary employer contributions. No expenses were incurred related to the 2022 401(k)&#160;Plan during the year ended December&#160;31, 2022 and the 2022 401(k)&#160;Plan lapsed during 2022 due to inactivity.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On May&#160;31, 2023, the Board voted to adopt a 401(k)&#160;Safe Harbor Non<span class="nobreak">-Elective</span> Plan (the &#8220;2023 401(k)&#160;Plan&#8221;). The 2023 401(k)&#160;Plan was an employee savings and retirement plan to which substantially all employees could have contributed, including the Company&#8217;s named executive officers, effective July&#160;1, 2023. Pursuant to the 2023 401(k)&#160;Plan, employee and Company contributions would vest immediately, subject to a three<span class="nobreak">-month</span> waiting period for new hires. The Company was required to contribute 3% of gross pay to eligible employees&#8217; 401(k)&#160;Plans. On November&#160;16, 2023, the 2023 401(k)&#160;Plan was terminated. No expenses were incurred related to the 2023 401(k)&#160;Plan during the year ended December&#160;31, 2023.</p>
		<p class="H3" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Defined Benefit Plan</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix sponsors a defined benefit pension plan covering certain eligible employees. The Swiss Plan provides retirement benefits based on&#160;years of service and compensation levels.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The value of the pension obligation is determined using the Projected Unit Credit method. This method sees each period of service as giving rise to an additional unit of benefit entitlements/employee benefits. The value of the Company&#8217;s employee benefit obligations for active employees, or the Projected Benefit Obligation, on the reporting date is the same as the present value of the degree of entitlement existing on this date, in terms of future salary and pension increases and turnover rates. The valuation of pension obligations of pensioners is made on the basis of the present value of current pensions taking into account future increases in pensions. The service costs are calculated using the present value of the entitlements to employee benefits earned during the year for which calculations are made.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As is customary with Swiss pension plans, the assets of the Swiss Plan are invested in a collective fund with multiple employers. Neither Proteomedix nor Onconetix have investment authority over the assets of the Swiss Plan that are held and invested by a Swiss insurance company. Investment holdings are made with respect to Swiss laws and target allocations for plan assets, and are 38% debt securities and cash, 26% equity securities, 12% alternative investments and 24% real estate investments. The valuation of the collective fund assets as a whole is a Level 3 measurement; however, the individual investments of the fund are generally Level 1 (equity securities), Level 2 (fixed income) and Level 3 (real estate, infrastructure and alternative) investments. We determine the fair value of the plan assets based on information provided by the collective fund. See Note&#160;3, &#8220;Summary of Significant Accounting Policies&#8221; for additional information on the three<span class="nobreak">-tier</span> fair value hierarchy.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following significant actuarial assumptions were used in calculating the benefit obligation and the net periodic <span style="-sec-ix-hidden: hidden-fact-304">benefit cost</span> as of December&#160;31, 2023:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Discount rate</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.45</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected long-term rate of return on plan assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.45</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Rate of compensation increase</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.00</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Changes in these assumptions may have a material impact on the plan&#8217;s obligations and costs.</p><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The components of net periodic benefit cost for the period from December&#160;15, 2023 to December&#160;31, 2023 are as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Service cost</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,278</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest cost</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,943</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected return on plan assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,581</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amortization of net (gain)/loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,534</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Settlements (gain)/loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,157</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,949</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The components of accumulated comprehensive loss attributable to the Company&#8217;s pension plan for the period from December&#160;15, 2023 to December&#160;31, 2023 are as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss (gain)</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,277</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amortization of net gain</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,534</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effect of settlement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,157</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other adjustments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,005</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total recorded during the period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,963</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, the funded status of the plan and the amounts recognized in the accompanying consolidated balance sheet are as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Projected benefit obligation</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,299,970</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fair value of plan assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,743,674</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Overfunded (underfunded) status</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(556,296</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">There were no Company contributions made to the plan during the period from December&#160;15, 2023 to December&#160;31, 2023.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A reconciliation of the beginning and ending balances of the accumulated benefit obligation is provided in the table below:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">As of December&#160;15, 2023</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,288,273</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Service cost</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,278</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest cost</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,943</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Actuarial (gain) loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,979</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Benefits paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(905</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ordinary contributions paid by employees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,005</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contributions paid by plan participants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">769</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Settlements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,372</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Projected benefit obligation as of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,299,970</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Actuarial (gain)/loss due to assumption changes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8,834</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Actuarial (gain)/loss due to plan experience</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(855</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated benefit obligation as of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,307,949</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A reconciliation of the beginning and ending balances of the plan assets is provided in the table below:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">As of December&#160;15, 2023</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,739,889</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Actual return on plan assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,283</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contributions paid by employer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,005</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ordinary contributions paid by employees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,005</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contributions paid by plan participants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">769</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Benefits paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(905</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Settlements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,372</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">As of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,743,674</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Projected benefit payments for the next five&#160;years as of December&#160;31, 2023 are as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Years ending December&#160;31,</span></p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-303">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">95,100</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2026</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">95,100</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2027</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">95,100</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2028</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">95,100</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thereafter</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">553,900</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">934,300</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666109157616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p class="H2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Note&#160;14 &#8212; Subsequent Events</span></p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On January&#160;23, 2024, the Company issued a non<span class="nobreak">-convertible</span> debenture (the &#8220;Debenture&#8221;) to the PMX Investor, a related party, in the principal sum of $5.0&#160;million, in connection with the Subscription Agreement discussed in Note&#160;8. The Debenture has an interest rate of 4.0% per annum, and the principal and accrued interest are payable in full upon the earlier of (i)&#160;the closing under the Subscription Agreement and (ii)&#160;June&#160;30, 2024. Additionally, the $5.0&#160;million subscription amount under the Subscription Agreement shall be increased by the amount of interest payable under the Debenture.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Effective as of January&#160;10, 2024, Dr.&#160;Neil Campbell resigned as President and Chief Executive Officer and a member of the Board of Directors of the Company. The Company and Dr.&#160;Campbell entered into a Release of Claims agreement, pursuant to which Dr.&#160;Campbell will receive a severance payment of $158,333 in two equal payments.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;6, 2024, the Company appointed Thomas Meier, PhD, as a member of the Company&#8217;s board of directors. Dr.&#160;Meier provides consulting services to Proteomedix, through a consulting agreement that was executed on January&#160;4, 2024.</p>
		<p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During March&#160;2024, Zydus Life Sciences received FDA approval for a combined finasteride<span class="nobreak">-tadalafil</span> capsule, which is a direct competitor product to ENTADFI.&#160;The Company determined that this is a triggering event during the first quarter of 2024 for its ENTADFI asset group, which includes long<span class="nobreak">-lived</span> assets with a remaining carrying amount of approximately $3.3&#160;million as of December&#160;31, 2023. As such, it is reasonably possible that the resulting impairment test will result in additional impairment losses in the near term.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666108125776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The preparation of the consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of </p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">revenue and expenses during the reporting periods. The most significant estimates in the Company&#8217;s consolidated financial statements relate to accounting for acquisitions, valuation of inventory, the useful life of the amortizable intangible assets, estimates of future cash flows used to evaluate impairment of intangible assets, accrued research and development expenses, assumptions related to the pension benefit obligation, stock<span class="nobreak">-based</span> compensation, the valuation of preferred stock, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in financial institutions, which, at times, exceed the Federal Depository Insurance Coverage limit for those maintained in the United&#160;States and exceed the Swiss Financial Market Supervisory Authority for those maintained in Switzerland. As of December&#160;31, 2023 and 2022, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Segment Information</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;), or decision<span class="nobreak">-making</span> group, in deciding how to allocate resources and in assessing performance. Prior to the acquisition of ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> during the quarter ended June&#160;30, 2023, the Company managed one distinct business segment, which was vaccine discovery and development. During the second quarter of 2023, as a result of the acquisition of ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span>, the Company operated in two business segments: research and development and commercial. During the third quarter of 2023, the Company deprioritized its vaccine discovery and development programs, and accordingly, as of December&#160;31, 2023, the Company was operating in one segment: commercial. Management&#8217;s determination of its operating segments is consistent with the financial information regularly reviewed by the CODM for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The distribution of revenue by geographical area was as follows:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Years Ended <br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">United&#160;States</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-233">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-234">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Switzerland</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">58,465</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-235">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">58,465</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-236">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
				</tr>

		</table><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The distribution of long<span class="nobreak">-lived</span> assets by geographical area, which includes property and equipment and the Company&#8217;s right of use asset, was as follows:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Years Ended <br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">United&#160;States</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,956</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,089</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Switzerland</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">198,240</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-237">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">209,196</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">14,089</span></p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Foreign Currency Translation</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The financial statements of Proteomedix, the Company&#8217;s foreign subsidiary, are measured using the local currency, which is the Swiss Franc, as the functional currency. Assets and liabilities of this subsidiary are translated into U.S.&#160;dollars at exchange rates as of the consolidated balance sheet date. Equity is translated at historical exchange rates. Revenues and expenses are translated into U.S.&#160;dollars at average rates of exchange in effect during the period. The resulting cumulative translation adjustments have been recorded as a separate component of stockholders&#8217; equity, as accumulated other comprehensive income or loss. Foreign currency transaction gains and losses are included in the results of operations, and were not significant for the&#160;years ended December&#160;31, 2023, or 2022.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts receivable</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accounts receivable</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company performs periodic credit evaluations of its customers&#8217; financial condition and extends credit to virtually all of its customers on an uncollateralized basis. Credit losses to date have been insignificant and within management&#8217;s expectations. The Company provides an allowance for doubtful accounts that is based upon a review of outstanding receivables, historical collection information, expected future losses, and existing economic conditions. As of December&#160;31, 2023, there was no allowance for doubtful accounts. As of December&#160;31, 2023, substantially all of the Company&#8217;s accounts receivable are due from a single customer.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Inventories</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Inventories consist of product acquired in the ENTADFI and Proteomedix transactions. Inventories are stated at the lower of cost or net realizable value, with cost determined on a first<span class="nobreak">-in</span>, first<span class="nobreak">-out</span> basis, aside from inventories acquired in an asset acquisition or business combination, which are recorded at fair value. The Company periodically reviews the composition of inventory in order to identify excess, obsolete, slow<span class="nobreak">-moving</span> or otherwise non<span class="nobreak">-saleable</span> items taking into account anticipated future sales compared with quantities on hand, and the remaining shelf life of goods on hand. If non<span class="nobreak">-saleable</span> items are observed and there are no alternate uses for the inventory, the Company records a write<span class="nobreak">-down</span> to net realizable value in the period that the decline in value is first recognized. The Company recorded an impairment of inventory in the amount of approximately $1.2&#160;million during the year ended December&#160;31, 2023, as a result of the delay in launching ENTADFI and the Company&#8217;s decision to pause related commercialization activities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment consists of laboratory equipment, computers, and office furniture and fixtures, all of which are recorded at cost. Depreciation is recorded using the straight<span class="nobreak">-line</span> method over the respective useful lives of the assets ranging from <span style="-sec-ix-hidden: hidden-fact-250">two</span> to <span style="-sec-ix-hidden: hidden-fact-251">ten</span>&#160;years. Depreciation expense was approximately $7,000 for each of the&#160;years ended December&#160;31, 2023 and 2022 and is included in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AcquisitionsPolicyTextBlock', window );">Acquisitions</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Acquisitions</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluates acquisitions to first determine whether a set of assets acquired constitutes a business and should be accounted for as a business combination. If the assets acquired are not a business, the transaction is accounted as an asset acquisition in accordance with Accounting Standards Codification (&#8220;ASC&#8221;)&#160;805<span class="nobreak">-50</span>, <span class="Italic" style="font-style:italic;font-weight:normal;">Asset Acquisitions</span> (&#8220;ASC&#160;805<span class="nobreak">-50</span>&#8221;), which requires the acquiring entity to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, except for non<span class="nobreak">-qualifying</span> assets including financial assets such as inventory. Further, the cost of the acquisition includes the fair value of consideration transferred and direct transaction costs attributable to the acquisition. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. Contingent consideration payments in asset acquisitions are recognized when the contingency is determined to be probable and reasonably estimable. If the assets acquired are a business, the Company accounts for the transaction as a business combination. Business combinations are accounted for by using the acquisition method </p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective fair values. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Acquisition related expenses are expensed as incurred, and are included in selling, general and administrative expense in the consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Goodwill and Other Intangible Assets</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Goodwill and Other Intangible Assets</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Goodwill represents the excess of the cost of a business combination over the fair value of the net assets acquired. Goodwill and intangible assets deemed to have indefinite lives are not amortized but are subject to impairment tests on an annual basis, and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Goodwill is allocated to the reporting unit from which it was created. A reporting unit is an operating segment or sub<span class="nobreak">-segment</span> to which goodwill is assigned when initially recorded. The Company tests indefinite lived intangible assets for impairment, on an annual basis in the fourth quarter, or more frequently if an event occurs or circumstances indicate that the indefinite lived assets may be impaired. The Company may perform a qualitative assessment to determine whether it is more<span class="nobreak">-likely-than-not</span> that the fair value of a reporting unit is less than its carrying amount. If the Company determines this is the case, the Company then performs further quantitative analysis to identify and measure the amount of goodwill impairment loss to be recognized, if any. To perform its quantitative test, the Company compares the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of its net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. The Company did not test its goodwill or indefinite lived assets for impairment during the year ended December&#160;31, 2023, given that the acquisition date occurred after the annual testing date, and given that there were no impairment indicators from the date of acquisition through the end of the reporting period. The Company has determined that no impairment of its goodwill or indefinite lived intangible assets occurred as of December&#160;31, 2023.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Intangible assets with finite lives are reported at cost, less accumulated amortization, and are amortized over their estimated useful lives, starting when sales for the related product begin. Amortization is calculated using the straight<span class="nobreak">-line</span> method, and recorded within selling, general, and administrative expenses, or cost of revenue, depending on the nature and use of the asset.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the ordinary course of business, the Company has entered into certain license and asset purchase agreements. Potential milestone payments for development, regulatory, and commercial milestones are recorded when the milestone is probable of achievement. Upon a milestone being achieved, the associated milestone payment is capitalized and amortized over the remaining useful life for approved products, or expensed as research and development expense for milestones relating to products whose FDA approval has not yet been obtained.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company reviews long<span class="nobreak">-lived</span> assets, including intangible assets with finite useful lives, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable (a &#8220;triggering event&#8221;). Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the long<span class="nobreak">-lived</span> asset in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long<span class="nobreak">-lived</span> asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long<span class="nobreak">-lived</span> asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value. During the fourth quarter of 2023, the Company determined that there were certain triggering events that indicated that the carrying amount of the assets recorded in connection with the ENTADFI acquisition (see Note&#160;5) may not be fully recoverable. A related impairment loss of $14.7&#160;million was recorded during the year ended December&#160;31, 2023 (see Note&#160;4). The Company also recorded an impairment loss of </p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">approximately $267,000 during the year ended December&#160;31, 2023, related to implementation costs incurred under cloud computing hosting arrangements that were capitalized during the year. There were no other impairment losses on long<span class="nobreak">-lived</span> assets for the&#160;years ended December&#160;31, 2023 and 2022.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value Measurements</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S.&#160;GAAP establishes a three<span class="nobreak">-tier</span> fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level<span class="nobreak"> </span>1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level<span class="nobreak"> </span>2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level<span class="nobreak"> </span>3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. Financial instruments, including cash, inventory, accounts receivable, receivables from related party, accounts payable, accrued liabilities, operating lease liabilities, and notes payable are carried at cost, which management believes approximates fair value due to the short<span class="nobreak">-term</span> nature of these instruments.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of the contingent warrant liability that became issuable upon the closing of the private placements the Company closed on during 2022, the warrant inducement the Company closed on during 2023 (see Note&#160;9), and the subscription agreement liability that was recorded in connection with a subscription agreement (see Note&#160;8) are valued using significant unobservable measures and other fair value inputs, and are therefore classified as Level 3 financial instruments.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of financial instruments measured on a recurring basis is as follows:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="11" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 59.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">As of December&#160;31, 2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Description</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 1</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 2</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 3</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contingent warrant liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,641</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-238">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-239">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,641</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subscription agreement liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">864,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-240">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-241">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">864,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">866,641</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-242">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-243">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">866,641</p>	</td>
				</tr>

		</table><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="9" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 59.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">As of December&#160;31, 2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Description</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 1</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 2</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 3</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contingent warrant liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,021</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-244">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-245">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,021</p>	</td>
				</tr>

		</table><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December&#160;31, 2023, in connection with the acquisition of Proteomedix, the Company recorded intangible assets, which were recognized at fair value (see Note&#160;5). None of the Company&#8217;s other non<span class="nobreak">-financial</span> assets or liabilities are recorded at fair value on a non<span class="nobreak">-recurring</span> basis. There were no transfers between levels during the periods presented.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the activity for the subscription agreement liability, using unobservable Level 3 inputs, for the year ended December&#160;31, 2023:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Subscription</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Agreement</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Liability</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance at December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-246">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fair value upon issuance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">729,900</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in fair value</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">134,100</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance at December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">864,000</p>	</td>
				</tr>

		</table><p style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;"></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the activity for the contingent warrant liability, using unobservable Level 3 inputs, for the&#160;years ended December&#160;31, 2023 and 2022:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Contingent</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Warrant</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Liability</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance at December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-247">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fair value at issuance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">75,431</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in fair value</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(61,410</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance at December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,021</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fair value at issuance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25,837</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Reclassification to equity</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(129,184</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in fair value</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,967</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance at December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,641</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Deferred Offering Costs</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company capitalizes certain legal, professional accounting and other third<span class="nobreak">-party</span> fees that are directly associated with in<span class="nobreak">-process</span> equity financing as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#8217; equity as a reduction of proceeds generated as a result of the offering. Should the in<span class="nobreak">-process</span> equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to expenses in the consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for leases in accordance with ASC&#160;842, <span class="Italic" style="font-style:italic;font-weight:normal;">Leases</span>. The Company has one lease agreement for office space, which contains an initial term of two&#160;years with renewal options. The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Operating lease right of use assets and operating lease liabilities are recognized on the lease commencement date. Operating lease right of use assets represent the Company&#8217;s right to use an underlying asset for the estimated lease term and operating lease liabilities represent the Company&#8217;s present value of its future lease payments. In assessing its lease and determining its lease liability at lease commencement or upon modification, the Company was not able to readily determine the rate implicit for its lessee arrangements, and thus has used its incremental borrowing rate on a collateralized basis to determine the present value of the lease payments. The Company&#8217;s right of use asset is measured as the balance of the lease liability plus or minus any prepaid or accrued lease payments and any unamortized initial direct costs. The operating lease payments are recognized as lease expense on a straight<span class="nobreak">-line</span> basis over the lease term, and are included in selling, general and administrative expenses in the accompanying consolidated statements of </p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">operations and comprehensive loss. Lease payments included in the measurement of the lease liability are comprised of fixed payments. If the Company&#8217;s lease agreements include renewal option periods, the Company includes such renewal options in its calculation of the estimated lease term when it determines the options are reasonably certain to be exercised. When such renewal options are deemed to be reasonably certain, the estimated lease term determined under ASC&#160;842 will be greater than the non<span class="nobreak">-cancelable</span> term of the contractual arrangement.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Leases with an initial term of 12&#160;months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight<span class="nobreak">-line</span> basis over the lease term. The Company applies this policy to all underlying asset categories.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company additionally evaluates leases at their inception to determine if the leases are to be accounted for as an operating lease or a finance lease. Lease expense for operating leases is recognized on a straight<span class="nobreak">-line</span> basis over the lease term. Variable lease payments are recognized in the period in which the obligations for those payments are incurred. Lease expense for finance leases is bifurcated into two components, with the amortization expense component of the right<span class="nobreak">-of-use</span> asset recognized on a straight<span class="nobreak">-line</span> basis and the interest expense component recognized using the effective interest method over the lease term. The Company has no financing leases as of December&#160;31, 2023 or 2022.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock', window );">Defined Benefit Pension Plan</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Defined Benefit Pension Plan</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix sponsors a defined benefit pension plan (the &#8220;Swiss Plan&#8221;) covering its eligible Swiss employees. The Swiss Plan is government<span class="nobreak">-mandated</span> and provides retirement benefits based on employees&#8217;&#160;years of service and compensation levels. The Company recognizes an asset for the Swiss Plan&#8217;s overfunded status or a liability for underfunded status in its consolidated balance sheets. Additionally, the Company measures its plan&#8217;s assets and obligations that determine its funded status as of the end of the year and recognizes the changes in the funded status in the year in which the changes occur. Those changes are reported in accumulated other comprehensive loss in the accompanying consolidated statements of convertible redeemable preferred stock and stockholders&#8217; equity. The Company uses actuarial valuations to determine its pension and postretirement benefit costs and credits. The amounts calculated depend on a variety of key assumptions, including discount rates and expected return on plan assets. Current market conditions are considered in selecting these assumptions.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Agreements</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Collaborative Agreements</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company periodically enters into strategic alliance agreements with counterparties to produce products and/or provide services to customers. Alliances created by such agreements are not legal entities, have no employees, no assets and have no true operations. These arrangements create contractual rights and the Company accounts for these alliances as a collaborative arrangement by reporting costs incurred and reimbursements received from transactions within research and development expense within the consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Revenue Recognition</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During the year ended December&#160;31, 2023, the Company recorded approximately $59,000 of revenue, which was solely generated from Proteomedix development services from the period from the acquisition date of December&#160;15, 2023, through December&#160;31, 2023.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Proteomedix provides a range of services to life sciences customers referred to as &#8220;Development Services&#8221; including testing for biomarker discovery, assay design and development. These Development Services are performed under individual statement of work (&#8220;SOW&#8221;) arrangements with specific deliverables defined by the customer. Development Services are generally performed on a time and materials basis. During the performance and through completion of the service to the customer in accordance with the SOW, the Company has the right to bill the customer for the agreed upon price and recognizes the Development Services revenue over the period estimated to complete the SOW.&#160;The Company generally identifies each SOW as a single performance obligation.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Completion of the service and satisfaction of the performance obligation under a SOW is typically evidenced by access to the data or test made available to the customer or any other form or applicable manner of delivery defined in the SOW.&#160;However, for certain SOWs under which work is performed pursuant to the customer&#8217;s highly customized specifications, the Company has the enforceable right to bill the customer for work completed, rather than upon completion of the SOW.&#160;For those SOWs, the Company recognizes revenue over a period of time during which the work is performed based on the expended efforts (inputs). As the performance obligation under the SOW is satisfied, any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed to the customer as of the date of the consolidated financial statements are recorded as contract assets and are included in prepaids and other current assets as of the financial statement date, and these amounts as of December&#160;31, 2023 are not significant. Amounts recorded in contract assets are reclassified to accounts receivable in our consolidated financial statements when the customer is invoiced according to the billing schedule in the contract. Accounts receivable was approximately $87,000 and $150,000 as of December&#160;15, 2023, the date of acquisition of Proteomedix (see Note&#160;5), and December&#160;31, 2023, respectively.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In circumstances where a SOW includes a variable consideration component, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on which method is expected to better predict the amount of consideration to which the Company will be entitled. The value of variable consideration is included in the transaction price if, and to the extent, it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are reassessed each reporting period, as required, and any adjustment required is recorded on a cumulative catch<span class="nobreak">-up</span> basis, which would affect revenue and net loss in the period of adjustment.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company expenses the cost of research and development as incurred. Research and development expenses include costs incurred in funding research and development activities, license fees, and other external costs. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company&#8217;s behalf will be expensed as services are rendered or when the milestone is achieved. When billing terms under research and development contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end to those third parties. Accrual estimates are based on several factors, including the Company&#8217;s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs (see Note&#160;6).</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic&#160;730<span class="nobreak">-10-25-1</span>, <span class="Italic" style="font-style:italic;font-weight:normal;">Research and Development,</span> costs incurred in obtaining licenses and patent rights are charged to research and development expense if the technology licensed has not reached commercial feasibility and has no alternative future use. The licenses purchased by the Company (see Note&#160;6) require substantial completion of research and development, regulatory and marketing approval efforts to reach commercial feasibility and have no alternative future use. Accordingly, the total purchase price for the licenses acquired is reflected as research and development on the Company&#8217;s consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Contingencies</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Accruals are recorded for loss contingencies when it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been </p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">accrued previously. Considering facts known at the time of the assessment, the Company determines whether potential losses are considered reasonably possible or probable and whether they are estimable. Based upon this assessment, the Company carries out an evaluation of disclosure requirements and considers possible accruals in the consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company expenses stock<span class="nobreak">-based</span> compensation to employees and non<span class="nobreak">-employees</span> over the requisite service period based on the estimated grant<span class="nobreak">-date</span> fair value of the awards. Stock<span class="nobreak">-based</span> awards to employees with graded<span class="nobreak">-vesting</span> schedules are recognized, using the accelerated attribution method, on a straight<span class="nobreak">-line</span> basis over the requisite service period for each separately vesting portion of the award.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company estimates the fair value of stock option grants using the Black<span class="nobreak">-Scholes</span> option pricing model and the assumptions used in calculating the fair value of stock<span class="nobreak">-based</span> awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Expected Term</span>&#160;&#8212;&#160;The expected term of options represents the period that the Company&#8217;s stock<span class="nobreak">-based</span> awards are expected to be outstanding based on the simplified method, which is the half<span class="nobreak">-life</span> from vesting to the end of its contractual term. The simplified method is used as the Company has insufficient historical information to provide a basis for an estimate of the expected term.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Expected Volatility</span>&#160;&#8212;&#160;Volatility is a measure of the amount by which the Company&#8217;s share price has historically fluctuated or is expected to fluctuate (i.e., expected volatility) during a period. Due to the lack of an adequate history of a public market for the trading of the Company&#8217;s common stock and a lack of adequate company<span class="nobreak">-specific</span> historical and implied volatility data, the Company computes stock price volatility over expected terms based on comparable companies&#8217; historical common stock trading prices. For these analyses, the Company has selected companies with comparable characteristics, including enterprise value, risk profiles, and position within the industry.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Common Stock Fair Value</span>&#160;&#8212;&#160;The fair value of the common stock underlying the Company&#8217;s stock options is based on the closing price of the Company&#8217;s common stock, as reported by the Nasdaq Capital Market, on the grant date of the award.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Risk</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Free</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Interest Rate</span>&#160;&#8212;&#160;The Company bases the risk<span class="nobreak">-free</span> interest rate on the implied yield available on U.S.&#160;Treasury securities with a remaining term commensurate with the estimated expected term.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Expected Dividend</span>&#160;&#8212;&#160;The Company has never declared or paid any cash dividends on its shares of common stock and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company recognizes forfeitures of equity awards as they occur.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the jurisdictions and&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in operations in the period that includes the enactment date. Deferred tax assets are reduced to estimated amounts expected to be realized by the use of a valuation allowance.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company is required to report all components of comprehensive loss, including net loss, in the accompanying consolidated financial statements in the period in which they are recognized. Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non<span class="nobreak">-owner</span> sources. The Company&#8217;s comprehensive loss for the year ended December&#160;31, 2023 is comprised of net loss, the effect of currency translation adjustments, and the change in pension benefit obligation. Net loss and comprehensive loss were the same for the year ended December&#160;31, 2022.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial instruments</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Financial instruments</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company determines the accounting classification of financial instruments that are issued, including its warrants and a subscription agreement, as either liability or equity, by first assessing whether the financial instruments are freestanding financial instruments, and if they meet liability classification in accordance with ASC&#160;480, <span class="Italic" style="font-style:italic;font-weight:normal;">Distinguishing Liabilities from Equity</span>, (&#8220;ASC&#160;480&#8221;), and then in accordance with ASC&#160;815<span class="nobreak">-40</span>, <span class="Italic" style="font-style:italic;font-weight:normal;">Derivatives and Hedging&#160;&#8212;&#160;Contracts in Entity&#8217;s Own Equity </span>(&#8220;ASC&#160;815<span class="nobreak">-40</span>&#8221;). Under ASC&#160;480<span class="nobreak">-10</span>, financial instruments are considered liability<span class="nobreak">-classified</span> if the instruments are mandatorily redeemable, obligate the issuer to settle the instruments or the underlying shares by paying cash or other assets, or must or may require settlement by issuing a variable number of shares.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">If the instruments do not meet liability classification under ASC&#160;480, the Company assesses the requirements under ASC&#160;815<span class="nobreak">-40</span>, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the financial instruments do not require liability classification under ASC&#160;815<span class="nobreak">-40</span>, in order to conclude equity classification, the Company assesses whether the instruments are indexed to the Company&#8217;s common stock and whether the instruments are classified as equity under ASC&#160;815<span class="nobreak">-40</span> or other applicable GAAP.&#160;After all relevant assessments are made, the Company concludes whether the instruments are classified as liability or equity. Liability<span class="nobreak">-classified</span> instruments are required to be accounted for at fair value both on the date of issuance and on subsequent accounting period ending dates, with all changes in fair value after the issuance date recorded as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. Equity<span class="nobreak">-classified</span> instruments are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Preferred Stock</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Preferred Stock</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company applies the guidance enumerated in ASC&#160;480, when determining the classification and measurement of preferred stock. Preferred stock subject to mandatory redemption, if any, is classified as a liability and is measured at fair value. The Company classifies conditionally redeemable preferred stock, which includes preferred stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control, as temporary equity. At all other times, the Company classifies its preferred stock in stockholders&#8217; equity.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_TreasuryStockPolicyPolicyTextBlock', window );">Treasury Stock</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Treasury Stock</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company records treasury stock activities under the cost method whereby the cost of the acquired stock is recorded as treasury stock.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Net Loss Per Share</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Basic loss per share is computed by dividing the net loss applicable to common shares by the weighted average number of common shares outstanding during the period. The weighted average number of shares of common stock outstanding includes (i)&#160;pre<span class="nobreak">-funded</span> warrants because their exercise requires only nominal consideration for delivery of shares and (ii)&#160;the shares held in abeyance because there is no consideration required for delivery of the shares; </p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">it does not include any potentially dilutive securities or any unvested restricted stock of common stock. Certain restricted shares, although classified as issued and outstanding at December&#160;31, 2023 are considered contingently returnable until the restrictions lapse and will not be included in the basic net loss per share calculation until the shares are vested. Unvested shares of the Company&#8217;s restricted stock do not contain non<span class="nobreak">-forfeitable</span> rights to dividends and dividend equivalents. Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the Company&#8217;s Series&#160;A preferred stock, warrants, unvested restricted stock, and stock options. Diluted loss per share excludes the shares issuable upon the conversion of Series&#160;A preferred stock, as well as unvested restricted stock, common stock options and warrants, from the calculation of net loss per share if their effect would be anti<span class="nobreak">-dilutive</span>.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The two<span class="nobreak">-class</span> method is used to determine earnings per share based on participation rights of participating securities in any undistributed earnings. Each preferred stock that includes rights to participate in distributed earnings is considered a participating security and the Company uses the two<span class="nobreak">-class</span> method to calculate net income available to the Company&#8217;s common stockholders per common share&#160;&#8212;&#160;basic and diluted.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following securities were excluded from the computation of diluted shares outstanding for the periods presented, as they would have had an anti<span class="nobreak">-dilutive</span> impact on the Company&#8217;s net loss:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Years Ended <br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,904,830</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,392,654</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Warrants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,899,661</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,264,274</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">256,580</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-248">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock issuable upon conversion of Series&#160;A preferred stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,709,935</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-249">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">15,771,006</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">6,656,928</span></p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">New Accounting Pronouncement</span><span class="Bold" style="font-style:normal;font-weight:bold;">s</span></p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In November&#160;2023, the FASB issued ASU No.&#160;2023<span class="nobreak">-07</span>, Segment Reporting (Topic&#160;280): <span class="Italic" style="font-style:italic;font-weight:normal;">Improvements to Reportable Segment Disclosures</span>. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (&#8220;CODM&#8221;) and included within each reported measure of a segment&#8217;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment&#8217;s profit or loss in assessing segment performance and deciding how to allocate resources. This ASU is effective for annual periods beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2023, the FASB issued ASU No.&#160;2023<span class="nobreak">-09</span>, Income Taxes (Topic&#160;740<span class="Italic" style="font-style:italic;font-weight:normal;">): Improvements to Income Tax Disclosures</span>. This ASU requires disclosure of specific categories in the rate reconciliation and additional information for reconciling items that meet a quantitative threshold. The amendment also includes other changes to improve the effectiveness of income tax disclosures, including further disaggregation of income taxes paid for individually significant jurisdictions. This ASU is effective for annual periods beginning after December&#160;15, 2024. Adoption of this ASU should be applied on a prospective basis. Early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.</p><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_AcquisitionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of policy of acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_AcquisitionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_TreasuryStockPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_TreasuryStockPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480598/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy election to measure plan assets and benefit obligations as of the month-end that is closest to the fiscal year-end.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (u)<br> -SubTopic 20<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481288/505-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666107258400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of Revenue by Geographical Area</a></td>
<td class="text"><div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The distribution of revenue by geographical area was as follows:</p></div><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Years Ended <br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">United&#160;States</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-233">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-234">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Switzerland</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">58,465</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-235">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">58,465</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-236">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of Long-lived by Geographical Area</a></td>
<td class="text"><div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The distribution of long<span class="nobreak">-lived</span> assets by geographical area, which includes property and equipment and the Company&#8217;s right of use asset, was as follows:</p></div><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Years Ended <br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">United&#160;States</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,956</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,089</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Switzerland</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">198,240</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-237">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">209,196</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">14,089</span></p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value of Financial Instruments Measured on a Recurring Basis</a></td>
<td class="text"><div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of financial instruments measured on a recurring basis is as follows:</p></div><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="11" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 59.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">As of December&#160;31, 2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Description</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 1</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 2</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 3</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contingent warrant liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,641</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-238">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-239">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,641</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subscription agreement liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">864,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-240">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-241">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">864,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">866,641</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-242">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-243">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">866,641</p>	</td>
				</tr>

		</table><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="9" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 59.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">As of December&#160;31, 2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Description</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 1</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 2</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Level 3</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contingent warrant liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,021</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-244">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-245">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,021</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Activity for the Subscription Agreement Liability</a></td>
<td class="text"><div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the activity for the subscription agreement liability, using unobservable Level 3 inputs, for the year ended December&#160;31, 2023:</p></div><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Subscription</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Agreement</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Liability</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance at December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-246">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fair value upon issuance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">729,900</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in fair value</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">134,100</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance at December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">864,000</p>	</td>
				</tr>

		</table><p style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Activity for the Contingent Warrant Liability</a></td>
<td class="text"><div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the activity for the contingent warrant liability, using unobservable Level 3 inputs, for the&#160;years ended December&#160;31, 2023 and 2022:</p></div><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Contingent</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Warrant</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Liability</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance at December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-247">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fair value at issuance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">75,431</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in fair value</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(61,410</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance at December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,021</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fair value at issuance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25,837</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Reclassification to equity</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(129,184</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in fair value</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,967</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance at December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,641</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Computation of Diluted Shares Outstanding</a></td>
<td class="text"><div style="-sec-ix-redline:true;-keep: true"><p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following securities were excluded from the computation of diluted shares outstanding for the periods presented, as they would have had an anti<span class="nobreak">-dilutive</span> impact on the Company&#8217;s net loss:</p></div><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Years Ended <br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,904,830</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,392,654</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Warrants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,899,661</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,264,274</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">256,580</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-248">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock issuable upon conversion of Series&#160;A preferred stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,709,935</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-249">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">15,771,006</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">6,656,928</span></p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666107638992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Inventories primarily relate to ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> product and consisted of the following as of December&#160;31, 2023 and 2022:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Raw materials</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">139,208</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-252">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Work-in-process</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">194,805</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-253">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Finished goods</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">30,039</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-254">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">364,052</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-255">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Prepaid expenses and other current assets consisted of the following as of December&#160;31, 2023 and 2022:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid insurance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">122,004</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">148,789</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid regulatory fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">312,551</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-256">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">89,195</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">231,981</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid professional fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">70,708</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-257">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">175,695</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">88,462</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">770,153</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">469,232</span></p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Intangible assets, which were recorded during the year ended December&#160;31, 2023 in connection with the ENTADFI and Proteomedix acquisitions (see Note&#160;5), is comprised of customer relationships, product rights for developed technology, and a trade name, and consisted of the following as of December&#160;31, 2023:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Cost</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Impairment</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Effect of</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Currency</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Translation</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Balance</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cost basis:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Trade name</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,018,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-258">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">294,739</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,312,739</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Product rights for developed technology</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">28,447,771</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(14,610,128</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">344,514</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,182,157</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Customer relationships</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,891,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-259">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">61,803</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,952,803</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">39,356,771</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(14,610,128</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">701,056</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">25,447,699</span></p>	</td>
				</tr>

		</table><table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Amortization</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Balance</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Accumulated amortization:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Trade name</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-260">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-261">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Product rights for developed technology</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(31,213</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(31,213</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Customer relationships</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,599</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,599</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(36,812</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(36,812</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Intangible assets, net</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">25,410,887</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Annual Amortization Expense</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Future annual amortization expense related to the Company&#8217;s finite lived intangible assets is as follows as of December&#160;31, 2023:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Years ending December&#160;31,</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,012,870</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,326,837</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2026</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,326,837</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2027</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,326,837</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2028</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,326,837</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thereafter</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,777,930</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">16,098,148</span></p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Goodwill was recorded during the year ended December&#160;31, 2023, in connection with the Proteomedix acquisition (see Note&#160;5), and consisted of the following as of December&#160;31, 2023:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance as of December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-262">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">PMX Transaction goodwill</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">53,914,055</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effect of currency translation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,762,087</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance as of December&#160;31, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">55,676,142</span></p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Accrued expenses consisted of the following as of December&#160;31, 2023 and 2022:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">847,747</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">487,579</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,132,859</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued deferred offering costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">125,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">125,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued professional fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">550,415</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-263">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued implementation fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">93,787</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-264">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other accrued expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">265,849</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">125,922</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued franchise taxes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">60,530</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">177,600</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2,199,867</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2,409,128</span></p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666106915040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock', window );">Schedule of Aggregate Consideration Transferred for the Assets Acquired</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the aggregate consideration transferred for the assets acquired by the Company in connection with the Veru APA:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Consideration</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Transferred</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Consideration transferred at closing</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,000,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fair value of notes payable issued</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12,947,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Transaction costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">79,771</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total consideration transferred</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">19,026,771</span></p>	</td>
				</tr>

		</table><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The acquisition<span class="nobreak">-date</span> fair value of the consideration transferred totaled approximately $65.1&#160;million, which consisted of the following:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Consideration</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Transferred</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">875,484</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;B convertible preferred stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">64,236,085</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total consideration transferred</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">65,111,569</span></p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Schedule of Assets Acquired</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the assets acquired with the Veru APA:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Assets</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Recognized</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Inventory</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,120,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">ENTADFI<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> Intangible</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17,906,771</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total fair value of identifiable assets acquired</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">19,026,771</span></p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value of the Proteomedix Stock Options</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of the Proteomedix stock options assumed as part of the PMX Transaction was determined using a Black<span class="nobreak">-Scholes</span> option pricing model with the following significant assumptions:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercise price</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">$1.15&#160;&#8211;&#160;28.83</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock price</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">128.11</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Term (years)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">0.17&#160;&#8211;&#160;3.59</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected stock price volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">90%</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free rate of interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">4.07%&#160;&#8211;&#160;5.47%</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Estimated Fair Values of Assets Acquired and Liabilities</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed at the acquisition date:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Net Assets</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Recognized</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,056,578</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">87,445</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Inventories</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">80,593</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid expenses and other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">114,615</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right of use asset</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">149,831</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39,779</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Trade name</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,018,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Customer relationships</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,891,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Product rights for developed technology</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,541,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Goodwill</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">53,914,055</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total assets acquired</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">76,892,896</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(234,029</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(732,814</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(149,831</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,994,669</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pension benefit obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(548,384</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Note payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(115,096</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total liabilities assumed</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,774,823</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">72,118,073</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less non-controlling interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,006,504</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net assets acquired</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">65,111,569</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock', window );">Schedule of Consolidated Statements of Operations and Comprehensive Loss</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The amounts of revenue and loss of Proteomedix, included in the Company&#8217;s consolidated statements of operations and comprehensive loss from the Acquisition Date through December&#160;31, 2023 are as follows:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Revenue</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">58,465</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">315,688</p>	</td>
				</tr>

		</table><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Unaudited</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">For the&#160;Years Ended</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Revenue</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,601,310</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">392,460</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">38,577,046</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16,326,247</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedIncomeStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent consideration in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666109226336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subscription Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SubscriptionAgreementDisclosureAbstract', window );"><strong>Subscription Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used in Monte-Carlo Model, Which Utilizes Level 3 Inputs</a></td>
<td class="text">The significant assumptions used in the Monte<span class="nobreak">-Carlo</span> model, which utilizes Level 3 inputs (see Note&#160;3), are as follows as of the commitment date and at December&#160;31, 2023:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;18,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercise price</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.25</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.25</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Term (years)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.5</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.2</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected stock price volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">95</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free rate of interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.64</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.64</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_SubscriptionAgreementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_SubscriptionAgreementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666107982576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock', window );">Schedule of Fair Value of the Preferred Investment Options</a></td>
<td class="text">The increase in the fair value of the preferred investment options as a result of the exchange was approximately $860,000, and was determined using the Black<span class="nobreak">-Scholes</span> option pricing model, with the following assumptions:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Original</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Exchanged</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercise price</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.65</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.546</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Term (years)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.67</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.0</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected stock price volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">116.2</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">120.2</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free rate of interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.16</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.98</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock', window );">Schedule of Valuation of the Contingent Warrant Liability</a></td>
<td class="text">The following significant assumptions were used in the valuation of the contingent warrant liability, related to the August Contingent Warrants, as of the date of the August&#160;2022 Private Placement and as of December&#160;31, 2022:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">August&#160;11,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercise price</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.3938</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.3938</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Term (years)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.00</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.61</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected stock price volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">127.8</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">120.8</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free rate of interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.98</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.03</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Warrants, Excluding Contingent Warrants</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following summarizes activity related to the Company&#8217;s outstanding warrants, excluding contingent warrants issuable upon exercise of the preferred investment options, for the year ended December&#160;31, 2023:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Number of<br/>Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life<br/>(in&#160;years)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding as of December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,910,914</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.37</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.7</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,121,601</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.10</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(3,132,854</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.865</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-268">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-269">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding as of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,899,661</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.68</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.3</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Warrants vested and exercisable as of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,899,661</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.68</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.3</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following summarizes activity related to the Company&#8217;s stock options under the 2019 Plan and the 2022 Plan for the year ended December&#160;31, 2023:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Number of<br/>Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Total<br/>Intrinsic<br/>Value</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(in&#160;years)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding as of December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,392,654</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.30</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">670,161</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.2</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">962,154</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.48</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-270">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited/cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(404,058</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.87</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-271">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(45,920</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.01</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45,920</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding as of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,904,830</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.63</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">94,239</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.4</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and exercisable as of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">861,177</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.23</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">94,239</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.1</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock', window );">Schedule of Fair Value of Options Granted</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of options granted in 2023 and 2022 was estimated using the following assumptions:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-28" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">For the <br/>Year Ended <br/>December&#160;31, <br/>2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">For the <br/>Year Ended <br/>December&#160;31, <br/>2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercise price</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">$0.26&#160;&#8211;&#160;1.29</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">$1.06&#160;&#8211;&#160;6.45</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Term (years)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5.00&#160;&#8211;&#160;10.00</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5.00&#160;&#8211;&#160;10.00</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected stock price volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">101.1%&#160;&#8211;&#160;119.5</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">112.6%&#160;&#8211;&#160;121.2%</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 60.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free rate of interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3.5%&#160;&#8211;&#160;4.7%</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2.9%&#160;&#8211;&#160;4.3%</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Unvested Restricted Stock</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;16, 2023 and October&#160;4, 2023, upon their respective resignations, the Company&#8217;s former CEO and former CFO forfeited 150,000<span class="nobreak"> </span>shares and 75,000<span class="nobreak"> </span>shares of unvested restricted stock, respectively.</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Number of<br/>Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Nonvested as of December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-272">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-273">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">512,940</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.01</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited/cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(250,110</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.02</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,250</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.03</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Nonvested as of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">256,580</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.03</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Stock<span class="nobreak">-based</span> compensation expense for the&#160;years ended December&#160;31, 2023 and 2022 was as follows:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">For the&#160;Years Ended</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Selling, general and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">234,298</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,309,687</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">95,462</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">664,879</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">329,760</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">1,974,566</span></p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Fair Value of Options Granted in 2023 And 2022.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ScheduleOfFairValueOfOptionsGrantedIn2023And2022TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Valuation of the Contingent Warrant Liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ScheduleOfValuationOfTheContingentWarrantLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about asset and liability measured at fair value under fair value option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-30<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-31<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666108184912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNetAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Loss Before Income Tax</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The components of loss before income taxes are as follows:</p><table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">For the&#160;Years Ended</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">U.S.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(37,106,599</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(13,419,830</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Foreign</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(315,688</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-287">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total loss before income taxes</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(37,422,287</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(13,419,830</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The tax effects of the temporary differences and carryforwards that give rise to deferred tax assets and liabilities consist of the following:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">As of December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Deferred tax assets:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net-operating loss carryforward</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,214,760</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,986,738</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Intangibles</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,349,919</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">885,176</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,171,320</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-288">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">690,760</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">308,552</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deposit on WraSer APA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">854,896</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-289">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">150,099</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">186,573</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">License agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">49,157</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">82,626</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">520,207</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">65,886</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Gross deferred tax assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17,001,118</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,515,551</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(15,697,701</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,512,546</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Deferred tax assets, net of allowance</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,303,417</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,005</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Deferred tax liabilities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Intangible assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,345,449</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-290">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fixed assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,560</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(3,005</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(29,189</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-291">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total deferred tax liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,377,198</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(3,005</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net deferred tax liability</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(3,073,781</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-292">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Taxes Differs from the Statutory Federal Rate</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The provision for income taxes on earnings subject to income taxes differs from the statutory Federal rate at December&#160;31, 2023 and 2022, due to the following:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">For the&#160;Years Ended</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected income tax benefit at Federal statutory tax rate</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,858,680</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,818,164</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">State and local taxes, net of Federal tax benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,192,605</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(501,277</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-293">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(16,477</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Foreign NOL expirations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">315,927</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-294">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">196,025</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-295">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subscription agreement liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">181,440</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-296">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Officer&#8217;s compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(126,337</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-297">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Acquisition related costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">164,073</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-298">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Permanent items</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55,486</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">194,705</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">State rate adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(23,135</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">19,600</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">60,599</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(37,260</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8,214,614</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,158,873</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Income tax benefit</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">(12,593</span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-299">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></p>

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">For the&#160;Years Ended</span><span class="CharOverride-4" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Beginning balance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17,010</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-300">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Increases related to prior year tax positions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-301">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,517</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Increases related to current year tax positions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-302">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,493</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ending balance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17,010</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17,010</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666111414752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAbstract', window );"><strong>Retirement Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock', window );">Schedule of Benefit Obligation and the Net Periodic Benefit Cost</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The following significant actuarial assumptions were used in calculating the benefit obligation and the net periodic <span style="-sec-ix-hidden: hidden-fact-304">benefit cost</span> as of December&#160;31, 2023:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Discount rate</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.45</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected long-term rate of return on plan assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.45</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Rate of compensation increase</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.00</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock', window );">Schedule of Accompanying Consolidated Balance Sheet</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The components of net periodic benefit cost for the period from December&#160;15, 2023 to December&#160;31, 2023 are as follows:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Service cost</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,278</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest cost</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,943</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected return on plan assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,581</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amortization of net (gain)/loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,534</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Settlements (gain)/loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,157</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,949</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Comprehensive Loss</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">The components of accumulated comprehensive loss attributable to the Company&#8217;s pension plan for the period from December&#160;15, 2023 to December&#160;31, 2023 are as follows:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss (gain)</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,277</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amortization of net gain</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,534</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effect of settlement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,157</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other adjustments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(4,005</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total recorded during the period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,963</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock', window );">Schedule of Accompanying Consolidated Balance Sheet</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, the funded status of the plan and the amounts recognized in the accompanying consolidated balance sheet are as follows:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Projected benefit obligation</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,299,970</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fair value of plan assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,743,674</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Overfunded (underfunded) status</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(556,296</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock', window );">Schedule of the Beginning and Ending Balances of the Accumulated Benefit Obligation</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A reconciliation of the beginning and ending balances of the accumulated benefit obligation is provided in the table below:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">As of December&#160;15, 2023</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,288,273</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Service cost</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,278</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest cost</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,943</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Actuarial (gain) loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,979</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Benefits paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(905</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ordinary contributions paid by employees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,005</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contributions paid by plan participants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">769</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Settlements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,372</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Projected benefit obligation as of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,299,970</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Actuarial (gain)/loss due to assumption changes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8,834</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Actuarial (gain)/loss due to plan experience</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(855</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated benefit obligation as of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,307,949</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">A reconciliation of the beginning and ending balances of the plan assets is provided in the table below:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">As of December&#160;15, 2023</p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,739,889</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Actual return on plan assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,283</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contributions paid by employer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,005</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ordinary contributions paid by employees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,005</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Contributions paid by plan participants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">769</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Benefits paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(905</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Settlements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,372</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">As of December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,743,674</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Benefit Payments</a></td>
<td class="text"><p class="Text_ind" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">Projected benefit payments for the next five&#160;years as of December&#160;31, 2023 are as follows:</p><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Years ending December&#160;31,</span></p>

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-303">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">95,100</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2026</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">95,100</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2027</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">95,100</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2028</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">95,100</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thereafter</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">553,900</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">934,300</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accompanying consolidated balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ScheduleOfAccompanyingConsolidatedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedFinancialStatementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts related to pension plans and/or other employee benefit plans in accumulated other comprehensive income or loss that have not yet been recognized as components of net periodic benefit cost, such as the net gain (loss), net prior service cost or credit, and net transition asset or obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Subparagraph (j)<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666103967984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 23, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 15, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Reclassifications cash flow activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Offering costs</a></td>
<td class="nump">$ 17,100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 18,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance', window );">Convertible preferred stock shares (in Shares)</a></td>
<td class="nump">5,626,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=onco_ProteomedixMember', window );">Proteomedix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Subsidiary owned, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_InitialPublicOfferingShares', window );">Common stock (in Shares)</a></td>
<td class="nump">2,222,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PublicOfPerShare', window );">Public of per share (in Dollars per share)</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Offering costs</a></td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=onco_OnconetixMember', window );">Onconetix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_InitialPublicOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued initial public offering of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_InitialPublicOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_PublicOfPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The share of public of per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_PublicOfPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of nonredeemable convertible preferred shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=onco_ProteomedixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=onco_ProteomedixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=onco_OnconetixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=onco_OnconetixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666110909744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern and Management&#8217;s Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 23, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_GoingConcernandManagementsPlansDetailsLineItems', window );"><strong>Going Concern and Management&#8217;s Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherInvestments', window );">Proceeds from preferred investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,554,335<span></span>
</td>
<td class="nump">$ 25,752,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_WorkingCapitalDeficit', window );">Working capital deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAppropriated', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (56,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_GoingConcernandManagementsPlansDetailsLineItems', window );"><strong>Going Concern and Management&#8217;s Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_GoingConcernandManagementsPlansDetailsLineItems', window );"><strong>Going Concern and Management&#8217;s Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherInvestments', window );">Proceeds from preferred investment</a></td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_GoingConcernandManagementsPlansDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_GoingConcernandManagementsPlansDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_WorkingCapitalDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working capital deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_WorkingCapitalDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAppropriated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A segregation of retained earnings which is unavailable for dividend distribution. Includes also retained earnings appropriated for loss contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(30)(a)(3)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481142/505-10-45-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481142/505-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAppropriated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666108385648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 15, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Operating segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserve</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment loss</a></td>
<td class="nump">14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment loss of long lived assets</a></td>
<td class="nump">267,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecognitionOfDeferredRevenue', window );">Revenue</a></td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">$ 87,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Property and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481058/954-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecognitionOfDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecognitionOfDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666108138448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Geographical Area - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 58,465<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CH', window );">Switzerland [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 58,465<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666108144752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Long-lived by Geographical Area - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total long-lived asset</a></td>
<td class="nump">$ 209,196<span></span>
</td>
<td class="nump">$ 14,089<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total long-lived asset</a></td>
<td class="nump">10,956<span></span>
</td>
<td class="nump">14,089<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CH', window );">Switzerland [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total long-lived asset</a></td>
<td class="nump">$ 198,240<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666110833712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Fair Value of Financial Instruments Measured on a Recurring Basis - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Contingent warrant liability</a></td>
<td class="nump">$ 2,641<span></span>
</td>
<td class="nump">$ 14,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SubscriptionAgreementLiabilityNoncurrent', window );">Subscription agreement liability</a></td>
<td class="nump">864,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">866,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Contingent warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SubscriptionAgreementLiabilityNoncurrent', window );">Subscription agreement liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Contingent warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SubscriptionAgreementLiabilityNoncurrent', window );">Subscription agreement liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Contingent warrant liability</a></td>
<td class="nump">2,641<span></span>
</td>
<td class="nump">$ 14,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SubscriptionAgreementLiabilityNoncurrent', window );">Subscription agreement liability</a></td>
<td class="nump">864,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 866,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_SubscriptionAgreementLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subscription agreement liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_SubscriptionAgreementLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666108422464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Activity for the Subscription Agreement Liability - Subscription Agreement Liability [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at beginning</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues', window );">Fair value upon issuance</a></td>
<td class="nump">729,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="nump">134,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at ending</a></td>
<td class="nump">$ 864,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=onco_SubscriptionAgreementLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=onco_SubscriptionAgreementLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666108135312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Activity for the Contingent Warrant Liability - Contingent Warrant Liability [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Balance at beginning</a></td>
<td class="nump">$ 14,021<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues', window );">Fair value at issuance</a></td>
<td class="nump">25,837<span></span>
</td>
<td class="nump">75,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ReclassificationToEquity', window );">Reclassification to equity</a></td>
<td class="num">(129,184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="nump">91,967<span></span>
</td>
<td class="num">(61,410)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Balance at ending</a></td>
<td class="nump">$ 2,641<span></span>
</td>
<td class="nump">$ 14,021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ReclassificationToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents the reclassification to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ReclassificationToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=onco_ContingentWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=onco_ContingentWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666108384240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Computation of Diluted Shares Outstanding - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">15,771,006<span></span>
</td>
<td class="nump">6,656,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onco_StockOptionsMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">1,904,830<span></span>
</td>
<td class="nump">1,392,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">7,899,661<span></span>
</td>
<td class="nump">5,264,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">256,580<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onco_CommonStockIssuableUponConversionOfSeriesAPreferredStockMember', window );">Common stock issuable upon conversion of Series A preferred stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">5,709,935<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onco_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onco_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onco_CommonStockIssuableUponConversionOfSeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onco_CommonStockIssuableUponConversionOfSeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666106932848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_BalanceSheetDetailsDetailsLineItems', window );"><strong>Balance Sheet Details (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense related to intangible assets</a></td>
<td class="nump">$ 36,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostOfOperatingRevenue', window );">Cost of revenue</a></td>
<td class="nump">31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative expenses</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="nump">14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment charge of long-lived assets</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average remaining amortization period</a></td>
<td class="text">13 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedTradeNames', window );">Indefinite life intangible assets</a></td>
<td class="nump">$ 9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=onco_ENTADFIMember', window );">ENTADFI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_BalanceSheetDetailsDetailsLineItems', window );"><strong>Balance Sheet Details (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense related to intangible assets</a></td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment charge of long-lived assets</a></td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Product Rights Intangible Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_BalanceSheetDetailsDetailsLineItems', window );"><strong>Balance Sheet Details (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense related to intangible assets</a></td>
<td class="nump">31,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="nump">14,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Fixed Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_BalanceSheetDetailsDetailsLineItems', window );"><strong>Balance Sheet Details (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_ProteomedixMember', window );">Proteomedix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_BalanceSheetDetailsDetailsLineItems', window );"><strong>Balance Sheet Details (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_ENTADFIMember', window );">ENTADFI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_BalanceSheetDetailsDetailsLineItems', window );"><strong>Balance Sheet Details (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_BalanceSheetDetailsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_BalanceSheetDetailsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedTradeNames">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trade name to gain or protect exclusive use thereof for a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedTradeNames</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostOfOperatingRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other costs incurred during the reporting period related to other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostOfOperatingRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=onco_ENTADFIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=onco_ENTADFIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_ProteomedixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_ProteomedixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_ENTADFIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_ENTADFIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666110902624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details (Details) - Schedule of Inventories - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Schedule of Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 139,208<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">194,805<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">30,039<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 364,052<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666103133776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details (Details) - Schedule of Prepaid Expenses and Other Current Assets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Schedule of Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 122,004<span></span>
</td>
<td class="nump">$ 148,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid regulatory fees</a></td>
<td class="nump">312,551<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PrepaidsResearchAndDevelopment', window );">Prepaid research and development</a></td>
<td class="nump">89,195<span></span>
</td>
<td class="nump">231,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PrepaidProfessionalFees', window );">Prepaid professional fees</a></td>
<td class="nump">70,708<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid other</a></td>
<td class="nump">175,695<span></span>
</td>
<td class="nump">88,462<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 770,153<span></span>
</td>
<td class="nump">$ 469,232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_PrepaidProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid professional fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_PrepaidProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_PrepaidsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_PrepaidsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666110863152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Details) - Schedule of Intangible Assets - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_CostBasisAbstract', window );"><strong>Cost basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_FiniteLivedIntangibleAssetCost', window );">Cost</a></td>
<td class="nump">$ 39,356,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ImpairmentOfIntangibleAssetExcludingGoodwill', window );">Impairment</a></td>
<td class="num">(14,610,128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss', window );">Effect of Currency Translation</a></td>
<td class="nump">701,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">25,447,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AccumulatedAmortizationAbstract', window );"><strong>Accumulated amortization:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="num">(36,812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation', window );">Effect of Currency Translation</a></td>
<td class="num">(36,812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">25,410,887<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade name [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_CostBasisAbstract', window );"><strong>Cost basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_FiniteLivedIntangibleAssetCost', window );">Cost</a></td>
<td class="nump">9,018,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ImpairmentOfIntangibleAssetExcludingGoodwill', window );">Impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss', window );">Effect of Currency Translation</a></td>
<td class="nump">294,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">9,312,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AccumulatedAmortizationAbstract', window );"><strong>Accumulated amortization:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation', window );">Effect of Currency Translation</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Product rights for developed technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_CostBasisAbstract', window );"><strong>Cost basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_FiniteLivedIntangibleAssetCost', window );">Cost</a></td>
<td class="nump">28,447,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ImpairmentOfIntangibleAssetExcludingGoodwill', window );">Impairment</a></td>
<td class="num">(14,610,128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss', window );">Effect of Currency Translation</a></td>
<td class="nump">344,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">14,182,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AccumulatedAmortizationAbstract', window );"><strong>Accumulated amortization:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="num">(31,213)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation', window );">Effect of Currency Translation</a></td>
<td class="num">(31,213)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_CostBasisAbstract', window );"><strong>Cost basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_FiniteLivedIntangibleAssetCost', window );">Cost</a></td>
<td class="nump">1,891,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ImpairmentOfIntangibleAssetExcludingGoodwill', window );">Impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss', window );">Effect of Currency Translation</a></td>
<td class="nump">61,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">1,952,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AccumulatedAmortizationAbstract', window );"><strong>Accumulated amortization:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="num">(5,599)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation', window );">Effect of Currency Translation</a></td>
<td class="num">$ (5,599)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_AccumulatedAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_AccumulatedAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_CostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_CostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_FiniteLivedIntangibleAssetCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of finite lived intangible assets cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_FiniteLivedIntangibleAssetCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of effect of currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_FiniteLivedIntangibleAssetsAccumulatedAmortizationEffectOfCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ImpairmentOfIntangibleAssetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ImpairmentOfIntangibleAssetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666111426400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details (Details) - Schedule of Annual Amortization Expense<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Schedule of Annual Amortization Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,012,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">1,326,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">1,326,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">1,326,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">1,326,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">9,777,930<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 16,098,148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666109449696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Details) - Schedule of Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ScheduleOfGoodwillAbstract', window );"><strong>Schedule of Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning Balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillTransfers', window );">PMX Transaction goodwill</a></td>
<td class="nump">53,914,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Effect of currency translation</a></td>
<td class="nump">1,762,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Ending Balance</a></td>
<td class="nump">$ 55,676,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ScheduleOfGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ScheduleOfGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillTransfers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers into (out of) an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillTransfers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666110641216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details (Details) - Schedule of Accrued Expenses - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Schedule of Accrued Expenses [Member]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AccruedResearchAndDevelopmentCurrent', window );">Accrued research and development</a></td>
<td class="nump">$ 616,707<span></span>
</td>
<td class="nump">$ 847,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedUtilitiesCurrentAndNoncurrent', window );">Accrued compensation</a></td>
<td class="nump">487,579<span></span>
</td>
<td class="nump">1,132,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AccruedDeferredOfferingCosts', window );">Accrued deferred offering costs</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Accrued professional fees</a></td>
<td class="nump">550,415<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Accrued implementation fees</a></td>
<td class="nump">93,787<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other accrued expenses</a></td>
<td class="nump">265,849<span></span>
</td>
<td class="nump">125,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Accrued franchise taxes</a></td>
<td class="nump">60,530<span></span>
</td>
<td class="nump">177,600<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 2,199,867<span></span>
</td>
<td class="nump">$ 2,409,128<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_AccruedDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_AccruedDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedUtilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for utilities, such as electrical power, heating oil, natural gas, and water.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedUtilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666104376704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 15, 2023</div></th>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Apr. 19, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 26, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_RoyaltySalesPercentage', window );">Royalty sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SalesPaymentsAmount', window );">Sales payments amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationDescription', window );">Business acquisition, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i)&#160;$3.5&#160;million in cash at signing of the WraSer APA; (ii)&#160;$4.5&#160;million in cash on the later of (x)&#160;90&#160;days after the signing of the WraSer APA or (y)&#160;the date that all closing conditions under the WraSer APA are met or otherwise waived (the &#8220;WraSer Closing Date&#8221;); (iii)&#160;1.0&#160;million shares of the Company&#8217;s common stock (the &#8220;Closing Shares&#8221;) issuable on the WraSer Closing Date, and (iv)&#160;$500,000 in cash one year from the WraSer Closing Date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AggregatePurchaseShares', window );">Aggregate shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,709,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_BusinessTransactionYeare', window );">Business transaction years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_InventoryFairValue', window );">Inventory fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ImpairmentRate', window );">Impairment rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts', window );">Cash payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_InitialPaymentAmount', window );">Initial payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_Payments', window );">Company payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Deposits', window );">Payment as deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash target amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Initial payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_VotingInterestPercentage', window );">Voting interest percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction', window );">Issuance of common stock (in Shares)</a></td>
<td class="nump">3,675,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_RoyaltyRate', window );">Royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,613,011<span></span>
</td>
<td class="nump">$ 860,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=onco_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction', window );">Issuance of common stock (in Shares)</a></td>
<td class="nump">2,696,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_NumberOfShares', window );">Number of shares (in Shares)</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=onco_ENTADFIMember', window );">ENTADFI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Estimated using discount percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_WeightedAverageDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_WeightedAverageDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Product Rights Developed Technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_WeightedAverageDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_WeightedAverageDiscountRateThereafter', window );">Discount rate thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=onco_ManagementServicesAgreementMember', window );">Management Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts', window );">Cash payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=onco_WraSerAPAMember', window );">WraSer APA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationDescription', window );">Business acquisition, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i)&#160;$2.2&#160;million to be paid at closing, (ii)&#160;$2.3&#160;million, to be paid in monthly installments of $150,000 commencing January&#160;2024 and (iii)&#160;789 shares of Series&#160;A Preferred Stock to be paid at closing<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts', window );">Cash payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=onco_BankruptcyCourtMember', window );">Bankruptcy Court [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationDescription', window );">Business acquisition, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The amendment also reduced the number of products the Company was acquiring by excluding pain medications and including only (i)&#160;Ciprofloxacin 0.3% and Fluocinolone 0.025% Otic Solution, under the trademark OTOVEL and its Authorized Generic Version approved under US FDA NDA No. 208251, (ii)&#160;Ciprofloxacin 0.2% Otic solution, under the trademark CETRAXAL, and (iii)&#160;Vorapaxar Sulfate tablets under the trademark Zontivity approved under US FDA NDA N204886.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=onco_WraSerMSAMember', window );">WraSer MSA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Deposits', window );">Payment as deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=onco_PMXTransactionMember', window );">PMX Transaction [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction', window );">Issuance of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,672,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=onco_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Consideration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=onco_ENTADFIMember', window );">ENTADFI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Consideration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Business acquisition, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i)&#160;$6.0&#160;million paid upon the closing of the Transaction on April&#160;19, 2023, (ii)&#160;an additional $4.0&#160;million in the form of a non-interest bearing note payable due on September&#160;30, 2023, and (iii)&#160;an additional $10.0&#160;million in the form of two $5.0&#160;million non-interest bearing notes payable, each due on April&#160;19, 2024 and September&#160;30, 2024.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationDescription', window );">Business acquisition, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$4.0&#160;million note payable originally due on September&#160;30, 2023 was deemed paid and fully satisfied upon (1)&#160;the payment to the Seller of $1.0&#160;million in cash on September&#160;29, 2023, and (2)&#160;the issuance to the Seller by October&#160;3, 2023 of 3,000 shares of Series&#160;A Convertible Preferred Stock (the &#8220;Series&#160;A Preferred Stock&#8221;) of the Company (see Note&#160;9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=onco_MilestonePaymentsMember', window );">Milestone Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Consideration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Business acquisition, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i)&#160;$10.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI&#174; of $100.0&#160;million during a calendar year, (ii)&#160;$20.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI&#174; of $200.0&#160;million during a calendar year, and (3)&#160;$50.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI&#174; of $500.0&#160;million during a calendar year.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=onco_PharmaceuticalServicesLLCMember', window );">Pharmaceutical Services, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationDescription', window );">Business acquisition, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i)&#160;$5.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI&#174; of $100.0&#160;million during a calendar year, (ii)&#160;$7.5&#160;million is payable upon the first time the Company achieves net sales from ENTADFI&#174; of $200.0&#160;million during a calendar year, and (3)&#160;$10.0&#160;million is payable upon the first time the Company achieves net sales from ENTADFI&#174; of $300.0&#160;million during a calendar year.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=onco_ProteomedixMember', window );">Proteomedix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Business acquisition, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">i)&#160;the Company obtained 100% of the outstanding common stock and voting interest of PMX, (ii)&#160;at closing of the PMX Transaction, the PMX shareholders were issued approximately 17% of Onconetix&#8217;s outstanding common stock and none of the former PMX shareholders held more than 5% of Onconetix&#8217;s common stock individually, (iii)&#160;the composition of executive management and the governing body did not change sufficiently to give PMX or its former shareholders control over these functions within Onconetix, and (iv)&#160;Onconetix was significantly larger when considering both total assets and operations.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=onco_FairValueConsiderationTransferredMember', window );">Fair Value Consideration Transferred [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,111,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_AggregatePurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of aggregate purchase shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_AggregatePurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_BusinessTransactionYeare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business transaction yeare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_BusinessTransactionYeare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ImpairmentRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ImpairmentRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_InitialPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of initial payment amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_InitialPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_InventoryFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_InventoryFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_NumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_NumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_Payments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_Payments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_RoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_RoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_RoyaltySalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>percentage of royalty sales percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_RoyaltySalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_SalesPaymentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of sales payments amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_SalesPaymentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and Series B Preferred Stock in connection with PMX Transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_VotingInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Voting interest percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_VotingInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_WeightedAverageDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_WeightedAverageDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_WeightedAverageDiscountRateThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of minimum average discount rate there after.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_WeightedAverageDiscountRateThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the pro forma information, nature of adjustments made to historical information to arrive at pro forma amounts, amounts excluded from pro forma information, any material-nonrecurring items included in the pro forma information and limitations of pro forma disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.12)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=onco_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=onco_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=onco_ENTADFIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=onco_ENTADFIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=onco_ManagementServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=onco_ManagementServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=onco_WraSerAPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=onco_WraSerAPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=onco_BankruptcyCourtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=onco_BankruptcyCourtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=onco_WraSerMSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=onco_WraSerMSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=onco_PMXTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=onco_PMXTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=onco_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=onco_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=onco_ENTADFIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=onco_ENTADFIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=onco_MilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=onco_MilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=onco_PharmaceuticalServicesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=onco_PharmaceuticalServicesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=onco_ProteomedixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=onco_ProteomedixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=onco_FairValueConsiderationTransferredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=onco_FairValueConsiderationTransferredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666108128992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Details) - Schedule of Aggregate Consideration Transferred for the Assets Acquired<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=onco_AggregateConsiderationTransferredMember', window );">Aggregate Consideration Transferred [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets', window );">Consideration transferred at closing</a></td>
<td class="nump">$ 6,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable', window );">Fair value of notes payable issued</a></td>
<td class="nump">12,947,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Transaction costs</a></td>
<td class="nump">79,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total consideration transferred</a></td>
<td class="nump">19,026,771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=onco_FairValueConsiderationTransferredMember', window );">Fair Value Consideration Transferred [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredOther1', window );">Common stock</a></td>
<td class="nump">875,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Series B convertible preferred stock</a></td>
<td class="nump">64,236,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration transferred</a></td>
<td class="nump">$ 65,111,569<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible and intangible assets included as part of consideration transferred in asset acquisition, classified as other. Excludes cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredOther1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredOther1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=onco_AggregateConsiderationTransferredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=onco_AggregateConsiderationTransferredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=onco_FairValueConsiderationTransferredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=onco_FairValueConsiderationTransferredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666108418064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Details) - Schedule of Assets Acquired - Assets Recognized	[Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AssetAcquisitionConsiderationTransferredInventory', window );">Inventory</a></td>
<td class="nump">$ 1,120,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible', window );">ENTADFI&#174; Intangible</a></td>
<td class="nump">17,906,771<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total fair value of identifiable assets acquired</a></td>
<td class="nump">$ 19,026,771<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset acquisition consideration transferred ENTADFI intangible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_AssetAcquisitionConsiderationTransferredENTADFIIntangible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_AssetAcquisitionConsiderationTransferredInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset acquisition, consideration transferred, inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_AssetAcquisitionConsiderationTransferredInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=onco_AssetsRecognizedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=onco_AssetsRecognizedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666111098272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions (Details) - Schedule of Fair Value of the Proteomedix Stock Options - Stock Option [Member]<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of measurement input</a></td>
<td class="nump">128.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Expected stock price volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of measurement input</a></td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Minimum [Member] | Term (years) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of measurement input</a></td>
<td class="nump">0.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Minimum [Member] | Risk-free rate of interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of measurement input</a></td>
<td class="nump">4.07<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Maximum [Member] | Term (years) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of measurement input</a></td>
<td class="nump">3.59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Maximum [Member] | Risk-free rate of interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of measurement input</a></td>
<td class="nump">5.47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=onco_MeasurementInputStockPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=onco_MeasurementInputStockPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666108202544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions (Details) - Schedule of Estimated Fair Values of Assets Acquired and Liabilities - Business Acquisition [Member]<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems', window );"><strong>Acquisitions (Details) - Schedule of Estimated Fair Values of Assets Acquired and Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">$ 1,056,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">87,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="nump">80,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">114,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset', window );">Right of use asset</a></td>
<td class="nump">149,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="nump">39,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Trade name</a></td>
<td class="nump">9,018,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships', window );">Customer relationships</a></td>
<td class="nump">1,891,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology', window );">Product rights for developed technology</a></td>
<td class="nump">10,541,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Goodwill</a></td>
<td class="nump">53,914,055<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="nump">76,892,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(234,029)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Accrued expenses</a></td>
<td class="num">(732,814)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation', window );">Operating lease liability</a></td>
<td class="num">(149,831)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="num">(2,994,669)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation', window );">Pension benefit obligation</a></td>
<td class="num">(548,384)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable', window );">Note payable</a></td>
<td class="num">(115,096)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="num">(4,774,823)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets</a></td>
<td class="nump">72,118,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Less non-controlling interest</a></td>
<td class="num">(7,006,504)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest', window );">Net assets acquired</a></td>
<td class="nump">$ 65,111,569<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_AcquisitionsDetailsScheduleofEstimatedFairValuesofAssetsAcquiredandLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of note payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of pension benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPensionBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of product rights for developed technology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductRightsForDevelopedTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of customer relationships.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesCustomerRelationships</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease obligation assumed in business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=onco_BusinessAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=onco_BusinessAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666111210768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Details) - Schedule of Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=onco_ProteomedixMember', window );">Proteomedix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems', window );"><strong>Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 58,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">315,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=onco_PMXTransactionMember', window );">PMX Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems', window );"><strong>Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Revenue</a></td>
<td class="nump">2,601,310<span></span>
</td>
<td class="nump">$ 392,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 38,577,046<span></span>
</td>
<td class="nump">$ 16,326,247<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=onco_ProteomedixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=onco_ProteomedixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=onco_PMXTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=onco_PMXTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666106139248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 29, 2023</div></th>
<th class="th"><div>Feb. 01, 2023</div></th>
<th class="th"><div>May 21, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jul. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Services payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,518,032<span></span>
</td>
<td class="nump">$ 87,518,032<span></span>
</td>
<td class="nump">$ 26,310,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,949,406<span></span>
</td>
<td class="nump">4,129,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">669,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_RoyaltyNetSalesPercentage', window );">Royalty net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyAccrualDiscountRate', window );">Percentage of product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_RoyaltyRates', window );">Royalty rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AggregateRoyaltiesAmount', window );">Aggregate payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentCosts', window );">Development milestones costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdministrativeFeesExpense', window );">Total amount of fee expenses</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturityDate', window );">Maturity term</a></td>
<td class="text">Jul. 14,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Expense related to contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AmountOfOtherPartyPayments', window );">Other party payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_RoyaltiesPercentage', window );">Royalties percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AmountOfOtherPartyPayments', window );">Other party payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_RoyaltiesPercentage', window );">Royalties percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesByIndustryAxis=onco_RegulatoryMilestonesMember', window );">Regulatory milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentCosts', window );">Development milestones costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesByIndustryAxis=us-gaap_CommercialAndIndustrialSectorMember', window );">Commercial milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentCosts', window );">Development milestones costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=onco_VendorAgreementMember', window );">Vendor Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Sales-related services fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_OlogyBioservicesIncMember', window );">Ology Bioservices, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AggregateAgreementAmountInitialAgreement', window );">Aggregate agreement amount initial agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Services payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AggregateeAmount', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_CostPlusPercentage', window );">Cost plus, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137,000<span></span>
</td>
<td class="nump">137,000<span></span>
</td>
<td class="nump">137,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">1,329,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 685,000<span></span>
</td>
<td class="nump">$ 685,000<span></span>
</td>
<td class="nump">$ 476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_CincinnatiChildrensHospitalMedicalCenterMember', window );">CHMC Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_CommercialSaleTerm', window );">Commercial sale term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_RoyaltyNetSalesPercentage', window );">Royalty net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_RoyaltyRates', window );">Royalty rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_RevenueRate', window );">Revenue rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FeeIncome', window );">Option fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AggregateRoyaltiesAmount', window );">Aggregate payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_OxfordUniversityInnovationLimitedMember', window );">Oxford University Innovation Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_RoyaltyNetSalesPercentage', window );">Royalty net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_RoyaltyRates', window );">Royalty rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfPropertyRepairsAndMaintenance', window );">Maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_OxfordUniversityInnovationLimitedMember', window );">Oxford University Innovation Limited [Member] | Regulatory milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentCosts', window );">Development milestones costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_OxfordUniversityInnovationLimitedMember', window );">Oxford University Innovation Limited [Member] | Commercial milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentCosts', window );">Development milestones costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_OxfordUniversityInnovationLimitedMember', window );">Oxford University Innovation Limited [Member] | Development milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentCosts', window );">Development milestones costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_OxfordUniversityInnovationLimitedMember', window );">Oxford University Innovation Limited [Member] | OUI Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfPropertyRepairsAndMaintenance', window );">Maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_StJudeChildrensHospitalMember', window );">St. Jude Children&#8217;s Hospital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_RoyaltyRates', window );">Royalty rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AggregateRoyaltiesAmount', window );">Aggregate payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PercentageOfConsiderationReceived', window );">Percentage of consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesAndLicenses', window );">License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Annual maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_StJudeChildrensHospitalMember', window );">St. Jude Children&#8217;s Hospital [Member] | Regulatory milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentCosts', window );">Development milestones costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_StJudeChildrensHospitalMember', window );">St. Jude Children&#8217;s Hospital [Member] | Commercial milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentCosts', window );">Development milestones costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_StJudeChildrensHospitalMember', window );">St. Jude Children&#8217;s Hospital [Member] | Development milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentCosts', window );">Development milestones costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_UniversityOfTexasHealthScienceCenterAtSanAntonioMember', window );">University of Texas Health Science Center at San Antonio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_RoyaltyNetSalesPercentage', window );">Royalty net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_RoyaltyRates', window );">Royalty rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AggregateRoyaltiesAmount', window );">Aggregate payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_UniversityOfTexasHealthScienceCenterAtSanAntonioMember', window );">University of Texas Health Science Center at San Antonio [Member] | Commercial milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentCosts', window );">Development milestones costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_UniversityOfTexasHealthScienceCenterAtSanAntonioMember', window );">University of Texas Health Science Center at San Antonio [Member] | Development milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentCosts', window );">Development milestones costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_UniversityOfTexasHealthScienceCenterAtSanAntonioMember', window );">University of Texas Health Science Center at San Antonio [Member] | UT Health Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_RoyaltyNetSalesPercentage', window );">Royalty net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_CoDevelopmentAgreementMember', window );">Co Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_LaboratorCorporationOfAmericaMember', window );">Laborator Corporation of America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_LicensedProductsPlusMilestonePaymentsDescription', window );">Description of licensed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;After the first sale of Proclarix as a laboratory developed test, Labcorp will pay an amount in the mid-six figures,&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;after Labcorp achieves a certain amount in the low seven figures in net sales of Licensed Products, Labcorp will pay Proteomedix an amount in the low seven figures,&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;after a certain amount in the mid-seven figures in net sales of Licensed Products, Labcorp will pay Proteomedix an amount in the low seven figures.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_AggregateAgreementAmountInitialAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of aggregate Agreement amount initial agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_AggregateAgreementAmountInitialAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_AggregateRoyaltiesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate royalties amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_AggregateRoyaltiesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_AggregateeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_AggregateeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_AmountOfOtherPartyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_AmountOfOtherPartyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_CommercialSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial sale term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_CommercialSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_CostPlusPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost plus, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_CostPlusPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_LicensedProductsPlusMilestonePaymentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of licensed products plus milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_LicensedProductsPlusMilestonePaymentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_PercentageOfConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of consideration received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_PercentageOfConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_RevenueRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_RevenueRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_RoyaltiesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_RoyaltiesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_RoyaltyNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_RoyaltyNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_RoyaltyRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_RoyaltyRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdministrativeFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for administrative fee from service provided, including, but not limited to, salary, rent, or overhead cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdministrativeFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfPropertyRepairsAndMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs of keeping the property in good condition but that do not appreciably prolong the life or increase the value of the property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfPropertyRepairsAndMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The capitalized costs incurred during the period (excluded from amortization) to obtain access to proved reserves and to provide facilities for extracting, treating, gathering and storing the oil and gas.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 932<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(7)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479664/932-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FeeIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fee income including, but not limited to, managerial assistance, servicing of investment, and origination and commitment fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FeeIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maturity date of long-term debt, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityContingencyAccrualDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate applied to the undiscounted amount of estimated damages for product liability to arrive at the present value recorded as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityContingencyAccrualDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesAndLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense, excluding income, excise, production and property taxes, and licenses and fees not related to production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesAndLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesByIndustryAxis=onco_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesByIndustryAxis=onco_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesByIndustryAxis=us-gaap_CommercialAndIndustrialSectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesByIndustryAxis=us-gaap_CommercialAndIndustrialSectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=onco_VendorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=onco_VendorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_OlogyBioservicesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_OlogyBioservicesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_CincinnatiChildrensHospitalMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_CincinnatiChildrensHospitalMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_OxfordUniversityInnovationLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_OxfordUniversityInnovationLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesByIndustryAxis=onco_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesByIndustryAxis=onco_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=onco_OUIAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=onco_OUIAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_StJudeChildrensHospitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_StJudeChildrensHospitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_UniversityOfTexasHealthScienceCenterAtSanAntonioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_UniversityOfTexasHealthScienceCenterAtSanAntonioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=onco_UTHealthAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=onco_UTHealthAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_CoDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_CoDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_LaboratorCorporationOfAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_LaboratorCorporationOfAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666102935984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 29, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 29, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 19, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 03, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PayableAverageDiscountRatePercentage', window );">Average discount rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.20%<span></span>
</td>
<td class="nump">8.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Note payable originally due</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_DebtInstrumentDueDate', window );">Note payable originally due</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_CashPaymentToTheSeller', window );">Cash payment to the seller</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 490,000<span></span>
</td>
<td class="num">$ (490,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_DebtInstrumentDueTerm', window );">Principal payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024 years<span></span>
</td>
<td class="text">2024 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Loan payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=onco_ProteomedixAcquisitionMember', window );">Proteomedix Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected', window );">Proteomedix acquisition (in Francs) | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Issuance shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Aggregate equity value measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Aggregate equity value measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Aggregate equity value measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=onco_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 19,  2024<span></span>
</td>
<td class="text">Apr. 19,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Accrue interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=onco_NotePayableMember', window );">Note Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=onco_ENTADFIMember', window );">ENTADFI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Accrue interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Asset Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_CashPaymentToTheSeller">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The payment to the seller in the form of cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_CashPaymentToTheSeller</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_DebtInstrumentDueDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument due date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_DebtInstrumentDueDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_DebtInstrumentDueTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument due term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_DebtInstrumentDueTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_PayableAverageDiscountRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of payable average discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_PayableAverageDiscountRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionPriceOfAcquisitionExpected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=onco_ProteomedixAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=onco_ProteomedixAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=onco_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=onco_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=onco_NotePayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=onco_NotePayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=onco_ENTADFIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=onco_ENTADFIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666110588544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subscription Agreement (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 18, 2023</div></th>
<th class="th"><div>Oct. 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SubscriptionAgreementDetailsLineItems', window );"><strong>Subscription Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SaleOfUnits', window );">Sale of units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Share of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per unit (in Dollars per share)</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ServicingLiabilityAtFairValueAdditions', window );">Fair value of Subscription agreement liability (in Dollars)</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ServicingLiabilityAtFairValueAmount', window );">Fair value of subscription agreement liability (in Dollars)</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage', window );">Estimated probability percentage</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SubscriptionAgreementDetailsLineItems', window );"><strong>Subscription Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Share of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SubscriptionAgreementDetailsLineItems', window );"><strong>Subscription Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Share of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_SaleOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_SaleOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_SubscriptionAgreementDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_SubscriptionAgreementDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the estimated recovery from third parties recorded in the period pertaining to product liability damages from specified products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ServicingLiabilityAtFairValueAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of new servicing liabilities, that are subsequently measured at fair value, acquired or created during the current period through assumptions of servicing obligations and servicing obligations that result from transfers of financial assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481229/860-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ServicingLiabilityAtFairValueAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ServicingLiabilityAtFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of a liability representing servicing arrangements under which the estimated future revenue from contractually specified servicing fees, late charges, and other ancillary revenues are not expected to adequately compensate the servicer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481229/860-50-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481260/860-50-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481260/860-50-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481260/860-50-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ServicingLiabilityAtFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666103965936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subscription Agreement (Details) - Schedule of Assumptions Used in Monte-Carlo Model, Which Utilizes Level 3 Inputs - Level 3 Inputs [Member]<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 18, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems', window );"><strong>Schedule of Assumptions Used in Monte-Carlo Model, Which Utilizes Level 3 Inputs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Significant assumptions</a></td>
<td class="nump">0.25<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems', window );"><strong>Schedule of Assumptions Used in Monte-Carlo Model, Which Utilizes Level 3 Inputs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Significant assumptions</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Expected Stock Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems', window );"><strong>Schedule of Assumptions Used in Monte-Carlo Model, Which Utilizes Level 3 Inputs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Significant assumptions</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Risk-free Rate of Interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems', window );"><strong>Schedule of Assumptions Used in Monte-Carlo Model, Which Utilizes Level 3 Inputs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Significant assumptions</a></td>
<td class="nump">4.64<span></span>
</td>
<td class="nump">4.64<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666107525520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 1 - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 15, 2023</div></th>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Sep. 29, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 19, 2022</div></th>
<th class="th"><div>Feb. 23, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Number of shares of common stock issued</a></td>
<td class="nump">22,841,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,724,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Liquidation preference (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in Dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Notes payable due (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred investment option price per share (in Dollars per share)</a></td>
<td class="nump">$ 0.5254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.52<span></span>
</td>
<td class="nump">$ 6.775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Preferred stock designated</a></td>
<td class="nump">5,709,935<span></span>
</td>
<td class="nump">2,696,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Number of shares of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Liquidation preference (in Dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=onco_SeriesSeedPreferredStockMember', window );">Series Seed Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares</a></td>
<td class="nump">1,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=onco_SeriesSeedPreferredStockMember', window );">Series Seed Convertible Preferred Stock [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares</a></td>
<td class="nump">1,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation per shares (in Dollars per share)</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SharesOfCommonStockRate', window );">Shares of common stock rate</a></td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares</a></td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Preferred stock designated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Preferred stock designated</a></td>
<td class="nump">269,672,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=onco_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Liquidation preference (in Dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, share issued</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=onco_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart1LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_SharesOfCommonStockRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of common stock rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_SharesOfCommonStockRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=onco_SeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=onco_SeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=onco_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=onco_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666104368144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 2 - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 15, 2023</div></th>
<th class="th"><div>Apr. 19, 2022</div></th>
<th class="th"><div>Feb. 23, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 2 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Preferred stock designated</a></td>
<td class="nump">5,709,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,696,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Stock options vested</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,626,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PercentageOfIssuedOfCommonStock', window );">Percentage of issued of common stock</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PercentageOfOutstandingOfCommonStock', window );">Percentage of outstanding of common stock</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred investment option price per share (in Dollars per share)</a></td>
<td class="nump">$ 0.5254<span></span>
</td>
<td class="nump">$ 1.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PercentageOfCumulativeDividends', window );">Percentage of cumulative dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_NettingProceeds', window );">Netting proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PercentageOfOriginalIssuePrice', window );">Original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeDividends', window );">Cumulative dividends (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,586,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 2 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred investment options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,146,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 2 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 2 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Preferred stock designated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares</a></td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 2 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Preferred stock designated</a></td>
<td class="nump">269,672,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=onco_SeriesSeedPreferredStockMember', window );">Series Seed Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 2 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares</a></td>
<td class="nump">1,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=onco_SeriesSeedPreferredStockMember', window );">Series Seed Preferred Stock [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 2 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,146,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=onco_SeriesSeedPreferredStockMember', window );">Series Seed Preferred Stock [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 2 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares</a></td>
<td class="nump">1,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart2LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_NettingProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of netting proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_NettingProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_PercentageOfCumulativeDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of cumulative dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_PercentageOfCumulativeDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_PercentageOfIssuedOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of issued of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_PercentageOfIssuedOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_PercentageOfOriginalIssuePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Original Issue Price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_PercentageOfOriginalIssuePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_PercentageOfOutstandingOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_PercentageOfOutstandingOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative cash dividends distributed to shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share amount of a dividend declared, but not paid, as of the financial reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=onco_SeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=onco_SeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666100722976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3 - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 18, 2022</div></th>
<th class="th"><div>Nov. 10, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Feb. 23, 2022</div></th>
<th class="th"><div>Feb. 17, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 15, 2023</div></th>
<th class="th"><div>May 24, 2022</div></th>
<th class="th"><div>Apr. 19, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,222,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonUnitIssued', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,675,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PercentageOfUnderwritingDiscount', window );">Percentage of underwriting discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOwnershipInterestsOfferingCosts', window );">Offering costs (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant liability (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 729,900<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 254,000<span></span>
</td>
<td class="nump">$ 14,770,678<span></span>
</td>
<td class="nump">$ 9,351,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Shares remaining repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Number of shares of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,841,975<span></span>
</td>
<td class="nump">15,724,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,626,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred investment option price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5254<span></span>
</td>
<td class="nump">$ 1.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_CancelledPreferredInvestmentOptionsShares', window );">Cancelled preferred investment options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,289,148<span></span>
</td>
<td class="nump">1,180,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">(in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Reduction of additional paid in capital (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onco_April2022PrivatePlacementMember', window );">April 2022 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 6.774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Number of shares of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">590,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">590,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,180,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred investment option price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Private placement were approximatel (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onco_AprilContingentWarrantsMember', window );">April Contingent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Value of liability (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onco_August2022PrivatePlacementMember', window );">August 2022 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant liability (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Number of shares of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,333,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,972,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred investment option price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Private placement were approximatel (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_CancelledPreferredInvestmentOptionsShares', window );">Cancelled preferred investment options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,180,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PrefundedWarrantsExercised', window );">Pre-funded warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646,640<span></span>
</td>
<td class="nump">1,686,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsShares', window );">Investment options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,486,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPriceDecrease', window );">Reduced exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred investment options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,486,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_IncreaseInTheFairValueOfThePreferredInvestmentOptions', window );">Increase in fair value of the preferred investment options (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 860,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onco_AugustContingentWarrantsMember', window );">August Contingent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.3938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,849<span></span>
</td>
<td class="nump">298,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_WarrantsIssuableUnderProvisionShares', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ContingentWarrantLiabilityShares', window );">Contingent warrant liability shares (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,841,975<span></span>
</td>
<td class="nump">$ 15,724,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,324,576<span></span>
</td>
<td class="nump">15,265,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">512,940<span></span>
</td>
<td class="nump">293,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Number of shares of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=onco_TreasuryStocksMember', window );">Treasury Stocks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Shares remaining repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,670<span></span>
</td>
<td class="nump">459,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Aggregate common stock value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119.50%<span></span>
</td>
<td class="nump">121.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.10%<span></span>
</td>
<td class="nump">112.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_HCWainwrightCoLLCMember', window );">H.C. Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred investment option price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.46875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Private placement were approximatel (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Issued shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AggregateNumberOfSharesPercenatge', window );">Aggregate number of shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_HCWainwrightCoLLCMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | April 2022 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_HCWainwrightCoLLCMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | April Contingent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred investment option price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.46875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">April Contingent Warrants issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_HCWainwrightCoLLCMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | August 2022 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">(in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_HCWainwrightCoLLCMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | August Wainwright Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.3938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AggregateNumberOfSharesPercenatge', window );">Aggregate number of shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_HCWainwrightCoLLCMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PlacementAgentFeeAndManagementFeePercentage', window );">Placement agent fee and management fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_HCWainwrightCoLLCMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Maximum [Member] | August 2022 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PlacementAgentFeeAndManagementFeePercentage', window );">Placement agent fee and management fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_HCWainwrightCoLLCMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PlacementAgentFeeAndManagementFeePercentage', window );">Placement agent fee and management fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_HCWainwrightCoLLCMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Minimum [Member] | August 2022 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PlacementAgentFeeAndManagementFeePercentage', window );">Placement agent fee and management fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 3 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_AggregateNumberOfSharesPercenatge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percenatge of aggregate number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_AggregateNumberOfSharesPercenatge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_CancelledPreferredInvestmentOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) cancelled during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_CancelledPreferredInvestmentOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ContingentWarrantLiabilityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of contingent warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ContingentWarrantLiabilityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart3LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_IncreaseInTheFairValueOfThePreferredInvestmentOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of fair value of the preferred investment options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_IncreaseInTheFairValueOfThePreferredInvestmentOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_PercentageOfUnderwritingDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of underwriting discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_PercentageOfUnderwritingDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_PlacementAgentFeeAndManagementFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of placement agent fee and management fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_PlacementAgentFeeAndManagementFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_PrefundedWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of prefunded share warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_PrefundedWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_WarrantsIssuableUnderProvisionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share warrants issuable under provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_WarrantsIssuableUnderProvisionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonUnitIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common units issued of limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonUnitIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOwnershipInterestsOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of offering costs allocated to the other unit holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB TOPIC 4.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOwnershipInterestsOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in conversion price of convertible preferred stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onco_April2022PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onco_April2022PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onco_AprilContingentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onco_AprilContingentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onco_August2022PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onco_August2022PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onco_AugustContingentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onco_AugustContingentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=onco_TreasuryStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=onco_TreasuryStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_HCWainwrightCoLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_HCWainwrightCoLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onco_AugustWainwrightWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onco_AugustWainwrightWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666095579600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 - USD ($)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 04, 2023</div></th>
<th class="th"><div>Oct. 04, 2023</div></th>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Aug. 16, 2023</div></th>
<th class="th"><div>Aug. 02, 2023</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 09, 2023</div></th>
<th class="th"><div>Mar. 29, 2023</div></th>
<th class="th"><div>Oct. 09, 2022</div></th>
<th class="th"><div>Aug. 11, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 23, 2023</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SharesOfCommonStockIssued', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,486,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_FixedCommissionRate', window );">Fixed commission rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceDecrease', window );">Reduced exercised price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AggregateNetProceeds', window );">Aggregate net proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Shares unissued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">911,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Fees and expenses of legal (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralExpense', window );">Non-accountable expenses (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AggregatePurchaseShares', window );">Purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,709,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PercentageOfCommonStockShares', window );">Percentage of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,346<span></span>
</td>
<td class="nump">298,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Equity issuance cost. (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205,093<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_WarrantsIssuedForSettlementOfContingentWarrants', window );">Warrants recognized (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,184<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant liability (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 729,900<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Aggregate fair value of stock options (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="nump">709,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ExercisePrice', window );">options granted exercise price (in Dollars per share)</a></td>
<td class="nump">$ 0.4305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_GrantDateFairValueOfStockOption', window );">Grant date fair value of stock option (in Dollars)</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Recognized stock based compensation expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Restricted shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,440<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested weighted average exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested weighted average term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 193 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value of options outstanding (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested intrinsic value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated', window );">Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onco_TwoThousandNinteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onco_TwoThousandTwentyTwoEquityIncentivePlanMember', window );">2022 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onco_TwoThousandTwentyTwoPlanMember', window );">2022 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">718,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onco_January2024Member', window );">January 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_RestrictedSharesGrantedVestPercentage', window );">Restricted shares granted vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onco_August2024Member', window );">August 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_RestrictedSharesGrantedVestPercentage', window );">Restricted shares granted vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onco_August2025Member', window );">August 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_RestrictedSharesGrantedVestPercentage', window );">Restricted shares granted vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onco_PMXOptionPlanMember', window );">PMX Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock option outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 131 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested weighted average term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 73 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 357 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SharesOfCommonStockIssued', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,972,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercisable shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,920<span></span>
</td>
<td class="nump">165,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PercentageOfGrossProceeds', window );">Percentage of gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.10%<span></span>
</td>
<td class="nump">112.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,486,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PercentageOfGrossProceeds', window );">Percentage of gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119.50%<span></span>
</td>
<td class="nump">121.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=onco_WarrantInducementMember', window );">Warrant Inducement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">(in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=onco_April2022PrivatePlacementMember', window );">April 2022 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,707,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=onco_August2022PrivatePlacementMember', window );">August 2022 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,121,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercisable shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,899,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Equity issuance cost. (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_WarrantsIssuedForSettlementOfContingentWarrants', window );">Warrants recognized (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant liability (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Value of liability (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onco_AugustContingentWarrantsMember', window );">August Contingent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.3938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,849<span></span>
</td>
<td class="nump">298,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of the contingent warrant liability (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Recognized stock based compensation expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Restricted shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeited shares of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=onco_ChiefBusinessOfficerMember', window );">CBO&#8217;s [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Recognized stock based compensation expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Restricted shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Restricted shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeited shares of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_GrantDateFairValueOfStockOption', window );">Grant date fair value of stock option (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Recognized stock based compensation expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Aggregate of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_InducementPIOSharesMember', window );">Inducement PIO Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=onco_MarketOfferingAgreementMember', window );">Market Offering Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SharesOfCommonStockIssued', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 288 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=onco_UnvestedRestrictedStockMember', window );">Unvested Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems', window );"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Part 4 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 208 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_AggregateNetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_AggregateNetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_AggregatePurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of aggregate purchase shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_AggregatePurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsPart4LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_FixedCommissionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fixed commission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_FixedCommissionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_GrantDateFairValueOfStockOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant date fair value of stock option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_GrantDateFairValueOfStockOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_PercentageOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Common Stock Shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_PercentageOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_PercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_PercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_RestrictedSharesGrantedVestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted shares granted vest percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_RestrictedSharesGrantedVestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_SharesOfCommonStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_SharesOfCommonStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_WarrantsIssuedForSettlementOfContingentWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants issued for settlement of contingent warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_WarrantsIssuedForSettlementOfContingentWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of plan compensation cost recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general expenses not normally included in Other Operating Costs and Expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of allocated shares held by the Employee Stock Option Plan at balance sheet date. Allocated shares are shares that have been assigned to individual participant accounts based on a known formula.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onco_TwoThousandNinteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onco_TwoThousandNinteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onco_TwoThousandTwentyTwoEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onco_TwoThousandTwentyTwoEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onco_TwoThousandTwentyTwoPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onco_TwoThousandTwentyTwoPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onco_January2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onco_January2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onco_August2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onco_August2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onco_August2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onco_August2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onco_PMXOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onco_PMXOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=onco_WarrantInducementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=onco_WarrantInducementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=onco_April2022PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=onco_April2022PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=onco_August2022PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=onco_August2022PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onco_AugustContingentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onco_AugustContingentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=onco_ChiefBusinessOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=onco_ChiefBusinessOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_InducementPIOSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onco_InducementPIOSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=onco_MarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=onco_MarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=onco_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=onco_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666111329936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Fair Value of the Preferred Investment Options<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=onco_OriginalMember', window );">Original [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Schedule of Fair Value of the Preferred Investment Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 6.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (years)</a></td>
<td class="text">3 years 8 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">116.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate of interest</a></td>
<td class="nump">3.16%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=onco_ExchangedMember', window );">Exchanged [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Schedule of Fair Value of the Preferred Investment Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 2.546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">120.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate of interest</a></td>
<td class="nump">2.98%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-30<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-31<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionQuantitativeDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=onco_OriginalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=onco_OriginalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=onco_ExchangedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=onco_ExchangedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666108464704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Valuation of the Contingent Warrant Liability - Private Placement [Member] - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 11, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems', window );"><strong>Schedule of Valuation of the Contingent Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 3.3938<span></span>
</td>
<td class="nump">$ 3.3938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (years)</a></td>
<td class="text">4 years 7 months 9 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">120.80%<span></span>
</td>
<td class="nump">127.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate of interest</a></td>
<td class="nump">4.03%<span></span>
</td>
<td class="nump">2.98%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofValuationoftheContingentWarrantLiabilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666107859088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Outstanding Warrants, Excluding Contingent Warrants - Warrant [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Outstanding Warrants, Excluding Contingent Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, ending</a></td>
<td class="nump">5,910,914<span></span>
</td>
<td class="nump">7,899,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, ending</a></td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="nump">$ 1.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, ending</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Warrants vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,899,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Warrants vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Warrants vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,121,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,132,854)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666106824944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Stock Options - Stock Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems', window );"><strong>Schedule of Stock Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, ending</a></td>
<td class="nump">1,392,654<span></span>
</td>
<td class="nump">1,904,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, ending</a></td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="nump">$ 1.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Total Intrinsic Value, ending</a></td>
<td class="nump">$ 670,161<span></span>
</td>
<td class="nump">$ 94,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, ending</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of Shares, Options vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">861,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Total Intrinsic Value, Options vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Options vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">962,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted', window );">Total Intrinsic Value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Forfeited / cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(404,058)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited / cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled', window );">Total Intrinsic Value, Forfeited / cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,920)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total Intrinsic Value, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,920<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofStockOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value for share based compensation payment intrinsic value forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeitedCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation payment arrangementintrinsic value granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666099176448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Fair Value of Options Granted - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems', window );"><strong>Schedule of Fair Value of Options Granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">101.10%<span></span>
</td>
<td class="nump">112.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate of interest</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems', window );"><strong>Schedule of Fair Value of Options Granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 1.29<span></span>
</td>
<td class="nump">$ 6.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">119.50%<span></span>
</td>
<td class="nump">121.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate of interest</a></td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofFairValueofOptionsGrantedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666111310448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Unvested Restricted Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems', window );"><strong>Schedule of Unvested Restricted Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Outstanding at beginning | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding at beginning | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">512,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">$ 1.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited / cancelled | shares</a></td>
<td class="num">(250,110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited / cancelled | $ / shares</a></td>
<td class="nump">$ 1.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested | shares</a></td>
<td class="num">(6,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">$ 1.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Outstanding at ending | shares</a></td>
<td class="nump">256,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding at ending | $ / shares</a></td>
<td class="nump">$ 1.03<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ConvertibleRedeemablePreferredStockandStockholdersEquityDetailsScheduleofUnvestedRestrictedStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666108137680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - Schedule of Stock-Based Compensation Expense - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expenses</a></td>
<td class="nump">$ 329,760<span></span>
</td>
<td class="nump">$ 1,974,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expenses</a></td>
<td class="nump">234,298<span></span>
</td>
<td class="nump">1,309,687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=onco_ResearchAndDevelopmentMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expenses</a></td>
<td class="nump">$ 95,462<span></span>
</td>
<td class="nump">$ 664,879<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=onco_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=onco_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666104150048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 09, 2022</div></th>
<th class="th"><div>May 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 07, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeasePayments', window );">Short-term lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Variable lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal expense</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Share issued of restricted common stock (in Shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Cancellation of warrants issued (in Shares)</a></td>
<td class="nump">111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Total restricted common stock issued</a></td>
<td class="nump">$ 264,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_PercentageOfSubscription', window );">Percentage of subscription</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AggregatePayments', window );">Aggregate payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees', window );">Termination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Related expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPaidinkind', window );">Approximately amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Share issued of restricted common stock (in Shares)</a></td>
<td class="nump">93,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=onco_SettlementAgreementMember', window );">Settlement Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FeeIncome', window );">Cash fee</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CH', window );">Zurich Switzerland [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Leases office rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_AggregatePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_AggregatePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_PercentageOfSubscription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of subscription .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_PercentageOfSubscription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPaidinkind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid paid-in-kind dividends (PIK) declared for classes of stock, for example, but not limited to, common and preferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPaidinkind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FeeIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fee income including, but not limited to, managerial assistance, servicing of investment, and origination and commitment fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FeeIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of early contract termination fees included in liabilities subject to compromise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482964/270-10-50-6A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term lease payment excluded from lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=onco_SettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=onco_SettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666110868560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Fees under consulting agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative expenses</a></td>
<td class="nump">$ 254,000<span></span>
</td>
<td class="nump">$ 14,770,678<span></span>
</td>
<td class="nump">$ 9,351,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SubscriptionAgreementPMXInvestorPercentage', window );">Subscription agreement PMX investor percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=onco_NonConvertibleDebentureMember', window );">Non convertible debenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=onco_CEOMember', window );">CEO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transactions amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=onco_CBOMember', window );">CBO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transactions amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Fees under consulting agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Related party receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 522,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Receivable from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">35,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_MiscellaneousExpenses', window );">Miscellaneous payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_MiscellaneousExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_MiscellaneousExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_SubscriptionAgreementPMXInvestorPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subscription agreement PMX investor percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_SubscriptionAgreementPMXInvestorPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=onco_NonConvertibleDebentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=onco_NonConvertibleDebentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=onco_CEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=onco_CEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=onco_CBOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=onco_CBOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666107843584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State NOLs</a></td>
<td class="num">$ (1,192,605)<span></span>
</td>
<td class="num">$ (501,277)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign NOLs</a></td>
<td class="nump">315,927<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance</a></td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 17,010<span></span>
</td>
<td class="nump">$ 17,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingIncomeLossMember', window );">Operating Income (Loss) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal income tax</a></td>
<td class="nump">27,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign income tax</a></td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State income tax</a></td>
<td class="nump">23,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">Federal NOL and state NOLs</a></td>
<td class="nump">$ 16,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal', window );">Taxable income</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State NOLs</a></td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign NOLs</a></td>
<td class="nump">$ 15,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingIncomeLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingIncomeLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666108292608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Loss Before Income Tax - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Schedule of Loss Before Income Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="num">$ (37,106,599)<span></span>
</td>
<td class="num">$ (13,419,830)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(315,688)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total loss before income taxes</a></td>
<td class="num">$ (37,422,287)<span></span>
</td>
<td class="num">$ (13,419,830)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666108339808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net-operating loss carryforward</a></td>
<td class="nump">$ 10,214,760<span></span>
</td>
<td class="nump">$ 2,986,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">3,349,919<span></span>
</td>
<td class="nump">885,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Capitalized research and development</a></td>
<td class="nump">1,171,320<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock-based compensation</a></td>
<td class="nump">690,760<span></span>
</td>
<td class="nump">308,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Deposit on WraSer APA</a></td>
<td class="nump">854,896<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">150,099<span></span>
</td>
<td class="nump">186,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_LicenseAgreement', window );">License agreement</a></td>
<td class="nump">49,157<span></span>
</td>
<td class="nump">82,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Other accrued expenses</a></td>
<td class="nump">520,207<span></span>
</td>
<td class="nump">65,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">17,001,118<span></span>
</td>
<td class="nump">4,515,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(15,697,701)<span></span>
</td>
<td class="num">(4,512,546)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of allowance</a></td>
<td class="nump">1,303,417<span></span>
</td>
<td class="nump">3,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(4,345,449)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(2,560)<span></span>
</td>
<td class="num">(3,005)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(29,189)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(4,377,198)<span></span>
</td>
<td class="num">(3,005)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="num">$ (3,073,781)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_LicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_LicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>186
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666110334176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Income Taxes Differs from the Statutory Federal Rate - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Schedule of Income Taxes Differs from the Statutory Federal Rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Expected income tax benefit at Federal statutory tax rate</a></td>
<td class="num">$ (7,858,680)<span></span>
</td>
<td class="num">$ (2,818,164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local taxes, net of Federal tax benefit</a></td>
<td class="num">(1,192,605)<span></span>
</td>
<td class="num">(501,277)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credits</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(16,477)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign NOL expirations</a></td>
<td class="nump">315,927<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">196,025<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability', window );">Derivative liability</a></td>
<td class="nump">181,440<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation', window );">Officer&#8217;s compensation</a></td>
<td class="num">(126,337)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Acquisition related costs</a></td>
<td class="nump">164,073<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Permanent items</a></td>
<td class="nump">55,486<span></span>
</td>
<td class="nump">194,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment', window );">State rate adjustment</a></td>
<td class="num">(23,135)<span></span>
</td>
<td class="nump">19,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">60,599<span></span>
</td>
<td class="num">(37,260)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">8,214,614<span></span>
</td>
<td class="nump">3,158,873<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">$ (12,593)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of state rate adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_IncomeTaxReconciliationNondeductibleExpenseDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Officer&#8217;s compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666111338496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Unrecognized Tax Benefits - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract', window );"><strong>Schedule of Unrecognized Tax Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 17,010<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">17,010<span></span>
</td>
<td class="nump">17,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases related to prior year tax positions</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">11,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,493<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666104327344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plans (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAbstract', window );"><strong>Retirement Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage', window );">Permits voluntary contributions</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_GrossPayPercentage', window );">Percentage of gross pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_DebtSecuritiesAndCash', window );">Debt securities and cash rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_EquitySecuritiesRate', window );">Equity securities rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AlternativeInvestmentsRate', window );">Alternative investments rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_RealEstateInvestmentsRate', window );">Real estate investments rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList', window );">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pension benefit obligation<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_AlternativeInvestmentsRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Alternative investments rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_AlternativeInvestmentsRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_DebtSecuritiesAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt securities and cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_DebtSecuritiesAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_EquitySecuritiesRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity securities rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_EquitySecuritiesRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_GrossPayPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of gross pay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_GrossPayPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_RealEstateInvestmentsRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Real estate investments rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_RealEstateInvestmentsRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes components of net periodic benefit cost (credit), excluding service cost component, for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>189
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666108757408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Retirement Plans (Details) - Schedule of Benefit Obligation and the Net Periodic Benefit Cost<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems', window );"><strong>Schedule of Benefit Obligation and the Net Periodic Benefit Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">1.45%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate', window );">Expected long-term rate of return on plan assets</a></td>
<td class="nump">1.45%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_RetirementPlansDetailsScheduleofBenefitObligationandtheNetPeriodicBenefitCostLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>190
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666108426304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plans (Details) - Schedule of Components of Net Periodic Benefit Cost<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract', window );"><strong>Schedule Of Components Of Net Periodic Benefit Cost Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 4,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">1,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(1,581)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net (gain)/loss</a></td>
<td class="num">(1,534)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1', window );">Settlements (gain)/loss</a></td>
<td class="num">(1,157)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Total</a></td>
<td class="nump">$ 1,949<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_ScheduleOfComponentsOfNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>191
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666107544864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plans (Details) - Schedule of Accumulated Comprehensive Loss<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Schedule of Accumulated Comprehensive Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent', window );">Net loss (gain)</a></td>
<td class="nump">$ 7,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_AmortizationOfNetGain', window );">Amortization of net gain</a></td>
<td class="nump">1,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_EffectOfSettlement', window );">Effect of settlement</a></td>
<td class="nump">1,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other adjustments</a></td>
<td class="num">(4,005)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegulatedAndUnregulatedOperatingRevenue', window );">Total recorded during the period</a></td>
<td class="nump">$ 5,963<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_AmortizationOfNetGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of net gain.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_AmortizationOfNetGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_EffectOfSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effect of settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_EffectOfSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive (income) loss for defined benefit plan, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegulatedAndUnregulatedOperatingRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of operating revenues recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegulatedAndUnregulatedOperatingRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>192
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666109187632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Retirement Plans (Details) - Schedule of Accompanying Consolidated Balance Sheet - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Schedule of Accompanying Consolidated Balance Sheet [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation', window );">Projected benefit obligation</a></td>
<td class="nump">$ 2,299,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,743,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent', window );">Overfunded (underfunded) status</a></td>
<td class="num">$ (556,296)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>193
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666109729312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plans (Details) - Schedule of the Beginning and Ending Balances of the Accumulated Benefit Obligation - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=onco_AccumulatedBenefitObligationMember', window );">Accumulated Benefit Obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Defined Benefit Plan, Benefit Obligation Begining Balance</a></td>
<td class="nump">$ 2,288,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">4,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">1,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gain) loss</a></td>
<td class="nump">7,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(905)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees', window );">Ordinary contributions paid by employees</a></td>
<td class="nump">4,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Contributions paid by plan participants</a></td>
<td class="nump">769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement', window );">Settlements</a></td>
<td class="num">(6,372)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation', window );">Projected benefit obligation as of December 31, 2023</a></td>
<td class="nump">2,299,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanOtherChanges', window );">Actuarial (gain)/loss due to assumption changes</a></td>
<td class="nump">8,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease', window );">Actuarial (gain)/loss due to plan experience</a></td>
<td class="num">(855)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Defined Benefit Plan, Benefit Obligation Ending Balance</a></td>
<td class="nump">2,307,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=onco_PlanAssetsMember', window );">Plan Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Defined Benefit Plan, Plan Assets Begining Balance</a></td>
<td class="nump">1,739,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">2,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions paid by employer</a></td>
<td class="nump">4,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees', window );">Ordinary contributions paid by employees</a></td>
<td class="nump">4,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Contributions paid by plan participants</a></td>
<td class="nump">769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(905)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(6,372)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Defined Benefit Plan, Plan Assets Ending Balance</a></td>
<td class="nump">$ 1,743,674<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ordinary contributions paid by employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_DefinedBenefitPlanBenefitObligationOrdinaryContributionsPaidByEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ordinary contributions paid by employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_DefinedBenefitPlanPlanAssetsOrdinaryContributionsPaidByEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 5<br> -Subsection 04<br> -Paragraph c<br> -Subparagraph Schedule I<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 7<br> -Subsection 05<br> -Paragraph c<br> -Subparagraph Schedule II<br> -Publisher SEC<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 9<br> -Subsection 06<br> -Publisher SEC<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increase benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases benefit obligation of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract. Excludes decreases to benefit obligation for remeasurement due to settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanOtherChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan from change, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanOtherChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=onco_AccumulatedBenefitObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=onco_AccumulatedBenefitObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=onco_PlanAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=onco_PlanAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>194
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666107685632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Retirement Plans (Details) - Schedule of Benefit Payments<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract', window );"><strong>Schedule of Benefit Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2024</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2025</a></td>
<td class="nump">95,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2026</a></td>
<td class="nump">95,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2027</a></td>
<td class="nump">95,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2028</a></td>
<td class="nump">95,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">Thereafter</a></td>
<td class="nump">553,900<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">$ 934,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>195
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139666110736848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 10, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 23, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Long-lived assets of carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Subscription amount of interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onco_SeverancePayment', window );">Severance payment</a></td>
<td class="nump">$ 158,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=onco_NonConvertibleDebentureMember', window );">Non convertible debenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=onco_NonConvertibleDebentureMember', window );">Non convertible debenture [Member] | Subsequent Event [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=onco_SubscriptionAgreementMember', window );">Subscription Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debenture interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=onco_ENTADFIMember', window );">ENTADFI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Long-lived assets of carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onco_SeverancePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of severance payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onco_SeverancePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=onco_NonConvertibleDebentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=onco_NonConvertibleDebentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=onco_SubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=onco_SubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=onco_ENTADFIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=onco_ENTADFIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
